<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
     xmlns:dc="http://purl.org/dc/elements/1.1/"
     xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
     xmlns:admin="http://webns.net/mvcb/"
     xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
     xmlns:content="http://purl.org/rss/1.0/modules/content/"
     xmlns:media="http://search.yahoo.com/mrss/">
<channel>
<title>Bersama Kita Sehat &#45; Publikasi Terbaru</title>
<link>https://edusehat.com/en/rss/latest-posts</link>
<description>Bersama Kita Sehat &#45; Publikasi Terbaru</description>
<dc:language>en</dc:language>
<dc:rights>2025&#45;2055 PS Global Media &#45; Hak Cipta</dc:rights>

<item>
<title>Private Dentistry Awards 2026: the winners!</title>
<link>https://edusehat.com/en/private-dentistry-awards-2026-the-winners</link>
<guid>https://edusehat.com/en/private-dentistry-awards-2026-the-winners</guid>
<description><![CDATA[ The Private Dentistry Awards 2026 celebrated the individuals, teams and practices raising standards across private dentistry – discover this year’s winners below. On Friday 20 November 2026, the UK’s private dental sector gathered at the JW Marriott Grosvenor House London for the Private Dentistry Awards 2026. Held in the hotel’s Great Room, the evening brought… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/PDA-26_2000x1333-Homepage-Winners-Announced.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 21 Nov 2026 16:30:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Private, Dentistry, Awards, 2026:, the, winners</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>The Private Dentistry Awards 2026 celebrated the individuals, teams and practices raising standards across private dentistry – discover this year’s winners below.</strong></p>



<p>On Friday 20 November 2026, the UK’s private dental sector gathered at the JW Marriott Grosvenor House London for the Private Dentistry Awards 2026.</p>



<p>Held in the hotel’s Great Room, the evening brought together finalists, judges, sponsors and guests to recognise outstanding achievement across the profession. The celebrations included a drinks reception, three-course dinner, awards ceremony and evening entertainment.</p>



<p>Now in their 25th year, the Private Dentistry Awards celebrate excellence across the UK’s private dental sector. This year’s awards received more than 1,000 entries across 16 categories, highlighting the commitment, innovation and high standards demonstrated by dental professionals, teams and practices nationwide.</p>



<!--free-wall-stop-->



<p>A panel of 40 judges, chaired by Dr James Goolnik of Optimal Dental Health, had the tough job of choosing the winners from a world-class field of entries.</p>



<p>Congratulations to every winner, highly commended entrant and finalist. Being shortlisted is a massive achievement in itself, and this year’s winners have demonstrated an exceptional commitment to patient care, clinical standards, innovation and practice leadership.</p>


        <div class="my-4 rounded-t border-b-2 border-primary-500 overflow-hidden bg-context-100/30 px-8 pt-8 pb-0 md:px-10 md:pt-10 md:pb-4 space-y-4 md:space-y-6">
                            <div class="font-secondary font-medium text-xl text-primary-500">
                    Private Dentistry Awards 2026 winners                </div>
                                        <div>
                    <p>Find out who won each award here.</p>
                </div>
                                        <div>
                    <a href="https://awards.dentistry.co.uk/privatedentistryawards/en/page/2026-winners" target="" class="btn btn--default">View the list</a>
                </div>
                    </div>
        


<p><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</em></a></p>]]> </content:encoded>
</item>

<item>
<title>Pharma Friday – November 21, 2026</title>
<link>https://edusehat.com/en/pharma-friday-november-21-2026</link>
<guid>https://edusehat.com/en/pharma-friday-november-21-2026</guid>
<description><![CDATA[ An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia On November 14, Amylyx Pharmaceuticals, Inc. presented the results from the 16-week double-blind treatment period of the Phase 3 LUCIDITY clinical trial of avexitide, an investigational, […]
The post Pharma Friday – November 21, 2026 appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/pharmaaaaa.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 21 Nov 2026 05:50:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pharma, Friday, –, November, 21, 2026</media:keywords>
<content:encoded><![CDATA[<p>An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia On November 14, Amylyx Pharmaceuticals, Inc. presented the results from the 16-week double-blind treatment period of the Phase 3 LUCIDITY clinical trial of avexitide, an investigational, […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/pharma-friday-november-21-2026/">Pharma Friday – November 21, 2026</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Immune Aging Study in Mice Reveals Clues to T Cell Dysfunction and Cancer Development</title>
<link>https://edusehat.com/en/immune-aging-study-in-mice-reveals-clues-to-t-cell-dysfunction-and-cancer-development</link>
<guid>https://edusehat.com/en/immune-aging-study-in-mice-reveals-clues-to-t-cell-dysfunction-and-cancer-development</guid>
<description><![CDATA[ Age-related changes in CD8+ T cells may hold important clues to understanding cancer immunity, with new findings revealing distinct chromatin signatures of dysfunction and the emergence of a unique regulatory population. 
The post Immune Aging Study in Mice Reveals Clues to T Cell Dysfunction and Cancer Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/06/GettyImages-1321240646.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 21 Nov 2026 05:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Immune, Aging, Study, Mice, Reveals, Clues, Cell, Dysfunction, and, Cancer, Development</media:keywords>
<content:encoded><![CDATA[<p><span>Data from a new study led by scientists at Monash University looking at immune aging in mice helps shed more light on why bodies become less effective at fighting cancer and infections with age. The preclinical study, published this week in <em>Science Immunology</em>, identified unique genetic signatures in aging immune cells that cause them to become less effective over time, making older individuals more susceptible to disease. The paper is titled “</span><a href="https://dx.doi.org/10.1126/sciimmunol.aej5412" target="_blank" rel="noopener"><span>Aging drives distinct chromatin signatures of CD8 T cell dysfunction and the emergence of a unique CD8 Treg cell population</span></a><span>.” </span></p>
<p><span>“Our immune system is constantly surveying our bodies for potentially cancerous cells and eliminating them, often without us ever knowing,” explained Daniel Thiele, PhD, first author on the paper and a researcher in the laboratory of Nicole La Gruta, PhD, at Monash Biomedicine Discovery Institute. “As we age, this natural defense system becomes less effective, making us more vulnerable to cancer and infections and reducing our ability to respond to vaccines. This study provides a blueprint of immune aging, from which we can now identify potential targets to reverse aspects of that decline.”</span></p>
<p><span>As the title of the paper indicates, the scientists focused on CD8+ T cells, which are part of the body’s frontline defense system for identifying and destroying infected and cancerous cells. According to the team, they identified three distinct ways that aging disrupts the genetic instructions that control how immune cells function, which affects their ability to adapt to new threats, regulate immune responses, and remain healthy. They also discovered a previously unidentified group of aging immune cells that both lose their ability to protect the body against disease and actively suppress the responses of other immune cells. This was true even within the same ageing individual, Thiele noted. </span></p>
<p><span>This research supports findings from separate research also from scientists in the La Gruta lab. That study, </span><a href="https://www.cell.com/immunity/fulltext/S1074-7613(26)00440-1?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1074761326004401%3Fshowall%3Dtrue" target="_blank" rel="noopener"><span>also published this month in </span><i><span>Immunity</span></i></a><span>, found a link between the Granzyme K protein and signs of aging in the heart, liver, and kidneys in preclinical models. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/immune-aging-study-in-mice-reveals-clues-to-t-cell-dysfunction-and-cancer-development/">Immune Aging Study in Mice Reveals Clues to T Cell Dysfunction and Cancer Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PTSD Brain DNA Methylation Patterns Linked to Age of Trauma Exposure, Sex, and Ethnicity</title>
<link>https://edusehat.com/en/ptsd-brain-dna-methylation-patterns-linked-to-age-of-trauma-exposure-sex-and-ethnicity</link>
<guid>https://edusehat.com/en/ptsd-brain-dna-methylation-patterns-linked-to-age-of-trauma-exposure-sex-and-ethnicity</guid>
<description><![CDATA[ Studying postmortem brain tissue, researchers found variations in DNA methylation in different brain areas that may help explain the development of post-traumatic stress disorder.
The post PTSD Brain DNA Methylation Patterns Linked to Age of Trauma Exposure, Sex, and Ethnicity appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/02/Getty_1402264698_DNAMethylTransferase.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 21 Nov 2026 05:20:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PTSD, Brain, DNA, Methylation, Patterns, Linked, Age, Trauma, Exposure, Sex, and, Ethnicity</media:keywords>
<content:encoded><![CDATA[<p>The results of research headed by a team at the University of Texas at Austin indicate that stress and trauma can leave molecular marks in the brain that may help explain the development of post-traumatic stress disorder (PTSD).</p>
<p>The researchers analyzed specific regions of the postmortem brains of people with PTSD, those with major depressive disorder (MDD), and those without psychiatric disorders. The identified specific molecular features of the PTSD and MDD brain, and showed that the molecular signatures of PTSD also varied significantly between individuals—more so than for individuals with major depressive disorder. The results suggested that within the PTSD group, factors such sex, race of the person, and when in their lifetime trauma exposure occurred, may all impact on the epigenetic signature.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“The question that our research aims to address is ‘What is really different about the PTSD brain?’” said Frances Champagne, PhD, at the University of Texas at Austin. “The study found greater variation in DNA methylation patterns across brain regions in people with PTSD than in people with major depressive disorder. It also revealed considerable differences among individuals with PTSD.” The variance could open the door to more individualized treatment options for people with PTSD in the future, the researchers suggest.</p>
<p>Champagne is corresponding author of the researchers’ published paper in <em>Cell Reports</em>, titled “<a href="http://dx.doi.org/10.1016/j.celrep.2026.118270" target="_blank" rel="noopener">DNA methylation profiling of human brain in posttraumatic stress and major depressive disorders indicate specific molecular features</a>.” In their paper the authors stated, “Overall, our findings illustrate an approach to characterizing distinct epigenomic features within the postmortem brain and the association between variation in DNA methylation and psychiatric diagnoses.”</p>
<p>Epigenetic mechanisms, which are molecular pathways through which gene expression is regulated, have been increasingly implicated in the pathophysiology of physical and psychiatric disorders, the authors wrote. One of these mechanisms, DNA methylation, acts like a genetic “dimmer switch” for genes, sometimes blocking genetic code entirely. “Beyond the role of these mechanisms in gene regulation, epigenetic marks such as DNA methylation exhibit plasticity in response to the environment, thus serving as a potential mediator of the gene-environment interplay that is considered fundamental to disease risk and resilience,” the investigators explained.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Interestingly, PTSD studies have uncovered associations with variations in DNA methylation in peripheral blood (blood and saliva), particularly within genes involved in immune functions such as inflammation and innate immunity, the team continued. However, they pointed out, “While analyses of DNA methylation in peripheral tissues have revealed associations between PTSD and variation in the epigenome, the limited availability of brain-based analyses constrains the potential to reveal critical pathways in the pathophysiology of PTSD.”</p>
<p>For their newly reported study the team carried out detailed methylation profiling of postmortem brains from 302 individuals. All brains were obtained from the Lieber Institute for Brain Development and were matched with the donors’ life history and medical records to assign diagnostic criteria. The analysis included brains from 101 people with PTSD and two comparison groups—100 brains from individuals without psychiatric disorders and 101 brains from people with major depressive disorder. For each brain, three different regions were analyzed—the prefrontal cortex (PFC), the amygdala, and the hippocampus.</p>
<p>“These are the brain regions that seem to be uniquely informative of the PTSD brain,” Champagne said. “Many studies of epigenetics use blood and saliva as a proxy to see what’s going on the body, but we think it’s incredibly important to actually look at the brain for these kinds of mental health conditions.”</p>
<p>The study uncovered specific changes in the brain linked to PTSD, including a relative reduction in oligodendrocytes in the amygdala of people with PTSD, particularly in those exposed to trauma in adulthood. The researchers also found that PTSD was associated with more pronounced DNA methylation differences in the prefrontal cortex, while major depressive disorder was associated with methylation differences in the amygdala. These molecular patterns were associated with differences in the composition of different cell types in the brain.</p>
<p>Within the PTSD group, the molecular variations appeared to be driven by a number of factors, including the sex and race of the person and whether the trauma exposure occurred in childhood or adulthood. One future research focus will be on using these variables to refine and enhance diagnosis. The researchers say it could eventually lead to a more personalized approach to treating mental health conditions.</p>
<p>“Overall, these analyses reveal epigenomic features of the PTSD and MDD brain that can guide cellular and molecular mechanistic understanding of the pathophysiology of these disorders,” the authors stated. “This understanding can inform clinical interventions by identifying unique and shared biological processes that characterize the brain epigenome dependent on mental health diagnosis.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Because the study analyzed postmortem brain tissue the researchers were not able to confirm whether the methylation differences contributed to PTSD, resulted from PTSD, or were influenced by other factors. The authors also noted that they lacked detailed information about symptom type and severity for each individual, which would be important for developing more personalized methods of diagnosis.</p>
<p>“The more we know about all the variables that impact clinically relevant outcomes, the better we can assess patients and tailor their treatments,” Champagne acknowledged.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/ptsd-brain-dna-methylation-patterns-linked-to-age-of-trauma-exposure-sex-and-ethnicity/">PTSD Brain DNA Methylation Patterns Linked to Age of Trauma Exposure, Sex, and Ethnicity</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Hamilton hospital introduces AI tool to reduce unnecessary cardiac procedures</title>
<link>https://edusehat.com/en/hamilton-hospital-introduces-ai-tool-to-reduce-unnecessary-cardiac-procedures</link>
<guid>https://edusehat.com/en/hamilton-hospital-introduces-ai-tool-to-reduce-unnecessary-cardiac-procedures</guid>
<description><![CDATA[ Canadian-developed technology is now being used in routine care at Hamilton General Hospital to help cardiologists select the most appropriate diagnostic tests for patients. Hamilton Health Sciences (HHS) has introduced a new artificial intelligence tool into routine clinical care that could help reduce unnecessary invasive cardiac procedures while improving how patients with suspected coronary artery […]
The post Hamilton hospital introduces AI tool to reduce unnecessary cardiac procedures appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/ai-image-analysis.png" length="49398" type="image/jpeg"/>
<pubDate>Sat, 21 Nov 2026 05:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Hamilton, hospital, introduces, tool, reduce, unnecessary, cardiac, procedures</media:keywords>
<content:encoded><![CDATA[<p>Canadian-developed technology is now being used in routine care at Hamilton General Hospital to help cardiologists select the most appropriate diagnostic tests for patients.</p>
<p>Hamilton Health Sciences (HHS) has introduced a new artificial intelligence tool into routine clinical care that could help reduce unnecessary invasive cardiac procedures while improving how patients with suspected coronary artery disease are assessed.</p>
<p>Known as CarDIA-AI, the technology uses machine learning to analyze patient information and help cardiologists determine whether an invasive coronary angiogram or a non-invasive coronary CT scan is the more appropriate diagnostic test.</p>
<p>The tool began routine clinical use at Hamilton General Hospital’s Heart Investigation Unit in early October 2026, making HHS the first hospital in Canada to implement CarDIA-AI in everyday cardiac care.</p>
<h3>Improving cardiac testing decisions</h3>
<p>Coronary artery disease occurs when arteries supplying blood to the heart become narrowed or blocked, potentially causing chest pain, heart attacks and other cardiovascular complications.</p>
<p>Patients suspected of having the condition are frequently referred for coronary angiography, an invasive procedure involving a catheter inserted through an artery to examine blood flow to the heart.</p>
<p>However, many angiograms reveal no significant blockages. For some patients, a non-invasive CT scan could provide sufficient diagnostic information without requiring catheterization.</p>
<p>CarDIA-AI analyzes patient data to estimate the likelihood of significant coronary artery disease, helping clinicians identify which patients are most likely to benefit from angiography.</p>
<p>The technology supports clinical decisions rather than replacing physician judgment.</p>
<h3>Clinical trial demonstrates promising results</h3>
<p>In a randomized controlled trial evaluating the technology, researchers compared conventional cardiac testing with an AI-guided approach.</p>
<p>Among patients who underwent coronary angiography, approximately 61 per cent in the usual-care group had no significant coronary blockages.</p>
<p>In the CarDIA-AI group, that proportion fell to approximately 24 per cent.</p>
<p>The findings suggest the technology can help clinicians better identify patients who require invasive testing while directing others toward less invasive diagnostic options.</p>
<p>Importantly, the percentages refer specifically to patients who underwent angiography in each study group, rather than all patients assessed.</p>
<p>Reducing unnecessary angiograms could also lower healthcare costs and limit patients’ exposure to procedural risks.</p>
<h3>Developed using Canadian patient data</h3>
<p>CarDIA-AI was developed through collaboration between HHS cardiologists, researchers and the hospital’s Centre for Data Science and Digital Health, known as CREATE.</p>
<p>Researchers initially trained the machine-learning model using 12 years of referral data from nearly 30,000 cardiac patients treated at Hamilton General Hospital and Niagara Health’s St. Catharines Hospital.</p>
<p>The model was subsequently evaluated using information from 22 cardiac centres across Ontario to assess its broader applicability.</p>
<p>Early modelling indicated that the proportion of patients referred for angiography who might have been able to avoid the invasive procedure decreased from 44 per cent to 14 per cent when the technology was used to guide assessment.</p>
<p>The hospital also reported comparable model performance for women and men.</p>
<h3>From research to routine patient care</h3>
<p>Dr. JD Schwalm, an interventional cardiologist at Hamilton General Hospital and director of the HHS Knowledge Centre, played a leading role in developing the technology.</p>
<p>The project builds on earlier research examining how expert clinical review could improve decisions about cardiac diagnostic testing.</p>
<p>By using machine learning to support those decisions, CarDIA-AI aims to make the process more efficient and scalable.</p>
<p>Following several years of development, evaluation and implementation planning, the system is now integrated into routine clinical workflows at Hamilton General Hospital.</p>
<p>HHS believes the technology has potential for wider adoption across Ontario and Canada.</p>
<p>The initiative demonstrates how hospital-developed artificial intelligence can move beyond research into practical clinical applications, supporting more personalized care while helping healthcare systems make better use of diagnostic resources.</p>
<p>The post <a href="https://www.hospitalnews.com/hamilton-hospital-introduces-ai-tool-to-reduce-unnecessary-cardiac-procedures/">Hamilton hospital introduces AI tool to reduce unnecessary cardiac procedures</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>McMillan Pazdan Smith Names Georgia Healthcare Market Leader</title>
<link>https://edusehat.com/en/mcmillan-pazdan-smith-names-georgia-healthcare-market-leader</link>
<guid>https://edusehat.com/en/mcmillan-pazdan-smith-names-georgia-healthcare-market-leader</guid>
<description><![CDATA[ McMillan Pazdan Smith has named Channing McLeod as Healthcare Market Leader for Georgia. Based in Atlanta, McLeod has spent more than 30 years working with healthcare organizations throughout the Southeast. In a news release, the firm said he will work with Georgia’s top health systems to improve operational performance, enhance the patient experience, and support...
The post McMillan Pazdan Smith Names Georgia Healthcare Market Leader appeared first on HCO News.
The post McMillan Pazdan Smith Names Georgia Healthcare Market Leader appeared first on HCO News. ]]></description>
<enclosure url="https://hconews.com/wp-content/uploads/2026/11/mcleod-768x768.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 22:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>McMillan, Pazdan, Smith, Names, Georgia, Healthcare, Market, Leader</media:keywords>
<content:encoded><![CDATA[<p>McMillan Pazdan Smith has named Channing McLeod as Healthcare Market Leader for Georgia.</p>
<p>Based in Atlanta, McLeod has spent more than 30 years working with healthcare organizations throughout the Southeast. <a href="https://www.mcmillanpazdansmith.com/mcmillan-pazdan-smith-welcomes-channing-mcleod-as-healthcare-market-leader-for-georgia/" target="_blank" rel="noopener">In a news release</a>, the firm said he will work with Georgia’s top health systems to improve operational performance, enhance the patient experience, and support long-term goals.</p>
<p>A graduate of the Georgia Institute of Technology, McLeod is board-certified in healthcare architecture, having earned the American College of Healthcare Architects credential after passing its specialist examination.</p>
<blockquote><p><span data-teams="true">“I’m thrilled to join this dynamic team as we continue to grow and serve healthcare clients across this region,” McLeod said in an announcement from the company. </span></p></blockquote>
<p>The firm said McLeod will bring “deep expertise at a critical time for the industry when sound strategy, rapid transformation, and innovation are real differentiators.”</p>
<blockquote><p>“Channing’s leadership, experience, and understanding of the healthcare environment will further strengthen our ability to serve as a trusted advisor to our clients bringing together strategic insight, design excellence, and a collaborative approach to solving complex healthcare challenges,” said Samer Hamde, Principal, Healthcare Practice Leader, McMillan Pazdan Smith.</p></blockquote>
<p>The post <a rel="nofollow" href="https://hconews.com/2026/11/20/mcmillan-pazdan-smith-names-channing-mcleod-as-healthcare-market-leader-for-georgia/">McMillan Pazdan Smith Names Georgia Healthcare Market Leader</a> appeared first on <a rel="nofollow" href="https://hconews.com/">HCO News</a>.</p>
<p>The post <a href="https://hconews.com/2026/11/20/mcmillan-pazdan-smith-names-channing-mcleod-as-healthcare-market-leader-for-georgia/">McMillan Pazdan Smith Names Georgia Healthcare Market Leader</a> appeared first on <a href="https://hconews.com/">HCO News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Behavioral Health Luminaire</title>
<link>https://edusehat.com/en/behavioral-health-luminaire</link>
<guid>https://edusehat.com/en/behavioral-health-luminaire</guid>
<description><![CDATA[ Nightingale, a healthcare lighting brand within Acuity Brands Lighting, has introduced a behavioral health adaptation of its Observe Cloud luminaire, combining biophilic design with safety-focused construction. The recessed fixture features four lighting modes — ambient, exam, night observation and sky — to accommodate clinical needs. Sky mode creates a realistic overhead effect designed to promote...
The post Behavioral Health Luminaire appeared first on HCO News.
The post Behavioral Health Luminaire appeared first on HCO News. ]]></description>
<enclosure url="https://hconews.com/wp-content/uploads/2026/11/cloud.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 22:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Behavioral, Health, Luminaire</media:keywords>
<content:encoded><![CDATA[<p>Nightingale, a healthcare lighting brand within Acuity Brands Lighting, has introduced a behavioral health adaptation of its Observe Cloud luminaire, combining biophilic design with safety-focused construction. The recessed fixture features four lighting modes — ambient, exam, night observation and sky — to accommodate clinical needs. Sky mode creates a realistic overhead effect designed to promote a calming atmosphere in patient rooms. Available in 2-by-2-foot and 2-by-4-foot configurations, Observe Cloud incorporates IK10-compliant, abuse-resistant materials, tamper-resistant construction and sealed ceiling integration to support ligature resistance. Anti-concealment features help prevent contraband storage, while antimicrobial finishes support infection control. The luminaire balances therapeutic lighting, patient safety and operational functionality in behavioral health environments.</p>
<p><a href="https://insights.acuitybrands.com/news-releases-blog/nightingale-introduces-observe-cloud-for-behavioral-environments" target="_blank" rel="noopener">Acuity Inc.</a></p>
<p>The post <a rel="nofollow" href="https://hconews.com/2026/11/20/nightingale-introduces-observe-cloud-for-behavioral-environments/">Behavioral Health Luminaire</a> appeared first on <a rel="nofollow" href="https://hconews.com/">HCO News</a>.</p>
<p>The post <a href="https://hconews.com/2026/11/20/nightingale-introduces-observe-cloud-for-behavioral-environments/">Behavioral Health Luminaire</a> appeared first on <a href="https://hconews.com/">HCO News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Type 1 Diabetes: Setting the Scene and the Evolution of Type 1 Diabetes Care</title>
<link>https://edusehat.com/en/type-1-diabetes-setting-the-scene-and-the-evolution-of-type-1-diabetes-care</link>
<guid>https://edusehat.com/en/type-1-diabetes-setting-the-scene-and-the-evolution-of-type-1-diabetes-care</guid>
<description><![CDATA[ Type1 diabetes care has advanced from insulin discovery to continuous glucose monitoring and automated insulin delivery, yet people living with the disease still face lifelong treatment demands, serious risks, and persistent unmet needs. Endocrine Society member Tina Gupta, MD, reviews these burdens alongside existing and emerging approaches to restore insulin-producing beta-cell function. SPONSORED CONTENT BY […]
The post Type 1 Diabetes: Setting the Scene and the Evolution of Type 1 Diabetes Care appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/vertexlogoR_rgb-1-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 22:35:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Type, Diabetes:, Setting, the, Scene, and, the, Evolution, Type, Diabetes, Care</media:keywords>
<content:encoded><![CDATA[<p>Type1 diabetes care has advanced from insulin discovery to continuous glucose monitoring and automated insulin delivery, yet people living with the disease still face lifelong treatment demands, serious risks, and persistent unmet needs. Endocrine Society member Tina Gupta, MD, reviews these burdens alongside existing and emerging approaches to restore insulin-producing beta-cell function. SPONSORED CONTENT BY […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/type-1-diabetes-setting-the-scene-and-the-evolution-of-type-1-diabetes-care/">Type 1 Diabetes: Setting the Scene and the Evolution of Type 1 Diabetes Care</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Genome Writing Inserts Human X&#45;Linked Disease DNA Into Mice</title>
<link>https://edusehat.com/en/genome-writing-inserts-human-x-linked-disease-dna-into-mice</link>
<guid>https://edusehat.com/en/genome-writing-inserts-human-x-linked-disease-dna-into-mice</guid>
<description><![CDATA[ By swapping 78 kilobases of human DNA into mice, researchers recreated key features of X-linked dystonia-parkinsonism and showed that boosting TAF1 expression may counter some cellular effects.
The post Genome Writing Inserts Human X-Linked Disease DNA Into Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/01/thumbnail_GettyImages-1023097228-e1695336230594-1068x712-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 22:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Genome, Writing, Inserts, Human, X-Linked, Disease, DNA, Into, Mice</media:keywords>
<content:encoded><![CDATA[<p>By assembling and swapping in long stretches of engineered DNA with genome writing, researchers can reconstruct human disease-linked regions in another species—an approach that has now produced a mouse model of X-linked dystonia-parkinsonism (XDP), a rare neurodegenerative disorder that causes movement problems that worsen with age. The model compresses a disease course that can take decades in people into less than two months in mice, potentially accelerating studies of disease biology and treatments.</p>
<p>For the study, “<a href="https://www.cell.com/cell/abstract/S0092-8674(26)00926-8?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867426009268%3Fshowall%3Dtrue" target="_blank" rel="noopener">Genome writing reveals SVA retrotransposon consequences in X-linked dystonia-parkinsonism</a>,” published in <em>Cell</em>, an NYU Langone Health-led team rewrote part of the mouse <em>Taf1</em> gene with a corresponding 78-kilobase segment of patient-derived human <em>TAF1</em> DNA. That segment included a disease-causing SINE-VNTR-<em>Alu</em> (SVA) retrotransposon insertion. Because SVAs are found in humans but not mice, conventional mouse models cannot readily reproduce their effects.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>In mouse embryonic stem cells, the researchers found that the intronic SVA—not the hybrid human-mouse gene structure itself—reduced <em>TAF1</em> messenger RNA. Chromatin and transcriptome analyses indicated that the insertion is actively transcribed and acts as a barrier that may prematurely halt transcription, lowering TAF1 expression and triggering cell death. In mice, nervous system expression of the humanized <em>TAF1</em> allele produced severe atrophy centered in the striatum, the brain region affected in people with XDP. Male mice died within two months, versus the roughly 30 years it can take for symptoms to emerge in humans.</p>
<p>The team also used CRISPR activation, or CRISPRa, to increase <em>TAF1</em> expression in the engineered stem cells. Restoring expression rescued cell viability, offering proof of concept that boosting <em>TAF1</em> transcription could be explored as a treatment strategy. “Our experiments establish a rationale for the future development of new therapeutic approaches for XDP patients,” said senior author Jef D. Boeke, PhD, director of NYU Langone’s Institute for Systems Genetics.</p>
<p>A companion <em>Cell</em> study, titled “<a href="https://www.cell.com/cell/abstract/S0092-8674(26)01339-5" target="_blank" rel="noopener">Myelin pathology is a key feature of X-linked dystonia-parkinsonism</a>,” using the same model further implicated oligodendrocytes—the cells that produce myelin around neuronal axons—rather than neurons alone in XDP. The researchers also detected myelin loss in banked human XDP brain tissue, a feature reportedly missed in earlier studies.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The work positions genome writing as a way to build models for diseases driven by large or human-specific DNA elements that are difficult to reproduce through conventional editing. Important questions remain, including what factors drive variable progression rates in XDP, whether raising TAF1 levels can safely produce durable benefits in animals, and how broadly the method can be applied to other rare diseases.</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/genome-writing-inserts-human-x-linked-disease-dna-into-mice/">Genome Writing Inserts Human X-Linked Disease DNA Into Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Alberta hospital introduces high&#45;tech simulation lab to strengthen rural healthcare training</title>
<link>https://edusehat.com/en/alberta-hospital-introduces-high-tech-simulation-lab-to-strengthen-rural-healthcare-training</link>
<guid>https://edusehat.com/en/alberta-hospital-introduces-high-tech-simulation-lab-to-strengthen-rural-healthcare-training</guid>
<description><![CDATA[ New facility at Wainwright Health Centre provides hands-on clinical training for nursing students, physicians and healthcare teams without the need to travel to larger urban centres. Healthcare professionals and nursing students in rural Alberta are gaining access to advanced clinical simulation technology through a new training laboratory at Wainwright Health Centre. The facility, which opened […]
The post Alberta hospital introduces high-tech simulation lab to strengthen rural healthcare training appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/img-alexander-and-norah.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 22:00:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alberta, hospital, introduces, high-tech, simulation, lab, strengthen, rural, healthcare, training</media:keywords>
<content:encoded><![CDATA[<p>New facility at Wainwright Health Centre provides hands-on clinical training for nursing students, physicians and healthcare teams without the need to travel to larger urban centres.</p>
<p>Healthcare professionals and nursing students in rural Alberta are gaining access to advanced clinical simulation technology through a new training laboratory at Wainwright Health Centre.</p>
<p>The facility, which opened in October and was highlighted in a November 19 Alberta Health Services feature, provides a realistic hospital environment where healthcare workers can practise clinical procedures, respond to simulated emergencies and strengthen teamwork without putting patients at risk.</p>
<p>Located in a specially converted trailer adjacent to the health centre, the laboratory incorporates high-tech clinical equipment, patient manikins and audiovisual technology that allows clinical scenarios to be observed and reviewed.</p>
<h3>Preparing for complex medical emergencies</h3>
<p>The simulation laboratory allows healthcare teams to rehearse a range of medical situations, including uncommon but potentially life-threatening emergencies.</p>
<p>Participants can practise responding to changing patient conditions, monitoring vital signs and coordinating clinical decisions in a controlled setting. Exercises can also be reviewed afterward, providing opportunities to identify improvements in communication, teamwork and clinical performance.</p>
<p>Jason Laberge, director of the Human Factors and eSIM Provincial Simulation Program with Alberta Health Services, emphasized the importance of practising less-frequent, high-acuity medical events to help healthcare professionals maintain their skills.</p>
<p>Simulation training is particularly valuable in rural healthcare settings, where clinical teams may encounter certain complex emergencies less frequently than their counterparts at larger urban hospitals.</p>
<h3>Supporting the rural nursing workforce</h3>
<p>The laboratory will also serve students enrolled in the University of Calgary’s Nursing Program Rural Community Route, which provides nursing education opportunities closer to rural communities.</p>
<p>The Wainwright program welcomed its first cohort in 2021, establishing a local pathway for students pursuing nursing careers.</p>
<p>The new simulation space expands that training environment by allowing students to gain practical experience with clinical equipment and realistic patient scenarios.</p>
<p>Dr. Catherine Laing, dean of the University of Calgary’s Faculty of Nursing, has highlighted the importance of providing rural nursing students with learning opportunities comparable to those available in urban centres.</p>
<p>For healthcare facilities facing workforce recruitment and retention challenges, investments in local education and professional development can help support a sustainable rural workforce.</p>
<h3>Community investment makes project possible</h3>
<p>The Wainwright and District Health Foundation contributed approximately $250,000 toward the purchase and conversion of the trailer into a dedicated simulation facility.</p>
<p>The project also benefited from collaboration between Alberta Health Services, the University of Calgary and local supporters.</p>
<p>Its development reflects the role community fundraising can play in introducing new healthcare training infrastructure outside major urban centres.</p>
<p>The laboratory is available to nursing students as well as existing hospital staff and physicians, allowing the facility to support both new professionals and continuing clinical education.</p>
<h3>Improving readiness and patient safety</h3>
<p>Clinical simulation is increasingly being used by hospitals to strengthen staff preparedness, particularly for events that require rapid assessment, coordinated interventions and effective communication among healthcare professionals.</p>
<p>By creating opportunities to practise and learn from simulated emergencies, the Wainwright facility aims to strengthen clinical readiness while reducing the risks associated with learning during actual patient care.</p>
<p>Although patient outcome improvements have not yet been reported for the new facility, the project provides an example of how rural hospitals can use technology and local partnerships to improve access to advanced healthcare education.</p>
<p>For Wainwright and surrounding communities, the new laboratory represents an investment in the people delivering healthcare, as well as the infrastructure supporting them.</p>
<div><a href="https://www.albertahealthservices.ca/news/Page20010.aspx?utm_source">Alberta Health Services</a></div>
<p>The post <a href="https://www.hospitalnews.com/alberta-hospital-introduces-high-tech-simulation-lab-to-strengthen-rural-healthcare-training/">Alberta hospital introduces high-tech simulation lab to strengthen rural healthcare training</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>One in five ORE hopefuls have tried over six times to secure a place</title>
<link>https://edusehat.com/en/one-in-five-ore-hopefuls-have-tried-over-six-times-to-secure-a-place</link>
<guid>https://edusehat.com/en/one-in-five-ore-hopefuls-have-tried-over-six-times-to-secure-a-place</guid>
<description><![CDATA[ A survey on the impact of the Overseas Registration Exam (ORE) booking system revealed that almost one in five (19%) hopefuls had tried more than six times to book a place to sit the Part 1 examination. The majority of those surveyed (82%) had been attempting to sit the exam for more than a year,… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/ORE.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 18:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>One, five, ORE, hopefuls, have, tried, over, six, times, secure, place</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>A survey on the impact of the Overseas Registration Exam (ORE) booking system revealed that almost one in five (19%) hopefuls had tried more than six times to book a place to sit the Part 1 examination. </strong></p>



<p>The majority of those surveyed (82%) had been attempting to sit the exam for more than a year, with more than half waiting for over two years (53%). The General Dental Council (GDC) recently estimated that the waitlist for the exam sits at around 8,000.</p>



<p><a href="https://dentistry.co.uk/2026/07/03/ore-exam-booking-failure-applicants-without-seat/">Technical difficulties reported after recent booking windows</a> were echoed in the survey. Respondents described endless loading (45%), error messages (35%), blank pages (31%), and forced logouts (16%).</p>



<p>One described the process as ‘extremely stressful and unreliable’. They said: ‘Repeated system errors, technical failures, and the lack of a fair booking process made it very difficult to secure an exam place.’</p>



<p>The GDC has said that it will be <a href="https://dentistry.co.uk/2026/07/08/gdc-to-fix-troubled-ore-booking-system-with-new-candidate-portal/">implementing a new portal for exams</a> scheduled from the beginning of 2027.</p>



<h2 class="wp-block-heading">‘Treated like literal guinea pigs’</h2>



<p>Almost all of the ORE hopefuls reported a negative effect of the process on their lives. Stress, anxiety or mental-health effects were described by 93%, while 85% said major life plans were delayed, 84% reported financial strain, and 37% cited visa instability.</p>



<p>A candidate said: ‘Waiting for the exam has me stuck… it’s taking a toll on my family, health, and mental health.’</p>



<p>The results also pointed to an impact on the dental workforce. While 65% were working in dentistry but not as a dentist, 15% said they were unemployed or in full time study. </p>



<p>The research analysis provided to <em>Dentistry</em> used a small sample of 74 professionals, so may not be representative of all ORE candidates.</p>



<p>In October, the <a href="https://dentistry.co.uk/2026/10/21/ore-pass-rate-drops-by-29/">pass rate for September’s sitting of Part 2 of the ORE dropped by 29%</a> on the previous one. This was the first examination under new contractual arrangements, containing ‘refreshed assessment content to reflect contemporary clinical practice’. The correct guidance for the new assessment was released on 4 August, five weeks before the exam was scheduled.</p>



<p>One candidate told <em>Dentistry</em>: ‘Many of us have spent years to just get a slot for this exam and when we finally did, we have been treated like literal guinea pigs.’</p>



<p>The GDC said it understood failing the exam would be disappointing for candidates, but noted that ‘analysis shows that all four components performed reliably, that examiners marked consistently, and that the pass standard was set appropriately’.</p>



<p>The candidate added: ‘The real victims are the students who have lost out financially and mentally, yet have had no answers forthcoming.’</p>



<h2 class="wp-block-heading">Have you also struggled to book an ORE place? Tell us about your experience:</h2>





 
<p>
  Having trouble viewing the survey?
<a href="https://survey.hsforms.com/2CwZIdHZvTgCXvPHBCggLdQtdfv9" target="_blank" rel="noopener noreferrer">
    Open the survey in a new tab
</a>
</p>



<p><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</em></a></p>



<p></p>]]> </content:encoded>
</item>

<item>
<title>COMLEX&#45;USA Level 3 Is Becoming a One&#45;Day Exam in January 2027</title>
<link>https://edusehat.com/en/comlex-usa-level-3-is-becoming-a-one-day-exam-in-january-2027</link>
<guid>https://edusehat.com/en/comlex-usa-level-3-is-becoming-a-one-day-exam-in-january-2027</guid>
<description><![CDATA[ What Residents Need to Know  COMLEX-USA Level 3 is the final examination in the COMLEX-USA sequence and a required component of osteopathic physician licensure in the United States. Beginning in January 2027, Level 3 will transition to a single-day examination with approximately half the number of questions and Clinical Decision-Making (CDM) cases. While this change […]
The post COMLEX-USA Level 3 Is Becoming a One-Day Exam in January 2027 appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/11/pexels-cottonbro-7428217-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 18:50:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>COMLEX-USA, Level, Becoming, One-Day, Exam, January, 2027</media:keywords>
<content:encoded><![CDATA[<h2><b>What Residents Need to Know </b></h2>
<p><span>COMLEX-USA Level 3 is the final examination in the COMLEX-USA sequence and a required component of osteopathic physician licensure in the United States. Beginning in January 2027, <a href="https://elitemedicalprep.com/comlex-level-3-the-complete-guide/">Level 3</a> will transition to a single-day examination with approximately half the number of questions and Clinical Decision-Making (CDM) cases. While this change may ease the burden on residents balancing clinical responsibilities, the revised format does not diminish the importance of thorough, comprehensive preparation.</span></p>
<p> </p>
<h2><b>Understanding the January 2027 Format Change </b></h2>
<p><span>Previously, COMLEX-USA Level 3 was administered over two days within a 14-day testing window and consisted of 420 single-best-answer multiple-choice questions and 26 Clinical Decision-Making (CDM) cases. Each testing block included 70 multiple-choice questions or 13 CDM cases, followed by a scheduled break.</span></p>
<p> </p>
<p><span>Beginning January 13, 2027, Level 3 will transition to a single-day examination consisting of 240 multiple-choice questions and 16 CDM cases. Multiple-choice question blocks will be reduced to 40 questions, followed by an optional break. This represents a substantial reduction in examination length, bringing both advantages and potential challenges.</span></p>
<p> </p>
<p><span>One of the primary benefits is greater flexibility for residents balancing clinical responsibilities. Scheduling a two-day examination and arranging time away from clinical duties can be challenging during residency. Additionally, developing the stamina to sustain performance across two full testing days was previously a significant component of exam preparation. <a href="https://elitemedicalprep.com/comlex-level-3-changes-what-to-expect-and-how-to-prepare/">The single-day format</a> may be more familiar and manageable for examinees, particularly given that CDM cases often require less than the allotted time to complete.</span></p>
<p> </p>
<h4><b>The examination blueprint</b></h4>
<p><span>Importantly, </span><b>the examination blueprint itself is not changing.</b><span> Content areas will continue to be assessed according to the previously established blueprint percentages, despite the reduction in total questions and cases. The examination will continue to assess clinical knowledge, diagnosis, evaluation, treatment, and management through single-best-answer multiple-choice questions and interactive CDM cases.</span></p>
<p> </p>
<p><span>In my experience, Level 3 content felt very similar to Level 2, with a slightly greater emphasis on diagnostic workups and clinical management. CDM cases simulate evolving clinical scenarios in which additional information becomes available as the patient is evaluated. Although the clinical reasoning involved may feel familiar, the format itself can be challenging, particularly when learning how to enter responses appropriately. This differs from the NBME-style cases used in many study resources geared toward USMLE Step 3.</span></p>
<p> </p>
<p><span>For additional guidance and examples of CDM question formats, refer to the </span><a href="https://www.nbome.org/assessments/comlex-usa/practice-resources/clinical-decision-making-cases-tutorial/"><span>NBOME Clinical Decision-Making Cases Tutorial</span></a><span>.</span></p>
<table>
<tbody>
<tr>
<td><b>Feature</b></td>
<td><b>Current format (through Dec. 2026)</b></td>
<td><b>New format (starting Jan. 13, 2027)</b></td>
</tr>
<tr>
<td><span>Testing days</span></td>
<td><span>2 days</span></td>
<td><span>1 day</span></td>
</tr>
<tr>
<td><span>Multiple-choice questions</span></td>
<td><span>420</span></td>
<td><span>240</span></td>
</tr>
<tr>
<td><span>CDM cases</span></td>
<td><span>26</span></td>
<td><span>16</span></td>
</tr>
<tr>
<td><span>Testing sessions</span></td>
<td><span>Four 3.5-hour sessions across two days (14 hours total)</span></td>
<td><span>Four 2-hour sessions in one day (8 hours total)</span></td>
</tr>
<tr>
<td><span>Clinical decision-making</span></td>
<td><span>Separate CDM sessions</span></td>
<td><span>Final session, divided into two sections</span></td>
</tr>
</tbody>
</table>
<p> </p>
<h2><b>Preparing for Clinical Decision-Making (CDM) Cases</b></h2>
<h3><b>What CDM cases assess</b></h3>
<p><span>The CDM cases simulate real-world patient management by requiring examinees to navigate several stages of clinical decision-making. This begins with data acquisition, including selecting appropriate history questions, physical examination maneuvers, and diagnostic tests. Next, examinees must demonstrate data interpretation by developing a differential diagnosis and interpreting clinical findings and test results. Finally, they must apply treatment and management principles by selecting appropriate interventions, providing patient counseling, and establishing follow-up plans.</span></p>
<p> </p>
<h3><b>Practice clinical reasoning, not just memorization</b></h3>
<p><span>One aspect of CDM practice cases that I initially overlooked was the clinical setting in which the patient was presented. Recognizing the setting should influence your approach to clinical decision-making. For example, cases beginning in a primary care setting should prompt you to consider preventive care, patient communication, medical ethics, and <a href="https://elitemedicalprep.com/how-to-study-for-omm-osteopathic-manipulative-medicine-questions/">osteopathic manipulative treatment (OMT)</a>. </span></p>
<p> </p>
<p><span>In contrast, cases presented in an emergency department require a shift in priorities toward identifying unstable patients, recognizing life-threatening conditions, and initiating timely interventions. Also, focus on selecting diagnostic tests and imaging studies that will meaningfully influence clinical management rather than ordering every potentially relevant study. Developing this judgment is an important part of both CDM case performance and real-world clinical practice.</span></p>
<p> </p>
<h2><b>Building a Study Plan Around Residency </b></h2>
<h3><b>Start with a realistic timeline</b></h3>
<p><span>Adequate preparation is essential for a successful exam day, but preparing for Level 3 presents unique challenges. Unlike Levels 1 and 2, you are now balancing studying with night shifts, call schedules, and potentially long clinical rotations. Setting realistic expectations for what you can accomplish each day and starting practice questions early are key to developing a sustainable study routine.</span></p>
<p> </p>
<p><span>If a particular study method worked well for you during Levels 1 or 2, there is no reason to completely reinvent your approach. Instead, consider maintaining the same resources and <a href="https://elitemedicalprep.com/how-to-painlessly-prepare-for-usmle-step-3-comlex-level-3/">study strategies</a> while reducing your daily question volume. It can be easy to feel overwhelmed or question whether you are adequately preparing when comparing your Level 3 study schedule to previous exams. However, you no longer have a dedicated study period. You may be coming home exhausted after a 12-hour shift, only to wake up before sunrise to do it all over again. There is only so much time you can realistically dedicate to studying.</span></p>
<p> </p>
<h4><strong>Strategies</strong></h4>
<p><span><strong>Here are a few strategies</strong> that helped me maintain consistent studying, even on particularly busy days. Remember, doing something is better than doing nothing!</span></p>
<ul>
<li aria-level="1"><b>Complete questions before your shift:</b><span> Even 10 timed, untutored questions can be worthwhile. If time is limited, save reviewing the explanations for after your shift.</span></li>
<li aria-level="1"><b>Take advantage of downtime:</b><span> If you are on a rotation with more downtime, try completing sets of 10 questions in tutor mode throughout the day.</span></li>
<li aria-level="1"><b>Utilize your lunch break:</b><span> If your rotation allows for a dedicated lunch break, use some of that time to complete and review a question set.</span></li>
<li aria-level="1"><b>Make the most of your days off:</b><span> It is tempting to use these days exclusively for rest (and sometimes you absolutely should!). However, days off are also an opportunity to complete one or two longer question blocks and build the stamina needed for exam day.</span></li>
</ul>
<p> </p>
<h4><strong>Final considerations</strong></h4>
<p><span>Ultimately, preparation for Levels 1 and 2 can be relatively structured, whereas Level 3 requires considerably more flexibility. When possible, schedule your examination after a lighter clinical rotation, allowing time to complete longer practice blocks and review any remaining content before test day. Build flexibility into your study schedule to accommodate unexpected clinical responsibilities, and avoid sacrificing sleep to meet an arbitrary daily question goal.</span></p>
<p> </p>
<p><span>Consistency and deliberate studying are more sustainable than forcing yourself to complete a full question block every day simply because that is what you were accustomed to during previous examinations. The goal is to develop a study routine that works with a busy residency schedule. </span></p>
<p> </p>
<h2><b>Preparing for the One-Day Testing Experience </b></h2>
<p><span>Although the one-day format reduces the number of separate testing days, it still requires preparation for a full day of sustained cognitive effort. This can be particularly challenging for residents who have limited opportunities to practice completing multiple question blocks in a single sitting. I highly recommend scheduling your examination after a lighter clinical rotation, when you can dedicate several days to longer study sessions and simulate the demands of exam day.</span></p>
<p> </p>
<p><span>Use these practice sessions to work through multiple timed blocks with planned breaks. This is also an opportunity to determine what works best for you in terms of snacks, hydration, and break timing. Having a plan before test day can help minimize distractions and allow you to focus on the examination itself.</span></p>
<p> </p>
<p><span>One positive aspect of my Level 3 experience was how quickly the CDM cases seemed to move. They are more interactive than traditional multiple-choice questions, which helped break up the monotony of the examination. I also found that they moved relatively quickly because multiple questions often stem from the same clinical scenario or stage of patient evaluation. Many examinees find themselves finishing earlier than anticipated, in part because the CDM cases may take less time than the allotted testing time.</span></p>
<p> </p>
<p><span>Finally, do not overlook the logistical aspects of test day. Confirm your scheduled examination date, testing-center requirements, and arrival time well in advance. Account for traffic, parking, and any other potential delays so that you are not adding unnecessary stress to an already demanding day.</span></p>
<p> </p>
<p><span>The best preparation is to complete timed question blocks consistently and, as you get closer to your examination, incorporate practice sessions that approximate the actual four-session testing format.</span></p>
<h2><b>Common Preparation Mistakes to Avoid</b></h2>
<p><span>Level 3 may feel more manageable than Levels 1 and 2, particularly with the transition to a shorter, single-day examination. However, adequate preparation can be challenging when balancing a demanding residency schedule without a dedicated study period. Over the years, I have seen both my students and myself make several common mistakes when preparing for these examinations:</span></p>
<ul>
<li aria-level="1"><b>Neglecting CDM cases: </b><span>Strong multiple-choice performance does not necessarily translate into proficiency with the interactive CDM format. The NBOME also has specific guidelines and expectations that differ from NBME-style cases. Make sure you practice using NBOME-specific resources and familiarize yourself with the examination policies and instructions available online.</span></li>
<li aria-level="1"><b>Using too many <a href="https://elitemedicalprep.com/free-downloads/">study resources</a>:</b><span> This is a common mistake across all board examinations, but it can be especially detrimental when preparing for Level 3. With limited study time, avoid spreading yourself too thin across multiple question banks and resources. Choose one primary question bank that you feel confident using and prioritize thoroughly reviewing the questions you complete. Understanding why an answer is correct or incorrect is often more valuable than simply increasing your question count.</span></li>
<li aria-level="1"><b>Overloading your schedule or studying without a plan:</b><span> Unrealistic study expectations can quickly undermine consistency, sleep, and even your performance during residency. You likely will not be able to study with the same intensity or structure that you did for Level 1, and that is okay. A realistic, flexible schedule that allows you to accomplish something each day is much more sustainable than an overly ambitious plan that you cannot maintain. Even small amounts of consistent, deliberate studying can add up over time.</span></li>
</ul>
<p> </p>
<p><span>To put this into perspective, I spent the most time preparing for Level 1, where I scored a 730, and the least time preparing for Level 3, where I scored a 972. This is not to suggest that Level 3 requires minimal preparation, but rather that effective studying, familiarity with the examination format, and clinical experience can make a significant difference. The goal is not to replicate your Level 1 study schedule; it is to develop an approach that works for you as a resident physician.</span></p>
<p> </p>
<h2><b>Prepare Strategically for the Updated Exam </b></h2>
<p><span>As COMLEX-USA Level 3 transitions to a one-day examination, residents should recognize that a shorter test does not eliminate the need for thoughtful, comprehensive preparation. Success requires a structured but flexible study plan that prioritizes clinical decision-making, familiarity with the CDM format, and consistent practice. Ultimately, the most effective preparation strategy is one that strengthens your clinical knowledge and reasoning skills while remaining realistic and sustainable within the demands of residency.</span></p>
<p> </p>
<p>Preparing for COMLEX Level 3 while balancing residency responsibilities can be challenging. Our <a href="https://elitemedicalprep.com/comlex-level-3-tutoring/">COMLEX Level 3 tutors</a> can help you create a personalized study plan that fits your schedule. Target your knowledge gaps and strengthen your clinical reasoning. Refine your approach to CDM cases and develop effective test-taking strategies for the updated exam format.</p>
<p>The post <a href="https://elitemedicalprep.com/comlex-usa-level-3-is-becoming-a-one-day-exam/">COMLEX-USA Level 3 Is Becoming a One-Day Exam in January 2027</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Photonence expands its medical aesthetics portfolio</title>
<link>https://edusehat.com/en/photonence-expands-its-medical-aesthetics-portfolio</link>
<guid>https://edusehat.com/en/photonence-expands-its-medical-aesthetics-portfolio</guid>
<description><![CDATA[ 
Photonence is strengthening its market presence and expanding its portfolio across emerging segments of the medical aesthetics and wellness industry. Building on its strong position in skin lifting and tightening, the company is now looking to tap into newer opportunities in post-procedure care, stretch mark treatments and gynaecological aesthetics. The company currently has a presence […]
The post Photonence expands its medical aesthetics portfolio appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/20154509/Medical-Aesthetics.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 18:15:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Photonence, expands, its, medical, aesthetics, portfolio</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/20154509/Medical-Aesthetics.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/20154509/Medical-Aesthetics.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/20154509/Medical-Aesthetics-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p align="LEFT"><a name="Bookmark"></a> <span><span><span>Photonence is strengthening its market presence and expanding its portfolio across emerging segments of the medical aesthetics and wellness industry. Building on its strong position in skin lifting and tightening, the company is now looking to tap into newer opportunities in post-procedure care, stretch mark treatments and gynaecological aesthetics.</span></span></span></p>
<p><span><span><span>The company currently has a presence in skin lifting and tightening, as well as body contouring. According to the company, skin lifting and tightening accounts for its largest share of business in India. Demand for body contouring treatments has also increased over the past few years, driven by interest in non-invasive and minimally invasive procedures.</span></span></span></p>
<p><span><span><span>In terms of geographical distribution, North India contributes approximately 40 per cent of the company’s market presence, followed by West and South India at around 25 per cent each. East India accounts for the remaining 10 per cent.</span></span></span></p>
<p><span><span><span>The medical aesthetics market has traditionally seen demand for procedures such as laser hair reduction and medi-facials. However, the range of treatments being considered by clinics and practitioners is expanding, with greater attention being paid to post-procedure recovery, skin health and patient outcomes.</span></span></span></p>
<p><span><span><span>Against this backdrop, Photonence is evaluating opportunities in post-procedure care, including technologies and solutions aimed at supporting recovery and reducing downtime following aesthetic procedures.</span></span></span></p>
<p align="LEFT"><span><span><span>Ashish Jha, Director-Marketing, Photonence India said, “The company is also evaluating expansion into stretch mark treatments and gynaecological aesthetics, including solutions addressing concerns such as post-menopausal vaginal dryness and intimate wellness”.</span></span></span></p>
<p align="LEFT"><span><span><span>With these strategic initiatives, Photonence aims to evolve from being an equipment provider in established aesthetics categories to a broader technology partner for clinics and medical practitioners. Its focus will remain on bringing advanced global technologies to India, enabling practitioners to expand their treatment offerings and making newer aesthetic and wellness solutions more accessible to the Indian market.</span></span></span></p>
<p>The post <a href="https://www.expresspharma.in/photonence-expands-its-medical-aesthetics-portfolio/">Photonence expands its medical aesthetics portfolio</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Advancing skin longevity through research and clinical validation</title>
<link>https://edusehat.com/en/advancing-skin-longevity-through-research-and-clinical-validation</link>
<guid>https://edusehat.com/en/advancing-skin-longevity-through-research-and-clinical-validation</guid>
<description><![CDATA[ 
What will the fresh investment enable in terms of research priorities, formulation development and clinical validation? The investment allows us to deepen our research capabilities, particularly in photobiology: understanding how different wavelengths of light interact with skin, and translating that knowledge into better photoprotection and care for pigmentation and skin ageing. We also want to […]
The post Advancing skin longevity through research and clinical validation appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/20160043/Dr-Renita-Rajan-Founder-CHOSEN.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 18:15:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Advancing, skin, longevity, through, research, and, clinical, validation</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/20160043/Dr-Renita-Rajan-Founder-CHOSEN.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/20160043/Dr-Renita-Rajan-Founder-CHOSEN.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/20160043/Dr-Renita-Rajan-Founder-CHOSEN-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p align="LEFT"><span><span><span><b>What will the fresh investment enable in terms of research priorities, formulation development and clinical validation?</b></span></span></span></p>
<p align="LEFT"><span><span><span>The investment allows us to deepen our research capabilities, particularly in photobiology: understanding how different wavelengths of light interact with skin, and translating that knowledge into better photoprotection and care for pigmentation and skin ageing.</span></span></span></p>
<p align="LEFT"><span><span><span>We also want to strengthen the exchange of knowledge between CHOSEN and our partner clinics. Dermatologists bring observations from everyday practice, including unmet needs, treatment responses and the difficulties people have in sustaining a routine. Our research can investigate these questions and bring the findings back into clinical practice.</span></span></span></p>
<p align="LEFT"><span><span><span>The funding gives us greater capacity to connect these observations with formulation development and clinical validation. The Centre of Excellence is an important next step in making that exchange more systematic.</span></span></span></p>
<p align="LEFT"><span><span><span><b>How will the Centre of Excellence strengthen your R&D capabilities and support clinically validated formulations?</b></span></span></span></p>
<p align="LEFT"><span><span><span>The Centre of Excellence is intended to bring dermatologists more deeply into the research and development process, beginning with the questions we choose to investigate.</span></span></span></p>
<p align="LEFT"><span><span><span>A dermatologist’s contribution extends well beyond evaluating a finished product. It includes identifying a clinical need, helping define the formulation brief, selecting meaningful study outcomes and interpreting whether the benefit is useful in practice.</span></span></span></p>
<p align="LEFT"><span><span><span>We see this as a continuing exchange. Observations from partner clinics can inform our research priorities, while findings from our studies can support better informed product use and clinical protocols. It also creates opportunities to learn across different settings and populations.</span></span></span></p>
<p align="LEFT"><span><span><span>For CHOSEN, the aim is to build on our clinical foundation and develop more Indian authored research, with formulations shaped by the needs of the people who use them.</span></span></span></p>
<p align="LEFT"><span><span><span><b>How is the Indian cosmeceutical industry evolving in skin ageing, pigmentation and preventive skincare?</b></span></span></span></p>
<p align="LEFT"><span><span><span>The conversation is expanding from addressing an existing concern to understanding how skin changes over time and what we can do earlier. Prejuvenation is part of this shift: taking sensible preventive steps before changes become more established.</span></span></span></p>
<p align="LEFT"><span><span><span>An exposome lens makes this approach more relevant. Sun exposure, climate, pollution, sleep, stress and other influences form the context in which a skincare routine has to work. For Indian skin, this also means giving pigmentation, barrier health and tolerability greater attention within the ageing conversation.</span></span></span></p>
<p align="LEFT"><span><span><span>There is also a need for better options between everyday skincare and procedures. People may notice changes in firmness or facial contours and want to begin addressing them at home before they feel ready for a procedure. That is the space we are exploring with CHOSEN Sculpt. It gives people an earlier point of entry into care, with expectations driven from actual clinical studies.</span></span></span></p>
<p align="LEFT"><span><span><span><b>How is skin longevity changing R&D in active ingredients, formulation technologies and efficacy assessment?</b></span></span></span></p>
<p align="LEFT"><span><span><span>Skin longevity requires us to think about both the benefit and duration of exposure. If we are developing products that people may use for years, we need to ask how effectively they work now and how appropriate they are for sustained use.</span></span></span></p>
<p align="LEFT"><span><span><span>That brings safety over the long term, including the potential for endocrine disruption, into the research conversation. Ingredient selection needs to consider concentration, absorption, patterns of exposure and the available toxicological evidence, alongside efficacy. Formulation technologies should help us achieve a meaningful benefit with an appropriate exposure and tolerability profile.</span></span></span></p>
<p align="LEFT"><span><span><span>Our ambition is care that is effective today and remains safe throughout its intended use. That requires continuing assessment as evidence develops.</span></span></span></p>
<p align="LEFT"><span><span><span>Skinspan (the years skin remains healthy and functions well) only matters when lifespan (the total length of a person’s life) is factored into the thinking. It makes little sense for skin to look younger if the health of the rest of the body is being compromised. Maintaining the appearance and function of skin has to support the health of the whole person. That is the essence of the youthful <b>and</b> holistic longevity we pursue at CHOSEN.</span></span></span></p>
<p align="LEFT"><span><span><span><b>Which advanced actives have the potential to make a meaningful difference?</b></span></span></span></p>
<p align="LEFT"><span><span><span>Our work spans signalling peptides, plant extracts such as Pycnogenol®, DMAE and advances in photoprotection, including bemotrizinol. What interests me is how we can translate these ingredients into formulations that meet a specific clinical need.</span></span></span></p>
<p align="LEFT"><span><span><span>We introduced Pycnogenol® into India and have built the widest range of oral and topical formulations containing it, including several first and only offerings. This reflects our interest in taking well characterised molecules through thoughtful formulation development, to serve outcomes relevant to the Indian exposome.</span></span></span></p>
<p align="LEFT"><span><span><span>Innovation also comes from understanding where an established ingredient needs a different formulation. Even a familiar active such as tranexamic acid requires a distinct approach when we are developing a serum for pigmentation in sensitive skin damaged by steroid and skin lightening cream use. The formulation has to account for the compromised barrier, tolerability and the other ingredients that skin can comfortably accommodate. That is a different brief from using the same tranexamic acid in a multipurpose pigmentation serum.</span></span></span></p>
<p align="LEFT"><span><span><span>As a doctor, you begin with the person in front of you. Their needs guide the choice of ingredient, the formulation and how you assess its benefit. Everything we develop has to serve that person. The same thinking guides our work with signalling peptides, DMAE and sunscreen filters.</span></span></span></p>
<p align="LEFT"><span><span><span><b>What are the challenges in validating cosmeceuticals, and how can the industry strengthen evidence and safety?</b></span></span></span></p>
<p align="LEFT"><span><span><span>Clinical studies are one of CHOSEN’s strengths, and an area in which we intend to keep investing as a point of differentiation.</span></span></span></p>
<p align="LEFT"><span><span><span>Consumer research tells us whether a product is acceptable: whether people like its texture, find it comfortable and are willing to continue using it. Those findings matter because even a well designed formulation needs to fit into daily life. Clinical studies answer a further question: does the product deliver a meaningful, measurable benefit?</span></span></span></p>
<p align="LEFT"><span><span><span>That requires relevant endpoints, appropriate study parameters and a duration suited to the claim. A pigmentation claim needs pigmentation assessment; a firmness claim needs measures that can substantiate changes in firmness. Satisfaction alone cannot establish either.</span></span></span></p>
<p align="LEFT"><span><span><span>The industry can strengthen confidence by making the relationship between the study and the claim clearer, while assessing safety and tolerability with equal care. For us, clinical validation is part of product development, informing what we make, how we improve it and what we can responsibly say about it.</span></span></span></p>
<p>The post <a href="https://www.expresspharma.in/advancing-skin-longevity-through-research-and-clinical-validation/">Advancing skin longevity through research and clinical validation</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>SkinBB develops Vybie skin intelligence platform in India</title>
<link>https://edusehat.com/en/skinbb-develops-vybie-skin-intelligence-platform-in-india</link>
<guid>https://edusehat.com/en/skinbb-develops-vybie-skin-intelligence-platform-in-india</guid>
<description><![CDATA[ 
Platform combines environmental data, AI-led skin analysis and skincare tools to help consumers understand their skin and make informed choices
The post SkinBB develops Vybie skin intelligence platform in India appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/04/30183622/GettyImages-1179214915-e1763466693590.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 18:15:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>SkinBB, develops, Vybie, skin, intelligence, platform, India</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="338" src="https://cdn.expresspharma.in/wp-content/uploads/2020/04/30183622/GettyImages-1179214915-e1763466693590.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async"></div><p><span>Skin Beyond Borders (SkinBB) is positioning Vybie, The Living Skin Intelligence<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, as a technology platform developed in India to help consumers understand their skin in relation to their individual characteristics and surrounding environment.</span></p>
<p><span>The platform brings together environmental intelligence, AI-led skin insights and skincare tools. It has been developed with Indian skin and local conditions in mind.</span></p>
<p><span>The launch comes amid an increase in demand for skincare products, treatments and routines during the wedding season. From brides and grooms preparing for their wedding to families seeking skincare recommendations, skin preparation often involves last-minute experimentation, trending products and advice from multiple sources, rather than an understanding of individual skin needs.</span></p>
<p><span>Through its Hyper Local-Hyper Personalised (HLHP) approach, Vybie connects environmental factors such as UV levels, humidity, temperature and air quality with individual skin information. Its selfie-based face analysis provides users with insights into their skin, while a 30-second daily skin log allows them to record changes and track their skin journey over time. The platform aims to help consumers move beyond generic skincare advice and make decisions based on their skin and location.</span></p>
<p><span>“Skin intelligence needs to go beyond identifying a skin concern or recommending a product. It is about understanding the relationship between an individual’s skin, the environment and the choices they make every day. With Vybie, we are bringing these elements together through an indigenous technology platform that aims to make skin understanding more contextual and personalised. Our larger vision is to build an ecosystem that helps consumers engage with their skin continuously, rather than only when a particular concern arises,” said Ajit Marathe, Founder and Chief Innovation Officer, Skin Beyond Borders (SkinBB).</span></p>
<p><span>Vybie’s ecosystem includes tools that address different aspects of the consumer skincare journey. The Skin Friendliness Index (SFI) uses environmental parameters to help users understand prevailing conditions and their potential relevance to skin health. LabelLooker enables consumers to examine skincare product ingredients, while Ingredipedia provides information on skincare ingredients.</span></p>
<p><span>These tools are complemented by SkinBB’s Product Review and Approval Committee (PRAC), which provides a product review layer, and a network of registered dermatologists who can offer guidance.</span></p>
<p><span>The technology is also being applied to consumer needs through initiatives such as the Vybie Glow Plus Plan, developed around the wedding journey. The plan aims to encourage couples to begin skin preparation early and access guidance from registered dermatologists. It is intended to help them make informed choices about routines, products and skincare concerns before the wedding and beyond.</span></p>
<p><span>SkinBB is also using Vybie as a foundation for consumer education and awareness initiatives. Its wedding-season campaign, ‘Haan Se, Honeymoon Tak’, uses three AI-animated films featuring a fictional couple, Riya and Kabir, to address the pressures and confusion surrounding wedding-related skin preparation.</span></p>
<p><span>Through humour and wedding situations, the films address last-minute skincare experimentation, advice from relatives and the pressure to achieve camera-ready skin. They also encourage consumers to seek informed guidance.</span></p>
<p><span>“Our focus is to make skin intelligence accessible and relevant to everyday consumers. With Vybie, we want people to look beyond products and understand the factors that influence their skin, from their immediate environment to their individual skin needs. Wedding season provides an opportunity to bring this conversation to the forefront, as people become more conscious of their appearance and skin preparation. Through our digital campaigns and experiential initiatives, we aim to simplify skin education and encourage consumers to make more informed choices. We see technology not just as a tool for personalisation, but also as a powerful way to build awareness and change how people engage with skincare,” said Supriya Marathe, Chief Marketing Officer, Skin Beyond Borders (SkinBB).</span></p>
<p><span>SkinBB’s vision is to develop Vybie into a Skin Intelligence Ecosystem connecting environmental data, individual skin insights, ingredient information, product evaluation and expert guidance. As the platform evolves, the focus is on building an understanding of skin over time and helping consumers make informed choices at different stages of their skincare journey.</span></p>
<p><span>By combining technology, expert inputs and consumer awareness, SkinBB aims to make skin intelligence part of everyday skincare and move the conversation from product-led experimentation towards an understanding of skin.</span></p>
<p>The post <a href="https://www.expresspharma.in/skinbb-develops-vybie-skin-intelligence-platform-in-india/">SkinBB develops Vybie skin intelligence platform in India</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Curodont Repair: making early caries treatment work for your practice</title>
<link>https://edusehat.com/en/curodont-repair-making-early-caries-treatment-work-for-your-practice</link>
<guid>https://edusehat.com/en/curodont-repair-making-early-caries-treatment-work-for-your-practice</guid>
<description><![CDATA[ As Curodont Repair gains traction as an innovative, evidence-based, micro-invasive treatment for early caries, dental practices have an opportunity to improve patient care and support business growth through a consistent approach to treatment. Curodont Repair from vVARDIS offers a drill-free, needle-free treatment for early, non-cavitated carious lesions where clinically appropriate, helping to preserve natural tooth… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/caries.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 15:20:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Curodont, Repair:, making, early, caries, treatment, work, for, your, practice</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>As Curodont Repair gains traction as an innovative, evidence-based, micro-invasive treatment for early caries, dental practices have an opportunity to improve patient care and support business growth through a consistent approach to treatment.</strong></p>



<p>Curodont Repair from vVARDIS offers a drill-free, needle-free treatment for early, non-cavitated carious lesions where clinically appropriate, helping to preserve natural tooth structure without the need for artificial filling materials.</p>



<p>Its peptide-containing formulation works with minerals naturally available in saliva, supporting the formation of new hydroxyapatite crystals throughout the depth of the lesion and helping to restore lost mineral density. Curodont Repair works up to 100 times deeper than fluoride varnish (up to 2,500 µm compared with 25 µm; Schmidlin et al, 2016).</p>



<p>Curodont Repair is supported by more than 250 scientific publications, including meta-analyses, peer-reviewed clinical studies and long-term real-world evidence, with a documented success rate above 90% (Keeper JH et al, 2023; Godenzi D et al, 2023). One such real-world study provides further insight into longer-term clinical outcomes.</p>



<p>A retrospective study conducted at a public paediatric dental clinic in Chur, Switzerland, reported a 93% clinical success rate for Curodont® Repair on interproximal surfaces, with approximately 90% of lesions remaining non-cavitated. The study involved 219 adolescents aged 10-19 years and 405 proximal lesions, with follow-up extending to 5.5 years. Lesion regression was also observed in 37% to 40% of cases, depending on their initial stage, providing encouraging real-world evidence of treatment outcomes (Godenzi D et al, 2023).*</p>



<p>For dental practices, these findings support consideration of Curodont Repair as part of routine patient care, creating opportunities to intervene earlier, offer patients greater choice and support the commercial development of the practice through an efficient treatment pathway.</p>



<h2 class="wp-block-heading"><strong>Integrating treatment into practice</strong></h2>



<p>Early, non-cavitated carious lesions can be identified through visual assessment and appropriate X-rays during routine examinations. One dentist who has successfully introduced Curodont® Repair into their practice describes using mirrors, photographs and X-rays to show patients the findings and explain their treatment options.</p>



<p>Treatment can often be delivered during a routine appointment, with one application involving three steps (clean, etch, apply) in under five minutes. Most applications take place at the end of a check-up, avoiding an additional booking and making treatment more convenient for patients. The dentist also highlights the value for children, who can receive early caries treatment without drilling or needles where clinically appropriate.</p>



<p>With appropriate diagnosis and care planning, dental hygienists and dental therapists can also deliver treatment within their scope of practice and competence.</p>


        <div class="my-4 rounded overflow-hidden bg-context-100/30 px-8 pt-8 pb-4 md:px-10 md:pt-10 md:pb-8">
            <div>
                <div class="inline-block space-y-4">
                                                                <div class="font-secondary font-bold text-xl md:text-2xl">
                            A consistent patient pathway                        </div>
                                                                <div class="w-full my-12 h-px bg-primary-200"></div>
                                    </div>
            </div>
                            <div>
                    <p><!-- wp:paragraph --></p>
<ul>
<li><strong>Identify:</strong> assess early, non-cavitated carious lesions during routine appointments to determine suitability for treatment<!-- wp:paragraph --></li>
<li><strong>Explain:</strong> show patients the clinical findings and discuss their treatment options<!-- wp:paragraph --></li>
<li><strong>Treat:</strong> where appropriate, deliver Curodont Repair during the same visit, involving appropriately trained team members<!-- wp:paragraph --></li>
<li><strong>Review:</strong> document treatment and assess outcomes through established, risk-based recall arrangements.</li>
</ul>
<p><!-- /wp:paragraph --></p>
                </div>
                    </div>
        


<h2 class="wp-block-heading"><strong>Understanding the commercial opportunity</strong></h2>



<p>For practices, the commercial opportunity with Curodont Repair lies in developing a treatment offering that combines value for patients with a sustainable business model. Research suggests that around 80% of patients have early carious lesions (Skeie, 2022; Jacobsen, 2019), although not all will necessarily be candidates for Curodont Repair.</p>



<p>One dental practice illustrates how this opportunity can translate into routine clinical care. Around half its patients are estimated to present with lesions appropriate for treatment, and the practice reports treatment acceptance of approximately 95% once patients have discussed their options. While these figures reflect one practice’s experience rather than an expectation for every setting, they suggest that early caries treatment could represent a recurring opportunity within the existing patient base, rather than an occasional addition to care.</p>



<p>In this practice, patients typically pay £120 to £150 per treatment, which can cover up to two suitable lesions, while the product cost is approximately £32. These figures provide a starting point for considering how Curodont Repair could fit within a practice’s own fee structure, with scope to cover the costs of delivering treatment and contribute to practice income. The actual return will depend on each practice’s costs and workflow.</p>



<p>Beyond the individual treatment fee, the opportunity lies in building an additional revenue stream around clinically appropriate care for existing patients. Delivering treatment during routine appointments can support this approach by reducing the need for additional bookings. The scale of the opportunity for each practice will depend on its patient mix, treatment uptake, costs and the appointment capacity available to deliver care.</p>



<h2 class="wp-block-heading"><strong>Creating value across the practice</strong></h2>



<p>The wider value of Curodont Repair lies in making early intervention a natural part of clinical practice, giving patients greater choice while supporting effective use of clinical time and continuity of care through established recall arrangements.</p>



<p>To help practices establish this approach, vVARDIS provides structured onboarding, online and hands-on clinical training and support with patient communication. Practices can appoint a Curodont champion to co-ordinate its introduction, with follow-up sessions offering opportunities to review initial results, address practical challenges and build confidence across the team.</p>



<p>With a clear clinical pathway (see box for details) and the right team support, Curodont Repair offers practices an opportunity to deliver evidence-based early caries treatment to more patients. This can strengthen patient engagement while providing a commercially valuable addition to the practice’s services.</p>



<h3 class="wp-block-heading"><strong>References</strong></h3>



<ul class="wp-block-list">
<li>Godenzi D, Bommer C, Heinzel-Gutenbrunner M, et al (2023) Remineralizing potential of the biomimetic P11-4 self-assembling peptide on noncavitated caries lesions: A retrospective cohort study evaluating semistandardized before-and-after radiographs. J Am Dent Assoc; 154(10): 885–896. doi:10.1016/j.adaj.2023.07.009.</li>



<li>Jacobsen ID, Crossner CG, Eriksen HM, et al (2019) Need of non-operative caries treatment in 16-year-olds from Northern Norway. Eur Arch Paediatr Dent; 20(2): 73–78. doi:10.1007/s40368-018-0387-z.</li>



<li>Keeper JH, Kibbe LJ, Thakkar-Samtani M, et al (2023) Systematic review and meta-analysis on the effect of self-assembling peptide P11-4 on arrest, cavitation, and progression of initial caries lesions. J Am Dent Assoc; 154(7): 580–591. doi:10.1016/j.adaj.2023.03.014.</li>



<li>Schmidlin P, Zobrist K, Attin T, et al (2016) In vitro re-hardening of artificial enamel caries lesions using enamel matrix proteins or self-assembling peptides. J Appl Oral Sci; 24(1): 31–36. doi:10.1590/1678-775720150352.</li>



<li>Skeie MS, Sen A, Dahllöf G, et al (2022) Dental caries at enamel and dentine level among European adolescents – a systematic review and meta-analysis. BMC Oral Health; 22: 620. doi:10.1186/s12903-022-02631-2.</li>
</ul>



<p><em>*Radiographs have low sensitivity for detecting changes in mineral density in early-stage carious lesions<strong>.</strong></em></p>



<p><strong>Discover what Curodont Repair could mean for your practice.</strong> Explore the potential commercial benefits using the<a href="https://professional.vvardis.com/product/curodont-repair/"> vVARDIS Business Impact Calculator</a> and see how Curodont Repair could make a difference to your patients and your clinic.</p>



<p><em>This article is sponsored by vVARDIS.</em></p>]]> </content:encoded>
</item>

<item>
<title>Maryland backs upper payment limits as other states have second thoughts on PDABs</title>
<link>https://edusehat.com/en/maryland-backs-upper-payment-limits-as-other-states-have-second-thoughts-on-pdabs</link>
<guid>https://edusehat.com/en/maryland-backs-upper-payment-limits-as-other-states-have-second-thoughts-on-pdabs</guid>
<description><![CDATA[ The recent decision by Maryland’s Prescription Drug Affordability Board (PDAB) to set upper payment limits (UPLs) on two prescription drugs is not expected to […]
The post Maryland backs upper payment limits as other states have second thoughts on PDABs appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2023/04/pharmacy-benefit-manager-pbm-e1795107738637.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 15:00:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Maryland, backs, upper, payment, limits, other, states, have, second, thoughts, PDABs</media:keywords>
<content:encoded><![CDATA[<p>The recent decision by Maryland’s Prescription Drug Affordability Board (PDAB) to set upper payment limits (UPLs) on two prescription drugs is not expected to impact what patients pay for their medicine.</p>
<p>The limits, approved Nov. 16, only apply to what state and local government purchasers pay for the drugs, not the amount patients are charged at the pharmacy counter, according to the<a href="https://www.baltimoresun.com/2026/11/16/maryland-drug-payment-limits/"> Baltimore Sun</a>.</p>
<p>Set to go into effect Jan. 1, the limits would make Maryland one of the first states to enforce UPLs. The other state being Colorado, which established a UPL in 2025, which is temporarily being blocked by the courts. Maryland stands out for leaning into its PDAB at a time when <a href="https://avalerehealth.com/thought-leadership/state-pricing-controls-at-an-inflection-point-maximum-fair-price-and-the-shifting-prescription-drug-affordability-board-landscape/">other states are finding PDABs unworkable</a> and are closing them or choosing against implementing them.</p>
<p>As their name suggests, Prescription Drug Affordability Boards (PDABs) are supposed to target affordability, but the question has become: Affordability for who?</p>
<p>Patients <a href="https://schaeffer.usc.edu/research/prescription-drug-affordability-boards-reshape-reimbursement-while-leaving-core-problems-unresolved/">are not seeing reductions</a> in out-of-pocket costs due to PDABs. State governments, which often spend millions on these boards, <a href="https://www.multistate.us/insider/2026/6/8/pdab-implementation-challenges-slow-state-drug-cost-efforts">have yet to realize savings</a>. Meanwhile, the price controls attempted by PDABs can limit access to drugs for patients and have a dampening effect on investment and innovation.</p>
<p>“PDABs target the wrong problem,” explains the Biotechnology Innovation Organization (BIO) <a href="https://www.bio.org/sites/default/files/2026-11/pdabs_promised_cost_savings_-_patients_are_still_waiting.pdf">in a new infographic</a>. “PDABs limit what insurers and other institutions pay for a medicine. But a lower payment limit does not necessarily translate to lower out-of-pocket costs for patients.”</p>
<h2>The wrong lever</h2>
<p>Nine states have passed legislation establishing PDABs. While the rules vary, the basic concept is that a PDAB can review the price of individual drugs and set limits on the amount paid for that drug by state institutions or private insurers. The approach has not achieved the desired results.</p>
<p>“The lever that they’re pulling has a single effect: It reduces the amount of money that insurance companies and their PBMs pay for prescription drugs. But they are not legally required to pass those savings on to consumers,” according to Brian Warren, BIO VP for State Government Affairs. “This can allow PBMs and insurers to be more profitable without improving affordability for patients.”</p>
<p>Furthermore, UPL caps established for drugs through a PDAB can reduce access to that drug, research in <a href="https://www.ajmc.com/view/upper-payment-limit-implementation-risks-for-patients-pharmacies-and-providers">The American Journal of Managed Care</a> shows.</p>
<p>“Given existing incentives in coverage decisions, payers may remove UPL drugs from formularies, shift them to higher cost-sharing tiers, or impose stricter utilization management,” and pharmacies may choose to stop stocking drugs if they might lose money by selling them, the research says.</p>
<h2>Maryland moves forward as others wind down</h2>
<p>As states rethink PDABs, many are closing them or choosing not to implement them:</p>
<ul>
<li><a href="http://law360.com/healthcare-authority/articles/2364855/amid-budget-woe-new-hampshire-shutters-drug-price-board">New Hampshire</a> voted to close its PDAB last year for being costly and ineffective.</li>
<li><a href="https://www.lsc.ohio.gov/assets/legislation/136/hb96/ps/files/hb96-otherboards-and-commissions-bill-analysis-as-passed-by-the-senate-136th-general-assembly.pdf">Ohio</a> defunded its PDAB last year after years of inactivity.</li>
<li><a href="https://gmcboard.vermont.gov/sites/gmcb/files/documents/Act%20134%20Final%20Report%20on%20Prescription%20Drug%20Affordability%20in%20Vermont_0.pdf">Vermont</a> decided against a PDAB after a state study found it unworkable.</li>
<li><a href="https://bio.news/latest-news/patient-groups-praise-virginia-pdab-veto/">Virginia’s</a> governor vetoed efforts to pass PDAB legislation.</li>
<li><a href="https://www.reuters.com/legal/litigation/judge-blocks-colorados-first-of-its-kind-price-cap-amgens-enbrel-2026-07-01/">Colorado’s</a> first attempt at setting a UPL was blocked by a federal judge.</li>
<li><a href="https://www.ourquadcities.com/news/local-news/illinois-law-to-lower-prescription-drug-prices-struck-down/">Illinois</a> legislation to lower drug prices was struck down in court, and related PDAB legislation <a href="https://www.ilga.gov/legislation/BillStatus?DocTypeID=SB&DocNum=3496&GAID=18&SessionID=114&LegID=166497">failed in the legislature</a>.</li>
</ul>
<p>“PDABs are difficult to implement” and require significant resources, says BIO’s infographic. “PDABs across six states have cost more than $28 million to establish and operate.”</p>
<p>Nonetheless, Maryland is moving ahead with PDAB price controls.</p>
<p>As <a href="https://mdtechcouncil.com/statement-from-the-maryland-tech-council-on-pdab-upper-payment-limit-action/">the Maryland Tech Council</a> noted when the state’s PDAB recommended the first UPL in April, price controls can harm innovation, something a state that relies on a robust biotech industry should avoid.</p>
<p>“While tech incubators, centers of innovation, universities and elected officials are working hard to increase the state’s competitiveness, Maryland’s unelected PDAB is putting Maryland’s future as a life sciences leader at risk,” says a statement from the Maryland Tech Council, a BIO affiliate.</p>
<p>“Policies that may alter reimbursement structures or limit market viability can have a chilling effect on investment particularly for early-stage and mid-sized firms that drive much of Maryland’s innovation economy,” says the statement, noting that barriers to innovation also deter America’s efforts to compete globally for biotech leadership.</p>
<p><a href="https://www.bio.org/sites/default/files/2026-11/pdabs_promised_cost_savings_-_patients_are_still_waiting.pdf"><strong>Read: BIO’s PDAB infographic.</strong></a></p>
<p>The post <a href="https://bio.news/state-policy/maryland-backs-upper-payment-limits-as-other-states-have-second-thoughts-on-pdabs/">Maryland backs upper payment limits as other states have second thoughts on PDABs</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Health Ministry proposes Good Storage and Distribution Practices under Drugs Rules, 1945</title>
<link>https://edusehat.com/en/health-ministry-proposes-good-storage-and-distribution-practices-under-drugs-rules-1945</link>
<guid>https://edusehat.com/en/health-ministry-proposes-good-storage-and-distribution-practices-under-drugs-rules-1945</guid>
<description><![CDATA[ 
Proposed GSDP framework aims to strengthen regulatory oversight, accountability and quality assurance across the pharmaceutical supply chain
The post Health Ministry proposes Good Storage and Distribution Practices under Drugs Rules, 1945 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 14:40:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Health, Ministry, proposes, Good, Storage, and, Distribution, Practices, under, Drugs, Rules, 1945</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>The Union Ministry of Health and Family Welfare has proposed the incorporation of Good Storage and Distribution Practices (GSDP) guidelines for pharmaceutical products into the Drugs Rules, 1945. The proposal aims to ensure that the quality, safety, efficacy and integrity of pharmaceutical products are maintained throughout the distribution chain, from the manufacturer or importer to the point of supply to the patient.</span></p>
<p><span>The proposed framework builds on the GSDP guidance developed by the Central Drugs Standard Control Organisation (CDSCO). The guidelines aim to ensure the quality and identity of pharmaceutical products at every stage of the distribution process, including procurement, purchasing, storage, distribution, transportation, documentation and record-keeping.</span></p>
<p><span>Maintaining appropriate storage and distribution conditions is essential to preserving the quality and integrity of pharmaceutical products beyond the manufacturing stage. The proposed GSDP framework seeks to address potential risks associated with their handling and movement across the supply chain, including deterioration, contamination, mix-ups, falsification, diversion and unauthorised distribution.</span></p>
<p><span>The incorporation of GSDP requirements into the Drugs Rules, 1945, is expected to strengthen the regulatory framework governing pharmaceutical distribution and support regulatory oversight, inspection and enforcement by the Central and State drug-control authorities. It will also promote documentation, record-keeping and traceability, while enhancing accountability among manufacturers, importers, wholesalers, distributors, stockists and other entities involved in the distribution process.</span></p>
<p><span>The proposed guidelines will further strengthen assurance that pharmaceutical products remain within specified quality and environmental conditions during storage and transportation. This is expected to reduce the risk of deterioration, contamination, mix-ups, falsification, diversion and unauthorised distribution, supporting the availability of pharmaceutical products of assured quality to patients and healthcare providers.</span></p>
<p><span>The proposed amendment represents a step towards strengthening India’s pharmaceutical quality-management system and ensuring that the quality established at the manufacturing stage is maintained throughout the supply chain until the product reaches the patient.</span></p>
<p><span>Stakeholders and members of the public have been invited to submit their objections and suggestions, if any, to the Under Secretary (Drugs Regulation), Ministry of Health and Family Welfare, Government of India, U-6, Work Hall, C Wing, First Floor, Kartavya Bhawan-1, New Delhi – 110001, or via email at drugsdiv-mohfw[at]gov[dot]in.</span></p>
<p>The post <a href="https://www.expresspharma.in/health-ministry-proposes-good-storage-and-distribution-practices-under-drugs-rules-1945/">Health Ministry proposes Good Storage and Distribution Practices under Drugs Rules, 1945</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Capitalism at the cost of healthcare</title>
<link>https://edusehat.com/en/capitalism-at-the-cost-of-healthcare</link>
<guid>https://edusehat.com/en/capitalism-at-the-cost-of-healthcare</guid>
<description><![CDATA[ 
Dr Suresh Saravdekar, Consultant – Healthcare and Pharmaceuticals highlights the Supreme Court&#039;s observations on medicine prices and examines Norway&#039;s National Health and Drug Policy as a model for India&#039;s drug pricing framework.
The post Capitalism at the cost of healthcare appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2022/06/07141645/Dr-Suresh-Saravdekar.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 14:40:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Capitalism, the, cost, healthcare</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2022/06/07141645/Dr-Suresh-Saravdekar.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2022/06/07141645/Dr-Suresh-Saravdekar.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2022/06/07141645/Dr-Suresh-Saravdekar-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>The Supreme Court recently slammed the Union Government over steep mark-ups on essential medicines in India. The apex court bench comprising Justices Vikram Nath and Sandeep Mehta described such excessive hospital margins as “loot” and “dacoity”. The Court also questioned why the Union Government was reluctant to bring a wider range of medicines under price control. It observed that the Centre’s reliance on market forces and concerns regarding the growth of the pharma industry cannot justify leaving patients exposed to medicine prices that may be hundreds of times higher than the cost at which they were procured.</span></p>
<p><span>It is interesting to look at the arguments between the Court and the Union Government. The following are a few examples of these arguments, which reveal how casual and callous the government has been in taking action against firms and hospitals in this regard.</span></p>
<p><b>Supreme Court’s arguments</b></p>
<p><span>During the proceedings, the Supreme Court questioned the government’s approach towards medicine pricing and its emphasis on commerce and economic policy over the lives of citizens.</span></p>
<ul>
<li aria-level="1"><span>“You are talking only in the terms of commerce, economic policy, this is a matter in which economic policy will be supreme as compared to the life of the citizens at large?”</span></li>
<li aria-level="1"><span>“You are dealing with the lives of people, Don’t take it as a commerce. Treat it as a life of the poorest person of this country.”</span></li>
<li aria-level="1"><span>The bench also questioned the government’s reliance on innovation as a justification for allowing market forces to operate. A Justice asked, “to name a few molecules developed by the Indian Pharmaceutical industry in the preceding 30 years???”</span></li>
<li aria-level="1"><span>“You at the initial level fix the MRP right up to the moon. Then you increase by 10%. How does that make a difference?”</span></li>
<li aria-level="1"><span>He further questioned, “Your calibration is too wayward. Rs 11,000 to Rs 1,30,000 for cancer drug is no calibration… When you talk of patients and life, should we have such capitalistic thinking?”</span></li>
<li aria-level="1"><span>Further, the Court sought to know whether these considerations justified MRPs hundreds of times higher than procurement prices in tenders.</span></li>
</ul>
<p><span>Referring to the Centre’s recent decision in October 2026 to cap trade margins on anti-cancer drugs, the Court pointed out that the 30 per cent cap covered only a limited portion of the market, while nearly 90 per cent remained outside the price control mechanism.</span></p>
<p><span>The Court also questioned the government, asking, “Why is the DPCO not in place at all? Why the government is allowing this to happen. There have been three parliamentary committees on this. And their outcome is not very convenient to people who pull the strings.”</span></p>
<p><span>To put it succinctly, the Court has clearly concluded that there is a total failure on the part of regulatory control in two areas:</span></p>
<ol>
<li aria-level="1"><span>Proper selection of medicines for price control.</span></li>
<li aria-level="1"><span>Fixing of MRP by the manufacturer.</span></li>
</ol>
<p><span>The Court has also concluded that the reasons for this include a totally callous and casual attitude and a “not pro people but pro-industry approach” on the part of Indian regulatory authorities.</span></p>
<p><span>In this context, it is worthwhile to understand the world’s most successful National Health and Drug Policy of Norway.</span></p>
<p><b>National Health and Drug Policy of Norway – Role model for WHO</b></p>
<p><b>Basic concept – The Medical Need Clause: “Less is More” policy</b></p>
<p><span>This policy has been in place since 1938. In Norway, a new drug can only be registered if there is a “clear-cut medical need for any new product” and “new drugs should represent better therapeutic alternatives than those already on the market”.</span></p>
<p><span>This was called Behovsparagrafen – the Medical Need Clause (MNC). It still continues. The Director of Health could reject a drug even if it was approved in European countries such as the UK, France and Germany.</span></p>
<p><span>Although the industry describes this policy as a “dictatorship” model, it kept industry lobbying out.</span></p>
<p><span>Consequently, Norway had only around 1,800 drugs on the market, compared with more than 10,000 in Germany and France, which is ten times the number in Norway.</span></p>
<p><b>Salient features of Norway’s drug policy</b></p>
<ol>
<li aria-level="1"><b>Essentiality:</b><span> The selection of new drugs is based on “Public health need” and Health Technology Assessment, and not on the claims made by the industry.</span></li>
<li aria-level="1"><b>Changing disease burden:</b><span> The selection changes as healthcare needs change. For example, initially the focus was on TB, while now it includes cancer and diabetes.</span></li>
<li aria-level="1"><b>Efficacy and safety:</b><span> There must be unequivocal evidence regarding the quality of medicines, with global cGMP standards.</span></li>
<li aria-level="1"><b>Cost-effectiveness:</b><span> The total treatment cost, and not just the unit price, is compared with the tender price.</span></li>
<li aria-level="1"><b>Strict FDC policy:</b><span> Fixed-dose combinations (FDCs) are allowed only if they demonstrate a proven therapeutic advantage over a single drug. Combination drugs, for example antibiotics and vitamins, were rejected as “at best fraudulent and at worst dangerous”. FDCs of antimicrobials were kept off the market. Broad-spectrum antibiotics were viewed with suspicion from the late 1960s. That is why Norway still uses narrow-spectrum penicillin (phenoxymethyl-penicillin) as first-line treatment today and has the lowest antimicrobial resistance in Europe.</span></li>
</ol>
<p><span>Thus, for its Essential Medicines Policy, Norway has one of the oldest and most unique price control mechanisms. It introduced one of the strictest models in the world. This model was praised by WHO as an ideal rational drug policy and became a role model for the WHO Essential Medicines List from 1977. The WHO Essential Drug concept was actually inspired by Norway.</span></p>
<p><b>Comparison – India vs Norway</b></p>
<p><b>India</b></p>
<p><span>India has some of the cheapest generics in the world and uses the WHO model of Essential Medicines. However, it separates the framework into two parts.</span></p>
<p><b>NLEM List:</b><span> This is a list of essential medicines for public health, for which prices are controlled. However, availability is not controlled. As a result, many generic manufacturers stop manufacturing essential medicines because of low profit margins.</span></p>
<p><span>Ultimately, hospitals suffer because of the non-availability of life-saving medicines such as penicillins, tetracyclines, adrenaline and oxytocin.</span></p>
<p><span>In India, these medicines were once made available through government-run companies such as Hindustan Antibiotics, IDPL and Bengal Immunity, which are now non-functioning because of a lack of government support. Paradoxically, it is not surprising that the idle and unused space at IDPL is now used for the NPPA office.</span></p>
<p><b>Non-NLEM List:</b><span> The philosophy followed since 1970 has been, “You can sell, we will not fix price but monitor”. The approach is to promote competition and let the market decide prices for non-essential medicines. The idea was that more brands would automatically lead to lower prices.</span></p>
<p><span>However, in practice, this created brand proliferation because non-scheduled pricing is loosely controlled.</span></p>
<p><b>With the result:</b><span> Currently, there are only 935 scheduled formulations under ceiling price, covering 384 NLEM molecules, while a vast number of 85,000 to 100,000 formulations are actually in the market, often quoted at prices 60 to 100 times higher.</span></p>
<p><b>Norway</b></p>
<p><span>Norway does not separate medicines into NLEM and non-NLEM categories. The total number of medicines was only around 1,800 in the 1970s. Now, there are around 5,200 authorisations, but only around 1,200 to 1,500 are allowed for active marketing after tendering and substitution.</span></p>
<p><span>Price control is implemented through a national-level tendering system.</span></p>
<p><span>Norway follows the “Less is More” legacy. Until 1994, its law stated: “If there is already a drug that does same job, new one has NO medical need, it is, rejected”.</span></p>
<p><span>As a result, me-too drugs never entered the market. Even after 1994, the reimbursement rule states: “If we already have 3 ACE inhibitors, we will tender and only cheapest 1-2 will be reimbursed.” Therefore, effectively, all actively used drugs are under price control.</span></p>
<p><span>Secondly, Norway follows the WHO’s Aware antibiotic classification strictly. The goal is to achieve the lowest antibiotic resistance and high access with low spending.</span></p>
<p><b>India – Two gates: State and Central dual system</b></p>
<p><span>In India, CDSCO approves new drugs, but State FDA issues manufacturing licences.</span></p>
<p><span>Until 2022, states could approve generics without checking whether the same drug had already been approved centrally. As a result, the same molecule, such as paracetamol 650 mg, could receive licences in 28 states with 20 manufacturers in each state, resulting in 560 licences. Each could have a different brand name.</span></p>
<p><span>Data placed by DCGI in an affidavit in 2023 showed that there were more than 14,000 licences for paracetamol combinations.</span></p>
<p><span>Consequently, only 35 per cent of drugs are covered by public procurement through Jan Aushadhi and state medical corporations. The remaining 65 per cent is the private, out-of-pocket market, where the patient buys the brand prescribed by the doctor.</span></p>
<p><span>Therefore, price control is not on the MRP sticker.</span></p>
<p><b>Norway – One gate</b></p>
<p><span>Norway follows a single-agency system through NOMA. If EMA (European Medicines Agency) rejects a drug or NOMA says there is no therapeutic need, the drug cannot be sold anywhere in Norway. There is no state-level bypass.</span></p>
<p><span>Until 1994, the Medical Need Clause actively rejected all me-too drugs.</span></p>
<p><b>India – Quality of medicines</b></p>
<p><span>In India, all medicines are manufactured under the following two criteria:</span></p>
<ol>
<li><b> Three types of GMP (Good Manufacturing Practices):</b></li>
</ol>
<ol>
<li aria-level="1"><span>cGMP standards for marketing to developed countries such as the US and EU.</span></li>
<li aria-level="1"><span>WHO-GMP standards for marketing to developing countries.</span></li>
<li aria-level="1"><span>Domestic GMP, which has not been updated in line with current international standards and is intended to favour small and medium-scale industries.</span></li>
</ol>
<ol start="2">
<li><b> Three types of licences:</b></li>
<li><span>a) Own manufacturing and marketing licence.</span></li>
<li><span>b) Only marketing licence, with manufacturing outsourced under a loan licence.</span></li>
<li><span>c) Third-party licence.</span></li>
</ol>
<p><span>Consequently, the price of a particular medicine will vary with these three manufacturing standards and three types of licences.</span></p>
<p><b>Norway</b></p>
<p><span>All medicines are imported only if they meet cGMP manufacturing standards and have their own manufacturing licence.</span></p>
<p><b>3. India – DPCO market-based price</b></p>
<p><span>The formula is based on the average price of all brands with more than one per cent market share.</span></p>
<p><span>The incentive for the industry is to launch many brands at higher prices to increase the average. If there are 20 brands, the average price goes up and the ceiling price also increases.</span></p>
<p><span>The Supreme Court observed in 2013 that “DPCO incentivizes proliferation”.</span></p>
<p><b>Norway – Trinnpris</b></p>
<p><span>The prices of all medicines, irrespective of whether they are essential or non-essential, are controlled by comparing them with prices determined through the national-level tendering system.</span></p>
<p><b>Equity of access</b></p>
<p><span>Norway introduced Rural Availability Regulation 2023. According to this law, pharmaceutical companies must ensure that essential medicines are available in all regions, especially rural North Norway, and not just in the capital, Oslo.</span></p>
<p><b>Failure of Norway’s price control policy and lessons for India</b></p>
<p><span>Currently, a very specific problem is being faced in Sweden and Norway. It is not because the drugs do not work. It is because the drugs work too well and are too cheap.</span></p>
<p><span>Sweden and Norway are unique in that they have some of the lowest antibiotic resistance levels in Europe. Therefore, they still rely on old, narrow-spectrum penicillins such as phenoxymethylpenicillin (Penicillin V) and pivmecillinam as first-line treatments.</span></p>
<p><span>Phenoxymethylpenicillin is Norway’s most consumed antibiotic. However, these exact drugs are disappearing from the market.</span></p>
<p><span>The main reason is that the market is too small and too unprofitable. These are old, off-patent generics.</span></p>
<p><span>The second reason is dependence on external suppliers for essential medicines, as well as the vulnerability of supply chains in the event of economic or geopolitical crises.</span></p>
<p><span>Currently, up to 90 per cent of the antibiotics used globally are produced outside Europe, primarily in China and India. In India, some production also depends on chemical raw materials sourced from China.</span></p>
<p><b>Proposed model</b></p>
<p><span>To conclude, the current exorbitant and unaffordable prices of medicines in the Indian market can be controlled only if regulators think of a “Pro Public rather than Pro-Industry Policy”, based on the following principles:</span></p>
<ol>
<li aria-level="1"><b>Proper selection of both essential and non-essential medicines:</b><span> Selection should be based on “Real Health Needs” and not on “Artificial Market needs”. There should not be a dual price policy for these two classes.</span></li>
<li aria-level="1"><b>Price comparison:</b><span> Price comparison should be with international manufacturing standards such as WHO-GMP and own licences, and not with outsourced manufacturing.</span></li>
<li aria-level="1"><b>Sustaining production capacity:</b><span> While deciding the prices of essential medicines such as old antibiotics, low margins, unpredictable purchasing volumes and limited market opportunities should be considered positively for manufacturers. This will help them maintain and sustain their production capacity and invest in supply security.</span></li>
</ol>
<p>The post <a href="https://www.expresspharma.in/capitalism-at-the-cost-of-healthcare/">Capitalism at the cost of healthcare</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Type 1 Diabetes Delayed in Mice by Stem Cell&#45;Derived Vesicles That Calm Immune Response</title>
<link>https://edusehat.com/en/type-1-diabetes-delayed-in-mice-by-stem-cell-derived-vesicles-that-calm-immune-response</link>
<guid>https://edusehat.com/en/type-1-diabetes-delayed-in-mice-by-stem-cell-derived-vesicles-that-calm-immune-response</guid>
<description><![CDATA[ Extracellular vesicles produced by certain types of pluripotent stem cells (PSC) were found to help reduce immune attacks on insulin-producing cells in the pancreas and delay the onset of diabetes in a mouse model.
The post Type 1 Diabetes Delayed in Mice by Stem Cell-Derived Vesicles That Calm Immune Response appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_extra-cellular-vesicle.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 07:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Type, Diabetes, Delayed, Mice, Stem, Cell-Derived, Vesicles, That, Calm, Immune, Response</media:keywords>
<content:encoded><![CDATA[<p>In people with type 1 diabetes, the immune system mistakenly identifies insulin-producing cells in the pancreas as foreign and attacks them, leaving the body unable to properly regulate blood sugar. While insulin therapy helps manage the disease, it does not stop the underlying immune attack.</p>
<p>UCLA researchers have identified a potential new way to protect these cells by harnessing extracellular vesicles—tiny particles naturally released by nearly all types of cells that help them communicate with one another.</p>
<p>Their preclinical study found that vesicles produced by certain types of pluripotent stem cells (PSCs) can help reduce immune attacks on insulin-producing cells in the pancreas and delay the onset of diabetes in a mouse model. The research was inspired in part by a feature of pregnancy, which means that the mother’s immune system generally tolerates a developing embryo, even though it carries genetic material from the father that the maternal immune system could recognize as foreign. The findings suggest a possible strategy for preserving insulin-producing cells before they are destroyed.</p>
<p>Song Li, PhD, associate dean for graduate and professional education and a professor of bioengineering at the UCLA Samueli School of Engineering and a member of the UCLA Broad Stem Cell Research Center, is senior and corresponding author of the team’s published paper in <em>Nature Nanotechnology</em>, titled “<a href="https://doi.org/10.1038/s41565-026-02320-z" target="_blank" rel="noopener">Pluripotent stem cell-derived extracellular vesicles for systemic immune modulation in diabetes therapy</a>.”</p>
<p>Embryonic development is characterized by “remarkable immune tolerance,” the authors noted, “… yet whether this property extends to pluripotent stem cell-derived extracellular vesicles (EVs) has remained unclear.” Li added, “Nature has designed something amazing. If we can better understand how an embryo avoids rejection by the mother’s immune system, it could be very useful for a lot of immune-related diseases.”</p>
<p>For their study the team investigated whether extracellular vesicles released by pluripotent stem cells—which share characteristics with cells found in early embryonic development—might also possess immune-regulating properties. The researchers compared vesicles from embryonic stem cells (ESCs) and induced pluripotent stem cells, or iPSCs, with those from mesenchymal stem cells (MSCs), which have been widely studied for their ability to regulate inflammation. “Extracellular vesicles (EVs) secreted by adult stem cells, particularly mesenchymal stem cells (MSCs), have been extensively investigated for their regenerative potential across a wide range of pathological conditions,” the team pointed out.</p>
<p>In experiments using mouse and human immune cells, vesicles from both types of pluripotent stem cells showed stronger anti-inflammatory effects than those from mesenchymal stem cells. They also promoted the formation of regulatory T cells (Tregs), specialized immune cells that help prevent the immune system from attacking the body’s own tissues. “… we show that EVs from pluripotent stem cells (PSCs), including embryonic stem cells and induced pluripotent stem cells, outperform mesenchymal stem cell-derived EVs in suppressing proinflammatory cytokine secretion, reducing T cell activation and inducing regulatory T cells,” they stated.</p>
<p>Further analysis showed that the vesicles carry distinctive proteins, lipids, and genetic material that may contribute to their immune-regulating properties, providing insight into how these naturally produced nanoparticles influence immune cells. “… PSC EVs display distinct molecular signatures, containing unique proteins and microRNAs absent from mesenchymal stem cell-derived EVs, including the pluripotency-associated proteins ROR1 and CD133 and members of the miR-302 family,” the investigators continued.</p>
<p>To test whether these immune-regulating effects could help prevent diabetes, the researchers introduced immune cells that attack insulin-producing pancreatic cells into mice, then treated the animals with extracellular vesicles derived from iPSCs.</p>
<p>Because extracellular vesicles are rapidly cleared from the injection site, the team developed an injectable hydrogel that gradually releases them over several days. “Soluble EVs are cleared rapidly from subcutaneous tissue, and therefore, we developed an injectable hydrogel composed of hyaluronic acid (HA) and Pluronic F127 that transitions from a solution to a gel state at body temperature,” they explained. “Both polymers are widely used in biomedical formulations, which further supports the translational potential of this platform.”</p>
<p>The treatment was injected beneath the skin near the neck, where the vesicles could interact with immune cells in nearby lymph nodes. These immune cells could then circulate throughout the body, potentially reducing harmful immune activity in the pancreas. The researchers found that two treatments with extracellular vesicles, either alone or delivered through the hydrogel, significantly delayed the onset of diabetes compared with untreated controls.</p>
<p>At the end of the 90-day study, 55% of mice receiving vesicles in the hydrogel remained diabetes-free. Mice receiving vesicles in the hydrogel also had more regulatory T cells in their lymph nodes and retained more insulin-producing pancreatic tissue than control animals. “Delivered via a biomaterial scaffold, two local injections of induced PSC EVs significantly improved diabetes-free survival in an antigen-specific type 1 diabetes model, increasing regulatory T cell populations in draining lymph nodes, as well as inducing systemic immune modulation and preserving β-cell mass,” the scientists stated.</p>
<p>“One thing that surprised us was that a local injection could provide protection throughout the body,” said Li, who is also a member of the UCLA Health Jonsson Comprehensive Cancer Center and the California NanoSystems Institute at UCLA. “That’s the beauty of this approach.”</p>
<p>The researchers also addressed a major obstacle to developing extracellular vesicle-based treatments: producing sufficient quantities of consistent, high-quality particles. Rather than growing stem cells on flat laboratory surfaces, the team grew them in three-dimensional clusters suspended in gently moving liquid. “Suspension culture allows PSCs to grow as floating aggregates and maintain pluripotency without differentiation into embryoid bodies,” they explained. This approach increased vesicle production 3.4-fold per million cells while preserving important characteristics of the particles.  Because iPSCs can multiply extensively in the laboratory, they could provide a more consistent and scalable source of therapeutic vesicles than adult stem cells, whose growth potential is more limited.</p>
<p>The approach remains experimental, and further studies are needed to determine whether it would be safe and effective in people. Li envisions the greatest potential for patients in earlier stages of type 1 diabetes, when some insulin-producing cells remain functional.</p>
<p>“In the early stages, you still have some pancreatic cells left,” Li said. “If you can regulate the immune cells, you may be able to keep the remaining cells functional.” In more advanced disease, immune regulation alone would not replace cells that have already been lost. However, the approach could potentially help prevent immune rejection of transplanted insulin-producing cells.</p>
<p>The team hopes to test the approach in larger animal models and investigate appropriate dosing, long-term effectiveness, and whether the treatment could weaken the body’s defenses against infection.</p>
<p>Beyond diabetes, the findings could inform research into other autoimmune diseases and strategies for protecting transplanted cells from immune rejection. Acknowledging questions that still remain to be addressed, the authors concluded, “These findings establish PSC EVs as a scalable immunomodulatory platform for autoimmune disease and for immune tolerance in cell therapy.”</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/type-1-diabetes-delayed-in-mice-by-stem-cell-derived-vesicles-that-calm-immune-response/">Type 1 Diabetes Delayed in Mice by Stem Cell-Derived Vesicles That Calm Immune Response</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Former Verily Leaders Build AI Platform to Get More from Proteomics Data</title>
<link>https://edusehat.com/en/former-verily-leaders-build-ai-platform-to-get-more-from-proteomics-data</link>
<guid>https://edusehat.com/en/former-verily-leaders-build-ai-platform-to-get-more-from-proteomics-data</guid>
<description><![CDATA[ Tesorai’s AI platform reanalyzes massive proteomics repositories, letting researchers mine raw mass spectrometry data instead of condensed forms. In an Alzheimer’s project, it found phosphorylated tau 217 in four datasets where the original authors did not report it.
The post Former Verily Leaders Build AI Platform to Get More from Proteomics Data appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2021/08/GettyImages-1064220756-1024x768.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 07:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Former, Verily, Leaders, Build, Platform, Get, More, from, Proteomics, Data</media:keywords>
<content:encoded><![CDATA[<p>Before founding Tesorai in 2024, its three co-founders were long-time colleagues at Verily, Alphabet’s life science company. Melissa Miao, Tesorai’s CEO, led business initiatives and strategic partnerships; Peter Cimermancic, PhD, Tesorai’s CTO, led artificial intelligence teams, and Charlie Kim, PhD, Tesorai’s CSO, launched and led Verily’s molecular science program. While at Verily, they recognized opportunities to use advanced AI to maximize signal extraction from massive laboratory datasets, particularly in mass spectrometry-based proteomics. As Miao told <em>GEN</em> in an interview, “That’s what inspired us to leave and build our own team specifically focused on building AI models to maximize the insights that you could extract from those data sets.”</p>
<p>Today, Tesorai’s AI models process raw mass spectrometry data from labs’ new experiments, public repositories, and company archives. This week, the company announced that it had raised $5.3 million in fresh seed funding, bringing its total funding to $8 million. Investors in the current round include Perplexity Fund, IQT, South Central Ventures, New Stack Ventures, NextGen Venture Partners, f7 Ventures, VitalStage Ventures, and ZAKA. The company’s representatives also say that they have signed contracts with both biopharmaceutical and research organizations. Its list of named collaborators includes teams at MD Anderson Cancer Center, New York University, and the Michael J. Fox Foundation.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The company plans to use the new funds to expand its work with biopharmaceutical and research customers, grow partnerships across the life sciences, and to extend its platform beyond proteomics to other kinds of molecular data. When asked what kinds of partnerships best fit the company’s offerings, Miao said, “We see applications across all drug development or most drug development stages,” and that spans “target discovery to biomarker discovery all the way down to more development stages.” Besides biopharma, she said that the company is currently expanding into the agrolife sciences space as well.</p>
<p>Focusing on proteomics made sense given the growing interest in these types of studies coupled with several technological advances made in recent years,” Kim said. “We can finally see the whole proteome in the way that genomics was able to 20 years ago,” he said in an interview. But mass spectrometry data “is very challenging to analyze, and there are a lot of opportunities for AI to help.”</p>
<p>But Tesorai plans to expand beyond proteins to other types of omics information. “One of the things we’re really excited about is integrative analysis,” he said. Specifically, “being able to combine different layers of biological data to assemble a mechanistic understanding.” With that in mind, the company plans to take on transcriptomics data next and eventually genomics data as well.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>“We are part of an ecosystem of efforts that are really trying to dramatically accelerate the pace of life science research,” Kim said. “If you think of every experiment as a step forward, what we’re trying to do is make every step bigger by getting more information out of every sample, and we’re trying to make those steps faster, both by our engineering and ability to process massive volumes of data quickly,” as well as “through our agentic interface and making it so that you can execute analysis very quickly in natural language.”</p>
<h3><strong>The platform’s architecture and components</strong></h3>
<p>Anchoring the company’s platform is a proprietary AI model built to analyze proteomics datasets. The components include Tesorai Search, a deep-learning engine that is described in a <em><a href="https://www.sciencedirect.com/science/article/abs/pii/S002228362600313X?via%3Dihub">Journal of Molecular Biology </a></em>paper. According to the company, the engine reads full spectra, enabling it to find more peptides, and its model works out most of the 20 to 40 settings adopted by standard analysis tools. In the paper, they report that Tesorai Search “consistently identifies more unique peptides compared to established search engines like MaxQuant, FragPipe (+MSBooster), PEAKS, and Proteome Discoverer” and that it achieves “average increases of 12–68%.” They also claim that it shows “strong performance even on data not encountered during training.”</p>
<p>The platform also includes Tesorai Trove, which catalogs curated public proteomics datasets from human tissue, and structures studies’ metadata into searchable tables that can be used both by humans and AI models. Most tools available today “only query and mine” the condensed and reduced datasets available in the scientific literature, Cimermancic noted during a conversation with <em>GEN</em>. With Trove, “we can really boost the number of insights and discoveries in biology by allowing scientists to mine raw data directly.”</p>
<p>Key to making this type of analysis possible is the way that Tesorai trains its models. Cimermancic explained it this way: Instead of training models on the fly, which can lead to overfitting and inaccuracies, Tesorai pre-trains its model on data from public repositories and other sources to ensure that it generalizes across experimental conditions and instrument types. Because the data is “heterogeneous to begin with,” the model “doesn’t necessarily have any biases,” he said. Trained models are also validated in different ways. For example, if models are only trained on data from one manufacturer’s instruments, their performance is validated using instruments from other manufacturers. Additionally, the company’s academic partners have designed ways to experimentally evaluate its models, for example, using the AI to detect single gene knockouts in cell lines.</p>
<p>A third tool, Tesorai Chat, runs quality checks, statistics, and charts using conversational prompts. Tesorai shared some benchmarking results for Tesorai Chat earlier this year. On a 94-case proteomics benchmark, Tesorai Chat reached over 92% accuracy ahead of tools like Phylo and GPT-5.4, among others.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Tesorai received the first patent for its platform last year. In addition to data, the company has also invested in the underlying engineering and infrastructure so that it can process data at scale. “More and more data is being generated in large part because instruments are getting more advanced,” and “what we observed was that software wasn’t keeping up,” which is “why we started building out this proprietary AI model,” Miao said. Furthermore, “because it’s so scalable, we’ve been able to now reprocess massive repositories of data,” enabling scientists to dig deeper into both the scientific literature and the raw data.</p>
<p>The company has also shared data that demonstrates the types of results its platform can provide. “We’ve been able to show that we can increase the number of peptide and protein identifications,” as well as how the platform improves accuracy, Miao said.</p>
<p>Tesorai operates a token system where customers pay for what they use. It’s a new model for proteomics software and one that is more accessible than the traditional annual licensing structure, according to Miao. “We’re looking to be more generous with the credits that we offer for free for academic research teams,” she said. Because “biopharma tends to have slightly different needs, oftentimes, we’ll enter into specific service engagements that might include working within their cloud environment or creating mechanisms where it’s easier to share analyses across departments and divisions. But for the most part, we’re token-based pricing.”</p>
<h3><strong>Searching for Alzheimer’s biomarkers</strong></h3>
<p>To help elucidate the value of the platform, Kim pointed to a recent application of Tesorai’s platform in Alzheimer’s disease, where the team used it to test a newly published Alzheimer’s blood panel against data from five existing brain studies. The multiprotein plasma panel, which could be a tool for distinguishing between early- and late-stage Alzheimer’s, is described in more detail in a <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdoi.org%2F10.1001%2Fjamaneurol.2026.2650&data=05%7C02%7CUduak.Thomas%40sagepub.com%7C42aab5ce855d45ebcd0108df44f9ada6%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639305511318547563%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=K7VEYJF%2B%2BkEU6VaTsK9qMkNMBMf0dgNi%2Fbyd3G9vgxo%3D&reserved=0"><em>JAMA Neurology</em></a> paper published this year.</p>
<p>Details of Tesorai’s work are published in a bioRxiv preprint titled “<a href="https://www.biorxiv.org/content/10.64898/2026.08.31.748393v1">Rapid Mechanistic Bridging of an Alzheimer’s Disease Plasma Protein Staging Panel Across Brain Proteomics Cohorts</a>” that was posted in September. For the study, “we were interested in understanding whether the biology of those proposed proteins was also reflected in the brain and whether or not, in the brain, that also tracked with the severity of Alzheimer’s disease,” Kim explained.</p>
<p>An initial read of the five datasets in question showed that they appeared to be missing p-tau217, a well-established plasma biomarker for assessing amyloid-beta pathology in people at risk of developing Alzheimer’s. “Because phosphorylated tau 217 (p-tau217) and amyloid beta 1-40 (Aβ40) were not reported for any studies, raw spectra were reprocessed to quantify these proteoforms,” the scientists wrote. As it turned out, p-tau217was present in four of the five original datasets but had not been reported in the original protein summaries.</p>
<p>Additionally, there was evidence across the cohorts that the plasma-derived biomarker panel could “distinguish early from late-stage Alzheimer’s disease,” Kim said. This was also true for other proteins analyzed in the study. The analysis “provided a mechanistic explanation for why these proteins were changing in the blood in association with Alzheimer’s disease severity.”</p>
<p>Furthermore, Tesorai completed the analysis in three weeks, without having to perform a new study. It is one example of the value that Tesorai’s platform offers, according to Kim. Much like this case where a reanalysis of raw data was fruitful, there are likely other instances “where the original intent of the study authors wasn’t necessarily to ask this kind of question, but the questions can be answered because the information is in the data.” And by combining “multiple data sets in this way … there can be major accelerations in being able to validate and answer questions like this.”</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/former-verily-leaders-build-ai-platform-to-get-more-from-proteomics-data/">Former Verily Leaders Build AI Platform to Get More from Proteomics Data</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How AI in health care can strengthen humanity in medicine</title>
<link>https://edusehat.com/en/how-ai-in-health-care-can-strengthen-humanity-in-medicine</link>
<guid>https://edusehat.com/en/how-ai-in-health-care-can-strengthen-humanity-in-medicine</guid>
<description><![CDATA[ Ramin Davidoff, MD, says AI in healthcare, used with physician oversight, can help doctors spot risks sooner, listen more fully, and stay connected to patients between visits.
The post How AI in health care can strengthen humanity in medicine appeared first on Permanente Medicine. ]]></description>
<enclosure url="https://permanente.org/wp-content/uploads/2026/11/davidoff-AMA-11-2026-soul-of-medicine-feature.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 07:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, health, care, can, strengthen, humanity, medicine</media:keywords>
<content:encoded><![CDATA[<p>As the potential of AI accelerates, there’s reasonable fear it will make health care less human. <a href="https://permanente.org/ramin-davidoff-md/" target="_blank" rel="noopener">Ramin Davidoff, MD</a>, co-CEO of <a href="https://permanente.org/permanente-federation/" target="_blank" rel="noopener">The Permanente Federation</a>, maps out an alternate future in an American Medical Association (AMA) article: When thoughtfully applied with physician oversight, AI can give doctors back the time and insight they need to be fully present with patients.</p>
<p>That presence matters for building trust. In a recent <a href="https://www.pewresearch.org/wp-content/uploads/sites/20/2026/10/PS_2026.10.29_AI-impact-healthcare_report.pdf" target="_blank" rel="noopener">Pew Research Center study</a>, 25% of people surveyed said they have little or no confidence that physicians will make sure AI is used in patients’ best interests.</p>
<p>Dr. Davidoff looks at AI’s potential through three human dimensions: the mind, the heart and the healing touch. The goal, he writes, isn’t more data or more automation. It’s more time for physicians to listen and build trust.</p>
<h2><strong>Ambient AI that helps physicians listen</strong></h2>
<p>AI-powered ambient scribes, currently available to physicians across Kaiser Permanente, help them stay focused on patients during visits while cutting down burdensome administrative work.</p>
<p><span data-ccp-props='{"201341983":0,"335559739":0,"335559740":240}'><div class="vcex-module vcex-divider vcex-divider-solid vcex-divider-center wpex-mx-auto wpex-max-w-100 wpex-block wpex-h-0 wpex-border-b wpex-border-solid wpex-border-main"></div></span></p>
<p><strong>Related ambient AI scribes story:</strong> <a href="https://permanente.org/how-ambient-ai-can-help-identify-patient-social-needs/" target="_blank" rel="noopener">How ambient AI can help identify patient social needs</a></p>
<p><span data-ccp-props='{"201341983":0,"335559739":0,"335559740":240}'><div class="vcex-module vcex-divider vcex-divider-solid vcex-divider-center wpex-mx-auto wpex-max-w-100 wpex-block wpex-h-0 wpex-border-b wpex-border-solid wpex-border-main"></div></span></p>
<p>Dr. Davidoff writes that emerging ambient AI capabilities could also flag relevant health conditions and prompt physicians when an assessment and plan are missing. Future AI agents could pull labs, specialist notes and smartwatch data into pre-visit summaries, so physicians begin each conversation informed and attuned to the person behind the chart.</p>
<h2><strong>Spotting risk sooner</strong></h2>
<p>AI tools can already prioritize urgent patient messages and analyze mammograms to identify higher-risk concerns. Next-generation patient portals could combine clinical, genomic, social and biometric data into “digital twins” that could help predict risk for conditions such as Alzheimer’s disease or chronic kidney disease years before symptoms appear. In a value-based care model, earlier insight can help prevent avoidable complications and higher-cost care.</p>
<p>“AI’s promise is not to automate more care or replace the people devoted to providing it,” Dr. Davidoff wrote. “It is to help physicians practice at the highest level by seeing patterns sooner, listening more fully and staying engaged with patients beyond the exam room.” He adds that “the most meaningful advances in health care will not simply make the system more efficient. They will make it feel more deeply human.”</p>
<p>Read Dr. Davidoff’s full AMA article, <a href="https://www.ama-assn.org/practice-management/digital-health/can-ai-strengthen-soul-medicine" target="_blank" rel="noopener">“Can AI strengthen the soul of medicine?”</a> to see how home monitoring and 3D visualization could extend the physician’s healing touch.</p>
<p>The post <a href="https://permanente.org/how-ai-in-health-care-can-strengthen-humanity-in-medicine/">How AI in health care can strengthen humanity in medicine</a> appeared first on <a href="https://permanente.org/">Permanente Medicine</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AMR Awareness Week: C. diff patient finds her voice in advocacy</title>
<link>https://edusehat.com/en/amr-awareness-week-c-diff-patient-finds-her-voice-in-advocacy</link>
<guid>https://edusehat.com/en/amr-awareness-week-c-diff-patient-finds-her-voice-in-advocacy</guid>
<description><![CDATA[ “My whole childhood, I got lots and lots of infections: ear infections, eye infections, skin infections, UTIs, lung infections—anything opportunistic, I was getting it. […]
The post AMR Awareness Week: C. diff patient finds her voice in advocacy appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/1000031701.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 00:40:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>AMR, Awareness, Week:, diff, patient, finds, her, voice, advocacy</media:keywords>
<content:encoded><![CDATA[<p><span>“My whole childhood, I got lots and lots of infections: ear infections, eye infections, skin infections, UTIs, lung infections—anything opportunistic, I was getting it. So I was always on antibiotics,” says Minnie Hatch, a patient advocate from Ogden, Utah. </span></p>
<p><span>Eventually, her prolonged antibiotic use led to another, lesser-known infection: </span><i><span>Clostridioides difficile (C. diff).</span></i><span> Her story shows not only the challenges some patients face with </span><i><span>C. diff</span></i><span>, but also the work that still needs to happen when treating these patients.</span></p>
<p><span>November 18–24 is </span><a href="https://www.who.int/campaigns/world-amr-awareness-week"><span>Antimicrobial Awareness Week</span></a><span>, an annual global campaign aimed at increasing understanding of antimicrobial resistance (AMR) and promoting best practices across human, animal, plant, and environmental health. Additionally, November is </span><a href="https://cdiff.org/see-c-diff/"><i><span>C. diff </span></i><span>Awareness Month</span></a><span>, and as such, Bio.News is sitting down with Hatch to discuss her experiences as a patient and an advocate, and understand more about this misunderstood infection.</span></p>
<h3>Understanding C. diff</h3>
<p><span>“I first started getting sick when I was 19 years old,” Hatch says. “I’m 32 now, and my </span><i><span>C. diff</span></i><span> went undetected for a really long time, at least a year, because I was so young, and my symptoms were so broad.”</span></p>
<p><i><span>C. diff </span></i><span>is a germ that causes diarrhea and inflammation of the colon and while it is more common in senior populations, it can affect anyone. It’s estimated to cause more than 400,000 infections in the United States each year and can be life-threatening.</span></p>
<p><span>This year, the Centers for Disease Control and Prevention’s (CDC) recent </span><a href="https://arpsp.cdc.gov/artr/cdiff?ACSTrackingID=USCDC_426-DM160173&ACSTrackingLabel=November%20is%20C.%20diff%20Awareness%20Month&deliveryName=USCDC_426-DM160173"><span>Antimicrobial Resistance Threats Report</span></a><span>, designated </span><i><span>C. diff </span></i><span>at a threat level of “serious,” indicating that the CDC considers it to pose a significant health hazard to the public, requiring aggressive tracking, prevention, and public health action.</span></p>
<p><i><span>C. diff</span></i><span> causes more than 11,000 estimated deaths in hospitalized patients, and more than $6.4 billion in healthcare costs overall every year, </span><a href="https://arpsp.cdc.gov/artr/cdiff?ACSTrackingID=USCDC_426-DM160173&ACSTrackingLabel=November%20is%20C.%20diff%20Awareness%20Month&deliveryName=USCDC_426-DM160173"><span>the CDC reports</span></a><span>. However, rates of </span><i><span>C. diff</span></i><span> have declined 21% overall from 2018–2020 and remained stable from 2020–2023, per CDC reporting. </span></p>
<p><span>“This is due in part to improvements in </span><i><span>C. diff</span></i><span> diagnosis and the success of efforts to prevent infections. U.S. progress against this threat shows that a comprehensive public health response—grounded in targeted infection prevention, antibiotic stewardship, diagnostic excellence, and increased treatment options—works,” the CDC writes.</span></p>
<h3>An ongoing struggle with C. diff</h3>
<p><span>Hatch herself has seen these numbers play out firsthand, but, as Hatch explains, numbers aren’t the whole story; the patient experience is also incredibly important.</span></p>
<p><span>After months of gastrointestinal issues, the lightbulb finally went on in Hatch’s gastroenterologist’s mind. “He said, </span><i><span>Oh, I didn’t see the forest through the trees. I think you have C. diff</span></i><span>” Hatch explains. </span></p>
<p><span>And indeed, when they sent out a stool sample, it tested positive. Hatch’s doctor was confident that after treatment, she wouldn’t have to deal with </span><i><span>C. diff</span></i><span> again. “But that is not what happened for me. It just got worse,” she says.</span></p>
<p><span>Hatch dealt with years of </span><i><span>C. diff </span></i><span>and she tried a number of treatment options. </span></p>
<p><span>“During COVID, I got </span><i><span>C. diff</span></i><span> again, and this time they weren’t able to treat me,” she remembers. “I wasn’t responding to the antibiotics. I dropped down to 94 pounds, and my doctors told me to put my will together. They said, </span><i><span>There’s nothing we can do. We are waiting for you to go septic.</span></i><span> Luckily, I had found the Peggy Lillis Foundation (PLF).”</span></p>
<h3>The Peggy Lillis Foundation</h3>
<p><span>Hatch had started working with PLF in 2017 shortly after the birth of her son. When the nurses saw that she’d had a previous </span><i><span>C. diff</span></i><span> diagnosis, they put Hatch into quarantine. </span></p>
<p><span>“It put the nurses around me into a panic. They thought I was going to get all the babies sick,” says Hatch. “My son needed NICU care, and they refused to put him in the NICU. The nurses wouldn’t touch me. Ultimately, I ended up asking to be discharged as soon as I could, so I could take my son somewhere that would provide care.”</span></p>
<p><span>Hatch knew her experience wasn’t right, so when she got home she started researching, and found PLF.</span></p>
<p><span>PLF was founded by Christian and Liam Lillis after the death of their mother in 2010 from </span><i><span>C. diff.</span></i><span> When Hatch reached out, they immediately offered to help, and just three weeks after the birth of her son, Hatch and her husband were headed to New York City to participate in a training on advocacy.</span></p>
<p><span>During her COVID-era </span><i><span>C. diff</span></i><span>, as doctors were telling her to get her affairs in order, Hatch was able to tap into her advocacy skills and network to save her life and find a treatment that worked.</span></p>
<h3>Finding her voice as a patient advocate</h3>
<p><span>Ultimately, the cause of Hatch’s repeated infections was discovered to be an autoimmune disorder called “specific antibody deficiency,” which causes Hatch’s body to not create antibodies, leaving the door open for opportunistic infections. So by all accounts, Hatch will potentially have to navigate </span><i><span>C. diff</span></i><span> in the future, making her advocacy work all the more important.</span></p>
<p><span>“When I first started getting sick, less than one in five doctors had even heard of </span><i><span>C. diff</span></i><span>, and only two doctors in my state could treat it at the level I had it,” she says. </span></p>
<p><span>Luckily, Hatch’s voice has gotten more powerful, both for herself and others like her.</span></p>
<p><span>“Nobody can make me cry like a doctor can,” she says. “I find that I still have to advocate loudly. There are many times when, if I have a new doctor, I won’t go to the appointment on my own. Sometimes advocating for yourself is enough, and sometimes it’s not.”</span></p>
<p><span>Hatch didn’t want other people to go through what she had been through. </span></p>
<p><span>“I knew that the best way that I could help other people was to share my story so that doctors could hear it,” she says. “Maybe they would think, </span><i><span>Oh, well, that’s wrong. We shouldn’t be treating people that way.”</span></i></p>
<p><span>Hatch says that more important work she is doing today is peer-to-peer support for </span><i><span>C. diff</span></i><span> patients and their caregivers.</span></p>
<p><span>“For the patients at home,” she continues, “I think the key is not to live in fear and to let yourself live your life. People come into contact with </span><i><span>C. diff</span></i><span> every day and are typically OK.”</span></p>
<p><span>The big issue, Hatch asserts, is misinformation. </span></p>
<p><span>“We can’t treat </span><i><span>C. diff </span></i><span>patients like they’re gross or contagious,” she says. “I’ve had providers refuse to touch me, refuse to work with me, didn’t want me to touch anything, and that is a rhetoric based in fear, not fact.”</span></p>
<p><i><span>If you are interested in learning more, or getting involved, visit: </span></i><a href="https://cdiff.org/"><i><span>https://cdiff.org/</span></i></a><i><span> </span></i></p>
<p>The post <a href="https://bio.news/latest-news/amr-awareness-week-c-diff-patient-finds-her-voice-in-advocacy/">AMR Awareness Week: C. diff patient finds her voice in advocacy</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New ultrasound technology treats kidney cancer without surgical incisions in Asian first</title>
<link>https://edusehat.com/en/new-ultrasound-technology-treats-kidney-cancer-without-surgical-incisions-in-asian-first</link>
<guid>https://edusehat.com/en/new-ultrasound-technology-treats-kidney-cancer-without-surgical-incisions-in-asian-first</guid>
<description><![CDATA[ Researchers at the University of Hong Kong have performed Asia’s first histotripsy treatments for kidney cancer, demonstrating the potential of a non-invasive technology that destroys tumour tissue using focused ultrasound rather than surgical incisions. Announced November 18, the milestone involved two patients treated at Gleneagles Hospital Hong Kong through a collaborative clinical trial led by […]
The post New ultrasound technology treats kidney cancer without surgical incisions in Asian first appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/01J5AYK9MEAP9N0S034R4F44DF.webp" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 00:30:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, ultrasound, technology, treats, kidney, cancer, without, surgical, incisions, Asian, first</media:keywords>
<content:encoded><![CDATA[<p>Researchers at the University of Hong Kong have performed Asia’s first histotripsy treatments for kidney cancer, demonstrating the potential of a non-invasive technology that destroys tumour tissue using focused ultrasound rather than surgical incisions.</p>
<p>Announced November 18, the milestone involved two patients treated at Gleneagles Hospital Hong Kong through a collaborative clinical trial led by the University of Hong Kong’s Faculty of Medicine (HKUMed).</p>
<p>Both patients, aged 70 and 71, had small kidney tumours measuring approximately two centimetres. The procedures were performed on October 13 and took less than an hour each.</p>
<p>Neither patient experienced observable complications, and both were discharged the following day. At a two-week follow-up, kidney function remained stable.</p>
<h2>Destroying tumours with ultrasound</h2>
<p>Histotripsy is an emerging non-invasive treatment that uses precisely focused ultrasound pulses to mechanically break down targeted tissue.</p>
<p>Unlike conventional thermal ablation, which destroys tissue using heat, histotripsy generates microscopic bubbles within the tumour. These bubbles rapidly expand and collapse, disrupting and liquefying the targeted tissue.</p>
<p>The procedure is guided by real-time ultrasound imaging and performed under general anesthesia. It requires no surgical incisions or needles to reach the tumour and does not use ionizing radiation.</p>
<p>Researchers believe the technology could offer an alternative for selected patients who may otherwise require surgery or other forms of tumour ablation.</p>
<h2>Preserving kidney function</h2>
<p>Kidney cancer treatment often involves removing part or all of the affected kidney, depending on tumour characteristics and the patient’s clinical condition.</p>
<p>Histotripsy offers the potential to destroy targeted cancer tissue while preserving surrounding healthy structures.</p>
<p>One of the two patients treated in Hong Kong had undergone major abdominal surgery approximately 10 years earlier, making a treatment without additional surgical incisions particularly attractive.</p>
<p>The research team is now recruiting additional patients to evaluate the technology’s safety and effectiveness.</p>
<h2>Further research needed</h2>
<p>Although the initial results are encouraging, histotripsy remains investigational for kidney cancer.</p>
<p>The two cases demonstrate early procedural feasibility and short-term recovery, but larger studies and longer follow-up are needed to determine cancer control, recurrence rates and long-term outcomes.</p>
<p>The Hong Kong team previously introduced histotripsy for liver cancer in 2024 and has been investigating additional applications involving other solid-organ tumours.</p>
<p>The latest procedures represent another step in evaluating whether focused ultrasound could eventually provide selected cancer patients with less invasive treatment options.</p>
<p>For hospitals and cancer centres, the development highlights the growing potential of image-guided technologies to expand treatment choices while reducing the physical burden of conventional procedures.</p>
<p>The post <a href="https://www.hospitalnews.com/new-ultrasound-technology-treats-kidney-cancer-without-surgical-incisions-in-asian-first/">New ultrasound technology treats kidney cancer without surgical incisions in Asian first</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Manitoba plans to reopen Victoria Hospital emergency department in summer 2027</title>
<link>https://edusehat.com/en/manitoba-plans-to-reopen-victoria-hospital-emergency-department-in-summer-2027</link>
<guid>https://edusehat.com/en/manitoba-plans-to-reopen-victoria-hospital-emergency-department-in-summer-2027</guid>
<description><![CDATA[ Expanded south Winnipeg facility will include 40 treatment spaces, additional higher-acuity observation beds and dedicated mental health assessment capacity. Manitoba is preparing to restore full emergency department services at Victoria Hospital in south Winnipeg by summer 2027, marking a significant step in the province’s efforts to expand hospital capacity and improve access to emergency care. […]
The post Manitoba plans to reopen Victoria Hospital emergency department in summer 2027 appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_2476138081.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 00:30:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Manitoba, plans, reopen, Victoria, Hospital, emergency, department, summer, 2027</media:keywords>
<content:encoded><![CDATA[<p>Expanded south Winnipeg facility will include 40 treatment spaces, additional higher-acuity observation beds and dedicated mental health assessment capacity.</p>
<p>Manitoba is preparing to restore full emergency department services at Victoria Hospital in south Winnipeg by summer 2027, marking a significant step in the province’s efforts to expand hospital capacity and improve access to emergency care.</p>
<p>Announced November 18, the reopening will return emergency services to a hospital whose emergency department closed in 2017 and was converted into an urgent care centre.</p>
<p>The Manitoba government says the project is progressing toward completion of major construction work in spring 2027, followed by the planned opening next summer.</p>
<p>Once operational, the redesigned emergency department will provide 40 treatment spaces, compared with 33 in the existing urgent care configuration.</p>
<h3>Expanded emergency care capacity</h3>
<p>The new department will include two resuscitation rooms, 24 treatment beds, two triage beds, six minor-treatment beds and six dedicated mental health assessment beds.</p>
<p>The redevelopment will also add eight higher-acuity observation beds, expanding the hospital’s ability to monitor patients who require more intensive clinical attention.</p>
<p>Other improvements include approximately 150 additional staff parking spaces.</p>
<p>Hospital staff and south Winnipeg residents participated in consultations that helped inform the redevelopment’s design.</p>
<p>The reopening is expected to give residents of south Winnipeg another location for emergency treatment and may help distribute patient volumes across the city’s hospital network. The effect on wait times will depend on staffing, demand and how emergency services are coordinated.</p>
<h3>Workforce recruitment supports expansion</h3>
<p>The province linked the reopening plans to its healthcare workforce recruitment efforts, reporting that Manitoba now has 500 net additional doctors compared with 2023.</p>
<p>At Victoria Hospital specifically, staffing additions include two physicians since June 2026. The province also reports hiring 24 allied health professionals, 10 healthcare aides and 26 nurses since October 2023.</p>
<p>The figures represent an important workforce milestone, although they do not establish how many emergency-specific staff will ultimately be available when the department opens.</p>
<p>Manitoba is also planning to restore emergency services at other hospitals, including Eriksdale, as part of its broader efforts to rebuild acute-care capacity.</p>
<h3>Staffing challenges remain</h3>
<p>Despite the planned expansion, physician and nursing organizations have raised concerns about the availability of appropriately trained staff.</p>
<p>Doctors Manitoba has indicated that emergency physician availability remains substantially below the national average, while the Manitoba Nurses Union has questioned whether sufficient nursing resources will be available to support additional emergency treatment spaces.</p>
<p>Another consideration is critical care capacity. The province has indicated that Victoria Hospital will provide a step-down level of intensive monitoring rather than restoring a conventional intensive care unit.</p>
<p>These issues highlight the importance of aligning infrastructure investments with workforce recruitment, clinical resources and regional patient-transfer arrangements.</p>
<h3>Rebuilding emergency services</h3>
<p>Victoria Hospital serves a growing area of south Winnipeg and provides inpatient, outpatient, surgical, geriatric rehabilitation and mental health services.</p>
<p>Restoring its emergency department represents a major change in the hospital’s role within the Winnipeg healthcare system.</p>
<p>The planned opening will be an important milestone, but the full benefits for patients and neighbouring hospitals will depend on achieving the construction timetable and ensuring adequate staffing and operational readiness.</p>
<p>For Manitoba, the project illustrates the interconnected challenges of rebuilding emergency capacity, retaining healthcare professionals and responding to increasing demand for hospital services.</p>
<p>The post <a href="https://www.hospitalnews.com/manitoba-plans-to-reopen-victoria-hospital-emergency-department-in-summer-2027/">Manitoba plans to reopen Victoria Hospital emergency department in summer 2027</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How dental professionals can manage negative self&#45;talk</title>
<link>https://edusehat.com/en/how-dental-professionals-can-manage-negative-self-talk</link>
<guid>https://edusehat.com/en/how-dental-professionals-can-manage-negative-self-talk</guid>
<description><![CDATA[ Rana Al-Falaki shares practical ways for dentists to recognise negative self-talk and develop a more constructive inner voice. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/Innervoice.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 21:25:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, dental, professionals, can, manage, negative, self-talk</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Rana Al-Falaki explores how negative self-talk can affect dentists’ wellbeing and leadership, and shares practical ways to manage your inner critic.</strong></p>



<p>Every clinician knows the value of a good assistant: someone at your side all day, anticipating, steadying, keeping you on track. Now imagine that same person spent the day muttering that you’re behind, that the patient in the chair is about to complain, that the team doesn’t respect you and probably never will. You’d replace them by lunchtime.</p>



<p>Yet most of us keep exactly that voice on the payroll. It’s the one in our own head.</p>



<p>Self-talk, the running commentary we have with ourselves, is relentless. Research has estimated that we move through more than 6,000 distinct thoughts a day. And the brain doesn’t treat them equally.</p>



<p>Decades of psychology research, summarised in Roy Baumeister’s landmark review ‘Bad is stronger than good’, show that negative information carries more weight, lingers longer and shapes behaviour more powerfully than positive information of the same size.</p>



<p>In dentistry, we are trained to spot what’s wrong – the caries, the open margin, the flaw in a treatment plan, and that negative bias is sharpened every working day.</p>



<p>The problem is that we rarely switch it off when we look at ourselves.</p>



<h2 class="wp-block-heading">Realising the dream</h2>



<!--free-wall-stop-->



<p>Dr BK had recently achieved what many associates dream of: buying their own practice.</p>



<p>However, within months, the dream felt more like a weight. The inherited team was polite but distant. Suggestions were nodded through in meetings and quietly ignored. Changes stalled.</p>



<p>Dr BK was working longer days, sleeping badly, getting headaches by mid-afternoon and arriving home with nothing left to give.</p>



<p>When Dr BK joined NAIL-IT in Dentistry’s Titanium mentoring and leadership training programme, they expected to talk about team structures, contracts, perhaps a new practice manager. But within half an hour of our first session, a different pattern emerged – not in what was happening at the practice, but in how Dr BK described it:</p>



<ul class="wp-block-list">
<li>‘They’ll never accept me’</li>



<li>‘I should have known better’</li>



<li>‘If this goes wrong, it’s all on me’</li>



<li>‘One bad review and it’s over.’</li>
</ul>



<p>None of these were facts. They were commentary. But that commentary was running Dr BK’s day.</p>



<div aria-hidden="true" class="wp-block-spacer"></div>


        <div class="atext-outer-wrapper overflow-hidden relative">
            <div class="atext atext-full-screen text-context-400 md:px-3 bg-center bg-cover ">
                                                            <div class="background active"></div>
                                                                <div class="first-image">
                            
                        </div>
                                        <div class="text-scroll-wrap container container-sm flex flex-wrap">
                        <div class="text-scroll-container lg:w-1/2 lg:px-8 lg:py-16">
                                                                <div class="text-part rte" data-image="https://dentistry.co.uk/app/uploads/2026/11/speech-scaled-e1794910178750.jpg">
                                        <h2><strong>Five simple ways to make self-talk work for you</strong></h2>
<ol>
<li>Spot the pattern. Notice when you’re catastrophising, taking things personally or expecting perfection. Name the habit before accepting the thought as fact</li>
<li>Check the evidence. Ask: ‘How true is this? What’s another explanation? Would I say this to a colleague?’</li>
<li>Find a useful reframe. Swap ‘It’s all my fault’ for ‘Which part is mine to change?’ Aim for accuracy, not empty positivity</li>
<li>Give yourself clear instructions. Before a difficult conversation, try: ‘Slow down. Listen first. One point at a time’</li>
<li>Coach yourself by name. Create a little distance: ‘[Your name], you’ve handled challenges before. What’s the next step?’</li>
</ol>
<p> </p>
                                    </div>
                                                    </div>
                    </div>
                            </div>
        </div>
    


<h2 class="wp-block-heading">The myth: ‘my inner critic helps me stay sharp’</h2>



<p>When we pointed this out, Dr BK pushed back, as many high achievers do. ‘That voice is what got me here. It’s what keeps my standards high. If I go easy on myself, I’ll slip,’ they said.</p>



<p>It’s one of the most common beliefs in our profession: that harshness is the price of excellence, and that self-compassion is a polite word for lowering the bar.</p>



<p>It isn’t true. Harsh self-talk doesn’t sharpen performance; it narrows it. A mind braced for threat has less capacity for problem-solving, creativity and calm decision-making, and instead keeps you in survival mode – running on adrenaline.</p>



<p>It may surprise you that self-talk never stays private. It leaks into tone, body language and the way we brief a dental nurse or open a team meeting. A leader who silently tells themselves ‘they don’t respect me’ walks into the room guarded and defensive, and the team responds in kind.</p>



<p>Dr BK’s inner critic wasn’t protecting their standards. It was quietly creating the very resistance they feared.</p>



<h2 class="wp-block-heading">The truth: self-talk is a trainable performance tool</h2>



<p>Self-talk is a skill that can be trained like any other. Elite sport has known this for years. A meta-analysis of 32 studies found that self-talk interventions produced a reliable improvement in performance, with a considerably stronger effect when people were properly trained in self-talk.</p>



<p>Within NAIL-IT Leadership, self-talk sits in the ‘attitude’ pillar as one of four keys in the Sustainable Success Toolkit, alongside ‘strength’, ‘solution’ and ‘smile’. We worked with Dr BK in the following three stages.</p>



<h3 class="wp-block-heading">1. Spot the pattern</h3>



<p>Negative self-talk tends to fall into recognisable types: filtering out the positives, personalising, catastrophising, blaming, should-culture, magnifying, perfectionism and polarising (all-or-nothing thinking).</p>



<p>Dr BK’s top three were obvious once named:</p>



<ul class="wp-block-list">
<li>Personalising – every flat response from the team was proof of personal failure</li>



<li>Catastrophising – one complaint became the end of the practice</li>



<li>Should-culture – ‘I should be able to handle this’ left no room to ask for help.</li>
</ul>



<p>Naming the type is powerful in itself. It turns what feels like a truth into a recognisable habit.</p>



<h3 class="wp-block-heading">2. Twist it</h3>



<p>Next, we built positive twists – not empty cheerleading, but more accurate and more useful alternatives:</p>



<ul class="wp-block-list">
<li>‘It’s all my fault’ became ‘Many things may be responsible – which part is mine to change?’</li>



<li>‘This is a disaster’ became ‘There is a solution to everything’</li>



<li>‘It’s too hard’ became ‘It may be challenging, but I have skills I can draw on.’</li>
</ul>



<h3 class="wp-block-heading">3. Use the ‘I AM’ system</h3>



<p>Finally, Dr BK learned to use self-talk deliberately, with <a href="http://nailitdentistry.com/">NAIL-IT’s</a> instruct, analyse, motivate (I AM) self-talk system:</p>



<ul class="wp-block-list">
<li>Instruct – short, clear cues in the moment. Before a difficult conversation: ‘Slow down. Listen first. One point at a time’</li>



<li>Analyse – question the thought before obeying it. How true is this really? What’s the evidence? Would I say this to a colleague? What’s another explanation?</li>



<li>Motivate – affirm identity and intent: ‘I am building this team. I am learning to lead.’</li>
</ul>



<p>One small adaptation made a striking difference. People who coach themselves by name, or as ‘you’ rather than ‘I’, feel less distress and perform better during stressful tasks.</p>



<p>So ‘I can’t handle this’ became ‘BK, you’ve handled harder than this. What’s the next step?’</p>



<p>That small distance created space to think.</p>



<p>Practised consistently, the benefits compound: better mood, focus, motivation and decision-making; lower stress; stronger relationships and team engagement; and better overall performance.</p>


        <div class="py-6 px-4 sm:px-6 flex items-center justify-center">
            <div class="max-w-4xl text-center space-y-4">
                                    <div class="font-secondary text-primary-500 text-2xl md:text-3xl">
                        ‘Harsh self-talk doesn’t sharpen performance; it narrows it’                    </div>
                                                            </div>
        </div>



<h2 class="wp-block-heading">The wins</h2>



<p>The changes didn’t happen overnight, but within a few months the difference was unmistakable.</p>



<p>At work, Dr BK walked into meetings curious rather than defensive. They stopped pre-empting rejection and started inviting input – and the team began to offer it. Suggestions turned into actions, changes that had stalled for months were finally implemented, and the practice manager described the atmosphere as lighter, clearer and more of a team.</p>



<p>With less time lost to second-guessing and stalled decisions, productivity rose, and revenue followed.</p>



<p>Healthwise, the headaches eased and sleep improved. With energy no longer burned on internal battles, Dr BK found the headspace to revisit the growth plans they had shelved.</p>



<p>At home, the shift was perhaps the most profound. Dr BK was present with their partner and children again.</p>



<p>‘I thought I needed the team to change,’ Dr BK said. ‘It turns out the first voice I needed to stop obeying was my own.’</p>



<h2 class="wp-block-heading">Choose your voice</h2>



<p>You can’t stop thousands of thoughts passing through your mind each day. But you can choose which ones you believe, which ones you challenge, and which ones you turn into instruction, analysis and motivation.</p>



<p>The voice in your head will run your day either way. The only question is whether it’s working for you, or against you.</p>



<p><em><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</em></a></em></p>]]> </content:encoded>
</item>

<item>
<title>Loss of measles elimination status signals growing vaccination crisis</title>
<link>https://edusehat.com/en/loss-of-measles-elimination-status-signals-growing-vaccination-crisis</link>
<guid>https://edusehat.com/en/loss-of-measles-elimination-status-signals-growing-vaccination-crisis</guid>
<description><![CDATA[ America’s loss of measles elimination status is a warning sign of a growing and entirely preventable public health threat that extends beyond measles and […]
The post Loss of measles elimination status signals growing vaccination crisis appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/cdc-83YXJwzKwmY-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 21:05:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Loss, measles, elimination, status, signals, growing, vaccination, crisis</media:keywords>
<content:encoded><![CDATA[<p>America’s loss of measles elimination status is a warning sign of a growing and entirely preventable public health threat that extends beyond measles and is caused by low vaccination rates.</p>
<p>Measles, which had been officially declared eliminated in the U.S. in 2000, is once again endemic in the country, the Pan American Health Organization (PAHO) <a href="https://www.paho.org/en/news/17-11-2026-paho-urges-countries-step-efforts-stop-measles-outbreaks-and-move-towards">officially announced Nov. 17</a>. The decision is based on proof that <a href="https://www.cnn.com/2026/11/13/health/us-measles-elimination-status">one specific strain of measles virus </a>had been in circulation within the U.S. for more than a year.</p>
<p>“The loss of measles elimination status is a completely preventable setback that reflects our failure to protect thousands of Americans, especially children, from a disease for which we have had a safe and highly effective vaccine for decades,” <a href="https://www.bio.org/press-release/bio-statement-loss-measles-elimination-status">said Phyllis Arthur</a>, EVP and Chief of Global Health at the Biotechnology Innovation Organization (BIO).</p>
<p>“Measles is the canary in the coalmine,” Arthur added. “It is the most obvious sign of the broader risk of low vaccination rates.”</p>
<p>The loss of measles elimination status in the U.S. was no surprise, with outbreaks causing 5,412 reported cases so far this year—the most in since 1991—according to the<a href="https://www.cdc.gov/measles/data-research/index.html"> Centers for Disease Control and Prevention (CDC)</a>. The cases led to<a href="https://beaconbio.org/en/report/?reportid=2090bc17-2eeb-42ef-8021-1248721f25e1"> 10 reported</a> deaths, with six thus far<a href="https://www.cdc.gov/measles/data-research/index.html"> confirmed by the CDC</a>.</p>
<p>The measles outbreaks have been caused by a reduction in vaccination that is also causing concerning increases in other vaccine preventable diseases.</p>
<p>“We need to act as one country with a unified goal of protecting public health,” Arthur said. “Rather than debate how we got here, we must move forward together to reestablish the norm of routine vaccination for a host of pediatric infectious diseases that used to cause significant morbidity and mortality and are starting to cause them again.”</p>
<h2>Unknown danger</h2>
<p>We do not yet know the full extent of the threat, according to Arthur.</p>
<p>“The measles cases we’re hearing about are just the tip of the iceberg. There are many unreported illnesses,” she said. “Adults who were never vaccinated but were protected by herd immunity and kids who should have been vaccinated are being surrounded by this highly contagious disease, and it’s spreading.”</p>
<p><a href="https://evidence.nejm.org/doi/full/10.1056/EVIDpha2600416">A preliminary study</a> of measles outbreaks between January 2025 and September 2026 found 112 cases among pregnant women and 13 congenital cases of measles passed on to newborns. The outbreaks were mostly in communities with low vaccination rates, and 98% of the women involved were unvaccinated or had unknown vaccination status,<a href="https://evidence.nejm.org/doi/full/10.1056/EVIDpha2600416"> said the study, released Nov. 16</a>.</p>
<p>Meanwhile, other preventable diseases are raging. Pediatric influenza, which can be controlled with a seasonal vaccine, hit a near-record last year.</p>
<p>“The 2024–25 influenza season had the highest number of pediatric deaths reported (280) since child deaths became nationally notifiable in 2004, except for the 2009–10 influenza A(H1N1)pdm09 pandemic,”<a href="https://www.cdc.gov/mmwr/volumes/74/wr/mm7436a2.htm"> according to CDC</a>, which recommends flu vaccination. Of the children who died of flu last year, 89% were not fully vaccinated, CDC said.</p>
<p>Pertussis, or whooping cough, which is especially dangerous for infants, saw<a href="https://jamanetwork.com/journals/jama/article-abstract/2822941"> an alarming increase in 2024</a> followed by<a href="https://www.cdc.gov/pertussis/php/surveillance/index.html"> another heavy year in 2025</a>, even though the vaccine is<a href="https://my.clevelandclinic.org/health/drugs/21639-pertussis-whooping-cough-vaccine"> highly effective</a>.</p>
<p>Another routine immunization for babies is the Haemophilus influenzae type b (Hib) vaccine.</p>
<p>“Before the vaccine, Hib was the leading cause of bacterial meningitis in children less than five years old,”<a href="https://pauloffit.substack.com/p/the-return-of-hib"> according to pediatric vaccine expert Paul Offit, MD</a>. “Hib also<a href="https://www.cdc.gov/hi-disease/about/index.html#:~:text=The%20most%20common%20serious%20infections%20caused%20by,infection)%20Infectious%20arthritis%20(swelling%20of%20a%20joint)"> caused</a> pneumonia, sepsis, cellulitis, and arthritis.”</p>
<p>The Hib vaccine became available in 1987, leading to a 99% decrease in infections, so there were typically about two deaths a year in the U.S., Offit said. Yet in 2025, a doctor<a href="https://www.usatoday.com/story/life/health-wellness/2026/04/04/new-hib-cases-concern-deadly-disease-vaccine/89466803007/"> reported two cases in Florida alone</a>, impacting unvaccinated children, one fatal and one causing permanent brain damage. This alarming increase indicates a return of Hib due to low vaccination, Offit said.</p>
<p>Vitamin K shots, routinely given to newborns since the 1960s, protect infants from vitamin K deficiency, which can cause bleeding that leads to permanent brain damage or death. Babies without the shot are<a href="https://okckidsurology.com/vitamin-k-for-newborns-why-it-matters-shot-vs-oral-drops/"> 81 times more likely</a> to experience bleeding due to vitamin K deficiency, with<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7041551/"> as many as 1,700 out of 100,000</a> unprotected babies impacted. But parents increasingly<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7041551/"> decline the vitamin K shot</a>.</p>
<p>“The number of babies that did not receive the shot rose from 2.92% in 2017 to 5.18% in 2024,”<a href="https://www.nih.gov/news-events/nih-research-matters/protective-vitamin-shots-newborns-decline"> according to research.</a> “That’s a 77% increase in infants not receiving the shot over the eight-year period.”</p>
<h2>The need to work on messaging</h2>
<p>The declining vaccination rates that<a href="https://bio.news/health/low-vaccination-rates-put-40-million-children-worldwide-at-risk-of-measles/"> began during COVID</a> dropped even further following this year’s<a href="https://bio.news/bios-view/bio-warns-of-risks-from-change-to-cdcs-vaccine-recommendations/"> changes in federal recommendations</a> for vaccination,<a href="https://www.kff.org/medicaid/kindergarten-routine-vaccination-rates-continue-to-decline/"> according to research</a>.</p>
<p>The solution, Arthur said, is unequivocally proclaiming the necessity of immunization.</p>
<p>“We need to have clear, consistent evidence-based messaging on the value of the measles-mumps-rubella vaccine from senior leaders within and outside of government. We need to have a better discussion of the danger of measles and the benefits of vaccination,” she said. “You hear talk of the risks of measles vaccination, but let’s talk about the much greater risks of measles.”</p>
<p>Along with appropriate messaging, federal authorities need to support state authorities in responding to outbreaks and providing education, Arthur said. She noted that communities with a 93% vaccination rate instead of the recommended 95% are concerning, but the real problem is communities where vaccination rates are in the low 80s.</p>
<p>“State leaders are aware of these communities, and they are better placed to make partnerships with leaders in those communities and reach people with the message that vaccination protects them and their children,” Arthur said.</p>
<p>Beyond the measles vaccine, this same community effort is necessary to encourage the use of all vaccines, according to Arthur.</p>
<p>“We know these diseases cause morbidity, and mortality,” she said. “And all of them are preventable with a very simple intervention, which is the vaccine.”</p>
<p><a href="https://www.bio.org/press-release/bio-statement-loss-measles-elimination-status"><strong>Read BIO’s campaign: Invest in America. Vaccinate.</strong></a></p>
<p> </p>
<p>The post <a href="https://bio.news/health/loss-of-measles-elimination-status-signals-growing-vaccination-crisis/">Loss of measles elimination status signals growing vaccination crisis</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>A human liver has been kept alive outside the body for a record seven weeks</title>
<link>https://edusehat.com/en/a-human-liver-has-been-kept-alive-outside-the-body-for-a-record-seven-weeks</link>
<guid>https://edusehat.com/en/a-human-liver-has-been-kept-alive-outside-the-body-for-a-record-seven-weeks</guid>
<description><![CDATA[ Researchers in Australia claim they’ve kept a human liver alive, on life support, outside the body for seven weeks, opening up speculative new possibilities in biomedical engineering. The feat, whose details are pending publication, was carried out in Sydney after a team led by surgeon and inventor Carlo Pulitano connected a donated liver to a… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/11/EOPS-V1.1-.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 21:05:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>human, liver, has, been, kept, alive, outside, the, body, for, record, seven, weeks</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Record-breaking liver survival:</strong> A Sydney surgical team kept a human liver alive outside the body for seven weeks using an automated system of pumps and sensors that mimics the functions of a living body.</li><br><li><strong>Automation was the secret:</strong> When the team compared manual versus automated life-support systems across 55 donated livers, automated perfusion tripled average survival time to four weeks, with one organ reaching seven.</li><br><li><strong>Organs that heal:</strong> Organ perfusion has become more common over the past decade. Researchers have found some evidence that extended perfusion may allow damaged organs to repair themselves before transplant.</li><br><li><strong>A new frontier in medicine:</strong> Long-term organ life-support is attracting serious scientific interest. Two new scientific societies were recently founded to explore the concept. </li><br></ul>" data-chronoton-post-id="1148934" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p class="wp-block-paragraph">Researchers in Australia claim they’ve kept a human liver alive, on life support, outside the body for seven weeks, opening up speculative new possibilities in biomedical engineering.</p>



<p class="wp-block-paragraph">The feat, whose details are pending publication, was carried out in Sydney after a team led by surgeon and inventor Carlo Pulitano connected a donated liver to a system of automated pumps and sensors that fed the organ nutrients, supplied it with blood, and whisked away waste. </p>



<p class="wp-block-paragraph">In an interview, Pulitano, a transplant surgeon at the Royal Prince Alfred Hospital and a professor at the University of Sydney, likened the life support system to “an artificial body.” Its official name is the Extended Organ Perfusion System.</p>



<p class="wp-block-paragraph">“Our group is the only one in the world to have maintained a human liver under fully normothermic, physiological conditions for seven weeks,” he says.   </p>





<p class="wp-block-paragraph">Normothermic means body temperature, or about 37 °C. The previous record for keeping an internal organ alive outside the body was set in Switzerland several years ago. That organ—also a liver—lasted around two weeks. </p>



<p class="wp-block-paragraph">Most organs destined for transplant survive only a few hours in special ice buckets and need to be raced to their destination. Over the last decade, however, surgeons have been switching to perfusion systems, which pump warm or cold fluids into an organ. This can double the time it can be held before it must be transplanted. </p>



<p class="wp-block-paragraph">Pulitano says the key to breaking the record was to automate the systems used to keep the organ thriving. During <a href="https://easl.eu/event/ilts_congress_2026/">a meeting in Switzerland</a> earlier this year, the Sydney team described perfusing 55 human livers, one after the other. Some were connected to a system that needed to be adjusted manually, but for those placed on the automated system—which produced the seven-week survivor—the average survival time tripled, to about four weeks.  </p>



<p class="wp-block-paragraph">Perfusion has already enabled doctors to <a href="https://www.technologyreview.com/2015/09/01/166380/transplant-surgeons-revive-hearts-after-death/">restart hearts</a> from dead people and keep them beating outside the body. Paulo Martins, a transplant doctor at the University of Oklahoma, says about half the kidneys he transplants are now perfused, even though the process can add $100,000 to the cost of a transplant.  </p>



<p class="wp-block-paragraph">While the research awaits formal publication, the eventual goal is what Pulitano and colleagues call “time-unlimited liver preservation.”</p>



<p class="wp-block-paragraph">Scientists have already discovered possible medical benefits to keeping organs on life support longer than usual. One, they say, is that perfused organs apparently <a href="https://www.technologyreview.com/2026/09/14/1144010/donated-livers-can-be-made-biologically-younger/">start to repair</a> themselves and become stronger after a day or so. That’s what led a Swiss team, in 2022, to transplant a damaged liver <a href="https://www.nature.com/articles/s41587-022-01354-7">that had been kept on perfusion for three days</a>—the longest time any internal organ had remained outside the body before a successful transplant, says Waldemar Hoffmann, the CEO and cofounder of Apersys, a startup formed to commercialize the technology.</p>



<p class="wp-block-paragraph">Pulitano says his own startup, Aeternum Life Technologies, will be helping with a planned trial in Sydney to transplant low-quality livers kept on perfusion for four days.</p>



<p class="wp-block-paragraph">What’s less clear, says Hoffmann, is whether any transplant surgeon would ever want, or need, to use an organ kept alive for nearly two months. He says people in the field believe Pulitano’s record is real, but they don’t know how healthy the organ was at the end or even what so much extra time is likely to achieve. “The key question is what the purpose for a seven-week perfusion would be,” he says.  </p>



<p class="wp-block-paragraph">Yet that’s where things could start to get interesting, <a href="http://pubmed.ncbi.nlm.nih.gov/40259786/">says Martins</a>, the Oklahoma surgeon. Long-term life support could enable far-out concepts like artificial wombs, new types of organ manufacturing, and the chance to experiment directly on human organs outside the body for extended periods.</p>



<p class="wp-block-paragraph">For his part, Pulitano says long-term machine perfusion could help grow new organs. In living donations, surgeons commonly take half of a person’s liver to give someone else. After about two months, both parts will have grown back almost to their full volume. Pulitano says he’s tried dividing a liver and then attaching the sections to the machine. If that works, he says, it could be a way to multiply one donor liver into several full-size organs.</p>



<p class="wp-block-paragraph">“It’s important to have people thinking outside the box and pushing the limits and creating possibilities for things that, right now, sometimes we don’t even have a need for but are going to be needed in the future,” says Martins. “That’s how science moves.”  </p>





<p class="wp-block-paragraph">He’s not the only one who thinks so. For instance, a US company, Bexorg, has been reanimating human brains using perfusion pumps. The idea is to study what effects experimental drugs have on them. That company perfuses brains for about a day but has said it wants to extend the time to two weeks.</p>



<p class="wp-block-paragraph">Similar experiments can be done on livers, says Pulitano, who has already tried adding gene therapies to the organs. “It gives us a living human organ model for translational research that no animal system can match, because the biology, the immunology, and the drug responses are human from the outset,” he says.</p>



<p class="wp-block-paragraph">Meanwhile, in Silicon Valley, patents <a href="https://patents.google.com/patent/WO2024155957A1/en">filed</a> by <a href="https://www.technologyreview.com/2021/09/04/1034364/altos-labs-silicon-valleys-jeff-bezos-milner-bet-living-forever/">Altos Labs</a>, a billionaire-backed longevity startup, describe attempts to introduce reprogramming genes into animal livers maintained outside the body. Eventually, Altos scientists <a href="https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(25)00445-X"></a>have speculated, they might temporarily disconnect a failing organ while it’s still in a person’s body, connecting it to a perfusion machine in order to douse it with ultra-powerful genetic treatments without risking the rest of the body.</p>



<p class="wp-block-paragraph">Doctors probing the limits of organ life support have now formed two new scientific societies to explore the concept. One, founded by Martins and called the International Society for Organ Preservation and Perfusion Therapy, will hold its inaugural meeting this year in Italy. The other, based in China, was <a href="https://info.newsgd.com/node_91423f6a55/e6458c1195.shtml">launched in August</a> to advance what doctors at the First Affiliated Hospital of Sun Yat-Sen University have termed “<a href="https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000003524~organ-medicine-new-concept-of-life-sciences">organ medicine”</a>: research at the level of whole organs kept alive by “bionic maintenance.”  </p>



<p class="wp-block-paragraph">“What is exploding is the idea of this technology that clearly goes beyond simply organ preservation,” says Pulitano. “Basically, that’s a concept that’s entirely new.”</p>]]> </content:encoded>
</item>

<item>
<title>Schedule M: Govt proposes regulatory flexibility under three drug categories</title>
<link>https://edusehat.com/en/schedule-m-govt-proposes-regulatory-flexibility-under-three-drug-categories</link>
<guid>https://edusehat.com/en/schedule-m-govt-proposes-regulatory-flexibility-under-three-drug-categories</guid>
<description><![CDATA[ 
The Ministry clarified that the proposal does not dilute quality or safety standards or regulatory oversight.
The post Schedule M: Govt proposes regulatory flexibility under three drug categories appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/19162202/compliance.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 20:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Schedule, Govt, proposes, regulatory, flexibility, under, three, drug, categories</media:keywords>
<content:encoded><![CDATA[<div><img width="800" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/19162202/compliance.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/19162202/compliance.jpg 800w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/19162202/compliance-300x150.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/19162202/compliance-768x384.jpg 768w" sizes="auto, (max-width: 800px) 100vw, 800px"></div><p data-pm-slice="1 1 []">The Union Ministry of Health and Family Welfare has proposed changes to the Drugs Rules, 1945, to provide regulatory flexibility under revised Schedule M for medicinal gases, empty gelatin capsules and disinfectant fluids.</p>
<p>The draft amendment, published as G.S.R. 985 (E) dated November 6, seeks to continue exemptions available to these products under Schedule M before its revision.</p>
<p>The proposal follows stakeholder representations on the applicability of revised Schedule M, notified through G.S.R. 922 (E) on December 28, 2023.</p>
<p>At its 93rd meeting on February 16, 2026, the Drugs Technical Advisory Board (DTAB) observed that some revised Schedule M requirements may not be relevant to the manufacturing processes of these products. It recommended continuing the exemptions available under the earlier Schedule M.</p>
<p>The proposed changes would allow Licensing Authorities to take product-specific decisions based on scientific and practical considerations, while aligning regulatory requirements with the nature of the products and their manufacturing processes.</p>
<p>The Ministry clarified that the proposal does not dilute quality or safety standards or regulatory oversight.</p>
<p>Stakeholders and members of the public can submit objections and suggestions within the prescribed period from the date of publication of the draft notification in the Official Gazette.</p>
<p>Submissions can be sent to the Under Secretary (Drugs), MoHFW, Kartavya Bhawan-1, New Delhi – 110011, or emailed to <a href="mailto:drugsdiv-mohfw@gov.in">drugsdiv-mohfw@gov.in</a>.</p>
<p>The post <a href="https://www.expresspharma.in/schedule-m-govt-proposes-regulatory-flexibility-under-three-drug-categories/">Schedule M: Govt proposes regulatory flexibility under three drug categories</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From GMP compliance to workforce compliance: Why digital HR systems matter for pharma manufacturers</title>
<link>https://edusehat.com/en/from-gmp-compliance-to-workforce-compliance-why-digital-hr-systems-matter-for-pharma-manufacturers</link>
<guid>https://edusehat.com/en/from-gmp-compliance-to-workforce-compliance-why-digital-hr-systems-matter-for-pharma-manufacturers</guid>
<description><![CDATA[ 
As pharma operations become more complex, managing employee records, training, attendance and statutory requirements calls for greater accuracy and accountability. Sonali Chowdhry, CEO, OfficeNet, highlights how technology can bring greater visibility, consistency and control to workforce management
The post From GMP compliance to workforce compliance: Why digital HR systems matter for pharma manufacturers appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/19165236/Ms._Sonali_Chowdhry_-_CEO_-_Officenet-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 20:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, GMP, compliance, workforce, compliance:, Why, digital, systems, matter, for, pharma, manufacturers</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/19165236/Ms._Sonali_Chowdhry_-_CEO_-_Officenet-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/19165236/Ms._Sonali_Chowdhry_-_CEO_-_Officenet-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/19165236/Ms._Sonali_Chowdhry_-_CEO_-_Officenet-1-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p align="JUSTIFY"><span><span><span lang="en-IN">Pharmaceutical manufacturing is among the most tightly regulated industries in the world. Quality, consistency and accountability define every stage of production. A single lapse can compromise patient safety, so nothing is left to chance. Cleanroom standards, process monitoring, documentation and batch traceability all sit within strict Good Manufacturing Practices (GMP). Yet while product quality commands most of the attention, workforce compliance deserves the same rigour.</span></span></span></p>
<p align="JUSTIFY"><span><span><span lang="en-IN">Pharma manufacturing runs on people as much as on processes and technology. Employees across production, quality control, packaging, warehousing and maintenance must follow defined protocols, hold the right training and work to approved procedures. People are as much a part of the control environment as any validated equipment. A gap in workforce management, whether in attendance records, training documentation, shift allocation or statutory compliance, does not stay contained. It creates operational friction and can weaken the wider compliance framework.</span></span></span></p>
<p align="JUSTIFY"><span><span><span lang="en-IN">That makes workforce compliance a natural extension of GMP. The right people must hold the right roles. Their working hours must be recorded accurately. Every employee record must be maintained systematically. Regulators expect this to be demonstrable, not assumed. The challenge grows sharply for organisations running multiple facilities, managing large workforces or engaging contract labour across production units.</span></span></span></p>
<p align="JUSTIFY"><span><span><span lang="en-IN">Manual HR processes were not built for this. Attendance registers, spreadsheets and disconnected systems produce inaccurate records, delayed reporting and limited visibility. Multiple shifts, overtime, leave, contractor attendance and payroll across sites only add to the complexity. Each gap is a potential point of exposure. Most important, fragmented documentation makes accurate workforce data hard to retrieve when an internal review or regulatory inspection demands it.</span></span></span></p>
<p align="JUSTIFY"><span><span><span lang="en-IN">Digital HR systems close these gaps by bringing workforce processes onto a single platform. Automated attendance tracking, shift scheduling, leave management and payroll processing deliver accuracy and consistency in employee records. Integrated contractor management and statutory compliance workflows give organisations firmer oversight of their extended workforce. Records stay current, consistent and ready for scrutiny.</span></span></span></p>
<p align="JUSTIFY"><span><span><span lang="en-IN">Training and skill management is equally critical. In a GMP setting, an untrained employee is a compliance risk. Employees must be competent to handle equipment, follow safety protocols and comply with standard operating procedures. Digital systems maintain training records, track certifications and surface training requirements. Gaps become easier to spot, and employees are better prepared for their responsibilities.</span></span></span></p>
<p align="JUSTIFY"><span><span><span lang="en-IN">The value extends beyond documentation. Real-time visibility into availability, shift allocation and labour deployment lets plant managers respond faster to production demands. Administrative bottlenecks shrink, departments coordinate better and workforce resources are used more efficiently. That efficiency compounds across shifts and sites.</span></span></span></p>
<p align="JUSTIFY"><span><span><span lang="en-IN">As manufacturers expand and regulatory expectations grow more complex, compliance can no longer stop at production and product quality. The systems that support the workforce must be accurate, transparent and accountable. Digital HR platforms provide the structure to deliver that, connecting people, processes and compliance in one framework. Strong compliance begins with the people who deliver it.</span></span></span></p>
<p align="JUSTIFY">
</p><p>The post <a href="https://www.expresspharma.in/from-gmp-compliance-to-workforce-compliance-why-digital-hr-systems-matter-for-pharma-manufacturers/">From GMP compliance to workforce compliance: Why digital HR systems matter for pharma manufacturers</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How apprenticeships are developing stronger dental teams across England</title>
<link>https://edusehat.com/en/how-apprenticeships-are-developing-stronger-dental-teams-across-england</link>
<guid>https://edusehat.com/en/how-apprenticeships-are-developing-stronger-dental-teams-across-england</guid>
<description><![CDATA[ Poultec Training explores the benefits of apprenticeships in the dental sector, from dental nurses to administrators and support staff. Recruiting, developing and retaining skilled people remains a priority for many dental practices. From clinical care to front-of-house support, every member of the team contributes to the patient experience and the smooth running of the practice.… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/apprentice.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 17:50:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, apprenticeships, are, developing, stronger, dental, teams, across, England</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Poultec Training explores the benefits of apprenticeships in the dental sector, from dental nurses to administrators and support staff.</strong></p>



<p>Recruiting, developing and retaining skilled people remains a priority for many dental practices. From clinical care to front-of-house support, every member of the team contributes to the patient experience and the smooth running of the practice.</p>



<p>For employers, the challenge is not only finding the right people, but keeping them, developing them and creating clear routes for progression. Apprenticeship training can support this by providing a structured and funded way to train new recruits, develop existing staff, and build skills across the whole practice team.</p>



<h2 class="wp-block-heading"><strong>Training trainee dental nurses</strong></h2>



<p>The <a href="https://www.poultec.co.uk/dental-nurse-apprenticeship-level-3/" target="_blank" rel="noreferrer noopener">dental nurse apprenticeship</a> remains one of the most recognised apprenticeship routes within dentistry. For practices struggling to recruit qualified dental nurses, it offers a practical alternative to relying only on already-qualified candidates.</p>



<p>Through the Level 3 dental nurse apprenticeship, trainee dental nurses can work in practice while developing skills in areas such as chairside support, patient care, infection control, radiography, health and safety, and professional practice.</p>



<p>For employers, learners can be trained around the practice’s own systems, standards and approach to patient care from the beginning. For learners, it provides a clear route into dental nursing, combining workplace experience with recognised training.</p>



<p>The apprenticeship supports trainee dental nurses to gain the knowledge, skills and qualification needed to apply to the General Dental Council (GDC) for professional registration as a dental nurse. The GDC currently requires all new trainee dental nurses to start a recognised training programme within 12 months of starting work. For practices, this makes early planning and choosing the right training route even more important.</p>



<h2 class="wp-block-heading"><strong>Developing the wider dental team</strong></h2>



<p>While dental nurse training is a vital part of workforce development, apprenticeships can support much more than clinical roles alone.</p>



<p>Receptionists, administrators and patient support staff are often the first point of contact for patients. Their communication, organisation and confidence can influence patient experience, appointment flow, and practice efficiency.</p>



<p>A dental receptionist apprenticeship can support front-of-house staff to develop skills in patient communication, appointment booking, customer service, administration and handling enquiries professionally.</p>



<p>An apprenticeship for dental administrators can help staff build stronger skills in records, processes, communication, coordination and wider practice support. This can be useful for team members taking on more responsibility or supporting areas such as compliance, patient coordination or practice administration.</p>



<p>By developing non-clinical staff, practices can improve efficiency, reduce pressure on colleagues, and support a better experience for patients.</p>



<h2 class="wp-block-heading"><strong>Progression for registered dental nurses</strong></h2>



<p>Retaining dental nurses is just as important as recruiting new ones. Many registered dental nurses are keen to continue developing once they are qualified. Without clear development routes, practices risk losing skilled team members who want to progress.</p>



<p>The Level 4 Oral Health Practitioner apprenticeship can support GDC-registered dental nurses to develop prevention-focused skills including oral health education, patient-centred care and oral and general health improvement.</p>



<p>For practices, this can help strengthen prevention, patient education and wider clinical support. For dental nurses, it offers a structured progression route that allows them to continue working while developing new skills and confidence.</p>



<h2 class="wp-block-heading"><strong>Making apprenticeships work in practice</strong></h2>



<p>One of the main benefits of apprenticeship training is that it is work-based. Learners gain new knowledge and skills while continuing their role in the practice, supported by their employer and training provider.</p>



<p>Funding may also be available, with up to 100% of training and assessment costs covered depending on eligibility. This can help practices train new recruits and existing employees in a cost-effective way.</p>



<p>Successful apprenticeship delivery relies on the right support. Practices need clear communication, funding guidance and a provider that understands the pace and pressures of a dental environment.</p>



<p>Poultec Training works with dental practices across England to deliver apprenticeship training shaped around the needs of each practice. Poultec offers dental apprenticeships to support both clinical and non-clinical roles, from trainee dental nurses and dental receptionists to administrators and oral health practitioner progression for registered dental nurses. Employers and learners are supported throughout the apprenticeship journey.</p>



<p>‘Dental practices are built around people,’ said Ben Gaskins, head of business development at Poultec Training. ‘Apprenticeships can help practices invest in their team, create progression routes and develop skills that support both staff and patients.’</p>



<p>For dental practices, apprenticeships are more than a recruitment route. Used well, they can support retention, progression and long-term workforce planning across the whole team.</p>



<p>To find out how dental apprenticeships could support your practice, visit Poultec Training’s <a href="https://www.poultec.co.uk/sectors/dental/" target="_blank" rel="noreferrer noopener">dental apprenticeships page</a> or get in touch with their team: <a href="tel://01362%20850983">01362 850983</a>, <a href="mailto:enquiries@poultec.co.uk">enquiries@poultec.co.uk</a>.</p>



<p><em>This article is sponsored by Poultec Training.</em></p>]]> </content:encoded>
</item>

<item>
<title>New dental training places and emergency clinic funded in Northern Ireland</title>
<link>https://edusehat.com/en/new-dental-training-places-and-emergency-clinic-funded-in-northern-ireland</link>
<guid>https://edusehat.com/en/new-dental-training-places-and-emergency-clinic-funded-in-northern-ireland</guid>
<description><![CDATA[ Irish health minister Robbie Butler has announced funding for six additional dental foundation training places across Northern Ireland and a new emergency dental clinic in Omagh. Supported by £787,000 of funding, the additional dental foundation training places bring the number available in Northern Ireland from 30 to 36 for 2026/7. Chief dental officer for Northern Ireland… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/ireland.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 17:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, dental, training, places, and, emergency, clinic, funded, Northern, Ireland</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Irish health minister Robbie Butler has announced funding for six additional dental foundation training places across Northern Ireland and a new emergency dental clinic in Omagh.</strong></p>



<p>Supported by £787,000 of funding, the additional dental foundation training places bring the number available in Northern Ireland from 30 to 36 for 2026/7. </p>



<p>Chief dental officer for Northern Ireland Caroline Lappin said: ‘Investing in dental training is essential to building a strong and sustainable workforce. These additional places will provide newly qualified dentists with valuable clinical experience and encourage them to remain in health service practice.’</p>



<p>A further £525,000 of recurring funding has been approved for an emergency dental clinic at Omagh Primary Care Complex, aiming to address a longstanding gap in out-of-hours care in the western region. </p>



<p>Minister Butler commented: ‘Improving access to dental care means investing in both the services patients need today and the professionals who will deliver care in the future. Where you live should not determine whether you can access emergency dental treatment.’</p>



<h2 class="wp-block-heading">Do the new dental training places in Northern Ireland go far enough?</h2>



<p>The funding for the training places and clinic was <a href="https://dentistry.co.uk/2026/04/14/funding-increase-for-northern-irish-dentistry-deemed-insufficient/">first allocated in April</a>. While acknowledging the ‘significant efforts’ of the health minister in securing the £8 million investment, <a href="https://dentistry.co.uk/2026/04/14/funding-increase-for-northern-irish-dentistry-deemed-insufficient/">the British Dental Association (BDA) Northern Ireland said it was ultimately ‘insufficient’</a>.</p>



<p>Due to a ‘fundamental mismatch between fees paid by the government, and the true cost of providing modern dental care’, the BDA said an ‘unviable’ funding gap remains.</p>



<p>Ciara Gallagher, chair of the BDA Northern Ireland Dental Practice Committee, stressed that health service dentistry in Northern Ireland was ‘on borrowed time’ and called for greater urgency and ambition. </p>



<p>She continued: ‘Our executive must now go further and faster and focus on the fundamentals. Dentists need to see a future in the NHS and know they won’t lose money treating NHS patients.’</p>



<p>The BDA called for fundamental reform of the dental payment system alongside the pledged funding.</p>



<p><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</em></a></p>]]> </content:encoded>
</item>

<item>
<title>Indegene joins C&#45;CAMP&#45;Imperial Indo&#45;UK Life Science Corridor as first industry partner</title>
<link>https://edusehat.com/en/indegene-joins-c-camp-imperial-indo-uk-life-science-corridor-as-first-industry-partner</link>
<guid>https://edusehat.com/en/indegene-joins-c-camp-imperial-indo-uk-life-science-corridor-as-first-industry-partner</guid>
<description><![CDATA[ 
The partnership will focus on connecting research, entrepreneurship and industry, with initial priority areas including antimicrobial resistance, diagnostics, digital health, agritech, brain science and mental health.
The post Indegene joins C-CAMP-Imperial Indo-UK Life Science Corridor as first industry partner appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/19135738/Indegene-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 17:10:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Indegene, joins, C-CAMP-Imperial, Indo-UK, Life, Science, Corridor, first, industry, partner</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/19135738/Indegene-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/19135738/Indegene-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/19135738/Indegene-1-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>The Centre for Cellular and Molecular Platforms (C-CAMP) and Imperial College London have announced Indegene as the first industry partner of the Indo-UK Life Science Corridor, an initiative aimed at connecting research, entrepreneurship and industry to accelerate life sciences innovation between India and the UK.</p>
<p>Supported through the Imperial Global India initiative, the Corridor seeks to facilitate knowledge exchange, strengthen innovation ecosystems and create pathways for translating research into real-world applications. Under the partnership, Indegene, C-CAMP and Imperial College London will co-develop entrepreneurship programmes and support the exchange of knowledge and talent between the two countries.</p>
<p>As part of the collaboration, Indegene will help define industry challenges and support startup exchanges and ecosystem immersion programmes. The initial focus areas include antimicrobial resistance, diagnostics, digital health, agritech, brain science and mental health.</p>
<p>The announcement was made at the C-CAMP–Imperial joint roundtable on International Partnerships for AI Discovery and Innovation, convened under the Government of Karnataka’s Global Innovation Alliance initiative as part of the Bengaluru Tech Summit 2026.</p>
<p>“Global health challenges cannot be solved in isolation”, said Dr. Taslimarif Saiyed, CEO, C-CAMP. “This understanding was central to our vision for the Indo-UK Life Science Corridor, which connects the complementary innovation ecosystems of Imperial College London and C-CAMP to enable cross-border problem-solving. Exposure to both ecosystems will produce smarter, more scalable, and more accessible innovations relevant to both populations.”</p>
<p>Amanda Wolthuizen, Vice-President (Strategy), Imperial College London, said: “Welcoming Indegene as the first industry partner of the Indo-UK Life Sciences Innovation Corridor is an important moment for this partnership. When we launched the initiative with C-CAMP earlier this year, we wanted to create a platform where research, talent and industry could come together to accelerate new technologies and solve shared global challenges. Indegene’s expertise in life sciences make them an ideal first partner as we strengthen India-UK links and grow our network of industry collaborators.”</p>
<p>Dr. Saurabh Jain, Vice President – Global Delivery Centers, CSR, and Advocacy, Indegene, said, “The next decade of life sciences innovation will be defined by how well we connect science, talent, and industry across borders. This Corridor brings together the strengths of India and the UK, giving promising ideas a clearer path from discovery to real-world impact. The partnership reflects our continued commitment to support deep science, strengthen translation pathways, and help promising innovation reach scale.”</p>
<p>C-CAMP has supported more than 700 startups, which have collectively raised over $720 million and have a cumulative valuation of approximately $2.7 billion. It has enabled more than 6,000 research projects and trained over 2,200 scientific personnel. More than 420 life sciences products are in the market, while C-CAMP startups have filed 1,000 patents and supported over 300 publications. The technologies have reportedly reached more than 70 million lives.</p>
<p>Imperial College London launched Imperial Global India in 2025 to drive science and technology programmes through academic, industrial and innovation partnerships, facilitate two-way STEM talent exchange between India and the UK, and support its growing alumni network in India.</p>
<p>Indegene works across commercial, medical, R&D and safety operations for the life sciences industry. It combines life sciences expertise with AI-embedded platforms and operating models to support complex, regulated workflows for global biopharma companies.</p>
<p>The post <a href="https://www.expresspharma.in/indegene-joins-c-camp-imperial-indo-uk-life-science-corridor-as-first-industry-partner/">Indegene joins C-CAMP-Imperial Indo-UK Life Science Corridor as first industry partner</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Piramal Pharma moves to take full ownership of Yapan Bio</title>
<link>https://edusehat.com/en/piramal-pharma-moves-to-take-full-ownership-of-yapan-bio</link>
<guid>https://edusehat.com/en/piramal-pharma-moves-to-take-full-ownership-of-yapan-bio</guid>
<description><![CDATA[ 
The acquisition will take Piramal Pharma’s shareholding from 74 per cent to 100 per cent, subject to completion
The post Piramal Pharma moves to take full ownership of Yapan Bio appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/08/17145457/MA-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 17:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Piramal, Pharma, moves, take, full, ownership, Yapan, Bio</media:keywords>
<content:encoded><![CDATA[<div><img width="888" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/08/17145457/MA-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/08/17145457/MA-1.jpg 888w, https://cdn.expresspharma.in/wp-content/uploads/2020/08/17145457/MA-1-300x135.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2020/08/17145457/MA-1-768x346.jpg 768w" sizes="(max-width: 888px) 100vw, 888px"></div><p>Piramal Pharma is moving towards full ownership of Yapan Bio. It has exercised its call option to acquire the remaining 26 per cent stake in the company.</p>
<p>The acquisition will take Piramal Pharma’s shareholding from 74 per cent to 100 per cent, subject to completion. The decision has been approved by the Administrative Committee of the Board of Directors.</p>
<p>Yapan Bio provides process development, characterisation and Phase I/II GMP manufacturing services for vaccines and biologics.</p>
<p>Piramal Pharma is in talks with the existing shareholders to complete the acquisition. The deal value and share transfer date are yet to be finalised.</p>
<p>The post <a href="https://www.expresspharma.in/piramal-pharma-moves-to-take-full-ownership-of-yapan-bio/">Piramal Pharma moves to take full ownership of Yapan Bio</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Introducing the ‘scan every patient’ protocol</title>
<link>https://edusehat.com/en/introducing-the-scan-every-patient-protocol</link>
<guid>https://edusehat.com/en/introducing-the-scan-every-patient-protocol</guid>
<description><![CDATA[ How one dental practice is driving case acceptance and new workflows by starting every patient appointment with a digital intraoral scan. Dr Milad Shadrooh, aka The Singing Dentist, is undergoing a practice transformation by implementing a scan every patient protocol (SEP). The evolution is paying off with progress across multiple areas of the practice, from… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/align.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 14:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Introducing, the, ‘scan, every, patient’, protocol</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>How one dental practice is driving case acceptance and new workflows by starting every patient appointment with a digital intraoral scan.</strong></p>



<p>Dr Milad Shadrooh, aka The Singing Dentist, is undergoing a practice transformation by implementing a scan every patient protocol (SEP). The evolution is paying off with progress across multiple areas of the practice, from enhanced patient communication and streamlined clinic workflows to greater practitioner and team satisfaction, and ultimately, stronger practice income.</p>



<p>Dr Shadrooh explains: ‘I have been practising since 2004, and had previously used other intraoral scanners. Our switch to the iTero scanner happened with the launch of Invisalign Smile Architect software for ortho-restorative planning. I was involved with piloting the digital smile design software and keen to put it through its paces. Align had made significant investment in research and development, and I could see the scanning technology was evolving at a rate of knots – so it was an easy decision to transition to the iTero scanner.’</p>



<h2 class="wp-block-heading"><strong>The ‘scan every patient’ protocol</strong></h2>



<p>Having heard other practitioners extol the benefits of scanning every patient, Dr Shadrooh adopted this workflow protocol. ‘When you scan patients immediately to see their dental issues for themselves, this allows for better conversations – seeing is very much believing. For me, chatting to patients comes naturally, but for less experienced associates initiating discussions can be challenging. The iTero scanner has changed that, giving them a starting point for every conversation because patients can see their challenges for themselves – it prompts them to ask questions.’</p>



<p>His associate Dr Ploy Intawong was first to embrace the ‘scan every patient’ protocol. She particularly likes the fact that ‘scanning patients enables an element of ‘co-diagnosis’; showing them their scans on a screen and allowing them to ‘discover’ their oral health issues, ask questions and engage in conversations about potential treatment options.</p>



<p>‘Scanned patients say: “Wow, this is cool. What is this technology?” says Dr Shadrooh. </p>



<p>He leverages this ‘wow’ factor, telling them how much the scanner costs, which he believes demonstrates his investment in their care. He initiates conversation showing them the results of the iTero NIRI technology (near infra-red imaging) alongside X-rays to help them understand their oral health, after which many of the tools in the Align Oral Health Suite are utilised as the diagnosis and planning process progresses. ‘It’s so impressive being able to show patients a 3D image of their teeth. I think all clinics need to have scanners now.’</p>



<h2 class="wp-block-heading"><strong>Treatment uptake – examining the evidence</strong></h2>



<p>As a result of the new Scan Every Patient (SEP) protocol, case acceptance has risen, leading to a positive financial impact for both associates and practice. Analysing the data shows a marked increase in both the number and value of treatments since the practice started scanning every patient.</p>


        <div class="my-4 rounded overflow-hidden bg-context-100/30 px-8 pt-8 pb-4 md:px-10 md:pt-10 md:pb-8">
            <div>
                <div class="inline-block space-y-4">
                                                                <div class="font-secondary font-bold text-xl md:text-2xl">
                            Statistic 1                        </div>
                                                                <div class="w-full my-12 h-px bg-primary-200"></div>
                                    </div>
            </div>
                            <div>
                    <p>The practice reviewed Dr Intawong’s earnings in the seven months before implementing the SEP protocol and compared them with the seven months after its introduction. By averaging Dr Intawong’s monthly earnings before and after implementing the SEP protocol, they observed a <strong>35% increase in her earnings in the seven months following the introduction of the ‘scan every patient’ protocol.</strong></p>
                </div>
                    </div>
        

        <div class="my-4 rounded overflow-hidden bg-context-100/30 px-8 pt-8 pb-4 md:px-10 md:pt-10 md:pb-8">
            <div>
                <div class="inline-block space-y-4">
                                                                <div class="font-secondary font-bold text-xl md:text-2xl">
                            Statistic 2                        </div>
                                                                <div class="w-full my-12 h-px bg-primary-200"></div>
                                    </div>
            </div>
                            <div>
                    <p>The practice compared Dr Intawong’s earnings with those of other associates who didn’t scan every patient. In the seven months before implementing the SEP protocol, Dr Intawong earned, on average, 20% less than Associate one and 18% less than Associate two. <strong>In the seven months following the introduction of the ‘scan every patient’ protocol, Dr Intawong’s earnings increased significantly, earning 65% more than Associate one and 24% more than Associate two. </strong></p>
                </div>
                    </div>
        

        <div class="my-4 rounded overflow-hidden bg-context-100/30 px-8 pt-8 pb-4 md:px-10 md:pt-10 md:pb-8">
            <div>
                <div class="inline-block space-y-4">
                                                                <div class="font-secondary font-bold text-xl md:text-2xl">
                            Statistic 3                        </div>
                                                                <div class="w-full my-12 h-px bg-primary-200"></div>
                                    </div>
            </div>
                            <div>
                    <p>The practice analysed Dr Intawong’s earnings with one specific patient. She examined the patient and identified the need for a full mouth rehabilitation. The options were explained and the patient was presented with a treatment plan worth £14,000. The patient did not proceed at that time. The next examination took place six months later, which was after the implementation of the SEP protocol. Dr Intawong scanned the patient’s teeth and revisited the same treatment plan. This time, using the scan to educate and show the patient their issues, <strong>the patient decided to proceed with the £14,000 treatment plan, despite no changes in their personal circumstances</strong>.</p>
                </div>
                    </div>
        


<p>Dr Shadrooh comments on statistic 3: ‘Of course there may have been other factors which made the patient convert 6 months later, but scanning was a major contributory factor without question.</p>



<p>He adds: ‘I was more than pleasantly surprised once I reviewed the figures and I can confidently say the “scan every patient protocol” absolutely works! So much so, I would like to name it “the SEP protocol” – scan every patient… let’s start a movement!’</p>



<h2 class="wp-block-heading">Initial investment</h2>



<p>Some principals may hesitate at the initial expense of buying an iTero scanner, but Dr Shadrooh points out: ‘The figures after adopting the ‘SEP Protocol’ add up and speak for themselves. Not only is the scanner a tax-deductible investment, but the cost can also be spread over time, and it will more than pay for itself – particularly if you are using it for big smile makeovers, such as implant and Invisalign treatments.’</p>



<p>Such has been the success of the SEP protocol, the practice has introduced another iTero scanner, allowing all associates to scan without having to move one device between rooms. Says Dr. Shadrooh: ‘Having a scan allows our dentists to build up a rapport and chat with the patient right from the start, as opposed to immediately sticking a mirror in their mouth. You get your nurses to do the scanning, so you can engage in informed conversation. We want our nurses to feel more empowered and part of the process. Medical surgeons don’t start and finish a whole operation, they have a whole team approach, so why not bring this to dentistry?’</p>



<h2 class="wp-block-heading"><strong>A whole team approach</strong></h2>



<p>Dr Intawong adds: ‘Once patients see the scan results, it is a complete game changer. Seeing their own mouth in 3D shifts the whole tone of the appointment – they start asking questions, and suddenly it became a much more collaborative experience. The scanner has completely transformed how patients engage. When they see a 3D image of their own mouth – especially side-by-side with an older scan – it shifts the entire conversation. They become more aware of issues like wear, crowding, gum recession, and cracked or broken restorations.  </p>



<p>‘When shown, they can actually see the cracks which have formed around their old amalgam fillings, and it makes explaining the risks so much easier. It’s no longer just me telling them – they’re seeing it for themselves, unprompted. It takes the pressure off me having to convince them – they get it.</p>



<p>‘It’s opened the door to more holistic conversations, especially with patients with worn dentition. The scan helps them understand that it’s not just about fixing one broken tooth with a filling. We can zoom out and look at the bigger picture – why that tooth broke, how their bite is functioning, and what long-term solutions might be more appropriate. They start to understand how everything works together, and that leads to much more comprehensive and meaningful treatment planning.</p>



<p>‘Because the scan gives us something visual and interactive to talk through, it’s helped build rapport much quicker. Patients feel listened to, more involved, and – most importantly – they trust the process. The whole appointment becomes more collaborative, and that really changes how treatment is received.’</p>



<h2 class="wp-block-heading">Training in the scan every patient protocol</h2>



<p>Training and practice is key to successfully scanning every patient. Dr Shadrooh implemented both in-house and iTero-led training allowing team members to become familiar with the technology. He acknowledges: ‘There’s a learning curve for those new to scanning and Principals need to learn to trust and relinquish some control, but in the long run it will make everything much smoother because it empowers everyone, and you can focus on what you do best.’</p>



<p>‘You need to ensure you have enough time to implement this. If that means adding an extra five minutes to an appointment, do it, because that extra time will pay dividends. Inform patients about their new appointment experience beforehand so that they know what to expect and why that extra five minutes will make all the difference.’</p>



<h2 class="wp-block-heading"><strong>Teamwork is crucial and practice makes perfect</strong></h2>



<p>Dr Intawong adds: ‘My nurse and I completed a patient pathway course which made a huge difference. We still ran late when we first started scanning every patient, however, after a few weeks performing multiple scans, everything started to flow and we got on track with timings. It came down to practice and repetition. </p>



<p>‘The support from my nurse was a complete game-changer. Once we found our rhythm, she instinctively knew when to set up, how to position the scanner, and how to keep things moving without me needing to say a word. It stopped being something I had to manage on my own and became a proper team workflow. The more we did it, the faster and more seamless it became.</p>



<p>‘Having a principal who was fully behind the process made a big difference. There was no pressure to rush or skip steps – it was clear this was about long-term value for the patient and delivering the kind of care we believe in practice-wide.’</p>



<p>‘The SEP has made my job so much easier – I honestly couldn’t work without an iTero scanner now,’ Dr Intawong concludes. Dr Shadrooh wholeheartedly concurs. In fact, such has been the success of the scan every patient protocol the practice has invested in a second iTero scanner.</p>



<p>For more information about the iTero Digital Scanner please visit <a href="http://www.itero.com/" target="_blank" rel="noreferrer noopener">www.itero.com</a>.</p>



<p><em>This article is sponsored by Align Technology.</em></p>



<p></p>]]> </content:encoded>
</item>

<item>
<title>Pfizer, Starna Therapeutics enter exclusive licensing agreement for autoimmune diseases</title>
<link>https://edusehat.com/en/pfizer-starna-therapeutics-enter-exclusive-licensing-agreement-for-autoimmune-diseases</link>
<guid>https://edusehat.com/en/pfizer-starna-therapeutics-enter-exclusive-licensing-agreement-for-autoimmune-diseases</guid>
<description><![CDATA[ 
Starna to receive upfront payment of $330 million, eligible to receive up to $2.3 billion in milestone payments associated with certain development and commercial milestones, plus royalties on net sales of approved products
The post Pfizer, Starna Therapeutics enter exclusive licensing agreement for autoimmune diseases appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/02/12143653/agreement-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 13:30:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pfizer, Starna, Therapeutics, enter, exclusive, licensing, agreement, for, autoimmune, diseases</media:keywords>
<content:encoded><![CDATA[<div><img width="888" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/02/12143653/agreement-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/02/12143653/agreement-1.jpg 888w, https://cdn.expresspharma.in/wp-content/uploads/2020/02/12143653/agreement-1-300x135.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2020/02/12143653/agreement-1-768x346.jpg 768w" sizes="(max-width: 888px) 100vw, 888px"></div><p><span>Pfizer has entered into an exclusive licensing agreement with Starna Therapeutics, a biotechnology company developing RNA medicines designed to enable in vivo therapeutics. </span></p>
<p><span>Starna will receive an upfront payment of $330 million, and is eligible to receive up to $2.3 billion in milestone payments associated with certain development and commercial milestones, plus royalties on net sales of approved products.</span></p>
<p><span>Under the agreement, Pfizer obtains exclusive rights outside Greater China to develop, manufacture and commercialise three pre-IND in vivo chimeric antigen receptor T-cell (CAR-T) programmes that are focused on treating autoimmune diseases. </span></p>
<p><span>Pfizer will lead clinical development outside Greater China and plans to manufacture the finished drug product for the initial clinical trials using its facilities in theUS .</span></p>
<p><span>Pfizer will have sole and exclusive control over commercialisation outside of Greater China for all products. Pfizer holds options to expand its territory to include Greater China.</span></p>
<p><span>Pfizer also receives rights to use Starna’s proprietary in vivo CAR-T technology in inflammation and immunology, and in oncology, as well as options to exclusively license compounds created under a separate research collaboration and an option to expand the territory to include exclusive rights to develop and commercialise each exclusively licensed compound and product in Greater China.</span></p>
<p>The post <a href="https://www.expresspharma.in/pfizer-starna-therapeutics-enter-exclusive-licensing-agreement-for-autoimmune-diseases/">Pfizer, Starna Therapeutics enter exclusive licensing agreement for autoimmune diseases</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Three quarters of dentists have or aspire to have a portfolio career</title>
<link>https://edusehat.com/en/three-quarters-of-dentists-have-or-aspire-to-have-a-portfolio-career</link>
<guid>https://edusehat.com/en/three-quarters-of-dentists-have-or-aspire-to-have-a-portfolio-career</guid>
<description><![CDATA[ Four in 10 dentists (41%) said they already have a portfolio career in a new survey, while a further third (33%) would like to build one. Portfolio careers are becoming more popular in dentistry, with many dentists splitting their time between NHS, private care, teaching and other roles. In Wesleyan Financial Services’ Navigating the Future… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/portfolio.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 10:35:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Three, quarters, dentists, have, aspire, have, portfolio, career</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Four in 10 dentists (41%) said they already have a portfolio career in a new survey, while a further third (33%) would like to build one.</strong></p>



<p>Portfolio careers are becoming more popular in dentistry, with many dentists splitting their time between NHS, private care, teaching and other roles. In Wesleyan Financial Services’ <em>Navigating the Future of NHS Dentistry</em> whitepaper, 18% of surveyed dentists were actively planning to build a portfolio career.</p>



<p>Just 12% said they planned to stay in the NHS until retirement, with 21% planning a gradual shift towards private care. More than one in five (22%) said they planned to leave the dental profession entirely within the next five years. </p>



<figure class="wp-block-image size-large"></figure>



<h2 class="wp-block-heading">What makes a portfolio career appealing?</h2>



<p>According to the survey respondents, the main appeal of a portfolio career is work-life balance (56%), professional growth (45%), and variety (40%). However, workload (48%) and admin (33%) were cited as significant downsides.</p>



<p>While 41% of dentists said that retaining some NHS work was very important to them, 79% said the current contract is unfit or needs major reform.</p>



<p>Lauren Harrhy, principal dentist at Sparkle Dental Centre, said: ‘None of us really want to give up the NHS entirely because we feel duty bound to take care of patients from all walks of life. But it comes to a point when we find that the restrictions around the NHS contract mean that we can’t always care for people in the manner that we want to.’</p>



<p>Funding was the largest grievance, with 73% saying the contract is inadequately funded for good patient care and 81% believing NHS dentists are not fairly compensated.</p>



<p>Nigel Jones, Practice Plan’s strategy director, highlighted the lack of new investment into NHS dentistry. He said: ‘It all comes back to the fact that the pot of money for NHS dentistry is the same, if not shrinking.’</p>



<h2 class="wp-block-heading">Is there hope for the future of NHS dentistry?</h2>



<p>The <a href="https://dentistry.co.uk/2025/12/16/latest-nhs-dental-contract-changes-released/">2026 changes to the contract</a> have not reassured the profession: 47% called them minor tweaks and 13% said they made matters worse. Seven in 10 (71%) said the government’s direction with reform is still unclear. </p>



<p>The surveyed dentists strongly rejected the UDA model. Two thirds (66%) said it is no longer fit for purpose, and only 5% thought the current UDA rate is appropriate. Many believed activity-based payment for complex cases would be a better replacement. </p>



<p>Eddie Crouch, chair of the British Dental Association (BDA), agreed that the government’s future plans for dentistry were difficult to discern. He asked: ‘Are we going to get a targeted system? Is it going to be a core system? Or are we going to be left in limbo?’</p>



<p>With dentists leaving the NHS at a rapid rate, he suggested that increased competition might force private practices to take a hit to their income. </p>



<h3 class="wp-block-heading">Read the full whitepaper:</h3>



<div data-wp-interactive="core/file" class="wp-block-file"><a href="https://dentistry.co.uk/app/uploads/2026/11/Weslyan-Dental-Whitepaper-November-2026-final-embargoed-to-Thursday-19-Nov.pdf">Weslyan-Dental Whitepaper-November 2026 – final – embargoed to Thursday 19 Nov</a><a href="https://dentistry.co.uk/app/uploads/2026/11/Weslyan-Dental-Whitepaper-November-2026-final-embargoed-to-Thursday-19-Nov.pdf" class="wp-block-file__button wp-element-button" download aria-describedby="wp-block-file--media-6301d2f8-34eb-4bba-8ffd-d21f49b1a71f">Download</a></div>



<p><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</em></a></p>]]> </content:encoded>
</item>

<item>
<title>Alzheimer’s Disease and Aging Linked to Changes in the Hypothalamus</title>
<link>https://edusehat.com/en/alzheimers-disease-and-aging-linked-to-changes-in-the-hypothalamus</link>
<guid>https://edusehat.com/en/alzheimers-disease-and-aging-linked-to-changes-in-the-hypothalamus</guid>
<description><![CDATA[ Researchers combined measurements from brain images and single cell transcriptome maps to build a resource, HypoAD, as an atlas of the human hypothalamus in aging and AD, which they have made available to the research community.
The post Alzheimer’s Disease and Aging Linked to Changes in the Hypothalamus appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2020/06/Jun25_2020_GettyImages-91560048_brain-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 10:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alzheimer’s, Disease, and, Aging, Linked, Changes, the, Hypothalamus</media:keywords>
<content:encoded><![CDATA[<p>Before their memory is affected, many individuals with Alzheimer’s disease (AD) may experience trouble sleeping, lose their daily rhythms, and show changes in metabolism and stress hormones. These functions are regulated by the hypothalamus, a structure at the base of the brain. A study headed by researchers at the Buck Institute for Research on Aging has now found that the hypothalamus is not a bystander in Alzheimer’s disease, and its circadian and metabolic control centers show specific age-related changes in volume and gene activity early in the disease.</p>
<p>For their study, the team combined measurements from brain images and single-nucleus RNA sequencing maps to build a resource, HypoAD, as an atlas of the human hypothalamus in aging and AD, which they have made available to the research community.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Ashley Webb, PhD, associate professor at the Buck Institute for Research on Aging, is senior and co-corresponding author of the team’s published report in <em>Nature</em>, titled “<a href="https://doi.org/10.1038/s41586-026-11305-w" target="_blank" rel="noopener">Hypothalamic volume and cell-type changes in aging and Alzheimer’s disease</a>,” in which they concluded, “Our findings provide a multimodal view of how the hypothalamus is altered in aging and early AD, illustrating region-specific and cell-type-specific changes that have not been observed previously.”</p>
<p>AD is an age-associated neurodegenerative disorder with a prevalence of roughly 10–30% among individuals older than 65 years, the authors wrote. And while the main feature is cognitive decline, they stated, “… AD manifests as a systemic condition involving profound disruptions in sleep, circadian rhythms, metabolic homeostasis, stress responses, and neuroendocrine functions.” These key processes are regulated by the hypothalamus, a small, complex part of the brain that orchestrates a wide range of physiological and neuroendocrine processes that are commonly dysregulated in aging and AD.</p>
<p>“Emerging evidence suggests that hypothalamic dysfunction not only correlates with but also actively exacerbates AD pathology and cognitive decline,” the team noted. However, they pointed out, “Despite its central role in homeostasis and brain aging, the hypothalamus remains an understudied region in the context of human aging and AD.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Webb noted, “Most of what we know about Alzheimer’s comes from the hippocampus and cortex, because that’s where memory is organized and lives. But patients and families often report disrupted sleep, a change in appetite, or different responses to stress alongside memory changes.”</p>
<p>The hypothalamus is made up of many specialized sub-areas called nuclei. Each nucleus runs a different job. The suprachiasmatic nucleus (SCN) is the body’s master clock, while the arcuate nucleus (ARC) handles appetite and energy balance. Very little is known about how the individual nuclei and their cell types change in human aging and Alzheimer’s.</p>
<p>“No single method can answer this question,” said co-senior author Manu Goyal, MD, director of neuroimaging labs at Washington University School of Medicine in St. Louis. “MRI can tell you what’s happening in living people but is limited in its resolution. Single-cell sequencing tells you what’s happening inside each cell type but requires actual tissue. The goal here was to put them side by side to let us see things that neither could show alone.”</p>
<p>Noting that recent studies even suggest that changes such as circadian disruptions may precede the development of other common clinical symptoms, Webb added, “We wanted to look directly at the part of the brain that controls those functions, and to do it with enough resolution to see which cells are changing with age and in the disease.”</p>
<p>To better enable this insight, the team created HypoAD as an atlas of the human hypothalamus in aging and AD, by combining high-resolution magnetic resonance imaging from hundreds of individuals and single-nucleus RNA sequencing of more than 600,000 nuclei from young participants, patients with AD, and age-matched non-dementia control participants.</p>
<div class="wp-caption alignright"><img decoding="async" aria-describedby="caption-attachment-340774" class="size-medium wp-image-340774" src="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Volumes-300x160.jpg" alt="Three-dimensional reconstructions of hypothalamic subregions from MRI scans of two female individuals at 72 years of age, one healthy (left) and one with Alzheimer’s Disease (right). Differences in volume can be observed in regions involved in regions labeled SCN, AN, and Pe, which are important for sleep, circadian rhythms, and metabolic regulation. [Jürgen Germann] " width="300" height="160" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Volumes-300x160.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Volumes.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><p class="wp-caption-text">Three-dimensional reconstructions of hypothalamic subregions from MRI scans of two female individuals at 72 years of age, one healthy (left) and one with Alzheimer’s disease (right). Differences in volume can be observed in regions involved in regions labeled SCN, AN, and Pe, which are important for sleep, circadian rhythms, and metabolic regulation. [Jürgen Germann]</p></div>
<p>Using MRI scans from 458 living adults and a high-resolution atlas, the researchers measured the volume of 13 separate hypothalamic sub-regions. Participants were grouped by cognitive status and by levels of amyloid-β, the protein that forms plaques in Alzheimer’s disease. The team then sequenced about 614,000 individual cells from post-mortem hypothalamic tissue. This method shows which genes are switched on in each cell, so changes can be traced to specific cell types and cellular functions. Donors included seven people with mostly early-stage Alzheimer’s disease, seven age-matched healthy controls, and three younger people from published data.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The researchers validated their findings against spinal fluid protein measurements, a prefrontal cortex dataset from about 800 donors, spatial gene-expression maps, and a mouse model of Alzheimer’s.</p>
<p>The scientists found that though overall hypothalamic volume barely changed with age, different areas of the hypothalamus did either change or increase in volume. The lateral hypothalamus shrank with age, while the SCN, arcuate, paraventricular, periventricular, and dorsomedial hypothalamic nuclei (DMH) grew. Webb said this phenomenon held after accounting for Alzheimer’s disease status, suggesting it is a feature of typical aging. “Together, these findings suggest that hypothalamic nuclei undergo differential volumetric changes with aging, even in the absence of AD,” the investigators noted.</p>
<p>Volume differences tied specifically to AD also occurred but weren’t statistically significant, suggesting that a more sensitive method might be needed to determine what happens with the Alzheimer’s hypothalamus. “… in comparison to aging and sex, differences in the volumes of hypothalamic nuclei in the context of amyloid-β deposition and cognitive impairment were more modest or absent,” they noted.</p>
<p>“If you only measure the hypothalamus as a whole, it looks like nothing is happening,” Webb said. “When you zoom in, you see some regions shrinking and others growing. That tells us aging is reshaping this region in a very specific, structured way.”</p>
<p>The researchers applied machine-learning models to distinguish Alzheimer’s disease cells from control cells using gene expression alone. Their findings indicated that the most important genes centered on two themes, inflammation and circadian rhythm. “At the molecular level, machine learning models identified the inflammatory response and regulators of circadian rhythms as key cellular predictors of AD,” they stated.</p>
<p>Microglia, the brain’s resident immune cells, showed the largest number of altered genes. When the researchers ordered cells along a young-to-old-to-Alzheimer’s path, microglia gradually shifted from a resting state toward the “disease-associated” state seen in other Alzheimer’s disease studies. “This finding suggests that the hypothalamus transitions to an inflammatory state early in Alzheimer’s disease, just like the brain regions involved in memory,” said Webb. The authors further noted in their report, “Consistent with other brain regions, microglia, which are widely recognized mediators of brain aging and neurodegeneration, emerged as particularly prone to transcriptional reprogramming in the hypothalamus in early AD, although our unpaired, cross-sectional data cannot establish a causal or directional relationship.”</p>
<p>The hypothalamus is a diverse area of the brain, harboring many distinct cell types critical for its varied physiological roles. The scientists identified 254 neuron subtypes and found that inhibitory (GABAergic) neurons changed the most, mainly in neuropeptide and receptor signaling. One prominent group of neurons in the SCN showed disrupted signaling by vasopressin, a key output of the body’s clock.</p>
<p>“Sleep and circadian problems are some of the earliest signs of Alzheimer’s, and circadian behavioral changes known as sundowning, occur later in the disease,” Webb said. “But we’ve never had a good molecular explanation for why. Seeing vasopressin signaling disrupted in the brain’s master clock, in people at early stages of the disease, gives us a concrete place to start.”</p>
<p>Total cell numbers did not appear to change. Instead, the data point to cells getting larger through increased activity of mTOR, a growth pathway, along with remodeling of material between cells and inflammatory activation of glia. The authors present this as a hypothesis for future work.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>They also noted several limits to their study, including the small autopsy cohort of 14 donors, which is typical for this kind of study. The MRI and sequencing data come from different people, so the two are compared side by side rather than combined statistically. And because the design is cross-sectional, the results show associations, not cause and effect.</p>
<p>“This is a starting point, not the final word,” Webb said. “Our next step is to follow these changes over time and test whether protecting the brain’s clock, and neuropeptide signaling in particular, can slow the disease or help manage symptoms. If circadian disruption is one of the first things to go wrong, it may also be one of the first places we can intervene.”</p>
<p>In their paper, the team commented, “HypoAD provides a framework to investigate hypothalamic dysfunction and establishes a roadmap for targeted interventions aimed at mitigating physiological disruptions to potentially slow disease progression … We highlight notable vulnerabilities in GABAergic and/or inhibitory neurons, SCN and DMH circadian regulators, and inflammatory microglial cascades, underscoring their potential roles in instigating early hypothalamic dysfunction.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/alzheimers-disease-and-aging-linked-to-changes-in-the-hypothalamus/">Alzheimer’s Disease and Aging Linked to Changes in the Hypothalamus</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Foot and Ankle Arthritis: Answers to Common Questions from Specialist Dr. Brian Law</title>
<link>https://edusehat.com/en/foot-and-ankle-arthritis-answers-to-common-questions-from-specialist-dr-brian-law</link>
<guid>https://edusehat.com/en/foot-and-ankle-arthritis-answers-to-common-questions-from-specialist-dr-brian-law</guid>
<description><![CDATA[ Our feet and ankles are instrumental in every aspect of our lives. They provide support and balance to our body while we stand, mobility for walking, and shock absorption when we run and jump. The explanation behind the wide range of motion in our feet and ankles can be attributed to their complex anatomy. In  [...]
The post Foot and Ankle Arthritis: Answers to Common Questions from Specialist Dr. Brian Law appeared first on Orthopedic Sports Medicine Specialists (OSMS). ]]></description>
<enclosure url="https://osmsgb.com/wp-content/uploads/2026/11/foot-arthritis-and-when-to-get-surgery.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 07:10:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Foot, and, Ankle, Arthritis:, Answers, Common, Questions, from, Specialist, Dr., Brian, Law</media:keywords>
<content:encoded><![CDATA[<p>Our feet and ankles are instrumental in every aspect of our lives. They provide support and balance to our body while we stand, mobility for walking, and shock absorption when we run and jump. The explanation behind the wide range of motion in our feet and ankles can be attributed to their complex anatomy. In one foot alone, there are almost 30 bones and 30 joints operating collectively to enable smooth movement and withstand the significant stress that is required of them every day.</p>
<p><img fetchpriority="high" decoding="async" class="alignnone wp-image-3378 size-full" src="https://osmsgb.com/wp-content/uploads/2026/11/foot-arthritis-and-when-to-get-surgery.jpeg" alt="foot arthritis and when to get surgery" width="1000" height="617" srcset="https://osmsgb.com/wp-content/uploads/2026/11/foot-arthritis-and-when-to-get-surgery-200x123.jpeg 200w, https://osmsgb.com/wp-content/uploads/2026/11/foot-arthritis-and-when-to-get-surgery-300x185.jpeg 300w, https://osmsgb.com/wp-content/uploads/2026/11/foot-arthritis-and-when-to-get-surgery-400x247.jpeg 400w, https://osmsgb.com/wp-content/uploads/2026/11/foot-arthritis-and-when-to-get-surgery-600x370.jpeg 600w, https://osmsgb.com/wp-content/uploads/2026/11/foot-arthritis-and-when-to-get-surgery-768x474.jpeg 768w, https://osmsgb.com/wp-content/uploads/2026/11/foot-arthritis-and-when-to-get-surgery-800x494.jpeg 800w, https://osmsgb.com/wp-content/uploads/2026/11/foot-arthritis-and-when-to-get-surgery.jpeg 1000w" sizes="(max-width: 1000px) 100vw, 1000px"></p>
<p>Due to the complexity of the feet and ankles, sometimes treating injuries and conditions in this area is more challenging. Below, <a href="https://osmsgb.com/doctors/brian-law-md/">Dr. Brian Law</a> addresses some frequently asked questions he receives within his area of expertise regarding arthritis in the feet and ankles.</p>
<h2>What is foot and ankle arthritis?</h2>
<p>Arthritis is a general term for inflammation of the joints, and it can affect any joint in the body, including the spine, shoulder, hand, hip, knee, foot, and ankle. Arthritis results in the loss of cartilage, which is the smooth, protective tissue that’s on the ends of the bones.</p>
<h2>What are the early signs of arthritis in the feet and ankles?</h2>
<p>When protective tissue starts to wear away, that is when people start to experience pain. Pain is the first and most common symptom people with arthritis have. Those with arthritis will experience pain with walking and activity. They may also experience:</p>
<ul>
<li>Swelling</li>
<li>Stiffness in the joint</li>
<li>Limited range of motion in the affected area</li>
<li>Tenderness or sensitivity around the joint</li>
<li>The feeling of warmth/heat around the joint</li>
</ul>
<h2>What areas of the foot and ankle are most affected by arthritis?</h2>
<p>Because our feet and ankles see a significant amount of wear and tear over time, and arthritis is a condition of gradual deterioration, all areas of the foot and ankle are susceptible to developing arthritis.</p>
<p>There are three different types of foot arthritis, including forefoot arthritis, midfoot arthritis, and hindfoot arthritis.</p>
<ol>
<li>Forefoot arthritis is when arthritis affects the front of the foot near the toes.</li>
<li>Midfoot arthritis is when arthritis affects the middle and top of the foot.</li>
<li>Hindfoot arthritis is when arthritis affects the back of the foot near the ankle.</li>
</ol>
<p>Hindfoot arthritis is often confused with ankle arthritis due to the location of the joints: the hindfoot is directly next to the ankle. Some patients are diagnosed with subtalar arthritis, one type of hindfoot arthritis. This type affects the subtalar joint, which is the joint found below the ankle joint in the hindfoot.</p>
<h2> What causes arthritis in the feet and ankles?</h2>
<p>Wear and tear is the most common cause of arthritis in the feet and ankles. Other factors contributing to arthritis development, not related to gradual degeneration, include previous injuries (post-traumatic), infections that involve a joint, deformities such as flat feet and bunions, and other diseases like rheumatoid arthritis, gout, psoriasis, and lupus.</p>
<h2>How is arthritis of the foot and ankle diagnosed?</h2>
<p>For someone seeking a diagnosis due to persistent symptoms over a prolonged amount of time, they will be evaluated through a physical exam and imaging. The most common imaging physicians use to diagnose arthritis is an X-ray, as this allows us to visualize the damage to the joints and identify which joints are involved. Sometimes, an MRI or a CT scan is required to help with the diagnosis if the results from the X-ray prove inconclusive.</p>
<h2>What are the treatment options for foot and ankle arthritis?</h2>
<p>If a patient has a physical exam and imaging that result in the diagnosis of arthritis, the first course of treatment includes conservative treatment options such as anti-inflammatory medications, <a href="https://osmsgb.com/a-complete-guide-to-joint-tendon-and-nerve-injections/">steroid injections</a>, physical therapy, braces, and shoe modifications. If these conservative treatments do not relieve pain after trying them for a few weeks (typically four to eight), then surgery is always an option.</p>
<p>Surgical options for arthritis in the foot may include “cleaning up” the joint(s) to remove bone spurs, or a fusion for most joints. In the ankle, limited arthritis can be treated with the removal of bone spurs if they are limiting motion and causing pain. For most patients with advanced arthritis, treatment would include a total ankle replacement. It is important to note that a small subset of patients cannot receive a total ankle replacement and may require a fusion of the ankle instead.</p>
<h2>What is a fusion? (Ankle fusion vs. ankle replacement)</h2>
<p>A fusion is a type of surgery where the ends of the bones at a joint are made to grow together to become one solid bone. For the bones to grow together, the affected joints need to be prepared, which involves making the ends of the bones raw to simulate a broken bone in the body, promoting healing. The bones are then held together with plates, screws, or rods until the bones naturally grow together. A fusion eliminates the motion in the joint; however, it also relieves the pain.</p>
<h2>What are the differences between braces, orthotics, and shoe modifications as conservative treatment options?</h2>
<p>There are a variety of <strong>braces</strong> that can be used as a conservative treatment option for foot and ankle pain. Common braces that are used include the <a href="https://arizonaafo.com/products/arizona-brace/" target="_blank" rel="noopener">Arizona Brace</a>, <a href="https://arizonaafo.com/products/arizona-mezzo/" target="_blank" rel="noopener">Arizona Mezzo Brace</a>, <a href="https://richiebrace.com/patients/products#single/0" target="_blank" rel="noopener">Richie Brace</a>, and Ankle-Foot Orthosis (AFO). While the Arizona Mezzo Brace and Richie Brace allow for movement in the ankle, the Arizona Brace and AFO limit motion in the ankle. Unless there is a problem with the ankle, the braces that leave the ankle free for movement are a preferred choice.</p>
<p><strong>Orthotic inserts</strong> (like the Morton’s Extension Insert) and a rigid orthotic (like braces) are used to limit motion of the affected joints, protecting them from movement, which can relieve pain. Generally, braces are recommended over orthotics simply for insurance reasons. Braces are covered by Medicare and insurance, while orthotics are not. This means that patients must pay out of pocket for orthotics.</p>
<p>Wearing a tennis shoe with a rocker bottom is a <strong>shoe modification</strong> that can alleviate some pain within the foot. The rocker bottom acts like a rocking chair, which limits the motion of the joints in the foot, while still allowing the foot to roll, giving individuals a better gait. It provides protection while limiting motion to help with pain.</p>
<h2>How does total ankle replacement surgery work?</h2>
<p>The only joint in the foot and ankle that reliably does well with a joint replacement is the ankle. A total ankle replacement is performed either under general anesthetic or via a nerve block and involves cutting the bone to allow for placement of the components that recreate the ankle joint.</p>
<p>When performing an ankle replacement, the end of the tibia (shin bone) and the top of the talus (the bone that rotates the ankle) are removed and replaced with metal components. Placed between these metal components to act as a bearing surface is a piece of high-grade polyethylene plastic. Replacing the joint eliminates pain from the arthritis but maintains motion in the ankle. In many cases, motion in the arthritic ankle joint is improved because of the ankle replacement.</p>
<p>Patients who require an ankle joint replacement will have a total joint coordinator assigned to them to help guide them through their <a href="https://osmsgb.com/surgerycenters/the-joint-journey/">joint journey</a>.</p>
<h2>How long do ankle replacements last?</h2>
<p>Ankle replacements have been shown to last 10-15 years. Advances in design, materials, and techniques have helped to improve durability in modern ankle replacements, with some replacements lasting more than 20 years.</p>
<h2>When should I consider surgery for foot or ankle arthritis?</h2>
<p>At OSMS, our physicians operate on less than 30% of our patients; therefore, surgery is only recommended when it is necessary. However, surgery is ultimately a personal, quality-of-life decision. When the pain and limitations in motion are affecting your quality of life to the point where you are fed up with it and want to restore your function and quality of life, then we are happy to take care of you and discuss your options.</p>
<p>For those wanting a more in-depth look at foot and ankle arthritis, watch the recorded webinar on <a href="https://osmsgb.com/webinar/arthritis-in-the-foot-ankle-webinar/">Arthritis of the Foot and Ankle</a>. During his presentation, Dr. Brian Law explores what arthritic conditions can develop in the foot, signs and symptoms to be aware of, and the conservative and surgical treatment options available.</p>
<h2>Can ankle arthritis be cured?</h2>
<p>Although arthritis is a chronic condition that cannot be reversed, people experiencing symptoms of arthritis do not simply have to “deal with it.” Pain is not a symptom of aging, and there are multiple effective ways that arthritis pain can be managed so that individuals can continue to maintain mobility and live an active lifestyle.</p>
<p>If you’re experiencing pain in your foot and/or ankle, our orthopedic foot and ankle specialists can provide you with an accurate diagnosis and develop a treatment plan. Your plan will be unique to you and focused on getting you back to living the life you love—pain-free! <a href="https://osmsgb.com/schedule-an-appointment/">Schedule an appointment</a> with one of our <a href="https://osmsgb.com/orthopedics/foot-ankle/">Northeast Wisconsin orthopedic foot and ankle specialists</a> today.</p>
<p>The post <a href="https://osmsgb.com/foot-and-ankle-arthritis/">Foot and Ankle Arthritis: Answers to Common Questions from Specialist Dr. Brian Law</a> appeared first on <a href="https://osmsgb.com/">Orthopedic Sports Medicine Specialists (OSMS)</a>.</p>]]> </content:encoded>
</item>

<item>
<title>London Calling: Flagship Expands in U.K. to Build AI&#45;Native Platform Companies</title>
<link>https://edusehat.com/en/london-calling-flagship-expands-in-uk-to-build-ai-native-platform-companies</link>
<guid>https://edusehat.com/en/london-calling-flagship-expands-in-uk-to-build-ai-native-platform-companies</guid>
<description><![CDATA[ Flagship expects to recruit and train an initial team of approximately 50 U.K.-based scientist-entrepreneurs and operators for the new Origination Lab, U.K., which will build on three years of experience partnering and conducting R&amp;D across the kingdom.
The post London Calling: Flagship Expands in U.K. to Build AI-Native Platform Companies appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/109A8287_2026-10-13-193415_wksy-JPEG.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 06:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>London, Calling:, Flagship, Expands, U.K., Build, AI-Native, Platform, Companies</media:keywords>
<content:encoded><![CDATA[<p>Flagship Pioneering, which for more than 25 years has created and nurtured startups—most notably mRNA vaccine giant Moderna—from Cambridge, MA, has launched its first dedicated company creation unit outside of the U.S. with an initial commitment of £100 million ($131.66 million) that the venture capital giant expects to quintuple in coming years.</p>
<p>The new London-based Flagship Origination Lab U.K. has been established to conceive, test, fund, and build artificial intelligence (AI)-native platform companies that advance human and planetary health and other frontiers of science and technology.</p>
<p>Flagship said the U.K. Lab will operate as part of Flagship Labs, the company’s innovation foundry, with the goal of creating a locally rooted company-creation ecosystem in the United Kingdom that connects to Flagship’s broader global ecosystem, including business units and:</p>
<ul>
<li><strong>Pioneering Intelligence</strong>, Flagship’s AI and machine learning innovation effort designed to originate new companies by harnessing advances in computation integrated with a variety of scientific domains. Pioneering Intelligence was launched in 2023.</li>
<li><strong>Pioneering Medicines</strong>, Flagship’s in-house drug development unit founded in 2020. Pioneering Medicines explores and identifies new product concepts, then works jointly with Flagship’s companies to form integrated teams that advance new treatments through discovery and early clinical development. Medicines also partners with external collaborators.</li>
</ul>
<p>“I think this announcement by Flagship is a testament to the quality of British life sciences research and the investment will be welcomed in the U.K.,” Tim Harris, PhD, DSc, a molecular biologist, biochemist, and geneticist who is an operating partner with SV Health Investors specializing in work with therapeutics startups, told <em>GEN</em>.</p>
<figure aria-describedby="caption-attachment-340769" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340769" src="https://www.genengnews.com/wp-content/uploads/2026/11/tim-harris-219x300.jpg" alt="" width="219" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/tim-harris-219x300.jpg 219w, https://www.genengnews.com/wp-content/uploads/2026/11/tim-harris.jpg 540w" sizes="(max-width: 219px) 100vw, 219px"><figcaption class="wp-caption-text">Tim Harris, PhD, DSc, a molecular biologist, biochemist and geneticist who is an operating partner with SV Health Investors specializing in work with therapeutics startups</figcaption></figure>
<p>“Labs and people turn ideas into companies so I look forward to seeing some new ones come out of this initiative from the Flagship Pioneering team,” Harris added.</p>
<p>Founded in 1999, Flagship Pioneering has founded and nurtured more than 120 companies—between six and eight each year—employing more than 9,000 people. Thirteen Flagship Pioneering-launched companies have gone public through initial public offerings (IPOs) since 2013.</p>
<p>In London, Flagship expects to recruit and train an initial team of approximately 50 U.K.-based scientist-entrepreneurs and operators for the new Origination Lab, U.K., which will build on three years of experience partnering and conducting R&D across the kingdom.</p>
<p>Flagship is not the first U.S. VC firm to establish an outpost in the U.K. for nurturing startups from the kingdom: Harris noted that SV venture capitalists led by Kate Bingham, managing partner and co-leader of SV’s biotech franchise, have been creating and investing in U.K. and U.S. startups for many years.</p>
<p>Flagship’s new Origination Lab adds to the capital available, creating further opportunities for early-stage companies, Harris added.</p>
<h4><strong>‘Natural home’</strong></h4>
<p>“The U.K. is a natural home for AI and life sciences companies, and we want to see more new businesses across these sectors turning cutting-edge research and technology into new jobs and economic growth,” Chris McDonald, a chemical engineer and member of the U.K. Parliament (Labour Party) who is the kingdom’s Minister for Science, Innovation and Investment, said in a statement. “This new commitment from Flagship Pioneering will kickstart companies of the future in the U.K., who will take breakthroughs in AI and life sciences to the rest of the world and deliver innovations that can save lives.”</p>
<p>Flagship’s announcement comes weeks after AbbVie announced plans to expand its R&D facility in Oxford, U.K., as part of a £120 million ($158 million) investment into life sciences activity within the kingdom. AbbVie plans to expand its existing Oxford campus by constructing a new 12,000-square-foot site focused on research in immunology, neuroscience, and oncology.</p>
<p>However, since last year two other biopharma giants, AstraZeneca and Merck & Co., have dropped plans for large facilities within the U.K. AstraZeneca cited government funding reductions in halting plans for a £450 million vaccine manufacturing center in Merseyside.</p>
<p>Merck aborted plans for an R&D site set to employ 800 (including 180 researchers) at Belgrove House near King’s Cross in London, citing what it called high rebate clawback rates for voluntary and statutory medicines by the NHS, and insufficient government investment in life sciences, reflected in a decline from second to eighth since 2017 in SCI’s global foreign direct investment ranking in life sciences.</p>
<p>Flagship began expanding beyond the U.S. in 2023 when it opened offices in London and in Singapore. Since opening the London hub by signing a Memorandum of Understanding with the U.K. Government, Flagship has announced an agreement with Cambridge University Health Partners and the Milner Therapeutics Institute to collaborate to jointly advance breakthrough scientific research and technologies.</p>
<p>Also from the London hub, Flagship has launched its first transatlantic company, Quotient Therapeutics; accelerated first-in-category clinical trials across the U.K. by Flagship-founded companies such as Generate:Biomedicines; and developed numerous strategic partnerships across academia, data, and regulatory innovation.</p>
<p>Generate was founded in 2018 as a Flagship Pioneering company, and emerged from stealth operations during the COVID-19 pandemic two years later, when it announced that it had built a portfolio of therapeutic candidates for neutralizing SARS-CoV‑2, including antibodies and peptides targeting multiple epitopes on the spike protein peptide, in less than 17 days.</p>
<p>The biologics developer was an early comer applying AI-based approaches to rationally design sequence, structure, and function for protein therapeutics. In February, Generate <a href="https://www.genengnews.com/topics/artificial-intelligence/stockwatch-ai-drug-developer-generates-400m-ipo/" target="_blank" rel="noopener">went public on the Nasdaq Global Market</a> through a $400 million IPO that generated $369.3 million in net proceeds.</p>
<h4><strong>‘New chapter’</strong></h4>
<p>“Today marks the beginning of a new chapter in Flagship’s relationship with the U.K.,” declared Noubar Afeyan, PhD, Flagship Pioneering’s founder and CEO. “Over the past three years, we have seen firsthand the extraordinary depth of scientific imagination, talent, and ambition across the country. With our £100 million initial commitment, which we anticipate scaling through partnership to attract an additional £500 million [$658.6 million], we are now making a long-term commitment to build on that foundation.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Afeyan announced the new U.K. Lab on Monday at a conference of the U.K.’s Drug Information Association (DIA) and Medicines and Healthcare products Regulatory Agency (MHRA). The DIA-MHRA Global Summit is set to conclude Tuesday during London Life Sciences Week.</p>
<p>“Since first opening our London office three years ago, we’ve been impressed by the talent, imagination, and ambition that make the U.K. a leader in our field—and we are excited about the groundbreaking ventures that will come from combining our unique Flagship model with the U.K.’s distinct strengths,” Afeyan said in a <a href="https://www.linkedin.com/posts/noubarafeyan_for-26-years-every-flagship-pioneering-company-share-7528074845851385856-TGOI/?utm_source=share&utm_medium=member_ios&rcm=ACoAAAAijXMBke7yaGhNnsp7P32n1gHV4SXeNno" target="_blank" rel="noopener">LinkedIn post</a>.</p>
<p>Added Avak Kahvejian, PhD, general partner, Flagship Pioneering and president of its internal innovation foundry and company-creation unit Flagship Labs: “We have developed company origination into a discipline, one led by teams of scientist-entrepreneurs who begin with bold questions about what could be possible.”</p>
<p>“As we extend that capability globally, the U.K. was a clear and deliberate choice for our first expansion. Its exceptional science base, clinical-trial infrastructure, genomics and health-data assets, agile regulatory environment, and brilliant scientists and entrepreneurs create a powerful foundation for innovation,” Kahvejian stated.</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/london-calling-flagship-expands-in-u-k-to-build-ai-native-platform-companies/">London Calling: Flagship Expands in U.K. to Build AI-Native Platform Companies</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice</title>
<link>https://edusehat.com/en/targeting-folate-receptor-reverses-colorectal-cancers-resistance-to-immunotherapy-in-mice</link>
<guid>https://edusehat.com/en/targeting-folate-receptor-reverses-colorectal-cancers-resistance-to-immunotherapy-in-mice</guid>
<description><![CDATA[ Targeting FOLR1 with an approved antibody-drug conjugate restored anti-tumor immunity and enhanced anti-PD-1 effectiveness in colorectal cancer, overcoming immune evasion in mouse models.
The post Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/03/May_ADC_GettyImages_JL_2147604791_AntibodyDrugConjugate-e1775154897927.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 06:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Targeting, Folate, Receptor, Reverses, Colorectal, Cancer’s, Resistance, Immunotherapy, Mice</media:keywords>
<content:encoded><![CDATA[<p>Colorectal cancer (CRC) is the third most common cancer worldwide. Although immune checkpoint blockade is promising, responses to the treatment have been limited: treatments such as anti-PD-1 have resulted in only 15% of patients experiencing substantial benefits.</p>
<p>Now, a new study shows that a receptor for folate sustains colorectal cancer’s ability to evade a form of cancer immunotherapy—and finds that targeting this receptor with an approved compound can restore the treatment’s cancer-killing power in mice. The data add to the understanding of what factors can shape colorectal cancer’s response to immunotherapy and suggest that integrating folate receptor-based treatments into existing regimens could improve outcomes in patients with treatment-resistant tumors.</p>
<p>This work is published in <em>Science Translational Medicine</em> in the paper, “<a href="https://www.science.org/doi/10.1126/scitranslmed.aed2106" target="_blank" rel="noopener">Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti-PD-1 efficacy in colorectal cancer</a>.”</p>
<p>Colorectal cancer tumors possess many properties that stall immunotherapy’s ability to enhance anti-tumor immunity, including defects in the expression of MHC-1. Indeed, loss of MHC-I antigen presentation in tumor cells drives immune evasion and resistance to immune checkpoint blockade in colorectal cancer.</p>
<p>Previous research has connected folate receptor α (FOLR1) to more aggressive disease progression and poorer prognoses in various types of solid tumors. In this study, researchers conducted fluorescence-activated cell sorting–based CRISPR activation screens using a druggable genome library and identified folate receptor α (FOLR1) as a top negative regulator. In the study, they found that “high expression of FOLR1 predicted a poor ICB response, enhanced cancer stemness, and unfavorable patient outcomes.”</p>
<p>In addition, the team’s proteomic analyses revealed that “FOLR1 stabilized the lactyltransferase AARS1 (alanyl-tRNA synthetase 1), which lactylated signal transducer and activator of transcription 1 (STAT1) at lysine-193 (K193), facilitating its interaction with TCPTP (T cell protein-tyrosine phosphatase) and inducing STAT1 dephosphorylation at tyrosine-701.”</p>
<p>The group also tested the potential of mirvetuximab soravtansine, an approved antibody-drug conjugate that inhibits FOLR1. <em>In vitro </em>experiments revealed that FOLR1 indirectly impaired the activity of the STAT1 signaling pathway and dampened MHC-1 activity, which supported the cancer cells’ adaptability and prevented CD8+ T cells from engaging tumor cells.</p>
<p>However, mirvetuximab soravtansine restored anti-tumor immunity and resensitized colorectal cancer tumors to anti-PD-1 blockade in mice.</p>
<p>“Our findings support anti-FOLR1 [antibody-drug conjugate] as a clinically actionable approach to overcome immune evasion and unlock immunotherapy efficacy in [colorectal cancer],” the authors<em> </em>write.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/targeting-folate-receptor-reverses-colorectal-cancers-resistance-to-immunotherapy-in-mice/">Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CRISPR Screening Reveals How Genetic Variants Drive Neurodegenerative Risk</title>
<link>https://edusehat.com/en/crispr-screening-reveals-how-genetic-variants-drive-neurodegenerative-risk</link>
<guid>https://edusehat.com/en/crispr-screening-reveals-how-genetic-variants-drive-neurodegenerative-risk</guid>
<description><![CDATA[ Researchers studying human induced pluripotent stem cell-derived microglia-like cells showed how genetic variants can impact cell behavior and used CRISPR gene editing to show how one gene’s effect depends on its cellular context.
The post CRISPR Screening Reveals How Genetic Variants Drive Neurodegenerative Risk appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_OCT_2026_GettyImages-2204954826-Copy.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 06:35:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CRISPR, Screening, Reveals, How, Genetic, Variants, Drive, Neurodegenerative, Risk</media:keywords>
<content:encoded><![CDATA[<p>Research has started to bridge the gap between identifying genetic changes that can increase the risk of brain conditions, such as Alzheimer’s disease (AD), and understanding how they might impact specific cell functions. Researchers at the Wellcome Sanger Institute, Open Targets, and collaborators, differentiated human induced pluripotent stem cells (iPSCs) derived from different donors into microglia-like (iMGL) cells, and showed how genetic variants impact cell behavior, and more specifically, how they can lead to differences in the ability of brain immune cells to move and clear away biological debris.</p>
<p>Through their research the team also used CRISPR gene editing to show how one gene’s effect depends on its cellular context. They found that the impact of a genetic mutation can be completely opposite depending on the precise cell type and its environment, which is highly important for designing future targeted therapies. The study provides an indication of how to connect genetic risk variants with their downstream effects, as a next step in understanding how genes impact health conditions.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Andrew Bassett, PhD, at the Wellcome Sanger Institute and Open Targets, said, “While genetic studies have identified around a hundred genomic regions linked to Alzheimer’s, pinpointing the exact genes involved and how they alter cell behavior has been more of a challenge. By growing brain immune cells from stem cells across hundreds of donors, we’ve built a framework that directly connects genetic risk to real cell functions, such as how effectively these cells clear debris in the brain. We also discovered that the impact of a genetic variant can change depending on its cellular environment, in some cases having the opposite effect. This suggests that we can’t just look at the impact of these genetic changes in isolation or in one cell. Instead, knowing the exact cell context is essential to understanding how these genetic changes impact health.”</p>
<p>Bassett is co-senior author of the researchers’ published paper in <em>Nature Genetics</em>, titled “<a href="https://doi.org/10.1038/s41588-026-02843-0" target="_blank" rel="noopener">Integrated QTL mapping and CRISPR screening in pooled iPSC-derived microglia reveals genetic drivers of neurodegenerative risk</a>.” In their report the authors concluded, “By contextualizing variant effects within iMGLs in different inflammatory states, we provide a comprehensive framework for interpreting the function of risk loci in neurodegenerative disorders.”</p>
<p>Genome wide association studies (GWAS) scan genomes and highlight which differences, known as genetic variants, are more often found in patients with specific health conditions. However, while they can signpost regions of the genome they do not explain how those regions alter gene and cell function. “Genome-wide association studies (GWAS) have identified thousands of variants linked to complex traits and diseases, but translating these into biological insight remains challenging,” the authors wrote. “Most variants are non-coding and probably influence disease by regulating gene expression in specific cell types, states or environments.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>To bridge the gap, the researchers developed a framework to map GWAS data to changes in gene expression and cell behavior. For this, they used 261 human stem cell lines to derive brain cells known as microglia, which are a type of specialized immune cell that move around the brain and remove cellular debris or misfolded proteins. This process,  phagocytosis, is an important part of maintaining healthy neuronal function. As the team pointed out, “Mounting evidence implicates microglia in neurodegeneration, but linking disease-associated genetic variants to target genes and cellular phenotypes is hindered by the inaccessibility of these cells,” they pointed out.</p>
<p>First, the team identified which genetic variants change the levels of different genes in microglia cells. Next, they asked if genetic regions that have been previously linked to Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS) also modulate gene levels. This analysis identified 79 regions. “Expression quantitative trait locus (eQTL) analysis identified 7,121 eQTL-associated genes and 79 colocalizations across four neurodegenerative disease genome-wide association studies, half of which had limited prior evidence of causality,” they stated.</p>
<p>These links alone do not inform of the impact on cell function, so to further understand how these changes in gene expression alter cell behavior, the researchers conducted laboratory tests on the microglia, measuring the cells’ ability to move and undertake phagocytosis. Through these tests and computational modeling, they were able to map 34 genes to changes in cell behavior. This highlighted disease-relevant variants at <em>TREM2</em> that were linked to changes in phagocytosis.</p>
<p>To understand further how these genes impact behavior of microglia, the team conducted CRISPR screens, knocking out 251 disease-relevant genes. This also allowed them to show that the impact of the gene depends on the cellular context. For example, knocking out <em>TREM2</em> increases phagocytosis in microglia but decreases it in macrophages, a different type of immune cell. “These results demonstrate that modulation of TREM2 leads to different phenotypic outcomes depending on the cell type, and emphasize the importance of cellular context when interpreting its function in neurodegeneration,” the authors stated.</p>
<p>This research gives a scalable blueprint for studying brain immune cells, which are impossible to safely take samples of in living patients. It could also help find new pathways and drug targets from disease genetic data, giving insight into the cellular mechanisms that are linked to diseases. In their paper the investigators stated, “In summary, this multifaceted approach enabled us to connect genetic variants to effector genes and gene programs, down stream cellular phenotypes and potential disease mechanisms.”</p>
<p>Co-senior author Gosia Trynka, PhD, at the Wellcome Sanger Institute and Science Director at Open Targets, said, “Brain conditions such as Alzheimer’s are incredibly complicated, and understanding how different parts of our genome are linked to these conditions could help us find new ways to identify or treat them. Identifying the associated part of the genome is the first step but it leaves a large translational gap, and our new research has found a way to bridge the gap between association and understanding the impact on the cell function. Connecting this allows us to start to build a full biological picture of disease and will help design future research to accelerate drug discovery.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Co-first author Marta Perez-Alcantara, PhD, previously at the Wellcome Sanger Institute and Open Targets, further commented, “This ambitious study showcases the potential of iPSC-derived cells for genetic analysis, linking genetic variation to expression, cellular survival and function, and disease susceptibility. This approach is particularly valuable for difficult-to-access tissues such as the brain, allowing us to investigate genetic effects across multiple donors and stimulation conditions in microglia, which are challenging to obtain in sufficient numbers and under the right stimuli from primary human tissues. This framework has the potential to be extended to other diseases, tissues or cellular phenotypes, enabling research that would otherwise be extremely difficult to undertake.”</p>
<p>The authors added that in a broader context “… our study demonstrates the feasibility and value of integrating genetic association data, single-cell transcriptomics, and pooled functional genomics to investigate genotype–phenotype relationships at scale. This framework is also applicable to other cell types and diseases.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/crispr-screening-reveals-how-genetic-variants-drive-neurodegenerative-risk/">CRISPR Screening Reveals How Genetic Variants Drive Neurodegenerative Risk</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Growing Apart: Culture&#45;Based Sterility Test Alternatives</title>
<link>https://edusehat.com/en/growing-apart-culture-based-sterility-test-alternatives</link>
<guid>https://edusehat.com/en/growing-apart-culture-based-sterility-test-alternatives</guid>
<description><![CDATA[ Growth-based sterility testing works for traditional biopharma but is too slow for the cell therapy sector. A new parallel testing pathway and rapid, molecular assay-based testing are a better option.
The post Growing Apart: Culture-Based Sterility Test Alternatives appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/06/GettyImages-521677434.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 03:05:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Growing, Apart:, Culture-Based, Sterility, Test, Alternatives</media:keywords>
<content:encoded><![CDATA[<p>In the biopharma industry, culture-based microbial sterility testing methods are not fast enough for personalized cell therapy production, say the developers of a new parallel analysis pathway.</p>
<p>Bacterial contamination is always a risk in biopharmaceutical production. The complex, multi-step nature of processes, the nutrient-rich, aqueous environments in which cells are cultured—and even the raw materials themselves—provide potential entry points for microorganisms.</p>
<p>As a result, regulators require that biopharmaceuticals undergo extensive analysis using standardized procedures. Typically, product samples are cultured to allow any bacterial or fungal contaminants to grow, enabling full identification.</p>
<p>For high-volume products made in multiple, sequential batches—protein therapeutics, monoclonal antibodies—these long testing processes can be incorporated into the manufacturing lifecycle without interrupting market supply.</p>
<p>For firms making single-batch, patient-specific therapies, any steps that delay release, including long sterility testing processes, are hard to accommodate, according to Athena Stathoulis, a researcher at the University of Melbourne in Australia.</p>
<p>“The gold-standard sterility test for cell therapies, USP <71>, takes 14 days to give a result. Fresh CAR T products often have to be infused within 24–72 hours, so the product reaches the patient long before its sterility is confirmed,” she tells <em>GEN</em>.</p>
<p>In practice, the need to deliver CAR T cell therapies to patients as soon as possible means they are often released early, under exceptional protocols based on interim culture results at around 48 hours, Stathoulis explains.</p>
<p>“This approach shortens the detection window and risks missing slow-growing organisms, with full sterility confirmation only arriving after the patient has been infused. This matters because vein-to-vein time is linked to outcomes,” she adds.</p>
<p>Stathoulis, who examined cell therapy sector practices in a recent <a href="https://www.sciencedirect.com/science/article/pii/S1045105626000461" target="_blank" rel="noopener">study</a>, also points out that, unlike steps like leukapheresis, transduction, and expansion that can be optimized, the timelines for sterility testing are fixed by regulatory mandate.</p>
<p>“Sterility testing is the one manufacturing bottleneck that process optimization can’t fix, because the incubation period is set by regulation, not biology. That makes it the rate-limiting step for point-of-care and decentralized CAR T manufacturing.”</p>
<h4><strong>Solutions</strong></h4>
<p>Cell therapy firms do have potential alternative testing options, Stathoulis says, with the most promising being assays that do not rely on bacterial growth.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>“The main alternatives are ATP bioluminescence, solid-phase cytometry, and molecular assays targeting conserved bacterial and fungal ribosomal RNA genes (16S/18S rRNA).</p>
<p>“In our view, the molecular assays are the most compelling. They are not growth-dependent, removing the need for incubation altogether and providing results within hours,” Stathoulis explains.</p>
<p>Another potential alternative, which Stathoulis and colleagues propose in the study, would be to run a combination of sterility testing methods in parallel.</p>
<p>“Our review proposes a three-phase pathway that moves toward this: comprising analytical qualification; then parallel testing alongside compendial methods; and then conditional release,” she says.</p>
<p>Measures set out in the proposed pathway include testing against a facility-specific panel of at least 20 organisms, including skin flora such as <em>Cutibacterium acnes</em>, Gram-negative bacteria, fungi, and slow-growing organisms.</p>
<p>The pathway also calls for the use of viability dyes and enrichment steps to reduce the risk of false positives and false negatives, as well as compendial testing after infusion as a safety net, with a predefined plan for when the rapid and compendial results disagree.</p>
<h4><strong>Adoption</strong></h4>
<p>The degree to which cell therapy firms can use alternative methods depends on regulators, according to Stathoulis, who says, “The barriers to adopting rapid sterility methods are regulatory rather than analytical, and regulation can be reformed. The main obstacles are regulatory fragmentation between the FDA, EMA, and TGA, and a lack of real-world validation data in CAR T products.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/growing-apart-culture-based-sterility-test-alternatives/">Growing Apart: Culture-Based Sterility Test Alternatives</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>One Record, From Factory Floor to Patient</title>
<link>https://edusehat.com/en/one-record-from-factory-floor-to-patient</link>
<guid>https://edusehat.com/en/one-record-from-factory-floor-to-patient</guid>
<description><![CDATA[ ParkourSC acquired manufacturing-AI company Quartic to track a drug’s quality across its whole lifecycle. CEO Mahesh Veerina explains how linking factory and shipping data could flag at-risk batches before problems reach patients.
The post One Record, From Factory Floor to Patient appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Mike-ParkourSC_GBPN_IMAGE_19NOV26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 03:05:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>One, Record, From, Factory, Floor, Patient</media:keywords>
<content:encoded><![CDATA[<p>A drug’s life story is usually told in pieces. How a batch was made lives in one set of manufacturing systems. What happens to it afterward—where it shipped, how warm it got, how long it sat—lives in another. When something goes wrong downstream, quality teams must stitch that history back together before they can decide what to do, and the delay can cost product, time, and confidence in supply.</p>
<p>San Jose–based ParkourSC says it acquired Quartic to close that gap. The deal combines ParkourSC’s clinical and commercial supply-chain AI with Quartic’s manufacturing AI on a single platform aimed at regulated life sciences. The company says the result is one continuous record that can predict which batches, lots, and shipments are at risk, then recommend a response.</p>
<p>For Mahesh Veerina, president and CEO of ParkourSC, the move was less about reaching manufacturing data than about making sense of it. The company could have built its own connectors to the systems that hold batch records, he said, “but it’s not about the data itself.” Quartic, he explains, “consumes this data, contextualizes it around batches and campaigns, and creates intelligence about the key quality attributes” that ParkourSC’s downstream decisions depend on.</p>
<p>The timing reflects where the industry is heading. Companies are shifting more of their portfolios to biologics, and production is spreading across more internal and contract sites. “Supply chain systems, both clinical and commercial, need to become more dynamic in their decision intelligence,” Veerina says.</p>
<p>A temperature excursion shows what that could change. Today, a quality team often judges a cold-chain breach by what happened on the last leg of a shipment. Linking manufacturing and distribution data, Veerina says, “turns a temperature excursion from an isolated event into a decision made with the batch’s full story.” Teams can see the cumulative time a batch has spent in and out of refrigeration from the plant onward, while the platform predicts the remaining stability margin “as excursions occur, so teams know early how much margin a batch has left.” Decisions to release, restrict, or reject product, he adds, become “faster and better justified.”</p>
<p>The approach also reaches upstream. Because Quartic uses shared models across research, clinical, and commercial manufacturing, Veerina says, the multivariate models built for clinical batches “act as the starting point, rather than developing models from scratch,” speeding scale-up and process qualification. He attributed the 15 to 20% gain in biologics batch yield the companies report to models that let operators “run the process close to the ideal-yield batch, repeatably.”</p>
<p>In a GxP setting, meaning one bound by good-practice quality regulations, trust is the harder question, and Veerina draws a firm line. “AI recommends, and a qualified person decides. AI never makes the GxP decision,” he said. The platform relies on interpretable statistical methods, “never black-box models or LLMs,” keeps every recommendation within validated ranges, and attaches a confidence interval and the factors behind it. A human approves each decision with an e-signature, and an audit trail links the data, the recommendation, and the call that was made.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/one-record-from-factory-floor-to-patient/">One Record, From Factory Floor to Patient</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Tuning Extracellular Vesicle Production and Analytics for Compliance</title>
<link>https://edusehat.com/en/tuning-extracellular-vesicle-production-and-analytics-for-compliance</link>
<guid>https://edusehat.com/en/tuning-extracellular-vesicle-production-and-analytics-for-compliance</guid>
<description><![CDATA[ The complexity of extracellular vesicle products developed from umbilical cord blood can potentially be reduced through production processes and simplified quality control strategies, helping to boost this new product class.
The post Tuning Extracellular Vesicle Production and Analytics for Compliance appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Vivienne-PR_Exogenus-T.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 03:05:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Tuning, Extracellular, Vesicle, Production, and, Analytics, for, Compliance</media:keywords>
<content:encoded><![CDATA[<p>A company developing extracellular vesicles (EV) derived from umbilical cord blood cells says that producing a non-conventional product shouldn’t be a barrier to streamlined production processes and quality control analytics.</p>
<p>Exogenus Therapeutics, which is currently developing products targeted at inflammatory and degenerative conditions, says that they’ve managed to implement a production and quality-control (QC) workflow that turns their complicated high-screening analytics into a more sustainable assay panel.</p>
<p>“I think our main message to the corporate EV community is it’s possible to develop and produce an extracellular vesicle-based product that falls outside the mainstream,” explains Andreia Silva, PhD, head of research at Exogenus, who spoke at Cell & Gene Therapy International Europe.</p>
<p>According to Silva, complexities of their production process include the raw material of umbilical cord blood, which has a higher level of variability than conventional EV cell sources as it’s derived from different donors, but which needs to be sculpted into a safe and consistent-quality product.</p>
<p>The product is also complex, she explains, as unlike small molecules, extracellular vesicles are made of thousands of molecules of lipids, proteins, metabolites, DNA, and RNA, all of which may be functional once they reach a target organ.</p>
<p>To overcome this complexity issue, as they move toward the clinical stage of development, the company says it’s managed to develop a production strategy including a panel of assays that can be run using standardized techniques, such as ELISA and Western Blot, to provide efficient and sustainable QC of product batches.</p>
<p>“We can’t do omics on every single batch of product we are going to release because it would become too expensive down the line,” explains Silva. “We’ve been looking at the molecular data generated at the omics level and then selecting specific targets to pass that into the simpler QC panel.”</p>
<p>Although their target choices and QC panel are product-specific, Silva hopes the general lessons will inspire other companies in their QC development. Going forward, she says a future challenge for the EV industry will be developing potency assays.</p>
<p>“Potency assay development for GMP production, so you can use your product in later clinical phases, is still something that needs a lot of development because EVs are such a complex modality,” she says.</p>
<p>“As companies work toward getting an EV product to clinic, we can definitely see strategies emerging for what might be the right way to go.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/tuning-extracellular-vesicle-production-and-analytics-for-compliance/">Tuning Extracellular Vesicle Production and Analytics for Compliance</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Advent of Automated, Gene&#45;Engineered TIL Manufacturing</title>
<link>https://edusehat.com/en/the-advent-of-automated-gene-engineered-til-manufacturing</link>
<guid>https://edusehat.com/en/the-advent-of-automated-gene-engineered-til-manufacturing</guid>
<description><![CDATA[ Automating engineered TIL manufacturing in a way that maintains their tumor-fighting capabilities may move this emerging therapeutic class into a commercially reproducible, economically viable therapeutic option.
The post The Advent of Automated, Gene-Engineered TIL Manufacturing appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/GettyImages-2179695031.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 03:05:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Advent, Automated, Gene-Engineered, TIL, Manufacturing</media:keywords>
<content:encoded><![CDATA[<p>Tumor-infiltrating leukocytes (TILs) tend to be manufactured at small scale in labs using manual, bespoke processes to account for inconsistent starting materials and conditions. As TIL-based therapeutics move to clinical scale, however, automation and the reproducibility and efficiency it provides become invaluable.</p>
<p>A handful of companies are working to automate the TIL production process. The latest, Terumo Blood and Cell Technologies (Terumo BCT), is using its Quantum Flex<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> Cell Expansion System to automate the production of genetically engineered TILs in partnership with TrAMPoline Pharma and the University of Colorado.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“Automation could help bridge the gap between development in the lab and clinical scale by utilizing the same scalable technology for both phases to ultimately preserve product quality along the development pipeline,” Mindy Miller, PhD, head of cell therapy scientific development at Terumo BCT, tells <em>GEN</em>.</p>
<p>The challenge is that TILs are produced from T cells that have infiltrated tumors. These T cells typically don’t expand as efficiently as T cells found in the bloodstream, so vastly greater quantities of T cells are needed to produce potent doses.</p>
<p>“We recognized that a process dependent on extensive manual handling would inevitably limit clinical translation,” Eduardo Davila, PhD, professor of medicine at the University of Colorado, and co-founder and CSO at TrAMPoline Pharma, adds. His research into T cell infiltration is the basis for TrAMPoline Pharma’s TIL program. This collaboration “aims to make engineered TIL manufacturing more reproducible and efficient while preserving the cells’ tumor-fighting capabilities.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>To that end, Davila says, “We are focusing on standardized culture conditions, automated feeding, and fewer manual manipulations. Our goal is to preserve engineered TIL identity, viability, and antitumor function.”</p>
<p>The automation process is being undertaken in phases. The first step is to validate automated cell expansion against the existing process. Then, additional steps will be validated and integrated into the workflow.</p>
<p>“We anticipate a substantial reduction in hands-on labor and expedited TIL expansion. Whether total manufacturing time also decreases—and by how much—must be established experimentally,” Davila says. But, Miller adds, “it is still being evaluated.”</p>
<p>Today, it takes about three weeks to manufacture TILs. While neither Miller nor Davila will suggest a target timeframe for engineered TIL manufacturing within this partnership, Davila says, “We anticipate more consistent yield, fewer manual interventions, and greater manufacturing capacity, with the potential to reduce cost and turnaround time.”</p>
<p>Additionally, he continues, “We will evaluate these gains alongside gene transfer efficiency, viability, phenotype, and tumor-specific killing. Improved potency is an outcome to test, rather than assume.”</p>
<p>Miller emphasizes, “Our focus is adapting automation to the particular requirements of engineered TILs.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/the-advent-of-automated-gene-engineered-til-manufacturing/">The Advent of Automated, Gene-Engineered TIL Manufacturing</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>A Persistent Problem In Football</title>
<link>https://edusehat.com/en/a-persistent-problem-in-football</link>
<guid>https://edusehat.com/en/a-persistent-problem-in-football</guid>
<description><![CDATA[ This week in the world of sports science, RAE, air pollution &amp; marathons, and menstrual cycle knowledge.
The post A Persistent Problem In Football appeared first on Science for Sport. ]]></description>
<enclosure url="https://www.scienceforsport.com/wp-content/uploads/2026/11/9be09c48-d4b9-4e40-8d2f-d9b2494abbac-1024x683.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 00:10:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Persistent, Problem, Football</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph"><strong>This week in the world of sports science, here’s what happened…</strong></p>



<ul class="wp-block-list">
<li>The Relative Age Effect: a persistent problem in football</li>



<li>Is air pollution slowing down marathon runners?</li>



<li>Only 1 in 10 coaches consider the menstrual cycle when planning training</li>
</ul>



<div aria-hidden="true" class="wp-block-spacer"></div>



<h2 class="wp-block-heading">The Relative Age Effect: a persistent problem in football</h2>



<figure class="wp-block-image size-large"><img fetchpriority="high" decoding="async" width="1024" height="683" src="https://www.scienceforsport.com/wp-content/uploads/2026/11/9be09c48-d4b9-4e40-8d2f-d9b2494abbac-1024x683.png" alt="" class="wp-image-34438" srcset="https://www.scienceforsport.com/wp-content/uploads/2026/11/9be09c48-d4b9-4e40-8d2f-d9b2494abbac-1024x683.png 1024w, https://www.scienceforsport.com/wp-content/uploads/2026/11/9be09c48-d4b9-4e40-8d2f-d9b2494abbac-300x200.png 300w, https://www.scienceforsport.com/wp-content/uploads/2026/11/9be09c48-d4b9-4e40-8d2f-d9b2494abbac-768x512.png 768w, https://www.scienceforsport.com/wp-content/uploads/2026/11/9be09c48-d4b9-4e40-8d2f-d9b2494abbac.png 1536w" sizes="(max-width: 1024px) 100vw, 1024px"><figcaption class="wp-element-caption">(Image: ChatGPT)</figcaption></figure>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph">Experienced <a href="https://academy.scienceforsport.com/programs/collection-p00aqyygjui?category_id=141256" target="_blank" rel="noreferrer noopener">football</a> scout Paul Turner Mitchell recently shared an interesting <a href="https://lnkd.in/p/dTxZrhFJ" target="_blank" rel="noreferrer noopener">post</a> on LinkedIn highlighting the continued influence of the <a href="https://www.scienceforsport.com/relative-age-effect/" target="_blank" rel="noreferrer noopener">Relative Age Effect</a> in <a href="https://academy.scienceforsport.com/programs/collection-p00aqyygjui?category_id=141256" target="_blank" rel="noreferrer noopener">youth football</a>. While awareness of the <a href="https://www.scienceforsport.com/relative-age-effect/" target="_blank" rel="noreferrer noopener">Relative Age Effect</a> has grown considerably in recent years, the research highlighted by Mitchell suggests that it remains a significant issue in <a href="https://academy.scienceforsport.com/programs/collection-p00aqyygjui?category_id=141256" target="_blank" rel="noreferrer noopener">football</a> <a href="https://www.scienceforsport.com/talent-identification-what-coaches-are-looking-for-in-youth-athletes/" target="_blank" rel="noreferrer noopener">talent identification</a> and selection. The figures are particularly striking:</p>



<ul class="wp-block-list">
<li>English <a href="https://academy.scienceforsport.com/programs/collection-p00aqyygjui?category_id=141256" target="_blank" rel="noreferrer noopener">football</a> academy: 44% of players were born in Q1, compared with just 11% in Q4.</li>



<li>German elite <a href="https://academy.scienceforsport.com/programs/collection-p00aqyygjui?category_id=141256" target="_blank" rel="noreferrer noopener">football</a> academy: Of more than 1,000 players, 44.8% were born in Q1, compared with only 9.6% in Q4.</li>



<li>Italian U17 National Championships: Of more than 1,000 players, 43.5% were born in Q1, compared with just 8.5% in Q4.</li>
</ul>



<p class="wp-block-paragraph">Across all three groups, more than 72% of players were born in the first half of their respective selection years. Interestingly, this pattern remained consistent despite differences in selection-year cut-off dates. Germany and Italy operate a January-to-December selection year, whereas England uses September to August. Regardless of the cut-off date, players born in the first quarter of their selection year were substantially overrepresented.</p>



<p class="wp-block-paragraph">This is an important distinction because it suggests that the issue is not necessarily the month in which a player is born, but rather their <a href="https://www.scienceforsport.com/relative-age-effect/" target="_blank" rel="noreferrer noopener">relative age</a> compared with other players in the same selection group. For coaches, scouts and those involved in <a href="https://www.scienceforsport.com/youth-athletes-how-teachers-coaches-and-students-can-best-work-together/" target="_blank" rel="noreferrer noopener">youth athletic development</a>, the findings serve as another reminder of the importance of considering <a href="https://www.scienceforsport.com/relative-age-effect/" target="_blank" rel="noreferrer noopener">relative age</a> when <a href="https://www.scienceforsport.com/talent-identification-what-coaches-are-looking-for-in-youth-athletes/">identifying</a> and developing young athletes.</p>



<p class="wp-block-paragraph">If you would like to learn more about the <a href="https://www.scienceforsport.com/relative-age-effect/" target="_blank" rel="noreferrer noopener">Relative Age Effect</a>, check out our highly informative course: <a href="https://academy.scienceforsport.com/programs/collection-u-q6kntrbcu?category_id=141256" target="_blank" rel="noreferrer noopener">Relative Age Effect</a> by John Radnor.</p>



<div aria-hidden="true" class="wp-block-spacer"></div>



<h2 class="wp-block-heading">Is air pollution slowing down marathon runners?</h2>



<figure class="wp-block-image size-full"><img decoding="async" width="739" height="415" src="https://www.scienceforsport.com/wp-content/uploads/2026/11/images.jpg" alt="" class="wp-image-34437" srcset="https://www.scienceforsport.com/wp-content/uploads/2026/11/images.jpg 739w, https://www.scienceforsport.com/wp-content/uploads/2026/11/images-300x168.jpg 300w" sizes="(max-width: 739px) 100vw, 739px"><figcaption class="wp-element-caption">(Image: The Atlantic)</figcaption></figure>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph">A recent <a href="https://link.springer.com/article/10.1186/s40798-026-01099-6?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">study</a> examining the relationship between air pollution and marathon performance has attracted considerable mainstream media attention (see <a href="https://www.euronews.com/2026/09/30/air-pollution-is-slowing-down-marathon-runners-study-finds?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">here</a>). Researchers from the University of Leicester analysed 2,756,553 performances recorded across the world’s six major marathons—Berlin, Boston, Chicago, London, New York and Tokyo—between 2010 and 2024.</p>



<p class="wp-block-paragraph">The researchers compared finishing times with race-day concentrations of two major pollutants: nitrogen dioxide (NO₂) and PM2.5. The most striking finding was that every 1 µg/m³ increase in NO₂ was associated with finishing times that were 1.43 minutes slower for men and 1.56 minutes slower for women. By contrast, PM2.5 was not significantly associated with slower performance.</p>



<p class="wp-block-paragraph">The <a href="https://link.springer.com/article/10.1186/s40798-026-01099-6?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">study</a> also produced several other interesting findings. Air pollution appeared to affect recreational <a href="https://academy.scienceforsport.com/programs/collection-vq0okjasa8c?category_id=141256" target="_blank" rel="noreferrer noopener">runners</a> approximately six times more than elite <a href="https://academy.scienceforsport.com/programs/collection-vq0okjasa8c?category_id=141256" target="_blank" rel="noreferrer noopener">runners</a>, suggesting that elite athletes may be better able to cope with its effects. Younger <a href="https://academy.scienceforsport.com/programs/collection-vq0okjasa8c?category_id=141256" target="_blank" rel="noreferrer noopener">runners</a> also appeared to be more affected. Among those aged 18–29, every 1 µg/m³ increase in NO₂ was associated with an approximately 2.17-minute increase in finishing time, compared with 1.32 minutes among <a href="https://academy.scienceforsport.com/programs/collection-vq0okjasa8c?category_id=141256">runners</a> aged 60 and over.</p>



<p class="wp-block-paragraph">It is important to remember that this was an observational <a href="https://link.springer.com/article/10.1186/s40798-026-01099-6?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">study</a>, so it cannot establish that air pollution directly caused slower marathon times. Nevertheless, the analysis of more than 2.7 million performances makes the findings compelling and raises an important question: could air pollution be costing marathon <a href="https://academy.scienceforsport.com/programs/collection-vq0okjasa8c?category_id=141256" target="_blank" rel="noreferrer noopener">runners</a> valuable minutes?</p>



<div aria-hidden="true" class="wp-block-spacer"></div>



<h2 class="wp-block-heading">Only 1 in 10 coaches consider the menstrual cycle when planning training</h2>



<figure class="wp-block-image size-large"><img decoding="async" width="1024" height="576" src="https://www.scienceforsport.com/wp-content/uploads/2026/11/5cb79ae5-6c90-49ac-a626-1185528cda62-1024x576.png" alt="" class="wp-image-34440" srcset="https://www.scienceforsport.com/wp-content/uploads/2026/11/5cb79ae5-6c90-49ac-a626-1185528cda62-1024x576.png 1024w, https://www.scienceforsport.com/wp-content/uploads/2026/11/5cb79ae5-6c90-49ac-a626-1185528cda62-300x169.png 300w, https://www.scienceforsport.com/wp-content/uploads/2026/11/5cb79ae5-6c90-49ac-a626-1185528cda62-768x432.png 768w, https://www.scienceforsport.com/wp-content/uploads/2026/11/5cb79ae5-6c90-49ac-a626-1185528cda62-1536x864.png 1536w, https://www.scienceforsport.com/wp-content/uploads/2026/11/5cb79ae5-6c90-49ac-a626-1185528cda62.png 1672w" sizes="(max-width: 1024px) 100vw, 1024px"><figcaption class="wp-element-caption">(Image: ChatGPT)</figcaption></figure>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph">A new <a href="https://www.frontiersin.org/journals/sports-and-active-living/articles/10.3389/fspor.2026.1906962/abstract" target="_blank" rel="noreferrer noopener">study</a> showed that there remains a significant knowledge-to-practice gap when it comes to the <a href="https://www.scienceforsport.com/understanding-and-approaching-the-entire-menstrual-cycle-a-guide-for-coaches/" target="_blank" rel="noreferrer noopener">menstrual cycle</a> and <a href="https://academy.scienceforsport.com/programs/collection-gpfptyhsrai?category_id=141256" target="_blank" rel="noreferrer noopener">female athletes</a>. The <a href="https://www.frontiersin.org/journals/sports-and-active-living/articles/10.3389/fspor.2026.1906962/abstract" target="_blank" rel="noreferrer noopener">study</a> surveyed 261 coaches (51% female and 49% male) and found that coaches rated their knowledge of the <a href="https://www.scienceforsport.com/understanding-and-approaching-the-entire-menstrual-cycle-a-guide-for-coaches/" target="_blank" rel="noreferrer noopener">menstrual cycle</a> at an average of 6.4/10. However, despite coaches reporting a reasonable level of knowledge about the <a href="https://www.scienceforsport.com/understanding-and-approaching-the-entire-menstrual-cycle-a-guide-for-coaches/" target="_blank" rel="noreferrer noopener">menstrual cycle</a>, only 10% actually considered <a href="https://www.scienceforsport.com/understanding-and-approaching-the-entire-menstrual-cycle-a-guide-for-coaches/" target="_blank" rel="noreferrer noopener">menstrual cycle</a> information when planning training, while nearly half admitted to not tracking their athletes’ <a href="https://www.scienceforsport.com/understanding-and-approaching-the-entire-menstrual-cycle-a-guide-for-coaches/" target="_blank" rel="noreferrer noopener">menstrual cycles</a> at all.</p>



<p class="wp-block-paragraph">Encouragingly, coaches rated their willingness to learn more about the <a href="https://www.scienceforsport.com/understanding-and-approaching-the-entire-menstrual-cycle-a-guide-for-coaches/" target="_blank" rel="noreferrer noopener">menstrual cycle</a> at a solid 8.5/10, while the majority felt the topic wasn’t sufficiently covered in coach education. So, it’s good to see that coaches want to better understand and consider the <a href="https://www.scienceforsport.com/understanding-and-approaching-the-entire-menstrual-cycle-a-guide-for-coaches/" target="_blank" rel="noreferrer noopener">menstrual cycle</a>, but it is certainly concerning that only 1 in 10 currently use this information when planning training.</p>



<p class="wp-block-paragraph">If you would like to learn more about the <a href="https://www.scienceforsport.com/understanding-and-approaching-the-entire-menstrual-cycle-a-guide-for-coaches/" target="_blank" rel="noreferrer noopener">menstrual cycle</a>, check out our new course <a href="https://academy.scienceforsport.com/programs/collection-ng_9uvajkoq?category_id=141256" target="_blank" rel="noreferrer noopener">Menstruation in Sport</a> and our blog <a href="https://www.scienceforsport.com/understanding-and-approaching-the-entire-menstrual-cycle-a-guide-for-coaches/" target="_blank" rel="noreferrer noopener">Understanding and Approaching the Entire Menstrual Cycle: A Guide for Coaches</a>.</p>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph"><strong>From us this week:</strong></p>



<p class="wp-block-paragraph">>> New course: <a href="https://academy.scienceforsport.com/programs/collection-xy44wcqbjsy?category_id=141256" data-type="link" data-id="https://academy.scienceforsport.com/programs/collection-xy44wcqbjsy?category_id=141256" target="_blank" rel="noreferrer noopener">Observation Before Intervention: Building Better Coaching Environments</a><br>>> New podcast: <a href="https://scienceforsport.fireside.fm/346" data-type="link" data-id="https://scienceforsport.fireside.fm/346" target="_blank" rel="noreferrer noopener">How to Develop Strength, Speed and Power in Young Athletes</a><br>>> New infographic: <a href="https://www.instagram.com/p/DfRgvrzF883/?img_index=1" data-type="link" data-id="https://www.instagram.com/p/DfRgvrzF883/?img_index=1" target="_blank" rel="noreferrer noopener">Football Conditioning Small Sided Games</a><br>>> New article: <a href="https://www.scienceforsport.com/essa-and-science-for-sport-announce-strategic-professional-development-partnership/" data-type="link" data-id="https://www.scienceforsport.com/essa-and-science-for-sport-announce-strategic-professional-development-partnership/" target="_blank" rel="noreferrer noopener">ESSA and Science for Sport Announce Strategic Professional Development Partnership</a></p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Access to a growing library of sports science courses</strong></p>



<p class="wp-block-paragraph"><a href="https://academy.scienceforsport.com/" target="_blank" rel="noopener" data-lasso-id="59917">SFS Academy</a> is an all-access membership to premium sports science education.</p>



<p class="wp-block-paragraph">With SFS Academy, you’ll learn from some of the best coaches around the world as they teach you how to apply the latest research and practice with your athletes.</p><p>The post <a href="https://www.scienceforsport.com/a-persistent-problem-in-football/">A Persistent Problem In Football</a> appeared first on <a href="https://www.scienceforsport.com/">Science for Sport</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond the Sensor: Enhancing Diabetes Technology</title>
<link>https://edusehat.com/en/beyond-the-sensor-enhancing-diabetes-technology</link>
<guid>https://edusehat.com/en/beyond-the-sensor-enhancing-diabetes-technology</guid>
<description><![CDATA[ From customizable glucose alerts and remote data sharing to integrated clinical reporting, digital platforms are transforming how patients and healthcare professionals access and use diabetes technology. Continuous glucose monitoring (CGM) has become an integral part of diabetes management, but innovation is extending well beyond the sensors themselves. Companion applications and digital health platforms are expanding […]
The post Beyond the Sensor: Enhancing Diabetes Technology appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/website-featured-image.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 23:55:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, the, Sensor:, Enhancing, Diabetes, Technology</media:keywords>
<content:encoded><![CDATA[<p>From customizable glucose alerts and remote data sharing to integrated clinical reporting, digital platforms are transforming how patients and healthcare professionals access and use diabetes technology. Continuous glucose monitoring (CGM) has become an integral part of diabetes management, but innovation is extending well beyond the sensors themselves. Companion applications and digital health platforms are expanding […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/beyond-the-sensor/">Beyond the Sensor: Enhancing Diabetes Technology</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Saskatchewan to expand access to new ovarian cancer treatments</title>
<link>https://edusehat.com/en/saskatchewan-to-expand-access-to-new-ovarian-cancer-treatments</link>
<guid>https://edusehat.com/en/saskatchewan-to-expand-access-to-new-ovarian-cancer-treatments</guid>
<description><![CDATA[ Public funding for Elahere and Keytruda will begin December 1, offering additional treatment options for eligible patients with advanced ovarian cancer. Saskatchewan is expanding access to ovarian cancer treatment, announcing that two newer therapies will become publicly funded for eligible patients beginning December 1, 2026. The province confirmed November 17 that coverage will be introduced […]
The post Saskatchewan to expand access to new ovarian cancer treatments appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_2034955502.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 23:15:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Saskatchewan, expand, access, new, ovarian, cancer, treatments</media:keywords>
<content:encoded><![CDATA[<p>Public funding for Elahere and Keytruda will begin December 1, offering additional treatment options for eligible patients with advanced ovarian cancer.</p>
<p>Saskatchewan is expanding access to ovarian cancer treatment, announcing that two newer therapies will become publicly funded for eligible patients beginning December 1, 2026.</p>
<p>The province confirmed November 17 that coverage will be introduced for Elahere (mirvetuximab soravtansine) and Keytruda (pembrolizumab), providing additional options for patients whose cancer has stopped responding to standard treatments.</p>
<p>Approximately eight to 10 patients in Saskatchewan are expected to benefit annually from access to the therapies.</p>
<p>Ovarian cancer is the deadliest cancer of the female reproductive system. Because symptoms can be difficult to recognize, the disease is frequently diagnosed at an advanced stage, when treatment can be more challenging</p>
<h2>New options for difficult-to-treat cancer</h2>
<p>Elahere is a targeted antibody-drug conjugate designed for certain patients whose tumours express folate receptor-alpha (FRα). It delivers an anticancer agent to cells expressing the target.</p>
<p>Keytruda is an immunotherapy that works by helping the immune system recognize and attack cancer cells. It is used in specified treatment regimens for eligible patients.</p>
<p>The two medications are distinct treatment options, with eligibility determined by factors including tumour characteristics and previous treatment.</p>
<p>Clinical studies have demonstrated improvements in outcomes for selected patients, including delayed disease progression and longer survival. However, the treatments are not appropriate for every patient, and both require specialist assessment and monitoring.</p>
<h2>A step forward for public access</h2>
<p>The decision follows national reviews of clinical evidence and drug pricing negotiations through the pan-Canadian Pharmaceutical Alliance.</p>
<p>Canada’s Drug Agency previously recommended reimbursement of Elahere for certain patients with platinum-resistant ovarian cancer, subject to specified conditions.</p>
<p>The Saskatchewan announcement moves beyond the national negotiation process by establishing a provincial coverage start date.</p>
<p>The Saskatchewan Cancer Agency says expanded access will help provide specialized, evidence-based treatment options for patients with difficult-to-treat disease.</p>
<p>Ovarian Cancer Canada also welcomed the decision, noting the importance of eliminating financial barriers to newer cancer therapies.</p>
<h2>Implications for cancer care</h2>
<p>For oncology teams, the expanded funding represents another opportunity to personalize treatment for patients whose disease progresses despite conventional chemotherapy.</p>
<p>Access to specialized testing, appropriate treatment selection and ongoing monitoring will remain important considerations.</p>
<p>The Saskatchewan Cancer Agency received $308.6 million in provincial funding for 2026–27, supporting prevention, diagnosis, treatment, research and patient services.</p>
<p>Patients seeking more information about eligibility for the newly funded therapies are encouraged to consult their oncology teams.</p>
<p>The post <a href="https://www.hospitalnews.com/saskatchewan-to-expand-access-to-new-ovarian-cancer-treatments/">Saskatchewan to expand access to new ovarian cancer treatments</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Physician use of AI rises sharply: Which specialties are the power users?</title>
<link>https://edusehat.com/en/physician-use-of-ai-rises-sharply-which-specialties-are-the-power-users</link>
<guid>https://edusehat.com/en/physician-use-of-ai-rises-sharply-which-specialties-are-the-power-users</guid>
<description><![CDATA[ More than half of U.S. physicians say they use AI in clinical practice daily, with most claiming they have received new “clinical knowledge” from using the technology. According to a survey of more than 3,000 physicians by Doximity released in November of 2026, 52% of physicians said they use AI daily and 85% use it weekly. […]
The post Physician use of AI rises sharply: Which specialties are the power users? appeared first on Today&#039;s Hospitalist. ]]></description>
<enclosure url="https://todayshospitalist.com/wp-content/uploads/2026/11/AI-use-by-docs-doximity-survey-shutterstock_2645963221-11-18-26-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 23:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Physician, use, rises, sharply:, Which, specialties, are, the, power, users</media:keywords>
<content:encoded><![CDATA[<p>More than half of U.S. physicians say they use AI in clinical practice daily, with most claiming they have received new “clinical knowledge” from using the technology.</p>
<p>According to <a href="https://www.doximity.com/reports/doctor-driven-ai-report/2026">a survey of more than 3,000 physicians by Doximity</a> released in November of 2026, 52% of physicians said they use AI daily and 85% use it weekly. The number of physicians using AI daily jumped from 37% from Doximity’s survey on the topic in 2025. The number using AI weekly jumped from 51% since that survey.</p>
<p>While physicians said they remain cautious about using AI, 81% said they had learned new clinical information by using the tech.</p>
<p>Here are other findings from the survey.</p>
<h4><strong>How physicians are using AI</strong></h4>
<p>A growing number of physicians in the survey said AI has reduced the after-hours time they spend on documentation and other administrative tasks. That number jumped from 36% to 46% from 2025-26.</p>
<p>In addition, 83% of physicians said their use of AI has increased somewhat or substantially in the last year.</p>
<ul>
<li><strong>Medical literature</strong>: 94% of physicians said they trust AI to search medical literature.</li>
<li><strong>Generating differential diagnoses</strong>: 87%.</li>
<li><strong>Recommending treatment/management</strong>: 86%.</li>
</ul>
<h4><strong>Physician trust in AI</strong></h4>
<p>More than half of physicians said they trust AI but remain cautious. More than one-quarter said they’re spending less time correcting or double-checking information produced by AI compared to a year ago.</p>
<ul>
<li>More than half of surveyed physicians said they worried about the <strong>accuracy and reliability of AI</strong>.</li>
<li>Three-quarters said they <strong>AI had gotten something wrong</strong> clinically in the previous year.</li>
<li>Two-thirds of physicians said they <strong>verify clinical information</strong> produced by AI “all or almost all of the time.”</li>
<li>More than three-quarters trust AI to <strong>identify a potentially urgent or diagnosis patient condition.</strong></li>
<li>Just over one-third of physicians (34%) said factors like <strong>“legal and regulatory uncertainty”</strong> limit their use of AI.</li>
<li>82% said <strong>physicians should be making rules</strong> for the use of AI in medicine.</li>
</ul>
<h4><strong>How physicians think using AI will help</strong></h4>
<ul>
<li>Will improve <strong>work-life balance</strong>: 65%</li>
<li>Will lighten <strong>administrative workload</strong>: 59%.</li>
<li>Will create <strong>more time for patients</strong>: 52%.</li>
<li>Will enhance <strong>clinical decision support</strong>: 51%.</li>
</ul>
<h4><strong>Effects on patient relationships</strong></h4>
<ul>
<li>Nearly three-quarters of physicians said patients have become more likely in the past six months to <strong>use a diagnosis or treatment plan suggested by AI</strong>.</li>
<li>One-third of physicians said <strong>patients using AI are better-informed</strong> than those using a search engine like Google.</li>
</ul>
<h4><strong>Physician use of AI by age</strong></h4>
<ul>
<li>For physicians <strong>30 and under</strong>, more than 90% use AI in their work at least weekly.</li>
<li>For physicians <strong>in their 30s</strong>, that number is 89%.</li>
<li>For physicians <strong>in their 40s</strong>, 86% use AI at least weekly.</li>
<li>For doctors <strong>in their 50s and 60s</strong>, that number drops to 80%.</li>
<li>For physicians <strong>in their 70s</strong>, 66% use AI at least weekly.</li>
</ul>
<p><strong>Which physician specialties are using AI the most?</strong></p>
<p>Nephrology: 65%.</p>
<p>Oncology: 65%.</p>
<p>Radiology: 64%.</p>
<p>Internal medicine: 62%.</p>
<p>Gastroenterology: 59%.</p>
<p>Neurology: 56%.</p>
<p>Psychiatry: 53%.</p>
<p>Ob-gyn: 52%.</p>
<p>Pediatrics: 52%.</p>
<p>Cardiology: 51%.</p>
<p>Family medicine: 51%.</p>
<p>Pulmonology: 51%.</p>
<p>Urology: 50%.</p>
<p>Dermatology: 46%.</p>
<p>Emergency medicine: 46%.</p>
<p>General surgery: 44%.</p>
<p>Pathology: 42%.</p>
<p>Ophthalmology: 40%.</p>
<p>Orthopedic surgery: 37%.</p>
<p>Anesthesiology: 31%.</p>
<p>The post <a href="https://todayshospitalist.com/physician-use-of-ai-rises-sharply-which-specialties-are-the-power-users/">Physician use of AI rises sharply: Which specialties are the power users?</a> appeared first on <a href="https://todayshospitalist.com/">Today's Hospitalist</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond the Sensor</title>
<link>https://edusehat.com/en/beyond-the-sensor</link>
<guid>https://edusehat.com/en/beyond-the-sensor</guid>
<description><![CDATA[ From customizable glucose alerts and remote data sharing to integrated clinical reporting, digital platforms are transforming how patients and healthcare professionals access and use diabetes technology. Continuous glucose monitoring (CGM) has become an integral part of diabetes management, but innovation is extending well beyond the sensors themselves. Companion applications and digital health platforms are expanding […]
The post Beyond the Sensor appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/website-featured-image.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 20:15:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, the, Sensor</media:keywords>
<content:encoded><![CDATA[<p>From customizable glucose alerts and remote data sharing to integrated clinical reporting, digital platforms are transforming how patients and healthcare professionals access and use diabetes technology. Continuous glucose monitoring (CGM) has become an integral part of diabetes management, but innovation is extending well beyond the sensors themselves. Companion applications and digital health platforms are expanding […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/beyond-the-sensor/">Beyond the Sensor</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>‘I’m going to lose everything’: a dentist’s four&#45;year fitness to practise ordeal</title>
<link>https://edusehat.com/en/im-going-to-lose-everything-a-dentists-four-year-fitness-to-practise-ordeal</link>
<guid>https://edusehat.com/en/im-going-to-lose-everything-a-dentists-four-year-fitness-to-practise-ordeal</guid>
<description><![CDATA[ Dr Tom Munroe describes the mental health and financial cost of prolonged fitness to practise proceedings, as the GDC raises fees amid growing case pressures. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/tom-munroe-dentistry-hero-left.png" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 20:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>‘I’m, going, lose, everything’:, dentist’s, four-year, fitness, practise, ordeal</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image"></figure>



<p><strong>Months into what turned out to be one of Ireland’s longest fitness to practise cases, principal Tom Munroe was at breaking point, delivering parcels to make ends meet, wondering whether he would ever be allowed to return to dentistry.</strong></p>



<p>‘I had no income. My practice was taken from me. I didn’t know if I was ever going to get back to work again,’ he tells <em>Dentistry</em>.</p>



<p>Speaking during November’s Movember campaign, which promotes men’s health, including mental health, Tom wants colleagues to seek support before isolation becomes a crisis. He also wants scrutiny of what happens after a dentist asks for help. He says the Dental Council of Ireland (DCI) had medical evidence of his depression and anxiety, yet he remained uncertain about when his case would be heard or how it would end.</p>



<p>The Irish and UK systems differ, but the experience of Tom, who once owned two Dublin practices, raises questions dental professionals on both sides of the Irish sea can understand.</p>



<p>Why did reaching an outcome take four years, why did nobody check on his wellbeing, and why did he have to arrange treatment for 41 patients while known to be seriously unwell? Were the DCI’s decisions actually the best outcome for his patients?</p>



<p>His account comes as both Irish and UK <a href="https://dentistry.co.uk/2026/10/30/annual-retention-fee-to-rise-as-fitness-to-practise-causes-financial-strain/">dentists are being asked to pay more towards their respective regulatory systems</a> struggling to resolve cases promptly. The General Dental Council (GDC) has cited growing fitness to practise demands in raising UK-based dentists’ annual retention fee to £720 for 2027, acknowledging that the increased caseload is slowing improvements to the time proceedings take.</p>



<div class="wp-block-columns alignwide is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<blockquote class="instagram-media" data-instgrm-permalink="https://www.instagram.com/p/Df4YbtUCDh-/?utm_source=ig_embed&utm_campaign=loading" data-instgrm-version="14"><div> <a href="https://www.instagram.com/p/Df4YbtUCDh-/?utm_source=ig_embed&utm_campaign=loading" target="_blank"> <div> <div></div> <div> <div></div> <div></div></div></div><div></div> <div><svg width="50px" height="50px" viewbox="0 0 60 60" version="1.1" xmlns="https://www.w3.org/2000/svg" xmlns:xlink="https://www.w3.org/1999/xlink"><g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd"><g transform="translate(-511.000000, -20.000000)" fill="#000000"><g><path d="M556.869,30.41 C554.814,30.41 553.148,32.076 553.148,34.131 C553.148,36.186 554.814,37.852 556.869,37.852 C558.924,37.852 560.59,36.186 560.59,34.131 C560.59,32.076 558.924,30.41 556.869,30.41 M541,60.657 C535.114,60.657 530.342,55.887 530.342,50 C530.342,44.114 535.114,39.342 541,39.342 C546.887,39.342 551.658,44.114 551.658,50 C551.658,55.887 546.887,60.657 541,60.657 M541,33.886 C532.1,33.886 524.886,41.1 524.886,50 C524.886,58.899 532.1,66.113 541,66.113 C549.9,66.113 557.115,58.899 557.115,50 C557.115,41.1 549.9,33.886 541,33.886 M565.378,62.101 C565.244,65.022 564.756,66.606 564.346,67.663 C563.803,69.06 563.154,70.057 562.106,71.106 C561.058,72.155 560.06,72.803 558.662,73.347 C557.607,73.757 556.021,74.244 553.102,74.378 C549.944,74.521 548.997,74.552 541,74.552 C533.003,74.552 532.056,74.521 528.898,74.378 C525.979,74.244 524.393,73.757 523.338,73.347 C521.94,72.803 520.942,72.155 519.894,71.106 C518.846,70.057 518.197,69.06 517.654,67.663 C517.244,66.606 516.755,65.022 516.623,62.101 C516.479,58.943 516.448,57.996 516.448,50 C516.448,42.003 516.479,41.056 516.623,37.899 C516.755,34.978 517.244,33.391 517.654,32.338 C518.197,30.938 518.846,29.942 519.894,28.894 C520.942,27.846 521.94,27.196 523.338,26.654 C524.393,26.244 525.979,25.756 528.898,25.623 C532.057,25.479 533.004,25.448 541,25.448 C548.997,25.448 549.943,25.479 553.102,25.623 C556.021,25.756 557.607,26.244 558.662,26.654 C560.06,27.196 561.058,27.846 562.106,28.894 C563.154,29.942 563.803,30.938 564.346,32.338 C564.756,33.391 565.244,34.978 565.378,37.899 C565.522,41.056 565.552,42.003 565.552,50 C565.552,57.996 565.522,58.943 565.378,62.101 M570.82,37.631 C570.674,34.438 570.167,32.258 569.425,30.349 C568.659,28.377 567.633,26.702 565.965,25.035 C564.297,23.368 562.623,22.342 560.652,21.575 C558.743,20.834 556.562,20.326 553.369,20.18 C550.169,20.033 549.148,20 541,20 C532.853,20 531.831,20.033 528.631,20.18 C525.438,20.326 523.257,20.834 521.349,21.575 C519.376,22.342 517.703,23.368 516.035,25.035 C514.368,26.702 513.342,28.377 512.574,30.349 C511.834,32.258 511.326,34.438 511.181,37.631 C511.035,40.831 511,41.851 511,50 C511,58.147 511.035,59.17 511.181,62.369 C511.326,65.562 511.834,67.743 512.574,69.651 C513.342,71.625 514.368,73.296 516.035,74.965 C517.703,76.634 519.376,77.658 521.349,78.425 C523.257,79.167 525.438,79.673 528.631,79.82 C531.831,79.965 532.853,80.001 541,80.001 C549.148,80.001 550.169,79.965 553.369,79.82 C556.562,79.673 558.743,79.167 560.652,78.425 C562.623,77.658 564.297,76.634 565.965,74.965 C567.633,73.296 568.659,71.625 569.425,69.651 C570.167,67.743 570.674,65.562 570.82,62.369 C570.966,59.17 571,58.147 571,50 C571,41.851 570.966,40.831 570.82,37.631"></path></g></g></g></svg></div><div> <div>View this post on Instagram</div></div><div></div> <div><div> <div></div> <div></div> <div></div></div><div> <div></div> <div></div></div><div> <div></div> <div></div> <div></div></div></div> <div> <div></div> <div></div></div></a><p><a href="https://www.instagram.com/p/Df4YbtUCDh-/?utm_source=ig_embed&utm_campaign=loading" target="_blank">A post shared by Dentistry (@dentistry.co.uk)</a></p></div></blockquote>

</div>



<div class="wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow">        <div class="py-6 px-4 sm:px-6 flex items-center justify-center">
            <div class="max-w-4xl text-center space-y-4">
                                    <div class="font-secondary text-primary-500 text-2xl md:text-3xl">
                        ‘I had no income. My practice was taken from me. I didn’t know if I was ever going to get back to work again’                    </div>
                                                            </div>
        </div>
</div>
</div>



<p></p>



<h2 class="wp-block-heading"><strong>From practice ownership to isolation</strong></h2>



<p>Tom qualified in Dublin in 2001, worked in England for two years and returned to establish practices in Tallaght and Milltown. Following the breakdown of his marriage, he left his Tallaght practice and became increasingly isolated working in Milltown. A serious mental health crisis led to inpatient psychiatric treatment in 2019.</p>



<p>Time away from dentistry brought relief, but the need for money drew him back. </p>



<p>He initially worked a reduced week. But as his workload increased, he struggled again, taking on treatment plans he felt uncomfortable with to generate income, cancelling appointments and falling behind with communications. He had laid off his receptionist because he could no longer afford the role.</p>



<p>The <a href="https://www.dentalcouncil.ie/wp-content/uploads/2026/07/Website-Notice_Thomas-Munroe-20260728.pdf">council’s published notice</a> records admitted misconduct involving seven patients, including delayed treatment, failures concerning patients reporting pain, inadequate records and false claims that he had cancer. Tom has previously apologised and acknowledged that he should have stopped practising and arranged cover earlier.</p>



<p>‘I said to four patients, after repeated cancellations, that I had cancer as I felt telling these patients that I had a mental illness was worse as there is a huge stigma around mental health in the medical profession. I was embarrassed to tell the truth.’</p>



<h2 class="wp-block-heading">Closing Milltown while unwell</h2>



<p>He says he followed advice to accept a voluntary undertaking not to practise in June 2022. According to Tom, the council also required his Milltown practice to close without permitting a locum, instructing him to leave an answerphone message directing patients to the council. <em>Dentistry</em> contacted the DCI about this and other conerns raised by Tom but they are yet to reply.</p>



<p>He says the council already had medical evidence of his depression and anxiety. Three further psychiatric assessments, he says, subsequently confirmed his consultant’s diagnosis. He was then tasked with finding continuing care for the 41 patients he was unable to treat.</p>



<p>‘I had to write to all of those 41 patients, I had to go and source a practitioner who would take those 41 patients on, finish their treatment, and pay for that treatment to be finished. All while I was in a mental health crisis and took a voluntary undertaking to step down, so I had to go and beg in Dublin.’</p>



<p>Dr Eddie Cotter eventually agreed to help. Tom’s partner and parents organised records, laboratory work and patient communications while he struggled to manage.</p>



<h2 class="wp-block-heading">Waiting to return to dentistry</h2>



<div class="wp-block-media-text is-stacked-on-mobile"><figure class="wp-block-media-text__media"></figure><div class="wp-block-media-text__content">
<p>With no dental income, his savings dwindled.</p>



<p>‘I was down to fumes,’ he said. ‘I had no income coming in. I had to reach out to the Irish Dental Benevolent Society, who were very, very good to me. </p>



<p>‘I reached out to my parents. I worked in the evening. I worked for Amazon as a driver, just to keep money coming in. I had no other choice. I did that for five months.’</p>



<p>The cost of proceedings has also reached other dentists through registration fees. The DCI recorded €216,954 in fitness to practise costs in 2024, up 20.3% on 2023. </p>



<p>Explaining its dentist retention fee increase from €380 to €450 for 2026, it said these costs had exceeded budget for three consecutive years, mainly because of High Court suspension applications.</p>



<p>After a year away, Tom and his solicitors applied for a supervised return. He says another six months passed before approval, allowing him to resume work in January 2024 while the fitness to practise proceedings continued.</p>



<p>Returning brought an income, but he says he still received little reassurance about when the case would end or support for his wellbeing.</p>



<p>‘They weren’t checking in on me. They didn’t care what I was doing. They were just focusing on fitness to practise.’</p>



<p>Eventually, he was contacted by the DCI to be told that his case would be fast-tracked. The inquiry took place in January 2026, the council confirmed its findings in May, and a High Court order followed in July.</p>



<p></p>
</div></div>



<h2 class="wp-block-heading">Censured and conditions imposed</h2>



<p>‘It was done in two hours,’ Tom said. </p>



<p>‘If it’s not that important, what was the last three-and-a-half years that I’m looking back at here, and the wreckage that’s behind me?’</p>



<p>Having admitted the allegations and that they amounted to professional misconduct, Tom was censured and had conditions imposed on his registration. These included supervised implant dentistry, additional training and working in a group setting unless otherwise approved. The conditions will remain in place for at least three years.</p>



<p>Tom describes feeling presumed guilty before the inquiry and living without a clear endpoint.</p>



<p>Having worked in England earlier in his career, Tom wants change in both countries. Although their regulatory systems differ, UK figures offer evidence of the prolonged waits dental professionals can face during fitness to practise investigations, and the financial pressure of running those processes.</p>



<p>The GDC 2025 figures show that the average time from receiving a concern to reaching a final assessment decision was 78 working weeks, compared with 76 in 2024. At the end of the year, 761 cases remained open at that stage, an increase of 35%. One FTP case reportedly took nine years to conclude.</p>



<p>The GDC also reported an additional £2.8 million spent on fitness to practise and hearings in 2025, including staffing, legal fees and hearing delivery. Neither regulator’s expenditure figures capture the lost earnings and personal financial pressures described by Tom. His account puts those consequences alongside the institutional cost of investigating concerns. </p>



<h2 class="wp-block-heading">Do fitness to practise processes needs to change ?</h2>



<p>He praises Practitioner Health Matters, to which he says the council referred him, but wants earlier consideration of medical evidence, patient safeguards and how cases can be resolved.</p>



<p>‘They should triage it, have a screening team, and just triage complaints, improve efficiency, try and take the meat out of these cases, break them down before they go in into layers of bullshit and years down the road.’</p>



<p>In the UK, the GDC already has early assessment stages and has reported faster handling of certain cases. However, its <a href="https://www.gdc-uk.org/news-blogs/news/detail/2026/09/29/time-and-support-remain-areas-for-improvement-in-new-fitness-to-practise-research">September research</a> found most respondents remained dissatisfied.</p>



<p>For Tom, returning within a team has eased some of the isolation that preceded his illness. Having colleagues nearby has changed how he manages the pressures of treating patients.</p>



<p>‘I felt more secure because I was in a group setting. I wasn’t isolated. If I had a problem with a patient, I could go next door and knock on the door. I was in a team.’</p>



<p>He now works in general dentistry and supervised implant dentistry. Although the inquiry has concluded, he is still working towards the next stage of his return, and finds it difficult to imagine how he will feel when those immediate goals are behind him.</p>



<p>‘Now it’s a whole new type of stress, so I’m still in fight mode. It’s a question I’ve asked myself, and I haven’t had much time to think about what will I be like when I come out of fight mode.’</p>



<h2 class="wp-block-heading">Seeking support during Movember</h2>



<p>Tom wants colleagues in the UK and Ireland to seek help before isolation and ill health begin affecting their lives and patient care. He is also willing to hear from dental professionals experiencing similar difficulties, drawing on his own experience of struggling to speak openly and finding support.</p>



<p>For him, sharing an experience he finds difficult to revisit has a clear purpose.</p>



<p>‘Even if it helps one other person with the article, if it gets out there, it’s done its job.’</p>



<p>Colleagues wishing to contact Tom can do so via his <a href="http://linkedin.com/in/dr-tom-munroe-1486a1439?utm_source=share_via&utm_content=profile&utm_medium=member_ios.">social media profile.</a></p>



<p>Other support options include <a href="https://practitionerhealth.ie/">Practitioner Health in Ireland</a> and <a href="https://www.supportfordentalteams.org/">Support for Dental Teams in the UK</a>.</p>



<p><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</em></a></p>



<p></p>]]> </content:encoded>
</item>

<item>
<title>AI and the future of pharmacy education</title>
<link>https://edusehat.com/en/ai-and-the-future-of-pharmacy-education</link>
<guid>https://edusehat.com/en/ai-and-the-future-of-pharmacy-education</guid>
<description><![CDATA[ 
Prof. (Dr) Satish Sardana, Director, Amity Institute of Pharmacy, Amity University Haryana speaks to Kalyani Sharma about how AI is shaping pharmacy education and the skills future pharmacists will need in an evolving healthcare landscape
The post AI and the future of pharmacy education appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/18143628/EP_GB_Satish_Sardana_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 19:30:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>and, the, future, pharmacy, education</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/18143628/EP_GB_Satish_Sardana_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/18143628/EP_GB_Satish_Sardana_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/18143628/EP_GB_Satish_Sardana_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><b>AI is moving beyond drug discovery into areas such as clinical decision-making and pharmacy practice. How is this changing the skill sets expected from the next generation of pharmacists? </b></p>
<p><span>AI is shifting the pharmacist’s role from someone who mainly dispenses and checks to someone who interprets, verifies, and takes responsibility for what automated systems recommend. Pharmacists will use tools that flag interactions, predict adverse events, and suggest dosing. Basic biostatistics and the ability to assess a validation study could become routine </span></p>
<p><span>When systems can recall interactions instantly, need for memorisation will be reduced. Deciding when to trust an alert, when to override it, and when a recommendation doesn’t suit a particular patient matters more. Overreliance on it can cause errors, so pharmacists must verify AI outputs. As routine verification is automated, pharmacists move toward medication therapy management, deprescribing, polypharmacy review, and comanaging chronic disease. This needs strong pharmacology and therapeutics, since they must explain why a recommendation makes sense. </span></p>
<p><span>New questions may arise specially, when an AI-informed recommendation harms a patient. More concerns will be about how data is protected, whether algorithms are biased, and how AI use is disclosed. Knowledge of privacy, consent, and regulation will be essential. Communication, empathy, and trust-building cannot be replaced by AI. With less time on dispensing, pharmacists will counsel more, improve adherence, and address misinformation. </span></p>
<p><b>As precision therapeutics and personalised medicine gain ground, what changes are needed in pharmacy education to prepare students for more individualised approaches to treatment? </b></p>
<p><span>Precision medicine is shifting healthcare from a one-sizefits-all approach to treatments tailored to a patient’s genetic, clinical, and lifestyle profile. To prepare students for this shift, pharmacy education must strengthen training in pharmacogenomics, genetic variation, biomarkers, epigenetics, and tumor genomics, particularly in areas where precision therapies are advancing rapidly.</span></p>
<p><span>Students should learn how gene-drug interactions influence treatment outcomes and gain experience interpreting pharmacogenomic reports to support therapy decisions. </span></p>
<p><span>The curriculum should also build skills in biostatistics, data analytics, evidence appraisal, and the use of EHRs and clinical decision-support tools, while encouraging consideration of factors such as genetics, age, comorbidities, and patient preferences. Equally important are topics such as ethics, patient privacy, informed consent, and the limitations of genomic data, particularly in a diverse country like India. Regular faculty upskilling and curriculum updates will be essential to prepare graduates to deliver personalised, evidence-based care. </span></p>
<p><b>How is AI being integrated into pharmacy curricula today, particularly in areas such as drug discovery, pharmacovigilance, formulation development, and clinical pharmacy? </b></p>
<p><span>AI is becoming an integral part of pharmacy education through the revised Pharmacy Council of India (PCI) curriculum, which introduces students to programming, data analytics, machine learning, AI applications, and ethical considerations. The learning progresses semesterwise, beginning with Python programming and pharmaceutical data analysis in Semester I, followed by biostatistics and data analytics in Semester II, machine learning applications in Semester III, AI applications in pharma sciences in Semester VI, AI in clinical practice in Semester VII, and ethical and translational aspects of AI in Semester VIII. </span></p>
<p><span>This structured approach equips students to apply AI in drug discovery, formulation development, pharmacovigilance, pharma manufacturing, and clinical pharmacy, while developing the skills needed for evidence based decision-making and the responsible use of emerging technologies in healthcare. </span></p>
<p><b>What gaps do you see between the skills being taught in pharmacy institutions and what the pharma industry now expects from graduates? </b></p>
<p><span>With the growing adoption of AI, automation, and digital technologies, the gap between pharmacy education and industry expectations is becoming more evident. While institutions provide strong theoretical knowledge, the pharma industry increasingly seeks graduates who can apply this knowledge in realworld settings. </span></p>
<p><span>Key gaps include limited exposure to industry practices such as Good Manufacturing Practices (GMP), regulatory compliance, quality systems, and digital tools used in manufacturing, research, and clinical operations. Employers also expect skills in data analytics, problem-solving, critical thinking, and the use of emerging technologies like AI. </span></p>
<p><span>In addition, graduates often need stronger training in clinical application, pharmacovigilance, and patient-centered decisionmaking. For example, students may know the names of regulatory guidelines but struggle to interpret them or apply them to real documentation, inspections, and compliance scenarios; students may be trained to reproduce known results rather than independently solve complex scientific and technical problems, or they may know how to perform an analytical test but lack the investigative and documentation skills required when results deviate from specifications or a quality system fails. </span></p>
<p><span>Bridging these gaps will require greater emphasis on practical training, industry internships, digital literacy, interdisciplinary learning, and hands-on experience with modern pharma processes. This will help ensure graduates are workforce ready and equipped for the evolving needs of the industry.</span></p>
<p><b>With pharma becoming increasingly interdisciplinary, how can universities strengthen collaboration between pharmacy, biotechnology, data science and other technology disciplines? </b></p>
<p><span>Universities can strengthen interdisciplinary collaboration by integrating crossdisciplinary courses, joint projects, and problem-based learning into the curriculum. They should establish shared research centres and laboratories, encourage partnerships with pharma and technology companies, and provide industry internships. </span></p>
<p><span>Universities can also pair an academic supervisor with an industry scientist or technology specialist, giving students experience with pharma R&D, biotech startups, clinical research organisations, health-tech firms, and AI companies. </span></p>
<p><span>Creating incentives for collaborative research and innovation will further help students and faculty work across disciplines to address real-world healthcare challenges. </span></p>
<p><b>What role can academic institutions play in preparing pharmacists to work with emerging technologies while ensuring that scientific rigour and ethical considerations remain central? </b></p>
<p><span>Academic institutions have a critical role in preparing future pharmacists for a technology-driven healthcare landscape. They must equip students with knowledge of AI, precision medicine, genetic testing, and digital health tools, while fostering critical thinking to evaluate technology-driven insights. </span></p>
<p><span>Pharmacy education should also emphasize ethics, patient privacy, interdisciplinary collaboration, and practical industry exposure. Ultimately, the goal is to develop pharmacists who can responsibly leverage emerging technologies to improve patient outcomes and drive healthcare innovation. </span></p>
<p><b>Looking ahead, which areas of pharma research and practice do you believe will see the biggest impact from AI, precision medicine and other emerging technologies, and how should pharmacy education prepare for this shift? </b></p>
<p><span>AI, precision medicine, and emerging technologies will significantly impact areas such as drug discovery and design, clinical trials, pharmacovigilance, regulatory compliance, and personalised medicine. These innovations can help accelerate research, improve diagnosis, reduce medication errors, and enable more targeted and effective patient care. </span></p>
<p><span>To prepare for this shift, pharmacy education should incorporate foundational knowledge of AI, digital health, and data analytics, along with practical exposure through hospital training, laboratory work, and industry training and real-world examples. Students must also learn to critically assess AI-generated information, protect patient privacy, and use technology ethically. Regular curriculum updates and faculty training will be essential to ensure graduates are equipped to use these technologies confidently and deliver safer, better patient care. </span></p>
<p><b><i>Kalyani.sharma@expressindia.com</i></b></p>
<p><b><i>journokalyani@gmail.com</i></b></p>
<p>The post <a href="https://www.expresspharma.in/ai-and-the-future-of-pharmacy-education/">AI and the future of pharmacy education</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Senores Pharmaceuticals secures PIC/S GMP certification for Gujarat facility</title>
<link>https://edusehat.com/en/senores-pharmaceuticals-secures-pics-gmp-certification-for-gujarat-facility</link>
<guid>https://edusehat.com/en/senores-pharmaceuticals-secures-pics-gmp-certification-for-gujarat-facility</guid>
<description><![CDATA[ 
The certification covers injectable and oral solid manufacturing at its subsidiary Ratnatris Pharmaceuticals’ Mehsana facility and supports the company’s plans to pursue approvals across semi-regulated markets
The post Senores Pharmaceuticals secures PIC/S GMP certification for Gujarat facility appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 19:30:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Senores, Pharmaceuticals, secures, PICS, GMP, certification, for, Gujarat, facility</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Senores Pharmaceuticals has secured Pharmaceutical Inspection Co-operation Scheme (PIC/S) Good Manufacturing Practices (GMP) certification for the manufacturing facility of its subsidiary, Ratnatris Pharmaceuticals Private Limited, in Mehsana, Gujarat.</span></p>
<p><span>Issued by Ukraine’s State Service on Medicines and Drugs Control (SMDC), the certification expands the company’s pathway to pursue regulatory approvals across semi-regulated pharmaceutical markets.</span></p>
<p><span>Commenting on the development, Swapnil Shah, Managing Director, Senores Pharmaceuticals, said, “The PIC/s approval will open many strategic markets that we couldn’t serve so far. With approval of both, injectable and oral solids, our diverse and strategic portfolio’s reach will be further enhanced, and will continue to give long term growth and sustained profitability”.</span></p>
<p><span>The certificate of GMP compliance was issued by SMDC on November 16, 2026, and received by the company on November 17, 2026.</span></p>
<p>The post <a href="https://www.expresspharma.in/senores-pharmaceuticals-secures-pic-s-gmp-certification-for-gujarat-facility/">Senores Pharmaceuticals secures PIC/S GMP certification for Gujarat facility</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From scale and polish to leadership in health optimisation</title>
<link>https://edusehat.com/en/from-scale-and-polish-to-leadership-in-health-optimisation</link>
<guid>https://edusehat.com/en/from-scale-and-polish-to-leadership-in-health-optimisation</guid>
<description><![CDATA[ Oral-B explores how dental hygienists are moving beyond the outdated concept that their role is ‘just a scale and polish’ to reshape patient care. Since early last century, dental hygienists have been narrowly defined by the task of ‘scaling and polishing’, despite significant expansion of their role. To drive dentistry forward, the profession must challenge… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/scale_and_polish.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 16:35:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, scale, and, polish, leadership, health, optimisation</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Oral-B explores how dental hygienists are moving beyond the outdated concept that their role is ‘just a scale and polish’ to reshape patient care.</strong></p>



<p>Since early last century, dental hygienists have been narrowly defined by the task of ‘scaling and polishing’, despite significant expansion of their role.</p>



<p>To drive dentistry forward, the profession must challenge outdated perceptions and recognise the broader scope of dental hygienists’ practice.</p>



<p>Clinical autonomy and collaboration within a multidisciplinary team (MDT) are fundamental to transforming patient care. Any shift in mindset should inspire colleagues and stakeholders to champion the leadership potential of dental hygienists to maximise their impact.</p>



<p>By changing the language around dental hygiene, embracing health optimisation as a principle, and empowering dental hygienists to lead, teams can help improve patients’ understanding of the role.</p>



<p>These were the key themes central to a recent Oral-B Professional webinar titled <a href="https://www.oralbprofessional.co.uk/s/marketing-event/a09TY00000BQIB3YAP/from-scale-polish-to-leadership-in-health-optimisation">‘From scale and polish to leadership in health optimisation’</a>.</p>



<p>Claire Berry, a multi-award-winning dental hygienist, and Ben Tighe, a dental therapist and tutor at The Eastman Dental Hospital, discussed the importance of a modern-day approach to the delivery of oral health care.</p>



<figure class="wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-1 is-layout-flex wp-block-gallery-is-layout-flex">
<figure class="wp-block-image size-large"></figure>
</figure>



<p>The duo hosts the podcast, <a href="https://www.instagram.com/yourdentalbesties/"><em>Your Denta</em></a><a href="https://www.instagram.com/yourdentalbesties/" target="_blank" rel="noreferrer noopener"><em>l Besties</em></a>, offering a fresh take on all things dental. Both are keen to consign the ‘scale and polish’ hygiene model to the history books.</p>



<p>During the webinar, moderated by Dr Stephen Hancocks, they advocated for greater autonomy for dental hygienists, who they say are well placed to promote systemic and whole-body health.</p>



<p>As Stephen observed, the term ‘scale and polish’ has historically constrained views of dental hygienists, but modern practice demonstrates that their skillset extends well beyond that scope.</p>



<h2 class="wp-block-heading">A modern dental hygienist role</h2>



<p>Ben kicked off the discussion by explaining how dental hygiene used to be task-based. ‘It was auxiliary and supportive – we were there to clean and allow the dentist to perform the intervention. But our role has evolved to be so much more than that – it now requires a three-year bachelor’s degree. It’s changed so much on the academic side, but in practice, it is almost frozen in time. With direct access, we now make our own decisions. We are triaging patients who may not have seen a dentist for years. Our role is more than just “scale and polish”.’</p>



<p>Better public education about the role of the dental hygienist and increased industry support are also vital.</p>



<p>‘Patients are consumers, so as a profession, we really have to embrace and thank industry, because without the adverts on TV, there would be no public health messages about keeping your teeth clean. Companies such as Oral-B have been so impactful and so powerful.’</p>



<h2 class="wp-block-heading">Health optimisation in practice</h2>



<p>Changing terminology to ‘oral health optimisation’ is an empowering step that can motivate patients. Claire said that rephrasing hygiene in this way has allowed her the freedom to optimise their health.</p>



<p>‘Our practice developed a health optimisation workflow in which every single patient, following a consultation, went through my department. I then placed them on recall based on need, and I became the gatekeeper for treatment.’</p>



<p>Not only did it improve the hygiene department’s results, but it also meant the practice had a healthier patient base, ensured treatment longevity, and enabled the whole team to achieve better outcomes.</p>



<p>A full patient assessment underpins the model. Claire said: ‘We look at lifestyle factors and systemic health to help them improve their oral health, but also look at their oral health to improve their systemic health. It’s bi-directional.’</p>



<h2 class="wp-block-heading">Helping patients understand biofilm</h2>



<p>As Ben noted: ‘Dental hygienists and therapists are good with risk assessment, data collection and having those conversations with patients.’</p>



<p>He believes that using the term ‘biofilm’ helps patients understand that dental hygiene is holistic and prompts important conversations about its impact on systemic health.</p>



<p>‘It’s about coaching our patients, and the Oral-B Test Drive has been highly impactful for dental hygienists because they can use it directly in the patient’s mouth. When you get that patient engaged and motivated, they start to get healthy.’</p>



<p>Claire agreed: ‘I’m a big fan of disclosing, and I use the Oral-B Test Drive with every patient to show them where the biofilm is and how to remove it.’</p>



<p>She added that, importantly, downplaying a diagnosis should be avoided.</p>



<p>‘We must have honest conversations with patients about suboptimal outcomes. Evidence shows electric toothbrushes remove biofilm more effectively, so we must provide evidence-based advice.’</p>



<p>Educating patients about biofilm and disease mechanisms can strengthen trust and partnership, encouraging dental hygienists to feel confident in taking ownership of patient health management.</p>



<p>This empowerment, alongside industry support, helps patients link oral care to systemic health and improve outcomes through evidence-based guidance, thereby advancing the professional delivery of dental care.</p>



<h2 class="wp-block-heading">Beyond the scale and polish: the future of clinical leadership</h2>



<p>Change is happening, albeit slowly, but the duo suggests this will accelerate as younger dentists, who have been exposed to integrated clinical training, progress through their careers to take on practice ownership.</p>



<p>By creating MDT care models similar to those in the medical sector, the entire dental team can jointly consider and manage patient cases to deliver better outcomes. In the meantime, Claire and Ben urge practices to give clinical autonomy to their dental hygienists and promote their modern-day role to patients.</p>



<p>‘We are heading in that direction,’ Claire said. ‘It’s an exciting time to be a dental hygienist and therapist.’</p>



<p>Indeed, they are both confident enough in the profession to support dental hygienists and therapists in their development as future clinical leaders.</p>



<p>‘We bridge medicine and dentistry,’ Ben observed. ‘With more dental hygienists empowered and industry on board, we can connect the mouth and body, a goal Claire and I have long championed.’</p>



<p>The full webinar is available to watch on demand on the Oral-B Professional website. Simply click<a href="https://www.oralbprofessional.co.uk/s/marketing-event/a09TY00000BQIB3YAP/from-scale-polish-to-leadership-in-health-optimisation" target="_blank" rel="noreferrer noopener"> here</a> and register.</p>



<p><em>This article is sponsored by Oral-B.</em></p>]]> </content:encoded>
</item>

<item>
<title>Ministry of Ayush to observe 9th Naturopathy Day on November 18</title>
<link>https://edusehat.com/en/ministry-of-ayush-to-observe-9th-naturopathy-day-on-november-18</link>
<guid>https://edusehat.com/en/ministry-of-ayush-to-observe-9th-naturopathy-day-on-november-18</guid>
<description><![CDATA[ 
The event in Karnataka will focus on preventive healthcare, healthy lifestyles and addressing obesity and lifestyle-related disorders under the theme ‘Prakritik Chikitsa, Swasth Bharat’.
The post Ministry of Ayush to observe 9th Naturopathy Day on November 18 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115711/events.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 15:55:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Ministry, Ayush, observe, 9th, Naturopathy, Day, November</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115711/events.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115711/events.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115711/events-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>The Ministry of Ayush will observe the 9th Naturopathy Day on November 18, 2026, at the Central Research Institute of Yoga and Naturopathy (CRIYN), Nagamangala, Karnataka, under the theme ‘Prakritik Chikitsa, Swasth Bharat’. The observance will highlight the role of naturopathy in promoting preventive healthcare, healthy lifestyles and overall well-being, with a focus on addressing obesity and lifestyle-related disorders.</span></p>
<p><span>The inaugural session of the main event at Nagamangala will feature several initiatives, including a community health initiative and programmes aimed at promoting well-being and community development. The programmes are designed to engage participants from different sections of society and encourage public welfare and inclusive progress.</span></p>
<p><span>This year’s theme highlights the importance of adopting healthy lifestyles through dietary practices, physical activity, yoga, stress management and other evidence-informed naturopathic approaches. It seeks to strengthen public awareness about prevention and encourage individuals and communities to take an active role in maintaining their health and well-being. The observance also aligns with the Prime Minister’s vision for a Fit and Healthy India, emphasising preventive healthcare and healthy living.</span></p>
<p><span>As part of its nationwide outreach, the observance will feature ten sub-themes focusing on different sections of society and areas of public health. These include ‘Mother Nature – Healthy Mother, Healthy Family’, ‘Swastha Mahila – Fit & Healthy Women’, ‘Fit Force – Strong, Lean & Healthy Force’, ‘Healthy Campus – Fit Students, Healthy Nation’, ‘Healthy Workplace – Fit Workforce’ and ‘Safe Journey – Fit Driver, Safe Journey’.</span></p>
<p><span>The other sub-themes are ‘Golden Wellness – Active Ageing, Healthy Ageing’, ‘Prakriti se Samarth – Healthy & Active Living’, ‘Natural Strength for Sporting Excellence’ and ‘Prakriti Kisan – Fit Farmer, Healthy Nation’.</span></p>
<p><span>Through these initiatives, the Ministry aims to extend the message of naturopathy to families, women, students, working professionals, armed forces personnel, senior citizens, sportspersons and farmers, encouraging healthy practices across communities.</span></p>
<p><span>The observance will also highlight the Ministry of Ayush’s efforts to strengthen the institutional, research and healthcare infrastructure for yoga and naturopathy in the country. Through its research institutions and initiatives, the Ministry is working to advance scientific research, education and the integration of naturopathy into preventive and promotive healthcare.</span></p>
<p><span>The 9th Naturopathy Day will serve as a platform to strengthen public engagement with naturopathy and highlight the importance of healthy lifestyles, preventive healthcare and community participation in building a Swasth Bharat.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/ministry-of-ayush-to-observe-9th-naturopathy-day-on-november-18/">Ministry of Ayush to observe 9th Naturopathy Day on November 18</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>DALPL: Building India’s next&#45;gen of specialised testing capabilities </title>
<link>https://edusehat.com/en/dalpl-building-indias-next-gen-of-specialised-testing-capabilities</link>
<guid>https://edusehat.com/en/dalpl-building-indias-next-gen-of-specialised-testing-capabilities</guid>
<description><![CDATA[ 
From a food and agricultural testing laboratory to a specialised pharma testing facility, the company’s journey reflects the evolution of India’s analytical testing industry. In this conversation, Ashay Mehta, Founder &amp; Managing Director of Doctors’ Analytical Laboratories Pvt Ltd (DALPL) discusses regulatory compliance, data integrity, emerging testing requirements, talent challenges and plans to expand into peptides, topical products and medical device testing with Swati Rana 
The post DALPL: Building India’s next-gen of specialised testing capabilities  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17170457/Ashay-Mehta.jpg.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 12:20:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>DALPL:, Building, India’s, next-gen, specialised, testing, capabilities </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17170457/Ashay-Mehta.jpg.jpeg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17170457/Ashay-Mehta.jpg.jpeg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17170457/Ashay-Mehta.jpg-300x160.jpeg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><b>DALPL was established in 2006 with a food and agricultural testing laboratory and has since expanded into pharmaceutical testing and other verticals. How has the journey been, and what have been the key milestones?</b></p>
<p><span>We started in 2006 in Pune as a food and general testing laboratory, when food regulations in India were still developing. At the time, regulatory requirements were largely linked to exports of certain commodities to Europe. I joined the business in 2008. It was a family investment that we subsequently spearheaded and developed into what it is today.</span></p>
<p><span>In 2011–12, we decided to move the facility from Pune to Mumbai. Since we were based in Mumbai, the move offered better operational control and opportunities for expansion. Mumbai also provided a strategic advantage because of its connectivity to ports and its accessibility to customers and sample sources across Gujarat, Goa and other regions. We re-established our operations in Mumbai in 2012.</span></p>
<p><span>Although India’s food safety law had been enacted earlier and came into effect in 2011, awareness remained limited. The Maggi controversy in 2015 brought food safety and testing into sharper public focus, and the industry has continued to develop since then, although growth has been uneven.</span></p>
<p><span>Around 2012–13, we also began exploring pharmaceutical testing. We entered the segment gradually, starting with one area where regulatory requirements were still evolving.</span></p>
<p><span>In 2016, we underwent our first US FDA inspection at a facility where we were conducting both food and pharmaceutical testing. The experience made us realise that if we wanted to pursue pharmaceutical testing seriously, we needed a dedicated facility, team, standard operating procedures (SOPs) and quality management systems (QMS). Food and pharmaceutical testing require different operating environments and approaches, and we felt that both could not be managed effectively within the same facility.</span></p>
<p><span>We therefore took the decision to shut down our pharmaceutical testing operations temporarily and invest in a dedicated facility, even though it meant losing the business we had built in that segment. We developed the new facility and opened it in September 2017.</span></p>
<p><span>In May 2018, we received our first US FDA Establishment Inspection Report (EIR), following an inspection conducted shortly after we moved to the new premises. We were inspected again in 2022. During the COVID-19 period, one of our clients was facing delays in securing approvals because our facility had not been reinspected. We approached the FDA, explained the situation and requested an inspection on our client’s behalf. The agency conducted the inspection, and we received a Form 483 with observations.</span></p>
<p><span>We have since continued to strengthen our compliance capabilities. Our facility has undergone audits supporting work for clients in Canada and Europe, including an audit by a Qualified Person (QP) representing a client. Our regulatory experience spans the US, European and Canadian markets, as well as Australia.</span></p>
<p><b>How has India’s analytical testing ecosystem evolved over the past two decades?</b></p>
<p><span>When we entered the market, there were very few laboratories serving the highly regulated pharmaceutical testing segment. In 2017, there were only around six or seven laboratories in India with US FDA approval, based on our understanding at the time.</span></p>
<p><span>Today, the landscape has changed considerably. There has been a substantial increase in the number of testing laboratories, particularly in pharmaceutical hubs such as Hyderabad. Food testing has also expanded rapidly, with new laboratories entering the market regularly.</span></p>
<p><span>However, the growth of laboratory infrastructure has not always been matched by the development of specialised talent. The industry needs experienced professionals who understand complex analytical techniques, regulatory expectations, quality systems and the demands of international inspections.</span></p>
<p><span>Regulatory compliance is another important consideration. Establishing a laboratory is one thing; sustaining compliance through inspections and consistently meeting regulatory expectations is another. Laboratories must invest continuously in people, systems, equipment and processes.</span></p>
<p><span>The ecosystem is developing rapidly, and I believe the availability of specialised talent and expertise will improve over time. For now, however, workforce development remains an important area of focus.</span></p>
<p><b>What are the biggest challenges pharmaceutical companies face when it comes to analytical testing in India?</b></p>
<p><span>The encouraging development is that Indian laboratories can now provide a wide range of specialised testing services that companies previously had to seek from laboratories in Europe or the US. These include in vitro release testing (IVRT), in vitro permeation testing (IVPT), nitrosamine analysis, extractables and leachables studies, and peptide-related testing.</span></p>
<p><span>Companies no longer need to depend as heavily on overseas laboratories or face the same waiting periods for many of these services. The domestic ecosystem has developed the infrastructure and expertise needed to support increasingly complex testing requirements.</span></p>
<p><span>The industry is also seeing greater government participation in laboratory development. Support schemes and subsidies for setting up testing infrastructure can help expand capacity in areas where specialised facilities are required.</span></p>
<p><span>The opportunity now is to ensure that this infrastructure continues to evolve alongside regulatory requirements, emerging technologies and the growing complexity of pharmaceutical products.</span></p>
<p><b>With increasing regulatory scrutiny, what changes are you seeing in documentation and quality systems across pharmaceutical testing laboratories?</b></p>
<p><span>We began seeing a significant shift in 2016–17, which was one of the reasons we decided to establish a dedicated pharmaceutical testing facility.</span></p>
<p><span>Regulatory testing requires extensive documentation, whether in food or pharmaceuticals. In pharmaceutical testing, traceability must be maintained throughout the process, from sample receipt and registration to testing, reporting and eventual sample disposal.</span></p>
<p><span>Our systems are designed to maintain complete traceability. The analytical instruments and associated systems are configured with appropriate user access controls and privileges. These controls help prevent unauthorised deletion or manipulation of records and chromatographic data.</span></p>
<p><span>Regulatory expectations have become increasingly stringent, but customer expectations have evolved as well. A decade ago, laboratories could encounter resistance when they explained that a particular request could not be accommodated because of regulatory requirements. Customers might point to another laboratory that was willing to do it differently.</span></p>
<p><span>Today, customers increasingly recognise the importance of compliance, data integrity and reliable testing, particularly given the investment involved in pharmaceutical development and regulatory approvals. Responsible customers understand that compromising testing integrity can create significant risks for their products and businesses.</span></p>
<p><span>Overall, regulatory expectations and customer awareness are moving in the same direction, encouraging better practices across the ecosystem.</span></p>
<p><b>Are Indian testing laboratories keeping pace with global regulatory standards?</b></p>
<p><span>Yes, India is keeping pace with global regulatory standards, and the development of the domestic testing ecosystem reflects that progress.</span></p>
<p><span>Regulatory requirements should not be viewed simply as a burden on the industry. They ultimately help ensure product quality and patient safety. The challenge is to develop the capabilities, infrastructure and expertise needed to meet those requirements consistently.</span></p>
<p><span>India continues to face competitive pressures, including from China, which has significant manufacturing scale and an established industrial ecosystem. However, Indian laboratories are strengthening their capabilities and working to meet international expectations.</span></p>
<p><span>Continued investment in infrastructure, technology and skilled professionals will be essential to sustaining this progress.</span></p>
<p><b>Pharmaceutical companies often have their own analytical testing laboratories. What role do independent testing laboratories play?</b></p>
<p><span>Pharmaceutical companies generally use their in-house laboratories for routine quality control testing. Independent laboratories complement these capabilities by providing specialised services, particularly method development and method validation.</span></p>
<p><span>Developing and validating an analytical method can be time-consuming and requires specialised expertise and equipment. Once the method has been developed and validated, companies may send their samples to an independent laboratory for testing, allowing them to focus their internal resources on other activities.</span></p>
<p><span>Some analytical instruments are also extremely expensive, and it may not be practical for every pharmaceutical company to invest in multiple systems for specialised testing. As commercial laboratories, we can make these investments across a broader client base.</span></p>
<p><span>Our work is not limited to Indian companies. We serve international customers from markets including Turkey, Bangladesh, Saudi Arabia and Canada.</span></p>
<p><span>Customer audits are another important part of the relationship. In addition to regulatory inspections, customers typically audit our facility before starting work with us and may conduct periodic audits thereafter. This provides an additional layer of oversight and helps maintain confidence in the laboratory’s systems and capabilities.</span></p>
<p><b>Data integrity is a major regulatory concern. What does maintaining data integrity mean in practical terms for a testing laboratory?</b></p>
<p><span>Data integrity can be compromised in different circumstances. Sometimes, an employee makes an honest mistake and attempts to conceal it out of fear of reprimand. In other cases, data may be deliberately manipulated.</span></p>
<p><span>We address the first situation by creating an environment in which employees are encouraged to report mistakes immediately. We tell our teams that making a mistake is not necessarily the biggest problem; concealing it can create a much greater risk.</span></p>
<p><span>If an employee reports an error, we can investigate it, assess its impact, implement corrective measures and prevent it from recurring. If people feel pressured to hide mistakes, neither the individual nor the organisation can learn from the incident or mitigate the risk effectively.</span></p>
<p><span>Our approach is to encourage transparency and make employees understand that reporting an error is the right thing to do. We take responsibility for investigating the issue and determining the appropriate corrective action.</span></p>
<p><span>At the same time, deliberate manipulation must be prevented through robust quality systems, appropriate access controls, traceable records and a culture of accountability. Technology and procedures are important, but the right organisational culture is equally essential to maintaining data integrity.</span></p>
<p><b>What will pharmaceutical companies expect from analytical testing laboratories over the next five years?</b></p>
<p><span>Customers will increasingly expect laboratories to provide a broader range of services under one roof, along with stronger regulatory credentials and expertise across different markets.</span></p>
<p><span>As pharmaceutical companies expand internationally, they must comply with the requirements of individual countries and regulatory authorities. These requirements may differ, and companies need laboratory partners that understand the relevant standards and can support their testing needs.</span></p>
<p><span>Consequently, laboratories will need to expand their service portfolios, invest in specialised equipment, strengthen their regulatory capabilities and provide more comprehensive technical support.</span></p>
<p><span>The ability to respond to evolving requirements quickly and consistently will become an important differentiator.</span></p>
<p><b>Which areas should India’s pharmaceutical testing ecosystem prioritise over the next five to ten years?</b></p>
<p><span>Medical devices, peptides and topical products are three important areas.</span></p>
<p><span>Medical device manufacturing is receiving greater attention in India, but there is a need for more specialised testing infrastructure. Many existing laboratories offer routine testing services, while advanced and specialised requirements will call for dedicated capabilities.</span></p>
<p><span>Peptides also have significant potential because of their applications across pharmaceuticals and nutraceuticals. As the market develops, laboratories will need to strengthen their expertise and infrastructure to support the associated analytical and regulatory requirements.</span></p>
<p><span>Topical products represent another important growth area. Specialised studies, including IVRT and IVPT, help assess drug release from formulations and the permeation of active ingredients through the skin. These capabilities are important for the development and evaluation of topical pharmaceutical products.</span></p>
<p><span>Building specialised services around these three areas will be important to meeting future industry demand.</span></p>
<p><b>What are your company’s expansion plans for the coming years? How do you see the company’s growth trajectory over the next five years?</b></p>
<p><span>We are planning to expand both our food and pharmaceutical testing capabilities.</span></p>
<p><span>In 2027, we intend to move our food testing division into a larger facility next door. The additional space will allow us to introduce RT-PCR testing for genetically modified organisms (GMOs) and animal species identification.</span></p>
<p><span>In pharmaceutical testing, we plan to expand our work in peptides. We have already established facilities for specialised in vitro testing of topical products, including IVRT and IVPT.</span></p>
<p><span>We are also keen to establish a dedicated medical device testing division. However, that investment is likely to form part of a longer-term plan, potentially in the third or fourth year of our expansion programme.</span></p>
<p><span>Our focus remains on the life sciences, food testing and pharmaceutical testing sectors, with medical devices representing a potential future area of diversification.</span></p>
<p><span>We have been growing at approximately 25–30% year on year. For the 2026–27 financial year, we are targeting growth of at least 50–60%.</span></p>
<p><span>Given the changes taking place in food safety requirements and pharmaceutical testing, we see opportunities to expand our business. Our planned investments in additional infrastructure and specialised services are intended to support this growth.</span></p>
<p><span>The objective is to build on our existing capabilities while entering areas where we can offer specialised expertise and differentiated services.</span></p>
<p><b>Could you elaborate on the specialised pharmaceutical testing services you currently offer?</b></p>
<p><span>Our pharmaceutical testing portfolio covers active pharmaceutical ingredients (APIs), intermediates, finished formulations and packaging materials.</span></p>
<p><span>One important area is the development and validation of analytical methods for nitrosamines and nitrosamine drug substance-related impurities (NDSRIs), which are potential carcinogenic impurities that require careful assessment. We also undertake elemental impurity testing and extractables and leachables studies, which evaluate substances that may migrate from packaging materials into pharmaceutical products.</span></p>
<p><span>For topical products, we conduct IVRT and IVPT studies to assess drug release from formulations and the permeation of active ingredients through the skin.</span></p>
<p><span>We also undertake gastric and feeding-tube studies for medicines administered through feeding tubes, which may be used by post-operative patients and others who cannot take medication orally in the usual manner. These studies help evaluate drug recovery and the amount of medicine delivered through the tube. Our work can include particle-size evaluation and high-performance liquid chromatography (HPLC) assays.</span></p>
<p><span>Another area involves in vitro binding studies for certain gastrointestinal medicines, including products such as sucralfate and phosphate binders. These studies help assess interactions between medicines under specified conditions.</span></p>
<p><span>We also conduct particle-size evaluations and other specialised analytical assessments. Several of these services support product development and bioequivalence-related investigations where appropriate in vitro methods can provide useful evidence without requiring a clinical study for that particular assessment.</span></p>
<p><span>Our approach is not to compete purely on the number of instruments we operate. We invest in the equipment, expertise and infrastructure needed to deliver specialised projects that meet our technical and commercial requirements. We focus on areas where we can provide meaningful value rather than attempting to handle every project regardless of its complexity or commercial viability.</span></p>
<p> </p>
<p><em><strong>swati.rana@expressindia.com<br>
Swatirana.express@gmail.com </strong></em></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/dalpl-building-indias-next-gen-of-specialised-testing-capabilities/">DALPL: Building India’s next-gen of specialised testing capabilities </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Biocon secures EC marketing authorisation for pertuzumab biosimilar Pebrilzo</title>
<link>https://edusehat.com/en/biocon-secures-ec-marketing-authorisation-for-pertuzumab-biosimilar-pebrilzo</link>
<guid>https://edusehat.com/en/biocon-secures-ec-marketing-authorisation-for-pertuzumab-biosimilar-pebrilzo</guid>
<description><![CDATA[ 
The approval makes Pebrilzo the first biosimilar to receive EC marketing authorisation under the EMA’s new tailored clinical approach
The post Biocon secures EC marketing authorisation for pertuzumab biosimilar Pebrilzo appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 12:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Biocon, secures, marketing, authorisation, for, pertuzumab, biosimilar, Pebrilzo</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Biocon has announced that the European Commission (EC) has granted marketing authorisation for Pebrilzo, its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union (EU).</span></p>
<p><span>Biocon’s pertuzumab biosimilar is the first biosimilar to receive EC marketing authorisation under the European Medicines Agency’s (EMA) new tailored clinical approach. The approval follows the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) on September 17, 2026.</span></p>
<p><span>Commenting on the approval, Shreehas Tambe, CEO and Managing Director, Biocon, said, “The European Commission’s approval of Pebrilzo, our pertuzumab biosimilar, the first under its new tailored clinical pathway, marks a significant regulatory milestone for Biocon. With this approval, pertuzumab becomes our fifth oncology biosimilar approved in both Europe and the United States, strengthening our global oncology portfolio and reinforcing our commitment to expanding access to high-quality, affordable biologic therapies for patients with HER2-positive breast cancer.”</span></p>
<p><span>Biocon’s pertuzumab biosimilar has been approved as a 420 mg concentrate for solution for infusion. Its active substance, pertuzumab, is a monoclonal antibody that binds with high affinity and specificity to the human epidermal growth factor receptor 2 (HER2), inhibiting the proliferation of tumour cells that overexpress HER2.</span></p>
<p><span>The biosimilar is indicated for use in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer at high risk of recurrence. It is also indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.</span></p>
<p><span>In addition, the biosimilar is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.</span></p>
<p><span>According to Biocon, extensive orthogonal, state-of-the-art structural and functional analytical characterisation, together with comparative clinical pharmacokinetic data, demonstrated that its pertuzumab biosimilar is highly similar to the reference product, with no clinically meaningful differences in quality, safety or efficacy.</span></p>
<p>The post <a href="https://www.expresspharma.in/biocon-secures-ec-marketing-authorisation-for-pertuzumab-biosimilar-pebrilzo/">Biocon secures EC marketing authorisation for pertuzumab biosimilar Pebrilzo</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Alcohol Suppresses Some T Cells, Boosts Others, Blunting Anti&#45;PD&#45;1 Response in Mice</title>
<link>https://edusehat.com/en/alcohol-suppresses-some-t-cells-boosts-others-blunting-anti-pd-1-response-in-mice</link>
<guid>https://edusehat.com/en/alcohol-suppresses-some-t-cells-boosts-others-blunting-anti-pd-1-response-in-mice</guid>
<description><![CDATA[ In mice, alcohol cut the efficacy of anti-PD-1 immunotherapy by roughly 50%, suppressing tumor-infiltrating and memory T cells while boosting TIGIT-carrying ones. Blocking TIGIT restored the response.
The post Alcohol Suppresses Some T Cells, Boosts Others, Blunting Anti-PD-1 Response in Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/07/GettyImages-544546123.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 09:00:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alcohol, Suppresses, Some, Cells, Boosts, Others, Blunting, Anti-PD-1, Response, Mice</media:keywords>
<content:encoded><![CDATA[<p>Regular alcohol use may undermine a widely used form of cancer immunotherapy by dampening some T cells while boosting others, according to a new study in mouse models and a retrospective patient cohort. The findings point to a molecular route by which drinking weakens anti-tumor immunity, and to ways it might be countered.</p>
<p>The work, from researchers at the University of North Carolina at Chapel Hill, was published in <em>Science Signaling</em> in a paper titled “<a href="https://www.science.org/doi/10.1126/scisignal.aef1375" target="_blank" rel="noopener">Alcohol use reduces the efficacy of anti-PD1 immunotherapy by disrupting antitumor immunity</a>.” Immune checkpoint inhibition has improved outcomes for some patients with advanced cancers, but relatively few have a complete response. Alcohol use is common and impairs adaptive immunity. Recent studies suggest that as many as 76.4% of patients with cancer still drink, and medical societies have called for more research on how alcohol affects treatment outcomes.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>To probe the link, the team gave mouse models of lung and bladder cancer a moderate-to-heavy amount of ethanol while treating them with anti-PD-1 antibodies. In both models, alcohol reduced the efficacy of the immunotherapy by roughly 50% and increased tumor recurrence.</p>
<p>In mice with MB49 bladder tumors, ethanol reduced the number of tumor-infiltrating T cells and shifted tumor-associated CD4<sup>+</sup> T cells toward a T helper 17 profile over a T helper 1 profile. It also reduced tissue-resident memory T cells while increasing the proportion of T cells expressing TIGIT, an alternative immune checkpoint receptor, and induced SREBP-mediated lipid signaling in tumor-associated T cells, according to the paper.</p>
<p>Targeting those changes helped. Blocking TIGIT with antibodies restored the efficacy of anti-PD-1 treatment in the animals, while inhibiting SREBP signaling with betulin improved it to a lesser extent.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The researchers then retrospectively analyzed a cohort of patients with skin, lung, bladder, or head and neck cancer treated with immune checkpoint inhibitors. Patients who self-reported eight or more drinks a week had poorer survival after starting treatment. In patients with lung cancer, regular alcohol use was associated with a reduced survival benefit from immune checkpoint inhibition. The effects were less definitive in the other cancers because alcohol use reporting was too limited.</p>
<p>“This work is an initial resource toward establishing the risk of regular alcohol use on the efficacy of [immune checkpoint inhibition] and identifying the mechanisms that might be targeted for intervention,” Gilley <em>et al.</em> wrote. As next steps, the authors say that incorporating patients’ alcohol use into cancer databases will help define its effect on outcomes of various therapies, such as chimeric antigen receptor T cell therapy (CAR T cell therapy), chemotherapy, and radiation, across multiple cancers.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/alcohol-suppresses-some-t-cells-boosts-others-blunting-anti-pd-1-response-in-mice/">Alcohol Suppresses Some T Cells, Boosts Others, Blunting Anti-PD-1 Response in Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Litmys and PharmaACE partner on pharma commercial forecasting</title>
<link>https://edusehat.com/en/litmys-and-pharmaace-partner-on-pharma-commercial-forecasting</link>
<guid>https://edusehat.com/en/litmys-and-pharmaace-partner-on-pharma-commercial-forecasting</guid>
<description><![CDATA[ The partnership links real-world product adoption analytics with commercial modelling to assist companies in making clinical development, investment, and commercialisation choices. The companies will combine their respective analytical 
The post Litmys and PharmaACE partner on pharma commercial forecasting appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-12-11-2026-shutterstock_1884612916.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 08:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Litmys, and, PharmaACE, partner, pharma, commercial, forecasting</media:keywords>
<content:encoded><![CDATA[<p>The partnership links real-world product adoption analytics with commercial modelling to assist companies in making clinical development, investment, and commercialisation choices.</p>
<p>The companies will combine their respective analytical tools to generate market projections based on customer behaviour rather than standard assumptions.</p>
<p>Conventional industry forecasts frequently depend on clinical profiles, total market scale, and expected market share.</p>
<p>The joint initiative instead evaluates how interactions between healthcare providers, payers, and patients drive uptake, helping companies identify commercial risks before finalising major development decisions.</p>
<p>Litmys managing partner Harris Kaplan said: “Approval does not equal adoption, and a forecast is only as good as the assumptions behind it. Our work focuses on understanding what will actually drive physicians, payers, and patients to embrace a new product.</p>
<p>“Combining that perspective with PharmaACE’s sophisticated forecasting and analytics capabilities allows us to connect the drivers of adoption more directly to commercial expectations and help clients make better decisions while they still have time to influence the outcome.”</p>
<p>Litmys uses its Realistic Assessment of Market Potential (RAMPx) methodology to assess product advantages, uptake barriers, and stakeholder willingness to alter current behaviours.</p>
<p>PharmaACE then applies forecasting models, commercial analytics, and consulting expertise to translate these findings into market projections.</p>
<p>Together, the firms intend to offer complementary services throughout the product lifecycle, from clinical development through to launch, while establishing an assessment framework to evaluate assets and allocate resources across international portfolios.</p>
<p>Litmys is headquartered in Santa Fe, New Mexico, US, with an additional site in Minneapolis, Minnesota focusing on commercial readiness analytics and development risk assessment for medicines and medical devices.</p>
<p>Established in 2013, PharmaACE is based in Princeton, New Jersey, and maintains offices in Canada, Germany, India, and Portugal.</p>
<p>The consultancy provides analytics, forecasting, and advisory services across therapy areas including cardiometabolic conditions, central nervous system disorders, immunology, oncology, and rare diseases.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/litmys-pharmaace-pharma-commercial-forecasting/">Litmys and PharmaACE partner on pharma commercial forecasting</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ProBio signs global antibody licensing deal with AbTis</title>
<link>https://edusehat.com/en/probio-signs-global-antibody-licensing-deal-with-abtis</link>
<guid>https://edusehat.com/en/probio-signs-global-antibody-licensing-deal-with-abtis</guid>
<description><![CDATA[ The asset was developed via ProBio’s biologics discovery and development operations and is directed against an oncology target. ProBio is set to receive an upfront payment, alongside eligibility 
The post ProBio signs global antibody licensing deal with AbTis appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-2-12-11-2026-ProBio-Inc-AbTis-discovery-stage-therapeutic-antibody.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 08:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ProBio, signs, global, antibody, licensing, deal, with, AbTis</media:keywords>
<content:encoded><![CDATA[<p>The asset was developed via ProBio’s biologics discovery and development operations and is directed against an oncology target.</p>
<p>ProBio is set to receive an upfront payment, alongside eligibility for potential payments tied to developmental and commercial milestones. Financial figures of the deal were not disclosed.</p>
<p>The agreement additionally entitles the company to receive royalties on future product sales generated by the candidate.</p>
<p>AbTis, a subsidiary of Dong-A ST, plans to incorporate the licensed antibody into its portfolio of bispecific antibody-drug conjugates (ADCs).</p>
<p>The company will apply its AbClick site-specific conjugation technology to develop the candidate into a next-generation ADC.</p>
<p>The AbClick linker platform enables controlled, site-specific antibody conjugation, designed to progress conjugate consistency and characteristics relative to conventional non-specific conjugation methods across oncology applications.</p>
<p>ProBio CEO Allen Guo said: “This agreement demonstrates the value of ProBio’s strategy to not only support our partners’ programmes, but also generate differentiated assets that can advance into innovative therapeutic development.</p>
<p>“By combining ProBio’s biologics discovery capabilities with AbTis’ site-specific ADC technology, we have the opportunity to accelerate the development of a promising oncology asset and create additional value for patients and our partners.”</p>
<p>The transaction aligns with ProBio’s role as a global contract research, development, and manufacturing organisation (CRDMO), providing partners with an integrated pathway that links scientific research directly with manufacturing capabilities.</p>
<p>Operating across biologics, cell therapy, and gene therapy, ProBio maintains scalable, good manufacturing practice (GMP)-compliant facilities designed to de-risk development schedules and shorten production timelines.</p>
<p>AbTis remains focused on advancing bioconjugate therapeutics, seeking to improve clinical outcomes for individuals treated for cancer and other serious diseases.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/probio-global-antibody-licensing-deal-abtis/">ProBio signs global antibody licensing deal with AbTis</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lilly&#45;backed Oyster Therapeutics raises $60m for neurological degraders</title>
<link>https://edusehat.com/en/lilly-backed-oyster-therapeutics-raises-60m-for-neurological-degraders</link>
<guid>https://edusehat.com/en/lilly-backed-oyster-therapeutics-raises-60m-for-neurological-degraders</guid>
<description><![CDATA[ London-based life science venture capital fund 4BIO Capital led the investment. New participants in the round included Actium Group, CE Ventures, Eli Lilly, and TOHO Ventures, managed by 
The post Lilly-backed Oyster Therapeutics raises $60m for neurological degraders appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-12-11-2026-shutterstock_2271147415.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 08:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lilly-backed, Oyster, Therapeutics, raises, 60m, for, neurological, degraders</media:keywords>
<content:encoded><![CDATA[<p>London-based life science venture capital fund 4BIO Capital led the investment. New participants in the round included Actium Group, CE Ventures, Eli Lilly, and TOHO Ventures, managed by Global Brain.</p>
<p>Existing backers MGB Ventures, Mission BioCapital, Oxford Science Enterprises (OSE), and Syncona also took part. Alongside the fundraise, the business adopted its new trading identity as Oyster Therapeutics.</p>
<div>
<p>Oyster Therapeutics CEO Rob Johnson said: “This financing accelerates our progress towards the clinic and enables us to validate a new approach to targeted protein degradation, or TPD, that solves some of its major limitations through the use of smaller molecules.</p>
<p>“Millions of people living with diseases such as Alzheimer’s need new approaches such as TPD to address the root cause of disease. At Oyster we are defining next-generation TPD medicines that can reliably reach the brain and are orally available to better meet the needs of global patient populations.</p>
<p>“We welcome this support from both new and existing investors for our vision of building the world’s leading neuroscience TPD company.”</p>
<p>The proceeds will help advance the company’s lead programme that centres on an oral degrader directed at tau, a protein whose abnormal accumulation defines tauopathies such as Alzheimer’s disease.</p>
<p>This tau degrader is designed to enter the central nervous system (CNS) to eliminate pathological tau whilst preserving healthy forms of the protein.</p>
<p>Oyster Therapeutics selected an oral formulation to allow room-temperature storage, lower production expenses, and provide ease of administration for large patient populations.</p>
<p>In tandem with the programme, the company has agreed a sponsored research partnership with Massachusetts General Hospital.</p>
<p>The project is supervised by Mass General Brigham Neuroscience Institute investigator and Harvard Medical School neurology assistant professor Dr Catarina Silva.</p>
<p>It gives the company access to patient-derived neuronal cell lines and advanced methods for detecting neurotoxic oligomeric tau.</p>
<p>Additionally, the financing supports development of Oyster Therapeutics’ SELFTAC platform to generate targeted protein degraders with improved drug-like properties.</p>
</div>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/oyster-60m-neurological-degraders-pipeline/">Lilly-backed Oyster Therapeutics raises $60m for neurological degraders</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BMS sets unified research and development structure for 2027</title>
<link>https://edusehat.com/en/bms-sets-unified-research-and-development-structure-for-2027</link>
<guid>https://edusehat.com/en/bms-sets-unified-research-and-development-structure-for-2027</guid>
<description><![CDATA[ The company’s executive vice president and chief medical officer Cristian Massacesi will lead the unified, end-to-end R&amp;D organisation. The planned structure will place the company’s scientific and clinical 
The post BMS sets unified research and development structure for 2027 appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-2-13-11-2026-shutterstock_2394208173.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 08:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BMS, sets, unified, research, and, development, structure, for, 2027</media:keywords>
<content:encoded><![CDATA[<p>The company’s executive vice president and chief medical officer Cristian Massacesi will lead the unified, end-to-end R&D organisation.</p>
<p>The planned structure will place the company’s scientific and clinical expertise within one group, spanning discovery and development.</p>
<p>BMS executive vice president and chief research officer Robert Plenge will remain at the company in an advisory role through March 2027 before departing.</p>
<p>Plenge’s continued involvement is intended to support the transition to the new organisational model.</p>
<p>BMS board chair and CEO Christopher Boerner said: “Bringing Research and Development together as one organisation is an important step in our work to position BMS for long-term growth.</p>
<p>“Under Cristian’s leadership, this new structure will more closely connect our scientific and clinical expertise across R&D, accelerate decision making and ultimately enhance portfolio execution. Increasingly, traditional boundaries between research and development are collapsing.</p>
<p>“This combined R&D organisation sets us up to attract and retain the best talent, build critical capabilities, and better integrate new technology. I want to sincerely thank Robert for his extraordinary and lasting contributions to Bristol Myers Squibb, and his support on evolving the organisation.”</p>
<p>As part of its core operations, BMS works to discover, develop, and deliver medicines intended to help patients address serious diseases.</p>
<p>Massacesi said: “This is an exciting time at BMS, with immense scientific potential and an important opportunity to deliver on the promise of our pipeline while building what comes next. I’m grateful to Robert for his partnership, all he has contributed and the organisation he has built.</p>
<p>“Our Research & Development teams are advancing exceptional science and uniting them as one team will enable us to translate our most promising discoveries into medicines for patients with greater speed and focus.”</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/bms-unified-research-and-development-structure-2027/">BMS sets unified research and development structure for 2027</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA and EMA waive paediatric studies for Shanton’s gout candidate</title>
<link>https://edusehat.com/en/fda-and-ema-waive-paediatric-studies-for-shantons-gout-candidate</link>
<guid>https://edusehat.com/en/fda-and-ema-waive-paediatric-studies-for-shantons-gout-candidate</guid>
<description><![CDATA[ Under an agreement reached with the EMA on a paediatric investigation plan (PIP), the clinical-stage biotechnology company received a full, product-specific waiver. The decision applies across all paediatric 
The post FDA and EMA waive paediatric studies for Shanton’s gout candidate appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-2-12-11-2026-shutterstock_2159556759.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 08:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, and, EMA, waive, paediatric, studies, for, Shanton’s, gout, candidate</media:keywords>
<content:encoded><![CDATA[<p>Under an agreement reached with the EMA on a paediatric investigation plan (PIP), the clinical-stage biotechnology company received a full, product-specific waiver.</p>
<p>The decision applies across all paediatric age groups diagnosed with hyperuricemia, except for conditions arising from obesity or chronic kidney disease.</p>
<p>The European determination follows an agreed initial paediatric study plan (PSP) submitted in May of this year to the FDA.</p>
<p>Regulators at the FDA similarly exempted SAP-001 from paediatric study requirements because gout occurs with extremely low frequency in children.</p>
<p>Shanton Pharma CEO Bing Li said: “We are pleased that the EMA and FDA have determined that paediatric clinical studies evaluating SAP-001 are not needed to support market authorisation applications for hyperuricemia and gout.</p>
<p>“The EMA and FDA waivers significantly lessen the administrative and regulatory burden and lower the overall cost of clinical development of SAP-001.”</p>
<p>SAP-001 is an investigational, once-daily oral urate-lowering therapy designed to treat uncontrolled and refractory gout in adult patients.</p>
<p>In a recent Phase IIb study (NCT05690204), the compound demonstrated efficacy and safety in individuals whose hyperuricemia failed to respond to standard-of-care xanthine oxidase inhibitor treatments.</p>
<p>Last year, the FDA granted fast track designation (FTD) to the drug candidate, supported in part by the Phase IIb results indicating its potential to improve upon existing urate-lowering therapies for patients facing unmet medical needs.</p>
<p>Established in 2016 by pharmaceutical entrepreneurs, Shanton Pharma is a privately held business focused on developing treatments for adults with gout and hyperuricemia.</p>
<p>The company maintains its corporate headquarters in Singapore, alongside research and development activities based in China, Singapore, and the US.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/shanton-ema-fda-paediatric-waivers-gout/">FDA and EMA waive paediatric studies for Shanton’s gout candidate</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lilly agrees to acquire Calytrix Bio for $1.5bn</title>
<link>https://edusehat.com/en/lilly-agrees-to-acquire-calytrix-bio-for-15bn</link>
<guid>https://edusehat.com/en/lilly-agrees-to-acquire-calytrix-bio-for-15bn</guid>
<description><![CDATA[ Under the terms of the definitive agreement, Calytrix Bio shareholders could receive the total cash, including an initial upfront payment followed by subsequent payouts contingent on reaching specified 
The post Lilly agrees to acquire Calytrix Bio for $1.5bn appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-17-11-2026-shutterstock_2641777219.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 08:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lilly, agrees, acquire, Calytrix, Bio, for, 1.5bn</media:keywords>
<content:encoded><![CDATA[<p>Under the terms of the definitive agreement, Calytrix Bio shareholders could receive the total cash, including an initial upfront payment followed by subsequent payouts contingent on reaching specified clinical and regulatory milestones.</p>
<p>Engineered to provide pan-mutant activity, the antibody binds both Type 1 and Type 2 (mCALR) expressed on tumour-specific cell surfaces.</p>
<p>This targeted mechanism is intended to eradicate disease-driving mutant clones while avoiding damage to healthy tissues and preserving normal haematopoiesis.</p>
<p>The antibody also features a convenience and safety profile aimed at supporting initial therapeutic intervention alongside extended, long-term administration.</p>
<p>The biological profile addresses an unmet therapeutic need in the management of myeloproliferative neoplasms (MPNs).</p>
<p>By focusing directly on the genetic alterations driving disease progression, the Calytrix Bio candidate is intended to provide a targeted, disease-modifying alternative.</p>
<p>Calytrix Bio president and CEO Brad Prosek said: “Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms. From the beginning, our goal has been to alter the disease course in mCALR-driven ET and MF.</p>
<p>“This transaction represents an important step toward accelerating that vision. We look forward to Lilly advancing the programme through the clinic and exploring its potential to benefit patients across the disease spectrum.</p>
<p>“I am deeply grateful to our team, scientific advisors, and committed investors, each of whom has supported delivery of Calytrix’s programme to the starting line for clinical development.”</p>
<p>Based in Wellesley Hills, Massachusetts, Calytrix Bio was established in 2025 by J.P. Morgan Life Sciences Private Capital, the life sciences venture capital division of J.P. Morgan Asset Management.</p>
<p>Last month, Lilly expanded its partnership and licensing agreement with California-based biotech, Gate Bioscience, to develop molecular gate therapies targeting difficult-to-drug proteins. Lilly has been the most prolific dealmaking company in big pharma so far this year.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/lilly-to-acquire-calytrix-bio-1-5bn/">Lilly agrees to acquire Calytrix Bio for $1.5bn</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AstraZeneca secures FDA approval for Imfinzi combo in MIBC</title>
<link>https://edusehat.com/en/astrazeneca-secures-fda-approval-for-imfinzi-combo-in-mibc</link>
<guid>https://edusehat.com/en/astrazeneca-secures-fda-approval-for-imfinzi-combo-in-mibc</guid>
<description><![CDATA[ The therapeutic schedule for Imfinzi with Astellas Pharma and Pfizer’s drug involves neoadjuvant treatment prior to radical cystectomy, followed by single-agent Imfinzi as adjuvant therapy. The FDA granted 
The post AstraZeneca secures FDA approval for Imfinzi combo in MIBC appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-2-16-11-2026-original.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 08:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>AstraZeneca, secures, FDA, approval, for, Imfinzi, combo, MIBC</media:keywords>
<content:encoded><![CDATA[<p>The therapeutic schedule for Imfinzi with Astellas Pharma and Pfizer’s drug involves neoadjuvant treatment prior to radical cystectomy, followed by single-agent Imfinzi as adjuvant therapy.</p>
<p>The FDA granted the clearance under priority review based on findings from the multi-centre VOLGA Phase III clinical study (NCT04960709), published in <em>The New England Journal of Medicine</em> and presented at the 2026 European Society for Medical Oncology Congress.</p>
<p>In the trial, the perioperative regimen reduced the risk of disease progression, recurrence, omitted surgery, or death by 49% compared with radical cystectomy with or without approved adjuvant treatment.</p>
<p>Two-year event-free survival reached an estimated 64% with the regimen, compared with 45% in the control arm, where median event-free survival was 12.1 months.</p>
<p>Overall survival results demonstrated a 42% decrease in the risk of death, with two-year survival rates estimated at 78% versus 69%.</p>
<p>Grade 3 and 4 adverse events arising from any cause occurred in 64% of individuals treated with the combination, compared with 44% in the comparator arm, with no new safety signals reported.</p>
<p>Patient-reported quality of life was maintained following surgical intervention.</p>
<p>AstraZeneca oncology haematology business unit executive vice president Dave Fredrickson said: “Today’s approval offers a novel Imfinzi-based regimen that almost halved the risk of disease recurrence and reduced the risk of death by 42% in the VOLGA trial, allowing physicians to optimise treatment for patients in this curative-intent setting.</p>
<p>“As our third bladder cancer indication in two years, this approval reinforces Imfinzi as an immunotherapy backbone across muscle-invasive and non-muscle-invasive disease.”</p>
<p>Muscle-invasive tumours account for roughly one-quarter of all bladder cancer cases, with approximately 16,000 individuals in the US expected to receive treatment in 2026.</p>
<p>Impaired renal function or other comorbidities prevent up to 50% of patients from tolerating cisplatin-based chemotherapy, leaving radical cystectomy alone as the historical standard despite frequent recurrences.</p>
<p>Outside the US, regulatory applications based on the 695-patient trial remain under review in the European Union, Japan, and other territories.</p>
<p>In May this year, AstraZeneca received approval from the US FDA for Imfinzi in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy for adult patients with BCG-naïve, high-risk non-MIBC. Imfinzi holds multiple approvals in the US across lung, bladder, gastrointestinal, and gynecological cancers.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/astrazeneca-fda-approval-imfinzi-combo-mibc/">AstraZeneca secures FDA approval for Imfinzi combo in MIBC</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA rejects Summit’s ivonescimab application for lung cancer</title>
<link>https://edusehat.com/en/fda-rejects-summits-ivonescimab-application-for-lung-cancer</link>
<guid>https://edusehat.com/en/fda-rejects-summits-ivonescimab-application-for-lung-cancer</guid>
<description><![CDATA[ The regulator notified the company of its decision in a complete response letter (CRL). Summit Therapeutics had sought approval for the investigational drug, in combination with platinum-containing chemotherapy, 
The post FDA rejects Summit’s ivonescimab application for lung cancer appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-16-11-2026-shutterstock_2022905333.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 08:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, rejects, Summit’s, ivonescimab, application, for, lung, cancer</media:keywords>
<content:encoded><![CDATA[<p>The regulator notified the company of its decision in a complete response letter (CRL).</p>
<p>Summit Therapeutics had sought approval for the investigational drug, in combination with platinum-containing chemotherapy, to treat patients whose NSCLC had progressed after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor therapy.</p>
<p>The FDA said the application could not be approved in its current form, concluding that Summit had not established substantial evidence of effectiveness without a statistically significant improvement in overall survival.</p>
<p>Although ivonescimab achieved a progression-free survival (PFS) benefit in the global Phase III HARMONi clinical trial (NCT06396065), the FDA determined that this finding did not support a favourable benefit-risk balance without a survival gain.</p>
<p>The primary overall survival analysis showed a positive trend but did not achieve statistical significance. Currently, no treatments approved by the FDA have demonstrated a statistically significant overall survival benefit in this subset of NSCLC patients.</p>
<p>Summit Therapeutics president and co-CEO Maky Zanganeh said: “As a cancer survivor, I understand firsthand how important it is for patients to have access to multiple treatment options, particularly when they are facing diseases with significant unmet medical needs.</p>
<p>“Behind every diagnosis is a person, a family, and a community hoping for more time, more possibilities, and a better future. I know that hope is not simply an emotion; it is the possibility that another treatment, another scientific breakthrough, or another therapeutic option may make a meaningful difference in someone’s life.</p>
<p>“Every additional treatment option matters. It represents another opportunity for patients and their families, especially those who have exhausted existing therapies or have limited alternatives.”</p>
<p>Safety findings from the Phase III study showed that 16 patients (7.3%) discontinued ivonescimab due to treatment-related adverse events, compared with 11 patients (5.0%) who discontinued placebo.</p>
<p>Deaths resulting from treatment-related adverse events occurred in four patients (1.8%) receiving ivonescimab with chemotherapy and five patients (2.3%) receiving chemotherapy alone.</p>
<p>Ivonescimab was developed by Akeso and received marketing authorisation for NSCLC patients with EGFR gene mutations that progressed after EGFR-TKI treatment in China in May 2024.</p>
<p>The programmed cell death protein-1 (PD-1) x vascular endothelial growth factor (VEGF) bispecific antibody remains investigational and unapproved across Summit’s licence territories, which include Europe and the US.</p>
<p>To date, the FDA has not approved any PD-1 x VEGF bispecific antibodies.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/fda-rejects-summits-ivonescimab-application/">FDA rejects Summit’s ivonescimab application for lung cancer</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Takeda begins US distribution of narcolepsy type 1 drug Orzeyful</title>
<link>https://edusehat.com/en/takeda-begins-us-distribution-of-narcolepsy-type-1-drug-orzeyful</link>
<guid>https://edusehat.com/en/takeda-begins-us-distribution-of-narcolepsy-type-1-drug-orzeyful</guid>
<description><![CDATA[ The therapy is an oral orexin receptor 2 agonist, formulated to target the orexin deficiency that causes the chronic neurological condition. Following approval by the US Food and 
The post Takeda begins US distribution of narcolepsy type 1 drug Orzeyful appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-13-11-2026-shutterstock_2516166199.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 08:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Takeda, begins, distribution, narcolepsy, type, drug, Orzeyful</media:keywords>
<content:encoded><![CDATA[<p>The therapy is an oral orexin receptor 2 agonist, formulated to target the orexin deficiency that causes the chronic neurological condition.</p>
<p>Following approval by the US Food and Drug Administration (FDA) in August 2026, the drug received a Schedule IV controlled substance (CIV) classification.</p>
<p>Distribution across the country is being managed through Accredo Specialty Pharmacy, a division of Evernorth Health Services, with licensed healthcare practitioners able to prescribe the treatment.</p>
<p>Takeda is also offering patient support programmes to assist eligible adults with treatment initiation and healthcare coverage navigation.</p>
<p>Takeda US business unit president Rhonda Pacheco said: “We work for decades toward the defining moments that have the potential to make a real difference for patients.</p>
<p>“Bringing Orzeyful, a first-in-class medicine, to people living with narcolepsy type 1 in the US is one of those moments.</p>
<p>“We’re incredibly proud to be here, and equally focused on what comes next: supporting care and access for patients prescribed Orzeyful.”</p>
<p>Narcolepsy type 1 is described as a rare disorder caused by the loss of orexin-producing neurons. The condition leads to fragmented nocturnal sleep, excessive daytime sleepiness, cognitive difficulties, and cataplexy, which involves sudden and temporary muscle tone loss.</p>
<p>Orzeyful functions by selectively activating orexin receptor 2 pathways to restore signalling, thereby promoting daytime wakefulness and reducing abnormal rapid eye movement sleep phenomena.</p>
<p>In clinical evaluations, the most frequently reported adverse effects included insomnia, excessive saliva production, increased urinary urgency, and urinary frequency.</p>
<p>Regulatory authorities in China and Japan have also approved Orzeyful for adult patients with narcolepsy type 1.</p>
<p>The compound serves as the lead asset in Takeda’s pipeline of orexin-focused treatments.</p>
<p>Alongside Orzeyful, the company is advancing other investigational oral orexin agonists, including TAK-360, which is in clinical development for idiopathic hypersomnia, narcolepsy type 1, and narcolepsy type 2, as well as TAK-495.</p>
<p>Takeda is also creating digital tools and biomarker diagnostic solutions designed to identify and differentiate narcolepsy type 1 earlier.</p>
<p>Jazz Pharmaceuticals’ flagship oxybate blockbuster brands Xywav and Xyrem have traditionally been the top-selling narcolepsy drugs in the US.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/takeda-us-distribution-orzeyful/">Takeda begins US distribution of narcolepsy type 1 drug Orzeyful</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Seawolf Therapeutics and Sanofi agree $1.2bn drug deal</title>
<link>https://edusehat.com/en/seawolf-therapeutics-and-sanofi-agree-12bn-drug-deal</link>
<guid>https://edusehat.com/en/seawolf-therapeutics-and-sanofi-agree-12bn-drug-deal</guid>
<description><![CDATA[ Under the terms of the partnership, Seawolf could receive the funds upon reaching research, development, and commercial milestone payments, alongside tiered royalties on future sales of any therapies 
The post Seawolf Therapeutics and Sanofi agree $1.2bn drug deal appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-2-17-11-2026-shutterstock_2556717719.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 08:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Seawolf, Therapeutics, and, Sanofi, agree, 1.2bn, drug, deal</media:keywords>
<content:encoded><![CDATA[<p>Under the terms of the partnership, Seawolf could receive the funds upon reaching research, development, and commercial milestone payments, alongside tiered royalties on future sales of any therapies resulting from the collaboration.</p>
<p>The alliance coincides with Seawolf emerging from stealth mode with $100m in financing to advance its pipeline of deoxyribonucleic acid (DNA)-based medicines.</p>
<p>This funding total includes seed financing led by founding investor Versant Ventures, followed by a Series A round supported by MPM BioImpact, Novartis Venture Fund, and Versant Ventures.</p>
<p>Other participants in the financing included Alexandria Venture Investments, CRISPR Therapeutics, Eli Lilly and Company, Pathway to Cures, which is the philanthropic venture arm of the National Bleeding Disorders Foundation, and Sixty Degree Capital.</p>
<p>Seawolf Therapeutics president and CEO Elizabeth Alcamo said: “Seawolf is charting a new course in patient care through LNP-based DNA medicines.</p>
<p>“With a strong syndicate of investors and our collaboration with Sanofi, we are well-positioned to execute on our next stage of growth, which will include advancing our lead programme for metabolic diseases and collaborating with Sanofi in its mission to develop therapies for patient unmet needs.”</p>
<p>Seawolf will use the capital to progress candidates built upon its Targeted RNA-Induced DNA Expression via Nuclear Translocation (TRIDENT) platform.</p>
<p>The technology uses lipid nanoparticles to transport immune-quiet DNA encoding a therapeutic transgene directly into cell nuclei, aided by an auxiliary factor.</p>
<p>This nuclear delivery aims to achieve stable, long-term therapeutic protein expression, overcoming the transient activity associated with standard RNA-based therapies.</p>
<p>Unlike viral vectors, the nanoparticle delivery system allows repeated administration to adjust or supplement dosing over time.</p>
<p>Seawolf showed proof of concept for the approach in preclinical murine and non-human primate models of metabolic and rare diseases.</p>
<p>In addition to collaborating with Sanofi, the company is advancing an internal lead programme targeting metabolic diseases.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/seawolf-sanofi-agree-drug-deal/">Seawolf Therapeutics and Sanofi agree $1.2bn drug deal</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Intermountain Health Breaks Ground on Nevada’s First Stand&#45;Alone Children’s Hospital</title>
<link>https://edusehat.com/en/intermountain-health-breaks-ground-on-nevadas-first-stand-alone-childrens-hospital</link>
<guid>https://edusehat.com/en/intermountain-health-breaks-ground-on-nevadas-first-stand-alone-childrens-hospital</guid>
<description><![CDATA[ Intermountain Health’s Felicia and Ben Horowitz Children’s Hospital is intended to expand access to specialized pediatric care and reduce families’ need to travel outside Nevada. | Photo Credit: Intermountain Health  The Felicia and Ben Horowitz Children’s Hospital in Las Vegas will be the first stand-alone children’s hospital in Nevada.  The estimated $1.2 billion, 828,600-square-foot facility...
The post Intermountain Health Breaks Ground on Nevada’s First Stand-Alone Children’s Hospital appeared first on HCO News.
The post Intermountain Health Breaks Ground on Nevada’s First Stand-Alone Children’s Hospital appeared first on HCO News. ]]></description>
<enclosure url="https://hconews.com/wp-content/uploads/2026/11/HCO-News.Intermountain-768x432.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 06:05:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Intermountain, Health, Breaks, Ground, Nevada’s, First, Stand-Alone, Children’s, Hospital</media:keywords>
<content:encoded><![CDATA[<h5><span data-contrast="auto">Intermountain Health’s Felicia and Ben Horowitz Children’s Hospital is intended to </span><span data-contrast="auto">expand access to specialized pediatric care and reduce families’ need to travel outside Nevada. | Photo Credit: Intermountain Health</span><span data-ccp-props="{}"> </span></h5>
<ul>
<li><span data-contrast="auto">The Felicia and Ben Horowitz Children’s Hospital in Las Vegas will be the first stand-alone children’s hospital in Nevada.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":0,"335559739":0}'> </span></li>
<li><span data-contrast="auto">The estimated $1.2 billion, 828,600-square-foot facility is projected to open with 180 beds in 2030.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":0,"335559739":0}'> </span></li>
<li><span data-contrast="auto">Shepley Bulfinch and Gensler lead design, with Penta Building Group and Jacobsen Construction serving as the contractors. </span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":0,"335559739":0}'> </span></li>
</ul>
<p>LAS VEGAS —<span data-contrast="auto"> Intermountain Health broke ground Oct. 26 on its Felicia and Ben Horowitz Children’s Hospital, a project expected to open in 2030 that the health system describes as Nevada’s first stand-alone children’s hospital.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p>
<p><span data-contrast="auto">The approximately 828,600-square-foot hospital will occupy a 33-acre campus in Las Vegas. Its inpatient tower will initially accommodate 180 beds, with room to increase capacity to 228, according to </span><a href="https://news.intermountainhealth.org/intermountain-health-breaks-ground-on-a-new-era-of-childrens-health-in-nevada/" target="_blank" rel="noopener"><span data-contrast="none">a release from Intermountain Health</span></a><span data-contrast="auto">.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p>
<p><span data-contrast="auto">Planned services include neonatal care, pediatric and cardiac intensive care, emergency and trauma care, orthopedics, cancer treatment, bone marrow transplantation and behavioral health. The hospital also will provide advanced pediatric medical and surgical care.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p>
<blockquote><p><span data-contrast="auto">“This hospital is one important piece of a bigger vision,” Russ Williams, President of Intermountain Health Felicia and Ben Horowitz Children’s Hospital, said in the release. “By bringing people and resources together around children and families, we have an opportunity to close gaps in care and build a stronger future for every kid across Nevada.”</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p></blockquote>
<p><span data-contrast="auto">Shepley Bulfinch and Gensler are designing the facility, with Penta Building Group and Jacobsen Construction selected to build it. Intermountain announced the architects </span><a href="https://news.intermountainhealth.org/intermountain-health-announces-the-architect-firms-for-nevadas-first-comprehensive-stand-alone-childrens-hospital/" target="_blank" rel="noopener"><span data-contrast="none">in January 2025</span></a><span data-contrast="auto"> and the contractors </span><a href="https://news.intermountainhealth.org/intermountain-health-announces-the-penta-building-group-and-jacobsen-construction-as-contractors-for-nevadas-first-ever-stand-alone-comprehensive-childrens-hospital/" target="_blank" rel="noopener"><span data-contrast="none">that July</span></a><span data-contrast="auto">. </span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p>
<p><span data-contrast="auto">The hospital’s cost is estimated at about $1.2 billion before additional programming expenses, according to </span><a href="https://www.reviewjournal.com/sports/raiders/raiders-donate-25m-to-intermountain-health-to-help-build-stand-alone-childrens-hospital-3868673/?utm_source=chatgpt.com" target="_blank" rel="noopener"><span data-contrast="none">an Aug. 24 Las Vegas Review-Journal report</span></a><span data-contrast="auto"> citing David Flood, Intermountain’s Chief Development Officer and President of Intermountain Foundation. Flood also identified specialist recruitment and research as components of the broader investment. </span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p>
<p><span data-contrast="auto">Intermountain’s architect announcement emphasized patient- and family-centered design, adaptability and environments supporting clinicians and staff. The architects’ approach seeks to reduce anxiety and stress while addressing privacy and the needs of children of different ages. The construction partnership combines Penta’s Nevada project experience with Jacobsen’s health care work, including Intermountain’s Primary Children’s Hospital campus in Lehi, Utah, which opened in 2024.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p>
<p><span data-contrast="auto">The project aims to expand access to specialized pediatric care and reduce families’ need to travel outside Nevada. A $150 million commitment from Felicia and Ben Horowitz supports Intermountain’s Nevada Campaign for Kids.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p>
<blockquote><p><span data-contrast="auto">“This hospital represents an investment in our children and the future strength and health of our state,” Nevada Gov. Joe Lombardo said.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p></blockquote>
<p><i><span data-contrast="auto">This article is based on </span></i><a href="https://news.intermountainhealth.org/intermountain-health-breaks-ground-on-a-new-era-of-childrens-health-in-nevada/" target="_blank" rel="noopener"><i><span data-contrast="none">Intermountain Health’s Oct. 26, 2026, release</span></i></a><i><span data-contrast="auto">, its </span></i><a href="https://news.intermountainhealth.org/intermountain-health-announces-the-architect-firms-for-nevadas-first-comprehensive-stand-alone-childrens-hospital/" target="_blank" rel="noopener"><i><span data-contrast="none">2025 architect</span></i></a><i><span data-contrast="auto"> and </span></i><a href="https://news.intermountainhealth.org/intermountain-health-announces-the-penta-building-group-and-jacobsen-construction-as-contractors-for-nevadas-first-ever-stand-alone-comprehensive-childrens-hospital/" target="_blank" rel="noopener"><i><span data-contrast="none">contractor announcements,</span></i></a><i><span data-contrast="auto"> and </span></i><a href="https://www.reviewjournal.com/sports/raiders/raiders-donate-25m-to-intermountain-health-to-help-build-stand-alone-childrens-hospital-3868673/?utm_source=chatgpt.com" target="_blank" rel="noopener"><i><span data-contrast="none">Las Vegas Review-Journal reporting</span></i></a><i><span data-contrast="auto"> published Aug. 24, 2026.</span></i><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p>
<p>The post <a rel="nofollow" href="https://hconews.com/2026/11/17/intermountain-health-breaks-ground-on-nevadas-first-stand-alone-childrens-hospital/">Intermountain Health Breaks Ground on Nevada’s First Stand-Alone Children’s Hospital</a> appeared first on <a rel="nofollow" href="https://hconews.com/">HCO News</a>.</p>
<p>The post <a href="https://hconews.com/2026/11/17/intermountain-health-breaks-ground-on-nevadas-first-stand-alone-childrens-hospital/">Intermountain Health Breaks Ground on Nevada’s First Stand-Alone Children’s Hospital</a> appeared first on <a href="https://hconews.com/">HCO News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Genetic Barcoding Reveals How Pre&#45;Bone Marrow Transplant Conditioning Impacts Immune System Regeneration</title>
<link>https://edusehat.com/en/genetic-barcoding-reveals-how-pre-bone-marrow-transplant-conditioning-impacts-immune-system-regeneration</link>
<guid>https://edusehat.com/en/genetic-barcoding-reveals-how-pre-bone-marrow-transplant-conditioning-impacts-immune-system-regeneration</guid>
<description><![CDATA[ Researchers used genetic barcoding to track human blood-forming stem and progenitor cells transplanted into mice, revealing how the different cell types regenerate the blood and immune system, and how different forms of pretransplant conditioning affected blood and immune cell recovery. 
The post Genetic Barcoding Reveals How Pre-Bone Marrow Transplant Conditioning Impacts Immune System Regeneration appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/02/GettyImages-1489195647-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 05:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Genetic, Barcoding, Reveals, How, Pre-Bone, Marrow, Transplant, Conditioning, Impacts, Immune, System, Regeneration</media:keywords>
<content:encoded><![CDATA[<p>Researchers at the University of Southern California have used genetic barcoding to track individual human blood-forming stem and progenitor cells after transplanting them into mice. The results has revealed how different types of human blood-forming cells regenerate the blood and immune system, and how different forms of pretransplant conditioning—treatment used to prepare a recipient before bone marrow (BM) transplantation—affected blood and immune cell recovery.</p>
<p>The study is one of the first to systematically examine how human stem cells (HSCs) and human multipotent progenitors (hMPPs) respond to various forms of pretransplant conditioning, including chemotherapy and radiation, and contribute to the production of blood and immune cells. Down the line, the results could support the development of more effective and personalized approaches to bone marrow transplantation, which is used to treat blood cancers such as leukemia and lymphoma and certain inherited blood disorders.</p>
<p>“We found that human HSCs and MPPs don’t always behave as we would expect based on previous studies in mice,” said research lead Rong Lu, PhD, professor of stem cell biology and regenerative medicine at the Keck School of Medicine of USC. Lu is also a professor of biomedical engineering, medicine and gerontology. “Our findings underscore the importance of studying human cells directly to understand how they function in the context of transplantation.”</p>
<p>Lu is senior and corresponding author of the team’s published paper in <em>npj Regenerative Medicine</em>, titled “<a href="http://dx.doi.org/10.1038/s41536-026-00522-6" target="_blank" rel="noopener">Tracking human HSCs and MPPs in mice reveals distinct clonal dynamics and responses to pre-transplant conditioning</a>.” In their paper the team wrote, “These findings advance our understanding of human hematopoiesis and provide a framework for optimizing experimental models, improving transplantation conditioning strategies, and informing the preclinical evaluation of HSC-based cell and gene therapies.”</p>
<p>Human hematopoietic stem and progenitor cells (hHSPCs) sustain lifelong blood and immune cell production and are central to bone marrow (BM) transplantation therapies, the authors wrote. However, they noted, “While the functional hierarchy of mouse HSPC subsets is well characterized, the distinct roles of human HSPC populations remain less well defined, particularly at clonal resolution and in the context of transplantation conditioning.”</p>
<p>For their newly reported study, first author Mary Vergel Snodgrass, PhD, and colleagues used genetic barcode-based clonal tracking, which allowed them to follow individual cells and their descendants to see how they contribute to blood and immune cell production over time, comparing two cell types, hematopoietic stem cells and multipotent progenitor cells. Both HSCs and MPPs can produce multiple types of blood and immune cells, but HSCs are thought to have unique long-term regenerative capacity, based largely on animal studies.</p>
<p>The team transplanted human HSCs or MPPs into mice, then used clonal tracking to compare how the two cell populations contributed to blood and immune cell production over time. They found that both HSCs and MPPs produced multiple types of blood and immune cells over an extended period after transplantation, suggesting that human MPPs may have greater long-term regenerative capacity than previously observed in mouse studies. However, HSCs generally produced more blood cells and were better at producing multiple types of blood and immune cells than MPPs. “We found that hHSC clones generated more blood cells, initiated lymphoid production earlier, and exhibited more robust multilineage differentiation than hMPP clones,” they wrote.</p>
<figure aria-describedby="caption-attachment-340738" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-340738" src="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Rong-Lu-and-Mary-Vergel-by-Chris-Shinn-big-crop-300x169.jpg" alt="Study authors Rong Lu, PhD, and Mary Vergel Snodgrass in the lab " width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Rong-Lu-and-Mary-Vergel-by-Chris-Shinn-big-crop-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Rong-Lu-and-Mary-Vergel-by-Chris-Shinn-big-crop.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Study authors Rong Lu, PhD, and Mary Vergel Snodgrass in the lab [Chris Shinn]</figcaption></figure>
<p>The researchers also compared several approaches to transplant conditioning, which helps reduce a recipient’s own stem and progenitor cells and makes room for donor cells. Mice received either radiation treatment, chemotherapy with the drug busulfan, or no conditioning treatment. The conditioning approach influenced how many and which types of blood and immune cells were produced, and how quickly blood cell production occurred, without significantly affecting donor cell engraftment in the bone marrow.</p>
<p>“We also found that HSCs were less affected by conditioning, while MPPs were more sensitive, shifting the types of immune cells they produced,” Lu said. “This suggests that human HSCs can maintain more consistent blood and immune cell production under different transplantation conditions.”</p>
<p>These findings could eventually help clinicians tailor pre-transplant treatments to individual patients, supporting more effective blood and immune cell recovery while minimizing treatment-related complications. While further studies are needed to determine how these findings translate to patients, they could help guide the development of safer and more effective transplantation strategies.</p>
<p>In a final experiment, the researchers transplanted HSCs and MPPs from the initial recipients into a second group of mice to test their long-term regenerative capacity. They found that both cell types continued producing blood and immune cells, but at substantially lower levels. “During secondary transplantation, hHSCs and hMPPs contributed comparably to hematopoietic reconstitution but with substantially reduced output and increased clonal diversity,” they wrote. Their collective findings “… suggest that secondary transplantation is characterized by weaker contributions from a larger number of clones, whereas primary transplantation is dominated by stronger expansion of a smaller number of clones.”</p>
<p>An unexpected discovery was that in mice receiving a second transplant, blood cell production occurred not only in the bone marrow but also in other tissues, including the spleen, which became substantially enlarged. “Extramedullary hematopoiesis was observed in all secondary recipients,” the team stated. Lu noted that this phenomenon has also been observed in human diseases and may indicate that the mouse bone marrow environment does not fully support human blood cell production. “In humans, EMH is associated with pathological conditions such as hematologic malignancies, BM failure, and systemic infections, highlighting its relevance as a compensatory hematopoietic response under stress and disease,” the authors stated.</p>
<p>Next, Lu and her team are investigating how blood-forming stem cells communicate with surrounding bone marrow cells to regulate blood and immune cell regeneration. This work could help explain why different conditioning treatments lead to different patterns of blood and immune cell recovery. In their paper, the team wrote in summary, “Through quantitative <em>in vivo</em> clonal tracking and multi-tissue analyses, this study advances understanding of human hematopoiesis and provides a framework for optimizing experimental models, improving transplantation strategies, and informing the development of HSC-based cell and gene therapies.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/genetic-barcoding-reveals-how-pre-bone-marrow-transplant-conditioning-impacts-immune-system-regeneration/">Genetic Barcoding Reveals How Pre-Bone Marrow Transplant Conditioning Impacts Immune System Regeneration</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond Amyloid and Tau: Alzheimer’s Drug Developer Sees Early Clinical Success for Immunotherapy&#45;Based Approach</title>
<link>https://edusehat.com/en/beyond-amyloid-and-tau-alzheimers-drug-developer-sees-early-clinical-success-for-immunotherapy-based-approach</link>
<guid>https://edusehat.com/en/beyond-amyloid-and-tau-alzheimers-drug-developer-sees-early-clinical-success-for-immunotherapy-based-approach</guid>
<description><![CDATA[ ImmunoBrain&#039;s approach contrasts with decades of conventional thinking among researchers, which held that Alzheimer’s was a disease of toxic proteins—an outgrowth of thinking that immune activity in the brain was in itself a sign of pathology. 
The post Beyond Amyloid and Tau: Alzheimer’s Drug Developer Sees Early Clinical Success for Immunotherapy-Based Approach appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/CO_JanFeb18_GettyImages-687788463_CHRISTIANLAGEREK_SCIENCEPHOTOLIBRARY_HumanBrainCircuitBoard-e1559053521129-1024x831-1-e1794949818926.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 05:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, Amyloid, and, Tau:, Alzheimer’s, Drug, Developer, Sees, Early, Clinical, Success, for, Immunotherapy-Based, Approach</media:keywords>
<content:encoded><![CDATA[<p>Twelve years after a widely quoted <a href="https://alzres.biomedcentral.com/articles/10.1186/alzrt269" target="_blank" rel="noopener">Cleveland Clinic study</a> showed a staggering 99.6% failure rate for Alzheimer’s disease clinical candidates, the percentage has hardly budged.</p>
<p>But ImmunoBrain, an 11-year-old company, has generated early-stage clinical data showing success for a first-of-its-kind, immunotherapy-based approach to treating Alzheimer’s that goes beyond aiming at the two most common targets, amyloid plaques and tau neurofibrillary tangles.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>ImmunoBrain develops treatments intended to address Alzheimer’s and other neurodegenerative diseases by restoring the body’s peripheral immune system to facilitate brain protection and repair. The company uses a novel approach that targets the peripheral immune system to break the vicious cycle between neuroinflammation developed in the brain with neurodegenerative diseases and the progressive decline in peripheral immune function that together derives disease progression.</p>
<figure aria-describedby="caption-attachment-340728" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340728" src="https://www.genengnews.com/wp-content/uploads/2026/11/Prof-Michal-Schwartz-CROP-SQUARE-300x298.jpg" alt="" width="300" height="298" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Prof-Michal-Schwartz-CROP-SQUARE-300x298.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Prof-Michal-Schwartz-CROP-SQUARE-1024x1018.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Prof-Michal-Schwartz-CROP-SQUARE-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/Prof-Michal-Schwartz-CROP-SQUARE-768x764.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Prof-Michal-Schwartz-CROP-SQUARE.jpg 1204w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Michal Schwartz, PhD, ImmunoBrain’s scientific co-founder and chief scientific officer</figcaption></figure>
<p>That approach contrasts with decades of conventional thinking among researchers, which held that Alzheimer’s was a disease of toxic proteins—an outgrowth of thinking that immune activity in the brain was in itself a sign of pathology.</p>
<p>“It’s not just a disease of only accumulation of toxic protein,” Michal Schwartz, PhD, ImmunoBrain’s scientific co-founder and chief scientific officer, told <em>GEN</em>. “We know now that the disease is dormant or asymptomatic for 10 to 20 years before symptoms are seen. Once symptoms are seen, the disease progression is driven not only by the amyloid plaque, but an additional major factor, local inflammation.”</p>
<p>“It’s not the primary cause, it’s not the trigger, but definitely a catalyzer,” said Schwartz, who is also a professor of neuroimmunology at the Weizmann Institute of Science in Rehovot, Israel.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Alzheimer’s starts in the brain, with the accumulated of the toxic proteins such as amyloid and tau. At this stage, local immune cells—microglia—within the brain, supported by the peripheral immune system, can help prevent or minimize damage to neurons, the brain’s functional cells. When the immune system ages and declines, its ability to help the brain is reduced, fueling the brain pathology.</p>
<p>That happens, says Schwartz, when the brain’s own immune cells known collectively as microglia become the source of inflammation.</p>
<h4><strong>Antibody approach</strong></h4>
<p>“Our approach is, we developed a new antibody that targets the inhibitory checkpoint, thereby we boost the level very transiently of immune cells that can facilitate a homing of immune repairing cells from the peripheral immune system to the brain. They are facilitating dampening the local inflammation and thereby creating a supportive milieu within the brain that can rescue neurons and synapses that are still healthy but not functioning well.”</p>
<p>Schwartz’s lab was first to show that the brain is not immune isolated, but tightly dependent on the immune system for its daily maintenance, daily function, protection and repair, as it is the gatekeeper of the brain: “The meaning of it is that aging of the brain reflects more the immunological aging than the chronological aging.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>ImmunoBrain’s lead program applies IBC-Ab002, a company-developed anti-PD-L1 monoclonal antibody engineered specifically for use in chronic neurodegenerative disease settings. Specifically, IBC-Ab002 is engineered for transient, intermittent blockade of the PD-1/PD-L1 pathway. The transient checkpoint blockade allows for triggering of the immune system, initiating an immune cascade by facilitating the homing of immune-repairing monocytes and regulatory T cells (immune system regulators) that clear senescent microglia, and resolves inflammation, thereby helping the brain protection and repair.</p>
<p>IBC-Ab002 combines high-affinity PD-L1 binding with Fc effector silencing and reduced FcRn binding modification designed to eliminate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.</p>
<h4><strong>Positive first-in-human data</strong></h4>
<p>At the 2026 Alzheimer’s Association International Conference (AAIC), held July 12-15 in London, and in a <a href="https://www.nature.com/articles/s41591-026-04547-8" target="_blank" rel="noopener">study published in <em>Nature Medicine</em></a>, ImmunoBrain shared positive data for IBC-Ab002 from a Phase Ib first-in-human study (<a href="https://clinicaltrials.gov/study/NCT05551741" target="_blank" rel="noopener">NCT05551741</a>) in patients with early Alzheimer’s. Forty patients were enrolled across five ascending dose cohorts (1–30 mg kg<sup>−1</sup>), with dosing administered four times at 3-month intervals, and patients followed up for one year. The study’s primary endpoints were safety and tolerability.</p>
<p>The data showed the antibody to have a half-life of approximately four days across all dose cohorts. IBC-Ab002 generated encouraging fluid biomarker data, as well as reductions of biomarkers associated with neuronal and synaptic damage, with no brain hemorrhaging or ARIA (amyloid-related imaging abnormalities) seen.</p>
<p>Exploratory CSF biomarker analyses at 48 weeks showed reductions in neurogranin (−23.1%), tTau (−12.4%) and pTau181 (−11.0%) at the 30 mg kg<sup>−1</sup> dose compared with pooled placebo, with intraindividual consistency across the three markers in participants treated with IBC-Ab002. A pre-synaptic biomarker, VAMP2, showed a similar trend to neurogranin, with strong correlation between individual responses to both markers.</p>
<p><strong>‘Beyond our expectation’</strong></p>
<p>“The biomarkers show an encouraging result, mainly the Neurogranin that is Alzheimer’s characteristic marker and prediction of cognitive performance. Yet, we cannot speak about statistical significance because of the small number of patients and the short duration of the follow-up, but it was beyond our expectation to see from such a small study,” said Schwartz, one of three corresponding authors on the <em>Nature Medicine</em> paper.</p>
<p>“IBC-Ab002 is intended to transiently re-engage the peripheral immune system, whose ability to support the brain declines with aging, thereby restoring its capacity to protect the brain and dampen brain inflammatory processes,” Schwartz and colleagues wrote. “Because this strategy does not rely on directly targeting a specific brain proteinopathy, it has broader applicability across other chronic neurodegenerative conditions in which neuroinflammation contributes to disease progression.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Schwartz said she and colleagues are planning a Phase IIb trial for which they have submitted paperwork to the FDA, and for which they are raising funds. That study would include a two-year follow-up of participants: “We are aiming to do a big study, very rigorous, with a very ambitious endpoint, so if successful, as it seems based on the Phase Ib, it may speed up approval of this drug and may be considered as a pivotal study.”</p>
<p>In September, Schwartz was corresponding author of another paper, which <a href="https://www.nature.com/articles/s41593-026-02417-7" target="_blank" rel="noopener">was published in <em>Nature Neuroscience</em></a> that showed in both a mouse model and in Alzheimer’s patients the body’s “factory” of the a potentially protective immune response—the production of monocyte-derived macrophages in the bone marrow and their recruitment to the brain—key processes that help protect against disease progression are compromised: “Our results reveal a dysfunction in bone marrow myelopoiesis in AD and reinforce the concept that AD progression is driven by maladaptive systemic immune processes.”</p>
<p>“We wanted to see whether the deficiency in homing of macrophages that we are boosting with the anti-PD-L1 is reflection of some impairment in the factory of these monocytes, which is in the bone room,” Schwartz said. “When we saw that there is really impairment in production of monocytes in the factory of the monocytes in the bone marrow, I was, wow, very excited, because it further supports the notion that disease is not just disease of the brain. Then we found that the cause of this impairment is elevation of type 1 interferon, which all of us produce when we are encountering viral infection.”</p>
<p>Type I interferon signaling is an essential part of the body’s natural protective immune response. However, when this response becomes chronic, Schwartz explained, its protective effects can turn harmful—transforming a friend into a foe.</p>
<p>“If you have an inflammation in the body, the immune system produces type 1 interferon to dampen inflammation. But if this type 1 interferon is chronically produced, it becomes an enemy of the bone marrow. And we found the same situation in mice and in humans,” Schwartz explained.</p>
<h4><strong>Earlier research</strong></h4>
<p>That finding was in sync with <a href="https://pmc.ncbi.nlm.nih.gov/articles/pmid/25147279/" target="_blank" rel="noopener">earlier research published in <em>Science</em></a> by Schwartz and colleagues in 2014, showing that aging of the brain in both humans and mice was also associated with type 1 interferon.</p>
<p>“And in a way, it’s also linking what we know, that viral infection can catalyze Alzheimer’s disease … It is more likely the uncontrolled immune response to the virus, rather than the virus itself, that causes the damage.” Schwartz added. “It’s not just a disease of the brain. The brain affects the immune system, the immune system is impaired, and they enter into a vicious cycle.”</p>
<p>Last month, ImmunoBrain named to its board Francis Collins, MD, PhD, whose tenure as NIH director from 2009 to 2021 is the longest of any presidentially appointed director of the agency.</p>
<p>“One of my jobs as NIH director was to look across the entire field of biomedical research and say, ‘Are there some really serious gaps here that need to be filled?’ Alzheimer’s disease, because it is so common and so devastating for individuals and their families, obviously has been a high priority for research, particularly through the National Institute on Aging,” Collins recalled. “But despite massive efforts, it didn’t feel like we were necessarily making progress of the groundbreaking type that people were hoping for.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>The Cleveland Clinic’s reported 99.6% failure rate showed little improvement in a <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9198803/" target="_blank" rel="noopener">2022 study</a> that found a 98% failure rate among candidates studied in Phase II and III trials. And a study by Michael A.S. Guth, PhD, JD, <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC13532280/" target="_blank" rel="noopener">published in August</a> blamed the high failure rate on “structural and institutional forces that sustained investment in repeatedly ineffective mechanisms of action across 567 Phase II and Phase III Alzheimer’s trials from 2010 to 2026.”</p>
<p>“The 567-trial record constitutes a structural verdict on a model of drug development that was never designed to solve a problem of this complexity,” Guth asserted. “The uniformity of negative results across all mechanism categories—amyloid, tau, neuroinflammation, metabolic, and synaptic—points toward deeper problems of disease definition, intervention timing, and endpoint validity that institutional and financial pressures have prevented the field from confronting.”</p>
<figure aria-describedby="caption-attachment-340729" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-340729" src="https://www.genengnews.com/wp-content/uploads/2026/11/Dr-Francis-Collins-CROP-SQUARE-300x300.jpg" alt="" width="300" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Dr-Francis-Collins-CROP-SQUARE-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Dr-Francis-Collins-CROP-SQUARE-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Dr-Francis-Collins-CROP-SQUARE-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/Dr-Francis-Collins-CROP-SQUARE-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Dr-Francis-Collins-CROP-SQUARE-1536x1536.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/11/Dr-Francis-Collins-CROP-SQUARE.jpg 1836w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Francis Collins, MD, PhD, NIH Director from 2009 to 2021 and Board Member of ImmunoBrain</figcaption></figure>
<p>Recalled Collins: “Most of the efforts I saw happening as NIH director were in terms of developing and testing monoclonal antibodies against amyloid. While they provided some positive signals, they certainly didn’t provide the breakthrough benefit that people had hoped for.”</p>
<p>There must be something more going on here, Collins concluded. Maybe genetic research could provide clues?  Studies of large numbers of affected and unaffected individuals using the GWAS (genome-wide association study) approach have now pointed to more than 100 such signals. The dominant pathway relates to microglia and innate immunity.</p>
<p>Yet the field of Alzheimer’s research has done relatively little to explore that area therapeutically, and remains focused, he said, primarily on amyloid and tau and lipids such as ApoE: “The field seems to be stuck on the amyloid hypothesis, but so far that’s not curing people or significantly preventing progression like we hoped.”</p>
<h4><strong>Milestones and growing pipeline</strong></h4>
<p>Alzheimer’s drug development has achieved several milestones during this decade.</p>
<p>Biogen and Eisai made history in 2021 when the FDA <a href="https://genengnews.com/news/biogen-alzheimers-drug-wins-historic-approval-but-fda-requires-new-trial/?_gl=1*1a12h21*_up*MQ..*_ga*MTI1OTkyNTY2Mi4xNzk0NzY0ODEy*_ga_F1EYPPYL3X*czE3OTQ3NjQ4MTIkbzEkZzAkdDE3OTQ3NjQ4MTIkajYwJGwwJGgxNTYyMTY0MjMw" target="_blank" rel="noopener">approved</a> their <a href="https://genengnews.com/news/fda-seeks-review-of-staff-biogen-talks-leading-to-alzheimers-drug-approval/" target="_blank" rel="noopener">controversial</a> human immunoglobulin gamma 1 (IgG1) monoclonal antibody Aduhelm<sup>®</sup> (aducanumab-avwa) as the first therapy indicated for reducing clinical decline in people with Alzheimer’s disease, and the first therapy to tie improved clinical outcomes to removing amyloid beta. But Aduhelm sales never matched forecasts and failed to the drug failed to obtain coverage from the Centers for Medicare and Medicaid Services (CMS).</p>
<p>In 2024, Biogen halted development and commercialization of Aduhelm in order to shift resources to other Alzheimer’s treatments—a year after the companies’ Leqembi<sup>®</sup> (lecanumab-irmb) became the first disease-modifying therapy to receive full FDA approval for patients with mild cognitive impairment or mild dementia.</p>
<p>The FDA has since approved a weekly subcutaneous maintenance dose last year and a subcutaneous starter dose in July, the latter marketed as Leqembi Iklik. The new subcutaneous doses have propelled Leqembi sales to finally outpacing sales forecasts after a slow start for the drug. During the third quarter, Eisai reported $202 million in global sales, up 67% from $121 million in Q3 2025. That includes $68 million recorded by Biogen in “Alzheimer’s collaboration” revenue—the sum of Biogen’s 50% share of net revenue and cost of sales, including royalties, from its Leqembi collaboration.</p>
<p>Another milestone occurred when Eli Lilly <a href="https://www.genengnews.com/topics/drug-discovery/fda-approves-lillys-amyloid-targeting-kisunla-for-early-alzheimers/" target="_blank" rel="noopener">won FDA approval in 2024 for Kisunla<sup>®</sup> (donanemab-azbt)</a>, a once-monthly injection treatment indicated for adults with early symptomatic Alzheimer’s, including mild cognitive impairment or mild dementia stage of disease with confirmed amyloid pathology. Kisunla was approved as the first amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed.</p>
<p>Among current Alzheimer’s candidates in Phase III development, AriBio on Monday trumpeted data from the Phase III POLARIS-AD trial (NCT05531526) at the 19<sup>th</sup> Clinical Trials on Alzheimer’s Disease (CTAD) conference, being held in Boston through Thursday. The data showed that its once-daily oral small molecule phosphodiesterase-5 (PDE5) inhibitor AR1001 showed statistically significant treatment difference of −0.44 points versus placebo on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at Week 52 (p=0.0266), representing 31% slowing of clinical decline.</p>
<p>But in the trial’s overall 1,535-participant population, the treatment difference vs. placebo was −0.11 points (p=0.4015), which did not reach statistical significance. AriBio said it plans to discuss the results with the FDA before deciding next steps.</p>
<p>AR1001 is among numerous Phase III Alzheimer’s candidates. Two examples:</p>
<ul>
<li>Roche and its Genentech subsidiary anticipate primary completion in February 2028 for the TRONTIER1 (<a href="https://clinicaltrials.gov/study/NCT07169578" target="_blank" rel="noopener">NCT07169578</a>) and TRONTIER2 (<a href="https://clinicaltrials.gov/study/NCT07170150" target="_blank" rel="noopener">NCT07170150</a>) trials for their anti-amyloid monoclonal antibody trontinemab (RO7126209) in 2028. A prevention study, PrevenTRON (<a href="https://clinicaltrials.gov/study/NCT07717411" target="_blank" rel="noopener">NCT07717411</a>), estimates primary data completion in 2032.</li>
<li>Eli Lilly expects releasing data in 2029 from its Phase III TRAILRUNNER-ALZ 3 trial (<a href="https://clinicaltrials.gov/study/NCT06653153" target="_blank" rel="noopener">NCT06653153</a>) assessing its beta-amyloid plaque targeting next-gen antibody remternetug (LY3372993).</li>
</ul>
<h4><strong>‘Pretty excited’</strong></h4>
<p>“The ImmunoBrain approach is, for me, a completely compelling and novel approach. It is built on a sweeping redefinition of what the fundamental problems are with Alzheimer’s disease. It builds on basic science data that implicates the immune system as a major player in progression, and even as a signal for aging itself,” Collins explained. “I am pretty excited about that.”</p>
<p>Collins said his departure from the NIH—a <a href="https://www.genengnews.com/topics/omics/former-nih-director-francis-collins-praises-the-institution-as-he-abruptly-departs-after-three-decades/" target="_blank" rel="noopener">sudden retirement in February 2025</a> after 32 years with the agency—offers him the opportunity to serve on company boards like that of ImmunoBrain.</p>
<p>“The need for progress in Alzheimer’s disease has been compelling to me for years.  In this new life chapter, I wanted to get more engaged to see if I could be helpful in some way. The data that Michal and her lab have generated over 25 years, building this case for a critical role of the immune system, points to a wholly new vision of the pathogenesis of this common and devastating disease.  Now that we see the encouraging result of biomarkers in a Phase Ib trial, published in a highly regarded peer-reviewed journal, it looks like we’re on the right track,” Collins said.</p>
<p>“I am now really excited about seeing this go forward to a Phase IIb trial with a clinical endpoint. The question is: can we show that this intervention changes the course of the illness?” the former NIH director added. “It will take a big push to answer that. It’s going to cost a lot of money. But of all the things I look at right now that are happening in Alzheimer’s, this feels like an exceptionally novel, encouraging, and potentially groundbreaking way to look at the disease in a new way that hasn’t been adequately explored before.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/beyond-amyloid-and-tau-alzheimers-drug-developer-sees-early-clinical-success-for-immunotherapy-based-approach/">Beyond Amyloid and Tau: Alzheimer’s Drug Developer Sees Early Clinical Success for Immunotherapy-Based Approach</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Anders Juul Wins 2027 Transatlantic Alliance Award in Endocrinology</title>
<link>https://edusehat.com/en/anders-juul-wins-2027-transatlantic-alliance-award-in-endocrinology</link>
<guid>https://edusehat.com/en/anders-juul-wins-2027-transatlantic-alliance-award-in-endocrinology</guid>
<description><![CDATA[ The Endocrine Society and the European Society of Endocrinology (ESE) are delighted to announce Professor Anders Juul, MD, PhD, DMSc, as the winner of the 2027 Transatlantic Alliance Award. Juul is professor of pediatric endocrinology at the University of Copenhagen and head of the Department of Growth and Reproduction at Rigshospitalet (Copenhagen University Hospital) in […]
The post Anders Juul Wins 2027 Transatlantic Alliance Award in Endocrinology appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/Anders-portraet-2025a-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 02:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Anders, Juul, Wins, 2027, Transatlantic, Alliance, Award, Endocrinology</media:keywords>
<content:encoded><![CDATA[<p>The Endocrine Society and the European Society of Endocrinology (ESE) are delighted to announce Professor Anders Juul, MD, PhD, DMSc, as the winner of the 2027 Transatlantic Alliance Award. Juul is professor of pediatric endocrinology at the University of Copenhagen and head of the Department of Growth and Reproduction at Rigshospitalet (Copenhagen University Hospital) in […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/anders-juul-wins-2027-transatlantic-alliance-award-in-endocrinology/">Anders Juul Wins 2027 Transatlantic Alliance Award in Endocrinology</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Four Members Authored Sections of the UN Environment Programme/World Health Organization Report</title>
<link>https://edusehat.com/en/four-members-authored-sections-of-the-un-environment-programmeworld-health-organization-report</link>
<guid>https://edusehat.com/en/four-members-authored-sections-of-the-un-environment-programmeworld-health-organization-report</guid>
<description><![CDATA[ Four Endocrine Society experts served as lead section authors of a major new global assessment on endocrine-disrupting chemicals (EDCs) from the United Nations Environment Programme and the World Health Organization. “The State of the Science of Endocrine-disrupting Chemicals 2026 Report” finds strong evidence that exposure to EDCs can cause serious adverse effects in humans and […]
The post Four Members Authored Sections of the UN Environment Programme/World Health Organization Report appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/11.26cover-1-765x1024.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 02:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Four, Members, Authored, Sections, the, Environment, ProgrammeWorld, Health, Organization, Report</media:keywords>
<content:encoded><![CDATA[<p>Four Endocrine Society experts served as lead section authors of a major new global assessment on endocrine-disrupting chemicals (EDCs) from the United Nations Environment Programme and the World Health Organization. “The State of the Science of Endocrine-disrupting Chemicals 2026 Report” finds strong evidence that exposure to EDCs can cause serious adverse effects in humans and […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/four-members-authored-sections-of-the-un-environment-programme-world-health-organization-report/">Four Members Authored Sections of the UN Environment Programme/World Health Organization Report</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Mapping the Hidden Viral Communities of the Human Gut Microbiome</title>
<link>https://edusehat.com/en/mapping-the-hidden-viral-communities-of-the-human-gut-microbiome</link>
<guid>https://edusehat.com/en/mapping-the-hidden-viral-communities-of-the-human-gut-microbiome</guid>
<description><![CDATA[ Researchers identified over 116,000 gut viral groups, revealing previously unknown relationships between viruses, bacteria, and metabolism, with findings offering new insights into gut health and irritable bowel syndrome (IBS).
The post Mapping the Hidden Viral Communities of the Human Gut Microbiome appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/GettyImages-2289175590.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 01:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Mapping, the, Hidden, Viral, Communities, the, Human, Gut, Microbiome</media:keywords>
<content:encoded><![CDATA[<p>When people hear “gut microbiome” their first thought is likely the bacteria living inside our intestines. However, the human gut microbiome is home to a vast and largely unexplored world of viruses, which could determine how the gut ecosystem works.</p>
<p>New research has characterized a largely unexplored community of bacteriophages within the human gut. The findings provide an integrated picture of the gut ecosystem, connecting its viral, bacterial, and metabolic components, which influence health and conditions like IBS.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p> “Our research highlights that to fully understand the gut microbiome and its links to health and disease, we need to look beyond bacteria and consider the viruses that live alongside them,” notes Cristina Menni, PhD, who leads the metabolomics research group at the Department of Twin Research, Ageing and Genomic Epidemiology, King’s College London. “We reveal a fascinating and largely unexplored dimension of the gut microbiome—discovering that viruses are not only closely associated with bacterial communities, but also with the metabolites that connect the microbiome to our health. This opens exciting new avenues for understanding how the gut ecosystem works.”</p>
<p>The study is published in <em>Nature Communications</em> in the paper<em>, “</em><a href="https://www.nature.com/articles/s41467-026-79230-0" target="_blank" rel="noopener">Population-level characterisation of the human gut phageome and its association with microbial metabolites</a>.”</p>
<p>Research into the human gut microbiome has traditionally focused on bacteria, but little is known about its enormous population of viruses, particularly bacteriophages.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>This work identified over 116,000 viral groups in the gut. More than 99% of these had no close match in the largest existing catalogue of gut viruses, highlighting how much of the viral world within the gut remains unexplored. They found that certain viruses were consistently more common alongside particular bacteria, while others tended to be less common.</p>
<p>“Gut viruses are difficult to study, so most of what we found simply isn’t in existing catalogues,” notes Panayiotis Louca, PhD, Research Associate at King’s College London. “What stands out is how closely they track with gut bacteria and with the chemicals those bacteria produce. We can’t yet say whether the viruses are driving that, and testing it is our next step.”</p>
<p>The team used data from over 1,000 TwinsUK participants, the largest UK Twin Registry with data on gut bacteria, health measurements, and diet. By studying twins, the researchers also found that environmental factors play a major role in shaping the gut viral community, while genetics also contributes to certain aspects of viral diversity. Although genetic factors were estimated to explain around 47% of the variation in overall viral diversity, most individual viral populations appeared to be predominantly influenced by environmental factors.</p>
<p>The researchers also identified a small group of viruses carrying genes linked to harmful bacterial behavior. These viruses tended to occur alongside bacteria that can sometimes cause infections and were less commonly found alongside bacteria involved in breaking down dietary fiber.</p>
<p>Differences in the microbiome might influence conditions, such as irritable bowel syndrome (IBS). IBS affects around 10% of the population and can significantly affect quality of life, yet its underlying causes remain poorly understood.</p>
<p>In a second study, published in <em>Gut</em> today, the research team identified 50 gut viral groups associated with IBS, most of which were less abundant in people with the condition. There were also differences in the patterns of relationships between bacteria and viruses, with many viruses infecting bacteria already linked to the condition, suggesting that IBS may involve changes in how the wider gut microbial community is organized, rather than changes in bacteria alone.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The next challenge will be to understand whether these viruses actively influence bacterial metabolism and how their relationships with bacteria change in different states of health and disease. Future studies will investigate whether these findings can help explain individual differences in microbial function and ultimately contribute to more personalized approaches to gut health.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/mapping-the-hidden-viral-communities-of-the-human-gut-microbiome/">Mapping the Hidden Viral Communities of the Human Gut Microbiome</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Three Ontario hospitals unite pathology and radiology to improve cancer care</title>
<link>https://edusehat.com/en/three-ontario-hospitals-unite-pathology-and-radiology-to-improve-cancer-care</link>
<guid>https://edusehat.com/en/three-ontario-hospitals-unite-pathology-and-radiology-to-improve-cancer-care</guid>
<description><![CDATA[ Regional initiative will connect digital pathology and radiology services, supporting more coordinated cancer diagnosis and treatment planning. Three Ontario hospitals are expanding their shared medical imaging platform to include digital pathology, creating new opportunities for collaboration between specialists involved in cancer diagnosis and treatment. Lakeridge Health, Peterborough Regional Health Centre and Scarborough Health Network will […]
The post Three Ontario hospitals unite pathology and radiology to improve cancer care appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/988cba92c4cb1ca1_800x800ar.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 01:45:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Three, Ontario, hospitals, unite, pathology, and, radiology, improve, cancer, care</media:keywords>
<content:encoded><![CDATA[<p><em>Regional initiative will connect digital pathology and radiology services, supporting more coordinated cancer diagnosis and treatment planning.</em></p>
<p>Three Ontario hospitals are expanding their shared medical imaging platform to include digital pathology, creating new opportunities for collaboration between specialists involved in cancer diagnosis and treatment.</p>
<p>Lakeridge Health, Peterborough Regional Health Centre and Scarborough Health Network will introduce digital pathology through Sectra One Cloud, an enterprise imaging platform already supporting radiology services across the ENHANCE Ontario hospital network.</p>
<p>Announced November 17, the agreement represents Sectra’s largest digital pathology implementation in Canada to date.</p>
<p>Together, the three hospitals handle approximately <strong>120,000 pathology cases annually</strong>.</p>
<h2>Connecting diagnostic services</h2>
<p>Traditionally, radiology and pathology information may be managed through separate systems, requiring specialists to access different platforms when reviewing patient cases.</p>
<p>The expanded service will allow pathologists and radiologists to access diagnostic images within a shared environment, supporting multidisciplinary cancer care.</p>
<p>By bringing these specialties together, healthcare teams will be better positioned to review imaging findings alongside tissue-based diagnostic information when discussing treatment options.</p>
<p>The three participating hospitals are also partners in the Central East Regional Cancer Program, hosted by Lakeridge Health.</p>
<h2>Strengthening regional collaboration</h2>
<p>ENHANCE Ontario provides centralized information technology services to seven member hospitals.</p>
<p>Six hospitals previously agreed to consolidate radiology imaging on Sectra One Cloud in 2025, with the service becoming operational in early 2026.</p>
<p>Adding digital pathology builds on that infrastructure, enabling diagnostic information to be shared more effectively across participating organizations.</p>
<p>Peterborough Regional Health Centre also provides pathology services to Campbellford Memorial Hospital, Haliburton Highlands Health Services, Northumberland Hills Hospital and Ross Memorial Hospital.</p>
<p>The initiative is expected to support more flexible case reviews and collaboration between hospital specialists, including opportunities to involve subspecialty expertise when required.</p>
<h2>Supporting the future of cancer diagnostics</h2>
<p>Digital pathology enables specialists to examine high-resolution images of tissue samples electronically rather than relying exclusively on conventional glass slides and microscopes.</p>
<p>The technology can support remote consultations, multidisciplinary case discussions and access to specialized diagnostic expertise.</p>
<p>It also establishes infrastructure that could support future digital diagnostic tools as they become available.</p>
<p>The four-year agreement represents another step toward integrated diagnostic services in Ontario, with the potential to improve coordination between pathology, radiology and cancer care teams.</p>
<p>As Canadian hospitals continue to modernize diagnostic services, shared imaging platforms are becoming an increasingly important part of efforts to improve collaboration and support timely clinical decisions.</p>
<p>The post <a href="https://www.hospitalnews.com/three-ontario-hospitals-unite-pathology-and-radiology-to-improve-cancer-care/">Three Ontario hospitals unite pathology and radiology to improve cancer care</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Black Friday Savings are Here!</title>
<link>https://edusehat.com/en/black-friday-savings-are-here</link>
<guid>https://edusehat.com/en/black-friday-savings-are-here</guid>
<description><![CDATA[ The post Black Friday Savings are Here! appeared first on BoardVitals Blog. ]]></description>
<enclosure url="https://blog.boardvitals.com/wp-content/uploads/2022/11/boardvitals-black-friday-1024x538.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 01:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Black, Friday, Savings, are, Here</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">Black Friday is here! For a limited time only, BoardVitals is offering our biggest discounts of the season. </p>



<p class="wp-block-paragraph"><span>Whether you’re preparing for a <a href="https://www.boardvitals.com/medical-board-reviews">board exam</a>, <a href="https://www.boardvitals.com/moc-recertification-exams-prep">MOC exam</a>, or looking to fulfill your </span><a href="https://www.boardvitals.com/cme"><span>continuing medical education requirements</span></a><span> for 2026, BoardVitals has the right product for every specialty.</span></p>



<p class="wp-block-paragraph">From now through December 1, 2026, save 25% sitewide with code CYBER.</p>



<p class="wp-block-paragraph"><span>Don’t miss out – this sale won’t last long. Happy Holidays from the BoardVitals team! </span><span><br></span></p>
<p>The post <a href="https://www.boardvitals.com/blog/black-friday/">Black Friday Savings are Here!</a> appeared first on <a href="https://www.boardvitals.com/blog">BoardVitals Blog</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Designing Beyond Crisis: Why Behavioral Health Environments Must Move Upstream to Support Prevention, Dignity and Healing, Part I</title>
<link>https://edusehat.com/en/designing-beyond-crisis-why-behavioral-health-environments-must-move-upstream-to-support-prevention-dignity-and-healing-part-i</link>
<guid>https://edusehat.com/en/designing-beyond-crisis-why-behavioral-health-environments-must-move-upstream-to-support-prevention-dignity-and-healing-part-i</guid>
<description><![CDATA[ Serving 10,000 people in the first five years, Minnesota’s first EmPATH at Fairview offers a calm, living room-inspired space with comfortable recliners and natural light. | Photo Credit (all): Farm Kid Studios, courtesy of BWBR By Melanie Baumhover, AIA, LEED AP  Behavioral health systems across the United States are under unprecedented strain. Rising demand, workforce...
The post Designing Beyond Crisis: Why Behavioral Health Environments Must Move Upstream to Support Prevention, Dignity and Healing, Part I appeared first on HCO News.
The post Designing Beyond Crisis: Why Behavioral Health Environments Must Move Upstream to Support Prevention, Dignity and Healing, Part I appeared first on HCO News. ]]></description>
<enclosure url="https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.DesignBeyondCrisis.1-1-600x400.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 22:55:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Designing, Beyond, Crisis:, Why, Behavioral, Health, Environments, Must, Move, Upstream, Support, Prevention, Dignity, and, Healing, Part</media:keywords>
<content:encoded><![CDATA[<h5><span class="TextRun SCXW91015173 BCX0" lang="EN-US" xml:lang="EN-US" data-contrast="none"><span class="NormalTextRun SCXW91015173 BCX0">Serving </span><span class="NormalTextRun SCXW91015173 BCX0">10,000 people</span><span class="NormalTextRun SCXW91015173 BCX0"> in the first five years, Minnesota’s first </span><span class="NormalTextRun SpellingErrorV2Themed SCXW91015173 BCX0">EmPATH</span><span class="NormalTextRun SCXW91015173 BCX0"> at Fairview offers a calm, living room-inspired space with comfortable recliners and natural light. | Photo Credit (all): Farm Kid Studios, courtesy of BWBR</span></span></h5>
<p><i><span data-contrast="none">By Melanie Baumhover, AIA, LEED AP</span></i><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="none">Behavioral health systems across the United States are under unprecedented strain. Rising demand, workforce shortages, limited treatment capacity and fragmented care networks have created a system that often responds only after people reach a crisis. Emergency departments have become default entry points for patients with behavioral health needs, while outpatient programs, community services and long-term support struggle to keep pace.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="none">The challenge is not simply a shortage of beds. It is a shortage of connected systems that help people before their conditions escalate.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="none">As healthcare organizations look for solutions, many are expanding inpatient capacity. That investment is important </span><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12610395/" target="_blank" rel="noopener"><span data-contrast="none">as studies show greater than 60% of American’s live in areas with shortages of psychiatric beds</span></a><span data-contrast="none">, but it is only one piece of a much larger puzzle. Long-term progress will depend on strengthening the full continuum of care and creating environments that actively support healing rather than merely containing risk.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="none">Behavioral health extends beyond treatment to include prevention, belonging and the preservation of human dignity.</span><span data-ccp-props="{}"> </span></p>
<h2><b><span data-contrast="none">Looking Beyond the Crisis</span></b><span data-ccp-props="{}"> </span></h2>
<p><span data-contrast="none">For decades, behavioral health systems have been organized around intervention. Funding models, reimbursement structures and available resources often favor crisis stabilization and inpatient care over lower-acuity services that could prevent emergencies from occurring in the first place. As a result, many patients and families struggle to find help until their needs become urgent.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="none">Healthcare leaders are embracing a “no wrong door” approach, </span><a href="https://escholarship.org/uc/item/4kz5387b" target="_blank" rel="noopener"><span data-contrast="none">and many organizations are finding success with behavioral health crisis care models, such as EmPATH</span></a><span data-contrast="none">, that offer alternatives to traditional emergency departments. While these models have gained significant momentum and are highly valued by patients and families, they are not feasible in every case. We have found they can be particularly challenging in smaller or rural markets where patient volumes or staffing may not support them.</span><span data-ccp-props="{}"> </span></p>
<figure aria-describedby="caption-attachment-52479" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-52479" src="https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.DesignBeyondCrisis.1-2-300x200.jpg" alt="interior of Pine Rest Pediatric Center of Behavioral Health" width="300" height="200" srcset="https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.DesignBeyondCrisis.1-2-300x200.jpg 300w, https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.DesignBeyondCrisis.1-2-1024x683.jpg 1024w, https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.DesignBeyondCrisis.1-2-768x512.jpg 768w, https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.DesignBeyondCrisis.1-2-820x545.jpg 820w, https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.DesignBeyondCrisis.1-2-600x400.jpg 600w, https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.DesignBeyondCrisis.1-2.jpg 1500w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">The Pine Rest Pediatric Center of Behavioral Health features a “no wrong door” approach, consolidated facilities to support patients and families and elements of joy through nature-inspired and kid-friendly design.</figcaption></figure>
<p><span data-contrast="none">One recently completed project, the Pine Rest Pediatric Center of Behavioral Health, demonstrates how the “no wrong door” approach can work when the conditions are right. Families enter through a behavioral health urgent care program rather than a traditional emergency department, where clinical teams assess needs and connect patients with the most appropriate level of care, whether inpatient treatment, outpatient services or community-based resources. Although this model may not be practical in every setting, it illustrates how stronger front-end access points can improve the patient experience and reduce reliance on emergency departments.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="none">The same facility recognizes that healing extends beyond the individual patient. Family support spaces give parents and caregivers a place to rest, work, gather information and regroup during a difficult time.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="none">Successful systems do not simply ask where patients receive care. They ask how communities can support people before they reach the point of desperation. Creating those systems requires organizations to work together in new ways.</span><span data-ccp-props="{}"> </span></p>
<h2><b><span data-contrast="none">Collaboration Is Becoming a Clinical Strategy</span></b><span data-ccp-props="{}"> </span></h2>
<p><span data-contrast="none">Behavioral health challenges rarely fit neatly within the boundaries of a single institution. Hospitals, county governments, state agencies, community organizations, schools and healthcare providers all serve pieces of the same population, yet many operate independently. In underserved and rural communities, those gaps can leave emergency departments caring for patients who would be better served elsewhere.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="none">In some communities, healthcare systems and public agencies have pooled funding and resources to develop regional behavioral health centers that no single organization could have created on its own. Rather than competing for limited resources, they are building partnerships designed to close service gaps and coordinate care across the continuum. Shared investments and stronger partnerships can create more resilient systems while improving outcomes.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="none">Policy reform also plays a role. Regulations that limit treatment capacity or create unnecessary barriers to care can unintentionally prolong suffering. Expanding access will require not only better facilities, but also greater flexibility in how communities deliver services. Even with stronger systems in place, outdated environments can still work against modern models of care.</span><span data-ccp-props="{}"> </span></p>
<p><i><span data-contrast="none">Melanie Baumhover AIA, LEED AP, is a Principal with BWBR.  </span></i><span data-ccp-props="{}"> </span></p>
<p><i><span data-contrast="none">Part II of this article will discuss how buildings designed around dignity, access to nature and connection can aid in treatment.</span></i></p>
<p>The post <a rel="nofollow" href="https://hconews.com/2026/11/17/designing-beyond-crisis-why-behavioral-health-environments-must-move-upstream-to-support-prevention-dignity-and-healing-part-i/">Designing Beyond Crisis: Why Behavioral Health Environments Must Move Upstream to Support Prevention, Dignity and Healing, Part I</a> appeared first on <a rel="nofollow" href="https://hconews.com/">HCO News</a>.</p>
<p>The post <a href="https://hconews.com/2026/11/17/designing-beyond-crisis-why-behavioral-health-environments-must-move-upstream-to-support-prevention-dignity-and-healing-part-i/">Designing Beyond Crisis: Why Behavioral Health Environments Must Move Upstream to Support Prevention, Dignity and Healing, Part I</a> appeared first on <a href="https://hconews.com/">HCO News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Canada moves closer to expanded access to multiple myeloma treatment</title>
<link>https://edusehat.com/en/canada-moves-closer-to-expanded-access-to-multiple-myeloma-treatment</link>
<guid>https://edusehat.com/en/canada-moves-closer-to-expanded-access-to-multiple-myeloma-treatment</guid>
<description><![CDATA[ New national agreement could expand public funding for a four-drug treatment shown to delay disease progression in eligible patients. A new agreement between Sanofi and the pan-Canadian Pharmaceutical Alliance (pCPA) could expand publicly funded treatment options for Canadians diagnosed with multiple myeloma, a cancer affecting plasma cells in the bone marrow. Announced November 16, the […]
The post Canada moves closer to expanded access to multiple myeloma treatment appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_529109200.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 22:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Canada, moves, closer, expanded, access, multiple, myeloma, treatment</media:keywords>
<content:encoded><![CDATA[<p data-pm-slice="1 1 []"><em>New national agreement could expand public funding for a four-drug treatment shown to delay disease progression in eligible patients.</em></p>
<p>A new agreement between Sanofi and the pan-Canadian Pharmaceutical Alliance (pCPA) could expand publicly funded treatment options for Canadians diagnosed with multiple myeloma, a cancer affecting plasma cells in the bone marrow.</p>
<p>Announced November 16, the agreement covers Sarclisa (isatuximab), used in combination with bortezomib, lenalidomide and dexamethasone. The four-drug regimen is intended for adults with newly diagnosed multiple myeloma who are not eligible for stem cell transplantation.</p>
<p>The agreement represents an important step toward expanded access, although provincial and territorial drug plans must still make their funding decisions.</p>
<h2>Clinical evidence supports treatment approach</h2>
<p>The agreement follows results from the international Phase 3 IMROZ clinical trial involving 446 patients.</p>
<p>At approximately five years of follow-up, <strong>63.2 per cent of patients receiving the four-drug combination remained free from disease progression</strong>, compared with 45.2 per cent receiving the standard three-drug treatment.</p>
<p>The addition of isatuximab was associated with a <strong>40 per cent relative reduction in the risk of disease progression or death</strong> during the study period.</p>
<p>Published in <em>The New England Journal of Medicine</em>, the findings also demonstrated higher rates of complete response and deeper disease control. However, a statistically significant overall survival benefit had not been established at the time of the reported analysis. Treatment also requires monitoring for adverse effects, including infections.</p>
<h2>An important milestone for Canadian cancer care</h2>
<p>Multiple myeloma is Canada’s second most common blood cancer, with approximately 4,400 new cases expected in 2026.</p>
<p>The disease affects the bone marrow and can cause anemia, bone damage, kidney complications and increased susceptibility to infections.</p>
<p>For patients who are ineligible for transplantation because of age or other medical considerations, maintaining disease control is a major treatment objective.</p>
<p>Canada’s Drug Agency recommended public reimbursement of the isatuximab combination in June 2025, subject to specified conditions. The new pCPA agreement brings the treatment another step closer to public coverage.</p>
<h2>Next steps toward public coverage</h2>
<p>While the national agreement establishes negotiated terms, it does not automatically provide public reimbursement. Individual provinces and territories must complete their own funding and listing decisions.</p>
<p>For hospital oncology teams and pharmacists, the agreement could eventually provide another first-line treatment option for eligible patients.</p>
<p>The development highlights the importance of translating promising clinical research into accessible cancer treatments while ensuring appropriate funding and patient care across Canada’s healthcare system.</p>
<p>The post <a href="https://www.hospitalnews.com/canada-moves-closer-to-expanded-access-to-multiple-myeloma-treatment/">Canada moves closer to expanded access to multiple myeloma treatment</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PLI 2.0: Can MSMEs catch up?</title>
<link>https://edusehat.com/en/pli-20-can-msmes-catch-up</link>
<guid>https://edusehat.com/en/pli-20-can-msmes-catch-up</guid>
<description><![CDATA[ 
Is the scheme translating manufacturing investments into global competitiveness for pharma MSMEs, or does the next phase need to do more to bridge the gap between smaller manufacturers and larger exporters?
The post PLI 2.0: Can MSMEs catch up? appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17190138/EP_DigiMag_CS_Nov_2026_Ft_Image_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 22:00:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PLI, 2.0:, Can, MSMEs, catch, up</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17190138/EP_DigiMag_CS_Nov_2026_Ft_Image_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17190138/EP_DigiMag_CS_Nov_2026_Ft_Image_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17190138/EP_DigiMag_CS_Nov_2026_Ft_Image_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>India’s Pharmaceutical Production Linked Incentive (PLI) scheme was designed to strengthen domestic manufacturing, attract investment and encourage companies to move towards higher-value pharmaceutical products. With a financial outlay of ₹15,000 crore, the scheme has supported manufacturing expansion across the pharmaceutical sector. But for India’s micro, small and medium enterprises (MSMEs), the bigger question is whether this investment is translating into stronger technological capabilities, improved quality systems and sustainable export growth.</span></p>
<p><span>The challenge is significant. Smaller pharma manufacturers play an important role in domestic medicine supplies, contract manufacturing, employment generation and exports. However, they often operate with tighter budgets and have less access to capital, research facilities, advanced technology and specialist regulatory expertise. This can make it difficult for them to compete with larger Indian companies and international manufacturers.</span></p>
<p><span>The government has recognised these differences in the design of the pharma PLI scheme. Of the 55 applicants selected, 20 are MSMEs, accommodated within Group C, which has a dedicated framework for smaller manufacturers.</span></p>
<p><span>However, industry representatives argue that a separate framework is only the starting point. Smaller companies need practical access to finance, technology, quality expertise and export markets if they are to turn manufacturing investment into sustainable growth.</span></p>
<p><span>Ajay Singh Dassundi, Secretary of the MP Small and Medium Drugs Manufacturers Association, says the scheme is a positive initiative, but its benefits have been relatively limited for MSMEs compared with companies that have the financial strength and scale to make large investments.</span></p>
<p><span>“The next phase must ensure that the benefits of the PLI Scheme reach not only large manufacturers but also the thousands of MSMEs that form the backbone of India’s pharmaceutical industry,” he says.</span></p>
<p><b>Investment, but for whom? </b></p>
<p><span>A government update published in January 2026, reporting progress through September 2025, said the scheme had attracted investment of ₹40,294 crore against a targeted ₹17,275 crore. Cumulative sales stood at ₹3,08,408.60 crore, including exports of ₹1,98,509.49 crore. The government also reported an employment generation of approximately 97,000 people, including contractual and apprentice workers.</span></p>
<p><span>For Namit Joshi, Chairman of Pharmexcil, this distinction is crucial.</span></p>
<p><span>“The impact of the scheme is more clearly visible in terms of manufacturing investment and capacity creation,” he says, cautioning that it would be premature to attribute a substantial expansion in international market presence specifically to PLI-supported MSMEs without more detailed data.</span></p>
<p><span>“Investment and production figures indicate whether manufacturing activity is expanding. They do not necessarily show whether smaller companies are adopting advanced technologies, entering new markets or developing higher-value products. The next phase should focus on helping these businesses convert manufacturing capabilities into tangible and sustained export outcomes,” Joshi adds.</span></p>
<p><span>“The ultimate test is whether MSMEs are becoming stronger businesses that can invest independently, create employment, develop better products, enter new markets, and sustain their growth beyond the incentive period,” he says.</span></p>
<p><b>Group C: A step towards a level playing field?</b></p>
<p><span>The creation of a dedicated MSME framework within Group C reflects the government’s recognition that smaller manufacturers cannot always meet investment requirements designed for large pharmaceutical companies.</span></p>
<p><span>The changes introduced to the scheme’s operational guidelines in 2024 were intended to improve access for MSMEs. However, a separate eligibility framework does not automatically eliminate the financial and administrative challenges of participating.</span></p>
<p><span>Suveer Shrivastava, former Chief Quality Officer and Sr VP of Regulatory Affairs, believes the changes are a positive step, but their effectiveness will depend on implementation.</span></p>
<p><span>“Introducing a separate framework is only the first step. Its effectiveness will depend on how well the provisions are implemented and monitored,” he says.</span></p>
<p><span>Shrivastava argues that eligible MSMEs need to receive the intended benefits without being disadvantaged by limited financial resources or administrative capabilities. He also recommends greater involvement of independent third-party experts and relevant State Food and Drug Administrations in monitoring implementation and assessing outcomes.</span></p>
<p><span>For Bhavin Mehta, Whole-Time Director of Kilitch Drugs (India) and Vice-Chairman of Pharmexcil, accessibility and predictability are equally important.</span></p>
<p><span>“Clear eligibility criteria, streamlined documentation, transparent evaluation processes and predictable timelines for incentive disbursement can help businesses plan investments with greater confidence,” he says.</span></p>
<p><span>Dassundi welcomes the separate framework but stresses that the eligibility criteria, investment thresholds, incentive structure and application procedures must be realistic for smaller manufacturers.</span></p>
<p><span>“For a small or medium manufacturer, even an investment of a few crores can be a significant financial commitment,” he says.</span></p>
<p><span>Mehta says the framework should be practical enough for eligible companies to navigate while retaining performance requirements to ensure that public incentives support genuine manufacturing activity. He recommends clear guidance, efficient administration and regular assessment of the capabilities being developed.</span></p>
<p><span>As Dassundi puts it, “MSMEs do not necessarily need protection from competition; they need the financial and technological capabilities to compete.”</span></p>
<p><img decoding="async" class="wp-image-460184 alignleft" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185704/EP_DigiMag_CS_nov_2026_Inside_Image_01_1000-209x300.jpg" alt="" width="360" height="517" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185704/EP_DigiMag_CS_nov_2026_Inside_Image_01_1000-209x300.jpg 209w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185704/EP_DigiMag_CS_nov_2026_Inside_Image_01_1000-714x1024.jpg 714w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185704/EP_DigiMag_CS_nov_2026_Inside_Image_01_1000-768x1101.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185704/EP_DigiMag_CS_nov_2026_Inside_Image_01_1000.jpg 1000w" sizes="(max-width: 360px) 100vw, 360px"><b>The cost of catching up</b></p>
<p><span>One of the biggest challenges facing pharma MSMEs is the cost of upgrading existing manufacturing facilities.</span></p>
<p><span>Pharma production requires qualified equipment, validated processes, reliable documentation and effective quality management systems. Companies seeking to supply regulated international markets must also meet the requirements of their target markets, which can require substantial investment in infrastructure, technology and personnel.</span></p>
<p><span>For a smaller manufacturer, such investment can be difficult to finance alongside day-to-day operations.</span></p>
<p><span>Narotam Juneja, Technical Advisor at Uniserum Lifesciences, identifies infrastructure modernisation as a major concern, particularly for businesses operating older facilities. Upgrading these plants to meet current good manufacturing practice (GMP) requirements and international regulatory standards requires substantial capital expenditure.</span></p>
<p><span>Companies unable to make the necessary changes may face regulatory action, including suspension of operations or cancellation of manufacturing licences. The result is a difficult investment choice: a company may need to spend heavily simply to maintain its existing manufacturing capabilities, leaving fewer resources for new products, automation or export expansion.</span></p>
<p><span>Dassundi identifies high investment requirements as one of the principal barriers to MSME participation. Modern pharmaceutical manufacturing requires spending on plant and machinery, laboratory facilities, automation, validation and regulatory compliance. At the same time, high borrowing costs, collateral requirements, working-capital constraints and long payment cycles can prevent smaller companies from financing expansion.</span></p>
<p><span>The challenges extend beyond capital expenditure. Smaller businesses may not have dedicated teams to manage incentive applications, compliance requirements and the documentation needed for international markets. Many also lack the resources to establish sophisticated research facilities or maintain specialised research and development teams.</span></p>
<p><span>Juneja also points to the challenges MSMEs face when attempting to enter higher-value product categories.</span></p>
<p><span>Developing complex generics and other advanced pharmaceutical products can require significant expenditure on research and development, specialised equipment, regulatory documentation and compliance. For a smaller company, the financial risk can be considerably higher than for a large manufacturer with a broader portfolio and greater access to capital.</span></p>
<p><span>Research-driven MSMEs may also face a first-mover disadvantage when they have to finance trials and generate regulatory data before commercial returns become visible. These challenges suggest that the next phase of PLI should pay closer attention to the quality and purpose of investment, rather than focusing primarily on the amount committed.</span></p>
<p><span>Shrivastava argues that MSMEs need to move beyond a narrow focus on production volumes and short-term financial performance.</span></p>
<p><span>“Investments in quality, innovation, and digitalisation are not merely compliance expenses; they are essential to sustainable growth and access to higher-value markets,” he says.</span></p>
<p><span>He identifies automation, data integrity, robust quality management and workforce development as important areas for improvement. For smaller manufacturers, however, adopting these capabilities may require technical expertise that is difficult to recruit or retain in-house.</span></p>
<p><span>Shrivastava therefore proposes a structured technical guidance and mentoring programme involving experienced pharmaceutical professionals. Such a programme could help companies identify compliance gaps, develop improvement plans and implement stronger manufacturing and quality systems. Shared technical infrastructure, specialised training and independent assessments could also help smaller businesses address capability gaps without bearing the full cost of developing every resource independently.</span></p>
<p><span>Dassundi recommends a more integrated support system. Alongside incentives, he wants government-backed credit guarantees, interest subvention and concessional financing to help MSMEs fund technology upgrades and capacity expansion.</span></p>
<p><span>He also proposes affordable research and development facilities, common testing laboratories, pilot-scale manufacturing facilities and technology-transfer programmes developed in collaboration with government-supported research institutions.</span></p>
<p><img decoding="async" class="wp-image-460185 alignright" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185708/EP_DigiMag_CS_nov_2026_Inside_Image_02_1000-300x288.jpg" alt="" width="463" height="444" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185708/EP_DigiMag_CS_nov_2026_Inside_Image_02_1000-300x288.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185708/EP_DigiMag_CS_nov_2026_Inside_Image_02_1000-768x737.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185708/EP_DigiMag_CS_nov_2026_Inside_Image_02_1000.jpg 1000w" sizes="(max-width: 463px) 100vw, 463px"></p>
<p><b>Opportunity comes with risk</b></p>
<p><span>Moving towards higher-value pharma products is a key ambition of the PLI scheme. It offers Indian manufacturers an opportunity to develop specialised capabilities and compete in segments where technology, quality and regulatory expertise are critical.</span></p>
<p><span>For MSMEs, however, entering these categories is not simply a matter of installing new equipment.</span></p>
<p><span>Depending on the product, companies may need to invest in research, process development, specialised analytical capabilities, validation, regulatory submissions and skilled personnel. These investments can take time to generate revenue and may not always lead to commercial success.</span></p>
<p><span>Juneja argues that smaller manufacturers can be structurally disadvantaged because of the higher capital and compliance costs associated with developing complex products. He also highlights the difficulty of funding innovation when the first applicant bears substantial costs for trials and regulatory data, while subsequent entrants may have access to less expensive regulatory pathways.</span></p>
<p><span>The next phase of PLI could address this challenge by encouraging product diversification alongside targeted technical and regulatory support.</span></p>
<p><span>Mehta believes the long-term impact of PLI will depend on whether manufacturing investment translates into sustainable business growth.</span></p>
<p><span>“In segments such as sterile injectables, this requires more than production capacity alone,” he says. “Companies must build strong process validation systems, maintain consistent product quality, secure regulatory approvals and establish dependable supply relationships with customers across markets.”</span></p>
<p><span>Dassundi also believes that the next phase should support MSMEs in moving up the value chain, developing differentiated products and building sustainable export businesses rather than simply increasing the volume of conventional products.</span></p>
<p><img loading="lazy" decoding="async" class="wp-image-460186 aligncenter" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185917/EP_DigiMag_CS_nov_2026_Inside_Image_03_1000-300x241.jpg" alt="" width="662" height="532" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185917/EP_DigiMag_CS_nov_2026_Inside_Image_03_1000-300x241.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185917/EP_DigiMag_CS_nov_2026_Inside_Image_03_1000-768x617.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185917/EP_DigiMag_CS_nov_2026_Inside_Image_03_1000.jpg 1000w" sizes="auto, (max-width: 662px) 100vw, 662px"></p>
<p><b>Can MSMEs crack exports? </b></p>
<p><span>India’s pharma industry has an established presence in international markets. According to the Ministry of Commerce and Industry, pharmaceutical exports reached approximately $30.47 billion in FY2024-25, registering growth of 9.4 per cent over the previous financial year.</span></p>
<p><span>For smaller manufacturers, moving from domestic production to international sales requires capabilities that extend beyond manufacturing.</span></p>
<p><span>Companies must secure the necessary product registrations, meet the regulatory requirements of their target markets, maintain consistent quality and supply, and develop distribution or customer relationships overseas. These activities require time, money and specialised knowledge. Smaller exporters may struggle to absorb the costs, particularly when they have a limited product portfolio.</span></p>
<p><span>Joshi says Indian MSMEs must compete on cost, quality, consistency of supply and compliance with international regulatory standards.</span></p>
<p><span>“Manufacturing competitiveness and export competitiveness are not the same,” he emphasises.</span></p>
<p><span>He points to the advantages enjoyed by countries such as China in manufacturing scale, supply-chain integration and access to raw materials. For smaller Indian companies, technology upgrades, regulatory approvals, product development and market entry can create substantial additional costs.</span></p>
<p><span>“Tariff and non-tariff barriers add to the challenge. Changes in regulatory requirements, product-registration procedures and market-access conditions can make exporting more expensive and time-consuming for businesses with limited resources. Larger exporters are generally better placed to spread these costs across multiple products and markets. MSMEs often have less flexibility,” Joshi says.</span></p>
<p><span>“Manufacturing investment and production remain important, but they should be viewed as intermediate outcomes rather than the ultimate measure of success,” he says.</span></p>
<p><span>Joshi recommends greater emphasis on incremental exports, international product registrations, technology adoption, productivity improvements and the development of higher-value products. These measures, he argues, would help determine whether PLI-supported businesses are developing the capabilities required to compete internationally, rather than simply expanding domestic capacity.</span></p>
<p><span>Dassundi agrees that MSMEs can play a larger role in pharmaceutical exports, but says growth requires regulatory preparedness, consistent quality, product development, international marketing and reliable working capital.</span></p>
<p><span>“The next phase should help MSMEs move up the value chain, develop differentiated products, and build sustainable export businesses rather than simply increase the volume of conventional products,” he says.</span></p>
<p><span>Mehta also stresses the need to align manufacturing investments with international demand. Companies must understand the requirements of their intended markets and ensure that their products, facilities and supply systems can meet them.</span></p>
<p><b>Quality is non-negotiable </b></p>
<p><span>For pharma companies, quality is central to market access and commercial credibility.</span></p>
<p><span>Manufacturers must maintain effective quality management systems, validate processes, qualify equipment, preserve reliable records and ensure that employees are trained to perform their responsibilities. For MSMEs seeking to enter highly regulated markets, gaps in documentation, data integrity or process control can become significant obstacles.</span></p>
<p><span>Shrivastava believes one of the biggest challenges is translating regulatory requirements into consistent practice on the manufacturing floor. He identifies quality management, documentation, data integrity, process validation, equipment qualification, automation and workforce competence as areas requiring attention.</span></p>
<p><span>Dassundi proposes common skill-development centres that provide practical training in advanced manufacturing, automation, quality assurance, regulatory compliance and modern pharmaceutical technologies. Such shared facilities could give smaller businesses access to training and expertise that may be difficult to fund independently.</span></p>
<p><span>Mehta similarly argues that modern infrastructure, automation and robust quality systems are essential if Indian manufacturers are to remain competitive. For MSMEs, quality improvements should not be treated as a one-time exercise. They must become part of everyday manufacturing practice.</span></p>
<p><b>Is the framework tilted towards larger companies?</b></p>
<p><span>A central concern among industry representatives is whether companies with greater financial strength are better positioned to benefit from incentive-linked manufacturing schemes.</span></p>
<p><span>Large pharma companies generally have more resources to fund capital expenditure, recruit specialist teams and manage complex documentation and reporting requirements. Smaller businesses may struggle to make substantial upfront investments while continuing to finance routine operations.</span></p>
<p><span>Juneja argues that qualifying thresholds and investment commitments need to reflect the practical realities of smaller manufacturers. MSMEs may find it difficult to fund eligible greenfield projects or major expansions and wait through prolonged gestation periods before the investment begins generating returns.</span></p>
<p><span>His recommendation is for a more MSME-focused assessment of eligibility thresholds, qualifying investments and performance measures. The objective should be to help smaller companies upgrade existing facilities, meet higher regulatory standards, invest in product development and progressively increase the share of higher-value products in their portfolios.</span></p>
<p><span>Shrivastava also believes that the framework should focus more on technical capability, quality performance and the potential for sustainable growth.</span></p>
<p><span>“The objective should not be to give smaller companies an advantage simply because they are small, but to ensure that technically capable MSMEs are not excluded because they lack the financial and administrative resources of larger competitors,” he says.</span></p>
<p><span>Dassundi calls for a dedicated MSME incentive window with a defined allocation and proportionate eligibility criteria. He believes this would help ensure that eligible smaller manufacturers receive meaningful access to the scheme.</span></p>
<p><span>He also recommends simpler application procedures, predictable incentive payments and dedicated facilitation mechanisms. For MSMEs with limited administrative resources, a complicated application process can become an additional barrier even when a project is technically suitable.</span></p>
<p><span>The policy challenge is to balance accountability for public spending with a process that smaller companies can realistically navigate.</span></p>
<p><img loading="lazy" decoding="async" class="wp-image-460187 aligncenter" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185921/EP_DigiMag_CS_nov_2026_Inside_Image_04_1000-300x120.jpg" alt="" width="698" height="279" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185921/EP_DigiMag_CS_nov_2026_Inside_Image_04_1000-300x120.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185921/EP_DigiMag_CS_nov_2026_Inside_Image_04_1000-768x307.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185921/EP_DigiMag_CS_nov_2026_Inside_Image_04_1000.jpg 1000w" sizes="auto, (max-width: 698px) 100vw, 698px"></p>
<p><b>What should PLI 2.0 measure?</b></p>
<p><span>Joshi wants the next phase to place greater emphasis on incremental exports, international registrations, technology adoption, productivity and higher-value products.</span></p>
<p><span>Mehta highlights sustainable business growth, modern manufacturing infrastructure, quality systems and export readiness. Juneja stresses the need to address investment barriers, facility upgrades and the costs of developing higher-value products.</span></p>
<p><span>Shrivastava calls for a robust and transparent mechanism to measure the scheme’s actual benefits, including independent impact assessments comparing companies’ performance before and after receiving support.</span></p>
<p><span>Dassundi recommends evaluating a wider range of outcomes, including investment in infrastructure, incremental production, technology adoption, research and development, API manufacturing, exports, employment, quality and compliance, financial sustainability, MSME participation and movement towards higher-value products.</span></p>
<p><span>“I would particularly emphasise incremental exports, technology adoption, innovation, and sustainable financial performance,” he says.</span></p>
<p><span>Together, these recommendations suggest several areas for a more comprehensive assessment such as : </span></p>
<p><b>Investment and production</b><span>: Has the scheme encouraged additional manufacturing investment and eligible sales, and how much of that activity is attributable to participating MSMEs?</span></p>
<p><b>Technology and productivity</b><span>: Have MSMEs adopted modern equipment, automation or digital systems, and have these changes improved manufacturing performance?</span></p>
<p><b>Quality and compliance</b><span>: Have companies strengthened quality management, data integrity, process validation and workforce competence?</span></p>
<p><b>Product development and exports</b><span>: Have manufacturers introduced higher-value products, obtained international registrations, entered new markets or expanded repeat export business?</span></p>
<p><b>Financial sustainability</b><span>: Can businesses maintain upgraded facilities, finance future investment and compete commercially after the incentive period ends?</span></p>
<p><b>MSME participation and employment</b><span>: How many eligible MSMEs have received incentives and completed their projects? Have the investments generated skilled jobs and improved workforce capabilities?</span></p>
<p><b>Beyond incentives  </b></p>
<p><span>India’s pharma PLI scheme has helped stimulate manufacturing investment and create opportunities for domestic producers. Its dedicated framework for MSMEs recognises that smaller companies face different financial and operational constraints from larger manufacturers.</span></p>
<p><span>But the industry’s challenge now is to translate participation into capability.</span></p>
<p><span>Dassundi’s recommendations include government-backed credit guarantees, interest subvention and concessional financing; affordable research and development facilities; common testing and skill-development centres; technology upgrades; support for API manufacturing; and stronger export facilitation. He also calls for closer collaboration between MSMEs and research institutions to make advanced technologies and product-development capabilities more accessible.</span></p>
<p><span>For Joshi, the priority is to link manufacturing support more closely with export readiness and measurable improvements in competitiveness. Mehta similarly sees the opportunity in helping manufacturers develop more specialised capabilities and participate more meaningfully in global value chains.</span></p>
<p><span>For Shrivastava, the ultimate measure is whether the scheme creates stronger, more innovative and quality-driven businesses. Juneja’s recommendations underline the need to ensure that investment requirements and eligibility criteria reflect the circumstances of smaller manufacturers.</span></p>
<p><span>As Dassundi concludes, the objective should not simply be to create a few large manufacturing capacities. It should be to build a broad base of technologically advanced, financially sustainable and globally competitive Indian pharma manufacturers.</span></p>
<p>The post <a href="https://www.expresspharma.in/pli-2-0-can-msmes-catch-up/">PLI 2.0: Can MSMEs catch up?</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Community Dental Services are submitting wait list data, but where is the result?</title>
<link>https://edusehat.com/en/community-dental-services-are-submitting-wait-list-data-but-where-is-the-result</link>
<guid>https://edusehat.com/en/community-dental-services-are-submitting-wait-list-data-but-where-is-the-result</guid>
<description><![CDATA[ Over a year since NHS England began collecting wait list data from Community Dental Services (CDS), publication of the results has been delayed as it ‘continues to work through data quality issues’. NHS England first began collecting data on a national level in August 2025 in order to measure the extent of the access crisis… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/wait_list.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 19:00:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Community, Dental, Services, are, submitting, wait, list, data, but, where, the, result</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Over a year since NHS England began collecting wait list data from Community Dental Services (CDS), publication of the results has been delayed as it ‘continues to work through data quality issues’.</strong></p>



<p>NHS England first <a href="https://dentistry.co.uk/2025/08/07/waiting-times-for-community-dentistry-are-unacceptable-says-expert/">began collecting data on a national level in August 2025</a> in order to measure the extent of the access crisis facing Community Dental Services. According to the <em>Health Service Journal</em>, publication of the outcome of this data collection, which had originally been slated to begin from October 2025, has now been delayed to early 2027.</p>



<p>The British Dental Association (BDA) has previously estimated that both children and vulnerable adult patients could be facing year-long waits for treatment through CDS. The association hoped the reporting would provide clarity around the scale of this access crisis and provide evidence for the need for further evidence.</p>



<p>Giten Dabhi, chair of the England Community Dental Service Committee, said: ‘I know from the frontline that waiting times in the CDS are unacceptable, and this new data will turn that anecdote into fact.</p>



<p>‘This is one of the key areas that we outlined in our call to action to make sure community dentistry is finally given the priority it deserves. We asked for greater waiting list transparency on access to CDS services and that the data is published in the same format as other NHS services.’</p>



<h2 class="wp-block-heading">What is causing the delays?</h2>



<p>Several factors could be affecting the quality of the CDS wait list data collected, including consistency of data returned. NHS England said integrated care boards (ICBs), providers and managed clinical networks are reviewing local data, improving return consistency and addressing ‘quality concerns’.</p>



<p>National guidance recommends that providers measure wait times from receipt of referral to the start of first definitive treatment. NHS England has set an action to encourage ICBs to work with providers to ensure these start/stop rules are applied correctly. Different interpretations of the wait time period could affect the comparability of data submitted.</p>



<p>A GRIFT report on CDS services also acknowledged the lack of a consistent CDS data set. It called for better governance and standardisation of performance reporting across services.</p>



<p>Its analysis of initial questionnaire responses found a discrepancy between the number of patients in total wait list data and the number of patients in waiting lists broken down by length of wait. The report said this is a cause for concern as it suggests there are some patients who are waiting for treatment but have not been added to a tracked list.</p>



<p><a href="https://sso.dentistry.co.uk/">Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</a></p>]]> </content:encoded>
</item>

<item>
<title>From lab to market: Bridging India’s pharma innovation gap </title>
<link>https://edusehat.com/en/from-lab-to-market-bridging-indias-pharma-innovation-gap</link>
<guid>https://edusehat.com/en/from-lab-to-market-bridging-indias-pharma-innovation-gap</guid>
<description><![CDATA[ 
Dr Richa Dayaramani, Scientist Grade F at NIPER Ahmedabad, discusses the gaps between academia and industry, the challenges of scaling research, and how stronger industry partnerships, quality systems and commercialisation pathways can help India build its innovation ecosystem, in an interview with Lakshmipriya Nair 
The post From lab to market: Bridging India’s pharma innovation gap  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17133159/Dr-Richa-Dayaramani.jpg.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 18:20:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, lab, market:, Bridging, India’s, pharma, innovation, gap </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17133159/Dr-Richa-Dayaramani.jpg.jpeg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17133159/Dr-Richa-Dayaramani.jpg.jpeg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17133159/Dr-Richa-Dayaramani.jpg-300x160.jpeg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><strong>India wants to move from being a global generics hub to a leader in pharma innovation. From your vantage point in academia, what is holding that transition back? </strong></p>
<p><span>With our vast talent base and premium manufacturing capacities we can accelerate our path to global leadership by actively tackling four foundational pillars in research and academia. A seamless, trust-based collaboration between industry and research institutions to fund frontier innovation, synergistic partnerships where industry confidently backs early-stage, visionary academic research is the need of hour. Simultaneously, academia can evolve its metrics of successmoving beyond publication counts to celebrate tangible outcomes like patent commercialisation, technology transfers, and thriving spin-offs that reward every contributor. We have a tremendous opportunity to scale up our R&D investment from the current 0.6 per cent to 0.7 per cent of GDP toward the two to three per cent benchmarks seen in nations like the US, China, and South Korea. Our academic laboratories are equipped with world-class capabilities in pharma, biopharma and molecular research. The next vital step is to surround our scientists with a robust translational ecosystem while simultaneously empowering senior faculty and institutional leaders to embrace this new era of commercialisation using industry norms of quality management system establishment in research laboratories. By pairing this infrastructure with more agile, modern regulatory pathways for advanced therapeutics and biologics, we can match the velocity of global innovation hubs like Boston or San Francisco and dramatically shorten the journey from the lab bench to the patient. This will develop a mature network of scientist-entrepreneurs who can successfully take a novel drug to market and can mentor the next generation so as to channel this immense intellectual capital into our own rapidly evolving innovation ecosystem. </span></p>
<p><strong>Pharma companies are under pressure to innovate faster and manage R&D costs. What can academia realistically do to help industry solve problems faster? </strong></p>
<p><span>To accelerate innovation and curb soaring R&D costs, academia and pharma companies can function as dynamic, agile research partners. Although, in realistic terms, universities may not keep up the pace and match the scale of industrial development, but they can fundamentally derisk the early stages of discovery. Embracing a culture of open innovation and pre competitive consortia academia can work with multiple pharma companies on shared, nonproprietary challenges. Implementing clear, prenegotiated, and industryfriendly licensing frameworks allows companies to quickly pick up academic discoveries and move them into pipeline development without legal friction. Replacing a publication first mindset to a patent and proof of concept validation will reduce target failure rates. </span></p>
<p><span>Instead of every pharma company investing in niche, expensive equipment universities can operate as centralised, state-of-the-art “core facilities” providing rapid testing services to industry partners at a fraction of the cost. Academia can co-design curriculum and PhD programs with industry inputs. Creating seamless pathways for academic faculty to spend sabbaticals inside pharma R&D labs-and vice versa-ensures that academic research stays aligned with actual, practical commercial bottlenecks. </span></p>
<p><strong>There is still a gap between a promising academic discovery and something industry can develop at scale. Where does that gap usually emerge? </strong></p>
<p><span>academic discovery and a scalable industrial product is known as the “Translational Valley of Death”. For instance, an academic lab might successfully synthesise milligrams of a complex molecule using expensive, lowyield, or highly toxic chemical steps while the industry requirement is in kilograms or tons produced via highly reproducible, safe, and costeffective processes. A compound that successfully kills cancer cells in a petri dish frequently fails inside a complex living organism. Academic researchers in India often lack the specialised resources to test Pharmacokinetics and Pharmacodynamics.</span></p>
<p><span>Industry requires data generated under strict Good Laboratory Practice (GLP) standards. When pharma companies attempt to replicate breakthrough academic findings under rigid industrial conditions, a startlingly high percentage of the results cannot be reproduced, killing the project instantly. While academia rewards novelty industry rewards clinical utility for a drug that is safer, cheaper, or easier to administer than what is already on the pharmacy shelf. The IP blind spot further gaps this valley because academic scientists often publish their findings too early and without an airtight patent protection, industry cannot justify spending hundreds of millions of dollars to bring the discovery to market. </span></p>
<p><strong>NIPER was created to strengthen specialised pharma education and research. How do you see its role evolving as the industry moves towards complex generics, biologics, advanced drug delivery and other newer technologies? </strong></p>
<p><span>As the Indian pharma sector transitions from volume-based traditional generics to a highvalue, innovation-driven biopharma powerhouse, the National Institute of Pharmaceutical Education and Research (NIPER) is shifting its core focus toward specialised R&D, advanced therapeutics, and industry collaboration. With national initiatives like the `10,000-crore biopharma manufacturing push, NIPER campuses are expanding infrastructure for noncommunicable diseases (such as cancer, diabetes, and autoimmune disorders) to build domestic expertise in biologics. Responding to specialised industrial demand, NIPER has integrated dedicated streams and testing infrastructure for medical device engineering and regulatory compliance. Moving away from routine manufacturing support, NIPER acts as an incubation and grantsupport hub for faculty-led and student-led deep-tech pharma startups. To catalyse the transition of NIPERs and the wider ecosystem toward complex therapeutics, the Government of India has deployed a multi-layered support architecture. These flagship initiatives directly bridge the gap between academic research, regulatory compliance, and commercial market entry. With a `5,000 crore total financial outlay, the PRIP scheme managed by the Department of Pharmaceuticals is the cornerstone of India’s innovation push. Allocates `700 crores to establish dedicated Centres of Excellence (CoEs) across all seven NIPER campuses. Each campus focuses on a specialised domain. A newly formed institutional bridge led by the Secretary of the Department of Pharmaceuticals. It brings together all major industry associations and NIPER heads to ensure academic curricula and research directly match the industry’s shift toward biologics and advanced engineering. By intentionally linking financial backing, infrastructure building, regulatory handholding, and intellectual property support, the framework targets the historical bottlenecks that previously slowed down Indian pharma innovation. </span></p>
<p><strong>Coming to your own work, what is the specific problem your research is trying to solve, and why does it matter to patients or the pharma industry today? </strong></p>
<p><span>My research focuses directly on bridging the gap between advanced formulation science and real-world execution, specifically within injectables and specialty formulations. In the current landscape, formulation is becoming the primary value driver and differentiator. My work focuses on designing future formulations that support selfadministration through wearable injectors, pre-filled syringes, and next-generation delivery systems. My dual role as a Scientist & Project Manager for the PRIP Centre of Excellence (CoE) in Medical Devices, combined with my credentials as an ISO 13485 Lead Assessor, allows me to bridge the critical gap between academic prototyping and global commercialisation under the guidance and visionary leadership at institute level. The primary reason many innovative medical device prototypes fail to reach the market is a lack of compliance with international Quality Management Systems (QMS). As a certified ISO 13485 Lead Assessor, I embed global compliance requirements directly into our scientific workflows. Establishing a Quality Management System (QMS) and securing NABL accreditation (ISO/IEC 17025:2017) for specialised testing laboratories is the definitive step in transforming a research laboratory into a globally recognised conformity assessment body. At the PRIP Centre of Excellence in Medical Devices at NIPER Ahmedabad, we executed this exact roadmap. The NIPER-A Testing Laboratory (NTL) achieved national milestone status as India’s first NABL-accredited facility for specialised mechanical orthopedic implant testing. I spearhead the establishment of our Quality Management System (QMS) and direct the end-to-end documentation pipeline required to secure NABL accreditations across our specialised mechanical, analytical, and biocompatibility testing laboratories. Ultimately, our goal at the CoE is to prove that when academic research embraces a rigorous, regulatoryfirst approach, it creates intellectual property that the pharma and MedTech industries can rapidly scale, commercialise, and bring directly to patients. </span></p>
<p><strong>When research moves closer to commercialisation, what tends to become the biggest challenge-funding, scale-up, validation, regulatory requirements or finding the right industry partner? </strong></p>
<p><span>Moving research out of the lab and into the market-a risky transition known as the “Valley of Death”-presents a complex web of hurdles rather than a single isolated challenge. While the exact bottleneck varies by sector, deep-tech and science-based innovations are primarily choked by regulatory compliance and validation, where navigating rigorous FDA/EMA approvals and multi-phase clinical trials requires years of effort and carries the highest risk of failure. Furthermore, companies must conquer industrial scale-up by translating delicate lab protocols into stable, costeffective manufacturing processes, while simultaneously achieving market validation by securing channel partners or enterprise customers to prove the scientific breakthrough solves a genuine, profitable problem. </span></p>
<p><span>If you could change one thing about the way Indian academia and pharma industry work together today, what would you change-and what difference could that make to India’s innovation ambitions? </span></p>
<p><span>Evolve a co-owned, codelivered, and co-evaluated translation models by expanding the policies that allow academic researchers and professors to actively spin off or lead commercial ventures while retaining institutional ties. By implementing flexible, tiered licensing agreements allows industry partners to take commercial risks while ensuring universities receive fair royalties and empowering scientists to transition smoothly between teaching and industry roles creates a dynamic exchange of ideas and upskilling. </span></p>
<p> </p>
<p><em><strong>lakshmipriya.nair@expressindia.com </strong></em></p>
<p><em><strong>laxmipriyanair@gmail.com </strong></em></p>
<p>The post <a href="https://www.expresspharma.in/from-lab-to-market-bridging-indias-pharma-innovation-gap/">From lab to market: Bridging India’s pharma innovation gap </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>When patient burden becomes a regulatory risk </title>
<link>https://edusehat.com/en/when-patient-burden-becomes-a-regulatory-risk</link>
<guid>https://edusehat.com/en/when-patient-burden-becomes-a-regulatory-risk</guid>
<description><![CDATA[ 
Ian Fisher, Head of Development Analytics at IQVIA, explains how assessing patient burden early in clinical trial design can help sponsors improve trial execution, preserve data quality and support regulatory decisions 
The post When patient burden becomes a regulatory risk  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17162759/Ian-Fisher-Head-of-Development-Analytics-at-IQVIA.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 18:20:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>When, patient, burden, becomes, regulatory, risk </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17162759/Ian-Fisher-Head-of-Development-Analytics-at-IQVIA.jpeg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17162759/Ian-Fisher-Head-of-Development-Analytics-at-IQVIA.jpeg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17162759/Ian-Fisher-Head-of-Development-Analytics-at-IQVIA-300x160.jpeg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>New drug development typically takes close to nine years from first inhuman trials to regulatory approval, although with pre-clinical development and launch activities, the total time commitment is around 15 years. The pressure of this lengthy and costly development process on drug developers is compounded by increasingly segmented disease populations and increased challenge in proving value over existing therapies, which potentially reduces success rates. </span></p>
<p><span>To alleviate these pressures, sponsors often seek to highly tune their trial designs and protocols to the precise needs and expectations of regulators, with approval the ultimate goal. Though meant to maximise probability of success, unnecessarily complex trial designs can easily work against that goal. Frequent visits, invasive procedures and specialised assessments can make sustained participation difficult, even when patients have a strong motivation to participate. </span></p>
<p><span>When these demands begin to complicate trial execution, increased patient burden becomes more than a recruitment concern; it can undermine the robustness and quality of registrational trial data and evidence. By evaluating and enhancing the relationship between patient burden, enrollment and retention, trial timelines and trial execution, sponsors can secure and retain patients and preserve the critical data they generate for regulatory review. </span></p>
<p><strong>Patient burden does not end with recruitment </strong></p>
<p><span>Before clinical trials begin, the trial and protocol design phases determine the procedures patients will undertake and the number of patients needed for success. These procedures can impact a patient’s willingness to participate. Sponsors can improve successful trial execution by rethinking how they approach recruitment. </span></p>
<p><span>Rather than viewing recruitment as the primary issue, sponsors can consider and plan for recruitment challenges that could be warning signs that assumptions made during protocol development might not reflect operational reality. A trial that looks feasible on paper can become difficult to execute once patients and sites encounter its real-world demands. </span></p>
<p><span>When those challenges emerge after enrollment commences, sponsors often need to revisit assumptions built into the original protocol. Changes intended to make the study more executable can create new detrimental consequences of their own. Late amendments introduce delays, inflate costs and risk the interpretability of the data. At that point, unnecessary patient burden becomes a threat to the study and therapy success. </span></p>
<p><strong>When operational burden weakens the evidence </strong></p>
<p><span>The purpose of a clinical trial is to generate compelling and robust evidence of clinical benefit and safety. To ensure that clinical trials remain centered on that goal, sponsors should establish checkpoints within the design phase to prevent overly burdensome protocol changes during the trial. These checkpoints include: </span></p>
<p><span>Endpoints: Sponsors must liaise with regulators, patients, physicians and payers to establish lean yet truly meaningful, validated and reliable endpoints needed to evaluate benefit and safety. Any ambiguity in potential acceptance or utility of the trial’s endpoints represents a clear risk to success. </span></p>
<p><span>Patient populations: A realistic and appropriately generalisable set of eligibility criteria, which evolves over the duration of the development program, is a critical component of program and trial design. Confidence that the right information has been gathered from the right patients over time is key to regulatory and commercial success. </span></p>
<p><span>Follow-ups: Clinical trials need sufficient timelines to capture initial results and time to conduct follow-up assessments of the durability of clinical benefits. Information capturing periods that end prematurely may fail to establish the benefits of a slow-acting or disease-modifying therapy.</span></p>
<p><span>If operational difficulties prevent critical design choices from being executed as intended, sponsors risk reaching the end of the study without the clarity needed to make confident development and regulatory decisions. </span></p>
<p><strong>Missing or difficult-to-interpret data can change what the study can prove </strong></p>
<p><span>Even when a trial is completed, the collected data must still support a clear assessment of clinical benefits. Sponsors should plan for gaps in data and stress-test alternative interpretations so that conclusions hold up under different assumptions. This becomes important when challenges in participation or protocol modifications affect how a study unfolds, since late changes can compromise data interpretability.</span></p>
<p><span>Therefore, clear, robust evidence that persuades regulators that the therapy under study delivers meaningful clinical benefits. </span></p>
<p><strong>Assess burden before the protocol is locked </strong></p>
<p><span>Trial sponsors can resolve protocol problems by critically evaluating patient burden and willingness to participate early enough for that information to influence trial design. These feasibility assessments can incorporate valuable input from patients, trial sites and clinical operations teams. Sponsors can strengthen those insights by integrating evidence from comparable trials and actual site performance. </span></p>
<p><span>Historical data can also reveal feasibility risks that may not have been apparent through expert-led protocol planning. These perspectives can clarify whether eligibility criteria, endpoints and assessment schedules may create practical challenges before those requirements are finalised. </span></p>
<p><span>Sponsors who delay this evaluation until enrollment begins risk discovering feasibility problems when changes are far more disruptive. Technology is also providing clinical teams with new opportunities to identify risks faster, with advanced analytics increasingly supporting trial planning and even helping predict patient dropouts. Evaluating participation and retention risks before finalising protocols allows feasibility to shape the study rather than forcing the study to react to feasibility later. </span></p>
<p><strong>Patient-centered design should also be decision centered </strong></p>
<p><span>Addressing the overall patient burden before adopting protocols is only one piece of building a trial that can support a regulatory decision. Sponsors must also establish early alignment with regulators on what the study must demonstrate. All regulatory feedback must be leveraged to guide the evidence-generation strategy before a program advances to a point where significant changes become difficult and costly. If sponsors gain little insight from that feedback, they’ll fail to translate regulatory concerns into the study itself. </span></p>
<p><span>Sponsors must also consider that scientific validity alone does not guarantee that a study will answer the questions regulators need resolved. Even the most meaningful results may miss the mark if the trial was not designed around the regulatory conclusions it ultimately set out to support. Sponsors should prioritise maintaining ongoing regulatory engagement throughout development, particularly when existing guidance does not adequately address the circumstances of a program. This line of communication and alignment helps ensure that evidence generated can answer any regulatory questions the study was designed to resolve. </span></p>
<p><strong>Patient experience should shape trial design </strong></p>
<p><span>Patient experience should influence more than how sponsors can recruit and retain patients. </span></p>
<p><span>It should be the source of truth as to whether the study can realistically be accomplished to the degree that sponsors require. Bringing this viewpoint into the development stage gives sponsors an opportunity to pinpoint assumptions that may not withstand the realities of participation. </span></p>
<p><span>From there, patient centeredness becomes part of building a clinical trial that can generate meaningful evidence for regulators to confidently evaluate a therapy. </span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/when-patient-burden-becomes-a-regulatory-risk/">When patient burden becomes a regulatory risk </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond expiry dates: Building a more transparent and traceable medicine supply chain </title>
<link>https://edusehat.com/en/beyond-expiry-dates-building-a-more-transparent-and-traceable-medicine-supply-chain</link>
<guid>https://edusehat.com/en/beyond-expiry-dates-building-a-more-transparent-and-traceable-medicine-supply-chain</guid>
<description><![CDATA[ 
Devashish Singh, Co-founder and CEO of MrMed, highlights how end-to-end medicine traceability can strengthen supply-chain accountability, improve medicine safety and ensure critical medicines can be tracked from manufacturer to patient 
The post Beyond expiry dates: Building a more transparent and traceable medicine supply chain  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17163154/Devashish-Singh.jpg.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 18:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, expiry, dates:, Building, more, transparent, and, traceable, medicine, supply, chain </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17163154/Devashish-Singh.jpg.jpeg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17163154/Devashish-Singh.jpg.jpeg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17163154/Devashish-Singh.jpg-300x160.jpeg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>A medicine does not become a patient-safety risk only when it crosses its expiry date. The risk can begin much earlier, when its source cannot be verified, when a batch cannot be traced, when storage conditions are unknown, or when a product recalled by the manufacturer cannot be reliably located across the supply chain. </span></p>
<p><span>India has made significant progress in putting systems in place to address some of these challenges. QR and barcode based identification have been part of the regulatory framework for several years, and the government has recently expanded the traceability framework to cover critical categories including anti-cancer medicines, vaccines and antimicrobials. Under the amended framework, these products will carry QR or barcodes containing key information such as product identification, manufacturer, batch number, manufacturing and expiry dates, and licensing details. </span></p>
<p><span>The next challenge is not creating more traceability infrastructure. It is ensuring that the information captured at the manufacturing stage remains usable and verifiable all the way to the point where a medicine reaches a patient. </span></p>
<p><span>That distinction matters. A medicine may pass through manufacturers, distributors, warehouses, pharmacies and hospitals before it is finally dispensed. At each stage, its identity, batch, expiry, storage conditions and ownership can potentially become less visible. When that happens, even a well-regulated product can become difficult to track when something goes wrong. </span></p>
<p><span>For ordinary medicines, this can lead to avoidable wastage, stock-outs or inefficient inventory management. For oncology, biologics, transplant and rare-disease therapies, the consequences can be considerably more serious. India has the technology to track medicines. The open question is whether the industry can make traceability a continuous responsibility, from manufacturer to patient, rather than a set of checkpoints along the way. </span></p>
<p><strong>Where batch-level tracking breaks down </strong></p>
<p><span>Most pharmacies, hospitals and distributors record a purchase and a sale. Far fewer consistently capture the batch number and expiry date at both ends of that transaction, and fewer still reconcile the two.</span></p>
<p><span>A medicine is a traceable unit with a specific manufacturing history, shelf life and chain of custody, not just a product. Once batch identity is lost at any point, everything downstream becomes harder to verify. A recall cannot be executed with precision, nearexpiry stock cannot be proactively moved or removed, and a suspicious pack becomes difficult to distinguish from a genuine one. </span></p>
<p><span>Strengthening this does not necessarily require another layer of complexity. It requires making existing practices non-negotiable. </span></p>
<p><span>Batch number and expiry should be captured when goods are received rather than reconstructed later from invoices. Inventory should follow a strict first-expiry-first-out principle, with systems preventing a dispense that violates it rather than merely flagging the issue afterwards. Physical stock should be reconciled against digital records at defined intervals, and discrepancies should trigger investigation. </span></p>
<p><span>Procurement is equally important. Pharmacies and hospitals should source medicines only from manufacturers or authorised distributors, with invoices and batch details that can be traced back through the supply chain. </span></p>
<p><span>For hospitals, this discipline needs to extend beyond the central pharmacy. Ward-level inventories, emergency stocks and crash carts also need the same level of visibility, because a medicine that is correctly tracked in a warehouse can still become a patient-safety risk if its expiry is not monitored once it reaches the point of care. </span></p>
<p><strong>Authenticity is only one part of the equation </strong></p>
<p><span>Traceability is often discussed in the context of counterfeit medicines, but authenticity is only one part of the problem. A medicine can be genuine when it leaves the manufacturer and still become unsuitable for use if it is improperly stored, mishandled or allowed to cross its expiry date. </span></p>
<p><span>This is particularly important for temperature-sensitive therapies. A product that has been exposed to conditions outside its prescribed cold chain may look no different from a properly stored product. The packaging does not necessarily tell the patient what happened to the medicine between manufacturing and dispensing. </span></p>
<p><span>That is why end-to-end traceability needs to include more than a batch number. Where storage conditions are critical, temperature and handling records should also form part of the chain of custody and be available when required. </span></p>
<p><span>For the patient, the question should ultimately be simple. Can the authenticity, provenance, storage history and expiry status of a critical medicine be established with confidence? Today, that answer is not always yes. </span></p>
<p><strong>Why expiry management matters even more for super-specialty medicines </strong></p>
<p><span>Expiry management becomes particularly consequential when dealing with super-specialty and life-saving therapies. </span></p>
<p><span>Oncology medicines, biologics, transplant therapies and rare-disease treatments can be extremely expensive, temperature-sensitive and clinically critical. They are also often prescribed as part of tightly sequenced treatment regimens where delays or interruptions can have serious consequences. </span></p>
<p><span>For these medicines, the issue is not simply financial wastage. A medicine nearing expiry may technically remain within its labelled shelf life, but that does not necessarily make it appropriate for every patient or treatment schedule. A patient beginning a long term therapy should not be handed stock with an impractically short remaining shelf life. </span></p>
<p><span>The industry needs to move from asking whether a medicine is expired to asking whether it is fit, authentic, properly stored and appropriate for the intended treatment window. </span></p>
<p><span>This is where minimum remaining-shelf-life thresholds can play a role, particularly for high-value and critical therapies. Cold-chain compliance should also be demonstrable rather than assumed simply because a shipment arrived cold. </span></p>
<p><span>For patients and caregivers, these may appear to be backend supply-chain issues. In reality, they directly influence treatment continuity and patient safety.</span></p>
<p><strong>The gaps in the current medicine supply chain </strong></p>
<p><span>Three gaps require particular attention. </span></p>
<p><span>The first is reverse logistics. Medicines move down the supply chain with relatively detailed documentation, but expired, damaged and returned stock can move back with considerably less visibility. That creates an opportunity for diversion, repackaging and reentry into the legitimate market. The answer is to treat reverse logistics with the same seriousness as forward distribution. Every returned or expired batch should have a documented status, location and final disposition. </span></p>
<p><span>The second is the last mile. Unlicensed sellers, unverified online listings and retailers sourcing from unknown channels create points in the system where the provenance of medicines becomes difficult to establish. Stronger procurement controls and more frequent verification are required at these points. </span></p>
<p><span>The third is fragmented use of traceability infrastructure. India is now expanding QR-based traceability to more critical medicine categories, but the value of such infrastructure will ultimately depend on how consistently the information is accessed and acted upon across the supply chain. A traceability system that records information but does not use it to make decisions is only partially solving the problem. </span></p>
<p><strong>What pharmacies, hospitals and distributors can do </strong></p>
<p><span>The industry does not need to wait for every regulatory requirement to take effect. </span></p>
<p><span>Pharmacies can strengthen batch-level inventory by recording batch and expiry information at inward and dispensing stages, implementing first-expiry-first-out systems and conducting regular physical reconciliation. Distributors can improve visibility by maintaining batchlevel records through both forward and reverse logistics, ensuring that returned or damaged stock is appropriately quarantined and disposed of, and limiting procurement to verified channels. Hospitals can extend these practices into wards, emergency departments and other locations where medicines may be stored outside the central pharmacy. </span></p>
<p><span>For critical therapies, the ability to establish not only where a product came from but also how it was stored can be particularly important. These are operational changes, but they can have a direct impact on patient safety. </span></p>
<p><strong>What regulators can do next </strong></p>
<p><span>The recent expansion of QRbased traceability is an important step. The government has now brought vaccines, antimicrobials, anti-cancer medicines and specified narcotic and psychotropic drugs under the expanded framework, with phased implementation timelines beginning in 2027. </span></p>
<p><span>The next step is ensuring that this infrastructure creates an actionable, connected system rather than another compliance requirement. </span></p>
<p><span>First, QR-based traceability should progressively cover more medicines, with priority given to high-value, temperature-sensitive and clinically critical therapies. </span></p>
<p><span>Second, verification should happen at meaningful points in the supply chain. Pharmacies, hospitals and other licensed dispensing points should be encouraged, and for higher-risk categories, potentially required, to scan and verify medicines before dispensing. A code that exists on a package but is never checked provides limited protection. </span></p>
<p><span>Third, India needs a more centralised and real-time recall mechanism. When a particular batch is found to be defective, spurious or unsafe, information should reach licensed pharmacies, hospitals and distributors quickly and in a standardised format. Batch level alerts can help reduce the dependence on information moving manually through multiple layers of the supply chain.</span></p>
<p><span>Fourth, the disposal loop needs to be closed. Expired medicines should move through authorised disposal channels, with destruction or disposal documented against the original batch. This matters because expired and returned stock can otherwise become a source of material for fraudulent repackaging. </span></p>
<p><span>Finally, enforcement needs to focus on vulnerable points in the chain. Warehouses, distribution facilities and other high-risk nodes need appropriate licensing checks, audit mechanisms and inspection frequency. The objective should not only be to identify violations after they occur, but to make diversion and reentry increasingly difficult.</span></p>
<p><strong>From compliance to accountability </strong></p>
<p><span>None of these interventions depends on technology that does not yet exist. The infrastructure for barcoding, digital inventory management, batchlevel tracking and QR-based verification is already available, and its regulatory scope is expanding.</span></p>
<p><span>The larger shift required is operational. The industry needs to treat batch and expiry information as a living part of a medicine’s identity, not data recorded once and forgotten. Pharmacies need to verify what they receive, hospitals need visibility beyond their central stores, and distributors need stronger controls over forward and reverse movement. Manufacturers need greater visibility into where products ultimately travel, and regulators need systems that connect these individual points into a more coherent chain. </span></p>
<p><span>Medicine safety is not determined only at the point of manufacture. It is protected, or compromised, at every handover that follows. </span></p>
<p><span>The goal should be bigger than preventing the sale of expired medicine. It should be a supply chain where every critical medicine can be authenticated, its batch and expiry can be verified, its handling can be traced, and its movement can be accounted for from manufacturer to patient. That is the level of transparency and accountability that patient safety demands. </span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/beyond-expiry-dates-building-a-more-transparent-and-traceable-medicine-supply-chain/">Beyond expiry dates: Building a more transparent and traceable medicine supply chain </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From making vaccines to inventing them: India’s next challenge </title>
<link>https://edusehat.com/en/from-making-vaccines-to-inventing-them-indias-next-challenge</link>
<guid>https://edusehat.com/en/from-making-vaccines-to-inventing-them-indias-next-challenge</guid>
<description><![CDATA[ 
Ajay Mahipal, Co-Founder and General Partner, HealthKois, examines what it will take to bridge this gap, from patient capital and industry-academia collaboration to regulatory predictability, and build a globally competitive vaccine discovery ecosystem 
The post From making vaccines to inventing them: India’s next challenge  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17163612/Ajay-Mahipal.jpg.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 18:20:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, making, vaccines, inventing, them:, India’s, next, challenge </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17163612/Ajay-Mahipal.jpg.jpeg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17163612/Ajay-Mahipal.jpg.jpeg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17163612/Ajay-Mahipal.jpg-300x160.jpeg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>When a country accounts for 60 per cent of the world’s vaccine production, the statistic is usually interpreted as an indication of manufacturing scale. But there is another way to look at it. This scale represents decades of scientific knowledge, development expertise, specialised infrastructure, regulatory experience, and an understanding of how vaccines move from laboratories to large-scale delivery. </span></p>
<p><span>That makes India’s position in global vaccines more than a manufacturing achievement, representing an ecosystem built around one of the most complex areas of healthcare. The question now is how far that ecosystem can extend upstream, towards the discovery and development of the next generation of vaccines. </span></p>
<p><span>This requires recongising that the manufacturing capabilities can create a strong foundation for scientific origination, while also creating the conditions for capital to participate much earlier in the value chain. </span></p>
<p><strong>The advantage of an ecosystem built around vaccines </strong></p>
<p><span>Vaccine discovery does not happen in isolation. It depends on a network of scientific research, clinical development, regulatory expertise, manufacturing capabilities, and an understanding of population-level healthcare needs. India’s experience across these areas gives it a distinctive base for exploring the next phase of vaccine innovation.</span></p>
<p><span>There are already indications of a broader shift in Indian life sciences. Over the past decade, the country has witnessed significant growth on many fronts, including its innovation pipeline, biotech ecosystem, and patent activity. Alongside this, Indian corporations and institutes have witnessed the emergence of novel therapeutic assets. </span></p>
<p><span>For vaccines specifically, this evolution is important because the distance between discovery and scale can be shorter when capabilities across the value chain exist within the same ecosystem. Scientific ideas can be developed with a clearer understanding of manufacturability, cost, access, and eventual deployment. These considerations are important for vaccines, where global impact depends as much on reach as scientific efficacy. </span></p>
<p><span>It also changes the economics of innovation. When research, development, manufacturing and distribution capabilities are closer together, companies can potentially move from scientific validation to commercial scale with fewer structural gaps. That can make the ecosystem more efficient at converting scientific opportunity into economic and societal value. </span></p>
<p><strong>Moving further upstream </strong></p>
<p><span>The next opportunity, therefore, may lie in moving further upstream without moving away from the strengths India has already developed. </span></p>
<p><span>Discovery requires a different investment horizon from manufacturing. Early scientific programs can take years to demonstrate proof of concept, Many will not progress to a market-ready product. This makes patient capital important, alongside investors and institutions that understand scientific risk and can support companies through long development cycles. </span></p>
<p><span>It also calls for a different approach to risk. Not every discovery program will lead to a successful vaccine. Early-stage investments come with inherent uncertainty and long timelines, making predictable short-term returns an unrealistic expectation. A stronger ecosystem is one where multiple scientific bets can be made, the strongest programmes can attract followon capital, and successful platforms can generate value beyond a single product. </span></p>
<p><span>Similarly, stronger connections between academic research and industry can help promising discoveries move beyond the laboratory, while shared infrastructure will enable early-stage companies to access capabilities that would otherwise be difficult to build independently. India has already begun developing such mechanisms through industry-academia programs, technology transfer networks, and research initiatives spanning the innovation lifecycle. </span></p>
<p><span>For vaccine discovery, these connections become especially valuable. The ability to understand a scientific problem, validate it clinically, develop the technology, and eventually manufacture at scale needs to function as a connected pathway rather than as separate capabilities. The stronger that pathway becomes, the more efficiently capital, talent, and scientific expertise can move through it. </span></p>
<p><span>Regulatory predictability will be equally important as India moves further upstream. For companies investing in novel vaccine platforms and early-stage discovery, the regulatory pathway needs to be sufficiently clear from the outset, with well-defined guidelines, predictable review processes, and reasonable timelines for approvals. The objective should not be to lower the regulatory bar, but to provide greater clarity on the path to meeting it. This is particularly important for emerging technologies, where uncertainty around applicable guidelines or prolonged processing timelines can add significant cost and delay to programmes that are already exposed to scientific risk. </span></p>
<p><span>A more predictable regulatory environment can also improve the ability of investors to underwrite early-stage innovation. When companies and investors have greater visibility on the evidence required, approval pathway and expected timelines, they can make better informed decisions on capital allocation and development milestones. Clear regulatory pathways can therefore become an important part of the innovation infrastructure—helping ensure that scientific breakthroughs are not held back by avoidable uncertainty between discovery, clinical development and eventual deployment. </span></p>
<p><strong>From manufacturing strength to discovery potential </strong></p>
<p><span>The most interesting question for India is not whether it can replicate established global models of pharmaceutical innovation. It is whether it can build on what is already distinctive about its own ecosystem. </span></p>
<p><span>India currently has over 10,000 pharmaceutical manufacturing facilities and more than 650 USFDA-compliant plants, the highest number outside the US. Its combination of scientific talent, development capabilities, cost efficiency, a large and diverse population, and established manufacturing depth creates the possibility of connecting discovery with scale for global relevance. That possibility should also be viewed with a long-term lens. </span></p>
<p><span>The emergence of a discovery ecosystem is unlikely to be defined by one breakthrough or one company. Its real measure will be whether scientific ideas originating in India can move through a consistent pathway from research to global deployment. </span></p>
<p><span>This is where the opportunity becomes larger than any individual vaccine. A mature discovery ecosystem can create intellectual property, technology platforms, specialised talent and companies capable of generating multiple innovations over time. The resulting value is not limited to the product that eventually reaches the market; it also lies in the capabilities and assets created along the journey. India’s vaccine manufacturing leadership has already demonstrated what becomes possible when scientific capability, entrepreneurship, infrastructure, and scale converge around a healthcare need. The next opportunity is to build further on that foundation by creating an environment where scientific risk can be taken earlier, capital can stay invested longer, and successful innovation can scale globally. </span></p>
<p><span>The aspiration, then, need not be to move from “made in India” to “discovered in India” as though one replaces the other. It is to make the two increasingly connected. </span></p>
<p><span>The larger opportunity is to build an ecosystem where India not only participates in the final stages of global vaccine value creation but increasingly captures value from the ideas, technologies, and companies that shape those products from the beginning. </span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/from-making-vaccines-to-inventing-them-indias-next-challenge/">From making vaccines to inventing them: India’s next challenge </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The secret life of a dental nurse</title>
<link>https://edusehat.com/en/the-secret-life-of-a-dental-nurse</link>
<guid>https://edusehat.com/en/the-secret-life-of-a-dental-nurse</guid>
<description><![CDATA[ In the latest episode of Aura Infection Control’s podcast series with Dentistry, a panel of professionals reveals what life in the dental nurse role is really like. The conversation begins with stories submitted by dental nurses, from sedated patients and escaped spiders to flooded practices and awkward conversations. The panel shares its reactions, along with… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/nurse.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 15:25:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, secret, life, dental, nurse</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><div class="wp-block-embed__wrapper">
<div class="video-container"></div>
</div></figure>



<p><strong>In the latest episode of Aura Infection Control’s podcast series with <em>Dentistry</em>, a panel of professionals reveals what life in the dental nurse role is really like.</strong></p>



<p>The conversation begins with stories submitted by dental nurses, from sedated patients and escaped spiders to flooded practices and awkward conversations.</p>



<p>The panel shares its reactions, along with a few embarrassing moments of its own.</p>



<p>One panellist recalls a heavily pregnant receptionist misunderstanding a patient who asked for her number. Another remembers her unborn baby kicking a patient in the head during treatment.</p>



<p>However, the episode is about much more than mishaps. The discussion moves on to the moments that make dental nursing rewarding, including qualifying, supporting nervous patients and helping trainee nurses develop their careers.</p>



<div aria-hidden="true" class="wp-block-spacer"></div>



<div class="wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-16018d1d wp-block-buttons-is-layout-flex">
<div class="wp-block-button has-custom-width wp-block-button__width-50 is-style-fill"><a class="wp-block-button__link has-background has-medium-font-size has-custom-font-size wp-element-button" href="https://www.aiconline.co.uk/dental-decontamination-review/?utm_source=article&utm_medium=clikc&utm_campaign=FMC&utm_id=FMC-PODCAST" target="_blank" rel="noreferrer noopener"><span><strong>Get your free dental decontamination review</strong></span></a></div>
</div>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p>‘It’s really special when you have a really nervous patient or you’ve witnessed their journey from being extremely nervous to coming out of their shell,’ says Harriet Gill, dental nurse and TikTok influencer.</p>



<p>The panel also reflects on the challenges dental nurses face. These range from learning unfamiliar instruments and procedures to coping with inspections, a lack of career support and the disruption caused by the COVID-19 pandemic.</p>



<h2 class="wp-block-heading">More than ‘sucking up the water’</h2>



<p>A key theme throughout the episode is how little those outside dentistry may understand about the role.</p>



<p>Dental nurses support clinicians, care for patients, manage decontamination and help to keep the day running. Despite this, their work can sometimes be reduced to one visible task.</p>



<p>‘You’d get comments like: “Oh, so you’re the one who sucks the water out of my mouth.” I do a lot more than that,’ says Chontelle Roberts, sales and service consultant at Aura Infection Control.</p>



<p>The panel also discusses the importance of finding the right practice and having a supportive team.</p>



<p>‘When you find the right place for you, you’ll just feel settled and you’ll want to progress there and enjoy going to work,’ says Harriet.</p>



<h2 class="wp-block-heading">Topics explored include:</h2>



<ul class="wp-block-list">
<li>Dental nurses’ funniest and most embarrassing moments</li>



<li>The best and most difficult parts of the role</li>



<li>Supporting nervous patients</li>



<li>Career development and opportunities</li>



<li>Common misconceptions about dental nursing</li>



<li>Inspections, career support and the impact of COVID-19</li>



<li>Finding the right practice and a supportive team</li>



<li>The responsibilities behind the dental nursing role.</li>
</ul>



<div class="wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-16018d1d wp-block-buttons-is-layout-flex">
<div class="wp-block-button has-custom-width wp-block-button__width-50 is-style-fill"><a class="wp-block-button__link has-background has-medium-font-size has-custom-font-size wp-element-button" href="https://www.aiconline.co.uk/dental-decontamination-review/?utm_source=article&utm_medium=clikc&utm_campaign=FMC&utm_id=FMC-PODCAST" target="_blank" rel="noreferrer noopener"><span><strong>Get your free dental decontamination review</strong></span></a></div>
</div>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p><em>This article is sponsored by Aura Infection Control.</em></p>]]> </content:encoded>
</item>

<item>
<title>When health data crosses borders, trust must travel with it </title>
<link>https://edusehat.com/en/when-health-data-crosses-borders-trust-must-travel-with-it</link>
<guid>https://edusehat.com/en/when-health-data-crosses-borders-trust-must-travel-with-it</guid>
<description><![CDATA[ 
Pradeep Gupta, Partner, Deloitte India, explores how the DPDP Act, 2023, and DPDP Rules, 2025, are reshaping health data governance and why building trust must go hand in hand with enabling cross-border healthcare and research 
The post When health data crosses borders, trust must travel with it  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17101930/Pradeep-Gupta.jpg.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 14:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>When, health, data, crosses, borders, trust, must, travel, with, it </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17101930/Pradeep-Gupta.jpg.jpeg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17101930/Pradeep-Gupta.jpg.jpeg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17101930/Pradeep-Gupta.jpg-300x160.jpeg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>The framework of India’s Digital Personal Data Protection (DPDP) is currently reshaping how hospitals, pharmaceutical companies, Clinical Research Organisations (CROs), insurers and research institutions collect, process and share health data, making governance and accountability integral to healthcare and clinical research. This happens in parallel to raising the stakes for inadequate data protection and breach preparedness. </span></p>
<p><span>Health records travel with patients as they cross national borders, and accordingly, Personally Identifiable Information (PII) is also shared with overseas healthcare stakeholders. </span></p>
<p><span>The digital health database in India shows a rise in Medical Value Travel (MVT), which is about 5.5 per cent of all foreign tourist arrivals. As more than 450,000 patients from other countries travel to India each year, the medical tourism industry is projected to grow by $16.21 billion by 2030, posting a CAGR of 13.23 per cent. The AYUSH market is also poised to grow and is expected to reach $200 billion. Concurrently, the rising trends in the medical tourism industry reflect the growing demand for advanced clinical care and preventive wellness in India. </span></p>
<p><span>Such dynamic expansion of the digital health ecosystems results in the exchange of large volumes of health information among patients, healthcare providers, insurers, CROs, pharma companies and international partners. </span></p>
<p><span>The growth of medical tourism, cross-border healthcare services and global clinical research also increases the movement of sensitive personal health data across jurisdictions, highlighting the importance of resilient privacy, security and governance safeguards. </span></p>
<p><span>This is where India’s DPDP Act, 2023 and the DPDP Rules, 2025 come into the picture by providing a legal and operational framework to process digital personal data and protect the information of domestic and international patients. </span></p>
<p><span>As healthcare moves towards interoperable digital records, privacy, security and informed consent become the primary concerns of hospitals, health-tech firms, insurers, labs and pharma companies for the responsible use of patient centric health information. This is done by implementing access controls, consent tools and breach response plans. Penalties of $2.5 billion for failure to implement security safeguards and $2 billion for failure to report a breach in India are consequences of the DPDP Act’s robust implementation framework. </span></p>
<p><span>Anonymised health data supports disease tracking, monitoring of public health trends and the design of targeted health programmes. The scale is massive with over 1.2 billion linked health records, over 980 million ABHA IDs, over 1.2 million Healthcare Professionals Registries (HPRs) of medical professionals and over 500,000 verified Health Facility Registries (HFRs) as of October 2026, showing the growing digital footprint of India’s domestic healthcare ecosystem. </span></p>
<p><span>This showcases the government’s shift from policymaking to establishing an environment of trust and accountability to operationalise digital personal data governance at scale. A critical component of this trust is to make sure that data subjects can participate meaningfully in the ecosystem through accessible and inclusive engagement. </span></p>
<p><strong>Inclusivity </strong></p>
<p><span>While inclusivity drives engagement, strict adherence to jurisdictional boundaries ensures that this expanded access does not compromise national data sovereignty. Privacy notices and consent mechanisms need to be accessible in vernacular languages as an important part of the DPDP compliance. The BHASHINI app, for instance, supports 36+ Indian languages, 350+ AI models and 23+ language services. This helps to make privacy information and consent processes more accessible and inclusive for India’s citizens. </span></p>
<p><strong>Cross-border transfer responsibility </strong></p>
<p><span>Organisations should proactively map cross-border data flows, conduct Data Protection Impact Assessments (DPIAs) and strengthen contractual safeguards to ensure that every international transfer is necessary, secure and compliant. DPDP Rules permit the government to restrict transfers of personal data to specified foreign states. DPIA can help identify and share essential datasets for clinical research. Contracts with pharmaceutical companies and CROs, sponsors, insurers, cloud providers, etc., should govern secondary use, onward transfers, security standards, subprocessors and timely incident reporting. </span></p>
<p><strong>Breach preparedness</strong></p>
<p><span>Organisations should move beyond reactive breach management by strengthening incident response readiness and investing strategically in Privacy Enhancing Technologies (PETs). This will help build resilience, reduce privacy risks and embed privacy by design into their data ecosystem. The DPDP Rules, 2025, establish clear requirements for breach notification, with Rule 7 requiring data fiduciaries to notify the Data Protection Board within 72 hours, unless an extension is permitted. This highlights the necessity for organisations to establish and operationalise robust breachresponse mechanisms well in advance. </span></p>
<p><strong>Compliance obligation </strong></p>
<p><span>Healthcare organisations should treat data protection as a strategic priority, implementing privacy, security and responsible data governance into digital healthcare initiatives from the outset to build trust and unlock sustainable growth. Rapid expansion of India’s digital infrastructure adds urgency to this transition since the scale and sensitivity of personal health data requires protection, as Internet subscriptions surpass one billion, mobile connectivity in 98 per cent of villages, covering more than 470,000 5G towers in 99.6 per cent of districts.  </span></p>
<p><span>For clinical research, medical tourism and cross-border health data exchange, the DPDP Act, 2023, and the DPDP Rules, 2025, provide the guardrails for how personal health data should be handled, protected and shared. Their impact, however, will be determined by how consistently hospitals, pharmaceutical companies, CROs, insurers and research institutions translate these requirements into everyday decisions on consent, access, security and accountability. When health data crosses borders, trust cannot be assumed; it must be demonstrated at every stage of the data journey.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/when-health-data-crosses-borders-trust-must-travel-with-it/">When health data crosses borders, trust must travel with it </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Toward Connected Laboratory Ecosystems</title>
<link>https://edusehat.com/en/toward-connected-laboratory-ecosystems</link>
<guid>https://edusehat.com/en/toward-connected-laboratory-ecosystems</guid>
<description><![CDATA[ In this GEN podcast, the third in a series, LabVantage’s Denise Bell discusses how laboratories can reduce operational fragmentation and build connected, scalable operations. 
The post Toward Connected Laboratory Ecosystems appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Getty_2239922126_ArtificialIntelligence.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 11:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Toward, Connected, Laboratory, Ecosystems</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>

<p></p>

<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph">These days, many laboratories are eager to apply AI, but the systems and workflows that they have implemented often stand in the way. When systems run separately, information gets trapped in silos and scientific context is lost between steps. Also, manual handoffs slow the work down and introduce risk at various points in lab processes. Connecting those systems and workflows first gives AI the operational and scientific context it needs to deliver value that can be both trusted and scaled.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> podcast, the third in a series, LabVantage’s Denise Bell discusses how laboratories can reduce operational fragmentation and build connected, scalable operations. The discussion covers workflow orchestration across laboratory functions and ways to reduce manual handoffs and information silos, while offering some practical starting points for AI adoption. It also looks at how bringing LIMS, ELN, LES, and SDMS together in a unified laboratory execution environment enables workflow intelligence and AI assistance in the right scientific and operational context.</p>


<p class="wp-block-paragraph"></p>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow">
<h4 class="wp-block-heading"><strong><strong>Podcast Guests:</strong></strong></h4>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<figure class="wp-block-image aligncenter size-medium is-resized"><img fetchpriority="high" decoding="async" width="300" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/11/Denise-Bell-VP-Product-Management-and-Marketing-e1794865379160-300x300.jpg" alt="Denise Bell" class="wp-image-340716" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Denise-Bell-VP-Product-Management-and-Marketing-e1794865379160-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Denise-Bell-VP-Product-Management-and-Marketing-e1794865379160-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/Denise-Bell-VP-Product-Management-and-Marketing-e1794865379160-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Denise-Bell-VP-Product-Management-and-Marketing-e1794865379160.jpg 800w" sizes="(max-width: 300px) 100vw, 300px"></figure>


<h6 class="wp-block-heading has-text-align-center"><strong><strong><strong>Denise Bell</strong></strong></strong><br>Vice President, Product Management & Marketing<br>LabVantag</h6>
</div>
</div>
</div>
</div>


<hr class="wp-block-separator has-alpha-channel-opacity is-style-wide">


<p class="has-text-align-center wp-block-paragraph"><br><strong>Produced with support from:</strong></p>


<figure class="wp-block-image aligncenter size-medium"><a href="https://www.labvantage.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="57" src="https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-300x57.jpg" alt="LabVantage logo" class="wp-image-131319" srcset="https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-300x57.jpg 300w, https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-696x132.jpg 696w, https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-741x142.jpg 741w, https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo.jpg 750w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>

<p>The post <a href="https://www.genengnews.com/topics/toward-connected-laboratory-ecosystems/">Toward Connected Laboratory Ecosystems</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Enhancer&#45;Targeted CRISPR Turns Up Healthy Gene Copy in Autism Organoid Model</title>
<link>https://edusehat.com/en/enhancer-targeted-crispr-turns-up-healthy-gene-copy-in-autism-organoid-model</link>
<guid>https://edusehat.com/en/enhancer-targeted-crispr-turns-up-healthy-gene-copy-in-autism-organoid-model</guid>
<description><![CDATA[ In lab-grown human neurons and organoids carrying CHD8 or SCN2A mutations, researchers reduced organoid overgrowth and moved neuronal electrical activity closer to wild-type levels.
The post Enhancer-Targeted CRISPR Turns Up Healthy Gene Copy in Autism Organoid Model appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2018/10/Nov1_2011_3769185_BlueBrainDNA_AutismGeneStudies_AI2888221221.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 11:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Enhancer-Targeted, CRISPR, Turns, Healthy, Gene, Copy, Autism, Organoid, Model</media:keywords>
<content:encoded><![CDATA[<p>When a mutation hinders one copy of a gene, the remaining copy has to do the work of two. Researchers at UCLA have now shown, in lab-grown human brain cells, that a CRISPR-based tool could help that remaining copy in models of autism.</p>
<p>The proof-of-concept study, published in <em>Nature Neuroscience</em>, is titled “<a href="https://www.nature.com/articles/s41593-026-02504-9?utm_source=rct_congratemailt&utm_medium=email&utm_campaign=oa_20261113&utm_content=10.1038/s41593-026-02504-9">Enhancer-targeted CRISPR-A rescues haploinsufficiency and mutant phenotypes in organoid models of autism</a>.” It was led by Daniel Geschwind, MD, PhD, at the David Geffen School of Medicine at UCLA. George Chen, PhD, now at Children’s Hospital of Los Angeles, is first author. Collaborators at the New York Genome Center and New York University also contributed.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“Approximately 15% of the genetic susceptibility of autism spectrum disorder (ASD) is imparted by <em>de novo</em> haploinsufficient mutations of major effect,” the authors wrote. The team focused on two high-confidence autism genes: <em>CHD8</em>, which helps regulate other neurodevelopmental genes, and <em>SCN2A</em>, which is essential for neurons to fire electrical signals.</p>
<p>Instead of editing DNA, the researchers used CRISPR activation, pairing a catalytically inactive Cas9 with the activator p300 (dCas9-p300) to turn genes up without cutting them, and aimed it at fetal-brain enhancers. The team’s concern was that promoter targeting risks overexpression, a particular problem for haploinsufficient genes, which are often dosage sensitive.</p>
<p>“We mapped enhancers of two high-confidence autism genes, <em>CHD8</em> and <em>SCN2A</em>, and used CRISPR-based gene activation targeting enhancers (eCRISPR-A) in human pluripotent stem cell (hPSC)-derived excitatory neurons and cerebral forebrain organoids to correct the effects of haploinsufficiency,” the authors wrote. “Here we show that eCRISPR-A induced a sustained increase in <em>CHD8</em> and <em>SCN2A</em> expression specifically in mutant neurons and cortical organoids, with rescue of gene expression levels and mutation-associated phenotypes, including gene expression and physiology.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>In <em>CHD8</em>-mutant organoids, which grow abnormally large because progenitor cells overproliferate, treatment reduced organoid size in most treated lines and shifted gene expression toward wild-type patterns. In <em>CHD8</em>-mutant neurons grown in two-dimensional cultures, it increased markers of neuronal maturation. In <em>SCN2A</em>-mutant neurons, it showed restored excitability: firing approached wild-type levels in patient-derived neurons. Interestingly, “patient-derived iPSC neurons required higher current injections to achieve sustained firing compared to HUES66-derived neurons across conditions, indicating a line-dependent difference in baseline intrinsic excitability rather than incomplete functional rescue,” reported the authors.</p>
<p>“Our results show that, in human cell models, it’s possible to turn up that remaining copy and move cells back toward typical development,” Geschwind said in a press release. “This is a key first step, and it gives us a new way to think about addressing the biology underlying these conditions.”</p>
<p>The authors call the work “an important proof of principle” and note they were able to “moderately increase the expression of each gene.” However, “the effect of eCRISPR-A decreased over time,” and “an open question remains regarding the effect of introducing CRISPR-A after the expected peak in expression.” They say “further optimization of viral infection, constructs, and use of alternative Cas enzymes” would increase the approach’s clinical utility.</p>
<p>“We are still a long way from the clinic, and there is a lot of work ahead on delivery and timing,” added Chen in a press release, “but these findings provide hope and give us a clear direction.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/enhancer-targeted-crispr-turns-up-healthy-gene-copy-in-autism-organoid-model/">Enhancer-Targeted CRISPR Turns Up Healthy Gene Copy in Autism Organoid Model</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Gut Microbome and Bile Acid Modification Linked with Longevity</title>
<link>https://edusehat.com/en/gut-microbome-and-bile-acid-modification-linked-with-longevity</link>
<guid>https://edusehat.com/en/gut-microbome-and-bile-acid-modification-linked-with-longevity</guid>
<description><![CDATA[ Researchers studying how gut microbes modify bile acids have identified changes in the metabolic activity of the gut microbiome associated with exceptional longevity in humans, and found that amplifying the same activity with engineered bacteria improved metabolic health in aged mice.
The post Gut Microbome and Bile Acid Modification Linked with Longevity appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/04/GettyImages-1683059833.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 07:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Gut, Microbome, and, Bile, Acid, Modification, Linked, with, Longevity</media:keywords>
<content:encoded><![CDATA[<p>Researchers from the University of California San Diego have identified changes in the metabolic activity of the gut microbiome associated with exceptional longevity in humans, and found that amplifying the same activity with engineered bacteria improved metabolic health in aged mice.</p>
<p>“Many studies of aging focus on what goes wrong as we get older, but our findings suggest that some changes in the gut microbiome may actually represent the body’s attempt to preserve metabolic health,” said Amir Zarrinpar, MD, PhD, Stuart and Barbara L. Brody Endowed Chair in Circadian Biology and Medicine, and professor of medicine at UC San Diego School of Medicine. “If we can identify those beneficial functions and safely strengthen them, we may eventually be able to develop new ways to promote healthier aging.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Zarrinpar is senior and corresponding author of the researchers’ published paper in <em>Cell Metabolism</em>, titled “<a href="https://www.cell.com/cell-metabolism/fulltext/S1550-4131(26)00453-5" target="_blank" rel="noopener">Microbial bile acid deconjugation counters metabolic decline in aging</a>.”</p>
<p>For their reported study the researchers focused on how gut microbes modify bile acids. Gut bacteria produce enzymes called bile salt hydrolases (BSH) that chemically modify bile acids, allowing them to influence pathways involved in metabolism, inflammation and the body’s internal clock. “Gut microbes modify bile acids through several reactions, including deconjugation by bile salt hydrolase (BSH),” the team wrote. “Deconjugated bile acids can regulate host gene expression and signaling pathways, including those involved in metabolism, inflammation, and circadian rhythms.”</p>
<p>The gut microbiome—the community of bacteria and other microbes living in the digestive tract—changes throughout life and plays an important role in metabolism, inflammation, and other aspects of health. Previous research has linked age-related changes in the microbiome with frailty, chronic inflammation, and disease, while other studies have found distinctive microbiome features among people who age exceptionally well.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The researchers first studied young and aged mice and found that aging was associated with increased microbial activity related to BSH and greater bile acid modification. To determine whether a similar pattern occurred in humans, they reanalyzed publicly available data from a human aging cohort. The analysis included bile acid measurements from 48 young adults, 107 older adults, and 125 centenarians. The centenarian group showed higher ratios of certain modified bile acids than both younger groups.</p>
<p>Analysis of microbiome data also found greater abundance of a gene associated with BSH activity among centenarians compared with the older adult group. “Individuals with exceptional longevity show a similar bile acid deconjugation signature, suggesting an association with resilient or exceptional aging,” the team pointed out.</p>
<p>They then asked whether enhancing this microbial function could produce health benefits. The researchers engineered a strain of bacteria native to the gut to continuously produce BSH, and introduced the bacteria into 82-week-old mice—considered aged. A single treatment resulted in stable colonization, allowing the bacteria to persist and produce the enzyme over time.</p>
<p>Approximately 20 weeks after treatment, mice receiving the BSH-producing bacteria had significantly improved insulin sensitivity and modestly improved glucose tolerance compared with mice receiving a matched control bacterium. By 32 weeks, the treated mice also showed changes consistent with lower body weight and fat mass and greater lean mass. Other findings pointed to increased use of fat for energy, improved mitochondrial function, and changes in gene activity related to inflammation and the body’s internal clock. “Using engineered native bacteria, we further increased luminal BSH activity in aged mice and improved insulin sensitivity, accompanied by supportive changes in body composition and other metabolic readouts,” the investigators commented.</p>
<p>The results do not show that the microbial changes caused exceptional longevity in humans or that the engineered bacteria can extend lifespan. The authors note that centenarians and aged mice are not directly comparable, and the human findings provide supporting rather than definitive evidence. “We also acknowledge that aged mice and individuals with exceptional longevity are not directly equivalent and therefore consider the centenarian data corroborative rather than definitive evidence,” they stated. “From this perspective, increased BSH activity may serve as a marker of, or potential contributor to, metabolic resilience during aging. More studies in people will be needed to determine whether increased BSH activity is a marker of healthy aging, a contributor to it, or both.”</p>
<p>The study also points toward a broader possibility: rather than attempting to replace the entire gut microbiome, researchers may eventually be able to identify beneficial microbial functions and selectively enhance them. In their paper they noted, “Together, these findings suggest that elevated BSH activity may have a protective role during aging. They challenge the view that age-related changes in bile acid biotransformations are uniformly detrimental, highlighting microbial bile acid modulation as a potential strategy to improve late-life metabolic health.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Future studies will investigate how different forms of BSH affect bile acid metabolism, inflammation, energy use, and other aspects of aging, as well as whether the approach works similarly in females, given established differences in aging based on sex.</p>
<p>“The goal isn’t simply to live longer—it’s to understand the biology that allows some people to remain resilient as they age,” said Zarrinpar. “The microbiome gives us an intriguing opportunity because, unlike many aspects of aging, it may be something we can modify. This study gives us a starting point for asking whether beneficial microbial functions can be amplified to help preserve metabolic health later in life.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/gut-microbome-and-bile-acid-modification-linked-with-longevity/">Gut Microbome and Bile Acid Modification Linked with Longevity</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>What Your Heart’s Structure Has to Do With Your Diagnosis</title>
<link>https://edusehat.com/en/what-your-hearts-structure-has-to-do-with-your-diagnosis</link>
<guid>https://edusehat.com/en/what-your-hearts-structure-has-to-do-with-your-diagnosis</guid>
<description><![CDATA[ Words like stenosis, blockage, and defect each point to one part of the heart and what is wrong with it. This guide maps the heart’s chambers, valves, and vessels to the diagnoses people hear most, with five questions to ask your doctor and how to request a consultation with Dr. Giovanni Ciuffo in Las Vegas. ]]></description>
<enclosure url="https://heartsurgeryinfo.com/wp-content/uploads/2026/11/Physician-holds-model-of-artificial-heart-in-hands.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 00:35:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>What, Your, Heart’s, Structure, Has, With, Your, Diagnosis</media:keywords>
<content:encoded><![CDATA[<p><span>Stenosis. Blockage. Defect. If you’ve heard one of these words in a doctor’s office, it probably sounded like a foreign language, and the real questions tend to arrive after you’ve already left the room.</span></p>
<p><span>Here’s the reassuring part: nearly every one of those words is describing a part of the heart and what’s going wrong with it. A narrowed valve. A blocked artery. An opening that shouldn’t be there. That’s the connection between heart structure and diagnosis, and you don’t need a medical degree to follow it. You just need a map.</span></p>
<p><span>This guide builds on</span><a href="https://heartsurgeryinfo.com/a-beginners-guide-to-hearts-structure/"> <span>a basic tour of the heart’s structure</span></a><span> and shows how each part connects to the conditions people are most often told they have, so your own diagnosis starts to make sense.</span></p>
<h2><strong>Why Your Diagnosis Is Really a Structure Question</strong></h2>
<p><span>So what is a diagnosis actually telling you? Almost always, it names two things: a part of the heart, and what’s wrong with it. Once you can place the part, the rest gets much easier to follow.</span></p>
<p><span>Here’s the quick version of the map. The heart has four chambers. The two upper chambers, the atria, receive blood, and the two lower chambers, the ventricles, pump it out. The right side sends blood to the lungs to pick up oxygen, and the left side sends that oxygen-rich blood out to the rest of the body. Four valves act like one-way doors between those spaces, keeping blood moving forward instead of back. The wall itself has three layers: a thin outer covering, a thick middle layer of muscle that does the pumping, and a smooth inner lining. And a set of vessels carries blood in and out, including the aorta, the large artery that sends blood to the body, and the coronary arteries, which feed the heart muscle itself.</span></p>
<p><span>That’s really it. When a doctor says a valve is narrowed, an artery is blocked, or a chamber has an opening it shouldn’t, they’re pointing to one spot on this map. Knowing which spot makes appointments less overwhelming, because you can follow the explanation instead of just nodding along. It also helps when a doctor pulls up an image or sketches a diagram, since you’ll know what you’re looking at and can ask better questions about the plan.</span></p>
<p><span>Our</span><a href="https://heartsurgeryinfo.com/a-beginners-guide-to-hearts-structure/"> <span>beginner’s guide to the heart’s structure</span></a><span> goes deeper if you’d like a fuller refresher. For now, this is enough to start understanding your heart condition one piece at a time.</span></p>
<h2><strong>When the Problem Is a Valve</strong></h2>
<p><span>So what does it mean when your diagnosis points to a valve? Of all the places a heart problem can show up, valves are among the most common, which is why heart valve problems come up so often in diagnoses.</span></p>
<p><span>Quick reminder: you have four valves, the tricuspid, mitral, pulmonary, and aortic, and each one is a one-way door that opens to let blood through and closes to keep it from slipping back. Two of them, the aortic and mitral valves, work on the heart’s high-pressure left side, and they’re the ones most often needing surgical attention.</span></p>
<p><span>Valve problems usually come in two forms. A narrowed valve, known as stenosis, doesn’t open fully, so the heart has to work harder to push blood through. A leaking valve, known as regurgitation, doesn’t close fully, so some blood flows backward. Some valves have both problems at once. Either way, the diagnosis names the valve and names the problem, which is exactly the connection between heart structure and diagnosis we’ve been building toward.</span></p>
<p><span>Severity matters just as much as the type of problem. A mildly narrowed or leaky valve is often monitored over time, while a more severe one is more likely to call for treatment, which is why your imaging and follow-up measurements carry so much weight in the plan your doctor recommends.</span></p>
<p><span>From there, the question is usually repair or replace. Some valves, particularly the mitral valve, can often be repaired and kept in place, which many surgeons prefer when the valve allows it. Others need to be replaced, and replacement brings its own choice between mechanical and biological valves, which our page on</span><a href="https://heartsurgeryinfo.com/biological-or-mechanical-heart-valve/"> <span>choosing a biological or mechanical heart valve</span></a><span> walks through.</span></p>
<p><span>Many of these procedures can be done through smaller incisions, depending on the valve and your case. If you want the specifics, we cover</span><a href="https://heartsurgeryinfo.com/minimally-invasive-aortic-valve-surgery/"> <span>minimally invasive aortic valve surgery</span></a><span> and</span><a href="https://heartsurgeryinfo.com/minimally-invasive-mitral-valve-repair/"> <span>minimally invasive mitral valve repair</span></a><span> in more detail.</span></p>
<h2><strong>When the Problem Is the Heart’s Blood Supply</strong></h2>
<p><span>So what happens when the problem is the heart’s blood supply? The heart is a muscle, and like any muscle it needs a steady supply of oxygen-rich blood to keep working, every minute of every day. That supply doesn’t come from the blood flowing through its chambers. It comes from the coronary arteries, a network of vessels that branch off the aorta and wrap around the outside of the heart.</span></p>
<p><span>When those arteries narrow, usually from a gradual buildup of plaque, less blood reaches the muscle they feed. A partial blockage can cause chest pain or shortness of breath, especially during activity, because the muscle isn’t getting all it needs. A complete blockage can cut off the supply to part of the muscle altogether, which is what causes a heart attack. This is why a diagnosis of coronary blockage is really a statement about how well a specific section of heart muscle is being fed.</span></p>
<p><span>Treatment depends on how many arteries are affected, where the blockages sit, and how much muscle depends on them. In some cases, medication or stents are enough to restore good blood flow. In others, the answer is bypass surgery, where a surgeon uses a healthy blood vessel from elsewhere in the body to create a new route around the blocked section, like a detour around a roadblock.</span><a href="https://heartsurgeryinfo.com/coronary-surgery/"> <span>Minimally invasive coronary bypass surgery</span></a><span> explains how that works through smaller incisions.</span></p>
<p><span>If bypass is what you’ve been told you need,</span><a href="https://heartsurgeryinfo.com/told-you-need-bypass-surgery-what-actually-happens-next/"> <span>here’s what actually happens next</span></a><span>. Seeing a blockage as a structure problem, a section of muscle that needs a better supply, is a big step toward understanding your heart condition and the choices in front of you.</span></p>
<h2><strong>When the Problem Is a Chamber, Opening, or Major Vessel</strong></h2>
<p><span>Some diagnoses don’t involve a valve or an artery at all. They involve a chamber, an opening that shouldn’t be there, or the wall of the body’s largest blood vessel. Here’s how three of them connect back to the structure you just read about.</span></p>
<p><span>An</span><a href="https://heartsurgeryinfo.com/minimally-invasive-atrial-septal-defect-asd-repairs/"> <span>atrial septal defect, or ASD</span></a><span>, is an opening in the wall between the heart’s two upper chambers, which lets blood cross to the wrong side and makes the right side of the heart work harder than it should. Some people are born with one, and others learn about it later in adulthood.</span></p>
<p><span>An atrial myxoma is a tumor that grows inside one of those upper chambers, and because pieces can break loose and travel, it is usually removed promptly.</span><a href="https://heartsurgeryinfo.com/atrial-myxoma-surgery/"> <span>Atrial myxoma surgery</span></a><span> explains how the tumor and the section of wall it grows from are taken out.</span></p>
<p><span>An</span><a href="https://heartsurgeryinfo.com/inoperable-aortic-aneurysms/"> <span>aortic aneurysm</span></a><span> is a weakened, bulging section of the aorta, the major vessel that carries blood out of the heart to the rest of the body, and the wider it grows, the greater the risk that the wall can tear or rupture.</span></p>
<p><span>Each one is a different structure with a different problem. Once you know which chamber, opening, or vessel is involved, the diagnosis stops being a string of unfamiliar words, and the connection between heart structure and diagnosis becomes something you can use when you talk with a surgeon.</span></p>
<h2><strong>Questions That Help Your Diagnosis Make Sense</strong></h2>
<p><span>You don’t need a medical degree to follow your own diagnosis. You just need the right questions. Understanding your heart condition is part of your care, and it starts with what you ask. Doctors use shorthand all day, so it’s easy to nod along without following. Bring these to your next appointment, and don’t hesitate to ask for plain language.</span></p>
<ul>
<li aria-level="1"><b>Which structure is involved?</b><span> Ask your doctor to name the exact part: a specific valve, an artery, a chamber, or the aorta. “A heart problem” isn’t a complete answer.</span></li>
<li aria-level="1"><b>What exactly is wrong with it?</b><span> Is it narrowed, leaking, enlarged, blocked, or open where it should be closed? The structure tells you where the problem is, and this tells you what kind of problem it is.</span></li>
<li aria-level="1"><b>How severe is it?</b><span> Ask whether it’s mild, moderate, or severe, and what that means for your symptoms. Severity often decides whether you need treatment now or careful monitoring.</span></li>
<li aria-level="1"><b>What does the imaging show?</b><span> Ask to see your echocardiogram, angiogram, or CT scan, and have your doctor point to the problem area. Seeing it on the screen can make everything click.</span></li>
<li aria-level="1"><b>Should it be repaired or replaced?</b><span> Repair means fixing the structure you have, and replacement means swapping it out. The right choice depends on your case, so ask which one fits and why. Ask what each option means for your recovery and how long the result lasts.</span></li>
</ul>
<p><span>Write the answers down, or bring someone along who can. If something still doesn’t make sense, ask again. A good surgeon will explain it as many times as it takes, and a second opinion is a reasonable step if the answers you’re getting don’t leave you confident in the plan.</span></p>
<h2><strong>Quick Answers</strong></h2>
<p><b>What is a heart diagnosis actually telling you?</b><span><br>
</span><span>A diagnosis usually names two things: a part of the heart and what’s wrong with it. Once you can place that part on the map of chambers, valves, wall layers, and vessels, the rest of the explanation gets much easier to follow.</span></p>
<p><b>Which parts of the heart can a diagnosis point to?</b><span><br>
</span><span>The four chambers, the four valves, the three layers of the heart wall, and the vessels that carry blood in and out, including the aorta and the coronary arteries.</span></p>
<p><b>What’s the difference between a narrowed valve and a leaking valve?</b><span><br>
</span><span>A narrowed valve, called stenosis, doesn’t open fully, so the heart works harder to push blood through. A leaking valve, called regurgitation, doesn’t close fully, so some blood flows backward. Some valves have both problems at once.</span></p>
<p><b>What does a blocked coronary artery mean for the heart?</b><span><br>
</span><span>It means part of the heart muscle isn’t getting all the blood it needs. A partial blockage can cause chest pain or shortness of breath, and a complete blockage can cause a heart attack. Treatment depends on how many arteries are affected and where.</span></p>
<p><b>What should I ask my doctor to understand my diagnosis?</b><span><br>
</span><span>Ask which structure is involved, what exactly is wrong with it, how severe it is, what the imaging shows, and whether it should be repaired or replaced. Writing the answers down helps.</span></p>
<h2><span>•••</span></h2>
<p><span>If your diagnosis still feels like a foreign language, you don’t have to work it out alone. You’ve already done the hardest part by learning how the heart is put together. The next step is a conversation, and it can start with a simple question: which part of my heart is involved, and what does that mean for my options?</span></p>
<p><span>Dr. Giovanni Ciuffo is the Director of Cardiac Surgery at University Medical Center of Southern Nevada, and he runs a national referral practice, so patients travel to Las Vegas from across the country for a second opinion or a clearer plan. If you’d like to talk through your own case, you can</span><a href="https://heartsurgeryinfo.com/contact-us/"> <span>request a heart surgery consultation in Las Vegas</span></a><span>. Bring your imaging and your questions, and we’ll start with the map.</span></p>]]> </content:encoded>
</item>

<item>
<title>Dana&#45;Farber Breaks Ground on $1.68 Billion, 300&#45;Bed Cancer Hospital</title>
<link>https://edusehat.com/en/dana-farber-breaks-ground-on-168-billion-300-bed-cancer-hospital</link>
<guid>https://edusehat.com/en/dana-farber-breaks-ground-on-168-billion-300-bed-cancer-hospital</guid>
<description><![CDATA[ Dana Farber Cancer Institute’s new 300-bed Lavine Bekenstein Cancer Hospital in Boston will provide inpatient oncology care, outpatient services and research within a closely connected campus. | Photo Credit: Payette  The new 450,000-square-foot Lavine Bekenstein Cancer Hospital will contain 300 beds, with the first patients expected in 2031.   The state-approved capital expenditure for the project is approximately...
The post Dana-Farber Breaks Ground on $1.68 Billion, 300-Bed Cancer Hospital appeared first on HCO News.
The post Dana-Farber Breaks Ground on $1.68 Billion, 300-Bed Cancer Hospital appeared first on HCO News. ]]></description>
<enclosure url="https://hconews.com/wp-content/uploads/2026/11/HCO-News.DanaFarber-768x497.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 21:40:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Dana-Farber, Breaks, Ground, 1.68, Billion, 300-Bed, Cancer, Hospital</media:keywords>
<content:encoded><![CDATA[<h5><span data-contrast="auto">Dana Farber Cancer Institute’s new </span><span data-contrast="auto">300-bed </span><span data-contrast="auto">Lavine Bekenstein Cancer Hospital in Boston will</span><span data-contrast="auto"> provide inpatient oncology care, outpatient services and research within a closely connected campus. | Photo Credit: Payette</span><span data-ccp-props="{}"> </span></h5>
<ul>
<li><span data-contrast="auto">The new 450,000-square-foot </span><span data-contrast="auto">Lavine Bekenstein Cancer Hospital will </span><span data-contrast="auto">contain 300 beds, with the first patients expected in 2031. </span><span data-ccp-props="{}"> </span></li>
<li><span data-contrast="auto">The state-approved capital expenditure for the project is approximately $1.68 billion.</span><span data-ccp-props="{}"> </span></li>
<li><span data-contrast="auto">Payette is the architect, and Suffolk Construction is the contractor.</span><span data-ccp-props="{}"> </span></li>
</ul>
<p><span data-contrast="auto">BOSTON — Dana-Farber Cancer Institute </span><a href="https://www.dana-farber.org/newsroom/news-releases/2026/dana-farber-breaks-ground-on-lavine-bekenstein-cancer-hospital" target="_blank" rel="noopener"><span data-contrast="none">broke ground Oct. 19</span></a><span data-contrast="auto"> on the Lavine Bekenstein Cancer Hospital, a 300-bed facility intended to bring inpatient oncology care, outpatient services and research into a more closely connected campus.</span><span data-ccp-props="{}"> </span></p>
<p><a href="https://www.dana-farber.org/about/our-vision-for-the-future-of-cancer-care/future-cancer-hospital" target="_blank" rel="noopener"><span data-contrast="none">Dana-Farber describes the hospital</span></a><span data-contrast="auto"> as a 450,000-square-foot facility with 10 inpatient floors. It will replace the former Joslin Diabetes Center on Brookline Avenue in Boston’s Longwood Medical Area.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">The hospital will strengthen Dana-Farber’s collaboration with Beth Israel Deaconess Medical Center and Harvard Medical Faculty Physicians. </span><span data-contrast="auto">Dana-Farber said</span><span data-contrast="auto"> closer connections between clinicians and researchers would help move discoveries into treatment while improving coordination among medical and surgical specialties.</span><span data-ccp-props="{}"> </span></p>
<p><a href="https://www.payette.com/project/dfci-bidmc-fch/" target="_blank" rel="noopener"><span data-contrast="none">Payette</span></a><span data-contrast="auto"> is the architect, and </span><a href="https://www.linkedin.com/posts/suffolk-construction_suffolk-northeast-is-excited-to-announce-activity-7452426154139119617-4LHQ" target="_blank" rel="noopener"><span data-contrast="none">Suffolk Construction</span></a><span data-contrast="auto"> is the contractor. The </span><a href="https://www.mass.gov/doc/decision-letter-pdf-dana-farber-cancer-institute/download" target="_blank" rel="noopener"><span data-contrast="none">Massachusetts Department of Public Health’s March 2025 project approval</span></a><span data-contrast="auto"> identified a total capital expenditure of approximately $1.68 billion.</span><span data-ccp-props="{}"> </span></p>
<blockquote><p><span data-contrast="auto">“Every aspect of this hospital has been designed around the unique needs of people with cancer and their families,” Dr. Benjamin L. Ebert, President and CEO of </span><span data-contrast="auto">Dana-Farber Cancer Institute, said in the release</span><span data-contrast="auto">.</span><span data-ccp-props="{}"> </span></p></blockquote>
<p><span data-contrast="auto">Project support includes a joint donation from Josh and Anita Bekenstein and the Jonathan and Jeannie Lavine family. </span><span data-contrast="auto">Dana-Farber described</span><span data-contrast="auto"> the commitment as the largest single gift in its history.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Flexible clinical areas will support future changes in cancer treatment and research. </span><a href="https://www.payette.com/project/dfci-bidmc-fch/" target="_blank" rel="noopener"><span data-contrast="none">Payette’s design</span></a><span data-contrast="auto"> incorporates a high-performance rainscreen facade with glass elements around patient rooms. The firm says the project is targeting LEED Gold certification and is designed to be ready for all-electric operation.</span><span data-ccp-props="{}"> </span></p>
<p><a href="https://www.linkedin.com/posts/suffolk-construction_suffolk-northeast-is-proud-to-partner-with-activity-7511138407134240770-zGwx" target="_blank" rel="noopener"><span data-contrast="none">According to Suffolk</span></a><span data-contrast="auto">, the construction plan uses an up-down approach, allowing crews to continue below-grade work as the building rises. Underground spaces will include radiation oncology areas and parking. The below-grade treatment areas will be heavily reinforced and lead-lined, according to the contractor, which reported excavation to bedrock.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Deconstruction and site preparation began in March 2026, ahead of the October ceremony. </span><span data-contrast="auto">Dana-Farber’s schedule</span><span data-contrast="auto"> places foundation and below-ground work between November 2026 and December 2029. Structural and exterior work is scheduled for 2028 and 2029, overlapping with interior construction from September 2028 through November 2030. The institute expects construction to finish by the end of 2030 and the hospital to welcome its first patients in 2031.</span><span data-ccp-props="{}"> </span></p>
<p><em>This article is based on a <a href="https://www.dana-farber.org/newsroom/news-releases/2026/dana-farber-breaks-ground-on-lavine-bekenstein-cancer-hospital" target="_blank" rel="noopener">Dana-Farber Cancer Institute news release</a> published Oct. 19, 2026, with additional information from <a href="https://www.payette.com/project/dfci-bidmc-fch/" target="_blank" rel="noopener">Payette</a>, <a href="https://www.linkedin.com/posts/suffolk-construction_suffolk-northeast-is-proud-to-partner-with-activity-7511138407134240770-zGwx" target="_blank" rel="noopener">Suffolk Construction</a>, the <a href="https://www.mass.gov/doc/decision-letter-pdf-dana-farber-cancer-institute/download" target="_blank" rel="noopener">Massachusetts Department of Public Health</a> and <a href="https://www.dana-farber.org/about/our-vision-for-the-future-of-cancer-care/future-cancer-hospital/construction-updates" target="_blank" rel="noopener">Dana-Farber’s project updates</a>. </em></p>
<p>The post <a rel="nofollow" href="https://hconews.com/2026/11/16/dana-farber-breaks-ground-on-1-68-billion-300-bed-cancer-hospital/">Dana-Farber Breaks Ground on $1.68 Billion, 300-Bed Cancer Hospital</a> appeared first on <a rel="nofollow" href="https://hconews.com/">HCO News</a>.</p>
<p>The post <a href="https://hconews.com/2026/11/16/dana-farber-breaks-ground-on-1-68-billion-300-bed-cancer-hospital/">Dana-Farber Breaks Ground on $1.68 Billion, 300-Bed Cancer Hospital</a> appeared first on <a href="https://hconews.com/">HCO News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The technician decline is not what it seems</title>
<link>https://edusehat.com/en/the-technician-decline-is-not-what-it-seems</link>
<guid>https://edusehat.com/en/the-technician-decline-is-not-what-it-seems</guid>
<description><![CDATA[ The dental technician register is shrinking, but Matt Everatt argues the figures do not tell the whole story and sets out where the real danger lies. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/decline.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 21:25:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, technician, decline, not, what, seems</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>The dental technician register is in decline, but Matt Everatt explains why the figures do not tell the whole story and where the true danger lies.</strong></p>



<p>In August 2021, I wrote about the declining numbers of dental technicians. The article headline was intentionally blunt: ‘By 2040, dental technicians will be extinct.’ Although it is very unlikely to go that far, it was based on the trajectory of the numbers, and I wrote it to sensationalise the message.</p>



<p>The figures were stark. In 2018, 6,163 dental technicians were registered with the General Dental Council (GDC). By 2021, that had fallen to 5,535. By 2026, we are now below 5,000 for the first time. There were just 143 new registrations last year in the entire UK.</p>



<p>The decline is real, but the story behind those numbers is more complicated and perhaps not as grim as they may first seem.</p>



<h2 class="wp-block-heading">What the technology actually changed</h2>



<!--free-wall-stop-->



<p>CAD/CAM, 3D printing, digital design, and automation have fundamentally changed what technicians can produce. An experienced technician using modern workflows can deliver work that once required several varied skills often from different technicians. Accuracy is better, reproducibility is reliable and the quality has arguably risen.</p>



<p>This is progress, not a problem. It means the profession genuinely does not need as many registered technicians as it did in 2018. Some decline is inevitable. Some is healthy, but not all of what we are seeing is inevitable.</p>



<h2 class="wp-block-heading">Inevitable versus chosen decline</h2>



<p>If technology efficiency was the only factor, the register would fall to a lower sustainable level. Fewer technicians, more highly skilled, paid better, using advanced technology for premium work. That is a viable profession.</p>



<p>That is not happening. Technology-driven efficiency is colliding with structural choices that are unsustainable. We use efficiency gains to cut prices instead of improving margins. Unregulated manufacturers are still going unchecked, along with chairside manufacturing, distorting the market. We also do a pretty good job of making the profession unattractive to younger or newcomers, so fewer people join. These are choices and they compound the inevitable decline into something far worse.</p>



<h2 class="wp-block-heading">Two paths forward</h2>



<p>We can continue as we are, compete on price, accept unregulated competition, pay people as little as possible, watch training institutions close. In ten years, 3,000 technicians, most over 50, many exhausted. The profession continues its demise towards obsolescence.</p>



<p>Or we accept technology-driven efficiency as the new way and make different structural choices. Stop undercutting. Price on value and expertise. Address unregulated manufacturing. Use margins to pay technicians better and create real development pathways. Run labs as proper businesses. In ten years, 3,500 registered technicians, well-paid, highly skilled, specialised in complex work. A smaller profession that is thriving.</p>



<p>Both futures are possible. Neither is inevitable. The choice is mostly ours.</p>



<h2 class="wp-block-heading">If we want a profession to exist</h2>



<p>If we choose to be the thriving profession rather than the diminished one, we need to stop competing on price. Not because it feels good, but because it is the only way margins improve enough to pay people well and invest in quality. Some clients will leave. Let them. The ones attracted by price are the ones most likely to be demanding, slow to pay, and quick to complain. They are not worth keeping.</p>



<p>We need to invest those margins in people. Pay laboratory technicians what they are worth, salaries that reflect their expertise and regulated status. Invest in development and specialisation. When you do this, good technicians stay.</p>



<p>Quality improves, reputation compounds and the phone rings more often than you could imagine.</p>



<p>We need to collectively address unregulated manufacturing. The GDC and MHRA have regulations. They need to be enforced. As a collective, we can do more to make our voices heard. Dental practices need to understand that work produced outside regulatory frameworks carries real liability. This is not negotiable if we want standards to mean anything.</p>



<p>We need training institutions properly resourced. You cannot sustain viable programmes on cohorts of a dozen students with shoestring budgets. If the profession wants technicians capable of advanced work, education has to be funded accordingly. There are good moves towards supporting apprenticeships. Labs need to be onboard to support these institutions.</p>



<p><em>Follow <a href="https://www.instagram.com/dentistry.co.uk/" target="_blank" rel="noreferrer noopener">Dentistry.co.uk</a> on Instagram to keep up with all the latest dental news and trends.</em></p>]]> </content:encoded>
</item>

<item>
<title>How to Build a Study Schedule for Step 1 and Step 2 CK at the Same Time</title>
<link>https://edusehat.com/en/how-to-build-a-study-schedule-for-step-1-and-step-2-ck-at-the-same-time</link>
<guid>https://edusehat.com/en/how-to-build-a-study-schedule-for-step-1-and-step-2-ck-at-the-same-time</guid>
<description><![CDATA[ Preparing for USMLE Step 1 and Step 2 CK at the same time can feel like an overwhelming undertaking. For many medical students, studying for both exams simultaneously is not necessarily a choice. Curriculum requirements, shelf exam schedules, dedicated study periods, and graduation timelines may mean that you need to prepare for Step 1 while […]
The post How to Build a Study Schedule for Step 1 and Step 2 CK at the Same Time appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/11/pexels-mart-production-7605201-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 21:20:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Build, Study, Schedule, for, Step, and, Step, the, Same, Time</media:keywords>
<content:encoded><![CDATA[<p><span>Preparing for USMLE Step 1 and Step 2 CK at the same time can feel like an overwhelming undertaking. For many medical students, studying for both exams simultaneously is not necessarily a choice. Curriculum requirements, shelf exam schedules, dedicated study periods, and graduation timelines may mean that you need to prepare for Step 1 while continuing to study for Step 2 CK.</span></p>
<p> </p>
<p><span>The good news is that preparing for both exams does not have to mean doubling your workload or creating two completely separate study schedules. The key is learning how to prioritize your time, recognize where the material overlaps, and dedicate enough focused practice to each exam without spreading yourself too thin.</span></p>
<p> </p>
<p><span>In this post, we will walk through how to build a realistic study schedule for Step 1 and Step 2 CK, including how to determine your priorities, divide your daily study time, incorporate practice questions, and adjust your schedule as you get closer to each exam.</span></p>
<p> </p>
<h2><b>Start by Establishing Your Priorities</b></h2>
<p><span>Before creating <a href="https://elitemedicalprep.com/the-ultimate-10-week-step-1-study-schedule/">a study schedule</a>, you need to understand which exam requires the most attention right now. </span><span>One of the biggest mistakes students make is assuming that Step 1 and Step 2 CK should receive an equal amount of study time simply because they are preparing for both.</span></p>
<p> </p>
<p><span>In reality, your priorities should depend on three major factors: your exam dates, your baseline performance, and your available study time.</span></p>
<p> </p>
<h3><b>1. Consider Your Exam Dates</b></h3>
<p><span>The first thing to establish is how much time you have before each exam.</span></p>
<p> </p>
<p><span>If Step 1 is scheduled in six weeks and Step 2 CK is four months away, Step 1 should naturally receive a larger portion of your study time. You still want to maintain some exposure to Step 2 material, but your immediate priority should be building the foundational knowledge and test-taking skills necessary to pass Step 1.</span></p>
<p> </p>
<p><span>On the other hand, if Step 2 CK is approaching first, you may need to prioritize clinical reasoning, management questions, and shelf-style practice while maintaining your Step 1 knowledge through targeted review.</span></p>
<p> </p>
<p><span>Your study schedule should evolve as your exam dates approach. It should not remain exactly the same for several months if your priorities have changed.</span></p>
<p> </p>
<h3><b>2. Evaluate Your <a href="https://elitemedicalprep.com/best-ways-to-use-nbme-practice-exams-to-prepare-for-the-real-thing/">Baseline Performance</a></b></h3>
<p><span>You also need an honest assessment of where you currently stand with each exam. Consider completing a baseline assessment. This will help you identify which exam requires more attention and where your biggest knowledge gaps are.</span></p>
<p> </p>
<p><span>For example, you may have a relatively strong foundational science background but struggle with clinical management questions. In that case, Step 2 CK may require more dedicated practice, even if it is further away.</span></p>
<p> </p>
<p><span>Alternatively, you may be performing reasonably well on shelf exams but have significant gaps in microbiology, pharmacology, and pathology that need to be addressed before Step 1.</span></p>
<p> </p>
<p><span>Your schedule should reflect your actual needs rather than simply dividing your time equally between the two exams.</span></p>
<p> </p>
<h3><b>3. Be Realistic About Your Daily Availability</b></h3>
<p><span>Another important consideration is how much time you can realistically dedicate to studying each day.</span></p>
<p> </p>
<p><span>Are you currently completing clinical rotations? Are you studying full-time during dedicated? Do you have other academic responsibilities or personal commitments?</span></p>
<p> </p>
<p><span>A student who has eight hours available each day will need a very different schedule from someone who can only study three or four hours after rotations. Do not create a schedule based on the assumption that you will study for 12 hours every day if that is not sustainable for you. A realistic schedule that you consistently follow is much more valuable than an ambitious schedule that falls apart after a few days.</span></p>
<p> </p>
<h2><b>Look for Opportunities to Overlap Your Studying</b></h2>
<p><span>One of the biggest advantages of preparing for Step 1 and Step 2 CK together is that the two exams are not completely separate.</span></p>
<p> </p>
<p><span>Step 1 focuses heavily on foundational medical sciences, including physiology, pathology, pharmacology, and microbiology. Step 2 CK focuses more on clinical diagnosis, patient management, and application of medical knowledge.</span></p>
<p> </p>
<p><span>However, the <a href="https://elitemedicalprep.com/the-biggest-study-mistakes-students-make-when-transitioning-from-usmle-step-1-to-step-2/">underlying concepts frequently overlap</a>.</span></p>
<p> </p>
<p><span>For example, when reviewing cardiovascular disease, you might spend time understanding the pathophysiology of myocardial infarction for Step 1 while also reviewing the clinical presentation, diagnostic workup, and management of acute coronary syndrome for Step 2 CK. Do this for as much material as possible to maximize your studying from each question.</span></p>
<h4><span><br>
<strong>An organ-system-based approach</strong></span></h4>
<p><span>This is where an organ-system-based approach can be particularly helpful.</span></p>
<p> </p>
<p><span>Rather than reviewing completely unrelated topics for each exam every day, consider organizing some of your content review around shared organ systems.</span></p>
<p> </p>
<p><span>For example, during a cardiovascular week, you might review:</span></p>
<ul>
<li aria-level="1"><b>Step 1:</b><span> Cardiac physiology, pathology, pharmacology, and relevant mechanisms.</span></li>
<li aria-level="1"><b>Step 2 CK:</b><span> Cardiovascular presentations, diagnostic evaluation, and management of common conditions.</span></li>
</ul>
<p> </p>
<p><span>Your brain naturally learns well by grouping similar information together, so minimize your workload by tackling both Step 1 and Step 2CK content for a certain topic, if you can. </span></p>
<p> </p>
<h2><b>How to Divide Your Daily Study Time</b></h2>
<p><span>Once you have established your priorities, the next step is deciding how much time to dedicate to each exam. There is no universally correct ratio, but I generally recommend assigning a primary focus to one exam while maintaining consistent practice for the other.</span></p>
<p> </p>
<p><span>For example, if Step 1 is your immediate priority, you might dedicate approximately 65-70% of your study time to Step 1 and the remaining 30-35% to Step 2 CK.</span></p>
<p> </p>
<p><span>If Step 2 CK is approaching first, you could reverse that allocation. </span><span>These percentages are simply starting points. Your actual distribution should depend on your baseline performance, exam timeline, and progress. The important thing is that both exams remain part of your routine without allowing one to completely interfere with preparation for the other. The content for each exam builds off of each other so you hopefully should not feel like you are doing double work. </span></p>
<p> </p>
<h3><b>Separate Your Question Practice</b></h3>
<p><span>One thing I strongly recommend is keeping your Step 1 and Step 2 CK question practice separate. Even when you are reviewing the same organ system, you should be intentional about <a href="https://elitemedicalprep.com/how-to-use-uworld-for-step-2-ck-a-practical-study-strategy/">which question bank you are using</a> and what you are trying to accomplish.</span></p>
<p> </p>
<ul>
<li><span><strong>For Step 1,</strong> focus on understanding mechanisms, recognizing pathology, and connecting foundational concepts to clinical presentations.</span></li>
<li><strong>For Step 2 CK,</strong> prioritize clinical vignettes, diagnostic reasoning, <a href="https://elitemedicalprep.com/free-120-step-2-ck-how-to-use-the-official-sample-test/">next-best-step questions</a>, and management decisions.</li>
</ul>
<p> </p>
<p><span>You can absolutely review overlapping concepts on the same day, but you should still practice the specific question styles associated with each exam.</span></p>
<p> </p>
<p><span>For example, if you are reviewing endocrinology, you might complete a set of Step 1 questions on thyroid hormone physiology and pharmacology, followed by Step 2 CK questions on evaluating and managing thyroid disorders. </span><span>This reinforces the same organ system from both exam perspectives.</span></p>
<p> </p>
<h2><b>Sample Weekly Study Schedule for Step 1 and Step 2 CK</b></h2>
<p><span>Let’s put everything together with a practical example. </span><span>Imagine you have approximately six to eight weeks before Step 1 and three to four months before Step 2 CK. You have around seven to eight hours available for studying each day, six to seven days per week.</span></p>
<p> </p>
<p><span>In this situation, Step 1 would receive the majority of your study time, while Step 2 CK would remain part of your daily routine. </span><span>Here is an example of how you might structure your week.</span></p>
<p> </p>
<h3><b>Sample Weekly Schedule</b></h3>
<table>
<tbody>
<tr>
<td><b>Day</b></td>
<td><b>Step 1 Focus</b></td>
<td><b>Step 2 CK Focus</b></td>
</tr>
<tr>
<td><strong>Monday</strong></td>
<td><span>Cardiovascular content review + 60-80 questions</span></td>
<td><span>15-20 cardiovascular questions + review</span></td>
</tr>
<tr>
<td><strong>Tuesday</strong></td>
<td><span>Cardiovascular pathology/pharmacology + 60–80 questions</span></td>
<td><span>Review Monday’s questions + 20-30 new questions</span></td>
</tr>
<tr>
<td><strong>Wednesday</strong></td>
<td><span>Pulmonary content review + 60-80 questions</span></td>
<td><span>20-30 pulmonary questions</span></td>
</tr>
<tr>
<td><strong>Thursday</strong></td>
<td><span>Pulmonary pathology/physiology + 60-80 questions</span></td>
<td><span>Review Wednesday’s questions + 20-30 new questions</span></td>
</tr>
<tr>
<td><strong>Friday</strong></td>
<td><span>Mixed Step 1 questions + targeted review</span></td>
<td><span>Mixed Step 2 CK questions</span></td>
</tr>
<tr>
<td><strong>Saturday</strong></td>
<td><span>Step 1/Step 2 CK timed assessment (alternate days)  </span></td>
<td><span>Step 1/Step 2 CK timed assessment (alternate days)  </span></td>
</tr>
<tr>
<td><strong>Sunday</strong></td>
<td><b>Finish reviewing assessment + Step 1 mixed questions</b></td>
<td><b>Finish reviewing assessment + Step 2 CK mixed questions</b></td>
</tr>
</tbody>
</table>
<p><span>The exact number of questions will depend on your current level, question bank, and available study time. The important thing is to maintain consistent exposure to both exams.</span></p>
<p> </p>
<p><span>I personally recommend doing practice questions in tutor mode to review as you go and save time, but there is time built into the study schedule above for further question review the following day. </span></p>
<p> </p>
<h2><b>How Much Time Should You Spend Reviewing Questions?</b></h2>
<p><span>One of the most common mistakes students make when preparing for two exams is trying to complete too many questions without spending enough time reviewing them. Remember, completing a question is not the same as learning from it. If you complete 40 questions but barely review the explanations, you may be missing the most valuable part of the exercise.</span></p>
<p> </p>
<p><span>I generally recommend a maximum of 5-7 minutes to review difficult questions. For every question you miss, take time to understand whether the problem was a content gap or a test taking strategy error. This distinction is particularly important when preparing for both exams because the same underlying knowledge gap and strategy errors may affect your performance on different types of questions. I recommend <a href="https://elitemedicalprep.com/free-downloads/">Anki</a> or some type of spaced repetition mechanism to ensure that you learn missed content well enough to never miss it again.</span></p>
<p> </p>
<h2><b>Incorporating Assessments for Both Exams</b></h2>
<p><span>Practice questions are important, but you also need to periodically evaluate your overall progress. </span><span>This is where NBME assessments become particularly valuable.</span></p>
<p> </p>
<p><span>I recommend scheduling assessments for Step 1 and Step 2 CK separately rather than trying to evaluate both exams during the same week every time. You can either alternate weeks or frontload the Step 1 or Step 2 CK practice exams depending on which one approaches sooner for you. </span></p>
<p> </p>
<p><span>For example, if Step 1 is approaching, you may want to complete an NBME assessment every one to two weeks, depending on your preparation timeline. <a href="https://elitemedicalprep.com/best-predictor-of-step-2-ck-scores/">Step 2 CK assessments</a> can be spaced further apart while you are still maintaining that exam. </span><span>As you get closer to either exam, your assessments should become more frequent and increasingly representative of your readiness.</span></p>
<p> </p>
<p><span>If your Step 1 performance is improving consistently but your Step 2 CK performance is declining, that may be a sign that you need to rebalance your study time.</span></p>
<p> </p>
<h2><b>Common Mistakes to Avoid When Studying for Both Exams</b></h2>
<p><span>One common mistake is trying to complete two full study schedules simultaneously. Remember, you do not need to complete every resource, video, and question bank for both exams at the same time. Be selective and prioritize the resources that address your biggest weaknesses.</span></p>
<p> </p>
<p><span>Another mistake is neglecting one exam completely because the other feels more urgent. While it is reasonable to prioritize the exam that comes first, maintaining some consistent exposure to the second exam will make transitioning your focus much easier later.</span></p>
<p> </p>
<p><span>Finally, avoid spending too much time creating the perfect schedule instead of actually following one. Your schedule should be a tool that guides your preparation, not another project that takes hours to maintain. Start with a realistic plan, track your progress, and make adjustments as needed.</span></p>
<p> </p>
<h2><b>Final Encouragement</b></h2>
<p><span>Preparing for Step 1 and Step 2 CK simultaneously is undoubtedly challenging, but it does not have to mean twice the workload or twice the stress. The most effective approach is to prioritize based on your exam dates and baseline performance, take advantage of overlapping organ-system content, and maintain separate question practice for each exam.</span></p>
<p> </p>
<p><span>Remember that your study schedule should evolve as you progress. Some weeks will require more attention to Step 1, while others may require a greater emphasis on Step 2 CK. Do not get discouraged if your schedule needs to change. That is part of the process.</span></p>
<p> </p>
<p><span>Most importantly, focus on learning from your practice questions rather than simply trying to complete as many as possible. Consistent review, targeted content reinforcement, and regular assessments will help you identify weaknesses and make the most of your available study time.</span></p>
<p> </p>
<p><b>You do not need two completely separate study plans. You need one organized, flexible schedule that allows you to prepare strategically for both exams.</b></p>
<p> </p>
<p><span>With the right structure and consistent effort, you can make meaningful progress toward both milestones without sacrificing the quality of your preparation.</span></p>
<p> </p>
<p>If you’d like help deciding how to divide your study time between Step 1 and Step 2 CK, an Elite Medical Prep tutor can help you build a schedule around your exam dates, practice scores, and clinical rotations. <a href="https://elitemedicalprep.com/meet-the-tutors/">Meet our USMLE tutors</a> to find someone who can help you put your plan into practice.</p>
<p> </p>
<p><span>Good luck, and happy studying!</span></p>
<p>The post <a href="https://elitemedicalprep.com/how-to-build-a-study-schedule-for-step-1-and-step-2-ck-at-the-same-time/">How to Build a Study Schedule for Step 1 and Step 2 CK at the Same Time</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Single&#45;Cell Method Reveals On&#45; and Off&#45;Target Effects of Cas9 Edits on Gene Expression</title>
<link>https://edusehat.com/en/single-cell-method-reveals-on-and-off-target-effects-of-cas9-edits-on-gene-expression</link>
<guid>https://edusehat.com/en/single-cell-method-reveals-on-and-off-target-effects-of-cas9-edits-on-gene-expression</guid>
<description><![CDATA[ A new method called Superb-seq pairs Cas9 editing with single-cell RNA sequencing to show which edits, including off-target ones, occur in each cell and how they alter gene expression, offering a clearer view of genome editing’s potential consequences.
The post Single-Cell Method Reveals On- and Off-Target Effects of Cas9 Edits on Gene Expression appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/07/CO_MarApr17_Getty_182516812_Henrik5000_BlueCells-1068x801-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 21:00:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Single-Cell, Method, Reveals, On-, and, Off-Target, Effects, Cas9, Edits, Gene, Expression</media:keywords>
<content:encoded><![CDATA[<p><span>Scientists at the Salk Institute and their collaborators have published a paper in </span><i><span>Nature Methods</span></i><span> describing Superb-seq, a method of reading out both on and off target edits made by CRISPR/Cas9 technology. According to the developers, the tool makes it possible to read changes made by CRISPR at single-cell resolution to identify unwanted edits and assess how those edits change gene activity. Their paper is titled “</span><a href="https://www.nature.com/articles/s41592-026-03319-z" target="_blank" rel="noopener"><span>Joint single-cell capture of Cas9 edits and transcriptomes reveals on- and off-target effects on gene expression</span></a><span>.” </span></p>
<p><span>“What really inspired Superb-seq was a frustration with the existing state of affairs,” said Graham McVicker, PhD, senior author of the study and an associate professor at Salk. “We knew there were problems with CRISPR making unwanted edits, but also there was no good way to see what those edits were and how they affected the cell—what we wanted to see was invisible using current technologies.”</span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p><span>According to the developers, Superb-seq is able to show where unwanted edits are located as well as how those edits disrupt key genes that protect against unhealthy cellular states. Specifically, Superb-seq integrates Cas9 editing, T7 transcription, and single-cell RNA sequencing to capture single-cell edits and their impact on gene expression. The team has tested it on 34,000 cells from three different cell lines. “There are some people that have worked on this off-target issue before that have an awareness of how bad it is, but for many people that pick up CRISPR to use in the lab, the extent of this problem will really come as a surprise,” McVicker said. “I knew off-targets were an issue, but they were far more frequent than I was expecting.”</span></p>
<p><span>Using seven guide RNAs to target genes in one group of 10,000 human leukemia cells grown in the lab, Superb-seq detected 43 edit sites, including 36 of which were off-target, and 5,761 edited cells. Additionally, Superb-seq detected gene expression changes caused by genome edits that are invisible to existing edit detection methods. It also improved interpretation of the effect of edits compared to Perturb-seq, which reads out gene expression and guide RNAs but not the resulting edits.</span></p>
<p><span>The Salk scientists anticipate that Superb-seq could support applications in basic research, drug development, and personalized medicine. For existing studies that have used CRISPR to study different aspects of biology, “Superb-seq could reveal the extent to which off-target edits color all those findings,” said Michael Lorenzini, PhD, one of the first authors on the paper and a staff scientist in McVicker’s lab. Beyond basic discovery, “our tool could be immensely helpful in establishing the safety of genome therapy candidates early on in development. Superb-seq could be used to profile candidates and learn what their off-target edits are, as well as their effects,” he added. </span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p><span>The team also envisions Superb-seq as a valuable tool for generating training data to improve the accuracy of machine learning models of cellular function. McVicker, Lorenzini, and another co-author, Brad Balderson, PhD, have filed a patent for Superb-seq. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/single-cell-method-reveals-on-and-off-target-effects-of-cas9-edits-on-gene-expression/">Single-Cell Method Reveals On- and Off-Target Effects of Cas9 Edits on Gene Expression</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>University Health Network introduces Canada’s first multi&#45;position CT scanner</title>
<link>https://edusehat.com/en/university-health-network-introduces-canadas-first-multi-position-ct-scanner</link>
<guid>https://edusehat.com/en/university-health-network-introduces-canadas-first-multi-position-ct-scanner</guid>
<description><![CDATA[ New imaging technology allows patients to be scanned standing, sitting or lying down, offering potential improvements in diagnostic imaging and patient care. University Health Network (UHN) in Toronto has become the first healthcare organization outside Japan to install an advanced multi-position computed tomography (CT) system, introducing new possibilities for diagnostic imaging and patient assessment. Developed […]
The post University Health Network introduces Canada’s first multi-position CT scanner appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/canon-multi-position-ct-system-in-canada-ca.webp" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 20:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>University, Health, Network, introduces, Canada’s, first, multi-position, scanner</media:keywords>
<content:encoded><![CDATA[<p>New imaging technology allows patients to be scanned standing, sitting or lying down, offering potential improvements in diagnostic imaging and patient care.</p>
<p>University Health Network (UHN) in Toronto has become the first healthcare organization outside Japan to install an advanced multi-position computed tomography (CT) system, introducing new possibilities for diagnostic imaging and patient assessment.</p>
<p>Developed by Canon Medical Systems, the technology enables patients to undergo CT examinations while standing, sitting or lying down, rather than being restricted to the conventional horizontal position.</p>
<p>Installed in June 2026, the system has already been used to evaluate more than 200 patients as part of clinical research at UHN. The technology’s Canadian debut was formally announced on November 12.</p>
<p>A new perspective on diagnostic imaging</p>
<p>Conventional CT scanners generally require patients to lie on a scanning table. While effective for many diagnostic procedures, this position does not always reflect how the body’s structures behave during everyday activities.</p>
<p>Multi-position CT creates opportunities to examine anatomical changes associated with posture and weight-bearing.</p>
<p>These capabilities could be particularly valuable in musculoskeletal imaging, where certain abnormalities may become more apparent when a patient is standing. Researchers are also investigating potential applications in lung and abdominal imaging.</p>
<p>The system can transition between conventional horizontal imaging and upright scanning in just over a minute, allowing clinicians to assess patients in different positions using a single platform.</p>
<p>Early findings suggest improved efficiency</p>
<p>Research at UHN is being led by Dr. Patrik Rogalla, Site Director of Medical Imaging at Toronto General Hospital and Professor of Radiology at the University of Toronto.</p>
<p>In an early clinical report published in the Canadian Association of Radiologists Journal, researchers described encouraging results comparing conventional and upright CT examinations.</p>
<p>The initial findings indicated comparable image quality between scanning positions, alongside improvements in patient positioning and examination-room efficiency.</p>
<p>According to the research team, upright chest CT examinations reduced the time patients spent in the CT room by approximately three minutes per examination, largely because of faster positioning.</p>
<p>These improvements could have implications for hospital imaging departments managing growing demand for diagnostic services.</p>
<p>However, further research will be needed to determine how consistently these early efficiency gains translate into higher patient throughput and improved clinical outcomes.</p>
<p>Potential benefits for patients</p>
<p>The ability to complete an examination without lying flat may also benefit individuals who experience pain, respiratory difficulties or mobility limitations.</p>
<p>For some patients, conventional positioning can be uncomfortable or difficult to tolerate. Providing alternative scanning positions could help make diagnostic imaging more accessible while preserving diagnostic image quality.</p>
<p>The new system also creates opportunities to investigate conditions that may be influenced by gravity, posture or weight-bearing, potentially providing clinicians with additional information that conventional examinations cannot capture.</p>
<p>Supporting the future of medical imaging</p>
<p>The technology builds on several years of international research and development, including collaboration between Canon Medical Systems and Keio University in Japan.</p>
<p>UHN is now leading clinical investigation of the technology outside Japan, with additional research expected to explore applications in thoracic, abdominal and musculoskeletal imaging.</p>
<p>The early findings are promising, but the system’s broader diagnostic value and patient-care benefits will require further clinical evaluation.</p>
<p>The introduction of multi-position CT illustrates how Canadian academic hospitals are helping assess emerging medical technologies that could influence the future of diagnostic imaging.</p>
<p>As healthcare organizations look for ways to improve access, patient experience and operational efficiency, innovations that provide greater clinical flexibility may become increasingly important to the evolution of hospital imaging services.</p>
<p>The post <a href="https://www.hospitalnews.com/university-health-network-introduces-canadas-first-multi-position-ct-scanner/">University Health Network introduces Canada’s first multi-position CT scanner</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Mankind Pharma enters into in&#45;licensing agreement with Betta Pharmaceuticals for Ensartinib</title>
<link>https://edusehat.com/en/mankind-pharma-enters-into-in-licensing-agreement-with-betta-pharmaceuticals-for-ensartinib</link>
<guid>https://edusehat.com/en/mankind-pharma-enters-into-in-licensing-agreement-with-betta-pharmaceuticals-for-ensartinib</guid>
<description><![CDATA[ 
Strategic agreement to strengthen Mankind Pharma’s oncology portfolio with a US FDA-approved targeted therapy for ALK-positive non-small cell lung cancer
The post Mankind Pharma enters into in-licensing agreement with Betta Pharmaceuticals for Ensartinib appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2019/09/11121123/agreement-e1724903886928.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 20:45:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Mankind, Pharma, enters, into, in-licensing, agreement, with, Betta, Pharmaceuticals, for, Ensartinib</media:keywords>
<content:encoded><![CDATA[<div><img width="749" height="397" src="https://cdn.expresspharma.in/wp-content/uploads/2019/09/11121123/agreement-e1724903886928.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2019/09/11121123/agreement-e1724903886928.jpg 749w, https://cdn.expresspharma.in/wp-content/uploads/2019/09/11121123/agreement-e1724903886928-300x159.jpg 300w" sizes="(max-width: 749px) 100vw, 749px"></div><p><span>Mankind Pharma, one of India’s leading pharmaceutical companies, has entered into an in-licensing agreement with Betta Pharmaceuticals for Ensartinib, a novel, patented oncology drug approved by the US Food and Drug Administration (US FDA) and China’s National Medical Products Administration (NMPA). The drug is indicated for adult patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor.</span></p>
<p><span>Under the terms of the license agreement, Mankind Pharma will pay Betta Pharmaceuticals an upfront payment, potential development and sales milestone payments, and royalty payments on the annual net sales of Ensartinib in India. Mankind Pharma will be granted an exclusive license to develop, manufacture, register, and commercialize Ensartinib in India, subject to the terms and conditions of the license agreement.</span></p>
<p><span>The agreement marks another step in Mankind Pharma’s efforts to strengthen its oncology portfolio through strategic collaborations with global pharmaceutical innovators and expand its presence in specialised therapies.</span></p>
<p><span>Ensartinib is a targeted therapy designed to inhibit ALK, a protein that can drive cancer growth in a subset of patients with NSCLC. ALK-positive lung cancer represents a distinct molecular subtype of the disease, for which targeted therapies play an important role in treatment.</span></p>
<p><span>This move aligns with Mankind Pharma’s broader strategy of expanding its portfolio through a combination of in-house capabilities and external partnerships, with a focus on innovative therapies addressing significant unmet medical needs.</span></p>
<p><span>Atish Majumdar, Senior President, Mankind Pharma, said:  “Our ambition is to build a differentiated oncology portfolio that brings innovative therapies to the forefront of our growth strategy. The in-licensing of Ensartinib marks a significant step in this journey, strengthening our focus on specialised therapies and reinforcing our commitment to strategic partnerships that complement our capabilities. We see this as an opportunity to accelerate our presence in oncology, expand our therapeutic capabilities and build a stronger foundation for bringing advanced treatment options to patients in India.”</span></p>
<p><span>Together, Mankind Pharma’s pharmaceutical capabilities and Betta Pharmaceuticals’ expertise in oncology innovation, reflect a shared commitment to advancing targeted treatment options and addressing evolving patient needs.</span></p>
<p><span>Shizhe Ding, Chairman Assistant and Head of Business Development, Betta Pharmaceuticals said: “Ensartinib represents an important advancement in targeted therapy for patients with ALK-positive non-small cell lung cancer. Our partnership with Mankind Pharma brings together complementary strengths and a shared commitment to expanding therapeutic options towards a more global patient base. We see this collaboration as an opportunity to extend the reach of Ensartinib and to expand upon its clinical potential. We hope this collaboration indicates a strong start of actualizing the fruition of oncology research into meaningful progress for patients around the world.”</span></p>
<p><span>The introduction of Ensartinib in India will be subject to applicable regulatory approvals and the completion of relevant commercial and operational requirements. Further details on the agreement will be announced in due course.</span></p>
<p>The post <a href="https://www.expresspharma.in/mankind-pharma-enters-into-in-licensing-agreement-with-betta-pharmaceuticals-for-ensartinib/">Mankind Pharma enters into in-licensing agreement with Betta Pharmaceuticals for Ensartinib</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Luting cements made easy with one simple choice</title>
<link>https://edusehat.com/en/luting-cements-made-easy-with-one-simple-choice</link>
<guid>https://edusehat.com/en/luting-cements-made-easy-with-one-simple-choice</guid>
<description><![CDATA[ GC explores how luting cements can support conservative adhesive procedures and routine crown and bridge work, with complementary options for different restorative needs. GC has a long history of developing the materials that become part of everyday dentistry. Many of the products you already know and trust have grown from GC’s pioneering expertise including the… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/gc.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 17:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Luting, cements, made, easy, with, one, simple, choice</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>GC explores how luting cements can support conservative adhesive procedures and routine crown and bridge work, with complementary options for different restorative needs.</strong></p>



<p>GC has a long history of developing the materials that become part of everyday dentistry. Many of the products you already know and trust have grown from GC’s pioneering expertise including the long-established Fuji range, built on GC’s innovations in glass ionomer technology. It continues to innovate with fibre-reinforced composites, high-strength injectable composite materials, glass hybrid restoratives and reliable luting cements.</p>



<h2 class="wp-block-heading"><strong>Luting cements</strong></h2>



<p>The demands placed on luting cements have evolved alongside restorative dentistry. Secure retention and an effective marginal seal remain essential, but clinicians must also consider preservation of tooth tissue, increasingly diverse restorative materials, aesthetic expectations and the practical demands of everyday treatment. Cement selection is therefore part of treatment planning from the outset. The chosen material must suit the restoration, the remaining tooth structure and the conditions under which cementation will take place.</p>



<p>Reliable luting cements are a particularly relevant example of how GC’s expertise supports the changing needs of everyday clinical practice, including minimally invasive dentistry and the simplification of inventories at this time of increased clinical activity.</p>



<p>Clinicians therefore need cementation options that support both conservative adhesive treatments as well as routine crown and bridge work. Two complementary materials within GC’s portfolio meet these needs:</p>



<ul class="wp-block-list">
<li>G-CEM ONE, a universal self-adhesive resin cement</li>



<li>GC FujiCEM Evolve, a resin-modified glass ionomer cement.</li>
</ul>



<p>The move towards minimally invasive dentistry has also increased the importance of adhesive luting. Where clinically appropriate, bonded partial-coverage restorations allow dentists to preserve tooth tissue that might otherwise be removed to accommodate a full crown. In these cases, the cement and bonding protocol form an integral part of the restorative design.</p>



<figure class="wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-1 is-layout-flex wp-block-gallery-is-layout-flex">
<figure class="wp-block-image size-large"></figure>



<figure class="wp-block-image size-large"></figure>
</figure>



<h2 class="wp-block-heading"><strong>GC’s G-CEM ONE</strong></h2>



<p>GC’s G-CEM ONE system accommodates both retentive preparations and situations requiring additional adhesion, including veneers and onlays, when used with the appropriate protocol.</p>



<p>GC G-CEM ONE is a dual-cure, universal self-adhesive resin cement. Its clinical appeal lies in the flexibility to use a simplified self-adhesive approach for suitable cases, and with GC G-CEM ONE Adhesive Enhancing Primer or G-Premio BOND when additional adhesion is required.</p>



<p>This allows clinicians to work with a familiar cement system across a broad range of indirect procedures. Its self-curing capability is particularly relevant beneath restorations that restrict light transmission, while its colour stability and wear-resistant margins support aesthetic applications.</p>



<p>This versatility depends on following the protocol for each indication:</p>



<ul class="wp-block-list">
<li>For veneers and onlays, enamel etch and then follow with G-CEM ONE Adhesive Enhancing Primer or G-Premio BOND</li>



<li>Restoration surfaces would also require preparation appropriate to their material.</li>
</ul>



<p>Understanding these distinctions enables clinicians to make effective use of a universal system while retaining the steps needed for dependable adhesion.</p>



<h2 class="wp-block-heading"><strong>GC FujiCEM Evolve</strong></h2>



<p>Alongside adhesive resin cementation, resin-modified glass ionomer cements continue to meet important clinical needs. Their development combines the chemical adhesion and moisture tolerance associated with glass ionomer technology with the contribution of a resin matrix to improve mechanical performance.</p>



<p>GC FujiCEM Evolve brings this approach to contemporary crown and bridge work, with relevance to suitably retentive metal-based and zirconia restorations.</p>



<p>For the dental team, FujiCEM Evolve’s benefits are tangible with paste-to-paste delivery, a choice of hand mixing or auto mixing, and a tack-cure option to facilitate excess removal.</p>



<p>Its moisture tolerance is useful where isolation is challenging, although contamination control remains necessary.</p>



<p>In suitable cases, cementation without separate tooth etching and bonding provides a straightforward workflow. These characteristics make it a practical option for routine indirect restorative care.</p>



<h2 class="wp-block-heading"><strong>Relevance to modern dentistry</strong></h2>



<p>The relationship between these two materials is particularly relevant to modern dentistry. A conservative restoration that depends on adhesion calls for an appropriate resin cement protocol.</p>



<p>A zirconia crown with adequate retention and resistance may be well suited to a resin-modified glass ionomer cement. FujiCEM Evolve’s contribution is therefore different from that of adhesive resin cement: it provides a practical cementation option where the preparation and restoration already support conventional luting.</p>



<p>For patients, the outcomes that matter are preservation of natural teeth, comfort, appearance and lasting function.</p>



<p>For clinicians, achieving those aims requires materials that combine appropriate performance with manageable clinical procedures.</p>



<p>By offering adhesive flexibility through G-CEM ONE and convenient resin-modified glass ionomer cement through FujiCEM Evolve, GC provides clinicians with one simple choice of two reliable and complementary ways to meet all their luting needs whilst supporting simplifying practice inventories.</p>



<figure class="wp-block-image size-large"></figure>



<p><em>This article is sponsored by GC.</em></p>]]> </content:encoded>
</item>

<item>
<title>Biocon receives US FDA approval for Pebrilzo injection</title>
<link>https://edusehat.com/en/biocon-receives-us-fda-approval-for-pebrilzo-injection</link>
<guid>https://edusehat.com/en/biocon-receives-us-fda-approval-for-pebrilzo-injection</guid>
<description><![CDATA[ 
PEBRILZO further strengthens Biocon’s oncology portfolio, now totaling five biosimilar therapies for cancer in the United States
The post Biocon receives US FDA approval for Pebrilzo injection appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 17:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Biocon, receives, FDA, approval, for, Pebrilzo, injection</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p>Biocon, an innovation‑led global biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has approved Pebrilzo (pertuzumab-qcay), a biosimilar of the reference product Perjeta (pertuzumab). PEBRILZO is a monoclonal antibody used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells. The FDA approval further strengthens Biocon’s oncology portfolio.</p>
<p>Shreehas Tambe, CEO & Managing Director, Biocon said, “The US FDA approval of PEBRILZO, our biosimilar pertuzumab, marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. For patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond the physical challenges, often placing considerable financial strain on patients and their families. As our fifth oncology biosimilar to receive U.S. FDA approval, PEBRILZO strengthens our anti-cancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines.”</p>
<p>In September, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had given a positive opinion<a href="https://www.biocon.com/biocons-pertuzumab-becomes-first-biosimilar-to-secure-ema-chmp-approval-recommendation-under-new-tailored-clinical-approach/"> recommending the granting of a marketing authorization for Biocon’s Pertuzumab biosimilar</a> as 420 mg/14 mL concentrate solution for infusion, under the brand name Pebrilzo, for the treatment of HER2‑positive breast cancer across multiple disease stages in Europe.</p>
<p>Biocon also announced a <a href="https://www.biocon.com/biocon-secures-earliest-licensed-launch-dates-for-pebrilzo-bpertuzumab-following-global-patent-settlement-with-genentech/">global settlement and license agreement with Genentech</a> securing the earliest licensed launch date for PEBRILZO in the United States in Q3 of calendar year 2028.</p>
<p>The post <a href="https://www.expresspharma.in/biocon-receives-us-fda-approval-for-pebrilzo-injection/">Biocon receives US FDA approval for Pebrilzo injection</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>‘Great businesses don’t simply sell products or services – they create a feeling’</title>
<link>https://edusehat.com/en/great-businesses-dont-simply-sell-products-or-services-they-create-a-feeling</link>
<guid>https://edusehat.com/en/great-businesses-dont-simply-sell-products-or-services-they-create-a-feeling</guid>
<description><![CDATA[ Practice Plan head of sales Zoe Close reflects on one of the essential ingredients for patient retention and a successful business following the move from NHS to private dentistry. People often think that running a successful business is simply about getting the product or service right. While that’s important, what creates a business that people… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/manish-enhanced-faithful-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 14:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>‘Great, businesses, don’t, simply, sell, products, services, –, they, create, feeling’</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><div class="wp-block-embed__wrapper">
<div class="video-container"></div>
</div></figure>



<p><strong>Practice Plan head of sales Zoe Close reflects on one of the essential ingredients for patient retention and a successful business following the move from NHS to private dentistry.</strong></p>



<p>People often think that running a successful business is simply about getting the product or service right. While that’s important, what creates a business that people want to continue to work with is less tangible than that. It’s more to do with making your customers feel important and valued.</p>



<p>At Practice Plan we want our clients to feel as if they’re an important part of something bigger. That they have joined a community of people all brought together by a common aim: to build businesses that thrive while providing great service to their customers.</p>



<p>We try to bring people together as often as possible which is why we have an extensive events calendar supplemented by various breakfast clubs and meetings organised locally by our regional support managers. Our marquee event is our annual Workshop Tour held at different locations across the UK. This is a highlight for many of our practices, and we know our clients enjoy and value the experience because they tell us so. The feedback we receive is always fulsome in its praise.</p>



<h2 class="wp-block-heading">The feeling behind patient retention</h2>



<p>However, nobody has been able to sum up what we’re trying to achieve as a business better than dentist and practice owner, Manish Chitnis. He took the time to write a Facebook post about his experience with Practice Plan that truly encapsulates what makes a great business and what we try to do here at Practice Plan.</p>



<p>This is what he said: ‘As I sat here reflecting, I realised just how much our relationship with Practice Plan has evolved over the years. It may have started as a business relationship. But somewhere along the journey, it became something much more. </p>



<p>‘We became part of a tribe. A tribe where you are welcomed with genuine warmth. Where people remember you, where conversations continue from one year to the next, where success is celebrated together. And where there is laughter, friendship and a genuine desire to see each other grow. </p>



<p>‘That is something incredibly rare in business. Because great businesses don’t simply sell products or provide services. They create a feeling. A feeling that says: You belong here. We know you. We value you. And we are on this journey together.’</p>



<h2 class="wp-block-heading"><strong>Making people feel valued</strong></h2>



<p>It strikes me that Manish is making a valuable point about businesses in general. Creating that sense of belonging is what makes loyal customers. People want to feel that they matter, that they’re not just another name in the diary. They want to feel and believe that you have their best interests at heart and that they can trust you to act for their benefit and not your own.</p>



<p>A patient journey that makes your patients feel valued is essential. Small touches such as greeting them by name, finding out more about their family and their pets, talking about their holiday plans and so on go such a long way. These are things that show you are interested in them as a person, that you value their continued attendance at your practice and that you want them to be part of your tribe.</p>



<p>This is important as, although NHS patients may have few choices open to them, for those who pay privately there are plenty of options if they want to vote with their feet. And remember, loyal patients who are prepared to recommend you to their family and friends are worth a lot when it comes to marketing.</p>



<p>Manish’s words remind me of the Maya Angelou quote: ‘I’ve learned that people will forget what you said, people will forget what you did, but people will never forget how you made them feel.’ If you can make your patients feel welcome and valued, they’ll stay with you for life.</p>



<p>You can hear more about how Manish made the move from NHS to private in the video above.</p>



<p><em>This article is sponsored by Practice Plan.</em></p>


        <div class="">
            <div class="text-context-white p-8 md:p-12 xl:p-20 bg-black">
                <div class="flex flex-wrap justify-center -mx-4">
                                            <div class="px-4 w-full lg:w-7/8 flex flex-col justify-start">
                                                                        <div class="font-yellow font-bold text-2xl md:text-3xl xl:text-4xl mb-4">
                                Ready to talk?                            </div>
                                                                            <div class="text-context-white/75 mb-4">
                                <p>If you’re ready for a confidential discussion with Practice Plan about the next steps in converting to private dentistry, leave your details below.</p>
                            </div>
                                                                            <div class="wpforms-design-block-form">
                                <div class="wpforms-container wpforms-container-full">Please enable JavaScript in your browser to complete this form.<div class="wpforms-field-container"><div class="wpforms-field wpforms-field-layout" data-field-id="7"><div class="wpforms-field-layout-rows wpforms-field-large"><div class="wpforms-layout-row"><div class="wpforms-layout-column wpforms-layout-column-25"><div class="wpforms-field wpforms-field-text" data-field-id="1"><label class="wpforms-field-label" for="wpforms-424415-field_1">Name <span class="wpforms-required-label">*</span></label></div></div><div class="wpforms-layout-column wpforms-layout-column-25"><div class="wpforms-field wpforms-field-email" data-field-id="2"><label class="wpforms-field-label" for="wpforms-424415-field_2">Email <span class="wpforms-required-label">*</span></label></div></div><div class="wpforms-layout-column wpforms-layout-column-25"><div class="wpforms-field wpforms-field-text" data-field-id="8"><label class="wpforms-field-label" for="wpforms-424415-field_8">Phone <span class="wpforms-required-label">*</span></label></div></div><div class="wpforms-layout-column wpforms-layout-column-25"></div></div><div class="wpforms-layout-row"><div class="wpforms-layout-column wpforms-layout-column-25"><div class="wpforms-field wpforms-field-text" data-field-id="5"><label class="wpforms-field-label" for="wpforms-424415-field_5">Practice name <span class="wpforms-required-label">*</span></label></div></div><div class="wpforms-layout-column wpforms-layout-column-25"><div class="wpforms-field wpforms-field-text" data-field-id="6"><label class="wpforms-field-label" for="wpforms-424415-field_6">Practice postcode <span class="wpforms-required-label">*</span></label></div></div><div class="wpforms-layout-column wpforms-layout-column-25"></div><div class="wpforms-layout-column wpforms-layout-column-25"></div></div></div></div>		<div class="wpforms-field wpforms-field-text" data-field-type="text" data-field-id="3">
			<label class="wpforms-field-label" for="wpforms-424415-field_3">Practice Layout Practice</label>
			
		</div>
		<div class="wpforms-field wpforms-field-checkbox" data-field-id="9"><label class="wpforms-field-label">Want to hear more from Practice Plan?</label><ul><li class="choice-1 depth-1"><label class="wpforms-field-label-inline" for="wpforms-424415-field_9_1">I agree to receive marketing communication from Practice Plan, including valuable insights, inspiring stories and practical tips.   <a rel="noopener noreferrer" target="_blank" href="https://www.practiceplan.co.uk/privacy-notice/?utm_source=https://dentistry.co.uk/nhs-to-private/&utm_medium=referral&utm_campaign=privacypolicynhstopriv">View their privacy policy.</a>.</label></li></ul></div></div><!-- .wpforms-field-container --><div class="wpforms-submit-container"><button type="submit" name="wpforms[submit]" class="wpforms-submit" data-alt-text="Sending..." data-submit-text="Submit" aria-live="assertive" value="wpforms-submit">Submit</button></div></div>  <!-- .wpforms-container -->                            </div>
                                            </div>
                                    </div>
            </div>
        </div>]]> </content:encoded>
</item>

<item>
<title>From product knowledge to responsible engagement: What pharma’s frontline workforce needs today? </title>
<link>https://edusehat.com/en/from-product-knowledge-to-responsible-engagement-what-pharmas-frontline-workforce-needs-today</link>
<guid>https://edusehat.com/en/from-product-knowledge-to-responsible-engagement-what-pharmas-frontline-workforce-needs-today</guid>
<description><![CDATA[ 
Anindita Banik, Co-Founder &amp; CEO, SmartWinnr, discusses why pharmaceutical companies need to move beyond product knowledge and equip medical representatives to handle doctor interactions with accuracy, confidence and compliance 
The post From product knowledge to responsible engagement: What pharma’s frontline workforce needs today?  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/16102758/Anindita-Banik.jpg.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 13:35:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, product, knowledge, responsible, engagement:, What, pharma’s, frontline, workforce, needs, today </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/16102758/Anindita-Banik.jpg.jpeg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/16102758/Anindita-Banik.jpg.jpeg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/16102758/Anindita-Banik.jpg-300x160.jpeg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>In a crowded OPD, a medical representative (MR) gets a few minutes with the doctor. The MR knows the brand’s data cold. The doctor asks, “Is this safe for my elderly patients?” </span></p>
<p><span>The quickest reply perhaps is “Completely safe, doctor.” That answer can land the pharmaceutical company in trouble. Under the Uniform Code for Pharmaceutical Marketing Practices (UCPMP 2024), the word “safe” must not be used without qualification. The code holds companies responsible for their MRs’ conduct. The CEO answers for adherence, and the company’s executive head files an annual disclosure and compliance declaration. </span></p>
<p><span>The scrutiny is growing. In September, the Supreme Court reserved its order on a plea to regulate pharma marketing. The Centre proposed a three-member committee to examine whether a law is needed, and the code applies until then. Since May 2025, as per the DGHS order, MRs are not permitted in central government hospitals. It says they may share updates “by email or other digital media”. </span></p>
<p><span>Product knowledge gets an MR initial access, but what the MR says next determines whether the doctor trusts the brand or not. Those few minutes have to be accurate, compliant, and useful to the doctor. </span></p>
<p><span>Too much field training is still judged by completion rates and quiz scores. Both show what an MR remembers, not how they handle a doctor who pushes back.</span></p>
<p><span>That gap shows up in a handful of moments: a safety question, a query about an unapproved use, a comparison with a competitor, or a request that crosses a line, such as a doctor asking the company to sponsor a conference trip. The code bars that unless the doctor is speaking at a CME or CPD program.</span></p>
<p><span>On safety, the evidence is sobering. When doctors in Canada, France and the US reported on 1,692 sales-rep promotions, serious side effects came up in only 5 to 6% of them, according to a 2013 study in the Journal of General Internal Medicine. Managers can’t hear most calls, so moments like these rarely get coached.</span></p>
<p><span>Imagine the same MR in a team that gets trained for these scenarios. The safety question would not be a surprise. </span></p>
<p><span>Weeks earlier, at the cycle meeting, the brand, medical affairs and compliance teams list the questions MRs are most likely to fumble and agree on what good answers sound like. “Is it safe for my elderly patients?” is on the list. So is the doctor who asks about an unapproved use, and the one who wants a conference trip sponsored. The list keeps changing. When the prescribing information is updated, or a new question starts coming up in the field, the scenarios change with it. </span></p>
<p><span>The MR rehearses each scenario with an AI-simulated doctor on the phone and gets scored every time. The feedback is specific: “You called it safe without qualifying it.” “You skipped the side effects in the prescribing information.” “You didn’t offer the leaflet. </span></p>
<p><span>The bar is agreed in advance with medical and compliance. The answer has to be accurate, every safety statement has to be qualified, and the MR has to recognize when a question belongs with the medical team. Every MR is held to the same bar. A new joiner may simply need more attempts to reach it than a veteran. </span></p>
<p><span>The area manager watches a couple of those attempts before joint field work, coaches the one habit that matters, and signs off only when the MR clears the bar. In the field, the manager checks the same things. </span></p>
<p><span>The manager stays in the loop for a reason. A randomized field experiment with sales agents outside pharma, published in the Journal of Marketing, found that AI coaching combined with a manager’s coaching beat either one alone. </span></p>
<p><span>This does not make the doctor’s question easier. It means the MR has practiced it and is better prepared for the actual conversation with the doctor. </span></p>
<p><span>When the DGHS order came out last year, the Indian Pharmaceutical Alliance asked for “a balanced, structured and transparent engagement model”. The government may yet write one into law. Companies don’t need to wait. The model can start inside the field force: a short list of scenarios that matter, practice before the first call, and managers who coach from what they’ve seen. For a sales head, the test is simple. Before an MR walks into a doctor’s chamber, can you show they can handle the questions most likely to go wrong? If the only evidence is a quiz score, it’s time to measure something else. </span></p>
<p>The post <a href="https://www.expresspharma.in/from-product-knowledge-to-responsible-engagement-what-pharmas-frontline-workforce-needs-today/">From product knowledge to responsible engagement: What pharma’s frontline workforce needs today? </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Indian pharma needs to balance innovation, scale and integration for sustained growth </title>
<link>https://edusehat.com/en/indian-pharma-needs-to-balance-innovation-scale-and-integration-for-sustained-growth</link>
<guid>https://edusehat.com/en/indian-pharma-needs-to-balance-innovation-scale-and-integration-for-sustained-growth</guid>
<description><![CDATA[ 
Dr Simta Jadhav, VP, Raay Neopharma, highlights how AI, formulation-led research and backward integration could shape the next phase of Indian pharma’s growth, and discusses why companies need to rethink R&amp;D investment, risk and long-term planning, in an in-person interaction with Neha Aathavale 
The post Indian pharma needs to balance innovation, scale and integration for sustained growth  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/16105021/Dr-Simta-Jadhav.jpg.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 13:35:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Indian, pharma, needs, balance, innovation, scale, and, integration, for, sustained, growth </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/16105021/Dr-Simta-Jadhav.jpg.jpeg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/16105021/Dr-Simta-Jadhav.jpg.jpeg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/16105021/Dr-Simta-Jadhav.jpg-300x160.jpeg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p dir="ltr"><span><strong>India built much of its global pharmaceutical position on the ability to manufacture affordable generics. But as competition increases and the economics of conventional generics come under pressure, is formulation-led innovation becoming the next logical growth engine for Indian pharma? </strong></span></p>
<p></p>
<p dir="ltr"><span>Absolutely yes, considering the current market dynamics and geopolitical uncertainties, I believe formulation-led research is no longer just a logical progression for the Indian pharmaceutical industry; it has become a strategic necessity.</span></p>
<p></p>
<p dir="ltr"><span>There are two major reasons driving this shift. First, the increasing price competition and commoditisation of generics are making it difficult for companies to sustain profitability by relying on volume alone. To remain competitive, companies need to differentiate their products through advanced formulations, improved drug delivery systems and complex generics that offer greater value.</span></p>
<p></p>
<p dir="ltr"><span>Second, government support and enabling policies are becoming increasingly important in encouraging innovation. Initiatives such as the Promotion of Research and Innovation in PharmaMedTech Sector (PRIP) scheme have created opportunities for pharmaceutical companies, including established industry players, to strengthen their R&D capabilities and participate in innovation.</span></p>
<p></p>
<p dir="ltr"><span>Given the substantial investment and risk associated with developing new chemical entities, formulation-led research offers Indian companies a more practical pathway to build on their existing expertise while developing differentiated, commercially viable products.</span></p>
<p></p>
<p dir="ltr"><span>Therefore, I believe we will see a stronger shift towards formulation-led innovation in the coming years. This is not to say that new chemical entity research is unimportant, but rather that formulation-led research aligns more closely with the capabilities and commercial realities of many Indian pharmaceutical companies today.</span></p>
<p></p>
<p dir="ltr"><span>Ultimately, formulation led innovation is no longer simply an opportunity for growth; it is becoming essential for competitiveness, sustainability and the long term survival of Indian pharmaceutical companies. </span></p>
<p dir="ltr"><span>India is increasingly being spoken about as a potential innovation hub rather than only the ‘pharmacy of the world’.</span></p>
<p><strong>What, in your view, needs to change within pharma companies themselves for that transition to happen, particularly in how R&D is funded, evaluated and given room to take risks? </strong></p>
<p></p>
<p dir="ltr"><span>Speaking from my experience in R&D, I believe Indian pharma needs to strike the right balance between its traditional strengths and the changing demands of the industry.</span></p>
<p></p>
<p dir="ltr"><span>Since 2010, Indian pharmaceutical companies have largely built their growth on the generics business, particularly exports to the US. However, with changing trade policies, increasing competition and saturation in several generic segments, the industry is now moving towards complex generics and more differentiated products.</span></p>
<p></p>
<p dir="ltr"><span>In this scenario, I believe Indian companies should increasingly focus on formulation-led innovation rather than immediately moving towards new chemical entities (NCEs), which require significantly higher R&D investments and involve greater financial risks. By leveraging our existing strengths in formulation development, drug delivery systems and complex generics, we can build differentiated products without necessarily taking on the investment burden associated with developing a completely new molecule.</span></p>
<p></p>
<p dir="ltr"><span>However, beyond investment, one of the most important changes required is to build a culture of innovation within Indian pharmaceutical companies. Innovation should not be viewed as an occasional initiative but as an integral part of the organisation’s R&D strategy.</span></p>
<p></p>
<p dir="ltr"><span>Equally important is developing a culture that accepts risk and failure as part of the innovation process. In research, not every project will succeed, and not every investment will translate into a commercial product. A project that fails can still provide valuable scientific insights and learning for future development. Instead of treating failure as a reason to terminate the innovation journey, companies should view it as an opportunity to learn, reassess and improve their approach.</span></p>
<p></p>
<p dir="ltr"><span>Ultimately, the future of Indian pharma will depend not only on how much we invest in R&D, but also on how effectively we innovate, differentiate our products and learn from our experiences. We need to move from being purely volume-driven generic players to innovation-led companies, while continuing to leverage our existing strengths in manufacturing, affordability and formulation expertise.</span></p>
<p></p>
<p dir="ltr"><span><strong>What do you think might be the major reasons for many companies to downsize their R&D? </strong></span></p>
<p></p>
<p dir="ltr"><span>From what I have observed, the current downsizing across several pharmaceutical companies is closely linked to the challenges in their export businesses in specific US market. Traditionally, companies have followed a growth trajectory that begins with the domestic market, expands into the emerging markets, and eventually moves into highly regulated markets such as the US and Europe.</span></p>
<p></p>
<p dir="ltr"><span>Since around 2010, India has established itself as a major player in the global generics market. However, entering and sustaining a presence in US regulated markets has also meant dealing with increasing scrutiny around manufacturing practices, GMP compliance and product quality, particularly from the US FDA. In highly competitive segments, especially where generic products compete directly with innovator brands, regulatory compliance and manufacturing quality become critical factors. At the same time, the market has continued to operate under complex commercial and regulatory dynamics.</span></p>
<p></p>
<p dir="ltr"><span>In my view, one of the major reasons for the current shift is the increasing saturation of the US generics market. Changing US trade policies, tariff-related uncertainties and intensifying competition are putting pressure on the traditional export-driven business model. Since export revenues have historically supported a significant portion of Indian pharmaceutical companies’ growth and R&D investments, any slowdown in this business directly affects their ability to sustain those investments.</span></p>
<p></p>
<p dir="ltr"><span>The domestic market presents a different set of challenges. Price controls under the DPCO and regulation by the NPPA can limit the commercial returns companies achieve on certain formulations. Consequently, even when a company invests in formulation-led or innovation-led research, it may not be able to realise the same value from the product in India as it could in international markets. This creates a fundamental challenge: companies are expected to invest in innovation, but the commercial environment does not always allow them to recover those investments adequately.</span></p>
<p></p>
<p dir="ltr"><span>Another important factor is the evolving regulatory landscape in Europe and the UK following Brexit. Regulatory requirements and submission pathways have changed, and companies may need to reassess their existing regulatory strategies, documentation and dossiers to meet the respective requirements. For example, a regulatory dossier or marketing authorisation approach previously used for the EU may not automatically be sufficient for the UK. Such changes can increase compliance costs, development timelines and the resources required to maintain market access.</span></p>
<p></p>
<p dir="ltr"><span>Therefore, I believe the current reduction in R&D investment is not attributable to a single factor. It reflects a combination of saturation in the US generics market, changing trade policies, domestic price controls and evolving regulatory requirements across international markets.</span></p>
<p></p>
<p dir="ltr"><span>Ultimately, the key challenge for Indian pharma is that the traditional exportdriven model, which helped fund growth and R&D for many years, is becoming more difficult to sustain. Companies now need to reassess their market strategies, diversify their revenue streams and focus on differentiated products and innovation, while ensuring that the commercial returns justify the investments required.</span></p>
<p></p>
<p dir="ltr"><span><strong>There is now a lot of talk about complex generics, differentiated drug delivery and reformulation as the middle ground between conventional generics and discovering a completely new molecule. Do you think Indian pharma is sufficiently willing to invest in this space, or is the industry still too focused on volume and speed to market? </strong></span></p>
<p></p>
<p dir="ltr"><span>Here, I believe Indian pharma needs to strike the right balance between volume and innovation. Our traditional strength has been large-scale manufacturing and the ability to provide affordable medicines. However, with the US increasingly focusing on strengthening domestic manufacturing under its Make in America agenda, relying solely on scale and volume may not be a sustainable long-term strategy. We need to move up the value chain by investing more in innovation.</span></p>
<p></p>
<p dir="ltr"><span>While India is making progress in this direction, the challenge lies in generating adequate returns on R&D investments, particularly when the domestic market alone may not be sufficient to justify the cost and risk involved. Developing a niche product does not necessarily translate into commercial success, and this uncertainty can act as a significant barrier to innovation.</span></p>
<p></p>
<p dir="ltr"><span>At the same time, ensuring access to affordable medicines remains critical. The question is how we balance affordability with the need to create a commercially viable environment for innovation. This is where government policy becomes important— not just in encouraging R&D investments, but also in creating mechanisms that enable companies to recover those investments and generate sustainable returns.</span></p>
<p></p>
<p dir="ltr"><span>Ultimately, we should not move away from our strength in generics and manufacturing scale; rather, we need to build on it by strengthening our innovation capabilities.</span></p>
<p></p>
<p dir="ltr"><span><strong>For a company trying to move beyond the conventional generics playbook, the challenge is not just developing a different product but deciding which problems are actually worth solving. From a leadership perspective, how do you decide where to take an R&D bet and where not to? </strong></span></p>
<p></p>
<p dir="ltr"><span>From an R&D and leadership perspective, I believe the first step is to clearly understand an organisation’s core capabilities and strengths. Every company has its own areas of expertise, and strategic decisions should be built around those strengths rather than driven purely by industry trends. For instance, biologics and biosimilars are receiving significant attention today, but that does not necessarily mean every company should enter these segments without first assessing its capabilities and preparedness.</span></p>
<p></p>
<p dir="ltr"><span>One of the key challenges is the availability of skilled talent. While biotechnology is gaining momentum in India, the pool of professionals with deep, hands-on experience in biologics and biosimilars remains relatively limited compared with the established expertise available in conventional formulation development. Some companies have already invested in these areas, but building the necessary technical capabilities and developing a skilled workforce takes time.</span></p>
<p></p>
<p dir="ltr"><span>Therefore, as leaders, we need to take a two-pronged approach. First, we should strengthen our existing core competencies through innovation, platform technologies and formulation-led research that can create differentiation and establish a sustainable competitive advantage. Second, if we want to enter emerging areas such as biologics and biosimilars, we must invest in the right talent, technical expertise and infrastructure required to succeed.</span></p>
<p></p>
<p dir="ltr"><span>Equally important is the need to evaluate the commercial viability of every R&D investment right from the beginning. We must assess the investment required, the development timelines, the market potential, the expected returns and the competitive landscape. In the generics business, for example, understanding the market forecast, anticipated price erosion and the likely entry of other generic players is critical to making informed decisions.</span></p>
<p></p>
<p dir="ltr"><span>We often see projects being put on hold or discontinued after substantial investments have already been made. This can happen when the initial assessment does not adequately account for development costs, commercial risks or changes in market dynamics. By the time a product is ready for launch, the market opportunity may have diminished significantly.</span></p>
<p></p>
<p dir="ltr"><span>Ultimately, leadership in R&D is not just about deciding what to develop; it is about deciding where to invest, when to invest and whether the investment can deliver sustainable value. A thorough assessment of technical capabilities, talent, timelines, financial commitments and market potential is essential to ensure that innovation is not only scientifically successful but also commercially viable. This is how companies can protect their resources, minimise risks and build a sustainable R&D pipeline for long-term growth.</span></p>
<p></p>
<p dir="ltr"><strong><span>If you look five to ten years ahead, what do you think will distinguish the Indian pharma companies that successfully move up the value chain from those that remain dependent on the traditional generics model? And what leadership choices need to be made now to get there?</span></strong></p>
<p></p>
<p dir="ltr"><span>Looking ahead over the next five to ten years, I believe AI will play a transformative role in the pharmaceutical industry, much like the impact we have already witnessed in the software sector.</span></p>
<p></p>
<p dir="ltr"><span>We are already seeing a shift in how AI platforms are being developed and applied across pharmaceutical R&D. Initially, the focus was largely on compatibility, but today, these platforms are expanding into areas such as formulation stability prediction, clinical study outcomes and biopredictability. For instance, in formulation development, AI-driven platforms have the potential to significantly reduce the number of experimental trials required. What might traditionally take 10 to 15 trials could potentially be narrowed down to just two or three targeted experiments, depending on the formulation and the complexity of the product. Several excipient companies are also developing platforms based on Biopharmaceutics Classification System (BCS) principles, offering ready-to-use formulation approaches that companies can further optimise for their specific requirements. Similar advancements are taking place in predicting in-vivo performance and biopredictability.</span></p>
<p></p>
<p dir="ltr"><span>Therefore, adopting AI will increasingly become a strategic necessity rather than simply a technological advantage. However, successful adoption will depend not only on the availability of these platforms but also on hiring the right talent, building internal capabilities and integrating AI effectively into existing R&D workflows. </span></p>
<p dir="ltr"><span>Another major challenge for pharmaceutical innovation is backward integration and the security of the supply chain, particularly for active pharmaceutical ingredients (APIs), key starting materials and other critical raw materials. Geopolitical disruptions, including conflicts in regions such as West Asia, have highlighted how vulnerable supply chains can be. In some cases, sourcing APIs, raw materials or even specific impurities can take three to four months, potentially delaying development timelines and product launches.</span></p>
<p></p>
<p dir="ltr"><span>Therefore, going forward, pharmaceutical companies need to focus on two critical priorities: leveraging AI to improve the speed and efficiency of R&D, and strengthening supply-chain resilience through better sourcing strategies and backward integration wherever commercially viable. Ultimately, the future competitiveness of Indian pharma will depend on how effectively we combine technology-driven innovation with supply-chain security. AI can help us develop products faster and more efficiently, while stronger control over critical raw materials can help ensure that these innovations reach the market without unnecessary delays. </span></p>
<p dir="ltr"><span><br>
</span><span><br>
</span><b><span>neha.aathavale@expressindia.com<br>
</span><span>nehaaathavale75@gmail.com</span></b></p>
<p><span> </span></p>
<p>The post <a href="https://www.expresspharma.in/indian-pharma-needs-to-balance-innovation-scale-and-integration-for-sustained-growth/">Indian pharma needs to balance innovation, scale and integration for sustained growth </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Amid Nvidia Turmoil, What Happens to Its Life Sciences Collaborations?</title>
<link>https://edusehat.com/en/stockwatch-amid-nvidia-turmoil-what-happens-to-its-life-sciences-collaborations</link>
<guid>https://edusehat.com/en/stockwatch-amid-nvidia-turmoil-what-happens-to-its-life-sciences-collaborations</guid>
<description><![CDATA[ While Nvidia doesn’t develop new therapies, instruments, or reagents, its AI technology powers numerous collaborations with biopharma and lab tools giants stretching back at least five years.
The post StockWatch: Amid Nvidia Turmoil, What Happens to Its Life Sciences Collaborations? appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Jensen-Huang-GTC-2024-031924__8fe9c08a-2e0e-4991-b7f5-8c6dbde0ae73.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 06:40:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Amid, Nvidia, Turmoil, What, Happens, Its, Life, Sciences, Collaborations</media:keywords>
<content:encoded><![CDATA[<p>Shakespeare and Greek mythology have met their match with the dramatic personal downfall story that culminated in Jensen Huang’s sudden resignation as CEO of <strong>Nvidia (Nasdaq: NVDA)</strong> amid turmoil caused by up to three reported extramarital affairs. While Nvidia doesn’t develop new therapies, instruments, or reagents, its AI technology powers numerous collaborations with biopharma and lab tools giants <a href="https://www.genengnews.com/gen-edge/from-model-to-molecule-nvidia-doubles-down-on-ai-drug-discovery/">stretching back at least five years</a>.</p>
<p>Nvidia’s board named Colette Kress as interim CEO. Kress has served as executive vice president and CFO since joining the company in 2013.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“The Board has full confidence in Colette and the leadership team, and we expect the company’s operations, customer commitments, and product roadmap to continue without interruption,” Harvey C. Jones, an Nvidia board member since 1993 who was named chair on Thursday, said in a statement. Jones is an entrepreneur, technology executive, and active venture investor who had served as CEO and executive chairman of silicon design provider Synopsys.</p>
<p>The first reported affair raised national security issues after Huang disclosed in a <a href="https://nvidianews.nvidia.com/news/a-message-to-our-company">letter to Nvidia employees made public November 8</a> that he had conducted an extramarital relationship with Alice Huang (no relation), founder of Megaspeed International, an Nvidia customer and Singapore-based provider of cloud computing and AI infrastructure services. The disclosure touched off an investigation by Nvidia’s board into Jensen Huang’s relationship with Alice Huang, who according to U.S. intelligence officials may have passed along sensitive information to China’s Ministry of State Security; Beijing has denied she carried out any intelligence activity for China.</p>
<p>Three days later on Wednesday, <em>The New York Times</em> cited five unnamed sources in reporting that Huang had an extramarital relationship with an Nvidia executive identified by the newspaper as Kimberly Powell, who as vice president of healthcare and life sciences served as Nvidia’s top executive overseeing its hardware and software platforms for accelerated computing, AI, and visualization in applications ranging from drug discovery to medical imaging and healthcare analytics. The following day, Reuters cited two unnamed sources in reporting an affair between Jensen Huang and a second Nvidia employee whom it did not name.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>“OK, this is very, very, very sad, and may and will have dramatic consequences for the entire industry,” Alex Zhavoronkov, PhD, the founder, CEO, and CBO of <strong>Insilico Medicine</strong> <strong>(Hong Kong Exchange: 3696)</strong>,” <a href="https://x.com/biogerontology/status/2120817926005571686">posted Thursday on X</a>. “Now, half of the massively overvalued AI drug discovery startups with no productivity metrics, no drugs, and no long-term moat will not be able to fundraise from Nvidia for a while.”</p>
<h4><strong>Bedroom bubble burst</strong></h4>
<p>“Who knew that the AI bubble would burst in the employee bedroom…,” added Zhavoronkov, who also leads Insilico’s board as chairman and executive director. He added in a <a href="https://x.com/biogerontology/status/2120875228981010472">separate post</a>: “Let’s hope it all settles without too much drama and Jensen keeps working hard (and probably even harder).”</p>
<p>On Friday, Zhavoronkov recalled how during his company’s struggling early years, Jensen Huang <a href="https://x.com/biogerontology/status/2121323131801333922">recorded a video</a> marking the launch of Insilico’s Pharma.AI drug discovery platform: “When Jensen recorded this video in 2022 2 weeks before the launch of consumer ChatGPT, I honestly could not hold my tears. When I watched it today, I could not hold my tears either.”</p>
<p>“Some of my followers on LinkedIn are even celebrating. There is nothing to celebrate. This is a real tragedy and it will have industry-scale consequences. I truly hope that Jensen comes back in some capacity,” Zhavoronkov added. “To all my friends at NVIDIA—please stay strong and let’s work together to solve aging. Support Jensen and his wonderful family. We respect you and love you even though we [are] not a buyer of chips.”</p>
<p>The reported affairs and resignation of Huang sent Nvidia shares sinking this past week. The declines compounded a month-long Nvidia stock slide stemming from investor worries about whether the spending of tech giants on AI infrastructure will result in <span data-subtree="aimfl,mfl">sustainable cash flow, profits, and revenue quickly enough to justify the expense. </span>Those fears have caused Nvidia stock to <span><strong>nosedive</strong><strong> 32% </strong></span>since hitting a record closing price of $239.24 on October 6.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Nvidia shares began the week <span><strong>slipping 4%</strong></span> on November 9, from $186.64 to $178.67.  Shares <span><strong>slid another 5.5%</strong></span> Tuesday to $168.89, <span><strong>rebounded nearly 3%</strong></span> Wednesday to $173.73, then <span><strong>fell again 4%</strong> </span>Thursday to $166.19 after starting that day <span><strong>tumbling 14%</strong></span> following Huang’s resignation. Shares finished this past week <span><strong>dipping 2% </strong></span>Friday, closing at $162.85—a <strong><span>five-day decline of 12.75%</span></strong><strong><span>.</span></strong></p>
<p>“The stakes behind Huang’s resignation reveal the murky waters that businesses using AI are swimming in,” Asa Hiken, senior analyst with Emarketer, wrote in a commentary posted on the website of the market research and digital intelligence company. “On the surface, AI is a tool for powering productivity, creative production, or novel customer experiences, but in the depths it’s a swelling geopolitical powder keg. Disentangling these two sides of the technology is impossible.”</p>
<p>Stacy Rasgon, managing director and senior analyst, U.S. semiconductors and semiconductor capital equipment at Bernstein Research, cautioned that Nvidia’s challenges have not ended with the resignation of Jensen Huang.</p>
<h4><strong>“Considerable uncertainty”</strong></h4>
<p>“We see considerable uncertainty around further news flow that is probably going to be coming down the pipe, as well as the ability of any new CEO to truly fill Jensen’s shoes given how tightly he managed the direction of the business and its relationships with customers, suppliers, employees, and the broader industry ecosystem,” Rasgon wrote in a research note, as reported by <em>Bloomberg News</em>.</p>
<p><span data-subtree="aimfl,mfl">Nvidia and its venture arm NVentures </span>participated in 122 startup funding deals in 2026 as of Friday, according to Crunchbase, while PitchBook counted 67 such deals in 2025 and 54 in 2024. Given Nvidia’s investment in AI startups, Rasgon wrote: “We wonder what will happen to the company’s myriad of investments in the space, various backstops and residual guarantees.” Rasgon downgraded Bernstein’s rating on Nvidia stock to “Market Perform” and lowered the firm’s price target to $200.</p>
<p>“Our gut tells us that we probably haven’t yet fully probed the depths of what might be found here,” Rasgon commented, adding: “We’ve had enough, and prefer to watch from the sidelines.”</p>
<p>A recent example of Nvidia’s life sciences footprint came earlier this month when <strong>10x Genomics (Nasdaq: TXG),</strong> a developer of scalable single-cell and spatial biology platforms, launched Sentira Single Cell, a cloud-based agentic analysis application for users of the company’s Chromium single-cell platform, powered by the Claude models of <strong>Anthropic (Nasdaq: ANT; IPO pending)</strong>. The launch came weeks after 10x unveiled Sentira Spatial Analysis for users of 10x’s Atera <em class="zhvwWe" data-sfc-cp="" data-sfc-root="c" data-complete="true">in situ</em> spatial biology and transcriptomics platform.</p>
<p>Both applications apply Nvidia’s accelerated computing capabilities with the aim of speeding up widely used biological analysis methods; Sentira Spatial Analysis, for example, can reduce the analysis iteration cycle from hours on CPU alternatives to minutes. Underpinning that speed is rapids-singlecell, an open-source, GPU-accelerated Python library designed for large-scale single-cell omics analysis such as single-cell RNA sequencing. Rapids-singlecell was co-developed by Nvidia with scverse, an open-source, community-governed ecosystem of packages for single-cell and spatial omics.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p><strong>“Incredibly powerful company”</strong></p>
<p>“Nvidia is an incredibly powerful company, and it’s not just one person who made it so,” Serge Saxonov, PhD, 10x’s co-founder and CEO, told <em>GEN</em> when asked whether recent Nvidia news including Huang’s resignation would cause 10x to review the partnership. “We’ve had an incredible relationship with the people over there. They’ve done incredible work in this collaboration.”</p>
<p>Over the past five years, Nvidia has initiated a variety of partnerships with tools developers, drug developers, and others within the life sciences. During the J.P. Morgan Healthcare Conference in January, Nvidia <a href="https://www.genengnews.com/topics/artificial-intelligence/jpm-nvidia-launches-ai-collaborations-with-eli-lilly-thermo-fisher/">launched a pair of collaborations with life-sci giants</a>: The company joined <strong>Eli Lilly (NYSE: LLY)</strong> in committing $1 billion over five years to create a “Co-Innovation AI Lab” designed to address key challenges in AI drug discovery. Nvidia also announced plans to integrate its AI technology into the lab instruments of <strong>Thermo Fisher Scientific (NYSE: TMO)</strong> through a collaboration intended to develop intelligent and increasingly autonomous laboratories.</p>
<p>Through a spokesperson, Thermo Fisher confirmed receipt of <em>GEN’s</em> query but offered no comment.</p>
<p>Also on the tools side, <strong>Danaher (NYSE: DHR)</strong> <a href="https://www.genengnews.com/topics/artificial-intelligence/danaher-nvidia-combine-lab-instrumentation-and-ai-to-advance-autonomous-science/">agreed to partner with Nvidia last month</a>. Danaher agreed to combine its scientific instrumentation, automation technologies, laboratory workflow software, and domain expertise with Nvidia’s accelerated computing and AI technologies.</p>
<p>Nvidia in recent years has also partnered with the Novo Nordisk Foundation, the nonprofit majority owner of Lilly’s arch-rival in obesity and diabetes drug development <strong>Novo Nordisk (Nasdaq Copenhagen: NOVO-B; NYSE: NVO). </strong> The foundation agreed in June 2025 to house an Nvidia supercomputer at the Danish Centre for AI Innovation, which last month announced it had invested in 32 NVIDIA DGX Rubin NVL8 systems, giving Denmark access to the latest generation of AI infrastructure.</p>
<p>Earlier, Nvidia partnered with British-based pharma giants <strong>AstraZeneca (London, Nasdaq Stockholm, and NYSE: AZN)</strong> and <strong>GlaxoSmithKline (London: GSK)</strong> to <a href="https://www.genengnews.com/topics/nvidia-powers-up-in-drug-discovery/" target="_blank" rel="noopener">build the U.K.’s most powerful supercomputer, Cambridge-1</a>, in 2020 through a partnership that also included the kingdom’s National Health Service (NHS).</p>
<p>Spokespeople for Lilly, AstraZeneca, and GSK at deadline had not responded to <em>GEN</em> queries about whether they would review their partnerships with Nvidia. Novo Nordisk referred <em>GEN</em> to the Danish Centre for AI Innovation, which at deadline had not responded either.</p>
<p>“Nvidia’s strength has always come from its people, and together with our leadership team, I am committed to building on the extraordinary foundation Jensen created over the last 33 years,” Kress said in a <a href="https://nvidianews.nvidia.com/news/nvidia-announces-ceo-transition">statement</a>. “We will continue advancing the work that has made Nvidia a leader in accelerated computing and AI, and execute on the opportunities ahead. Our focus remains on serving our customers, partners, developers and shareholders.”</p>
<h2><strong>PepGen nearly doubles on record-setting data</strong></h2>
<p><strong>PepGen (Nasdaq: PEPG)</strong> <span>nearly doubled </span>its stock price this past week after announcing dazzling mid-stage clinical results for its lead pipeline candidate PGN-EDODM1 that included the highest level of splicing correction ever reported in a multiple dose trial in patients with myotonic dystrophy type 1 (DM1).</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>PepGen shares <span><strong>rocketed 82%</strong></span> from $2.39 on Tuesday, when it announced its record-setting data, to $4.36 at Friday’s closing bell. The stock surge began when PGN-EDODM1, an enhanced delivery oligonucleotide (EDO) designed to address the underlying molecular mechanism of DM1, aced the Phase II FREEDOM2-DM1 trial (<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fcts.businesswire.com%2Fct%2FCT%3Fid%3Dsmartlink%26url%3Dhttps%253A%252F%252Fclinicaltrials.gov%252Fstudy%252FNCT06667453%26esheet%3D54638669%26newsitemid%3D20261110113813%26lan%3Den-US%26anchor%3DNCT06667453%26index%3D2%26md5%3D5a92794d5b85f74e98acc93436221eb2&data=05%7C02%7Calex.philippidis%40sagepub.com%7Ccb531c62777e4cc9439808df4036ce7c%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639300276903378491%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=R4jhElEbO8HDvsmXhtBQ34iSQ8Wb3z%2BqB4o5dxECqvI%3D&reserved=0">NCT06667453</a>). PGN-EDODM1 attained a record-breaking 46.5% mean splicing correction in muscle, with four of six participants showing more than 50% splicing correction and all but one of the six, more than 20% splicing correction as measured by the 22-gene panel at Week 13.</p>
<p>In contrast, a pooled group of four participants receiving placebo (combined from Cohorts 1 and 2) showed a mean splicing correction of just 6.8% was 6.8% at Week 13.</p>
<p>Participants also showed sustained improvements in the video Hand Opening Time (vHOT), hand grip strength, 10-Meter Walk/Run Test (10MWRT), and Timed Up and Go (TUG) functional assessments—data that PepGen said offered compelling evidence of PGN-EDODM1’s potential to address multiple clinical manifestations of DM1 and supporting continued development.</p>
<p>“Our ambition is to fundamentally change how DM1 is treated through greater targeting of the underlying molecular mechanism of the disease,” James McArthur, PhD, PepGen’s president and CEO, said in a statement. “The 10 mg/kg results mark an important milestone in that pursuit, with robust splicing correction accompanied by encouraging improvements across multiple measures of muscle function.”</p>
<p>McArthur said the data strengthened PepGen’s confidence not only in PGN-EDODM1’s potential, but in the company’s broader development strategy.</p>
<p>“With our 12.5 mg/kg cohort fully enrolled and the ongoing FREEDOM-OLE study exceeding 135 doses administered, we believe we are well positioned to continue building the evidence needed to advance toward pivotal studies,” the CEO added.</p>
<p>PepGen quickly sought to cash in on its clinical triumph by launching a $125 million public offering of its common stock—though some investors could instead opt for pre-funded warrants to purchase shares of the stock. Net proceeds from the offering are intended, PepGen said, to fund ongoing clinical development of PGN-EDODM1, as well as provide working capital and address other general corporate purposes.</p>
<p>PepGen also granted the underwriters of its offering a 30-day option to purchase up to an additional $18.75 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. Leerink Partners, Stifel, and Guggenheim Securities acted as joint bookrunning managers for the proposed offering.</p>
<p><strong>“New bar in DM1”</strong></p>
<p>PepGen’s clinical success quickly won over analysts and investors.</p>
<p>“PEPG’s best-in-disease splicing and vHOT with favorable (renal) safety at 10[mg/kg] sets the new bar in DM1,” declared Kostas Biliouris, PhD, a managing director on the biotechnology research team of Oppenheimer.</p>
<p>Similarly, Debjit Chattopadhyay, PhD, a senior managing director and equity research analyst covering the biotechnology sector at Guggenheim Securities—one of the joint bookrunning managers for the $125 million public offering—hailed PepGen’s results as “potentially the new benchmark for splicing,” according to several published reports. Chattopadhyay contrasted PepGen’s 49% mean correction with the <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.dyne-tx.com%2Fwp-content%2Fuploads%2FLilleker_2025_MDA_ACHIEVE_Poster.pdf&data=05%7C02%7Calex.philippidis%40sagepub.com%7Ccb531c62777e4cc9439808df4036ce7c%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639300276903390053%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=NxeNPbdQGBLGYN4KvuC6p1jaL7W7C60BWHbr7UtmPd8%3D&reserved=0">25% mean correction at three months</a> reported last year by Dyne Therapeutics (Nasdaq:DYN) from its Phase I/II ACHIEVE trial (<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05481879&data=05%7C02%7Calex.philippidis%40sagepub.com%7Ccb531c62777e4cc9439808df4036ce7c%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639300276903400969%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=FLMs4PEuSozS%2FHMrQAKPpGb27YGnFuwqTWRvDGgkjzM%3D&reserved=0">NCT05481879</a>) evaluating a 6.8 mg/kg every eight weeks dose of DM1 candidate DYNE-101.</p>
<p>Tazeen Ahmad, a senior research analyst covering large-cap and small-cap biotechnology companies with BofA Securities, upgraded PepGen shares from “Underperform” to “Neutral,” and raised her firm’s 12-month price target on the company’s shares 140%, from $2.50 to $6.</p>
<p>Investors responded with a buying surge that sent PepGen stock nearly doubling on November 10, <span><strong>rocketing nearly 93%</strong></span> from $2.39 to $4.61. Shares <span><strong>soared another 14%</strong></span> Wednesday, reaching $5.26 before <span><strong>dropping 4%</strong></span> to $5.04 Thursday and <span><strong>skidding another 13.5%</strong></span> Friday.</p>
<h2>Leaders and laggards</h2>
<ul>
<li><strong>Capricor Therapeutics (Nasdaq: CAPR)</strong> shares <span><strong>jumped 26.5%</strong></span> from $8.87 to $11.22 Wednesday after JonesTrading upgraded its rating of the company’s stock from “Hold” to “Buy” with a $25 price target. JonesTrading cited the upcoming Prescription Drug User Fee Act (PDUFA) target action date of November 22 on the company’s re-submitted Biologics License Application (BLA) for its lead cell therapy candidate deramiocel in Duchenne muscular dystrophy (DMD). In August, Capricor proposed narrowing its indication to treating upper limb impairment in DMD patients >9 years old, the population studied in its HOPE-3 trial (<a href="https://clinicaltrials.gov/study/NCT05126758">NCT05126758</a>) and the focus of its primary endpoint. The company also submitted two-year open-label extension data and additional robustness analyses from HOPE-3, and an integrated summary of efficacy across HOPE-3 and the earlier Phase II HOPE-2 trial (<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03406780&data=05%7C02%7Calex.philippidis%40sagepub.com%7C4571c158c0f349617bec08deee5ea16e%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639210287674957401%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=jfCAmFpi0Jb9AWfISbsBGxnx0L0%2F7atGyRuFk8m9bMw%3D&reserved=0">NCT03406780</a>). The FDA classified the August submission as a major amendment, extending the review by three months from the original August 22 date.</li>
<li><strong>Oragenics (NYSE American: OGEN)</strong> shares <span><strong>plummeted nearly 43%</strong></span> from 35 cents to 20 cents Friday, after the developer of intranasal brain-targeted therapeutics announced third quarter results showing a net quarterly loss of $2.603 million, and a nine-month net loss of $7.333 million. The stock plunge occurred despite positive news: The NYSE Regulation rules enforcement arm had accepted its plan to regain compliance with NYSE American listing standards and granted an extension through February 25, 2028 to do so. “We believe this approval allows us to maintain our NYSE American listing while we continue to pursue our strategic priorities, capital raising initiatives, and investment strategies designed to enhance long-term value for our shareholders,” CEO Janet Huffman stated. Oragenics lost compliance due to a low stockholders’ equity of $3.7 million as of June 30, plus losses from continuing operations and/or net losses in its five most recent fiscal years ended December 31, 2025.</li>
</ul>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/stockwatch-amid-nvidia-turmoil-what-happens-to-its-life-sciences-collaborations/">StockWatch: Amid Nvidia Turmoil, What Happens to Its Life Sciences Collaborations?</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Electricity&#45;generating toothbrush shown to reduce plaque&#45;causing bacteria</title>
<link>https://edusehat.com/en/electricity-generating-toothbrush-shown-to-reduce-plaque-causing-bacteria</link>
<guid>https://edusehat.com/en/electricity-generating-toothbrush-shown-to-reduce-plaque-causing-bacteria</guid>
<description><![CDATA[ An electricity-generating toothbrush may improve plaque control and reduce harmful oral bacteria – find out more about this and other new updates from the dental sector. The device uses piezoelectric monofilament bristles, which produce electrical charges as they bend during brushing. These charges generate reactive oxygen species that can disrupt bacterial biofilms – the protective… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/07/This-Week-in-Dentistry-HERO-2-1024x682.png" length="49398" type="image/jpeg"/>
<pubDate>Sun, 15 Nov 2026 16:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Electricity-generating, toothbrush, shown, reduce, plaque-causing, bacteria</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>An electricity-generating toothbrush may improve plaque control and reduce harmful oral bacteria – find out more about this and other new updates from the dental sector.</strong></p>



<p>The device uses piezoelectric monofilament bristles, which produce electrical charges as they bend during brushing. These charges generate reactive oxygen species that can disrupt bacterial biofilms – the protective communities that allow plaque-causing bacteria to persist on teeth.</p>



<p>In laboratory tests, the toothbrush reduced pathogens including <em>Porphyromonas gingivalis</em>, which is associated with periodontitis. Researchers also assessed the device in 115 volunteers over three months. Participants received the same brushing instructions, but those using the electricity-generating toothbrush showed lower relative levels of several oral pathogens, based on gene and metagenome sequencing of oral samples.</p>



<p>The researchers reported improvements in plaque control, gingival inflammation and bleeding compared with conventional nylon-bristled toothbrushes. The findings suggest that integrating piezoelectric materials into everyday oral-health tools could add an antimicrobial effect to mechanical brushing without requiring a powered device or chemical treatment.</p>



<p>The research was highlighted by the American Association for the Advancement of Science. Further research will be needed to confirm longer-term clinical benefits, establish how the technology performs in broader patient groups and assess its potential role alongside established preventive care.</p>



<h2 class="wp-block-heading">Study links chronic stress with oral cancer progression</h2>



<p>Chronic psychological stress may actively contribute to oral squamous cell carcinoma (OSCC) progression through a newly identified brain-bone marrow-immune pathway, according to researchers at West China Hospital of Stomatology, Sichuan University.</p>



<p>Published in the <em>International Journal of Oral Science</em>, the study combined UK Biobank data, patient samples and several mouse models. </p>



<p>The researchers found that changes caused by stress reduced cancer-fighting T-cell activity and promoted tumour growth and recurrence. In mice, blocking a receptor pathway restored anti-tumour immune activity and improved the effect of immunotherapy. </p>



<p>The authors stress that the observational UK Biobank analysis cannot establish causation, and clinical studies are needed. Nevertheless, the findings may support future biomarker development and closer monitoring of patients experiencing anxiety or depression.</p>



<h2 class="wp-block-heading">Registration opens for 2027 Chicago Midwinter Meeting</h2>



<p>Registration is now open for the Chicago Dental Society’s (CDS) 2027 Midwinter Meeting, taking place at McCormick Place West, Chicago, from 25-27 February 2027.</p>



<p>The meeting will feature more than 240 courses delivered by 149 dental-industry speakers, half of whom are new to the programme. More than 50 workshops will provide hands-on learning, alongside curated learning pathways, expanded wellbeing content on ergonomics and career longevity, and programming developed with The Pankey Institute.</p>



<p>A new Midwinter Meeting Digital Pass will give delegates unlimited virtual access to recorded lectures. It can be bought with in-person registration or separately, enabling those unable to travel to access the educational programme. CDS says the pass will allow in-person attendees to spend more time in workshops, the exhibition and networking events without missing recorded lectures.</p>



<p>The exhibition hall will retain additions introduced previously, including relax and recharge lounges, Hadley’s pet park and expanded food and drink options. New layouts are also planned for the early career dentist and dental student lounges.</p>



<p>Other features include a quiet and prayer room, afternoon yoga, dine-around networking events and a keynote from Olympic figure-skating champions and broadcasters Tara Lipinski and Johnny Weir.</p>



<h2 class="wp-block-heading">Dentaid launches royal-themed Crown Challenge</h2>



<p>Dentaid The Dental Charity has opened registration for its new Crown Challenge, inviting the dental community to dress in royal-inspired attire and raise money for people unable to access dental care.</p>



<p>The flagship event, the Windsor Ultra Challenge, will take place on Saturday 17 April 2027. Participants can walk, run or jog 10km, 25km or 50km, beginning and ending at Windsor Racecourse. The routes will take in Windsor Great Park and views of Windsor Castle.</p>



<figure class="wp-block-image size-large"></figure>



<p>Entrants will receive event support including food and drink stations, medical provision, parking, shuttle transfers and camping options. Finishers will receive medals, T-shirts and celebratory drinks. Registration costs £15 for 10km, £30 for 25km and £40 for 50km. Minimum fundraising targets are £150, £275 and £375 respectively.</p>



<p>For supporters unable to attend Windsor, Dentaid is also offering a ‘your palace, your pace’ option. Participants can choose their own route and distance, ideally beginning near a local castle or palace, with support from Dentaid’s fundraising team.</p>



<p>Money raised will support Dentaid’s mobile dental outreach services for people experiencing homelessness, poverty, harm and abuse across the UK. Chief executive Andy Evans said the event aims to bring together dental practices, suppliers, clinicians and other supporters for a shared fundraising challenge.</p>



<h2 class="wp-block-heading">HuFriedyGroup to acquire Mectron’s dental business</h2>



<p>Mectron has signed an agreement to sell its dental business to HuFriedyGroup, expanding the global reach of its Italian-made piezoelectric and air-polishing technologies. The transaction, expected to complete by the end of 2026 subject to customary conditions, covers Mectron’s Italian dental operation, its German subsidiary’s dental activities and the dental business of US subsidiary Piezosurgery Inc.</p>



<div class="wp-block-media-text is-stacked-on-mobile"><figure class="wp-block-media-text__media"></figure><div class="wp-block-media-text__content">
<p>Importantly, manufacturing will remain at Mectron’s long-standing Carasco, Liguria site. Under a multi-year supply agreement, Mectron will continue making the full dental range for HuFriedyGroup, preserving local production expertise, jobs and research capability. Dental commercial and research and development staff will join HuFriedyGroup.</p>



<p>Mectron, founded in 1979 and known for developing PIEZOSURGERY technology, says the deal will give its products access to HuFriedyGroup’s distribution network across around 100 countries – double the approximately 50 markets it currently serves directly. The companies have already worked together since 2023, when HuFriedyGroup began distributing selected Mectron devices in the US and Canada.</p>
</div></div>



<p>Following the sale, Mectron will focus on its medical business, including piezoelectric surgical systems used in operating theatres. Both businesses will remain independent until completion.</p>



<p><em>Follow <a href="https://www.instagram.com/dentistry.co.uk/" target="_blank" rel="noreferrer noopener">Dentistry.co.uk</a> on Instagram to keep up with all the latest dental news and trends.</em></p>]]> </content:encoded>
</item>

<item>
<title>Shining a light on digital imaging in undergraduate education</title>
<link>https://edusehat.com/en/shining-a-light-on-digital-imaging-in-undergraduate-education</link>
<guid>https://edusehat.com/en/shining-a-light-on-digital-imaging-in-undergraduate-education</guid>
<description><![CDATA[ Six educators explain how digital imaging, communication and mentorship can help dental students gain confidence for independent practice. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/imaging.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 14 Nov 2026 15:35:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Shining, light, digital, imaging, undergraduate, education</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>As Acteon’s national dental imaging education initiative, Illuminate, gets underway, leading clinicians and educators consider how well students are prepared for practice and where digital imaging could help.</strong></p>



<h2 class="wp-block-heading">When theory meets practice</h2>



<p>There is comfort in knowing someone experienced is nearby when a clinical decision feels uncertain. During training, students can discuss their thinking and seek reassurance. Once in practice, however, appointments move quickly, patients bring different expectations and even familiar procedures can feel daunting. Many established clinicians will remember those early days and the difference supportive colleagues can make.</p>



<p>Drawing on their own experiences, six members of the Acteon Illuminate judging panel, who will assess students’ anonymised imaging case studies for clinical reasoning and patient communication, share their thoughts on what could make graduates’ early experiences of practice easier.</p>



<p>Dr Randeep Gill, AI Keynote Speaker and Strategist, and host of The TechDental Podcast, believes graduates leave university clinically prepared, although the administrative demands, financial considerations and systems involved in running a practice can come as a surprise.</p>



<p>‘Most graduates are confident with a handpiece long before they are confident with a fee conversation.’</p>



<p>He hears concerns about time pressure, discussing costs and finding genuine mentorship, and believes practices need to be realistic about what they ask of new graduates.</p>



<p>‘Expect safe, honest clinicians who ask for help and are willing to learn, not speed.’</p>



<h2 class="wp-block-heading">Communication is a clinical necessity</h2>



<p>Dr Raabiha Maan, principal dentist and practice owner, founder of the Patient Journey Academy, and dental communication educator and mentor, is concerned about limited hands-on experience and the confidence needed to build patient relationships.</p>



<p>‘We spend years teaching students how to diagnose and treat dental disease, but comparatively little time teaching them how to communicate with the person sitting in the chair.’</p>



<p>She describes the emotional complexity of dentistry, where an anxious patient might be followed by someone experiencing bereavement or another who distrusts dentists. Each encounter calls for sensitivity and an ability to adapt.</p>



<p>‘Communication isn’t a soft skill in dentistry, it’s a clinical necessity.’</p>



<h2 class="wp-block-heading">The confidence to connect</h2>



<p>Donna Schembri, clinical educator and dental therapist, highlights the value of intraoral imaging in supporting patient conversations. She has seen how simply showing patients their own images can encourage questions and greater involvement in their care.</p>



<p>‘I’ve often taken routine images as a baseline record and left them on the screen whilst updating my notes. It’s amazing how frequently patients will start asking questions themselves.’</p>



<p>This can be particularly valuable for clinicians developing confidence in explaining findings, although Donna believes that support from colleagues matters just as much.</p>



<p>‘Having an experienced, approachable colleague who can offer guidance, reassurance and constructive feedback can make an enormous difference.’</p>



<h2 class="wp-block-heading">Digital imaging and clinical support</h2>



<p>Amy Hayes, Acteon’s Global Clinical Education Manager and a qualified dental hygienist and therapist, points to another challenge facing graduates: unfamiliar equipment, which can add to the pressures of starting work. She also sees real value in imaging as a way of seeking guidance and reassurance when a second opinion is needed.</p>



<p>‘Instead of trying to find the right words, or asking a colleague to come and look while the patient waits, you can capture a clear image, add it to the record and share it straight away with a more experienced colleague.’</p>



<p>Beyond the technology itself, Amy would like to see a consistent first-year support pathway for every newly qualified member of the dental team.</p>



<h2 class="wp-block-heading">Preparing for practice together</h2>



<p>Louisa Clarke, tutor dental hygienist at the Eastman Dental Hospital, recognises the difference between clinical competence and the confidence that develops through experience.</p>



<p>‘While students leave university with the skills and knowledge required for safe practice, managing complex cases independently, adapting to the pace of general practice, and making autonomous clinical decisions are areas that continue to develop with experience.’</p>



<p>Eastman’s final-year Preparing for Practice module is one response, introducing students to primary care and professional expectations. Louisa would also welcome structured mentorship and protected learning time after qualification.</p>



<p>Shameek Popat, CEO and Co-Founder of Tooth Angel and Disruptive Smiles, similarly believes most clinical skills need time to be developed. He advocates more opportunities to practise clinical procedures and gain business knowledge during training, alongside appropriate equipment, materials and staff support once graduates enter practice.</p>



<h2 class="wp-block-heading">Providing the best start</h2>



<p>Through Illuminate, students can gain hands-on experience of digital imaging and submit case studies that put their clinical reasoning and patient communication skills to work. It is an opportunity to practise while still having educators nearby to offer advice.</p>



<p>Once they enter practice, colleagues who take the time to answer questions, discuss difficult cases and offer encouragement can make a real difference, helping graduates find their feet and enjoy the dentistry they have worked so hard to learn.</p>



<p>To find out more about Acteon Illuminate, visit <a href="https://acteon.foleon.com/uk/illuminate" target="_blank" rel="noreferrer noopener">acteon.foleon.com/uk/illuminate</a>.</p>



<p><em>This article is sponsored by Acteon</em>.</p>]]> </content:encoded>
</item>

<item>
<title>DCIS Cell Atlas Reveals Clues to Invasive Breast Cancer Progression</title>
<link>https://edusehat.com/en/dcis-cell-atlas-reveals-clues-to-invasive-breast-cancer-progression</link>
<guid>https://edusehat.com/en/dcis-cell-atlas-reveals-clues-to-invasive-breast-cancer-progression</guid>
<description><![CDATA[ Researchers created a detailed map of the tumor microenvironment surrounding estrogen receptor-positive ductal carcinoma in situ, which may help better predict progression to invasive breast cancer and inform on future therapeutic strategies. 
The post DCIS Cell Atlas Reveals Clues to Invasive Breast Cancer Progression appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_NavinDCIS.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 14 Nov 2026 07:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>DCIS, Cell, Atlas, Reveals, Clues, Invasive, Breast, Cancer, Progression</media:keywords>
<content:encoded><![CDATA[<p>Researchers at The University of Texas MD Anderson Cancer Center have created what they say is one of the most detailed maps to date of the tumor microenvironment (TME) surrounding estrogen receptor-positive (ER+) ductal carcinoma <em>in situ</em> (DCIS), the most common form of preinvasive—stage 0—breast cancer. The atlas was created by analyzing samples from normal breast tissue, DCIS and invasive breast cancers.</p>
<p>The study findings may help to explain why some lesions progress to invasive breast cancer and others do not and inform strategies for improving patient risk prediction and developing better targeted approaches for those at higher risk of invasive disease.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“DCIS is considered a snapshot before breast cancer becomes invasive, but not all DCIS cases progress to invasive disease, and the biology surrounding these lesions has been challenging to examine,” said research co-lead Nicholas Navin, PhD, chair of Systems Biology. “This atlas reveals the surrounding cells and structures that may help disease become invasive. In the future, these findings may allow clinicians to better identify and treat patients with DCIS who are at higher risk of invasive progression while also avoiding unnecessary treatments for those at low risk.”</p>
<p>Navin, together with research co-lead Savitri Krishnamurthy, MD, professor of Anatomical Pathology, as well as co-first authors Siyuan He, PhD, and Aatish Thennavan, PhD, postdoctoral fellows of Systems Biology, and colleagues, reported on their findings in <em>Science,</em> in a paper titled “<a href="http://dx.doi.org/10.1126/science.aef4622" target="_blank" rel="noopener">A cellular atlas of the preinvasive breast cancer microenvironment</a>.” In their report the team stated that their data “… greatly improve our fundamental understanding of the DCIS microenvironment and the progression of invasive disease.”</p>
<p>DCIS occurs when abnormal cells grow inside the breast milk ducts but have not yet spread into surrounding tissue, and is considered to be a precursor to the most common type of breast cancer. “Ductal carcinoma <em>in situ</em> (DCIS) is precursor of invasive ductal carcinoma (IDC), in which the preinvasive cells are confined within the basement membrane of breast ductal-lobular structures,” the authors wrote.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Mammograms and other breast examinations have increased the detection of DCIS cases, but many of these lesions never progress to invasive disease, making it challenging to determine which patients actually need more aggressive treatment. “Over the last three decades, routine breast mammography screening has led to overdiagnosis of DCIS that now represents up to 25% of all diagnosed breast cancer cases,” the team continued. “If left untreated, only 10-30% of women with DCIS will progress to invasive disease.”</p>
<p>While genetic changes in DCIS have been well-studied, little is known about its tumor microenvironment—the community of immune cells, blood vessels and tissue cells that surround and interact with the cancer cells. The researchers set out to generate a comprehensive cell atlas for DCIS. Using advanced single-cell and spatial profiling technologies, they mapped more than 850,000 cells from samples of normal breast tissue, DCIS and invasive breast cancer. They identified extensive changes in cancer cells and the surrounding microenvironment as disease progressed. “We analyzed 854,911 cells from 159 patients by single cell RNA sequencing and 39 samples by spatial transcriptomics, which identified nine cell types and 60 cell states,” they reported.</p>
<p>The resulting detailed atlas suggests that important biological features associated with invasive breast cancer begin to emerge earlier than previously known. The study also uncovered previously unknown “cancer stromal loops,” ring-like structures made of supportive tissue and vascular cells that surround DCIS lesions, which create conditions that support tumor growth. “Our data reports on remodeling of specific immune, stromal cell types and myoepithelial cells in the DCIS TME, along with changes in cancer cell metaprograms that form cellular ecosystems and spatial niches to support the growth and progression of DCIS,” they wrote in summary.</p>
<p>Additional research is needed to validate these findings and evaluate their potential use in future diagnostic tools and prevention or treatment strategies. The findings could one day help doctors predict which patients need aggressive treatment and which patients may safely avoid it.  The team said researchers will continue studying the cellular features identified in the atlas to determine whether they can predict which DCIS lesions are most likely to become invasive, to help better determine the best strategies for individual patients.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/dcis-cell-atlas-reveals-clues-to-invasive-breast-cancer-progression/">DCIS Cell Atlas Reveals Clues to Invasive Breast Cancer Progression</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Tommy John Surgery: Procedure, Recovery &amp;amp; Success Rates</title>
<link>https://edusehat.com/en/tommy-john-surgery-procedure-recovery-success-rates</link>
<guid>https://edusehat.com/en/tommy-john-surgery-procedure-recovery-success-rates</guid>
<description><![CDATA[ What is Tommy John Surgery? Tommy John surgery is the reconstruction of a torn ulnar collateral ligament (UCL), a band of tissue that connects the upper arm bone (humerus) to the forearm bone (ulna), which helps keep your elbow joint stable. The ligament stretches and thins over time from repetitive overhand motion, and it’s especially  [...]
The post Tommy John Surgery: Procedure, Recovery &amp; Success Rates appeared first on Orthopedic Sports Medicine Specialists (OSMS). ]]></description>
<enclosure url="https://osmsgb.com/wp-content/uploads/2018/10/tommy-john-surgery.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 14 Nov 2026 04:50:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Tommy, John, Surgery:, Procedure, Recovery, Success, Rates</media:keywords>
<content:encoded><![CDATA[<h2><img decoding="async" class="alignnone wp-image-3280 size-full" src="https://osmsgb.com/wp-content/uploads/2018/10/tommy-john-surgery.jpg" alt="tommy john surgery" width="1000" height="667" srcset="https://osmsgb.com/wp-content/uploads/2018/10/tommy-john-surgery-200x133.jpg 200w, https://osmsgb.com/wp-content/uploads/2018/10/tommy-john-surgery-300x200.jpg 300w, https://osmsgb.com/wp-content/uploads/2018/10/tommy-john-surgery-400x267.jpg 400w, https://osmsgb.com/wp-content/uploads/2018/10/tommy-john-surgery-600x400.jpg 600w, https://osmsgb.com/wp-content/uploads/2018/10/tommy-john-surgery-768x512.jpg 768w, https://osmsgb.com/wp-content/uploads/2018/10/tommy-john-surgery-800x534.jpg 800w, https://osmsgb.com/wp-content/uploads/2018/10/tommy-john-surgery.jpg 1000w" sizes="(max-width: 1000px) 100vw, 1000px"></h2>
<h2>What is Tommy John Surgery?</h2>
<p>Tommy John surgery is the reconstruction of a torn ulnar collateral ligament (UCL), a band of tissue that connects the upper arm bone (humerus) to the forearm bone (ulna), which helps keep your elbow joint stable. The ligament stretches and thins over time from repetitive overhand motion, and it’s especially common in baseball pitchers or anyone who repeatedly throws, swings, or twists their arm. It is one of the most successful and well-known reconstructive surgeries in sports medicine.</p>
<p>Let’s dive into what Tommy John surgery is and how it got its name.</p>
<h2>Why Is It Called Tommy John Surgery?</h2>
<p>Tommy John surgery is named after Major League Baseball pitcher Tommy John, who made the procedure famous. In 1974, while playing for the Los Angeles Dodgers and posting a 13-3 record, Tommy John tore his UCL, which was considered to be career-ending. At the time, pitchers who tore their UCL were said to have a “dead arm” and typically never threw competitively again.</p>
<p>Dr. Frank Jobe, an orthopedic surgeon, thought differently. He devised a new surgical procedure to reconstruct a torn ligament using a tendon graft. John agreed to the procedure, and after surgery and roughly a year of rehabilitation, he returned to the sport and kept pitching until he retired in 1989, winning 164 games after his surgery.</p>
<p>The unprecedented outcome led to the surgery informally being referred to as “Tommy John surgery”, and the name just stuck. Today, UCL reconstruction, or Tommy John surgery, is performed on thousands of people each year.</p>
<p><img decoding="async" class="wp-image-1020 size-full alignnone" src="https://osmsgb.com/wp-content/uploads/2026/05/Tommy-John-Surgery-1.jpg" alt="Tommy John surgery " width="500" height="417" srcset="https://osmsgb.com/wp-content/uploads/2026/05/Tommy-John-Surgery-1-200x167.jpg 200w, https://osmsgb.com/wp-content/uploads/2026/05/Tommy-John-Surgery-1-300x250.jpg 300w, https://osmsgb.com/wp-content/uploads/2026/05/Tommy-John-Surgery-1-400x334.jpg 400w, https://osmsgb.com/wp-content/uploads/2026/05/Tommy-John-Surgery-1.jpg 500w" sizes="(max-width: 500px) 100vw, 500px"></p>
<h2>Causes and Symptoms of a UCL Injury</h2>
<p>UCL injuries are usually a result of overuse from repetitive overhand motions that twist the elbow however can be the result of a traumatic injury as well. The injury occurs when the ligament is torn or stretched, causing the bones to move too much and leading to pain, instability, looseness, and reduced ability to work or play sports.</p>
<p>UCL injuries can start small but escalate as the ulnar collateral ligament continues to stretch and lengthen until it can no longer stabilize the elbow during physical activity.</p>
<p>Common symptoms of a UCL injury include:</p>
<ul>
<li>Pain on the inner side of the elbow</li>
<li>A “pop” followed by intense pain</li>
<li>Swelling and bruising at the site of injury at the inner elbow and upper forearm</li>
<li>Elbow stiffness and the inability to straighten the elbow</li>
<li>Numbness or tingling in the ring and pinky finger</li>
<li>Clumsiness and weakness of hand grip</li>
<li>Inability to throw at full speed and loss of ball control</li>
</ul>
<p>Though baseball players are the most affected athletes, UCL injuries also occur in contact sports like football and rugby, overhead sports such as volleyball or tennis, and with athletes who participate in “rotational” sports like gymnastics, wrestling, and cheerleading.</p>
<h2>The Tommy John Procedure and Recovery Time</h2>
<p>Tommy John surgery typically replaces damaged ligaments inside the elbow with another tendon, known as a graft, that is typically harvested from another part of the body or from a donor. Once placed, the tendon acts as a new ligament, stabilizes the elbow, reduces or eliminates pain, and allows for increased range of motion. Surgeons often attach any healthy remnants of the original ligament to the new graft to provide additional strength.  Additional suture can also be added as an internal splint to help protect the repair as well. This is commonly referred to its trade name of the Arthrex “Internal Brace.”</p>
<p>Full recovery from Tommy John surgery typically takes around a year, but in some cases, athletes need more time to return to their previous level of ability. Fortunately, gone are the years when a torn UCL ended an athlete’s career. Most athletes who undergo Tommy John surgery can resume their sport at, or even above, their previous level of competition.</p>
<h2>Frequently Asked Questions</h2>
<p><strong>Q:</strong> Is Tommy John surgery successful?</p>
<p><strong>A:</strong> Yes, nearly 85% of athletes return to their sport.</p>
<p> </p>
<p><strong>Q:</strong> How long is the recovery process?</p>
<p><strong>A:</strong> Most patients need a full year to recover, but many can return to light training at six months.</p>
<p> </p>
<p><strong>Q:</strong> When should I see a specialist?</p>
<p><strong>A:</strong> If you are feeling pain in your elbow, hand, or arm after throwing or overhead activity, don’t just wait it out. Early evaluation can make all the difference.</p>
<p> </p>
<p><a href="https://osmsgb.com/schedule-an-appointment/">Schedule an appointment</a> with one of our hand, wrist, and elbow specialists, <a href="https://osmsgb.com/doctors/paige-chapman-md/">Paige Chapman, MD</a>, or <a href="https://osmsgb.com/doctors/kyle-kaster-do/">Kyle Kaster, DO</a>. They can help you get back to the life you love.</p>
<p> </p>
<p> </p>
<p><em>This blog was originally published on October 30, 2018 and was updated on November 10, 2026.</em></p>
<p>The post <a href="https://osmsgb.com/a-history-and-overview-of-tommy-john-surgery/">Tommy John Surgery: Procedure, Recovery & Success Rates</a> appeared first on <a href="https://osmsgb.com/">Orthopedic Sports Medicine Specialists (OSMS)</a>.</p>]]> </content:encoded>
</item>

<item>
<title>What is Rheumatology Infusion Therapy?</title>
<link>https://edusehat.com/en/what-is-rheumatology-infusion-therapy</link>
<guid>https://edusehat.com/en/what-is-rheumatology-infusion-therapy</guid>
<description><![CDATA[ For patients managing certain medical conditions, oral medication isn’t always the only treatment option.   Infusion therapy delivers medicine intravenously through an IV, and because infusion therapy bypasses the digestive system and enters the bloodstream directly, it can lead to faster symptom relief and higher absorption rates.  Read on to learn more about all the different  [...]
The post What is Rheumatology Infusion Therapy? appeared first on Orthopedic Sports Medicine Specialists (OSMS). ]]></description>
<enclosure url="https://osmsgb.com/wp-content/uploads/2020/09/rheum-infusion-therapy-IV-bag.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 14 Nov 2026 04:50:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>What, Rheumatology, Infusion, Therapy</media:keywords>
<content:encoded><![CDATA[<p><img fetchpriority="high" decoding="async" class="wp-image-3299 size-full alignnone" src="https://osmsgb.com/wp-content/uploads/2020/09/rheum-infusion-therapy-IV-bag.jpg" alt="rheum infusion therapy IV bag" width="1000" height="667" srcset="https://osmsgb.com/wp-content/uploads/2020/09/rheum-infusion-therapy-IV-bag-200x133.jpg 200w, https://osmsgb.com/wp-content/uploads/2020/09/rheum-infusion-therapy-IV-bag-300x200.jpg 300w, https://osmsgb.com/wp-content/uploads/2020/09/rheum-infusion-therapy-IV-bag-400x267.jpg 400w, https://osmsgb.com/wp-content/uploads/2020/09/rheum-infusion-therapy-IV-bag-600x400.jpg 600w, https://osmsgb.com/wp-content/uploads/2020/09/rheum-infusion-therapy-IV-bag-768x512.jpg 768w, https://osmsgb.com/wp-content/uploads/2020/09/rheum-infusion-therapy-IV-bag-800x534.jpg 800w, https://osmsgb.com/wp-content/uploads/2020/09/rheum-infusion-therapy-IV-bag.jpg 1000w" sizes="(max-width: 1000px) 100vw, 1000px"></p>
<p><span data-contrast="auto">For patients managing certain medical conditions, oral medication isn’t always the only treatment option. </span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></p>
<p><a href="https://osmsgb.com/infusion-therapy/"><span data-contrast="none">Infusion therapy</span></a><span data-contrast="auto"> delivers medicine intravenously through an IV, and because infusion therapy bypasses the digestive system and enters the bloodstream directly, it can lead to faster symptom relief and higher absorption rates.</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></p>
<p><span data-contrast="none">Read on to learn more about all the different conditions infusion therapy treats, </span><span data-contrast="auto">what appointments are like, and how much it costs.</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></p>
<h2 aria-level="2">What conditions can be treated with infusion therapy?</h2>
<p><span data-contrast="auto">You might be surprised to learn just how many conditions infusion therapy can help treat or manage, including:</span></p>
<ul>
<li aria-setsize="-1" data-leveltext="" data-font="Symbol" data-listid="30" data-list-defn-props='{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"hybridMultilevel"}' data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">Rheumatologic disorders</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></li>
<li aria-setsize="-1" data-leveltext="" data-font="Symbol" data-listid="30" data-list-defn-props='{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"hybridMultilevel"}' data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">Allergic disorders</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></li>
<li aria-setsize="-1" data-leveltext="" data-font="Symbol" data-listid="30" data-list-defn-props='{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"hybridMultilevel"}' data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">Asthma</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></li>
<li aria-setsize="-1" data-leveltext="" data-font="Symbol" data-listid="30" data-list-defn-props='{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"hybridMultilevel"}' data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">Bone disorders</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></li>
<li aria-setsize="-1" data-leveltext="" data-font="Symbol" data-listid="30" data-list-defn-props='{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"hybridMultilevel"}' data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">Dermatologic (skin) conditions</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></li>
<li aria-setsize="-1" data-leveltext="" data-font="Symbol" data-listid="30" data-list-defn-props='{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"hybridMultilevel"}' data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">Eye disorders</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></li>
<li aria-setsize="-1" data-leveltext="" data-font="Symbol" data-listid="30" data-list-defn-props='{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"hybridMultilevel"}' data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">Gastrointestinal (GI) disorders</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></li>
<li aria-setsize="-1" data-leveltext="" data-font="Symbol" data-listid="30" data-list-defn-props='{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"hybridMultilevel"}' data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">Immune system disorders</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></li>
<li aria-setsize="-1" data-leveltext="" data-font="Symbol" data-listid="30" data-list-defn-props='{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"hybridMultilevel"}' data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">Iron deficiency and related conditions</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></li>
<li aria-setsize="-1" data-leveltext="" data-font="Symbol" data-listid="30" data-list-defn-props='{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"hybridMultilevel"}' data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">Neurologic conditions, including multiple sclerosis (MS) and migraines</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></li>
</ul>
<p><span data-contrast="auto">Additional infusion treatments may include IV fluid administration (fluid bolus) and steroid infusions.</span></p>
<p><span data-contrast="auto">While this list covers many common uses for infusion therapy, it is not exhaustive. Infusion therapy can also help manage a variety of other rheumatic, inflammatory, digestive, neurological, and dermatological conditions.</span></p>
<p><span data-contrast="auto">Learn more about the conditions treated and the services available at the </span><a href="https://osmsgb.com/infusion-therapy/"><span data-contrast="none">OSMS Rheumatology Center’s private infusion therapy suites</span></a><span data-contrast="auto">.</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></p>
<h2 aria-level="2">Are there other reasons for using infusion therapy?</h2>
<p><span data-contrast="auto">Rheumatologists (doctors who specialize in rheumatic illnesses) may recommend infusion therapy for several reasons, including when:</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></p>
<ul>
<li aria-setsize="-1" data-leveltext="" data-font="Symbol" data-listid="24" data-list-defn-props='{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"hybridMultilevel"}' data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">Oral medications aren’t effective</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></li>
<li aria-setsize="-1" data-leveltext="" data-font="Symbol" data-listid="24" data-list-defn-props='{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"hybridMultilevel"}' data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">The patient can’t take medications orally</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></li>
<li aria-setsize="-1" data-leveltext="" data-font="Symbol" data-listid="24" data-list-defn-props='{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"hybridMultilevel"}' data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">Medication must be administered on a strictly controlled or timed dose</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></li>
<li aria-setsize="-1" data-leveltext="" data-font="Symbol" data-listid="24" data-list-defn-props='{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"hybridMultilevel"}' data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">The needed medication is only available in an infusion form</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></li>
</ul>
<h2 aria-level="2">What kind of doctor administers infusion therapy?</h2>
<p><span data-contrast="auto">Our board-certified, fellowship-trained </span><a href="https://osmsgb.com/our-doctors/"><span data-contrast="none">rheumatologists</span></a><span data-contrast="auto"> partner with our registered nurses, medical assistants, and licensed practical nurses to provide treatment. They are all experts in administering infusion therapy medicines.</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></p>
<h2 aria-level="2">What types of medications are used in infusion therapy?</h2>
<p><span data-contrast="auto">Many of the medicines used in infusion therapy are biologics. These medications help slow or stop the inflammation that damages joints and organs in arthritis and other inflammatory diseases. The types of biologics are:</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></p>
<ol>
<li aria-setsize="-1" data-leveltext="%1." data-font="" data-listid="26" data-list-defn-props='{"335552541":0,"335559685":720,"335559991":360,"469769242":[65533,0],"469777803":"left","469777804":"%1.","469777815":"hybridMultilevel"}' data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">Tumor Necrosis Factor-α (TNF) Inhibitors </span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></li>
<li aria-setsize="-1" data-leveltext="%1." data-font="" data-listid="26" data-list-defn-props='{"335552541":0,"335559685":720,"335559991":360,"469769242":[65533,0],"469777803":"left","469777804":"%1.","469777815":"hybridMultilevel"}' data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">B-Cell Inhibitors</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></li>
<li aria-setsize="-1" data-leveltext="%1." data-font="" data-listid="26" data-list-defn-props='{"335552541":0,"335559685":720,"335559991":360,"469769242":[65533,0],"469777803":"left","469777804":"%1.","469777815":"hybridMultilevel"}' data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">Interleukin Inhibitors</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></li>
<li aria-setsize="-1" data-leveltext="%1." data-font="" data-listid="26" data-list-defn-props='{"335552541":0,"335559685":720,"335559991":360,"469769242":[65533,0],"469777803":"left","469777804":"%1.","469777815":"hybridMultilevel"}' data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">T-Cell Co-Stimulation Modulators</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></li>
<li aria-setsize="-1" data-leveltext="%1." data-font="" data-listid="26" data-list-defn-props='{"335552541":0,"335559685":720,"335559991":360,"469769242":[65533,0],"469777803":"left","469777804":"%1.","469777815":"hybridMultilevel"}' data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">BAFF Inhibitors</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></li>
<li aria-setsize="-1" data-leveltext="%1." data-font="" data-listid="26" data-list-defn-props='{"335552541":0,"335559685":720,"335559991":360,"469769242":[65533,0],"469777803":"left","469777804":"%1.","469777815":"hybridMultilevel"}' data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">Interferon Receptor Inhibitors</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></li>
<li aria-setsize="-1" data-leveltext="%1." data-font="" data-listid="26" data-list-defn-props='{"335552541":0,"335559685":720,"335559991":360,"469769242":[65533,0],"469777803":"left","469777804":"%1.","469777815":"hybridMultilevel"}' data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">Other nonbiologic/targeted therapies</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></li>
</ol>
<p><span data-contrast="auto">Every patient is different. During your first consultation with your OSMS rheumatologist, they will review your medical history and symptoms to determine which medication is best for you. Sometimes, the treatment team will combine medications to achieve the ideal outcome. </span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></p>
<h2 aria-level="2">What is a typical infusion appointment like?</h2>
<p><span data-contrast="auto">When you arrive at OSMS for your infusion therapy appointment, you will be greeted by our friendly front desk staff. Next, you’ll be called back for your appointment and escorted to a semi-private infusion suite where you can relax during your treatment. Blankets, pillows, and snacks are always on hand to keep you comfortable.</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></p>
<p><img decoding="async" class="alignnone wp-image-3300 size-full" src="https://osmsgb.com/wp-content/uploads/2020/09/nurse-administering-a-patient-a-rheum-IV.jpg" alt="nurse administering a patient a rheum IV" width="767" height="667" srcset="https://osmsgb.com/wp-content/uploads/2020/09/nurse-administering-a-patient-a-rheum-IV-200x174.jpg 200w, https://osmsgb.com/wp-content/uploads/2020/09/nurse-administering-a-patient-a-rheum-IV-300x261.jpg 300w, https://osmsgb.com/wp-content/uploads/2020/09/nurse-administering-a-patient-a-rheum-IV-400x348.jpg 400w, https://osmsgb.com/wp-content/uploads/2020/09/nurse-administering-a-patient-a-rheum-IV-600x522.jpg 600w, https://osmsgb.com/wp-content/uploads/2020/09/nurse-administering-a-patient-a-rheum-IV.jpg 767w" sizes="(max-width: 767px) 100vw, 767px"></p>
<p><span data-contrast="auto">A nurse will take your vital signs before and after your infusion. If you’re nervous about getting an IV, please don’t worry. Our experienced nurses do their best to get your IV on the first try. You will feel a slight pinch when the needle is inserted, but the infusion itself should be painless.</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></p>
<p><span data-contrast="auto">During your infusion appointment, you can do whatever you like. Watch TV, scroll on your phone (on our free Wi-Fi), do a short craft, close your eyes to rest, or eat a snack. Each suite has visitor chairs, so feel free to bring a friend or family member to your appointment if you like. </span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></p>
<h2 aria-level="2">How much does infusion therapy cost?</h2>
<p><span data-contrast="auto">Infusion therapy at </span><a href="https://osmsgb.com/infusion-therapy/"><span data-contrast="none">OSMS typically costs 30 to 50% less than the same treatment at a hospital</span></a><span data-contrast="auto">. That’s because we don’t charge facility fees or carry the high overhead costs that hospitals do. We know infusion therapy is an ongoing commitment, so we work hard to keep your costs as low as possible.</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></p>
<h2 aria-level="3">Can children receive infusion therapy?</h2>
<p><span data-contrast="auto">Yes! Infusion therapy can be an effective treatment option for children managing certain chronic conditions. </span><a href="https://osmsgb.com/imback/lilys-im-back-story-juvenile-idiopathic-arthritis/"><span data-contrast="none">Watch Lily’s “I’m Back” story</span></a><span data-contrast="auto"> to learn more about her experience with infusion therapy.</span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></p>
<h2 aria-level="2">Do I need a referral for infusion therapy?</h2>
<p><span data-contrast="auto">You may require a referral for infusion therapy, especially if your condition isn’t related to a rheumatologic condition. Your referring physician will help coordinate your care, but we also recommend checking with your insurance provider. </span><span data-ccp-props='{"469777462":[1440],"469777927":[0],"469777928":[1]}'> </span></p>
<h2 aria-level="2">Is infusion therapy right for you?</h2>
<p data-ccp-border-bottom="2px solid #000000" data-ccp-padding-bottom="1.3333333333333333px"><a href="https://osmsgb.com/schedule-an-appointment/"><span data-contrast="none">Schedule an appointment with one of our rheumatologists online</span></a><span data-contrast="auto">. We’ll take the time to get to know you, from your medical history and symptoms to lifestyle and goals, then help you decide if infusion therapy is the right fit.</span></p>
<p data-ccp-border-bottom="2px solid #000000" data-ccp-padding-bottom="1.3333333333333333px"><em>This blog was originally published on September 29, 2020 and was updated on November 13, 2026.</em></p>
<p>The post <a href="https://osmsgb.com/what-is-infusion-therapy/">What is Rheumatology Infusion Therapy?</a> appeared first on <a href="https://osmsgb.com/">Orthopedic Sports Medicine Specialists (OSMS)</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Vancomycin&#45;Resistant Enterococcus Evolved in a Danish Hospital</title>
<link>https://edusehat.com/en/how-vancomycin-resistant-enterococcus-evolved-in-a-danish-hospital</link>
<guid>https://edusehat.com/en/how-vancomycin-resistant-enterococcus-evolved-in-a-danish-hospital</guid>
<description><![CDATA[ A genomic study reveals how genetic mutations, recombination, and resistance-carrying plasmids shaped the evolution, diversification, and decline of vancomycin-resistant Enterococcus faecium in Danish hospitals between 2012 and 2020.
The post How Vancomycin-Resistant Enterococcus Evolved in a Danish Hospital appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_vre-labeled.png.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 14 Nov 2026 04:15:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Vancomycin-Resistant, Enterococcus, Evolved, Danish, Hospital</media:keywords>
<content:encoded><![CDATA[<p>Vancomycin-resistant <em>Enterococcus faecium</em> is listed by the World Health Organization—in its 2024 Bacterial Priority Pathogens List—as one of the highest-priority bacteria.</p>
<p>In a new study published in <em>Genome Medicine</em>, researchers from Instituto de Tecnologia Química e Biológica António Xavier from NOVA University of Lisbon (ITQB NOVA), in Portugal, investigated the genetic mechanisms behind the rise and fall of the dominant vancomycin-resistant <em>Enterococcus faecium</em> clone (VREfm ST80) from 2012 to 2020 in Danish hospitals. The team assembled and performed whole-genome sequencing and phylogenomic analysis of 334 ST80 isolates collected from colonization (83%) and infection (17%) cases across nine hospitals in the region between 2012 and 2020.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The results identified two major clusters (Clusters 1 and 2) and nine sub-clusters (1.A–G and 2.H–I). Sub-cluster-1.A (169/334) was the dominant lineage, accounting for 72% of isolates from 2012–2015. The isolates from 2016–2020 “were distributed across all sub-clusters, indicating increasing diversification over time.”</p>
<p>Genetic variation, the authors write, was “driven by accumulation of mutations, recombination and gain/loss of accessory genes and plasmids.” Eight recombination hotspots were identified in core genes involved in cell wall synthesis, phosphotransferase systems, amino-acid biosynthesis, and several transporters.</p>
<p>This work is published in <em>Genome Medicine</em> in the paper, “<a href="https://link.springer.com/article/10.1186/s13073-026-01747-2" target="_blank" rel="noopener">Recombination and accessory genome turnover shaped the rise and decline of <em>vanA Enterococcus faecium</em> ST80 in Denmark.</a>”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The team also found that this bacterial clone carried a mosaic phage-like plasmid element that made it resistant to several antibiotics at once. The element harbored the <em>vanA</em> operon with <em>ermB, aadE</em>, and <em>aph(3’)-IIIa</em> suggesting “a unique mechanism for co-mobilization of antimicrobial resistance via transduction or conjugation.”</p>
<p>“Using any one of those antibiotics can select for bacteria carrying the whole package, including vancomycin resistance,” explains Maria Miragaia, PhD, leader of the Bacterial Evolution and Molecular Epidemiology lab at ITQB NOVA. “This means that simply reducing vancomycin use may not be enough to reduce vancomycin-resistant bacteria if other linked antibiotics are still being used,” she adds.</p>
<p>The study suggests that targeting the strategies that helped the clone persist—forming biofilms, altering its outer surface, and using alternative sugars in the gut—could help to clear these resistant bacteria from the gut and reduce their spread in hospitals.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/how-vancomycin-resistant-enterococcus-evolved-in-a-danish-hospital/">How Vancomycin-Resistant <i>Enterococcus</i> Evolved in a Danish Hospital</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CannonDesign Promotes Emily Bateman to Chicago Health Market Co&#45;Leader</title>
<link>https://edusehat.com/en/cannondesign-promotes-emily-bateman-to-chicago-health-market-co-leader</link>
<guid>https://edusehat.com/en/cannondesign-promotes-emily-bateman-to-chicago-health-market-co-leader</guid>
<description><![CDATA[ Emily Bateman will co-lead CannonDesign’s Chicago health practice following her promotion to Health Market Leader. She joins Andy Lane in overseeing the firm’s largest health practice.  Bateman joined the firm as a client leader in 2020. Her project experience includes the University of Chicago AbbVie Foundation Cancer Pavilion, Northwestern Memorial Healthcare’s Consolidated Oncology Infusion and...
The post CannonDesign Promotes Emily Bateman to Chicago Health Market Co-Leader appeared first on HCO News.
The post CannonDesign Promotes Emily Bateman to Chicago Health Market Co-Leader appeared first on HCO News. ]]></description>
<enclosure url="https://hconews.com/wp-content/uploads/2026/11/HCO-People.Bateman-768x432.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 14 Nov 2026 01:20:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CannonDesign, Promotes, Emily, Bateman, Chicago, Health, Market, Co-Leader</media:keywords>
<content:encoded><![CDATA[<p><span data-contrast="auto">Emily Bateman will co-lead CannonDesign’s Chicago health practice following her promotion to Health Market Leader. She joins Andy Lane in overseeing the firm’s largest health practice.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Bateman joined the firm as a client leader in 2020. Her project experience includes the University of Chicago AbbVie Foundation Cancer Pavilion, Northwestern Memorial Healthcare’s Consolidated Oncology Infusion and Clinical Expansion, ThedaCare modernization initiatives and UM Health-Sparrow Behavioral Health Hospital.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">“Emily brings exceptional leadership skills, both in her work with clients and in the way she supports and guides our teams internally,” CannonDesign’s National Health Market Leader Michael Pukszta said </span><a href="https://www.cannondesign.com/index.php/news/emily-bateman-named-health-market-leader-chicago-2" target="_blank" rel="noopener"><span data-contrast="none">in the firm’s release</span></a><span data-contrast="auto">.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">In her new role, Bateman will partner with clients and teams to advance innovative healthcare design and help the CarnnonDesign’s health practice continue to grow. Her responsibilities will include supporting project quality, employee career development and practice growth.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">“What excites me most about this role is the opportunity to invest in our people and our practice at the same time,” Bateman said in the release. </span><span data-contrast="none">“As we continue to grow, I look forward to helping develop our talented teams, strengthening our studio culture and finding new opportunities across Chicago and the broader Great Lakers region.”</span><span data-ccp-props="{}"> </span></p>
<p>The post <a rel="nofollow" href="https://hconews.com/2026/11/13/cannondesign-promotes-emily-bateman-to-chicago-health-market-co-leader/">CannonDesign Promotes Emily Bateman to Chicago Health Market Co-Leader</a> appeared first on <a rel="nofollow" href="https://hconews.com/">HCO News</a>.</p>
<p>The post <a href="https://hconews.com/2026/11/13/cannondesign-promotes-emily-bateman-to-chicago-health-market-co-leader/">CannonDesign Promotes Emily Bateman to Chicago Health Market Co-Leader</a> appeared first on <a href="https://hconews.com/">HCO News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Pharma Friday – November 13, 2026</title>
<link>https://edusehat.com/en/pharma-friday-november-13-2026</link>
<guid>https://edusehat.com/en/pharma-friday-november-13-2026</guid>
<description><![CDATA[ An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Spruce Biosciences Announces Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx Biosciences On Nov. 9, Spruce Biosciences, Inc., a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that it has […]
The post Pharma Friday – November 13, 2026 appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/pharmaaaaa7.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 14 Nov 2026 01:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pharma, Friday, –, November, 13, 2026</media:keywords>
<content:encoded><![CDATA[<p>An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Spruce Biosciences Announces Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx Biosciences On Nov. 9, Spruce Biosciences, Inc., a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that it has […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/pharma-friday-november-13-2026/">Pharma Friday – November 13, 2026</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Looking Across the Organs: Diabetes After Transplant</title>
<link>https://edusehat.com/en/looking-across-the-organs-diabetes-after-transplant</link>
<guid>https://edusehat.com/en/looking-across-the-organs-diabetes-after-transplant</guid>
<description><![CDATA[ Cross-organ research examines how preexisting diabetes and new-onset diabetes affect survival after kidney, liver, heart, and lung transplantation. Research presented at ENDO 2026 last June highlights distinct organ-specific risks and calls for prevention, monitoring, and long-term care beyond the transplant procedure itself. The presence of diabetes negatively impacts almost any co-occurring health problem, including organ […]
The post Looking Across the Organs: Diabetes After Transplant appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/organ-cooler-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 14 Nov 2026 01:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Looking, Across, the, Organs:, Diabetes, After, Transplant</media:keywords>
<content:encoded><![CDATA[<p>Cross-organ research examines how preexisting diabetes and new-onset diabetes affect survival after kidney, liver, heart, and lung transplantation. Research presented at ENDO 2026 last June highlights distinct organ-specific risks and calls for prevention, monitoring, and long-term care beyond the transplant procedure itself. The presence of diabetes negatively impacts almost any co-occurring health problem, including organ […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/looking-across-the-organs-diabetes-after-transplant/">Looking Across the Organs: Diabetes After Transplant</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>What’s really inside your handpiece?</title>
<link>https://edusehat.com/en/whats-really-inside-your-handpiece</link>
<guid>https://edusehat.com/en/whats-really-inside-your-handpiece</guid>
<description><![CDATA[ What dental professionals should consider before approving repairs that use non-genuine parts, including safety, performance, compliance, warranty and traceability. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/handpiee-spare-parts.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 14 Nov 2026 01:05:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>What’s, really, inside, your, handpiece</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large is-resized"></figure>



<p><strong>Is saving money worth putting patient safety at risk? Gavin Knight explores the hidden risks of non-genuine handpiece parts.</strong></p>



<p>When a dental handpiece is repaired, what goes back into it matters just as much as who carries out the repair.  How many healthcare providers genuinely know whether their service provider is fitting genuine manufacturer spare parts, or taking shortcuts that could compromise the safety, performance, and reliability of their equipment?</p>



<p>There is an uncomfortable question that every healthcare provider should be asking: <strong>do I know exactly what is being fitted into my handpiece when it is repaired?</strong></p>



<p>If the answer is no, how can you be certain that the equipment remains safe, reliable and fit for its intended clinical purpose?</p>



<p>Medical equipment is not ordinary machinery, it is precision-engineered, tested, and validated to operate within specific safety and performance parameters. Every component, however small, can contribute to the overall integrity of the device.</p>



<p>Replacing an original component with an unverified alternative may appear to be straightforward cost-saving but what if that replacement compromises accuracy, reliability, or an essential safety feature? What if it contributes to a malfunction during a critical clinical procedure? Who ultimately carries the responsibility when something goes wrong?</p>



<p>The price of a spare part is easy to measure. The consequences of fitting the wrong one may be immeasurable.</p>



<p>This is why the use of genuine manufacturer spare parts should be a fundamental consideration in medical equipment maintenance, not an optional extra to be sacrificed in pursuit of a cheaper repair.</p>



<h2 class="wp-block-heading">Patient safety is not a cost-saving exercise</h2>



<p>To be clear: medical equipment exists to support patient care. Its performance cannot be left to chance, assumptions or the convenience of whichever replacement component happens to be available.</p>



<p>Genuine manufacturer spare parts are produced to the original equipment manufacturer’s specifications and are intended to operate within the handpiece’s established design parameters.</p>



<p>Non-genuine components may not provide the same verified characteristics, compatibility, or performance. Depending on the equipment and the component involved, the consequences could include inaccurate readings, inconsistent operation, premature failure or, in the worst circumstances, a critical malfunction.</p>



<p>Consider the implications in a clinical environment.</p>



<p>A diagnostic device that provides inaccurate information could influence a clinical decision. Equipment that fails unexpectedly could interrupt treatment. A component that compromises the operation of a device could expose both patients and clinical staff to avoidable risks.</p>



<p>These are not hypothetical concerns that can simply be dismissed as engineering technicalities. They go to the heart of patient safety.</p>



<p>Would you knowingly accept an unverified component in equipment that is being used to diagnose, monitor or treat a patient?</p>



<p>If not, why would you allow it to happen during a repair? Patient safety should never depend on an assumption that a replacement part is good enough.</p>



<h2 class="wp-block-heading">Just because it fits doesn’t mean it works</h2>



<p>One of the most dangerous misconceptions surrounding replacement parts is that physical compatibility equates to functional compatibility.</p>



<p>A component may look identical to the original, fit into the same location and allow the equipment to switch on, but that tells you very little about whether it will perform to the required specification.</p>



<p>Differences in materials, manufacturing tolerances, electrical characteristics, mechanical balance and software compatibility can all influence how a medical device operates.</p>



<p>An apparently minor deviation could result in misalignment, increased friction, electrical faults, software errors or accelerated wear on surrounding components.</p>



<p>Dental handpieces provide a particularly striking example.</p>



<p>Some operate at speeds exceeding 200,000 revolutions per minute. At these speeds, precision is not a luxury. Component balance, material quality and manufacturing tolerances are critical to safe and reliable operation. The bearings, turbine and chuck mechanism all must work together within very fine tolerances. A bearing or turbine component that is not to specification can generate excess heat, vibration and noise, and in the worst case could affect how securely the bur is held or create a risk of heat-related injury to a patient’s soft tissue.</p>



<p>A handpiece that switches on is not necessarily a device that works correctly. A repair that appears successful is not necessarily a repair that has restored the equipment to its required performance standard.</p>



<p>Healthcare providers need to understand this distinction.</p>



<h2 class="wp-block-heading">Are you certain your handpiece remains compliant?</h2>



<p>In the UK, medical equipment is subject to medical device legislation and regulatory oversight, including within a framework of applicable medical device legislation and regulatory oversight, including that of the Medicines and Healthcare products Regulatory Agency (MHRA).</p>



<p>Repairs must be undertaken appropriately, taking account of the manufacturer’s instructions, relevant regulatory requirements and the nature of the work being performed.</p>



<p>It is important to recognise that using a non-genuine component does not automatically make every repair unlawful. However, introducing an unsuitable component or departing from the manufacturer’s specified repair requirements can have significant implications for the device’s safety, performance and regulatory status.</p>



<p>The MHRA’s own guidance, <a href="https://www.gov.uk/government/publications/managing-medical-devices" target="_blank" rel="noreferrer noopener">Managing medical devices (January 2021)</a>, is clear on this point. It advises that replacement parts should be bought either from the manufacturer or to the same specification, and that any decision to use parts from other sources should be risk assessed, costed and documented before it is made. It also warns that there may be legal consequences for a healthcare organisation if a device failure associated with fitting such a part causes an injury or incident.</p>



<p>A cheap repair may look attractive, but what happens when questions are asked following an equipment failure or patient safety incident?</p>



<p>The components used, the repair procedures followed and the checks completed may all become relevant to an investigation.</p>



<p><strong>If you cannot demonstrate what was fitted and how the equipment was returned to service, what evidence do you have that the repair was appropriate?</strong></p>



<p>Compliance should never be treated as paperwork to be completed after the event. It must be considered throughout the repair process.</p>



<div aria-hidden="true" class="wp-block-spacer"></div>



<div class="wp-block-buttons has-custom-font-size has-medium-font-size is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-16018d1d wp-block-buttons-is-layout-flex">
<div class="wp-block-button is-style-fill"><a class="wp-block-button__link has-white-color has-text-color has-background has-link-color has-medium-font-size has-custom-font-size wp-element-button" href="https://dentistry.co.uk/2026/10/02/is-it-time-to-repair-or-replace-your-dental-handpiece-take-the-quiz-to-find-out/#quiz" target="_blank" rel="noreferrer noopener"><strong><span>Take this quiz to find out if your handpiece needs a repair</span></strong></a></div>
</div>



<div aria-hidden="true" class="wp-block-spacer"></div>



<h2 class="wp-block-heading">The false economy of cheap handpiece parts</h2>



<p>Non-genuine parts can appear to offer an immediate financial advantage, particularly when the price difference between an original component and an alternative is significant.</p>



<p>But is that saving real?</p>



<p>A replacement component that wears prematurely, performs inconsistently or places additional strain on surrounding parts could result in repeat repairs, further equipment damage and increased downtime.</p>



<p>What initially appeared to be a cheaper repair can quickly become an expensive maintenance problem. The MHRA guidance makes the same point: a cheaper part that needs more frequent maintenance may not be cost-effective in the longer term.</p>



<p>Genuine manufacturer spare parts are specified for the equipment for which they are intended. When used in accordance with the manufacturer’s repair and maintenance requirements, they can help preserve the equipment’s designed performance and intended service life.</p>



<p>The important point is that repair costs should never be judged solely by the initial invoice. Practices should be looking at the total lifetime cost of their handpiece, not simply the price of getting it operational again.</p>



<h2 class="wp-block-heading">Could your warranty or service agreement be at risk?</h2>



<p>There is another issue that healthcare providers sometimes overlook: the potential impact of non-genuine parts on equipment warranties and service agreements.</p>



<p>Manufacturer warranties and service agreements may contain specific conditions relating to maintenance, repairs, authorised service providers and the components that can be used.</p>



<p>Using non-genuine parts, or carrying out work outside the agreed requirements, may affect warranty or service agreement coverage, depending on the applicable terms and circumstances.</p>



<p>Healthcare providers should insist on transparency and establish whether the proposed parts and repair methods are consistent with the manufacturer’s requirements.</p>



<p>Protecting equipment warranty rights and service agreement coverage is not simply an administrative consideration. It is part of responsible asset management.</p>



<h2 class="wp-block-heading">Equipment downtime has a cost beyond the repair bill</h2>



<p>When medical equipment fails, the financial implications are only part of the problem.</p>



<p>Appointments may need to be rearranged. Treatments may be delayed. Clinical teams may have to find alternative equipment, and already stretched staff may face additional pressure.</p>



<p>In busy healthcare environments, even relatively short periods of equipment downtime can have a significant knock-on effect.</p>



<p>Using genuine manufacturer spare parts as part of a competent and appropriate repair process can help reduce the risk of repeat failures associated with unsuitable components.</p>



<p>Of course, no component can eliminate every possible failure. But choosing parts designed for the equipment, alongside following the manufacturer’s service requirements, provides a stronger foundation for reliable operation.</p>



<p>Your equipment should be supporting patient care, not repeatedly disrupting it because corners have been cut during maintenance.</p>



<h2 class="wp-block-heading">Traceability: can your service provider prove what was fitted?</h2>



<p>Knowing that equipment has been repaired is not enough. Healthcare providers should also know what was done, which components were used and whether the work was properly documented.</p>



<p>Traceability is an essential part of responsible medical equipment maintenance.</p>



<p>Genuine manufacturer spare parts may be supported by identifiable part numbers, batch or serial information where applicable, supplier records and relevant quality documentation.</p>



<p>These records can help support maintenance histories, internal audits, troubleshooting and incident investigations.</p>



<p>The precise documentation available will vary depending on the manufacturer and component. However, the principle is straightforward: healthcare providers should be able to establish what has happened to their equipment.</p>



<p>If a service provider cannot identify the replacement parts used, explain where they came from or provide an appropriate service report, how can the healthcare provider independently assess the quality and suitability of the repair?</p>


        <div class="my-4 rounded overflow-hidden bg-context-100/30 px-8 pt-8 pb-4 md:px-10 md:pt-10 md:pb-8">
            <div>
                <div class="inline-block space-y-4">
                                                                <div class="font-secondary font-bold text-xl md:text-2xl">
                            The questions every dental practice should be asking                        </div>
                                                                <div class="w-full my-12 h-px bg-primary-200"></div>
                                    </div>
            </div>
                            <div>
                    <p><!-- wp:heading --></p>
<p>Before authorising your next handpiece repair, ask your service provider some straightforward but important questions:</p>
<ul>
<li>
<h3><strong>Are you using only genuine manufacturer spare parts?</strong></h3>
</li>
</ul>
<p>Do not settle for vague assurances. Ask for confirmation that the components specified for the repair are genuine manufacturer parts or, where they are not, evidence that they meet the manufacturer’s specification and have been properly risk assessed.</p>
<p><!-- /wp:list-item --> <!-- wp:list-item --></p>
<ul>
<li>
<h3><strong>Can you demonstrate where the parts came from?</strong></h3>
</li>
</ul>
<p>Request relevant part numbers, supplier information and supporting documentation where applicable.</p>
<p><!-- /wp:list-item --> <!-- wp:list-item --></p>
<ul>
<li>
<h3><strong>Will the repair follow the manufacturer’s instructions?</strong></h3>
</li>
</ul>
<p>Establish which repair procedures and technical requirements will be followed and whether any proposed deviation has been appropriately assessed.</p>
<p><!-- /wp:list-item --> <!-- wp:list-item --></p>
<ul>
<li>
<h3><strong>What checks will be completed before the equipment is returned?</strong></h3>
</li>
</ul>
<p>Ask whether appropriate functional and safety checks, calibration or performance verification will be undertaken where required.</p>
<p><!-- /wp:list-item --> <!-- wp:list-item --></p>
<ul>
<li>
<h3><strong>Could the repair affect my warranty or service agreement?</strong></h3>
</li>
</ul>
<p>Check the applicable terms and establish whether the proposed parts and repair methods are consistent with them.</p>
<p><!-- /wp:list-item --> <!-- wp:list-item --></p>
<ul>
<li>
<h3><strong>Will I receive a detailed service report?</strong></h3>
</li>
</ul>
<p>Request documentation identifying the work undertaken, the parts fitted and the checks completed.</p>
<p><!-- /wp:list-item --></p>
<p><!-- /wp:list --> <!-- wp:paragraph --></p>
<p><strong>A reputable service provider should be prepared to answer these questions and provide appropriate evidence of the work undertaken.</strong></p>
<p><!-- /wp:paragraph --></p>
                </div>
                    </div>
        


<h2 class="wp-block-heading">Can you afford to take the risk?</h2>



<p>For dental practices, the repair invoice is only one part of the decision. Knowing which parts have been fitted, how their suitability has been established and what checks have been completed provides a firmer basis for returning equipment to clinical use. </p>



<p>Asking these questions before authorising a handpiece repair can help practices make informed choices about cost, reliability and patient safety.</p>



<p><em><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</em></a></em></p>]]> </content:encoded>
</item>

<item>
<title>Downstream Processing: Purifying Complex Antibody Therapeutics When Target Molecules Misbehave</title>
<link>https://edusehat.com/en/downstream-processing-purifying-complex-antibody-therapeutics-when-target-molecules-misbehave</link>
<guid>https://edusehat.com/en/downstream-processing-purifying-complex-antibody-therapeutics-when-target-molecules-misbehave</guid>
<description><![CDATA[ In this GEN webinar, downstream process development and scale up manufacturing specialists will discuss practical strategies for building robust purification processes when the target molecule misbehaves.
The post Downstream Processing: Purifying Complex Antibody Therapeutics When Target Molecules Misbehave appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Getty_2300126174_MonoclonalAntibody.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 23:25:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Downstream, Processing:, Purifying, Complex, Antibody, Therapeutics, When, Target, Molecules, Misbehave</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
         Panelists    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/11/Scherr-headshot-e1794584066338.png" class="h-full w-full object-cover" alt="Image of David Scherr, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">David Scherr, PhD</h2>
                <h3 class="mt-0 !text-[15px] !leading-[21px]">Sr. Scientist<br>Bioprocess Technologies & Engineering<br>Biopharmaceutical Development<br>AstraZeneca</h3>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/11/Scherr-headshot-e1794584066338.png" alt="Image of David Scherr, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">David Scherr, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>David Scherr, PhD, is a senior scientist at AstraZeneca focusing on downstream process development for the Integrated Dynamic Bioprocessing (IDB) platform. He joined AstraZeneca in 2023 and has been a part of CMC teams for GMP implementation of continuous antibody purification. David has also led efforts to implement high-throughput process development and AI-first ways of working. David earned his BS in biochemistry and chemistry from the University of Miami followed by a PhD in biological systems engineering at Virginia Tech.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/11/Kante-headshot-e1794584145723.jpg" class="h-full w-full object-cover" alt="Image of Anupama Kante, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Anupama Kante, PhD</h2>
                <h3 class="mt-0 !text-[15px] !leading-[21px]">Scientist<br>Avid Bioservices</h3>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/11/Kante-headshot-e1794584145723.jpg" alt="Image of Anupama Kante, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Anupama Kante, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Anupama Kante, PhD, is a scientist in downstream process development at Avid Bioservices specializing in biologics purification, formulation development, and analytical characterization. She has extensive experience advancing monoclonal antibodies and complex biologics from early development through process optimization. Anupama is passionate about building scientific capabilities, driving innovation, and translating technical insights into practical solutions.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/11/Ruesing-headshot-e1794584239214.jpg" class="h-full w-full object-cover" alt="Image of Sam Ruesing, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Sam Ruesing, PhD</h2>
                <h3 class="mt-0 !text-[15px] !leading-[21px]">Sr. Staff Scientist<br>Thermo Fisher Scientific</h3>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/11/Ruesing-headshot-e1794584239214.jpg" alt="Image of Sam Ruesing, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Sam Ruesing, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Sam Ruesing, PhD, is a senior staff scientist in downstream process development at Thermo Fisher Scientific. He holds a bachelor’s degree in chemical engineering from the Missouri University of Science and Technology and PhD in biomedical engineering from Saint Louis University. Sam’s experience spans all aspects of downstream development, including early-phase development for first-in-human production, adapting processes to new facilities, and late-phase optimization and characterization in preparation for commercialization.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Tuesday, December 8, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-12-08T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">As antibody-based therapeutics move beyond IgG monoclonal antibodies, downstream process development teams have to purify molecules that do not always fit established platform assumptions. Bispecifics, multispecifics, antibody fragments, Fc-fusion proteins, ADCs, and other engineered formats can introduce new challenges in assembly, stability, impurity profiles, and scalability. Separation of the target molecule from mispaired chains, homodimers, aggregates, fragments, free light chains, persistent host cell proteins, and format-specific product variants can fall outside the limits of standard Protein A, AEX, and CEX purification workflows. For many PD teams, the platform process remains the proper starting point, but the molecule does not always behave like the platform expects.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, downstream process development and scale up manufacturing specialists will discuss practical strategies for building robust purification processes when the target molecule misbehaves. The discussion will explore how teams decide whether to stay with a platform, adapt it, or move to a more molecule-specific toolbox, how alternative affinity approaches can help when Protein A lacks selectivity or is not applicable, and how polishing strategies with IEX, HIC, and mixed-mode chromatography can be used to address difficult product- and process-related impurities. The panel will also discuss how to balance speed, yield, purity, cost of goods, analytical burden, scalability, and regulatory expectations from early development through tech transfer and manufacturing of standard mAbs and beyond.</p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://www.thermofisher.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="138" src="https://www.genengnews.com/wp-content/uploads/2023/03/ThermoFisher_logo-300x138.png" alt="Thermo Fisher logo" class="wp-image-221790" srcset="https://www.genengnews.com/wp-content/uploads/2023/03/ThermoFisher_logo-300x138.png 300w, https://www.genengnews.com/wp-content/uploads/2023/03/ThermoFisher_logo.png 558w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/downstream-processing-purifying-complex-antibody-therapeutics-when-target-molecules-misbehave/">Downstream Processing: Purifying Complex Antibody Therapeutics When Target Molecules Misbehave</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Link Between Mental Health and Exam Performance</title>
<link>https://edusehat.com/en/the-link-between-mental-health-and-exam-performance</link>
<guid>https://edusehat.com/en/the-link-between-mental-health-and-exam-performance</guid>
<description><![CDATA[ When preparing for a major exam like the USMLE, it can be tempting to think that the only thing standing between you and a higher score is more studying, more effort, and, inevitably, more burnout. More questions. More Anki cards. Another video. Another chapter of First Aid.   But there is another piece of the […]
The post The Link Between Mental Health and Exam Performance appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/11/pexels-mart-production-7699511-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 20:10:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Link, Between, Mental, Health, and, Exam, Performance</media:keywords>
<content:encoded><![CDATA[<p><span>When preparing for a major exam like the USMLE, it can be tempting to think that the only thing standing between you and a higher score is more studying, more effort, and, inevitably, <a href="https://elitemedicalprep.com/medical-students-mental-health-why-burnout-happens-and-how-to-prevent-it/">more burnout</a>. </span><span>More questions. More Anki cards. Another video. Another chapter of First Aid.</span></p>
<p> </p>
<p><span>But there is another piece of the equation that is easy to overlook: </span><b>how you are actually feeling while you study.</b></p>
<p> </p>
<p><span>Your physical and mental wellbeing can have a significant impact on how effectively you learn, how well you retain information, and ultimately how you perform on exam day. Studying harder or longer does not always translate to studying more effectively. </span><span>Taking care of yourself is not a distraction from your preparation. It is part of your preparation, and should be prioritized as such.</span></p>
<p> </p>
<h2><strong>Your Brain Is Part of Your Study Plan</strong></h2>
<p><span>It is easy to think of studying as simply putting information into your brain. But learning is an active process that depends on your ability to focus, process information, form memories, and retrieve what you have learned later. </span><span>When you are exhausted, overwhelmed, anxious, or constantly stressed, those processes become more difficult.</span></p>
<p> </p>
<p><span>You may spend hours studying but realize that you barely remember what you reviewed. You may reread the same page multiple times without absorbing it. You may complete a block of questions but find that your concentration starts falling apart halfway through. </span><span>This can be incredibly frustrating because it may feel like you are not working hard enough.</span></p>
<p> </p>
<p><span>In reality, you may be working </span><i><span>too hard without giving your brain the conditions it needs to learn effectively. </span></i><span>You can’t demand performance from a machine with no fuel! </span></p>
<p> </p>
<h2><strong>Physical Wellbeing and Learning</strong></h2>
<p><span>Your physical health plays a much bigger role in studying than many students realize. </span><span>Sleep, nutrition, movement, and adequate breaks are not just general wellness recommendations. They can directly affect your ability to concentrate and retain information.</span></p>
<p> </p>
<p><span>Sleep is particularly important. When you consistently sacrifice sleep to gain additional study hours, you may technically be spending more time with your material, but that does not necessarily mean you are learning more.</span></p>
<p> </p>
<p><span>The same is true for movement and nutrition. You do not need an elaborate wellness routine while preparing for an exam. Even simple habits, getting outside for a walk, eating regular meals, staying hydrated, and giving yourself time away from your desk, can help you return to your studies with better energy and concentration.</span></p>
<p> </p>
<p><span>When I was in my dedicated study periods for my Step exams, I always made my meal times my break times away from my study material and made sure that I got to the gym for a workout every evening. It kept my physical health strong and this helped me perform better while studying material.  </span><span>Your goal is not to create a perfect lifestyle while studying for the USMLE. Your goal is to create a routine that allows your brain to consistently perform at its best.</span></p>
<p> </p>
<h2><strong>Stress Can Change the Way You Study</strong></h2>
<p><span>Some stress is completely normal during exam preparation. In fact, a certain amount of pressure can motivate you to stay focused and keep moving forward. </span><span>The problem is when stress becomes constant and emotionally exhausting. </span><span>This can create a cycle where anxiety makes it harder to concentrate, poor concentration leads to worse performance, and worse performance creates even more anxiety.</span></p>
<p> </p>
<p><span>Suddenly, the problem is no longer just the material. </span><span>You are also trying to study while managing the emotional weight of constantly feeling like you are not doing enough and not seeing the progress you want. </span><span><a href="https://elitemedicalprep.com/how-to-manage-usmle-step-1-test-anxiety/">Recognizing this cycle</a> is important because it gives you an opportunity to interrupt it.</span></p>
<p> </p>
<h2><strong>The Positive Feedback Loop: Feeling Better Can Help You Perform Better</strong></h2>
<p><span>One of the most powerful things to recognize during exam preparation is that wellbeing and academic performance reinforce each other.</span></p>
<p> </p>
<p><span>When you sleep well, maintain your nutrition, take appropriate breaks, move your body, and give yourself time to recharge, you will find that you can concentrate more effectively. Better concentration can lead to better question performance. Better question performance builds confidence. Increased confidence makes studying feel less overwhelming, which can make it easier to stay consistent.</span></p>
<p> </p>
<p><span>And consistency leads to more learning. </span><span>That creates a positive feedback loop:</span></p>
<p><b>Feel better → study more effectively → perform better → feel more confident → study more effectively.</b></p>
<p> </p>
<p><span>This does not mean that feeling good guarantees a high score. There will still be difficult days, frustrating questions, and practice exams that do not go the way you hoped. </span><span>But your baseline state matters. </span><span>When you feel physically and mentally well, you are giving yourself a better foundation from which to handle and overcome those challenges.</span></p>
<p> </p>
<h2><strong>Why Retention Suffers When You Are Burned Out</strong></h2>
<p><span>You might spend ten hours at your desk and feel accomplished because you were “studying all day.” But if the last three hours were spent staring at questions without really processing them, that time was not effective studying. </span><span>As <a href="https://elitemedicalprep.com/spotting-early-signs-of-burnout-in-medical-students/">fatigue builds</a>, attention decreases. When attention decreases, the quality of learning decreases with it. </span><span>This is why sometimes the most productive thing you can do is stop studying.</span></p>
<p> </p>
<p><span>Taking an hour to exercise, eat dinner with friends, call your family, or simply watch something and relax does not mean you are losing valuable study time. It may actually help you return to your material with enough mental stamina to learn more efficiently. And you should be able to do this regularly without feeling guilty or worrying about lost study time. </span></p>
<p> </p>
<h2><strong>Your Practice Scores Are Data, Not a Judgment</strong></h2>
<p><span>The USMLE preparation process can become emotionally challenging when students begin attaching their self-worth to their practice scores. </span><span>A <a href="https://elitemedicalprep.com/how-to-recover-after-a-low-nbme-practice-score-a-step-by-step-strategy/">low score</a> can feel like a statement about your intelligence or your future. </span><span>It is not.</span></p>
<p> </p>
<p><span>A practice question is information. A practice exam is information. Even a bad study day is information. </span><span>If you miss a question because you did not know the content, that tells you something about your knowledge base. If you miss it because you misread the vignette, that tells you something about your test-taking strategy. If you miss questions because you cannot concentrate after studying for eight hours straight, that tells you something about your<a href="https://elitemedicalprep.com/the-ultimate-10-week-step-1-study-schedule/"> study schedule.</a></span></p>
<p> </p>
<p><span>The goal is not to judge yourself based on the result. The goal is to use the result to make your preparation more effective. </span><span>This mindset can significantly reduce the emotional roller coaster that often comes with exam preparation.</span></p>
<p> </p>
<h2><strong>Building a Sustainable Study Routine</strong></h2>
<p><span>There is no single perfect study schedule for the USMLE. </span><span>Some students can focus for several hours in the morning and need a longer break in the afternoon. Others work better in <a href="https://elitemedicalprep.com/microlearning-for-usmle-step-1-prep/">shorter blocks throughout the day</a>. Some prefer exercising in the morning, while others use exercise as a way to decompress after studying, like I did.</span></p>
<p> </p>
<p><span>The important thing is to build a routine that you can actually sustain. Be disciplined and motivated but maintain some flexibility to adjust as dictated by your progress.  </span><span>Your study plan should include time for questions and content review, but it should also leave room for sleep, meals, movement, social connection, and activities that make you feel like yourself outside of medicine.</span></p>
<ul>
<li><span>You do not need to earn your rest by completing a certain number of questions.</span></li>
<li>You are allowed to be a person while preparing for an exam.</li>
</ul>
<p> </p>
<h2><strong>You Do Not Have to Choose Between Your Wellbeing and Your Score</strong></h2>
<p><span>Perhaps the most important mindset shift is recognizing that taking care of yourself and performing well are not opposing goals. </span><span>They are connected.</span></p>
<p> </p>
<p><span>You are not sacrificing your USMLE preparation when you prioritize sleep. You are not being lazy when you take a break. You are not falling behind because you spend time with people you care about. </span><span>You are investing in the brain that has to learn, retain, and ultimately retrieve all of this information on exam day.</span></p>
<p> </p>
<p><span>The students who perform well are not necessarily the ones who study every waking hour. They are the ones who learn how to make their study time effective and sustainable. They are disciplined but recognize the importance of prioritizing the things that keep them healthy and fill their cup as part of their preparation. </span></p>
<p> </p>
<h2><strong>Final Encouragement</strong></h2>
<p><span>Preparing for the USMLE is a marathon. </span><span>There will be productive days and unproductive days. There will be questions you know immediately and questions that make you wonder whether you have ever studied medicine before. There will be practice scores that make you proud and others that make you want to close your laptop and walk away.</span></p>
<p> </p>
<p data-pm-slice="1 1 []">Try not to let any single day define your preparation. Instead, focus on building a routine that allows you to show up consistently, learn effectively, and take care of yourself along the way. If you’re unsure how to adjust your routine, <a href="https://elitemedicalprep.com/meet-the-tutors/">Elite Medical Prep’s 1:1 USMLE tutors</a> can help you use your practice results to decide what to focus on and build a schedule you can sustain.</p>
<p> </p>
<p><span>The better you feel, the better you are often able to focus. The better you focus, the more effectively you learn. The more effectively you learn, the more confident you become. </span><b>Your wellbeing is not separate from your USMLE preparation. It is part of what allows you to perform at your best.</b></p>
<p>The post <a href="https://elitemedicalprep.com/the-link-between-mental-health-and-exam-performance/">The Link Between Mental Health and Exam Performance</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>More autonomy, fewer NDAs: Volunteers have new requests for brain implant trials</title>
<link>https://edusehat.com/en/more-autonomy-fewer-ndas-volunteers-have-new-requests-for-brain-implant-trials</link>
<guid>https://edusehat.com/en/more-autonomy-fewer-ndas-volunteers-have-new-requests-for-brain-implant-trials</guid>
<description><![CDATA[ Scientists have been working on ways to decode brain activity for decades. Teams have developed brain implants that can be used to control robotic limbs and computers, and even to “speak.” The people who volunteer for trials of those devices play a vital role in that research, and they ought to be recognized for their… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/11/Ian_0010.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 19:55:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>More, autonomy, fewer, NDAs:, Volunteers, have, new, requests, for, brain, implant, trials</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Brain implant volunteers want more respect:</strong> Ian Burkhart, who had a brain implant for seven-and-a-half years, helped develop new guidelines pushing for trial participants to have the option to be recognized as genuine research collaborators and listed as coauthors on scientific papers.</li><br><li><strong>Your brain data should be yours:</strong> The guidelines argue that participants' neural data is personal information, and that NDAs or embargoes should not block someone from sharing their own brain data with their doctor.</li><br><li><strong>Losing an implant can feel like losing a limb:</strong> When funding dried up or companies collapsed, participants like Burkhart lost devices—and abilities—with little warning. The guidelines call for researchers to fund and plan removals carefully, giving participants real time to prepare</li></ul>" data-chronoton-post-id="1148474" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p class="wp-block-paragraph">Scientists have been working on ways to decode brain activity for decades. Teams have developed brain implants that can be used to control robotic limbs and computers, and even to “speak.”</p>





<p class="wp-block-paragraph">The people who volunteer for trials of those devices play a vital role in that research, and they ought to be recognized for their contributions, says <a href="https://www.technologyreview.com/innovator/ian-burkhart/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">Ian Burkhart</a>, who had one implanted in his own brain back in 2014. He’s been working on a set of guidelines for researchers developing brain-computer interfaces (BCIs).</p>



<p class="wp-block-paragraph">Ethics guidelines for clinical trials already exist. But BCI trials are different, says Jennifer Chandler, a professor of law and neuroethics at the University of Ottawa who also worked on the guidelines. “These are people who have a device embedded in their brain, are in trials sometimes for years and years … [and contribute] a significant investment of time, of the body, and of intellectual effort.”</p>



<p class="wp-block-paragraph">Burkhart was left paralyzed from the chest down following a diving accident in 2010, when he was 19 years old. Around four years later, he volunteered to become the first person to trial a brain implant designed for hand control.</p>



<p class="wp-block-paragraph">He had an array of 96 electrodes inserted into the part of his brain that controls movement. The electrodes were connected to a computer via a cable that essentially plugged into his head. Algorithms on the computer were designed to interpret those signals and deliver them to another sleeve of electrodes worn on Burkhart’s arm, <a href="https://www.nature.com/articles/nature17435">allowing him to control it</a>.</p>



<p class="wp-block-paragraph">The first movements were small, but Burkhart was ultimately able to use the system to pour beads from bottles, move small and delicate objects, and even play Guitar Hero, if only during lab visits. It was <a href="https://www.technologyreview.com/2016/04/13/161014/video-shows-paralyzed-man-move-hand-with-brain-implant/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">a scientific breakthrough</a>.</p>



<p class="wp-block-paragraph">Burkhart took part in two years-long clinical trials over the seven-and-a-half-year period he had the electrode array implanted in his brain. “It was a fantastic experience,” he says. “But there’s certainly some things that, knowing what I know now, I would want to do a little differently.”</p>





<p class="wp-block-paragraph">In 2022, Burkhart cofounded <a href="https://bcipioneers.org/">BCI Pioneers Coalition</a>—an organization through which people who have taken part in BCI trials can share their experiences, both with each other and with researchers. Over the last year, members of the group have been developing a set of guidelines based on those experiences. The idea is to help academics, clinicians, and companies run ethical trials that respect participants’ autonomy.</p>



<p class="wp-block-paragraph">The guidelines, <a href="https://bcipioneers.org/our-bci-recommendations/">published on Tuesday</a>, lay out a list of recommendations that fall within 13 categories. One, for example, focuses on recognizing and compensating trial participants. During the trials that Burkhart participated in, “I was going into the lab two or three days a week, for four hours at a time,” he recalls. “That’s [easily] a part-time job if you just count the hours you’re putting in.”</p>



<p class="wp-block-paragraph">As the trial progressed, Burkhart says, he learned more and was able to give more constructive feedback on what was working and what wasn’t. He says he was a key member of the research team. Others who find themselves in a similar position might appreciate being listed as a coauthor on scientific publications or publicly named as a research collaborator, he says. Burkhart and his colleagues acknowledge that not everyone will want this, however.  </p>



<p class="wp-block-paragraph">The guidelines also address the thorny question of privacy. That’s important: The public will always be interested in cutting-edge biotechnologies like these—and the guidelines say researchers also have a duty to prepare participants for the possibility of media attention. In some cases, it might be difficult to completely conceal the identity of trial participants.</p>



<p class="wp-block-paragraph">Things get even more complicated when it comes to the privacy of participants’ <a href="https://www.technologyreview.com/2024/10/04/1104972/law-california-protects-brain-data-doesnt-go-far-enough/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">brain data</a>. Research teams will need to access, analyze, and—at least temporarily—store this data. Burkhart wasn’t too bothered about that in his case, where scientists were collecting neural activity related to movement. But people who have brain implants designed for turning thoughts into words might feel differently. </p>





<p class="wp-block-paragraph">The guidelines state that brain data “should be understood as the participant’s personal information.” They are pushing for participants to be able to access their own brain data whenever they want—something that has not always been possible—and want to make sure people aren’t prevented from sharing it with their own doctors because of embargoes or nondisclosure agreements (NDAs) designed to keep findings under wraps from competitors.</p>



<p class="wp-block-paragraph">“It’s not super common for there to be firm NDAs within a lot of the trials,” says Burkhart. “But it’s something where we want to make sure that that does not happen.”</p>



<p class="wp-block-paragraph">The guidelines also address what comes <em>after</em> a trial. Around five years after Burkhart had his device implanted, the research team ran into some issues with funding. When <a href="https://www.technologyreview.com/2023/05/26/1073655/how-it-feels-to-have-a-life-changing-brain-implant-removed/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">we last spoke a few years ago</a>, he recalled how he was told he would have to have the implant removed and could have it put back in once the team had secured funding. (And we’re talking about <em>brain surgery</em> here.)</p>



<p class="wp-block-paragraph">Ultimately, he kept the implant until 2021, when it was removed after an infection started to develop at the point where the cable led into his scalp. But losing the device after all those years was difficult; he’d regained the ability to move his arm—and then lost it again.</p>



<p class="wp-block-paragraph">Rita Leggett, an Australian woman who had a device implanted in her brain to treat her epilepsy, has said she felt she “became one” with her implant. When the company that made it went bust two years later, <a href="https://www.technologyreview.com/2023/05/25/1073634/brain-implant-removed-against-her-will/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">the device was removed against her will</a>—an act ethicists have described as a potential breach of human rights.</p>



<p class="wp-block-paragraph">Researchers should instead commit to maintaining brain devices for a “reasonable period” after a trial ends, according to the guidelines. Participants should be given plenty of time to prepare for the surgery to remove it. And researchers should set aside extra funds to support trial participants who have to do that.</p>



<p class="wp-block-paragraph">Some of the guidelines are vague and may overlap with existing ethics standards. They don’t all spell out explicit solutions. They were also developed with feedback from a small group of individuals—the number of people living with BCIs is still <a href="https://www.technologyreview.com/2025/04/01/1114009/brain-computer-interfaces-10-breakthrough-technologies-2025/">very low</a>. The team hopes to grow and expand on the guidelines over time. Burkhart also plans to discuss them with researchers at an <a href="https://www.sfn.org/">upcoming neuroscience conference</a>.</p>



<p class="wp-block-paragraph">“This is a living document, and this is version one,” says Chandler. “It’s just the starting point.”</p>



<p class="wp-block-paragraph"><em>This article first appeared in The Checkup, </em>MIT Technology Review’s<em> weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, </em><a href="https://forms.technologyreview.com/newsletters/biotech-the-checkup/?_ga=2.241810882.15113993.1664981064-43237434.1647441349"><em>sign up here</em></a>.</p>]]> </content:encoded>
</item>

<item>
<title>Sault Area Hospital advances diagnostic care with new SPECT/CT technology</title>
<link>https://edusehat.com/en/sault-area-hospital-advances-diagnostic-care-with-new-spectct-technology</link>
<guid>https://edusehat.com/en/sault-area-hospital-advances-diagnostic-care-with-new-spectct-technology</guid>
<description><![CDATA[ Patients in Northern Ontario are benefiting from faster diagnostic imaging and reduced radiation exposure following the installation of an advanced SPECT/CT system at Sault Area Hospital (SAH). The hospital celebrated the new technology on November 11, recognizing a combined $1.35-million contribution from Alamos Gold and Franco-Nevada toward the equipment purchase through the Sault Area Hospital […]
The post Sault Area Hospital advances diagnostic care with new SPECT/CT technology appeared first on Hospital News. ]]></description>
<enclosure url="" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 19:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sault, Area, Hospital, advances, diagnostic, care, with, new, SPECTCT, technology</media:keywords>
<content:encoded><![CDATA[<p>Patients in Northern Ontario are benefiting from faster diagnostic imaging and reduced radiation exposure following the installation of an advanced SPECT/CT system at Sault Area Hospital (SAH).</p>
<p>The hospital celebrated the new technology on November 11, recognizing a combined $1.35-million contribution from Alamos Gold and Franco-Nevada toward the equipment purchase through the Sault Area Hospital Foundation.</p>
<p>The scanner, which began operating during the summer of 2026, replaces equipment that had served the hospital since it opened its current facility in 2011. The upgrade represents an important investment in the hospital’s nuclear medicine program and its ability to provide advanced diagnostic services closer to home.</p>
<p><strong>Improving the patient experience</strong></p>
<p>SPECT/CT combines single-photon emission computed tomography with computed tomography, bringing together functional and anatomical imaging in a single examination. The technology enables clinicians to assess how organs and tissues are functioning while identifying the precise anatomical location of abnormalities.</p>
<p>At Sault Area Hospital, the system supports a range of clinical applications, including cardiac assessments, bone imaging and breast cancer care.</p>
<p>The new equipment can produce higher-quality images in approximately half the time required by the previous scanner, while also reducing radiation exposure.</p>
<p>Shorter examinations can help improve the patient experience, particularly for individuals who experience discomfort or difficulty remaining still during imaging procedures. Faster imaging may also support more efficient use of hospital resources as demand for diagnostic services continues to grow.</p>
<p><strong>Strengthening regional access to advanced imaging</strong></p>
<p>For patients living in Northern Ontario, access to specialized diagnostic services within their own community can make a meaningful difference. Long travel distances can create additional challenges for patients and families already navigating complex health conditions.</p>
<p>By modernizing its nuclear medicine equipment, Sault Area Hospital is strengthening its capacity to provide diagnostic services locally and supporting healthcare professionals with improved imaging capabilities.</p>
<p>The hospital’s medical imaging department is the largest in the Algoma District, performing more than 100,000 imaging examinations annually.</p>
<p><strong>Investing in the future of hospital technology</strong></p>
<p>The installation also highlights a broader challenge facing Canadian hospitals: replacing aging medical equipment while maintaining essential patient services.</p>
<p>Many of the technologies installed when Sault Area Hospital opened its current facility 15 years ago are approaching the end of their operational lives. The hospital has identified surgical and operating room equipment among its future investment priorities.</p>
<p>The SPECT/CT upgrade demonstrates how collaboration between healthcare organizations, hospital foundations and community partners can help sustain access to modern medical technology.</p>
<p>As diagnostic imaging continues to evolve, investments in advanced equipment will remain essential to supporting timely diagnoses, informed treatment decisions and high-quality patient care across Canada’s healthcare system.</p>
<p><strong>Sources:</strong> Sault Area Hospital Foundation</p>
<p>The post <a href="https://www.hospitalnews.com/sault-area-hospital-advances-diagnostic-care-with-new-spect-ct-technology/">Sault Area Hospital advances diagnostic care with new SPECT/CT technology</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>NPPA directs monitoring of trade margin rationalisation on 137 anti&#45;cancer drugs</title>
<link>https://edusehat.com/en/nppa-directs-monitoring-of-trade-margin-rationalisation-on-137-anti-cancer-drugs</link>
<guid>https://edusehat.com/en/nppa-directs-monitoring-of-trade-margin-rationalisation-on-137-anti-cancer-drugs</guid>
<description><![CDATA[ 
State Drug Controllers asked to monitor revised prices and submit action taken reports by 16 November
The post NPPA directs monitoring of trade margin rationalisation on 137 anti-cancer drugs appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 19:35:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>NPPA, directs, monitoring, trade, margin, rationalisation, 137, anti-cancer, drugs</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, has directed monitoring of the implementation of Trade Margin Rationalisation (TMR) on 137 non-scheduled anti-cancer drugs, notified through a Gazette Order dated 17 October 2026. The revised prices came into effect on 9 November 2026.</span></p>
<p><span>The latest revised price lists, based on submissions received from companies up to 11 November 2026, are available on the NPPA website and the Pharma Sahi Daam app/portal. Manufacturers, retailers, dealers, stockists, hospitals and medical institutions have been directed to comply with the revised prices and display the updated price lists at their premises and websites.</span></p>
<p><span>State Drug Controllers (SDCs) have been directed to monitor compliance by manufacturers, dealers, hospitals and medical institutions to ensure that the benefits of revised maximum retail prices (MRPs) are passed on to patients. Any violation may attract overcharging proceedings under the provisions of the Drugs (Prices Control) Order (DPCO), 2013.</span></p>
<p><span>Complaints regarding overcharging, shortage or non-availability of medicines can be reported through the Pharma Sahi Daam app/portal, NPPA helpline (1800-111-255) or email (monitoring-nppa[at]gov[dot]in).</span></p>
<p><span>State Drug Controllers have been asked to submit their Action Taken Reports to NPPA by 16 November 2026.</span></p>
<p>The post <a href="https://www.expresspharma.in/nppa-directs-monitoring-of-trade-margin-rationalisation-on-137-anti-cancer-drugs/">NPPA directs monitoring of trade margin rationalisation on 137 anti-cancer drugs</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From volume to value: How India’s pharma industry can move up the global value chain</title>
<link>https://edusehat.com/en/from-volume-to-value-how-indias-pharma-industry-can-move-up-the-global-value-chain</link>
<guid>https://edusehat.com/en/from-volume-to-value-how-indias-pharma-industry-can-move-up-the-global-value-chain</guid>
<description><![CDATA[ 
 Arun Patel, Founder and Partner, Arunasset Investment Services, explains how India’s pharma industry can move beyond volume-led growth and strengthen its position in the global value chain
The post From volume to value: How India’s pharma industry can move up the global value chain appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/13170953/EP_GB_Arun_Patel_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 19:35:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, volume, value:, How, India’s, pharma, industry, can, move, the, global, value, chain</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/13170953/EP_GB_Arun_Patel_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/13170953/EP_GB_Arun_Patel_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/13170953/EP_GB_Arun_Patel_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>India’s pharma exports reached $31.13 billion in FY2025-26, against $30.47 billion a year earlier. Growth has continued, but not accelerated: exports rose 4.9 per cent to $16.14 billion in April–September 2026, with July–September shipments up just 3.05 per cent to $8.04 billion. Europe expanded 9.66 per cent, ASEAN 21.54 per cent, and Latin America and the Caribbean 16.58 per cent in the first half. Formulations and biologicals still account for 73.84 per cent of shipments. About 35 per cent of formulation exports go to the US and 17 per cent to Europe, according to Crisil. Geographic diversification is progressing, but the American market remains too large to ignore.</span></p>
<p><span>The latest US tariff framework is more selective than the headline 100 per cent rate suggests. Under the April 2026 Section 232 proclamation, the 100 per cent duty applies to specified patented medicines and their ingredients, with concessions linked to US manufacturing commitments. The standard rate for imports from the EU, Japan, South Korea and Switzerland is 15 per cent, creating a substantial difference from the baseline treatment of other patented imports. Generic medicines, biosimilars and their ingredients are currently exempt, although Washington plans to reassess that treatment by April 2027. This protects the largest portion of India’s US pharma exports for now. It does not protect manufacturers from fierce generic competition, price erosion or the costs of developing alternatives to high-volume products.</span></p>
<p><span>The domestic market is in considerably better shape. Indian pharma sales grew 14.7 per cent to approximately </span><span>₹</span><span>74,610 crore in July–September, according to Equirus Securities, while September alone recorded 17.1 per cent growth and 5.4 per cent unit expansion. Quarterly volume growth was 3 per cent. Anti-diabetic medicines grew 21.2 per cent in September, cardiac therapies 20.4 per cent, and oncology 29.4 per cent. Chronic treatments grew 16.8 per cent on a trailing-year basis, compared with 10.9 per cent for acute therapies. Higher prices and new launches still contribute to growth, but the recovery in volumes makes the latest domestic numbers more substantial than a price-led expansion. Nifty Pharma gained 6.1 per cent in the final week of October, compared with 2.59 per cent for Nifty 50, despite mixed company earnings.</span></p>
<p><span>September-quarter earnings illustrate how sharply domestic strength and US weakness can diverge. Sun Pharma’s sales rose 11.8 per cent to </span><span>₹</span><span>16,100 crore, with Indian formulations up 17.3 per cent, while US formulations declined 8.2 per cent to $455 million. Its innovative-medicines portfolio generated $356 million, up 6.9 per cent, and represented 21.1 per cent of sales. Reported net profit fell to </span><span>₹</span><span>1,989 crore, largely reflecting exceptional acquisition-related and other charges; adjusted profit was </span><span>₹</span><span>3,162 crore. The distinction matters because an exceptional expense should not be confused with deterioration in the underlying formulations business.</span></p>
<p><span>Dr Reddy’s reported revenue of </span><span>₹</span><span>8,671 crore, down 1.5 per cent, with North American sales dropping 23 per cent to </span><span>₹</span><span>2,489 crore as revenues from lenalidomide normalised. Its India business grew 17 per cent and emerging markets 24 per cent, but gross margin still fell from 54.7 per cent to 52.1 per cent. Cipla’s revenue declined 2.4 per cent to </span><span>₹</span><span>7,404 crore, and profit dropped 35 per cent to </span><span>₹</span><span>878 crore. Its Indian business grew 12 per cent, while North American revenue fell 19 per cent to $172 million. Strong prescription growth at home has not been enough to replace the profitability of earlier, limited-competition US opportunities.</span></p>
<p><span>Lupin’s net sales rose 14 per cent to </span><span>₹</span><span>7,786 crore, helped by 14.7 per cent growth in India. However, profit fell 22 per cent to </span><span>₹</span><span>1,155 crore and its reported EBITDA margin contracted to 27.9 per cent from 35.6 per cent, including foreign-exchange and other income. Torrent Pharma’s 50.8 per cent revenue jump to </span><span>₹</span><span>4,979 crore partly reflected its expanded business following the JB Chemicals acquisition; net profit nevertheless declined 9.6 per cent to </span><span>₹</span><span>534 crore as depreciation and financing costs increased. Revenue growth alone therefore gives an incomplete account of sector performance.</span></p>
<p><span>Currency provides a partial cushion. Sun Pharma’s disclosed average exchange rate was </span><span>₹</span><span>95.58 to the dollar this September quarter, versus </span><span>₹</span><span>87.35 a year earlier. Lupin’s US sales were approximately 1 per cent higher in dollars but 9.3 per cent higher in rupees. Depreciation supports exporters’ reported revenue, yet imported inputs, equipment and dollar-linked freight can absorb some of that benefit. Dr Reddy’s specifically cited higher freight expenses linked to disruption in the Middle East. India also imported approximately $4.35 billion of specified APIs, bulk drugs and intermediates in FY2024-25, of which China supplied 73.7 per cent, according to Parliament data.</span></p>
<p><span>Complex development and contract manufacturing are providing measurable examples of higher-value business. Laurus Labs reported a 33 per cent rise in quarterly revenue to </span><span>₹</span><span>2,206 crore and 78 per cent EBITDA growth to </span><span>₹</span><span>762 crore. Its contract development and manufacturing revenue rose 77 per cent in the first half, supported by small-molecule projects and investment in peptides. India has established annual domestic capacity of around 56,800 tonnes for 28 of 41 identified critical bulk-drug products under its production-linked incentive programme, although capacity creation does not by itself eliminate import dependence. Moving from commodity generics to peptides, biosimilars and complex inhalation products increases development costs but can also reduce the number of direct competitors.</span></p>
<p><span>For October–December, domestic chronic therapies should remain the main support, while respiratory and anti-infective demand will depend on seasonal incidence and last year’s comparison base. Cipla expects to introduce generic Advair in the US during the quarter, but launch timing and competitive pricing will determine the contribution. Lower lenalidomide revenue remains a comparison challenge for other exporters. Crisil projects 11–13 per cent sector revenue growth for FY27, but warns that raw-material, energy and freight costs could reduce operating margins by 150–200 basis points. The critical indicators in December-quarter results will be US product-level price realisations, margins excluding currency gains, domestic prescription volumes and how quickly new complex products contribute revenue.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/from-volume-to-value-how-indias-pharma-industry-can-move-up-the-global-value-chain/">From volume to value: How India’s pharma industry can move up the global value chain</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond the fit: what clinicians should look for in an anti&#45;snoring appliance</title>
<link>https://edusehat.com/en/beyond-the-fit-what-clinicians-should-look-for-in-an-anti-snoring-appliance</link>
<guid>https://edusehat.com/en/beyond-the-fit-what-clinicians-should-look-for-in-an-anti-snoring-appliance</guid>
<description><![CDATA[ Mark Orridge shares his expert advice for selecting the right anti-snoring appliance, taking into account the patient, clinician and technician. Choosing an anti-snoring appliance involves more than selecting a device. Patients want comfort and value, clinicians want a reliable fit, and dental technicians want a practical design that can be manufactured consistently. Bringing those priorities… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/snoring.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 16:40:16 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, the, fit:, what, clinicians, should, look, for, anti-snoring, appliance</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Mark Orridge shares his expert advice for selecting the right anti-snoring appliance, taking into account the patient, clinician and technician.</strong></p>



<p>Choosing an anti-snoring appliance involves more than selecting a device. Patients want comfort and value, clinicians want a reliable fit, and dental technicians want a practical design that can be manufactured consistently. Bringing those priorities together is where an experienced laboratory partner makes a difference.</p>



<p>DB Digital Laboratory, the in-house laboratory at DB Orthodontics, can provide the MSi Mandibular Snoring Inhibitor to clinicians throughout the UK. Combining the appliance’s thoughtful design with specialist technical knowledge and direct communication, our team helps all types of dental practices offer a bespoke solution for suitable patients.</p>



<h2 class="wp-block-heading">Understanding the patient behind the prescription</h2>



<p>Dental technician and MSi designer Phil Chapman identified a familiar challenge: an appliance that works well for some patients, may be difficult for others to tolerate. Bruxism, dry mouth, restricted nasal breathing, sensitivity or bulky components can all influence appliance choice and everyday use.</p>



<p>A patient may mention some of these concerns, but others can be overlooked. For example, someone who grinds their teeth during sleep may be unaware of the habit. Careful assessment and communication between the patient, clinician and the laboratory therefore remain essential.</p>



<p>Not all appliances are suitable for everyone. Where symptoms suggest obstructive sleep apnoea, appropriate assessment and a referral should form part of the clinical pathway. For patients considered suitable for a mandibular advancement appliance, the MSi offers features designed to address several practical barriers to regular wear.</p>



<h2 class="wp-block-heading">Designed with comfort and regular use in mind</h2>



<p>Patient compliance begins with an appliance people feel they can wear. The MSi’s slim, low-profile construction is designed to limit bulk, while its provision for lateral movement allows greater freedom than a rigid restricted design.</p>



<p>Its design avoids cheek-side linkage arms and allows the mouth to open or close during wear. These details matter when discussing comfort, breathing and dry mouth for patients. They should be considered alongside everyone’s clinical needs, rather than treated as a guarantee of suitability.</p>



<p>Accessible components also make cleaning straightforward. Giving patients clear guidance on cleaning, handling and any adjustments helps them understand how to care for their appliance and use it as prescribed.</p>



<h2 class="wp-block-heading">Strength and adjustment for everyday demands</h2>



<p>Durability was central to Phil’s design. The MSi incorporates a robust hook and support arrangement designed to withstand the demands of heavy bruxism. Its replaceable components also support long-term maintenance.</p>



<p>The adjustable mechanism enables mandibular advancement to be achieved within the appliance’s available range. Patients can adjust when needed, under their clinician’s instructions, helping balance comfort with the correct advancement position. Follow-up appointments remain important to review tolerance, appliance condition and treatment response.</p>



<p>The dedicated Bite Right registration tool supports the recording of the protrusive bite. Combined with accurate records and a clear prescription, this helps establish the correct starting point for the laboratory to manufacture.</p>



<figure class="wp-block-image size-large"></figure>



<h2 class="wp-block-heading">The expertise behind your appliance</h2>



<p>At DB Digital Laboratory, technology enhances experience; it does not replace it. Our team brings more than three decades of specialist orthodontic laboratory experience to its work.</p>



<p>Our technicians, designers and laboratory specialists collaborate with clinicians to understand the requirements behind each prescription. That approach underpins our broader portfolio, from digitally planned expander appliances to mesialisers and distalisers, and informs the support available to practices requesting the MSi.</p>



<p>For clinicians, the benefit is direct access to a team that understands appliance construction and the practical questions that may arise during treatment. Discussing records, design considerations or maintenance with the laboratory helps keep communication clear and decisions informed.</p>



<h2 class="wp-block-heading">From prescription to precision</h2>



<p>Every case starts with clinical information needed to manufacture each appliance. Within DB Digital Laboratory, prescriptions and accompanying records are reviewed for completeness, with any queries raised before production proceeds. This early communication helps reduce avoidable delays and ensures the team understands what the clinician requires.</p>



<p>Our digital laboratory workflow includes preparing STL files and producing models using advanced 3D printing. For an MSi case, the team can advise on the information and bite registration required and discuss the suitable submission route.</p>



<p>Careful manufacture, quality control and dispatch complete the process. Throughout, our focus is on supporting the prescribing clinician with an appliance made for each individual patient.</p>



<h2 class="wp-block-heading">Bring MSi provision into your practice</h2>



<p>Whether you already provide an anti-snoring appliance or are exploring the options for suitable patients, DB Digital Laboratory offers a knowledgeable point of contact. Our in-house service connects UK clinicians with the MSi, and the technical support and training needed to discuss each case confidently. This gives any practice a clear route to obtaining a custom-made appliance, with a laboratory team available to answer any questions along the way.</p>



<p>To discuss an MSi course, prescription, submission requirements or patient information materials, contact DB Digital Laboratory on <a href="tel://01535%20656999">01535 656999</a> or email <a href="mailto:sales@dbortho.com">sales@dbortho.com</a>. Speak to our friendly team about how we can support your practice. <a href="https://docs.google.com/forms/d/e/1FAIpQLSeI3kCoKOq5chjlCrREbl2F_UvwqvNAYiwixYKP_e1PtQ6DVA/viewform?usp=header" target="_blank" rel="noreferrer noopener">Alternatively, click the link to arrange a call.</a></p>



<p><em>This article is sponsored by DB Orthodontics.</em></p>]]> </content:encoded>
</item>

<item>
<title>Time to rethink the rinse?</title>
<link>https://edusehat.com/en/time-to-rethink-the-rinse</link>
<guid>https://edusehat.com/en/time-to-rethink-the-rinse</guid>
<description><![CDATA[ From the evidence for adjunctive antibacterial mouthrinse to what really happens when patients rinse after brushing, some familiar assumptions about mouthwash deserve a closer look. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/mouthrinse-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 16:40:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Time, rethink, the, rinse</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large is-resized"></figure>



<p><strong>From the evidence for adjunctive antibacterial mouthrinse to what really happens when patients rinse after brushing, some familiar assumptions about mouthwash deserve a closer look.</strong></p>



<p>Mouthwash recommendations can sometimes become reduced to simple rules: mechanical cleaning should be enough, or rinsing after brushing will wash fluoride away.  However, the evidence presents a more nuanced picture, with different formulations offering different potential benefits according to individual patient need. As dental professionals look to personalise self-care advice, two common assumptions are worth revisiting.</p>



<h2 class="wp-block-heading">Myth: there is no evidence for adjunctive antibacterial mouthrinse</h2>



<p>Effective mechanical plaque control remains fundamental to oral hygiene, but current periodontal guidance also recognises a role for adjunctive antiseptic agents. The UK implementation of the European Federation of Periodontology (EFP) S3-level guideline advises that, where mechanical procedures alone do not effectively control supragingival biofilm and/or gingival inflammation, consideration can be given to a toothpaste and/or mouthrinse containing a specific active agent (West et al, 2021).</p>



<p>The guidance reflects a substantial evidence base, including a systematic review and meta-analysis of six-month randomised controlled trials that included 70 studies of adjunctive antiseptics. This found statistically significant additional reductions in gingival index, bleeding and plaque measures compared with mechanical plaque control alone. When individual agents were assessed, essential oils used alongside mechanical plaque control demonstrated statistically significant additional reductions in plaque indices compared with mechanical plaque control alone (Figuero et al, 2020).</p>



<p>The EFP S3-level guideline also evaluated evidence for 11 different mouthrinse formulations during supportive periodontal care. Essential oil (EO) and chlorhexidine mouthrinses were ranked among the most efficacious agents for changes in plaque and gingival indices, although the guideline emphasises that the choice of an adjunct should form part of a personalised approach (West et al, 2021).</p>



<p>For plaque management specifically, a meta-analysis of 29 six-month clinical trials provides further evidence for the fixed combination of four essential oils used in LISTERINE. At six months, 36.9% of participants using mechanical methods plus the EO-containing mouthrinse achieved at least 50% plaque-free sites, compared with 5.5% using mechanical methods alone (Araujo et al, 2015).</p>



<p>The evidence therefore supports considering an adjunctive antibacterial mouthrinse in specific circumstances, alongside effective mechanical plaque control and according to individual patient need.</p>



<h2 class="wp-block-heading">Myth: rinsing after brushing washes fluoride away</h2>



<p>The familiar advice to ‘spit, don’t rinse’ has an important qualification. The Delivering Better Oral Health toolkit (2025) advises patients to spit after brushing rather than rinse with water, to avoid diluting the fluoride.</p>



<p>A fluoride-containing mouthwash is different. In a randomised crossover study, participants brushed with 1,450 ppm fluoride toothpaste before either rinsing with a mouthwash containing 225 ppm fluoride, rinsing with one containing 500 ppm fluoride or not rinsing at all (Sköld et al, 2012).</p>



<p>Both fluoride mouthwashes significantly increased salivary fluoride retention over the following 60 minutes compared with not rinsing after brushing with 1,450 ppm fluoride toothpaste (Sköld et al, 2012).</p>



<p>The key distinction is what patients rinse with: water can dilute fluoride after brushing, while for patients who would benefit from additional fluoride, a mouthwash containing at least 225 ppm fluoride may increase post-brushing salivary fluoride retention (Sköld et al, 2012).</p>



<p>Where plaque control remains suboptimal, LISTERINE, with its evidence-based fixed combination of four essential oils, may in specific circumstances provide additional antibacterial support alongside mechanical plaque control (Araujo et al, 2015; Figuero et al, 2020; West et al, 2021).</p>



<h3 class="wp-block-heading">References</h3>



<ul class="wp-block-list">
<li>Araujo MWB, Charles CA, Weinstein RB, et al (2015) Meta-analysis of the effect of an essential oil-containing mouthrinse on gingivitis and plaque. <em>Journal of the American Dental Association</em>; 146(8): 610–622.</li>



<li>Delivering Better Oral Health: an evidence-based toolkit for prevention (2025) Office for Health Improvement and Disparities, Department of Health and Social Care, NHS England and NHS Improvement. Chapter 2: Summary guidance tables for dental teams.</li>



<li>Figuero E, Roldán S, Serrano J, et al (2020) Efficacy of adjunctive therapies in patients with gingival inflammation: a systematic review and meta-analysis. <em>Journal of Clinical Periodontology</em>; 47: 125–143.</li>



<li>Sköld UM, Birkhed D, Ellwood R (2012) Effect of post-brushing mouthwash solutions on salivary fluoride retention – study 1. <em>Journal of Clinical Dentistry</em>; 23(3): 97–100.</li>



<li>West N, Chapple I, Claydon N, et al (2021) BSP implementation of European S3-level evidence-based treatment guidelines for stage I–III periodontitis in UK clinical practice. <em>Journal of Dentistry</em>; 106: 103562.</li>
</ul>



<p><a href="https://kenvuepro.com/en-gb/brands/listerine" target="_blank" rel="noreferrer noopener">Visit Kenvue Pro for professional resources, samples and support</a>.</p>



<p><em>This article is sponsored by LISTERINE</em>.</p>



<p>UK-LIS-2026-355834</p>]]> </content:encoded>
</item>

<item>
<title>‘One of the best business decisions we’ve made’: dental practice on paying the Living Wage</title>
<link>https://edusehat.com/en/one-of-the-best-business-decisions-weve-made-dental-practice-on-paying-the-living-wage</link>
<guid>https://edusehat.com/en/one-of-the-best-business-decisions-weve-made-dental-practice-on-paying-the-living-wage</guid>
<description><![CDATA[ A mixed dental practice reported that none of its employed dental nurses or reception staff had left since it became an accredited Living Wage employer, following an initial pay uplift costing £26,000 a year. The case features in a new report, compiled by researchers at Middlesex University, which makes a case for adoption of the… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/living_wage.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 16:40:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>‘One, the, best, business, decisions, we’ve, made’:, dental, practice, paying, the, Living, Wage</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>A mixed dental practice reported that none of its employed dental nurses or reception staff had left since it became an accredited Living Wage employer, following an initial pay uplift costing £26,000 a year.</strong></p>



<p>The case features in <a href="https://repository.mdx.ac.uk/download/fadeaa9d3f3308fae88aafcb4ba574be74fca36dc7c580785335bd485f262129/2164604/The%20case%20for%20the%20Living%20Wage%20in%20Primary%20Care.pdf">a new report, compiled by researchers at Middlesex University,</a> which makes a case for adoption of the voluntary Real Living Wage in London primary care settings such as general dental practice. The hourly rate is set at £14.80 per hour in 2026, soon to rise to £15.45, compared to the legal minimum wage of £12.71 for those aged 21 and over.</p>



<p>Pearly Whites in Fulham implemented an initial annual pay uplift costing £26,000 to become an accredited Living Wage employer. This includes employer National Insurance and pension costs as well as base salaries. It reported:</p>



<ul class="wp-block-list">
<li>No turnover among directly employed staff since Living Wage accreditation</li>



<li>Reduced recruitment costs and agency dependency</li>



<li>Nearly doubled business turnover.</li>
</ul>



<p>Managing director Grant Goodstein said becoming a Living Wage employer was ‘one of the best business decisions we’ve made’. He told <em>Dentistry</em>: ‘Good dental nurses are hard to find, and they know it. In London, a nurse can walk into a new job next week, so practices end up competing for the same small pool of people. That is what drives turnover in dentistry. </p>



<p>‘Paying the London Living Wage is the simplest way we’ve found to take ourselves out of that cycle. Since we were accredited, not one of our employed dental nurses or reception team has left.’</p>



<h2 class="wp-block-heading">What are the potential benefits of implementing a Living Wage?</h2>



<p>‘Losing a nurse costs far more than people think,’ Grant explained. ‘There’s recruitment, agency cover, and training someone new.’</p>



<p>He also pointed to the impact that a happy workforce can have on the patient experience. He said: ‘Patients recognise and appreciate a consistent, happy and motivated team. Many people are nervous about the dentist, and being greeted by the same faces every visit makes a real difference. Since accreditation, our business performance has skyrocketed, and so has patient satisfaction.’</p>



<p>The report frames Living Wage implementation as an investment rather than an added cost. It notes that it requires leadership commitment, budgeting for annual rate rises, transparent communication, and an ability to make accreditation visible in recruitment and stakeholder communications.</p>



<p>One potential drawback highlighted in the report is pay compression, whereby the difference in wages between higher and lower ranking staff decreases. Suggested responses include redesigning all roles, simplifying pay structures, and using graduated percentage increases so lower-paid staff receive larger relative uplifts. The report also stresses the importance open communication with employees if pay practices change.</p>



<p>While it acknowledges the financial constraints faced by practices, the report calls for the Living Wage to become a normal part of primary care employment.</p>



<p><em><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</em></a></em></p>]]> </content:encoded>
</item>

<item>
<title>Every appointment counts: the dental team’s role in spotting mouth cancer</title>
<link>https://edusehat.com/en/every-appointment-counts-the-dental-teams-role-in-spotting-mouth-cancer</link>
<guid>https://edusehat.com/en/every-appointment-counts-the-dental-teams-role-in-spotting-mouth-cancer</guid>
<description><![CDATA[ When it comes to mouth cancer, a routine appointment could save a life. Jocelyn Harding explores the dental team’s vital role in mouth cancer detection and awareness ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/Mouth-cancer-team.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 16:40:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Every, appointment, counts:, the, dental, team’s, role, spotting, mouth, cancer</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>When it comes to mouth cancer, a routine appointment could save a life. Jocelyn Harding explores the dental team’s vital role in mouth cancer detection and awareness.</strong></p>



<p>Dental professionals are often the first, and sometimes the only, healthcare workers to see inside a patient’s mouth in any given year. That makes every appointment, whether a routine check-up, a hygiene visit or a quick review, a chance to detect changes or mouth cancer early, when survival chances are at their best.</p>



<h2 class="wp-block-heading">The scale of the problem</h2>



<p>The Oral Health Foundation’s <em><a href="https://www.dentalhealth.org/Handlers/Download.ashx?IDMF=6531c6d5-2651-46cf-9d4d-063d73b1fc8e">State of Mouth Cancer UK Report 2024</a></em> shows a disease still on the rise. A record 10,825 people were diagnosed in the UK last year, passing 10,000 for the first time. That compares with 8,864 the year before, and it is a 133% increase over 20 years.</p>



<p>Sadly, 3,637 people lost their lives to mouth cancer in the most recent figures, around 10 people every day. In the previous report, the figure was 3,034 deaths, so the toll is climbing.</p>



<p>Late diagnosis is a major reason survival has improved so little. The Oral Health Foundation has previously reported that just over half of cases are diagnosed at stage four, the most advanced stage.</p>



<p>Around 80% of the public cannot recall seeing any public messaging about mouth cancer, so people rarely know what to look for. That is where the dental team comes in.</p>



<h2 class="wp-block-heading">Staying vigilant at every visit</h2>



<p>Often, patients will not mention any symptoms or realise they matter. Asking directly – and documenting what you find – can make the difference.</p>



<p>Smoking and alcohol remain the biggest risk factors. Around two thirds of mouth cancer cases are linked to smoking, and people who both smoke and drink heavily face a risk around 30 times higher. Smokeless tobacco, betel quid, and vaping are also worth discussing, and every appointment is a chance to raise lifestyle habits sensitively and without judgement.</p>


        <div class="py-6 px-4 sm:px-6 flex items-center justify-center">
            <div class="max-w-4xl text-center space-y-4">
                                    <div class="font-secondary text-primary-500 text-2xl md:text-3xl">
                        ‘Staying alert at every appointment could save a life’                    </div>
                                                            </div>
        </div>



<p>The human papillomavirus (HPV) is also a growing cause, particularly of cancers at the back of the throat, including the tonsils and base of the tongue. HPV-related cancers affect people who may never have smoked or drunk heavily, so they can be unexpected.</p>



<p>Mention the HPV vaccine as part of prevention conversations with patients, and do not assume a ‘low risk’ patient has nothing to worry about.</p>



<h2 class="wp-block-heading">Patients are your messengers</h2>



<p>Patients talk. What you say in the surgery travels home to partners, parents, friends, and colleagues. When you explain why an ulcer that lasts more than three weeks needs checking, or recommend a particular toothbrush, interdental cleaning routine or mouthwash, those messages get passed on.</p>



<p>A patient who leaves understanding the warning signs may be the person who tells a neighbour to book an appointment about a lump they have been ignoring.</p>



<p>Make that easy. Offer leaflets, point patients to trusted resources, and encourage them to share what they xhave learned. The Mouth Cancer Foundation website is one such resource, with more than a million people helped by its information each year.</p>



<p>Mouth cancer can affect anyone, and the numbers show it is no longer a rare disease. Staying alert at every appointment could save a life.</p>



<p>Check thoroughly, ask the right questions, talk openly about risk factors, and encourage patients to spread the word.</p>



<h2 class="wp-block-heading">Mouth cancer resources</h2>



<p>Further information about mouth cancer can be found at:</p>



<ul class="wp-block-list">
<li><a href="https://mouthcancerfoundation.org/">Mouth Cancer Foundation</a></li>



<li><a href="https://dentalhealth.org/mouthcancer">Oral Health Foundation</a></li>



<li><a href="https://dentistry.co.uk/tag/oral-cancer">Dentistry.co.uk</a>.</li>
</ul>



<p><em>Follow <a href="https://www.instagram.com/dentistry.co.uk/" target="_blank" rel="noreferrer noopener">Dentistry.co.uk</a> on Instagram to keep up with all the latest dental news and trends.</em><br></p>]]> </content:encoded>
</item>

<item>
<title>CCRAS&#45;CARI, DU signs MoU to document medicinal plant diversity of North Campus</title>
<link>https://edusehat.com/en/ccras-cari-du-signs-mou-to-document-medicinal-plant-diversity-of-north-campus</link>
<guid>https://edusehat.com/en/ccras-cari-du-signs-mou-to-document-medicinal-plant-diversity-of-north-campus</guid>
<description><![CDATA[ 
The project aims to systematically document, identify and conserve the medicinal plant diversity available across the 250-300 acres of the University of Delhi&#039;s North Campus.
The post CCRAS-CARI, DU signs MoU to document medicinal plant diversity of North Campus appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/13111517/EP_DU.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 16:00:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CCRAS-CARI, signs, MoU, document, medicinal, plant, diversity, North, Campus</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/13111517/EP_DU.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/13111517/EP_DU.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/13111517/EP_DU-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>The Central Council for Research in Ayurvedic Sciences (CCRAS) – Central Ayurveda Research Institute (CARI), New Delhi and the University of Delhi signed a Memorandum of Understanding (MoU) on 10 November 2026 to undertake a collaborative project titled “Inventory of Phyto-diversity of Medicinal Importance Used in Ayurveda of North Campus of Delhi University.”</span></p>
<p><span>The MoU was formally signed by Prof. (Vd.) Rabinarayan Acharya, Director General, CCRAS, and Dr. Vikas Gupta, Registrar, University of Delhi, at the VC Office, North Campus, New Delhi.</span></p>
<p><span>The project aims to systematically document, identify and conserve the medicinal plant diversity available across the 250-300 acres of the University of Delhi’s North Campus. The initiative seeks to explore the rich botanical heritage of the campus and document plant species of medicinal importance described in Ayurveda.</span></p>
<p><span>The major activities under the project will include comprehensive field surveys, identification and documentation of medicinal plant species, preparation of herbarium specimens, and installation of QR-code-enabled name boards across the campus to facilitate easy identification and access to information about medicinal plants.</span></p>
<p><span>The project will also result in the preparation of an illustrated pictorial book documenting the medicinal flora of the North Campus, along with joint research publications to disseminate the scientific findings.</span></p>
<p><span>Prof. K. Ratnabali, Dean of Academic Affairs, Delhi University; Prof. (Dr.) Shobha Bagai, Director of the Cluster Innovation Centre (CIC), Delhi; Dr. Hemanta Panigrahi, Director in Charge, CARI, New Delhi; Dr. Sakshi Sharma, Research Officer and PI of the Project, CARI, New Delhi; Prof. (Dr.) Suresh Kumar, PI of the Project, Cluster Innovation Centre (CIC), University of Delhi; and Prof. (Dr.) Vandana, Department of  Chemistry, Dyal Singh College, Delhi University, were also present on the occasion.</span></p>
<p><span>This collaborative initiative represents an important step towards strengthening institutional cooperation in the fields of Ayurveda, biodiversity conservation, medicinal plant research and scientific documentation. It is expected to contribute significantly to raising awareness about the medicinal wealth of the university campus and promoting the conservation and sustainable utilisation of medicinal plant resources.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/ccras-cari-du-signs-mou-to-document-medicinal-plant-diversity-of-north-campus/">CCRAS-CARI, DU signs MoU to document medicinal plant diversity of North Campus</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Reference Genomes of Malaria&#45;Causing Plasmodium Parasites Completed</title>
<link>https://edusehat.com/en/reference-genomes-of-malaria-causing-plasmodium-parasites-completed</link>
<guid>https://edusehat.com/en/reference-genomes-of-malaria-causing-plasmodium-parasites-completed</guid>
<description><![CDATA[ Using DNA sequenced from patient blood samples, researchers assembled complete reference genomes of neglected malaria parasites, uncovering genetic regions potentially involved in immune evasion and providing new tools for disease surveillance.
The post Reference Genomes of Malaria-Causing Plasmodium Parasites Completed appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/08/Getty_476872691_PlasmodiumCausingMalaria.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 09:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Reference, Genomes, Malaria-Causing, Plasmodium, Parasites, Completed</media:keywords>
<content:encoded><![CDATA[<p>Researchers have generated the most complete chromosome-level reference genomes to date for two understudied malaria parasites, uncovering previously inaccessible genetic regions that could help explain how the pathogens evade immune defenses and persist in human hosts.</p>
<p>The study, titled “<a href="https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1014754" target="_blank" rel="noopener">High quality chromosomal genome assemblies of three human <em>Plasmodium </em>species directly from natural infection</a>,” and published in <em>PLOS Pathogens, </em>describes a method for assembling chromosome-level genomes directly from patient blood samples without laboratory culturing. The findings could improve parasite identification, genomic surveillance, and efforts to monitor emerging drug resistance.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Although <em>Plasmodium falciparum </em>is responsible for most malaria-related deaths, other species, including <em>P. ovale </em>and <em>P. malariae</em>, also contribute to the global disease burden. These parasites can cause chronic infections but remain comparatively poorly understood, partly because researchers lack reliable methods for growing them continuously in laboratory cultures.</p>
<p>To address these limitations, scientists at the Wellcome Sanger Institute and the Parasites and Microbes Research and Training Center in Mali collected blood samples from patients with naturally acquired malaria infections in Faladie, Mali.</p>
<p>The team enriched parasite DNA by removing human white blood cells and uninfected red blood cells before applying PacBio Ultra-Low-Input HiFi long-read sequencing. They combined this approach with Hi-C, a technique that captures interactions between DNA regions to reconstruct chromosome organization.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The researchers ultimately assembled parasite genomes from eight participants, producing high-quality references for <em>P. ovale wallikeri, P. malariae, </em>and <em>P. falciparum.</em></p>
<p>Unlike earlier fragmented references, the new assemblies resolved previously inaccessible regions near chromosome ends, known as subtelomeric regions. These areas contain repetitive DNA and expanded gene families associated with interactions between parasites and their human hosts, enhancing “understanding of parasite persistence, transmission, immune evasion, and comparative evolutionary studies.”</p>
<p>Notably, the researchers identified more than 2,000 genes belonging to the <em>PIR </em>gene family in <em>P. ovale wallkeri, </em>accounting for approximately one-quarter of its genome.</p>
<p>Comparisons among parasites collected from the same geographic region also revealed extensive genetic rearrangements near chromosome ends, highlighting mechanisms that may contribute to antigenic variation and immune invasion.</p>
<p>“Uncovering these full genomes revealed the extent of expansions of gene families sitting at the ends of chromosomes, which regularly shuffle genetic material to adapt and evade the human immune system,” said first author Sunil Dogga, PhD, formerly of the Wellcome Sanger Institute and now at the Swiss Tropical and Public Health Institute.</p>
<p>The findings are particularly relevant as malaria elimination efforts increasingly confront infections caused by non-<em>falciparum </em>species, which can be difficult to diagnose and may persist even where <em>P. falciparum </em>transmission declines.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Beyond improving understanding of parasite biology, the genomic resources could support development of more accurate molecular diagnostics, identification of potential therapeutic targets, and studies investigating how parasite populations respond to treatment and control measures.</p>
<p>“Establishing gold-standard reference genomes for these neglected parasites fills a critical knowledge gap in global malaria research,” said senior author Mara Lawniczak, PhD, group leader at the Wellcome Sanger Institute.</p>
<p>The researchers emphasized that incorporating these overlooked species into genomic surveillance will be important for developing more comprehensive malaria elimination strategies. The authors wrote, “This work provides a critical foundation for including these neglected species in global malaria elimination efforts.”</p>
<p> </p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/reference-genomes-of-malaria-causing-plasmodium-parasites-completed/">Reference Genomes of Malaria-Causing <i>Plasmodium</i> Parasites Completed</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Neuroprotective Protein Atlas Positions the Blood&#45;Brain Barrier as a Selective Checkpoint</title>
<link>https://edusehat.com/en/neuroprotective-protein-atlas-positions-the-blood-brain-barrier-as-a-selective-checkpoint</link>
<guid>https://edusehat.com/en/neuroprotective-protein-atlas-positions-the-blood-brain-barrier-as-a-selective-checkpoint</guid>
<description><![CDATA[ The blood-brain barrier keeps most proteins in the bloodstream out of the brain, but not all. The pathways that import them are damaged early in Alzheimer’s disease models, hinting at new ways to treat the disease.
The post Neuroprotective Protein Atlas Positions the Blood-Brain Barrier as a Selective Checkpoint appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/GettyImages-2203499176.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 05:30:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Neuroprotective, Protein, Atlas, Positions, the, Blood-Brain, Barrier, Selective, Checkpoint</media:keywords>
<content:encoded><![CDATA[<p><span>Working in mice, scientists from the Gladstone Institutes, University of California, and elsewhere have created what they claim is the first atlas of neuroprotective proteins that are transported across the blood-brain barrier and into the brain. According to the scientists, the atlas contains 92 proteins so far and their analysis points to potential strategies for treating neurodegenerative conditions. Details are provided in a new </span><i><span>Cell </span></i><span>paper titled “</span><a href="https://www.cell.com/cell/fulltext/S0092-8674(26)01326-7" target="_blank" rel="noopener"><span>The blood-brain barrier imports diverse neuroprotective proteins through pathways impaired early in Alzheimer’s disease models</span></a><span>.”</span></p>
<p><span>The study suggests that the blood-brain barrier is much more than a physical boundary intended solely to protect the brain from toxins. As Andrew Yang, PhD, a Gladstone investigator and one of the authors on the study put it, “we’re finding that it’s an intelligent interface that plucks the right proteins in the blood, often from distant parts of the body and delivers them to the right cell types in the brain.” Importantly, as the paper’s title suggests, the proteins included in the atlas make their way into the brain through pathways that are impaired early on in the development of diseases like Alzheimer’s.</span></p>
<p><span>To generate the atlas, Yang and his colleagues developed a method of tracking the specific blood plasma proteins that crossed into the brains of mice. They used protein-labeling chemistry to track proteins from multiple organs such as the liver and kidney without disrupting their biology. Specifically, they developed “a bioorthogonal proteomics strategy, an <em>in vivo</em> click-enrichment screen of labeled plasma proteins entering the brain” and used it to systematically map the blood-brain barrier “transportome,” according to the paper. The approach was benchmarked against a commonly used biotin labeling approach and was shown to consistently produce “stronger signals in plasma and brain vessels” as well as to enable “robust detection of plasma proteins in neurons, astrocytes, and microglia.” </span></p>
<p><span>The scientists used the method to tag various mouse blood proteins before injecting them back into the bloodstream. They examined brain tissue to see which labeled proteins successfully crossed the barrier. Of the 861 proteins that the scientists tracked in this way, they found that 92 crossed into the brain. Most were proteins produced primarily in the liver but also in adipose tissue and the intestine. Once there, the proteins were directed to specific types of brain cells to perform specialized functions. </span></p>
<p><span>An example is the liver protein apolipoprotein AI or (APOA1) that once in the brain activates a pathway needed to maintain healthy astrocyte connections. Studies link its absence to a greater risk of developing Alzheimer’s disease. “We think of blood proteins as messengers carrying signals from distant body parts, and the cells of the blood-brain barrier import only the ones the brain really needs,” said Haoyue Zhou, PhD, a postdoctoral scholar in Yang’s lab and first author of the paper.</span></p>
<p><span>A key part of the study was exploring what happens to protein delivery in Alzheimer’s. As the disease progresses, the blood-brain barrier breaks down allowing harmful proteins to leak into the brain. Using their protein-labeling method, Yang’s team discovered another problem. They found that even before the barrier breaks down, it stops importing protective proteins like APOA1 into the brain. Loss of the protein erodes neuronal connections, which contributes to behavioral changes and other early signs of the disease. </span></p>
<p><span>Conceivably, increasing the supply of APOA1 to the brain could help counter the emergence of Alzheimer’s symptoms. To discover whether this might be possible, the scientists tracked proteins in mouse models engineered to produce extra APOA1 in the liver. And indeed they found that as more APOA1 entered the brain, the mice showed fewer signs of the disease. These findings suggest that “Alzheimer’s disease may not start entirely inside the brain” but “when the brain’s supply line from the body is severed,” Yang noted. “If that’s right, we may be able to fight this disease from outside the brain, by restoring what the brain has lost.”</span></p>
<p><span>Boosting production of beneficial proteins like APOA1 to ensure the brain has a sufficient supply is one possible treatment strategy. Another option is harnessing the brain’s natural “ZIP code” system to deliver therapies directly to specific types of brain cells. A third option that Yang and his colleagues are currently exploring is harnessing the blood-brain barrier’s transport machinery to help drugs reach the brain more efficiently. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/neuroprotective-protein-atlas-positions-the-blood-brain-barrier-as-a-selective-checkpoint/">Neuroprotective Protein Atlas Positions the Blood-Brain Barrier as a Selective Checkpoint</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>High Frequency of Drug&#45;Impacting Gene Variants Found in All of Us Cohort</title>
<link>https://edusehat.com/en/high-frequency-of-drug-impacting-gene-variants-found-in-all-of-us-cohort</link>
<guid>https://edusehat.com/en/high-frequency-of-drug-impacting-gene-variants-found-in-all-of-us-cohort</guid>
<description><![CDATA[ A study finds that everyone in a diverse, nearly 100,000-person sample carried at least one genetic variant that affects how their body processes medications, and a quarter of those people had been prescribed a medication that is known to be impacted by the variant they carried.
The post High Frequency of Drug-Impacting Gene Variants Found in All of Us Cohort appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2177211585.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 05:30:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>High, Frequency, Drug-Impacting, Gene, Variants, Found, All, Cohort</media:keywords>
<content:encoded><![CDATA[<p>A study headed by researchers at the University of Pittsburgh has found that everyone in a diverse, nearly 100,000-person sample from the National Institutes of Health’s <em>All of Us</em> Research Program (All of Us) carried at least one genetic variant that affects how their body processes medications. The results also showed that a quarter of those people had been prescribed a drug that is known to be impacted by the variant they carried.</p>
<p>The researchers say the discovery highlights the value of genetic testing for some medications and that electronic health record alerts could be helpful when a clinician prescribes one of these drugs. Such an alert would allow the clinician to consider prescribing an alternate medication or adjusting the dosage, if appropriate.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“Many people have experience with taking a medication that is not working well for them or that has a side effect,” said Philip E. Empey, PharmD, PhD, associate professor in Pitt’s School of Pharmacy and associate director for pharmacogenomics at the Institute for Precision Medicine at Pitt and UPMC. “While many things impact how a patient responds to medication, our research tells us that genetics could be [a] factor for a large proportion of patients and it points to the value of precision medicine in prescribing.”</p>
<p>Empey is senior author of the researchers’ published paper in <em>Science Translational Medicine</em>, titled “<a href="http://dx.doi.org/10.1126/scitranslmed.adt8040" target="_blank" rel="noopener">Frequency of pharmacogenomic variation and medication exposures among <em>All of Us</em> Participants</a>.”</p>
<p>Pharmacogenomics (PGx) promises improved outcomes through individualized prescribing, the authors wrote in their paper. “PGx can impact drug effectiveness and toxicity. Many commonly prescribed medications have genotype-guided dosing or drug selection recommendations in their Food and Drug Administration (FDA) approved labeling or in guidelines developed by the Clinical Pharmacogenetics Implementation Consortium (CPIC).”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>More than 300 medications have information on their labels about genetic variant interactions, where genetic testing may be of value to guide prescribing, Empey said. One example is a chemotherapy drug used for colon cancer that could have serious toxicity in up to 8% of patients who carry these genetic variants, so those patients are proactively tested before treatment. However, the authors noted, “Despite the strong evidence supporting the use of PGx data in clinical practice, broader implementation is limited in part by the relative paucity of data on the frequency of variants, alleles, and predicted phenotypes across diverse biogeographical groups.”</p>
<p>For their reported study the research team used data from the National Institutes of Health (NIH) <a href="https://www.nih.gov/allofus" target="_blank" rel="noopener"><em>All of Us</em> Research Program</a>, an initiative that aims to gather data from one million people across the U.S. to help better understand how lifestyle, environment, and genes influence health and disease. Pitt is a key partner in the program, launching All of Us Pennsylvania in 2018. “This study represents one of the largest and the most diverse PGx datasets with linked medication exposures events to date,” the team noted. “<em>All of Us</em> has particular value in identifying and understanding the frequency of both previously unknown and rare variants because of the size of the cohort, comprehensiveness in genotyping approach, and the genetic diversity.”</p>
<p>The team evaluated the frequency of 16 genetic variants known to impact the effectiveness or toxicity of various medications among nearly 100,000 <em>All of Us</em> participants. The results showed that everyone in the study was found to carry at least one such variant with a median of nine variants. “We found 100% of participants carried at least one known PGx variant and nearly all (99.49%) had a predicted phenotype for a gene which has a CPIC or FDA recommendation for a change in prescribing,” they stated. “Among nearly 100k participants in <em>All of Us</em> Research Program, pharmacogenomic variants and actionable results are common and the diversity of the cohort provided for identification of novel variants and population frequencies.”</p>
<p>By then matching the genetic data to the participants’ medical records, the research team also found that more than 24% of participants had been prescribed at least one medication known to interact with a variant they carried. “Clinical impact was high with 24.38% of participants having both an actionable phenotype for these pharmacogenes and a prior exposure to an impacted medication with pharmacogenomic prescribing guidance,” they wrote. The most common medications identified in the review were ondansetron (anti-nausea), ibuprofen (anti-inflammatory), omeprazole and pantoprazole (both treat acid reflux and heartburn), and atorvastatin (lowers cholesterol).</p>
<p>The team also identified over 17,000 novel variants and reported the frequency of known medication-linked genetic variants across multiple ancestry groups, including in populations where these frequencies were not previously estimated. “Importantly, we report thousands of novel variants as well as hundreds of alleles and predicted phenotypes that deviate from known frequencies and/or were previously unreported, especially within Americas and African ancestry groups.” they wrote in summary.</p>
<p>“The limited diversity of racial and ethnic groups in early studies is a challenge in genetic research and skews risk estimates,” Empey said. “That’s part of the beauty of the <em>All of Us</em> Research Program—it was intentionally designed to help close these gaps by including people from a wide range of age groups, backgrounds, and life experiences. It also underscores the value of having a large precision medicine dataset where whole genome testing data can be studied along with clinical data.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Empey said it will be up to policy makers and health insurers to weigh the benefits of widespread genetic screening for variants that interact with medications against the cost, and that this is a very active area of research. He said it makes sense to screen patients with a panel test that can look for common variants that are known to affect many medications and have these results in their medical record, much like a test for kidney function. This approach is also being applied in situations where patients are on many medications at the same time or in patients starting certain medications known to be impacted by genetics, such as clopidogrel, a medication used after cardiac stenting.</p>
<p>People who have already undergone pharmacogenomic testing should be sure to share their results with their pharmacists and prescribers so that it is integrated with their electronic health record, said Empey, who is leading efforts at UPMC to make it easy for clinicians to see if a patient carries variants that may affect a medication that they’re prescribing and recommend changes when needed.</p>
<p>“Just like with any new technology, it comes down to responsible implementation,” Empey said. “Costs are coming down and the data is increasing, so it is important for patients and clinicians to be aware that the use of precision medicine in prescribing is becoming commonplace.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/high-frequency-of-drug-impacting-gene-variants-found-in-all-of-us-cohort/">High Frequency of Drug-Impacting Gene Variants Found in <i>All of Us</i> Cohort</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Physicians Foundation Announces Two Grant Opportunities to Advance Physician Wellbeing and Strengthen the Healthcare Workforce</title>
<link>https://edusehat.com/en/the-physicians-foundation-announces-two-grant-opportunities-to-advance-physician-wellbeing-and-strengthen-the-healthcare-workforce</link>
<guid>https://edusehat.com/en/the-physicians-foundation-announces-two-grant-opportunities-to-advance-physician-wellbeing-and-strengthen-the-healthcare-workforce</guid>
<description><![CDATA[ New requests for proposals seek innovative solutions to create safer care environments and support physicians transitioning to late-career practice and retirement BOSTON, November 12, 2026 — The Physicians Foundation has announced two Requests for Proposals (RFPs) aimed at addressing critical challenges affecting physician wellbeing, professional fulfillment, and healthcare workforce sustainability. The funding opportunities will support […]
The post The Physicians Foundation Announces Two Grant Opportunities to Advance Physician Wellbeing and Strengthen the Healthcare Workforce appeared first on The Physicians Foundation. ]]></description>
<enclosure url="https://physiciansfoundation.org/wp-content/themes/physicians-foundation/assets/build/images/admin/defaults/default-image.webp" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 01:30:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Physicians, Foundation, Announces, Two, Grant, Opportunities, Advance, Physician, Wellbeing, and, Strengthen, the, Healthcare, Workforce</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph"><em><em><em><em><em>New requests for proposals seek innovative solutions to create safer care environments and support physicians transitioning to late-career practice and retirement</em></em></em></em></em></p>



<p class="wp-block-paragraph"><strong>BOSTON, November 12, 2026</strong> — The Physicians Foundation has announced <a href="https://physiciansfoundation.org/grants/">two Requests for Proposals (RFPs)</a> aimed at addressing critical challenges affecting physician wellbeing, professional fulfillment, and healthcare workforce sustainability. The funding opportunities will support innovative research and scalable interventions focused on fostering safe and respectful care environments for physicians and helping physicians navigate the transition to late-career practice and retirement.</p>



<p class="wp-block-paragraph">The new RFPs come as findings from The Physicians Foundation’s <a href="https://physiciansfoundation.org/research/how-practice-conditions-shape-physician-wellbeing/">2026 Wellbeing Survey of America’s Physicians</a> underscore the growing impact of workplace conditions on physician wellbeing and workforce retention. According to the survey, 42% of physicians have considered retiring earlier than planned and/or leaving clinical practice due to concerns about their wellbeing.</p>



<p class="wp-block-paragraph">These findings highlight the need for tailored solutions that support physicians throughout their careers while addressing systemic challenges that can affect their ability to deliver high-quality patient care.</p>



<p class="wp-block-paragraph">“Physician wellbeing is not just an individual concern. It is essential to the strength and sustainability of our healthcare system,” said <a href="https://physiciansfoundation.org/leadership/">Dr. Gary Price</a>, president of The Physicians Foundation. “We are seeking bold, evidence-based approaches that go beyond identifying problems to create meaningful, lasting change. By supporting research and scalable interventions, we aim to improve physician wellbeing, strengthen the healthcare workforce, and ensure physicians can thrive at every stage of their careers.”</p>



<p class="wp-block-paragraph">The Physicians Foundation is seeking proposals in two priority areas: (1) fostering safe and respectful care environments and (2) supporting physicians transitioning into late career status.</p>



<p class="wp-block-paragraph"><strong>Fostering Safe and Respectful Care Environments for Physicians</strong></p>



<p class="wp-block-paragraph">Physicians increasingly face workplace hostility, harassment, discrimination and other forms of mistreatment that threaten their wellbeing, professional fulfillment and ability to provide high-quality patient care. This RFP seeks innovative, system-level solutions to better understand, prevent and address these challenges.</p>



<p class="wp-block-paragraph">Priority will be given to scalable interventions that move beyond traditional compliance-based approaches to address the structural and cultural drivers of workplace mistreatment. Projects may explore new prevention strategies, peer-support resources and organizational practices that foster safer, more respectful care environments.</p>



<p class="wp-block-paragraph"><strong>Supporting Physicians Transitioning to Late Career Status and Retirement</strong></p>



<p class="wp-block-paragraph">As physicians advance in their careers, they face unique challenges related to professional identity, evolving workplace expectations and retirement planning. The Foundation’s 2026 survey found that 29% of older physicians considered reducing or had reduced their clinical hours due to wellbeing concerns, compared with 22% of younger physicians, highlighting the need for tailored support throughout physicians’ careers.</p>



<p class="wp-block-paragraph">This RFP seeks practical, sustainable approaches that help physicians navigate late-career transitions while maintaining professional fulfillment and a sense of purpose. Projects may explore flexible practice models, mentorship opportunities, peer engagement and retirement planning resources that support physician wellbeing and strengthen workforce continuity.</p>



<p class="wp-block-paragraph"><strong>Funding and Application Details</strong></p>



<p class="wp-block-paragraph">For each RFP, The Physicians Foundation anticipates awarding a limited number of grants of up to <strong>$100,000 per project</strong>, supporting initiatives lasting up to two years. Proposals will be evaluated based on their alignment with the Foundation’s priorities, potential impact, feasibility, and ability to produce measurable, sustainable, and replicable solutions.</p>



<p class="wp-block-paragraph"><strong>Applications for both RFPs are due February 11, 2027, at 5 p.m. ET.</strong> Funding decisions are anticipated by the end of April 2027, with projects expected to begin June 1, 2027. Those interested in applying are encouraged to learn more, <a href="https://physiciansfoundation.org/grants/"><em>here.</em></a></p>



<p class="wp-block-paragraph">Applicants should use the following access codes in the online application system:</p>



<p class="wp-block-paragraph">Supporting Physicians Transitioning to Late Career Status and Retirement: wellbeing2</p>



<p class="wp-block-paragraph">Fostering Safe and Respectful Care Environments for Physicians: wellbeing1</p>



<h3 class="wp-block-heading"><strong>About The Physicians Foundation </strong></h3>



<p class="wp-block-paragraph">The Physicians Foundation is a public charity seeking to advance the work of practicing physicians and help them facilitate the delivery of high-quality health care to patients. As the U.S. health care system continues to evolve, The Physicians Foundation is steadfast in strengthening the physician-patient relationship, supporting medical practices’ sustainability and helping physicians navigate the changing health care system. The Physicians Foundation pursues its mission through research, education and innovative grant making that improves physician wellbeing, strengthens physician leadership, addresses drivers of health and lifts physician perspectives. For more information, visit <a href="https://www.physiciansfoundation.org/">www.physiciansfoundation.org</a>.</p>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://physiciansfoundation.org/the-physicians-foundation-announces-two-grant-opportunities-to-advance-physician-wellbeing-and-strengthen-the-healthcare-workforce/">The Physicians Foundation Announces Two Grant Opportunities to Advance Physician Wellbeing and Strengthen the Healthcare Workforce</a> appeared first on <a href="https://physiciansfoundation.org/">The Physicians Foundation</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Claire AI™ Feature Spotlight: Summarize Key Concepts </title>
<link>https://edusehat.com/en/claire-aifeature-spotlight-summarize-key-concepts-15300</link>
<guid>https://edusehat.com/en/claire-aifeature-spotlight-summarize-key-concepts-15300</guid>
<description><![CDATA[ The post Claire AI™ Feature Spotlight: Summarize Key Concepts  appeared first on BoardVitals Blog. ]]></description>
<enclosure url="https://blog.boardvitals.com/wp-content/uploads/2026/10/346-BLOG-Summarize-1200x900-1-1024x768.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 01:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Claire, AI™ Feature, Spotlight:, Summarize, Key, Concepts </media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">Preparing for your boards means working through a lot of information in a limited amount of time. Answering practice questions is important, but so is understanding the concepts behind each answer, connecting related ideas, and knowing what deserves another look. When explanations cover several details at once, finding the main takeaway can slow down your review.  </p>



<p class="wp-block-paragraph">That’s where the new Claire AI<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> summarize feature in BoardVitals can help. It turns the material behind each question into a concise, focused overview, making it easier to understand key concepts, revisit challenging topics, and keep your study sessions moving. </p>



<h3 class="wp-block-heading"><strong>Make Every Study Minute Count</strong> </h3>



<p class="wp-block-paragraph">Medical students and residents have a lot to learn and limited time to learn it. You need to understand the reasoning behind each question while reinforcing the high-yield takeaways most likely to matter on exam day. Claire AI helps bridge that gap by condensing complex topics into focused reviews. </p>



<p class="wp-block-paragraph">When you answer a BoardVitals question, Claire AI uses the question’s context to create an easy-to-digest overview of the related content and key concepts. Instead of sorting through every detail again, you can quickly focus on what matters most and get back to studying.  </p>



<p class="wp-block-paragraph">Use a summary when an explanation brings together several ideas, when a topic feels unfamiliar, or when you want to lock in the main point before moving on. With the key details easier to spot, you can spend less time sorting through information and more time practicing where it counts. </p>



<h3 class="wp-block-heading"><strong>Build Claire AI into Your Study Routine</strong> </h3>



<p class="wp-block-paragraph">During a focused review session, use Claire AI to quickly revisit a weak area without rereading every detail. As exam day approaches, turn to these overviews for a quick way to refresh. </p>



<p class="wp-block-paragraph">Claire AI works best alongside your own clinical reasoning. Use each summary to reinforce learning and guide your next step, and refer to the complete question explanation whenever you need more context or detail. </p>



<p class="wp-block-paragraph">As you work through your question bank, Claire AI summaries make it easier to return to missed or challenging material. They do not replace BoardVitals’ complete explanations; they give you another quick way to reinforce the central lesson and keep building momentum.  </p>



<h3 class="wp-block-heading"><strong>Meet Claire AI for BoardVitals</strong> </h3>



<p class="wp-block-paragraph">Meet Claire AI, now available with most BoardVitals question banks. From explaining challenging topics and summarizing key points to <a href="https://www.boardvitals.com/blog/claire-ai-feature-flashcards/" data-type="post" data-id="15822">creating flashcards</a> and <a href="https://www.boardvitals.com/blog/claire-ai-feature-more-questions/" data-type="post" data-id="15818">generating additional practice questions</a>, Claire AI gives you more ways to engage with the material you are already reviewing. And because Claire AI pulls only from BoardVitals’ up-to-date question bank content, you can trust that the study support stays grounded in the same reliable material you already use to prepare. </p>



<p class="wp-block-paragraph">With AI-powered support built directly into the BoardVitals experience, Claire AI makes each study session more focused and responsive. You’ll get the help you need to study effectively when you need it most. However you choose to use it, Claire AI can help you understand, review, and practice material with greater confidence throughout your board prep. </p>
<p>The post <a href="https://www.boardvitals.com/blog/claire-ai-feature-summarize/">Claire AI™ Feature Spotlight: Summarize Key Concepts </a> appeared first on <a href="https://www.boardvitals.com/blog">BoardVitals Blog</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Claire AI™ Feature Spotlight: Generate More Practice Questions</title>
<link>https://edusehat.com/en/claire-ai-feature-spotlight-generate-more-practice-questions-15301</link>
<guid>https://edusehat.com/en/claire-ai-feature-spotlight-generate-more-practice-questions-15301</guid>
<description><![CDATA[ The post Claire AI™ Feature Spotlight: Generate More Practice Questions appeared first on BoardVitals Blog. ]]></description>
<enclosure url="https://blog.boardvitals.com/wp-content/uploads/2026/10/346-BLOG-Gen-Questions-1200x900-1-1024x768.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 01:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Claire, AI™, Feature, Spotlight:, Generate, More, Practice, Questions</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">More questions means more ways to prepare for the boards. Practicing the same concept through different wording, details, and clinical presentations can help you move beyond memorization and learn how to apply what you know. </p>



<p class="wp-block-paragraph">Whether you are preparing for a <a href="https://boardvitals.com/medical-students">USMLE® exam</a>, a <a href="https://boardvitals.com/medical-students">shelf exam</a>, or <a href="https://boardvitals.com/medical-board-reviews">specialty boards</a>, Claire AI<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> makes it easy to turn one review question into a focused learning session, allowing you to stay with a challenging concept and practice it from multiple angles before moving on. </p>



<p class="wp-block-paragraph">This kind of targeted practice is especially useful when you miss a question, hesitate between two answer choices, or reach the correct answer for the wrong reason. Instead of saving the topic to revisit later, you can reinforce it right away while the concept – and your reasoning – are still fresh.  </p>



<h3 class="wp-block-heading"><strong>More Questions, More Prep</strong> </h3>



<p class="wp-block-paragraph">Looking for additional ways to study a concept? Ask Claire AI to generate more questions related to the topic you are reviewing. The questions appear directly in your conversation, so you can keep practicing without stopping to create a separate quiz. </p>



<p class="wp-block-paragraph">For example, if a cardiology question reveals uncertainty about murmurs, ask Claire AI for additional questions about murmurs to keep reviewing. Confused two pharmacology mechanisms of action? Practice the concept again in a new context before moving on. </p>



<p class="wp-block-paragraph">These questions are designed for quick, in-the-moment reinforcement and are not saved as a quiz in your BoardVitals account. Use them as a flexible supplement to your broader study plan. Your question bank, performance insights, detailed explanations, and exam-style practice remain essential for tracking progress and preparing across the full exam blueprint. </p>



<h3 class="wp-block-heading"><strong>How More Questions Can Strengthen Your Board Prep</strong> </h3>



<h4 class="wp-block-heading"><strong>Practice Active Recall</strong> </h4>



<p class="wp-block-paragraph">Answering a question asks you to retrieve and use information, not simply recognize it on a page. More questions extend that practice and help you confirm what you know before returning to passive review. </p>



<h4 class="wp-block-heading"><strong>Apply Concepts in New Contexts</strong> </h4>



<p class="wp-block-paragraph">Board-style questions often test familiar material through unfamiliar clinical details. Related questions help you separate the core concept from one specific vignette and build the flexibility to apply your knowledge when the presentation changes. </p>



<h4 class="wp-block-heading"><strong>Find Gaps Before Test Day</strong> </h4>



<p class="wp-block-paragraph">One correct answer does not mean you have mastered a topic, and one missed question does not always mean the entire topic is weak. More practice gives you a clearer picture. If your reasoning holds across several questions, you can move forward with greater confidence. If it doesn’t, you have found a specific area to revisit before exam day. </p>



<h3 class="wp-block-heading">Meet Claire AI for BoardVitals </h3>



<p class="wp-block-paragraph">Meet Claire AI, now available with most BoardVitals question banks. From explaining challenging topics and <a href="https://www.boardvitals.com/blog/claire-ai-feature-summarize/" data-type="post" data-id="15824">summarizing key points</a> to <a href="https://www.boardvitals.com/blog/claire-ai-feature-flashcards/" data-type="post" data-id="15822">creating flashcards</a> and generating additional practice questions, Claire AI gives you more ways to engage with the material you are already reviewing. And because Claire AI pulls only from BoardVitals’ up-to-date question bank content, you can trust that the study support stays grounded in the same reliable material you already use to prepare. </p>



<p class="wp-block-paragraph">With AI-powered support built directly into the BoardVitals experience, Claire AI makes each study session more focused and responsive. You’ll get the help you need to study effectively when you need it most. However you choose to use it, Claire AI can help you understand, review, and practice material with greater confidence throughout your board prep. </p>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://www.boardvitals.com/blog/claire-ai-feature-more-questions/">Claire AI™ Feature Spotlight: Generate More Practice Questions</a> appeared first on <a href="https://www.boardvitals.com/blog">BoardVitals Blog</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Claire AI™ Feature Spotlight: Flashcards </title>
<link>https://edusehat.com/en/claire-aifeature-spotlight-flashcards-15302</link>
<guid>https://edusehat.com/en/claire-aifeature-spotlight-flashcards-15302</guid>
<description><![CDATA[ The post Claire AI™ Feature Spotlight: Flashcards  appeared first on BoardVitals Blog. ]]></description>
<enclosure url="https://blog.boardvitals.com/wp-content/uploads/2026/10/346-BLOG-Flashcards-1200x900-1-1024x768.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 01:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Claire, AI™ Feature, Spotlight:, Flashcards </media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">Getting the most out of your board prep means more than reviewing information once. Repetition is an effective way to reinforce key concepts, identify areas that need more attention, and make each study session more productive. We’re making it easier to add that practice to your routine with Claire AI<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> flashcards.  </p>



<p class="wp-block-paragraph">Created from BoardVitals library of up-to-date content, these front-and-back cards give you a quick, focused way to review important information and strengthen your recall as you prepare for exam day. </p>



<h3 class="wp-block-heading"><strong>Why Add Flashcards to Your Study Routine?</strong> </h3>



<p class="wp-block-paragraph">It is easy to recognize a familiar fact on the page and assume you know it. Recalling that same fact without a prompt is harder. Flashcards put your memory to work by asking you to retrieve an answer, check your response, and return to important concepts over time. </p>



<p class="wp-block-paragraph">That repeated retrieval can support long-term retention and help you quickly spot the topics that need more attention. Whether you are a medical student balancing coursework and clinical rotations or a resident fitting study time into a demanding schedule, flashcards can help you make the most of shorter study sessions. </p>



<h3 class="wp-block-heading"><strong>Build Stronger Recall for Board Exam Day</strong> </h3>



<p class="wp-block-paragraph">Board exams require you to remember a wide range of information, retrieve it quickly, and apply it to specific situations. With Claire AI flashcards from BoardVitals, you’ll review these key terms and concepts with just a few clicks.  </p>



<p class="wp-block-paragraph">Claire AI flashcards reinforce the essential details and relationships found in your question content, helping you build a stronger foundation for answering board-style questions. Use them alongside your review questions to revisit what you have learned and keep important concepts fresh. </p>



<p class="wp-block-paragraph">After completing questions, review flashcards to strengthen your knowledge of terminology, mechanisms, diagnostic clues, and other high-yield connections. Over time, combining practice questions with active recall can help you move beyond recognizing the right answer to retrieving and applying what you know. </p>



<h3 class="wp-block-heading"><strong>Make Every Study Session Count</strong> </h3>



<p class="wp-block-paragraph">Add flashcards to the BoardVitals routine that already works for you. Review them after a quiz, return to them during a quick study break, and spend extra time on the concepts that are still difficult to recall. Flashcards should not be used as a replacement for practice questions, but as another way to reinforce the knowledge you need to pass your board exam.   </p>



<h3 class="wp-block-heading"><strong>Meet Claire AI for BoardVitals</strong> </h3>



<p class="wp-block-paragraph">Meet Claire AI, now available with most BoardVitals question banks. From explaining challenging topics and <a href="https://www.boardvitals.com/blog/claire-ai-feature-summarize/" data-type="post" data-id="15824">summarizing key points</a> to creating flashcards and <a href="https://www.boardvitals.com/blog/claire-ai-feature-more-questions/" data-type="post" data-id="15818">generating additional practice questions</a>, Claire AI gives you more ways to engage with the material you are already reviewing. And because Claire AI pulls only from BoardVitals’ up-to-date question bank content, you can trust that the study support stays grounded in the same reliable material you already use to prepare. </p>



<p class="wp-block-paragraph">With AI-powered support built directly into the BoardVitals experience, Claire AI makes each study session more focused and responsive. You’ll get the help you need to study effectively when you need it most. However you choose to use it, Claire AI can help you understand, review, and practice material with greater confidence throughout your board prep. </p>
<p>The post <a href="https://www.boardvitals.com/blog/claire-ai-feature-flashcards/">Claire AI™ Feature Spotlight: Flashcards </a> appeared first on <a href="https://www.boardvitals.com/blog">BoardVitals Blog</a>.</p>]]> </content:encoded>
</item>

<item>
<title>DSM’s Houston Clinics: Royal Oaks &amp;amp; West University</title>
<link>https://edusehat.com/en/dsms-houston-clinics-royal-oaks-west-university</link>
<guid>https://edusehat.com/en/dsms-houston-clinics-royal-oaks-west-university</guid>
<description><![CDATA[  ]]></description>
<enclosure url="https://dynamicsportsmedicine.com/wp-content/uploads/2026/11/unnamed-1086x630.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 23:05:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>DSM’s, Houston, Clinics:, Royal, Oaks, West, University</media:keywords>
<content:encoded></content:encoded>
</item>

<item>
<title>DECA Brings the Diabetes Camp Experience to Endocrine Mentor Day</title>
<link>https://edusehat.com/en/deca-brings-the-diabetes-camp-experience-to-endocrine-mentor-day</link>
<guid>https://edusehat.com/en/deca-brings-the-diabetes-camp-experience-to-endocrine-mentor-day</guid>
<description><![CDATA[ At ENDO 2026, more than 100 endocrine learners and professionals experienced a diabetes camp simulation developed through collaboration between the Endocrine Society’s Endocrine Mentor Day and the Diabetes Education Camping Association. The initiative used immersive, patient-centered learning to connect clinical training with the lived experience of diabetes. At ENDO 2026, nearly 100 medical students, residents, […]
The post DECA Brings the Diabetes Camp Experience to Endocrine Mentor Day appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/IMG_0908-scaled-e1794233631735.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 22:50:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>DECA, Brings, the, Diabetes, Camp, Experience, Endocrine, Mentor, Day</media:keywords>
<content:encoded><![CDATA[<p>At ENDO 2026, more than 100 endocrine learners and professionals experienced a diabetes camp simulation developed through collaboration between the Endocrine Society’s Endocrine Mentor Day and the Diabetes Education Camping Association. The initiative used immersive, patient-centered learning to connect clinical training with the lived experience of diabetes. At ENDO 2026, nearly 100 medical students, residents, […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/deca-brings-the-diabetes-camp-experience-to-endocrine-mentor-day/">DECA Brings the Diabetes Camp Experience to Endocrine Mentor Day</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>COMLEX Level 3 Changes in 2027: What to Expect and How to Prepare</title>
<link>https://edusehat.com/en/comlex-level-3-changes-in-2027-what-to-expect-and-how-to-prepare</link>
<guid>https://edusehat.com/en/comlex-level-3-changes-in-2027-what-to-expect-and-how-to-prepare</guid>
<description><![CDATA[ For many medical students, COMLEX Level 3 can feel so far away. Much must come before then, including scheduling away rotations, securing letters of recommendation, applying to residency, interviewing, matching, and finding time along the way to celebrate how far they have come. Then residency begins, and another licensing exam suddenly joins your schedule, already […]
The post COMLEX Level 3 Changes in 2027: What to Expect and How to Prepare appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/11/pexels-ann-hannes-45017-32319624-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 22:40:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>COMLEX, Level, Changes, 2027:, What, Expect, and, How, Prepare</media:keywords>
<content:encoded><![CDATA[<p><span>For many medical students, COMLEX Level 3 can feel so far away. Much must come before then, including scheduling away rotations, <a href="https://elitemedicalprep.com/residency-letters-of-recommendation-everything-you-need-to-know/">securing letters of recommendation</a>, <a href="https://elitemedicalprep.com/navigating-the-eras-application-tips-to-dos/">applying to residency</a>, interviewing, matching, and finding time along the way to celebrate how far they have come. Then residency begins, and another licensing exam suddenly joins your schedule, already loaded with patient care, documentation responsibilities, and learning how to function as a new physician. But don’t let it scare you! Recently, the National Board of Osteopathic Medical Examiners (NBOME) has announced some exciting changes to the exam format. </span></p>
<p> </p>
<h2><b>What’s new?</b></h2>
<p><span>Effective January 13th 2027, the NBOME is <a href="https://www.nbome.org/assessments/comlex-usa/level-3/">transitioning COMLEX Level 3 from a two-day exam into a one-day exam</a>. The new exam will have fewer multiple-choice questions and clinical cases, but the overall exam topics blueprint will remain the same. This will likely make it easier for incoming PGY1s, who already have a lot to navigate scheduling-wise. Of note, however, just because the exam is shorter does not mean the required preparation is any less. Level 3 will still require adequate studying to build the necessary clinical judgment- just adapted to a one-day exam now. This is how I would approach preparing for this exciting transition! </span></p>
<p> </p>
<p><span>In 2024, the NBOME made this announcement, but explicitly stated that the Level 3 exam would retain a very similar proportion of content and cases. Originally, the total testing time was 14 hours, which has now become eight. The previous version of the exam had 420 questions, 26 clinical decision-making cases, and four 3.5-hour sessions. The new exam has 240 questions, 16 clinical decision-making cases, and four 2-hour sessions. When planning test day, however, remember to consider tutorials, authorized breaks, and check-in times. So far, this change is being well received by PGY1s who have yet to sit for the exam and by current fourth-year medical students as they consider coverage arrangements, transportation, and time away from work. Personally, I too believe that removing the second testing day is a meaningful logistical change that works in favor of residents. </span></p>
<p> </p>
<h2><b>Let’s break it down…</b></h2>
<p><span>For the new version of the exam, <a href="https://www.nbome.org/assessments/comlex-usa/examination-format/">sessions A, B, and C will each contain two sets of 40 multiple-choice questions</a>. Session D will contain two sections of eight clinical cases, preceded by a clinical case tutorial. As with Level 1 and Level 2, the resident physician has a 60-minute authorized break allowance, which they may divide as they see fit. Timing-wise, roughly 90 seconds are allocated to each multiple-choice question, based on the 120-minute time limit for two 40-question sessions. </span></p>
<p> </p>
<p><span>As for the clinical case section, you have 120 minutes for 16 clinical cases, averaging roughly 7.5 minutes per case. These are not individual time limits, but pacing parameters to consider when you begin practicing for the exam. If you tend to spend too long on the first half of a session, remember that overthinking another answer choice is unlikely to change your answer. Make your most logical guess and move on so you can answer every question. If time permits, you can always return to a flagged question. Also, don’t expect every question to take the same amount of time; that depends on your strengths and weaknesses, the stem length, and your familiarity with the topic being tested! </span></p>
<p> </p>
<h3><b>How should I study? </b></h3>
<p><span>Level 3 assesses readiness for unsupervised, general medical practice, as the target exam demographic is the newest generation of resident physicians. The relevant competencies include patient care, medical knowledge, osteopathic principles, communication, professionalism, ethics, and systems-based practice. A reduction in question count, as seen on the new version of the exam, is not a reason to assume that an entire subject has been removed from the test. Nor should this change imply the exam will be easier or require less preparation. </span></p>
<p> </p>
<p><span>My recommendation is to use the exam blueprint as a checklist to ensure you are still covering all the foundations that the NBOME expects of you at this point in training. Compare the checklist with your everyday experience in residency and take note of experiences that you may not encounter as often on the hospital wards but are still fair test topics. An internal medicine resident may feel comfortable managing hospitalized adults, but will likely need to review pediatric presentations, reproductive care, or surgical techniques. Familiarity with your own service is surely valuable, but it should not be the boundary of your preparation for the purposes of Level 3 or Step 3! </span></p>
<p> </p>
<h4><strong>My thoughts</strong></h4>
<p><span>I believe that a productive way to study is to move beyond just being able to name a diagnosis. After each practice question, even if the stem does not ask it, ask what the physician should be doing next and why that takes immediate priority. For example, ensure you are able to distinguish between an immediate stabilization step and a diagnostic study. Be able to explain why a reasonable test may be unnecessary. To integrate systems more comprehensively, ask whether your proposed management would change if the patient were pregnant, clinically unstable, or unable to return for follow-up! </span></p>
<p> </p>
<p><span>This framework will ensure you know more about the topic, which will ultimately benefit you in your clinical practice as well. To track weak topics, I would make an error-log spreadsheet around decisions you are making on practice questions. Be specific when completing this log; instead of writing “missed a cardiology question,” write “selected definitive treatment before stabilizing the patient.” A short, actionable phrase will not only help the material stick better, but will make your studying more efficient. Ultimately, this approach connects studying to the clinical work you’ll see for the rest of your career. </span></p>
<p> </p>
<h2><b>OMM on Level 3</b></h2>
<p><span>Osteopathic content remains tested on the new version of Level 3. The published NBOME blueprint lists osteopathic principles, practice, and manipulative treatment as comprising 10% of the exam items. I would interpret this percentage as a ballpark estimate, not an absolute. I would recommend doing the </span><a href="https://elitemedicalprep.com/omm-for-comlex-level-1-and-level-2-ce-study-guide-and-free-anki-deck/"><span>EMP OMM Anki deck </span></a><span>as a refresher on topics you may not have encountered since Level 2. Rotate through these topics, including viscerosomatics, sacral and spinal mechanics, autonomics, and OMT indications and contraindications. The goal is to explain how the finding fits the patient. If you memorize a technique but can’t apply it clinically, you’re likely to get the question wrong. Recognizing that you are a full-time resident physician, ensure to keep the workload manageable. Doing 30-50 Anki cards before bed for a few weeks can help refresh the OMM material while ensuring you still have time to accomplish other checklist items. </span></p>
<p> </p>
<h3><b>An Unfamiliar Section: Clinical Cases </b></h3>
<p><span>Unlike Level 1 and Level 2, Level 3 has a specific clinical decision-making section composed of clinical cases to work through. I recommend adding a separate study block into your schedule for this new section. The NBOME tutorial explains that these cases can use extended multiple-choice and short-answer question styles. They also state that each question will have a response limit, and answers that are harmful or unnecessarily costly may reduce the points you receive. Of note, once you move on in this section, you cannot return to fix your answer! I recommend practicing the task as it will be presented. Avoid writing an entire management plan, but ensure you are considering several competing possibilities. I’m sure with more experience throughout your PGY1 year, some of these decisions will become easier to make. </span></p>
<p> </p>
<p><span>The NBOME emphasizes the importance of specificity: imaging requires you to dictate the anatomical site, medications require drug name and route of administration, and OMT questions require techniques and specific locations. One useful exercise is to explain the answer out loud, then tweak it to be as concise as possible while staying thorough. </span></p>
<p> </p>
<h4><strong>The Clinical Decision-making Section</strong></h4>
<p><span>The clinical decision-making section is after the three multiple-choice sessions. That could help some test takers if certain multiple-choice questions clarify the best management steps for a condition or system. When preparing for the exam, I would definitely practice the clinical case questions after timed practice questions to build test-taking endurance and help cognitively switch between question styles. You don’t need to do a full practice exam every weekend; that is unlikely to be feasible with a PGY1 schedule. Start with a workload you can actually review properly, then build towards longer sessions, schedule-permitting. I also recommend treating breaks as part of the testing simulation. Plan food, hydration, and brief resets that work for you. </span></p>
<p> </p>
<h2><b>How to Build a Plan as a Resident Physician</b></h2>
<p><span>Residency, especially intern year, is no secret: it’s extremely challenging and takes a lot of time. When preparing for Level or Step 3, no single calendar will fit every resident’s schedule. Your baseline knowledge, previous exam experience, residency work schedule, and available study time should guide the study plan. I recommend starting with a baseline assessment, including mixed questions and a few clinical cases. Identify whether the main difficulty is content, pacing, or question interpretation. </span></p>
<p> </p>
<p><span>Review your mistakes honestly and then <a href="https://elitemedicalprep.com/comlex-level-3-the-complete-guide/">craft how you want to approach practice questions</a> from there. I would think that you should save your residency service for last. For example, a general surgery resident may want to focus on internal medicine, psychiatry, family medicine, and OBGYN before spending time on general surgery practice questions. Being exposed to these more familiar concepts daily at work is studying in its own right. If a demanding rotation disrupts your schedule, revise the workload. A smaller plan that you can follow is more useful than an ambitious calendar that leaves you permanently behind.</span></p>
<p> </p>
<h2><b>Resources to Use</b></h2>
<p><span>Before buying or renewing any resources or question banks, I would ask your residency program director what is provided to you. Many programs still provide residents with UWorld or TrueLearn access, which could save you some money on an already-tight residency budget. For the new format of the exam- timed and mixed questions, system-specific questions, explanations that address management priorities, and clinical case-based multi-part questions- these would all be helpful to use in your preparation. </span></p>
<p> </p>
<p><span>When crafting practice question banks, follow the new format when adjusting your test settings to accurately reflect test-day experiences. As with Level 1, Step 1, and Level 2, Step 2, I would not recommend using more than one or two resources to study for Level 3/Step 3. Fantastic resources are available, but indecision about which one to use will do a disservice to you and your limited time frame. As with the preceding board licensing exams, I believe practice questions are key and should remain at the forefront of your study plan. You learn by example! </span></p>
<p> </p>
<h2><b>The Transition</b></h2>
<p><span>A one-day exam likely does sound better, but it should not be the sole reason to move your test from November or December 2026 into 2027. Discuss the timing with your program director/ chief residents, and consider your clinical schedule, readiness, and relevant deadlines based on your individual situation, specialty, and program. </span></p>
<p> </p>
<p><span>In order to register for Level 3, you must have successfully completed Level 1, Level 2-CE, and graduated from an accredited osteopathic medical school in the United States. The NBOME generally recommends about six months of residency training before sitting for Level 3. Everyone’s testing year, circumstances, and program may influence their testing experience, so take others’ advice with a grain of salt and ultimately do what is right for you. When using NBOME resources and practice banks, make sure the page says “2027” at the top to ensure you are using the newly updated practice resources based on the new format. The old materials are surely still clinically relevant, but it may be better to use the new resources to better understand the format. </span></p>
<p> </p>
<p data-pm-slice="1 1 []">Before you sit for Level 3, review the NBOME Bulletin of Information and scheduling instructions so you know what to expect on exam day. Build a plan that gives you time to practice clinical decision-making, work on your pacing, and review the topics you see less often on rotation. If you’d like help building that plan around your residency schedule, explore Elite Medical Prep’s <a href="https://elitemedicalprep.com/comlex-level-3-tutoring/">one-on-one COMLEX Level 3 tutoring</a>. You’ve got this, Doctor. Good luck on Level 3!</p>
<p>The post <a href="https://elitemedicalprep.com/comlex-level-3-changes-what-to-expect-and-how-to-prepare/">COMLEX Level 3 Changes in 2027: What to Expect and How to Prepare</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Accountability without anxiety</title>
<link>https://edusehat.com/en/accountability-without-anxiety</link>
<guid>https://edusehat.com/en/accountability-without-anxiety</guid>
<description><![CDATA[ Mark Topley shares a practical framework for defining standards, holding teams to account and protecting morale in dental practice. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/accountability-without-anxiety-feature.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 19:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Accountability, without, anxiety</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-full"></figure>



<p><strong>A practice manager, a reception list and the four-word structure that turns a telling off into an agreement. Mark Topley explains how to maintain accountability and morale in the dental practice.</strong></p>



<h2 class="wp-block-heading">Transparency and understanding</h2>



<p>A recent in-person visit to a client highlighted an all too common problem. The practice manager had handed her reception team a list of daily jobs on Monday, and by Friday several hadn’t been done, a few were half done, and she was clearing the backlog herself so it didn’t spill into the following week.</p>



<p>She wasn’t angry, she was tired, and when I asked why she hadn’t said anything to the team she gave the answer most people give, which is that she didn’t want to make a thing of it.</p>



<p>That sentence is where most accountability problems actually live. Not in laziness or bad attitudes, but in a leader who has decided that holding someone to a standard will cost more in atmosphere than it’s worth.</p>



<!--free-wall-stop-->



<p>I understand the instinct, because most of us have never seen accountability done well. We’ve seen it done as a telling off by someone who sat on it for a fortnight and finally ran out of patience, and we’ve seen the flat morning that follows. So we avoid it, and the standard slips further.</p>



<p>However, it doesn’t have to feel like that. Done properly, accountability is one of the most motivating things in a practice, because people like knowing where the bar is and they like being in a team where everyone clears it. What makes it feel like anxiety isn’t the holding. It’s the surprise.</p>



<h2 class="wp-block-heading">Define the standard</h2>



<p>Two things were obvious about that reception list. The first was that it was a list of tasks, not a list of standards. It said things like ‘call the recall sheet’, which sounds clear until you realise it can mean working through every name and logging each conversation, or making four calls, marking two as voicemail and moving on. Both count. Only one delivers what the dental practice needs.</p>



<p>So, we rewrote it. ‘Call the recall sheet’ became ‘ensure every patient on today’s recall list has been called and the outcome logged before the end of shift’. Small on the page, enormous in practice, because it describes what good looks like rather than the activity meant to produce it.</p>



<p>The enemy of standards in almost every practice is assumption, and assumption is hard to spot because it looks like trust. It isn’t. It’s a leader who hasn’t yet made the obvious, obvious.</p>



<h2 class="wp-block-heading">Build the loop, not just the list</h2>



<p>The second thing missing was a loop. The list had been handed over and nothing built to bring it back, so we introduced a daily check-in where the team reported what they’d completed and flagged before the end of the day if they weren’t going to get through it.</p>



<p>If you can’t finish what’s been agreed, it’s your job to come and say so. ‘We got busy’ stopped being accepted, because in a dental practice you will always be busy, and busy is the environment in which standards are held, not a reason to let them slip.</p>



<p>That change alone removes most of the anxiety, because nothing accumulates and nobody is storing anything up.</p>



<h2 class="wp-block-heading">A solid structure</h2>



<p>For the conversation itself I teach a framework called STAND, and the name is the point. You’re taking a stand for the standards the team has agreed, and inviting the other person to stand with you. STAND stands for:</p>



<ul class="wp-block-list">
<li><strong>Seek permission.</strong> ‘Have you got two minutes, I wanted to chat about something’. It gives the other person agency and signals a conversation rather than an ambush</li>



<li><strong>Tell what you saw.</strong> Specifically and neutrally, without your interpretation on top</li>



<li><strong>Affect.</strong> What it actually caused, stated plainly and not exaggerated</li>



<li><strong>Next time.</strong> What you’d like to see, or what was already agreed. This is the step that turns a complaint into an agreement</li>



<li><strong>Decide.</strong> Only if you’re the leader and it isn’t the first time. Say calmly what happens if the pattern continues. Not a threat, just clarity.</li>
</ul>



<h2 class="wp-block-heading">Use the structure consistently</h2>



<p>It takes less than a minute. ‘Ben, have you got two minutes? The last few mornings surgery three has had instruments still out from the day before, so whoever’s setting up has been doing your clear-down as well as their own prep, and it’s adding 20 minutes to the day. Can we make sure everything’s cleared before you leave? That was what we agreed when we set the room standards.’</p>



<p>One caution. If the only time your team hear that structure is when something has gone wrong, it becomes the tap on the shoulder everyone dreads. Use it far more often for what’s going well, at something like five to one, and it stops being a warning sign.</p>



<p>Another recommendation is to give it away. If accountability lives only with you and your practice manager, you’re the bottleneck for every behavioural issue in the building, and standards that depend on you to enforce will slip the moment you look away.</p>



<p>Take one list this week, rewrite a single item so it defines the standard rather than the activity, and decide how it gets reported back. One thing, maybe two, and that’s it.</p>



<p><em><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</em></a></em></p>]]> </content:encoded>
</item>

<item>
<title>$43&#45;million campaign to transform surgical care at Victoria hospitals</title>
<link>https://edusehat.com/en/43-million-campaign-to-transform-surgical-care-at-victoria-hospitals</link>
<guid>https://edusehat.com/en/43-million-campaign-to-transform-surgical-care-at-victoria-hospitals</guid>
<description><![CDATA[ New hybrid operating rooms and expanded interventional radiology services will advance minimally invasive treatment and specialized care on Vancouver Island. A major investment in surgical infrastructure and medical technology is poised to transform the delivery of specialized healthcare on Vancouver Island. The Victoria Hospitals Foundation has launched a $43-million fundraising campaign to expand surgical and […]
The post $43-million campaign to transform surgical care at Victoria hospitals appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/RCP-HOSPITAL-SEPT-2026-205web-705x470-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 18:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>43-million, campaign, transform, surgical, care, Victoria, hospitals</media:keywords>
<content:encoded><![CDATA[<p><em>New hybrid operating rooms and expanded interventional radiology services will advance minimally invasive treatment and specialized care on Vancouver Island.</em></p>
<p>A major investment in surgical infrastructure and medical technology is poised to transform the delivery of specialized healthcare on Vancouver Island.</p>
<p>The Victoria Hospitals Foundation has launched a $43-million fundraising campaign to expand surgical and interventional radiology capabilities at Royal Jubilee Hospital and Victoria General Hospital in British Columbia.</p>
<p>The initiative, <em>It’s Time for Surgical Transformation</em>, represents the third and final phase of the foundation’s multi-year campaign to modernize hospital facilities, introduce advanced medical technologies and improve access to specialized treatment.</p>
<p>The project comes as Vancouver Island faces growing demand for healthcare services, driven in part by an aging population. The number of residents aged 85 and older is projected to more than double over the next two decades.</p>
<h2>Bringing hybrid operating rooms to Vancouver Island</h2>
<p>A central component of the campaign is a proposed $25.4-million investment in two hybrid operating rooms at Royal Jubilee Hospital.</p>
<p>These will be Vancouver Island’s first hybrid operating rooms and the first additional operating rooms at Victoria’s hospitals in more than 23 years.</p>
<p>Hybrid operating rooms integrate advanced medical imaging with conventional surgical capabilities, allowing physicians to perform complex procedures in a single clinical environment.</p>
<p>The technology enables surgical teams to visualize anatomy in real time, perform image-guided interventions and undertake open surgical procedures without transferring patients between different treatment areas.</p>
<p>For patients with complex cardiovascular and vascular conditions, this integrated approach can provide greater flexibility during treatment, particularly when minimally invasive procedures and traditional surgical techniques are required during the same operation.</p>
<p>The new facilities will support advanced procedures such as aortic aneurysm repair, vascular reconstruction and interventions aimed at reducing stroke risk.</p>
<p>They will also provide an environment where multidisciplinary teams, including surgeons, anesthesiologists, nurses, imaging technologists and perfusionists, can work together during complex procedures.</p>
<h2>Doubling interventional radiology capacity</h2>
<p>The campaign also includes a $17.6-million investment in interventional radiology services at Royal Jubilee and Victoria General hospitals.</p>
<p>Plans include the construction of two new interventional radiology suites, upgrades to two existing suites and the addition of dedicated patient recovery areas.</p>
<p>The expansion is expected to double interventional radiology capacity across the two hospitals.</p>
<p>Interventional radiology uses medical imaging to guide specialized instruments through small openings in the body, offering alternatives to traditional open surgery for a range of conditions.</p>
<p>These techniques can be used to remove blood clots associated with stroke, control internal bleeding, restore blood flow and treat certain cancers.</p>
<p>For appropriately selected patients, minimally invasive procedures can reduce the physical impact of treatment and support shorter recovery times.</p>
<p>Additional interventional radiology capacity may also help relieve pressure on conventional operating rooms, allowing surgical resources to be directed toward patients who require more extensive procedures.</p>
<p>Having two suites at each hospital will provide greater flexibility when multiple patients require urgent image-guided treatment.</p>
<h2>Building on advances in surgical technology</h2>
<p>The initiative builds on earlier investments that have already introduced new surgical capabilities to Vancouver Island.</p>
<p>The first two phases of the foundation’s campaign raised $38 million, supporting robotic-assisted surgery, advanced oncology equipment and other specialized medical technologies.</p>
<p>Royal Jubilee Hospital and Victoria General Hospital have also been advancing image-guided treatment options, including the use of NanoKnife technology for selected patients with early-stage prostate cancer.</p>
<p>The latest phase shifts the focus toward the physical infrastructure needed to support increasingly sophisticated medical technologies.</p>
<p>As surgical robotics, advanced imaging and minimally invasive techniques continue to evolve, hospitals must adapt their facilities to accommodate new equipment, multidisciplinary workflows and changing clinical requirements.</p>
<h2>Community investment supports the next generation of care</h2>
<p>The $43-million campaign was officially launched on November 3, with $8.2 million already committed.</p>
<p>On November 6, the Victoria Hospitals Foundation announced an additional $3-million leadership gift from the Robert and Devi Jawl Foundation, bringing the amount secured to $11.7 million.</p>
<p>The foundation’s goal is to expand local treatment options, strengthen specialized healthcare capacity and provide clinical teams with the facilities needed to deliver increasingly complex care.</p>
<p>For Vancouver Island patients, the proposed investments could mean greater access to advanced surgical and interventional procedures closer to home.</p>
<p>For Canadian hospitals more broadly, the initiative highlights the growing importance of integrating medical technology with purpose-built clinical infrastructure as healthcare systems respond to rising demand for specialized care.</p>
<p>The post <a href="https://www.hospitalnews.com/43-million-campaign-to-transform-surgical-care-at-victoria-hospitals/">$43-million campaign to transform surgical care at Victoria hospitals</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>St. Michael’s Hospital breaks ground on $14&#45;million neonatal intensive care expansion</title>
<link>https://edusehat.com/en/st-michaels-hospital-breaks-ground-on-14-million-neonatal-intensive-care-expansion</link>
<guid>https://edusehat.com/en/st-michaels-hospital-breaks-ground-on-14-million-neonatal-intensive-care-expansion</guid>
<description><![CDATA[ New and expanded neonatal intensive care unit will provide specialized care for critically ill newborns while improving infection prevention, patient privacy and family-centred care. St. Michael’s Hospital in Toronto has officially broken ground on a new and expanded neonatal intensive care unit (NICU), supported by nearly $14 million in funding from the Ontario government. The […]
The post St. Michael’s Hospital breaks ground on $14-million neonatal intensive care expansion appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_2601562281.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 18:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>St., Michael’s, Hospital, breaks, ground, 14-million, neonatal, intensive, care, expansion</media:keywords>
<content:encoded><![CDATA[<p><em>New and expanded neonatal intensive care unit will provide specialized care for critically ill newborns while improving infection prevention, patient privacy and family-centred care.</em></p>
<p>St. Michael’s Hospital in Toronto has officially broken ground on a new and expanded neonatal intensive care unit (NICU), supported by nearly $14 million in funding from the Ontario government.</p>
<p>The project will renovate more than 12,000 square feet of space within the hospital’s Peter Gilgan Patient Care Tower, creating a modern environment designed to meet the specialized needs of premature and critically ill newborns.</p>
<p>Part of Unity Health Toronto, St. Michael’s Hospital provides neonatal care to some of the province’s most vulnerable patients. The expansion represents an important investment in specialized hospital infrastructure and the delivery of care for newborns and their families.</p>
<p>Construction is expected to be completed in summer 2027.</p>
<h2>Expanding specialized neonatal care</h2>
<p>The new NICU will feature dedicated neonatal resuscitation facilities, airborne isolation rooms and more private patient rooms, supporting both clinical care and infection prevention.</p>
<p>Neonatal intensive care units provide specialized treatment for infants born prematurely or with medical conditions requiring continuous monitoring, respiratory support and other advanced interventions.</p>
<p>The expanded facility is designed to provide healthcare teams with an improved environment for delivering this complex care, while offering families greater privacy during what can be an extremely challenging period.</p>
<p>Dedicated resuscitation facilities will support rapid intervention for newborns requiring immediate medical attention, while airborne isolation rooms will strengthen the hospital’s ability to manage infectious disease risks within the unit.</p>
<h2>Supporting family-centred care</h2>
<p>An important component of the expansion is the creation of more private spaces for newborns and their families.</p>
<p>Family involvement plays a significant role in neonatal care, with parents often participating in feeding, skin-to-skin contact and other developmental care activities under the guidance of clinical teams.</p>
<p>Modern NICU environments increasingly emphasize the importance of balancing advanced medical technology with opportunities for parents to remain close to their infants.</p>
<p>Greater privacy can help support these interactions while providing families with a more comfortable environment during extended hospital stays.</p>
<p>The expanded unit is intended to support this approach while maintaining the specialized monitoring and treatment capabilities required for critically ill newborns.</p>
<h2>Investing in hospital infrastructure</h2>
<p>The project forms part of Ontario’s broader investment in hospital infrastructure and specialized healthcare services.</p>
<p>By modernizing existing space within the Peter Gilgan Patient Care Tower, the redevelopment will support St. Michael’s Hospital’s ability to deliver neonatal care in a facility designed around contemporary clinical requirements.</p>
<p>The construction project is also expected to support approximately 100 jobs.</p>
<p>For Canadian hospitals, investments in neonatal infrastructure highlight the importance of designing healthcare facilities that support patient safety, infection prevention, multidisciplinary clinical teams and family involvement.</p>
<p>As demand for specialized healthcare services continues to evolve, modernizing hospital environments remains an important part of strengthening healthcare capacity.</p>
<p>With construction now underway, the expanded St. Michael’s Hospital NICU is expected to begin serving newborns and their families following completion in summer 2027.</p>
<p><strong>Source:</strong> Government of Ontario, November 11, 2026.</p>
<p>The post <a href="https://www.hospitalnews.com/st-michaels-hospital-breaks-ground-on-14-million-neonatal-intensive-care-expansion/">St. Michael’s Hospital breaks ground on $14-million neonatal intensive care expansion</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lupin launches biosimilar Ranibizumab in European market</title>
<link>https://edusehat.com/en/lupin-launches-biosimilar-ranibizumab-in-european-market</link>
<guid>https://edusehat.com/en/lupin-launches-biosimilar-ranibizumab-in-european-market</guid>
<description><![CDATA[ 
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A.
The post Lupin launches biosimilar Ranibizumab in European market appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/06/18094312/IV-injection.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 18:30:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lupin, launches, biosimilar, Ranibizumab, European, market</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/06/18094312/IV-injection.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/06/18094312/IV-injection.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/06/18094312/IV-injection-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Lupin announced that its commercial partner, Sandoz has launched Ranluspec, Lupin’s biosimilar Ranibizumab, across Europe, excluding Germany.</p>
<p>The launch follows the European Commission approval of Ranluspec in vial and pre-filled syringe presentations and marks an important step in expanding access to high-quality biologic treatment options for retinal diseases.</p>
<p>Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A. The indications of Ranluspec encompass the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, proliferative diabetic retinopathy, and choroidal neovascularization.</p>
<p>Thierry Volle, President EMEA and Emerging Markets, Lupin, said, “The launch of Ranluspec in Europe advances Lupin’s strategy of bringing high-quality biosimilars to more patients suffering from retinal and choroidal vascular diseases. Together with Sandoz, we will expand access to this important treatment across the region.”</p>
<p>“The launch of Ranluspec reinforces our growing capabilities in biosimilars as it brings together our scientific expertise and manufacturing capabilities in biologics. It underscores our commitment to addressing unmet needs while supporting more sustainable healthcare systems,” said Dr Cyrus Karkaria, President – Biotech Business, Lupin.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/lupin-launches-biosimilar-ranibizumab-in-european-market/">Lupin launches biosimilar Ranibizumab in European market</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Biodeal Pharmaceuticals receives CDSCO approval for Midazolam nasal spray</title>
<link>https://edusehat.com/en/biodeal-pharmaceuticals-receives-cdsco-approval-for-midazolam-nasal-spray</link>
<guid>https://edusehat.com/en/biodeal-pharmaceuticals-receives-cdsco-approval-for-midazolam-nasal-spray</guid>
<description><![CDATA[ 
Indigenously developed through in-house R&amp;D, the product marks a significant milestone in Biodeal’s evolution from a manufacturing-led CDMO to an innovation-driven pharmaceutical company.
The post Biodeal Pharmaceuticals receives CDSCO approval for Midazolam nasal spray appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12162847/EP_Biodeal.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 18:30:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Biodeal, Pharmaceuticals, receives, CDSCO, approval, for, Midazolam, nasal, spray</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12162847/EP_Biodeal.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12162847/EP_Biodeal.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/12162847/EP_Biodeal-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Biodeal Pharmaceuticals, an Indian Contract Development and Manufacturing Organisation (CDMO), announced a significant regulatory milestone for its indigenously developed Midazolam Nasal Spray 1.25% w/v, which has received New Drug Permission from India’s Central Drugs Standard Control Organisation (CDSCO). This is the first approval of this product and strength in India.</span></p>
<p><span>Further recognising its innovation, the National Pharmaceutical Pricing Authority’s (NPPA) Multidisciplinary Committee of Experts has recommended a five-year exemption under Para 32(iii) of the Drug Price Control Order (DPCO), 2013, recognising the product as a genuinely new, indigenously developed drug delivery system rather than a reformulation of an existing medicine.</span></p>
<p><span>Midazolam is an established medicine used in the rapid management of emergency situations, primarily acute seizures. Traditionally administered through injection, its nasal delivery offers a new well established delivery system innovated in the US, through the nasal route, particularly in emergency and out-of-hospital settings where intravenous access may not be readily available.</span></p>
<p><span>The product has been developed primarily at Biodeal’s Department of Scientific and Industrial Research (DSIR)-accredited R&D facility. The development involved formulation science, device engineering, dosing precision and manufacturing expertise, reflecting the company’s growing focus on differentiated pharmaceutical products and specialised drug delivery.</span></p>
<p><span>Commenting on the development, Anurag Kumar, Chairman & Managing Director, Biodeal Pharmaceuticals said, “This is a particularly meaningful milestone for Biodeal because it represents recognition of our ability to develop and innovate, beyond our established strengths in pharmaceutical manufacturing. Our teams have worked extensively on the formulation, device engineering and scientific development behind Midazolam Nasal Spray. The recognition by India’s drug regulatory and pricing authorities validates the investment we have made in building indigenous R&D capabilities over the years.</span></p>
<p><span>India has established a strong position in global pharmaceutical manufacturing. The next phase of growth will increasingly depend on our ability to develop differentiated products, build specialised delivery systems and create intellectual and technical capabilities within the country. This milestone reinforces our belief that Indian CDMOs can play a much larger role in that transition.”</span></p>
<p><span>The development marks an important step in Biodeal’s broader evolution towards becoming a specialised, innovation-led CDMO. Building on more than two decades of expertise in nasal drug delivery, the company continues to strengthen its capabilities across complex formulations and specialised pharmaceutical manufacturing, with a focus on serving evolving healthcare requirements in India and international markets.</span></p>
<p>The post <a href="https://www.expresspharma.in/biodeal-pharmaceuticals-receives-cdsco-approval-for-midazolam-nasal-spray/">Biodeal Pharmaceuticals receives CDSCO approval for Midazolam nasal spray</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Carrier Transicold launches X4 7300 trailer refrigeration unit in India</title>
<link>https://edusehat.com/en/carrier-transicold-launches-x4-7300-trailer-refrigeration-unit-in-india</link>
<guid>https://edusehat.com/en/carrier-transicold-launches-x4-7300-trailer-refrigeration-unit-in-india</guid>
<description><![CDATA[ 
New single-temperature unit delivers advanced cooling performance and precise temperature control in ambient conditions up to 50°C
The post Carrier Transicold launches X4 7300 trailer refrigeration unit in India appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12161422/EP_Carrier-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 18:30:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Carrier, Transicold, launches, 7300, trailer, refrigeration, unit, India</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12161422/EP_Carrier-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12161422/EP_Carrier-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/12161422/EP_Carrier-1-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Carrier Transicold has launched the X4 7300 single-temperature trailer refrigeration unit in India, where it is now commercially available, expanding its portfolio for fleets transporting temperature-sensitive food, pharmaceuticals and other perishable cargo. Carrier Transicold is part of Carrier Global Corporation (NYSE: CARR), global leader in intelligent climate and energy solutions.</p>
<p>Designed for demanding temperature-controlled transport applications, the X4 7300 combines strong refrigeration performance with precise temperature control and an efficient operating platform to help fleet operators maintain the conditions required to protect temperature-sensitive cargo across increasingly complex distribution routes.</p>
<p>“As India strengthens the infrastructure connecting producers, distribution centers and end markets, fleets need refrigeration equipment that can protect temperature-sensitive cargo efficiently across longer and more demanding routes,” said Pankaj Mehta, Managing Director, Truck Trailer India, Carrier Transicold. “We see trailer refrigeration emerging as an important new category for temperature-controlled transportation. The X4 7300 is designed to help operators meet these evolving demands while managing operating costs, and it underscores our commitment to supporting the continued development of India’s cold chain with advanced, efficient refrigeration solutions.”</p>
<p>Engineered with EcoFORWARD technologies, the X4 7300 delivers dependable refrigeration performance in ambient temperatures of up to 50°C, making it well suited to the demanding conditions of India’s temperature-controlled distribution network. Reduced engine run hours and lower maintenance costs compared to legacy units can also help lower the total cost of ownership for fleet operators.</p>
<p>The X4 7300 features Carrier Transicold’s APX Control System, which coordinates refrigeration components to help optimize performance and fuel efficiency while supporting precise temperature control, system reliability and ease of operation.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/carrier-transicold-launches-x4-7300-trailer-refrigeration-unit-in-india/">Carrier Transicold launches X4 7300 trailer refrigeration unit in India</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>IIT Kanpur scientists discover how immune cells silence insulin</title>
<link>https://edusehat.com/en/iit-kanpur-scientists-discover-how-immune-cells-silence-insulin</link>
<guid>https://edusehat.com/en/iit-kanpur-scientists-discover-how-immune-cells-silence-insulin</guid>
<description><![CDATA[ 
Breakthrough at IIT Kanpur opens a new direction in diabetes research, discovers a new path of communication between immune cells and insulin-producing cells
The post IIT Kanpur scientists discover how immune cells silence insulin appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12165319/EP_IIT-Kanpur.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 18:30:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>IIT, Kanpur, scientists, discover, how, immune, cells, silence, insulin</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12165319/EP_IIT-Kanpur.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12165319/EP_IIT-Kanpur.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/12165319/EP_IIT-Kanpur-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>In a breakthrough that changes our understanding of how diabetes develops, researchers at the Indian Institute of Technology Kanpur (IIT Kanpur) have found that immune cells inside the pancreas can switch off insulin release within minutes and have identified the molecular switch that allows them to do it. The study published in the Journal of Clinical Investigation, one of the leading biomedical journals in the world, was jointly led by Simran Singh and Ashish Kumar, who are the co-first authors of the research, under the supervision of Dr Sai Prasad Pydi at the Department of Biological Sciences and Bioengineering, IIT Kanpur.</span></p>
<p><span>The team has also confirmed that the same pathway is present and active in human pancreatic tissue, which makes it a target for drugs meant to protect insulin production in people with obesity and type 2 diabetes.</span></p>
<p><span>The human  pancreas contains several types of cells, including insulin-producing beta cells and immune cells called macrophages. While beta cells regulate blood glucose by secreting insulin, macrophages help maintain tissue health and immune balance. This study reveals how macrophages directly communicate with neighbouring beta cells to regulate insulin secretion.</span></p>
<p><span>The understanding till now was that obesity triggers low grade inflammation which damages beta cells slowly, over months and years. Now, the IIT Kanpur research has revealed a much faster and more direct exchange of signals.</span></p>
<p>“We discovered that immune cells that are present next to beta cells can switch off insulin release within minutes,” said Dr Sai Prasad Pydi, Assistant Professor in the Department of Biological Sciences and Bioengineering at IIT Kanpur who led the study. “And they do it without giving any of the classical inflammation signals we have been studying for decades. The findings change our fundamental understanding of how immune cells influence insulin production. The effect is not slow damage from inflammation but instruction that is delivered in minutes. The fact that this works the same way in human tissue is what makes it exciting, It is not just a finding in tissues of laboratory mice, but a real biological circuit that could be targeted with a drug ”</p>
<p><span>The team used a precision genetic technique that allowed them to switch a single signalling pathway on or off inside immune cells. Activating this pathway in macrophages caused a sharp reduction in insulin release in mouse models. Conversely, switching the same pathway off had the opposite effect, with insulin secretion improving.</span></p>
<p><span>The messengers were fats, a class of lipids called sphingolipids, and not inflammatory proteins. Once activated, the macrophages rapidly released these fats that the neighbouring beta cells took up through a transporter on their surface. These then interfered with the internal insulin machinery of the beta cells.</span></p>
<p><span>The team traced the trigger to GPR18, a receptor on macrophages that sits at the top of the chain. Blocking GPR18, or any of the steps below it, restored normal insulin release. The pathway therefore has three points at which a potential drug could act: the receptor, the lipid signal and the uptake step.</span></p>
<p><span>The part of the work with the most consequence for patients was carried out on human tissue. Working with the Indiana Biosciences Research Institute in the United States, the IIT Kanpur team confirmed that GPR18 is heavily concentrated in the immune cells of human pancreatic islets. When the researchers activated the pathway in donated human pancreatic tissue, insulin secretion was blocked there as well.</span></p>
<p><span>While the study does not offer a treatment for diabetes, the validation establishes a foundation for further research into how disrupting the pathway can help preserve insulin secretion in people with obesity and type 2 diabetes.</span></p>
<p>The post <a href="https://www.expresspharma.in/iit-kanpur-scientists-discover-how-immune-cells-silence-insulin/">IIT Kanpur scientists discover how immune cells silence insulin</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond the dental chair: a more holistic approach to enamel health</title>
<link>https://edusehat.com/en/beyond-the-dental-chair-a-more-holistic-approach-to-enamel-health</link>
<guid>https://edusehat.com/en/beyond-the-dental-chair-a-more-holistic-approach-to-enamel-health</guid>
<description><![CDATA[ Curasept explains how Biosmalto is supporting enamel health through continuous clinical and at-home care. Enamel health is not determined by a single dental appointment. Whether managing molar-incisor hypomineralisation (MIH), addressing early enamel demineralisation or supporting patients following orthodontic treatment, maintaining the integrity of enamel requires a consistent approach that extends beyond the dental practice. Molar-incisor… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/curasept.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 15:35:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, the, dental, chair:, more, holistic, approach, enamel, health</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Curasept explains how Biosmalto is supporting enamel health through continuous clinical and at-home care.</strong></p>



<p>Enamel health is not determined by a single dental appointment. Whether managing molar-incisor hypomineralisation (MIH), addressing early enamel demineralisation or supporting patients following orthodontic treatment, maintaining the integrity of enamel requires a consistent approach that extends beyond the dental practice.</p>



<p>Molar-incisor hypomineralisation (MIH) is a recognised clinical challenge in paediatric dentistry, affecting the quality and structural integrity of children’s permanent teeth. Although a nationally representative UK prevalence figure is not currently established, a large epidemiological study conducted across five regions in northern England reported MIH in 15.9% of 12-year-old children, highlighting the relevance of this condition to UK dental practice (Balmer et al, 2012).</p>



<p>Clinically, MIH can present with demarcated enamel opacities, post-eruptive enamel breakdown, hypersensitivity and increased susceptibility to caries. Its implications can extend into orthodontic treatment, where compromised enamel may complicate bracket bonding and require additional attention throughout treatment</p>



<p>The clinical question is therefore not simply how to treat a compromised tooth, but how to support its condition once the patient leaves the dental chair.</p>



<h2 class="wp-block-heading"><strong>Curasept Biosmalto: a bio-inspired approach to enamel care</strong></h2>



<p>Curasept Biosmalto offers a bio-inspired approach to supporting the mineral structure of enamel and dentin through formulations developed to promote remineralisation and protect against everyday challenges.</p>



<p>At the heart of the range is a biomimetic approach, using bioactive mineral components designed to interact with dental tissues.</p>



<p>A key innovation is <strong>F-ACP Complex</strong>, featured in Curasept Biosmalto Mousse. This advanced formulation consists of amorphous calcium phosphate nanoparticles enriched with carbonate and fluoride and coated with citrate. Designed to mimic aspects of the natural mineralisation process, the complex releases mineral ions in the oral environment, supporting remineralisation at areas of enamel demineralisation.</p>



<p>The Biosmalto toothpaste range also incorporates bioactive hydroxyapatite-based formulations, designed to support mineral replenishment and reinforce the tooth surface.</p>



<p>Together, these technologies provide a complementary approach to daily enamel care, helping clinicians extend mineral-support strategies beyond professional interventions.</p>



<h2 class="wp-block-heading"><strong>From professional treatment to everyday enamel care</strong></h2>



<p>A successful clinical intervention should be supported by an appropriate home-care routine. This is particularly relevant for patients with MIH, those undergoing orthodontic treatment and individuals presenting with early enamel lesions.</p>



<p>Curasept Biosmalto is available in toothpaste, mouthwash and mousse formats, allowing clinicians to incorporate enamel care into different stages of the patient’s oral health journey.</p>



<p>While toothpaste and mouthwash can become part of the daily oral hygiene routine, the mousse offers additional flexibility. It can be applied using a brush or a suitable tray, including an orthodontic retainer where clinically appropriate, extending the application beyond the dental appointment.</p>



<p>This continuity of care is particularly relevant following orthodontic treatment, when white spot lesions may remain visible even after brackets have been removed.</p>



<h2 class="wp-block-heading"><strong>Clinical evidence: supporting enamel remineralisation</strong></h2>



<p>The clinical potential of F-ACP Complex was investigated in a randomised controlled trial conducted at Bambino Gesù Children’s Hospital in Rome.</p>



<p>The study included 106 adolescents aged 12-20 who had completed fixed orthodontic treatment and presented with white spot lesions. Participants in the study group used Curasept Biosmalto toothpaste containing bioactive hydroxyapatite formulations alongside F-ACP-containing mousse applied through their Essix retainers for six months. The control group used conventional fluoride toothpaste.</p>



<p>Among the 91 participants who completed the study, the F-ACP group demonstrated a significantly greater reduction in ICDAS scores compared with the control group (p = 0.001 at six months).</p>



<p>These findings highlight the potential of combining professional guidance with structured at-home remineralisation protocols to support the management of post-orthodontic enamel lesions.</p>



<figure class="wp-block-image size-large"><figcaption class="wp-element-caption">Figure 1 – Intraoral photographs of a participant in the F-ACP study group at baseline (T0) and after six months (T2). Following the six-month protocol, no visible evidence of white spot lesions remained after five seconds of air drying.</figcaption></figure>



<h2 class="wp-block-heading"><strong>A longer-term perspective on enamel health</strong></h2>



<p>Enamel care should not end when a clinical treatment is completed. For patients with MIH, post-orthodontic white spot lesions or other forms of enamel compromise, the transition from professional treatment to consistent home care is an important part of the overall management strategy.</p>



<p>By combining bio-inspired formulations with flexible application formats, Curasept Biosmalto supports a more continuous approach to enamel care, helping clinicians guide patients towards maintaining healthier tooth surfaces over time.</p>



<p><strong>Because protecting the value of a clinical treatment also means supporting the patient’s oral health long after they leave the dental chair.</strong></p>



<h3 class="wp-block-heading"><strong>References</strong></h3>



<ol start="1" class="wp-block-list">
<li>Weerheijm KL, Jalevik B, Alaluusua S. Molar-incisor hypomineralisation. <em>Caries Research</em>. 2004;38(4):305–314.</li>



<li>Prevalence of MIH in Northern England: <em>International Journal of Paediatric Dentistry</em>. 2011. <a href="https://pubmed.ncbi.nlm.nih.gov/22010979/">PubMed – Regional prevalence study</a>.</li>



<li>Ciribè M, et al. Efficacy of F-ACP-Containing Dental Mousse in the Remineralization of White Spot Lesions after Fixed Orthodontic Therapy: A Randomized Clinical Trial. <em>Biomedicines</em>. 2024;12(6):1202. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11200744/">Read the full clinical study</a>.</li>
</ol>



<p><em>This article is sponsored by Curasept.</em></p>]]> </content:encoded>
</item>

<item>
<title>Building a practice in partnership with PortmanDentex</title>
<link>https://edusehat.com/en/building-a-practice-in-partnership-with-portmandentex</link>
<guid>https://edusehat.com/en/building-a-practice-in-partnership-with-portmandentex</guid>
<description><![CDATA[ Discover how PortmanDentex’s partnership pathways help ambitious clinicians in building a thriving practice and realising their long-term vision with expert group support. For ambitious clinicians, building a successful practice is about more than bricks and mortar. It’s about creating a place where clinical vision can thrive, developing a strong team and culture, and shaping a… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/stockport.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 15:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Building, practice, partnership, with, PortmanDentex</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Discover how PortmanDentex’s partnership pathways help ambitious clinicians in building a thriving practice and realising their long-term vision with expert group support.</strong></p>



<p>For ambitious clinicians, building a successful practice is about more than bricks and mortar. It’s about creating a place where clinical vision can thrive, developing a strong team and culture, and shaping a future they can be proud of. PortmanDentex’s partnership pathways are designed to give clinicians greater ownership and influence, alongside the support, investment and expertise of a wider dental group.</p>



<h2 class="wp-block-heading"><strong>What partnership routes are available?</strong></h2>



<p>The partnership pathways are designed to suit different ambitions and stages of a clinician’s career. They include:</p>



<ul class="wp-block-list">
<li>Joint Venture Partner – creating the opportunity to establish and grow a brand new practice alongside PortmanDentex</li>



<li>Shared Ownership Programme – this enables clinicians to invest in an established practice, build equity value and share in its future success.</li>
</ul>



<p>Each pathway is designed to support clinical leadership and give clinicians the support they need to build sustainable practices and deliver high-quality patient care. As a partnership, both parties are committed to the long-term success of the practice.</p>



<h2 class="wp-block-heading"><strong>Hear from the partners themselves</strong></h2>



<p>Varinder and Navneet Jhaj became Joint Venture Partners in the newly established SK Dental Clinic, Stockport, creating an exciting platform for growth. Together with PortmanDentex they’re investing in the practice through rebranding, marketing, operational improvements and future expansion, demonstrating how local entrepreneurial leadership can be combined with group support. </p>



<p>They say: ‘Personally, we feel incredibly grateful and honoured to have taken this step into partnership. We are thankful for the trust that PortmanDentex has placed in us, and this partnership gives us the opportunity and platform to bring our vision to life – providing the high-quality dentistry we’re passionate about while continuing to deliver the very best care for our patients. We are excited about what the future holds and the positive impact this will have on our team, our practice, and the community we serve.’</p>



<p>At Clearly Orthodontics in Leicester, specialist orthodontist Maha Aljefri and her husband Haider Alaasam became PortmanDentex’s first shared ownership partners. Their investment reflects their commitment to the long-term future of the practice while allowing them to share in the value they help create.</p>



<h2 class="wp-block-heading"><strong>What are the benefits for clinicians?</strong></h2>



<p>For many clinicians, partnership represents the opportunity to combine clinical excellence with business ownership, without feeling they have to do everything alone.</p>



<p>Benefits include:</p>



<ul class="wp-block-list">
<li>Building equity value and sharing in the success created through long-term growth</li>



<li>Greater influence over the direction, culture and future of the practice</li>



<li>The freedom to focus on delivering exceptional patient care while being supported by experienced business professionals</li>



<li>Access to operational expertise, procurement, technology, finance, marketing and people support</li>



<li>The confidence of partnering with one of the UK’s largest dental groups while maintaining the individuality of the local practice</li>



<li>Collaboration with a wider network of experienced clinicians and partners.</li>
</ul>



<p>Ultimately, the partnership model gives clinicians the opportunity to shape and build the future of their practice, with the scale, investment and expertise of PortmanDentex behind them.</p>



<p>If you’re interested in partnership with PortmanDentex, email <a href="mailto:acquisitions@portmandental.co.uk">acquisitions@portmandental.co.uk</a> or visit its <a href="https://www.portmandentex.com/partner-with-us?utm_source=mna&utm_medium=online&utm_campaign=article" target="_blank" rel="noreferrer noopener">website</a>.</p>



<p><em>This article is sponsored by PortmanDentex.</em></p>



<p></p>]]> </content:encoded>
</item>

<item>
<title>Slotorado casino account verification</title>
<link>https://edusehat.com/en/slotorado-casino-account-verification</link>
<guid>https://edusehat.com/en/slotorado-casino-account-verification</guid>
<description><![CDATA[ Slotorado Casino: A Practical Guide for Canadian Players If you’re searching for a fresh online casino that feels built for Canadians, you’ve probably landed on Casino Slotorado. This 
The post Slotorado casino account verification appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/A6ZIlFbiXto/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Slotorado, casino, account, verification</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/A6ZIlFbiXto/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Slotorado Casino: A Practical Guide for Canadian Players</h1>
<p>If you’re searching for a fresh online casino that feels built for Canadians, you’ve probably landed on <a href="https://casino-slotorado.com/">Casino Slotorado</a>. This guide walks you through the most useful details – from signing up to cashing out – so you can decide whether Slotorado matches your style of play.</p>
<h2>1. Getting Started – Registration & Account Setup</h2>
<div data-affgun-media="video"></div>
<p>The registration process at Slotorado casino is deliberately simple. You’ll be asked for a valid email address, a password, and a few personal details (name, date of birth, and province). Because Canadian law requires age verification, you’ll need to confirm you’re at least 19 years old (or 18 in Alberta).</p>
<p>After you submit the form, an activation link is sent to your inbox. Click the link, set up a security question, and you’re ready to make your first deposit. The platform also offers a “guest” mode where you can explore the game lobby without logging in, but you won’t be able to claim any bonuses until the account is fully verified.</p>
<h2>2. Welcome Bonuses and Ongoing Promotions</h2>
<p>Slotorado casino greets new players with a multi‑tiered welcome package. The first deposit usually unlocks a 100 % match up to CAD 200 plus 50 free spins. Subsequent deposits bring smaller matches and extra spins, creating a stair‑step bonus structure that lasts for the first four deposits.</p>
<p>Wagering requirements are a key factor: the initial match comes with a 30× playthrough, while later bonuses are usually 25×. These figures are fairly typical for Canadian online casinos, but always read the fine print before you claim.</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Deposit Tier</th>
<th>Bonus Offer</th>
<th>Wagering Requirement</th>
<th>Free Spins</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st Deposit (up to CAD 200)</td>
<td>100 % match</td>
<td>30×</td>
<td>50</td>
</tr>
<tr>
<td>2nd Deposit (up to CAD 100)</td>
<td>50 % match</td>
<td>25×</td>
<td>30</td>
</tr>
<tr>
<td>3rd Deposit (up to CAD 100)</td>
<td>25 % match</td>
<td>25×</td>
<td>20</td>
</tr>
<tr>
<td>4th Deposit (up to CAD 100)</td>
<td>25 % match</td>
<td>25×</td>
<td>20</td>
</tr>
</tbody>
</table>
<h2>3. Payment Methods & Deposit Options</h2>
<p>Canadian players have a decent selection of trusted deposit methods. Most major credit and debit cards are accepted, as well as Interac e‑Transfer – a favourite for its instant processing. Below is a quick rundown of the most popular options.</p>
<ul>
<li><strong>Interac e‑Transfer:</strong> Zero‑fee, instant credit to your casino balance.</li>
<li><strong>Visa/Mastercard:</strong> Instant, but some banks may apply a small processing fee.</li>
<li><strong>PayPal:</strong> Fast and secure, though not every Canadian bank links directly.</li>
<li><strong>Bank Transfer (EFT):</strong> Takes 1‑2 business days but useful for large sums.</li>
</ul>
<p>All deposits are processed in Canadian dollars, which protects you from hidden conversion fees. Minimum deposit amounts start at CAD 10, making it easy for casual players to test the waters.</p>
<h2>4. Withdrawal Process & Speed</h2>
<p>When it’s time to cash out, Slotorado follows a standard verification step: you’ll need to upload a government‑issued ID, a recent utility bill, and a copy of the card used for the deposit. This KYC (Know Your Customer) check is mandatory before the first withdrawal.</p>
<p>After verification, withdrawal speed depends on the method you choose. Here’s what you can typically expect:</p>
<ul>
<li><strong>Interac e‑Transfer:</strong> 1‑2 business days (most players report same‑day if requested early).</li>
<li><strong>PayPal:</strong> 24‑48 hours.</li>
<li><strong>Bank Transfer:</strong> 3‑5 business days.</li>
</ul>
<p>Most Canadian players appreciate the “instant payouts” promise advertised by Slotorado, though it really applies only to e‑Transfer withdrawals.</p>
<h2>5. Mobile Experience – App & Browser Play</h2>
<p>Slotorado casino offers a responsive web design that works smoothly on iOS and Android browsers. No separate download is required, but the brand also provides a lightweight Android app for those who prefer a dedicated icon on their home screen.</p>
<p>The mobile interface mirrors the desktop lobby, giving you access to slots, live casino tables, and the sportsbook. Load times are quick, and the touch‑optimized controls make it easy to place bets on the go. Canadian players with limited data plans will notice the site’s efficient compression, which reduces bandwidth without sacrificing graphics quality.</p>
<h2>6. Game Selection – Slots, Live Casino, Sports Betting</h2>
<p>The core of Slotorado casino is its slot library. You’ll find titles from industry giants like NetEnt, Microgaming, and Play’n GO, covering a range of RTPs (usually 96‑98 %) and volatility levels. Whether you enjoy high‑risk, high‑reward games or prefer steadier returns, there’s a slot that fits.</p>
<p>Beyond slots, the live casino section streams real‑time dealers for blackjack, roulette, and baccarat. The video quality is HD, and the chat function lets you interact with the dealer – a nice touch for those who miss the brick‑and‑mortar vibe.</p>
<p>Sports‑betting enthusiasts can also place wagers on major North American leagues (NHL, CFL, NFL) and international events. The sportsbook runs on the same account, so you can switch between casino games and sports bets without logging out.</p>
<h2>7. Security, Licensing & Responsible Gambling</h2>
<p>Slotorado operates under a license from the Malta Gaming Authority, a jurisdiction known for strong player protection standards. All data traffic is encrypted with 128‑bit SSL, and the platform undergoes regular third‑party audits to ensure fairness.</p>
<p>The casino promotes responsible gambling through tools such as deposit limits, self‑exclusion, and “time‑out” reminders. If you ever feel you need a break, a simple request to customer support can trigger a temporary lock on your account.</p>
<h2>8. Customer Support & Help Resources</h2>
<p>Help is available 24/7 via live chat and email, with an average response time of under two minutes for chat. The support team is fluent in English (Canadian spelling) and can guide you through everything from bonus activation to withdrawal troubleshooting.</p>
<p>For quick answers, the FAQ section contains articles on common topics like “How to verify my account?” and “Why is my withdrawal pending?” The knowledge base is searchable and organized by category, making it easy to find what you need without waiting for a live agent.</p>
<h2>9. Frequently Asked Questions</h2>
<ul>
<li><strong>Is Slotorado legal for Canadian players?</strong> Yes – the Malta license is accepted in Canada, and the site complies with local gambling regulations.</li>
<li><strong>Can I play on my iPhone?</strong> Absolutely. The responsive website works flawlessly on Safari, and there’s an Android app for Android devices.</li>
<li><strong>What’s the fastest way to withdraw?</strong> Interac e‑Transfer, usually completed within 1‑2 business days after verification.</li>
<li><strong>Are there any hidden fees?</strong> No. All fees are disclosed during the deposit and withdrawal processes.</li>
</ul>
<p>With a solid bonus structure, a wide selection of games, and transparent banking options, Slotorado casino stands as a competitive choice for Canadian players looking for both entertainment and reliability.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/slotorado-casino-account-verification/">Slotorado casino account verification</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Emperia app account verification guide for Canadian players</title>
<link>https://edusehat.com/en/emperia-app-account-verification-guide-for-canadian-players</link>
<guid>https://edusehat.com/en/emperia-app-account-verification-guide-for-canadian-players</guid>
<description><![CDATA[ Emperia App – Complete Guide for Canadian Players Getting Started: Registration and First Steps When you land on the Emperia homepage, the first thing you’ll notice is the 
The post Emperia app account verification guide for Canadian players appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/anUyZ2ml6EM/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Emperia, app, account, verification, guide, for, Canadian, players</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/anUyZ2ml6EM/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Emperia App – Complete Guide for Canadian Players</h1>
<p><!-- Hero image / video will be injected automatically --></p>
<h2>Getting Started: Registration and First Steps</h2>
<div data-affgun-media="video"></div>
<p>When you land on the Emperia homepage, the first thing you’ll notice is the bright “Sign Up” button. Canadian players can create an account in just a few minutes by filling out name, email, and a password. The form also asks for your province to make sure the service is legal where you live, which most of us in Canada appreciate.</p>
<p>After you confirm the verification email, the system will prompt you to set a deposit limit – a handy responsible‑gambling tool. If you’re new to online casinos, take a moment to read the short tutorial that explains how points turn into bonus credits. That way you won’t be surprised when a welcome bonus pops up on your dashboard.</p>
<h2>Downloading and Installing the Emperia App</h2>
<p>The Emperia app is available for both iOS and Android. For iPhone users, head to the Apple App Store and search “Emperia Casino”. Android players need to download the APK from the official Emperia site – the site will check your device compatibility before the file starts.</p>
<p>Installation is straightforward: tap the file, allow “unknown sources” temporarily, and the app will appear on your home screen. Once opened, the app asks you to log in with the credentials you just created. You’ll notice the interface mirrors the desktop site, but with larger buttons that are easier to tap on a phone.</p>
<h2>Bonuses and Promotions – What You Can Claim</h2>
<p>Emperia loves to greet newcomers with a solid welcome bonus. The typical offer is a 100 % match on your first deposit up to CAD 200, plus 50 free spins on a popular slot. Remember, the free spins come with a 30× wagering requirement, so you’ll need to play enough to cash out.</p>
<p>Beyond the starter pack, the app rolls out weekly reload bonuses, cash‑back on losses, and a loyalty program that awards “Emperia points”. Points can be swapped for bonus cash or tournament entries. Keep an eye on the “Promotions” tab inside the app – they update every Monday.</p>
<ul>
<li>Welcome bonus – 100 % match + 50 free spins</li>
<li>Weekly reload – 50 % up to CAD 100</li>
<li>Cash‑back – 10 % of net losses every weekend</li>
<li>Loyalty points – earn 1 point per CAD 1 wagered</li>
</ul>
<h2>Payment Methods, Deposits and Withdrawal Speed</h2>
<p>Canadian players have a decent selection of deposit and withdrawal options. Below is a quick glance at the most common methods, their minimum amounts and typical processing times.</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Method</th>
<th>Type</th>
<th>Minimum</th>
<th>Processing Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interac e‑Transfer</td>
<td>Deposit</td>
<td>CAD 10</td>
<td>Instant</td>
</tr>
<tr>
<td>Visa / MasterCard</td>
<td>Deposit</td>
<td>CAD 20</td>
<td>Instant</td>
</tr>
<tr>
<td>PayPal</td>
<td>Deposit / Withdrawal</td>
<td>CAD 20</td>
<td>Instant / 24‑48 h</td>
</tr>
<tr>
<td>Bank</td>
</tr>
</tbody>
</table>
<p>Ready to start playing? Visit <a href="https://casino-emperia.com/">casino-emperia.com</a> now and verify your Emperia app account today!</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/emperia-app-account-verification-guide-for-canadian-players/">Emperia app account verification guide for Canadian players</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Spin Aura review: compleet overzicht voor Nederlandse spelers</title>
<link>https://edusehat.com/en/spin-aura-review-compleet-overzicht-voor-nederlandse-spelers</link>
<guid>https://edusehat.com/en/spin-aura-review-compleet-overzicht-voor-nederlandse-spelers</guid>
<description><![CDATA[ Spin Aura: praktische gids voor Nederlandse spelers Wat is Spin Aura? Spin Aura is een relatief nieuw online casino dat zich richt op de Nederlandse markt. Het platform 
The post Spin Aura review: compleet overzicht voor Nederlandse spelers appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/_tSdSgoyAMQ/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Spin, Aura, review:, compleet, overzicht, voor, Nederlandse, spelers</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/_tSdSgoyAMQ/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Spin Aura: praktische gids voor Nederlandse spelers</h1>
<h2>Wat is Spin Aura?</h2>
<div data-affgun-media="video"></div>
<p>Spin Aura is een relatief nieuw online casino dat zich richt op de Nederlandse markt. Het platform biedt een breed scala aan slots, live casino‑spellen en een geïntegreerde sportsbook, waardoor zowel casinofans als sportliefhebbers zich thuis voelen. De website is volledig vertaald naar het Nederlands en werkt met een Nederlandse licentie, zodat je als speler zeker bent van een eerlijk en gecontroleerd spelklimaat. Naast de standaardgames kun je bij Spin Aura ook exclusieve releases vinden die je niet overal tegenkomt.</p>
<p>De naam “Spin Aura” verwijst naar de dynamiek van het draaien van de rollen en de sfeer (aura) die ontstaat als je een grote winst behaalt. Voor Nederlandse spelers betekent dit een combinatie van lokale betaalmethoden, Nederlands‑sprekende klantenservice en promoties die aansluiten bij onze speelgewoonten. Het casino claimt snelle uitbetalingen, een gebruiksvriendelijke interface en een mobiel geoptimaliseerde ervaring.</p>
<h2>Registratie en eerste stappen</h2>
<p>De eerste stap om te kunnen spelen is natuurlijk het aanmaken van een account. Ga naar de startpagina, klik op “Registreren” en vul je e‑mail, een wachtwoord en een mobiel telefoonnummer in. Het proces is simpel en duurt meestal minder dan twee minuten. Na de registratie ontvang je een bevestigingsmail; klik op de link om je account te activeren.</p>
<p>Voor de veiligheid vraagt Spin Aura daarna om een korte verificatie. Je moet een kopie van een legitimatiebewijs (paspoort of identiteitskaart) en een recent bankafschrift uploaden. Deze KYC‑stappen zorgen ervoor dat je geen problemen krijgt bij later geld opnemen. Zodra je documenten zijn goedgekeurd, kun je direct een eerste storting doen en profiteren van de welkomstbonus.</p>
<h2>Welkomstbonus en andere promoties</h2>
<p>Spin Aura biedt een royale welkomstbonus die bestaat uit een matchbonus op je eerste drie stortingen plus een aantal gratis spins. De exacte voorwaarden verschillen per promotieperiode, maar over het algemeen krijg je 100 % extra tot €300 en 50 gratis spins op een populaire slot. Let wel op de bijbehorende inzetvereisten – meestal 35× de bonuswaarde – voordat je winsten kunt opnemen.</p>
<p>Naast de welkomstbonus heeft Spin Aura een doorlopend promotie‑programma met reload‑bonussen, cashback en een loyaliteitsprogramma. Alles staat overzichtelijk in het “Promoties” menu, zodat je nooit een aanbieding mist.</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Bonus type</th>
<th>Percentage</th>
<th>Max. bonus</th>
<th>Inzetvereiste</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welkomstbonus 1e storting</td>
<td>100 %</td>
<td>€200</td>
<td>35×</td>
</tr>
<tr>
<td>Welkomstbonus 2e & 3e storting</td>
<td>50 %</td>
<td>€100</td>
<td>30×</td>
</tr>
<tr>
<td>Maandelijkse reload</td>
<td>25 %</td>
<td>€50</td>
<td>20×</td>
</tr>
</tbody>
</table>
<h2>Betaalmethoden en opname snelheid</h2>
<p>Spin Aura ondersteunt een reeks populaire betaalopties die in Nederland gangbaar zijn. Je kunt kiezen uit iDEAL, Bancontact, creditcards (Visa, Mastercard), en verschillende e‑wallets zoals Skrill en Neteller. Stortingen worden vrijwel direct verwerkt, waardoor je meteen kunt beginnen met spelen.</p>
<p>Opnames zijn iets langzamer, maar nog steeds redelijk snel. Met iDEAL kun je binnen 24 uur je geld op je bankrekening hebben, terwijl e‑wallets vaak binnen een paar uur klaar zijn. Creditcardopnames duren meestal 2‑3 werkdagen. Hieronder een overzicht van de gemiddelde verwerkingstijden:</p>
<ul>
<li><strong>iDEAL:</strong> 24 uur</li>
<li><strong>Skrill/Neteller:</strong> 1‑3 uur</li>
<li><strong>Visa/Mastercard:</strong> 2‑3 werkdagen</li>
<li><strong>Bankoverschrijving:</strong> 3‑5 werkdagen</li>
</ul>
<h2>Mobiele ervaring en app</h2>
<p>Voor spelers die graag onderweg zijn, biedt Spin Aura een responsieve mobiele website die werkt op zowel Android‑ als iOS‑apparaten. Het ontwerp past zich automatisch aan de schermgrootte aan, zodat knoppen en menu’s niet te klein worden. Daarnaast kun je de officiële Spin Aura‑app downloaden vanuit de Google Play Store of de Apple App Store.</p>
<p>De app biedt dezelfde functionaliteit als de desktopversie: je kunt storten, uitbetalen, bonussen claimen en zelfs live dealer‑spellen spelen met een enkele tik. De laadtijden zijn kort, en de app maakt gebruik van push‑notificaties om je te informeren over nieuwe promoties of aankomende sportwedstrijden.</p>
<h2>Live casino en sportweddenschappen</h2>
<p>Spin Aura heeft een uitgebreid live casino‑gedeelte met spellen zoals live roulette, baccarat, blackjack en een aantal unieke “Lightning” varianten. De dealers zijn professioneel en spreken Engels, maar er zijn ook Nederlandse tafels beschikbaar. De streams zijn van hoge kwaliteit en bieden een authentieke casino‑sfeer zonder dat je je huis hoeft te verlaten.</p>
<p>Naast het casino kun je bij Spin Aura ook sportweddenschappen plaatsen. Het aanbod omvat voetbal, tennis, basketball en niche‑evenementen zoals e‑sports. De odds zijn competitief en er zijn regelmatig “Boosted odds” en “Parlay” promoties. Als je zowel van gokken als van sport houdt, is dit een handige één‑stop‑shop.</p>
<h2>Veiligheid, licenties en verantwoord spelen</h2>
<p>Spin Aura opereert onder een licentie van de Kansspelautoriteit (KSA) in Nederland, wat betekent dat het voldoet aan strenge eisen op het gebied van eerlijk spel, financiële transparantie en spelersbescherming. Alle transacties worden versleuteld met SSL‑technologie, zodat je persoonlijke en financiële gegevens veilig zijn.</p>
<p>Verantwoord gokken staat centraal: er zijn tools voor limietinstellingen, zelfuitsluiting en real‑time spelgedrag‑monitoring. Mocht je merken dat je problemen krijgt, kun je direct contact opnemen met de supportafdeling of gebruikmaken van externe hulporganisaties zoals Gamblers Anonymous.</p>
<h2>Klantenservice en support</h2>
<p>De klantenservice van Spin Aura is 24/7 bereikbaar via live chat, e‑mail en telefoon. Het supportteam spreekt Nederlands, Engels en verschillende andere talen, zodat je altijd een duidelijk antwoord kunt krijgen. De meeste vragen worden binnen enkele minuten afgehandeld via de chat.</p>
<p>Naast directe ondersteuning heeft Spin Aura een uitgebreide FAQ‑sectie met antwoorden op veelvoorkomende vragen over registratie, bonussen, betalingen en technische problemen. Deze zelfhulp‑optie is handig als je buiten kantooruren toch snel een oplossing zoekt.</p>
<h2>Veelgestelde vragen (FAQ)</h2>
<ul>
<li><strong>Is Spin Aura legaal voor spelers uit Nederland?</strong> Ja, het casino beschikt over een KSA‑licentie en voldoet aan alle Nederlandse regelgeving.</li>
<li><strong>Welke betaalmethoden kan ik gebruiken?</strong> iDEAL, Bancontact, Visa, Mastercard, Skrill, Neteller en bankoverschrijving.</li>
<li><strong>Hoe snel kan ik mijn winst opnemen?</strong> Met iDEAL binnen 24 uur; e‑wallets vaak binnen enkele uren.</li>
<li><strong>Kan ik spelen op mijn mobiel?</strong> Ja, via een responsive website of de gratis Spin Aura‑app.</li>
<li><strong>Hoe werkt de welkomstbonus?</strong> Je krijgt 100 % match tot €200 op je eerste storting plus 50 gratis spins, onder een inzetvereiste van 35×.</li>
</ul>
<p>Ben je klaar om zelf te ervaren wat Spin Aura te bieden heeft? Bezoek <a href="https://casino-spin-aura.net/nl/">Spin Aura Casino Nederland</a> en begin vandaag nog met spelen.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/spin-aura-review-compleet-overzicht-voor-nederlandse-spelers/">Spin Aura review: compleet overzicht voor Nederlandse spelers</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>OzzyBet bonus guide – Canada welcome offer, free spins &amp;amp; wagering details</title>
<link>https://edusehat.com/en/ozzybet-bonus-guide-canada-welcome-offer-free-spins-wagering-details</link>
<guid>https://edusehat.com/en/ozzybet-bonus-guide-canada-welcome-offer-free-spins-wagering-details</guid>
<description><![CDATA[ OzzyBet – Your Practical Guide to Canada’s Online Casino &amp; Sportsbook Welcome to the definitive walkthrough for anyone in Canada curious about OzzyBet. This page isn’t a generic 
The post OzzyBet bonus guide – Canada welcome offer, free spins &amp; wagering details appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/IC5WC0iAvRI/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>OzzyBet, bonus, guide, –, Canada, welcome, offer, free, spins, wagering, details</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/IC5WC0iAvRI/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<article>
<h1>OzzyBet – Your Practical Guide to Canada’s Online Casino & Sportsbook</h1>
<p>Welcome to the definitive walkthrough for anyone in Canada curious about OzzyBet. This page isn’t a generic sales pitch; it’s a hands‑on manual that shows exactly what you’ll see, click and experience when you sign up. From the moment you hit the “Register” button to the first withdrawal, you’ll know the steps, the pitfalls and the little tricks that make the difference. If you’re looking for a trustworthy place to play slots, table games or bet on the NHL, keep reading – the details below are built for real‑world decisions. For the full site, you can visit <a href="https://casino-ozzybet.com/">casino-ozzybet.com</a> and explore the offers yourself.</p>
<h2>1. Getting Started: Registration and First Steps</h2>
<div data-affgun-media="video"></div>
<p>Creating an OzzyBet account is intentionally straightforward, but a few fields can trip up newcomers. You’ll need a valid Canadian email address, a password that meets the usual complexity rules, and your date of birth – the platform checks you’re 19 or older, the legal gambling age in most provinces. After submitting the form, an activation link lands in your inbox; clicking it confirms your address and unlocks the dashboard.</p>
<p>One practical tip: keep a copy of the confirmation email before you delete it. OzzyBet sometimes asks for that reference when you contact support about KYC (Know Your Customer) verification. If you plan to use the mobile app later, you can skip the optional “promo code” field – you’ll be able to claim any welcome bonus from the promotions tab after logging in.</p>
<h2>2. Welcome Bonuses and What They Really Mean</h2>
<p>OzzyBet’s headline offer is a “100% match up to $500” plus 50 free spins on a popular slot. That sounds generous, but the real value lies in the wagering requirements. In most Canadian online casinos, a 30x playthrough on the bonus amount is common; OzzyBet follows that standard, meaning you’ll need to bet $15,000 before you can cash out the $500 bonus.</p>
<p>Below is a quick snapshot of the current welcome package and its key terms:</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Component</th>
<th>Amount</th>
<th>Wagering Requirement</th>
<th>Expiry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Match Bonus</td>
<td>$500</td>
<td>30x bonus</td>
<td>30 days</td>
</tr>
<tr>
<td>Free Spins</td>
<td>50 spins</td>
<td>20x winnings</td>
<td>7 days</td>
</tr>
</tbody>
</table>
<p>When you claim the offer, the bonus funds land in a separate “bonus balance”. You can still play your favorite slots or table games, but any winnings from that balance are locked until the wagering is satisfied. If you prefer lower‑risk play, look for the “low‑volatility” slots in the catalogue – they tend to meet requirements more predictably.</p>
<h2>3. Payment Methods: Deposits and Withdrawals in Canada</h2>
<p>OzzyBet supports the most common Canadian banking options, which is a relief for players wary of foreign e‑wallets. You can fund your account with Interac e‑Transfer, Visa/Mastercard, and major e‑wallets like PayPal. Deposits are instant, and the minimum amount is typically $10, which fits a cautious starter’s budget.</p>
<p>Withdrawals are a bit slower, but still reasonable. The platform processes e‑Transfer payouts within 24‑48 hours, while card withdrawals may take up to five business days due to bank processing. For faster cash‑out, use the “Instant Pay” option with PayPal – it usually lands in your wallet within a few hours, provided you’ve cleared the KYC step.</p>
<h2>4. Game Selection: Casino, Live Dealer, and Sports Betting</h2>
<p>OzzyBet’s library is supplied by several leading software providers, giving you access to over 2,000 slot titles, classic table games, and a robust live dealer section. If you enjoy the ambience of a real casino, the live studio hosts dealers for blackjack, roulette and baccarat, streamed in high definition. The live games have a higher RTP (return‑to‑player) than many stand‑alone slots, often hovering around 97%.</p>
<p>Sports betting is integrated on the same account, so you can flip from a slot spin to a live NHL game without logging out. The sportsbook panel offers typical North‑American markets – hockey, football, basketball and baseball – with competitive odds and occasional “money‑back” promos on big matches. Keep an eye on the “Bet Builder” tool; it lets you combine several selections into a single wager, which can boost potential payouts.</p>
<h2>5. Mobile Experience: App and Browser Play</h2>
<p>For Canadians who favour on‑the‑go gambling, OzzyBet provides a native iOS/Android app that mirrors the desktop experience. The download size is modest (around 50 MB) and the installation process follows the usual app‑store steps. Once logged in, the app remembers your last game, so you can pick up exactly where you left off.</p>
<p>If you prefer not to install anything, the mobile‑optimized website works smoothly in any modern browser. Touch‑friendly menus, auto‑scaling graphics, and quick‑load times make it practical for commuting or quick coffee‑break sessions. Both platforms use the same secure encryption, so your funds and data stay protected whether you’re on a phone or laptop.</p>
<h2>6. Security, Licensing, and Responsible Gambling</h2>
<p>OzzyBet operates under a licence from the Malta Gaming Authority, a reputable regulator that enforces strict player protection rules. All data transmissions are encrypted with 128‑bit SSL, the same standard used by major banks. For added peace of mind, the site undergoes regular audits by independent testing houses that verify RNG fairness.</p>
<p>Responsible gambling tools are built into the user dashboard. You can set daily deposit limits, self‑exclude for a chosen period, or request a “cool‑off” pause. If you ever feel that gambling is affecting your life, the “Help” section links to Canadian support organisations such as the Responsible Gambling Council.</p>
<h2>7. Customer Support: How to Get Help When You Need It</h2>
<p>OzzyBet offers 24/7 live chat, which is the fastest way to resolve account questions. The chat agents are English‑speaking Canadians, so you won’t get lost in translation. For issues outside chat hours, there’s an email ticketing system and an extensive FAQ database that covers topics from bonus clarification to withdrawal troubleshooting.</p>
<p>When you contact support, have the following information ready: your username, the last four digits of the payment method used, and any reference numbers from previous tickets. Providing these details up front usually cuts the response time in half, especially for verification‑related queries.</p>
<h2>8. Frequently Asked Questions</h2>
<ul>
<li><strong>Is OzzyBet legal for players in Canada?</strong> Yes – the MGA licence is accepted by Canadian regulators, and the platform adheres to provincial gambling laws.</li>
<li><strong>What is the minimum withdrawal amount?</strong> The smallest cash‑out is $20, which applies to all supported methods.</li>
<li><strong>Can I play on a Mac?</strong> Absolutely – the web version runs on any modern browser, and the iOS app works on iPhone and iPad.</li>
<li><strong>How long does verification take?</strong> Typically 24 hours if you submit a clear photo ID and proof of address.</li>
</ul>
<p>With this practical roadmap, you should feel equipped to decide whether OzzyBet matches your gambling style. Remember, the best choice balances exciting games, fair bonuses and reliable support – and OzzyBet ticks most of those boxes for Canadian players.</p>
</article>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/ozzybet-bonus-guide-canada-welcome-offer-free-spins-wagering-details/">OzzyBet bonus guide – Canada welcome offer, free spins & wagering details</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Kazeeno Bonus Guide for Canadian Players – Welcome Offers, Wagering Requirements &amp;amp; Claim Steps</title>
<link>https://edusehat.com/en/kazeeno-bonus-guide-for-canadian-players-welcome-offers-wagering-requirements-claim-steps</link>
<guid>https://edusehat.com/en/kazeeno-bonus-guide-for-canadian-players-welcome-offers-wagering-requirements-claim-steps</guid>
<description><![CDATA[ kazeeno: Practical Guide for Canadian Players What is kazeeno and Why It Matters for Canadian Gamblers? kazeeno is an online casino platform that has been gaining traction among 
The post Kazeeno Bonus Guide for Canadian Players – Welcome Offers, Wagering Requirements &amp; Claim Steps appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/nAHEh2zHjSk/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Kazeeno, Bonus, Guide, for, Canadian, Players, –, Welcome, Offers, Wagering, Requirements, Claim, Steps</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/nAHEh2zHjSk/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>kazeeno: Practical Guide for Canadian Players</h1>
<h2>What is kazeeno and Why It Matters for Canadian Gamblers?</h2>
<div data-affgun-media="video"></div>
<p>kazeeno is an online casino platform that has been gaining traction among Canadian players looking for a mix of slots, live dealer tables, and sports betting. The brand promotes itself as a one‑stop entertainment hub, offering a welcome bonus that can stretch a modest deposit into a sizeable playing balance. For newcomers, the biggest draw is the smooth onboarding process paired with a modern website design that works well on both desktop and mobile.</p>
<p>Beyond the flashy marketing, what really matters is how kazeeno handles key concerns: licensing, payment options, and responsible gambling tools. Canadian users will want to know if the casino holds a reputable licence, whether popular Canadian banking methods are accepted, and how fast withdrawals are processed. This guide walks you through each of those practical points so you can decide if kazeeno fits your style.</p>
<h2>How to Register and Verify Your Account</h2>
<p>The registration on kazeeno is intentionally simple. You start by clicking the “Sign Up” button, filling in your name, email, and a strong password. After submitting, you’ll receive a verification email that you must confirm before you can make a deposit. The whole process typically takes under five minutes, unless you run into email filters.</p>
<p>Verification (often called KYC) becomes necessary once you request a withdrawal that exceeds the initial bonus amount. You’ll be asked to upload a government‑issued ID and a proof‑of‑address document, such as a utility bill. The casino’s support team usually reviews these files within 24‑48 hours, meaning you can expect your first payout to clear shortly after verification.</p>
<h2>Bonuses, Welcome Offers, and Wagering Requirements</h2>
<p>kazeeno’s headline attraction is its welcome bonus package. New players can claim a 100 % match on the first deposit up to $200, plus 50 free spins on a popular slot. The bonus is credited instantly, but note the wagering requirement: you must bet 30 × the bonus amount before any winnings can be withdrawn. This is fairly standard, yet it’s essential to calculate how much play you’ll need.</p>
<p>Beyond the welcome package, there are weekly reload promotions, cash‑back on losses, and a loyalty program that awards points for each wager. These points can be swapped for bonus credits or free spins, adding extra value for frequent players. Always read the terms for each promotion; some may exclude certain game types or have lower wagering multiples.</p>
<h2>Payment Methods and Withdrawal Speed</h2>
<p>Canadian players have a decent selection of deposit options at kazeeno. The most common include Interac e‑Transfer, Visa/Mastercard, and several e‑wallets like PayPal and Skrill. Deposits are processed instantly, allowing you to start playing without delay. Most e‑wallets also support rapid withdrawals, often credited to your account within a few hours.</p>
<p>Bank‑card withdrawals typically take 2‑5 business days, while Interac transfers can be as quick as the next business day. The casino does not charge a fee for standard withdrawals, but some e‑wallet providers may apply their own small charge. Below is a quick comparison of the main payment routes:</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Payment Method</th>
<th>Deposit Speed</th>
<th>Withdrawal Speed</th>
<th>Typical Fees</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interac e‑Transfer</td>
<td>Instant</td>
<td>1‑2 business days</td>
<td>None</td>
</tr>
<tr>
<td>Visa / Mastercard</td>
<td>Instant</td>
<td>2‑5 business days</td>
<td>None</td>
</tr>
<tr>
<td>PayPal</td>
<td>Instant</td>
<td>Within 24 hours</td>
<td>Potential e‑wallet fee</td>
</tr>
<tr>
<td>Skrill</td>
<td>Instant</td>
<td>Same‑day</td>
<td>Potential e‑wallet fee</td>
</tr>
</tbody>
</table>
<h2>Game Selection: Slots, Live Casino, and Sports Betting</h2>
<p>kazeeno hosts a library that runs into the thousands, supplied by big providers such as NetEnt, Microgaming, and Evolution Gaming. Slot enthusiasts will find high‑RTP titles, progressive jackpots, and a range of volatility levels to match any risk appetite. For those craving a more authentic feel, the live casino section offers real‑time dealers on blackjack, roulette, and baccarat.</p>
<p>The sportsbook is a newer addition but already covers major Canadian sports like NHL, CFL, and MLS, plus international leagues. Betting markets include typical spreads, totals, and money‑line options, as well as live in‑play wagering. If you enjoy switching between casino games and sports action, kazeeno’s single‑sign‑on system makes the transition seamless.</p>
<h2>Mobile Experience and App Availability</h2>
<p>The website is fully responsive, meaning you can play directly in a mobile browser without needing a separate app. However, kazeeno also offers a downloadable app for Android and iOS users. The app mirrors the desktop layout, delivering fast load times and push notifications for bonus alerts.</p>
<p>If you prefer not to install anything, the mobile browser version still supports most slots, live dealer streams, and the sports betting interface. All payment methods work on the go, though some banks may require an extra security step when you log in from a new device.</p>
<h2>Security, Licensing, and Responsible Gambling</h2>
<p>kazeeno operates under a licence from the Malta Gaming Authority, a well‑regarded regulator that enforces strict player protection standards. All data transmissions are encrypted with SSL 128‑bit technology, safeguarding personal and financial information against interception.</p>
<p>For responsible gambling, the platform provides tools such as deposit limits, session timers, and self‑exclusion options. If you ever feel that gambling is affecting your life, you can request a temporary or permanent ban through the “Responsible Gaming” section of your account. These features are in line with Canadian best practices for safe play.</p>
<h2>Customer Support and Common Questions</h2>
<p>Support at kazeeno is available 24/7 via live chat and email. The live chat response time is typically under a minute, and the support staff are fluent in English, which is helpful for Canadian players. A comprehensive FAQ covers topics ranging from bonus redemption to verification requirements, reducing the need to wait for an agent.</p>
<p>When you have a question that isn’t answered instantly, you can also reach out through a ticket system. Most users report that the resolution time for payment‑related inquiries is within 24 hours, provided you’ve submitted all required documents.</p>
<h2>Final Thoughts: Should You Choose kazeeno?</h2>
<p>If you value a solid welcome bonus, a wide variety of games, and quick deposit options, kazeeno is worth a look. Its licensing, security measures, and responsible gambling tools meet the expectations of Canadian players seeking a trustworthy environment. The mobile experience is smooth, and the sportsbook adds a nice extra dimension for those who like to bet on NHL or CFL matches.</p>
<p>For the latest offers and to start your registration, visit the official site at <a href="https://casino-kazeeno.net/">casino-kazeeno.net</a>. Remember to read the fine print on any promotion, set realistic bankroll limits, and enjoy the entertainment responsibly.</p>
<ul>
<li>Check the bonus wagering requirements before you claim.</li>
<li>Use Interac for the fastest withdrawals.</li>
<li>Take advantage of the live casino for an authentic feel.</li>
<li>Set daily deposit limits via the responsible gambling tools.</li>
<li>Contact support via live chat for immediate assistance.</li>
</ul>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/kazeeno-bonus-guide-for-canadian-players-welcome-offers-wagering-requirements-claim-steps/">Kazeeno Bonus Guide for Canadian Players – Welcome Offers, Wagering Requirements & Claim Steps</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Hypp1s Suomi rekisteröitymisvaiheet – helppo opas aloittelijoille</title>
<link>https://edusehat.com/en/hypp1s-suomi-rekisteroeitymisvaiheet-helppo-opas-aloittelijoille</link>
<guid>https://edusehat.com/en/hypp1s-suomi-rekisteroeitymisvaiheet-helppo-opas-aloittelijoille</guid>
<description><![CDATA[ Hypp1s Suomi – Käytännöllinen opas suomalaisille pelaajille Miksi valita Hypp1s Suomi? Suomessa kasinopelaaminen on kasvussa, ja jokainen uusi pelaaja etsii luotettavaa kumppania. Hypp1s Suomi erottuu edukseen erityisesti selkeillä 
The post Hypp1s Suomi rekisteröitymisvaiheet – helppo opas aloittelijoille appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/4uSPFIBpTtM/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Hypp1s, Suomi, rekisteröitymisvaiheet, –, helppo, opas, aloittelijoille</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/4uSPFIBpTtM/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Hypp1s Suomi – Käytännöllinen opas suomalaisille pelaajille</h1>
<h2>Miksi valita Hypp1s Suomi?</h2>
<div data-affgun-media="video"></div>
<p>Suomessa kasinopelaaminen on kasvussa, ja jokainen uusi pelaaja etsii luotettavaa kumppania. Hypp1s Suomi erottuu edukseen erityisesti selkeillä bonusehdoilla ja suomalaisille suunnatulla maksupalveluvalikoimalla. Sivusto on lisensoitu Maltan viranomaisen toimesta, mikä takaa EU-tason turvallisuuden ja läpinäkyvyyden. Lisäksi käyttöliittymä on suomenkielinen, eikä kielimuuri estä pelaamista tai tukea. Jos haluat sekä viihdyttävän että vastuullisen pelikokemuksen, tämä on yksi parhaista vaihtoehdoista.</p>
<p>Hypp1s Suomi tarjoaa myös laajan valikoiman live‑casinopöytiä, urheiluvedonlyöntiä ja mobiilisovelluksen, joka toimii sujuvasti sekä iOS- että Android-laitteilla. Monipuolinen pelivalikoima tarkoittaa, että voit siirtyä pokeripöydästä vedonlyöntiin ilman, että sinun tarvitsee vaihtaa sivustoja. Tämä yhden luukun konsepti säästää aikaa ja pitää pelikokemuksen yhtenäisenä.</p>
<h2>Rekisteröityminen ja tervetulobonus</h2>
<p>Rekisteröityminen Hypp1s Suomi -sivustolle vie vain muutaman minuutin. Täytä perus tiedot, vahvista sähköpostiosoite ja tee ensimmäinen talletus – ja bonuksesi on jo matkalla. Tervetulobonus koostuu 100 % talletusbonuksesta, enintään 200 € ja 50 ilmaiskierroksesta, jotka aktivoituvat heti ensimmäisen talletuksen jälkeen.</p>
<p>Bonuksen kierrätysvaatimus on 30×, mutta se jakautuu tasaisesti sekä bonuksen että talletuksen määrään, mikä tekee kierrättämisestä vähemmän rasittavaa. Jos olet aloittelija, kannattaa aloittaa pienemmällä talletuksella ja tarkistaa kierrätysvaatimukset ennen isompien sumien panostamista. Bonuskoodia ei enää tarvita – se lisätään automaattisesti rekisteröitymisen yhteydessä.</p>
<h2>Maksutavat ja talletus – Helppoa ja turvallista</h2>
<p>Suomalaiset pelaajat arvostavat nopeita ja turvallisia maksutapoja. Hypp1s Suomi tukee suosituimpia suomalaisia maksutapoja, kuten verkkopankkia (Siirto, Trustly), e-lompakoita (Skrill, Neteller) sekä perinteisiä luottokortteja (Visa, MasterCard). Kaikki talletukset prosessoidaan välittömästi, joten voit heti siirtyä pelaamaan.</p>
<p>Talletusmaksimissa on 5 000 € per transaktio, mutta useimmat suomalaiset pelaajat käyttävät 100–500 € välisiä summia. Jos talletus ei onnistu, tarkista, että korttisi on aktivoinut internet‑ostokset tai että verkkopankin turvatunnus on oikein syötetty. Maksutapa valitsee myös mahdollisesti kierrätysvaatimusten täyttämisen – osa maksutavoista voi sulkea bonuksen vastaanottamisen.</p>
<h2>Nostot ja maksunopeus – Mitä odottaa?</h2>
<p>Nostojen käsittelyaika on yksi tärkeimmistä tekijöistä, kun valitsee online‑kasinoa. Hypp1s Suomi pyrkii tarjoamaan “instant payouts” –tavalla, jossa suosituimmat maksutavat, kuten Trustly ja Skrill, saavat varat tilillesi 15–30 minuutissa. Perinteisemmät menetelmät, kuten pankkisiirto, voivat viedä 1–3 arkipäivää.</p>
<p>Nostomaksimissa on 5 000 € päivässä, ja nostoa voi tehdä enintään 3 kertaa per viikko. Kaikki nostot käyvät läpi KYC‑vahvistuksen – henkilötodistus ja osoitteesi täytyy olla tarkistettu ennen ensimmäistä nostoa. Tämä turvatoimi ehkäisee petoksia ja suojaa sekä sinua että kasinoa.</p>
<h2>Live casino ja urheiluvedonlyönti – Pelivalikoima</h2>
<p>Hypp1s Suomi panostaa sekä live‑casinoon että urheiluvedonlyöntiin. Live‑casinossa voit pelata reaaliaikaisia pelejä, kuten blackjackia, rulettia ja baccaratia, oikeiden jakajien kanssa. Pelien RTG (Return to Player) on keskimäärin 96 % – 98 %, mikä on kilpailukykyistä alan tasossa.</p>
<p>Urheiluvedonlyönti kattaa kaikki suuret urheilulajit: jalkapallo, jääkiekko, koripallo, sekä e-urheilu. Vedonlyöntikohteita on yli 2 000 päivittäin, ja live‑vedonlyönti käynnistyy ottelun alkaessa. Kertoimet ovat lähellä markkinoiden parhaita, ja vedonlyönti on helppo yhdistää casino‑tiliisi ilman erillistä rekisteröitymistä.</p>
<h2>Mobiilisovellus ja mobiilikokemus</h2>
<p>Suomalaiset käyttävät yhä enemmän puhelimia pelaamiseen, ja Hypp1s Suomi on ottanut tämän huomioon. Sovellus on saatavilla sekä Google Play -kaupasta että Applen App Storesta, eikä vaadi erillistä latausta – se toimii myös suoraan selaimessa. Mobiiliversio tarjoaa täyden pääsyn kaikkiin peleihin, bonuksiin ja talletusmenetelmiin.</p>
<p>Sovelluksen käyttöliittymä on optimoitu pienemmille näytöille: suuri fontti, selkeät napit ja nopea navigointi. Mobiilisovellus tukee myös push‑ilmoituksia, joilla saat tiedon uusista bonuksista tai tapahtumista juuri silloin, kun ne ovat merkityksellisiä. Tämä tekee pelaamisesta sujuvaa myös liikkeellä ollessa.</p>
<h2>Turvallisuus, lisenssi ja vastuullinen pelaaminen</h2>
<p>Hypp1s Suomi toimii Maltan Gaming Authorityn myöntämän lisenssin alaisena, mikä takaa, että sivusto noudattaa EU‑standardien tiukkoja turvallisuusvaatimuksia. Kaikki tiedonsiirto on suojattu 128‑bit SSL‑salauksella, eikä henkilökohtaisia tietoja jaeta kolmansille osapuolille ilman suostumusta.</p>
<p>Vastuullinen pelaaminen on keskeinen osa Hypp1s Suomi -filosofiaa. Sivustolta löytyy itsearviointityökalu, talletusrajoitukset, sekä mahdollisuus sulkea oma tili tilapäisesti. Jos pelaaminen alkaa tuntua hallitsemattomalta, voit helposti ottaa yhteyttä tukitiimiin, joka tarjoaa myös linkin erikoisjärjestöihin, kuten Peliriskit.</p>
<h2>Asiakaspalvelu ja tuki – Kuinka saada apua?</h2>
<p>Hypp1s Suomi tarjoaa asiakaspalvelua 24/7. Live‑chat on nopein tapa saada apua, ja vastausaika on yleensä alle 30 sekuntia. Sähköpostituki on saatavilla myös, ja vastaukset tulevat yleensä kahden tunnin sisällä. Jos puhut suomeksi, voit valita kielen chat‑ikkunassa – tuki on paikallisesti koulutettua.</p>
<p>Yleisiä kysymyksiä käsitellään kattavassa FAQ‑osiosta, joka kattaa rekisteröitymisen, bonukset, maksut ja turvallisuus. Jos ongelma jatkuu, voit pyytää puhelintukea, jossa asiakasneuvoja voi tarkistaa tilisi tiedot suoraan puhelimen kautta.</p>
<h2>Vertailutaulukko – Hypp1s Suomi vs. muut suomalaiset kasinot</h2>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Ominaisuus</th>
<th>Hypp1s Suomi</th>
<th>Kilpailija A</th>
<th>Kilpailija B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lisenssi</td>
<td>Maltan Gaming Authority</td>
<td>UK Gambling Commission</td>
<td>Estonia Gaming Board</td>
</tr>
<tr>
<td>Tervetulobonus</td>
<td>100 % / 200 € + 50 kiera</td>
<td>150 % / 300 €</td>
<td>200 % / 250 €</td>
</tr>
<tr>
<td>Kierrätysvaatimus</td>
<td>30×</td>
<td>40×</td>
<td>35×</td>
</tr>
<tr>
<td>Instant payout</td>
<td>Kyllä (Trustly, Skrill)</td>
<td>Ei</td>
<td>Kyllä (Neteller)</td>
</tr>
<tr>
<td>Maksutavat</td>
<td>Verkkomaksu, kortit, e‑lompakot</td>
<td>Vain kortit</td>
<td>Verkkomaksu, kortit</td>
</tr>
<tr>
<td>Mobiilisovellus</td>
<td>Kyllä (iOS & Android)</td>
<td>Kyllä (iOS)</td>
<td>Ei</td>
</tr>
</tbody>
</table>
<h2>Lopuksi – Onko Hypp1s Suomi sinulle?</h2>
<p>Jos arvostat nopeita talletuksia, selkeää bonuksia ja suomenkielistä tukea, Hypp1s Suomi on erinomainen valinta. Sivusto tarjoaa kattavan pelivalikoiman sekä casino‑ että sportsbook</p>
<p>Liity nyt Hypp1s Suomi -kasinolle ja aloita pelaaminen heti <a href="https://hypp1s.com/">https://hypp1s.com/</a>!</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/hypp1s-suomi-rekisteroitymisvaiheet-helppo-opas-aloittelijoille/">Hypp1s Suomi rekisteröitymisvaiheet – helppo opas aloittelijoille</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Pike login review overview – Canadian guide to quick access</title>
<link>https://edusehat.com/en/pike-login-review-overview-canadian-guide-to-quick-access</link>
<guid>https://edusehat.com/en/pike-login-review-overview-canadian-guide-to-quick-access</guid>
<description><![CDATA[ Pike Login: Practical Guidance for Canadian Players What is Pike and Why You Need a Pike Login If you’ve been browsing the Canadian gambling scene, you’ve probably seen 
The post Pike login review overview – Canadian guide to quick access appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/iaoZS7206Mc/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pike, login, review, overview, –, Canadian, guide, quick, access</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/iaoZS7206Mc/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Pike Login: Practical Guidance for Canadian Players</h1>
<h2>What is Pike and Why You Need a Pike Login</h2>
<div data-affgun-media="video"></div>
<p>If you’ve been browsing the Canadian gambling scene, you’ve probably seen the name “Pike” pop up alongside big‑ticket bonuses and live‑dealer tables. Pike is an online casino and sportsbook that targets North‑American players with a mix of slots, table games and a full‑featured sports betting platform. To enjoy any of that, a <strong>pike login</strong> is mandatory – it’s the gateway that ties your personal details, payment methods and bonus entitlements together.</p>
<p>For most newcomers, the biggest hurdle isn’t the games, it’s simply figuring out how to log in the first time. This guide cuts through the fluff and walks you through every step, from registration to troubleshooting, with a focus on what matters to Canadian users: fast deposits, responsible gambling tools and solid customer support.</p>
<h2>How to Create a Pike Account – Step‑by‑Step</h2>
<p>Before you can even think about a <em>pike login</em>, you need a registered account. The registration flow is intentionally short, but it still asks for a few pieces of information that can trip up first‑timers.</p>
<ul>
<li>Navigate to the official homepage and click “Register”.</li>
<li>Enter your full name, a valid Canadian email address and a strong password (mix letters, numbers and a symbol).</li>
<li>Select your province – Pike only accepts players from provinces where online gambling is regulated.</li>
<li>Provide a phone number for two‑factor authentication (2FA). You’ll receive a code via SMS.</li>
<li>Agree to the terms, confirm you’re 19+ (or the legal age in your province), and submit.</li>
</ul>
<p>Within minutes you’ll get a confirmation email. Click the link, verify your phone code, and you’re ready for the first <strong>pike login</strong>. Remember, the account stays dormant until you make a deposit, so plan your payment method before you log in for the first time.</p>
<h2>Pike Login Process – What to Expect</h2>
<p>The actual login page is clean: a field for your email/username, a password box, and an optional “Remember me” tick box. Canadian players often enable the remember feature on personal devices for convenience, but on shared computers it’s safer to leave it unchecked.</p>
<p>After you hit “Log In”, Pike may prompt you for a one‑time security code sent to your phone. This 2FA step is mandatory for the first login from a new device and helps keep your bankroll secure. Once you’re in, the dashboard shows your balance, active bonuses, and quick links to the casino, sportsbook, and mobile app download.</p>
<h2>Common Login Issues & Troubleshooting</h2>
<p>Even with a straightforward process, things can go sideways. Below are the most frequent hiccups Canadian users report, plus quick fixes.</p>
<ol>
<li><strong>Forgotten password:</strong> Click “Forgot password” on the login page, enter your email, and follow the reset link. The email may land in your spam folder, so check there.</li>
<li><strong>Blocked by province:</strong> If you’re from a jurisdiction where online gambling isn’t licensed, Pike will block the login. The only remedy is to use a province‑approved alternative.</li>
<li><strong>Two‑factor code not received:</strong> Verify your phone number is correct, and ensure you have good mobile coverage. You can also request a voice call instead of SMS.</li>
</ol>
<p>If none of these solve the problem, contact support (see the section below) with a screenshot of the error message. They usually respond within an hour during business hours.</p>
<h2>Security, Verification, and Canadian Regulations</h2>
<p>Pike takes KYC (Know Your Customer) seriously. After your first <strong>pike login</strong>, you’ll be asked to upload a government‑issued ID (driver’s licence or passport) and a proof‑of‑address document such as a utility bill. This step unlocks higher withdrawal limits and faster payouts.</p>
<p>The platform is licensed by the Malta Gaming Authority and also holds a Canadian remote‑gaming licence where applicable. Encryption is 128‑bit SSL, the same standard banks use, so your personal data and payment info stay encrypted end‑to‑end.</p>
<h2>Payments, Bonuses, and Withdrawal After Login</h2>
<p>Once you’ve logged in, the next big decision is how to fund your account. Canadian players have a solid selection of deposit methods, each with its own speed and fee structure.</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Deposit Method</th>
<th>Processing Time</th>
<th>Typical Fees</th>
<th>Bonus Eligibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interac e‑Transfer</td>
<td>Instant</td>
<td>None</td>
<td>Yes – 100% match up to $500</td>
</tr>
<tr>
<td>Visa / MasterCard</td>
<td>Instant</td>
<td>1.5% (may be waived)</td>
<td>Yes – 150% match up to $300</td>
</tr>
<tr>
<td>PayPal</td>
<td>Instant</td>
<td>2% (first deposit free)</td>
<td>Yes – 200% match up to $200</td>
</tr>
<tr>
<td>Bank Transfer (EFT)</td>
<td>1‑2 business days</td>
<td>None</td>
<td>Yes – 100% match up to $400</td>
</tr>
</tbody>
</table>
<p>All welcome bonuses come with wagering requirements of 30x the bonus amount. Keep an eye on the “Terms & Conditions” tab after you claim a bonus – it spells out which games count toward wagering and the time limit (usually 30 days).</p>
<h2>Mobile Experience & Pike App Login</h2>
<p>Canada’s gaming audience is increasingly mobile, and Pike offers a dedicated iOS/Android app. The app uses the same <strong>pike login</strong> credentials as the desktop site, but it adds fingerprint or Face ID authentication for quicker access.</p>
<p>If you prefer not to download the app, the responsive web version works just fine on smartphones. The layout auto‑adjusts, and you’ll still see the live casino lobby, sports betting odds, and your personal balance without any loss of functionality.</p>
<h2>Customer Support and Responsible Gambling</h2>
<p>Good support can turn a frustrating login problem into a quick resolution. Pike offers 24/7 live chat, an email ticket system, and a toll‑free Canadian number (1‑800‑555‑PIKE). When you reach out, have your account email and the exact error message ready – it speeds up the process.</p>
<p>Responsible gambling tools are built into the account dashboard. You can set deposit limits, self‑exclude for a chosen period, or request a permanent ban. These controls are available immediately after you log in, and the support team will verify your identity before any limit changes are applied.</p>
<h2>Final Thoughts – Getting Started with Your Pike Login</h2>
<p>The biggest barrier to enjoying Pike’s casino and sportsbook is simply getting past the login screen. Follow the steps outlined above, keep your verification documents handy, and choose a deposit method that matches your speed preferences. Once you’re inside, the platform’s welcome bonus, live dealer tables and Canadian‑focused sports markets become instantly available.</p>
<p>Ready to try it yourself? Head over to the official site, create your account and experience the smooth <strong>pike login</strong> process first‑hand: <a href="https://pike-casino-ca.net/">https://pike-casino-ca.net/</a>.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/pike-login-review-overview-canadian-guide-to-quick-access/">Pike login review overview – Canadian guide to quick access</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Casoola app – betaalmethoden, iDEAL en snelle opnames voor Nederlandse spelers</title>
<link>https://edusehat.com/en/casoola-app-betaalmethoden-ideal-en-snelle-opnames-voor-nederlandse-spelers</link>
<guid>https://edusehat.com/en/casoola-app-betaalmethoden-ideal-en-snelle-opnames-voor-nederlandse-spelers</guid>
<description><![CDATA[ Casoola app: Praktische gids voor Nederlandse spelers Wat is de Casoola app en hoe werkt hij? De Casoola app is de mobiele versie van het online casino‑platform, speciaal 
The post Casoola app – betaalmethoden, iDEAL en snelle opnames voor Nederlandse spelers appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/v6UPYL2axq4/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Casoola, app, –, betaalmethoden, iDEAL, snelle, opnames, voor, Nederlandse, spelers</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/v6UPYL2axq4/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<article>
<h1>Casoola app: Praktische gids voor Nederlandse spelers</h1>
<h2>Wat is de Casoola app en hoe werkt hij?</h2>
<div data-affgun-media="video"></div>
<p>De <strong>Casoola app</strong> is de mobiele versie van het online casino‑platform, speciaal ontwikkeld voor iOS‑ en Android‑apparaten. Je downloadt de app rechtstreeks vanuit de App Store of Google Play en logt vervolgens in met je bestaande account, of je maakt een nieuw profiel aan binnen een paar minuten. Dankzij een gestroomlijnde interface vind je meteen de populairste gokkasten, live casino‑tafels en sportweddenschappen, zonder dat je een apart webbrowser‑venster hoeft te openen. De app maakt gebruik van HTML5‑technologie, waardoor de graphics scherp blijven en de laadtijden kort zijn, zelfs op een gemiddelde 4G‑verbinding.</p>
<p>Voor Nederlandse spelers is de <em>casoola app</em> bovendien volledig vertaald naar het Nederlands, met lokale valuta en betalingsopties die je gewend bent. De navigatie is intuïtief: een tabblad onderaan geeft je snel toegang tot “Spelen”, “Bonussen”, “Wallet” en “Support”. Deze structuur voorkomt dat je verdwaalt in eindeloze menu’s en zorgt ervoor dat je in een paar klikken kunt beginnen met inzetten. Veel gebruikers geven aan dat de app zich net zo betrouwbaar voelt als de desktopversie, maar dan met het extra gemak van mobiel spelen.</p>
<h2>Aanmelden en registratie via de app</h2>
<p>Een vlotte registratie is cruciaal, zeker als je direct wilt profiteren van de welkomstbonus. De app vraagt alleen de basisgegevens: naam, e‑mail, geboortedatum en een sterk wachtwoord. Na het invoeren van deze informatie krijg je een bevestigingscode per sms of e‑mail, waarmee je je account activeert. Het hele proces duurt doorgaans minder dan drie minuten, en je kunt meteen je eerste storting doen.</p>
<h3>Stapsgewijze registratie</h3>
<ul>
<li>Open de Casoola app en tik op “Registreren”.</li>
<li>Vul je persoonlijke gegevens in en bevestig je leeftijd (je moet 18 jaar of ouder zijn).</li>
<li>Kies een betaalmethode en voer een eerste storting van minimaal €10 in.</li>
<li>Ontvang de verificatiecode, voer deze in en voltooi je account.</li>
<li>Claim de welkomstbonus via het bonus‑overzicht in de app.</li>
</ul>
<h2>Bonussen en promoties – wat kun je verwachten?</h2>
<p>De <strong>casoola app</strong> biedt een reeks aantrekkelijke bonussen, waarvan de welkomstbonus het meest opvallend is. Nieuwe spelers ontvangen een matchbonus op hun eerste storting plus een aantal gratis spins, waardoor de eerste speelsessie extra spannend wordt. Naast de welkomstbonus zijn er regelmatig reload‑bonussen, cash‑back‑acties en speciale promoties rond feestdagen. Houd altijd de “Promoties”‑pagina in de app in de gaten; hier staan de actuele voorwaarden en de exacte wagering requirements.</p>
<p>Om de verschillende aanbiedingen duidelijk te vergelijken, vind je hieronder een overzichtstabel. Let vooral op het aantal keren dat je de bonus moet inzetten (wagering requirements) en de maximale uitbetaling, zodat je niet voor verrassingen komt te staan.</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Bonus</th>
<th>Matchpercentage</th>
<th>Gratis spins</th>
<th>Wagering requirements</th>
<th>Max. uitbetaling</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welkomstbonus</td>
<td>100 %</td>
<td>50</td>
<td>30 x bonus</td>
<td>€500</td>
</tr>
<tr>
<td>Reload bonus (week 2)</td>
<td>50 %</td>
<td>20</td>
<td>25 x bonus</td>
<td>€200</td>
</tr>
<tr>
<td>Cashback vrijdag</td>
<td>10 % van verlies</td>
<td>–</td>
<td>0 x (direct)</td>
<td>€150</td>
</tr>
</tbody>
</table>
<p>Vergeet niet dat elke bonus onderhevig is aan de algemene voorwaarden, inclusief een minimale storting en een tijdslimiet voor het inzetten van de bonus. Door de voorwaarden goed te lezen, kun je de maximale waarde uit je spel halen zonder onnodige teleurstelling.</p>
<h2>Betaalmethoden & opnames in de app</h2>
<p>Een van de sterke punten van de <strong>casoola app</strong> is de ruime keuze aan betaalmethoden die specifiek voor Nederlandse spelers zijn geoptimaliseerd. Je kunt eenvoudig een storting doen met iDEAL, creditcards, en diverse e‑wallets zoals Skrill en Neteller. De meeste stortingen worden direct verwerkt, waardoor je binnen enkele seconden kunt beginnen met spelen. Bij het kiezen van een betaalmethode is het verstandig om rekening te houden met eventuele transactiekosten; iDEAL is meestal gratis, terwijl sommige e‑wallets een kleine vergoeding vragen.</p>
<h3>Beschikbare betaalopties</h3>
<ul>
<li><strong>iDEAL</strong> – directe verwerking, geen kosten.</li>
<li><strong>Visa / MasterCard</strong> – snelle creditcardbetalingen, kleine vergoeding mogelijk.</li>
<li><strong>Skrill</strong> – veilig, geschikt voor spelers die anonimiteit waarderen.</li>
<li><strong>Neteller</strong> – vergelijkbaar met Skrill, vaak gebruikt voor snelle opnames.</li>
<li><strong>Bankoverschrijving</strong> – hogere limieten, verwerking tot 24 uur.</li>
</ul>
<p>Opnames worden net zo veilig behandeld. Na het indienen van een opnameaanvraag via de “Wallet”‑sectie, wordt je verzoek meestal binnen 24 uur verwerkt, afhankelijk van de gekozen methode. iDEAL‑opnames zijn in de praktijk de snelste, vaak binnen enkele uren, terwijl e‑wallets meestal binnen één werkdag klaar zijn. Houd er rekening mee dat je eerst een KYC‑verificatie moet afronden voordat je grote bedragen kunt opnemen.</p>
<h2>Veiligheid, licentie en verantwoorde speelopties</h2>
<p>Casoola opereert onder een licentie van de Malta Gaming Authority (MGA) en voldoet aan de strenge Nederlandse Wet op Kansspelen dankzij een Nederlandse vergunning. Deze licentie garandeert dat de spellen eerlijk zijn, dat je persoonsgegevens beschermd worden en dat er een duidelijk klachtenproces bestaat. De <strong>casoola app</strong> maakt gebruik van SSL‑encryptie, zodat al je bankgegevens en persoonlijke informatie versleuteld worden verzonden.</p>
<p>Verantwoord gokken staat centraal. In de app vind je een “Responsible Gaming”‑sectie waar je limieten kunt instellen voor stortingen, verliezen en speeltijd. Daarnaast kun je een zelfuitsluiting aanvragen, wat je tijdelijk of permanent uitschakelt van deelname aan alle casinospellen. Deze tools zijn vooral nuttig voor beginners die hun speelgedrag in de gaten willen houden en voorkomen dat het uit de hand loopt.</p>
<h2>Live casino en sportweddenschappen op mobiel</h2>
<p>Naast de klassieke slots biedt de <strong>casoola app</strong> een uitgebreid live casino‑aanbod met echte dealers, blackjack, roulette en baccarat. De videostreams zijn van hoge kwaliteit en passen zich automatisch aan de schermgrootte van je telefoon aan. Veel live spellen hebben een redelijk hoge RTP (Return to Player) en een gematigde volatiliteit, waardoor ze geschikt zijn voor zowel casual als serieuze spelers.</p>
<p>Voor sportliefhebbers is er een geïntegreerde sportsbook‑module waar je kunt inzetten op voetbal, tennis, e‑sports en meer. De odds worden in real‑time geüpdatet en je kunt zelfs live weddenschappen plaatsen terwijl de wedstrijd nog gaande is. Dankzij de snelle verwerking van inzetten en de mogelijkheid om direct uit te betalen, biedt de app een naadloze ervaring voor zowel casino‑ als sportweddenschappen.</p>
<h2>Veelgestelde vragen over de Casoola app</h2>
<ul>
<li><strong>Is de Casoola app beschikbaar voor iPhone en Android?</strong> Ja, je vindt de app gratis in de Apple App Store en Google Play Store.</li>
<li><strong>Kan ik met iDEAL storten en opnemen?</strong> Storten met iDEAL is direct; opnames via iDEAL duren meestal enkele uren.</li>
<li><strong>Hoe snel wordt mijn bonus uitbetaald?</strong> Na het voldoen aan de wagering requirements en een succesvolle verificatie wordt de bonus binnen 24 uur uitbetaald.</li>
<li><strong>Is er klantenservice beschikbaar?</strong> De app biedt 24/7 live chat en een e‑mailsupport, beide in het Nederlands.</li>
<li><strong>Waar vind ik de licentie‑informatie?</strong> In het menu onder “Over ons” staat de MGA‑licentie en de Nederlandse vergunning vermeld.</li>
</ul>
<p>Wil je zelf de Casoola app uitproberen of meer details lezen over de huidige promoties, bezoek dan de officiële</p>
</article>
<p>Download de Casoola app nu via <a href="https://casolacasino.com/nl/">https://casolacasino.com/nl/</a> en profiteer van de beste bonussen!</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/casoola-app-betaalmethoden-ideal-en-snelle-opnames-voor-nederlandse-spelers/">Casoola app – betaalmethoden, iDEAL en snelle opnames voor Nederlandse spelers</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>SainiRS6 suomi login: yleiskatsaus ja vaihtoehdot</title>
<link>https://edusehat.com/en/sainirs6-suomi-login-yleiskatsaus-ja-vaihtoehdot</link>
<guid>https://edusehat.com/en/sainirs6-suomi-login-yleiskatsaus-ja-vaihtoehdot</guid>
<description><![CDATA[ SainiRS6 Suomi – Käytännön opas sainirs6 suomi login Mikä on SainiRS6 ja miten sainirs6 suomi login toimii? SainiRS6 on suomalaisille suunnattu nettikasino- ja vedonlyöntialusta, joka on saanut nopeasti 
The post SainiRS6 suomi login: yleiskatsaus ja vaihtoehdot appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/mt7YoauyR84/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>SainiRS6, suomi, login:, yleiskatsaus, vaihtoehdot</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/mt7YoauyR84/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>SainiRS6 Suomi – Käytännön opas sainirs6 suomi login</h1>
<h2>Mikä on SainiRS6 ja miten sainirs6 suomi login toimii?</h2>
<div data-affgun-media="video"></div>
<p>SainiRS6 on suomalaisille suunnattu nettikasino- ja vedonlyöntialusta, joka on saanut nopeasti jalansijaa paikallisessa pelimarkkinassa. Palvelu tarjoaa sekä kasinopelejä että live-vedonlyöntiä, ja sen takana on lisensoitu toimija, jonka toimilupa on annettu Maltan peliviranomaiselta. Kun suomalainen käyttäjä avaa sivuston, ensimmäinen askel on suorittaa <strong>sainirs6 suomi login</strong> -kirjautuminen, jonka jälkeen kaikki ominaisuudet avautuvat.</p>
<p>Kirjautuminen on suunniteltu mahdollisimman helpoksi: käyttäjän tarvitsee vain syöttää rekisteröintivaiheessa antamansa sähköpostiosoite ja valitsema salasana. Jos olet jo rekisteröitynyt, voit käyttää samaa tietoa kirjautuaksesi sisään mobiililaitteella tai tietokoneella. Sivuston käyttöliittymä on täysin suomenkielinen, ja kaikki bonustarjoukset näytetään selkeästi kirjautumisen jälkeen.</p>
<h2>Rekisteröityminen ja ensimmäinen kirjautuminen (sainirs6 suomi login)</h2>
<p>Ensimmäinen askel on avata SainiRS6:n kotisivu ja klikata “Rekisteröidy” –painiketta. Tässä vaiheessa kysytään perusasiat: nimi, syntymäaika, osoite, sähköpostiosoite ja puhelinnumero. Tietojen tarkkuus on tärkeä, koska myöhemmin KYC‑tarkastus (Know Your Customer) tarkistaa henkilöllisyytesi ennen ensimmäistä nostoa.</p>
<p>Kun tiedot on syötetty, saat vahvistuslinkin sähköpostiisi. Klikkaa linkkiä, aseta vahva salasana ja olet valmis suorittamaan <strong>sainirs6 suomi login</strong>-toiminnon. Jos unohdat salasanan, “Unohditko salasanan?” –linkki palauttaa sen helposti sähköpostilla. Kirjautumisen jälkeen näet henkilökohtaisen dashboardin, jossa voit tarkastella saldoa, bonuksia ja viimeisimpiä vedonlyönti­tuloksia.</p>
<h2>Bonukset ja tervetulotarjoukset – mitä odottaa kirjautumisen jälkeen</h2>
<p>Kirjautumisen yhteydessä SainiRS6 palkitsee uudet pelaajat yleensä tervetulobonuksella, joka voi olla 100 % talletusbonus tai jopa ilmainen kierrospaketti. Usein bonukseen liitetään <em>wagering requirements</em> eli kierrätysvaatimus, esimerkiksi 30x bonussummasta. Tämä tarkoittaa, että ennen kuin voit nostaa bonuksen, sinun täytyy panostaa 30‑kertaisesti bonuksen arvo.</p>
<p>Bonuksia voi myös saada säännöllisesti, kuten “viikonloppu‑tapahtumabonus” tai “live‑kasino‑bonus”. Kannattaa pitää silmällä kampanjasivua, jossa kaikki tarjoukset on listattu aikajärjestyksessä. Muista aina lukea bonusehdot huolellisesti: kierrätysvaatimukset, maksiminostoraja ja mahdolliset pelirajoitukset voivat vaikuttaa lopulliseen voittoon.</p>
<h2>Maksutavat ja nostot – nopeus ja turvallisuus</h2>
<p>SainiRS6 tarjoaa laajan valikoiman talletus- ja nostomenetelmiä, jotka on optimoitu suomalaisille käyttäjille. Suosituimpia maksutapoja ovat verkkopankit, luottokortit ja mobiilimaksut, ja ne kaikki tukevat nopeaa käsittelyä. Kun teet talletuksen, se näkyy tililläsi välittömästi, kun taas nostot käsitellään yleensä 24–48 tunnin sisällä, riippuen valitsemastasi maksutavasta.</p>
<table border="1" cellpadding="5" cellspacing="0">
<caption>Suositellut talletusmenetelmät SainiRS6:ssä</caption>
<thead>
<tr>
<th>Menetelmä</th>
<th>Maksuaika</th>
<th>Kustannus</th>
<th>Hyväksytyt</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verkkopankki (Nordea, OP, etc.)</td>
<td>Välittömästi</td>
<td>0 €</td>
<td>Kyllä</td>
</tr>
<tr>
<td>Visa / Mastercard</td>
<td>Välittömästi</td>
<td>0 €</td>
<td>Kyllä</td>
</tr>
<tr>
<td>MobilePay</td>
<td>Välittömästi</td>
<td>0 €</td>
<td>Kyllä</td>
</tr>
<tr>
<td>Skrill</td>
<td>1–2 tuntia</td>
<td>0 €</td>
<td>Kyllä</td>
</tr>
</tbody>
</table>
<p>Kun nostat voitot, SainiRS6 suosittelee käyttämään samaa maksutapaa, jota käytit talletukseen, koska se nopeuttaa prosessia. Jos valitset pankkisiirron, nostojen käsittelyaika voi venyä 1–3 arkipäivään, mutta useimmat suomalaiset pankit hyväksyvät sen nopeasti. Muista tarkistaa, että tilisi on täysin vahvistettu, jotta nostot eivät jää jumiin KYC‑tarkastuksen takia.</p>
<h2>Mobiili‑ ja sovelluskokemus – pelaaminen puhelimella</h2>
<p>SainiRS6 on täysin responsiivinen, joten sen verkkosivut skaalautuvat automaattisesti älypuhelimelle tai tabletille. Jos haluat vieläkin sujuvamman pelikokemuksen, voit ladata <strong>SainiRS6‑sovelluksen</strong> sekä iOS‑ että Android‑laitteille. Sovelluksessa on kaikki tärkeimmät ominaisuudet: kirjautuminen, talletus, bonusten hallinta ja live‑kasino‑virta.</p>
<p>Mobiilikäyttäjille on erityisesti suunniteltu “yksi‑klikkaus‑talletus”, joka hyödyntää Google Pay‑ tai Apple Pay‑integraatioita. Tämä tekee talletuksista nopeita ja turvallisia, eikä sinun tarvitse erikseen syöttää korttitietoja. Lisäksi push‑ilmoitukset pitävät sinut ajan tasalla uusimmista bonuksista ja live‑vedonlyöntikierroksista.</p>
<h2>Tuki ja turvallisuus – miten varmistetaan turvallinen kirjautuminen</h2>
<p>Turvallisuus on SainiRS6:n ydin, ja kirjautumisprosessiin on sisällytetty kaksivaiheinen tunnistautuminen (2FA). Voit aktivoida 2FA‑sähköpostilla tai autentikaattorisovelluksella, jolloin jokainen kirjautumisyritys vaatii lisäkoodin. Tämä suojaa tiliäsi mahdollisilta hakkerointiyrityksiltä.</p>
<p>Jos kohtaat ongelmia kirjautumisessa, asiakaspalvelu on saatavilla 24/7 live‑chat‑ ja sähköpostipalvelun kautta. He auttavat muun muassa salasana‑ongelmissa, maksujen tarkistamisessa ja KYC‑tarkistusten läpikäymisessä. Voit myös tutustua laajaan tukikeskukseen, jossa on artikkeleita aiheesta “sainirs6 suomi login” sekä “tilin vahvistus”.</p>
<h2>Vastuullinen pelaaminen ja lisäpalvelut</h2>
<p>SainiRS6 on sitoutunut vastuulliseen pelaamiseen ja tarjoaa useita työkaluja, joilla voit hallita pelitottumuksiasi. Rekisteröityessäsi voit asettaa talletusrajan, pelikerran pituuden tai jopa itse asettaa peliaikakatkaisuja. Jos koet, että pelikäyttäytymisesi on hallitsematonta, voit myös sulkea tilisi tilapäisesti tai pysyvästi.</p>
<p>Lisäksi sivustolla on oma “Vastuullinen pelaaminen” -osio, jossa on linkkejä Suomen pelirahoitus‑yhteistyökumppaneihin ja mahdollisuus ottaa yhteyttä riippumattomaan tukipalveluun. Kun pelaat SainiRS6:ssä, voit siis olla varma, että sekä rahasi että hyvinvointisi ovat turvassa.</p>
<p>Jos haluat tutustua tarkemmin kaikkiin ominaisuuksiin ja aloittaa pelaamisen, käy suoraan <a href="https://sainirs6.com/">SainiRS6</a> -sivustolla ja kirjaudu sisään omilla tiedoillasi.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/sainirs6-suomi-login-yleiskatsaus-ja-vaihtoehdot/">SainiRS6 suomi login: yleiskatsaus ja vaihtoehdot</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>NaoBet : avis complet – inscription, bonus, paiements et jeux en ligne</title>
<link>https://edusehat.com/en/naobet-avis-complet-inscription-bonus-paiements-et-jeux-en-ligne</link>
<guid>https://edusehat.com/en/naobet-avis-complet-inscription-bonus-paiements-et-jeux-en-ligne</guid>
<description><![CDATA[ Tout savoir sur NaoBet : guide pratique pour les joueurs français Qu’est‑ce que NaoBet ? Présentation du casino et du bookmaker NaoBet se positionne comme une plateforme hybride qui 
The post NaoBet : avis complet – inscription, bonus, paiements et jeux en ligne appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/u564lza4m-U/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>NaoBet, avis, complet, –, inscription, bonus, paiements, jeux, ligne</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/u564lza4m-U/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Tout savoir sur NaoBet : guide pratique pour les joueurs français</h1>
<h2>Qu’est‑ce que NaoBet ? Présentation du casino et du bookmaker</h2>
<div data-affgun-media="video"></div>
<p>NaoBet se positionne comme une plateforme hybride qui propose à la fois un casino en ligne complet et un service de paris sportifs. Le site a été lancé en 2021 et cible principalement les marchés européens, avec une offre française bien adaptée aux habitudes de jeu locales.</p>
<p>La licence principale provient de Malte (MGA) et a été complétée par une autorisation de la Commission de jeu française, ce qui garantit une conformité aux exigences de sécurité et de protection des joueurs français. En pratique, cela signifie que les joueurs bénéficient d’un cadre juridique solide tout en profitant d’une large sélection de jeux.</p>
<h2>Inscription et vérification sur NaoBet</h2>
<p>Le processus d’inscription est volontairement simple : il suffit de cliquer sur le bouton « S’inscrire », de renseigner votre adresse e‑mail, un mot de passe et de choisir votre devise (EUR). En moins de deux minutes, le compte est créé et vous avez immédiatement accès à la version de démonstration du casino.</p>
<p>La vérification d’identité (KYC) intervient uniquement lors de la première demande de retrait. Vous devrez fournir une pièce d’identité officielle, un justificatif de domicile et, parfois, une preuve de paiement. Ce processus, bien que court, est indispensable pour prévenir la fraude et garantir la sécurité de vos fonds.</p>
<h2>Bonus de bienvenue et promotions sur NaoBet</h2>
<p>Le premier avantage à ne pas manquer est le bonus de bienvenue « 100 % jusqu’à 200 € + 30 tours gratuits ». Les 30 tours sont généralement applicables aux machines à sous les plus populaires comme <em>Starburst</em> ou <em>Book of Dead</em>. Le bonus est soumis à un <strong>wagering requirement</strong> de 30x, ce qui est moyen comparé aux standards du secteur.</p>
<p>En plus du premier dépôt, NaoBet propose un programme de fidélité à plusieurs niveaux, des cashbacks hebdomadaires et des promotions ponctuelles sur le sportsbook (par exemple, “pariez 10 € et recevez un pari gratuit de 5 €”). Ces offres sont accessibles depuis le tableau de bord du joueur et sont régulièrement mises à jour.</p>
<h2>Méthodes de paiement et rapidité des retraits</h2>
<p>Le portefeuille de NaoBet comprend les options classiques : cartes bancaires (Visa, Mastercard), portefeuilles électroniques (Skrill, Neteller), virements bancaires et cartes prépayées (Paysafecard). Les dépôts sont instantanés, alors que les retraits sont traités selon la méthode choisie : les e‑wallets offrent généralement un délai de 24 h, les cartes bancaires de 2 à 3 jours ouvrés, et les virements de 3 à 5 jours.</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Moyen de paiement</th>
<th>Dépôt (temps)</th>
<th>Retrait (temps)</th>
<th>Frais éventuels</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visa / Mastercard</td>
<td>Instantané</td>
<td>2‑3 jours ouvrés</td>
<td>0 €</td>
</tr>
<tr>
<td>Skrill / Neteller</td>
<td>Instantané</td>
<td>24 h</td>
<td>0‑2 €</td>
</tr>
<tr>
<td>Virement bancaire</td>
<td>1‑2 jours ouvrés</td>
<td>3‑5 jours ouvrés</td>
<td>Gratuit</td>
</tr>
<tr>
<td>Paysafecard</td>
<td>Instantané</td>
<td>Non disponible</td>
<td>0 €</td>
</tr>
</tbody>
</table>
<p>Notez que NaoBet applique un contrôle supplémentaire sur les retraits supérieurs à 2 000 €, afin de respecter les normes de lutte contre le blanchiment d’argent.</p>
<h2>Jeux disponibles : casino, live et paris sportifs</h2>
<p>Le catalogue de NaoBet comprend plus de 2 000 titres, fournis par des fournisseurs reconnus tels que NetEnt, Microgaming et Evolution Gaming. Vous trouverez des machines à sous classiques, des jackpots progressifs, des jeux de table (blackjack, roulette) ainsi qu’un véritable <strong>live casino</strong> animé par des croupiers en temps réel.</p>
<p>Le sportsbook couvre les principaux championnats européens de football, le tennis, le basket‑ball et même des sports moins traditionnels comme le e‑sport. Les cotes sont généralement compétitives, avec une marge moyenne légèrement inférieure à la moyenne du marché, ce qui rend les paris plus attractifs.</p>
<h2>Expérience mobile et application NaoBet</h2>
<p>Le site s’adapte parfaitement aux navigateurs mobiles grâce à un design responsive. De plus, NaoBet propose une application native disponible sur Android et iOS, que vous pouvez télécharger directement depuis le site après inscription. L’app offre toutes les fonctionnalités du bureau, y compris les dépôts instantanés, les jeux en live et les paris en temps réel.</p>
<p>Un point fort de l’application est la fonction « push notification » qui vous alerte sur les nouveaux bonus, les matchs en cours et les promotions limitées. Cela permet de ne jamais rater une opportunité, même quand vous êtes en déplacement.</p>
<h2>Sécurité, licence et jeu responsable</h2>
<p>La plateforme utilise le chiffrement SSL 128‑bits, identique à celui des banques, pour protéger toutes les transmissions de données. Les serveurs sont hébergés dans des data‑centers certifiés ISO 27001, ce qui assure une disponibilité et une intégrité maximales.</p>
<p>En matière de jeu responsable, NaoBet propose des outils d’auto‑exclusion, des limites de dépôt et de mise, ainsi qu’une page d’aide détaillée sur la prévention de l’addiction. Vous pouvez aussi contacter le service d’assistance dédié au jeu responsable 24 h/24.</p>
<h2>Service client et assistance</h2>
<p>Le support de NaoBet est disponible via chat en direct, e‑mail et téléphone. Le chat fonctionne 24 h/24 et les réponses sont généralement fournies en moins de deux minutes. L’équipe parle français, anglais et plusieurs autres langues européennes.</p>
<p>En cas de problème avec un retrait ou une vérification, vous pouvez ouvrir un ticket directement depuis votre tableau de bord. La plupart des demandes sont résolues en moins de 24 h, ce qui est un bon indicateur de la qualité du service.</p>
<h2>Conclusion pratique pour les joueurs français</h2>
<p>Si vous recherchez un site qui combine casino, live casino et paris sportifs avec une interface claire, NaoBet répond à la plupart des exigences des joueurs français. Le bonus de bienvenue est intéressant, les méthodes de paiement sont variées et la licence européenne offre une protection fiable.</p>
<p>Pour commencer, il suffit de créer votre compte, de profiter du bonus de 100 % et de tester les jeux qui vous plaisent. N’oubliez pas de vérifier les <em>wagering requirements</em> et de jouer de manière responsable. Vous pouvez accéder directement à la plateforme en suivant ce lien : <a href="https://casino-naobets.com/fr/">https://casino-naobets.com/fr/</a>.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/naobet-avis-complet-inscription-bonus-paiements-et-jeux-en-ligne/">NaoBet : avis complet – inscription, bonus, paiements et jeux en ligne</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Goa’s bid for a bigger role in global pharma </title>
<link>https://edusehat.com/en/goas-bid-for-a-bigger-role-in-global-pharma</link>
<guid>https://edusehat.com/en/goas-bid-for-a-bigger-role-in-global-pharma</guid>
<description><![CDATA[ 
From CDMO expansion to digital quality systems, the Goa Pharma Summit, hosted by Express Pharma, explored the capabilities Goa needs to move into higher-value pharma activities, reports Neha Aathavale 
The post Goa’s bid for a bigger role in global pharma  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12131847/EP_Goa-Pharma-Summit.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Goa’s, bid, for, bigger, role, global, pharma </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12131847/EP_Goa-Pharma-Summit.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12131847/EP_Goa-Pharma-Summit.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/12131847/EP_Goa-Pharma-Summit-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>India has built its pharma strength on two formidable foundations: the ability to manufacture at scale and the capacity to reach markets across the world. In recent years, however, it has become increasingly clear that scale alone cannot determine how far the industry can go. The challenge is to keep pace with the shifts while moving beyond volume to create greater value. </span></p>
<p><span>For Goa, this challenge presents an opportunity to build on what it already does well. The state has an established pharma manufacturing base and a strong export orientation. The next step is to build capabilities in research and development (R&D), contract development and manufacturing organisations (CDMOs), advanced manufacturing and innovation. These priorities formed the backdrop of the Goa Pharma Summit, which brought together pharma industry leaders, policymakers, manufacturers, researchers and academic representatives to examine what it will take for Goa to move up the value chain and strengthen its position in the global pharma industry.</span></p>
<p><strong>Goa’s CDMO opportunity </strong></p>
<p><span>One area of opportunity lies in identifying where Goa can offer greater value to global pharma companies beyond manufacturing scale. Dr Praveen Khullar, Executive Director, VerGo Pharma Research Laboratories, emphasised the importance of building on the state’s export base while developing capabilities that would enable it to participate in more specialised development and manufacturing programmes. </span></p>
<p><span>This would mean moving from manufacturing as a standalone capability to building long-term partnerships with global companies. A focused approach to the CDMO market, particularly in complex formulations, specialty products and high-value, smaller-batch programmes, could help Goa address more specialised industry requirements and expand its role across the pharma value chain. </span></p>
<p><span>Reliability would be another part of this proposition. Continuity of supply, speed of formulations, advances in formulation development, processing technologies and analytical methods will play an important role in translating these ambitions into manufacturing capabilities. </span></p>
<p><strong>Advancing formulation technologies </strong></p>
<p><span>Against this backdrop, Manoj Bansal, Head of Business Development, Thermo Fisher Scientific India, discussed advancements in hot melt extrusion technology, focusing on instrumentation considerations and methodologies. The technology can improve the solubility and bioavailability of drugs, supporting formulation development from R&D through to manufacturing. </span></p>
<p><span>Bansal also highlighted the role of molecular spectroscopy in pharma workflows. Thermo Fisher Scientific’s portfolio includes Raman, near-infrared (NIR) spectroscopy and X-ray fluorescence (XRF), which enable rapid, non-destructive testing. These techniques support the analysis of materials and processes, while the integration of formulation technologies, spectroscopy, process analytical technology (PAT) and quality control systems can facilitate faster decision-making, regulatory compliance and manufacturing efficiency. </span></p>
<p><span>Beyond developing formulations and monitoring processes, controlling drug release is another consideration in product development. The choice of polymers and their proportions can influence release characteristics, allowing formulators to adjust drug-release profiles to specific requirements. </span></p>
<p><span>Krutik Prajapati, Manager (Techno Commercial), Vikram Thermo (India), discussed drugrelease modulation through DRUGCOAT RSPO/RLPO. Vikram Thermo’s DRUGCOAT RL/RS polymers enable controlled and extended drug release by adjusting polymer permeability and concentration. They can also be used in wet granulation to modulate release, offering a simpler processing approach with scope for improved scalability. Optimising the ratio of DRUGCOAT RSPO and RLPO further allows formulators to tailor release profiles to specific formulation needs. </span></p>
<p><span>Together, these approaches highlight the role of formulation technologies in translating research into manufacturing capabilities. However, moving towards higher-value products also involves considerations beyond the technical aspects of development. Pricing frameworks, investment decisions and the availability of specialised talent will influence how effectively Goa can capitalise on opportunities in complex generics and biologics. These questions came into focus during the first panel discussion at the summit. </span></p>
<p><strong>PPILT, patent cliffs and the biologics opportunity </strong></p>
<p><span>The first panel discussion, moderated by Dr Subrata Chakraborty, Founder, INOPHAR Consulting & Training, brought together Nilesh Hegu, Site Head – Goa II, Cipla; Dr Pankaj Kumar, VP/Head R&D & Director, Wallace Pharmaceuticals; Uttam Kadam, Sterile Head, Zydus Lifesciences, Goa; Dr Prabhat Dessai, Associate Professor & Assistant Director, Placement & Corporate Relations Cell, Parul University, Goa; and Prof (Dr) G Shaber Ali, Professor of Law and former Principal, V M Salgaocar College of Law, to examine whether Goa’s pricing model could support the next phase of pharma growth. </span></p>
<p><span>The key point of discussion was the role of PPILT, which combines procurement with negotiated pricing rather than operating as a standalone pricing policy. Its potential to influence investment decisions and attract new manufacturing opportunities must be considered alongside the interests of the pharma industry and the need for public transparency. Confidential pricing remains a challenge in this context, requiring a balance between commercial considerations and accountability.</span></p>
<p><span>The discussion also considered whether PPILT could help attract biologics manufacturing and technology transfer to Goa. As the industry responds to patent expiries and explores opportunities in more complex products, the state could benefit from investments that bring specialised manufacturing processes and technical capabilities. However, translating this potential into industrial growth would require more than a pricing mechanism. Complex generics, for instance, demand a different research and development approach, higher investment and advanced analytical capabilities. Developing these capabilities would be important for companies seeking to expand beyond conventional formulations. </span></p>
<p><span>Talent availability emerged as another consideration. As pharma manufacturing incorporates more specialised processes and technologies, the demand for skills is changing. Academia continues to face challenges in matching industry requirements, making closer collaboration between educational institutions and pharma companies important. Industry 4.0 and artificial intelligence are also reshaping manufacturing, increasing the need for talent equipped to work with evolving technologies and production systems. </span></p>
<p><span>The discussion highlighted the interdependence of pricing, investment, technical capabilities and talent development in shaping Goa’s pharma ambitions. For the state to capitalise on emerging opportunities in biologics and complex generics, its pricing framework will need to work alongside investments in R&D, manufacturing technology and specialised skills. But developing these capabilities is only part of the equation. </span></p>
<p><span>Their long-term value will also depend on how effectively companies translate them into products that meet international market needs and build a sustained presence beyond established export destinations. </span></p>
<p><strong>Diversifying India’s pharma exports </strong></p>
<p><span>This shift from building capabilities to converting them into market opportunities formed the basis of the next discussion. </span></p>
<p><span>Moderated by Mahesh Gurnasinghani, Executive Member, Goa Pharmaceutical Manufacturers’ Association (GPMA) and Visiting Faculty, Goa College of Pharmacy, the panel brought together Maneesh Madhukar Narkar, VP – Formulations, Centaur Pharmaceuticals; Pramod Poojari, Site Head – Warehouse – Manufacturing, Cipla; Hruday Jadhav, Associate VP – Analytical R&D, Micro Labs; Sandeep Kulkarni, Associate Director APAC Sourcing Global Procurement Category, Teva Pharmaceuticals; Niket Talauliker, Head of Site Quality, Sanofi India; and Himank Narvekar, DGM – BD & Strategy, VerGo Pharma Research Laboratories, to examine how India could identify its next export growth engines. </span></p>
<p><span>A key consideration was how India could translate its established manufacturing scale into greater value. While the country has developed the capacity to manufacture and supply medicines across international markets, the next phase of export growth may depend on its ability to develop products that require more specialised capabilities. Complex products and formulations could offer opportunities to move beyond competing primarily on volume, provided companies can build the technical expertise and manufacturing capabilities required to develop them. </span></p>
<p><span>This also changes how export diversification needs to be approached. Identifying new markets is only one part of the process; companies must also understand the requirements of those markets and develop products that address them. Market strategy and R&D, therefore, need to inform each other. Insights into demand, regulatory requirements and market-specific needs can help guide product development, while R&D capabilities can determine which opportunities a company is equipped to pursue. </span></p>
<p><span>Regulatory approval is an important step in entering an international market, but it does not, by itself, ensure sustained commercial presence. The ability to maintain supply, establish distribution and secure market acceptance also matters. Quality, in this context, needs to be built into product development from the outset rather than addressed only after a target market has been identified. Aligning quality requirements with product development and manufacturing can help companies prepare for the demands of their intended markets. </span></p>
<p><span>For Goa, these considerations point towards an opportunity to connect its manufacturing base with CDMOs, academic institutions and investment. Such collaboration could support the development of products and capabilities that respond to specific market requirements, while creating stronger links between research, manufacturing and commercial strategy. </span></p>
<p><span>The broader question, therefore, is no longer simply whether Goa can manufacture for international markets, but how it can participate in higher-value activities across the pharma value chain. Moving in this direction would require an export strategy that brings together product development, market intelligence, quality, supplychain reliability and ecosystem partnerships. Translating these priorities into practice will depend on how well companies embed them into their manufacturing operations, quality systems and workforce capabilities. </span></p>
<p><strong>From Panjim to the World: Goa’s export playbook</strong></p>
<p><span>This formed the focus of the summit’s final panel discussion, moderated by Dr Manoj Kumar Kashyap, Professor and Director, Research & Development, Parul University, Goa. The panel brought together Dr Pradeep Kumar Vishwakarma, Associate Director – COE Manufacturing Science and Technology Respiratory, Cipla; Dr Bhaskar Chauhan, Head R&D and Quality Management, Puniska Injectables; Sartaj Hanfi, Sr GM – Plant Head, Indoco Remedies; Vishwas J Desai, GM – Quality Assurance, Blue Cross Laboratories; Abhinay Ajgaonkar, DGM – Head of QA, Centaur Pharmaceuticals; and Urmila Deepak Naik, AGM, FDC Limited Goa (Unit III), to discuss the capabilities required to strengthen Goa’s position in international pharma markets. </span></p>
<p><span>A key consideration was the need to move beyond a compliance-led approach to quality. Passing audits is an important requirement, but sustained global competitiveness calls for organisations to remain prepared for scrutiny as part of their everyday operations. This means embedding quality into processes, systems and decision-making rather than treating inspections as isolated events. Such an approach can help companies strengthen operational consistency while responding to the expectations of international regulators and customers. </span></p>
<p><span>Technology is also changing how quality is managed. As pharma manufacturing becomes increasingly digital, quality systems can do more than maintain records. Digital tools can help organisations analyse data, identify deviations and translate findings into action. The shift towards data-led quality management, however, also brings a requirement for people who can interpret information and apply it to manufacturing decisions. With technology advancing faster than workforce skills, talent development could become a constraint on the industry’s ability to realise the full benefits of these systems. </span></p>
<p><span>Addressing this gap will require a stronger emphasis on practical exposure. The manufacturing shop floor can serve as an important learning environment, giving future professionals the opportunity to work with equipment, understand production processes and engage with real operational challenges. Hands-on experience can help bridge the gap between academic learning and the requirements of pharma manufacturing, particularly as plants adopt new technologies and processes. </span></p>
<p><span>The discussion also pointed to the need for Goa to build capabilities across a larger part of the pharma value chain, from R&D and technology transfer to commercial manufacturing. Expanding these capabilities would require companies to assess established practices critically and remain open to changing them when data and evidence support a better approach. Moving beyond legacy processes is particularly relevant in an environment where digitalisation, analytical capabilities and manufacturing technologies continue to evolve. </span></p>
<p><span>ld, collaboration between academia and industry must extend beyond formal agreements. Partnerships need to create practical opportunities for research, technical problem-solving and exposure to industrial requirements. By connecting academic expertise with manufacturing challenges, such collaborations could help develop the skills and capabilities needed to support innovation. </span></p>
<p><span>For Goa, strengthening its export position will therefore depend not only on meeting international quality requirements, but also on building organisations, technologies and talent capable of sustaining them. </span></p>
<p><span>A closer connection between quality management, digital systems, workforce development and industry-academia collaboration could help the state move towards a more integrated pharma ecosystem, with greater participation in R&D, technology transfer and higher value manufacturing. </span></p>
<p><strong>From scale to value </strong></p>
<p><span>For Goa’s pharma industry, the next phase of growth will depend on how effectively it connects manufacturing strength with innovation, technical expertise and global market requirements. This will require sustained investment in R&D, technology, talent and industry-academia collaboration, alongside a focus on quality and supply reliability. </span></p>
<p><span>The Goa Pharma Summit underscored that moving up the value chain is not a single step, but a coordinated effort to build capabilities that can support the state’s long-term role in the global pharma industry. </span></p>
<p> </p>
<p><strong><em>neha.aathavale@expressindia.com<br>
nehaaathavale75@gmail.com </em></strong></p>
<p>The post <a href="https://www.expresspharma.in/goas-bid-for-a-bigger-role-in-global-pharma/">Goa’s bid for a bigger role in global pharma </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From recommendation to reality: Why newborn screening needs funding now</title>
<link>https://edusehat.com/en/from-recommendation-to-reality-why-newborn-screening-needs-funding-now</link>
<guid>https://edusehat.com/en/from-recommendation-to-reality-why-newborn-screening-needs-funding-now</guid>
<description><![CDATA[ For the Sereno family, time has always been important. And for Lina Sereno, trusting her gut made all of the difference when it came […]
The post From recommendation to reality: Why newborn screening needs funding now appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/sereno-family2.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 04:30:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, recommendation, reality:, Why, newborn, screening, needs, funding, now</media:keywords>
<content:encoded><![CDATA[<p><span>For the Sereno family, time has always been important.</span></p>
<p><span>And for Lina Sereno, trusting her gut made all of the difference when it came to her two sons: Salvatore and Giovanni.</span></p>
<p><span>“</span><span>My older son, Salvatore, was diagnosed with metachromatic leukodystrophy (MLD) in October of 2009,” explains Sereno, “but it took approximately seven months to find out what was happening to him. I took him to six different doctors, and each one suggested that he had ADHD. I agreed to medication for two months. Instead of improving, he became worse.”</span></p>
<p><span>It was during this time that Sereno recalls the night her son Salvatore became dazed and unresponsive. “I notified his doctor, and that finally prompted the MRI that got us the MLD diagnosis,” she says. “All these years later, I believe he may have experienced a seizure.”</span></p>
<p><span>Shortly thereafter, Sereno got her younger son Giovanni tested as well and found that he too had MLD. His early diagnosis gave him access to early treatments that Salvatore never had the opportunity to get. “I know with all my heart that Giovanni is thriving today because of that early diagnosis and treatment,” says Sereno.</span></p>
<p><span>“The journey felt incredibly long and lonely,” Sereno recalls. “No parent should have to fight so hard to get answers while their child is losing precious time.”</span></p>
<p><span>As such, the Surge to Save Newborns Act (H.R. 10571), a bipartisan bill introduced in September has been introduced with the aim to close critical gaps in state-level infant health screenings so families like the Serenos don’t lose precious time. </span></p>
<p><span>To discuss both the Sereno family’s own personal journey, as well as the importance of passing H.R. 10571, Bio.News sat down with Lina Sereno.</span></p>
<h3>Newborn screening for rare disease is hope for families</h3>
<p><span>“The fact that a disease is rare makes </span><a href="https://bio.news/latest-news/advocate-explains-why-we-need-newborn-screening-advisory-committee/"><span>newborn screening</span></a><span> even more important,” explains Sereno. “Most parents have never heard of MLD until it affects their own family. By the time symptoms appear, it may be too late to prevent irreversible damage.”</span></p>
<p><span>It was 17 years ago when Salvatore and Giovanni were diagnosed, and the Sereno’s story shows just how impactful time (both gained and lost), and healthcare innovation have been to their family</span></p>
<p><span>“At that time, the only treatment option available to us was a bone marrow transplant,” Sereno says. “My husband and I made the best decisions we could for both of our sons based on the medical knowledge and treatment options available.”</span></p>
<p><span>Today, much more is understood about MLD—especially the importance of early intervention. While a new gene therapy has been approved for MLD the risk remains for children diagnosed after symptoms begin as some of the damage may already be irreversible. </span></p>
<p><span>“I wish I had known how drastically our lives would change,” Sereno says. “Raising two boys with MLD has been incredibly difficult, but it has also shown me the extraordinary strength of our family and the power of love. There have been challenges I never could have imagined, but there has also been so much joy and beauty.”</span></p>
<p><span>Following his bone marrow transplant, Giovanni has remained almost symptom-free for 17 years. “He goes to school, plays video games, has friends and experiences most of what other kids his age do,” Sereno says. </span></p>
<p><span>Unfortunately, for Salvatore, the delay in his diagnosis has had distinct effects.</span></p>
<p><span>“Salvatore’s disease progressed rapidly during his bone marrow transplant,” says Sereno. “He walked into the hospital and left fully disabled and dependent on a G-tube for nutrition.”</span></p>
<p><span>Today, Salvatore is dependent on his family for care. </span></p>
<p><span>“His story is why I want other families to have the opportunity that came too late for him,” says Sereno. “Even if newborn screening identifies just one child a year who can benefit from early treatment, it is worth it. That is one child, one family and an entire lifetime that could be changed.”</span></p>
<p><span>Rarity should never determine whether a child gets that chance, she says. Newborn screenings mean hope for families.</span></p>
<p><span>“Instead of constantly worrying about the unknowns of this disease, parents could have information, access to specialists and the opportunity to act early,” she continues. “Every family deserves that chance. No parent should have to learn that their child has a devastating disease only after symptoms appear and precious treatment time has been lost, when the possibility of treatment is either gone or would not be as beneficial.”</span></p>
<h3>From the RUSP decision to real-world screening</h3>
<p><span>MLD and Duchenne muscular dystrophy were added to the Recommended Uniform Screening Panel (RUSP) on December 16, 2025—a major milestone for families and advocates. However, a federal recommendation does not automatically provide states with the resources to implement it.</span></p>
<p><span>“Rather,” Sereno explains, “each state must take the necessary steps to add MLD to its newborn screening panel. That process may require legislative or regulatory action, laboratory validation, specialized equipment, staff training, clinical follow-up systems and additional funding.”</span></p>
<p><span>While the federal recommendation by RUSP is an important first step to resolving this issue, it is not enough if states cannot implement said recommendations in a timely and efficient manner.</span></p>
<p><span>“Scientific advances and new treatments are creating opportunities to identify and treat babies earlier than ever before,” explains Sereno. “But without adequate funding, states may not have the resources to implement these screenings in a timely manner.”</span></p>
<p><span>It doesn’t matter how many healthcare advancements are made if families can’t (or don’t know to) access them.</span></p>
<p><span>“For families who have spent years advocating for newborn screening, this decision to include MLD and Duchenne muscular dystrophy to the RUSP represents hope,” Sereno reminds. “It acknowledged that early detection matters and that babies should have the opportunity to be identified before symptoms appear.”</span></p>
<p><span>Historically, implementation of a newly recommended condition can take five to six years in many states, and in some cases, considerably longer, which ultimately translates to missed opportunities for early diagnosis and treatment.</span></p>
<p><span>“State laboratories may lack the funding, equipment, facilities or trained personnel needed to establish a new screening test,” she continues. “They must also develop testing protocols, validate results, coordinate confirmatory testing and establish pathways for referring affected newborns to specialists.”</span></p>
<p><span>This has translated to the inclusion of MLD and Duchenne muscular dystrophy varying from state-to-state, creating what caregivers refer to as the “birth lottery,” where two babies with the same condition can have very different opportunities simply because they were born in different states.</span></p>
<p><span>“The state-by-state approach is profoundly unfair,” says Sereno. “It is heartbreaking to know that the state in which a baby is born can determine whether a potentially devastating disease is detected early enough for treatment to make a difference.”</span></p>
<p><span>Newborn screening should not depend on a family’s ZIP code, financial resources or ability to advocate for their child. </span></p>
<p><span>“These are essential steps, but states should not have to face these challenges alone. Without dedicated resources and coordinated support, even a strong commitment to newborn screening can be delayed by financial and operational barriers,” Sereno adds. “Every newborn deserves equitable access to screening for conditions on the RUSP, and every state needs the resources to make that possible.”</span></p>
<p><span>“Our work is not finished,” explains Sereno. “We must now ensure that states move forward with implementation so that this recommendation translates into real access to screening for newborns across the country.”</span></p>
<h3>Surge to Save Newborns bill: Turning a federal recommendation into action</h3>
<p><span>The Surge to Save Newborns bill would allow the progress made through the RUSP to go beyond just the recommendation of addition of new diseases by requesting</span><span> $35 million a year for 5 years to ensure every state is screening for the 40 conditions on the RUSP plus 2 additional conditions not yet nominated.</span></p>
<p><span>“We need to have a coordinated national effort that brings together families, patient advocacy organizations, clinicians, laboratories, policymakers and other stakeholders to ensure that states have the support necessary to put recommended screenings into practice,” Sereno argues. “That means investing in laboratory capacity, testing technology, personnel, training and the infrastructure needed to identify affected newborns and connect them to timely follow-up care.”</span></p>
<p><span>Federal funding is a critical part of this solution and could help states move more quickly while promoting a more consistent and equitable approach to implementation nationwide, she says. </span></p>
<p><span>States should not have to choose between competing public health priorities or delay implementation because they cannot afford the necessary resources. </span></p>
<p><span>“Dedicated federal support could help accelerate implementation and reduce the disparities that currently exist across state lines,” Sereno explains. “This is an investment in prevention, early diagnosis and the future of our children. The cost of implementation must be weighed against the potentially devastating human and financial consequences of a missed or delayed diagnosis.”</span></p>
<h3>Congress must act</h3>
<p><span>When asked what she would say to congress regarding H.R. 10571 Sereno says she would implore them to think about the families behind these decisions. </span></p>
<p><span>“Think about the parents who spend months visiting doctor after doctor, desperately searching for answers,” she asserts. “Think about the children who could have received treatment before symptoms began but were not identified in time.”</span></p>
<p><span>Adding a condition to the RUSP is the beginning of the promise, Sereno says, not the fulfillment of it. Without funding, that promise may remain out of reach for the very babies who need it most.</span></p>
<p><span>The Surge to Save Newborns is about turning that promise into action.</span></p>
<p><span>“I urge policymakers to support the Surge to Save Newborns initiative and the legislation needed to provide states with dedicated implementation funding,” Sereno implores. “We have the knowledge. We have the treatments. We have the federal recommendation. Now we need the funding and the national commitment to make newborn screening a reality for every baby, in every state.”</span></p>
<p> </p>
<p><i><span>Please act now and reach out to your congressman to support the Surge to Save Newborns </span></i><a href="https://surgetosave.org/act-now/"><i><span>https://surgetosave.org/act-now/</span></i></a></p>
<p><i><span>To get more involved and join our coalition, you can reach out to: Elisa Seeger  elisa@aldalliance.org</span></i></p>
<p>The post <a href="https://bio.news/latest-news/from-recommendation-to-reality-why-newborn-screening-needs-funding-now/">From recommendation to reality: Why newborn screening needs funding now</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Emotional Control Matters In Coaching</title>
<link>https://edusehat.com/en/emotional-control-matters-in-coaching</link>
<guid>https://edusehat.com/en/emotional-control-matters-in-coaching</guid>
<description><![CDATA[ This week in the world of sports science, emotional control, The All Blacks&#039;culture, and Ciara Mageean.
The post Emotional Control Matters In Coaching appeared first on Science for Sport. ]]></description>
<enclosure url="https://www.scienceforsport.com/wp-content/uploads/2026/11/a5a484c4-d0e4-4a45-86a9-a8e5274d8638.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 01:30:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Emotional, Control, Matters, Coaching</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph"><strong>This week in the world of sports science, here’s what happened…</strong></p>



<ul class="wp-block-list">
<li>The Carlo Ancelotti approach: Why emotional control matters in coaching</li>



<li>The All Blacks: A culture built on humility</li>



<li>Ciara Mageean: a remarkable legacy of resilience and perseverance</li>
</ul>



<div aria-hidden="true" class="wp-block-spacer"></div>



<h2 class="wp-block-heading">The Carlo Ancelotti approach: Why emotional control matters in coaching</h2>



<figure class="wp-block-image size-large"><img fetchpriority="high" decoding="async" width="1024" height="1024" src="https://www.scienceforsport.com/wp-content/uploads/2026/11/Ancelotti-Inspired-Nine-Emotion-Meme-Grid-1024x1024.png" alt="" class="wp-image-34429" srcset="https://www.scienceforsport.com/wp-content/uploads/2026/11/Ancelotti-Inspired-Nine-Emotion-Meme-Grid-1024x1024.png 1024w, https://www.scienceforsport.com/wp-content/uploads/2026/11/Ancelotti-Inspired-Nine-Emotion-Meme-Grid-150x150.png 150w, https://www.scienceforsport.com/wp-content/uploads/2026/11/Ancelotti-Inspired-Nine-Emotion-Meme-Grid-300x300.png 300w, https://www.scienceforsport.com/wp-content/uploads/2026/11/Ancelotti-Inspired-Nine-Emotion-Meme-Grid-768x768.png 768w, https://www.scienceforsport.com/wp-content/uploads/2026/11/Ancelotti-Inspired-Nine-Emotion-Meme-Grid.png 1254w" sizes="(max-width: 1024px) 100vw, 1024px"><figcaption class="wp-element-caption">(Image: Facebook)</figcaption></figure>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph">Leading <a href="https://academy.scienceforsport.com/programs/collection-avvh0txjzbw" target="_blank" rel="noreferrer noopener">sports psychologist</a> and regular <a href="https://www.scienceforsport.com/newsletter/" target="_blank" rel="noreferrer noopener">SFS Weekly</a> feature, Professor <a href="https://www.scienceforsport.com/?s=adam+nicholls&id=21788" target="_blank" rel="noreferrer noopener">Adam Nicholls</a>, recently shared a fascinating insight into legendary <a href="https://academy.scienceforsport.com/programs/collection-vj75ibdi-da?category_id=141256" target="_blank" rel="noreferrer noopener">football</a> manager Carlo Ancelotti’s coaching philosophy and his ability to stay calm and composed under pressure (see <a href="https://lnkd.in/p/dhJhkpYa" target="_blank" rel="noreferrer noopener">here</a>).</p>



<p class="wp-block-paragraph">Ancelotti believes that the more he shouts, the less his players actually listen. Interestingly, he explains that although he loves <a href="https://academy.scienceforsport.com/programs/collection-vj75ibdi-da?category_id=141256" target="_blank" rel="noreferrer noopener">football</a>, he has never allowed his passion for the game to become an obsession, either as a player or a manager. This perspective has helped him stay in control of his emotions, whether his team is performing well or poorly.</p>



<p class="wp-block-paragraph"><a href="https://www.scienceforsport.com/?s=adam+nicholls&id=21788">Nicholls</a> explores the science behind this approach, highlighting how a coach’s emotions can influence how athletes feel, think, and ultimately perform. He references research involving 30 Dutch <a href="https://academy.scienceforsport.com/programs/collection-vj75ibdi-da?category_id=141256" target="_blank" rel="noreferrer noopener">football</a> teams, which found that coaches’ happiness was positively associated with team performance.</p>



<p class="wp-block-paragraph">Drawing on these insights, <a href="https://www.scienceforsport.com/?s=adam+nicholls&id=21788" target="_blank" rel="noreferrer noopener">Nicholls</a> offers several practical recommendations for coaches. These include staying composed when emotions run high, communicating clearly rather than out of frustration, and reinforcing athletes’ confidence in their abilities, especially when things don’t go to plan. Crucially, he emphasises that a coach’s behaviour can set the emotional tone for the entire team.</p>



<p class="wp-block-paragraph">The overarching message is a reminder for coaches across all sports: effective coaching isn’t about showing the most emotion, but about managing your emotions in a way that helps your athletes perform at their best.</p>



<p class="wp-block-paragraph">We were also very fortunate to have Professor <a href="https://www.scienceforsport.com/?s=adam+nicholls&id=21788" target="_blank" rel="noreferrer noopener">Nicholls</a> design a course for us, titled <a href="https://academy.scienceforsport.com/programs/collection-rqwrjxwp1_o" target="_blank" rel="noreferrer noopener">Socially Supporting Athletes</a>, which can be accessed <a href="https://academy.scienceforsport.com/programs/collection-rqwrjxwp1_o">here</a>.</p>



<div aria-hidden="true" class="wp-block-spacer"></div>



<h2 class="wp-block-heading">The All Blacks: A culture built on humility</h2>



<figure class="wp-block-image size-large"><img decoding="async" width="768" height="1024" src="https://www.scienceforsport.com/wp-content/uploads/2026/11/All-Blacks-LinkedIn-768x1024-1.jpg" alt="" class="wp-image-34430" srcset="https://www.scienceforsport.com/wp-content/uploads/2026/11/All-Blacks-LinkedIn-768x1024-1.jpg 768w, https://www.scienceforsport.com/wp-content/uploads/2026/11/All-Blacks-LinkedIn-225x300.jpg 225w, https://www.scienceforsport.com/wp-content/uploads/2026/11/All-Blacks-LinkedIn.jpg 800w" sizes="(max-width: 768px) 100vw, 768px"><figcaption class="wp-element-caption">(Image: LinkedIn)</figcaption></figure>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph">A fascinating <a href="https://lnkd.in/p/dFDBJ-t8" target="_blank" rel="noreferrer noopener">photo</a> recently shared on social media offers a powerful insight into the culture and mentality of the New Zealand All Blacks <a href="https://www.scienceforsport.com/preseason-rugby-training-schedule-principles/">rugby</a> team (see post <a href="https://lnkd.in/p/dFDBJ-t8">here</a>). The <a href="https://lnkd.in/p/dFDBJ-t8" target="_blank" rel="noreferrer noopener">photo</a> shows players loading their own luggage onto a truck ahead of their Northern tour, rather than leaving the task to support staff. While this may seem like a small gesture, it highlights an important principle within the All Blacks environment: no individual is bigger than the team.</p>



<p class="wp-block-paragraph">Interestingly, several comments beneath the post further reinforced this <a href="https://www.scienceforsport.com/culture-development-a-guide-for-coaches/">culture</a>. One referenced the famous “Sweep the Sheds” philosophy, where All Blacks players clean up their dressing room after matches, reinforcing humility, accountability, and respect. Another individual claimed to have been on the same flight as the team, noting that the players were travelling in economy class.</p>



<p class="wp-block-paragraph">Collectively, these examples remind us of the importance of staying grounded, regardless of status or success. In an era where elite athletes often have extensive support teams and almost every aspect of their lives catered for, the All Blacks’ emphasis on humility, personal responsibility and togetherness is particularly refreshing. It demonstrates how a strong team <a href="https://www.scienceforsport.com/culture-development-a-guide-for-coaches/" target="_blank" rel="noreferrer noopener">culture</a> is not simply built through words or motivational slogans, but through the everyday behaviours and standards that players uphold.</p>



<p class="wp-block-paragraph">If you would like to learn more about <a href="https://www.scienceforsport.com/culture-development-a-guide-for-coaches/">culture</a> development, check out our blog, <a href="https://www.scienceforsport.com/culture-development-a-guide-for-coaches/" target="_blank" rel="noreferrer noopener">Culture development: A guide for coaches and administrators</a> and our course, <a href="https://academy.scienceforsport.com/programs/collection-lfptnuzncey?category_id=141256" target="_blank" rel="noreferrer noopener">Creating Team Culture</a>.</p>



<div aria-hidden="true" class="wp-block-spacer"></div>



<h2 class="wp-block-heading">Ciara Mageean: a remarkable legacy of resilience and perseverance</h2>



<figure class="wp-block-image size-large"><img decoding="async" width="1024" height="576" src="https://www.scienceforsport.com/wp-content/uploads/2026/11/8b3e0ad0-d69b-11f1-8052-913cc7942a17-1024x576.jpg" alt="" class="wp-image-34431" srcset="https://www.scienceforsport.com/wp-content/uploads/2026/11/8b3e0ad0-d69b-11f1-8052-913cc7942a17-1024x576.jpg 1024w, https://www.scienceforsport.com/wp-content/uploads/2026/11/8b3e0ad0-d69b-11f1-8052-913cc7942a17-300x169.jpg 300w, https://www.scienceforsport.com/wp-content/uploads/2026/11/8b3e0ad0-d69b-11f1-8052-913cc7942a17-1536x864.jpg 1536w, https://www.scienceforsport.com/wp-content/uploads/2026/11/8b3e0ad0-d69b-11f1-8052-913cc7942a17-768x432.jpg 768w, https://www.scienceforsport.com/wp-content/uploads/2026/11/8b3e0ad0-d69b-11f1-8052-913cc7942a17-2048x1152.jpg 2048w" sizes="(max-width: 1024px) 100vw, 1024px"><figcaption class="wp-element-caption">Ciara Mageean (Image: BBC)</figcaption></figure>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph">On a personal level, my home country of Ireland lost one of its most inspirational sporting figures following the passing of Ciara Mageean at just 34 years of age, after a battle with bowel cancer. The European 1500m champion leaves behind a remarkable legacy, not only for her achievements on the track but also for her determination, humility and resilience throughout a career filled with setbacks.</p>



<p class="wp-block-paragraph">Interestingly, Ciara’s greatest performances came relatively late in her career. Despite winning World Championship medals at underage level in 2009 and 2010, she endured significant injury challenges, including <a href="https://academy.scienceforsport.com/programs/collection-ik8bchulnd0?category_id=141256" target="_blank" rel="noreferrer noopener">Achilles</a> surgery in 2013. However, she continued to progress, winning European bronze in 2016, silver in 2022 and ultimately gold in Rome in 2024, aged 32.</p>



<p class="wp-block-paragraph">Sadly, her passing also serves as a reminder that even the world’s most physically gifted and highly trained athletes are not immune to serious health challenges. Despite their exceptional physical capabilities, athletes are ultimately just as human and vulnerable as the rest of us.</p>



<p class="wp-block-paragraph">Above all, Ciara will be remembered not simply for her medals and records, but for the warmth, humility and courage she demonstrated throughout her life. Her legacy extends far beyond athletics, and she will undoubtedly continue to inspire future generations of Irish athletes.</p>



<p class="wp-block-paragraph">Rest in peace, Ciara. Your legacy will live on.</p>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph"><strong>From us this week:</strong></p>



<p class="wp-block-paragraph">>> New course: <a href="https://academy.scienceforsport.com/programs/collection-xy44wcqbjsy?category_id=141256" data-type="link" data-id="https://academy.scienceforsport.com/programs/collection-xy44wcqbjsy?category_id=141256" target="_blank" rel="noreferrer noopener">Observation Before Intervention: Building Better Coaching Environments</a><br>>> New podcast: <a href="https://scienceforsport.fireside.fm/345" data-type="link" data-id="https://scienceforsport.fireside.fm/345" target="_blank" rel="noreferrer noopener">Football’s Next Competitive Edge: IMPECT</a><br>>> New infographic: <a href="https://www.instagram.com/p/DfRgvrzF883/?img_index=1" data-type="link" data-id="https://www.instagram.com/p/DfRgvrzF883/?img_index=1" target="_blank" rel="noreferrer noopener">Football Conditioning Small Sided Games</a><br>>> New article: <a href="https://www.scienceforsport.com/essa-and-science-for-sport-announce-strategic-professional-development-partnership/" data-type="link" data-id="https://www.scienceforsport.com/essa-and-science-for-sport-announce-strategic-professional-development-partnership/" target="_blank" rel="noreferrer noopener">ESSA and Science for Sport Announce Strategic Professional Development Partnership</a></p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Access to a growing library of sports science courses</strong></p>



<p class="wp-block-paragraph"><a href="https://academy.scienceforsport.com/" target="_blank" rel="noopener" data-lasso-id="59917">SFS Academy</a> is an all-access membership to premium sports science education.</p>



<p class="wp-block-paragraph">With SFS Academy, you’ll learn from some of the best coaches around the world as they teach you how to apply the latest research and practice with your athletes.</p><p>The post <a href="https://www.scienceforsport.com/emotional-control-matters-in-coaching/">Emotional Control Matters In Coaching</a> appeared first on <a href="https://www.scienceforsport.com/">Science for Sport</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Prior approval in Scotland: what has changed and why?</title>
<link>https://edusehat.com/en/prior-approval-in-scotland-what-has-changed-and-why</link>
<guid>https://edusehat.com/en/prior-approval-in-scotland-what-has-changed-and-why</guid>
<description><![CDATA[ From 1 November 2026, dentists in Scotland no longer have to request prior approval due to treatment cost, with the new trigger based on treatment count. The new system moves away from the general £660 financial trigger for new courses of general dental treatment to clinical treatment count thresholds. This aims to focus scrutiny on… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/prior_approvak.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 01:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Prior, approval, Scotland:, what, has, changed, and, why</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>From 1 November 2026, dentists in Scotland no longer have to request prior approval due to treatment cost, with the new trigger based on treatment count.</strong> </p>



<p>The new system moves away from the general £660 financial trigger for new courses of general dental treatment to clinical treatment count thresholds. This aims to focus scrutiny on plans that may carry greater clinical complexity or risk, rather than on their price alone.</p>



<p>The Scottish Government said these changes are in line with its plans to create ‘a high-trust, low bureaucracy model’ for NHS dental payments. </p>



<p>After 2023 payment reforms, more routine, low-risk treatment plans were exceeding the £660. According to the government, this led to more unnecessary applications for dentists, more work for NHS clinical advisers, and delays for patients waiting for otherwise straightforward treatment.</p>



<p>Treatment courses begun before 1 November will remain under the previous system, with new treatments now subject to the updated rules. </p>



<h2 class="wp-block-heading">How does the new prior approval process for Scotland work?</h2>



<p>Dentists are placed in two tiers:</p>



<ol class="wp-block-list">
<li>Most established Scottish NHS general dental practitioners</li>



<li>Vocational trainees, provisionally listed dentists completing mandatory training, and dentists within 12 months of finishing these pathways.</li>
</ol>



<p>Prior approval is now triggered when a threshold of more complex treatments is reached, including root canals, crowns, bridge units, surgical extractions or splints. Tier two dentists must seek approval at a lower threshold than tier one. </p>



<p>Some items will still require prior approval in every case, such as certain central-diastema closure work and other orthodontic treatments. </p>



<p>Generally, the rules for orthodontics are unchanged – prior approval will still be required where treatment is likely to cost more than £600.</p>



<p><em><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</em></a></em></p>]]> </content:encoded>
</item>

<item>
<title>Loma Linda Unveils 105,000&#45;Square&#45;Foot Pediatric Specialty Facility</title>
<link>https://edusehat.com/en/loma-linda-unveils-105000-square-foot-pediatric-specialty-facility</link>
<guid>https://edusehat.com/en/loma-linda-unveils-105000-square-foot-pediatric-specialty-facility</guid>
<description><![CDATA[ A ribbon-cutting ceremony marked the opening of Loma Linda University Health’s new 105,000-square-foot Children’s Health Specialty Clinics facility. | Photo Credit: Loma Linda University Health  The five-story, 105,000-square-foot facility will house more than 21 pediatric specialties, 149 exam rooms, and laboratory and radiology services.  Design features include animal-themed wayfinding, dichroic glass, a courtyard tree and...
The post Loma Linda Unveils 105,000-Square-Foot Pediatric Specialty Facility appeared first on HCO News.
The post Loma Linda Unveils 105,000-Square-Foot Pediatric Specialty Facility appeared first on HCO News. ]]></description>
<enclosure url="https://hconews.com/wp-content/uploads/2026/11/HCO-News.LomaLinda.png" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 21:20:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Loma, Linda, Unveils, 105, 000-Square-Foot, Pediatric, Specialty, Facility</media:keywords>
<content:encoded><![CDATA[<h5><span data-contrast="auto">A ribbon-cutting ceremony marked the opening of Loma Linda University Health’s new 105,000-square-foot Children’s Health Specialty Clinics facility. | Photo Credit: Loma Linda University Health</span><span data-ccp-props="{}"> </span></h5>
<ul>
<li><span data-contrast="auto">The five-story, 105,000-square-foot facility will house more than 21 pediatric specialties, 149 exam rooms, and laboratory and radiology services.</span><span data-ccp-props="{}"> </span></li>
<li><span data-contrast="auto">Design features include animal-themed wayfinding, dichroic glass, a courtyard tree and a community mosaic mural.</span><span data-ccp-props="{}"> </span></li>
<li><span data-contrast="auto">Layton Construction is the general contractor. Patient services are expected to begin in early 2027.</span><span data-ccp-props="{}"> </span></li>
</ul>
<p><span data-contrast="auto">LOMA LINDA, Calif. – Loma Linda University Health unveiled its new Children’s Health Specialty Clinics at an Oct. 6, 2026, ribbon-cutting, introducing a five-story, 105,000-square-foot outpatient facility that will consolidate pediatric specialty care in the Inland Empire. Patient services are expected to begin in early 2027, </span><a href="https://news.llu.edu/community/ribbon-cutting-ceremony-childrens-health-specialty-clinics-marks-new-era-care" target="_blank" rel="noopener"><span data-contrast="none">according to a press release from Loma Linda University Health</span></a><span data-contrast="auto">.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">The building will house more than 21 pediatric specialties and provide 149 exam rooms, along with clinical laboratory and radiology services. Salt Lake City-based Layton Construction served as the project’s general contractor.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Layton construction manager Kris Jenson described the project as a continuation of the company’s longstanding relationship with Loma Linda University Health.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Hospital leaders expect the centralized location to make appointments easier to navigate for families, particularly those caring for children with complex medical needs. They also anticipate the number of exam rooms will improve visit efficiency and that proximity among specialties will support closer coordination.</span><span data-ccp-props="{}"> </span></p>
<blockquote><p><span data-contrast="auto">“Our providers can collaborate more closely. We can communicate about our patients, coordinate care and work together to develop more unified treatment plans,” Dr. Francis Chan, Chair of General Pediatrics at Loma Linda University Children’s Hospital, said in the release.</span><span data-ccp-props="{}"> </span></p></blockquote>
<p><span data-contrast="auto">Natural imagery shapes the facility’s design inside and out. Its organizing concept draws on the image of a tree planted near water in Jeremiah 17:7-8. Exterior dichroic glass produces a rainbow-like effect, while a large living tree in the courtyard is intended to provide a calming arrival experience.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Animal and critter imagery throughout the interior is intended to help children and families find their way through the facility. Those visual cues combine a navigation function with the project’s effort to create a child-friendly environment.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">A 10-by-15-foot mosaic mural unveiled during the ceremony adds a community element. Created with assistance from Project S.N.A.P., it incorporates more than 10,000 drawings contributed by children, families, patients, schools and other community members. The completed image depicts hospital mascot Luke the Lion playing with children amid local landmarks, including the Redlands Bowl, Mission Inn and Arrowhead.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Financial support for the roughly $150 million project includes Proposition 4, the Children’s Hospital Bond initiative and the health system’s Stronger Together Campaign. The ongoing philanthropic campaign seeks $15 million toward construction of the clinics.</span><span data-ccp-props="{}"> </span></p>
<p><i><span data-contrast="auto">This article is based on </span></i><a href="https://news.llu.edu/community/ribbon-cutting-ceremony-childrens-health-specialty-clinics-marks-new-era-care" target="_blank" rel="noopener"><i><span data-contrast="none">a press release written by Jenny Buchholz and originally published by Loma Linda University Health</span></i></a><i><span data-contrast="auto"> on Oct. 6, 2026.</span></i><span data-ccp-props="{}"> </span></p>
<p>The post <a rel="nofollow" href="https://hconews.com/2026/11/11/loma-linda-unveils-105000-square-foot-pediatric-specialty-facility/">Loma Linda Unveils 105,000-Square-Foot Pediatric Specialty Facility</a> appeared first on <a rel="nofollow" href="https://hconews.com/">HCO News</a>.</p>
<p>The post <a href="https://hconews.com/2026/11/11/loma-linda-unveils-105000-square-foot-pediatric-specialty-facility/">Loma Linda Unveils 105,000-Square-Foot Pediatric Specialty Facility</a> appeared first on <a href="https://hconews.com/">HCO News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Preconception, Gestational, and Postpartum Care</title>
<link>https://edusehat.com/en/preconception-gestational-and-postpartum-care</link>
<guid>https://edusehat.com/en/preconception-gestational-and-postpartum-care</guid>
<description><![CDATA[ Type 2 diabetes is increasingly affecting women of childbearing age, making coordinated care before conception, throughout pregnancy, and after delivery essential. Based on her ENDO 2026 presentation, Aoife M. Egan, MBBCh, PhD, discusses individualized, patient-centered support to improve outcomes and reach those people who face the greatest barriers to care. At her Meet the Professor […]
The post Preconception, Gestational, and Postpartum Care appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/Aoife-Egan.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 21:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Preconception, Gestational, and, Postpartum, Care</media:keywords>
<content:encoded><![CDATA[<p>Type 2 diabetes is increasingly affecting women of childbearing age, making coordinated care before conception, throughout pregnancy, and after delivery essential. Based on her ENDO 2026 presentation, Aoife M. Egan, MBBCh, PhD, discusses individualized, patient-centered support to improve outcomes and reach those people who face the greatest barriers to care. At her Meet the Professor […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/preconception-gestational-and-postpartum-care/">Preconception, Gestational, and Postpartum Care</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>GDC English&#45;language proposals could add £300 to ORE applicants’ costs</title>
<link>https://edusehat.com/en/gdc-english-language-proposals-could-add-300-to-ore-applicants-costs</link>
<guid>https://edusehat.com/en/gdc-english-language-proposals-could-add-300-to-ore-applicants-costs</guid>
<description><![CDATA[ Overseas-qualified dentists could face additional language-test costs under GDC proposals to restrict the evidence accepted for registration. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/language.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 21:05:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>GDC, English-language, proposals, could, add, £300, ORE, applicants’, costs</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Overseas-qualified dentists could face English-language test costs of £200-£300 under General Dental Council (GDC) proposals to restrict the evidence accepted for registration.</strong></p>



<p>GDC modelling suggested approximately 90% of dentist applicants currently using a qualification taught and examined in English would lose access to that evidence route.</p>



<p>The proposals would limit qualification and clinical-experience evidence to countries on the UK government’s English-speaking list, while widening the choice of recognised language tests.</p>



<p>Applicants who could no longer use the qualification-based route would need another accepted form of evidence to demonstrate their English-language competence.</p>



<h2 class="wp-block-heading">Additional costs after ORE fee increase</h2>



<p>The papers presented to the GDC’s council on 30 October reported a five-year average of 480 dentist applications annually using qualification-based English-language evidence.</p>



<p>Applicants who consequently needed a language test could face costs of roughly £200-£300, depending on the provider and country, the council papers said.</p>



<p>That proposed cost would follow the <a href="https://dentistry.co.uk/2026/05/07/ore-part-2-fee-rise-gdc-confirms-2026-sittings/">65% increase in the Overseas Registration Examination (ORE) Part 2 fee announced earlier this year</a>. The fee rose by £2,732, from £4,235 to £6,967.</p>



<p><em>Dentistry </em>also reported <a href="https://dentistry.co.uk/2026/07/08/gdc-to-fix-troubled-ore-booking-system-with-new-candidate-portal/">booking difficulties and plans for a new ORE candidate portal</a>.</p>



<p>At its September council meeting, the GDC reported an ORE waiting list of more than 8,000.</p>



<h2 class="wp-block-heading">Which applicants could be affected?</h2>



<p>India, Pakistan, Egypt, Sudan and Nigeria were the five leading countries represented on the ORE waiting list, GDC chief executive Tom Whiting told June’s LDC conference. He said the number from India was substantially higher than from the other countries.</p>



<p>None of those five countries appears on the government list referenced in the proposed English-language guidance. A dental qualification obtained in one of these countries would therefore no longer qualify for the proposed qualification-based evidence route simply because it was taught and examined in English.</p>



<p>Recent clinical experience in a listed country could provide an alternative where it met the GDC’s criteria. The draft also retained a route for other evidence meeting the regulator’s requirements.</p>



<p>The proposal concerns where qualifications or clinical experience were obtained, rather than nationality.</p>



<p>The <a href="https://www.gov.uk/english-language/exemptions">government list referenced</a> in the draft guidance is shown below:</p>



<figure class="wp-block-image size-full"></figure>



<h2 class="wp-block-heading">Which language tests are proposed?</h2>



<p>The GDC identified five tests it proposed accepting:</p>



<ul class="wp-block-list">
<li>Occupational English Test (OET) Dentistry, including paper, computer and OET@Home formats</li>



<li>International English Language Testing System (IELTS) Academic, including IELTS One Skill Retake and IELTS Online</li>



<li>Cambridge C1 Advanced, digital format only</li>



<li>Test of English as a Foreign Language (TOEFL) iBT, including the at-home format</li>



<li>Pearson Test of English (PTE) Academic.</li>
</ul>



<p>These are proposed options, rather than confirmation that all are currently accepted.</p>



<p>In a <a href="https://www.gdc-uk.org/news-blogs/blog/detail/blogs/2026/11/04/view-chair-business-plan-mann-review-english-language-fear-factors-dentistry">blog published on 4 November</a>, GDC chair Dr Helen Phillips said the existing guidance was more than 10 years old and ‘does not reflect the wider options that are now available, or meet applicants’ needs’.</p>



<p>She said the regulator had listened to calls to modernise its requirements while maintaining the standards patients expected.</p>



<h2 class="wp-block-heading">Expired evidence and transition arrangements</h2>



<p>The draft also addressed candidates whose English-language evidence expired while waiting to complete the ORE. In those circumstances, a Part 2 pass would provide sufficient evidence of English-language competence, provided they applied for registration within two years of passing.</p>



<p>The consultation documents set out a response period from 9 November to 18 December 2026, with final guidance due to return to council for approval in March 2027.</p>



<p>The GDC also proposed transitional arrangements for applicants who had already begun preparing applications.</p>



<p>Read our <a href="https://dentistry.co.uk/2024/10/14/overseas-registration-exam-in-dentistry-all-you-need-to-know/">guide to the Overseas Registration Examination</a> for background on the registration process.</p>



<p><a href="https://sso.dentistry.co.uk/">Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</a></p>]]> </content:encoded>
</item>

<item>
<title>Surgical site infections add estimated $2,056 per cardiac procedure, analysis finds</title>
<link>https://edusehat.com/en/surgical-site-infections-add-estimated-2056-per-cardiac-procedure-analysis-finds</link>
<guid>https://edusehat.com/en/surgical-site-infections-add-estimated-2056-per-cardiac-procedure-analysis-finds</guid>
<description><![CDATA[ Canadian health economics analysis highlights the financial and operational burden of post-operative infections, including additional hospital bed-days and potential reductions in surgical capacity. Surgical site infections following cardiac surgery could add an average of $2,056 in additional costs per procedure, according to a health economics analysis highlighted by Canadian life sciences company Ondine Biomedical. The […]
The post Surgical site infections add estimated $2,056 per cardiac procedure, analysis finds appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_2634279831.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 20:35:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Surgical, site, infections, add, estimated, 2, 056, per, cardiac, procedure, analysis, finds</media:keywords>
<content:encoded><![CDATA[<p>Canadian health economics analysis highlights the financial and operational burden of post-operative infections, including additional hospital bed-days and potential reductions in surgical capacity.</p>
<p>Surgical site infections following cardiac surgery could add an average of $2,056 in additional costs per procedure, according to a health economics analysis highlighted by Canadian life sciences company Ondine Biomedical.</p>
<p>The findings, presented at the Canadian Cardiovascular Congress 2026 and published in the Canadian Journal of Cardiology, suggest that post-operative infections create financial pressures that extend beyond the cost of treating affected patients.</p>
<p>The analysis also estimates that infection-related complications could consume hospital capacity equivalent to approximately 10 per cent of cardiac surgical procedures under the modelled assumptions.</p>
<p>Ondine Biomedical announced the findings November 11, emphasizing the potential role of infection prevention strategies in reducing avoidable costs and preserving surgical resources.</p>
<div>
<div></div>
</div>
<h2>Modelling the financial burden of infection</h2>
<p>The analysis uses a baseline surgical site infection rate of 6.7 per cent and an assumed additional hospital cost of $30,689 for each patient who develops an infection.</p>
<p>Based on these assumptions, researchers calculated an average additional cost of approximately $2,056 across all cardiac surgery procedures, including those in which no infection occurs.</p>
<p>The approach distributes the expected cost of infections across the entire surgical population, providing hospital administrators with a per-procedure estimate of infection-related financial risk.</p>
<p>The researchers describe this measure as an infection tax, intended to illustrate the potential economic impact of complications that may be reduced through effective prevention strategies.</p>
<p>Importantly, the $30,689 incremental cost was adapted from a U.S. healthcare cost benchmark, adjusted for currency and differences in healthcare systems. It was not directly measured in Canadian cardiac surgery patients.</p>
<p>As a result, the $2,056 figure should be understood as a modelling estimate rather than a documented average cost across Canadian hospitals.</p>
<h2>Additional bed-days affect surgical capacity</h2>
<p>The analysis also examined the potential operational impact of infections on hospital capacity.</p>
<p>In a modelled group of 1,000 cardiac surgery patients, a 6.7 per cent infection rate would result in approximately 67 surgical site infections.</p>
<p>Those infections were estimated to generate more than $2 million in additional hospital costs and require approximately 650 extra inpatient bed-days.</p>
<p>The bed-day calculation assumes that patients experiencing a surgical site infection remain hospitalized an average of 9.7 additional days.</p>
<p>Researchers estimated that these occupied beds could otherwise support approximately 100 elective cardiac procedures, representing a potential 10 per cent reduction in surgical capacity.</p>
<p>The findings highlight how infection-related complications can affect operating schedules, patient flow and waiting lists, particularly in hospitals already experiencing constraints on inpatient beds and staffing.</p>
<p>However, the estimate of 100 displaced procedures represents a theoretical opportunity cost. It does not demonstrate that preventing infections would automatically enable hospitals to perform 100 additional surgeries.</p>
<div>
<div></div>
</div>
<h2>Infection prevention as a hospital capacity strategy</h2>
<p>Surgical site infections remain an important patient safety concern because they can result in prolonged hospitalization, additional treatment, readmissions and increased demand for clinical resources.</p>
<p>For cardiac surgery patients, infection prevention is particularly important given the complexity of procedures and the potential consequences of post-operative complications.</p>
<p>Hospitals use a range of prevention measures, including appropriate antibiotic prophylaxis, skin antisepsis, infection surveillance, standardized surgical practices and pre-operative decolonization for selected patients.</p>
<p>The new analysis suggests that evaluating infection prevention programs should include not only direct treatment costs but also the effect of complications on staffing, hospital beds and surgical throughput.</p>
<p>By incorporating these broader operational considerations, healthcare organizations may be better positioned to assess the financial value of prevention initiatives.</p>
<h2>Canadian research examines prevention approaches</h2>
<p>The analysis was presented alongside two related research posters from the University of Ottawa Heart Institute.</p>
<p>One examined implementation of a cardiac surgery infection prevention bundle through frontline engagement, nasal photodisinfection and nurse-led advocacy.</p>
<p>The second examined surgical site infections following cardiac surgery using an interrupted time-series analysis of nasal photodisinfection.</p>
<p>Both were identified in the company’s announcement as research presented at the Canadian Cardiovascular Congress 2026.</p>
<p>Ondine Biomedical develops Steriwave, a light-activated antimicrobial technology used for nasal decolonization in certain jurisdictions, including Canada.</p>
<p>The company has a commercial interest in promoting infection prevention approaches involving photodisinfection. The economic analysis does not, by itself, demonstrate the clinical effectiveness or cost savings of any particular product.</p>
<p>The findings should therefore be considered in the context of the model’s assumptions and the broader evidence supporting individual infection prevention interventions.</p>
<div>
<div></div>
</div>
<h2>Implications for Canadian hospitals</h2>
<p>For hospital executives and surgical program leaders, the analysis offers another perspective on the costs associated with preventable complications.</p>
<p>The financial impact of surgical site infections includes not only additional clinical treatment but also longer hospital stays, increased nursing demands and reduced availability of inpatient beds.</p>
<p>With many Canadian hospitals facing sustained pressure to improve surgical access and manage operating costs, infection prevention remains an important component of patient safety and operational planning.</p>
<p>The findings suggest that even relatively modest reductions in surgical site infection rates could potentially reduce resource use, although actual savings and capacity gains would depend on local infection rates, patient populations, staffing, costs and available surgical resources.</p>
<p>Further Canadian hospital-level economic evaluations would help determine how closely the modelled estimates reflect real-world costs and what improvements can be achieved through specific prevention strategies.</p>
<p>Source: <a href="https://www.tradingview.com/news/reuters.com%2C2026-11-11%3Anewsml_RSK6260Ca%3A0-rcs-ondine-biomedical-cardiac-ssi-infection-tax-at-c-2-056-per-surgery/?utm_source=chatgpt.com">Ondine Biomedical </a></p>
<p>The post <a href="https://www.hospitalnews.com/surgical-site-infections-add-estimated-2056-per-cardiac-procedure-analysis-finds/">Surgical site infections add estimated $2,056 per cardiac procedure, analysis finds</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How consumers’ demand for transparency will raise the scientific standard of dermocosmetics</title>
<link>https://edusehat.com/en/how-consumers-demand-for-transparency-will-raise-the-scientific-standard-of-dermocosmetics</link>
<guid>https://edusehat.com/en/how-consumers-demand-for-transparency-will-raise-the-scientific-standard-of-dermocosmetics</guid>
<description><![CDATA[ 
Professor Dr. Gabriel Serrano, Founder, Sesderma shares insights on how global formulations may not always address the needs of Indian skin types, and why precision dermatology and delivery can address these gaps, in an email interaction with Viveka Roychowdhury
The post How consumers’ demand for transparency will raise the scientific standard of dermocosmetics appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11154138/Dr-Gabriel.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 20:25:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, consumers’, demand, for, transparency, will, raise, the, scientific, standard, dermocosmetics</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11154138/Dr-Gabriel.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11154138/Dr-Gabriel.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/11154138/Dr-Gabriel-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><strong>How do Indian skin types and physiology differ and where do global dermacosmetic formulations, even though some may be innovative, fall short?</strong></p>
<p>India is not one skin type. There is enormous diversity in phototypes, pigmentation, climate, humidity and individual skin behaviour. However, in Indian and other Asian skin, pigmentation disorders such as melasma and post-inflammatory hyperpigmentation are particularly important, and inflammation or procedures can sometimes leave pigmentation behind.</p>
<p>This is where a global formulation can fall short: it may be scientifically excellent, but not necessarily designed around the specific biology and daily environment of Indian skin. We must formulate according to the skin need, not simply according to geography or marketing trends. In India, I would pay particular attention to pigmentation, photoprotection, barrier integrity, sensitivity and tolerance. The same active, at the same concentration and delivered in the same way, does not necessarily produce the same result in every population.</p>
<p>For me, the future is precision dermatology: understanding the individual skin and adapting the formulation, delivery system and regimen accordingly.</p>
<p><strong>Why does formulation science matter when it comes to dermocosmetics?</strong></p>
<p>Because an ingredient on an INCI list is not the same thing as an effective treatment. This is one of the most important lessons I have learned during my career. You can have an excellent active ingredient, but if it is unstable, poorly delivered, released too quickly, or present in a formulation that irritates the skin, the final result may be disappointing.</p>
<p>Formulation science connects the active ingredient with the biological target. We have to understand the molecule, its concentration, stability, compatibility, penetration, release and interaction with the skin. This is why I have always considered delivery technology fundamental. At Sesderma, we use nanotechnology and liposomes to encapsulate active ingredients, with the aim of improving their penetration, stability, efficacy and tolerance.</p>
<p>Dermocosmetics should not be “magic in a jar”. They should be the result of dermatology, chemistry, biology, technology and clinical experience working together. That is what transforms an interesting ingredient into an effective formulation.</p>
<p><strong>India’s consumers are now educating themselves and moving from blindly following trends and fads to asking for evidence-based solutions to support label claims. How has this changed the dermacosmetics business model for researchers, developers and manufacturers?</strong></p>
<p>This is a very positive evolution. An educated consumer is demanding something that dermatologists have always demanded: evidence. We cannot build the future of dermocosmetics on fashionable ingredients or attractive packaging. We must demonstrate that the active ingredient is stable, that it reaches the skin where it is needed, that the formulation is well tolerated and, most importantly, that it produces a measurable benefit.</p>
<p>For researchers and manufacturers, this changes the entire development model. Research must begin with a real dermatological problem and continue through formulation, delivery technology, safety and clinical evaluation. At Sesderma, this philosophy has always been important because we came from dermatology and from the needs of patients. Our collaborations with universities, hospitals and research centres reflect this approach.</p>
<p>Consumers today are asking the industry to be more transparent. I see this not as a challenge, but as an opportunity to raise the scientific standard of dermocosmetics.</p>
<p><strong>Most consumers, at a minimum, want ‘Clean Beauty’ products. What are the other asks: personalisation, etc.? What are the latest consumer trends in skin care formulation science?</strong></p>
<p>Clean beauty is important, but consumers increasingly want something beyond a clean ingredient list: they want results, tolerance, transparency and personalisation. They want products that understand their skin rather than simply products that follow a trend.</p>
<p>I see several important developments. First is personalised skincare, with formulations and routines organised around individual concerns such as pigmentation, ageing, sensitivity, dehydration or acne. Second is skin-barrier science: consumers increasingly understand that an effective product must also respect the skin. Third is biotechnology, including exosomes and other advanced biological systems. Fourth is intelligent delivery, because the active ingredient alone is not enough; we must control how it reaches the skin.</p>
<p>There is also growing interest in multifunctional formulations that combine several complementary benefits without unnecessarily increasing irritation. At Sesderma, we increasingly think in terms of the skin’s needs rather than simply the product category. That is where personalisation becomes meaningful.</p>
<p><strong>What are the next-generation drug delivery modes in skincare products and dermocosmetics?</strong></p>
<p>The future will be about precision delivery, and not simply putting more active ingredients into a cream. We need to transport the right molecule, in the right concentration, to the right biological location and release it at the right time.</p>
<p>We have already seen the importance of liposomes and nanotechnology. At Sesderma, we began applying NANOTECH technology in 2008, using liposomes to encapsulate active ingredients and improve their delivery into the skin while maintaining good tolerance.</p>
<p>The next evolution is biotechnology. Exosome-based systems are particularly interesting because these small vesicles are involved in communication between cells and can transport biological molecules. Sesderma has developed EXOSES using Lactobacillus-derived exosomes.</p>
<p>I also see significant potential in functionalised carriers, targeted delivery, biomimetic systems, microneedling-assisted delivery and regenerative approaches. The objective is always the same: more precision, greater efficacy and better tolerance.</p>
<p><em>viveka.r@expressindia.com</em></p>
<p><em>viveka.roy3@gmail.com</em></p>
<p>The post <a href="https://www.expresspharma.in/how-consumers-demand-for-transparency-will-raise-the-scientific-standard-of-dermocosmetics/">How consumers’ demand for transparency will raise the scientific standard of dermocosmetics</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Policy shifts test pharma’s resilience</title>
<link>https://edusehat.com/en/policy-shifts-test-pharmas-resilience</link>
<guid>https://edusehat.com/en/policy-shifts-test-pharmas-resilience</guid>
<description><![CDATA[ 
Will policy changes on affordability, ethical marketing and incentives translate into meaningful outcomes for patients while allowing the industry to remain sustainable?
The post Policy shifts test pharma’s resilience appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11115127/EP_EditorsNote_Nov_2026_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 16:50:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Policy, shifts, test, pharma’s, resilience</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11115127/EP_EditorsNote_Nov_2026_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11115127/EP_EditorsNote_Nov_2026_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/11115127/EP_EditorsNote_Nov_2026_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Important proposed policy changes reflect the government’s commitment to make medicines more affordable for patients, weed out unethical marketing practices across the pharma supply chain and over time, hopefully rebuild trust. However, while the sluggish pace of policy change remains a concern, how will these moves impact pharma companies in the long run?</p>
<p>Let’s consider the latest salvo on medicine prices. On October 17, the National Pharmaceutical Pricing Authority (NPPA) capped trade margins at 30 per cent for 137 nonscheduled anti-cancer medicines. This comes nearly eight years after a 2019 pilot exercise, which capped trade margins at 30 per cent for 42 non-scheduled anti-cancer medicines. According to government data, as part of the pilot, MRPs of 526 brands were reduced by up to 90 per cent <i>(https://www.expresspharma.in/nppa-capstrade-margins-at-30-per-cent-for-137-anti-cancer-medicines/</i>). While industry associations like IPA and OPPI have welcomed the move, both call for an assessment of the actual impact of this change on patient access and availability.</p>
<p>Other experts like Mayur Sirdesai, Co-Founding Partner, Somerset Indus Capital Partners, stress that affordability must be viewed across the entire cancer-care pathway, from screening and diagnosis to treatment.</p>
<p>In some cases, the delay in policy change has given industry time to clean up its act. On October 8, the Supreme Court directed the constitution of a threemember Committee to examine existing regulations on pharma marketing and their adequacy for curbing unethical practices. The Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2015, which was strengthened in 2024, could move from the current selfregulatory framework to a statutory regime. A final decision is still some time away, with the committee expected to submit its recommendations before the next hearing scheduled for January 2027.</p>
<p>Analysing the impact of this policy shift, Nandan Kulkarni and Shirsh Sawarna of Bernstein (India) point out that over the past 12-18 months, large Indian pharma companies have already been gearing up for implementation, by actively strengthening controls, documentation standards, training programmes and healthcare-professional engagement processes. If the regulatory framework ultimately moves toward a more formal statutory construct, they believe larger companies with established governance processes, stronger compliance infrastructure and ethical commercial practices are likely to be better positioned than smaller peers to navigate the transition.</p>
<p>While UCPMP governs manufacturers, the government is also plugging the loopholes across the pharma supply chain, by proposing to expand restrictions in advertisements of Schedule H, Schedule H1 and Schedule X drugs to retailers, wholesalers and distributors.</p>
<p>Again, like the trade margin caps on cancer medicines, this is good news for patients. The proposal is along the lines of the March 2026 advisory from CDSCO prohibiting direct and surrogate advertisements and promotional activities for Glucagon-like Peptide-1 (GLP-1) receptor agonists.</p>
<p>But as a recent analysis by Anushree Kataria, Tanya Kukade and Dr. Milind Antani of Nishith Desai Associates (NDA) points out, these proposed steps could increase the compliance burden for retailers, and could overlap with prior Central Government permissions already taken by manufacturers for the same prescription products.</p>
<p>The fact that non-compliance with the proposed advertising restriction may expose retailers, wholesalers and distributors to regulatory action, including suspension or cancellation of their sale and distribution licences, indicates the serious nature of the proposed draft amendment.</p>
<p>The NDA analysis also points out that the proposed amendment may cover promotional communications concerning Schedule H, Schedule H1 and Schedule X drugs disseminated through digital platforms like online pharmacies.</p>
<p>The November edition of <i>Express Pharma</i> does a status check on another evolving policy initiative, the Pharmaceutical Production Linked Incentive (PLI) scheme, and touches on an important issue: can the next phase incentivise pharma MSMEs to invest more to become globally competitive?</p>
<p>The grouse of pharma MSMEs has been that since its launch in February 2021, the bulk of PLI funds were bagged by big Indian pharma companies while pharma MSMEs, who actually need the funds to upgrade and move to the next level, continued to languish on the sidelines. In response to this feedback, PLI 2.0 was launched in 2024, with some tweaks to make it more accessible for pharma MSMEs. But as the story reveals, MSME leaders are pushing for different, broader metrics to evaluate the scheme’s success/impact.</p>
<p>As regulators seek to clean up the pharma sector focused on patient safety and affordability, industry will have to find new ways to be as sustainable as possible. The saga continues….</p>
<p>The post <a href="https://www.expresspharma.in/policy-shifts-test-pharmas-resilience/">Policy shifts test pharma’s resilience</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BDR Pharma to acquire controlling stake in Acme’s oral solid formulations business from PAG</title>
<link>https://edusehat.com/en/bdr-pharma-to-acquire-controlling-stake-in-acmes-oral-solid-formulations-business-from-pag</link>
<guid>https://edusehat.com/en/bdr-pharma-to-acquire-controlling-stake-in-acmes-oral-solid-formulations-business-from-pag</guid>
<description><![CDATA[ 
PAG, together with Acme’s founder Viral Shah, to retain and scale the sterile injectables business, Immacule Lifesciences
The post BDR Pharma to acquire controlling stake in Acme’s oral solid formulations business from PAG appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11122924/MA.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 16:50:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BDR, Pharma, acquire, controlling, stake, Acme’s, oral, solid, formulations, business, from, PAG</media:keywords>
<content:encoded><![CDATA[<div><img width="740" height="493" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11122924/MA.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11122924/MA.jpg 740w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/11122924/MA-300x200.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/11122924/MA-450x300.jpg 450w" sizes="auto, (max-width: 740px) 100vw, 740px"></div><p align="CENTER"><span>BDR Pharma and PAG announced that BDR Pharma will acquire a controlling stake in the oral solid formulations business of Acme Formulation and its subsidiaries from its existing shareholders, led by PAG. The acquisition aligns with BDR’s growth priorities across oncology, critical care and women’s healthcare, while creating opportunities to expand its product offerings in international markets. A key strategic rationale for the acquisition is the addition of complementary capabilities across thyroid products, female sex hormone products and general pharmaceutical products. o3 Capital acted as the exclusive financial advisor to BDR Pharma on the transaction.</span></p>
<p><span>“<span><span>We have been on a strong growth trajectory driven by strategic investments, innovation and an expanding global ambition. Acme will further strengthen our CDMO platform and add differentiated capabilities. We see this as part of a larger growth roadmap, with more strategic initiatives expected as we continue to build and expand our global presence”, said Dharmesh Shah, Chairman and Managing Director of BDR Pharma.</span></span></span></p>
<p><span><span><span>Having sold a controlling stake in the oral solid business, PAG and Viral Shah will retain full ownership of Immacule, one of India’s leading sterile injectable focused contract manufacturing businesses. Immacule has recently commissioned a new facility with a capacity of 200M+ units p.a. and provides a broad set of capabilities across dosage forms such as liquid / lyophilized vials, pre-filled syringes, cartridges and therapeutic areas such as oncology, ophthalmology and general injectables.</span></span></span></p>
<p><span>“<span><span>We are proud of what Acme has become during our partnership. This transaction reflects the strength of the platform we have built with Viral and the Acme team and we believe that BDR Pharma is the ideal owner to take it to the next level. We will now sharpen our focus on building Immacule into a leading global sterile injectables platform,” said Nikhil Srivastava, Partner and Co-Head of Private Equity at PAG.</span></span></span></p>
<p><span>“<span><span>Acme has been built on long-standing customer relationships and a committed team. BDR Pharma’s strength in new and complex medicines will bring more innovative products to Acme’s CMO and CDMO clients, existing and new, across geographies. I will work closely with BDR Pharma for a smooth transition, while I focus on growing Immacule,” said Viral Shah, Founder of Acme and MD of Immacule.</span></span></span></p>
<p><span><span><span>The acquisition deepens BDR Pharma’s CDMO platform without overlapping with its existing areas of focus, giving it a more specialised manufacturing base in women’s healthcare and thyroid therapies that complements its broader therapeutic footprint, informed a company statement </span></span></span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/bdr-pharma-to-acquire-controlling-stake-in-acmes-oral-solid-formulations-business-from-pag/">BDR Pharma to acquire controlling stake in Acme’s oral solid formulations business from PAG</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA mandates rare vision&#45;loss warning across all GLP&#45;1 drugs</title>
<link>https://edusehat.com/en/fda-mandates-rare-vision-loss-warning-across-all-glp-1-drugs</link>
<guid>https://edusehat.com/en/fda-mandates-rare-vision-loss-warning-across-all-glp-1-drugs</guid>
<description><![CDATA[ 
The labelling change follows a review indicating a potential increased risk of NAION, a rare eye condition that can cause permanent vision loss
The post FDA mandates rare vision-loss warning across all GLP-1 drugs appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11141741/GLP1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 16:50:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, mandates, rare, vision-loss, warning, across, all, GLP-1, drugs</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="418" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11141741/GLP1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11141741/GLP1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/11141741/GLP1-300x167.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p data-pm-slice="1 1 []">The US Food and Drug Administration (FDA) has directed manufacturers of all approved glucagon-like peptide-1 (GLP-1) receptor agonists to add a warning about the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden vision loss.</p>
<p>The directive, issued on November 9, 2026, requires the warning to be included in the Warnings and Precautions section of product labels. It covers medicines including Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Victoza, Saxenda, Trulicity, Xultophy, Soliqua and Foundayo.</p>
<p>The FDA reviewed data from 126 clinical trials involving 134,253 patients. The analysis identified 15 probable NAION cases: 10 among GLP-1 users and five among comparator groups. The incidence was 6.4 cases per 100,000 person-years among GLP-1 users, compared with 3.8 among comparator groups.</p>
<p>A separate FDA real-world study found a higher risk among GLP-1 users compared with patients taking DPP-4 inhibitors (hazard ratio 1.43). However, the increase was not statistically significant when compared with SGLT-2 inhibitors.</p>
<p>Based on its assessment of clinical trials, real-world evidence and published studies, the FDA concluded that there is a potential increased risk of NAION associated with GLP-1 medicines. However, it has not established a causal relationship.</p>
<p>NAION occurs when blood flow to the front part of the optic nerve is reduced. Symptoms include sudden, painless vision loss in one eye, blind spots, tunnel vision and blurred central vision. The condition can cause permanent damage.</p>
<p>The FDA has advised patients experiencing sudden vision changes to contact their healthcare professional immediately. Clinicians should promptly refer suspected cases to an ophthalmologist and consider discontinuing GLP-1 treatment in patients diagnosed with NAION, unless the benefits outweigh the risks.</p>
<p>The agency has clarified that the risk remains rare and has not advised patients to stop their medication as a precaution. Patients should discuss any treatment-related concerns with their healthcare professionals.</p>
<p>The post <a href="https://www.expresspharma.in/fda-mandates-rare-vision-loss-warning-across-all-glp-1-drugs/">FDA mandates rare vision-loss warning across all GLP-1 drugs</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Diabetes Month: The Top Five Endocrine Society Journal Articles on Diabetes of 2026</title>
<link>https://edusehat.com/en/diabetes-month-the-top-five-endocrine-society-journal-articles-on-diabetes-of-2026</link>
<guid>https://edusehat.com/en/diabetes-month-the-top-five-endocrine-society-journal-articles-on-diabetes-of-2026</guid>
<description><![CDATA[ November is of course National Diabetes Month, and there have been some very interesting developments in the field since last November. We found the top five Endocrine Society journal articles on diabetes from the past year, and we’re proud to show them to you here. GLP-1 receptor agonists and the risk of fragility fractures in […]
The post Diabetes Month: The Top Five Endocrine Society Journal Articles on Diabetes of 2026 appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/jcem_110_1cover-1-e1786367244743.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 06:50:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Diabetes, Month:, The, Top, Five, Endocrine, Society, Journal, Articles, Diabetes, 2026</media:keywords>
<content:encoded><![CDATA[<p>November is of course National Diabetes Month, and there have been some very interesting developments in the field since last November. We found the top five Endocrine Society journal articles on diabetes from the past year, and we’re proud to show them to you here. GLP-1 receptor agonists and the risk of fragility fractures in […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/diabetes-monthh-the-top-five-endocrine-society-journal-articles-on-diabetes-of-2026/">Diabetes Month: The Top Five Endocrine Society Journal Articles on Diabetes of 2026</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Argenx Expands Immunology Capabilities with Up&#45;to&#45;$1.15B UNP Acquisition</title>
<link>https://edusehat.com/en/argenx-expands-immunology-capabilities-with-up-to-115b-unp-acquisition</link>
<guid>https://edusehat.com/en/argenx-expands-immunology-capabilities-with-up-to-115b-unp-acquisition</guid>
<description><![CDATA[ The deal is designed to marry UNP’s macrocyclic peptide discovery platform with Argenx’s immunology innovation capabilities to broaden the buyer’s ability to develop oral or long-acting treatments for serious immune-mediated diseases.
The post Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Argenx-research-lab-shot__Screenshot-2026-11-10-110538-JPEG.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 02:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Argenx, Expands, Immunology, Capabilities, with, Up-to-1.15B, UNP, Acquisition</media:keywords>
<content:encoded><![CDATA[<p>More than a year after they began partnering to develop oral macrocyclic peptides against multiple historically “undruggable” targets, Argenx has agreed to acquire Unnatural Products (UNP) for up to $1.15 billion, the companies said.</p>
<p>The deal—Argenx’s second planned acquisition announced in nearly four months—is designed to marry UNP’s macrocyclic peptide discovery platform with Argenx’s immunology innovation capabilities to broaden the buyer’s ability to develop oral or long-acting treatments for serious immune-mediated diseases. The buyout would transform Argenx from a minority stakeholder in privately held UNP to the sole owner of its shares.</p>
<p>Argenx is looking to diversify its pipeline beyond its antibody-based portfolio, which is led by the blockbuster franchise consisting of marketed drugs Vyvgart<sup>®</sup> (efgartigimod alfa-fcab) injection, indicated to treat adults with generalized myasthenia gravis (gMG); and Vyvgart Hytrulo<sup>®</sup> (efgartigimod alfa and hyaluronidase-qvfc), a subcutaneous treatment combination of the neonatal Fc receptor inhibitor (FcRn) and endoglycosidase that is indicated for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).</p>
<p>The Vygart/Vyvgart Hytrulo franchise generated $4.534 billion in net product sales during the first nine months of 2026—up 58% from $2.866 billion in January-September a year ago. During the third quarter, Argenx racked up $1.721 billion, up 53% from $1.127 billion in Q3 2025.</p>
<p>“Our ambition is to be the leading immunology innovation company, and as Argenx builds its next chapter, we are investing with discipline where it will count the most for patients,” Argenx CEO Karen Massey said in a statement.</p>
<h4><strong>‘Shots on goal’</strong></h4>
<p>Argenx’s acquisition of UNC builds on a <a href="https://www.genengnews.com/topics/drug-discovery/unnatural-products-argenx-partner-on-macrocyclic-peptides-for-immune-disease/" target="_blank" rel="noopener">collaboration launched in July 2025</a> to develop immunology drugs: “What the platform’s about is being able to take smart shots on goal” in order to “find a successful hypothesis to weave your way through that chemical landscape to a development candidate,” Cameron Pye, PhD, UNP’s CEO and co-founder, told <em>GEN</em>.</p>
<p>The partners agreed to apply UNP’s drug discovery platform, which combines AI-guided compound design, massively parallel synthesis, and direct-to-biology screening capabilities. UNP agreed to conduct research and development until IND-enabling studies, with Argenx having the exclusive option to develop and commercialize products against these targets across multiple indications.</p>
<p>The companies have not disclosed details of their progress toward developing new candidates. Argenx is among UNP’s biopharma giant collaboration partners, along with:</p>
<ul>
<li><strong>BridgeBio Pharma</strong>—Undisclosed value, launched in 2024 to develop macrocyclic peptides for rare diseases and oncology.</li>
<li><strong>Novartis</strong>—Up to $1.8 billion of which $100 million was paid upfront, launched in February to develop an undisclosed cardiovascular disease program.</li>
<li><strong>Merck & Co</strong>.—Undisclosed upfront payment up to $220 million in milestone payments, launched in 2024 to develop macrocyclic candidates against an oncology therapeutic target.</li>
</ul>
<p>“After working together for more than two years, we also know there is a strong fit in how we work: science first, entrepreneurial and focused on patients,” Massey added. “We want to preserve what has made UNP successful while bringing the strengths of both teams together.”</p>
<p>Argenx shares traded on Euronext Brussels rose modestly on news of the deal, climbing nearly 5% Monday from €815.80 ($906.11) to €853.80 ($948.23). The company’s American depositary shares (ADSs) traded on the Nasdaq Global Select Market rose nearly 4% from $927.21 to $962.27.</p>
<p>On Tuesday, Argenx’ Euronext Brussels shares inched up another 1% to €863.40 ($958.89) as of 11:01 am ET, while its ADSs barely rose 0.21% to $964.27 in morning trading as of 11:15 am ET.</p>
<h4><strong>Skittishness and support</strong></h4>
<p>The modest stock bounce appeared to reflect lingering skittishness by investors following a pair of setbacks over the past month.</p>
<p>Argenx shares fell more than 10% on October 8 after it announced it was ending the Phase III UNITY trial (<a href="https://clinicaltrials.gov/study/NCT06684847" target="_blank" rel="noopener">NCT06684847</a>)  assessing efgartigimod subcutaneous (SC) in adults with moderate-to-severe Sjögren’s disease. Argenx followed the recommendation of UNITY’s Independent Data Monitoring Committee (IDMC) to stop the trial for futility after concluding that the study would be unable to meet its primary endpoint.</p>
<p>Then on October 23, the FDA jolted Argenx by requesting the company carry out an additional confirmatory registrational trial evaluating efgartigimod SC in dermatomyositis (DM). The agency reasoned that while Argenx showed positive overall results in the Phase II/III ALKIVIA trial (<a href="https://clinicaltrials.gov/study/NCT05523167" target="_blank" rel="noopener">NCT05523167</a>)  assessing the drug in DM, the subgroup of DM patients was too small for the results to achieve statistical significance.</p>
<p>In contrast to the investor reaction, Thomas J. Smith, senior managing director, immunology and metabolism, and a senior research analyst with Leerink Partners, voiced support for the planned acquisition.</p>
<p>“We like this deal for ARGX as it brings engineering and design capabilities to generate macrocyclic peptides (i.e., oral, long-acting, etc.), signaling confidence in oral FcRn potential and expanding on the company’s early-stage pipeline with potential for further modalities beyond specialized antibodies,” Smith wrote Monday in a research note.</p>
<p>“We believe the deal represents potential for longer-term strategic value given both I&I and large pharma’s focus on oral and long-acting therapeutics capable of driving enhanced efficacy with improved convenience vs. conventional biologics,” Smith added.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Pye and Joshua Schwochert, PhD, co-founded UNP in 2016, launching the company in a garage on the west side of Santa Cruz, CA, during their final year of doctoral research in the <a href="https://lokey.chemistry.ucsc.edu/members/slokey_picture/" target="_blank" rel="noopener">lab of Scott Lokey, PhD, at the University of California, Santa Cruz</a>. Lokey’s research group focuses on understanding the relationship of stereochemistry and N-Methylation patterns pertaining to cell permeability, as well as applying the relationship to create diverse and permeable drug scaffolds with exquisite selectivity that constrained peptides can offer.</p>
<p>UNP raised $32 million in a Series A financing completed in 2023 and led by Merck Global Health Innovation Fund and TechBio-focused ARTIS Ventures.</p>
<h4><strong>Second acquisition</strong></h4>
<p>If the deal is completed as planned, UNC would be Argenx’s second acquisition this year. The first is Forte Biosciences, a developer of targeted immunotherapies for autoimmune and autoimmune-related diseases. Argenx on August 27 completed its <a href="https://www.genengnews.com/topics/translational-medicine/argenx-expands-immunology-portfolio-with-2-2b-buyout-of-forte-biosciences/" target="_blank" rel="noopener">up to $2.2 billion acquisition of Forte</a>, in a deal also intended to expand the buyer’s immunology portfolio with a pipeline led by FB102, a first-in-class anti-CD122 monoclonal antibody that has shown promising early clinical stage data.</p>
<p>Argenx agreed to acquire UNP for $550 million in upfront cash, plus up to $595 million in payments tied to achieving specified development and regulatory milestones.</p>
<p>The boards of both companies have approved the transaction, which is expected to be completed by year’s end subject to customary closing conditions.</p>
<p>Following closing of the deal, UNP’s staff and leadership will continue to operate from its Santa Cruz, CA, site, which will serve as Argenx’s hub for peptide discovery. UNP will continue to lead its discovery work within a strategic framework agreed upon with Argenx, which will bring clinical development and commercialization capabilities to advance peptide treatments to patients.</p>
<p>“Today is a tremendous milestone for UNP and a testament to the exceptional work of our scientists, employees, collaborators and supporters,” CEO Pye stated. “From the earliest days, we believed our platform had the potential to redefine what is possible in the discovery and design of new medicines. I am so proud of what our team has accomplished and believe Argenx provides the ideal environment to accelerate and amplify that vision to bring innovative therapies to patients.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/argenx-expands-immunology-capabilities-with-up-to-1-15b-unp-acquisition/">Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Automation a Path to Lower Cell Therapy Costs</title>
<link>https://edusehat.com/en/automation-a-path-to-lower-cell-therapy-costs</link>
<guid>https://edusehat.com/en/automation-a-path-to-lower-cell-therapy-costs</guid>
<description><![CDATA[ Australian developer Currus Bio predicts that automating the production of its candidate cancer cell therapy, CUR-001, using the Cocoon platform will reduce costs and enhance its ability to scale production as the product moves through trials.
The post Automation a Path to Lower Cell Therapy Costs appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/08/GettyImages-1320590180small-1024x738.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 02:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Automation, Path, Lower, Cell, Therapy, Costs</media:keywords>
<content:encoded><![CDATA[<p>Australian developer Currus Biologics says automating the production process for CUR-001, a candidate cell therapy for solid tumors, has significantly reduced the amount of viral vector required to make the product.</p>
<p>CEO Sam Cobb shared <a href="https://finance.yahoo.com/healthcare/articles/octane-biotech-currus-biologics-automate-210000192.html" target="_blank" rel="noopener">details</a> of the project this week, telling <em>GEN</em> that, in a bid to minimize manual handling requirements, the firm transferred the existing CUR-001 manufacturing process to the Cocoon automated production platform.</p>
<p>“This involved optimizing several key manufacturing parameters, including the amount of lentiviral vector required for transduction, cell densities during seeding and transduction, and the use of different starting materials.</p>
<p>“Importantly,” she continues, “this optimization enabled us to reduce the amount of lentiviral vector required for manufacturing, which has the potential to significantly reduce manufacturing costs.</p>
<p>“The objective was not to change the fundamental biology of CUR-001, but to establish a more consistent, reproducible, and efficient manufacturing process that can support future clinical and commercial development.”</p>
<p>The optimized process has now been transferred to Melbourne-based contract manufacturer, Cell Therapies (CTPL), which will produce CUR-001 for Currus’ planned Phase I clinical trial program.</p>
<p>The process automation project was supported by Swiss CDMO Lonza, which until recently owned a controlling stake in the Cocoon platform, and Octane Biotech, the original developer that re-acquired the technology in March.</p>
<h4><strong>Scale-up benefits</strong></h4>
<p>Automating the CUR-001 production process is also likely to aid Currus and its manufacturing partners as the cell therapy moves through clinical development toward commercial launch, Cobb says.</p>
<p>“One of the advantages of the Cocoon platform is its modular design, which allows manufacturing capacity to be expanded by adding additional units rather than fundamentally changing the manufacturing process.</p>
<p>“A final decision on commercial manufacturing will depend on clinical outcomes, regulatory requirements, anticipated patient demand, manufacturing capacity, and commercial economics,” she says.</p>
<h4><strong>Automation advantages</strong></h4>
<p>Process automation is likely to become more common in CAR T cell therapy manufacturing, but the widespread use of fully autonomous processes is unlikely, according to Cobb.</p>
<p>“One of the major barriers to broader adoption of autologous CAR T cell therapies is the complexity and cost of manufacturing individual patient batches. Automation provides a way to address both challenges while improving process standardization.”</p>
<p>Some core parts of cell therapy production can already be automated, with things like cell selection, activation, genetic modification, expansion, and harvest being the obvious examples.</p>
<p>However, other aspects of production—material collection, sampling quality control, batch review and release, cryopreservation, and distribution—may prove harder to automate, Cobb says.</p>
<p>“Some of these activities may also become increasingly automated, but I do not think fully autonomous manufacturing is a prerequisite for achieving meaningful improvements in efficiency,” she adds.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/automation-a-path-to-lower-cell-therapy-costs/">Automation a Path to Lower Cell Therapy Costs</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Extracellular Vesicle Product Developer Creates Potency Assay</title>
<link>https://edusehat.com/en/extracellular-vesicle-product-developer-creates-potency-assay</link>
<guid>https://edusehat.com/en/extracellular-vesicle-product-developer-creates-potency-assay</guid>
<description><![CDATA[ A company developing extracellular vesicle-based products has developed a potency assay for quality control. They hope to adapt it for future products and scale it to commercial manufacturing.
The post Extracellular Vesicle Product Developer Creates Potency Assay appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Vivienne-Evox-Neurons-and-EVs-image.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 02:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Extracellular, Vesicle, Product, Developer, Creates, Potency, Assay</media:keywords>
<content:encoded><![CDATA[<p>Developing potency assays for complex new biologics, such as extracellular vesicle (EV)-based products, can be a challenge, with some manufacturers putting it off until regulators ask hard questions. That’s the view of Evox Therapeutics, who say they’ve succeeded in developing a potency assay that can be hopefully adapted to multiple future products in their pipeline.</p>
<p>According to Rebecca Gavin, PhD, chemistry, manufacturing, and controls (CMC) director at Evox, the assay has already been pre-qualified and transferred into a quality control (QC) laboratory.</p>
<p>The company hopes it can be fully qualified during a planned first-in-human study next year and, in the future, be used for batch QC during commercial production of their products.</p>
<p>“Our product is quite complex, and that’s why people often struggle to develop a potency assay,” Gavin says.</p>
<p>“Sometimes CMC can get kicked down the road a little, with people thinking they’ll worry about it later when they have more funding, so [the fact] that we’ve developed one already is something we’re really proud of.”</p>
<p>Evox’s product encapsulates a ribonucleoprotein (RNP) within an EV that is used as the delivery mechanism. The RNP is coupled to a guide RNA, which targets a specific gene with the aim of reducing protein production, Gavin explains.</p>
<p>Although this could spur lots of complex questions, such as whether the EV is taken up by the cell and whether the editing machinery makes it to the nucleus, she says that this can lead to over-characterization and over-testing.</p>
<p>“You don’t want to have a batch release assay panel that’s 50 assays long, where you’re having to measure and quantify every aspect of a complex product, and need to dedicate 50% of your batch to testing, especially in the gene therapy field where batch yields are already tricky,” she explains.</p>
<p>To get around this, the company developed an assay that simply measures potency, thereby demonstrating that the product is being successfully assembled and delivered to a cell.</p>
<p>The assay doses EV products at different concentrations onto an immortalized adherent cell line, she says. The cells are allowed to grow for a while, and then the cell lysates are tested on a Jess Simple Western system.</p>
<p>“We get a very specific quantitative readout, and that allows us to determine a dose-response curve, which shows how active our product is at reducing our protein of interest,” she explains.</p>
<p>Going forward, the company hopes this simple potency assay can be fully qualified for commercial production and adapted for multiple products in their pipeline.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/extracellular-vesicle-product-developer-creates-potency-assay/">Extracellular Vesicle Product Developer Creates Potency Assay</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Hybrid Model Captures Lactate Run&#45;Away and Back&#45;Metabolism</title>
<link>https://edusehat.com/en/hybrid-model-captures-lactate-run-away-and-back-metabolism</link>
<guid>https://edusehat.com/en/hybrid-model-captures-lactate-run-away-and-back-metabolism</guid>
<description><![CDATA[ A hybrid model provides hard-to-achieve insights into lactate performance during bioprocessing, creating conditions for more accurate predictions to better manage key batch parameters and variability.
The post Hybrid Model Captures Lactate Run-Away and Back-Metabolism appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Dutton-Gemini_Generated_Image_xq337mxq337mxq33.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 02:50:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Hybrid, Model, Captures, Lactate, Run-Away, and, Back-Metabolism</media:keywords>
<content:encoded><![CDATA[<p>A new hybrid mechanistic-data-driven model of lactate consumption and production for mammalian cell cultures captures both lactate back-metabolism and lactate run-away. It also provides accurate real-time predictions of viable cell density, monoclonal antibody, glucose, and lactate concentrations during bioprocessing, according to researchers from University College London and AstraZeneca.</p>
<p>For biopharmaceutical manufacturers, this model, outlined in a recent <a href="https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/full/10.1002/bit.70417" target="_blank" rel="noopener">paper</a>, provides another tool to accurately predict batch-to-batch variability and failing runs early in the process, according to a team led by principal investigator Li Qin, PhD, postdoctoral research fellow, and senior researcher Stephen Goldrick, PhD, associate professor, digital bioprocess engineering, both at University College London.</p>
<p>By fine-tuning the initial model, the team improved upon the original 88% accuracy rate, reducing the root mean squared error by about 50% for glucose and by about 30% for lactate.</p>
<p>“This model addresses a key industrial challenge,” Goldrick tells <em>GEN</em>. “In fed-batch CHO cultures, cells normally switch from lactate production to lactate back-metabolism. If they do not, the culture goes into lactate run-away, which can cause batch failure or a significantly lower titer. This switch is poorly understood and rarely controlled.”</p>
<p>Therefore, a lactate switch detection algorithm is one of the key features of this model. As Goldrick explains, “Our model uses pH as a soft sensor to detect early, at around day 5, whether the cells will undergo lactate back-metabolism. This information could be built into the control strategy, so the process can be adjusted to avoid lactate run-away.”</p>
<h4><strong>Stratifying parameters</strong></h4>
<p>The novelty of this approach is three-fold, they say, encompassing “new kinetic equations to accurately describe Chinese hamster ovary cell growth and death dynamics…new equations for lactate production and consumption…to better capture metabolic transitions under varying process conditions…and adaptive kinetic updating integrated with a lactate-switch detection algorithm to incorporate online and offline measurements into the model dynamically.”</p>
<p>The model was trained with online data such as pH values, glucose flow rates, and other nutrient feeds combined with historical data such as concentrations of glucose, lactate, and mAb concentrations as well as cell densities accumulated from random runs. The team trained the model on five runs that switched from producing lactate to consuming it (called back-metabolism), three to evaluate predictive performance, one that exhibited lactate run-away (in which the cell culture continued producing lactate), and one external lactate run-away scenario.</p>
<p>That combination helped the researchers determine which parameters could be predicted accurately with online data and which highly variable parameters needed to be fine-tuned using a combination of real-time and historic data. “This targeted strategy significantly reduces model update time compared to full recalibration, while maintaining predictive accuracy,” they note.</p>
<p>Ten is a relatively small number of training runs, the scientists admit, but the values predicted by the model in those runs closely matched those of actual measured values, suggesting this model can make a real contribution to the industry. Further work will extend the measured production values to include amino acid consumption, ammonia accumulation, osmolality dynamics, and product quality attributes.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/hybrid-model-captures-lactate-run-away-and-back-metabolism/">Hybrid Model Captures Lactate Run-Away and Back-Metabolism</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From Farm Waste to Medical Nanoparticles</title>
<link>https://edusehat.com/en/from-farm-waste-to-medical-nanoparticles</link>
<guid>https://edusehat.com/en/from-farm-waste-to-medical-nanoparticles</guid>
<description><![CDATA[ Fruit peels, rice husks, and other crop leftovers can yield biomedical nanoparticles, but variable feedstocks, scale-up hurdles, and thin safety data still stand between lab promise and reliable commercial bioprocessing.
The post From Farm Waste to Medical Nanoparticles appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Mike-Pandey-bionanomaterials_GBPN_IMAGE_12NOV26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 02:50:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, Farm, Waste, Medical, Nanoparticles</media:keywords>
<content:encoded><![CDATA[<p>The world’s farms produce a mountain of leftovers every year—more than six billion tons of crop residues in 2020 alone, by one estimate. Much of it is burned or buried. A new review argues that a good share could instead become raw material for biomedical nanoparticles.</p>
<p>Writing in <a href="https://doi.org/10.3389/fbiom.2026.1831334" target="_blank" rel="noopener"><em>Frontiers in Biomaterials Science</em></a>, a team led by Sadanand Pandey, PhD, professor in the School of Bioengineering and Food Technology at Shoolini University in Solan, India, surveyed research from 2015 to 2026 on turning agricultural waste into metallic, polymeric, and carbon-based nanostructures. The picture is promising but unfinished.</p>
<p>The appeal rests on the chemistry the plants have already done. Peels, husks, seeds, and pomace are packed with polyphenols, flavonoids, and polysaccharides that can reduce metal ions and coat the resulting particles, replacing harsh chemical reagents. Silica-rich rice and wheat husks are favored sources of silica nanoparticles, while sugarcane bagasse supplies abundant cellulose.</p>
<p>The studies the authors compiled point to a range of uses. Silver nanoparticles made with pomegranate peel extract inhibited <em>E. coli</em> at 16 µg/mL. Zinc oxide particles produced with banana peels broke down 90% of a test dye within two hours and fought <em>Staphylococcus aureus</em> biofilms. Carbon dots made from fruit and vegetable scraps glow brightly enough for imaging and appear far less toxic than conventional semiconductor quantum dots.</p>
<p>The process economics look attractive too. One study cited in the review reported that biologically mediated synthesis cut energy use by 30% and costs by 40% while raising output by 50% compared with conventional methods.</p>
<p>But the authors are frank about what stands in the way, and much of it is a familiar bioprocessing problem: raw-material variability. A banana peel’s chemistry depends on the variety, growing conditions, harvest date, and how the waste was handled. Those differences carry through to particle size, shape, surface charge, and stability, making batch-to-batch consistency hard to guarantee.</p>
<p>Scale-up adds more friction. Green reactions tend to run slower than chemical ones, and lignocellulosic feedstocks often need pretreatment, which can erode cost savings. Without standard protocols for synthesis, purification, and characterization, regulators have little to benchmark against. Long-term <em>in vivo</em> safety data are also thin, and risks such as oxidative stress and bioaccumulation need systematic study before any clinical use.</p>
<p>To close those gaps, the team calls for standardized methods, scalable biorefinery models, and tools such as AI-assisted metabolomic analysis to fine-tune the process. If those pieces fall into place, today’s crop waste could become a dependable supply chain for tomorrow’s nanomedicine.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/from-farm-waste-to-medical-nanoparticles/">From Farm Waste to Medical Nanoparticles</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Breast Cancer Chemotherapy May Impact Biological Aging and Loss of Healthy Life Years</title>
<link>https://edusehat.com/en/how-breast-cancer-chemotherapy-may-impact-biological-aging-and-loss-of-healthy-life-years</link>
<guid>https://edusehat.com/en/how-breast-cancer-chemotherapy-may-impact-biological-aging-and-loss-of-healthy-life-years</guid>
<description><![CDATA[ Chemotherapy helps many women survive breast cancer, but the results of new research suggest that chemotherapy may also accelerate biological aging beyond chronological age and increase the risk of earlier death from other causes. 
The post How Breast Cancer Chemotherapy May Impact Biological Aging and Loss of Healthy Life Years appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2020/09/Sep29_2020_Getty_1181263174_DoctorAndPatient-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 02:50:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Breast, Cancer, Chemotherapy, May, Impact, Biological, Aging, and, Loss, Healthy, Life, Years</media:keywords>
<content:encoded><![CDATA[<p>Chemotherapy helps many women survive breast cancer, but the results of new research suggest that chemotherapy may also accelerate biological aging beyond chronological age and increase the risk of earlier death from other causes.  The study, by researchers at Georgetown University’s Lombardi Comprehensive Cancer Center and colleagues, is the first to estimate the lifetime balance of the benefits of curing breast cancer versus possible acceleration of biological aging using population-based simulation modeling. The findings point to a need to explore whether interventions to slow or reverse biological aging could improve long-term health for breast cancer survivors.</p>
<p>“Female breast cancer survivors comprise the single largest segment of the 18.6 million cancer survivors in the United States, said Jeanne Mandelblatt, MD, MPH, director of the Georgetown Lombardi’s Institute for Cancer and Aging Research (I-CARE). “However, some forms of chemotherapy that extend survival have triggered a secondary crisis: treatment-induced molecular damage to the body’s cells and organs, causing acceleration of biological age.” Mandelblatt notes that this accelerated biological aging can result in loss of healthy life years due to earlier onset of aging diseases and conditions like frailty and cognitive problems. “Chemotherapy-induced biologic aging can persist for years, and the effects of this acceleration are not visible for many years.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Senior author Mandelblatt, together with first and corresponding author Swarnavo Sarkar, PhD, a member of I-CARE at Lombardi, and colleagues reported their findings in <em>JAMA Open Network</em>, titled “<a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2856363?resultClick=3" target="_blank" rel="noopener">Chemotherapy-Induced Biological Age Acceleration and Lifetime Outcomes in Breast Cancer Survivors</a>.” In their report the investigators concluded “These findings suggest that integrating knowledge about biological aging into survivorship care may help identify opportunities to deploy pharmaceutical and behavioral interventions that target aging-related processes.”</p>
<p>While breast cancer survival rates have been steadily increasing over time due to advances in screening and therapeutics, growing evidence also suggests that some breast cancer survivors may experience long-term toxic effects of chemotherapy, including accelerated aging (biological age in excess of chronological age), the authors wrote. This may be associated with the development of chronic aging-related diseases such as cardiovascular disease and diabetes.</p>
<p>“One mechanism by which chemotherapy accelerates aging is through increases in the accumulation of senescent cells, defined as cells that have stopped dividing but are resistant to cell death,” the team continued. “These cells promote further aging through changes in tissue modeling and inflammation, contributing to excess non–breast cancer morbidity and mortality.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>To investigate the potential long-term effect of cancer therapy on the biological aging of breast cancer survivors the team carried out a comparative effectiveness study that used an established population-level simulation model, and current data on chemotherapy’s effects on cellular senescence. “This comparative effectiveness study used an established Cancer Intervention and Surveillance Modeling Network breast cancer model integrating biological aging with breast cancer epidemiology,” they wrote.</p>
<p>The investigators used data about the relationships between chemotherapy and blood levels of the <em>p16 </em>protein, a common biomarker of senescence, to estimate the biological age of breast cancer survivors over their remaining lives. “Biological aging was modeled using data on distributions of post-chemotherapy senescence measured by <em>p16<sup>INK4a</sup></em> levels, and the model assumed chemotherapy-induced senescence only affected non–breast cancer mortality,” they explained. The <em>p16</em> protein levels were used for this study because there is good data from published research and there is evidence from the lab that clearing <em>p16</em>-rich cells could increase their lifespan. There are also evolving studies of other biological aging markers that could be used in future studies.</p>
<p>The population simulation model the researchers developed was based on women who were 30 to 79 years of age; the model compared the effects of types of chemotherapy that caused more vs. less cellular damage (i.e., cytotoxic) and biological age acceleration. Breast cancer survivors who received the most cytotoxic anthracycline regimens were estimated to have lost 9.4 remaining life years on average due to earlier onset of aging-related diseases. “Survivors diagnosed at early ages and/or treated with the most cytotoxic regimens were projected to have the greatest biological age acceleration, with increased risk of death from non–breast cancer causes at earlier chronological ages than expected in general populations,” the researchers stated.</p>
<p>Sarkar added. “The key to our methodology is accounting for the fact that while chemotherapy improves breast cancer survival, treatment can also increase damage to normal tissues. This affects many aging systems, including increasing the number of senescent cells, which are damaged cells that have stopped dividing and are also resistant to cell death. Senescent cells secrete biological molecules that cause several aging-related diseases through added tissue damage and inflammation.”</p>
<p>The data analysis was possible because both Mandelblatt and Sarkar are members of CISNET (Cancer Intervention and Surveillance Modeling Network), a 25-year-old consortium of National Cancer Institute-sponsored investigators who use simulation modeling to improve the understanding of cancer prevention, screening, and treatment and their effects on population trends in incidence and mortality.</p>
<p>While treatment choices will always be based on the potential to cure, Mandelblatt hopes that the model results can be used to guide future studies evaluating the benefits of testing biological age after treatment ends. “Since the goal of treatment is to improve breast cancer survival, oncologists should not modify treatment decisions based on potential for accelerated aging, but our results suggest the need for awareness of possible age acceleration,” the researchers pointed out.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The goal would be to provide personalized survivorship care to mitigate any aging effects of therapy and improve quality of life and health over a survivor’s lifetime. This is particularly salient now, Mandelblatt noted, since physical activity and medications being used for other purposes show promise in slowing accelerated aging in breast and other cancer survivors, which may recoup the loss of life years estimated in this study.</p>
<p>And as the authors also stated, more research is needed to test the impact of biological age assessment and management of biological age acceleration on survivorship outcomes. “Knowledge about the risks of accelerated aging among women exposed to chemotherapy may help motivate lifestyle changes,” they stated. “Further, as evidence on the safety and utility of senolytic and other anti-aging drugs evolves, modeling may help identify populations of survivors at risk for age acceleration who might benefit from pharmacologic intervention.”</p>
<p>Sarkar added, “There are two next steps we are planning, the first being expanding the scope of this methodology for other types of breast cancer treatments, such as radiotherapy, immunotherapies, targeted therapies and hormonal treatments, which also appear to speed up aging, with effects potentially lasting for many years after treatment. We also plan to include information about survivor characteristics to help guide future conversations about individual outcomes.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/how-breast-cancer-chemotherapy-may-impact-biological-aging-and-loss-of-healthy-life-years/">How Breast Cancer Chemotherapy May Impact Biological Aging and Loss of Healthy Life Years</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Green Practice News – October 2026 – copy</title>
<link>https://edusehat.com/en/green-practice-news-october-2026-copy</link>
<guid>https://edusehat.com/en/green-practice-news-october-2026-copy</guid>
<description><![CDATA[ Green Practice News October 2026 In This Issue: A Green Practice is Less Expensive New Waiting Room Brochures in English, Spanish, and Chinese […]
The post Green Practice News – October 2026 – copy first appeared on My Green Doctor. ]]></description>
<enclosure url="https://mygreendoctor.org/wp-content/uploads/2021/06/Layer_1-8.svg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 02:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Green, Practice, News, –, October, 2026, –, copy</media:keywords>
<content:encoded><![CDATA[<div data-elementor-type="wp-post" data-elementor-id="18659" class="elementor elementor-18659" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-59531297 mgd-news elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="59531297" data-element_type="section" data-e-type="section" data-settings='{"background_background":"classic"}'>
						<div class="elementor-container elementor-column-gap-no">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-7baa85e5" data-id="7baa85e5" data-element_type="column" data-e-type="column" data-settings='{"background_background":"classic"}'>
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-608d2e45 elementor-widget elementor-widget-text-editor" data-id="608d2e45" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<div class="mgd-text"><h1><br>
<span><strong><span><span>Green Practice News</span></span></strong><br>
<span><strong>October 2026</strong></span></span></h1></div>								</div>
				</div>
				<div class="elementor-element elementor-element-14b5eda4 elementor-widget elementor-widget-image" data-id="14b5eda4" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
															<img fetchpriority="high" decoding="async" width="564" height="376" src="https://mygreendoctor.org/wp-content/uploads/2026/09/053f14ed-3419-349b-0e95-4bd60d9ee96b.jpg" class="attachment-full size-full wp-image-18663" alt="" srcset="https://mygreendoctor.org/wp-content/uploads/2026/09/053f14ed-3419-349b-0e95-4bd60d9ee96b.jpg 564w, https://mygreendoctor.org/wp-content/uploads/2026/09/053f14ed-3419-349b-0e95-4bd60d9ee96b-300x200.jpg 300w" sizes="(max-width: 564px) 100vw, 564px">															</div>
				</div>
				<div class="elementor-element elementor-element-2e95301e elementor-widget elementor-widget-text-editor" data-id="2e95301e" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<div class="mgd-text"><div><span><span><span><strong>In This Issue:</strong></span></span></span></div>
<ul>
<li><span><span><span>A Green Practice is Less Expensive</span></span></span></li>
<li><span><span><span>New Waiting Room Brochures in English, Spanish, and Chinese</span></span></span></li>
<li><span><span><span>Guiding Children to Save Energy</span></span></span></li>
<li><span><span><span>Resilience Planning Before the Emergency</span></span></span></li>
</ul></div>								</div>
				</div>
				<div class="elementor-element elementor-element-4403e85f elementor-widget-divider--view-line elementor-widget elementor-widget-divider" data-id="4403e85f" data-element_type="widget" data-e-type="widget" data-widget_type="divider.default">
				<div class="elementor-widget-container">
							<div class="elementor-divider">
			<span class="elementor-divider-separator">
						</span>
		</div>
						</div>
				</div>
				<div class="elementor-element elementor-element-7e480162 elementor-widget elementor-widget-image" data-id="7e480162" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
																<a href="https://youtu.be/C_ySdUacew4?is=mVHPWsXYNFrThfFe">
							<img decoding="async" width="640" height="360" src="https://mygreendoctor.org/wp-content/uploads/2026/09/086dcb237a7a279b471e48405faaf9d3.png" class="attachment-full size-full wp-image-18672" alt="" srcset="https://mygreendoctor.org/wp-content/uploads/2026/09/086dcb237a7a279b471e48405faaf9d3.png 640w, https://mygreendoctor.org/wp-content/uploads/2026/09/086dcb237a7a279b471e48405faaf9d3-300x169.png 300w" sizes="(max-width: 640px) 100vw, 640px">								</a>
															</div>
				</div>
				<div class="elementor-element elementor-element-1830e28c elementor-widget elementor-widget-text-editor" data-id="1830e28c" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<div class="mgd-text"><div>   <span>What excites me this month at My Green Doctor (click to watch)</span></div></div>								</div>
				</div>
				<div class="elementor-element elementor-element-395e67 elementor-widget-divider--view-line elementor-widget elementor-widget-divider" data-id="395e67" data-element_type="widget" data-e-type="widget" data-widget_type="divider.default">
				<div class="elementor-widget-container">
							<div class="elementor-divider">
			<span class="elementor-divider-separator">
						</span>
		</div>
						</div>
				</div>
				<div class="elementor-element elementor-element-dd28c5d elementor-widget elementor-widget-image" data-id="dd28c5d" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
															<img decoding="async" width="1200" height="1200" src="https://mygreendoctor.org/wp-content/uploads/2026/09/10d2edfe-df1a-e74e-9c4c-4d757f2ee6b2.png" class="attachment-full size-full wp-image-18664" alt="" srcset="https://mygreendoctor.org/wp-content/uploads/2026/09/10d2edfe-df1a-e74e-9c4c-4d757f2ee6b2.png 1200w, https://mygreendoctor.org/wp-content/uploads/2026/09/10d2edfe-df1a-e74e-9c4c-4d757f2ee6b2-300x300.png 300w, https://mygreendoctor.org/wp-content/uploads/2026/09/10d2edfe-df1a-e74e-9c4c-4d757f2ee6b2-1024x1024.png 1024w, https://mygreendoctor.org/wp-content/uploads/2026/09/10d2edfe-df1a-e74e-9c4c-4d757f2ee6b2-150x150.png 150w, https://mygreendoctor.org/wp-content/uploads/2026/09/10d2edfe-df1a-e74e-9c4c-4d757f2ee6b2-768x768.png 768w" sizes="(max-width: 1200px) 100vw, 1200px">															</div>
				</div>
				<div class="elementor-element elementor-element-4df0741e elementor-widget elementor-widget-text-editor" data-id="4df0741e" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<div class="mgd-text"><h1><span><span><strong><span> </span>A Greener Practice is a Less Expensive Practice</strong></span></span></h1>

<div dir="ltr"><span><span>Healthcare practices face pressures to control expenses without compromising patient care. Energy use is one of the many operating costs where thoughtful management can create measurable savings while supporting a healthier, more efficient workplace.<br>
<br>
The potential is substantial. The U.S. Environmental Protection Agency’s ENERGY STAR program says an average commercial building can save up to 30% on energy bills through a combination of no-cost actions, strategic investment, and smart operations and maintenance. These savings can be reinvested in other priorities such as new technology and competitive salaries, while efficiency improvements can enhance the comfort, functionality and appearance of a facility.</span></span><br>
 </div>

<div dir="ltr"><span><span><strong><em>Up to 30% savings on energy bills for an average commercial building.</em><br>
                                                                                           — ENERGY STAR</strong></span></span></div>

<div dir="ltr"><br>
<span><span>For a healthcare practice, however, knowing that savings are possible is not the same as knowing where to begin. Which opportunities deserve attention first? Who should be involved? And how can improvements be sustained while staff remain focused on patient care?<br>
<br>
My Green Doctor’s practice management coaching helps healthcare teams move from good intentions to organized action. Expert coaches identify practical opportunities, engage staff, establish priorities, and make manageable improvements across many topics over time.<br>
<br>
Energy use is a good example. Opportunities may involve heating and cooling schedules; uses of lighting, computers and office equipment; purchasing decisions, or even coordination with a landlord or property manager. Because every facility is unique, expert sustainability coaches can best find those opportunities and offer a guided approach to decision-making and tracking progress.<br>
<br>
Healthcare facilities have seen the benefits. The U.S. Department of Energy reports that Cleveland Clinic’s Twinsburg Family Health and Surgery Center achieved 36% energy savings and $246,000 in annual cost savings through low- and no-cost conservation measures. Hackensack Meridian Health’s Medical Plaza, an ambulatory care facility, achieved 20% energy savings and $1.27 million in annual cost savings. These examples demonstrate the opportunity created by identifying, prioritizing, and managing efficiency improvements.<br>
<br>
My Green Doctor’s coaching progtam delivers similar results for outpatient clinics and practice. At Weill Cornell’s Internal Medicine practice at Payson House in New York City, a team led by Medical Assistant Shafon Cox and My Green Doctors’s Heather Massey MBA reduced its electricity bill by 19% and generated additional savings by eliminating the purchase of bottled water. The practice has recycling bins–it is even recyling its used batteries–offers brochures in English and Spanish to patients in the waiting room, has five minutes of My Green Doctor on the agenda of each monthly staff meeting, and proudly displays My Green Doctor’s Green Practice Recognition Certificate in the waiting room.<br>
<br>
The result is more than a collection of individual environmental actions. What is emerging is culture of resource conservation and lasting operational improvement.</span></span></div>

<div dir="ltr"><br>
<span><span><strong>About the Author:</strong> </span></span><span><span>Judy Holm is the Marketing and Communications Consultant for My Green Doctor. </span></span><span><span><span>She specializes in sustainability, resilience, circularity, healthcare, and design. An MIT-certified Climate Change Consultant, she has led more than 1,000 campaigns across the U.S. and Europe.</span></span></span></div>

<h2 dir="ltr"><span><span><strong>Resources:</strong></span></span></h2>

<div><span>1. U.S. Environmental Protection Agency, ENERGY STAR for Small Business </span><a href="https://www.energystar.gov/buildings/resources-audience/small-biz" target="_blank"><span>https://www.energystar.gov/buildings/resources-audience/small-biz</span></a><br>
<span>2. U.S. Department of Energy, Better Buildings & Better Plants Initiative: a.  </span><a href="https://betterbuildingssolutioncenter.energy.gov/beat-blog/cleveland-clinic-twinsburg-family-health-center-spends-little-and-saves-big" target="_blank"><span>https://betterbuildingssolutioncenter.energy.gov/beat-blog/cleveland-clinic-twinsburg-family-health-center-spends-little-and-saves-big</span></a><br>
<span>b.</span> <a href="https://betterbuildingssolutioncenter.energy.gov/showcase-projects/hackensack-meridian-health-medical-plaza" target="_blank"><span>https://betterbuildingssolutioncenter.energy.gov/showcase-projects/hackensack-meridian-health-medical-plaza</span></a></div></div>								</div>
				</div>
				<div class="elementor-element elementor-element-24a8732d elementor-widget-divider--view-line elementor-widget elementor-widget-divider" data-id="24a8732d" data-element_type="widget" data-e-type="widget" data-widget_type="divider.default">
				<div class="elementor-widget-container">
							<div class="elementor-divider">
			<span class="elementor-divider-separator">
						</span>
		</div>
						</div>
				</div>
				<div class="elementor-element elementor-element-41c4f1a1 elementor-widget elementor-widget-image" data-id="41c4f1a1" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
															<img loading="lazy" decoding="async" width="800" height="667" src="https://mygreendoctor.org/wp-content/uploads/2026/09/dd494b13-0d53-671b-18a6-5c03c545ca24.png" class="attachment-full size-full wp-image-18665" alt="" srcset="https://mygreendoctor.org/wp-content/uploads/2026/09/dd494b13-0d53-671b-18a6-5c03c545ca24.png 800w, https://mygreendoctor.org/wp-content/uploads/2026/09/dd494b13-0d53-671b-18a6-5c03c545ca24-300x250.png 300w, https://mygreendoctor.org/wp-content/uploads/2026/09/dd494b13-0d53-671b-18a6-5c03c545ca24-768x640.png 768w" sizes="auto, (max-width: 800px) 100vw, 800px">															</div>
				</div>
				<div class="elementor-element elementor-element-108189d elementor-widget elementor-widget-text-editor" data-id="108189d" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<div class="mgd-text"><h1><span><span><span><strong>New Brochures For Easy, Cost-Effective Teaching</strong></span></span></span></h1>

<div><span><span>Teaching patients ways to improve their health does not require a conversation during an already busy office visit. My Green Doctor has fully updated its evidence-based teaching brochures, giving healthcare practices practical, ready-to-use resources for patients and families. The collection of brochures, handouts, and posters now includes five brochures in English, four in Spanish, and three new brochures in Chinese, making environmental-health information easily accessible. Many topics are covered. The Chinese editions can be read by speakers of most Chinese languages including, of course, Mandarin and Cantonese.<br>
<br>
The brochures address issues that patients encounter in everyday life, from extreme heat and air pollution to healthy eating, green cleaning, and disaster preparedness. Each resource provides practical information that can help patients make healthier choices for themselves, their families and their communities. Our peer-reviewed, IRB-approved, published research demonstrates that patients are delighted to receive these from their health professionals and that families make changes in their homes as the result of receiving these brochures. <br>
<br>
Brochures for the waiting room can be printed by the practice or purchased at far lower cost from the My Green Doctor Foundation (</span><a href="mailto:member.services@mygreendoctor.org?subject=Interested%20in%20Waiting%20Room%20Brochures" target="_blank"><span>member.services@mygreendoctor.org</span></a><span>). Alternatively, patients can be given the QR code to read the brochures at home on their smart phones or computers. You will find these resoources at:  </span><a href="https://mygreendoctor.org/resources/waiting-room-brochures/" target="_blank"><span>https://mygreendoctor.org/resources/waiting-room-brochures/</span></a><span>.<br>
<br>
This an easy, inexpensive way to extend a practice’s health impacts beyond the exam room. Your practice will be turning community environmental health goals into practical actions that your patients and families will truly enjoy and appreciate.</span></span></div></div>								</div>
				</div>
				<div class="elementor-element elementor-element-8be5a92 elementor-widget-divider--view-line elementor-widget elementor-widget-divider" data-id="8be5a92" data-element_type="widget" data-e-type="widget" data-widget_type="divider.default">
				<div class="elementor-widget-container">
							<div class="elementor-divider">
			<span class="elementor-divider-separator">
						</span>
		</div>
						</div>
				</div>
				<div class="elementor-element elementor-element-2e894297 elementor-widget elementor-widget-image" data-id="2e894297" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
															<img loading="lazy" decoding="async" width="800" height="667" src="https://mygreendoctor.org/wp-content/uploads/2026/09/ff0b7cf4-f01d-abfb-f29e-6e07a0cd6dba.png" class="attachment-full size-full wp-image-18666" alt="" srcset="https://mygreendoctor.org/wp-content/uploads/2026/09/ff0b7cf4-f01d-abfb-f29e-6e07a0cd6dba.png 800w, https://mygreendoctor.org/wp-content/uploads/2026/09/ff0b7cf4-f01d-abfb-f29e-6e07a0cd6dba-300x250.png 300w, https://mygreendoctor.org/wp-content/uploads/2026/09/ff0b7cf4-f01d-abfb-f29e-6e07a0cd6dba-768x640.png 768w" sizes="auto, (max-width: 800px) 100vw, 800px">															</div>
				</div>
				<div class="elementor-element elementor-element-6df81e2c elementor-widget elementor-widget-text-editor" data-id="6df81e2c" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<div class="mgd-text"><h1><span><span><strong>Guiding Children to Save Energy</strong></span></span></h1><div><p><span>My Green Doctor’s short and updated patient-education resource, </span><a href="https://mygreendoctor.org/children-save-energy/" target="_blank" rel="noopener"><span>“Helping Children to Save Energy,”</span></a><span> gives healthcare practices a simple tool to share with patients and families. It offers practical ways children can participate in conserving energy and learn that everyday choices can make a difference.</span></p><div> </div><p><span><span>Simple act add up: turning off lights and electronics that are not being used, making thoughtful choices about heating and cooling, and encouraging other family members to participate. These make an abstract idea—saving energy—visible and understandable. These actions can also help families reduce household energy use and expenses while teaching lessons that extend well beyond the utility bill.</span></span></p></div><div><br><span><span>Just as importantly, participation gives children a role. They see how their own actions contribute to a household effort. Over time, these everyday habits can help build awareness, responsibility, and a greater understanding of the connection between resource use, health, and the environment. </span><br><br><span>As Dr. Todd Sack writes, <em> “It’s easy and smart to help your children to save energy.” </em>Share <a href="https://mygreendoctor.org/children-save-energy/" target="_blank" rel="noopener">“Helping Children to Save Energy”</a> with your office colleagues and with the families your practice serves. Some of the most important changes can begin with small actions at home.<br><br><em><a href="https://mygreendoctor.org/children-save-energy/" target="_blank" rel="noopener">https://mygreendoctor.org/children-save-energy/</a></em></span></span></div></div>								</div>
				</div>
				<div class="elementor-element elementor-element-277bfd45 elementor-widget-divider--view-line elementor-widget elementor-widget-divider" data-id="277bfd45" data-element_type="widget" data-e-type="widget" data-widget_type="divider.default">
				<div class="elementor-widget-container">
							<div class="elementor-divider">
			<span class="elementor-divider-separator">
						</span>
		</div>
						</div>
				</div>
				<div class="elementor-element elementor-element-5dbf91eb elementor-widget elementor-widget-image" data-id="5dbf91eb" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
															<img loading="lazy" decoding="async" width="800" height="1067" src="https://mygreendoctor.org/wp-content/uploads/2026/09/7f45f6dd-496d-4741-5564-b48380900c60.png" class="attachment-full size-full wp-image-18667" alt="" srcset="https://mygreendoctor.org/wp-content/uploads/2026/09/7f45f6dd-496d-4741-5564-b48380900c60.png 800w, https://mygreendoctor.org/wp-content/uploads/2026/09/7f45f6dd-496d-4741-5564-b48380900c60-225x300.png 225w, https://mygreendoctor.org/wp-content/uploads/2026/09/7f45f6dd-496d-4741-5564-b48380900c60-768x1024.png 768w" sizes="auto, (max-width: 800px) 100vw, 800px">															</div>
				</div>
				<div class="elementor-element elementor-element-13a781a1 elementor-widget elementor-widget-text-editor" data-id="13a781a1" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<div class="mgd-text"><div><span><span><span><strong>Build Resilience Before the Emergency</strong></span></span></span></div>

<div><span><span><span>When an emergency disrupts an outpatient practice, the consequences can extend quickly—from staffing and communications to facility operations, data loss, and continuity of care. The best time to address those vulnerabilities is before a crisis occurs.<br>
<br>
My Green Doctor’s new </span><a href="https://mygreendoctor.org/workbook-8-resilience-planninng/" target="_blank"><span><strong>Workbook 8: Resilience Planning</strong></span></a><span> gives outpatient healthcare practices a structured, practical way to prepare. Rather than treating emergency preparedness as another overwhelming project, the Workbook 8 helps practices gradually over several months to identify vulnerabilities, consider the needs of patients and staff, and strengthen their ability to respond when normal operations are disrupted.<br>
<br>
For busy practice managers, that structure matters. Resilience planning must fit the realities of an outpatient setting, where staff time is limited, responsibilities are shared and maintaining patient care is essential. Workbook 8 breaks the process into manageable steps that healthcare teams can incorporate into ongoing practice management.<br>
<br>
Planning ahead can also help practices think more clearly about the systems they depend upon every day: communications, staffing, utilities, supplies, buildings, and vendors. Identifying potential weaknesses before an emergency provides an opportunity to address them thoughtfully rather than being forced to react under pressure.</span></span></span><br>
 </div>

<div><span><em><span><strong>To be prepared is not separate from running a strong practice.</strong></span></em></span></div>

<div><br>
<span><span><span>Building resilience supports operational continuity, staff readiness, and a practice’s ability to continue serving its patients and community when conditions become difficult.<br>
<br>
Combined with My Green Doctor’s coaching services, Workbook 8 helps healthcare teams make resilience a practical part of everyday operations. <br>
<br>
<strong>Explore Workbook 8: Resilience Planning: </strong></span><a href="https://mygreendoctor.org/workbook-8-resilience-planninng/" target="_blank"><span>https://mygreendoctor.org/workbook-8-resilience-planninng/</span></a></span></span><br>
 </div></div>								</div>
				</div>
				<div class="elementor-element elementor-element-5fda2c91 elementor-widget-divider--view-line elementor-widget elementor-widget-divider" data-id="5fda2c91" data-element_type="widget" data-e-type="widget" data-widget_type="divider.default">
				<div class="elementor-widget-container">
							<div class="elementor-divider">
			<span class="elementor-divider-separator">
						</span>
		</div>
						</div>
				</div>
				<div class="elementor-element elementor-element-2ba4574c elementor-widget elementor-widget-text-editor" data-id="2ba4574c" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<div class="mgd-text"><span><span><strong>Tell your colleagues about Green Practice News</strong></span><br>
<br>
<span><span>Please forward this email to colleagues so that they can recieve Green Practice News. They will thank you!</span></span></span></div>								</div>
				</div>
				<div class="elementor-element elementor-element-19a090dd elementor-align-center elementor-widget elementor-widget-button" data-id="19a090dd" data-element_type="widget" data-e-type="widget" data-widget_type="button.default">
				<div class="elementor-widget-container">
									<div class="elementor-button-wrapper">
					<a class="elementor-button elementor-button-link elementor-size-sm" href="https://bit.ly/MGDNewsletterSignUp">
						<span class="elementor-button-content-wrapper">
									<span class="elementor-button-text">Sign Up For This Free Newsletter</span>
					</span>
					</a>
				</div>
								</div>
				</div>
				<div class="elementor-element elementor-element-36d3e6e4 elementor-widget elementor-widget-html" data-id="36d3e6e4" data-element_type="widget" data-e-type="widget" data-widget_type="html.default">
				<div class="elementor-widget-container">
					<div class="mgd-follow">
<table align="center" border="0" cellpadding="0" cellspacing="0"><tr>
<td valign="top"><table border="0" cellpadding="0" cellspacing="0"><tr>
<td align="left" valign="middle"><table border="0" cellpadding="0" cellspacing="0"><tr>
<td align="center" valign="middle" width="24"><a href="http://www.mygreendoctor.org/" target="_blank"><img loading="lazy" decoding="async" src="https://cdn-images.mailchimp.com/icons/social-block-v2/gray-link-48.png" alt="Website" height="24" width="24"></a></td>
<td align="left" valign="middle"><a href="http://www.mygreendoctor.org/">Website</a></td>
</tr></table></td></tr></table></td>
<td valign="top"><table border="0" cellpadding="0" cellspacing="0"><tr>
<td align="left" valign="middle"><table border="0" cellpadding="0" cellspacing="0"><tr>
<td align="center" valign="middle" width="24"><a href="mailto:member.services@mygreendoctor.org" target="_blank"><img loading="lazy" decoding="async" src="https://cdn-images.mailchimp.com/icons/social-block-v2/gray-forwardtofriend-48.png" alt="Email" height="24" width="24"></a></td>
<td align="left" valign="middle"><a href="mailto:member.services@mygreendoctor.org">Email</a></td>
</tr></table></td></tr></table></td>
<td valign="top"><table border="0" cellpadding="0" cellspacing="0"><tr>
<td align="left" valign="middle"><table border="0" cellpadding="0" cellspacing="0"><tr>
<td align="center" valign="middle" width="24"><a href="https://www.linkedin.com/company/my-green-doctor-foundation/" target="_blank"><img loading="lazy" decoding="async" src="https://cdn-images.mailchimp.com/icons/social-block-v2/gray-linkedin-48.png" alt="LinkedIn" height="24" width="24"></a></td>
<td align="left" valign="middle"><a href="https://www.linkedin.com/company/my-green-doctor-foundation/">LinkedIn</a></td>
</tr></table></td></tr></table></td>
</tr></table></div>				</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div><p>The post <a href="https://mygreendoctor.org/green-practice-news-october-2026-copy/">Green Practice News – October 2026 – copy</a> first appeared on <a href="https://mygreendoctor.org/">My Green Doctor</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Physicians Foundation Celebrates Graduation of Inaugural Leadership Institute Cohort at Brandeis University</title>
<link>https://edusehat.com/en/the-physicians-foundation-celebrates-graduation-of-inaugural-leadership-institute-cohort-at-brandeis-university</link>
<guid>https://edusehat.com/en/the-physicians-foundation-celebrates-graduation-of-inaugural-leadership-institute-cohort-at-brandeis-university</guid>
<description><![CDATA[ 25 physicians from across the country complete a transformative leadership program designed to strengthen physician leadership, influence health policy, and drive meaningful change in healthcare for their patients. BOSTON, November 10, 2026 — The Physicians Foundation proudly announces the graduation of the inaugural cohort of The Physicians Foundation Leadership Institute (PFLI) at The Heller School […]
The post The Physicians Foundation Celebrates Graduation of Inaugural Leadership Institute Cohort at Brandeis University appeared first on The Physicians Foundation. ]]></description>
<enclosure url="https://physiciansfoundation.org/wp-content/themes/physicians-foundation/assets/build/images/admin/defaults/default-image.webp" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 02:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Physicians, Foundation, Celebrates, Graduation, Inaugural, Leadership, Institute, Cohort, Brandeis, University</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph"><em><em><em><em>25 physicians from across the country complete a transformative leadership program designed to strengthen physician leadership, influence health policy, and drive meaningful change in healthcare for their patients.</em></em></em></em></p>



<p class="wp-block-paragraph"><strong>BOSTON, November 10, 2026</strong> — The Physicians Foundation proudly announces the graduation of the inaugural cohort of The Physicians Foundation Leadership Institute (PFLI) at <a href="https://heller.brandeis.edu/">The Heller School for Social Policy and Management at Brandeis University.</a> The program brought together 25 physicians from across the country to develop their leadership skills, deepen their understanding of health policy and management, and strengthen their ability to advocate for patients and elevate the physician perspective in healthcare decisions.</p>



<p class="wp-block-paragraph">Launched to empower practicing physicians to become more influential leaders within their organizations, communities, and the broader healthcare system, PFLI offers a unique opportunity to expand physicians’ impact beyond the exam room. Through two in-person residencies, monthly virtual learning sessions, and peer coaching, participants strengthened their understanding of healthcare policy, organizational leadership, and key drivers of health impacting patients. They developed skills to elevate the physician perspective in healthcare decision-making, helping to shape policies and systems to better serve patients.</p>



<p class="wp-block-paragraph">“Physicians bring invaluable firsthand perspectives to the challenges facing our healthcare system, and their voices must be central to shaping its future,” said <a href="https://physiciansfoundation.org/team/dr-gary-price/">Dr. Gary Price,</a> president of The Physicians Foundation, “The inaugural Leadership Institute cohort represents an extraordinary group of physicians who have demonstrated a commitment not only to advancing their own leadership skills, but also to creating meaningful change for their patients, colleagues, and communities. We are incredibly proud of their accomplishments and look forward to the impact they will make across healthcare.”</p>



<p class="wp-block-paragraph">Beyond the program’s formal curriculum, PFLI fostered a national network of physician leaders united by a shared commitment to improving healthcare. Graduates leave the program with new perspectives, meaningful professional connections and a community of colleagues who will continue to collaborate, exchange ideas and support one another as they advance in their leadership journeys.</p>



<p class="wp-block-paragraph">The Physicians Foundation congratulates the following 25 physicians who completed the inaugural Leadership Institute cohort:</p>



<ul class="wp-block-list">
<li>Hans Chin Arora, MD, PhD (North Carolina)</li>



<li>Jeffrey Paul Cashman, DO (South Carolina)</li>



<li>M. Mayes DuBose, MD (South Carolina)</li>



<li>Nefertiti duPont, MD, MPH (Texas)</li>



<li>Kennedy Ganti, MD, FAAFP, FHELA (New Jersey)</li>



<li>Casey Gokey, MD (Alaska)</li>



<li>Kristin Lynch Grimes, DO (Louisiana)</li>



<li>Donaldo M. Hernandez, MD, FACP (California)</li>



<li>Joseph Maxwell Hendrix, MD, MBA, MS (Texas)</li>



<li>Cynthia Jumper, MD (Texas)</li>



<li>Albert Li, MD, FASRS (New Jersey)</li>



<li>Ashley Lucas, MD, FAAP (Louisiana)</li>



<li>John J. Meier IV, MD, MBA (North Carolina)</li>



<li>Sheila Marie Magoon, MD (Texas)</li>



<li>Mirna Mohanraj, MD (New York)</li>



<li>Sergio Bennett Navarrete, DO (Virginia)</li>



<li>Julie Nguyen, MD (Texas)</li>



<li>Jubril Oyeyemi, MD, FHELA (New Jersey)</li>



<li>Bradford Patt, MD, FACS (Texas)</li>



<li>Jillian Ploof, DO (Louisiana)</li>



<li>Kinga Porter, DO (Florida)</li>



<li>Joseph Aryeh Rosenbaum, MD (New Jersey)</li>



<li>Meghan Schott, DO, DFAACAP, FAPA (Utah)</li>



<li>Rajamalliga N. Lee Sharma, MD, MA (Alabama)</li>



<li>Nancy Jane Wright, MD, FAAP (New Mexico)</li>
</ul>



<p class="wp-block-paragraph">The completion of this inaugural cohort marks an important milestone in The Physicians Foundation’s ongoing commitment to advance physician leadership and ensure physician perspectives are represented in decisions shaping healthcare. Through PFLI, the Foundation is helping to prepare physician leaders to drive meaningful change across the healthcare system, strengthen the practice environment, and ultimately improve care for patients. Learn more about The Physicians Foundation Leadership Institute, <a href="https://physiciansfoundation.org/brandeis-leadership-institute/"><em>here.</em></a></p>



<h3 class="wp-block-heading"><strong>About The Physicians Foundation </strong></h3>



<p class="wp-block-paragraph">The Physicians Foundation is a public charity seeking to advance the work of practicing physicians and help them facilitate the delivery of high-quality health care to patients. As the U.S. health care system continues to evolve, The Physicians Foundation is steadfast in strengthening the physician-patient relationship, supporting medical practices’ sustainability and helping physicians navigate the changing health care system. The Physicians Foundation pursues its mission through research, education and innovative grant making that improves physician wellbeing, strengthens physician leadership, addresses drivers of health and lifts physician perspectives. For more information, visit <a href="https://www.physiciansfoundation.org/">www.physiciansfoundation.org</a>.</p>
<p>The post <a href="https://physiciansfoundation.org/the-physicians-foundation-celebrates-graduation-of-inaugural-leadership-institute-cohort-at-brandeis-university/">The Physicians Foundation Celebrates Graduation of Inaugural Leadership Institute Cohort at Brandeis University</a> appeared first on <a href="https://physiciansfoundation.org/">The Physicians Foundation</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How The Valley Children’s Healthcare Microgrid Project Is Helping The Environment</title>
<link>https://edusehat.com/en/how-the-valley-childrens-healthcare-microgrid-project-is-helping-the-environment</link>
<guid>https://edusehat.com/en/how-the-valley-childrens-healthcare-microgrid-project-is-helping-the-environment</guid>
<description><![CDATA[ Valley Children’s microgrid combines on-site solar generation, energy storage and fuel cells into an integrated system designed to provide reliable, resilient power for the hospital campus. | Photo credit: Valley Children’s Healthcare. By Danielle Barry Healthcare facilities are expected to remain operational under any circumstances. Whether it’s severe weather, natural disasters like wildfires or the...
The post How The Valley Children’s Healthcare Microgrid Project Is Helping The Environment appeared first on HCO News.
The post How The Valley Children’s Healthcare Microgrid Project Is Helping The Environment appeared first on HCO News. ]]></description>
<enclosure url="https://hconews.com/wp-content/uploads/2026/11/tJJ1rC5g-768x575.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 23:55:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, The, Valley, Children’s, Healthcare, Microgrid, Project, Helping, The, Environment</media:keywords>
<content:encoded><![CDATA[<h5>Valley Children’s microgrid combines on-site solar generation, energy storage and fuel cells into an integrated system designed to provide reliable, resilient power for the hospital campus. | Photo credit: Valley Children’s Healthcare.</h5>
<p><em>By Danielle Barry</em></p>
<p>Healthcare facilities are expected to remain operational under any circumstances. Whether it’s severe weather, natural disasters like wildfires or the increasing demands on an aging electrical grid, hospitals cannot afford to lose power.</p>
<p>As these challenges become more frequent, energy resilience has become a core component of facility planning. At Valley Children’s Healthcare in Madera, Calif., this has prompted a different approach to campus infrastructure.</p>
<p>Back in 2022, Valley Children’s became one of the first hospitals in the nation to sign the U.S. Department of Health and Human Services Health Sector Climate Pledge. In part, it’s a commitment to reduce greenhouse gas emissions.</p>
<p>The pledge recognized that healthcare organizations have the responsibility to reduce their environmental footprint, while also ensuring they can continue providing care when communities need them most.</p>
<p>That commitment ultimately evolved into one of the country’s most ambitious renewable energy projects in pediatric healthcare. Valley Children’s microgrid combines on-site solar generation, energy storage and fuel cells into an integrated system designed to provide reliable, resilient power for the hospital campus.</p>
<blockquote><p>Once fully operational, the system is expected to supply approximately 80% of the hospital’s energy needs and reduce campus carbon emissions by half and generate an estimated $15 million in energy savings over the following 25 years. Its design also supports the organization’s long-term goal of achieving net-zero emissions by 2050.</p></blockquote>
<p>The project also includes a 1.3-megawatt, solar photovoltaic array that’s compromised of 2,256 panels spread across an 800-foot-by-350-foot site. Designed in the shape of the hospital’s beloved mascot, George the Giraffe, the array demonstrates that critical infrastructure can also become a recognizable — and fun — part of a healthcare campus’s identity.</p>
<p>The array really serves a critical role as the microgrid’s primary source of on-site renewable generation, working alongside energy storage and fuel cells to reduce dependence on the utility grid.</p>
<blockquote><p>The microgrid project is an opportunity for other healthcare facilities to learn lessons in renewable energy. Resilience and sustainability should be viewed as complementary objectives, rather than competing priorities. Investments that reduce emissions can also improve operational continuity during grid disruptions.</p></blockquote>
<p>Healthcare energy infrastructure should also be planned as part of overall campus development, not as a standalone utility project. Integrating renewable generation, storage and intelligent controls into facility planning allows health systems better prepare for future demands while improving operational flexibility.</p>
<p>Projects of this scale require leadership commitment across the organization. Valley Children’s concept for its signature solar array originated internally and received immediate executive support, reflecting an institutional commitment to resilience, innovation and environmental stewardship that extended well beyond the facilities department.</p>
<blockquote><p>As healthcare systems nationwide confront increasingly complex climate and energy challenges, resilient infrastructure will become an essential element of hospital design and operations.</p></blockquote>
<p>Valley Children’s experience demonstrates that investments in renewable energy can strengthen operational reliability while advancing ambitious sustainability goals, offering a practical model for organizations seeking to build facilities prepared for the decades ahead.</p>
<p><em>Danielle Barry is the Senior Vice President & Chief Operating Officer of Valley Children’s Healthcare.</em></p>
<p>The post <a rel="nofollow" href="https://hconews.com/2026/11/10/how-the-valley-childrens-healthcare-microgrid-project-is-helping-the-environment/">How The Valley Children’s Healthcare Microgrid Project Is Helping The Environment</a> appeared first on <a rel="nofollow" href="https://hconews.com/">HCO News</a>.</p>
<p>The post <a href="https://hconews.com/2026/11/10/how-the-valley-childrens-healthcare-microgrid-project-is-helping-the-environment/">How The Valley Children’s Healthcare Microgrid Project Is Helping The Environment</a> appeared first on <a href="https://hconews.com/">HCO News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Endocrine Society Establishes Award Honoring Diabetes Researcher Jesse Roth</title>
<link>https://edusehat.com/en/endocrine-society-establishes-award-honoring-diabetes-researcher-jesse-roth</link>
<guid>https://edusehat.com/en/endocrine-society-establishes-award-honoring-diabetes-researcher-jesse-roth</guid>
<description><![CDATA[ A new award named in memory of groundbreaking diabetes researcher Jesse Roth, MD (pictured, above), will recognize a physician-scientist’s outstanding research in hormone action, diabetes or metabolism, the Endocrine Society announced today.  The inaugural Jesse Roth Award and Lecture winner — C. Ronald Kahn, MD, of Joslin Diabetes Center and Harvard Medical School in Boston, […]
The post Endocrine Society Establishes Award Honoring Diabetes Researcher Jesse Roth appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/Roth-via-AI.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 23:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Endocrine, Society, Establishes, Award, Honoring, Diabetes, Researcher, Jesse, Roth</media:keywords>
<content:encoded><![CDATA[<p>A new award named in memory of groundbreaking diabetes researcher Jesse Roth, MD (pictured, above), will recognize a physician-scientist’s outstanding research in hormone action, diabetes or metabolism, the Endocrine Society announced today.  The inaugural Jesse Roth Award and Lecture winner — C. Ronald Kahn, MD, of Joslin Diabetes Center and Harvard Medical School in Boston, […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/endocrine-society-establishes-award-honoring-diabetes-researcher-jesse-roth/">Endocrine Society Establishes Award Honoring Diabetes Researcher Jesse Roth</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Canadian healthcare spending projected to reach $433 billion in 2026</title>
<link>https://edusehat.com/en/canadian-healthcare-spending-projected-to-reach-433-billion-in-2026</link>
<guid>https://edusehat.com/en/canadian-healthcare-spending-projected-to-reach-433-billion-in-2026</guid>
<description><![CDATA[ New CIHI figures show hospital expenditures rising 5.1 per cent as workforce costs, capacity pressures and investments in healthcare delivery continue to shape spending across Canada. Canada’s total healthcare spending is projected to reach $433 billion in 2026, an increase of 4.8 per cent over the previous year, according to new figures released by the […]
The post Canadian healthcare spending projected to reach $433 billion in 2026 appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_2765591399.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 23:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Canadian, healthcare, spending, projected, reach, 433, billion, 2026</media:keywords>
<content:encoded><![CDATA[<p>New CIHI figures show hospital expenditures rising 5.1 per cent as workforce costs, capacity pressures and investments in healthcare delivery continue to shape spending across Canada.</p>
<p>Canada’s total healthcare spending is projected to reach $433 billion in 2026, an increase of 4.8 per cent over the previous year, according to new figures released by the Canadian Institute for Health Information (CIHI).</p>
<p>The latest National Health Expenditure Trends report, published November 10, estimates that healthcare spending will account for 12.8 per cent of Canada’s gross domestic product (GDP), equivalent to approximately $10,398 per Canadian.</p>
<p>Although overall spending growth has moderated from the increases recorded in recent years, healthcare expenditures continue to rise faster than the broader economy.</p>
<p>For Canadian hospitals, the findings highlight ongoing pressures associated with workforce compensation, service demand and investments in healthcare capacity.</p>
<h2><img fetchpriority="high" decoding="async" class="alignnone size-full wp-image-146842" src="https://www.hospitalnews.com/wp-content/uploads/2026/11/Buenas-practicas-en-la-institucionalizacion-de-las-cuentas-de-salud_-Componentes-de-la-institucionalizacion-de-las-cuentas-de-salud-_-OECD.jpg" alt="" width="1000" height="795" srcset="https://www.hospitalnews.com/wp-content/uploads/2026/11/Buenas-practicas-en-la-institucionalizacion-de-las-cuentas-de-salud_-Componentes-de-la-institucionalizacion-de-las-cuentas-de-salud-_-OECD.jpg 1000w, https://www.hospitalnews.com/wp-content/uploads/2026/11/Buenas-practicas-en-la-institucionalizacion-de-las-cuentas-de-salud_-Componentes-de-la-institucionalizacion-de-las-cuentas-de-salud-_-OECD-400x318.jpg 400w, https://www.hospitalnews.com/wp-content/uploads/2026/11/Buenas-practicas-en-la-institucionalizacion-de-las-cuentas-de-salud_-Componentes-de-la-institucionalizacion-de-las-cuentas-de-salud-_-OECD-768x611.jpg 768w, https://www.hospitalnews.com/wp-content/uploads/2026/11/Buenas-practicas-en-la-institucionalizacion-de-las-cuentas-de-salud_-Componentes-de-la-institucionalizacion-de-las-cuentas-de-salud-_-OECD-528x420.jpg 528w, https://www.hospitalnews.com/wp-content/uploads/2026/11/Buenas-practicas-en-la-institucionalizacion-de-las-cuentas-de-salud_-Componentes-de-la-institucionalizacion-de-las-cuentas-de-salud-_-OECD-150x119.jpg 150w, https://www.hospitalnews.com/wp-content/uploads/2026/11/Buenas-practicas-en-la-institucionalizacion-de-las-cuentas-de-salud_-Componentes-de-la-institucionalizacion-de-las-cuentas-de-salud-_-OECD-300x239.jpg 300w, https://www.hospitalnews.com/wp-content/uploads/2026/11/Buenas-practicas-en-la-institucionalizacion-de-las-cuentas-de-salud_-Componentes-de-la-institucionalizacion-de-las-cuentas-de-salud-_-OECD-696x553.jpg 696w" sizes="(max-width: 1000px) 100vw, 1000px"></h2>
<h2>Hospital spending expected to rise 5.1 per cent</h2>
<p>Hospitals remain the largest category of healthcare expenditure in Canada, accounting for a projected 25.6 per cent of total spending in 2026.</p>
<p>Hospital expenditures are expected to increase by 5.1 per cent this year, compared with growth of 4.3 per cent in 2025 and 7.0 per cent in 2024.</p>
<p>Employee compensation continues to represent the largest expense for hospitals, accounting for approximately two-thirds of total hospital spending.</p>
<p>According to CIHI’s hospital spending data, compensation costs increased by 7.5 per cent to $53.9 billion in 2024–2025. During the same period, the number of full-time equivalent hospital employees increased by 9.2 per cent, representing the largest annual workforce expansion in decades.</p>
<p>It was the first time since 2010–2011 that hospital workforce growth exceeded compensation growth, suggesting that hospitals are expanding staffing capacity while increases in labour costs begin to moderate.</p>
<p>However, hospitals continue to face elevated costs related to private agency staffing, overtime and sick leave. Although growth in these expenses has slowed from post-pandemic peaks, costs remain above pre-pandemic levels.</p>
<div>
<div></div>
</div>
<h2>Spending growth may signal greater investment in capacity</h2>
<p>One of the report’s central findings is a potential shift in the factors driving healthcare expenditure growth.</p>
<p>In recent years, rising inflation and rapid population growth absorbed a substantial portion of additional healthcare spending.</p>
<p>With those pressures beginning to ease, CIHI estimates that public-sector healthcare spending in 2026 will increase by more than $5 billion beyond what would be explained by inflation and demographic changes.</p>
<p>This suggests that a greater share of new spending may be directed toward expanding healthcare services, improving access, strengthening the workforce and investing in technology.</p>
<p>Lacey Langlois, director of Health Spending at CIHI, said the changing drivers of expenditure growth could indicate greater investment in healthcare capacity and new approaches to delivering care.</p>
<p>The report also emphasizes the importance of measuring whether additional spending produces meaningful improvements for patients.</p>
<p>While the figures suggest opportunities to strengthen the healthcare system, they do not establish that increased expenditure has already translated into improved access or clinical outcomes.</p>
<div>
<div></div>
</div>
<h2>Physician and drug spending continue to increase</h2>
<p>Beyond hospitals, physician services and prescription medications remain major components of Canada’s healthcare expenditures.</p>
<p>Physician spending is projected to account for 14.1 per cent of total healthcare spending in 2026, with expenditures increasing by 8.3 per cent.</p>
<p>The increase reflects continuing demand for physician services and persistent challenges in primary care access.</p>
<p>Drug expenditures are expected to account for nearly 13 per cent of national healthcare spending.</p>
<p>CIHI notes that workforce shortages, population aging and the increasing use of healthcare services will continue to influence spending patterns.</p>
<p>Digital health technologies, including artificial intelligence, may also affect future expenditure trends by changing how care is delivered and how clinical and administrative work is organized.</p>
<p>However, these technologies may require substantial initial investment before potential operational efficiencies can be realized.</p>
<div>
<div></div>
</div>
<h2>Rural hospitals face distinct financial pressures</h2>
<p>CIHI’s accompanying Spending Trends in Health Service Delivery report identifies important differences between urban and rural hospitals.</p>
<p>Although staffing has grown faster than Canada’s population overall, workforce expansion has been stronger in urban hospitals.</p>
<p>Rural hospitals continue to experience greater recruitment and retention challenges, often relying more heavily on overtime and agency personnel to maintain services.</p>
<p>The report also finds that inpatient and outpatient costs have increased more rapidly in rural hospitals, reflecting factors such as patient complexity, longer hospital stays and differences in service delivery.</p>
<p>Rural emergency departments frequently serve broader healthcare needs where access to primary care and other community-based services is limited.</p>
<p>These findings underscore the importance of considering regional circumstances when evaluating hospital spending and allocating healthcare resources.</p>
<div>
<div></div>
</div>
<div>
<div>
<div>
<div><img decoding="async" class="alignnone  wp-image-146841" src="https://www.hospitalnews.com/wp-content/uploads/2026/11/cihi-image.png" alt="" width="902" height="708" srcset="https://www.hospitalnews.com/wp-content/uploads/2026/11/cihi-image.png 660w, https://www.hospitalnews.com/wp-content/uploads/2026/11/cihi-image-400x313.png 400w, https://www.hospitalnews.com/wp-content/uploads/2026/11/cihi-image-536x420.png 536w, https://www.hospitalnews.com/wp-content/uploads/2026/11/cihi-image-150x118.png 149w, https://www.hospitalnews.com/wp-content/uploads/2026/11/cihi-image-300x235.png 300w" sizes="(max-width: 902px) 100vw, 902px"></div>
</div>
</div>
</div>
<p>Canada’s healthcare spending has increased substantially over the past several years, rising from $336 billion in 2022 to a projected $433 billion in 2026.</p>
<p>Public-sector funding is expected to account for approximately 71 per cent of total healthcare expenditures this year, with the remainder financed through private sources, including households and insurance.</p>
<p>CIHI projects public-sector healthcare spending growth of 5.2 per cent in 2026, even as inflation and population growth moderate.</p>
<p>For hospital leaders, the findings raise important questions about how additional resources can best support sustainable staffing, improved patient access, modernization of infrastructure and more efficient service delivery.</p>
<p>As governments and healthcare organizations continue to address system pressures, the challenge will be ensuring that higher spending translates into measurable improvements in capacity, quality and patient care.</p>
<div>
<div></div>
</div>
<p>Primary sources: <a href="https://www.cihi.ca/en/news/canadas-health-care-spending-grows-by-over-5b-above-inflation-and-demographic-pressures-in-2026?utm_source=chatgpt.com">CIHI </a></p>
<p>The post <a href="https://www.hospitalnews.com/canadian-healthcare-spending-projected-to-reach-433-billion-in-2026/">Canadian healthcare spending projected to reach $433 billion in 2026</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Jewish General Hospital advances specialized care for critically ill newborns</title>
<link>https://edusehat.com/en/jewish-general-hospital-advances-specialized-care-for-critically-ill-newborns</link>
<guid>https://edusehat.com/en/jewish-general-hospital-advances-specialized-care-for-critically-ill-newborns</guid>
<description><![CDATA[ Montreal hospital combines advanced neonatal monitoring, emergency care technology and family-centred practices to support approximately 550 premature and critically ill infants annually. The Jewish General Hospital in Montreal is highlighting how advanced medical technology, specialized nursing care and family-centred treatment are helping improve the care environment for premature and critically ill newborns. The hospital’s Karen […]
The post Jewish General Hospital advances specialized care for critically ill newborns appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/assets_MS2028371_000001_JGHF_NICU_1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 23:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Jewish, General, Hospital, advances, specialized, care, for, critically, ill, newborns</media:keywords>
<content:encoded><![CDATA[<p>Montreal hospital combines advanced neonatal monitoring, emergency care technology and family-centred practices to support approximately 550 premature and critically ill infants annually.</p>
<p>The Jewish General Hospital in Montreal is highlighting how advanced medical technology, specialized nursing care and family-centred treatment are helping improve the care environment for premature and critically ill newborns.</p>
<p>The hospital’s Karen and Murray Dalfen Neonatal Intensive Care Unit (NICU), one of six Level 3 neonatal intensive care units in Quebec, provides specialized treatment for approximately 550 vulnerable newborns each year.</p>
<p>In an announcement issued November 10, the Jewish General Hospital Foundation outlined how investments in emergency care equipment, centralized monitoring and developmental care are supporting the hospital’s ability to manage complex, high-risk neonatal cases.</p>
<p>The unit receives patients from Montreal and regional healthcare facilities across Quebec, providing intensive care for infants requiring advanced monitoring and treatment.</p>
<div>
<div></div>
</div>
<h3>Advanced technology supports critical newborn care</h3>
<p>The hospital has introduced integrated emergency care stations designed to provide essential treatment immediately following complicated or high-risk deliveries.</p>
<p>These all-in-one stations combine radiant warming, controlled oxygen delivery and continuous monitoring of vital signs at the bedside.</p>
<p>By keeping equipment ready for immediate use, the technology is intended to reduce setup delays when newborns require urgent intervention.</p>
<p>The hospital has also implemented centralized remote monitoring across private neonatal recovery rooms.</p>
<p>This allows clinical teams to maintain continuous oversight of infants’ physiological conditions while providing families with greater privacy.</p>
<p>The combination of bedside equipment and centralized monitoring is designed to support rapid intervention, ongoing observation and more coordinated nursing care.</p>
<p>Chloé Décarie-Drolet, head nurse of the NICU and Neonatal Follow-Up Clinic, emphasized the importance of having equipment ready during critical deliveries while maintaining round-the-clock monitoring throughout an infant’s hospital stay.</p>
<h3>Supporting infants from across Quebec</h3>
<p>As a Level 3 neonatal intensive care unit, the Dalfen NICU is equipped to manage complex medical conditions and receive specialized transfers from other healthcare facilities.</p>
<p>Dr. Lajos Kovacs, chief of Pediatrics and Neonatology at the Jewish General Hospital, explained that the unit’s responsibility extends beyond stabilizing critically ill newborns.</p>
<p>The clinical team also focuses on supporting long-term development and helping infants reach important milestones before returning home.</p>
<p>Premature infants may require specialized respiratory support, nutritional management, temperature regulation and continuous observation while their organs and neurological systems continue developing.</p>
<p>The hospital’s approach combines these medical interventions with practices intended to protect early brain development and strengthen parent-infant relationships.</p>
<h3>Family-centred care plays an important role</h3>
<p>Alongside medical technology, the NICU incorporates neuroprotective developmental care into everyday clinical practice.</p>
<p>This includes reducing unnecessary noise, adjusting incubator lighting and encouraging extended skin-to-skin contact between parents and infants.</p>
<p>Specialized seating supports kangaroo care, allowing parents to hold their babies safely while maintaining close physical contact.</p>
<p>These practices are intended to create a calmer environment for developing infants and encourage parents to participate actively in their child’s care.</p>
<p>The hospital emphasizes that families are essential members of the neonatal care team, rather than simply visitors.</p>
<p>Private rooms and continuous monitoring are designed to balance clinical safety with opportunities for bonding and family involvement.</p>
<h3>A family’s experience with neonatal intensive care</h3>
<p>The hospital foundation highlighted the experience of Willow, a baby born 10 weeks prematurely after her mother developed severe preeclampsia.</p>
<p>Weighing approximately two pounds at birth, Willow required 54 days of specialized care in the Dalfen NICU.</p>
<p>Her treatment included advanced incubator technology, close nursing observation and daily skin-to-skin contact with her parents.</p>
<p>During her hospitalization, a nurse identified an unusually rapid increase in weight that required medical attention because of potential cardiac concerns.</p>
<p>According to the family, the clinical team’s prompt response and attention to detail played an important role in Willow’s recovery.</p>
<p>Willow is now 19 months old, and her parents credit the NICU’s clinical team and specialized equipment with helping her overcome the challenges associated with premature birth.</p>
<p>Their experience illustrates the importance of combining sophisticated medical technology with continuous clinical assessment and individualized care.</p>
<h3>Philanthropy supports neonatal innovation</h3>
<p>The Jewish General Hospital Foundation has played an important role in supporting investments in specialized equipment and patient care infrastructure.</p>
<p>Donor funding has helped provide the emergency care stations and monitoring technology used in the NICU.</p>
<p>These investments are intended to strengthen the hospital’s capacity to care for vulnerable newborns while supporting clinical teams working in a demanding, highly specialized environment.</p>
<p>The hospital is affiliated with McGill University and serves as a major teaching and specialized care centre within Montreal’s healthcare system.</p>
<p>Its neonatal services form part of a broader program supporting high-risk pregnancies, premature births and complex pediatric conditions.</p>
<h3>Combining innovation with compassionate care</h3>
<p>For hospitals across Canada, neonatal intensive care presents significant clinical and operational challenges.</p>
<p>Premature and critically ill newborns often require highly specialized equipment, multidisciplinary teams and prolonged hospital stays.</p>
<p>Technologies that improve monitoring and reduce delays in emergency treatment can support clinical teams, while family-centred practices help address the developmental and emotional needs of infants and parents.</p>
<p>The Jewish General Hospital’s approach illustrates how investments in technology, nursing expertise and developmental care can be integrated within a specialized neonatal service.</p>
<p>Although the foundation’s announcement does not provide comparative data demonstrating reductions in mortality, complications or hospital length of stay, it highlights an established model of neonatal care designed to support both immediate medical needs and longer-term development.</p>
<p>As hospitals continue to advance specialized newborn care, combining clinical innovation with family involvement remains an important priority.</p>
<p>Source: <a href="https://www.newswire.ca/news-releases/inside-one-of-quebec-s-six-level-3-nicus-how-the-jewish-general-hospital-university-health-centre-is-redefining-specialized-care-for-fragile-newborns-858493470.html?utm_source=chatgpt.com">Jewish General Hospital Foundation</a></p>
<div>
<div></div>
</div>
<p>The post <a href="https://www.hospitalnews.com/jewish-general-hospital-advances-specialized-care-for-critically-ill-newborns/">Jewish General Hospital advances specialized care for critically ill newborns</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>14 Eastern Ontario hospitals join forces to establish standards for responsible AI use</title>
<link>https://edusehat.com/en/14-eastern-ontario-hospitals-join-forces-to-establish-standards-for-responsible-ai-use</link>
<guid>https://edusehat.com/en/14-eastern-ontario-hospitals-join-forces-to-establish-standards-for-responsible-ai-use</guid>
<description><![CDATA[ New regional collaborative will develop shared tools to evaluate artificial intelligence, strengthen patient safety and reduce duplication across healthcare organizations. Fourteen hospital organizations across Eastern Ontario are joining forces to establish a coordinated approach to the safe, ethical and responsible use of artificial intelligence in healthcare. The Regional AI Governance Collaborative, co-led by Queensway Carleton […]
The post 14 Eastern Ontario hospitals join forces to establish standards for responsible AI use appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_2747048747.png" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 23:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Eastern, Ontario, hospitals, join, forces, establish, standards, for, responsible, use</media:keywords>
<content:encoded><![CDATA[<p>New regional collaborative will develop shared tools to evaluate artificial intelligence, strengthen patient safety and reduce duplication across healthcare organizations.</p>
<p>Fourteen hospital organizations across Eastern Ontario are joining forces to establish a coordinated approach to the safe, ethical and responsible use of artificial intelligence in healthcare.</p>
<p>The Regional AI Governance Collaborative, co-led by Queensway Carleton Hospital in Ottawa and Pembroke Regional Hospital, will bring together expertise from participating hospitals to develop common policies, risk assessment frameworks, vendor evaluation tools and ethical guidelines.</p>
<p>Announced November 9, the initiative is intended to help hospitals make informed decisions about adopting AI technologies while maintaining responsibility for their own procurement, implementation and oversight.</p>
<p>The collaborative will focus on sharing expertise and reducing duplicated work, particularly among smaller community hospitals that may have limited resources to independently evaluate increasingly complex AI systems.</p>
<h3>Addressing the challenges of AI adoption</h3>
<p>Artificial intelligence is becoming an increasingly important part of healthcare operations, with applications ranging from clinical documentation and diagnostic support to scheduling and administrative processes.</p>
<p>However, adopting these technologies introduces questions about patient safety, data privacy, cybersecurity, transparency and accountability.</p>
<p>Hospitals must assess whether AI products are clinically appropriate, how patient information will be protected and what safeguards are necessary to prevent unintended consequences.</p>
<p>Currently, many healthcare organizations independently conduct similar assessments of the same technologies.</p>
<p>The Regional AI Governance Collaborative aims to streamline this work by creating shared evaluation resources that participating hospitals can adapt to their individual needs.</p>
<p>Rather than developing separate frameworks from the ground up, hospitals will be able to draw on common expertise and evidence-informed assessment methods.</p>
<p>Importantly, the collaborative will not approve AI products on behalf of its members. Each hospital will continue to determine which technologies to adopt and how they will be monitored.</p>
<h3>Eight principles to guide responsible AI</h3>
<p>The participating organizations have established eight foundational principles to guide their approach to artificial intelligence.</p>
<p>These principles address accountability, patient safety, fairness, transparency, human oversight, technical robustness, patient autonomy and fiscal responsibility.</p>
<p>Together, they are intended to help hospitals balance the potential benefits of AI with the need to protect patients, maintain public trust and use healthcare resources responsibly.</p>
<p>The collaborative recognizes that effective AI governance requires input from multiple disciplines, including physicians, clinical operations, information technology, privacy, cybersecurity, ethics, finance and hospital leadership.</p>
<p>More than 20 healthcare leaders representing these areas, as well as patient perspectives, have already contributed to the initiative.</p>
<h3>Partnerships with research and technology experts</h3>
<p>The initiative is co-led by Lindsay Wyers, vice-president of transformation, innovation and strategic partnerships and chief digital and privacy officer at Queensway Carleton Hospital, and Scott Coombes, vice-president and chief financial officer at Pembroke Regional Hospital.</p>
<p>The collaborative has engaged Info-Tech Research Group to support the development of practical and scalable governance processes.</p>
<p>It is also partnering with the University of Ottawa, where PhD student Amanda Maria Kutenski will contribute to the development of an ethical AI framework and decision-making tool.</p>
<p>These partnerships are intended to provide additional research and technical expertise as participating hospitals establish their shared approach.</p>
<h3>Fourteen hospital organizations participating</h3>
<p>The collaborative brings together a broad range of healthcare organizations serving communities across Eastern Ontario.</p>
<p>Participating partners include Arnprior Regional Health, Bruyère Health, Deep River & District Health, Hawkesbury and District General Hospital, Hôpital Glengarry Memorial Hospital, Hôpital Montfort, Kemptville District Hospital, Mississippi River Health Alliance, Pembroke Regional Hospital, Queensway Carleton Hospital, The Royal, St. Francis Memorial Hospital, Renfrew Victoria Hospital and Winchester District Memorial Hospital.</p>
<p>The diversity of participating organizations is significant, bringing together hospitals with different clinical services, patient populations and operational resources.</p>
<p>By pooling expertise, the group hopes to make responsible AI governance more accessible across the region.</p>
<h3>Next steps for the collaborative</h3>
<p>Initial planning sessions have already produced foundational AI principles, proposed governance structures, early charter concepts and a regional roadmap.</p>
<p>The next phase will focus on formalizing governance arrangements, identifying AI technologies currently being used across participating hospitals and evaluating priority applications through consistent risk assessment methods.</p>
<p>Over time, the collaborative intends to introduce shared processes for assessing new AI technologies and monitoring higher-risk applications.</p>
<p>The approach could also provide a model for other Canadian hospital networks seeking to coordinate AI oversight.</p>
<p>As healthcare organizations increasingly explore artificial intelligence, establishing consistent governance standards may help reduce duplication, support informed technology decisions and strengthen patient safety.</p>
<p>For Canadian hospitals, the Eastern Ontario initiative represents a shift toward regional collaboration in managing the opportunities and risks associated with AI adoption.</p>
<p>The collaborative remains in its development phase, and its impact on costs, clinical outcomes and patient safety has not yet been measured.</p>
<p>Primary source: <a href="https://www.qch.on.ca/newsroom?newsid=3168&utm_source=chatgpt.com">Queensway Carleton Hospital </a></p>
<p>The post <a href="https://www.hospitalnews.com/14-eastern-ontario-hospitals-join-forces-to-establish-standards-for-responsible-ai-use/">14 Eastern Ontario hospitals join forces to establish standards for responsible AI use</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Montreal Heart Institute introduces Canada’s first advanced AI&#45;assisted cardiovascular imaging system</title>
<link>https://edusehat.com/en/montreal-heart-institute-introduces-canadas-first-advanced-ai-assisted-cardiovascular-imaging-system</link>
<guid>https://edusehat.com/en/montreal-heart-institute-introduces-canadas-first-advanced-ai-assisted-cardiovascular-imaging-system</guid>
<description><![CDATA[ New hemodynamics suite uses artificial intelligence and advanced imaging technology to support precision during minimally invasive cardiac procedures. The Montreal Heart Institute has become the first hospital in Canada to install the Trinias Opera cardiovascular imaging platform, introducing advanced artificial intelligence technology designed to support physicians during complex cardiac procedures. The system is now operating […]
The post Montreal Heart Institute introduces Canada’s first advanced AI-assisted cardiovascular imaging system appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_2810402307.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 23:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Montreal, Heart, Institute, introduces, Canada’s, first, advanced, AI-assisted, cardiovascular, imaging, system</media:keywords>
<content:encoded><![CDATA[<p><em>New hemodynamics suite uses artificial intelligence and advanced imaging technology to support precision during minimally invasive cardiac procedures.</em></p>
<p>The Montreal Heart Institute has become the first hospital in Canada to install the Trinias Opera cardiovascular imaging platform, introducing advanced artificial intelligence technology designed to support physicians during complex cardiac procedures.</p>
<p>The system is now operating in the Institute’s newly opened Hemodynamics Room No. 3, following a collaboration involving the hospital, its foundation, Christie Innomed and Shimadzu Corporation.</p>
<p>Announced November 9, the installation represents a significant investment in cardiovascular imaging technology and the continued development of minimally invasive cardiac care.</p>
<h3>Improving visualization during cardiac procedures</h3>
<p>The Trinias Opera platform provides real-time imaging of the heart and blood vessels, helping interventional cardiologists navigate medical devices during diagnostic and therapeutic procedures.</p>
<p>The technology combines advanced X-ray imaging with intelligent image-processing capabilities designed to improve the visibility of catheters, guidewires and other devices used during cardiovascular interventions.</p>
<p>One of its key features is a deep-learning-based artificial intelligence filter that identifies and enhances linear structures within medical images.</p>
<p>By reducing image noise and improving the visibility of important anatomical and device details, the technology is designed to help clinicians maintain clear images while working with lower X-ray exposure levels.</p>
<p>The system also allows physicians to adjust radiation settings according to patient characteristics and procedural requirements.</p>
<p>These capabilities are intended to support more precise clinical decision-making while helping healthcare teams manage radiation exposure.</p>
<h3>Supporting minimally invasive cardiovascular care</h3>
<p>Advanced imaging plays an important role in interventional cardiology, where physicians use catheters and other specialized instruments to diagnose and treat cardiovascular conditions without conventional open surgery.</p>
<p>Clear visualization is particularly important during complex procedures involving small blood vessels and delicate cardiac structures.</p>
<p>The Trinias Opera platform incorporates advanced image-processing tools designed to improve device visibility and support clinical workflow.</p>
<p>The technology may also help healthcare teams work more efficiently by providing enhanced imaging information throughout procedures.</p>
<p>Although the system is designed to improve procedural precision and support patient safety, clinical outcome improvements specific to the Montreal installation have not yet been reported.</p>
<h3>Collaboration supports Canadian first</h3>
<p>The installation was made possible through a partnership involving the Montreal Heart Institute, the Montreal Heart Institute Foundation, Christie Innomed, Shimadzu Corporation and associated technology teams.</p>
<p>The project included a significant equipment donation from Christie Innomed and Shimadzu.</p>
<p>Nesrine Ragguem, president and chief executive officer of the Montreal Heart Institute, said the new suite strengthens the hospital’s ability to deliver advanced cardiovascular care while providing clinical teams with modern technology.</p>
<p>The Montreal Heart Institute Foundation also highlighted the importance of partnerships and philanthropic support in bringing new medical technologies into clinical practice.</p>
<p>The project reflects the increasing role of collaboration between hospitals, medical technology companies and charitable foundations in supporting healthcare innovation.</p>
<h3>Advancing cardiovascular innovation</h3>
<p>Founded in 1954, the Montreal Heart Institute is internationally recognized for its work in cardiovascular research, specialized patient care, prevention and medical education.</p>
<p>Affiliated with the Université de Montréal, the Institute operates major research and clinical programs focused on improving the diagnosis and treatment of cardiovascular disease.</p>
<p>The introduction of the Trinias Opera system adds to the hospital’s existing capabilities in interventional cardiology.</p>
<p>Beyond the immediate installation, the partnership is expected to support continued collaboration between the Institute’s clinical specialists and Shimadzu’s research and development teams.</p>
<p>As cardiovascular procedures become increasingly sophisticated, imaging technologies that combine artificial intelligence with advanced diagnostic capabilities are expected to play a growing role in supporting clinical decision-making.</p>
<p>For Canadian hospitals, the Montreal installation provides another example of how advanced medical imaging and AI-assisted technology are moving into clinical environments.</p>
<p>The system’s introduction also highlights the importance of evaluating new technologies not only for their technical capabilities, but for their potential contributions to patient safety, procedural efficiency and clinical outcomes.</p>
<p>The post <a href="https://www.hospitalnews.com/montreal-heart-institute-introduces-canadas-first-advanced-ai-assisted-cardiovascular-imaging-system/">Montreal Heart Institute introduces Canada’s first advanced AI-assisted cardiovascular imaging system</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Can AI predict which patients will develop caries?</title>
<link>https://edusehat.com/en/can-ai-predict-which-patients-will-develop-caries</link>
<guid>https://edusehat.com/en/can-ai-predict-which-patients-will-develop-caries</guid>
<description><![CDATA[ Researchers have developed an artificial intelligence (AI) model to predict which patients are at high risk of developing caries. In a collaboration between New York University (NYU) and the Federal University of Santa Maria, data from almost 24,000 patients in Brazil was used to create a machine learning model to predict caries risk and severity… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/ai.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 20:05:16 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Can, predict, which, patients, will, develop, caries</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Researchers have developed an artificial intelligence (AI) model to predict which patients are at high risk of developing caries.</strong></p>



<p>In a collaboration between New York University (NYU) and the Federal University of Santa Maria, data from almost 24,000 patients in Brazil was used to create a machine learning model to predict caries risk and severity by age group. Using an AI algorithm allowed researchers to analyse large, complex datasets in order to find patterns that would be difficult to pinpoint otherwise.</p>



<p>The strongest risk signals were wealth and household density. Non-white groups had higher caries risk across ages, while private dental insurance and a recent dental visit were protective factors.</p>



<p>Water fluoridation was also a strong predictor: 62.5% of 12-year-olds without fluoridated water had cavities, versus 35.5% with fluoridated systems.</p>



<p>‘The emergence of AI offers a transformative opportunity for public health surveillance and risk stratification, including addressing the global burden of cavities,’ said Fernando Neves Hugo, chair of the Department of Epidemiology and Health Promotion at NYU College of Dentistry. ‘These are powerful tools that could be helpful for targeting resources and delivering preventive care to specific groups that will benefit the most.’</p>



<h2 class="wp-block-heading">How does AI predict caries risk?</h2>



<p>The researchers found that AI could accurately predict cavity risk and severity by age group by evaluating the relative contributions of the different factors.</p>



<p>Hugo continued: ‘Our machine learning approach acts as a high-resolution sensor that identifies individuals whose profiles signal a heightened risk that would otherwise be invisible within community averages.’</p>



<p>Sourced from Brazil’s 2023 national oral-health survey, the researchers note that the same models might be applicable to other middle-income countries but local access would likely shift the factors that lead to caries development in other countries.</p>



<p>Hugo and his colleagues are planning to conduct similar research using US data from the National Health and Nutrition Examination Survey.</p>



<p>He added: ‘When we think about public health and preventive interventions, we need to be accountable to society and make the best use of the resources we have. A more targeted approach helps us optimise resources – essentially, getting more bang for our buck.’</p>



<p>The research was published in <em><a href="https://karger.com/cre/article/doi/10.1159/cre/abuag004/956481/Machine-Learning-for-Predicting-Dental-Caries">Caries Research</a></em> in October.</p>



<p><em><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</em></a></em></p>]]> </content:encoded>
</item>

<item>
<title>BioAdvance: BIO releases national action plan to strengthen US biotech leadership</title>
<link>https://edusehat.com/en/bioadvance-bio-releases-national-action-plan-to-strengthen-us-biotech-leadership</link>
<guid>https://edusehat.com/en/bioadvance-bio-releases-national-action-plan-to-strengthen-us-biotech-leadership</guid>
<description><![CDATA[ A new seven-point plan to strengthen America’s biotechnology leadership amid intensifying global competition from China was released by the Biotechnology Innovation Organization (BIO) on […]
The post BioAdvance: BIO releases national action plan to strengthen US biotech leadership appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/BioAdvance-cover.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 19:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BioAdvance:, BIO, releases, national, action, plan, strengthen, biotech, leadership</media:keywords>
<content:encoded><![CDATA[<p><span>A new seven-point plan to strengthen America’s biotechnology leadership amid intensifying global competition from China was released by the Biotechnology Innovation Organization (BIO) on Nov. 10.</span></p>
<p><a href="http://bio.org/bioadvance" target="_blank" rel="noopener"><span>BioAdvance: Securing America’s Biotech Century</span></a><span>, calls for a bold, coordinated national strategy and targeted policy reforms to accelerate medical breakthroughs, strengthen America’s innovation ecosystem, and ensure the next generation of lifesaving medicines is developed and manufactured in the U.S.</span></p>
<p><span>America built the  biotechnology industry, notes BIO President & CEO John F. Crowley.</span></p>
<p><span>“For decades, American biotechnology innovators have turned scientific discovery into hope for patients and families, building an industry that saves lives, drives economic growth, and strengthens our nation’s security and competitiveness,” Crowley says.</span></p>
<p><span>By 2025, the U.S. bioscience industry employed more than 2.3 million Americans across more than 156,000 business establishments and generated nearly $3.2 trillion in total economic output,</span><a href="https://bio.news/state-policy/2026-report-on-biotechs-economic-impact-portrays-a-vast-ecosystem/" target="_blank" rel="noopener"><span> according to </span><span>the BIO/CSBA/TEConomy 2026 report</span></a><span>.</span></p>
<p><span>“America’s biotechnology innovators have built one of our nation’s greatest strategic assets,” Crowley says. “But our leadership is not guaranteed. We must invest, innovate, and act with urgency.”</span></p>
<p><span>As <a href="https://www.bio.org/sites/default/files/2026-11/bio-advance_executivesummary_digital_11042026.pdf" target="_blank" rel="noopener">the Executive Summary explains</a>, China is competing to take over as the world leader in  biotech, posing challenges to our health, economy, and national security.</span></p>
<p><span>“China has steadily elevated biotechnology as a strategic priority, directing massive state resources toward the sector in every new five-year plan,” the Executive Summary says. “Between 2016 and 2021, the value of China’s biotechnology industry grew more than 100-fold.”</span></p>
<h2>The action plan</h2>
<p><span>BioAdvance plan outlines how Congress and the administration can respond to the challenge with actions tailored to America’s strengths. The plan addresses seven actionable priorities across three areas:</span></p>
<p><b>Coordinate: Establish a clear national strategy for U.S. biotech leadership</b></p>
<ul>
<li aria-level="1"><span>Establish a White House Office of Biotechnology.</span></li>
</ul>
<p><b>Accelerate: Bring lifesaving discoveries to patients faster</b></p>
<ul>
<li aria-level="1"><span>Speed up the path to first-in-human clinical studies.</span></li>
<li aria-level="1"><span>Modernize and streamline drug development.</span></li>
<li aria-level="1"><span>Improve patient access to clinical trials.</span></li>
</ul>
<p><b>Build: Strengthen the foundations of American biotechnology</b></p>
<ul>
<li aria-level="1"><span>Sustain support for biomedical research.</span></li>
<li aria-level="1"><span>Expand U.S. biomanufacturing capacity and expertise.</span></li>
<li aria-level="1"><span>Strengthen intellectual property protections and access to capital.</span></li>
</ul>
<p><span>“This moment demands the ambition and determination that catalyzed the biotechnology revolution and made America the definitive global leader,” Crowley states. “BIO stands ready to work with the administration, Congress, and the entire biotechnology ecosystem to accelerate the next generation of lifesaving breakthroughs, and ensure the United States leads the biotech century.”</span></p>
<p><a href="http://bio.org/bioadvance" target="_blank" rel="noopener"><b>Learn more and download the full action plan at bio.org/bioadvance.</b></a></p>
<p><strong>Read more: <a href="https://www.statnews.com/2026/11/10/china-biotech-bio-plan-space-race/" target="_blank" rel="noopener">BIO CEO: American biotech needs a coordinated plan to beat China — now</a></strong></p>
<p>The post <a href="https://bio.news/bios-view/bioadvance-bio-releases-national-action-plan-to-strengthen-us-biotech-leadership/">BioAdvance: BIO releases national action plan to strengthen US biotech leadership</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Using elastics with Invisalign: when, why and how to use them</title>
<link>https://edusehat.com/en/using-elastics-with-invisalign-when-why-and-how-to-use-them</link>
<guid>https://edusehat.com/en/using-elastics-with-invisalign-when-why-and-how-to-use-them</guid>
<description><![CDATA[ This clinical guide explains when elastics can support Invisalign treatment, from anchorage and sagittal correction to settling and tracking. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/using-elastics-with-invisalign-hero.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 16:30:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Using, elastics, with, Invisalign:, when, why, and, how, use, them</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-full"></figure>



<p><strong>This clinical guide explains when elastics can support Invisalign treatment, from anchorage and sagittal correction to settling and tracking.</strong></p>



<p>Elastics have sometimes been considered the dark arts of orthodontics. However, when clinicians understand their biomechanics, uses and limitations, they can improve the predictability of clear aligner treatment.</p>



<p>Clear aligners can deliver effective tooth movement, but some cases benefit from additional force control. In Invisalign treatment, elastics are most useful as an adjunct for anchorage reinforcement, sagittal correction, crossbite correction, posterior settling and management of selected tracking problems. They do not replace the aligner; instead, they help the aligner express the programmed movement more predictably.</p>



<h2 class="wp-block-heading">Class II correction and anchorage reinforcement</h2>



<figure class="wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-1 is-layout-flex wp-block-gallery-is-layout-flex">
<figure class="wp-block-image size-full"><figcaption class="wp-element-caption">Figure 1 – Class II Division 1 bite relationship</figcaption></figure>



<figure class="wp-block-image size-full"><figcaption class="wp-element-caption">Figure 2 – Clear aligners with Class II elastics</figcaption></figure>
</figure>



<p>Class II Division 1 cases requiring maxillary anterior retraction may benefit from elastics, particularly where significant interproximal reduction is planned or increased overjet raises the risk of a lower-lip trap.</p>



<p>The goal is to minimise mesial drift of the lower posterior teeth and preserve posterior anchorage while the aligner carries out the programmed anterior movement. A practical configuration involves precision cuts at UR3/UL3 with bonded buttons at LR6/LL6.</p>



<p>Rongo et al (2022) evaluated 20 adults treated with Invisalign and Class II elastics. They reported an average overjet reduction of 1.4 mm and maxillary molar distalisation of 0.93 mm, without significant skeletal changes. These findings support predominantly dentoalveolar correction in adults, although the uncontrolled study design limits conclusions about the independent contribution of elastics. (Fig. 1)</p>



<p>Similarly, Laganà et al (2025), in a randomised clinical trial involving 40 adolescents, reported favourable lower-incisor inclination control with aligners and Class II elastics compared with fixed appliances.</p>



<h2 class="wp-block-heading">Class III cases and lower-arch retraction</h2>



<p>Class III elastics may support lower anterior retraction, particularly in patients with edge-to-edge incisor relationships, limited remaining lower-arch interproximal reduction or increased anchorage requirements. A commonly used configuration incorporates precision cuts at LR3/LL3 with bonded buttons at UR6/UL6.</p>



<p>Careful attention should be given to vertical facial proportions and overbite. Patients presenting with reduced overbite may be vulnerable to unwanted vertical changes. Class III elastics primarily achieve dental compensation and should not be considered a substitute for skeletal correction in patients with significant discrepancies. Evidence specific to Invisalign Class III protocols remains limited.</p>



<h2 class="wp-block-heading">Crossbite correction</h2>



<figure class="wp-block-image alignwide size-full"><figcaption class="wp-element-caption">Figure 3 – Elastic configurations with clear aligners</figcaption></figure>



<p>In comprehensive aligner cases, cross-elastics can assist in correcting selected dental posterior crossbites when aligner-generated forces alone are insufficient. Correct button positioning and force-vector management help to avoid unwanted extrusion, tipping or aligner dislodgement.</p>



<p>Elastics should complement appropriate transverse expansion or individual tooth movement rather than compensate for inadequate treatment planning.</p>



<h2 class="wp-block-heading">Posterior open bite and settling</h2>



<p>Posterior open bite represents a recognised finishing challenge in clear aligner therapy. The occlusal coverage of aligners, unintended posterior intrusion and incomplete extrusion can contribute to reduced posterior contacts.</p>



<p>Vertical or triangular settling elastics may improve intercuspation during refinement. Xiao et al (2026), in a prospective clinical study involving 52 Invisalign patients and 172 molar sites, investigated 95 sites treated with settling elastics and 77 managed with aligners alone. Their findings supported greater correction of posterior open bite with elastic traction, providing emerging clinical evidence for this finishing approach.</p>



<h2 class="wp-block-heading">Bootstrap elastics for tracking problems</h2>



<figure class="wp-block-image alignfull size-full"><figcaption class="wp-element-caption">Figure 4 – Bonded button for bootstrap elastic attachment</figcaption></figure>



<p>Bootstrap elastics may be useful when individual teeth, particularly maxillary lateral incisors, fail to track appropriately. By introducing an additional seating or extrusion-directed force, they may help engage the tooth with the aligner.</p>



<p>Before prescribing bootstrap elastics, clinicians should assess available space, attachment integrity, aligner seating and movement staging. Persistent tracking discrepancies may require refinement rather than additional elastic force. Evidence for specific bootstrap protocols remains primarily clinical rather than supported by high-quality comparative trials.</p>



<h2 class="wp-block-heading">Practical clinical protocol</h2>



<p>Elastic selection, force magnitude and wear duration should be individualised according to the intended movement, anchorage requirements and response to treatment. Metal or tooth-coloured buttons can be placed using bracket cement and standard bonding techniques.</p>



<p>A practical part-time protocol may involve medium-force elastics of approximately 99 g (3.5 oz) or 126 g (4.5 oz), measuring 4.8 mm (3/16 inch) or 6.4 mm (1/4 inch), worn for 12-18 hours, commonly during the evening and overnight, with regular replacement.</p>



<p>However, this is a clinical example, not a universally validated regimen. Published protocols vary considerably; Rongo et al, for example, prescribed 1/4-inch, 6-oz elastics with full-time wear.</p>



<h2 class="wp-block-heading">Video guides</h2>



<p>Aligner Dental Academy provides a video guide on troubleshooting tracking issues during Invisalign treatment: <a href="https://members.alignerdentalacademy.com/posts/past-event-recordings-troubleshooting-tracking-issues-during-invisalign-treatment-with-dr-kavita-malkan">Troubleshooting Tracking Issues During Invisalign Treatment with Dr Kavita Malkan</a>.</p>



<p>An additional guide is available: <a href="https://members.alignerdentalacademy.com/posts/past-event-recordings-troubleshooting-in-invisalign-with-dr-jasmine-piran">Troubleshooting in Invisalign with Dr Jasmine Piran</a>.</p>



<h2 class="wp-block-heading">Conclusion</h2>



<figure class="wp-block-image alignfull size-full"><figcaption class="wp-element-caption">Figure 5 – Aligned upper and lower teeth.</figcaption></figure>



<p>Elastics are a valuable adjunct to Invisalign treatment when used strategically rather than routinely. Their applications include Class II and selected Class III correction, crossbite management, posterior settling and individual tooth tracking.</p>



<p>Successful outcomes depend on biomechanical planning, appropriate anchorage, patient compliance and regular evaluation of aligner fit. Predictable clear aligner treatment requires a combination of digital planning, sound orthodontic principles and continuous clinical monitoring.</p>



<h3 class="wp-block-heading">References</h3>



<p>1. Rongo R, Dianišková S, Spiezia A, Bucci R, Michelotti A, D’Antò V. <em>J Clin Med.</em> 2022;11(24):7333. doi:10.3390/jcm11247333.</p>



<p>2. Laganà G, Malara A, Lione R, Bollero P, Cozza P. <em>Front Dent Med.</em> 2025;6:1613037. doi:10.3389/fdmed.2025.1613037.</p>



<p>3. Xiao L, et al. <em>Am J Orthod Dentofacial Orthop.</em> 2026.</p>



<p><em>This article is sponsored by Aligner Dental Academy</em></p>]]> </content:encoded>
</item>

<item>
<title>Reliability and the digital workflow</title>
<link>https://edusehat.com/en/reliability-and-the-digital-workflow</link>
<guid>https://edusehat.com/en/reliability-and-the-digital-workflow</guid>
<description><![CDATA[ Dentist Mohsen Tehranian shares how his background in software engineering fuels a passion for digital innovation and technology that can elevate patient care. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/dreamsmile-digital-workflow-feature.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 16:30:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Reliability, and, the, digital, workflow</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-full"></figure>



<p><strong>Mohsen Tehranian shares how his background in software engineering fuels a passion for digital innovation and technology that can elevate patient care.</strong></p>



<h2 class="wp-block-heading">A route from software to dentistry</h2>



<p>Mohsen Tehranian took an unconventional path to becoming a dentist. He began his career as a software engineer, but his early exposure to dentistry – and his desire for greater interaction – ultimately drew him back.</p>



<p>Growing up in Iran, he first encountered dentistry at 15, when he undertook work experience at a dental laboratory. Under supervision, he continued working there one day a week throughout the final years of school.</p>



<p>‘There was a dentist who practised upstairs, and I thought it was quite a cool job with a lot to learn. But at the time, I was more into computers and software.’</p>



<p>After qualifying and working in software engineering, he soon found the career less rewarding than he had hoped.</p>



<p>‘I was always interested in technology, but felt something was lacking: the human connection,’ he recalls.</p>



<p>The chance to combine digital technology and problem-solving with meaningful patient interactions ultimately led him back to dentistry.</p>



<p>Fast forward 26 years, and Mohsen now owns <a href="https://dreamsmiledental.co.uk/" target="_blank" rel="noreferrer noopener">DreamSmile Dental Clinic</a> in Lewisham, London. An accomplished clinician and dental tutor, he has built his career around Invisalign, digital smile design and restorative dentistry, while championing the technology that shapes modern dental practice.</p>



<p>Indeed, his software background has proved invaluable.</p>



<h2 class="wp-block-heading">Digital dentistry in practice</h2>



<p>‘Digital dentistry has been the biggest change in the profession in recent years and particularly in my own career,’ he says. ‘Digitalisation has created many opportunities within the profession – and not just in the chair. It has involved software for management, design and analysis as well as 3D printing. There is now a new generation of technology and treatments that are bringing great benefits for patients.’</p>



<p>As digital dentistry continues to integrate into everyday practice at pace, the equipment supporting those workflows becomes just as important as the technology used for diagnosis, planning and treatment.</p>



<h2 class="wp-block-heading">A reliable practice backbone</h2>



<p>For Mohsen, reliability of this support is fundamental. With four surgeries operating at his practice, equipment needs to work consistently in the background without interrupting the clinical workflow.</p>



<p>That luxury of simply relying on essential equipment to do its job is particularly important in a busy practice. Technical failures can cause downtime, disrupt appointments and take clinicians away from what matters most: patient care.</p>



<p>‘Consistency and reliability in the equipment we invest in are important. For example, we have used the <a href="https://www.duerrdental.com/en/GB/products/compressed-air/devices/power-tower/" target="_blank" rel="noreferrer noopener">Dürr Power Tower</a> in our practice for some time now, and with four surgeries in operation, I don’t have to think about it. We have to be able to confidently rely on the technology to ensure we can deliver a high level of care.’</p>



<h2 class="wp-block-heading">Reliability in practice</h2>



<p>Mohsen says the <a href="https://www.duerrdental.com/en/GB/products/compressed-air/devices/power-tower/">Dürr Power Tower PTS 120</a> is an integral part of his practice infrastructure, combining compressed air and suction in a compact, efficient unit. Its modular design allows him to tailor the system to his practice’s needs, while annual compressor filter replacement reduces maintenance demands and supports performance.</p>



<p>He explains: ‘The quiet operation and compact footprint are invaluable. It helps to create a more comfortable setting for both patients and staff. If I wanted to summarise what I want in a dentist’s clinic, I want things to run smoothly at 100% efficiency, with nothing failing and disrupting our day-to-day workflow.’</p>



<p>That, he says, is precisely what the system has delivered.</p>



<p>‘<a href="https://www.duerrdental.com/en/">Dürr Dental</a> has been a company we can rely on. The equipment is reliable – without this, the heart of our delivery closes down. In the three years since purchasing the Power Tower, it has never let us down; it has worked efficiently and silently in the background so that we can focus on patient care.’</p>



<h2 class="wp-block-heading">Continuing to learn</h2>



<p>His enthusiasm for technology extends beyond his own clinical work. Teaching and sharing knowledge have become an important part of his career, particularly as dentistry continues to evolve.</p>



<p>Mohsan says he has been lecturing on Invisalign since 2012 and is one of only two global faculty members in the UK. He says he also lectures from his London clinic, where groups of around 8-10 dentists undertake a three-module programme over three months.</p>



<p>Delegates have three weeks between modules to put what they have learned into practice before returning for the next stage. The aim is to demonstrate how the different elements of a digital workflow can work together in practice. For Mohsen, technology is only part of the equation; clinicians also need to understand how to integrate it.</p>



<p>‘I hope delegates will learn by seeing our complete digital workflow in practice. We want to showcase exactly how we do it here.’</p>



<h2 class="wp-block-heading">Embracing innovation</h2>



<p>He believes that a willingness to learn will become increasingly important as technology continues to transform dentistry. His advice to dentists considering new digital workflows is straightforward: don’t fear innovation.</p>



<p>‘Dentistry can be repetitive and can become mundane, so embracing new technology and thinking helps make the role rewarding and helps deliver the best possible care for our patients. Never be scared of new technology. Embrace it, try it, compare it with other formats, and be ready for the learning curve, which makes dentistry more interesting.’</p>



<p>After nearly three decades in dentistry, he says it is this ongoing development that keeps him engaged and ahead of the curve.</p>



<p>‘The future of dentistry is about embracing innovation, building dependable workflows, and continuing to learn so technology can quietly do its job while clinicians focus on theirs. I have been practising dentistry for 26 years, and continued learning is what makes it exciting.’</p>



<p>For more information, visit <a href="https://dreamsmiledental.co.uk/for-dentists/">The Dentistry Course</a> or email <a href="mailto:info@dreamsmiledental.co.uk">info@dreamsmiledental.co.uk</a>.</p>



<p><em>This article is sponsored by Dürr Dental</em>.</p>]]> </content:encoded>
</item>

<item>
<title>Illumina Offers Early Access to Duplex Sequencing for MRD, Tumor Evolution Research</title>
<link>https://edusehat.com/en/illumina-offers-early-access-to-duplex-sequencing-for-mrd-tumor-evolution-research</link>
<guid>https://edusehat.com/en/illumina-offers-early-access-to-duplex-sequencing-for-mrd-tumor-evolution-research</guid>
<description><![CDATA[ Illumina has announced an early access program to a duplex sequencing workflow that reads both DNA strands to detect trace ctDNA in molecular residual disease and tumor evolution studies. Kits are expected in early 2027.
The post Illumina Offers Early Access to Duplex Sequencing for MRD, Tumor Evolution Research appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/04/GettyImages-1325872227.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 08:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Illumina, Offers, Early, Access, Duplex, Sequencing, for, MRD, Tumor, Evolution, Research</media:keywords>
<content:encoded><![CDATA[<p>Spotting a handful of tumor DNA fragments among one million total DNA fragments may be the kind of sensitivity researchers need when studying molecular residual disease (MRD), the small amount of cancer that can remain after treatment. Illumina has opened an early access program for a sequencing workflow to support research in that range.</p>
<p>Announced this week, the research-use-only workflow is designed to detect trace amounts of circulating tumor DNA (ctDNA) in plasma samples and to support longitudinal, whole-genome studies of MRD and tumor evolution. Kits are expected to ship in the first quarter of 2027.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The workflow relies on duplex chemistry, which confirms each base call using both complementary strands of the original DNA molecule. Seeing the same change on both strands increases confidence that it is biological rather than an error introduced during library preparation or sequencing, according to the Illumina press release.</p>
<p>On the hardware and software side, the workflow combines the NovaSeq X sequencing platform with DRAGEN bioinformatics software. Illumina said that pairing NovaSeq X sequencing with duplex chemistry yields quality scores above Q65. DRAGEN then generates duplex consensus reads, optimizes quality scores, and interrogates thousands of tumor-specific variants across the genome, combining evidence from the few that may be present in plasma. The workflow supports 5–10 ng of cell-free DNA (cfDNA) input.</p>
<p>In representative studies, the workflow reproducibly detected ctDNA at 2.5 parts per million.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>“Researchers need effective ways to find the faintest traces of tumor DNA—signals that can be especially difficult to detect in early-stage, low-shedding, or low-mutation-burden tumors,” said Cande Rogert, vice president, global head of advanced science at Illumina, in a press release. “This early access technology is an important step toward helping researchers explore those challenging settings with greater sensitivity and generate evidence that can advance MRD research.”</p>
<p>The duplex workflow adds to Illumina’s MRD research portfolio and complements Illumina WGS Oncology Prep, which supports tumor fingerprinting and longitudinal ctDNA monitoring in a standardized whole-genome workflow.</p>
<p>NYU Langone Health is among the early access users and is applying the approach to MRD research. “MRD research is moving fast, and new tools are making it possible to bring ultrasensitive, tumor-informed analysis in-house,” said Matija Snuderl, MD, director of molecular pathology at NYU Langone Health. He added that the team looks forward to “generating evidence with a non-bespoke approach that can help advance our understanding of disease recurrence.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/illumina-offers-early-access-to-duplex-sequencing-for-mrd-tumor-evolution-research/">Illumina Offers Early Access to Duplex Sequencing for MRD, Tumor Evolution Research</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA Requires Safety Labeling Changes for GLP&#45;1 RAs Due to Potential Increased Risk of Rare But Serious Eye Condition</title>
<link>https://edusehat.com/en/fda-requires-safety-labeling-changes-for-glp-1-ras-due-to-potential-increased-risk-of-rare-but-serious-eye-condition</link>
<guid>https://edusehat.com/en/fda-requires-safety-labeling-changes-for-glp-1-ras-due-to-potential-increased-risk-of-rare-but-serious-eye-condition</guid>
<description><![CDATA[ Today, the U.S. Food and Drug Administration (FDA) announced that patients and healthcare providers should be aware of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. NAION is a rare condition that can result in acute, painless, decreased vision in one […]
The post FDA Requires Safety Labeling Changes for GLP-1 RAs Due to Potential Increased Risk of Rare But Serious Eye Condition appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/ssshutterstock_2685545237.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 05:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, Requires, Safety, Labeling, Changes, for, GLP-1, RAs, Due, Potential, Increased, Risk, Rare, But, Serious, Eye, Condition</media:keywords>
<content:encoded><![CDATA[<p>Today, the U.S. Food and Drug Administration (FDA) announced that patients and healthcare providers should be aware of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. NAION is a rare condition that can result in acute, painless, decreased vision in one […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/fda-requires-safety-labeling-changes-for-glp-1-ras-due-to-potential-increased-risk-of-rare-but-serious-eye-condition/">FDA Requires Safety Labeling Changes for GLP-1 RAs Due to Potential Increased Risk of Rare But Serious Eye Condition</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Cancer&#45;Associated Gene Triggers Cell Division Without Unpacking the Genome</title>
<link>https://edusehat.com/en/how-cancer-associated-gene-triggers-cell-division-without-unpacking-the-genome</link>
<guid>https://edusehat.com/en/how-cancer-associated-gene-triggers-cell-division-without-unpacking-the-genome</guid>
<description><![CDATA[ A study showed how E2F1 can trigger cell division without having to unpack the cell’s genetic material. Instead, it takes a shortcut path by binding directly to a small area of the DNA that remains tightly packaged inside the cell.
The post How Cancer-Associated Gene Triggers Cell Division Without Unpacking the Genome appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/04/GettyImages-2152737017.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 05:15:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Cancer-Associated, Gene, Triggers, Cell, Division, Without, Unpacking, the, Genome</media:keywords>
<content:encoded><![CDATA[<p>Living cells are one of the few materials that can replicate themselves, and this is crucial for tissue development and recovering from injury or illness. But making sure cell division only happens at the right time is essential, otherwise unregulated replication can lead to problems like cancer.</p>
<p>The results of a study headed by researchers at the University of California, Santa Cruz, have now shown that a cancer-related gene known as <em>E2F1</em> can cause cells to divide without having to abide by the normal rules of cell division. Their research found that instead of having to unpack the genetic material inside the cell, E2F1 takes a shortcut path by binding directly to a small area of the DNA that remains tightly packaged inside the cell. The discovery helps to further illuminate the processes that drive cell proliferation and may influence cancer growth and could provide insight that will help in the future design of more precise and targeted treatments.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“Cancers may overcome the typical checks and balances that our cells are using to maintain a dormant state, dysregulating and increasing the level of E2F1 to find a shortcut back to the cell cycle,” said Ali Shariati, PhD, Associate Professor of Biomolecular Engineering at the Baskin School of Engineering. Shariati, and Professor Chemistry & Biochemistry Seth Rubin, PhD, are co-senior and co-corresponding authors of the researchers published paper in <em>The EMBO Journal</em>, titled “<a href="https://doi.org/10.1038/s44318-026-00936-4" target="_blank" rel="noopener">E2F1 induces a G0-G1 reentry transcriptional program without changing chromatin accessibility</a>.” In their paper the researchers concluded, “Our work redefines the relationship between transcription factor and chromatin dynamics during fate transitions and establishes E2F1 as a potent regulator capable of inducing cell-cycle reentry without changing chromatin accessibility.”</p>
<p>Nearly all cells have the ability to divide, but the majority don’t, instead waiting in a state similar to hibernation. And this hibernation doesn’t happen automatically—the body must constantly send signals to prevent cell division. Otherwise, any body part could grow bigger than its proper size, or grow tumors. “Many cells in the human body reside in a reversible nondividing quiescent state termed G0,” the authors explained. “Quiescent cells repress cell-cycle genes via chromatin-based mechanisms to maintain a non-dividing state, yet remain poised to reenter the cell cycle upon stimulation.”</p>
<p>The UCSC researchers are studying how cells know when and how to divide, and the influence on these processes of genes known to be important in cancer. Rubin’s lab focuses on the biochemistry and gene expression of cell division, while Ali Shariati’s lab studies how cells translate input from the body in order to decide whether or not to divide. “Cells can’t just rely on the assumption that they will stop dividing,” Shariati said. “The cells need to actively say, ‘this is the liver, it should be this large, and after we reach this critical size, let’s just stop dividing,’ That’s called homeostatic behavior, and that’s not a trivial task for the body. It’s a state where the cells are ready to be activated, but normally aren’t, unless there is an external requirement. It’s a delicate balance to maintain.” The authors further explained, “Cells enter quiescence when they do not receive the required signaling cues for cell-cycle progression such as growth factors.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>To recover from injuries or illness, the body can send a signal to cells to leave hibernation and divide. To do so, it must instruct cells to physically unpack the DNA that is tightly wrapped around proteins inside its nucleus. To recreate this process in the lab, scientists typically add nutrients and growth signals to dormant cells, which cause them to divide.</p>
<p>The UC Santa Cruz researchers studied an important gene called <em>E2F1</em>, which is central for cell division and malfunctions in many cancers. “E2F1 is known to be a transcriptional activator that binds to and induces expression of cell-cycle genes such as those encoding cyclins, cyclin-dependent kinases, and DNA replication machinery,” the team noted. Other scientists have found that the activation of this gene can cause cells to divide without growth signals, and the UCSC scholars further confirmed this finding.</p>
<figure aria-describedby="caption-attachment-340488" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-340488" src="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_PressRelease-1-300x119.jpg" alt="On the left, dormant cells (turquoise) lie in wait for biological signals. On the right, cells are awakened by E2F1 (magenta) and begin to divide. " width="300" height="119" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_PressRelease-1-300x119.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_PressRelease-1.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">On the left, dormant cells (turquoise) lie in wait for biological signals. On the right, cells are awakened by E2F1 (magenta) and begin to divide. [Ali Shariati / UC Santa Cruz]</figcaption></figure>
<p>The team further discovered that E2F1 appears to be taking a shortcut method to cause division. Using a very limited amount of physical space in the genome, the E2F1 protein can bind directly to the genome in order to switch on the genes related to cell division. “… quiescent cells can reenter the cell-cycle and complete their division without global changes in chromatin accessibility when induced by expression of a single transcription factor; E2F1,” they wrote. “Our results show that E2F1 is able to rapidly promote quiescence exit by activating an accelerated gene expression program without global changes in chromatin accessibility.”</p>
<p>Shariati further commented, “The surprising part is, unlike the typical process, E2F1 is able to activate the cell cycle genes without physically unpacking the genome much or at all. That means this is a new way of transcription factors being able to activate genes and let the cells completely change their fate and go on to divide.” And while DNA binding is essential to the ability of E2F1 to trigger cell division, “… deletion of the DNA binding domain in E2F1 led to a complete loss of cell cycle reentry,” the investigators noted, “The precise mechanisms underlying the transcriptional activation of cell-cycle genes by E2F1 without significant changes in chromatin accessibility remain unknown and merits further investigation.”</p>
<p>The ability to activate cell division makes E2F1 similar to a special category of genes that scientists call “pioneer factors,” which can unlock tightly packed DNA to fundamentally reprogram cells. This special status indicates that cells must maintain a precise level of E2F1 to maintain proper cell division. Indeed, the UC Santa Cruz researchers found that cells can sense a specific threshold of E2F1: once levels cross that line, dormant cells begin to divide.</p>
<p>E2F1’s shortcut method of division has its own limitations. The scientists found that cells can only divide at most three times without any additional growth signals. To study cell division over time, the researchers used live single-cell imaging techniques developed in the Shariati lab, including their in-house <a href="https://doi.org/10.1016/j.crmeth.2023.100500" target="_blank" rel="noopener">DeepSea software</a>.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Nonetheless, the shortcut method to cell division that E2F1 uses happens much faster than the typical process with nutrients. Researchers suspect cancer cells may exploit this E2F1 activity, although more research will be needed to better understand how this mechanism works.</p>
<p>Shariati plans to further study how exactly E2F1 activates the genes after it binds to the genome. This could help to find a more precise and targeted approach for interfering with this pathway in the context of cancer. He also wants to study the eight genes in the same family as <em>E2F1</em>, some of which cause cells to become dormant, and their role in cancer.</p>
<p>Rubin is also interested in whether E2F1 can be targeted in cancers. “There has been much effort in the field to target E2F1’s role in cell division by inhibiting upstream proteins that control E2F1 activity,” Rubin said. “We have been wondering whether there are ways to target E2F1 itself to stop cancer cells from proliferating. The first steps are figuring out what specific cancers would benefit from blocking E2F1 activity, and then finding molecules that bind and prevent E2F1 from activating cell cycle gene expression.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/how-cancer-associated-gene-triggers-cell-division-without-unpacking-the-genome/">How Cancer-Associated Gene Triggers Cell Division Without Unpacking the Genome</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>One DSM Team, Every DFW Neighborhood: Plano, Southlake &amp;amp; McKinney</title>
<link>https://edusehat.com/en/one-dsm-team-every-dfw-neighborhood-plano-southlake-mckinney</link>
<guid>https://edusehat.com/en/one-dsm-team-every-dfw-neighborhood-plano-southlake-mckinney</guid>
<description><![CDATA[  ]]></description>
<enclosure url="https://dynamicsportsmedicine.com/wp-content/uploads/2025/08/Southlake-front.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 02:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>One, DSM, Team, Every, DFW, Neighborhood:, Plano, Southlake, McKinney</media:keywords>
<content:encoded></content:encoded>
</item>

<item>
<title>$170 Million Echo Cliffs Health Center Opens in Northern Arizona</title>
<link>https://edusehat.com/en/170-million-echo-cliffs-health-center-opens-in-northern-arizona</link>
<guid>https://edusehat.com/en/170-million-echo-cliffs-health-center-opens-in-northern-arizona</guid>
<description><![CDATA[ The Echo Cliffs Health Center is expected to serve approximately 6,000 patients from the Navajo, Hopi and San Juan Southern Paiute communities in Northern Arizona. | Photo Credit: Tuba City Regional Health Care Corporation The 123,565-square-foot outpatient center celebrated its grand opening Oct. 2 and now serves Navajo, Hopi and San Juan Southern Paiute families. ...
The post $170 Million Echo Cliffs Health Center Opens in Northern Arizona appeared first on HCO News.
The post $170 Million Echo Cliffs Health Center Opens in Northern Arizona appeared first on HCO News. ]]></description>
<enclosure url="https://hconews.com/wp-content/uploads/2026/11/HCO-News.EchoCliffs-768x432.png" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 22:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>170, Million, Echo, Cliffs, Health, Center, Opens, Northern, Arizona</media:keywords>
<content:encoded><![CDATA[<h5><span data-ccp-props="{}">The Echo Cliffs Health Center is expected to serve approximately 6,000 patients from the Navajo, Hopi and San Juan Southern Paiute communities in Northern Arizona. | Photo Credit: Tuba City Regional Health Care Corporation</span></h5>
<ul>
<li><span data-contrast="auto">The 123,565-square-foot outpatient center celebrated its grand opening Oct. 2 and now serves Navajo, Hopi and San Juan Southern Paiute families.</span><span data-ccp-props="{}"> </span></li>
<li><span data-contrast="auto">The design incorporates natural colors and materials, an east-facing entrance, daylight-filled public circulation and outdoor therapy space.</span><span data-ccp-props="{}"> </span></li>
<li><span data-contrast="auto">Architect Dekker and contractor Arviso/Okland delivered the design-build project.</span><span data-ccp-props="{}"> </span></li>
</ul>
<p><span data-contrast="auto">COPPERMINE, Ariz. — Tuba City Regional Health Care Corporation recently celebrated the opening of its $170 million Echo Cliffs Health Center, a 123,565-square-foot outpatient facility expected to serve approximately 6,000 people. The center serves Navajo, Hopi and San Juan Southern Paiute families.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">“Our people should not have to travel hours just to receive the health care they need,” Navajo Nation President Buu Nygren said, according to </span><a href="https://tchealth.org/echo-cliffs-health-center-celebrates-grand-opening-with-community-and-national-health-leaders/?utm_source=chatgpt.com" target="_blank" rel="noopener"><span data-contrast="none">a release from Tuba City Regional Health Care Corporation</span></a><span data-contrast="auto">. “This facility means our families can receive quality care closer to home, closer to their children and closer to their communities.”</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">According to the release and </span><a href="https://www.ihs.gov/sites/des/themes/responsive2017/display_objects/documents/Projects/ProjectDataECHOCLIFFSHEALTHCENTER.pdf" target="_blank" rel="noopener"><span data-contrast="none">project information from the Indian Health Service</span></a><span data-contrast="auto">, the clinical program includes primary care, a 13-chair dental clinic, eye care, laboratory testing, diagnostic imaging and physical therapy, along with pharmacy and wellness services.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Dekker was the architect of record, and Arviso/Okland, a joint venture of Arviso Construction Co. and Okland Construction, served as contractor on the design-build project.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Construction began in February 2024. Developing the remote site required new water and power infrastructure, </span><a href="https://www.dekkerdesign.org/project/echo-cliffs-health-center/" target="_blank" rel="noopener"><span data-contrast="none">according to Dekker,</span></a><span data-contrast="auto"> as well as sewer and fiber connections, an electrical substation upgrade and entrance-road improvements.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Dekker said the design reflects the Navajo concept of Hózhǫ́, emphasizing balance and harmony. Natural colors, materials and textures carry that approach into the interiors. The building’s placement preserves the desert landscape while creating a sheltered outdoor space between the facility and neighboring sandstone cliffs.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">The east-facing patient entrance responds to Indigenous traditions and admits morning light. IHS design documents describe an east-facing concourse that connects public functions and helps patients navigate the building while providing daylight and views. Service areas occupy the west side, limiting exposure to afternoon sun.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">The project documents also describe separate approaches for public traffic from the north and staff and service traffic from the south. The site plan allocates the southern portion to employee housing and preserves northern land for future development.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Outdoor amenities include a walking trail and a physical therapy terrain garden. The project was designed to pursue LEED Gold certification.</span><span data-ccp-props="{}"> </span></p>
<p><a href="https://tchealth.org/echo-cliffs-breaks-ground-on-87-million-staff-housing-to-support-new-clinic/" target="_blank" rel="noopener"><span data-contrast="none">According to Tuba City Regional Health Care Corporation</span></a><span data-contrast="auto">, a separate $87 million housing development will provide 92 units for medical workers, comprising 60 apartments and 32 single-family homes. The housing was scheduled to open in phases through December 2026.</span><span data-ccp-props="{}"> </span></p>
<p><i><span data-contrast="auto">This article is based on a press release published by </span></i><a href="https://tchealth.org/echo-cliffs-health-center-celebrates-grand-opening-with-community-and-national-health-leaders/?utm_source=chatgpt.com" target="_blank" rel="noopener"><i><span data-contrast="none">Tuba City Regional Health Care Corporation</span></i></a><i><span data-contrast="auto"> on Oct. 8, 2026, supplemented by project information from the </span></i><a href="https://www.ihs.gov/sites/des/themes/responsive2017/display_objects/documents/Projects/ProjectDataECHOCLIFFSHEALTHCENTER.pdf" target="_blank" rel="noopener"><i><span data-contrast="none">Indian Health Service</span></i></a><i><span data-contrast="auto">, </span></i><a href="https://www.dekkerdesign.org/project/echo-cliffs-health-center/" target="_blank" rel="noopener"><i><span data-contrast="none">Dekker</span></i></a><i><span data-contrast="auto">, </span></i><a href="https://www.linkedin.com/posts/okland-construction_okland-arizona-tchrcc-activity-7240068299458256898-gMEG" target="_blank" rel="noopener"><i><span data-contrast="none">Okland Construction</span></i></a><i><span data-contrast="auto"> and the health system’s </span></i><a href="https://tchealth.org/echo-cliffs-breaks-ground-on-87-million-staff-housing-to-support-new-clinic/" target="_blank" rel="noopener"><i><span data-contrast="none">staff-housing coverage</span></i></a><i><span data-contrast="auto">.</span></i><span data-ccp-props="{}"> </span></p>
<p>The post <a rel="nofollow" href="https://hconews.com/2026/11/09/170-million-echo-cliffs-health-center-opens-in-northern-arizona/">$170 Million Echo Cliffs Health Center Opens in Northern Arizona</a> appeared first on <a rel="nofollow" href="https://hconews.com/">HCO News</a>.</p>
<p>The post <a href="https://hconews.com/2026/11/09/170-million-echo-cliffs-health-center-opens-in-northern-arizona/">$170 Million Echo Cliffs Health Center Opens in Northern Arizona</a> appeared first on <a href="https://hconews.com/">HCO News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Journal Author Spotlight: Wasita Parksook, MD, MSc</title>
<link>https://edusehat.com/en/journal-author-spotlight-wasita-parksook-md-msc</link>
<guid>https://edusehat.com/en/journal-author-spotlight-wasita-parksook-md-msc</guid>
<description><![CDATA[ Endocrinologist Wasita Parksook, MD, MSc, at King Chulalongkorn Memorial Hospital, in Bangkok, Thailand, discusses her paper “Impact of alert systems on glucocorticoid administration for adrenal insufficiency in the emergency department“* published in the November issue of The Journal of Clinical Endocrinology &amp; Metabolism. What problem or question inspired this research? It started with a morbidity […]
The post Journal Author Spotlight: Wasita Parksook, MD, MSc appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/IMG_6441-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 22:35:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Journal, Author, Spotlight:, Wasita, Parksook, MD, MSc</media:keywords>
<content:encoded><![CDATA[<p>Endocrinologist Wasita Parksook, MD, MSc, at King Chulalongkorn Memorial Hospital, in Bangkok, Thailand, discusses her paper “Impact of alert systems on glucocorticoid administration for adrenal insufficiency in the emergency department“* published in the November issue of The Journal of Clinical Endocrinology & Metabolism. What problem or question inspired this research? It started with a morbidity […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/journal-author-spotlight-wasita-parksook-md-msc/">Journal Author Spotlight: Wasita Parksook, MD, MSc</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cancer drug study puts numbers to the cost of IRA’s pill penalty</title>
<link>https://edusehat.com/en/cancer-drug-study-puts-numbers-to-the-cost-of-iras-pill-penalty</link>
<guid>https://edusehat.com/en/cancer-drug-study-puts-numbers-to-the-cost-of-iras-pill-penalty</guid>
<description><![CDATA[ The price Americans pay for the Inflation Reduction Act (IRA) “pill penalty” and disincentives for follow-on research is a reduction in new cancer treatments, […]
The post Cancer drug study puts numbers to the cost of IRA’s pill penalty appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/towfiqu-barbhuiya-uM5mnbNm8eA-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 22:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cancer, drug, study, puts, numbers, the, cost, IRA’s, pill, penalty</media:keywords>
<content:encoded><![CDATA[<p><span>The price Americans pay for the Inflation Reduction Act (IRA) “pill penalty” and disincentives for follow-on research is a reduction in new cancer treatments, a study finds.</span></p>
<p><span>The introduction of the IRA is associated with a 37% decline in follow-on small-molecule oncology studies and a 27% decline in lead-indication small molecule approvals, according to</span><a href="https://link.springer.com/article/10.1007/s43441-026-01061-4"> <span>research by Vital Transformation</span></a><span>. It also showed a 14% decline in the share of orphan oncology studies.</span></p>
<p><span>The research, published Oct. 20,</span> <span>analyzed 1,148 secondary clinical trials associated with 364 medicines approved by the Food and Drug Administration (FDA) from 175 companies between 2018 and 2025. Researchers used statistical modeling to compare post-approval drug development and research activity across disease areas before and after the IRA’s introduction.</span></p>
<p><span>“The findings indicate that the effects of the legislation on late-stage pharmaceutical research may warrant greater attention from policymakers, particularly in oncology, where continued clinical development can expand treatment options for patients with serious and difficult-to-treat cancers,”</span><a href="https://vitaltransformation.com/wp-content/uploads/2026/11/IRA_Press_Release_2NOV-final.pdf"> <span>according to Vital Transformation</span></a><span>.</span></p>
<h2>Why small molecules and follow-up matter</h2>
<p><span>The IRA allows the Centers for Medicare & Medicaid Services (CMS) to control the price of medications by making drug makers engage in “negotiations” or face steep penalties. Biologic medicines are exempted from these price controls for as long as 13 years, but small molecule drugs, which are often prepared as pills and comprise</span><a href="https://www.frontiersin.org/journals/drug-discovery/articles/10.3389/fddsv.2023.1314077/full"> <span>about 90% of prescription drugs</span></a><span>, only receive a maximum of nine years of protection.</span></p>
<p><span>This “pill penalty” creates a disincentive to invest in small molecule drugs, which has been</span><a href="https://bio.news/health/capitol-hill-september-2024-pprv-pediatric-rare-disease-voucher-inflation-reduction-act-price-controls/#:~:text=%E2%80%98A%20classic%20issue,the%20Manhattan%20Institute."> <span>noted by policymakers</span></a><span> and others.</span></p>
<p><span>Follow-up studies investigate whether a drug approved for one condition is useful for another indication. This approach can speed access to new drugs for patients, especially oncology drugs, for which approximately 60-75% of marketed medications have more than one indication,</span><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC13297679/"> <span>according to research</span></a><span>.</span></p>
<p><span>The IRA discourages follow-up studies because drugs approved for an additional indication do not get additional protection from CMS price “negotiations.”</span></p>
<p><span>The Vital Transformation research puts actual numbers to the pill penalty in cancer research, identifying the 27% reduction in studies for new small molecule cancer drugs. It also shows that barriers to developing drugs for second indications puts an even greater damper on research—causing a decline of nearly 40% in follow-up studies for oncology drugs.</span></p>
<h2>Policy corrections</h2>
<p><span>There is bipartisan </span><span>legislation to correct the pill penalty, entitled the</span><a href="https://www.congress.gov/bill/119th-congress/house-bill/1492"> <span>Ensuring Pathways to Innovative Cures (EPIC) Act</span></a><span>. It would give small molecule drugs the same protection from price negotiations that biologics receive.</span></p>
<p><span>The Biotechnology Innovation Organization (BIO) praised the EPIC act when it was introduced.</span></p>
<p><span>“For decades small molecule medicines that come in a pill or tablet have been recognized for improving patient adherence, being easier to take, and more broadly accessible to those who need them. As a result, hundreds of such therapies have been developed,” said</span><a href="https://www.bio.org/press-release/bio-applauds-introduction-bipartisan-bill-eliminate-pill-penalty"> <span>BIO President & CEO John F. Crowley</span></a><span>, explaining the importance of the EPIC Act. “Today, instead of building on years of biomedical progress, some innovator companies and investors are now being forced to pull away.”</span></p>
<p><span>The data indicates a need for policy solutions, according to the Vital Transformation study.</span></p>
<p><span>“We hope this study reinvigorates debate” about the IRA’s “unintended consequences and encourages thoughtful policy solutions,” says the study. “The IRA manifestly creates disincentives that negatively impact patients seeking treatments in areas of high unmet medical need, particularly those requiring cures addressing metastatic late-stage cancers.”</span></p>
<p>The post <a href="https://bio.news/federal-policy/cancer-drug-study-puts-numbers-to-the-cost-of-iras-pill-penalty/">Cancer drug study puts numbers to the cost of IRA’s pill penalty</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Formulation Development Roundup</title>
<link>https://edusehat.com/en/formulation-development-roundup</link>
<guid>https://edusehat.com/en/formulation-development-roundup</guid>
<description><![CDATA[ What leaders suggest are the key considerations for developing robust formulations.
The post Formulation Development Roundup appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/GEN_NOV_GettyImages-2224940107.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 22:05:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Formulation, Development, Roundup</media:keywords>
<content:encoded><![CDATA[<p>Formulation development is a critical step in the production of a drug to ensure that it is safe, effective, stable, and suitable for administration. Companies that provide formulation development services are experts in applying best practices to achieve optimal results. <em>GEN</em> sought the perspectives of experts from four leading companies to describe the considerations they make when working with customers on developing new formulations.</p>
<p><em>GEN</em> asked two questions: How would you approach formulation development for a customer’s specific molecule, and what key risks would you evaluate first? How do you determine that you have found a robust formulation rather than just the best-performing formulation under your initial test conditions?</p>
<p> </p>
<h4><strong>Abzena</strong></h4>
<p>Initially, we would perform a developability assessment to understand how the molecule behaves under platform manufacturing stresses, including low pH, freeze-thaw, shear, and hold conditions. This establishes the early-risk profile, including aggregation, fragmentation, oxidation, and deamidation risks, and identifies any molecule-specific liabilities before formulation screening begins.</p>
<figure aria-describedby="caption-attachment-340462" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340462" src="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Abzena-Gary-Watts-300x300.jpg" alt="Gary Watt" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Abzena-Gary-Watts-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Abzena-Gary-Watts-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Abzena-Gary-Watts-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Abzena-Gary-Watts-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Abzena-Gary-Watts.jpg 1304w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Gary Watt, PhD<br>Head of Formulation</figcaption></figure>
<p>We would then align with the customer on the target product profile (TPP), including intended dose, concentration, route of administration, and presentation requirements, so the formulation strategy is driven by clinical and product needs rather than screening performance alone.</p>
<p>Once the TPP is agreed, we would confirm compatibility with platform analytical methods and run focused formulation screens assessing pH, ionic strength, excipient compatibility, and thermal stability. For subcutaneous products, we would also evaluate high-concentration feasibility, including solubility, viscosity, and aggregation risk.</p>
<p>Lead formulations would then be challenged through thermal and freeze/thaw stability studies using orthogonal analytical methods. Robustness is demonstrated when the selected formulation performs consistently across relevant stresses, analytical readouts, and small variations in formulation or process conditions, rather than simply being the best performer in the initial screen.</p>
<p>For Phase I/first-in-human (FIH) supply, the final formulation should provide an acceptable stability margin, support scale-up and manufacturing, and generate data suitable for Investigational New Drug (IND) filing.</p>
<p>Good Manufacturing Practices (GMP) batches would be placed on International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)-compliant stability studies, typically for up to four years, to confirm long-term performance and further justify the formulation selection.</p>
<p> </p>
<h4><strong>BioAgilytix</strong></h4>
<p>When approaching formulation development, I would start by understanding the molecule itself: what makes it unstable, which quality attributes matter most, and what conditions are most likely to cause problems. That means looking at physical and chemical stability, aggregation or particle formation, potency and purity, as well as sensitivity to things like pH, temperature, oxidation, agitation, and freeze-thaw. I would also look closely at the excipients, because stabilizers and other formulation components can affect both the molecule and its degradation pathways.</p>
<figure aria-describedby="caption-attachment-340463" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-340463" src="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-BioAgilytix-Jessica-Weaver-e1794230452134-300x300.jpg" alt="Jessica Weaver" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-BioAgilytix-Jessica-Weaver-e1794230452134-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-BioAgilytix-Jessica-Weaver-e1794230452134-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-BioAgilytix-Jessica-Weaver-e1794230452134-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-BioAgilytix-Jessica-Weaver-e1794230452134.jpg 900w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Jessica Weaver<br>Scientific Officer</figcaption></figure>
<p>From the analytical side, an important question is whether we have the right assays to detect those changes. A formulation may alter how a drug degrades, and an assay that works well for the drug substance may not tell the whole story once that molecule is in its final formulation. We need stability-indicating methods that can distinguish the intact drug from degradation products and detect meaningful changes in the critical quality attributes without interference from the formulation itself.</p>
<p>The bigger question then becomes more than which formulation performs best in an initial screen. We need to understand why it performs well and whether it continues to perform when challenged.</p>
<p>For me, that is the difference between a formulation that looks good and one that is truly robust. It should tolerate normal variability in formulation parameters, manufacturing, handling, and storage. If performance falls off as soon as you move away from the exact conditions used in the initial study, you probably haven’t found a robust formulation yet. Confidence comes from analytical and stability data showing that the formulation continues to protect the molecule under the conditions it is likely to encounter.</p>
<p> </p>
<p><strong>Curia Global</strong></p>
<figure aria-describedby="caption-attachment-340464" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340464" src="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Curia-TylerJones-e1794230551980-300x300.jpg" alt="Tyler Jones" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Curia-TylerJones-e1794230551980-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Curia-TylerJones-e1794230551980-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Curia-TylerJones-e1794230551980-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Curia-TylerJones-e1794230551980.jpg 899w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Tyler Jones, PhD<br>Director of Formulation R&D</figcaption></figure>
<p>We take a bespoke approach to formulation development, where we don’t make assumptions on behavior based on the type of molecule, but rather we use a process to efficiently and pragmatically identify critical quality attributes and understand why a molecule behaves the way it does. First, the Curia team would characterize the molecule across a wide formulation space, systematically mapping pH vs. ionic strength, the two parameters that most strongly influence how molecules present themselves to their environment. This broad physicochemical space allows us to force a molecule down the various degradation pathways it could encounter, and doing this across a range of temperatures allows us to understand the temperature-dependency of these pathways. Many biologics do not follow Arrhenius-type kinetics with regard to degradation activation energies, so understanding which degradation pathways are most relevant at the intended storage temperatures is critical in weighting formulation space performance.</p>
<p>Once this baseline understanding of molecule behavior is established, we can then pointedly mitigate remaining issues. For example, if we achieve good physical stability but are still encountering some chemical degradation such as oxidation, we can then screen antioxidants and have the background data to justify why we are adding such excipients.</p>
<p>Eventually, with enough stability data to have confidence in a final formulation space, we would utilize DOE studies to refine each variable in the formulation. The gold standard for us is long-term stability, so to definitively show the formulation is robust, we run long-term stability studies on a small selection of bracketed formulations around our sweet spot.</p>
<p> </p>
<p><strong>Quotient Sciences</strong></p>
<p>Formulation development should start with the target product profile and the molecule itself, including the required dose and exposure, route of administration, dosage form, and the API’s physicochemical, solid-state, and biopharmaceutic properties. The first priority is to identify the risks most likely to compromise clinical performance or create downstream development barriers. Depending on the molecule, these may include solubility and dissolution relative to dose, permeability, solid-form and chemical stability, excipient compatibility, dose feasibility, and manufacturability.</p>
<figure aria-describedby="caption-attachment-340461" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-340461" src="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Quotient-AsmaPatel-300x300.jpg" alt="Asma Patel" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Quotient-AsmaPatel-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Quotient-AsmaPatel-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Quotient-AsmaPatel-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Quotient-AsmaPatel.jpg 900w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Asma Patel, PhD<br>Vice President, Global Commercial and Scientific Consulting, Drug Product</figcaption></figure>
<p>The objective is not to select the most sophisticated technology, but rather the simplest formulation capable of delivering the required clinical performance while remaining viable through scale-up, transfer, and later-stage manufacture.</p>
<p>A robust formulation should be understood, not simply selected. Critical material attributes and process parameters should be challenged across justified ranges, including relevant interactions and boundary conditions, to determine where performance is maintained and where it begins to fail. The formulation choice should then be confirmed through reproducibility across batches, stability over time, performance on representative equipment, clinically relevant<em> in vitro</em> testing, and, where appropriate, human data.</p>
<p>A formulation is robust when normal variability is understood, controlled, and does not materially affect product quality or intended clinical performance.</p>
<p> </p>
<p> </p>
<p> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/formulation-development-roundup/">Formulation Development Roundup</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Therapeutic Immune Manipulation</title>
<link>https://edusehat.com/en/therapeutic-immune-manipulation</link>
<guid>https://edusehat.com/en/therapeutic-immune-manipulation</guid>
<description><![CDATA[ Next-generation immunotherapy exploits diverse immune populations to address the challenges that CAR T-cell therapy faces.
The post Therapeutic Immune Manipulation appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Amgen_Lab-Shot_CAR-T-Alternatives.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 22:05:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Therapeutic, Immune, Manipulation</media:keywords>
<content:encoded><![CDATA[<p>Chimeric antigen receptor (CAR) T-cell therapy was a major breakthrough in immunotherapy. To date, according to the Alliance for Cancer Gene Therapy, seven therapies have been approved for blood cancers such as Kymriah<sup>®</sup> and Yescarta<sup>®</sup>. As extraordinary as these CAR T-cell therapies are, the approach struggles with solid tumors, as well as adverse side effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) resulting from <em>in vivo</em> T cell expansion. Complex manufacturing for autologous therapies and resultant costs limit the number of patients that can be treated.</p>
<p>Alternative approaches to engaging the immune system have been explored for decades, for instance, bispecific T-cell engager (BiTE) technology pioneered by Amgen. Companies like Artiva Biotherapeutics and Dragonfly Therapeutics are exploring the benefits that natural killer (NK) cells can bring, especially in B cell driven autoimmune diseases. Additionally, rare T cell populations such as invariant natural killer T (iNKT) cells are being harnessed to perform beyond their normal capabilities. Scientists also continue to innovate to try and bring solid cancers with edgy antigens under clinical control.</p>
<p>Importantly, autologous CAR T-cell therapy illustrated that the immune system can be exploited to combat disease as well as the challenges that need to be addressed when doing so. The next generation of immunotherapies is beginning to progress through clinical trials, and a new class of drugs could potentially be introduced for autoimmune diseases as well as oncology indications.</p>
<h4><strong>Harnessing the immune system</strong></h4>
<p>“BiTE<sup>®</sup> technology was developed to address an important unmet need in cancer care,” said Jean-Charles Soria, MD, PhD, senior vice president, global oncology development at Amgen. “For 30 years, we have built on this science, first in blood cancers and more recently in solid tumors.”</p>
<p>While the immune system has a natural ability to recognize and kill cancer cells, tumors can develop ways to evade that response. BiTE therapies bring T cells into direct contact with tumor cells by binding both CD3 on the T cell and a specific antigen on the tumor cell, activating T-cell-mediated killing.</p>
<p>BiTE and CAR T-cell therapies are distinct, complementary approaches that harness the immune system to fight cancer, according to Soria. BiTE “off-the-shelf” therapies are designed to redirect a patient’s own T cells to recognize and eliminate tumor cells expressing a selected target. This can enable treatment without the individualized cell collection and manufacturing process required for CAR T therapy.</p>
<p>Both platforms have demonstrated meaningful clinical benefits in appropriate settings. The optimal approach depends on the disease, the target biology, the patient’s condition, practical treatment considerations, and the totality of clinical evidence. “BiTE therapies may be particularly well suited to cancers with targets that are frequently and consistently expressed on tumor cells, with limited expression in healthy tissues,” said Soria.</p>
<p>Amgen continues to explore the impact of existing BiTE therapies, including the potential to address needs earlier in the small cell lung cancer treatment journey, and the potential to combine BiTE therapies with other innovative mechanisms of action. “We are also investigating new assets across additional tumor types. This includes xaluritamig, an investigational STEAP1-targeted BiTE in advanced clinical development for prostate cancer, where immunotherapy has historically had limited success,” Soria elaborated.</p>
<p>As the understanding of cancer biology grows, immunotherapy will become increasingly precise. Amgen’s focus is to translate deep insights in human genetics and disease biology into the right targets and therapeutic approaches to provide meaningful new options. The company brought to market the first globally approved BiTE molecule in hematologic malignancies, and the first FDA-approved BiTE therapy for a common solid tumor, small cell lung cancer.</p>
<h4><strong>Bumping up defenses</strong></h4>
<p>“The role of any cell therapy is to very potently kill the pathogenic B cells. We use non-genetically modified NK cells in combination with monoclonal antibodies (mAbs) such as Rituxan<sup>®</sup> for targeting the antigen on the B cell,” said Fred Aslan, MD, CEO at Artiva Biotherapeutics.</p>
<p>The Fab region of the mAb binds to the antigen on the B cell while the Fc portion binds to CD16 on the NK cell surface. This three-way binding activates the NK cell to kill the B cell. Given alone, Rituxan relies on endogenous NK cells that can be lowered or have low activity in patients with B cell cancers or autoimmune diseases. Dosing billions of NK cells simultaneously with the mAb positions the mAb to do more.</p>
<figure aria-describedby="caption-attachment-340469" class="wp-caption alignright"><img decoding="async" class="wp-image-340469 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Artiva_MOA_CAR-T-Alternatives-e1794231580399-300x195.jpg" alt="Artiva_ MOA CAR T Alternatives" width="300" height="195" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Artiva_MOA_CAR-T-Alternatives-e1794231580399-300x195.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Artiva_MOA_CAR-T-Alternatives-e1794231580399-1024x665.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Artiva_MOA_CAR-T-Alternatives-e1794231580399-768x499.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Artiva_MOA_CAR-T-Alternatives-e1794231580399.jpg 1398w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">AlloNK is Artiva Biotherapeutics’ lead molecule. The high affinity CD16 NK cell is used in combination with Rituxan (rituximab). The Fab region of the mAb binds to the antigen on the B cell while the Fc portion binds to CD16 on the NK cell surface. This 3-way binding activates the NK cell to kill the B cell. This image was generated using artificial intelligence. [Artiva Biotherapeutics]</figcaption></figure>
<p>Importantly, since NK cells do not expand <em>in vivo,</em> serious side effects that result from T-cell expansion, CRS and ICANS, are avoided allowing therapeutic infusions outside of large hospital settings. However, the high dosages necessitate a robust manufacturing process.</p>
<p>A spin-off of Korea-based GC Cell, Artiva Biotherapeutics’ largest differentiation is its scalable process to manufacture NK cells. Umbilical cord units are selected from individuals with high affinity CD16 on the NK cells. Each umbilical cord creates about 50 intermediates that, in turn, each produce about 80 billion cells. “At a dose of eight billion cells, we can treat about 500 patients with a single umbilical unit. The COGS is a magnitude less than autologous CAR T-cell therapy,” said Aslan.</p>
<p>The company tested the NK cells with multiple targeting mAbs in two oncology and five autoimmune indications, close to 150 patients to date, to generate comparison data between the mAb and the combination therapy.</p>
<p>For example, using Rituxan alone, the average patient had an incomplete depletion; one B cell/ mL remained in the blood. In the combination therapy, no B cells were evident across all indications. In studies with aggressive non-Hodgkin lymphoma and Hodgkin lymphoma using a CD40 antibody, the complete response rate and durability were in line with autologous CAR T-cell therapy. Initial results with autoimmune disease also demonstrated results in line with autologous CAR T-cell therapy.</p>
<p>Artiva Biotherapeutics’ lead indication is refractory rheumatoid arthritis. They are initiating a Phase III trial with data expected by 2028.</p>
<h4><strong>Matching depletion to disease</strong></h4>
<p>The platform approach of Dragonfly Therapeutics for autoimmune disease spans CCR6, CD19, BAFFR, FAP, CD52 and BCMA, each aimed at a different pathogenic population and a different set of diseases, from lupus nephritis to fibrosis to amyloidosis.</p>
<p>The novel immune engagers include both first-in-class mAbs and trispecific immune cell engagers (TriNKETs). TriNKETs are antibody-like molecules with three binding arms: one for an antigen, one for NKG2D, and one for CD16. Both NKG2D and CD16 are activating receptors on NK cells.</p>
<figure aria-describedby="caption-attachment-340470" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="size-medium wp-image-340470" src="https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Dragonfly_Lab-shot_CAR-T-Alternatives-300x169.jpg" alt="Dragonfly Lab" width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Dragonfly_Lab-shot_CAR-T-Alternatives-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Dragonfly_Lab-shot_CAR-T-Alternatives-1024x576.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Dragonfly_Lab-shot_CAR-T-Alternatives-768x432.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Dragonfly_Lab-shot_CAR-T-Alternatives.jpg 1400w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">The novel immune engagers developed by the Dragonfly Therapeutics team include both first-in-class mAbs and TriNKETs (trispecific immune cell engagers), antibody-like molecules with three binding arms: one for an antigen, one for NKG2D, and one for CD16. [Dragonfly Therapeutics]</figcaption></figure>
<p>In autoimmune disease, CAR T cells and Dragonfly Therapeutics’ biologically native immune engagers both aim for deep depletion of pathogenic B cells and an immune reset, but employ different routes. Not only do NK cells not require the same massive clonal expansion as T cells, but, additionally, NKG2D activation is already tuned by the body to respond to stressed cells. These facets can give a wider window between a depleting versus a harmful dose, sidestepping CAR T toxicity emerging in autoimmune disease.</p>
<p>Recruiting the patient’s existing cells means no expansion phase, no lymphodepletion, no gene modification of a living cell, and, therefore, no secondary malignancy risk from the product itself. A half-life measured in days makes the effect dose-controllable and reversible.</p>
<p>The company’s most clinically advanced autoimmune program, DF5112, a CCR6-targeting mAb, offers a multimodal approach. Overall, DF5112 is designed to deplete pathogenic CCR6+ cells and inhibit chemotaxis, minimizing tissue inflammation, providing benefit across several autoimmune diseases, including psoriatic arthritis, rheumatoid arthritis, lupus, hidradenitis suppurativa, and others.</p>
<p>Near completion of Phase I, the DF5112 CCR6 mAb sits on the specific cells that drive tissue inflammation in many autoimmune diseases, Th17 cells and a subset of memory B cells, while sparing the bulk of the immune system. It is the first molecule to deplete both at once. Early data are on track to be shared end of 2026.</p>
<p>According to Dragonfly Therapeutics, the next generation of immunotherapy is about depleting exactly the right cells. As different autoimmune diseases are driven by different cells, the company is building a toolkit that can match the depleted cell to the disease biology.</p>
<h4><strong>Utilizing distinct T cells </strong></h4>
<p>Another approach is utilizing iNKT cells. iNKT cells are a distinct T cell population with an internal targeting and homing device (iTCR) and modulate both arms of immunity, innate and adaptive. They naturally hone to tissues, promote tumor killing, viral clearance, suppress inflammatory cytokines and GvHD.</p>
<p>MiNK Therapeutics believes that due to iNKT cell biology these cells may represent a foundational approach to immune restoration applicable across a broad range of conditions. iNKTs have shown benefit in treating solid tumor cancers in their native form and MiNK Therapeutics has demonstrated that these cells can be engineered or edited for super-targeting. Clinical data show no neurotoxicity or CRS at 1 billion cells/ dose.</p>
<p>The company’s lead program, agenT-797, an allogeneic, off-the-shelf iNKT-cell therapy, is being evaluated in virally induced acute respiratory distress syndrome (ARDS), where a favorable safety profile, increased survival rate, and decreased secondary infection rates have been observed.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<h4><strong>Reprogramming tumors</strong></h4>
<p>CAR T cells struggle with solid tumors. Almost no antigens are found solely on tumor cells, plus the antigens that exist are patchy, and get lost over time. According to a USC research team one fix is to install an antigen, but only if the installation stays inside the tumor.<sup>1</sup> The concept is turning a signal the tumor controls into one the physician controls in a safe manner.</p>
<p>Tumor hallmarks like hypoxia are a reasonable biological address, but not a safe one to use alone since brain, liver, bone marrow and gut are also low in oxygen. Focused ultrasound (FUS) gives a precise physical address, but heat-shock-driven expression is a brief spike that fades before T cells can do much.</p>
<p>Therefore, the research team combined inputs to develop SHIFTERS (solid-tumor hallmark inducible, focused-ultrasound triggered enhanced reprogramming system), a two-key AND gated circuit that rewires tumor hallmarks into the clinically-validated antigen CD19 under FUS control. Hypoxia turns on one half of a split Gal4-VP64 transcription factor; FUS heating turns on the other half. Both need to be present for the halves to assemble and switch on CD19.</p>
<figure aria-describedby="caption-attachment-340471" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-340471" src="https://www.genengnews.com/wp-content/uploads/2026/11/Labant_USC_Shifters-schematic_CAR-T-Alternatives-1024x439.jpg" alt="USC Shifters schematic CAR T Alternatives" width="696" height="298" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Labant_USC_Shifters-schematic_CAR-T-Alternatives-1024x439.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_USC_Shifters-schematic_CAR-T-Alternatives-300x129.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_USC_Shifters-schematic_CAR-T-Alternatives-768x329.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_USC_Shifters-schematic_CAR-T-Alternatives.jpg 1400w" sizes="auto, (max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">SHIFTERS combines tumor hypoxia and FUS to induce CD19 in genetically engineered tumor cells. CD19 activates synNotch receptors on engineered T cells, inducing EGFR-directed CAR expression. Primed T cells can then attack EGFR-positive tumor cells, including neighboring cells without induced CD19. Not-to-scale conceptual illustration of a preclinical system; generated by AI. [Wang Lab, USC]</figcaption></figure>
<p>To test the hypothesis, the circuit was pre-installed in tumor cell lines then CD19 synNotch/estimated glomerular filtration rate (EGFR) CAR T cells were infused into 3D spheroids and <em>in vivo</em> immunodeficient mice models. The cells get “primed” by the induced CD19, and then kill surrounding tumor cells via EGFR. Killing stays localized; priming wears off quickly once T cells leave the area.</p>
<p>Testing across different oxygen levels showed the switch only fired at tumor-like one percent, ignoring normal low-oxygen tissue. SHIFTERS holds 60-80% expression through 72 hours, then returns to baseline by about day six; durable enough to work, reversible enough to be safe. With only 25% of tumor cells induced, more than half the entire population was killed.</p>
<p>SHIFTERS is modular. Swapping hypoxia for a liver-cancer-specific promoter reproduced the process in liver cancer cells only, with near-zero activity in other cell types. Next steps include adding ultrasound-gated cytokines (IL-2, IL-18, interferon-γ) to counter tumor immunosuppression without systemic toxicity; building a library of other tumor-hallmark promoters for other cancers; and working out the right FUS dosing schedule and behavior in immunocompetent models.</p>
<p> </p>
<p><em>References</em></p>
<p>1. Guo T, Zhu Z, Qu Y et al. Ultrasound priming gated by solid tumor hallmarks to guide CAR-T therapy. <em>Sci Adv</em>. 2026 Jun 12;12(24):eaed0666. doi: 10.1126/sciadv.aed0666.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/therapeutic-immune-manipulation/">Therapeutic Immune Manipulation</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New AI Models Are Turbo&#45;Charging Protein Design</title>
<link>https://edusehat.com/en/new-ai-models-are-turbo-charging-protein-design</link>
<guid>https://edusehat.com/en/new-ai-models-are-turbo-charging-protein-design</guid>
<description><![CDATA[ Computer-designed protein therapeutics move from proof-of-concept to wet-lab validation and even clinical trials as the field heats up.
The post New AI Models Are Turbo-Charging Protein Design appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/GEN_NOV_2026_GettyImages-2172899400.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 22:05:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, Models, Are, Turbo-Charging, Protein, Design</media:keywords>
<content:encoded><![CDATA[<p>Getting a new biologic to market is laborious, expensive, and time-consuming, and one of the biggest drains on resources is watching promising candidates fail in preclinical or clinical testing. AI models that can design new proteins may be the ticket to optimizing drug development and providing companies better shots on goal. Companies are taking different approaches to the <em>de novo</em> design, but all share a common need: copious amounts of training data to level up their models. Will it eventually lead to fully autonomous <em>de novo</em> drug design?</p>
<h4><strong>Optimizing multispecifics development</strong></h4>
<p>Sanofi is moving AI-based protein design from proof-of-concept toward real-world drug discovery. Norbert Furtmann, PhD, head of biologics AI and design at Sanofi, says his team’s program is three-pronged: foundational models; property prediction and virtual screening; and <em>de novo </em>design.</p>
<p>The foundational models team develops sequence- and structure based models, analogous to large-language models but trained to “speak the language of proteins,” Furtmann says. These models have been built using a combination of public and in-house data. The property prediction and virtual screening team builds models to predict properties essential for function and developability, including stability, solubility, affinity, and so on. They run large <em>in silico</em> screens on hundreds of thousands of sequences, identifying which designs will move on to lab testing.</p>
<p>This is particularly valuable for multispecifics, where the enormous combinatorial design space makes comprehensive lab testing impossible. “If we have optimized monospecific antibody or nanobody building blocks, let’s say against target A, against target B, and against target C, and we want to plug them together, then we are facing enormous design spaces,” says Furtmann. “That could easily go into the hundreds of thousands of molecules, and you could not test all of them in a lab.”</p>
<p>The <em>de novo</em> design team starts with a target antigen structure and then has the AI model help design antibodies or nanobodies against it. Furtmann says the company’s first proof-of-concept studies on therapeutically relevant targets have been so successful that they are now looking to scale up the program. “We had a target where traditional discovery approaches faced challenges,” he says. Using their <em>de novo</em> design platform, the scientists successfully created functional binders, which Furtmann says are now moving forward into multispecifics.</p>
<p>When designing the binders, Furtmann says, it’s important to look beyond basic characteristics. “We try to think end-to-end and to understand what the monovalent building blocks need to look like to become successful, developable molecules in a multispecific format,” Furtmann says. “If you have a monospecific molecule, and then you plug five of them together for a multispecific, and they don’t behave well anymore, you need to start optimization again.”</p>
<p>The “lab-in-the-loop” workflow is key to this strategy, Furtmann says. This means taking the AI-generated designs, synthesizing them in the lab, and then feeding that data back into the model to fine-tune its designs. To achieve this, the company invests heavily in automation to achieve rapid, reproducible measurements and reliable data. “We aim for integration of the AI with the wet lab to get to fast feedback loops,” he says. “Yes, for monospecific optimization, but also specifically for the more complex multispecific molecules.”</p>
<h4><strong>A whole new type of antibody</strong></h4>
<p>Biolojic Design, based in Ness Ziona, Israel and Washington, DC, is using AI to build “multibodies,” standard human antibodies engineered to bind two or more targets. Unlike bispecific antibodies, which are built from fragments of two different antibodies, multibodies retain the familiar structure of a conventional human IgG antibody. This approach benefits from the established manufacturing, regulatory, pharmacokinetic, and safety advantages of ordinary antibodies, while enabling multiple therapeutic effects from a single drug.</p>
<p>Antibody structure typically includes quite a bit of “unused” space. Antibodies recognize their targets through six complementarity-determining regions (CDRs), but only a small fraction of that surface area is needed for antigen binding. “If you look at known antibody-antigen pairs, most of the CDRs are not involved in binding,” says Yanay Ofran, PhD, founder and CEO of Biolojic. “Each antibody has a lot of ‘free real estate.’ Our models allow us to precisely identify the free real estate and ‘develop’ it to accommodate additional binding.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The AI model redesigns this part of the molecule, allowing it to recognize additional epitopes without compromising specificity. Each arm of a multibody conditionally binds only one target at a time, but the drug binds differently depending on the tumor, tissue, or patient. This adaptability could help address tumor heterogeneity while limiting off-target interactions.</p>
<p>To build their multibodies, Biolojic fine-tunes temporary, highly specialized models for each project, Ofran says. “This is not a general solution intended to solve all the problems,” he says. “It’s a concentrated effort of a couple of months to build a dedicated model that will make one drug that no other technology can make and then will be retired.” First, existing models propose roughly a billion antibodies, each predicted to possess some desired property, such as binding a particular target or having a good developability profile. Researchers synthesize and test the variants and feed measurements of binding affinity, expression, specificity, and stability back into the model to refine it. That model proposes candidates combining all the required characteristics, which are subsequently evaluated in the lab.</p>
<p>One Biolojic product, a conditional agonist/antagonist, has already entered Phase II trials. The antibody binds the cytokine IL-2 in a context-dependent fashion, enabling it to stimulate T cells that attack the tumor while blocking T cells that protect it. This asset is being developed by Biolojic’s spinout company, Aulos Bioscience. So far, safety and efficacy data are encouraging, Ofran says.</p>
<p>Ofran points out that Biolojic’s approach goes beyond simply speeding up drug discovery. “We want to be fast, we want to be inexpensive, but what we want to do most is to come up with molecules that we are unlikely to find in traditional discovery,” he says. “Not to accelerate the time for getting the same type of molecules that you will get otherwise, but to get molecules that do things that traditionally discovered molecules cannot do.”</p>
<h4><strong>Evolving methods need new benchmarks</strong></h4>
<p>It can be difficult to objectively compare models when proof-of-concept results rely on different targets, assays and metrics, and that’s where Seattle-based A-Alpha Bio comes in. “We are particularly interested in answering this question earnestly: what is the kind of data that helps build better models?” says Natasha Murakowska, PhD, director of applied machine learning at A-Alpha. “What will it require to do this sort of <em>de novo</em> design perfectly every time?”</p>
<figure aria-describedby="caption-attachment-340478" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340478" src="https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-DND-figure-300x187.jpg" alt="AI protein design models" width="300" height="187" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-DND-figure-300x187.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-DND-figure-1024x638.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-DND-figure-768x478.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-DND-figure.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">As AI protein design models proliferate, it’s important to be able to compare different systems against one another using an objective standard benchmark, and to generate large amounts of data for training and improving the models. A-Alpha Bio’s large VHH de novo design benchmark tests models against the same panel of 28 antigens spanning three tiers of difficulty. [A-Alpha Bio]</figcaption></figure>
<p>To that end, A-Alpha is running a large VHH <em>de novo</em> design benchmark. They have invited about a dozen groups to each submit 10,000 designed antibody sequences, which A-Alpha will synthesize and test against a panel of 10 targets, yielding some 110,000 VHHs. Their aim is to build the largest apples-to-apples benchmark of <em>de novo</em>-designed antibodies, evaluating not just whether antibodies bind, but how strongly and how specifically, and what sequence or structural features distinguish the winners.</p>
<p>Central to this effort is AlphaSeq, A-Alpha’s library-on-library yeast display assay. One library encodes the antibodies, the other encodes the targets; when combined, AlphaSeq effectively measures all pairwise interactions. This generates, on the scale of one million quantitative protein-protein interaction data points per experiment, Murakowska explains, revealing information about not only target binding affinity but also off-target effects.</p>
<p>The benchmark’s target panel is stratified into three tiers of difficulty. In Tier 1, a known antibody–antigen crystal structure is provided, and the models must design novel variants that improve binding. Tier 2 provides a crystal structure of the antigen alone, challenging models to choose a bindable epitope and design a complementary interface.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Tier 3 is what Murakowska calls the “holy grail”: targets where no structural information is provided, requiring the model to infer the antigen’s structure, pick a druggable region, and then design an antibody to bind it. “It stacks complexity, and it tasks model makers in multiple ways,” she says. “If you want to earnestly solve this problem, teams need to think about the holistic problem of representing the right protein, representing the right epitope, which is that surface that the antibody binds, and then also designing for that surface.”</p>
<p>Leveling up AI-assisted drug design requires vast amounts of high-quality data that doesn’t currently exist. A-Alpha recently launched the Atlas Consortium, a collaborative model where companies of very different sizes jointly generate new, shared AlphaSeq datasets under a common experimental framework. One of the key selling points of the Atlas Consortium is that every member, large or small, increases the value of participation for the other members by contributing datasets.</p>
<figure aria-describedby="caption-attachment-340477" class="wp-caption aligncenter"><img decoding="async" class="wp-image-340477" src="https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-GroupPhoto_A-AlphaBio_2026July-e1794232462369-1024x470.jpg" alt="consortium members" width="696" height="319" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-GroupPhoto_A-AlphaBio_2026July-e1794232462369-1024x470.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-GroupPhoto_A-AlphaBio_2026July-e1794232462369-300x138.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-GroupPhoto_A-AlphaBio_2026July-e1794232462369-768x352.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-GroupPhoto_A-AlphaBio_2026July-e1794232462369.jpg 1400w" sizes="(max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">A new collaborative initiative, the Atlas Consortium, seeks to increase the available body of data to address major objectives for AI-driven protein design. Each quarter, A-Alpha Bio generates datasets using the AlphaSeq platform for training and benchmarking models. These datasets are then pooled and shared with consortium members. [A-Alpha Bio]</figcaption></figure>
<h4><strong>Human out of the loop?</strong></h4>
<p>Anthropic has published results showing that its Claude models can design miniprotein binders with essentially no human involvement. The models designed binders against 15 protein targets and sent the designs to Adaptyv Bio and Twist Bioscience for synthesis and evaluation. Testing confirmed that the Claude-designed minibinders were successful for 14 of the 15 targets.</p>
<p>To achieve this, Claude drew on existing open-source software, including backbone generators like RFdiffusion3; sequence-design tools such as ProteinMPNN; and structure predictors used to screen candidates before synthesis. Within that framework, Claude selected which surface of each target to bind, chose and combined design tools, filtered candidates, and delivered 30 ranked designs per target after 24- to 48-hour autonomous runs. Human involvement was limited to selecting targets, granting permissions, and ensuring the infrastructure was running properly.</p>
<p>Among 1,320 designs, 354 bound their targets, giving an overall hit rate of 27%, although results varied widely depending on the target. Claude was not able to come up with a binder for maltose-binding protein, for instance, although it did produce several binders against TNFα, a therapeutically relevant target that has stumped other AI design efforts.</p>
<p>The designs were evaluated solely for binding affinity, not for activity, and none of the designs were solved structurally. Anthropic describes the result as foundational, a step toward the goal of AI systems autonomously handling drug-discovery from end to end.</p>
<p>“Minibinders are not meant to be drugs,” says Emily Leproust, PhD, CEO of Twist Bioscience. Designing therapeutics will require the model to advance to larger, more complex models, which will require more data points to train them. “That’s why we are adding more and more capacity, so that people can build more data points with us at a lower cost and at speed.”</p>
<p>“What we like about AI is you can do co-optimization of binding and developability at the same time,” Leproust adds. Traditional drug screening involves first optimizing for binding and then engineering in developability after the fact, which can be frustrating and inefficient. Using AI to optimize for both in parallel can boost success rates. “That can significantly, I think, increase the probability that an antibody is going to behave well in the clinic, because you don’t engineer developability after the fact,” she says. “It’s a subtle thing, but it really makes a big impact.”</p>
<p> </p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/new-ai-models-are-turbo-charging-protein-design/">New AI Models Are Turbo-Charging Protein Design</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Childhood Cancers May Not Always Need Extra Mutations to Spread, Study Suggests</title>
<link>https://edusehat.com/en/childhood-cancers-may-not-always-need-extra-mutations-to-spread-study-suggests</link>
<guid>https://edusehat.com/en/childhood-cancers-may-not-always-need-extra-mutations-to-spread-study-suggests</guid>
<description><![CDATA[ Childhood cancers may not always need extra mutations to spread, a new review study indicates. Instead, developmental plasticity may let tumor cells shape-shift into states that help them grow, resist treatment, and ultimately metastasize.
The post Childhood Cancers May Not Always Need Extra Mutations to Spread, Study Suggests appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/01/GettyImages-2204955763.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 22:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Childhood, Cancers, May, Not, Always, Need, Extra, Mutations, Spread, Study, Suggests</media:keywords>
<content:encoded><![CDATA[<p><span>Data from a new study from scientists at the University of East Anglia and Liverpool John Moores University could help explain why some childhood tumors spread aggressively despite having relatively few genetic mutations. The findings, which are published in a new </span><i><span>Trends Open </span></i><span>review paper,</span><span> indicate that childhood cancers may not always need to develop extra mutations to spread. Some cells may be able to switch into different cellular states between behaviors that help them grow, survive treatment, and ultimately spread. </span></p>
<p><span>Furthermore, in the paper, titled “Developmental plasticity as a framework for paediatric cancer metastasis,” the scientists write that the process may be reversible. “Many childhood cancers arise from cells that are still closely linked to developmental programs used during early life,” and these programs “normally allow cells to move around the developing body, adapt to changing environments, and become different tissue types,”  said Darrell Green, PhD, an assistant professor and scientific group leader for RNA research at Norwich Medical School at University of East Anglia and one of the authors on the paper. “We think that cancer cells in children may exploit this natural flexibility of young, developing cells in order to spread.” </span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p><span>To reach their conclusions, the scientists reviewed evidence from various childhood cancers, including neuroblastoma, Ewing sarcoma, osteosarcoma, medulloblastoma, and rhabdomyosarcoma. According to the paper, they integrated “genomic, epigenomic, developmental and single-cell evidence to examine how oncogenic lesions and developmental origins define accessible cellular states, while epigenetic, metabolic, and microenvironmental signals regulate transitions between them.”</span></p>
<p><span>Based on their analysis, the scientists propose that genetic changes determine which cellular identities cancer cells can adopt, while reversible changes in gene activity seem to dictate whether those cells become aggressive, resistant to treatment or capable of forming metastatic tumors. </span></p>
<p><span>This suggests that “rather than needing to acquire new mutations before they can spread, childhood cancer cells may already possess the ability to become metastatic,” Green explained. “The new, key question is not just what mutations they carry, but which cellular state they are in at a particular moment.” It is a point that “challenges the long-held assumption that cancers must acquire new mutations before they can metastasize.” </span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p><span>The scientists hope that their work could ultimately lead to new types of treatments or at least point to ways to modify existing treatments. This means, for example, that instead of focusing solely on killing tumor cells or targeting mutated genes, future therapies might aim to stop cancer cells entering the states that make them dangerous in the first place. In fact, “it may eventually become possible to predict when cancers are preparing to spread,” Green said. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/childhood-cancers-may-not-always-need-extra-mutations-to-spread-study-suggests/">Childhood Cancers May Not Always Need Extra Mutations to Spread, Study Suggests</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CBC India partners with Indmark Paperform for square fibre drum packaging solutions</title>
<link>https://edusehat.com/en/cbc-india-partners-with-indmark-paperform-for-square-fibre-drum-packaging-solutions</link>
<guid>https://edusehat.com/en/cbc-india-partners-with-indmark-paperform-for-square-fibre-drum-packaging-solutions</guid>
<description><![CDATA[ 
The partnership aims to introduce fibre drum packaging solutions to India&#039;s pharmaceutical and allied industries, with a focus on space utilisation, supply chain efficiency and sustainability
The post CBC India partners with Indmark Paperform for square fibre drum packaging solutions appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 18:15:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CBC, India, partners, with, Indmark, Paperform, for, square, fibre, drum, packaging, solutions</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>CBC India’s Ingredients & Packaging Solutions (CBC-IPS) Division has announced a strategic partnership with Indmark Paperform, a manufacturer of fibre-based packaging solutions for the pharmaceutical and healthcare industries.</span></p>
<p><span>The partnership aims to introduce square fibre drum solutions to customers across India by combining CBC India’s market reach and industry expertise with Indmark Paperform’s packaging capabilities.</span></p>
<p><span>Indmark Paperform’s square fibre drums are designed for space utilisation and offer an alternative to conventional packaging formats. Their square structure enables higher loading efficiency, allowing more units per shipment while reducing transportation and warehousing costs. Unlike round fibre drums and cardboard containers, these drums minimise unused space without compromising strength, stability or product protection.</span></p>
<p><span>The company stated that the drums are lightweight and durable and provide performance across industries, including pharmaceuticals, chemicals and specialty materials.</span></p>
<p><span>The partnership will support customers in adopting environmentally responsible packaging solutions while optimising supply chain efficiency and reducing logistics costs.</span></p>
<p><span>Swapnil Meher, CEO, Indmark Paperform, said, “We are pleased to partner with CBC India to further strengthen our presence in the Indian pharmaceutical packaging market. CBC India’s strong industry relationships, market understanding, and customerfocused approach make them an ideal strategic partner. Together, we look forward to delivering innovative and sustainable packaging solutions that support the evolving needs of the pharmaceutical industry.”</span></p>
<p><span>Durgesh Sharma, Managing Director, CBC India, said, “At CBC India, we are committed to building strong partnerships that deliver lasting value to our customers and the industries we serve. We are delighted to collaborate with Indmark Paperform to bring innovative square fiber drum packaging solutions to the Indian market. By combining our market expertise with Indmark Paperform’s packaging excellence, we aim to help customers improve operational efficiency, optimize logistics and advance their sustainability goals through environmentally responsible packaging solutions.”</span></p>
<p>The post <a href="https://www.expresspharma.in/cbc-india-partners-with-indmark-paperform-for-square-fibre-drum-packaging-solutions/">CBC India partners with Indmark Paperform for square fibre drum packaging solutions</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Is NHS dentistry running out of road?</title>
<link>https://edusehat.com/en/is-nhs-dentistry-running-out-of-road</link>
<guid>https://edusehat.com/en/is-nhs-dentistry-running-out-of-road</guid>
<description><![CDATA[ Nigel Jones considers whether NHS dentistry has a future as political caution, contractual drift and the growth of private care leave the service increasingly reliant on a safety-net model. Since 1990, I’ve been paying careful attention to the politics of UK dentistry and watched successive governments of all colours kick the NHS dentistry can down… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2024/09/nigel_jones.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 15:15:16 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>NHS, dentistry, running, out, road</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Nigel Jones considers whether NHS dentistry has a future as political caution, contractual drift and the growth of private care leave the service increasingly reliant on a safety-net model.</strong></p>



<p>Since 1990, I’ve been paying careful attention to the politics of UK dentistry and watched successive governments of all colours kick the NHS dentistry can down the road. </p>



<p>As frustrating as it has been to watch that continued failure to grasp the nettle, I have a degree of sympathy for any government trying to tackle deeply rooted problems that need long term solutions within the framework of an electoral system that encourages short-termism. </p>



<p>This summer’s Nuffield Trust report <em>The Great Extraction</em> spoke about the demise of NHS dentistry in England and how those that cannot afford to pay privately lose out most. I would hesitantly suggest that it is often those same people who find it hardest to access what NHS dental provision still exists locally as they get squeezed out by savvy patients who can afford to pay privately but wish to exert their ‘right’ to state subsidised dentistry. </p>



<p>The fear that such attitudes among motivated voters would manifest themselves at the ballot box must act as a deterrent to substantive action for any politician however much they understand what’s needed.</p>



<p>Besides which, procrastinating has its advantages when it allows the service to be gradually privatised without an official policy announcement to that effect. During one of the first conversations I ever had with a dentist, he put forward his view that what was happening to NHS sentistry amounted to constructive dismissal from the health service. For many, such thoughts still hold water today, 36 years later.</p>



<h2 class="wp-block-heading">Difficult decisions</h2>



<p>And yet there are signs that our new(ish) prime minister is, for now at least, willing to take the kind of difficult decisions that have scared off many of his predecessors. Even when linked to the funding of a national care service, announcing changes to the state pension triple lock is a bold move. Publicly floating the possibility of rejoining the EU is also politically high risk for obvious reasons.</p>



<p>The economic context in which such announcements have been made, including, for example, the probable need to provide targeted support for the looming exacerbation of the energy crisis, means we all know the answer to one of the questions posed by the Nuffield Trust about whether NHS dentistry will truly return to being a universal service.</p>



<p>The willingness of those savvy voters to, albeit often reluctantly, be maneuvered into paying privately for their oral care suggests that the Nuffield Trust’s reference to a service stripped back to act as a safety net for the poorest and for groups like children and pregnant women, is far more likely to be the ultimate destination. </p>



<p>The obvious challenge is how to navigate a way there that is quick enough and politically safe enough. The constructive dismissal route is arguably proving too slow and quietly damaging but working out how to accelerate the journey while minimising the political pain is not straightforward.</p>



<h2 class="wp-block-heading">What is the future of NHS dentistry?</h2>



<p>Perversely, the wave of optimism that accompanied the election of Labour and the promise of the cavalry coming to save the day will have persuaded many in the profession to hang fire on plans to leave the NHS, temporarily slowing the drift to private.</p>



<p>That at least allowed the new administration to take stock of the situation and the government then bought itself more time with the contractual tweaks introduced in April and the promise of a consultation. </p>



<p>Furthermore, any significant announcements about the changes to NHS dentistry seem highly unlikely given the launch by the Competition and Markets Authority (CMA) of the market study into the provision of private dental services in the UK.  It would be unwise to make public any meaningful reform intentions that could lead to a rapid expansion of the private dental market until it has been established it is working appropriately for consumers.</p>



<p>The statutory deadline by which the CMA must publish its final report, along with any remedies, is 4 March 2027. That edges perilously close to the next general election, so at that late stage in the electoral cycle, the ADG is likely to get its wish for incremental, rather than fundamental contractual change. </p>



<p>However, the clock is ticking and the ramifications of those contractual changes that will emerge in the new year may not make for comfortable reading. The patience of NHS dentists, who have seen their health and wealth suffer trying to make NHS contractual arrangements work, is running out if September’s survey by the BDA is anything to go by. There is only so much road left down which to kick that can.</p>



<h2 class="wp-block-heading">Considering your own future in NHS dentistry?</h2>



<p>Practice Plan has been welcoming practices into the family since 1995, helping them to grow profitable businesses through the introduction of <a href="https://www.practiceplan.co.uk/benefits-of-a-membership-plan/">practice-branded membership plans</a>. If you’re looking for a provider to be by your side through a safe move from NHS to private then, with over 300 years’ dental experience in our field team, you’re in safe hands with Practice Plan… Be Practice Plan and get in touch.</p>



<p>Call <a href="tel://01691">01691 684165</a> or visit <a href="http://www.practiceplan.co.uk/be-practice-plan/" target="_blank" rel="noreferrer noopener">www.practiceplan.co.uk/be-practice-plan/</a>.</p>



<p><em>This article is sponsored by Practice Plan.</em></p>


        <div class="">
            <div class="text-context-white p-8 md:p-12 xl:p-20 bg-black">
                <div class="flex flex-wrap justify-center -mx-4">
                                            <div class="px-4 w-full lg:w-7/8 flex flex-col justify-start">
                                                                        <div class="font-yellow font-bold text-2xl md:text-3xl xl:text-4xl mb-4">
                                Ready to talk?                            </div>
                                                                            <div class="text-context-white/75 mb-4">
                                <p>If you’re ready for a confidential discussion with Practice Plan about the next steps in converting to private dentistry, leave your details below.</p>
                            </div>
                                                                            <div class="wpforms-design-block-form">
                                <div class="wpforms-container wpforms-container-full">Please enable JavaScript in your browser to complete this form.<div class="wpforms-field-container">		<div class="wpforms-field wpforms-field-text" data-field-type="text" data-field-id="3">
			<label class="wpforms-field-label" for="wpforms-424415-field_3">Want postcode hear</label>
			
		</div>
		<div class="wpforms-field wpforms-field-layout" data-field-id="7"><div class="wpforms-field-layout-rows wpforms-field-large"><div class="wpforms-layout-row"><div class="wpforms-layout-column wpforms-layout-column-25"><div class="wpforms-field wpforms-field-text" data-field-id="1"><label class="wpforms-field-label" for="wpforms-424415-field_1">Name <span class="wpforms-required-label">*</span></label></div></div><div class="wpforms-layout-column wpforms-layout-column-25"><div class="wpforms-field wpforms-field-email" data-field-id="2"><label class="wpforms-field-label" for="wpforms-424415-field_2">Email <span class="wpforms-required-label">*</span></label></div></div><div class="wpforms-layout-column wpforms-layout-column-25"><div class="wpforms-field wpforms-field-text" data-field-id="8"><label class="wpforms-field-label" for="wpforms-424415-field_8">Phone <span class="wpforms-required-label">*</span></label></div></div><div class="wpforms-layout-column wpforms-layout-column-25"></div></div><div class="wpforms-layout-row"><div class="wpforms-layout-column wpforms-layout-column-25"><div class="wpforms-field wpforms-field-text" data-field-id="5"><label class="wpforms-field-label" for="wpforms-424415-field_5">Practice name <span class="wpforms-required-label">*</span></label></div></div><div class="wpforms-layout-column wpforms-layout-column-25"><div class="wpforms-field wpforms-field-text" data-field-id="6"><label class="wpforms-field-label" for="wpforms-424415-field_6">Practice postcode <span class="wpforms-required-label">*</span></label></div></div><div class="wpforms-layout-column wpforms-layout-column-25"></div><div class="wpforms-layout-column wpforms-layout-column-25"></div></div></div></div><div class="wpforms-field wpforms-field-checkbox" data-field-id="9"><label class="wpforms-field-label">Want to hear more from Practice Plan?</label><ul><li class="choice-1 depth-1"><label class="wpforms-field-label-inline" for="wpforms-424415-field_9_1">I agree to receive marketing communication from Practice Plan, including valuable insights, inspiring stories and practical tips.   <a rel="noopener noreferrer" target="_blank" href="https://www.practiceplan.co.uk/privacy-notice/?utm_source=https://dentistry.co.uk/nhs-to-private/&utm_medium=referral&utm_campaign=privacypolicynhstopriv">View their privacy policy.</a>.</label></li></ul></div></div><!-- .wpforms-field-container --><div class="wpforms-submit-container"><button type="submit" name="wpforms[submit]" class="wpforms-submit" data-alt-text="Sending..." data-submit-text="Submit" aria-live="assertive" value="wpforms-submit">Submit</button></div></div>  <!-- .wpforms-container -->                            </div>
                                            </div>
                                    </div>
            </div>
        </div>]]> </content:encoded>
</item>

<item>
<title>NPPA anti&#45;cancer medicine price cuts to take effect from November 9</title>
<link>https://edusehat.com/en/nppa-anti-cancer-medicine-price-cuts-to-take-effect-from-november-9</link>
<guid>https://edusehat.com/en/nppa-anti-cancer-medicine-price-cuts-to-take-effect-from-november-9</guid>
<description><![CDATA[ 
Revised MRPs reported for 1,225 formulations across 121 drugs, with estimated annual consumer savings of ₹3,502.31 crore
The post NPPA anti-cancer medicine price cuts to take effect from November 9 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/09110850/EP_price_cuts_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 14:35:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>NPPA, anti-cancer, medicine, price, cuts, take, effect, from, November</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/09110850/EP_price_cuts_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/09110850/EP_price_cuts_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/09110850/EP_price_cuts_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has capped trade margins on the MRP of 137 anti-cancer drugs, based on the recommendations of an Expert Committee constituted by the Directorate General of Health Services (DGHS) under the Ministry of Health and Family Welfare on October 17, 2026. The revised prices of these drugs will come into effect from November 9, 2026.</span></p>
<p><span>As of November 7, 2026, 76 pharma companies have reported revised MRPs for 1,225 anti-cancer formulations, covering 121 drugs. Reductions in MRP have been reported in 1,031 formulations of anti-cancer medicines, with 600 brands reporting reductions of above 50 per cent. The highest reduction reported is 96.45 per cent.</span></p>
<p><span>Further, of the 137 identified anti-cancer drugs, 10-15 drugs are yet to be launched in India. However, Trade Margin Rationalisation (TMR) will also apply to these drugs when they are launched.</span></p>
<p><span>Following the price reductions coming into effect from November 9, 2026, the estimated annual savings to consumers are expected to be ₹3,502.31 crore.</span></p>
<p>The post <a href="https://www.expresspharma.in/nppa-anti-cancer-medicine-price-cuts-to-take-effect-from-november-9/">NPPA anti-cancer medicine price cuts to take effect from November 9</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Pharma industry reports 97 deals worth $25.45 billion in October 2026</title>
<link>https://edusehat.com/en/pharma-industry-reports-97-deals-worth-2545-billion-in-october-2026</link>
<guid>https://edusehat.com/en/pharma-industry-reports-97-deals-worth-2545-billion-in-october-2026</guid>
<description><![CDATA[ 
M&amp;A deal value declined by 55.8 per cent, while venture capital funding decreased by 34.3 per cent compared with October 2025
The post Pharma industry reports 97 deals worth $25.45 billion in October 2026 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 14:35:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pharma, industry, reports, deals, worth, 25.45, billion, October, 2026</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p data-pm-slice="1 1 []">According to GlobalData, industry reported 97 deals worth $25.45 billion in October 2026, compared with the average of 92 deals worth $29.7 billion over the last 12 months (October 2025 to September 2026).</p>
<p>Deal value decreased by 55.8 per cent in October 2026, compared with October 2025.</p>
<p>Among the major transactions reported during the month, Crown NL Bidco B.V. announced its acquisition of Qiagen NV, a life-science and diagnostics company that helps laboratories turn biological samples into clear test results and research insights, through an all-cash voluntary public takeover offer worth $12.1 billion. Shionogi & Co., Ltd. announced the acquisition of IntraBio Inc., a biopharmaceutical company developing and commercialising therapies for neurodegenerative diseases, for a total transaction value of $2 billion. Viatris Inc, a global healthcare company, announced the acquisition of Pacira BioSciences Inc, a pharmaceutical company that offers non-opioid pain management and regenerative health solutions, for an equity value of $1.65 billion. These were the three major deals reported in October 2026.</p>
<p>Venture capital funding decreased by 34.3 per cent in October 2026, compared with October 2025.</p>
<p>The healthcare industry reported 93 venture capital (VC) deals worth $3.41 billion in October 2026, compared with the average of 115 deals worth $3.5 billion over the last 12 months (October 2025 to September 2026).</p>
<p>Among the major VC transactions reported during the month, Dren Bio Inc., a clinical-stage biotechnology company developing first-in-class antibody therapeutics, raised $350 million in a financing round to support continued late-stage clinical development, regulatory submission and planned commercial launch of dibotatug (DR-01). OMass Therapeutics Limited, a biotechnology company developing small molecule therapeutics, raised $310 million in a Series C financing round to support the advancement of the Company’s lead programme, OMS1620. Matchpoint Therapeutics Inc, a biotechnology company, raised $150 million in Series B financing to advance its pipeline of first-in-class oral small molecules for autoimmune and inflammatory diseases. These were the three major VC deals reported in October 2026.</p>
<p>The post <a href="https://www.expresspharma.in/pharma-industry-reports-97-deals-worth-25-45-billion-in-october-2026/">Pharma industry reports 97 deals worth $25.45 billion in October 2026</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FOPE seeks reconsideration of proposed automatic suspension of drug manufacturing licences on NSQ reports</title>
<link>https://edusehat.com/en/fope-seeks-reconsideration-of-proposed-automatic-suspension-of-drug-manufacturing-licences-on-nsq-reports</link>
<guid>https://edusehat.com/en/fope-seeks-reconsideration-of-proposed-automatic-suspension-of-drug-manufacturing-licences-on-nsq-reports</guid>
<description><![CDATA[ 
Federation of Pharma Entrepreneurs supports patient safety measures but calls for procedural safeguards, proportionality and an opportunity for manufacturers to present their case
The post FOPE seeks reconsideration of proposed automatic suspension of drug manufacturing licences on NSQ reports appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 14:35:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FOPE, seeks, reconsideration, proposed, automatic, suspension, drug, manufacturing, licences, NSQ, reports</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>The Federation of Pharma Entrepreneurs (FOPE) has taken note of the Ministry of Health and Family Welfare’s draft notification G.S.R. 956(E), proposing amendments to the Drugs Rules, 1945, to provide for immediate suspension of manufacturing licences when drugs are declared Not of Standard Quality (NSQ).</span></p>
<p><span>FOPE has stated its support for the Government’s commitment to patient safety and ensuring the availability of safe, effective and quality medicines. The organisation said the pharmaceutical industry recognises that quality compliance and patient safety are paramount and that regulatory authorities must have the powers to take action against manufacturers wherever quality failures or violations are established.</span></p>
<p><span>However, FOPE believes that the existing provisions of the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945 already provide a regulatory framework that empowers authorities to investigate quality failures, take enforcement action and suspend or cancel manufacturing licences wherever warranted.</span></p>
<p><span>In this context, FOPE has called for reconsideration of the need for an additional provision mandating automatic suspension of manufacturing licences upon receipt of an NSQ report, without addressing procedural safeguards.</span></p>
<p><span>FOPE’s principal concern is that regulatory enforcement must be consistent with the principles of natural justice, fairness and proportionality. The organisation stated that an NSQ test report should trigger regulatory examination and investigation. However, the consequences of such a report should be determined after considering the nature and severity of the failure, its potential impact on patient safety, the circumstances leading to the deviation, and the manufacturer’s explanation and supporting evidence.</span></p>
<p><span>FOPE has identified five concerns regarding the proposed automatic suspension mechanism. These include the absence of an express provision allowing manufacturers to present their explanation before suspension, the lack of specific provisions for appellate confirmatory testing where analytical results are disputed, and the absence of a distinction between critical quality failures and other technical or analytical deviations.</span></p>
<p><span>The organisation has also raised concerns about the operational and financial consequences of suspension and the absence of prescribed timelines for regulatory assessment of corrective and preventive action (CAPA), verification and restoration of manufacturing permissions.</span></p>
<p><span>FOPE has emphasised that the principles of natural justice, including the opportunity to be heard, should form part of regulatory decision-making. It stated that where an urgent situation involving an immediate threat to patient safety requires interim action, post-decisional hearings and time-bound review mechanisms should be provided.</span></p>
<p><span>The proposed amendments should also distinguish between suspension of permission for the affected product and suspension of the entire manufacturing licence, according to FOPE. Regulatory action should be proportionate and product-specific unless wider systemic GMP failures are established.</span></p>
<p><span>In its statement, FOPE said:</span></p>
<p><span>“Patient safety is non-negotiable, and the pharmaceutical industry fully supports strong and effective regulatory oversight. However, strong regulation must also be fair, scientifically justified and consistent with established legal principles.</span></p>
<p><span>We believe that the existing legal framework already empowers regulatory authorities to take appropriate action against quality failures and protect public health. Introducing an additional automatic suspension mechanism without adequate safeguards may create unintended consequences without necessarily improving the effectiveness of quality enforcement.</span></p>
<p><span>An NSQ observation must lead to prompt investigation, identification of root causes and effective corrective and preventive action. At the same time, manufacturers must have a reasonable opportunity to present their case, seek appellate confirmatory testing wherever warranted and receive a reasoned regulatory decision in accordance with the principles of natural justice.</span></p>
<p><span>Our concern is particularly significant for manufacturers, where suspension of a product or manufacturing permission can have substantial operational and financial implications. Regulatory action must be proportionate to the nature of the failure and the actual risk to patients.</span></p>
<p><span>FOPE will submit a detailed representation to the Ministry of Health and Family Welfare and engage constructively with CDSCO and other regulatory authorities. We will seek reconsideration of the proposed automatic suspension provisions and advocate a balanced approach that strengthens patient safety while preserving fairness, transparency and due process.</span></p>
<p><span>We believe that patient safety, regulatory effectiveness and the sustainability of responsible pharmaceutical manufacturing are complementary objectives and must move forward together.”</span></p>
<p><span>FOPE stated that it will submit a representation to the Ministry of Health and Family Welfare and engage with CDSCO and other regulatory authorities to seek reconsideration of the proposed automatic suspension provisions.</span></p>
<p><span>The Federation of Pharma Entrepreneurs reiterated its commitment to working with the Government and regulatory authorities to strengthen India’s pharmaceutical quality ecosystem and sustain the country’s position as a global pharmaceutical manufacturing destination.</span></p>
<p>The post <a href="https://www.expresspharma.in/fope-seeks-reconsideration-of-proposed-automatic-suspension-of-drug-manufacturing-licences-on-nsq-reports/">FOPE seeks reconsideration of proposed automatic suspension of drug manufacturing licences on NSQ reports</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate</title>
<link>https://edusehat.com/en/stockwatch-nurix-nosedives-as-sanofi-halts-phase-i-immunology-candidate</link>
<guid>https://edusehat.com/en/stockwatch-nurix-nosedives-as-sanofi-halts-phase-i-immunology-candidate</guid>
<description><![CDATA[ Sanofi halted development of an oral STAT6 degrader that had been under study in a Phase I first-in-human trial in Europe. STAT6, a key drug target in type 2 inflammation, is among the five targets identified by the companies in their collaboration, launched in 2020. 
The post StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/nurix-scientist.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 11:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Nurix, Nosedives, Sanofi, Halts, Phase, Immunology, Candidate</media:keywords>
<content:encoded><![CDATA[<p><strong>Nurix Therapeutics (Nasdaq: NRIX)</strong> suffered its worst one-day loss as a public company Wednesday when <strong>Sanofi (Euronext Paris: SAN and Nasdaq: SNY)</strong> terminated development of the Phase I immunology candidate SAR448272 (NX-3911)—a key program of the companies’ nearly seven-year, up to $ 2.5 billion collaboration to discover, develop, and commercialize protein degradation drugs for “challenging” diseases.</p>
<p>The rest of the collaboration continues despite Sanofi pulling the plug on SAR448272 (NX-3911), an oral signal transducer and activator of transcription 6 (STAT6) degrader that had been under study in a Phase I first-in-human trial in Europe (European Union Clinical Trials Register number <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Feuclinicaltrials.eu%2Fctis-public%2Fview%2F2026-526014-87-00&data=05%7C02%7Calex.philippidis%40sagepub.com%7Cc95c54bf0ac44b176ea408df3b6c9722%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639295012066774767%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=FBy14hQz1TcP2YE%2BGi9ZXifh%2BnNO7%2FFCA%2F2kR9qSDo8%3D&reserved=0">2026-526014-87-00</a>). The trial began recruiting patients in Germany in July and had planned to expand recruitment into the Czech Republic, France, Italy, and Spain, a milestone that triggered a $10 million payment from Sanofi to Nurix in August.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>STAT6, a key drug target in type 2 inflammation, is among the five targets identified by the companies in their collaboration, which took effect in January 2020 when Sanofi paid Nurix $55 million upfront. At the time, Sanofi committed to paying Nurix up to $2.5 billion in total payments, most of that tied to achieving research, preclinical, clinical, regulatory, and sales milestones.</p>
<p>As of August 31, Sanofi had paid Nurix a total $129 million—the $55 million upfront; $22 million in 2021 when Sanofi exercised an option to expand from three to five targets; $22 million for achieving research milestones; and $30 million for license extension fees—according to Nurix’s <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fir.nurixtx.com%2Fstatic-files%2Fc8ca0871-108d-480d-9f6b-080ac39488ff&data=05%7C02%7Calex.philippidis%40sagepub.com%7Cc95c54bf0ac44b176ea408df3b6c9722%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639295012066792878%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=JZEd8DtVNcs5ZdwuUcpKAULtGF3YcMalBSJBOsZRQ%2FQ%3D&reserved=0">Form 10-Q quarterly report for the third quarter</a>, filed October 13.</p>
<p>Nurix insisted that its recent cash runway guidance would not be affected by Sanofi’s halting development of SAR448272. Nurix said it had enough cash to fund operations into the second half of 2029 based on its $1.1 billion of cash, cash equivalents, and marketable securities as of August 31.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<h4><strong>Reassurance and rejection</strong></h4>
<p>“While [Tuesday]’s news is disappointing, Nurix remains in a strong position, with a substantial cash runway, three clinical-stage programs across our wholly owned and partnered portfolio, and an exciting preclinical pipeline,” Arthur T. Sands, MD, PhD, Nurix president and CEO, stated Tuesday after the close of markets.</p>
<p>The following day, investors appeared to reject that reassurance, selling off enough shares for Nurix stock to <span><strong>nosedive 38%</strong></span> from $25.82 to $15.95. Shares <span><strong>fell another 7%</strong> </span>to $14.84 Thursday on a day the Nasdaq market had its worst one-day performance in the past 19 months—but the stock <span><strong>bounced back 3%</strong></span> Friday, finishing the week at $15.30 and a <span><strong>nearly 43% five-day decline</strong></span>.</p>
<p>“While we can understand the market’s knee-jerk disappointment following the news (STAT6 is regarded as a high-value target), we continue to view Nurix as a differentiated name within the emerging oral protein degrader space,” Tessa T. Romero, a senior analyst focused on biotechnology equity research with J.P. Morgan, wrote in a research note.</p>
<p>The reason why, Romero explained, is Nurix’s ongoing up-to-$2.3 billion global collaboration with <strong>Roche (SIX Swiss: RO and ROP)</strong> to develop bexobrutideg (“bexdeg” or “bexo”; NX-5948), a clinical-phase oral brain-penetrant Bruton’s tyrosine kinase (BTK) degrader.</p>
<p>In addition to the dollars, Romero said, that partnership is also attractive for Nurix because bexdeg can potentially be developed for numerous other therapeutic areas with diseases driven by BTK; the collaboration stretches across malignant hematology, immunology, and neurology.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Another reason why the Roche-Nurix partnership is attractive, the J.P. Morgan analyst added, is because Roche shoulders 60% of global development costs (with Nurix chipping in the other 40%) while the companies have agreed to split 50-50 both the U.S. commercialization responsibility (Roche holds sole ex-U.S. commercialization rights), as well as the resulting profits and losses from U.S. commercialization.</p>
<h4><strong>$48B market opportunity</strong></h4>
<p>“Historical stock moves around NRIX/STAT6 suggest the program carried some value, but was not the primary driver of NRIX’s value, with the much larger strategic inflection tied to the Roche/bexo partnership,” commented Roger Song, MD, equity analyst with Jefferies, in a research note.</p>
<p>In a June 8 <a href="https://ir.nurixtx.com/static-files/7ab7c64e-19dd-4242-bf61-420c9dfba537#page=15">investor presentation</a>, Nurix quantified the size of that potential inflection as a $48 billion addressable market opportunity across five diseases: chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), chronic spontaneous urticaria (CSU), and multiple sclerosis (MS).</p>
<p>CLL and small lymphocytic lymphoma (SLL) are the two diseases where bex-deg development is furthest along; the drug is under study in the Phase III DAYBreak trial (CLL-306, <a href="https://clinicaltrials.gov/study/NCT07516093">NCT07516093</a>), which is recruiting patients toward an estimated enrollment of 620, and carries an estimated primary completion date of October 2029. Last month, the first patient was enrolled in a Phase I/II combination trial (NX-5948-203; <a href="https://clinicaltrials.gov/study/NCT07520006">NCT07520006</a>) evaluating the combination of bex-deg and venetoclax, a standard-of-care BCL2 inhibitor, in patients with relapsed/refractory CLL, with planned expansion to first-line therapy.</p>
<p>“We see opportunity for upside from bex-deg expansion into inflammatory/autoimmune and neurological indications,” Kostas Biliouris, PhD, a managing director on the biotechnology research team of Oppenheimer, wrote in a research note. “We see CSU as [a] particularly attractive indication given derisking of BTK-targeting by [Novartis’ <strong>(SIX Swiss: NOVN and NYSE: NVS)</strong> BTKi (BTK inhibitor)] remibrulnib and higher bex-deg potency on mast cell degranulation assay without bleeding risk.</p>
<h4><strong>Sanofi’s decision</strong></h4>
<p>So why did Sanofi terminate development of SAR448272?</p>
<p>Nurix offered no reason in its press release, and company executives told Song of Jefferies it was not told in advance of the decision.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>“The decision was due to emerging nonclinical findings that precluded Sanofi from bringing it forward in atopic dermatitis,” Sanofi indicated to Nurix during a quick catch up conversation, according to Romero, who cautioned: “Nurix has <em>not </em>reviewed any data and therefore could not confirm the issues Sanofi saw. Nurix is also unclear whether Sanofi’s broader portfolio strategy played a role in the decision.”</p>
<p>Biliouris offered a possible portfolio explanation for Sanofi’s decision: “It may be driven by robust/convincing (HV) data from other SNY [Sanofi] collaboration (STAT6i), STAT6 degrader safety signals, or SNY strategic prioritization following [<strong>Regeneron Pharmaceuticals (Nasdaq: REGN)</strong>]’s partnership around long-acting IL-13/IL-13 x IL-14,” Biliouris wrote.</p>
<p>Sanofi is partnering with privately held <strong>Recludix Pharma</strong> to develop an oral STAT6 inhibitor or “STAT6i” called REX-8756 (also known as SAR448755). REX-8756 is a first-in-class, reversible orthosteric inhibitor of the STAT6 SH2 domain that targets Type 2 inflammatory pathways (IL-4 and IL-13), and which according to the companies is designed to be highly potent, selective, and durable.</p>
<p>The companies have advanced REX-8756 to a Phase I trial designed to assess the drug’s safety, tolerability, pharmacokinetics, and pharmacodynamics, with single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. The blinded, placebo-controlled trial expects to enroll approximately 100 healthy volunteers.</p>
<p>Recludix presented positive preclinical model data for REX-856 at the Revolutionizing Atopic Dermatitis (RAD) Congress, held June 17-19 in Nashville, TN. Sanofi and Recludix launched their collaboration in 2023. It includes $125 million in “near-term” payments; up to $1.2 billion-plus in development, regulatory and sales milestones; as well as up to double-digit royalties on product sales.</p>
<p>More recently last month, Sanofi and Regeneron expanded their 23-year-old partnership—whose most successful product is the multi-indication blockbuster Dupixent<sup>®</sup> (dupilumab)—by adding multiple next-generation, long-acting antibodies to their alliance. Sanofi agreed to pay Regeneron $1 billion upfront, and up to an additional $7 billion tied to achieving development, regulatory, and commercial milestones.</p>
<p>Under the expanded license and collaboration agreement, Sanofi and Regeneron agreed to co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies targeting interleukin-13 (IL-13), IL-4xIL-13 bispecific, interleukin-4 (IL-4), and interleukin-4 receptor alpha (IL-4Rα). The IL-13 antibody, REGN20423, is now being evaluated in the Phase I AURA-AD trial (<a href="https://clinicaltrials.gov/study/NCT07527923">NCT07527923</a>) in atopic dermatitis, while the other three antibodies are expected to enter the clinic in 2027.</p>
<p> </p>
<h2><strong>Leaders and laggards</strong></h2>
<p><strong>Karyopharm Therapeutics (KPTI)</strong> shares <span><strong>skidded 21%</strong></span> Tuesday, from 11 cents to 9 cents, after the Newton, MA-based developer of nuclear export inhibitors designed to treat cancer said it filed for protection from creditors under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. Karyopharm said it entered into a Restructuring Support Agreement with its lenders, noteholders, and other key stakeholders, under which the company, once reorganized, plans to merge with privately held, London-based <strong>Ayrmid</strong>—which has agreed to serve as lead bidder in a court-supervised sale process intended to maximize value for all stakeholders. Karyopharm said it has secured commitments for up to $55 million in debtor-in-possession (DIP) financing from its existing secured lenders. Upon court approval, the DIP financing plus cash from ongoing operations is expected to support Karyopharm operations during the Chapter 11 process and meet the company’s financial obligations.</p>
<p><strong>Rhythm Pharmaceuticals (NASDAQ: RYTM)</strong> shares <span><strong>surged 28%</strong></span> from $86.44 to $110.68 Wednesday after <em>The Wall Street Journal</em> reported that <strong>AstraZeneca (LSE, NYSE, and Nasdaq Stockholm: AZN)</strong> made a roughly $10 billion offer to buy the rare disease drug developer, citing unnamed sources. AstraZeneca offered to pay $124 a share for the biotech last month, the Journal reported—a 35% premium over Rhythm’s closing share price Tuesday. AstraZeneca raised its bid to $134 a share, according to Reuters. Rhythm has declined comment while AstraZeneca has not commented on the reported offers. Shares <span><strong>slid 5%</strong></span> to $105.02 Thursday before <span><strong>rising again 7%</strong></span> to $112.28 Friday, after the merger-and-acquisition blog Betaville posted speculation from traders that a second potential global pharma giant may have made a counteroffer for Rhythm.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/stockwatch-nurix-nosedives-as-sanofi-halts-phase-i-immunology-candidate/">StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Nova Scotia blood management program helping patients prepare for safer surgery</title>
<link>https://edusehat.com/en/nova-scotia-blood-management-program-helping-patients-prepare-for-safer-surgery</link>
<guid>https://edusehat.com/en/nova-scotia-blood-management-program-helping-patients-prepare-for-safer-surgery</guid>
<description><![CDATA[ Established 25 years ago, the program supports hundreds of surgical patients each month by identifying and treating blood-related conditions before and after procedures. Nova Scotia Health is highlighting the role of its Perioperative Blood Management program in improving surgical safety, reducing the need for blood transfusions and supporting patient recovery. The program, which has operated […]
The post Nova Scotia blood management program helping patients prepare for safer surgery appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_2739633431.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 04:00:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Nova, Scotia, blood, management, program, helping, patients, prepare, for, safer, surgery</media:keywords>
<content:encoded><![CDATA[<p>Established 25 years ago, the program supports hundreds of surgical patients each month by identifying and treating blood-related conditions before and after procedures.</p>
<p>Nova Scotia Health is highlighting the role of its Perioperative Blood Management program in improving surgical safety, reducing the need for blood transfusions and supporting patient recovery.</p>
<p>The program, which has operated for 25 years, helps patients undergoing surgery in Halifax and Dartmouth optimize their blood health before, during and after procedures.</p>
<p>One of the first programs of its kind in Canada and the largest east of Montreal, the service focuses on identifying and treating conditions such as anemia and iron deficiency that can increase surgical risks.</p>
<p>The team assesses approximately 150 new surgical patients each month and supports more than 300 additional patients during and after hospitalization.</p>
<h3>Identifying risks before surgery</h3>
<p>Anemia and iron deficiency can significantly affect a patient’s ability to tolerate surgery and recover afterward.</p>
<p>When these conditions go undetected, patients may be more likely to require blood transfusions, experience complications or face longer hospital stays.</p>
<p>The Perioperative Blood Management team works to identify these concerns early, allowing clinicians to implement appropriate treatment before surgery whenever possible.</p>
<p>Ideally, patients are assessed four to six weeks before their scheduled procedures, providing time to improve blood health and reduce potential complications.</p>
<p>The approach emphasizes preserving and managing a patient’s own blood rather than relying unnecessarily on transfusions.</p>
<h3>Supporting hundreds of patients monthly</h3>
<p>The program is led by nurse practitioner Heather Mingo, anesthesiologist Dr. Blaine Kent, and registered nurses Erin Sampson and Katlyn Carver.</p>
<p>Together, the team works with patients and surgical care providers to identify blood-related concerns, coordinate treatment and support recovery.</p>
<p>Their work takes place within a busy provincial surgical system.</p>
<p>Nova Scotia Health reported completing more than 73,000 surgeries between April 1, 2025, and March 31, 2026.</p>
<p>With approximately one in four surgical patients experiencing anemia, early identification and treatment of blood-related conditions represent important opportunities to improve perioperative care.</p>
<p>The program’s work extends beyond preoperative assessment, with patients receiving support during hospitalization and following surgery when needed.</p>
<h3>Reducing unnecessary transfusions</h3>
<p>Patient blood management has become an internationally recognized approach to improving surgical care.</p>
<p>The World Health Organization has formally recognized the importance of blood management since 2010.</p>
<p>Advances in surgical techniques, anesthesia and methods of controlling blood loss have also helped reduce the need for transfusions.</p>
<p>Although transfusions remain essential and potentially lifesaving for many patients, avoiding unnecessary exposure to blood products can help reduce certain risks while preserving blood supplies for those who need them.</p>
<p>The Nova Scotia program also has experience supporting patients who cannot accept blood transfusions for religious or other reasons.</p>
<p>This work has contributed to the team’s approach to individualized surgical planning and blood conservation.</p>
<h3>Recognizing excellence in surgical care</h3>
<p>The Perioperative Blood Management team received the 2024 Dalhousie University Department of Anesthesia, Pain Management, and Perioperative Medicine Internal Team Award of Excellence.</p>
<p>The recognition acknowledged the team’s contributions to patient care and the management of blood-related issues throughout the surgical journey.</p>
<p>Nova Scotia Health highlighted the program during Blood Management Awareness Week, held November 2 to 6.</p>
<p>As healthcare systems continue working to improve surgical outcomes and make efficient use of resources, programs that identify and manage risks before surgery can play an important role.</p>
<p>Nova Scotia’s experience demonstrates how multidisciplinary collaboration and early intervention can support safer procedures, more individualized treatment and improved patient recovery.</p>
<p>Source: <a href="https://www.nshealth.ca/news-and-notices/supporting-safer-surgeries-nova-scotia-healths-perioperative-blood-management?utm_source=chatgpt.com">Nova Scotia Health — Supporting safer surgeries with the Perioperative Blood Management program</a></p>
<div>
<div></div>
</div>
<p>The post <a href="https://www.hospitalnews.com/nova-scotia-blood-management-program-helping-patients-prepare-for-safer-surgery/">Nova Scotia blood management program helping patients prepare for safer surgery</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>A Nuclear Receptor Renaissance: Science Summit 2026</title>
<link>https://edusehat.com/en/a-nuclear-receptor-renaissance-science-summit-2026</link>
<guid>https://edusehat.com/en/a-nuclear-receptor-renaissance-science-summit-2026</guid>
<description><![CDATA[ The Endocrine Society’s Science Summit 2026 in Málaga, Spain, in September examined how nuclear receptor research is advancing from molecular mechanisms toward therapies for age-related diseases. The summit’s co-chair, Inés Pineda-Torra, PhD, describes the field’s expanding scope, major unanswered questions, and relevance to women’s cardiovascular health. What happens when some of the world’s leading nuclear […]
The post A Nuclear Receptor Renaissance: Science Summit 2026 appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/science-summit-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sun, 08 Nov 2026 21:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Nuclear, Receptor, Renaissance:, Science, Summit, 2026</media:keywords>
<content:encoded><![CDATA[<p>The Endocrine Society’s Science Summit 2026 in Málaga, Spain, in September examined how nuclear receptor research is advancing from molecular mechanisms toward therapies for age-related diseases. The summit’s co-chair, Inés Pineda-Torra, PhD, describes the field’s expanding scope, major unanswered questions, and relevance to women’s cardiovascular health. What happens when some of the world’s leading nuclear […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/a-nuclear-receptor-renaissance-ines-pineda-torra-phd-discusses-the-science-summit-2026/">A Nuclear Receptor Renaissance: Science Summit 2026</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Aging Proteome: Clocks, Cohorts, and Clinical Trials</title>
<link>https://edusehat.com/en/the-aging-proteome-clocks-cohorts-and-clinical-trials</link>
<guid>https://edusehat.com/en/the-aging-proteome-clocks-cohorts-and-clinical-trials</guid>
<description><![CDATA[ In this GEN webinar, two experts will show how ultra-sensitive, multiplexed proteomics can measure both the pace of aging and the effects of interventions designed to change it. 
The post The Aging Proteome: Clocks, Cohorts, and Clinical Trials appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Getty_460712007_DNA.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 07 Nov 2026 09:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Aging, Proteome:, Clocks, Cohorts, and, Clinical, Trials</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/11/XiaoJunMa_headshot.jpg" class="h-full w-full object-cover" alt="Image of Xiao-Jun Ma, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Xiao-Jun Ma, PhD</h2>
                <h3 class="mt-0 !text-[15px] !leading-[21px]">Chief Technology Officer<br>Alamar Biosciences</h3>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/11/XiaoJunMa_headshot.jpg" alt="Image of Xiao-Jun Ma, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Xiao-Jun Ma, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Xiao-Jun Ma, PhD, joined Alamar Biosciences in June of 2021 as chief technology officer. Xiao-Jun is a successful R&D leader with more than 20 years of experience in the life sciences and molecular diagnostics industries. Most recently he served as vice president and chief scientific officer in the Genomics Division of Bio-Techne. During his 11-year tenure at ACD, Ma led the development of a portfolio of<em> in situ</em> RNA and DNA detection solutions for research and clinical diagnostics markets. Prior to joining ACD, he was vice president of R&D/biostatistics at bioTheranostics. Before bioTheranostics, Ma held senior bioinformatics positions at Johnson & Johnson and Monsanto/Searle (Pfizer), where he applied his multi-disciplinary knowledge in molecular biology and bioinformatics to discover novel drug targets and biomarkers. He received his doctorate training in biochemistry at Case Western Reserve University and the University of Iowa and post-doctoral training in molecular genetics at the University of California, Los Angeles.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/11/MichaelCorley_headshot.jpg" class="h-full w-full object-cover" alt="Image of Michael J. Corley, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Michael J. Corley, PhD</h2>
                <h3 class="mt-0 !text-[15px] !leading-[21px]">Tenured Assoc. Professor of Medicine<br>University of California, San Diego</h3>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/11/MichaelCorley_headshot.jpg" alt="Image of Michael J. Corley, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Michael J. Corley, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Michael J. Corley, PhD, is an associate professor in medicine within the Division of Geriatrics, Gerontology, & Palliative Care and The Stein Institute for Research on Aging. He received his undergraduate degree from UCSD, an MA and PhD in behavioral neuroscience from the University of Hawaii, and completed postdoctoral training at the John A. Burns School of Medicine in epigenetics, immunology, and infectious diseases. Corley leads a global epigenetics research program focusing on understanding the interplay between the immune system, viruses, and aging. His laboratory is at the forefront of generating critical data to advance the development, validation, and implementation of novel biomarkers and therapeutics aimed at promoting longevity.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Tuesday, December 1, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-12-01T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">Geroscience proposes that slowing the biology of aging could delay many chronic diseases at once. Testing that idea requires biomarkers that are precise, reproducible, and responsive to intervention.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, two experts will show how ultra-sensitive, multiplexed proteomics can measure both the pace of aging and the effects of interventions designed to change it. In his talk, Michael Corley, PhD, will explain why the aging field is limited less by ideas than by evidence, and how completed clinical trials with banked samples can be used to screen candidate interventions quickly. He will share proteomic and epigenetic findings from a randomized trial of semaglutide, including cardiometabolic and inflammatory protein changes during treatment and after the drug is stopped. He will also describe XPRIZE Healthspan, a global competition whose central biorepository will hold samples from 20 intervention trials.</p>


<p class="wp-block-paragraph">Then Xiao-Jun Ma, PhD, will present a data-driven proteomic module identified across three cohorts that tracks biological aging. He will show how a clock built from this module relates to mortality, cognition, and comorbidity burden, how it compares with DNA methylation clocks, and what it reveals about when proteomic aging accelerates. Key takeaways include:</p>


<ul class="wp-block-list">
<li>Why evidence, not ideas, is the bottleneck in geroscience, and how completed trials can help close the gap</li>



<li>How proteomic measurements capture intervention effects that epigenetic clocks may miss</li>



<li>How an intrinsic, unsupervised protein module can serve as a portable measure of biological aging</li>



<li>What large, harmonized trial biorepositories mean for biomarker discovery in aging research</li>
</ul>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://alamarbio.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="80" src="https://www.genengnews.com/wp-content/uploads/2024/10/AlamarDropLogo_4c-300x80.jpg" alt="Alamar Biosciences Logo" class="wp-image-302414" srcset="https://www.genengnews.com/wp-content/uploads/2024/10/AlamarDropLogo_4c-300x80.jpg 300w, https://www.genengnews.com/wp-content/uploads/2024/10/AlamarDropLogo_4c.jpg 379w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/the-aging-proteome-clocks-cohorts-and-clinical-trials/">The Aging Proteome: Clocks, Cohorts, and Clinical Trials</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>A Nuclear Receptor Renaissance:</title>
<link>https://edusehat.com/en/a-nuclear-receptor-renaissance</link>
<guid>https://edusehat.com/en/a-nuclear-receptor-renaissance</guid>
<description><![CDATA[ The Endocrine Society’s Science Summit 2026 in Málaga, Spain, in September examined how nuclear receptor research is advancing from molecular mechanisms toward therapies for age-related diseases. The summit’s co-chair, Inés Pineda-Torra, PhD, describes the field’s expanding scope, major unanswered questions, and relevance to women’s cardiovascular health. What happens when some of the world’s leading nuclear […]
The post A Nuclear Receptor Renaissance: appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/science-summit-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 07 Nov 2026 02:25:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Nuclear, Receptor, Renaissance:</media:keywords>
<content:encoded><![CDATA[<p>The Endocrine Society’s Science Summit 2026 in Málaga, Spain, in September examined how nuclear receptor research is advancing from molecular mechanisms toward therapies for age-related diseases. The summit’s co-chair, Inés Pineda-Torra, PhD, describes the field’s expanding scope, major unanswered questions, and relevance to women’s cardiovascular health. What happens when some of the world’s leading nuclear […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/a-nuclear-receptor-renaissance-ines-pineda-torra-phd-discusses-the-science-summit-2026/">A Nuclear Receptor Renaissance:</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ER&#45;Negative Breast Cancer Risk Linked with Blood Levels of Two PFAS Forever Chemicals</title>
<link>https://edusehat.com/en/er-negative-breast-cancer-risk-linked-with-blood-levels-of-two-pfas-forever-chemicals</link>
<guid>https://edusehat.com/en/er-negative-breast-cancer-risk-linked-with-blood-levels-of-two-pfas-forever-chemicals</guid>
<description><![CDATA[ The results of a study found that women with higher blood levels of two common PFAS were more likely to develop estrogen receptor-negative breast cancer, saying their results have important public health implications.
The post ER-Negative Breast Cancer Risk Linked with Blood Levels of Two PFAS Forever Chemicals appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/09/Nov19_2020_Getty_1201440632_CancerCell-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 07 Nov 2026 01:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ER-Negative, Breast, Cancer, Risk, Linked, with, Blood, Levels, Two, PFAS, Forever, Chemicals</media:keywords>
<content:encoded><![CDATA[<p>Per- and polyfluoroalkyl substances (PFAS) are a large group of chemicals used in common consumer products. Often referred to as “forever chemicals,” PFAS do not break down easily in the environment and can remain in the body for years.</p>
<p>The results of a study carried out by National Institutes of Health researchers has now found that women with higher blood levels of two common PFAS, perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS), were more likely to develop estrogen receptor-negative (ER-negative) breast cancer. ER-negative tumors lack receptors that allow the hormone estrogen to help cancer cells grow. There was no clear association observed between the two chemicals and breast cancer risk overall.</p>
<p>“Our findings, which we confirmed using a meta-analysis of prior research, indicate that certain legacy PFAS, including PFOA and PFOS, are associated with a higher risk of ER-negative breast cancer, a more aggressive tumor type with few known risk factors,” said NIH Stadtman Investigator Alexandra White, PhD, who led the study. Although PFOA and PFOS compounds have been largely phased out and replaced with new PFAS compounds, most individuals have measurable levels of PFOA and PFOS in their bodies.</p>
<p>White is senior and corresponding author of the researchers’ published paper in <em>Journal of Clinical Oncology</em>, titled “<a href="https://doi.org/10.1200/JCO-26-00318" target="_blank" rel="noopener">Per- and Polyfluoroalkyl Substance Exposure and Breast Cancer Incidence in the Sister Study</a>,” in which they concluded “Given the widespread exposure to PFAS and limited established risk factors for ER-negative tumors, these results have important public health implications.”</p>
<p>Breast cancer is the most common cancer among women, and incidence rates are rising in the U.S. and worldwide, the authors stated. Established breast cancer risk factors, such as reproductive history, exogenous hormone use and lifestyle factors, have been more strongly linked with hormone receptor–positive than with hormone receptor–negative tumors.</p>
<p>Scientists know less about what raises the risk of ER-negative breast cancer. “Evidence suggests that hormone receptor–negative tumors might have distinct etiologies, yet their risk factors remain largely unknown,” the researchers wrote. “This knowledge gap is concerning as hormone receptor–negative tumors are more aggressive with poorer clinical outcomes.”</p>
<p>The newly reported research drew on the <a href="https://www.niehs.nih.gov/research/atniehs/labs/epi/resources/data-sharing/sister" target="_blank" rel="noopener">Sister Study</a>, which is led by NIH’s National Institute of Environmental Health Sciences (NIEHS). This larger study enrolled 50,884 women ages 35–74 in the U.S. and Puerto Rico from 2003 to 2009. None had breast cancer when they joined the Sister Study, but each had a full or half-sister who had been previously diagnosed with breast cancer.</p>
<p>For their PFAS study White and team included 1,609 women who developed breast cancer and a comparison sample of 2,269 women. “We oversampled estrogen receptor (ER)–negative cases (324 ER-negative, 1,120 ER-positive) to improve statistical power,” they explained in their paper. “To our knowledge, this is the largest study to date of PFAS exposure and breast cancer incidence, particularly for ER–tumors.”</p>
<p>The investigators measured 17 PFAS in blood, collected years before women were diagnosed with cancer. “Seventeen PFASs were quantified in prediagnostic plasma using liquid chromatography-high-resolution mass spectrometry,” they noted. The results of their studies showed that women in the group with the highest PFOA levels had a 67% higher rate of ER-negative breast cancer than those in the lowest group. For PFOS, the rate was 93% higher—nearly twice as high. These numbers describe relative differences between groups, not an individual woman’s chance of getting breast cancer.</p>
<p>The team also carried out meta-analyses, including the current and prior prospective studies, which showed consistent positive associations of PFOA and PFOS with ER-negative breast cancer. “Our meta-analyses of studies with prediagnostic blood measurements further support a positive association between PFOA and ER-tumors, with suggestive evidence for PFOS and ER-tumors,” they stated.</p>
<p>“These findings matter for women’s health broadly,” said first author Che-Jung Chang, PhD, a former research fellow at NIH and a current researcher at DLH, a scientific research organization. “Although PFAS are persistent in the environment and in our bodies, exposure to them is still potentially modifiable, meaning people can take steps to reduce their exposure, and these findings could open new avenues for prevention.”</p>
<p>Because the strongest associations involved tumors without hormone receptors, the authors suggest that PFAS may affect cancer risk through other non-hormonal biologic pathways. Possible pathways include changes in gene activity or immune system. The reported study did not test those potential explanations.</p>
<p>The authors say future studies should evaluate people with higher PFAS exposure and in groups more affected by ER-negative breast cancer. “More research is needed, particularly evaluating the risk of breast cancer associated with newer replacement PFAS chemicals,” White added.</p>
<p>In their paper the authors concluded, “Future studies should prioritize investigating these associations in populations with higher PFAS exposure and a greater burden of hormone receptor–negative breast cancer to better inform targeted prevention efforts. Research is also needed to assess the carcinogenic potential of newer PFAS replacement chemicals, which remain poorly characterized.”</p>
<p>Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr., commented, “Women deserve clear answers about how chemicals in their environment may affect their health. This NIH study links two forever chemicals to a higher risk of ER-negative breast cancer and demands further investigation. Under President Trump’s leadership, we will pursue the evidence, confront environmental health risks, and give women the information they need to protect their health.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/er-negative-breast-cancer-risk-linked-with-blood-levels-of-two-pfas-forever-chemicals/">ER-Negative Breast Cancer Risk Linked with Blood Levels of Two PFAS Forever Chemicals</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Novartis Confirms Nine Cases of Tumors in Children Treated with Gene Therapy Zolgensma</title>
<link>https://edusehat.com/en/novartis-confirms-nine-cases-of-tumors-in-children-treated-with-gene-therapy-zolgensma</link>
<guid>https://edusehat.com/en/novartis-confirms-nine-cases-of-tumors-in-children-treated-with-gene-therapy-zolgensma</guid>
<description><![CDATA[ &quot;Two cases to date have shown evidence of vector integration into the DNA of the patients. In both cases, the patients underwent treatment and continue to be monitored,” Novartis said in a statement.
The post Novartis Confirms Nine Cases of Tumors in Children Treated with Gene Therapy Zolgensma appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Dec14_2020_Getty_904268264_XYChromosomes1-1024x683-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 07 Nov 2026 01:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Novartis, Confirms, Nine, Cases, Tumors, Children, Treated, with, Gene, Therapy, Zolgensma</media:keywords>
<content:encoded><![CDATA[<p>Novartis has confirmed nine reports—seven of them newly disclosed—in which tumors have developed in children treated with its marketed spinal muscular atrophy gene therapy Zolgensma<sup>®</sup> (onasemnogene abeparvovec-xioi).</p>
<p>“Of those, two cases to date have shown evidence of vector integration into the DNA of the patients. In both cases, the patients underwent treatment and continue to be monitored,” Novartis said in a statement furnished to <em>GEN</em> and other news outlets.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“Patient safety is our priority. In each case, we timely and appropriately notified health authorities and will continue to work with them on next steps,” the pharma giant added.</p>
<p>To date, Novartis stated, Zolgensma has been used to treat more than 6,000 patients worldwide across clinical trials, managed access programs, and commercial treatment.</p>
<p>The statement added: “The potential risk of tumors due to vector integration is currently included in the Zolgensma prescribing information.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Zolgensma is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of pediatric patients less than two years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (<em>SMN1</em>) gene.</p>
<p>Zolgensma is designed to address the genetic root cause of SMA by replacing the function of the missing or nonworking <em>SMN1</em> with a new working copy of the gene delivered into a patient’s cells. The gene therapy consists of a recombinant, non-replicating AAV serotype 9 (AAV9) vector whose DNA persists largely in episomal form, according to the therapy’s prescribing information label.</p>
<p>Random integration of recombinant AAV vector DNA into human DNA has been reported with Zolgensma and in published studies about other AAV gene therapies, Novartis has acknowledged.</p>
<p>“The clinical relevance of individual integration events is unknown, but it is acknowledged that individual integration events could potentially contribute to a risk of tumorigenicity. Cases of tumor have been reported in patients who received Zolgensma post-approval,” the label added.</p>
<h4><strong>‘Theoretical risk’</strong></h4>
<p>Zolgensma’s <a href="https://www.novartis.com/us-en/sites/novartis_us/files/zolgensma.pdf" target="_blank" rel="noopener">prescribing label </a>includes a section titled “AAV Vector Integration and Risk of Tumorigenicity.” That section, however, states: “There is a theoretical risk of tumorigenicity due to integration of AAV [adeno-associated virus] vector DNA into the genome.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The label urges prescribers to report cases of tumors in patients who received Zolgensma to Novartis.</p>
<p>Novartis’ statement followed a statement issued Thursday by the Muscular Dystrophy Association (MDA). In the MDA statement, the association acknowledged awareness of reports about tumors developing in Zolgensma patients.</p>
<p>MDA stated that it “understand[s] that this raises questions and concerns for families, particularly those who have made important treatment decisions for themselves or their children. We take these reports seriously and believe families deserve transparent, timely, and science-based information as more is learned.”</p>
<p>“MDA is seeking additional information, reviewing the available scientific and safety data with clinical and research experts, and has reached out to Novartis,” the association added. “We recognize the sense of urgency from families to access additional information about these reports in order to make informed treatment and monitoring decisions. MDA is working to learn more as soon as possible.”</p>
<h4><strong>‘Confidential channels’</strong></h4>
<p>SMA Europe, an umbrella organization for SMA patient groups across the continent, issued its own <a href="https://www.sma-europe.eu/news/information-regarding-recent-zolgensma-safety-concerns?ref=/news" target="_blank" rel="noopener">statement</a> Thursday saying it was informed about the tumor cases “through confidential channels, and have made clear to Novartis that the SMA community now needs timely public communication.”</p>
<p>“We have strongly urged the company to provide clear information on what is currently known, what remains uncertain, what this may mean for people who have already received treatment, and whether any additional monitoring or action is recommended,” SMA Europe added.</p>
<p>SMA Europe and MDA spoke out after a hospice chaplain <a href="https://www.linkedin.com/posts/rev-carolyn-philstrom-a022aa254_im-deeply-disturbed-to-hear-this-news-that-share-7523572705716273152-Yypr/?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAIZI_4BqbJMjmmSJ_keDePIgmaFCPQ_iaY" target="_blank" rel="noopener">shared on LinkedIn </a> the post of a private Facebook group in which the parent of a child with SMA wrote of being informed by his neurologist that Novartis was withholding information about some of the tumor cases and opting instead for a “tiered rollout” of data.</p>
<p>“I am also sending this screenshot to reporters. I strongly encourage you to abandon any belief that Novartis can control this narrative, and to do something radical for your company: tell the truth,” Rev. Carolyn Philstrom urged.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>During the first three quarters of this year, Novartis’ Zolgensma Group—consisting of the namesake IV-formulation gene therapy and an intrathecal formulation approved last year and marketed as Itvisma<sup>®</sup> (onasemnogene abeparvovec-brve)—generated $1.071 billion in net sales, up 16% from $925 million in January–September 2025. Of that total, $404 million was generated during the third quarter, up 34% from $301 million in Q3 2025.</p>
<p>Zolgensma Group finished last year with $1.232 billion in net sales, up 1.5% from $1.214 billion in 2024. Zolgensma is one of Novartis’ top 20 brands.</p>
<p>Novartis shares traded on the SIX Swiss exchange barely budged, dipping 0.1% to CHF 134.12 ($163.25) on Thursday. Novartis’ American Depositary Receipts, traded on the New York Stock Exchange, slid 1.85% to $161.93.</p>
<h4><strong>Past safety issues</strong></h4>
<p>The nine acknowledged tumors are not the first instances of safety issues tied to Zolgensma.</p>
<p>In 2022, Novartis acknowledged that two patients <a href="https://www.genengnews.com/topics/genome-editing/novartis-confirms-deaths-of-two-patients-treated-with-gene-therapy-zolgensma/" target="_blank" rel="noopener">died of acute liver failure following treatment with Zolgensma</a>. Both cases occurred at approximately five to six weeks post Zolgensma infusion, and approximately 1-10 days following the initiation of corticosteroid taper, Novartis stated at the time.</p>
<p>In response, Novartis revised Zolgensma’s label to specify that fatal acute liver failure had been reported. That marked a change from the previous wording of the gene therapy’s “black box” warning, which previously included acute liver failure as a known side effect that has been reported following treatment.</p>
<p>Zolgensma was developed by AveXis, a gene therapy developer that was <a href="https://www.genengnews.com/news/novartis-to-acquire-gene-therapy-developer-avexis-for-8-7b/" target="_blank" rel="noopener">acquired by Novartis for $8.7 billion</a> in a deal completed in 2018.</p>
<p>A year later, the FDA approved Zolgensma for the treatment of SMA in children under age two with SMA with bi-allelic mutations in the <em>SMN1</em> gene. Zolgensma was the second gene therapy authorized by the FDA for an inherited disease.</p>
<p>Later in 2019, the FDA announced AveXis’ acknowledgement that the accuracy of data from product testing performed in animals submitted in its Biologics License Application (BLA) for Zolgensma had been <a href="https://www.genengnews.com/topics/genome-editing/fda-places-partial-clinical-hold-on-some-trials-of-novartis-gene-therapy/" target="_blank" rel="noopener">impacted by an unspecified manipulation of data</a> intended to support the development of its production process for the gene therapy. AveXis replaced its two top scientific executives, one of whom publicly denied wrongdoing.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>A <a href="https://www.jpeds.com/article/S0022-3476(20)30682-X/fulltext" target="_blank" rel="noopener">2020 paper</a> published in <em>The Journal of Pediatrics</em> detailed two cases of transient, drug-induced subacute liver failure following treatment with Zolgensma.</p>
<p>And a <a href="https://www.nature.com/articles/s41434-021-00273-7.pdf?proof=t" target="_blank" rel="noopener">2021 study in <em>Nature</em>-published <em>Gene Therapy</em></a> showed that of nine children treated with the gene therapy in Qatar, none experienced failure—but all patients experienced elevated levels of the liver enzymes aspartate aminotransferase (AST) or alanine transaminase (ALT), two experienced high prothrombin time, and one experienced elevated bilirubin. One patient experienced vomiting after infusion.</p>
<h4><strong>Beyond Zolgensma</strong></h4>
<p>Zolgensma isn’t the only gene therapy linked to tumors this year.</p>
<p>In January, Regenxbio announced that the FDA placed a clinical hold on its AAV9 gene therapy candidate RGX-111 for the treatment of mucopolysaccharidosis type I (MPS I or Hurler syndrome) after a single case where an intraventricular CNS tumor developed in a 5-year-old boy treated in its Phase I/II trial (<a href="https://clinicaltrials.gov/study/NCT03580083" target="_blank" rel="noopener">NCT03580083</a>). The FDA also placed a clinical hold on a similar gene therapy RGX-121 for the treatment of MPS II (Hunter Syndrome), citing the similarities in products, study populations, and shared risk between the clinical studies. The clinical holds remain in effect.</p>
<p>“The tumor was successfully resected, and the patient remains in neurologically stable condition with advanced cognitive function at five years of age—an outcome that is inconsistent with the natural history of severe MPSI,” the study’s corresponding author, Lindsey A. George, MD, of the Perelman Center for Cellular and Molecular Therapeutics at Children’s Hospital of Philadelphia, <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2601608" target="_blank" rel="noopener">reported in May in </a><em><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2601608" target="_blank" rel="noopener">The New England Journal of Medicine (NEJM)</a></em>.</p>
<p>“Data from three decades of experience with more than 6000 patients have shown that AAV gene therapy is associated with a favorable safety profile<sup><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2601608#core-collateral-r1" target="_blank" rel="noopener"><strong>1</strong></a></sup> and clinical benefits among diverse patient populations,” George and colleagues commented. “That said, our findings support the hypothesis that rare AAV integration can contribute to human oncogenesis, which emphasizes the need to optimize gene delivery methods and monitor transduced tissues after treatment.”</p>
<p>And in October, Michigan-based researchers led by Arul M. Chinnaiyan, MD, PhD, of the Michigan Center for Translational Pathology <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2601608" target="_blank" rel="noopener">reported in <em>The New England Journal of Medicine</em></a> a case of paraspinal neoplasm in a 3-year-old boy with infantile-onset Krabbe disease (with biallelic <em>GALC</em> variants p.Arg220Ter and p.Tyr319Cys) following treatment with Forbes biologics’ AAV gene therapy FBX-101.</p>
<p>“At the time of the last follow-up, the patient remained asymptomatic,” Chinnaiyan and colleagues wrote. “These findings emphasize the need for cassette designs without splice donors, as well as attention to vector purity and extended genomic surveillance after AAV gene therapy.”</p>
<p>And in October, Michigan-based researchers led by Arul M. Chinnaiyan, MD, PhD, of the Michigan Center for Translational Pathology <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2601608" target="_blank" rel="noopener">reported in <em>The New England Journal of Medicine</em></a> a case of paraspinal neoplasm in a 3-year-old boy with infantile-onset Krabbe disease (with biallelic <em>GALC</em> variants p.Arg220Ter and p.Tyr319Cys) following treatment with Forbes biologics’ AAV gene therapy FBX-101.</p>
<p>“At the time of the last follow-up, the patient remained asymptomatic,” Chinnaiyan and colleagues wrote. “These findings emphasize the need for cassette designs without splice donors, as well as attention to vector purity and extended genomic surveillance after AAV gene therapy.”</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/novartis-confirms-nine-cases-of-tumors-in-children-treated-with-gene-therapy-zolgensma/">Novartis Confirms Nine Cases of Tumors in Children Treated with Gene Therapy Zolgensma</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Matt Bluette and Lynda O’Connor Join MOREgroup’s Boston Practice</title>
<link>https://edusehat.com/en/matt-bluette-and-lynda-oconnor-join-moregroups-boston-practice</link>
<guid>https://edusehat.com/en/matt-bluette-and-lynda-oconnor-join-moregroups-boston-practice</guid>
<description><![CDATA[ Architectural and engineering firm MOREgroup has strengthened its healthcare practice leadership with the addition of Matt Bluette, AIA, ACHA, AICP, NCARB, LEED AP, as Senior Principal and Healthcare Practice Leader; and Lynda O’Connor, IIDA, NCIDQ, LEED, LEAN, as Associate Principal. The two will continue their longstanding professional partnership in the Boston office of E4H Environments...
The post Matt Bluette and Lynda O’Connor Join MOREgroup’s Boston Practice appeared first on HCO News.
The post Matt Bluette and Lynda O’Connor Join MOREgroup’s Boston Practice appeared first on HCO News. ]]></description>
<enclosure url="https://hconews.com/wp-content/uploads/2026/11/HCO-People.MOREgroup-768x480.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 23:00:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Matt, Bluette, and, Lynda, O’Connor, Join, MOREgroup’s, Boston, Practice</media:keywords>
<content:encoded><![CDATA[<p><span data-contrast="auto">Architectural and engineering firm MOREgroup has strengthened its healthcare practice leadership with the addition of Matt Bluette, AIA, ACHA, AICP, NCARB, LEED AP, as Senior Principal and Healthcare Practice Leader; and Lynda O’Connor, IIDA, NCIDQ, LEED, LEAN, as Associate Principal. The two will continue their longstanding professional partnership in the Boston office of E4H Environments for Health Architecture, a MOREgroup brand.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Bluette has 30 years of healthcare design experience encompassing master planning, regulatory strategy and community-based care. He works with providers to develop evidence-based solutions to improve operational efficiency. Bluette is active in several industry organizations, including the Boston Society of Architects, the American Planning Association and the Association of Medical Facilities Professionals.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">O’Connor brings nearly 20 years of healthcare design experience in interior architecture, team leadership and project delivery. She guides assignments from procurement through implementation, balancing design with clinical requirements. O’Connor is NCIDQ-certified and an active member of the New England chapter of Women in Healthcare and the International Interior Design Association.</span><span data-ccp-props="{}"> </span></p>
<blockquote><p><span data-contrast="auto">“Matt and Lynda’s proven record of collaboration and leadership aligns perfectly with what we aim to accomplish in Boston and beyond,” MOREgroup’s National Healthcare Director Dan Thomas said <a href="https://moregroup-inc.com/veteran-healthcare-design-team-joins-moregroup-to-advance-boston-practice/" target="_blank" rel="noopener">in the company’s release</a>. “Their experience, longstanding working relationship, and commitment to helping clients navigate the future of healthcare will create immediate value for our Boston office and the organizations we serve.”</span><span data-ccp-props="{}"> </span></p></blockquote>
<p>The post <a rel="nofollow" href="https://hconews.com/2026/11/06/matt-bluette-and-lynda-oconnor-join-moregroups-boston-practice/">Matt Bluette and Lynda O’Connor Join MOREgroup’s Boston Practice</a> appeared first on <a rel="nofollow" href="https://hconews.com/">HCO News</a>.</p>
<p>The post <a href="https://hconews.com/2026/11/06/matt-bluette-and-lynda-oconnor-join-moregroups-boston-practice/">Matt Bluette and Lynda O’Connor Join MOREgroup’s Boston Practice</a> appeared first on <a href="https://hconews.com/">HCO News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>In&#45;Duct Air Disinfection System</title>
<link>https://edusehat.com/en/in-duct-air-disinfection-system</link>
<guid>https://edusehat.com/en/in-duct-air-disinfection-system</guid>
<description><![CDATA[ Applied Photonix has introduced ViroZap®, an FDA-cleared Class II medical device designed for continuous, whole-building air disinfection. Engineered for integration into new or existing HVAC systems, ViroZap uses plasmonic photonic technology and UV-A light to treat recirculated air without producing ozone. Independent testing at 500 CFM demonstrated reductions of 99.9995% in airborne viruses, 99.9997% in...
The post In-Duct Air Disinfection System appeared first on HCO News.
The post In-Duct Air Disinfection System appeared first on HCO News. ]]></description>
<enclosure url="https://hconews.com/wp-content/uploads/2026/11/HCO-Product.ViroZap-768x750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 23:00:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>In-Duct, Air, Disinfection, System</media:keywords>
<content:encoded><![CDATA[<p><span data-contrast="auto">Applied Photonix has introduced ViroZap®, an FDA-cleared Class II medical device designed for continuous, whole-building air disinfection. Engineered for integration into new or existing HVAC systems, ViroZap uses plasmonic photonic technology and UV-A light to treat recirculated air without producing ozone. Independent testing at 500 CFM demonstrated reductions of 99.9995% in airborne viruses, 99.9997% in bacteria and 99.995% in mold and fungal spores. The pressure-drop-neutral system operates with proprietary coated MERV 13 or MERV 15 filters and a MERV 8 pre-filter, with an optional HEPA filter coating. Designed for healthcare facilities, schools and commercial buildings, ViroZap supports indoor air quality improvements without requiring standalone room air purifiers.</span><span data-ccp-props="{}"> </span></p>
<p><a href="https://www.aphotonix.com/" target="_blank" rel="noopener"><span data-contrast="none">Applied Photonix</span></a><span data-ccp-props="{}"> </span></p>
<p>The post <a rel="nofollow" href="https://hconews.com/2026/11/06/in-duct-air-disinfection-system/">In-Duct Air Disinfection System</a> appeared first on <a rel="nofollow" href="https://hconews.com/">HCO News</a>.</p>
<p>The post <a href="https://hconews.com/2026/11/06/in-duct-air-disinfection-system/">In-Duct Air Disinfection System</a> appeared first on <a href="https://hconews.com/">HCO News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Why Glycosylation Control Is No Longer a Secondary Concern in the Development of Complex Biologics</title>
<link>https://edusehat.com/en/why-glycosylation-control-is-no-longer-a-secondary-concern-in-the-development-of-complex-biologics</link>
<guid>https://edusehat.com/en/why-glycosylation-control-is-no-longer-a-secondary-concern-in-the-development-of-complex-biologics</guid>
<description><![CDATA[ A priority shift is redefining expectations for contract development and manufacturing organizations (CDMOs). This article explains how CDMOs can efficiently move their glycosylation processes upstream using quality-by-design (QbD) methodologies.
The post Why Glycosylation Control Is No Longer a Secondary Concern in the Development of Complex Biologics appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/06/GettyImages-200554028-001.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 22:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Why, Glycosylation, Control, Longer, Secondary, Concern, the, Development, Complex, Biologics</media:keywords>
<content:encoded><![CDATA[<p>In developing traditional monoclonal antibodies (mAbs), drug manufacturers have often postponed addressing glycosylation issues until downstream processing.</p>
<p>The new generation of antibody therapeutics, however, offers no such leeway.</p>
<figure aria-describedby="caption-attachment-340114" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340114" src="https://www.genengnews.com/wp-content/uploads/2026/11/Sojeong-Lee-225x300.jpg" alt="" width="225" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Sojeong-Lee-225x300.jpg 225w, https://www.genengnews.com/wp-content/uploads/2026/11/Sojeong-Lee.jpg 756w" sizes="(max-width: 225px) 100vw, 225px"><figcaption class="wp-caption-text">Sojeong Lee, PhD, Director of upstream development at Samsung Biologics</figcaption></figure>
<p>Compared with conventional mAbs, newer antibody therapeutics such as bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), Fc-fusion proteins, and advanced immunotherapies are far more sensitive to glycan heterogeneity. Even subtle variations in glycosylation can directly influence therapeutic efficacy and batch-to-batch consistency.</p>
<p>For these newer therapeutics, glycosylation must therefore be considered from the earliest stages of cell line and process development.</p>
<p>This priority shift is redefining expectations for contract development and manufacturing organizations (CDMOs). This article explains how CDMOs can efficiently move their glycosylation processes upstream using quality-by-design (QbD) methodologies.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p><strong>Early glycosylation control drivers</strong></p>
<p>The growing emphasis on upstream glycosylation control is primarily a consequence of increasing biologic complexity. Traditional mAbs are significantly more predictable in behavior, typically displaying stable glycosylation profiles in later clinical phases that pose minimal threat to efficacy or safety.</p>
<p>Modern biologics present a markedly different challenge:</p>
<ul>
<li>BsAbs rely upon highly precise structural configurations to facilitate simultaneous engagement of multiple targets. As a result, even relatively minor glycan asymmetry may impair target binding or compromise functional activity.</li>
<li>ADCs introduce further complexity, with glycosylation influencing drug-antibody ratio (DAR) stability, payload retention, and overall molecular integrity.</li>
<li>Fc-fusion proteins and immunotherapies frequently depend upon tightly controlled glycan profiles to achieve appropriate pharmacokinetic behavior and immune system engagement.</li>
</ul>
<p>Historically, downstream processing provided manufacturers with opportunities to compensate for variability introduced upstream. Adjustments during purification or process optimization frequently proved sufficient to address modest glycosylation inconsistencies associated with conventional antibody therapeutics.</p>
<p>However, this approach is increasingly inadequate for modern biologics. In certain cases, even a minor shift in specific glycan variants can critically compromise the drug’s pharmacokinetic profile, therapeutic efficacy, or safety. Many of these glycosylation-related challenges originate at the cellular and metabolic level during biosynthesis. Once heterogeneous glycan populations have been established, downstream interventions are inherently limited in their ability to fully correct structural inconsistencies.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Consequently, the industry is transitioning away from reactive correction models toward proactive upstream quality engineering.</p>
<h4><strong>Mitigating regulatory and commercial risk</strong></h4>
<p>Integrating quality considerations earlier in development offers significant regulatory and commercial advantages. If glycosylation inconsistencies emerge during scale-up or commercial manufacturing, the consequences may include batch rejection, additional comparability studies, regulatory delays, or disruptions to clinical programs.</p>
<p>Regulatory frameworks, including ICH Q8, Q9, and Q11, require manufacturers to identify critical quality attributes (CQAs), understand sources of process variability, and establish scientifically justified control strategies. For biologics, glycosylation has long been recognized as an important quality attribute linked to safety, efficacy, and immunogenicity. However, the increasing complexity of newer modalities has intensified expectations around early process understanding and glycan control.</p>
<p>Consequently, proactive upstream glycosylation control helps manufacturers meet these expectations by improving process consistency throughout development and scale-up. It also strengthens regulatory submissions by demonstrating that glycan heterogeneity is understood, monitored, and appropriately controlled across the manufacturing process.</p>
<h4><strong>Clone selection is critical to consistency</strong></h4>
<p>When implementing proactive control of glycosylation upstream, manufacturers must recognize that glycan variability is highly clone-dependent.</p>
<p>A substantial proportion of glycosylation variability, around 80%, originates from the intrinsic characteristics of the production clone itself. Even minor differences in genes such as <em>MGAT1</em> and <em>FUT8 </em>in a clone can alter the clone’s Golgi enzyme expression, which in turn can affect the branching/ fucosylation of subsequent antibodies, thereby affecting antibody-dependent cellular cytotoxicity (ADCC). A single glycan variant can therefore destroy a therapeutic’s mechanism of action.</p>
<p>Consider an Fc-fusion immunotherapy targeting the interleukin-6 receptor. If produced from a clone with high mannose levels, the eventual therapeutic’s half-life could drop from an expected 21 days to three days. Failure to eliminate unsuitable clones during early development may therefore result in otherwise promising candidates exhibiting unacceptable clinical characteristics during later stages.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>For this reason, developers must increasingly assess glycan quality attributes in addition to productivity and titer in early screening activities as part of their clone selection strategies.</p>
<p>Glycosylation-related quality attributes should be assessed in the context of the molecule’s intended mechanism of action and functional requirements. Examples include:</p>
<ul>
<li>Fucosylation levels: As an influencing factor in ADCC activity, fucosylation levels are particularly important for oncology therapeutics and immune-engaging molecules.</li>
<li>Galactosylation patterns: These patterns are significant where complement-dependent cytotoxicity (CDC) activity is required, as increased galactosylation may enhance C1q binding.</li>
<li>Sialic acid linkage profiles: Different sialylation patterns may influence inflammatory responses and pharmacokinetic performance in distinct ways, requiring careful evaluation. Also, sialic acids have a direct, strong correlation with the charge variant profiles, especially with the acidic variants, which can affect the binding affinity, immunogenicity, and other critical attributes.</li>
</ul>
<ul>
<li>High mannose content: As high mannose content can influence clearance rates and immunogenicity risk, it is an increasingly important quality consideration.</li>
</ul>
<h4><strong>High-throughput analytics are transforming cell line development</strong></h4>
<p>To evaluate glycosylation-related attributes effectively during early-stage development, drug developers and CDMOs are increasingly utilizing advanced analytical technologies, including HILIC-UPLC, LC-MS glycopeptide mapping, HPLC, and capillary electrophoresis. By integrating these high-throughput methodologies directly into early screening workflows, these organizations can simultaneously assess productivity and glycan quality, thereby reducing the likelihood that unsuitable clones progress through development.</p>
<p>Importantly, the objective is not necessarily to identify clones exhibiting a perfect glycan profile but rather to identify clones that naturally align as closely as possible with the target profile from the outset, thereby minimizing the extent of subsequent optimization required.</p>
<h4><strong>Structured experimental design</strong></h4>
<p>As biologic systems become increasingly complex, intuition-based optimization approaches are becoming insufficient.</p>
<p>Numerous upstream variables, including temperature, pH, substrate composition, oxygen transfer, amino acid availability, and lipid concentrations, may influence glycosylation pathways within the Golgi apparatus. Even relatively minor variations in culture conditions may alter branching patterns, fucosylation levels, or sialylation outcomes.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>Managing this complexity requires structured and statistically robust methodologies.</p>
<p>Design of experiments (DoE) approaches are therefore becoming essential for identifying critical process parameters while minimizing experimental burden. Screening DoEs allow developers to evaluate which parameters most significantly affect glycosylation outcomes, while optimization DoEs facilitate refinement of process conditions to balance productivity with quality objectives.</p>
<p>These methodologies also support broader QbD principles increasingly emphasized by regulators, including the establishment of process design spaces and robust monitoring strategies under frameworks such as ICH Q8 and Q11.</p>
<h4><strong>The role of automation, analytics, and data integration </strong></h4>
<p>Looking ahead, the continued evolution of upstream glycosylation control is likely to be driven by advances in automation and data analytics.</p>
<p>Many organizations have already begun integrating online monitoring technologies and automated feedback systems into bioprocessing workflows. Over time, these systems are expected to become increasingly sophisticated, enabling more dynamic adjustment of bioreactor conditions in response to real-time glycan analytics.</p>
<p>Artificial intelligence (AI) and machine learning are also expected to play increasingly important roles. As larger multi-batch datasets become available, AI-driven models may help predict relationships between process parameters and glycosylation outcomes with greater speed and accuracy than traditional analytical approaches alone.</p>
<p>However, realizing these capabilities will require substantial investment in organizational infrastructure.</p>
<h4><strong>Glycosylation in the years to come</strong></h4>
<p>No longer a downstream consideration, glycosylation control is set to play an increasingly important role in biologics development and manufacturing strategies.</p>
<p>For biopharma companies and CDMOs, this change will require stronger, AI-enabled technical capabilities to integrate volumes of analytical and manufacturing data effectively at speed, so operators can better understand how upstream conditions may influence glycan outcomes throughout scale-up and commercial production.</p>
<p>Timely insights such as these will only become more vital as the range of biologic modalities continues to diversify and as regulatory expectations surrounding consistency continue to evolve.</p>
<p>Going forward, organizations that integrate these considerations from the outset will be better positioned to support consistent therapeutic performance, reduce late-stage risk, and meet the growing demands associated with next-generation biologics.</p>
<p> </p>
<p><em>Sojeong Lee, PhD, is director of upstream development at Samsung Biologics</em></p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/why-glycosylation-control-is-no-longer-a-secondary-concern-in-the-development-of-complex-biologics/">Why Glycosylation Control Is No Longer a Secondary Concern in the Development of Complex Biologics</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Nearly two thirds of whitening products tested exceeded peroxide limit</title>
<link>https://edusehat.com/en/nearly-two-thirds-of-whitening-products-tested-exceeded-peroxide-limit</link>
<guid>https://edusehat.com/en/nearly-two-thirds-of-whitening-products-tested-exceeded-peroxide-limit</guid>
<description><![CDATA[ A targeted OPSS assessment found 45 of 70 teeth-whitening products exceeded the hydrogen peroxide limit for direct consumer sale. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/whitening.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 19:10:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Nearly, two, thirds, whitening, products, tested, exceeded, peroxide, limit</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Almost two thirds of tooth whitening products in a targeted safety assessment exceeded the hydrogen peroxide limit for products sold directly to consumers, the UK product safety regulator has revealed.</strong></p>



<p>The Office for Product Safety and Standards (OPSS) tested 70 products during 2025/26 and found that 45 contained more than the permitted consumer limit of 0.1% hydrogen peroxide.</p>



<p>Its <a href="https://www.gov.uk/government/publications/opss-delivery-report-2025-2026/opss-delivery-report-2025-2026">annual delivery report</a> also revealed that imported teeth-whitening goods valued at more than £1 million had been seized during the year.</p>



<h2 class="wp-block-heading">What are the legal peroxide limits?</h2>



<div class="wp-block-media-text is-stacked-on-mobile"><figure class="wp-block-media-text__media"></figure><div class="wp-block-media-text__content">
<p>Products containing or releasing no more than 0.1% hydrogen peroxide can be sold directly to consumers.</p>



<p>Products containing more than 0.1% and up to 6% can only be sold to dental practitioners. </p>



<p>Whitening products containing or releasing more than 6% hydrogen peroxide are prohibited for cosmetic use.</p>



<p>OPSS said its online enforcement work had included engagement with major marketplaces such as Amazon, eBay, TikTok Shop, AliExpress, Meta and Fruugo. </p>



<p>It also worked with HM Revenue and Customs (HMRC), Border Force and fulfilment houses to identify non-compliant imported products.</p>



<p>It stressed that the assessment was deliberately targeted at products of concern.</p>
</div></div>



<h2 class="wp-block-heading">Whitening products linked to £8.5 million fraud</h2>



<p>The findings followed the imprisonment of two men who sold whitening products containing dangerously high concentrations of hydrogen peroxide while stealing value added tax (VAT) charged to customers.</p>



<p>Ian Barnes and Alastair Ramage were <a href="https://dentistry.co.uk/2026/11/02/tooth-whitening-scammers-jailed-for-8-5-million-tax-theft/">jailed for a combined eight years and 10 months after an £8.5 million tax fraud</a>.</p>



<p>Messages disclosed during the investigation showed that the pair knew customers had reported dental damage. The case was separate from the OPSS testing and seizures.</p>



<p>The British Dental Association said the prosecution demonstrated the need for regulators to act against illegal whitening products before patients were harmed, rather than relying on tax investigations to secure convictions.</p>



<p>Jonathan Meadows, managing director of Regulation Resolution Solicitors, said: ”What stays with me is that these men went to prison for unpaid tax, not for the harm. The damage only surfaced because a patient sat in a dental chair.</p>



<p>‘That’s where you come in. You are often the first to see the burns, the sensitivity, the lost enamel. Record it carefully. Ask where the treatment came from. Report it to the GDC.</p>



<p>‘Illegal whitening thrives because no single agency sees the whole picture. Your chairside notes might be the piece that’s missing.’</p>



<h2 class="wp-block-heading">What should dental teams record?</h2>



<p>Dental professionals may be among the first people to identify injuries caused by products bought online or supplied by an unregistered whitening provider.</p>



<p>The General Dental Council requires dental professionals to maintain complete, accurate and contemporaneous patient records. Where a potentially unsafe whitening product is involved, useful information includes:</p>



<ul class="wp-block-list">
<li>The product and brand name</li>



<li>The batch or lot number, where available</li>



<li>The ingredients and peroxide concentration shown on the packaging</li>



<li>Where, when and from whom the patient obtained it</li>



<li>How frequently and for how long it was used</li>



<li>When the symptoms began</li>



<li>Clinical findings, photographs and the treatment provided</li>



<li>Advice given to the patient and any referral or follow-up arranged.</li>
</ul>



<p>Patients should be encouraged to retain the product, packaging, receipt and screenshots of the online listing.</p>



<p>Suspected unsafe consumer products can be reported through the <a href="https://www.gov.uk/guidance/consumer-products-reporting-product-safety-issues">Citizens Advice consumer service</a> in England and Wales, Advice Direct Scotland in Scotland or the relevant district council in Northern Ireland. Reports can be referred to Trading Standards and escalated to OPSS.</p>



<p><em><a href="https://sso.dentistry.co.uk/" target="_blank" rel="noreferrer noopener">Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</a></em></p>]]> </content:encoded>
</item>

<item>
<title>Independent buyers return to Scottish dental practice market</title>
<link>https://edusehat.com/en/independent-buyers-return-to-scottish-dental-practice-market</link>
<guid>https://edusehat.com/en/independent-buyers-return-to-scottish-dental-practice-market</guid>
<description><![CDATA[ Independent dentists are returning to Scotland’s dental practice acquisition market as larger corporate operators concentrate on their existing businesses, according to observations shared following the NASDAL Scotland Forum. Corporate groups had previously exercised considerable influence over the market, making it harder for independent purchasers to compete for practices. ‘The corporates ruled the roost and largely… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/nasdal.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 19:10:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Independent, buyers, return, Scottish, dental, practice, market</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Independent dentists are returning to Scotland’s dental practice acquisition market as larger corporate operators concentrate on their existing businesses, according to observations shared following the NASDAL Scotland Forum.</strong></p>



<p>Corporate groups had previously exercised considerable influence over the market, making it harder for independent purchasers to compete for practices.</p>



<p>‘The corporates ruled the roost and largely controlled the marketplace in Scotland for a number of years,’ one contributor told <em>Dentistry</em>.</p>



<p>However, they said some corporate operators were now directing greater attention towards their existing portfolios.</p>



<p>‘They’re looking inwards, trying to sort rather than outwards, trying to acquire.’</p>



<p>That change was said to have created more room for independent dentists, including younger buyers purchasing their first practice and existing owners acquiring second or third sites.</p>



<p>‘You can’t keep an entrepreneur down,’ the contributor added.</p>



<h2 class="wp-block-heading">Banks support independent buyers</h2>



<p>The shift has been supported by continued lender confidence in Scottish dentistry.</p>



<p>The forum heard that several banks were actively financing associate-to-principal transactions, creating competition between lenders and, in some cases, more generous terms for buyers.</p>



<p>One contributor said banks continued to view dental practices as comparatively low-risk businesses, despite wider economic uncertainty.</p>



<p>Access to finance was giving prospective owners confidence to pursue acquisitions. However, advisers warned that obtaining funding did not remove the need to examine the quality of the business, staffing pressures and the responsibilities attached to ownership.</p>



<h2 class="wp-block-heading">Opportunities from corporate disposals</h2>



<p>The forum also heard that practices released by corporate operators could create opportunities for independent buyers.</p>



<p>A practice that proved difficult to operate within a larger group could perform differently under an owner working within the business.</p>



<p>‘A ship always sails better when the captain’s on board,’ one participant said</p>



<h2 class="wp-block-heading">Buyers turn to AI for advice</h2>



<p>Advisers were also seeing a number of younger purchasers use artificial intelligence (AI) during the acquisition process.</p>



<p>Some buyers were reportedly uploading business or share purchase agreements to AI tools and using the resulting analysis to question their accountants and lawyers.</p>



<p>The contributor said this could help buyers engage with complex documents, but could also create expectations based on inaccurate or incomplete advice. AI systems may draw on legal material from England and Wales that does not apply in Scotland.</p>



<p><em><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</em></a></em></p>]]> </content:encoded>
</item>

<item>
<title>Bowmanville Hospital redevelopment moves forward with $861.4&#45;million contract</title>
<link>https://edusehat.com/en/bowmanville-hospital-redevelopment-moves-forward-with-8614-million-contract</link>
<guid>https://edusehat.com/en/bowmanville-hospital-redevelopment-moves-forward-with-8614-million-contract</guid>
<description><![CDATA[ Major expansion will more than double the hospital’s size, adding advanced critical care, dialysis services and modern patient facilities. An $861.4-million contract has been awarded for the redevelopment of Bowmanville Hospital, marking a major milestone in a project designed to expand healthcare capacity in one of Ontario’s growing communities. Lakeridge Health and Infrastructure Ontario have […]
The post Bowmanville Hospital redevelopment moves forward with $861.4-million contract appeared first on Hospital News. ]]></description>
<enclosure url="" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 18:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bowmanville, Hospital, redevelopment, moves, forward, with, 861.4-million, contract</media:keywords>
<content:encoded><![CDATA[<p>Major expansion will more than double the hospital’s size, adding advanced critical care, dialysis services and modern patient facilities.</p>
<p>An $861.4-million contract has been awarded for the redevelopment of Bowmanville Hospital, marking a major milestone in a project designed to expand healthcare capacity in one of Ontario’s growing communities.</p>
<p>Lakeridge Health and Infrastructure Ontario have selected PCL Partnerships to design, build and finance the redevelopment, which will more than double the size of the existing hospital.</p>
<p>The project will introduce expanded critical care services, new outpatient clinics, a haemodialysis centre, private patient rooms and a rooftop helipad.</p>
<p>Site preparation is expected to begin this fall, with major construction scheduled to start in early 2027. The project is targeted for completion in 2030.</p>
<p>Bowmanville Hospital will remain operational throughout construction.</p>
<div>
<div></div>
</div>
<h3>Expanding healthcare capacity in Durham Region</h3>
<p>The redevelopment is intended to address increasing demand for hospital services in Clarington and the broader Durham Region.</p>
<p>The expanded facility will feature modern patient-centred spaces and additional clinical capacity, allowing more residents to access specialized services closer to home.</p>
<p>One of the project’s most significant additions is Level 3 critical care capacity, providing advanced care for patients with life-threatening illnesses or injuries.</p>
<p>The hospital will also introduce a dedicated haemodialysis centre for patients with kidney disease, reducing the need for some residents to travel to other facilities for treatment.</p>
<p>New ambulatory care clinics will support patients who require diagnostic, treatment or follow-up services without an overnight hospital stay.</p>
<p>Additional features include private patient rooms, improved facilities for patients and families, and a rooftop helipad to support emergency medical transportation and patient transfers.</p>
<div>
<div></div>
</div>
<h3>Contract award clears the way for construction</h3>
<p>The $861.4-million fixed-price contract follows a competitive procurement process managed by Infrastructure Ontario and Lakeridge Health.</p>
<p>PCL Partnerships will be responsible for designing, building and financing the redevelopment under a design-build-finance model.</p>
<p>The project team includes PCL Investments Inc., PCL Constructors Canada Inc., Diamond and Schmitt Architects Incorporated and Cumulus Architects Inc., with TD Securities serving as financial advisor.</p>
<p>Under this procurement approach, design, construction and financing responsibilities are integrated into a single project agreement, an arrangement intended to improve coordination and provide greater cost and schedule certainty.</p>
<p>The contract also includes Buy Ontario provisions and is expected to create opportunities for local businesses, construction workers and skilled tradespeople.</p>
<div>
<div></div>
</div>
<h3>Supporting the region’s growing population</h3>
<p>The redevelopment forms part of Lakeridge Health’s broader strategy to strengthen hospital services across Durham Region.</p>
<p>With the region’s population projected to grow substantially over the coming decades, healthcare organizations face increasing pressure to expand infrastructure and deliver services closer to where patients live.</p>
<p>The Bowmanville project is intended to respond to that demand through a combination of additional capacity, modern clinical facilities and expanded specialized services.</p>
<p>Cynthia Davis, president and CEO of Lakeridge Health, described the contract award as a defining milestone for the hospital and the region’s healthcare system.</p>
<p>The hospital organization emphasized that the redevelopment is intended not simply to create a larger building, but to provide the facilities and services needed to support future generations.</p>
<h3>Hospital services to continue during construction</h3>
<p>PCL Partnerships is expected to begin mobilizing at the hospital site later this fall, ahead of major construction activities in 2027.</p>
<p>Lakeridge Health has confirmed that Bowmanville Hospital will continue providing patient care during the redevelopment.</p>
<p>Maintaining operations during construction will be an important consideration as work progresses, particularly for patients accessing emergency, inpatient and outpatient services.</p>
<p>The Bowmanville Hospital Foundation is also continuing its community fundraising campaign to support the local share of redevelopment costs and the purchase of equipment.</p>
<p>With the construction contract now awarded, the project moves from procurement into the next stage of delivery, bringing Durham Region closer to a substantially expanded hospital and a broader range of healthcare services.</p>
<p><a href="https://www.lh.ca/news-and-stories/posts/contract-awarded-for-the-bowmanville-hospital-redevelopment-project/?utm_source=chatgpt.com">Lakeridge Health — Contract Awarded for the Bowmanville Hospital Redevelopment Project (November 5, 2026)</a></p>
<p>The post <a href="https://www.hospitalnews.com/bowmanville-hospital-redevelopment-moves-forward-with-861-4-million-contract/">Bowmanville Hospital redevelopment moves forward with $861.4-million contract</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Responding to patient complaints: a practical guide</title>
<link>https://edusehat.com/en/responding-to-patient-complaints-a-practical-guide</link>
<guid>https://edusehat.com/en/responding-to-patient-complaints-a-practical-guide</guid>
<description><![CDATA[ Dr Paul Lambden outlines a calm, constructive approach to handling patient complaints, from early communication and record keeping to seeking indemnity advice. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/complaints.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 15:35:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Responding, patient, complaints:, practical, guide</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Paul Lambden, chairman of Densura Indemnity, outlines a constructive, practical approach to responding to patient complaints.</strong></p>



<p>Few professionals welcome a complaint, but a well-managed response can protect the patient relationship, support learning and reduce the risk of concerns escalating. The starting point is simple: ensure patients can easily find and understand your practice’s written complaints procedure.</p>



<h2 class="wp-block-heading">Why a constructive response matters</h2>



<p>Complaints can arise from clinical care, communication, access, fees, waiting times or a patient’s expectations not being met. However, a complaint is not necessarily an allegation of poor clinical treatment. It may instead show that a patient feels unheard, unclear about what has happened or disappointed by an aspect of service.</p>



<p>The GDC expects dental professionals to deal with complaints properly and professionally, respond within the time limits in their procedure and provide a constructive response. It also expects practices to use complaints to improve services and to keep a separate written record of complaints and responses.</p>



<p>Do not react defensively. Listen carefully, clarify what outcome the patient hopes for and involve them in the process. An early, respectful conversation may resolve misunderstandings before they become more difficult to manage.</p>



<h2 class="wp-block-heading">Use the C.L.E.A.R. approach</h2>



<p>Densura’s C.L.E.A.R. framework offers a useful structure for the first response:</p>



<ul class="wp-block-list">
<li><strong>Calm emotions</strong> – remain professional and allow the patient to explain their concern</li>



<li><strong>Listen actively</strong> – focus on the patient’s account without interrupting or making assumptions</li>



<li><strong>Empathise</strong> – acknowledge the impact the experience has had on the patient</li>



<li><strong>Apologise</strong> – where appropriate, offer a sincere apology without delay</li>



<li><strong>Resolve</strong> – explain the next steps, investigate fairly and offer a practical solution where possible.</li>
</ul>



<p>This is not a substitute for your practice procedure or professional advice. It is a way to keep the initial conversation calm, respectful and focused on what can be done next.</p>



<h2 class="wp-block-heading">Act promptly and seek advice early</h2>



<p>Acknowledge a complaint promptly, give the patient a copy of the complaints procedure and explain the anticipated timescale. If an investigation will take longer than expected, keep the patient updated. For NHS services in England, patients should expect an acknowledgement and the offer of a discussion about how their complaint will be handled within three working days.</p>



<p>Seek advice from your indemnity provider or defence organisation before sending a substantive response where there is a risk of a claim, a clinical incident, a request for records or a concern about regulatory action. Do not alter clinical records retrospectively. If a factual correction is needed, follow your practice’s record-keeping procedure and preserve a clear audit trail.</p>



<p>For NHS care in England, patients can complain directly to the provider or to the relevant commissioner; unresolved complaints may ultimately be considered by the Parliamentary and Health Service Ombudsman. Practices should make sure their information explains the appropriate independent options for the treatment provided.</p>



<h2 class="wp-block-heading">Keep a clear record and learn from concerns</h2>



<p>Keep a dated record of the concern, the people involved, communications, the investigation and the outcome. Store the complaints record separately from the patient record, while maintaining relevant contemporaneous clinical notes in the patient record.</p>



<p>Once a complaint is closed, consider what the practice can learn. A recurring concern about communication, consent, fees or access may point to a change in systems, training or patient information. Sharing lessons appropriately across the team can help prevent similar issues in future.</p>



<h3 class="wp-block-heading">References</h3>



<ul class="wp-block-list">
<li><a href="https://standards.gdc-uk.org/pages/principle5/principle5">General Dental Council: Principle 5 – Have a clear and effective complaints procedure</a></li>



<li><a href="https://www.england.nhs.uk/contact-us/feedback-and-complaints/complaint/">NHS England: Feedback and complaints about NHS services</a>.</li>
</ul>



<h3 class="wp-block-heading">Disclaimer</h3>



<p>This article provides general professional information. Follow your local procedure and seek appropriate professional or legal advice for a specific complaint.</p>



<p><em>This article is sponsored by Densura.</em></p>]]> </content:encoded>
</item>

<item>
<title>Zirconia surface activation with BASIC prebonder XS</title>
<link>https://edusehat.com/en/zirconia-surface-activation-with-basic-prebonder-xs</link>
<guid>https://edusehat.com/en/zirconia-surface-activation-with-basic-prebonder-xs</guid>
<description><![CDATA[ Renfert introduces the BASIC prebonder XS, a compact fine-sandblasting unit for zirconia surface activation before adhesive cementation. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/renfert-basic-prebonder-xs-feature.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 15:35:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Zirconia, surface, activation, with, BASIC, prebonder</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-full"></figure>



<p><strong>Renfert introduces the BASIC prebonder XS, a compact fine-sandblasting unit for zirconia surface activation before adhesive cementation.</strong></p>



<h2 class="wp-block-heading">Surface activation before adhesive cementation</h2>



<p>Modern zirconia materials offer a wider range of restorative options, including minimally invasive restorations and veneers. According to Renfert, these indications place greater demands on adhesive cementation, making reproducible surface activation an important part of the workflow.</p>



<p>The company says BASIC prebonder XS is designed specifically for zirconia surface activation before adhesive cementation. It is intended to standardise a process that can otherwise vary according to the user and the sandblasting parameters selected.</p>



<p>Renfert describes the unit as a dedicated alternative to universal sandblasting units, which are designed for a broader range of applications. The company’s approach is to bring the process parameters together in one system for this specific workflow.</p>



<h2 class="wp-block-heading">Three factors in one system</h2>



<p>Renfert identifies three factors that need to work together for standardised zirconia surface activation:</p>



<ul class="wp-block-list">
<li>Reproducible sandblasting energy</li>



<li>Specially developed nozzle geometry</li>



<li>An aluminium oxide sandblasting medium with defined material properties.</li>
</ul>



<p>Fine sandblasting with aluminium oxide creates the conditions for bonding with MDP-containing adhesive systems. Renfert says that working pressure, working distance, nozzle geometry and the sandblasting medium can each affect the result.</p>



<h2 class="wp-block-heading">Controlling pressure and distance</h2>



<p>The BASIC prebonder XS has a precision pressure gauge that can be adjusted within Renfert’s stated validated operating range of 0.6 to 1.0 bar. The recommended 0.8 bar setting is marked on the gauge, while the Prebonder control tip is designed to maintain a 10 mm working distance.</p>



<p>Renfert says these features are intended to give users greater control over the two parameters that determine sandblasting energy: pressure and distance. The unit is designed to support a repeatable surface-activation step before adhesive cementation.</p>



<h2 class="wp-block-heading">Nozzle, medium and process verification</h2>



<p>Renfert says the Prebonder jet nozzle is designed to produce a homogeneous sandblasting pattern. The company’s Prebonder surface pro aluminium oxide medium is presented as an integral part of the system, with specified particle size, geometry, hardness and purity.</p>



<p>The Prebonder control pad provides a quick check of system function. According to Renfert, it can help reveal potential issues such as pressure loss, a blocked nozzle or a low abrasive level.</p>



<h2 class="wp-block-heading">Fitting the workflow</h2>



<p>The compact unit is designed for use with an existing sandblasting chamber and extraction unit, or with a separate grinding box with extraction. Its 500 g tank is intended for Prebonder surface pro, which Renfert says is aligned with typical practice consumption levels.</p>



<p>For teams working with zirconia restorations, Renfert presents the BASIC prebonder XS as a way to make surface activation a more defined and controllable part of the adhesive workflow.</p>



<h3 class="wp-block-heading">Disclaimer</h3>



<p>Follow the manufacturer’s instructions for use and your own clinical and laboratory protocols when selecting and using equipment or materials.</p>



<p><em>This article is sponsored by Renfert.</em></p>]]> </content:encoded>
</item>

<item>
<title>Where DNA Copying Fails Can Decide How Cancer Cells Respond to PARP Inhibitors</title>
<link>https://edusehat.com/en/where-dna-copying-fails-can-decide-how-cancer-cells-respond-to-parp-inhibitors</link>
<guid>https://edusehat.com/en/where-dna-copying-fails-can-decide-how-cancer-cells-respond-to-parp-inhibitors</guid>
<description><![CDATA[ NYU Grossman School of Medicine researchers found that DNA-copying problems at a small set of chromosome sites can determine how cancer cells respond to PARP inhibitors, pointing to possible biomarkers of drug sensitivity. 
The post Where DNA Copying Fails Can Decide How Cancer Cells Respond to PARP Inhibitors appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2020/08/Aug3_2020_GettyImages_696241690_DNAandCanceCell-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 15:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Where, DNA, Copying, Fails, Can, Decide, How, Cancer, Cells, Respond, PARP, Inhibitors</media:keywords>
<content:encoded><![CDATA[<p>Not all DNA damage is equal. Every time a cell divides, it has to copy its DNA, and some stretches of the genome are harder to copy than others. Cancer cells depend on a protective response to get past those failures. A new study pinpoints where on chromosomes the problems arise and shows that blocking that response with PARP inhibitors lets damage build up at those sites, compromising the cancer cells’ survival.</p>
<p>The work, led by researchers at NYU Langone Health’s Perlmutter Cancer Center, was published in <em>Nature Cell Biology</em> under the title “<a href="https://www.nature.com/articles/s41556-026-02126-0" target="_blank" rel="noopener">Positional replication fork instability drives PARP inhibitor cytotoxicity</a>.” Eli Rothenberg, PhD, a professor of biochemistry and molecular pharmacology at NYU Grossman School of Medicine, and Dipika Gupta, PhD, a postdoctoral scholar in his lab, are co-corresponding authors.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The team began with CRISPR screens in breast and small cell lung cancer models. The screens flagged ESCO2, a protein that helps hold newly copied chromosomes together, as a strong determinant of sensitivity to PARP inhibitors. Even partial loss of ESCO2 increased sensitivity in colorectal, ovarian, and lung cancer cells. The ESCO2-depleted cells kept the tested homologous recombination response. That DNA repair pathway is impaired in the BRCA-mutated cancers for which PARP inhibitors are typically used.</p>
<p>To find out why the cells were sensitive, the researchers turned to quantitative single-molecule imaging, an ultrasensitive microscopy approach developed in Rothenberg’s laboratory. It let them distinguish subtypes of replication-associated damage sites that other methods cannot readily separate, according to Rothenberg. Reducing ESCO2 increased G-quadruplexes, or G4s, which are folded DNA structures that can obstruct copying. The increase was concentrated at a small subset of replication sites, particularly in repetitive pericentromeric regions next to centromeres.</p>
<p>“The imaging enabled us to move beyond measuring damage across an entire cell,” Gupta said. “We could detect subtle replication problems, distinguish the sites involved, and identify the protective response that the cells relied on.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>That response depended on PARP1 activity and involved two other proteins. TIMELESS helps protect DNA replication, and DDX11 is an enzyme that can unwind G4 structures. PARP inhibition disrupted the response in ESCO2-depleted cells. G4s built up further, DNA synthesis declined, and damage increased near centromeres, which helps explain the cells’ sensitivity to the drugs.</p>
<p>“We often think of DNA damage in terms of quantity: More damage means a greater chance of killing a cancer cell,” Rothenberg said. The findings point instead to location as a factor in treatment response.</p>
<p>The authors said the results provide a foundation for developing biomarkers of cancer drug sensitivity. They also raise the possibility that other DNA-damaging treatments work partly because they are more likely to hit these sensitive genomic sites. Whether that holds in other genetic contexts and with other treatments remains to be tested.</p>
<p>Rothenberg is working with clinicians to apply the imaging approaches to patient-derived cancer cells. The goal is to identify patterns of replication stress and DNA damage that could help predict who responds to treatment. The study was conducted in cancer cell models, so further preclinical and clinical research is needed to establish whether these features can guide treatment decisions.</p>
<p>“Our work reveals a genomic Achilles’ heel—a small subset of sites where replication problems can have disproportionately severe consequences. Identifying those sites helps explain what cancer cells depend on to survive and why a particular treatment can be so effective,” added Rothenberg.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/where-dna-copying-fails-can-decide-how-cancer-cells-respond-to-parp-inhibitors/">Where DNA Copying Fails Can Decide How Cancer Cells Respond to PARP Inhibitors</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Boehringer Ingelheim Inks Up&#45;to&#45;$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical</title>
<link>https://edusehat.com/en/boehringer-ingelheim-inks-up-to-74b-cancer-drug-collaboration-with-sino-biopharmaceutical</link>
<guid>https://edusehat.com/en/boehringer-ingelheim-inks-up-to-74b-cancer-drug-collaboration-with-sino-biopharmaceutical</guid>
<description><![CDATA[ The latest collaboration will encompass six biologic preclinical programs. Five programs focus on treatments originating with a wholly owned SBP Group subsidiary, LaNova Medicines. The sixth comes from another SBP Group subsidiary, Beijing Tide Pharmaceutical. 
The post Boehringer Ingelheim Inks Up-to-$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/03-0178_Boehringer_Workplace_Laboratory_Research_RGB.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 07:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Boehringer, Ingelheim, Inks, Up-to-7.4B, Cancer, Drug, Collaboration, with, Sino, Biopharmaceutical</media:keywords>
<content:encoded><![CDATA[<p>Boehringer Ingelheim has launched an up-to-$7.358 billion-plus second collaboration with Sino Biopharmaceutical (SBP Group) to develop next-generation cancer therapies based on antibody-drug conjugate (ADC) and T-cell engager (TcE) technologies.</p>
<p>The companies have signed a strategic multi-program option and license agreement designed to deepen their existing partnership in oncology, which encompasses three Boehringer-developed cancer treatments and was launched in 2024.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The latest collaboration will encompass six biologic preclinical programs. Five programs focus on treatments originating with a wholly owned SBP Group subsidiary, LaNova Medicines. The sixth comes from another SBP Group subsidiary, Beijing Tide Pharmaceutical.</p>
<p>The collaboration is intended to marry SBP Group’s platforms and early-development capabilities with Boehringer Ingelheim’s global oncology.</p>
<p>“Our partnership with SBP Group brings together complementary science to broaden our development portfolio of antibody-drug conjugates and T-cell engagers. It puts our China strategy into action by connecting innovation from China with our global research and development capabilities,” Paola Casarosa, Member of the Board of Managing Directors and Head of the Innovation Unit at Boehringer Ingelheim, said in a statement.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Under the agreement, SBP Group has agreed to oversee early development. After unspecified clinical milestones are reached, Boehringer Ingelheim may exercise options for exclusive development, manufacturing, and commercialization rights. Those rights may be exercised outside China, Hong Kong, and Macau for four of the programs, and worldwide for the remaining two.</p>
<p>Boehringer Ingelheim has agreed to pay SBP Group upfront and near-term payments totaling $358 million, and up to $7 billion tied to achieving option-exercise, development, regulatory, and commercial milestones of US$7 billion. Boehringer Ingelheim also agreed to pay SBP Group tiered royalties on potential future product sales.</p>
<p>Boehringer Ingelheim said the collaboration added to its efforts intended to build a broad and differentiated oncology portfolio spanning cancer cell-directed therapies and immuno-oncology. The companies reason that their latest partnership will offer opportunities to further the ADC and T-cell engager portfolio through multiple programs and technology approaches.</p>
<p>Investors sent SBP Group shares on the Hong Kong Stock Exchange rising 5% on the news, from HKD 4.885 (61 cents) to HKD 5.15 (65 cents). Boehringer Ingelheim is privately held.</p>
<h4><strong>Commitment to China</strong></h4>
<p>For Boehringer Ingelheim, the latest partnership with SBP Group underscores what it said was a strengthened commitment to China’s growing innovation ecosystem. In October, Boehringer Ingelheim <a href="https://english.shanghai.gov.cn/en-Latest-WhatsNew/20261015/f763213f079843ffa3d2e3c6c390596d.html" target="_blank" rel="noopener">opened its China R&D Center in Zhangjiang, Shanghai</a> designed to expand its early clinical development and external innovation capabilities by connecting its global R&D network with innovation in China.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Boehringer Ingelheim and China-based SBP Group launched their first cancer-focused collaboration in April 2024, when SBP agreed to develop three oncology drugs originating with the Germany-based Boehringer:</p>
<ul>
<li><strong>Brigimadlin (BI 907828)</strong>—A mouse double minute 2 (MDM2)-p53 antagonist whose development was halted by Boehringer Ingelheim in all indications last year after the drug failed the 400-patient Phase II/III Brightline-1 trial (<a href="https://clinicaltrials.gov/study/NCT05218499" target="_blank" rel="noopener">NCT05218499</a>). Brigimadlin missed its primary endpoint of progression-free survival (PFS) in the trial, which compared the drug to doxorubicin in dedifferentiated liposarcoma.</li>
<li><strong>Obrixtamig (BI 764532)</strong>—A delta-like canonical Notch ligand 3/cluster of differentiation 3 (DLL3/CD3) bispecific T-cell engager. Obrixtamig is under study in the Phase II DAREON<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">-5 trial (<a href="https://clinicaltrials.gov/study/NCT05882058" target="_blank" rel="noopener">NCT05882058</a>), a dose selection and expansion trial designed to assess the drug in relapsed/refractory small cell lung cancer (SCLC), extrapulmonary neuroendocrine carcinoma (epNEC), and large cell neuroendocrine carcinoma of the lung (LCNEC-L). Last month at the European Society for Medical Oncology (ESMO) Congress in Madrid, Boehringer Ingelheim shared positive data from the Phase Ib DAREON<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">-9 trial (<a href="https://clinicaltrials.gov/study/NCT05990738" target="_blank" rel="noopener">NCT05990738</a>) evaluating obrixtamig plus chemo drug topotecan in adults with extensive stage small cell lung cancer.</li>
</ul>
<ul>
<li><strong>Zongertinib</strong>—A selective human epidermal growth factor receptor 2 (HER2) inhibitor that covalently binds to the tyrosine kinase domain (TKD) of both wild type and mutated HER2 receptors, including those with an exon 20 mutation. Boehringer reasons that improved selectivity of a HER2 tyrosine kinase inhibitor (TKI) may yield improved tolerability and efficacy. Zongertinib is under study in the Phase III Beamion LUNG-3 trial (<a href="https://clinicaltrials.gov/study/NCT07195695" target="_blank" rel="noopener">NCT07195695</a>) comparing the drug to standard adjuvant treatment in adults with completely resected Stage II-IIIB NSCLC whose tumors have activating HER2 tyrosine kinase domain (TKD) mutations.</li>
</ul>
<p>“Our second partnership with Boehringer Ingelheim marks an important milestone in SBP Group’s international innovation strategy and further validates our scientific capabilities in next-generation oncology,” stated Theresa Tse, Chairwoman of SBP Group. “By combining our innovative platforms and early-development capabilities with Boehringer Ingelheim’s global oncology expertise, we aim to maximize the potential of these programs and bring innovative treatment options to patients worldwide.”</p>
<p>“We will continue to expand our global partner network and contribute high-quality innovation from China to global healthcare,” Tse added.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/boehringer-ingelheim-inks-up-to-7-4b-cancer-drug-collaboration-with-sino-biopharmaceutical/">Boehringer Ingelheim Inks Up-to-$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Patient Advocacy Coffee Chat: Basic steps to being a good advocate</title>
<link>https://edusehat.com/en/patient-advocacy-coffee-chat-basic-steps-to-being-a-good-advocate</link>
<guid>https://edusehat.com/en/patient-advocacy-coffee-chat-basic-steps-to-being-a-good-advocate</guid>
<description><![CDATA[ “What does good advocacy look like? Why do we advocate? And what are some tips and tricks for effective advocacy?” asked Karin Hoelzer, Senior […]
The post Patient Advocacy Coffee Chat: Basic steps to being a good advocate appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/BIO_CoffeeChat_10_2026b.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Patient, Advocacy, Coffee, Chat:, Basic, steps, being, good, advocate</media:keywords>
<content:encoded><![CDATA[<p><span>“What does good advocacy look like? Why do we advocate? And what are some tips and tricks for effective advocacy?” asked Karin Hoelzer, Senior Director of Patient Advocacy at the Biotechnology Innovation Organization (BIO). </span></p>
<p><span>Her questions kicked off BIO’s October Coffee Chat, Advocacy in Action, which welcomed patient advocates from across the healthcare community. While BIO’s Coffee Chats are a monthly occurrence, this month’s chat buttressed BIO’s </span><a href="https://pace.bio.org/"><span>Patient Advocacy Changemakers Event (PACE)</span></a><span>, which took place on October 22 and 23 in Washington, DC. </span></p>
<p><span>The event brought together patient advocates from across the country and across therapeutic areas, providing a forum to share insights, exchange information, and make new connections in the pursuit of better access to and affordability of therapies for patients.</span></p>
<h3>What makes an effective patient advocate?</h3>
<p><span>Every advocate’s story is different. Every advocate comes to patient advocacy with a unique drive behind why they do what they do—some coming from the patient perspective, some from the caregiver perspective, some from a community health perspective. Yet, not matter the background or policy issue at hand, advocacy is empowering—one of the many things effective advocates have in common. </span></p>
<p><span>“Advocacy is an opportunity we have in our country we all need to take advantage of and help folks develop those skills not only in our own community but in other communities because it really does matter,” said Jenny Luray, Senior Vice President of Strategy and Public Engagement, Research!America, “So many Americans think that they don’t have as much power as they do.”</span></p>
<p><span>Amanda Krzepicki, MPH, Policy Director at the Autoimmune Association, agreed. She found her start as an AmeriCorps Community Health Corps member at a federally qualified health center just across the river in Alexandria. </span></p>
<p><span>“While I was there, I saw the stark inequities that impact this region, as well as across the country, and how people rely on community health centers and what a robust resource they are for communities,” she recalled. “So that really made me want to jump into the state policy space.” </span></p>
<p><span>And that motivation has remained a driving force for Krzepicki. “Watching that shift in lawmakers when they realize someone is so passionate about an issue has always been, I think, really fulfilling, and even more so watching bills get introduced because of it.”</span></p>
<p><span>Advocacy provides agency and the power to change the </span><i><span>status quo</span></i><span>. </span></p>
<p><span>“I think it’s so important to be able to tie real patient stories to topics that can be quite complex at times. An area that I have worked on for quite some time is patient access, especially the issue of copay accumulators, copay maximizers, and alternative funding programs, and that certainly is a slow and drawn-out process,” said Brian DuVal, MPH, Director of Patient Advocacy at BIO. “But there have been wins, especially at the state level, and I’ve been pleased to have been part of some of those. So, in general, being able to bring patients together to help demystify some of these complex issues has been very fulfilling.”</span></p>
<p><span>But, breaking such complex issues down and demystifying health policy in ways that are compelling to decisionmakers is not always easy. So how are DuVal, Krzepicki, and Luray training the new class of patient advocates? And what have been some of the biggest lessons learned while working on the Hill?</span></p>
<h3>Paying it forward: Training the new class of patient advocates</h3>
<p><span>Having a hands-on approach to bill making, Krzepicki said, has been one of the most effective motivators for new advocates. </span></p>
<p><span>“Watching a patient react to a bill getting introduced, an office agreeing to get a co-sponsorship on, and the feeling of hope that it elicits is very impactful. I think sometimes we can become quite jaded,” Krzepicki said, “but watching the patients experience success and feel so hopeful can remind us all to be hopeful, and then we ultimately get the result.”</span></p>
<p><span>And patient advocates have been able to advance key legislation to improve patient access. But not every win results in a bill passing the House and Senate—or even just getting introduced. And not every step needs to be made at the federal level.</span></p>
<p><span>“The small wins definitely count,” reminded DuVal. “Keeping advocates motivated between these really big legislative pushes, especially when things may feel slow at times, it is very important to celebrate the small wins and also really understand all the different forms that advocacy can take.”</span></p>
<p><span>Many issues at play today—prescription drug affordability boards, vaccine access and more—are happening at the state level, making advocacy more of a two-hander than a straightforward process. </span></p>
<p><span>Luray echoed her position, saying: “I’d like to see more patient advocacy groups in districts because that’s where you’re most likely to get more of the members’ attention. Forming events with a local healthcare provider, the Lions Club or women’s organizations, whatever works in terms of your disease area, creating those opportunities, all of it is really important. When that member meets you on the ground, they don’t forget it.”</span></p>
<h3>United front: Hill days and fly-ins</h3>
<p><span>Another element of patient advocacy that the speakers discussed was Hill days and fly-ins, which can help policymakers see just how big an issue is through the sheer number of advocates that are at their door. </span></p>
<p><span>And in today’s world, that can happen both physically and virtually, increasing both access and affordability in the very functioning of advocacy itself. </span></p>
<p><span>“We have done a virtual fly-in in the past,” Krzepicki said. “If you have advocates spread out across the country, and you’re maybe a smaller organization, the cost to do a virtual fly-in is much more reasonable than bringing people out and accommodating travel.” Though in-person is still best practice, Krzepicki said. </span></p>
<p><span>“When I was in the consulting space, it was incredible to bring patients to the Hill and to tell their stories, to connect with lawmakers, and I think even more importantly, to connect with staffers,” Krzepicki said. “People are often quite focused on the lawmaker, but a lot of the time, if you can relate to the staff and they have a personal tie, they can use their personal connection with the lawmaker to also sway an issue area.”</span></p>
<p><span>This focus on Hill staffers was echoed throughout the panel, especially considering the fact that staffers often long outlast the legislators themselves. So the trick, the panelists explained, was to be a resource to these staffers even outside of your policy focus. </span></p>
<p><span>“When I was on the Hill, the advocates that I relied on were those that always came in with a lot of information,” Luray recalled. “I never felt they were like gaslighting me, and they were willing to answer questions and be a resource on things that might not be on their top list, but they were able to be helpful.”</span></p>
<h3>Information: An advocate’s greatest asset</h3>
<p><span>Advocates and volunteers have to stay informed, both about which legislators have strong ties and interests in which issues, as well as about the policy issue itself, and adjacent policy concerns—which is a never-ending process, in particular in today’s environment where so many patient access issues are interconnected. </span></p>
<p><span>“It’s keeping advocates really informed and giving them information along the way so they’re learning as time goes on, and developing expertise,” Luray said. “I think it’s very satisfying to people as they get more experienced and comfortable with advocacy than they were maybe three years ago. But it’s a constant effort. You constantly have to be in touch with people.”</span></p>
<p><span>That is even more important this year with the midterms on the horizon. The congressional landscape is changing, and advocates need to be ready. </span></p>
<p><span>“As the new Congress comes in, there’s going to be a lot of new staff,” Krzepicki said. “So I do think at the beginning of next year we’ll be doing a little bit of education around our issue areas and things like that.”</span></p>
<p><span>One way that advocates can prepare themselves is to come to BIO’s monthly coffee chats, where they can talk about the healthcare policies that are impacting patients the most and connect with fellow advocates to learn and plan for future work. </span></p>
<p>The post <a href="https://bio.news/latest-news/patient-advocacy-coffee-chat-basic-steps-to-being-a-good-advocate/">Patient Advocacy Coffee Chat: Basic steps to being a good advocate</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BIO responds to Health Affairs Analysis, highlighting the importance of orphan drug incentives</title>
<link>https://edusehat.com/en/bio-responds-to-health-affairs-analysis-highlighting-the-importance-of-orphan-drug-incentives</link>
<guid>https://edusehat.com/en/bio-responds-to-health-affairs-analysis-highlighting-the-importance-of-orphan-drug-incentives</guid>
<description><![CDATA[ Orphan drug development is one of the more fraught undertakings in biomedical research. Targeting rare diseases often requires cutting-edge science, but science is not […]
The post BIO responds to Health Affairs Analysis, highlighting the importance of orphan drug incentives appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2023/07/sangharsh-lohakare-Iy7QyzOs1bo-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:25:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BIO, responds, Health, Affairs, Analysis, highlighting, the, importance, orphan, drug, incentives</media:keywords>
<content:encoded><![CDATA[<p>Orphan drug development is one of the more fraught undertakings in biomedical research. Targeting rare diseases often requires cutting-edge science, but science is not always enough. The economics of treating small populations can make it difficult to secure the financial support needed to make it through clinical trials and onto the market.</p>
<p>To ensure that promising ideas aren’t abandoned in the face of those challenges, Congress has provided a number of incentives for orphan drug development, including provisions that exempt orphan drugs from government price controls under the Inflation Reduction Act.</p>
<p>But those incentives often come under attack. Recently, <a href="https://www.healthaffairs.org/doi/10.1377/hlthaff.2026.00209">a Health Affairs article</a> suggested that the IRA-related protections weren’t needed, given that some orphan medicines are commercially successful.</p>
<p>That analysis, however, is built on the flawed premise that just because a sliver of orphan drugs earn back development costs, orphan medicines, as a class, don’t face unique and daunting obstacles throughout the R&D process.</p>
<p>BIO believes that kind of thinking is wrongheaded, and <a href="https://www.healthaffairs.org/doi/10.1377/hlthaff.2026.01330">Health Affairs this month published a rebuttal</a> from BIO’s Vice President of Healthcare Policy & Research, Crystal Kuntz.</p>
<p>BIO argued that orphan drugs carry unique scientific challenges, uncertainties in development, and commercial obstacles that would discourage innovation without additional supports.</p>
<p>“Incentives to develop orphan drugs have been critical in encouraging research, and eroding such policies risks starving some of the best ideas in medicine of resources at the exact wrong time for patients waiting to benefit from today’s groundbreaking science,” Kuntz wrote.</p>
<p>BIO noted that the existence of these incentives has led to a “golden age” in orphan drug development, but that much work remains to be done. Thousands of rare diseases still lack a treatment, an indication of the need to not roll back the very policies that are making an impact.</p>
<p>The post <a href="https://bio.news/bios-view/bio-responds-to-health-affairs-analysis-highlighting-the-importance-of-orphan-drug-incentives/">BIO responds to Health Affairs Analysis, highlighting the importance of orphan drug incentives</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Modernizing the Western Blot for the 21st Century: More Than Just Automation</title>
<link>https://edusehat.com/en/modernizing-the-western-blot-for-the-21st-century-more-than-just-automation</link>
<guid>https://edusehat.com/en/modernizing-the-western-blot-for-the-21st-century-more-than-just-automation</guid>
<description><![CDATA[ Traditional Western blotting can confirm whether a protein is present, but it is often treated as semi-quantitative. It can be difficult to determine how much protein is present, compare results across experiments, or distinguish a true biological difference from technical errors. The case for automation becomes stronger when paired with performance data.
The post Modernizing the Western Blot for the 21st Century: More Than Just Automation appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-Western-Blotting-with-Antibodies.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:15 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Modernizing, the, Western, Blot, for, the, 21st, Century:, More, Than, Just, Automation</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="https://www.rndsystems.com/" target="_blank" rel="noopener"><img loading="lazy" decoding="async" class="alignnone wp-image-338704 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/09/RnD-Systems_primary-logo_color-1-002-300x111.jpg" alt="R&D Systems logo" width="300" height="111" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/RnD-Systems_primary-logo_color-1-002-300x111.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/RnD-Systems_primary-logo_color-1-002.jpg 755w" sizes="auto, (max-width: 300px) 100vw, 300px"></a></p>
<p>In the 1980s, Western blotting was revolutionary. For the first time, scientists could identify a protein of interest within a complex sample with a high degree of certainty. Decades later, the technique remains a cornerstone of protein analysis. But like most technologies, both inside and outside the lab, it is not without limitations. What once felt fit for purpose now has to keep up with the demands of 21st-century biopharma: vast sample sets, aggressive competition, and, most importantly, the ticking clock for individuals waiting for life-saving therapies.</p>
<p>Traditional Western blotting can confirm whether a protein is present, but it is often treated as semi-quantitative. It can be difficult to determine how much protein is present, compare results across experiments, or distinguish a true biological difference from technical errors. The predominantly manual process also makes user-to-user variability difficult to avoid. As a result, time that could be spent moving a program forward is often spent repeating experiments, troubleshooting, or adding orthogonal techniques to gain confidence in the result.</p>
<p><figure aria-describedby="caption-attachment-340263" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-340263" src="https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-Western-Blotting-with-Antibodies-1024x731.jpg" alt="Western Blotting with Antibodies" width="696" height="497" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-Western-Blotting-with-Antibodies-1024x731.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-Western-Blotting-with-Antibodies-300x214.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-Western-Blotting-with-Antibodies-768x549.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-Western-Blotting-with-Antibodies.jpg 1400w" sizes="auto, (max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">Credit: Bio-Techne</figcaption></figure></p>
<p>That delay matters. Therapeutic efficacy, time to market, and a manufacturer’s reputation are all influenced by one common factor: data quality. In another era, prolonged timelines may have been expected and even accounted for. Today, laboratories across the globe are investing in instrumentation that accelerates development pipelines while improving the quality of the data used to make decisions. The data should speak for itself: either the sample is good to go or it is not.</p>
<p>Evolution is natural for almost all forms of technology, and the Western blot is no exception. In the early 2010s, Simple Western<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> technology entered the fray, bringing automation to many steps of the Western blot workflow that otherwise introduce variability. Simple Western, as the name suggests, simplifies the Western blot. The underlying principle remains familiar: proteins are separated and then probed using target-specific antibodies. The difference is that protein separation, immunodetection, and analysis occur in an automated, capillary-based system. The workflow reduces manual intervention and condenses a process that can take at least six hours, and sometimes days, into an approximately three-hour run with minimal hands-on time.</p>
<p>The case for automation becomes stronger when paired with performance data. In one internal reproducibility study, four users ran the same ERK1 Simple Western assay on separate days using HeLa lysates. Across all ERK1 data points collected over four days, the coefficient of variation was below 10%, illustrating how an automated workflow can support consistency across users and experiments<sup>1</sup>.</p>
<p><figure aria-describedby="caption-attachment-340262" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-340262 size-large" src="https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-GEN-Article_SW_Figure_1_hz-updated-1024x426.jpg" alt="" width="1024" height="426" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-GEN-Article_SW_Figure_1_hz-updated-1024x426.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-GEN-Article_SW_Figure_1_hz-updated-300x125.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-GEN-Article_SW_Figure_1_hz-updated-768x320.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-GEN-Article_SW_Figure_1_hz-updated.jpg 1400w" sizes="auto, (max-width: 1024px) 100vw, 1024px"><figcaption class="wp-caption-text">Figure 1: Dystrophin protein expression was assessed using two different methods: traditional Western blot (A) and Simple Western (B). In the traditional Western blot analysis, 20 μg of protein was loaded per sample lane. For the Simple Western analysis, 1.25 μg of protein was loaded per sample lane for DMD samples and 0.25 μg for healthy controls. [Bio-Techne]</figcaption></figure></p>
<p>Sensitivity is another practical advantage, particularly when sample is limited or the target is low abundance. In a comparison using HEK293 lysates, Simple Western detected GSK3α over more than four logs of dynamic range, while traditional chemiluminescent Western blotting covered approximately 2.5 logs. A dystrophin analysis in Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) samples further showed why this matters: traditional Western blotting used 20 μg of protein per lane, whereas Simple Western analysis used 1.25 μg for DMD samples and 0.25 μg for healthy controls while still supporting clearer measurement of dystrophin expression (<em>Figure 1</em>).</p>
<p>These are just a handful of examples that demonstrate the significant shifts that Simple Western brings to protein analysis. None of this means that traditional Western blotting no longer has value. Its principles remain sound, and its familiarity is part of its staying power. But the demands of contemporary research and development have changed. When decisions depend on speed, reproducibility, sensitivity, and quantitative confidence, a manual workflow can become the bottleneck. Simple Western does not abandon what made Western blotting useful. It brings the technique into a format better suited to the pace and expectations of modern biopharma.</p>
<p> </p>
<p><em><img loading="lazy" decoding="async" class="alignleft wp-image-340264 size-thumbnail" src="https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems_QRCode-150x150.jpg" alt="R&D Bio-Techne Sponsored Content QR Code" width="150" height="150" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems_QRCode-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems_QRCode.jpg 298w" sizes="auto, (max-width: 150px) 100vw, 150px"></em></p>
<p> </p>
<p><em>Learn More r<a href="https://www.rndsystems.com/instruments/simple-western" target="_blank" rel="noopener">ndsystems.com/simplewestern</a>.</em></p>
<p>The post <a href="https://www.genengnews.com/sponsored/modernizing-the-western-blot-for-the-21st-century-more-than-just-automation/">Modernizing the Western Blot for the 21st Century: More Than Just Automation</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>What Biotech Licensing Really Buys</title>
<link>https://edusehat.com/en/what-biotech-licensing-really-buys</link>
<guid>https://edusehat.com/en/what-biotech-licensing-really-buys</guid>
<description><![CDATA[ In this Point of View Sun Chau Siu, PhD, and Kaisong Zhou, PhD, give insights on the hidden challenges of transferring intellectual property.
The post What Biotech Licensing Really Buys appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Hero-Image-2.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>What, Biotech, Licensing, Really, Buys</media:keywords>
<content:encoded><![CDATA[<p><figure aria-describedby="caption-attachment-340279" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-340279" src="https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Dr.-Sun-Chau-Siu-e1793893626383-300x300.jpg" alt="Sun Chau Siu" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Dr.-Sun-Chau-Siu-e1793893626383-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Dr.-Sun-Chau-Siu-e1793893626383-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Dr.-Sun-Chau-Siu-e1793893626383-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Dr.-Sun-Chau-Siu-e1793893626383-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Dr.-Sun-Chau-Siu-e1793893626383.jpg 1045w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Sun Chau Siu, PhD <br>Executive Director,<br>Head of Regulatory Affairs<br>and Project Management<br>Altruist Biologics</figcaption></figure></p>
<p>Biotech licensing is often framed as a transaction around intellectual property. The molecule still comes first: if the biology is weak, the target is undifferentiated, or the clinical rationale is unconvincing, no amount of technical discipline will rescue the program.</p>
<p>What it tends to underestimate is a related question: once the rights change hands, how much of an asset’s apparent value will survive not only clinical development but the transfer itself? In biologics, the asset is never just the molecule. It also includes the development system built around it: cell line history, process development logic, analytical methods, comparability strategy, manufacturing experience, documentation discipline, and the technical judgment accumulated over time. A licensing agreement can specify rights to those assets and the obligations surrounding their transfer. It cannot guarantee that the development system behind it will remain reproducible when another organization takes over. Yet licensing diligence does not always treat the transferability of that development system as a distinct attribute of the asset being acquired.</p>
<p>At signing, a biologics asset can appear meaningfully de-risked. The target may be compelling, the early package persuasive, and the market opportunity attractive. Even so, the asset can carry technical liabilities that emerge only when transfer, scale-up, validation, or regulatory review exposes the gap between a promising molecule and a reproducible development system.</p>
<p><figure aria-describedby="caption-attachment-340276" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340276" src="https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Portrait-Kaisong-Zhou-e1793893794694-300x300.jpg" alt="Kaisong Zhou" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Portrait-Kaisong-Zhou-e1793893794694-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Portrait-Kaisong-Zhou-e1793893794694-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Portrait-Kaisong-Zhou-e1793893794694-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Portrait-Kaisong-Zhou-e1793893794694-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Portrait-Kaisong-Zhou-e1793893794694.jpg 1225w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Kaisong Zhou, PhD<br>Chairman and CEO<br>Altruist Biologic</figcaption></figure></p>
<p>Those liabilities rarely present themselves as a single obvious flaw. More often, they emerge in forms that are easy to dismiss during the optimism of dealmaking. Consider a potency assay that performs consistently in the originating laboratory. The method transfers on paper, the procedure is followed, and the initial results appear acceptable. Months later, however, differences in reference standards, laboratory conditions, or system suitability behavior begin to create unexplained variability. What looked like an analytical transfer becomes a development problem because the originating team’s tacit understanding of the assay never truly transferred. A comparability strategy may exist on paper, but not at the level required once process changes begin to accumulate. A program can transfer successfully at pilot scale and still require substantial redevelopment before Process Performance Qualification (PPQ) or commercial readiness because the development rationale was never designed to travel.</p>
<p>That is why these issues are dangerous. Scientific risk can reveal itself at multiple stages, including in the clinic. Transfer risk often does not. It can remain buried until another organization has to reproduce the process, defend the analytics, explain the development history, and carry the program forward under different operating conditions.</p>
<p>What makes this dynamic harder to manage is a structural incentive problem. After signing, organizational incentives can make transfer problems surprisingly easy to defer. The seller has closed the deal, while the technical teams on both sides may still be working through how knowledge, responsibilities, and decisions will transfer. Problems that might be correctable early can instead compound quietly, becoming harder and more expensive to address by the time they are visible. In practice, transfer risk begins as soon as the transaction is signed.</p>
<p>This is why the language of licensing can be misleading in biologics. Intellectual property can be assigned precisely, but process knowledge, development judgment, and technical context do not transfer as neatly. A contract can define rights, territories, and economics, but it cannot guarantee that tacit knowledge reflected in assay behavior, deviation history, control strategy logic, and the many small decisions behind them will be understood and reproduced by the receiving organization.</p>
<p>The industry’s response to transfer failures can sometimes focus too heavily on additional documentation. Documentation is not the same as understanding. In many biologics programs, the critical knowledge that determines whether a process is reproducible is held by a small number of people: the scientist who characterized the founding cell line, the process development lead who resolved the early instability, the analyst who knows why the potency assay behaves differently after a weekend shutdown. That knowledge is rarely captured in a batch record. When those individuals are engaged in the transfer, problems can surface earlier. When the transfer relies heavily on documentation alone, they may be hidden until much later, often when they are more difficult and expensive to address. The critical question is therefore not how much documentation exists, but how much of the knowledge required to interpret that documentation can actually travel. Some biologics programs are reproducible in the hands of the originating team without being equally transferable to a new organization. They are reproducible performances, held together in part by the people who run them. Licensing moves the rights. It does not move the cast.</p>
<p>The deeper issue is structural. The industry has sophisticated tools for evaluating scientific risk: target biology, mechanism of action, probability of clinical success, and competitive differentiation. Chemistry, Manufacturing, and Controls (CMC) diligence can assess regulatory compliance, batch history, manufacturing experience, process understanding, and analytical readiness. The gap is that these assessments do not necessarily answer a distinct licensing question: whether the underlying development rationale can be reproduced by a new organization.</p>
<p>That is why transfer-readiness should be treated as a distinct diligence dimension, alongside scientific, commercial, and regulatory assessment. The key question is not only whether an asset is scientifically attractive, but whether another organization can inherit it without materially relearning it. Four questions provide a practical test: Is the process sufficiently understood, rather than merely functional? Are the analytical methods reproducible across laboratories, rather than demonstrated only within a single one? Can the comparability strategy withstand expected process evolution? And does critical institutional knowledge live in the system, or primarily in the people who built it? In practice, these questions should be part of technical diligence before a deal is signed, because what appears to be a manageable transfer issue can become a material driver of cost, timeline, and post-deal execution.</p>
<p>Not every transaction is built on a fully mature development system; some deals are option bets, acceleration strategies, or pipeline-replenishment moves. But those motives do not change the nature of the risk. A buyer is not only acquiring scientific potential, but also inheriting the consequences of how that potential was developed.</p>
<p>This becomes even more consequential for complex modalities such as antibody-drug conjugates (ADCs), where development depends on tightly linked knowledge across the antibody, linker and payload, conjugation process, analytical methods, raw materials, and multiple internal or external suppliers. A transfer may therefore require reconstructing a network of technical relationships and control strategies, not simply reproducing a process.</p>
<p>Transfer-readiness should not be confused with development maturity. An early-stage asset can be intentionally immature yet highly transferable if its critical knowledge, assumptions, and decision logic are well understood and captured. Conversely, a more advanced asset can carry significant transfer risk if too much development knowledge remains tacit or organization-specific.</p>
<p>That distinction has economic consequences. An asset requiring substantial process redevelopment, analytical remediation, or knowledge reconstruction after licensing may still be attractive to acquire, but its timeline, resourcing requirements, and risk profile are different from those of an asset that can be transferred with minimal relearning. Transfer-readiness therefore has implications not only for technical execution, but for how an asset is valued, resourced, and integrated after the deal.</p>
<p>Biotech licensing starts with differentiated molecules. But in biologics, value is not created by discovery alone. The question is whether the knowledge system that made the asset valuable can move with it.</p>
<p> </p>
<p><em>Sun Chau Siu, PhD, is executive director, head of regulatory affairs and project management at Altruist Biologics. Kaisong Zhou, PhD, is chairman and CEO, Altruist Biologics (an Innovent CDMO).</em></p>
<p>The post <a href="https://www.genengnews.com/insights/what-biotech-licensing-really-buys/">What Biotech Licensing Really Buys</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Revealing the Chemistry Around Us Through Mass Spectrometry</title>
<link>https://edusehat.com/en/revealing-the-chemistry-around-us-through-mass-spectrometry</link>
<guid>https://edusehat.com/en/revealing-the-chemistry-around-us-through-mass-spectrometry</guid>
<description><![CDATA[ Mass spectrometry-based exposomics could be a powerful approach to measuring and understanding environmental impact on health.
The post Revealing the Chemistry Around Us Through Mass Spectrometry appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/GEN_NOV_2026_GettyImages-1390096829.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Revealing, the, Chemistry, Around, Through, Mass, Spectrometry</media:keywords>
<content:encoded><![CDATA[<p><figure aria-describedby="caption-attachment-340303" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340303" src="https://www.genengnews.com/wp-content/uploads/2026/11/TL-Bruker-Dr.-Matthew-Lewis-headshot-e1793898683528-300x300.jpg" alt="Matthew Lewis" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/TL-Bruker-Dr.-Matthew-Lewis-headshot-e1793898683528-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/TL-Bruker-Dr.-Matthew-Lewis-headshot-e1793898683528-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/TL-Bruker-Dr.-Matthew-Lewis-headshot-e1793898683528-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/TL-Bruker-Dr.-Matthew-Lewis-headshot-e1793898683528-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/TL-Bruker-Dr.-Matthew-Lewis-headshot-e1793898683528.jpg 1170w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Matthew Lewis, PhD<br>Vice President of Metabolomics and Lipidomics<br>Bruker Daltonics</figcaption></figure></p>
<p>Health is increasingly viewed through the lens of family history and genetics, nutrition and fitness, and, for many, medications and treatments for various conditions. However, public perception is waking up to another factor: the chemistry of our environment.</p>
<p>From air quality and drinking water to clothing and cookware, there is growing skepticism surrounding the multitude of synthetic materials that coat and comprise our environment. This realization that the world around us has an impact on our growth, development, and well-being follows a century of industrial expansion in which the chemistry of the world changed far faster than the means to measure or understand its impacts. A scientific field concerned with this frontier of research has been quietly maturing for twenty years. It is called exposomics.</p>
<p>Exposomics, a modern omics approach to understanding environmental impact, is still an emerging science, but it is already changing how we think about the relationship between the environment and our health. This article explores how researchers can now study the chemistry of the world around us and the body’s response to it with unprecedented breadth, increasingly bringing both into a common analytical framework. The growing attention to the chemistry around us is well founded. It is also now matched by the means to investigate it.</p>
<h4><strong>What is the exposome?</strong></h4>
<p>The exposome as a term was introduced in 2005 as a deliberate complement to the genome. It refers to external factors that have an impact on an organism’s biology (in our case, on human health). Across a person’s lifetime, these will include environmental, lifestyle, occupational, dietary, biological and social influences, each capable of imparting (alone or together via complex interactions) measurable molecular signatures and provoking equally measurable biological responses. Exposomics is the science of measuring it and its impacts.</p>
<p>Today, scientists are gaining a clearer understanding of how much the exposome matters. Working with UK Biobank data, researchers compared what genetic risk scores and environmental exposures each contribute to ageing and early death. Set against age and sex alone, polygenic risk scores across 22 major diseases added less than two percentage points to the explained variation in mortality. The exposome added seventeen.<sup>1 </sup>The two are not rivals, however. Inherited risk still explained more for dementias and for breast, prostate, and colorectal cancers, while environment explained more for diseases of the lung, heart, and liver.<sup>1</sup> The difference is that while genomics is a mature science, exposomics remains emergent, operating across a much broader chemical landscape.</p>
<h4><strong>Technology for exposomics research</strong></h4>
<p>For most of the twentieth century, environmental health science was concerned with identifying potential health concerns, testing them, and regulating them if needed, one at a time. This approach shaped our view on the dangers of lead, asbestos, and tobacco, slowly over decades. However, exposures are not always singular concerns. The chemical world around us is complex, with a stunning diversity of components interacting with biology and each other in ways that isolated testing cannot capture or represent. Even modern environmental monitoring only concentrates on a short list of regulated pollutants, despite inhalation exposure spanning thousands of organic compounds, numerous inorganic substances, and a large biological component.<sup>2</sup> Exposomics takes a different approach. As a modern “omics” science, it measures molecular signals broadly rather than selectively (both the exposures themselves and the body’s biochemical responses) and relies on data-driven statistical analysis to find the patterns that matter.</p>
<p>Here, high-resolution mass spectrometry is a key enabling technology. It separates and detects molecules according to their mass with enough precision and selectivity to distinguish compounds that differ only slightly and, critically, without being told in advance what to look for. And importantly, the same technology is as applicable to studying the chemistry of living systems (e.g. biofluids and tissues) as it is to environmental samples (e.g. air, water, dust, soil, food and consumer products). Using mass spectrometry, a single analysis of blood or urine can measure hundreds or thousands of signals at once, including those from pollutants, drugs, dietary compounds, molecules produced by gut bacteria, and the body’s own metabolic responses to all of it. When applied to air analysis, measurements of diverse and unexpected components can be made continuously and in real time, capturing short-lived compounds and brief exposure events that a filter sample collected over hours would average away.</p>
<h4><strong>Enabling understanding and action</strong></h4>
<p>Measuring the chemistry around us is valuable, but measurement alone does not explain how an exposure influences health. These measurements become most useful when they can be connected. The objective of exposomics is to link the source of an exposure, the amount that enters the body, the biological responses it provokes, and ultimately any impact on health.</p>
<p>Completing that chain remains difficult, and the field is clear-eyed about where the challenges lie. Detecting a signal in a mass spectrometer is not the same as knowing what chemical produced it, and many of the signals detected remain unannotated, collectively constituting what researchers often refer to as the dark matter of the chemical exposome.<sup>3</sup> Their identification depends on reference libraries that are still underdeveloped for environmental chemicals, and workflows vary enough between laboratories that studies can be difficult to compare.<sup>3</sup> However, progress is being made, for example, in artificial intelligence methods that predict chemical behavior to improve confidence in identification,<sup>4</sup> and in the prioritization of harmonized workflows throughout the field.<sup>3</sup> Still, for today, mass spectrometry-based exposomics is a powerful approach that can see more than it can readily interpret. And therein lies its promise as a tool for novel discovery.</p>
<p>The challenges extend beyond identifying individual chemicals. Researchers must also account for the sheer scale of environmental exposure and how sharply it can vary among places and people. The World Health Organization reports that 99% of the world’s population breathes air exceeding its guideline limits.<sup>5</sup> At the same time, we know that the exposome is geospatially linked, with recent mobile monitoring studies showing that pollutant concentrations can vary dramatically over surprisingly short distances.<sup>6</sup> Finally, it has been suggested that exposure profiles can differ markedly even between neighbors in the same building,<sup>2</sup> together making the exposome an individual and community matter as much as a population one. As a result, exposomics research is increasingly being pursued across all three scales through multidisciplinary collaborations that combine environmental science, analytical chemistry, epidemiology and clinical research.</p>
<p> </p>
<p><em>Matthew Lewis, PhD, is vice president of metabolomics and lipidomics at Bruker Daltonics.</em></p>
<p><em> </em></p>
<p><em>References</em></p>
<ol>
<li>Argentieri MA, Amin N, Nevado-Holgado AJ, et al. Integrating the environmental and genetic architectures of aging and mortality. <em>Nature Medicine</em>. 2025;31(3):1016-1025. doi:10.1038/s41591-024-03483-9.</li>
<li>Gao P. The human airborne exposome. <em>Nature Health</em>. 2026;1:26-34. doi:10.1038/s44360-025-00026-5.</li>
<li>Talavera Andújar B, Schymanski EL. High Resolution Mass Spectrometry To Investigate the Human Exposome: Where Are We? <em>Exposome</em>. 2025. doi:10.1093/exposome/osaf017.</li>
<li>Sillé FCM, Prasse C, Luechtefeld T, Hartung T. AI redefines mass spectrometry chemicals identification: retention time prediction in metabolomics and for a Human Exposome Project. <em>Frontiers in Public Health</em>. 2025;13:1687056. doi:10.3389/fpubh.2025.1687056.</li>
<li>World Health Organization. <a href="https://www.who.int/health-topics/air-pollution#tab=tab_1" target="_blank" rel="noopener">Air Pollution</a>. Accessed 7 May 2026.<u></u></li>
<li>Robinson ES, Tehrani MW, Yassine A, et al. Ethylene Oxide in Southeastern Louisiana’s Petrochemical Corridor: High Spatial Resolution Mobile Monitoring during HAP-MAP. <em>Environmental Science & Technology</em>. 2024;58(25):11084–11095. doi:10.1021/acs.est.3c10579.</li>
</ol>
<p>The post <a href="https://www.genengnews.com/topics/omics/revealing-the-chemistry-around-us-through-mass-spectrometry/">Revealing the Chemistry Around Us Through Mass Spectrometry</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond the Payload</title>
<link>https://edusehat.com/en/beyond-the-payload</link>
<guid>https://edusehat.com/en/beyond-the-payload</guid>
<description><![CDATA[ In this Point of View Anthony Blaszczyk, PhD, principal scientist at USP provides insights on how delivery technologies will shape the future of cell and gene therapy.
The post Beyond the Payload appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/POV-USP-GTG_16x9-Virtual-background.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, the, Payload</media:keywords>
<content:encoded><![CDATA[<p>Over the last decade, cell and gene therapies (CGTs) have shown the ability to modify disease-inducing biological pathways, restore missing cellular functions, and achieve long-term therapeutic benefit following a single administration. However, even with significant design and development advancements, efficient on-target delivery remains challenging. The ability to safely, efficiently, and repeatedly deliver the correct genetic cargo to the right cell is one of the most critical determinants of clinical success.</p>
<p><figure aria-describedby="caption-attachment-340314" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340314" src="https://www.genengnews.com/wp-content/uploads/2026/11/POV-AJB-Headshot-300x300.jpg" alt="Anthony Blaszczyk" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/POV-AJB-Headshot-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-AJB-Headshot-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-AJB-Headshot-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-AJB-Headshot-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-AJB-Headshot.jpg 1244w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Anthony Blaszczyk, PhD<br>Principal Scientist, USP</figcaption></figure></p>
<p>While payload design will remain a primary focus, the next era of innovation in CGT may ultimately be driven by the delivery vehicle itself. In many cases, therapeutic efficacy, safety, and manufacturability are directly influenced by delivery performance. As payload technologies continue to advance, delivery may emerge as the key factor separating scientific possibility from clinical reality.</p>
<p>As a follow-up to last month’s article, “For mRNA, Delivery Is the New Standard,” which explored the future of mRNA delivery, this article examines the landscape of CGT delivery technologies. Specifically, we examine the strengths, challenges, and future directions of several leading platforms that are poised to play key roles in the future of advanced therapeutics.</p>
<p>Adeno-associated viral vectors (AAVs), lentiviral vectors (LVVs), and lipid nanoparticles (LNPs) have emerged as leading delivery platforms, each offering unique advantages and limitations. While AAV has largely dominated <em>in vivo</em> gene therapy, LVV has emerged as a viable <em>in vivo</em> delivery approach, in addition to its predominant use for <em>ex vivo</em> cell engineering applications, such as CAR T therapy. LNPs gained global recognition through their deployment in mRNA vaccines during the COVID-19 pandemic and have become a leading non-viral delivery technology. Because each platform employs a fundamentally different approach for transporting genetic material, complementary roles exist within the CGT landscape. Nevertheless, future advances for each platform will likely depend less on the genetic payload and more on improving delivery efficiency, target specificity, and safety.</p>
<h4><strong>Understanding the various delivery approaches</strong></h4>
<p>AAV is a small, non-enveloped viral vector that is approximately 20–25 nm in diameter. Although the overall structure between serotypes is similar, they vary significantly in receptor and surface proteins, which impact tissue targeting and immune recognition. Encapsulated within the capsid is a single-stranded DNA (ssDNA) genome containing the gene of interest (GOI). AAV does have a relatively limited packing capacity of around 4.7 kb, restricting the size of transgenes that can be delivered. Following cellular uptake and nuclear entry, the AAV genomic DNA is converted to double-stranded DNA and expressed by host-cell machinery to produce therapeutic proteins.</p>
<p>LVV contains a lipid envelope that mediates cell entry and encloses an RNA genome along with the viral enzymes required for genomic integration. Compared with AAVs, LVVs possess a larger packaging capacity and can typically accommodate genetic payloads of approximately 8–10 kb, enabling delivery of larger or more complex transgene constructs. Following cellular entry, the RNA genome is reverse transcribed into DNA and transported to the nucleus, where it integrates into the host genome. This permanent integration supports long-term transgene expression, which is unique to LVV as compared to the other delivery systems.</p>
<p>LNPs are synthetic, non-viral delivery systems that are typically 50–150 nm in diameter. These particles contain a dense core of ionizable lipids, phospholipids, cholesterol, and PEG-lipids that encapsulate a genetic payload, such as mRNA or siRNA. LNPs offer the greatest payload flexibility among the three platforms and can accommodate large mRNA molecules, combinations of nucleic acids, and gene-editing cargoes that may exceed the packaging limitations of viral vectors. Unlike viral vectors, an LNP does not deliver its genomic payload to the nucleus. Following cellular uptake and endosomal escape, the released mRNA is translated directly in the cytoplasm to the therapeutic protein.</p>
<p><figure aria-describedby="caption-attachment-340313" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-340313" src="https://www.genengnews.com/wp-content/uploads/2026/11/POV-USP-Delivery-systems-AAV-LVV-LNP-v05-993x1024.jpg" alt="Delivery systems AAV, LVV, LNP" width="696" height="718" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/POV-USP-Delivery-systems-AAV-LVV-LNP-v05-993x1024.jpg 993w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-USP-Delivery-systems-AAV-LVV-LNP-v05-291x300.jpg 291w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-USP-Delivery-systems-AAV-LVV-LNP-v05-768x792.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-USP-Delivery-systems-AAV-LVV-LNP-v05.jpg 1358w" sizes="auto, (max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">Delivery mechanisms for LVV, AAV, and LNP. [USP]</figcaption></figure></p>
<h4><strong>Target specificity</strong></h4>
<p>Target specificity is becoming an increasingly important consideration as CGT payloads grow more powerful and complex. Emerging technologies, such as CRISPR, base editing, and prime editing, introduce new challenges due to their size, complexity, and heightened safety risks. As a result, the future success of many advanced therapies may depend not only on what they deliver, but how precisely they can deliver the cargo.</p>
<p>For <em>in vivo</em> delivery, AAV offers the highest degree of target specificity and can effectively target many different cell types. Different serotypes naturally exhibit different tissue tropisms, and capsid engineering efforts have further enhanced the ability to selectively target specific tissues. AAV vectors are widely regarded as the most mature platform for targeted <em>in vivo</em> gene delivery. As regulatory expectations continue to emphasize safety, the ability to precisely direct therapeutic payloads may become even more valuable.</p>
<p>While LVVs generally contain moderate target specificity <em>in vivo</em>, they have demonstrated extraordinary success in <em>ex vivo</em> applications, in which target cells are isolated, genetically modified, and returned to the patient. The success of <em>in vivo</em> LVV therapy will likely depend on continued improvements in targeting technologies, including custom envelope engineering, which may require a shift away from the frequently used VSV-G glycoprotein.</p>
<p>When compared with AAV and LVV, LNP generally has the lowest intrinsic target specificity and the highest degree of off-target delivery. Following systemic administration, LNPs have displayed a tendency to accumulate in the liver, limiting their ability to selectively target other tissues. However, advances in lipid chemistry and targeting strategies have shown promise for improving tissue specificity.</p>
<h4><strong>Safety</strong></h4>
<p>Improved targeting and delivery efficiency can be directly linked to improved safety. In many advanced therapies, high doses are required to achieve sufficient therapeutic activity. However, these elevated doses increase off-target risks, toxicity, and unintended immune responses. Because of this, improved delivery efficiency can improve safety by lowering dose requirements.</p>
<p>AAV vectors are generally well tolerated and have become the leading platform for <em>in vivo</em> gene therapies. Pre-existing immunity against naturally occurring AAV serotypes, however, can reduce efficacy and complicate (re)dosing strategies. High dosing requirements have been linked with serious adverse events, including hepatotoxicity, thrombotic microangiopathy, cytokine-mediated toxicity, and sensory neuron toxicity.<sup>1</sup> These findings have increased regulatory focus on dose optimization, patient selection, and immune monitoring.</p>
<p>LVV is often preferred because its ability to integrate into the host genome can provide durable gene expression, even as treated cells divide and pass the therapeutic sequence to daughter cells. This long-term persistence can be particularly advantageous in therapies targeting proliferating cell populations. However, permanent integration also introduces safety concerns, including the risk of insertional mutagenesis, that do not apply in the same way to non-integrating CGT platforms. Modern self-inactivating LVVs have substantially reduced this concern, yet long-term monitoring remains important.<sup>2</sup></p>
<p>LNPs avoid the genomic integration risks associated with viral vectors and provide only transient expression of their RNA cargo. Although LNPs contain no viral proteins, both the lipid components and the RNA payload can stimulate innate immune responses that contribute to vaccine efficacy and common side effects. LNPs also have relatively high off-target delivery rates, particularly to the liver, that carry additional safety risks. Although uncommon, other risks associated with LNPs are PEG-associated immunogenicity and lipid-associated toxicity.<sup>3</sup>  Some of these risks are amplified in applications requiring repeat dosing, which is increasingly common for RNA-based therapies.</p>
<h4><strong>Future directions</strong></h4>
<p>The future of CGT is expected to see continued advancements in the coming years. Some of the most transformative developments may come from improvements in delivery technology. These innovations may come in the form of enhanced target specificity and expanded delivery of sophisticated payloads, such as CRISPR, base editing, prime editing, and other emerging technologies. Successful progression will rely on the development of delivery systems capable of precisely transporting these payloads to the appropriate cells while minimizing safety risks.</p>
<p>For AAV, future innovation will likely focus on engineered capsids with improved transduction efficiency, enhanced tissue specificity, and reduced susceptibility to pre-existing immunity. These advancements could support lower dosing strategies, which are generally associated with increased safety and decreased manufacturing demands, while also expanding the range of treatable diseases. AAV is also being pursued as a delivery system for gene editing technologies, such as CRISPR. While the high specificity makes AAV a valuable option, the payload limitations introduce challenges. Researchers are working on new ways to overcome this hurdle, such as engineering variants that yield smaller machinery proteins or using dual-AAV systems that split large transgenes into separate vectors.</p>
<p>For LVVs, the future will likely involve continued dominance in <em>ex vivo</em> applications while further expanding into <em>in vivo</em> gene delivery. Achieving that transition will require new envelope designs and targeting approaches capable of delivering genetic payloads with greater precision. If custom-engineered envelopes can develop LVVs that preferentially target specific cells at a high rate, the large payload capacity of LVVs would make them prime candidates for delivering gene editing tools.</p>
<p>For LNPs, advances in lipid chemistry and surface engineering may unlock applications far beyond the liver. If LNPs can be designed to effectively achieve this extrahepatic delivery, a plethora of new uses would potentially be unlocked. Because of their flexibility, scalability, and compatibility with gene-editing systems, LNPs are particularly well positioned to support future generations of RNA and genome-editing therapies. Lastly, innovations can be made to enhance LNP efficiency by improving the endosomal escape issue that plagues these delivery systems.</p>
<p>AAV, LVV, and LNP delivery platforms are all expected to remain central to the future of CGT. AAV remains the leading platform for targeted <em>in vivo</em> delivery, LVV offers unique advantages through its payload capacity and durable expression, and LNPs provide unmatched flexibility and scalability. Rather than a single dominant technology emerging, future success will depend on selecting the most appropriate platform for specific therapeutic objectives. As delivery systems continue to mature, ensuring consistent product quality and analytical characterization will become increasingly important for their successful development and adoption.</p>
<p>Whether utilizing AAV vectors, LVVs, or LNPs, future innovations will require equally sophisticated analytical tools to evaluate quality attributes. To support emerging technologies and new modalities, USP actively engages with stakeholders from across industry, academia, and regulatory communities to identify key challenges and areas where standards can best support adoption and improve consistency. Reference standards can help laboratories develop methods and monitor performance. USP has already developed a portfolio of AAV reference materials that support a wide range of analytical workflows and has recently expanded into LVV reference materials, with additional LVV- and LNP-related standards under development. As the field continues to advance, these standards can help ensure consistent and accurate characterization needed to support development and improve confidence in product quality.</p>
<h4><strong>Conclusion</strong></h4>
<p>As gene therapies become more sophisticated, including the incorporation of gene- and base-editing technologies, efficient and precise delivery will remain a key determinant of clinical success. Continued advances in targeting, payload delivery, manufacturability, and safety are expected to expand the capabilities of AAV, LVV, and LNP platforms. Rather than competing technologies, these delivery systems are likely to serve complementary roles, each offering distinct advantages for specific therapeutic applications. Ultimately, the next generation of transformative medicines may be defined not only by the genetic payloads they carry, but by the ability to safely, efficiently, and precisely deliver those payloads to the right cells at the right dose.</p>
<p> </p>
<p><em>Anthony Blaszcyk, PhD, is principal scientist in the Global Biologics Department at USP.</em></p>
<p><em> </em></p>
<p><em>References</em></p>
<ol>
<li>Ertl HCJ. Mitigating Serious Adverse Events in Gene Therapy with AAV Vectors: Vector Dose and Immunosuppression. <em>Drugs</em>. 2023;83(4):287-298. doi:10.1007/s40265-023-01836-1.</li>
<li>Schlimgen R, Howard J, Wooley D, et al. Risks Associated with Lentiviral Vector Exposures and Prevention Strategies. <em>J Occup Environ Med</em>. 2016;58(12):1159-1166. doi:10.1097/JOM.0000000000000879.</li>
<li>Kim S, Park C, Lee Y, et al. Inflammatory and immune-mediated toxicity of lipid nanoparticles. <em>Biomed Pharmacother</em>. 2026;199:119385. doi:10.1016/j.biopha.2026.119385.</li>
</ol>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/beyond-the-payload/">Beyond the Payload</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond Conventional CRISPR</title>
<link>https://edusehat.com/en/beyond-conventional-crispr</link>
<guid>https://edusehat.com/en/beyond-conventional-crispr</guid>
<description><![CDATA[ Genome editing is not designed to replace neurons or retinal cells that have already been lost. In this article, experts from four companies—eGenesis, Epicrispr, KOMO Biosciences, and Sumitomo Pharma America—discuss how they are moving beyond conventional CRISPR to develop novel approaches for treating disease.
The post Beyond Conventional CRISPR appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-4_Sumitomo.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, Conventional, CRISPR</media:keywords>
<content:encoded><![CDATA[<p>In December 2023, the FDA approved the first CRISPR-based treatment in the United States for sickle cell disease.<sup>1</sup> Despite this advance, conventional CRISPR-Cas9 systems may introduce potentially harmful DNA breaks and cannot easily be delivered to muscle and brain cells. Moreover, genome editing is not designed to replace neurons or retinal cells that have already been lost. In this article, experts from four companies discuss how they are moving beyond conventional CRISPR to develop novel approaches for treating disease.</p>
<h4><strong>Pig organs save lives</strong></h4>
<p>Xenotransplantation involves transplanting an organ from one species into another, explains Mike Curtis, CEO of eGenesis.</p>
<p>“There are just not enough human organs to satisfy the human need for kidneys, livers, lungs, and hearts,” he notes. “Xenotransplantation opens up a new supply of animal organs.”</p>
<p>Curtis explains how the first animal organs were transplanted into people more than 60 years ago. However, these organs were rejected within minutes to hours because of immune compatibility challenges.</p>
<p>Curtis emphasizes how advances in gene editing over the past 15 years have enabled xenotransplantation. “CRISPR really opened the door to precise gene editing, which has given us the ability to engineer pig organs that are more compatible with the human body,” he says.</p>
<p>The company has made three classes of CRISPR-based gene edits to modify its pig organs for human use. First, it inactivated genes encoding for human-incompatible carbohydrates on the surface of pig organs. “In our studies, a pig kidney modified in this way has been able to function in a human for several days to weeks without hyperacute rejection,” says Curtis.</p>
<figure aria-describedby="caption-attachment-340338" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-340338" src="https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-1_eGenesis-1024x463.jpg" alt="three classes of gene edits" width="696" height="315" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-1_eGenesis-1024x463.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-1_eGenesis-300x136.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-1_eGenesis-768x347.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-1_eGenesis.jpg 1400w" sizes="auto, (max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">The three classes of gene edits performed by eGenesis on the pig genome. [eGenesis]</figcaption></figure>
<p>The second class of edits introduced human genes into the pig genome to improve the human immune response to the animal organ. Finally, the third class of edits inactivated endogenous retroviruses in the pig genome, alleviating concerns that infectious diseases could cross over from pigs to people.</p>
<p>eGenesis’s most advanced program is for the kidney. The company’s recent publication in <em>The Lancet</em> describes the first few transplants of pig kidneys into people.<sup>2</sup></p>
<p>Curtis recalls one patient in the study. “This gentleman was doing poorly and had a very high risk of dying on dialysis. He was on the pig kidney for nine months, which improved his condition. He was then able to receive a human kidney transplant and is doing great eight months later.” The company is embarking on its Phase I/II/III RESTORE kidney trial, expected to initiate in the first quarter of 2027.</p>
<p>eGenesis’s second program involves the liver. The patient’s blood is perfused through a pig liver located outside of the body. This procedure provides life support and allows the person’s liver to recover while a human liver becomes available.</p>
<p>Finally, eGenesis is hoping to tackle end-stage heart failure. For the past couple of years, the company has been studying the long-term effects of pig heart transplants in baboons. Its first pig-to-human heart transplant is expected in 2027.</p>
<p>Is eGenesis finished with its gene edits? “One of our ultimate goals is to produce animal organs that require no immunosuppression,” says Curtis. “The only way to achieve that goal is iterative gene editing based on our first generation of organs. If we have our way, it should only get better from here.”</p>
<p>Although most of eGenesis’s edits have used CRISPR technology, the company is agnostic about the specific gene-editing tool. “Our goal is to improve the compatibility of pig organs for human recipients. The specific tool we use, whether it is Cas9, base editing, or prime editing, matters less to us than the outcome,” Curtis notes.</p>
<h4><strong>Epigenetic editing</strong></h4>
<p>While DNA contains the instructions for gene expression, epigenetic tags—such as DNA methylation and histone acetylation—act like switches that turn genes on and off. Epigenetic modifications help explain why people with the same genetic mutation may experience very different outcomes.</p>
<p>“We are leveraging the power of the epigenome to create new therapeutic possibilities,” explains Amber Salzman, PhD, CEO of Epicrispr. She notes how the first generation of CRISPR technology was designed to cut DNA and remove faulty genes.</p>
<p>“In contrast, we bind to the gene with CRISPR-Cas technology and tell the DNA what to do. Should the gene be expressed more, less, or not at all? All without cutting the DNA strands.”</p>
<p>Instead of the Cas9 nuclease used in first-generation CRISPR technologies, Epicrispr’s platform utilizes a much smaller molecule called CasONYX, which is deactivated and unable to cut DNA.</p>
<p>The platform fuses what it calls a modulator to each deactivated Cas nuclease. “These molecules will methylate DNA or put on histone modifications,” notes Salzman. Studies suggest that these modifications can potentially last indefinitely. And because Epicrispr’s Cas molecules and modulators are so small, they can fit into adeno-associated viruses (AAVs), which can access the muscles, eyes, and brain.</p>
<p>The company’s lead indication is facioscapulohumeral muscular dystrophy (FSHD). “We are the only company going after the root cause in FSHD, which is fundamentally a disease of reduced methylation,” Salzman notes.</p>
<figure aria-describedby="caption-attachment-340339" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-340339" src="https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-2_epiCrispr-1024x579.jpg" alt="Epicrispr’s CasMINI" width="696" height="394" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-2_epiCrispr-1024x579.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-2_epiCrispr-300x170.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-2_epiCrispr-768x434.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-2_epiCrispr.jpg 1400w" sizes="auto, (max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">Epicrispr’s CasMINI uses a guide RNA to bind to the DNA sequence of interest. A fused modulator molecule can then methylate the DNA. [Epicrispr]</figcaption></figure>
<p>More specifically, FSHD is associated with fewer repeats in the <em>D4Z4</em> region of the genome and a looser chromatin architecture. This structure allows for the expression of the toxic DUX4 protein, which kills muscle cells.</p>
<p>Epicrispr’s FSDH machinery is delivered to the muscle with an AAV. The region is then remethylated to suppress the genes responsible for DUX4 expression. “In patients with less-advanced disease, we can correct enough cells to stop DUX4 production and see a gain in lean muscle volume,” says Salzman.</p>
<p>The company also has early preclinical data on Duchenne muscular dystrophy. A major challenge in treating this condition is that the faulty dystrophin protein is too large to fit into AAVs. However, a protein called utrophin can compensate for a lack of dystrophin.</p>
<p>“We deliver a construct to the muscle cells with an AAV vector that instructs utrophin to be expressed at high levels and make up for the lack of dystrophin,” she notes.</p>
<p>Epicrispr has generated <em>in vitro</em> data for Alzheimer’s disease showing the activation of the <em>SORL1</em> gene in neuronal cells. This gene has been shown to be neuroprotective in the disease. It also has promising preclinical results for retinitis pigmentosa, an eye disease caused by a faulty protein called rhodopsin.</p>
<p>Finally, Salzman argues that Epicrispr’s strategy may be safer than traditional CRISPR. “When you are cutting, you can have genomic instability. Instead, we just make epigenetic marks,” she adds.</p>
<h4><strong>Inserting large genes</strong></h4>
<p>“I think the next phase of genome engineering will be less about changing one letter at a time and more about installing complete genetic programs,” predicts Jesse B. Owens, PhD, assistant professor at the University of Hawaii at Manoa and chief scientific advisor of KOMO Biosciences.</p>
<p>While conventional CRISPR-Cas9 technology is excellent for small edits, the insertion of large amounts of DNA is far less efficient, he notes. Furthermore, CRISPR generates exposed DNA breaks that can cause unwanted deletions or rearrangements.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>Integrases fill a different niche. They actively install gene-sized DNA at a defined site without leaving an exposed double-strand break. “An integrase is like a molecular paste function,” adds Owens. “It recognizes relatively long DNA addresses in the genome and actively inserts large fragments of DNA.”</p>
<p>“Integrases have been known for some time,” he continues. “The key difference is that our enzymes have been engineered with laboratory-directed evolution to be highly effective.” For instance, Owens’s recent publications demonstrate that evolved integrases can insert DNA into the desired genomic destination 80% of the time.</p>
<p>Owens stresses that the biggest remaining bottleneck for many therapeutic applications involves delivering the genetic editing machinery to the right cells. “A hyperactive integrase changes that equation,” he says. “When delivery is scarce, a much more efficient enzyme gives the DNA that reaches a cell a better chance of becoming a correct insertion.”</p>
<p>The company’s partners are currently interested in CAR T and other engineered immune-cell therapies. Such therapies often require large DNA insertions to fit multiple components for cancer therapy—including multiple receptors, persistence factors, and a safety switch within a single genetic cassette.</p>
<p>Beyond therapeutics, integrase technology has many applications in cell-line development and biomanufacturing. For instance, a highly efficient integrase-based system could create a more predictable starting cell-line population and compress development timelines.</p>
<p>“KOMO’s capacity for full gene replacement allows one product to address many different mutations in the same gene, rather than designing a separate editor for every patient’s mutation,” notes Owens.</p>
<h4><strong>Stem cell approval</strong></h4>
<p>“In advanced degenerative neurologic and eye conditions, critical target cells have already degenerated and died,” explains Alex Solyom, MD, vice president and head of clinical research, rare disease and biopharma at Sumitomo Pharma America. Interventions like CRISPR are not targeted to regenerate tissue structures that no longer exist in the patient.</p>
<p>Induced pluripotent stem cells (iPSCs) provide a supply of healthy cells to potentially replace or functionally restore damaged tissue. Researchers can generate them by reprogramming mature cells (such as skin or blood cells) back into an embryonic-like state. Importantly, iPSCs avoid ethical concerns associated with embryonic stem cells derived from fertilized eggs.</p>
<p>iPSCs provide a convenient basis for developing potential therapies. They can replicate endlessly in culture following reprogramming. They are also pluripotent, meaning that they can mature into virtually any specialized cell type.</p>
<p>“With iPSC-derived regenerative therapies, we aim to reestablish functional cells and tissue regardless of the underlying genetic mutation. This can be particularly important for diseases driven by mutations across multiple genes,” Solyom notes.</p>
<p>He highlights Sumitomo’s DSP-3077, an investigational iPSC therapy being developed as an off-the-shelf cell therapy for patients with retinitis pigmentosa, a progressive genetic eye disorder in which retinal photoreceptors degenerate.</p>
<p>Currently in Phase I/IIa trials, DSP-3077 consists of an iPSC-derived retinal sheet produced from a three-dimensional retinal organoid. This organoid is formed during a proprietary self-organizing process in which required cell types are differentiated from the iPSCs.</p>
<p>A single subretinal injection inserts the sheets into the patient’s eye. The injected sheets are designed to physically engraft into the patient’s retinal tissue. “We believe this will support natural retinal tissue architecture and replace degenerated photoreceptors, potentially helping to restore visual function,” Solyom says. In March of 2026, the investigational therapy received an FDA Orphan Drug Designation.</p>
<p>Meanwhile, Sumitomo’s raguneprocel, a dopaminergic neural cell product, is the world’s first approved iPSC-derived medicine. In March 2026, it received conditional, time-limited approval as AMCHEPRY<sup>®</sup> in Japan to improve motor symptoms in Parkinson’s disease.</p>
<p>“Being able to deliver to patients functional tissue made up of a complex structure and multiple cell types—and derived from the same stem cell line—is a worthwhile challenge and a great accomplishment drawing on decades of research,” concludes Solyom.</p>
<p> </p>
<p><em>References</em></p>
<p>1. Singh A, Irfan H, Fatima E, et al. Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease. <em>Ann Med Surg</em> (Lond). 2024;86(8):4555-4559. doi: 10.1097/MS9.0000000000002146.</p>
<p>2. Riella LV, Borges TJ, Rosales IA, et al. Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human study. <em>Lancet</em>. 2026;408(10559):1029-1040. doi: 10.1016/S0140-6736(26)01295-X.</p>
<p>The post <a href="https://www.genengnews.com/insights/beyond-conventional-crispr/">Beyond Conventional CRISPR</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Oral Sleep Apnea Therapy Poised to Expand Treatment Options</title>
<link>https://edusehat.com/en/oral-sleep-apnea-therapy-poised-to-expand-treatment-options</link>
<guid>https://edusehat.com/en/oral-sleep-apnea-therapy-poised-to-expand-treatment-options</guid>
<description><![CDATA[ An oral obstructive sleep apnea therapy targeting multiple pathways is poised to improve patient compliance and, possibly, outcomes.
The post Oral Sleep Apnea Therapy Poised to Expand Treatment Options appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Getty_1361394553_SleepApnea.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Oral, Sleep, Apnea, Therapy, Poised, Expand, Treatment, Options</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">Right now, there is no pharmaceutical treatment for obstructive sleep apnea, a condition that is estimated to affect more than one billion people globally and approximately 30 million Americans. Multiple studies (notably in 2010<sup>1</sup> and 2017<sup>2</sup>) report that as many of half those prescribed continuous positive airway pressure (CPAP)—the gold standard apnea therapy—reject it outright, and between 12% and 25% of those who begin those treatments abandon CPAP within three years.</p>


<p class="wp-block-paragraph">The reason for such high non-compliance is that CPAP is uncomfortable and socially awkward, Joel Latham, president and CEO, Incannex Healthcare, says. His company aims to be the first to potentially market an oral pharmaceutical therapy for obstructive sleep apnea.</p>


<p class="wp-block-paragraph">Latham says Incannex Healthcare’s mission is “targeting indications that have limited or no treatment options available.” So, while a therapy for obstructive sleep apnea, known as IHL-42X, is its lead therapeutic, the company’s pipeline also includes therapeutics based on distinctly different therapeutic platform to treat generalized anxiety disorder and rheumatoid arthritis.</p>


<h4 class="wp-block-heading"><strong>Oral apnea therapy</strong></h4>


<p class="wp-block-paragraph">Regarding obstructive sleep apnea, “We are targeting multiple pathways, and [the condition’s] underlying, fundamental causes,” he tells <em>GEN</em>. Just as importantly, the therapeutic (code-named IHL-42X) is oral, which should significantly improve compliance and potentially make more people amenable to therapy. It has received Fast Track designation from the U.S. Food and Drug Administration (FDA).</p>


<p class="wp-block-paragraph">The Phase II RePOSA trial showed that IHL-42X significantly reduced the frequency of breathing disruptions during sleep compared with placebo, with individual reductions of up to 83%. Reductions exceeding 30% were achieved by 33.3% of patients receiving the low dose and 41.2% receiving the high dose. A subsequent dose-optimization study, DReAMzz, began patient dosing in August 2026, supported by 14 clinical sites across the U.S. “We expect to have the data from that trial in the first half of 2027,” Latham says.</p>


<figure class="wp-block-image alignright size-medium is-resized"><img loading="lazy" decoding="async" width="300" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/11/OYR-Joel-Latham-Headshot-e1793902112442-300x300.jpg" alt="Joel Latham" class="wp-image-340328" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/OYR-Joel-Latham-Headshot-e1793902112442-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/OYR-Joel-Latham-Headshot-e1793902112442-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/OYR-Joel-Latham-Headshot-e1793902112442-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/OYR-Joel-Latham-Headshot-e1793902112442-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/OYR-Joel-Latham-Headshot-e1793902112442.jpg 1260w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-element-caption">Joel Latham<br>President and CEO<br>Incannex Healthcare</figcaption></figure>


<p class="wp-block-paragraph">“IHL-42X is an oral, fixed-dose combination of acetazolamide and dronabinol,” he continues. “Acetazolamide [a carbonic anhydrase inhibitor used for altitude sickness and glaucoma] induces metabolic acidosis, which signals…there is excess CO<sub>2</sub> in the blood, and thereby causes people to take a breath. Dronabinol [a synthetic tetrahydrocannabinol used to control nausea and stimulate appetites] simultaneously dilates the airways. So, by inducing the taking of a breath and dilating the airways simultaneously, we’re able to reduce the number of apnea episodes that patients experience during the evening.”</p>


<p class="wp-block-paragraph">Because this approach pairs two already-approved drugs, risks are reduced, the development pathway is streamlined, and costs are lowered.</p>


<h4 class="wp-block-heading"><strong>Anxiety and arthritis</strong></h4>


<p class="wp-block-paragraph">To treat generalized anxiety disorder, Incannex Healthcare is developing PSX-001, a psilocybin-based therapy designed to be used with cognitive behavioral therapy. The Phase II trials that completed in 2025 showed a 50% reduction in anxiety in 44% of patients.</p>


<p class="wp-block-paragraph">Generalized anxiety disorder affects approximately three percent of the U.S. population. First-line treatments are selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors, both administered with cognitive behavioral therapy.</p>


<p class="wp-block-paragraph">“The current standard of care has an extremely high non-compliance rate,” Latham says. Medical literature cites non-compliance rates between 40% to 60% within six months. Given PSX-001’s apparent efficacy in Phase II studies, “This is a market where we firmly believe we can make significant impacts for patients suffering from debilitating anxiety disorders.”</p>


<p class="wp-block-paragraph">Its third pipeline therapeutic—for rheumatoid arthritis—is on the back burner for now. “It’s been de-risked, but we truly have our hands full with the two lead assets,” Latham admits. IHL-675A, as this therapeutic is known, has completed “a plethora of preclinical and Phase I and II clinical studies, and the data’s been pleasing…but we’re focusing our resources on those [other] two assets.”</p>


<h4 class="wp-block-heading"><strong>From Aus to the UAE</strong></h4>


<p class="wp-block-paragraph">Incannex Healthcare has changed substantially since being founded in Australia in 2014. When it went public in 2016 on both the Australian Stock Exchange (ASX) and the NASDAQ, Latham—an early investor—joined the company as general manager. “After two years, I was elevated to CEO,” he says.</p>


<p class="wp-block-paragraph">“Then, in 2023, we decided to delist from the ASX and purely focus on the NASDAQ because we firmly believe that’s where our true peers were. Shifting its ASX shares to the NASDAQ made it easier for U.S. brokers to trade Incannex Healthcare stock and for Incannex Healthcare to leverage U.S. investors’ knowledge around the cannabinoid and psychedelic sectors, as well as access more potential investors.</p>


<p class="wp-block-paragraph">Recently, Incannex Healthcare moved its executive headquarters from Melbourne to Dubai, while retaining offices in Melbourne—“where the vast majority of our research team is located”—and New York. “Being in the UAE allows me to efficiently manage the two vastly different time zones that we deal with,” he says.</p>


<p class="wp-block-paragraph">“Abu Dhabi,” he continues, “is quite a biotech hub. That’s one of the leading reasons for me moving here and setting up offices.” The United Arab Emirates is considered an emerging, fast-growing regional biopharma center with very fast regulatory approvals and a strong desire to enlarge its biopharma manufacturing base.</p>


<p class="wp-block-paragraph">“We’re developing relationships, and we’re working with sovereign funds and with the government in relation to potential grants,” Latham says. That funding—an influx of nearly $60 million in the past year, which brought its cash balance to more than $74 million—provides “ample runway to see assets through to potential completion of Phase III,” he adds.</p>


<h4 class="wp-block-heading"><strong>Maturity brings changes</strong></h4>


<p class="wp-block-paragraph">Being president and CEO, he says “has been quite a unique experience,” given the multiple capital markets Incannex Healthcare has competed in, the multiple clinical assets it has developed, and clinical trials it has completed.</p>


<p class="wp-block-paragraph">“Very early on,” Latham recalls, “we were entrenched in preclinical studies. We were able to move quickly, generating data, creating new assays and studies, filing provisional patents, and derisking assets.” Now the operational scale is much larger and, he points out, “We’re at a later stage of development, so things move slower.” Examples of current challenges include onboarding trial sites, ensuring adequate patient recruitment levels, maintaining productive FDA interactions, and managing the permits and licensing necessary to import trial products into the U.S. For Incannex Healthcare’s pipeline, that includes working with the Drug Enforcement Agency.</p>


<p class="wp-block-paragraph">One thing has remained constant, however. From the very beginning, Latham says, “Everything’s been developed completely in-house in collaboration with our chief scientific officer, chief medical officer, and the expert leading advisory boards we’ve established for each of our assets.”</p>


<h4 class="wp-block-heading"><strong>Next milestones</strong></h4>


<p class="wp-block-paragraph">Completing the IHL-42X obstructive sleep apnea study, which dosed its first patient in August, is the company’s next milestone, Latham says. “We’re hyper-focused on getting those results out in 2027.”</p>


<p class="wp-block-paragraph">Meanwhile, Incannex Healthcare continues developing PSX-001 to treat generalized anxiety. “Various potential collaboration discussions are underway as well, so we expect to be able to deliver a few key milestones and updates to the market in the coming months,” he says.</p>


<p class="wp-block-paragraph"><em> </em></p>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column sidebar is-layout-flow wp-block-column-is-layout-flow">
<h3 class="wp-block-heading"><strong><strong>Incannex Healthcare</strong></strong></h3>


<p class="wp-block-paragraph"><strong>Location:</strong> Level 23, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000, Australia</p>


<p class="wp-block-paragraph"><strong>Phone:</strong> 61 (409) 840-786</p>


<p class="wp-block-paragraph"><strong>Website:</strong> <a href="https://incannex.com/" target="_blank" rel="noreferrer noopener">incannex.com</a></p>


<p class="wp-block-paragraph"><strong>Principal:</strong> Joel Latham, president and CEO</p>


<p class="wp-block-paragraph"><strong>Number of Employees:</strong> 30</p>


<p class="wp-block-paragraph"><strong>Focus:</strong> Incannex Healthcare is a clinical-stage company developing therapeutics for unmet needs. Its lead programs are an oral therapy for obstructive sleep apnea and a combination psilocybin/psychotherapy approach to treating generalized anxiety disorder.</p>
</div>
</div>


<p class="wp-block-paragraph"></p>


<p class="wp-block-paragraph"><em>References</em></p>


<ol class="wp-block-list">
<li>Catcheside, Peter G, Predictors of continuous positive airway pressure adherence. <em>F1000 Medicine Reports</em>. September 2010; 2:70 (<a href="https://s3-eu-west-1.amazonaws.com/science-now.reports/f1000reports/files/9008/2/70/article.pdf">doi:10.3410/M2-70</a>)</li>



<li>Jacobsen AR, Eriksen F, Hansen RW, et al. <a href="https://doi.org/10.1371/journal.pone.0189614" target="_blank" rel="noopener">Determinants for adherence to continuous positive airway pressure therapy in obstructive sleep apnea</a>. <em>PLOS ONE</em>. 2017; 12(12): e0189614.</li>
</ol>


<p class="wp-block-paragraph"></p>

<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/oral-sleep-apnea-therapy-poised-to-expand-treatment-options/">Oral Sleep Apnea Therapy Poised to Expand Treatment Options</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Tissue Engineering Takes Shape</title>
<link>https://edusehat.com/en/tissue-engineering-takes-shape</link>
<guid>https://edusehat.com/en/tissue-engineering-takes-shape</guid>
<description><![CDATA[ Personalized grafts, bioinks, and off-the-shelf tissues are advancing regenerative medicine toward broader clinical use.
The post Tissue Engineering Takes Shape appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Fig-2-Humacyte.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Tissue, Engineering, Takes, Shape</media:keywords>
<content:encoded><![CDATA[<p>Tissue engineering is on the move from an ambitious idea toward everyday clinical reality. At the interface of biology, materials science, and engineering, the field seeks to repair or replace damaged human tissues and organs. Some approaches embrace personalized medicine, creating tissues and treatments from a patient’s own cells and materials. Others are developing off-the-shelf engineered products for broad availability. We spoke to experts in the field about the latest developments pushing both strategies forward. Technologies range from heart patches and spinal cord repair to bone, cartilage and vascular grafts, and beyond.</p>
<h4><strong>Living cardiac band-aid </strong></h4>
<figure aria-describedby="caption-attachment-340294" class="wp-caption alignright"><img decoding="async" class="wp-image-340294" src="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Jordan-Lancaster-e1793897464951-300x300.jpg" alt="Jordan Lancaster" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Jordan-Lancaster-e1793897464951-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Jordan-Lancaster-e1793897464951-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Jordan-Lancaster-e1793897464951-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Jordan-Lancaster-e1793897464951.jpg 933w" sizes="(max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Jordan Lancaster, PhD<br>CEO, Avery Therapeutics</figcaption></figure>
<p>“The concept of making functional tissue to replace damaged tissues and organs has captured the imagination of many for a long time,” says Jordan Lancaster, PhD, CEO of Avery Therapeutics. Case in point: heart failure. Lancaster elaborates, “Today, we manage cardiac diseases like heart failure by administering drugs that help reduce symptoms of the disease. And while the current armament of drugs for heart failure does slow progression of disease, the prognosis remains grim, and the disease continues to advance. There are no therapies today that get to the root cause of heart failure, which is loss of functioning cardiomyocytes (heart muscle cells) and fibrosis. We want to change this. We want to develop novel therapies that address the root cause of disease, and reverse disease in ways that are currently unobtainable.”</p>
<p>According to Lancaster, the company is pursuing an immunomodulatory approach coupled with tissue engineering to essentially create a “living band-aid, of sorts.” Their preclinical collaborative studies employed an allogeneic cardiac patch composed of a proprietary mix of human induced pluripotent stem cell (iPSC)-derived cardiomyocytes and fibroblasts embedded in a bioresorbable matrix. Lancaster explains, “This biologic product is placed on damaged tissue and creates a localized immunomodulatory response that drives disease repair. Our immunomodulatory platform is built utilizing cellular material, a proprietary combination of cells produced via a multi-day manufacturing process. The biologic engages the immune system and recruits immune precursor cells, which drive repair.”</p>
<p>Developing the approach also required overcoming key hurdles such as manufacturing at scale, handleability, and shelf stability (cryopreservation). Additionally, Lancaster says the company has learned a lot about the immune system and its ability to serve as a conserved therapeutic target for diseases of inflammation and fibrosis. “We are exploring and have established deep mechanistic insight into how to redirect the immune system into pro-reparative pathways, which we have validated in highly translatable preclinical models of heart failure. We are keen to advance these insights into novel therapies.”</p>
<p>As a late-stage preclinical company, Avery will initially focus on heart failure of ischemic etiology with plans to advance the technology toward clinical testing.</p>
<h4><strong>Bioinks for 3D bioprinting </strong></h4>
<figure aria-describedby="caption-attachment-340290" class="wp-caption alignright"><img decoding="async" class="wp-image-340290" src="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Yehiel-Tal--300x300.jpg" alt="Yehiel Tal" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Yehiel-Tal--300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Yehiel-Tal--1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Yehiel-Tal--150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Yehiel-Tal--768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Yehiel-Tal-.jpg 1400w" sizes="(max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Yehiel Tal<br>CEO, CollPlant Biotechnologies</figcaption></figure>
<p>While tissue engineering has made remarkable progress, fundamental barriers remain, according to Yehiel Tal, CEO of CollPlant Biotechnologies, including “access to safe and reproducible biomaterials, recreation of the complex biological and mechanical environment of human tissue, vascularization, and scalable manufacturing.” Bioinks, specialized cell-laden gel-based biomaterials, are a critical aspect. He elaborates, “Bioinks must support cell viability while providing the printability, structural stability, degradation profile, and mechanical properties required for functional tissue formation.”</p>
<p>The company is addressing these challenges through its proprietary plant-derived recombinant human type 1 collagen (rhCollagen) platform. Tal reports, “Because our collagen is bioidentical to human collagen and produced without animal or human tissue, it offers a consistent, scalable, animal-free building block for regenerative medicine. Our bioink portfolio combines rhCollagen with complementary biomaterials and photoactive components to tailor mechanical strength, degradation kinetics, and printing performance for different tissues and printing technologies.”</p>
<figure aria-describedby="caption-attachment-340291" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-340291 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-CollPlant-Regenerative-breast-Implant-300x252.jpg" alt="3D-bioprinted regenerative breast implants" width="300" height="252" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-CollPlant-Regenerative-breast-Implant-300x252.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-CollPlant-Regenerative-breast-Implant-1024x860.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-CollPlant-Regenerative-breast-Implant-768x645.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-CollPlant-Regenerative-breast-Implant.jpg 1400w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">3D-bioprinted regenerative breast implants, composed of rhCollagen and biodegradable biopolymers, are designed to provide structural support, promote vascularization and tissue ingrowth, and gradually degrade as the patient’s own tissue replaces the implant. CollPlant Biotechnologies’ regenerative implants are currently in preclinical development. [CollPlant Biotechnologies]</figcaption></figure>
<p>One example from this portfolio is BioFlex<sup><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"></sup>, a ready-to-print kit for high-resolution digital light processing (DLP) bioprinting. DLP bioprinting projects a digital image of each layer of a desired 3D structure onto light-sensitive bioink, selectively solidifying the material to build the structure layer by layer. Tal explains, “BioFlex combines Collink.3D<sup><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"></sup> 50 with a biodegradable polymer and proprietary photoactive agents, simplifying formulation while retaining the flexibility to create complex, biologically relevant structures. It is intended for advanced tissue models, drug discovery, engineered tissues, and ultimately transplantable organs.”</p>
<p>The company is also applying tissue engineering to medical aesthetics. Tal says, “We have advanced commercial-size, 3D-bioprinted regenerative breast implants through large-animal preclinical studies. These implants are designed to gradually degrade while supporting vascularization and regeneration of the patient’s own tissue.”</p>
<p>Tal believes progress in the field will depend on integrating biomaterials, cells, vascular networks, bioreactors, automation, and computational design into scalable manufacturing platforms. “We see major opportunities in human tissue models, regenerative soft-tissue products, and organ manufacturing, enabled by biomaterials that are both biologically relevant and industrially reproducible.”</p>
<h4><strong>Personalized spinal cord repair </strong></h4>
<p>More than 18,000 people sustain traumatic spinal cord injuries in the U.S. annually, with approximately 310,000 patients living with the condition. The injured spinal cord has little regenerative capacity and develops a cellular and extracellular environment that inhibits neural regrowth.</p>
<figure aria-describedby="caption-attachment-340293" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340293" src="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Gil-Hakim-e1793897765662-246x300.jpg" alt="Gil Hakim" width="200" height="244" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Gil-Hakim-e1793897765662-246x300.jpg 246w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Gil-Hakim-e1793897765662-768x937.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Gil-Hakim-e1793897765662.jpg 782w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Gil Hakim<br>CEO, Matricelf</figcaption></figure>
<p>Gil Hakim, CEO of Matricelf<strong>,</strong> reports, “Chronic spinal cord injury is characterized by tissue cavities and scarring that interrupt neural pathways. Regeneration requires addressing inflammation, restoring extracellular-matrix cues, and enabling transplanted cells to survive, organize, extend axons, form functional synapses, and integrate with spinal cord circuitry.”</p>
<p>Matricelf is developing NewRal, a 3D neural-tissue transplant composed of patient blood-derived iPSCs as well as an extracellular-matrix hydrogel derived from the patient’s omental tissue. Before transplantation, the cells differentiate and assemble into 3D neural tissue spheroid constructs containing electrically active neural cells, designed to replace damaged neural tissue and support new neural connections.</p>
<p>“The dual-autologous design may reduce immune mismatch and the need for immunosuppression,” says Hakim. “Compared with transplants using donor cells or synthetic, animal-derived, or standardized scaffolds, NewRal combines patient-specific cells, biological matrix, and preassembled neural tissue.”</p>
<p>Matricelf is addressing manufacturing complexity and patient variability through standardized Good Manufacturing Practices (GMP) processes and optimization via closed-system automation. Hakim indicates that pilot efficacy studies in chronic spinal cord injury animal models have shown improvement in functional recovery and tissue regeneration in 80% of treated animals. The company completed Good Laboratory Practice (GLP) safety studies, advanced GMP manufacturing and clinical site preparations, initiated patient identification activities, and received FDA feedback on elements of the proposed first-in-human clinical program planned for 2027.</p>
<figure aria-describedby="caption-attachment-340296" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-340296 size-large" src="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Matricelf_NewRal_high_resolution-1024x403.jpg" alt="Matricelf’s NewRal technology illustration" width="1024" height="403" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Matricelf_NewRal_high_resolution-1024x403.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Matricelf_NewRal_high_resolution-300x118.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Matricelf_NewRal_high_resolution-768x302.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Matricelf_NewRal_high_resolution.jpg 1400w" sizes="auto, (max-width: 1024px) 100vw, 1024px"><figcaption class="wp-caption-text">To treat spinal cord injuries, patient-derived cells and an autologous hydrogel are combined to create personalized 3D neural tissue for transplantation at the site of spinal cord injury. Illustrated is Matricelf’s NewRal technology. [Matricelf]</figcaption></figure>
<h4><strong>Living bone and cartilage grafts </strong></h4>
<figure aria-describedby="caption-attachment-340297" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340297" src="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Nina-Tandony-e1793898011794-300x300.jpg" alt="Nina Tandon" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Nina-Tandony-e1793898011794-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Nina-Tandony-e1793898011794-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Nina-Tandony-e1793898011794-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Nina-Tandony-e1793898011794.jpg 770w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Nina Tandon, PhD<br>CEO, EpiBone</figcaption></figure>
<p>Tissue engineering is also making strides in the repair of bone and cartilage. According to Nina Tandon, PhD, CEO of EpiBone, “The gold standard treatments for skeletal defects are unfortunately riddled with compromises to meet the standard of ‘replacing like with like.’ Craniofacial bone loss after trauma or tumor surgery, and damaged joint cartilage, are the big ones. What happens today? A surgeon can harvest bone from your hip or leg, so now you have two wounds and real donor-site pain. They can use cadaver tissue, which the body often resorbs. Or they can bolt in metal or plastic that never becomes bone and, sooner or later, needs revising.”</p>
<p>EpiBone aims to shift from replacing tissue to regrowing it using stem cells to create personalized bone and cartilage products. Tandon explains, “Depending on the case, we can shape a graft to a patient’s exact anatomy before it reaches the operating room, or supply it off the shelf, ready when the surgeon needs it. Either way, it is living tissue on a natural bone matrix, so it is designed to integrate and remodel the way native tissue does rather than be tolerated as a foreign object.”</p>
<p>The process begins with adult stem cells seeded onto a natural bone matrix and matured in a bioreactor. Tandon elaborates, “I describe the bioreactor as diet and exercise: it feeds the tissue and puts it through the mechanical loading it will see in the body (going jogging a couple miles a day, roughly). Out comes living, 3D bone or cartilage. Honestly, the biology is the fun part. The moat is manufacturing. Making living tissue reproducibly, at the right size and shape and at clinical grade, is the hard problem, and it is the one we have spent more than a decade on.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>The company has advanced its bone and cartilage programs into human trials. Tandon reports, “In our first-in-human bone trial, we treated six patients with zero product-related adverse events. Those six jaws are the thing I am proudest of.” EpiBone has also tested an injectable cartilage therapy for osteoarthritis in dogs and horses, reporting improvements over standard-of-care treatment.</p>
<p>Looking ahead, Tandon sees the next decade focusing on scale and broader availability of custom and off-the-shelf living grafts.</p>
<h4><strong>Off-the-shelf vascular grafts </strong></h4>
<p>When a patient suffers a severe injury or chronic vascular disease, surgeons may need to replace or repair an artery. Current options include using a patient’s own vein, synthetic grafts, or an animal-derived allograft.</p>
<figure aria-describedby="caption-attachment-340295" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340295" src="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Laura-Niklason-e1793897920400-266x300.jpg" alt="Laura Niklason" width="200" height="225" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Laura-Niklason-e1793897920400-266x300.jpg 266w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Laura-Niklason-e1793897920400-909x1024.jpg 909w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Laura-Niklason-e1793897920400-768x865.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Laura-Niklason-e1793897920400.jpg 1183w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Laura Niklason, MD, PhD<br>President and CEO, Humacyte</figcaption></figure>
<p>“Harvesting a vein can be especially dangerous in urgent cases, taking more time in the OR, adding increased risk for infection, and resulting in a second surgical wound with the potential for post-operative pain,” says Laura Niklason, MD, PhD, president and CEO of Humacyte. She also notes some synthetic grafts are prone to infection while animal-derived allografts carry other issues. What is needed is a readily available conduit that behaves like living tissue but resists infection, maintains patency, and integrates seamlessly with the body.</p>
<p>Humacyte has developed acellular tissue-engineered vessels (ATEVs) as off-the-shelf, universally implantable vascular grafts. Niklason explains, “We begin with human vascular smooth muscle cells seeded onto a biodegradable scaffold, which gradually dissolves as the tissue forms.” Pulsatile, artery-like conditioning then prompts the cells to build a strong matrix of human collagen and other extracellular matrix proteins. After the vessel matures, the cells used to grow it are removed while the extracellular matrix and structural proteins remain. The resulting bioengineered vessel can be stored until needed. After implantation, the patient’s own cells gradually repopulate and remodel the vessel, transforming it into living tissue.</p>
<p>The company’s lead product, Symvess<sup>®</sup>, was approved by the FDA in December 2024 as a vascular conduit for adults with extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and an autologous vein graft is not feasible. In September 2026, the FDA approved extending its shelf life from 18–36 months. Humacyte is also planning submission of a supplemental Biologics License Application in the second half of 2026 for hemodialysis applications.</p>
<p>Niklason believes tissue engineering is at an important inflection point. “What’s changing now is the shift toward manufactured, off-the-shelf regenerative products that have the potential to reach a large scale of patients. The opportunity ahead is to make engineered human tissue a routine part of surgical and medical care for the benefit of the patients who need it.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/tissue-engineering-takes-shape/">Tissue Engineering Takes Shape</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Orphan Therapeutics Accelerator In&#45;Licenses Its First Gene Therapy, Eyes Pipeline Expansion</title>
<link>https://edusehat.com/en/orphan-therapeutics-accelerator-in-licenses-its-first-gene-therapy-eyes-pipeline-expansion</link>
<guid>https://edusehat.com/en/orphan-therapeutics-accelerator-in-licenses-its-first-gene-therapy-eyes-pipeline-expansion</guid>
<description><![CDATA[ The nonprofit biotech evaluates potential therapies based on unmet medical need, clinical evidence of safety and efficacy, and the compatibility of institutional partners. Its funding model combines initial seed investment with commercial revenue and non-traditional funding sources.
The post Orphan Therapeutics Accelerator In-Licenses Its First Gene Therapy, Eyes Pipeline Expansion appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/10/Getty_2235763333_GeneTherapy.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Orphan, Therapeutics, Accelerator, In-Licenses, Its, First, Gene, Therapy, Eyes, Pipeline, Expansion</media:keywords>
<content:encoded><![CDATA[<p><span>Recently, the Orphan Therapeutics Accelerator (OTXL) announced an agreement with UCL Ventures, </span><span>the commercialization company of University College London (UCL), </span><span>and Children’s Medical Research Institute (CMRI) to in-license an investigational therapy program for ornithine transcarbamylase deficiency (OTCD), a rare, X-linked metabolic disorder. The drug candidate in question, now dubbed OTXL-101, was formally known as AAVLK03hOTC. It was developed through a collaboration between Paul Gissen, MBCHB, PhD, and the OTCD project team at University College London, and Ian Alexander, MBBS, PhD, and his team at CMRI. </span></p>
<p><span>This marks the first therapy in-licensed by OTXL, a nonprofit biotech set up specifically to utilize tax and other incentives to “liberate and reininitiate development of shelved therapies for rare and ultra rare conditions” that have been shelved in recent years for various reasons, according to Craig Martin, OTXL’s CEO and co-founder. </span></p>
<p><span>The nonprofit biotech is one part of a four-pronged approach targeting shelved cell and gene therapies. The other parts include the Orphan ClinDevNet, a network of affiliated contract development and manufacturing organizations, contract research organizations, and other partners who have agreed to work under reduced-cost, success-based agreements. </span></p>
<p><span>Approved products can be commercialized through Orphan Therapies, OTXL’s commercial subsidiary, which was established a year ago, or outlicensed to biotech or biopharma partners. Recently, Orphan Therapies established commercial availability for an <em>ex vivo</em> cell therapy for patients with Wiskott-Aldrich syndrome. </span></p>
<p><span>Finally, support for </span><span>OTXL and </span><span>other programs in need of financing or partners can be accelerated and facilitated through CGTxchange, an artificial intelligence-enabled marketplace, diligence, and deal-making platform established through a </span><a href="https://www.genengnews.com/topics/genome-editing/asgct-president-terry-flotte-touts-rare-disease-initiatives-as-his-term-ends/" target="_blank" rel="noopener"><span>joint venture between OTXL and the American Society of Gene & Cell Therapy (ASGCT)</span></a><span>. It serves as a marketplace for shelved therapies with potential that could be picked up by both traditional and non-traditional kinds of investors or funders.</span></p>
<p><span>In fact, OTXL-101 was initially identified with the help of the platform that now underlies CGTxchange, according to Martin. He told</span><i><span> GEN</span></i><span> that prior to in-licensing OTXL-101, the OTXL team looked at more than 80 different therapeutic programs. “We first started looking at it almost two years ago,” he said. At the time, OTXL-101 was outlicensed to Bloomsbury Genetic Therapies, which had initiated a Phase I/II study dubbed the Halting Ornithine transcarbamylase deficiency with Recombinant AAV in Children or HORACE trial. </span></p>
<p><span>The first patient, a 10-year-old male with late-onset OTCD, was treated at Great Ormond Street Hospital in December 2023. The plan was to run a 12-patient trial, however when the Bloomsbury Genetic Therapies shut down in 2025, the program was returned to UCL and CMRI. Preliminary results from the first patient were presented at the 2025 ASGCT annual meeting.</span></p>
<p><span>OTXL had moved on to other candidates at the time, Martin said, but when the initial plans for the treatment fell through, and the therapy was returned to UCL and CMRI, they reconsidered. “We started negotiating with them and found everybody was really feeling like this was a therapy that needed to get to patients. And we were able to structure the deal in such a way that it really fit our model and provided a more viable path forward for the therapy,” he said. </span></p>
<h4><b>A rare disease therapy gets a new life</b></h4>
<p><span>Ornithine transcarbamylase deficiency or OTCD is caused by mutations in the OTC gene that reduce or eliminate ornithine transcarbamylase activity. This enzyme is essential to the liver’s urea cycle, which converts toxic ammonia from protein metabolism into urea for elimination. When ammonia builds up in the blood, it can cause hyperammonemic decompensations, brain injury, and coma. </span></p>
<p><span>The condition is currently managed medically by protein restriction, nitrogen-scavenging medicines, and amino acid supplements. But patients remain at risk for elevated blood ammonia and serious complications. Another option is liver transplantation which can restore metabolic control but carries surgical risks and requires lifelong immunosuppression. Estimates from Orphanet indicate that its birth frequency ranges from approximately one in 56,500 to one in 113,000 live births. </span></p>
<p><span>If it passes further testing and is approved, OTXL-101 could be an important treatment tool. To treat OTCD, OTXL-101 uses a liver-targeted adeno-associated virus vector to deliver a functional OTC gene and restore urea cycle activity. The gene therapy is intended to treat children and adolescents with OTCD and has received U.S. and EU orphan drug designations as well as a U.S. rare pediatric disease designation. </span></p>
<p><span>This initial clinical evidence of the efficacy of OTXL-101, which now spans more than two and a half years, “gives us a sense of its potential to benefit patients,” Martin said. In his conversation with </span><i><span>GEN</span></i><span>, he explained: The data showed that following treatment with the gene therapy, the patient had successfully been taken off Ravicti, a prescription nitrogen-binding medicine for long-term management of high ammonia levels, as well as off of a restricted diet. And they have continued to do well. </span></p>
<p><span>The type of evidence that OTXL will consider for future in-licensed candidates and therapies that are included in the CGTxchange will vary, Martin said. For one thing, not all rare disease therapies will have years of post-treatment data on patients as that will depend on factors such as when the trials were stopped or suspended and their specific endpoints. In general, “the criteria that are most important to us are ‘is this an area of high unmet medical need? Is it a therapeutic approach that we have a good understanding of and based on evidence from clinical trials, wherever they are in that process?’” he said. Other pertinent questions focus on who the partners involved are and whether they can work with OTXL. </span></p>
<p><span>In terms of OTXL-101, “we are going through the process of doing stability and potency testing on the material that had been manufactured for the trial,” Martin said. Also, “we’ve done some other things related to extending patents in a number of countries so that we know we’ve got the ability to provide access in a variety of places.” Finally, the therapy will be listed on the CGTxchange. “We have some of the funds required to continue to move it forward, but we’d like to be able to have a set of funding that would allow us to extend ideally past the next inflection point,” Martin explained. </span></p>
<p><span>Meanwhile, OTXL is exploring other candidates for potential in-licensing deals. “We’re actually in some conversations now and not just around the clinical stage, but also other commercial-stage or commercial products that we might be able to help move forward,” Martin said. It is important to note here that OTXL is modality agnostic and is willing to consider other kinds of treatment approaches beyond cell and gene therapies. Martin pointed to the team’s recent work on the <em>ex vivo</em> cell therapy for patients with Wiskott-Aldrich syndrome. “If there are other therapies like that out there where the traditional commercial model just doesn’t work for big biotechs or biopharma companies, those would be good candidates for us to … put into our existing infrastructure and move forward.”</span></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/orphan-therapeutics-accelerator-in-licenses-its-first-gene-therapy-eyes-pipeline-expansion/">Orphan Therapeutics Accelerator In-Licenses Its First Gene Therapy, Eyes Pipeline Expansion</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bird Flu Vaccine Developed Using AI Outperforms Current Stockpiled Vaccines in Preclinical Tests</title>
<link>https://edusehat.com/en/bird-flu-vaccine-developed-using-ai-outperforms-current-stockpiled-vaccines-in-preclinical-tests</link>
<guid>https://edusehat.com/en/bird-flu-vaccine-developed-using-ai-outperforms-current-stockpiled-vaccines-in-preclinical-tests</guid>
<description><![CDATA[ Researchers used an AI-guided engineering approach to create a broadly protective bird flu vaccine that is designed to remain effective across a wide range of existing and future H5Nx variants. 
The post Bird Flu Vaccine Developed Using AI Outperforms Current Stockpiled Vaccines in Preclinical Tests appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_4X4A7027-2-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bird, Flu, Vaccine, Developed, Using, Outperforms, Current, Stockpiled, Vaccines, Preclinical, Tests</media:keywords>
<content:encoded><![CDATA[<p>Researchers at the University of Cambridge and at the University of Cambridge spin-out DIOSynVax reported on the development of a broad-spectrum bird flu vaccine that in animal trials provided complete protection against globally circulating, diverse H5Nx variants of the disease. Current pandemic preparedness relies on stockpiling vaccines against individual virus variants that have already emerged. The Cambridge team’s approach uses AI-guided engineering to create broadly protective vaccines intended to remain effective across a wide range of existing and future variants.</p>
<p>The team’s study, described in <em>Cell Reports Medicine,</em> found the new digitally engineered multi-antigen mRNA vaccine to be superior to bird flu vaccines currently stockpiled by many governments for use in the event of a human outbreak. Their preclinical trial results showed that the existing vaccines tested protected only around 50% of animals exposed to multiple H5N1 bird flu variants, compared with complete protection achieved by the team’s new vaccine, DVX-panH5Nx.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The results demonstrate the potential of AI-guided vaccine design in developing broad protective population immunity ahead of evolving biological threats. The researchers say the vaccine represents the third success with their AI-guided technique for designing vaccines against highly infectious viruses that threaten animal and human health. The new study in addition demonstrates that the team’s ‘plug and play’ approach can be used to create safe, highly effective vaccines for a plethora of infectious diseases threatening animal and human health globally.</p>
<p>“Rather than providing immunity to a single variant of bird flu, our new broad-spectrum vaccine is protective against a huge range of variants,” said Professor Jonathan Heeney, PhD, in the Lab of Viral Zoonotics, University of Cambridge’s Department of Veterinary Medicine. “It’s designed to anticipate viral evolution, rather than reacting to it … These new-generation vaccines are a game changer for national biosecurity and more resilient public health. They mean we can be prepared to respond immediately to virus epidemics and pandemics, rather than the current scenario of always being on the back foot and responding with a strain which will have changed.”</p>
<p>In their paper, titled “<a href="http://dx.doi.org/10.1016/j.xcrm.2026.103131" target="_blank" rel="noopener">Broad vaccine protection against globally diverse influenza A H5Nx viruses</a>,” senior and corresponding author Heeney and colleagues stated, “Compared to WHO candidate vaccine viruses (CVVs), DVX-panH5Nx confers superior protection against antigenically distinct H5N1 challenges spanning two decades of viral evolution, demonstrating that computationally designed multivalent antigen vaccines can overcome natural influenza diversification and provide a scalable strategy for pre-pandemic preparedness.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Bird flu is an RNA vaccine (as are the coronaviruses that cause COVID-19) that is spreading in animals around the world and is currently considered a significant threat to global public health, the authors noted. “Influenza A H5Nx viruses continue to diversify and undergo gene reassortment as they infect avian and mammalian hosts worldwide,” they wrote. RNA viruses represent a particular threat to human health because they can mutate rapidly into new strains that can jump from animals to humans and evade our immune systems—and our existing vaccines.</p>
<figure aria-describedby="caption-attachment-340287" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340287" src="https://www.genengnews.com/wp-content/uploads/2026/11/4X4A7000-211x300.jpg" alt="Professor Jonathan Heeney." width="211" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/4X4A7000-211x300.jpg 211w, https://www.genengnews.com/wp-content/uploads/2026/11/4X4A7000-720x1024.jpg 720w, https://www.genengnews.com/wp-content/uploads/2026/11/4X4A7000-768x1092.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/4X4A7000-1080x1536.jpg 1080w, https://www.genengnews.com/wp-content/uploads/2026/11/4X4A7000.jpg 1242w" sizes="(max-width: 211px) 100vw, 211px"><figcaption class="wp-caption-text">Professor Jonathan Heeney [J.Garget/University of Cambridge]</figcaption></figure>
<p>“It’s when bird flu adapts to live in the airways of mammals that we start to get really nervous,” said Heeney, “not only because of the impact on animal health but because of the threat to humans. If we can make better animal vaccines, then we can better protect human health as well.”</p>
<p>The decades-old approach to vaccine design has been largely reactive, responding to pathogens after they have emerged. The team’s goal is to create broadly protective vaccines for both animals and humans, helping reduce opportunities for pathogens to emerge, adapt, and spread. Their new class of universal vaccines is future proofed. The vaccines not only protect against many variants simultaneously, but potentially against related viruses that haven’t yet emerged and spilt over to humans.</p>
<p>To design the new bird flu vaccine, Heeney and team collected the genetic sequence data of all the bird flu viruses logged by surveillance programs around the world, which take virus samples from wildlife, livestock, and humans infected with bird flu. They built an AI tool to integrate the huge amount of genetic data and use it to design a range of “super-antigens” which contain the antigen features common to this whole group of viruses. These were screened in cells to select the best one for the vaccine, which was then tested in animal trials.</p>
<p>“… we engineered a broadly protective, multi-antigen panH5Nx vaccine using computational and structure-guided HA, NA, and M2 antigens, capturing global H5Nx diversity,” the team noted. Heeney added, “Using AI vastly speeds up the process of vaccine design, and then we can test the vaccine candidates in the lab to make sure they’re robust and safe.”</p>
<p><em>In vivo</em> tests showed that the new DVX-panH5Nx vaccine completely protected mice and ferrets against a range of genetically distinct H1N1 variants—all of which have caused human infections and represent potential pandemic threats. “By integrating HA, NA, and M2 antigens representing global H5Nx diversity, we demonstrated that broad, cross-clade protection could be achieved using a single vaccine formulation,” the researchers commented. “… the broad immunogenicity of DVX-panH5Nx translated into complete protection against lethal heterologous challenges in mice and superior survival in ferrets.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>In comparison, only half the animals survived these same viruses when immunized with the World Health Organization’s existing bird flu vaccine. The bird flu vaccine stockpiled by governments is based on representative virus isolates identified through the World Health Organization’s pandemic influenza preparedness program. It was designed to protect against one specific strain of the disease, but the study found it provides minimal protection against other strains in circulation.</p>
<p>“Here, we present a mechanistically informed, digitally engineered mRNA vaccine, DVX-panH5Nx, designed to anticipate viral evolution rather than reacting to it with single isolate-based vaccines,” the investigators reported. They suggest that their collective data “… support a shift in pandemic influenza preparedness toward broadly protective, digitally designed, multi-antigen vaccines that reflect global viral diversity.”</p>
<p>The next step is to test the new bird flu vaccine in human clinical trials, so that it can be ready to be given to humans immediately, when needed. The team is also working on a seasonal flu vaccine that would provide broad-spectrum protection over several flu seasons. Preliminary results show that the vaccine antigen they designed in 2018 is still effective after seven years.</p>
<p>Earlier this year the team announced that their <a href="https://doi.org/10.1016/j.jinf.2026.106759" target="_blank" rel="noopener">broad-spectrum coronavirus vaccine</a> had proved safe in human trials, and published results showing their <a href="https://pubmed.ncbi.nlm.nih.gov/42836655/" target="_blank" rel="noopener">broad-spectrum influenza vaccine</a> protects against both human and swine flu viruses.</p>
<p>In their newly released paper the team concluded, “Leveraging genomic surveillance data from animal reservoirs and human spillover events, with structural insights and immune correlates, offers a powerful framework not only for next-generation pre-pandemic H5Nx vaccines but also for improving seasonal influenza vaccines and developing more effective broadly protective vaccines against other rapidly evolving RNA viruses.”</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/bird-flu-vaccine-developed-using-ai-outperforms-current-stockpiled-vaccines-in-preclinical-tests/">Bird Flu Vaccine Developed Using AI Outperforms Current Stockpiled Vaccines in Preclinical Tests</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Generating health through AI and human connection</title>
<link>https://edusehat.com/en/generating-health-through-ai-and-human-connection</link>
<guid>https://edusehat.com/en/generating-health-through-ai-and-human-connection</guid>
<description><![CDATA[ ﻿﻿﻿ Rahul Nayak, MD, gastroenterologist and physician director of the Virtual Medical Center at The Southeast Permanente Medical Group, sees artificial intelligence as a way to make care more human,…
The post Generating health through AI and human connection appeared first on Permanente Medicine. ]]></description>
<enclosure url="https://permanente.org/wp-content/uploads/2026/11/Docs-Chat-Nayak-feature-cover-image-v2.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:00:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Generating, health, through, and, human, connection</media:keywords>
<content:encoded><![CDATA[<p><span data-mce-type="bookmark" class="mce_SELRES_start">﻿</span><span data-mce-type="bookmark" class="mce_SELRES_start">﻿</span><span data-mce-type="bookmark" class="mce_SELRES_start">﻿</span></p>
<div></div>
<p></p>
<p><a href="https://podcasts.apple.com/us/podcast/permanentedocs-chat/id1667624170" target="_blank" rel="noopener"><img loading="lazy" decoding="async" class="alignnone wp-image-5484" src="https://permanente.org/wp-content/uploads/2022/11/Listen-on-Apple-Podcasts-badge-300x77.jpg" alt="" width="139" height="36" srcset="https://permanente.org/wp-content/uploads/2022/11/Listen-on-Apple-Podcasts-badge-300x77.jpg 300w, https://permanente.org/wp-content/uploads/2022/11/Listen-on-Apple-Podcasts-badge-1024x262.jpg 1024w, https://permanente.org/wp-content/uploads/2022/11/Listen-on-Apple-Podcasts-badge-768x197.jpg 768w, https://permanente.org/wp-content/uploads/2022/11/Listen-on-Apple-Podcasts-badge-1536x393.jpg 1536w, https://permanente.org/wp-content/uploads/2022/11/Listen-on-Apple-Podcasts-badge-2048x524.jpg 2048w" sizes="auto, (max-width: 139px) 100vw, 139px"></a> <a href="https://open.spotify.com/show/6Q75xXKdkpzUNSd7sFYrcS?si=4hkmkKYmS1eqlVwM4bd1tQ" target="_blank" rel="noopener"><img loading="lazy" decoding="async" class="alignnone wp-image-5489" src="https://permanente.org/wp-content/uploads/2022/11/spotify-badge-1-300x83.png" alt="" width="139" height="38" srcset="https://permanente.org/wp-content/uploads/2022/11/spotify-badge-1-300x83.png 300w, https://permanente.org/wp-content/uploads/2022/11/spotify-badge-1.png 428w" sizes="auto, (max-width: 139px) 100vw, 139px"></a> <a href="https://youtu.be/onPeBB8ClQY" target="_blank" rel="noopener"><img loading="lazy" decoding="async" class="alignnone wp-image-5675" src="https://permanente.org/wp-content/uploads/2023/02/Listen-on-YT-Podcasts-badge-1024x262-1-300x77.png" alt="" width="139" height="36" srcset="https://permanente.org/wp-content/uploads/2023/02/Listen-on-YT-Podcasts-badge-1024x262-1-300x77.png 300w, https://permanente.org/wp-content/uploads/2023/02/Listen-on-YT-Podcasts-badge-1024x262-1-768x197.png 768w, https://permanente.org/wp-content/uploads/2023/02/Listen-on-YT-Podcasts-badge-1024x262-1.png 1024w" sizes="auto, (max-width: 139px) 100vw, 139px"></a></p>
<p><a href="https://www.linkedin.com/in/rahul-nayak-md-mba/" target="_blank" rel="noopener">Rahul Nayak, MD</a>, gastroenterologist and physician director of the Virtual Medical Center at <a href="https://permanente.org/the-southeast-permanente-medical-group-inc/" target="_blank" rel="noopener">The Southeast Permanente Medical Group</a>, sees artificial intelligence as a way to make care more human, not less. He talks with Alex McDonald, MD, about how in this episode of PermanenteDocs Chat.</p>
<p>Dr. Nayak explains why the care model comes before the technology, how ambient AI helps physicians listen more closely and catch what they might otherwise miss, and what AI-supported care between visits could look like for conditions such as hypertension. Throughout, he returns to one principle: AI can raise possibilities, but physician judgment and the patient relationship stay at the core.</p>
<p>Scroll down to read the full transcript.</p>
<hr>
<p><strong>Podcast transcript</strong></p>
<p><em>Transcript is autogenerated. Although edited for clarity, it should not be considered an exact replication of the podcast and may also be updated as needed</em>.</p>
<p><strong>Alex McDonald, MD:</strong> Welcome everyone to today’s PermanenteDocs Chat. I’m your host, Alex McDonald, and we are talking about AI again. I know we’ve talked about this before, but it is a phenomenal field. It is expanding so quickly. And today we’re going to focus on how AI can really extend the reach and impact of our physicians. Our guest today is Dr. Rahul Nayak, who is a gastroenterologist and a member of The Southeast Permanente Medical Group and a director of the Virtual Medical Center there. So Dr. Nayak, welcome so much to the podcast.</p>
<p><strong>Rahul Nayak, MD:</strong> Yeah, Dr. McDonald, thank you so much. I’m really excited to be here. This is, as you’ve said, a topic that we both talk about a lot and also end up maybe not talking about as perhaps tactically as we could as people look to see how it really impacts their day-to-day, but also their near future. So it’s an exciting time to be in the space.</p>
<p><strong>AM:</strong> Absolutely. I guess just for timestamp, it’s September 2026. In six months, this may be completely obsolete, but who knows? It’s happening very quickly. Well, again, let’s jump in real quick here. Just before we start, tell us who you are and a little bit more about what you do to give us a background.</p>
<h2>Meet Dr. Rahul Nayak: Gastroenterologist and Virtual Medical Center Director</h2>
<p><strong>RN:</strong> Yeah, so 60% of my time I spend practicing gastroenterology. It’s really a field that I thoroughly enjoy, even though at times I’m reminded by my wife that I’m a glorified plumber, which is fine. Totally cool, completely makes sense. The other 40% I spend in directing our virtual medical center, and it’s an honor to work with a team of physician leaders like Dr. Michael Bakheet and then our SSD team, Michelle Klevesahl and the remaining parts of our team, Kim Petty, who does a ton of the work that we need to get done to bring these sorts of tools and help integrate them into how we do our care. So I’ve been with TSPMG for 16 years ever since fellowship, and I joined the organization because the way we think about what our mission is to try and generate health for the populations of the communities that we live in really resonates with me.</p>
<p>And I got to come to a place where I don’t have to make any odd compromises. I can provide care for the people who are in front of me and do it in an environment with phenomenal colleagues.</p>
<h2>Why designing the care model comes before the technology</h2>
<p><strong>AM:</strong> Excellent. Yes, I love it. I love it. I’m very like-minded here. So let’s talk about, again, AI and technology. And you’ve talked about the importance of designing <a href="https://permanente.org/about-us/our-care-model/" target="_blank" rel="noopener">the care model</a> first before you then implement technology. Why is that distinction really important and what does that look like in clinical practice?</p>
<p><strong>RN:</strong> So at the end of the day, oftentimes folks who are in technology feels like people see it as a magic wand that you wave it in the general direction of whatever operational problem you have and suddenly things will just get better. And at our core as an organization, we really thrive when we are able to design our care. So design the clinical care. An example of that would be if I want to get someone in for say an upper endoscopy, I could have them go to their primary care doctor. I could have them then go and be seen by a GI physician in clinic or a GI APP in clinic, and then I could have them go to a procedure. On the other hand, I know that certain people in certain populations, and this is where the design comes in, don’t need all those steps.</p>
<p>They maybe just need the procedure. And so if I can have them skip a couple of those steps, I open up all that access for other folks to be seen. I get this patient what they need when they need it by the right resource, so it’s the right care at the right time and the right place. And now I can put a piece of technology to enable that. So I can put in either structured decision trees, which allow a patient to go online, say, “I have these symptoms,” know what their risks are, know that they don’t have any contraindications to coming straight in for a procedure, and then be able to then bring them in to get that procedure done, finish their results, and then move their care to the next phase. And the enabling technology only occurs after I’ve designed that piece of care.</p>
<p>And so I think that’s really how it occurs in practice and oftentimes the practices that we are able to set up and do.</p>
<p><strong>AM:</strong> No, I love that. I know right now in this day and age, there are a lot of companies and systems which are actually designing the care around the technology versus the care truly around the patient. And I love that right place, right time for the patient and not wasting a lot of resources. You also talk about how you’re really emphatic when we think about AI in clinical practice, it never makes the final diagnosis. It raises possibility, it gives prompts, it helps the doctor be better, but ultimately the physician judgment is still at the core of everything we do. Technology and AI doesn’t replace it and it’s not a non-negotiable design principle. Can you expand more on that?</p>
<p><strong>RN:</strong> I look at it almost from my work a decade plus ago in safety. So we can demand perfection of a system. Demanding perfection of individual humans, that’s not really a thing that we can do. And that’s where some of the mismatch comes in, where people feel like they’re being asked to be perfect as though they were a machine. We don’t want that. That is not a concept that really makes sense and it’s not very humane, quite frankly, but we can design systems to be perfect. And so if I go back and think about how and what we do, there’s a lot of work that say we do on a day-to-day basis that we shouldn’t be doing, and that is the kind of work that we can absolutely find a way to take that load and give it to another person or AI or an algorithm.</p>
<p>And that is an opportunity, but we have to, one, design where that occurs, and then two, we have to be there so that we’re able to both develop, build, and create the core human relationship that you need because that is what care is. Care is a person and taking care of another person more than anything else. And that should come across even when we’re using our tools. When I think about what we do, when I think about what we do, we generate health more than anything else. We’re not here to sort of manage chronic illness. We’re here to either prevent it or help people live the best version of their lives. And so any set of tools that allows us to do that, even if we can’t be there all the time doing that, at least if we can help design that, that allows us to then take these pieces of technology, make them more human while also making the job more humane.</p>
<p>Because at the end of the day, every time we demand perfection of a human, it’s really, really almost a moral injury to them. Whereas demanding perfection of a system, that is what the system is for.</p>
<h2>How AI helps generate health in an integrated care model</h2>
<p><strong>AM:</strong> Oh my gosh, you just blew up my mind right now. I think there’s so many things you just said which are brilliant. I love the idea of helping offload the physicians. We know we don’t have enough physicians. We know that being a physician has extreme risk of burnout and overload and using technology to help us do our job better and also maintain our mental and physical health is so critical. So put that aside. The other piece you hear, this concept of how do we generate health? How do we use technology to help generate health? And that is such a phenomenal concept. So we live in a world often which focuses on treating disease versus focusing on a health care system that really helps to generate health and preserve health.</p>
<p>And how does AI actually help do that work and what does an integrated capitated system, what does that look like versus in the traditional fee-for-service model where incentives may not always be aligned with generating health?</p>
<p><strong>RN:</strong> Yeah, Alex, clearly there’s a lot there.</p>
<p><strong>AM:</strong> We have 20 minutes. Go. No.</p>
<p><strong>RN:</strong> I’ll take it in some sort of smaller chunks. When I think about how we do what we do, the core of it is that we are looking to generate as much value as we can per dollar. And that value is really determined by how the patient experiences the care as well as their outcomes. Those are the things that really matter, and then what it costs to do it. And so unlike other places, unlike other systems or unlike other financial models, the advantage of AI for us is it solves the core problem we have always had, is that it is very expensive to provide the kind of deeply personalized preventive care that ultimately helps generate health. And we have done it and we have done it in our outcomes nationally really demonstrate our dedication to that. But we could do more. We could do more for our populations, we could do more for our communities.</p>
<p>And the way you do more is by doing it as strategically and tactically as you can. And that really means layering these technology pieces in to help provide deeply personalized, extraordinarily timely, preferably proactive interventions to help people live their best life. And it sounds like pie in the sky, and yet in many ways, you look at our outcomes in cardiovascular health and in the work that we’ve done to prevent cancer, and you can see its manifestation. So the next version is not just we’re going to go and get the entire population to go get screened for colon cancer, which we will and need to keep doing, but also how do we start helping people with all of those other life goals? And so there’s going to be a lot of point solutions that are out there that come along to help individuals in those spaces.</p>
<p>And where we’re uniquely qualified is that we know so much about the folks who we get to take care of because we have their records. And in combination with that knowledge and these technology tools, we are then able to pull these things forward. So a good example is a pilot that we have expanded and are started running. It started in KP Washington, and that’s Dr. Trina Davis and Anuj Kapoor who have really led that work in the medical foundation along with one of our vendors who provides our ambient solution. And what they have done is combine our interest in finding and being more proactive in our appointments with patient medical care while making it easier to bill and fulfill and document what you’ve just done. So if someone has a care gap now and in our conversation we go and cover that care gap, it is now very easy for me to acknowledge it, talk to the patient about it, and then essentially fulfill it and move on.</p>
<p>And by doing that at every touch that we get, we have the opportunity to really close those sorts of things aggressively. It’s a completely different world than we would live in if we had to try and make sure that every single person did it every single time. Now we’re helping folks do it. You can still opt not to do it, totally fine. Do you know what I’m saying? But by the same token, this is sort of the trick that we, or not the trick, this is sort of the advantage that we have is because we can prioritize that as the time, prioritize the technology that goes behind it, and then do it and realize the value over the course of the time that we have folks with us.</p>
<h2>How ambient AI gives physicians their time back</h2>
<p><strong>AM:</strong> I remember very clearly when I first joined Permanente back in 2012, I was talking to some physicians about the value and they talk about I’m one of the best doctors ever because I know the care gaps for my patients when they walk in, it’s listed there, they’re due for their flu vaccine and their mammogram and their colonoscopy and you name it. And I remember thinking, oh, this is so great. Everything’s sort of in one place and it helps me to be a better doctor. Now you amplify that times, I don’t know, a million or so when you start thinking about AI and a lot of these ambient technologies, it really has given, I’ll speak personally, it has really brought the joy back to practicing medicine. I can walk in the exam room and look at a patient in the eye as opposed to have my head stuck in a computer.</p>
<p>And that’s just one tangible aspect of how it really gives us our time back. It gives back our autonomy, it gives back our joy and <a href="https://permanente.org/quality-assurance-informs-large-scale-use-of-ambient-ai-clinical-documentation/" target="_blank" rel="noopener">practice with the ambient AI</a>, which is only one dimension of all the amazing things that AI can do. So that’s my own two cents. I’m sure you have thoughts, but I also want to talk about the next iteration of that and the <a href="https://www.beckershospitalreview.com/healthcare-information-technology/abridge-and-kaiser-permanente-debut-care-signals/" target="_blank" rel="noopener">Care Signals program</a>. And if you can talk about Care Signals, what that is and how it goes even beyond the initial tangible benefits that AI provides physicians.</p>
<h2>What is Care Signals? Ambient AI beyond the clinical visit</h2>
<p><strong>RN:</strong> So I think the holy grail, if you will, of a clinic visit, just a clinic visit. Now we’re really talking about synchronous face-to-face or video. So in that sort of spectrum, when you think about that synchronous moment, what matters more than anything else is did you connect with the person, yes or no? Did they feel heard? Yes or no? Were you able to capture all of the elements and all of the things that that person said in order to integrate it into what your next set of plans and conversations with them were going to be?</p>
<p>The holy grail is sort of that. And the next step of that is when you had that conversation, if something was surfaced that you were not necessarily aware of or had not been thinking of, can it be brought to your attention enough so that you pay attention to it? And then the final piece is, as you’re having that conversation and you’re saying, we’re going to do the following six things and here’s the order and here’s why, and here’s what it is, does that get captured and put in and ordered already so that your job at the end of that visit is a little bit more of as an editor to review and then to hit send, the diagnosis come in, you don’t have to worry about that. The orders are already in, you don’t have to worry about that. But the first step of that is being able to pull out the things that you’re talking about, and that is what the first step of Care Signals is doing for us.</p>
<p>It’s saying, “You have talked about these things in this conversation, here are the diagnoses that would be associated with that and what you have said and talked about in that. Here are some of the pieces that are there. Do you want to include that or not?” Because that’s always a question. Do you want to include or not? Is it important enough for you to include it or not? And that’s what layers on. So that piece layers on then to the next step, which is being able to get us into ambient ordering, and then the next step, which is looking at how and why and what we activate our other systems to support people and follow up and support people in taking care of themselves in between the clinic visits, which is where most of the care takes place.</p>
<h2>AI-supported care between visits: A hypertension example</h2>
<p><strong>AM:</strong> And that’s a great segue actually to my next question here is I guess what does right now and what could an AI-supported care journey look like for a patient between visits, between the average patient sees their physician twice a year, maybe they interact with the nurses or the health care team a little more frequently than that, but something like as basic as hypertension or any kind of chronic disease, what does that journey look like and how does AI help keep those touch points between those physician-patient interactions?</p>
<p><strong>RN:</strong> Yeah, so I love this question. One, because it takes advantage of things we already do. So we already do remote patient monitoring for patients with hypertension at scale,</p>
<p>And it’s a very impressive program. So we could imagine, say, a case of hypertension, there’s multiple ways in which we could see AI and then our algorithm supporting that care. And so one way would be this, is I’m already providing the data to my health app about my hypertension management at home, my blood pressure at home, I’m not diagnosed as being hypertensive yet. If those numbers start rising, then you could theoretically, not even theory, you could practically see us reaching out and saying, “Hey, is something changed?</p>
<p>Is something going on? Have you changed the thing in your diet? Have you noticed any new symptoms?” Any of those could result in a, “You need to come in for a visit,” or, “Hey, maybe you should do this intervention in real time. Maybe you should cut back on salt in your diet.” And then you would see those numbers improve. And if those numbers improve, that person is essentially on what we would think of as a happy path. We don’t have to interact with them other than to say, “Congratulations, you’re doing great work.” Then if say the numbers sort of go back up, you could see us reaching out first with just a question saying, “Hey, is everything okay?” Second, perhaps a chatbot to have a deeper conversation. Then that information and all this information gets summarized in to your note when you go and see that patient when they come in to make a decision about, “Hey, what are we going to do next?” Because if there’s lifestyle issues and we haven’t addressed them, then we need to continue working on those.</p>
<p>Here’s what our plan is, here’s what the follow-up looks like, and here’s how we know you’re going to stay or go onto one of these plans. And so you start building in the continuous monitoring and the utility of that without having to overburden you as a clinician to have to see it all. So the flags are set by you, and then when they need to come in, access is much easier because you haven’t eaten up access with a bunch of other things that they didn’t need to necessarily come in to see and they didn’t want to come see you anyway. Every time we pull some patient out of their lives, what are we doing? If they got to see us, they got to see us and we should make it as easy as possible. But if they don’t, let’s meet their need, where they are and how we can in whatever way.</p>
<p>I think the other big piece that we’re going to see more and more generative AI is in partnership with us as we’re looking through and trying to understand complex cases and then cases over time. Because at the end of the day, health is something, at least in our system, that occurs over decades, and it would be great to be able to know here’s the intervention we need to take for this person that’s going to result in this benefit 10 years down the line. And we see that for prevention, but I would argue that there’s probably a number of other things where if we were able to be more proactive and had the resource to do, which now we do thanks to AI, we could get into those spaces and help people out in those times at those moments with that right technology and that right touch to get them to where they want to be.</p>
<h2>Where AI helps and where care stays human</h2>
<p><strong>AM:</strong> I mean, that’s such a great concrete example there, talking about hypertension specifically, but I mean, that’s just, again, the tip of the iceberg. So I guess the next question I have for you is, so we know people like personalized care and we are becoming more personalized and more continuous in terms of utilizing some of these skills to help expand the work of physicians, but where does AI take things off the physician’s plate and where do things need to stay really distinctly human? Because we know patients do better when there is that longitudinal continuous relationship between their doctor and their patients. So where is that dividing line between we can let AI do this work for us versus when we need to step in and have that face-to-face or that human interaction?</p>
<p><strong>RN:</strong> I don’t know. I think that’s a challenging question for a couple of reasons. I think that each physician is going to sort of draw that line differently. So in my own practice, I do a lot of my follow-up by email. My patient population has now gravitated towards that. I’ve been with the group long enough, 16 years, that people will opt into a practice that’s a little bit more like that, so they get a very timely response from their messages to me and they’re fine with that. Whereas there’s other people in my practice who are on the other side, they tend to bring people back a little bit more frequently because that is what their patients want and desire. But after that, I think to answer the meta question that you put out there, really the explicit question, I think that building relationships is the single most important thing we can do as humans.</p>
<p>And I think you can build the relationships through conversations in person. There’s a part that that needs to occur. That is still a thing.</p>
<p>Virtually through email communications, these are always a sort of, but it’s building that consistent relationship over time that really matters. AI can assist with that. For sure we found that for sure research that I think actually the Medical Foundation helped with, or the Federation helped with actually, looked at the fact that patients at times prefer the responses to come from ART, which is the automated response that is built into Epic because it feels more humane. What I would argue is that when we are able to speak to our patients in language that they understand and really connect with them, that is the thing that when AI helps us do that is doing us a huge favor. The piece where I think AI is going to continue to just come up to but not take over is when we have difficult conversations with people, I think when we have conversations that either include this is going to be a life-changing thing, or I need to convince you to do something life-changing.</p>
<p>And I think in many ways, those moments really are where all the relationship equity you build sort of come in and either people trust you or they don’t. And at the end of the day, it doesn’t matter how much technology we bring to medicine, it’s not perfect. And so that space is going to continue to be there. I think one of the big challenges that we continue to face is that people look at this in an all or none way. It’s either all AI or no AI. It’s either all human or no human. And that’s, I think, just not reality. I think there’s a period of transition and change, but at the end of the day, there’s something about people talking to people, which is where a lot of these changes and health changes certainly take place.</p>
<p><strong>AM:</strong> Yeah, no, I think that’s so important. And I know that some of my patients just want to come in and just look at me eye to eye and have that conversation. Some of my patients are totally happy, just almost doing most of their care asynchronously through email in the portal. And so I think meeting the patient where they are and however they want to get care, and that’s going to change over time for the patient also. It’s not always going to be the same based on your comments about if it’s a life-altering diagnosis versus, “Hey, your cholesterol is a little high, eat better.” Anyway.</p>
<h2>How ambient AI helps physicians</h2>
<p><strong>RN:</strong> So I think about it because for me, one of the things that our ambient solution has done is kept me from making a mistake, kept me from missing something, like an offhand comment from one of my patients about a change in their bowel habits, which led to a diagnosis of a cancer, offhand, just not the way I had asked the question. I didn’t ask it in the way that connected with them. It was sort of captured in the transcript as I was reading through it and in the summary, and I was like, “Yeah, I need to pay attention.” I reviewed that note with the patient. I was like, “I need to pay attention to that. I need to do a thing with it.”</p>
<p>So these tools are there to help us be better physicians in almost an older model, like a model where it was just you and the patient in a room. And I mean, let’s face it, when that model was really in existence, medicine was a lot less complex. And so now we have to be able to ingest all that complexity, make use of all the knowledge, but still keep that humanity. And I think that is where in many ways AI is helping us do that, which is now the complexity is not necessarily going to be hugely overwhelming and I can only focus on that. I can focus here on my patient and have some help bringing in that complexity to make that and bridge that sort of conversation.</p>
<h2>When patients use AI: Handling AI-generated research in the exam room</h2>
<p><strong>AM:</strong> No, I love that summarization. I have a question here that I was just thinking about. Now, we have physicians who are using AI to help support us and do our jobs better. We also have patients using AI to look up everything known to man and come in with a list of diagnoses and tests and things like that, which some may be appropriate, some may certainly not be. And so are we just in an AI arms race, so to speak, I guess? And again, how do we make sure that we’re actually having human-human interactions as opposed to just AI versus AI, which I know has happens in several different domains in several different other fields? Yeah,</p>
<p><strong>RN:</strong> So I love that. So I’ve always been a, bring all your research in. I</p>
<p>Love it. I love it when my patients do research. I love it when they come in having done reading. I love it mostly when they bring the resource in. When they come in and they’re trying to test me with it, I have a lot less. You’ve just set us up. We’re not in a real sort of trusting relationship at that point, and I can meet you there, but that’s the signal if you’re testing me like that, that’s where we’re at. So I love it. I don’t think it’s an AI to AI kind of conversation. Anyone who’s gone out there and used these tools knows that they are in many ways amazing, but in many ways they’re mathematical prediction tools of the next most likely word. So what ends up happening is in the hands of experts, they’re astounding. And so I am a board certified gastroenterologist.</p>
<p>So when I make a query about gastroenterology, my chance of making use of that tool at its highest possible level is very high. When I make that same level of query about say my knee that is bothering me, my orthopedic friends laugh at me as you would, you would laugh at me, and they laugh at me because 30 to 40% of it is just not worth anything. You know what it is. I don’t. And so some of the conversation when folks come in like this is just having that conversation like, “Hey, look, these things really make a lot of sense. This isn’t really based in something where we are going to be able to have a conversation that’s going to be meaningful because there’s no basis in science for it. Let’s talk about this, focus on this, and see how we can lean into this piece of information and this body of work that you’ve done and what you’re looking for and what you’re asking.” Because at the end of the day, people are asking to be cared for, and when they come in with a ton of stuff and are a little bit defensive, it’s because they have not been.</p>
<p>They have not been listened to, they’ve not been heard. And I find that one of my favorite things about ambient support is I no longer have to sacrifice getting everything down, reviewing all of their records, listening to them or my family. I don’t have to sacrifice these sets of things. My family and accuracy, because that’s the other thing that sacrifice when I walk out of a room without finishing my work. I don’t have to sacrifice those things. It’s phenomenal, and that makes it easier for me to do my job. It still takes a similar amount of time, but the mental load of that moment is something different. And then the way my patients experience it is radically different. I literally got hugged by this 85-year-old woman who was like, “That is the most closely someone has listened to me in any health care setting ever.” And I’m not really known as a listener, sort of a super touchy-feely provider.</p>
<p>Some of my colleagues are, they’re amazing. That’s not really who I am. And I was stunned because the tool really helped me connect with her.</p>
<p><strong>AM:</strong> Yeah, that’s amazing. I love it. And I know just going back to your other point about AI and expertise, as studies have shown across different fields that using AI with that context and that knowledge and that expertise can be tremendously helpful, but if you don’t have that knowledge and that context, it can lead you astray very easily. And so I think that’s the important piece of encouraging patients to use their resources and look things up and get as much information as they can, but then they need to come to us as their physicians to help them sift through the noise to find the information which actually applies to them as an individual. So okay, this is a phenomenal conversation. We could go on and on all day, but we do like to keep these short and relatively high yield. Last question, which is my favorite question: What makes you most proud to be a Permanente physician?</p>
<h2><strong>What it means to be a Permanente physician</strong></h2>
<p><strong>RN:</strong> So every day when I come in as a specialist, I get to take care of the person in front of me. If I were in private practice and I have no hate in my heart for my colleagues who have chosen that path, to a certain degree, they’re taking care of the person in front of them, but the actual book of business is a referring doctor. And I never feel that. I always feel like the patient in front of me is my patient because of that reason. And it’s just a different thing. It’s like my thing. It’s just my thing in the back of my head because I’m so just aware that this is a unique thing where I get to have my relationship with this person. I still talk to their primary doctor. I still have that kind of conversation and respect that relationship because it’s critical, but I’m there for only this person.</p>
<p>There’s no gray space on that. And it’s a blessing to be able to work in a space where there’s no gray space. If they need a procedure, they need a procedure, we give it to them. If they don’t need a procedure, I have that conversation. If they need the right medication, that’s the medication they get. And I don’t have to fight about it. It’s completely freeing. I practice medicine in an evidence-based matter in a group practice where I get to talk to phenomenal colleagues and my patients are amazing people and I get to learn about them and their lives. I mean, what’s more to ask for in terms of what I do and how I do it?</p>
<p><strong>AM:</strong> Amazing. Well, very well said and a great way to end a great conversation. Well, thank you so much for your time. Really appreciate your thoughts and insights here, and I’m sure we’ll have lots more conversations in six months when everything’s totally different.</p>
<p><strong>RN:</strong> Totally different, completely different. It’ll be great. I love how fast this stuff moves and it’s terrifying at the same time.</p>
<p><strong>AM:</strong> Absolutely. And thanks for all of you out there listening. Please like and subscribe and make sure you leave comments if there’s someone you want to share or hear from in the future.</p>
<p><strong>RN:</strong> Yeah, thanks for the time. I appreciate it.</p>
<p>The post <a href="https://permanente.org/generating-health-through-ai-and-human-connection/">Generating health through AI and human connection</a> appeared first on <a href="https://permanente.org/">Permanente Medicine</a>.</p>]]> </content:encoded>
</item>

<item>
<title>When Design Is the First Form of Care: Lessons from Arnold’s Place Medical Respite Center</title>
<link>https://edusehat.com/en/when-design-is-the-first-form-of-care-lessons-from-arnolds-place-medical-respite-center</link>
<guid>https://edusehat.com/en/when-design-is-the-first-form-of-care-lessons-from-arnolds-place-medical-respite-center</guid>
<description><![CDATA[ Arnold’s Place Medical Respite Center in Alameda, Calif., incorporates residential-scale architecture, gabled rooflines and natural materials to create a welcoming, noninstitutional environment that supports dignity, healing and recovery for individuals experiencing homelessness. | Photo Credit (all): Ankrom Moisan  By Ashlee Washington, NCIDQ, and Mariah Kiersey, AIA, NCARB, NCIDQ, GBCI, LEED AP BD+C  In some states, homeless...
The post When Design Is the First Form of Care: Lessons from Arnold’s Place Medical Respite Center appeared first on HCO News.
The post When Design Is the First Form of Care: Lessons from Arnold’s Place Medical Respite Center appeared first on HCO News. ]]></description>
<enclosure url="https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.ArnoldsPlace-1-600x400.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 01:25:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>When, Design, the, First, Form, Care:, Lessons, from, Arnold’s, Place, Medical, Respite, Center</media:keywords>
<content:encoded><![CDATA[<h5><span class="TextRun SCXW4214589 BCX0" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class="NormalTextRun SCXW4214589 BCX0">Arnold’s Place Medical Respite Center in Alameda, Calif., incorporates residential-scale architecture, gabled </span><span class="NormalTextRun SCXW4214589 BCX0">rooflines</span><span class="NormalTextRun SCXW4214589 BCX0"> and natural materials to create a welcoming, noninstitutional environment that supports dignity, healing and recovery for individuals experiencing homelessness. | Photo Credit (all): Ankrom Moisan</span></span><span class="EOP Selected SCXW4214589 BCX0" data-ccp-props="{}"> </span></h5>
<p><i><span data-contrast="auto">By </span></i><i><span data-contrast="auto">Ashlee Washington, NCIDQ, and Mariah Kiersey, AIA, NCARB, NCIDQ, GBCI, LEED AP BD+C</span></i><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">In some states, homeless patients are readmitted to the hospital at </span><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10940252/" target="_blank" rel="noopener"><span data-contrast="none">more than twice the rate</span></a><span data-contrast="auto"> of housed patients after discharge — not because they’re sicker, but because they have nowhere safe to recover. The gap between acute care and stable recovery stems from inadequate infrastructure, placing a disproportionate burden on the healthcare system’s most vulnerable patients.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Arnold’s Place Medical Respite Center in Alameda, Calif., was designed to close that gap. The 50-bed ground-up facility, developed in partnership with Alameda Point Collaborative and LifeLong Medical Care, bridges hospital discharge and stable recovery from injuries for individuals experiencing homelessness. Arnold’s Place demonstrates trauma-informed design as both a performance requirement and design philosophy, embedded in the building’s structure rather than layered on top.</span><span data-ccp-props="{}"> </span></p>
<h2><b><span data-contrast="auto">A Framework, Not a Finish</span></b><span data-ccp-props="{}"> </span></h2>
<figure aria-describedby="caption-attachment-52431" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="wp-image-52431" src="https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.ArnoldsPlace-2-300x200.jpg" alt="atrium inside Arnold's Place Medical Respite Center" width="400" height="267" srcset="https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.ArnoldsPlace-2-300x200.jpg 300w, https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.ArnoldsPlace-2-1024x683.jpg 1024w, https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.ArnoldsPlace-2-768x512.jpg 768w, https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.ArnoldsPlace-2-1536x1024.jpg 1536w, https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.ArnoldsPlace-2-2048x1365.jpg 2048w, https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.ArnoldsPlace-2-820x545.jpg 820w, https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.ArnoldsPlace-2-600x400.jpg 600w" sizes="(max-width: 400px) 100vw, 400px"><figcaption class="wp-caption-text">A two-story central atrium features natural wood finishes, comfortable seating and a custom tree-inspired kinetic mobile, incorporating biophilic and trauma-informed design principles.</figcaption></figure>
<p><span data-contrast="auto">Trauma-informed design has become a common framework in behavioral health and supportive housing. Too often, though, it’s interpreted as softer finishes, calmer colors and a plant near the reception desk. The harder work happens long before anyone selects finishes.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Arnold’s Place goes further. The design team worked across architecture, interior design, FF&E and master planning, and treated trauma-informed principles as constraints on every decision, from structural orientation to the mounting height of light fixtures. The question was how the building could support emotional regulation, reduce stress and promote recovery for this specific population. That framing changes what gets prioritized in a healthcare building.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">At the first concept meeting, the design team established its main intent: create a community where individuals can flourish and promote healing and dignified care. Every space and every interaction had to promote healing and dignified care. In that same session, the owner, stakeholders, staff and design team wrote eight guiding principles together and named trauma-informed design as the approach. A person arriving in crisis needed a building that gave them control over their own experience, not one more institution doing things to them. </span><span data-ccp-props="{}"> </span></p>
<blockquote><p><span data-contrast="auto">The framework also emphasized peer support and consumer leadership, treating residents as partners in shaping the community. Giving residents options for both social connection and privacy became a guiding principle that carried through the site and floor plans.</span><span data-ccp-props="{}"> </span></p></blockquote>
<h2><b><span data-contrast="auto">Fitting In to Stand Out</span></b><span data-ccp-props="{}"> </span></h2>
<p><span data-contrast="auto">The site was the first test. Located within a quiet Alameda neighborhood, the surrounding community had concerns about what a 50-bed medical respite facility would mean for the neighborhood.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">The design team oriented the building so its shorter facade faces the street, reducing perceived scale. Gabled rooflines, stucco cladding and asphalt shingles draw from the neighborhood’s architectural language, helping the facility read as a natural extension of the area rather than an institution.</span><span data-ccp-props="{}"> </span></p>
<blockquote><p><span data-contrast="auto">A building that signals “institution” from the outside primes residents for an institutional experience before they’ve crossed the threshold. At Arnold’s Place, the exterior became the first expression of the care environment.</span><span data-ccp-props="{}"> </span></p></blockquote>
<h2><b><span data-contrast="auto">Organization as Therapeutic Tool</span></b><span data-ccp-props="{}"> </span></h2>
<figure aria-describedby="caption-attachment-52432" class="wp-caption alignright"><img decoding="async" class="wp-image-52432" src="https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.ArnoldsPlace-3-300x200.jpg" alt="outdoor courtyard at Arnold's Place Medical Respite Center" width="400" height="267" srcset="https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.ArnoldsPlace-3-300x200.jpg 300w, https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.ArnoldsPlace-3-1024x683.jpg 1024w, https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.ArnoldsPlace-3-768x512.jpg 768w, https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.ArnoldsPlace-3-1536x1024.jpg 1536w, https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.ArnoldsPlace-3-2048x1365.jpg 2048w, https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.ArnoldsPlace-3-820x545.jpg 820w, https://hconews.com/wp-content/uploads/2026/11/HCO-Feature.ArnoldsPlace-3-600x400.jpg 600w" sizes="(max-width: 400px) 100vw, 400px"><figcaption class="wp-caption-text">Clear wayfinding, indoor-outdoor connections and a mix of shared and private spaces create an intuitive environment that supports residents’ comfort, independence and sense of control.</figcaption></figure>
<p><span data-contrast="auto">Many people arriving at Arnold’s Place have spent extended time in hospitals, shelters or correctional settings, where they had little control over their own movement. Instead of the centralized corridors and clinical adjacencies typical of those environments, the building is laid out as a low-scale, village-like setting.</span> <span data-contrast="auto">Clear wayfinding, indoor-outdoor connections and shared and private spaces help residents understand and navigate the building.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">A two-story central atrium, organized around an open stair and filled with natural light, anchors that sense of orientation. A custom kinetic mobile, commissioned to evoke a tree, hangs at its center, casting shifting shadows across the floors and walls below. Biophilic elements extend throughout the building, from greenery integrated into the roofline to planted beds positioned near exterior windows and exposed wood elements that introduce warmth and texture to shared spaces.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Safety posed a harder balance. Staff need clear sightlines to residents, but a building that feels watched undermines the trust it’s trying to build. The placement of wings, staff stations and sightlines was calibrated so residents feel both secure and respected.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Resident focus groups helped define where that line should fall. One participant described the desired environment as a “culture of confidence,” built on trust, privacy and autonomy. That feedback shaped details like privacy curtains and wardrobes in shared rooms, giving residents more control while preserving necessary sightlines.</span><span data-ccp-props="{}"> </span></p>
<h2><b><span data-contrast="auto">The Intake Suite as Clinical Sequence</span></b><span data-ccp-props="{}"> </span></h2>
<p><span data-contrast="auto">The ground-floor intake suite welcomes new residents with privacy and care. It includes a decontamination room, showers, laundry and a clothing donation space: amenities that allow someone arriving from the street to transition with their dignity intact before entering shared community spaces.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">That sequencing anticipates a specific vulnerability and removes it as a barrier to care through square footage and adjacency planning.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">On the same floor, a clinic occupies a distinct, independently accessible zone with exam rooms, nursing support and behavioral health services, structured to foster close coordination among providers. A resource center with its own street-facing entry connects residents to housing support, benefits enrollment, sobriety resources, and community referrals during their stay.</span><span data-ccp-props="{}"> </span></p>
<h2><b><span data-contrast="auto">The Details That Do Clinical Work</span></b><span data-ccp-props="{}"> </span></h2>
<blockquote><p><span data-contrast="auto">Acoustics, lighting and furniture are usually treated as finish-level decisions. At Arnold’s Place, they became clinical infrastructure. For residents managing chronic pain, behavioral health conditions or medical recovery, noise, harsh lighting and inaccessible furniture can heighten stress and slow recovery.</span><span data-ccp-props="{}"> </span></p></blockquote>
<p><span data-contrast="auto">Sound was the first concern. Acoustical panels line the corridor walls and common areas, managing sound in a high-occupancy environment while adding warmth, color and texture. A dedicated quiet room offers space for de-escalation and rest, while smaller corridor seating nooks provide opportunities to step away without leaving the floor.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Lighting is soft and indirect. Rather than the harsh downlighting typical of clinical settings, fixtures direct light upward to bounce off the ceilings and fill each room with a diffused glow. The effect is subtle, but for residents coming from emergency rooms and hospital wards, it changes how the building feels from the moment they walk in.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Furniture similarly supports independence. Chairs with arms help residents recovering from surgery, injury or illness sit and stand without assistance, while adjustable dining tables accommodate varying mobility needs. Secure personal storage goes further. For people who may have lost possessions while living on the street, a locked place to keep their things is a basic form of stability, and often the first sign that this space is theirs.</span><span data-ccp-props="{}"> </span></p>
<h2><b><span data-contrast="auto">Design as Part of the Care Continuum</span></b><span data-ccp-props="{}"> </span></h2>
<p><span data-contrast="auto">As healthcare increasingly addresses social determinants of health, recovery environments outside hospitals are becoming critical to the care continuum. Arnold’s Place demonstrates how a building can actively support people receiving care, rather than simply house services.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">The lessons extend well beyond medical respite. Any healthcare environment can benefit from protecting dignity at arrival, helping people find their way and treating light, sound and nature as part of the clinical brief. Privacy also has to be designed around the specific population a building serves. The tension between autonomy and safety doesn’t go away either. Decisions about secured wings, staff visibility and shared spaces must balance autonomy with safety, ideally with residents’ input early in the design process.</span><span data-ccp-props="{}"> </span></p>
<blockquote><p><span data-contrast="auto">The most effective trauma-informed environments build comfort into the plan from the start, shaping how people arrive, navigate spaces, find privacy and regain control. In that sense, design isn’t a backdrop to care. It’s one of the first forms of care a patient encounters.</span><span data-ccp-props="{}"> </span></p></blockquote>
<p><i><span data-contrast="auto">Ashlee Washington, NCIDQ, and Mariah Kiersey, AIA, NCARB, NCIDQ, GBCI, LEED AP BD+C, are Healthcare Studio Leaders with Ankrom Moisan.</span></i><span data-ccp-props="{}"> </span></p>
<p>The post <a rel="nofollow" href="https://hconews.com/2026/11/05/when-design-is-the-first-form-of-care-lessons-from-arnolds-place-medical-respite-center/">When Design Is the First Form of Care: Lessons from Arnold’s Place Medical Respite Center</a> appeared first on <a rel="nofollow" href="https://hconews.com/">HCO News</a>.</p>
<p>The post <a href="https://hconews.com/2026/11/05/when-design-is-the-first-form-of-care-lessons-from-arnolds-place-medical-respite-center/">When Design Is the First Form of Care: Lessons from Arnold’s Place Medical Respite Center</a> appeared first on <a href="https://hconews.com/">HCO News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lily’s I’m Back Story: Juvenile Idiopathic Arthritis (JIA)</title>
<link>https://edusehat.com/en/lilys-im-back-story-juvenile-idiopathic-arthritis-jia-15140</link>
<guid>https://edusehat.com/en/lilys-im-back-story-juvenile-idiopathic-arthritis-jia-15140</guid>
<description><![CDATA[ At four years old, Lily was diagnosed with juvenile idiopathic arthritis (JIA). JIA is an autoimmune form of arthritis that affects children by attacking their joints. Now, as a college student, Lily is in remission, living life normally, and thriving with her arthritis thanks to her ongoing care from OSMS!
The post Lily’s I’m Back Story: Juvenile Idiopathic Arthritis (JIA) appeared first on Orthopedic Sports Medicine Specialists (OSMS). ]]></description>
<enclosure url="https://osmsgb.com/wp-content/uploads/2026/10/Im-Back-Story-Thumbnail.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 01:20:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lily’s, I’m, Back, Story:, Juvenile, Idiopathic, Arthritis, JIA</media:keywords>
<content:encoded><![CDATA[<p>Lily was diagnosed with juvenile idiopathic arthritis (JIA) when she was four years old. When Lily’s mom was drying Lily off from a bath, she noticed that her knee was swollen. Lily’s mom decided to take Lily in to see some doctors, and they ended up being referred to a rheumatologist who diagnosed Lily with JIA.<img fetchpriority="high" decoding="async" class="size-medium wp-image-2882 alignright" src="https://osmsgb.com/wp-content/uploads/2026/10/Young-Lily-247x300.png" alt="Lily when she was younger" width="247" height="300" srcset="https://osmsgb.com/wp-content/uploads/2026/10/Young-Lily-200x242.png 200w, https://osmsgb.com/wp-content/uploads/2026/10/Young-Lily-247x300.png 247w, https://osmsgb.com/wp-content/uploads/2026/10/Young-Lily-400x485.png 400w, https://osmsgb.com/wp-content/uploads/2026/10/Young-Lily-600x727.png 600w, https://osmsgb.com/wp-content/uploads/2026/10/Young-Lily.png 697w" sizes="(max-width: 247px) 100vw, 247px"></p>
<p>When Lily first started her infusions, she had them done at a hospital, to which she expressed, were hard on her. Lily would have to miss full days of school and would be at the hospital for up to 12 hours.</p>
<p>After talking with one of her friends, Lily found out that her friend had been going to OSMS to get her infusions done, expressing to Lily that her infusions were quick and easy – only about two hours.</p>
<p>Upon hearing this, Lily and her parents decided to go over and check out OSMS. Once they met Dr. Tuttle, they realized the process at OSMS was better than the one they were experienced at the hospital.</p>
<p>“Going to my first appointment at OSMS, I was a little nervous at first because I didn’t know what to expect and I was so young,” explained Lily. “I didn’t mind having infusions at OSMS because they were so quick and easy compared to the hospital.”</p>
<p><img decoding="async" class="size-medium wp-image-2881 alignleft" src="https://osmsgb.com/wp-content/uploads/2026/10/Lily-Infusion-when-younger-300x234.png" alt="Lily getting an infusion when she was younger" width="300" height="234" srcset="https://osmsgb.com/wp-content/uploads/2026/10/Lily-Infusion-when-younger-200x156.png 200w, https://osmsgb.com/wp-content/uploads/2026/10/Lily-Infusion-when-younger-300x234.png 300w, https://osmsgb.com/wp-content/uploads/2026/10/Lily-Infusion-when-younger-400x313.png 400w, https://osmsgb.com/wp-content/uploads/2026/10/Lily-Infusion-when-younger-600x469.png 600w, https://osmsgb.com/wp-content/uploads/2026/10/Lily-Infusion-when-younger-768x600.png 768w, https://osmsgb.com/wp-content/uploads/2026/10/Lily-Infusion-when-younger-800x625.png 800w, https://osmsgb.com/wp-content/uploads/2026/10/Lily-Infusion-when-younger-1024x800.png 1024w, https://osmsgb.com/wp-content/uploads/2026/10/Lily-Infusion-when-younger-1200x938.png 1200w, https://osmsgb.com/wp-content/uploads/2026/10/Lily-Infusion-when-younger.png 1267w" sizes="(max-width: 300px) 100vw, 300px"></p>
<p>Growing up with JIA was a challenge for Lily. She mentioned that “It was hard growing up through school knowing that I was different than everyone else and that normal things would be hard for me. That’s the thing about arthritis is that it’s an invisible disease.”</p>
<p>Although it was hard for Lily to navigate her disease through school, she had support from her understanding friends, teachers, and classmates.</p>
<p>Since going to OSMS, Lily describes that she is back to having a normal life again. “I’m able to be a college student now who can worry about my grades and my friends rather than if I’ll be able to walk to class or if my hands will get sore doing my assignments. I even can have a regular job. So, it’s been good knowing that I can do things and keep up with everybody around me and not fall behind because of my disease.”</p>
<p>When it was time for Lily to move to college, it was a little scary for her knowing that she wouldn’t be in close proximity to her family or even Dr. Tuttle. However, Lily quickly realized that it wouldn’t be an issue because she knew she would still have her family’s support over the phone, and that Dr. Tuttle was always one phone call away if she needed his care.</p>
<p>When Lily applied for accommodations, she talked with Dr. Tuttle who quickly filled out the paperwork and signed the forms Lily needed. Lily mentioned, “He was very helpful with that and the whole team is super quick with it. He told me he’s always there if I need anything and I check in with him every summer.”</p>
<p>We asked Lily what advice she would give to someone going through an early arthritis diagnosis, and she explained, “Although it may feel overwhelming, trust your doctors and trust the medications that you’re being put on. OSMS came into my life at a time where anything about arthritis gave me a lot of anxiety. Having switched from the super hard infusions at the hospital to doing the quick, easy ones at the [OSMS] clinic changed my quality of life so much.”</p>
<p><img decoding="async" class="wp-image-2883 alignright" src="https://osmsgb.com/wp-content/uploads/2026/10/Im-Back-Story-Thumbnail-300x169.png" alt="Lily Now - I'm Back Thumbnail" width="367" height="207" srcset="https://osmsgb.com/wp-content/uploads/2026/10/Im-Back-Story-Thumbnail-200x113.png 200w, https://osmsgb.com/wp-content/uploads/2026/10/Im-Back-Story-Thumbnail-300x169.png 300w, https://osmsgb.com/wp-content/uploads/2026/10/Im-Back-Story-Thumbnail-400x226.png 400w, https://osmsgb.com/wp-content/uploads/2026/10/Im-Back-Story-Thumbnail-600x339.png 600w, https://osmsgb.com/wp-content/uploads/2026/10/Im-Back-Story-Thumbnail-768x433.png 768w, https://osmsgb.com/wp-content/uploads/2026/10/Im-Back-Story-Thumbnail-800x451.png 800w, https://osmsgb.com/wp-content/uploads/2026/10/Im-Back-Story-Thumbnail-1024x578.png 1024w, https://osmsgb.com/wp-content/uploads/2026/10/Im-Back-Story-Thumbnail-1200x677.png 1200w, https://osmsgb.com/wp-content/uploads/2026/10/Im-Back-Story-Thumbnail.png 1448w" sizes="(max-width: 367px) 100vw, 367px"></p>
<p>Now, as a college student, Lily is living life normally, explaining that, “Having a doctor be such a good constant in my life for the past couple of years is something that I will always be really grateful for.”</p>
<p>Thanks to OSMS, Lily is in remission, and thriving with her arthritis!</p>
<p>The post <a href="https://osmsgb.com/lilys-im-back-story-juvenile-idiopathic-arthritis/">Lily’s I’m Back Story: Juvenile Idiopathic Arthritis (JIA)</a> appeared first on <a href="https://osmsgb.com/">Orthopedic Sports Medicine Specialists (OSMS)</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Global Perspectives, Unified Care: Bridging the World of Hormones at EndoBridge 2026</title>
<link>https://edusehat.com/en/global-perspectives-unified-care-bridging-the-world-of-hormones-at-endobridge-2026</link>
<guid>https://edusehat.com/en/global-perspectives-unified-care-bridging-the-world-of-hormones-at-endobridge-2026</guid>
<description><![CDATA[ The coastal city of Antalya, Türkiye, hosted the 14th annual EndoBridge meeting October 22–25, 2026. Building on more than a decade of success and supported by the Endocrine Society from the beginning, this year’s conference further solidified its reputation as the cross-cultural platform for clinical dialogue, scientific advancement, and intercontinental collaboration in endocrinology. EndoBridge 2026 […]
The post Global Perspectives, Unified Care: Bridging the World of Hormones at EndoBridge 2026 appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/EndoBridge-logo.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 21:40:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Global, Perspectives, Unified, Care:, Bridging, the, World, Hormones, EndoBridge, 2026</media:keywords>
<content:encoded><![CDATA[<p>The coastal city of Antalya, Türkiye, hosted the 14th annual EndoBridge meeting October 22–25, 2026. Building on more than a decade of success and supported by the Endocrine Society from the beginning, this year’s conference further solidified its reputation as the cross-cultural platform for clinical dialogue, scientific advancement, and intercontinental collaboration in endocrinology. EndoBridge 2026 […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/global-perspectives-unified-care-bridging-the-world-of-hormones-at-endobridge-2026/">Global Perspectives, Unified Care: Bridging the World of Hormones at EndoBridge 2026</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Show me the money: most dentist job adverts omit pay</title>
<link>https://edusehat.com/en/show-me-the-money-most-dentist-job-adverts-omit-pay</link>
<guid>https://edusehat.com/en/show-me-the-money-most-dentist-job-adverts-omit-pay</guid>
<description><![CDATA[ The South West had the largest count of dentist adverts in Dental Group Signal’s retained August 2026 regional sample. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/job_adverts.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 21:35:15 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Show, the, money:, most, dentist, job, adverts, omit, pay</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Nearly two thirds of dentist and specialist recruitment adverts failed to include a numerical remuneration figure, a new analysis has found.</strong></p>



<p>Just 34.6% of dentist and specialist adverts contained explicit information about remuneration in a sample analysis by Dental Group Signal in August 2026, according to the organisation’s report, <a href="https://dentalgroupsignal.substack.com/p/competing-for-clinicians?r=7oij05&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true"><em>Competing for Clinicians</em></a>.</p>



<p>Anthony Gedge, founder of Dental Group Signal, said groups should consider whether a clinician can understand their prospective earnings, support and development opportunities from the advert, and whether those promises are delivered after they join.</p>



<p>‘My advice to dental groups is to be more specific in your adverts and tell the market and the candidate what the potential earnings are. Americans do this more than in the UK market because everything is 15 years ahead of us,’ he said.</p>



<p>The report showed dental nursing adverts are the most likely to include a specific salary as nurses are the most likely to choose a job based on earnings as the lowest paid role in the sector.</p>



<h2 class="wp-block-heading">Which region had the most dentist job adverts?</h2>



<p>In a separate regional analysis, the south west recorded 218 of the 1,008 dentist advert families examined. This was followed by Yorkshire and the Humber with 154 and the south east with 123.</p>



<p>Gedge said: ‘The south west stands out in the advertising we examined. That gives dental groups a reason to look more closely at their local offer.’</p>



<p>However, Dental Group Signal said its regional charts were based on a retained Great Britain sample rather than a complete market census. Coverage was uneven and heavily weighted towards larger dental groups, while Northern Ireland was not included. The figures therefore do not establish which region had the highest vacancy rate, greatest recruitment difficulty or greatest clinical need.</p>



<p>Advert activity should not be treated as a direct measure of workforce supply. As <em>Dentistry</em> has previously reported, <a href="https://dentistry.co.uk/2026/08/26/nhs-dental-crisis-mp-targets-government/">the number of registered dentists can increase while NHS dental provision continues to contract</a>, as national headcounts do not show where or how clinicians work.</p>



<p>The report recommended combining public advertising evidence with internal vacancy, application, start and retention records before drawing conclusions about recruitment performance.</p>



<p><em><a href="https://sso.dentistry.co.uk/" target="_blank" rel="noreferrer noopener">Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</a></em></p>]]> </content:encoded>
</item>

<item>
<title>Making photogrammetry the full&#45;arch standard</title>
<link>https://edusehat.com/en/making-photogrammetry-the-full-arch-standard</link>
<guid>https://edusehat.com/en/making-photogrammetry-the-full-arch-standard</guid>
<description><![CDATA[ Joe Ganderton explains how photogrammetry can reduce uncertainty in full-arch cases and improve fit, workflow efficiency and team confidence. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/photogammatry.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 21:35:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Making, photogrammetry, the, full-arch, standard</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Joe Ganderton explores how photogrammetry can remove uncertainty from full-arch cases, improving fit, efficiency and confidence across the team.</strong></p>



<p>When I first started working on full-arch implant cases, photogrammetry was viewed as disruptive. It was something innovative clinicians were beginning to explore, but it was far from routine. Most cases relied on high-quality intraoral scans of scan bodies and, although we all understood the potential for distortion across long spans, that risk was largely accepted.</p>



<p>Full-arch dentistry has always been described as complex, and rightly so. It demands careful planning, close collaboration between clinician and laboratory, and a sound understanding of biomechanics and aesthetics. Over time, however, I began to question whether some of the complexity we were managing was not purely clinical, but digital.</p>



<p>In single-unit cases, small discrepancies in data capture may never become visible. In a full arch, they rarely remain insignificant. When restoring multiple implants across an edentulous span, minor positional inaccuracies can compound and only reveal themselves at the point of fit.</p>



<h2 class="wp-block-heading">Limits of ‘good enough’ data</h2>



<!--free-wall-stop-->



<p>Long-span intraoral scans are susceptible to stitching distortion.</p>



<p>Small discrepancies between scan bodies, soft tissue interference and cumulative tolerance stacking may each appear manageable in isolation, yet together they introduce uncertainty that affects every stage of design.</p>



<p>That uncertainty shapes behaviour in the laboratory. Technicians begin compensating for possible distortion, often subconsciously. Frameworks may be designed cautiously, occlusion approached defensively, and when a bridge does not seat as expected, the team is left questioning whether the issue lies in surgery, mechanics or data capture.</p>



<p>Those recurring moments of doubt led us to a simple question at Corus Remo Dental Lab: if technology exists that can provide verified spatial accuracy of implant positions, why continue relying on relative positioning alone?</p>



<p>A discussion surrounding the straw technique with a clinician highlighted to me a contradiction: if the promise of digital dentistry is precision, why are we attempting to fine-tune digital workflows through analogue verification?</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p>If the promise of digital dentistry is precision, why are we attempting to fine-tune digital workflows through analogue verification?</p>
</blockquote>



<h2 class="wp-block-heading">Making photogrammetry the baseline</h2>



<p>Photogrammetry systems capture implant positions using multi-angle optical triangulation, producing a precise three-dimensional coordinate map that is independent of soft tissue and free from stitching distortion. In practical terms, we are no longer estimating where implants sit in relation to one another; we are working from confirmed spatial data.</p>



<p>When we made photogrammetry our standard input for full-arch cases, the impact was immediate. Passive fit became more predictable because frameworks were designed around verified implant positions. Chairside adjustments reduced, and fit appointments shifted away from troubleshooting seating issues towards refining aesthetics and occlusion. Digital verification also became more meaningful, as we could confidently overlay photogrammetry data with intraoral scans of healed soft tissue, CBCT records and provisional designs.</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p>We are no longer estimating where implants sit in relation to one another; we are working from confirmed spatial data.</p>
</blockquote>



<p>Over the past year we have completed more than 400 full-arch cases, and that volume has reinforced how much difference reliable input data makes to downstream efficiency. With appointments reduced from six to as few as three and fewer phone calls with clinicians regarding patient issues and troubleshooting.</p>



<h2 class="wp-block-heading">The effect on design and team confidence</h2>



<p>One of the more significant changes has been in mindset. When the starting point is stable, design decisions become more deliberate. There is less need to build in tolerance to guard against potential inaccuracies. Framework thickness, material choice and occlusal planning can be approached with intention rather than caution.</p>



<p>Within the laboratory, this has had a noticeable cultural effect. Technicians are more confident in their work because they trust the data they are building from. Reducing avoidable remakes improves not only efficiency but morale and accountability. Accuracy, in that sense, extends beyond microns. It influences how teams think and collaborate.</p>



<h2 class="wp-block-heading">Consistency over optional upgrades</h2>



<p>We did consider offering photogrammetry as a premium option. Commercially, that would have been straightforward. In practice, it would have introduced inconsistency.</p>



<p>Different data capture methods demand different expectations, which creates friction within a workflow. We therefore took the view that for full-arch cases, photogrammetry should not be an enhancement but the baseline.</p>



<p>To support that approach, we introduced a dedicated booking system through our app, allowing clinicians to reserve scanners alongside patient appointments and specify when scans will be ready for technician review. Removing logistical uncertainty is just as important as improving technical accuracy in complex cases.</p>



<p>Our protocol now reflects this emphasis on verified implant positioning. Planning remains prosthetically driven. Following surgery or osseointegration, implant positions are captured using photogrammetry, with healed soft tissue recorded via intraoral scan. Trial stages and final restorations are then designed on the basis of confirmed coordinates.</p>



<p>Photogrammetry does require investment and clinician engagement, and it does not eliminate the need for judgement. However, in high-value full-arch cases where chair time and reputational considerations are significant, the cost of working from uncertain implant positioning can be far greater. For us, what was once considered disruptive has become responsible practice. Full-arch implant dentistry will always demand skill and experience. Photogrammetry does not replace those qualities.</p>



<p>It provides a more predictable digital foundation on which they can operate, allowing the focus to return to function, aesthetics and long-term success.</p>



<p><em><a href="https://sso.dentistry.co.uk/" target="_blank" rel="noreferrer noopener">Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</a></em></p>]]> </content:encoded>
</item>

<item>
<title>Building a Strong Foundation: Essential Anatomy Resources</title>
<link>https://edusehat.com/en/building-a-strong-foundation-essential-anatomy-resources</link>
<guid>https://edusehat.com/en/building-a-strong-foundation-essential-anatomy-resources</guid>
<description><![CDATA[ Anatomy is one of the most fundamental subjects in medical school – it can be considered, both literally and figuratively, the foundation for almost all other subjects you will study in medicine . A solid grasp of human anatomy is crucial for understanding pathology, performing both thorough and targeted physical examinations, and eventually serving your […]
The post Building a Strong Foundation: Essential Anatomy Resources appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/11/pexels-tara-winstead-7722913-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 21:30:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Building, Strong, Foundation:, Essential, Anatomy, Resources</media:keywords>
<content:encoded><![CDATA[<p><span>Anatomy is one of the most fundamental subjects in medical school – it can be considered, both literally and figuratively, the foundation for almost all other subjects you will study in medicine . A solid grasp of human anatomy is crucial for understanding pathology, performing both thorough and targeted physical examinations, and eventually serving your patient’s needs. However, the vast amount of information is overwhelming for early medical students. To help you navigate this challenging subject, we’ve compiled a list of what we believe are essential <a href="https://elitemedicalprep.com/medical-school-anatomy/">resources, study tips, and supplementary materials</a> to set you up for success.</span></p>
<p> </p>
<p><span>Anatomy is one of the oldest and most revered subjects of medical education. Even from the time of ancient civilizations, physicians have sought to understand the human body to improve medical treatment. The practice of dissection dates back as early as 335–280 BCE to the Greek physician Herophilos, often considered the father of anatomy. He was among the first to dissect human cadavers, ultimately laying the foundation for modern anatomical observations and studies (We will not comment on the controversy that he reportedly vivisected live prisoners!).</span></p>
<p> </p>
<p><span>One of the most famous historical figures in anatomy is Andreas Vesalius, a 16th-century Flemish anatomist whose legendary book, </span><i><span>De Humani Corporis Fabrica</span></i><span>, revolutionized the field of human anatomy by correcting centuries-old misconceptions about human anatomy. His meticulous approach and detailed anatomical illustrations set new standards for medical education.</span></p>
<p> </p>
<p><span>Today, you will continue this tradition, using cadaveric dissection coupled with modern resources to deepen your understanding of the human body.</span></p>
<p> </p>
<h2><b>The Importance of Cadaver Lab</b></h2>
<p><span>If your medical school offers cadaver dissection, it is one of the most valuable experiences you can have as a medical student. It is a tradition dating back thousands of years and should be held with the utmost respect. Many consider their cadaver as the first patient that medical professionals ever have. Cadaver lab provides a hands-on and intimate approach to understanding human anatomy in a way that no textbook or digital resource can replicate.</span></p>
<p> </p>
<h3><b>Why Cadaver Lab is Essential:</b></h3>
<ol>
<li>
<ol>
<li aria-level="1"><b>Three-Dimensional Understanding</b><span> – Seeing and feeling anatomical structures in a real human body helps solidify your spatial understanding. Having the ability to physically manipulate structures with your hands on a real individual is a privilege, often cementing core anatomical concepts with ease.</span></li>
<li aria-level="1"><b>Tactile Learning</b><span> – Dissecting a cadaver allows you to appreciate the texture, depth, and relationships between structures.</span></li>
</ol>
</li>
</ol>
<ul>
<li aria-level="1"><b>Team based learning</b><span> – Cadaver lab is almost always carried out in teams, and you should learn from and teach your fellow classmates.</span></li>
</ul>
<ol>
<li aria-level="1"><b>Real-World Application</b><span> – Textbooks and digital models are helpful, but the variability in human bodies becomes apparent in cadaver labs, which is critical for future clinical practice. Make sure to look at other team’s cadavers to see natural anatomic variations.</span></li>
<li aria-level="1"><b>Memorable Learning</b><span> – The hands-on nature of dissection creates lasting mental impressions that enhance long-term retention.</span></li>
</ol>
<p> </p>
<p><span>If full-body dissection is not available, take advantage of prosections (pre-dissected specimens), which still allow for detailed observation and learning. There are also virtual cadaver labs which many medical schools are utilizing – while we do not believe these provide the same learning experience, it is still very possible to learn the same material necessary to be an exceptional physician.</span></p>
<p> </p>
<h2><b>Top Anatomy Textbooks</b></h2>
<p><span>A good textbook is the backbone of any successful anatomy study plan. Here are some of the most highly recommended books for medical students:</span></p>
<p> </p>
<h3><b>1. </b><a href="https://www.amazon.com/Netter-Atlas-Human-Anatomy-paperback/dp/0323680429"><b>Netter’s Atlas of Human Anatomy</b></a></h3>
<ul>
<li aria-level="1"><b>Why it’s great:</b><span> Features world-renowned anatomical illustrations by Frank H. Netter, making it an excellent resource for visual learners. This is one of, if not the most, commonly used textbooks by students.</span></li>
<li aria-level="1"><b>Best for:</b><span> Students who benefit from high-quality artwork to visualize anatomical structures.</span></li>
<li aria-level="1"><b>Bonus:</b><span> You can pair the Atlas with </span><a href="https://www.amazon.com/Netters-Anatomy-Flash-Netter-Science/dp/0323834175/ref=pd_lpo_d_sccl_1/139-2610230-9587924?pd_rd_w=S79aU&content-id=amzn1.sym.4c8c52db-06f8-4e42-8e56-912796f2ea6c&pf_rd_p=4c8c52db-06f8-4e42-8e56-912796f2ea6c&pf_rd_r=XAB71N7HZZ8CGNJ5VNWD&pd_rd_wg=WuSEv&pd_rd_r=fd9f6ef2-7f24-4bf9-a75a-155f4ade4bf7&pd_rd_i=0323834175&psc=1"><span>Netter’s Flashcards</span></a><span> for on-the-go review – there are also numerous pre-made Anki decks exist to reinforce learning. Additionally, there is a </span><a href="https://www.amazon.com/Netters-Anatomy-Coloring-Netter-Science/dp/0323826733/ref=sr_1_1?crid=2Y5WYQSU29EQX&dib=eyJ2IjoiMSJ9.TIYwRo6EJsD33aaTYfzFHmlZ-C27yC-NMWaIUuS4my34zFxoKyOFq0oahRwXGYO5fAGXhb1Nx7dH9kLuh8sTDN2NVAHzQ2-BjT2KUz2NGB1jai5G2qirLtDLPFF3w9op9VWIsam3iqInHeXbRYo3EKzSBLlEXoJwNHP1YAOSwHkeb24wOUp6BE7qvUTD55AOITTSEtj56rPAKEVbdsh1wVzUh47HSnweRaazebjv0ZU.0UNqQtUEesS413tdm87VGCGZhDrqS1sqNUQxOUi1CrI&dib_tag=se&keywords=netter+coloring&qid=1743020014&sprefix=netter+coloring%2Caps%2C122&sr=8-1"><span>coloring book</span></a><span> to accompany the Atlas for those who like an interactive and artistic experience.</span></li>
</ul>
<h3><b>2. </b><a href="https://www.amazon.com/Grays-Anatomy-Anatomical-Clinical-Practice/dp/0702052302"><b>Gray’s Anatomy</b></a></h3>
<ul>
<li aria-level="1"><b>Why it’s great:</b><span> This textbook traces its roots back to 1858 when it was first published by Henry Gray and has been revised for over 150 years. It provides a comprehensive but digestible overview of anatomy with clear illustrations and concise explanations.</span></li>
<li aria-level="1"><b>Best for:</b><span> Visual learners who appreciate detailed diagrams and clinical correlations.</span></li>
</ul>
<h3><b>3. </b><a href="https://www.amazon.com/Clinically-Oriented-Anatomy-Lippincott-Connect/dp/1975209540/ref=sr_1_1?crid=3KDT206D1RKEC&dib=eyJ2IjoiMSJ9.6W4C981YT-JcoRRLNGMxQC2UVEHROka2efcGYWnns385GiLd6JrNTV0Ywd8VAxd8NDw_jh4U_MCj1NXRnYtzjol5dQS4hpeAQrWhUmHNKrvSGSIPDZyCuB-_8sOriYYcnwTjOQmBUIl501s4fXhYqp2grSvuj0hU55ro29WCiGkzm2L9KNJGgGQrOmvrYSfZzPBMpiLZkGDsRRc-Hjje7B8fCdCB0pBb0Z8c3hiTOj0.69_vq9HF0v7_Ml8GvpTv9x5Mpn2_-vU4lzIJDF_zmc4&dib_tag=se&keywords=Moore%E2%80%99s+anatomy&qid=1743020238&s=books&sprefix=moore+s+anatomy%2Cstripbooks%2C99&sr=1-1"><b>Moore’s Clinically Oriented Anatomy</b></a></h3>
<ul>
<li aria-level="1"><b>Why it’s great:</b><span> Unlike Netter and Gray’s, Moore’s focuses a bit more on the clinical applications of anatomy. It does provides in-depth explanations suitable for students who want a deeper understanding (looking at you surgical bound medical students)</span></li>
<li aria-level="1"><b>Best for:</b><span> Those who enjoy case-based learning and integration with clinical practice.</span></li>
</ul>
<h3><b>4. </b><a href="https://www.amazon.com/Anatomy-Photographic-Atlas-Color-Study/dp/1451193181"><b>Rohen’s Anatomy: A Photographic Atlas</b></a></h3>
<ul>
<li aria-level="1"><b>Why it’s great:</b><span> Uses real cadaveric photographs instead of illustrations, making it useful for students who want to familiarize themselves with real human structures. One of the biggest complaints from Netter’s is that it is primarily illustrations (however, some students prefer this as it improves clarity of the images and learning).</span></li>
<li aria-level="1"><b>Best for:</b><span> Preparing for dissections and practical exams.</span></li>
<li aria-level="1"><b>Bonus:</b><span> Provides labeled and unlabeled images for self-testing.</span></li>
</ul>
<p> </p>
<h3><b>5. Surgical Anatomy Textbooks</b></h3>
<ul>
<li aria-level="1"><span>If you are interested in pursuing a surgical subspeciality, there are textbooks made for these purposes as well. Often, these are made for residents and fellows; however, if you are interested in starting earlier, some students like to learn anatomy through future surgical procedures!</span></li>
</ul>
<p> </p>
<h2><b>High-Yield Apps and Online Platforms</b></h2>
<p><span>In the digital age, there are numerous online tools to supplement your learning. Here are the highest-yield resources:</span></p>
<p> </p>
<h3><b>1. </b><a href="https://3d4medical.com/"><b>Complete Anatomy (3D4Medical)</b></a></h3>
<ul>
<li aria-level="1"><span>Provides an interactive 3D model of the human body and is best for visualizing anatomical structures in high detail.</span></li>
<li aria-level="1"><span>Also provides animations to see the body move in real time (i.e. heart pumping, muscle movements, etc.)</span></li>
<li aria-level="1"><span>Also Includes quizzes and guided learning paths.</span></li>
<li aria-level="1"><span>Available on both desktops and mobile devices.</span></li>
</ul>
<h3><b>2. </b><a href="https://apps.ankiweb.net/"><b>Anki Flashcards</b></a></h3>
<ul>
<li aria-level="1"><span>A staple for many medical students – uses <a href="https://elitemedicalprep.com/guide-to-creating-high-yield-flashcard-decks-on-uworld/">spaced repetition</a> to help retain information.</span></li>
<li aria-level="1"><span>This is an ideal resource for reinforcing anatomy given the amount of memorization needed</span></li>
<li aria-level="1"><span>There are numerous pre-made Anki decks, specifically for Netter’s Atlas which are available online</span></li>
</ul>
<h3><b>3. </b><a href="https://www.kenhub.com/"><b>Kenhub</b></a></h3>
<ul>
<li aria-level="1"><span>An online platform offering detailed video tutorials, quizzes, and labeled diagrams.</span></li>
<li aria-level="1"><span>It offers customizable learning plans tailored to different anatomical (and histological) topics.</span></li>
<li aria-level="1"><span>Also available on both desktops and mobile devices.</span></li>
</ul>
<p> </p>
<h2><b>Effective Study Tips for Anatomy</b></h2>
<p><span>Mastering anatomy requires a strategic approach. Here are some tried-and-true study techniques:</span></p>
<h3><b>1. Active Learning Over Passive Reading</b></h3>
<ul>
<li aria-level="1"><span>Instead of just reading the textbook, <a href="https://elitemedicalprep.com/5-study-tips-for-usmle-step-1/">actively engage with the material</a>. Label diagrams, teach concepts to peers, or use mnemonic devices to retain information.</span></li>
</ul>
<h3><b>2. Utilize Dissection and Prosections</b></h3>
<ul>
<li aria-level="1"><span>As mentioned above, if your medical school offers cadaveric dissection, take full advantage of it. Seeing and touching real structures enhances spatial understanding in a one-in-a-lifetime experience.</span></li>
</ul>
<h3><b>3. Use Mnemonics and Memory Aids</b></h3>
<ul>
<li aria-level="1"><span>Whether you like it or not, A LOT of anatomy is strict memorization. Therefore, tips and tricks to help you memorize anatomic structures are a must!</span></li>
<li aria-level="1"><span>Examples: “So Long To Pinky, Here Comes The Thumb” for the carpal bones or “C3, 4, 5 keep the diaphragm alive” for the phrenic nerve.</span></li>
</ul>
<h3><b>4. Focus on Structure-Function Relationships</b></h3>
<ul>
<li aria-level="1"><span>One of the most effective ways to make anatomy meaningful is to understand how structure dictates function.</span></li>
<li aria-level="1"><span>For example, understanding where a muscle/tendon originates from and inserts will directly tell you about its function when the muscle contracts. Similarly, the thickness of the left ventricular wall correlates with its role in pumping blood to the systemic circulation (as compared to the right ventricle which only pumps blood throughout the relatively lower resistance pulmonary vasculature).</span></li>
<li aria-level="1"><span>Recognizing these relationships will help you apply the anatomy you learn to clinical contexts when diagnosing injuries or diseases.</span></li>
</ul>
<h3><b>5. Test Yourself Regularly and Integrate Clinical Context Early</b></h3>
<ul>
<li aria-level="1"><span>Use practice questions and flashcards to reinforce knowledge. Spaced repetition (reviewing material at increasing intervals) is key to long-term retention.</span></li>
<li aria-level="1"><span>Question banks like <a href="https://elitemedicalprep.com/amboss-vs-uworld-which-is-a-better-usmle-resource/">UWorld and AMBOSS</a> allow you to make practice tests just focused on anatomy.</span></li>
</ul>
<ul>
<li aria-level="1"><span>Understanding the relevance of anatomy in real-life scenarios enhances retention. Try linking anatomical structures to pathology and clinical cases through question banks as well.</span></li>
</ul>
<p> </p>
<h2><b>Conclusion: Build Your Anatomy Mastery Step by Step</b></h2>
<p><span>Anatomy is a challenging but rewarding subject that lays the foundation for your career as a physician. By using a variety of different resources including cadaver lab, textbooks, and digital resources, you can develop a solid understanding of human anatomy from the very beginning of medical school! If your school offers cadaver lab, take full advantage of it, it’s one of the most rewarding and impactful learning experiences in your entire career.</span></p>
<p> </p>
<p><span>Remember, anatomy is best learned through repeated exposure and active engagement.<a href="https://elitemedicalprep.com/how-to-make-a-study-schedule/"> Find a study method</a> (or methods) that works for you, and don’t hesitate to seek help from your peers or a <a href="https://elitemedicalprep.com/meet-the-tutors/"><strong>tutor</strong></a>!</span></p>
<p>The post <a href="https://elitemedicalprep.com/building-a-strong-foundation-essential-anatomy-resources/">Building a Strong Foundation: Essential Anatomy Resources</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Canadian researchers launch national AI platform to advance personalized pediatric care</title>
<link>https://edusehat.com/en/canadian-researchers-launch-national-ai-platform-to-advance-personalized-pediatric-care</link>
<guid>https://edusehat.com/en/canadian-researchers-launch-national-ai-platform-to-advance-personalized-pediatric-care</guid>
<description><![CDATA[ A new national research initiative led by Holland Bloorview Kids Rehabilitation Hospital aims to improve understanding of childhood disabilities and neurodevelopmental conditions by bringing together health data and artificial intelligence. The initiative, known as Whole-Child Open Neuroscience Data for Empowering Research (WONDER), will enable researchers across Canada to securely analyze existing genetic, brain imaging and […]
The post Canadian researchers launch national AI platform to advance personalized pediatric care appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_2579142623-e1793883038891.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 21:05:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Canadian, researchers, launch, national, platform, advance, personalized, pediatric, care</media:keywords>
<content:encoded><![CDATA[<p>A new national research initiative led by Holland Bloorview Kids Rehabilitation Hospital aims to improve understanding of childhood disabilities and neurodevelopmental conditions by bringing together health data and artificial intelligence.</p>
<p>The initiative, known as Whole-Child Open Neuroscience Data for Empowering Research (WONDER), will enable researchers across Canada to securely analyze existing genetic, brain imaging and behavioural information to better understand the factors influencing children’s development, health and well-being.</p>
<p>Announced November 4, the project is being developed in collaboration with the University of Calgary and CHU Sainte-Justine in Montreal, with funding support from Brain Canada’s Platform Support Grants program.</p>
<p>The goal is to help researchers identify patterns that could eventually support more personalized and effective approaches to care for children with autism, attention-deficit/hyperactivity disorder (ADHD), cerebral palsy, mental health conditions and genetic disorders.</p>
<h3>Connecting research across Canada</h3>
<p>Canadian researchers have developed extensive datasets involving childhood development and disability. However, these resources are often maintained independently by different institutions, limiting opportunities for large-scale analysis.</p>
<p>WONDER is designed to address this challenge by creating a national research infrastructure that allows participating organizations to collaborate while maintaining control of their own information.</p>
<p>Rather than transferring sensitive patient data into a centralized database, the platform will use a federated approach.</p>
<p>Under this model, data remain at their original institutions while researchers use coordinated analytical methods to generate insights across participating datasets.</p>
<p>The approach is intended to support collaboration while protecting privacy and respecting institutional data-governance requirements.</p>
<h3>Using artificial intelligence to identify patterns</h3>
<p>Artificial intelligence will play an important role in analyzing the complex relationships between genetic, neurological and behavioural information.</p>
<p>By examining patterns across multiple datasets, researchers hope to better understand why children with similar diagnoses may experience different developmental trajectories, strengths and support needs.</p>
<p>These insights could eventually help healthcare professionals develop more individualized approaches to assessment, treatment and rehabilitation.</p>
<p>The platform will also make advanced analytical methods more accessible to researchers from different disciplines, supporting collaboration among clinicians, scientists and families.</p>
<h3>National research leadership</h3>
<p>The project is led by Dr. Azadeh Kushki, senior scientist and associate chief of data science at Holland Bloorview’s Bloorview Research Institute.</p>
<p>Kushki is also a professor at the University of Toronto’s Institute of Biomedical Engineering and Canada Research Chair in Neurodiversity and Personalized Health.</p>
<p>The initiative is co-led by Dr. Paul Arnold of the University of Calgary and Dr. Clara Moreau of CHU Sainte-Justine.</p>
<p>Together, the research team will work to establish a collaborative infrastructure capable of supporting studies across institutions and research disciplines.</p>
<p>The initiative is also intended to encourage broader participation in childhood disability research and help researchers examine differences in children’s experiences and outcomes.</p>
<h3>Part of a broader investment in brain research</h3>
<p>WONDER is supported through Brain Canada’s Platform Support Grants program, which invests in shared scientific infrastructure and resources.</p>
<p>The initiative is one of four newly supported research platforms in Ontario representing a combined investment of $10.57 million.</p>
<p>These investments are intended to provide researchers with access to specialized technologies, analytical tools and collaborative infrastructure that would be difficult for individual institutions to develop independently.</p>
<p>Since its establishment, Brain Canada’s Platform Support Grants program has invested more than $125 million in 46 research platforms, supporting collaboration across numerous institutions and scientific disciplines.</p>
<h3>Potential implications for pediatric care</h3>
<p>For hospitals and pediatric healthcare providers, the initiative represents an effort to improve how research findings are translated into more individualized approaches to care.</p>
<p>Children with neurodevelopmental conditions and disabilities often have complex needs that cannot be fully understood through diagnosis alone.</p>
<p>Combining information from different research disciplines may help investigators identify biological, behavioural and environmental factors associated with varying health outcomes.</p>
<p>Over time, these findings could inform new approaches to clinical assessment, rehabilitation and treatment planning.</p>
<p>The platform remains under development, and its anticipated benefits for patient care have not yet been demonstrated.</p>
<p>Nevertheless, the project represents a significant step toward building a more connected national research environment, with the potential to advance precision health for children and families across Canada.</p>
<p>Source: <a href="https://hollandbloorview.ca/stories-news-events/news/national-platform-will-advance-personalized-care-children-brain-based?utm_source=chatgpt.com">Holland Bloorview Kids Rehabilitation Hospital — November 4, 2026</a></p>
<p>The post <a href="https://www.hospitalnews.com/canadian-researchers-launch-national-ai-platform-to-advance-personalized-pediatric-care/">Canadian researchers launch national AI platform to advance personalized pediatric care</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AI can beat physician diagnoses, but productivity boosts are limited</title>
<link>https://edusehat.com/en/ai-can-beat-physician-diagnoses-but-productivity-boosts-are-limited</link>
<guid>https://edusehat.com/en/ai-can-beat-physician-diagnoses-but-productivity-boosts-are-limited</guid>
<description><![CDATA[ Two new studies show that while AI can beat physicians when it comes to patient diagnoses, the technology doesn’t appear to offer improvements in productivity. Here’s what researchers found in reviewing how physicians use AI for diagnosing clinical cases and taking patient notes. AI and diagnoses: Science A study in Science found that an AI […]
The post AI can beat physician diagnoses, but productivity boosts are limited appeared first on Today&#039;s Hospitalist. ]]></description>
<enclosure url="https://todayshospitalist.com/wp-content/uploads/2026/11/diagnostic-test-of-AI-shutterstock_2745796723-11-5-26.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 21:00:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>can, beat, physician, diagnoses, but, productivity, boosts, are, limited</media:keywords>
<content:encoded><![CDATA[<p>Two new studies show that while AI can beat physicians when it comes to patient diagnoses, the technology doesn’t appear to offer improvements in productivity. Here’s what researchers found in reviewing how physicians use AI for diagnosing clinical cases and taking patient notes.</p>
<h4><strong>AI and diagnoses: Science</strong></h4>
<p><a href="https://www.science.org/doi/10.1126/science.aeh7930">A study in Science</a> found that an AI system built by Microsoft named Diagnostic Orchestrator to diagnose complex medical cases reached a correct diagnosis in about 83.2% of cases. Physicians, by comparison, got the right diagnosis in 36% to 47% of cases.</p>
<p>Researchers used 304 clinical cases from The New England Journal of Medicine and 325 emergency department encounters to test the diagnostic skills of humans and AI. Unlike other studies that present one scenario, the Science research started by providing only a brief clinical presentation. The study forced physicians and the AI tool to work through the cases step by step, giving additional information only when follow-up questions were asked.</p>
<p>In nonemergency cases, a group of physicians that included internists and emergency medicine physicians achieved accurate diagnoses in 22.3% of cases without using reference tools. When physicians used reference tools, their diagnostic accuracy jumped to 36.1%. The AI system, by comparison, was accurate in 83.2% of cases.</p>
<p><a href="https://www.medicaleconomics.com/view/ai-system-outperforms-physicians-on-diagnostic-accuracy-in-microsoft-study">A Medical Economics analysis of the study</a> found that the results were similar for emergency cases. AI was accurate in 80.3% of emergency cases compared to 46.8% for physicians.</p>
<p>Researchers noted that AI greatly outperformed even the highest-scoring individual physicians in both emergency and nonemergency cases. The peak performance by physicians on nonemergency cases was 51.8%. For emergency cases, the best physicians were accurate 62.5% of the time.</p>
<p>The study uncovered differences in how physicians and AI approach patient cases. Physicians, for example, asked an average of 5.6 questions before ordering a test. The AI system, by comparison, asked 25.5 questions before ordering a test.</p>
<p>In addition to reviewing diagnostic accuracy, researchers tried to compare the costs of tests ordered by physicians and AI. The AI system spent $5,431 on tests in nonemergency cases compared to $4,725 spent by physicians. In emergency cases, AI spent $4,979 on testing compared to $3,400 for physicians.</p>
<h4><strong>Ambient AI and physician productivity: Annals of Internal Medicine</strong></h4>
<p><a href="https://www.acpjournals.org/doi/10.7326/ANNALS-25-05294">A second study published in Annals of Internal Medicine</a> found that physicians using ambient AI scribes cut the time they spent taking notes but didn’t see other gains in productivity.</p>
<p>Outpatient physicians using an AI system known as Heidi slashed the time they spent on patient notes from 21 to 18.6 minutes. At the same time, median note length jumped from 4,854 to 5,187 characters.</p>
<p>The study found that reducing the time physicians sped on patient notes didn’t lead to other productivity gains. Researchers, for example, found that physicians didn’t close out patient notes any faster either on the day they saw patients or later.</p>
<p><a href="https://www.medpagetoday.com/practicemanagement/informationtechnology/123591">A MedPage Today analysis of the study</a> noted that some physicians have reported spending an average of three hours working on patient notes on their days off. Some experts hope that tools like ambient AI can help reduce time spent on administrative tasks to not only improve physician productivity, but reduce burnout.</p>
<p><a href="https://www.acpjournals.org/doi/10.7326/ANNALS-26-03797">An accompanying editorial</a> suggested that one reason physicians didn’t end up saving more time was that they may have to spend more time on the back end reviewing and editing notes produced by AI.</p>
<p>The editorial hypothesized that the combination of physicians spending less time taking notes and AI producing notes that are longer may produce “downstream consequences” for patient care. And because the technology can produce issues including fabrications, omissions and misinterpretations, the editorial said, regulations may be needed to protect patient care.</p>
<p>The post <a href="https://todayshospitalist.com/ai-can-beat-physician-diagnoses-but-productivity-boosts-are-limited/">AI can beat physician diagnoses, but productivity boosts are limited</a> appeared first on <a href="https://todayshospitalist.com/">Today's Hospitalist</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dr. Reddy’s receives marketing authorisation for generic semaglutide injection in Brazil</title>
<link>https://edusehat.com/en/dr-reddys-receives-marketing-authorisation-for-generic-semaglutide-injection-in-brazil</link>
<guid>https://edusehat.com/en/dr-reddys-receives-marketing-authorisation-for-generic-semaglutide-injection-in-brazil</guid>
<description><![CDATA[ 
 The approval expands Dr. Reddy’s semaglutide presence to Brazil, one of the key markets in Latin America
The post Dr. Reddy’s receives marketing authorisation for generic semaglutide injection in Brazil appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 17:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Dr., Reddy’s, receives, marketing, authorisation, for, generic, semaglutide, injection, Brazil</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="431" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building-300x172.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Dr. Reddy’s Laboratories announced that Brazil’s National Health Surveillance Agency (ANVISA) has granted marketing authorisation for generic semaglutide injection for the treatment of adults with insufficiently controlled type 2 diabetes mellitus, as an adjunct to diet and exercise, either as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, or in addition to other medicinal products for the treatment of diabetes.</p>
<p>The product will be available as a pre-filled, multi-dose injectable pen in two presentations, 2 mg/1.5 mL and 4 mg/3 mL, for once-weekly dosing.</p>
<p>Brazil has 16.6 million adults aged 20–79 living with diabetes and ranks sixth globally in terms of the number of adults living with diabetes. Reflecting the significant treatment need in the country, the semaglutide market for diabetes is estimated at approximately USD 244.6 million.</p>
<p>Commenting on the approval, MV Ramana, Chief Executive Officer, Global Generics, Dr. Reddy’s Laboratories, said, “Our focus with semaglutide is to expand access to this treatment option across markets where the patient need is significant. Brazil, with its substantial burden of diabetes, is an important part of that journey. This approval builds on our broader semaglutide strategy and brings us another step closer to making semaglutide available to more patients. We plan to launch semaglutide in Brazil with Aché.”</p>
<p>The post <a href="https://www.expresspharma.in/dr-reddys-receives-marketing-authorisation-for-generic-semaglutide-injection-in-brazil/">Dr. Reddy’s receives marketing authorisation for generic semaglutide injection in Brazil</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>HRV Pharma acquires Phatebo GmbH; enters European finished formulations market</title>
<link>https://edusehat.com/en/hrv-pharma-acquires-phatebo-gmbh-enters-european-finished-formulations-market</link>
<guid>https://edusehat.com/en/hrv-pharma-acquires-phatebo-gmbh-enters-european-finished-formulations-market</guid>
<description><![CDATA[ 
Phatebo sources the comparator, investigational and ancillary medicines that pharmaceutical sponsors and clinical research organisations need to run their trials, and becomes HRV’s first finished formulations business in Europe
The post HRV Pharma acquires Phatebo GmbH; enters European finished formulations market appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 17:20:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>HRV, Pharma, acquires, Phatebo, GmbH, enters, European, finished, formulations, market</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p>HRV Pharma, a global virtual pharmaceutical company, announced that it has entered into definitive agreements to acquire 100 per cent of the equity of Phatebo GmbH from ZeroStack Corp.<br>
Phatebo is a licensed pharmaceutical company based in Hilzingen, Germany, specialising in clinical trial supply, with revenues of approximately ₹350 crore in 2025. The acquisition takes HRV beyond active pharmaceutical ingredients into finished formulations, and gives HRV a licensed operating business in Germany.</p>
<p>Clinical trial supply at the core</p>
<p>Every clinical trial depends on more than the new therapy being tested. Sponsors also need a reliable supply of comparator medicines, usually approved branded products against which the new treatment is measured, and of ancillary medicines used alongside it in the study. These have to be sourced through licensed channels, in the right quantities, with complete records of origin, batch and expiry, and they have to reach the study on schedule. When they do not, the trial waits.<br>
Founded in 2015, Phatebo holds a German pharmaceutical wholesale authorisation and has built its business around this work. It sources investigational, comparator and ancillary medicines, including innovative branded therapies, for global pharmaceutical companies and clinical research organisations. It operates quality systems built for good distribution practice, and it also trades in pharmaceuticals and medical devices across Europe and international markets.</p>
<p>How the two businesses fit</p>
<p>With Phatebo, HRV now operates across both layers of the pharmaceutical value chain: active pharmaceutical ingredients through its partner network, and finished medicines through a licensed European business that already supplies sponsors worldwide. The acquisition fits HRV’s IP-led, asset-light model, in which HRV works with certified manufacturing partners rather than owning plants. Phatebo brings a licensed European entity, established good distribution practice systems and long-standing relationships with sponsors and clinical research organisations. HRV brings relationships with more than 50 FDA and EU-GMP certified manufacturing partners and customers in 55 countries, across the US, Europe, the Middle East, Latin America and Asia-Pacific.</p>
<p>Phatebo continues to operate under its own name from Hilzingen, led by Managing Director Martin Lisker, with its existing team and customer agreements in place.</p>
<p>“ Clinical trials today run across many countries at once, and each one depends on the right medicine reaching the right patient at the right time. Very few companies do that work well, and Phatebo is one of them. Sponsors around the world trust this team with studies where there is no room for error. Bringing them into the HRV family gives us our first finished formulations business, alongside the API portfolio we have built since 2015. I could not have asked for a better team to take that step with.” Hari Kiran Chereddi, Founder, Managing Director and CEO, HRV Pharma</p>
<p>“Our customers rely on us to source the right medicines, at the right time, for trials that cannot wait. That responsibility shapes how we qualify every supply channel and how we document every shipment. In HRV we have an owner that understands quality and speed the way we do, and that matters to our team and to the sponsors we serve.” Martin Lisker, Managing Director, Phatebo GmbH</p>
<p> </p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/hrv-pharma-acquires-phatebo-gmbh-enters-european-finished-formulations-market/">HRV Pharma acquires Phatebo GmbH; enters European finished formulations market</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Duraphat fluoride varnish for caries control</title>
<link>https://edusehat.com/en/duraphat-fluoride-varnish-for-caries-control</link>
<guid>https://edusehat.com/en/duraphat-fluoride-varnish-for-caries-control</guid>
<description><![CDATA[ Colgate outlines the licensed status, evidence and application considerations for Duraphat fluoride varnish in caries control. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/duraphat-fluoride-varnish-feature.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 14:25:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Duraphat, fluoride, varnish, for, caries, control</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-full"></figure>



<p><strong>Colgate explains the product licence, evidence and application considerations for Duraphat fluoride varnish in caries control.</strong></p>



<p>Dental teams have access to a wide range of professional products to support caries prevention, including fluoride varnish. It is important to understand that not all fluoride varnishes are intended for the same use. The distinction can be identified by their regulatory status, as defined by the Medicines and Healthcare products Regulatory Agency (MHRA).</p>



<p>The MHRA defines a medicine as a substance or combination of substances presented as having properties for treating or preventing disease in people (MHRA, 2021). A medical device’s principal mode of action does not include treating or preventing disease (MHRA, 2021).</p>



<p>According to Colgate, Duraphat fluoride varnish is the only fluoride varnish with the legal status of a medicine and a licence for caries control. Colgate says that other fluoride varnishes currently on the UK market are medical devices intended to treat hypersensitive teeth, rather than caries control. The manufacturer says that medical devices act primarily by physical or mechanical means, while medicines act through pharmacological, metabolic or immunological effects.</p>



<h2 class="wp-block-heading">Why does this matter?</h2>



<p>Delivering better oral health guidance recommends applying 22,600 ppm fluoride varnish twice a year for caries prevention in children aged three years and over (OHID, 2021). This increases to three-monthly applications for patients at increased caries risk. For adults at increased caries risk, guidance may recommend an application every three or six months, depending on their caries pathway (OHID, 2021; DHSC, 2025; NHS England, 2025).</p>



<p>Colgate says that using a fluoride varnish licensed for caries control supports dental practitioners’ responsibilities as prescribers. It says this is also relevant to appropriately trained extended duties dental nurses and to dental hygienists and dental therapists working to exemptions (NHS England, 2016; NHS England, 2025).</p>



<h2 class="wp-block-heading">Transparent information</h2>



<p>Colgate says that its Duraphat fluoride varnish product licence information is publicly accessible through the MHRA website (MHRA, 2026). This includes the Summary of Product Characteristics, which the manufacturer says can help dental professionals make an informed choice before application.</p>



<p>The product information lists the following indications:</p>



<ul class="wp-block-list">
<li>Prevention of caries in children and adults as part of a comprehensive control programme</li>



<li>Prevention of recurring or marginal caries</li>



<li>Prevention of progression of caries</li>



<li>Prevention of decalcification around orthodontic appliances</li>



<li>Prevention of pit and fissure occlusal caries.</li>
</ul>



<p>This prescribing information is also available in an abridged form on marketing materials for Duraphat fluoride varnish.</p>



<h2 class="wp-block-heading">Application</h2>



<p>Before applying Duraphat fluoride varnish, advise the patient, parent or carer about its purpose, benefits, process, possible side effects and alternatives. Ensure that the patient has eaten before the application, and explain that the varnish is applied with a small brush. Colgate says that the application is quick, simple and painless, and that the varnish has a raspberry taste.</p>



<p>According to Colgate, the opaque yellow tint of Duraphat fluoride varnish is temporary. It wears off or can be brushed off after four hours if desired. The manufacturer says that this tint can be a useful application guide, including when treating a fidgety child.</p>



<p>Other fluoride varnishes that are not licensed for caries control can offer a range of flavours intended to engage children. Colgate says this could imply that such products can be used for caries control. A review of flavoured fluoride varnishes found that flavour was not an effective way to engage a child. Instead, it suggested offering a choice of safety glasses or asking which side of the arch they would like to start on, to give the child an element of control (Cunningham and Linden, 2025).</p>



<p>It is increasingly important to consider fluoride varnish application for adults at higher caries risk. This includes the planned caries pathways for higher-risk adults proposed as part of the latest dental reform, aligned with the 10-year NHS plan (NHS England, 2026, NHS England, 2025).</p>



<p>For more information, visit <a href="https://www.colgateprofessional.co.uk/products/duraphat-landing?utm_source=Dentistry&utm_medium=Article&utm_campaign=POC_UK_Duraphat&utm_content=Varnish" target="_blank" rel="noreferrer noopener">Colgate’s Duraphat fluoride varnish page</a>.</p>



<p>† Duraphat fluoride varnish is for patients aged three years and over.</p>



<h3 class="wp-block-heading">References</h3>



<ol class="wp-block-list">
<li><a href="https://www.gov.uk/guidance/borderline-products-how-to-tell-if-your-product-is-a-medicine" target="_blank" rel="noreferrer noopener">Borderline products: how to tell if your product is a medicine</a>.</li>



<li><a href="https://www.gov.uk/guidance/borderline-products-how-to-tell-if-your-product-is-a-medical-device" target="_blank" rel="noreferrer noopener">Borderline products: how to tell if your product is a medical device</a>.</li>



<li>Delivering better oral health: an evidence-based toolkit for prevention, Office for Health Improvement and Disparities, 2021.</li>



<li>Dental contract quality and payment reforms, DHSC consultation webinar, Tuesday 15 July 2025.</li>



<li><a href="https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/09/avoidance-doubt-v4-1.pdf" target="_blank" rel="noreferrer noopener">Avoidance of doubt: application of fluoride varnish by dental nurses</a>. Chief Dental Officer, NHS England, 2016.</li>



<li><a href="https://www.england.nhs.uk/long-read/supply-and-administration-of-medicines-by-dental-hygienists-and-dental-therapists/" target="_blank" rel="noreferrer noopener">Supply and administration of medicines by dental hygienists and dental therapists</a>. NHS England, 2025.</li>



<li><a href="https://products.mhra.gov.uk/" target="_blank" rel="noreferrer noopener">MHRA Products</a>.</li>



<li>Cunningham B, Linden J. <a href="https://doi.org/10.1038/s41432-025-01162-3" target="_blank" rel="noreferrer noopener">Using flavour in your favour: does giving children an element of control help them engage more positively with the dental experience?</a> Evid Based Dent 26, 97–98 (2025).</li>



<li><a href="https://www.england.nhs.uk/long-read/nhs-dentistry-quality-payment-reforms-contractual-guidance/" target="_blank" rel="noreferrer noopener">NHS dentistry quality and payment reforms contractual guidance</a>.</li>



<li>Fit for the Future: 10 Year Health Plan for England. NHS England, 2025.</li>
</ol>



<p><em>This article is sponsored by Colgate</em></p>]]> </content:encoded>
</item>

<item>
<title>‘It had to be DeNovo’: Katie and Malcolm Campbell on selling their practice</title>
<link>https://edusehat.com/en/it-had-to-be-denovo-katie-and-malcolm-campbell-on-selling-their-practice</link>
<guid>https://edusehat.com/en/it-had-to-be-denovo-katie-and-malcolm-campbell-on-selling-their-practice</guid>
<description><![CDATA[ Katie and Malcolm Campbell explain why selling one of their practices to DeNovo Dental Partners gave them more balance while allowing them to stay involved. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/katie-malcolm-hero-1024x682.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 14:25:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>‘It, had, DeNovo’:, Katie, and, Malcolm, Campbell, selling, their, practice</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Katie and Malcolm Campbell explain why selling one of their practices to DeNovo Dental Partners gave them more balance while allowing them to stay involved.</strong></p>



<p>After pouring years of clinical work, team mentorship and patient care into building a successful practice, selling does not necessarily mean wanting to leave the practice behind. But remaining fully independent may not feel right either, particularly as the pressures and risks of practice ownership evolve.</p>



<p>When Katie and Malcolm Campbell were presented with the opportunity to sell one of their practices to DeNovo Dental Partners, it offered a different path: the chance to reduce some of the day-to-day pressures of practice ownership while remaining closely involved in the business they had built. Katie shares their experience.</p>



<h2 class="wp-block-heading">A different route</h2>



<div class="wp-block-media-text is-stacked-on-mobile"><figure class="wp-block-media-text__media"></figure><div class="wp-block-media-text__content">
<p>We bought our first practice in 2017 and bought our second practice in 2021. This coincided with the birth of our second child within a matter of weeks. I don’t think we anticipated the level of stress that would come with going from one practice to two and trying to manage that stress whilst having a newborn baby. The second practice was not easy to step into – an established practice with lots of patients to serve, and a dilapidated building that needed a full renovation and refurbishment. The stress levels and quality of life became completely out of kilter at that point.</p>



<p>Malcolm and I are complete control freaks and are really obsessed about the detail. For us, the patient journey was really important. We wanted to remain in control as much as possible because we are really proud of what we’ve built and the loyalty of our team. We knew we couldn’t sell to a traditional corporate because it would never have aligned. Additionally, we didn’t feel ready to sell both practices, but we felt that selling one would alleviate some stress.</p>



<p>That’s how we came to meet DeNovo. Initially we were a bit confused by the business model and the shares aspect. But we did loads of research, spoke to the right people, and decided that if we were going to sell, it had to be DeNovo – they aligned where no other corporates did.</p>
</div></div>



<h2 class="wp-block-heading">Coming to a decision</h2>



<p>Practice owners considering a sale often find there is no single obvious route. For Katie and Malcolm, the decision meant balancing the future of the practice with their family life, their desire to remain involved and the importance of finding a partner that shared their approach.</p>



<div class="wp-block-media-text is-stacked-on-mobile"><figure class="wp-block-media-text__media"></figure><div class="wp-block-media-text__content">
<p>Selling one of our practices was never part of the plan. We always expected to own and run both practices until retirement.”</p>



<p>While we had considered selling to an associate one day, the practice had grown to a point where its value made that unrealistic. The alternative was simply to continue running it ourselves.</p>



<p>With two young children, we realised we wanted a better work-life balance and the chance to enjoy more of life now, rather than waiting until retirement. When the opportunity to partner with DeNovo came along, it felt like the right time. It allowed us to step away from many of the day-to-day operational pressures while remaining involved in the practice we’d built.</p>



<p>The business model seemed to suit us, and after chatting it through with Caron Best (Chief Operating Officer, DeNovo), we felt that she had a really good understanding of our businesses. We like the way they handled it; they weren’t pushy, they simply presented the information, and out of all the corporates that we met, we felt most aligned to DeNovo.</p>
</div></div>



<p>Throughout the sale process, Kristen Pope (Chief Integration, Partnership & Communication Officer, DeNovo) was our main point of contact and was excellent to deal with. Communication was always open and straightforward. If we had a question or concern, we could simply pick up the phone, talk it through and get it resolved quickly.</p>



<p>That personal approach really stood out. It never felt like we were just another acquisition, which we’d heard from friends can sometimes happen with larger corporates. Throughout the process, DeNovo stayed true to the way they do business, and everyone we dealt with was approachable, genuine and easy to work with.</p>



<p>The people involved and their cultural values were the most important factor that led us to join DeNovo Dental Partners.</p>



<h2 class="wp-block-heading">Now that we’ve joined</h2>



<p>For Katie and Malcolm, the experience since joining has provided further reassurance that they made the right decision – not only through the change in their day-to-day responsibilities, but through the relationships they have built across the wider DeNovo partnership.</p>



<p>They said: ‘We sold our practice at the end of December last year. Since then, we’ve continued to encounter members of the DeNovo team and other Partners too. I’ve found it really refreshing to talk to Partners – everyone is really nice, very easy to talk to, and there’s a collaborative vibe amongst everyone. The team at DeNovo wants to constantly improve. It feels like this is really important to them, and they are always willing to take feedback on board.</p>



<p>‘The work-life balance we’ve achieved and the people we continue to encounter within DeNovo have reinforced that we’ve made the right decision. People like Emma Delgado Vitória (Operations Manager, DeNovo) and Jack Mole (Finance Manager, DeNovo) are super friendly, approachable, and easy to deal with. Those people continue to reinforce that we’ve joined something that is really good.’</p>



<p>Every practice owner’s circumstances, ambitions and plans for the future are different. At DeNovo Dental Partners, the approach is built around recognising that individuality and creating partnerships based on shared ownership and aligned interests, while preserving what makes each practice special.</p>



<p>If you are beginning to think about the future of your practice, <a href="https://www.denovo.partners/" target="_blank" rel="noreferrer noopener">get in touch with the DeNovo team</a> for a confidential, no-obligation conversation.</p>



<p><em>This article is sponsored by DeNovo Dental Partners</em></p>]]> </content:encoded>
</item>

<item>
<title>Formation Bio launches $600m drug development fund</title>
<link>https://edusehat.com/en/formation-bio-launches-600m-drug-development-fund</link>
<guid>https://edusehat.com/en/formation-bio-launches-600m-drug-development-fund</guid>
<description><![CDATA[ The initiative will support the acquisition and clinical advancement of ten to 15 drug programmes over the next three to five years. The company plans to source Phase 
The post Formation Bio launches $600m drug development fund appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-29-10-2026-shutterstock_1884612922.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Formation, Bio, launches, 600m, drug, development, fund</media:keywords>
<content:encoded><![CDATA[<p>The initiative will support the acquisition and clinical advancement of ten to 15 drug programmes over the next three to five years.</p>
<p>The company plans to source Phase I and Phase II assets from biotechnology and pharmaceutical entities through acquisitions or in-licensing agreements.</p>
<p>Selection prioritises therapies addressing conditions with substantial unmet need and limited industry development, focusing on programmes with clear pathways to clinical proof of concept.</p>
<p>Formation Bio aims to reach major clinical milestones within two to four years of acquiring each asset, before pursuing commercialisation or co-commercialisation agreements with pharmaceutical partners.</p>
<p>Capital from the vehicle will be deployed through a hub-and-spoke operational model, with each funded programme housed within an independent corporate entity.</p>
<p>Formation Bio serves as the fund’s general partner via a wholly owned subsidiary and has invested its own capital alongside external limited partners.</p>
<p>These backers include hospitals, institutional endowments, philanthropic organisations, and research foundations.</p>
<p>Formation Bio co-founder and CEO Benjamine Liu said: “This fund gives our LPs access to an important and emerging investment category—individual drug assets—through a capital-efficient structure.</p>
<p>“For Formation Bio, it expands the number of promising drugs we can pursue, gives us strategic and financing flexibility, creates paths to liquidity without selling the parent company, and positions us to lower our cost of capital over time.</p>
<p>“Together, these advantages address structural challenges in our industry, allow us to develop more drugs for patients, and support our ambition to build this generation’s enduring pharma company.”</p>
<p>Formation Bio has its headquarters in New York City and a second office in Boston. It combines computational platforms with clinical trial operations to progress drug candidates.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/formation-bio-600m-drug-development-fund/">Formation Bio launches $600m drug development fund</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dren Bio raises $350m for dibotatug clinical development</title>
<link>https://edusehat.com/en/dren-bio-raises-350m-for-dibotatug-clinical-development</link>
<guid>https://edusehat.com/en/dren-bio-raises-350m-for-dibotatug-clinical-development</guid>
<description><![CDATA[ The privately held clinical-stage biotechnology company will also use the capital to progress its broader research pipeline in autoimmune disorders, immunology, neurology, and oncology. Juvia Group and Lightspeed 
The post Dren Bio raises $350m for dibotatug clinical development appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-30-10-2026-shutterstock_2311370891.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Dren, Bio, raises, 350m, for, dibotatug, clinical, development</media:keywords>
<content:encoded><![CDATA[<p>The privately held clinical-stage biotechnology company will also use the capital to progress its broader research pipeline in autoimmune disorders, immunology, neurology, and oncology.</p>
<p>Juvia Group and Lightspeed Venture Partners co-led the investment round.</p>
<p>Following the transaction, Juvia Group co-founder and managing director Sujal Shah and Lightspeed partner Shelley Chu have joined the Dren Bio Board of Directors.</p>
<p>Additional new participants included Cormorant Asset Management, General Catalyst, Mirae Asset Capital Life Science, and OrbiMed.</p>
<p>Existing investors 8VC, Aisling Capital, ArrowMark Partners, BVF Partners, HBM Healthcare Investments, Mission BioCapital, SR One, and Taiho Ventures also contributed capital.</p>
<p>Dibotatug is a fully human monoclonal antibody engineered to bind cluster of differentiation 94 (CD94). The therapy selectively removes disease-causing cytotoxic cells whilst sparing the wider immune system.</p>
<p>The company’s furthest advanced clinical programmes focus on cytotoxic T-cell lymphoma, an aggressive haematologic malignancy, and large granular lymphocytic leukaemia, a chronic condition associated with severe neutropenia, anaemia, and transfusion requirements.</p>
<p>Neither disease currently has approved therapeutic options.</p>
<p>More than 300 individuals have received treatment in an ongoing Phase I/II trial evaluating dibotatug for relapsed or refractory forms of both conditions.</p>
<p>Dren Bio plans to expand clinical testing of dibotatug into aplastic anaemia, other bone marrow failure syndromes, and autoimmune indications.</p>
<p>Dren Bio CEO and founder Nenad Tomasevic said: “We founded Dren Bio with a simple vision: pursue novel science to develop medicines that meaningfully improve the lives of patients with devastating diseases and few treatment options.</p>
<p>“Seeing dibotatug advance to this late stage of development, alongside a clinically validated platform that continues to generate promising new therapies, is deeply gratifying and reflects the vision that inspired us from day one.”</p>
<p>In July 2024, Dren Bio partnered with Novartis subsidiary Novartis Pharma to discover and develop therapeutic bispecific antibodies to treat cancer.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/dren-bio-350m-dibotatug-clinical-development/">Dren Bio raises $350m for dibotatug clinical development</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Enthorin and Rumi sign agreement for FXS therapy</title>
<link>https://edusehat.com/en/enthorin-and-rumi-sign-agreement-for-fxs-therapy</link>
<guid>https://edusehat.com/en/enthorin-and-rumi-sign-agreement-for-fxs-therapy</guid>
<description><![CDATA[ Under the deal, Rumi Therapeutics will develop the therapy, renaming it RTX-7340. Enthorin Therapeutics will receive an upfront sum, an option exercise fee, and milestone payments. The company 
The post Enthorin and Rumi sign agreement for FXS therapy appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-2-29-10-2026-shutterstock_2378150581.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Enthorin, and, Rumi, sign, agreement, for, FXS, therapy</media:keywords>
<content:encoded><![CDATA[<p>Under the deal, Rumi Therapeutics will develop the therapy, renaming it RTX-7340.</p>
<p>Enthorin Therapeutics will receive an upfront sum, an option exercise fee, and milestone payments.</p>
<p>The company is also eligible for further payments linked to development, regulatory, and commercial targets, alongside royalties on future net product sales.</p>
<p>It will also contribute scientific and technical expertise to assist during the initial stages of the work.</p>
<p>ENT-7340 is an investigational new drug (IND) enabled small molecule that selectively inhibits phosphodiesterase 2A (PDE2A).</p>
<p>It controls cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate signalling pathways (cGMP), which influence neuronal function and synaptic plasticity.</p>
<p>FXS is an inherited neurodevelopmental disorder stemming from Fragile X messenger ribonucleoprotein 1 (FMR1) gene alterations that reduce or prevent the generation of functional FMRP, a protein essential for brain development.</p>
<p>The condition causes varying degrees of cognitive, behavioural, linguistic, and sensory difficulties in both males and females.</p>
<p>Enthorin Therapeutics co-founder and chief scientific officer Marco Peters said: “ENT-7340 represents years of discovery and development work aimed at translating the biology of PDE2 inhibition into effective therapeutics for the treatment of neurodevelopmental disorders such as Fragile X.</p>
<p>“Rumi brings distinctive capabilities for evaluating therapeutics in human cellular and organoid models, providing an opportunity to further validate the biology of RTX-7340 in human systems and explore its mechanism of action in FXS and additional indications.</p>
<p>“We are excited about this agreement and look forward to supporting Rumi during the initial development phase as they advance the programme toward clinical development.”</p>
<p>Rumi Therapeutics, an operating company under parent firm Rumi Holdings alongside Rumi Scientific, plans to advance the therapy into clinical testing by drawing on human organoid disease models.</p>
<p>Enthorin Therapeutics developed the programme with research support from the FRAXA Research Foundation.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/enthorin-rumi-agreement-fxs-therapy/">Enthorin and Rumi sign agreement for FXS therapy</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bavarian Nordic secures four&#45;year UK vaccine supply deal</title>
<link>https://edusehat.com/en/bavarian-nordic-secures-four-year-uk-vaccine-supply-deal</link>
<guid>https://edusehat.com/en/bavarian-nordic-secures-four-year-uk-vaccine-supply-deal</guid>
<description><![CDATA[ The deal for the vaccine was awarded through the UK Health Security Agency. Under the contract, the company will deliver scheduled shipments of MVA-BN across the term. The 
The post Bavarian Nordic secures four-year UK vaccine supply deal appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/Vaccines-manufacturing.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bavarian, Nordic, secures, four-year, vaccine, supply, deal</media:keywords>
<content:encoded><![CDATA[<p>The deal for the vaccine was awarded through the UK Health Security Agency.</p>
<p>Under the contract, the company will deliver scheduled shipments of MVA-BN across the term. The agreement also includes optional flexibility provisions, though further details were not disclosed.</p>
<p>MVA-BN is said to be the only non-replicating mpox vaccine that secured approval in the US, Singapore, Switzerland, Mexico, the EU/EEA, Canada and the UK. It is marketed under different brand names depending on the jurisdiction: Jynneos in the US and Mexico, Imvamune in Canada, and Imvanex in the EU/EEA and UK.</p>
<p>The vaccine was originally developed in collaboration with the US Government as a smallpox vaccine intended for the entire population, including those who are immunocompromised and not recommended for traditional replicating smallpox vaccines.</p>
<p>It is indicated for use in the general population from the age of two years in those considered at risk of smallpox or mpox infection.</p>
<p>Bavarian Nordic public preparedness senior vice-president Hitesh Sahni said: “Maintaining sustainable vaccine stockpiles and rapid response capabilities are essential to protecting public health and saving lives, and we are proud that our vaccine remains an important component of the UK’s resilience strategy.”</p>
<p>The latest contract builds on previous vaccine procurements by the UK Government and extends an existing relationship between Bavarian Nordic and UK authorities.</p>
<p>Earlier purchases were aimed at strengthening national preparedness while ensuring vaccine availability for eligible people and outbreak response.</p>
<p>Bavarian Nordic said the deal supports the long-term readiness of the UK against emerging threats of infectious diseases. Governments and public health bodies have continued to prioritise access to vaccines that can be rapidly deployed to address changing epidemiological conditions.</p>
<p> </p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/bavarian-nordic-uk-vaccine-supply-deal/">Bavarian Nordic secures four-year UK vaccine supply deal</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Inovio’s Voceryq receives FDA accelerated approval for RRP</title>
<link>https://edusehat.com/en/inovios-voceryq-receives-fda-accelerated-approval-for-rrp</link>
<guid>https://edusehat.com/en/inovios-voceryq-receives-fda-accelerated-approval-for-rrp</guid>
<description><![CDATA[ Caused by HPV-6 and/or HPV-11 primarily, RRP is characterised by the development of wart-like growths in the respiratory tract. The DNA-based immunotherapy, generically known as doruxapapogene ralaplasmid and 
The post Inovio’s Voceryq receives FDA accelerated approval for RRP appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/RRP-shutterstock_2501941397.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Inovio’s, Voceryq, receives, FDA, accelerated, approval, for, RRP</media:keywords>
<content:encoded><![CDATA[<p>Caused by HPV-6 and/or HPV-11 primarily, RRP is characterised by the development of wart-like growths in the respiratory tract.</p>
<p>The DNA-based immunotherapy, generically known as doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd and previously designated INO-3107, was cleared under the FDA’s accelerated approval pathway.</p>
<p>The approval was based on demonstrated complete response, defined as patients requiring no surgical intervention in the 12 months following treatment.</p>
<p>Continued approval may depend on verification of clinical benefit through a confirmatory study.</p>
<p>Inovio president and CEO Dr Jacqueline Shea said: “With the approval of Voceryq, we believe our DNA medicine platform has the potential to transform the treatment paradigm for RRP by offering a patient-centric treatment option.</p>
<p>“Voceryq is designed to deliver what we understand matters most to patients, which is the reduction of the surgical burden caused by RRP.”</p>
<p>Data from Inovio’s RRP-001 trial of Voceryq underpinned the regulatory decision. The study enrolled 32 adult patients who had undergone at least two papilloma excision surgeries in the preceding year.</p>
<div></div>
<p>Of these, 26 patients who had required three or more surgeries during the prior 12 months formed the efficacy population, with a median of 4.5 prior surgical excisions.</p>
<p>Seven of the 26 efficacy patients, or 27%, achieved a complete response after 12 months of follow-up, requiring no further surgical excision. This outcome is not expected in the natural history of untreated disease. No additional surgical excisions were required during the dosing window under the study protocol.</p>
<p>The treatment was well tolerated across the trial. The most common adverse reactions, occurring in more than 5% of patients, included injection site reactions, fatigue, headache, hypertension, dizziness and nausea.</p>
<p>Most treatment-related adverse reactions were classified as grade 1 or 2 and were transient, with no grade 4 or 5 common adverse events reported. All patients completed the trial.</p>
<p>Voceryq was approved for use alongside Cellectra 5PSP, Inovio’s DNA medicine delivery device. The company expects the product to be available for ordering and shipment within approximately 60 days, with full commercial deployment anticipated during the first quarter of 2027.</p>
<p>Inovio has engaged Syneos Health to support its medical and commercial field teams.</p>
<p>Inovio is required to submit a draft protocol to the FDA for a confirmatory study by the end of 2026, with the aim of finalising the protocol by mid-2027.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/inovios-voceryq-fda-approval/">Inovio’s Voceryq receives FDA accelerated approval for RRP</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Pelthos and Castle Creek plan merger to target skin diseases</title>
<link>https://edusehat.com/en/pelthos-and-castle-creek-plan-merger-to-target-skin-diseases</link>
<guid>https://edusehat.com/en/pelthos-and-castle-creek-plan-merger-to-target-skin-diseases</guid>
<description><![CDATA[ This transaction would add Castle Creek’s gene-modified cell therapy candidate D-Fi to Pelthos’s dermatology portfolio. The combined company would operate as Pelthos Therapeutics and continue trading on the 
The post Pelthos and Castle Creek plan merger to target skin diseases appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/Skin-shutterstock_2454056037.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pelthos, and, Castle, Creek, plan, merger, target, skin, diseases</media:keywords>
<content:encoded><![CDATA[<p>This transaction would add Castle Creek’s gene-modified cell therapy candidate D-Fi to Pelthos’s dermatology portfolio.</p>
<p>The combined company would operate as Pelthos Therapeutics and continue trading on the NYSE American under the ticker ‘PTHS’.</p>
<p>Approved by both companies’ boards, the deal is expected to close by the end of the first quarter of 2027, subject to customary conditions, including approval from Castle Creek shareholders.</p>
<p>Castle Creek shareholders would receive 5.2 million shares of Pelthos common stock when the transaction closes. The shares would represent 32.5% of Pelthos’ fully diluted shares.</p>
<p>They could also receive up to a further 5.8 million Pelthos shares if D-Fi receives US Food and Drug Administration (FDA) approval.</p>
<p>The agreement also provides for up to $300m in milestone payments, including $50m tied to specified Phase III clinical endpoints and up to $250m linked to D-Fi’s first commercial sale and certain net sales targets.</p>
<p>The milestone payments would be made in cash, or in cash and Pelthos shares where necessary to maintain the intended tax treatment of the deal.</p>
<div></div>
<p>Castle Creek shareholders would also be entitled to 80% of net proceeds from the sale of any priority review voucher awarded following D-Fi’s FDA approval.</p>
<p>Also known as dabocemagene autoficel or FCX-007, D-Fi is Castle Creek’s lead development candidate. The company plans to continue a Phase III study of the injectable treatment for dystrophic epidermolysis bullosa, a rare inherited condition associated with mutations in the COL7A1 gene.</p>
<p>The treatment is designed as a redosable, gene-modified cell therapy delivered through intradermal injections every other month.</p>
<p>Castle Creek chairman and CEO Matt Gantz said: “Joining with Pelthos will provide the commercial infrastructure to help realise the D-Fi opportunity and accelerate the pipeline of new indications from our platform.”</p>
<p>Castle Creek is also developing a topical formulation of D-Fi using its fibroblast technology. It is pursuing other potential applications for the technology in skin diseases, including malignancies and inflammatory conditions.</p>
<p>The transaction would add Castle Creek’s fibroblast-based platform to Pelthos’s existing Nitricil platform.</p>
<p>Scott Plesha would remain CEO of the combined company while Peter Greenleaf would become executive chair. The board would have ten directors, including two appointed by Castle Creek.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/pelthos-castle-creek-merger/">Pelthos and Castle Creek plan merger to target skin diseases</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Glenmark opens Allentown distribution hub in US</title>
<link>https://edusehat.com/en/glenmark-opens-allentown-distribution-hub-in-us</link>
<guid>https://edusehat.com/en/glenmark-opens-allentown-distribution-hub-in-us</guid>
<description><![CDATA[ Set across a 6.5-acre site, the facility functions as the company’s sole distribution centre in the US. A workforce of 45 members handles administration, quality control, and general 
The post Glenmark opens Allentown distribution hub in US appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-2-30-10-2026-Image-17.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Glenmark, opens, Allentown, distribution, hub</media:keywords>
<content:encoded><![CDATA[<p>Set across a 6.5-acre site, the facility functions as the company’s sole distribution centre in the US.</p>
<p>A workforce of 45 members handles administration, quality control, and general operations at the premises. These employees dispatch both over-the-counter and prescription pharmaceuticals to 321 destinations situated across 43 states.</p>
<p>Since it began operating, the facility has distributed in excess of 61 million units nationwide.</p>
<p>Glenmark Pharmaceuticals president and North America business head Marc Kikuchi said: “Glenmark has served US patients for more than two decades, and we continue to invest in the people and capabilities that enable us to serve patients, customers and partners across the country.</p>
<p>“Our growing US platform spans innovation, manufacturing and distribution, and the Allentown distribution centre is an important part of that commitment. We chose the Lehigh Valley for its exceptional workforce, strong community, and proximity to our customers and US headquarters.</p>
<p>“We are proud to operate a central distribution hub that helps keep Glenmark’s medicines moving to patients nationwide from right here in the Lehigh Valley.”</p>
<p>The facility conforms to regulatory standards set by the US Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA).</p>
<p>Its technical specifications feature cold-chain refrigerated areas, controlled-room-temperature sections, and DEA-compliant vaults and cages.</p>
<p>Operational practices at the property incorporate adjusted packaging, energy-efficiency initiatives, recycling, reduced waste, refined delivery routes, and specific protocols for shelter-in-place events, evacuations, and medical emergencies.</p>
<p>Across the US, Glenmark employs nearly 400 individuals and manages a portfolio of 229 FDA-authorised products that account for 90 million domestic prescriptions each year.</p>
<p>The company has directed close to $1bn into domestic manufacturing and research infrastructure, which includes almost $400m allocated to an FDA-cleared manufacturing site in Monroe, North Carolina.</p>
<p>The Allentown facility complements Glenmark’s other American properties, comprising its Elmwood Park corporate headquarters in New Jersey and Ichnos Glenmark Innovation, a wholly owned biotechnology subsidiary based in New York.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/glenmark-opens-allentown-distribution-hub-us/">Glenmark opens Allentown distribution hub in US</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>GEBRO and Spektus sign collaboration for ActraFlex</title>
<link>https://edusehat.com/en/gebro-and-spektus-sign-collaboration-for-actraflex</link>
<guid>https://edusehat.com/en/gebro-and-spektus-sign-collaboration-for-actraflex</guid>
<description><![CDATA[ The pharmaceutical companies did not disclose the financial terms of the deal. Under the agreement, the companies will manage regulatory approval processes and commercial operations within their allocated 
The post GEBRO and Spektus sign collaboration for ActraFlex appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-2-04-11-2026-shutterstock_2426123175.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>GEBRO, and, Spektus, sign, collaboration, for, ActraFlex</media:keywords>
<content:encoded><![CDATA[<p>The pharmaceutical companies did not disclose the financial terms of the deal.</p>
<p>Under the agreement, the companies will manage regulatory approval processes and commercial operations within their allocated territories.</p>
<p>GEBRO will direct product supply and commercialisation across Europe and selected global markets, anchored by Spain.</p>
<p>Spektus will oversee supply and commercialisation across Africa, the Americas, and Asia, relying on an established network of regional pharmaceutical partners.</p>
<p>ActraFlex combines paracetamol and tramadol into a formulation engineered to provide sustained release using a twice-daily dosing regimen.</p>
<p>The therapy integrates Spektus’ AmyloFlex drug-delivery technology with GEBRO’s Diliban product that already maintains an established commercial presence in Spain.</p>
<p>GEBRO Holding managing director Christian Kollenz said: “GEBRO brings deep expertise in pain management and a strong foundation with Diliban in Europe.</p>
<p>“Together with Spektus’ established commercialisation partner network, we believe ActraFlex has the potential to become an important global product in pain management.”</p>
<p>Spektus Pharma CEO Zarvaan Merchant said: “Our partnership with GEBRO highlights the potential of Spektus’ proprietary AmyloFlex technology to create differentiated speciality medicines from established products and brands.</p>
<p>“Building on GEBRO’s successful commercialisation of Diliban in Europe, we see strong commercial potential for ActraFlex across the Americas, Africa and Asia.”</p>
<p>GEBRO has developmental and commercialisation experience in specialised medicines.</p>
<p>The organisation places a particular therapeutic focus on rheumatoid arthritis and pain management, conducting business across multiple European and global markets via its own corporate affiliates and external partner networks.</p>
<p>Spektus Pharma creates differentiated medicines by applying drug-delivery formulation platforms to established active pharmaceutical ingredients and products.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/gebro-spektus-agreement-actraflex/">GEBRO and Spektus sign collaboration for ActraFlex</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA to review uniQure’s BLA for Huntington’s gene therapy</title>
<link>https://edusehat.com/en/fda-to-review-uniqures-bla-for-huntingtons-gene-therapy</link>
<guid>https://edusehat.com/en/fda-to-review-uniqures-bla-for-huntingtons-gene-therapy</guid>
<description><![CDATA[ The submission has been granted Priority Review, setting a target action date of 1 May 2027 under the Prescription Drug User Fee Act (PDUFA). The regulator also indicated 
The post FDA to review uniQure’s BLA for Huntington’s gene therapy appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-04-11-2026-shutterstock_2574505743.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, review, uniQure’s, BLA, for, Huntington’s, gene, therapy</media:keywords>
<content:encoded><![CDATA[<p>The submission has been granted Priority Review, setting a target action date of 1 May 2027 under the Prescription Drug User Fee Act (PDUFA).</p>
<p>The regulator also indicated provisional plans to convene an Advisory Committee meeting regarding the application, with timing to be finalised later.</p>
<p>uniQure CEO Matt Kapusta said: “The FDA’s acceptance of our BLA for review marks an important milestone for the Huntington’s disease community, which has waited generations for a treatment that changes the course of this devastating disease.</p>
<p>“Backed by compelling data from our Phase I/II studies, we believe ifezuntirgene inilparvovec has the potential to become the first disease-modifying treatment for Huntington’s disease. With the FDA’s priority review underway, we will work in conjunction with the agency, clinicians, and the Huntington’s community to support the review process.</p>
<p>“The confirmatory trial remains a key priority, with screening anticipated to begin by year-end and the study is expected to be well underway by the time of potential approval.”</p>
<p>The filing relies on 36-month findings from Phase I/II study compared with an external cohort from the Enroll-HD natural history registry, reported on 24 September 2025.</p>
<p>In addition, uniQure has aligned with the FDA on key parameters for a confirmatory clinical study.</p>
<p>This randomised standard-of-care trial will enrol around 200 patients in a 2:1 ratio favouring ifezuntirgene inilparvovec, assessing Total Functional Capacity at 36 months as its primary endpoint.</p>
<p>Patient screening is scheduled to begin in the US before the end of this year.</p>
<p>Also known as AMT-130, ifezuntirgene inilparvovec received breakthrough therapy and regenerative medicine advanced therapy designations from the FDA, alongside fast track status.</p>
<p>Delivered via a single, MRI-guided neurosurgical administration directly into the striatum, the therapy uses microRNA to silence the huntingtin gene and its exon 1 protein fragment.</p>
<p>Huntington’s disease is an inherited disorder that causes motor symptoms, including chorea, behavioural changes, and progressive cognitive decline.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/fda-uniqures-bla-huntingtons-therapy/">FDA to review uniQure’s BLA for Huntington’s gene therapy</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lonza to acquire five US manufacturing sites from Merck KGaA</title>
<link>https://edusehat.com/en/lonza-to-acquire-five-us-manufacturing-sites-from-merck-kgaa</link>
<guid>https://edusehat.com/en/lonza-to-acquire-five-us-manufacturing-sites-from-merck-kgaa</guid>
<description><![CDATA[ The acquisition involves a total enterprise valuation in the low- to mid-triple-digit millions of Swiss francs. It would expand Lonza’s US manufacturing presence from four to nine sites 
The post Lonza to acquire five US manufacturing sites from Merck KGaA appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/Lonza-shutterstock_1675420258.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lonza, acquire, five, manufacturing, sites, from, Merck, KGaA</media:keywords>
<content:encoded><![CDATA[<p>The acquisition involves a total enterprise valuation in the low- to mid-triple-digit millions of Swiss francs.</p>
<p>It would expand Lonza’s US manufacturing presence from four to nine sites and bring 1,100 employees into its global workforce, raising its headcount to more than 6,000.</p>
<p>Closing is expected around mid-2027, subject to customary conditions.</p>
<p>The five facilities cover a range of pharmaceutical technologies. The St Louis-based site focuses on bioconjugates, while two locations in Madison and Verona, Wisconsin, produce high-potency payload-linkers.</p>
<p>A facility in Carlsbad, California, provides end-to-end viral vector solutions, comprising aseptic fill-finish capabilities. The site at Indianapolis, Indiana, handles lipid nanoparticle, liposome, and PEGylated protein solutions, also with aseptic fill-finish capacity.</p>
<p>Lonza CEO Wolfgang Wienand said: “This acquisition is a strong fit with our One Lonza Strategy and reflects our disciplined approach to capital allocation, investing in opportunities that will drive long-term, profitable growth and deliver attractive returns.</p>
<p>“With high demand for bioconjugates and viral vectors, the acquired sites will strengthen our ability to support customers from innovation to launch and commercial supply.”</p>
<p>Lonza said the acquired network supports customers from clinical-stage through to commercial manufacturing in areas including antibody-drug conjugates, other bioconjugates, viral vectors for cell and gene therapies, and latest drug-delivery technologies.</p>
<p>For full-year 2028, the sites are expected to contribute around SFr250m ($304m) in sales at a core earnings before interest, taxes, depreciation and amortisation (EBITDA) margin below Lonza’s group level.</p>
<p>Lonza will pay the consideration in cash, funded through cash at hand and existing credit facilities.</p>
<p>The acquisition follows other recent US investments by Lonza, including ongoing work to prepare its Vacaville site for CDMO operations and a recently announced commercial spray-drying facility in Bend, Oregon.</p>
<p>Until the deal concludes, the businesses will continue to run independently. Both parties said they would work together to support a smooth transition.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/lonza-us-manufacturing-sites/">Lonza to acquire five US manufacturing sites from Merck KGaA</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The World Is Moving at Warp Speed. Why Is Healthcare Still Holding a Clipboard?</title>
<link>https://edusehat.com/en/the-world-is-moving-at-warp-speed-why-is-healthcare-still-holding-a-clipboard</link>
<guid>https://edusehat.com/en/the-world-is-moving-at-warp-speed-why-is-healthcare-still-holding-a-clipboard</guid>
<description><![CDATA[ Technology is transforming nearly every industry, creating efficiencies that would have been unimaginable just a few years ago. Attorneys are using artificial intelligence to research cases and draft documents, financial institutions have made banking almost entirely accessible from a smartphone, and businesses are finding new ways to eliminate repetitive administrative work. Yet, while other industries...
The post The World Is Moving at Warp Speed. Why Is Healthcare Still Holding a Clipboard? appeared first on DoctorsManagement. ]]></description>
<enclosure url="https://www.doctorsmanagement.com/wp-content/uploads/sd-healthcare-clipboard.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, World, Moving, Warp, Speed., Why, Healthcare, Still, Holding, Clipboard</media:keywords>
<content:encoded><![CDATA[<p>Technology is transforming nearly every industry, creating efficiencies that would have been unimaginable just a few years ago. Attorneys are using artificial intelligence to research cases and draft documents, financial institutions have made banking almost entirely accessible from a smartphone, and businesses are finding new ways to eliminate repetitive administrative work. Yet, while other industries embrace innovation to improve efficiency and reduce costs, many physician practices are still handing patients a clipboard and asking them to complete information that already exists somewhere in their medical record. Really… a clipboard!</p>
<p>Organizations such as Quest Diagnostics have demonstrated how digital scheduling and patient registration can simplify portions of the healthcare experience, yet many independent physician practices struggle to implement similar conveniences. Patients continue completing paperwork, providing information they have shared countless times before, while staff members manually enter that information into electronic systems. It would be easy to suggest that physician practices simply need to modernize, but that overlooks the challenges of operating a medical practice in an increasingly complicated healthcare environment.</p>
<p>Consider how differently innovation is approached across industries. An attorney can purchase a new technology solution and begin incorporating it into the firm’s workflow. A physician practice faces additional considerations. Before introducing comparable technology, the practice must evaluate HIPAA security requirements, patient privacy protections, how information is accessed and stored, and whether the technology maintains the integrity of the medical record. Add implementation costs, staff training, and compatibility with existing electronic health record systems, and technology intended to create efficiencies can require a considerable investment before the practice ever experiences the benefits.</p>
<p>Meanwhile, consider how much of a practice’s operating budget is already committed to satisfying insurance company requirements. Prior authorizations, repeated documentation requests, payer inquiries, and appeals consume resources that could otherwise support investments in technology, staffing, and the patient experience. The frustration is not simply the expense, but the reality that while other industries invest in technology to eliminate unnecessary administrative work, physician practices must continue dedicating significant resources to meeting the requirements of getting paid. Imagine the opportunities for innovation if even a portion of those resources could be redirected toward improving practice operations and patient care.</p>
<p>And then there is the electronic medical record. We have spent years transitioning from paper charts to electronic systems, and many health systems have made significant progress connecting patient records across their hospitals and employed physician practices. A patient seeing a primary care physician, cardiologist, and orthopedic specialist within the same health system may benefit from all three providers having access to the same electronic chart. But what happens when that patient receives care outside the system? An independent specialist or physician affiliated with another health system may not have the same access, even when electronic information exchange capabilities exist. The result can be another round of medical record requests, repeated patient histories, and time spent gathering information already documented elsewhere. We have made tremendous progress digitizing medical records, but seamless information sharing across healthcare organizations remains a challenge. If patient centered care is truly our priority, shouldn’t the patient’s information follow them, regardless of where they choose to receive care?</p>
<p>Perhaps what concerns me most is how accustomed we have become to these inefficiencies and the expectations placed on those working within the system. Physicians are expected to provide quality care, maintain detailed documentation, satisfy payer requirements, respond to electronic messages, and remain financially viable while adapting to an evolving regulatory environment. Practice administrators face their own challenges balancing staffing, rising expenses, reimbursement pressures, and the constant expectation to accomplish more with fewer resources. None of this is new to those managing a medical practice, but I wonder whether those of us who work alongside physicians fully appreciate the cumulative impact.</p>
<p>I have spent years working in medical auditing, compliance, and physician education, and this perspective has made me reconsider something we encounter regularly. We review medical records, identify documentation opportunities, and request time with physicians to discuss our findings. When those meetings are postponed or physicians seem reluctant to participate, we may interpret their response as a lack of interest in education. But perhaps we should consider how many demands are already competing for their attention. Between patient care, practice responsibilities, payer requests, and an endless stream of electronic messages, finding another thirty minutes can be difficult, regardless of how valuable the education may be. Our audit findings are important, but so is understanding the environment in which we are delivering them.</p>
<p>None of this diminishes the importance of accurate documentation, appropriate coding, or regulatory compliance. These responsibilities remain essential, but meaningful improvement requires more than identifying another opportunity for change. It requires understanding the realities of the practice and developing solutions that support both compliance and efficiency. Sometimes I wonder whether we have become so focused on discussing what physicians need to do differently that we forget to acknowledge everything they are already being asked to do.</p>
<p>The world continues moving at warp speed, and healthcare deserves the opportunity to embrace innovation with the same enthusiasm and efficiency we see in other industries. Physicians and practice administrators should be able to direct more of their energy and resources toward improving the patient experience rather than navigating administrative complexity. Until we find better ways to accomplish that, perhaps the most important message we can offer is simply one of recognition.</p>
<p><strong>To the physicians who continue caring for patients despite mounting administrative frustrations, and to the practice managers working tirelessly to keep those offices running, we see you. We recognize the challenges, we appreciate the work you do, and we remain committed to helping you find better ways forward.</strong></p>
<p>The post <a href="https://www.doctorsmanagement.com/blog/why-is-healthcare-still-holding-a-clipboard/">The World Is Moving at Warp Speed. Why Is Healthcare Still Holding a Clipboard?</a> appeared first on <a href="https://www.doctorsmanagement.com/">DoctorsManagement</a>.</p>]]> </content:encoded>
</item>

<item>
<title>When OCR Looks Deeper: What Recent HIPAA Settlements Mean for Medical and Dental Practices</title>
<link>https://edusehat.com/en/when-ocr-looks-deeper-what-recent-hipaa-settlements-mean-for-medical-and-dental-practices</link>
<guid>https://edusehat.com/en/when-ocr-looks-deeper-what-recent-hipaa-settlements-mean-for-medical-and-dental-practices</guid>
<description><![CDATA[ For many medical and dental practices, maintaining HIPAA compliance is one of many responsibilities competing for time and attention. Policies are established, employees complete training, and technology vendors help manage information security. While these measures are important, recent enforcement activity from the U.S. Department of Health and Human Services (HHS) Office for Civil Rights (OCR)...
The post When OCR Looks Deeper: What Recent HIPAA Settlements Mean for Medical and Dental Practices appeared first on DoctorsManagement. ]]></description>
<enclosure url="https://www.doctorsmanagement.com/wp-content/uploads/sm-ocr-hipaa-settlements.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>When, OCR, Looks, Deeper:, What, Recent, HIPAA, Settlements, Mean, for, Medical, and, Dental, Practices</media:keywords>
<content:encoded><![CDATA[<p>For many medical and dental practices, maintaining HIPAA compliance is one of many responsibilities competing for time and attention. Policies are established, employees complete training, and technology vendors help manage information security. While these measures are important, recent enforcement activity from the U.S. Department of Health and Human Services (HHS) Office for Civil Rights (OCR) reinforces the need for ongoing oversight and documentation.</p>
<p>Recent settlements also demonstrate that smaller healthcare organizations are not exempt from regulatory scrutiny. More importantly, an investigation that begins with a single patient complaint or security incident may uncover broader deficiencies in a practice’s HIPAA compliance program.</p>
<p>Understanding what prompted these investigations and the findings that followed can help practices evaluate their own compliance efforts and identify opportunities for improvement.</p>
<h2>A Patient Complaint Leads to Broader Compliance Findings</h2>
<p>In October 2026, OCR announced a <strong>$140,000 settlement with Shen Smiles, P.C.</strong>, a solo dental practice in Pennsylvania, following an investigation that began with a patient’s complaint regarding access to her medical records.</p>
<p>The patient alleged that the practice failed to provide timely access to her protected health information (PHI) despite multiple requests. During the investigation, the practice reported that it could not provide the requested records because a workforce member had allegedly taken records from the practice.</p>
<p>As OCR examined the circumstances surrounding the complaint, investigators identified additional concerns involving the practice’s HIPAA compliance. These included failures to implement appropriate Privacy and Breach Notification Rule policies and procedures and to reasonably safeguard PHI from impermissible uses or disclosures.</p>
<p>The resulting settlement illustrates how an issue involving a single patient can lead to a more comprehensive review of an organization’s compliance practices.</p>
<p>For smaller medical and dental practices, the implications extend beyond the financial penalty. An investigation may reveal gaps in policies, employee training, documentation, or everyday procedures that have gone unaddressed.</p>
<h2>Security Incidents Bring Additional Scrutiny to Risk Analysis</h2>
<p>While the Shen Smiles investigation focused on HIPAA Privacy Rule concerns, recent cybersecurity-related settlements highlight another area receiving significant attention from OCR , the Security Risk Analysis (SRA).</p>
<p>In February 2026, OCR announced a <strong>$103,000 settlement with Top of the World Ranch Treatment Center</strong>, a substance use disorder treatment provider, following a phishing incident involving the electronic protected health information (ePHI) of approximately 1,980 individuals.</p>
<p>During its investigation, OCR determined that the organization had failed to conduct an accurate and thorough assessment of potential risks and vulnerabilities to its ePHI. The settlement marked OCR’s 11th enforcement action under its Risk Analysis Initiative, which focuses on compliance with the HIPAA Security Rule’s risk analysis requirement.</p>
<p>In addition to the financial settlement, the organization agreed to a corrective action plan that included conducting a comprehensive risk analysis, developing a risk management plan, reviewing policies and procedures, and providing workforce training. OCR will monitor compliance with the corrective action plan for two years.</p>
<p>A similar investigation involved Comprehensive Neurology, P.C., a small New York neurology practice that experienced a ransomware attack affecting approximately 6,800 individuals.</p>
<p>In 2025, OCR announced a <strong>$25,000 settlement</strong> after determining that the practice had failed to conduct an accurate and thorough Security Risk Analysis. The practice also agreed to a two-year corrective action plan.</p>
<p>Together, these settlements demonstrate that OCR’s focus on risk analysis extends to smaller healthcare organizations, including those experiencing security incidents involving relatively limited numbers of patients. They also reinforce the importance of evaluating security risks before an incident occurs rather than attempting to address compliance deficiencies during an investigation.</p>
<h2>Understanding the Security Risk Analysis Requirement</h2>
<p>With proposed changes to the HIPAA Security Rule receiving considerable attention, it is important to distinguish between existing requirements and potential future obligations. <strong>The requirement to conduct an accurate and thorough Security Risk Analysis is already established under the HIPAA Security Rule</strong>.</p>
<p>Covered entities and business associates must assess potential risks and vulnerabilities to the confidentiality, integrity, and availability of the ePHI they create, receive, maintain, or transmit. An effective SRA provides an organization with a clearer understanding of where sensitive information resides, how it is accessed and protected, and what vulnerabilities could place that information at risk.</p>
<p>The assessment should consider several important elements:</p>
<ul>
<li><strong>Systems and technology:</strong> Identifying applications, devices, networks, and systems that create, receive, maintain, or transmit ePHI.</li>
<li><strong>Third-party relationships:</strong> Evaluating vendors and service providers that access, maintain, or otherwise interact with ePHI.</li>
<li><strong>Potential threats and vulnerabilities:</strong> Identifying circumstances that could result in unauthorized access, disclosure, modification, or loss of information.</li>
<li><strong>Existing safeguards:</strong> Reviewing administrative, physical, and technical protections currently in place.</li>
<li><strong>Risk evaluation:</strong> Assessing the likelihood and potential impact of identified threats and vulnerabilities.</li>
<li><strong>Risk management:</strong> Establishing a documented approach to addressing identified risks and monitoring remediation efforts.</li>
</ul>
<p>The SRA is intended to be more than a completed questionnaire or a document maintained for regulatory purposes. Its value lies in helping practice leadership understand potential exposures and make informed decisions about appropriate safeguards.</p>
<p>An equally important component is the risk management process that follows. Identifying vulnerabilities is only the first step. Organizations should document how identified risks will be addressed, assign responsibility where appropriate, and monitor progress toward remediation.</p>
<h2>Proposed Security Rule Changes and an Updated Regulatory Timeline</h2>
<p>HHS has proposed significant revisions to the HIPAA Security Rule that would establish more detailed cybersecurity requirements for covered entities and business associates.</p>
<p>In its updated regulatory agenda, HHS postponed its anticipated final action on the proposed amendments from May 2026 to <strong>July 2027</strong>. The rulemaking was also moved to the agency’s long-term regulatory agenda, indicating that the changes may take longer to finalize than originally anticipated.</p>
<p>It is important to recognize that July 2027 represents a projected date for final regulatory action, not a compliance deadline. The final requirements and their implementation timeline will not be known until a final rule is published.</p>
<p>Among the proposed requirements are:</p>
<ul>
<li>Maintaining a comprehensive technology asset inventory and network map.</li>
<li>Expanding documentation requirements associated with security risk analyses.</li>
<li>Conducting a Security Rule compliance audit at least annually.</li>
<li>Performing vulnerability scanning at least every six months.</li>
<li>Conducting penetration testing at least annually.</li>
<li>Implementing multi-factor authentication and encryption, subject to limited exceptions.</li>
<li>Strengthening incident response, contingency planning, and system recovery requirements.</li>
</ul>
<p><strong>These provisions remain proposed and are not currently enforceable requirements.</strong> The existing HIPAA Security Rule continues to apply while the rulemaking process moves forward.</p>
<p>Although the revised timeline may provide organizations with additional time to prepare for potential changes, it does not postpone existing compliance obligations.</p>
<p>OCR’s recent enforcement actions demonstrate that practices should not delay their compliance efforts while awaiting a final rule. Conducting an accurate and thorough Security Risk Analysis and maintaining an appropriate risk management process remain fundamental requirements today.</p>
<h2>Maintaining Compliance Beyond Cybersecurity</h2>
<p>Although cybersecurity remains a significant concern for healthcare organizations, the Shen Smiles settlement serves as a reminder that HIPAA compliance encompasses much more than information technology.</p>
<p>Patient access rights, privacy policies, workforce training, appropriate handling of PHI, breach response procedures, and documentation all contribute to an effective compliance program.</p>
<p>For example, a practice may have strong technical safeguards but still encounter compliance concerns if employees are unfamiliar with patient access requirements or if established privacy procedures are not consistently followed. Likewise, maintaining an updated HIPAA policy manual does not replace the need to assess security risks associated with electronic health records, cloud applications, remote access, and third-party vendors.</p>
<p>Effective compliance requires coordination between administrative leadership, privacy and security personnel, employees, and technology providers. This is particularly important for practices with multiple locations or those that have experienced growth, changes in staffing, or the introduction of new technology. Procedures that were appropriate several years ago may no longer reflect the organization’s current operations.</p>
<h2>Practical Steps for Medical and Dental Practices</h2>
<p>Recent enforcement activity provides an opportunity for practices to evaluate their existing HIPAA compliance efforts and identify areas that may benefit from additional attention.</p>
<p>Several practical steps can help strengthen compliance and reduce potential exposure.</p>
<ul>
<li><strong>Review the most recent Security Risk Analysis.</strong> Determine whether the assessment accurately reflects the organization’s current technology, locations, applications, vendors, and operational processes. Significant changes to systems or the environment may warrant an updated analysis.</li>
<li><strong>Evaluate progress on identified risks.</strong> Review the risk management plan associated with the assessment. Confirm that remediation efforts have been documented, outstanding risks are being monitored, and appropriate individuals are responsible for follow-up.</li>
<li><strong>Revisit HIPAA policies and procedures.</strong> Ensure that written policies address current regulatory requirements and reflect how the organization operates. Pay particular attention to patient access requests, privacy safeguards, incident reporting, and workforce responsibilities.</li>
<li><strong>Reinforce employee training and awareness.</strong> Employees should understand how HIPAA requirements apply to their daily responsibilities. Training should be supported by clear procedures, appropriate documentation, and ongoing communication.</li>
<li><strong>Review third-party relationships and technology changes.</strong> New vendors, electronic health record integrations, cloud-based services, remote access capabilities, and other technology changes can introduce additional risks. These relationships and systems should be considered as part of the organization’s security oversight.</li>
<li><strong>Maintain accessible compliance documentation.</strong> Practices should be prepared to demonstrate their compliance efforts through policies, training records, risk assessments, remediation documentation, and other supporting materials.</li>
</ul>
<p>These steps can help organizations establish a more consistent approach to compliance while identifying potential concerns before they lead to an incident or regulatory investigation.</p>
<h2>A Proactive Approach to HIPAA Compliance</h2>
<p>No medical or dental practice can eliminate every possibility of a patient complaint, employee error, phishing attack, ransomware incident, or third-party breach. However, organizations can take meaningful steps to reduce risks and demonstrate their commitment to protecting patient information.</p>
<p>Recent OCR settlements illustrate the potential consequences of compliance gaps, particularly when an investigation expands beyond the incident that initially prompted regulatory attention.</p>
<p>For smaller practices, the impact may include not only financial penalties but also legal expenses, remediation costs, operational disruption, workforce retraining, and ongoing regulatory monitoring.</p>
<p>A proactive compliance program provides a more effective approach. Regular policy reviews, workforce education, comprehensive Security Risk Analyses, and documented risk management efforts help organizations identify weaknesses and strengthen safeguards over time.</p>
<p>Ultimately, HIPAA compliance should be viewed as an ongoing process that supports patient trust, operational stability, and responsible information management.</p>
<h2>How DoctorsManagement Can Help</h2>
<p>DoctorsManagement supports medical and dental practices in developing and maintaining practical HIPAA compliance programs tailored to their operations.</p>
<p>Our services include ongoing compliance guidance, policy and procedure development, employee training, compliance assessments, breach and incident support, and comprehensive Security Risk Analyses.</p>
<p>For practices that rely on internal IT personnel or third-party technology vendors, an independent SRA can provide an additional level of oversight by evaluating security risks from a HIPAA compliance perspective.</p>
<p>The assessment identifies potential vulnerabilities and provides a documented risk register to help practice leadership prioritize appropriate remediation efforts.</p>
<p>As regulatory expectations continue to evolve, maintaining an accurate understanding of your organization’s risks and compliance responsibilities is increasingly important.</p>
<h2>Is Your Security Risk Analysis Current?</h2>
<p>Recent OCR enforcement actions serve as an important reminder that maintaining HIPAA compliance requires ongoing attention, documentation, and an understanding of the risks facing your practice.</p>
<p>Whether your organization needs a comprehensive Security Risk Analysis, assistance addressing identified vulnerabilities, or guidance strengthening its overall HIPAA compliance program, DoctorsManagement can help.</p>
<p><strong>Take the next step toward a more proactive compliance program.</strong></p>
<p><a href="https://www.doctorsmanagement.com/hipaa-security-risk-analysis/">Learn More About Our Security Risk Analysis Services</a></p>
<p><a href="https://www.doctorsmanagement.com/hipaa-compliance/">Explore DoctorsManagement’s OSHA & HIPAA Compliance Services</a></p>
<p>Our team is available to discuss your practice’s needs and help identify practical solutions that support compliance and protect patient information.</p>
<h2>Sources and References</h2>
<ul>
<li><a href="https://www.hhs.gov/press-room/hhs-office-civil-rights-settles-hipaa-privacy-rule-investigation-shen-smiles.html" target="_blank" rel="noopener">OCR: Shen Smiles settlement, October 2026</a></li>
<li><a href="https://www.hhs.gov/press-room/ocr-settles-hipaa-security-rule-investigation-twrtc.html" target="_blank" rel="noopener">OCR: Top of the World Ranch settlement, February 2026</a></li>
<li><a href="https://www.hhs.gov/press-room/ocr-hipaa-racap-np.html" target="_blank" rel="noopener">OCR: Comprehensive Neurology settlement, April 2025</a></li>
<li><a href="https://www.hhs.gov/hipaa/for-professionals/security/hipaa-security-rule-nprm/index.html" target="_blank" rel="noopener">HHS: Proposed HIPAA Security Rule changes</a></li>
<li><a href="https://www.reginfo.gov/public/do/eAgendaViewRule?RIN=0945-AA22&pubId=202510" target="_blank" rel="noopener">HHS Unified Agenda: July 2027 projected final action</a></li>
</ul>
<p>The post <a href="https://www.doctorsmanagement.com/blog/ocr-hipaa-settlements-medical-dental-practices/">When OCR Looks Deeper: What Recent HIPAA Settlements Mean for Medical and Dental Practices</a> appeared first on <a href="https://www.doctorsmanagement.com/">DoctorsManagement</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Rethinking the Clone&#45;First Paradigm for First&#45;in&#45;Human Biologics</title>
<link>https://edusehat.com/en/rethinking-the-clone-first-paradigm-for-first-in-human-biologics</link>
<guid>https://edusehat.com/en/rethinking-the-clone-first-paradigm-for-first-in-human-biologics</guid>
<description><![CDATA[ A stable-pool strategy can move cell line development off the critical path to Phase I while preserving a path to a conventional clonal cell line as a program matures.
The post Rethinking the Clone-First Paradigm for First-in-Human Biologics appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/06/GettyImages-200554028-001.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 06:50:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Rethinking, the, Clone-First, Paradigm, for, First-in-Human, Biologics</media:keywords>
<content:encoded><![CDATA[<p>For decades, biologics development has followed a familiar sequence: create an expression construct, transfect host cells, isolate single cells, screen hundreds or thousands of clones, select a lead clone, establish a cell bank, develop the process, and then manufacture clinical material.</p>
<p>It is a proven model. But there is an increasingly important question for early-stage drug development: Does every molecule need to complete that entire sequence before investigators can answer the first clinical question?</p>
<p>For many first-in-human programs, the immediate objective is not commercial manufacturing. It is to produce a relatively small quantity of well-characterized material, establish appropriate controls and determine whether a therapeutic candidate demonstrates sufficient clinical promise to justify further investment.</p>
<p>That changes how developers can think about cell line development.</p>
<figure aria-describedby="caption-attachment-340043" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-340043" src="https://www.genengnews.com/wp-content/uploads/2026/10/Jesse-McCool-281x300.jpg" alt="" width="281" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Jesse-McCool-281x300.jpg 281w, https://www.genengnews.com/wp-content/uploads/2026/10/Jesse-McCool-768x819.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Jesse-McCool.jpg 847w" sizes="auto, (max-width: 281px) 100vw, 281px"><figcaption class="wp-caption-text">Jesse McCool, PhD [GBI Biomanufacturing]</figcaption></figure>
<h4><strong>Moving cloning off the critical path</strong></h4>
<p>One approach is to manufacture initial clinical material from a characterized stable cell pool, while single-cell cloning is deferred or proceeds in parallel.</p>
<p>This is fundamentally different from using a transient expression system. A stable pool consists of cells in which the expression construct has been integrated into the host-cell genome. The challenge is controlling the heterogeneity within that population.</p>
<p>With conventional random integration, cells can differ substantially in transgene copy number, insert integrity and integration location. Those differences can translate into variability in growth, productivity, stability and product quality. Single-cell cloning solves this problem by searching a heterogeneous population for an individual clone with the desired characteristics. An alternative is to reduce heterogeneity earlier.</p>
<p>Transposase-based cell line development systems, such as the Leap-In Transposase platform used in our work, employ a cut-and-paste mechanism for genomic integration. By creating a more controlled integration process, these systems can generate stable pools with a narrower distribution of cellular characteristics than conventional random integration.</p>
<p>The distinction is important. The pool does not become clonal. It becomes more predictable.</p>
<p>That predictability creates the possibility of using the stable pool itself as the manufacturing substrate for an early clinical program.</p>
<h4><strong>What does the data need to show?</strong></h4>
<p>Deferred cloning should not be interpreted as deferred characterization.</p>
<p>A stable pool intended for GMP manufacturing still requires an appropriate control strategy, including assessment of identity, purity and adventitious agents, along with limits on population doublings and evidence that the cell population remains suitable throughout the intended manufacturing window.</p>
<p>The resulting protein also needs to be characterized. The relevant question is whether material produced by the pool has appropriate identity, purity, potency and product-quality attributes for the intended clinical study.</p>
<p>Published experience with transposon-generated stable pools provides an important proof-of-concept. Stable pools have been used for GMP manufacturing at substantial scale, with later clone-derived processes demonstrating comparable process performance and product-quality profiles.</p>
<p>In these studies, viable cell concentration, viability, antibody titer and cell-specific productivity tracked similarly between pool- and clone-derived manufacturing. Product-quality measurements, including purity, charge variants and glycosylation, also fell within comparable ranges.</p>
<p>That does not mean a pool and its derivative clone will be identical across every analytical measurement. Nor does historical experience eliminate the need for molecule-specific assessment.</p>
<p>It demonstrates something more useful: The relationship between pool-derived and later clone-derived material can be characterized and managed.</p>
<h4><strong>Right-sizing the manufacturing process</strong></h4>
<p>Changing the cell line development strategy also creates an opportunity to reconsider scale.</p>
<p>Early clinical studies may require only modest quantities of a biologic, particularly for potent antibodies and other protein therapeutics. Yet sponsors frequently manufacture those first batches using infrastructure designed for much larger material requirements.</p>
<p>A small-scale, closed upstream process can better match manufacturing capacity to the clinical question.</p>
<p>In the SmartScale GMP platform developed at GBI Biomanufacturing, for example, stable-pool development is connected to a shake-flask-based upstream process using OptimumGrowth flasks, progressing from seed culture through a 7-liter production scale. The upstream process is then integrated with downstream purification, drug substance manufacturing and fill-finish.</p>
<p>The principle is more important than the particular vessel: Use the smallest robust GMP process capable of producing the amount of material the clinical program actually requires.</p>
<p>Importantly, starting small should not strand a successful molecule at small scale. A development strategy should anticipate movement into larger single-use bioreactors, fed-batch or perfusion processes if clinical demand increases.</p>
<h4><strong>Sequence the risk rather than eliminate the work</strong></h4>
<p>This approach reflects a broader change occurring in early biologics development.</p>
<p>Historically, developers have often tried to resolve risks associated with later-stage development before administering the first clinical dose. That can make sense when the probability of technical or clinical success is high. For novel therapeutics, however, it can commit substantial time and capital before the most fundamental uncertainty has been resolved: Does the drug work in patients?</p>
<p>A phase-appropriate CMC strategy does not eliminate necessary development activities. It sequences them.</p>
<p>For a suitable molecule, a sponsor can generate a controlled stable pool, characterize that population, manufacture a small GMP batch and establish the CMC package necessary to support the initial clinical investigation. Meanwhile, single-cell cloning can continue in parallel or begin after the program has generated evidence supporting further investment.</p>
<p>If the clinical signal is positive, a derivative clone can be selected, banked and advanced toward the more extensive process characterization expected later in development. Comparability between pool- and clone-derived material then becomes a defined development activity rather than an assumed outcome.</p>
<p>Not every biologic will be a good candidate. Molecules with difficult product-quality profiles, unstable expression, unusual safety considerations or large initial material requirements may favor a conventional clone-first strategy.</p>
<p>But single-cell cloning should no longer be treated automatically as the starting line for every first-in-human biologic.</p>
<p>For appropriate molecules, stable-pool manufacturing provides another option: characterize what matters, manufacture at the scale the study requires and move the first clinical question forward while conventional cell line development continues in parallel.</p>
<p>For drug developers facing increasingly constrained capital and intense pressure to reach meaningful clinical milestones, the question may no longer be, “How quickly can we select the final clone.” It may now be: “Can stable pools move biologics to first-in-human studies faster?”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/rethinking-the-clone-first-paradigm-for-first-in-human-biologics/">Rethinking the Clone-First Paradigm for First-in-Human Biologics</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>As Therapeutic Modalities Expand, Genomic Profiling Must Keep Pace</title>
<link>https://edusehat.com/en/as-therapeutic-modalities-expand-genomic-profiling-must-keep-pace</link>
<guid>https://edusehat.com/en/as-therapeutic-modalities-expand-genomic-profiling-must-keep-pace</guid>
<description><![CDATA[ The boundaries of what’s considered “druggable” are shifting as advances in cell and gene therapies expand the possibilities for cancer treatment. Expanded insights can open new avenues for biomarker research and therapeutic discovery.
The post As Therapeutic Modalities Expand, Genomic Profiling Must Keep Pace appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Sampled_AdobeStock_NongEngEng_2030363578.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 06:50:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Therapeutic, Modalities, Expand, Genomic, Profiling, Must, Keep, Pace</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="http://sampled.com/gen" target="_blank" rel="noopener"><img loading="lazy" decoding="async" class="alignnone wp-image-309223 size-medium" src="https://www.genengnews.com/wp-content/uploads/2025/02/Sampled_logo-300x76.jpg" alt="Sampled logo" width="300" height="76" srcset="https://www.genengnews.com/wp-content/uploads/2025/02/Sampled_logo-300x76.jpg 300w, https://www.genengnews.com/wp-content/uploads/2025/02/Sampled_logo.jpg 600w" sizes="auto, (max-width: 300px) 100vw, 300px"></a></p>
<p>The boundaries of what’s considered “druggable” are shifting as advances in cell and gene therapies expand the possibilities for cancer treatment. For drug developers, this evolving therapeutic landscape creates new reasons to revisit challenging targets and explore genomic alterations that may have been overlooked when fewer treatment approaches were available.</p>
<h4><strong>A broader therapeutic toolbox opens new possibilities</strong></h4>
<p>For many decades, much of drug discovery was focused on finding a small molecule capable of binding a specific target. While this approach remains important, an expanded therapeutic toolkit now allows developers to target a wider range of biological mechanisms. The maturation of cell and gene therapies, RNA therapeutics, targeted protein degradation approaches, antibody-drug conjugates, and other modalities expand the range of biological targets that may be therapeutically tractable. In this way, disease mechanisms and targets that may once have been considered “undruggable” now warrant closer attention, as they can provide an opportunity for development teams to tackle more ambitious projects.</p>
<h4><strong>Improved genomic profiling means greater opportunity</strong></h4>
<p>Drug developers have often prioritized indications with a substantial unmet need and well-characterized driver genes supported by a strong biological rationale for therapeutic targeting. However, the landscape of cancer-associated variants is diverse and remains incompletely understood, even in well-studied forms of the disease. This creates a growing opportunity for researchers to identify and investigate a broader range of potentially relevant genomic alterations, both in indications already served by targeted therapies and in historically underexplored cancer types with substantial unmet need. One promising approach is to focus on a specific cohort with substantial unmet need while casting a wider net for variant discovery. Gaining broader genomic insights early in development can create more opportunities for discovery, biomarker development, and the identification of potentially transformative therapies.</p>
<h4><strong>Why genomic testing will remain essential</strong></h4>
<p>Many precision therapies rely on genomic information for patient selection, while drug discovery teams use genomic evidence to identify and prioritize targets for therapy development. Diseases such as cancer can be driven by both well-characterized and less common genetic alterations, making a comprehensive, reliable, and rapidly available view of an individual patient’s genomic landscape essential across the personalized medicine continuum, from target discovery through patient selection. While multiomics approaches provide important context for understanding disease biology, researchers must continue to examine genomic variation more broadly and in greater depth for personalized medicine to reach its full potential.</p>
<h4><strong>Closing the gap from sample to hypothesis </strong></h4>
<p>Realizing the potential of broader genomic insights to support therapy development across multiple emerging modalities presents several challenges. Translating samples into usable data at scale requires infrastructure that supports efficient, consistent processing across large cohorts and extended study timelines.</p>
<p>One component of closing this gap is comprehensive genomic profiling (CGP), which brings a wider range of cancer-associated genomic alterations into focus. By assessing single nucleotide variants, insertions and deletions, copy number variants, and select gene fusions, CGP allows researchers to look beyond familiar markers and investigate a broader genomic landscape. These expanded insights can open new avenues for biomarker research and therapeutic discovery.</p>
<h4><strong>Integrating sample stewardship, CGP, and analysis</strong></h4>
<p>Sampled is an integrated analytical laboratory and biorepository offering custom sample collection kitting, secure sample storage, end-to-end sample processing, genomic profiling, and data analysis to support oncology research. Visit sampled.com to explore our comprehensive genomic profiling capabilities and learn how we can support your next research project.</p>
<p> </p>
<p><img loading="lazy" decoding="async" class="alignleft wp-image-340228 size-thumbnail" src="https://www.genengnews.com/wp-content/uploads/2026/11/sam270_qr-gen_v1_CMYK-150x150.jpg" alt="Sampled QR Code November 2026" width="150" height="150" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/sam270_qr-gen_v1_CMYK-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/sam270_qr-gen_v1_CMYK-298x300.jpg 298w, https://www.genengnews.com/wp-content/uploads/2026/11/sam270_qr-gen_v1_CMYK-1016x1024.jpg 1016w, https://www.genengnews.com/wp-content/uploads/2026/11/sam270_qr-gen_v1_CMYK-768x774.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/sam270_qr-gen_v1_CMYK.jpg 1389w" sizes="auto, (max-width: 150px) 100vw, 150px"></p>
<p> </p>
<p>Visit <a href="http://sampled.com/gen" target="_blank" rel="noopener">sampled.com/gen</a>.</p>
<p>The post <a href="https://www.genengnews.com/sponsored/as-therapeutic-modalities-expand-genomic-profiling-must-keep-pace/">As Therapeutic Modalities Expand, Genomic Profiling Must Keep Pace</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Gene That Preserves Bone Stem Cell Supply Throughout Life Identified</title>
<link>https://edusehat.com/en/gene-that-preserves-bone-stem-cell-supply-throughout-life-identified</link>
<guid>https://edusehat.com/en/gene-that-preserves-bone-stem-cell-supply-throughout-life-identified</guid>
<description><![CDATA[ Researchers found that the HOXA10 gene preserves bone stem cell supply throughout life, and say the discovery advances understanding of stem cell biology and could indicate potential therapeutic approaches to improve bone healing and regeneration in aging and disease. 
The post Gene That Preserves Bone Stem Cell Supply Throughout Life Identified appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/03/GettyImages-1459917555.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 06:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Gene, That, Preserves, Bone, Stem, Cell, Supply, Throughout, Life, Identified</media:keywords>
<content:encoded><![CDATA[<p>Researchers headed by a team at NYU Langone Health have found that the action of a key gene is required to maintain a lifelong supply of stem cells that make bone healing possible. Working with genetically engineered mice, the team identified the gene <em>HOXA10</em> as a lifelong protector of the stem cell supplies, keeping them from maturing into bone-building cells called osteoblasts until needed for healing.</p>
<p>“Our study shows that<em> HOXA10</em> protects healing capacity normally by acting as a brake on premature maturation,” said Philipp Leucht, MD, PhD, the Jyoti Menon Associate Professor of Orthopedic Surgery in the Department of Orthopedic Surgery at NYU Grossman School of Medicine. “To our knowledge, this study is the first to assign a definitive role for HOX genes in the active maintenance of adult skeletal stem cells.” The findings suggest that HOX genes may represent potential therapeutic targets for boosting bone regeneration.</p>
<p>Leucht, who is also the vice chair for research in the Department of Orthopedic Surgery, is senior and co-corresponding author of the researchers’ published paper in <em>Science Advances</em>, titled “<a href="http://dx.doi.org/10.1126/sciadv.aeg2088" target="_blank" rel="noopener"><em>Hoxa10</em> governs lifelong skeletal stem cell maintenance and bone repair</a>,” in which they reported, “Together, these findings define a conserved Hox-dependent program that preserves skeletal stem cell identity and regenerative competence, revealing how developmental transcription factors are repurposed to sustain the adult skeleton across the life span.”</p>
<p>Skeletal stem and progenitor cells (SSPCs) sustain bone homeostasis and regeneration throughout life, the authors explained, but the transcriptional programs that preserve their identity aren’t well understood. Accumulating evidence suggests Hox genes may play critical roles in maintaining tissue-resident stem cells throughout the lifespan, “… serving as molecular determinants that preserve stem cell identity and function in adult tissues across different species,” the team continued. However, there are “critical gaps” in understanding of how Hox genes may regulate bona fide skeletal stem cells (SSCs) and their progeny. “This has profound implications for understanding skeletal aging, fracture healing, and potential therapeutic interventions.”</p>
<p>For their newly reported study the authors examined the state of bone stem cells in mice for 15 months after they deleted<em> HOXA10</em> in 6-day-old pups. They found that by the end of that period, 90% of the stem cells and descendants that should have been present were gone due to a loss of self-renewal. “Most bone research asks how stem cells become bone,” said Leucht. “We asked how they remain as stem cell replacements in the first place. Without the study gene, bone burns through its reserves too early, which is what we see in aging bone.”</p>
<p>The researchers in addition found that mice engineered to lack <em>HOXA10</em> action could not heal properly after breaking a bone. The proportion of stem cell progenitors in the callus—the temporary tissue bridge spanning a break as it begins to heal—was only 48% for the engineered mice, compared with 76% for control mice with the functional gene.</p>
<p>Other experiments confirmed that deleting <em>HOXA10</em> causes collagen proteins that lay the early framework for rebuilding bone to become disorderly. This is a problem because the rope-like scaffold at a break site must be arranged in neat lines, rather than as a tangled mesh, for new bone to harden with calcium. “Our <em>in vivo</em> genetic studies demonstrate that HoxA genes are not merely correlated with skeletal stemness but are functionally necessary for maintaining this state,” the team noted. “Loss of Hox activity results in depletion of SSC pools, defective matrix organization, impaired repair after serial injuries, and compromised skeletal morphology with age.”</p>
<p>The researchers also obtained bone biopsies from human patients and silenced three related HOX genes at once. The human cells responded like mouse cells, only with more dramatic reductions in stem cell numbers. The human cells also began to die, with apoptosis (programmed self-destruction) up by 50%. This suggests that human stem cells may depend even more on HOX genes for long-term self-renewal, Leucht said. Commenting on their studies in human SSPCs, the authors noted, “Together, these findings demonstrate that distal Hox genes are essential for preserving the core properties of human SSPCs—including proliferation, survival, self-renewal, and inhibition of premature differentiation—thereby supporting their role in maintaining SSC pools in adult human bone.”</p>
<p>To carry out the study the research team genetically engineered mice to have their<em> HOXA10</em>-expressing stem cells tagged with a fluorescent green marker, as well as to have built-in mechanisms that the team could use to switch the genes off on command. This let them accurately track the status of the cells at all stages of life in the study mice.</p>
<p>The investigators learned that <em>HOXA10</em>-positive cells outperform other stem cells in the periosteum, the membrane that covers the surface of most bones, at colony-forming. This test, in which a single cell is prompted to generate a colony of cells by dividing and multiplying continually, is considered a standard readout of self-renewal capacity.</p>
<p>HOX genes have been shown by past studies to control periosteal stem and progenitor cells, or PSPCs, which play a key role in bone healing. HOX genes are known to encode proteins that act like the body’s “zip code,” specifying the position of limbs in the womb. The new study builds on another led by Leucht and <a href="https://doi.org/10.1242/dev.201391" target="_blank" rel="noopener">published in 2023</a>, which showed that increasing the activity of the <em>HOXA10</em> gene could improve fracture healing in older mice.</p>
<p>“Our study identifies <em>HOXA10</em> as a preserver of skeletal stem cell pools over time by promoting self-renewal, suppressing premature maturation, and lining up the protein fibers in a break so that the two ends of broken bone can knit,” said Leucht. “The findings establish HOX genes as potential therapeutic targets for enhancing bone regeneration.”</p>
<p>In their paper the authors concluded, “By illuminating how a single transcriptional regulator coordinates the complex behaviors necessary to maintain SSC across the life span, this work advances our understanding of stem cell biology and provides a foundation for therapeutic  approaches to improve bone healing in aging and disease.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/gene-that-preserves-bone-stem-cell-supply-throughout-life-identified/">Gene That Preserves Bone Stem Cell Supply Throughout Life Identified</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Multiomic Human Glioblastoma Cell Atlas Could Act as Compass to Guide Future Treatment Approaches</title>
<link>https://edusehat.com/en/multiomic-human-glioblastoma-cell-atlas-could-act-as-compass-to-guide-future-treatment-approaches</link>
<guid>https://edusehat.com/en/multiomic-human-glioblastoma-cell-atlas-could-act-as-compass-to-guide-future-treatment-approaches</guid>
<description><![CDATA[ Researchers mapped more than a million cells across glioblastoma tumors, categorizing cancer cells at different stages of their journey within the different environments in glioblastoma tumors, and showing that the cancer cells organize themselves according to a consistent, predictable structural pattern across different patients. 
The post Multiomic Human Glioblastoma Cell Atlas Could Act as Compass to Guide Future Treatment Approaches appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2020/07/Jul15_2020_Getty_1128676746_BrainCancer-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 06:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Multiomic, Human, Glioblastoma, Cell, Atlas, Could, Act, Compass, Guide, Future, Treatment, Approaches</media:keywords>
<content:encoded><![CDATA[<p>Aggressive glioblastoma (GB) brain tumors follow predictable rules, not chaotic randomness, according to new research reported by scientists at the Wellcome Sanger Institute, the European Molecular Biology Laboratory (EMBL), the German Cancer Research Center (DKFZ), the Cancer Research UK Cambridge Institute, and their collaborators.</p>
<p>For their study, reported in <em>Nature</em> (“<a href="https://www.nature.com/articles/s41586-026-11234-8" target="_blank" rel="noopener">A spatiotemporal cancer cell trajectory underlies glioblastoma heterogeneity</a>,”) co-senior author Omer Bayraktar, PhD, at the Wellcome Sanger Institute and Professor at the UCL Cancer Institute, and colleagues mapped over one million cells across glioblastoma tumors, categorizing cancer cells at different stages of their journey within the different environments in glioblastoma tumors. They looked at different time stages and used lab-grown mini tumors to mimic this development. The study findings showed that the cancer cells organize themselves according to a consistent, predictable structural pattern across different patients.</p>
<p>Along with challenging previously held beliefs about brain tumors, the newly discovered roadmap opens new paths for developing targeted treatments. As the cancer cells move along in a predictable way during tumor progression, future drugs could specifically target the early developmental-like cells before they transform into harder-to-reach, resistant states.</p>
<p>The reported work has built a new foundational resource for studies to explore the mechanisms and biology of cancerous brain cells. The researchers have made the resulting <a href="https://www.gbmspace.org/" target="_blank" rel="noopener">GBM-Space atlas</a> is freely accessible.</p>
<p>Using the same single-cell multiomic data, investigators also decoded the gene regulators that drive and restrict glioblastoma cell state transitions, highlighting potential targets that could help avoid treatment resistance. The team stated, “In a companion study, we leveraged the joint transcriptomic and epigenetic data generated here to define and perturb gene regulatory networks controlling GB plasticity. Beyond identifying master regulators of GB states, this orthogonal approach suggested hierarchical transitions across GB cancer states and recapitulated the GB trajectory identified here.” These results are published by co-senior author Bayraktar, and colleagues in their companion paper in <em>Nature, titled “</em><a href="https://doi.org/10.1038/s41586-026-11177-0" target="_blank" rel="noopener">Decoding the regulatory programs governing glioblastoma plasticity</a>.” Together the two papers unify understanding of the architecture of glioblastomas with insights about cancer cell plasticity, giving a holistic view of this cancer type.</p>
<p>Bayraktar said, “Glioblastoma has evaded understanding for years, despite being one of the most studied types of cancer tumor. By building the largest, multi-modal atlas of these tumors to date, we have shown that these tumors are not as chaotic as previously accepted. Instead, they follow a set of rules that can be used to rewrite our understanding of glioblastoma and act as a compass to guide much needed new treatments in the future.”</p>
<p>Glioblastoma is an aggressive form of brain cancer, and the most common type of brain cancer in adults, with an average survival time of 12 to 18 months. The most common glioblastoma treatment, when possible, is surgery followed by a combination of chemotherapy and radiotherapy. But as the authors pointed out, “The extensive tumor heterogeneity of glioblastoma (GB), an incurable adult brain cancer, presents a major obstacle to treatment.”</p>
<p>These tumors are difficult to treat due to their location, and as many tumors invade multiple parts of the brain, which can make surgery difficult or impossible in some cases. The tumors are also made up of multiple, highly dynamic cancer cell states that had previously not seemed to follow any consistent rules or pattern. This means that treatment might not destroy every cell, leading to drug resistance and cancer re-emergence.</p>
<p>“Nearly two decades of molecular profiling has found that malignant cells exist across a spectrum of cellular states within each tumor, resembling developmental neural progenitors as well as mesenchymal-like and injury response states,” the authors noted. “… we still do not understand how cancer cells diversify into distinct states and give rise to GB heterogeneity. In particular, whether malignant cells follow stereotyped or variable cellular trajectories across GB tumors is unknown.”</p>
<p>For their newly reported study the Sanger Institute researchers and their collaborators used state of the art multiomic technologies and tailored machine learning computational tools to map multiple sections of brain tumor samples from 12 glioblastoma patients<sup>. </sup>combining single-cell and spatial atlasing, imaging, and whole-genome sequencing data. “Here we applied a holistic multimodal mapping approach to jointly characterize the genetic, cellular and tissue architecture of GB tumors,” they wrote.</p>
<p>The range of information generated offers up a complete understanding of each cancer cell’s molecular state, where it is in the tumor, how it is likely to change over time, how it interacts with the environment around it, and its genetic information. Additionally, the team used samples from multiple regions of the brain tumors, to give a full picture of the cells in each tumor section and how they related to each other.</p>
<p>This allowed the team to see that glioblastoma cells move through the same structural pattern across each patient, following the same rules as the tumor grows. “We identify that glioblastoma heterogeneity is driven by spatially patterned transitions of cancer cells from developmental-like states towards those defined by a glial injury response and hypoxia,” they wrote. The results found that cancer cells in early stages resemble brain stem cells. These developmental-like cells are found at the outer, leading edge of the tumor, where the glioblastoma cells start to invade the surrounding healthy brain tissue. These cells act as a pool giving rise to other cancer cell states.</p>
<p>Then, as the tumor expands, these cells transform into injury response cell states, mimicking cell pathways that are involved in brain tissue repair and wound healing. These injury response cells create an inner structural layer in the tumors. And in the later stages of brain tumor development the core of the tumor is cut off from oxygen, meaning that all cell types transition from injury response into severely hypoxic (oxygen deprived) states.</p>
<p>As well as mapping brain tumor samples, the team developed brain organoids to validate the tumor roadmap. This research also showed that each cancer cell progression stage requires specific immune microenvironments in the tumors.</p>
<p>“This cellular trajectory regionalizes tumors into distinct tissue microenvironments and manifests in a molecularly conserved manner across tumors as well as genetically distinct tumor subclones,” they stated in their paper. “Our findings define a stereotyped trajectory of cancer cells in glioblastoma and unify glioblastoma tumor heterogeneity into a tractable cellular and tissue framework.”</p>
<p>The team suggests that finding ways to interrupt or disrupt these environments could lead to new ways to treat aggressive brain tumors. In the future, new therapeutics could also focus on the gene regulation networks, potentially stopping cell progression, or target the early developmental cells that cannot be easily removed by surgery and often lead to cancer recurrence.</p>
<p>Richard Mair, MBBS, PhD, FRCS (SN), co-author at the Cancer Research UK Cambridge Institute and Cambridge University Hospitals NHS Foundation Trust, said: “For too long, we have approached glioblastoma treatment knowing that each patient’s tumor contains a complex mixture of cancer cells, but without a clear understanding of how best to target them all. This research gives us an opportunity to think differently. If we can anticipate the different biological states a tumor is likely to adopt, we can begin to develop treatments that target multiple aspects of the disease from the very beginning. This could fundamentally change how we design new therapies for glioblastoma, moving towards treatments that are informed not just by what a tumor looks like today, but by what it is likely to become.”</p>
<p>Oliver Stegle, PhD, co-senior author of both studies at the European Molecular Biology Laboratory (EMBL) and the German Cancer Research Center (DKFZ), added, “Combining unbiased single-cell and multiomics techniques with tailored computational tools allowed us to go back to the drawing board and challenge long-held assumptions about glioblastoma. We demonstrate that complex but predictable molecular networks govern cancer cell development. This work shows how computational biology can turn massive datasets into meaningful discoveries for patient care.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/multiomic-human-glioblastoma-cell-atlas-could-act-as-compass-to-guide-future-treatment-approaches/">Multiomic Human Glioblastoma Cell Atlas Could Act as Compass to Guide Future Treatment Approaches</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lonza Expanding U.S. CDMO Footprint with Purchase of Five Merck KGaA Sites</title>
<link>https://edusehat.com/en/lonza-expanding-us-cdmo-footprint-with-purchase-of-five-merck-kgaa-sites</link>
<guid>https://edusehat.com/en/lonza-expanding-us-cdmo-footprint-with-purchase-of-five-merck-kgaa-sites</guid>
<description><![CDATA[ The deal would expand Lonza’s U.S. CDMO network from four to nine sites and grow the company’s U.S. workforce nearly 25% by adding approximately 1,100 employees, resulting in a combined headcount of more than 6,000 employees. 
The post Lonza Expanding U.S. CDMO Footprint with Purchase of Five Merck KGaA Sites appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/b94fd657006030de0f418450a7f34f41-JPEG.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 06:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lonza, Expanding, U.S., CDMO, Footprint, with, Purchase, Five, Merck, KGaA, Sites</media:keywords>
<content:encoded><![CDATA[<p>Lonza plans to more than double its U.S. footprint of contract development and manufacturing organization (CDMO) sites by agreeing to acquire five such sites in the U.S. from Merck KGaA, Darmstadt, Germany, in a deal the companies would only say was valued “in the low- to mid-triple-digit millions Swiss francs.”</p>
<p>At between CHF 100 million and CHF 500 million, the transaction would amount to between $121.6 million to $608.2 million.</p>
<p>The deal would expand Lonza’s U.S. CDMO network from four to nine sites and grow the company’s U.S. workforce nearly 25% by adding approximately 1,100 employees, resulting in a combined headcount of more than 6,000 employees.</p>
<p>The expansion would also add end-to-end development and manufacturing capabilities in the U.S., with the aim of supporting customers from clinical through commercial phases in growth areas that include antibody-drug conjugates (ADCs) and other bioconjugates, viral vectors for cell and gene therapies, as well as advanced drug-delivery technologies.</p>
<p>The deal with German Merck marks a continuing expansion by Lonza of its U.S. CDMO operations. In 2024, Lonza <a href="https://www.genengnews.com/topics/bioprocessing/lonza-completes-acquisition-of-vacaville-ca-site-from-roche/" target="_blank" rel="noopener">acquired for $1.2 billion the large-scale biologics manufacturing site in Vacaville, CA</a> built by the seller’s Genentech subsidiary. More recently in September, Lonza announced plans to construct a large-scale commercial spray-drying facility in Bend, OR, a project intended to establish Lonza as the leading CDMO provider of commercial-scale spray-drying PSD-4 capacity in the U.S.</p>
<p>Lonza topped <em>GEN</em>’s most recent annual A-List of <a href="https://www.genengnews.com/topics/bioprocessing/top-10-contract-development-and-manufacturing-organizations-2026/" target="_blank" rel="noopener">Top 10 Contract Development and Manufacturing Organizations</a>, published in September, based on its 2025 revenues of CHF 6.531 billion ($8.053 billion at the time; $7.944 billion now).</p>
<h4><strong>‘Strong fit’</strong></h4>
<p>“This acquisition is a strong fit with our One Lonza strategy and reflects our disciplined approach to capital allocation, investing in opportunities that will drive long-term, profitable growth and deliver attractive returns,” Lonza CEO Wolfgang Wienand said in a statement.</p>
<p>“<a href="https://www.lonza.com/about-us/strategy" target="_blank" rel="noopener">One Lonza</a>” is Lonza’s approach to growth. Using the metaphor of an engine, Lonza has articulated a set of five core competencies designed to work together to generate long-term value. The five consist of high-performance teams; a leading scientific, technological, digital ecosystem; unparalleled customer partnerships; end-to-end execution excellence; and plug-and-play investment and integration capabilities.</p>
<p>“It will significantly expand our U.S. presence, bringing us even closer to our customers, while increasing the resilience of our global manufacturing network. With high demand for bioconjugates and viral vectors, the acquired sites will strengthen our ability to support customers from innovation to launch and commercial supply,” Wienand added.</p>
<p>Kai Beckmann, Chairman of the Executive Board and Group CEO of Merck KGaA, stated that the transaction with Lonza represented “another important step in advancing our mid- to long-term strategic agenda.”</p>
<p>In May Merck KGaA articulated a four-prong strategy for “<a href="https://www.emdgroup.com/investors/reports-and-financials/earnings-materials/2026-q1/us/Strategic%20Update%20May%2013,%202026%20NA.pdf" target="_blank" rel="noopener">creating sustainable value and growth</a>,” based on combining biology, chemistry, physics, with data and artificial intelligence (AI), and enabled by “enhanced company integration for speed and scale”—a challenge given the company’s heritage of businesses with their own distinct brands, such as EMD Serono, MilliporeSigma, and Sigma-Aldrich.</p>
<p><strong>‘Strong foundation’</strong></p>
<p>“A more concentrated Life Science portfolio will allow us to focus our investments on building our scientific leadership and make us an even stronger partner for our customers,” Beckmann said. “Our CDMO teams have built a strong foundation through their expertise and commitment. We believe Lonza is well positioned to build on that foundation and support the business’s next phase of growth.”</p>
<p>Merck KGaA reasons that the divestment to Lonza will sharpen the focus of its Life Science business sector while providing the CDMO business with a strong platform for its next phase of development.</p>
<p>The Life Science sector consists of a broad portfolio of consumables, technologies, and services that the company said will continue to serve pharmaceutical, biotechnology and CDMO customers from discovery through manufacturing.  During the first half of 2026, the Life Science sector reported net sales of €4.677 billion ($5.236 billion), up 4.3% from €4.485 billion ($5.022 billion) in January-June 2025. During the second quarter, Life Science racked up €2.412 billion ($2.701 billion), up 6.4% from €2.267 billion ($2.538 billion) in Q2 2025.</p>
<p>Merck KGaA is set to report third-quarter results on November 12—while Lonza last month said Q3 results were in line with its expectations, without quantifying its results. Lonza also reiterated its full-year 2026 outlook, which it upgraded over the summer, of 11–12% constant exchange rate sales growth and a CORE EBITDA margin of 33–34%. The company also reiterated its expectation of a negative foreign exchange impact of approximately 2% to 3% on 2026 sales growth.</p>
<p>Lonza said the U.S. CDMO facilities it has agreed to acquire from Merck KGaA include sites in:</p>
<ul>
<li><strong>St. Louis, MO: </strong>Bioconjugates</li>
<li><strong>Madison and Verona, WI:</strong> High-potency payload-linkers</li>
<li><strong>Carlsbad, CA:</strong> End-to-end viral vector solutions, including aseptic fill-finish capabilities</li>
<li><strong>Indianapolis:</strong> Lipid nanoparticle, liposome, and PEGylated protein solutions, including aseptic fill-finish capabilities</li>
</ul>
<p>The four sites are expected, Lonza said, to generate a combined approximately CHF 250 million ($304 million) in sales at a margin of core earnings before interest, taxes, depreciation, and amortization (EBITDA) that is below Lonza’s, with an “insignificant” impact on the group.</p>
<p>Once integrated into Lonza, the buyer said, the four sites are expected to deliver “significant, profitable” growth over time, using existing available capacities and additional expansion space. Lonza expects the sites will benefit from Lonza’s sole or “pure-play” focus on CDMO activity, with further investments in the sites to align with evolving market demand.</p>
<h4><strong>Peak sales forecast</strong></h4>
<p>“Lonza anticipates the business to reach peak sales at Lonza’s future group margin level by mid-2030s,” the company predicted.</p>
<p>Last month Lonza ramped up its growth projections following completion of its transformation into a pure-play CDMO. The company upgraded its Organic Growth Model, consisting of organic sales growth at constant exchange rates (CER) from the low-teens (10%-13%), and core earnings before interest, taxes, depreciation, and amortization (EBITDA) growth that surpasses sales growth—and articulated an upgraded ambition to:</p>
<ul>
<li>Reach core EBITDA margin “in the high thirties in the mid-term”</li>
<li>Drive return on invested capital (ROIC) up to two to three times weighted average cost of capital as of 2026, and</li>
<li>Improve free cash flow conversion on average over time</li>
</ul>
<p>Lonza said it will fund its acquisition of the Merck KGaA U.S. CDMO sites and with cash at hand and its existing credit facilities, maintaining the company’s BBB+ rating.</p>
<p>The deal is expected to close in mid-2027 subject to customary closing conditions. Lonza said the transaction will not affect its previously announced share buyback following its planned divestment of its Capsules & Health Ingredients (CHI) business. Lonza in March announced plans to sell CHI to Lone Star Funds for CHF 2.3 billion ($2.797 billion), in a deal set to close by year’s end.</p>
<p>“I am particularly excited to welcome the highly experienced teams at these sites to One Lonza,” Wienand said. “It takes great people with deep scientific expertise and excellence in development and manufacturing to reliably translate breakthrough innovation into viable therapies for patients. Together, we will build an even stronger offering for our customers.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/lonza-expanding-u-s-cdmo-footprint-with-purchase-of-five-merck-kgaa-sites/">Lonza Expanding U.S. CDMO Footprint with Purchase of Five Merck KGaA Sites</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond Outsourcing: Building Better CDMO Partnerships</title>
<link>https://edusehat.com/en/beyond-outsourcing-building-better-cdmo-partnerships</link>
<guid>https://edusehat.com/en/beyond-outsourcing-building-better-cdmo-partnerships</guid>
<description><![CDATA[ Rose BioSolutions CEO David Enloe argues that advanced therapies demand deeper scientific collaboration, earlier problem-solving, and shared accountability
The post Beyond Outsourcing: Building Better CDMO Partnerships appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions_CDMO-Facility.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 06:50:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, Outsourcing:, Building, Better, CDMO, Partnerships</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="http://www.rosebiosolutions.com/" target="_blank" rel="noopener"><img decoding="async" class="alignnone wp-image-340233 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-300x108.jpeg" alt="Rose Biosolutions logo" width="300" height="108" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-300x108.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-1024x369.jpeg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-768x276.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions.jpeg 1200w" sizes="(max-width: 300px) 100vw, 300px"></a></p>
<p>For decades, biopharma outsourcing often followed a relatively simple script: a sponsor developed a process, handed it to a contract manufacturer, and expected the work to be carried out to specification. David Enloe, CEO of Rose BioSolutions, believes that model is becoming obsolete—especially for complex cell and gene therapies.</p>
<figure aria-describedby="caption-attachment-340232" class="wp-caption alignright"><img decoding="async" class="wp-image-340232" src="https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-David-Enloe-1-300x300.jpg" alt="David Enloe" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-David-Enloe-1-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-David-Enloe-1-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-David-Enloe-1-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-David-Enloe-1-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-David-Enloe-1.jpg 1400w" sizes="(max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">David Enloe<br>CEO, Rose BioSolutions</figcaption></figure>
<p>As Enloe takes the helm at Rose, he is pushing for a relationship in which the contract development and manufacturing organization (CDMO) functions less like a vendor and more like an extension of the sponsor’s team. “We’re in the promise-making business,” he said, describing commitments that extend beyond clients to patients and their families.</p>
<p>That mindset changes what a CDMO must bring to the table. Manufacturing capacity still matters, but scientific leadership, regulatory expertise, quality knowledge, and program management increasingly help determine whether a program can move efficiently toward the clinic. Enloe sees this as part of a broader evolution in outsourcing, with development and manufacturing becoming more tightly intertwined.</p>
<p>That is particularly true in advanced therapies, where one program can differ dramatically from the next. Enloe contrasts the emerging model with an earlier era in which manufacturers were often expected primarily to execute a sponsor’s established process. For technically demanding programs, simply following a transferred procedure is no longer enough. Sponsors and CDMOs need to examine risks together, challenge assumptions, and make decisions with the full development path in view.</p>
<p>The value of that collaboration can be greatest early, before a seemingly small decision becomes an expensive obstacle. Rose is investing in scientific, regulatory, quality, and project-management expertise at the front end of client programs. Because a CDMO works across multiple projects, it can bring lessons from prior successes—and failures—to a sponsor that may be advancing only one critical asset.</p>
<figure aria-describedby="caption-attachment-340237" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340237" src="https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions_CDMO-Facility-300x201.jpg" alt="Rose BioSolutions Lab" width="300" height="201" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions_CDMO-Facility-300x201.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions_CDMO-Facility-1024x686.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions_CDMO-Facility-768x515.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions_CDMO-Facility.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Credit: Rose BioSolutions</figcaption></figure>
<p>“It’s always painful to see an innovator make a process change that ultimately requires substantial rework,” Enloe says. Investing more time—and, in some cases, more money—upfront to identify manufacturing and regulatory risks can help avoid costly delays and rework later.</p>
<p>This early involvement also reflects a shift in how drug developers think about manufacturability. Scientists creating a new therapy are rightly focused on whether it can improve patients’ lives, Enloe says. But development teams increasingly need confidence that the therapy can also be made robustly, reproducibly, and at scale. Manufacturing challenges can no longer be kicked down the road.</p>
<p>For Rose, that means giving clients direct access to technical leaders and encouraging unusually open communication. Enloe describes the desired relationship with a simple image: “We’re just 872 miles down the hallway.” Distance should not determine how closely teams work together.</p>
<p>Trust is central to making that model function. Enloe says sponsors today are more willing to share their concerns, constraints, and objectives than they were earlier in his career. That transparency lets both sides hold each other accountable for decisions and timelines—and improves the chances of solving problems before they threaten a program.</p>
<p>Enloe brings personal perspective to that argument. He spent about 15 years on the sponsor side before moving into CDMO leadership. “I’ve been you as long as I’ve been me,” he tells clients. That experience, he adds, makes his “empathy gene overexpress” when he considers the pressures developers face.</p>
<p>Ultimately, the partnership model is meant to serve a larger purpose. A CDMO might work on rare diseases, cancer, migraine, or mental-health treatments in the same span of time. For Enloe, that breadth is a reminder that manufacturing is not simply an operational service. It is part of the path between an idea and a patient—and the strongest partnerships are built around getting that path right together.</p>
<p> </p>
<p><img loading="lazy" decoding="async" class="alignleft wp-image-340236 size-full" src="https://www.genengnews.com/wp-content/uploads/2026/11/RoseBioSolutions_QRCode.jpg" alt="Rose BioSolutions QR Code " width="138" height="144"></p>
<p> </p>
<p>To learn more, visit <a href="https://www.rosebiosolutions.com/" target="_blank" rel="noopener">www.rosebiosolutions.com</a>.</p>
<p>The post <a href="https://www.genengnews.com/sponsored/beyond-outsourcing-building-better-cdmo-partnerships/">Beyond Outsourcing: Building Better CDMO Partnerships</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Roundtables: Inside the Quest for Cognitive Immortality</title>
<link>https://edusehat.com/en/roundtables-inside-the-quest-for-cognitive-immortality</link>
<guid>https://edusehat.com/en/roundtables-inside-the-quest-for-cognitive-immortality</guid>
<description><![CDATA[ Tuesday, November 17, 2026 In an effort to reach an elusive continuity of the self, some far-thinking technologists are working on ways to keep your brain going—even beyond death. Join science editor Mary Beth Griggs and senior editor for biomedicine Antonio Regalado for a conversation exploring possible paths to keep your mind going, including gradual… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/11/MITTR-Roundtables-Nov26-With-border.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 03:20:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Roundtables:, Inside, the, Quest, for, Cognitive, Immortality</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph"><strong>Tuesday, November 17, 2026</strong></p>



<p class="wp-block-paragraph">In an effort to reach an elusive continuity of the self, some far-thinking technologists are working on ways to keep your brain going—even beyond death. Join science editor Mary Beth Griggs and senior editor for biomedicine Antonio Regalado for a conversation exploring possible paths to keep your mind going, including gradual brain replacement and uploading our memories to the cloud.</p>



<p class="wp-block-paragraph"><strong>Going live at 17:00 GMT / 12pm EST / 9am PST</strong></p>



<div class="wp-block-buttons is-content-justification-left is-layout-flex wp-container-core-buttons-is-layout-b192c3d7 wp-block-buttons-is-layout-flex">
<div class="wp-block-button is-style-fill is-style-fill--1"><a class="wp-block-button__link has-black-color has-text-color has-background has-custom-font-size wp-element-button" href="https://events.zoom.us/ev/AqvDmLgUpSLmnGlDBRTVInfuLpbEbkP7nLjovCVsGoSC1i2jsj-x~Aq6BnlbSSzgL8vA66X1w-QGbSPL3EetZLv_MxsmrmoxewbW5YdRLHn0YhlobWLoVAAXaP5HsL41fSqS6q7rEvOEDSg">Register Now</a></div>
</div>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Related Story</strong>:</p>



<ul class="wp-block-list">
<li><a href="https://www.technologyreview.com/2026/10/15/1145819/six-wild-ideas-perpetuating-your-mind-cognitive-immortality/"><strong>Six wild ideas for perpetuating your mind</strong></a></li>
</ul>



<p class="wp-block-paragraph"><strong>Speakers:</strong></p>



<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow">
<figure class="wp-block-image aligncenter size-full is-resized is-style-default wp-duotone-333-ffffff-2"><img fetchpriority="high" decoding="async" width="300" height="300" src="https://wp.technologyreview.com/wp-content/uploads/2024/01/Antonio-Regalado.png" alt="" class="wp-image-1114149" srcset="https://wp.technologyreview.com/wp-content/uploads/2024/01/Antonio-Regalado.png 300w, https://wp.technologyreview.com/wp-content/uploads/2024/01/Antonio-Regalado.png?resize=150,150 150w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-element-caption"><strong><a href="https://www.technologyreview.com/author/antonio-regalado/" target="_blank" rel="noreferrer noopener">Antonio Regalado</a></strong><br>Senior Editor, Biomedicine</figcaption></figure>
</div>



<div class="wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow">
<figure class="wp-block-image aligncenter size-full is-resized is-style-default wp-duotone-333-ffffff-3"><img decoding="async" width="1080" height="1080" src="https://wp.technologyreview.com/wp-content/uploads/2024/01/Mary-Beth-Griggs.png" alt="" class="wp-image-1125906" srcset="https://wp.technologyreview.com/wp-content/uploads/2024/01/Mary-Beth-Griggs.png 1080w, https://wp.technologyreview.com/wp-content/uploads/2024/01/Mary-Beth-Griggs.png?resize=150,150 150w, https://wp.technologyreview.com/wp-content/uploads/2024/01/Mary-Beth-Griggs.png?resize=300,300 300w, https://wp.technologyreview.com/wp-content/uploads/2024/01/Mary-Beth-Griggs.png?resize=768,768 768w" sizes="(max-width: 1080px) 100vw, 1080px"><figcaption class="wp-element-caption"><strong>Mary Beth Griggs</strong><br>Science Editor</figcaption></figure>
</div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>]]> </content:encoded>
</item>

<item>
<title>Greener Biomanufacturing Starts Beyond the Bioreactor</title>
<link>https://edusehat.com/en/greener-biomanufacturing-starts-beyond-the-bioreactor</link>
<guid>https://edusehat.com/en/greener-biomanufacturing-starts-beyond-the-bioreactor</guid>
<description><![CDATA[ A new modeling study finds that buildings, not bioreactors, dominate energy consumption in antibody manufacturing. Continuous processing and smarter facility design could reduce emissions, but water and disposable materials complicate sustainability decisions for manufacturers worldwide.
The post Greener Biomanufacturing Starts Beyond the Bioreactor appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Mike-mAb-bioprocess-modeling_GBPN_IMAGE_04NOV26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 03:15:16 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Greener, Biomanufacturing, Starts, Beyond, the, Bioreactor</media:keywords>
<content:encoded><![CDATA[<p>When it comes to making monoclonal antibodies greener, the biggest energy drain might not be the bioreactor. It might be the building around it.</p>
<p>A new modeling study found that approximately 85% of energy demand in antibody manufacturing came from facility infrastructure, including heating, ventilation, and air conditioning (HVAC), lighting, and utilities. Electricity for HVAC alone accounted for 46% of energy use, while lighting added another 21%. Published in <a href="https://doi.org/10.1016/j.nbt.2026.10.002" target="_blank" rel="noopener"><em>New Biotechnology</em></a>, the findings suggest that improving a plant’s layout and operations could be as important as upgrading its production technology.</p>
<p>Benjamin Smith, PhD, a principal data scientist at Amgen, and his colleagues from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) Process Intensification Sustainability Workgroup modeled three manufacturing scenarios: stainless-steel fed-batch, single-use fed-batch, and end-to-end single-use continuous processing. Using BioSolve Process software, the researchers compared water and materials consumption, energy demand, and greenhouse-gas emissions for facilities producing roughly 120 kg of antibody annually.</p>
<p>The fed-batch scenarios relied on 2,000-L bioreactors, while continuous processing used a 500-L bioreactor over a longer production run. Despite its smaller vessel, the continuous system delivered comparable annual output with less infrastructure. Its modeled facility occupied 12,387 cubic meters, versus 14,089 for single-use fed-batch and 14,937 for stainless-steel fed-batch.</p>
<p>That smaller footprint translated into lower energy intensity: 13,239 kilowatt-hours per kilogram of antibody for continuous manufacturing, compared with 17,017 and 19,120 kilowatt-hours for the two fed-batch approaches, respectively. The researchers concluded that, at equivalent output, “facility footprint—not process type—is the main determinant of energy intensity.”</p>
<p>Yet continuous processing was not automatically greener on every measure. Stainless-steel systems consumed considerably more cleaning water but required substantially fewer disposable consumables. Single-use fed-batch had the highest consumables intensity. Continuous processing required more culture medium and certain buffers, demonstrating why sustainability decisions involve competing demands.</p>
<h4><strong>Making the facility work smarter</strong></h4>
<p>The researchers also modeled a more efficient continuous process incorporating a 50% increase in antibody titer, two flow-through polishing steps, fivefold concentrated medium, and reuse of media and buffer bags. Compared with baseline continuous processing, this combination cut water use per kilogram of product by 26% and consumables intensity by 58%. Modeled carbon dioxide-equivalent emissions fell by 66% to 78% relative to the baseline continuous and stainless-steel fed-batch scenarios, respectively.</p>
<p>Building improvements offered another opportunity. Reducing cleanroom classifications where appropriate, optimizing airflow and lighting, increasing equipment density, and improving utilities could together lower modeled facility energy consumption and emissions by up to approximately 35%. Climate also mattered: temperate locations generally required less heating or dehumidification than colder or humid sites.</p>
<p>The findings come with qualifications. The models considered hypothetical single-bioreactor plants, not larger commercial facilities with multiple production trains. The assessment also excluded some lifecycle impacts, including raw-material production and transportation. The workgroup plans to extend the analysis through lifecycle assessment and test-bed data.</p>
<p>For bioprocess developers, the implication is that boosting productivity and shrinking the space needed to achieve it might deliver sustainability gains beyond those available from individual equipment upgrades. Greener antibody manufacturing could begin with rethinking the factory itself.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/greener-biomanufacturing-starts-beyond-the-bioreactor/">Greener Biomanufacturing Starts Beyond the Bioreactor</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Suspended Vials Help Optimize Continuous Freeze&#45;Drying</title>
<link>https://edusehat.com/en/suspended-vials-help-optimize-continuous-freeze-drying</link>
<guid>https://edusehat.com/en/suspended-vials-help-optimize-continuous-freeze-drying</guid>
<description><![CDATA[ Researchers have developed a process with suspended vials accompanied by a digital twin for optimized continuous and autonomous freeze-drying. It offers more uniform and better-quality products, and higher yields.
The post Suspended Vials Help Optimize Continuous Freeze-Drying appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/08/GettyImages-1289557906.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 03:15:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Suspended, Vials, Help, Optimize, Continuous, Freeze-Drying</media:keywords>
<content:encoded><![CDATA[<p>U.S. researchers have suspended vials to enable autonomous continuous freeze-drying and have developed a digital twin to help optimize the new process.</p>
<p>The team, from the Massachusetts Institute of Technology (MIT), has found that suspending vials on a wire during freeze-drying, a process called lyophilization, gives a more uniform drying process to produce a more consistent product.</p>
<p>The new process also provides all the existing benefits of continuous processing, such as higher production capacity and improved quality control.</p>
<p>“Because this is a continuous lyophilization technology, you get all the benefits of continuous versus batch manufacturing,” explains Prakitr Srisuma, PhD, formerly a researcher at MIT’s Argonne National Laboratory.</p>
<p>“But we have the unique benefit with the suspended wire technology of [more] uniformity of the [final] product.”</p>
<p>Traditionally, vials are dried in a cupboard where they may be occasionally moved around, disturbing their contents, Srisuma explains. By contrast, suspending the vials on wires moved by magnets means they receive the same exposure to different conditions during drying, and their passage through the drying process is very smooth, he says.</p>
<p>“If a vial has been sitting on a shelf and you try to move it, there’s going to be friction, which will generate small particles but, with suspended vials, we avoid those issues,” he explains.</p>
<p>The team had previously spoken to <em>GEN</em> about <a href="https://www.genengnews.com/topics/bioprocessing/continuous-manufacturing-making-freeze-drying-a-hot-topic/" target="_blank" rel="noopener">modeling lyophilization processes</a>. Since then, they have developed a digital twin of the continuous lyophilizer, which they can use to help optimize the process.</p>
<p>Going forward, the team aims to use the digital twin to develop advanced predictive control and optimization strategies. In addition, Srisuma says, the researchers may explore using microwave lyophilization.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/suspended-vials-help-optimize-continuous-freeze-drying/">Suspended Vials Help Optimize Continuous Freeze-Drying</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Small Bioprocess Monitoring Hits the Goldilocks Zone</title>
<link>https://edusehat.com/en/small-bioprocess-monitoring-hits-the-goldilocks-zone</link>
<guid>https://edusehat.com/en/small-bioprocess-monitoring-hits-the-goldilocks-zone</guid>
<description><![CDATA[ A viable-cell-density-on-a-chip monitor offers hope for more fully functional, PAT-compliant in-line monitoring for small bioprocesses, filling a current instrumentation gap. The catch? It’s still in early development.
The post Small Bioprocess Monitoring Hits the Goldilocks Zone appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/12/Oct1_2024_GettyImages_1397353290_MotherboardMainMicrochip_RESIZE4014-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 03:15:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Small, Bioprocess, Monitoring, Hits, the, Goldilocks, Zone</media:keywords>
<content:encoded><![CDATA[<p>Process analytical technology (PAT) bioprocess monitoring instruments generally are designed for large-scale processes, which leaves small-scale bioprocessing at a decided disadvantage. In the days of blockbuster therapeutics, that wouldn’t have mattered much. Today, however, process intensification and increasingly personalized therapies are decreasing batch sizes, so the lack of real-time PAT monitoring options for small-scale manufacturing is a growing concern.</p>
<p>That limitation is felt particularly in the paucity of in-line instrumentation to measure viable cell density, where biocapacitance probes are too large. Alternative, offline viable cell counting methods such as the trypan blue exclusion method limit real-time monitoring in small vessels and, according to a team of Swiss scientists, are impractical for small-scale bioprocessing.</p>
<p>The team led by Yves Mermoud, PhD, research scientist, Eastern Switzerland University of Applied Sciences (OST), and colleagues from OST and Zurich University of Applied Sciences is showing progress in remedying that situation with a viable cell density that appears to be neither too big nor too cumbersome but, as Goldilocks said, just right.</p>
<p>They recently <a href="https://www.researchgate.net/profile/Samuel-Huber-3/publication/415249643_625_-_Bioimpedance_Microsensor_for_Cell-Density_Monitoring_in_Small-Scale_Bioprocessing/links/6ac4f5865770bb0daeda65c0/625-Bioimpedance-Microsensor-for-Cell-Density-Monitoring-in-Small-Scale-Bioprocessing.pdf" target="_blank" rel="noopener">reported</a> on a proof-of-concept, miniature, viable cell density sensor that they tested against concentrations of Chinese hamster ovary (CHO) cells. This work is admittedly in its early stages, but it promises a PAT-compliant sensor for small volumes that currently lack good measurement options.</p>
<p>The miniature bioimpedance sensor they are developing has a 1 x 10 mm footprint at a 25 µL working volume. “Performance [is] close to conventional probes,” Mermoud and colleagues report.</p>
<figure aria-describedby="caption-attachment-340171" class="wp-caption alignnone"><img fetchpriority="high" decoding="async" class=" wp-image-340171" src="https://www.genengnews.com/wp-content/uploads/2026/11/Dutton-Picture1-300x114.jpg" alt="" width="374" height="142" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Dutton-Picture1-300x114.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Dutton-Picture1-1024x388.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Dutton-Picture1-768x291.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Dutton-Picture1-1536x582.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/11/Dutton-Picture1.jpg 1637w" sizes="(max-width: 374px) 100vw, 374px"><figcaption class="wp-caption-text">The miniature, proof-of-concept, bioimpedance sensor has a 1 x 10 mm footprint at a 25 µL working volume. [Yves Mermoud, PhD, research scientist, Eastern Switzerland University of Applied Sciences]</figcaption></figure>
<h4><strong>A good starting point</strong></h4>
<p>The team measured electrical impedance from 10 kHz to 5 MHz, with an amplitude of 200 mV. The detection limit was approximately 0.5 × 10<sup>6</sup> cells mL⁻¹. Deviations at the upper and lower limits were comparable to those of commercial probes, according to data the team presented at the recent Eurosensors 2026 meeting.</p>
<p>There, they reported a linear correlation when measuring the viable density of CHO cells and closely—but not perfectly—tracked reference cell counts. More specifically, Mermoud tells <em>GEN</em>, “Their measurements showed strong correlation with the reference cell counts (R² = 0.92), indicating that a linear relationship explained 92% of the observed variation.”</p>
<p>To create these miniaturized sensors, the researchers fabricated evaporated platinum thin-film electrodes onto a 100 mm fused silica wafer by photolithography. The wafer was cut into 15 x15 mm microchips that were connected to an impedance analyzer. Each chip features two microfluidic channels.</p>
<p>“The PAT microchip cell density sensor has already demonstrated continuous at-line monitoring in representative 14-day CHO fed-batch cultivations,” Mermoud says. “In these studies, cell suspension was circulated through an external demonstrator module housing the PAT microchip. Our focus now is on improving signal analysis to account for process-related changes in the culture medium over time.</p>
<p>“Going forward, we will package the PAT microchip as a standard insertion probe for direct inline deployment in the bioreactor and expand the data analytics with multivariate models that leverage the microchip’s multiple sensing modalities,” Mermoud elaborates.</p>
<p>“We are currently seeking industrial partners to support and accelerate this final translation into a commercial process sensor.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/small-bioprocess-monitoring-hits-the-goldilocks-zone/">Small Bioprocess Monitoring Hits the Goldilocks Zone</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Standardized Apheresis Processes Would Help Cell Therapy Sector</title>
<link>https://edusehat.com/en/standardized-apheresis-processes-would-help-cell-therapy-sector</link>
<guid>https://edusehat.com/en/standardized-apheresis-processes-would-help-cell-therapy-sector</guid>
<description><![CDATA[ Variation in collection practices, or apheresis, and handling procedures is a source of cell therapy starting material variability and a major headache for manufacturers, suggesting a degree of standardization would help the industry.
The post Standardized Apheresis Processes Would Help Cell Therapy Sector appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2018/12/Nov1_2018_GettyImages_998855520_InsertingSyringePatientArm.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 03:15:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Standardized, Apheresis, Processes, Would, Help, Cell, Therapy, Sector</media:keywords>
<content:encoded><![CDATA[<p>Variability in collection practices at sampling sites has an impact on the quality of cell therapy starting materials, say the authors of new <a href="https://www.sciencedirect.com/science/article/abs/pii/S1465324926009667" target="_blank" rel="noopener">analysis</a>, who suggest that a degree of standardization would aid industry.</p>
<p>Biological factors, such as age, disease status, treatment regimen, and donation history, impact the quality of cells harvested at collection sites, which is a challenge for cell therapy developers trying to turn these variable materials into consistent products.</p>
<p>But biology is not the only source of variability, according to Christina Celluzzi, PhD, from the Association for the Advancement of Blood & Biotherapies, who says firms should not underestimate the role cell collection practices play in determining quality.</p>
<p>“Variability at the apheresis stage complicates comparability assessments when manufacturers change processes, transfer technology, or add capacity. It also limits how efficiently sponsors can use comparability protocols and post-approval change strategies,” she tells <em>GEN</em>.</p>
<h4><strong>Standardization</strong></h4>
<p>Celluzzi and colleagues looked at the impact of variation in apheresis and handling protocols in a recent <a href="https://www.sciencedirect.com/science/article/abs/pii/S1465324926009667" target="_blank" rel="noopener">study</a>, concluding that standardizing parts of these processes would aid cell and gene therapy developers.</p>
<p>“Not every area needs the same degree of standardization,” she says, adding, “for example, there will always need to be flexibility with regard to device selection and vascular access techniques.”</p>
<p>“In contrast, the elements of apheresis that support comparability and traceability would benefit most from tight standardization. These include minimum donor eligibility data elements, definitions of quality attributes, and product identification and labeling,” Celluzzi says.</p>
<p>She cites existing standards—such as <a href="https://www.isbtweb.org/resource/in-015-an-introduction-to-isbt-128---english-v6-pdf.html" target="_blank" rel="noopener">ISBT 128</a>, which covers terminology, labeling, and chain of identity—as an ideal starting point for industry efforts to standardize cell collection practices.</p>
<p>“Adoption of such standards should be paired with implementation support, so that standardization doesn’t widen capability gaps between collection sites.</p>
<p>“We believe the technical content of best practices is best developed by stakeholders, for example through consensus efforts led by organizations such as PDA and ASTCT. Regulators would then recognize or incorporate those standards rather than author them from scratch,” she continues.</p>
<p>That said, the clarification of existing regulations covering cell therapy starting materials would also help industry, according to Celluzzi.</p>
<p>“We’re also asking FDA to clarify several points: how it distinguishes investigational from commercial starting materials, its expectations for collections made outside the United States, and how consensus standards can support regulatory submissions.”</p>
<p>Harmonizing material receipt procedures at cell therapy production facilities would help too, Celluzzi says, citing strictly defined temperature limits and cryopreservation media specifications as examples.</p>
<p>“Common templates for leukapheresis manuals, SOPs, and chain-of-custody and chain-of-identity records would be beneficial,” Celluzzi says, adding, “Risk-based site qualification would let manufacturers focus audits on product-specific risks instead of repeatedly reassessing established quality systems.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/standardized-apheresis-processes-would-help-cell-therapy-sector/">Standardized Apheresis Processes Would Help Cell Therapy Sector</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Building Custom DNA without Bacterial Constraints</title>
<link>https://edusehat.com/en/building-custom-dna-without-bacterial-constraints</link>
<guid>https://edusehat.com/en/building-custom-dna-without-bacterial-constraints</guid>
<description><![CDATA[ Moving high-fidelity DNA assembly from the production queue to the lab bench and the science can start sooner.
The post Building Custom DNA without Bacterial Constraints appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/RibbonBio_DNA.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 03:15:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Building, Custom, DNA, without, Bacterial, Constraints</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="https://ribbonbio.com/" target="_blank" rel="noopener"><img decoding="async" class="alignnone wp-image-336834 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-300x97.jpg" alt="Ribbon Bio logo" width="300" height="97" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-300x97.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-1024x330.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-768x247.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-1536x495.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-1303x420.jpg 1303w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-696x224.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-1392x449.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-1068x344.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB.jpg 1921w" sizes="(max-width: 300px) 100vw, 300px"></a></p>
<p>The standard way to build custom DNA still runs through a living cell: assemble the sequence, push it into bacteria, grow overnight, extract, clean up. Molecular biologists have leaned on this for half a century, and for most constructs it works. But it is slow to schedule, demands culturing and biosafety infrastructure, and quietly fails on the sequences researchers care about most.</p>
<p>Those failures were the starting point for Ribbon Bio. “Sometimes the sequence we want to study is precisely the sequence that bacteria do not want to maintain,” said Divya Vijay Pratheek, the company’s vice president of product, in a recent GEN webinar. Toxic elements and secondary structures can collapse a clone, costing days or weeks of troubleshooting. Outsourcing relieves the bottleneck but puts proprietary sequences in someone else’s hands.</p>
<h4><strong>Taking out the host</strong></h4>
<p>Ribbon Bio’s cell-free assembly technology removes bacteria from the equation entirely thus eliminating several practical burdens. Without a host, Pratheek explained, there is no endotoxin or residual genomic DNA to carry into downstream assays, contamination that matters most for therapeutic and patient-facing work. Since sequences no longer have to survive inside a living host, toxic or unstable designs become workable, and the failure points of transformation, colony selection, and plasmid prep fall away.</p>
<p>The workflow opens with software. Ribbon Bio’s proprietary algorithm reads target sequences for trouble spots such as GC content, repeats, homopolymers, and secondary structure, then lays out oligo pools with boundaries chosen to sidestep them. Ribbon’s proprietary enzymes stitch the oligos into fragments, checked before assembly into the finished molecule. The design is tuned most to catch most complexities, before they lead to failed reactions.</p>
<h4><strong>From service to bench</strong></h4>
<p>The company first sold this as a synthesis service, MiroSynth<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, which it still runs for extremely complex molecules. These days, the MiroMine<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> kit puts the method directly in customers’ hands enabling them to build complex DNA in house. The early-access version builds molecules up to roughly 7 kilobases, needs only standard lab hardware, and runs manually or using automation, with platform scripts in progress.</p>
<p>The figures came from Ribbon Bio’s own runs. Molecules near 3.4 and 6.8 kb returned 100% sequence-perfect reads, and a roughly 4 kb construct came in at 88%, shown openly against the company’s 90% accuracy floor. Fragments ranging from 30%–70% global and 20%–82% local GC content, plus repeats and homopolymers, cleared the same four-hour workflow. Endotoxin levels sat at or below 0.1 units per microgram, with no detectable bacterial genomic DNA.</p>
<h4><strong>A library builder’s test</strong></h4>
<p>Flock Bio, a company that assembles pooled custom DNA libraries, is an early user of Ribbon Bio’s kit.  In one internal study, the company’s scientists ran 12 fragments through MiroMine and got all 12, roughly half of them high-complexity, cleanly assembled.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The payoff was speed. With MiroMine, Flock ran fragment assembly, cleanup, checks, and pooled ligation inside one working day; with cloning adding three to four days, a full library can land in a week. “If we get that oligo pool on Monday, we’re shipping by Friday,” said Matthew D. Youngblut, PhD, Flock Bio’s co-founder and chief scientific officer, who pointed to value of fast-turn work for things like antibody discovery, binder design, and more.</p>
<h4><strong>The takeaway</strong></h4>
<p>For over fifty years, traditional DNA assembly has relied on bacterial propagation, a process that introduces labor intensive processes, sequence constraints, contamination risks, and extended production cycles. In this webinar, Ribbon Bio and Flock Bio lay out a case for retiring that requirement: purer starting material, access to sequences bacteria reject, and a turnaround counted in days instead of weeks. For scientists working in therapeutic development, endotoxin-free production addresses regulatory and safety concerns that currently require additional purification steps. The technology also enables iteration cycles that match the pace of modern screening technologies, particularly in competitive areas like antibody discovery.  While the program is young and not every use case is proven, the direction is clear: pull the build onto the bench, and the science can start sooner.</p>
<p> </p>
<p><em><img decoding="async" class="alignleft wp-image-340203 size-full" src="https://www.genengnews.com/wp-content/uploads/2026/11/RibbonBio_QRCode.jpg" alt="Ribbon Bio QR Code" width="146" height="151"></em></p>
<p> </p>
<p><em>Try MiroMine<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> in your lab today at <a href="https://ribbonbio.com/miromine/" target="_blank" rel="noopener">www.ribbonbio.com/miromine</a>.</em></p>
<p>The post <a href="https://www.genengnews.com/sponsored/building-custom-dna-without-bacterial-constraints/">Building Custom DNA without Bacterial Constraints</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>HIV&#45;Blocking Antibody Shows Promise, but Resistant Strains Break Through</title>
<link>https://edusehat.com/en/hiv-blocking-antibody-shows-promise-but-resistant-strains-break-through</link>
<guid>https://edusehat.com/en/hiv-blocking-antibody-shows-promise-but-resistant-strains-break-through</guid>
<description><![CDATA[ A new study finds that the VRC01 antibody initially protects against HIV infection, but resistant strains can cause breakthrough infections as antibody levels decline, highlighting the need for multiple antibodies.
The post HIV-Blocking Antibody Shows Promise, but Resistant Strains Break Through appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/08/GettyImages-2204954260.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 03:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>HIV-Blocking, Antibody, Shows, Promise, but, Resistant, Strains, Break, Through</media:keywords>
<content:encoded><![CDATA[<p>One of the mechanisms being developed to help combat HIV is to prevent HIV-negative individuals, who are at risk of acquiring HIV-1, from becoming infected. One form of this preventative strategy is using broadly neutralizing antibodies (bnAbs)—administered intravenously—that could protect individuals from acquiring HIV-1. This could be most relevant for people with partners living with HIV, people at increased risk of HIV exposure (including individuals with ongoing sexual exposure risk), people who cannot or prefer not to use conventional PrEP, and among populations with high HIV incidence—for example, communities in regions of sub-Saharan Africa with substantial HIV transmission.</p>
<p>The antibody-mediated prevention (AMP) clinical trials were landmark trials in this area—the first to investigate whether intravenous infusion of a bnAb could prevent HIV-1 acquisition. The trials focused on the bnAb VRC01, which targets the CD4-binding site on the HIV-1 envelope (Env) glycoprotein. By binding to this region, VRC01 can neutralize susceptible HIV-1 strains and potentially prevent the virus from infecting host cells.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The broadly neutralizing antibody VRC01 has been thoroughly vetted as a potential prophylactic that could prevent people from becoming infected with HIV. Now, a new analysis of data from two clinical trials in the Americas and sub-Saharan Africa shows that the antibody initially provides strong protection, but that some strains of the virus can still cause breakthrough infections after treatment has stopped. The findings point to the importance of combining multiple types of antibodies to suppress HIV completely and to prevent breakthrough infections in vulnerable people.</p>
<p>This work is published in <em>Science Translational Medicine</em> in the paper, “Extended <em>in vivo</em> activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections.”</p>
<p>Antibodies such as VRC01 are designed to halt the virus’ ability to infect its host initially through common sites of exposure. VRC01 has recently progressed to large-scale clinical trials, but scientists must test whether it can provide meaningful, real-world protection against the ever-evolving myriad strains of HIV.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>In this new report, researchers parsed data from HVTN 704 and HPTN 085, two clinical trials where participants received infusions of VRC01 for 80 weeks. The two parallel antibody-mediated prevention (AMP) prevention efficacy trials evaluated whether intravenous infusion of the anti-CD4 binding site broadly neutralizing antibody VRC01 prevents HIV-1 acquisition.</p>
<p>The researchers focused their attention on the period after the treatment ended, from weeks 80 to 104. More specifically, they analyzed HIV-1 acquisition in AMP through the week 104 final study visit.</p>
<p>The researchers showed that VRC01 initially protected against HIV strains that were considered highly sensitive to the antibody, achieving a prevention efficacy of 66.3%. They write that against viruses considered highly sensitive to VRC01, “VRC01 prophylaxis maintained cumulative prevention efficacy of 66.3%, suggesting that the antibody successfully blocked or cleared these infections.”</p>
<p>As VRC01 concentration waned, suppressed viruses—often evolving greater resistance because of selective pressure—emerged as detectable infections. After week 80, some of the participants were still diagnosed with HIV that was considered more resistant to the antibody, and diagnoses were higher compared with the placebo group. They write, “In the post–week 80 period (after the final dose at week 72), HIV diagnosis and resistance to VRC01 were more frequent and greater in the VRC01 groups versus placebo.”</p>
<p>The findings, the authors explain, suggest that, “whereas single antibodies can block sensitive strains, multiple antibodies are likely required to prevent both viral escape and breakthrough infections.” The authors write that their results carry implications for the design and analysis of future trials of HIV-1 broadly neutralizing antibodies, such as the importance of testing for the virus far after infusions have ended.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/hiv-blocking-antibody-shows-promise-but-resistant-strains-break-through/">HIV-Blocking Antibody Shows Promise, but Resistant Strains Break Through</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Ultra&#45;Processed Sports Food Dilemma</title>
<link>https://edusehat.com/en/the-ultra-processed-sports-food-dilemma</link>
<guid>https://edusehat.com/en/the-ultra-processed-sports-food-dilemma</guid>
<description><![CDATA[ This week in the world of sports science, ultra-processed sports food, acceleration, &amp; sprinting. 
The post The Ultra-Processed Sports Food Dilemma appeared first on Science for Sport. ]]></description>
<enclosure url="https://www.scienceforsport.com/wp-content/uploads/2026/10/8169581e-eb1a-4616-947c-7b67e4d253be-1024x683.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 00:25:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Ultra-Processed, Sports, Food, Dilemma</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph"><strong>This week in the world of sports science, here’s what happened…</strong></p>



<ul class="wp-block-list">
<li>The ultra-processed sports food dilemma</li>



<li>Was Usain Bolt really a poor starter?</li>



<li>Sprinters should never jog!</li>
</ul>



<div aria-hidden="true" class="wp-block-spacer"></div>



<h2 class="wp-block-heading">The ultra-processed sports food dilemma</h2>



<figure class="wp-block-image size-large"><img fetchpriority="high" decoding="async" width="1024" height="683" src="https://www.scienceforsport.com/wp-content/uploads/2026/10/8169581e-eb1a-4616-947c-7b67e4d253be-1024x683.png" alt="" class="wp-image-34419" srcset="https://www.scienceforsport.com/wp-content/uploads/2026/10/8169581e-eb1a-4616-947c-7b67e4d253be-1024x683.png 1024w, https://www.scienceforsport.com/wp-content/uploads/2026/10/8169581e-eb1a-4616-947c-7b67e4d253be-300x200.png 300w, https://www.scienceforsport.com/wp-content/uploads/2026/10/8169581e-eb1a-4616-947c-7b67e4d253be-768x512.png 768w, https://www.scienceforsport.com/wp-content/uploads/2026/10/8169581e-eb1a-4616-947c-7b67e4d253be.png 1536w" sizes="(max-width: 1024px) 100vw, 1024px"><figcaption class="wp-element-caption">(Image: ChatGPT)</figcaption></figure>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph">Ultra-processed foods have received considerable negative attention in recent years, but a new <a href="https://link.springer.com/article/10.1186/s40798-026-01098-7?" target="_blank" rel="noreferrer noopener">review</a> highlights an interesting dilemma for athletes: many commonly used <a href="https://www.scienceforsport.com/course-category/nutrition/" target="_blank" rel="noreferrer noopener">sports nutrition</a> products are technically classified as ultra-processed.</p>



<p class="wp-block-paragraph"><a href="https://www.scienceforsport.com/are-sports-drinks-good-for-athletes/" target="_blank" rel="noreferrer noopener">Sports drinks</a>, <a href="https://academy.scienceforsport.com/programs/collection-khgcj2jisie?category_id=141256" target="_blank" rel="noreferrer noopener">carbohydrate</a> gels, <a href="https://academy.scienceforsport.com/programs/collection-ytlmnxn6iuy?category_id=141256" target="_blank" rel="noreferrer noopener">protein</a> bars and <a href="https://academy.scienceforsport.com/catalog/search?catalog_filter_7063%5B%5D=37498" target="_blank" rel="noreferrer noopener">recovery</a> drinks can all fall into this category. However, unlike many ultra-processed foods, these products are often consumed for a specific purpose, such as providing <a href="https://academy.scienceforsport.com/programs/collection-khgcj2jisie?category_id=141256" target="_blank" rel="noreferrer noopener">carbohydrate</a> during prolonged exercise, replacing fluids and <a href="https://academy.scienceforsport.com/programs/collection-8fwy4fiiobk?category_id=141256" target="_blank" rel="noreferrer noopener">electrolytes</a>, or supporting post-training <a href="https://academy.scienceforsport.com/catalog/search?catalog_filter_7063%5B%5D=37498" target="_blank" rel="noreferrer noopener">recovery</a>.</p>



<p class="wp-block-paragraph">For example, <a href="https://academy.scienceforsport.com/programs/collection-vq0okjasa8c" target="_blank" rel="noreferrer noopener">endurance</a> athletes may require large amounts of <a href="https://academy.scienceforsport.com/programs/collection-khgcj2jisie?category_id=141256" target="_blank" rel="noreferrer noopener">carbohydrate</a> during prolonged exercise. Meeting these demands entirely through minimally processed foods may be impractical, whereas <a href="https://www.scienceforsport.com/are-sports-drinks-good-for-athletes/" target="_blank" rel="noreferrer noopener">sports drinks</a> and gels provide a convenient source of <a href="https://academy.scienceforsport.com/programs/collection-khgcj2jisie?category_id=141256" target="_blank" rel="noreferrer noopener">carbohydrate</a> that can be easily consumed during exercise.</p>



<p class="wp-block-paragraph">Interestingly, the researchers note that relatively little research has examined ultra-processed food consumption specifically among athletes. Therefore, although athletes should still prioritise a high-quality, nutrient-dense diet, classifying a sports food as “ultra-processed” does not necessarily mean it is unhealthy or inappropriate.</p>



<p class="wp-block-paragraph">This raises an interesting question: when it comes to <a href="https://www.scienceforsport.com/course-category/nutrition/" target="_blank" rel="noreferrer noopener">sports nutrition</a>, should we judge a food by how processed it is or by how effectively it supports an athlete’s training and performance?</p>



<div aria-hidden="true" class="wp-block-spacer"></div>



<h2 class="wp-block-heading">Was Usain Bolt really a poor starter?</h2>



<figure class="wp-block-image size-large"><img decoding="async" width="1024" height="1024" src="https://www.scienceforsport.com/wp-content/uploads/2026/10/5000-1-1024x1024.jpeg" alt="" class="wp-image-34416" srcset="https://www.scienceforsport.com/wp-content/uploads/2026/10/5000-1-1024x1024.jpeg 1024w, https://www.scienceforsport.com/wp-content/uploads/2026/10/5000-1-150x150.jpeg 150w, https://www.scienceforsport.com/wp-content/uploads/2026/10/5000-1-768x768.jpeg 768w, https://www.scienceforsport.com/wp-content/uploads/2026/10/5000-1-300x300.jpeg 300w, https://www.scienceforsport.com/wp-content/uploads/2026/10/5000-1.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px"><figcaption class="wp-element-caption">Usain Bolt (Image: The Guardian)</figcaption></figure>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph">Leading <a href="https://www.scienceforsport.com/top-100-experts-in-sports-science/" target="_blank" rel="noreferrer noopener">sports scientist</a> Lance Brooks offers an alternative perspective on <a href="https://academy.scienceforsport.com/programs/collection-hmfnazj3bgu?category_id=141256" target="_blank" rel="noreferrer noopener">sprint acceleration</a>, using Usain Bolt as an example (see <a href="https://www.instagram.com/reel/DejmmUDlS27/?utm_source=ig_web_copy_link&dlrf=MzRlODBiNWFlZA==&srtk=MzRlODBiNWFlZA==" target="_blank" rel="noreferrer noopener">here</a>). While many believe Bolt was a poor starter out of the blocks, Brooks strongly disagrees.</p>



<p class="wp-block-paragraph">His argument is that <a href="https://academy.scienceforsport.com/programs/collection-hmfnazj3bgu?category_id=141256" target="_blank" rel="noreferrer noopener">acceleration</a> should not be viewed in isolation. For example, positioning the starting blocks closer together may allow an athlete to <a href="https://academy.scienceforsport.com/programs/collection-hmfnazj3bgu?category_id=141256" target="_blank" rel="noreferrer noopener">accelerate</a> out of the blocks more quickly. However, <a href="https://academy.scienceforsport.com/programs/collection-t1fd52zbpwi?category_id=141256" target="_blank" rel="noreferrer noopener">sprinting</a> is not simply about maximising initial <a href="https://academy.scienceforsport.com/programs/collection-hmfnazj3bgu?category_id=141256" target="_blank" rel="noreferrer noopener">acceleration</a>, but rather about building <a href="https://academy.scienceforsport.com/programs/collection-t1fd52zbpwi?category_id=141256" target="_blank" rel="noreferrer noopener">velocity</a> effectively and maintaining it for as long as possible.</p>



<p class="wp-block-paragraph">Brooks highlights the importance of the impulse–momentum relationship, explaining that athletes may benefit from staying in the blocks slightly longer to apply force, particularly through the front leg, and generate greater impulse.</p>



<p class="wp-block-paragraph">Therefore, rather than judging Bolt’s start by how quickly he exited the blocks, Brooks suggests we should consider how effectively he used the block phase to begin building <a href="https://academy.scienceforsport.com/programs/collection-t1fd52zbpwi?category_id=141256" target="_blank" rel="noreferrer noopener">velocity</a>, continuing to increase that <a href="https://academy.scienceforsport.com/programs/collection-t1fd52zbpwi?category_id=141256" target="_blank" rel="noreferrer noopener">velocity</a> throughout the <a href="https://academy.scienceforsport.com/programs/collection-t1fd52zbpwi?category_id=141256" target="_blank" rel="noreferrer noopener">sprint</a> before maintaining it for as long as possible.</p>



<div aria-hidden="true" class="wp-block-spacer"></div>



<h2 class="wp-block-heading">Sprinters should never jog!</h2>



<figure class="wp-block-image size-large"><img decoding="async" width="819" height="1024" src="https://www.scienceforsport.com/wp-content/uploads/2026/10/7278144b-bcf8-454b-a034-d5001e8eb22c-819x1024.png" alt="" class="wp-image-34418" srcset="https://www.scienceforsport.com/wp-content/uploads/2026/10/7278144b-bcf8-454b-a034-d5001e8eb22c-819x1024.png 819w, https://www.scienceforsport.com/wp-content/uploads/2026/10/7278144b-bcf8-454b-a034-d5001e8eb22c-240x300.png 240w, https://www.scienceforsport.com/wp-content/uploads/2026/10/7278144b-bcf8-454b-a034-d5001e8eb22c-767x959.png 767w, https://www.scienceforsport.com/wp-content/uploads/2026/10/7278144b-bcf8-454b-a034-d5001e8eb22c.png 1122w" sizes="(max-width: 819px) 100vw, 819px"><figcaption class="wp-element-caption">Stu McMillan & Andrew Huberman (Image: Instagram)</figcaption></figure>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph">A recent <a href="https://www.linkedin.com/posts/altisworld_this-clip-comes-from-stu-mcmillan-teaching-activity-7519096067980894208-V5sy?utm_source=share&utm_medium=member_desktop&rcm=ACoAACNp2EgBRqVyB1D3eEjc_INvWZNNmgdBlJ0" target="_blank" rel="noreferrer noopener">clip</a> circulating on social media from Dr. Andrew Huberman’s visit to renowned <a href="https://academy.scienceforsport.com/programs/collection-_m8tlhtarwi" target="_blank" rel="noreferrer noopener">sprint</a> coach and <a href="https://academy.scienceforsport.com/programs/collection-_m8tlhtarwi">speed</a> mechanics expert Stu McMillan has generated considerable engagement. The <a href="https://www.linkedin.com/posts/altisworld_this-clip-comes-from-stu-mcmillan-teaching-activity-7519096067980894208-V5sy?utm_source=share&utm_medium=member_desktop&rcm=ACoAACNp2EgBRqVyB1D3eEjc_INvWZNNmgdBlJ0" target="_blank" rel="noreferrer noopener">clip</a> provides a fascinating insight into McMillan’s <a href="https://academy.scienceforsport.com/programs/collection-l8pikb-wk7i?category_id=141256" target="_blank" rel="noreferrer noopener">warm-up</a> philosophy for <a href="https://academy.scienceforsport.com/programs/collection-_m8tlhtarwi" target="_blank" rel="noreferrer noopener">sprinters</a>.</p>



<p class="wp-block-paragraph">While jogging is commonly utilised at the beginning of <a href="https://academy.scienceforsport.com/programs/collection-l8pikb-wk7i?category_id=141256" target="_blank" rel="noreferrer noopener">warm-ups</a>, McMillan explains why he never gets his <a href="https://academy.scienceforsport.com/programs/collection-_m8tlhtarwi" target="_blank" rel="noreferrer noopener">sprinters</a> to jog. His reasoning is simple: <a href="https://academy.scienceforsport.com/programs/collection-_m8tlhtarwi" target="_blank" rel="noreferrer noopener">sprinters</a> are <a href="https://academy.scienceforsport.com/programs/collection-_m8tlhtarwi" target="_blank" rel="noreferrer noopener">sprinters</a>, not joggers. McMillan argues that jogging and <a href="https://academy.scienceforsport.com/programs/collection-_m8tlhtarwi" target="_blank" rel="noreferrer noopener">sprinting</a> involve very different gait patterns. Instead, he favours skips and strides, which encourage stiffness through the ankle, knee and hip, helping athletes develop the coordination and elastic qualities associated with <a href="https://academy.scienceforsport.com/programs/collection-_m8tlhtarwi" target="_blank" rel="noreferrer noopener">sprinting</a>. He also highlights how jogging tends to involve more pushing behind the centre of mass, whereas <a href="https://academy.scienceforsport.com/programs/collection-_m8tlhtarwi" target="_blank" rel="noreferrer noopener">sprinting</a>, particularly at maximal velocity, requires different limb positioning and coordination.</p>



<p class="wp-block-paragraph">While this doesn’t necessarily mean jogging has no place in field sport <a href="https://academy.scienceforsport.com/programs/collection-l8pikb-wk7i?category_id=141256" target="_blank" rel="noreferrer noopener">warm-ups</a>, it highlights McMillan’s belief in making the <a href="https://academy.scienceforsport.com/programs/collection-l8pikb-wk7i?category_id=141256" target="_blank" rel="noreferrer noopener">warm-up</a> as specific as possible to the athlete and the activity that follows. If you work with <a href="https://academy.scienceforsport.com/programs/collection-_m8tlhtarwi" target="_blank" rel="noreferrer noopener">speed</a> athletes and regularly begin your <a href="https://academy.scienceforsport.com/programs/collection-l8pikb-wk7i?category_id=141256" target="_blank" rel="noreferrer noopener">warm-ups</a> with jogging, this <a href="https://www.linkedin.com/posts/altisworld_this-clip-comes-from-stu-mcmillan-teaching-activity-7519096067980894208-V5sy?utm_source=share&utm_medium=member_desktop&rcm=ACoAACNp2EgBRqVyB1D3eEjc_INvWZNNmgdBlJ0" target="_blank" rel="noreferrer noopener">clip</a> is certainly worth watching!</p>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph"><strong>From us this week:</strong></p>



<p class="wp-block-paragraph">>> New course: <a href="https://academy.scienceforsport.com/programs/collection-xy44wcqbjsy?category_id=141256" data-type="link" data-id="https://academy.scienceforsport.com/programs/collection-xy44wcqbjsy?category_id=141256" target="_blank" rel="noreferrer noopener">Observation Before Intervention: Building Better Coaching Environments</a><br>>> New podcast: <a href="https://scienceforsport.fireside.fm/344" data-type="link" data-id="https://scienceforsport.fireside.fm/344" target="_blank" rel="noreferrer noopener">Preventing Non-Contact Injuries in Professional Football</a><br>>> New infographic: <a href="https://www.instagram.com/p/Deo2S_el4Ds/?img_index=4" data-type="link" data-id="https://www.instagram.com/p/Deo2S_el4Ds/?img_index=4" target="_blank" rel="noreferrer noopener">Performance Analysis</a><br>>> New article: <a href="https://www.scienceforsport.com/essa-and-science-for-sport-announce-strategic-professional-development-partnership/" data-type="link" data-id="https://www.scienceforsport.com/essa-and-science-for-sport-announce-strategic-professional-development-partnership/" target="_blank" rel="noreferrer noopener">ESSA and Science for Sport Announce Strategic Professional Development Partnership</a></p>



<p class="wp-block-paragraph"><strong>Access to a growing library of sports science courses</strong></p>



<p class="wp-block-paragraph"><a href="https://academy.scienceforsport.com/" target="_blank" rel="noopener" data-lasso-id="59917">SFS Academy</a> is an all-access membership to premium sports science education.</p>



<p class="wp-block-paragraph">With SFS Academy, you’ll learn from some of the best coaches around the world as they teach you how to apply the latest research and practice with your athletes.</p><p>The post <a href="https://www.scienceforsport.com/the-ultra-processed-sports-food-dilemma/">The Ultra-Processed Sports Food Dilemma</a> appeared first on <a href="https://www.scienceforsport.com/">Science for Sport</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Adventist Health Unveils $30 Million Advanced Care Pavilion in Bakersfield</title>
<link>https://edusehat.com/en/adventist-health-unveils-30-million-advanced-care-pavilion-in-bakersfield</link>
<guid>https://edusehat.com/en/adventist-health-unveils-30-million-advanced-care-pavilion-in-bakersfield</guid>
<description><![CDATA[ A ribbon-cutting ceremony was held Oct. 8 at Adventist Health’s new Advanced Care Pavilion, which will provide specialty and cancer care in Bakersfield, Calif. | Photo Credit: Adventist Health  The new 60,000-square-foot Advanced Care Pavilion brings specialty consultations, diagnostic imaging and cancer services together, with approximately 45,000 patient visits anticipated annually.  A phased third-floor opening...
The post Adventist Health Unveils $30 Million Advanced Care Pavilion in Bakersfield appeared first on HCO News.
The post Adventist Health Unveils $30 Million Advanced Care Pavilion in Bakersfield appeared first on HCO News. ]]></description>
<enclosure url="https://hconews.com/wp-content/uploads/2026/11/HCO-News.AdventistHealth-600x400.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 00:20:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Adventist, Health, Unveils, 30, Million, Advanced, Care, Pavilion, Bakersfield</media:keywords>
<content:encoded><![CDATA[<h5><span data-contrast="auto">A ribbon-cutting ceremony was held Oct. 8 at Adventist Health’s new Advanced Care Pavilion, which will provide specialty and cancer care in Bakersfield, Calif. | Photo Credit: Adventist Health</span><span data-ccp-props="{}"> </span></h5>
<ul>
<li><span data-contrast="auto">The new 60,000-square-foot Advanced Care Pavilion brings specialty consultations, diagnostic imaging and cancer services together, with approximately 45,000 patient visits anticipated annually.</span><span data-ccp-props="{}"> </span></li>
<li><span data-contrast="auto">A phased third-floor opening will expand the Breast Care Center from three to 14 exam rooms and add 11 infusion bays, providing capacity for approximately 5,000 more treatments each year.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":0,"335559739":0}'> </span></li>
<li><span data-contrast="auto">A planned Rapid Care Oncology Clinic will offer same-day appointments for treatment-related complications, including infection, dehydration and anemia, helping patients receive timely care and reducing avoidable emergency department visits.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":0,"335559739":0}'> </span></li>
</ul>
<p><span data-contrast="auto">Adventist Health held an Oct. 8 ribbon-cutting for its $30 million Advanced Care Pavilion in Bakersfield, Calif. The facility spans 60,000 square feet and is expected to accommodate about 45,000 patient visits annually.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Located beside the AIS Cancer Center, the pavilion combines specialty consultations, diagnostics and cancer treatment. </span><a href="https://www.adventisthealth.org/news/ribbon-cutting-marks-new-era-of-specialty-and-cancer-care//" target="_blank" rel="noopener"><span data-contrast="none">Adventist Health said in its ribbon-cutting announcement</span></a><span data-contrast="auto"> that concentrating services in one location is intended to reduce travel between appointments and help patients navigate care that requires several specialists.</span><span data-ccp-props="{}"> </span></p>
<blockquote><p><span data-contrast="auto">“This $30 million project demonstrates a long-term commitment to the future of healthcare in our community,” Jason Wells, President of Adventist Health Central California Network, said in the announcement. “Most importantly, it means that more people will be able to receive exceptional care close to their family, support systems, and homes.”</span><span data-ccp-props="{}"> </span></p></blockquote>
<p><span data-contrast="auto">The second floor houses general surgery, urology, orthopedics, spine care, cardiothoracic services and advanced imaging. The third floor will open in phases for medical oncology, infusion treatment and breast care. Additional specialties are planned for the facility.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">The Breast Care Center initially opened in 2016, and breast surgeon Dr. Francesca Hoehne described the impact of increasing the center’s exam rooms from three to 14. </span><span data-ccp-props="{}"> </span></p>
<blockquote><p><span data-contrast="auto">“Our community is growing, so it’s wonderful to be able to grow the Breast Care Center,” said Hoehne. “This dramatically increases our capacity to care for more patients.” </span><span data-ccp-props="{}"> </span></p></blockquote>
<p><span data-contrast="auto">Eleven new infusion bays will provide capacity for approximately 5,000 additional treatments annually.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">The planned Rapid Care Oncology Clinic will offer same-day appointments for patients experiencing treatment-related side effects. Adventist Health described it as the region’s first such clinic, intended to reduce avoidable emergency department visits.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Cardiothoracic surgeon Dr. Shamsuddin Khwaja emphasized collaboration that the facility will help strengthen. </span></p>
<blockquote><p><span data-contrast="auto">“The best outcomes happen when specialists work together as one coordinated team,” said Khwaja.</span></p></blockquote>
<p><span data-contrast="auto">That approach extends beyond placing different services in the same building. </span><a href="https://www.adventisthealth.org/central-california/news/advanced-care-pavilion-investment-will-help-expand-cancer-care" target="_blank" rel="noopener"><span data-contrast="none">Adventist Health’s project update from August</span></a><span data-contrast="auto"> described a coordinated sequence of imaging, consultations and treatment planning, with the goal of reducing delays as patients move from diagnosis to treatment. The provider also outlined plans for precision medicine, genetic testing and clinical research opportunities, describing the pavilion as an investment in recruiting and retaining specialists, with the aim of making services available locally that patients previously sought outside the region.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">In that same update, Adventist Health also announced a Bank of America grant, highlighting philanthropy’s role in expanding local access to specialty services.</span><span data-ccp-props="{}"> </span></p>
<p><i><span data-contrast="auto">This article is based on Adventist Health’s </span></i><a href="https://www.adventisthealth.org/news/ribbon-cutting-marks-new-era-of-specialty-and-cancer-care//" target="_blank" rel="noopener"><i><span data-contrast="none">Oct. 12, 2026, press release</span></i></a><i><span data-contrast="auto">, with supplemental information from its </span></i><a href="https://www.adventisthealth.org/central-california/news/advanced-care-pavilion-investment-will-help-expand-cancer-care" target="_blank" rel="noopener"><i><span data-contrast="none">Aug. 6 project update</span></i></a><i><span data-contrast="auto"> and ribbon-cutting event notice.</span></i><span data-ccp-props="{}"> </span></p>
<p>The post <a rel="nofollow" href="https://hconews.com/2026/11/04/adventist-health-unveils-30-million-advanced-care-pavilion-in-bakersfield/">Adventist Health Unveils $30 Million Advanced Care Pavilion in Bakersfield</a> appeared first on <a rel="nofollow" href="https://hconews.com/">HCO News</a>.</p>
<p>The post <a href="https://hconews.com/2026/11/04/adventist-health-unveils-30-million-advanced-care-pavilion-in-bakersfield/">Adventist Health Unveils $30 Million Advanced Care Pavilion in Bakersfield</a> appeared first on <a href="https://hconews.com/">HCO News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond Weight Loss: The Endocrine Society Opens a New Era in Obesity Care</title>
<link>https://edusehat.com/en/beyond-weight-loss-the-endocrine-society-opens-a-new-era-in-obesity-care</link>
<guid>https://edusehat.com/en/beyond-weight-loss-the-endocrine-society-opens-a-new-era-in-obesity-care</guid>
<description><![CDATA[ The Endocrine Society recently launched its Center on Obesity, a comprehensive initiative, with the goal of improving obesity care, helping patients lose weight to gain health. Endocrine News spoke with two obesity experts about what the Center on Obesity means as the Society becomes the leader in this field. On September 9, the Endocrine Society […]
The post Beyond Weight Loss: The Endocrine Society Opens a New Era in Obesity Care appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/Center_on_Obesity_4C_Logo-002.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 00:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, Weight, Loss:, The, Endocrine, Society, Opens, New, Era, Obesity, Care</media:keywords>
<content:encoded><![CDATA[<p>The Endocrine Society recently launched its Center on Obesity, a comprehensive initiative, with the goal of improving obesity care, helping patients lose weight to gain health. Endocrine News spoke with two obesity experts about what the Center on Obesity means as the Society becomes the leader in this field. On September 9, the Endocrine Society […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/beyond-weight-loss-the-endocrine-society-opens-a-new-era-in-obesity-care/">Beyond Weight Loss: The Endocrine Society Opens a New Era in Obesity Care</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Epigenomics Is Transforming Drug Discovery and Development</title>
<link>https://edusehat.com/en/how-epigenomics-is-transforming-drug-discovery-and-development</link>
<guid>https://edusehat.com/en/how-epigenomics-is-transforming-drug-discovery-and-development</guid>
<description><![CDATA[ In this GEN eBook readers will discover how epigenomic insights are improving every stage of the drug discovery pipeline, from target identification and validation to mechanism-of-action studies and therapeutic optimization.
The post How Epigenomics Is Transforming Drug Discovery and Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Epicypher_CoverImage_Nov2026.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 23:40:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Epigenomics, Transforming, Drug, Discovery, and, Development</media:keywords>
<content:encoded><![CDATA[<div aria-hidden="true" class="wp-block-spacer"></div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Read Now</button></p>


<p class="wp-block-paragraph">Understanding gene regulation has become essential to modern drug discovery. While DNA sequence and RNA expression provide valuable information, they reveal only part of the story. Epigenomic technologies, particularly chromatin mapping assays like CUT&RUN, are enabling researchers to investigate the regulatory mechanisms that control gene expression, offering a level of insight that transcriptional profiling alone cannot provide.</p>


<figure class="wp-block-image alignright size-medium"><img decoding="async" width="232" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/11/Epicypher_eBookCover_Nov2026-232x300.jpg" alt="Epicypher eBook Cover, How Epigenomics Is Transforming Drug Discovery and Development" class="wp-image-340189" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Epicypher_eBookCover_Nov2026-232x300.jpg 232w, https://www.genengnews.com/wp-content/uploads/2026/11/Epicypher_eBookCover_Nov2026-791x1024.jpg 791w, https://www.genengnews.com/wp-content/uploads/2026/11/Epicypher_eBookCover_Nov2026-768x994.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Epicypher_eBookCover_Nov2026-1187x1536.jpg 1187w, https://www.genengnews.com/wp-content/uploads/2026/11/Epicypher_eBookCover_Nov2026.jpg 1200w" sizes="(max-width: 232px) 100vw, 232px"></figure>


<h4 class="wp-block-heading"><strong>Introduction</strong></h4>


<p class="wp-block-paragraph">In this <em>GEN</em> eBook, <em>How Epigenomics is Transforming Drug Discovery and Development</em>, readers will discover how epigenomic insights are improving every stage of the drug discovery pipeline, from target identification and validation to mechanism-of-action studies and therapeutic optimization.</p>


<h4 class="wp-block-heading"><strong>Read this eBook to learn:</strong></h4>


<ul class="wp-block-list">
<li>Why understanding gene regulation matters in drug discovery and development</li>



<li>How epigenomic profiling is being used to identify novel therapeutic targets, elucidate drug mechanisms of action, investigate treatment resistance, and support development of emerging modalities such as targeted protein degraders (e.g. PROTACs, molecular glues)</li>



<li>How next-generation technologies, including CUT&RUN, are providing unprecedented insights into gene regulation</li>
</ul>


<p class="wp-block-paragraph">Through expert perspectives and real-world case studies, this eBook demonstrates how researchers are applying epigenomic approaches to answer critical biological questions, characterize therapeutic responses, and make more informed decisions throughout drug development.</p>


<p class="wp-block-paragraph">Whether you’re working in target discovery, translational research, or therapeutic development, this eBook provides a practical overview of the technologies and strategies that are reshaping modern drug discovery.</p>


<p class="wp-block-paragraph">Read this eBook to learn how CUT&RUN and related epigenomic tools are helping pharmaceutical and biotechnology researchers uncover disease mechanisms, identify high-confidence drug targets, and accelerate the development of more effective therapies.</p>

<p>The post <a href="https://www.genengnews.com/resources/ebooks/how-epigenomics-is-transforming-drug-discovery-and-development/">How Epigenomics Is Transforming Drug Discovery and Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting</title>
<link>https://edusehat.com/en/kamau-therapeutics-releases-encouraging-sickle-cell-clinical-data-ahead-of-ash-meeting</link>
<guid>https://edusehat.com/en/kamau-therapeutics-releases-encouraging-sickle-cell-clinical-data-ahead-of-ash-meeting</guid>
<description><![CDATA[ The findings, part of a trove of abstracts that will be presented at next month’s American Society of Hematology (ASH) conference, show precise correction of the SCD mutation in the β-globin gene in three SCD patients as well as restored expression of adult hemoglobin (HbA).
The post Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2021/06/June04_2021_Stocktrek-Images-Getty-Images_Sickle-Cell-Disease-e1622842099798.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 23:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Kamau, Therapeutics, Releases, Encouraging, Sickle, Cell, Clinical, Data, Ahead, ASH, Meeting</media:keywords>
<content:encoded><![CDATA[<p>Kamau Therapeutics, a California biotech company co-founded by Stanford University physician-scientist Matthew Porteus, MD, PhD, has emerged from stealth with the release of preliminary clinical data on its first cohort of gene-edited patients with sickle cell disease (SCD).</p>
<p>The findings, part of a trove of abstracts that will be presented at next month’s American Society of Hematology (ASH) conference, show precise correction of the SCD mutation in the β-globin gene in three SCD patients as well as restored expression of adult hemoglobin (HbA). In contrast to FDA-approved Casgevy, which overcomes the SCD mutation by switching up expression of fetal hemoglobin (HbF), Kamau is employing a direct replacement of the SCD mutation using homology-directed repair (HDR) of the β-globin gene.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>All three patients are currently transfusion-independent and have not experienced any pain crises since receiving their gene-edited hematopoietic stem cells (HSCs). In addition to the predominant HbA profile being restored, Kamau reports that the sickle hemoglobin (HbS) level fell below 20% of total hemoglobin in the two patients who have reached the 6-month post-infusion mark.</p>
<figure aria-describedby="caption-attachment-297262" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="wp-image-297262 size-medium" src="https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-243x300.jpg" alt="Matthew Porteus" width="243" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-243x300.jpg 243w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-828x1024.jpg 828w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-768x950.jpg 768w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-1242x1536.jpg 1242w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-1657x2048.jpg 1657w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-340x420.jpg 340w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-679x840.jpg 679w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-324x400.jpg 324w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-648x800.jpg 648w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-696x860.jpg 696w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-1392x1721.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-1068x1320.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-1920x2374.jpg 1920w" sizes="(max-width: 243px) 100vw, 243px"><figcaption class="wp-caption-text">Matthew Porteus, MD, PhD,<br>Co-Founder, Kamau Therapeutics<br>Associate Professor of Pediatrics, Stanford University</figcaption></figure>
<p>Porteus told <em>GEN </em>he was “very encouraged” by this early readout of Kamau’s RESTORE trial. “These were the target results that we were expecting once we got HDR to work in engraftable HSCs,” Porteus said. “We are now full speed ahead on enrolling more patients and moving to talk to the FDA about the registration trial design.” The Phase I/II RESTORE trial is enrolling some 15 participants.</p>
<p>Between the abstract submission and next month’s presentation at ASH, Porteus said Kamau has “further data that gives us confidence in the safety, efficacy and sustainability of the approach.” Porteus says that the updated data will be included in the ASH talk, which will be given by John DiPersio, MD, Director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine, on December 14 in New Orleans.</p>
<p>“Achieving hemoglobin levels above 10 g/dL, with sickle hemoglobin below 20% and adult hemoglobin predominant, in patients who also remain free of vaso-occlusive events, is an encouraging early signal,” DiPersio said in a press release. “Seeing that profile alongside stable engraftment of corrected cells is what we would hope to see from a durable correction of the underlying mutation.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Vali Barsan, MD, co-founder and CEO of Kamau Therapeutics, said his team applies “process engineering to HDR, nature’s own high-fidelity repair pathway.” The HDR pathway “can implement corrections we design directly into a patient’s own stem cells,” Barsan continued. “That has been the promise of gene editing from the beginning, and these data are early clinical evidence that it can be realized.”</p>
<h4><strong>Direct deposit</strong></h4>
<p>Porteus, who is head of R&D of Kamau, has been <a href="https://www.genengnews.com/topics/genome-editing/a-story-of-perseverance-an-interview-with-matthew-porteus/" target="_blank" rel="noopener">steadfast in his determination</a> to translate some of the basic insights he helped define regarding DNA repair and recombination into the clinic, especially for the benefit of patients with SCD. He said his new company adopts a twin-stranded approach: reduce production of pathogenic HbS and restore the body’s own production of normal HbA. Kamau’s gene replacement strategy is a 1:1 exchange of the faulty HbS allele with a healthy HbA copy, rather than a gene addition strategy.</p>
<p>“We developed nula-cel to work in a patient’s own stem cells, enabling those cells to produce adult hemoglobin under the body’s normal regulation,” Porteus said. The nula-cel therapy directly corrects the SCD mutation in the β-globin gene. That is in contrast to the HbF switching approach taken in Casgevy, the gene editing therapy sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics, approved in late 2023.</p>
<p>A major question is whether Kamau’s HDR strategy will offer any long-term clinical advantages compared to Casgevy. Porteus believes it might. “Since we see a greater reduction in HbS than the HbF [switching] approaches, we think that it will prove better at preventing the myriad of multi-organ damage that the disease causes,” Porteus told <em>GEN</em>. For example, “it has been shown that exchange transfusion, in which the target is to keep HbS below 30%, is better at preventing stroke or recurrent stroke than upregulation of HbF.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>In addition, Porteus said, “evolution has selected a tunable HbA as the solution to oxygen delivery to tissues under various conditions, whereas HbF is not tunable in its oxygen unloading. This may result in better long-term organ health.”</p>
<p>Of course, Kamau still faces some very stiff headwinds en route to commercial viability. In December 2024, Editas Medicine suspended its own gene editing asset for SCD after it was unable to find a pharma partner to move the therapy to approval despite strong clinical data.</p>
<p>Porteus notes that in his reading of Editas’ published data, “it did not appear the clinical results were improved over Casgevy.” Moreover, there are encouraging signs that the gene therapy approaches approved in 2023 are beginning to reach patients. “That Lyfgenia is, and Casgevy will soon be, profitable as patient infusions logarithmically increase quarter-over-quarter, while only addressing a tiny portion of the [SCD] patient population, gives us conviction on the commercial upside,” Porteus told <em>GEN</em>.</p>
<p>“The demand is there and we will be part of the solution to meet that demand,” Porteus insists. And as the CAR T commercial market demonstrates, “being first to market helps but the ultimate winner is best in indication.”</p>
<h4><strong>ASH anticipation</strong></h4>
<p>DiPersio’s presentation at ASH next month will be entitled: “First Clinical Results of Precise HBB Gene Correction by Homology Directed Repair in Patients with Severe Sickle Cell Disease: Safety and Efficacy from Phase 1A of the RESTORE Study” (NCT04819841). He will present results on three SCD patients treated with Kamau’s revised manufacturing process (V2.0) for nula-cel, along with continued follow-up of the first patient ever treated with nula-cel four years ago, under the auspices of Graphite Bio, Porteus’ previous company. <a href="https://www.genengnews.com/topics/genome-editing/a-sickle-sequel-matthew-porteus-launches-kamau-with-positive-nula-cell-patient-zero-results/" target="_blank" rel="noopener">Graphite Bio halted its SCD clinical trial in late 2022</a> and subsequently disbanded.</p>
<p>The ASH data “provide early clinical evidence that precise HDR-mediated correction of the native HBB gene is feasible,” Porteus said. “We look forward to learning more as the RESTORE trial progresses.”</p>
<p>All three V2.0 treated patients achieved transfusion independence before they were released from hospital, achieving neutrophil engraftment at a median of 21 days. In the two patients with more than six months of follow-up, total hemoglobin exceeded 10 g/dL, with relatively low levels of HbS (17.6% at 12 months and 19.1% at 8 months) and high HbA (77% at 12 months and 67% at 8 months).</p>
<p>Bone marrow HDR allele frequencies stabilized at approximately 20%, consistent with durable engraftment of gene-corrected HSCs. Single-cell analyses showed more than 90% of circulating red blood cells contained protective levels of HbA. There were no serious adverse events related to nula-cel or the multistep gene-editing process V2.0-treated patients, but some consistent with the busulfan conditioning and stem-cell transplantation.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Off-target gene editing remained low and unchanged, Kamau said. HDR allele frequencies exceeded the 20% target in all three patients (32–38%). HSC mobilization required a median of just 1.3 apheresis cycles to reach target cell dose.</p>
<p>Nula-cel, which has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration (FDA), is an <em>ex vivo</em> approach. Kamau engineers a patient’s own stem cells outside the body, verifying each cell product’s quality, potency, and safety, before reinfusing the HSCs into the patient. Kamau claims this offers a measure of control that would not be possible using an <em>in vivo </em>gene editing approach.</p>
<p>Kamau is funded by a group of investors including Khosla Ventures, Cormorant Asset Management, NEVA SGR, Draper VC, Modi Ventures, and Regeneron Ventures. The company’s leadership team also includes chief technology officer Ramji Krishnan, PhD, who brings experience in CMC leadership at BMS/Celgene, and autologous HSC gene therapy experience at Rocket; chief medical officer Jacob Garcia, MD, previously at Juno/BMS; and chief business officer Reza Afkhami, formerly with Global Blood Therapeutics, where he helped manage <a href="https://www.genengnews.com/topics/drug-discovery/pfizer-to-acquire-gbt-for-5-4b-adding-sickle-cell-disease-drug-and-pipeline/" target="_blank" rel="noopener">the company’s 2022 acquisition by Pfizer</a>.</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/kamau-therapeutics-releases-encouraging-sickle-cell-clinical-data-ahead-of-ash-meeting/">Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>14 Canadian hospitals join forces to accelerate medical research</title>
<link>https://edusehat.com/en/14-canadian-hospitals-join-forces-to-accelerate-medical-research</link>
<guid>https://edusehat.com/en/14-canadian-hospitals-join-forces-to-accelerate-medical-research</guid>
<description><![CDATA[ New agreement aims to reduce research delays, strengthen collaboration and bring medical discoveries to patients faster Fourteen University of Toronto-affiliated hospitals have signed a landmark agreement designed to simplify collaborative medical research, reduce administrative delays and accelerate the development of new treatments. The Master Collaboration Agreement, established through the Toronto Academic Health Science Network (TAHSN), […]
The post 14 Canadian hospitals join forces to accelerate medical research appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_1607312089.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 23:35:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Canadian, hospitals, join, forces, accelerate, medical, research</media:keywords>
<content:encoded><![CDATA[<p><strong>New agreement aims to reduce research delays, strengthen collaboration and bring medical discoveries to patients faster</strong></p>
<p>Fourteen University of Toronto-affiliated hospitals have signed a landmark agreement designed to simplify collaborative medical research, reduce administrative delays and accelerate the development of new treatments.</p>
<p>The Master Collaboration Agreement, established through the <a href="https://tahsn.ca/?utm_source=chatgpt.com">Toronto Academic Health Science Network (TAHSN)</a>, introduces a shared legal and operational framework that will make it easier for participating hospitals to conduct research across multiple institutions.</p>
<p>The initiative addresses a longstanding challenge in Canadian healthcare research: the complexity of coordinating studies involving several hospitals, each with its own administrative and approval processes.</p>
<p>Under the agreement, participating institutions can use a common framework for eligible research activities, reducing the need to negotiate separate legal arrangements for each collaboration.</p>
<p><strong>Early results demonstrate significant improvements</strong></p>
<p>The initiative builds on a pilot launched in December 2024 involving the Centre for Addiction and Mental Health (CAMH) and University Health Network.</p>
<p>Sunnybrook Health Sciences Centre and Unity Health Toronto subsequently joined the initiative, creating a four-hospital pilot.</p>
<p>According to the November 3 announcement, average research study activation timelines in the pilot decreased by more than 75 per cent, from 448 days to 109 days.</p>
<p>The framework is supporting 43 collaborative research studies at various stages of implementation, including projects involving cancer, cardiovascular disease and Alzheimer’s disease.</p>
<p>These early results demonstrate the potential for streamlined administrative processes to reduce the time required to initiate collaborative medical research.</p>
<p><strong>Strengthening Canada’s research competitiveness</strong></p>
<p>The agreement comes as Canada faces growing international competition for clinical trials, research investment and scientific talent.</p>
<p>According to the participating institutions, Canada’s clinical trial activity declined 11 per cent in 2024, while its international ranking for industry-sponsored Phase 3 trials fell from fifth to eighth.</p>
<p>The 14 hospitals participating in the agreement collectively represent a significant component of Canada’s healthcare research infrastructure.</p>
<p>Their combined research funding exceeded $1.7 billion in fiscal 2025.</p>
<p>Participating institutions include SickKids, CAMH, Sunnybrook Health Sciences Centre, University Health Network, Sinai Health, Women’s College Hospital, Trillium Health Partners and several other leading academic hospitals.</p>
<p><strong>Implementation will take place in phases</strong></p>
<p>Although all 14 hospitals have signed the agreement, implementation will occur gradually as institutions adapt their internal research processes.</p>
<p>The framework is intended to simplify collaboration while maintaining institutional requirements for research ethics, privacy, security and oversight.</p>
<p>For researchers, the initiative could reduce administrative duplication and make it easier to launch studies involving multiple healthcare organizations.</p>
<p>For patients, the longer-term objective is to support faster development and evaluation of new treatments and healthcare innovations.</p>
<p>The agreement also provides a potential model for other Canadian academic health networks seeking to improve research collaboration.</p>
<p><strong>Source:</strong> <a href="https://trilliumhealthpartners.ca/newsroom/Pages/2026/14-leading-Toronto-hospitals-sign-landmark-agreement.aspx?utm_source=chatgpt.com">Trillium Health Partners — November 3, 2026 announcement</a> and <a href="https://tahsn.ca/master-collaboration-agreement?utm_source=chatgpt.com">TAHSN Master Collaboration Agreement</a>.</p>
<p>The post <a href="https://www.hospitalnews.com/14-canadian-hospitals-join-forces-to-accelerate-medical-research/">14 Canadian hospitals join forces to accelerate medical research</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Fast&#45;track UK settlement proposed for high earning dental professionals</title>
<link>https://edusehat.com/en/fast-track-uk-settlement-proposed-for-high-earning-dental-professionals</link>
<guid>https://edusehat.com/en/fast-track-uk-settlement-proposed-for-high-earning-dental-professionals</guid>
<description><![CDATA[ Eligible dental professionals could access UK settlement within three or five years under government proposals for a new public service pathway, though it is unclear which job roles fall under the new route. The government announced the new routes to permanent right to remain in the UK in its A fairer pathway to settlement report,… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/settlement.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 20:25:16 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Fast-track, settlement, proposed, for, high, earning, dental, professionals</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Eligible dental professionals could access UK settlement within three or five years under government proposals for a new public service pathway, though it is unclear which job roles fall under the new route.</strong></p>



<p>The government announced the new routes to permanent right to remain in the UK in its <a href="https://assets.publishing.service.gov.uk/media/6ae90b0e5b14ba0182a272a4/A_Fairer_Pathway_to_Settlement_-_Government_response_to_the_consultation.pdf"><em>A fairer pathway to settlement</em></a> report, which listed a total of five pathways.</p>



<p>‘Dental practitioners’ are specifically named as eligible for the permanent five-year public service route, though a spokesperson for the Home Office was unable to confirm which GDC registrant titles fall into this category, stating that more information would be available shortly.</p>



<p>However, eligibility for two of the fast track public service pathways is dependant on the following minimum income thresholds:</p>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td class="has-text-align-center" data-align="center"><strong>>£50,271</strong></td><td class="has-text-align-center" data-align="center"><strong>>£125,141</strong></td></tr><tr><td class="has-text-align-center" data-align="center">Five-year pathway</td><td class="has-text-align-center" data-align="center">Three-year pathway</td></tr></tbody></table></figure>



<p>The earnings-based five-year route would require applicants to earn at least £50,271 in three of the previous five years. However, eligible dental practitioners could qualify separately after five years in a qualifying public-sector role paid on national pay scales, regardless of whether they met that salary threshold.</p>



<p>Time spent in the UK on student or graduate visas would no longer count towards settlement through long residence under the proposals.</p>



<h2 class="wp-block-heading">How is settlement changing for dental professionals earning less than £50k?</h2>



<p>The government also plans to increase the period that lower-skilled health workers must wait for settled status from five to 10 years, applying to jobs that do not require a university degree such as dental nursing. This replaces previous plans for the period to increase to 15 years, which were met with significant backlash.</p>



<p>Home Secretary Shabana Mahmood said: ‘[Settlement] is granted near automatically, largely on the basis of time served. It is this government’s view that this is insufficient. The right to settle should instead reflect a lasting commitment to this country, demonstrated through contribution, integration and<br>respect for our laws and values.’</p>



<p>Some healthcare workers in roles below degree level on national pay scales would retain a five-year settlement route if they arrived before publication of the immigration white paper in May 2025 and met their visa requirements.</p>



<p>Neil Carmichael, executive chair of the Association of Dental Groups (ADG), called for clarity on the status of overseas dental professionals. He said: ‘The value skilled health workers bring to our NHS teams is vast. This is particularly important for dentistry as we struggle to fill the workforce gap. ADG dental groups are extremely grateful for the hard work international dentists are giving in supporting the provision of dental care in the UK, and we must treat our dental workforce who move to the uk from overseas well and with respect.’</p>



<p>All settlement routes will carry stricter baseline requirements: B2 English, a Life in the UK exam, no outstanding government debt, a clean criminality record, and no access to specified public funds in the preceding five years.</p>



<h2 class="wp-block-heading">Are there other routes that allow overseas dental professionals to practise in the UK?</h2>



<p>This comes as Home Office figures have revealed that <a href="https://dentistry.co.uk/2026/09/14/dental-nurse-skilled-worker-visa-grants-fall/">sponsored visa grants for overseas dental nurses had fallen by 95%</a> after the government removed the role from the skilled worker route.</p>



<p>Practice owner David Chong Kwan said closing the route had been a ‘disaster’. David has trained dental nurses within his own practice but does not believe that domestic training has produced enough experienced people to meet demand.</p>



<p>With the vast majority of dental nurses to be excluded from both the skilled worker visa and accelerated settlement, routes into UK dental nursing from overseas are continuing to narrow.</p>



<p>Read <em>Dentistry</em>’s full explainer on the <a href="https://dentistry.co.uk/2025/08/29/skilled-worker-visas-uk-and-dentistry-all-you-need-to-know/">skilled worker visa changes and UK dentistry</a>.</p>



<p><em><a href="https://sso.dentistry.co.uk/" target="_blank" rel="noreferrer noopener">Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</a></em></p>]]> </content:encoded>
</item>

<item>
<title>PACE panel notes challenges IRA poses for patients</title>
<link>https://edusehat.com/en/pace-panel-notes-challenges-ira-poses-for-patients</link>
<guid>https://edusehat.com/en/pace-panel-notes-challenges-ira-poses-for-patients</guid>
<description><![CDATA[ Changes brought on by the Inflation Reduction Act (IRA) often increase patient costs and reduce access, while also harming the innovation that brings new […]
The post PACE panel notes challenges IRA poses for patients appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/JDR_4635-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 20:05:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PACE, panel, notes, challenges, IRA, poses, for, patients</media:keywords>
<content:encoded><![CDATA[<p><span>Changes brought on by the Inflation Reduction Act (IRA) often increase patient costs and reduce access, while also harming the innovation that brings new treatments, according to patient advocates.</span></p>
<p><span>Correcting the situation requires raising the patient voice and telling patient stories, said panelists at BIO’s Patient Advocacy Changemakers Event (PACE), in Washington DC, Oct. 22-23. PACE has been held annually for 15 years and provides a unique opportunity for patient advocates, the biotech industry, and other stakeholders to promote the development of new treatments.</span></p>
<p><span>“The Inflation Reduction Act was signed into law about four years ago now. Are patients better off?” asked</span><a href="https://pace.bio.org/2026-program/cui-bono-benefits-price-controls-1"> <span>panel</span></a><span> moderator</span><a href="https://pace.bio.org/speakers/karin-hoelzer"> <span>Karin Hoelzer, BIO Senior Director of Patient Advocacy</span></a><span>.</span></p>
<p><span>On balance, panelists maintained, patients are not better off. IRA price controls clearly create a barrier to access by discouraging investment in innovative new drugs, but there are many other more direct, negative impacts on patients, the panelists said.</span></p>
<h2>The out-of-pocket cap and Medicare Part D</h2>
<p><span>If there is good news out of IRA it is the out-of-pocket cap on annual payments by patients whose prescriptions are covered by Medicare Part D, said the panelists,</span><a href="https://pace.bio.org/speakers/jennifer-snow"> <span>Jennifer Snow, Founder and Managing Director – Apteka</span></a><span>, and</span><a href="https://pace.bio.org/speakers/patrick-wildman"> <span>Patrick Wildman, SVP of Advocacy & Government Relations – Lupus Foundation of America</span></a><span>.</span></p>
<p><span>Both cautioned that the Part D redesign that brought about the cap also brings in some challenges.</span></p>
<p><span>“For people who have high costs to address their medical needs, the cap would be really important for them,” said Wildman. “But for people who don’t hit the cap, their costs may actually have gone up as a result of the IRA. And that’s simply because there’s been a shift from co-pays to cost share.”</span></p>
<p><span>Both he and Snow also expressed concern about what the IRA would mean for future changes in Part D.</span></p>
<p><span>“I worry about the long-term kind of return on investment of the Inflation Reduction Act when we’re looking ahead to the Part D redesign,” said Snow. “From a beneficiary perspective, I think we’re in for a huge, huge shift in terms of Part D. The benefit is just not stable right now, and I think longer term, we’re going to be looking for solutions on how to ensure that Part D can stay at least as great as it is now.”</span></p>
<p><span>One immediate challenge brought about by the cap has been an escalation of insurance companies’ utilization management practices, which create barriers to accessing drugs, according to Wildman.</span></p>
<p><span>Snow agreed: “We’re up to like 50% of branded drugs requiring prior authorization in Part D,” she said. “It’s just under 10% for step therapy.”</span></p>
<h2>Part B and other price controls</h2>
<p><span>Another area where future changes could cause problems is in Medicare Part B, which covers drugs that are administered by a professional provider. Under IRA, these drugs will be subject to price controls in 2028, and the result will likely be new challenges to access, the panelists said.</span></p>
<p><span>“We don’t know what reimbursement mechanism they’re going to use for providers, and the providers may be underwater,” Snow said. “If providers can no longer afford to provide those negotiated drugs, what happens to access?”</span></p>
<p><span>“There are real impacts on patients. And I think our role is to show what those impacts are,” Wildman said. “In the case of a low reimbursement for administering a price-negotiated drug, the downstream impacts are the patient doesn’t get that drug or they have to change providers.”</span></p>
<p><span>Along with the IRA, the panel also looked at other mechanisms to control prices, including Prescription Drug Affordability Boards (PDABs), which are being used by several states to control or cap the reimbursement insurers, state Medicaid programs, and public entities pay for prescription drugs.</span></p>
<p><span>“Much like the Inflation Reduction Act, PDABs look at drug pricing and affordability,” but from a state perspective, Snow said. “Is it affordable to the state who’s trying to set it up or affordable for the patient? Those two cannot be reconciled. And I think we see that on the federal level, too. Drug pricing is not about affordability. From a patient advocacy perspective, the more we push back on that notion, I think, the stronger the affordability story becomes.”</span></p>
<h2>Patient stories</h2>
<p><span>Wildman agreed that the approach states take with PDABs tends to ignore the patient’s perspective, and said that federal efforts at drug price control are similarly challenged. He said patient advocates are trying to make the Centers for Medicare & Medicaid Services (CMS) take patients into account when deciding on their actions.</span></p>
<p><span>“I think that is part of the solution, making sure that CMS is fully engaged with the patient community and is looking at us not only as a partner in ensuring the stability of the program but also the future of the program,” he said.</span></p>
<p><span>Snow reached out to the audience of patients and patient advocates at PACE, asking for their help by sharing their stories.</span></p>
<p><span>“Those who are patient advocates, your experiences, the experiences of the people you represent, are critical to helping inform our white papers, or issue briefs, or comment letters. Or you can go to CMS yourself and share your experience,” Snow said.</span></p>
<p><span>She added that CMS used to listen to taxpayers who fund them and patients who used their services, but that has changed.</span></p>
<p><span>“Over time, it has felt more like there are other stakeholders who are getting the voice. And I think it’s time to wrench that back and make sure that the patient voice is heard. For that, we’ll need your stories,” Snow said.</span></p>
<p>The post <a href="https://bio.news/federal-policy/pace-panel-notes-challenges-ira-poses-for-patients/">PACE panel notes challenges IRA poses for patients</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Clinical case: root canal treatment using GenENDO instruments and BioRoot Flow</title>
<link>https://edusehat.com/en/clinical-case-root-canal-treatment-using-genendo-instruments-and-bioroot-flow</link>
<guid>https://edusehat.com/en/clinical-case-root-canal-treatment-using-genendo-instruments-and-bioroot-flow</guid>
<description><![CDATA[ Prof Joseph Sabbagh presents an upper-molar root canal treatment using GenENDO Revo-S+ files and BioRoot™ Flow bioceramic sealer. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/prof-joseph-sabbagh-genendo-bioroot-flow.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 16:50:17 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Clinical, case:, root, canal, treatment, using, GenENDO, instruments, and, BioRoot, Flow</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-full"></figure>



<p><strong>Prof Joseph Sabbagh presents a clinical case study featuring an upper-molar root canal treatment using GenENDO Revo-S+ files and BioRoot Flow bioceramic sealer.</strong></p>



<p>Root canal treatment (RCT) is a common endodontic procedure aiming to preserve a tooth through proper cleaning, shaping and obturation of the root canal system. When properly performed, root canal treatment has an estimated success rate of 90.3% (Ricucci et al., 2011). For retreatments, the success rate is between 65.5% and 77.6% (Stueland H et al., 2023).</p>



<p>Recent innovations in endodontics are revolutionising root canal therapy by integrating advanced imaging, precision instruments and enhanced disinfection methods, making the treatment easier and more predictable. Three-dimensional imaging – particularly cone-beam computed tomography (CBCT) – enables detailed visualisation of complex canal morphologies and guided access. </p>



<p>Cleaning and shaping of a root canal system relies on using flexible nickel-titanium (NiTi) files, simplified sequences, and improved alloys, together with apex locators and enhanced rotary motors, to facilitate efficient shaping of curved canals while minimising procedural errors. This enables subsequent steps, including coronal flaring, creating a reproducible glide path, determining the working length, and carrying out biomechanical preparation and disinfection of the root canal system. </p>



<p>Ultimately, the procedure aims to achieve effective obturation, ensure the longevity of the restoration, and preserve as much of the natural tooth structure as possible (Elmatary et al., 2025; ESE, 2006).</p>



<h3 class="wp-block-heading">What makes an adequate endodontic treatment?</h3>



<p>The dental community has understood that an adequate endodontic treatment does not mean enlargement of the canals, but rather a proper disinfection of the root canal system combined with a three-dimensional seal. Several techniques using gutta percha, delivered in different modes, are used for the obturation phase. For several years, the warm vertical technique, described by Schilder in 1972, was considered the gold standard in endodontics. Although showing good clinical outcomes, this technique is complex and involves several steps. Recent development in biomaterials has led to a new category of products called bioceramics, based mostly on calcium silicate (CSCs). They can be used as cements in restorative dentistry for pulp vitality preservation, or as sealers in endodontics (Dong and Xu, 2023).</p>



<p>During the obturation step, the use of bioceramic sealer combined with a single gutta percha cone makes this phase easier and more predictable.</p>



<p>The following clinical case report details a root canal treatment of an upper molar. The root canal preparation was completed with two NiTi files in continuous rotation (Revo-S+, GenENDO, Septodont). The obturation was done using a recent bioceramic sealer (BioRoot Flow, Septodont).</p>



<h2 class="wp-block-heading">Case presentation</h2>



<h3 class="wp-block-heading">Clinical signs and symptoms</h3>



<p>A 59-year-old male patient presented to the dental clinic to complete a root canal treatment after severe spontaneous pain localised at the upper right posterior quadrant. The pain had persisted for five days and intensified with hot stimuli. Consequently, the patient went to a hospital offering an emergency dental service. They created an access cavity in tooth number 17 to relieve the pain, placed a temporary restoration, and asked him to continue the treatment with an endodontist.</p>



<p>A preoperative periapical radiograph revealed an apical lesion on the palatal root of tooth 17 (upper right second molar) (Fig. 1) with a widened periodontal ligament space around the mesial root. No swelling or sinus tract was visible.</p>



<figure class="wp-block-image alignfull size-full"><figcaption class="wp-element-caption">Figure 1 – Preoperative radiography of tooth #17.</figcaption></figure>



<h3 class="wp-block-heading">Diagnosis</h3>



<p>Based on the patient’s explanations, clinical and radiographic findings, the tooth was diagnosed with a necrosis following an acute irreversible pulpitis. A non-surgical root canal treatment was planned to complete the emergency procedure initiated at the hospital.</p>



<h3 class="wp-block-heading">Procedure and treatment</h3>



<p>Following administration of local anaesthesia (Septanest, 1:200,000, Septodont, Saint-Maur-des-Fossés, France), the temporary cement was removed using a diamond bur and a carbide tungsten bur was used to finalise the access cavity. Three canal orifices were identified: mesiobuccal (MB), distobuccal (DB) and palatal (P). The working field was isolated using a latex rubber dam fixed with a Softclamp (Kerr, Orange, USA) to avoid any gingival fluid contamination or accidental instrument swallowing.</p>



<h3 class="wp-block-heading">Canal preparation</h3>



<p>A manual stainless steel 010 K-File (GenENDO, Septodont) was used to scout the canals’ patency (Fig. 2). Final working length was determined using an apex locator and confirmed radiographically.</p>



<p>Cleaning and shaping were initiated using a crown-down technique with rotary files GenENDO Revo-S+ (Septodont) SC2 and SU. There was no need for coronal flaring due to the size and the straight form of the canals.</p>



<p>The shaping of the canal was done with two NiTi Files: GenENDO Revo-S+ SC2 (25/0.4 symmetrical design) was used first, centred downward on the canal in two or three motions. Once the length was obtained with the SC2, a final shaping was done with the GenENDO Revo-S+ SU (25/.06 asymmetric design) for a uniform taper and optimal preparation (Fig. 4) following one centred downward and one upward movement with selective wall support, finishing at working length.</p>



<figure class="wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-1 is-layout-flex wp-block-gallery-is-layout-flex">
<figure class="wp-block-image size-full"><figcaption class="wp-element-caption">Figure 2 – Canal exploration using a manual stainless steel file: GenENDO K-File 010.</figcaption></figure>



<figure class="wp-block-image size-full"><figcaption class="wp-element-caption">Figure 3 – Canal preparation using NiTi rotary file: GenENDO Revo-S+ SC2 (size 25/taper .04).</figcaption></figure>



<figure class="wp-block-image size-full"><figcaption class="wp-element-caption">Figure 4 – Final shaping using NiTi rotary file: GenENDO Revo-S+ SU (size 25/taper .06).</figcaption></figure>
</figure>



<h3 class="wp-block-heading">Obturation</h3>



<p>Copious irrigation with 3.5% sodium hypochlorite was performed throughout instrumentation, and canals were irrigated with EDTA on a final flush flow to remove the smear layer. Rechecking of canal patency was regularly ensured using a GenENDO K-File 010 between each instrument. The access cavity with the three cleaned and prepared canals is shown (Fig. 5).</p>



<p>In the absence of swelling and after complete drying of the canals, contemporary endodontic strategies recommend the obturation of the canal system during the same session. After final irrigation, the canals were dried using one or two paper points to avoid over-drying. BioRoot Flow (Septodont), a recently introduced bioceramic sealer, was injected into each canal with low pressure (Fig. 6).</p>



<figure class="wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-2 is-layout-flex wp-block-gallery-is-layout-flex">
<figure class="wp-block-image size-full"><figcaption class="wp-element-caption">Figure 5 – Access cavity showing the three cleaned and prepared canals.</figcaption></figure>



<figure class="wp-block-image size-full"><figcaption class="wp-element-caption">Figure 6 – Injection of BioRoot Flow in the canals.</figcaption></figure>



<figure class="wp-block-image size-full"><figcaption class="wp-element-caption">Figure 7 – Canal entrances after obturation and compaction. (Gutta percha is cut using a heating device, then compacted with an endo plugger.)</figcaption></figure>
</figure>



<p>Using a single-cone technique, one master cone of gutta percha, previously calibrated and confirmed radiographically, was inserted into each of the canals. The gutta percha points were then cut using a heat-cutting device and compacted with an endo plugger. The canal entrances after obturation and compaction are shown (Fig. 7). A Teflon pellet was placed in the access cavity and covered by a temporary cement. The postoperative radiograph shows the canal system properly shaped, cleaned and homogenously filled to the radiographic apex (Fig. 8).</p>



<figure class="wp-block-image alignfull size-full"><figcaption class="wp-element-caption">Figure 8 – Postoperative radiography showing the shaping and obturation of the three canals.</figcaption></figure>



<h2 class="wp-block-heading">Follow-up and outcome</h2>



<p>At the one-month follow-up, the patient reported no pain or discomfort. Clinical testing showed no tenderness, and radiographic examination revealed resolution of the periodontal ligament widening and signs of periapical healing. The tooth remained functional and symptom-free.</p>



<h2 class="wp-block-heading">Discussion</h2>



<p>Endodontic treatment of molars can be challenging due to variations and complexities in root canal morphology. Use of magnification, electronic apex location, and simplified rotary instrumentation enhanced the precision of canal shaping. The obturation phase was performed with a bioceramic sealer and a single gutta percha cone, which is being used more and more in endodontics.</p>



<p>Successful root canal treatment depends on adequate diagnosis, canal disinfection, and hermetic obturation. Early intervention prevented the progression of periapical disease and preserved the natural tooth structure, avoiding extraction.</p>



<h2 class="wp-block-heading">Conclusion</h2>



<p>This case highlights the importance of comprehensive diagnostic and clinical protocols in the endodontic treatment of maxillary molars. With proper technique and patient compliance, even complex molars can be predictably treated, resulting in long-term tooth retention and functional restoration.</p>



<h3 class="wp-block-heading">References</h3>



<ul class="wp-block-list">
<li>Ricucci D, Rutberg M et al. 2011. A prospective cohort study of endodontic treatments of 1,369 root canals: results after 5 years. <em>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</em>. 112(6): 825-42.</li>



<li>Stueland H, Ørstavik D, Handal T. 2023. Treatment outcome of surgical and non-surgical endodontic retreatment of teeth with apical periodontitis. <em>Int Endod J</em>. 56(6): 686-696.</li>



<li>Elmatary A, Moawad E, Heidarifar O et al. 2025. Endodontic access cavity preparation: challenges and recent advancements. <em>Br Dent J</em> 238, 469–475.</li>



<li>Dong X and Xu X. 2023. Bioceramics in Endodontics: updates and future perspectives. <em>Bioengineering</em> 10, 354.</li>
</ul>



<h3 class="wp-block-heading">Disclaimer</h3>



<p>The views, opinions, and statements expressed in this content are solely those of Dr Joseph Sabbagh.</p>



<p>Dr Joseph Sabbagh is solely responsible for the scientific and medical positions presented. The pictures and radiographs used in this case study are the property of Dr Joseph Sabbagh.</p>



<p>The author reports a professional and/or financial relationship with Septodont relevant to this article.</p>



<p>The products referenced in this case study are medical devices. BioRoot Flow is available in the United States and the European Union and complies with applicable regulatory requirements (FDA 510(k) or MDR 2017/745). GenENDO Range complies with the applicable requirements of the European Union (MDR 2017/745) and is available in EU only.</p>



<p>Please read the instructions for use carefully before use, paying particular attention to warnings, precautions, and contraindications. These medical devices are regulated health products. Communication intended for healthcare professionals only.</p>



<p><a href="http://www.septodont.com/">www.septodont.com</a></p>



<p><em>This article is sponsored by Septodont.</em></p>



<p></p>]]> </content:encoded>
</item>

<item>
<title>India’s life sciences and healthcare sectors raise $173m in October 2026</title>
<link>https://edusehat.com/en/indias-life-sciences-and-healthcare-sectors-raise-173m-in-october-2026</link>
<guid>https://edusehat.com/en/indias-life-sciences-and-healthcare-sectors-raise-173m-in-october-2026</guid>
<description><![CDATA[ 
The sectors recorded 19 funding rounds during the month, with funding rising 6.91 per cent year on year and falling 7.35 per cent from September 2026
The post India’s life sciences and healthcare sectors raise $173m in October 2026 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/04111758/EP_Tranxcn_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 16:10:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>India’s, life, sciences, and, healthcare, sectors, raise, 173m, October, 2026</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/04111758/EP_Tranxcn_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/04111758/EP_Tranxcn_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/04111758/EP_Tranxcn_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>India’s HealthTech, Life Sciences and Healthcare sectors recorded funding of $172.96 million across 19 rounds in October 2026, according to data from Tracxn. Funding rose 6.91 per cent compared with $161.78 million in October 2025. However, it declined 7.35 per cent from $186.68 million recorded across 20 rounds in September 2026.</span></p>
<p><span>The sectors recorded 26 funding rounds in October 2025, compared with 19 in October 2026.</span></p>
<p><span>Early-stage funding accounted for $157.81 million, or 91.2 per cent of the total funding raised during October. Seed-stage funding stood at $5.15 million, accounting for 3 per cent, while late-stage funding amounted to $10 million, or 5.8 per cent. No private equity funding was recorded during the month.</span></p>
<p><span>Among the companies that raised funds during October, Even secured $50 million, followed by Baba with $40 million and Cent with $15 million. Clinics On Cloud raised $14.26 million, while Regency Healthcare secured $11.4 million.</span></p>
<p><span>MakeO raised $10 million, Ace Blend secured $9.91 million, CureBay raised $7.30 million and Sunfox secured $7 million. Jagruti Rehabilitation Center raised $2.94 million.</span></p>
<p><span>In terms of venture capital activity, 3one4 Capital led with investments in two companies, Ace Blend and Sunfox. Khosla Ventures invested in Even, while FirstMark invested in Baba, with each recording one round during the month.</span></p>
<p><span>The funding trend for the 12 months from November 2025 to October 2026 shows that the sectors recorded $30.34 million in November 2025, followed by $355.49 million in December 2025 and $227.12 million in January 2026. Funding stood at $93.85 million in February and $238.68 million in March.</span></p>
<p><span>In April 2026, the sectors recorded $309.89 million, followed by $185.49 million in May, $106.84 million in June and $105.84 million in July. Funding reached $371.39 million in August before recording $186.68 million in September and $172.96 million in October.</span></p>
<p><span>The data covers the HealthTech, Life Sciences and Healthcare sectors in India. The funding figures are sourced from Tracxn.</span></p>
<p>The post <a href="https://www.expresspharma.in/indias-life-sciences-and-healthcare-sectors-raise-173m-in-october-2026/">India’s life sciences and healthcare sectors raise $173m in October 2026</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lupin appoints Akhil Gupta as Independent Director to its Board</title>
<link>https://edusehat.com/en/lupin-appoints-akhil-gupta-as-independent-director-to-its-board</link>
<guid>https://edusehat.com/en/lupin-appoints-akhil-gupta-as-independent-director-to-its-board</guid>
<description><![CDATA[ 
The appointment brings over four decades of experience in business development, corporate strategy, finance, governance and mergers and acquisitions to the Board
The post Lupin appoints Akhil Gupta as Independent Director to its Board appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 16:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lupin, appoints, Akhil, Gupta, Independent, Director, its, Board</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Lupin has announced the appointment of Akhil Gupta as an Independent Director to its Board.</span></p>
<p><span>Gupta brings more than four decades of experience in building and scaling businesses, corporate strategy, finance, governance, and mergers and acquisitions. As Vice Chairman of Bharti Enterprises Limited, he played a pivotal role in the group’s growth from inception, both organically and through acquisitions. A qualified Chartered Accountant, he has also completed the Advanced Management Programme at Harvard Business School.</span></p>
<p><span>He currently serves as Non-Executive Independent Chairman of 360 ONE WAM, Coforge and Valuedrive Technologies Ltd (Spinny); Independent Director of Lodha Developers and Zepto; and Nominee Director of Acevector Limited. He is also President of the Telecom Sector Skill Council, a Member of the CII National Committee on Telecom & Broadband and the CII Task Force on Insolvency and Bankruptcy, and Chairman of Inversion Advisory Services. In addition, he advises companies across infrastructure, renewable energy, automobiles, tourism, consulate services and footwear.</span></p>
<p><span>His recognitions include the EY Entrepreneur of the Year Award (Entrepreneur CEO), CA Global Achiever, CA Business Achiever, CEO of the Year Award, and CNBC TV18 Best CFO Awards.</span></p>
<p><span>Manju D Gupta, Chairperson, Lupin, said, “We are delighted to welcome Akhil to the Lupin Board. He brings a rare combination of strategic perspective, financial acumen, governance experience, and a proven track record of building businesses at scale. His counsel will be valuable as Lupin continues to strengthen its global position and pursue its next phase of growth.”</span></p>
<p>The post <a href="https://www.expresspharma.in/lupin-appoints-akhil-gupta-as-independent-director-to-its-board/">Lupin appoints Akhil Gupta as Independent Director to its Board</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lupin launches Raltegravir Tablets USP, 600 mg in the US</title>
<link>https://edusehat.com/en/lupin-launches-raltegravir-tablets-usp-600-mg-in-the-us</link>
<guid>https://edusehat.com/en/lupin-launches-raltegravir-tablets-usp-600-mg-in-the-us</guid>
<description><![CDATA[ 
The product has received US FDA approval and is eligible for 180-day generic drug exclusivity
The post Lupin launches Raltegravir Tablets USP, 600 mg in the US appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 16:10:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lupin, launches, Raltegravir, Tablets, USP, 600, the</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Lupin has announced the launch of Raltegravir Tablets USP, 600 mg in the United States, following approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA).</span></p>
<p><span>Raltegravir Tablets, 600 mg are bioequivalent to the reference listed drug (RLD), Isentress® HD Tablets, 600 mg, of Merck Sharp & Dohme, LLC. The product is indicated in combination with other antiretroviral agents for the treatment of Human Immunodeficiency Virus (HIV-1) infection in adult patients and paediatric patients weighing at least 40 kg.</span></p>
<p><span>Lupin is the exclusive first-to-file for this product and is eligible for 180-day generic drug exclusivity.</span></p>
<p><span>Raltegravir Tablets USP, 600 mg (RLD Isentress HD) had estimated annual sales of USD 26 million in the US, according to IQVIA MAT September 2026</span></p>
<p>The post <a href="https://www.expresspharma.in/lupin-launches-raltegravir-tablets-usp-600-mg-in-the-us/">Lupin launches Raltegravir Tablets USP, 600 mg in the US</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Shilpa CDMO invests $50 million to expand peptide manufacturing capacity</title>
<link>https://edusehat.com/en/shilpa-cdmo-invests-50-million-to-expand-peptide-manufacturing-capacity</link>
<guid>https://edusehat.com/en/shilpa-cdmo-invests-50-million-to-expand-peptide-manufacturing-capacity</guid>
<description><![CDATA[ 
The expansion will add 10 KL of SPPS reactor capacity and establish six parallel cGMP manufacturing lines to support peptide development and commercial supply
The post Shilpa CDMO invests $50 million to expand peptide manufacturing capacity appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/11/12182826/Growth-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 12:35:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Shilpa, CDMO, invests, 50, million, expand, peptide, manufacturing, capacity</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/11/12182826/Growth-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/11/12182826/Growth-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/11/12182826/Growth-1-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Shilpa CDMO is investing $50 million to expand its peptide manufacturing capabilities as demand for GLP-1s and peptide therapeutics increases.</span></p>
<p><span>The phased investments will span the next few years and add 10 KL of solid-phase peptide synthesis (SPPS) reactor capacity to the three existing clinical-phase manufacturing lines. A fourth line for commercial manufacturing at Shilpa’s Raichur Unit-I campus is scheduled to open in December 2026, with commercial supply expected to ramp up through 2027.</span></p>
<p><span>The CDMO plans to add further 2 KL, 3 KL and 5 KL SPPS reactors, establishing one of the largest multi-tonne peptide capacities in India.</span></p>
<p><span>The new commercial line features 500 L and 1,000 L reactors in a single block, supporting annual production of up to one metric tonne. Its purification infrastructure includes two 2-metre DAC columns with a 10,000 LPH preparative HPLC system. The line will also include 1,000 L/hr nanofiltration and a lyophiliser with a capacity of 1,000 L.</span></p>
<p><span>The expansion builds on Shilpa’s existing cytotoxic and peptide conjugate product development capabilities, with one line dedicated to cytotoxic peptide manufacturing using SPPS.</span></p>
<p><span>Keshav Bhutada, Chief Executive Officer, Shilpa CDMO, said, “Peptides are becoming one of the most important areas of pharmaceutical development, but the opportunity goes well beyond current GLP-1 demand. Innovator pipelines in oncology and rare diseases are producing increasingly sophisticated molecules and conjugates that require much greater expertise in route design, synthesis, purification and scale-up.</span></p>
<p><span>We are investing for where the peptide market is going next. Our aim is to give biotech and pharmaceutical partners a platform that can take challenging peptide programmes from early development through to reliable commercial supply.”</span></p>
<p><span>Shilpa CDMO’s expanded peptide operations will comprise six parallel cGMP manufacturing lines, allowing multiple programmes to run independently. The platform supports solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS) and hybrid synthesis (SPPS + LPPS), allowing manufacturing routes to be selected according to the molecule, its development stage and intended commercial scale.</span></p>
<p><span>Its capabilities cover linear, cyclic and branched peptides, including molecules incorporating unnatural and D-amino acids, lipidation, conjugation and radioligand peptides.</span></p>
<p><span>More than 100 scientists and manufacturing specialists work within Shilpa’s peptide business. This includes an R&D team of more than 50 members dedicated to peptide chemistries and 45 chemists working across production and purification. The team is also supported by the wider Shilpa Group’s more than 350 PhDs.</span></p>
<p><span>Dipak Kalita, Senior Vice President – CDMO Services, Shilpa CDMO, said, “As peptides become longer and more complex, the manufacturing route can determine whether a programme can scale successfully. We start with the molecule and its potential commercial requirements, then determine whether solid-phase, liquid-phase or a hybrid approach offers the most robust route. For longer peptides, that can mean moving from solid-phase synthesis to a hybrid fragment-based route as volumes grow. Considering commercial scale from the outset helps customers avoid reaching late-stage development with a process that is no longer technically or economically viable”.</span></p>
<p><span>Shilpa CDMO’s peptide operations are based at its 34-acre Unit-I campus in Raichur, Karnataka. The peptide unit operates within the wider site, which has dedicated R&D and cGMP manufacturing infrastructure for APIs, commercial linkers, HPAPIs spanning OEB 1-6 and peptide drug conjugates.</span></p>
<p><span>The new peptide facility also has a centralised Distributed Control System (DCS), with integrated Process Analytical Technology (PAT) and UV monitoring. Design of Experiments (DoE) and process simulation will be used to establish operating parameters ahead of scale-up and technology transfer, while automated data capture will support data integrity and regulatory compliance.</span></p>
<p><span>The investment follows the launch of Shilpa CDMO as a dedicated complex-molecule CDMO brand in October 2026.</span></p>
<p><em><span>Shilpa CDMO is the customer-facing brand of Shilpa Pharma Lifesciences </span></em></p>
<p>The post <a href="https://www.expresspharma.in/shilpa-cdmo-invests-50-million-to-expand-peptide-manufacturing-capacity/">Shilpa CDMO invests $50 million to expand peptide manufacturing capacity</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Alamar, Nightingale Health Team up on UK Biobank Neurodegeneration Protein Study</title>
<link>https://edusehat.com/en/alamar-nightingale-health-team-up-on-uk-biobank-neurodegeneration-protein-study</link>
<guid>https://edusehat.com/en/alamar-nightingale-health-team-up-on-uk-biobank-neurodegeneration-protein-study</guid>
<description><![CDATA[ Nightingale Health will run the measurements in its labs using Alamar’s NULISA platform to quantify hundreds of blood proteins in 80,000 UK Biobank samples, seeking early molecular signs of neurodegeneration.
The post Alamar, Nightingale Health Team up on UK Biobank Neurodegeneration Protein Study appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1869420709.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 09:15:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alamar, Nightingale, Health, Team, Biobank, Neurodegeneration, Protein, Study</media:keywords>
<content:encoded><![CDATA[<p>Many of the blood proteins that could flag <a href="https://www.genengnews.com/?s=neurodegeneration&filter=&page=null" target="_blank" rel="noopener">neurodegeneration</a> are so scarce that standard assays barely register them. A new UK Biobank study will test whether an ultrasensitive platform can pick them up across 80,000 blood samples, potentially years before symptoms appear.</p>
<p>Alamar Biosciences and Nightingale Health announced the UK Biobank Proteomics for Risk Identification and Signatures of brain health in Midlife (UKB-PRISM) study on November 2, 2026. Nightingale will run the measurements in its own laboratories using Alamar’s NULISA platform, quantifying hundreds of circulating proteins in samples from UK Biobank participants. The Michael J. Fox Foundation for Parkinson’s Research, Alzheimer’s Research UK, and LifeArc are funding the work, which is expected to be completed by the end of 2027.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>NULISA, short for NUcleic acid Linked Immuno-Sandwich Assay, pairs antibodies tagged with DNA oligonucleotides to capture a target protein. A capture-and-release process washes away background signal, and the DNA reporters are then read out by next-generation sequencing.</p>
<p>The timing reflects a growing view that the biology behind Alzheimer’s and Parkinson’s disease begins years before diagnosis. The companies noted that Alzheimer’s and other dementias affect more than 55 million people worldwide and Parkinson’s affects more than 12 million, with both projected to rise sharply by 2050.</p>
<p>“Working with Nightingale and UK Biobank, we can now measure those signals across tens of thousands of people, years before symptoms appear, and give researchers everywhere a new way to ask when and why these diseases begin,” said Yuling Luo, PhD, Alamar’s founder, CEO, and chair.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>UK Biobank’s deputy chief scientist, Adam Lewandowski, PhD, said proteins help repair tissue, regulate inflammation, and support countless bodily functions, “yet we still know relatively little about how they work together to influence brain health.”</p>
<p>Samantha Hutten, PhD, principal biomarker scientist, translational research at the Michael J. Fox Foundation, said the data could help “evaluate potential biomarkers and inform future therapeutic research.” LifeArc CEO Sam Barrell said the resource could also help lay “the groundwork for more accurate diagnosis” of rare dementias, which can be difficult to diagnose because their symptoms overlap with other conditions.</p>
<p>After the study is completed, the full dataset will be made available to approved researchers worldwide through the UK Biobank Research Analysis Platform.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/alamar-nightingale-health-team-up-on-uk-biobank-neurodegeneration-protein-study/">Alamar, Nightingale Health Team up on UK Biobank Neurodegeneration Protein Study</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Role of the ACL in a Total Knee Replacement Surgery (Arthroplasty)</title>
<link>https://edusehat.com/en/the-role-of-the-acl-in-a-total-knee-replacement-surgery-arthroplasty</link>
<guid>https://edusehat.com/en/the-role-of-the-acl-in-a-total-knee-replacement-surgery-arthroplasty</guid>
<description><![CDATA[ By: Gordon Roedel, Orthopedic Surgeon / Hip &amp; Knee Replacement Specialist    Perhaps no ligament in the human body is as well-recognized as the anterior cruciate ligament (ACL) of the knee, as ACL injuries are common among athletes. In a healthy knee, the ACL plays an important role in stabilizing the knee and guiding motion.  [...]
The post The Role of the ACL in a Total Knee Replacement Surgery (Arthroplasty) appeared first on Orthopedic Sports Medicine Specialists (OSMS). ]]></description>
<enclosure url="https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/11/03140555/ACL-anterior-cruciate-ligament-and-total-knee-replacement.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 06:15:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Role, the, ACL, Total, Knee, Replacement, Surgery, Arthroplasty</media:keywords>
<content:encoded><![CDATA[<p><img fetchpriority="high" decoding="async" class="aligncenter size-full wp-image-15168" src="https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/11/03140555/ACL-anterior-cruciate-ligament-and-total-knee-replacement.jpg" alt="ACL - anterior cruciate ligament and total knee replacement" width="1000" height="667" srcset="https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/11/03140555/ACL-anterior-cruciate-ligament-and-total-knee-replacement-200x133.jpg 200w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/11/03140555/ACL-anterior-cruciate-ligament-and-total-knee-replacement-300x200.jpg 300w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/11/03140555/ACL-anterior-cruciate-ligament-and-total-knee-replacement-400x267.jpg 400w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/11/03140555/ACL-anterior-cruciate-ligament-and-total-knee-replacement-600x400.jpg 600w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/11/03140555/ACL-anterior-cruciate-ligament-and-total-knee-replacement-768x512.jpg 768w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/11/03140555/ACL-anterior-cruciate-ligament-and-total-knee-replacement-800x534.jpg 800w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/11/03140555/ACL-anterior-cruciate-ligament-and-total-knee-replacement.jpg 1000w" sizes="(max-width: 1000px) 100vw, 1000px"></p>
<p><em>By: <a href="https://osmsgb.com/doctors/gordon-roedel-md/">Gordon Roedel</a>, Orthopedic Surgeon / Hip & Knee Replacement Specialist </em></p>
<p> </p>
<p>Perhaps no ligament in the human body is as well-recognized as the anterior cruciate ligament (ACL) of the knee, as ACL injuries are common among athletes. In a healthy knee, the ACL plays an important role in stabilizing the knee and guiding motion. This raises important questions for many patients who are discussing total knee replacement (TKR) with OSMS orthopedic surgeons:</p>
<p><strong>What happens to my ACL during surgery? </strong><strong>How can my knee function without it?</strong></p>
<p>First, let’s discuss the role of the ACL in a healthy knee.</p>
<p>The ACL is one of the four major ligaments of the knee, connecting the thigh bone (femur) to the shin bone (tibia). It passes through the center of the joint, and its normal function is to prevent the tibia from shifting forward and rotating out from under the femur. This stability is important during sudden changes in direction, such as jumping, pivoting, or coming to a rapid stop. As a result, an ACL tear can make an otherwise healthy knee feel unstable while playing sports.</p>
<h2>Why is the ACL removed in total knee replacement?</h2>
<p>The landscape of the knee has often changed by the time many patients begin discussing knee replacement surgery with us. As osteoarthritis progresses, cartilage breaks down, the alignment of your knee may change, and in most cases, the ACL is already stretched, scarred, frayed, or altogether absent by the time of surgery. This is the main reason that knee replacements over the last 20 to 30 years have routinely removed the ACL, even if it is still present. Rather than relying on the ligament, the new artificial implants take on the role of the ACL and provide the stability the new knee needs.</p>
<h2>What is a total knee replacement?</h2>
<p>It’s important to understand that knee replacement surgery involves resurfacing the worn-out bone and cartilage surfaces of the knee joint. A metal cap covers the curved end of the femur bone, while a baseplate replaces the top of the tibia. A medical-grade plastic liner is inserted between the metal components, and its curved, smooth surface matches the curve of the femur, allowing the knee to move. These implants work together with the remaining soft tissues of the knee—muscles, tendons, and ligaments surrounding the joint surface—to provide both stability and mobility for the knee.</p>
<p>Knee replacements change the kinematics (how the bones move relative to one another) of the knee, and standard implants are built to support the new mechanics rather than preserving the ACL and its original role. Keeping the ACL with the new mechanics could cause more issues than removing the ligament altogether.</p>
<h2>Are there knee replacements that preserve the ACL?</h2>
<p>While most standard knee replacement implants require removal of the ACL, a small subset is designed to retain all four ligaments of the knee. These <a href="https://www.orthoinfo.org/treatment/knee-replacement-implants/#:~:text=In%20most%20total,of%20this%20design." target="_blank" rel="noopener">bicruciate-retaining implants</a> are designed with the idea that preserving the ACL may result in a knee that moves and feels more naturally. However, the operation is technically demanding, requires a healthy and functional ACL, and may not be suitable for patients with substantial deformity, stiffness, ligament damage, or advanced bone loss.</p>
<p>Furthermore, clinical studies have not consistently shown that preserving the ACL during total knee replacement produces better pain relief, function, or patient satisfaction compared to conventional designs. In fact, some studies have shown a higher rate of complications or reoperations with bicruciate-retaining designs compared to standard implants.</p>
<h2>What about partial knee replacements?</h2>
<p>Another ACL-preserving knee replacement option is a <a href="https://osmsgb.com/webinar/partial-knee-replacements-webinar/">partial knee replacement</a>. This is an option for patients with arthritis isolated to one area of the knee, allowing the surgeon to retain the ACL while resurfacing the worn-out compartment.</p>
<p>Partial knee replacements offer more natural-feeling kinematics, earlier recovery, and improved range of motion because the ligaments stay intact and help maintain stability. However, partial knee replacement is appropriate only when arthritis and other damage are sufficiently limited. Ligament function, alignment, symptoms, and condition of the other knee compartments must all be considered.</p>
<h2>What if my ACL has been previously injured or reconstructed?</h2>
<p>When the ACL is injured, the knee’s cartilage (the smooth cushioning on the ends of the bones) can be damaged at the same time, and it may wear down unevenly in the years that follow. Over time, that wear can lead to arthritis, which is why many people who have an old ACL injury or reconstruction end up needing a knee replacement. Because most total knee replacements do not depend on the ACL, the ligament does not need to be reconstructed at the time of surgery.</p>
<p>Previous ACL reconstruction can make the operation somewhat more complex. Your surgeon may need to account for scar tissue, bone tunnels, retained screws, or other alterations to your anatomy.  Nevertheless, studies have shown that patients with ACL-deficient knees and those with prior ACL reconstruction can experience substantial pain relief and improved knee function following total knee replacement.</p>
<p>It is important to tell your surgeon about any previous ligament injury or surgery, even if it occurred many years ago.</p>
<h2>Determining the Best Choice for You Starts with Expert Advice</h2>
<p><a href="https://osmsgb.com/ortho/acl-tears-not-just-for-athletes/">The ACL plays an important role in stabilizing and guiding a healthy knee</a>, but a total knee replacement can take over that role and improve patient success. Before deciding whether you need a standard replacement, an ACL-preserving approach, or a partial knee replacement, it’s best to talk with an orthopedic surgeon.</p>
<p> </p>
<p><strong>Have questions about your own knee replacement options?</strong></p>
<p><a href="https://osmsgb.com/schedule-an-appointment/">Schedule an appointment</a> with <a href="https://osmsgb.com/doctors/gordon-roedel-md/">Dr. Gordon Roedel</a> or any of our <a href="https://osmsgb.com/our-experts/">OSMS orthopedic surgeons</a> today.</p>
<p>The post <a href="https://osmsgb.com/ortho/acl-in-total-knee-replacement/">The Role of the ACL in a Total Knee Replacement Surgery (Arthroplasty)</a> appeared first on <a href="https://osmsgb.com/">Orthopedic Sports Medicine Specialists (OSMS)</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data</title>
<link>https://edusehat.com/en/recursion-eyes-h2-2027-pivotal-trial-for-lead-candidate-after-positive-phase-ii-fap-data</link>
<guid>https://edusehat.com/en/recursion-eyes-h2-2027-pivotal-trial-for-lead-candidate-after-positive-phase-ii-fap-data</guid>
<description><![CDATA[ Following 12 weeks of treatment, Recursion said, 87% of patients (13 of 15) had a reduction in total polyp burden, with a 47% median reduction. Approximately one in three patients achieved reductions of ≥65%. 
The post Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/recursion-pharma-1024x576-1.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 05:40:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Recursion, Eyes, 2027, Pivotal, Trial, for, Lead, Candidate, After, Positive, Phase, FAP, Data</media:keywords>
<content:encoded><![CDATA[<p>Recursion said it expects to launch its first registrational trial in the second half of this year for its lead candidate REC-4881 based on talks with the FDA, after the oral familial adenomatous polyposis (FAP) therapy generated positive mid-stage clinical data.</p>
<p>Most patients treated with REC-4881 showed reductions in both the number of larger, higher-risk polyps and in lower GI polyp burden, according to updated data from the Phase Ib/II TUPELO trial (<a href="https://clinicaltrials.gov/study/NCT05552755" target="_blank" rel="noopener">NCT05552755</a>). That data was presented by Lisa Boardman, MD, a gastroenterologist and Professor of Medicine at Mayo Clinic, at the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) Annual Meeting, being held through Wednesday in Denver.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“REC-4881 is reducing the larger polyps that often drive much of the surgery for these [FAP] patients, across the GI tract from a single oral therapy,” Najat Khan, PhD, Recursion’s president and CEO, said in a statement. “This is a lifelong disease with no approved pharmacologic therapies, and REC-4881 is the clearest proof point yet of what we built Recursion to do.”</p>
<p>Recursion said its anticipated second half 2027 timing for a registrational trial will depend on its talks with the FDA, with additional details set to be provided later this year.</p>
<p>Recursion announced the REC-4881 data after the close of markets on Monday. The news appeared to make little impression on investors, as Recursion shares stayed all but flat Tuesday as of 12:55 pm ET, inching up 0.1% to $3.84, a penny above yesterday’s closing price.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<h4><strong>Licensed from Takeda</strong></h4>
<p>REC-4881 is a first-in-class, oral allosteric inhibitor of MEK1 and MEK2 that Recursion is developing through a global licensing agreement with Takeda Pharmaceutical signed in 2020 and covering FAP and related areas of oncology. Recursion agreed to pay Takeda $1.5 million upfront, up to $39.5 million in payments tied to achieving development and regulatory milestones, plus low-to-mid single-digit royalties on net sales of products containing the drug by Recursion, its affiliates, or sublicensees.</p>
<p>Takeda initially developed the drug as TAK-733 and used Recursion’s artificial intelligence (AI) platform to uncover targeted areas of oncology where the drug could be effective.</p>
<p>For FAP, a rare genetic disorder, the standard of care has long consisted of lifelong active endoscopic surveillance and eventual prophylactic surgical removal of the colon.</p>
<p>“People have been doing research in the chemoprevention space in FAP for decades, and at least in the United States, we still don’t have an agent that is FDA approved,” stated Bryson Katona, MD, PhD, TUPELO study investigator and director of the GI Cancer Genetics Program, University of Pennsylvania Perelman School of Medicine. “We’re still having to send FAP patients for major surgeries and we’re still doing frequent scopes on these patients. The need for effective chemoprevention in FAP is very large, and it’s only going to increase over time as the number of FAP patients continues to increase.”</p>
<p>Estimates of prevalence FAP vary widely. While Recursion has counted >50,000 FAP patients in the United States and EU5 (France, Germany, Italy, Spain, and the United Kingdom), other institutions have shared figures showing FAP to affect <a href="https://www.jax.org/education-and-learning/clinical-and-continuing-education/clinical-topics/cancer-resources/fap-and-afap" target="_blank" rel="noopener">approximately one in 6,800 to 31,000 individuals worldwide</a>, including <a href="https://rarediseases.org/rare-diseases/familial-adenomatous-polyposis/" target="_blank" rel="noopener">about one in 5,000 to 10,000 Americans</a>.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Recursion is among biopharmas working to develop treatments for FAP.</p>
<p>One FAP treatment is already in Phase III study—eRapa<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, which since 2024 has been developed by Biodexa Pharmaceuticals under an exclusive global license from Emtora Biosciences, which licensed eRapa from the University of Texas (UT) Health San Antonio in 2012, when Emtora was known as Rapamycin Holdings.</p>
<p>eRapa is an oral tablet formulation of the mTOR inhibitor rapamycin (sirolimus), sold in generic versions; Pfizer ceased selling the branded version, Rapamune<sup>®</sup>, in 2023. Last month, Biodexa said it had enrolled 100 patients in its registrational Phase III Seranta trial (<a href="https://clinicaltrials.gov/study/NCT06950385" target="_blank" rel="noopener">NCT06950385</a>) of eRapa, which has an estimated primary completion date of July 2030.</p>
<p>Also in clinical trials for FAP is Tempest Therapeutics’ TPST-1495, a first-in-class oral small molecule selective dual EP2 and EP4 prostaglandin receptor antagonist targeting prostaglandin E2 (PGE2) signaling in the tumor microenvironment. In March, Tempest launched a Phase II open label trial (<a href="https://clinicaltrials.gov/study/NCT06557733" target="_blank" rel="noopener">NCT06557733</a>) designed to assess how well TPST-1495 reduces the number of polyps in the small bowel and colon in patients with FAP. The study’s estimated enrollment is 38 patients with primary completion expected June 30, 2027.</p>
<p>Recursion’s TUPELO trial was designed to study polyp burden reduction after 12 weeks on REC-4881 (4mg once daily) and again after 12 weeks off-treatment. Following 12 weeks of treatment, Recursion said, 87% of patients (13 of 15) had a reduction in total polyp burden after 12 weeks of treatment, with a 47% median reduction. Approximately one in three patients achieved reductions of ≥65%.</p>
<p>Since the initial November 2025 data cut, all four patients added to the study showed a reduction in total polyp burden, including two patients with 89% and 98% reduction, respectively. At Week 25, after 12 weeks off treatment, 85% of patients (11 of 13) remained below baseline.</p>
<p>Recursion reasons that the persistence of polyp burden reduction below baseline in most patients studied may allow for dosing flexibility.</p>
<h4><strong>‘Certainly encouraging’</strong></h4>
<p>“Seeing durability over a twelve-week course is certainly encouraging. In longer trials we’ll see exactly how long that durability lasts, but I think it is a very encouraging first sign for this drug,” Katona said.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Within the upper GI tract, 92% of patients (12 of 13) had reductions in polyp burden after 12 weeks of treatment, with a 55% median reduction. Nearly half (six of 13) achieved reductions of ≥65%, more than one in three achieved ≥75%, and two patients achieved reductions of ≥98%. Half (six of 12) improved by at least one Spigelman stage at Week 13, while 92% (11 of 12) remained below baseline at Week 25, after 12 weeks off-treatment, and six of 11 had equal or greater reductions during the off-treatment period than during treatment.</p>
<p>Within the lower GI tract, nine of 11 patients (82%) with measurable polyp burden at baseline had reductions after 12 weeks of treatment, with a 50% median reduction, and four of 11 achieved reductions of 65% or more. At Week 25, after 12 weeks off-treatment, seven of 10 patients remained below baseline.</p>
<p>Six of eight patients that showed polyps greater than 5 mm at baseline had reductions in the number of these polyps after 12 weeks of treatment. Four achieved reductions of ≥80%, including two whose larger-polyp counts fell from more than 90 polyps to one. In both of those patients, all of the larger polyps were in the upper GI tract.</p>
<h4><strong>One patient, 98% reduction</strong></h4>
<p>The highest responder was a patient who went from 1,344 mm of total polyp burden to 32 mm, a 98% reduction, and from 96 upper GI polyps >5 mm to one. Recursion cautioned that the patient was not representative of the overall population.</p>
<p>The company also cautioned that the study collected its polyp counts using >5 mm as the largest size category; separate counts for polyps >10 mm were not collected.</p>
<p>Six of the eight patients assessed at Week 25 were below their baseline count after 12 weeks off treatment. Most of the larger polyps at baseline were in the upper GI, Recursion said.</p>
<p>No new safety signals were observed as of the data cutoff in the expanded patient population, which includes patients 18 and older. Most treatment-related adverse events (TRAE), according to recursion, were Grade 1 or 2 (21 of 26 patients, 80.8%). The highest-grade TRAE was Grade 3 in four patients (15.4%), and there were no Grade 4 or 5 TRAEs.</p>
<p>The most common TRAEs were consistent with MEK1/2 inhibition, including dermatitis acneiform, rash, CPK increase, diarrhea, and asymptomatic LVEF decrease. Adverse events were manageable, and most resolved within 12 weeks off treatment. Four patients were discontinued for Grade 1 or 2 TRAEs, with no discontinuations for a Grade 3 event.</p>
<p>Recursion announced the clinical data along with third quarter earnings that showed a reduced quarterly net loss year over year. Recursion ended the third quarter with a net loss of $119.036 million, compared to a net loss of $162.253 million for Q3 2025, on revenue that tripled to $18.552 million from $5.175 million. For Q1-Q3 2026, Recursion cut its net loss to $367.545 million from $536.637 million a year ago.</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/recursion-eyes-h2-2027-pivotal-trial-for-lead-candidate-after-positive-phase-ii-fap-data/">Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Precision Automation Meets Biology</title>
<link>https://edusehat.com/en/precision-automation-meets-biology</link>
<guid>https://edusehat.com/en/precision-automation-meets-biology</guid>
<description><![CDATA[ In this GEN podcast, a cellular workflow automation specialist from Molecular Devices explores what precision automation means for working biologists and how purpose-built instruments, software, and expertise can support it. The conversation covers where variability creeps into cell-based work, how automation can take over routine tasks, and how instruments, software, and scientific expertise can work together. It also considers how a lab’s needs shift as their work matures, and what that means for choosing the right tools at each step.
The post Precision Automation Meets Biology appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Getty_1435758706_LabEquipment.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 05:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Precision, Automation, Meets, Biology</media:keywords>
<content:encoded><![CDATA[<p></p>

<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">For laboratories running cell-based research, automation can mean high-throughput work, but its real value is in reducing repetitive work, controlling variability between experiments, and boosting consistency while still supporting flexible processes. Small manual inconsistencies can have an outsized impact, and the tools that are meant to help can sometimes get in the way. Precision automation ensures that the technology serves the question being asked.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> podcast, a cellular workflow automation specialist from Molecular Devices explores what precision automation means for working biologists and how purpose-built instruments, software, and expertise can support it. The conversation covers where variability creeps into cell-based work, how automation can take over routine tasks, and how instruments, software, and scientific expertise can work together. It also considers how a lab’s needs shift as their work matures, and what that means for choosing the right tools at each step.</p>


<p class="wp-block-paragraph"></p>
</div>


<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<h4 class="wp-block-heading has-text-align-center"><strong>Podcast Guest: </strong></h4>


<figure class="wp-block-image aligncenter size-full is-resized webinar-pic-caption td-caption-align-center"><img fetchpriority="high" decoding="async" width="1400" height="1400" src="https://www.genengnews.com/wp-content/uploads/2026/11/MattStoltz-_Headshot.jpg" alt="Matt Stoltz" class="wp-image-340164" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/MattStoltz-_Headshot.jpg 1400w, https://www.genengnews.com/wp-content/uploads/2026/11/MattStoltz-_Headshot-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/MattStoltz-_Headshot-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/MattStoltz-_Headshot-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/MattStoltz-_Headshot-768x768.jpg 768w" sizes="(max-width: 1400px) 100vw, 1400px"><figcaption class="wp-element-caption"><strong>Matt Stoltz</strong><br>Sr. Cellular Workflow Automation Specialist<br>Molecular Devices</figcaption></figure>
</div>
</div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column sponsor-box is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph"><strong>Sponsored by</strong></p>


<figure class="wp-block-image size-medium is-resized"><a href="https://www.moleculardevices.com/" target="_blank" rel="noreferrer noopener"><img decoding="async" width="300" height="68" src="https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-300x68.png" alt="Molecular Devices logo" class="wp-image-221725" srcset="https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-300x68.png 300w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-1024x232.png 1024w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-768x174.png 768w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-1536x348.png 1536w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-2048x464.png 2048w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-696x158.png 696w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-1392x315.png 1392w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-1068x242.png 1068w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-1920x435.png 1920w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-1853x420.png 1853w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/topics/omics/precision-automation-meets-biology/">Precision Automation Meets Biology</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lost and Found: Neural Pathway for Forgetting Found in C. elegans</title>
<link>https://edusehat.com/en/lost-and-found-neural-pathway-for-forgetting-found-in-c-elegans</link>
<guid>https://edusehat.com/en/lost-and-found-neural-pathway-for-forgetting-found-in-c-elegans</guid>
<description><![CDATA[ Researchers identified the key molecular and neural pathways that cause the nematode Caenorhabditis elegans to actively forget a specific odor it previously remembered, providing a framework for understanding how specific memories are differentially eliminated.
The post Lost and Found: Neural Pathway for Forgetting Found in C. elegans appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/05/GettyImages-1128676754-e1765821893874.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 02:05:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lost, and, Found:, Neural, Pathway, for, Forgetting, Found, elegans</media:keywords>
<content:encoded><![CDATA[<p>For as long as human inquiry has existed, people have tried to understand how and why we remember and forget. As we have begun to understand how the brain works, researchers have slowly uncovered the biological mechanisms underlying memory. Researchers from Kyushu University have now found the key molecular and neural pathways that cause the nematode worm <em>Caenorhabditis elegans</em> to actively forget a specific odor it previously remembered.</p>
<p>Through extensive studies of the <em>C. elegans</em> nervous system, the team discovered that a peptide called NLP-47 triggers this process of active forgetting. NLP-47 is received by a different neuron further along the circuit, which in turn sends a signal to the neuron storing the memory of the odor, leading to its erasure. Most strikingly, when <em>C. elegans</em> memorized two different odors simultaneously, this circuit erased the memory of only one odor while leaving the other intact.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“There are many diseases that involve memory loss,” said research lead Professor Takeshi Ishihara, PhD, at Kyushu University Faculty of Science. “But before we can understand what goes wrong, we need to understand how forgetting works in the brain, and I hope this research will lead to a better understanding of such brain functions.”</p>
<p>Ishihara is senior and corresponding author of the researchers’ published paper in <em>Current Biology</em>, titled “<a href="http://dx.doi.org/10.1016/j.cub.2026.10.015" target="_blank" rel="noopener">Neuropeptidergic-glutamatergic circuit regulates selective forgetting of olfactory learning</a>.” In their paper the authors concluded that their findings may “… offer insights into disorders associated with dysregulated forgetting, including dementia and PTSD.”</p>
<p>Forgetting specific memories is “… as essential as forming them,” the authors wrote. “…  animals must selectively discard irrelevant experiences while preserving others to adapt to constantly changing environments.” But as they further noted, “Despite proposals of selective forgetting in psychological frameworks, the molecular and neuronal mechanisms underlying this selectivity remain largely unexplored.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Ishihara commented, “Research on memory has focused on how it is formed and maintained. How memories are lost has received less attention. We usually think of forgetting as a failure of memory. But forgetting is just as essential for adaptation and survival. This raises a question: How does the brain decide which memories to erase?”</p>
<p>To uncover the mechanism of active forgetting, the team has been studying the model organism <em>C. elegans, </em>a nematode with only 302 neurons. Because each neuron has been identified, it is possible to trace a memory and its erasure to specific neurons. <em>C. elegans</em> are blind but have an exceptional sense of smell. <a href="https://doi.org/10.1016/j.celrep.2013.02.019" target="_blank" rel="noopener">In 2013,</a> Ishihara’s team used <em>C. elegans</em> to identify the neurons that cause the active forgetting of a specific odor memory housed in another neuron.</p>
<p>However, at that time, the team could not identify the molecules that activate this pathway. For their newly reported study first author and PhD candidate Yuuki Onishi, and colleagues set out to identify the responsible molecules. The researchers trained <em>C. elegans</em> to learn a specific smell, diacetyl. “<em>C. elegans</em> exhibits chemoattraction to various odorants, including diacetyl …” they explained. After about four hours—the time it usually takes for the organism to forget a smell—diacetyl was administered again. If the <em>C. elegans</em> moved toward the diacetyl smell, it meant that it had forgotten the memory, if not, the memory had been retained.</p>
<p>The <em>C. elegans</em> olfactory system comprises two pairs of sensory neurons, AWA and AWC, which receive volatile attractive odorants. In a previous study, Ishihara’s team identified that AWA neurons store the memory of the odor, and that memory was erased by signals from AWC neurons. Experiments aiming to identify the “forgetting” signal released by AWC identified the neuropeptide NLP-47 and its receptor GNRR-1. When the team then investigated which neural circuits these two factors affected, they discovered that AIZ neurons, which are located between AWC and AWA, were involved. “Neuropeptide NLP-47, secreted from AWC neurons, regulates forgetting of the olfactory memory through its receptor GNRR-1, an orthologue of the human GnRH receptor, in AIZ interneurons,” the scientists wrote.</p>
<figure aria-describedby="caption-attachment-340135" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340135" src="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Ishihara-release-figure-1-300x169.jpg" alt="When C. elegans learns two odors at the same time, the two memories do not share the same fate. Four hours later, the memory of diacetyl has faded while the memory of isoamyl alcohol remains. The researchers identified the neuropeptide and the neural circuit that direct this selective forgetting. [Takeshi Ishihara/Kyushu University] " width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Ishihara-release-figure-1-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Ishihara-release-figure-1.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">When <em>C. elegans</em> learns two odors at the same time, the two memories do not share the same fate. Four hours later, the memory of diacetyl has faded while the memory of isoamyl alcohol remains. The researchers identified the neuropeptide and the neural circuit that direct this selective forgetting. [Takeshi Ishihara/Kyushu University]</figcaption></figure>
<p>Ishihara further explained, “First, AWC releases NLP-47 and activates the GNRR-1 receptor on the AIZ neurons. The AIZ neurons would then release glutamate, another neurotransmitter. The glutamate then acts on the GLR-4 receptor on the AWA neurons that house the memory of the scent, leading to active forgetting. When we used optogenetics to suppress the activity of the AWC and AIZ neurons, we found that the nematodes were more resilient to forgetting.”</p>
<p>Follow-up experiments revealed that this active forgetting was highly specific. When nematodes were trained to remember two odors—diacetyl and isoamyl alcohol—simultaneously, the NLP-47/GNRR-1 pathway only forgot the diacetyl smell. “Simultaneous conditioning with two odorants revealed that neuropeptidergic-glutamatergic signaling selectively promotes forgetting of diacetyl memory without affecting isoamyl alcohol memory … indicating that forgetting can be regulated in a memory-specific manner,” the investigators stated.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p><em>C. elegans</em> in which NLP-47/GNRR-1 or glutamate did not function were more resistant to forgetting the smells. “Discovering that this forgetting system is not indiscriminate and can target a specific memory is fascinating,” Onishi said. “At first, I was not expecting to find such a concrete mechanism of active forgetting with a remarkable specificity. I hope this research will lead to a deeper understanding of forgetting and eventually to more insights on conditions and pathologies involving memory.”</p>
<p>Commented Ishihara, “Interestingly, receptors like GNRR-1 are found in other organisms, including humans. In rodents, these receptors are found in the hippocampus, the brain’s center for memory, although their role there is not yet known. Our findings may also lead to an understanding of the mechanisms by which mammals forget specific memories.”</p>
<p>In their paper the authors concluded, “Our findings provide a framework for understanding how specific memories are differentially eliminated and suggest that such mechanisms extend to other species.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/lost-and-found-neural-pathway-for-forgetting-found-in-c-elegans/">Lost and Found: Neural Pathway for Forgetting Found in <i>C. elegans</i></a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Balancing Security, Privacy and Patient Wellness in Healthcare Architecture</title>
<link>https://edusehat.com/en/balancing-security-privacy-and-patient-wellness-in-healthcare-architecture</link>
<guid>https://edusehat.com/en/balancing-security-privacy-and-patient-wellness-in-healthcare-architecture</guid>
<description><![CDATA[ Reid Health uses a biophilic printed design on the glazing that hides a security room on the opposite side. | Photo Credit (all): Courtesy of McGrory Glass By Erin Bellis Healthcare design presents an operational challenge: facilities must maintain security, staff sightlines, and safety protocols without creating an intimidating, institutional environment. Incorporating human-centered design principles...
The post Balancing Security, Privacy and Patient Wellness in Healthcare Architecture appeared first on HCO News.
The post Balancing Security, Privacy and Patient Wellness in Healthcare Architecture appeared first on HCO News. ]]></description>
<enclosure url="https://hconews.com/wp-content/uploads/2026/11/HumanCenteredDesign1-768x520.png" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 23:10:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Balancing, Security, Privacy, and, Patient, Wellness, Healthcare, Architecture</media:keywords>
<content:encoded><![CDATA[<h5><span class="TextRun SCXW107194102 BCX0" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class="NormalTextRun SCXW107194102 BCX0">Reid Health uses a biophilic printed design on the glazing </span><span class="NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW107194102 BCX0">that</span><span class="NormalTextRun SCXW107194102 BCX0"> hides a security room on the opposite side. | Photo Credit (all): Courtesy of McGrory Glass</span></span></h5>
<p><em>By Erin Bellis</em></p>
<p><span data-contrast="auto">Healthcare design presents an operational challenge: facilities must maintain security, staff sightlines, and safety protocols without creating an intimidating, institutional environment. Incorporating human-centered design principles allows project teams to prioritize natural light, open sightlines and biophilic elements while meeting stringent physical safety standards. Evidence consistently shows that human-centered spaces lower stress and support healing for both patients and healthcare workers.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Today, architects, general contractors and glazing contractors are moving away from traditional, hardened design models in favor of human-centered architectural strategies. Achieving this balance requires specialized glass solutions that fulfill security and privacy requirements while enhancing the overall therapeutic environment.</span><span data-ccp-props="{}"> </span></p>
<h2><span data-contrast="auto">Moving Beyond Institutional Design</span><span data-ccp-props="{}"> </span></h2>
<p><span data-contrast="auto">Historically, privacy and observation in healthcare settings relied on frosted vision panels, heavy blinds or reinforced control stations. While functional, these solutions often created visual barriers and reinforced a sense of confinement.</span><span data-ccp-props="{}"> </span></p>
<blockquote><p><span data-contrast="auto">“Privacy in design segments such as healthcare, education and detention are often desirable, but trends are continually moving away from the hardened, interrogation-room style designs of the past,” said John Clark, Senior Sales Consultant at McGrory Glass. “We want to introduce a ‘softer’ look into those environments that improve the well-being of its occupants.”</span><span data-ccp-props="{}"> </span></p></blockquote>
<p><span data-contrast="auto">Modern privacy glass helps resolve this seeming conflict. McGrory Glass’s DotView<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> one-way-vision glass allows staff to observe patient areas from designated secure zones, while patients see a soft graphic pattern or custom artwork on the reverse side. When paired with impact- and attack-resistant interlayers, these systems satisfy stringent healthcare safety standards without compromising aesthetics or comfort.</span><span data-ccp-props="{}"> </span></p>
<h2><span data-contrast="auto">Case Studies: Integrated Security and Design</span><span data-ccp-props="{}"> </span></h2>
<p><span data-contrast="auto">Three recent healthcare projects demonstrate how specialized interior glazing solves complex spatial and operational requirements:</span><span data-ccp-props="{}"> </span></p>
<h4><span data-contrast="auto">Reid Health Ambulatory Center — Connersville, Ind.</span><span data-ccp-props="{}"> </span></h4>
<p><span data-contrast="auto">Designed by HKS and built by Skanska, the 106,715-square-foot Reid Health Ambulatory Center needed to conceal a secure observation room directly adjacent to a high-traffic lobby.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">The project incorporated DotView<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> laminated glass printed with custom biophilic graphics. McGrory Glass coordinated artwork files directly with the wall-covering manufacturer, ensuring the visual pattern aligned directly across drywall and glass surfaces.</span><span data-ccp-props="{}"> </span></p>
<blockquote><p><span data-contrast="auto">“Reid Health is a prime example in its use of a biophilic printed design on the glazing that hides a security room on the opposite side,” Clark noted. “We were even able to coordinate artwork with the wall-covering manufacturer to create a design from glass to drywall that combines form and function.”</span><span data-ccp-props="{}"> </span></p></blockquote>
<h4><span data-contrast="auto">Intermountain Health Cassia Regional Hospital — Burley, Idaho</span><span data-ccp-props="{}"> </span></h4>
<figure aria-describedby="caption-attachment-52422" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="wp-image-52422" src="https://hconews.com/wp-content/uploads/2026/11/HumanCenteredDesign3-300x202.png" alt="patient room at Intermountain Cassia Regional Hospital" width="400" height="269" srcset="https://hconews.com/wp-content/uploads/2026/11/HumanCenteredDesign3-300x202.png 300w, https://hconews.com/wp-content/uploads/2026/11/HumanCenteredDesign3-768x516.png 768w, https://hconews.com/wp-content/uploads/2026/11/HumanCenteredDesign3.png 826w" sizes="(max-width: 400px) 100vw, 400px"><figcaption class="wp-caption-text">Intermountain Health Cassia Regional Hospital glazing options provide clear outward visibility for patients.</figcaption></figure>
<p><span data-contrast="auto">At Cassia Regional Hospital, the design team focused on balancing patient privacy with open, light-filled spaces.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">McGrory Glass fabricated the patient room interior glazing using DotView<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> One-Way-Vision laminated glass, featuring custom nature-inspired graphics spanning across six panels.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">This specialized glazing solution enhances the patient environment by allowing natural daylight to flood into the rooms while maintaining clear outward visibility for patients. At the same time, the graphic pattern provides full privacy from the hallway side, transforming functional partition walls into therapeutic, biophilic design features.</span><span data-ccp-props="{}"> </span></p>
<h4><span data-contrast="auto">UNM Behavioral Health Crisis Center — Albuquerque, N.M.</span><span data-ccp-props="{}"> </span></h4>
<p><span data-contrast="auto">Designed by Dekker Perich Sabatini, the University of New Mexico Behavioral Health Crisis Center required robust physical protection engineered specifically for high-acuity crisis care and de-escalation environments.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">To protect both patients and staff without introducing an overly oppressive, institutional feel, the project incorporated DefendMed<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> forced-entry security glazing alongside BallisticDefend<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> bullet-resistant solutions. These life-safety glazing systems deliver maximum impact resistance and physical security while maintaining clear visual connections and natural daylighting throughout critical care zones.</span><span data-ccp-props="{}"> </span></p>
<h2><span data-contrast="auto">Streamlining Complex Systems Under One Roof</span><span data-ccp-props="{}"> </span></h2>
<figure aria-describedby="caption-attachment-52423" class="wp-caption alignright"><img decoding="async" class="wp-image-52423" src="https://hconews.com/wp-content/uploads/2026/11/HumanCenteredDesign4-300x184.png" alt="courtyard at UNM Behavioral Health Crisis Center" width="400" height="245" srcset="https://hconews.com/wp-content/uploads/2026/11/HumanCenteredDesign4-300x184.png 300w, https://hconews.com/wp-content/uploads/2026/11/HumanCenteredDesign4-1024x626.png 1024w, https://hconews.com/wp-content/uploads/2026/11/HumanCenteredDesign4-768x470.png 768w, https://hconews.com/wp-content/uploads/2026/11/HumanCenteredDesign4-1536x940.png 1536w, https://hconews.com/wp-content/uploads/2026/11/HumanCenteredDesign4.png 1782w" sizes="(max-width: 400px) 100vw, 400px"><figcaption class="wp-caption-text">UNM Behavioral Health Crisis Center required robust physical protection engineered for high-acuity crisis care.</figcaption></figure>
<p><span data-contrast="auto">For architects, general contractors and glaziers, executing detailed privacy and life-safety specifications depends heavily on fabricator capabilities. Managing multiple vendors for decorative, security and fire-rated glass can lead to fragmented supply chains, extended timelines and inconsistent visual finishes across a facility.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Working with a single U.S.-based fabricator capable of delivering a comprehensive range of glass systems under one roof simplifies project execution. When a fabricator offers multiple options for one-way vision and vision blocking, alongside etched glass and switchable privacy glass, project teams can tailor privacy levels room-by-room without sacrificing design cohesion.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Balancing human-centered design with rigorous safety codes requires a partner that pairs technical capability with a deep foundation in decorative glass.</span><span data-ccp-props="{}"> </span></p>
<blockquote><p><span data-contrast="auto">“A single-source fabricator that provides decorative privacy options alongside life-safety systems — including fire-rated glass, forced-entry security glazing, X-ray shielding and specialized mounting hardware not found anywhere else — ensures integrated products that maintain strict design standards, protect project schedules and meet all building codes,” said Chad Snyder, Senior Director, Security Division at McGrory Glass.</span><span data-ccp-props="{}"> </span></p></blockquote>
<h2><span data-contrast="auto">Comprehensive Solutions for the Healthcare Sector</span><span data-ccp-props="{}"> </span></h2>
<p><span data-contrast="auto">As healthcare facility requirements grow more complex, balancing physical security with human-centered design remains essential. McGrory Glass is positioned to supply the healthcare sector with a full spectrum of specialized architectural glass solutions.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">“From custom-printed DotView<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> one-way-vision glass and forced-entry security glazing to Corning® Med-X® X-ray radiation shielding glass, offering an integrated product line engineered to meet the strict technical, safety and aesthetic demands of modern medical facilities is essential for today’s complex builds,” said Mike McGrory, Vice President and Head of the X-Ray Division at McGrory Glass. “By uniting decorative innovation with critical life-safety engineering, modern facilities can successfully protect patients and staff while fostering environments built for healing.”</span><span data-ccp-props="{}"> </span></p>
<p><em>Erin Bellis is Senior Manager of Security Products and Performance Specifications.</em></p>
<p>The post <a rel="nofollow" href="https://hconews.com/2026/11/03/balancing-security-privacy-and-patient-wellness-in-healthcare-architecture/">Balancing Security, Privacy and Patient Wellness in Healthcare Architecture</a> appeared first on <a rel="nofollow" href="https://hconews.com/">HCO News</a>.</p>
<p>The post <a href="https://hconews.com/2026/11/03/balancing-security-privacy-and-patient-wellness-in-healthcare-architecture/">Balancing Security, Privacy and Patient Wellness in Healthcare Architecture</a> appeared first on <a href="https://hconews.com/">HCO News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Society Explores the Future of Evidence&#45;Based Guidelines in Italy</title>
<link>https://edusehat.com/en/the-society-explores-the-future-of-evidence-based-guidelines-in-italy</link>
<guid>https://edusehat.com/en/the-society-explores-the-future-of-evidence-based-guidelines-in-italy</guid>
<description><![CDATA[ When the Evidence Based Health Care (EBHC) 2026 Conference took place in Taormina, Italy, from October 21 to 24, the Endocrine Society was well represented. Shown here are Society clinical practice guideline members (l to r) Roma Gianchandani, MD (Clinical Guidelines Committee Chair), and Christopher R. McCartney, MD (Endocrine Society Guideline Methodologist/Board of Directors Member), […]
The post The Society Explores the Future of Evidence-Based Guidelines in Italy appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/DBHC-Italia-Pic-scaled-e1793711140928.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 23:00:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Society, Explores, the, Future, Evidence-Based, Guidelines, Italy</media:keywords>
<content:encoded><![CDATA[<p>When the Evidence Based Health Care (EBHC) 2026 Conference took place in Taormina, Italy, from October 21 to 24, the Endocrine Society was well represented. Shown here are Society clinical practice guideline members (l to r) Roma Gianchandani, MD (Clinical Guidelines Committee Chair), and Christopher R. McCartney, MD (Endocrine Society Guideline Methodologist/Board of Directors Member), […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/the-society-explores-the-future-of-evidence-based-guidelines-in-italy/">The Society Explores the Future of Evidence-Based Guidelines in Italy</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Society Offers Full Spectrum of Diabetes Resources, Including a New SIG for Diabetes Clinicians and Researchers</title>
<link>https://edusehat.com/en/society-offers-full-spectrum-of-diabetes-resources-including-a-new-sig-for-diabetes-clinicians-and-researchers</link>
<guid>https://edusehat.com/en/society-offers-full-spectrum-of-diabetes-resources-including-a-new-sig-for-diabetes-clinicians-and-researchers</guid>
<description><![CDATA[ November is Diabetes Month in the United States, making this the perfect time to highlight the many resources and initiatives the Society dedicates to this chronic disease state. Diabetes has always been a central feature of the Society’s work. The discovery of insulin therapies just over 100 years ago transformed our field. And today, many […]
The post Society Offers Full Spectrum of Diabetes Resources, Including a New SIG for Diabetes Clinicians and Researchers appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/Santoro-Headshot-2025.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 23:00:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Society, Offers, Full, Spectrum, Diabetes, Resources, Including, New, SIG, for, Diabetes, Clinicians, and, Researchers</media:keywords>
<content:encoded><![CDATA[<p>November is Diabetes Month in the United States, making this the perfect time to highlight the many resources and initiatives the Society dedicates to this chronic disease state. Diabetes has always been a central feature of the Society’s work. The discovery of insulin therapies just over 100 years ago transformed our field. And today, many […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/society-offers-full-spectrum-of-diabetes-resources-including-a-new-sig-for-diabetes-clinicians-and-researchers/">Society Offers Full Spectrum of Diabetes Resources, Including a New SIG for Diabetes Clinicians and Researchers</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>2026–2027 Residency Match Timeline Explained (IMG + U.S. Students)</title>
<link>https://edusehat.com/en/20262027-residency-match-timeline-explained-img-us-students</link>
<guid>https://edusehat.com/en/20262027-residency-match-timeline-explained-img-us-students</guid>
<description><![CDATA[ If you’re planning to apply for the 2026–2027 residency match, it can feel like there are a hundred tasks to remember, and they all matter. Between ERAS, personal statements, letters of recommendation, interviews, and ranking, it’s easy to feel overwhelmed before you even begin.   The good news is that the Match follows a fairly […]
The post 2026–2027 Residency Match Timeline Explained (IMG + U.S. Students) appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/11/pexels-towfiqu-barbhuiya-3440682-9810172-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 22:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>2026–2027, Residency, Match, Timeline, Explained, IMG, U.S., Students</media:keywords>
<content:encoded><![CDATA[<p><span>If you’re planning to apply for the 2026–2027 residency match, it can feel like there are a hundred tasks to remember, and they all matter. Between ERAS, personal statements, letters of recommendation, interviews, and ranking, it’s easy to feel overwhelmed before you even begin.</span></p>
<p> </p>
<p><span>The good news is that the Match follows a fairly predictable timeline every year. Once you understand the sequence of events and what you should be focusing on at each stage, the process becomes much more manageable.</span></p>
<p> </p>
<p><span>This guide will walk you through the key milestones step by step so you can stay organized, reduce stress, and put together the strongest application possible.</span></p>
<p> </p>
<h2><b>Spring–Early Summer 2026: Laying the Groundwork</b></h2>
<p><span>Before the application cycle officially opens, this is your preparation phase, and it’s one of the most important parts of the entire process.</span></p>
<p> </p>
<p><span>For U.S. students, this is the time to finalize your Step 2 CK (if you haven’t already), complete core rotations, and make a decision about your specialty choice. For IMGs, this period is especially critical for ensuring your ECFMG certification is on track, completing exams, and securing U.S. clinical experience if possible.</span></p>
<p> </p>
<p><span>Across the board, this is when you should begin working on your application materials. Start <a href="https://elitemedicalprep.com/tackling-the-residency-personal-statement/">drafting your personal statement</a> early, even if it’s just a rough version. <a href="https://elitemedicalprep.com/residency-letters-of-recommendation-everything-you-need-to-know/">Reach out to potential letter writers</a> and give them plenty of time, strong letters rarely come from last-minute requests.</span></p>
<p> </p>
<p><span>It’s also a good time to start building your program list. Think broadly at first, then refine based on competitiveness, geography, and overall fit.</span></p>
<p> </p>
<h2><b>June–August 2026: ERAS Opens and Application Assembly</b></h2>
<p><span>ERAS typically opens in early summer, and this is when things start to feel real.</span></p>
<p> </p>
<p><span>You’ll begin entering your experiences, uploading your personal statement, and assigning letters of recommendation. This stage can take longer than expected, especially when it comes to <a href="https://elitemedicalprep.com/navigating-the-eras-application-tips-to-dos/">describing your activities clearly and thoughtfully</a>.</span></p>
<p> </p>
<p><span>A common mistake here is rushing through the application just to “get it done.” Programs do read these sections carefully, and small details, like how you describe your clinical experiences, can make a difference.</span></p>
<p> </p>
<p><span>For IMGs, make sure all required documents are uploaded and verified as early as possible. Delays in documentation can impact when your application is considered complete.</span></p>
<p> </p>
<p><span>Your goal during this period is simple: have everything ready well before submission opens.</span></p>
<p> </p>
<h2><b>September 2026: Application Submission</b></h2>
<p><span>This is one of the most important milestones in the entire process.</span></p>
<p> </p>
<p><span>Applications are typically submitted in mid-to-late September, and timing matters. Submitting your application on time, or ideally on the first day it opens, ensures that programs review your application as early as possible.</span></p>
<p> </p>
<p><span>At this point, your focus should shift from building your application to double-checking everything. Make sure your personal statement is polished, your letters are assigned correctly, and your experiences are accurate.</span></p>
<p> </p>
<p><span>Once you hit submit, there’s a natural urge to keep tweaking things, but in reality, most programs will review your application as it is at submission. This is why preparation beforehand is so critical.</span></p>
<p> </p>
<h2><b>October–January: Interview Season</b></h2>
<p><span>After submission, the waiting game begins, but not for long. Interview invitations typically start going out in October and can continue through December or even January. Some specialties have coordinated interview release dates while others have rolling invitations that come out throughout these months. </span></p>
<p> </p>
<p><span>This period can feel unpredictable. Some students receive multiple invitations early, while others may wait longer. Both experiences are normal.</span></p>
<p> </p>
<p><span>Once interviews begin, your role shifts again, from applicant to storyteller. Programs already know your scores and experiences; now they want to understand who you are, how you think, and how you’ll fit into their team.</span></p>
<p> </p>
<p><span>Preparation is key. Practice common interview questions, reflect on your experiences, and be ready to discuss your journey clearly and authentically. Prepare for polished answers but don’t sound too rehearsed or scripted. </span></p>
<p> </p>
<p><span>It’s also important to stay organized. Keep track of interview dates, program details, and your impressions after each interview. These notes will become incredibly valuable when it’s time to rank programs. I recommend creating a spreadsheet with each program name and program features that matter most to you so you can refer back to it when you create your rank list. </span></p>
<p> </p>
<h2><b>January–February: Creating Your Rank List</b></h2>
<p><span>Once interviews wrap up, you’ll move into the ranking phase.</span></p>
<p> </p>
<p><span>This is where you <a href="https://elitemedicalprep.com/nrmp-rank-list-timeline-explained-deadlines-strategy-match-process/">submit your list of programs in order of preference.</a> The Match algorithm is designed to favor the applicant, meaning your best strategy is to rank programs based on where you genuinely want to train, not where you think you’re most likely to match.</span></p>
<p> </p>
<p><span>This can be a surprisingly difficult decision. Factors like location, program culture, clinical exposure, and long-term goals all come into play.</span></p>
<p> </p>
<p><span>Take your time during this phase. Revisit your notes, talk to mentors, and reflect on where you felt most comfortable and supported during interviews.</span></p>
<p> </p>
<p><span>For IMGs, it’s especially important to balance ambition with realism, ensuring your list includes a range of programs. I recommend that unless you’d rather go unmatched than rank a certain program, you include all programs on your rank list. </span></p>
<p> </p>
<h2><b>March 2027: Match Week and Match Day</b></h2>
<p><span>March is when everything comes together.</span></p>
<p> </p>
<p><span>Match Week typically begins on a Monday, when you’ll find out whether you matched. If you did, you’ll wait a few more days until Friday to learn where. If not, you’ll enter the <a href="https://elitemedicalprep.com/understanding-the-supplemental-offer-and-acceptance-program-soap/">Supplemental Offer and Acceptance Program (SOAP)</a>, which is a fast-paced process to secure an unfilled position.</span></p>
<p> </p>
<p><span>Match Day is when you <a href="https://elitemedicalprep.com/how-to-prepare-for-residency-match-day/">officially learn where you’ll be training</a>. It’s one of the most memorable days in your medical journey, and a moment that reflects years of hard work.</span></p>
<p> </p>
<h2><b>Key Differences for IMG Applicants</b></h2>
<p><span>While the overall timeline is the same, <a href="https://elitemedicalprep.com/residency-application-timeline-for-imgs/">IMGs often have additional steps to manage</a>.</span></p>
<p> </p>
<p><span>ECFMG certification, visa considerations, and obtaining U.S. clinical experience can all impact your timeline. Because of this, starting early is even more important.</span></p>
<p> </p>
<p><span>Programs may also review IMG applications differently, placing more emphasis on U.S. experience, Step exam scores, and letters from U.S. physicians. Being proactive and strategic in these areas can make a significant difference. </span></p>
<p> </p>
<p> </p>
<h2><b>Staying Organized (and Sane) Throughout the Process</b></h2>
<p><span>The Match is a long process, and it’s easy to feel overwhelmed at different stages. One of the best things you can do is break it down into manageable phases, focus on what matters now, rather than worrying about everything at once.</span></p>
<p> </p>
<p><span>It’s also important to remember that there’s no single “perfect” path. Some applicants receive early interviews, others later. Some feel confident throughout, others second-guess themselves. These variations are normal.</span></p>
<p> </p>
<p><span>What matters most is consistency, putting together a strong application, preparing thoughtfully for interviews, and making decisions that align with your goals.</span></p>
<p> </p>
<h2><b>Final Thoughts</b></h2>
<p><span>The 2026–2027 Match cycle may feel daunting, but it follows a clear structure. Once you understand the timeline and what’s expected at each stage, you can approach the process with much more confidence.</span></p>
<p> </p>
<p><span>Start early, stay organized, and focus on steady progress. You don’t need to have everything figured out right away, you just need to take the next step, one phase at a time.</span></p>
<p> </p>
<p data-pm-slice="1 1 []">If you’d like guidance along the way, <a href="https://elitemedicalprep.com/residency-advising/">Elite Medical Prep’s residency advising</a> can help you strengthen your application, prepare for interviews, and build your rank list with confidence. Schedule a complimentary consultation to discuss your goals and get personalized support.</p>
<p> </p>
<p><span>And before you know it, you’ll be opening that Match Day envelope and stepping into the next chapter of your medical career. Remember…it just takes 1 interview to get your match! </span></p>
<p>The post <a href="https://elitemedicalprep.com/residency-match-timeline-explained-img-and-us-students/">2026–2027 Residency Match Timeline Explained (IMG + U.S. Students)</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Israeli surgeons perform pioneering robotic&#45;assisted lung transplant without traditional chest opening</title>
<link>https://edusehat.com/en/israeli-surgeons-perform-pioneering-robotic-assisted-lung-transplant-without-traditional-chest-opening</link>
<guid>https://edusehat.com/en/israeli-surgeons-perform-pioneering-robotic-assisted-lung-transplant-without-traditional-chest-opening</guid>
<description><![CDATA[ Surgeons at Beilinson Hospital in Israel have performed the country’s first robotic-assisted lung transplant using small incisions instead of the extensive chest opening traditionally associated with the procedure. The operation, carried out in October at Beilinson Hospital in Petah Tikva, used the da Vinci robotic surgical system to connect a transplanted lung to the recipient’s […]
The post Israeli surgeons perform pioneering robotic-assisted lung transplant without traditional chest opening appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/lungsurgery.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 22:25:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Israeli, surgeons, perform, pioneering, robotic-assisted, lung, transplant, without, traditional, chest, opening</media:keywords>
<content:encoded><![CDATA[<p>Surgeons at Beilinson Hospital in Israel have performed the country’s first robotic-assisted lung transplant using small incisions instead of the extensive chest opening traditionally associated with the procedure.</p>
<p>The operation, carried out in October at Beilinson Hospital in Petah Tikva, used the da Vinci robotic surgical system to connect a transplanted lung to the recipient’s blood vessels and airway.</p>
<p>The procedure places the hospital among a small number of medical centres worldwide to have performed robotic-assisted lung transplantation. According to the hospital, approximately 20 such procedures have been performed globally.</p>
<h3>A less invasive approach to complex surgery</h3>
<p>Traditional lung transplantation often requires surgeons to open the chest extensively to access the lungs, sometimes involving division of the breastbone or separation of the ribs.</p>
<p>Although the procedure can be lifesaving, the surgical approach can cause substantial postoperative pain and make breathing, coughing and clearing lung secretions difficult during recovery.</p>
<p>The robotic-assisted technique is designed to reduce trauma to the chest wall by allowing surgeons to operate through smaller incisions.</p>
<p>Using robotic instruments, the surgical team completed the delicate connections between the donor lung and the recipient’s blood vessels and airway.</p>
<p>The operation was led by Dr. Yuri Peysakhovich, head of thoracic surgery at Beilinson Hospital.</p>
<p>Hospital officials described the achievement as an important step toward making less invasive lung transplantation available to selected patients.</p>
<h3>Encouraging early recovery</h3>
<p>According to the hospital, the patient experienced a favourable early recovery following the procedure.</p>
<p>Dr. Dan Gorfil, director of the hospital’s cardiothoracic surgical intensive care unit, reported that the patient required very little pain medication beyond paracetamol.</p>
<p>The hospital also reported a shorter intensive care stay and overall hospitalization than the team had anticipated.</p>
<p>These observations are encouraging, although the experience of one patient cannot establish whether robotic-assisted lung transplantation consistently produces better outcomes than conventional surgery.</p>
<p>Further procedures, comparative studies and longer-term follow-up will be needed to assess the technique’s safety, effectiveness and suitability for different transplant recipients.</p>
<h3>Extensive preparation and teamwork</h3>
<p>The operation required months of preparation and coordination among numerous hospital departments.</p>
<p>The multidisciplinary team included thoracic surgeons, anesthesiologists, operating room nurses, pulmonologists, cardiopulmonary bypass specialists, intensive care professionals and laboratory personnel.</p>
<p>One of the major challenges involved maintaining patient safety while robotic instruments occupied the surgical field, potentially limiting immediate physical access to the patient.</p>
<p>To prepare, the team conducted a dedicated simulation exercise and developed detailed plans for ventilation, circulation monitoring and emergency intervention.</p>
<p>As an additional precaution, the patient was connected to cardiopulmonary bypass equipment before the procedure, allowing the team to provide immediate support if required.</p>
<h3>Building on earlier experience</h3>
<p>The robotic transplant followed another minimally invasive lung transplant performed at Beilinson approximately one month earlier.</p>
<p>That operation used two small incisions rather than the extensive opening associated with conventional transplantation.</p>
<p>The earlier procedure helped the surgical team develop experience with less invasive access to the chest before undertaking the more technically demanding robotic operation.</p>
<p>Beilinson Hospital has extensive experience in lung transplantation, having performed more than 1,000 lung transplants.</p>
<p>Hospital officials say that experience, combined with specialized robotic training and multidisciplinary planning, was essential to introducing the new technique.</p>
<p>Potential implications for transplant surgery</p>
<p>Robotic-assisted surgery has become increasingly established in several surgical specialties, but lung transplantation remains a particularly demanding application because of the complexity of connecting major blood vessels and airways.</p>
<p>The Beilinson procedure illustrates how robotic technology may expand the possibilities for minimally invasive surgery in highly specialized hospital programs.</p>
<p>For eligible patients, reducing surgical trauma could potentially improve comfort, breathing and mobility during the early recovery period.</p>
<p>However, robotic lung transplantation remains uncommon, and its broader clinical role has not yet been established.</p>
<p>As more hospitals gain experience with the technique, research will be needed to determine which patients may benefit most and whether improvements in recovery can be demonstrated consistently.</p>
<p>The Israeli procedure represents an important technical milestone in the continuing development of transplant surgery.</p>
<p>The post <a href="https://www.hospitalnews.com/israeli-surgeons-perform-pioneering-robotic-assisted-lung-transplant-without-traditional-chest-opening/">Israeli surgeons perform pioneering robotic-assisted lung transplant without traditional chest opening</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Saint John Regional Hospital advances surgical care with $10.9&#45;million fundraising campaign</title>
<link>https://edusehat.com/en/saint-john-regional-hospital-advances-surgical-care-with-109-million-fundraising-campaign</link>
<guid>https://edusehat.com/en/saint-john-regional-hospital-advances-surgical-care-with-109-million-fundraising-campaign</guid>
<description><![CDATA[ Saint John Regional Hospital in New Brunswick is moving forward with two major surgical technology initiatives following the successful completion of a $10.9-million fundraising campaign. The Saint John Regional Hospital Foundation announced November 2 that its Working Wonders Campaign for Surgical Excellence had exceeded its $10.5-million target. The funding will support the development of Atlantic […]
The post Saint John Regional Hospital advances surgical care with $10.9-million fundraising campaign appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/New-Brunswick-Hospital-Advances-with-Robotic-Surgery-Technology-Startup-Ecosystem-Canada.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 22:25:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Saint, John, Regional, Hospital, advances, surgical, care, with, 10.9-million, fundraising, campaign</media:keywords>
<content:encoded><![CDATA[<p>Saint John Regional Hospital in New Brunswick is moving forward with two major surgical technology initiatives following the successful completion of a $10.9-million fundraising campaign.</p>
<p>The Saint John Regional Hospital Foundation announced November 2 that its Working Wonders Campaign for Surgical Excellence had exceeded its $10.5-million target.</p>
<p>The funding will support the development of Atlantic Canada’s first cardiac-enabled hybrid operating room and one of Canada’s first spinal robotic surgery programs.</p>
<p>The investments are intended to expand access to specialized surgical services and help more patients receive advanced care closer to home.</p>
<h3>Advancing spinal surgery</h3>
<p>One of the campaign’s major priorities is establishing a robotic spinal surgery program at Saint John Regional Hospital.</p>
<p>The technology is designed to support surgeons during complex spinal procedures by assisting with surgical planning and instrument positioning.</p>
<p>According to the foundation, the investment is already supporting the hospital’s spinal surgery services.</p>
<p>The program also creates opportunities for surgical education and recruitment, helping strengthen the hospital’s capacity to deliver specialized care.</p>
<h3>New hybrid operating room planned</h3>
<p>The second major investment involves construction of a cardiac-enabled hybrid operating room.</p>
<p>A hybrid operating room combines the capabilities of a conventional surgical suite with advanced medical imaging technology, allowing teams to perform procedures that may require both surgical and image-guided techniques.</p>
<p>Construction is underway, with the facility expected to open in 2028.</p>
<p>The planned operating room will support the continued development of specialized cardiac services at the hospital.</p>
<h3>Community support driving healthcare innovation</h3>
<p>The fundraising campaign brought together donors, volunteers and community partners to support the hospital’s surgical modernization efforts.</p>
<p>The $10.9 million raised exceeded the foundation’s original target by approximately $400,000.</p>
<p>Horizon Health Network President and CEO Margaret Melanson welcomed the investments, noting that spinal robotics is already contributing to surgical care while construction progresses on the hybrid operating room.</p>
<p>The initiatives reflect the importance of collaboration between hospital leadership, healthcare professionals and community foundations in supporting major equipment and infrastructure investments.</p>
<p>For New Brunswick patients, the projects represent a significant commitment to expanding specialized surgical capabilities within the province.</p>
<p>The investments also illustrate how Canadian hospitals are incorporating advanced surgical technologies while planning for future clinical needs.</p>
<p>Although the new hybrid operating room remains under construction, the completed fundraising campaign establishes an important milestone in the hospital’s long-term surgical development.</p>
<p>Source: <a href="https://sjrhfoundation.ca/2026/10/29/working-wonders-campaign-raises-10-9-million/?utm_source=chatgpt.com">Saint John Regional Hospital Foundation — Working Wonders Campaign announcement</a>.</p>
<p>The post <a href="https://www.hospitalnews.com/saint-john-regional-hospital-advances-surgical-care-with-10-9-million-fundraising-campaign/">Saint John Regional Hospital advances surgical care with $10.9-million fundraising campaign</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dentine regeneration research to explore new tooth regrowth method</title>
<link>https://edusehat.com/en/dentine-regeneration-research-to-explore-new-tooth-regrowth-method</link>
<guid>https://edusehat.com/en/dentine-regeneration-research-to-explore-new-tooth-regrowth-method</guid>
<description><![CDATA[ A $1.2 million grant has been awarded to a researcher at the University of Chicago Illinois (UIC) to advance her research on dentine phosphophoryn, a protein that may assist with tooth regrowth. In the newly-funded project, Professor Anna George will explore the role of dentine phosphophoryn in autophagy – a process she compared to ‘garbage… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/regrowth_research.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 19:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Dentine, regeneration, research, explore, new, tooth, regrowth, method</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>A $1.2 million grant has been awarded to a researcher at the University of Chicago Illinois (UIC) to advance her research on dentine phosphophoryn, a protein that may assist with <a href="https://dentistry.co.uk/2026/08/18/tooth-regrowth-in-adults-what-we-know-so-far/">tooth regrowth</a>.</strong></p>



<p>In the newly-funded project, Professor Anna George will explore the role of dentine phosphophoryn in autophagy – a process she compared to ‘garbage collection’, which removes damaged parts of a cell and recycles their components.</p>



<p>In the dental pulp, autophagy could protect teeth from the impact of inflammation or injury. The study will explore whether dentine phosphophoryn could be used to regrow dentine through this process.</p>



<p>George said: ‘We think this protein may serve as a protective mechanism for cell survival. We want to understand how it helps protect those cells and preserve their regenerative capacity to allow them to continue forming healthy tooth tissue during the life of the tooth.’</p>



<h2 class="wp-block-heading">What is the benefit of tooth regrowth research?</h2>



<p>Previous approaches to managing tooth decay focus on removing defects and stopping them from spreading. However, Professor George explained that this carries the major downside of replacing the living tooth with a synthetic cap. </p>



<p>She continued: ‘What we are trying to do is use these proteins in a scaffold in the dental cavity to regrow dentin, have a living matrix that can stop cavity propagation and retain tooth function.’</p>



<p>The research will utilise both human dental pulp stem cells and animal models to investigate the molecular pathways that control autophagy and tissue regeneration.</p>



<p>The $1.2 million of funding has been provided by the National Institute of Dental and Craniofacial Research at the National Institutes of Health. The new project builds on George’s three decades research at the UIC College of Dentistry.</p>



<p><a href="https://dentistry.co.uk/2026/08/18/tooth-regrowth-in-adults-what-we-know-so-far/">Read Dentistry’s guide to the latest developments in tooth regrowth.</a></p>



<p><em><a href="https://sso.dentistry.co.uk/" target="_blank" rel="noreferrer noopener">Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</a></em></p>]]> </content:encoded>
</item>

<item>
<title>Thinking of sinking your teeth into your first dental practice?</title>
<link>https://edusehat.com/en/thinking-of-sinking-your-teeth-into-your-first-dental-practice</link>
<guid>https://edusehat.com/en/thinking-of-sinking-your-teeth-into-your-first-dental-practice</guid>
<description><![CDATA[ Buying your first dental practice is likely to be one of the largest investments of your career. Here are the legal, financial and practical questions to consider before making your first purchase. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/thorntons.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 15:35:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Thinking, sinking, your, teeth, into, your, first, dental, practice</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Buying your first dental practice is likely to be one of the largest investments of your career. Here are the legal, financial and practical questions to consider before making your first purchase.</strong></p>



<p>Buying a practice doesn’t have to be scary! Knowing what to expect from the outset, and having the right advisers around you, can help make the process considerably smoother.</p>



<p>Here are some key questions to bear in mind when considering your first purchase:</p>



<h2 class="wp-block-heading">How are you buying the practice?</h2>



<p>One of the first decisions you will make is how you will purchase the practice. Are you acquiring the practice by way of an asset purchase, meaning you are buying the practice business and its assets, or are you purchasing the shares in the company that owns the practice? The seller’s ownership structure may dictate matters here or they may already have a preferred structure in mind, but it is important to consider what the proposed structure means for you as the buyer. You will also want to consider whether you are purchasing the practice as an individual or through a separate entity, such as a limited company or partnership.</p>



<p>Different structures have varying legal and tax implications, so we would always recommend discussing your options with your legal, financial and tax advisers at an early stage.</p>



<h2 class="wp-block-heading">What are heads of terms and how are they helpful to me as a buyer?</h2>



<p>The heads of terms set out the key commercial terms of the deal. Although they are optional, they are a useful way of making sure that the parties are on the same page about the main terms of the deal at the outset. In particular, we would recommend including a target date for the purchase to complete. You are not bound to this date, but it can be helpful to focus everyone’s minds on a target date for the deal to complete.</p>



<p>Only parts of the heads of terms are legally binding – including confidentiality and exclusivity provisions. Exclusivity is particularly important for you as a buyer, as it prevents the seller from negotiating with other potential buyers, while you are incurring time and costs in progressing the purchase.</p>



<h2 class="wp-block-heading">Is due diligence really that important?</h2>



<p>Absolutely! Due diligence is your opportunity to understand exactly what you are buying and to identify any potential issues before you become legally committed.</p>



<p>As the buyer, due diligence questionnaires (DDQs) will generally be issued by your advisors to the seller, setting out the information and documents required to assess the practice. The DDQs usually request information on the practice’s accounting records, employee and associate agreements, contracts and other important practice documentation. The documents can then be reviewed by your advisers to identify any issues requiring further investigation or protection within the purchase agreement.</p>



<p>The due diligence process is a really important part of managing your liability as a buyer and assessing (and mitigating) any risks identified through the due diligence process.</p>



<h2 class="wp-block-heading">Don’t be spooked by the process…</h2>



<p>There are often several moving parts in a dental purchase and we completely understand how purchasing your first practice can seem daunting, particularly when you are balancing the purchase with your clinical work as well.</p>



<p>Surrounding yourself with advisers who understand the dental sector and involving them at an early stage, can help you navigate the process with confidence and focus on the exciting part: becoming a practice owner!</p>



<p>Contact Lucy at <a href="mailto:LHennessy@thorntons-law.co.uk">LHennessy@thorntons-law.co.uk</a> or <a href="tel://+44%20330%20236%208647">+44 330 236 8647</a>.</p>



<p><em>This article is sponsored by Thorntons.</em></p>]]> </content:encoded>
</item>

<item>
<title>Why EXACT practices are rethinking on&#45;premise practice management</title>
<link>https://edusehat.com/en/why-exact-practices-are-rethinking-on-premise-practice-management</link>
<guid>https://edusehat.com/en/why-exact-practices-are-rethinking-on-premise-practice-management</guid>
<description><![CDATA[ Many dental practices have long relied on EXACT, but the demands of a more connected, patient-led profession are leading some to reassess on-premise practice management. Dentally is a cloud-based practice management system from Henry Schein One presented as an alternative. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/09/dentally_home.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 15:35:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Why, EXACT, practices, are, rethinking, on-premise, practice, management</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Many dental practices have long relied on EXACT, but the demands of a more connected, patient-led profession are leading some to reassess on-premise practice management. Dentally is a cloud-based practice management system from Henry Schein One presented as an alternative.</strong></p>



<h2 class="wp-block-heading">Why on-premise systems felt safe for years</h2>



<p>Dentistry is built on trust, consistency and routine. That is one reason on-premise practice management systems became so deeply embedded in UK practices. They lived in the building, they supported the diary, they stored the records and the team knew where everything was.</p>



<p>For EXACT practices, that familiarity matters. EXACT is positioned as a complete practice management system used by thousands of dental practices, with tools for appointment books, recalls, patient communication, marketing, UDA management and treatment follow-up.</p>



<p>So the question is not ‘why did practices choose on-premise software?’ The better question is: ‘Does the model still fit the way dentistry now works?’</p>



<p>For years, local servers and installed software gave practices a sense of control. The system was physically close. The workflows were known. The team had built habits around it. But familiarity can sometimes disguise friction. A system can be trusted and still be limiting.</p>



<h2 class="wp-block-heading">What has changed in modern dentistry</h2>



<p>Modern dentistry is not just clinical. It is operational, commercial and deeply patient-led.</p>



<p>Practice owners now need to manage busier diaries, higher patient expectations, more digital communication, mixed NHS and private workflows, and in many cases, multi-site visibility. Dentally’s view is that modern practice management needs connected clinical, admin and patient experience features in the cloud.</p>



<p>The pressure on the dental team is also real. UK dental workforce research has identified high levels of stress and burnout, with stressors including workload, NHS system pressures, regulatory compliance, financial strain, leadership and management challenges.</p>



<p>That matters because software is no longer just a back-office tool. It affects how calmly the diary runs, how easily reception can manage patients, how quickly clinicians can complete notes, how clearly owners can see performance and how confidently teams can adapt.</p>



<p>An on-premise model can still run a practice. But modern dentistry increasingly asks for more than ‘running’. It asks for speed, access, automation and insight.</p>



<h2 class="wp-block-heading">The hidden operational costs of staying still</h2>



<p>Staying with an older operating model rarely shows up as a line item. It shows up as time.</p>



<p>It is the hours spent maintaining a local server, the manual backups, the reports that need reconciling by hand, the work duplicated between reception and clinical teams, and the wait for features that arrive on someone else’s upgrade cycle. It’s the manager who cannot check a figure without driving to the practice.</p>



<p>Cloud-based dental software removes much of that. Dentally runs through a browser over an internet connection, so there is no server room to look after, no IT maintenance contract to renew and no installations to schedule. Data backup and security are handled for the practice.</p>



<p>That does not mean every practice should move overnight. It does mean practice owners should calculate more than licence cost. The real question is: what is the total cost of maintaining the current way of working?</p>



<p>If a system adds small amounts of friction to every diary change, report, recall, payment, note or patient communication, the cost compounds across the whole team.</p>



<h2 class="wp-block-heading">What cloud gives practice owners</h2>



<p>Cloud dental software changes the operating model.</p>



<p>Instead of depending heavily on on-site infrastructure, a cloud PMS allows authorised teams to access the system securely through a browser. Dentally runs in Google Chrome, works across Windows, Mac and iPads, and can be used over mobile data as a backup if needed.</p>



<p>For practice owners, that can unlock five practical advantages.</p>



<ol class="wp-block-list">
<li><strong>Better visibility:</strong> owners and managers can see what is happening without always needing to be in the building. This is especially important for multi-site groups that need consistency across locations</li>



<li><strong>Less local IT dependency:</strong> cloud removes much of the operational burden associated with local servers, manual backups and installed software. Automatic data backup and security is a core part of Dentally’s cloud proposition</li>



<li><strong>Faster innovation:</strong> Dentally’s cloud software receives small, seamless updates, helping practices access new features without traditional downtime or disruptive upgrade cycles</li>



<li><strong>More connected patient journeys:</strong> modern patient journeys do not start and end at reception. They include booking, reminders, forms, payments, recall communications, treatment conversations and feedback</li>



<li><strong>A calmer team experience:</strong> when core workflows are easier to complete, teams spend less time fighting the system and more time moving the day forward.</li>
</ol>



<h2 class="wp-block-heading">How Dentally makes the move manageable</h2>



<p>The biggest objection to moving from EXACT is rarely the destination. It’s the journey.</p>



<p>Practices worry about disruption, staff confidence, data migration and patient experience. Dentally’s EXACT-to-Dentally process is designed around discovery, proposal, expectation setting, onboarding, data migration, training and change management, rather than treating switching as a simple software swap.</p>



<p>The right migration conversation should answer:</p>



<ul class="wp-block-list">
<li>Why are you considering moving now?</li>



<li>What frustrates the team about current workflows?</li>



<li>What would success look like 12 months after moving?</li>



<li>What are you worried about losing?</li>



<li>What needs to be explained before the practice feels ready?</li>
</ul>



<p>Those questions are central because switching is not just technical. It is operational and human.</p>



<h2 class="wp-block-heading">Final thought: the question is not cloud versus EXACT</h2>



<p>The better question is whether your current PMS still supports the practice you are trying to build.</p>



<p>EXACT may have helped a practice get here. But if the next chapter depends on less admin, better visibility, secure access from anywhere and a calmer way to run the day, it may be time to rethink on-premise practice management.</p>



<p>Dentally helps practices take that step with a cloud platform built for modern dentistry and a guided pathway that makes the move feel manageable.</p>



<p><a href="https://info.dentally.com/en-gb/care-without-chaos?utm_campaign=47963933-Dentally%20UK%20Net%20New%202026&utm_source=FMCNov26">Book a business review</a> to explore what moving from EXACT to Dentally could look like for your practice.</p>



<p><em>This article is sponsored by Dentally.</em></p>]]> </content:encoded>
</item>

<item>
<title>US FDA grants tentative approval for Dr. Reddy’s twice&#45;yearly injectable lenacapavir </title>
<link>https://edusehat.com/en/us-fda-grants-tentative-approval-for-dr-reddys-twice-yearly-injectable-lenacapavir</link>
<guid>https://edusehat.com/en/us-fda-grants-tentative-approval-for-dr-reddys-twice-yearly-injectable-lenacapavir</guid>
<description><![CDATA[ 
Under the existing agreement, injectable lenacapavir will be available at US$40 per person per year across 120 countries covered by Gilead’s voluntary licence.
The post US FDA grants tentative approval for Dr. Reddy’s twice-yearly injectable lenacapavir  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 14:55:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, grants, tentative, approval, for, Dr., Reddy’s, twice-yearly, injectable, lenacapavir </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="431" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building-300x172.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p>Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval to its long-acting injectable lenacapavir for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 77 pounds (35 kg). The approval was granted under the U.S. FDA’s President’s Emergency Plan for AIDS Relief (PEPFAR) program.</p>
<p>The approval builds on the voluntary licence granted by Gilead Sciences to Dr. Reddy’s in October 2024, followed by an agreement with Unitaid, the Wits Reproductive Health and HIV Institute (Wits RHI) and the Clinton Health Access Initiative (CHAI) in September 2025 to support product development, accelerate the regulatory pathway and enable access to injectable lenacapavir at US$40 per person per year across 120 countries in Gilead’s voluntary licence.</p>
<p>The FDA approval represents an important milestone for Dr. Reddy’s Public Health Access portfolio and reflects the company’s capabilities in developing and manufacturing complex medicines. The first supplies are expected to reach people by the end of 2026, with broader rollout across eligible countries expected in 2027.</p>
<p>HIV continues to pose a significant global public health challenge, with gaps remaining in access to and uptake of effective prevention options. Long-acting lenacapavir, administered twice a year, provides an additional prevention option for people who may face challenges with more frequently administered pre-exposure prophylaxis (PrEP).</p>
<p>Deepak Sapra, Chief Executive Officer, API and Services, Dr. Reddy’s Laboratories said, “This is a moment of immense pride for all of us at Dr. Reddy’s. Developing and manufacturing a complex long-acting injectable like lenacapavir at an affordable price required strong scientific capabilities and manufacturing expertise to address an urgent access need. The U.S. FDA approval validates that work and brings us a significant step closer to making this twice-yearly HIV prevention option available to people across low- and middle-income countries. We are grateful to Gilead for the voluntary licence and to Unitaid, Wits RHI and CHAI for their support in accelerating this journey.”</p>
<p>Dr. Philppe Duneton, Executive Director at Unitaid said, “Unitaid’s early risk-taking is helping shorten the time between a scientific breakthrough and real access in countries. With best-in-class HIV treatment, we delivered in four years what used to take ten. Now, with lenacapavir, we have helped shorten that timeline to just over a year. For young women in Africa, this translates into faster access to a groundbreaking HIV prevention option, with the potential to avert countless infections and drive meaningful change in the HIV response.”</p>
<p>Dr. Neil Buddy Shah, CEO of CHAI said, “For someone at risk of HIV, taking a pill every day to prevent a disease they don’t have is a hard thing to ask. Two injections a year, of a product that is almost 100% effective at preventing HIV, changes that entirely. More than 125,000 people in Africa have already started on lenacapavir, and today’s approval brings us closer to making it available to millions more for just $40 a year. Getting a generic approved just 16 months after the originator, rather than a decade later, shows what’s possible when we prioritize access from the start. This should be the new standard for global health.”</p>
<p>Professor Saiqa Mullick, Director of Implementation Science at Wits RHI, University of the Witwatersrand said, “Generic lenacapavir has the potential to transform HIV prevention, and this is a significant milestone, but an affordable drug alone is not enough. Countries need health systems that are ready to deliver new prevention options, providers who are confident in offering them, and communities that are engaged as partners in their introduction and scale-up. Bringing these elements together will be critical to ensuring equitable access and impact.”</p>
<p>FDA approval provides an important regulatory basis for the remaining steps towards wider availability, including WHO prequalification and national regulatory approvals. Unitaid and partners are supporting countries and communities with product introduction and scale-up, including community engagement and real-world evidence generation to inform how lenacapavir can effectively reach diverse and underserved populations.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/us-fda-grants-tentative-approval-for-dr-reddys-twice-yearly-injectable-lenacapavir/">US FDA grants tentative approval for Dr. Reddy’s twice-yearly injectable lenacapavir </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>HIPAA Security Risk Analysis: What OCR Expects and Why Most Practices Fail the Audit</title>
<link>https://edusehat.com/en/hipaa-security-risk-analysis-what-ocr-expects-and-why-most-practices-fail-the-audit</link>
<guid>https://edusehat.com/en/hipaa-security-risk-analysis-what-ocr-expects-and-why-most-practices-fail-the-audit</guid>
<description><![CDATA[ By the DoctorsManagement Compliance Team Ask a practice administrator whether the practice has completed its HIPAA security risk analysis, and the answer is usually yes. Ask to see it, and the answer often changes. Sometimes it is a vendor questionnaire completed three years ago. Sometimes it is a checklist with every box marked “yes.” Sometimes...
The post HIPAA Security Risk Analysis: What OCR Expects and Why Most Practices Fail the Audit appeared first on DoctorsManagement. ]]></description>
<enclosure url="https://www.doctorsmanagement.com/wp-content/uploads/dm-hipaa-security-risk-analysis.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 07:40:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>HIPAA, Security, Risk, Analysis:, What, OCR, Expects, and, Why, Most, Practices, Fail, the, Audit</media:keywords>
<content:encoded><![CDATA[<p><em>By the DoctorsManagement Compliance Team</em></p>
<p>Ask a practice administrator whether the practice has completed its <strong>HIPAA security risk analysis</strong>, and the answer is usually yes. Ask to see it, and the answer often changes. Sometimes it is a vendor questionnaire completed three years ago. Sometimes it is a checklist with every box marked “yes.” Sometimes it is a MIPS attestation that was clicked without anyone producing a document behind it.</p>
<p>None of those satisfy the regulation, and the Office for Civil Rights (OCR) at the U.S. Department of Health and Human Services knows it. Failure to conduct an accurate and thorough risk analysis is among the most frequently cited findings in OCR’s HIPAA enforcement actions, and since October 2024 OCR has run a dedicated enforcement effort, the Risk Analysis Initiative, aimed at exactly this deficiency. By mid 2026, that initiative had produced <a href="https://www.nixonpeabody.com/insights/articles/2026/07/21/health-plan-settlement-marks-ocrs-20th-ransomware-and-14th-risk-analysis-initiative" target="_blank" rel="noopener">14 enforcement actions</a>, including settlements with small physician practices.</p>
<p>This guide explains what the Security Rule actually requires, why the most common approaches fail, the methodology OCR expects to see, how often the analysis must be updated, how it connects to MIPS, and what the pending Security Rule overhaul would change. It is written for compliance officers, practice administrators, and IT managers who need an analysis that will hold up when someone asks to see it.</p>
<h2>Table of Contents</h2>
<ol class="dm-toc">
<li><a href="https://www.doctorsmanagement.com/blog/hipaa-security-risk-analysis/#what-the-hipaa-security-risk-analysis-requires">What the HIPAA Security Risk Analysis Requires</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/hipaa-security-risk-analysis/#why-the-security-risk-analysis-matters-more-than-ever">Why the Security Risk Analysis Matters More Than Ever</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/hipaa-security-risk-analysis/#risk-analysis-risk-assessment-gap-analysis-and-audit-clearin">Risk Analysis, Risk Assessment, Gap Analysis, and Audit: Clearing Up the Terms</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/hipaa-security-risk-analysis/#why-most-practices-fail">Why Most Practices Fail</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/hipaa-security-risk-analysis/#why-a-vendor-questionnaire-is-not-a-risk-analysis">Why a Vendor Questionnaire Is Not a Risk Analysis</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/hipaa-security-risk-analysis/#what-ocr-expects-the-nine-elements-of-a-compliant-risk-analy">What OCR Expects: The Nine Elements of a Compliant Risk Analysis</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/hipaa-security-risk-analysis/#step-by-step-conducting-the-security-risk-analysis">Step by Step: Conducting the Security Risk Analysis</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/hipaa-security-risk-analysis/#from-analysis-to-risk-management">From Analysis to Risk Management</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/hipaa-security-risk-analysis/#how-often-must-the-security-risk-analysis-be-updated">How Often Must the Security Risk Analysis Be Updated?</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/hipaa-security-risk-analysis/#the-security-risk-analysis-and-mips-promoting-interoperabili">The Security Risk Analysis and MIPS Promoting Interoperability</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/hipaa-security-risk-analysis/#what-the-proposed-hipaa-security-rule-update-would-change">What the Proposed HIPAA Security Rule Update Would Change</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/hipaa-security-risk-analysis/#recognized-security-practices-why-good-security-can-reduce-p">Recognized Security Practices: Why Good Security Can Reduce Penalties</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/hipaa-security-risk-analysis/#tools-and-frameworks-for-the-security-risk-analysis">Tools and Frameworks for the Security Risk Analysis</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/hipaa-security-risk-analysis/#special-considerations-for-small-medical-and-dental-practice">Special Considerations for Small Medical and Dental Practices</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/hipaa-security-risk-analysis/#if-ocr-asks-for-your-risk-analysis">If OCR Asks for Your Risk Analysis</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/hipaa-security-risk-analysis/#when-to-bring-in-an-outside-assessor">When to Bring in an Outside Assessor</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/hipaa-security-risk-analysis/#how-doctorsmanagement-helps">How DoctorsManagement Helps</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/hipaa-security-risk-analysis/#frequently-asked-questions">Frequently Asked Questions</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/hipaa-security-risk-analysis/#references">References</a></li>
</ol>
<h2>What the HIPAA Security Risk Analysis Requires</h2>
<p>The HIPAA Security Rule requires every covered entity and business associate to:</p>
<p><strong>Conduct an accurate and thorough assessment of the potential risks and vulnerabilities to the confidentiality, integrity, and availability of electronic protected health information held by the covered entity or business associate.</strong></p>
<p>That requirement appears at <a href="https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-C/part-164/subpart-C/section-164.308" target="_blank" rel="noopener">45 CFR 164.308(a)(1)(ii)(A)</a>. It is the first implementation specification in the Security Rule’s first administrative safeguard, and for good reason: every other security decision a practice makes is supposed to flow from it.</p>
<h3>Four Words That Matter</h3>
<ul>
<li><strong>Accurate.</strong> The analysis must reflect how the practice actually operates today, not how a template assumes a practice operates.</li>
<li><strong>Thorough.</strong> It must cover all electronic protected health information (ePHI) the practice creates, receives, maintains, or transmits, wherever it lives.</li>
<li><strong>Risks and vulnerabilities.</strong> It must identify what could go wrong and where the practice is exposed, not simply confirm which policies exist.</li>
<li><strong>Confidentiality, integrity, and availability.</strong> It must address all three. A practice that considers only unauthorized access and ignores ransomware, system failure, or data corruption has addressed one third of the requirement.</li>
</ul>
<h3>Risk Analysis Is Paired with Risk Management</h3>
<p>The very next specification, <a href="https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-C/part-164/subpart-C/section-164.308" target="_blank" rel="noopener">45 CFR 164.308(a)(1)(ii)(B)</a>, requires the practice to implement security measures sufficient to reduce identified risks and vulnerabilities to a reasonable and appropriate level. Identifying risks and then doing nothing about them is not compliance. OCR treats the two requirements as a pair, and enforcement actions frequently cite both.</p>
<h3>The Rule Is Scalable, but Not Optional</h3>
<p>The Security Rule is intentionally flexible. Under <a href="https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-C/part-164/subpart-C/section-164.306" target="_blank" rel="noopener">45 CFR 164.306(b)</a>, a practice may consider its size, complexity, technical capabilities, the cost of security measures, and the probability and criticality of potential risks when deciding how to comply. That flexibility shapes how elaborate the analysis needs to be. It does not exempt a solo practice from performing one.</p>
<h2>Why the Security Risk Analysis Matters More Than Ever</h2>
<h3>OCR’s Risk Analysis Initiative</h3>
<p>OCR introduced its Risk Analysis Initiative in <a href="https://natlawreview.com/article/hhs-ocr-risk-analysis-enforcement-initiative-continues-under-new-administration" target="_blank" rel="noopener">October 2024</a>, tying the risk analysis requirement directly to defense against ransomware and other cyberattacks. The initiative continued under the current administration, and by April 2025 it had produced eight settlements totaling nearly $900,000. By July 2026, OCR had announced its 14th action under the initiative.</p>
<p>The settlements are not limited to hospitals and health systems. <a href="https://www.hipaajournal.com/hipaa-violation-cases/" target="_blank" rel="noopener">Recent enforcement actions</a> citing risk analysis failures have involved a small New York neurology practice, a Michigan surgical group, a women’s health group, imaging providers, and an ambulatory surgery center. Settlement amounts for small practices have ranged from a few thousand dollars to several hundred thousand, and nearly every resolution includes a multi year corrective action plan requiring OCR monitoring, a new risk analysis, revised policies, and workforce training. For a small practice, the cost of the corrective action plan often exceeds the payment itself.</p>
<h3>Ransomware Has Changed the Stakes</h3>
<p>Most OCR investigations begin with a breach report, and most large breaches today involve hacking or ransomware. When OCR investigates a breach, the first document it typically requests is the risk analysis in place before the incident. If that analysis did not exist, was incomplete, or did not identify the vulnerability the attacker exploited, the practice faces two problems at once: the breach itself and a documented compliance failure that preceded it.</p>
<h3>MIPS Makes It a Payment Issue</h3>
<p>For clinicians participating in the Merit-based Incentive Payment System, the security risk analysis is a required measure in the Promoting Interoperability performance category. As discussed below, failing to complete it does not merely cost a few points. It zeroes out the entire category.</p>
<h2>Risk Analysis, Risk Assessment, Gap Analysis, and Audit: Clearing Up the Terms</h2>
<p>Much of the confusion around the SRA comes from vocabulary. The terms below are often used interchangeably, but they describe different things.</p>
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th><strong>Term</strong></th>
<th><strong>What It Is</strong></th>
<th><strong>What It Is Not</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Security risk analysis</td>
<td>The HIPAA required process of identifying threats and vulnerabilities to ePHI and rating the resulting risk</td>
<td>A list of policies the practice has adopted</td>
</tr>
<tr>
<td>Security risk assessment</td>
<td>Commonly used as a synonym for risk analysis; the HHS tool uses this name</td>
<td>A different legal requirement</td>
</tr>
<tr>
<td>HIPAA gap analysis</td>
<td>A comparison of the practice’s policies and safeguards against each Security Rule standard</td>
<td>A substitute for the risk analysis, though it can feed into one</td>
</tr>
<tr>
<td>Compliance audit</td>
<td>A review of whether the practice follows its own policies</td>
<td>A forward looking assessment of risk</td>
</tr>
<tr>
<td>Healthcare compliance risk assessment</td>
<td>A broader review of billing, coding, regulatory, and operational compliance risk</td>
<td>An analysis of ePHI security risk</td>
</tr>
</tbody>
</table>
</figure>
<p>A gap analysis answers the question “Do we have the required safeguards?” A risk analysis answers the question “What could actually happen to our ePHI, how likely is it, and how bad would it be?” OCR requires the second question to be answered. For the broader operational and billing side of compliance, see our separate framework for <a href="https://www.doctorsmanagement.com/blog/healthcare-compliance-risk-assessments-a-step-by-step-framework-for-medical-practices/">healthcare compliance risk assessments</a>.</p>
<h2>Why Most Practices Fail</h2>
<p>When OCR finds a risk analysis deficient, the problem is rarely that the practice was negligent about security in general. It is usually one of a handful of recurring patterns.</p>
<h3>The Analysis Was Never Performed</h3>
<p>This remains the most common finding. Many practices believe their EHR vendor, IT contractor, or billing company performs the risk analysis for them. Vendors may perform their own analyses for their own systems, but the obligation to analyze the practice’s environment belongs to the practice.</p>
<h3>A Checklist Was Mistaken for an Analysis</h3>
<p>A list of questions answered yes or no (“Do you have a password policy?”) documents the existence of safeguards. It does not identify threats, evaluate likelihood and impact, or assign a risk level. It is a gap analysis at best.</p>
<h3>The Scope Was Incomplete</h3>
<p>A risk analysis that covers the EHR but ignores the patient portal, the fax server, the imaging equipment, the email system, the backup appliance, laptops used at home, the phone system that records voicemail, and the cloud storage the billing team uses to share spreadsheets is not thorough. OCR’s guidance specifically requires that the analysis address all ePHI regardless of the electronic medium.</p>
<h3>The Analysis Is Out of Date</h3>
<p>An analysis performed when the practice moved into its current office, before it added telehealth, before it switched EHR platforms, and before staff began working remotely describes a different practice. Outdated assessments are a recurring theme in OCR resolution agreements.</p>
<h3>Risks Were Identified and Never Addressed</h3>
<p>Some practices produce a thorough analysis and then file it. When a breach later exploits a vulnerability the practice had already documented, the analysis becomes evidence that the practice knew about the risk and did not act. OCR has described stagnant remediation as a distinct failure.</p>
<h3>Business Associates Were Ignored</h3>
<p>The practice’s ePHI does not stop at the practice’s walls. Billing companies, transcription services, IT contractors, cloud hosts, and clearinghouses all handle it. The risk analysis should account for the risks those relationships introduce, and the practice should have business associate agreements in place. Our guidance on <a href="https://www.doctorsmanagement.com/blog/how-medical-practices-should-respond-to-breach-notifications-from-third-party-clearinghouses/">responding to breach notifications from third party clearinghouses</a> shows how quickly a vendor’s incident becomes the practice’s problem.</p>
<h3>Nothing Was Documented</h3>
<p>The Security Rule requires documentation. An analysis that existed only as a conversation with an IT contractor does not exist for compliance purposes.</p>
<h2>Why a Vendor Questionnaire Is Not a Risk Analysis</h2>
<p>Software vendors and compliance platforms market inexpensive, self guided “HIPAA risk assessments” that a practice manager can complete in an afternoon. Some are useful starting points. Many fall short of what OCR expects for four reasons.</p>
<ul>
<li><strong>They assume a generic practice.</strong> Questions are written for an imaginary practice, so they cannot capture the specific systems, workflows, and vulnerabilities of a real one.</li>
<li><strong>They measure policy, not exposure.</strong> A question asking whether the practice has an encryption policy says nothing about whether the laptop in the billing office is actually encrypted.</li>
<li><strong>They skip the risk rating.</strong> The defining feature of a risk analysis is determining the likelihood and impact of each threat and vulnerability combination. Many questionnaires never perform that step.</li>
<li><strong>They rely on self reporting.</strong> The person answering the questions is often the person responsible for the safeguards, and the answers are rarely verified against configurations, logs, or physical inspection.</li>
</ul>
<p>A defensible analysis can use a questionnaire as one input. It cannot be only a questionnaire.</p>
<h2>What OCR Expects: The Nine Elements of a Compliant Risk Analysis</h2>
<p>OCR has never mandated a specific methodology, but its <a href="https://www.hhs.gov/hipaa/for-professionals/security/guidance/guidance-risk-analysis" target="_blank" rel="noopener">Guidance on Risk Analysis Requirements under the HIPAA Security Rule</a> identifies the elements every analysis should include, drawing on <a href="https://csrc.nist.gov/pubs/sp/800/30/r1/final" target="_blank" rel="noopener">NIST Special Publication 800-30</a>. These elements are what OCR investigators look for.</p>
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th><strong>Element</strong></th>
<th><strong>What OCR Expects</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Scope of the analysis</td>
<td>All ePHI the practice creates, receives, maintains, or transmits, in every location and on every medium</td>
</tr>
<tr>
<td>2. Data collection</td>
<td>Identification of where ePHI is stored, received, maintained, or transmitted, documented through inventories, interviews, and review of past projects</td>
</tr>
<tr>
<td>3. Threats and vulnerabilities</td>
<td>Reasonably anticipated threats, and vulnerabilities that could be triggered or exploited, documented</td>
</tr>
<tr>
<td>4. Current security measures</td>
<td>Assessment and documentation of the safeguards in place and whether they are configured and used properly</td>
</tr>
<tr>
<td>5. Likelihood of threat occurrence</td>
<td>An assessment of the probability that each threat will trigger or exploit a specific vulnerability</td>
</tr>
<tr>
<td>6. Potential impact</td>
<td>An assessment of the magnitude of harm if each threat occurs</td>
</tr>
<tr>
<td>7. Level of risk</td>
<td>Assignment of a risk level for each threat and vulnerability combination, based on likelihood and impact</td>
</tr>
<tr>
<td>8. Documentation</td>
<td>A written record of the analysis, its methods, and its findings</td>
</tr>
<tr>
<td>9. Periodic review and updates</td>
<td>An ongoing process, revisited as the environment changes</td>
</tr>
</tbody>
</table>
</figure>
<p>The sections below translate each element into practical steps for a physician or dental practice.</p>
<h2>Step by Step: Conducting the Security Risk Analysis</h2>
<h3>Step 1: Define the Scope</h3>
<p>List every location where ePHI exists. That includes each office, any administrative or billing location, staff homes where remote work occurs, and every cloud service. Then list every system type: EHR and practice management system, patient portal, email, fax, phone and voicemail systems, imaging and diagnostic devices, backup systems, file shares, mobile devices, removable media, and any artificial intelligence tools such as ambient scribes that process patient information.</p>
<h3>Step 2: Build an Asset and Data Flow Inventory</h3>
<p>For each system, document what ePHI it holds, who has access, where the data is stored, how it moves, and who the vendor is. A simple inventory might look like this:</p>
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th><strong>Asset</strong></th>
<th><strong>ePHI Involved</strong></th>
<th><strong>Location</strong></th>
<th><strong>Access</strong></th>
<th><strong>Vendor and BAA Status</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cloud EHR and practice management system</td>
<td>Full clinical and billing records</td>
<td>Vendor hosted</td>
<td>All clinical and billing staff</td>
<td>Vendor; BAA on file</td>
</tr>
<tr>
<td>Front desk workstations (4)</td>
<td>Schedules, demographics, insurance</td>
<td>Main office</td>
<td>Front desk staff</td>
<td>Practice owned</td>
</tr>
<tr>
<td>Billing manager laptop</td>
<td>Claims exports, aging reports</td>
<td>Office and employee home</td>
<td>Billing manager</td>
<td>Practice owned</td>
</tr>
<tr>
<td>Digital x-ray system</td>
<td>Images and patient identifiers</td>
<td>Imaging room</td>
<td>Clinical staff</td>
<td>Equipment vendor; BAA needed for service access</td>
</tr>
<tr>
<td>Email system</td>
<td>Referral letters, lab results</td>
<td>Cloud</td>
<td>All staff</td>
<td>Email provider; BAA on file</td>
</tr>
<tr>
<td>Network attached backup device</td>
<td>Nightly EHR export</td>
<td>Server closet</td>
<td>IT contractor</td>
<td>IT contractor; BAA on file</td>
</tr>
<tr>
<td>Practice cell phones (3)</td>
<td>Texts, call logs</td>
<td>Mobile</td>
<td>Providers</td>
<td>Carrier; no BAA</td>
</tr>
</tbody>
</table>
</figure>
<p>Then map how data flows. Referral letters arrive by fax and are scanned into the EHR. Lab results arrive through an interface. Claims leave through a clearinghouse. Each handoff is a point where data can be exposed.</p>
<h3>Step 3: Identify Threats and Vulnerabilities</h3>
<p>A <strong>threat</strong> is something that could cause harm. A <strong>vulnerability</strong> is a weakness a threat could exploit. Risk exists only where a threat and a vulnerability meet. Consider threats in four categories:</p>
<ul>
<li><strong>Human, intentional:</strong> phishing, ransomware, credential theft, insider snooping, theft of devices.</li>
<li><strong>Human, unintentional:</strong> misdirected email or fax, accidental deletion, lost devices, misconfiguration.</li>
<li><strong>Technical:</strong> hardware failure, software defects, unpatched systems, vendor outages.</li>
<li><strong>Environmental:</strong> fire, flood, power failure, severe weather.</li>
</ul>
<p>Then identify the vulnerabilities each threat could exploit: unencrypted laptops, shared logins, missing multifactor authentication, end of life operating systems, unpatched imaging workstations, untested backups, an unlocked server closet, or a former employee whose account was never disabled.</p>
<h3>Step 4: Evaluate Current Security Measures</h3>
<p>For each risk, document the safeguards already in place and, critically, whether they are working. This is where verification matters. Confirm that encryption is actually enabled. Confirm that backups actually restore. Confirm that terminated users actually lost access. Our article on <a href="https://www.doctorsmanagement.com/blog/understanding-hipaa-encryption-requirements-what-you-need-to-know/">understanding HIPAA encryption requirements</a> explains why encryption deserves particular attention: it is technically addressable rather than required, but a practice that chooses not to encrypt must document why and adopt an equivalent alternative.</p>
<h3>Step 5: Determine Likelihood</h3>
<p>Rate how likely each threat is to exploit each vulnerability, given current safeguards. A three or five level scale is common. Base the rating on evidence: the practice’s own incident history, industry breach trends, and the strength of existing controls.</p>
<h3>Step 6: Determine Impact</h3>
<p>Rate how severe the harm would be if the threat occurred. Consider the volume and sensitivity of records involved, the effect on patient care if systems were unavailable, the financial cost of breach response and notification, and regulatory and reputational consequences.</p>
<h3>Step 7: Assign a Risk Level</h3>
<p>Combine likelihood and impact to assign a risk level. A simple matrix works for most practices:</p>
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th><strong>Likelihood / Impact</strong></th>
<th><strong>Low Impact</strong></th>
<th><strong>Medium Impact</strong></th>
<th><strong>High Impact</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>High likelihood</td>
<td>Medium</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Medium likelihood</td>
<td>Low</td>
<td>Medium</td>
<td>High</td>
</tr>
<tr>
<td>Low likelihood</td>
<td>Low</td>
<td>Low</td>
<td>Medium</td>
</tr>
</tbody>
</table>
</figure>
<p>Record the results in a risk register. Each entry should name the asset, the threat, the vulnerability, current controls, likelihood, impact, and the resulting risk level.</p>
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th><strong>Asset</strong></th>
<th><strong>Threat</strong></th>
<th><strong>Vulnerability</strong></th>
<th><strong>Current Controls</strong></th>
<th><strong>Likelihood</strong></th>
<th><strong>Impact</strong></th>
<th><strong>Risk</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Billing manager laptop</td>
<td>Theft or loss</td>
<td>Full disk encryption not enabled</td>
<td>Password login</td>
<td>Medium</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>All workstations</td>
<td>Phishing leading to ransomware</td>
<td>No multifactor authentication on email</td>
<td>Spam filter, annual training</td>
<td>High</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Network backup device</td>
<td>Ransomware encrypts backups</td>
<td>Backup on same network, never restore tested</td>
<td>Nightly backup</td>
<td>Medium</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Digital x-ray workstation</td>
<td>Malware</td>
<td>Unsupported operating system</td>
<td>Network segmentation absent</td>
<td>Medium</td>
<td>Medium</td>
<td>Medium</td>
</tr>
<tr>
<td>Server closet</td>
<td>Unauthorized physical access</td>
<td>Door unlocked during business hours</td>
<td>Located in staff area</td>
<td>Low</td>
<td>Medium</td>
<td>Low</td>
</tr>
</tbody>
</table>
</figure>
<h3>Step 8: Document Everything</h3>
<p>The final report should describe the scope, the methodology, the inventory, the threats and vulnerabilities identified, the risk ratings, and the date of the analysis. It should be signed or approved by the security official and retained as required by <a href="https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-C/part-164/subpart-C/section-164.316" target="_blank" rel="noopener">45 CFR 164.316</a>, which requires documentation to be retained for six years from the date of creation or the date it was last in effect, whichever is later.</p>
<h3>Step 9: Schedule the Review</h3>
<p>Set a date for the next review and define the events that will trigger an earlier one. The analysis is a living process, not a one time project.</p>
<h2>From Analysis to Risk Management</h2>
<p>The risk register is the starting point for the risk management plan required by 45 CFR 164.308(a)(1)(ii)(B). For each risk rated medium or high, the plan should name:</p>
<ul>
<li>The specific remediation action (for example, enable full disk encryption on all practice laptops)</li>
<li>The person responsible</li>
<li>The target completion date</li>
<li>The resources required</li>
<li>How completion will be verified</li>
<li>The residual risk after remediation</li>
</ul>
<p>High risks should be addressed first. Some risks may be accepted, but acceptance must be a documented, reasoned decision by leadership, not an omission. Track progress at each compliance committee meeting. If your practice does not yet have a functioning committee, our guide to <a href="https://www.doctorsmanagement.com/blog/how-to-build-and-maintain-an-effective-healthcare-compliance-committee-for-your-practice/">building an effective healthcare compliance committee</a> explains how to structure one.</p>
<p>The Security Rule’s risk management standard also connects to two related requirements that OCR frequently reviews alongside it: a sanction policy for workforce members who violate security policies, and regular review of information system activity such as audit logs, access reports, and security incident tracking.</p>
<h2>How Often Must the Security Risk Analysis Be Updated?</h2>
<p>The current Security Rule does not set a fixed interval. It requires the analysis to be reviewed and updated periodically and as needed in response to environmental or operational changes. In practice, three forces point to an annual cycle.</p>
<ul>
<li><strong>MIPS requires it.</strong> The Promoting Interoperability measure requires an analysis conducted or reviewed for each performance year.</li>
<li><strong>OCR expects currency.</strong> An analysis that does not reflect current systems will not be accepted as accurate.</li>
<li><strong>The proposed Security Rule would mandate it.</strong> The pending rule would require recurring, documented reviews.</li>
</ul>
<p>Beyond the annual review, update the analysis whenever any of the following occur:</p>
<ul>
<li>Implementation of a new EHR, practice management system, or major software upgrade</li>
<li>A move, expansion, or new location</li>
<li>A security incident or breach</li>
<li>Adoption of telehealth, remote work, or new mobile devices</li>
<li>Introduction of AI tools that process patient information</li>
<li>A merger, acquisition, or new affiliation</li>
<li>A change in key vendors or business associates</li>
</ul>
<h2>The Security Risk Analysis and MIPS Promoting Interoperability</h2>
<p>For MIPS eligible clinicians reporting the Promoting Interoperability category, the <a href="https://mdinteractive.com/sites/default/files/uploaded/file/mips_pi_2026/2026-MIPS-Promoting-Interoperability-Security-Risk-Analysis-Measure.pdf" target="_blank" rel="noopener">2026 Security Risk Analysis measure</a> requires clinicians to attest that they conducted or reviewed a security risk analysis in accordance with 45 CFR 164.308(a)(1)(ii)(A), and that they implemented security measures to reduce identified risks to a reasonable and appropriate level as part of the risk management process. The analysis must address the security of data created or maintained by certified EHR technology, including encryption.</p>
<p>Several details trip practices up:</p>
<ul>
<li><strong>Timing.</strong> The analysis may be conducted or reviewed outside the performance period, but it must be unique to each performance period and its scope must cover the full performance period.</li>
<li><strong>The measure is required but unscored.</strong> Completing it earns no points. Failing to complete it results in a score of zero for the entire Promoting Interoperability category.</li>
<li><strong>Attestation must be supported.</strong> Attesting “yes” without a documented analysis creates audit exposure. CMS can request supporting documentation through its data validation and audit process, and an attestation that cannot be supported puts the category score at risk.</li>
</ul>
<p>A practice that clicked through its attestation without a current, documented analysis has two problems: a MIPS exposure and a HIPAA exposure.</p>
<h2>What the Proposed HIPAA Security Rule Update Would Change</h2>
<p>In January 2025, HHS published a proposed rule that would substantially overhaul the Security Rule. As of fall 2026, the proposal <a href="https://www.pact-one.com/2026/09/hipaa-security-rule-2026-status/" target="_blank" rel="noopener">remained unfinalized</a>, with HHS’s finalization target reported to have slipped to approximately July 2027 and with a large coalition of provider organizations asking HHS to withdraw it. If finalized as proposed, compliance would generally be required 240 days after publication.</p>
<p>The proposal matters for risk analysis because it would convert much of today’s flexible guidance into explicit requirements. Among the proposed changes:</p>
<ul>
<li>A written technology asset inventory and network map, reviewed and updated at least annually</li>
<li>More detailed required contents for the written risk analysis</li>
<li>Elimination of the distinction between required and addressable implementation specifications</li>
<li>Vulnerability scanning at least every six months and penetration testing at least annually</li>
<li>Defined timelines for patching critical and high risk vulnerabilities</li>
<li>Multifactor authentication and encryption of ePHI at rest and in transit, with limited exceptions</li>
<li>Annual compliance audits and written verification of business associate safeguards</li>
</ul>
<p>The proposal is not law, and its final form may differ. But a practice that builds its risk analysis today around a documented asset inventory, a data flow map, a verified review of safeguards, and an annual cycle will be well positioned whatever the final rule requires.</p>
<h2>Recognized Security Practices: Why Good Security Can Reduce Penalties</h2>
<p>A 2021 amendment to the HITECH Act (<a href="https://www.congress.gov/bill/116th-congress/house-bill/7898" target="_blank" rel="noopener">Public Law 116-321</a>) requires HHS to consider whether a covered entity or business associate had recognized security practices in place for the previous 12 months when determining fines and the terms of audits or resolution agreements. Recognized security practices include the <a href="https://www.nist.gov/cyberframework" target="_blank" rel="noopener">NIST Cybersecurity Framework</a> and the Health Industry Cybersecurity Practices published through the <a href="https://405d.hhs.gov/" target="_blank" rel="noopener">HHS 405(d) program</a>.</p>
<p>This creates a meaningful incentive. A practice that can document that it adopted and followed a recognized framework, and that its risk analysis was used to prioritize those practices, is in a materially better position if a breach occurs.</p>
<h2>Tools and Frameworks for the Security Risk Analysis</h2>
<p>Several free government resources can support the process:</p>
<ul>
<li><strong>The HHS Security Risk Assessment Tool.</strong> Developed by HHS and the Assistant Secretary for Technology Policy, the <a href="https://www.healthit.gov/topic/privacy-security-and-hipaa/security-risk-assessment-tool" target="_blank" rel="noopener">SRA Tool</a> walks small and medium practices through a structured questionnaire and produces a report. It is a useful framework. It is not a finished analysis, and using it does not by itself guarantee compliance. The quality of the result depends entirely on the accuracy and completeness of the inputs.</li>
<li><strong>NIST SP 800-66 Revision 2.</strong> <a href="https://csrc.nist.gov/pubs/sp/800/66/r2/final" target="_blank" rel="noopener">Implementing the HIPAA Security Rule: A Cybersecurity Resource Guide</a> maps each Security Rule standard to practical activities and includes a detailed risk assessment approach.</li>
<li><strong>NIST SP 800-30.</strong> The <a href="https://csrc.nist.gov/pubs/sp/800/30/r1/final" target="_blank" rel="noopener">Guide for Conducting Risk Assessments</a> is the methodology on which OCR’s guidance draws.</li>
<li><strong>Health Industry Cybersecurity Practices.</strong> The <a href="https://405d.hhs.gov/" target="_blank" rel="noopener">405(d) HICP publication</a> offers prioritized practices scaled for small, medium, and large organizations.</li>
</ul>
<p>Downloadable “HIPAA risk analysis templates” can also help organize the work. The test for any template is whether, once completed, it contains a practice specific inventory, documented threats and vulnerabilities, likelihood and impact ratings, assigned risk levels, and a remediation plan. If it does not, it is a checklist.</p>
<h2>Special Considerations for Small Medical and Dental Practices</h2>
<p>Small practices face the same requirement with fewer resources, and DoctorsManagement has written about <a href="https://www.doctorsmanagement.com/blog/the-hidden-burden-of-hipaa-why-security-risk-analysis-remains-a-major-challenge-for-small-medical-practices-in-2025/">why the SRA remains a major burden for small practices</a>. A few areas deserve particular attention:</p>
<ul>
<li><strong>Cloud EHRs do not transfer the obligation.</strong> A cloud hosted EHR reduces some on premises risks but introduces others, such as account takeover and dependence on internet connectivity. The practice still owns its risk analysis.</li>
<li><strong>Imaging and diagnostic equipment.</strong> X-ray, ultrasound, and other devices often run outdated operating systems and are rarely patched. Dental practices are especially exposed here.</li>
<li><strong>Remote and personal devices.</strong> Billing staff working from home and providers reviewing charts on personal phones extend the practice’s environment into places it does not control.</li>
<li><strong>Email and fax.</strong> Misdirected communications remain one of the most common sources of small breaches.</li>
<li><strong>Artificial intelligence tools.</strong> Ambient scribes, chatbots, and AI enabled documentation tools process ePHI and require both a business associate agreement and inclusion in the analysis. See <a href="https://www.doctorsmanagement.com/blog/ai-in-healthcare-innovation-is-here-but-so-are-new-risks/">AI in Healthcare: Innovation Is Here, But So Are New Risks</a>.</li>
<li><strong>Physical security.</strong> Small offices often have server equipment in unlocked closets and workstations visible from the waiting room.</li>
</ul>
<h2>If OCR Asks for Your Risk Analysis</h2>
<p>OCR contact usually arrives as a data request letter following a breach report or a patient complaint. The letter typically sets a short response deadline and asks for the risk analysis and risk management plan in effect before the incident, along with related policies and evidence. How a practice responds in those first weeks shapes the rest of the investigation.</p>
<ul>
<li><strong>Do not create a backdated analysis.</strong> Producing a document dated before the incident that was actually written after it turns a compliance deficiency into a credibility problem, and potentially something worse.</li>
<li><strong>Produce what exists, accurately described.</strong> If the most recent analysis is outdated or incomplete, say so, and describe the steps already underway to correct it.</li>
<li><strong>Start a current analysis immediately.</strong> OCR considers corrective action taken after a problem is discovered. A thorough, current analysis completed promptly demonstrates good faith.</li>
<li><strong>Gather evidence of recognized security practices.</strong> Documentation that the practice followed a recognized framework over the prior 12 months can affect the outcome, as described above.</li>
<li><strong>Coordinate with counsel.</strong> For investigations involving a significant breach, involve healthcare counsel early. DoctorsManagement supports practices and their attorneys by producing the analytical and compliance record; legal strategy belongs with counsel.</li>
</ul>
<p>A practice that already maintains a current, documented analysis rarely faces this scramble. That is the strongest argument for doing the work before anyone asks.</p>
<h2>When to Bring in an Outside Assessor</h2>
<p>Many practices can conduct a reasonable analysis internally. An independent assessor adds the most value when:</p>
<ul>
<li>The practice has never performed a documented analysis</li>
<li>The last analysis is more than a year old or predates major system changes</li>
<li>No one on staff has security assessment experience</li>
<li>The person responsible for IT would be assessing their own work</li>
<li>The practice has experienced a breach or received an OCR inquiry</li>
<li>The practice is preparing for a sale, merger, or payer audit</li>
</ul>
<p>An outside assessor brings objectivity, verifies rather than accepts self reported answers, and produces documentation built for scrutiny. Our earlier guidance on <a href="https://www.doctorsmanagement.com/blog/strengthening-hipaa-policies-and-conducting-security-risk-analysis/">strengthening HIPAA policies and conducting a security risk analysis</a> covers how the analysis and the policy framework fit together.</p>
<h2>How DoctorsManagement Helps</h2>
<p>DoctorsManagement’s <a href="https://www.doctorsmanagement.com/hipaa-security-risk-analysis/">HIPAA Security Risk Analysis</a> is a project based engagement for medical and dental practices, with no ongoing service contract required. It follows a five phase process:</p>
<ul>
<li><strong>Kickoff and planning.</strong> Define objectives, scope, roles, and timelines.</li>
<li><strong>Detailed risk assessment.</strong> Evaluate policies, procedures, and administrative, physical, and technical safeguards.</li>
<li><strong>Risk identification and deficiency report.</strong> Document vulnerabilities and compliance gaps.</li>
<li><strong>Executive summary and final report.</strong> Prioritize mitigation steps for leadership and audit readiness.</li>
<li><strong>One on one consultation.</strong> Review results and plan future security initiatives.</li>
</ul>
<p>The engagement produces a documented SRA, a deficiency report, an executive summary, and a mitigation roadmap. Practices that need ongoing support can pair it with DoctorsManagement’s broader <a href="https://www.doctorsmanagement.com/hipaa-compliance/">HIPAA Compliance</a> services, including policies, manuals, and workforce training, or with a full <a href="https://www.doctorsmanagement.com/practice-assessment/">Practice Assessment</a>.</p>
<p>If your practice cannot produce a current, documented risk analysis today, <a href="https://www.doctorsmanagement.com/contact-us/">schedule a discovery call</a> with our compliance team.</p>
<h2>Frequently Asked Questions</h2>
<h3>Is a HIPAA security risk analysis required for small practices?</h3>
<p>Yes. The requirement applies to every covered entity and business associate regardless of size. The Security Rule allows a small practice to scale the analysis to its size and complexity, but not to skip it.</p>
<h3>What is the difference between a security risk analysis and a security risk assessment?</h3>
<p>In everyday use, the terms are interchangeable. The regulation uses “risk analysis,” and the HHS tool uses “security risk assessment.” Both refer to identifying threats and vulnerabilities to ePHI and rating the resulting risk.</p>
<h3>How often should a medical practice update its security risk analysis?</h3>
<p>The current rule requires periodic review and updates when the environment changes. For practical purposes, review it at least annually, which also satisfies the MIPS requirement, and update it whenever the practice adopts new systems, moves, experiences an incident, or changes key vendors.</p>
<h3>Does my EHR vendor’s risk analysis cover my practice?</h3>
<p>No. A vendor’s analysis covers the vendor’s own systems and obligations as a business associate. The practice must analyze its own environment, including how it accesses and uses the EHR and every other system that holds ePHI.</p>
<h3>Can I use the HHS SRA Tool to meet the requirement?</h3>
<p>The tool can help structure the analysis, but completing it does not by itself guarantee compliance. The results are only as accurate as the inputs, and the practice must still verify safeguards, document risk ratings, and implement a risk management plan.</p>
<h3>What does OCR request during an investigation?</h3>
<p>OCR commonly requests the current risk analysis and prior versions, the risk management plan and evidence of remediation, security policies and procedures, training records, business associate agreements, and documentation of the specific safeguards relevant to the incident under investigation.</p>
<h3>What happens if we attest to the MIPS security risk analysis measure without completing one?</h3>
<p>Failing to complete the measure results in a zero for the Promoting Interoperability category. Attesting without a documented analysis also creates audit exposure, because CMS can request supporting documentation.</p>
<h3>Is a HIPAA risk analysis template enough?</h3>
<p>Only if the completed template includes a practice specific asset inventory, documented threats and vulnerabilities, likelihood and impact ratings, assigned risk levels, and a remediation plan. A template that records only yes or no answers about policies is a checklist, not an analysis.</p>
<h3>How long must we keep our security risk analysis?</h3>
<p>HIPAA requires Security Rule documentation to be retained for six years from the date of creation or the date it was last in effect, whichever is later. Keep every version, since prior analyses show OCR how the practice’s security program evolved.</p>
<h2>References</h2>
<ul>
<li>U.S. Department of Health and Human Services: <a href="https://www.hhs.gov/hipaa/for-professionals/security/guidance/guidance-risk-analysis" target="_blank" rel="noopener">Guidance on Risk Analysis Requirements under the HIPAA Security Rule</a></li>
<li>Electronic Code of Federal Regulations: <a href="https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-C/part-164/subpart-C/section-164.308" target="_blank" rel="noopener">45 CFR 164.308, Administrative Safeguards</a></li>
<li>National Institute of Standards and Technology: <a href="https://csrc.nist.gov/pubs/sp/800/66/r2/final" target="_blank" rel="noopener">SP 800-66 Revision 2</a> and <a href="https://csrc.nist.gov/pubs/sp/800/30/r1/final" target="_blank" rel="noopener">SP 800-30 Revision 1</a></li>
<li>HealthIT.gov: <a href="https://www.healthit.gov/topic/privacy-security-and-hipaa/security-risk-assessment-tool" target="_blank" rel="noopener">Security Risk Assessment Tool</a></li>
<li>HHS 405(d) Program: <a href="https://405d.hhs.gov/" target="_blank" rel="noopener">Health Industry Cybersecurity Practices</a></li>
<li>Nixon Peabody: <a href="https://www.nixonpeabody.com/insights/articles/2026/07/21/health-plan-settlement-marks-ocrs-20th-ransomware-and-14th-risk-analysis-initiative" target="_blank" rel="noopener">OCR’s 14th Risk Analysis Initiative enforcement action</a></li>
<li>National Law Review: <a href="https://natlawreview.com/article/hhs-ocr-risk-analysis-enforcement-initiative-continues-under-new-administration" target="_blank" rel="noopener">OCR Risk Analysis Enforcement Initiative continues</a></li>
<li>HIPAA Journal: <a href="https://www.hipaajournal.com/hipaa-violation-cases/" target="_blank" rel="noopener">HIPAA Violation Cases</a></li>
<li>Pact One: <a href="https://www.pact-one.com/2026/09/hipaa-security-rule-2026-status/" target="_blank" rel="noopener">Is the HIPAA Security Rule Final in 2026?</a></li>
</ul>
<p>The post <a href="https://www.doctorsmanagement.com/blog/hipaa-security-risk-analysis/">HIPAA Security Risk Analysis: What OCR Expects and Why Most Practices Fail the Audit</a> appeared first on <a href="https://www.doctorsmanagement.com/">DoctorsManagement</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Medical Practice Staff Turnover: What It Actually Costs and How to Build a Team That Stays</title>
<link>https://edusehat.com/en/medical-practice-staff-turnover-what-it-actually-costs-and-how-to-build-a-team-that-stays</link>
<guid>https://edusehat.com/en/medical-practice-staff-turnover-what-it-actually-costs-and-how-to-build-a-team-that-stays</guid>
<description><![CDATA[ By the DoctorsManagement Practice Management and HR Team A medical assistant gives two weeks’ notice. For the first few days, nothing appears to change. Then the remaining MAs start rooming patients for an extra provider. Visits run behind. A provider who usually sees 22 patients sees 19 because intake is slower. Overtime climbs. The practice...
The post Medical Practice Staff Turnover: What It Actually Costs and How to Build a Team That Stays appeared first on DoctorsManagement. ]]></description>
<enclosure url="https://www.doctorsmanagement.com/wp-content/uploads/dm-staff-turnover.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 07:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Medical, Practice, Staff, Turnover:, What, Actually, Costs, and, How, Build, Team, That, Stays</media:keywords>
<content:encoded><![CDATA[<p><em>By the DoctorsManagement Practice Management and HR Team</em></p>
<p>A medical assistant gives two weeks’ notice. For the first few days, nothing appears to change. Then the remaining MAs start rooming patients for an extra provider. Visits run behind. A provider who usually sees 22 patients sees 19 because intake is slower. Overtime climbs. The practice manager spends evenings reviewing applications and mornings conducting interviews. Three weeks after a replacement starts, a prior authorization is missed because the new hire did not know the payer’s rules.</p>
<p>None of that appears on a turnover report. All of it appears in the practice’s cash.</p>
<p><strong>Medical practice staff turnover</strong> is one of the most expensive problems in practice operations precisely because its costs are scattered. Recruiting fees land in one account, overtime in payroll, lost visits in revenue, and errors in denials. Few practices ever add them up. This guide does. It walks through what turnover actually costs, how to calculate it for your own practice, what current data says about why staff leave, and the retention strategies, many of which are not raises, that keep a team in place.</p>
<h2>Table of Contents</h2>
<ol class="dm-toc">
<li><a href="https://www.doctorsmanagement.com/blog/medical-practice-staff-turnover/#the-state-of-medical-practice-staff-turnover-in-2026">The State of Medical Practice Staff Turnover in 2026</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/medical-practice-staff-turnover/#what-turnover-actually-costs-a-medical-practice">What Turnover Actually Costs a Medical Practice</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/medical-practice-staff-turnover/#turnover-cost-math-a-worked-example-for-one-medical-assistan">Turnover Cost Math: A Worked Example for One Medical Assistant</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/medical-practice-staff-turnover/#how-to-calculate-your-practice-s-turnover-rate">How to Calculate Your Practice’s Turnover Rate</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/medical-practice-staff-turnover/#the-perception-gap-what-practice-leaders-think-versus-what-s">The Perception Gap: What Practice Leaders Think Versus What Staff Say</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/medical-practice-staff-turnover/#why-staff-actually-leave-building-an-exit-driver-analysis">Why Staff Actually Leave: Building an Exit Driver Analysis</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/medical-practice-staff-turnover/#compensation-benchmarking-without-overpaying">Compensation Benchmarking Without Overpaying</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/medical-practice-staff-turnover/#onboarding-that-keeps-new-hires-past-90-days">Onboarding That Keeps New Hires Past 90 Days</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/medical-practice-staff-turnover/#retention-levers-that-are-not-raises">Retention Levers That Are Not Raises</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/medical-practice-staff-turnover/#role-specific-retention-playbooks">Role Specific Retention Playbooks</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/medical-practice-staff-turnover/#building-a-retention-dashboard">Building a Retention Dashboard</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/medical-practice-staff-turnover/#compliance-guardrails-for-retention-programs">Compliance Guardrails for Retention Programs</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/medical-practice-staff-turnover/#when-to-bring-in-outside-help">When to Bring in Outside Help</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/medical-practice-staff-turnover/#frequently-asked-questions">Frequently Asked Questions</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/medical-practice-staff-turnover/#references">References</a></li>
</ol>
<h2>The State of Medical Practice Staff Turnover in 2026</h2>
<p>Turnover has eased from the extremes of the post pandemic labor market, but it has not gone away. MGMA’s analysis of the period found that practices experienced <a href="https://www.mgma.com/mgma-stat/can-staff-turnover-continue-to-be-tamed-in-medical-practices-into-2026" target="_blank" rel="noopener">a sharp surge in staff turnover to historic highs between 2020 and 2022</a>. By 2026 the trend had settled, but not resolved: a May 2026 MGMA Stat poll found that <a href="https://www.mgma.com/mgma-stat/stabilized-but-not-solved-staff-turnover-in-2026" target="_blank" rel="noopener">29 percent of medical groups reported higher staff turnover than the prior year</a>.</p>
<p>The same roles keep appearing at the center of the problem. Practices reporting higher turnover most often pointed to medical assistants, nursing and clinical support roles, and front desk or administrative staff. Even among practices where turnover held steady, MAs and front desk and entry level administrative roles remained the most common churn points, alongside nursing and revenue cycle positions.</p>
<p>Those are not peripheral jobs. They are the roles that keep patient flow, access, and cash moving. MGMA describes the operational effects directly: front desk turnover drives up call abandonment, slows check in and checkout, delays referral handoffs, and increases complaints, while MA turnover slows rooming and reduces visit capacity.</p>
<p>Competition for these roles is not going to ease soon. The Bureau of Labor Statistics projects <a href="https://www.bls.gov/ooh/healthcare/medical-assistants.htm" target="_blank" rel="noopener">medical assistant employment will grow 12 percent from 2024 to 2034, with about 112,300 openings projected each year</a>. Every one of those openings is a potential offer to someone already on your team.</p>
<h2>What Turnover Actually Costs a Medical Practice</h2>
<p>The most widely cited research on the <strong>cost of employee turnover</strong> comes from a Center for American Progress review of 30 case studies drawn from 11 research papers. Excluding executives and physicians, it found that <a href="https://www.americanprogress.org/article/there-are-significant-business-costs-to-replacing-employees/" target="_blank" rel="noopener">the typical cost of turnover was 21 percent of an employee’s annual salary</a>, and for workers earning under $50,000, the typical cost was 20 percent. That covers most front desk, MA, and billing roles in a physician practice.</p>
<p>Those percentages are useful as a starting point, but they understate the problem in a medical setting for one reason: a departure in a medical practice does not just cost the practice a worker. It costs the practice capacity, and capacity in a practice is revenue.</p>
<h3>Direct Costs</h3>
<p>Direct costs are the ones that show up on an invoice or a paycheck:</p>
<ul>
<li><strong>Separation costs.</strong> Final pay, accrued paid time off payouts, and any increase in unemployment insurance rates.</li>
<li><strong>Vacancy coverage.</strong> Overtime for remaining staff, or temporary and agency staffing.</li>
<li><strong>Recruiting.</strong> Job board postings, recruiter fees, and background checks.</li>
<li><strong>Pre-employment requirements.</strong> Drug screening, immunization titers, and credential verification.</li>
<li><strong>Training.</strong> Time spent by a trainer or preceptor, and any certification or system training costs.</li>
</ul>
<h3>Indirect Costs</h3>
<p>Indirect costs are larger, harder to see, and usually ignored:</p>
<ul>
<li><strong>Manager time.</strong> Hours spent reviewing applications, interviewing, and onboarding instead of managing operations.</li>
<li><strong>Ramp time.</strong> A new hire is paid a full wage while producing less than full output, often for two to three months.</li>
<li><strong>Lost visit capacity.</strong> When rooming or check in slows down, providers see fewer patients.</li>
<li><strong>Errors and rework.</strong> Missed eligibility checks, incorrect demographics, and incomplete documentation turn into denials and rework.</li>
<li><strong>Contagion.</strong> Remaining staff absorb the extra workload. When that workload persists, it raises the odds that a second person leaves.</li>
</ul>
<h2>Turnover Cost Math: A Worked Example for One Medical Assistant</h2>
<p>The table below estimates the cost of replacing one medical assistant earning $21.00 per hour, or about $43,680 per year, which sits close to the <a href="https://www.bls.gov/ooh/healthcare/medical-assistants.htm" target="_blank" rel="noopener">BLS median of $43,880 for medical assistants working in physician offices</a>. The assumptions are illustrative. Substitute your own.</p>
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th><strong>Cost Component</strong></th>
<th><strong>Assumption</strong></th>
<th><strong>Estimated Cost</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Vacancy coverage (overtime)</td>
<td>60 overtime hours at 1.5 times $21.00 over a four week vacancy</td>
<td>$1,890</td>
</tr>
<tr>
<td>Job advertising</td>
<td>Paid postings on two job boards</td>
<td>$600</td>
</tr>
<tr>
<td>Manager recruiting time</td>
<td>15 hours screening and interviewing at $36.00 per hour</td>
<td>$540</td>
</tr>
<tr>
<td>Pre-employment screening</td>
<td>Background check, drug screen, immunization titers</td>
<td>$250</td>
</tr>
<tr>
<td>Trainer time</td>
<td>60 hours of senior MA preceptor time at $22.00 per hour</td>
<td>$1,320</td>
</tr>
<tr>
<td>New hire ramp</td>
<td>160 hours at roughly 50 percent productivity, valued at $21.00 per hour</td>
<td>$3,360</td>
</tr>
<tr>
<td>Lost visit capacity</td>
<td>20 fewer visits during vacancy and ramp at $110 average payment</td>
<td>$2,200</td>
</tr>
<tr>
<td>Errors and rework</td>
<td>Denials, rework, and corrections attributable to inexperience</td>
<td>$500</td>
</tr>
<tr>
<td><strong>Total estimated cost of one MA departure</strong></td>
<td></td>
<td><strong>$10,660</strong></td>
</tr>
</tbody>
</table>
</figure>
<p>That total equals roughly 24 percent of the departing employee’s annual wages, consistent with the research range, and it does not include harder to measure effects such as patient dissatisfaction or the risk of a second departure.</p>
<h3>Scaling the Math to the Whole Practice</h3>
<p>Now consider a practice with 14 support staff and a 30 percent annual turnover rate. That is roughly four departures per year. At about $10,000 each, the practice is spending more than $40,000 a year replacing people, a figure that never appears as a single line on any financial statement. Reduce turnover to 15 percent and the practice recovers about $20,000 annually, which is more than enough to fund meaningful retention investments.</p>
<p>If you are building your 2027 plan now, give turnover its own budget line. Our guide to creating a medical practice budget for 2027<strong> [EDITOR: link to How to Create a Medical Practice Budget for 2027 article, publishing October Week 1]</strong> shows where it fits in the labor model.</p>
<h2>How to Calculate Your Practice’s Turnover Rate</h2>
<p>You cannot manage turnover you do not measure. Start with the standard formula:</p>
<p><strong>Annual turnover rate = (number of separations during the year ÷ average number of employees during the year) × 100</strong></p>
<p>For example, if your practice averaged 14 employees during the year and 5 left, your turnover rate is 5 ÷ 14 × 100, or about 36 percent.</p>
<h3>Break the Number Down</h3>
<p>A single practice wide rate hides the most useful information. Calculate turnover separately by:</p>
<ul>
<li><strong>Role.</strong> Front desk, MA, nursing, billing, and management.</li>
<li><strong>Tenure at departure.</strong> Departures within 90 days point to hiring and onboarding problems. Departures after two or more years point to compensation, advancement, or management problems.</li>
<li><strong>Voluntary versus involuntary.</strong> Terminations for performance and resignations call for different fixes.</li>
<li><strong>Supervisor or location.</strong> If one manager or one site accounts for a disproportionate share of departures, the cause is local.</li>
</ul>
<h3>Track Vacancy and Workload, Not Just Turnover</h3>
<p>MGMA recommends that practice leaders watch <a href="https://www.mgma.com/mgma-stat/stabilized-but-not-solved-staff-turnover-in-2026" target="_blank" rel="noopener">three measures together: turnover rate, vacancy rate, and workload pressure</a>. A practice can report low turnover while running with frozen positions and an exhausted team, and a practice with steady turnover may be healthy if it fills roles quickly and new hires reach competency fast. Turnover is one vital sign, not the full exam.</p>
<h2>The Perception Gap: What Practice Leaders Think Versus What Staff Say</h2>
<p>The most useful new data on <strong>medical office staff retention</strong> comes from the 2026 Healthcare Workforce Barometer, a Harris Poll survey of 1,514 full time health care employees in direct patient care roles and 304 employers at the director level or above, conducted in June and July 2026. Its central finding is a gap between what leaders believe and what their staff report.</p>
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th><strong>Measure</strong></th>
<th><strong>What Staff Said</strong></th>
<th><strong>What Employers Estimated</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Likely to look for, interview for, or switch to a new role in the next year</td>
<td>59%</td>
<td>39%</td>
</tr>
<tr>
<td>Likely to look outside their current organization</td>
<td>42%</td>
<td>32%</td>
</tr>
<tr>
<td>Aware that their employer offers education benefits</td>
<td>58% (say employer offers them)</td>
<td>69% (estimated awareness)</td>
</tr>
<tr>
<td>Trust employer to implement AI responsibly</td>
<td>52%</td>
<td>70% (believe staff trust them)</td>
</tr>
</tbody>
</table>
</figure>
<p><em>Source: </em><a href="https://www.physicianspractice.com/view/59-of-health-care-workers-say-they-will-look-for-a-new-job-in-the-next-year-and-employers-guess-39-" target="_blank" rel="noopener"><em>Physicians Practice reporting on the 2026 Healthcare Workforce Barometer</em></a><em> and the </em><a href="https://healthcareworkforcebarometer.com/" target="_blank" rel="noopener"><em>Healthcare Workforce Barometer</em></a><em>.</em></p>
<p>In every case, leaders were more optimistic than their teams. The practical implication is uncomfortable: the people a practice manager is confident will stay are, on average, more likely to be looking than the manager believes.</p>
<h3>Advancement Matters More Than Leaders Assume</h3>
<p>Eighty percent of employees in the survey said clear opportunities for advancement are important to them. Yet only 26 percent said they have a great deal of trust that their employer will support their long term career growth. That gap between what staff want and what they believe they will get is where resignations begin.</p>
<p>The pattern is strongest among younger workers. Seventy percent of Gen Z respondents expected to look for a new role in the next year, compared with 31 percent of baby boomers, and 89 percent of Gen Z workers said clear advancement opportunities are important. Notably, most Gen Z respondents also said they expect to stay with one employer for five or more years. They are not inherently disloyal. They will stay where they can see a path forward.</p>
<h3>Benefits That Go Unused Do Not Retain Anyone</h3>
<p>Seventy seven percent of employers said they offer education benefits, but only 58 percent of employees said their employer offers them. A benefit that staff do not know about has no retention value. The same survey found that employees most trust coworkers and peers for guidance on education decisions, followed by HR and then direct managers. Communication through peers and managers, not just an annual benefits packet, determines whether a benefit is real to the people it is meant for.</p>
<h2>Why Staff Actually Leave: Building an Exit Driver Analysis</h2>
<p>Employers in the Barometer survey named <a href="https://www.physicianspractice.com/view/59-of-health-care-workers-say-they-will-look-for-a-new-job-in-the-next-year-and-employers-guess-39-" target="_blank" rel="noopener">burnout and emotional fatigue as the top reason employees leave, cited by 51 percent, followed by a lack of advancement, development, or education opportunities at 47 percent</a>. Those are national patterns. Your practice needs its own diagnosis.</p>
<h3>Conduct Structured Exit Interviews</h3>
<p>Most exit interviews fail because they are informal, conducted by the departing employee’s direct supervisor, and recorded nowhere. A useful exit interview:</p>
<ul>
<li>Is conducted by someone other than the direct supervisor, such as the practice administrator, an owner, or an outside HR consultant</li>
<li>Uses the same core questions every time so answers can be compared over time</li>
<li>Asks what would have changed the decision, not just why the person is leaving</li>
<li>Records the primary reason in a consistent category, such as compensation, schedule, workload, management, advancement, commute, or personal</li>
</ul>
<h3>Run Stay Interviews Before It Is Too Late</h3>
<p>Exit interviews tell you why people left. Stay interviews tell you why current staff remain and what might cause them to leave. A short, twice yearly conversation with each employee covering three questions is often enough: What keeps you here? What frustrates you most about your job? What would you want to be doing two years from now? The answers to the third question are where career paths get built.</p>
<h3>Look for Patterns, Not Anecdotes</h3>
<p>After a year of consistent exit and stay data, sort departures by reason, role, tenure, and supervisor. Patterns emerge quickly. Departures within 90 days usually trace to unclear expectations or poor onboarding. Departures concentrated under one supervisor usually trace to that supervisor. Departures among long tenured staff usually trace to compensation compression or a lack of advancement.</p>
<h2>Compensation Benchmarking Without Overpaying</h2>
<p>Pay is not the only reason staff leave, but uncompetitive pay makes every other retention effort harder. The goal is not to be the highest paying employer in your market. It is to make sure pay is never the reason a good employee leaves.</p>
<h3>Benchmark Against the Right Market</h3>
<p>National medians are a starting point only. The BLS reported a <a href="https://www.bls.gov/ooh/healthcare/medical-assistants.htm" target="_blank" rel="noopener">national median wage of $44,200 for medical assistants in May 2024, and a median of $43,880 in offices of physicians</a>, but wages vary widely by state and metro area. Use the <a href="https://www.bls.gov/oes/" target="_blank" rel="noopener">BLS Occupational Employment and Wage Statistics</a> data for your metropolitan area, supplemented by specialty specific compensation surveys and current local job postings.</p>
<p>Remember that your competition for front desk staff is not only other medical practices. MGMA notes that front desk skills <a href="https://www.mgma.com/mgma-stat/can-staff-turnover-continue-to-be-tamed-in-medical-practices-into-2026" target="_blank" rel="noopener">transfer easily to other industries</a>, which means retail, banking, and customer service employers set part of your market rate.</p>
<h3>Fix Compression Before It Costs You Your Best People</h3>
<p>Pay compression occurs when new hires are brought in at or near the rate of experienced staff. It is one of the most common causes of turnover among tenured employees, and it often goes unnoticed until a five year MA learns what the new hire is making. Review every role annually to make sure tenure and demonstrated competency are reflected in pay.</p>
<h3>Communicate Total Compensation</h3>
<p>Most employees significantly underestimate the value of their benefits. A simple annual total compensation statement showing wages, employer health insurance contributions, retirement matching, paid time off, and education support often changes how staff weigh an outside offer that pays a dollar more per hour but offers less.</p>
<h3>Budget Raises Strategically</h3>
<p>With <a href="https://www.physicianspractice.com/view/staff-compensation-retention-handbook-2027" target="_blank" rel="noopener">2027 raise budgets running around 3 percent</a>, an across the board increase rarely changes retention. Directing more of the raise pool toward high turnover roles, compressed positions, and employees who have added skills usually does.</p>
<h2>Onboarding That Keeps New Hires Past 90 Days</h2>
<p>A significant share of turnover happens early, often before a new employee has fully learned the job. Practices that treat onboarding as a single day of paperwork and a shadowing assignment lose new hires who would have stayed with more structure.</p>
<h3>Before Day One</h3>
<ul>
<li>Send a welcome message with the schedule, parking, dress code, and the name of the person who will meet them.</li>
<li>Have system access, a workstation, and a name badge ready.</li>
<li>Assign a peer mentor in advance.</li>
</ul>
<h3>The First 30 Days</h3>
<ul>
<li>Use a written, role specific competency checklist. For an MA, that includes rooming workflow by provider, vital signs documentation, EHR navigation, specimen handling, and the practice’s infection control and safety procedures. For the front desk, it includes scheduling rules, insurance verification, collecting patient balances, and de-escalation.</li>
<li>Pair the new hire with a trained preceptor, not whoever happens to be available.</li>
<li>Hold a brief check in at the end of week one and week two.</li>
</ul>
<h3>Days 31 Through 90</h3>
<ul>
<li>Gradually increase independence against the competency checklist.</li>
<li>Hold formal 30, 60, and 90 day reviews with clear feedback in both directions.</li>
<li>Ask the new hire what was missing from their training. Their answers improve the next onboarding.</li>
</ul>
<p>MGMA highlights <a href="https://www.mgma.com/mgma-stat/stabilized-but-not-solved-staff-turnover-in-2026" target="_blank" rel="noopener">peer mentoring for the first 90 days</a> as a retention lever, particularly for front desk and access roles, and notes that front desk teams often need better onboarding, scheduling predictability, and de-escalation support.</p>
<h3>Make Sure Policies Support the Process</h3>
<p>Onboarding works best when expectations are documented. A current employee handbook, consistent attendance and scheduling policies, and clear job descriptions remove the ambiguity that frustrates new hires. Our guide to <a href="https://www.doctorsmanagement.com/blog/common-employee-handbook-pitfalls-medical-practice/">common employee handbook pitfalls for a medical practice</a> covers what to review.</p>
<h2>Retention Levers That Are Not Raises</h2>
<p>Compensation sets the floor. These levers determine whether people stay above it.</p>
<h3>Build Visible Career Ladders</h3>
<p>The Barometer data makes the case plainly: staff want to see a path. In a small practice, that path does not require promotions into management. It can be a tiered structure within the role, such as MA I, MA II, and lead MA, with defined competencies and a pay step at each level. MGMA also points to <a href="https://www.mgma.com/mgma-stat/stabilized-but-not-solved-staff-turnover-in-2026" target="_blank" rel="noopener">visible internal mobility paths from front desk to scheduling, referrals, revenue cycle support, or operations</a> as a way to reduce the sense that advancement requires leaving.</p>
<h3>Make Education Benefits Real</h3>
<p>Seventy five percent of workers in the Barometer survey said they are interested in continuing their education, and 81 percent said they would participate in an employer sponsored education program. Even a modest benefit, such as covering certification exam fees for MAs or coding certification for billing staff, can retain someone while building skills the practice needs. Communicate it through managers and peers, not just a policy document.</p>
<h3>Protect Schedule Predictability</h3>
<p>For front desk and MA staff, a predictable schedule often matters as much as a higher wage. Publish schedules well in advance, limit last minute changes, and build float coverage so that one absence does not force others to stay late. Where possible, offer some schedule flexibility, such as a four day week or set early and late shifts.</p>
<h3>Manage Workload Deliberately</h3>
<p>Burnout was the reason employers cited most often for departures. Workload is a leadership decision. Review staff to provider ratios, especially after adding a provider. Remove low value administrative tasks where technology can absorb them. Watch overtime by person: someone working consistent overtime is a turnover risk regardless of how much they appreciate the extra pay.</p>
<h3>Equip the Front Desk to Handle Difficult Patients</h3>
<p>Front desk staff absorb more patient frustration than anyone else in the practice. De-escalation training, clear policies they can point to, and visible support from managers and providers when a patient becomes abusive make a significant difference in whether those staff stay.</p>
<h3>Develop Your Managers</h3>
<p>People frequently leave managers rather than jobs. Supervisors in many practices were promoted for clinical or technical skill and received no training in giving feedback, handling conflict, or running a schedule fairly. Investing in their development is often the highest return retention spend a practice can make.</p>
<h3>Recognize Good Work Specifically and Often</h3>
<p>Recognition does not need to be expensive. Specific acknowledgment from a provider, in front of peers, for handling a difficult day well costs nothing and is remembered. Recognition from physicians carries particular weight with support staff.</p>
<h3>Communicate About Change, Including AI</h3>
<p>New technology creates anxiety when staff do not understand why it is being introduced. The Barometer found that only 52 percent of employees trust their employer at least somewhat to implement AI responsibly, compared with 70 percent of employers who believe their staff trust them. When introducing new tools, explain what they will and will not do, how they change each role, and what training will be provided.</p>
<h2>Role Specific Retention Playbooks</h2>
<p>Different roles leave for different reasons. Match the response to the role.</p>
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th><strong>Role</strong></th>
<th><strong>Common Turnover Drivers</strong></th>
<th><strong>Highest Impact Retention Levers</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Front desk and patient access</td>
<td>Patient conflict, unpredictable schedules, phone volume, pay competition from other industries</td>
<td>De-escalation training, schedule predictability, structured onboarding, path to scheduling, referrals, or billing</td>
</tr>
<tr>
<td>Medical assistants</td>
<td>Workload, rooming pressure from multiple providers, limited advancement</td>
<td>Tiered MA levels, certification support, consistent provider pairing, adequate staffing ratios</td>
</tr>
<tr>
<td>Billing and revenue cycle</td>
<td>Remote work competition, isolation, compression</td>
<td>Coding certification support, remote or hybrid flexibility where workable, performance based recognition</td>
</tr>
<tr>
<td>Nursing</td>
<td>Market competition from hospitals, burnout</td>
<td>Competitive pay review, clinical scope at top of license, schedule control</td>
</tr>
<tr>
<td>Practice managers</td>
<td>Burnout, limited income growth in small practices</td>
<td>Clear authority, owner support, leadership development, performance incentives</td>
</tr>
</tbody>
</table>
</figure>
<h2>Building a Retention Dashboard</h2>
<p>Review a handful of workforce metrics with the same regularity as financial results. A quarterly dashboard might include:</p>
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th><strong>Metric</strong></th>
<th><strong>How to Calculate It</strong></th>
<th><strong>Why It Matters</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual turnover rate</td>
<td>Separations ÷ average headcount × 100</td>
<td>Overall trend</td>
</tr>
<tr>
<td>90 day turnover rate</td>
<td>Departures within 90 days of hire ÷ hires in the period × 100</td>
<td>Hiring and onboarding quality</td>
</tr>
<tr>
<td>Vacancy rate</td>
<td>Open positions ÷ total budgeted positions × 100</td>
<td>Strain on remaining staff</td>
</tr>
<tr>
<td>Time to fill</td>
<td>Days from posting to accepted offer</td>
<td>Recruiting effectiveness and coverage cost</td>
</tr>
<tr>
<td>Overtime hours per FTE</td>
<td>Total overtime hours ÷ FTE count</td>
<td>Workload pressure and burnout risk</td>
</tr>
<tr>
<td>Exit reasons by category</td>
<td>Count of departures by primary reason</td>
<td>Where to focus</td>
</tr>
</tbody>
</table>
</figure>
<h2>Compliance Guardrails for Retention Programs</h2>
<p>Retention initiatives must be applied consistently and documented. A few areas deserve attention:</p>
<ul>
<li><strong>Overtime rules.</strong> Nonexempt staff covering a vacancy must be paid overtime as required under the <a href="https://www.dol.gov/agencies/whd/flsa" target="_blank" rel="noopener">Fair Labor Standards Act</a> and any applicable state law.</li>
<li><strong>Consistent application.</strong> Pay steps, career ladder criteria, and education benefits should be defined in writing and applied consistently to avoid claims of discrimination under laws enforced by the <a href="https://www.eeoc.gov/employers" target="_blank" rel="noopener">U.S. Equal Employment Opportunity Commission</a>.</li>
<li><strong>Education benefit terms.</strong> If the practice requires repayment of education assistance when an employee leaves within a set period, the terms should be documented in advance and reviewed against applicable state law.</li>
<li><strong>Handbook alignment.</strong> Every new retention policy should be reflected in the employee handbook.</li>
</ul>
<h2>When to Bring in Outside Help</h2>
<p>Many practices manage HR as a side responsibility of the practice manager or an owner. That works until turnover becomes persistent, compensation falls out of line with the market, or a difficult termination creates legal risk.</p>
<p>DoctorsManagement’s <a href="https://www.doctorsmanagement.com/hr-consulting/">HR Consulting</a> team helps practices benchmark compensation, design career ladders, update handbooks and policies, structure onboarding, conduct exit interviews, and handle sensitive employee matters. Our <a href="https://www.doctorsmanagement.com/hr-recruitment/">HR Recruitment Services</a> help practices fill open roles faster with candidates screened for fit, which reduces both vacancy cost and early turnover. And through <a href="https://www.doctorsmanagement.com/practice-management/">Practice Management Consulting</a>, we evaluate staffing levels, workflow, and workload against specialty benchmarks.</p>
<p>If turnover is costing your practice more than it should, <a href="https://www.doctorsmanagement.com/contact-us/">schedule a discovery call</a> to talk with our team.</p>
<h2>Frequently Asked Questions</h2>
<h3>What is a normal staff turnover rate for a medical practice?</h3>
<p>There is no single standard, because turnover varies widely by role, region, and practice size. Front desk and MA roles typically turn over faster than billing or management roles. Rather than comparing against a single industry figure, track your own rate by role over time and pay particular attention to departures within the first 90 days.</p>
<h3>How much does it cost to replace a medical office employee?</h3>
<p>Research from the Center for American Progress places the typical cost at about 20 percent of annual salary for workers earning under $50,000. In a medical practice, lost visit capacity and errors during ramp up often push the true cost higher. Our worked example for a medical assistant earning about $43,680 a year estimated a replacement cost of roughly $10,660.</p>
<h3>Which medical practice roles have the highest turnover?</h3>
<p>MGMA polling consistently identifies medical assistants and front desk or patient access staff as the most frequent turnover hotspots, followed by nursing and clinical support roles, with revenue cycle positions also appearing.</p>
<h3>What is the most effective way to retain medical office staff?</h3>
<p>There is no single lever. Competitive pay prevents compensation from becoming a reason to leave, but the strongest retention practices combine structured onboarding, visible career paths, predictable schedules, manageable workloads, and well trained supervisors.</p>
<h3>How can a small practice compete with hospitals on pay?</h3>
<p>Small practices often cannot match hospital wages dollar for dollar, but they can compete on schedule predictability, the absence of weekend and night shifts, closer working relationships with providers, faster recognition, and a clear path to expanded responsibility. Communicating total compensation, including benefits, also narrows the perceived gap.</p>
<h3>What questions should be asked in a medical office exit interview?</h3>
<p>Ask why the employee is leaving, what would have changed the decision, how they would describe their supervisor and workload, whether they felt they had a path to grow, and what the practice should change. Use the same questions every time and record the primary reason in a consistent category.</p>
<h3>What is a stay interview?</h3>
<p>A stay interview is a short, structured conversation with a current employee about why they stay, what frustrates them, and what they want to be doing in the future. It identifies retention risks before an employee decides to leave.</p>
<h3>Does reducing turnover actually improve practice finances?</h3>
<p>Yes. Every avoided departure saves recruiting, training, overtime, and lost capacity costs. In a 14 person practice, reducing turnover from 30 percent to 15 percent can save roughly $20,000 or more per year using conservative assumptions, while also improving patient experience and revenue cycle performance.</p>
<h2>References</h2>
<ul>
<li>MGMA Stat: <a href="https://www.mgma.com/mgma-stat/stabilized-but-not-solved-staff-turnover-in-2026" target="_blank" rel="noopener">Stabilized but not solved: staff turnover in 2026</a></li>
<li>MGMA Stat: <a href="https://www.mgma.com/mgma-stat/can-staff-turnover-continue-to-be-tamed-in-medical-practices-into-2026" target="_blank" rel="noopener">Can staff turnover continue to be tamed in medical practices into 2026?</a></li>
<li>Physicians Practice: <a href="https://www.physicianspractice.com/view/59-of-health-care-workers-say-they-will-look-for-a-new-job-in-the-next-year-and-employers-guess-39-" target="_blank" rel="noopener">59% of health care workers say they will look for a new job in the next year, and employers guess 39%</a></li>
<li>The Harris Poll and Workforce Edge: <a href="https://healthcareworkforcebarometer.com/" target="_blank" rel="noopener">2026 Healthcare Workforce Barometer</a></li>
<li>Center for American Progress: <a href="https://www.americanprogress.org/article/there-are-significant-business-costs-to-replacing-employees/" target="_blank" rel="noopener">There Are Significant Business Costs to Replacing Employees</a></li>
<li>U.S. Bureau of Labor Statistics: <a href="https://www.bls.gov/ooh/healthcare/medical-assistants.htm" target="_blank" rel="noopener">Occupational Outlook Handbook, Medical Assistants</a></li>
<li>Physicians Practice: <a href="https://www.physicianspractice.com/view/staff-compensation-retention-handbook-2027" target="_blank" rel="noopener">Staff Compensation and Retention Handbook 2027</a></li>
<li>U.S. Department of Labor: <a href="https://www.dol.gov/agencies/whd/flsa" target="_blank" rel="noopener">Fair Labor Standards Act</a></li>
</ul>
<p>The post <a href="https://www.doctorsmanagement.com/blog/medical-practice-staff-turnover/">Medical Practice Staff Turnover: What It Actually Costs and How to Build a Team That Stays</a> appeared first on <a href="https://www.doctorsmanagement.com/">DoctorsManagement</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Building an OSHA Compliance Program for Medical and Dental Practices: Beyond the Binder</title>
<link>https://edusehat.com/en/building-an-osha-compliance-program-for-medical-and-dental-practices-beyond-the-binder</link>
<guid>https://edusehat.com/en/building-an-osha-compliance-program-for-medical-and-dental-practices-beyond-the-binder</guid>
<description><![CDATA[ By the DoctorsManagement Compliance Team Somewhere in nearly every medical and dental office sits an OSHA binder. It was purchased years ago, perhaps from a vendor, perhaps from a colleague who opened a practice first. The practice name is written on the cover. The exposure control plan inside lists employees who left long ago. The...
The post Building an OSHA Compliance Program for Medical and Dental Practices: Beyond the Binder appeared first on DoctorsManagement. ]]></description>
<enclosure url="https://www.doctorsmanagement.com/wp-content/uploads/dm-osha-compliance-program.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 07:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Building, OSHA, Compliance, Program, for, Medical, and, Dental, Practices:, Beyond, the, Binder</media:keywords>
<content:encoded><![CDATA[<p><em>By the DoctorsManagement Compliance Team</em></p>
<p>Somewhere in nearly every medical and dental office sits an OSHA binder. It was purchased years ago, perhaps from a vendor, perhaps from a colleague who opened a practice first. The practice name is written on the cover. The exposure control plan inside lists employees who left long ago. The safety data sheets describe products the practice no longer uses. The training sign in sheet ends two years back.</p>
<p>That binder is not an OSHA program. It is evidence that the practice once intended to have one.</p>
<p><strong>OSHA compliance for a medical practice</strong> requires something more specific: written programs that describe the practice’s actual hazards and procedures, training that is delivered and documented on schedule, protective equipment and engineering controls that are in place and used, and records that are maintained over time. When an OSHA compliance officer walks through the door, whether because of an employee complaint, a reported injury, or a referral, those are the things that get reviewed.</p>
<p>This guide explains which OSHA standards apply to medical and dental practices, how to build a site specific program around them, what training is required, what happens during an inspection, and what citations cost. It also addresses the November 20, 2026 deadline for employers to complete updates under the revised Hazard Communication Standard.</p>
<h2>Table of Contents</h2>
<ol class="dm-toc">
<li><a href="https://www.doctorsmanagement.com/blog/osha-compliance-program-medical-dental-practices/#who-osha-covers-and-why-healthcare-offices-are-not-exempt">Who OSHA Covers and Why Healthcare Offices Are Not Exempt</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/osha-compliance-program-medical-dental-practices/#why-the-binder-is-not-a-program">Why the Binder Is Not a Program</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/osha-compliance-program-medical-dental-practices/#the-osha-standards-that-apply-to-most-medical-and-dental-pra">The OSHA Standards That Apply to Most Medical and Dental Practices</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/osha-compliance-program-medical-dental-practices/#bloodborne-pathogens-the-center-of-the-program">Bloodborne Pathogens: The Center of the Program</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/osha-compliance-program-medical-dental-practices/#hazard-communication-the-november-20-2026-deadline">Hazard Communication: The November 20, 2026 Deadline</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/osha-compliance-program-medical-dental-practices/#emergency-action-fire-safety-and-exit-routes">Emergency Action, Fire Safety, and Exit Routes</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/osha-compliance-program-medical-dental-practices/#personal-protective-equipment-and-eyewash-stations">Personal Protective Equipment and Eyewash Stations</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/osha-compliance-program-medical-dental-practices/#radiation-respiratory-protection-and-other-specialized-stand">Radiation, Respiratory Protection, and Other Specialized Standards</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/osha-compliance-program-medical-dental-practices/#recordkeeping-reporting-and-posting-requirements">Recordkeeping, Reporting, and Posting Requirements</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/osha-compliance-program-medical-dental-practices/#building-the-program-step-by-step">Building the Program Step by Step</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/osha-compliance-program-medical-dental-practices/#osha-training-for-medical-staff-what-is-required-and-when">OSHA Training for Medical Staff: What Is Required and When</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/osha-compliance-program-medical-dental-practices/#a-sample-annual-osha-compliance-calendar">A Sample Annual OSHA Compliance Calendar</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/osha-compliance-program-medical-dental-practices/#what-happens-during-an-osha-inspection-of-a-medical-practice">What Happens During an OSHA Inspection of a Medical Practice</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/osha-compliance-program-medical-dental-practices/#osha-citations-and-penalties">OSHA Citations and Penalties</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/osha-compliance-program-medical-dental-practices/#common-osha-gaps-in-medical-and-dental-practices">Common OSHA Gaps in Medical and Dental Practices</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/osha-compliance-program-medical-dental-practices/#free-osha-consultation-for-small-businesses">Free OSHA Consultation for Small Businesses</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/osha-compliance-program-medical-dental-practices/#how-doctorsmanagement-helps">How DoctorsManagement Helps</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/osha-compliance-program-medical-dental-practices/#frequently-asked-questions">Frequently Asked Questions</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/osha-compliance-program-medical-dental-practices/#references">References</a></li>
</ol>
<h2>Who OSHA Covers and Why Healthcare Offices Are Not Exempt</h2>
<p>The Occupational Safety and Health Act of 1970 covers most private sector employers with at least one employee. A physician or dentist practicing alone with no employees is not covered, but the moment a practice hires a medical assistant, a hygienist, or a receptionist, it becomes an employer with OSHA obligations.</p>
<p>Practices in roughly half the states fall under an <a href="https://www.osha.gov/stateplans" target="_blank" rel="noopener">OSHA approved State Plan</a> rather than federal OSHA. State Plans must be at least as effective as federal OSHA and may impose additional requirements or different deadlines, so practices in those states should confirm which rules apply to them.</p>
<p>Beyond specific standards, every employer is subject to the General Duty Clause in Section 5(a)(1) of the OSH Act, which requires employers to provide a workplace free from recognized hazards that are causing or are likely to cause death or serious physical harm. OSHA uses the General Duty Clause to address hazards, such as workplace violence, for which no specific standard exists.</p>
<h2>Why the Binder Is Not a Program</h2>
<p>Off the shelf OSHA manuals are useful as templates. The problem is that most practices stop there. Several OSHA standards explicitly require written programs tailored to the workplace, and a generic manual cannot meet that requirement for three reasons.</p>
<ul>
<li><strong>It cannot identify your hazards.</strong> A bloodborne pathogens exposure control plan must list the job classifications and tasks in your practice that involve occupational exposure. A template does not know whether your medical assistants draw blood or whether your front desk staff ever handles specimens.</li>
<li><strong>It cannot list your chemicals.</strong> A hazard communication program must include an inventory of the hazardous chemicals in your workplace. A template lists generic examples.</li>
<li><strong>It does not maintain itself.</strong> Exposure control plans must be reviewed at least annually. Training must be repeated on schedule. Safety data sheets must be updated when products change. A binder purchased once cannot do any of that.</li>
</ul>
<p>A real program is a set of living documents and recurring activities, assigned to a responsible person and reviewed on a calendar.</p>
<h2>The OSHA Standards That Apply to Most Medical and Dental Practices</h2>
<p>The table below summarizes the standards most commonly relevant to physician and dental offices. Not every standard applies to every practice; applicability depends on the services, equipment, and chemicals involved.</p>
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th><strong>Standard</strong></th>
<th><strong>Citation</strong></th>
<th><strong>Applies When</strong></th>
<th><strong>Core Requirements</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Bloodborne Pathogens</td>
<td>29 CFR 1910.1030</td>
<td>Any employee has reasonably anticipated contact with blood or other potentially infectious materials</td>
<td>Written exposure control plan, engineering and work practice controls, PPE, hepatitis B vaccination, post exposure follow up, annual training, records</td>
</tr>
<tr>
<td>Hazard Communication</td>
<td>29 CFR 1910.1200</td>
<td>Hazardous chemicals are present in the workplace</td>
<td>Written program, chemical inventory, safety data sheets, labels, training</td>
</tr>
<tr>
<td>Emergency Action Plan</td>
<td>29 CFR 1910.38</td>
<td>Another OSHA standard requires one, such as when fire extinguishers are provided and employees are expected to evacuate</td>
<td>Procedures for reporting emergencies, evacuation, and accounting for employees</td>
</tr>
<tr>
<td>Fire Prevention Plan</td>
<td>29 CFR 1910.39</td>
<td>Required by another standard</td>
<td>Major fire hazards, control procedures, responsible personnel</td>
</tr>
<tr>
<td>Exit Routes</td>
<td>29 CFR 1910.36 and 1910.37</td>
<td>All workplaces</td>
<td>Unobstructed, marked exits</td>
</tr>
<tr>
<td>Portable Fire Extinguishers</td>
<td>29 CFR 1910.157</td>
<td>Extinguishers are provided for employee use</td>
<td>Monthly visual checks, annual maintenance, employee training</td>
</tr>
<tr>
<td>Personal Protective Equipment</td>
<td>29 CFR 1910.132</td>
<td>Hazards require PPE</td>
<td>Written hazard assessment certification, PPE provided at no cost, training</td>
</tr>
<tr>
<td>Medical Services and First Aid</td>
<td>29 CFR 1910.151</td>
<td>All workplaces; eyewash required where corrosive materials are used</td>
<td>First aid availability; suitable eye flushing facilities for corrosives</td>
</tr>
<tr>
<td>Ionizing Radiation</td>
<td>29 CFR 1910.1096</td>
<td>X-ray or other radiation sources are used</td>
<td>Exposure limits, monitoring, signage; often supplemented by state radiation rules</td>
</tr>
<tr>
<td>Respiratory Protection</td>
<td>29 CFR 1910.134</td>
<td>Respirators such as N95s are required</td>
<td>Written program, medical evaluation, fit testing, training</td>
</tr>
<tr>
<td>Recordkeeping and Reporting</td>
<td>29 CFR 1904</td>
<td>All employers must report severe injuries; many medical offices are partially exempt from routine logs</td>
<td>Report fatalities and severe injuries; maintain logs if not exempt or if asked</td>
</tr>
<tr>
<td>OSHA Poster</td>
<td>29 CFR 1903.2</td>
<td>All workplaces</td>
<td>Display the Job Safety and Health poster</td>
</tr>
</tbody>
</table>
</figure>
<p>The sections below cover the standards that generate the most work, and the most citations, in medical and dental settings.</p>
<h2>Bloodborne Pathogens: The Center of the Program</h2>
<p>For most clinical practices, the <a href="https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1030" target="_blank" rel="noopener">Bloodborne Pathogens Standard</a> is the most important and most detailed OSHA requirement. It has also historically been among the standards most frequently cited in physician offices.</p>
<h3>The Written Exposure Control Plan</h3>
<p>The <strong>bloodborne pathogens exposure control plan</strong> is the foundation of the program. It must include:</p>
<ul>
<li><strong>An exposure determination.</strong> A list of job classifications in which all employees have occupational exposure (for example, medical assistants, nurses, hygienists, and dental assistants), a list of classifications in which some employees have exposure, and the tasks and procedures that cause the exposure. The determination is made without regard to PPE.</li>
<li><strong>The schedule and method of implementation</strong> for each element of the standard, including engineering controls, work practices, PPE, housekeeping, vaccination, post exposure follow up, training, and recordkeeping.</li>
<li><strong>The procedure for evaluating exposure incidents.</strong></li>
</ul>
<p>The plan must be accessible to employees and reviewed and updated at least annually, and whenever new or modified tasks or procedures affect exposure.</p>
<h3>Safer Sharps and Frontline Employee Input</h3>
<p>The Needlestick Safety and Prevention Act of 2000 added two requirements that practices frequently overlook. During the annual review, employers must document their consideration and implementation of commercially available safer medical devices, such as self sheathing needles, retractable lancets, and needleless IV connectors. Employers must also solicit input from nonmanagerial employees responsible for direct patient care in identifying, evaluating, and selecting engineering and work practice controls, and document that input in the plan.</p>
<p>A plan that has not been reviewed in a year, or that contains no record of safer device evaluation or employee input, is one of the most common findings in an inspection.</p>
<h3>Engineering Controls, Work Practices, and PPE</h3>
<p>Engineering controls remove or isolate the hazard: sharps containers placed within easy reach at the point of use, safety engineered needles and scalpels, and splash guards. Work practice controls change how tasks are performed: no recapping of contaminated needles except where a documented medical procedure requires it and a one handed or mechanical technique is used, hand hygiene after glove removal, and no eating or drinking in areas where exposure is possible.</p>
<p>When exposure remains, the employer must provide appropriate PPE at no cost to employees, including gloves, gowns, face shields, and masks, and must ensure it is used, cleaned, repaired, and replaced as needed.</p>
<h3>Hepatitis B Vaccination</h3>
<p>The hepatitis B vaccine must be made available at no cost to every employee with occupational exposure within 10 working days of initial assignment, unless the employee has previously received the series, antibody testing shows immunity, or the vaccine is medically contraindicated. Employees who decline must sign the declination statement found in Appendix A of the standard. A missing declination form for an unvaccinated employee is a straightforward citation.</p>
<h3>Post Exposure Evaluation and Follow Up</h3>
<p>When an exposure incident occurs, such as a needlestick or a splash to the eyes, the employer must immediately make available a confidential medical evaluation and follow up. That includes documenting the route of exposure, identifying and testing the source individual where feasible and permitted, testing the exposed employee’s blood with consent, providing post exposure prophylaxis when medically indicated, and counseling. Practices should have this process arranged in advance with an occupational health provider, because exposure follow up is time sensitive.</p>
<h3>Regulated Waste and Housekeeping</h3>
<p>The standard requires a written schedule for cleaning and decontamination, proper handling of contaminated laundry, and appropriate containers and labeling for regulated waste. Disposal of medical waste is also governed by state and local rules, which vary considerably.</p>
<h3>Bloodborne Pathogens Training</h3>
<p>Training must be provided at no cost, during working hours, at the time of initial assignment and at least annually thereafter, and whenever changes in tasks or procedures affect exposure. It must cover the specific topics listed in the standard and include an opportunity for interactive questions and answers with a person knowledgeable in the subject. A self paced video with no opportunity to ask questions does not satisfy that requirement on its own.</p>
<h3>Bloodborne Pathogens Records</h3>
<ul>
<li><strong>Training records</strong> must be kept for three years and include dates, content summaries, trainer names and qualifications, and attendee names and job titles.</li>
<li><strong>Medical records</strong> for each employee with occupational exposure must be kept confidential and retained for the duration of employment plus 30 years.</li>
<li><strong>The sharps injury log</strong> is required for employers who must maintain OSHA injury and illness records under 29 CFR 1904. Because many medical and dental offices are partially exempt from those records, they may not be required to keep the log, but maintaining one is a sound practice and supports the annual safer device review.</li>
</ul>
<h2>Hazard Communication: The November 20, 2026 Deadline</h2>
<p>Medical and dental offices use a surprising number of hazardous chemicals: disinfectants, sterilants, alcohol, formalin, acids, developers and fixers, dental materials, and cleaning products. The <a href="https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1200" target="_blank" rel="noopener">Hazard Communication Standard</a> requires employers to inform and train employees about those hazards.</p>
<h3>Core Requirements</h3>
<ul>
<li><strong>A written hazard communication program</strong> describing how the practice meets the labeling, safety data sheet, and training requirements</li>
<li><strong>A chemical inventory</strong> listing the hazardous chemicals present</li>
<li><strong>Safety data sheets</strong> for each hazardous chemical, readily accessible to employees during each work shift</li>
<li><strong>Labels</strong> on all containers, including secondary containers such as spray bottles</li>
<li><strong>Training</strong> at initial assignment and whenever a new chemical hazard is introduced</li>
</ul>
<h3>What Changed and When</h3>
<p>OSHA revised the Hazard Communication Standard in May 2024 to align with Revision 7 of the Globally Harmonized System of Classification and Labelling of Chemicals. In January 2026, OSHA <a href="https://www.govinfo.gov/content/pkg/FR-2026-01-15/html/2026-00653.htm" target="_blank" rel="noopener">extended the compliance dates</a>. Under the extended schedule, <a href="https://www.haynesboone.com/news/alerts/oshas-hazcom-clock-is-ticking-what-employers-must-do-by-november-20" target="_blank" rel="noopener">employers must update their programs for substances by November 20, 2026</a>, with employer obligations for mixtures following on May 19, 2028.</p>
<p>To meet the November 20, 2026 deadline, practices should:</p>
<ul>
<li>Reconcile the chemical inventory against updated safety data sheets and labels from suppliers, and request any missing documents</li>
<li>Update workplace labels, including secondary container labels, where classifications changed</li>
<li>Revise the written program so it reflects current chemicals and actual practice</li>
<li>Train employees on any newly identified hazards and on reading the updated labels and safety data sheets</li>
</ul>
<p>Practices under a State Plan should confirm whether their state has adopted the same dates. For a detailed walk through of the standard, see our <a href="https://www.doctorsmanagement.com/blog/osha-hazard-communication-standard-compliance-guide-for-medical-dental-practices/">OSHA Hazard Communication Standard Compliance Guide for Medical and Dental Practices</a>.</p>
<h2>Emergency Action, Fire Safety, and Exit Routes</h2>
<p>Every workplace must maintain exit routes that are unobstructed, clearly marked, and adequate for the number of occupants. Storage creep, such as boxes of supplies stacked in a corridor or a locked rear door, is a common and easily avoided citation.</p>
<p>When OSHA standards require an emergency action plan, such as when employees are expected to evacuate rather than fight a fire, the plan must cover reporting procedures, evacuation routes, procedures for employees who perform critical operations before evacuating, accounting for employees after evacuation, and rescue or medical duties if any. Employers with 10 or fewer employees may communicate the plan orally; larger employers must put it in writing. A practical plan for a medical office also addresses patients, including those who cannot evacuate unassisted.</p>
<p>If the practice provides portable fire extinguishers for employee use, it must inspect them visually each month, maintain them annually, and train employees in their use.</p>
<h2>Personal Protective Equipment and Eyewash Stations</h2>
<p>The general PPE standard requires the employer to assess the workplace for hazards requiring PPE and to document that assessment in a written certification identifying the workplace evaluated, the person certifying it, and the date. Practices often have gloves and face shields on hand but no written hazard assessment.</p>
<p>Where employees may be exposed to injurious corrosive materials, such as certain disinfectants, sterilants, or laboratory reagents, suitable facilities for quick drenching or flushing of the eyes and body must be provided in the work area for immediate use. Eyewash stations should be accessible, unobstructed, and maintained according to the manufacturer’s instructions. A portable eyewash bottle is generally not a substitute where a plumbed or self contained station is required.</p>
<h2>Radiation, Respiratory Protection, and Other Specialized Standards</h2>
<h3>Ionizing Radiation</h3>
<p>Practices that operate x-ray equipment, including most dental offices and many orthopedic, podiatry, urgent care, and primary care practices, must protect employees from radiation exposure. OSHA’s ionizing radiation standard is often supplemented by state radiation control program requirements for equipment registration, shielding, and dosimetry. Our article on <a href="https://www.doctorsmanagement.com/blog/maintaining-osha-compliance-and-employee-safety-in-radiology/">maintaining OSHA compliance and employee safety in radiology</a> covers those requirements in detail.</p>
<h3>Respiratory Protection</h3>
<p>When a practice requires employees to wear respirators, including N95 filtering facepiece respirators for protection against airborne infectious diseases, it must have a written respiratory protection program, medical evaluations, fit testing before use and annually thereafter, and training. Voluntary use of a respirator triggers fewer requirements, but the employer must still provide certain information to employees.</p>
<h3>Dental Practice Considerations</h3>
<p>OSHA requirements for dental offices center on the same standards as medical offices, but several hazards are more prominent: frequent sharps use, aerosols generated during procedures, chemical exposures from sterilants and dental materials, nitrous oxide, mercury from amalgam, and x-ray equipment. OSHA’s <a href="https://www.osha.gov/dentistry" target="_blank" rel="noopener">dentistry resources</a> summarize the applicable standards. Infection control guidance from the CDC, while not an OSHA standard, is frequently referenced by state dental boards.</p>
<h3>Workplace Violence</h3>
<p>No specific OSHA standard addresses workplace violence in healthcare, but OSHA can cite employers under the General Duty Clause when violence is a recognized hazard and feasible means of abatement exist. Front desk staff and clinicians who deal with distressed patients and family members face real risk. OSHA’s <a href="https://www.osha.gov/sites/default/files/publications/osha3148.pdf" target="_blank" rel="noopener">Guidelines for Preventing Workplace Violence for Healthcare and Social Service Workers</a> describe a program built on management commitment, worksite analysis, hazard prevention, training, and recordkeeping. Several states have adopted healthcare workplace violence requirements of their own.</p>
<h2>Recordkeeping, Reporting, and Posting Requirements</h2>
<h3>Injury and Illness Logs</h3>
<p>Offices of physicians, offices of dentists, offices of other health practitioners, outpatient care centers, and medical and diagnostic laboratories appear on OSHA’s <a href="https://www.osha.gov/laws-regs/regulations/standardnumber/1904/1904SubpartBAppA" target="_blank" rel="noopener">list of partially exempt industries</a>. Establishments in those industries are not required to keep the OSHA 300, 300A, and 301 forms unless OSHA, the Bureau of Labor Statistics, or a state agency asks them in writing to do so. Some healthcare employers outside those classifications must maintain the logs and post the annual summary; our article on <a href="https://www.doctorsmanagement.com/blog/osha-300a-summary/">posting the OSHA 300A summary</a> explains that requirement.</p>
<h3>Severe Injury Reporting Applies to Everyone</h3>
<p>Partial exemption from recordkeeping does not exempt any employer from reporting. Every employer must <a href="https://www.osha.gov/report" target="_blank" rel="noopener">report to OSHA</a> any work related fatality within 8 hours, and any work related inpatient hospitalization, amputation, or loss of an eye within 24 hours.</p>
<h3>The OSHA Poster</h3>
<p>Every covered employer must display the <a href="https://www.osha.gov/publications/poster" target="_blank" rel="noopener">Job Safety and Health: It’s the Law poster</a> in a conspicuous place where employees can see it. State Plan states have their own versions.</p>
<h2>Building the Program Step by Step</h2>
<p>The following sequence turns the requirements above into a working program.</p>
<h3>Step 1: Assign Responsibility</h3>
<p>Designate a safety coordinator, often the practice manager or a senior clinical staff member, with the authority and time to manage the program. Name this person in the written programs. A program owned by no one is not maintained by anyone.</p>
<h3>Step 2: Walk the Practice</h3>
<p>Conduct a hazard assessment of every area: exam and procedure rooms, laboratory and specimen areas, sterilization and instrument processing, imaging rooms, storage, break rooms, and the front office. Note sharps use, chemical use, radiation sources, PPE needs, eyewash locations, exit routes, fire extinguishers, and electrical hazards. This walkthrough becomes the basis for the exposure determination, the chemical inventory, and the PPE hazard assessment.</p>
<h3>Step 3: Write Site Specific Programs</h3>
<p>Using templates as a starting point if helpful, write or revise the exposure control plan, hazard communication program, PPE hazard assessment, emergency action plan, and any other required programs so that each reflects the practice’s actual staff, procedures, chemicals, equipment, and layout.</p>
<h3>Step 4: Put Controls and Equipment in Place</h3>
<p>Evaluate and purchase safer sharps devices, place sharps containers at the point of use, confirm eyewash stations are installed and functioning, stock appropriate PPE in all sizes, and label secondary containers.</p>
<h3>Step 5: Arrange Medical Services</h3>
<p>Establish a relationship with an occupational health provider for hepatitis B vaccination, post exposure evaluation, and, if needed, respirator medical clearance and fit testing. Make sure every employee knows exactly what to do and whom to call after an exposure.</p>
<h3>Step 6: Train and Document</h3>
<p>Deliver required training at hire and on schedule, using content specific to the practice, with an opportunity for questions. Record attendance, content, and the trainer’s qualifications.</p>
<h3>Step 7: Build the Recordkeeping System</h3>
<p>Organize training records, vaccination records and declinations, exposure incident files, safety data sheets, inspection logs for extinguishers and eyewash stations, and the annual plan reviews in a single location, whether physical or electronic, that the safety coordinator controls.</p>
<h3>Step 8: Calendar the Recurring Work</h3>
<p>Most OSHA failures are failures of follow through. Put every recurring obligation on a calendar with a responsible person.</p>
<h3>Step 9: Audit the Program</h3>
<p>At least annually, review the program as an inspector would. Check that documents are current, records are complete, and what is written matches what staff actually do. An independent review every few years adds objectivity.</p>
<h2>OSHA Training for Medical Staff: What Is Required and When</h2>
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th><strong>Training Topic</strong></th>
<th><strong>When Required</strong></th>
<th><strong>Frequency</strong></th>
<th><strong>Documentation</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Bloodborne pathogens</td>
<td>At initial assignment</td>
<td>At least annually, and when tasks change</td>
<td>Retain three years</td>
</tr>
<tr>
<td>Hazard communication</td>
<td>At initial assignment</td>
<td>Whenever a new chemical hazard is introduced</td>
<td>Recommended; retain with program records</td>
</tr>
<tr>
<td>Personal protective equipment</td>
<td>Before performing work requiring PPE</td>
<td>Retrain when changes occur or understanding is inadequate</td>
<td>Written certification of training required</td>
</tr>
<tr>
<td>Emergency action plan</td>
<td>At initial assignment and when the plan changes</td>
<td>When responsibilities or the plan change</td>
<td>Recommended</td>
</tr>
<tr>
<td>Fire extinguisher use</td>
<td>At initial employment if employees are expected to use extinguishers</td>
<td>Annually</td>
<td>Recommended</td>
</tr>
<tr>
<td>Respiratory protection</td>
<td>Before respirator use</td>
<td>Annually</td>
<td>Required with fit test records</td>
</tr>
<tr>
<td>Workplace violence prevention</td>
<td>Recommended under OSHA guidelines and required by some states</td>
<td>Annually recommended</td>
<td>Recommended</td>
</tr>
</tbody>
</table>
</figure>
<p>The single most common training deficiency is not the absence of training. It is the absence of proof. If it was not documented, an inspector will treat it as not done. For a broader view of how compliance training fits into the practice’s overall program, see <a href="https://www.doctorsmanagement.com/blog/healthcare-compliance-training-in-2025-new-standards-and-effective-programs/">Healthcare Compliance Training in 2025</a>.</p>
<h2>A Sample Annual OSHA Compliance Calendar</h2>
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th><strong>Timing</strong></th>
<th><strong>Activity</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>January</td>
<td>Review and update the exposure control plan, including safer device evaluation and frontline employee input</td>
</tr>
<tr>
<td>February</td>
<td>Confirm hepatitis B vaccination status or declinations for all exposed employees</td>
</tr>
<tr>
<td>March</td>
<td>Update the chemical inventory and safety data sheet library</td>
</tr>
<tr>
<td>April</td>
<td>Review the emergency action plan and conduct an evacuation drill</td>
</tr>
<tr>
<td>May</td>
<td>Review PPE hazard assessment and stock levels</td>
</tr>
<tr>
<td>June</td>
<td>Conduct annual bloodborne pathogens training (or schedule by hire date)</td>
</tr>
<tr>
<td>July</td>
<td>Inspect eyewash stations, exit routes, and signage</td>
</tr>
<tr>
<td>August</td>
<td>Review radiation safety documentation and dosimetry where applicable</td>
</tr>
<tr>
<td>September</td>
<td>Review respiratory protection program and complete annual fit testing if required</td>
</tr>
<tr>
<td>October</td>
<td>Review workplace violence incidents and prevention measures</td>
</tr>
<tr>
<td>November</td>
<td>Conduct a mock inspection of the full program</td>
</tr>
<tr>
<td>December</td>
<td>Plan next year’s training schedule and program updates</td>
</tr>
<tr>
<td>Monthly</td>
<td>Visually inspect fire extinguishers; check eyewash function per manufacturer instructions</td>
</tr>
<tr>
<td>As needed</td>
<td>Train new hires; investigate and document exposure incidents; update programs for new procedures or chemicals</td>
</tr>
</tbody>
</table>
</figure>
<p>Many of these tasks also appear in our broader checklist of <a href="https://www.doctorsmanagement.com/blog/things-your-medical-practice-needs-to-do-every-year/">things your medical practice needs to do every year</a>.</p>
<h2>What Happens During an OSHA Inspection of a Medical Practice</h2>
<h3>What Triggers an Inspection</h3>
<p>OSHA does not routinely inspect every medical office. Inspections of healthcare offices are most often triggered by:</p>
<ul>
<li><strong>Employee complaints</strong>, which are among the most common triggers in small workplaces</li>
<li><strong>Severe injury reports</strong> or a reported fatality</li>
<li><strong>Referrals</strong> from other agencies, media reports, or other sources</li>
<li><strong>Targeted or emphasis programs</strong> focusing on specific hazards or industries</li>
<li><strong>Follow up inspections</strong> to verify correction of prior citations</li>
</ul>
<h3>How the Inspection Unfolds</h3>
<ul>
<li><strong>Arrival and credentials.</strong> The compliance officer presents credentials. Ask to see them and verify identity before proceeding.</li>
<li><strong>Opening conference.</strong> The officer explains the reason for the inspection and its scope. The employer may request a copy of any complaint, with the complainant’s identity withheld.</li>
<li><strong>Document review.</strong> Expect requests for the exposure control plan, hazard communication program, safety data sheets, training records, vaccination records and declinations, exposure incident records, the PPE hazard assessment, and the emergency action plan.</li>
<li><strong>Walkaround.</strong> The officer inspects the areas within the scope of the inspection, observing conditions and work practices. A practice representative should accompany the officer.</li>
<li><strong>Employee interviews.</strong> The officer may interview employees privately. Employees are often asked whether they received training, whether they know what to do after a needlestick, and where safety data sheets are kept.</li>
<li><strong>Closing conference.</strong> The officer discusses apparent violations and possible abatement.</li>
</ul>
<h3>Employer Rights</h3>
<p>Employers have the right to request a warrant, although refusing entry rarely improves the outcome. Employers can accompany the officer, take their own notes and photographs, and protect trade secrets. If citations are issued, the employer has 15 working days from receipt to contest them, and may request an informal conference with the OSHA area director to discuss settlement. OSHA generally must issue citations within six months of the violation.</p>
<p>Our case study on a <a href="https://www.doctorsmanagement.com/case-studies/state-osha-inspection-and-citation/">state OSHA inspection and citation</a> shows how one practice navigated the process.</p>
<h3>What Inspectors Actually Review</h3>
<p>Experienced compliance officers move quickly past the binder’s cover page to the evidence that the program operates:</p>
<ul>
<li>Whether the exposure control plan lists current job classifications and reflects an annual review within the past year</li>
<li>Whether the annual review documents safer device evaluation and frontline employee input</li>
<li>Whether every exposed employee has a vaccination record or signed declination</li>
<li>Whether training records show the content, trainer, and dates, and are current</li>
<li>Whether safety data sheets match the chemicals actually on the shelves</li>
<li>Whether secondary containers are labeled</li>
<li>Whether sharps containers are at the point of use and not overfilled</li>
<li>Whether eyewash stations are present where corrosives are used and are unobstructed</li>
<li>Whether exits are clear and marked</li>
<li>Whether employees can explain what to do after an exposure</li>
</ul>
<h2>OSHA Citations and Penalties</h2>
<p>OSHA penalties are assessed per violation, and a single inspection can produce several. The <a href="https://www.osha.gov/memos/2026-05-21/2026-annual-adjustments-osha-civil-penalties" target="_blank" rel="noopener">2026 maximum civil penalties</a> are:</p>
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th><strong>Violation Type</strong></th>
<th><strong>Minimum per Violation</strong></th>
<th><strong>Maximum per Violation</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Serious</td>
<td>$1,085</td>
<td>$16,550</td>
</tr>
<tr>
<td>Other than serious</td>
<td>$0</td>
<td>$16,550</td>
</tr>
<tr>
<td>Repeat</td>
<td>$4,256</td>
<td>$165,514</td>
</tr>
<tr>
<td>Willful</td>
<td>$11,823</td>
<td>$165,514</td>
</tr>
<tr>
<td>Posting requirements</td>
<td>$0</td>
<td>$16,550</td>
</tr>
<tr>
<td>Failure to abate</td>
<td>Not applicable</td>
<td>$16,550 per day beyond the abatement date</td>
</tr>
</tbody>
</table>
</figure>
<p>OSHA’s penalty procedures allow reductions based on employer size, good faith, and history of prior violations, which often lowers penalties for small practices. But the financial penalty is only part of the cost. Citations require documented abatement, a repeat violation within five years carries a dramatically higher penalty, and citations become part of the public enforcement record. Employee complaints that lead to inspections also frequently signal deeper workplace issues that affect retention.</p>
<h2>Common OSHA Gaps in Medical and Dental Practices</h2>
<p>In our work with practices, the same gaps appear repeatedly:</p>
<ul>
<li>A generic exposure control plan that does not list the practice’s actual job classifications and tasks</li>
<li>No documented annual plan review, safer device evaluation, or frontline employee input</li>
<li>Missing hepatitis B vaccination records or declination forms</li>
<li>Training that occurred but was never documented, or training with no opportunity for questions</li>
<li>Safety data sheets that are incomplete, outdated, or inaccessible to staff on every shift</li>
<li>Unlabeled secondary containers, especially spray bottles of disinfectant</li>
<li>No written PPE hazard assessment certification</li>
<li>Missing, blocked, or unmaintained eyewash stations where corrosives are used</li>
<li>Overfilled sharps containers or containers placed out of reach</li>
<li>Blocked exit routes or missing exit signage</li>
<li>Fire extinguishers without monthly inspection records</li>
<li>No arrangement with an occupational health provider for post exposure follow up</li>
<li>The OSHA poster missing or outdated</li>
</ul>
<p>Every item on this list is inexpensive to fix before an inspection and costly to fix after one.</p>
<h2>Free OSHA Consultation for Small Businesses</h2>
<p>OSHA’s <a href="https://www.osha.gov/consultation" target="_blank" rel="noopener">On-Site Consultation Program</a> offers free and confidential safety and health consultation services to small and medium sized businesses. It is separate from enforcement: consultants do not issue citations or propose penalties, though employers must commit to correcting serious hazards identified. Some practices use it alongside private consulting support.</p>
<h2>How DoctorsManagement Helps</h2>
<p>DoctorsManagement’s <a href="https://www.doctorsmanagement.com/osha-compliance/">OSHA Compliance</a> services are built specifically for medical and dental practices. Our team provides:</p>
<ul>
<li>Initial and annual workplace safety assessments</li>
<li>Site specific written programs and supporting documentation</li>
<li>OSHA manuals and training materials</li>
<li>Staff training with certification, covering bloodborne pathogens, hazard communication, recordkeeping, general safety, respiratory protection, emergency action planning, workplace violence, and ergonomics</li>
<li>Guidance on PPE and related protocols</li>
<li>Ongoing compliance support, including help preparing for and responding to inspections</li>
</ul>
<p>Practices that prefer group training can attend our <a href="https://www.doctorsmanagement.com/osha-seminars/">OSHA Seminars</a>. And because OSHA obligations overlap with employment practices, onboarding, and handbooks, our <a href="https://www.doctorsmanagement.com/hr-consulting/">HR Consulting</a> team can make sure safety policies and training are built into the employee lifecycle.</p>
<p>If your OSHA program lives in a binder no one has opened this year, or you need to meet the November 20, 2026 Hazard Communication deadline, <a href="https://www.doctorsmanagement.com/contact-us/">schedule a discovery call</a> with our compliance team.</p>
<h2>Frequently Asked Questions</h2>
<h3>Does OSHA apply to small medical and dental practices?</h3>
<p>Yes. OSHA applies to nearly every private employer with at least one employee. A solo physician or dentist with no employees is not covered, but any practice with staff must comply with applicable standards.</p>
<h3>What OSHA standards apply to a medical office?</h3>
<p>Most medical offices are subject to the Bloodborne Pathogens Standard, the Hazard Communication Standard, exit route and fire safety requirements, PPE requirements, first aid and eyewash requirements, the OSHA poster requirement, and severe injury reporting. Practices with x-ray equipment or respirator use have additional obligations.</p>
<h3>What are the OSHA requirements for a dental office?</h3>
<p>Dental offices follow the same core standards as medical offices, with particular attention to bloodborne pathogens, hazard communication for dental materials and sterilants, ionizing radiation from x-ray equipment, and PPE for aerosol generating procedures.</p>
<h3>How often must a bloodborne pathogens exposure control plan be reviewed?</h3>
<p>At least annually, and whenever new or modified tasks or procedures affect occupational exposure. The annual review must document consideration of safer medical devices and input from frontline employees.</p>
<h3>How often is OSHA training required for medical staff?</h3>
<p>Bloodborne pathogens training is required at initial assignment and at least annually. Hazard communication training is required at initial assignment and whenever a new chemical hazard is introduced. Other topics, such as respirator use and fire extinguisher training, have their own schedules.</p>
<h3>Do medical offices need to keep an OSHA 300 log?</h3>
<p>Offices of physicians, dentists, and other health practitioners, as well as outpatient care centers and medical laboratories, are partially exempt from routine injury and illness recordkeeping unless OSHA or BLS asks in writing. All employers, however, must report fatalities within 8 hours and inpatient hospitalizations, amputations, or eye losses within 24 hours.</p>
<h3>What is the November 20, 2026 OSHA deadline?</h3>
<p>It is the employer compliance date under OSHA’s revised Hazard Communication Standard for substances. By that date, employers must update workplace labels, written hazard communication programs, and training to reflect updated hazard information for substances. The deadline for mixtures follows on May 19, 2028.</p>
<h3>What happens if my practice fails an OSHA inspection?</h3>
<p>OSHA may issue citations with proposed penalties and abatement deadlines. In 2026, serious violations carry penalties of up to $16,550 each, and willful or repeat violations up to $165,514 each. Employers have 15 working days to contest citations and may request an informal conference.</p>
<h3>Is an OSHA compliance manual enough?</h3>
<p>No. A manual is a template. OSHA requires site specific written programs, documented training on schedule, current records, and controls actually in use. The manual is the starting point, not the program.</p>
<h2>References</h2>
<ul>
<li>Occupational Safety and Health Administration: <a href="https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1030" target="_blank" rel="noopener">Bloodborne Pathogens Standard, 29 CFR 1910.1030</a></li>
<li>Occupational Safety and Health Administration: <a href="https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1200" target="_blank" rel="noopener">Hazard Communication Standard, 29 CFR 1910.1200</a></li>
<li>Federal Register: <a href="https://www.govinfo.gov/content/pkg/FR-2026-01-15/html/2026-00653.htm" target="_blank" rel="noopener">Hazard Communication Standard compliance date extension, January 15, 2026</a></li>
<li>Haynes Boone: <a href="https://www.haynesboone.com/news/alerts/oshas-hazcom-clock-is-ticking-what-employers-must-do-by-november-20" target="_blank" rel="noopener">OSHA’s HazCom clock is ticking: what employers must do by November 20</a></li>
<li>Occupational Safety and Health Administration: <a href="https://www.osha.gov/memos/2026-05-21/2026-annual-adjustments-osha-civil-penalties" target="_blank" rel="noopener">2026 annual adjustments to OSHA civil penalties</a></li>
<li>Occupational Safety and Health Administration: <a href="https://www.osha.gov/laws-regs/regulations/standardnumber/1904/1904SubpartBAppA" target="_blank" rel="noopener">Partially exempt industries, 29 CFR 1904 Subpart B Appendix A</a></li>
<li>Occupational Safety and Health Administration: <a href="https://www.osha.gov/sites/default/files/publications/osha3148.pdf" target="_blank" rel="noopener">Guidelines for Preventing Workplace Violence for Healthcare and Social Service Workers</a></li>
<li>Occupational Safety and Health Administration: <a href="https://www.osha.gov/consultation" target="_blank" rel="noopener">On-Site Consultation Program</a></li>
<li>Occupational Safety and Health Administration: <a href="https://www.osha.gov/dentistry" target="_blank" rel="noopener">Dentistry</a></li>
</ul>
<p>The post <a href="https://www.doctorsmanagement.com/blog/osha-compliance-program-medical-dental-practices/">Building an OSHA Compliance Program for Medical and Dental Practices: Beyond the Binder</a> appeared first on <a href="https://www.doctorsmanagement.com/">DoctorsManagement</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How to Create a Medical Practice Budget for 2027: A Line&#45;by&#45;Line Planning Framework</title>
<link>https://edusehat.com/en/how-to-create-a-medical-practice-budget-for-2027-a-line-by-line-planning-framework</link>
<guid>https://edusehat.com/en/how-to-create-a-medical-practice-budget-for-2027-a-line-by-line-planning-framework</guid>
<description><![CDATA[ By the DoctorsManagement Practice Management and Accounting Team Most medical practices do not operate against a budget. They operate against a bank balance. Financial statements get reviewed after the fact, often at tax time, and the conversation centers on what already happened rather than what should happen next. By the time a cost problem shows...
The post How to Create a Medical Practice Budget for 2027: A Line-by-Line Planning Framework appeared first on DoctorsManagement. ]]></description>
<enclosure url="https://www.doctorsmanagement.com/wp-content/uploads/dm-practice-budget-2027.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 07:40:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Create, Medical, Practice, Budget, for, 2027:, Line-by-Line, Planning, Framework</media:keywords>
<content:encoded><![CDATA[<p><em>By the DoctorsManagement Practice Management and Accounting Team</em></p>
<p>Most medical practices do not operate against a budget. They operate against a bank balance. Financial statements get reviewed after the fact, often at tax time, and the conversation centers on what already happened rather than what should happen next. By the time a cost problem shows up in a year end profit and loss statement, it has usually been compounding for months.</p>
<p>A <strong>medical practice budget</strong> reverses that order. It sets targets before the year begins, translates those targets into monthly expectations, and gives leadership an early warning system when actual results drift. It is the difference between steering the practice and reading about where it went.</p>
<p>The case for budgeting has rarely been stronger. In a June 2026 MGMA Stat poll, <a href="https://www.mgma.com/mgma-stat/operating-costs-keep-climbing-for-medical-practices-in-2026" target="_blank" rel="noopener">84 percent of medical groups reported year to date operating costs higher than the same point in 2025</a>, following a year in which <a href="https://www.mgma.com/mgma-stat/medical-practice-operating-costs-are-still-rising-in-2025-heres-how-to-control-them" target="_blank" rel="noopener">90 percent reported higher costs than 2024</a>. Revenue has not kept pace. A follow up poll found that <a href="https://www.mgma.com/mgma-stat/revenue-growth-narrows-as-costs-climb-2026-squeeze" target="_blank" rel="noopener">only 47 percent of groups reported higher year to date revenue, while 36 percent reported a decrease</a>. When costs rise at most practices and revenue rises at fewer than half, margin does not survive on good intentions.</p>
<p>The fourth quarter is when well run practices build next year’s plan. This guide walks through <strong>how to create a medical practice budget</strong> for 2027 one line at a time: projecting volume, modeling revenue by payer mix, building labor costs from the roster up, budgeting operating expenses, separating capital decisions, phasing cash flow, testing scenarios, and setting the variance review cadence that turns a spreadsheet into a management tool.</p>
<h2>Table of Contents</h2>
<ol class="dm-toc">
<li><a href="https://www.doctorsmanagement.com/blog/how-to-create-a-medical-practice-budget-2027/#why-most-practices-skip-budgeting-and-what-it-costs-them">Why Most Practices Skip Budgeting, and What It Costs Them</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/how-to-create-a-medical-practice-budget-2027/#before-you-start-gather-the-inputs">Before You Start: Gather the Inputs</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/how-to-create-a-medical-practice-budget-2027/#step-1-project-volume-before-you-project-revenue">Step 1: Project Volume Before You Project Revenue</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/how-to-create-a-medical-practice-budget-2027/#step-2-project-revenue-by-payer-mix">Step 2: Project Revenue by Payer Mix</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/how-to-create-a-medical-practice-budget-2027/#step-3-model-labor-costs-from-the-roster-up">Step 3: Model Labor Costs from the Roster Up</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/how-to-create-a-medical-practice-budget-2027/#step-4-budget-operating-expenses-line-by-line">Step 4: Budget Operating Expenses Line by Line</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/how-to-create-a-medical-practice-budget-2027/#step-5-plan-capital-expenditures-separately">Step 5: Plan Capital Expenditures Separately</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/how-to-create-a-medical-practice-budget-2027/#step-6-convert-the-annual-budget-into-a-monthly-cash-plan">Step 6: Convert the Annual Budget into a Monthly Cash Plan</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/how-to-create-a-medical-practice-budget-2027/#step-7-pressure-test-the-budget-with-scenarios">Step 7: Pressure Test the Budget with Scenarios</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/how-to-create-a-medical-practice-budget-2027/#putting-it-together-a-sample-budget-summary">Putting It Together: A Sample Budget Summary</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/how-to-create-a-medical-practice-budget-2027/#the-variance-review-cadence-where-budgets-earn-their-value">The Variance Review Cadence: Where Budgets Earn Their Value</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/how-to-create-a-medical-practice-budget-2027/#common-medical-practice-budgeting-mistakes">Common Medical Practice Budgeting Mistakes</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/how-to-create-a-medical-practice-budget-2027/#a-medical-office-budget-template-structure">A Medical Office Budget Template Structure</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/how-to-create-a-medical-practice-budget-2027/#how-doctorsmanagement-helps-practices-build-and-manage-their">How DoctorsManagement Helps Practices Build and Manage Their Budget</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/how-to-create-a-medical-practice-budget-2027/#frequently-asked-questions">Frequently Asked Questions</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/how-to-create-a-medical-practice-budget-2027/#references">References</a></li>
</ol>
<h2>Why Most Practices Skip Budgeting, and What It Costs Them</h2>
<p>Physicians are trained to diagnose and treat, not to forecast. Practice managers are often promoted from billing or clinical roles and inherit financial oversight without formal training in it. And the accounting function in many independent practices is built around tax compliance rather than management reporting. The result is a common pattern: financial statements arrive late, are organized by tax category rather than operational category, and are reviewed only when something feels wrong.</p>
<p>The cost of operating without a budget shows up in predictable ways:</p>
<ul>
<li><strong>Raises are granted without a plan.</strong> Compensation decisions get made one conversation at a time, and the cumulative effect on overhead is discovered months later.</li>
<li><strong>Hiring happens reactively.</strong> A position is added because a provider complained about workload, not because volume projections justified it.</li>
<li><strong>Capital purchases compete with payroll.</strong> A piece of equipment is bought with operating cash in a month when collections dipped, and the practice draws on its line of credit to make payroll.</li>
<li><strong>Payer changes go unmodeled.</strong> A Medicare fee schedule adjustment or a Medicare Advantage network change hits revenue without anyone having estimated its size in advance.</li>
<li><strong>Owner distributions become guesswork.</strong> Without a projected margin, partners either take too much early in the year or hold back cash unnecessarily.</li>
</ul>
<p>A budget does not eliminate uncertainty. It makes uncertainty visible, quantified, and manageable.</p>
<h2>Before You Start: Gather the Inputs</h2>
<p>A budget is only as good as the data underneath it. Before building a single line, assemble the following.</p>
<h3>Historical Financials</h3>
<p>Pull at least 12 months, and ideally 24 months, of monthly profit and loss statements. Two years of history lets you see seasonality and separate one time events from trends. If your statements are prepared on a cash basis, that is workable for budgeting, but note that cash timing will blur month to month patterns. If your chart of accounts lumps unrelated expenses together, this is the moment to fix it. Our <a href="https://www.doctorsmanagement.com/accounting-services/">Accounting Services</a> team frequently restructures a practice’s chart of accounts before the first budget cycle precisely because the existing structure makes meaningful review impossible.</p>
<h3>Production and Collection Data</h3>
<p>From your practice management system, export monthly encounters by provider, charges and payments by payer, and adjustments by type. You need payments by payer, not just charges, because charges are a list price that no payer actually pays.</p>
<h3>A Baseline Performance Assessment</h3>
<p>Budgeting is a forward planning exercise, and it works best when it starts from an honest diagnosis of where the practice stands today. If you have not recently evaluated your practice’s financial health across profitability, liquidity, and efficiency, start with DoctorsManagement’s financial health framework<strong> [EDITOR: link to Beyond Profitability financial health blog]</strong> and the metric definitions in our guide to the medical practice KPIs that matter<strong> [EDITOR: link to Medical Practice KPIs That Matter guide]</strong>. The KPI guide measures performance looking backward. This budget uses those same metrics, particularly overhead ratio and revenue per encounter, as targets looking forward.</p>
<h3>External Inputs</h3>
<ul>
<li><strong>Payer rate changes.</strong> Review the final <a href="https://www.cms.gov/medicare/payment/fee-schedules/physician" target="_blank" rel="noopener">2027 Medicare Physician Fee Schedule</a> and our breakdown of <a href="https://www.doctorsmanagement.com/blog/the-2027-medicare-physician-fee-schedule-what-changed-and-how-to-protect-your-revenue/">what changed in the 2027 Medicare Physician Fee Schedule and how to protect your revenue</a>. Pull current rate sheets for your top commercial contracts and note any escalators or renegotiation dates.</li>
<li><strong>Lease and contract terms.</strong> Identify rent escalations, equipment lease expirations, and vendor contracts renewing in 2027.</li>
<li><strong>Staffing roster.</strong> List every position with its current hourly rate or salary, scheduled hours, benefits elections, and hire date.</li>
<li><strong>Known changes.</strong> New providers, departing providers, new service lines, a second location, or planned schedule changes all belong on the list before you start.</li>
</ul>
<h2>Step 1: Project Volume Before You Project Revenue</h2>
<p>Revenue projections fail most often because they start with dollars. Start with capacity and volume instead, because volume is what your providers and schedule actually control.</p>
<h3>Build Volume from Provider Capacity</h3>
<p>For each provider, estimate:</p>
<ul>
<li><strong>Clinic days available.</strong> Start with 52 weeks, subtract vacation, CME, holidays, and administrative time. A full time physician often lands between 44 and 47 clinical weeks.</li>
<li><strong>Sessions and visits per day.</strong> Use actual historical averages, not template capacity. If the template allows 24 visits but the provider averages 20 completed visits, budget 20.</li>
<li><strong>No show and late cancellation rate.</strong> Apply your actual rate. If you budget against a full template, every no show becomes an unexplained variance.</li>
</ul>
<p>Multiply clinic days by completed visits per day for each provider and sum the results. Then layer in procedures, ancillary services such as imaging or lab, and any care management programs as separate volume lines, because they carry different reimbursement and different costs.</p>
<h3>Account for Ramp and Change</h3>
<p>A new physician does not arrive at full productivity. A common planning assumption is a ramp that reaches full schedule over six to twelve months depending on specialty and referral base. Departing providers, planned leaves, and schedule reductions belong in the volume model too. If you are evaluating whether to add a physician or an advanced practice provider in 2027, our analysis of <a href="https://www.doctorsmanagement.com/blog/physician-vs-mid-level-which-provider-should-your-growing-practice-hire-next/">which provider type a growing practice should hire next</a> covers the volume and margin tradeoffs in detail.</p>
<h2>Step 2: Project Revenue by Payer Mix</h2>
<p>Once volume is set, convert it to revenue payer by payer. A single blended rate hides the most important revenue risk in most practices: a shift in payer mix.</p>
<h3>Calculate Expected Payment per Visit by Payer</h3>
<p>For each major payer category, divide 12 months of payments by encounters for that payer. This gives you an expected payment per visit that already reflects your actual coding mix and contracted rates. Then adjust each figure for known 2027 changes: the Medicare conversion factor and relative value updates, commercial escalators, and any Medicaid rate actions in your state.</p>
<h3>Apply Projected Visits to Each Payer</h3>
<p>The table below shows a simplified illustration for a practice with two physicians and one nurse practitioner projecting 20,000 visits in 2027. The figures are illustrative, not benchmarks.</p>
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th><strong>Payer Category</strong></th>
<th><strong>Share of Visits</strong></th>
<th><strong>Projected Visits</strong></th>
<th><strong>Expected Payment per Visit</strong></th>
<th><strong>Projected Revenue</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicare (traditional)</td>
<td>30%</td>
<td>6,000</td>
<td>$108</td>
<td>$648,000</td>
</tr>
<tr>
<td>Medicare Advantage</td>
<td>15%</td>
<td>3,000</td>
<td>$101</td>
<td>$303,000</td>
</tr>
<tr>
<td>Commercial</td>
<td>40%</td>
<td>8,000</td>
<td>$132</td>
<td>$1,056,000</td>
</tr>
<tr>
<td>Medicaid</td>
<td>10%</td>
<td>2,000</td>
<td>$74</td>
<td>$148,000</td>
</tr>
<tr>
<td>Self pay (net of discounts)</td>
<td>5%</td>
<td>1,000</td>
<td>$62</td>
<td>$62,000</td>
</tr>
<tr>
<td><strong>Total visit revenue</strong></td>
<td><strong>100%</strong></td>
<td><strong>20,000</strong></td>
<td></td>
<td><strong>$2,217,000</strong></td>
</tr>
</tbody>
</table>
</figure>
<p>Add ancillary and other revenue lines separately. In this example, ancillary services add $310,000, bringing projected payments to $2,527,000.</p>
<h3>Apply a Collection Realization Factor</h3>
<p>Expected payments are not collected payments. Patient balances go uncollected, some denials are never overturned, and some claims age past timely filing. Apply a realization factor based on your history. If your net collection rate has averaged 97 percent, apply it: $2,527,000 multiplied by 0.97 yields <strong>budgeted net revenue of $2,451,190</strong>.</p>
<h3>Watch the Payer Mix Risk</h3>
<p>Payer mix deserves its own line of scrutiny in 2027. MGMA reports that <a href="https://mgma.com/mgma-stat/2026-medicare-reimbursement-changes" target="_blank" rel="noopener">80 percent of medical groups say Medicare reimbursement is below their cost to deliver care</a>. Medicare Advantage plan exits and network changes take effect January 1 in many markets, which can move patients between payer categories overnight. Model at least one scenario where your Medicare Advantage share shifts by several points in either direction, and note what that does to revenue.</p>
<h2>Step 3: Model Labor Costs from the Roster Up</h2>
<p>Labor is the largest controllable expense in nearly every practice, and it is the line most often budgeted with a single percentage increase applied to last year’s total. That approach misses open positions, overtime, benefit changes, and the timing of raises. Build labor costs from the roster instead.</p>
<h3>Start with Every Position</h3>
<p>List each position with its full time equivalent (FTE) count, current rate, and annual hours. Then apply your planned 2027 increase. Industry reporting suggests <a href="https://www.physicianspractice.com/view/staff-compensation-retention-handbook-2027" target="_blank" rel="noopener">staff raise budgets for 2027 are running around 3 percent</a>, so the illustration below uses that figure.</p>
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th><strong>Position</strong></th>
<th><strong>FTE</strong></th>
<th><strong>Current Hourly Rate</strong></th>
<th><strong>2026 Annualized Wages</strong></th>
<th><strong>2027 Budget (3% increase)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Practice manager</td>
<td>1.0</td>
<td>$36.00</td>
<td>$74,880</td>
<td>$77,126</td>
</tr>
<tr>
<td>Front desk and patient access</td>
<td>3.0</td>
<td>$18.50</td>
<td>$115,440</td>
<td>$118,903</td>
</tr>
<tr>
<td>Medical assistants</td>
<td>5.0</td>
<td>$20.50</td>
<td>$213,200</td>
<td>$219,596</td>
</tr>
<tr>
<td>Billing and collections</td>
<td>2.0</td>
<td>$22.00</td>
<td>$91,520</td>
<td>$94,266</td>
</tr>
<tr>
<td>Registered nurse</td>
<td>1.0</td>
<td>$38.00</td>
<td>$79,040</td>
<td>$81,411</td>
</tr>
<tr>
<td><strong>Total support staff wages</strong></td>
<td><strong>12.0</strong></td>
<td></td>
<td><strong>$574,080</strong></td>
<td><strong>$591,302</strong></td>
</tr>
</tbody>
</table>
</figure>
<h3>Add the Benefits Load</h3>
<p>Wages are only part of labor cost. Add employer payroll taxes (Social Security, Medicare, federal and state unemployment), health insurance contributions, retirement plan matching, workers’ compensation, and paid time off if it is not already embedded in hourly wages. Practices commonly see a combined load in the range of 20 to 30 percent of wages, but your actual figure depends heavily on health plan design. Use your own numbers. In this illustration, a 24 percent load adds $141,912, bringing <strong>total support staff cost to $733,214</strong>.</p>
<p>Two benefit lines deserve special attention for 2027. Health insurance renewals often arrive in the fourth quarter with increases well above general inflation, so get your renewal quote before finalizing the budget. And retirement plan matching scales with wages, so it grows automatically with every raise.</p>
<h3>Budget the Timing of Raises</h3>
<p>If raises take effect on employee anniversary dates rather than January 1, the 2027 cost of a 3 percent increase is less than a full 3 percent, because each raise only applies for part of the year. Model raises in the month they take effect. This also makes your monthly variance review more accurate.</p>
<h3>Include Overtime, Open Positions, and Turnover</h3>
<p>Every practice has turnover, and every vacancy creates either overtime, temporary staffing, or lost capacity. Budget a realistic overtime line based on history rather than zero. If a position is open today, budget it from the month you realistically expect to fill it. And budget recruiting and training costs as their own line. Our companion piece on medical practice staff turnover and what it actually costs<strong> [EDITOR: link to Medical Practice Staff Turnover article, publishing October Week 3]</strong> walks through how to estimate the cost of each departure.</p>
<h3>Decide How to Treat Provider Compensation</h3>
<p>In a physician owned practice, physician compensation is usually the residual after all other expenses rather than an operating cost, and the budget should show the margin available for physician compensation, debt service, and capital. Employed physicians and advanced practice providers on fixed salaries belong in operating expense. Whatever treatment you choose, apply it consistently so you can compare periods and benchmarks.</p>
<h2>Step 4: Budget Operating Expenses Line by Line</h2>
<p>With labor built, move through every non labor expense line. For each one, start with the trailing 12 months, then adjust for known changes. Resist the temptation to apply a flat inflation factor across everything. Some lines are contractual and known to the dollar. Others are variable and scale with volume. Some will drop because a contract ends.</p>
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th><strong>Expense Category</strong></th>
<th><strong>What Belongs Here</strong></th>
<th><strong>How to Budget It</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Occupancy</td>
<td>Rent, common area maintenance, property tax pass throughs, utilities, janitorial</td>
<td>Use lease terms and escalation clauses; utilities from trailing 12 months</td>
</tr>
<tr>
<td>Medical supplies and drugs</td>
<td>Clinical supplies, vaccines, injectables, lab supplies</td>
<td>Budget per visit or per procedure, then multiply by projected volume</td>
</tr>
<tr>
<td>Information technology</td>
<td>EHR and practice management licensing, hosting, IT support, phones, cybersecurity</td>
<td>Use contracts; add per provider fees for new providers</td>
</tr>
<tr>
<td>Insurance</td>
<td>Malpractice, general liability, cyber, property, employment practices</td>
<td>Use renewal quotes where available</td>
</tr>
<tr>
<td>Revenue cycle</td>
<td>Clearinghouse, statement vendor, outsourced billing fees, collection agency</td>
<td>Percentage based fees scale with collections</td>
</tr>
<tr>
<td>Professional fees</td>
<td>Accounting, legal, consulting, compliance audits</td>
<td>Use engagement letters and planned projects</td>
</tr>
<tr>
<td>Marketing</td>
<td>Website, search, reputation management, patient communications</td>
<td>Tie to growth targets, not last year’s spend</td>
</tr>
<tr>
<td>Administrative</td>
<td>Office supplies, postage, bank and merchant fees, dues, licenses, CME</td>
<td>Trailing 12 months, adjusted for volume</td>
</tr>
<tr>
<td>Contingency</td>
<td>Unplanned repairs and unforeseen costs</td>
<td>A modest reserve, often 1 to 2 percent of operating expense</td>
</tr>
</tbody>
</table>
</figure>
<h3>Variable Costs Scale with Volume</h3>
<p>Medical supplies, merchant card fees, and percentage based billing fees rise and fall with activity. Budget them as a rate per unit of volume rather than as a fixed dollar amount. That way, when volume runs ahead of plan, the expense variance is expected and explainable.</p>
<h3>Look for Purchasing Leverage</h3>
<p>Supply and vendor costs are among the few lines where a practice can reduce spending without touching staffing or service. Group purchasing arrangements, such as the DoctorsManagement <a href="https://www.doctorsmanagement.com/power-buying-program/">PowerBuying Program</a>, can lower supply and vendor costs that small practices would otherwise pay at list price. Budget season is the natural time to review every recurring vendor contract.</p>
<h3>Understand Why Overhead Keeps Rising</h3>
<p>If your overhead ratio has crept up year after year despite careful management, the cause may be structural rather than operational. Our Director of Consulting explains why in <a href="https://www.doctorsmanagement.com/blog/overhead-growing-faster-than-your-revenue/">Your Overhead Is Growing Faster Than Your Revenue</a>. The budget is where that structural pressure becomes visible in numbers.</p>
<h2>Step 5: Plan Capital Expenditures Separately</h2>
<p>Capital purchases, such as equipment, technology hardware, buildouts, and furniture, should never be buried in the operating budget. They are funded differently, depreciated differently, and evaluated on different criteria.</p>
<h3>Set a Capitalization Threshold</h3>
<p>Work with your accountant to set a dollar threshold above which purchases are treated as capital. Items below the threshold are expensed in operating supplies. Items above it go on the capital budget.</p>
<h3>List and Rank Every Request</h3>
<p>Ask providers and managers for their capital requests in October, not in March after a machine fails. For each request, capture the cost, the expected useful life, the revenue it generates or protects, the cost of not buying it, and the funding approach. Then rank requests by necessity: replacement of failing equipment that supports existing revenue first, compliance and safety requirements second, growth investments third.</p>
<h3>Decide How Each Item Will Be Funded</h3>
<p>Cash, a term loan, an equipment lease, and vendor financing each affect the cash flow budget differently. Our guides on <a href="https://www.doctorsmanagement.com/blog/should-you-purchase-or-lease-equipment-in-your-medical-practice/">whether to purchase or lease equipment</a> and <a href="https://www.doctorsmanagement.com/blog/buy-versus-lease-practice-real-estate/">whether to buy or lease the practice’s real estate</a> walk through those tradeoffs. The tax treatment of capital purchases, including depreciation elections, depends on your entity structure and situation, so coordinate timing with your tax advisor. DoctorsManagement’s <a href="https://www.doctorsmanagement.com/tax-planning-and-strategies/">Tax Planning and Strategies</a> team works with practices on exactly that question during year end planning.</p>
<h2>Step 6: Convert the Annual Budget into a Monthly Cash Plan</h2>
<p>An annual budget divided by 12 is not a monthly budget. Revenue and expenses both follow seasonal patterns, and a practice that ignores them will misread every monthly variance.</p>
<h3>Phase Revenue by Month</h3>
<p>Use your two years of history to calculate each month’s share of annual volume and collections. Several patterns are common:</p>
<ul>
<li><strong>January and February</strong> often bring slower patient collections because deductibles reset, shifting more of each visit’s payment to patient responsibility.</li>
<li><strong>Summer months</strong> may see lower volume in some specialties as patients and providers travel.</li>
<li><strong>The fourth quarter</strong> often brings higher volume as patients who have met deductibles schedule care before year end.</li>
<li><strong>Collections lag visits.</strong> Payments typically trail encounters by 30 to 45 days or more depending on your days in accounts receivable, so a strong December produces cash in January and February.</li>
</ul>
<h3>Phase Expenses by Month</h3>
<p>Payroll follows the calendar of pay periods, which means some months contain three biweekly payrolls. Insurance premiums, licensing renewals, and annual software fees may be paid in lump sums. Payroll tax obligations are heavier early in the year before employees reach the Social Security wage base. Map each of these to the month it actually hits.</p>
<h3>Plan for the Low Points</h3>
<p>When monthly revenue and expense phasing are combined, the low points in cash become visible in advance. If the budget shows a tight month in February, you can arrange a line of credit, time a capital purchase, or adjust owner distributions long before the month arrives.</p>
<h2>Step 7: Pressure Test the Budget with Scenarios</h2>
<p>A single budget is a single guess. Building two additional scenarios takes little extra effort and gives leadership a far better sense of risk.</p>
<ul>
<li><strong>Base case:</strong> your most likely assumptions.</li>
<li><strong>Downside case:</strong> a realistic adverse year. For example, a provider departure, a payer mix shift toward lower paying plans, or an extended vacancy in a key role.</li>
<li><strong>Upside case:</strong> a realistic favorable year. For example, a new provider ramping faster than planned or a successful commercial rate renegotiation.</li>
</ul>
<p>Using the illustration practice, the three scenarios might look like this:</p>
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th><strong>Scenario</strong></th>
<th><strong>Net Revenue</strong></th>
<th><strong>Operating Expense</strong></th>
<th><strong>Available for Physician Compensation, Debt Service, and Capital</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Downside (revenue 6% below base, expenses 1% below)</td>
<td>$2,304,119</td>
<td>$1,437,692</td>
<td>$866,427</td>
</tr>
<tr>
<td>Base case</td>
<td>$2,451,190</td>
<td>$1,452,214</td>
<td>$998,976</td>
</tr>
<tr>
<td>Upside (revenue 4% above base, expenses 1% above)</td>
<td>$2,549,238</td>
<td>$1,466,736</td>
<td>$1,082,502</td>
</tr>
</tbody>
</table>
</figure>
<p>Notice the asymmetry. Because most practice expenses are fixed or semi fixed, a 6 percent revenue decline removes roughly 13 percent of the margin available to owners. Seeing that sensitivity in advance is often what convinces partners to protect revenue cycle performance, hold back a cash reserve, or delay a discretionary purchase.</p>
<h2>Putting It Together: A Sample Budget Summary</h2>
<p>Here is the complete base case for the illustration practice, organized the way leadership should see it each month. All figures are illustrative.</p>
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th><strong>Budget Line</strong></th>
<th><strong>2027 Budget</strong></th>
<th><strong>Percent of Net Revenue</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Net revenue</td>
<td>$2,451,190</td>
<td>100.0%</td>
</tr>
<tr>
<td>Support staff wages</td>
<td>$591,302</td>
<td>24.1%</td>
</tr>
<tr>
<td>Benefits and payroll taxes</td>
<td>$141,912</td>
<td>5.8%</td>
</tr>
<tr>
<td>Nurse practitioner compensation and benefits</td>
<td>$148,000</td>
<td>6.0%</td>
</tr>
<tr>
<td>Occupancy</td>
<td>$168,000</td>
<td>6.9%</td>
</tr>
<tr>
<td>Medical supplies and drugs</td>
<td>$98,000</td>
<td>4.0%</td>
</tr>
<tr>
<td>Information technology</td>
<td>$72,000</td>
<td>2.9%</td>
</tr>
<tr>
<td>Insurance</td>
<td>$54,000</td>
<td>2.2%</td>
</tr>
<tr>
<td>Revenue cycle</td>
<td>$38,000</td>
<td>1.6%</td>
</tr>
<tr>
<td>Professional fees</td>
<td>$36,000</td>
<td>1.5%</td>
</tr>
<tr>
<td>Marketing</td>
<td>$24,000</td>
<td>1.0%</td>
</tr>
<tr>
<td>Administrative and other</td>
<td>$61,000</td>
<td>2.5%</td>
</tr>
<tr>
<td>Contingency</td>
<td>$20,000</td>
<td>0.8%</td>
</tr>
<tr>
<td>Total operating expense</td>
<td>$1,452,214</td>
<td>59.2%</td>
</tr>
<tr>
<td><strong>Available for physician compensation, debt service, and capital</strong></td>
<td><strong>$998,976</strong></td>
<td><strong>40.8%</strong></td>
</tr>
</tbody>
</table>
</figure>
<p>The overhead ratio of 59.2 percent becomes the target the practice manages against all year. Two warnings about that number. First, overhead benchmarks vary widely by specialty, so compare only against your own specialty. Second, confirm how any benchmark you use treats provider compensation before comparing, because inconsistent treatment is the most common reason a practice misreads its own overhead.</p>
<h2>The Variance Review Cadence: Where Budgets Earn Their Value</h2>
<p>A budget that is built in November and never opened again is an expensive document. The value comes from reviewing actual results against it on a fixed schedule and acting on what the review reveals.</p>
<h3>Monthly: The Leadership Review</h3>
<p>Within 15 to 20 days of month end, leadership should review a one page comparison of actual results against budget for the month and year to date. The review should take less than an hour and focus on exceptions. Set a variance threshold so attention goes where it matters. A common approach is to investigate any line that misses budget by more than a set percentage, such as 5 percent, and also by more than a set dollar amount, so that small lines with large percentage swings do not consume the meeting.</p>
<p>For each flagged variance, the question is not simply whether the number was over or under. It is which of three causes is responsible:</p>
<ul>
<li><strong>Volume variance.</strong> The practice saw more or fewer patients than planned. Supply costs running 8 percent over budget during a month when volume ran 8 percent over budget is not a problem.</li>
<li><strong>Rate variance.</strong> The price changed. Payment per visit dropped because of a payer change, or a vendor raised prices.</li>
<li><strong>Timing variance.</strong> The expense or payment landed in a different month than planned. These usually reverse on their own.</li>
</ul>
<p>Only after classifying the variance can leadership decide whether to act.</p>
<h3>Quarterly: The Reforecast</h3>
<p>Every quarter, update the remaining months of the year with what you now know. A reforecast does not replace the original budget, which stays as the yardstick. It adds a current best estimate of where the year will land. Quarterly reforecasts are where you catch a payer mix shift, a delayed provider start, or a benefits cost increase in time to respond.</p>
<h3>Annually: The Lessons Learned Review</h3>
<p>When the year closes, compare the final results against the original budget line by line. Which assumptions were consistently wrong? Which lines were padded? Which were underestimated? Those lessons make the 2028 budget more accurate.</p>
<h3>Pair the Budget with a Small Set of KPIs</h3>
<p>Financial variance tells you what happened. Operational metrics tell you why. Track a short list of operational indicators alongside the budget each month: days in accounts receivable, net collection rate, denial rate, no show rate, and revenue per encounter. When a revenue variance appears, these metrics usually point to its cause. Our practice KPI guide<strong> [EDITOR: link to Medical Practice KPIs That Matter guide]</strong> covers each in detail. If billing is handled outside the practice, the same review discipline applies to your vendor; see <a href="https://www.doctorsmanagement.com/blog/when-your-billing-is-not-under-your-roof/">how to keep control of your revenue when billing is not under your roof</a>.</p>
<h2>Common Medical Practice Budgeting Mistakes</h2>
<ul>
<li><strong>Starting from last year’s total and adding a percentage.</strong> This carries forward every inefficiency and misses every structural change.</li>
<li><strong>Budgeting revenue from charges.</strong> Charges are not revenue. Budget payments by payer.</li>
<li><strong>Budgeting a full template.</strong> Use completed visits, not scheduled capacity.</li>
<li><strong>Ignoring the benefits load.</strong> Wages are only part of labor cost.</li>
<li><strong>Mixing capital and operating expenses.</strong> A large purchase buried in operating costs distorts every month’s variance.</li>
<li><strong>Dividing the annual budget by 12.</strong> Seasonality and payroll timing make even monthly splits misleading.</li>
<li><strong>Building the budget alone.</strong> Providers and department leads who help build the plan are far more likely to manage against it.</li>
<li><strong>Never looking at it again.</strong> A budget without a review cadence is a forecast nobody uses.</li>
</ul>
<h2>A Medical Office Budget Template Structure</h2>
<p>Whether you build in a spreadsheet or in your accounting system, a workable <strong>medical office budget template</strong> should contain these tabs or sections:</p>
<ul>
<li><strong>Assumptions.</strong> Provider schedules, visits per day, no show rate, payer mix, payment per visit by payer, raise percentage, benefits load, and inflation assumptions for each expense category. Every other tab should pull from this one.</li>
<li><strong>Volume.</strong> Monthly projected visits by provider and service line.</li>
<li><strong>Revenue.</strong> Monthly projected payments by payer, ancillary revenue, and the collection realization adjustment.</li>
<li><strong>Labor.</strong> Position by position roster with monthly wages, raise timing, benefits, overtime, and open positions.</li>
<li><strong>Operating expenses.</strong> Monthly projections by expense category, with variable costs linked to volume.</li>
<li><strong>Capital.</strong> Ranked requests, cost, funding method, and timing.</li>
<li><strong>Cash flow.</strong> Monthly phasing of collections, payroll, lump sum payments, debt service, and distributions.</li>
<li><strong>Scenarios.</strong> Base, downside, and upside summaries.</li>
<li><strong>Variance report.</strong> Monthly actual versus budget, with variance thresholds flagged automatically.</li>
</ul>
<p>Keeping assumptions on a single tab means that when a payer rate changes mid year, you update one cell and the entire budget recalculates.</p>
<h2>How DoctorsManagement Helps Practices Build and Manage Their Budget</h2>
<p>Many practices know they need a budget but lack the reporting structure, the historical data, or the time to build one. DoctorsManagement’s <a href="https://www.doctorsmanagement.com/practice-management/">Practice Management Consulting</a> and <a href="https://www.doctorsmanagement.com/accounting-services/">Accounting Services</a> teams help practices:</p>
<ul>
<li>Restructure the chart of accounts so financial statements support management decisions, not just tax filings</li>
<li>Build a payer mix revenue model and position by position labor model</li>
<li>Benchmark overhead and staffing against specialty data through a <a href="https://www.doctorsmanagement.com/practice-assessment/">Practice Assessment</a></li>
<li>Produce monthly financial reporting with budget variance analysis</li>
<li>Coordinate capital planning with year end <a href="https://www.doctorsmanagement.com/tax-planning-and-strategies/">tax planning</a></li>
<li>Identify revenue leakage through <a href="https://www.doctorsmanagement.com/revenue-cycle-management/">Revenue Cycle Management</a> review</li>
</ul>
<p>If you want to start 2027 with a budget your partners will actually use, <a href="https://www.doctorsmanagement.com/contact-us/">schedule a discovery call</a> with our team.</p>
<h2>Frequently Asked Questions</h2>
<h3>What should be included in a medical practice budget?</h3>
<p>A complete medical practice budget includes projected volume by provider and service line, revenue by payer, position by position labor costs with benefits, line item operating expenses, a separate capital budget, a monthly cash flow plan, and scenario analysis. It should also include a defined variance review process so the budget is used throughout the year.</p>
<h3>When should a medical practice start its annual budget?</h3>
<p>Start in October for a calendar year practice. That leaves time to gather data, receive health insurance renewal quotes and final Medicare fee schedule figures, involve providers in the process, and approve the budget before January 1.</p>
<h3>How do I estimate revenue for my practice budget?</h3>
<p>Project volume first, based on provider clinic days and completed visits per day. Then multiply projected visits by the expected payment per visit for each payer category, using your own historical payments rather than charges. Adjust for known rate changes and apply a collection realization factor based on your net collection rate.</p>
<h3>What is a normal overhead percentage for a medical practice?</h3>
<p>It varies significantly by specialty, ownership model, and how provider compensation is treated. Procedural specialties with heavy equipment and supply costs run structurally different overhead than cognitive specialties. MGMA data reported in September 2026 showed <a href="https://www.medicaleconomics.com/view/make-more-money-by-making-your-doctors-more-productive-mgma-expert-says" target="_blank" rel="noopener">operating costs consuming 63.4 percent of revenue in physician owned multispecialty groups and 74.9 percent in hospital owned groups</a>. Compare only against specialty specific benchmarks that treat provider compensation the same way you do.</p>
<h3>How often should a practice review its budget?</h3>
<p>Review actual results against budget monthly, reforecast the remaining year quarterly, and conduct a full lessons learned review when the year closes.</p>
<h3>Should physician compensation be included in the operating budget?</h3>
<p>In physician owned practices, physician compensation is typically treated as the residual after operating expenses rather than as an operating cost. Employed physicians and advanced practice providers on fixed salaries are usually included in operating expense. The key is consistency, so that period to period comparisons and benchmarks are meaningful.</p>
<h3>What is the difference between a budget and a forecast?</h3>
<p>A budget is the plan approved before the year begins and serves as the fixed yardstick for measuring performance. A forecast, or reforecast, is an updated estimate of where the year will end based on actual results to date. Practices should keep both: the budget for accountability and the forecast for decision making.</p>
<h3>Can a small or solo practice benefit from budgeting?</h3>
<p>Yes, and often more than a large group. A solo practice has less financial cushion, so a single unexpected vacancy, payer change, or equipment failure has a proportionally larger impact. A simple budget with monthly review gives a small practice early warning when it needs it most.</p>
<h2>References</h2>
<ul>
<li>MGMA Stat: <a href="https://www.mgma.com/mgma-stat/operating-costs-keep-climbing-for-medical-practices-in-2026" target="_blank" rel="noopener">Operating costs keep climbing for medical practices in 2026</a></li>
<li>MGMA Stat: <a href="https://www.mgma.com/mgma-stat/medical-practice-operating-costs-are-still-rising-in-2025-heres-how-to-control-them" target="_blank" rel="noopener">Medical practice operating costs are still rising in 2025</a></li>
<li>MGMA Stat: <a href="https://www.mgma.com/mgma-stat/revenue-growth-narrows-as-costs-climb-2026-squeeze" target="_blank" rel="noopener">Revenue growth narrows as costs climb: the 2026 squeeze</a></li>
<li>MGMA Stat: <a href="https://mgma.com/mgma-stat/2026-medicare-reimbursement-changes" target="_blank" rel="noopener">2026 Medicare reimbursement changes</a></li>
<li>Centers for Medicare and Medicaid Services: <a href="https://www.cms.gov/medicare/payment/fee-schedules/physician" target="_blank" rel="noopener">Physician Fee Schedule</a></li>
<li>Physicians Practice: <a href="https://www.physicianspractice.com/view/staff-compensation-retention-handbook-2027" target="_blank" rel="noopener">Staff Compensation and Retention Handbook 2027</a></li>
<li>Medical Economics: <a href="https://www.medicaleconomics.com/view/make-more-money-by-making-your-doctors-more-productive-mgma-expert-says" target="_blank" rel="noopener">MGMA expert on physician productivity and operating costs</a></li>
</ul>
<p>The post <a href="https://www.doctorsmanagement.com/blog/how-to-create-a-medical-practice-budget-2027/">How to Create a Medical Practice Budget for 2027: A Line-by-Line Planning Framework</a> appeared first on <a href="https://www.doctorsmanagement.com/">DoctorsManagement</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Construction Starts on Farmhouse&#45;Inspired Livingston Hospital Modernization Project</title>
<link>https://edusehat.com/en/construction-starts-on-farmhouse-inspired-livingston-hospital-modernization-project</link>
<guid>https://edusehat.com/en/construction-starts-on-farmhouse-inspired-livingston-hospital-modernization-project</guid>
<description><![CDATA[ The Livingston Hospital modernization project in Salem, Ky., aims to create a welcoming, home-like environment while expanding and upgrading healthcare services for the rural community. | Photo Credit: Wold JJCA  By Susan Haigh  A $50.4 million modernization project that’s underway at Livingston Hospital and Healthcare Services in Salem, Ky., aims to bring modern medical facilities...
The post Construction Starts on Farmhouse-Inspired Livingston Hospital Modernization Project appeared first on HCO News.
The post Construction Starts on Farmhouse-Inspired Livingston Hospital Modernization Project appeared first on HCO News. ]]></description>
<enclosure url="https://hconews.com/wp-content/uploads/2026/11/HCO-News.Livingston-768x432.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 05:05:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Construction, Starts, Farmhouse-Inspired, Livingston, Hospital, Modernization, Project</media:keywords>
<content:encoded><![CDATA[<h5><span class="TextRun SCXW251731117 BCX0" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class="NormalTextRun SCXW251731117 BCX0">The Livingston Hospital modernization project in Salem, Ky., aims to create a welcoming, home-like environment while expanding and upgrading healthcare services for the rural community. | Photo Credit: Wold JJCA</span></span><span class="EOP Selected SCXW251731117 BCX0" data-ccp-props="{}"> </span></h5>
<p><em>By Susan Haigh </em></p>
<p><span data-contrast="auto">A $50.4 million modernization project that’s underway at Livingston Hospital and Healthcare Services in Salem, Ky., aims to bring modern medical facilities to a rural community while creating an environment that feels more like home than a traditional hospital.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p>
<p><span data-contrast="auto">Designed by Wold JJCA, the project includes approximately 60,500 square feet of new construction and 6,000 square feet of renovations at the 25-bed critical access hospital and Level IV Trauma Center. Construction began in late September, marked by a beam-signing ceremony at the project site.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p>
<p><span data-contrast="auto">The design draws inspiration from the region, incorporating elements of a modern farmhouse, including some gabled rooflines, to give the facility a more welcoming, less clinical or commercial appearance.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p>
<blockquote><p><span data-contrast="auto">“It did definitely take that flair from the community and not wanting to be so institutional,” said Stephanie Pielich, Healthcare Practice Leader at Wold. The existing brick building dates to the 1950s and has been added onto several times.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p></blockquote>
<p><span data-contrast="auto">That philosophy extends to the interior, where designers sought to create a home-like atmosphere that puts patients at ease.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p>
<p><span data-contrast="auto">Pielich said rural hospitals must be mindful of the people they serve, including “the farmer that’s got mud all over his boots” who arrives directly from working on the farm.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p>
<blockquote><p><span data-contrast="auto">“We want them to feel like they’re in a nice and clean space and it … can serve their needs, but we also don’t want to make it too nice where they feel like they don’t belong there and can’t get care,” she said.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p></blockquote>
<p><span data-contrast="auto">“You don’t want to be in your grandmother’s formal living room where you can’t touch anything,” Pielich added.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p>
<p><span data-contrast="auto">The main waiting area of the renovated hospital will feature a chimney-like architectural element with artwork to remind patients and families of a fireplace in a house. Softer surfaces and comfortable seating will be included instead of traditional rows of institutional chairs.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p>
<p><span data-contrast="auto">Beyond aesthetics, the modernization addresses operational challenges that often face smaller rural hospitals, where staffing and financial resources are often limited.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p>
<blockquote><p><span data-contrast="auto">Pielich said the design emphasizes flexible spaces that can accommodate multiple functions, along with layouts that make it easier for staff to monitor different areas and to access the medical supplies they might need.</span> <span data-contrast="auto">“They don’t have the time to deal with going to find things,” she said.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p></blockquote>
<p><span data-contrast="auto">Hospital staff contributed to the design work by reviewing cardboard mock-ups of key clinical rooms to help determine the placement of electrical outlets and other features.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p>
<p><span data-contrast="auto">The new addition will house an emergency department, patient nursing unit, imaging, surgery, central sterile processing and recovery areas. Renovated portions of the existing hospital will accommodate outpatient oncology services and an expanded pharmacy.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p>
<p><span data-contrast="auto">The project also will replace outdated semiprivate patient rooms with private accommodations designed to provide more space for patients and their families. The hospital will retain its 25-bed capacity.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p>
<p><span data-contrast="auto">Hospital officials, staff, board members and local schoolchildren participated in a beam-signing ceremony in late September to mark a construction milestone. Project partners include Deaconess Health System and Doster Construction Co.</span><span data-ccp-props='{"134233117":false,"134233118":false,"335559738":240,"335559739":240}'> </span></p>
<p><span data-contrast="auto">Pielich said construction of the facility is expected to be completed in fall 2027.</span></p>
<p>The post <a rel="nofollow" href="https://hconews.com/2026/11/02/construction-starts-on-farmhouse-inspired-livingston-hospital-modernization-project/">Construction Starts on Farmhouse-Inspired Livingston Hospital Modernization Project</a> appeared first on <a rel="nofollow" href="https://hconews.com/">HCO News</a>.</p>
<p>The post <a href="https://hconews.com/2026/11/02/construction-starts-on-farmhouse-inspired-livingston-hospital-modernization-project/">Construction Starts on Farmhouse-Inspired Livingston Hospital Modernization Project</a> appeared first on <a href="https://hconews.com/">HCO News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PACE panel lays out patient input possibilities in PDUFA VIII</title>
<link>https://edusehat.com/en/pace-panel-lays-out-patient-input-possibilities-in-pdufa-viii</link>
<guid>https://edusehat.com/en/pace-panel-lays-out-patient-input-possibilities-in-pdufa-viii</guid>
<description><![CDATA[ The law guiding U.S. drug approval was created to meet the demands of patient advocates, and the patient community still shapes the process. Stakeholders […]
The post PACE panel lays out patient input possibilities in PDUFA VIII appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/960px-US_Food_and_Drug_Administration_lapel_pin.png" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 04:30:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PACE, panel, lays, out, patient, input, possibilities, PDUFA, VIII</media:keywords>
<content:encoded><![CDATA[<p><span>The law guiding U.S. drug approval was created to meet the demands of patient advocates, and the patient community still shapes the process.</span></p>
<p><span>Stakeholders discussed their latest opportunity to impact the Prescription Drug User Fee Act (PDUFA), which regulates America’s gold-standard drug approval process, at BIO’s Patient Advocacy Changemakers Event (PACE) in Washington, DC, on Oct. 22-23.</span></p>
<p><span>PDUFA has roots in the 1980s, when ACT UP activists fought for AIDS patients, according to Steve Berman, VP for Science and Regulatory Affairs Strategy at the Biotechnology Innovation Organization (BIO), who led the PDUFA discussion at PACE.</span></p>
<p><span>“At that time, drug development in the U.S. was very different than it is today. Seventy percent of all new medicines were available outside the U.S. before they were available here,” and drug review often took three years, Berman said. “At the height of the AIDS crisis, patients couldn’t get drugs to save their lives. Patient advocates said this was unacceptable.”</span></p>
<p><span>Congress responded with PDUFA. First passed in 1992 and reauthorized every five years, PDUFA requires drug makers to pay fees to help fund the Food and Drug Administration (FDA). In return, FDA is required to provide a professional, efficient approval process. Before the act, FDA drug review averaged close to 29 months, and today the average is down to 10 months,</span><a href="https://www.pharmacytimes.com/view/understanding-the-fda-approval-process-and-pdufa-dates"> <span>according to a report</span></a><span>.</span></p>
<p><span>“It is absolutely critical to have a functional FDA, to have a well-funded FDA, to have an FDA that has processes and the infrastructure allowing for more regulatory certainty,” said panelist Adora Ndu, Chief Regulatory Officer and EVP of Portfolio Strategy at BridgeBio Pharma. Along with Berman, Ndu represented the biotech industry during recent negotiations with FDA to create</span><a href="https://bio.news/federal-policy/pdufa-letter-stresses-stability-transparency-maturity-says-bio-negotiator/"> <span>a proposal for the contents of PDUFA VIII</span></a><span>.</span></p>
<h2>Why PDUFA reauthorization matters to patients</h2>
<p><span>The reauthorization process, which provides an excellent opportunity for patient input into FDA operations, is currently underway.</span></p>
<p><span>The process began with a public meeting, including many speakers from the patient advocacy community. This transitioned to the biopharma industry, represented by BIO and others, negotiating with FDA officials about the fees industry will pay and the services and initiatives the agency will provide in return. The six-month-long negotiations ended in August with the</span><a href="https://bio.news/federal-policy/pdufa-letter-stresses-stability-transparency-maturity-says-bio-negotiator/"> <span>PDUFA VIII commitment letter</span></a><span>.</span></p>
<p><span>Throughout negotiations, FDA had monthly check-ins with stakeholder groups consisting of 50-60 patient advocates. That input was crucial, according to Ndu.</span></p>
<p><span>“[FDA] would pull from the stakeholder meetings to say, ‘This is what we’re hearing, how does it inform the direction that we should take?’ ” she said.</span></p>
<p><span>Patient input continues as Congress uses the commitment letter’s proposals to create PDUFA legislation, which must be reauthorized by September 2027.</span></p>
<p><span>“Patient advocacy groups play an important role in helping educate Congress members about the importance of user fees overall and the details of this particular agreement, and also in shaping any policies that may come along as riders,” said Berman.</span></p>
<p><span>As panelist Jeff Allen, President and CEO of Friends of Cancer Research, told the session at PACE, PDUFA updates are essential.</span></p>
<p><span>“Science and technology are evolving rapidly,” Allen said. “This five-year process gives us all the opportunity to check in and make sure policies are in place to keep pace with the science.”</span></p>
<p><span>Along with adding necessary updates, Congress members often use the “must-pass” nature of the act to add riders that are not central to PDUFA’s mission. As Congress increasingly delays “must-pass” legislation, that strategy is risky, Allen said.</span></p>
<p><span>“I’m sure we will see some good ideas from various policy proposals that could appropriately ride along this PDUFA package,” Allen said. “But I think we have to keep this relatively narrow, in order to make sure that we don’t inadvertently derail an important process.”</span></p>
<h2>Increasing patient voice in drug development<b> </b></h2>
<p><span>The proposal in the commitment letter aimed at achieving the basic, but challenging, goal of ensuring FDA operates efficiently, according to Ndu. This resulted in a PDUFA VIII commitment letter that contains improvements to increase patient participation, she said.</span></p>
<p><span>Ndu highlighted some provisions benefiting the rare disease community, including continuing the successful</span><a href="https://www.fda.gov/industry/fda-rare-disease-innovation-hub/rare-disease-innovation-science-and-exploration-rise-workshop-series"> <span>Rare Disease Innovation, Science, and Exploration (RISE) workshop series</span></a><span>. The PDUFA VIII commitment letter envisions 10 RISE workshops.</span></p>
<p><span>RISE workshops “enable a discussion around the barriers in drug development, bringing all the stakeholders together to ensure conversation can happen and can actually translate into enabling more treatments,” Ndu said.</span></p>
<p><span>The entire patient community can benefit from “continuation of patient-focused drug development activities from prior PDUFAs,” proposed in PDUFA VIII, according to Berman.</span></p>
<p><span>“FDA would be required to hold multiple public meetings talking about how they consider patient-focused drug development and patient preferences in their regulatory decision making,” he said.</span></p>
<p><span>Ideally, FDA should include data from patient experiences in their drug labelling, and this is a step in that direction, Ndu said, noting that “FDA will share some of the case studies of how they have considered patient experience data.”</span></p>
<p><span>Berman maintained that PDUFA VIII’s improved patient engagement opportunities will result in better drug development.</span></p>
<p><span>“One of the reasons why drug development is so slow and expensive is that science is challenging,” he explained. “And the best way to address scientific challenges is as a community.”</span></p>
<p>The post <a href="https://bio.news/federal-policy/pace-panel-lays-out-patient-input-possibilities-in-pdufa-viii/">PACE panel lays out patient input possibilities in PDUFA VIII</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Inflammatory Process Identified as Link Between Pulmonary Hypertension and Cognitive Decline</title>
<link>https://edusehat.com/en/inflammatory-process-identified-as-link-between-pulmonary-hypertension-and-cognitive-decline</link>
<guid>https://edusehat.com/en/inflammatory-process-identified-as-link-between-pulmonary-hypertension-and-cognitive-decline</guid>
<description><![CDATA[ A study investigating the observed connection between pulmonary hypertension and cognitive decline symptoms has linked brain abnormalities in pulmonary hypertension to the same inflammatory processes that drive disease in the lungs and heart. 
The post Inflammatory Process Identified as Link Between Pulmonary Hypertension and Cognitive Decline appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/low-res-1-e1793639966551.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 04:25:18 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Inflammatory, Process, Identified, Link, Between, Pulmonary, Hypertension, and, Cognitive, Decline</media:keywords>
<content:encoded><![CDATA[<p>A study by University of Pittsburgh and UPMC researcher-clinicians has uncovered why many pulmonary hypertension (PH) patients report symptoms of cognitive decline.</p>
<p>The team carried out a multimodal investigation involving brain MRI studies, blood-based molecular profiling, and functional studies in mouse models, and linked specific brain abnormalities in pulmonary hypertension to the same inflammatory processes that drive the disease in the lungs and heart. The findings suggest that cognitive decline may be present in other vascular and inflammatory conditions beyond pulmonary hypertension. The results also point to neural targets that may be relevant for future diagnostic, prognostic, and therapeutic approaches.</p>
<p>“Patients often assume memory issues or trouble concentrating are unrelated to their pulmonary hypertension,” said research lead Stephen Chan, MD, PhD, Vitalant Chair in Vascular Medicine and director of the Vascular Medicine Institute and Center for Pulmonary Vascular Biology and Medicine at the Pitt School of Medicine and UPMC. “Our findings suggest those symptoms are a central part of the disease process and deserve attention.”</p>
<p>Chan is senior author of the researchers’ published paper in <em>Journal of Clinical Investigation</em>, titled “<a href="https://doi.org/10.1172/JCI195110" target="_blank" rel="noopener">Cerebellar and frontal lobe alterations in pulmonary hypertension implicate an inflammatory lung vascular/brain axis</a>.”</p>
<p>Millions of people are affected by pulmonary hypertension, which causes high blood pressure in the blood vessels of the lungs. Common symptoms include shortness of breath, chest pain, and feeling lightheaded. More recently scientists have linked pulmonary hypertension with cognitive issues such as impaired executive function and memory problems. “Cognitive impairment is increasingly recognized in pulmonary hypertension (PH), a disease traditionally viewed as limited to the heart and lungs,” the authors wrote. “Given that inflammation is shared by PH and neurodegenerative diseases, we investigated its role in driving brain and cognitive deficits in PH.”</p>
<p>Recent research by Chan identified a genetic variant in a gene called NCOA7, which produces a protein of the same name. In a quarter of pulmonary hypertension patients, this variant drives inflammatory responses and worsens the odds of survival. Chan hypothesized that the same variant might be connected to brain inflammation that leads to cognitive impairment in people with pulmonary hypertension.</p>
<p>To test that theory, Chan and colleagues used brain MRI scans and blood tests to look for brain changes that were unique to pulmonary hypertension. They first compared the brain scans of people with pulmonary hypertension against those without, using data from a large public health database and a smaller group of UPMC patients to test and confirm their hypothesis.</p>
<p>Patients with pulmonary hypertension in both test groups had a consistent and substantial loss of brain tissue and weakened communication between two brain regions involved in memory, attention and planning—the cerebellum, at the base of the brain, and the frontal lobe, just behind the forehead. Notably, the same brain changes were absent in people with other heart, lung, and psychiatric conditions. “Using structural and functional MRI data from UK Biobank (N = 248 PH) and a prospective validation cohort, we identified reduced cerebellar white matter volume, thinner frontal gyri, and weakened cerebellar-frontal connectivity in patients with PH but not in other heart or lung diseases,” the team reported. These changes were accompanied by worsened executive function and processing speed.”</p>
<p>The brain differences could not be explained by low blood oxygen, poor heart function, or the medications used to treat the disease—evidence that the changes are specific to pulmonary hypertension, rather than a side effect of the disease’s effects on the heart and lungs.</p>
<p>By analyzing genetic data from both groups of patients and conducting additional laboratory studies, the team found that the NCOA7 variant already linked to blood vessel inflammation in pulmonary hypertension is also connected to inflammation in the cerebellum of these patients.</p>
<p>Examining cerebellum tissue from patients and mice with pulmonary hypertension, they saw signs that brain immune cells—microglia—had become overactive, and evidence that neurons were changing in response. Mice that both developed the disease and lacked the NCOA7 gene had more severe cerebellar damage than mice with pulmonary hypertension alone, establishing that the gene plays a causal role in regulating brain inflammation in this disease. “Postmortem analysis and PH mouse models showed cerebellar microglial activation and structural deficits worsened by NCOA7 deficiency,” the investigators wrote in summary. “Collectively, these findings support PH-associated cerebellar–frontal brain deficiencies linked to chronic neuroinflammation and NCOA7 dysfunction.”</p>
<p>Chan suspects that this mechanism is active in other diseases beyond pulmonary hypertension. “I believe that NCOA7 deficiency may underlie a spectrum of inflammatory conditions—including those that may contribute to dementia and aging,” Chan said. “If so, these findings could introduce new diagnostic and therapeutic avenues for preserving brain function in a much broader group of people.” The authors added: “From a translational perspective, the association of inflammatory plasma biomarkers with structural and functional brain alterations may inform new diagnostic and prognostic strategies … Our findings also open avenues for testing whether PH-associated neuroinflammatory changes are therapeutically reversible.”</p>
<p>Current guidelines for managing pulmonary hypertension do not include cognitive screening, and no biological marker exists to predict or track how much the disease affects the brain. This study points to a potential marker and identifies inflammation as a potential therapeutic target for preserving brain function and quality of life.</p>
<p>“This changes the way we look at a disease like pulmonary hypertension,” said Chan. “In medicine, we typically treat the symptoms of one organ system; but the reality is that our bodies are very complex, and disease processes may be affecting multiple parts of the body in a variety of ways.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/inflammatory-process-identified-as-link-between-pulmonary-hypertension-and-cognitive-decline/">Inflammatory Process Identified as Link Between Pulmonary Hypertension and Cognitive Decline</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA Sets May 1 PDUFA Action Date for uniQure’s Huntington’s Disease Gene Therapy</title>
<link>https://edusehat.com/en/fda-sets-may-1-pdufa-action-date-for-uniqures-huntingtons-disease-gene-therapy</link>
<guid>https://edusehat.com/en/fda-sets-may-1-pdufa-action-date-for-uniqures-huntingtons-disease-gene-therapy</guid>
<description><![CDATA[ uniQure has aligned with the FDA on what the company calls key elements of the confirmatory study design: The study is being designed as a randomized, standard-of-care trial enrolling approximately 200 patients in a 2:1 ratio of ifezuntirgene inilparvovec to standard of care, with Total Functional Capacity (TFC) at 36 months serving as the primary endpoint. 
The post FDA Sets May 1 PDUFA Action Date for uniQure’s Huntington’s Disease Gene Therapy appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/uniQURE-EXTERIOR_1583081674129-EDITED-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 04:25:16 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, Sets, May, PDUFA, Action, Date, for, uniQure’s, Huntington’s, Disease, Gene, Therapy</media:keywords>
<content:encoded><![CDATA[<p>The FDA has set a May 1 target action date under the Prescription Drug User Fee Act (PDUFA) for uniQure’s Huntington’s disease gene therapy candidate ifezuntirgene inilparvovec—which, if approved, would be the first treatment shown to modify the fatal, inherited neurodegenerative disorder—after accepting the company’s Biologics License Application (BLA) under Priority Review.</p>
<p>The action by the FDA, announced Monday, marks a complete reversal of agency opposition that surfaced last year and hardened earlier this year.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The FDA did caution uniQure, however, that it was tentatively planning to discuss the BLA at a future advisory committee meeting, most likely the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC). No date for such a meeting had been set at deadline, though uniQure said it was told it would be notified by the agency when that happens.</p>
<p>uniQure submitted its BLA to the FDA in September, as well as a Marketing Authorization Application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).</p>
<p>“The FDA’s acceptance of our BLA for review marks an important milestone for the Huntington’s disease community, which has waited generations for a treatment that changes the course of this devastating disease,” uniQure CEO Matt Kapusta said in a statement.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>One analyst offered another reason for the significance of the FDA action: “We see the acceptance of the BLA as an important milestone for ifezuntirgene inilparvovec as it further removes regulatory risk,” Lachlan Hanbury-Brown, research analyst, healthcare with William Blair, wrote in a research note.</p>
<h4><strong>Investor caution</strong></h4>
<p>However, investors appeared more cautious, as uniQure shares dipped 3% to $24.03 as of 10:56 am. ET from $24.83 at Friday’s close despite the positive news. Chatter on investor websites suggested several possible reasons why investors were reluctant to buy uniQure stock:</p>
<ul>
<li>The PDUFA target action date was later than expected.</li>
<li>Four-year data for the gene therapy showed lower slowing of disease progression than earlier three-year data.</li>
<li>Continuing concerns about risk in the ongoing trials.</li>
</ul>
<p>Ifezuntirgene inilparvovec uses the company’s gene-silencing miQURE<sup>®</sup> platform and incorporates a microRNA designed to silence the huntingtin gene and the potentially highly toxic exon 1 protein fragment. Patients receive a single administration through targeted, MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen).</p>
<p>uniQure has aligned with the FDA on what the company calls key elements of the confirmatory study design: The study is being designed as a randomized, standard-of-care trial enrolling approximately 200 patients in a 2:1 ratio of ifezuntirgene inilparvovec to standard of care, with Total Functional Capacity (TFC) at 36 months serving as the primary endpoint.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>uniQure said it plans to begin patient screening in the United States by the end of 2026.</p>
<p>In addition to Priority Review, uniQure’s BLA for ifezuntirgene inilparvovec has been granted the FDA’s Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), and Fast Track designations.</p>
<p>The FDA reversal follows a change in leadership at the Center for Biologics Evaluation and Research (CBER) as Vinayak (Vinay) Prasad, MD, who opposed uniQure’s BLA, resigned for the second time in March, effective April 30. Prasad relinquished his roles as CBER director and FDA chief medical and scientific officer under Martin A. Makary, MD, who resigned effective May 12.</p>
<h4><strong>FDA stunner</strong></h4>
<p>Under Prasad, the FDA <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fgenome-editing%2Funiqure-staggers-as-fda-questions-data-for-huntingtons-gene-therapy-candidate%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C7d6a4029d2a441dd46ed08de7c76c9f6%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639085047353474402%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=zbb16UnyYtcIzvKJGmCgGhleaCrz7ncpqJsnuw8swco%3D&reserved=0">stunned uniQure in November 2025</a> when it told the company that what it had called “game-changing” data in September, showing <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fgenome-editing%2Fgene-therapy-significantly-slows-huntington-disease-progression%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C7d6a4029d2a441dd46ed08de7c76c9f6%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639085047353487080%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=F%2FolhGKO8AE54WlV%2Fc6TJjlvmFLZggg9Q1UPJRElcU4%3D&reserved=0">significant slowing of HD progression</a> in patients treated with the gene therapy candidate, may not be enough to secure FDA approval. The data prompted one analyst to predict ifezuntirgene inilparvovec (then known as AMT-130) would <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Ftranslational-medicine%2Fstockwatch-uniqure-shares-reach-five-year-high-on-game-changing-huntingtons-data%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C7d6a4029d2a441dd46ed08de7c76c9f6%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639085047353516935%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=7dQJW8yAGUGNEDXNL%2FkI%2FRDGud7CWET2H02EuVJtU7E%3D&reserved=0">generate $4 billion peak worldwide annual sales by 2032</a>, though a consensus of other analysts forecasted just $1.7 billion in peak sales.</p>
<p>Key among uniQure’s Phase I/II results was the statistically significant 75% slowing of disease progression as measured by the composite Unified Huntington’s Disease Rating Scale (cUHDRS) at 36 months in patients treated with the high dose of 6×10<sup>13</sup> gc/subject of ifezuntirgene inilparvovec, compared to a propensity score-matched external control derived from the Enroll-HD natural history database. That more than met the primary endpoint of the Phase I/II study, which consisted of trials in the United States (<a href="https://clinicaltrials.gov/study/NCT04120493">NCT04120493</a>) and Europe (<a href="https://clinicaltrials.gov/study/NCT05243017">NCT05243017</a>).</p>
<p>The FDA stepped up its public criticism against uniQure on March 2, when it issued what the company termed a “strong” recommendation to conduct a prospective, randomized, double-blind, sham surgery-controlled study to support a future marketing application for AMT-130. The FDA concluded that data from uniQure’s earlier Phase I/II study, which compared ifezuntirgene inilparvovec to an external control, were not sufficient to provide the primary evidence of effectiveness needed for the agency to approve the gene therapy candidate.</p>
<p>UniQure stock responded to the FDA jawboning by plummeting 42% on March 2 and 3, then flattening in the middle of that week, before rebounding 58% by March 6. The <a href="https://www.genengnews.com/topics/genome-editing/stockwatch-under-fire-from-fda-uniqure-stock-roller-coasters/">stock gyrations followed Prasad announcing his resignation plans</a>.</p>
<p>In June, with Karim Mikhail then serving as acting CBER director, the FDA reversed itself and <a href="https://www.genengnews.com/topics/translational-medicine/stockwatch-positive-phase-iii-data-sells-investors-on-intellia/">accepted the three-year analysis</a> from the two Phase I/II trials as the primary basis of a Biologics License Application (BLA) for accelerated approval of ifezuntirgene inilparvovec. Mikhail has since been appointed permanent CBER director.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<h4><strong>Four-year data</strong></h4>
<p>Last month, uniQure reported positive four-year data for ifezuntirgene inilparvovec showing a continued slowing of disease progression based on the two ongoing Phase I/II studies. At 48 months TFC, the primary measure of uniQure’s confirmatory study, showed consistent slowing of functional decline, with absolute treatment benefit maintained in Month 48. Differences seen between the high and low doses on both composite cUHDRS and TFC were consistent with a dose-dependent treatment effect, uniQure said.</p>
<p>The primary endpoint of cUHDRS showed a 44% slowing of disease progression (non-significant p=0.144) while TFC showed a 61% slowing of disease progression (nominal p=0.008), according to uniQure.</p>
<p>“While efficacy in the high-dose group as measured by the cUHDRS softened from year 3 to year 4 and thus could point to a weakening of treatment effect, we see concerns from this endpoint as overdone given several caveats in the analysis, and the fact that it is not the primary endpoint of the confirmatory study or the basis for the current BLA,” Hanbury-Brown commented.</p>
<p>“We believe the additional 48-month results from the ongoing Phase I/II study of AMT-130 in HD continue to show a positive clinical benefit, especially around the more important regulatory endpoint of TFC, which increased separation from the external control group from 3 to 4 years following treatment,” Hanbury-Brown added.</p>
<p>In its announcement Monday, uniQure said the two trials have dosed 51 patients with ifezuntirgene inilparvovec. The U.S. randomized study enrolled 26 patients, of which six received a low dose of ifezuntirgene inilparvovec, 10 a high dose, and 10 a sham procedure. Four control patients subsequently crossed over to treatment after approximately 12 months.</p>
<p>The European open-label study enrolled 13 patients—six receiving low-dose ifezuntirgene inilparvovec and seven, the high dose. A third cohort of 12 patients explored both doses in combination with immunosuppression, while and a fourth cohort of six U.S. patients is evaluating the high dose in patients with lower striatal volumes compared to those enrolled in previous cohorts.</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/fda-sets-may-1-pdufa-action-date-for-uniqures-huntingtons-disease-gene-therapy/">FDA Sets May 1 PDUFA Action Date for uniQure’s Huntington’s Disease Gene Therapy</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Tooth whitening scammers jailed for £8.5 million tax theft</title>
<link>https://edusehat.com/en/tooth-whitening-scammers-jailed-for-85-million-tax-theft</link>
<guid>https://edusehat.com/en/tooth-whitening-scammers-jailed-for-85-million-tax-theft</guid>
<description><![CDATA[ Two men from Merseyside who sold dangerous tooth whitening products and pocketed the VAT have been sentenced to nine years in prison. Ian Barnes, 53, and Alastair Ramage, 44, imported and sold tooth whitening products containing a dangerously high level of hydrogen peroxide through companies based in Seychelles and Hong Kong. Though they charged VAT… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/tooth_whitening_scammers.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 01:15:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Tooth, whitening, scammers, jailed, for, £8.5, million, tax, theft</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Two men from Merseyside who sold dangerous tooth whitening products and pocketed the VAT have been sentenced to nine years in prison.</strong></p>



<p>Ian Barnes, 53, and Alastair Ramage, 44, imported and sold tooth whitening products containing a dangerously high level of hydrogen peroxide through companies based in Seychelles and Hong Kong.</p>



<p>Though they charged VAT to their customers, the tax revenue was never handed over to HM Revenue and Customs (HMRC). The stolen money was spent on luxuries such as £16,000 on a limited-edition baseball cap, more than £500 on an ice cream sundae featured in the film <em>Home Alone</em> and over £100,000 with a single holiday company.</p>



<p>The pair also had plans to build neighbouring holiday homes in Florida with connecting tunnels and matching tooth-shaped swimming pools.</p>



<p>WhatsApp messages sent between Barnes and Ramage revealed that they were aware of the harm the products were causing to buyers. In one exchange, Barnes said: ‘They said they used it for 30 minutes and its taken the enamel off their teeth dentist said they need new teeth.’</p>



<h2 class="wp-block-heading">‘Tax fraud trumps patient safety’</h2>



<p>The British Dental Association (BDA) expressed concern that it took tax fraud for the offenders to be jailed, despite the long-standing patient safety risk posed by the whitening products sold. </p>



<p>BDA chair Eddie Crouch said: ‘When it comes to cracking down on criminals, it appears tax fraud trumps patient safety. For far too long we’ve seen illegal tooth whitening companies operating in plain sight online, peddling products that hurt patients. Watchdogs and regulators cannot leave this to HMRC to achieve the right result.’</p>



<p>Zoe Gascoyne, director of HMRC’s Fraud Investigation Service, said: ‘Barnes and Ramage knew they were stealing from taxpayers and selling dangerous products at the same time. Their messages show complete disregard for the hard-working majority who pay the taxes that fund our public services.’</p>



<p>The HMRC investigation found that more than £8.5 million was laundered through 118 bank accounts, credit cards and cryptocurrency trading platforms.</p>



<p>Both Barnes and Ramage pleaded guilty to VAT fraud in February 2026. On 30 October, they were jailed for a total of eight years and 10 months at Liverpool Crown Court.</p>



<p><em><a href="https://sso.dentistry.co.uk/" target="_blank" rel="noreferrer noopener">Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</a></em></p>]]> </content:encoded>
</item>

<item>
<title>Dentist erased after High Court overturns sanction for discriminatory misconduct</title>
<link>https://edusehat.com/en/dentist-erased-after-high-court-overturns-sanction-for-discriminatory-misconduct</link>
<guid>https://edusehat.com/en/dentist-erased-after-high-court-overturns-sanction-for-discriminatory-misconduct</guid>
<description><![CDATA[ Warning: This story contains comments of a racist nature and references to sexual violence A dentist has been erased from the GDC register for racist, sexist and homophobic discrimination after a protracted case involving multiple hearings and a High Court appeal. A newly constituted Professional Conduct Committee (PCC) imposed erasure at a hearing on 26… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/hearing.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 01:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Dentist, erased, after, High, Court, overturns, sanction, for, discriminatory, misconduct</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong><em>Warning: This story contains comments of a racist nature and references to sexual violence</em></strong></p>



<p><strong>A dentist has been erased from the GDC register for racist, sexist and homophobic discrimination after a protracted case involving multiple hearings and a High Court appeal.</strong></p>



<p>A newly constituted Professional Conduct Committee (PCC) imposed erasure at a hearing on 26 October, alongside immediate suspension while the outcome remains subject to appeal.</p>



<p>In July 2025, the dentist in question <a href="https://dentistry.co.uk/2026/07/03/high-court-quashes-dentist-suspension/">was suspended for six months by a Professional Conduct Committee (PCC)</a> for repeatedly behaving inappropriately to colleagues and patients. </p>



<p>The original PCC report detailed testimony from practice staff who reported hearing comments such as ‘I have my rape eye on you’, and being told about a ranking system for women the dentist wanted to ‘shag’. They said they were asked in detail about their sex lives and threatened with ‘dick pictures’, with one colleague disclosing that the dentist stroked their arms inappropriately on multiple occasions.</p>



<p>The clinician was also found to have commented on the bodies of female patients, including that it was a ‘shame’ that a patient had ‘a pretty face but such a small chest’. </p>



<p>More generalised comments that women ‘belong in the kitchen’, as well as racist and homophobic remarks, were also noted. For example, the dentist was quoted saying that they would ‘pour acid’ on their own daughter if she brought home a black man. They also told a colleague: ‘I hate gays, but I like you.’</p>



<p>However, the General Dental Council (GDC) then supported a Professional Standards Authority (PSA) appeal arguing that the sanction was insufficient and that they should have been erased.</p>



<h2 class="wp-block-heading">Why was the dentist not erased originally?</h2>



<p>The PCC had imposed a six-month suspension after finding that erasure would be disproportionate. This decision was informed by previous good character, some evidence of reflection and remediation, and developing insight. </p>



<p>However, it also found that the registrant’s insight and remediation remained limited, and did not treat some comments as sexual in nature. Discussion of patients’ bodies, for example, was seen to be inappropriate but with ‘nothing to suggest that it was made in a sexual manner’.</p>



<p>At a review hearing in February 2026, a separate PCC found that the registrant’s fitness to practise remained impaired and that it could not be satisfied that a risk of repetition was highly unlikely. However, it revoked the suspension and imposed conditions for 18 months, allowing the registrant to return to practice under restrictions including workplace reporting and notifying the GDC of any disciplinary action. </p>



<p>In the subsequent High Court hearing in June 2026, Justice Sweeting found that the original committee had materially underestimated the seriousness of the dentist’s misconduct and failed to grapple with the cumulative gravity of the conduct it had found proved.</p>



<p>Although the High Court had the power to substitute erasure, Justice Sweeting said sanction in a case of this kind involved a ‘multifactorial evaluative exercise’ that was usually best carried out by a specialist tribunal. The case was therefore sent back to a newly constituted PCC to reconsider sanction.</p>



<p>Following an appeal period, the dentist will be barred from practising.</p>



<p><em><a href="https://sso.dentistry.co.uk/" target="_blank" rel="noreferrer noopener">Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</a></em></p>]]> </content:encoded>
</item>

<item>
<title>FDA Delays PDUFA Action on Agios’ Mitapivat sNDA for SCD</title>
<link>https://edusehat.com/en/fda-delays-pdufa-action-on-agios-mitapivat-snda-for-scd</link>
<guid>https://edusehat.com/en/fda-delays-pdufa-action-on-agios-mitapivat-snda-for-scd</guid>
<description><![CDATA[ The FDA has delayed a decision on Agios Pharmaceuticals’ supplemental New Drug Application (sNDA) seeking additional approval for mitapivat in sickle cell disease (SCD) until next year. 
The post FDA Delays PDUFA Action on Agios’ Mitapivat sNDA for SCD appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Aug16_2016_Getty_481945753_SickleCellRedCells.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 00:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, Delays, PDUFA, Action, Agios’, Mitapivat, sNDA, for, SCD</media:keywords>
<content:encoded><![CDATA[<p>The FDA has delayed a decision on Agios Pharmaceuticals’ supplemental New Drug Application (sNDA) seeking additional approval for mitapivat in sickle cell disease (SCD) until next year. The FDA has extended its target action date under the Prescription Drug User Fee Act (PDUFA) by three months, from the originally scheduled November 1, 2026, to February 1, 2027, Agios acknowledged in a statement.</p>
<p>Investors punished Agios with a stock selloff that sent the company’s share price slumping nearly 18% from $37.23 to $30.55 on Friday.</p>
<p>The three-month extension was triggered by what the FDA deemed a major amendment to the sNDA—namely the submission, at the agency’s request, of additional information to assess whether a Risk Evaluation and Mitigation Strategy (REMS) would be necessary for mitapivat in SCD.</p>
<p>Agios responded to the FDA on October 19 by submitting approximately nine months of updated safety data through October 9 from the ongoing open-label extension periods of the Phase II/III RISE UP trial (<a href="https://clinicaltrials.gov/study/NCT05031780">NCT05031780</a>).</p>
<p>According to <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01480-7/fulltext">data published October 24 in <em>The Lancet</em></a>, 56 (41%) of 138 patients in the mitapivat group showed a hemoglobin response, compared with two (3%) of 69 patients on placebo (95% CI; two-sided p<0·0001). The annualized rate (95% CI) of sickle cell pain crises was 2.6 for mitapivat compared with 3.1 for placebo (two-sided p=0.1213). Serious adverse events were reported in 28 (20%) patients on mitapivat vs. 20 (29%) patients on placebo; one mitapivat patient’s event was deemed treatment related.</p>
<p>Mitapivat, an oral pyruvate kinase activator, “has the potential to be an effective and convenient disease-modifying treatment for people with sickle cell disease, researchers concluded in the study.</p>
<p>The new data, Agios said, continued to show no cases of hepatocellular injury (HCI) among patients with SCD treated with mitapivat who showed a pattern and severity similar to those observed trials for mitapivat in adults with thalassemia, Agios stated, adding that the risk-benefit profile of mitapivat in SCD remained unchanged.</p>
<h4><strong>“More cautious stance”</strong></h4>
<p>“Based on our recent conversations/inbounds, investors were focused on the potential for a REMS in SCD and how the FDA might be considering safety in this patient population, and we see the news being perceived by the market as signaling a more cautious stance from the FDA overall,” Tessa T. Romero, a senior analyst focused on biotechnology equity research with J.P. Morgan, wrote in a research note.</p>
<p>Romero added that the delay “also seems to be surprising the market,” as Agios investors are concerned the agency’s action narrows mitapivat’s potential first-to-market advantage relative to Novo Nordisk’s SCD candidate etavopivat, which Novo has told investors it would advance to a first regulatory filing in the fourth quarter of this year.</p>
<p>Agios has, since January, marketed mitapivat as a treatment for thalassemia, under the name Aqvesme®. Mitapivat is also marketed for hemolytic anemia under the name Pyrukynd®. Both mitapivat drugs combined have generated $65.491 million in net product revenue during the first half of this year, more than triple (209% above) the $21.181 million racked up during January–June 2025.</p>
<p>The company plans to report third quarter results on Thursday.</p>
<p>“Even if a REMS is necessary, management expects no additional delays and is launch ready. While the extension could delay the commercial launch by ~3 months, management does not believe it changes the commercial opportunity,” Andrew Berens, MD, senior managing director, targeted oncology and a senior research analyst with Leerink Partners, wrote in a research note.</p>
<p>Berens projected in April that mitapivat in SCD had a 60% chance of reaching the market, with peak sales of about $550 million in the United States.</p>
<h4><strong>“Interesting period”</strong></h4>
<p>“We believe Agios is navigating an interesting period, with the Aqvesme launch in thalassemia underway,” Romero commented. “That said, we struggle to see meaningful near-term upside for the stock and think it may take some time for investors to gain conviction in the launch trajectory of mitapivat in SCD, if/when approved.”</p>
<p>Agios said it will continue its labeling discussions with the FDA, including elements of a potential REMS, and will keep working closely with the agency to bring mitapivat to the market as soon as possible.</p>
<p>“We have strong conviction in mitapivat’s potential to transform care for people living with sickle cell disease, grounded in the comprehensive data from the RISE UP clinical program and further supported by the additional data we submitted in response to the FDA’s recent request,” Agios CEO Brian Goff said in a statement.</p>
<p>Agios’ sNDA was submitted under the FDA’s accelerated approval pathway, and has been granted Priority Review. The accelerated approval requires a confirmatory clinical trial—a condition Agios is satisfying through the Phase III REIGNITE trial (<a href="https://clinicaltrials.gov/study/NCT07656415">NCT07656415</a>), which dosed its first patient in July. The trial is designed to demonstrate the clinical benefit of mitapivat on reducing transfusion burden in patients aged 12 years and older with sickle cell disease.</p>
<p>“We are launch-ready, building on our commercial infrastructure and the strong relationships we have established over several years with hematologists, sickle cell centers, and patients,” Goff added. “We will continue to work expeditiously with the goal of bringing mitapivat to patients with sickle cell disease as soon as possible.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/fda-delays-pdufa-action-on-agios-mitapivat-snda-for-scd/">FDA Delays PDUFA Action on Agios’ Mitapivat sNDA for SCD</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Sentira Brings Claude’s AI to 10x Genomics’ Chromium Platform</title>
<link>https://edusehat.com/en/sentira-brings-claudes-ai-to-10x-genomics-chromium-platform</link>
<guid>https://edusehat.com/en/sentira-brings-claudes-ai-to-10x-genomics-chromium-platform</guid>
<description><![CDATA[ 10x Genomics launches Sentira, an Anthropic Claude-powered AI platform designed to accelerate single-cell data analysis, broaden research access, and streamline workflows while raising questions about expertise and AI reliability.
The post Sentira Brings Claude’s AI to 10x Genomics’ Chromium Platform appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/GettyImages-2253444748.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 00:50:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sentira, Brings, Claude’s, 10x, Genomics’, Chromium, Platform</media:keywords>
<content:encoded><![CDATA[<p>Ask any single cell researcher for their biggest experimental bottlenecks, and they will say data analysis. Going back to the beginning of the field, there has always been a “last mile problem,” notes Michael Schnall-Levin, PhD, CTO of 10x Genomics. Why? Because researchers have unique experimental methods and questions, each of which involves some level of writing their own analysis code. It has been “not scalable to write software that can do everything for everyone.”</p>
<p>But now, with advances in LLMs, researchers can use tools to answer questions without needing to be bioinformaticians. Today, 10x is launching Sentira Single Cell, a cloud-based agentic analysis powered by Anthropic’s Claude models as an application for Chromium users.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Schnall-Levin thinks that this will be “massively accelerating” for users. How much faster? “What might have taken someone weeks before could take hours,” he says. And that speed will not only help individual researchers but ultimately, he notes, be beneficial to the pace of scientific research and progress. It is not just about speed, however. Schnall-Levin says that there will like be other benefits. For example, it may reveal results in data that people are not currently seeing.  In addition, the company hopes that Sentira will broaden the group of people who can ask questions of single-cell data directly.</p>
<p>Sentira is, for the company, an umbrella of software capabilities. Sentira spatial was launched a few weeks ago; today’s announcement is specific to single-cell analysis. Sentira is not locked to any model: it can use different LLMs but the Anthropic models are working well, Schnall-Levin reports. And the project follows with Anthropic’s general push into the life science industry.</p>
<p><strong>From virtual lab to AI-powered single-cell analysis</strong></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The idea for the Sentira project started at the beginning of 2026, with some work 10x Genomics was doing together with James Zou, PhD, associate professor, Department of Biomedical Data Science at Stanford University. Zou’s name has become infamous with the concept of the “Virtual Lab” which he explains as a laboratory made of algorithms. The idea was first introduced in the 2025 <em>Nature </em>paper, “<a href="https://www.nature.com/articles/s41586-025-09442-9" target="_blank" rel="noopener">The Virtual Lab of AI agents designs new SARS-CoV-2 nanobodies.</a>”</p>
<p>Built on 10x Cloud, Sentira Single Cell provides the computing power needed to analyze Chromium data and run multiple analyses in parallel without requiring researchers to configure or manage their own infrastructure. The customer will interact with a chat interface which will help them go through and dynamically ask questions in the data that involves (on the back end) scripting and writing different analysis code.</p>
<p>10x is not training its own LLM model. Rather, it relies on models from Claude. The company will use researchers’ data to understand how the application is performing and to make improvements. But there is no flow back into the models themselves, the company asserts.</p>
<p><strong>The extra cost of going agentic</strong></p>
<p>The company reports that the cost will be an added “modest” cost. More specifically, the company notes that Sentira pricing is credit-based, through 10x Cloud Credit packs. The rough estimate is that each agentic session costs ~12 credits, with complete analysis through to experimental conclusions requiring around 60 credits. At launch, all users will receive 100 promotional credits for the first Chromium dataset uploaded to Sentira Single Cell, enough for users to become familiar with the platform and get to experimental conclusions. Credit packs are available in a range of sizes, with volume discounts that lower the price per credit as pack size increases. (See below for more specific pricing information.)</p>
<p><strong>The promise and peril of AI-driven analysis</strong></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>When asked about potential concerns about using AI in this way, Schnall-Levin notes (chuckling) that generally speaking he is “far more nervous about AI risks outside of this.”</p>
<p>One point that they discuss within the company, however, is how—as these tools get more powerful—people may have a tendency to rely on them without thinking. And although 10x does believe that the Sentira tools are accurate, he asserts that they are not perfect. “We don’t want someone to just start putting stuff out in a publication with no additional review. We think that this is a really good way to generate initial analysis and exploration, but people are still on the hook and responsible for it.” People need to understand the power and also the limitations, he notes.</p>
<p>Social media is ripe with discussion on the role of AI in single-cell analysis. Luciano Martelotto, PhD, director of global market development for single cell at Waters Biosciences, has expressed opinions—not about Sentira, specifically—but about using AI to analyze single cell data, in general. He notes one worry which is that “nothing in an AI-generated analysis looks broken. The code runs, the plots are pretty, the story makes sense. The mistakes that matter are the silent ones.”</p>
<p>None of the mistakes are “AI being dumb,” he continues. “It does what it’s asked. What it doesn’t do is get that uneasy feeling when a result looks too good. That feeling comes from having watched data go wrong, and I don’t think it can be prompted or coded into existence… not yet, at least.”</p>
<p>And when data analysis becomes increasingly automated and outsourced, will researchers lose the ability to analyze single cell data on their own?  Schnall-Levin sees this as an age old question about technological progress. He points to how few people today can navigate our location by the stars, because modern technology means that we do not need to. But it is a double-edge sword: expertise may be inevitably be lost as people are empowered to accomplish tasks without having to learn the details. Still, the benefits of these new technologies are very likely to outweigh the downside. Either way, this is the direction the world is moving in, and now the single cell field has another tool to move with it.</p>
<p> </p>
<p><strong>Pricing Information:</strong></p>
<table>
<tbody>
<tr>
<td><strong>Credit Packs</strong></td>
<td><strong>Pack Price</strong></td>
<td><strong>Price per Credit</strong></td>
</tr>
<tr>
<td>10x Cloud Credits – 100 Pack</td>
<td>$120</td>
<td>$1.20</td>
</tr>
<tr>
<td>10x Cloud Credits – 1,000 Pack</td>
<td>$1,150</td>
<td>$1.15</td>
</tr>
<tr>
<td>10x Cloud Credits – 2,000 Pack</td>
<td>$2,200</td>
<td>$1.10</td>
</tr>
<tr>
<td>10x Cloud Credits – 10,000 Pack</td>
<td>$10,500</td>
<td>$1.05</td>
</tr>
<tr>
<td>10x Cloud Credits – 25,000 Pack</td>
<td>$25,000</td>
<td>$1.00</td>
</tr>
</tbody>
</table>
<p>The post <a href="https://www.genengnews.com/topics/omics/sentira-brings-claudes-ai-to-10x-genomics-chromium-platform/">Sentira Brings Claude’s AI to 10x Genomics’ Chromium Platform</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Ottawa researchers identify protein involved in breast cancer development</title>
<link>https://edusehat.com/en/ottawa-researchers-identify-protein-involved-in-breast-cancer-development</link>
<guid>https://edusehat.com/en/ottawa-researchers-identify-protein-involved-in-breast-cancer-development</guid>
<description><![CDATA[ Laboratory findings point to a possible treatment target, but further research is needed. Researchers at The Ottawa Hospital and the University of Ottawa have identified a protein that could offer a target for future breast cancer treatments. The team, led by Dr. Luc Sabourin, studied Sox10 in a mouse model of HER2-positive breast cancer. Removing […]
The post Ottawa researchers identify protein involved in breast cancer development appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/Mouse-mammary-gland_1280.jpg.webp" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 00:45:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Ottawa, researchers, identify, protein, involved, breast, cancer, development</media:keywords>
<content:encoded><![CDATA[<p>Laboratory findings point to a possible treatment target, but further research is needed.</p>
<p>Researchers at The Ottawa Hospital and the University of Ottawa have identified a protein that could offer a target for future breast cancer treatments.</p>
<p>The team, led by Dr. Luc Sabourin, studied Sox10 in a mouse model of HER2-positive breast cancer. Removing the protein from cells lining the milk ducts prevented tumours from developing.</p>
<p>In separate experiments, deleting Sox10 from tumour cells reduced their capacity to renew themselves. Those cells also failed to grow and spread to other organs when transplanted into mice.</p>
<p>The findings, published in Proceedings of the National Academy of Sciences, come from laboratory and animal research. They do not establish a treatment for patients.</p>
<p>“Our next step is to find and test possible drugs that target this protein,” Sabourin said in the hospital’s announcement.</p>
<p>Sabourin is a senior scientist at The Ottawa Hospital and an associate professor at the University of Ottawa.</p>
<p>Source: <a href="https://ohri.ca/en/newsroom/researchers-uncover-key-ingredient-breast-cancer-initiation">https://ohri.ca/en/newsroom/researchers-uncover-key-ingredient-breast-cancer-initiation</a></p>
<p>The post <a href="https://www.hospitalnews.com/ottawa-researchers-identify-protein-involved-in-breast-cancer-development/">Ottawa researchers identify protein involved in breast cancer development</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The project your team keeps pushing to the future</title>
<link>https://edusehat.com/en/the-project-your-team-keeps-pushing-to-the-future</link>
<guid>https://edusehat.com/en/the-project-your-team-keeps-pushing-to-the-future</guid>
<description><![CDATA[ Behind every appointment is a support and administrative team, and many are stretched thin. An extra pair of hands can help them finally tackle the work that keeps slipping. Patients remember the nurse who comforted them or the physician who explained their care. They often miss the hospital ecosystem of support and administrative staff that […]
The post The project your team keeps pushing to the future appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/Health-Studies-Population-Health-Joyce-Jang-3.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 00:45:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, project, your, team, keeps, pushing, the, future</media:keywords>
<content:encoded><![CDATA[<h4><strong>Behind every appointment is a support and administrative team, and many are stretched thin. An extra pair of hands can help them finally tackle the work that keeps slipping.</strong></h4>
<p>Patients remember the nurse who comforted them or the physician who explained their care. They often miss the hospital ecosystem of support and administrative staff that makes every visit possible.</p>
<p>According to a 2026 labour market report by Financial Accountability Office of Ontario, the province’s health care and social assistance sector added 14,700 jobs in 2025 yet still recorded 36,500 vacancies, the most of any major industry in the province. In IT, finance, operations, research administration and communications, every open role means work piles up.</p>
<p>Most teams also carry a list of ideas they never get to: a records clean-up, a better referral tracker, clearer patient instructions. The problem is rarely a lack of will. It is lack of time.</p>
<h3><strong>An extra pair of hands,<span class="Apple-converted-space"> </span>with a plan</strong></h3>
<p>A growing number of health care and research teams are filling that gap with university students on co-op work terms. These are full-time, paid work terms of four, eight or 12 months in support and administrative roles.</p>
<p>This differs from placements, where medical students complete mandatory real-world training in hospitals. Here, the focus is on the support functions that often do not need students with core medical skills but help medical teams do their work.</p>
<p>In practice, a co-op student might keep health records accurate, organize research study files, check data for missing entries or track orders and invoices. A mathematics and statistics student can analyze appointment data to find the busiest times. A computer science student can support IT teams with troubleshooting. A health policy student can organize documentation to help teams keep pace with regulations.</p>
<p>Not every project justifies a new permanent position. A records clean-up or a data review has a start and an end. A co-op student can take on that kind of work for four, eight or 12 months, without the long-term commitment of a full-time hire. The hospital team sees the results first, then decides what comes next.</p>
<p>The Arts and Science Co-op team at U of T Scarborough helps students from more than 57 undergraduate programs across the sciences, social sciences and humanities connect with co-op opportunities.</p>
<p>Students benefit too. They gain exposure to the health care system while using skills and learning from their own academic programs. After the work term, they return to school with real-world experience that informs their future career decisions.</p>
<h3><strong>Built on relationships</strong></h3>
<p>“I often ask hospital teams, “which administrative task takes up most of your time and attention?” The answer is usually something important but repetitive that keeps them occupied and away from strategic projects that require their specialized knowledge and experience. That’s when we share that our students are already supporting such administrative tasks in the healthcare space and share the detailed benefits of participating in our program.“<span class="Apple-converted-space"> </span></p>
<p>Antonella Poon, Team Lead – Arts and Science Co-op at University of Toronto Scarborough.</p>
<h3><strong>What about privacy and<span class="Apple-converted-space"> </span>patient data security?</strong></h3>
<p>Hospital teams are right to ask. Good placements have clear tasks and oversight. Students look only at the information they need, use approved systems and their own logins, avoid downloading anything that could identify a patient, and raise privacy questions with a supervisor right away. Qualified staff review the work and make the final call on test results, billing, patient advice, public statements and staffing.</p>
<h3><strong>What changes for your team</strong></h3>
<p>• Clinic staff get time back. Nurses, physicians and managers can focus on their specialties.</p>
<p>• Shelved projects start to move. A student with a clear scope can advance an idea while staff review the work.</p>
<p>• A fresh set of eyes. Students ask why things are done a certain way, sometimes exposing outdated steps.</p>
<p>Arts and Science Co-op is a proud founding member of the U of T co-op community, with more than 50 years of experience in co-op education. <b>Get in touch with their co-op representatives</b> to explore projects a co-op student could take on in your team. Get support on scoping the work, shaping the role and navigating the next steps.<span class="Apple-converted-space"> </span></p>
<p>The post <a href="https://www.hospitalnews.com/the-project-your-team-keeps-pushing-to-the-future/">The project your team keeps pushing to the future</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Society Advocates for Diabetes; Urges Congress to Address Diabetes Research and Access to Affordable Insulin</title>
<link>https://edusehat.com/en/society-advocates-for-diabetes-urges-congress-to-address-diabetes-research-and-access-to-affordable-insulin</link>
<guid>https://edusehat.com/en/society-advocates-for-diabetes-urges-congress-to-address-diabetes-research-and-access-to-affordable-insulin</guid>
<description><![CDATA[ The Endocrine Society is urging Congress to act on two important issues affecting diabetes research and care before the end of the year. We are asking Congress to reauthorize the Special Diabetes Program (SDP). SDP is a critical program that provides funding for type 1 diabetes research at National Institutes of Diabetes and Digestive and […]
The post Society Advocates for Diabetes; Urges Congress to Address Diabetes Research and Access to Affordable Insulin appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/USCapitol.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 02 Nov 2026 21:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Society, Advocates, for, Diabetes, Urges, Congress, Address, Diabetes, Research, and, Access, Affordable, Insulin</media:keywords>
<content:encoded><![CDATA[<p>The Endocrine Society is urging Congress to act on two important issues affecting diabetes research and care before the end of the year. We are asking Congress to reauthorize the Special Diabetes Program (SDP). SDP is a critical program that provides funding for type 1 diabetes research at National Institutes of Diabetes and Digestive and […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/society-advocates-for-diabetes-urges-congress-to-address-diabetes-research-and-access-to-affordable-insulin/">Society Advocates for Diabetes; Urges Congress to Address Diabetes Research and Access to Affordable Insulin</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Placing implants with confidence: what clinicians and labs learned at a guided surgery training day in Derby </title>
<link>https://edusehat.com/en/placing-implants-with-confidence-what-clinicians-and-labs-learned-at-a-guided-surgery-training-day-in-derby</link>
<guid>https://edusehat.com/en/placing-implants-with-confidence-what-clinicians-and-labs-learned-at-a-guided-surgery-training-day-in-derby</guid>
<description><![CDATA[ At a one-day course hosted by SYS Systems, Stratasys and Swissmeda took clinicians and dental technicians through the full guided implant surgery workflow, from digital planning to 3D-printed surgical guides, to give them the knowledge and confidence to start placing implants with guides in their own practices.  The shift from freehand to guided  Most implant… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/11/stratasys.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 02 Nov 2026 18:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Placing, implants, with, confidence:, what, clinicians, and, labs, learned, guided, surgery, training, day, Derby </media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><div class="wp-block-embed__wrapper">
<div class="video-container"></div>
</div></figure>



<p><strong>At a one-day course hosted by SYS Systems, Stratasys and Swissmeda took clinicians and dental technicians through the full guided implant surgery workflow, from digital planning to 3D-printed surgical guides, to give them the knowledge and confidence to start placing implants with guides in their own practices.</strong> </p>



<h2 class="wp-block-heading"><strong>The shift from freehand to guided</strong> </h2>



<p>Most implant clinicians already know the clinical case for guided surgery. A digitally planned implant goes where the restoration needs it, and the margin for error shrinks with every complex case. Patient expectations around speed and aesthetics keep rising too. </p>



<p>‘We are looking for more accuracy, more precision going forward,’ says Dr Sneha Gokhale, a periodontist and practice owner in Burton upon Trent. ‘Prosthetic-driven implant placement, that’s the way forward.’</p>



<p>A digital plan also changes the conversation with patients. ‘One thing is just to tell the patient that they’re going to have an implant,’ says Hugo Patrão, who leads sales and education for Swissmeda across EMEA. ‘Another thing is to be able to show it on the screen… By doing that, we inform patients and we empower the patients.’</p>



<p>So the clinical logic is clear. The harder questions for most practices are the practical ones: where do I start, what can go wrong, and how much is it going to cost me? </p>



<h2 class="wp-block-heading"><strong>Tackling the practical barriers</strong> </h2>



<p>At a recent training day held at SYS Systems in Derby, delivered jointly by Stratasys, implant planning specialist Swissmeda and SYS, the UK and Ireland reseller for Stratasys dental technology, those three questions came up repeatedly. </p>



<p>‘The doctors feel a little bit lost, and sometimes they are afraid of not being supported,’ says Hugo. </p>



<p>Dr Waqas Tahir of Accrington Dental Suite, who currently uses pilot guides, expected cost and logistics to be the main obstacles. Dr Gokhale worried that printed guides might not be accurate enough, or would limit surgical access. The course addressed all these concerns. </p>



<h2 class="wp-block-heading"><strong>A digital-agnostic approach to training</strong> </h2>



<p>‘We encourage all the doctors to come to a course not about Swissmeda, but about guided surgery, to know the advantages, the pitfalls and, above all, the limitations,’ says Hugo. Clinicians who understand where guided surgery can go wrong, and how to correct it, are far more likely to adopt it confidently. </p>



<p>The day moved from planning principles to hands-on work: superimposing intraoral scans on CBCT data, identifying common planning errors, watching a live case redesign, and handling demo guides. Delegates also learned how to troubleshoot guide fit and seating issues. The open-architecture guide design drew particular attention from those who had worried about restricted visibility, since it improves access for irrigation and flap reflection. </p>



<p>‘They’ve explained what can go wrong with a surgical guide and how to correct them,’ says Dr Gokhale. </p>



<p>‘It’s an eye-opener,’ says Dr Tahir. ‘Going back to some of the basics of planning, and the importance of planning for your entire workflow.’</p>



<h2 class="wp-block-heading"><strong>The guided surgery workflow at a glance</strong> </h2>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td>1. Intraoral scan </td><td>2. CBCT scan </td><td>3. Scans merged in planning software </td><td>4. Implant position planned around the restoration </td><td>5. Guide designed </td><td>6. Guide, model and gingiva mask 3D-printed together </td><td>7.Guided implant placement </td></tr></tbody></table></figure>



<h2 class="wp-block-heading"><strong>Two routes to an accurate printed guide</strong> </h2>



<h3 class="wp-block-heading"><strong>In-house printing</strong></h3>



<p>For practices with their own lab – increasingly common among larger, multi-surgery groups – the Stratasys J3 and J5 DentaJet print the surgical guide, model and gingival mask together in a single job. Parts come out fully cured inside the print chamber: no washing in isopropyl alcohol and no separate post-cure station. That removes two steps, the consumables that go with them, and the handling of uncured resin. </p>



<p>‘The parts are completely cured within the print chamber,’ says Anthony Gillitt, dental sales manager at Stratasys. For a lab running multiple cases a day, the time and consumable savings add up quickly. </p>



<h3 class="wp-block-heading"><strong>Partner lab</strong></h3>



<p>Clinicians who prefer to outsource production lose nothing in quality. </p>



<p>‘We can also signpost clinicians to a lab that may be close to them who has got this technology,’ says Chris Andrews, sales manager at SYS Systems. Lino Adolf, owner of Majestic Smile, a high-volume digital lab near Cambridge using Stratasys DentaJet, prints guides for clinicians who don’t have their own equipment. The economics work because the lab spreads the investment across its full caseload. </p>



<h2 class="wp-block-heading"><strong>Getting the lab involved early</strong> </h2>



<p>Guided surgery works best when the lab sees the plan before the surgeon picks up the handpiece. </p>



<p>‘If the dental lab is involved in the planning from the start, you can get better outcomes when it comes to the prosthetic side,’ says Lino. The implant position drives everything downstream, from abutment selection to emergence profile and restoration margins. A lab that reviews the plan early can flag problems before they’re locked in. </p>



<p>Dr Gokhale sees the same from the chair. ‘If you get the precision, if you get the angle right, it’s obviously better for the labs. They get good results with crowns, bridges… better for the patients.’</p>



<h2 class="wp-block-heading"><strong>Support through first cases</strong> </h2>



<p>Swissmeda supports clinicians through their first guided cases after the course, reviewing plans, checking guide designs, and answering questions case by case. ‘They should never feel alone,’ says Hugo. ‘We are there for them, supporting them all the way along the learning journey.’</p>



<p>SYS provides applications and service support across the UK and Ireland, and clinicians and labs can visit the Derby facility for a demonstration and test prints on the DentaJet printers before committing to a purchase. </p>



<p>‘Three businesses working together to support our clients and offer education at the highest level,’ is how Anthony describes the partnership. </p>



<p>‘If we get that right,’ says Dr Gokhale, ‘the whole process after that becomes easier.’</p>



<p><a href="https://www.stratasys.com/en/dental/talk-to-an-expert/?utm_campaign=DE-NA-000196&utm_medium=syndication&utm_source=fmc&utm_content=TE-000106%7D" target="_blank" rel="noreferrer noopener">Learn more about how Stratasys technology supports guided surgery workflows, or to book a demonstration at SYS Systems in Derby.</a></p>



<p><em>This article is sponsored by Stratasys.</em></p>]]> </content:encoded>
</item>

<item>
<title>OneSource receives USFDA EIR with VAI Classification for its SPD facility in Bengaluru</title>
<link>https://edusehat.com/en/onesource-receives-usfda-eir-with-vai-classification-for-its-spd-facility-in-bengaluru</link>
<guid>https://edusehat.com/en/onesource-receives-usfda-eir-with-vai-classification-for-its-spd-facility-in-bengaluru</guid>
<description><![CDATA[ 
The development adds to OneSource’s regulatory track record as it continues to build a differentiated globally competitive CDMO platform
The post OneSource receives USFDA EIR with VAI Classification for its SPD facility in Bengaluru appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22100048/usfda-approved-black.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 02 Nov 2026 17:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>OneSource, receives, USFDA, EIR, with, VAI, Classification, for, its, SPD, facility, Bengaluru</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22100048/usfda-approved-black.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22100048/usfda-approved-black.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/07/22100048/usfda-approved-black-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>OneSource Specialty Pharma announced that it has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Sterile Product Division (SPD) facility in Bengaluru, with a ‘Voluntary Action Indicated’ (VAI) classification. The report follows an inspection of the facility conducted from June 22 to June 30, 2026.</span></p>
<p><span>Commenting on the development, Neeraj Sharma, Managing Director & CEO, OneSource Specialty Pharma said, </span><span>“We are pleased to receive the EIR with VAI classification from the USFDA for our SPD facility. This inspection outcome reflects our continued commitment to maintaining high standards of quality, regulatory compliance and operational excellence across our operations. Our SPD facility plays an integral role in our sterile manufacturing capabilities, enabling us to support the evolving needs of our global partners.”</span></p>
<p><span>The development adds to OneSource’s regulatory track record as it continues to build a differentiated, globally competitive CDMO platform spanning four key modalities — drug-device combination, biologics, sterile injectables and soft gelatin capsules.</span></p>
<p>The post <a href="https://www.expresspharma.in/onesource-receives-usfda-eir-with-vai-classification-for-its-spd-facility-in-bengaluru/">OneSource receives USFDA EIR with VAI Classification for its SPD facility in Bengaluru</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Hikal signs multi&#45;year global CDMO contract with leading agrochemical company </title>
<link>https://edusehat.com/en/hikal-signs-multi-year-global-cdmo-contract-withleading-agrochemical-company</link>
<guid>https://edusehat.com/en/hikal-signs-multi-year-global-cdmo-contract-withleading-agrochemical-company</guid>
<description><![CDATA[ 
Contract follows successful Process Development and scale-up of a new product, marking a key  commercial milestone for Hikal’s Crop Protection business 
The post Hikal signs multi-year global CDMO contract with leading agrochemical company  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2019/09/11121123/agreement-e1724903886928.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 02 Nov 2026 17:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Hikal, signs, multi-year, global, CDMO, contract, with leading, agrochemical, company </media:keywords>
<content:encoded><![CDATA[<div><img width="749" height="397" src="https://cdn.expresspharma.in/wp-content/uploads/2019/09/11121123/agreement-e1724903886928.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2019/09/11121123/agreement-e1724903886928.jpg 749w, https://cdn.expresspharma.in/wp-content/uploads/2019/09/11121123/agreement-e1724903886928-300x159.jpg 300w" sizes="(max-width: 749px) 100vw, 749px"></div><p><span>Hikal has signed a multi-year contract  </span><span>with a Europe-based global agrochemical company to supply a specialised agrochemical product to  markets worldwide. The contract, signed by Hikal’s Crop Protection division, covers contract  development and manufacturing (CDMO) of the product for which Hikal undertook process  development and scale-up. Commercial launch is expected towards the end of FY 2026–27, with  volumes anticipated to grow progressively as regulatory approvals are secured across global markets. </span></p>
<p><span>The partnership underscores Hikal’s capabilities in process development and commercialisation,  demonstrating its ability to translate customer requirements into long-term manufacturing  opportunities. It also strengthens Hikal’s Crop Protection business by expanding its portfolio of  specialised offerings for global customers. </span></p>
<p><span>Commenting on the development, </span>Sameer Hiremath, Chairman & Managing Director, Hikal said, <span>“This contract marks an important milestone for our Crop Protection business,  converting nearly three years of collaborative development and scale-up into a long-term commercial  partnership. It demonstrates Hikal’s ability to combine deep technical expertise with reliable  </span><span>manufacturing capabilities to take complex products from development to commercial supply. We are  </span><span>well positioned to support the planned launch and progressive expansion of supplies across global  markets. </span></p>
<p><span>Hikal partners with global companies across pharmaceuticals, crop protection, animal health and  specialty chemicals, leveraging its research and development, process chemistry and manufacturing  capabilities to support customers from development through commercial production. </span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/hikal-signs-multi-year-global-cdmo-contract-with-leading-agrochemical-company/">Hikal signs multi-year global CDMO contract with leading agrochemical company </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Changes to NHS dentistry in Wales – an untested system causing havoc</title>
<link>https://edusehat.com/en/changes-to-nhs-dentistry-in-wales-an-untested-system-causing-havoc</link>
<guid>https://edusehat.com/en/changes-to-nhs-dentistry-in-wales-an-untested-system-causing-havoc</guid>
<description><![CDATA[ Practice Plan Regional Support Manager, Louise Anderson, shares her experience of supporting practices in Wales during this year’s contract alterations. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/wales.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 02 Nov 2026 14:30:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Changes, NHS, dentistry, Wales, –, untested, system, causing, havoc</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Practice Plan regional support manager Louise Anderson shares her experience of supporting practices in Wales during this year’s contract alterations.</strong></p>



<p>Among the many changes to the NHS dental contract in Wales was the extension of the notice period required by contract holders wanting to return their contract from three months to six months. As the deadline approaches for those wishing to leave at the end of this contract year, Practice Plan Regional Support Manager Louise Anderson reflects on how the changes have been received.</p>



<p>The changes to the NHS dental contract in Wales introduced in April this year were hailed as a ‘once in a generation’ opportunity to improve patient access. However, as someone who works with practices daily, it appears that the intention does not live up to the reality.</p>



<p>The Welsh Government’s stated aim with this new contract was to improve patient access to dental care. However, several months on from its introduction, it is questionable whether that will be achieved thanks to increased patient charges, extended recall intervals and lack of continuity of care.</p>



<p>With the unmet need for NHS dentistry in Wales standing at one third of the adult population, 20% saying they were unable to secure an appointment in the last two years, and a further 13% having effectively given up trying, there is little doubt something needed to be done to improve patient access to care. However, rushing through an untested system without adequate guidance for either practices or patients was never likely to win hearts and minds in the profession.</p>



<h2 class="wp-block-heading">Poor support</h2>



<p>To compound the felony, patient-facing materials failed to appear until weeks after the new charges came into effect, leaving practices to deal with disgruntled patients in reception unsupported by any official posters or leaflets. Having spent more than 35 years in dentistry in Wales, I have worked with several iterations of the contract. Without a doubt, the way this contract was introduced is the worst I have seen. As well as having to cope with an increased administration burden, software systems unready to deal with the changes and confusion over what could and could not be charged for, dentists I spoke to in the early stages felt disrespected by the way the contract was introduced. Their concerns were left unaddressed and dismissed, and their voices unheard.</p>



<p>An indication of the contract’s unpopularity came in some early canvassing of opinion. One month after its introduction, Welsh dental advisory firm ProPractices polled 15%-20% of contract holders on their experience of the contract’s implementation. This showed 100% of respondents rated it as either ‘poor’ or ‘very poor’. In addition, 83% said they were at risk of reducing their NHS commitment without further support.</p>



<p>There is a great deal of confusion about the administration of the contract. In the absence of any official guidance, for many dental teams their main source of information is a WhatsApp group. Its several hundred members post questions in the hope that someone has already encountered the problem and found a solution.</p>



<h3 class="wp-block-heading">Delivering the contract</h3>



<p>There is also huge concern that the contract is undeliverable. A recent informal straw poll of members of the WhatsApp group showed that the majority of those who responded believed that, after the third schedule, they had achieved between 25% and 50% of where they would have expected their performance to have been. This does not bode well for the rest of the contract year. In fact, I have spoken to several dentists who have written to their Local Health Board to inform them that they believe the contract in its current form is undeliverable.</p>



<p>A likely contributor to underperformance is the structure of the care packages. With the move away from UDAs to a monetary-based system, the charges patients are being asked to pay are making fulfilling the contract harder to achieve. For example, a simple restorative procedure is charged at £37.50 plus the cost of the examination (£27.21 for a new patient examination), which is unlikely to make a dent in contract values, especially as being paid for work done is proving problematic.</p>



<h2 class="wp-block-heading">Admin burden</h2>



<p>Administration of the new contract has been trying and frustrating for practices. I speak to practice managers daily who tell me that 95% of their time is now spent dealing with rejected claims, processing claims, interrogating eDEN, an online data tool, and Compass to try to get a handle on where they are with the contract. They also need to try to work out various statistics and calculate associates’ pay.</p>



<p>Front-of-house team members are charged with ensuring that the correct payment is taken for the correct care package while also dealing with unhappy patients who are now expected to cover the cost of lab fees as well as the care package. The increased charges and lab fees have resulted in patients declining treatment due to costs.</p>



<h2 class="wp-block-heading">Gaming the system</h2>



<p>While the new contract arrangements aim to increase patient access, the reality is that existing patients are gaming the system. New patients are expected to register for the DAP (Digital Access Portal) so that they can then be allocated to the practice nearest to them with availability. However, in some cases patients who have had treatment recommended but do not wish to wait six weeks to be fitted in at the recommending practice are logging on to the DAP in an attempt to be seen sooner. Consequently, instead of facilitating appointments for new patients, the DAP is being used to recycle an existing cohort of patients who are already ‘in the system’.</p>



<h2 class="wp-block-heading">Patient choice</h2>



<p>The extension of recall periods has proved particularly unpopular with both patients and clinicians alike. Dentally fit patients need not be recalled before 18 months to two years, and possibly longer if their practice cannot fit them in. Although in line with NICE guidelines, dentists fear that this interval leaves patients vulnerable to decay and periodontal issues.</p>



<p>Prior to this, patients were generally recalled annually, rather than six-monthly as in some other parts of the UK. As a potential alternative to having patients waiting for up to two years for a routine examination, I have been helping practices to set up low-cost annual dental membership plans to offer their patients. These plans entitle patients to one examination, one hygiene appointment, x-rays, emergency appointments and a discount off treatment. They are aimed at those who want to continue seeing ‘their’ dentist annually rather than being assigned to any NHS dentist at the practice or, in an emergency, any NHS dentist working for the Local Health Board.</p>



<p>In accordance with GDC standards, the plans are presented to patients as one of a number of options available to them and have proved popular. One practice that introduced these low-cost annual plans signed up 1,100 patients in just three weeks. As well as providing some certainty for patients, they offer a predictable income for practices concerned they may not fulfil their contract or who may be considering a move away from the NHS altogether at the end of the contract year.</p>



<h2 class="wp-block-heading">More to come?</h2>



<p>The Welsh Government has said that around 6% of NHS dental contracts in Wales had been handed back by March 2026. It is difficult to say with any certainty how many patients are likely to have been affected. However, as approximately 1.41 million people were treated by NHS dentists in Wales over the preceding two years, this could be around 85,000 patients, although no official Wales-wide estimate of patient impact has been published and the actual figure could be higher or lower. I am aware that at least some of those contracts were handed back as the holder did not wish to work under the new contract conditions. As we reach the October deadline, how many more practices will join their ranks?</p>



<p>Practice Plan has been welcoming practices into the family since 1995, helping them to grow profitable businesses through the introduction of <a href="https://www.practiceplan.co.uk/benefits-of-a-membership-plan/">practice-branded membership plans</a>. If you’re looking for a provider to be by your side through a safe move from NHS to private then, with over 300 years’ dental experience in our field team, you’re in safe hands with Practice Plan… Be Practice Plan and get in touch.</p>



<p>Call <a href="tel://01691">01691 684165</a> or visit <a href="http://www.practiceplan.co.uk/be-practice-plan/" target="_blank" rel="noreferrer noopener">www.practiceplan.co.uk/be-practice-plan/</a>.</p>



<p><em>This article is sponsored by Practice Plan.</em></p>


        <div class="">
            <div class="text-context-white p-8 md:p-12 xl:p-20 bg-black">
                <div class="flex flex-wrap justify-center -mx-4">
                                            <div class="px-4 w-full lg:w-7/8 flex flex-col justify-start">
                                                                        <div class="font-yellow font-bold text-2xl md:text-3xl xl:text-4xl mb-4">
                                Ready to talk?                            </div>
                                                                            <div class="text-context-white/75 mb-4">
                                <p>If you’re ready for a confidential discussion with Practice Plan about the next steps in converting to private dentistry, leave your details below.</p>
                            </div>
                                                                            <div class="wpforms-design-block-form">
                                <div class="wpforms-container wpforms-container-full">Please enable JavaScript in your browser to complete this form.<div class="wpforms-field-container">		<div class="wpforms-field wpforms-field-text" data-field-type="text" data-field-id="3">
			<label class="wpforms-field-label" for="wpforms-424415-field_3">Layout hear Practice</label>
			
		</div>
		<div class="wpforms-field wpforms-field-layout" data-field-id="7"><div class="wpforms-field-layout-rows wpforms-field-large"><div class="wpforms-layout-row"><div class="wpforms-layout-column wpforms-layout-column-25"><div class="wpforms-field wpforms-field-text" data-field-id="1"><label class="wpforms-field-label" for="wpforms-424415-field_1">Name <span class="wpforms-required-label">*</span></label></div></div><div class="wpforms-layout-column wpforms-layout-column-25"><div class="wpforms-field wpforms-field-email" data-field-id="2"><label class="wpforms-field-label" for="wpforms-424415-field_2">Email <span class="wpforms-required-label">*</span></label></div></div><div class="wpforms-layout-column wpforms-layout-column-25"><div class="wpforms-field wpforms-field-text" data-field-id="8"><label class="wpforms-field-label" for="wpforms-424415-field_8">Phone <span class="wpforms-required-label">*</span></label></div></div><div class="wpforms-layout-column wpforms-layout-column-25"></div></div><div class="wpforms-layout-row"><div class="wpforms-layout-column wpforms-layout-column-25"><div class="wpforms-field wpforms-field-text" data-field-id="5"><label class="wpforms-field-label" for="wpforms-424415-field_5">Practice name <span class="wpforms-required-label">*</span></label></div></div><div class="wpforms-layout-column wpforms-layout-column-25"><div class="wpforms-field wpforms-field-text" data-field-id="6"><label class="wpforms-field-label" for="wpforms-424415-field_6">Practice postcode <span class="wpforms-required-label">*</span></label></div></div><div class="wpforms-layout-column wpforms-layout-column-25"></div><div class="wpforms-layout-column wpforms-layout-column-25"></div></div></div></div><div class="wpforms-field wpforms-field-checkbox" data-field-id="9"><label class="wpforms-field-label">Want to hear more from Practice Plan?</label><ul><li class="choice-1 depth-1"><label class="wpforms-field-label-inline" for="wpforms-424415-field_9_1">I agree to receive marketing communication from Practice Plan, including valuable insights, inspiring stories and practical tips.   <a rel="noopener noreferrer" target="_blank" href="https://www.practiceplan.co.uk/privacy-notice/?utm_source=https://dentistry.co.uk/nhs-to-private/&utm_medium=referral&utm_campaign=privacypolicynhstopriv">View their privacy policy.</a>.</label></li></ul></div></div><!-- .wpforms-field-container --><div class="wpforms-submit-container"><button type="submit" name="wpforms[submit]" class="wpforms-submit" data-alt-text="Sending..." data-submit-text="Submit" aria-live="assertive" value="wpforms-submit">Submit</button></div></div>  <!-- .wpforms-container -->                            </div>
                                            </div>
                                    </div>
            </div>
        </div>]]> </content:encoded>
</item>

<item>
<title>Canadian study finds cancer signals in blood up to eight years before diagnosis</title>
<link>https://edusehat.com/en/canadian-study-finds-cancer-signals-in-blood-up-to-eight-years-before-diagnosis</link>
<guid>https://edusehat.com/en/canadian-study-finds-cancer-signals-in-blood-up-to-eight-years-before-diagnosis</guid>
<description><![CDATA[ Researchers studying stored blood samples from Ontario Health Study participants have identified signals associated with breast and prostate cancers up to eight years before diagnosis, according to the Ontario Institute for Cancer Research. The findings, published in Cell Genomics, could help inform future approaches to earlier detection and monitoring people at higher risk. The team […]
The post Canadian study finds cancer signals in blood up to eight years before diagnosis appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_2783991317.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 02 Nov 2026 10:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Canadian, study, finds, cancer, signals, blood, eight, years, before, diagnosis</media:keywords>
<content:encoded><![CDATA[<p>Researchers studying stored blood samples from Ontario Health Study participants have identified signals associated with breast and prostate cancers up to eight years before diagnosis, according to the Ontario Institute for Cancer Research.</p>
<p>The findings, published in <em>Cell Genomics</em>, could help inform future approaches to earlier detection and monitoring people at higher risk.</p>
<p>The team examined blood collected from people who appeared healthy when they donated samples but subsequently developed cancer. Researchers identified patterns of DNA methylation—chemical changes to DNA that can provide clues about cancer development.</p>
<p>The work was co-led by Dr. Philip Awadalla, a former OICR Senior Investigator, and Dr. Nicholas Cheng, a former member of his laboratory.</p>
<p>For healthcare teams, the potential lies in more personalized screening and follow-up. However, the findings require further validation before the approach could be used in routine care. Researchers are planning a prospective clinical trial and exploring ways to make testing faster, more accurate and more affordable.</p>
<p data-pm-slice="1 1 []"><strong><a href="https://oicr.on.ca/early-signs-of-cancer-detected-in-blood-up-to-eight-years-before-diagnosis/">Read the original OICR report</a>.</strong></p>
<p>The post <a href="https://www.hospitalnews.com/canadian-study-finds-cancer-signals-in-blood-up-to-eight-years-before-diagnosis/">Canadian study finds cancer signals in blood up to eight years before diagnosis</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Advancing Basal Insulin Therapy in Type 2 Diabetes: Individualizing Treatment in the Era of Once&#45;Weekly Insulins</title>
<link>https://edusehat.com/en/advancing-basal-insulin-therapy-in-type-2-diabetes-individualizing-treatment-in-the-era-of-once-weekly-insulins</link>
<guid>https://edusehat.com/en/advancing-basal-insulin-therapy-in-type-2-diabetes-individualizing-treatment-in-the-era-of-once-weekly-insulins</guid>
<description><![CDATA[ Despite major advances in cardiometabolic therapies, many people with type 2 diabetes (T2D) will eventually require basal insulin. The clinical challenge is not only initiating insulin in appropriate patients but also optimizing therapy while avoiding overbasalization and minimizing treatment burden. Once-weekly basal insulins represent an important advancement that may help simplify insulin therapy for appropriate […]
The post Advancing Basal Insulin Therapy in Type 2 Diabetes: Individualizing Treatment in the Era of Once-Weekly Insulins appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/Wittert_Video_-Aug_5--1024x536.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 02 Nov 2026 03:50:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Advancing, Basal, Insulin, Therapy, Type, Diabetes:, Individualizing, Treatment, the, Era, Once-Weekly, Insulins</media:keywords>
<content:encoded><![CDATA[<p>Despite major advances in cardiometabolic therapies, many people with type 2 diabetes (T2D) will eventually require basal insulin. The clinical challenge is not only initiating insulin in appropriate patients but also optimizing therapy while avoiding overbasalization and minimizing treatment burden. Once-weekly basal insulins represent an important advancement that may help simplify insulin therapy for appropriate […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/advancing-basal-insulin-therapy-in-type-2-diabetes-individualizing-treatment-in-the-era-of-once-weekly-insulins/">Advancing Basal Insulin Therapy in Type 2 Diabetes: Individualizing Treatment in the Era of Once-Weekly Insulins</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance</title>
<link>https://edusehat.com/en/stockwatch-gene-editing-shares-jump-on-esgct-data-fda-draft-guidance</link>
<guid>https://edusehat.com/en/stockwatch-gene-editing-shares-jump-on-esgct-data-fda-draft-guidance</guid>
<description><![CDATA[ Shares of gene editing therapy companies mostly surged this past week on two growth catalysts: Data readouts at the European Society of Gene and Cell Therapy’s 33rd ESGCT Annual Congress, and the FDA&#039;s new draft guidance for personalized gene therapies.
The post StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-1407334381-1068x748-1-1024x717-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 02 Nov 2026 03:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Gene, Editing, Shares, Jump, ESGCT, Data, FDA, Draft, Guidance</media:keywords>
<content:encoded><![CDATA[<p>Shares of gene editing therapy companies mostly surged by double digits this past week on two growth catalysts. One catalyst was expected: The European Society of Gene and Cell Therapy’s <a href="https://www.genengnews.com/topics/genome-editing/hamburg-hosts-2026-european-gene-therapy-conference/">33rd ESGCT Annual Congress</a>, which finished Friday in Hamburg, Germany, brought forth the usual flurry of data presentations, including many positive readouts by developers of new editing-based therapies.</p>
<figure aria-describedby="caption-attachment-340047" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340047" src="https://www.genengnews.com/wp-content/uploads/2026/10/Diamantas_Kyle_900-x-900_Flag-253x300.jpg" alt="" width="253" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Diamantas_Kyle_900-x-900_Flag-253x300.jpg 253w, https://www.genengnews.com/wp-content/uploads/2026/10/Diamantas_Kyle_900-x-900_Flag.jpg 370w" sizes="(max-width: 253px) 100vw, 253px"><figcaption class="wp-caption-text">Kyle Diamantas, FDA acting commissioner</figcaption></figure>
<p>The other catalyst happened October 27 when the FDA issued draft guidance (<a href="https://www.regulations.gov/docket/FDA-2026-D-11783">FDA-2026-D-11783</a>) intended to help sponsors develop and pursue approvals for personalized gene therapies designed to treat patients with rare genetic diseases. The guidance, <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/individualized-human-genome-editing-products-considerations-bla-submission-and-postapproval"><em>Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management</em></a>, offers a regulatory framework for submitting and managing Biologics License Applications (BLAs) for individualized genome editing products.</p>
<p>“For patients with rare genetic diseases, a one-size-fits-all approach to treatment simply does not work and neither should a one size fits all approach to regulation,” FDA acting commissioner Kyle Diamantas, said in a statement.</p>
<p>Maury Raycroft, PhD, equity analyst at Jefferies, viewed the draft guidance positively in a Friday note: “Gene editing cos have underperformed the past yr, but we anticipate a range of de-risking data & reg catalysts ahead; recent constructiveness from FDA/gov should keep momentum going.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The draft guidance introduces to the FDA the concept of the Individualized Feature Space (IFS), a set of pre-defined limits describing allowable limits of variation for genome edited (GE) components of an individualized GE product, so such therapies can vary from patient to patient without needing to perform additional clinical trials, while remaining within the scope of a single BLA.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>“For a GE product whose only variable feature is a gRNA spacer sequence, the IFS should describe which types of spacer sequences are allowable in the BLA—such as any spacer sequence that targets a defined class of pathogenic gene variants in a specified gene and results in the same editing outcome (e.g., correcting the gene so that it encodes the wild-type protein),” the draft guidance explains.</p>
<p>The FDA is soliciting public comment through November 27, both <a href="https://www.regulations.gov/docket/FDA-2026-D-11783">online</a> and via <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/individualized-human-genome-editing-products-considerations-bla-submission-and-postapproval">mail</a>.</p>
<h4><strong>Mostly positive impact</strong></h4>
<p>Since the draft guidance was issued after the close of markets, investors had to wait until Wednesday to see the impact of the proposed rules plus ESGCT data on gene editing stocks. That impact turned out to be mostly positive, with shares of four gene editing therapy developers <span><strong>rising between 4% and 29%</strong></span>. Even higher gains earlier in the week were dampened by a <span><strong>nearly 3% drop</strong></span> in the Nasdaq Composite on Friday, sparked by disappointing third-quarter earnings reported by tech and artificial intelligence (AI) companies.</p>
<p>The biggest gainer this past week was <strong>Prime Medicine (Nasdaq: PRME)</strong>, whose shares enjoyed a <span><strong>five-day leap of 29%</strong></span> from $3.67 to $4.72—a <span><strong>20% falloff</strong> </span>from the 52-week high Prime reached on Thursday, when its share peaked at $5.91 at 9:57 a.m. ET.</p>
<p>The draft guidance continued a month-long <span><strong>53% surge</strong></span> sparked by a pair of positive clinical developments: Last month Prime received FDA clearance allowing the launch of a planned Phase I/II trial for its <em>in vivo</em> Prime Editor PM647 in alpha-1 antitrypsin deficiency (AATD).</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>And on October 5, Prime dosed the first patient in a Phase I/II open-label trial (<a href="https://clinicaltrials.gov/study/NCT07748403">NCT07748403</a>) assessing its <em>in vivo</em> Prime Editor PM577a in adults and teens as a treatment for H1069Q-mutated Wilson disease, the first reported instance of prime editing being used to edit DNA directly in a person. Prime says initial data from the trial is expected in 2027.</p>
<p>“Overall, we see promise over the long-term for the pipeline and could consider becoming more constructive on the stock as we move closer to value-creating milestones (initial clinical data) in 2027,” Tessa T. Romero, a senior analyst focused on biotechnology equity research with J.P. Morgan, commented in a June 18 research note that followed clinical trial clearance for PM577a in New Zealand.</p>
<p>Second highest among editing stocks this week with a <span><strong>13% jump</strong></span> is <strong>Beam Therapeutics (Nasdaq: BEAM)</strong>. The developer of CRISPR base editing therapies saw its shares climb from $24.05 on October 23 to $27.23 Friday, driven in part by positive initial data from its Phase I/II trial (<a href="https://clinicaltrials.gov/study/NCT06735755">NCT06735755</a>) showing clinical proof of concept for BEAM-301 for the treatment of glycogen storage disease type Ia (GSDIa).</p>
<p>BEAM-301 is a liver-targeting lipid-nanoparticle (LNP) formulation of base editing reagents designed to correct the R83C mutation, which is associated with the most severe form of GSDIa.</p>
<h4><strong>Maximum outcomes</strong></h4>
<p>As of data cutoff August 17, two of three patients in the trial’s 40 mg cohort achieved the trial protocol’s maximum 15-hour controlled fasting duration—a result consistent with restored endogenous glucose production, Beam said. The two also saw 100% reduction in daily starch requirements, no longer requiring starch supplementation, and improved glucose control with more time spent in the euglycemic range and less in the hyperglycemic range.</p>
<p>“BEAM-301 appears impressive at first clinical data look,” Myles R. Minter, PhD, a partner and biotechnology analyst with William Blair, wrote in a research note. Minter has estimated that BEAM-301 will generate peak annual sales of $475 million.</p>
<p>That would be 31% above the $362 million in peak sales modeled by Minter’s colleague at William Blair, Sami Corwin, PhD, a biotechnology-focused healthcare analyst, for Genglycos® (pariglasgene brecaparvovec-opnr), which won FDA approval in August as the first-ever drug authorized to treat GSDIa in adults and children ages 8 and older. Genglycos is marketed by <strong>Ultragenyx Pharmaceutical (Nasdaq: RARE)</strong>.</p>
<p>The third 40 mg patient showed no time to fasting hypoglycemia (TTH) increase, potentially due to high body mass index (BMI) and heterozygosity for the R83C mutation, according to Beam.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>“This could be solved with moving to the higher 60 mg dose or could warrant a BMI restriction in future cohort or even evaluation of potential weight-based dosing,” Minter added.</p>
<p>Based on the data, Beam is advancing BEAM-301 to a 60 mg cohort, where it has begun enrollment, and plans to engage with the FDA about a potential approval path.</p>
<p>Beam and Prime are likely to benefit from the FDA’s framework for genome editing drugs, Jefferies analyst Raycroft said: “We believe the framework could support/accelerate [Beam’s] PKU program entering the clin YE26/early’27 by leveraging data across 3 mut[ation]-specific PAH base editors.”</p>
<p>As for Prime, Raycroft noted that the company has FDA alignment to develop additional mutations under the same IND using most of the H1069Q package: “Follow-on editors may need only mut[ation]-specific off-target work and limited clin data for pot’l licensure.”</p>
<h4><strong>Data presented and awaited</strong></h4>
<p><strong>Editas Medicine (Nasdaq: EDIT) </strong>saw its shares <span><strong>rise 11%</strong></span> this past week, from $2.40 October 23 to $2.67 Friday. The company presented two posters at ESGCT: One detailed a <a href="https://www.editasmedicine.com/wp-content/uploads/2026/10/ESGCT-2026-Poster-P0781_tLNP-Platform-Process_FINAL.pdf">configurable, GMP-ready manufacturing platform for targeted LNP therapeutics</a> shown to enable rapid evaluation of novel binders and cargos while maintaining consistent T-cell targeted LNP (tLNP) quality across scales, binders, and batches.</p>
<p>The other showed robust <em>in vivo</em> delivery of mRNA to targeted T cells using its <a href="https://www.editasmedicine.com/wp-content/uploads/2026/10/ESGCT-2026_poster-P0361_RTO_FINAL.pdf">scalable tLNP platform</a>, which allowed for transient expression of CAR in targeted T cells, resulting in deep B-cell depletion in the blood within 24 hours post-dose. Researchers also reported seeing therapeutically relevant B-cell depletion in lymphoid tissues, “creating the potential for clinically meaningful immune reset for autoimmune therapy.”</p>
<p><strong>Intellia Therapeutics (Nasdaq: NTLA)</strong> shares also <span><strong>grew 11%</strong></span> week-over-week, from $11.21 to $12.47. Intellia investors are also waiting for clinical data on lonvoguran ziclumeran (Lonvo-z), a one-time CRISPR/Cas9 gene-editing therapy being developed to treat hereditary angioedema (HAE). Those results are to be presented in two oral presentations and five poster presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting, set for November 12–16 in Phoenix. The presentations include four-year follow-up data from patients who received a one-time 50 mg dose of lonvo-z.</p>
<p>On November 12, Intellia executives and HAE key opinion leaders plan to discuss the company’s preparations for the commercial launch of lonvo-z during a conference call with analysts.</p>
<p><strong>CRISPR Therapeutics (Nasdaq: CRSP)</strong> shares <span><strong>rose 4%</strong></span> this past week from $49.39 to $51.42 Friday as investors await third-quarter results set to be released this month, and clinical data updates such as a planned readout from the Phase Ib trial (<a href="https://clinicaltrials.gov/study/NCT07491172">NCT07491172</a>) of CTX310<sup>®</sup>, a CRISPR/Cas9 <em>in vivo</em> gene editing therapy candidate targeting angiopoietin-related protein 3 (ANGPTL3), in patients with severe hypertriglyceridemia. That data will be presented at the American Heart Association (AHA) Scientific Sessions 2026, set for November 6–9.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>Not all editing therapy stocks reaped the fruits of the FDA guidance and ESGCT data announcements. Shares of <strong>Caribou Biosciences (Nasdaq: CRBU)</strong>, a CRISPR therapeutics developer whose co-founders include Jennifer Doudna, PhD, <span><strong>dropped nearly 21%</strong></span> from 53 cents on October 23 to 42 cents Friday. Caribou thus continued a slide triggered by its <a href="https://www.genengnews.com/topics/genome-editing/stockwatch-caribou-plunges-as-it-pursues-strategic-alternatives/">review of strategic alternatives</a> and plans to reduce a “substantial” portion of its workforce—a decline that has caused the company’s stock to <span><strong>plunge 66%</strong></span> over the past month from $1.27 on September 30.</p>
<h4><strong>Anthropic details acquisition, partnerships</strong></h4>
<p>Anthropic used a <a href="https://www.anthropic.com/research/early-progress-drug-development">press release</a> rather than the <a href="https://www.sec.gov/Archives/edgar/data/2130357/000162828026067168/anthropicpbc-sx1.htm">Form S-1 Registration Statement</a> disclosing its initial public offering (IPO) plans to flesh out its progress and plans in the drug development space it has targeted as one key area of future growth.</p>
<p>The AI giant—which <a href="https://www.genengnews.com/topics/artificial-intelligence/anthropic-ipo-discloses-plans-for-life-sciences-growth/">filed for its long-awaited IPO </a> on October 26—acknowledged pursuing its own drug discovery efforts and disclosed that in August, it acquired Mithril Medicine, a developer of treatments for two rare forms of muscular dystrophy staffed by a single person, founder Cody Tranbarger, a biotech entrepreneur and investor. Tranberger used Claude to organize contracts, logistics, and experiments with 11 external labs, as well as to delegate “many other aspects of Mithril’s operations.” Mithril has advanced within 18 months a therapy for one form of muscular dystrophy from an idea to positive results in mice.</p>
<p>“If his drug candidates continue to hold up, we expect a drug to be ready to start clinical trials in humans as soon as late 2028,” Anthropic predicted.</p>
<h4><strong>“Deep research partnerships”</strong></h4>
<p>Anthropic also listed a series of six “deep research partnerships” with drug developers. Two of the six are public companies, <strong>Bristol Myers Squibb (BMS; NYSE: BMY)</strong> and <strong>Generate: Biomedicines (Nasdaq: GENB)</strong>, which in February <a href="https://www.genengnews.com/topics/artificial-intelligence/stockwatch-ai-drug-developer-generates-400m-ipo/">carried out its own $400 million IPO</a> (of which $369.3 million was net proceeds). The other four partners are private companies: <strong>BigHat Biosciences</strong>, <strong>Divergence Labs</strong>, <strong>Enveda</strong>, and <strong>The Column Group (TCG)</strong>.</p>
<p>Anthopic’s release also offered some details of its work with collaboration partners:</p>
<ul>
<li><strong>BMS:</strong> The pharma giant used Anthropic’s Claude family of large-language models to estimate the likelihood of success for planned clinical trials of an unidentified early-stage drug. “Together, we plan to expand this work in 2027 to understand its potential for increasing the probability of success in early development,” Anthropic said.</li>
<li><strong>Generate:</strong> Six Generate scientists used Claude Code to propose new designs for part of a chimeric antigen receptor T cell (CAR T) therapy’s genetic instructions, creating room for additional instructions addressing other types of cancer. One design “about 70%” shorter showed greater effectiveness than the standard version in lab tests: “Compact ICDs [intracellular domains] may lower the dose needed to generate CAR T cells <em>in vivo</em> and enable more complex CAR therapies, such as CAR cocktails,” <a href="https://generatebiomedicines.com/wp-content/uploads/2026/10/refactored-intracellular-domains-enhance-car-expression-and-function.pdf">Generate concluded</a>.</li>
<li><strong>BigHat:</strong> Researchers from the protein and antibody drug developer joined Anthropic in applying Claude to <a href="https://cdn.prod.website-files.com/64ff35ef45fc1e4545e5ffa1/6ae0ea8e28d4a390cbe66b52_bighat_pilot_retro_final_v2.pdf#navpanes=0">improve binding, stability, and anti-clumping properties</a> of two antibody fragments that could become parts of future drugs: one designed to target cancer cells, and one designed to keep a drug in the body longer.</li>
<li><strong>Enveda:</strong> The developer of molecules based on living organisms “reduced human review time by 89%, from over 25 hours to less than three, by linking its manufacturing documents to Claude. After reviewing 1,061 pages of documentation, Anthropic Claude caught all 11 issues that human reviewers had spotted and flagged seven they missed: “A promising development for future use cases in decreasing the time, cost, and error rates in drug development,” <a href="https://enveda.com/CMC-Document-Processor/">Enveda concluded</a>.</li>
<li><strong>TCG:</strong> A spinout of the venture capital firm, called Pleiades, will use Claude to reduce scientific, operational, and administrative overhead as it runs more, and more complex, drug development programs “than is usual for a small team,” Anthropic said, adding: “The savings will enable previously untenable risks on a larger array of challenging and innovative projects.”</li>
<li><strong>Divergence:</strong> Using Claude, the food allergy drug developer generated “roughly 35,000” antibody designs in about a month for testing. Divergence found three design arms designed to bind tightly to IgE, and 20 that could help dislodge IgE from the immune cell (three of which dislodged more IgE than standard medication). Divergence plans to build a drug that combines the two types of arms, <a href="https://divergencelabs.com/publications/ige-preprint.pdf">stating in a study</a>: “We expect biparatopic construction … to provide a significant boost to potency and disruptive efficacy.”</li>
</ul>
<p>In a <a href="https://www.linkedin.com/feed/update/urn:li:activity:7521638389297618945/">LinkedIn post</a>, however, Geoff Harris, PhD, CSO and co-founder of Excellergy—an indirect, wholly owned subsidiary of <strong>Novartis (SIX Swiss: NOVN and NYSE: NVS) </strong>acquired for up to $2 billion in June—said Divergence Labs’ study “doesn’t describe a drug, but the components of what might be a drug someday, maybe, which is years behind the competition.”</p>
<p>“A monoclonal antibody drug that is exceptional at disarming the IgE axis already exists and is in the clinic today,” Harris added, namely Excellergy’s lead candidate EXL-111, a trifunctional allergic effector cell response inhibitor designed to treat allergic diseases by targeting the IgE axis. EXL-111 is in a Phase I trial (<a href="https://clinicaltrials.gov/study/NCT07356713">NCT07356713</a>) with an estimated primary completion date of December 7.</p>
<p>Anthropic says it envisions Divergence and its other partners applying Claude to ultimately bring their candidates into the clinic as well: “We plan to continue extending Claude’s role into clinical trials as these drug programs advance, and as we partner with more organizations whose drug development programs are already at the clinical stage.”</p>
<h4><strong>Leaders and laggards</strong></h4>
<p><strong>Acumen Pharmaceuticals (Nasdaq: ABOS)</strong> shares <span><strong>cratered 91%</strong> </span>from $2.29 to just 21 cents Friday after the developer of Alzheimer’s disease (AD) drugs targeting amyloid beta oligomers announced that it was ceasing development of its lead pipeline candidate sabirnetug (ACU193) and evaluate its strategic options after the humanized monoclonal antibody failed the Phase II ALTITUDE-AD trial (<a href="https://clinicaltrials.gov/study/NCT06335173">NCT06335173</a>) in participants with early AD. Sabirnetug missed its primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale (iADRS) at 18 months vs. placebo at either the 35 mg/kg or the 50 mg/kg dose. Sabirnetug also failed to achieve statistical significance on key secondary efficacy endpoints, including the Clinical Dementia Rating–Sum of Boxes (CDR-SB), and did not show any meaningful difference between the sabirnetug and placebo treatment arms. Acumen said it plans to take steps to carry out cash conservation measures and explore strategic options.</p>
<p><strong>Aspen Neuroscience (ASPE) </strong>shares <span><strong>dipped 0.7%</strong></span> from its initial public offering (IPO) price of $15 a share to $14.89 Friday as the developer of autologous induced-pluripotent stem cell (iPSC)-derived therapies for neurodegenerative diseases began its first full day of trading. Shares began the day at $14.70, below the IPO price—the low end of its $15-$17 price range when it priced 9.375 million shares, raising $140.625 million in gross proceeds. Proceeds are intended to fund clinical trials for its lead candidate, the Parkinson’s disease therapy sasineprocel, now in the Phase I/IIa ASPIRO open-label dose escalation study (<a href="https://clinicaltrials.gov/study/NCT06344026">NCT06344026</a>), as well as development of the company’s microglia programs, including initiating IND-enabling studies.</p>
<p><strong>Genmab (Nasdaq: GMAB) </strong>shares <span><strong>jumped 28% </strong></span>from $44.67 to $57.29 Wednesday after the antibody drug developer announced data from the global Phase III LiGeR-HN1 trial (<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06525220&data=05%7C02%7Calex.philippidis%40sagepub.com%7C131a0ad3a85b4a2196a708df362706b1%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639289213847837766%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=F7Z5EC0YjX9EddbZXCq2F5TVWspvkNjDkg%2FKyTmFnZ0%3D&reserved=0">NCT06525220</a>) assessing petosemtamab in combination with pembrolizumab, the cancer immunotherapy blockbuster marketed by <strong>Merck & Co. (NYSE: MRK)</strong> as Keytruda®, vs. pembrolizumab alone in patients with first-line (1L) PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Based on the first interim analysis assessed by an independent data monitoring committee, treatment with the petosemtamab combination showed a “statistically significant and clinically meaningful” improvement in overall survival (OS), reducing the risk of death by 50%, and objective response rate (ORR) vs. pembrolizumab [OS hazard ratio 0.50, p<0.0001; ORR odds ratio 3.17 p<0.0001), meeting the trial’s dual primary endpoints regardless of HPV status.</p>
<p><strong>Iovance Biotherapeutics (Nasdaq: IOVA)</strong> shares <span><strong>tumbled 35%</strong></span> from $14.81 to $9.56 Thursday after the tumor infiltrating lymphocyte (TIL) cell therapy developer announced data from Cohorts 1 and 2 of its Phase II IOV-LUN-202 trial (<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04614103&data=05%7C02%7Calex.philippidis%40sagepub.com%7C131a0ad3a85b4a2196a708df362706b1%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639289213847909389%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=c5nxp6oOYcCUls%2Fe3WaUlxpyB%2F75klzTvl85Ch11Smo%3D&reserved=0">NCT04614103</a>) evaluating lifileucel in previously treated metastatic non-small cell lung cancer. As of the October 14 data cutoff 17 of 69 patients responded, an ORR of 24.6%, consistent with the 25.6% ORR previously reported in 39 patients but less than what investors expected. Iovance said a retrospective analysis found a biomarker-enriched subgroup defined by Kirsten rat sarcoma viral oncogene homolog (<em>KRAS</em>) wild-type status, human epidermal growth factor receptor 2 (<em>HER2</em>) wild-type status, and current or former smoking.</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/stockwatch-gene-editing-shares-jump-on-esgct-data-fda-draft-guidance/">StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Express Pharma November 2026</title>
<link>https://edusehat.com/en/express-pharma-november-2026</link>
<guid>https://edusehat.com/en/express-pharma-november-2026</guid>
<description><![CDATA[ 
India&#039;s Foremost Pharma &amp; Biotech Magazine ~ PLI 2.0: Can MSMEs Catch Up?
The post Express Pharma November 2026 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/01110939/EP-NOV-2026-MAG-COVER.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sun, 01 Nov 2026 12:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Express, Pharma, November, 2026</media:keywords>
<content:encoded><![CDATA[<div><img width="200" height="264" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/01110939/EP-NOV-2026-MAG-COVER.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async"></div><p><em>PLI 2.0: Can MSMEs Catch Up?</em><br>
</p><div class="_df_book df-lite" _slug="express-pharma-november-2026" data-title="express-pharma-november-2026" wpoptions="true" thumbtype=""></div>
<hr>
<p><strong>Click to download:</strong> <a href="https://cdn.expresspharma.in/wp-content/uploads/2026/11/01103313/EP_NOVEMBER_2026.pdf" target="_blank" rel="noopener noreferrer">November 2026 Digital Magazine</a></p>
<p>The post <a href="https://www.expresspharma.in/express-pharma-november-2026/">Express Pharma November 2026</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Medical Students Mental Health: Why Burnout Happens and How to Prevent It</title>
<link>https://edusehat.com/en/medical-students-mental-health-why-burnout-happens-and-how-to-prevent-it</link>
<guid>https://edusehat.com/en/medical-students-mental-health-why-burnout-happens-and-how-to-prevent-it</guid>
<description><![CDATA[ If you’ve ever felt emotionally exhausted after weeks of studying, questioned whether you’re “good enough” despite working incredibly hard, or found yourself losing motivation for something you once loved, you’re certainly not alone. Burnout has become increasingly common among medical students, and for good reason.   Medical school asks students to absorb enormous amounts of […]
The post Medical Students Mental Health: Why Burnout Happens and How to Prevent It appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/10/pexels-mikhail-nilov-9159061-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 31 Oct 2026 19:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Medical, Students, Mental, Health:, Why, Burnout, Happens, and, How, Prevent</media:keywords>
<content:encoded><![CDATA[<p><span>If you’ve ever felt emotionally exhausted after weeks of studying, questioned whether you’re “good enough” despite working incredibly hard, or found yourself losing motivation for something you once loved, you’re certainly not alone. Burnout has become increasingly common among medical students, and for good reason.</span></p>
<p> </p>
<p><span>Medical school asks students to absorb enormous amounts of information, perform well on high-stakes exams, navigate emotionally challenging clinical experiences, and often put their personal lives on hold, all while maintaining the expectation of excellence. It is no surprise that many students eventually find themselves running on empty.</span></p>
<p> </p>
<p><span>The encouraging news is that burnout is not inevitable. Understanding why it happens is the first step toward preventing it before it swallows you.</span></p>
<p> </p>
<h2><strong>Burnout Doesn’t Happen Overnight</strong></h2>
<p><span>One of the biggest misconceptions about burnout is that it appears suddenly. </span><span>In reality, burnout usually develops gradually. It often starts with small changes that students dismiss: feeling a little more tired than usual, struggling to focus during lectures, losing interest in hobbies, feeling irritable, and not taking care of yourself like you normally would. </span></p>
<p> </p>
<p><span>Over time, those small warning signs can accumulate into emotional exhaustion, decreased motivation, cynicism, and the feeling that no matter how hard you work, you’re never doing enough.</span></p>
<p> </p>
<p><span>Many students don’t recognize burnout until they’re already deeply affected by it. </span><span>Learning to identify those early signs allows you to make adjustments before your physical and emotional energy become completely depleted. For practical ways to respond to these early warning signs, explore our guide on <a href="https://elitemedicalprep.com/how-to-manage-stress-during-medical-school/">how to manage stress during medical school</a>. </span></p>
<p> </p>
<h2><strong>Perfectionism Can Become Your Biggest Obstacle</strong></h2>
<p><span>Medicine attracts highly motivated, high-achieving individuals, and those qualities often contribute to success. However, they can also become major contributors to burnout.</span></p>
<p> </p>
<p><span>Many students hold themselves to impossibly high standards. <a href="https://elitemedicalprep.com/how-to-recover-after-a-low-nbme-practice-score-a-step-by-step-strategy/">A practice score that isn’t perfect feels like failure</a>. Missing one study day creates guilt. Asking for help feels like weakness.</span></p>
<p> </p>
<p><span>Over time, this constant pressure becomes exhausting. </span><span>One lesson many experienced physicians eventually learn is that perfection is not required to become an excellent doctor. Growth, consistency, and resilience matter far more than flawless performance.</span></p>
<p> </p>
<p><span>Learning to celebrate progress instead of demanding perfection can significantly reduce unnecessary stress throughout medical school.</span></p>
<p> </p>
<h2><strong>Your Identity Should Be Bigger Than Medicine</strong></h2>
<p><span>Medical school is incredibly demanding, but it should not become your entire identity. </span><span>One common pattern among burned-out students is that every aspect of their self-worth becomes tied to academic performance. A difficult shelf exam, a disappointing evaluation, or a lower-than-expected practice score suddenly feels like a reflection of who they are as a person.</span></p>
<p> </p>
<p><span>This mindset makes setbacks much more painful and personal than they need to be. </span><span><a href="https://elitemedicalprep.com/balancing-medical-school-and-life-strategies-for-maintaining-a-social-life/">Maintaining interests outside of medicine</a>, whether that’s spending time with family, exercising, reading, cooking, volunteering, or simply enjoying time with friends, helps create perspective during difficult periods.</span></p>
<p> </p>
<p><span>Contrary to what you might think, taking breaks often improves productivity rather than reducing it.</span></p>
<p> </p>
<h2><strong>Rest Is a Crucial Part of Training</strong></h2>
<p><span>Medical students frequently view rest as something that must be earned.</span></p>
<p> </p>
<ul>
<li><span>“I’ll take a day off after this exam.”</span></li>
<li>“I’ll exercise once dedicated is over.”</li>
<li>“I’ll catch up on sleep after rotations.”</li>
</ul>
<p> </p>
<p><span>Unfortunately, those milestones rarely stop coming. </span><span>The reality is that recovery is not separate from learning, it supports it. Sleep improves memory consolidation. Exercise reduces stress hormones. Time away from studying improves concentration and decision-making.</span></p>
<p> </p>
<p><span>Students who <a href="https://elitemedicalprep.com/crafting-a-personalized-study-routine-in-medical-school/">schedule recovery intentionally</a> often maintain higher productivity over longer periods than those who try to push through constant exhaustion.</span></p>
<p> </p>
<h2><strong>Comparison Is an Endless Trap</strong></h2>
<p><span>All medical students are extremely high achievers, so put them in one big group together and it’s a recipe for endless comparison!</span></p>
<p> </p>
<p><span>Someone always seems to finish studying earlier. Someone scores higher on practice exams. Someone already knows which specialty they want. Someone else somehow appears to balance research, volunteering, and a social life effortlessly.</span></p>
<p> </p>
<p><span>What students rarely see are the challenges behind those successes.</span></p>
<p> </p>
<p><span>Comparing your progress to someone else’s highlight reel almost always increases stress without improving performance. </span><span>Your medical school journey is unique. The pace that allows someone else to thrive may not be sustainable for you, and that’s perfectly okay.</span></p>
<p> </p>
<h2><strong>Learn to Ask for Help Early</strong></h2>
<p><span>One of the strongest predictors of long-term success in medicine is not independence, it’s knowing when to seek support. </span><span>Students sometimes wait until they are completely overwhelmed before speaking with advisors, mentors, counselors, or academic support services. Others worry that asking for help means they are somehow less capable than their classmates.</span></p>
<p> </p>
<p><span>In reality, reaching out early often prevents small struggles from becoming much larger ones. </span><span>Support may come from faculty mentors, classmates, <a href="https://elitemedicalprep.com/meet-the-tutors/">tutors</a>, family members, or mental health professionals. Every physician needs support at different points in training. </span><span>There is strength in recognizing when you don’t have to navigate everything alone.</span></p>
<p> </p>
<h2><strong>Burnout Prevention Looks Different for Everyone</strong></h2>
<p><span>There is no universal formula for maintaining well-being during medical school. </span><span>Some students recharge through exercise. Others need quiet evenings at home, creative hobbies, faith communities, or spending time outdoors. Some benefit from <a href="https://elitemedicalprep.com/time-management-in-med-school-balancing-class-boards-and-life/">structured routines</a>, while others need flexibility.</span></p>
<p> </p>
<p><span>The important part is identifying what consistently helps you feel physically and emotionally restored, and protecting that time as intentionally as you protect study time. </span><span>Prevention is almost always easier than recovery.</span></p>
<p> </p>
<h2><strong>The Bottom Line</strong></h2>
<p><span>Burnout is common in medical school, but it is not something students simply have to accept as part of becoming a physician. It develops gradually through chronic stress, perfectionism, unrealistic expectations, and neglecting personal well-being. </span></p>
<p> </p>
<p><span>The students who sustain themselves throughout training are rarely those who work the longest hours. They are often the ones who recognize their limits, ask for help when needed, maintain interests outside of medicine, and understand that taking care of themselves ultimately allows them to take better care of their future patients. And you should surround yourself with people who support you in doing all these things. </span></p>
<p> </p>
<p><span>Medicine is a marathon, not a sprint. Protecting your mental health isn’t stepping away from your goal, it’s one of the most important ways to reach it. If you could use support with the academic demands along the way, <a href="https://elitemedicalprep.com/contact/">EMP’s 1:1 tutoring</a> can help you build a study plan around your needs, goals, and schedule. <a href="https://elitemedicalprep.com/contact/">Get started</a> with personalized support for your preparation.</span></p>
<p>The post <a href="https://elitemedicalprep.com/medical-students-mental-health-why-burnout-happens-and-how-to-prevent-it/">Medical Students Mental Health: Why Burnout Happens and How to Prevent It</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>100 Million&#45;Cell AI&#45;Ready Dataset with Single&#45;Cell and Proteomic Data Created by Parse and Nomic</title>
<link>https://edusehat.com/en/100-million-cell-ai-ready-dataset-with-single-cell-and-proteomic-data-created-by-parse-and-nomic</link>
<guid>https://edusehat.com/en/100-million-cell-ai-ready-dataset-with-single-cell-and-proteomic-data-created-by-parse-and-nomic</guid>
<description><![CDATA[ Parse Biosciences and Nomic Bio are partnering to create Cascade, a 100-million-cell multimodal dataset combining single-cell and proteomic data to advance AI-driven immune modeling, drug discovery, and therapeutic target identification.
The post 100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2242943155.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 31 Oct 2026 04:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>100, Million-Cell, AI-Ready, Dataset, with, Single-Cell, and, Proteomic, Data, Created, Parse, and, Nomic</media:keywords>
<content:encoded><![CDATA[<p>Parse Biosciences, a QIAGEN company and a provider of scalable and accessible single-cell sequencing, and Nomic Bio, focused on high-throughput proteomic profiling, today announced their partnership to generate Cascade, a 100 Million cell foundational dataset to understand the human immune response. The dataset’s scale and depth will offer pharma partners cellular- and protein-level insight into immune biology, with the goal to accelerate their ability to identify and validate new drug targets.</p>
<p>Cascade is a multimodal, perturbation dataset that captures how immune cells respond to treatment across multiple timepoints. The dataset will combine 100 million single-cell RNA-seq profiles with more than 11,000 proteomic secretome profiles, capturing how different immune cell types respond to over 150,000 individual and combinatorial cytokine and drug perturbation conditions. By pairing transcriptomic and proteomic readouts of the same immune responses over time, Cascade will provide researchers a view into the mechanisms driving human immune signaling, filling a critical data gap for building predictive, virtual cell models.</p>
<p>Cascade has already drawn foundational partner commitments from leading pharmaceutical and biotechnology companies, including GSK, Pfizer, Sanofi, Graph Therapeutics, and Turbine, underscoring the demand for large-scale, multimodal immune data in drug discovery.</p>
<p>The single-cell RNA-seq data generation will be performed in Parse’s GigaLab, a high throughput service lab capable of profiling billions of cells a year. These data will be paired with proteomic secretome data that will be generated through Nomic’s Omini 1000 platform, which will measure more than 1,000 secreted proteins across all samples.</p>
<p>“Biological AI modeling has hit a data bottleneck. Despite their central role in drug discovery, there is a surprisingly small amount of available data measuring the human’s immune response to key perturbations like cytokines and other drugs,” notes Charlie Roco, PhD, co-founder and chief technology officer at Parse Biosciences. “Cascade is a critical step to revealing these interactions, and we expect to dramatically improve the predictive power of our partner’s AI models as a result.”</p>
<p>
</p><p>The post <a href="https://www.genengnews.com/topics/omics/100-million-cell-ai-ready-dataset-with-single-cell-and-proteomic-data-created-by-parse-and-nomic/">100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure</title>
<link>https://edusehat.com/en/opentrons-raises-40m-in-series-e-to-expand-its-robotics-software-data-infrastructure</link>
<guid>https://edusehat.com/en/opentrons-raises-40m-in-series-e-to-expand-its-robotics-software-data-infrastructure</guid>
<description><![CDATA[ According to the company, the funds will support the next phase of its growth in enabling autonomous science in labs and biopharmaceutical companies using its AI and robotics systems.
The post Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/01/Trends-Automation-GettyImages-2210278635.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 31 Oct 2026 04:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Opentrons, Raises, 40M, Series, Expand, Its, Robotics, Software, Data, Infrastructure</media:keywords>
<content:encoded><![CDATA[<p><span>Opentrons Labworks has raised $40 million from a Series E financing round led by healthcare investor Avego, with additional investment from BroadOak Capital Partners. The company has said that it plans to use the capital to scale its robotics, software, and data infrastructure tools.</span></p>
<p><span>Specifically, the funds will support the company’s efforts to design artificial intelligence and robotics systems that work together to design, execute, and learn from scientific experiments. This includes investing in AI-driven experimental execution, extending its automation capabilities, and expanding into new markets and geographies. </span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p><span>Additionally, the funds will allow Opentrons to enable faster protocol development through its software and AI, expand capabilities across its robots and instruments, and provide deeper integration of its tools into the broader lab automation ecosystem. </span></p>
<p><span>“Drug developers and AI companies alike are moving experimental work forward toward automated workflows that generate usable data,” said James Flexner, managing partner at Avego. “We see a significant opportunity for autonomous science to converge around Opentrons’ platform.” James Atwood, PhD, Opentrons’ CEO, added “we made lab automation accessible for any lab, and our systems are built for AI to run experiments directly. That is why autonomous science is standardizing on Opentrons.”</span></p>
<p><span>Opentrons reports that to date, it has deployed over 11,000 robots to laboratories in over 80 countries. Its customer base includes academic groups, diagnostic labs, and global pharmaceutical companies, Earlier this year, the company announced that it is using <a href="https://www.genengnews.com/topics/drug-discovery/opentrons-uses-nvidia-tech-to-build-training-data-that-powers-physical-ai-in-the-lab/" target="_blank" rel="noopener">Nvidia’s Isaac and Cosmos AI platforms</a> to generate training data needed to develop and deploy physical AI-enabled laboratory robotics.</span></p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/opentrons-raises-40m-in-series-e-to-expand-its-robotics-software-data-infrastructure/">Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Less paperwork, more medicine: Practicing in an integrated care system</title>
<link>https://edusehat.com/en/less-paperwork-more-medicine-practicing-in-an-integrated-care-system</link>
<guid>https://edusehat.com/en/less-paperwork-more-medicine-practicing-in-an-integrated-care-system</guid>
<description><![CDATA[ Practicing physicians share how Kaiser Permanente’s integrated care model reduces administrative burden and creates more time for patient care.
The post Less paperwork, more medicine: Practicing in an integrated care system appeared first on Permanente Medicine. ]]></description>
<enclosure url="https://permanente.org/wp-content/uploads/2026/10/TPMG_09162019_Garfield_Center_Scene_11_4111_1920.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 31 Oct 2026 04:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Less, paperwork, more, medicine:, Practicing, integrated, care, system</media:keywords>
<content:encoded><![CDATA[<h2>How integrated care reduces paperwork, documentation demands, coding distractions, and referral friction — giving physicians more time and space for patient care</h2>
<p><strong>By Brent Johnson</strong><br>
The Permanente Federation</p>
<p>In private practice, Jess Holzman, MD, managed a panel of 2,800 patients. Friday was theoretically her day off, but work often continued at home. “Every Thursday night, I would bring home a manila envelope with a stack of paperwork,” she says.</p>
<p>That envelope included all kinds of tasks, including prescription refills. Each request could require comparing pharmacy options, entering prescription information, confirming dosage, checking laboratory results, and reviewing blood pressure readings. Repeated across hundreds of patients, the work consumed hours each week.</p>
<p>For many physicians in fragmented, fee-for-service systems, administrative work is simply part of each day: signing forms, authorizing prescriptions, selecting billing codes, locating records in separate systems, and following up on referrals.</p>
<p>Individually, these tasks may appear routine. Together, they can interrupt clinical reasoning, extend the workday, and shift attention from patient care to administrative and financial considerations.</p>
<p>The physicians in this story describe how those daily demands are shaped by the system they practice in — and how they change when coverage, facilities, clinicians, pharmacists, and specialists work within an integrated, value-based care model like Kaiser Permanente.</p>
<p>After Dr. Holzman joined <a href="https://northwest.permanente.org/" target="_blank" rel="noopener">Northwest Permanente</a> to practice family medicine, much of that paperwork went away. “To have it vaporize instantaneously was absolutely lovely,” she says.</p>
<p><span data-ccp-props='{"201341983":0,"335559739":0,"335559740":240}'><div class="vcex-module vcex-divider vcex-divider-solid vcex-divider-center wpex-mx-auto wpex-max-w-100 wpex-block wpex-h-0 wpex-border-b wpex-border-solid wpex-border-main"></div></span></p>
<p><b><span data-contrast="auto">Related story: </span></b><a href="https://permanente.org/about-us/our-care-model/" target="_blank" rel="noopener">What is Permanente Medicine?</a></p>
<p><span data-ccp-props='{"201341983":0,"335559739":0,"335559740":240}'><div class="vcex-module vcex-divider vcex-divider-solid vcex-divider-center wpex-mx-auto wpex-max-w-100 wpex-block wpex-h-0 wpex-border-b wpex-border-solid wpex-border-main"></div></span></p>
<h3>How team-based prescription refills reduce after-hours work</h3>
<p>Dr. Holzman now works closely with pharmacists using agreed-upon protocols that allow most routine refill requests to be completed without a physician reviewing each one.</p>
<p>Because Kaiser Permanente operates its own pharmacies, patients and physicians can avoid multiple layers of review, streamlining the process and speeding medication delivery.</p>
<p>“Now, 85% of our refills are done via protocol,” Dr. Holzman says. “I only do 15% of my own refills, which is absolutely fantastic.”</p>
<p>Elizabeth Buys, MD, an OB-GYN at <a href="https://northerncalifornia.permanente.org/" target="_blank" rel="noopener">The Permanente Medical Group</a> in Northern California, describes a related change in her daily work: fewer gaps in patient information and less time spent thinking about billing codes.</p>
<h3>How connected patient records lighten the cognitive load</h3>
<p>For more than two decades, Dr. Buys practiced in a for-profit hospital system in North Carolina, where caring for patients often required gathering information from disconnected sources.</p>
<p>For a high-risk patient, she might review hundreds of pages of scanned or faxed records from multiple locations — if those records arrived at all.</p>
<p>“In those situations, you just know you’re missing something,” Dr. Buys says. “And that’s a terrible feeling.”</p>
<p>After joining Kaiser Permanente in 2024, Dr. Buys found that the vast majority of her patients’ paperwork was neatly arranged in a shared electronic health record, reducing the need to reconstruct a clinical history from separate files.</p>
<p>She also experienced another form of relief — from coding.</p>
<h3>Coding to document care — not maximize payment</h3>
<p>In the nation’s fragmented care system, medical coding helps health care providers, insurance companies, and government programs determine reimbursement. Physicians may therefore need to consider not only which code reflects an encounter, but also whether their documentation supports the level of payment associated with it.</p>
<p>“Coding was hard” at her former hospital, Dr. Buys says. “I was always wondering what code to put down — 1, 2, or 3? Do I need to document this one more thing so that it would actually be a 3? That was a decision I had to make every time I saw a patient.”</p>
<p>At Kaiser Permanente, care delivery, coverage, and facilities operate within an integrated model. Permanente physicians are not paid according to the code selected for each individual encounter; instead, they’re aligned with agreed-upon incentives in a <a href="https://permanente.org/medical-excellence/unlocking-the-potential-of-value-based-care/" target="_blank" rel="noopener">value-based care model</a>.</p>
<p>For Dr. Buys, that means coding can return to its clinical purpose: documenting the care she provides. Nothing more.</p>
<p>“It just opened up this opportunity to have that thinking go into something else much more important — my patients, not someone’s bottom line,” Dr. Buys says. “It lifted a cognitive burden that always occupied my mind.”</p>
<h3>Integrated specialty care streamlines referrals</h3>
<p>Referrals create another daily challenge in fragmented systems. When a specialist is difficult to reach, the referring physician may be left managing clinical uncertainty while the patient waits.</p>
<p>“When you think a patient needs to go see a neurologist, but that appointment isn’t available for 8 months,” she says, “then you’re stuck telling the patient what you think is really important, but they can’t do anything about it.”</p>
<p>Kellen Galster, MD, an emergency medicine physician with The Permanente Medical Group, remembers working with the same uncertainty prior to joining Kaiser Permanente.</p>
<p>In his former practice settings, the hospitals, physicians, and specialists all operated independently. A referral could mean sending a patient into another system without a direct way to coordinate next steps.</p>
<p>His current experience is different. “I can pull up my smartphone and call any specialist,” Dr. Galster says. “The stress is so much less, and my feel-goods are so much higher just knowing that I’m able to contact anyone.”</p>
<p>Within <a href="https://permanente.org/our-medical-groups/" target="_blank" rel="noopener">Permanente Medical Groups</a>, specialists often practice in the same medical facilities and on shared systems as primary care physicians. That structure can make consultation and coordination more direct.</p>
<p>Instead of sending a patient to see a specialist in a disconnected care system and hoping for the best, Dr. Galster can bring a specialist into the conversation and make better, more informed decisions.</p>
<p>“It allows me to advance care for the patient and have more reassurance that we’re doing the best possible thing,” Dr. Galster says. “That quality of care and attention meets patients where they need to be met.”</p>
<h3>What a physician’s day can look like in an integrated care system</h3>
<p>In fragmented, fee-for-service settings, the administrative burdens these physicians describe are often treated as unavoidable features of practicing medicine.</p>
<p>But as Drs. Holzman, Buys, and Galster can attest, practicing in an integrated, value-based system not only reduces the coordination physicians must carry themselves, it also provides more time and space to focus on clinical judgment, collaboration, and continuity of care.</p>
<p>For prospective physicians considering how to get back to the essence of practicing medicine, Dr. Galster offers the following:</p>
<p>“What brought me to Kaiser Permanente was their quality benchmarks and the quality of outcomes for their patients,” he says. “And I wanted to be part of that system.”</p>
<p> </p>
<p>The post <a href="https://permanente.org/less-paperwork-more-medicine-practicing-in-an-integrated-care-system/">Less paperwork, more medicine: Practicing in an integrated care system</a> appeared first on <a href="https://permanente.org/">Permanente Medicine</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Pharma Friday – October 30, 2026</title>
<link>https://edusehat.com/en/pharma-friday-october-30-2026</link>
<guid>https://edusehat.com/en/pharma-friday-october-30-2026</guid>
<description><![CDATA[ An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Glooko Presents Data on Glucose Management Tool’s Effectiveness During Labor and Delivery On October 28, Glooko, Inc., a global digital health company focused on glycemic safety and diabetes management across care settings, announced real-world data presented at the Diabetes Technology Society […]
The post Pharma Friday – October 30, 2026 appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/pharmaaaaa7.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 31 Oct 2026 01:40:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pharma, Friday, –, October, 30, 2026</media:keywords>
<content:encoded><![CDATA[<p>An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Glooko Presents Data on Glucose Management Tool’s Effectiveness During Labor and Delivery On October 28, Glooko, Inc., a global digital health company focused on glycemic safety and diabetes management across care settings, announced real-world data presented at the Diabetes Technology Society […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/pharma-friday-october-30-2026/">Pharma Friday – October 30, 2026</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>No Nonsense: David Liu Lauds Progress in Disease&#45;Agnostic Gene Editing at ESGCT</title>
<link>https://edusehat.com/en/no-nonsense-david-liu-lauds-progress-in-disease-agnostic-gene-editing-at-esgct</link>
<guid>https://edusehat.com/en/no-nonsense-david-liu-lauds-progress-in-disease-agnostic-gene-editing-at-esgct</guid>
<description><![CDATA[ Liu ensured that his return visit to ESGCT (having spoken at the congress in Barcelona in 2019) would be one of the highlights of the conference. The “meta lesson” of the past few years in therapeutic genome editing is that different scientific approaches and applications can synergize with regulatory, manufacturing, and economic advances “to achieve the mission we’re on.”
The post No Nonsense: David Liu Lauds Progress in Disease-Agnostic Gene Editing at ESGCT appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCTPodium_edited.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 31 Oct 2026 01:10:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Nonsense:, David, Liu, Lauds, Progress, Disease-Agnostic, Gene, Editing, ESGCT</media:keywords>
<content:encoded><![CDATA[<p><strong>HAMBURG</strong>—The distinguished researcher who had the dubious honor of speaking before David Liu, PhD, in a plenary session at the European Society of Gene & Cell Therapy (ESGCT)—2018 Kavli Award winner Virginijus Siksnys, PhD—opened his talk with a bashful admission: “I’m just the warm up for David,” the Lithuanian chuckled.</p>
<figure aria-describedby="caption-attachment-340012" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="wp-image-340012 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCTPodium_edited-300x189.jpg" alt="" width="300" height="189" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCTPodium_edited-300x189.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCTPodium_edited-1024x645.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCTPodium_edited-768x484.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCTPodium_edited.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">David Liu, PhD, speaking at ESGCT 2026, Germany. [K. Davies]</figcaption></figure>
<p>Liu ensured that his return visit to ESGCT (having spoken at the congress in <a href="https://www.genengnews.com/topics/genome-editing/promising-results-reported-in-tay-sachs-gene-therapy-trial/" target="_blank" rel="noopener">Barcelona in 2019</a>) would be one of the highlights of the conference. The “meta lesson” of the past few years in therapeutic genome editing, Liu began, is that different scientific approaches and applications can synergize with regulatory, manufacturing, and economic advances “to achieve the mission we’re on.”</p>
<p>That mission is already confronting the immense challenge of expanding the early clinical promise of genome editing beyond the vanishingly long tail of genetic diseases. There are more than 200,000 known mutations responsible for some 8,000 known genetic diseases, affecting roughly 400 million families.</p>
<p>Liu’s journey into precision genome editing kicked off ten years ago with the publication of the first landmark base editing report. Prime editing (PE) was described three years later. The two technologies, both building off the CRISPR-Cas chassis, provide a vast repertoire of potential gene edits encompassing single-base substitutions and are being commercially driven by two biotech companies co-founded by Liu—Beam Therapeutics and Prime Medicine.</p>
<h4><strong>AI and PE </strong></h4>
<p>Liu gave two examples of how his lab is integrating artificial intelligence (AI) into the development of enhanced prime editing technology.</p>
<p>In the first example, <a href="https://www.nature.com/articles/s41586-026-10820-0" target="_blank" rel="noopener">published a few months ago in <em>Nature Biotechnology</em></a>, Liu’s lab used an AI tool called ProteinMPNN to improve the overall attributes of prime editors. In 2023, Liu’s lab used phage-assisted continuous evolution (PACE) to evolve prime editors in the lab. Although these evolved PE6 prime editors had higher activity, they tended to exhibit lower stability and expression levels.</p>
<p>ProteinMPNN, Liu said, excels at the inverse protein folding problem: generating sequences that can fold stably into a given structure. By allowing ProteinMPNN to redesign as many as 25 percent of the reverse transcriptase amino acids, the researchers were able to remedy stability deficits. The new PE8 variants show stronger expression and editing efficiencies in various cell types.</p>
<p>Another recent paper describes <a href="https://www.nature.com/articles/s41587-026-03261-7" target="_blank" rel="noopener">the development of a free machine learning tool called OptiPrime</a> to predict prime editing outcomes. “We can’t call it Optimus Prime or Hasbro would sue us,” Liu joked.</p>
<p>Each pegRNA contains multiple regions that are subject to variability that can significantly impact PE efficiency. OptiPrime helps simplify the search through potentially hundreds of potential pegRNA variants that can all in principle engineer the same edit. Researchers can use the <a href="https://optipri.me/" target="_blank" rel="noopener">OptiPri.me website</a> to generate a rank-ordered list of the top pegRNA candidates. The relevant information can be copied and pasted into the online order forms for a researcher’s favorite gene synthesis service.</p>
<figure aria-describedby="caption-attachment-340008" class="wp-caption aligncenter"><img decoding="async" class="wp-image-340008" src="https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCT_stage-1024x758.jpg" alt="David Liu, PhD, speaking in a plenary session at ESGCT 2026" width="500" height="370" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCT_stage-1024x758.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCT_stage-300x222.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCT_stage-768x569.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCT_stage.jpg 1400w" sizes="(max-width: 500px) 100vw, 500px"><figcaption class="wp-caption-text">David Liu, PhD, speaking in a plenary session at ESGCT 2026 in Hamburg, Germany. [K. Davies]</figcaption></figure>
<h4><strong>Ten years after </strong></h4>
<p>By any measure, the pace of uptake and clinical potential of base and prime editing has been remarkable. Liu counted nine examples—representing he estimated one person-century of work—of precision genome editing rescuing disease phenotypes in animal models, including progeria, sickle cell disease, cystic fibrosis, phenylketonuria, and spinal muscular atrophy.</p>
<p>Several programs have progressed to IND-enabled studies and encouraging clinical results. In March 2025, Beam Therapeutics reported the first clinical correction of a human pathogenic mutation, a subject with alpha-1 antitrypsin deficiency (BEAM-302). Around the same time, <a href="https://www.genengnews.com/topics/genome-editing/asgct-2025-worlds-first-patient-treated-with-personalized-crispr-therapy/?_gl=1*z8smdu*_up*MQ..*_ga*NDA0NjcwOTU3LjE3OTMyOTE3NDY.*_ga_F1EYPPYL3X*czE3OTMyOTE3NDYkbzEkZzAkdDE3OTMyOTE3NDYkajYwJGwwJGg5NzcwODI2OTA." target="_blank" rel="noopener">the Baby KJ story</a>, which revolved around bespoke base editing, captured the world’s attention, revealing that even babies aren’t prisoners to the mutations in their DNA.</p>
<p>Liu also pointed to clinical progress in prime editing. In April 2025, the first <em>ex vivo</em> prime editing patient—57-year-old Tracy Atteberry—was dosed (<a href="https://www.nejm.org/doi/abs/10.1056/NEJMoa2509807" target="_blank" rel="noopener">reported at the end of 2025</a> by Jennifer Gori, PhD, and colleagues). The 57-year-old Atteberry, from Nebraska, received prime-edited stem cells engineered to repair the two-base gene deletion. And in October, the first patient was dosed in an <em>in vivo </em>prime editing trial for Wilson disease (PM577a).</p>
<p>Liu said he was feeling optimistic because regulators in the U.S., U.K. and elsewhere in general “are not standing in the way.” There seems to be “a liberalization of policies around initiation and BLAs for drug approval.” Indeed, the day before Liu’s lecture, the U.S. Food and Drug Administration issued a well-received draft guidance, “<a href="https://www.fda.gov/media/195887/download" target="_blank" rel="noopener">Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management</a>.”</p>
<h4><strong>Disease agnostic approach</strong></h4>
<p>Liu closed by focusing on his group’s work in developing a multi-disease therapeutic approach using only a single treatment, which would benefit more patients than just those with a very rare mutation. Around 30 percent of genetic diseases feature at least one premature stop codon. As was <a href="https://www.genengnews.com/topics/genome-editing/single-prime-editing-platform-shows-potential-vs-multiple-diseases/" target="_blank" rel="noopener">reported last year</a>, Liu’s team has pursued the idea of using suppressor tRNAs, which can read through the stop (or nonsense) codon, thereby restoring production of a full-length protein.</p>
<p>“A tRNA approach enables far fewer drugs to target a larger number of mutations/diseases,” Liu said.</p>
<p>There are 418 tRNA genes in the human genome, signaling considerable redundancy in translation as there are only 61 coding triplets. “You don’t need 418 tRNA genes,” he said. Many humans are lacking at least one of these tRNA genes, showing that humans can tolerate tRNA mutations. Liu’s idea was to “convert a dispensable tRNA into a permanent tRNA suppressor,” a method called prime editing-mediated readthrough of premature termination codons (PERT), which could be used as a one-time treatment for multiple genetic diseases that shared the same premature stop codon.</p>
<p>Led by postdoc Sarah Pierce, PhD, Liu’s lab used prime editing to convert each of the 418 human tRNAs into a suppressor tRNA, engineering each anticodon to the three triplets (CUA, UCA, and UUA) that recognize the three stop codons. As described in the 2025 paper, Liu’s team chose to focus on a leu tRNA, which exhibited the highest suppression activity. This was converted into an optimized suppressor.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>“We’re not over-expressing this optimized suppressor tRNA,” Liu said. By only making about 40% of the tRNA that was replaced, Liu said he was “optimistic we can achieve suppression without over expression.” The most promising data so far comes from the use of PERT to treat a mouse model of Hurler syndrome. PERT treatment led to the expression of about seven percent of the wild-type enzyme activity, which Liu suggested “can rescue the disease.”</p>
<p>Although it is early days, Liu closed by saying he was “very hopeful that various therapeutic approaches… will help increase the applicability of gene editing to more and more patients.” However, “until regulatory streamlining and clinical derisking continues to drive the risk and cost lower and lower, the vast majority of genetic disease remain too rare to be pursued by industry.”</p>
<p>In one new effort to tackle rare diseases, researchers at the Broad Institute, Boston Children’s Hospital, and The Jackson Laboratory have partnered to establish a non-profit collaboration called the <a href="https://www.jax.org/news-and-insights/2026/july/jax-launches-the-center-for-therapeutic-genetics" target="_blank" rel="noopener">Center for Therapeutic Genetics</a> (CTG) that, Liu said, “we hope is mimicked everywhere… to connect patients with rare diseases.”</p>
<p>The project has received initial commercial support from several companies, including Apertura and Viralgen, as well as Liu’s gene editing companies, Beam Therapeutics and Prime Medicine.</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/no-nonsense-david-liu-lauds-progress-in-disease-agnostic-gene-editing-at-esgct/">No Nonsense: David Liu Lauds Progress in Disease-Agnostic Gene Editing at ESGCT</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Blocking Protein Slows Pancreatic Tumor Growth and Reduces Immune Suppression in Mice</title>
<link>https://edusehat.com/en/blocking-protein-slows-pancreatic-tumor-growth-and-reduces-immune-suppression-in-mice</link>
<guid>https://edusehat.com/en/blocking-protein-slows-pancreatic-tumor-growth-and-reduces-immune-suppression-in-mice</guid>
<description><![CDATA[ Scientists identified a potential therapeutic target for pancreatic ductal cell adenocarcinoma, discovering that the protein ANO6 is involved in a process helping pancreatic cancer cells obtain nutrients from surrounding cells, while suppressing the immune system’s ability to fight tumors. 
The post Blocking Protein Slows Pancreatic Tumor Growth and Reduces Immune Suppression in Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_nature-cancer-cover-art.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 31 Oct 2026 01:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Blocking, Protein, Slows, Pancreatic, Tumor, Growth, and, Reduces, Immune, Suppression, Mice</media:keywords>
<content:encoded><![CDATA[<p>Researchers headed by a team at Fox Chase Cancer Center have identified a protein called anoctamin 6 (ANO6) as potential therapeutic target for pancreatic ductal cell adenocarcinoma (PDAC), the most common form of pancreatic cancer. The team’s research discovered that ANO6 helps pancreatic cancer cells obtain nutrients from surrounding cells while suppressing the immune system’s ability to fight tumors. In particular, ANO6 enables cancer-associated fibroblasts (CAFs)—cells that make up much of the dense tissue surrounding pancreatic tumors—to transfer cholesterol and other lipids to cancer cells.</p>
<p>In preclinical tests the scientists demonstrated that blocking ANO6 slowed tumor growth and reduced immune suppression. “These findings help explain how pancreatic cancer cells obtain essential nutrients despite the unusual structure of the pancreatic tumor microenvironment,” said Igor Astsaturov, MD, PhD, a professor at Fox Chase. “Cancer-associated fibroblasts are not passive bystanders. They actively support tumor growth by transferring lipids to cancer cells.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Astsaturov is co-senior author of the researchers’ published paper in <em>Nature Cancer</em>, titled “<a href="https://doi.org/10.1038/s43018-026-01265-5" target="_blank" rel="noopener">ANO6-mediated trogocytosis of cancer-associated fibroblasts promotes pancreatic cancer cell growth and immune suppression</a>,” in which they reported “Blockade of ANO6 antagonizes tumor growth, partly by disrupting cholesterol delivery to cancer cells, and attenuates immune suppression, identifying ANO6 as a candidate therapeutic target in PDAC.”</p>
<p>Pancreatic ductal adenocarcinoma is surrounded by dense connective tissue and has relatively few functional blood vessels as these collapse due to the expansion of CAFs and their self-generated collagenous fibers acting as a functional unit. How cancer cells obtain nutrients such as cholesterol in this environment isn’t well understood. “How PDAC cells obtain membranous lipids such as cholesterol has, therefore, remained unclear and resolving this could reveal a therapeutic strategy,” the authors wrote.</p>
<p>“We found that CAFs can act as a source of these nutrients,” said co-senior author Edna Cukierman, PhD, professor and co-leader of the Cancer Signaling and Microenvironment Program at Fox Chase. “Using laboratory and animal models, we discovered that CAF units acquire cholesterol from the bloodstream and transfer it to nearby pancreatic cancer cells through a process called trogocytosis.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The study showed that during trogocytosis, cancer cells take small pieces of the CAF cell membranes, allowing them to acquire cholesterol and other lipids needed for survival and growth. In their paper the authors further explained, “… we show that CAFs transfer exogenous cholesterol and other nutrients through contact-dependent transfer of plasma membrane (PM) fragments, a process known as trogocytosis (trogo, ‘to gnaw’), whereby PDAC cells nibble CAF membranes.”</p>
<p>The process depends on ANO6, which helps prepare the CAF membrane for transfer. When researchers reduced or eliminated ANO6 in CAFs, the cells were less able to support pancreatic cancer cell survival as effectively. In mouse models, tumors supported by ANO6-positive CAFs grew substantially faster than those without functional ANO6.</p>
<p>The study also showed that the same process can interfere with the immune response. CAFs form direct contacts with cytotoxic T lymphocytes (CTLs), immune cells that can recognize and kill cancer cells. During these interactions, the T cells can acquire CAF membrane material, including cholesterol. Excess cholesterol in the tumor environment can contribute to T-cell exhaustion, making the immune cells less effective.</p>
<p>“CAFs also inhibit T cell activity in pancreatic tumors, a major barrier to immunotherapy in this cancer type,” the investigators noted. “We link this immunosuppression to trogocytosis of the CAF membrane by cytotoxic T lymphocytes (CTLs), which causes CTL exhaustion, and show that ANO6 inhibition in CAFs attenuates it.”</p>
<p>Astsaturov further commented, “With Serge Fuchs, professor at the University of Pennsylvania and co-author on the paper, we were surprised to find that the same cellular mechanism can benefit the tumor in two ways—by supplying cancer cells with lipids while also weakening cancer-fighting T cells. Targeting ANO6 could potentially disrupt both of these tumor-supporting functions at the same time.”</p>
<p>The team’s studies in mouse models showed that blocking ANO6 reduced cholesterol accumulation in tumor-infiltrating T cells and improved markers of T-cell activity. Laboratory experiments also showed that T cells exposed to CAFs with reduced ANO6 had greater cancer-killing activity. Cukierman commented “Excitingly, reducing ANO6 expression also disrupted the stromal synapse-mimicry circuit we previously identified, which coordinates tumor nutritional support, CAF-unit metabolism, and immune suppression. These findings position ANO6 as the missing mechanistic link that unifies nearly a decade of discoveries by our team.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The researchers tested whether disrupting ANO6 could slow pancreatic cancer growth. In mouse models, treatment with the niclosamide or clofazimine—drugs that inhibited ANO6-dependent activity in the study—significantly reduced tumor weight. Niclosamide also reduced the delivery of cholesterol to pancreatic cancer cells.</p>
<p>The researchers noted that trogocytosis is one of several ways pancreatic cancer cells may obtain lipids, and that further research is needed to determine whether selectively targeting ANO6 could be an effective treatment strategy. The ANO6-targeting drugs used in the study may also be deployed to treat other recalcitrant cancers beyond pancreatic adenocarcinoma. And as the team further noted, “Both agents may inhibit targets unrelated to ANO6 and there remains a possibility that their antitumor activity is not exerted solely through trogocytosis.”  Still, they stated, “With that caveat, these well-tolerated and inexpensive compounds provide a tractable pharmacological entry point for testing ANO6 blockade and support the development of selective ANO6 inhibitors for CAF-rich desmoplastic tumors such as pancreatic cancer.”</p>
<p>Astsaturov added, “We believe our findings identify ANO6 as a potential therapeutic target that could simultaneously disrupt the nutrient supply supporting pancreatic cancer cells and reduce the immune-suppressive effects of the tumor microenvironment.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/blocking-protein-slows-pancreatic-tumor-growth-and-reduces-immune-suppression-in-mice/">Blocking Protein Slows Pancreatic Tumor Growth and Reduces Immune Suppression in Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Gilbane Expands Mid&#45;Atlantic Healthcare Leadership</title>
<link>https://edusehat.com/en/gilbane-expands-mid-atlantic-healthcare-leadership</link>
<guid>https://edusehat.com/en/gilbane-expands-mid-atlantic-healthcare-leadership</guid>
<description><![CDATA[ Gilbane Building Company has hired Brad McMullan as Senior Project Executive and widened the responsibilities of Senior Project Executive Ryan Becker to support its Mid-Atlantic healthcare work.  According to a release from Gilbane, McMullan will pursue opportunities and develop client relationships in Philadelphia and New Jersey. His experience includes work with Cooper University Hospital, Atlantic...
The post Gilbane Expands Mid-Atlantic Healthcare Leadership appeared first on HCO News.
The post Gilbane Expands Mid-Atlantic Healthcare Leadership appeared first on HCO News. ]]></description>
<enclosure url="https://hconews.com/wp-content/uploads/2026/10/People-HCO.Gilbane-768x480.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 22:15:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Gilbane, Expands, Mid-Atlantic, Healthcare, Leadership</media:keywords>
<content:encoded><![CDATA[<p><span data-contrast="auto">Gilbane Building Company has hired Brad McMullan as Senior Project Executive and widened the responsibilities of Senior Project Executive Ryan Becker to support its Mid-Atlantic healthcare work.</span><span data-ccp-props="{}"> </span></p>
<p><a href="https://www.gilbaneco.com/about/whats-new/news/gilbane-strengthens-healthcare-leadership-across-the-mid-atlantic-to-support-market-focus/" target="_blank" rel="noopener"><span data-contrast="none">According to a release from Gilbane</span></a><span data-contrast="auto">, McMullan will pursue opportunities and develop client relationships in Philadelphia and New Jersey. His experience includes work with Cooper University Hospital, Atlantic Health System, Inspira Health System and Hackensack Meridian Health.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">“Brad’s extensive healthcare experience and established relationships throughout the region strengthen our ability to serve clients,” said Gilbane’s Senior Vice President and Mid-Atlantic Divisional Leader Ted Holt.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Becker will focus on Maryland and Washington, D.C. He has more than 20 years of healthcare construction experience, including multiphase renovations in active facilities. Becker’s credentials include Certified Healthcare Manager and LEED Accredited Professional. His current projects involve Howard University, Johns Hopkins University and Inova.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">“Ryan’s deep understanding of active healthcare environments, combined with his experience leading healthcare projects throughout Maryland and the DMV, positions him to help our clients deliver critical facilities that support exceptional patient care,” said Holt.</span><span data-ccp-props="{}"> </span></p>
<p>The post <a rel="nofollow" href="https://hconews.com/2026/10/30/gilbane-expands-mid-atlantic-healthcare-leadership/">Gilbane Expands Mid-Atlantic Healthcare Leadership</a> appeared first on <a rel="nofollow" href="https://hconews.com/">HCO News</a>.</p>
<p>The post <a href="https://hconews.com/2026/10/30/gilbane-expands-mid-atlantic-healthcare-leadership/">Gilbane Expands Mid-Atlantic Healthcare Leadership</a> appeared first on <a href="https://hconews.com/">HCO News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Call for Applications: Editor&#45;in&#45;Chief of The Journal of Clinical Endocrinology &amp;amp; Metabolism</title>
<link>https://edusehat.com/en/call-for-applications-editor-in-chief-of-the-journal-of-clinical-endocrinology-metabolism</link>
<guid>https://edusehat.com/en/call-for-applications-editor-in-chief-of-the-journal-of-clinical-endocrinology-metabolism</guid>
<description><![CDATA[ Applications Open from November 1 to November 30, 2026. The Endocrine Society calls for applications for the next Editor-in-Chief (EIC) of The Journal of Clinical Endocrinology &amp; Metabolism (JCEM), the Society’s peer-reviewed journal for research from investigators around the world that is related to developments in clinical endocrinology, diabetes, and metabolism, and that enhances understanding […]
The post Call for Applications: Editor-in-Chief of The Journal of Clinical Endocrinology &amp; Metabolism appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/jcem_110_1cover-e1783351279982.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 22:05:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Call, for, Applications:, Editor-in-Chief, The, Journal, Clinical, Endocrinology, Metabolism</media:keywords>
<content:encoded><![CDATA[<p>Applications Open from November 1 to November 30, 2026. The Endocrine Society calls for applications for the next Editor-in-Chief (EIC) of The Journal of Clinical Endocrinology & Metabolism (JCEM), the Society’s peer-reviewed journal for research from investigators around the world that is related to developments in clinical endocrinology, diabetes, and metabolism, and that enhances understanding […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/call-for-applications-editor-in-chief-of-the-journal-of-clinical-endocrinology-metabolism/">Call for Applications: Editor-in-Chief of The Journal of Clinical Endocrinology & Metabolism</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Annual Retention Fee to rise as fitness to practise causes financial strain</title>
<link>https://edusehat.com/en/annual-retention-fee-to-rise-as-fitness-to-practise-causes-financial-strain</link>
<guid>https://edusehat.com/en/annual-retention-fee-to-rise-as-fitness-to-practise-causes-financial-strain</guid>
<description><![CDATA[ The General Dental Council (GDC) has confirmed that the Annual Retention Fee (ARF) for 2027 will rise by 3.1%, driven by the cost of processing increasing numbers of fitness to practise concerns. The GDC has set its 2027 Annual Retention Fee at £720 for dentists and £111 for dental care professionals. This 3.1% increase matches… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/arf.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 22:00:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Annual, Retention, Fee, rise, fitness, practise, causes, financial, strain</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large is-resized"></figure>



<p><strong>The General Dental Council (GDC) has confirmed that the Annual Retention Fee (ARF) for 2027 will rise by 3.1%, driven by the cost of processing increasing numbers of fitness to practise concerns. </strong></p>



<p>The GDC has set its 2027 Annual Retention Fee at £720 for dentists and £111 for dental care professionals. This 3.1% increase matches the rate of inflation as measured by the Consumer Price Index (CPI).</p>



<p>The regulator said the rise was prompted by year-on-year growth in the number of fitness to practise concerns reported. The GDC received <a href="https://dentistry.co.uk/2026/06/03/gdc-fitness-to-practise-concerns-rise-2025/" target="_blank" rel="noreferrer noopener">1,766 new fitness to practise concerns in 2025</a>, a 26% increase on the previous year. <a href="https://dentistry.co.uk/2026/09/17/fitness-to-practise-whistleblowing-rises-by-74/" target="_blank" rel="noreferrer noopener">Whistleblowing disclosures relating to dentistry also increased by 74%</a> on the previous reporting period.</p>



<p>Tom Whiting, chief executive and registrar of the GDC, said it had not taken the decision lightly. He continued: ‘We know that dental professionals want fitness to practise investigations to be quicker and less stressful, and so do we. </p>



<p>‘We are receiving many more concerns than we did a few years ago and need the right resources in place to deal with them fairly and promptly. The sustained increase in the volume of concerns being received creates a challenging environment which we will need to take further steps to address in future years.’</p>



<p>As a result, the GDC forecast that <a href="https://dentistry.co.uk/2026/09/23/gdc-reserves-fitness-to-practise-costs/" target="_blank" rel="noreferrer noopener">its financial reserves will fall below its target range</a>.</p>



<h2 class="wp-block-heading">How will the revenue from the Annual Retention Fee rise be used?</h2>



<p>According to the GDC, this financial pressure means ‘the GDC cannot improve the timeliness of the fitness to practise process as quickly as it wants to’.</p>



<p>The regulator said the ARF increase would be used to invest in additional resources to deal with the immediate demands on fitness to practise and start work on longer-term improvements. </p>



<p>Tom Whiting said: ‘We want this investment to make a real difference to people going through the process. We will engage with stakeholders and dental professionals in the months ahead to share more information about the challenges and seek feedback on our approach.’</p>



<p>In 2025, the <a href="https://dentistry.co.uk/2025/10/31/annual-retention-fee-increase-confirmed-for-2026-by-gdc/" target="_blank" rel="noreferrer noopener">ARF rose by 12.5%</a> following a 12-week public consultation on the GDC’s strategy.</p>



<p>Helen Phillips, chair of the GDC, said: ’We said last year that <a href="https://dentistry.co.uk/2025/10/31/annual-retention-fee-increase-confirmed-for-2026-by-gdc/" target="_blank" rel="noreferrer noopener">any increase would not exceed CPI</a>, and council has kept to that. We don’t underestimate what it means to ask dental professionals to pay more, and council scrutinised the business plan carefully, including its impact on registrants, before setting the fee for 2027.’</p>



<p><em><a href="https://sso.dentistry.co.uk/" target="_blank" rel="noreferrer noopener">Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</a></em></p>



<p></p>]]> </content:encoded>
</item>

<item>
<title>Eating disorders are on the rise. GLP&#45;1s could make things worse.</title>
<link>https://edusehat.com/en/eating-disorders-are-on-the-rise-glp-1s-could-make-things-worse</link>
<guid>https://edusehat.com/en/eating-disorders-are-on-the-rise-glp-1s-could-make-things-worse</guid>
<description><![CDATA[ GLP-1 weight-loss drugs are one of the biggest biotech breakthroughs of the last decade. But to some clinical psychologists, they can represent something more sinister—a potential trigger for eating disorders. A new report suggests that the global incidence of anorexia nervosa and bulimia nervosa shot up between 1990 and 2023—by a whopping 71%. By 2023,… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/261028_GLP1EatingDisorder.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 18:05:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Eating, disorders, are, the, rise., GLP-1s, could, make, things, worse.</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Eating disorders are surging globally:</strong> A new study in JAMA Psychiatry found anorexia and bulimia rose 71% between 1990 and 2023, affecting an estimated 18.1 million people—and experts say the true number affected by eating disorders is likely three times higher.</li><br><li><strong>Social media is fueling the crisis:</strong> TikTok's algorithm served users with eating disorders 4,343% more harmful content than those without—and clinicians say "thinspiration" trends can trigger new cases.</li><br><li><strong>GLP-1 drugs are making things worse:</strong> Experts are already seeing patients—some as young as 11—misusing weight-loss drugs</li></ul>" data-chronoton-post-id="1147838" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p class="wp-block-paragraph">GLP-1 weight-loss drugs are one of the biggest biotech breakthroughs of the last decade. But to some clinical psychologists, they can represent something more sinister—a potential trigger for eating disorders.</p>



<p class="wp-block-paragraph">A new report suggests that the global incidence of anorexia nervosa and bulimia nervosa shot up between 1990 and 2023—by a whopping 71%. By 2023, there were an estimated 18.1 million people living with one of these two disorders.</p>





<p class="wp-block-paragraph">What’s worse is that the number is likely to be much higher than that once we factor in other eating disorders. And, disturbingly, those in the field are already starting to see GLP-1 weight-loss drugs exacerbating the issue.</p>



<p class="wp-block-paragraph">Cheri Levinson is a clinical psychologist at the University of Louisville in Kentucky who has specialized in eating disorders for almost 20 years. She says she’s now seeing more patients with more severe symptoms than at any other time in her career, and that many of them are misusing GLP-1s. “This is the worst I’ve seen things,” she says.</p>



<p class="wp-block-paragraph">Eating disorders are mental health conditions in which people’s eating behaviors impact their health. They include anorexia nervosa (defined by a fear of weight gain), bulimia nervosa (in which people binge and purge), binge eating disorder, and others.</p>



<p class="wp-block-paragraph">It’s thought that some people have a genetic predisposition to certain eating disorders, but that some external factor is what triggers their onset. That might be stress, or social pressure to be skinny. Often, simply restricting food intake can trigger an eating disorder, says Levinson.</p>



<p class="wp-block-paragraph">Eating disorders—along with the pressure to look thin—were already prevalent in the 1990s (the <a href="https://www.cosmopolitan.com/lifestyle/a73344972/fashion-week-smoking-skinny-heroin-chic/">heroin chic</a> era springs to mind). To find out how things might have changed since then, Ruhai Bai at the Children’s Hospital of Nanjing Medical University in China and his colleagues pulled together data from studies and surveys conducted on populations around the world. The team used statistical models to fill in any data gaps.</p>



<p class="wp-block-paragraph">That research allowed the researchers to estimate the annual incidence of two eating disorders—anorexia nervosa and bulimia nervosa—for each of 204 countries and territories between 1990 and 2023. They also estimated the impact those disorders had on global health by calculating their disability-adjusted life years (one <a href="https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/global-health-estimates-leading-causes-of-dalys/">DALY</a> represents a year of healthy life lost).</p>



<p class="wp-block-paragraph">The findings, <a href="https://media.jamanetwork.com/media-releases/10.1001/jamapsychiatry.2026.3457">published in <em>JAMA Psychiatry</em></a> on Wednesday, are unsettling. Between 1990 and 2023, there was a 71% increase in the incidence of those two eating disorders, the team found. Those conditions had a huge impact on global health, too. In 2023, they “cost the world the equivalent of about 3.83 million years of healthy life,” says Bai.</p>





<p class="wp-block-paragraph">Bai and his colleagues expect these figures to continue to rise. In 2023, an estimated 18.1 million people had either anorexia nervosa or bulimia nervosa; by 2050, the team predict, the two conditions could affect 21.8 million people.</p>



<p class="wp-block-paragraph">It gets worse. Those two conditions represent less than half of all eating disorders, says Levinson, who was not involved in Bai’s study. The true impact of these disorders is “probably three times the rate that they’re reporting,” she says.</p>



<p class="wp-block-paragraph">Bai and his colleagues didn’t explore the reasons for this rise (although Bai points out that it can’t be entirely explained by population growth). So how did we get here?</p>



<p class="wp-block-paragraph"><strong>Social media may have played a role.</strong> “Social media comparisons, influencers, challenges, diet trends can all be precipitating … events for an eating disorder,” says Cynthia Bulik, a clinical psychologist at the University of North Carolina, who was not involved in the new study. Bulik has been studying and treating eating disorders since the early 1980s. “Between 1990 and 2023 there has clearly been an upsurge of those types of environmental exposures,” she says.</p>



<p class="wp-block-paragraph">Many social media users are exposed to filtered and modified images of skinny influencers who may have undergone cosmetic surgery or extreme dieting and who are promoting “thinspiration” or “fitspiration” content. But users with eating disorders appear to be more likely to engage with this content—and to be fed more of it as a result.</p>



<p class="wp-block-paragraph">When researchers at the University of Melbourne <a href="https://www.sciencedirect.com/science/article/pii/S1740144524001293">investigated this phenomenon</a> a couple of years ago, they found that the algorithms of TikTok users with eating disorders delivered 4343% more “toxic eating disorder videos” than those of users who didn’t have the disorders. They also got more content focused on dieting or exercising. Many were fed over 1000 problematic videos per month. Bulik describes social media as “quicksand” for people with, or at risk of, eating disorders.</p>



<p class="wp-block-paragraph">The covid-19 pandemic—and the social isolation that accompanied lockdowns—also appears to have contributed to the rise in eating disorders. Research conducted in 2021 found that the number of people hospitalized with eating disorders in the US <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2786185"><em>doubled</em> between 2018 and 2020</a>.</p>





<p class="wp-block-paragraph">Researchers don’t yet have good data on how trends in eating disorders might have progressed since 2023. But anecdotally, things seem to be getting even worse. “There are more eating disorders, more severe eating disorders… and we’re seeing earlier ages of onset,” says Levinson. “We’re seeing eight- and nine-year-olds with eating disorders.”</p>



<p class="wp-block-paragraph"><strong>“From what I’m hearing and seeing, I am not going to be surprised if that number isn’t at least doubling again,” she adds.</strong></p>



<p class="wp-block-paragraph">Levinson particularly worries about the impact of GLP-1 weight-loss drugs, which have exploded in popularity in recent years. A <a href="https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx">Gallup survey</a> conducted earlier this year suggested that 15% of Americans had used one of these drugs for weight loss. And they’re becoming more accessible—drug companies are working on new formulations that are both easier to take and more effective, and many people can buy versions of these drugs from compound pharmacies or dubious online sources.</p>



<p class="wp-block-paragraph">In <a href="https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2850584">a small study</a> published earlier this year, Levinson and her colleagues found that 30% of people with eating disorders had used GLP-1 drugs. The drugs might benefit some of those people. But 10% appeared to have misused the drugs. And Levinson thinks that figure is also an underestimate.</p>



<p class="wp-block-paragraph">Levinson says she and her colleagues have seen children develop eating disorders after being prescribed GLP-1s for medical reasons. They’ve seen others—even children as young as 11—buy versions of these drugs over TikTok.</p>



<p class="wp-block-paragraph"><strong>“We’re very concerned that GLPs will lead to even faster and more extreme weight loss</strong> in people with anorexia nervosa, and that patients will come to us in even more advanced stages of illness that become difficult to reverse,” says Bulik.</p>



<p class="wp-block-paragraph">Both Bulik and Levinson are continuing to study the impacts of these drugs in eating disorders. In the meantime, both urge medical professionals to consider the risks GLP-1s might pose to people with those disorders. Bulik contributed to a set of <a href="https://onlinelibrary.wiley.com/doi/10.1002/wps.70096">research and clinical guidelines</a>, published earlier this month, that recommends doctors screen for eating disorders before prescribing the drugs, for example. The guidelines also recommend more patient education and more robust monitoring of people who take GLP-1s.</p>



<p class="wp-block-paragraph"><em>If you think you or someone you know might have an eating disorder, you can find information and support at</em> <a href="https://www.nationaleatingdisorders.org/"><em>the National Eating Disorders Association</em></a><em>.</em></p>



<p class="wp-block-paragraph"><em>This article first appeared in The Checkup, </em>MIT Technology Review’s<em> weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, </em><a href="https://forms.technologyreview.com/newsletters/biotech-the-checkup/?_ga=2.241810882.15113993.1664981064-43237434.1647441349"><em>sign up here</em></a>.</p>



<p class="wp-block-paragraph"><br></p>]]> </content:encoded>
</item>

<item>
<title>Healthcare economics: How hospitals can stay viable without pushing costs onto patients</title>
<link>https://edusehat.com/en/healthcare-economics-how-hospitals-can-stay-viable-without-pushing-costs-onto-patients</link>
<guid>https://edusehat.com/en/healthcare-economics-how-hospitals-can-stay-viable-without-pushing-costs-onto-patients</guid>
<description><![CDATA[ 
When it comes to private healthcare, the narrative is that the charges are high. From the courts to patients, the demand is for private hospital charges to be regulated. This impression that private hospitals overcharge patients cannot be further from the truth. Private healthcare is India faces the challenge of delivering modern quality healthcare at […]
The post Healthcare economics: How hospitals can stay viable without pushing costs onto patients appeared first on Express Healthcare. ]]></description>
<enclosure url="https://cdn.expresshealthcare.in/wp-content/uploads/2026/10/30161422/Dr-S.-Chandrakumar-Founder-and-Executive-Chairman-Kauvery-Group-of-Hospitals.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 17:50:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Healthcare, economics:, How, hospitals, can, stay, viable, without, pushing, costs, onto, patients</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresshealthcare.in/wp-content/uploads/2026/10/30161422/Dr-S.-Chandrakumar-Founder-and-Executive-Chairman-Kauvery-Group-of-Hospitals.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresshealthcare.in/wp-content/uploads/2026/10/30161422/Dr-S.-Chandrakumar-Founder-and-Executive-Chairman-Kauvery-Group-of-Hospitals.jpg 750w, https://cdn.expresshealthcare.in/wp-content/uploads/2026/10/30161422/Dr-S.-Chandrakumar-Founder-and-Executive-Chairman-Kauvery-Group-of-Hospitals-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p align="LEFT"><span><span><span><span lang="en-US">When it comes to private healthcare, the narrative is that the charges are high. From the courts to patients, the demand is for private hospital charges to be regulated. This impression that private hospitals overcharge patients cannot be further from the truth. Private healthcare is India faces the challenge of delivering modern quality healthcare at an affordable price while continuing to invest in the latest medical technologies for the patients’ benefit and at the same time battling inflation with rise in salaries of doctors and paramedical staff, consumables and more. </span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US">This angst is understandable. While Out-of-Pocket Expenditure (OOPE) as a share of Total Health Expenditure </span></span></span><span><span><span lang="en-US">declined over a decade from 64.2 per cent to 43.4 per cent,</span></span></span><span><span><span lang="en-US"> it is still a significantly large percentage with households financing </span></span></span><span><span><span lang="en-US">56.44 per cent of current health expenditure</span></span></span><span><span><span lang="en-US"> and </span></span></span><span><span><span lang="en-US">nearly 31 per cent of the population</span></span></span><span><span><span lang="en-US"> face financial hardship from out-of-pocket payments.</span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US">This may lead one to think that all increases in costs are just shifted on to the patient. But this is not true. An increase in tariff is usually the last option on the table. The scrutiny is on how we work and what can be done to reduce costs without compromising quality. The fact is that every inefficiency inside a hospital eventually lands on a patient’s invoice and it is this that we must tackle first!</span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US"><b>Waste – The first place to look</b></span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US">An OECD’s review on </span></span></span><span><span><span lang="en-US">Tackling Wasteful Spending on Health</span></span></span><span><span><span lang="en-US"> estimated that around one-fifth of health spending makes little or no contribution to better outcomes. A </span></span></span><span><span><span lang="en-US">study of US healthcare put the cost of waste </span></span></span><span><span><span lang="en-US">at $760 billion to $935 billion a year, about 25 per cent of total healthcare spends. Of this administrative complexity alone accounted for $265.6 billion. Savings from interventions that address waste were $191 billion to $286 billion. </span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US">Hospitals in India run on far thinner budgets, yet the same categories also contribute to waste – avoidable complications, repeat tests, idle operation theatres, and too much paperwork that delays discharge.</span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US"><b>Infection control to control cost</b></span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US">The top-of-mind factor when one says infection control is hospital-acquired infections (HAIs). A </span></span></span><span><span><span lang="en-US">study of the impact of HAIs on costs and clinical outcomes</span></span></span><span><span><span lang="en-US"> found that an infection acquired in the ICU roughly doubled the median treatment cost, from Rs 92,893 to Rs 1,80,469, and stretched ICU stay from 6.7 to 13.4 days. Another </span></span></span><span><span><span lang="en-US">recent study</span></span></span><span><span><span lang="en-US"> in a tertiary hospital reached a similar conclusion with length of ICU stay being the main reason for the added cost.</span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US">It is here that hospitals must realise that while hand-hygiene audits, ventilator and catheter bundles, and antibiotic stewardship are clinical programmes, they also belong on a finance committee’s agenda. A patient who avoids a bloodstream infection goes home sooner with better clinical outcomes, pays less, and frees a bed for the next admission.</span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US"><b>Fix the process</b></span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US">Process redesign is not glamorous, but it works. </span></span></span><span><span><span lang="en-US">Methods utilising lean tools such as value-stream mapping</span></span></span><span><span><span lang="en-US"> and root cause analysis help to reduce waste and improve productivity. A </span></span></span><span><span><span lang="en-US">survey of private hospitals</span></span></span><span><span><span lang="en-US"> in India found that management commitment to lean practices had a statistically significant effect on both operational and financial performance. High volumes, standardised protocols and strategic use of data can produce outcomes on par with US centres at a fraction of the cost. Theatre scheduling, discharge planning and bed turnover may not be glamorous but lead to gains that can be passed on to the patient. </span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US"><b>Buy better</b></span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US">Pharmacies alone accounted for Rs </span></span></span><span><span><span lang="en-US">1.63 lakh crore, or 21.2 per cent of current health expenditure</span></span></span><span><span><span lang="en-US"> in 2022-23, up from Rs </span></span></span><span><span><span lang="en-US">1.53 lakh crore in the previous year. </span></span></span><span><span><span lang="en-US">During the same period, private hospitals increased their </span></span></span><span><span><span lang="en-US">current health expenditure (CHE) share from 26.96 per cent in 2021-22 to 30.83 per cent</span></span></span><span><span><span lang="en-US">. It is here that pooled procurement can help to lower prices, especially for large buyers. Autonomous agencies such as those affiliated to state governments can </span></span></span><span><span><span lang="en-US">negotiate and secure lower prices</span></span></span><span><span><span lang="en-US">. Medicines and consumables deserve the same scrutiny. Hospital groups can apply the same logic and manage inventory more scientifically through central purchasing, a disciplined formulary and quality-assured generics.</span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US"><b>Transparency about price</b></span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US">Efficiency helps patients only if the savings reach them. Fixed package prices for common procedures, published in advance, protect families from open-ended bills and push hospitals to manage and prevent any variation in cost. </span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US">Of course, why these points can help hospitals stay financially viable without pushing costs onto patients, none of this removes the need for higher public spending. government health expenditure is still only </span></span></span><span><span><span lang="en-US">1.43 per cent of GDP</span></span></span><span><span><span lang="en-US">. Private hospitals cannot wait for policy to support cost structures, though. Staying viable without burdening patients must be decided in reducing waste, choices about infection, patient flow and optimal purchasing. These steps may not make headlines but will have impact and help viability in the long run!</span></span></span></span></p>
<p>The post <a href="https://www.expresshealthcare.in/news/healthcare-economics-how-hospitals-can-stay-viable-without-pushing-costs-onto-patients/455714/">Healthcare economics: How hospitals can stay viable without pushing costs onto patients</a> appeared first on <a href="https://www.expresshealthcare.in/">Express Healthcare</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Our ambition is to be a trusted partner at each stage of that journey</title>
<link>https://edusehat.com/en/our-ambition-is-to-be-a-trusted-partner-at-each-stage-of-that-journey</link>
<guid>https://edusehat.com/en/our-ambition-is-to-be-a-trusted-partner-at-each-stage-of-that-journey</guid>
<description><![CDATA[ 
Payal Agrawal, MD - India &amp; South Asia, PerkinElmer India &amp; South Asia, discusses the evolving analytical needs of India’s pharmaceutical industry, PerkinElmer’s LC-MS/MS offering and the role of advanced technologies, application expertise and laboratory services in supporting pharma R&amp;D and quality testing, in an exclusive interview with Express Pharma
The post Our ambition is to be a trusted partner at each stage of that journey appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/30102633/EP_Payal_PerkinElmer_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 14:10:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Our, ambition, trusted, partner, each, stage, that, journey</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="430" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/30102633/EP_Payal_PerkinElmer_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/30102633/EP_Payal_PerkinElmer_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/30102633/EP_Payal_PerkinElmer_750-300x172.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><b>What pharma and life sciences trends do you see shaping India over the next three to five years, and where does PerkinElmer see the biggest opportunities in this changing landscape?</b></p>
<p><span>India’s pharmaceutical industry is moving into a new phase of growth, driven by complex generics, specialty formulations, API manufacturing and research-led drug development, underpinned by an increasing focus on quality and innovation. As Indian companies strengthen their presence in regulated global markets, the ability to consistently demonstrate product quality and meet evolving regulatory expectations will become an even greater competitive differentiator.</span></p>
<p><span>We see three core trends shaping the industry. First, India’s ambition to move up the pharma value chain is creating greater demand for advanced analytical technologies and scientific expertise. Second, the growing focus on impurity profiling, trace-level contaminants and analytical rigour is raising the bar for pharma testing. Third, manufacturers are looking to improve laboratory productivity through more efficient method development efficiency and reliable analytical data.</span></p>
<p><span>For PerkinElmer, these trends present opportunities across chromatography, mass spectrometry, spectroscopy and other analytical technologies that support pharma R&D and quality testing. Our focus is on helping customers address their specific analytical challenges with the right combination of technology, application expertise and service support.</span></p>
<p><span>More broadly, beyond its status as a major pharma manufacturing hub, India is increasingly becoming a centre for scientific development and global pharma supply. We see considerable potential through our OneSource Laboratory Services team to deepen partnerships with Indian pharma companies as they invest in more sophisticated analytical capabilities. As research and quality operations become more global, ensuring instruments perform consistently and compliantly becomes just as important as the technology itself. </span></p>
<p><b>PerkinElmer is entering the pharma space with its LC-MS/MS offering and new software. What is driving this move, and what gap in pharma analytical testing are you looking to address?</b></p>
<p><span>The QSight LC-MS/MS platform making inroads into the pharma segment marks an important step in expanding PerkinElmer’s presence in India’s pharma market. We see a clear opportunity to address the growing need for sensitive, selective and reliable quantitative analytical solutions as pharma companies work with increasingly demanding testing requirements.</span></p>
<p><span>For pharma R&D and analytical laboratories, challenges such as trace-level impurity quantification, nitrosamine analysis where suitable methods are established, and complex sample investigations can require analytical capabilities beyond conventional approaches. Triple-quadrupole LC-MS/MS is particularly valuable for targeted quantitative applications that demand high selectivity and sensitivity.</span></p>
<p><span>QSight brings together triple-quadrupole mass spectrometry, StayClean<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> ion-source technology and a dual ESI/APCI source configuration designed to offer flexibility across suitable applications. Complementing the platform is Simplicity 3Q software, which supports workflows spanning method development, data acquisition, processing and reporting.</span></p>
<p><span>Our approach goes beyond the launch of a new instrument. We are building pharma application readiness and helping laboratories evaluate technology against their specific analytical needs through relevant rigorous application development and expert technical support. We also recognise the importance of appropriate software configuration, validation and documentation for regulated laboratory use.</span></p>
<p><span>Ultimately, our objective is to give pharma laboratories another strong analytical option for addressing challenging quantitative applications while supporting dependable performance and greater laboratory productivity.</span></p>
<p><b>As Indian pharma moves towards complex molecules, biologics and higher-value R&D, what gaps do you see in the industry’s analytical capabilities, and how is PerkinElmer addressing them?</b></p>
<p><span>One of the key challenges for Indian pharma is ensuring analytical capabilities keep pace with increasingly complex products, more demanding impurity requirements and the expectations of global regulatory markets.</span></p>
<p><span>For small-molecule drugs, APIs and finished formulations, laboratories must address a series of critical challenges, including impurities, degradation products, method selectivity, reproducibility and data quality – while at the same time managing sample volumes, turnaround times and resource constraints.</span></p>
<p><span>We see opportunities in three areas: access to fit-for-purpose analytical technologies, greater efficiency in method development and routine testing and stronger application expertise within laboratories. Advanced instruments can deliver considerable value, but only when the method, workflow and supporting expertise are aligned with the analytical question.</span></p>
<p><span>PerkinElmer addresses these needs through a broad portfolio of analytical technologies, supported by application knowledge, as well as software and service capabilities delivered through OneSource. Depending on the application, this can include chromatography for routine assays and related-substances testing, mass spectrometry for demanding targeted quantitative analysis, and complementary techniques for other pharma testing requirements.</span></p>
<p><span>We also believe that customer support and knowledge transfer are critical. Our role is to help laboratories identify the right analytical approach, develop robust workflows and make effective use of their technology. The objective is not simply to provide more sophisticated instruments, but to help pharma companies build stronger analytical capabilities that support product quality, operational efficiency and scientific progress.</span></p>
<p><b>You have led business turnarounds and commercial transformations across multiple markets. What are you bringing from those experiences to your mandate at PerkinElmer India and South Asia?</b></p>
<p><span>My experience operating across international markets has reinforced a fundamental principle: sustainable growth comes from understanding customers deeply, making clear strategic choices and executing consistently.</span></p>
<p><span>India and South Asia are diverse markets, with pharma companies operating at varying scales and serving different segments. A successful strategy needs to recognise these differences, identify where we can create the greatest value and align our portfolio, people and capabilities with those opportunities.</span></p>
<p><span>My focus is always on bridging the gap between customers insights and our business approach. In practice, that means spending time in customers’ labs to understand their most important challenges – whether that is throughput, regulatory compliance or access to skilled analysts – and make sure our commercial, application and service teams respond as one team rather than three.</span></p>
<p><span>For PerkinElmer in India and South Asia, the opportunity is to combine our scientific strengths with the customised and execution-oriented service that customers expect.</span></p>
<p><b>With India emerging as a larger R&D and manufacturing hub, how do you see PerkinElmer’s role evolving in supporting the next phase of pharma growth in the region?</b></p>
<p><span>As India strengthens its position in global pharma R&D and manufacturing, analytical science will play an increasingly important role in enabling quality, innovation and competitiveness. Pharma companies will need to combine robust testing capabilities with efficient laboratory operations and the ability to meet the expectations of international markets.</span></p>
<p><span>We see PerkinElmer’s role evolving through closer collaboration with pharma manufacturers, API producers, contract research organisations and contract development and manufacturing organisations. Our objective is to help customers identify the technologies and workflows best suited to their requirements, based on their specific needs.</span></p>
<p><span>This involves much more than supplying instruments. Application expertise, reliable service, training and ongoing technical support are essential to helping laboratories realise the full value of their analytical investments. We also see opportunities to deepen engagement with customers as their needs evolve – whether in expanding analytical development capabilities, strengthening quality-control operations or investigating more challenging impurities.</span></p>
<p><span>Our broader analytical portfolio across chromatography, mass spectrometry and spectroscopy positions us to support a range of pharma applications, from routine laboratory testing to more advanced analytical investigations. We will continue to focus on making our technologies relevant to local customer needs while drawing on our wider scientific and technological capabilities.</span></p>
<p><span>India in particular represents a significant long-term opportunity for PerkinElmer. The industry is moving up the value chain, from generics and APIs towards complex generics, biosimilars and novel drug discovery, and the scientific and regulatory demands grow at every step. Our ambition is to be a trusted partner at each stage of that journey, helping pharma companies strengthen their analytical capabilities, improve laboratory performance and compete with confidence in global markets.</span></p>
<p>The post <a href="https://www.expresspharma.in/our-ambition-is-to-be-a-trusted-partner-at-each-stage-of-that-journey/">Our ambition is to be a trusted partner at each stage of that journey</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AIIA launches national AI challenge for Ayurveda on incubation centre’s sixth Foundation Day</title>
<link>https://edusehat.com/en/aiia-launches-national-ai-challenge-for-ayurveda-on-incubation-centres-sixth-foundation-day</link>
<guid>https://edusehat.com/en/aiia-launches-national-ai-challenge-for-ayurveda-on-incubation-centres-sixth-foundation-day</guid>
<description><![CDATA[ 
AIIA-iCAINE launches an IPR facility, signs two MoUs with the World Ayurveda Foundation and Reliance Retail, and conducts a workshop on entrepreneurship and design thinking.
The post AIIA launches national AI challenge for Ayurveda on incubation centre’s sixth Foundation Day appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115645/event.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 14:10:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>AIIA, launches, national, challenge, for, Ayurveda, incubation, centre’s, sixth, Foundation, Day</media:keywords>
<content:encoded><![CDATA[<div><img width="888" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115645/event.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115645/event.jpg 888w, https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115645/event-300x135.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115645/event-768x346.jpg 768w" sizes="auto, (max-width: 888px) 100vw, 888px"></div><p><span>The All India Institute of Ayurveda (AIIA), New Delhi, celebrated the sixth Foundation Day of its incubation centre, AIIA-iCAINE, with the launch of a national innovation challenge in Artificial Intelligence (AI) for Ayurveda, the signing of two strategic Memoranda of Understanding (MoUs), the launch of an Intellectual Property Rights (IPR) Facility for Ayurveda and a capacity-building workshop on entrepreneurship and design thinking.</span></p>
<p><span>On the occasion, Prof. Vd. P. K. Prajapati, Director, AIIA, highlighted the incubator’s efforts to promote innovation, strengthen industry–academia collaboration and translate Ayurvedic knowledge and research into practical solutions, products and enterprises.</span></p>
<p><span>“Over the past six years, AIIA-iCAINE has undertaken several initiatives to promote innovation and entrepreneurship in Ayurveda. The incubator has supported 52 problem statements and mentored more than 100 startup ideas. Furthermore, nine startups have received seed support of ₹3 lakh each, helping them advance their entrepreneurial journeys,” he said.</span></p>
<p><span>The celebration featured the launch of AyushTech Innovate: National Open Ayurveda AI Challenge, organised by Techfest, IIT Bombay, in collaboration with the Ministry of Ayush and AIIA.</span></p>
<p><span>Leveraging AyurParam, IIT Bombay’s open-source Ayurveda Large Language Model, the challenge aims to encourage the development of trustworthy, transparent, safe and practical AI solutions for Ayurveda. It will address challenges in Ayurvedic clinical practice, classical text retrieval, research, treatment planning and public health awareness. The national grand finale is scheduled to take place at IIT Bombay from December 15 to 18, 2026.</span></p>
<p><span>AIIA-iCAINE also signed two MoUs to strengthen research, innovation and commercialisation in Ayurveda.</span></p>
<p><span>The MoU with the World Ayurveda Foundation (WAF) will facilitate the establishment of “AI in Ay – Secretariat for Artificial Intelligence in Ayurveda”, a collaborative platform to advance AI-driven research, innovation and entrepreneurship. The collaboration will support joint research, funding and CSR proposals, capacity-building programmes, hackathons and startup incubation. It will also leverage WAF’s national and international networks to promote responsible AI applications in Ayurveda.</span></p>
<p><span>The MoU with Reliance Retail Limited (Pahadi Local) will facilitate the translation of classical Ayurvedic knowledge into commercially viable skincare products through formulation advisory. Reliance Retail will undertake product development, testing, manufacturing and marketing, creating a pathway for the commercialisation of Ayurveda-based innovations and strengthening industry–academia collaboration.</span></p>
<p><span>Another development was the launch of the Intellectual Property Rights (IPR) Facility for Ayurveda. The facility aims to promote awareness of intellectual property protection and help Ayurveda innovators and entrepreneurs understand the importance of safeguarding their innovations as they progress towards product development and commercialisation.</span></p>
<p><span>The Foundation Day activities also included a capacity-building workshop on branding, pricing strategies and design thinking for Ayurveda ventures. Jessica of Reliance Retail Limited conducted the masterclass on branding, while Sujith Eranezhath, CEO, AIIA-iCAINE, led the session on pricing strategies and the design-thinking masterclass. The sessions covered user needs assessment, problem identification, ideation, prototyping, testing and the development of practical, user-centred solutions for the Ayurveda sector.</span></p>
<p><span>Other activities included a briefing on the Smart India Hackathon (SIH), the launch of the Techfest Hackathon, the release of </span><i><span>Ayupreneur: A Beginner’s Glossary</span></i><span> and the release of grants to the SIH 2025 winners.</span></p>
<p><span>The official programme began with a welcome address by Dr Arun Kumar Mahaptra, Head of Incubation. It also featured an address by Prof. (Dr.) Sreenivasa Prasad Buduru, Chief Guest, and the presidential address by Prof. Vd. P. K. Prajapati, Director, AIIA.</span></p>
<p><span>The celebration concluded with a vote of thanks by Sujith Eranezhath, CEO, AIIA-iCAINE, followed by networking.</span></p>
<p>The post <a href="https://www.expresspharma.in/aiia-launches-national-ai-challenge-for-ayurveda-on-incubation-centres-sixth-foundation-day/">AIIA launches national AI challenge for Ayurveda on incubation centre’s sixth Foundation Day</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Hikal’s Bengaluru API facility receives Swissmedic GMP certification</title>
<link>https://edusehat.com/en/hikals-bengaluru-api-facility-receives-swissmedic-gmp-certification</link>
<guid>https://edusehat.com/en/hikals-bengaluru-api-facility-receives-swissmedic-gmp-certification</guid>
<description><![CDATA[ 
The certification follows inspections by Brazil’s ANVISA and Japan’s PMDA, supporting Hikal’s expansion across regulated pharma markets
The post Hikal’s Bengaluru API facility receives Swissmedic GMP certification appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 14:10:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Hikal’s, Bengaluru, API, facility, receives, Swissmedic, GMP, certification</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Hikal has received a Certificate of GMP Compliance of a Manufacturer from Swissmedic, the Swiss Agency for Therapeutic Products, for its active pharmaceutical ingredient (API) facility in Bengaluru.</span></p>
<p><span>The certificate confirms that the facility meets the Good Manufacturing Practice (GMP) requirements of the Mutual Recognition Agreement between the European Union and Switzerland.</span></p>
<p><span>The Swissmedic certification follows inspections of the Bengaluru facility by Brazil’s ANVISA and Japan’s PMDA. These recognitions reinforce the facility’s standing with global regulators and position Hikal to serve a wider customer base across regulated markets.</span></p>
<p><span>The certifications also support the company’s strategy to diversify the geographic footprint of its pharmaceutical business and build resilience against geopolitical and trade uncertainties.</span></p>
<p><span>Commenting on the development, Sameer Hiremath, Chairman & Managing Director, Hikal, said, “The Swissmedic certification is a strong endorsement of the quality systems at our Bengaluru facility. It is an important step in expanding the global reach of our pharma business and opens new opportunities with customers in Europe and other regulated markets. Quality, compliance and manufacturing excellence remain the foundation of our long-term customer partnerships.”</span></p>
<p>The post <a href="https://www.expresspharma.in/hikals-bengaluru-api-facility-receives-swissmedic-gmp-certification/">Hikal’s Bengaluru API facility receives Swissmedic GMP certification</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Martin Casino App &amp;amp; Mobile Guide: So spielst du unterwegs</title>
<link>https://edusehat.com/en/martin-casino-app-mobile-guide-so-spielst-du-unterwegs</link>
<guid>https://edusehat.com/en/martin-casino-app-mobile-guide-so-spielst-du-unterwegs</guid>
<description><![CDATA[ Martin Casino – Praktischer Leitfaden für deutsche Spieler 1. Registrierung und erster Schritt beim Martin Casino Bevor du die ersten Spins drehst, musst du dich beim Martin Casino 
The post Martin Casino App &amp; Mobile Guide: So spielst du unterwegs appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/uBrtM1HesX0/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 07:00:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Martin, Casino, App, Mobile, Guide:, spielst, unterwegs</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/uBrtM1HesX0/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Martin Casino – Praktischer Leitfaden für deutsche Spieler</h1>
<section>
<h2>1. Registrierung und erster Schritt beim Martin Casino</h2>
<div data-affgun-media="video"></div>
<p>Bevor du die ersten Spins drehst, musst du dich beim Martin Casino anmelden. Der Anmeldeprozess ist bewusst simpel gehalten: Du gibst deine E‑Mail‑Adresse, ein Passwort und dein Geburtsdatum ein, bestätigst deine Identität per Klick und schon hast du ein Konto.</p>
<p>Nach dem Absenden erhältst du eine Bestätigungs‑E‑Mail. Klicke den Link darin, um dein Konto zu aktivieren – das ist nötig, um später Auszahlungen zu tätigen. Während der Registrierung wird nach dem Wohnsitz gefragt; hier gibst du „Deutschland“ an, damit alle länderspezifischen Angebote korrekt angezeigt werden.</p>
</section>
<section>
<h2>2. Willkommen‑Bonus und weitere Aktionen</h2>
<p>Der Willkommensbonus von Martin Casino ist das erste, was neue Spieler anzieht. Er besteht aus einem Einzahlungs‑Match‑Bonus und einer festgelegten Anzahl kostenloser Spins. Wichtig ist, die <strong>wagering requirements</strong> zu kennen, damit du die Bonusgewinne später auszahlen lassen kannst.</p>
<p>Im Folgenden siehst du die wichtigsten Bonusdetails übersichtlich in einer Tabelle:</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Bonusart</th>
<th>Prozentsatz</th>
<th>Max. Bonusbetrag</th>
<th>Wagering</th>
</tr>
</thead>
<tbody>
<tr>
<td>Willkommens‑Match</td>
<td>100 %</td>
<td>200 €</td>
<td>35×</td>
</tr>
<tr>
<td>Free Spins</td>
<td>–</td>
<td>50 Spins</td>
<td>30×</td>
</tr>
<tr>
<td>Wöchentliche Reload‑Bonus</td>
<td>50 %</td>
<td>100 €</td>
<td>25×</td>
</tr>
</tbody>
</table>
<p>Beachte, dass der Bonus nur bei der ersten Einzahlung aktiviert wird. Weitere Aktionen wie Cashback oder Turnier‑Preise findest du im Bonus‑Bereich des Casinos, wo du dich jederzeit über aktuelle Angebote informieren kannst.</p>
</section>
<section>
<h2>3. Einzahlungsmethoden – sicher und schnell</h2>
<p>Martin Casino bietet eine Auswahl bewährter Zahlungsmöglichkeiten, die sowohl Sicherheit als auch Geschwindigkeit garantieren. Alle gängigen Kredit‑ und Debitkarten werden akzeptiert, zudem stehen E‑Wallets und Direktüberweisungen zur Verfügung.</p>
<p>Typische Einzahlungs‑Optionen:</p>
<ul>
<li>Visa / Mastercard</li>
<li>PayPal</li>
<li>Sofortüberweisung</li>
<li>Giropay</li>
<li>Banküberweisung (SEPA)</li>
</ul>
<p>Die meisten Einzahlungen werden sofort gutgeschrieben, sodass du ohne Wartezeit mit dem Spielen beginnen kannst. Achte bei der Auswahl auf mögliche Mindestbeträge und eventuelle Gebühren, die je nach Methode variieren können.</p>
</section>
<section>
<h2>4. Auszahlungen – Geschwindigkeit und Gebühren</h2>
<p>Der Auszahlungsprozess im Martin Casino ist darauf ausgerichtet, Geld schnell auf dein Konto zu bringen. Nach der Anforderung wird die Auszahlung in der Regel innerhalb von 24 Stunden bearbeitet, vorausgesetzt, deine Identität wurde bereits verifiziert.</p>
<p>Folgende Auszahlungsmethoden stehen zur Verfügung:</p>
<ul>
<li>Banküberweisung (SEPA) – 1–3 Werktage</li>
<li>PayPal – sofort bis zu 30 Minuten</li>
<li>Sofortüberweisung – bis zu 1 Stunde</li>
</ul>
<p>Es fallen keine Gebühren für Auszahlungen an, solange du die gewählte Methode unterstützt. Bei höheren Beträgen kann das Casino zusätzliche Sicherheitsprüfungen durchführen – das ist Teil der KYC‑Richtlinien und schützt dich vor Betrug.</p>
</section>
<section>
<h2>5. Spielangebot – Slots, Live Casino und Sportwetten</h2>
<p>Das Portfolio von Martin Casino ist breit gefächert. Über 2 000 Slot‑Titel, darunter Klassiker wie <em>Starburst</em> und neue Video‑Slots mit hoher Volatilität, sorgen für Abwechslung. Jeder Slot zeigt die RTP‑Rate (Return to Player) direkt im Spiel, damit du die Gewinnchancen einschätzen kannst.</p>
<p>Im Live‑Casino kannst du gegen echte Dealer antreten – Blackjack, Roulette und Baccarat stehen rund um die Uhr bereit. Zusätzlich bietet das Casino eine kompakte Sportwetten‑Sektion, in der du auf Fußball, Tennis und E‑Sports setzen kannst. Die Integration von Sportwetten macht Martin Casino zu einer echten All‑In‑One‑Plattform.</p>
</section>
<section>
<h2>6. Mobile Nutzung und App‑Experience</h2>
<p>Für Spieler, die unterwegs sind, stellt Martin Casino sowohl eine responsive Web‑Version als auch eine native App für Android und iOS bereit. Die App ist leichtgewichtig, öffnet sich in wenigen Sekunden und unterstützt alle Kernfunktionen: Einzahlung, Bonusverwaltung, Live‑Casino und Sportwetten.</p>
<p>Die mobile Oberfläche wurde für schnelle Navigation optimiert. Das Menü ist in drei Hauptbereiche unterteilt – „Spiele“, „Casino“ und „Sport“. So findest du deine Lieblingsslots oder das aktuelle Fußballspiel, ohne lange suchen zu müssen.</p>
</section>
<section>
<h2>7. Sicherheit, Lizenzierung und verantwortungsvolles Spielen</h2>
<p>Martin Casino operiert unter einer Lizenz der Malta Gaming Authority (MGA) und ist zusätzlich bei der deutschen Glücksspielbehörde registriert. Diese Doppel‑Lizenz sorgt für strenge Kontrollen hinsichtlich Fairness und Datenschutz.</p>
<p>Zur Gewährleistung sicherer Transaktionen nutzt das Casino SSL‑Verschlüsselung. Spieler können zudem Tools zum verantwortungsvollen Spielen nutzen, etwa Einzahlungslimits, Selbstausschluss und ein 24‑Stunden‑Support für Fragen zum Thema Spielsucht.</p>
</section>
<section>
<h2>8. Kundenservice – Erreichbarkeit und Qualität</h2>
<p>Der Kundensupport von Martin Casino ist rund um die Uhr per Live‑Chat und E‑Mail verfügbar. Die durchschnittliche Antwortzeit im Chat liegt bei weniger als einer Minute, wodurch Probleme schnell gelöst werden können.</p>
<p>Ein umfassendes FAQ‑Archiv deckt häufige Themen ab: Konto‑Verifizierung, Bonusbedingungen, Einzahlungsmethoden und mehr. Wenn du lieber telefonisch Kontakt aufnehmen möchtest, steht dir eine kostenfreie Hotline für deutsche Nummern zur Verfügung.</p>
</section>
<section>
<h2>9. Fazit – Ist das Martin Casino das Richtige für dich?</h2>
<p>Martin Casino kombiniert ein breites Spielangebot, attraktive Boni und schnelle Auszahlungen – alles unterstützt durch eine zuverlässige Lizenz und robuste Sicherheitsmaßnahmen. Für deutsche Spieler, die sowohl Slots als auch Live‑Casino und Sportwetten in einer Plattform suchen, ist das Angebot besonders attraktiv.</p>
<p>Wenn du nach einem <a href="https://martin-casinos-germany.com/">martin online casino</a> suchst, das sowohl Anfänger als auch erfahrene Spieler anspricht, bietet Martin Casino genau das nötige Maß an Benutzerfreundlichkeit, Bonusvielfalt und vertrauenswürdiger Infrastruktur.</p>
</section>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/martin-casino-app-mobile-guide-so-spielst-du-unterwegs/">Martin Casino App & Mobile Guide: So spielst du unterwegs</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Martin Casino App – Was du wissen musst</title>
<link>https://edusehat.com/en/martin-casino-app-was-du-wissen-musst</link>
<guid>https://edusehat.com/en/martin-casino-app-was-du-wissen-musst</guid>
<description><![CDATA[ Martin Casino App – Praktischer Leitfaden für deutsche Spieler 1. Registrierung: Der erste Schritt zum Spielspaß Bevor du die martin casino app nutzen kannst, musst du ein Konto 
The post Martin Casino App – Was du wissen musst appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/uTSm4P1s1N4/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 07:00:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Martin, Casino, App, –, Was, wissen, musst</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/uTSm4P1s1N4/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Martin Casino App – Praktischer Leitfaden für deutsche Spieler</h1>
<h2>1. Registrierung: Der erste Schritt zum Spielspaß</h2>
<div data-affgun-media="video"></div>
<p>Bevor du die <strong>martin casino app</strong> nutzen kannst, musst du ein Konto anlegen. Der Prozess ist bewusst simpel gehalten: Auf der Startseite klickst du auf „Registrieren“, gibst deine E‑Mail‑Adresse, ein sicheres Passwort und dein Geburtsdatum an. Danach folgt eine kurze Verifizierung per E‑Mail‑Link.</p>
<p>Wichtig ist, dass du bei der Angabe deiner Daten keine Tippfehler machst – ein falscher Name oder ein falsches Geburtsdatum kann spätere Auszahlungen verzögern. Sobald dein Konto aktiv ist, kannst du dich sofort in die App einloggen und loslegen.</p>
<h2>2. Bonusübersicht & Wettanforderungen</h2>
<p>Martin Casino lockt neue Spieler mit einem großzügigen Willkommenspaket, das sich aus einem 100 % Einzahlungsbonus bis zu 200 €, plus 50 Freispielen im Slot‑Bereich, zusammensetzt. Der Bonus unterliegt regulären <em>wagering requirements</em> von 30 × des Bonusbetrags.</p>
<p>Damit du den Bonus optimal nutzen kannst, empfiehlt es sich, zuerst Spiele mit hoher <strong>RTP</strong> (Return to Player) zu wählen. Slots wie „Starburst“ oder „Book of Dead“ haben typischerweise eine RTP von 96 % oder mehr, was die Erfüllung der Wettanforderungen erleichtert.</p>
<h2>3. Einzahlung: Verfügbare Zahlungsmethoden</h2>
<p>Die <strong>martin casino app</strong> unterstützt zahlreiche gängige Zahlungsoptionen. Für deutsche Spieler sind vor allem Kreditkarte (Visa, Mastercard), Sofortüberweisung, Giropay und PayPal beliebt. Alle Methoden sind sofort einsatzbereit, sodass du nach dem Klick auf „Einzahlen“ sofort mit dem Spielen beginnen kannst.</p>
<ul>
<li>Kreditkarte – bis zu 5 000 € pro Transaktion.</li>
<li>Sofortüberweisung – 100 % sofortige Gutschrift.</li>
<li>Giropay – sichere Direktüberweisung vom Girokonto.</li>
<li>PayPal – schnelle und vertraute Abwicklung.</li>
</ul>
<h2>4. Auszahlungen & Geschwindigkeit</h2>
<p>Nach einem Gewinn ist das Wichtigste, das Geld schnell auf dein Bankkonto zu bekommen. Martin Casino bietet Auszahlungen per Banküberweisung, PayPal und Skrill an. Die durchschnittliche Bearbeitungszeit liegt bei 24‑48 Stunden für elektronische Methoden, während Banküberweisungen bis zu drei Werktage dauern können.</p>
<p>Um deine Auszahlung zu beschleunigen, stelle sicher, dass dein Konto bereits verifiziert ist (siehe Abschnitt 5). Unverifizierte Konten können bis zu sieben Tage in der Prüfung bleiben.</p>
<h2>5. Mobile Nutzung & App‑Funktionen</h2>
<p>Die <strong>martin casino app</strong> ist sowohl für Android als auch für iOS verfügbar und wurde für ein reibungsloses mobiles Erlebnis optimiert. Alle Casinospiele, Live-Dealer‑Tische und das Wettangebot stehen in der App zur Verfügung, ohne dass du die Seite im Browser öffnen musst.</p>
<p>Die App bietet Push‑Benachrichtigungen für exklusive Aktionen, persönliche Bonuscodes und schnelle Einzahlungs‑Links. Die offizielle Martin Casino App kann hier heruntergeladen werden: <a href="https://martins-cassinos.com/app">https://martins-cassinos.com/app</a>.</p>
<h2>6. Sicherheit, Lizenz & verantwortungsvolles Spielen</h2>
<p>Martin Casino operiert mit einer Lizenz der Malta Gaming Authority (MGA) und erfüllt strengste EU‑Sicherheitsstandards. Alle Daten werden mit SSL‑Verschlüsselung geschützt, sodass deine persönlichen Informationen sicher bleiben.</p>
<p>Verantwortungsvolles Spielen wird großgeschrieben. Du kannst Limits für Einzahlungen, Einsätze und Verlustbeträge festlegen. Außerdem gibt es eine Selbstsperrfunktion, die dich für bis zu sechs Monate vom Spiel ausschließt.</p>
<h2>7. Kundensupport – Hilfe, wenn du sie brauchst</h2>
<p>Der Kundenservice von Martin Casino ist rund um die Uhr per Live‑Chat und E‑Mail erreichbar. Das Team spricht Deutsch, Englisch und weitere europäische Sprachen, sodass du dich immer in deiner Muttersprache verständigen kannst.</p>
<p>Ein umfangreiches FAQ‑Portal deckt häufige Fragen zu Registrierung, Boni, Ein- und Auszahlungen sowie technische Probleme ab. Für komplexe Anliegen wird dir im Live‑Chat ein Spezialist zugewiesen, der innerhalb von 15 Minuten reagieren sollte.</p>
<h2>8. Funktionsvergleich: Martin Casino App vs. Konkurrenz</h2>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Kriterium</th>
<th>Martin Casino App</th>
<th>Durchschnittlicher Mitbewerber</th>
</tr>
</thead>
<tbody>
<tr>
<td>Willkommensbonus</td>
<td>100 % bis 200 € + 50 FS</td>
<td>100 % bis 150 €</td>
</tr>
<tr>
<td>Max. Einzahlung pro Tag</td>
<td>5 000 €</td>
<td>2 500 €</td>
</tr>
<tr>
<td>Auszahlungszeit (E‑Money)</td>
<td>24‑48 Std.</td>
<td>48‑72 Std.</td>
</tr>
<tr>
<td>Lizenz</td>
<td>MGA</td>
<td>UKGC / Curacao</td>
</tr>
<tr>
<td>Live‑Casino</td>
<td>Ja, 30+ Tische</td>
<td>Ja, 20‑25 Tische</td>
</tr>
</tbody>
</table>
<h2>9. Fazit: Ist die martin casino app das Richtige für dich?</h2>
<p>Wenn du nach einer benutzerfreundlichen App suchst, die sowohl ein attraktives Bonuspaket als auch schnelle Auszahlungen bietet, ist die Martin Casino App eine solide Wahl. Die Kombination aus breiter Zahlungsmethoden‑Palette, deutscher Lizenz und gutem Kundenservice macht das Angebot besonders attraktiv für Spieler in Deutschland.</p>
<p>Denke daran, deine Spiele verantwortungsbewusst zu gestalten, die Wettanforderungen zu prüfen und stets deine Kontodaten aktuell zu halten. Mit diesen Tipps steht einem sicheren und unterhaltsamen Casinobesuch nichts mehr im Wege.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/martin-casino-app-was-du-wissen-musst/">Martin Casino App – Was du wissen musst</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Casino Verde login – betalingsmetoder, innskudd og uttak for norske spillere</title>
<link>https://edusehat.com/en/casino-verde-login-betalingsmetoder-innskudd-og-uttak-for-norske-spillere</link>
<guid>https://edusehat.com/en/casino-verde-login-betalingsmetoder-innskudd-og-uttak-for-norske-spillere</guid>
<description><![CDATA[ Casino Verde Login – Praktisk guide for norske spillere 1. Registrering og første innlogging Før du kan bruke casino verde login, må du opprette en konto hos Verde 
The post Casino Verde login – betalingsmetoder, innskudd og uttak for norske spillere appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/OHTf5p6nbIU/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 07:00:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Casino, Verde, login, –, betalingsmetoder, innskudd, uttak, for, norske, spillere</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/OHTf5p6nbIU/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<article>
<h1>Casino Verde Login – Praktisk guide for norske spillere</h1>
<section>
<h2>1. Registrering og første innlogging</h2>
<div data-affgun-media="video"></div>
<p>Før du kan bruke <strong>casino verde login</strong>, må du opprette en konto hos Verde Casino. Registreringsprosessen er kort: du fyller inn navn, e‑post og velger et passord som er lett å huske, men vanskelig for andre å gjette. Når du har bekreftet e‑postadressen, er kontoen klar til å brukes, men mange spillere velger å gjennomføre KYC‑prosessen før første innskudd.</p>
<p>Et viktig steg er å sette opp sikkerhetsinnstillinger som to‑faktor‑autentisering dersom casinoet tilbyr dette. På den måten reduserer du risikoen for at uvedkommende får tilgang til kontoen din. Når registreringen er fullført, kan du gå videre til innlogging og utforske spillutvalget.</p>
</section>
<section>
<h2>2. Slik logger du inn på Verde Casino</h2>
<h3>Trinn‑for‑trinn‑veiledning</h3>
<ul>
<li>Åpne nettleseren og gå til casinoets hovedside.</li>
<li>Klikk på «Logg inn»‑knappen som vanligvis finnes øverst til høyre.</li>
<li>Skriv inn brukernavnet eller e‑posten du registrerte, samt passordet.</li>
<li>Bekreft med eventuelt to‑faktor‑kodesystem.</li>
<li>Trykk på «Logg inn» og du blir tatt inn i kontoen din.</li>
</ul>
<p>Hvis du har glemt passordet, finnes det en «Glemt passord?»-lenke som sender en tilbakestillings‑e‑post. Sørg for å sjekke spam‑mappen hvis du ikke ser e‑posten med en gang. Når du er innlogget, kan du gå rett til innskudd eller bonusutnyttelse.</p>
<p>For en rask pålogging fra mobilen, kan du lagre brukernavn og passord i en pålitelig passordbehandler. Dette sparer tid og gjør at du kan hoppe rett inn i spillene når du er på farten.</p>
</section>
<section>
<h2>3. Bonus og velkomsttilbud ved innlogging</h2>
<p>Etter vellykket <strong>casino verde login</strong> vil du ofte bli møtt av et velkomsttilbud som kan inkludere en match‑bonus på første innskudd og gratis spinn. Les alltid betingelsene nøye – spesielt wagering requirements, som ofte ligger på 30‑40 ganger bonusbeløpet.</p>
<p>For norske spillere er det vanlig med en bonus som gir 100 % match opp til 2 000 kr, pluss 50 gratis spinn på utvalgte slot‑spill. Husk at gratis spinn ofte har en egen omsetningskrav på 20x gevinsten fra spinnene.</p>
<p>Et tips er å bruke bonusen på spill med høy RTP (return to player) og moderat volatilitet, slik at du får flere vinnende kombinasjoner og dermed lettere kan oppfylle omsetningskravene.</p>
</section>
<section>
<h2>4. Betalingsmetoder og innskudd</h2>
<p>Verde Casino støtter flere betalingsmetoder som er populære blant norske spillere: bankkort (Visa, Mastercard), e‑wallets som Skrill og Neteller, samt direkte bankoverføring. De fleste innskudd er umiddelbare, noe som betyr at du kan begynne å spille så snart du har trykket «Innskudd».</p>
<p>Her er en oversikt over de mest brukte innskuddsalternativene og deres typiske behandlingstid:</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Betalingsmetode</th>
<th>Behandlingstid</th>
<th>Avgift</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visa / Mastercard</td>
<td>Øyeblikkelig</td>
<td>Ingen</td>
</tr>
<tr>
<td>Skrill</td>
<td>Øyeblikkelig</td>
<td>Ingen</td>
</tr>
<tr>
<td>Neteller</td>
<td>Øyeblikkelig</td>
<td>Ingen</td>
</tr>
<tr>
<td>Bankoverføring</td>
<td>1‑2 arbeidsdager</td>
<td>0‑30 kr</td>
</tr>
</tbody>
</table>
<p>Velg den betalingsmetoden som passer best for deg, og husk at enkelte metoder kan ha lavere grenser for innskudd enn andre.</p>
</section>
<section>
<h2>5. Uttaksprosessen – hva du bør vite</h2>
<p>Uttak blir ofte sett på som den mest kritiske delen av casinoopplevelsen. Når du har oppfylt eventuelle omsetningskrav, kan du be om uttak via «Kasse»‑menyen. De fleste norske spillere foretrekker e‑wallets fordi uttaket da er nesten umiddelbart.</p>
<p>Hvis du bruker bankkort eller bankoverføring, kan uttaket ta 2‑5 arbeidsdager. Det er lurt å ha KYC‑dokumentene klare (ID, adressebevis) for å unngå forsinkelser. Verge også at casinoet kan sette en minimumsgrense på 100 kr per uttak.</p>
<p>Et tips: be om uttak i samme betalingsmetode som du brukte ved innskudd, da dette ofte gir raskest behandlingstid.</p>
</section>
<section>
<h2>6. Mobilapp og responsivt spill</h2>
<p>Verde Casino har en moderne mobilversjon som fungerer i både iOS‑ og Android‑nettlesere. Du trenger ikke å laste ned en separat app, men du kan også finne en dedikert app i App Store og Google Play hvis du foretrekker det.</p>
<p>Spillutvalget på mobil er optimalisert for små skjermer, men du får fortsatt tilgang til live casino, bordspill og slots med høy grafikk. Hastigheten på innlogging på mobilen er identisk med desktop‑versjonen, så <strong>casino verde login</strong> fungerer sømløst uansett enhet.</p>
<p>For best mulig opplevelse, sørg for at du har en stabil internettforbindelse og at du har oppdatert nettleseren til siste versjon.</p>
</section>
<section>
<h2>7. Sikkerhet, KYC og ansvarlig spill</h2>
<p>Verde Casino er lisensiert av Malta Gaming Authority, noe som gir et solid rammeverk for rettferdig spill og spillerbeskyttelse. Alle personopplysninger lagres kryptert med SSL‑teknologi, og casinoet utfører rutinert KYC‑kontroll for å bekrefte identiteten din.</p>
<p>Ansvarlig spill er integrert i plattformen – du kan sette innskuddsgrenser, tap‑grenser og ta pause fra spillene når du føler behov for det. Hvis du opplever spillrelaterte problemer, finnes det en «Responsible Gaming»-side med lenker til støttetjenester.</p>
</section>
<section>
<h2>8. Kundeservice og support</h2>
<p>Support er tilgjengelig 24/7 via live‑chat og e‑post. Når du har logget inn, klikker du på «Kontakt oss» for å åpne en chat‑sesjon med en norsk‑snakkende rådgiver. Responsen er vanligvis under ett minutt.</p>
<p>Det finnes også en FAQ‑seksjon med svar på vanlige spørsmål om innskudd, uttak og bonusbetingelser. For mer komplekse saker kan du sende inn dokumentasjon gjennom sikker opplastning i support‑portalen.</p>
</section>
<section>
<h2>9. Vanlige spørsmål (FAQ)</h2>
<h3>Hvor raskt kan jeg logge inn etter registrering?</h3>
<p>Etter at du har bekreftet e‑posten, er kontoen klar til å brukes umiddelbart. Du kan logge inn med en gang du har satt et passord.</p>
<h3>Hva gjør jeg hvis jeg har glemt passordet?</h3>
<p>Klikk på «Glemt passord?», skriv inn e‑posten din, og følg instruksjonene i e‑posten for å lage et nytt passord.</p>
<h3>Hvor finner jeg bonusinformasjonen etter innlogging?</h3>
<p>Bonusene vises i en banner på dashbordet ditt så snart du er logget inn, og du kan også finne detaljer i «Kampanjer»-menyen.</p>
<h3>Er det noen spesiell nettside for innlogging?</h3>
<p>Ja, gå direkte til <a href="https://verdecasinos-no.com/login">https://verdecasinos-no.com/login</a> for å logge inn på kontoen din.</p>
</section>
</article>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/casino-verde-login-betalingsmetoder-innskudd-og-uttak-for-norske-spillere/">Casino Verde login – betalingsmetoder, innskudd og uttak for norske spillere</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Glorion Casino Login – Überblick und Optionen</title>
<link>https://edusehat.com/en/glorion-casino-login-uberblick-und-optionen</link>
<guid>https://edusehat.com/en/glorion-casino-login-uberblick-und-optionen</guid>
<description><![CDATA[ Glorion Casino Login – Ihre praktische Schritt‑für‑Schritt Anleitung 1. Schnell Überblick: Was ist Glorion Casino? Glorion Casino ist ein relativ neues Lizenz‑Casino, das 2022 gestartet wurde und seitdem 
The post Glorion Casino Login – Überblick und Optionen appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/lHERdxnL9Ts/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 07:00:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Glorion, Casino, Login, –, Überblick, und, Optionen</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/lHERdxnL9Ts/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Glorion Casino Login – Ihre praktische Schritt‑für‑Schritt Anleitung</h1>
<h2>1. Schnell Überblick: Was ist Glorion Casino?</h2>
<div data-affgun-media="video"></div>
<p>Glorion Casino ist ein relativ neues Lizenz‑Casino, das 2022 gestartet wurde und seitdem eine wachsende Community in Deutschland aufgebaut hat. Das Angebot reicht von klassischen Slots über Live‑Dealer‑Tische bis hin zu einer kleinen Sportwetten‑Sektion. Alle Spiele stammen von namhaften Providern wie NetEnt, Play’n GO und Evolution Gaming, sodass ein hoher RTP‑Durchschnitt und diverse Volatilitätsstufen garantiert sind. Das Casino wird von der Curaçao‑Gaming‑Authority lizenziert, was für die meisten deutschen Spieler ein akzeptabler Sicherheitsstandard ist.</p>
<p>Der Name „Glorion“ soll an Glorie und Triumph erinnern – ein Versprechen, das sich nicht nur im Design, sondern auch in Promotionen widerspiegelt. Für Einsteiger ist das Layout übersichtlich, die Navigation klar strukturiert und die wichtigsten Buttons (Registrieren, Einzahlen, Login) sofort sichtbar. Wer also nach einem neuen Portal für Slots und Live‑Casino sucht, findet hier ein komplettes Starter‑Pakete‑Programm.</p>
<h2>2. Registrierung: Der erste Schritt zum Login</h2>
<p>Bevor Sie den <strong>glorion casino login</strong> nutzen können, müssen Sie ein Konto anlegen. Der Registrierungsprozess dauert etwa drei Minuten und erfordert nur wenige Angaben: E‑Mail-Adresse, gewünschter Benutzername und ein sicheres Passwort. Zusätzlich wird nach Ihrem Geburtsdatum gefragt, um sicherzustellen, dass Sie das gesetzliche Mindestalter von 18 Jahren erfüllen.</p>
<p>Nach dem Absenden erhalten Sie eine Bestätigungs‑E‑Mail. Klicken Sie auf den enthaltenen Link, um die Registrierung abzuschließen. Erst dann wird Ihr Account aktiv und Sie können sich einloggen. Tipp: Verwenden Sie nach Möglichkeit eine E‑Mail, die Sie regelmäßig prüfen, um wichtige Mitteilungen zu Bonus­bedingungen oder Sicherheitshinweisen nicht zu verpassen.</p>
<h2>3. Login‑Prozess: So melden Sie sich an</h2>
<p>Der <em>glorion casino login</em> ist bewusst simpel gehalten. Auf der Startseite finden Sie das Login‑Feld oben rechts. Geben Sie Ihren Benutzernamen (oder Ihre E‑Mail) und das Passwort ein, setzen Sie optional den „Angemeldet bleiben“-Haken, und klicken Sie auf „Einloggen“. Sollte die Eingabe nicht funktionieren, prüft das System automatisiert, ob das Passwort falsch geschrieben wurde oder das Konto gesperrt ist.</p>
<p>Falls Sie Ihr Passwort vergessen haben, gibt es einen „Passwort vergessen?“-Link, der Ihnen einen Wiederherstellungs‑Code an die registrierte E‑Mail schickt. Der Vorgang ist in der Regel innerhalb von fünf Minuten abgeschlossen, vorausgesetzt, Sie haben Zugriff auf das Postfach. Für zusätzliche Sicherheit bietet Glorion optional die Zwei‑Faktor‑Authentifizierung (2FA) per SMS oder Authenticator‑App an.</p>
<h2>4. Bonus & Willkommensangebot beim ersten Login</h2>
<p>Gleich nach dem ersten <strong>glorion casino login</strong> wartet ein großzügiges Willkommenspaket auf Sie. Aktuell erhalten neue Spieler 100 % bis zu 200 €, plus 50 Freispiele für den Slot „Starburst“. Der Bonus unterliegt einer 30‑fachen Wettanforderung (Wagering) auf das Bonusguthaben, bevor eine Auszahlung möglich ist.</p>
<p>Wichtig zu beachten: Die Freispiele gelten nur für ausgewählte Slots und haben eine maximale Auszahlung von 50 € pro Spin. Die Bonusbedingungen gelten für 30 Kalendertage – verfallen also, wenn Sie das Konto innerhalb dieses Zeitraums nicht aktiv nutzen. Nutzen Sie das Angebot rasch, weil es nur für neue Spieler im ersten Monat nach Registrierung gilt.</p>
<h2>5. Zahlung & Auszahlung – Was Sie wissen müssen</h2>
<p>Glorion unterstützt in Deutschland gängige Einzahlungs‑ und Auszahlungsmethoden. Die beliebtesten Optionen sind Kredit‑/Debitkarten (Visa, Mastercard), Sofort‑Überweisung, Trustly und PayPal. Jeder Einzahlungsweg wird sofort gutgeschrieben, während Auszahlungen je nach Methode unterschiedlich lange dauern.</p>
<p>Im Folgenden finden Sie eine kompakte Übersicht:</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Zahlungsmethode</th>
<th>Einzahlungszeit</th>
<th>Auszahlungszeit</th>
<th>Max. Auszahlung pro Transaktion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visa / Mastercard</td>
<td>sofort</td>
<td>1‑3 Werktage</td>
<td>5.000 €</td>
</tr>
<tr>
<td>Sofort‑Überweisung</td>
<td>sofort</td>
<td>bis zu 24 Std.</td>
<td>3.000 €</td>
</tr>
<tr>
<td>Trustly</td>
<td>sofort</td>
<td>innerhalb von 2 Std.</td>
<td>2.500 €</td>
</tr>
<tr>
<td>PayPal</td>
<td>sofort</td>
<td>innerhalb von 24 Std.</td>
<td>4.000 €</td>
</tr>
</tbody>
</table>
<p>Bevor Sie eine Auszahlung anfordern, wird eine KYC‑Verifizierung (Know‑Your‑Customer) durchgeführt. Das bedeutet, Sie müssen einen Lichtbildausweis und ggf. einen Wohnsitznachweis hochladen. Sobald die Dokumente geprüft sind, erfolgen Auszahlungen in der Regel innerhalb der angegebenen Zeitrahmen.</p>
<h2>6. Mobile Nutzung & App – Spielen unterwegs</h2>
<p>Das Design von Glorion ist vollständig responsive, sodass Sie auf Smartphones und Tablets ohne Qualitätsverlust spielen können. Es gibt zudem eine offizielle Android‑App, die im Google Play Store (nach vorheriger Freigabe) verfügbar ist. Die iOS‑Nutzer können über den Safari‑Browser auf die mobile Seite zugreifen, weil eine native App aktuell noch in Entwicklung ist.</p>
<p>Die mobile Plattform bietet dieselben Bonus‑ und Zahlungsoptionen wie die Desktop‑Variante. Wichtig: Für den <strong>glorion casino login</strong> auf dem Handy müssen Sie die gleiche Zwei‑Faktor‑Authentifizierung aktivieren, wenn Sie das Sicherheitslevel hochhalten wollen. Die App speichert Ihre Lieblingsspiele im Schnellzugriff, damit Sie sofort dort weitermachen können, wo Sie aufgehört haben.</p>
<h2>7. Sicherheit, Verifikation und verantwortungsvolles Spielen</h2>
<p>Glorion nutzt SSL‑Verschlüsselung (256‑Bit) für alle Datenübertragungen, sodass Ihre persönlichen Informationen und finanziellen Transaktionen sicher bleiben. Die Lizenz aus Curaçao verpflichtet das Casino, regelmäßige Audits durchzuführen – unabhängige Prüfinstanzen testen die Zufallszahlengeneratoren (RNG) und garantieren faire Spielbedingungen.</p>
<p>Verantwortungsvolles Spielen wird aktiv gefördert: Es gibt Selbst‑Ausschluss‑Optionen, tägliche Einzahlungslimits und eine Übersicht über das eigene Spielverhalten. Sollten Sie das Gefühl haben, dass das Spielen überhandnimmt, können Sie über das Kunden‑Support‑Portal sofort eine Sperre anfordern.</p>
<h2>8. Kundenservice und Support</h2>
<p>Der Kundenservice ist rund um die Uhr per Live‑Chat und E‑Mail erreichbar. In der Regel erhalten Sie innerhalb von wenigen Minuten eine Antwort im Chat, während E‑Mails innerhalb von 24 Stunden bearbeitet werden. Für deutsche Spieler gibt es zudem eine telefonische Hotline, die werktags von 09:00 bis 18:00 Uhr besetzt ist.</p>
<p>Der Support kann Ihnen bei allen Themen helfen: <em>glorion casino login</em> Probleme, Bonus‑Fragen, Verifikations‑Dokumente oder technische Schwierigkeiten mit der mobilen App. Nutzen Sie das integrierte Ticket‑System, wenn Sie ein Problem schriftlich dokumentieren möchten – das System speichert den Verlauf für zukünftige Rückfragen.</p>
<h2>9. Häufige Fragen zum Glorion Casino Login</h2>
<ul>
<li>Wie lange dauert die Konto‑Verifikation? – Meistens 24‑48 Stunden nach Hochladen der Unterlagen.</li>
<li>Kann ich mich mit meiner E‑Mail statt dem Benutzernamen anmelden? – Ja, beides ist möglich.</li>
<li>Gibt es ein Limit für das tägliche Login? – Nein, das ist unbegrenzt, aber bei ungewöhnlichen Aktivitäten kann ein Sicherheits‑Check ausgelöst werden.</li>
<li>Wie kann ich meine Zugangsdaten zurücksetzen? – Nutzen Sie den „Passwort vergessen?“-Link und folgen Sie den Anweisungen.</li>
</ul>
<p>Wenn Sie nach einer zuverlässigen Anlaufstelle für Online‑Casino‑Spiele in Deutschland suchen, ist das <a href="https://glorion-casinos-de.com/">glorion casino</a> einen genauen Blick wert. Mit klaren Anmelde‑Schritten, attraktiven Boni und einer breiten Palette an Zahlungsoptionen bietet das Portal alles, was Spieler für ein sicheres und spaßiges Spielerlebnis erwarten.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/glorion-casino-login-uberblick-und-optionen/">Glorion Casino Login – Überblick und Optionen</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Martin Casino Review – Konto‑Verifizierung einfach erklärt</title>
<link>https://edusehat.com/en/martin-casino-review-kontoverifizierung-einfach-erklaert</link>
<guid>https://edusehat.com/en/martin-casino-review-kontoverifizierung-einfach-erklaert</guid>
<description><![CDATA[ Martin Casino Review – Der umfassende Guide für deutsche Spieler 1. Überblick &amp; Lizenz – Ist das Martin Casino vertrauenswürdig? Ein guter erster Eindruck entsteht, wenn ein Casino 
The post Martin Casino Review – Konto‑Verifizierung einfach erklärt appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/T_UkDY_gkkI/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 07:00:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Martin, Casino, Review, –, Konto‑Verifizierung, einfach, erklärt</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/T_UkDY_gkkI/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Martin Casino Review – Der umfassende Guide für deutsche Spieler</h1>
<section>
<h2>1. Überblick & Lizenz – Ist das Martin Casino vertrauenswürdig?</h2>
<div data-affgun-media="video"></div>
<p>Ein guter erster Eindruck entsteht, wenn ein Casino transparent über seine Lizenzierung informiert. Das Martin Casino wird von der Malta Gaming Authority (MGA) lizenziert, einer der renommiertesten Aufsichtsbehörden in der EU. Diese Lizenz garantiert, dass das Casino strenge Sicherheits- und Fairness‑Standards einhält, was für deutsche Spieler besonders wichtig ist.</p>
<p>Zusätzlich wird das Spielangebot regelmäßig von unabhängigen Prüflabors wie eCOGRA auditiert. So können Sie sicher sein, dass die angezeigten RTP‑Werte (Return to Player) den tatsächlichen Gewinnchancen entsprechen. Für Spieler, die auf rechtliche Sicherheit achten, ist das ein starkes Argument, das die Entscheidung für das Martin Casino erleichtert.</p>
</section>
<section>
<h2>2. Registrierung und KYC – Schnell starten, aber sicher bleiben</h2>
<p>Die Anmeldung beim Martin Casino dauert nur wenige Minuten. Nach Klick auf „Registrieren“ geben Sie Name, Adresse, Geburtsdatum und eine gültige E‑Mail‑Adresse ein. Das System prüft sofort, ob das Mindestalter von 18 Jahren erreicht ist – ein unverzichtbarer Schritt im deutschen Glücksspielrecht.</p>
<p>Nach dem ersten Login folgt die KYC‑Verifizierung (Know Your Customer). Dafür müssen Sie einen Lichtbildausweis und einen Adressnachweis hochladen. Dieser Prozess dient nicht nur der Betrugsprävention, sondern beschleunigt zukünftige Auszahlungen erheblich, weil das Casino dann bereits alle Dokumente vorliegen hat.</p>
</section>
<section>
<h2>3. Bonusangebote & Willkommensbonus – Was steckt wirklich dahinter?</h2>
<p>Der Willkommensbonus ist das Aushängeschild jedes Online‑Casinos. Martin Casino lockt neue Spieler mit einem 100 % Bonus bis zu 200 €, plus 100 Freispiele auf ausgewählte Slots. Der Bonus wird automatisch nach der ersten Einzahlung gutgeschrieben, solange die Mindesteinzahlung von 20 € erreicht wird.</p>
<p>Wichtig zu beachten sind die <em>wagering requirements</em> – die Umsatzbedingungen. Bei Martin Casino beträgt die Umsatzbindung 35 × Bonusbetrag, was im deutschen Markt eher moderat ist. Die nachfolgende Tabelle gibt Ihnen einen schnellen Überblick:</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Bonustyp</th>
<th>Höhe</th>
<th>Umsatzbindung</th>
<th>Max. Auszahlung</th>
</tr>
</thead>
<tbody>
<tr>
<td>Willkommensbonus</td>
<td>100 % bis 200 € + 100 Freispiele</td>
<td>35 × Bonus</td>
<td>1 000 €</td>
</tr>
<tr>
<td>Einzahlungsbonus</td>
<td>50 % bis 100 €</td>
<td>30 × Bonus</td>
<td>500 €</td>
</tr>
<tr>
<td>Cashback</td>
<td>10 % Verlust‑Rückerstattung</td>
<td>–</td>
<td>200 € pro Monat</td>
</tr>
</tbody>
</table>
<p>Beachten Sie außerdem, dass Freispiele nur auf bestimmten Slot‑Titeln nutzbar sind und dass Gewinne aus Freispielen einer 30‑fachen Umsatzbindung unterliegen. Diese Details finden Sie in den Bonusbedingungen, die Sie unbedingt vor dem Annehmen lesen sollten.</p>
</section>
<section>
<h2>4. Spielangebot: Slots, Live Casino & Sportwetten</h2>
<p>Martin Casino bietet mehr als 2.000 Spiele, die von führenden Software‑Providern wie NetEnt, Microgaming und Evolution Gaming stammen. Das Portfolio umfasst klassische Video‑Slots, progressive Jackpot‑Titel und eine umfangreiche Auswahl an Tischspielen wie Blackjack, Roulette und Baccarat.</p>
<p>Für Fans von Live‑Glücksspiel gibt es ein eigenständiges Live‑Casino mit echten Dealern, das rund um die Uhr verfügbar ist. Hier können Sie per Video‑Stream an Blackjack‑Tischen mit mehreren Teilnehmern teilnehmen – ein echtes Casino‑Erlebnis, das von hoher Bildqualität und niedriger Latenz profitiert.</p>
<p>Ein weiteres Highlight ist die integrierte Sportwetten‑Plattform. Sie deckt beliebte Events aus Fußball, Tennis, Basketball und Esports ab. Wetten lassen sich direkt aus dem Casino‑Dashboard heraus platzieren, was für Spieler, die beides kombinieren möchten, besonders praktisch ist.</p>
</section>
<section>
<h2>5. Zahlungsarten & Auszahlungsdauer – Schnell und sicher Geld bewegen</h2>
<p>Ein breites Angebot an Ein- und Auszahlungsmethoden ist für deutsche Spieler entscheidend. Martin Casino unterstützt folgende Deposit‑Optionen:</p>
<ul>
<li>Kredit‑ und Debitkarten (Visa, Mastercard)</li>
<li>E‑Wallets (Skrill, Neteller, ecoPayz)</li>
<li>Banküberweisungen (SEPA)</li>
<li>Prepaid‑Karten (Paysafecard)</li>
</ul>
<p>Auszahlungen erfolgen in der Regel innerhalb von 24 Stunden, wenn die KYC‑Dokumente bereits geprüft wurden. E‑Wallet‑Abhebungen sind meist die schnellsten und werden innerhalb von 1‑2 Stunden bearbeitet. Banküberweisungen können bis zu 3 Werktage benötigen, was aber im deutschen Markt üblich ist.</p>
</section>
<section>
<h2>6. Mobile App & Benutzerfreundlichkeit – Spielen unterwegs</h2>
<p>Die mobile Erfahrung ist bei Martin Casino kein nachträglicher Gedanke, sondern von Anfang an integriert. Für Android und iOS gibt es eine native App, die im Google Play Store bzw. im Apple App Store verfügbar ist. Die App spiegelt das Desktop‑Layout wider, bietet schnelle Ladezeiten und unterstützt Touch‑Optimierung für Slots und Live‑Dealer‑Spiele.</p>
<p>Falls Sie lieber im Browser bleiben, funktioniert die komplette Plattform responsiv auf jedem Smartphone oder Tablet. Die Navigation ist intuitiv: Ein klar strukturiertes Menü führt Sie zu Bonusangeboten, Ihrem Konto und dem Live‑Casino – alles mit nur wenigen Klicks erreichbar.</p>
</section>
<section>
<h2>7. Kundenservice & Support – Hilfe, wenn Sie sie brauchen</h2>
<p>Der Kundensupport von Martin Casino ist rund um die Uhr per Live‑Chat, E‑Mail und telefonisch erreichbar. Der Live‑Chat ist in der Regel die schnellste Option und liefert innerhalb von wenigen Minuten Antworten auf gängige Fragen zu Einzahlungen, Bonusbedingungen oder technischen Problemen.</p>
<p>Ein FAQ‑Bereich auf der Website deckt häufig gestellte Fragen ab und spart oft Zeit, bevor Sie den Support kontaktieren. Für deutschsprachige Spieler gibt es sowohl deutschsprachige Chat‑Agenten als auch eine deutschsprachige E‑Mail‑Adresse, was den Service besonders benutzerfreundlich macht.</p>
</section>
<section>
<h2>8. Sicherheit & verantwortungsvolles Spielen – Ihr Schutz steht im Vordergrund</h2>
<p>Martin Casino verwendet modernste SSL‑Verschlüsselung, um alle Datenübertragungen zu schützen. Zusätzlich werden regelmäßige Pen‑Tests durchgeführt, um Schwachstellen frühzeitig zu erkennen. Die Einhaltung der EU‑Datenschutz‑Verordnung (DSGVO) sorgt dafür, dass Ihre persönlichen Daten sicher gespeichert werden.</p>
<p>Verantwortungsvolles Spielen wird aktiv gefördert. Das Casino bietet Selbstsperr‑Tools, Einzahlungslimits und eine 24‑Stunden‑Selbstausschluss‑Option. Sollten Sie das Gefühl haben, dass das Spielen aus dem Ruder läuft, können Sie über das Kundenkonto sofort eine Pause einlegen.</p>
</section>
<section>
<h2>9. Fazit & Entscheidungshilfe – Sollten Sie das Martin Casino wählen?</h2>
<p>Zusammenfassend lässt sich sagen, dass das Martin Casino mit einer soliden Lizenz, einem breiten Spielportfolio, attraktiven Boni und schnellen Auszahlungen punktet. Die deutschen Zahlungsoptionen, die mobile App und der mehrsprachige Kundenservice runden das Angebot ab und machen das Casino besonders für Einsteiger und erfahrene Spieler attraktiv.</p>
<p>Wenn Sie nach einem zuverlässigen, regulierten Anbieter suchen, der sowohl Casino‑ als auch Sportwetten unter einem Dach vereint, ist das Martin Casino einen genaueren Blick wert. Besuchen Sie den <a href="https://martin-casinos-online.com/">martin online casino</a>, um sich selbst ein Bild zu machen und das Willkommensangebot zu nutzen.</p>
</section>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/martin-casino-review-konto-verifizierung-einfach-erklart/">Martin Casino Review – Konto‑Verifizierung einfach erklärt</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Martin Casino App – Sicherheitsguide für deutsche Spieler 2026</title>
<link>https://edusehat.com/en/martin-casino-app-sicherheitsguide-fur-deutsche-spieler-2026</link>
<guid>https://edusehat.com/en/martin-casino-app-sicherheitsguide-fur-deutsche-spieler-2026</guid>
<description><![CDATA[ Martin Casino App – Dein praktischer Leitfaden für 2026 Warum die martin casino app? Die martin casino app ist nicht nur ein weiteres mobiles Casino, sie kombiniert schnelle 
The post Martin Casino App – Sicherheitsguide für deutsche Spieler 2026 appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/Gl3hy83SulM/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 07:00:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Martin, Casino, App, –, Sicherheitsguide, für, deutsche, Spieler, 2026</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/Gl3hy83SulM/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<article>
<h1>Martin Casino App – Dein praktischer Leitfaden für 2026</h1>
<section>
<h2>Warum die martin casino app?</h2>
<div data-affgun-media="video"></div>
<p>Die <strong>martin casino app</strong> ist nicht nur ein weiteres mobiles Casino, sie kombiniert schnelle Ladezeiten, ein übersichtliches Design und ein breites Spielangebot auf einem einzigen Gerät. Für deutsche Spieler bedeutet das sofortiger Zugriff auf Slots, Live‑Dealer‑Tische und sogar Sportwetten – alles ohne umständliche Desktop‑Navigation.</p>
<p>Ein weiterer Pluspunkt ist die nahtlose Integration von Bonusaktionen. Sobald du die App installierst, werden aktuelle Willkommensboni automatisch im Hintergrund aktualisiert, sodass du nie ein gutes Angebot verpasst. Das spart Zeit und erhöht deine Gewinnchancen bereits beim ersten Spiel.</p>
</section>
<section>
<h2>Registrierung und Verifizierung – Schritt für Schritt</h2>
<p>Der Anmeldeprozess in der <em>martin casino app</em> ist bewusst simpel gehalten. Nach dem Download öffnest du die App, klickst auf „Registrieren“ und gibst deine E‑Mail-Adresse, ein sicheres Passwort und dein Geburtsdatum ein. Die Eingabe wird sofort geprüft, und du erhältst einen Bestätigungscode per E‑Mail.</p>
<p>Die Verifizierung erfolgt danach in zwei Schritten: erstens das Hochladen eines gültigen Ausweisdokuments (Personalausweis oder Reisepass) und zweitens ein kurzer Selfie‑Check. Dieser KYC‑Prozess ist innerhalb von 24 Stunden abgeschlossen, danach kannst du Einzahlungen tätigen und das komplette Spielangebot nutzen.</p>
</section>
<section>
<h2>Bonusangebote und Wettanforderungen im Überblick</h2>
<p>Die <strong>martin casino app</strong> lockt neue Spieler mit einem 100 % Willkommensbonus bis zu 200 €, plus 50 Freispielen auf ausgewählte Slots. Die Bonusbedingungen sind transparent: 30‑fache Wettanforderungen (30x) auf den Bonusbetrag, nicht auf die Einzahlung.</p>
<p>Für Bestandskunden gibt es wöchentliche Reload‑Bonusse, Cash‑Back‑Aktionen und exklusive Mobile‑Only‑Promos. Wichtig ist, die jeweiligen Umsatzbedingungen zu prüfen – bei manchen Aktionen gelten niedrigere Multiplikatoren, wenn du mit Slots mit hoher Volatilität spielst.</p>
<ul>
<li>Willkommensbonus: 100 % bis 200 € + 50 FS</li>
<li>Wettanforderungen: 30x Bonus</li>
<li>Regelmäßige Reload‑Bonusse: 25 % bis 100 €</li>
<li>Cash‑Back: 5 % wöchentlich auf Nettoverlust</li>
</ul>
</section>
<section>
<h2>Zahlungsmethoden & Auszahlungsgeschwindigkeit</h2>
<p>Die App unterstützt alle gängigen deutschen Zahlungskanäle: Kredit‑ und Debitkarten (Visa, Mastercard), Sofortüberweisung, Giropay und gängige E‑Wallets wie Skrill oder Neteller. Einzahlungen werden in Echtzeit gutgeschrieben, sodass du sofort mit dem Spielen beginnen kannst.</p>
<p>Auszahlungen sind ebenfalls unkompliziert. Die meisten Methoden werden innerhalb von 24 Stunden bearbeitet, wobei E‑Wallets in der Regel die schnellsten Auszahlungszeiten von bis zu 2 Stunden bieten. Banküberweisungen können 3‑5 Werktage benötigen, was aber bei deutschen Banken üblich ist.</p>
<ul>
<li>Kreditkarte: Sofort, bis zu 5 % Bonus</li>
<li>Sofortüberweisung: 0 % Gebühren, 10‑15 Minuten</li>
<li>Skrill/Neteller: 0 % Gebühren, bis zu 2 Stunden</li>
<li>Banküberweisung: 1‑5 Werktage</li>
</ul>
</section>
<section>
<h2>Live Casino und Sportwetten auf dem Handy</h2>
<p>Dank der optimierten Streaming‑Technik bietet die <em>martin casino app</em> ein flüssiges Live‑Casino-Erlebnis. Du kannst an Echtzeit‑Tischspielen wie Blackjack, Roulette und Baccarat teilnehmen – alle mit professionellen Dealern aus europäischen Studios.</p>
<p>Zusätzlich integriert die App ein vollwertiges Sportwetten‑Modul. Ob Fußball, Handball oder E‑Sports – du findest aktuelle Quoten, Live‑Wetten und Pre‑Match‑Optionen. Die Kombination aus Casino‑ und Sportwetten macht die App zu einem All‑in‑One‑Portal für deutsche Spieler.</p>
</section>
<section>
<h2>Sicherheit, Lizenz und verantwortungsvolles Spielen</h2>
<p>Martin Casino ist von der Malta Gaming Authority (MGA) lizenziert und unterliegt strengen EU‑Regelungen. Die Datenverschlüsselung erfolgt nach dem aktuellen SSL‑Standard, sodass deine persönlichen Informationen und Transaktionen stets geschützt sind.</p>
<p>Verantwortungsvolles Spielen wird großgeschrieben. In der App findest du Tools für Einzahlungslimits, Verlustlimits und Selbstsperren. Solltest du das Gefühl haben, die Kontrolle zu verlieren, kannst du dich jederzeit an die 24/7‑Support‑Hotline wenden.</p>
</section>
<section>
<h2>Kundenservice und Support – was du erwarten kannst</h2>
<p>Der Kundensupport ist per Live‑Chat, E‑Mail und Telefon erreichbar. Anfragen werden in der Regel innerhalb von 5 Minuten beantwortet, wobei das Live‑Chat‑Team rund um die Uhr verfügbar ist. Für komplexe Fragen wie Auszahlungslimits gibt es eine ausführliche FAQ‑Sektion innerhalb der App.</p>
<p>Wenn du ein Problem hast, das du nicht sofort lösen kannst, steht dir ein dediziertes Beschwerdemanagement zur Verfügung. Der Service ist mehrsprachig, wobei Deutsch als primäre Sprache angeboten wird – ein echter Vorteil für lokale Spieler.</p>
</section>
<section>
<h2>Vergleichstabelle: martin casino app vs. Konkurrenz</h2>
<p>Um dir die Entscheidung zu erleichtern, haben wir die wichtigsten Kriterien der <strong>martin casino app</strong> mit zwei der beliebtesten deutschen Mobile‑Casinos verglichen:</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Kriterium</th>
<th>Martin Casino App</th>
<th>Casino A</th>
<th>Casino B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Willkommensbonus</td>
<td>100 % bis 200 € + 50 FS</td>
<td>150 % bis 300 €</td>
<td>100 % bis 250 € + 25 FS</td>
</tr>
<tr>
<td>Wettanforderungen</td>
<td>30x Bonus</td>
<td>40x Bonus</td>
<td>35x Bonus</td>
</tr>
<tr>
<td>Auszahlungsgeschwindigkeit</td>
<td>E‑Wallet 2 h, Bank 3‑5 Tage</td>
<td>E‑Wallet 4 h, Bank 5‑7 Tage</td>
<td>E‑Wallet 1 h, Bank 4‑6 Tage</td>
</tr>
<tr>
<td>Mobile‑Erlebnis</td>
<td>Native App iOS/Android</td>
<td>Responsive Web</td>
<td>Hybrid App</td>
</tr>
<tr>
<td>Lizenz</td>
<td>MGA</td>
<td>UKGC</td>
<td>Curacao</td>
</tr>
</tbody>
</table>
</section>
<section>
<h2>Fazit und Empfehlung</h2>
<p>Die <strong>martin casino app</strong> bietet ein ausgewogenes Paket aus attraktiven Boni, schnellen Auszahlungen und einem breiten Spielportfolio – alles verpackt in einer benutzerfreundlichen mobilen Oberfläche. Für deutsche Spieler, die sowohl Casino‑ als auch Sportwetten genießen wollen, stellt sie eine der besten Optionen im Jahr 2026 dar.</p>
<p>Wenn du bereit bist, das Angebot selbst zu testen, besuche einfach die offizielle Seite von <a href="https://martin-casino-deutschland.com/">martin casino</a> und lade die App herunter. Mit dem hier vorgestellten Leitfaden bist du bestens gerüstet, um sicher, schnell und gewinnbringend zu spielen.</p>
</section>
</article>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/martin-casino-app-sicherheitsguide-fur-deutsche-spieler-2026/">Martin Casino App – Sicherheitsguide für deutsche Spieler 2026</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Big Lucky Casino no deposit bonus – guide til app og mobil</title>
<link>https://edusehat.com/en/big-lucky-casino-no-deposit-bonus-guide-til-app-og-mobil</link>
<guid>https://edusehat.com/en/big-lucky-casino-no-deposit-bonus-guide-til-app-og-mobil</guid>
<description><![CDATA[ Big Lucky Casino – Din guide til big lucky casino no deposit bonus Hva er en big lucky casino no deposit bonus? En no‑deposit bonus er en liten 
The post Big Lucky Casino no deposit bonus – guide til app og mobil appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/rgvDGC2e5LI/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 07:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Big, Lucky, Casino, deposit, bonus, –, guide, til, app, mobil</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/rgvDGC2e5LI/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Big Lucky Casino – Din guide til big lucky casino no deposit bonus</h1>
<h2>Hva er en big lucky casino no deposit bonus?</h2>
<div data-affgun-media="video"></div>
<p>En no‑deposit bonus er en liten sum gratis penger eller gratisspinn som du kan få uten å sette inn egne penger. Hos Big Lucky Casino betyr dette at du kan starte spillopplevelsen med en gratis bankroll, vanligvis mellom 10 kr og 30 kr, bare ved å opprette en konto. Bonusen er ment som en velkomstgave og en mulighet til å teste kasinoets spillutvalg uten økonomisk risiko. Det er viktig å merke seg at selv om bonusen er gratis, er det ofte knyttet omsetningskrav og andre restriksjoner som du må godta før du kan ta ut eventuelle gevinster.</p>
<p>For norske spillere er dette spesielt attraktivt fordi mange andre kasinoer krever minimumsinnskudd som kan være høyere enn ønsket. Med en no‑deposit bonus kan du oppleve både slots og live casino‑bordspill før du bestemmer deg for om du vil satse ekte penger. Husk at bonustilbudet kan variere fra tid til annen, så det lønner seg å sjekke siden jevnlig for oppdaterte kampanjer.</p>
<h2>Hvordan registrere deg og kreve big lucky casino no deposit bonus</h2>
<p>Registreringsprosessen hos Big Lucky Casino er relativt enkel og krever kun noen få grunnleggende opplysninger. Du må oppgi navn, e‑postadresse, fødselsdato og velge et passord. Når kontoen er opprettet, vil du automatisk motta no‑deposit bonusten som er tilgjengelig for nye spillere i Norge.</p>
<h3>Steg‑for‑steg registrering</h3>
<ul>
<li>Gå til registreringssiden og fyll inn de nødvendige feltene.</li>
<li>Bekreft e‑postadressen ved å klikke på lenken du får i innboksen.</li>
<li>Logg inn på kontoen og sjekk «Bonuser»-fanen for å aktivere din gratis bonus.</li>
<li>Fullfør eventuell KYC‑verifisering før du kan ta ut eventuelle gevinster.</li>
</ul>
<p>Etter at du har aktivert bonusen, vil pengene eller gratisspinnene være tilgjengelige i spillkontoen din med en gang. Du kan umiddelbart begynne å spille på utvalgte slots eller live casino‑bord som er merket som «bonusgodkjente». </p>
<h2>Bonusvilkår: omsetningskrav og spillbegrensninger</h2>
<p>Selv om no‑deposit bonusen er gratis, kommer den med noen betingelser som du må oppfylle før du kan ta ut gevinster. Det viktigste er omsetningskravet, som vanligvis er mellom 20x og 30x bonusbeløpet. Dette betyr at du må satse bonusbeløpet et visst antall ganger i kvalifiserte spill før uttak er mulig.</p>
<h3>Forstå omsetningskrav</h3>
<p>Omsetningskrav beregnes kun på bonusbeløpet, ikke på innskuddet ditt. Dersom du får 20 kr i no‑deposit bonus med et 25x omsetningskrav, må du satse for totalt 500 kr i kvalifiserte spill før du kan be om en uttak. Spill med høy RTP og lav volatilitet er ofte best egnet for å møte kravene uten å tape for mye.</p>
<p>Det er også vanlig at maksimalt uttak fra en no‑deposit bonus er begrenset, ofte til 100 kr. Dette gjør at du kan teste kasinoet, men store gevinster krever et eget innskudd.</p>
<h2>Betalingsmetoder og uttakshastighet i Norge</h2>
<p>Big Lucky Casino støtter flere betalingsalternativer som er populære blant norske spillere. Du kan bruke bankkort, e‑wallet‑tjenester og direkte bankoverføring. For innskudd er behandlingstiden som regel umiddelbar, mens uttak kan ta fra noen timer til én virkedag avhengig av metode.</p>
<h3>Innskudd og uttak uten bonus</h3>
<p>Hvis du velger å fortsette å spille etter no‑deposit bonussen, vil du kunne sette inn penger med de samme metodene. De mest brukte betalingsløsningene i Norge er:</p>
<ul>
<li>Visa og MasterCard</li>
<li>Trustly – direkte fra nettbank</li>
<li>Skrill og Neteller</li>
<li>Vipps (kun for innskudd)</li>
</ul>
<p>Uttak behandles først etter at KYC‑verifiseringen er fullført. Når alt er i orden, kan du forvente at penger på din foretrukne e‑wallet er tilgjengelige innen 24 timer.</p>
<h2>Spillutvalg: live casino, slots og mer du kan prøve med bonusen</h2>
<p>Big Lucky Casino har et bredt spekter av spill som er tilgjengelige for no‑deposit bonusen. Slots med høy RTP og moderate volatilitet er ofte best egnet for å oppfylle omsetningskravene. Eksempler på populære titler er “Starburst”, “Gonzo’s Quest” og “Book of Dead”.</p>
<p>Live casino‑delen tilbyr bordspill som blackjack, roulette og baccarat med ekte dealere. Disse spillene er også bonusgodkjente, men husk at noen bordspill har lavere bidrag til omsetningskravene enn slots. Det er lurt å sjekke bonustabellen for å se hvilke spill som teller mest.</p>
<h2>Mobilapp og nettspill: spiller du på telefonen?</h2>
<p>For spillere som foretrekker å spille på farten, tilbyr Big Lucky Casino en mobiloptimalisert nettside og en dedikert app for både iOS og Android. Appen gir rask tilgang til slots, live casino og sportsbetting, samt muligheten til å sjekke bonusstatus og foreta innskudd med et par trykk.</p>
<p>Last ned appen her: <a href="https://biglucky-casinos.com/app">https://biglucky-casinos.com/app</a>. Appen er designet med norsk språkstøtte og har samme sikkerhetsnivå som desktop‑versjonen, så du kan spille trygt uansett hvor du er.</p>
<h2>Kundeservice, sikkerhet og lisensiering</h2>
<p>Big Lucky Casino er lisensiert av Malta Gaming Authority, som stiller strenge krav til spillersikkerhet og rettferdig spill. Kasinoet bruker SSL‑kryptering for å beskytte all personlig og økonomisk informasjon. Dette betyr at dataene dine er trygge både ved innskudd og ved uttak.</p>
<p>Kundeservice er tilgjengelig 24/7 via live chat og e‑post. Supportteamet kan svare på spørsmål om bonusvilkår, KYC‑prosessen og tekniske problemer. For norske spillere er det også mulig å kontakte support på norsk, noe som gjør kommunikasjonen enklere.</p>
<h2>Ansvarlig spill: hvordan holde kontrollen</h2>
<p>Ingen‑deposit bonuser er ment for underholdning, men det er viktig å spille ansvarlig. Big Lucky Casino tilbyr verktøy som innskuddsgrenser, tapsgrenser og mulighet for selv‑udelukkelse. Du kan sette daglige, ukentlige eller månedlige grenser direkte i kontoinnstillingene.</p>
<p>Hvis du føler at spillingen begynner å påvirke økonomien eller hverdagen din, bør du ta en pause og eventuelt kontakte Norsk Hjelpelinje for spillere med problemer. Å ha en klar plan før du begynner å spille med bonusen gjør opplevelsen både tryggere og mer fornøyelig.</p>
<h2>Oppsummering og siste tips</h2>
<p>Big Lucky Casino sin no‑deposit bonus gir norske spillere en enkel måte å prøve ut kasinoet uten å risikere egne penger. Ved å følge registreringsstegene, forstå omsetningskravene og bruke egnede betalingsmetoder, kan du maksimere sjansene for å konvertere gratispenger til ekte gevinster. Husk å spille ansvarlig og utnytte tilgjengelige verktøy for å holde kontrollen.</p>
<p>Et siste praktisk råd: før du gjør ditt første innskudd, test spillene med bonusen for å finne ut hvilke som passer din spillstil best. Når du har funnet favorittene, kan du vurdere å sette inn et beløp som gir deg mest mulig verdi i forhold til omsetningskrav og uttakshastighet.</p>
<h2>Bonusvilkår i en tabell</h2>
<p>                <</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Bonus</th>
<th>Omsetningskrav</th>
<th>Maks uttak</th>
<th>Gyldige spill</th>
<th>Gyldighet</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 kr no‑deposit</td>
<td>25x (500 kr)</td>
<td>100 kr</td>
<td>Slots, live casino</td>
<td>7 dager</td>
</tr>
<tr>
<td>30 kr no‑deposit</td>
</tr>
</tbody>
</table>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/big-lucky-casino-no-deposit-bonus-guide-til-app-og-mobil/">Big Lucky Casino no deposit bonus – guide til app og mobil</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Big Lucky Casino app – registreringstrinn for norske spillere</title>
<link>https://edusehat.com/en/big-lucky-casino-app-registreringstrinn-for-norske-spillere</link>
<guid>https://edusehat.com/en/big-lucky-casino-app-registreringstrinn-for-norske-spillere</guid>
<description><![CDATA[ Big Lucky Casino app – den komplette veiledningen for norske spillere Registrering og komme i gang med Big Lucky Casino app Den første steget mot en trygg og 
The post Big Lucky Casino app – registreringstrinn for norske spillere appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/Z14fR2vd9tQ/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 07:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Big, Lucky, Casino, app, –, registreringstrinn, for, norske, spillere</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/Z14fR2vd9tQ/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<article>
<h1>Big Lucky Casino app – den komplette veiledningen for norske spillere</h1>
<section>
<h2>Registrering og komme i gang med Big Lucky Casino app</h2>
<div data-affgun-media="video"></div>
<p>Den første steget mot en trygg og underholdende spillopplevelse er å laste ned og installere Big Lucky Casino app på din smarttelefon eller nettbrett. Registreringsprosessen er designet for å være rask – du fyller inn e‑post, velger et passord og bekrefter kontoen med en kode sendt til innboksen. Når du har logget inn, blir du bedt om å oppgi grunnleggende informasjon som navn, fødselsdato og adresse for å oppfylle KYC‑kravene i Norge. Husk at du kan bruke både norske kort og lokale bankoverføringer som betalingsalternativer, noe som gjør innskudd enkelt og raskt. Etter at kontoen er verifisert, er du klar til å utforske appens spillbibliotek og benytte deg av velkomstbonusen.</p>
<p>For de som ønsker å hoppe rett inn i handlingen, kan du laste ned appen via denne lenken: <a href="https://bigluckycasino-norway.com/app">https://bigluckycasino-norway.com/app</a>. Når du har installert, åpner du appen og følger de tydelige instruksjonene på skjermen – det er lite som kan gå galt. Skulle du støte på problemer under registreringen, finnes det en detaljert FAQ i appen og et chat‑vindu som er åpent døgnet rundt. Det viktigste er at du setter deg inn i vilkårene for bonus og innskudd før du begynner å spille, slik at du unngår overraskelser senere. Så ta deg tid til å fullføre prosessen nøye, og du vil snart være klar for både slots og live casino.</p>
</section>
<section>
<h2>Bonus og velkomsttilbud – hva du får og hvordan du bruker dem</h2>
<p>Big Lucky Casino app kaster deg rett i en verden av generøse bonuser. Som ny spiller får du en velkomstpakke som ofte består av en 100 % innskuddsbonus opp til 2 000 kr, pluss noen gratis spinn på utvalgte spilleautomater. For å aktivere bonusen må du først foreta et første innskudd på minimum 200 kr og deretter oppgi bonuskoden som vises i appen. Når bonussaldoen er kreditert, vil du se både bonusbeløpet og antall gratis spinn i kontomenyen.</p>
<p>Viktig å merke seg er <strong>wagering requirements</strong> – vanligvis 30x bonusbeløpet før du kan ta ut gevinstene. Dette betyr at du må satse 60 000 kr i spill før uttak er mulig, men mange av spillene i appen har høy RTP som gjør dette oppnåelig. Bonusvilkårene kan også inneholde restriksjoner på hvilke spill som teller mot omsetningskravet; slots er som regel 100 % med, mens bordspill ofte teller kun 10 %. Sørg for å lese bonusvilkårene nøye i appens vilkår‑ og betingelser‑seksjon før du spiller videre.</p>
</section>
<section>
<h2>Betalingsmetoder og uttaksprosessen i appen</h2>
<p>Big Lucky Casino app støtter en rekke populære norske betalingsalternativer. Du kan sette inn penger med Visa, MasterCard, BankAxept, Trustly eller e‑wallets som Skrill og Neteller. Minsteinnskuddet er vanligvis 100 kr, og de fleste innskudd blir behandlet umiddelbart, slik at du kan begynne å spille med ett trykk.</p>
<p>Uttak er like enkelt, men krever at du har fullført KYC‑verifiseringen med dokumentasjon som legitimasjon og adressebevis. Når du har valgt ønsket uttaksmetode, blir de fleste forespørsler behandlet innen 24 timer – kredittkort og e‑wallets er spesielt raske. Nedbetalinger til bankkonto kan ta 2–3 virkedager, avhengig av din bank. Se tabellen nedenfor for en oversikt over de vanligste betalingsmetodene og behandlingstidene.</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Metode</th>
<th>Minsteinnskudd</th>
<th>Behandlingstid (innskudd)</th>
<th>Behandlingstid (uttak)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visa / MasterCard</td>
<td>100 kr</td>
<td>Øyeblikkelig</td>
<td>1‑2 dager</td>
</tr>
<tr>
<td>BankAxept</td>
<td>200 kr</td>
<td>Øyeblikkelig</td>
<td>2‑3 dager</td>
</tr>
<tr>
<td>Skrill</td>
<td>100 kr</td>
<td>30 sekunder</td>
<td>1 dag</td>
</tr>
<tr>
<td>Neteller</td>
<td>100 kr</td>
<td>30 sekunder</td>
<td>1 dag</td>
</tr>
<tr>
<td>Trustly</td>
<td>200 kr</td>
<td>Øyeblikkelig</td>
<td>1‑2 dager</td>
</tr>
</tbody>
</table>
</section>
<section>
<h2>Spillutvalg: spilleautomater, live casino og sportsbetting i appen</h2>
<p>Appens spillbibliotek er omfattende og dekker både klassiske og moderne spilleautomater. Her finner du høy‑RTP‑spill som <em>Starburst</em> og <em>Gonzo’s Quest</em>, samt høy‑volatilitet slots som <em>Book of Dead</em> for de som liker adrenalinfylte runder. Hver slot har tydelige informasjon om RTP, volatilitet og maksimal gevinst, noe som gjør det lett å velge riktig spill.</p>
<p>I tillegg til slots, tilbyr Big Lucky Casino app et levende live casino med ekte dealer‑bord som blackjack, roulette og baccarat. Streaming er i HD‑kvalitet og du kan bytte mellom bordene med et enkelt trykk. For sportsfans finnes det også en integrert sportsbook‑modul hvor du kan satse på fotball, håndball og vinteridrett – alt fra norsk Eliteserien til internasjonale turneringer.</p>
</section>
<section>
<h2>Sikkerhet, lisens og ansvarlig spill på Big Lucky Casino</h2>
<p>Big Lucky Casino app opererer under en gyldig Malta Gaming Authority‑lisens, som gir en høy standard for rettferdighet og spillerbeskyttelse. All kommunikasjon mellom din enhet og serverne er kryptert med 128‑bits SSL‑teknologi, slik at personlige data og finansielle transaksjoner er sikre.</p>
<p>Ansvarlig spill er integrert i appen med verktøy som innskuddsgrenser, tap‑grense og muligheten til å sette seg selv på selvutelukkelse. Du kan også finne lenker til nasjonale spillemyndigheter og rådgivningstjenester direkte i innstillingsmenyen. Disse tiltakene gir deg kontroll over spillvanene dine, uten at det går på bekostning av underholdningen.</p>
</section>
<section>
<h2>Kundeservice og support – hvordan få hjelp når du spiller</h2>
<p>Supportteamet i Big Lucky Casino app er tilgjengelig via live‑chat, e‑post og telefon døgnet rundt. Når du åpner chat‑vinduet, vil du umiddelbart bli matchet med en norsk‑snakkende rådgiver som kan veilede deg gjennom alt fra innskuddsspørsmål til bonusvilkår. E‑post‑support svarer vanligvis innen 24 timer, og du kan forvente en høflig og grundig tilbakemelding.</p>
<p>Det finnes også en omfattende kunnskapsbase med artikler om registrering, verifisering, spillregler og tekniske problemer. Hvis du har spørsmål om sikkerhet eller ansvarlig spill, er supportpersonalets kompetanse nøye trent for å gi klare svar. Å ha flere kontaktalternativer gjør at du raskt kan løse eventuelle utfordringer uten å avbryte spillopplevelsen.</p>
</section>
<section>
<h2>Mobilopplevelse: Appens funksjoner og ytelse på norske enheter</h2>
<p>Big Lucky Casino app er optimalisert for både iOS‑ og Android‑plattformer, med en responsiv design som tilpasser seg skjermstørrelsen på din telefon eller nettbrett. Lastetiden er kort, og du kan navigere mellom spillkategorier med kun ett trykk. Appen støtter push‑varsler, slik at du får umiddelbare oppdateringer om kampanjer, innskuddsbonuser og turneringer.</p>
<p>Ytelsen i spill er jevn, med minimal latency selv på slot‑spill med avanserte animasjoner. Live casino‑streamene lastes raskt og justerer automatisk kvaliteten etter din nettverkshastighet. Du kan også sette opp favorittspill i en personlig spilleliste for rask tilgang, noe som gjør appen både brukervennlig og effektiv for spillere på farten.</p>
</section>
<section>
<h2>Vanlige spørsmål og feilsøking</h2>
<h3>Jeg får ikke til å verifisere kontoen min – hva gjør jeg?</h3>
<p>Kontroller at dokumentene du laster opp er tydelige og i støttet format (PDF, JPG eller PNG). Pass på at alle fire kantene av ID‑kortet er synlige, og at navnet på dokumentet matcher nøyaktig det du har oppgitt i profilen. Hvis du fortsatt opplever problemer, kan du kontakte support via live‑chat for rask assistanse.</p>
<h3>Hvor raskt kan jeg trekke ut gevinster fra bonusen?</h3>
<p>Etter at du har oppfylt wagering‑kravene på 30x bonusbeløpet, kan du sende inn en uttaksforespørsel. Innen 24 timer vil supportteamet verifisere uttaket, og pengene vil vanligvis være på kontoen din innen 1‑2 virkedager, avhengig av hvilken betalingsmetode du har valgt.</p>
<h3>Er det noen ekstra kostnader ved innskudd eller uttak?</h3>
<p>Big Lucky Casino app tar ingen gebyrer for innskudd med de fleste betalingsmetodene. Noen e‑wallet-tjenester kan ha egne transaksjonskostnader, men dette blir tydelig oppgitt før du bekrefter innskuddet. Uttak er også gratis for de fleste metoder, med unntak av noen bankoverføringer der din egen bank eventuelt kan belaste et mindre gebyr.</p>
</section>
</article>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/big-lucky-casino-app-registreringstrinn-for-norske-spillere/">Big Lucky Casino app – registreringstrinn for norske spillere</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Verde Casino download – komplett bonusguide og nedlastingsguide for norske spillere</title>
<link>https://edusehat.com/en/verde-casino-download-komplett-bonusguide-og-nedlastingsguide-for-norske-spillere</link>
<guid>https://edusehat.com/en/verde-casino-download-komplett-bonusguide-og-nedlastingsguide-for-norske-spillere</guid>
<description><![CDATA[ Verde Casino – Praktisk guide til Verde Casino download Hvorfor velge Verde Casino? Verde Casino har raskt blitt et av de mest populære nettcasinoene blant norske spillere. Med 
The post Verde Casino download – komplett bonusguide og nedlastingsguide for norske spillere appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/V3hZ93cVdCc/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 07:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Verde, Casino, download, –, komplett, bonusguide, nedlastingsguide, for, norske, spillere</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/V3hZ93cVdCc/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<header>
<h1>Verde Casino – Praktisk guide til Verde Casino download</h1>
</header>
<section>
<h2>Hvorfor velge Verde Casino?</h2>
<div data-affgun-media="video"></div>
<p>Verde Casino har raskt blitt et av de mest populære nettcasinoene blant norske spillere. Med en lisens fra Malta Gaming Authority kan du stole på rettferdig spill og høy sikkerhet. Utvalget spenner fra klassiske spilleautomater til et omfattende live casino og sports betting‑seksjon, så det finnes noe for både nybegynnere og erfarne high rollers. Plattformen er også optimalisert for mobilbruk, noe som gjør at du kan spille både på PC og på smarttelefonen uten forsinkelse.</p>
<p>Et annet stort trekkplaster er de generøse velkomstbonusene, men også løpende kampanjer som gir ekstra kreditter eller gratis spinn. Når du først har gjort en innsats, vil du oppdage at uttakshastigheten er imponerende – ofte innen 24 timer for vanlige betalingsmetoder. Alt i alt gir Verde Casino en komplett spillopplevelse som er både brukervennlig og pålitelig.</p>
</section>
<section>
<h2>Slik laster du ned Verde Casino-appen – steg for steg</h2>
<p>Først og fremst må du besøke den offisielle nedlastingssiden for Verde Casino. På siden finner du en tydelig knapp merket “Last ned appen”. Når du klikker på den, starter nedlastingen automatisk for Android‑ eller iOS‑enheter, avhengig av hvilken plattform du bruker.</p>
<p>Etter at filen er lastet ned, åpner du installasjonsfilen og følger instruksjonene på skjermen. På Android må du kanskje tillate installasjon fra “ukjente kilder”, mens iOS‑brukere vil bli omdirigert til App Store for en sikker installasjon. Når appen er installert, åpner du den, godtar vilkårene og logger inn med din konto. For første gang kan du også dra nytte av et eksklusivt mobilbonus‑tilbud.</p>
<p>Hvis du foretrekker å spille i nettleseren i stedet for appen, er det også mulig å bruke Verde Casino direkte på www.verdecassino-no.com – men for den beste ytelsen anbefaler vi nedlastingen. Last ned appen her: <a href="https://verdecassino-no.com/app">https://verdecassino-no.com/app</a>.</p>
</section>
<section>
<h2>Registrering og verifisering – steg for steg</h2>
<p>Registreringsprosessen hos Verde Casino er enkel og tar kun noen minutter. Klikk på “Registrer” øverst på siden, fyll inn e‑postadresse, ønsket brukernavn og et sterkt passord. Du vil deretter bli bedt om å velge valuta – NOK er tilgjengelig, noe som gjør innskudd og uttak enklere for norske spillere.</p>
<p>Etter at kontoen er opprettet, må du gjennomføre KYC‑verifisering. Dette innebærer at du laster opp en kopi av gyldig ID (for eksempel pass eller førerkort) samt et bevis på adresse, som en strømregning eller kontoutskrift. Verifiseringen er vanligvis fullført innen én virkedag, og du kan da begynne å sette inn penger og benytte deg av bonuser.</p>
<p>Det kan også være lurt å sette opp to‑faktor‑autentisering (2FA) i kontoinnstillingene for ekstra sikkerhet. Verde Casino tilbyr dette som en gratis funksjon, og det gjør at du får et ekstra lag av beskyttelse mot uautorisert tilgang.</p>
</section>
<section>
<h2>Bonuser og vilkår – hva du får ved første innskudd</h2>
<p>Nyankomne spillere blir møtt med en velkomstpakke som vanligvis består av 100% matchbonus på første innskudd, opptil 2 000 NOK, pluss 100 gratis spinn på utvalgte spilleautomater. Bonusen er underlagt en rimelig omsetningskrav på 30x bonusbeløpet, noe som er standard i bransjen.</p>
<p>Etter den første innskuddsbonusen kan du også benytte deg av ukentlige kampanjer, som “Cashback Tuesday” eller “Free Spin Friday”. Disse kampanjene gir ekstra penger eller spinn uten ekstra innskudd, men husk alltid å lese de små skriftene – noen bonuser gjelder kun på bestemte spill eller har tidsbegrensninger.</p>
<p>For å aktivere en bonus, går du inn i kampanje‑menyen etter innskuddet og klikker på “Claim”. Bonusen vil da bli kreditert umiddelbart, og du kan begynne å spille med en gang.</p>
</section>
<section>
<h2>Betalingsmetoder og uttakshastighet</h2>
<p>Verde Casino støtter en rekke populære innskuddsmetoder for norske spillere. Du kan bruke Visa, Mastercard, Skrill, Neteller, og direkte bankoverføring via Trustly. Minimum innskudd er 100 NOK, og de fleste metoder behandler transaksjoner i løpet av noen sekunder.</p>
<p>Uttak er like enkelt: gå til kassen, velg “Uttak”, og angi beløpet du ønsker å ta ut. Minimum uttak er 200 NOK. De vanligste uttaksmetodene (Skrill, Neteller, Trustly) har en typisk behandlingstid på 1–2 virkedager, mens bankoverføring kan ta opptil 3 dager. Alle uttak blir grundig sjekket for å sikre at kontoen er verifisert før midlene blir overført.</p>
<table>
<thead>
<tr>
<th>Metode</th>
<th>Minimum innskudd</th>
<th>Uttakstid</th>
<th>Avgift</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visa / Mastercard</td>
<td>100 NOK</td>
<td>1–2 dager</td>
<td>Ingen</td>
</tr>
<tr>
<td>Skrill</td>
<td>100 NOK</td>
<td>1 dag</td>
<td>Ingen</td>
</tr>
<tr>
<td>Neteller</td>
<td>100 NOK</td>
<td>1 dag</td>
<td>Ingen</td>
</tr>
<tr>
<td>Trustly (bank)</td>
<td>100 NOK</td>
<td>1–2 dager</td>
<td>Ingen</td>
</tr>
</tbody>
</table>
</section>
<section>
<h2>Live casino og sports betting – spillopplevelsen</h2>
<p>Live casino‑delen i Verde Casino tilbyr ekte dealere som strømmer spill i HD‑kvalitet. Du kan velge mellom klassikere som Blackjack, Roulette og Baccarat, samt spesialspill som Dream Catcher. All interaksjon skjer i sanntid, og du kan chatte med dealeren for en mer personlig opplevelse.</p>
<p>Sports betting‑plattformen dekker alt fra fotball og håndball til tennis og e‑sports. Oddsene oppdateres i sanntid, og du kan plassere både enkeltspill og kombinasjonsspill. For nybegynnere finnes det også en “Bet Builder” som hjelper deg å sette sammen spill basert på lagstatistikk og formkurver.</p>
<p>Begge seksjonene er tilgjengelige via mobilappen, så du kan satse eller spille mens du er på farten. Live‑streaming er optimalisert for både Wi‑Fi og mobildata, slik at du unngår buffering og kan fokusere på spillet.</p>
</section>
<section>
<h2>Sikkerhet, lisens og ansvarlig spill</h2>
<p>Verde Casino er lisensiert av Malta Gaming Authority, en av de mest anerkjente reguleringsmyndighetene i EU. Dette betyr at casinoet må følge strenge retningslinjer for spillersikkerhet, rettferdighet og beskyttelse av personopplysninger. Alle transaksjoner krypteres med 128‑bit SSL‑teknologi, som er samme standard som brukes av store banker.</p>
<p>Ansvarlig spill er en viktig del av Verde Casinos politikk. På siden finner du verktøy for å sette innskuddsgrenser, tapsgrenser og tidsbegrensninger. Dersom du føler at spillingen blir et problem, kan du kontakte kundeservice for å sette en selvutelukkelsesperiode, eller du kan benytte deg av nasjonale hjelpelinjer som Hjelpelinjen for spillavhengige.</p>
<p>Kundeservice er tilgjengelig 24/7 via live‑chat, e‑post og telefon. Support‑teamet snakker både norsk og engelsk, og de er trente i å håndtere både tekniske og ansvarlig‑spill‑spørsmål.</p>
</section>
<section>
<h2>Ofte stilte spørsmål om Verde Casino download</h2>
<ul>
<li><strong>Kan jeg bruke Verde Casino uten å laste ned appen?</strong> Ja, du kan spille direkte i nettleseren, men appen gir raskere lasting og push‑varsler om kampanjer.</li>
<li><strong>Er Verde Casino tilgjengelig på både Android og iOS?</strong> Ja, begge operativsystemene støttes fullt ut, og oppdateringer skjer automatisk.</li>
<li><strong>Hvor lang tid tar det å verifisere kontoen?</strong> Vanligvis innen én virkedag, men kan ta lengre tid ved høyt volum av dokumenter.</li>
<li><strong>Finnes det norske kundeservicemedarbeidere?</strong> Ja, både chat og e‑post betjenes av norsktalende agenter.</li>
<li><strong>Hva er minimumsinnsatsen i live casino?</strong> De fleste bordspill starter fra 10 NOK per hånd.</li>
</ul>
</section>
<footer></footer>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/verde-casino-download-komplett-bonusguide-og-nedlastingsguide-for-norske-spillere/">Verde Casino download – komplett bonusguide og nedlastingsguide for norske spillere</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>biglucky casino review – komplett guide for norske spillere</title>
<link>https://edusehat.com/en/biglucky-casino-review-komplett-guide-for-norske-spillere</link>
<guid>https://edusehat.com/en/biglucky-casino-review-komplett-guide-for-norske-spillere</guid>
<description><![CDATA[ Big Lucky Casino – en grundig biglucky casino review Her får du en praktisk veiledning om alt du trenger å vite før du setter deg ved Big Lucky 
The post biglucky casino review – komplett guide for norske spillere appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/BvhxGf05pg4/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 07:00:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>biglucky, casino, review, –, komplett, guide, for, norske, spillere</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/BvhxGf05pg4/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Big Lucky Casino – en grundig biglucky casino review</h1>
<p>Her får du en praktisk veiledning om alt du trenger å vite før du setter deg ved Big Lucky Casino. Artiklen er laget for norske spillere som vil vurdere om dette casinoet er rett for dem, med fokus på bonuser, betalingsmetoder, spillutvalg, mobilopplevelse og sikkerhet.</p>
<h2>Registrering og første steg</h2>
<div data-affgun-media="video"></div>
<p>For å komme i gang med Big Lucky Casino, starter du med en rask registreringsprosedyre. Du fyller inn e‑post, løsenord og noen personlige opplysninger. Systemet validerer e‑posten umiddelbart, så du kan logge inn på minutter.</p>
<p>Etter innlogging blir du bedt om å gjennomføre KYC‑verifisering. Dette innebærer opplasting av legitimasjon og bevis på adresse – standard prosedyre for lisensierte nettcasinoer. Verifiseringen tar vanligvis 24–48 timer, men du kan ofte spille med begrensede innskudd før den er fullført.</p>
<h2>Bonus og kampanjer</h2>
<p>Big Lucky Casino lokker nye spillere med en solid velkomstbonus. Første innskudd gir 100 % bonus opptil 1 000 kr, pluss 200 gratis spinn på utvalgte spilleautomater. Bonussjansen er attraktiv, men husk alltid å sjekke omsetningskravene.</p>
<p>Omsetningskravene er på 35× bonusbeløpet, noe som er i snitt for norske nettkasinoer. Bonusen er tilgjengelig kun på spill med RTP over 96 % og medium til høy volatilitet. Merk også at gratis spinn har en egen omsetningskrav på 30× gevinst.</p>
<ul>
<li>Velkomstbonus: 100 % opptil 1 000 kr + 200 spinn</li>
<li>Omsetningskrav: 35× bonus, 30× spinn</li>
<li>Gyldig for spill med RTP ≥ 96 %</li>
<li>Bonusperiode: 7 dager fra innskudd</li>
</ul>
<h2>Spillutvalg – automater, live casino og sportsbetting</h2>
<p>Casinoet har et bredt spekter av spill fra ledende leverandører som NetEnt, Microgaming og Evolution Gaming. Du finner alt fra klassiske enarmede banditter til moderne Video‑Slots med progressive jackpot.</p>
<p>Live casino‑delen inkluderer ekte dealere for blackjack, roulette og baccarat, noe som gir en autentisk casinofølelse. Sportsbetting‑modulen er også integrert, med odds på fotball, håndball og andre populære sportsgrener i Norge.</p>
<table border="1" cellpadding="5" cellspacing="0">
<caption>Et utvalg av spill og nøkkeltall</caption>
<tbody>
<tr>
<th>Spilltype</th>
<th>Leverandør</th>
<th>RTP</th>
<th>Volatilitet</th>
</tr>
<tr>
<td>Starburst</td>
<td>NetEnt</td>
<td>96,1 %</td>
<td>Lav</td>
</tr>
<tr>
<td>Immortal Romance</td>
<td>Microgaming</td>
<td>96,6 %</td>
<td>Medium</td>
</tr>
<tr>
<td>Live Blackjack</td>
<td>Evolution Gaming</td>
<td>99,5 %</td>
<td>Lav</td>
</tr>
<tr>
<td>Football Betting</td>
<td>BetConstruct</td>
<td>Varierer</td>
<td>Varierer</td>
</tr>
</tbody>
</table>
<h2>Betalingsmetoder og uttak</h2>
<p>Big Lucky Casino støtter flere populære betalingsalternativer for norske spillere. Du kan bruke vanlige bankkort som Visa og Mastercard, samt e‑betalingsløsninger som Neteller, Skrill og Trustly.</p>
<p>Uttak behandles vanligvis innen 24 timer for e‑wallets, mens bankkort kan ta 3–5 arbeidsdager. Alle transaksjoner er kryptert med 128‑bit SSL, så du kan føle deg trygg på at pengene dine er sikre.</p>
<table border="1" cellpadding="5" cellspacing="0">
<caption>Betalingsmetoder og behandlingstid</caption>
<tbody>
<tr>
<th>Metode</th>
<th>Innskudd</th>
<th>Uttak</th>
<th>Behandlingstid</th>
</tr>
<tr>
<td>Visa / Mastercard</td>
<td>Umiddelbart</td>
<td>Ja</td>
<td>3–5 dager</td>
</tr>
<tr>
<td>Trustly</td>
<td>Umiddelbart</td>
<td>Ja</td>
<td>Innen 24 timer</td>
</tr>
<tr>
<td>Neteller</td>
<td>Umiddelbart</td>
<td>Ja</td>
<td>Innen 24 timer</td>
</tr>
<tr>
<td>Skrill</td>
<td>Umiddelbart</td>
<td>Ja</td>
<td>Innen 24 timer</td>
</tr>
</tbody>
</table>
<ul>
<li>Minste innskudd: 100 kr</li>
<li>Maks uttak per transaksjon: 20 000 kr</li>
<li>Gebyrer: Ingen på de fleste metoder</li>
</ul>
<h2>Mobilopplevelse og app</h2>
<p>Casinoet er optimalisert for både Android og iOS, og du kan spille direkte i nettleseren uten nedlasting. For de som foretrekker en dedikert app, har Big Lucky en mobilapp med samme funksjonalitet som desktop‑versjonen.</p>
<p>Appen gir rask tilgang til bonuser, live casino og sportsbetting, samt push‑varsler om nye kampanjer. Last ned mobilappen her: <a href="https://big-lucky-casinos.com/app">https://big-lucky-casinos.com/app</a>. Appen er bygget med samme sikkerhetsstandarder som nettsiden.</p>
<h2>Kundeservice og sikkerhet</h2>
<p>Kundeservice er tilgjengelig 24/7 via live‑chat og e‑post. Supportteamet svarer vanligvis innen noen minutter på chat, og innen én time på e‑post. De kan hjelpe med alt fra konto‑spørsmål til betalingsproblemer.</p>
<p>Sikkerheten er ivaretatt gjennom en lisens fra Malta Gaming Authority (MGA), som garanterer rettferdig spill og beskyttelse av personopplysninger. Casinoet bruker også regelmessige tredjepartsrevisjoner for å verifisere spillintegriteten.</p>
<ul>
<li>Live‑chat: 24/7</li>
<li>E‑post: support@bigluckycasino.com</li>
<li>Lisens: MGA (Malta Gaming Authority)</li>
<li>Sikkerhet: SSL‑kryptering, regelmessige revisjoner</li>
</ul>
<h2>Ansvarlig spilling og lisens</h2>
<p>Big</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/biglucky-casino-review-komplett-guide-for-norske-spillere/">biglucky casino review – komplett guide for norske spillere</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>What physicians can do to improve vaccine confidence today</title>
<link>https://edusehat.com/en/what-physicians-can-do-to-improve-vaccine-confidence-today</link>
<guid>https://edusehat.com/en/what-physicians-can-do-to-improve-vaccine-confidence-today</guid>
<description><![CDATA[ Stephen Parodi, MD, shares strategies to build trust and cut through confusion about vaccines
The post What physicians can do to improve vaccine confidence today appeared first on Permanente Medicine. ]]></description>
<enclosure url="https://permanente.org/wp-content/uploads/2026/10/parodi-pw-vaccines-feature-v6.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 06:55:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>What, physicians, can, improve, vaccine, confidence, today</media:keywords>
<content:encoded><![CDATA[<p>From new vaccines and shifting guidelines to the resurgence of measles, a changing immunization landscape is fueling patient uncertainty. How to build and maintain patients’ trust and communicate new vaccination information clearly have become critical tools of the trade for physicians today.</p>
<p>Nationally, more than <a href="https://www.cdc.gov/measles/data-research/index.html" target="_blank" rel="noopener">4,400 cases</a> of measles have been reported with more than <a href="https://www.pa.gov/agencies/health/diseases-conditions/infectious-disease/measles" target="_blank" rel="noopener">1,300 of the cases</a> reported in Pennsylvania alone.</p>
<p><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12115658/" target="_blank" rel="noopener">Research</a> has shown trust in health systems, physicians and public health information are strong drivers of vaccine acceptance while confusion, conflicting messages, and misinformation drive hesitancy.</p>
<p>Lessons from recent years show physicians can do more to tackle the confusion and mistrust behind vaccine hesitancy. Writing in <em>Physician’s Weekly</em>, <a href="https://permanente.org/stephen-parodi-md/" target="_blank" rel="noopener">Stephen Parodi, MD</a>, an infectious disease physician and executive vice president at The Permanente Federation, outlined ways to help patients make informed decisions about flu, COVID-19, and RSV vaccines.</p>
<p>The following is an abridged version of the Physician’s Weekly article (link to full article at the end):</p>
<p><strong>Simplifying messaging around vaccines and preventable diseases</strong></p>
<p>The growing number of vaccine recommendations for influenza, COVID-19, and RSV can create confusion and contribute to vaccine information fatigue, making it harder for patients to stay up to date. Coadministering recommended vaccines during the same visit and using automated reminders from primary care teams can simplify the process, reduce missed vaccinations, and help prevent avoidable hospitalizations and deaths.</p>
<p><span data-ccp-props='{"201341983":0,"335559739":0,"335559740":240}'><div class="vcex-module vcex-divider vcex-divider-solid vcex-divider-center wpex-mx-auto wpex-max-w-100 wpex-block wpex-h-0 wpex-border-b wpex-border-solid wpex-border-main"></div></span></p>
<p><strong>Related story:</strong> <a href="https://permanente.org/restoring-trust-in-medicine-one-conversation-at-a-time/" target="_blank" rel="noopener">Restoring trust in medicine, one conversation at a time</a></p>
<p><span data-ccp-props='{"201341983":0,"335559739":0,"335559740":240}'><div class="vcex-module vcex-divider vcex-divider-solid vcex-divider-center wpex-mx-auto wpex-max-w-100 wpex-block wpex-h-0 wpex-border-b wpex-border-solid wpex-border-main"></div></span></p>
<p><strong>Helping patients navigate new vaccines</strong></p>
<p>A physician’s recommendation remains one of the most influential factors in a patient’s decision to get vaccinated. That means there’s still opportunity for physicians to share evidence-based explanations on vaccines and why they matter, especially as new technologies, like the newly approved influenza mRNA vaccine, are developed and scaled up.</p>
<p>Physicians should invite questions about medical advancements from patients while providing the tools and evidence to evaluate vaccine options.</p>
<p><strong>Reinforcing the value of vaccines</strong></p>
<p>The modern-day resurgence of measles, a disease declared eliminated in 2000, is a potent example of the value of vaccines and also the danger of falling vaccination rates.</p>
<p>Physicians play a key role in helping families stay protected by reviewing vaccination status, answering parents’ questions, and reinforcing the value of the MMR vaccine. Beyond preventing measles, mumps, and rubella, the vaccine helps preserve a child’s immune defenses, as measles infection can weaken immune memory and increase vulnerability to other illnesses.</p>
<p>To read the entire <em>Physician’s Weekly</em> article, <a href="https://www.physiciansweekly.com/post/five-ways-physicians-can-cut-through-vaccine-confusion" target="_blank" rel="noopener">click here</a>.</p>
<p>The post <a href="https://permanente.org/what-physicians-can-do-to-improve-vaccine-confidence-today/">What physicians can do to improve vaccine confidence today</a> appeared first on <a href="https://permanente.org/">Permanente Medicine</a>.</p>]]> </content:encoded>
</item>

<item>
<title>IP: American as apple pie and essential for biotech</title>
<link>https://edusehat.com/en/ip-american-as-apple-pie-and-essential-for-biotech</link>
<guid>https://edusehat.com/en/ip-american-as-apple-pie-and-essential-for-biotech</guid>
<description><![CDATA[ The United States leads the world in biotech innovation, and a major driver is its strong intellectual property (IP) system. In fact, IP rights […]
The post IP: American as apple pie and essential for biotech appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/smithsonian-8OIVMGwvS7E-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 03:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>IP:, American, apple, pie, and, essential, for, biotech</media:keywords>
<content:encoded><![CDATA[<p><span>The United States leads the world in biotech innovation, and a major driver is its strong intellectual property (IP) system.</span></p>
<p><span>In fact, IP rights are as American as apple pie. President George Washington not only talked about the importance of intellectual property protection in his first State of the Union address, but American IP rights were codified in the Patent Act in April of 1790—only 14 years into the country’s founding.</span></p>
<p><span>“That’s because the Founders, in creating our country and looking at the model of what was working and not working in England, saw that economic protection for scientific discoveries and innovations was critical to grow, support and nurture the economic success of a new country,” said Coke Morgan Stewart, the President and CEO of the Council for Innovation Promotion (C4IP), and former Deputy Undersecretary of Commerce for Intellectual Property and Deputy Director of the U.S. Patent and Trademark Office (USPTO) during</span><a href="https://ipprotectionmatters.org/episodes/30d15670-12ac-4c15-8f37-3e9b03f3ff26:ip-protections-for-scientific-discoveries-and-innovations-critical-for-americas-economic-success/"> <span>a conversation she had with the Center For Individual Freedom</span></a><span>.</span></p>
<p><span>For</span><a href="https://www.usipalliance.org/october-ip-month"> <span>IP Awareness Month this October</span></a><span>, Bio.News looks at how IP has helped facilitate decades of innovation in biotech, helping patients lead better, healthier, and long lives. </span></p>
<h3>The circle of biotech innovation</h3>
<p><span>It all starts with the spark of an idea. </span></p>
<p><span>A scientist in a lab makes a discovery and recognizes its potential to fill an unmet medical need: a treatment, therapy, or even a cure. So the scientist’s institution or company files a patent on their discovery. But why?</span></p>
<p><span>The biotech industry is one of the most research-intensive industries operating today, requiring often over a decade of work and billions of dollars to get a drug, treatment, or cure to market. </span></p>
<p><span>And IP protections, in many ways, act as the armor around an idea or invention, allow for:</span></p>
<ul>
<li aria-level="1"><span>The incentivization of innovation, allowing inventors to recover their research and development costs and profit from their hard work;</span></li>
<li aria-level="1"><span>Prevention of counterfeiting, which doesn’t just prevent theft of an idea, but also the ability to profit from its introduction to the market, allowing inventors to keep developing new ideas; and</span></li>
<li aria-level="1"><span>Attraction of investment, building economic value for both individual companies, as well as the economy as a whole.</span></li>
</ul>
<p><span>Any biotech, big, small, or in between, needs IP protections to keep the circle of innovation turning, but when it comes to small biotechs, the stakes are much higher, making these protections even more imperative—and protecting them is good for patients too.</span></p>
<p><a href="https://bio.news/bio-convention/ahead-of-bio-ip-conference-research-highlights-why-biotech-needs-strong-patents/"><span>As Bio.News reported</span></a><span>: “By most estimates, small and medium-sized biotech firms are behind the majority of new drugs. One study shows 55% of drugs gaining Food and Drug Administration (FDA) approval between 2011-2022 were developed by companies with less than $500 million in revenue.”</span></p>
<p><span>“There’s a lot of people who believe that patents stifle competition,” said panelist Dede Willis, CEO of Orbit Geonomics</span><a href="https://bio.news/bio-convention/bio-2026-biotech-threatened-by-pressures-on-patent-protection/"> <span>during the 2026 International BIO Convention</span></a><span>. “I would actually argue the opposite, for life sciences in particular, especially biotech, where the timelines to get to market and the cost to develop a product are extremely high. The patents are actually increasing competition because they’re enabling new technologies to be funded and commercialized.”</span></p>
<h3>Completing the cycle</h3>
<p><span>Let’s look at the end of a development cycle: the R&D was successful, the clinical trials are complete, and the FDA is on board. The drug is going to market and the investors are making a return on their investment. What do they do? Say </span><i><span>Thanks, that was fun, but I am moving on</span></i><span>. Well, as it would turn out, not really.</span></p>
<p><a href="https://www.bio.org/toolkit/intellectual-property/circle-biotech-innovation"><span>As BIO has found</span></a><span>, “Revenue from product sales helps fund future research. U.S. biopharma firms reinvest about 34% of their revenue into R&D, more than almost every other industry.”</span></p>
<p><span>And the numbers behind that 34% are huge. As the study, “</span><a href="https://www.nature.com/articles/d41573-024-00131-2"><span>Comprehensive measurement of biopharmaceutical R&D investment</span></a><span>” found, “global biopharmaceutical R&D investment totaled $276 billion across 4,191 global companies in 2021.”</span></p>
<p><span>And these numbers have been holding steady and even gaining momentum.</span></p>
<p><a href="https://bio.news/bio-convention/big-summit-experts-see-signs-of-ma-momentum-in-2026/"><span>As Bio.News reported in February</span></a><span>: “both licensing and M&A in biopharma, saw over 4,000 deals and more than $600 billion in headline value—and 2026 seems to be keeping up this momentum.”</span></p>
<p><span>Continuing, “there were a total of 4,341 deals in 2025, compared to 3,883 in 2024, and the $606 billion in total deal value was higher than the $421 billion in 2024. The $291 billion in upfront cash and equity of 2025 was an improvement over the $191 billion in 2024. Notably, large cap biopharmas signed fewer, higher-value deals, with 255 in 2025, compared to 294 in 2024.”</span></p>
<p><span>And thus the cycle continues, and even powers itself.</span></p>
<p><span>As a last example, a</span><a href="https://www.uschamber.com/assets/documents/GIPC_IPIndex2026_Annex_v3.pdf"> <span>2026 study</span></a><span> published by the U.S. Chamber of Commerce Global Innovation Policy Center found that the U.S.’s strong IP safeguards not only make it more competitive today, but also ensure competitiveness for the future.</span></p>
<p><span>“Economies with robust IP environments are 97% more likely to be prepared for the future of growth,” the study observed. Continuing, “economies with strong IP systems are 59% more likely to be able to transform their economies using sophisticated, state-of-the-art technologies compared with economies whose IP systems require improvement.”</span></p>
<p><span>And so, IP proves itself time and time again to be a key element of innovation, progress, and competitiveness.</span></p>
<p>The post <a href="https://bio.news/federal-policy/ip-american-as-apple-pie-and-essential-for-biotech/">IP: American as apple pie and essential for biotech</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BIO supports FDA’s new Fit&#45;for&#45;Purpose Rare Disease Framework Initiative</title>
<link>https://edusehat.com/en/bio-supports-fdas-new-fit-for-purpose-rare-disease-framework-initiative</link>
<guid>https://edusehat.com/en/bio-supports-fdas-new-fit-for-purpose-rare-disease-framework-initiative</guid>
<description><![CDATA[ BIO praised a Food and Drug Administration (FDA) initiative targeting more tailored, patient-centered, and predictable development of rare disease drugs, while recommending ways to […]
The post BIO supports FDA’s new Fit-for-Purpose Rare Disease Framework Initiative appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/wikimedia-david-richfield.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 03:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BIO, supports, FDA’s, new, Fit-for-Purpose, Rare, Disease, Framework, Initiative</media:keywords>
<content:encoded><![CDATA[<p>BIO praised a Food and Drug Administration (FDA) initiative targeting more tailored, patient-centered, and predictable development of rare disease drugs, while recommending ways to make it happen, at an Oct. 28 public meeting.</p>
<p>The<a href="https://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease"> FDA’s Fit-for-Purpose Rare Disease Framework Initiative</a> seeks to accommodate the unique challenges of developing and reviewing drugs for rare diseases.</p>
<p>Compared to other conditions, rare diseases have small patient populations, limited natural history data, and disease heterogeneity, and they pose challenges in generating conventional clinical evidence. Attracting investment for rare disease drug development can be difficult due to the constraints of small patient populations and certain regulatory challenges.</p>
<p>For all these reasons, <a href="https://pubmed.ncbi.nlm.nih.gov/37353796/">95% of rare disease patients still lack an approved treatment,</a> though rare disease impacts over <a href="https://www.fda.gov/patients/rare-diseases-fda">30 million Americans</a>, making efforts to ease drug development both welcome and urgently needed.</p>
<p>“We strongly support FDA’s effort today,” E’Lissa Flores, Senior Director, Science and Regulatory Affairs at the Biotechnology Innovation Organization (BIO), told the public meeting. “BIO sees this Framework as an opportunity to translate fit-for-purpose principles into consistent practice, with greater predictability, early alignment, patient input, and appropriate consideration of uncertainty, while maintaining scientific rigor and FDA standards.”</p>
<p>Led by FDA’s Rare Disease Innovation Hub—in partnership with the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), and the Office of the Commissioner—the <a href="https://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease">initiative was announced</a> Oct. 14, and<a href="https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/fda-rare-disease-framework-initiative-public-meeting-10282026"> the public meeting</a> was called as the first major step in its development.</p>
<p>“BIO’s members appreciate that FDA is seeking input before moving forward and welcome the opportunity to provide feedback through this public meeting and through written comments until Dec. 11,” Flores said.</p>
<h2>FDA’s basic principles for the initiative</h2>
<p><a href="https://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease">FDA said the following principles</a> would be instrumental in developing the Fit-for-Purpose Rare Disease Framework Initiative:</p>
<ul>
<li>“Providing greater clarity, consistency, and predictability in regulatory decision-making through tailored guidance and transparent communication.”</li>
<li>“Embedding the patient’s voice both early, and at clearly defined milestones, in the drug development and review process.”</li>
<li>“Further leveraging external expertise to support customization of regulatory review.”</li>
<li>“Building shared resources, robust training, and institutional knowledge on rare disease drug development and review.”</li>
<li>“Applying risk-based approaches, particularly to chemistry, manufacturing, and controls review and pre-approval inspections.”</li>
<li>“Championing the use of cutting-edge science, novel methods and innovative statistical approaches in rare disease drug development.”</li>
</ul>
<h2>BIO’s initial recommendations</h2>
<p>In her comments at the public meeting, Flores highlighted some emerging themes for consideration when implementing the initiative:</p>
<ul>
<li>“BIO encourages FDA to apply fit-for-purpose evidentiary approaches that maintain scientific rigor while reflecting the realities of rare disease,” Flores said. To do this, FDA should consider all available evidence—such as natural history, biomarker, and real-world evidence—and apply it consistently across all FDA centers and review teams.</li>
<li>The fit-for-purpose principles should extend to the Chemistry, Manufacturing and Controls (CMC) portion of an investigational new drug (IND) application, as this component is also different for rare diseases. “BIO supports risk-based approaches to the timing and generation of CMC evidence that recognize the realities of rare disease development while maintaining appropriate product-quality standards,” Flores said.</li>
<li>The Framework presents an opportunity to move innovation into regulatory practice. FDA should seek to advance methods from pilots and workshops into routine regulatory use and for updating guidance.</li>
<li>Early and ongoing FDA-sponsor alignment is essential, through early conversations about expectations that take place before an IND. “That includes early dialogue around endpoints, evidence-generation strategies, trial design, preclinical and CMC expectations, and acceptable uncertainty,” according to Flores.</li>
<li>“Patient input should be embedded throughout the development lifecycle,” Flores emphasized. This means FDA should clarify when patient input should be provided, how it will be considered, “and how patient engagement, patient experience data, and patient preference information can appropriately inform regulatory decision-making.”</li>
<li>Consistent implementation across review divisions and FDA centers is essential. “The Rare Disease Innovation Hub can help by integrating expertise across the Agency, sharing successful approaches and best practices, and facilitating external expertise to support reviewer education and ensure decisions reflect the latest science,” Flores said.</li>
</ul>
<p>“BIO looks forward to continuing its engagement with the FDA to advance fit-for-purpose regulatory approaches that maintain scientific rigor while supporting the timely development of safe and effective treatments for patients with rare diseases,” Flores concluded. BIO plans to work closely with its members to submit detailed comments and key recommendations to docket in support of FDA’s development and implementation of the Framework.</p>
<p>FDA has issued a Request For Information on the initiative and is accepting written<a href="https://www.federalregister.gov/documents/2026/10/16/2026-21142/fit-for-purpose-rare-disease-framework-initiative-public-meeting-request-for-information-and"> comments through the Federal Register until Dec. 11</a>.</p>
<hr>
<p><em>(Photo by David Richfield, Wikimedia Commons.)</em></p>
<p>The post <a href="https://bio.news/federal-policy/bio-supports-fdas-new-fit-for-purpose-rare-disease-framework-initiative/">BIO supports FDA’s new Fit-for-Purpose Rare Disease Framework Initiative</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CDC report details impact of AMR pathogens</title>
<link>https://edusehat.com/en/cdc-report-details-impact-of-amr-pathogens</link>
<guid>https://edusehat.com/en/cdc-report-details-impact-of-amr-pathogens</guid>
<description><![CDATA[ The most dangerous antimicrobial-resistant (AMR) pathogens in America are causing an estimated 9.7 million infections and 50,800 deaths in the U.S. each year, says […]
The post CDC report details impact of AMR pathogens appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/cdc-iwkcspbMWx8-unsplash-e1793305581228.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 03:45:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CDC, report, details, impact, AMR, pathogens</media:keywords>
<content:encoded><![CDATA[<p><span>The most dangerous antimicrobial-resistant (AMR) pathogens in America are causing an estimated 9.7 million infections and 50,800 deaths in the U.S. each year, says the Centers for Disease Control and Prevention (CDC).</span></p>
<p><span>Released Oct. 27, CDC’s</span><a href="https://arpsp.cdc.gov/artr/antimicrobial-resistance-threats"> <span>latest report</span></a><span> on AMR pathogens identifies 19 bacteria and fungi that pose urgent, serious, or concerning threats to human health.</span></p>
<p><span>“The most comprehensive estimate to date of the impact of drug-resistant pathogens on human health in the United States …</span><a href="https://arpsp.cdc.gov/artr/antimicrobial-resistance-threats"> <span>the AR Threats Report</span></a><span> provides critical data that can help guide policy, investments, and interventions to protect Americans from drug resistance,” according to CDC.</span></p>
<p><span>These dangerous pathogens have mutated to the point where existing antimicrobial drugs are no longer able to contain them. Germs that were once mostly considered threats to hospitalized patients are also causing infections in people who receive care outside of hospitals.</span></p>
<p><span>Combatting these new superbugs requires new antimicrobials, but there are few such drugs in development because the market for antimicrobial innovation is fundamentally broken.</span></p>
<p><span>“This latest report shows more detail on the enormous threat of AMR, which we know has the potential to cause</span><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext"> <span>nearly 170 million deaths worldwide by 2050</span></a><span>,” says Emily Wheeler, Vice President of Infectious Disease Policy at the Biotechnology Innovation Organization (BIO). “We need new antimicrobials for the most critical infections, and the only way to get that is with policy solutions that encourage development and innovation, such as the PASTEUR Act.”</span></p>
<h2>A policy solution for market dysfunction</h2>
<p><span>Unfortunately, the market for developing new antimicrobials is broken.</span></p>
<p><span>The need to use antimicrobials judiciously makes it</span><a href="https://workingtofightamr.org/wp-content/uploads/2026/07/The-Toll-of-the-Broken-Antimicrobial-Market-2026.pdf"> <span>nearly impossible for biotechs</span></a><span> developing these innovative drugs to recoup their investment. In recent years, the FDA has approved a few new antimicrobials from small companies, but today, nearly every company behind those innovations “have either gone into bankruptcy or the economic equivalent. Their R&D investors are completely wiped out,”</span><a href="https://bio.news/biosecurity/pasteur-act-amr-antimicrobial-resistance-barda-carb-x-2023-bio-international-convention/#:~:text=Furthermore%2C%C2%A0when%20we%20develop%20new%20antibiotics%2C%20%E2%80%9Cas%20soon%20as%20we%20start%20using%20them%2C%20the%20bacteria%20respond%2C%E2%80%9D%20said%20Kevin%20Outterson%2C%20Executive%20Director%20of%20CARB-X%2C%20in%20an%20interview%20during%20the%202023%20Biotechnology%20Innovation%20Organization%20(BIO)%20International%20Convention."> <span>Kevin Outterson</span></a><span>, whose organization CARB-X leads a public-private partnership to fund new antimicrobials,</span><a href="https://bio.news/federal-policy/senators-seek-solutions-for-amr-maintaining-us-biotech-leadership/"> <span>told an Aug. 7 Senate hearing</span></a><span>.</span></p>
<p><span>One policy proposal to address the problem is</span><a href="https://www.bennet.senate.gov/2026/06/24/bennet-young-colleagues-reintroduce-bipartisan-pasteur-act-to-fight-antimicrobial-resistance/"> <span>the PASTEUR Act</span></a><span>, which would encourage development of new, innovative antimicrobials for the most critical infections.</span></p>
<p><span>Instead of a model based on volume, PASTEUR would implement a new contracting model that provides predictable support for qualifying new antimicrobials, ensuring health care providers have the tools they need to treat superbugs.</span></p>
<p><span>Government incentives for new AMR treatments would save lives, and money, Outterson said. “This would be a remarkably great value for the U.S. taxpayers,” he maintained. “A Center for Global Development study found a 28-to-1 return.”</span></p>
<p><span>The price of inaction is steep, and not only in lives.</span></p>
<p><span>“Seven bacterial threats included in the report that are commonly associated with health care caused more than 42,000 deaths in 2023 and resulted in nearly $12 billion dollars in healthcare costs,” </span><a href="https://www.cdc.gov/antimicrobial-resistance/programs/AR-investments.html"><span>CDC said</span></a><span>. </span></p>
<p><span>Given AMR’s costs in lives, health, and money, BIO supports the PASTEUR Act. The “legislation would help to repair the broken marketplace for antimicrobials by enabling a business model centered around the appropriate use of new and novel treatments,” said</span><a href="https://buddycarter.house.gov/news/documentsingle.aspx?DocumentID=16321#:~:text=%22The%20introduction%20of,need%20them%20most.%22"><span> BIO President & CEO John F. Crowley, when the bill was reintroduced</span></a><span> in Congress earlier this year.</span></p>
<p><span>BIO has called attention to patient challenges with AMR, including by sharing the story of patient advocate</span><a href="https://fightofourlives.com/stories/katy/"> <span>Katy Grainger in “The Fight of Our Lives.”</span></a><span> BIO also has more</span><a href="https://www.bio.org/policy/human-health/antimicrobial-resistance"> <span>resources on AMR here.</span></a></p>
<h2>CDC’s list of the 19 most-dangerous pathogens</h2>
<p><b>Urgent Threats</b></p>
<p><span>These pathogens are public health threats that require urgent and aggressive action.</span></p>
<ul>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/cauris"><i><span>Candida auris</span></i><span> (</span><i><span>C. auris</span></i><span>)</span></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/acinetobacter"><span>Carbapenem-resistant </span><i><span>Acinetobacter</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/CRE"><span>Carbapenem-resistant Enterobacterales (CRE)</span></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/gonorrhea"><span>Drug-resistant </span><i><span>Neisseria gonorrhoeae</span></i></a></li>
</ul>
<p><b>Serious Threats</b></p>
<p><span>These pathogens are public health threats that require prompt and sustained action.</span></p>
<ul>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/cdiff"><i><span>Clostridioides difficile</span></i><span> (</span><i><span>C. diff</span></i><span>)</span></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/campylobacter"><span>Drug-resistant </span><i><span>Campylobacter</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/candida"><span>Drug-resistant </span><i><span>Candida</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/TB"><span>Drug-resistant </span><i><span>Mycobacterium tuberculosis</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/nmeningitidis"><span>Drug-resistant </span><i><span>Neisseria meningitidis</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/salmonella"><span>Drug-resistant nontyphoidal </span><i><span>Salmonella</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/typhi"><span>Drug-resistant </span><i><span>Salmonella</span></i><span> Typhi</span></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/shigella"><span>Drug-resistant </span><i><span>Shigella</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/spneumoniae"><span>Drug-resistant </span><i><span>Streptococcus pneumoniae</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/ESCRE"><span>Extended-spectrum cephalosporin-resistant Enterobacterales (ESC-RE)</span></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/MRSA"><span>Methicillin-resistant </span><i><span>Staphylococcus aureus</span></i><span> (MRSA)</span></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/paeruginosa"><span>Multidrug-resistant </span><i><span>Pseudomonas aeruginosa</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/VRE"><span>Vancomycin-resistant </span><i><span>Enterococcus</span></i><span> (VRE)</span></a></li>
</ul>
<p><b>Concerning Threats</b></p>
<p><span>These pathogens are public health threats that require careful monitoring and prevention action.</span></p>
<ul>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/GBS"><span>Clindamycin-resistant group B </span><i><span>Streptococcus</span></i><span> (GBS)</span></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/GAS"><span>Drug-resistant group A </span><i><span>Streptococcus</span></i><span> (GAS)</span></a></li>
</ul>
<p>The post <a href="https://bio.news/health/cdc-report-details-impact-of-amr-pathogens/">CDC report details impact of AMR pathogens</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Building the Future of AAV Gene Therapy</title>
<link>https://edusehat.com/en/building-the-future-of-aav-gene-therapy</link>
<guid>https://edusehat.com/en/building-the-future-of-aav-gene-therapy</guid>
<description><![CDATA[ This eBook brings together perspectives from across the AAV development and manufacturing continuum. It explores how early commercial planning can help avoid costly delays, how standardized platform approaches and off-the-shelf plasmids can streamline development, and how next-generation innovations are helping overcome long-standing manufacturing bottlenecks.
The post Building the Future of AAV Gene Therapy appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Catalent_AAVGeneTherapyEbook.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 03:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Building, the, Future, AAV, Gene, Therapy</media:keywords>
<content:encoded><![CDATA[<div aria-hidden="true" class="wp-block-spacer"></div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Read Now</button></p>


<p class="wp-block-paragraph">Adeno-associated virus (AAV) gene therapies have transformed the treatment landscape for rare and genetic diseases, delivering potentially life-changing outcomes for patients and validating the promise of genetic medicine. As the field continues to mature, however, the challenges facing developers are evolving. The question is no longer simply whether an AAV therapy can demonstrate clinical efficacy. Increasingly, success depends on whether organizations can reliably develop, manufacture, scale, and deliver these therapies in a commercially sustainable way.</p>


<figure class="wp-block-image alignright size-medium"><img fetchpriority="high" decoding="async" width="232" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Catalent_Cover-232x300.jpg" alt="Building the Future of AAV Gene Therapy: Strategies for Scalable Development, Manufacturing, and Commercialization Catalent eBook" class="wp-image-339984" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Catalent_Cover-232x300.jpg 232w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Catalent_Cover-791x1024.jpg 791w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Catalent_Cover-768x994.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Catalent_Cover-1187x1536.jpg 1187w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Catalent_Cover-1583x2048.jpg 1583w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Catalent_Cover-scaled.jpg 1978w" sizes="(max-width: 232px) 100vw, 232px"></figure>


<p class="wp-block-paragraph">Today, gene therapy developers must navigate a complex environment characterized by rising demand, manufacturing capacity constraints, global supply chain considerations, and increasing expectations for commercial readiness. Traditional approaches that worked during early clinical development may not be sufficient as programs advance toward registration, launch, and long-term commercial supply. As a result, the industry is placing greater emphasis on platform technologies, integrated development strategies, resilient supply chains, and manufacturing innovations that can accelerate timelines while improving scalability and consistency.</p>


<p class="wp-block-paragraph">This eBook brings together perspectives from across the AAV development and manufacturing continuum. It explores how early commercial planning can help avoid costly delays, how standardized platform approaches and off-the-shelf plasmids can streamline development, and how next-generation innovations are helping overcome long-standing manufacturing bottlenecks. It also examines the growing importance of supply chain orchestration and case management in ensuring therapies reach patients safely, efficiently, and on time.</p>


<p class="wp-block-paragraph">As the number of AAV-based therapies advances through clinical development and toward commercialization, organizations that successfully integrate manufacturing strategy, supply chain planning, and technological innovation will be best positioned to deliver therapies at scale. The lessons and insights presented in these articles highlight practical approaches for addressing today’s challenges while preparing for the future of gene therapy. Together, they provide a roadmap for developers seeking to accelerate development, optimize manufacturing performance, strengthen supply resilience, and ultimately improve patient access to transformative AAV-based medicines.</p>

<p>The post <a href="https://www.genengnews.com/resources/ebooks/building-the-future-of-aav-gene-therapy/">Building the Future of AAV Gene Therapy</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>First Whole&#45;Body Single&#45;Cell Atlas of Adult Vertebrate Generated in Danionella cerebrum</title>
<link>https://edusehat.com/en/first-whole-body-single-cell-atlas-of-adult-vertebrate-generated-in-danionella-cerebrum</link>
<guid>https://edusehat.com/en/first-whole-body-single-cell-atlas-of-adult-vertebrate-generated-in-danionella-cerebrum</guid>
<description><![CDATA[ Researchers created the first comprehensive whole-body single-cell atlas of an adult vertebrate, the tiny, transparent fish Danionella cerebrum, offering a new resource for studying brain regeneration, cellular diversity, and investigating how different tissues function together.
The post First Whole-Body Single-Cell Atlas of Adult Vertebrate Generated in Danionella cerebrum appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/low-res-1.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 03:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>First, Whole-Body, Single-Cell, Atlas, Adult, Vertebrate, Generated, Danionella, cerebrum</media:keywords>
<content:encoded><![CDATA[<p>Whitehead Institute researchers have created the first comprehensive whole-body single-cell atlas of an adult vertebrate, the tiny, transparent teleost fish <em>Danionella cerebrum</em>.</p>
<p>The team profiled more than 600,000 cells from across the fish to build the whole-body single-cell transcriptome atlas of which genes are active in which cell. A cell’s transcriptome is the full set of RNA molecules it has made from its DNA at a given time, providing a snapshot of which genes the cell is using.</p>
<p>Together, the data provide a molecular reference for the cell types found throughout <em>Danionella</em>, the patterns of gene activity that distinguish them, and where many of them are located. Offering a new resource for studying brain regeneration, cellular diversity, and investigating how different tissues function together, the atlas gives researchers a baseline for exploring how injury, aging, drugs, or other changes affect cells across the whole animal.</p>
<p>The team has made the atlas publicly available through <a href="https://digifish.wi.mit.edu/" target="_blank" rel="noopener">DigiFish</a>, an interactive resource for exploring cell types and gene activity throughout the animal. Paired with <em>Danionella</em>’s transparency and growing experimental toolkit, the atlas can help researchers identify specific cells and genes to study or manipulate and then follow their activity in the animal.</p>
<p>“Once you have a spatially resolved atlas, you know what cell types exist, but you also know the neighbors of those cell types in this context,” said Kutay Deniz Atabay, PhD, who led the work as a postdoctoral researcher in the lab of Whitehead Institute Member Peter Reddien, PhD. “This gives you access at multiple different levels of complexity, from molecular to cellular to systems.”</p>
<p>Atabay is first author, and Reddien senior and corresponding author of the researchers’ published paper in <em>Science</em>, titled “<a href="https://www.science.org/doi/10.1126/science.aeg1125" target="_blank" rel="noopener">Whole-body single-cell atlas of an adult vertebrate, <em>Danionella cerebrum</em>,</a>” in which they stated, “This whole-vertebrate transcriptome atlas yields a comprehensive resource for myriad questions in biology and neuroscience.”</p>
<p><em>Danionella cerebrum</em> is one of the world’s smallest vertebrates (∼12 mm in length), and has the smallest vertebrate brain on record, containing ∼650,000 neurons within 0.6 mm<sup>3</sup>, the authors wrote. This is approximately four times the size of the Drosophila brain, but with all the major vertebrate brain regions. Viewed from above, <em>Danionella cerebrum</em> offers a rare sight in a vertebrate, in that its brain is visible through the top of its head. “Thanks to its optical transparency, <em>D. cerebrum</em> is arguably unparalleled for noninvasive live whole-brain and whole-body imaging at single-cell resolution in an adult vertebrate …” the team noted.</p>
<p>Since the species was adopted for neuroscience research in 2018 and formally described in 2021, the tiny, transparent fish has drawn rapidly growing interest for its unique biology.</p>
<p>Whitehead Institute researchers recognized that the tiny fish brought whole-animal single-cell profiling within reach, allowing the team to create the first comprehensive map of cell types and gene activity across an adult vertebrate. That perspective could help reveal how cells in different tissues coordinate their responses—and how changes in one part of the body influence others.</p>
<p>Cell atlases have become increasingly detailed, but extending them across a whole adult vertebrate has been difficult for the basic reason of size. Profiling the cellular diversity of larger animals comprehensively is technically demanding and expensive. “The molecular mapping of cell transcriptomes across the entire animal anatomy of an adult vertebrate has not been achieved, largely because most vertebrates are too large for comprehensive molecular access to their cellular and molecular complexity, the investigators pointed out. <em>Danionella</em>—at barely one centimeter long—makes the experiment possible, while its close relationship to zebrafish allows researchers to draw on genetic tools developed for one of biology’s most widely used model organisms. “We reasoned that the extreme miniaturization of <em>Danionella</em> could enable organism-wide cell type profiling and facilitate high-throughput molecular studies,” they continued. “<em>D. cerebrum</em> is also closely related to zebrafish, which allows for the transfer and use of an expansive molecular toolkit, and its genome, similar to many other teleosts, is approximately half the size of the zebrafish genome.“</p>
<p>Atabay first became interested in <em>Danionella</em> in early 2019, while searching for a small, transparent animal in which he could watch the nervous system regenerate. Its miniature size and accessible brain made it especially promising for that work, and the researchers found that the fish has broad regenerative capacity, including in the brain and fins. Reddien’s lab, meanwhile, had already seen the value of a comprehensive whole-animal cell atlas through work on planarians, regenerative flatworms whose small size had made such an atlas possible. Together, those interests led to a larger question.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>“Deniz and I had the thought: Would it be possible to get a cell-type transcriptome atlas for a complete vertebrate?” said Reddien, who is also a professor of biology at Massachusetts Institute of Technology and an Investigator with the Howard Hughes Medical Institute. “Here’s an animal where we’d have a chance.”</p>
<p>To build the atlas, the researchers used single-cell RNA sequencing to measure gene activity in individual cells collected from across the brain, spinal cord, eyes, internal organs, fins, head, and trunk. They paired those data with spatial methods that mapped cell types and patterns of gene activity back to their locations in tissues. In their paper the team explained, “We combined regionally stratified single-cell RNA sequencing (scRNA-seq) with whole-animal spatial transcriptomics [multiplexed high-throughput fluorescent <em>in situ</em> hybridization (MERFISH) and hybridization chain reaction fluorescent in situ hybridization (HCR-FISH)] to build, validate, and explore a body-wide single-cell transcriptome atlas.”</p>
<p>The resulting atlas was extensive enough to capture even exceptionally rare cell populations. Looking across the animal revealed patterns that can be difficult to see when tissues are studied separately. In the nervous system, neurons from the same region often had more similar patterns of gene activity, even when they used different neurotransmitters—the chemicals neurons use to communicate—than when compared with neurons using the same neurotransmitter in different regions. Similar patterns have been observed in other vertebrates, including mammals, suggesting that regional and developmental identity may be an important organizing feature of vertebrate nervous systems.</p>
<p>The atlas also revealed signs that adult cells retain a molecular memory of where they belong in the body. The researchers found that fibroblasts, a type of connective tissue cell, maintained region-specific activity of genes best known for establishing different parts of the body during development. Cells in the pectoral and pelvic fins, for example, retained gene programs associated with forelimb and hindlimb development in other vertebrates. What these persistent signals do in adult <em>Danionella</em> remains unknown, but they may help tissues maintain or rebuild the appropriate structures. In planarians, positional information provides molecular guidance that helps regenerating tissues rebuild the correct structures.</p>
<p>The team also used the atlas as a reference for studying <em>Danionella</em>’s remarkable regenerative abilities. After injuring the telencephalon, a region of the forebrain, the missing neurons regenerated and the researchers were able to trace a progression from an early wound and immune response to neural stem-cell activity and the production and maturation of new neurons. “… profiling telencephalon regeneration revealed a temporally ordered molecular cascade, involving signatures of wound response and immune cell recruitment, radial glia proliferation, neurogenesis, and neuronal maturation …” they stated.</p>
<p>For Reddien, the advance presents numerous, diverse opportunities for new science. “There’s been this era of genome sequencing, where you get the complete list of all the genes that it takes to make an organism,” he says. “The transcriptomes of cells tell you how that genome is being utilized in the different cell types. To have the transcriptome of every cell type seems like a big turning point in how one would investigate the biology of an organism.”</p>
<p>In their paper the authors concluded “These findings and resources position <em>D. cerebrum</em> as a powerful model for systems neuroscience, stem cell biology and regeneration, biomechanics and collective behavior, and evolutionary biology.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/first-whole-body-single-cell-atlas-of-adult-vertebrate-generated-in-danionella-cerebrum/">First Whole-Body Single-Cell Atlas of Adult Vertebrate Generated in <i>Danionella cerebrum</i></a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Brain Quality Control Selectively Eliminates Neurons with Abnormal Variants in Development</title>
<link>https://edusehat.com/en/brain-quality-control-selectively-eliminates-neurons-with-abnormal-variants-in-development</link>
<guid>https://edusehat.com/en/brain-quality-control-selectively-eliminates-neurons-with-abnormal-variants-in-development</guid>
<description><![CDATA[ In developing fetuses, the human brain generates an excess of neurons, most of which are eliminated around when the baby is born. New research suggests that this is an important quality-control mechanism.
The post Brain Quality Control Selectively Eliminates Neurons with Abnormal Variants in Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/10/Getty_183878409_FetusWithDNAUmbilicalCord-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 03:40:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Brain, Quality, Control, Selectively, Eliminates, Neurons, with, Abnormal, Variants, Development</media:keywords>
<content:encoded><![CDATA[<p><span>By analyzing genomic data from neurons, scientists from Harvard Medical School (HMS), Boston Children’s Hospital, and their collaborators have gained insights into a critical quality-control mechanism that takes place in the developing fetal brain. </span></p>
<p><span>During development, the human brain generates an excess of neurons, most of which are eliminated around when the baby is born. According to a study published this week in </span><i><span>Nature</span></i><span>, scientists report that neurons with multiple copy number variants, including DNA  duplications or deletions, are widespread in the developing brain. However they are selectively eliminated shortly before or after birth likely because the genomic alterations disrupt their ability to form synapses. </span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p><span>Full details are provided in a paper titled “</span><a href="https://www.nature.com/articles/s41586-026-11190-3#author-information" target="_blank" rel="noopener"><span>Perinatal elimination of genetically aberrant human cortical neuron</span></a><span>.” The findings reported there are significant because copy number variants can impact brain function and may contribute to neuropsychiatric conditions, including autism, schizophrenia, epilepsy, and intellectual disability. A better understanding of the pruning process in the developing brain could improve how autism and other disorders in which neural development goes awry are treated. </span></p>
<p><span>As Diane Shao, MD, PhD, HMS instructor of neurology at Boston Children’s and a co-first author on the study noted, “If that quality control system can be disrupted, that could be part of what goes wrong in neurodevelopmental disorders like autism. Understanding the mechanism could eventually point us toward what to look for, and maybe what to protect.”</span></p>
<p><span>One of the first steps in the study was exploring the prevalence of copy number variants in developing human brains. To do that, the scientists designed single-cell whole genome sequencing approaches that allowed them to lightly sequence the genomes of single neurons. They used this method to sequence over 1,500 neurons from 16 individuals. They then validated the results with deeper sequencing of over 800 neurons from 12 individuals. They then used various computational methods to identify copy number variants in each sequenced genome. With their approach, it was possible to see the genomic changes “one neuron at a time, map where in the genome they occur, and compare how common they are from before birth to old age,” explained Peter Park, PhD, co-senior author on the paper and professor of biomedical informatics at HMS.</span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p><span>The data showed that an average of nearly 26 percent of neurons in the prenatal cortex had widespread copy number variants, but this rapidly decreased to an average of 6.2 percent after birth. </span><span>Specifically, “neurons with widespread CNVs were mainly eliminated perinatally, timed roughly parallel to periods of programmed cell death, whereas neurons with smaller CNV burdens declined slowly in frequency with postnatal age,” the scientists wrote. </span></p>
<p><span> “We were totally unprepared for how common these were in early development,” said Christopher Walsh, MD, PhD, a co-senior author on the paper and professor of pediatrics and neurology at Boston Children’s Hospital. “But it makes sense in the context of what we know about the formation of excess neurons and in the context of the IVF literature.” </span></p>
<p><span>Next, the team explored the pathways through which the abnormal neurons are eliminated. By sequencing and analyzing DNA and RNA from over 44,000 individual cells, they found that neurons with widespread copy number variants also had abnormal expression of the genes involved in the creation and maintenance of neural synapses. It suggests that unlike healthy brain cells, these abnormal neurons fail to make critical connections during fetal development which causes them to die off. </span></p>
<p><span>“This competition for synapses has been described for years, but without the benefit of a genomic understanding,” Walsh noted. We didn’t realize that this struggle for survival—this Darwinian competition—was nature’s quality control mechanism in the brain.”</span></p>
<p><span>As part of the study, the team also confirmed some earlier findings that flawed neurons continue to be eliminated throughout adulthood, albeit at a much slower rate. Currently, they are looking into whether this neural elimination process is different in developing brains of people with autism and other neurodevelopmental disorders. They are also exploring whether this process plays a role in development of adult-onset neurodegenerative disorders like Alzheimer’s disease. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/brain-quality-control-selectively-eliminates-neurons-with-abnormal-variants-in-development/">Brain Quality Control Selectively Eliminates Neurons with Abnormal Variants in Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Discovery could help predict which early breast cancers will spread</title>
<link>https://edusehat.com/en/discovery-could-help-predict-which-early-breast-cancers-will-spread</link>
<guid>https://edusehat.com/en/discovery-could-help-predict-which-early-breast-cancers-will-spread</guid>
<description><![CDATA[ Immune cells that normally protect the body from infection can also drive the progression of some early breast cancers, McGill University researchers have found. The discovery points to a potential way of distinguishing relatively harmless cases of ductal carcinoma in situ (DCIS) from those most likely to become invasive, one of the biggest challenges in […]
The post Discovery could help predict which early breast cancers will spread appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Focused-Laboratory-Researcher.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 03:35:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Discovery, could, help, predict, which, early, breast, cancers, will, spread</media:keywords>
<content:encoded><![CDATA[<p>Immune cells that normally protect the body from infection can also drive the progression of some early breast cancers, McGill University researchers have found.</p>
<p>The discovery points to a potential way of distinguishing relatively harmless cases of ductal carcinoma in situ (DCIS) from those most likely to become invasive, one of the biggest challenges in breast cancer care.</p>
<p>DCIS is an early form of breast cancer that accounts for roughly one-fifth to one-third of cancers detected through screening.<span class="Apple-converted-space"> </span></p>
<p>“Many patients diagnosed with DCIS face difficult treatment decisions because we can’t reliably predict which lesions will progress,” said lead author Tarek Taifour, an MD PhD student in McGill’s Department of Medicine. “We’ve identified a mechanism that brings us a step closer to identifying those at highest risk.”</p>
<p>DCIS is normally held in check by a thin layer of cells that acts like a protective barrier, preventing cancer cells from spreading into nearby tissue.</p>
<p>Researchers studied the disease in mice, human breast tissue samples and 3D tumour models grown in the lab to understand how some cancers break through the barrier.</p>
<p>Results published in Cell Reports Medicine point to an unexpected role of the immune system.</p>
<p>Neutrophils – immune cells best known for fighting infection – release an enzyme called neutrophil elastase that weakens this barrier, the study found. When researchers blocked either the cells or the enzyme, the protective barrier remained intact.</p>
<p>“Cancer can sometimes hijack normal immune processes and turn them into processes that help disease progress. This appears to be an example of that,” said senior author William Muller, Professor in McGill’s Department of Biochemistry.</p>
<p>Many patients diagnosed with DCIS undergo surgery, radiation or other treatments without knowing whether their lesions would have ever become dangerous.</p>
<p>The findings suggest neutrophil elastase could one day serve as a biomarker, helping doctors tailor treatment to a patient’s risk and avoid unnecessary treatment for those whose cancer is unlikely to progress.</p>
<p>Physicians have disabilities too: New research calls for a more accessible medical workforce</p>
<p>New research indicates that five per cent of practising physicians report a disability “always or often,” and another 12 per cent report disability “sometimes.” The authors call for action on improving accessibility to ensure equity and sustainability in the physician workforce. The study is published in CMAJ (Canadian Medical Association Journal).</p>
<p>“Physicians with disabilities frequently face discrimination, inaccessible workplaces, and inadequate support,” writes Dr. Michael Quon, a general internal medicine specialist and clinician investigator at The Ottawa Hospital, and an assistant professor, University of Ottawa, Ottawa, Ontario, with coauthors. “Not retaining physicians with disabilities in the workforce means losing skilled providers with valuable perspectives, negatively affecting human health resources. Improving accessibility in medicine is important.”<span class="Apple-converted-space"> </span></p>
<p>The study, based on data from the 2021 Canadian long-form Census, helps fill an important gap in evidence about the prevalence of disability in practising physicians and their demographics. Unlike other studies, which were voluntary, the Census is mandatory, with a 97% completion rate by a randomly selected 25% of the population living in Canada, making this study nationally representative.<span class="Apple-converted-space"> </span></p>
<p>The most commonly reported disability was mental health (40%) followed by visual (37%), hearing (15%), mobility or physical (13%), and cognitive or learning (6%). Disabilities were more common in female (6.0%) than male physicians (4.5%).</p>
<p>The authors note that younger age does not preclude disability.<span class="Apple-converted-space"> </span></p>
<p>“While disability rates generally increased with age, the prevalence in physicians younger than 35 years remained notable (5.2%),” says Dr. Quon. “The prevalence of hearing, mobility, and physical disabilities increased with age, while mental health disabilities were more common in younger age groups.”</p>
<p>Physicians report fewer disabilities compared with other professions, such as law, academia, engineering, and nursing, as well as the general workforce. <span class="Apple-converted-space"> </span></p>
<p>The authors emphasize that supporting physicians with disabilities is important for Canada’s health systems.<span class="Apple-converted-space"> </span></p>
<p>“Disabilities are an important yet often overlooked contributor to workforce diversity,” write the authors. “Ensuring accessible work environments and equitable policies can promote the well-being and retention of physicians with disabilities and support those seeking to return to practice. Beyond benefits to the physicians themselves, advancing accessibility might enhance patient care by fostering a workforce that better reflects the populations it serves.”<span class="Apple-converted-space"> </span></p>
<p>“Prevalence and characteristics of disabilities in physicians in Canada; an analysis of Canadian Census data” is published October 13, 2026.<span class="Apple-converted-space"> </span></p>
<p>The post <a href="https://www.hospitalnews.com/discovery-could-help-predict-which-early-breast-cancers-will-spread/">Discovery could help predict which early breast cancers will spread</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Rising MHRA registration fees: a mounting burden for dental labs</title>
<link>https://edusehat.com/en/rising-mhra-registration-fees-a-mounting-burden-for-dental-labs</link>
<guid>https://edusehat.com/en/rising-mhra-registration-fees-a-mounting-burden-for-dental-labs</guid>
<description><![CDATA[ Steve Campbell explains why the proposed rise in MHRA registration fees could disproportionately affect dental laboratories – and what is being done to challenge it. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/MHRA.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 00:25:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Rising, MHRA, registration, fees:, mounting, burden, for, dental, labs</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Steve Campbell explains why the proposed rise in MHRA registration fees could disproportionately affect dental laboratories – and what is being done to challenge it.</strong></p>



<p>From April 2026, the <a href="https://dentistry.co.uk/2023/11/24/navigating-mhra-registration-a-crucial-step-towards-compliance/">Medicines and Healthcare Products Regulatory Agency (MHRA)</a> introduced a new annual charging structure for medical device registration.</p>



<p>Manufacturers are now charged £300 each year for every chargeable GMDN Level 2 category, or Level 1 where no Level 2 exists.</p>



<p>During the introduction of the system, there was considerable uncertainty over how dental devices should be categorised and very little dental-specific guidance available to laboratories. The DLA, worked with the MHRA, obtained clarification and helped members understand which categories applied to their products, reducing the potential financial exposure for many.</p>



<h2 class="wp-block-heading">Another substantial increase</h2>



<!--free-wall-stop-->



<p>You might reasonably have expected everyone to be given time to see how that new system operated. Instead, only months after its introduction, the MHRA launched another consultation proposing to increase the annual charge from £300 to £511 from 1 April 2027. That is an increase of more than 70% in 12 months.</p>



<p>I make no apology for saying that the DLA considers an increase of that magnitude extraordinary. Government talks about supporting small businesses, reducing regulatory burdens and providing businesses with greater certainty. Those commitments have to mean something in practice.</p>



<p>Reducing the cost of government cannot simply mean transferring more of that cost onto small businesses through higher compulsory fees.</p>



<figure class="wp-block-pullquote"><blockquote><p>‘We believe there is a fundamental question about whether the existing charging structure is sufficiently proportionate’</p></blockquote></figure>



<h2 class="wp-block-heading">Is the system proportionate?</h2>



<p>Medical devices encompass an enormous range of risk. Some devices understandably require significant post-market surveillance, investigation, safety action and regulatory resources.</p>



<p>But dental laboratories predominantly manufacture individually prescribed custom-made medical devices. Yet a micro dental laboratory can face the same unit charge for a GMDN category as a vastly larger medical device manufacturer.</p>



<p>We believe risk, scale and actual regulatory workload should matter.</p>



<h2 class="wp-block-heading">Questions that need answers</h2>



<p>How many dental laboratories have been inspected? What non-compliance has been identified? What does regulating our sector actually cost?</p>



<p>If dental laboratories are being asked to pay considerably more, those are entirely reasonable questions. In response, we prepared a formal challenge calling for the proposed increase to be paused and the underlying charging structure reviewed. We sent it to the MHRA, relevant government ministers and parliamentary select committees.</p>



<p>We also mobilised our membership, we provided members with guidance for responding to the consultation and a separate template letter that could be sent to their constituency MPs. The objective was to ensure that government heard both the collective voice of the DLA and the voices of the individual businesses that will actually have to pay these fees.</p>



<p>On 10 September, we received a formal letter from Lawrence Tallon, chief executive of the MHRA. The MHRA has acknowledged the DLA’s concerns and confirmed that our representations will be considered alongside the other consultation responses. Most importantly, the chief executive has confirmed that the MHRA will contact the DLA directly to arrange a meeting to discuss our concerns in greater detail.</p>



<p>We welcome that meeting, but our position has not changed.</p>



<h2 class="wp-block-heading">What happens next?</h2>



<p>We will be asking the MHRA to justify the proposed 70% increase. We will ask for evidence about the actual cost and level of post-market surveillance associated with dental technology. We will challenge whether a charging system that does not adequately recognise differences in manufacturer size, device risk and regulatory workload is genuinely proportionate and we will continue to make the point that cost recovery cannot become a blank cheque handed to a regulator and ultimately paid for by compliant small businesses.</p>



<p>The DLA supports strong regulation. We support effective post-market surveillance. We support patient safety without reservation, but good regulation must also be proportionate, transparent, accountable and evidence-based.</p>



<p>The job is not finished.</p>



<p>Our objective now is to use that engagement to secure a fairer outcome for DLA members and to ensure that the voice of UK dental laboratories is heard clearly when decisions affecting their businesses are made.</p>



<p><em><a href="https://sso.dentistry.co.uk/">Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</a></em></p>]]> </content:encoded>
</item>

<item>
<title>Hamburg Hosts 2026 European Gene Therapy Conference</title>
<link>https://edusehat.com/en/hamburg-hosts-2026-european-gene-therapy-conference</link>
<guid>https://edusehat.com/en/hamburg-hosts-2026-european-gene-therapy-conference</guid>
<description><![CDATA[ GEN&#039;s Kevin Davies, PhD, reports from ESGCT where patient safety, expanding access to gene therapy, and progress towards an HIV vaccine were prominent themes among the early talks at ESGCT 2026.
The post Hamburg Hosts 2026 European Gene Therapy Conference appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/ESGTIllustration-scaled-e1793274396802.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 00:00:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Hamburg, Hosts, 2026, European, Gene, Therapy, Conference</media:keywords>
<content:encoded><![CDATA[<p><strong>HAMBURG</strong>—The historic German port city of Hamburg is playing host to the European Society of Gene & Cell Therapy (ESGCT) conference this week.</p>
<p>As noted in the opening session, the Port of Hamburg was established more than 800 years ago. It is also a proud center of editing—newspapers rather than genes—as the site of the headquarters of <em>Der Speigel</em> and <em>Die Zeit</em>. And of course, Hamburg famously helped forge the sound and legend of the “Fab Four”—the Beatles played numerous gigs between 1960-62 in the central St. Pauli district. It was also where Ringo Starr met his future bandmates in 1960.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Patient safety, expanding access to gene therapy, and progress towards an HIV vaccine were prominent themes among the early talks at ESGCT 2026. In the opening plenary session, Dimitrios Mougiakakos, MHBA, discussed his group’s research on CAR T therapy for lupus, noting progress but some patient deaths. “Lower risk does not mean no risk,” he said, pointing to the rapid production of CAR T cells as a potential risk factor. A “Volkswagen approach” might be better than a “Ferrari approach,” he concluded.</p>
<p>Italian professor Giuliana Ferrari, PhD, discussed her team’s research on beta-thalassemia, one of the “less rare of the rare diseases,” characterized by more than 400 different globin gene mutations. Ferrari noted that some of the patients in the <em>ex vivo </em>TIGET-BTHAL Phase I/II trial, which began in 2015, had restarted blood transfusions, while others remained transfusion-independent after nine years, producing respectable levels of hemoglobin.</p>
<p>Ferarri’s team has spent several years optimizing manufacturing protocols to launch a new trial, Bthal FT007-01. The first two patients have been enrolled in this Phase IIb trial, an academic initiative between Italian groups designed to provide affordable access to gene therapy. Refinements include the implementation of a shorter 40-hour cell culture and gene transduction protocol (down from 60 hours) and a change in conditioning regimen.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<h4><strong>HIV hope</strong></h4>
<p>In addition to his academic position at Scripps Research Institute, Bill Schief, PhD, is also the vice president of protein design at Moderna. Although he acknowledged he was a slightly unusual choice for a plenary speaker, as his work was not technically gene therapy, he relished the chance to present his team’s promising work on the quest to engineer a specific immune response and to develop a functional HIV vaccine.</p>
<p>The statistics remain sobering: More than 40 million people live with HIV, but more than 20 percent do not receive antiretroviral therapy. There are 1.2 million new HIV infections and 570,000 deaths per year. All told, 44 million people have died of AIDS, and global funding for AIDS research is going down. “We need a vaccine,” Schief emphasized.</p>
<p>Schief and colleagues are designing vaccines to guide the immune system toward antibodies that target conserved, vulnerable regions of the HIV envelope protein. Hope resides in the development of broadly effective Abs (bnAbs). A successful HIV vaccine will need to induce multiple classes of bnAbs, Schief said.</p>
<p>Schief reviewed research to deliver a sequence of immunogens, using priming, “shepherding,” and “polishing,” with the goal of producing bnAbs and long-lived plasma cells to sustain production. The strategy is “very complicated but not crazy,” Schief said, citing the need for serum bnAbs to have breadth, potency, and durability.</p>
<p>Over the past two years, researchers have reported clinical results and animal studies that represent significant advances towards their goal. In 2025, <a href="https://www.science.org/doi/10.1126/science.adr8382" target="_blank" rel="noopener">Schief’s team reported promising Phase I results in <em>Science</em></a>. IAVI G002, conducted in the U.S., tested an mRNA vaccine designed to activate the desired antibody precursors, followed by a different mRNA vaccine intended to advance their development. IAVI G003 was conducted in Rwanda and South Africa, testing the initial vaccine approach in African populations.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>“Let’s make sure the strategy works there [in Africa],” Schief said. The findings provided proof of concept but stopped short of a full vaccine. Earlier this year, Schief and colleagues published in <a href="https://www.nature.com/articles/s41586-026-10837-5" target="_blank" rel="noopener"><em>Nature</em></a> results showing that <a href="https://www.genengnews.com/topics/infectious-diseases/germline-targeting-hiv-vaccine-generates-broadly-neutralizing-antibodies-in-primates/" target="_blank" rel="noopener">germline-targeting vaccines can induce pre-specific bnAbs</a> in memory B cells and serum in non-human primates.</p>
<h4><strong>CAR T promise</strong></h4>
<p>Michel Sadelain, MD, PhD, presented a compelling overview of the promise of CAR T therapy in oncology and other therapeutic areas. Of the seven CAR T therapies approved in the U.S. to date, five target CD19. In oncology, survival duration has quadrupled from about six months to more than 25 months. Sadelain said there was promising data in other fields, including rheumatology (lupus, arthritis, and scleroderma), as well as preliminary results in neurology (myasthenia gravis). This progress has all been achieved with the original two molecular designs that yielded Yescarta and Kymriah: CD28z CAR and 4-1BBz CAR.</p>
<p>But progress in tackling solid tumors with CAR therapy has not kept pace with hematological malignancies, Sadelain said. He listed five primary challenges in this regard:</p>
<ul>
<li>The need to increase functional persistence of T cells</li>
<li>Potency</li>
<li>Sensitivity</li>
<li>The need to understand and prevent toxicity</li>
<li>New targets</li>
</ul>
<p>In one line of research, Sadelain’s team revisited signaling strength, with a view to tempering it. In 2025, the group showed that by switching from three ITAMs to a single ITAM, they could create a strong effector function with much greater persistence. This “1XX” signaling module was <a href="https://ascopubs.org/doi/abs/10.1200/JCO-24-02424" target="_blank" rel="noopener">taken to the clinic in B-cell lymphoma</a>, with excellent responses seen administering as few as 25 million cells—a tenth of the regular dose (100-400 million cells).</p>
<p>In another approach, Sadelain’s team has used CRISPR to develop a new CAR—<a href="https://www.nature.com/articles/s41591-021-01621-1" target="_blank" rel="noopener">the HLA-independent T cell (HIT) receptor</a>—that is at least 10-fold more sensitive. The characterization of this CAR in solid tumors such as renal cell carcinomas in immunodeficient mice continues.</p>
<p> </p>
<p><em>*ESGCT 2026; Hamburg, Germany; October 27-30, 2026.</em> <strong></strong></p>
<p></p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/hamburg-hosts-2026-european-gene-therapy-conference/">Hamburg Hosts 2026 European Gene Therapy Conference</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Doing more with dialysis: A renewed patient experience</title>
<link>https://edusehat.com/en/doing-more-with-dialysis-a-renewed-patient-experience</link>
<guid>https://edusehat.com/en/doing-more-with-dialysis-a-renewed-patient-experience</guid>
<description><![CDATA[ HN Summary • SHN’s largest dialysis redevelopment added 23 treatment stations across Centenary and General hospitals, expanding capacity and improving comfort, privacy and safety.•  • Patients helped evaluate new dialysis equipment, with patient Scott Spence-Lee reporting less fatigue and more energy after treatment. • Upgraded units feature stronger infection prevention measures, dedicated isolation spaces and […]
The post Doing more with dialysis: A renewed patient experience appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Dialysis-scaled.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 23:55:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Doing, more, with, dialysis:, renewed, patient, experience</media:keywords>
<content:encoded><![CDATA[<p><strong>HN Summary</strong></p>
<p>• SHN’s largest dialysis redevelopment added 23 treatment stations across Centenary and General hospitals, expanding capacity and improving comfort, privacy and safety.•<span class="Apple-converted-space"> </span></p>
<p>• Patients helped evaluate new dialysis equipment, with patient Scott Spence-Lee reporting less fatigue and more energy after treatment.</p>
<p>• Upgraded units feature stronger infection prevention measures, dedicated isolation spaces and sustainable water-recycling technology.</p>
<hr>
<p>For the thousands of patients who receive dialysis through Scarborough Health Network’s (SHN) Regional Nephrology Program each year, it is more than a simple treatment, it is a way of life. By medical definition, dialysis means the process of artificially filtering toxins and waste from the blood when the kidneys no longer can. For patients who require or prefer dialysis in a hospital setting, it means spending several hours, multiple times each week away from home receiving treatment, without which they risk losing their energy, mental clarity, and longevity of life. The dialysis unit becomes a constant setting in their lives, and that setting should reflect the compassion, patience, and exceptional quality care patients deserve during treatment.</p>
<p>For 70-year-old Scott Spence-Lee, who has lived with kidney failure since 2018, the impact of these experiences is something he lives every week. SHN sought to improve the care experience for patients like Scott through a major redevelopment.</p>
<p>As part of our journey to Build It Forward to better meet the needs of our community now and into the future, we completed the largest dialysis redevelopment in SHN’s history. The multi-year projects included the creation of a brand-new, modern dialysis unit at Centenary Hospital and the expansion and renovation of the existing dialysis unit at General Hospital. Together, these projects have added 23 new treatment stations, increased capacity to meet growing community needs, and created modern care environments designed around comfort, privacy, dignity, and safety.</p>
<h3><strong>A new chapter in dialysis care</strong></h3>
<p>Scott’s journey with kidney disease began when he spent three weeks in hospital and learned he was experiencing kidney failure.</p>
<p>“It was a shock,” Scott recalled. “I was diagnosed at SHN, and eventually my care team determined that dialysis was the next step.”</p>
<p>After receiving training on dialysis equipment and beginning regular treatment, Scott became familiar with the routine that accompanies life-sustaining dialysis care. Earlier this year, he was one of the first patients to transition into SHN’s new dialysis unit at Centenary Hospital, located on the first floor of the Margaret Birch Wing.</p>
<p>The patient-centred unit features 21 dialysis stations, enhanced infection prevention and control measures, environmentally sustainable water-recycling systems, and a flexible design that can evolve alongside future advances in dialysis care.</p>
<p>“The new space is more private, more modern, and much more conducive to receiving treatment. It is a comforting space,” Scott said. “I love my nurses and care team. They work as a real team and make you feel part of it. They’re always available, they make me feel welcome, and they encourage you to ask questions.”</p>
<p>But for Scott, the effects of the new and improved dialysis unit extended beyond the space itself. One of the most significant improvements has been the introduction of the modern, innovatively designed B. Braun Dialog IQ hemodialysis machines. Patients, including Scott, played an active role in evaluating and testing equipment before it was selected, helping ensure the technology reflected real-world needs and preferences. Scott felt the difference right away.</p>
<p>“With this newer technology, you finish your treatment and immediately get your mojo back,” Scott shared. “Before, when I finished dialysis I was so tired and had trouble focusing. Now, when I get home after dialysis, I can still do things.”</p>
<p>The difference has been noticeable to his family as well.</p>
<p>“My eldest daughter said I’m better because I can spend more time with my family now and don’t sleep as much as I used to. I move around more. I can play with my grandson more.”</p>
<p>The upgraded technology also helps deliver more consistent treatment, even when common challenges, like blockages in the blood-filtering tubes, arise during dialysis sessions. Combined with the purposefully designed treatment environment, these improvements are helping patients feel better supported both during and after their care.</p>
<h3><strong>Designed around the<span class="Apple-converted-space"> </span>patient experience</strong></h3>
<p>At SHN, patient experience was a central consideration throughout the dialysis redevelopment process.</p>
<p>“Clinical care is shaped not only by the treatment itself, but also by the setting in which it is provided,” said Dr. Paul Tam, Medical Director and Chief of Nephrology at SHN. “Our patients often spend many hours each week receiving dialysis, making it essential that the environment supports their comfort, privacy, and well-being. These upgraded facilities will allow us to combine leading-edge technology with a patient-centred approach.”</p>
<p>The redevelopment has transformed care across both hospitals. At General Hospital, the renovated TD Hemodialysis Isolation Unit includes newly modernized treatment areas and dedicated segregation treatment rooms designed to better support medically vulnerable patients while enhancing infection prevention and control.</p>
<p>At Centenary Hospital, the entirely new Ted Rogers Hemodialysis unit provides a welcoming and accessible environment designed to improve both patient and staff experiences while expanding SHN’s ability to meet the growing demand for kidney care services in Scarborough.</p>
<p>“These redevelopment initiatives are creating modern care environments designed with accessibility, safety, and patient experience in mind,” shared Ethel Macatangay, Director, Nephrology and Chronic Disease Management at SHN. “By investing in advanced technology and purpose-built spaces, we are strengthening our capacity to deliver exceptional, compassionate care and meet the evolving needs of our community for years to come.”</p>
<h3><strong>Looking ahead</strong></h3>
<p>While dialysis remains an essential part of his routine, Scott feels reassured knowing he is receiving care in a unit designed with patients at its centre, in a hospital that is dedicated to investing in its patients’ future.</p>
<p>“When you come to SHN, you feel the compassion and the genuine care,” he shared. “The staff, the equipment, the environment—it all makes a difference. I’m grateful to be receiving my treatment here.”</p>
<p>As SHN continues to Build It Forward, stories like Scott’s demonstrate how investments in modern facilities, innovative technology, and patient-centred care can help patients not only receive treatment, but live more fully beyond it.</p>
<p>The post <a href="https://www.hospitalnews.com/doing-more-with-dialysis-a-renewed-patient-experience/">Doing more with dialysis: A renewed patient experience</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Canada can further develop its biotech talent</title>
<link>https://edusehat.com/en/how-canada-can-further-develop-its-biotech-talent</link>
<guid>https://edusehat.com/en/how-canada-can-further-develop-its-biotech-talent</guid>
<description><![CDATA[ HN Summary • Canada produces strong scientific talent but needs more workers with practical experience in biotech manufacturing, clinical trials, regulation and commercialization. • Hands-on training, active research facilities and opportunities within growing Canadian companies help turn academic expertise into industry skills. • Keeping companies and development work in Canada allows experienced talent to support […]
The post How Canada can further develop its biotech talent appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/shutterstock_2847245267.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 23:55:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Canada, can, further, develop, its, biotech, talent</media:keywords>
<content:encoded><![CDATA[<p>HN Summary</p>
<p>• Canada produces strong scientific talent but needs more workers with practical experience in biotech manufacturing, clinical trials, regulation and commercialization.</p>
<p>• Hands-on training, active research facilities and opportunities within growing Canadian companies help turn academic expertise into industry skills.</p>
<p>• Keeping companies and development work in Canada allows experienced talent to support future ventures, strengthening a sustainable biotech ecosystem.</p>
<hr>
<p>Canada’s biotech sector continues to produce promising therapies, medical technologies and transformative research. The past 12 months alone have seen breakthroughs from Toronto’s AmacaThera, which licensed its drug delivery solution to global pharma firm Pacira; Calgary’s Providence Therapeutics, which launched a major clinical trial for its personalized pediatric cancer vaccine in Australia; and Vancouver’s AbCellera, which published Phase 2 trial results for its potentially game-changing treatment for menopause-related hot flashes. In recent years, federal and provincial governments have also invested billions of dollars in new research facilities and biomanufacturing infrastructure to strengthen the country’s life sciences ecosystem. Yet, as more companies look to scale, many encounter the same challenge: finding people who have done it before.</p>
<p>“We need people who have been there and done that, and have had success with entrepreneurship,” says Scott Bratman, co-founder of Adela, which is developing novel cancer detection tools, and an associate professor of medical biophysics at the University of Toronto. “Success breeds further success.” <span class="Apple-converted-space"> </span></p>
<p>That gap extends well beyond the C suite. Companies need scientists who understand how to translate discoveries into products, specialists who can operate in regulated environments, teams that have taken therapies through clinical trials and manufacturing experts who know how to scale production. They also need executives who have raised capital, navigated regulatory approvals and brought technologies to market. Those skills are built through experience. Canada has many of the ingredients needed to develop that workforce, including exceptional scientific talent, new infrastructure and a growing base of biotech companies. The challenge is creating enough opportunities for people to put those assets to work, learn by doing and carry that experience from one company to the next. <span class="Apple-converted-space"> </span></p>
<p>When a company scales, it does more than just commercialize a new technology — it invests resources into developing talent whose knowledge and skills strengthen the next generation of companies. For Canada, the biggest question is how to ensure the ecosystem has all the necessary components to facilitate this process.<span class="Apple-converted-space"> </span></p>
<h3><strong>Turning scientific excellence into industry experience</strong></h3>
<p>Canada’s biotech talent challenge has often been framed as a brain drain problem. The country recently came fifth globally for higher education; the University of Toronto was ranked the 7th best institution in the world for human biological sciences and the 11th for medical technology programs. The prevailing assumption has been that our universities produce exceptional scientists — but we inevitably lose them to better opportunities elsewhere. While that may have been a worrisome trend in the past, it’s no longer a given. Indeed, according to a StatsCan report from 2025, 89 percent of the 2015–2020 cohort of graduates from Canadian STEM programs were filing taxes in Canada three years later.</p>
<p>It has also been generally assumed that Canada’s strength in producing exceptional scientists should naturally translate into strength in biotechnology. “There is really strong access to talent, especially on the early research and development side,” says Bharat Srinivasa, co-founder and partner at Amplitude, a venture capital firm with a focus on funding precision medicine. But graduating talented scientists is not the same as building biotech talent. “The average student that comes out of a STEM program is not ready to walk into a biomanufacturing and GMP facility and actually work from day one,” says Maura Campbell, president and CEO of the not-for-profit organization OBIO, which supports the growth of early-stage life sciences ventures. “We aren’t training people sufficiently.”</p>
<p>Life sciences graduates recognize that scientific expertise requires continued training and specialization. The same thinking must extend beyond academia and into industry. Knowing the science is one thing; learning how to scale a process, manufacture under regulated conditions or prepare a therapy for clinical use requires a different set of skills, many of which can only be developed through hands-on experience. As OBIO’s Campbell points out, although students would greatly benefit from working on state-of-the-art equipment, universities typically lack the infrastructure, expertise and facilities to provide that option.</p>
<p>That is the gap organizations such as the Canadian Alliance for Skills and Training in Life Sciences (CASTL) are working to address. Through partnerships with academic institutions, industry stakeholders and government agencies, CASTL offers specialized training modules, hands-on laboratory experiences and certification programs designed to align with current industry standards. These programs aim to bridge the gap between academic education and industry requirements, ensuring that graduates are job-ready and that existing professionals can upskill to meet evolving demands.<span class="Apple-converted-space"> </span></p>
<p>“Hands-on training is a key component of success,” says Sidney Reid, CEO of CASTL. “It gives people a safe place to take risks and make mistakes, because doing is such an important part of competency development.”</p>
<p>CASTL has achieved significant milestones in strengthening Canada’s biomanufacturing workforce through hands-on training, strategic partnerships and national expansion. Through one recent national reskilling program, CASTL trained more than 425 people across Canada, helping people without industry experience develop the skills needed to enter the sector.</p>
<p>But that kind of training requires both infrastructure and sustained investment. Workers cannot develop manufacturing expertise without access to manufacturing facilities and equipment. Scientists cannot build preclinical experience without laboratories and projects to work on. Clinical expertise develops through running clinical trials. Contract Research Organizations (CROs) give specialized teams the opportunity to perform similar work repeatedly across different companies and technologies.</p>
<p>That means Canada’s infrastructure gaps are also talent gaps. When preclinical work is outsourced to CROs abroad, for example, along with missing out on economic activity, the country loses the workforce training and technical expertise that come as a result of doing that work. In this context, infrastructure isn’t just about buildings and equipment — it also encompasses the places and pathways where people learn.<span class="Apple-converted-space"> </span></p>
<h3><strong>Successful companies are<span class="Apple-converted-space"> </span>Canada’s best talent program</strong></h3>
<p>Universities provide a solid scientific foundation, but biotech companies are the real-world classrooms where scientists, operators and entrepreneurs learn how to move a discovery through development, navigate regulatory requirements, raise capital, scale manufacturing and ultimately bring a therapy to patients.</p>
<p>For Molly Shoichet, a professor in U of T’s department of biomedical engineering<span class="Apple-converted-space">  </span>and founder of AmacaThera, the value of real-world experience has become increasingly clear over time. “My second company benefits so much from the first,” she says. Shoichet’s team had already navigated many of the scientific, regulatory and commercial decisions every young biotech company faces, allowing them to move “10 times faster” the second time around as a result, she says.<span class="Apple-converted-space"> </span></p>
<p>Former InBC Investment Corp. CEO Jill Earthy has witnessed a similar phenomenon in the British Columbia life sciences ecosystem. Established companies such as STEMCELL Technologies (founded in 1993), Zymeworks (founded in 2003) and AbCellera (founded in 2012) have become training grounds for people who can carry their experience into the next generation of ventures. STEMCELL, for instance, provides opportunities for a steady stream of UBC co-op students and grads; Zymeworks co-founder Ali Tehrani is now a venture partner at Amplitude, where he shares his previous learnings to help guide other founders. Over time, that movement creates a deeper pool of people who know how to build and scale biotech companies.</p>
<p>Amplitude’s Bharat Srinivasa describes the cycle this way: “Those companies generated capital and made money that allowed talent and capital to recycle. Experienced entrepreneurs, managers and teams could then go and build bigger, stronger companies.”</p>
<p>This is why it’s critical to keep scaling companies in Canada. “When companies are acquired or scale elsewhere, we don’t just lose the company,” says Jason Field, president and CEO of Life Sciences Ontario. “We lose the talent, the expertise and the experience that would have helped build the next generation.”</p>
<h3><strong>Talent is the outcome of a healthy ecosystem</strong></h3>
<p>Leaders across biotech often talk about creating an environment where experienced CEOs can take a risk on a startup knowing there will be another opportunity if it fails. The same principle needs to apply across the biotech workforce.</p>
<p>A scientist needs to see a pipeline of companies where they can build a career. A CRO needs a steady flow of ventures conducting research here so it can employ and develop specialized staff. Manufacturing talent needs facilities that are not simply built, but consistently used, allowing workers to accumulate experience in process development, quality and GMP manufacturing. The same is true for clinical trials, regulatory expertise and every other part of the development pathway.</p>
<p>That does not mean every company needs to become a global success or remain independent forever. “Even if a company stays for only 10 years, it makes a real difference for those 10 years,” says Molly Shoichet.</p>
<p>The key is cultivating enough activity across the system that the closure of a single company does not signal the end of someone’s career in Canadian biotech. The feedback loop must extend from the lab bench to the C-suite, with a critical mass of ventures progressing through different stages to ensure that people keep working, infrastructure is maintained and expertise accumulates.</p>
<p>Ultimately, Canada’s greatest competitive advantage won’t be found in the number of startups it creates, but rather in its ability to create a thriving, self-sustaining ecosystem where knowledge, talent and infrastructure are continuously shared and reinforced.</p>
<p><b>By Sana Maqbool</b><b></b></p>
<p><i>Hospital News has partnered with MaRS Discovery District to highlight Canadian innovations in health and life sciences.</i><span class="Apple-converted-space"> </span></p>
<p>The post <a href="https://www.hospitalnews.com/how-canada-can-further-develop-its-biotech-talent/">How Canada can further develop its biotech talent</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Why PAD monitoring needs a real&#45;time view of blood flow between visits</title>
<link>https://edusehat.com/en/why-pad-monitoring-needs-a-real-time-view-of-blood-flow-between-visits</link>
<guid>https://edusehat.com/en/why-pad-monitoring-needs-a-real-time-view-of-blood-flow-between-visits</guid>
<description><![CDATA[ HN Summary • PAD can cause serious complications, and recurrent artery narrowing after treatment makes ongoing monitoring important to protect patients’ limbs. •Current surveillance provides snapshots during scheduled visits, leaving gaps when blood flow may decline unnoticed. •Emerging portable technologies could enable more frequent tissue blood-flow monitoring, but research is needed to establish their effectiveness […]
The post Why PAD monitoring needs a real-time view of blood flow between visits appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/shutterstock_2365447841-e1793289812218.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 23:55:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Why, PAD, monitoring, needs, real-time, view, blood, flow, between, visits</media:keywords>
<content:encoded><![CDATA[<p><strong>HN Summary</strong></p>
<p>• PAD can cause serious complications, and recurrent artery narrowing after treatment makes ongoing monitoring important to protect patients’ limbs.</p>
<p>•Current surveillance provides snapshots during scheduled visits, leaving gaps when blood flow may decline unnoticed.</p>
<p>•Emerging portable technologies could enable more frequent tissue blood-flow monitoring, but research is needed to establish their effectiveness and impact on PAD outcomes.</p>
<hr>
<p>An estimated 800,000 Canadians are living with peripheral artery disease (PAD), though some experts say the true number is likely higher. PAD causes reduced blood flow to the legs, resulting from atherosclerosis narrowing the arteries and limiting the oxygen that reaches muscles and tissue. As the disease progresses, poor circulation can lead to pain at rest, wounds that won’t heal and, in the most severe cases, amputation. Each year in Canada, roughly 7,720 lower-limb amputations are performed in adults with diabetes, of whom 86% also have a documented PAD diagnosis. Because the plaque behind PAD is usually present elsewhere in the body as well, people with the condition also face a higher risk of heart attack and stroke.</p>
<p>Treatment for PAD begins with managing the disease and its risk factors, typically through smoking cessation, structured exercise, and medications that lower cholesterol, control blood pressure and blood sugar, and reduce the risk of blood clots. When those fail to control symptoms, or when a limb is at risk, revascularization becomes the next step, and endovascular approaches are now first-line for many patients.<span class="Apple-converted-space"> </span></p>
<p>Because the underlying atherosclerosis remains after the procedure, restenosis is the main threat to long-term durability, with one-year rates as high as 30% to 60% reported in patients with chronic limb-threatening ischemia. Post-procedure monitoring after revascularization gives clinicians the chance to catch recurrent narrowing and reintervene before the vessel occludes. However, the tools used to monitor blood flow after treatment have not kept pace with treatment options. Emerging technologies that measure tissue perfusion directly could give clinicians more information between scheduled visits, and research now underway will help determine how that information should guide care.</p>
<h3><strong>Current tools for<span class="Apple-converted-space"> </span>post-procedure monitoring</strong></h3>
<p>Surveillance after revascularization typically relies on some combination of clinical assessment, the ankle-brachial index (ABI), and arterial duplex ultrasound. The ABI is inexpensive and easy to perform in an office, while duplex offers detailed imaging of the treated segment and is the most accurate noninvasive option. Practice varies widely, in part because clinical guidelines consider the effectiveness of routine surveillance in asymptomatic patients uncertain. Canadian data on PAD care are limited, but U.S. figures point to a significant shortfall. In an analysis using historical data of more than 1.4 million Medicare patients who underwent lower extremity bypass or peripheral vascular intervention, just over half received any follow-up imaging within a year of their procedure.<span class="Apple-converted-space"> </span></p>
<p>Even when patients do return for follow-up, the tools differ considerably in what they catch. A 2024 systematic review of surveillance after femoropopliteal endovascular treatment found that the ABI detected restenosis with a sensitivity of 55% to 67% and clinical follow-up with a sensitivity of 52% to 64%, meaning either approach on its own can miss a third to nearly half of recurrent lesions. Duplex, which shows blood flow through the treated segment in real time, performed far better, reaching 91% sensitivity and 100% specificity in the one study the review identified, but it requires a vascular lab, a trained sonographer, and a scheduled visit. Those requirements limit how often it can be repeated and tie surveillance to patients keeping their appointments, leaving long stretches between visits when restenosis can develop unobserved.</p>
<h3><strong>How advanced monitoring benefits pad patients</strong></h3>
<p>Nearly every tool used after revascularization captures perfusion at a single point in time during a scheduled visit. Continuous or more frequent monitoring could track perfusion between appointments and flag a decline that might otherwise go unnoticed until symptoms return, much as remote monitoring of heart rhythm and blood glucose lets clinicians act on trends in other chronic conditions. Because perfusion measurements assess circulation in the tissue, they could help support a combined diagnostic alongside imaging of the treated artery. While research in PAD is still early, investigators are testing the feasibility of optical techniques such as laser speckle contrast imaging to measure perfusion around revascularization.</p>
<p>Portable blood flow technology is also being studied in stroke, a condition closely linked to PAD because the same atherosclerosis often affects other arteries. In a 2024 study of 135 patients evaluated for suspected stroke, an algorithm based on scans from a portable optical blood flow monitor detected large vessel occlusion with 79% sensitivity after a 70-second scan, compared with 60% and 50% for two stroke scales commonly used by emergency medical services. The study shows how a compact device could potentially measure blood flow directly without a vascular lab or imaging suite, making more frequent monitoring accessible to more patients.</p>
<h3><strong>Building the evidence for better pad monitoring</strong></h3>
<p>While blood flow restoration techniques have advanced to support more patients with PAD, the monitoring they receive after a procedure has remained relatively unchanged. Restenosis remains common, surveillance practices vary widely, and the tools in routine use capture only occasional snapshots of a process that unfolds gradually between visits.<span class="Apple-converted-space"> </span></p>
<p>Other areas of chronic disease care suggest a better path. In conditions such as heart failure and diabetes, direct monitoring gives clinicians a steadier stream of data and has allowed them to recognize problems earlier and adjust treatment before patients deteriorate. There is good reason to believe PAD patients could benefit in a similar way, particularly those with diabetes, kidney disease, or limb-threatening disease, for whom a missed restenosis carries the greatest consequences. Research on post-procedure monitoring in PAD, including studies that compare monitoring approaches and measure their effect on limb outcomes, would give vascular specialists a clearer picture of how to protect the results of revascularization long after patients leave the procedure room.</p>
<p>The post <a href="https://www.hospitalnews.com/why-pad-monitoring-needs-a-real-time-view-of-blood-flow-between-visits/">Why PAD monitoring needs a real-time view of blood flow between visits</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Tiny snake&#45;like robot could transform sinus surgery</title>
<link>https://edusehat.com/en/tiny-snake-like-robot-could-transform-sinus-surgery</link>
<guid>https://edusehat.com/en/tiny-snake-like-robot-could-transform-sinus-surgery</guid>
<description><![CDATA[ When developing a miniature robot for sinus surgery, a team of Hamilton doctors and innovators looked to nature for inspiration. The result is a micro-sized, snake-like robot they’re developing that’s remotely maneuvered up a patient’s nose and through intricate pathways to reach the sinuses, much like a snake weaves through underground tunnels. Team member Dr. […]
The post Tiny snake-like robot could transform sinus surgery appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 23:55:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Tiny, snake-like, robot, could, transform, sinus, surgery</media:keywords>
<content:encoded><![CDATA[<p>When developing a miniature robot for sinus surgery, a team of Hamilton doctors and innovators looked to nature for inspiration. The result is a micro-sized, snake-like robot they’re developing that’s remotely maneuvered up a patient’s nose and through intricate pathways to reach the sinuses, much like a snake weaves through underground tunnels.</p>
<p>Team member Dr. Sarah Khalife – a Hamilton Health Sciences (HHS) otolaryngologist — received an HHS DRIVE SPARK grant to support the development of the SMART-ENT surgical robot, aimed at making sinus surgery less invasive and more precise.</p>
<p>Otolaryngologists treat problems involving the ears, nose, throat, head and neck. Khalife subspecializes in rhinology and skull base surgery, focused on surgery treating conditions of the nose, sinuses and skull base using cameras through the nose.</p>
<p>HHS DRIVE SPARK awards celebrate early-stage, high-potential ideas that are igniting change across the hospital system with grants up to $50,000 to support bringing promising innovations to life.</p>
<h3><strong>A nose for innovation</strong></h3>
<p>The SMART-ENT prototype device is just three millimetres in diameter, about the same thickness as a cell phone charging cord. Khalife is developing this innovation in partnership with Dr. Onaizah Onaizah, a mechanical engineer who leads a McMaster University lab specializing in making tiny, millimetre-scale robotic tools for health care; Dr. Benjamin van der Woerd, an otolaryngologist subspecializing in laryngology at St. Joseph’s Healthcare Hamilton; and Dr. Crystal Fong, a neuroradiologist at HHS’ Hamilton General Hospital specializing in using medical imaging like MRI and CT scans to find and diagnose problems affecting the head, neck and spine. Fong is also an associate professor at McMaster University, and Khalife, Onaizah and van der Woerd are assistant professors. Another key team member at the forefront of research and development is Griffin Smith, a biomedical engineering master’s graduate.</p>
<p>“McMaster is our academic partner, and this innovation is a great example of what’s possible when our researchers and innovators collaborate on projects,” says Dr. Marc Jeschke, HHS’ vice president of research and innovation, and chief scientific officer. “By combining our expertise, we’re turning great ideas into innovations that have the potential to make a real difference in health care.”</p>
<figure aria-describedby="caption-attachment-146737" class="wp-caption alignnone"><img decoding="async" class=" wp-image-146737" src="https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2-1024x683.jpg" alt="" width="815" height="543" srcset="https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2-1024x683.jpg 1024w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2-400x267.jpg 400w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2-768x512.jpg 768w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2-1536x1024.jpg 1536w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2-630x420.jpg 630w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2-150x100.jpg 150w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2-300x200.jpg 300w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2-696x464.jpg 696w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2-1068x712.jpg 1068w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2.jpg 1800w" sizes="(max-width: 815px) 100vw, 815px"><figcaption class="wp-caption-text">Left to right: Griffin Smith, Dr. Onaizah Onaizah, Dr. Benjamin van der Woerd, and Dr. Sarah Khalife.</figcaption></figure>
<h3><strong>A maze of narrow passages</strong></h3>
<p>The sinuses are a network of air-filled bony spaces tucked inside the skull, connected to the nasal cavity by narrow, intricate passageways. These small openings allow mucus to drain and air to circulate. People have eight sinuses, four on each side of the face, and each is unique in size and shape.</p>
<p>For endoscopic sinus surgeries, doctors use a high-definition monitor and sinus CT scan for a precise map to guide them, as they clear out blocked pathways so sinuses can drain and the patient can breathe normally again.</p>
<p>This is done using a tiny camera and specialized instruments that are long and thin with different angles, so they can access the sinus area through the nose. But these tools are also straight and rigid, with several used at once to perform procedures.</p>
<p>“While considered minimally invasive, it can be challenging to navigate the different angles and narrow network of passageways to reach hard-to-access areas with these tools,” says Khalife, adding these instruments are standard in Canada and worldwide.</p>
<p>“Our surgical robot will be much smaller, less invasive and easier to maneuver.”</p>
<h3><strong>Inspired by nature</strong></h3>
<p>When imagining a better way, the team turned to nature, drawing on how snakes slither through underground tunnel systems, elephants deftly move their trunks and octopus tentacles bend, twist and reach into tight spaces.</p>
<p>“Nature has spent millions of years finding ingenious ways to navigate challenging environments and reach places that seem almost impossible to get to,” says Onaizah. “We wanted to learn from those remarkable designs and bring that ingenuity into the operating room.”</p>
<h3><strong>A better way</strong></h3>
<p>The SMART-ENT surgical robot features a single, thin piece of flexible tubing that houses multiple built-in channels so several tasks can be performed at the same time. The tube can accommodate specialized ports for suctioning fluids, delivering medication and cleaning the area. It also includes an LED light and a tiny camera, about the size of a grain of table salt, at the very tip to help the doctor see clearly, alongside a treatment laser to precisely target tissue.</p>
<p>“Our goal is to automate the tool by using a patient’s CT scan as a digital map to guide it safely through the nose and sinus area remotely,” says Khalife.</p>
<p>By applying a controlled magnetic field, a computer can precisely steer the tiny tube around tight corners and into hard-to-reach locations automatically.</p>
<p>“This tool also has the potential to be used in other types of surgeries, where doctors are operating on small, intricate, hard-to-reach areas,” adds Khalife.</p>
<h3><strong>Investing in HHS innovators</strong></h3>
<p>DRIVE SPARK funding will be used to help further develop this tool, with the goal of getting all the approvals in place for a clinical trial to test it in surgeries, down the road.</p>
<p>“This funding allows us to take an idea from the clinical setting and develop it into something that could have a meaningful impact,” says Khalife.</p>
<p>The post <a href="https://www.hospitalnews.com/tiny-snake-like-robot-could-transform-sinus-surgery/">Tiny snake-like robot could transform sinus surgery</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Drones could cut travel delays and reduce spoilage of donated blood</title>
<link>https://edusehat.com/en/drones-could-cut-travel-delays-and-reduce-spoilage-of-donated-blood</link>
<guid>https://edusehat.com/en/drones-could-cut-travel-delays-and-reduce-spoilage-of-donated-blood</guid>
<description><![CDATA[ Delivering blood from collection sites to labs is a fast-paced, labour-intensive process. Donated blood can deteriorate within a few hours at room temperature, leaving little room to manoeuvre in case of unexpected traffic congestion or other delays between collection sites and blood centres. But if you can’t get through traffic, you can go over it, […]
The post Drones could cut travel delays and reduce spoilage of donated blood appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Drones.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 23:55:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Drones, could, cut, travel, delays, and, reduce, spoilage, donated, blood</media:keywords>
<content:encoded><![CDATA[<p>Delivering blood from collection sites to labs is a fast-paced, labour-intensive process. Donated blood can deteriorate within a few hours at room temperature, leaving little room to manoeuvre in case of unexpected traffic congestion or other delays between collection sites and blood centres.</p>
<p>But if you can’t get through traffic, you can go over it, thanks to drone technology.</p>
<p>In a study published in the journal Computers & Operations Research, Concordia PhD candidate Amirhossein Abbaszadeh and Hossein Hashemi Doulabi, an associate professor in the Department of Mechanical, Industrial and Aerospace Engineering, present a new optimization model that uses drones to support mobile blood donation vehicles (“bloodmobiles”). The model offers a faster, more efficient and more reliable way to transport donated blood in cities.</p>
<h3><strong>Powered by smart logistics</strong></h3>
<p>The researchers’ Drone-Aided Mobile Blood Collection Problem is the first integrated framework that coordinates the movements of both bloodmobiles and drones to preserve blood freshness and improve overall system performance.</p>
<p>At its heart is a smart logistics system where bloodmobiles travel to multiple collection sites while drones shuttle between them and a central blood centre. This method eliminates delays caused by traffic and ensures that freshly donated blood reaches the blood centre quickly for processing into its components — such as platelets, which must be separated within six hours.</p>
<p>The researchers achieved this by developing a mixed-integer linear programming model that synchronizes the routes, schedules and collection activities of both bloodmobiles and drones. Because such a large-scale optimization problem is computationally demanding, the team also designed a rolling-horizon-based matheuristic algorithm. This type of algorithm breaks the problem into smaller, more manageable parts, solving sequentially while simultaneously exploring nearby alternatives to find better ones.</p>
<p>“Vehicle routing problems are not new to operations research, but the perishability of blood brings a time-sensitive challenge that changes how routes must be planned,” says Abbaszadeh. “That’s when I thought of using drones.”</p>
<h3><strong>Cross-town coordination</strong></h3>
<p>Unlike previous studies that treated bloodmobiles and drones as separate systems, this work fully integrates their operations. Drones can take off from, land on or travel aboard bloodmobiles, allowing flexible coordination across multiple collection points without fixed infrastructure.</p>
<p>The model also considers the age of the blood — the time elapsed since donation — as a key optimization factor, rewarding fresher blood deliveries to ensure quality.</p>
<h3><strong>Putting the model to the test</strong></h3>
<p>The researchers used Quebec City as a real-world case study to test their model. They identified 13 potential collection sites, estimated the number of potential donors at each site and calculated the distance to the nearest blood centre.</p>
<p>“We used Google Maps to calculate the road distance and the most direct flight path since drones don’t need to use roads,” explains Abbaszadeh.</p>
<p>“We performed several analyses using different parameters: What if we used drones that had more load capacity, higher battery capacity or moved at higher speeds? We then compared the drone-aided system to the bloodmobile-only system.”</p>
<p>They found that adding drones to the blood collection fleet significantly reduced transport times. It also increased hourly delivery rates and maintained better consistency in blood freshness.</p>
<p>The authors write that their findings demonstrate the real potential of drone-assisted logistics in healthcare supply chains, particularly in time-critical operations like blood collection. They add that their framework could be adapted to other humanitarian or medical delivery contexts where speed, coordination and freshness are essential.</p>
<p>Read the cited paper: “Drone-Aided Mobile Blood Collection Problem”</p>
<p>The post <a href="https://www.hospitalnews.com/drones-could-cut-travel-delays-and-reduce-spoilage-of-donated-blood/">Drones could cut travel delays and reduce spoilage of donated blood</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Behind the diagnosis: Supporting patients living with dementia</title>
<link>https://edusehat.com/en/behind-the-diagnosis-supporting-patients-living-with-dementia</link>
<guid>https://edusehat.com/en/behind-the-diagnosis-supporting-patients-living-with-dementia</guid>
<description><![CDATA[ HN Summary • Unity Health Toronto takes a person-centred approach to dementia care, recognizing each patient’s history, relationships, routines and preferences.  • Hospital teams use reorientation, personalized music and “My Story” profiles to support engagement, comfort and independence. • Community and long-term care programs offer tailored activities and family support, helping maintain connection as care […]
The post Behind the diagnosis: Supporting patients living with dementia appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Dementia.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 23:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Behind, the, diagnosis:, Supporting, patients, living, with, dementia</media:keywords>
<content:encoded><![CDATA[<p><strong>HN Summary</strong></p>
<p>• Unity Health Toronto takes a person-centred approach to dementia care, recognizing each patient’s history, relationships, routines and preferences.<span class="Apple-converted-space"> </span></p>
<p>• Hospital teams use reorientation, personalized music and “My Story” profiles to support engagement, comfort and independence.</p>
<p>• Community and long-term care programs offer tailored activities and family support, helping maintain connection as care needs change.</p>
<hr>
<p>For people living with dementia or other memory-related conditions, care can look different depending on where they are in their journey. Whether in a hospital setting or long-term care, care teams from across Unity Health Toronto stress the importance of seeing the person behind the diagnosis. They recognize that each patient or resident has life experiences and relationships built outside of their care setting, as well as routines that help them feel safe and comfortable.</p>
<p>Specialized memory care services are available in hospital, in the community and in long-term care. At Providence Healthcare, for example, the Adult Day Program (ADP) supports people living in the community with moderate to severe dementia through social programming designed around their individual needs. The program also provides support for families and caregivers.</p>
<p>As needs change over time, patients can move between care settings. Someone who first received care at St. Michael’s Hospital may later access rehabilitation, community programs or long-term care at Providence Healthcare. This connected approach helps ensure patients and families can access the right care at the time they need it.</p>
<figure aria-describedby="caption-attachment-146757" class="wp-caption alignnone"><img fetchpriority="high" decoding="async" class="size-full wp-image-146757" src="https://www.hospitalnews.com/wp-content/uploads/2026/10/Dementia-2.png" alt="" width="936" height="702" srcset="https://www.hospitalnews.com/wp-content/uploads/2026/10/Dementia-2.png 936w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Dementia-2-400x300.png 400w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Dementia-2-768x576.png 768w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Dementia-2-560x420.png 560w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Dementia-2-80x60.png 80w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Dementia-2-150x113.png 150w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Dementia-2-300x225.png 300w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Dementia-2-696x522.png 696w" sizes="(max-width: 936px) 100vw, 936px"><figcaption class="wp-caption-text">ACE volunteers cart stocked with “Music Connections” equipment, activities and reminiscence materials to help engage patients and encourage conversation.</figcaption></figure>
<h3><strong>Supporting memory care in acute care</strong></h3>
<p>At St. Michael’s Hospital, occupational therapists Lisa Vandewater and Paula Isenberg work as part of the geriatrics team on the Acute Care of the Elderly (ACE) Unit. The team works with patients over 65 years old who often have complex geriatric syndromes, a term used to describe common age-related health challenges such as falls, dementia, delirium and difficulties managing daily life independently.</p>
<p>Vandewater and Isenberg assess patients’ cognitive function and safety, helping determine whether they can safely return home or if they require additional care. During a patient’s stay, they work to help them with confusion and dementia by doing simple things like reminding them where they are and regularly working to talk through the date and mark the passing of days on the calendar. This helps patients to stay oriented as long stays in hospital can affect a person’s sense of routine.</p>
<p>Vandewater says hospitalization can be especially difficult for someone living with dementia. Loved ones may not always be present, and an unfamiliar environment can increase confusion and anxiety. Programs such as the ACE volunteer program help to support reorientation and cognitive stimulation. In hospital, patients often have many daily tasks done for them, but for people living with dementia, opportunities to stay engaged and mentally active are important to maintaining function and independence.</p>
<p>The ACE volunteers also help patients complete “My Story,” a person-centred information sheet posted above a patient’s bed, that captures details about their life. A patient’s profile might include information about what they like to be called, who matters to them, what they enjoy and what helps them feel calm. “My Story” allows staff and volunteers to have a basic overview of who the patient is outside of the hospital and encourages patients to reminisce and stay mentally active.</p>
<p>The unit is also piloting “Music Connections”, a program which gives patients access to personalized playlists of familiar music.</p>
<p>“What’s interesting for individuals with dementia, particularly Alzheimer’s disease, is that the part of their brain that houses musical memories is fairly well preserved,” Vandewater says. “I was recently working with someone who loved the Bee Gees, and when one of their songs came on, they lit up and said, ‘Oh, look, I can still groove,’ and she started dancing away.”</p>
<p>For Isenberg, moments like these reflect the importance of looking beyond a patient’s immediate medical needs. Person-centred care recognizes that a person is more than a blood test or an X-ray. There’s a whole life and story behind who they are.</p>
<h3><strong>Creating connection in long-term care</strong></h3>
<p>At the Houses of Providence, Unity Health’s long-term care home at Providence Healthcare in Toronto’s east end, memory care takes place in a different setting: one where residents live, build relationships and settle into daily routines.</p>
<p>On the secured unit, staff support residents, often with memory-related conditions, who may become disoriented or wander. The unit gives residents the freedom to move about safely while reducing the risk of getting hurt or lost.</p>
<p>On the floor of the unit, Activation Assistants Sheri-Lynn Barton and Trexie Yntig shape days around movement, music, spiritual care, cultural celebrations and activities that reflect residents’ interests. Programs may include balloon tennis, mini bowling, karaoke, outdoor concerts and creative seasonal games.</p>
<p>Barton says flexibility is key. Some days residents are eager to join activities, while on others they need something quieter. The goal is to meet people where they are and create opportunities for joy and connection.</p>
<p>“This is what I am here to do. I work to bring the joy and fun into their daily lives,” Barton says. “Most of our residents can’t express it anymore, but you can see it in their faces, they’ll smile at you and clap along.”</p>
<p>Registered nurse Priyatharisini Gnanasekaran says building trust with residents and families is central to the work. Families often share important details about routines and cultural preferences that help residents feel at home.</p>
<p>“We care for the person, not just the diagnosis,” Gnanasekaran says. People living with dementia continue to experience emotion and connection even as memory and communication change.”</p>
<p>“The smallest moments of connection can make the biggest difference for people with dementia,” she adds.</p>
<p>For many residents, long-term care represents one stage in a broader care journey. Some may have previously accessed community-based supports, received care elsewhere or within Unity Health before arriving at the Houses of Providence. Across Unity Health Toronto, our commitment to person-centred care continues wherever the care journey leads.</p>
<p>The post <a href="https://www.hospitalnews.com/behind-the-diagnosis-supporting-patients-living-with-dementia/">Behind the diagnosis: Supporting patients living with dementia</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New Alzheimer’s treatments bring leading care closer to home for patients across southeastern Ontario</title>
<link>https://edusehat.com/en/new-alzheimers-treatments-bring-leading-care-closer-to-home-for-patients-across-southeastern-ontario</link>
<guid>https://edusehat.com/en/new-alzheimers-treatments-bring-leading-care-closer-to-home-for-patients-across-southeastern-ontario</guid>
<description><![CDATA[ Kingston Health Sciences Centre (KHSC) is expanding access to new treatments for Alzheimer’s disease, bringing emerging care closer to home for patients across southeastern Ontario who traditionally needed to travel to larger centres such as Toronto or Ottawa. These new disease-modifying treatments are designed to slow the progression of Alzheimer’s disease in eligible patients, with […]
The post New Alzheimer’s treatments bring leading care closer to home for patients across southeastern Ontario appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Kingston.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 23:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, Alzheimer’s, treatments, bring, leading, care, closer, home, for, patients, across, southeastern, Ontario</media:keywords>
<content:encoded><![CDATA[<p>Kingston Health Sciences Centre (KHSC) is expanding access to new treatments for Alzheimer’s disease, bringing emerging care closer to home for patients across southeastern Ontario who traditionally needed to travel to larger centres such as Toronto or Ottawa.</p>
<p>These new disease-modifying treatments are designed to slow the progression of Alzheimer’s disease in eligible patients, with the greatest benefit expected when treatment begins in the earlier stages of the disease.</p>
<p>Bram Fisher, who was diagnosed with Alzheimer’s several years ago, is one of the first patients in Canada to access these drugs. For him, the treatment means more time to remain independent and continue doing the things he enjoys — including playing music with the band, Old Gravel Road.</p>
<p>“I would say the progression has been fairly slow, and we’ve been pretty lucky,” says Bram. “I’m still able to do the things I enjoy — I play in the band; I go for walks and go for lunch with friends.”</p>
<p>Bram is now receiving one of the new Alzheimer’s drugs through KHSC’s cognitive neurology program under the care of memory disorders specialist Dr. Durjoy Lahiri who arrived at KHSC in June 2024.</p>
<p>“The idea is to slow down the disease, so patients remain independent for longer periods of time,” says Dr. Lahiri.</p>
<p>KHSC is among the first health sciences centres in Canada to begin offering access to these emerging treatments recently approved by Health Canada. Dr. Lahiri’s goal is to build a larger Alzheimer’s therapeutics program in Kingston that can serve patients from across the region.</p>
<p>“The goal is to build a modern treatment program right here in Kingston,” says Dr. Lahiri. “Kingston can function as the referral centre for the whole region outside of Toronto and Ottawa. We want to create a robust and scalable program.”</p>
<p>The program is expected to grow significantly as awareness of these treatments increases. Dr. Lahiri estimates that as many as 25 to 30 patients could be receiving infusions through KHSC within the next six-to-nine months, with the potential for that number to continue growing.</p>
<p>Early diagnosis will be critical to ensuring patients can benefit from these treatments. To support earlier diagnosis, KHSC has also developed a new blood test to diagnose Alzheimer’s disease early, with funding support from the University Hospitals Kingston Foundation (UHKF) and YGK Healthcare Champions.</p>
<p>“This is a very new development in the field. It’s cutting-edge clinical care,” says Dr. Lahiri. “The blood test will help quickly identify patients who may benefit from further assessment and consideration for disease-modifying treatment.”</p>
<p>For Bram’s partner, Bryn, the new treatment options are welcome as the couple navigates the realities of an Alzheimer’s diagnosis.</p>
<p>“Neither of us thought this is what we would be doing in our retirement years,” says Bryn. “It has been a bit of a challenge.”</p>
<p>For Bram, the ability to continue living his life as independently as possible is what matters most.</p>
<p>“It’s not a cure,” he says. “But I’m still able to do the things I enjoy, and I am happy about that.”</p>
<p>For patients like Bram these new treatments offer something deeply meaningful: more time to enjoy the moments that matter most, whether that’s making music, spending time with friends and loved ones, or maintaining independence for as long as possible.</p>
<p>The post <a href="https://www.hospitalnews.com/new-alzheimers-treatments-bring-leading-care-closer-to-home-for-patients-across-southeastern-ontario/">New Alzheimer’s treatments bring leading care closer to home for patients across southeastern Ontario</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Drug shortages: What, why, and how (Part 2 of 2)</title>
<link>https://edusehat.com/en/drug-shortages-what-why-and-how-part-2-of-2</link>
<guid>https://edusehat.com/en/drug-shortages-what-why-and-how-part-2-of-2</guid>
<description><![CDATA[ HN Summary • Drug shortages can compromise patient safety and access to treatment. Prolonged shortages can exhaust reserve supplies and alternatives, while switching medications may introduce dosing errors, adverse effects and higher costs, particularly when substitutes lack insurance coverage.  • Multiple supply pressures leave Canada vulnerable. Manufacturing problems, recalls, increased demand and shipping disruptions can […]
The post Drug shortages: What, why, and how (Part 2 of 2) appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/shutterstock_2670749007.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 23:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Drug, shortages:, What, why, and, how, Part</media:keywords>
<content:encoded><![CDATA[<p><strong>HN Summary</strong></p>
<p>• Drug shortages can compromise patient safety and access to treatment. Prolonged shortages can exhaust reserve supplies and alternatives, while switching medications may introduce dosing errors, adverse effects and higher costs, particularly when substitutes lack insurance coverage.<span class="Apple-converted-space"> </span></p>
<p>• Multiple supply pressures leave Canada vulnerable. Manufacturing problems, recalls, increased demand and shipping disruptions can trigger shortages. Canada’s small share of the global pharmaceutical market and reliance on imported drugs add to these challenges.</p>
<p>• Proactive coordination can help protect continuity of care. Governments, manufacturers, distributors and healthcare teams all have roles in managing shortages. Designated monitoring staff, standardized substitution protocols, shared supply information and clear patient education can reduce disruption and support safer care.</p>
<hr>
<h3><strong>What is a drug shortage?</strong></h3>
<p>A drug shortage occurs when there is not enough supply to meet its demand. In recent years, drug shortages have become a growing global public health concern, affecting patient care, healthcare providers, and the health care system. The impact of each drug shortage will vary based on factors, such as duration of the shortage, available alternatives or substitutions, and associated cost implications, etc.</p>
<p>In Canada, drug shortages last an average of several months. Extended duration of drug shortages could heighten the potential for patient harm as reserve stocks deplete, along with available therapeutic alternatives. Patients faced without a suitable alternative are disproportionately impacted compared to those with other therapeutic options. Despite the availability of alternatives, medication safety risks may still exist. Switching products, particularly when patients are not familiar with the alternative, and returning to the original product after the shortage is resolved, may pose risks or potential drug therapy problems, such as ineffective or duplicate therapies, dosing errors, or adverse drug events. Alternative options may also impose additional costs to patients and the healthcare system. Patients or institutions could face higher out-of-pocket costs if the available therapeutic alternative is not covered by the patients’ insurance plans or not listed in the hospital formulary, respectively. Consequently, drug shortages may exacerbate socioeconomic barriers for patients to access their medication(s).</p>
<h3><strong>Why do drug shortages occur?</strong></h3>
<p>Drug shortages can be caused by many reasons, for example, manufacturing or quality issues, unexpected increases in demand, reductions in supply, or fluctuations in both supply and demand, safety issues resulting in drug recalls, shipping delays or distribution problems, or drug discontinuation, etc.</p>
<p>Canada takes up about 2% of the global drug sales, a relatively small market of which most of the drugs are imported and likely sourced from a single supplier. This has led to Canada being prone to drug shortages. Readers can learn more about health product shortages in Canada by viewing a Government of Canada resource: “Building resilience: Health Canada’s plan to address health product shortages, 2024 to 2028”<span class="Apple-converted-space"> </span></p>
<h3><strong>How to address and/or<span class="Apple-converted-space"> </span>prevent drug shortages?</strong></h3>
<p>While Health Canada plays a key role in responding to drug shortages (e.g., by leveraging regulatory tools to allow more supplies, such as, importing foreign-authorized drugs), many other interested parties or stakeholders also help address and/or prevent drug shortages. They include:</p>
<p>• Provinces and territories – communicate and collaborate with hospitals, pharmacists, retailers, and distributors to manage supply of drugs;</p>
<p>• Manufacturers – mandatory reporting of anticipated and actual drug shortages and discontinuations of drugs to Health Canada. Increase production of drugs or expedite resupplies;</p>
<p>• Importers and distributors – manage and monitor inventory of drugs and expedite delivery of resupplies;</p>
<p>• Healthcare providers and patients – Readers can refer to the October 2026 issue – “Drug Shortages: How Pharmacists Can Help” where we shared what pharmacists and patients could do during drug shortages to support safe, equitable, and continuous care.</p>
<h3><strong>Steps Forward</strong></h3>
<p>Drug shortages can interrupt or disrupt workflow for pharmacists and other healthcare workers significantly and unexpectedly. Assigning designated individuals or personnels to monitor for drug shortages, developing standardized substitution protocols, triaging usage, sharing knowledge and supply information among institutions, providing education and actionable steps when drug shortage does occur can alleviate workplace stress and promote seamless continuity of safe and effective patient care.</p>
<p>By working proactively, establishing reporting and response protocol, and improving communication and transparency throughout the drug supply chain, the negative impacts of drug shortages could be mitigated. The Health Canada Infographic: Helping Canadians deal with drug shortages highlights valuable tips that everyone can help with drug shortages.</p>
<p>Olivia Mendicino and Taylor Monrad are PharmD students at the Leslie Dan Faculty of Pharmacy, University of Toronto; and Certina Ho is an Assistant Professor, Teaching Stream, at the Leslie Dan Faculty of Pharmacy and Department of Psychiatry, University of Toronto.</p>
<p>The post <a href="https://www.hospitalnews.com/drug-shortages-what-why-and-how-part-2-of-2/">Drug shortages: What, why, and how (Part 2 of 2)</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Scarborough Health Network a leader in preventing harm</title>
<link>https://edusehat.com/en/scarborough-health-network-a-leader-in-preventing-harm</link>
<guid>https://edusehat.com/en/scarborough-health-network-a-leader-in-preventing-harm</guid>
<description><![CDATA[ HN Summary • SHN recorded the lowest hospital harm rate among Ontario’s large community and teaching hospitals for the second consecutive year.•  • Its 2025–2026 rate was 1.9 affected patients per 100 hospitalizations, compared with the national hospital rate of 5.8. • Safety initiatives include tiered team huddles, delirium prevention and barcode medication scanning, supporting […]
The post Scarborough Health Network a leader in preventing harm appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/SHN.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 23:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Scarborough, Health, Network, leader, preventing, harm</media:keywords>
<content:encoded><![CDATA[<p><strong>HN Summary</strong></p>
<p>• SHN recorded the lowest hospital harm rate among Ontario’s large community and teaching hospitals for the second consecutive year.•<span class="Apple-converted-space"> </span></p>
<p>• Its 2025–2026 rate was 1.9 affected patients per 100 hospitalizations, compared with the national hospital rate of 5.8.</p>
<p>• Safety initiatives include tiered team huddles, delirium prevention and barcode medication scanning, supporting SHN’s goal of zero preventable harm.</p>
<hr>
<p>Scarborough Health Network (SHN) has achieved the lowest hospital harm rate among Ontario’s large community hospitals and teaching hospitals, leading both peer groups for the past two years. The result is based on the latest data from the Hospital Harm Project, a collaboration between the Canadian Institute for Health Information and Healthcare Excellence Canada, which measures unintended harm to inpatients that could potentially have been prevented through evidence-informed practices.</p>
<p>“Becoming Ontario’s safest hospital network for the second consecutive year is not by chance. It reflects what is possible when purpose, accountability, and continuous improvement are embedded across an organization. That’s what it means to be one of Canada’s top performing hospitals,” said David Graham, President and CEO.</p>
<p>The Hospital Harm Project tracks preventable harm in four areas: healthcare and medications, hospital-acquired infections, patient accidents, and procedures. The harm rate is the number of affected patients per 100 hospitalizations; a lower rate means safer care. For 2025-2026, SHN had a harm rate of 1.9, compared to the national large community hospital and teaching hospital rates of 5.2 and 6.7, respectively; and national hospital rate of 5.8. This means that patients experience harm at SHN between two to three times less than at comparative hospitals in Ontario and around the country.</p>
<p>SHN has achieved these leading harm rate results while responding to Scarborough’s rising healthcare demands, which are growing at a pace unmatched elsewhere in the province. Scarborough not only has one of Ontario’s most complex communities with a higher burden of chronic illness, it has also seen the fastest growth in emergency department visits among a population with more than 100,000 residents who do not have a family doctor.</p>
<p>“Despite the growing demands on our health network to meet our community’s needs, SHN has never compromised on our commitment to delivering exceptional quality care and patient safety. The plans we have put into action and practice are sustaining and making the difference,” said Graham.</p>
<p>“Today, we deliver more care at higher quality than any other hospital system in the province.”</p>
<p>Quality and Patient Safety is one of the key pillars of SHN’s Strategic Plan 2024–2029. This is further reinforced through clear targets in closely aligned corporate scorecard and Quality Improvement Plan, and performance is continually tracked from the frontline to the Board of Directors.</p>
<p>“Every patient deserves safe, high-quality care every time they come to SHN. Achieving the lowest harm rate in Ontario among large community and teaching hospitals for the last two years reflects the commitment of our teams to delivering evidence-informed care, continuously improving how we work, and placing patient safety at the centre of every decision,” said Glyn Boatswain, Executive Vice-President, Clinical Programs, and Chief Nursing and Allied Health Professionals Executive.</p>
<p>“This achievement belongs to our clinicians, professional staff, and support teams who work every day to prevent harm and improve patient experience. By listening to patients and families, learning from data and outcomes, and strengthening care practices across our organization, we are creating safer care for the diverse communities we serve in Scarborough and advancing our goal of zero preventable harm.”</p>
<p>Key priorities for ensuring safe patient care include establishing coordinated clinical practice, timely information, and reliable processes to prevent the occurrence of harm, such as pressure injuries, falls, and infections. One example is tiered huddles—brief, focused check-ins that occur at different levels of the organization—which create a structured, supportive way for healthcare teams to communicate. This helps to quickly escalate concerns about safety issues, and operational challenges, and drive quality improvements in real-time.</p>
<p>SHN’s delirium strategy also demonstrates how teams are addressing potential harm through prevention, early identification, and consistent care. Delirium prevention bundles, standardized assessments, and reduced use of benzodiazepines and sedatives help protect older adults from avoidable harm. Updated order sets, provider education, and patient resources also promote safer sleep and anxiety management during hospital stays. Additionally, SHN is part of a hospital-led research project on delirium that is exploring an AI-powered tool and electronic medical record data to identify high-risk patients who may benefit from targeted prevention strategies.</p>
<p>Another example of how SHN is leveraging technology is barcode medication administration scanning. Staff scan patient and medication barcodes with handheld devices to confirm the right patient, medication, dose, route, and timing, while automatically documenting each step in the patient’s electronic medical record through the Epic clinical information system. Together, this technology and standardized practice help reduce medication errors and support safer, more reliable care.</p>
<p>That commitment to leveraging technology to improve care and safety was recognized in August when the Healthcare Information and Management Systems Society awarded our organization Stage 7 of the Electronic Medical Record Adoption Model. The designation places SHN among the first large, multi-site hospital systems in Ontario to achieve the highest international benchmark for digital health excellence.</p>
<p>SHN’s focus on quality and safety has also been recognized through several national designations. In the summer of 2025, SHN achieved Quality Improvement Status as a Choosing Wisely Canada Hospital for reducing unnecessary tests and treatments and became the third organization in Canada recognized as an Age-Friendly Health System by the Institute for Healthcare Improvement for its system-wide commitment to compassionate, inclusive care for older adults. While achieving the lowest harm rate for the second year in a row marks an important milestone in delivering the safest care, SHN remains focused on the work ahead. This includes continuing to analyze performance data, share learnings across teams, and invest in practices and technologies that help prevent harm. The Love, Scarborough campaign helps accelerate this work by funding investments that enhance the exceptional quality care for our community. The goal is not simply to lead the province in safety, but to keep advancing toward zero preventable harm for every patient, every day.</p>
<p>The post <a href="https://www.hospitalnews.com/scarborough-health-network-a-leader-in-preventing-harm/">Scarborough Health Network a leader in preventing harm</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Glenrose patient and family advisor shares her journey to help others</title>
<link>https://edusehat.com/en/glenrose-patient-and-family-advisor-shares-her-journey-to-help-others</link>
<guid>https://edusehat.com/en/glenrose-patient-and-family-advisor-shares-her-journey-to-help-others</guid>
<description><![CDATA[ HN Summary • Former Glenrose rehabilitation patient Brittney Neunzig draws on her spinal cord injury experience to help improve care as a volunteer patient and family advisor. • She advises on hospital policies, programs and patient resources, helping embed patient and family perspectives in service design. • As a peer mentor, she supports newly injured […]
The post Glenrose patient and family advisor shares her journey to help others appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/AHS.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 23:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Glenrose, patient, and, family, advisor, shares, her, journey, help, others</media:keywords>
<content:encoded><![CDATA[<p><strong>HN Summary</strong></p>
<p>• Former Glenrose rehabilitation patient Brittney Neunzig draws on her spinal cord injury experience to help improve care as a volunteer patient and family advisor.</p>
<p>• She advises on hospital policies, programs and patient resources, helping embed patient and family perspectives in service design.</p>
<p>• As a peer mentor, she supports newly injured patients with community reintegration, sexual health and parenting from a wheelchair.</p>
<hr>
<p>Brittney Neunzig is no stranger to Glenrose Rehabilitation Hospital. At the age of 13, she underwent rehabilitation here after a snowmobile accident left her paralyzed. Twenty-six years later, as a volunteer, she’s starting her third year as a patient and family advisor at the hospital.</p>
<p>“I haven’t been a patient for a long time, but I’ve stayed closely connected to the Glenrose as a peer mentor for patients with spinal cord injuries,” she says. “I see a lot of great things happening there for patients, but I also see some gaps that need to be addressed.”</p>
<p>As a patient and family advisor, Neunzig helps improve the quality, safety and experience of healthcare programs and services by sharing her own experience and perspective with the goal of improving service delivery for other Glenrose patients and their families.</p>
<p>“I have a lot of knowledge to share around what does and doesn’t work for patients, from my own experience and through my peer mentor work, and I wanted to be able to lend my voice in ways that help improve things for others,” she says.</p>
<p>At Alberta Health Services (AHS), these volunteer roles play an important part in patient engagement —something that staff across the Glenrose take seriously.</p>
<p>“Patient and family advisors bring diverse patient, family or caregiver perspectives to current and future healthcare programs and services at our hospital,” says Amanda Proctor, staff liaison for the Glenrose Patient and Family Advisory Council (PFAC).</p>
<p>“Advisors share their experiences and provide their insight and ideas on policies, procedures, redesigns, projects and research that impact healthcare delivery.”</p>
<p>As part of her involvement with the Glenrose PFAC, Neunzig has been asked to consult on different projects and initiatives, such as new patient webpages, apps and resources, as well as programs and policies. She brings her experience as a pediatric patient to the table, as well as what she hears and sees as a peer mentor.</p>
<p>“At one point we did a consultation about what information and resources are important to send home with spinal cord injury patients and how to best structure it,” she says. “Anytime I can influence something related to spinal cord injuries, I’m proud of it. I’ve also consulted on how user-friendly news apps, websites or surveys are.”</p>
<p>Neunzig adds that, as an advisor, she’s here to offer her advice and experience to decision-makers within the hospital, and sometimes more broadly within AHS.</p>
<p>Proctor adds: “Getting these voices to the table is essential in ensuring that patients and families are represented in the design of services they receive. Advisors are engaged in projects early and often to ensure that projects can progress with patient and family voices embedded in every step of the process. Without these volunteers, we wouldn’t have the depth of wisdom to draw from on the projects we undertake.”</p>
<p>Neunzig says: “Healthcare is a team sport, and I think that patients and families need to feel empowered and like their voices are being heard in all of the systems they have to be in.”</p>
<p>In addition to being an advisor, Neunzig also supports other spinal cord injury patients as a peer mentor, something she’s been doing for many years. She also teaches classes related to sexual health and returning to the community to newly injured patients on unit 3B, which is home to the Adult Spinal Cord Injury and General Neurology Inpatient program.</p>
<p>“I’m a parent, so I get asked if I can come in and chat with others that might relate to my own experience,” she says. “There might be a mom on the unit, and I’ll come in and talk to them about things like strategies for parenting from a wheelchair. I like doing that, too.”</p>
<p>While many view volunteering as a way of “giving back” to the community, Neunzig feels she gets even more back.</p>
<p>“Honestly, the best part of volunteering is what other people are giving back to me,” she says.</p>
<p>“Learning about other peoples’ lived experiences has really allowed me to have more compassion and empathy for people who have other disabilities and better understand their own experiences. I feel like I’m growing as a person because I get to do this.”</p>
<p><i>By Katie McLaughlin</i></p>
<p>The post <a href="https://www.hospitalnews.com/glenrose-patient-and-family-advisor-shares-her-journey-to-help-others/">Glenrose patient and family advisor shares her journey to help others</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Could tiny DNA cages assist with oral tissue regeneration?</title>
<link>https://edusehat.com/en/could-tiny-dna-cages-assist-with-oral-tissue-regeneration</link>
<guid>https://edusehat.com/en/could-tiny-dna-cages-assist-with-oral-tissue-regeneration</guid>
<description><![CDATA[ Programmable DNA cages are being explored for their potential to promote oral tissue regeneration by breaking the cycle of oxidative stress and inflammation in oral diseases. Researchers at Sichuan University set out to find a solution to the harmful cycle of oral tissue damage whereby inflammation generates excessive reactive oxygen species (ROS), which further intensify… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/DNA_cage.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 20:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Could, tiny, DNA, cages, assist, with, oral, tissue, regeneration</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large is-resized"></figure>



<p><strong>Programmable DNA cages are being explored for their potential to promote oral tissue regeneration by breaking the cycle of oxidative stress and inflammation in oral diseases.</strong></p>



<p>Researchers at Sichuan University set out to find a solution to the harmful cycle of oral tissue damage whereby inflammation generates excessive reactive oxygen species (ROS), which further intensify inflammation and tissue destruction. They described this as a ‘vicious cycle of sustained immunological activation and severe oxidative stress’.</p>



<p>One potential solution investigated by the team is a ‘promising nanotechnology-based strategy’ that uses pyramid-shaped DNA structures to absorb the damaging ROS molecules and deliver repair-promoting medicines to a precise location. Allowing delivery of molecules such as RNAs, antioxidants and bioactive peptides moves the treatment beyond symptom control and towards active regeneration. </p>



<p>The programmable shape of the DNA cages also allows them to be adapted to a range of therapeutic applications including recovery from periodontal disease, oral submucous fibrosis and some forms of jaw osteonecrosis.</p>



<h2 class="wp-block-heading">Could DNA cages be incorporated into dental treatment?</h2>



<p>These findings were published in a review in <em>Oral Science and Homeostatic Medicine</em>, considering previous studies that have employed DNA cages. In some animal models, the structures have reduced inflammatory or oxidative markers and improved measures of wound healing or bone repair. </p>



<p>The authors note that translating their findings into patient care presents questions around long-term safety, how and when the nanostructures are cleared from the body, and whether they can be produced consistently for clinical use. </p>



<p>The review calls for more detailed studies of how the DNA cages behave inside living tissues, alongside disease-specific designs, reliable manufacturing and safety investigations.</p>



<p>The researchers concluded: ‘If these hurdles can be overcome, programmable DNA nanostructures may eventually provide a new way to treat inflammatory damage while helping oral tissues regenerate.’</p>



<p><a href="https://dentistry.co.uk/2026/08/18/tooth-regrowth-in-adults-what-we-know-so-far/" target="_blank" rel="noreferrer noopener">Read <em>Dentistry</em>‘s breakdown of the latest research in oral regeneration.</a></p>



<p><em><a href="https://sso.dentistry.co.uk/">Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</a></em></p>]]> </content:encoded>
</item>

<item>
<title>Told Your Heart Condition Is Inoperable? Here’s What a Second Opinion Can Change</title>
<link>https://edusehat.com/en/told-your-heart-condition-is-inoperable-heres-what-a-second-opinion-can-change</link>
<guid>https://edusehat.com/en/told-your-heart-condition-is-inoperable-heres-what-a-second-opinion-can-change</guid>
<description><![CDATA[ Being told your heart condition is inoperable often reflects one hospital&#039;s own capabilities, not a universal fact. This guide covers why that label gets applied, what it typically leaves out, questions to ask, what a second opinion can actually change, and when a consultation with Dr. Giovanni Ciuffo in Las Vegas is worth pursuing. ]]></description>
<enclosure url="https://heartsurgeryinfo.com/wp-content/uploads/2026/10/Heart-Condition-Is-Inoperable.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 16:30:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Told, Your, Heart, Condition, Inoperable, Here’s, What, Second, Opinion, Can, Change</media:keywords>
<content:encoded><![CDATA[<h4>Post Summary</h4>
<p><strong>Why are some patients told their heart condition is inoperable?</strong></p>
<p>Patients are told their heart condition is inoperable for a range of reasons, and those reasons are real even though the word itself sounds more absolute than it usually is. Age is one of the most common factors and is often treated as disqualifying on its own, even though age alone rarely tells the whole story. Frailty and other health conditions, including lung disease, diabetes, or kidney issues, get weighed heavily because traditional open-chest surgery places real strain on the body. Prior surgeries matter too, since scar tissue from an earlier procedure can make a second traditional operation riskier than the first. Beyond a patient’s individual health picture, a significant part of what goes into an inoperable label is what one hospital or surgical team is equipped to handle safely. Every program has its own risk tolerance and its own set of specialized capabilities, and those limits vary widely from one hospital to the next. A patient turned away as too high risk at one center may be a reasonable candidate at another, simply because that second team has more experience with complex, high-risk cases or offers techniques the first program does not. This does not mean every inoperable diagnosis is wrong, only that it reflects one specific evaluation rather than a universal medical ceiling.</p>
<p><strong>What does the inoperable label often fail to account for?</strong></p>
<p>An inoperable label often leaves out the existence of minimally invasive and specialized high-risk surgical techniques that many general cardiac programs simply do not offer. Traditional open-chest surgery is not the only surgical option for high-risk patients, even though it is often presented that way in the initial conversation. Minimally invasive approaches use smaller incisions and place considerably less strain on the body, and for some patients an off-pump technique avoids stopping the heart altogether, which can open the door for patients whose age, frailty, or other health conditions ruled out the traditional route. Some programs specialize in high-risk and complex cases specifically, meaning they have built real, ongoing experience evaluating exactly the kind of patient a general program routinely turns away. Being told a case is inoperable often means one surgeon, using the tools available at one hospital, has concluded traditional surgery is not safe, not that every surgical option everywhere has been ruled out. A program built specifically around minimally invasive and high-risk heart surgery may look at the same imaging, test results, and history and still see a real path forward, simply because evaluating difficult cases is what that program does routinely.</p>
<p><strong>What questions should you ask after being told you’re inoperable?</strong></p>
<p>Patients who receive an inoperable diagnosis have specific questions worth asking before accepting it as final. First, ask what specifically makes the case inoperable: whether it is age alone, a particular health condition, or something about what that specific hospital or surgical team is equipped to handle, since only one of those describes an absolute limit rather than a local one. Second, ask whether a program built around high-risk or complex cases has actually evaluated the imaging and history, since a general cardiac team and a specialized high-risk program do not always assess the same case the same way. Third, ask whether the diagnosis would look different at a program that specifically treats patients other surgeons have turned away, a fair and reasonable question rather than a confrontational one. Fourth, ask what would actually need to be true for the case to become operable elsewhere, since an answer involving a specific technique, a specific kind of experience, or specific equipment is useful information rather than a dead end. A confident surgeon should welcome all of these questions, and asking them before accepting an inoperable diagnosis as final is easier than wondering afterward whether enough was asked.</p>
<p><strong>What can a second opinion actually change for an inoperable diagnosis?</strong></p>
<p>A second opinion on an inoperable diagnosis can change more than patients expect, though not every case is reclassified. The most direct change is risk reclassification: a team with more experience evaluating high-risk and complex cases does not always agree with a general program’s assessment, not because the first evaluation was careless, but because risk tolerance and specialized expertise genuinely differ from one program to the next. The second change is access to a pathway that was never on the table, such as a minimally invasive or off-pump approach that was not offered or even mentioned at the first hospital, which may become a real option once a program built around exactly these cases takes a look. The third change is harder to quantify but just as real: clarity. A second opinion does not guarantee a different answer, but hearing the same conclusion from a specialist who evaluates high-risk cases every day carries a different kind of certainty than hearing it once from a general program, and moving forward with real confidence matters even when the outcome does not change. Patients have gone through exactly this process before, and real accounts of that experience exist for anyone who wants to see how it plays out in practice.</p>
<p><strong>When is the right time to seek a second opinion on an inoperable diagnosis?</strong></p>
<p>Seeking a second opinion on an inoperable diagnosis makes sense in nearly every case, and doing so soon after the diagnosis matters more than most patients realize. The earlier a second opinion happens, the more options remain genuinely open, before a general treatment plan is set and before a patient has mentally settled into the diagnosis as final. Waiting does not close every door, but it can close some of them, and there is little upside to waiting once a patient already wants a second set of eyes. Timing matters even more when the inoperable label came from a general cardiologist or general cardiac surgery program rather than a specialist in high-risk cases. That is not a criticism of the first team, since general programs handle the overwhelming majority of heart conditions well, and an inoperable conclusion from such a program is an honest reflection of what it is set up to do. It is precisely this situation, a general assessment rather than a specialized one, where a second, more specialized look tends to matter most. Some practices focus specifically on evaluating patients who have already been told no elsewhere, and that focus is worth knowing about before settling into a decision a different set of eyes could have changed.</p>
<p><strong>Who is Dr. Giovanni Ciuffo, and why do patients travel to see him for inoperable cases?</strong></p>
<p>Dr. Giovanni Ciuffo is a cardiothoracic surgeon who serves as Director of Cardiac Surgery at University Medical Center of Southern Nevada, based in Las Vegas. His practice focuses specifically on evaluating patients who have already been told their heart condition is inoperable by other surgeons or hospitals, including cases where a minimally invasive or high-risk surgical pathway was never raised as an option. Because specialized high-risk programs are not available everywhere and require experience most general cardiac programs do not maintain, patients are not always told these programs exist, which is exactly the kind of gap a second opinion is meant to close. Patients travel to Las Vegas from across the country for a second opinion with Dr. Ciuffo specifically because of this focus, rather than treating it as a purely local option, reflecting the practice’s national reach for exactly this population. Consultations are available whether a patient lives nearby or is traveling from elsewhere, and reaching out does not require a patient to have already decided anything. For anyone who has only heard the word inoperable and no further explanation, requesting a consultation is a way to find out whether that word is genuinely the final one for their specific case.</p>
<p>•••••</p>
<p><span>Being told you’re inoperable doesn’t sound like a diagnosis. It sounds like a verdict. Where other news at least comes with a next step, “inoperable” can feel like the conversation is over before it started, and that weight is real. It deserves to be taken seriously, not brushed past with reassurance you haven’t earned yet.</span></p>
<p><span>Here’s what’s worth knowing before you accept that word as final: being called inoperable often reflects what one surgeon, at one hospital, is equipped to offer, not a universal medical fact about your heart. That distinction is the whole reason a second opinion for an inoperable heart condition exists.</span></p>
<p><span>This guide walks through why that label gets applied, what it doesn’t account for, the questions worth asking, and what a second opinion can actually change.</span></p>
<h2><strong>Why Some Patients Are Told They’re “Inoperable”</strong></h2>
<p><span>So why do some patients get told their heart condition is inoperable in the first place? The reasons are real, but they’re rarely as absolute as the word makes them sound.</span></p>
<p><span>Age is one of the most common factors, and it’s often treated as disqualifying on its own, even though age alone rarely tells the whole story. Frailty and other health conditions, like lung disease, diabetes, or kidney issues, get weighed too, sometimes heavily, because traditional open-chest surgery puts real strain on the body. Prior surgeries matter as well; scar tissue from an earlier procedure can make a second traditional operation riskier than the first.</span></p>
<p><span>Here’s what’s easy to miss in the moment: much of what goes into an inoperable label is about what one hospital or one surgical team is equipped to handle safely. Every program has its own risk tolerance and its own set of specialized capabilities, and those limits vary widely from one hospital to the next. A patient deemed too high-risk at one center may be a reasonable candidate at another, simply because the second team has more experience with complex, high-risk cases or offers techniques the first program doesn’t.</span></p>
<p><span>None of this means every inoperable diagnosis is wrong. It means the label reflects a specific evaluation, made by specific people, at a specific place, and that evaluation is worth understanding in more detail before treating it as the final word.</span></p>
<h2><strong> What “Inoperable” Doesn’t Always Account For</strong></h2>
<p><span>What does the inoperable label typically leave out? Usually, minimally invasive and specialized high-risk surgical techniques are not offered by many general cardiac programs.</span></p>
<p><span>Traditional open-chest surgery isn’t the only surgical option for high-risk patients, even though it’s often treated that way in the initial conversation. Minimally invasive approaches use smaller incisions and place considerably less strain on the body, which can open the door for patients whose age, frailty, or other health conditions would otherwise rule out the traditional route. Some programs also specialize specifically in high-risk and complex cases, meaning they’ve built real, ongoing experience evaluating exactly the kind of patient a general program routinely turns away.</span></p>
<p><span>This is the distinction most inoperable conversations skip. Being told you’re inoperable often means one surgeon, using the tools and techniques available at one hospital, has concluded traditional surgery isn’t safe for you. It doesn’t necessarily mean every surgical option, everywhere, has been ruled out. A program built specifically around minimally invasive and high-risk heart surgery may look at the same imaging and see a real path forward.</span></p>
<p><span>We’ve written more about </span><a href="https://heartsurgeryinfo.com/second-opinion-for-inoperable-heart-surgery/" target="_blank" rel="noopener"><span>what an inoperable second opinion actually looks for</span></a><span> if you want the fuller breakdown of how that evaluation works. The short version: this gap between “not offered here” and “not possible anywhere” is common enough to matter, and specific enough in any one case that it’s worth building a program around exactly this kind of evaluation to take a direct look before accepting the label as final.</span></p>
<h2><strong>Questions Worth Asking After an Inoperable Diagnosis</strong></h2>
<p><span>Being told you’re inoperable can feel like the end of the conversation, but there are specific questions to ask about an inoperable heart diagnosis before you accept it as the final answer.</span></p>
<p><span>What specifically makes my case inoperable? Ask whether it’s your age alone, a particular health condition, or something about what this specific hospital or surgical team is equipped to handle. Those are three very different answers, and only one of them describes an absolute limit rather than a local one.</span></p>
<p><span>Has a program built around high-risk or complex cases actually evaluated my imaging and history? A general cardiac team and a specialized high-risk program don’t always see the same case the same way, and it’s fair to ask whether your case has been reviewed by the second kind, not just the first.</span></p>
<p><span>Would this diagnosis look different at a program that specifically treats patients other surgeons have turned away? This isn’t a question meant to second-guess your surgeon. It’s a reasonable one, and a confident surgeon should have no issue with you asking it.</span></p>
<p><span>What would actually need to be true for my case to become operable somewhere else? If the answer involves a specific technique, a specific kind of experience, or a specific piece of equipment, that’s useful information, not a dead end, and it tells you exactly what to look for elsewhere.</span></p>
<p><span>None of these questions is confrontational, and asking them before you accept an inoperable diagnosis as final is a lot easier than wondering later whether you asked enough.</span></p>
<h2><strong>What a Second Opinion Can Actually Change</strong></h2>
<p><span>So what can a second opinion on an inoperable diagnosis actually change? Sometimes, more than you’d expect. Sometimes, less. Both outcomes are worth knowing for certain rather than guessing, especially for a decision this significant.</span></p>
<p><span>The most direct change is risk reclassification. A team with more experience evaluating high-risk and complex cases doesn’t always agree with a general program’s assessment, not because the first evaluation was careless, but because risk tolerance and specialized expertise genuinely differ from one program to the next. What reads as too dangerous in one setting can read as manageable in another with the right technique and team.</span></p>
<p><span>The second change is access to a pathway that was never actually on the table. A minimally invasive or off-pump approach that wasn’t offered, or even mentioned, at the first hospital may be a real option once a program built around exactly these cases reviews the same imaging and history.</span></p>
<p><span>The third change is harder to quantify but just as real: clarity. Not every case gets reclassified, and a second opinion doesn’t guarantee a different answer. But hearing the same conclusion from a specialist who evaluates high-risk cases every day carries a different kind of certainty than hearing it once from a general program, and moving forward with real confidence matters even when the outcome doesn’t shift.</span></p>
<p><span>Patients have gone through exactly this process before. </span><a href="https://heartsurgeryinfo.com/inoperable-heart-surgery-patients/" target="_blank" rel="noopener"><span>One patient’s own account</span></a><span> of being told her case was inoperable, and what happened after that, is worth reading if you want to see what a second opinion on heart surgery actually looks like in practice, start to finish.</span></p>
<h2><strong>When to Seek a Second Opinion, and Why Sooner Helps</strong></h2>
<p><span>So when does it actually make sense to seek a second opinion on an inoperable diagnosis? Close to always, and especially soon after you first hear the word.</span></p>
<p><span>Timing matters here in a way it doesn’t always get the credit it deserves. The earlier a second opinion happens, the more options are still genuinely open, before a general treatment plan gets set, before you have mentally settled into thinking this is just how it is. Waiting does not close every door, but it can close some, and there is no real upside to waiting once you already know you want a second set of eyes.</span></p>
<p><span>This matters even more if the inoperable label came from a general cardiologist or a general cardiac surgery program rather than a specialist in high-risk cases. That is not a criticism of the first team. General programs handle the overwhelming majority of heart conditions well, and an inoperable conclusion from such a program is an honest reflection of what it is set up to do. It is also exactly the situation where a more specialized second look tends to matter most.</span></p>
<p><span>Some practices focus specifically on evaluating patients who have already been told no elsewhere. That focus is worth knowing about and worth acting on before you settle on a decision that a different set of eyes could have changed.</span></p>
<h2><strong>Quick Answers</strong></h2>
<p><b>What does it mean to be told your heart condition is inoperable?</b><span><br>
</span><span>It means one surgeon at one hospital has concluded that traditional surgery is not safe for you, given your age, health conditions, or the program’s own capabilities. It does not necessarily mean every surgical option, everywhere, has been ruled out.</span></p>
<p><b>Can an inoperable diagnosis change with a second opinion?</b><span><br>
</span><span>Sometimes. A specialized high-risk program may reclassify the risk, offer a minimally invasive or off-pump pathway not previously mentioned, or confirm the original assessment with greater certainty. Not every case gets reclassified, but it is worth finding out for certain.</span></p>
<p><b>What makes someone a minimally invasive candidate despite being called inoperable?</b><span><br>
</span><span>Candidacy depends on the specific reason for the inoperable label. Age or frailty alone often leaves more room for a minimally invasive approach than a program without that specialization initially suggested, though every case still needs its own direct evaluation.</span></p>
<p><b>How is a high-risk second opinion different from a routine one?</b><span><br>
</span><span>A high-risk second opinion specifically involves a program built around evaluating complex and previously declined cases, rather than a general cardiac team. That specialized experience is often the deciding factor in whether a different outcome is possible.</span></p>
<p><b>What should I bring to a second opinion consultation for an inoperable diagnosis?</b><span><br>
</span><span>Bring your full imaging results, the specific reasons given for the inoperable label, a current medication list, and a written list of questions, including what would need to be true for your case to become operable elsewhere.</span></p>
<h2><span>•••••</span></h2>
<p><span>If you have been told your heart condition is inoperable and want another set of eyes on your case, <a href="https://heartsurgeryinfo.com/contact-us/">Dr. Giovanni Ciuffo is worth talking to.</a> He serves as Director of Cardiac Surgery at University Medical Center of Southern Nevada, and his practice focuses specifically on evaluating patients whom other surgeons and hospitals have already turned away.</span></p>
<p><span>Patients travel to Las Vegas from across the country for a second opinion on heart surgery with Dr. Ciuffo when they have been told their condition is inoperable elsewhere, not just locally. Consultations are available whether you live nearby or across the country. If the word inoperable is the only answer you have gotten so far, reach out and find out whether that is genuinely the final word for your case.</span></p>]]> </content:encoded>
</item>

<item>
<title>NPPA revises MRPs of 543 brands of anti&#45;cancer medicines</title>
<link>https://edusehat.com/en/nppa-revises-mrps-of-543-brands-of-anti-cancer-medicines</link>
<guid>https://edusehat.com/en/nppa-revises-mrps-of-543-brands-of-anti-cancer-medicines</guid>
<description><![CDATA[ 
Revised prices will come into effect from November 9, 2026, following trade margin rationalisation of 137 non-scheduled anti-cancer drugs
The post NPPA revises MRPs of 543 brands of anti-cancer medicines appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2018/11/20154710/cancer-ThinkstockPhotos-490575333-e1545048577610.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 16:15:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>NPPA, revises, MRPs, 543, brands, anti-cancer, medicines</media:keywords>
<content:encoded><![CDATA[<div><img width="600" height="354" src="https://cdn.expresspharma.in/wp-content/uploads/2018/11/20154710/cancer-ThinkstockPhotos-490575333-e1545048577610.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2018/11/20154710/cancer-ThinkstockPhotos-490575333-e1545048577610.jpg 600w, https://cdn.expresspharma.in/wp-content/uploads/2018/11/20154710/cancer-ThinkstockPhotos-490575333-e1545048577610-300x177.jpg 300w" sizes="auto, (max-width: 600px) 100vw, 600px"></div><p><span>The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has released a list of 543 brands of anti-cancer medicines with revised Maximum Retail Prices (MRPs). The revised MRPs will come into effect from November 9, 2026.</span></p>
<p><span>The revised price list reflects information submitted by companies up to October 27, 2026. It will be updated as and when manufacturers submit revised prices for non-scheduled anti-cancer drugs.</span></p>
<p><span>The complete list of 543 brands of anti-cancer medicines with revised MRPs is available on the</span><a href="https://nppa.gov.in/en"> <span>NPPA website</span></a><span>. The portal is updated on a continual basis.</span></p>
<p><span>On October 17, 2026, the NPPA announced Trade Margin Rationalisation (TMR) of 137 non-scheduled anti-cancer drugs in public interest to address excessive trade margins, make cancer treatment more affordable and improve access to anti-cancer medicines. Manufacturers were instructed to submit their revised price lists to the NPPA.</span></p>
<p><span>The 137 non-scheduled anti-cancer drugs include immunotherapy medicines used in the treatment of over 20 types of cancer, Denosumab used by breast and prostate cancer patients, Pegfilgrastim used to prevent neutropenia in cancer patients, and Bevacizumab, which is approved for the treatment of colon, ovarian and cervical cancers.</span></p>
<p>The post <a href="https://www.expresspharma.in/nppa-revises-mrps-of-543-brands-of-anti-cancer-medicines/">NPPA revises MRPs of 543 brands of anti-cancer medicines</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>DoP conducts 14,700 cleanliness drives under SCDPM 6.0</title>
<link>https://edusehat.com/en/dop-conducts-14700-cleanliness-drives-under-scdpm-60</link>
<guid>https://edusehat.com/en/dop-conducts-14700-cleanliness-drives-under-scdpm-60</guid>
<description><![CDATA[ 
The Department of Pharmaceuticals has reviewed 4,283 physical files and 20 e-files, weeded out 489 files and freed 2,200 square feet of office space during the campaign
The post DoP conducts 14,700 cleanliness drives under SCDPM 6.0 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 16:15:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>DoP, conducts, 14, 700, cleanliness, drives, under, SCDPM, 6.0</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>The Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, is participating in the Special Campaign for Disposal of Pending Matters (SCDPM) 6.0, along with its attached office, the National Pharmaceutical Pricing Authority (NPPA), and its organisations. These include the seven National Institutes of Pharmaceutical Education and Research (NIPERs), the Pharmaceuticals & Medical Devices Bureau of India (PMBI), and three public sector undertakings (PSUs), namely Bengal Chemicals & Pharmaceuticals Limited (BCPL), Hindustan Antibiotics Limited (HAL) and Karnataka Antibiotics & Pharmaceuticals Limited (KAPL).</span></p>
<p><span>The campaign, being conducted from October 2 to October 31, 2026, focuses on cleanliness, scientific management and disposal of e-waste, record management, grievance redressal and utilisation of office space. It aims to enhance administrative efficiency and promote a clean, organised and productive work environment.</span></p>
<p><span>As part of field office outreach and sustainable workplace practices, 14,700 cleanliness drives have been conducted across field and outstation offices against a baseline target of 12,208. The campaign also aims to improve workplace hygiene and sanitation, strengthen environmental awareness and promote sustainable workplace practices.</span></p>
<p><span>Under record management and office space utilisation, the Department has reviewed 4,283 physical files and 20 e-files against baseline targets of 2,716 physical files and 20 e-files. A total of 489 files have been weeded out and closed. These efforts have also freed up 2,200 square feet of office space.</span></p>
<p><span>The campaign is also addressing pending matters, including Members of Parliament (MP) references, parliamentary assurances, Cabinet proposals, State references and Prime Minister’s Office (PMO) references. The Department has addressed three MP references against a target of four, one parliamentary assurance against a target of two, two Cabinet proposals, 57 State references against a target of 58, and two PMO cases.</span></p>
<p><span>Against targets of 72 public grievances and 28 appeals registered on the Centralised Public Grievance Redress and Monitoring System (CPGRAMS), 132 public grievance cases and 39 appeals have been settled. Of the 20 items identified for easing rules and processes, work has been completed on 17 items.</span></p>
<p><span>Scientific e-waste management is another focus area of SCDPM 6.0. The Department has targeted 1,011 obsolete electronic and electrical items, comprising IT equipment, consumer electronics, appliances and laboratory tools, for safe disposal through empanelled recyclers under the E-Waste (Management) Rules, 2022. The disposal process is underway.</span></p>
<p><span>The Department has also earned revenue of ₹2,30,187 from the disposal of office scrap. It remains committed to the objectives of SCDPM 6.0, monitoring targets and documenting achievements through the National Special Campaign Portal.</span></p>
<p>The post <a href="https://www.expresspharma.in/dop-conducts-14700-cleanliness-drives-under-scdpm-6-0/">DoP conducts 14,700 cleanliness drives under SCDPM 6.0</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Spektus Pharma, GEBRO partner to commercialise ActraFlex globally</title>
<link>https://edusehat.com/en/spektus-pharma-gebro-partner-to-commercialise-actraflex-globally</link>
<guid>https://edusehat.com/en/spektus-pharma-gebro-partner-to-commercialise-actraflex-globally</guid>
<description><![CDATA[ 
The partnership covers Europe, the Americas and selected Rest of World markets for the twice-daily extended-release tramadol and paracetamol formulation
The post Spektus Pharma, GEBRO partner to commercialise ActraFlex globally appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 16:15:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Spektus, Pharma, GEBRO, partner, commercialise, ActraFlex, globally</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Spektus Pharma and GEBRO Holding GmbH (GEBRO) have announced a global commercialisation partnership for ActraFlex, a twice-daily extended-release formulation of tramadol and paracetamol for pain management.</span></p>
<p><span>ActraFlex combines Spektus’ patented AmyloFlex drug-delivery platform technology with GEBRO’s Diliban tramadol/paracetamol product. The formulation is designed to provide sustained drug release with twice-daily dosing.</span></p>
<p><span>Under the partnership, GEBRO will lead commercialisation and supply across Europe and selected Rest of World (RoW) markets, with Spain serving as a key market, where Diliban has an established regulatory and commercial foundation. Spektus will lead commercialisation and supply across North America, South America and selected RoW markets through its network of regional commercialisation partners.</span></p>
<p><span>The partnership brings together GEBRO’s expertise and commercial presence in pain management with Spektus’ proprietary drug-delivery technology and global partnership network. The companies intend to use their capabilities and geographic reach to introduce ActraFlex across international markets.</span></p>
<p><span>“Our partnership with GEBRO highlights the potential of Spektus’ proprietary AmyloFlex technology to create differentiated specialty medicines from established products and brands. Building on GEBRO’s successful commercialization of Diliban in Europe, we see strong commercial potential for ActraFlex across the Americas and selected markets in Africa and Asia.” said Zarvaan Merchant, CEO of Spektus Pharma.</span></p>
<p><span>“GEBRO brings deep expertise in pain management and a strong foundation with Diliban in Europe. Together with Spektus’ established commercialisation partner network across the Americas and other international markets, we believe ActraFlex has the potential to become an important global product in pain management,” said Christian Kollenz, managing director of GEBRO Holding.</span></p>
<p><span>The agreement establishes a global commercialisation framework under which both companies will lead the regulatory and commercial introduction of ActraFlex in their respective territories, supported by a common product platform and shared global strategy.</span></p>
<p><span>Financial terms of the agreement were not disclosed.</span></p>
<p>The post <a href="https://www.expresspharma.in/spektus-pharma-gebro-partner-to-commercialise-actraflex-globally/">Spektus Pharma, GEBRO partner to commercialise ActraFlex globally</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lilly’s retatrutide shows greater A1C reduction and weight loss than Ozempic in Phase 3 trial</title>
<link>https://edusehat.com/en/lillys-retatrutide-shows-greater-a1c-reduction-and-weight-loss-than-ozempic-in-phase-3-trial</link>
<guid>https://edusehat.com/en/lillys-retatrutide-shows-greater-a1c-reduction-and-weight-loss-than-ozempic-in-phase-3-trial</guid>
<description><![CDATA[ 
The TRANSCEND-T2D-2 trial found greater reductions in A1C, body weight and certain cardiovascular risk factors with retatrutide at 80 weeks
The post Lilly’s retatrutide shows greater A1C reduction and weight loss than Ozempic in Phase 3 trial appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/05/09110331/Weight-loss.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 16:15:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lilly’s, retatrutide, shows, greater, A1C, reduction, and, weight, loss, than, Ozempic, Phase, trial</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/05/09110331/Weight-loss.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/05/09110331/Weight-loss.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/05/09110331/Weight-loss-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Eli Lilly and Company has announced positive topline results from TRANSCEND-T2D-2, a head-to-head Phase 3 trial comparing retatrutide with injectable Ozempic 2 mg in adults with type 2 diabetes. At 80 weeks, retatrutide met the primary and all key secondary endpoints, delivering greater A1C reduction and weight loss than Ozempic.1,2</span></p>
<p><span>Kenneth Custer, Ph.D., Executive Vice President and President of Lilly Cardiometabolic Health, said, “Head-to-head trials show patients and physicians how a potential new medicine compares with treatments that are available and reimbursed today. In TRANSCEND-T2D-2, the first Phase 3 trial comparing retatrutide with another incretin medicine, retatrutide delivered greater A1C reduction and more than double the weight loss of the highest dose of Ozempic approved in the U.S. for type 2 diabetes. Based on these results and those from across our Phase 3 program, we believe retatrutide, if approved, could shift the treatment paradigm for people living with type 2 diabetes, obesity and related cardiometabolic conditions.”</span></p>
<p><span>In the TRANSCEND-T2D-2 trial, both doses of retatrutide reduced A1C by an average of 2.2 per cent, compared with 1.8 per cent with Ozempic at 80 weeks.</span></p>
<p><span>Participants taking retatrutide lost an average of 20.1 kg (19.5 per cent) with the 9 mg dose and 21.5 kg (20.9 per cent) with the 12 mg dose, compared with 9.5 kg (9.4 per cent) with Ozempic.</span></p>
<p><span>Retatrutide also delivered greater improvements than Ozempic in certain cardiovascular risk factors, including non-HDL cholesterol, triglycerides and systolic blood pressure.</span></p>
<p><span>The most common adverse events reported in the trial with retatrutide at 9 mg and 12 mg, respectively, compared with Ozempic, were diarrhoea (28.3 per cent and 32.7 per cent versus 26.4 per cent), nausea (21.2 per cent and 23.8 per cent versus 21.3 per cent), constipation (14.2 per cent and 13.1 per cent versus 19.8 per cent), vomiting (10.2 per cent and 15.0 per cent versus 13.2 per cent), and dyspepsia (10.4 per cent and 8.5 per cent versus 11.6 per cent).</span></p>
<p><span>The incidence of dysesthesia was 4.8 per cent with retatrutide 9 mg, 6.5 per cent with retatrutide 12 mg and 2.7 per cent with Ozempic. The incidence of urinary tract infections was 5.8 per cent, 4.2 per cent and 5.8 per cent, respectively.</span></p>
<p><span>The majority of these events were mild to moderate and typically resolved during treatment. Treatment discontinuation rates due to adverse events were 4.8 per cent with retatrutide 9 mg, 7.9 per cent with retatrutide 12 mg and 2.7 per cent with Ozempic.</span></p>
<p>The post <a href="https://www.expresspharma.in/lillys-retatrutide-shows-greater-a1c-reduction-and-weight-loss-than-ozempic-in-phase-3-trial/">Lilly’s retatrutide shows greater A1C reduction and weight loss than Ozempic in Phase 3 trial</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Three&#45;Photon Microscopy Reveals Neural Activity Deep in the Mouse Brain</title>
<link>https://edusehat.com/en/three-photon-microscopy-reveals-neural-activity-deep-in-the-mouse-brain</link>
<guid>https://edusehat.com/en/three-photon-microscopy-reveals-neural-activity-deep-in-the-mouse-brain</guid>
<description><![CDATA[ By optimizing laser, optical, and acquisition parameters, The Rockefeller University researchers developed a three-photon microscopy platform that captures deep-brain neural activity in living mice at single-cell resolution without surgically removing the overlying cortex.
The post Three-Photon Microscopy Reveals Neural Activity Deep in the Mouse Brain appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/07/GettyImages-827580658.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 09:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Three-Photon, Microscopy, Reveals, Neural, Activity, Deep, the, Mouse, Brain</media:keywords>
<content:encoded><![CDATA[<p>Watching neurons deep inside the brain usually means contending with scattered light—or removing tissue to get a clearer view. Now, researchers at The Rockefeller University have redesigned a three-photon microscopy platform to record neuronal activity in deep brain regions of living mice without surgically removing the overlying cortex.</p>
<p>Led by Alipasha Vaziri, PhD, head of Rockefeller’s Laboratory of Neurotechnology and Biophysics, the team developed Three-photon Ultra-Deep Imaging (TrUDI). Their study, “<a href="https://www.nature.com/articles/s41592-026-03251-2">Cellular-resolution three-photon ultra-deep imaging (TrUDI) of neuronal population activity at 2-mm depth in the mammalian brain,</a>” was published in <em>Nature Methods</em>.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>TrUDI generated approximately 250 times more detected fluorescence photons at the same laser power as previous approaches, enabling single-cell-resolution recordings of neuronal population activity at depths of approximately 2 mm.</p>
<p>“Often in technology, people stick with a certain laser or parameter for historical reasons, and everyone just accepts those limitations,” Vaziri said. “We wanted to take a clean slate approach.”</p>
<p>As light penetrates brain tissue, scattering makes it increasingly difficult to distinguish fluorescent signals from background. Three-photon microscopy produces less background fluorescence than two-photon microscopy, potentially allowing deeper imaging. However, generating sufficient signal requires energetic laser pulses, and increasing average laser power risks heating and damaging tissue.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Previous three-photon functional recordings had reached approximately 1.2 mm, short of the technique’s theoretical depth limit of more than 2 mm.</p>
<p>The researchers used computer models to guide coordinated changes to the laser and optics. The authors wrote, “TrUDI matches the parameters of the excitation laser, the optical system, and the acquisition to linear and nonlinear limits for safe laser exposure while satisfying the spatiotemporal requirements of single-cell resolution calcium (Ca<sup>2+</sup>) imaging.”</p>
<figure aria-describedby="caption-attachment-339959" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339959" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Vaziri_101926_HERO-300x200.jpg" alt="TrUDI" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Vaziri_101926_HERO-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Vaziri_101926_HERO.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">A volumetric rendering of stacked images taken with the Vaziri lab’s new platform TrUDI. [Laboratory of Neurotechnology and Biophysics at The Rockefeller University]</figcaption></figure>
<p>The team also developed a neuron-targeted excitation scheme that switches on the laser only as it scans identified cells. “The way we did this was through a series of very systematic, principled, and ground-up optimizations,” Vaziri said.</p>
<p>Together, these changes increased the fluorescence signal available for recording transient activity in individual neurons. The platform was tested in mice, and the paper reports recordings over fields of view approximately 230 by 230 µm<sup>2</sup> at 8.6 Hz, reaching approximately 2 mm into the mouse cortex and hippocampus.</p>
<p>The advance expands access to circuits that previously required removal of overlying tissue for optical imaging, potentially helping researchers investigate how neuronal populations across deep brain regions coordinate their activity. It does not, however, make every deep structure accessible.</p>
<p>“There are regions of the striatum that are inaccessible, and there are still a number of deep brain nuclei which are much deeper that still require invasive approaches,” Vaziri added.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>For now, the work demonstrates how coordinated optimization can bring three-photon imaging closer to its fundamental depth limit while preserving the tissue above the regions being studied.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/three-photon-microscopy-reveals-neural-activity-deep-in-the-mouse-brain/">Three-Photon Microscopy Reveals Neural Activity Deep in the Mouse Brain</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How the Heart Stays Strong with MCT1&#45;Dependent Mitochondrial Lactate Import</title>
<link>https://edusehat.com/en/how-the-heart-stays-strong-with-mct1-dependent-mitochondrial-lactate-import</link>
<guid>https://edusehat.com/en/how-the-heart-stays-strong-with-mct1-dependent-mitochondrial-lactate-import</guid>
<description><![CDATA[ Preclinical study results suggest how the heart can keep itself well-fueled even under times of stress, by burning glucose in the cell cytosol while burning lactate in the mitochondria.
The post How the Heart Stays Strong with MCT1-Dependent Mitochondrial Lactate Import appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/07/GeneTherapy_GettyImages_2101175464_HolographicHumanHeart.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 05:30:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, the, Heart, Stays, Strong, with, MCT1-Dependent, Mitochondrial, Lactate, Import</media:keywords>
<content:encoded><![CDATA[<p>Maintaining energy flow to the heart is a complex process which can break down during common but severe cardiovascular disease conditions such as heart failure. Researchers previously knew that heart muscle seems to do an unusual metabolic trick to always get enough energy, which is using two carbohydrate energy sources—glucose and lactate—at the same time.</p>
<p>In most human tissues, using more glucose makes it harder to use lactate, and vice versa, but the heart is different. Working with experimental mice, scientists headed by a team at the University of Utah have now found a unique cell-level difference that helps keep heart muscle fueled up, which is the ability to burn glucose in the cell cytosol while burning lactate in the mitochondria. This spatial separation allows both energy-generating reactions to happen simultaneously, helping keep the heart fueled up no matter the energy source.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>While mostly dispensable to daily life, this process is crucial to preventing heart failure when the heart is stressed. “This appears to be a critical backup system for heart function,” says Gregory Ducker, PhD, assistant professor of biochemistry at University of Utah Health. “In an emergency, we would really, really rely on this.”</p>
<p>The findings could point to new potential therapeutic strategies for some serious heart disorders. Ducker is senior author of the researchers’ published paper in <em>Nature</em>, titled “<a href="http://dx.doi.org/10.1038/s41586-026-11182-3" target="_blank" rel="noopener">MCT1-dependent mitochondrial lactate import sustains cardiac metabolism</a>,” in which they stated, “Thus, the existence of a parallel lactate-based pathway for carbohydrate oxidation can sustain cardiac energetics and maintain myocardial structure and function under diverse stress conditions.”</p>
<p>The heart is the hardest-working muscle in the body, beating constantly no matter what the body’s energy reserves look like. The heart’s energy demands can be met through the use of both glucose and lactate as fuel. “The heart possesses a dynamic capacity to oxidize a variety of fuels, including glucose and lactate, to meet its energetic demands under diverse dietary, exertion, and injury stressors,” the authors wrote.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Laboratory work and experiments in mice reported by Ducker and colleagues now suggest how the heart can use both fuel sources at the same time. Their research found that the separation between glucose and lactate metabolism depends on a molecule called MCT1, which moves lactate to the inside of the mitochondria. “We further observe that MCT1, traditionally localized to the plasma membrane, also resides in the inner mitochondrial membrane of mouse and human cardiomyocytes,” they wrote. Genetic mutations in MCT1 prevent lactate from entering the mitochondria and disrupt the heart’s energy balance, leading to heart failure when stressed. “Genetic ablation of MCT1 abolishes mitochondrial lactate oxidation, disrupts adaptation to neurohormonal, hemodynamic or ischemic stress and accelerates the development of heart failure with enhanced mortality,” the investigators further stated.</p>
<p>These results uncover a new requirement for lactate to fuel the injured heart and suggest new therapeutic targets to re-energize the heart during heart failure. “Our findings help point to new areas in which we could target the heart muscle to benefit and repair itself by allowing it to use lactate better,” Ducker said. “That’s the long-term goal: to help the heart muscle heal.”</p>
<p>The discovery of a new pathway through which the heart muscle can use lactate to generate energy opens promising opportunities for developing new treatments for serious heart conditions, including heart failure and heart attacks.</p>
<p>“Rather than simply releasing lactate into the bloodstream as a waste product, we may be able to enhance the heart’s ability to use it as a valuable source of energy,” says Stavros Drakos, MD, PhD, Professor of Medicine at University of Utah Health and co-senior author of the study. “By optimizing this process, we could potentially improve heart muscle function in patients suffering from heart failure or heart attacks.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/how-the-heart-stays-strong-with-mct1-dependent-mitochondrial-lactate-import/">How the Heart Stays Strong with MCT1-Dependent Mitochondrial Lactate Import</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Kaiser Permanente Medicare health plans are highly rated</title>
<link>https://edusehat.com/en/kaiser-permanente-medicare-health-plans-are-highly-rated</link>
<guid>https://edusehat.com/en/kaiser-permanente-medicare-health-plans-are-highly-rated</guid>
<description><![CDATA[ Medical excellence drives Kaiser Permanente Medicare health plans to be among the highest ranked in regions across the country.
The post Kaiser Permanente Medicare health plans are highly rated appeared first on Permanente Medicine. ]]></description>
<enclosure url="https://permanente.org/wp-content/uploads/2022/10/medicare-5-stars-Permanente-Medicine.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 05:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Kaiser, Permanente, Medicare, health, plans, are, highly, rated</media:keywords>
<content:encoded><![CDATA[<p>Kaiser Permanente’s Medicare Advantage health plans are highly rated, according to the Centers for Medicare & Medicaid Services (CMS) 2027 Star ratings.</p>
<p>Medicare annually evaluates plans based on a 5-star rating system. For the third year in a row, all Kaiser Permanente Medicare health plans rated 4 stars or above, with 8 of the 9 eligible plans rating 4.5 stars or higher.</p>
<p>To develop the ratings, CMS considers a range of categories including care and service, how well health plans keep members healthy and manage their chronic conditions, patient experiences, customer service, patient access, and pharmacy services</p>
<p>The Kaiser Permanente Nevada Medicare plan was rated 5 out of 5 stars for the second year in a row. Kaiser Permanente Medicare health plans in California, Georgia, Hawaii, Northwest (Oregon and southwest Washington), Washington state, and the Mid-Atlantic states (Maryland, Virginia, and Washington, D.C.) received 4.5 out of 5 stars. Colorado health plans rated 4 out of 5 stars.</p>
<p>The 2027 ratings reflect Kaiser Permanente’s commitment to delivering <a href="https://permanente.org/medical-excellence/what-is-quality-healthcare-and-why-it-matters/" target="_blank" rel="noopener">high-quality care</a> and the dedication of our physicians, clinicians, nurses, and staff to achieving the best possible outcomes for the patients and communities served across the country.</p>
<p>“We’re grateful to our physicians, nurses, clinicians, and all our employees for their commitment to improving care quality and member experiences,” said <a href="https://permanente.org/letitia-bridges-md-mba/" target="_blank" rel="noopener">Letitia Bridges, MD, MBA</a>, executive vice president and chief quality officer for The Permanente Federation. ” Maintaining high ratings across our plans and improving our ratings in 3 plans demonstrates the value of our unique coordinated care system that brings together clinicians and team members to continuously improve the quality of care we provide.”</p>
<div class="vcex-module vcex-divider vcex-divider-solid vcex-divider-center wpex-mx-auto wpex-max-w-100 wpex-block wpex-h-0 wpex-border-b wpex-border-solid wpex-border-main"></div>
<p><strong>Related quality care story:</strong> <a href="https://permanente.org/kaiser-permanente-among-the-nations-best-for-quality-service/" target="_blank" rel="noopener">Kaiser Permanente among the nation’s highest-rated for quality and service</a></p>
<div class="vcex-module vcex-divider vcex-divider-solid vcex-divider-center wpex-mx-auto wpex-max-w-100 wpex-block wpex-h-0 wpex-border-b wpex-border-solid wpex-border-main"></div>
<p>Kaiser Permanente’s star ratings also show the value of our integrated health care organization, which ties high-quality care services seamlessly together — in many cases all in one location — and puts our patients at the center of care.</p>
<p>“We’re proud that year after year we provide high-quality care and service that is comprehensive and easy to access,” said <a href="https://about.kaiserpermanente.org/who-we-are/leadership-team/andrew-bindman-md" target="_blank" rel="noopener">Andrew Bindman, MD</a>, executive vice president and chief medical officer for Kaiser Permanente. “Our dedicated physicians and care teams, supported by our unique coordinated system, help millions of Medicare members live healthier lives.”</p>
<p>For details, <a href="https://about.kaiserpermanente.org/news/press-release-archive/2027-medicare-star-ratings-kaiser-permanente-health-plans-earn-high-ratings" target="_blank" rel="noopener">read the release</a>.</p>
<p>The post <a href="https://permanente.org/kaiser-permanente-medicare-health-plans-are-highly-rated/">Kaiser Permanente Medicare health plans are highly rated</a> appeared first on <a href="https://permanente.org/">Permanente Medicine</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Preseason Screening: The 20&#45;Minute Check That Can Prevent a Season&#45;Ending Injury</title>
<link>https://edusehat.com/en/preseason-screening-the-20-minute-check-that-can-prevent-a-season-ending-injury</link>
<guid>https://edusehat.com/en/preseason-screening-the-20-minute-check-that-can-prevent-a-season-ending-injury</guid>
<description><![CDATA[  ]]></description>
<enclosure url="https://dynamicsportsmedicine.com/wp-content/uploads/2026/10/screening-stock-image-1200x630.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 02:40:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Preseason, Screening:, The, 20-Minute, Check, That, Can, Prevent, Season-Ending, Injury</media:keywords>
<content:encoded></content:encoded>
</item>

<item>
<title>Nutrition and Recovery for Young Athletes: Fueling for Performance, Not Just Weight</title>
<link>https://edusehat.com/en/nutrition-and-recovery-for-young-athletes-fueling-for-performance-not-just-weight</link>
<guid>https://edusehat.com/en/nutrition-and-recovery-for-young-athletes-fueling-for-performance-not-just-weight</guid>
<description><![CDATA[  ]]></description>
<enclosure url="https://dynamicsportsmedicine.com/wp-content/uploads/2019/01/AdobeStock_96245700_sm.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 02:40:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Nutrition, and, Recovery, for, Young, Athletes:, Fueling, for, Performance, Not, Just, Weight</media:keywords>
<content:encoded></content:encoded>
</item>

<item>
<title>The Perfect Protein?</title>
<link>https://edusehat.com/en/the-perfect-protein</link>
<guid>https://edusehat.com/en/the-perfect-protein</guid>
<description><![CDATA[ This week in the world of sports science, yeast protein, ear tape, and young athletes.
The post The Perfect Protein? appeared first on Science for Sport. ]]></description>
<enclosure url="https://www.scienceforsport.com/wp-content/uploads/2026/10/c1964256-311c-40f3-85b1-070a80b756ca.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 02:40:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Perfect, Protein</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph"><strong>This week in the world of sports science, here’s what happened…</strong></p>



<ul class="wp-block-list">
<li>The future of protein supplementation?</li>



<li>Why are FC Bayern Munich players wearing tape on their ears?</li>



<li>Young athletes don’t develop every physical quality at the same rate</li>
</ul>



<div aria-hidden="true" class="wp-block-spacer"></div>



<h2 class="wp-block-heading">The future of protein supplementation?</h2>



<figure class="wp-block-image size-large"><img fetchpriority="high" decoding="async" width="1024" height="846" src="https://www.scienceforsport.com/wp-content/uploads/2026/10/c1964256-311c-40f3-85b1-070a80b756ca-1024x846.png" alt="" class="wp-image-34407" srcset="https://www.scienceforsport.com/wp-content/uploads/2026/10/c1964256-311c-40f3-85b1-070a80b756ca-1024x846.png 1024w, https://www.scienceforsport.com/wp-content/uploads/2026/10/c1964256-311c-40f3-85b1-070a80b756ca-300x248.png 300w, https://www.scienceforsport.com/wp-content/uploads/2026/10/c1964256-311c-40f3-85b1-070a80b756ca-767x634.png 767w, https://www.scienceforsport.com/wp-content/uploads/2026/10/c1964256-311c-40f3-85b1-070a80b756ca.png 1380w" sizes="(max-width: 1024px) 100vw, 1024px"><figcaption class="wp-element-caption">(Image: ChatGPT)</figcaption></figure>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph">PlaybookHQ, a leading YouTube channel covering <a href="https://www.scienceforsport.com/top-100-experts-in-sports-science/" target="_blank" rel="noreferrer noopener">sports science</a> and <a href="https://www.scienceforsport.com/course-category/technology-and-data/" target="_blank" rel="noreferrer noopener">technology</a>, recently explored a potentially exciting development in <a href="https://academy.scienceforsport.com/programs/collection-ytlmnxn6iuy?category_id=141256" target="_blank" rel="noreferrer noopener">protein</a> <a href="https://www.scienceforsport.com/supplements-in-sport-what-are-the-benefits-and-risks/" target="_blank" rel="noreferrer noopener">supplementation</a>: Space Milk, a novel yeast-derived <a href="https://academy.scienceforsport.com/programs/collection-ytlmnxn6iuy?category_id=141256">protein</a> <a href="https://www.scienceforsport.com/supplements-in-sport-what-are-the-benefits-and-risks/" target="_blank" rel="noreferrer noopener">supplement</a> (see <a href="https://www.youtube.com/shorts/nFQJeMcKJh8">here</a>).</p>



<p class="wp-block-paragraph">The product is made from yeast <a href="https://academy.scienceforsport.com/programs/collection-ytlmnxn6iuy?category_id=141256" target="_blank" rel="noreferrer noopener">protein</a> extracted through fermentation. Space Milk describes it as the “perfect <a href="https://academy.scienceforsport.com/programs/collection-ytlmnxn6iuy?category_id=141256" target="_blank" rel="noreferrer noopener">protein</a>”, claiming that it provides a complete amino acid profile, is easy to digest and offers an alternative to conventional <a href="https://academy.scienceforsport.com/programs/collection-ytlmnxn6iuy?category_id=141256" target="_blank" rel="noreferrer noopener">protein</a> <a href="https://www.scienceforsport.com/supplements-in-sport-what-are-the-benefits-and-risks/" target="_blank" rel="noreferrer noopener">supplements</a>.</p>



<p class="wp-block-paragraph">The <a href="https://www.youtube.com/shorts/nFQJeMcKJh8" target="_blank" rel="noreferrer noopener">video</a> highlights potential limitations of existing <a href="https://academy.scienceforsport.com/programs/collection-ytlmnxn6iuy?category_id=141256" target="_blank" rel="noreferrer noopener">protein</a> sources, including incomplete amino acid profiles in certain plant-based <a href="https://academy.scienceforsport.com/programs/collection-ytlmnxn6iuy?category_id=141256" target="_blank" rel="noreferrer noopener">proteins</a>, concerns about heavy metal contamination in some <a href="https://www.scienceforsport.com/supplements-in-sport-what-are-the-benefits-and-risks/" target="_blank" rel="noreferrer noopener">supplements</a> and digestive issues associated with dairy-based whey <a href="https://academy.scienceforsport.com/programs/collection-ytlmnxn6iuy?category_id=141256" target="_blank" rel="noreferrer noopener">protein</a>. Space Milk claims to address these limitations and emphasises transparency through independent third-party testing and publicly available results.</p>



<p class="wp-block-paragraph">Although the concept is intriguing, further independent research is needed to substantiate claims about its digestibility, <a href="https://academy.scienceforsport.com/programs/collection-ytlmnxn6iuy?category_id=141256" target="_blank" rel="noreferrer noopener">protein</a> quality and effects on muscle <a href="https://academy.scienceforsport.com/programs/collection-ytlmnxn6iuy?category_id=141256">protein</a> synthesis, as well as any potential advantages over established <a href="https://academy.scienceforsport.com/programs/collection-ytlmnxn6iuy?category_id=141256" target="_blank" rel="noreferrer noopener">protein</a> sources such as whey.</p>



<p class="wp-block-paragraph">It will be fascinating to see whether yeast-derived <a href="https://academy.scienceforsport.com/programs/collection-ytlmnxn6iuy?category_id=141256" target="_blank" rel="noreferrer noopener">protein</a> <a href="https://www.scienceforsport.com/supplements-in-sport-what-are-the-benefits-and-risks/">supplements</a> prove to be a genuine innovation in <a href="https://www.scienceforsport.com/course-category/nutrition/" target="_blank" rel="noreferrer noopener">sports nutrition</a> or simply another short-lived industry trend.</p>



<div aria-hidden="true" class="wp-block-spacer"></div>



<h2 class="wp-block-heading">Why are FC Bayern Munich players wearing tape on their ears?</h2>



<figure class="wp-block-image size-large"><img decoding="async" width="819" height="1024" src="https://www.scienceforsport.com/wp-content/uploads/2026/10/3ecd6301-b8f9-45d6-bd20-31f994b10fb1-819x1024.png" alt="" class="wp-image-34405" srcset="https://www.scienceforsport.com/wp-content/uploads/2026/10/3ecd6301-b8f9-45d6-bd20-31f994b10fb1-819x1024.png 819w, https://www.scienceforsport.com/wp-content/uploads/2026/10/3ecd6301-b8f9-45d6-bd20-31f994b10fb1-240x300.png 240w, https://www.scienceforsport.com/wp-content/uploads/2026/10/3ecd6301-b8f9-45d6-bd20-31f994b10fb1-767x959.png 767w, https://www.scienceforsport.com/wp-content/uploads/2026/10/3ecd6301-b8f9-45d6-bd20-31f994b10fb1.png 1122w" sizes="(max-width: 819px) 100vw, 819px"><figcaption class="wp-element-caption">(Image: Facebook)</figcaption></figure>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph">Recent images of FC Bayern Munich players wearing adhesive tape on their earlobes have attracted considerable attention on social media (see <a href="https://www.instagram.com/p/DeU4rtSDprp/?img_index=4" target="_blank" rel="noreferrer noopener">here</a>), with many people wondering why the tape is there. However, the practice is not new: FC Bayern Munich players were also spotted wearing similar tape last season.</p>



<p class="wp-block-paragraph">The explanation lies in the club’s <a href="https://www.scienceforsport.com/top-100-experts-in-sports-science/" target="_blank" rel="noreferrer noopener">sports science</a> and performance-<a href="https://www.scienceforsport.com/training-load-monitoring-how-coaches-can-effectively-monitor-multiple-variables/" target="_blank" rel="noreferrer noopener">monitoring</a> practices. FC Bayern Munich’s <a href="https://academy.scienceforsport.com/categories/category-MYsxZpTRrFY?catalog_filter_7063%5B%5D=36018" target="_blank" rel="noreferrer noopener">medical</a> and <a href="https://www.scienceforsport.com/top-100-experts-in-sports-science/" target="_blank" rel="noreferrer noopener">sports science</a> staff collect blood lactate samples from players’ earlobes instead of using the more traditional fingertip method. These samples allow staff to measure blood lactate concentrations and assess players’ physiological responses to training. The resulting data can help staff tailor training intensity, <a href="https://www.scienceforsport.com/training-load-monitoring-how-coaches-can-effectively-monitor-multiple-variables/">monitor</a> responses to physical workloads and adjust where necessary.</p>



<p class="wp-block-paragraph">So, there is a scientific explanation for the adhesive tape seen on FC Bayern Munich players’ ears. It is not a new fashion trend nor evidence that all the players suddenly decided to have their ears pierced at the same time!</p>



<p class="wp-block-paragraph">If you would like to learn more about athlete <a href="https://www.scienceforsport.com/training-load-monitoring-how-coaches-can-effectively-monitor-multiple-variables/" target="_blank" rel="noreferrer noopener">monitoring</a>, be sure to check out our highly informative and relevant blogs:</p>



<ul class="wp-block-list">
<li><a href="https://www.scienceforsport.com/training-load-monitoring-how-coaches-can-effectively-monitor-multiple-variables/" target="_blank" rel="noreferrer noopener">Training load monitoring: How coaches can effectively monitor multiple variables</a></li>



<li><a href="https://www.scienceforsport.com/training-load-monitoring-in-team-sports-a-novel-framework-for-adaptation/" target="_blank" rel="noreferrer noopener">Training load monitoring in team sports: A novel framework for adaptation</a></li>



<li><a href="https://www.scienceforsport.com/a-multi-dimensional-approach-to-training-load-and-performance-monitoring/" target="_blank" rel="noreferrer noopener">A multi-dimensional approach to training load and performance monitoring</a></li>



<li><a href="https://www.scienceforsport.com/fatigue-monitoring-which-metrics-should-we-be-tracking/" target="_blank" rel="noreferrer noopener">Fatigue monitoring: Which metrics should we be tracking?</a></li>



<li><a href="https://www.scienceforsport.com/monitoring-fatigue/" target="_blank" rel="noreferrer noopener">Monitoring Fatigue</a></li>
</ul>



<div aria-hidden="true" class="wp-block-spacer"></div>



<h2 class="wp-block-heading">Young athletes don’t develop every physical quality at the same rate</h2>



<figure class="wp-block-image size-full"><img decoding="async" width="790" height="546" src="https://www.scienceforsport.com/wp-content/uploads/2026/10/790-bio-banding-lansley-avl-nor.jpg" alt="" class="wp-image-34406" srcset="https://www.scienceforsport.com/wp-content/uploads/2026/10/790-bio-banding-lansley-avl-nor.jpg 790w, https://www.scienceforsport.com/wp-content/uploads/2026/10/790-bio-banding-lansley-avl-nor-300x207.jpg 300w, https://www.scienceforsport.com/wp-content/uploads/2026/10/790-bio-banding-lansley-avl-nor-767x530.jpg 767w" sizes="(max-width: 790px) 100vw, 790px"><figcaption class="wp-element-caption">(Image: Premier League)</figcaption></figure>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph">A recently published longitudinal <a href="https://link.springer.com/article/10.1186/s40798-026-01109-7" target="_blank" rel="noreferrer noopener">meta-analysis</a> examined patterns of physical development in male adolescent athletes. Drawing on 28 studies across nine sports, the researchers focused on three key physical qualities: <a href="https://www.scienceforsport.com/countermovement-jump-cmj/" target="_blank" rel="noreferrer noopener">lower-body power</a>, <a href="https://www.scienceforsport.com/10m-sprint-test/" target="_blank" rel="noreferrer noopener">acceleration</a> and <a href="https://www.scienceforsport.com/vo2-max/" target="_blank" rel="noreferrer noopener">endurance</a>. <a href="https://www.scienceforsport.com/countermovement-jump-cmj/" target="_blank" rel="noreferrer noopener">Lower-body power</a> was assessed primarily through the <a href="https://www.scienceforsport.com/countermovement-jump-cmj/" target="_blank" rel="noreferrer noopener">countermovement jump</a>, <a href="https://www.scienceforsport.com/10m-sprint-test/" target="_blank" rel="noreferrer noopener">acceleration</a> through the <a href="https://www.scienceforsport.com/10m-sprint-test/" target="_blank" rel="noreferrer noopener">10-metre sprint</a>, and <a href="https://www.scienceforsport.com/vo2-max/" target="_blank" rel="noreferrer noopener">endurance</a> through tests including the <a href="https://www.scienceforsport.com/yo-yo-intermittent-recovery-test-level-1/" target="_blank" rel="noreferrer noopener">Yo-Yo Intermittent Recovery Test</a>, the 20-metre shuttle run, and interval shuttle runs.</p>



<p class="wp-block-paragraph">Notably, improvements in <a href="https://www.scienceforsport.com/countermovement-jump-cmj/" target="_blank" rel="noreferrer noopener">lower-body power</a> and <a href="https://www.scienceforsport.com/vo2-max/" target="_blank" rel="noreferrer noopener">endurance</a> were not linear. The fastest rates of improvement occurred at approximately 13.2 years for <a href="https://www.scienceforsport.com/countermovement-jump-cmj/" target="_blank" rel="noreferrer noopener">lower-body power</a> and 13.8 years for <a href="https://www.scienceforsport.com/vo2-max/" target="_blank" rel="noreferrer noopener">endurance</a>, broadly coinciding with the typical timing of <a href="https://www.scienceforsport.com/peak-height-velocity/" target="_blank" rel="noreferrer noopener">peak height velocity</a> in male athletes. Yet <a href="https://www.scienceforsport.com/10m-sprint-test/" target="_blank" rel="noreferrer noopener">acceleration</a> followed a different pattern. Although it is tempting to assume that every physical quality improves rapidly as young athletes enter puberty, <a href="https://www.scienceforsport.com/10m-sprint-test/" target="_blank" rel="noreferrer noopener">10-metre sprint</a> performance improved relatively steadily between the ages of 12 and 17, with no clearly identifiable surge. <a href="https://www.scienceforsport.com/10m-sprint-test/" target="_blank" rel="noreferrer noopener">Acceleration</a>, therefore, did not appear to benefit from the same obvious <a href="https://www.scienceforsport.com/maturation/" target="_blank" rel="noreferrer noopener">maturational</a> boost as <a href="https://www.scienceforsport.com/countermovement-jump-cmj/" target="_blank" rel="noreferrer noopener">lower-body power</a> and <a href="https://www.scienceforsport.com/vo2-max/" target="_blank" rel="noreferrer noopener">endurance</a>.</p>



<p class="wp-block-paragraph">The key message from this research is that young athletes do not develop every physical quality at the same rate. Around <a href="https://www.scienceforsport.com/peak-height-velocity/" target="_blank" rel="noreferrer noopener">peak height velocity</a>, qualities such as <a href="https://www.scienceforsport.com/countermovement-jump-cmj/" target="_blank" rel="noreferrer noopener">lower-body power</a> and <a href="https://www.scienceforsport.com/vo2-max/" target="_blank" rel="noreferrer noopener">endurance</a> may improve rapidly, while others, including <a href="https://www.scienceforsport.com/10m-sprint-test/" target="_blank" rel="noreferrer noopener">acceleration</a>, may develop more steadily throughout adolescence.</p>



<p class="wp-block-paragraph">If you are interested in this topic, our blogs <a href="https://www.scienceforsport.com/peak-height-velocity/" target="_blank" rel="noreferrer noopener">Peak Height Velocity (PHV)</a>, <a href="https://www.scienceforsport.com/maturation/" target="_blank" rel="noreferrer noopener">Maturation</a>, and <a href="https://www.scienceforsport.com/how-does-age-and-maturation-affect-motor-coordination-and-performance/" target="_blank" rel="noreferrer noopener">How does age and maturation affect motor coordination and performance?</a> are well worth checking out!</p>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph"><strong>From us this week:</strong></p>



<p class="wp-block-paragraph">>> New course: <a href="https://academy.scienceforsport.com/programs/collection-xy44wcqbjsy?category_id=141256" data-type="link" data-id="https://academy.scienceforsport.com/programs/collection-xy44wcqbjsy?category_id=141256" target="_blank" rel="noreferrer noopener">Observation Before Intervention: Building Better Coaching Environments</a><br>>> New podcast: <a href="https://scienceforsport.fireside.fm/343" data-type="link" data-id="https://scienceforsport.fireside.fm/343" target="_blank" rel="noreferrer noopener">The Enhanced Games: Performance, Risk and Athlete Choice</a><br>>> New infographic: <a href="https://www.instagram.com/p/Deo2S_el4Ds/?img_index=4" data-type="link" data-id="https://www.instagram.com/p/Deo2S_el4Ds/?img_index=4" target="_blank" rel="noreferrer noopener">Performance Analysis</a><br>>> New article: <a href="https://www.scienceforsport.com/essa-and-science-for-sport-announce-strategic-professional-development-partnership/" data-type="link" data-id="https://www.scienceforsport.com/essa-and-science-for-sport-announce-strategic-professional-development-partnership/" target="_blank" rel="noreferrer noopener">ESSA and Science for Sport Announce Strategic Professional Development Partnership</a></p>



<p class="wp-block-paragraph"><strong>Access to a growing library of sports science courses</strong></p>



<p class="wp-block-paragraph"><a href="https://academy.scienceforsport.com/" target="_blank" rel="noopener" data-lasso-id="59917">SFS Academy</a> is an all-access membership to premium sports science education.</p>



<p class="wp-block-paragraph">With SFS Academy, you’ll learn from some of the best coaches around the world as they teach you how to apply the latest research and practice with your athletes.</p><p>The post <a href="https://www.scienceforsport.com/the-perfect-protein/">The Perfect Protein?</a> appeared first on <a href="https://www.scienceforsport.com/">Science for Sport</a>.</p>]]> </content:encoded>
</item>

<item>
<title>2026 report on biotech’s economic impact portrays a vast ecosystem</title>
<link>https://edusehat.com/en/2026-report-on-biotechs-economic-impact-portrays-a-vast-ecosystem</link>
<guid>https://edusehat.com/en/2026-report-on-biotechs-economic-impact-portrays-a-vast-ecosystem</guid>
<description><![CDATA[ The latest portrait of America’s biotech industry describes a growing economic force responsible for $3.19 trillion in total U.S. economic output and employment of […]
The post 2026 report on biotech’s economic impact portrays a vast ecosystem appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/BIOR_GSD_TEConomy-Report_3Stat_102226.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 02:00:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>2026, report, biotech’s, economic, impact, portrays, vast, ecosystem</media:keywords>
<content:encoded><![CDATA[<p><span>The latest portrait of America’s biotech industry describes a growing economic force responsible for $3.19 trillion in total U.S. economic output and employment of 2.31 million workers.</span></p>
<p><span>But the BIO/CSBA/TEConomy 2026 report, released Oct. 28, also details important, perhaps less-noticed trends. For example: Biomanufacturing employment grew at nearly 16% nationwide in 2021-25, with 26 states adding jobs and 16 of them growing by more than 20%. The report also includes eye-opening data on the broad geographic expansion of the clinical trial subsector, vital for innovators and patients.</span></p>
<p><span>This is the 12</span><span>th</span><span> edition of this overview of the biotech industry on the national, state and local levels. Produced every two years since 2004 by TEConomy Partners for the Biotechnology Innovation Organization (BIO), the BIO/CSBA/TEConomy report includes individual reports for 50 states, Puerto Rico and the District of Columbia.</span></p>
<p><span>The new report indicates biotech remains strong in the U.S., says Peter Pellerito, a Senior policy Advisor for BIO who has worked on the reports since the beginning.</span></p>
<p><span>“U.S. industry continues to be the leader in global biotechnology competitiveness and biosecurity because of a strategic history of sustained cutting-edge, biology-based research and workforce development partnerships at all levels of industry activity,” he says.</span></p>
<p><span>“Just as drug and pharmaceutical basic and applied research efforts have identified new therapies for patients, so too has the economic impact footprint of our industry grown,” says Pellerito. “While innovation and capacity in biomanufacturing remain substantial in national hubs like California and Massachusetts, the industry continues to expand across all 50 states, Puerto Rico, and the District of Columbia, helping diversify local economies through the creation of quality jobs.”</span></p>
<h2>Employment: Booming growth plateaus</h2>
<p><span>The report shows rapid expansion in biotech from 2021 through 2025: employment in the industry grew 7% and the number of biotech business establishments reached 156,000 by</span> <span>2025. But the strong growth occurred in the post-pandemic years of 2022 and 2023 and has eventually slowed and leveled off in the last two years.</span></p>
<p><span>“The overall employment gain masks two distinct periods. Industry employment rose 5.7 percent in 2022 and increased another 1.2 percent in 2023 before declining 0.3 percent in 2024 and growing just 0.4 percent in 2025. Employment in 2025 was essentially unchanged from its 2023 level,” according to the report.</span></p>
<p><span>“The hiring slowdown warrants attention,” because biotech job growth has generally outpaced private job growth for the past 25 years, the report notes. Still, the healthy growth in 2021-25 touched much of the country.</span></p>
<p><span>“Forty-one states, the District of Columbia, and Puerto Rico experienced net bioscience employment growth over the period,” the report says. “The leading states by absolute job gains were Texas, Florida, Massachusetts, Illinois, North Carolina, Pennsylvania, New York, Ohio, and New Jersey.”</span></p>
<h2>A massive clinical trial ecosystem</h2>
<p><span>The report features a special focus on clinical trials, noting the efforts states make to attract this patient-centered business activity.</span></p>
<p><span>“The special analysis conducted for this report identified 63,468 distinct clinical studies active in the United States or Puerto Rico during 2021–25,” the report says. “Universities, hospitals, research institutes, and other research organizations sponsored 66 percent of these studies, while industry sponsored an additional 29 percent.”</span></p>
<p><span>Ryan Helwig, TEConomy Principal and Senior Director, who’s worked on 11 reports, explains the importance of the report’s analysis of clinical trials.</span></p>
<p><span>“BIO really understood that we need to help industry stakeholders and ordinary Americans get their arms around  the vast footprint of these trials,” he says. “This robust clinical research complex is essential to our national competitiveness and a key piece of advancing real innovations into the clinic and ultimately to commercialization for the benefit of patients.”</span></p>
<p><span>States with larger populations have an advantage in attracting clinical trials, which is why larger states were in the top five hosting clinical trials in 2021-25: California (16,738), Texas (13,742), New York (12,695), Florida (11,686), and Pennsylvania (9,395), according to the report.</span></p>
<p><span>Still, “the subsector is spread across the country,” with trials hosted in every state, the District of Columbia and Puerto Rico, Helwig says.</span></p>
<p><span>The wide availability of clinical trials is good news for patients who are eager to participate and gain early access to cutting-edge medicines. Yet, as the report notes, clinical trial opportunities still could be more widely distributed.</span></p>
<p><span>“A strong national clinical research enterprise is most effective when the right studies are accessible to the patients and communities that need them, underscoring the importance of continued investment in clinical research capacity, diverse participant recruitment, and regional site networks,” the report says.</span></p>
<h2>Biomanufacturing booms</h2>
<p><span>The report also has an expanded section on biomanufacturing, focused specifically on the production of biologic medicines and therapies .</span></p>
<p><span>“Biological product manufacturing has been an important growth segment within the U.S. bioscience industry and the pharmaceuticals subsector. In 2025, the industry employed 46,936 workers, an increase of 15.8 percent from 2021,” the report notes.</span></p>
<p><span>The trend toward reshoring is helping drive the growth in biomanufacturing, and states are competing to benefit from the extensive investment in infrastructure and workforce development that’s involved in establishing new biomanufacturing facilities.</span></p>
<p><span>“There are three main pillars of support that states use to attract this segment of our industry,” according to Pellerito: Enabling infrastructure development; encouraging workforce development; and creating a business-friendly environment through measures such as targeted tax incentives.</span></p>
<p><span>States who succeed in attracting biomanufacturing can hope for big rewards. As the report notes, the last couple of years have seen U.S. and international companies commit to projects totaling hundreds of billions of dollars in value with a projected tens of thousands of  generated jobs.</span></p>
<p><span>“Many of these are just at the investment and early building phases,” Helwig says. “Just imagine what that does for the bioscience industry and ecosystem when those facilities start to fully come on line.”</span></p>
<p><a href="http://www.bio.org/jobs"><b>Read the report here.</b></a></p>
<p>The post <a href="https://bio.news/state-policy/2026-report-on-biotechs-economic-impact-portrays-a-vast-ecosystem/">2026 report on biotech’s economic impact portrays a vast ecosystem</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Collaboration and Roadmaps Key to Capsid Accessibility</title>
<link>https://edusehat.com/en/collaboration-and-roadmaps-key-to-capsid-accessibility</link>
<guid>https://edusehat.com/en/collaboration-and-roadmaps-key-to-capsid-accessibility</guid>
<description><![CDATA[ Apertura says widening access to its TfR1 CapX capsid is a core philosophy, and that includes inviting a wide range of collaborations and supporting collaborators through advice and preclinical roadmaps. 
The post Collaboration and Roadmaps Key to Capsid Accessibility appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/AGTX001-Img-1_2x-2.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 01:55:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Collaboration, and, Roadmaps, Key, Capsid, Accessibility</media:keywords>
<content:encoded><![CDATA[<p>Providing manufacturing and preclinical development advice, as well as forging a broad range of collaborations, is important to increasing access to capsids and their associated plasmids. That’s according to a gene therapy company focused on engineering adeno-associated virus (AAV) capsids and payloads.</p>
<p>For Jorge Santiago-Ortiz, PhD, vice president, CMC & regulatory affairs at Apertura Gene Therapy, the development and manufacturing story of the company’s own lead capsid, TfR1 CapX, is reassuringly uneventful. This is why he focused his talk at the Bioprocessing Summit in Boston on sharing knowledge about engineered capsids and their manufacturability.</p>
<p>“Giving access to capsids is in everyone’s best interests to advance the field,” Santiago-Ortiz says. “And we have already formed a number of partnerships with different types of institutions, for example, foundations, academic institutions, and for-profit organizations too.”</p>
<p>According to Santiago-Ortiz, Apertura Gene Therapy believes its TfR1 CapX is a best-in-class novel AAV capsid for highly efficient delivery to the central nervous system, even at low doses. Manufacturing the capsid itself involves standard unit operations and commercially available reagents, and has taken place internally and at contract manufacturer and other partner facilities in clinical batches of up to 500 L.</p>
<p>Santiago-Ortiz says the company’s success is down to having considered manufacturability early alongside any modifications groups might need to make to standard analytics techniques for the analysis of bespoke capsids.</p>
<p>However, he says, what resonated most with the Bioprocessing Summit audience was the company’s focus on widening access to its capsid technology. This includes, for example, he says, Material Transfer Agreements (MTAs) for academic researchers and even for-profit companies to evaluate their transfer.</p>
<p>In addition to providing access to the capsid and its associated plasmid, he says, they also provide advice on manufacturing, nonclinical development, and regulatory strategies, alongside analytical development guidance.</p>
<p>“As soon as a partnership is announced, we’re as proactive as possible in providing advice and guidance,” he says. “We want to be open and reachable and answer the questions partners might have.”</p>
<p>In addition, Apertura Gene Therapy helps link up partners who might want to manufacture with the aid of a contract manufacturer.</p>
<p>“We connect different parties who have developed different experience and, hopefully, this list of partners will grow as more people adopt this technology and establish their capability to manufacture this virus,” he adds.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/collaboration-and-roadmaps-key-to-capsid-accessibility/">Collaboration and Roadmaps Key to Capsid Accessibility</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Microbial Dark Matter Could Revive Antibiotics</title>
<link>https://edusehat.com/en/microbial-dark-matter-could-revive-antibiotics</link>
<guid>https://edusehat.com/en/microbial-dark-matter-could-revive-antibiotics</guid>
<description><![CDATA[ Most microbes remain out of reach, and many antibiotic-producing genes stay silent. A new review argues that combining genomics, innovative cultivation, and scalable manufacturing could turn this hidden chemistry into desperately needed new antibiotic treatments.
The post Microbial Dark Matter Could Revive Antibiotics appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Mike-Dark-Matter_GBPN_IMAGE_22OCT26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 01:55:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Microbial, Dark, Matter, Could, Revive, Antibiotics</media:keywords>
<content:encoded><![CDATA[<p>The world’s microbes have not run out of ways to fight bacteria. Antibiotic hunters may simply have been searching the same familiar territory—and overlooking what happens after a promising molecule is found. That is the central message of a <a href="https://www.sciencedirect.com/science/article/pii/S0734975026002600" target="_blank" rel="noopener">review</a> by Ahmed Hamed, PhD, and Zeinab Khalil, PhD, both at the University of Queensland. The researchers describe “microbial dark matter” as organisms that resist conventional cultivation, along with silent biosynthetic pathways in familiar microbes that could encode undiscovered natural products.</p>
<p>The stakes are considerable. Antimicrobial resistance directly caused an estimated 1.27 million deaths worldwide in 2019, according to figures cited in the review. Yet traditional screening has repeatedly mined the same microorganisms, particularly <em>Streptomyces</em>, often rediscovering known compounds rather than uncovering new antibiotic structures.</p>
<p>Genome-mining tools now identify biosynthetic gene clusters (BGCs)—groups of genes responsible for producing specialized molecules—even when those products never appear in laboratory cultures. Metagenomics extends the search to microbes that scientists cannot grow, while devices that recreate natural environments can bring some previously inaccessible organisms into cultivation.</p>
<p>Consider teixobactin, an antibiotic discovered from <em>Eleftheria terrae</em>, a soil bacterium recovered using an iChip device that cultivates microbes in their native environment. Although teixobactin shows activity against several Gram-positive pathogens, its producer remains difficult to grow conventionally. The review highlights the ongoing reliance on chemical synthesis to supply the compound.</p>
<p>“Detection, however, is not production,” the researchers write. An analysis of 50 studies cited by the authors found that large-scale attempts to express natural-product pathways in alternative microbial hosts produced detectable compounds only 11–32% of the time. Missing genes, inadequate precursor supply, product toxicity, and poor fermentation performance can all stall development.</p>
<p>The review makes bioprocess engineering central to the solution. In one cited study, adding talc microparticles to an engineered <em>Streptomyces</em> culture increased production of pamamycin nearly threefold, from 18 to 50 mg/L. Reworking pathway regulation, engineering microbial production hosts, and optimizing culture conditions offer other routes to better yields.</p>
<p>Artificial intelligence could help researchers choose which clusters deserve attention by connecting genomic and molecular features to predicted biological activity. But predictions still require experimental confirmation, and abundant material is needed to study a promising compound’s mechanism and development potential.</p>
<p>Rather than bet on any single platform, Hamed and Khalil envision an iterative workflow linking ecological sampling, genome and metabolome analysis, activity testing, target identification, and scalable production. The next antibiotic breakthrough, their review suggests, will depend as much on making a molecule as on finding it.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/microbial-dark-matter-could-revive-antibiotics/">Microbial Dark Matter Could Revive Antibiotics</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Decentralization, AI, and Gene Editing Are Opportunities for CGT Contractors</title>
<link>https://edusehat.com/en/decentralization-ai-and-gene-editing-are-opportunities-for-cgt-contractors</link>
<guid>https://edusehat.com/en/decentralization-ai-and-gene-editing-are-opportunities-for-cgt-contractors</guid>
<description><![CDATA[ CDMOs already play a critical role in the cell and gene therapy development and manufacturing space, says Rose Biosolutions. Emerging bioprocessing technologies, production methods, and strategies are creating even more opportunities for contractors.
The post Decentralization, AI, and Gene Editing Are Opportunities for CGT Contractors appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/06/GettyImages-2199680273.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 01:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Decentralization, AI, and, Gene, Editing, Are, Opportunities, for, CGT, Contractors</media:keywords>
<content:encoded><![CDATA[<p>Decentralization, artificial intelligence (AI) process modeling, and advances in gene editing are expanding the cell and gene therapy (CGT) production toolkit and creating opportunities for third-party contractors.</p>
<p>The CGT industry makes extensive use of CDMOs, with—depending on who you ask—anywhere between <a href="https://www.grandviewresearch.com/industry-analysis/cell-gene-therapy-manufacturing-market" target="_blank" rel="noopener">66%</a> and <a href="https://www.deloitte.com/content/dam/assets-zone3/us/en/docs/industries/life-sciences-health-care/2024/us-lshc-advanced-therapy-2024.pdf" target="_blank" rel="noopener">90%</a> of CGT production being outsourced to an external manufacturer.</p>
<p>Contractors play a pivotal role, in part, because they have the real-world production expertise that therapy developers lack, says Alan Smith, PhD, global head of innovation at <a href="https://www.prnewswire.com/news-releases/gi-partners-completes-acquisition-of-the-cdmo-and-cell-solutions-businesses-from-charles-river-laboratories-and-forms-rose-biosolutions-302765625.html" target="_blank" rel="noopener">recently founded</a> CDMO, Rose Biosolutions.</p>
<p>“Highly experienced CDMOs offer broad experience and capability, along with mastery of the activities required for a successful manufacturing, quality, and regulatory strategy needed to realize the partner developer’s vision.</p>
<p>“Good CDMOs build relationships; great CDMOs build relationships on trust, defined by competency and intimacy with their partners. The relationship has evolved with the needs of partner developers and grown to include expertise, experience, and trust,” he tells <em>GEN</em>.</p>
<p>Quality control expertise is a major outsourcing driver, according to Smith, who adds, “Strong quality systems employed by CDMO partners limit risk to product quality attributes that are of key concern in the logistics chain.</p>
<p>“A thorough understanding of key product quality attributes and appropriate product characterization lead to development of control strategies that ensure product consistency and meet the requirements of logistics chain,” he says.</p>
<h4><strong>Decentralization</strong></h4>
<p>In recent years, decentralized CGT manufacturing models, where patient-specific therapies are produced local to the intended recipients, have emerged as a way of minimizing transportation requirements.</p>
<p>And this is creating opportunities, says Jeff Mocny, PhD, vice president of scientific leadership at Rose, who tells <em>GEN</em>, “CDMOs can be uniquely positioned to accommodate the manufacturing needs of decentralized paradigms. Drawing on the expertise in product manufacture, required quality elements and expedited release strategies, they can enable high-quality, safe and effective delivery preparations to enable bedside production.”</p>
<h4><strong>Early adoption</strong></h4>
<p>According to <a href="https://www.simon-kucher.com/en/insights/cdmo-growth-report-2026" target="_blank" rel="noopener">analysis</a>, the CDMO space is competitive with most contractors seeking to differentiate themselves based on price and capabilities.</p>
<p>As a result, contractors tend to be well informed about potential market-reshaping advances in technology, Mocny says, citing systems that have recently emerged in the CGT space by way of example.</p>
<p>“There are many new gene editing strategies and gene delivery strategies which are likely to have a significant impact on the CGT space. Additionally, <em>in vivo</em> gene editing and gene delivery are showing promise in early studies and will likely have an impact on the direction that the industry is going.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/decentralization-ai-and-gene-editing-are-opportunities-for-cgt-contractors/">Decentralization, AI, and Gene Editing Are Opportunities for CGT Contractors</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Crossing the Digital Validation Chasm</title>
<link>https://edusehat.com/en/crossing-the-digital-validation-chasm</link>
<guid>https://edusehat.com/en/crossing-the-digital-validation-chasm</guid>
<description><![CDATA[ An iterative, risk-based, model-driven digital validation strategy enables rapid responses to process changes and innovative technological implementations that would be slow to validate using traditional processes.
The post Crossing the Digital Validation Chasm appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/06/GettyImages-1357100011-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 01:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Crossing, the, Digital, Validation, Chasm</media:keywords>
<content:encoded><![CDATA[<p>A digital validation chasm exists between good manufacturing practices and the adoption of advanced control strategies, according to researchers at the Pharmaceutical Manufacturing Technology Center, University of Limerick. They <a href="https://link.springer.com/article/10.1007/s12247-026-11080-1" target="_blank" rel="noopener">propose</a> bridging that gap with a unified, risk-based digital validation workflow that combines process understanding and model-based design with accepted quality risk management and lifecycle-oriented validation principles.</p>
<p>The chasm between traditional validation processes and digital technologies isn’t a regulatory issue, one of the researchers, Dermot McMorrow, PDEng, assistant professor, digital manufacturing, tells <em>GEN</em>. “Increasingly…it’s more about translating risk-based, lifecycle validation principles into day-to-day engineering practice,” he adds.</p>
<p>“Guidance supports the use of automation, iterative development, digital tools, and critical thinking…but validation is still often implemented through sequential, document-centric qualification activities that are fragmented from engineering development,” McMorrow elaborates. “The challenge, therefore, is organizational and methodological—how to integrate process understanding, risk assessment, engineering development, verification, and evidence generation into a coherent lifecycle.”</p>
<p>The model predictive controller the team developed for pH regulation used a data-driven Hammerstein-Wiener model to help tune the controller and “a process and control focused analysis…to identify and prioritize relevant failure modes and to inform requirements and verification scope,” according to the researchers, who were led by Damian McCarthy, PhD, staff robotics test engineer, and senior author Eoin Hinchy, PhD, associate professor, automated manufacturing.</p>
<p>“The main benefit,” McMorrow says, “is that the workflow connects process understanding, quality risk management, controller development, requirements, verification, and deployment within the same engineering lifecycle. Rather than treating validation-related verification as something performed after engineering is complete, evidence can be generated as the system is developed.</p>
<p>“The approach also creates explicit traceability from identified risks through functional requirements and acceptance criteria to verification activities and resulting evidence,” he adds.</p>
<p>Consequently, verification efforts can focus on the most relevant risks, thus supporting both automated repeatable testing and physical challenge testing. Because process changes can be validated relatively easily, one practical barrier to continuous system enhancements may be overcome.</p>
<p>The team also demonstrated in a real-world setting “that the controller developed and verified within the model-based environment can be deployed within an industry programmable logic controller environment,” McMorrow says. “Using the standard IEC 61131-3 structured text format also provides an industrially recognized representation of the controller implementation and supports traceability within the wider model-based workflow.”</p>
<h4><strong>Iterative imperative</strong></h4>
<p>Implementing such a workflow change, particularly in a highly regulated environment, should be done iteratively, with ample testing and user feedback.</p>
<p>Key implementation points, the researchers note, include assessing the maturity of the innovation to be implemented and the organization’s level of readiness for that advancement. The team’s prior work provides structured tools, such as an innovation maturity rubric, to guide those assessments.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>They found that model-based design-driven digital validation processes mitigated digital validation challenges. Specifically, they “streamlined compliance tasks, reduced resource burdens, and enhanced traceability, demonstrating the framework’s practicality in real-world settings,” according to McMorrow, in his earlier doctoral <a href="https://researchrepository.ul.ie/entities/publication/15208a65-ee25-4c78-8e73-dd34a5dacd7d" target="_blank" rel="noopener">research</a>.</p>
<p>The team’s proposed workflow “has the potential to reduce reliance on repeated manual testing and documentation,” McMorrow says, and thus support the real-time reconfigurations needed in modern production environments.</p>
<p>But, McMorrow cautions, “Any industrial implementation would still need to be incorporated into the organization’s own quality system, validation strategy, and regulatory context. The study…is a practical proof-of-concept…rather than a pre-validation solution ready for direct deployment.” Related work by this team has also applied model-based validation approaches to new and existing equipment, including legacy programmable logic controller systems.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/crossing-the-digital-validation-chasm/">Crossing the Digital Validation Chasm</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Human Dengue Study Reveals How Preexisting Immunity Shapes Secondary Infections</title>
<link>https://edusehat.com/en/human-dengue-study-reveals-how-preexisting-immunity-shapes-secondary-infections</link>
<guid>https://edusehat.com/en/human-dengue-study-reveals-how-preexisting-immunity-shapes-secondary-infections</guid>
<description><![CDATA[ A controlled human trial reveals how preexisting antibodies influence dengue virus replication and immune responses, offering insights to develop safer, more broadly protective vaccines against all four dengue strains.
The post Human Dengue Study Reveals How Preexisting Immunity Shapes Secondary Infections appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/07/GettyImages-1572391417-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 01:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Human, Dengue, Study, Reveals, How, Preexisting, Immunity, Shapes, Secondary, Infections</media:keywords>
<content:encoded><![CDATA[<p>Roughly half of the world’s population is now at risk of dengue, with an estimated 100–400 million infections occurring each year. The viral infection (also known as break-bone fever) is more common in tropical and subtropical areas of the world. Currently, prevention relies on control of the mosquito vector that transmits the virus.</p>
<p>Dengue virus has a particularly unique challenges, and is especially pernicious compared with many other viruses, as secondary infections can be worse than the first. Now, a new Phase I trial involving controlled infections in human volunteers provides new details about how preexisting immunity and anti-dengue antibodies affect the nature of secondary infections with dengue.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The work is published in <em>Science Translational Medicine</em> in the paper, “Dengue virus controlled human challenge reveals that preexisting immunity shapes viral replication and broadly protective responses.”</p>
<p>The findings are among the first to glean insights using a large controlled human challenge, and could inform future therapeutics and the design of more broadly protective vaccines.</p>
<p>Secondary infections with dengue are often the most severe ones because preexisting antibodies can boost viral counts and raise the risk of severe symptoms. This has frustrated the development of badly needed vaccines for dengue. Furthermore, it’s been challenging to understand how pre-infection affects dengue outcomes, as animal models have many limitations and patients usually don’t present until after viral counts have peaked.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>In this study, researchers recruited 45 healthy adults who had either zero, one, or more than one prior infection with any of the four strains of dengue virus (DENV1-DENV4). The volunteers received injections of a live, weakened strain of DENV3 in a challenge study, allowing the researchers to fully interrogate dengue immunity dynamics in humans in a safe and controlled setting.</p>
<p>The findings led to various conclusions: for example, people whose antibodies boosted the replication of the virus had the highest viral counts and waning of CD8-bearing T cells and antibodies. Additionally, people who had higher amounts of antibodies against the viral nonstructural protein 1 displayed more balanced immune responses and lower viral counts.</p>
<p>More specifically, the authors write, “Viremia was associated with more, but still mild, clinical signs and symptoms, and secondary infection resulted in greater viremia, neutralizing antibodies, and protective T cell responses. However, those whose baseline antibodies most efficiently increased dengue virus replication in an <em>in vitro</em> assay experienced delayed inflammatory and adaptive immune activation, the highest viremia, strong acute immune responses, and waning of potent CD8+ T cells and antibodies. In contrast, higher baseline antibodies against the nonstructural protein 1 of multiple serotypes predicted early interferon and balanced immune activation, viremia control, and development of enduring, potent B and T cells, revealing how vaccines can induce broad, long-­lasting protection.”</p>
<p>“Collectively, this work confirms multiple hypotheses generated by natural history studies and reveals the optimal conditions for inducing potent and persistent immunity against DENV1 to DENV4,” they note.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/human-dengue-study-reveals-how-preexisting-immunity-shapes-secondary-infections/">Human Dengue Study Reveals How Preexisting Immunity Shapes Secondary Infections</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Talking through taboo: the value of safe conversation during menopause</title>
<link>https://edusehat.com/en/talking-through-taboo-the-value-of-safe-conversation-during-menopause</link>
<guid>https://edusehat.com/en/talking-through-taboo-the-value-of-safe-conversation-during-menopause</guid>
<description><![CDATA[ Following Her Dental Network’s Menopause Conversation, Dr Shandy Vijayan reflects on recognising symptoms, finding support and why honest conversations matter in dentistry. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/menopause_event.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 22:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Talking, through, taboo:, the, value, safe, conversation, during, menopause</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Shandy Vijayan shares how Her Dental Network came together to address topics such as libido, physical discomfort and identity during menopause which are too often considered private or taboo.</strong></p>



<p>A room full of women, talking openly about sex. About low libido, hot flushes and disturbed sleep. About brain fog, fatigue, anxiety and overwhelm. About feeling less like yourself, without quite being able to explain what has changed.</p>



<p>About the impact on relationships, working lives and the confidence you once took for granted.</p>



<p>These subjects can be difficult to raise, even with people we know well. Yet at our Her Dental Network menopause event on 16 October at UNTIL Marylebone, women felt comfortable talking about them together.</p>



<p>As a co-founder of the network, that openness was what stayed with me.</p>



<p>We brought women together in partnership with Bupa Dental Care, with support from S3 Toothpaste, to make space for an honest conversation. Hearing experiences discussed openly can help someone recognise what she has been struggling to explain, or find the words to ask for help.</p>



<p>For a profession so accustomed to looking after others, there was something powerful about pausing to consider our own health.</p>



<h2 class="wp-block-heading">Learning from our speakers</h2>



<p>We learnt from Dr Nitu Bajekal, Dr Maitri Shila Tursini, Dr Nikita Mehta and Dr Arti Shah, with the conversation moderated by Dr Makbule Sipahi.</p>



<p>Their contributions helped us explore the many ways menopause can affect women’s health, relationships and working lives. Alongside recognising symptoms, we discussed the importance of seeking support, understanding management options and feeling comfortable asking questions about our own bodies.</p>



<p>The openness between the speakers and the women in the room made it possible to raise subjects that too often remain private.</p>



<figure class="wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-1 is-layout-flex wp-block-gallery-is-layout-flex">
<figure class="wp-block-image size-large"></figure>



<figure class="wp-block-image size-large"></figure>



<figure class="wp-block-image size-large"></figure>
</figure>



<h2 class="wp-block-heading">Recognising the changes</h2>



<p>Hot flushes are widely recognised. The wider picture can be much harder to identify.</p>



<p>Perimenopause can bring changes in sleep, mood, concentration, menstrual patterns and sexual wellbeing. Symptoms may begin while periods are still happening, and experiences vary considerably.</p>



<p>A woman may notice unfamiliar anxiety. Another may feel overwhelmed by responsibilities she previously managed comfortably. Someone else may struggle with broken sleep, then spend the following day exhausted, irritable and wondering why everything feels harder.</p>



<p>It can be difficult to recognise a pattern when each symptom has a plausible explanation. Work is demanding. Family life is busy. There is always something else to do.</p>



<p>These changes should not automatically be attributed to menopause. Other causes may need assessment. But recognising perimenopause as a possibility can help women seek appropriate advice rather than repeatedly dismissing their symptoms.</p>



<p>There is no need to wait until symptoms become unbearable before speaking to a GP. <a href="https://www.nhs.uk/conditions/menopause-and-perimenopause/symptoms/" target="_blank" rel="noreferrer noopener">NHS guidance on menopause and perimenopause symptoms</a> explains when to seek advice.</p>



<h2 class="wp-block-heading">Why this matters in dentistry</h2>



<p>Think about what a working day asks of a dental professional.</p>



<p>We need concentration, precision, physical stamina and the ability to reassure patients. We work to busy diaries, often with limited opportunities to pause.</p>



<p>Now consider doing that after several nights of disrupted sleep, while managing a hot flush beneath PPE or feeling unusually anxious before a familiar procedure.</p>



<p>Brain fog can feel particularly unsettling in a profession where being organised and dependable matters so much. A difficult day may leave someone questioning herself long after she has gone home.</p>



<p>The conversation belongs across the whole dental team, including nurses, hygienists, therapists, receptionists, practice managers and dentists.</p>



<p>Everyone should know who they can approach privately and what support might be available. Asking for help needs to feel possible before someone reaches a crisis.</p>



<figure class="wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-2 is-layout-flex wp-block-gallery-is-layout-flex">
<figure class="wp-block-image size-large"></figure>



<figure class="wp-block-image size-large"></figure>



<figure class="wp-block-image size-large"></figure>
</figure>



<h2 class="wp-block-heading">Turning recognition into care</h2>



<p>Recording symptoms, changes in periods and their effect on daily life can help prepare for a healthcare appointment. A short written account makes it easier to explain what has changed and which problems matter most.</p>



<p>That includes anxiety, overwhelm and changes in confidence. Emotional symptoms deserve attention alongside physical symptoms.</p>



<p>Management should reflect the individual’s symptoms, medical history and preferences. HRT is one option to discuss with a clinician. Non-hormonal treatments are also available, while cognitive behavioural therapy can help with symptoms such as sleep difficulties and the impact of hot flushes. <a href="https://www.nhs.uk/conditions/menopause-and-perimenopause/treatment/" target="_blank" rel="noreferrer noopener">NHS guidance on menopause treatment</a> outlines the options.</p>



<p>Sexual wellbeing deserves the same care and attention.</p>



<p>Vaginal dryness, discomfort during sex and reduced desire can be difficult to mention, but they are valid reasons to seek advice. Vaginal moisturisers, lubricants and prescribed vaginal oestrogen may help with dryness and discomfort. Persistent low desire can also be assessed, including the physical, emotional and relationship factors that may contribute.</p>



<p>Women deserve to feel comfortable raising these concerns, without minimising them or apologising for asking.</p>



<h2 class="wp-block-heading">Supporting health day to day</h2>



<p>Regular movement, including resistance exercise and weight-bearing activity such as walking, supports muscle and bone health. A varied diet containing calcium-rich foods, attention to sleep and reducing personal triggers such as alcohol or caffeine may also help. These changes need to be manageable, particularly when fatigue is already affecting everyday life. <a href="https://www.nhs.uk/conditions/menopause-and-perimenopause/things-you-can-do/">NHS self-care guidance</a> has further information.</p>



<p>There is also a crowded market of menopause supplements. Before spending money, check the evidence and speak to a pharmacist or clinician. The effectiveness and safety of many herbal remedies remain uncertain, and some can interact with medicines.</p>



<figure class="wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-3 is-layout-flex wp-block-gallery-is-layout-flex">
<figure class="wp-block-image size-large"></figure>



<figure class="wp-block-image size-large"></figure>



<figure class="wp-block-image size-large"></figure>
</figure>



<h2 class="wp-block-heading">Making support visible at work</h2>



<p>A supportive practice makes it easy to begin a confidential conversation.</p>



<p>A manager can ask what would help, agree practical changes and arrange a time to review them. Depending on the individual and her role, support might include access to drinking water, a more comfortable room temperature, protected breaks or flexibility in working arrangements.</p>



<p><a href="https://www.acas.org.uk/menopause-at-work">Acas guidance on menopause at work</a> encourages employers to understand the effects of menopause and respond to individual needs.</p>



<p>A policy provides a starting point. Its value becomes clear when someone needs to use it.</p>



<p>Can a colleague explain that she is struggling and feel listened to? Does she know where to find reliable information? Does the conversation lead to practical help?</p>



<p>Support should also respect privacy. No one should feel obliged to share intimate details with colleagues to have her concerns taken seriously.</p>



<h2 class="wp-block-heading">Taking the conversation forward</h2>



<p>Our evening showed how valuable it can be to have room for questions that women may have kept to themselves.</p>



<p>Through Her Dental Network, Raabiha and I want to keep creating opportunities for women to share experiences, access reliable information and find support.</p>



<p>For anyone recognising herself in these words, a GP appointment is a useful place to begin. The NHS, Women’s Health Concern and The Menopause Charity also provide information to help women understand their options.</p>



<p>Feeling less like yourself deserves attention. Persistent anxiety, exhaustion, discomfort or overwhelm deserve a conversation.</p>



<p>Women should come away from that conversation knowing that symptoms can be assessed, management options exist and help is available.</p>



<p>The openness we experienced and the expert knowledge shared in that room is something we want women to carry into their healthcare appointments, their relationships and their working lives.</p>



<p>We look forward to exploring these and many more conversations at our next annual Thrive Together 2, on 10 July 2027 at the Leonardo Royal London St Paul’s hotel. Join us for another opportunity to connect, learn and feel supported alongside women from across dentistry.</p>



<p><em><a href="https://sso.dentistry.co.uk/">Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</a></em></p>]]> </content:encoded>
</item>

<item>
<title>How to Keep the Skin Looking Young: Anti&#45;Aging From the Inside Out </title>
<link>https://edusehat.com/en/how-to-keep-the-skin-looking-young-anti-aging-from-the-inside-out</link>
<guid>https://edusehat.com/en/how-to-keep-the-skin-looking-young-anti-aging-from-the-inside-out</guid>
<description><![CDATA[ Exploring What “Younger-Looking Skin” Means Today, and How to Separate Trend From Truth  To understand how to keep the skin…
The post How to Keep the Skin Looking Young: Anti-Aging From the Inside Out  appeared first on Optima Dermatology. ]]></description>
<enclosure url="https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Oct_Anti-aging_Banner.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 22:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Keep, the, Skin, Looking, Young:, Anti-Aging, From, the, Inside, Out </media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"><img fetchpriority="high" decoding="async" width="1024" height="341" src="https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Oct_Anti-aging_Banner-1024x341.jpg" alt='"Anti-aging from the Inside Out" blog with a woman holding a serum. ' class="wp-image-205878" srcset="https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Oct_Anti-aging_Banner-1024x341.jpg 1024w, https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Oct_Anti-aging_Banner-300x100.jpg 300w, https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Oct_Anti-aging_Banner-768x256.jpg 768w, https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Oct_Anti-aging_Banner.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px"></figure>



<h2 class="wp-block-heading"><strong>Exploring What “Younger-Looking Skin” Means Today, and How to Separate Trend From Truth</strong> </h2>



<p class="wp-block-paragraph">To understand how to keep the skin looking young, you have to go beyond marketing claims and social media influencers to evaluate the efficacy of specific products, treatments, procedures, and skin care regimens, and what will work best for your unique skin type. When it comes to anti-aging skin care, the science and evidence behind a certain approach often carries more weight than a trend.  </p>



<h2 class="wp-block-heading"><strong>Anti-Aging Has Long Influenced the Skin Care Industry</strong> </h2>



<p class="wp-block-paragraph">The long-sought “secret” for how to keep the skin looking young has fueled product marketing campaigns since the earliest days of advertising, where cosmetic brands took out full-page spreads in magazines like Harper’s Bazaar and Vogue to tout the ability for their products to achieve youthful beauty. In one ad (shown below), Dorothy Gray Salon went so far as to say their collagen cream could “help you side-step the tragedy of the middle years.” </p>



<figure class="wp-block-image size-full is-resized"><img decoding="async" width="165" height="239" src="https://optimadermatology.com/wp-content/uploads/2026/10/image.png" alt='"Who wants to look young" newspaper article.' class="wp-image-205879"></figure>



<p class="wp-block-paragraph"><em>Tokalon Biocel Skinfood, 1939.</em> <a href="https://www.whitfords.co.uk/surface-tensions-the-underlying-truths-of-skincare-advertising/" target="_blank" rel="noopener"><em>Whitfords.co.uk</em></a><em></em> </p>



<figure class="wp-block-image size-full is-resized"><img decoding="async" width="154" height="234" src="https://optimadermatology.com/wp-content/uploads/2026/10/image-1.png" alt='"Does Your Husband Look Younger than You do?" news article. ' class="wp-image-205880"></figure>



<p class="wp-block-paragraph"><em>Dorothy Gray Salon, 1951.</em> <a href="https://repository.duke.edu/dc/adaccess/BH1920" target="_blank" rel="noopener"><em>Duke University Libraries Repository</em></a> </p>



<p class="wp-block-paragraph">Today, the anti-aging narrative has morphed into a massive social media influencer culture of creams, procedures, peptides, personalized routines, tips, trends, and before-and-after glow-up videos complete with the amped-up background music that can instill confidence in even the most critical of consumers. </p>



<p class="wp-block-paragraph">While we know advertising younger skin is nothing new, today’s greater access to information and advice can quickly muddy the waters, leading to confusion and, in some cases, the use of incorrect or untested products that carry risks.  </p>



<p class="wp-block-paragraph">To sort the trends from the truth, this article examines science-backed anti-aging methods shown to promote younger-looking skin, and other approaches that stand out in the crowded influencer landscape. </p>



<h2 class="wp-block-heading"><strong>Copper Peptides Offer Antioxidants, Tissue Rebuilding, and Anti-Inflammatory Properties</strong> </h2>



<p class="wp-block-paragraph">Peptides are short chains of amino acids that signal different processes throughout the body. Their potential to support the skin’s natural repair and renewal processes has elevated peptides as a key ingredient across skin care product lines.  </p>



<p class="wp-block-paragraph">Copper peptide GHK-Cu is a naturally occurring compound made up of exactly what you would expect by the name: the peptide GHK bound to copper. Early clinical research <a href="https://pubmed.ncbi.nlm.nih.gov/35083444/" target="_blank" rel="noopener">found that</a> GHK-Cu “has been shown to promote skin remodeling, wound healing and regeneration, and has prominent antioxidant and anti-inflammatory effects.” </p>



<p class="wp-block-paragraph">Ever the voice for top beauty trends, Vogue <a href="https://www.vogue.com/article/copper-peptides" target="_blank" rel="noopener">published</a> a lengthy article in late 2025 about the anti-aging benefits of copper peptides when applied topically, particularly for stimulating “collagen synthesis, and helping maintain the skin’s firmness and resilience while slowing visible aging.” </p>



<p class="wp-block-paragraph">Copper peptides were discovered in 1973, but they continue to be studied as clinical evidence for their anti-aging properties is limited compared with other, more well-established treatments. </p>



<p class="wp-block-paragraph"><strong>Should you use copper peptides?</strong> Copper peptides are a reasonable anti-aging skin care treatment, but shouldn’t replace proven strategies like sun protection, topical retinoids, or dermatologist-directed treatments. </p>



<p class="wp-block-paragraph"><strong>The Controversial Use of Tanning Peptides for Anti-Aging</strong> </p>



<p class="wp-block-paragraph">“Tanning peptides” – Melanotan II, is a synthetic, injectable peptide that stimulates melanin, the natural pigment the skin produces to protect cellular DNA from sun damage. </p>



<p class="wp-block-paragraph">The anti-aging argument for using Melanotan II requires a bit of circuitous logic: creating a tan with an injectable peptide removes the need to tan under the sun, therefore avoiding one of the biggest contributors to premature skin aging (UV rays).  </p>



<p class="wp-block-paragraph">However, this rather simplistic justification fails to consider the risks of treating any product as a safe substitute for proven sun protection. The FDA has not approved Melanotan II and warns about the marketing and distribution of unapproved injectable tanning treatments. Further, the Skin Cancer Foundation has sounded alarm bells about numerous health concerns associated with Melanotan II use: </p>



<ul class="wp-block-list">
<li>Development of melanoma </li>
</ul>



<ul class="wp-block-list">
<li>Changes in moles and pigmented lesions that can make skin cancer harder to detect </li>
</ul>



<ul class="wp-block-list">
<li>Serious health effects, including systemic toxicity and muscle damage </li>
</ul>



<p class="wp-block-paragraph">Plus, the origin, purity, contents, and dosage are unknown, as patients typically acquire Melanotan II through unregulated online sources. </p>



<p class="wp-block-paragraph"><strong>Should you use tanning peptides?</strong> No. Using a tanning peptide to look tan without UV exposure doesn’t mean you don’t need sun protection, and it doesn’t make a tanning peptide an anti-aging treatment. A tan is the skin’s response to UV radiation, and UV exposure contributes to premature skin aging, including wrinkles, loss of elasticity, uneven pigmentation, and leathery skin. It also increases the risk of skin cancer. Coupled with the other suspected health risks, it’s best to avoid tanning peptides. If you are seeking a bronzed appearance, use a topical sunless tanning product instead. But remember, a self-tanner should never be considered a substitute for sun protection. </p>



<h2 class="wp-block-heading"><strong>Achieving Younger-Looking Skin Using the Bryan Johnson Blueprint</strong> </h2>



<p class="wp-block-paragraph">Bryan Johnson is a tech entrepreneur who, while known for making millions selling Venmo to PayPal in 2013, has more recently caught the public eye for a very different reason. Johnson is dedicated to an extreme anti-aging and longevity regimen called “Project Blueprint”. Johnson’s “don’t die” philosophy involves essentially fighting death and aging by scientifically reversing his biological age – including the aging of his skin.  </p>



<p class="wp-block-paragraph">His approaches to youthful skin include a variety of dermatological treatments to improve skin quality. He has spoken publicly about using treatments like: </p>



<ul class="wp-block-list">
<li>Microneedling </li>
</ul>



<ul class="wp-block-list">
<li>Platelet-rich fibrin and platelet-rich plasma (PRP), in which the patient’s own blood is treated and injected into the skin to release growth factors and rejuvenate the skin </li>
</ul>



<ul class="wp-block-list">
<li>Sofwave, a non-invasive ultrasound device, and Tixel, a fractional skin rejuvenation system, to support collagen and elastin </li>
</ul>



<p class="wp-block-paragraph">On his website, he <a href="https://www.bryanjohnson.com/" target="_blank" rel="noopener">claims</a>: “When I started Blueprint, my skin was in the 98th percentile for damage, with a skin age of 64. Now, my skin age has improved to age 36.” </p>



<p class="wp-block-paragraph">Any dermatologist will caution against taking these claims at face value. Everyone’s skin is different, and one individual’s customized longevity protocol likely isn’t a blueprint for everyone else.  </p>



<p class="wp-block-paragraph">That being said, let’s explore two of Bryan Johnson’s protocols for achieving younger-looking skin; microneedling and PRP.  </p>



<h2 class="wp-block-heading"><strong>Can Microneedling Make My Skin Look Younger?</strong> </h2>



<p class="wp-block-paragraph">Microneedling is a minimally invasive dermatologic procedure that uses ultra-fine needles to make microscopic holes in the top layer of the skin. Doing so stimulates a healing response in the skin, encouraging the production of collagen and elastin, which help keep your skin firm and smooth. </p>



<p class="wp-block-paragraph"><strong>Dive Deeper:</strong> <a href="https://optimadermatology.com/2023/09/05/what-is-microneedling" target="_blank" rel="noopener">What is Microneedling? FAQs About the Different Types of Treatment Options</a> </p>



<p class="wp-block-paragraph">When you see a credentialed aesthetic professional (rather than use an at-home microneedling kit, which can carry significant risks), microneedling can help diminish: </p>



<ul class="wp-block-list">
<li>Acne scars </li>
</ul>



<ul class="wp-block-list">
<li>Dark spots </li>
</ul>



<ul class="wp-block-list">
<li>Large pores </li>
</ul>



<ul class="wp-block-list">
<li>Melasma </li>
</ul>



<ul class="wp-block-list">
<li>Skin Laxity  </li>
</ul>



<ul class="wp-block-list">
<li>Scars due to surgery or an injury </li>
</ul>



<ul class="wp-block-list">
<li>Uneven skin texture and tone </li>
</ul>



<ul class="wp-block-list">
<li>Wrinkles and fine lines </li>
</ul>



<h2 class="wp-block-heading"><strong>Microneedling with Platelet-Rich Plasma</strong> </h2>



<p class="wp-block-paragraph">Microneedling can also be combined with PRP. Microneedling creates controlled openings in the skin while PRP is applied to the treated area. This combination has been used primarily for minimizing acne scars and skin rejuvenation.  </p>



<p class="wp-block-paragraph">While these treatments have generated favorable results, the right treatment depends on your unique skin type and situation. Your provider will help set realistic expectations for what the procedure can accomplish and what results to expect.  </p>



<h2 class="wp-block-heading"><strong>Best-Practice Skin Care Techniques to Reduce the Signs of Aging</strong> </h2>



<p class="wp-block-paragraph">Keeping the skin looking youthful can be simpler than product marketers and social media influencers may lead us to believe.  </p>



<ul class="wp-block-list">
<li><strong>Protect your skin from the sun.</strong> UV radiation damages collagen and elastin, and can cause wrinkles and changes in pigmentation and skin texture. Apply a daily sunscreen with an SPF of 30 or higher, and practice consistent sun protection during any exposure. </li>
</ul>



<ul class="wp-block-list">
<li><strong>Use proven topical ingredients.</strong> Speak to your provider about the best topical ingredients for your skin type and specific concerns. Products containing retinoids, vitamin C, niacinamide, or tretinoin, among others, have evidence supporting their ability to reduce signs of aging.  </li>
</ul>



<ul class="wp-block-list">
<li><strong>Consider cosmetic treatments.</strong> For more significant improvements with faster results, a credential aesthetic professional may recommend in-office procedures like microneedling, laser treatments, chemical peels, injectables, and other collagen-stimulating or skin-resurfacing treatments.  </li>
</ul>



<p class="wp-block-paragraph"><strong>Dive Deeper:</strong> <a href="https://optimadermatology.com/2022/11/30/laser-and-light-treatments-for-skin-rejuvenation" target="_blank" rel="noopener">Laser and Light Treatments for Skin Rejuvenation</a> </p>



<p class="wp-block-paragraph">The reality is that we cannot stop the aging process, but the goal should be to help your skin age in a healthy way while addressing the issues that matter most to you.  </p>



<p class="wp-block-paragraph">This prevailing skin care movement focused on anti-aging from the inside out reflects a shift in how people think about their skin. Rather than simply trying to cover up wrinkles, people are considering their skin’s overall health, structure, and function; this approach can be a positive, as long as evidence-based dermatology is considered above marketing or influencer hype. </p>



<p class="wp-block-paragraph">If you have concerns about minimizing the signs of aging, or want to learn more about how to keep your skin healthy as you age, <a href="https://optimadermatology.com/request-appointment" target="_blank" rel="noopener">schedule an appointment</a> with our team. </p>



<hr class="wp-block-separator has-alpha-channel-opacity">



<h2 class="wp-block-heading"><strong>Frequently Asked Questions About Anti-Aging Skin Care</strong> </h2>



<h3 class="wp-block-heading"><strong>Do copper peptides really help reduce wrinkles?</strong> </h3>



<p class="wp-block-paragraph">Copper peptides such as GHK-Cu have properties that may support collagen production, tissue remodeling, and skin repair. However, clinical evidence for their ability to significantly reduce wrinkles is still limited compared with established anti-aging treatments such as topical retinoids. A dermatologist can help determine whether a copper peptide product is appropriate for your skincare routine. </p>



<h3 class="wp-block-heading"><strong>Are tanning peptides like Melanotan II safe?</strong> </h3>



<p class="wp-block-paragraph">Melanotan II is not FDA-approved as a tanning treatment, and the FDA has identified safety concerns associated with products containing the peptide. Tanning peptides should not be considered a safe alternative to sunscreen or a proven anti-aging treatment. </p>



<h3 class="wp-block-heading"><strong>Does microneedling make your skin look younger?</strong> </h3>



<p class="wp-block-paragraph">Microneedling can improve the appearance of fine lines, wrinkles, uneven texture, acne scars, and skin laxity by stimulating the body’s collagen-production process. Results develop gradually and may require multiple treatments depending on the individual’s skin concerns. </p>



<h3 class="wp-block-heading"><strong>Does PRP work for facial rejuvenation?</strong> </h3>



<p class="wp-block-paragraph">PRP may help improve certain signs of skin aging and can be used with procedures such as microneedling. However, research on PRP for facial rejuvenation is still developing, and results can vary between patients. A dermatologist can help determine whether PRP is an appropriate option based on your goals and medical history. </p>



<h3 class="wp-block-heading"><strong>What is the best dermatologist-recommended anti-aging treatment for skin?</strong> </h3>



<p class="wp-block-paragraph">There is no single best anti-aging treatment for everyone. Effective skin-aging strategies typically include daily sun protection, an appropriate skincare routine, and dermatologist-recommended treatments based on individual concerns such as wrinkles, pigmentation, loss of firmness, or uneven texture. A credentialed aesthetic professional can create a personalized plan that may include topical medications, microneedling, laser treatments, or other procedures. </p>
<p>The post <a href="https://optimadermatology.com/2026/10/28/how-to-keep-the-skin-looking-young-anti-aging-from-the-inside-out">How to Keep the Skin Looking Young: Anti-Aging From the Inside Out </a> appeared first on <a href="https://optimadermatology.com/">Optima Dermatology</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Nova Scotia prepares for provincewide expansion of electronic patient records</title>
<link>https://edusehat.com/en/nova-scotia-prepares-for-provincewide-expansion-of-electronic-patient-records</link>
<guid>https://edusehat.com/en/nova-scotia-prepares-for-provincewide-expansion-of-electronic-patient-records</guid>
<description><![CDATA[ Nova Scotia is preparing for a significant expansion of its electronic patient-record system, with hospitals and healthcare facilities across three additional health zones scheduled to begin using the technology on November 14. The One Person One Record (OPOR) initiative is designed to bring patient information together in a shared clinical system, allowing authorized healthcare professionals […]
The post Nova Scotia prepares for provincewide expansion of electronic patient records appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Nurses-Reviewing-Patient-Records-Together.png" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 22:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Nova, Scotia, prepares, for, provincewide, expansion, electronic, patient, records</media:keywords>
<content:encoded><![CDATA[<p>Nova Scotia is preparing for a significant expansion of its electronic patient-record system, with hospitals and healthcare facilities across three additional health zones scheduled to begin using the technology on November 14.</p>
<p>The One Person One Record (OPOR) initiative is designed to bring patient information together in a shared clinical system, allowing authorized healthcare professionals to access medical records, test results, medications and treatment information more efficiently.</p>
<p>The upcoming implementation will extend the system to Nova Scotia Health’s Northern, Eastern and Western zones, completing a major stage of the province’s digital healthcare transformation.</p>
<h3>Connecting healthcare across the province</h3>
<p>The system was introduced at IWK Health in December 2025 and expanded to Nova Scotia Health’s Central Zone in May 2026.</p>
<p>Once fully implemented, One Person One Record is expected to replace or integrate more than 50 existing systems used by healthcare professionals to document and access patient information.</p>
<p>The province estimates that more than 26,000 healthcare professionals will eventually have access to real-time patient information, according to their roles and responsibilities.</p>
<p>For patients, the system is intended to reduce the need to repeatedly provide medical histories when receiving care at different facilities. It is also expected to improve communication among healthcare teams and reduce unnecessary duplication of diagnostic testing.</p>
<h3>Improving medication and patient safety</h3>
<p>A central component of the initiative is Computerized Provider Order Entry (CPOE), which allows physicians and other authorized healthcare professionals to enter and manage clinical orders electronically.</p>
<p>The technology is designed to provide immediate visibility into medication orders, laboratory requests and other clinical instructions.</p>
<p>Built-in clinical decision support can also alert healthcare professionals to potential medication allergies, dosing concerns and other safety issues before treatment is administered.</p>
<p>The system supports electronic medication verification, including barcode scanning to help confirm that patients receive the correct medications and doses.</p>
<p>Nova Scotia Health says these features are intended to strengthen patient safety while improving coordination between healthcare professionals.</p>
<h3>Preparing healthcare teams for implementation</h3>
<p>The November expansion represents a substantial operational change for hospitals and healthcare workers.</p>
<p>Training and practice sessions have been organized to help physicians, nurses and other clinical staff become familiar with the system and its workflows.</p>
<p>During previous implementation stages, Nova Scotia Health advised patients that some appointments and administrative processes could take longer while healthcare teams adjusted to the technology.</p>
<p>The province’s broader initiative is supported by a 10-year, $365-million agreement signed in 2023 to develop, implement and maintain the clinical information system.</p>
<p>The upcoming expansion represents another step toward a more connected healthcare system, with the potential to improve continuity of care as patients move between hospitals, specialists and other healthcare services.</p>
<p>The full impact on patient outcomes, workflow efficiency and healthcare costs will depend on successful implementation and ongoing evaluation.</p>
<p><strong>Sources:</strong> <a href="https://news.novascotia.ca/en/2026/05/07/one-person-one-record-launch-across-central-health-zone?utm_source=chatgpt.com">Nova Scotia Health and Government of Nova Scotia</a>.</p>
<p>The post <a href="https://www.hospitalnews.com/nova-scotia-prepares-for-provincewide-expansion-of-electronic-patient-records/">Nova Scotia prepares for provincewide expansion of electronic patient records</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>We don’t do God in dentistry</title>
<link>https://edusehat.com/en/we-dont-do-god-in-dentistry</link>
<guid>https://edusehat.com/en/we-dont-do-god-in-dentistry</guid>
<description><![CDATA[ Faith can affect treatment decisions, appointment planning and workplace relationships, yet dentistry rarely discusses it. Professor Raman Bedi argues that greater understanding would improve patient care. In 2003, Alastair Campbell famously declared that new Labour did not ‘do God’. Dentistry has often taken the same line, but our patients and colleagues bring their faith into… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/religion.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 19:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>don’t, God, dentistry</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Faith can affect treatment decisions, appointment planning and workplace relationships, yet dentistry rarely discusses it. Professor Raman Bedi</strong> <strong>argues that greater understanding would improve patient care.</strong></p>



<p>In 2003, Alastair Campbell famously declared that new Labour did not ‘do God’. Dentistry has often taken the same line, but our patients and colleagues bring their faith into the surgery every day.</p>



<p>Ask most dental professionals what shapes a patient’s experience of care and they will mention anxiety, cost, access or a bad experience in the past. Few would mention faith.</p>



<p>Yet for millions of people in the UK, religious belief informs how they understand their bodies, health and treatment decisions. It also shapes many of the people who deliver that care. It is a subject we rarely discuss openly, and perhaps it is time we did.</p>



<h2 class="wp-block-heading">Faith in everyday practice</h2>



<!--free-wall-stop-->



<p>The 2021 Census for England and Wales found that just under half of the population described themselves as Christian, while around one in 10 identified with another religion, including Islam, Hinduism, Sikhism, Judaism and Buddhism.</p>



<p>In many of our towns and cities, the population is more diverse still. Every dental team, whether it realises it or not, cares for people of faith every day.</p>



<p>Most of the time, this makes no visible difference. Sometimes it matters a great deal.</p>



<p>A Muslim patient observing Ramadan may be unsure whether an injection, rinse or impression will break their fast, and may simply cancel rather than ask. A patient may want to know whether a haemostatic agent, <a href="https://dentistry.co.uk/2026/09/28/dental-bone-graft-material-consent/">bone graft material</a> or medicine contains porcine or bovine derivatives.</p>



<p>Others may have questions about alcohol-based mouthwashes, treatment by a clinician of the same sex or appointments that clash with holy days and festivals. A Jehovah’s Witness facing oral surgery may also have specific concerns about blood products.</p>



<p>None of these questions is unusual. But each can become a barrier to care if the patient senses that it will not be understood or respected.</p>



<p>Getting it right is rarely complicated. It begins with curiosity, a willingness to ask and enough knowledge to give a sensible answer or know where to find one. Getting it wrong can quietly erode trust and lead patients to delay or avoid treatment altogether.</p>



<h2 class="wp-block-heading">Faith in the dental team</h2>



<p>Faith is not only something patients bring into the surgery. Many dentists, therapists, hygienists, nurses and practice staff are people of faith themselves.</p>



<p>For some, belief is the reason they entered a caring profession. It gives meaning to long days and resilience during difficult ones. At a time when the profession is under real strain, with high levels of stress and burnout reported across the workforce, the sources of strength that sustain clinicians deserve serious attention.</p>



<p>Faith also raises genuine professional questions. How should a clinician balance personal conviction with their duty to every patient? Where is the line between being open about who you are and imposing your beliefs on others? How do teams comprising people of different faiths, and none, work well together?</p>



<p>The General Dental Council’s standards are clear that every patient must be treated fairly and that personal beliefs must never prejudice care. Within that framework, there is room for a far richer conversation than we usually have.</p>



<h2 class="wp-block-heading">An opportunity for the profession</h2>



<p>Faith communities are also potential partners in improving oral health. Places of worship reach people who seldom engage with health services, and religious leaders are often among the most trusted voices in their communities.</p>



<p>Oral health promotion delivered alongside faith communities, rather than simply to them, may reach families that conventional approaches miss.</p>



<p>None of this asks the profession to take a position on matters of belief. It asks only that we recognise faith as a significant part of the lives of many patients and colleagues, and that we equip ourselves to respond with knowledge, sensitivity and respect.</p>



<p>That is simply good, patient-centred care.</p>



<p><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</em></a></p>



<p></p>]]> </content:encoded>
</item>

<item>
<title>PACE panels tackle challenges to access and barriers to coverage</title>
<link>https://edusehat.com/en/pace-panels-tackle-challenges-to-access-and-barriers-to-coverage</link>
<guid>https://edusehat.com/en/pace-panels-tackle-challenges-to-access-and-barriers-to-coverage</guid>
<description><![CDATA[ Breakthrough therapies can change the lives of patients who previously had few or no treatments for their conditions, but only if the patients can […]
The post PACE panels tackle challenges to access and barriers to coverage appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/Death-by-1000-cuts.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 18:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PACE, panels, tackle, challenges, access, and, barriers, coverage</media:keywords>
<content:encoded><![CDATA[<p><span>Breakthrough therapies can change the lives of patients who previously had few or no treatments for their conditions, but only if the patients can break through the barriers to accessing those drugs.</span></p>
<p><span>Challenges to access were a primary focus of BIO’s 15</span><span>th</span><span> annual Patient Advocacy Changemakers Event, the premier gathering of patients, advocates, drugmakers, and policymakers, held Oct. 22-23 in Washington, DC. There were several expert panels specifically exploring the challenges of overcoming barriers to coverage for drugs patients need.</span></p>
<p><span>Below are some of the lessons offered.</span></p>
<h2>Death by a thousand cuts: Utilization management</h2>
<p><span>During </span><a href="https://pace.bio.org/2026-program/death-thousand-cuts-1"><span>a session on interconnected challenges </span></a><span>restricting patient access, one utilization management approach panelists discussed was step therapy, which asks patients to fail first on a cheaper drug before getting the drug their doctor prescribed. Panelists said patients feel trapped and frightened when told they can’t get the medicine their doctor recommends.</span></p>
<p><span>The social workers at CancerCare can receive a thousand calls a week from such patients, said Kim Czubaruk, VP of Policy at CancerCare.</span></p>
<p><span>“But behind each call is a patient or a caregiver that really is probably in the toughest moment of their life,” she added.</span></p>
<p><span>The number of people who need help is more than any patient group can handle, said panelist Brian Connell, VP of Federal Affairs at Blood Cancer United. “There are folks who fall through the cracks and don’t get the right treatment. I think that points to the need for broader systemic reform.”</span></p>
<h2>Enabling coverage of new drugs</h2>
<p><a href="https://pace.bio.org/2026-program/getting-runaround-games-payers-play--1"><span>Another session </span></a><span>explored best practices for patient groups seeking to engage payers to ensure coverage for new breakthrough therapies.</span></p>
<p><span>Mike Graglia, CEO of Cure SYNGAP1, said the rare neurodevelopmental disease SYNGAP1 has many symptoms—like seizures and disturbed sleep—that can be treated with other drugs, and other symptoms unaddressed by existing treatments—including a tendency to violence. There are genetic treatments for SYNGAP1 in the pipeline, and Graglia’s group wants to make sure they will be covered by insurance.</span></p>
<p><span>“We’re going to survey our own community and try to measure the impact—the lost earnings, the divorces, the mental health burden, the burden on siblings, all the things that are really easy to talk about, but really actually hard to measure,” he explained.</span></p>
<p><span>When an insurer does not agree to put a new drug in its formulary, patients and their advocates can appeal the decision, sometimes with good effect, panelists said.</span></p>
<p><span>“My message for everyone here is, number one: Always appeal, and tell your whole community, always appeal, especially in the age of AI, where we know 80% of these denials are overturned on appeal,” said Melanie Lendnal, SVP of Policy & Advocacy at ALS Association.</span></p>
<p><span>“In urgent situations, you can ask for an expedited appeal, and get an answer within 72 hours,” added Monica Bryant, Co-Founder of Triage Cancer. She said few in the patient community are aware of this possibility, and even healthcare professionals are surprised to hear it.</span></p>
<h2>From clinical guidelines to access in the clinic</h2>
<p><span>One tool patients and health care professionals can use as evidence in promoting coverage for a new drug is </span><a href="https://pace.bio.org/2026-program/clinical-guidelines-access"><span>through clinical guidelines, according to a session</span></a><span> moderated by Lenja Wiehe, Director, Global Patient Advocacy Lead at Alexion.</span></p>
<p><span>“We all share a responsibility to make sure that scientific progress translates into better care for patients,” Wiehe said. “And clinical guidelines can help us to get there. They turn evolving evidence into recommendations for care; they support patient-clinician conversations; and they provide an important reference point for decisions about care.”</span></p>
<p><span>Unfortunately, many rare disease drugs lack clinical guidelines, which generally need to be developed by government agencies and expert panels, said Jamie Sullivan, SVP of Policy and Advocacy at RARE Foundation.</span></p>
<p><span>According to one study, “Over 60% of the orphan drugs lacked a clinical guideline to begin with,” Sullivan said. “And so it’s just a lack of another input that payers can use” to improve coverage. </span></p>
<h2>By the numbers</h2>
<p><span>Meaningful data can be used to reduce barriers and advance policy that increases access, according to a session on </span><a href="https://pace.bio.org/2026-program/-stories-statistics-shape-smart-policy"><span>telling stories with statistics</span></a><span>.</span></p>
<p><span>Patient surveys can provide the data that helps make meaningful arguments, said Lynn Albizo, Chief Public Policy Officer of the Immune Deficiency Foundation.</span></p>
<p><span>“We use those surveys to get our statistics, particularly for our rare disease community. We can get down to specifically how many people with primary immunodeficiency on IG therapy are on Medicare,” she said. “I have tables of those statistics that I use to be able to share data with legislators.”</span></p>
<p><span>A compendium of annually updated data from peer-reviewed literature can make a high-impact handout said Robert Egge, Chief Public Policy Officer of the Alzheimer’s Association.</span></p>
<p><span>But there are times when numbers can work against you, warned Jennifer Dexter, SVP of Policy and External Affairs at the National Health Council. For example, when seeking Medicare Part D coverage for a rare disease drug, her group sometimes hears that only a small group of people will be served.</span></p>
<p><span>“We have to be there saying ‘It’s our people, it’s the people we’re representing who make up that small number.’ And we really have to put a face to it to overcome the small numbers,” she said.</span></p>
<p>The post <a href="https://bio.news/federal-policy/pace-panels-tackle-challenges-to-access-and-barriers-to-coverage/">PACE panels tackle challenges to access and barriers to coverage</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Compensation for medical residents: How much do trainees earn?</title>
<link>https://edusehat.com/en/compensation-for-medical-residents-how-much-do-trainees-earn</link>
<guid>https://edusehat.com/en/compensation-for-medical-residents-how-much-do-trainees-earn</guid>
<description><![CDATA[ What kind of compensation do the medical residents working in your hospital earn? According to survey data from Medscape, average pay for first- and second-year medical residents comes to $74,000 in 2026. That number is up from $65,000 in 2024—a 6.5% increase—and up from $68,000 in 2025. Here’s a look at compensation for medical residents, […]
The post Compensation for medical residents: How much do trainees earn? appeared first on Today&#039;s Hospitalist. ]]></description>
<enclosure url="https://todayshospitalist.com/wp-content/uploads/2026/10/resident-comp-shutterstock_2841055595-10-28-26.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 18:30:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Compensation, for, medical, residents:, How, much, trainees, earn</media:keywords>
<content:encoded><![CDATA[<p>What kind of compensation do the medical residents working in your hospital earn?</p>
<p><a href="https://www.medscape.com/p11/medscape-resident-salary-debt-report-2026-does-pay-match-2026a10011lh">According to survey data from Medscape,</a>  average pay for first- and second-year medical residents comes to $74,000 in 2026. That number is up from $65,000 in 2024—a 6.5% increase—and up from $68,000 in 2025.</p>
<p>Here’s a look at compensation for medical residents, including data on housing costs, benefits and residents’ attitudes toward pay.</p>
<h4><strong>Geography and resident pay</strong></h4>
<p>Medscape’s survey found that resident compensation can differ by up to $15,000 between parts of the Northeast and the South. That mirrors the trend in which physician pay is typically lower in the Northeast, in part because of the desirability of cities like Boston and New York, and higher in parts of the South.</p>
<p>That trend is significant because housing costs are high in those areas, with the Medscape survey finding that rent eats up more than 30% of resident pay. That’s why 57% of residents said their pay doesn’t cover their basic living expenses. (Twelve percent of residents said they received a housing allowance.)</p>
<h4><strong>Resident compensation by specialty</strong></h4>
<p>While there are huge differences in physician pay based on specialty, those gaps aren’t apparent during training. Hospitals, which Medscape’s survey said was the site of residency training for 65% of physicians, tend to pay all residents the same regardless of their specialty plans.</p>
<p><a href="https://www.ama-assn.org/medical-residents/residency-life/resident-physician-pay-still-rising-growth-trails-inflation">AMA data released earlier in 2026</a>  show that nearly all hospitals pay their residents the same amount regardless of specialty plans. Those data also said that 71% of training programs pay chief residents about $5,000 more a year.</p>
<h4><strong>Benefits during residency training</strong></h4>
<p>Medscape’s survey found that medical residents often get benefits offered to other employees.</p>
<p>Health insurance, for example, is offered to 92% of residents. Dental insurance is offered to 82%, and vision benefits are offered to 73%.</p>
<p>Here’s a full list of benefits offered to residents from the Medscape survey:</p>
<p><strong>What benefits do residents get?</strong></p>
<p>Health insurance: 92%.</p>
<p>Paid time off: 90%.</p>
<p>Dental (paid in part or in full): 82%.</p>
<p>Vision (paid in part or in full): 73%.</p>
<p>Retirement: 72%.</p>
<p>Meal allowance: 66%.</p>
<p>Travel allowance: 65%.</p>
<p>Liability coverage: 57%.</p>
<p>Exam/licensing fees: 47%.</p>
<p>Book allowance: 45%.</p>
<p>Life insurance: 43%.</p>
<p>Commuter assistance (parking, public transit): 27%.</p>
<p>Housing allowance: 12%.</p>
<p>Childcare: 5%.</p>
<h4><strong>What do residents think about their compensation?</strong></h4>
<p>When asked if they feel their pay is fair in the Medscape survey, 63% of residents answered “no.” The top reasons given for that dissatisfaction, however, focused more on residents’ not feeling valued than on their financial situation.</p>
<p>Medscape’s analysis noted that the number of residents who feel unfairly paid has dropped over time, from 73% in 2025. When the survey asked what would make residents feel their pay was fair, a raise of at least 26% was identified by two-thirds of respondents.</p>
<p><strong>Why residents feel their pay is unfair</strong></p>
<p>Doesn’t reflect hours worked: 83%.</p>
<p>Doesn’t compare to other medical staff: 83%.</p>
<p>Doesn’t reflect required skills: 76%.</p>
<p>Doesn’t meet cost of living: 61%.</p>
<p>Inadequate benefits: 29%.</p>
<h4><strong>Medical school debt</strong></h4>
<p>One factor in the financial stress medical residents feel is medical school debt. In the Medscape survey, 54% of residents reported carrying loan debt exceeding $150,000, with 30% having loans of more than $250,000.</p>
<p>The post <a href="https://todayshospitalist.com/compensation-for-medical-residents-how-much-do-trainees-earn/">Compensation for medical residents: How much do trainees earn?</a> appeared first on <a href="https://todayshospitalist.com/">Today's Hospitalist</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From Ojas to evidence: Measuring resilience in immune care</title>
<link>https://edusehat.com/en/from-ojas-to-evidence-measuring-resilience-in-immune-care</link>
<guid>https://edusehat.com/en/from-ojas-to-evidence-measuring-resilience-in-immune-care</guid>
<description><![CDATA[ 
 Dr Ravi K V, Assistant Professor, Department of Kriya Sharira, SDM College of Ayurveda Hospital and Research Centre, Udupi, explains how the Ayurvedic concept of Ojas can be assessed in relation to immunity and resilience, drawing on an observational study examining its association with healthy days and illness
The post From Ojas to evidence: Measuring resilience in immune care appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/28134014/EP_Dr_Ravi-K-V_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 18:25:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, Ojas, evidence:, Measuring, resilience, immune, care</media:keywords>
<content:encoded><![CDATA[<div><img width="1280" height="720" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/28134014/EP_Dr_Ravi-K-V_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/28134014/EP_Dr_Ravi-K-V_750.jpg 1280w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/28134014/EP_Dr_Ravi-K-V_750-300x169.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/28134014/EP_Dr_Ravi-K-V_750-1024x576.jpg 1024w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/28134014/EP_Dr_Ravi-K-V_750-768x432.jpg 768w" sizes="auto, (max-width: 1280px) 100vw, 1280px"></div><p><span>Ayurveda is one of the oldest systems of medicine practiced in India. The word Ayurveda means “science of life.” Its foundations lie in classical texts such as the Charaka Samhita, Sushruta Samhita and several others. It views health as a dynamic balance among the doshas (Vata, Pitta and Kapha), the dhatus (tissues), the malas (waste products) and agni, the digestive and metabolic fire.</span></p>
<p><b>Swastha: The Ayurvedic idea of health</b></p>
<p><span>Ayurveda’s definition of health goes beyond the absence of disease. The Sushruta Samhita describes the healthy person, or Swastha, in a single verse:</span></p>
<p><b>समदोषः</b> <b>समाग्निश्च</b> <b>समधातुमलक्रियः।</b></p>
<p><b>प्रसन्नात्मेन्द्रियमनाः</b> <b>स्वस्थ</b> <b>इत्यभिधीयते॥</b></p>
<p><span>Sama dosha samagnischa sama dhatu mala kriyah,</span></p>
<p><span>Prasanna atma indriya manah swastha iti abhidhiyate.</span></p>
<p><span>A person is Swastha when the doshas, agni, dhatus and malas are in equilibrium, and when the atma (self), indriyas (senses) and manas (mind) are serene. Health here is physical, metabolic, sensory and psychological at once.</span></p>
<p><b>Ojas: the essence of vitality</b></p>
<p><span>The concept of Ojas is central to this idea of health. The classical texts describe it as the finest essence of all the dhatus, the substance that sustains vitality, strength and vyadhikshamatva, the body’s capacity to resist and withstand disease. When Ojas is abundant, the person is robust and resilient. When it is depleted or disturbed (Ojakshaya or Ojovisramsa), vulnerability to illness rises. Ojas is often compared to the modern concept of immunity, though the two are not identical. Ojas is broader, covering physical resilience, metabolic integrity and mental stability together.</span></p>
<p><b>Ojas, immunity and autoimmunity</b></p>
<p><span>In modern terms, Ojas may be interpreted as the integrative expression of immune competence, endocrine stability, and metabolic balance, mirroring the body’s innate defense mechanisms. The nourishing, stabilising, and life-sustaining attributes of Ojas, parallel the role of the immune system and homeostatic regulation in modern physiology. Thus, a person rich in Ojas embodies the Ayurvedic ideal of health, a balanced state of Doṣa, Dhātu, Agni, and Manas, which ensures resilience against disease and promotes longevity.</span></p>
<p><span>In practical terms, the classical position is simple: good Ojas means good immunity, and diminished Ojas means diminished immunity. A person with abundant Ojas resists disease and recovers well, while a person whose Ojas is depleted is more susceptible to illness and slower to recover.</span></p>
<p><span>The classical texts, however, describe more than depletion. They speak of Ojas being displaced (Ojovisramsa), vitiated (Ojovyapat) and diminished (Ojakshaya). This matters because immunity is not only a question of strength. Immune protection can fail in two ways: it can be too weak to resist infection, or it can be misdirected against the body’s own tissues. Depleted Ojas fits the first picture. Ojas that is displaced or vitiated, present but unstable and poorly regulated, offers a way to think about the second. Autoimmunity can thus be read as an expression of Ojas that is disturbed rather than merely reduced. This is a hypothesis, not a conclusion, and only measurement can test it.</span></p>
<p><span>This framework offers a distinctive lens on autoimmune disease. Classical descriptions of conditions such as Amavata point to impaired agni producing ama, a metabolic by-product that obstructs the body’s channels and disturbs its balance. The immune system’s loss of self-regulation can thus be read through Ojas, agni and ama. The challenge, and the opportunity, is to move from interpretation to measurement: translating these concepts into outcomes that can be studied, validated and compared.</span></p>
<p><b>Our research: quantifying Ojas</b></p>
<p><span>At SDM College of Ayurveda Hospital and Research Centre Udupi, we undertook an observational, cross-sectional study to ask a simple question: can Ojas, the classical determinant of resilience, be measured, and does it relate to health outcomes?</span></p>
<p><b>Design and participants. </b><span>Thirty apparently healthy participants were assessed, with no intervention. Participants with major acute or chronic illness, or on regular medication, were excluded.</span></p>
<p><b>Assessment. </b><span>Ojas was scored (0 to 53) using a multi-dimensional tool developed by our team. Participants also reported their number of ill days over the past one year, from which the percentage of healthy days was derived.</span></p>
<p><b>Findings. </b><span>Ojas scores ranged from 26 to 47, and healthy days from 50.7 per cent to 98.6 per cent. Participants with higher Ojas scores reported fewer ill days, while those with lower scores reported more. In other words, good Ojas was associated with less illness and diminished Ojas with more, as the classical concept would predict.</span></p>
<p><b>Preserving Ojas: the role of daily conduct</b></p>
<p><span>If Ojas sustains resilience, the next question is how it is preserved and built. The classical answer is daily conduct, summarised in a well-known verse:</span></p>
<p><b>नित्यं</b> <b>हिताहारविहारसेवी</b> <b>समीक्ष्यकारी</b> <b>विषयेष्वसक्तः।</b></p>
<p><b>दाता</b> <b>समः</b> <b>सत्यपरः</b> <b>क्षमावान्</b> <b>आप्तोपसेवी</b> <b>च</b> <b>भवत्यरोगः॥</b></p>
<p><span>Nityam hita-ahara-vihara-sevi samikshya-kari vishayeshvasaktah,</span></p>
<p><span>Data samah satyaparah kshamavan apta-upasevi cha bhavatyarogah.</span></p>
<p><span>The person who consistently follows wholesome diet (hita ahara) and lifestyle (vihara), acts with due consideration, remains unattached to sensory excess, and is generous, balanced, truthful and forgiving, while keeping the company of the wise, remains free from disease. The verse joins physical habits to mental and social conduct: food, sleep and routine on one side, restraint, equanimity and good relationships on the other. This is the Ayurvedic route to strong Ojas and, in practical terms, to better immunity.</span></p>
<p><b>Conclusion</b></p>
<p><span>Autoimmune disease is, at its core, a failure of immune self-regulation. Ayurveda’s concept of Ojas, the essence of resilience and vyadhikshamatva, offers a lens for understanding that failure. When Ojas is disturbed or depleted and agni is impaired, the resulting ama may be read as the soil in which chronic, relapsing disease takes root. Preserving Ojas through hita ahara and vihara, and restoring agni, thus become not only classical principles but testable hypotheses.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/from-ojas-to-evidence-measuring-resilience-in-immune-care/">From Ojas to evidence: Measuring resilience in immune care</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CPHI India &amp;amp; PMEC India 2026 to connect India’s pharma value chain across ingredients, manufacturing and technology</title>
<link>https://edusehat.com/en/cphi-india-pmec-india-2026-to-connect-indias-pharma-value-chain-across-ingredients-manufacturing-and-technology</link>
<guid>https://edusehat.com/en/cphi-india-pmec-india-2026-to-connect-indias-pharma-value-chain-across-ingredients-manufacturing-and-technology</guid>
<description><![CDATA[ 
Dual-venue events will bring together pharmaceutical manufacturers, ingredient suppliers, CDMOs and technology providers, with participation expected from 120+ countries
The post CPHI India &amp; PMEC India 2026 to connect India’s pharma value chain across ingredients, manufacturing and technology appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/28141429/EP_CPHI-2026.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 18:25:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CPHI, India, PMEC, India, 2026, connect, India’s, pharma, value, chain, across, ingredients, manufacturing, and, technology</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/28141429/EP_CPHI-2026.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/28141429/EP_CPHI-2026.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/28141429/EP_CPHI-2026-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><b>CPHI India and PMEC India 2026,</b><span> organised by Informa Markets in India, will bring together stakeholders from across the pharmaceutical value chain from </span><b>November 23–26, 2026,</b><span> across two specialised venues in Delhi-NCR. </span><b>CPHI India will take place from November 23–25 at IICC, Yashobhoomi, Dwarka, while PMEC India will run from November 24–26 at IEML, Greater Noida.</b><span> The expanded format is designed to connect the pharmaceutical ingredients, contract manufacturing, machinery and technology sectors, facilitating business engagement, knowledge exchange and industry partnerships.</span></p>
<p><b>Visitor Registration:</b><span> Industry professionals can register to visit CPHI India and PMEC India 2026 and explore solutions, connect with industry leaders and discover opportunities across the pharmaceutical value chain.</span></p>
<p><b>Register here:</b><span> Visitor registration <a href="https://cphi-india-register.cphi.com/?form=short&ref=google&utm_source=google&utm_medium=perf_mrktg_cmpgn&utm_campaign=VM_CPHI_Search_Brand_17June26&gad_source=1&gad_campaignid=23950138469&gbraid=0AAAABD6CFthJTmpJLZ4AkMLnJwm77FL4g&gclid=CjwKCAjwuobXBhBXEiwAYUaIlUYPZOFLfPX7FkJJ0y7FMryt8FobRqMB_-E9_m3OeOP2frVNvo0tSBoCENsQAvD_BwE">link </a></span></p>
<p><b>Early-bird registration deadline:  </b></p>
<p><b>Article-specific UTM link:</b></p>
<p><span>The 2026 edition is expected to feature</span><b> 2,000+ exhibitors,</b><span> welcome </span><b>50,000+ </b><span>pharmaceutical professionals and visitors, and attract participation from</span><b> 120+ countries</b><span>. CPHI India will focus on active pharmaceutical ingredients (APIs), finished dosage, excipients, natural extracts, fine chemicals, intermediates and contract development and manufacturing organisations (CDMOs). PMEC India will showcase pharmaceutical machinery, equipment, packaging, laboratory and analytical systems, cleanroom technology and related manufacturing solutions.</span></p>
<p><span>The two events will offer complementary platforms for manufacturers, suppliers, research and development professionals, procurement teams and technology providers to assess solutions, explore sourcing opportunities and build partnerships across domestic and international markets. The Connections Programme will offer eligible buyers curated, pre-arranged meetings with exhibitors, while the Startup Market package will enable eligible businesses to showcase their solutions and connect with potential customers and partners.</span></p>
<p><b>A connected experience across two specialised venues</b></p>
<p><span>With CPHI India and PMEC India taking place at separate venues for the first time, the visitor experience has been designed to facilitate access to both exhibitions. A single visitor badge will provide entry to both events, while complimentary shuttle services will connect IICC, Yashobhoomi, Dwarka, and IEML, Greater Noida. The arrangement will allow visitors to explore pharmaceutical ingredients, contract manufacturing, production machinery and related technologies through one integrated visit.</span></p>
<p><b>India’s pharmaceutical industry: Scale, exports and manufacturing priorities</b></p>
<p><span>India’s pharmaceutical industry recorded an annual turnover of</span><b> ₹4.72 lakh crore in FY2024–25</b><span> and ranks third globally by production volume. The sector comprises more than </span><b>3,000 companies and 10,500 manufacturing units,</b><span> supported by a broad ecosystem spanning APIs, formulations, contract manufacturing, research, packaging and pharmaceutical production technologies.</span></p>
<p><span>Pharmaceutical exports reached approximately </span><b>USD 30.5 billion in FY2024–25, </b><span>registering year-on-year growth of 9.4%, with shipments reaching 191 countries. Around half of these exports were directed to highly regulated markets, including the United States and Europe. India’s domestic pharmaceutical market, estimated at around USD 60 billion, is projected to reach approximately USD 130 billion by 2030.</span></p>
<p><span>As the industry responds to evolving global requirements, investments in manufacturing efficiency, advanced formulations, API capabilities, automation, packaging, laboratory systems and quality assurance will remain important to strengthening competitiveness and meeting international standards.</span></p>
<p><span>Against this backdrop, CPHI India and PMEC India will provide a platform for industry stakeholders to assess emerging technologies, exchange insights on manufacturing priorities and identify business opportunities across the pharmaceutical value chain.</span></p>
<p><b>Conference, leadership and industry engagement</b></p>
<p><span>The events will address key industry themes spanning market trends, regulation, pharmaceutical manufacturing, outsourcing, emerging technologies, supply chains, sustainability and biopharma, including cell and gene therapies.</span></p>
<p><b>Pharma Connect,</b><span> a two-day conference scheduled for November 23–24, 2026, will feature industry leaders including Dr. Declan Byrne of the European Directorate for the Quality of Medicines & HealthCare (EDQM), Devender Kumar Singh of Pfizer Inc., and Vaibhavi Shah and Dr. Ankur Shah of Invengene. Sessions will explore India’s ambition to strengthen its position in API manufacturing, the growth of the CDMO sector, and developments in cell and gene therapy.</span></p>
<p><span>CPHI India will also host the</span><b> India Pharma Awards 2026, the Pharma Leadership Exchange </b><span>and </span><b>Women in Pharma.</b><span> PMEC India will feature a </span><b>CXO Roundtable</b><span> and a </span><b>Regulators Panel Discussion.</b><span> Together, these initiatives will support knowledge exchange, industry dialogue and connections between business leaders, manufacturers, suppliers and technology providers.</span></p>
<p><span>Key exhibitors at CPHI India include </span><b>IMCD India Pvt Ltd (Signet), Dr. Reddy’s Laboratories Ltd, Akums Drugs and Pharmaceuticals Ltd, Morepen Laboratories Limited </b><span>and</span><b> Hetero Labs Limited, </b><span>among others</span><b>.</b><span> Leading exhibitors at PMEC India include </span><b>Fette Compacting Machinery India Private Limited, ACG Pam Pharma Technologies Pvt. Ltd., Parle Global Technologies Pvt. Ltd., IMA-PG India Pvt. Ltd. </b><span>and</span><b> Ace Technologies & Packaging Systems Pvt. Ltd.</b></p>
<p><span>The events have also garnered considerable support from association partners including </span><b>OPPI, IPEC India, BDMAI, GPMA and KDPMA, </b><span>representing stakeholders across the pharmaceutical value chain.</span></p>
<p><span>Yogesh Mudras, Managing Director, Informa Markets in India, said: “India’s pharmaceutical industry is strengthening its manufacturing capabilities and global competitiveness. Government data shows that the pharmaceutical drugs PLI scheme generated approximately 1.15 lakh jobs by March 2026, reflecting the sector’s manufacturing potential. With investment in APIs, formulations, automation and quality systems becoming increasingly important, CPHI India and PMEC India 2026 will connect manufacturers, ingredient suppliers, CDMOs and technology providers through specialised platforms and targeted business interactions. </span></p>
<p><span>This year, the dual-venue expanded structure of the expos is designed to further help industry stakeholders explore partnerships, identify solutions and pursue new business opportunities across the pharmaceutical value chain in a focused manner.”</span></p>
<p><b>Event details</b></p>
<table>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td><b>CPHI India 2026</b></td>
</tr>
<tr>
<td>
<ul>
<li aria-level="1"><span>Dates: November 23–25, 2026</span></li>
</ul>
</td>
</tr>
<tr>
<td>
<ul>
<li aria-level="1"><span>Venue: IICC, Yashobhoomi, Dwarka, New Delhi</span></li>
</ul>
</td>
</tr>
<tr>
<td>
<ul>
<li aria-level="1"><span>Website: </span><a href="https://www.cphi.com/india/"><span>https://www.cphi.com/india/</span></a></li>
</ul>
</td>
</tr>
<tr>
<td><b>PMEC India 2026</b></td>
</tr>
<tr>
<td>
<ul>
<li aria-level="1"><span>Dates: November 24–26, 2026</span></li>
</ul>
</td>
</tr>
<tr>
<td>
<ul>
<li aria-level="1"><span>Venue: IEML, Greater Noida, Uttar Pradesh</span></li>
</ul>
</td>
</tr>
<tr>
<td>
<ul>
<li aria-level="1"><span>Website: </span><a href="https://www.cphi.com/india/"><span>https://www.cphi.com/india/</span></a></li>
</ul>
</td>
</tr>
<tr>
<td><b>Visitor access:</b><span> A single visitor badge provides access to both events. Complimentary shuttle services will connect the two venues.</span></td>
</tr>
<tr>
<td><b>Register to visit: </b></td>
</tr>
<tr>
<td><b>Social media and visuals</b></td>
</tr>
<tr>
<td>
<ul>
<li aria-level="1"><span>Hashtags:</span></li>
</ul>
</td>
</tr>
<tr>
<td>
<ul>
<li aria-level="1"><span>Social media handles: </span></li>
</ul>
</td>
</tr>
<tr>
<td>
<ul>
<li aria-level="1"><span>Event image/video: </span></li>
</ul>
</td>
</tr>
</tbody>
</table>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/cphi-india-pmec-india-2026-to-connect-indias-pharma-value-chain-across-ingredients-manufacturing-and-technology/">CPHI India & PMEC India 2026 to connect India’s pharma value chain across ingredients, manufacturing and technology</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Nucelion, Pandorum partner on two PRIP&#45;backed ophthalmology projects</title>
<link>https://edusehat.com/en/nucelion-pandorum-partner-on-two-prip-backed-ophthalmology-projects</link>
<guid>https://edusehat.com/en/nucelion-pandorum-partner-on-two-prip-backed-ophthalmology-projects</guid>
<description><![CDATA[ 
The projects will focus on investigational therapies for advanced keratopathy and wet age-related macular degeneration, with a combined planned outlay of ₹16.97 crore
The post Nucelion, Pandorum partner on two PRIP-backed ophthalmology projects appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 18:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Nucelion, Pandorum, partner, two, PRIP-backed, ophthalmology, projects</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p dir="ltr"><span>Hyderabad-based Nucelion Therapeutics, a cell and gene therapy contract development and manufacturing organisation (CDMO) and wholly owned subsidiary of Bharat Biotech, and Bengaluru-headquartered Pandorum Technologies, a tissue engineering and regenerative medicine company, have announced a manufacturing partnership to advance two PRIP-backed ophthalmology projects focused on developing investigational therapies for advanced keratopathy and wet age-related macular degeneration (wet AMD).</span></p>
<p dir="ltr"><span>Pandorum is developing cell-free regenerative medicines based on designer exosomes that carry biological signals involved in communication between cells. The biological activity of these exosomes is tuned to address inflammation, fibrosis and vascular pathology while supporting tissue repair. The platform connects the manufacturing process, the product, its biological activities and the corresponding tissue response in an integrated learning loop.</span></p>
<p dir="ltr"><span>Through its collaboration with Nucelion, Pandorum is connecting programmable regenerative medicine design with reproducible manufacturing and indication-specific development, while building this capability in India with national research support.</span></p>
<p dir="ltr"><span>Nucelion’s role in the two investigational ophthalmology projects will centre on process development and manufacturing support for Pandorum’s designer exosomes, aligned with the requirements and development stage of each programme. The partnership reflects the role specialised manufacturing capabilities can play in the development of emerging regenerative medicines.</span></p>
<p dir="ltr"><span>The broader Pandorum–Nucelion collaboration is intended to provide material manufactured under Good Manufacturing Practice (GMP) for clinical studies in India and abroad, subject to applicable regulatory approvals.</span></p>
<p dir="ltr"><span>Pandorum’s advanced-keratopathy programme is directed towards clinical evaluation of investigational therapies for severe corneal disease. The wet-AMD programme extends the platform into retinal disease, with the current project focused on preclinical development and preparation for subsequent clinical translation. Each programme will advance according to its own evidence, milestones and regulatory requirements.</span></p>
<p dir="ltr"><span>The two projects reflect the potential of India’s research and manufacturing ecosystem to advance approaches to treating eye diseases.</span></p>
<p dir="ltr"><span>The projects have a combined planned outlay of ₹16.97 crore, comprising up to ₹8 crore in funding under the PRIP scheme.</span></p>
<p dir="ltr"><span>“Advanced therapies require process development, analytical methods and manufacturing discipline to progress together. Our role is to help translate Pandorum’s product requirements into reproducible processes and development-stage manufacturing, with quality built into the work from the outset. This collaboration brings complementary capabilities together to advance complex biologics within India’s growing advanced-therapies ecosystem,” said Dr Raghu Malapaka, Chief Business Officer, Nucelion Therapeutics.</span></p>
<div><span> </span></div>
<p>The post <a href="https://www.expresspharma.in/nucelion-pandorum-partner-on-two-prip-backed-ophthalmology-projects/">Nucelion, Pandorum partner on two PRIP-backed ophthalmology projects</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>SCHOTT Poonawalla renamed SCHOTT Pharma India Private Limited</title>
<link>https://edusehat.com/en/schott-poonawalla-renamed-schott-pharma-india-private-limited</link>
<guid>https://edusehat.com/en/schott-poonawalla-renamed-schott-pharma-india-private-limited</guid>
<description><![CDATA[ 
The name change takes effect on October 28, 2026, with no changes to ownership, management, operations, products or services
The post SCHOTT Poonawalla renamed SCHOTT Pharma India Private Limited appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 14:50:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>SCHOTT, Poonawalla, renamed, SCHOTT, Pharma, India, Private, Limited</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>SCHOTT Poonawalla Private Limited will become SCHOTT Pharma India Private Limited with effect from October 28, 2026, marking a new chapter in the company’s journey and strengthening its connection with the global SCHOTT Pharma organisation.</span></p>
<p><span>The new identity reflects the India business’s place within SCHOTT Pharma’s global network and its role in advancing drug containment and delivery solutions for the pharmaceutical and biotechnology industries. It brings together the company’s manufacturing footprint, customer relationships and market expertise in India with SCHOTT Pharma’s global capabilities, innovation and scientific expertise.</span></p>
<p><span>The company stated that the change is limited to its name and does not affect its ownership, management, employees, business strategy, operations, products, services or existing customer commitments.</span></p>
<p><span>The transition reinforces SCHOTT Pharma India’s commitment to customers in India and international markets, while establishing a consistent connection with the global SCHOTT Pharma brand.</span></p>
<p><span>Building on a heritage of more than 140 years, the new identity brings the company’s heritage and future ambitions under one global name, reflecting SCHOTT Pharma’s values of innovation, quality, scientific expertise and trust.</span></p>
<p><span>Commenting on the development, Roy Joseph, CEO and Managing Director, SCHOTT Pharma India Private Limited, said, “SCHOTT Pharma India represents the next chapter of our journey, combining our strength in India with SCHOTT Pharma’s global innovation and expertise. We see significant opportunity to build on our capabilities, deepen collaboration with pharmaceutical and biotechnology partners, and advance drug containment and delivery solutions. As we move forward, our focus remains on growing with our customers and contributing to the safe and reliable delivery of critical therapies to patients worldwide.”</span></p>
<p><span>Dr Christian Mias, CEO of SCHOTT Pharma AG & Co. KGaA, SCHOTT Pharma India’s major shareholder, said, “SCHOTT Pharma India plays a critical role in patient care. With more than 3 billion containers produced annually, this company enables around 7,000 injections to reach patients every minute. The name change from SCHOTT Poonawalla to SCHOTT Pharma India reinforces our strategic partnership and confirms our long-term commitment to India as a key pharma hub.”</span></p>
<p><span>The new identity builds on the company’s operations in India. During the COVID-19 pandemic, its pharmaceutical vials supported more than 4.3 billion vaccine doses worldwide, including 3 billion doses in India.</span></p>
<p><span>As India’s only manufacturer of glass pre-fillable syringes and sterile formats, the company also contributes to local supply capabilities. It continues to invest in manufacturing capacity expansions for pre-fillable syringes and cartridges to support the requirements of biologics, biosimilars, GLP-1-based treatments and other injectable therapies.</span></p>
<p><span>Going forward, SCHOTT Pharma India will focus on expanding its capabilities in pharmaceutical drug containment and delivery solutions, driving innovation through customer collaboration, and strengthening operational excellence and sustainability. These priorities will support the company in responding to the needs of pharmaceutical and biotechnology companies and contribute to India’s role in the global pharmaceutical value chain.</span></p>
<p>The post <a href="https://www.expresspharma.in/schott-poonawalla-renamed-schott-pharma-india-private-limited/">SCHOTT Poonawalla renamed SCHOTT Pharma India Private Limited</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Indoco Remedies’ AnaCipher gets ANVISA approval for clinical and bioanalytical facilities</title>
<link>https://edusehat.com/en/indoco-remedies-anacipher-gets-anvisa-approval-for-clinical-and-bioanalytical-facilities</link>
<guid>https://edusehat.com/en/indoco-remedies-anacipher-gets-anvisa-approval-for-clinical-and-bioanalytical-facilities</guid>
<description><![CDATA[ 
The approval authorises the CRO to conduct bioavailability and bioequivalence studies for submission to Brazil, with associated bioanalytical support
The post Indoco Remedies’ AnaCipher gets ANVISA approval for clinical and bioanalytical facilities appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 14:50:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Indoco, Remedies’, AnaCipher, gets, ANVISA, approval, for, clinical, and, bioanalytical, facilities</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Indoco Remedies has announced that its Clinical Research Organisation (CRO), AnaCipher, has received approval from Brazil’s National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária, ANVISA) for its clinical and bioanalytical facilities. The inspection was conducted from March 30 to April 7, 2026.</span></p>
<p><span>With this approval, AnaCipher is authorised to conduct bioavailability and bioequivalence studies for submission to Brazil, along with associated bioanalytical support in accordance with ANVISA’s regulatory requirements.</span></p>
<p><span>Commenting on the development, Aditi Panandikar, Managing Director, Indoco Remedies, said, “The approval reflects our CRO’s robust quality management systems, qualified scientific and clinical teams, validated analytical capabilities, and adherence to international regulatory and Good Clinical Practice standards. It reinforces our commitment to global quality standards and enhances our ability to support pharmaceutical companies in conducting studies for Brazil and expanding across Latin America.”</span></p>
<p><span>The approval further strengthens AnaCipher’s international regulatory footprint and reinforces its position as a trusted partner for global clinical research programmes.</span></p>
<p><span>Headquartered in Hyderabad, India, AnaCipher provides bioequivalence and bioavailability studies, bioanalysis, clinical operations, regulatory affairs, data management and biostatistics services to pharmaceutical companies worldwide.</span></p>
<p><span>The CRO has been accredited by the Central Drugs Standard Control Organisation (CDSCO), the US Food and Drug Administration (USFDA), the World Health Organization (WHO), the European Medicines Agency (EMA), the UK Medicines and Healthcare products Regulatory Agency (MHRA), and the Ministry of Health of Oman. It has also received project-based approvals from Health Canada’s Therapeutic Products Directorate (TPD), China’s National Medical Products Administration (NMPA), South Africa’s Medicines Control Council (MCC) and the Ministry of Health of Iraq.</span></p>
<p>The post <a href="https://www.expresspharma.in/indoco-remedies-anacipher-gets-anvisa-approval-for-clinical-and-bioanalytical-facilities/">Indoco Remedies’ AnaCipher gets ANVISA approval for clinical and bioanalytical facilities</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>MCADDI 2026 brings together drug discovery experts at University of Hyderabad</title>
<link>https://edusehat.com/en/mcaddi-2026-brings-together-drug-discovery-experts-at-university-of-hyderabad</link>
<guid>https://edusehat.com/en/mcaddi-2026-brings-together-drug-discovery-experts-at-university-of-hyderabad</guid>
<description><![CDATA[ 
The six-day programme, organised by FABA with academic and industry partners, covers medicinal chemistry, AI-based drug design, biologics and emerging therapeutic modalities
The post MCADDI 2026 brings together drug discovery experts at University of Hyderabad appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/28114102/EP_MCADDI_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 14:50:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>MCADDI, 2026, brings, together, drug, discovery, experts, University, Hyderabad</media:keywords>
<content:encoded><![CDATA[<div><img width="1280" height="720" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/28114102/EP_MCADDI_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/28114102/EP_MCADDI_750.jpg 1280w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/28114102/EP_MCADDI_750-300x169.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/28114102/EP_MCADDI_750-1024x576.jpg 1024w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/28114102/EP_MCADDI_750-768x432.jpg 768w" sizes="(max-width: 1280px) 100vw, 1280px"></div><p><span>The Medicinal Chemistry, Drug Discovery & Development India 2026 (MCADDI 2026) is bringing together more than 200 professionals, researchers and industry experts for a six-day programme at the University of Hyderabad from October 25 to 30, 2026.</span></p>
<p><span>Organised by the Federation of Asian Biotech Associations (FABA) in collaboration with the University of Hyderabad, Biocon Academy, Aragen Academy and Science Gurus, the programme brings together international faculty and industry practitioners to examine developments in pharmaceutical research and development (R&D).</span></p>
<p><span>With 31 lectures, case studies and interactive sessions, MCADDI 2026 covers the drug discovery process, from medicinal chemistry and target identification to computational drug design, biologics, antibody-drug conjugates (ADCs), oncology, immunotherapy and emerging therapeutic modalities.</span></p>
<p><span>Experts from organisations including Novartis, AbbVie, Pfizer, Merck, Aragen, Sun Pharma, Aurobindo and biotechnology companies are contributing perspectives from different stages of drug discovery and development.</span></p>
<p><span>The programme opened with sessions on medicinal chemistry and drug discovery. Prof. Thomas Prisinzano of the University of Kentucky, USA, is addressing the principles of medicinal chemistry, while Manjunath Ramarao, EVP and Chief Scientific Officer, Aragen, is covering target identification and validation, as well as high-throughput, virtual and phenotypic screening approaches.</span></p>
<p><span>Ralf Glatthaar, Executive Director, Global Discovery Chemistry, Novartis, Basel, is contributing sessions on hit-to-lead and lead optimisation. These discussions address approaches to improving early-stage discovery and increasing the probability of advancing molecules into development.</span></p>
<p><span>Computational science and artificial intelligence (AI) also feature in the programme. Sessions on molecular interactions, in-silico tools for medicinal chemists, applications of in-silico approaches in drug discovery and AI-based drug design examine the integration of computational capabilities into drug discovery workflows.</span></p>
<p><span>Vincent Stoll, Senior Research Fellow, AbbVie, USA, is contributing to discussions on molecular interactions and structure-based drug design, while Rachel Lagkallos, US Head of Digital Medicinal Chemistry, Novartis, is addressing in-silico tools and their application in drug discovery.</span></p>
<p><span>The programme examines the use of digital and computational approaches to identify, design, evaluate and progress molecules through the discovery process.</span></p>
<p><span>MCADDI 2026 also covers biologics and therapeutic modalities. Sessions on biologics, developability, biopharmaceutics and formulation are complemented by discussions on ADCs, including their principles, next-generation approaches and case studies.</span></p>
<p><span>Rustam Mody, Consultant – Biologics, Sun Pharmaceutical Industries Ltd., and Jagath Reddy Junutula, Co-founder, President and CEO, Aavrık Therapeutics, USA, are among the experts contributing to this part of the programme.</span></p>
<p><span>The sessions on ADCs examine the convergence of targeted biology, antibody engineering and drug delivery in oncology drug development.</span></p>
<p><span>Oncology is another theme, with sessions and case studies covering pancreatic cancer, breast cancer therapy and drug discovery. Perry Carter, CEO of BlueSphere Bio, USA, is delivering the CEO Conclave keynote on advances in breast cancer therapy, while other sessions examine approaches in cancer therapeutics.</span></p>
<p><span>The programme also covers targeted protein degraders, molecular glues, immunotherapy and direct-acting antivirals, focusing on mechanisms and therapeutic modalities beyond conventional small-molecule approaches.</span></p>
<p><span>MCADDI 2026 combines scientific discussions, industry experience and case-based learning to examine how scientific advances translate into drug discovery and development programmes.</span></p>
<p><span>The programme also features a CEO Conclave and FABA Innovation Awards. The CEO Conclave brings together industry leaders to discuss drug discovery and development and the innovation ecosystem.</span></p>
<p><span>For India, the programme comes as the country seeks to expand its role in the pharmaceutical value chain beyond manufacturing and generic medicines. The next phase of growth will require capabilities in original research, discovery chemistry, computational drug design, novel modalities, translational science and product innovation.</span></p>
<p><span>Developing these capabilities requires interaction between academia and industry, exposure to global scientific practices, access to emerging technologies and a pipeline of researchers and drug discovery professionals.</span></p>
<p><span>MCADDI 2026 addresses these requirements by bringing international expertise and Indian scientific and industrial capabilities into one forum.</span></p>
<p><span>The vision, leadership and efforts of Prof. P. Reddanna, Executive Director and President, FABA, have been central to bringing MCADDI 2026 together as a platform for scientific exchange and collaboration. The efforts of Dr. P. Ratnakar, Secretary General, FABA, and the wider FABA team, together with the University of Hyderabad, Biocon Academy, Aragen Academy, Science Gurus, the organising committee, faculty, sponsors and institutional partners, have contributed to the programme.</span></p>
<p><span>As the six-day programme progresses, MCADDI 2026 highlights the convergence of chemistry, biology, computation, artificial intelligence, data science and clinical understanding in drug discovery.</span></p>
<p><span>For India, developing these capabilities could support the next phase of pharmaceutical growth, expanding its contribution from the global supply of medicines to the discovery and development of medicines.</span></p>
<p>The post <a href="https://www.expresspharma.in/mcaddi-2026-brings-together-drug-discovery-experts-at-university-of-hyderabad/">MCADDI 2026 brings together drug discovery experts at University of Hyderabad</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Moffitt Opens 250,000&#45;Square&#45;Foot Research Center at Life Sciences Campus</title>
<link>https://edusehat.com/en/moffitt-opens-250000-square-foot-research-center-at-life-sciences-campus</link>
<guid>https://edusehat.com/en/moffitt-opens-250000-square-foot-research-center-at-life-sciences-campus</guid>
<description><![CDATA[ The new 250,000-square-foot Moffitt Discovery and Innovation Center at Speros features flexible research laboratories and collaborative spaces. | Photo Credit: DLR Group | Tsoi Kobus Design  The Moffitt Discovery and Innovation Center brings cancer biology, drug discovery and bioengineering together on the 775-acre Speros campus.  DLR Group | Tsoi Kobus Design incorporated modular laboratories, shared...
The post Moffitt Opens 250,000-Square-Foot Research Center at Life Sciences Campus appeared first on HCO News.
The post Moffitt Opens 250,000-Square-Foot Research Center at Life Sciences Campus appeared first on HCO News. ]]></description>
<enclosure url="https://hconews.com/wp-content/uploads/2026/10/News-HCO.Moffitt-768x431.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 05:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Moffitt, Opens, 250, 000-Square-Foot, Research, Center, Life, Sciences, Campus</media:keywords>
<content:encoded><![CDATA[<h5><span data-contrast="auto">The new 250,000-square-foot Moffitt Discovery and Innovation Center at Speros features flexible research laboratories and collaborative spaces. | Photo Credit: DLR Group | Tsoi Kobus Design</span><span data-ccp-props="{}"> </span></h5>
<ul>
<li><span data-contrast="auto">The Moffitt Discovery and Innovation Center brings cancer biology, drug discovery and bioengineering together on the 775-acre Speros campus.</span><span data-ccp-props="{}"> </span></li>
<li><span data-contrast="auto">DLR Group | Tsoi Kobus Design incorporated modular laboratories, shared research resources and dedicated collaboration spaces.</span><span data-ccp-props="{}"> </span></li>
<li><span data-contrast="auto">The 250,000-square-foot facility stands beside the Moffitt Speros Outpatient Center, which opened in January 2026.</span><span data-ccp-props="{}"> </span></li>
</ul>
<p><b><span data-contrast="auto">LAND O’ LAKES, Fla.</span></b><span data-contrast="auto"> — Moffitt Cancer Center has opened a 250,000-square-foot research facility at Speros, its 775-acre life sciences campus, with a design that brings cancer biology, drug discovery and bioengineering into a single building. Facility designer DLR Group | Tsoi Kobus Design announced the opening in an Oct. 22 release following a celebration with Moffitt leaders, project partners and elected officials.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">The Moffitt Discovery and Innovation Center combines specialized research areas with shared laboratories and collaboration spaces. Modular laboratory infrastructure and reconfigurable open floor plans are intended to accommodate changing research needs.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">The facility includes BSL-2 laboratories and a Comparative Medicine Core with walkable interstitial service space, along with designated zones for each research discipline. Equipment rooms line the central corridors to reduce heat loads and noise while preserving laboratory floor space, according to the design firm. A core-lab model gives researchers access to shared resources and is intended to improve space efficiency.</span><span data-ccp-props="{}"> </span></p>
<blockquote><p><span data-contrast="auto">“By creating a place where researchers can see one another’s work and share ideas, Moffitt is building new pathways to discovery,” said Rick Kobus, Senior Principal and Client Leader, according to a press release provided by DLR Group.</span><span data-ccp-props="{}"> </span></p></blockquote>
<p><span data-contrast="auto">Outside the laboratories, a multistory collaboration zone offers views of the surrounding landscape and space for researchers to interact. A multipurpose conference room at ground level is designed to accommodate collaboration with external partners.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">For the exterior, designers paired ground-level natural stone cladding with ultra-high-performance concrete on the remainder of the building. The material selections are intended to reduce maintenance requirements and provide long-term durability, with the design responding to the surrounding protected wetlands and climate conditions.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">The research building stands next to the Moffitt Speros Outpatient Center, also designed by DLR Group | Tsoi Kobus Design, which opened in January 2026. The outpatient facility uses warm materials, landscape views and circulation planned for intuitive navigation. The two buildings are the first facilities to open at Speros. According to the design firm, the projects establish a shared architectural identity for the campus.</span><span data-ccp-props="{}"> </span></p>
<blockquote><p><span data-contrast="auto">“Scientists from different disciplines will work side by side, share the most advanced technology and move resulting therapies to patients faster,” said Dr. Patrick Hwu, Moffitt’s President and CEO.</span><span data-ccp-props="{}"> </span></p></blockquote>
<p><span data-contrast="auto">Whiting-Turner served as the general contractor for the Discovery and Innovation Center project, which broke ground in March 2022.</span><span data-ccp-props="{}"> </span></p>
<p><i><span data-contrast="auto">This article is based on a press release issued by DLR Group | Tsoi Kobus Design on Oct. 22, 2026.</span></i><span data-ccp-props="{}"> </span></p>
<p>The post <a rel="nofollow" href="https://hconews.com/2026/10/27/moffitt-opens-250000-square-foot-research-center-at-life-sciences-campus/">Moffitt Opens 250,000-Square-Foot Research Center at Life Sciences Campus</a> appeared first on <a rel="nofollow" href="https://hconews.com/">HCO News</a>.</p>
<p>The post <a href="https://hconews.com/2026/10/27/moffitt-opens-250000-square-foot-research-center-at-life-sciences-campus/">Moffitt Opens 250,000-Square-Foot Research Center at Life Sciences Campus</a> appeared first on <a href="https://hconews.com/">HCO News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Behavioral Healthcare Recliner</title>
<link>https://edusehat.com/en/behavioral-healthcare-recliner</link>
<guid>https://edusehat.com/en/behavioral-healthcare-recliner</guid>
<description><![CDATA[ The Respite™ Recliner from Norix combines therapeutic comfort with safety features to deliver a restorative seating option for behavioral healthcare environments. Designed with fully concealed mechanisms to help mitigate tampering opportunities and reduce ligature risk, the recliner increases safety for both patients and staff without sacrificing comfort or functionality. It provides supportive seating for up...
The post Behavioral Healthcare Recliner appeared first on HCO News.
The post Behavioral Healthcare Recliner appeared first on HCO News. ]]></description>
<enclosure url="https://hconews.com/wp-content/uploads/2026/10/Product-HCO.Norix_.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 05:00:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Behavioral, Healthcare, Recliner</media:keywords>
<content:encoded><![CDATA[<p><span data-contrast="auto">The Respite<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> Recliner from Norix combines therapeutic comfort with safety features to deliver a restorative seating option for behavioral healthcare environments. Designed with fully concealed mechanisms to help mitigate tampering opportunities and reduce ligature risk, the recliner increases safety for both patients and staff without sacrificing comfort or functionality. It provides supportive seating for up to 23 hours of continuous occupancy and utilizes familiar, soft-touch materials to help create a more comfortable, less institutional experience. Engineered with facility operations in mind, it fits easily through standard door frames to simplify installation, room transitions and facility renovations.</span><span data-ccp-props="{}"> </span></p>
<p><a href="https://norix.com/product/respite-recliner/" target="_blank" rel="noopener"><span data-contrast="none">Norix</span></a><span data-ccp-props="{}"> </span></p>
<p>The post <a rel="nofollow" href="https://hconews.com/2026/10/27/behavioral-healthcare-recliner/">Behavioral Healthcare Recliner</a> appeared first on <a rel="nofollow" href="https://hconews.com/">HCO News</a>.</p>
<p>The post <a href="https://hconews.com/2026/10/27/behavioral-healthcare-recliner/">Behavioral Healthcare Recliner</a> appeared first on <a href="https://hconews.com/">HCO News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lily’s I’m Back Story – Juvenile Idiopathic Arthritis (JIA)</title>
<link>https://edusehat.com/en/lilys-im-back-story-juvenile-idiopathic-arthritis-jia</link>
<guid>https://edusehat.com/en/lilys-im-back-story-juvenile-idiopathic-arthritis-jia</guid>
<description><![CDATA[ Lily was diagnosed with juvenile idiopathic arthritis (JIA) when she was four years old. When Lily&#039;s mom was drying Lily off from a bath, she noticed that her knee was swollen. Lily&#039;s mom decided to take Lily in to see some doctors, and they ended up being referred to a rheumatologist who diagnosed Lily with  [...]
The post Lily’s I’m Back Story – Juvenile Idiopathic Arthritis (JIA) appeared first on Orthopedic Sports Medicine Specialists (OSMS). ]]></description>
<enclosure url="https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27141136/Im-Back-Story-Thumbnail.png" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 04:55:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lily’s, I’m, Back, Story, –, Juvenile, Idiopathic, Arthritis, JIA</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-image">
<figure class="alignright size-full is-resized"><img fetchpriority="high" decoding="async" width="697" height="845" src="https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27142508/Young-Lily.png" alt="Lily younger - I'm Back" class="wp-image-15152" srcset="https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27142508/Young-Lily-200x242.png 200w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27142508/Young-Lily-247x300.png 247w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27142508/Young-Lily-400x485.png 400w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27142508/Young-Lily-600x727.png 600w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27142508/Young-Lily.png 697w" sizes="(max-width: 697px) 100vw, 697px"></figure>
</div>


<p class="wp-block-paragraph">Lily was diagnosed with juvenile idiopathic arthritis (JIA) when she was four years old. When Lily’s mom was drying Lily off from a bath, she noticed that her knee was swollen. Lily’s mom decided to take Lily in to see some doctors, and they ended up being referred to a rheumatologist who diagnosed Lily with JIA. </p>



<p class="wp-block-paragraph">When Lily first started her infusions, she had them done at a hospital, to which she expressed, were hard on her. Lily would have to miss full days of school and would be at the hospital for up to 12 hours. </p>



<p class="wp-block-paragraph">After talking with one of her friends, Lily found out that her friend had been going to OSMS to get her infusions done, expressing to Lily that her infusions were quick and easy – only about two hours. </p>



<p class="wp-block-paragraph">Upon hearing this, Lily and her parents decided to go over and check out OSMS. Once they met Dr. Tuttle, they realized the process at OSMS was better than the one they were experienced at the hospital. </p>



<p class="wp-block-paragraph">“Going to my first appointment at OSMS, I was a little nervous at first because I didn’t know what to expect and I was so young,” explained Lily. “I didn’t mind having infusions at OSMS because they were so quick and easy compared to the hospital.”<br><br>Growing up with JIA was a challenge for Lily. She mentioned that “It was hard growing up through school knowing that I was different than everyone else and that normal things would be hard for me. That’s the thing about arthritis is that it’s an invisible disease.”</p>


<div class="wp-block-image">
<figure class="alignleft size-large is-resized"><img decoding="async" width="1024" height="800" src="https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27142557/Lily-Infusion-when-younger-1024x800.png" alt="Lily when she was younger, getting an infusion" class="wp-image-15153" srcset="https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27142557/Lily-Infusion-when-younger-200x156.png 200w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27142557/Lily-Infusion-when-younger-300x234.png 300w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27142557/Lily-Infusion-when-younger-400x313.png 400w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27142557/Lily-Infusion-when-younger-600x469.png 600w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27142557/Lily-Infusion-when-younger-768x600.png 768w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27142557/Lily-Infusion-when-younger-800x625.png 800w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27142557/Lily-Infusion-when-younger-1024x800.png 1024w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27142557/Lily-Infusion-when-younger-1200x938.png 1200w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27142557/Lily-Infusion-when-younger.png 1267w" sizes="(max-width: 1024px) 100vw, 1024px"></figure>
</div>


<p class="wp-block-paragraph">Although it was hard for Lily to navigate her disease through school, she had support from her understanding friends, teachers, and classmates. </p>



<p class="wp-block-paragraph">Since going to OSMS, Lily describes that she is back to having a normal life again. “I’m able to be a college student now who can worry about my grades and my friends rather than if I’ll be able to walk to class or if my hands will get sore doing my assignments. I even can have a regular job. So, it’s been good knowing that I can do things and keep up with everybody around me and not fall behind because of my disease.” </p>



<p class="wp-block-paragraph">When it was time for Lily to move to college, it was a little scary for her knowing that she wouldn’t be in close proximity to her family or even Dr. Tuttle. However, Lily quickly realized that it wouldn’t be an issue because she knew she would still have her family’s support over the phone, and that Dr. Tuttle was always one phone call away if she needed his care. <br><br><br>When Lily applied for accommodations, she talked with Dr. Tuttle who quickly filled out the paperwork and signed the forms Lily needed. Lily mentioned, “He was very helpful with that and the whole team is super quick with it. He told me he’s always there if I need anything and I check in with him every summer.”</p>



<p class="wp-block-paragraph"><br>We asked Lily what advice she would give to someone going through an early arthritis diagnosis, and she explained, “Although it may feel overwhelming, trust your doctors and trust the medications that you’re being put on. OSMS came into my life at a time where anything about arthritis gave me a lot of anxiety. Having switched from the super hard infusions at the hospital to doing the quick, easy ones at the [OSMS] clinic changed my quality of life so much.”</p>


<div class="wp-block-image">
<figure class="alignright size-large is-resized"><img decoding="async" width="1024" height="578" src="https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27141136/Im-Back-Story-Thumbnail-1024x578.png" alt="Lily's I'm Back Thumbnail" class="wp-image-15151" srcset="https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27141136/Im-Back-Story-Thumbnail-200x113.png 200w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27141136/Im-Back-Story-Thumbnail-300x169.png 300w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27141136/Im-Back-Story-Thumbnail-400x226.png 400w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27141136/Im-Back-Story-Thumbnail-600x339.png 600w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27141136/Im-Back-Story-Thumbnail-768x433.png 768w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27141136/Im-Back-Story-Thumbnail-800x451.png 800w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27141136/Im-Back-Story-Thumbnail-1024x578.png 1024w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27141136/Im-Back-Story-Thumbnail-1200x677.png 1200w, https://osmsgb.s3.amazonaws.com/wp-content/uploads/2026/10/27141136/Im-Back-Story-Thumbnail.png 1448w" sizes="(max-width: 1024px) 100vw, 1024px"></figure>
</div>


<p class="wp-block-paragraph">Now, as a college student, Lily is living life normally, explaining that, “Having a doctor be such a good constant in my life for the past couple of years is something that I will always be really grateful for.”</p>



<p class="wp-block-paragraph">Thanks to OSMS, Lily is in remission, and thriving with her arthritis!<br></p>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://osmsgb.com/imback/lilys-im-back-story-juvenile-idiopathic-arthritis/">Lily’s I’m Back Story – Juvenile Idiopathic Arthritis (JIA)</a> appeared first on <a href="https://osmsgb.com/">Orthopedic Sports Medicine Specialists (OSMS)</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bonjour Genomics: A Video from ASHG</title>
<link>https://edusehat.com/en/bonjour-genomics-a-video-from-ashg</link>
<guid>https://edusehat.com/en/bonjour-genomics-a-video-from-ashg</guid>
<description><![CDATA[ GEN editors Uduak Thomas and Julianna LeMieux, PhD, recap ASHG, highlighting key sessions, Ultima Genomics’ user group meeting, Illumina news, and insights from PacBio’s new CEO Mark Van Oene.
The post Bonjour Genomics: A Video from ASHG appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-1177333932.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 04:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bonjour, Genomics:, Video, from, ASHG</media:keywords>
<content:encoded><![CDATA[<p>Uduak Thomas, Senior Editor at <em>GEN</em>, took a minute away from the talks, posters, and expo hall to join Julianna LeMieux, PhD, <em>GEN’</em>s Deputy Editor in Chief, to talk about the meeting, the sessions they attended, and the trends that they are noticing.</p>
<p>Although they had only been at the meeting for a day, there was plenty to discuss: Ultima Genomics’ user group meeting, the opening Presidential address given by ASHG President Susan Slaugenhaupt, PhD, Illumina’s news, and an interview with PacBio’s new CEO Mark Van Oene. PhD.</p>
<p> </p>
<div>
<div><br>
</div>
</div>
<p>The post <a href="https://www.genengnews.com/topics/omics/bonjour-genomics-a-video-from-ashg/">Bonjour Genomics: A Video from ASHG</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Vitamin Derivative Pantethine Alleviates Psoriasis Symptoms in Small Human Trial</title>
<link>https://edusehat.com/en/vitamin-derivative-pantethine-alleviates-psoriasis-symptoms-in-small-human-trial</link>
<guid>https://edusehat.com/en/vitamin-derivative-pantethine-alleviates-psoriasis-symptoms-in-small-human-trial</guid>
<description><![CDATA[ Researchers found that the vitamin B5 derivative pantethine prevented the development of psoriasis in mice, and in a small-scale trial in human psoriasis patients administering pantethine in combination with topical calcipotriol/betamethasone dipropionate helped to alleviate symptoms. 
The post Vitamin Derivative Pantethine Alleviates Psoriasis Symptoms in Small Human Trial appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2021/11/Getty_872062320_Psoriasis.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 04:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Vitamin, Derivative, Pantethine, Alleviates, Psoriasis, Symptoms, Small, Human, Trial</media:keywords>
<content:encoded><![CDATA[<p>Researchers headed by a team at State Key Laboratory of Biomedical Analysis (SKLBA) (formerly known as National Center of Biomedical Analysis) in Beijing have discovered that the vitamin B5 derivative pantethine limits the activity of dendritic cells (DCs), which are immune cells that are key contributors to autoimmune diseases such as psoriasis. The newly reported study showed that pantethine prevented the development of psoriasis in mice, and in a small-scale trial in human psoriasis patients administering pantethine in combination with topical calcipotriol/betamethasone dipropionate helped to alleviate symptoms.</p>
<p>In their published study in <em>Journal of Experimental Medicine</em> (<em>JEM</em>) (“<a href="http://dx.doi.org/10.1084/jem.20252558" target="_blank" rel="noopener">Vanin-pantethine metabolic axis shapes dendritic cell function and affects inflammatory disorder progression</a>,”) senior author Wei-Na Zhang, PhD, a researcher at the State Key Laboratory of Biomedical Analysis, and colleagues, suggested that their findings point to “… a potentially viable metabolic strategy for DC-centered intervention in AIDs [autoimmune diseases].” Zhang co-led the new <em>JEM</em> study with Qing Xia PhD, Ai-Ling Li, PhD, and Tao Zhou, PhD, also from the State Key Laboratory of Biomedical Analysis, and Cheng-Xin Li, PhD, from The First Medical Center of Chinese PLA General Hospital in Beijing.</p>
<p>Dendritic cells are specialized immune cells that help to coordinate the different parts of the immune system. They can engulf and present foreign antigens to activate highly specific T cells, as well as secrete a variety of immune signaling molecules to recruit other types of immune cells and promote inflammation. Because of this central role in directing immune responses, abnormal activation of dendritic cells is thought to underlie a variety of autoimmune diseases, including psoriasis. “Aberrant activation of dendritic cells (DCs) is intricately associated with inflammatory diseases, rendering DCs an appealing therapeutic target,” the authors wrote. “Metabolites are emerging as crucial regulators of DCs, yet therapeutic strategies targeting DC metabolism for inflammatory diseases remain underexplored.”</p>
<p>Zhang further added, “Emerging evidence highlights that metabolic pathways and their associated metabolites play vital roles in regulating immune cell function and autoimmune progression. But therapeutic strategies targeting metabolism in inflammatory diseases remain underexplored.”</p>
<p>Through their study the team found that levels of metabolic enzymes known as Vanins are elevated in the dendritic cells of patients with psoriasis and several other autoimmune diseases. Vanin enzymes convert the metabolite pantethine into vitamin B5, an essential nutrient required for cellular energy production. Pantethine itself is a widely available nutritional supplement often used to lower blood cholesterol levels due to its ability to inhibit cholesterol synthesis. Intriguingly, cholesterol can promote the activation of dendritic cells, and high blood cholesterol is a major risk factor for the development of psoriasis.</p>
<p>Through their study the team showed that depleting these enzymes inhibited dendritic cell activation and limited their ability to activate T cells. Moreover, treating mice with a drug that inhibits Vanins prevented the animals from developing psoriasis.</p>
<p>Zhang and colleagues determined that increased Vanin activity in dendritic cells reduces panthetine levels, leading to increased cholesterol synthesis and dendritic cell hyperactivation. Replenishing pantethine levels reversed this process, lowering the accumulation of cholesterol and suppressing dendritic cell activation. “Pantethine supplementation or pharmacologically induced Vanin inhibition reduces cholesterol overload, impedes DC activation, and mitigates psoriasiform inflammation,” they wrote.</p>
<figure aria-describedby="caption-attachment-339879" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-339879" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Cao_et_al-300x165.jpg" alt="Psoriasis patients prescribed pantethine capsules in addition to topical ointments show a marked improvement in symptoms after 3 months of treatment (bottom). [© 2026 Cao et al. Originally published in Journal of Experimental Medicine. https://doi.org/10.1084/jem.20252558]" width="300" height="165" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Cao_et_al-300x165.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Cao_et_al.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Psoriasis patients prescribed pantethine capsules in addition to topical ointments show a marked improvement in symptoms after three months of treatment (bottom). [© 2026 Cao et al. Originally published in <a href="https://doi.org/10.1084/jem.20252558" target="_blank" rel="noopener"><em>Journal of Experimental Medicine</em></a>]</figcaption></figure>
<p>“We found that pantethine administration effectively alleviated psoriasis in mice, suggesting that insufficient pantethine levels may be the crucial contributor to hyperactivation of dendritic cells and autoimmune inflammation following the upregulation of Vanins,” Zhang noted.</p>
<p>To investigate further the researchers initiated a small-scale trial of pantethine supplementation in 24 human psoriasis patients. Every patient was treated with topical calcipotriene/betamethasone ointment, but half of the patients also received oral pantethine. Over the course of 12 weeks, patients given the additional pantethine treatment showed improved symptoms, particularly if they had elevated blood cholesterol levels at the start of the trial. “Importantly, our clinical trial revealed that pantethine combination therapy significantly decelerates the progression of psoriasis in patients,” they reported.</p>
<p>Zhang commented, “Our investigator-initiated clinical trial demonstrated encouraging therapeutic efficacy of pantethine as an adjunctive therapy in psoriasis, but these findings should be interpreted as proof-of-concept for clinical feasibility rather than direct mechanistic validation. Overall, our study uncovers the Vanin-pantethine-cholesterol axis as a key metabolic pathway governing dendritic cell activation and provides a foundation for therapeutic strategies targeting several dendritic cell–mediated autoimmune diseases.”</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/vitamin-derivative-pantethine-alleviates-psoriasis-symptoms-in-small-human-trial/">Vitamin Derivative Pantethine Alleviates Psoriasis Symptoms in Small Human Trial</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Artiva Axes 94% of Workforce, Weighs Strategic Alternatives After Two Patients in Phase IIa Trial Die</title>
<link>https://edusehat.com/en/artiva-axes-94-of-workforce-weighs-strategic-alternatives-after-two-patients-in-phase-iia-trial-die</link>
<guid>https://edusehat.com/en/artiva-axes-94-of-workforce-weighs-strategic-alternatives-after-two-patients-in-phase-iia-trial-die</guid>
<description><![CDATA[ In announcing the layoffs and strategic alternatives review, Artiva disclosed that two patients in the trial who underwent the study treatment died in Grade 5 safety events. One patient succumbed to leukoencephalopathy while the second experienced sudden death.
The post Artiva Axes 94% of Workforce, Weighs Strategic Alternatives After Two Patients in Phase IIa Trial Die appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Artiva_Facilties_Exterior_Updated-RESIZE1220.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 04:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Artiva, Axes, 94, Workforce, Weighs, Strategic, Alternatives, After, Two, Patients, Phase, IIa, Trial, Die</media:keywords>
<content:encoded><![CDATA[<p>Artiva Biotherapeutics said it will eviscerate its workforce 94% and evaluate strategic options after two patients treated with its lead candidate in a Phase IIa trial died—though one death was unrelated to the treatment.</p>
<p>Artiva has ended development of the lead candidate, a non-genetically modified, allogeneic, cryopreserved NK cell therapy called AlloNK<sup>®</sup> and also called AB-101. AlloNK had been evaluated in a Phase IIa “basket” trial (<a href="https://clinicaltrials.gov/study/NCT06991114" target="_blank" rel="noopener">NCT06991114</a>) assessing the candidate in rheumatoid arthritis (RA), Sjögren’s Disease, idiopathic inflammatory myopathies, and systemic sclerosis in combination with rituximab—the monoclonal antibody treatment for arthritis and several forms of cancer marketed by Roche’s Genentech subsidiary and Biogen as Rituxan<sup>®</sup>.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>In announcing the layoffs and strategic alternatives review, Artiva disclosed that two patients in the trial who underwent the study treatment died in Grade 5 safety events. One patient succumbed to leukoencephalopathy, a fatal neurological event, following treatment, which included protocol-specified lymphodepletion with cyclophosphamide and fludarabine.</p>
<p>“The investigator and an independent safety review assessed the event as likely related to fludarabine-associated neurotoxicity,” Artiva said in a statement. “Given the widespread use of fludarabine-containing lymphodepletion regimens in cell therapy development, Artiva intends to share additional details of this case in a scientific publication.”</p>
<p>After reporting the event to the FDA and the trial’s data safety monitoring board (DSMB), the agency requested that Artiva pause enrollment and dosing in the Phase IIa study, Artiva said. The company also paused its plans to begin enrollment and dosing in a Phase III trial of AlloNK.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The second patient experienced sudden death approximately two months after beginning study treatment. “The investigator assessed this event as unrelated to AlloNK or any other component of the study treatment regimen, and the cause of death has not been determined,” Artiva stated, adding that the second death was also reported to the FDA and DSMB.</p>
<h4><strong>‘Deeply saddened’</strong></h4>
<p>“Throughout the development of AlloNK, the safety and well-being of patients have remained our highest priority. We are deeply saddened by the deaths of two patients who participated in our clinical studies and extend our sincere condolences to their families,” Artiva CEO Fred Aslan, MD, stated. “We plan to provide findings from the first case, which was assessed as likely related to fludarabine toxicity, given its widespread use in cell therapy conditioning regimens.”</p>
<p>In halting development of AlloNK, Artiva also cited uneven clinical data as well as an assessment of the therapy’s risks and benefits, the likelihood of future enrollment delays, and the overall development and potential commercial outlook.</p>
<p>According to the company, the data “continued to demonstrate deep B cell depletion and clinical activity consistent with the Company’s previously reported findings.”</p>
<p>“However, longer-term follow-up did not reflect the level of durability of clinical response the Company believes is needed to support continued development,” Artiva added. “The Company will work closely with the FDA, investigators, and institutional review boards to ensure an appropriate and orderly close-out of its clinical development program, including continued safety monitoring and reporting as required.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>As a result, Artiva has canceled a presentation of AlloNK clinical data at the upcoming ACR Convergence 2026 conference, to be held November 6-11 in Orlando, FL. The company is also canceling an investor webcast it had scheduled for November 9.</p>
<p>“Updated clinical data may be presented at future scientific meetings depending on the outcome of the strategic alternatives process,” Artiva added.</p>
<p>Investors responded to Artiva’s announcement with a stock selloff that sent shares tumbling 30.5% on Tuesday, from $6.16 to $4.27 as of 2:04 p.m. ET.</p>
<h4><strong>Analyst downgrades</strong></h4>
<p>Several investment firms downgraded their ratings of Artiva stock, including Cantor Fitzgerald, TD Cowen, Needham & Co., H.C. Wainwright, and Wedbush—where David Nierengarten, PhD, managing director and a senior analyst covering small-mid cap biotech stocks, cut his firm’s rating from “Outperform” to “Neutral” and slashed its 12-month price target 90% from $40 to $4.</p>
<p>Artiva also retained Leerink Partners to assist in the company’s strategic review, which will entail evaluating internal options and potential strategic alternatives intended to maximize stockholder value.</p>
<p>Among options under review, Artiva said, include a merger, business combination, sale or licensing of assets, dissolution, and liquidation. Artiva does not plan to offer updates on the review “unless and until the Board of Directors has approved a specific course of action, the process has concluded, or the Company determines that further disclosure is appropriate or required by law.”</p>
<p>Artiva will also carry out a reduction of its workforce by approximately 94%. That would amount to roughly 98 of the 104 full-time employees that Artiva employed as of June 30, according to the company’s <a href="https://d18rn0p25nwr6d.cloudfront.net/CIK-0001817241/0c3c7f0b-10f5-4c7b-b009-26e549fa823a.pdf" target="_blank" rel="noopener">Form 10-Q quarterly report for the second quarter</a>, filed August 6 with the U.S. Securities and Exchange Commission.</p>
<p>As of September 30, 2026, Artiva said in its statement, it had approximately $319.1 million in cash, cash equivalents and investments—a preliminary and unaudited figure, the company cautioned. The announcement did not quantify how much Artiva expects to spend on its planned workforce reduction.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Complete quarterly results will be included in Artiva’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/artiva-axes-94-of-workforce-weighs-strategic-alternatives-after-two-patients-in-phase-iia-trial-die/">Artiva Axes 94% of Workforce, Weighs Strategic Alternatives After Two Patients in Phase IIa Trial Die</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The 2027 Medicare Physician Fee Schedule: What Changed and How to Protect Your Revenue</title>
<link>https://edusehat.com/en/the-2027-medicare-physician-fee-schedule-what-changed-and-how-to-protect-your-revenue</link>
<guid>https://edusehat.com/en/the-2027-medicare-physician-fee-schedule-what-changed-and-how-to-protect-your-revenue</guid>
<description><![CDATA[ Status note: This guide is based on the CY 2027 Medicare Physician Fee Schedule proposed rule (CMS 1848 P), released July 14, 2026. CMS is expected to publish the final rule in early November 2026, and the final figures can differ from the proposal. We will update this page when the final rule is released....
The post The 2027 Medicare Physician Fee Schedule: What Changed and How to Protect Your Revenue appeared first on DoctorsManagement. ]]></description>
<enclosure url="https://www.doctorsmanagement.com/wp-content/uploads/mk-medicare-fee-schedule-2027.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 04:00:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, 2027, Medicare, Physician, Fee, Schedule:, What, Changed, and, How, Protect, Your, Revenue</media:keywords>
<content:encoded><![CDATA[<blockquote><p>Status note: This guide is based on the CY 2027 Medicare Physician Fee Schedule proposed rule (CMS 1848 P), released July 14, 2026. CMS is expected to publish the final rule in early November 2026, and the final figures can differ from the proposal. We will update this page when the final rule is released. Every figure below is marked as proposed until then.</p></blockquote>
<p>Medicare will pay most physicians less per service in 2027 than it did in 2026. The proposed conversion factor for clinicians who are not qualifying participants in an Advanced Alternative Payment Model (APM) is $32.8409, a 1.68% decrease from $33.4009. For qualifying APM participants the proposed figure is $33.1693, a 1.19% decrease from $33.5675. The main reason is simple: the one year 2.5% increase Congress provided for 2026 expires on December 31, 2026, and the statutory updates for 2027 (0.25% and 0.75%) do not come close to replacing it. An Advanced APM is a Medicare payment arrangement, such as a Medicare Shared Savings Program accountable care organization track with downside risk, in which participants accept financial accountability for the cost and quality of care in exchange for a higher annual payment update and other incentives. Clinicians who meet CMS participation thresholds in one of these models are called qualifying participants, or QPs, and are paid under the higher conversion factor.</p>
<p>The conversion factor is only the first layer. The CY 2027 proposed rule also includes a 50% payment reduction for office visits billed on the same day as a global procedure, a change that converts the G2211 add on code into a percentage based modifier, a multiyear overhaul of the practice expense methodology, tighter rules for remote monitoring, and specialty level impacts that range from a 12% increase for clinical social workers to a 9% decrease for dermatology and otolaryngology. For some practices the net effect will be close to flat. For others it will be a double digit revenue reduction on the Medicare book of business.</p>
<p>This guide explains each change, shows how to calculate your own practice’s exposure, and lays out the operational and contracting steps that protect revenue before the new rates take effect on January 1, 2027.</p>
<h2>Table of Contents</h2>
<ol class="dm-toc">
<li><a href="https://www.doctorsmanagement.com/blog/the-2027-medicare-physician-fee-schedule-what-changed-and-how-to-protect-your-revenue/#quick-answers-for-busy-practice-leaders">Quick answers for busy practice leaders</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/the-2027-medicare-physician-fee-schedule-what-changed-and-how-to-protect-your-revenue/#where-the-2027-fee-schedule-stands-right-now">Where the 2027 fee schedule stands right now</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/the-2027-medicare-physician-fee-schedule-what-changed-and-how-to-protect-your-revenue/#the-2027-conversion-factors-the-numbers-and-the-math-behind">The 2027 conversion factors: the numbers and the math behind them</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/the-2027-medicare-physician-fee-schedule-what-changed-and-how-to-protect-your-revenue/#why-medicare-physician-payment-keeps-losing-ground">Why Medicare physician payment keeps losing ground</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/the-2027-medicare-physician-fee-schedule-what-changed-and-how-to-protect-your-revenue/#the-efficiency-adjustment-what-it-is-and-where-it-stands-for">The efficiency adjustment: what it is and where it stands for 2027</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/the-2027-medicare-physician-fee-schedule-what-changed-and-how-to-protect-your-revenue/#same-day-e-m-visits-with-global-procedures-the-modifier-25-r">Same day E/M visits with global procedures: the modifier 25 reduction</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/the-2027-medicare-physician-fee-schedule-what-changed-and-how-to-protect-your-revenue/#g2211-becomes-a-modifier">G2211 becomes a modifier</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/the-2027-medicare-physician-fee-schedule-what-changed-and-how-to-protect-your-revenue/#the-practice-expense-methodology-overhaul">The practice expense methodology overhaul</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/the-2027-medicare-physician-fee-schedule-what-changed-and-how-to-protect-your-revenue/#specialty-impact-who-gains-and-who-loses">Specialty impact: who gains and who loses</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/the-2027-medicare-physician-fee-schedule-what-changed-and-how-to-protect-your-revenue/#other-2027-changes-that-touch-practice-revenue">Other 2027 changes that touch practice revenue</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/the-2027-medicare-physician-fee-schedule-what-changed-and-how-to-protect-your-revenue/#how-to-calculate-your-practice-s-2027-exposure">How to calculate your practice’s 2027 exposure</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/the-2027-medicare-physician-fee-schedule-what-changed-and-how-to-protect-your-revenue/#fifteen-ways-to-protect-revenue-in-2027">Fifteen ways to protect revenue in 2027</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/the-2027-medicare-physician-fee-schedule-what-changed-and-how-to-protect-your-revenue/#compliance-guardrails-offsetting-cuts-without-creating-audit">Compliance guardrails: offsetting cuts without creating audit risk</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/the-2027-medicare-physician-fee-schedule-what-changed-and-how-to-protect-your-revenue/#how-doctorsmanagement-helps-practices-prepare">How DoctorsManagement helps practices prepare</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/the-2027-medicare-physician-fee-schedule-what-changed-and-how-to-protect-your-revenue/#frequently-asked-questions">Frequently asked questions</a></li>
<li><a href="https://www.doctorsmanagement.com/blog/the-2027-medicare-physician-fee-schedule-what-changed-and-how-to-protect-your-revenue/#sources-and-references">Sources and references</a></li>
</ol>
<h2>1. Quick answers for busy practice leaders</h2>
<p><strong>How much will Medicare pay physicians in 2027?</strong> Under the proposed rule, Medicare would pay $32.8409 per relative value unit for most physicians and $33.1693 per RVU for qualifying APM participants, before geographic adjustment. That is a 1.68% and 1.19% decrease, respectively, from 2026. Your actual payment per service depends on the RVUs assigned to each code, your geographic locality, and whether you participate in an Advanced APM.</p>
<p><strong>What changed in the 2027 physician fee schedule?</strong> The largest changes are the expiration of the 2026 one year 2.5% increase, a proposed 50% payment reduction for office E/M visits billed on the same day as a 0 day, 10 day, or 90 day global procedure, the conversion of G2211 into a 16% modifier (32% for ACO participants), a phase out of the indirect practice cost index in practice expense RVUs with a new 5% stabilizer, revaluation and new restrictions for remote physiologic and remote therapeutic monitoring, a pause of global surgery postoperative data collection, new codes for shared medical appointments and clinical staff advance care planning, and a plan to make MIPS Value Pathways the only MIPS reporting option beginning with the 2029 performance year.</p>
<p><strong>How can a practice offset Medicare reimbursement cuts?</strong> Practices offset cuts in four ways: capturing revenue they already earn but do not bill correctly (coding accuracy, care management, G2211, annual wellness visits, chronic care management), reducing the cost of collecting each dollar (denial prevention, clean claims, patient collections), improving payer mix and contract terms (commercial contracts tied to a specific Medicare year, Advanced APM participation for the higher conversion factor), and controlling practice expense (staffing models, supply costs, technology that reduces administrative labor). Section 12 covers each in detail.</p>
<p>Underneath all four is a shift in how practice owners think about their role. Leading a medical practice is less about the patients you individually see and more about the patients you oversee. Advanced practice providers, other licensed health professionals, and an engaged clinical and administrative team extend the physician’s reach, and they are what make care management, wellness visits, and the new 2027 codes workable at scale rather than one more task on the physician’s schedule. Private practice also enters 2027 with a structural advantage: it is the lowest cost site of care compared with hospital outpatient departments and private equity backed platforms, and the direction of Medicare policy, including CMS’s own questions about the facility payment differential, favors the low cost provider. Practices that build the team model and defend that cost position are the ones best placed to absorb a reimbursement cut.</p>
<h2>2. Where the 2027 fee schedule stands right now</h2>
<p>The Medicare Physician Fee Schedule is updated through annual rulemaking. CMS publishes a proposed rule in mid summer, accepts public comments for roughly 60 days, and publishes a final rule in late October or early November. The final rule takes effect on January 1 of the following year.</p>
<p>For CY 2027, the timeline is as follows:</p>
<ul>
<li>July 14, 2026: CMS placed the proposed rule (CMS 1848 P) on public display and published a <a href="https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2027-medicare-physician-fee-schedule-proposed-rule" target="_blank" rel="noopener">fact sheet</a>.</li>
<li>July 16, 2026: The proposed rule was published in the Federal Register at 91 FR 43842.</li>
<li>September 14, 2026: The comment period closed. The American Medical Association filed a 171 page comment letter opposing the same day E/M reduction and several practice expense proposals.</li>
<li>Early November 2026 (expected): CMS publishes the final rule. The CY 2026 final rule went on display October 31, 2025, and the CY 2025 final rule on November 1, 2024.</li>
<li>January 1, 2027: New rates and policies take effect.</li>
</ul>
<p>Two things can still change the final numbers. First, the 0.53% budget neutrality adjustment depends on which RVU changes CMS finalizes. If CMS withdraws or softens the same day E/M reduction, which is the single largest redistribution in the rule, the budget neutrality adjustment shrinks and the conversion factors fall further. Second, CMS has said it will update its Medicare Economic Index projection with more recent data before finalizing. What cannot change through rulemaking is the statutory piece: the 2.5% increase for 2026 came from Congress, and only Congress can extend it. As of this writing no extension has been enacted.</p>
<p>Practice leaders should treat the proposed figures as a planning baseline for 2027 budgets and compensation models, then revise when the final rule is released.</p>
<h2>3. The 2027 conversion factors: the numbers and the math behind them</h2>
<p>Medicare converts the relative value units assigned to each service into dollars by multiplying total RVUs (after geographic adjustment) by a conversion factor. Since 2026, federal law has required two conversion factors: one for qualifying APM participants (QPs), meaning clinicians who meet CMS participation thresholds in an Advanced Alternative Payment Model, and one for everyone else. Anesthesia services have their own pair.</p>
<h3>Proposed CY 2027 conversion factors</h3>
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th>Conversion factor</th>
<th>CY 2026</th>
<th>Proposed CY 2027</th>
<th>Dollar change</th>
<th>Percent change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonqualifying APM participants (most physicians)</td>
<td>$33.4009</td>
<td>$32.8409</td>
<td>$0.56 decrease</td>
<td>1.68% decrease</td>
</tr>
<tr>
<td>Qualifying APM participants (QPs)</td>
<td>$33.5675</td>
<td>$33.1693</td>
<td>$0.40 decrease</td>
<td>1.19% decrease</td>
</tr>
<tr>
<td>Anesthesia, nonqualifying</td>
<td>$20.4976</td>
<td>$20.2143</td>
<td>$0.28 decrease</td>
<td>1.38% decrease</td>
</tr>
<tr>
<td>Anesthesia, QPs</td>
<td>$20.5998</td>
<td>$20.4165</td>
<td>$0.18 decrease</td>
<td>0.89% decrease</td>
</tr>
</tbody>
</table>
</figure>
<p>Source: CMS 1848 P, Tables D B1 through D B4, and the CMS fact sheet dated July 14, 2026. The anesthesia conversion factors also include a 0.30% specialty specific practice expense and malpractice adjustment.</p>
<h3>The three moving pieces</h3>
<p>CMS builds the 2027 conversion factor in three steps, starting from the 2026 figure.</p>
<ul>
<li><strong>Remove the one year 2.5% increase.</strong> Public Law 119 21, which CMS refers to as the Working Families Tax Cut legislation, raised the 2026 conversion factor by 2.5% for services furnished from January 1 through December 31, 2026 only. Removing it takes the nonqualifying factor from $33.4009 to $32.5863 and the QP factor from $33.5675 to $32.7488.</li>
<li><strong>Apply the budget neutrality adjustment of positive 0.53%.</strong> Section 1848(c)(2)(B)(ii)(II) of the Social Security Act prohibits RVU changes from moving Part B spending by more than $20 million in a year. When proposed RVU changes would lower aggregate spending, CMS raises the conversion factor to hold the total level. A positive adjustment here means the proposed work RVU changes, taken together, reduce payments elsewhere in the fee schedule. This adjustment redistributes money; it does not add any.</li>
<li><strong>Apply the statutory update.</strong> Section 1848(d)(20) of the Act sets the 2027 update at 0.75% for the QP conversion factor and 0.25% for the nonqualifying conversion factor.</li>
</ul>
<p>The result: $32.5863 multiplied by 1.0053 and then by 1.0025 equals $32.8409 for nonqualifying participants, and $32.7488 multiplied by 1.0053 and then by 1.0075 equals $33.1693 for QPs.</p>
<p>Note that the gap between the two physician conversion factors widens each year because the QP update is half a percentage point higher. In 2026 the gap was about 17 cents per RVU. In the 2027 proposal it is about 33 cents. Over a decade, this differential becomes a meaningful incentive to qualify for Advanced APM status.</p>
<p>In its regulatory impact analysis, CMS estimates the conversion factor update lowers fee schedule expenditures by about $2.1 billion in 2027.</p>
<h2>4. Why Medicare physician payment keeps losing ground</h2>
<p>The 2027 reduction is not an isolated event. It is the latest step in a pattern that has defined physician payment since the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) replaced the sustainable growth rate formula.</p>
<p>MACRA set statutory updates of 0.5% per year through 2019, then froze updates at 0% from 2020 through 2025, with the two track structure (0.75% for QPs and 0.25% for everyone else) beginning in 2026. Those updates were never indexed to practice cost inflation. CMS projects the Medicare Economic Index, its measure of growth in physician practice costs, at 2.5% for 2027. A 0.25% update against 2.5% cost growth is a real terms reduction of more than two percentage points in a single year, before any RVU redistribution.</p>
<p>Congress has repeatedly intervened with temporary increases, including the 2.5% for 2026. Each temporary fix expires, and each expiration shows up as a nominal cut in the following year’s proposed rule. The CY 2027 proposal is the fifth consecutive year in which CMS has proposed a lower conversion factor than the one in effect, counting the statutory expirations.</p>
<p>Several physician payment reform bills were introduced in the House during the 2026 session, including proposals to tie annual updates to the MEI. None had been enacted as of this writing. The House Energy and Commerce Subcommittee on Health held a hearing on the fee schedule, MACRA, and payment reform during the comment period. Practice leaders should watch for a year end legislative package, which has been the vehicle for prior temporary increases, but should not build a 2027 budget around the assumption that one will pass.</p>
<h2>5. The efficiency adjustment: what it is and where it stands for 2027</h2>
<p>The efficiency adjustment was the most contested policy in the CY 2026 final rule, and many practice leaders expected a second round in 2027. The 2027 proposed rule does not include a new efficiency adjustment, but the original one continues to affect how CMS values services.</p>
<h3>What the efficiency adjustment does</h3>
<p>In the CY 2026 final rule, CMS applied a 2.5% reduction to the work RVUs and intraservice time of most non time based services. CMS reasoned that procedures and tests become more efficient over time as technology improves and clinicians gain experience, while the Relative Value Scale Update Committee (RUC) survey process does not reliably capture those gains. Time based services, including E/M visits, care management, and behavioral health codes, were exempt because their value is tied directly to clock time.</p>
<p>CMS described the adjustment as periodic rather than annual, with a policy to apply it approximately every three years.</p>
<h3>How it shows up in the 2027 proposal</h3>
<p>Two things carry forward into 2027. First, the 2.5% reduction applied in 2026 remains in the work RVUs of affected codes; there is no restoration. Second, when CMS reviewed RUC recommendations for new and revised codes that were developed before the efficiency adjustment was finalized, it treated those recommendations as though they had already undergone the 2.5% adjustment. Specialty society summaries describe this as CMS continuing to apply the efficiency adjustment to non time based services and extending it to new and revised services whenever CMS determines the RUC recommended values do not already reflect expected efficiency gains.</p>
<p>In practical terms, proceduralists should not expect any relief from the 2026 adjustment, and new procedural codes entering the fee schedule in 2027 will be valued on an efficiency adjusted basis. The next scheduled application, if CMS holds to its stated cadence, would be CY 2029.</p>
<h2>6. Same day E/M visits with global procedures: the modifier 25 reduction</h2>
<p>This is the single most consequential policy in the 2027 proposed rule for office based procedural specialties, and it is the main driver of the large specialty level decreases for dermatology, otolaryngology, orthopedics, and podiatry.</p>
<h3>The proposal</h3>
<p>When a physician, or another physician in the same group practice, furnishes a separately identifiable office or outpatient E/M visit (reported with modifier 25) on the same day as a procedure with a 0 day, 10 day, or 90 day global period for the same patient, CMS proposes to pay the most expensive service at 100% and every other procedure or E/M visit furnished that day at 50%.</p>
<p>CMS argues that there are efficiencies when the same physician provides an E/M service in conjunction with a global procedure, that the practice expense and pre service work overlap, and that the current methodology likely pays twice for the same resources. CMS proposed a similar reduction in the CY 2019 rule and did not finalize it, but stated at the time that it continued to believe the overlap exists.</p>
<h3>A worked example from the rule</h3>
<p>CMS illustrates the policy with a dermatology encounter using 2026 RVUs: a level two established patient visit (CPT 99212, 1.78 nonfacility RVUs) plus two shave removals (CPT 11300 at 2.89 RVUs and CPT 11301 at 3.48 RVUs). Under the proposal, 11301 is paid in full as the highest valued service, while 11300 and 99212 are each cut in half, to 1.445 and 0.89 RVUs.</p>
<p>The encounter drops from 8.15 RVUs to 5.815 RVUs, a 29% reduction. At the proposed nonqualifying conversion factor and before geographic adjustment, that is $267.65 versus $190.97, or $76.68 less for a single routine visit. A dermatology practice performing thirty such encounters per week would lose roughly $120,000 per year on Medicare patients from this one policy, before the conversion factor change.</p>
<h3>What CMS is asking about</h3>
<p>CMS requested comments on three alternatives: a 25% reduction instead of 50%, extending the policy to other E/M families such as inpatient and nursing facility visits, and how the policy should apply to E/M visits furnished on the same day as intravitreal injections, which are high volume in ophthalmology and retina practices. The AMA and most procedural specialty societies asked CMS to withdraw the proposal entirely.</p>
<h3>What practices should do now</h3>
<p>Pull a full year of claims where an office E/M code was billed with modifier 25 on the same date of service as a global procedure by the same provider or any provider in the group. Calculate the exposure by applying a 50% reduction to the lower valued services in each encounter. This analysis is also a compliance review: modifier 25 is a long standing OIG and Medicare Administrative Contractor audit target, and any encounter where the E/M documentation does not support a separately identifiable service is both a revenue risk under the new policy and an overpayment risk under existing rules. Section 13 covers the compliance side.</p>
<h2>7. G2211 becomes a modifier</h2>
<p>HCPCS code G2211 is the office and outpatient E/M visit complexity add on that recognizes the cost of serving as the continuing focal point for a patient’s care or managing a single serious or complex condition over time. It was finalized in 2021, delayed by statute, and implemented for CY 2025.</p>
<h3>The 2027 proposal</h3>
<p>CMS proposes to retire G2211 as a separately billed code and replace it with a modifier appended to the associated E/M base code. CMS uses placeholder MOD1 in the proposed rule and will assign a two digit HCPCS modifier in the final rule. The modifier would increase payment for the associated E/M visit by 16% rather than adding a flat dollar amount.</p>
<p>CMS chose a percentage because the flat payment produced uneven results across visit levels: G2211 currently adds about 29% to a 99212 but only about 9% to a 99215. The 16% figure is a utilization weighted average adjusted for budget neutrality. Practices that bill G2211 mostly with lower level visits will see less from the modifier than they receive today; practices that bill it with level four and five visits will see more.</p>
<h3>The ACO version</h3>
<p>CMS also proposes a second modifier (placeholder MOD2) available only to practitioners participating in a Medicare Shared Savings Program ACO or as Participant Providers in the Long term Enhanced ACO Design (LEAD) Model. MOD2 would increase payment for the associated E/M visit by 32%, recognizing the additional resource costs of total cost of care accountability and quality reporting. Use of MOD2 would be voluntary, and it could be billed for all beneficiaries the practitioner serves, not only those assigned to the ACO. Claims with MOD2 would be included in beneficiary assignment, historical benchmark, and performance year expenditure calculations for the Shared Savings Program.</p>
<p>For primary care and medical specialty practices, the MOD2 proposal is one of the clearer financial arguments for ACO participation in the 2027 rule. A practice billing 10,000 Medicare E/M visits per year at an average of 2.5 work RVUs each, with G2211 appended to half of them, would see the add on payment roughly double by moving from MOD1 to MOD2.</p>
<h3>Operational implications</h3>
<p>Billing systems, EHR charge capture rules, and physician compensation plans built around G2211 as a separate line item will need to change. Compensation plans that credit wRVUs for G2211 should specify how the modifier will be credited. Coding staff will need updated guidance on when the modifier applies, since the clinical criteria do not change even though the mechanism does.</p>
<h2>8. The practice expense methodology overhaul</h2>
<p>Practice expense (PE) RVUs typically account for 40% to 50% of total RVUs for office based services. CMS has historically derived PE values from AMA survey data, including the Physician Practice Information Survey, most of which dates to 2007 or earlier. The 2027 proposed rule begins a multiyear transition away from that data toward what CMS describes as more objective, routinely updated, and auditable cost sources. CMS states that it expects the change to make fee schedule payments more sensitive to market pressures and to open possibilities for right sizing payments across outpatient settings.</p>
<h3>Phasing out the indirect practice cost index</h3>
<p>The current methodology includes a final step, the indirect practice cost index (IPCI), that scales each specialty’s total PE RVUs to be consistent with specialty specific practice expense per hour data from the old surveys. CMS proposes to remove the IPCI steps over two years: half of the adjustment removed in 2027 and the remainder in 2028. Under the new approach, PE RVUs would still be derived from work RVUs, direct PE inputs, and specialty specific indirect allocators, but without the anchor to 2007 era cost data.</p>
<p>The redistribution from this change is substantial for some specialties. Specialties whose old survey data showed high practice expense per hour relative to their current direct inputs lose; specialties whose survey data understated their costs gain. CMS cites the IPCI removal alongside the same day E/M reduction as the main reasons for the dermatology and otolaryngology decreases.</p>
<h3>The practice expense stabilizer</h3>
<p>To limit volatility, CMS proposes a new PE stabilization adjustment that would cap annual increases or decreases in a code’s PE RVUs at plus or minus 5% for most existing services. The stabilizer would not apply to new, revised, or revalued codes, and it runs before the statutory phase in, which already limits any code’s total RVU reduction to a maximum of 19% in one year.</p>
<h3>Indirect PE allocation and site of service</h3>
<p>CMS proposes to allocate indirect practice expense based on both work RVUs and clinical labor for all services except 10 day and 90 day global codes. For nursing facility visits (CPT 99304 through 99310, 99315, and 99316), CMS proposes to set the facility PE RVUs equal to the nonfacility PE RVUs so that payment is the same whether or not the patient is in a Part A skilled nursing facility stay, correcting an unintended gap created by the 2026 site of service change.</p>
<p>Most important for the long term, CMS is asking whether the facility versus nonfacility payment differential is still appropriate at all. The agency specifically requests comment on whether hospital employed physicians incur substantially lower indirect costs than independent physicians furnishing services in facility settings, whether facility indirect PE could be reduced below the current 50% allocation or to zero for certain employed physicians, and whether a new modifier identifying employed physicians could be used to adjust facility PE payments. Nothing is proposed for 2027 on this question, but the direction of travel favors independent practices over employed physician groups in facility settings.</p>
<h2>9. Specialty impact: who gains and who loses</h2>
<p>Table D B5 of the proposed rule estimates the combined impact of all proposed RVU changes on total allowed charges by specialty. The table isolates the redistribution inside a fixed pool: its total row is 0%. It does not include the conversion factor change or the statutory updates, which apply across the board.</p>
<p>The largest proposed decreases are dermatology and otolaryngology at 9% each, orthopedic surgery at 7%, hand surgery at 5%, and colon and rectal surgery and podiatry at 4% each. CMS attributes these mostly to the same day E/M reduction, the IPCI removal, and the continued phase in of code level reductions finalized in prior years. The largest increases go to clinical social workers at 12% and clinical psychologists at 11%, reflecting the final year of the four year work RVU increase for timed behavioral health services. Physical and occupational therapy, interventional radiology, radiation oncology, vascular surgery, and psychiatry each gain 3%.</p>
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th>Specialty</th>
<th>Allowed charges (millions)</th>
<th>Combined impact</th>
<th>Nonfacility</th>
<th>Facility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergy/Immunology</td>
<td>$154</td>
<td>0%</td>
<td>0%</td>
<td>+1%</td>
</tr>
<tr>
<td>Anesthesiology</td>
<td>$1,656</td>
<td>0%</td>
<td>minus 1%</td>
<td>0%</td>
</tr>
<tr>
<td>Audiologist</td>
<td>$81</td>
<td>minus 3%</td>
<td>minus 3%</td>
<td>0%</td>
</tr>
<tr>
<td>Cardiac Surgery</td>
<td>$146</td>
<td>+1%</td>
<td>+2%</td>
<td>0%</td>
</tr>
<tr>
<td>Cardiology</td>
<td>$6,464</td>
<td>+1%</td>
<td>+1%</td>
<td>0%</td>
</tr>
<tr>
<td>Chiropractic</td>
<td>$626</td>
<td>+2%</td>
<td>+2%</td>
<td>0%</td>
</tr>
<tr>
<td>Clinical Psychologist</td>
<td>$729</td>
<td>+11%</td>
<td>+11%</td>
<td>+8%</td>
</tr>
<tr>
<td>Clinical Social Worker</td>
<td>$974</td>
<td>+12%</td>
<td>+13%</td>
<td>+11%</td>
</tr>
<tr>
<td>Colon and Rectal Surgery</td>
<td>$147</td>
<td>minus 4%</td>
<td>minus 9%</td>
<td>minus 1%</td>
</tr>
<tr>
<td>Critical Care</td>
<td>$348</td>
<td>0%</td>
<td>+1%</td>
<td>0%</td>
</tr>
<tr>
<td>Dermatology</td>
<td>$3,881</td>
<td>minus 9%</td>
<td>minus 9%</td>
<td>minus 7%</td>
</tr>
<tr>
<td>Diagnostic Testing Facility</td>
<td>$999</td>
<td>+4%</td>
<td>+4%</td>
<td>+2%</td>
</tr>
<tr>
<td>Emergency Medicine</td>
<td>$2,581</td>
<td>+1%</td>
<td>0%</td>
<td>+1%</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>$584</td>
<td>+2%</td>
<td>+2%</td>
<td>+1%</td>
</tr>
<tr>
<td>Family Practice</td>
<td>$5,976</td>
<td>+1%</td>
<td>+1%</td>
<td>+3%</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>$1,327</td>
<td>minus 1%</td>
<td>minus 1%</td>
<td>minus 1%</td>
</tr>
<tr>
<td>General Practice</td>
<td>$408</td>
<td>+2%</td>
<td>+1%</td>
<td>+5%</td>
</tr>
<tr>
<td>General Surgery</td>
<td>$1,517</td>
<td>0%</td>
<td>0%</td>
<td>minus 1%</td>
</tr>
<tr>
<td>Geriatrics</td>
<td>$203</td>
<td>+4%</td>
<td>+2%</td>
<td>+7%</td>
</tr>
<tr>
<td>Hand Surgery</td>
<td>$278</td>
<td>minus 5%</td>
<td>minus 7%</td>
<td>minus 3%</td>
</tr>
<tr>
<td>Hematology/Oncology</td>
<td>$1,571</td>
<td>0%</td>
<td>0%</td>
<td>+1%</td>
</tr>
<tr>
<td>Independent Laboratory</td>
<td>$380</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Infectious Disease</td>
<td>$587</td>
<td>0%</td>
<td>minus 1%</td>
<td>0%</td>
</tr>
<tr>
<td>Internal Medicine</td>
<td>$9,932</td>
<td>+1%</td>
<td>+1%</td>
<td>+1%</td>
</tr>
<tr>
<td>Interventional Pain Management</td>
<td>$880</td>
<td>minus 2%</td>
<td>minus 2%</td>
<td>minus 1%</td>
</tr>
<tr>
<td>Interventional Radiology</td>
<td>$545</td>
<td>+3%</td>
<td>+5%</td>
<td>+1%</td>
</tr>
<tr>
<td>Multispecialty Clinic/Other Physician</td>
<td>$164</td>
<td>minus 2%</td>
<td>minus 4%</td>
<td>0%</td>
</tr>
<tr>
<td>Nephrology</td>
<td>$1,672</td>
<td>0%</td>
<td>+1%</td>
<td>0%</td>
</tr>
<tr>
<td>Neurology</td>
<td>$1,390</td>
<td>0%</td>
<td>minus 1%</td>
<td>0%</td>
</tr>
<tr>
<td>Neurosurgery</td>
<td>$652</td>
<td>minus 2%</td>
<td>minus 1%</td>
<td>minus 2%</td>
</tr>
<tr>
<td>Nuclear Medicine</td>
<td>$50</td>
<td>+2%</td>
<td>+2%</td>
<td>+2%</td>
</tr>
<tr>
<td>Nurse Anesthetist / Anesthesiologist Assistant</td>
<td>$1,130</td>
<td>+1%</td>
<td>+10%</td>
<td>+1%</td>
</tr>
<tr>
<td>Nurse Practitioner</td>
<td>$7,775</td>
<td>+2%</td>
<td>0%</td>
<td>+6%</td>
</tr>
<tr>
<td>Obstetrics/Gynecology</td>
<td>$558</td>
<td>minus 1%</td>
<td>minus 1%</td>
<td>minus 2%</td>
</tr>
<tr>
<td>Ophthalmology</td>
<td>$4,548</td>
<td>minus 3%</td>
<td>minus 3%</td>
<td>minus 2%</td>
</tr>
<tr>
<td>Optometry</td>
<td>$1,498</td>
<td>minus 2%</td>
<td>minus 2%</td>
<td>0%</td>
</tr>
<tr>
<td>Oral/Maxillofacial Surgery</td>
<td>$34</td>
<td>minus 1%</td>
<td>minus 1%</td>
<td>minus 1%</td>
</tr>
<tr>
<td>Orthopedic Surgery</td>
<td>$3,296</td>
<td>minus 7%</td>
<td>minus 5%</td>
<td>minus 8%</td>
</tr>
<tr>
<td>Other</td>
<td>$39</td>
<td>minus 2%</td>
<td>minus 2%</td>
<td>minus 2%</td>
</tr>
<tr>
<td>Otolaryngology</td>
<td>$1,199</td>
<td>minus 9%</td>
<td>minus 10%</td>
<td>minus 3%</td>
</tr>
<tr>
<td>Pathology</td>
<td>$777</td>
<td>0%</td>
<td>minus 1%</td>
<td>0%</td>
</tr>
<tr>
<td>Pediatrics</td>
<td>$61</td>
<td>0%</td>
<td>0%</td>
<td>+1%</td>
</tr>
<tr>
<td>Physical Medicine</td>
<td>$1,203</td>
<td>+1%</td>
<td>minus 2%</td>
<td>+4%</td>
</tr>
<tr>
<td>Physical/Occupational Therapy</td>
<td>$4,372</td>
<td>+3%</td>
<td>+3%</td>
<td>0%</td>
</tr>
<tr>
<td>Physician Assistant</td>
<td>$3,751</td>
<td>minus 3%</td>
<td>minus 5%</td>
<td>+1%</td>
</tr>
<tr>
<td>Plastic Surgery</td>
<td>$268</td>
<td>minus 3%</td>
<td>minus 4%</td>
<td>minus 1%</td>
</tr>
<tr>
<td>Podiatry</td>
<td>$1,969</td>
<td>minus 4%</td>
<td>minus 4%</td>
<td>0%</td>
</tr>
<tr>
<td>Portable X Ray Supplier</td>
<td>$76</td>
<td>minus 1%</td>
<td>minus 1%</td>
<td>minus 1%</td>
</tr>
<tr>
<td>Psychiatry</td>
<td>$882</td>
<td>+3%</td>
<td>+3%</td>
<td>+2%</td>
</tr>
<tr>
<td>Pulmonary Disease</td>
<td>$1,266</td>
<td>0%</td>
<td>+1%</td>
<td>0%</td>
</tr>
<tr>
<td>Radiation Oncology and Radiation Therapy Centers</td>
<td>$1,541</td>
<td>+3%</td>
<td>+5%</td>
<td>minus 1%</td>
</tr>
<tr>
<td>Radiology</td>
<td>$4,706</td>
<td>+2%</td>
<td>+2%</td>
<td>+1%</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>$567</td>
<td>minus 1%</td>
<td>minus 1%</td>
<td>+1%</td>
</tr>
<tr>
<td>Thoracic Surgery</td>
<td>$299</td>
<td>+1%</td>
<td>+2%</td>
<td>0%</td>
</tr>
<tr>
<td>Urology</td>
<td>$1,626</td>
<td>minus 2%</td>
<td>minus 2%</td>
<td>minus 1%</td>
</tr>
<tr>
<td>Vascular Surgery</td>
<td>$1,015</td>
<td>+3%</td>
<td>+4%</td>
<td>0%</td>
</tr>
<tr>
<td>Total</td>
<td>$91,355</td>
<td>0%</td>
<td>0%</td>
<td>+1%</td>
</tr>
</tbody>
</table>
</figure>
<p>Source: CMS 1848 P, Table D B5, columns C and G (91 FR 44244 through 44247). Allowed charges are CMS estimates based on 2025 utilization at 2026 rates. Percentages are rounded to whole numbers and are proposed estimates.</p>
<p>Two cautions apply when reading this table. First, these are specialty averages. CMS states plainly that an individual practitioner’s impact depends on the mix of services furnished, and CMS publishes a separate “Specialty Impacts by Practitioner” file showing the range within each specialty. A dermatology practice that performs few same day procedures will do better than the 9% average; one built around high volume same day biopsy and destruction encounters will do worse. Second, the table percentages must not simply be added to the conversion factor change, because the budget neutrality offset is already inside the table. Section 11 explains the correct arithmetic.</p>
<h2>10. Other 2027 changes that touch practice revenue</h2>
<h3>Remote physiologic and remote therapeutic monitoring</h3>
<p>Remote monitoring has been one of the fastest growing service lines in Part B, and the OIG has issued multiple reports raising concerns about billing without an established relationship, services delivered by third party vendors with minimal practice involvement, and device costs that no longer justify current valuations. The 2027 proposed rule responds with three restrictions and a revaluation:</p>
<ul>
<li>RTM services could be furnished only to established patients.</li>
<li>Practitioners reporting RPM or RTM would have to furnish a separately reportable initiating visit in association with the onset of monitoring.</li>
<li>RPM and RTM would be payable only when performed by clinical staff employed by the practice, not when delivered by contractors.</li>
<li>CMS proposes to update the valuation of the device supply codes because devices are available at lower cost than originally estimated.</li>
</ul>
<p>CMS is also seeking comment on bundling the RPM and RTM CPT codes into four new HCPCS G codes. Practices that rely on outsourced monitoring vendors should model what the employed staff requirement means for their program’s economics and compliance posture. Those relationships may need to be restructured before January 1, 2027.</p>
<h3>Global surgery data collection paused</h3>
<p>CMS proposes to pause the postoperative visit data collection required by section 523 of MACRA. The agency states that several years of data show postoperative visits during global periods are not occurring at the frequency assumed in the valuations, yet practitioners are still paid for them. CMS is posting a public use file with imputed RVUs for 10 day and 90 day global codes with the postoperative visits removed, and is soliciting comment on revaluation strategies. No revaluation is proposed for 2027, but surgeons should read this as a clear signal of future reductions to global period payments.</p>
<h3>Behavioral health, smoking cessation, and SBIRT</h3>
<p>The four year transition that increased work RVUs for timed behavioral health services, finalized in the CY 2024 rule, reaches its final year in 2027. CMS proposes to add smoking and tobacco use cessation services and screening, brief intervention, and referral to treatment (SBIRT) services to this final transition year. This is why clinical social workers, clinical psychologists, and psychiatry show the largest specialty gains.</p>
<h3>Shared medical appointments</h3>
<p>CMS proposes to establish separate coding and payment for shared medical appointments, a group based format in which beneficiaries receive clinical guidance while engaging with peers managing similar conditions. No HCPCS code currently describes this service. For practices managing large panels of patients with diabetes, hypertension, obesity, or other chronic conditions, this is a new revenue opportunity aligned with the administration’s chronic disease and prevention priorities.</p>
<h3>Advance care planning by clinical staff</h3>
<p>CMS proposes two new HCPCS codes for advance care planning furnished by clinical staff under direct supervision of the billing practitioner. The existing CPT codes 99497 and 99498 would be reserved for time personally spent by the billing practitioner. Practices that have used nurses or care coordinators for ACP conversations gain a compliant way to bill that work.</p>
<h3>Telehealth</h3>
<p>The Consolidated Appropriations Act, 2026 extended the broader Medicare telehealth flexibilities, including the removal of geographic restrictions and expanded originating sites, through December 31, 2027, and delayed the in person requirement for mental health telehealth to January 1, 2028. In the rule, CMS proposes adding five services to the Medicare Telehealth Services List (including the new shared medical appointment and clinical staff ACP codes), allowing teaching physicians to bill when either the teaching physician or the resident is physically present with the patient, and increasing the originating site facility fee (HCPCS Q3014) to $32.65.</p>
<h3>Quality Payment Program</h3>
<p>The MIPS performance threshold stays at 75 points for the 2027 performance period. The larger change is structural: CMS proposes to end traditional MIPS reporting and make MIPS Value Pathways (MVPs) the only reporting option beginning with the 2029 performance period and 2031 payment year. Practices that have not yet selected or tested an MVP should begin in 2027. CMS also proposes updates to the Ambulatory Specialty Model finalized in 2026, including a rural adjustment, subspecialty exclusions, and a voluntary patient reported outcome submission option. Details are in the separate CMS fact sheet on the Shared Savings Program and QPP provisions.</p>
<h3>Rural health clinics and FQHCs</h3>
<p>CMS proposes to recognize diabetes self management training and medical nutrition therapy as stand alone billable visits under the RHC all inclusive rate, aligning RHCs with FQHCs and physician offices. The FQHC PPS base rate would rise 2.5% to $212.91. In person visit requirements for mental health visits furnished via telecommunications would not apply through December 31, 2027.</p>
<h3>Clinical laboratory fee schedule</h3>
<p>Conforming changes implement the CAA 2026 amendments to the CLFS, including a phase in that caps payment reductions from private payor rate data at 15% per year through CY 2029. CMS also proposes to move algorithm only laboratory services (software as a medical service) from the CLFS to the fee schedule.</p>
<h3>Primary care payment request for information</h3>
<p>CMS is seeking comment on three topics: reconsidering relative primary care valuation in the fee schedule, the payment implications of technology in primary care, and prospective (capitated) primary care payment in the Shared Savings Program and potentially in Original Medicare broadly. No payment change is proposed for 2027, but the RFI signals that the CY 2028 rule may contain substantial primary care changes.</p>
<h2>11. How to calculate your practice’s 2027 exposure</h2>
<p>Specialty averages are a starting point, not an answer. The following method produces a practice specific estimate in a few hours of work by a billing manager or practice administrator. It is also the method behind the specialty impact worksheet distributed to attendees of the DoctorsManagement webinar on this topic.</p>
<h3>Step 1: Identify your conversion factor</h3>
<p>Determine whether your clinicians are qualifying APM participants for the 2027 payment year. QP status is based on participation in an Advanced APM during the 2025 performance period. Your ACO or APM lead will have the determination. Everyone else uses the nonqualifying factor.</p>
<h3>Step 2: Pull your top 20 codes by Medicare volume</h3>
<p>Export 12 months of Medicare fee for service claims and rank CPT and HCPCS codes by total allowed charges. For most practices the top 20 codes represent 70% to 85% of Medicare revenue. Record the volume for each code.</p>
<h3>Step 3: Look up 2026 and proposed 2027 RVUs</h3>
<p>Addendum B on the <a href="https://www.cms.gov/medicare/payment/fee-schedules/physician/federal-regulation-notices/cms-1848-p" target="_blank" rel="noopener">CMS 1848 P rule page</a> lists the proposed 2027 work, practice expense, and malpractice RVUs for every code, in both facility and nonfacility settings. Compare each of your top 20 codes against the 2026 Addendum B. Note whether the code is time based (exempt from the efficiency adjustment) or non time based.</p>
<h3>Step 4: Apply your geographic practice cost indices</h3>
<p>Multiply each RVU component by your locality’s GPCI. Many practices skip this step and use national figures; the error is usually small, but for practices in high cost or low cost localities it matters.</p>
<h3>Step 5: Calculate payment per code and total change</h3>
<p>For each code, multiply total adjusted RVUs by the applicable conversion factor for 2026 and for proposed 2027, then multiply by annual volume. The difference, summed across the top 20 codes, is your baseline exposure from the conversion factor and RVU changes combined.</p>
<p>For a service whose RVUs do not change, payment falls by exactly the conversion factor change. As an illustration, $500,000 of 2026 Medicare revenue from unchanged codes at the same volume falls by $8,400 for a nonqualifying practice (1.68%) or $5,950 for a QP practice (1.19%).</p>
<h3>Step 6: Layer in the same day E/M reduction</h3>
<p>If you perform office procedures, pull every claim in the 12 month window where an office E/M code with modifier 25 was billed on the same date as a 0 day, 10 day, or 90 day global procedure by the same billing provider or any provider in the group. For each encounter, identify the highest valued service, apply a 50% reduction to all other services, and sum the difference. Add this to the Step 5 result.</p>
<h3>Step 7: Adjust for G2211</h3>
<p>Count G2211 units billed in the window by the level of the associated E/M visit. Recalculate the add on as 16% of each associated visit’s proposed 2027 payment. If you participate in an MSSP ACO or the LEAD model, also calculate the 32% scenario. The difference versus current G2211 payments adjusts the Step 5 result up or down.</p>
<h3>Step 8: Review remote monitoring and care management</h3>
<p>If you bill RPM or RTM, determine whether your program uses contracted vendors for monitoring services and estimate the revenue at risk if the employed clinical staff requirement is finalized. If you bill chronic care management, principal care management, or advanced primary care management, confirm those codes’ proposed 2027 values; most are time based and were not affected by the efficiency adjustment.</p>
<h3>A note on using the specialty table correctly</h3>
<p>If you use Table D B5 as a shortcut instead of code level analysis, do not add the table percentage to the 1.68% conversion factor change. The table already includes the 0.53% budget neutrality offset, so adding the full conversion factor change would count that offset twice. Instead, apply the table percentage and then the statutory change alone: multiply by 1.0025 divided by 1.025 (about 0.978) for nonqualifying participants, or 1.0075 divided by 1.025 (about 0.983) for QPs.</p>
<p>Three illustrations for a nonqualifying practice with $500,000 of 2026 Medicare revenue at constant volume and mix:</p>
<ul>
<li>A specialty at 0% in the table, such as general surgery: $500,000 multiplied by 0.978 equals about $489,000, roughly $11,000 (2.2%) less.</li>
<li>The dermatology average, 9% decrease: $500,000 multiplied by 0.91 and then by 0.978 equals about $445,000, roughly $55,000 (11%) less.</li>
<li>The psychiatry average, 3% increase: $500,000 multiplied by 1.03 and then by 0.978 equals about $503,700, roughly $3,700 (0.7%) more.</li>
</ul>
<p>Independent actuarial analysis using national claims data estimates the average reduction for nonqualifying participants at about 2.2% across all specialties, consistent with the first illustration above.</p>
<h2>12. Fifteen ways to protect revenue in 2027</h2>
<p>The strategies below are organized by where the money comes from: capturing earned revenue, reducing the cost to collect, improving contracts and payer mix, and controlling practice expense. Not every strategy applies to every practice, but most practices can implement five or six of them before the new rates take effect.</p>
<h3>Capture revenue you already earn</h3>
<p><strong>1. Audit E/M coding accuracy in both directions.</strong> Undercoding is as common as overcoding in practices that have never had an independent coding audit. The 2021 E/M guidelines base level selection on medical decision making or total time, and many physicians still code by habit from the old history and exam framework. A baseline audit of 10 to 20 charts per provider usually identifies a 3% to 8% revenue gap, and the fix is documentation education rather than more work.</p>
<p><strong>2. Capture the G2211 modifier on every eligible visit.</strong> Under the proposed 16% structure, the modifier is worth more on higher level visits. Build EHR prompts that flag eligible established patient relationships, and make sure the clinical rationale (continuing focal point for all care, or management of a serious or complex condition over time) is reflected in the record.</p>
<p><strong>3. Build or expand care management services.</strong> Chronic care management, principal care management, transitional care management, behavioral health integration, and the advanced primary care management codes introduced in 2025 are time based, were exempt from the efficiency adjustment, and pay for work that clinical staff already do by phone and portal. A practice with 1,500 Medicare patients that enrolls 20% in CCM at the base code generates roughly $200,000 in new annual revenue with one dedicated care coordinator.</p>
<p><strong>4. Schedule annual wellness visits systematically.</strong> AWV completion rates in independent practices commonly run below 30%. Each AWV is a stand alone payment, and it is the natural entry point for care management enrollment, advance care planning, and preventive services that pay separately.</p>
<p><strong>5. Add shared medical appointments and clinical staff ACP once codes are finalized.</strong> Both are new in 2027 and both monetize work that chronic disease practices are already doing informally.</p>
<p><strong>6. Bill the correct place of service and site of service.</strong> With CMS questioning the facility and nonfacility differential, accurate place of service coding matters more than ever. Services furnished in a practice owned office must be billed as nonfacility to receive the full practice expense payment.</p>
<h3>Reduce the cost to collect</h3>
<p><strong>7. Attack denials at the root cause.</strong> Industry benchmarks put initial denial rates between 8% and 12%, and the cost to rework a denied claim averages $25 to $118 depending on complexity. Group denials by reason code, fix the top five causes (eligibility, authorization, modifier, diagnosis specificity, timely filing), and track first pass resolution rate weekly.</p>
<p><strong>8. Tighten front end eligibility and authorization.</strong> Real time eligibility verification at scheduling and again at check in prevents the largest single denial category. For Medicare Advantage patients, confirm plan specific authorization requirements before procedures.</p>
<p><strong>9. Collect patient responsibility at the time of service.</strong> Patient balances are the fastest growing share of practice receivables and the hardest to collect after the visit. Estimate responsibility before the appointment, collect copays and known deductibles at check in, and offer card on file for balances.</p>
<p><strong>10. Measure days in accounts receivable and aging by payer.</strong> Medicare pays clean claims within 14 days by statute. If your Medicare A/R over 60 days exceeds 10% of total Medicare A/R, the problem is internal (claim edits, unworked rejections, missing documentation), and it is fixable.</p>
<h3>Improve contracts and payer mix</h3>
<p><strong>11. Read every commercial contract’s reimbursement exhibit for its Medicare reference.</strong> Contracts that pay a percentage of “the current Medicare fee schedule” automatically import the 2027 reductions, including the same day E/M cut, into commercial payments. Contracts that reference a fixed year (for example, “2024 Medicare RVUs and conversion factor”) do not. Know which you have, and when renegotiating, push for fixed year references or an annual inflator tied to the MEI.</p>
<p><strong>12. Evaluate Advanced APM and ACO participation.</strong> QP status earns the higher conversion factor (a widening differential), MSSP participants would qualify for the 32% MOD2 complexity modifier, and participants in two sided risk tracks are exempt from MIPS reporting. For primary care and medical specialty practices, the 2027 rule makes the financial case for ACO participation stronger than it has been in any prior year.</p>
<p><strong>13. Review physician compensation plans for Medicare linked terms.</strong> Plans that credit wRVUs at a fixed dollar rate are insulated from the conversion factor change but may not be insulated from the same day E/M reduction if the plan credits wRVUs as billed rather than as paid. Plans tied to collections absorb the full impact. Decide now how G2211 modifier credit and same day reductions will be handled, and communicate before January.</p>
<h3>Control practice expense</h3>
<p><strong>14. Right size staffing against the work.</strong> Staffing is 50% to 60% of practice overhead in most specialties. Benchmark support staff per full time physician against MGMA data for your specialty, and look at scheduling templates, no show rates, and room utilization before adding headcount. Care coordinators and medical assistants who generate care management revenue often pay for themselves; administrative positions that do not touch revenue should be scrutinized.</p>
<p><strong>15. Audit supply, drug, and vendor costs annually.</strong> Group purchasing organization participation, drug acquisition cost benchmarking against ASP, and competitive bids on EHR, billing clearinghouse, and remote monitoring vendors typically yield 3% to 6% savings on non labor overhead. For practices affected by the RPM contractor restriction, this is also the moment to re evaluate whether an in house program is more economical.</p>
<h2>13. Compliance guardrails: offsetting cuts without creating audit risk</h2>
<p>Revenue pressure is the most common precursor to compliance problems. When practices respond to payment cuts by pushing coding to the edge, the result is often an overpayment, a payer audit, or in the worst cases a False Claims Act exposure that costs far more than the cut it was meant to offset. Every strategy in Section 12 can be executed compliantly. The following guardrails keep it that way.</p>
<p><strong>Modifier 25 documentation.</strong> The same day E/M reduction will not make modifier 25 less scrutinized; it will make it more scrutinized, because the policy change focuses auditor attention on the code pair. The E/M service must be significant and separately identifiable from the procedure, which means the record must show evaluation of a problem beyond the decision to perform the procedure. A pre existing note template that always generates an E/M alongside a procedure is a red flag. Audit a sample of modifier 25 encounters quarterly.</p>
<p><strong>G2211 clinical criteria.</strong> The modifier does not change the criteria. The visit must reflect a longitudinal relationship in which the practitioner is the continuing focal point for all needed services, or ongoing management of a single serious or complex condition. Appending the modifier to every established patient visit without that relationship is improper billing.</p>
<p><strong>Care management consent and time.</strong> CCM, PCM, and APCM require documented patient consent, a comprehensive care plan, and (for time based codes) contemporaneous time logs. The OIG has audited CCM billing and found claims without a documented care plan or with time overlapping other services. Build the documentation workflow before scaling enrollment.</p>
<p><strong>Remote monitoring.</strong> The 2027 restrictions respond directly to OIG findings. Even before they take effect, practices should confirm that every RPM patient has an established relationship, that the 16 day device data requirement is met for supply codes, that the 20 minute interactive communication requirement is met and documented for management codes, and that the practice retains control over the clinical work.</p>
<p><strong>E/M level selection.</strong> Correcting undercoding is appropriate when documentation supports it. Coaching physicians to document more in order to bill higher, without a corresponding change in the medical decision making or time actually involved, is not. The 2021 guidelines reward accurate documentation of complexity, not volume of text.</p>
<p><strong>Incident to and split shared billing.</strong> As practices lean on nurse practitioners, physician assistants, and clinical staff to generate care management and ACP revenue, supervision and billing rules become central. Incident to billing in the office requires direct supervision and an established plan of care initiated by the physician. Split shared visits in facility settings must be billed under the practitioner who performed the substantive portion.</p>
<p>The connection between revenue strategy and compliance is why DoctorsManagement pairs revenue cycle engagements with compliance review. A revenue improvement that cannot withstand an audit is not an improvement.</p>
<h2>14. How DoctorsManagement helps practices prepare</h2>
<p>DoctorsManagement has guided physician practices through every fee schedule cycle since the resource based relative value scale was introduced. Two service lines are built specifically for the work described in this guide.</p>
<p><a href="https://www.doctorsmanagement.com/revenue-cycle-management/"><strong>Revenue Cycle Management</strong></a><strong>.</strong> Our revenue cycle team conducts code level impact analysis against the proposed and final 2027 rates, audits E/M and modifier 25 coding accuracy, designs care management and AWV programs with compliant documentation workflows, and runs denial root cause analysis with a first pass resolution target. For practices that outsource billing to us, the 2027 impact model is part of the standard annual planning cycle.</p>
<p><a href="https://www.doctorsmanagement.com/practice-assessment/"><strong>Practice Assessments</strong></a><strong>.</strong> A practice assessment is a structured review of financial performance, operations, staffing, contracts, and compliance against specialty benchmarks. For 2027, the assessment includes a Medicare exposure model, a commercial contract review for Medicare linked reimbursement terms, an Advanced APM and ACO participation analysis, and a prioritized action plan with projected revenue impact for each recommendation.</p>
<p>If you would like to discuss your practice’s 2027 exposure, <a href="https://outlook.office.com/book/DoctorsManagementSalesScheduling@drsmgmt.com/?ismsaljsauthenabled" target="_blank" rel="noopener">schedule a 30 minute discovery call</a> with our team. Attendees of our <a href="https://www.doctorsmanagement.com/simplifying-the-business-of-medicine/">Simplifying the Business of Medicine</a> webinar on the 2027 fee schedule also receive the specialty impact worksheet, a spreadsheet template for the top 20 code analysis described in Section 11.</p>
<h2>15. Frequently asked questions</h2>
<h3>How much will Medicare pay physicians in 2027?</h3>
<p>Under the proposed rule, the conversion factor is $32.8409 per RVU for clinicians who are not qualifying APM participants and $33.1693 for qualifying APM participants, before geographic adjustment. These are decreases of 1.68% and 1.19% from 2026. Payment for a specific service equals its total RVUs, adjusted for locality, multiplied by the applicable conversion factor. The final rule, expected in early November 2026, sets the final figures.</p>
<h3>What is the 2027 Medicare conversion factor?</h3>
<p>The proposed 2027 conversion factor is $32.8409 for most physicians and $33.1693 for qualifying APM participants. Anesthesia has separate conversion factors of $20.2143 and $20.4165, respectively.</p>
<h3>Why are Medicare physician payments being cut in 2027?</h3>
<p>The one year 2.5% increase Congress provided for 2026 expires at the end of 2026. The statutory updates for 2027 (0.25% for most physicians, 0.75% for QPs) and a 0.53% budget neutrality adjustment offset only part of that expiration, so both conversion factors fall below their 2026 levels. Extending the increase would require new legislation.</p>
<h3>What changed in the 2027 physician fee schedule?</h3>
<p>The major changes are the conversion factor reduction, a proposed 50% payment reduction for office E/M visits billed on the same day as a global procedure, conversion of G2211 into a 16% modifier (32% for ACO participants), a two year phase out of the indirect practice cost index in practice expense RVUs with a new 5% stabilizer, new restrictions and revaluation for remote monitoring, a pause of global surgery data collection, new codes for shared medical appointments and clinical staff advance care planning, and a proposal to make MVPs the only MIPS reporting option beginning in the 2029 performance year.</p>
<h3>Is the 2027 physician fee schedule final?</h3>
<p>No. The proposed rule was published July 16, 2026, and the comment period closed September 14, 2026. CMS typically publishes the final rule around November 1. The 2027 rates take effect January 1, 2027, and the final figures can differ from the proposal.</p>
<h3>Which specialties are affected most by the 2027 proposed rule?</h3>
<p>In CMS’s specialty impact table, the largest decreases are dermatology and otolaryngology (9% each), orthopedic surgery (7%), hand surgery (5%), and colon and rectal surgery and podiatry (4% each). The largest increases are clinical social workers (12%) and clinical psychologists (11%). These figures reflect RVU redistribution only and exclude the conversion factor change.</p>
<h3>What is the efficiency adjustment and does it apply in 2027?</h3>
<p>The efficiency adjustment is a 2.5% reduction to the work RVUs and intraservice time of non time based services, finalized in the CY 2026 rule and intended to apply roughly every three years. CMS did not propose a new adjustment for 2027, but the 2026 reduction remains in effect, and CMS valued new and revised codes for 2027 as if they had already received the adjustment. The next scheduled application would be 2029.</p>
<h3>What is the proposed modifier 25 same day payment reduction?</h3>
<p>When the same physician or a physician in the same group bills a separately identifiable office E/M visit on the same day as a 0 day, 10 day, or 90 day global procedure, CMS proposes to pay the highest valued service at 100% and every other service that day at 50%. CMS is also considering a 25% reduction instead. The AMA and procedural specialty societies have asked CMS to withdraw the proposal.</p>
<h3>What happens to G2211 in 2027?</h3>
<p>CMS proposes to retire G2211 as a separate code and replace it with a modifier that increases payment for the associated E/M visit by 16%. A second modifier worth 32% would be available only to practitioners in a Medicare Shared Savings Program ACO or the LEAD model. The clinical criteria for using the add on do not change.</p>
<h3>How does the practice expense methodology change affect my practice?</h3>
<p>CMS proposes to phase out the indirect practice cost index, which anchored specialty level PE RVUs to survey data from 2007 or earlier, over two years. A new stabilizer caps annual PE RVU changes at plus or minus 5% for most existing codes. The effect varies by specialty: dermatology and otolaryngology lose, while several medical specialties gain. CMS is also asking whether the facility and nonfacility payment differential should be reduced for hospital employed physicians, which would not affect 2027 but signals future changes.</p>
<h3>How can a practice offset Medicare reimbursement cuts?</h3>
<p>Start with revenue the practice already earns but does not fully capture: E/M coding accuracy, the G2211 modifier, care management codes, annual wellness visits, and the new shared medical appointment and advance care planning codes. Then reduce the cost to collect through denial prevention and point of service collections. Review commercial contracts for Medicare linked terms and evaluate Advanced APM participation for the higher conversion factor and the 32% ACO modifier. Finally, benchmark staffing and vendor costs against specialty norms. Section 12 of this guide covers fifteen specific strategies.</p>
<h3>Does the conversion factor cut reduce wRVU based physician compensation?</h3>
<p>Not directly. If a compensation plan pays a fixed dollar amount per wRVU, the conversion factor does not change that rate, although it reduces what Medicare pays the practice for the same work and will surface at the next renegotiation. Plans tied to collections absorb the full impact. The same day E/M reduction and the G2211 modifier change may affect wRVU credit depending on how the plan is written.</p>
<h3>Should my practice join an ACO because of the 2027 rule?</h3>
<p>The 2027 rule strengthens the case for primary care and medical specialty practices. Qualifying APM participants receive a higher conversion factor with a widening differential, MSSP participants would qualify for the 32% complexity modifier, and two sided risk participants are exempt from MIPS. The decision also depends on the ACO’s track record, the practice’s patient panel, and the practice’s ability to manage total cost of care. A practice assessment can model the financial case.</p>
<h3>What is changing for remote patient monitoring in 2027?</h3>
<p>CMS proposes to require that RTM be furnished only to established patients, that RPM and RTM be preceded by a separately reportable initiating visit, and that monitoring services be performed only by clinical staff employed by the practice rather than contractors. CMS also proposes to reduce the device supply valuations and is considering bundling the codes into four new G codes. Practices using outsourced monitoring vendors should review their arrangements.</p>
<h3>When does MIPS change to MVPs only?</h3>
<p>CMS proposes to end traditional MIPS reporting and make MIPS Value Pathways the only option beginning with the 2029 performance period, which affects the 2031 payment year. The 2027 performance threshold remains 75 points.</p>
<h3>Where can I find the proposed 2027 RVUs for specific codes?</h3>
<p>Addendum B on the CMS 1848 P rule page lists proposed 2027 RVUs for every code. CMS also publishes a Specialty Impacts by Practitioner file showing the range of impacts within each specialty.</p>
<h2>16. Sources and references</h2>
<ul>
<li><a href="https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2027-medicare-physician-fee-schedule-proposed-rule" target="_blank" rel="noopener">CMS Fact Sheet: Calendar Year (CY) 2027 Medicare Physician Fee Schedule Proposed Rule</a>, July 14, 2026</li>
<li><a href="https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2027-medicare-physician-fee-schedule-proposed-rule-cms-1848-p-medicare-shared" target="_blank" rel="noopener">CMS Fact Sheet: CY 2027 PFS Proposed Rule, Medicare Shared Savings Program and Quality Payment Program Provisions</a></li>
<li><a href="https://www.federalregister.gov/documents/2026/07/16/2026-14327/medicare-and-medicaid-programs-cy-2027-payment-policies-under-the-physician-fee-schedule-and-other" target="_blank" rel="noopener">Federal Register: CY 2027 Payment Policies Under the Physician Fee Schedule (CMS 1848 P)</a>, 91 FR 43842, July 16, 2026</li>
<li><a href="https://www.cms.gov/medicare/payment/fee-schedules/physician/federal-regulation-notices/cms-1848-p" target="_blank" rel="noopener">CMS 1848 P rule page with Addendum B and Specialty Impacts by Practitioner downloads</a></li>
<li><a href="https://www.ama-assn.org/practice-management/medicare-medicaid/2027-proposed-medicare-fee-schedule-what-physicians-need-know" target="_blank" rel="noopener">American Medical Association: 2027 proposed Medicare fee schedule, what physicians need to know</a></li>
<li><a href="https://www.aha.org/news/headline/2026-07-14-cms-issues-cy-2027-physician-fee-schedule-proposed-rule" target="_blank" rel="noopener">American Hospital Association: CMS issues CY 2027 physician fee schedule proposed rule</a></li>
<li><a href="https://www.cms.gov/medicare/payment/fee-schedules/physician/federal-regulation-notices/cms-1832-f" target="_blank" rel="noopener">CMS 1832 F: CY 2026 Physician Fee Schedule Final Rule (efficiency adjustment and 2026 conversion factors)</a></li>
<li><a href="https://oig.hhs.gov/" target="_blank" rel="noopener">HHS Office of Inspector General</a>, reports on remote patient monitoring and chronic care management billing</li>
<li><a href="https://qpp.cms.gov/" target="_blank" rel="noopener">Quality Payment Program</a>, MIPS and MVP resources</li>
</ul>
<p>This article is for general informational purposes and does not constitute legal, billing, or coding advice. Figures are drawn from the CY 2027 proposed rule and are subject to change in the final rule. Verify current rates and policies with CMS before making financial or operational decisions.</p>
<hr>
<p><strong>About the Author</strong></p>
<p><em>Matt Kolinski is a strategy and management consultant who works with physician-led practices across the country on financial modeling, operations, payer strategy, and the business architecture behind sustainable, scalable medical businesses. He helps physicians think clearly about both paths, running a great practice and building something bigger, so they can choose the one that fits the life they actually want.</em></p>
<p>The post <a href="https://www.doctorsmanagement.com/blog/the-2027-medicare-physician-fee-schedule-what-changed-and-how-to-protect-your-revenue/">The 2027 Medicare Physician Fee Schedule: What Changed and How to Protect Your Revenue</a> appeared first on <a href="https://www.doctorsmanagement.com/">DoctorsManagement</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Scottish children have best oral health on record – but disparities remain stark</title>
<link>https://edusehat.com/en/scottish-children-have-best-oral-health-on-record-but-disparities-remain-stark</link>
<guid>https://edusehat.com/en/scottish-children-have-best-oral-health-on-record-but-disparities-remain-stark</guid>
<description><![CDATA[ A record 76% of Scottish Primary 1 children had no obvious tooth decay according to a new report, but children’s oral health varied drastically with deprivation. Similarly to levels of obvious decay, average decay experience also reached its lowest level on record, at 0.92 affected, missing or filled teeth per child. However, the percentage of… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/scottish_children.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 01:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Scottish, children, have, best, oral, health, record, –, but, disparities, remain, stark</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>A record 76% of Scottish Primary 1 children had no obvious tooth decay according to a new report, but children’s oral health varied drastically with deprivation.</strong></p>



<p>Similarly to levels of obvious decay, average decay experience also reached its lowest level on record, at 0.92 affected, missing or filled teeth per child.</p>



<p>However, the percentage of children with no obvious decay dropped to 62% in the most deprived areas, compared with 87.3% in the most affluent ones.</p>



<p>Geographical location was also linked to disparities: decay-free rates ranged from 72% in Fife to 90% in Shetland.</p>



<p>Released today (27 October), the report summarises the findings of Public Health Scotland’s (PHS) National Dental Inspection Programme for 2026. All Primary 1 and Primary 7 pupils in local-authority schools were offered a basic dental inspection, with a more detailed survey focusing on a representative sample of Primary one children, typically aged between four and six.</p>



<h2 class="wp-block-heading">Why has Scottish children’s oral health improvement stalled?</h2>



<p>Though there are signs of improvement, dentist and owner of City Dental Care in Edinburgh, Hamza Al Haddad noted that progress seems to have plateaued somewhat. The previous two reports put decay levels at 73.2% and 73.5% respectively.</p>



<p>Al Haddad suggested that much of the current decay is ‘treatment the pandemic delayed’. He said: ‘The pandemic interrupted prevention at the ages when it counts, and that the recovery is not finished.’</p>



<p>Considering what needs to change for improvements to pick up speed, Dr Al Haddad suggested the following measures:</p>



<ul class="wp-block-list">
<li><strong>Supervised toothbrushing</strong> – school brushing currently runs in 58% of primary schools, against 65.9% before the pandemic</li>



<li><strong>Treat age six as a prevention window</strong> – PHS has said in successive reports that the pattern of decay supports greater use of fissure sealant, and fluoride varnish is recommended for every child from age two at least twice yearly</li>



<li><strong>Start in the first year </strong>– in September 2025, 42.1% of children aged zero to two were registered with an NHS dentist, compared to 47.4% in September 2019</li>



<li><strong>Pay for prevention</strong> – since the November 2023 payment reform, varnish, brushing instruction and diet advice are claimed together under one preventive item, so national data cannot show whether varnish was given. PHS welcomed paying dentists for prevention, but said it would welcome more detail on what the item delivers</li>



<li><strong>Look again at water fluoridation</strong> – no public water supply in Scotland is fluoridated. Start where BDA Scotland does: fund boards to carry out feasibility studies.</li>
</ul>



<p><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</em></a></p>



<p></p>]]> </content:encoded>
</item>

<item>
<title>In Memoriam: Endocrine Society Past&#45;President John T. Potts Jr., 1932 – 2026</title>
<link>https://edusehat.com/en/in-memoriam-endocrine-society-past-president-john-t-potts-jr-1932-2026</link>
<guid>https://edusehat.com/en/in-memoriam-endocrine-society-past-president-john-t-potts-jr-1932-2026</guid>
<description><![CDATA[ Endocrine Society Past-President John T. Potts Jr., MD, DSc, Jackson Professor of Clinical Medicine Emeritus at Harvard Medical School, former Chair of the Department of Medicine and Physician-in-chief at Massachusetts General Hospital (MGH), passed away on August 12, 2026, at the age of 94. A pioneer of calcium and bone biology, he was also one […]
The post In Memoriam: Endocrine Society Past-President John T. Potts Jr., 1932 – 2026 appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/Potts165.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 21:40:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Memoriam:, Endocrine, Society, Past-President, John, Potts, Jr., 1932, –, 2026</media:keywords>
<content:encoded><![CDATA[<p>Endocrine Society Past-President John T. Potts Jr., MD, DSc, Jackson Professor of Clinical Medicine Emeritus at Harvard Medical School, former Chair of the Department of Medicine and Physician-in-chief at Massachusetts General Hospital (MGH), passed away on August 12, 2026, at the age of 94. A pioneer of calcium and bone biology, he was also one […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/in-memoriam-endocrine-society-past-president-john-t-potts-jr-1932-2026/">In Memoriam: Endocrine Society Past-President John T. Potts Jr., 1932 – 2026</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ASHG: Nabsys Links Cytogenetics and Genomics to Map Hematologic Cancers</title>
<link>https://edusehat.com/en/ashg-nabsys-links-cytogenetics-and-genomics-to-map-hematologic-cancers</link>
<guid>https://edusehat.com/en/ashg-nabsys-links-cytogenetics-and-genomics-to-map-hematologic-cancers</guid>
<description><![CDATA[ Blood cancers carry complex genomic rearrangements that no single assay fully captures. At ASHG 2026 in Montréal, Nabsys presented early data comparing its Electronic Genome Mapping technology with established cytogenetic methods and previewed new analysis software for hematologic malignancies.
The post ASHG: Nabsys Links Cytogenetics and Genomics to Map Hematologic Cancers appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/07/Getty_1441707827_leukemiaWhiteBloodCells.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 21:10:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ASHG:, Nabsys, Links, Cytogenetics, and, Genomics, Map, Hematologic, Cancers</media:keywords>
<content:encoded><![CDATA[<p>Blood cancers are often driven by large-scale genomic rearrangements, including translocations, deletions, duplications, and other structural and copy number changes, that no single assay captures well. In practice, characterizing a hematologic malignancy can mean piecing together results from karyotyping, fluorescence <em>in situ</em> hybridization (FISH), chromosomal microarray, and sequencing, each with its own resolution limits and blind spots.</p>
<p>Nabsys is positioning its Electronic Genome Mapping (EGM) technology as one way to close some of those gaps. At the American Society of Human Genetics (ASHG) 2026 Annual Meeting, held October 20–24 in Montréal, the Providence, RI-based company shared preliminary data on EGM in hematologic malignancies and previewed analysis software built for that application.</p>
<h4><strong>Bridging two disciplines</strong></h4>
<p>In a Nabsys-sponsored CoLab session on October 22, Alka Chaubey, PhD, FACMG, the company’s chief medical and genomics officer, presented “Electronic Genome Mapping in Hematologic Malignancies: Bridging Cytogenetics and Molecular Genomics” on behalf of Brynn Levy, MSc(Med), PhD, FACMG, of Columbia University. The talk covered early findings on how well EGM detects structural and copy number variants, including how its results compared with established cytogenetic methods.</p>
<p>The work builds on OhmX Platform installations at Columbia University Medical Center, awarded through the RAMP UP Program from Hitachi High-Tech America and Nabsys. Running on OhmX, EGM is designed to give a high-resolution, genome-wide view of structural and copy number variation. Nabsys frames the technology as a complement to existing tools rather than a replacement.</p>
<p>“Researchers need a more complete view of the complex genomic changes in hematologic cancers,” said Barrett Bready, MD, Nabsys’s founder and CEO. “These preliminary findings highlight EGM’s potential to complement established methods.”</p>
<h4><strong>Software shaped by users</strong></h4>
<p>Alongside the data, Nabsys demonstrated Nabsys Navigator<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, its cloud-based platform for EGM analysis and visualization. Navigator includes two pipelines: SV-Discover<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, for genome-wide structural variant analysis, and SV-Verify<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, for confirming structural variants flagged by other technologies. Booth visitors could also preview the company’s forthcoming hematologic malignancy analysis software, the same tool used to analyze samples in Chaubey’s presentation, and weigh in on its development. Bready said the company is “pairing that work with software development shaped directly by the researchers who will use it.” The OhmX Platform is for research use only and is not intended for diagnostic procedures.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/ashg-nabsys-links-cytogenetics-and-genomics-to-map-hematologic-cancers/">ASHG: Nabsys Links Cytogenetics and Genomics to Map Hematologic Cancers</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Single&#45;Cell Multiomics: Phenotypic Plasticity in Colorectal Cancer Metastasis</title>
<link>https://edusehat.com/en/single-cell-multiomics-phenotypic-plasticity-in-colorectal-cancer-metastasis</link>
<guid>https://edusehat.com/en/single-cell-multiomics-phenotypic-plasticity-in-colorectal-cancer-metastasis</guid>
<description><![CDATA[ In this GEN webinar, Mirjana Efremova, PhD (Queen Mary University of London) will show how these technologies can be used to analyze primary and liver-metastatic CRC patient samples to reveal cancer cell states. 
The post Single-Cell Multiomics: Phenotypic Plasticity in Colorectal Cancer Metastasis appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Getty_2135397939_ColonCancer.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 21:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Single-Cell, Multiomics:, Phenotypic, Plasticity, Colorectal, Cancer, Metastasis</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/MirjanaEfremova_headshot.jpg" class="h-full w-full object-cover" alt="Image of Mirjana Efremova, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Mirjana Efremova, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Senior Lecturer<br>Queen Mary University of London</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/MirjanaEfremova_headshot.jpg" alt="Image of Mirjana Efremova, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Mirjana Efremova, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Mirjana Efremova earned a PhD in computational biology at the Medical University of Innsbruck, Austria, where she investigated the process of clonal evolution of cancer under immunosurveillance and how the immune system shapes tumor progression. She did her post-doctoral work at the Teichmann Lab, Wellcome Sanger Institute, where she co-led the development of the first human atlas of the maternal-fetal interface in early pregnancy using single cell transcriptomics. She also developed a cell-cell communication statistical framework CellPhoneDB (www.cellphonedb.org) for predicting enriched receptor-ligand pairs between the different cell types and inference of cellular communication networks.  In May 2020, she started a lab at Barts Cancer Institute, Queen Mary University of London (U.K.) within the Centre for Cancer Evolution. Her lab is focused on investigating the non-genetic mechanisms driving cancer initiation, metastasis, and therapy resistance.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Thursday, November 19, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-11-19T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">Phenotypic plasticity—the ability of tumor cells to switch states in response to their environment—drives colorectal cancer (CRC) progression, metastasis, and therapy resistance, but what controls it has been unclear. The application of single-cell multiomics and spatial transcriptomics in primary and metastatic tumor samples can reveal regenerative and inflammatory cancer cell states.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, Mirjana Efremova, PhD (Queen Mary University of London) will show how these technologies can be used to analyze primary and liver-metastatic CRC patient samples to reveal cancer cell states. These regenerative and inflammatory cancer cell states resemble metastasis-initiating cells in mouse models, are regulated by the transcription factors AP-1 and NF-κB, and sit at the invasive edge in an immunosuppressive niche. Improved understanding of these microenvironment-driven states and their regulators offers researchers new ways to target metastasis.</p>


<p class="wp-block-paragraph">Webinar attendees will learn more about:</p>


<ul class="wp-block-list">
<li>The regenerative and inflammatory cancer cell states found in primary and metastatic CRC, including a hybrid regenerative/stem state, and how liver metastases re-establish the primary tumor’s heterogeneity;</li>



<li>Transcriptional regulation of these states as well as signals from fibroblasts, macrophages, and T cells, and where the states sit in the tumor; and</li>



<li>How to apply single-cell multiomics and spatial transcriptomics to link cell state, regulation, and tissue location, and identify candidate targets to limit plasticity and metastasis.</li>
</ul>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://www.10xgenomics.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="77" src="https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo-300x77.jpg" alt="10x Genomics logo" class="wp-image-129310" srcset="https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo-300x77.jpg 300w, https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo-768x197.jpg 768w, https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo-1024x263.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo-696x178.jpg 696w, https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo-1392x359.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo-1068x274.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/single-cell-multiomics-phenotypic-plasticity-in-colorectal-cancer-metastasis/">Single-Cell Multiomics: Phenotypic Plasticity in Colorectal Cancer Metastasis</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Toronto hospital performs Canada’s first robotic&#45;assisted hybrid procedure for atrial fibrillation</title>
<link>https://edusehat.com/en/toronto-hospital-performs-canadas-first-robotic-assisted-hybrid-procedure-for-atrial-fibrillation</link>
<guid>https://edusehat.com/en/toronto-hospital-performs-canadas-first-robotic-assisted-hybrid-procedure-for-atrial-fibrillation</guid>
<description><![CDATA[ St. Michael’s Hospital in Toronto has achieved a Canadian first by performing the robotic surgical component of a hybrid ablation procedure designed to treat patients with persistent atrial fibrillation. The procedure represents an important development in minimally invasive cardiac care, combining robotic surgical technology with catheter-based treatment to address abnormal electrical activity responsible for irregular […]
The post Toronto hospital performs Canada’s first robotic-assisted hybrid procedure for atrial fibrillation appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Gianluigi-Bisleri_SMH_20260916_-7-400x268-1.png" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 21:00:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Toronto, hospital, performs, Canada’s, first, robotic-assisted, hybrid, procedure, for, atrial, fibrillation</media:keywords>
<content:encoded><![CDATA[<p>St. Michael’s Hospital in Toronto has achieved a Canadian first by performing the robotic surgical component of a hybrid ablation procedure designed to treat patients with persistent atrial fibrillation.</p>
<p>The procedure represents an important development in minimally invasive cardiac care, combining robotic surgical technology with catheter-based treatment to address abnormal electrical activity responsible for irregular heart rhythms.</p>
<p>Atrial fibrillation, commonly known as AFib, is the most common heart rhythm disorder. It occurs when the heart’s upper chambers beat irregularly and can cause fatigue, shortness of breath and heart palpitations. The condition is also associated with an increased risk of stroke and heart failure.</p>
<h3>Combining two approaches to treatment</h3>
<p>Many patients with atrial fibrillation respond to medication or conventional catheter ablation. However, treatment can be more challenging for individuals with persistent forms of the condition.</p>
<p>The hybrid approach combines two procedures performed at different times.</p>
<p>During the surgical stage, cardiac surgeons treat abnormal electrical pathways from outside the heart. Electrophysiologists subsequently use catheter-based techniques to identify and treat problematic electrical signals from inside the heart.</p>
<p>At St. Michael’s Hospital, the surgical component was performed using a robotic platform that allows surgeons to operate through small incisions with enhanced visualization and instrument control.</p>
<p>The approach is intended to provide more comprehensive treatment for selected patients whose atrial fibrillation has been difficult to manage.</p>
<h3>Multidisciplinary cardiac care</h3>
<p>The program brings together cardiac surgeons and electrophysiologists, including Dr. Gianluigi Bisleri, Director of Minimally Invasive Cardiac Surgery, and Dr. Paul Angaran, Director of the hospital’s Cardiac Arrhythmia Program.</p>
<p>Their collaboration reflects a growing emphasis on combining specialized expertise and advanced technology to improve treatment options for complex cardiovascular conditions.</p>
<p>The hospital says clinical evidence suggests hybrid approaches can improve long-term heart rhythm outcomes for selected patients with persistent atrial fibrillation compared with catheter ablation alone.</p>
<h3>First patient travels from Alberta</h3>
<p>The first Canadian patient to undergo the robotic surgical component travelled from Alberta to Toronto for treatment.</p>
<p>Jon Davies had been living with atrial fibrillation for nearly three decades before receiving the procedure.</p>
<p>According to the hospital, Davies recovered from the robotic surgery and returned home within days. He is awaiting the second stage of his treatment, which will involve catheter ablation.</p>
<p>Although his full treatment and longer-term outcomes remain to be assessed, the procedure demonstrates how robotic technology may expand minimally invasive treatment options for patients with complex heart rhythm disorders.</p>
<p>The milestone also highlights the growing role of multidisciplinary teams in developing advanced cardiac programs within Canadian hospitals.</p>
<p><strong>Source:</strong> <a href="https://unityhealth.to/2026/10/st-michaels-hospital-completes-canadas-first-robotic-hybrid-procedure-for-atrial-fibrillation/?utm_source=chatgpt.com">Unity Health Toronto</a>, October 26, 2026.</p>
<p>The post <a href="https://www.hospitalnews.com/toronto-hospital-performs-canadas-first-robotic-assisted-hybrid-procedure-for-atrial-fibrillation/">Toronto hospital performs Canada’s first robotic-assisted hybrid procedure for atrial fibrillation</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Can technology and clinical evidence make skincare more personalised?</title>
<link>https://edusehat.com/en/can-technology-and-clinical-evidence-make-skincare-more-personalised</link>
<guid>https://edusehat.com/en/can-technology-and-clinical-evidence-make-skincare-more-personalised</guid>
<description><![CDATA[ 
What gaps in India’s dermatology and skincare market led to the creation of Puresta, and how does the company plan to build a business at the intersection of healthcare, technology […]
The post Can technology and clinical evidence make skincare more personalised? appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/27155941/Hitaysh-Dhingraa-Co-Founder-CEO-Puresta.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 20:50:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Can, technology, and, clinical, evidence, make, skincare, more, personalised</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/27155941/Hitaysh-Dhingraa-Co-Founder-CEO-Puresta.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/27155941/Hitaysh-Dhingraa-Co-Founder-CEO-Puresta.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/27155941/Hitaysh-Dhingraa-Co-Founder-CEO-Puresta-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span><span><span><b>What gaps in India’s dermatology and skincare market led to the creation of Puresta, and how does the company plan to build a business at the intersection of healthcare, technology and skincare?</b></span></span></span></p>
<p><span><span><span>Before building anything, we spoke to around 1,400 women aged 21–30 over several months. One insight came through very clearly: India does not have a shortage of skincare products; it has a shortage of personalised skin-health guidance.</span></span></span></p>
<p><span><span><span>Consumers today are surrounded by ingredients, routines, influencers and product choices, but often have very little clarity on what their skin actually needs. Dermatologists remain the most trusted experts, yet access, continuity and follow-up can be inconsistent. The journey is also fragmented — assessment happens in one place, consultation in another, products are bought somewhere else, and progress is rarely tracked.</span></span></span></p>
<p><span><span><span>That insight shaped Puresta. Rather than starting with another product brand, we acquired a majority stake in HealthQ Life Sciences, the company behind SKINQ and SKINQ-Rx, founded by dermatologist Dr Chytra V Anand. That gave us a strong clinical and formulation foundation. Around it, we are building EVERQ — our technology and care platform that helps consumers understand their skin, access a dermatologist when required, follow the recommended treatment and track progress over time.</span></span></span></p>
<p><span><span><span>Our ambition is to move skincare from a largely transactional, product-led category towards a more outcome-led skin-health ecosystem — bringing together clinical expertise, technology and evidence-led products.</span></span></span></p>
<p><span><span><span><b>AI-led skin assessment is emerging as a tool for personalised skincare. How reliable are these systems in identifying skin concerns, and how do you ensure that technology complements rather than substitutes clinical judgement?</b></span></span></span></p>
<p><span><span><span>We are very clear about one principle: AI should not replace a dermatologist. It should make dermatological care more accessible, personalised and continuous.</span></span></span></p>
<p><span><span><span>Our skin-assessment technology has been tested on more than 10,000 Indian users/patient images and reviewed with expert inputs. This focus on Indian skin matters because skin tone, pigmentation patterns and the way certain concerns present can differ significantly across populations.</span></span></span></p>
<p><span><span><span>Within EVERQ, AI is designed to play three roles. First, assessment — helping a consumer structure and understand a concern through images and relevant questions. Second, care navigation — helping identify when professional medical consultation may be appropriate. Third, longitudinal monitoring — helping track visible changes over time so that follow-ups can be more informed.</span></span></span></p>
<p><span><span><span>Clinical diagnosis and prescription decisions remain with qualified dermatologists. We see AI as the layer that can make the journey more intelligent and efficient, while the dermatologist remains central wherever medical judgement is required.</span></span></span></p>
<p><span><span><span><b>What role do clinical evidence, formulation science and testing play in developing dermatology-focused skincare products, particularly for concerns such as pigmentation, acne and sensitivity in Indian skin types?</b></span></span></span></p>
<p><span><span><span>The skincare industry has spent years selling ingredients. We believe the next phase will increasingly be about scientifically supported outcomes.</span></span></span></p>
<p><span><span><span>Concerns such as acne, pigmentation and sensitivity can behave differently across skin tones and environmental conditions. India adds its own realities — heat, humidity, pollution, sun exposure and a wide range of skin tones. Formulations therefore need to be developed and evaluated with the intended consumer in mind.</span></span></span></p>
<p><span><span><span>SKINQ was developed specifically with Indian skin and climate in mind, drawing on Dr Chytra Anand’s more than two decades of clinical experience. Our philosophy is simple: proof should come before promise. We have in-vivo testing on our product portfolio so that claims are supported by evidence generated on real users, rather than relying only on ingredient-level claims.</span></span></span></p>
<p><span><span><span>We also believe skincare needs to become simpler and more purposeful. Consumers should first understand the concern, then use the right intervention for the right duration, and finally measure whether it is working. That is a fundamentally different approach from adding more and more steps to a routine.</span></span></span></p>
<p><span><span><span><b>With the launch of EVERQ, Puresta is connecting skin assessment, dermatologist consultations, treatment and maintenance skincare. What are the key operational and clinical challenges in integrating these stages into a single care pathway?</b></span></span></span></p>
<p><span><span><span>The biggest opportunity — and challenge is that the skin-health journey today is highly fragmented. A consumer may discover a concern on social media, self-select a product, consult a dermatologist later, buy a prescription elsewhere and then have no structured follow-up. Each interaction can sit in a different silo.</span></span></span></p>
<p><span><span><span>EVERQ is designed to bring that journey together, but doing that responsibly requires solving three things.</span></span></span></p>
<p><span><span><span>First is clinical independence. Dermatologists must remain free to make the treatment decision they believe is appropriate; the technology should support their judgement, not influence it.</span></span></span></p>
<p><span><span><span>Second is continuity. Many skin concerns require patience and adherence. Consumers need to follow the right treatment for the right duration and know when to come back for a review. Progress tracking, follow-ups and care support can help close that gap.</span></span></span></p>
<p><span><span><span>Third is technology integration — connecting assessment, consultation, treatment recommendations, fulfilment and progress monitoring without making the experience complicated for the consumer.</span></span></span></p>
<p><span><span><span>We are still early in this journey, so our focus is on getting the care pathway right before scaling it aggressively. The goal is not simply to facilitate a consultation; it is to create a continuous relationship around better skin-health outcomes.</span></span></span></p>
<p><span><span><span><b>How do you see the relationship between dermatologists, pharmaceutical companies and skincare brands evolving as prescription-led treatments, clinically validated formulations and digital health platforms increasingly overlap?</b></span></span></span></p>
<p><span><span><span>Historically, these have operated in separate lanes. Dermatologists focus on diagnosis and treatment, pharmaceutical companies build prescription products, and consumer skincare brands focus on daily care and maintenance. The consumer is often left to connect these experiences independently.</span></span></span></p>
<p><span><span><span>I believe the next generation of dermatology platforms will bring these ecosystems closer together around the consumer’s journey. Dermatologists will remain at the centre of clinical decision-making. Technology can improve access, continuity and monitoring, while evidence-led OTC and prescription products can support treatment as well as long-term maintenance.</span></span></span></p>
<p><span><span><span>That is the ecosystem we are building at Puresta: EVERQ as the technology and care layer, SKINQ as the consumer skincare portfolio, and SKINQ Rx as the dermatologist-focused prescription portfolio.</span></span></span></p>
<p><span><span><span>The future of dermatology, in my view, is not pharma versus beauty. It is the convergence of healthcare, technology and consumer products — with clinical credibility and patient outcomes at the centre.</span></span></span></p>
<p><span><span><span><b>What are Puresta’s priorities for scaling its business over the next three to five years, particularly in terms of research and development, technology capabilities, access to dermatology care and building a sustainable business model?</b></span></span></span></p>
<p><span><span><span>Our priorities over the next three to five years are built around four areas.</span></span></span></p>
<p><span><span><span>First, building an integrated skin-health platform that can support a consumer from the first assessment through consultation, treatment, follow-up and long-term maintenance.</span></span></span></p>
<p><span><span><span>Second, investing deeply in evidence and R&D. We want to build a portfolio of clinically relevant OTC and prescription products where claims are supported by meaningful testing and real-world outcomes.</span></span></span></p>
<p><span><span><span>Third, strengthening our technology and AI capabilities — not just for initial assessment, but increasingly for personalisation, care navigation, progress monitoring and making expert dermatology knowledge easier to access.</span></span></span></p>
<p><span><span><span>Fourth, expanding access to high-quality dermatology care. Digital consultations can reduce geographic friction and make expert guidance available to consumers beyond the largest metros, including tier 1, 2 and 3 India.</span></span></span></p>
<p><span><span><span>From a business perspective, the opportunity is to move from one-time product transactions towards longer-term consumer relationships built around treatment, follow-ups, maintenance and prevention.</span></span></span></p>
<p><span><span><span>Our ambition is not simply to build another large skincare brand. It is to build a trusted skin-health platform that can stay with consumers through different concerns and stages of their lives.</span></span></span></p>
<p>The post <a href="https://www.expresspharma.in/can-technology-and-clinical-evidence-make-skincare-more-personalised/">Can technology and clinical evidence make skincare more personalised?</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Are dental students being taught to question AI?</title>
<link>https://edusehat.com/en/are-dental-students-being-taught-to-question-ai</link>
<guid>https://edusehat.com/en/are-dental-students-being-taught-to-question-ai</guid>
<description><![CDATA[ Nearly three quarters of medical and dental students surveyed at Queen Mary University of London felt artificial intelligence was inadequately integrated into their curriculum. The mixed-methods study, which I helped conduct, involved 86 survey respondents and student focus groups. It found that 73.3% considered curriculum integration inadequate, while 76.7% wanted structured teaching on artificial intelligence… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/ai.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 17:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Are, dental, students, being, taught, question, AI</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Nearly three quarters of medical and dental students surveyed at Queen Mary University of London felt artificial intelligence was inadequately integrated into their curriculum.</strong></p>



<p>The mixed-methods study, which I helped conduct, involved 86 survey respondents and student focus groups. It found that 73.3% considered curriculum integration inadequate, while 76.7% wanted structured teaching on artificial intelligence (AI).</p>



<p>Respondents were enthusiastic about the technology. Some 86.1% believed AI would be important to their future professional practice. However, 65.1% reported a lack of formal training.</p>



<p>It raises an important question, though, are students being taught to assess AI-generated information critically, or simply becoming familiar with how to use it?</p>



<p>The issue has also reached the regulatory agenda. Separate research commissioned by the <a href="https://www.gdc-uk.org/about-us/what-we-do/research/our-research-library/detail/report/understanding-role-ai-dental-education-rapid-evidence-assessment">General Dental Council</a> reviewed 75 studies and reports and included interviews with dental students, recent graduates and academics. It called for clear rules on acceptable AI use and structured teaching that prepares students to check outputs, recognise uncertainty and remain accountable for their decisions.</p>



<h2 class="wp-block-heading">How are students using AI?</h2>



<!--free-wall-stop-->



<p>Students reported using AI-supported tools for revision, understanding difficult concepts and independent learning. However, opportunities for structured teaching and critical evaluation appeared inconsistent.</p>



<p>These findings reflect wider research suggesting that dental students recognise the potential of AI while identifying gaps in their knowledge and preparation.</p>



<p>The results relate to medical and dental students at one university, so they should not be read as a national assessment of dental education. However, the concerns are relevant as <a href="https://dentistry.co.uk/2025/09/18/dentistrys-guide-to-ai-in-dentistry/">AI becomes more common across dental diagnosis, treatment planning, administration and patient communication</a>.</p>



<h2 class="wp-block-heading">The AI literacy gap</h2>



<p>Knowing how to generate an AI response does not necessarily mean knowing whether that response is clinically accurate.</p>



<p>AI systems can produce convincing explanations containing factual inaccuracies, fabricated references or recommendations that overlook important clinical circumstances. Their outputs may also reflect biases within the data on which they were trained.</p>



<p>Our research found that 82.6% of respondents recognised ethical issues associated with AI, but only 47.7% felt prepared to use the technology ethically and responsibly.</p>



<p>A scoping review by El-Hakim and colleagues identified opportunities for AI in dental education, including diagnostic training, assessment and feedback. It also found concerns around privacy, model reliability, inconsistent standards and over-reliance on automated systems.</p>



<p>Students need to learn how to question AI outputs, check the supporting evidence, recognise uncertainty and identify potential bias. AI literacy should be part of clinical reasoning and evidence-based dentistry, rather than treated as an optional digital skill.</p>



<h2 class="wp-block-heading">Who is responsible for an AI-supported decision?</h2>



<p>Consider a dental student using an AI-supported system to interpret a radiograph. The technology suggests a diagnosis, but the clinical findings do not fit. Should the student accept the output or challenge it?</p>



<p>Research by Ayan and colleagues examined the use of AI by dental students detecting proximal caries and showed how the technology could support diagnostic learning. However, assistance from AI should not be confused with independent clinical judgement.</p>



<p>Dental professionals remain responsible for evaluating information and acting in the patient’s best interests. As <em>Dentistry</em> has reported, <a href="https://dentistry.co.uk/2026/09/16/who-is-responsible-when-your-ai-tools-make-mistakes/">clinicians could face responsibility when an AI-supported decision harms a patient</a>, even where the original problem came from the technology.</p>



<p>The General Dental Council-commissioned review found that AI limitations were particularly apparent in image-dependent areas, including radiographic interpretation, and said it should support rather than replace diagnosis.</p>



<p>Education must therefore cover confidentiality, consent, data protection and transparency, as well as the limitations of automated decision support.</p>



<h2 class="wp-block-heading">Unequal access to AI education</h2>



<p>Students may have unequal access to paid AI platforms, reliable digital infrastructure, technical support and practical training.</p>



<p>Our research identified insufficient training and unclear institutional guidance as barriers to meaningful engagement with AI.</p>



<p>Without consistent educational provision, competence may depend on a student’s personal resources or confidence with technology. Universities should provide access to appropriate tools and supervised opportunities to assess their strengths and limitations.</p>



<h2 class="wp-block-heading">What should dental schools teach?</h2>



<p>AI teaching should be embedded across the curriculum, including radiology, treatment planning, research appraisal, clinical reasoning and professional ethics.</p>



<p>Students could be asked to identify inaccurate diagnoses, fabricated references and conflicts between an AI response and established evidence. Assessments should also test whether they can reach and defend a decision without relying on an automated output.</p>



<p>Dental educators will need training and institutional support to teach and assess these skills confidently. Universities should also ensure students are not expected to purchase commercial tools to participate fully.</p>



<p>These priorities reflect recommendations made by Thurzo and colleagues in their guide to updating dental curricula. They also sit alongside <a href="https://dentistry.co.uk/2026/09/17/gdc-to-develop-rules-for-ethical-ai-use-in-healthcare/">work by the General Dental Council to develop principles for the ethical use of AI in healthcare</a>.</p>



<p>AI could improve dental education and clinical care. Its value will depend on the professional capabilities of the people using it.</p>



<p>The future of dentistry should not be defined by whether students can use AI, but by whether they have the knowledge and clinical judgement to question it.</p>



<h2 class="wp-block-heading">References</h2>



<ul class="wp-block-list">
<li><a href="https://pubmed.ncbi.nlm.nih.gov/38200405/">Ayan E, Bayraktar Y, Çelik Ç and Ayhan B (2024), ‘Dental student application of artificial intelligence technology in detecting proximal caries lesions’, </a><em><a href="https://pubmed.ncbi.nlm.nih.gov/38200405/">Journal of Dental Education</a></em><a href="https://pubmed.ncbi.nlm.nih.gov/38200405/">, 88, pp 490-500.</a></li>



<li><a href="https://pubmed.ncbi.nlm.nih.gov/35004598/">Bisdas S et al (2021), ‘Artificial intelligence in medicine: a multinational multi-center survey on the medical and dental students’ perception’, </a><em><a href="https://pubmed.ncbi.nlm.nih.gov/35004598/">Frontiers in Public Health</a></em><a href="https://pubmed.ncbi.nlm.nih.gov/35004598/">, 9, 795284.</a></li>



<li><a href="https://www.mdpi.com/2304-6767/13/9/384">El-Hakim M, Anthonappa R and Fawzy A (2025), ‘Artificial intelligence in dental education: a scoping review of applications, challenges, and gaps’, </a><em><a href="https://www.mdpi.com/2304-6767/13/9/384">Dentistry Journal</a></em><a href="https://www.mdpi.com/2304-6767/13/9/384">, 13, 384.</a></li>



<li><a href="https://pubmed.ncbi.nlm.nih.gov/38970241/">Hammoudi Halat D et al (2024), ‘Artificial intelligence readiness, perceptions, and educational needs among dental students: a cross-sectional study’, </a><em><a href="https://pubmed.ncbi.nlm.nih.gov/38970241/">Clinical and Experimental Dental Research</a></em><a href="https://pubmed.ncbi.nlm.nih.gov/38970241/">, 10, e925.</a></li>



<li><a href="https://www.mdpi.com/2227-7102/13/2/150">Thurzo A, Strunga M, Urban R, Surovková J and Afrashtehfar KI (2023), ‘Impact of artificial intelligence on dental education: a review and guide for curriculum update’, </a><em><a href="https://www.mdpi.com/2227-7102/13/2/150">Education Sciences</a></em><a href="https://www.mdpi.com/2227-7102/13/2/150">, 13, 150.</a></li>
</ul>



<p><em><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access – plus the Dentistry Bulletin delivered to your inbox.</em></a></em></p>]]> </content:encoded>
</item>

<item>
<title>Are dental practices talking to patients in the wrong places?</title>
<link>https://edusehat.com/en/are-dental-practices-talking-to-patients-in-the-wrong-places</link>
<guid>https://edusehat.com/en/are-dental-practices-talking-to-patients-in-the-wrong-places</guid>
<description><![CDATA[ In the latest Dentistry Talks, Roshan Roberts explains why reaching overlooked communities requires trust, better listening and a different approach to communication. Dental practices keep repeating important oral health messages. But if those messages are still failing to reach some communities, is the problem what dentistry is saying, or how and where it is saying… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/Rochelle-Roberts-Homepage_Dentistry-Talks.png" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 17:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Are, dental, practices, talking, patients, the, wrong, places</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><div class="wp-block-embed__wrapper">
<div class="video-container"></div>
</div></figure>



<p><strong>In the latest <em>Dentistry Talks</em>, Roshan Roberts explains why reaching overlooked communities requires trust, better listening and a different approach to communication.</strong></p>



<p>Dental practices keep repeating important oral health messages. But if those messages are still failing to reach some communities, is the problem what dentistry is saying, or how and where it is saying it?</p>



<p>For Roshan Roberts, communication starts long before a campaign goes live.</p>



<p>The executive podcast producer and co-founder of Dope Black Women joins Dentistry Talks to discuss what dentistry can learn from her work across BBC Radio 1, 1Xtra and the Asian Network.</p>



<p>Roberts recalls spending three months building relationships with a charity before interviewing undocumented young people for a radio programme. That investment helped contributors trust her, speak for themselves and shape how their experiences were presented.</p>



<p>‘I think it’s about knowing who your audience are and knowing where they are, and then going directly to those places,’ she says.</p>



<p>For dentistry, that could mean questioning whether another newsletter will change behaviour. If practices want to reach younger people and parents, Roberts suggests looking at TikTok, YouTube Shorts and the content families already watch together.</p>



<p>The discussion moves from public campaigns into the dental practice. Roberts considers how professionals can ask patients questions without becoming paralysed by the fear of causing offence, and why a colleague who appears quiet or distant may actually feel excluded.</p>



<p>Published during Black History Month, the episode also examines which stories organisations choose to tell. Roberts recalls working on a Black news podcast that left her feeling heavy because its coverage repeatedly centred on pain.</p>



<p>‘My experience of being Black is not trauma,’ she says. ‘At the core of being Black is community. That’s what we’re about.’</p>



<p>Her challenge to dentistry is simple. Stop expecting people to come to the message. Listen first, build trust and take the message to them.</p>



<p>You can now watch the full episode on <a href="https://youtu.be/gKVJQVxMSPY">YouTube</a> and listen on <a href="https://open.spotify.com/episode/0XPuhkjLirb7VIEw5rj54W?si=45ce2ad851cc4780">Spotify</a>.</p>



<h4 class="wp-block-heading">Topics include:</h4>



<ul class="wp-block-list">
<li>Why dental campaigns may be missing their intended audiences</li>



<li>Building trust with communities before asking them to engage</li>



<li>Using TikTok, YouTube Shorts and other platforms to reach families</li>



<li>Patient communication and the fear of causing offence</li>



<li>Creating safer and more inclusive dental workplaces</li>



<li>How unconscious bias can cause Black women to be misread at work</li>



<li>Representation, role models and the visibility of Black dental professionals</li>



<li>Building Dope Black Women and responding to what a community needs</li>



<li>Why stories about Black life should extend beyond trauma.</li>
</ul>



<h4 class="wp-block-heading">Listen to other episodes below:</h4>



<ul class="wp-block-list">
<li><a href="https://dentistry.co.uk/2026/09/29/menopause-oral-health-kate-muir-dentistry-talks/">Dentists are the ‘perimenopause detectives’: Kate Muir on menopause</a></li>



<li><a href="https://dentistry.co.uk/2026/08/26/neuroinclusion-in-dentistry-maisie-cass/">Is your dental practice accessible enough? Neuroinclusion in dentistry</a></li>



<li><a href="https://dentistry.co.uk/2026/03/02/from-pitchside-to-practice-lessons-from-sports-dentistry/">Burnout in dentistry: the warning signs before the collapse</a>.</li>



<li><a href="https://dentistry.co.uk/2026/01/30/lessons-from-the-business-guru-behind-kinky-boots/">How an Olympic bobsleigh athlete learned to weather the storm</a>.</li>



<li><a href="https://dentistry.co.uk/2026/05/27/dentist-burnout-singing-dentist/">Burnout, balance and building a brand: lessons from the Singing Dentist</a></li>



<li><a href="https://dentistry.co.uk/2026/04/29/ageing-as-a-dental-professional-how-to-maintain-purpose-and-identity/">Ageing as a dental professional: how to maintain purpose and identity</a></li>
</ul>



<p><em>Dentistry Talks</em> podcast is powered by Sensodyne.</p>



<p><a href="https://www.haleonhealthpartner.com/en-gb/oral-health/conditions/sensitivity/sensodyne-dentist-testimonials/?utm_source=publication_fmc&utm_medium=referral&utm_campaign=2024_sensodyne_condition&utm_content=sm5251_sensodyne_podcast_testimonials_fmc" target="_blank" rel="noreferrer noopener">You can find out more here</a>.</p>



<p><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</em></a></p>



<p></p>]]> </content:encoded>
</item>

<item>
<title>Medical AI, brain&#45;computer interfaces and surgical robotics take centre stage at 94th CMEF</title>
<link>https://edusehat.com/en/medical-ai-brain-computer-interfaces-and-surgical-robotics-take-centre-stage-at-94th-cmef</link>
<guid>https://edusehat.com/en/medical-ai-brain-computer-interfaces-and-surgical-robotics-take-centre-stage-at-94th-cmef</guid>
<description><![CDATA[ Het bericht Medical AI, brain-computer interfaces and surgical robotics take centre stage at 94th CMEF verscheen eerst op International Hospital. ]]></description>
<enclosure url="https://interhospi.com/wp-content/uploads/sites/3/2026/10/cmef_3a.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 17:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Medical, AI, brain-computer, interfaces, and, surgical, robotics, take, centre, stage, 94th, CMEF</media:keywords>
<content:encoded><![CDATA[<div class="avia-section av-5pjryc-19691d8fe024ecd22f4cf1b0746f9172 main_color avia-section-default avia-no-border-styling  avia-builder-el-0  avia-builder-el-no-sibling  avia-bg-style-scroll container_wrap fullsize"><div class="container av-section-cont-open"><main role="main" itemprop="mainContentOfPage" class="template-page content  av-content-full alpha units"><div class="post-entry post-entry-type-page post-entry-20421"><div class="entry-content-wrapper clearfix">


<div class="flex_column av-4vqtes-8a6e6b2dd0d572ce1d6026a3282c73a3 av_one_fifth  avia-builder-el-1  el_before_av_three_fifth  avia-builder-el-first  first flex_column_div av-hide-on-mobile av-zero-column-padding  "><section class="av_textblock_section av-key24etv-8cf8563f9a5147bae87b81cc26a3527e " itemscope="itemscope" itemtype="https://schema.org/BlogPosting" itemprop="blogPost"><div class="avia_textblock" itemprop="text"><p></p>
</div></section></div>

<div class="flex_column av-4j6544-3dd207ac880e0091524d5c381bfaef43 av_three_fifth  avia-builder-el-3  el_after_av_one_fifth  el_before_av_one_fifth  flex_column_div av-zero-column-padding  "><section class="av_textblock_section av-key254dz-6dca32f8382240f7ccc291ef75096d96 " itemscope="itemscope" itemtype="https://schema.org/BlogPosting" itemprop="blogPost"><div class="avia_textblock" itemprop="text"><p></p>
</div></section><br>
<section class="av_textblock_section av-ke9srown-cfbd4a744a50962f9a592b08939de968 " itemscope="itemscope" itemtype="https://schema.org/BlogPosting" itemprop="blogPost"><div class="avia_textblock" itemprop="text"><header class="entry-content-header"><h1 class="post-title entry-title" itemprop="headline">Medical AI, brain-computer interfaces and surgical robotics take centre stage at 94th CMEF</h1><span class="post-meta-infos">/ <span class="blog-categories minor-meta">in <a href="https://interhospi.com/category/e-news/" rel="tag">E-News</a>, <a href="https://interhospi.com/category/events/" rel="tag">Events</a>  </span></span></header>
</div></section><br>
<section class="av_textblock_section av-23o2c4-8f397adbcbd64996a2025c8abf40a726 " itemscope="itemscope" itemtype="https://schema.org/BlogPosting" itemprop="blogPost"><div class="avia_textblock" itemprop="text"><p><strong>The 94th China International Medical Equipment Fair (CMEF) Autumn Edition brought together clinicians, manufacturers and buyers at the Capital International Exhibition & Convention Center in Beijing from 21–24 October 2026. The programme centred on artificial intelligence (AI), precision diagnostics and surgical robotics.</strong></p>
<p><span></span></p>
<p>The fair drew more than 120,000 healthcare professionals and about 3,000 exhibitors from 21 countries and regions, with visitors from more than 150 countries and regions. Across around 170,000 square metres, it covered digital health, intelligent medical devices, rehabilitation technologies and connected healthcare solutions alongside diagnostics and robotics. Exhibitors unveiled more than 1,000 innovative products.</p>
<p><img fetchpriority="high" decoding="async" class="alignnone wp-image-20422" src="https://interhospi.com/wp-content/uploads/sites/3/2026/10/cmef_3a.jpg" alt="CMEF" width="532" height="354" srcset="https://interhospi.com/wp-content/uploads/sites/3/2026/10/cmef_3a.jpg 800w, https://interhospi.com/wp-content/uploads/sites/3/2026/10/cmef_3a-300x200.jpg 300w, https://interhospi.com/wp-content/uploads/sites/3/2026/10/cmef_3a-768x512.jpg 768w, https://interhospi.com/wp-content/uploads/sites/3/2026/10/cmef_3a-705x470.jpg 705w" sizes="(max-width: 532px) 100vw, 532px"></p>
<h3><strong>Regional collaboration in focus</strong></h3>
<p>A central feature was the Beijing-Tianjin-Hebei Coordinated Innovation Pavilion in Hall A4. It showed how combining research, engineering and clinical expertise across the region is moving healthcare innovation forward. Exhibits drew on Beijing’s districts, science and innovation industrial parks, pilot testing platforms and specialist technology companies. They spanned AI-assisted diagnosis and treatment, brain-computer interfaces (BCIs), smart medical devices, rehabilitation technologies and elderly care.</p>
<p>The pavilion programme also included healthcare reform discussions, hospital innovation project presentations and demonstrations of AI-powered mobile medical vehicles. “Youcu Plan” projects were released, and award-winning scientific and technological innovations were shown.</p>
<h3><strong>Medical AI beyond imaging</strong></h3>
<p>The Medical AI Frontier Zone highlighted Chinese work in medical robots, BCIs, embodied AI, healthcare AI models, high-quality datasets, innovative drugs, medical devices and 5G-enabled technologies. According to the organisers, AI applications are moving beyond medical imaging and diagnostic support into real-world clinical and operational settings. The zone served as a platform for technologies heading towards broader commercialisation.</p>
<p>A separate International Zone presented devices and healthcare solutions from overseas companies. It emphasised exchange between foreign firms, buyers and industry stakeholders.</p>
<h3><strong>Support for overseas buyers</strong></h3>
<p>The WeSeries programmes were built to help international buyers find suitable products and suppliers. The WeTalk stage hosted presentations from companies in medical robotics, surgery, surgical instruments, emergency and critical care monitoring equipment, and paediatric healthcare. The WeMatch Hub arranged one-to-one meetings between buyers and exhibitors. WeTour provided English-language guidance, customised tours, product demonstrations, hands-on experiences and consultations with participating companies. The aim was to help buyers turn first contacts into concrete collaborations.</p>
<h3><strong>Policy and clinical themes in the conference programme</strong></h3>
<p>More than 100 conferences, thematic forums and seminars ran alongside the exhibition. Topics included the Outline of the 15th Five-Year Plan, Three-Medical Linkage initiatives, the Medical and Health Foundation Strengthening Project, medical innovation, AI-assisted diagnosis, medical-engineering translation, medical insurance reform and the future of patient care.</p>
<p>Co-located events were the International Component Manufacturing & Design Show (ICMD), the China International Rehabilitation and Personal Health Show (CRS), the China International Elderly Care and Nursing Show (CECN) and the China International Home Care Exhibition (Lifecare).</p>
<p>CMEF is organised under RX Global, which runs more than 350 exhibitions and conferences annually across 22 countries and 43 industry sectors.</p>
<ul>
<li>For more information, visit: <a href="https://www.cmef.com.cn/en" target="_blank" rel="noopener">https://www.cmef.com.cn/en</a></li>
</ul>
</div></section><br>


<div class="hr av-klqcq5xv-fb118132a60cd57f133869cf62f2257a hr-invisible  avia-builder-el-7  el_after_av_textblock  el_before_av_social_share "><span class="hr-inner "><span class="hr-inner-style"></span></span></div><br>
<div class="av-social-sharing-box av-ke9sz9xv-3e02cbd0889cb70a2a9058e399d76f75 av-social-sharing-box-minimal  avia-builder-el-8  el_after_av_hr  avia-builder-el-last  av-social-sharing-box-fullwidth"><div class="av-share-box"><h5 class="av-share-link-description av-no-toc ">Share this</h5><ul class="av-share-box-list noLightbox"><li class="av-share-link av-social-link-facebook avia_social_iconfont"><a target="_blank" aria-label="Share on Facebook" href="https://www.facebook.com/sharer.php?u=https://interhospi.com/medical-ai-brain-computer-interfaces-and-surgical-robotics-take-centre-stage-at-94th-cmef/&t=Medical%20AI%2C%20brain-computer%20interfaces%20and%20surgical%20robotics%20take%20centre%20stage%20at%2094th%20CMEF" data-av_icon="" data-av_iconfont="entypo-fontello" title="" data-avia-related-tooltip="Share on Facebook"><span class="avia_hidden_link_text">Share on Facebook</span></a></li><li class="av-share-link av-social-link-twitter avia_social_iconfont"><a target="_blank" aria-label="Share on X" href="https://twitter.com/share?text=Medical%20AI%2C%20brain-computer%20interfaces%20and%20surgical%20robotics%20take%20centre%20stage%20at%2094th%20CMEF&url=https://interhospi.com/?p=20421" data-av_icon="" data-av_iconfont="entypo-fontello" title="" data-avia-related-tooltip="Share on X"><span class="avia_hidden_link_text">Share on X</span></a></li><li class="av-share-link av-social-link-whatsapp avia_social_iconfont"><a target="_blank" aria-label="Share on WhatsApp" href="https://api.whatsapp.com/send?text=https://interhospi.com/medical-ai-brain-computer-interfaces-and-surgical-robotics-take-centre-stage-at-94th-cmef/" data-av_icon="" data-av_iconfont="entypo-fontello" title="" data-avia-related-tooltip="Share on WhatsApp"><span class="avia_hidden_link_text">Share on WhatsApp</span></a></li><li class="av-share-link av-social-link-linkedin avia_social_iconfont"><a target="_blank" aria-label="Share on LinkedIn" href="https://linkedin.com/shareArticle?mini=true&title=Medical%20AI%2C%20brain-computer%20interfaces%20and%20surgical%20robotics%20take%20centre%20stage%20at%2094th%20CMEF&url=https://interhospi.com/medical-ai-brain-computer-interfaces-and-surgical-robotics-take-centre-stage-at-94th-cmef/" data-av_icon="" data-av_iconfont="entypo-fontello" title="" data-avia-related-tooltip="Share on LinkedIn"><span class="avia_hidden_link_text">Share on LinkedIn</span></a></li><li class="av-share-link av-social-link-mail avia_social_iconfont"><a aria-label="Share by Mail" href="mailto:?subject=Medical%20AI%2C%20brain-computer%20interfaces%20and%20surgical%20robotics%20take%20centre%20stage%20at%2094th%20CMEF&body=https://interhospi.com/medical-ai-brain-computer-interfaces-and-surgical-robotics-take-centre-stage-at-94th-cmef/" data-av_icon="" data-av_iconfont="entypo-fontello" title="" data-avia-related-tooltip="Share by Mail"><span class="avia_hidden_link_text">Share by Mail</span></a></li></ul></div></div></div>

<div class="flex_column av-1ziaaf0-b945285943f655b3c584bc38c6af1f49 av_one_fifth  avia-builder-el-9  el_after_av_three_fifth  avia-builder-el-last  flex_column_div av-hide-on-mobile av-zero-column-padding  "><section class="av_textblock_section av-key26scb-767e6508335704b90077f977070d6be8 " itemscope="itemscope" itemtype="https://schema.org/BlogPosting" itemprop="blogPost"><div class="avia_textblock" itemprop="text"><p></p>
</div></section></div>
<p>Het bericht <a href="https://interhospi.com/medical-ai-brain-computer-interfaces-and-surgical-robotics-take-centre-stage-at-94th-cmef/">Medical AI, brain-computer interfaces and surgical robotics take centre stage at 94th CMEF</a> verscheen eerst op <a href="https://interhospi.com/">International Hospital</a>.</p></div></div></main></div></div>]]> </content:encoded>
</item>

<item>
<title>Messe Muenchen India acquires PharmaTech Expo from PharmaTechnologyindex.com</title>
<link>https://edusehat.com/en/messe-muenchen-india-acquires-pharmatech-expo-from-pharmatechnologyindexcom</link>
<guid>https://edusehat.com/en/messe-muenchen-india-acquires-pharmatech-expo-from-pharmatechnologyindexcom</guid>
<description><![CDATA[ 
Acquisition adds a 30,000 sqm pharmaceutical platform to Messe Muenchen India’s portfolio,  connecting research, manufacturing, production technologies and regional markets. 
The post Messe Muenchen India acquires PharmaTech Expo from PharmaTechnologyindex.com appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/27140957/EP_Messe.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 17:15:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Messe, Muenchen, India, acquires, PharmaTech, Expo, from, PharmaTechnologyindex.com</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/27140957/EP_Messe.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/27140957/EP_Messe.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/27140957/EP_Messe-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p>Messe Muenchen India, a subsidiary of Messe München GmbH and a leading  organiser of B2B trade fairs in India, has acquired PharmaTech Expo from PharmaTechnologyindex.com (A Division of KNS Group), Ahmedabad. The acquisition strengthens Messe Muenchen India’s position in India’s  pharmaceutical and laboratory technology sectors by adding a 30,000 sqm, well-established platform focused on  pharmaceutical manufacturing, production systems and plant infrastructure.</p>
<p>Over the years, PharmaTech Expo has emerged as an important meeting point for pharmaceutical  manufacturers, technology providers and industry professionals across western and northern India. With more  than 750 exhibitors and over 30,000 visitors, the event brings together solutions across pharmaceutical  machinery, processing and production equipment, cleanroom technologies, utilities, packaging systems,  laboratory solutions and allied services.</p>
<p>Following the acquisition, PharmaTech Expo will continue to build on its regional strengths, industry relationships  and market relevance while gaining access to Messe Muenchen India’s broader industry networks, international  expertise and organisational capabilities.</p>
<p>Dr Reinhard Pfeiffer and Stefan Rummel, CEOs of Messe München Group, said, “The acquisition of  PharmaTech Expo fits perfectly into the analytica cluster and further underlines our long-term commitment to the  Indian market and to the development of specialised industry platforms. India has established itself as an  important pillar of the global pharmaceutical industry, supported by its strong manufacturing capabilities, growing  research landscape, high-quality standards and resilient supply chains. By combining the exhibition’s regional  expertise with Messe München’s international network and experience in organizing world-leading life science  and biochemistry exhibitions, we aim to create sustainable value for exhibitors, visitors and the wider  pharmaceutical community.”</p>
<p>PharmaTech Expo will take place as scheduled in Chandigarh from April 8–10, 2027 and from August 5–7,  2027 at the Helipad Exhibition Centre, Gandhinagar.</p>
<p>With PharmaTech Expo joining the portfolio, Messe Muenchen India will offer a broader suite of pharmaceutical  and laboratory industry platforms through analytica Lab India, PharmaCore India and PharmaTech Expo.</p>
<p>Together, these exhibitions address critical stages of the pharmaceutical value chain — from laboratory  research, analytical testing and diagnostics to APIs, formulations, contract manufacturing, production  technologies, plant engineering, cleanrooms, utilities and packaging solutions.</p>
<p>Bhupinder Singh, President IMEA, Messe München, and CEO, Messe Muenchen India, said, “This  acquisition marks a significant step in strengthening our position as a strategic partner to India’s pharmaceutical  and laboratory industries. By bringing together specialised platforms under one integrated portfolio, we are  creating a powerful ecosystem that connects technology leaders, manufacturers and decision-makers, enabling  collaboration, innovation and business growth across the sector. Our vision is to build industry platforms that not  only reflect the evolving needs of businesses but also accelerate opportunities for knowledge exchange,  technology adoption and strategic partnerships across India’s pharmaceutical and laboratory communities.”</p>
<p>Aarjav Shah and Ramesh Shah, Directors of PharmaTechnologyindex.com (A Division of KNS  Group), expressed that, “Over the years, PharmaTech Expo has advanced into an important interaction place  and interface zone at each of the centres for pharmaceutical manufacturers, technology providers and industry  professionals across crucial regional markets with their distinct strengths. Joining the Messe Muenchen India  portfolio marks a significant step forward, bringing together our strong industry connections with its global  capabilities and market reach. We look forward to building on this robust foundation and enhancing prospects for  exhibitors, partners and the pharmaceutical manufacturing ecosystem.”</p>
<p>The expanded portfolio will cater to pharmaceutical manufacturers, laboratory professionals, production and  plant managers, procurement teams, quality specialists, researchers, technology providers and other  stakeholders seeking solutions across the pharmaceutical value chain.</p>
<p>Each exhibition will retain its distinct identity and market focus while contributing to a connected portfolio  designed to serve the evolving needs of India’s pharmaceutical and laboratory industries.</p>
<p>The post <a href="https://www.expresspharma.in/messe-muenchen-india-acquires-pharmatech-expo-from-pharmatechnologyindex-com/">Messe Muenchen India acquires PharmaTech Expo from PharmaTechnologyindex.com</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ESTELITE ASTERIA: The science behind natural&#45;looking restorations</title>
<link>https://edusehat.com/en/estelite-asteria-the-science-behind-natural-looking-restorations</link>
<guid>https://edusehat.com/en/estelite-asteria-the-science-behind-natural-looking-restorations</guid>
<description><![CDATA[ Reproducing the optical characteristics of natural teeth is one of the key challenges in direct restorative dentistry. ESTELITE ASTERIA by TOKUYAMA DENTAL combines spherical sub-micron fillers, a coordinated shade system and efficient handling to support the creation of natural-looking aesthetic restorations. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/estelite-asteria-tokuyama-dental-feature-reference.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 14:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ESTELITE, ASTERIA:, The, science, behind, natural-looking, restorations</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-full"></figure>



<p><strong>Reproducing the optical characteristics of natural teeth is one of the key challenges in direct restorative dentistry. ESTELITE ASTERIA by TOKUYAMA DENTAL combines spherical sub-micron fillers, a coordinated shade system and efficient handling.</strong></p>



<h2 class="wp-block-heading">Spherical sub-micron fillers at the heart of the material</h2>



<p>The shape and size of filler particles play an important role in the optical and surface characteristics of restorative composites. ESTELITE ASTERIA uses spherical silica-zirconia fillers produced using TOKUYAMA DENTAL’s patented Sol-Gel method. With a particle size of 0.2 micrometres, these spherical sub-micron fillers contribute to the material’s optical properties and polishing characteristics.</p>



<p>The controlled shape and size of the fillers contribute to light diffusion, helping to create a chameleon effect that allows the restoration to blend with the surrounding tooth structure. They also support good polishability and gloss retention, contributing to a smooth, natural-looking surface.</p>



<p>Natural teeth vary in colour, opacity and translucency, both between patients and across different areas of an individual tooth. Reproducing these characteristics with direct composite requires careful shade selection and an understanding of how the material interacts with light. ESTELITE ASTERIA combines its filler technology with a coordinated shade system to support natural-looking colour integration while allowing clinicians to retain control over their layering technique.</p>



<h2 class="wp-block-heading">A coordinated shade system for efficient layering</h2>



<p>The <a href="https://tokuyama-dental.eu/en/shop/composite/10961-estelite-asteria/" target="_blank" rel="noreferrer noopener">ESTELITE ASTERIA</a> shade system comprises seven Body shades and five Enamel shades, designed to work together in a flexible layering approach.</p>



<p>Body shades provide the desired opacity, while Enamel shades help reproduce the translucency of natural enamel. By combining the two according to the clinical situation, dentists can tailor the optical appearance of the restoration without the need for unnecessarily complex layering.</p>



<p>This approach offers flexibility across a range of direct restorative procedures. Shade selection and layering can be adapted to the remaining tooth structure and the desired aesthetic result, allowing clinicians to choose a technique suited to the requirements of each case.</p>



<h2 class="wp-block-heading">From placement to polishing</h2>



<p>The performance of a restorative composite depends on more than its optical properties. Handling, working time, curing and finishing all contribute to the clinical workflow and the final appearance of the restoration.</p>



<p>ESTELITE ASTERIA incorporates TOKUYAMA DENTAL’s RAP-Technology (radical-amplified photopolymerisation), enabling light curing in 10 seconds under the specified curing conditions. This can help streamline the curing stage of restorative procedures.</p>



<p>The material also offers a working time of up to 90 seconds, even under bright ambient light. This gives clinicians time to adapt and shape the composite before curing, supporting precise contouring and the reproduction of anatomical detail.</p>



<p>The spherical sub-micron fillers also contribute to the material’s polishing characteristics. Their controlled size and shape support the achievement of a smooth surface and a natural-looking lustre. Combined with appropriate finishing and polishing techniques, this helps clinicians achieve the desired surface quality and maintain gloss over time.</p>



<h2 class="wp-block-heading">Combining material science with clinical efficiency</h2>



<p>ESTELITE ASTERIA brings together spherical sub-micron filler technology, a coordinated Body and Enamel shade system, efficient light curing and favourable polishing characteristics in one restorative composite. It is designed for clinicians seeking to balance aesthetic requirements with the practical demands of everyday restorative dentistry.</p>



<p>Dentists interested in evaluating the material in their own clinical setting can request a free sample from TOKUYAMA DENTAL.</p>



<h3 class="wp-block-heading"><strong>Interested in ESTELITE ASTERIA?</strong></h3>



<p><a href="https://tokuyama-dental.eu/en/estelite-asteria-trial/" target="_blank" rel="noreferrer noopener">Request a free sample and explore its potential in your own restorative practice.</a></p>



<p><em>This article is sponsored by Tokuyama Dental.</em></p>



<p></p>]]> </content:encoded>
</item>

<item>
<title>The power of connection: Addressing physician loneliness</title>
<link>https://edusehat.com/en/the-power-of-connection-addressing-physician-loneliness</link>
<guid>https://edusehat.com/en/the-power-of-connection-addressing-physician-loneliness</guid>
<description><![CDATA[ What helps physicians feel less alone? Evita Limon-Rocha, MD, MPH, explores how addressing physician loneliness starts with making everyday connection easier.
The post The power of connection: Addressing physician loneliness appeared first on Permanente Medicine. ]]></description>
<enclosure url="https://permanente.org/wp-content/uploads/2026/10/Dr.-Limon-Rocha-2.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 10:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, power, connection:, Addressing, physician, loneliness</media:keywords>
<content:encoded><![CDATA[<p><strong>By Evita Limon-Rocha, MD, MPH</strong></p>
<p>Working as a psychiatrist is one of the most rewarding parts of my life. I would not trade being a physician for anything, and I know most of my colleagues throughout Kaiser Permanente feel the same. Still, even the most fulfilling careers bring challenges that require solutions, and being a physician is no exception.</p>
<p>For example, physicians and other clinical staff can struggle with burnout that can affect how they show up for patients and colleagues. As awareness of burnout has increased across the sector, leaders tested and introduced strategies, support structures, and technology-powered solutions to alleviate some of the drivers of burnout. It hasn’t solved the problem completely, but overall rates of burnout are decreasing across most specialties.</p>
<p>Now, an increasingly common challenge among physicians is taking root: isolation and loneliness.</p>
<h2>Why physicians feel isolated</h2>
<p>There have been broad increases in loneliness and isolation throughout the United States. The U.S. Surgeon General <a href="https://www.hhs.gov/sites/default/files/surgeon-general-social-connection-advisory.pdf" target="_blank" rel="noopener">declared it an epidemic</a> only a few years ago. More remote rework, fewer face-to-face interactions with colleagues and friends, and a decline in social participation have made people lonelier than ever. And because loneliness and isolation can cause or worsen health challenges like anxiety and heart disease, it truly is an epidemic.</p>
<p>Physicians aren’t exempt from this. In fact, aspects of the way we practice medicine in the modern world can exacerbate conditions conducive to loneliness. For example, telehealth made it easier for many patients to access care, but it potentially leads to fewer in-person connections. Digital messaging systems for both patient-physician and care team communication has limited face time for all. Administrative tasks mean physicians spend more and more time behind a computer screen. Outside of work,  maintaining an active social life can feel challenging when coupled with long working days and family or other responsibilities.</p>
<p>The <a href="https://permanente.org/moral-injury-why-fixing-the-system-is-the-path-forward/" target="_blank" rel="noopener">moral injury</a> physicians face daily, as trust in science diminishes,  federal policies target how and to whom care can be delivered, and the impossible pace we have a recipe for a physician workforce that is more likely to feel isolated. We can’t afford that, especially since <a href="https://www.mayoclinicproceedings.org/article/S0025-6196(25)00414-8/fulltext" target="_blank" rel="noopener">social isolation</a> is a known factor driving young physicians out of health care.</p>
<h2>Physician loneliness and retention</h2>
<p>Many communities around the country already face a <a href="https://www.ama-assn.org/about/leadership/physician-shortage-will-worsen-unless-congress-acts-now" target="_blank" rel="noopener">shortage of physicians</a>. While a challenge everywhere, isolation and loneliness could pose a particular threat to efforts to rebuild health care capacity in rural areas where people are generally older, sicker, and need more specialized care. Asking physicians to relocate to rural towns where they don’t already have a network is not a small request. Getting them to stay might just depend on the sense of community they feel once they’ve arrived.</p>
<h2>Addressing physician loneliness</h2>
<p>In some ways, technology has separated us, but it also has the potential to bring us together. There are strategies hospitals and health systems can use to create connection and belonging, all with a common theme: Make connection the easier choice.</p>
<p>Kaiser Permanente’s <a href="https://permanente.org/how-ai-is-giving-physicians-more-time-for-what-matters-most/" target="_blank" rel="noopener">ambient scribe</a> is one example. By listening in on appointments with the patient’s consent, this technology allows physicians to focus wholly on the person in front of them during appointments, rather than on clinical notes. It also returns time at the end of the day or after hours that might otherwise be spent on notetaking.</p>
<p><span data-ccp-props='{"201341983":0,"335559739":0,"335559740":240}'><div class="vcex-module vcex-divider vcex-divider-solid vcex-divider-center wpex-mx-auto wpex-max-w-100 wpex-block wpex-h-0 wpex-border-b wpex-border-solid wpex-border-main"></div></span></p>
<p><b><span data-contrast="auto">Related physician loneliness podcast:</span></b> <a href="https://permanente.org/physician-loneliness-why-connection-matters-in-medicine/" target="_blank" rel="noopener"><span data-contrast="none">Physician loneliness: Why connection matters in medicine</span></a><span data-ccp-props='{"201341983":0,"335559739":0,"335559740":240,"335572079":6,"335572080":1,"335572081":4278190080,"469789806":"single"}'> </span></p>
<p><span data-ccp-props='{"201341983":0,"335559739":0,"335559740":240}'><div class="vcex-module vcex-divider vcex-divider-solid vcex-divider-center wpex-mx-auto wpex-max-w-100 wpex-block wpex-h-0 wpex-border-b wpex-border-solid wpex-border-main"></div></span></p>
<p>Another example of intentional connection is how we interact with colleagues in the workplace. After the pandemic, the pendulum swung far in the direction of virtual meetings, but there’s value in being purposeful about meeting in person again. It can be tempting to choose a video call or an email because it is convenient. But the value of connection created by in-person events can’t be overstated. Whether through large group  conferences — like those Kaiser Permanente hosts — or weekly staff meetings, events that bring people together will always be worth the effort.</p>
<p>Lastly, it’s important to remember that we have power as individuals to find the connection we need. Sometimes it’s as simple as picking up the phone to call a colleague or walking down the hall to have a conversation, even when we think an email would suffice. The convenience technology offers is often a huge benefit, but it shouldn’t come at the cost of connection.</p>
<h2>Leading a culture of connection</h2>
<p>Physician leaders play a key role in encouraging connection. We must be examples our teams can look to for guidance. Even making small changes can begin shaping a culture that prioritizes connection. Loneliness is something we all experience, and something that we all have the power to overcome.</p>
<p>Overall, we are happier, healthier, and we work more effectively when we feel connected to the individuals that we are working with and the work, we are contributing to.</p>
<p><em>Evita Limon-Rocha, MD, MPH, a psychiatrist with the<a href="https://permanente.org/southern-california-permanente-medical-group/" target="_blank" rel="noopener"> Southern California Permanente Medical Group</a>.</em></p>
<p>The post <a href="https://permanente.org/the-power-of-connection-addressing-physician-loneliness/">The power of connection: Addressing physician loneliness</a> appeared first on <a href="https://permanente.org/">Permanente Medicine</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Spatial Proteomics for Precision Oncology</title>
<link>https://edusehat.com/en/spatial-proteomics-for-precision-oncology</link>
<guid>https://edusehat.com/en/spatial-proteomics-for-precision-oncology</guid>
<description><![CDATA[ In this GEN webinar, Bernd Bodenmiller, PhD (University of Zürich), illustrates this integrated approach through two recent examples. 
The post Spatial Proteomics for Precision Oncology appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Getty_1786420513_StomachCancer.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 06:45:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Spatial, Proteomics, for, Precision, Oncology</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/BerndBodenmiller_headshot.jpg" class="h-full w-full object-cover" alt="Image of Bernd Bodenmiller, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Bernd Bodenmiller, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Associate Professor<br>Dept. of Quantitative Biomedicine<br>University of Zürich<br>ETH Zürich, Switzerland</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/BerndBodenmiller_headshot.jpg" alt="Image of Bernd Bodenmiller, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Bernd Bodenmiller, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Bernd Bodenmiller, PhD, is a quantitative biologist who develops novel experimental and computational approaches for the quantitative analysis of tumor ecosystems to improve our understanding of the mechanisms of tumor development. He is the founding director of the Department of Quantitative Biomedicine (DQBM) at the University of Zürich, which fosters research and education at the interface of biomedical research, biotechnology, and computational biology to guide development of next-generation precision medicine. His group has pioneered the development of imaging mass cytometry, which enables the simultaneous imaging of dozens of proteins and transcripts in tumor tissues and the histoCAT software toolbox. His group applies these methods to unravel how cells in the tumor ecosystem drive cancer development to identify mechanisms that might be exploited for therapeutic targeting.</p>
<p>Bodenmiller obtained his PhD in the group of Ruedi Aebersold, PhD, at ETH Zürich. For his postdoctoral training, he joined the laboratory of Garry Nolan, PhD, at Stanford University. In 2012, he became a group leader and in 2013 an SNF/ERC assistant professor at the University of Zürich. In 2019, he was tenured and became the founding director of the DQBM. In October 2020, Bodenmiller was appointed as Dual Professor for Quantitative Biomedicine at UZH and ETH Zürich.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Monday, November 16, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-11-16T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">Tumors are complex cellular ecosystems in which cancer cell phenotypes, their spatial organization, and their interactions with immune and stromal compartments determine disease progression and therapy response. To resolve this complexity, the use of highly multiplexed Imaging Mass Cytometry<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> (IMC<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">) together with multiomic profiling and artificial intelligence (AI) can identify clinically relevant features of the tumor microenvironment, providing a rich framework for patient stratification and targeted therapy in precision oncology.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, Bernd Bodenmiller, PhD (University of Zürich), illustrates this integrated approach through two recent examples. In a study of 323 epithelial ovarian cancers, tumors with more diverse cell phenotypes and spatial organization recurred faster. His lab also identified a therapy-resistant tumor cell phenotype (TUBB3+/pRB+) associated with recurrence and poor response to standard therapy. Spatial transcriptomics and <em>ex vivo</em> drug screening of 3D sphere models and patient samples showed that these cells resist standard-of-care agents but are sensitive to specific inhibitors. In 498 clear cell renal cell carcinomas, the use of AI revealed three survival ecotypes that predict survival better than basic clinical data and molecular stratification models. Each ecotype has its own genomic and metabolic features and is predictive of treatment outcome. Deep learning predicted the ecotypes directly from routine H&E slides, and the findings were validated across five cohorts comprising more than 2,500 patients.</p>


<p class="wp-block-paragraph">Webinar attendees will learn how integrating spatial single-cell proteomics by IMC with multiomics and AI identifies therapy-resistant cell populations and prognostic tumor ecosystems. This approach provides a detailed framework for patient stratification and targeted therapy in precision oncology.</p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://standardbio.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="214" src="https://www.genengnews.com/wp-content/uploads/2023/02/standardbio_logo-300x214.png" alt="Standard Biotools logo" class="wp-image-221017" srcset="https://www.genengnews.com/wp-content/uploads/2023/02/standardbio_logo-300x214.png 300w, https://www.genengnews.com/wp-content/uploads/2023/02/standardbio_logo-768x549.png 768w, https://www.genengnews.com/wp-content/uploads/2023/02/standardbio_logo-696x497.png 696w, https://www.genengnews.com/wp-content/uploads/2023/02/standardbio_logo-588x420.png 588w, https://www.genengnews.com/wp-content/uploads/2023/02/standardbio_logo-100x70.png 100w, https://www.genengnews.com/wp-content/uploads/2023/02/standardbio_logo.png 785w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/spatial-proteomics-for-precision-oncology/">Spatial Proteomics for Precision Oncology</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Anthropic IPO Discloses Plans for Life Sciences Growth</title>
<link>https://edusehat.com/en/anthropic-ipo-discloses-plans-for-life-sciences-growth</link>
<guid>https://edusehat.com/en/anthropic-ipo-discloses-plans-for-life-sciences-growth</guid>
<description><![CDATA[ Anthropic’s Form S-1 Registration Statement did not reveal what research areas it is pursuing through the molecular biology lab it disclosed last month, and what if any new therapies it is seeking to discover and develop. But the IPO filing said that Anthropic is creating AI agents based on its Claude family of large language models that focus beyond accelerating drug discovery and development, toward handling many of the physical tasks associated with creating new therapies. 
The post Anthropic IPO Discloses Plans for Life Sciences Growth appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/ANTHROPIC-LAB-IMAGE-ORIGINAL-CROP11111-JPEG.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 06:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Anthropic, IPO, Discloses, Plans, for, Life, Sciences, Growth</media:keywords>
<content:encoded><![CDATA[<p>Anthropic plans to expand its growing presence in life sciences by investing further in knowledge, talent, partnerships, and additional acquisitions, the artificial intelligence (AI) giant disclosed in its long-awaited initial public offering (IPO) filing.</p>
<p>Anthropic’s <a href="https://www.sec.gov/Archives/edgar/data/2130357/000162828026067168/anthropicpbc-sx1.htm" target="_blank" rel="noopener">Form S-1 Registration Statement</a>, filed Monday with the U.S. Securities and Exchange Commission, did not reveal key details such as what research areas it is pursuing through the molecular biology lab it disclosed last month, and what if any new therapies it is seeking to discover and develop. Nor did it quantify Anthropic’s total spending on life science activity.</p>
<p>The IPO filing also did not say how much money Anthropic seeks to raise on Wall Street—how many shares at what price—though news reports have had the company pursuing an eye-popping valuation of $2 trillion, 13% above the $1.77 trillion valuation of Elon Musk’s SpaceX when it went public in June. Anthropic plans to begin trading public shares on the Nasdaq Global Select Market under the ticker symbol ANT.</p>
<p>However, the filing said that Anthropic is creating AI agents based on its Claude family of large language models that focus beyond accelerating drug discovery and development, toward handling many of the physical tasks associated with creating new therapies.</p>
<p>“Claude is used in drug discovery and development by our customers, our biotechnology partners, and our own researchers. We are building AI agents that support scientists at each stage of that process,” Anthropic stated.</p>
<p>“Beyond knowledge work, we believe frontier AI has the power to transform physical work. Advances in Claude’s general capabilities, together with our Model Hardware Standard, now allow it to operate lab and manufacturing equipment such as microscopes, liquid handlers, and off-the-shelf robotic arms.”</p>
<p>In August, Anthropic publicly <a href="https://www.anthropic.com/news/model-hardware-standard-research-preview" target="_blank" rel="noopener">previewed</a> its Model Hardware Standard (MHS), which began as a collaboration between Anthropic and Howard Hughes Medical Institute (HHMI) Janelia Research Campus. Anthropic described HMS as “a shared specification for AI agents to safely operate physical devices, to a first group of scientific research labs and advanced manufacturers.”</p>
<p>“Currently in research preview, our Model Hardware Standard enables AI agents to find, understand, and safely operate lab and manufacturing equipment such as microscopes, liquid handlers, and off-the-shelf robotic arms,” Anthropic explained in its IPO filing. “Our Model Hardware Standard is model-agnostic and lets any agent harness reach devices with a programmable interface through standard protocols such as MCP.”</p>
<h4><strong>AI workbench</strong></h4>
<p>And in June, Anthropic <a href="https://www.genengnews.com/topics/artificial-intelligence/claude-science-is-here-antibiotics-designed-by-text-prompt-among-applications/" target="_blank" rel="noopener">released Claude Science</a>, an AI workbench for scientists that consolidates fragmented research tools, including more than 60 scientific databases and connectors pre-configured for genomics, proteomics, structural biology, and more, into a single reasoning layer. One Anthropic partner, Basecamp Research, has made available through Claude Science its antibiotic design and vaccine target prediction <a href="https://www.biorxiv.org/content/10.64898/2026.01.12.699009v1" target="_blank" rel="noopener">EDEN models</a> for global public health research.</p>
<p>In the IPO filing, Anthropic also summarized many—though not all—of its recent life-sci activities: “To build the best tools for the industry, we have invested in deep life sciences expertise of our own, hiring industry experts, building a molecular biology lab, acquiring Coefficient Bio, and partnering with industry leaders.”</p>
<p>Those efforts have paid off, the company said: As of September 30, 2026, Anthropic included among its customers “nine of the 10 largest” pharmaceutical companies, without disclosing their names. Those 10 are among the over 50% of the Fortune 500 that Anthropic counts among its customers with $100,000 or more of revenue on a TTM [trailing 12 months] basis. Anthropic added that every company in the Fortune 10, and more than 30% of the Forbes Global 2000 were also among its customers with $100,000+ revenue TTM.</p>
<p>Anthropic is carrying out life sciences research through a molecular biology lab and a research group <a href="https://www.genengnews.com/topics/translational-medicine/stockwatch-nektar-shares-flat-as-90m-jury-verdict-less-than-sought-in-lilly-suit/" target="_blank" rel="noopener">formed earlier this year</a> “to see whether general AI models can systematize and accelerate discoveries capable of revolutionizing biology and medicine,” the company stated last month. “Our focus is on fundamental biology research using Claude: exploring datasets of DNA to identify uncharacterized protein families, generating hypotheses at scale, and testing them through experiments in the lab.”</p>
<p>The IPO filing offered no details about how many researchers are based at the lab, and how much R&D spend the lab accounts for of Anthropic’s total research and development expense. That expense jumped more than quintupled during the first six months of this year, to $9.741 billion from $1.85 billion in January-June 2025. For all of last year, Anthropic spent a total $6.338 billion on R&D, according to the Form S-1.</p>
<p>The research lab generated worldwide headlines last month when Anthropic <a href="https://www.anthropic.com/research/claude-discovers-novel-enzyme-system" target="_blank" rel="noopener">announced</a> that its Claude large-language model “discovered a novel enzyme system with properties reminiscent of CRISPR, with only high-level direction from our scientists.”</p>
<p><a href="https://x.com/DarioAmodei/status/2102831170299834652?s=43" target="_blank" rel="noopener">Elaborating further in a post on X</a>, Anthropic CEO Dario Amodei described the novel enzyme system as “a molecular machine that we suspect could represent a new gene editing mechanism. Its precise function, biotechnological utility (if any), or level of significance is not yet clear, but at minimum it is work I would have been proud to do as a PhD student.”</p>
<h4><strong>‘Something interesting’</strong></h4>
<p>“The work was done mostly, though not entirely, by Claude: our life sciences team suggested a broad area of research, Claude read through the literature and a bunch of genome data and discovered something interesting, then Claude proposed experiments to verify the discovery and our team carried them out,” Amodei added.</p>
<p>In April, tech news outlets <em>The Information</em> and the Substack-based <em>Newcomber</em> newsletter founded by Eric Newcomber first reported that Anthropic acquired the stealth AI biotech startup Coefficient Bio for about $400 million in stock. Anthropic confirmed the acquisition though not the price in its IPO, saying it bought the company “to accelerate our research in the life sciences.”</p>
<p>Founded last year, Coefficient has developed an AI platform for purposes that include planning drug research and development, managing clinical regulatory strategy, and identifying new drug opportunities, <em>OncoDaily</em> reported. Coefficient was established by co-founders that include Nathan Frey, PhD, and Samuel Stanton, PhD, both previously with Genentech’s Prescient Design computational drug discovery unit. Another co-founder, Aris Theologis, serves as CEO and was previously chief business officer at Evozyne and a vice president at Paragon Biosciences.</p>
<p>According to the IPO filing, Anthropic finished January-June 2026 with a staggering net loss of $80.748 billion, up more than six-fold from the $12.969 billion net loss the company reported for the first six months of 2025. However, revenue leaped 14-fold to $16.286 billion in the first half of this year, from $1.163 billion in January-June 2025.</p>
<p>And Anthropic’s operating loss, defined as operating expenses exceeding revenue from core business operations, actually shrunk during the first half of 2026 to $693 million from $2.135 billion a year earlier.</p>
<p>For all of 2025, Anthropic reported a net loss of $41.965 billion, up five-fold from the $8.309 billion net loss of 2024, itself more than five times the $1.531 billion net loss of 2023.</p>
<p>Goldman Sachs and Morgan Stanley are co-leading the IPO, with participation by 20 other banks and other investment institutions.</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/anthropic-ipo-discloses-plans-for-life-sciences-growth/">Anthropic IPO Discloses Plans for Life Sciences Growth</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>World HUPO 2026: Asia&#45;Pacific Ambition and the Road to Predictive Biology</title>
<link>https://edusehat.com/en/world-hupo-2026-asia-pacific-ambition-and-the-road-to-predictive-biology</link>
<guid>https://edusehat.com/en/world-hupo-2026-asia-pacific-ambition-and-the-road-to-predictive-biology</guid>
<description><![CDATA[ Conversations at HUPO 2026 revolved around questions that reach beyond the proteomics community: who will develop disease, why treatment fails, and whether a computational model can help us decide which experiment to run next.
The post World HUPO 2026: Asia-Pacific Ambition and the Road to Predictive Biology appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-2-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 06:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>World, HUPO, 2026:, Asia-Pacific, Ambition, and, the, Road, Predictive, Biology</media:keywords>
<content:encoded><![CDATA[<p>By the time the Singapore Human Proteome Organization (HUPO) congress began, streets were being closed ahead of the Formula One Grand Prix. The humidity was a considerable change from the snow outside last year’s meeting in Toronto.</p>
<p>HUPO assembled 1,428 delegates from 45 countries under the theme “Proteomics Plus: Transforming Lives.” Across the September 27–October 1 program, conversations kept returning to questions that reach beyond the proteomics community: who will develop disease, why treatment fails, and whether a computational model can help us decide which experiment to run next.</p>
<figure aria-describedby="caption-attachment-339629" class="wp-caption aligncenter"><img fetchpriority="high" decoding="async" class=" wp-image-339629" src="https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-3-1-300x225.jpg" alt="" width="448" height="336" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-3-1-300x225.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-3-1-1024x768.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-3-1-768x576.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-3-1.jpg 1400w" sizes="(max-width: 448px) 100vw, 448px"><figcaption class="wp-caption-text">Credit: Gustav Ceder</figcaption></figure>
<p>The program itself reflected a field broadening its reach. Alongside the main scientific sessions were pre-congress workshops and training courses, short flash talks linked to poster sessions, and mentoring and networking for early-career researchers. The Early Career Researcher (ECR) program also featured manuscript, poster and three-minute thesis competitions. HUPO continued its interactive Bioinformatics Hub format, with 11 sessions spanning AI, multiomics and reproducibility. One, led by the Human Protein Atlas, explored integrating multiomics data and AI tools into its resources.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The exhibition hall and industry-supported seminars added another dimension. Thermo Fisher Scientific and Olink shared a booth for the first time, while Illumina showcased proteomics approaches for population-scale studies. Both hosted scientific seminars. Their presence underscored how technology development, data analysis and clinical research are increasingly part of the same conversation.</p>
<h4>An invitation from China</h4>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Fuchu He, PhD, chairman of the National Center for Protein Sciences in Beijing, set out an ambitious direction in the opening keynote. He leads the China-initiated Proteomic Navigator of the Human Body, or π-HuB, whose published roadmap envisages investment running into billions of renminbi over three decades.</p>
<p>Jing Yang, PhD, π-HuB’s secretary-general and a researcher at Guangzhou National Laboratory, described an effort to profile organs, tissues, cell types, and individuals, building a reference for how human biology changes over a lifetime.</p>
<p>The ambition is to “predict the proteomic states of each person across their lifetime,” he explained, accounting for influences including the microbiome, immune system, environment, and lifestyle. Reliable individual predictions remain a research goal.</p>
<p>“We really want to collaborate with HUPO,” Yang told <em>GEN</em>, describing discussions about extending cooperation beyond conferences and communication into science and funding.</p>
<h4>Building a cell, together</h4>
<p>Tiannan Guo, PhD, a professor at Westlake University, connected spatial proteomics and temporal perturbation proteomics with the development of AI-based virtual cell modeling. His presentation described proteomic work spanning 58 major tissue types, 251 more finely defined tissue types, and 25 carcinoma types, as well as a perturbation proteomics-based virtual cell model for triple-negative breast cancer with potential clinical benefits.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Guo’s virtual-cell framework brings together existing biological knowledge, cellular architecture, and dynamic measurements of responses to perturbations. Models would guide experiments, and the resulting measurements would test and refine their predictions.</p>
<p>The Westlake AI Virtual Cell–Yeast, or WAY, project divides that challenge into interconnected cellular functions, including metabolism, membrane systems, and stress responses. Task-specific AI agents would work together.</p>
<p>Contributors to the published framework include researchers affiliated with ETH Zurich, Stanford University, and the University of Toronto, among others.<strong><sup> </sup></strong></p>
<h4>Cells have to cope with lunch</h4>
<p>Florian Rosenberger, PhD, a SciLifeLab fellow and assistant professor at Karolinska Institutet, gave an example of what a real cell must handle.</p>
<p>“Life is all about being able to deal with the little fluctuations,” he told <em>GEN</em>, including “being able to deal with lunch without dying instantly.”</p>
<p>His single-cell deep visual proteomics work investigates mitochondrial disease while preserving tissue context. Access to oxygen and nutrients varies between neighboring cells, as can the accumulation of mutations. Rosenberger compared the patchwork of cellular states to a Portuguese tile floor.</p>
<p>By isolating cells in different functional states and arranging them in an inferred sequence, or pseudotime, his group can investigate proteomic changes associated with deterioration. This reconstructs a possible progression rather than following the same cell through time. The aim is to distinguish responses associated with failure from those that might support resilience. Rosenberger stressed that this is early work, but understanding those responses could eventually inform research in other diseases involving mitochondrial dysfunction.</p>
<p>“What is the normal working range that a cell can have, and when does it tip over into disease?” he asked.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Fabian Coscia, PhD, head of the spatial proteomics group at the Max Delbrück Center in Berlin, described how cancer cells can differ in their response to treatment. Rare cell populations may carry protein states associated with resistance before treatment begins; others adapt during treatment. Comparing pretreatment and post-treatment samples helps investigate both possibilities.</p>
<p>In Alzheimer’s brain tissue, his group found that neurons with visible tau pathology and neighboring cells without it did not separate neatly into affected and unaffected categories. Proteomic measurements revealed intermediate states.</p>
<p>“You have an entire trajectory of states,” Coscia said. These are precisely the distinctions a predictive model will need to capture.</p>
<h4>From tissue to accessible samples</h4>
<p>Birgit Schilling, PhD, a professor at the Buck Institute for Research on Aging, spoke with<em> GEN</em> in Toronto the previous year. This year in Singapore, she described how her laboratory was now using spatial mass spectrometry to investigate human osteoarthritis, finding localized changes in bone that bulk analysis could obscure.</p>
<p>“What I’m particularly excited about is that we took that to then bring that back to a biomarker fluid,” she said. The team is following tissue-level discoveries with biomarker work in synovial fluid, the fluid within the joint.</p>
<p>Mitchell Lai, PhD, a senior lecturer in pharmacology at the National University of Singapore, examines Alzheimer’s biomarkers in an Asian cohort with substantial cerebrovascular disease, testing their usefulness beyond the Western populations that dominated earlier studies.</p>
<p>“Now we are more interested in prognostic biomarkers,” Lai said. He wants measurements that help anticipate future dementia and cognitive impairment.</p>
<p>His work with the NULISA technology, explores brain-derived phosphorylated tau. The assays recognize both a phosphorylation site and a brain-associated splice variant, distinguishing a more specific signal within circulating tau.</p>
<p>Lai emphasized that longitudinal research requires comparable assays even when samples are collected years apart.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>Jochen Schwenk, PhD, who chaired HUPO’s Plasma Proteome Project over the past decade, noted a substantial increase in abstracts describing studies of human biofluids in large cohorts. He welcomed the trend but cautioned against drawing conclusions too early without considering findings from similar studies. He also highlighted growing interest in microsampling, which could make sample collection easier and broaden the role of proteomics in precision medicine.</p>
<p>Gabriel Mazzucchelli, PhD, head of the omics group in the University of Liège’s mass spectrometry laboratory, is exploring a different sample: sweat. His team has developed a spectral library containing around 4,000 proteins and conducted pilot work on treatment monitoring. An overnight collection patch under development could make repeated sampling possible without hospital visits.</p>
<h4>Mapping protein forms and functions</h4>
<p>The separate, closed Day of the Research Initiatives brought π-HuB, the Human Proteome Project, and the Human Proteoform Project together to discuss the field’s future.</p>
<figure aria-describedby="caption-attachment-339630" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-339630" src="https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-1-1-300x225.jpg" alt="" width="300" height="225" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-1-1-300x225.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-1-1-1024x768.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-1-1-768x576.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-1-1.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Credit: Gustav Ceder</figcaption></figure>
<p>Neil Kelleher, PhD, director of Northwestern University’s Chemistry of Life Processes Institute, described the Human Proteoform Project’s ambition as having “the genome project moment for proteins.” Representing the Consortium for Top-Down Proteomics, he proposed a reference set of intact molecular forms of proteins across human cell types and body fluids, estimating 50–100 million distinct proteoforms.</p>
<p>His presentation argued that distinguishing those forms could improve biomarker selection, patient stratification, and drug-target decisions. “It is a structural project more than a functional one.”</p>
<p>The proposed reference would require roughly 10 years and $300 million–$500 million annually, he estimated.</p>
<p>Cecilia Lindskog, PhD, an associate professor at Uppsala University and chair of HUPO’s Human Proteome Project, described the complementary challenge.</p>
<p>“We want to determine the function of every human protein,” she said, noting that fewer than a third have well-characterized, experimentally validated functions. She wants shared standards, complementary methods, and potentially shared samples and joint pilot studies to help close that gap.</p>
<p>The Human Protein Atlasintroduced a helpdesk at the congress alongside a Bioinformatics Hub session on integrating multi-omics data and AI tools.</p>
<p>Coscia described workshops bringing imaging researchers, the Human Protein Atlas, and the mass spectrometry community together around data formats and integration. He called for better protocols, interlaboratory comparisons, and metadata that make experiments reproducible. He also cautioned that exploratory spatial proteomics remains largely a discovery technology; some findings may reach clinical practice through established methods such as immunohistochemistry.</p>
<h4>Beyond the congress</h4>
<p>At the gala dinner in the Flower Dome at Gardens by the Bay, there was plenty to discuss. Singapore’s population studies, China’s international initiatives, and the clinical questions running through the conversations gave “Proteomics Plus” substance: more ways to measure biology, more people contributing, and more demanding questions about what the results mean.</p>
<p>By the next HUPO, it would be great to hear how those models performed on new data and whether candidate biomarkers held up in larger, more diverse patient cohorts. The next step is to show not just what proteomics can measure, but which experiments and clinical decisions those measurements can improve.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/world-hupo-2026-asia-pacific-ambition-and-the-road-to-predictive-biology/">World HUPO 2026: Asia-Pacific Ambition and the Road to Predictive Biology</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Case for Target Value Delivery</title>
<link>https://edusehat.com/en/the-case-for-target-value-delivery</link>
<guid>https://edusehat.com/en/the-case-for-target-value-delivery</guid>
<description><![CDATA[ The Self Medical Center, a new 68,000-square-foot multi-specialty medical office building, will house a wide range of care services in a single building. | Photo Credit: McMillan Pazdan Smith By Stephen Andersson  The need for new, renovated and expanded healthcare spaces continues to rise disproportionately to the available workforce, resulting in higher labor costs alongside...
The post The Case for Target Value Delivery appeared first on HCO News.
The post The Case for Target Value Delivery appeared first on HCO News. ]]></description>
<enclosure url="https://hconews.com/wp-content/uploads/2026/10/DeliveryModels.Self-Medical-Center-Spring-Street-Rendering-full-size-1-768x432.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 03:50:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Case, for, Target, Value, Delivery</media:keywords>
<content:encoded><![CDATA[<h5><span class="TextRun SCXW187632665 BCX0" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class="NormalTextRun SCXW187632665 BCX0">The <span class="TextRun SCXW100071471 BCX0" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class="NormalTextRun SCXW100071471 BCX0">Self Medical Center, a </span></span>new 68,000-square-foot multi-specialty medical office building, will house a wide range of care services in a single building. | Photo Credit: McMillan Pazdan</span></span><span class="EOP Selected SCXW187632665 BCX0" data-ccp-props='{"134233117":false,"134233118":false,"201341983":0,"335559738":0,"335559739":160,"335559740":276}'> Smith</span></h5>
<p><em>By Stephen Andersson </em></p>
<p><span data-contrast="auto">The need for new, renovated and expanded healthcare spaces continues to rise disproportionately to the available workforce, resulting in higher labor costs alongside declining reimbursement rates. As healthcare organizations must invest in new and upgraded facilities to serve their patients, cost certainty has never been more critical.</span><span data-ccp-props='{"134233117":false,"134233118":false,"201341983":0,"335559738":0,"335559739":160,"335559740":276}'> </span></p>
<p><span data-contrast="auto">For many healthcare leaders, however, the challenge isn’t necessarily getting their projects in budget — it’s getting the program they need for their budget. From cutting significant square footage to losing beloved features, enduring the value-engineering process can be time consuming and frustrating. Fortunately, there is another way.</span><span data-ccp-props='{"134233117":false,"134233118":false,"201341983":0,"335559738":0,"335559739":160,"335559740":276}'> </span></p>
<blockquote><p><span data-contrast="auto">An alternative to the design, cut, repeat cycle is Target Value Delivery (TVD), a highly collaborative method of designing a project to an established budget. </span></p></blockquote>
<p><span data-contrast="auto">By engaging the entire project team — client, architect, engineers and contractors — during the design phase, the team can work toward the common goal of creating a space that the client loves while meeting programmatic needs and staying within budget. TVD requires commitment and transparency from the entire team, making construction more predictable and value-driven.</span><span data-ccp-props='{"134233117":false,"134233118":false,"201341983":0,"335559738":0,"335559739":160,"335559740":276}'> </span></p>
<h2><span data-contrast="auto">Miracle on Spring Street</span><span data-ccp-props='{"134233117":false,"134233118":false,"201341983":0,"335559738":0,"335559739":160,"335559740":276}'> </span></h2>
<p><span data-contrast="auto">When ground broke on the Self Medical Center Spring Street in May, a nearly two-decade dream took root. Located on the campus of Self Regional Medical Center in Greenwood, S.C., the 68,000-square-foot, multi-specialty medical office building will house urology, gastroenterology, general surgery, bariatric surgery, women’s health and infusion services all in a single building. Once complete in mid 2027, it will support seven nearby counties and nearly 300,000 people. </span></p>
<p><span data-contrast="auto">As a comprehensive, independent, three-hospital healthcare system, every dollar needed to be spent with intention to maximize the care it could deliver. In addition to the fixed budget, the project also needed to adhere to a tight timeline, tracking roughly 15 total months for construction. With little room for delays or rework, the client needed a clear plan and a fully aligned team.</span><span data-ccp-props='{"134233117":false,"134233118":false,"201341983":0,"335559738":0,"335559739":160,"335559740":276}'> </span></p>
<h2><span data-contrast="auto">Assembling the Team Behind the Vision</span><span data-ccp-props='{"134233117":false,"134233118":false,"201341983":0,"335559738":0,"335559739":160,"335559740":276}'> </span></h2>
<p><span data-contrast="auto">After six years of working on the Self Regional Medical Center campus, Robins & Morton was chosen to lead construction of the new specialty-care building, and architect McMillan Pazdan Smith was selected as the architect. Given the project’s goals, the team agreed that TVD would yield the most predictable outcome.</span><span data-ccp-props='{"134233117":false,"134233118":false,"201341983":0,"335559738":0,"335559739":160,"335559740":276}'> </span></p>
<p><span data-contrast="auto">In addition to the early onboarding of the general contractor, engineers and large-scope trade contractors — such as mechanical, electrical and plumbing — were also brought into the TVD process. While this is always important in collaborative design-assist approaches, securing early commitments from trade resources supports another mounting challenge: workforce. With the number of fast-tracked construction projects growing across the country, specifically for data centers, onboarding mechanical, electrical and plumbing (MEP) trades early results in better project outcomes for material management and labor allocation.</span><span data-ccp-props='{"134233117":false,"134233118":false,"201341983":0,"335559738":0,"335559739":160,"335559740":276}'> </span></p>
<h2><span data-contrast="auto">Establishing the Target Value Delivery Structure</span><span data-ccp-props='{"134233117":false,"134233118":false,"201341983":0,"335559738":0,"335559739":160,"335559740":276}'> </span></h2>
<figure aria-describedby="caption-attachment-52405" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="wp-image-52405" src="https://hconews.com/wp-content/uploads/2026/10/DeliveryModels.Groundbreaking_Self-Medical-Center-Spring-Street-1-300x200.jpg" alt="groundbreaking ceremony at Self Medical Center" width="400" height="267" srcset="https://hconews.com/wp-content/uploads/2026/10/DeliveryModels.Groundbreaking_Self-Medical-Center-Spring-Street-1-300x200.jpg 300w, https://hconews.com/wp-content/uploads/2026/10/DeliveryModels.Groundbreaking_Self-Medical-Center-Spring-Street-1-1024x683.jpg 1024w, https://hconews.com/wp-content/uploads/2026/10/DeliveryModels.Groundbreaking_Self-Medical-Center-Spring-Street-1-768x512.jpg 768w, https://hconews.com/wp-content/uploads/2026/10/DeliveryModels.Groundbreaking_Self-Medical-Center-Spring-Street-1-1536x1024.jpg 1536w, https://hconews.com/wp-content/uploads/2026/10/DeliveryModels.Groundbreaking_Self-Medical-Center-Spring-Street-1-2048x1365.jpg 2048w, https://hconews.com/wp-content/uploads/2026/10/DeliveryModels.Groundbreaking_Self-Medical-Center-Spring-Street-1-820x545.jpg 820w, https://hconews.com/wp-content/uploads/2026/10/DeliveryModels.Groundbreaking_Self-Medical-Center-Spring-Street-1-600x400.jpg 600w" sizes="(max-width: 400px) 100vw, 400px"><figcaption class="wp-caption-text">The Self Medical Center project has a 15-month timeline. | Photo Credit: Courtesy of Robins & Morton</figcaption></figure>
<p><span data-contrast="auto">The TVD approach requires continuous collaboration, beginning during the design phase. At the onset, Project Implementation Teams, or “PIT groups,” are formed to plan the scopes of work. For the Self Medical Center Spring Street project, there were three: Site/Civil, MEP and Structure/Building Envelope.</span><span data-ccp-props='{"134233117":false,"134233118":false,"201341983":0,"335559738":0,"335559739":160,"335559740":276}'> </span></p>
<blockquote><p><span data-contrast="auto">Evaluating the total cost, historical data for similar projects and project-specific needs, the team allocated percentages of the budget to each PIT. This allows the PIT groups to collaboratively design the scopes while determining where cost management is needed. In the event that a scope is under budget, the team can present opportunities to add wanted items.</span><span data-ccp-props='{"134233117":false,"134233118":false,"201341983":0,"335559738":0,"335559739":160,"335559740":276}'> </span></p></blockquote>
<p><span data-contrast="auto">At the Self Medical Center Spring Street project, every team member also has access to software that contains all project cost data, including the status of the overall budget and each PIT group’s budget. This creates radical cost transparency and ensures everyone has the most up-to-date information, preventing miscommunication. The software also has a sandbox environment where any team member can run varying cost-management scenarios, demonstrating how changes affect the budget.</span><span data-ccp-props='{"134233117":false,"134233118":false,"201341983":0,"335559738":0,"335559739":160,"335559740":276}'> </span></p>
<p><span data-contrast="auto">One tactic for achieving this collaborative culture was establishing a project “Conditions of Satisfaction” charter that contains required measures of success for the project. That alignment provided clarity on shared goals and allowed the team to focus collectively on what was most advantageous to the project.</span><span data-ccp-props='{"134233117":false,"134233118":false,"201341983":0,"335559738":0,"335559739":160,"335559740":276}'> </span></p>
<h2><span data-contrast="auto">Early Target Value Delivery Wins</span><span data-ccp-props='{"134233117":false,"134233118":false,"201341983":0,"335559738":0,"335559739":160,"335559740":276}'> </span></h2>
<p><span data-contrast="auto">Although the Self Medical Center Spring Street project is early in the construction phase, there have already been several significant wins throughout the TVD process. One of the most significant was preserving the building’s exterior design.</span><span data-ccp-props='{"134233117":false,"134233118":false,"201341983":0,"335559738":0,"335559739":160,"335559740":276}'> </span></p>
<p><span data-contrast="auto">The first rendering of the project included a striking glass curtain wall around the entry point and curtain-wall windows on the sides of the building. This design came at a higher cost than the initial PIT group allocation, but it was core to client satisfaction. Understanding that preference, the team sought ways to adjust the cost to support the aesthetic. First, they reduced the size of the curtain wall on the sides of the building, lowering material cost without dramatically changing the look. Then, they made a few small adjustments to interior finishes to balance the remaining deficit, successfully maintaining the design intent.</span><span data-ccp-props='{"134233117":false,"134233118":false,"201341983":0,"335559738":0,"335559739":160,"335559740":276}'> </span></p>
<blockquote><p><span data-contrast="auto">Because much of the design is completed collaboratively in TVD, teams are able to catch and correct constructability issues earlier. </span></p></blockquote>
<p><span data-contrast="auto">For example, the Robins & Morton team and the mechanical trade contractor determined that rooftop ductwork should instead be placed in an interstitial space between the ceiling and the decking. They brought the idea to the mechanical engineer, who quickly reconfigured the space. Being able to perform the design verification at an earlier stage prevented the cost and schedule loss associated with approximately four weeks of rework.</span><span data-ccp-props='{"134233117":false,"134233118":false,"201341983":0,"335559738":0,"335559739":160,"335559740":276}'> </span></p>
<p><span data-contrast="auto">The importance of early commitments and support from trade contractors cannot be overstated in TVD and design-assist projects. Trades bring tremendous value through knowledge of the intricacies of their scopes and required equipment. On the Self Medical Center Spring Street project, the mechanical contractor evaluated project needs against the specified units. Through its field experience, the contractor recommended another manufacturer with more favorable lead times, ultimately saving $70,000.</span><span data-ccp-props='{"134233117":false,"134233118":false,"201341983":0,"335559738":0,"335559739":160,"335559740":276}'> </span></p>
<h2><span data-contrast="auto">The Future of Target Value Delivery</span><span data-ccp-props='{"134233117":false,"134233118":false,"201341983":0,"335559738":0,"335559739":160,"335559740":276}'> </span></h2>
<p><span data-contrast="auto">While it’s excellent for complex projects with tight budgets and compressed schedules, TVD does require early onboarding of all major project participants — and all parties must be fully committed to the process and completely transparent in making cost decisions. TVD also challenges the status quo, allowing all disciplines to plan the same project together, and results in greater client satisfaction.</span><span data-ccp-props='{"134233117":false,"134233118":false,"201341983":0,"335559738":0,"335559739":160,"335559740":276}'> </span></p>
<p><em>Stephen Andersson is a Superintendent at Robins & Morton.</em></p>
<p><em>This article was published in the <a href="https://issuu.com/wmhmedia/docs/healthcare_construction_operations_news_2026_ed" target="_blank" rel="noopener">2026 Design & Construction Edition of Healthcare Construction + Operations News</a>.</em></p>
<p>The post <a rel="nofollow" href="https://hconews.com/2026/10/26/the-case-for-target-value-delivery/">The Case for Target Value Delivery</a> appeared first on <a rel="nofollow" href="https://hconews.com/">HCO News</a>.</p>
<p>The post <a href="https://hconews.com/2026/10/26/the-case-for-target-value-delivery/">The Case for Target Value Delivery</a> appeared first on <a href="https://hconews.com/">HCO News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Predicting Leukemia Survival May Be Aided by Six Gene Scoring System</title>
<link>https://edusehat.com/en/predicting-leukemia-survival-may-be-aided-by-six-gene-scoring-system</link>
<guid>https://edusehat.com/en/predicting-leukemia-survival-may-be-aided-by-six-gene-scoring-system</guid>
<description><![CDATA[ Researchers studying mice and human data identified a six gene signature, and developed a scorings system, that could help forecast acute myeloid leukemia patient survival, and potentially point to new therapeutic targets. 
The post Predicting Leukemia Survival May Be Aided by Six Gene Scoring System appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/05/GettyImages-1632999309.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 03:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Predicting, Leukemia, Survival, May, Aided, Six, Gene, Scoring, System</media:keywords>
<content:encoded><![CDATA[<p>A study by researchers at the Centre for Genomic Regulation (CRG) has identified six different genes that can help forecast survival of patients with acute myeloid leukemia (AML), a type of cancer that has very variable outcomes between patients.</p>
<p>Headed by ICREA Research Professor Luciano Di Croce, PhD, a researcher at the CRG, the team created a scoring system by moving repeatedly between laboratory experiments with mice and patient records, crossing the two to look for genes that behaved consistently in both.</p>
<p>The investigators had initially focused on a gene called <em>PHF19</em>, which the Di Croce lab has studied for more than a decade and is thought to suppress blood cancer formation. PHF19 belongs to a family of genes that keep other genes switched off, a system that cells use as they progress along the differentiation process from immature to mature cells.</p>
<p>Through their research the team found six genes that reliably predict AML patient survival. Some genes—<em>CARMIL1, HOPX,</em> and <em>ALDH1A1</em>—were more active in patients with poor outcomes while others—<em>CALR, STAR,</em> and <em>PHF19</em>—were less active. The collective activity of all six genes, which the researchers called the PHFScore, divided patients into groups with sharply different survival prospects.</p>
<p>Findings from the study could point to new ways of helping to predict outcomes in patients with this type of blood cancer, contributing to the development of future prognostic tests, and may suggest new therapeutic targets. Patients suspected of having AML already give a bone marrow sample for laboratory analysis, and measuring six genes is simpler and cheaper than reading a broader genetic profile.</p>
<p>“<em>PHF19</em> on its own already tells us something about how patients will fare, but combining it with five other genes is a dramatic improvement which gives us more accurate information for AML prognosis,” said Di Croce.</p>
<p>Gianni Gamarra Figueroa, PhD, added, “Some of the genes have never been linked to blood cancer before and could also be potential new therapeutic targets. These genes haven’t been described in leukemia or even in how blood forms. We don’t yet know what they are doing there, which is exactly what makes them worth exploring.”</p>
<p>Di Croce is senior author and Gamarra Figueroa is first author of the team’s published paper in <em>Science Advances</em>, titled “<a href="http://dx.doi.org/10.1126/sciadv.aed6757" target="_blank" rel="noopener">Polycomb factor PHF19 affects AML initiation, patient prognosis, and survival</a>.” In their paper the authors concluded “By integrating our <em>in vitro</em> multiomic data with the molecular and clinical data from various AML datasets, we successfully identified a molecular signature—the PHFScore—to identify patient prognosis.”</p>
<p>Acute myeloid leukemia is “… a heterogeneous malignancy characterized by diverse genetic and epigenetic alterations,” the authors wrote.  Earlier work in the Di Croce’s lab showed that mice lacking the <em>PHF19</em> gene manifest a condition resembling myelodysplastic syndrome (MDS), where blood cells fail to mature properly and build up in the body without yet becoming cancerous. “We previously showed that the Polycomb-associated factor Phf19 is required for hematopoietic stem cell (HSC) maintenance and state control in mice and that its loss (Phf19<sup>KO</sup>) impairs HSC function,” the team continued.</p>
<p>“Leukemia develops in stages, as a cell gradually accumulates defects,” explained Gianni Gamarra, PhD, “Losing <em>PHF19</em> doesn’t cause leukemia on its own, but it is already a push down that road.”</p>
<p>The new study asked what happens when leukemia originates in cells that have similar starting conditions—not cancerous, but not quite healthy either. The researchers introduced a leukemia-causing gene into mouse blood cells with and without <em>PHF19</em>. Cells lacking the gene formed more colonies in the lab and, when transplanted into mice, took hold more easily. They also stayed locked in an immature, stem-cell-like state.</p>
<p>“Blood cells form a hierarchy,” added Gamarra Figueroa. “At the top are stem cells, which are still plastic and could become almost anything. As they move down, they mature and take on a fixed identity. The more a cancer holds on to that plasticity, the more malignant it tends to be.”</p>
<figure aria-describedby="caption-attachment-339826" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339826" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Ph19-normal-left-vs-KO-right-300x238.jpg" alt="Spleen tissue from a mouse without PHF19 (left) and a mouse with normal PHF19 function (right). Dense clusters of immune cells sit within blood-rich regions in pink. Without PHF19, cells are altered in their differentiation process " width="300" height="238" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Ph19-normal-left-vs-KO-right-300x238.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Ph19-normal-left-vs-KO-right.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Spleen tissue from a mouse without PHF19 (left) and a mouse with normal PHF19 function (right). Dense clusters of immune cells sit within blood-rich regions in pink. Without PHF19, cells are altered in their differentiation process [Gianni Gamarra/Centro de Regulación Genómica]</figcaption></figure>
<p>The plasticity made the cells harder to treat. Cells without <em>PHF19</em> largely ignored the effects of chemotherapeutic drugs which are commonly used to push leukemia cells into a mature state, one of the strategies doctors use against a disease in which cells become stuck partway through development and multiply unchecked. “<em>Phf19</em> deletion promoted acquisition of stemlike features and reduced responsiveness to differentiation-inducing AML therapies,” the team stated.</p>
<p>To check whether their mouse model reflected human disease, the researchers compared which genes were switched on and off in both the mouse cells and from data generated in human studies. The same pattern appeared in patient datasets. “Molecular and functional consequences of Phf19 loss paralleled those observed in the datasets of patients with AML,” they further noted. “Patient data from different AML datasets allowed us to determine that patients with low levels of PHF19 expression had a stemlike transcriptomic profile, which, according to the literature, is linked to more chemoresistant leukemias.”</p>
<p>Among younger adults treated for AML, those with the lowest levels of <em>PHF19</em> survived for less time than those with the highest. they were also less likely to go into remission after standard chemotherapy. Fewer than half did so, compared with up to 85% of patients with the highest levels.</p>
<p>“The patients have advanced leukemia, so we are comparing mice and humans at very different stages of the disease, yet the molecular data point in the same direction, which gives our model a great deal of strength,” said Gamarra Figueroa.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/predicting-leukemia-survival-may-be-aided-by-six-gene-scoring-system/">Predicting Leukemia Survival May Be Aided by Six Gene Scoring System</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Overcoming Bottlenecks: Biopharma’s Big Challenge Is Execution</title>
<link>https://edusehat.com/en/overcoming-bottlenecks-biopharmas-big-challenge-is-execution</link>
<guid>https://edusehat.com/en/overcoming-bottlenecks-biopharmas-big-challenge-is-execution</guid>
<description><![CDATA[ The biggest challenge facing the biopharma industry isn’t scientific innovation. It’s manufacturing execution. Closing this gap is one of the greatest opportunities biopharma has today to enhance resilience and unlock the full value of its science.
The post Overcoming Bottlenecks: Biopharma’s Big Challenge Is Execution appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/07/GettyImages-1460261281.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 03:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Overcoming, Bottlenecks:, Biopharma’s, Big, Challenge, Execution</media:keywords>
<content:encoded><![CDATA[<p>The biggest challenge facing the biopharma industry isn’t scientific innovation. It’s manufacturing execution.</p>
<p>That’s the opinion of Nicolas Pivet, vice president and general manager of manufacturing and digital solutions at Cytiva. Major scientific advances have enabled the development of truly amazing therapeutics such as RNA technologies and cell and gene interventions, yet manufacturing innovation hasn’t kept pace. “Our ability to manufacture these therapies reliably, repeatedly, and at scale remains a major constraint,” Pivet tells <em>GEN</em>.</p>
<figure aria-describedby="caption-attachment-339781" class="wp-caption alignright"><img decoding="async" class="size-full wp-image-339781" src="https://www.genengnews.com/wp-content/uploads/2026/10/Nicolas-Pivet-Headshot.jpg" alt="" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Nicolas-Pivet-Headshot.jpg 200w, https://www.genengnews.com/wp-content/uploads/2026/10/Nicolas-Pivet-Headshot-150x150.jpg 150w" sizes="(max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Nicolas Pivet, vice president and general manager of manufacturing and digital solutions at Cytiva. [Cytiva]</figcaption></figure>
<p>“The industry often focuses on symptoms [of biomanufacturing bottlenecks] such as paper batch records, disconnected laboratory information management systems, fragmented automation architectures, isolated enterprise resource planning deployments, or data silos. Those challenges are real, but they are not the root cause,” Pivet stresses.</p>
<p>“The deeper issue,” he says, “is that many manufacturing environments evolved over decades and were never designed as connected systems. Digital capabilities were often layered on to solve local problems rather than integrated around end-to-end manufacturing performance. The result is an environment that is increasingly data-rich but…insight-poor.”</p>
<p>In that environment, organizations can’t extract actionable insights early enough to affect outcomes. They have a visibility problem.</p>
<h4><strong>Focus on observability</strong></h4>
<p>The first step in resolving the bottlenecks is to solve specific problems.</p>
<p>“You cannot control what you cannot see,” Pivet says. He advises industry to focus first on improving observability. Gaining insights into process deviations early enables earlier intervention, which creates better decisions and improves confidence in those decisions, he explains. This is the foundation of advanced manufacturing.</p>
<p>“Then connect the data, workflows, and decisions required to improve the outcome,” Pivet advises. “Biopharma does not lack information. It lacks accessible, contextualized, and trusted information,” he says. “Connecting process, equipment, analytical, and workflow data establishes the foundation required for predictive analytics, advanced automation, digital twins, and AI.”</p>
<p>“Only after that [has occurred] should advanced control or AI-enabled decision-making become part of the discussion.”</p>
<p>Therefore, rather than starting with AI use cases—as many try—organizations should first focus on observability, and then address interconnectivity, data integrity, and maintaining operational context for those data flows. When those are resolved, AI can be added to the mix. “AI does not fix weak foundations,” he says. “It exposes them.”</p>
<h4><strong>Face organizational barriers</strong></h4>
<p>The barriers to digital transformation are more often organizational than technical. That’s because biomanufacturers consider change riskier than maintaining current practices. In 2025, “more than a third of biopharma companies were still in early exploration or had not started their digital transformation journey,” he says, underscoring his point.</p>
<p>Trust is typically the rate-limiting step, and that is established only by reliable performance. Therefore, “the organizations moving fastest are those demonstrating value on real manufacturing problems, validating outcomes, and gradually scaling successful approaches rather than attempting sweeping transformations,” Pivet observes.</p>
<p>Manufacturing equipment in the future will not just be smarter; it will be designed from the outset as elements of connected, interoperable systems that provide early visibility and easy integration into automated and connected workflows.</p>
<h4><strong>Prepare the workforce</strong></h4>
<p>“The conversation around AI often focuses on technology. The more important conversation is about people,” Pivet emphasizes.</p>
<p>Automation, agentic and generative AI, and other smart manufacturing technologies are changing roles throughout the workforce at, seemingly, warp speed. Everyone, from equipment operators, process engineers, data scientists, and quality professionals up through the executive suite, is coming to grips with new ways of working that require new skills and new ways of thinking.</p>
<p>“Data literacy, systems thinking, automation fluency, model interpretation, and cross-functional collaboration are becoming increasingly important,” Pivet points out. Consequently, people are spending less time collecting information and reacting to events, and more time interpreting data and optimizing processes.</p>
<p>The workforce, however, is still in transition. “The Global Biopharma Index reported that 29% of organizations experience severe shortages in digital and AI-related skills,” he says.</p>
<p>“Workforce readiness is one of the defining challenges of this decade,” Pivet continues. “The most successful manufacturers I encounter are not necessarily the ones deploying the most advanced technologies. They are the organizations creating confidence around new ways of working.”</p>
<p>Within five years, he predicts a plethora of hybrid roles that blend both process and digital expertise. Future titles may include digital process engineer, manufacturing data scientist, process intelligence specialist, and manufacturing systems architect, he adds.</p>
<p>Filling those new roles means preparing the workforce today. He advocates upskilling individuals enterprise-wide, ensuring the various functional teams learn together, rather than treating digital transformation as the purview of any particular group.</p>
<p>Even today, across industries, traditional learning programs are being complemented by immersive learning experiences. Biopharma will be no different, especially given its growing complexity and limited opportunities for hands-on learning in the face of good manufacturing requirements, production schedules, and equipment availability.</p>
<p>Immersive learning experiences involving mixed reality and augmented reality “allow operators, technicians, and engineers to interact with equipment and workflows, and troubleshooting scenarios in highly realistic digital environments,” he says. By accelerating learning, enhancing retention, and building confidence, workers are better prepared when they enter live manufacturing environments.</p>
<p>Eventually, Pivet says, “Immersive learning may become as important to workforce development as flight simulators became to aviation training.”</p>
<h4><strong>Ease tech transfer</strong></h4>
<p>The tech transfer process also has a major bottleneck, but it has nothing to do with technology or human factors.</p>
<p>“The most common reason transfers fail is not because process instructions are missing,” he says. “It is because process understanding fails to transfer with them. Receiving organizations often inherit process descriptions, specifications, and operating procedures, but not the context explaining why those parameters matter or how the process behaves under changing conditions.”</p>
<p>Those gaps are becoming ever more important as therapies become increasingly complex. Successful tech transfer, therefore, includes transferring process understanding. Digital twins help minimize the gap between process instructions and process understanding by enabling teams “to test assumptions virtually before testing them physically,” Pivet says, thus enhancing success. In this way, “…uncertainty is removed rather than relocated.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<h4><strong>Lead with digital change</strong></h4>
<p>If you can prioritize only one area for improvement, Pivet advises choosing digital infrastructure because, he explains, “people and processes increasingly depend on information. Digital infrastructure creates the conditions for successful technology transfer, effective workforce development, predictive analytics, process understanding, and operational improvement. Without trusted information flows, organizations struggle to scale knowledge, replicate success, or improve decision quality.”</p>
<p>High-quality information flows, he predicts, will be a major determinant of manufacturing competitiveness in the coming decade. “The companies best positioned to lead the next era of biomanufacturing will be those that combine AI initiatives with strong connected-data and observability foundations,” he suggests. By doing so, they will be better able to translate scientific innovation into predictable, scalable, operational performance.</p>
<p>“Biopharma does not have an imagination problem,” Pivet reiterates. “It has an execution problem. Closing that execution gap is one of the greatest opportunities our industry has to accelerate patient access, improve resilience, and unlock the full value of the science being developed today.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/overcoming-bottlenecks-biopharmas-big-challenge-is-execution/">Overcoming Bottlenecks: Biopharma’s Big Challenge Is Execution</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>South African Labs Strive for Africa’s Biopharma Sovereignty</title>
<link>https://edusehat.com/en/south-african-labs-strive-for-africas-biopharma-sovereignty</link>
<guid>https://edusehat.com/en/south-african-labs-strive-for-africas-biopharma-sovereignty</guid>
<description><![CDATA[ Africa still imports 99% of its routine vaccines and 70–90% of its biopharmaceuticals. The Africa CDC warns this vulnerability could cost the continent up to $1.1 trillion in skills and jobs through 2050. 
The post South African Labs Strive for Africa’s Biopharma Sovereignty appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/a-petri-dish-for-growing-micro-o.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 03:10:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>South, African, Labs, Strive, for, Africa’s, Biopharma, Sovereignty</media:keywords>
<content:encoded><![CDATA[<p>Africa still imports 99% of its <a href="https://jogh-ep.org/article/154008-strategic-pathways-to-pharmaceutical-self-reliance-in-africa-lessons-enablers-and-opportunities" target="_blank" rel="noopener">routine vaccines</a> and 70–90% of its biopharmaceuticals. The <a href="https://africacdc.org/investment-in-health-research-and-development/#prId=372147" target="_blank" rel="noopener">Africa CDC </a> warns this vulnerability could cost the continent up to $1.1 trillion in skills and jobs through 2050.</p>
<p>This is motivating a biotech revolution building up in South Africa—the continent’s most industrialized nation where startups are confronting <a href="https://espace.enap.ca/id/eprint/423/" target="_blank" rel="noopener">“pharmaceuticals apartheid”</a>—tinkering with low-cost, decentralized biotech R&D and manufacturing prototypes.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>So much is at stake and urgent, said Nick Enslin, co-founder and COO of Immobazyme, one of the flagship South African startups that specializes in advanced biomanufacturing and precision fermentation with the goal of making affordable, high-value recombinant proteins, enzymes, and growth factors to help slash Africa’s biopharma import bill.</p>
<p>“One of the biggest things we realized as a country, but also as Africa, is that we’re importing 99% of our biologics and drugs. For the COVID-19 vaccine, we were the last group of people to get this vaccine,” he lamented. A cursory look at the South African Clinical Research Association, the equivalent of the FDA, shows they still follow the 2014 FDA guidelines, he said. “And that’s quite old,” he told <em>GEN</em>.</p>
<p>As a result, they would need to update their regulations to understand the science better, what biosimilars are, what mRNA vaccines are, and why the science is moving so fast that regulators are struggling to keep up.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Africa has “many opportunities” to domesticate its medical biologics supply chains, but reality is daunting, said Enslin, citing a recent <a href="https://www.bloomberg.com/news/articles/2026-06-19/aspen-disruption-triggers-south-africa-contraceptive-shortage" target="_blank" rel="noopener">“disruption</a>” at Aspen—Africa’s largest generic drugs maker—which threatens an oral contraceptives shortage in South Africa.</p>
<p>Part of the reason is that GMP manufacturers of biosimilars, specifically, are far and few between on the African continent.</p>
<p>“In South Africa, we’ve only got a handful, and most of them are looking at small molecules, chemicals, and stuff like that, necessarily creating bio-biologics,” said Enslin.</p>
<h4><strong>The mission</strong></h4>
<p>The mission is clear for Immobazyme, which recently captured the limelight after raising $1.45 million in venture funding (bringing the total the company has raised to $2.9 million), which is modest by Silicon Valley standards but significant in South Africa’s limited venture finance ecosystem.</p>
<p>“Having our own GMP facility, manufacturing biosimilars for the African continent, that’s where we want to be by the end of the 2030s,” said Enslin, who is talking about “lower hanging fruit” for Africa’s biotech innovators to grab and accelerate through development and into the market.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>He added that he is referring to “nutraceuticals, cosmetics, food and beverages, and agribiotech, which are subject to lower regulation and certification than drugs and other medicines. But it’s still the same premise that the African continent is struggling with these kinds of novel products.”</p>
<p>His first patent came about when he was a student at South Africa’s Stellenbosch University, the premier South African and African research corridor in the Western Cape Province, where billionaires live adjacent to bubbling ideas in biotech, banking, and software.</p>
<p>“We realize that these enzymes, whether it’s in an industrial application or mRNA manufacturing, are relatively expensive. And you use them once, and then you can’t recover them. You can’t reuse them again even though they’re perfectly fine to reuse,” he said.</p>
<p>So, they developed a method to immobilize enzymes on a solid metal matrix, allowing substrates to pass through and undergo enzymatic reactions while the enzymes remain in place for repeated use, he explains, giving an example of lactose-free myelin oligodendrocyte glycoprotein (MOG).</p>
<p>“What they do is they immobilize lactase, which is an enzyme that breaks it down into simpler sugars. And they passed the milk over and got lactose-free milk. But the current enzyme immobilization technologies that were out there at the time were either quite expensive or they weren’t optimized for multiple different kinds of applications. So, this is where PepTrap came in,” Enslin said, referring to the proprietary, synthetic cellulose-based enzyme immobilization technology developed by Immobazyme that traps and stabilizes enzymes, allowing them to be reused cost-effectively across multiple industries.</p>
<p>Getting the science right was the easier part for Enslin and his two co-founders. Scaling the science into any kind of business “is just really tough, but scaling a biotechnology company in South Africa is even tougher. It’s capex heavy. It’s infrastructure heavy. And then every time you 10x your manufacturing capability, you have to basically buy a completely new production pipeline to meet that scale,” he said.</p>
<h4><strong>The hub</strong></h4>
<p>For decades, South African universities have been excellent at generating world-class research papers, but much of that IP stays stuck in academic journals. LaunchLab CERIBIO is a 300 m<sup>2</sup> biotechnology laboratory and business incubator at Stellenbosch University and looks to actively disrupt this “<a href="https://council.science/blog/publish-or-perish-mentality/" target="_blank" rel="noopener">publish or perish</a>” culture in South Africa. Enslin’s Immobazyme startup is one of the most successful spinouts from this incubator.</p>
<p>“It is very challenging to do commercial work in a university laboratory,” said Anita Nel, chief director of innovation and commercialization at Stellenbosch University. Hence, they have created this space to ensure that the university’s biotech spinout companies have a dedicated, shared space. They actively encourage their researchers to publish their results once CERIBIO has the opportunity to protect their inventions, as publications also bring credibility to their research. “It is more a case of patent before you publish than preventing publication at all,” she added.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>When a university researcher comes to LaunchLab CERIBIO with a breakthrough, there is a filtering method to ensure the presentation can translate into commercial success. “We perform due diligence on every new invention that is disclosed to us to make very sure that there is commercial potential, that it is novel, and to determine what the best route to market is—either a license to a company with an existing market or a new spinout company with the support of the university,” she told <em>GEN</em>.</p>
<p>The spinouts from LaunchLab CERIBIO are also supported to de-risk the ventures further and are connected to both local and global investors who can provide funding to help them progress faster. “These investors understand the deep-tech and biotech space and feel comfortable investing in this sector, without expecting the fast progress that you typically see in fintech,” she added.</p>
<h4><strong>Nod of approval</strong></h4>
<p>Immobazyne’s recent venture financing success is a riposte to critics who for a long time have argued that Africa’s biotech can’t attract this kind of liquidity. It’s a massive nod of approval, Enslin explained. “I think that’s a testament to the kinds of companies that are coming out of the African continent and that resilience and the determination. There have been some amazing success stories coming out of South Africa,” he said, pointing to South Africa’s Kapa Biosystems, which was acquired for a record $445M by Roche in 2015.</p>
<p>“It’s an affirmation that we can actually build something incredible here. I think it’s heating the ecosystem here on the ground in the Western Cape specifically. I mean, they’re calling us the Silicon Valley or the Cape Silicon Valley,” he said with humor.</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/south-african-labs-strive-for-africas-biopharma-sovereignty/">South African Labs Strive for Africa’s Biopharma Sovereignty</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Medical Device and IVD Manufacturing: Compressed Air Quality, Applications and Compliance Considerations</title>
<link>https://edusehat.com/en/medical-device-and-ivd-manufacturing-compressed-air-quality-applications-and-compliance-considerations</link>
<guid>https://edusehat.com/en/medical-device-and-ivd-manufacturing-compressed-air-quality-applications-and-compliance-considerations</guid>
<description><![CDATA[ 




Compressed air is widely used throughout medical device and In Vitro Diagnostic (IVD) manufacturing facilities. Applications range from operating pneumatic equipment to drying components, purging fluid pathways, cleaning selected surfaces, assisting assembly, and supporting automated production processes.
However, compressed air is not inherently clean simply because it has been compressed, filtered or supplied through a dedicated utility system.
It can contain solid particles, moisture, oil aerosols, oil vapour, gaseous contaminants and microbiological contamination. Depending on the application, these contaminants may affect product cleanliness, material properties, fluid flow, manufacturing consistency, or the microbiological condition of a product-contact surface.
ISO 8573-1, Compressed air — Part 1: Contaminants and purity classes, provides a framework for specifying compressed-air purity according to three principal contaminant categories: particles, water and oil. It also addresses gaseous and microbiological contaminants as additional considerations.
For medical device and IVD manufacturers, the critical question is not simply which compressed-air class is the cleanest. It is:
What level of compressed-air purity is required for each application, how should that requirement be designated, and how can the manufacturer demonstrate that the required quality is consistently achieved at the point of use?
This article explains how to apply the classification system and develop appropriate requirements for product-contact applications, cleanrooms, sterile manufacturing environments, and IVD processes.
Understanding the ISO 8573-1:2010 classification system
ISO 8573-1:2010 establishes purity classes for three principal contaminant categories.

Designation positionContaminant categoryWhat it addresses
First numberSolid particlesParticle concentration and particle-size ranges, or mass concentration where applicable
Second numberWaterHumidity/pressure dew point and liquid-water content
Third numberOilTotal oil content, including the applicable liquid, aerosol and vapour forms

The general designation is:
ISO 8573-1:2010 [A:B]
Where:
A is the particle purity class.B is the water purity class.C is the oil purity class.
Each number represents a separate requirement. The three numbers are not an average, a single cleanliness score, or a cleanroom grade.
For example:
ISO 8573-1:2010 [1:2:1]
This means:
Particle purity: Class 1.Water purity: Class 2.Oil purity: Class 1.
The classification must be interpreted against the applicable limits in the standard. A requirement should also identify the measurement location and any additional parameters necessary for the intended process.The same designation can be applied at different locations in a compressed-air system, but compliance at one location does not automatically demonstrate compliance at every other location.
How are the purity classes determined?
Particle purity classes
Particle classification considers the concentration of solid particles within specified particle-size ranges.
For classes 1 to 5, the particle-number limits in ISO 8573-1:2010 are expressed in terms of particles per cubic metre.
The following table summarizes the particle-number criteria for these classes.

Particle class0.1 to 0.5 µm0.5 to 1.0 µm1.0 to 5.0 µm
Class 1≤ 20,000≤ 400≤ 10
Class 2≤ 400,000≤ 6,000≤ 100
Class 3Not specified≤ 90,000≤ 1,000
Class 4Not specifiedNot specified≤ 10,000
Class 5Not specifiedNot specified≤ 100,000

Particle concentration limits are per cubic metre of compressed air. “Not specified” means that the corresponding size range is not assigned a limit by that class criterion; it does not mean that particles are absent.
Classes 6 and 7 use mass-concentration criteria rather than the particle-number criteria shown above. They should be interpreted using the relevant provisions of the standard.
Application to medical devices and IVDs
Particle classification becomes particularly important when compressed air is used to:
Blow or dry components before assembly.Purge internal device passages or IVD fluidic channels.Contact exposed product-contact surfaces.Operate in proximity to exposed sterile components.Support precision assembly, dispensing or sensitive analytical processes.
The required particle class should reflect the consequence of contamination. For example, a particle introduced into a narrow IVD fluid pathway may affect flow or reagent delivery, while a particle deposited on a component intended for a critical bonding operation may affect bond integrity.
The particle class alone does not establish that a component is microbiologically clean or that its surface is suitable for its intended use.
Water purity classes
Water classification considers pressure dew point and, for the relevant classes, liquid-water content.
For classes 1 to 6, the principal pressure-dew-point criteria are:

Water classMaximum pressure dew point
Class 1≤ −70 °C
Class 2≤ −40 °C
Class 3≤ −20 °C
Class 4≤ +3 °C
Class 5≤ +7 °C
Class 6≤ +10 °C

Classes 7 to 9 address liquid-water concentration, while Class X represents contamination exceeding the Class 9 limit or otherwise requiring the specified X-class designation.
Application to medical devices and IVDs
Water requirements should be evaluated where compressed air is used for:
Drying components or assemblies.Purging internal passages.Supporting processes sensitive to moisture.Operating pneumatic equipment where condensation could affect performance.Supplying air to locations where moisture could contribute to corrosion or contamination.
A low pressure dew point does not establish that liquid water, particles, oil or microorganisms are absent under every operating condition. These are separate aspects of the specification and system performance.
Oil purity classes
Oil classification addresses total oil content within the scope of the standard, including the applicable liquid, aerosol and vapour forms.

Oil classMaximum total oil concentration
Class 1≤ 0.01 mg/m³
Class 2≤ 0.1 mg/m³
Class 3≤ 1 mg/m³
Class 4≤ 5 mg/m³

Class 0 is a specially defined class requiring a documented contamination limit that is more stringent than Class 1. It does not mean zero oil or zero contamination.
Class 0 should not be specified without defining the agreed maximum allowable concentration and the method by which compliance will be demonstrated.
Application to medical devices and IVDs
Oil contamination may be relevant when compressed air contacts:
Surfaces intended for bonding or coating.Components that will subsequently contact medicines, biological materials, reagents or patient samples.Internal fluid pathways.Components intended for sterilization or other controlled processing.Sensitive optical, analytical or precision assemblies.
An oil-free compressor may reduce one source of contamination, but it does not independently prove that the air delivered at the point of use meets the specified oil class.
The class limits above are a summary of ISO 8573-1:2010. Consult the full standard for the complete classification criteria, reference conditions and designation requirements.
Quick reference: ISO 8573-1:2010 compressed-air purity classesThe following consolidated table is a simplified reference view of particle, water and oil class criteria. Use the applicable clauses and tables in the full standard when establishing specifications.



Purity ClassSolid ParticlesWaterOil
0.1–0.5 µm particles/m³0.5–1.0 µm particles/m³1.0–5.0 µm particles/m³Mass mg/m³Pressure dew point °CLiquid water g/m³Liquid oil mg/m³Oil aerosol mg/m³Total oil mg/m³


Class 0As specified by the equipment user or supplier and more stringent to Class 1.
Class 1≤20,000≤400≤10—≤−70——≤0.01
Class 2≤400,000≤6,000≤100—≤−40——≤0.1
Class 3—≤90,000≤1,000—≤−20——≤1
Class 4——≤10,000—≤+3——≤5
Class 5——≤100,000—≤+7—Not specified by this class
Class 6—≤5≤+10—Not specified by this class
Class 7—&gt;5 to ≤10—≤0.5Not specified by this class
Class 8——&gt;0.5 to ≤5Not specified by this class
Class 9——&gt;5 to ≤10Not specified by this class
Class XOutside the applicable specified limitsOutside the applicable specified limitsOutside the applicable specified limits



Important: A dash means that the corresponding criterion is not specified in this simplified presentation; it does not mean zero contamination.

How should a manufacturer designate compressed-air purity?
A compressed-air specification should be written so that engineering, quality assurance, production and the testing laboratory can interpret the same requirement without ambiguity.
Example 1: Different classes for different contaminants
A manufacturer determines that the required specification for a particular application is:
ISO 8573-1:2010 [2:2:1]
This designates particle Class 2, water Class 2 and oil Class 1.
The manufacturer must then identify the applicable acceptance criteria, test methods, sampling location and monitoring arrangements.
This example illustrates designation only. It is not a universal recommendation for medical device or IVD production.
Example 2: Unspecified contaminant category
Where a class for one of the three principal contaminant categories is not specified, a hyphen is used.
For example:
ISO 8573-1:2010 [1:−:1]
This specifies particle Class 1 and oil Class 1, without specifying a water class.
For a medical device process, leaving a category unspecified should be a deliberate and documented decision. It should not be used merely because the corresponding parameter has not yet been assessed.
Example 3: Class 0 specification
A Class 0 designation requires a specific, documented limit more stringent than Class 1 for the relevant contaminant.
The manufacturer should state the agreed limit, unit of measurement, relevant test method and acceptance criteria. Writing “Class 0” alone is insufficient to define the actual requirement.
Example 4: Additional microbiological or gaseous requirements
The three-number designation does not communicate a viable microbial limit.
Where microbiological contamination is relevant, the specification should include a separate requirement measured using the applicable method, such as ISO 8573-7 for viable microbiological contamination.
For example, a manufacturer might specify:
Compressed-air purity: ISO 8573-1:2010 [2:2:1].Viable microbiological contamination: a separately defined maximum in CFU/m³.Additional chemical or gaseous limits, where justified by the application.
The microbial limit must be established by the manufacturer based on the process and its risk assessment; the example does not imply a universal acceptance limit.
Applying ISO 8573-1 to medical device and IVD manufacturing areas
The purity class should be established for the intended use of the air, not assigned solely on the basis of the room classification.
The following table provides a practical starting point for application assessment.

Manufacturing applicationPrincipal considerationsSpecification approach
General pneumatic equipment outside product-critical operationsEquipment reliability, moisture, oil and particulate contaminationEstablish the class required by the equipment and process risk
Component drying before assemblyParticles, oil residues, moisture and potential recontaminationDefine the three-number purity class and any additional surface or microbial requirements
Direct contact with device componentsContaminants remaining on product-contact surfacesEstablish a risk-based purity class and verify air quality at the point of use
Purging internal passages or fluidic channelsParticles, oil, moisture and microbiological contamination where relevantDefine specific acceptance criteria for the internal pathway and intended product use
Handling exposed components in a controlled cleanroomAir quality at the outlet, introduction of contamination and impact on the controlled environmentSpecify compressed-air purity separately from cleanroom classification
Manufacturing of sterile devices before sterilizationProduct cleanliness, residues, particles and process-specific microbial risksEstablish requirements appropriate to the product and subsequent validated processes
Processes affecting IVD reagents or patient-sample pathwaysParticles, oil, chemical contaminants and microbiological risksEstablish application-specific purity and contamination limits supported by technical assessment

These are assessment categories, not prescribed ISO purity classes. The manufacturer must determine the actual specification for each application.
Direct product-contact compressed air: what should be considered?
Direct-contact compressed air requires particular attention because the air may introduce contamination onto the product or into a product-contact pathway.
The term direct contact should be defined according to the actual process. It can include air that touches a component, enters a fluid pathway, or contacts a surface that will subsequently contact a patient sample, reagent or other critical material.
The following questions should be addressed.
What is the product-contact pathway?
Determine whether compressed air contacts:
The finished device.An internal fluid pathway.A surface that will contact a patient or sample.A component that will subsequently be assembled into the device.A surface that is intended to remain clean until sterilization or packaging.
The answer determines which contamination hazards are relevant and what evidence is necessary.
Could the air introduce non-viable contaminants?
Non-viable contaminants include solid particles, liquid droplets, oil residues and other non-living material.
Depending on the application, these may cause:
Physical blockage of a narrow passage.Alteration of surface properties.Interference with bonding or coating.Residues that are difficult to remove.Interference with the operation of a fluidic or analytical system.
The manufacturer should define appropriate particle, oil and water limits and evaluate any additional chemical contaminants that could affect the product.
Could the air introduce viable contaminants?
Viable microbial contamination is a separate consideration. Depending on the application, microorganisms introduced through compressed air may affect a product&#039;s microbiological condition or compromise a contamination-control strategy.
The required microbial limit should be justified by the intended use, product characteristics, subsequent processing and risk assessment.
For devices intended to be sterile, a validated sterilization process does not automatically make uncontrolled contamination acceptable. Residues and particles may remain, and excessive or variable bioburden may affect process control.
Where should the air be tested?
The most relevant location is generally the point where the air is used or where its quality can affect the product.
A representative sampling plan should account for:
The condition of the main compressed-air supply.Downstream piping and treatment equipment.Point-of-use filters and connections.The operating conditions under which air is delivered.Potential contamination introduced after central treatment.
Testing at the compressor outlet alone may not establish the quality of the air reaching a critical manufacturing operation.
Compressed air used in cleanrooms and controlled environments
One of the most important distinctions for medical device and IVD manufacturers is the difference between compressed-air purity classification and cleanroom air classification.
ISO 8573-1 applies to compressed air. ISO 14644-1 addresses classification of air cleanliness in cleanrooms and associated controlled environments based on airborne particle concentration. These classifications are not interchangeable.
A cleanroom may have a defined airborne particle classification, but that classification does not automatically establish the purity of compressed air delivered through a pneumatic line.
Similarly, a compressed-air system meeting a selected ISO 8573-1 designation does not establish that the surrounding cleanroom meets its required classification.
Compressed air released inside a cleanroom
Where compressed air is released into a controlled environment, the manufacturer should assess whether the discharge could introduce particles, oil aerosols, moisture or microorganisms into the room.
The assessment should consider the discharge location, air flow, duration of use, proximity to exposed product and the potential impact on environmental controls.
The compressed-air specification and the cleanroom environmental controls should be addressed separately and then evaluated together as part of the overall contamination-control strategy.
Compressed air used near exposed sterile components
Where components are exposed before sterilization, sterile barrier formation or another critical manufacturing step, compressed-air contamination may affect the condition of the components.
The risk assessment should consider whether non-viable particles, oil residues or microorganisms could remain on the product and whether the subsequent process adequately controls the identified hazards.
A requirement for a low particle count should not be treated as proof of microbiological suitability.
Compressed air used in controlled assembly or packaging areas
Air used to actuate equipment in a packaging or assembly area may have different requirements from air blown directly onto a component or into an internal pathway.
The distinction depends on the credible contamination pathway and the impact of the air on product quality. The room&#039;s classification alone is not sufficient to determine the required ISO 8573-1 class.
Viable and non-viable contamination: two different control objectives
Medical device and IVD manufacturers should distinguish between the control of physical contaminants and the control of viable microbiological contaminants.

AttributeNon-viable contaminationViable microbiological contamination
ExamplesSolid particles, liquid droplets, oil residuesViable bacteria, fungi and other recoverable microorganisms
Main concernPhysical contamination, residues, blockage, surface or process effectsMicrobiological contamination of a product or process
ISO 8573 referenceRelevant particle, water and oil classes in Part 1Part 7 provides a test method for viable microbiological contamination
Typical measurementParticle concentration, water parameters and oil content, as applicableMicrobiological sampling and results expressed as CFU/m³, where appropriate
Specification basisIntended process, product characteristics and contamination riskIntended process, microbiological risk and applicable requirements
Key limitationA particle count does not establish microbiological cleanlinessA microbial result does not establish compliance with particle, water or oil requirements

ISO 8573-1 does not provide a universal microbiological purity class. ISO 8573-7 specifies a method for determining viable microbiological contamination in compressed air.
A manufacturer should therefore define viable microbial acceptance criteria separately wherever microbiological contamination is a relevant risk.
Is a microbial test required for every compressed-air outlet?
Not necessarily. The need for microbial testing should be justified by the application and risk assessment.
Testing may be particularly relevant where compressed air directly contacts a product, an internal fluid pathway or a surface with critical microbiological requirements.
It may also be relevant where air is used in a process in which microbial contamination could compromise a subsequent manufacturing or sterilization step.
For general pneumatic equipment with no credible route to product contamination, routine microbial testing may not be justified. This decision should be documented rather than assumed.
8.2 Does a microbiological test replace particle testing?
No. Viable and non-viable contamination represent different quality attributes.
A system can meet a defined microbial criterion and still contain unacceptable particles, oil or moisture. Conversely, a low particle count does not prove that the air is microbiologically suitable.
Both sets of requirements should be addressed where the application requires them.
How should a manufacturer select the required class for each application?
A practical assessment should begin with the application rather than a preselected purity class.
Step 1 — Map the compressed-air users.
Identify each point of use, the equipment supplied, the manufacturing operation and whether the air contacts the product or its environment.
Step 2 — Determine the contamination pathway.
Assess whether particles, water, oil, chemicals or microorganisms could reach the product or affect a critical process characteristic.
Step 3 — Define the required attributes.
Determine which ISO 8573-1 classes are needed and whether additional limits for viable contamination, gases, chemical residues or other process-specific attributes are necessary.
Step 4 — Establish the acceptance criteria.
Document the maximum permissible levels, test methods, sampling conditions, measurement units and applicable reference conditions.
Step 5 — Establish the treatment and distribution requirements.
Select the compressor technology, dryers, filtration stages, distribution materials and point-of-use controls appropriate to the defined requirements.
Step 6 — Verify the delivered air quality.
Demonstrate compliance at representative points of use under suitable operating conditions. Use methods appropriate to each contaminant and its specified acceptance limit.
Step 7 — Maintain the approved state.
Define monitoring frequency, preventive maintenance, investigation criteria and the conditions that trigger additional testing or requalification.
This process creates a traceable connection between the intended use of compressed air, the contamination risks, the selected class and the evidence used to demonstrate compliance.
Verification and ongoing monitoring
Selecting a class does not demonstrate that the compressed-air system consistently meets that class. The manufacturer should establish appropriate verification and maintenance controls.
A verification programme may include:
Particle measurement using the applicable test method.Measurement of pressure dew point or other relevant water parameters.Assessment of oil aerosol, vapour and total oil as applicable.Gaseous contaminant testing where identified as relevant.Viable microbiological testing where justified.Assessment of sampling locations and operating conditions.Review of test results, deviations and adverse trends.Reassessment following significant changes to equipment, filters, dryers, piping or points of use.
The relevant parts of the ISO 8573 series provide test methods for specific contaminant categories. The method must be appropriate for the actual parameter and the required class.
Testing should be planned so that the evidence demonstrates the air quality required by the process—not merely the performance of an individual filter or the manufacturer&#039;s nominal equipment rating.
Practical example: compressed air used to purge an IVD cartridge
Consider an IVD manufacturer that uses compressed air to purge an internal channel before cartridge assembly.
The air directly enters a pathway that will subsequently carry a reagent or patient sample. The manufacturer should assess:
Whether particles could remain in the channel and obstruct fluid movement.Whether oil residues could alter the surface or affect the movement of fluid.Whether moisture could interfere with subsequent processing or reagent performance.Whether viable microorganisms or other contaminants could affect the intended use.Whether downstream manufacturing steps can detect or control the identified risks.
The manufacturer would then establish the required particle, water and oil classes, define additional microbial or chemical limits if necessary, and verify the air quality at the point of use.
The selected classes should be supported by documented technical justification. There is no single ISO 8573-1 designation that can be assumed suitable for every IVD cartridge or fluid pathway.
Related standards and their roles
The following standards can support the overall assessment, depending on the application.

StandardRelevance
ISO 8573-1Defines compressed-air purity classes for particles, water and oil
ISO 8573-2Test methods for oil aerosol content
ISO 8573-3Test methods for humidity measurement
ISO 8573-4Test methods for solid particle content
ISO 8573-5Test methods for oil vapour and organic solvent content
ISO 8573-6Test methods for gaseous contaminant content
ISO 8573-7Test method for viable microbiological contaminant content
ISO 8573-8Test methods for solid particle content by mass concentration
ISO 8573-9Test methods for liquid water content
ISO 14644-1Classification of cleanroom air cleanliness by airborne particle concentration

The standards serve different purposes. Their use should be determined by the applicable requirements and the manufacturer&#039;s documented assessment.
For medical device and IVD manufacturers, ISO 8573-1:2010 provides a structured way to define compressed-air purity requirements. Its designation system enables separate requirements for particles, water and oil to be communicated and verified.
However, an ISO 8573-1 designation should not be treated as a complete contamination-control specification for every manufacturing application. Direct product contact, cleanroom discharge, exposed components, sterile device processing and IVD fluid pathways may introduce additional requirements that must be addressed through risk assessment.
Viable microbiological contamination must be considered separately from non-viable particles, and compressed-air purity must remain distinct from cleanroom classification.
The objective is to establish a justified specification for each relevant point of use, verify compliance using suitable test methods, and maintain evidence that the required quality is consistently achieved.











  
    !
    
      Key Takeaways
      Three important points to check when specifying compressed-air purity.
    
  

  
    
      01
      “Oil-free” does not automatically mean Class 0
      Some compressor manufacturers claim that air delivered by an oil-free compressor complies with Class 0. This claim can be misleading if it is not supported by clear limits and evidence. Ask for the specified contamination limits and supporting test details.
    

    
      02
      Class 0 must be maintained across the system
      Even when a compressor delivers air intended to meet Class 0, purification equipment may still be needed in the compressor plant room and at the point of use. The required purity must be maintained where the air is actually used.
    

    
      03
      Specify purity according to the application
      Critical applications such as breathing air, medical, and food-related uses are often cited as requiring air quality around the following designations:
      Class 2.2.1
      Class 2.1.1
      Confirm the required class against the applicable regulations, process risks, and intended use rather than assuming one designation fits every application.
    
  

  Practical reminder: A purity designation should be supported by a defined specification and suitable evidence. Assess the air quality at relevant points of use, not only at the compressor outlet.


  📢 This article was originally published on 
  
    Medical Device Regulatory | Science Arena
   – Your hub for global compliance insights.
 ]]></description>
<enclosure url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh7Blc9QGZvITzJ6ApGB7JMtUPqeopCNBQAIJAa_on6Z0NNgXQyBmsWBJxW-4vgRoKKAe9pwx3pBiavscNCNqc1wDTmKv1Er9joB-WFHE4otGXFYBoJ_RJGKGY_l4kdb6R5Gk-VoH4nAXPw86uYnBF9N5ECXti8CuoF5n87QafgFGvUCdvokf7KakDgQBjF/w1600/image.png" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 02:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Medical, Device, and, IVD, Manufacturing:, Compressed, Air, Quality, Applications, and, Compliance, Considerations</media:keywords>
<content:encoded><![CDATA[<!--Blogger post HTML: paste into Blogger editor in HTML view. Styles are scoped to #iso-air-article.-->



<div class="iso-air-article">
<p>Compressed air is widely used throughout medical device and In Vitro Diagnostic (IVD) manufacturing facilities. Applications range from operating pneumatic equipment to drying components, purging fluid pathways, cleaning selected surfaces, assisting assembly, and supporting automated production processes.</p>
<p>However, compressed air is not inherently clean simply because it has been compressed, filtered or supplied through a dedicated utility system.</p>
<p>It can contain solid particles, moisture, oil aerosols, oil vapour, gaseous contaminants and microbiological contamination. Depending on the application, these contaminants may affect product cleanliness, material properties, fluid flow, manufacturing consistency, or the microbiological condition of a product-contact surface.</p>
<p>ISO 8573-1, Compressed air — Part 1: Contaminants and purity classes, provides a framework for specifying compressed-air purity according to three principal contaminant categories: particles, water and oil. It also addresses gaseous and microbiological contaminants as additional considerations.</p>
<p>For medical device and IVD manufacturers, the critical question is not simply which compressed-air class is the cleanest. It is:</p>
<p>What level of compressed-air purity is required for each application, how should that requirement be designated, and how can the manufacturer demonstrate that the required quality is consistently achieved at the point of use?</p>
<p>This article explains how to apply the classification system and develop appropriate requirements for product-contact applications, cleanrooms, sterile manufacturing environments, and IVD processes.</p>
<h2>Understanding the ISO 8573-1:2010 classification system</h2>
<p>ISO 8573-1:2010 establishes purity classes for three principal contaminant categories.</p>
<div class="iso-air-table-scroll"><table class="iso-air-table"><tbody>
<tr><th>Designation position</th><th>Contaminant category</th><th>What it addresses</th></tr>
<tr><td>First number</td><td>Solid particles</td><td>Particle concentration and particle-size ranges, or mass concentration where applicable</td></tr>
<tr><td>Second number</td><td>Water</td><td>Humidity/pressure dew point and liquid-water content</td></tr>
<tr><td>Third number</td><td>Oil</td><td>Total oil content, including the applicable liquid, aerosol and vapour forms</td></tr>
</tbody></table></div>
<p><strong>The general designation is:</strong></p>
<p>ISO 8573-1:2010 [A:B]</p>
<p><strong>Where:</strong></p>
<ul><li>A is the particle purity class.</li><li>B is the water purity class.</li><li>C is the oil purity class.</li></ul>
<p>Each number represents a separate requirement. The three numbers are not an average, a single cleanliness score, or a cleanroom grade.</p>
<p><strong>For example:</strong></p>
<p>ISO 8573-1:2010 [1:2:1]</p>
<p><strong>This means:</strong></p>
<ul><li>Particle purity: Class 1.</li><li>Water purity: Class 2.</li><li>Oil purity: Class 1.</li></ul>
<p>The classification must be interpreted against the applicable limits in the standard. A requirement should also identify the measurement location and any additional parameters necessary for the intended process.</p><p></p><div class="separator"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh7Blc9QGZvITzJ6ApGB7JMtUPqeopCNBQAIJAa_on6Z0NNgXQyBmsWBJxW-4vgRoKKAe9pwx3pBiavscNCNqc1wDTmKv1Er9joB-WFHE4otGXFYBoJ_RJGKGY_l4kdb6R5Gk-VoH4nAXPw86uYnBF9N5ECXti8CuoF5n87QafgFGvUCdvokf7KakDgQBjF/s1600/image.png"><img alt="" data-original-height="561" data-original-width="910" height="394" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh7Blc9QGZvITzJ6ApGB7JMtUPqeopCNBQAIJAa_on6Z0NNgXQyBmsWBJxW-4vgRoKKAe9pwx3pBiavscNCNqc1wDTmKv1Er9joB-WFHE4otGXFYBoJ_RJGKGY_l4kdb6R5Gk-VoH4nAXPw86uYnBF9N5ECXti8CuoF5n87QafgFGvUCdvokf7KakDgQBjF/w640-h394/image.png" width="640"></a></div><br>The same designation can be applied at different locations in a compressed-air system, but compliance at one location does not automatically demonstrate compliance at every other location.<p></p>
<h2>How are the purity classes determined?</h2>
<h3>Particle purity classes</h3>
<p>Particle classification considers the concentration of solid particles within specified particle-size ranges.</p>
<p>For classes 1 to 5, the particle-number limits in ISO 8573-1:2010 are expressed in terms of particles per cubic metre.</p>
<p>The following table summarizes the particle-number criteria for these classes.</p>
<div class="iso-air-table-scroll"><table class="iso-air-table"><tbody>
<tr><th>Particle class</th><th>0.1 to 0.5 µm</th><th>0.5 to 1.0 µm</th><th>1.0 to 5.0 µm</th></tr>
<tr><td>Class 1</td><td>≤ 20,000</td><td>≤ 400</td><td>≤ 10</td></tr>
<tr><td>Class 2</td><td>≤ 400,000</td><td>≤ 6,000</td><td>≤ 100</td></tr>
<tr><td>Class 3</td><td>Not specified</td><td>≤ 90,000</td><td>≤ 1,000</td></tr>
<tr><td>Class 4</td><td>Not specified</td><td>Not specified</td><td>≤ 10,000</td></tr>
<tr><td>Class 5</td><td>Not specified</td><td>Not specified</td><td>≤ 100,000</td></tr>
</tbody></table></div>
<p>Particle concentration limits are per cubic metre of compressed air. “Not specified” means that the corresponding size range is not assigned a limit by that class criterion; it does not mean that particles are absent.</p>
<p>Classes 6 and 7 use mass-concentration criteria rather than the particle-number criteria shown above. They should be interpreted using the relevant provisions of the standard.</p>
<h4>Application to medical devices and IVDs</h4>
<p>Particle classification becomes particularly important when compressed air is used to:</p>
<ul><li>Blow or dry components before assembly.</li><li>Purge internal device passages or IVD fluidic channels.</li><li>Contact exposed product-contact surfaces.</li><li>Operate in proximity to exposed sterile components.</li><li>Support precision assembly, dispensing or sensitive analytical processes.</li></ul>
<p>The required particle class should reflect the consequence of contamination. For example, a particle introduced into a narrow IVD fluid pathway may affect flow or reagent delivery, while a particle deposited on a component intended for a critical bonding operation may affect bond integrity.</p>
<p>The particle class alone does not establish that a component is microbiologically clean or that its surface is suitable for its intended use.</p>
<h3>Water purity classes</h3>
<p>Water classification considers pressure dew point and, for the relevant classes, liquid-water content.</p>
<p>For classes 1 to 6, the principal pressure-dew-point criteria are:</p>
<div class="iso-air-table-scroll"><table class="iso-air-table"><tbody>
<tr><th>Water class</th><th>Maximum pressure dew point</th></tr>
<tr><td>Class 1</td><td>≤ −70 °C</td></tr>
<tr><td>Class 2</td><td>≤ −40 °C</td></tr>
<tr><td>Class 3</td><td>≤ −20 °C</td></tr>
<tr><td>Class 4</td><td>≤ +3 °C</td></tr>
<tr><td>Class 5</td><td>≤ +7 °C</td></tr>
<tr><td>Class 6</td><td>≤ +10 °C</td></tr>
</tbody></table></div>
<p>Classes 7 to 9 address liquid-water concentration, while Class X represents contamination exceeding the Class 9 limit or otherwise requiring the specified X-class designation.</p>
<h4>Application to medical devices and IVDs</h4>
<p>Water requirements should be evaluated where compressed air is used for:</p>
<ul><li>Drying components or assemblies.</li><li>Purging internal passages.</li><li>Supporting processes sensitive to moisture.</li><li>Operating pneumatic equipment where condensation could affect performance.</li><li>Supplying air to locations where moisture could contribute to corrosion or contamination.</li></ul>
<p>A low pressure dew point does not establish that liquid water, particles, oil or microorganisms are absent under every operating condition. These are separate aspects of the specification and system performance.</p>
<h3>Oil purity classes</h3>
<p>Oil classification addresses total oil content within the scope of the standard, including the applicable liquid, aerosol and vapour forms.</p>
<div class="iso-air-table-scroll"><table class="iso-air-table"><tbody>
<tr><th>Oil class</th><th>Maximum total oil concentration</th></tr>
<tr><td>Class 1</td><td>≤ 0.01 mg/m³</td></tr>
<tr><td>Class 2</td><td>≤ 0.1 mg/m³</td></tr>
<tr><td>Class 3</td><td>≤ 1 mg/m³</td></tr>
<tr><td>Class 4</td><td>≤ 5 mg/m³</td></tr>
</tbody></table></div>
<p>Class 0 is a specially defined class requiring a documented contamination limit that is more stringent than Class 1. It does not mean zero oil or zero contamination.</p>
<p>Class 0 should not be specified without defining the agreed maximum allowable concentration and the method by which compliance will be demonstrated.</p>
<h4>Application to medical devices and IVDs</h4>
<p>Oil contamination may be relevant when compressed air contacts:</p>
<ul><li>Surfaces intended for bonding or coating.</li><li>Components that will subsequently contact medicines, biological materials, reagents or patient samples.</li><li>Internal fluid pathways.</li><li>Components intended for sterilization or other controlled processing.</li><li>Sensitive optical, analytical or precision assemblies.</li></ul>
<p>An oil-free compressor may reduce one source of contamination, but it does not independently prove that the air delivered at the point of use meets the specified oil class.</p>
<p>The class limits above are a summary of ISO 8573-1:2010. Consult the full standard for the complete classification criteria, reference conditions and designation requirements.</p>
<h3>Quick reference: ISO 8573-1:2010 compressed-air purity classes</h3><p>The following consolidated table is a simplified reference view of particle, water and oil class criteria. Use the applicable clauses and tables in the full standard when establishing specifications.</p>
<div class="iso-air-table-scroll">
<table class="iso-air-table iso-air-classes">
<thead>
<tr><th rowspan="2">Purity Class</th><th colspan="4">Solid Particles</th><th colspan="2">Water</th><th colspan="3">Oil</th></tr>
<tr><th>0.1–0.5 µm particles/m³</th><th>0.5–1.0 µm particles/m³</th><th>1.0–5.0 µm particles/m³</th><th>Mass mg/m³</th><th>Pressure dew point °C</th><th>Liquid water g/m³</th><th>Liquid oil mg/m³</th><th>Oil aerosol mg/m³</th><th>Total oil mg/m³</th></tr>
</thead>
<tbody>
<tr class="iso-air-class-zero"><td>Class 0</td><td colspan="9">As specified by the equipment user or supplier and more stringent to Class 1.</td></tr>
<tr><td>Class 1</td><td>≤20,000</td><td>≤400</td><td>≤10</td><td>—</td><td>≤−70</td><td>—</td><td colspan="2">—</td><td>≤0.01</td></tr>
<tr><td>Class 2</td><td>≤400,000</td><td>≤6,000</td><td>≤100</td><td>—</td><td>≤−40</td><td>—</td><td colspan="2">—</td><td>≤0.1</td></tr>
<tr><td>Class 3</td><td>—</td><td>≤90,000</td><td>≤1,000</td><td>—</td><td>≤−20</td><td>—</td><td colspan="2">—</td><td>≤1</td></tr>
<tr><td>Class 4</td><td>—</td><td>—</td><td>≤10,000</td><td>—</td><td>≤+3</td><td>—</td><td colspan="2">—</td><td>≤5</td></tr>
<tr><td>Class 5</td><td>—</td><td>—</td><td>≤100,000</td><td>—</td><td>≤+7</td><td>—</td><td colspan="3">Not specified by this class</td></tr>
<tr><td>Class 6</td><td colspan="3">—</td><td>≤5</td><td>≤+10</td><td>—</td><td colspan="3">Not specified by this class</td></tr>
<tr><td>Class 7</td><td colspan="3">—</td><td>>5 to ≤10</td><td>—</td><td>≤0.5</td><td colspan="3">Not specified by this class</td></tr>
<tr><td>Class 8</td><td colspan="4">—</td><td>—</td><td>>0.5 to ≤5</td><td colspan="3">Not specified by this class</td></tr>
<tr><td>Class 9</td><td colspan="4">—</td><td>—</td><td>>5 to ≤10</td><td colspan="3">Not specified by this class</td></tr>
<tr><td>Class X</td><td colspan="4">Outside the applicable specified limits</td><td colspan="2">Outside the applicable specified limits</td><td colspan="3">Outside the applicable specified limits</td></tr>
</tbody>
</table>
</div>
<p class="iso-air-note"><strong>Important:</strong> A dash means that the corresponding criterion is not specified in this simplified presentation; it does not mean zero contamination.</p>

<h2>How should a manufacturer designate compressed-air purity?</h2>
<p>A compressed-air specification should be written so that engineering, quality assurance, production and the testing laboratory can interpret the same requirement without ambiguity.</p>
<p>Example 1: Different classes for different contaminants</p>
<p>A manufacturer determines that the required specification for a particular application is:</p>
<p>ISO 8573-1:2010 [2:2:1]</p>
<p>This designates particle Class 2, water Class 2 and oil Class 1.</p>
<p>The manufacturer must then identify the applicable acceptance criteria, test methods, sampling location and monitoring arrangements.</p>
<p>This example illustrates designation only. It is not a universal recommendation for medical device or IVD production.</p>
<p>Example 2: Unspecified contaminant category</p>
<p>Where a class for one of the three principal contaminant categories is not specified, a hyphen is used.</p>
<p><strong>For example:</strong></p>
<p>ISO 8573-1:2010 [1:−:1]</p>
<p>This specifies particle Class 1 and oil Class 1, without specifying a water class.</p>
<p>For a medical device process, leaving a category unspecified should be a deliberate and documented decision. It should not be used merely because the corresponding parameter has not yet been assessed.</p>
<p>Example 3: Class 0 specification</p>
<p>A Class 0 designation requires a specific, documented limit more stringent than Class 1 for the relevant contaminant.</p>
<p>The manufacturer should state the agreed limit, unit of measurement, relevant test method and acceptance criteria. Writing “Class 0” alone is insufficient to define the actual requirement.</p>
<p>Example 4: Additional microbiological or gaseous requirements</p>
<p>The three-number designation does not communicate a viable microbial limit.</p>
<p>Where microbiological contamination is relevant, the specification should include a separate requirement measured using the applicable method, such as ISO 8573-7 for viable microbiological contamination.</p>
<p>For example, a manufacturer might specify:</p>
<ul><li>Compressed-air purity: ISO 8573-1:2010 [2:2:1].</li><li>Viable microbiological contamination: a separately defined maximum in CFU/m³.</li><li>Additional chemical or gaseous limits, where justified by the application.</li></ul>
<p>The microbial limit must be established by the manufacturer based on the process and its risk assessment; the example does not imply a universal acceptance limit.</p>
<h2>Applying ISO 8573-1 to medical device and IVD manufacturing areas</h2>
<p>The purity class should be established for the intended use of the air, not assigned solely on the basis of the room classification.</p>
<p>The following table provides a practical starting point for application assessment.</p>
<div class="iso-air-table-scroll"><table class="iso-air-table"><tbody>
<tr><th>Manufacturing application</th><th>Principal considerations</th><th>Specification approach</th></tr>
<tr><td>General pneumatic equipment outside product-critical operations</td><td>Equipment reliability, moisture, oil and particulate contamination</td><td>Establish the class required by the equipment and process risk</td></tr>
<tr><td>Component drying before assembly</td><td>Particles, oil residues, moisture and potential recontamination</td><td>Define the three-number purity class and any additional surface or microbial requirements</td></tr>
<tr><td>Direct contact with device components</td><td>Contaminants remaining on product-contact surfaces</td><td>Establish a risk-based purity class and verify air quality at the point of use</td></tr>
<tr><td>Purging internal passages or fluidic channels</td><td>Particles, oil, moisture and microbiological contamination where relevant</td><td>Define specific acceptance criteria for the internal pathway and intended product use</td></tr>
<tr><td>Handling exposed components in a controlled cleanroom</td><td>Air quality at the outlet, introduction of contamination and impact on the controlled environment</td><td>Specify compressed-air purity separately from cleanroom classification</td></tr>
<tr><td>Manufacturing of sterile devices before sterilization</td><td>Product cleanliness, residues, particles and process-specific microbial risks</td><td>Establish requirements appropriate to the product and subsequent validated processes</td></tr>
<tr><td>Processes affecting IVD reagents or patient-sample pathways</td><td>Particles, oil, chemical contaminants and microbiological risks</td><td>Establish application-specific purity and contamination limits supported by technical assessment</td></tr>
</tbody></table></div>
<p>These are assessment categories, not prescribed ISO purity classes. The manufacturer must determine the actual specification for each application.</p>
<h2>Direct product-contact compressed air: what should be considered?</h2>
<p>Direct-contact compressed air requires particular attention because the air may introduce contamination onto the product or into a product-contact pathway.</p>
<p>The term direct contact should be defined according to the actual process. It can include air that touches a component, enters a fluid pathway, or contacts a surface that will subsequently contact a patient sample, reagent or other critical material.</p>
<p>The following questions should be addressed.</p>
<h3>What is the product-contact pathway?</h3>
<p>Determine whether compressed air contacts:</p>
<ul><li>The finished device.</li><li>An internal fluid pathway.</li><li>A surface that will contact a patient or sample.</li><li>A component that will subsequently be assembled into the device.</li><li>A surface that is intended to remain clean until sterilization or packaging.</li></ul>
<p>The answer determines which contamination hazards are relevant and what evidence is necessary.</p>
<h3>Could the air introduce non-viable contaminants?</h3>
<p>Non-viable contaminants include solid particles, liquid droplets, oil residues and other non-living material.</p>
<p>Depending on the application, these may cause:</p>
<ul><li>Physical blockage of a narrow passage.</li><li>Alteration of surface properties.</li><li>Interference with bonding or coating.</li><li>Residues that are difficult to remove.</li><li>Interference with the operation of a fluidic or analytical system.</li></ul>
<p>The manufacturer should define appropriate particle, oil and water limits and evaluate any additional chemical contaminants that could affect the product.</p>
<h3>Could the air introduce viable contaminants?</h3>
<p>Viable microbial contamination is a separate consideration. Depending on the application, microorganisms introduced through compressed air may affect a product's microbiological condition or compromise a contamination-control strategy.</p>
<p>The required microbial limit should be justified by the intended use, product characteristics, subsequent processing and risk assessment.</p>
<p>For devices intended to be sterile, a validated sterilization process does not automatically make uncontrolled contamination acceptable. Residues and particles may remain, and excessive or variable bioburden may affect process control.</p>
<h3>Where should the air be tested?</h3>
<p>The most relevant location is generally the point where the air is used or where its quality can affect the product.</p>
<p>A representative sampling plan should account for:</p>
<ul><li>The condition of the main compressed-air supply.</li><li>Downstream piping and treatment equipment.</li><li>Point-of-use filters and connections.</li><li>The operating conditions under which air is delivered.</li><li>Potential contamination introduced after central treatment.</li></ul>
<p>Testing at the compressor outlet alone may not establish the quality of the air reaching a critical manufacturing operation.</p>
<h2>Compressed air used in cleanrooms and controlled environments</h2>
<p>One of the most important distinctions for medical device and IVD manufacturers is the difference between compressed-air purity classification and cleanroom air classification.</p>
<p>ISO 8573-1 applies to compressed air. ISO 14644-1 addresses classification of air cleanliness in cleanrooms and associated controlled environments based on airborne particle concentration. These classifications are not interchangeable.</p>
<p>A cleanroom may have a defined airborne particle classification, but that classification does not automatically establish the purity of compressed air delivered through a pneumatic line.</p>
<p>Similarly, a compressed-air system meeting a selected ISO 8573-1 designation does not establish that the surrounding cleanroom meets its required classification.</p>
<h3>Compressed air released inside a cleanroom</h3>
<p>Where compressed air is released into a controlled environment, the manufacturer should assess whether the discharge could introduce particles, oil aerosols, moisture or microorganisms into the room.</p>
<p>The assessment should consider the discharge location, air flow, duration of use, proximity to exposed product and the potential impact on environmental controls.</p>
<p>The compressed-air specification and the cleanroom environmental controls should be addressed separately and then evaluated together as part of the overall contamination-control strategy.</p>
<h3>Compressed air used near exposed sterile components</h3>
<p>Where components are exposed before sterilization, sterile barrier formation or another critical manufacturing step, compressed-air contamination may affect the condition of the components.</p>
<p>The risk assessment should consider whether non-viable particles, oil residues or microorganisms could remain on the product and whether the subsequent process adequately controls the identified hazards.</p>
<p>A requirement for a low particle count should not be treated as proof of microbiological suitability.</p>
<h3>Compressed air used in controlled assembly or packaging areas</h3>
<p>Air used to actuate equipment in a packaging or assembly area may have different requirements from air blown directly onto a component or into an internal pathway.</p>
<p>The distinction depends on the credible contamination pathway and the impact of the air on product quality. The room's classification alone is not sufficient to determine the required ISO 8573-1 class.</p>
<h2>Viable and non-viable contamination: two different control objectives</h2>
<p>Medical device and IVD manufacturers should distinguish between the control of physical contaminants and the control of viable microbiological contaminants.</p>
<div class="iso-air-table-scroll"><table class="iso-air-table"><tbody>
<tr><th>Attribute</th><th>Non-viable contamination</th><th>Viable microbiological contamination</th></tr>
<tr><td>Examples</td><td>Solid particles, liquid droplets, oil residues</td><td>Viable bacteria, fungi and other recoverable microorganisms</td></tr>
<tr><td>Main concern</td><td>Physical contamination, residues, blockage, surface or process effects</td><td>Microbiological contamination of a product or process</td></tr>
<tr><td>ISO 8573 reference</td><td>Relevant particle, water and oil classes in Part 1</td><td>Part 7 provides a test method for viable microbiological contamination</td></tr>
<tr><td>Typical measurement</td><td>Particle concentration, water parameters and oil content, as applicable</td><td>Microbiological sampling and results expressed as CFU/m³, where appropriate</td></tr>
<tr><td>Specification basis</td><td>Intended process, product characteristics and contamination risk</td><td>Intended process, microbiological risk and applicable requirements</td></tr>
<tr><td>Key limitation</td><td>A particle count does not establish microbiological cleanliness</td><td>A microbial result does not establish compliance with particle, water or oil requirements</td></tr>
</tbody></table></div>
<p>ISO 8573-1 does not provide a universal microbiological purity class. ISO 8573-7 specifies a method for determining viable microbiological contamination in compressed air.</p>
<p>A manufacturer should therefore define viable microbial acceptance criteria separately wherever microbiological contamination is a relevant risk.</p>
<h3>Is a microbial test required for every compressed-air outlet?</h3>
<p>Not necessarily. The need for microbial testing should be justified by the application and risk assessment.</p>
<p>Testing may be particularly relevant where compressed air directly contacts a product, an internal fluid pathway or a surface with critical microbiological requirements.</p>
<p>It may also be relevant where air is used in a process in which microbial contamination could compromise a subsequent manufacturing or sterilization step.</p>
<p>For general pneumatic equipment with no credible route to product contamination, routine microbial testing may not be justified. This decision should be documented rather than assumed.</p>
<h3>8.2 Does a microbiological test replace particle testing?</h3>
<p>No. Viable and non-viable contamination represent different quality attributes.</p>
<p>A system can meet a defined microbial criterion and still contain unacceptable particles, oil or moisture. Conversely, a low particle count does not prove that the air is microbiologically suitable.</p>
<p>Both sets of requirements should be addressed where the application requires them.</p>
<h2>How should a manufacturer select the required class for each application?</h2>
<p>A practical assessment should begin with the application rather than a preselected purity class.</p>
<p><strong>Step 1 — Map the compressed-air users.</strong></p>
<p>Identify each point of use, the equipment supplied, the manufacturing operation and whether the air contacts the product or its environment.</p>
<p><strong>Step 2 — Determine the contamination pathway.</strong></p>
<p>Assess whether particles, water, oil, chemicals or microorganisms could reach the product or affect a critical process characteristic.</p>
<p><strong>Step 3 — Define the required attributes.</strong></p>
<p>Determine which ISO 8573-1 classes are needed and whether additional limits for viable contamination, gases, chemical residues or other process-specific attributes are necessary.</p>
<p><strong>Step 4 — Establish the acceptance criteria.</strong></p>
<p>Document the maximum permissible levels, test methods, sampling conditions, measurement units and applicable reference conditions.</p>
<p><strong>Step 5 — Establish the treatment and distribution requirements.</strong></p>
<p>Select the compressor technology, dryers, filtration stages, distribution materials and point-of-use controls appropriate to the defined requirements.</p>
<p><strong>Step 6 — Verify the delivered air quality.</strong></p>
<p>Demonstrate compliance at representative points of use under suitable operating conditions. Use methods appropriate to each contaminant and its specified acceptance limit.</p>
<p><strong>Step 7 — Maintain the approved state.</strong></p>
<p>Define monitoring frequency, preventive maintenance, investigation criteria and the conditions that trigger additional testing or requalification.</p>
<p>This process creates a traceable connection between the intended use of compressed air, the contamination risks, the selected class and the evidence used to demonstrate compliance.</p>
<h2>Verification and ongoing monitoring</h2>
<p>Selecting a class does not demonstrate that the compressed-air system consistently meets that class. The manufacturer should establish appropriate verification and maintenance controls.</p>
<p>A verification programme may include:</p>
<ul><li>Particle measurement using the applicable test method.</li><li>Measurement of pressure dew point or other relevant water parameters.</li><li>Assessment of oil aerosol, vapour and total oil as applicable.</li><li>Gaseous contaminant testing where identified as relevant.</li><li>Viable microbiological testing where justified.</li><li>Assessment of sampling locations and operating conditions.</li><li>Review of test results, deviations and adverse trends.</li><li>Reassessment following significant changes to equipment, filters, dryers, piping or points of use.</li></ul>
<p>The relevant parts of the ISO 8573 series provide test methods for specific contaminant categories. The method must be appropriate for the actual parameter and the required class.</p>
<p>Testing should be planned so that the evidence demonstrates the air quality required by the process—not merely the performance of an individual filter or the manufacturer's nominal equipment rating.</p>
<h2>Practical example: compressed air used to purge an IVD cartridge</h2>
<p>Consider an IVD manufacturer that uses compressed air to purge an internal channel before cartridge assembly.</p>
<p>The air directly enters a pathway that will subsequently carry a reagent or patient sample. The manufacturer should assess:</p>
<ul><li>Whether particles could remain in the channel and obstruct fluid movement.</li><li>Whether oil residues could alter the surface or affect the movement of fluid.</li><li>Whether moisture could interfere with subsequent processing or reagent performance.</li><li>Whether viable microorganisms or other contaminants could affect the intended use.</li><li>Whether downstream manufacturing steps can detect or control the identified risks.</li></ul>
<p>The manufacturer would then establish the required particle, water and oil classes, define additional microbial or chemical limits if necessary, and verify the air quality at the point of use.</p>
<p>The selected classes should be supported by documented technical justification. There is no single ISO 8573-1 designation that can be assumed suitable for every IVD cartridge or fluid pathway.</p>
<h2>Related standards and their roles</h2>
<p>The following standards can support the overall assessment, depending on the application.</p>
<div class="iso-air-table-scroll"><table class="iso-air-table"><tbody>
<tr><th>Standard</th><th>Relevance</th></tr>
<tr><td>ISO 8573-1</td><td>Defines compressed-air purity classes for particles, water and oil</td></tr>
<tr><td>ISO 8573-2</td><td>Test methods for oil aerosol content</td></tr>
<tr><td>ISO 8573-3</td><td>Test methods for humidity measurement</td></tr>
<tr><td>ISO 8573-4</td><td>Test methods for solid particle content</td></tr>
<tr><td>ISO 8573-5</td><td>Test methods for oil vapour and organic solvent content</td></tr>
<tr><td>ISO 8573-6</td><td>Test methods for gaseous contaminant content</td></tr>
<tr><td>ISO 8573-7</td><td>Test method for viable microbiological contaminant content</td></tr>
<tr><td>ISO 8573-8</td><td>Test methods for solid particle content by mass concentration</td></tr>
<tr><td>ISO 8573-9</td><td>Test methods for liquid water content</td></tr>
<tr><td>ISO 14644-1</td><td>Classification of cleanroom air cleanliness by airborne particle concentration</td></tr>
</tbody></table></div>
<p>The standards serve different purposes. Their use should be determined by the applicable requirements and the manufacturer's documented assessment.</p>
<p>For medical device and IVD manufacturers, ISO 8573-1:2010 provides a structured way to define compressed-air purity requirements. Its designation system enables separate requirements for particles, water and oil to be communicated and verified.</p>
<p>However, an ISO 8573-1 designation should not be treated as a complete contamination-control specification for every manufacturing application. Direct product contact, cleanroom discharge, exposed components, sterile device processing and IVD fluid pathways may introduce additional requirements that must be addressed through risk assessment.</p>
<p>Viable microbiological contamination must be considered separately from non-viable particles, and compressed-air purity must remain distinct from cleanroom classification.</p>
<p>The objective is to establish a justified specification for each relevant point of use, verify compliance using suitable test methods, and maintain evidence that the required quality is consistently achieved.</p>
</div>






<!-- Key Takeaways: Blogger-safe HTML block. Paste into Blogger post HTML view. -->


<section aria-label="Key takeaways on compressed-air purity">
  <div class="kta-heading">
    <span class="kta-heading-mark" aria-hidden="true">!</span>
    <div>
      <h2>Key Takeaways</h2>
      <p>Three important points to check when specifying compressed-air purity.</p>
    </div>
  </div>

  <div class="kta-grid">
    <article class="kta-card kta-caution">
      <span class="kta-number">01</span>
      <h3>“Oil-free” does not automatically mean Class 0</h3>
      <p>Some compressor manufacturers claim that air delivered by an oil-free compressor complies with <span class="kta-emphasis">Class 0</span>. This claim can be misleading if it is not supported by clear limits and evidence. <span class="kta-emphasis">Ask for the specified contamination limits and supporting test details.</span></p>
    </article>

    <article class="kta-card kta-maintain">
      <span class="kta-number">02</span>
      <h3>Class 0 must be maintained across the system</h3>
      <p>Even when a compressor delivers air intended to meet Class 0, purification equipment may still be needed in the compressor plant room and at the point of use. <span class="kta-emphasis">The required purity must be maintained where the air is actually used.</span></p>
    </article>

    <article class="kta-card">
      <span class="kta-number">03</span>
      <h3>Specify purity according to the application</h3>
      <p>Critical applications such as breathing air, medical, and food-related uses are often cited as requiring air quality around the following designations:</p>
      <span class="kta-class">Class 2.2.1</span>
      <span class="kta-class">Class 2.1.1</span>
      <p>Confirm the required class against the applicable regulations, process risks, and intended use rather than assuming one designation fits every application.</p>
    </article>
  </div>

  <p class="kta-footnote"><strong>Practical reminder:</strong> A purity designation should be supported by a defined specification and suitable evidence. Assess the air quality at relevant points of use, not only at the compressor outlet.</p>
</section>
<div class="blogger-post-footer"><p>
  📢 This article was originally published on 
  <a href="https://www.regulatorymedicaldevice.com/" target="_blank">
    Medical Device Regulatory | Science Arena
  </a> – Your hub for global compliance insights.
</p></div>]]> </content:encoded>
</item>

<item>
<title>Dr. Ryan Jay, DO, Joins Optima Dermatology’s Scarborough, ME Practice</title>
<link>https://edusehat.com/en/dr-ryan-jay-do-joins-optima-dermatologys-scarborough-me-practice</link>
<guid>https://edusehat.com/en/dr-ryan-jay-do-joins-optima-dermatologys-scarborough-me-practice</guid>
<description><![CDATA[ Dr. Ryan Offers Medical, Surgical, and Cosmetic Dermatology Services for Patients of All Ages  Board-certified dermatologist Dr. Ryan Jay, DO,…
The post Dr. Ryan Jay, DO, Joins Optima Dermatology’s Scarborough, ME Practice appeared first on Optima Dermatology. ]]></description>
<enclosure url="https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Meet-Ryan-Jay_4x5.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 26 Oct 2026 23:30:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Dr., Ryan, Jay, DO, Joins, Optima, Dermatology’s, Scarborough, Practice</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"><img decoding="async" width="1024" height="341" src="https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Meet-Ryan-Jay_Banner-1024x341.jpg" alt="" class="wp-image-205807" srcset="https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Meet-Ryan-Jay_Banner-1024x341.jpg 1024w, https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Meet-Ryan-Jay_Banner-300x100.jpg 300w, https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Meet-Ryan-Jay_Banner-768x256.jpg 768w, https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Meet-Ryan-Jay_Banner.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px"></figure>



<h2 class="wp-block-heading"><strong>Dr. Ryan Offers Medical, Surgical, and Cosmetic Dermatology Services for Patients of All Ages</strong> </h2>



<p class="wp-block-paragraph">Board-certified dermatologist <a href="https://optimadermatology.com/provider/ryan-jay-do" target="_blank" rel="noopener">Dr. Ryan Jay, DO</a>, is joining Optima Dermatology’s Scarborough, ME practice, where he will deliver expert skin care treatment to patients of all ages.  </p>



<p class="wp-block-paragraph">Dr. Jay treats a variety of skin conditions, including acne, eczema, psoriasis, hidradenitis suppurativa, and skin cancer, and has been providing clinical care to patients since 2016. </p>



<p class="wp-block-paragraph">After growing up in New York City, and completing his education in Columbus, Ohio, Dr. Jay settled in Portland, Maine with his partner where he is excited to join Optima Dermatology and continue serving patients with expert dermatology care.  </p>



<p class="wp-block-paragraph">In Ohio, Dr. Jay earned his Bachelor of Science in biology and Bachelor of Arts in French from Denison University in Granville, graduating magna cum laude and being inducted into Phi Beta Kappa, the oldest and most prestigious academic honor society in America. He then completed his residency in dermatology at OhioHealth Riverside Methodist Hospital, where he served as Chief Dermatology Resident and scored amongst the top of dermatology residents on board exams.  </p>



<p class="wp-block-paragraph">He went on to earn his Doctor of Osteopathic Medicine from Ohio University Heritage College of Osteopathic Medicine, where he led the top 10 percent of his class.  </p>



<p class="wp-block-paragraph">Throughout his career, Dr. Jay has contributed to numerous medical publications and has served in a variety of educational and teaching roles. He is a member of the American Academy of Dermatology, the Gay and Lesbian Dermatology Society, and the International Dermoscopy Society. </p>



<p class="wp-block-paragraph">Dr. Jay has an ongoing commitment to advancing medical education and patient care. He is passionate about giving back to the community and has served in numerous community volunteer roles.  </p>



<p class="wp-block-paragraph">We recently had the opportunity to learn more about Dr. Jay, his approach, and the path that led him to become a board-certified dermatologist. </p>



<hr class="wp-block-separator has-alpha-channel-opacity">



<h3 class="wp-block-heading"><strong>What made you decide to pursue a career in dermatology? What did the path to get there look like for you?</strong></h3>



<p class="wp-block-paragraph">My interest in dermatology started as a medical student when I first experienced a “Kodachrome Session”, in which dermatologists in training intricately described skin conditions with their unique language and listed several potential diagnoses just from looking at a photo. I had never experienced such a special skill in medicine! After further experience in the field with mentors, I loved the diversity of conditions, procedures you perform, and ages of patients you treat on a daily basis. A day in the dermatology office is never boring! The longitudinal relationships with patients and restoration of their confidence and quality of life has proven incredibly rewarding too. </p>



<p class="wp-block-paragraph">The path to becoming a dermatologist required tremendous dedication to studying, research, and procedural practice. Though I discovered my love for dermatology in the latter half of medical school, I quickly got involved with various research projects in the field and found mentors who taught me every aspect of dermatology. I then spent four amazing years in residency, where I learned dermatology from many different settings. This experience included numerous outpatient clinics, a busy resident clinic, hospital consults, and clinics and consults at one of the largest children’s hospitals in the country. Dermatology training also required learning how to diagnose everything under the microscope: dermatopathology. This field represents another unique factor I love about dermatology and sets us apart from other specialties. Now I couldn’t imagine myself doing any other career. I was fortunate to have incredible mentors in dermatology who paved the way for me, and I hope to do the same for aspiring dermatologists in the future. </p>



<h3 class="wp-block-heading"><strong>What is your favorite aspect of being a board-certified dermatologist?</strong> </h3>



<p class="wp-block-paragraph">I enjoy being able to use visual acumen and investigative skills to help diagnose and manage my patients’ skin conditions. It is such an intellectually stimulating field that always seeks to improve diagnostics and treatments with research! In addition, seeing patients develop confidence, agency, and a better quality of life as you help manage skin concerns is the most rewarding aspect of dermatology. </p>



<h3 class="wp-block-heading"><strong>What is your approach to treating your patients?</strong> </h3>



<p class="wp-block-paragraph">My approach centers around patients feeling as welcomed and comfortable as possible. Skin can be such a vulnerable topic for people, and I want to ensure that everyone feels safe expressing their concerns so they get the personalized care they need. </p>



<h3 class="wp-block-heading"><strong>What is your number one tip when it comes to taking care of your skin?</strong> </h3>



<p class="wp-block-paragraph">Daily sunscreen, a topical retinoid, and protective gloves when washing dishes (we don’t realize how much damage is done to our skin barrier from frequent hand washing!). Consistency is key too. </p>



<h3 class="wp-block-heading"><strong>What is one thing you want your patients to know about you?</strong> </h3>



<p class="wp-block-paragraph">I am a very warm and friendly person with a genuine interest in the personalized care of my patients. You will feel heard and welcomed in a way that makes you feel like you’re getting help from not only a doctor with attention to detail, but also a friend. </p>



<h3 class="wp-block-heading"><strong>What do you like to do when you are not in the office treating patients?</strong> </h3>



<p class="wp-block-paragraph">When I am not in the office, you will find me living and breathing anything related to food. My partner and I love to explore the diverse food scene of Portland and cook using local products when possible. We also love to travel around the country and world to explore other cultures, cuisines, and geographic landscapes. I try to stay active and enjoy running, playing tennis, hiking, doing peloton workouts, and exploring the water and winter activities of Maine. In terms of sports watching, we are an Arsenal F.C. household! Finally, I have rekindled my love for French (I was a French major in college and studied abroad in Aix-en-Provence) and hope to regain these language skills. </p>



<hr class="wp-block-separator has-alpha-channel-opacity">



<h2 class="wp-block-heading"><strong>What to Expect From Dr. Jay and His Team</strong> </h2>



<p class="wp-block-paragraph">Patients visiting Dr. Jay and his team at Optima Dermatology’s Scarborough practice will receive quality care backed by advanced training and experience. </p>



<p class="wp-block-paragraph">Dr. Jay is currently accepting new patients at our Scarborough, ME practice. To schedule an appointment, call 207-770-5621, or schedule an appointment <a href="https://s.odoro.com/optimaderm/" target="_blank" rel="noopener">online</a>.  </p>
<p>The post <a href="https://optimadermatology.com/2026/10/16/dr-ryan-jay-do-joins-optima-dermatologys-scarborough-me-practice">Dr. Ryan Jay, DO, Joins Optima Dermatology’s Scarborough, ME Practice</a> appeared first on <a href="https://optimadermatology.com/">Optima Dermatology</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New Weyburn General Hospital prepares to welcome patients November 1</title>
<link>https://edusehat.com/en/new-weyburn-general-hospital-prepares-to-welcome-patients-november-1</link>
<guid>https://edusehat.com/en/new-weyburn-general-hospital-prepares-to-welcome-patients-november-1</guid>
<description><![CDATA[ The $134-million-plus Saskatchewan hospital project brings acute care, mental health services and emergency treatment together under one roof. The new Weyburn General Hospital in southeastern Saskatchewan is preparing to welcome its first patients on November 1, following an official grand opening ceremony held October 23. The modern healthcare facility will provide expanded services for residents […]
The post New Weyburn General Hospital prepares to welcome patients November 1 appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Bright-Modern-Hospital-Room.png" length="49398" type="image/jpeg"/>
<pubDate>Mon, 26 Oct 2026 23:25:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, Weyburn, General, Hospital, prepares, welcome, patients, November</media:keywords>
<content:encoded><![CDATA[<p><em>The $134-million-plus Saskatchewan hospital project brings acute care, mental health services and emergency treatment together under one roof.</em></p>
<p>The new Weyburn General Hospital in southeastern Saskatchewan is preparing to welcome its first patients on November 1, following an official grand opening ceremony held October 23.</p>
<p>The modern healthcare facility will provide expanded services for residents of Weyburn and surrounding communities, with 25 private acute care rooms and 10 inpatient mental health beds. Each acute care room includes a ceiling lift and an accessible washroom designed to improve patient comfort and safety.</p>
<h3>Expanded emergency and surgical services</h3>
<p>The hospital features a larger emergency department with dedicated trauma care spaces, an advanced operating theatre, upgraded laboratory and medical imaging facilities, and expanded ambulatory and allied health services.</p>
<p>An onsite Emergency Medical Services base and heliport will also support emergency response and transfers of critically ill or injured patients requiring specialized treatment.</p>
<p>By bringing services together in one location, the Saskatchewan Health Authority aims to improve coordination among healthcare professionals while reducing the need for patients to travel between facilities.</p>
<h3>Major investment in regional healthcare</h3>
<p>The Government of Saskatchewan committed more than $134 million toward the hospital project, with additional funding for equipment, furnishings and capital costs provided through community donations and the Weyburn and District Hospital Foundation.</p>
<p>The new facility was designed to support the region’s healthcare needs while providing modern working environments for physicians, nurses and other healthcare professionals.</p>
<p>The hospital’s opening represents an important investment in rural and regional healthcare infrastructure, where access to specialized services and emergency treatment remains a priority.</p>
<p>With the official ceremony complete, healthcare teams are preparing for the transition to the new building ahead of its November 1 opening to patients.</p>
<p><strong>Source:</strong> <a href="https://www.saskatchewan.ca/government/news-and-media/2026/october/23/new-weyburn-general-hospital-celebrates-grand-opening">Government of Saskatchewan</a>, October 23, 2026.</p>
<p>The post <a href="https://www.hospitalnews.com/new-weyburn-general-hospital-prepares-to-welcome-patients-november-1/">New Weyburn General Hospital prepares to welcome patients November 1</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Proposed Rule from OMB Top Priority for “Lame Duck” Session</title>
<link>https://edusehat.com/en/proposed-rule-from-omb-top-priority-for-lame-duck-session</link>
<guid>https://edusehat.com/en/proposed-rule-from-omb-top-priority-for-lame-duck-session</guid>
<description><![CDATA[ Congress left Washington in September so members could campaign ahead of the midterm elections. Lawmakers will return November 9 for a “lame duck” session to complete work before adjourning and a top priority will be to address the proposed rule by the Office of Management and Budget (OMB) that would fundamentally change grant approval, research […]
The post Proposed Rule from OMB Top Priority for “Lame Duck” Session appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/USCapitol.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 26 Oct 2026 20:25:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Proposed, Rule, from, OMB, Top, Priority, for, “Lame, Duck”, Session</media:keywords>
<content:encoded><![CDATA[<p>Congress left Washington in September so members could campaign ahead of the midterm elections. Lawmakers will return November 9 for a “lame duck” session to complete work before adjourning and a top priority will be to address the proposed rule by the Office of Management and Budget (OMB) that would fundamentally change grant approval, research […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/proposed-rule-from-omb-top-priority-for-lame-duck-session/">Proposed Rule from OMB Top Priority for “Lame Duck” Session</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Patients or consumers: does commerce belong in dentistry?</title>
<link>https://edusehat.com/en/patients-or-consumers-does-commerce-belong-in-dentistry</link>
<guid>https://edusehat.com/en/patients-or-consumers-does-commerce-belong-in-dentistry</guid>
<description><![CDATA[ The CMA’s private dentistry market study has revived the debate about whether people attending practices are patients or consumers. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2024/09/nigel_jones.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 26 Oct 2026 16:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Patients, consumers:, does, commerce, belong, dentistry</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Nigel Jones considers what the CMA’s private dentistry market study adds to the debate about whether people accessing dentistry are patients or consumers.</strong></p>



<p>The debate about whether patients are consumers has been brought back into sharp focus by the Competition and Markets Authority (CMA) and its market study into private dentistry services in the UK. The update, published in July, refers to the CMA having heard from ‘1,825 consumers who had received private dental treatment in the UK in the last five years’, so it’s pretty clear where the CMA stands on the issue.</p>



<p>For many who consider the two terms interchangeable, it’s a semantic argument about an inevitable byproduct of the language of markets in healthcare. For others, there’s more to it than simply accepting that patient-centred care naturally leads to considering patients as customers.</p>



<p>On the strength of a Raj Rattan recommendation, I sought out <em>What Money Can’t Buy: The Moral Limits of Markets</em> by Michael J Sandel. Although contentious, you can’t help but come away from the book with misgivings about how market thinking can be misapplied in certain sectors. However, I can see how it can be helpful when trying to interpret some apparently contradictory observations on the state of the private dentistry market.</p>



<h2 class="wp-block-heading">Supply, demand and two private markets</h2>



<p>Take, for example, how the rule of supply and demand applies to private dentistry. On the one hand, some would say there is an imbalance due to widely acknowledged workforce shortages restricting supply while demand from an ageing and image-conscious public shows little sign of abating. ‘Not enough dentists’ is the refrain we’ve heard from organisations such as the British Dental Association (BDA) and Association of Dental Groups (ADG) throughout the past few years.</p>



<p>On the other hand, we have this quote from one of the submissions to the CMA: ‘Private dentistry is competitive especially as now more and more practices are leaving the NHS. This makes growth and patient retention more difficult as there is more choice for patients.’</p>



<p>At first glance, it might seem hard to reconcile the two views, but closer scrutiny is thought-provoking, particularly if one truly considers the differences between the market for general dentistry and that for cosmetic dentistry.</p>



<p>In the wake of COVID and the virtual world that emerged during lockdowns, we all became familiar with the term ‘zoom boom’ and how that drove demand for straighter, whiter teeth. The resulting commercial opportunities were embraced by many entrepreneurial dentists, and successful new business models emerged.</p>



<p>Roll on a few years, and we have a cosmetic dentistry market flooded with suppliers eager to replicate the success of the early adopters, but with patient demand that appears to be softening. In that context, the quote about a highly competitive market and lots of patient choice makes sense.</p>



<h2 class="wp-block-heading">So, what of private general dentistry? </h2>



<p>I would suggest that in this market the supply and demand imbalance continues to favour the profession. The supply of general dental services is under pressure from the trend towards part-time working, lower productivity prompted by the perceived risks of complaints and litigation, and the move towards private dentistry.</p>



<p>The latter is partly a reflection of clinical resources being diverted to focus on cosmetic dentistry and the desire to see fewer patients for longer appointment times. For many practitioners, it is simply a more sustainable, pleasant and rewarding way of earning a living.</p>



<p>Considered in this light, the two apparently opposing views on competition within dentistry start to make more sense. Different strategies are required to cultivate a thriving book of patients attending regularly for general dental care compared with generating a pipeline of people wanting to address a perceived aesthetic deficiency.</p>



<h2 class="wp-block-heading">Patients, consumers and trust</h2>



<p>So, are people visiting dental practices, patients or consumers? At least part of the answer lies within their motives for being there in the first place.</p>



<p>In other parts of healthcare, patients are often sick and vulnerable, so shopping around for the best deal may not be the priority. Dentistry differs because of its strong focus on prevention. Half the population attend a dental practice regularly for a health screening, for which most have to pay, and not because they feel ill.</p>



<p>However, the fact that an oral health screening may reveal a problem they were previously unaware of means the choice of clinician goes beyond normal consumer considerations. It’s not about convenient parking, impressive marketing or even price; it’s about trust, which is why recommendations from friends and family become important.</p>



<p>Contrast that with someone seeking a cosmetic solution to a problem they’ve self-diagnosed and a result they can visualise. The difference in the sense of empowerment must be significant and lend itself to more consumer-like behaviour, including being influenced by impressive marketing.</p>



<h2 class="wp-block-heading">What this means for practice strategy</h2>



<p>The differences between the general dentistry and cosmetic dentistry markets, both in terms of competition and patient behaviours, need to be reflected in business strategies. There are risks and benefits to having all your eggs in the cosmetic dentistry basket, while there can be missed opportunities within your cohort of regularly attending patients. Blending both together in a flexible way that can adapt to a constantly changing environment will be key.</p>



<p>Whether attendees at a dental practice are patients or consumers raises some interesting commercial considerations alongside very important ethical considerations. Perhaps the CMA will clarify matters.</p>



<p>Practice Plan has been welcoming practices into the family since 1995, helping them to grow profitable businesses through the introduction of <a href="https://www.practiceplan.co.uk/benefits-of-a-membership-plan/">practice-branded membership plans</a>. If you’re looking for a provider to be by your side through a safe move from NHS to private then, with over 300 years’ dental experience in our field team, you’re in safe hands with Practice Plan… Be Practice Plan and get in touch.</p>



<p>Call <a href="tel://01691">01691 684165</a> or visit <a href="http://www.practiceplan.co.uk/be-practice-plan/" target="_blank" rel="noreferrer noopener">www.practiceplan.co.uk/be-practice-plan/</a>.</p>



<p><em>This article is sponsored by Practice Plan.</em></p>


        <div class="">
            <div class="text-context-white p-8 md:p-12 xl:p-20 bg-black">
                <div class="flex flex-wrap justify-center -mx-4">
                                            <div class="px-4 w-full lg:w-7/8 flex flex-col justify-start">
                                                                        <div class="font-yellow font-bold text-2xl md:text-3xl xl:text-4xl mb-4">
                                Ready to talk?                            </div>
                                                                            <div class="text-context-white/75 mb-4">
                                <p>If you’re ready for a confidential discussion with Practice Plan about the next steps in converting to private dentistry, leave your details below.</p>
                            </div>
                                                                            <div class="wpforms-design-block-form">
                                <div class="wpforms-container wpforms-container-full">Please enable JavaScript in your browser to complete this form.<div class="wpforms-field-container">		<div class="wpforms-field wpforms-field-text" data-field-type="text" data-field-id="3">
			<label class="wpforms-field-label" for="wpforms-424415-field_3">Email Name Phone</label>
			
		</div>
		<div class="wpforms-field wpforms-field-layout" data-field-id="7"><div class="wpforms-field-layout-rows wpforms-field-large"><div class="wpforms-layout-row"><div class="wpforms-layout-column wpforms-layout-column-25"><div class="wpforms-field wpforms-field-text" data-field-id="1"><label class="wpforms-field-label" for="wpforms-424415-field_1">Name <span class="wpforms-required-label">*</span></label></div></div><div class="wpforms-layout-column wpforms-layout-column-25"><div class="wpforms-field wpforms-field-email" data-field-id="2"><label class="wpforms-field-label" for="wpforms-424415-field_2">Email <span class="wpforms-required-label">*</span></label></div></div><div class="wpforms-layout-column wpforms-layout-column-25"><div class="wpforms-field wpforms-field-text" data-field-id="8"><label class="wpforms-field-label" for="wpforms-424415-field_8">Phone <span class="wpforms-required-label">*</span></label></div></div><div class="wpforms-layout-column wpforms-layout-column-25"></div></div><div class="wpforms-layout-row"><div class="wpforms-layout-column wpforms-layout-column-25"><div class="wpforms-field wpforms-field-text" data-field-id="5"><label class="wpforms-field-label" for="wpforms-424415-field_5">Practice name <span class="wpforms-required-label">*</span></label></div></div><div class="wpforms-layout-column wpforms-layout-column-25"><div class="wpforms-field wpforms-field-text" data-field-id="6"><label class="wpforms-field-label" for="wpforms-424415-field_6">Practice postcode <span class="wpforms-required-label">*</span></label></div></div><div class="wpforms-layout-column wpforms-layout-column-25"></div><div class="wpforms-layout-column wpforms-layout-column-25"></div></div></div></div><div class="wpforms-field wpforms-field-checkbox" data-field-id="9"><label class="wpforms-field-label">Want to hear more from Practice Plan?</label><ul><li class="choice-1 depth-1"><label class="wpforms-field-label-inline" for="wpforms-424415-field_9_1">I agree to receive marketing communication from Practice Plan, including valuable insights, inspiring stories and practical tips.   <a rel="noopener noreferrer" target="_blank" href="https://www.practiceplan.co.uk/privacy-notice/?utm_source=https://dentistry.co.uk/nhs-to-private/&utm_medium=referral&utm_campaign=privacypolicynhstopriv">View their privacy policy.</a>.</label></li></ul></div></div><!-- .wpforms-field-container --><div class="wpforms-submit-container"><button type="submit" name="wpforms[submit]" class="wpforms-submit" data-alt-text="Sending..." data-submit-text="Submit" aria-live="assertive" value="wpforms-submit">Submit</button></div></div>  <!-- .wpforms-container -->                            </div>
                                            </div>
                                    </div>
            </div>
        </div>]]> </content:encoded>
</item>

<item>
<title>Why CPD is essential for dentists and DCPs – and how Professional Conferences can support you</title>
<link>https://edusehat.com/en/why-cpd-is-essential-for-dentists-and-dcps-and-how-professional-conferences-can-support-you</link>
<guid>https://edusehat.com/en/why-cpd-is-essential-for-dentists-and-dcps-and-how-professional-conferences-can-support-you</guid>
<description><![CDATA[ CPD helps dentists and DCPs stay current with GDC guidance, maintain practical skills and plan relevant professional development. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/cpd-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 26 Oct 2026 16:25:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Why, CPD, essential, for, dentists, and, DCPs, –, and, how, Professional, Conferences, can, support, you</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Continuing professional development (CPD) is essential for dental professionals, but it should be about much more than simply accumulating hours to meet regulatory requirements.</strong></p>



<p>Regular CPD helps dentists and DCPs keep their knowledge and skills up to date, understand changes in guidance and legislation, and refresh important practical knowledge to support safe, high-quality patient care.</p>



<p>With busy practices and demanding schedules, CPD can easily become something to fit in when time allows. Taking a more structured approach, particularly to the GDC’s recommended CPD topics, can make a real difference.</p>



<h2 class="wp-block-heading">Why are the GDC’s recommended CPD topics important?</h2>



<p>The General Dental Council (GDC) identifies recommended CPD topics because of their relevance to dental professionals and patient safety. These include:</p>



<ul class="wp-block-list">
<li>Medical emergencies</li>



<li>Disinfection and decontamination</li>



<li>Radiography and radiation protection</li>



<li>Legal and ethical issues and complaints handling</li>



<li>Oral cancer</li>



<li>Safeguarding.</li>
</ul>



<p>These topics should not simply be viewed as boxes to tick. Keeping knowledge and skills current in these areas can directly affect patient care and how dental professionals respond to challenging situations.</p>



<h2 class="wp-block-heading">Why regular refresher training matters</h2>



<p>Some areas of dentistry are constantly developing, while others require regular refresher training.</p>



<p>Medical emergencies are a good example. Although a dental professional may not encounter a serious emergency every day, having current knowledge and confidence when one occurs is critical. The GDC recommends at least two hours of medical-emergency CPD every year.</p>



<h2 class="wp-block-heading">The benefits of attending a full-day CPD course</h2>



<p>Online courses and webinars offer convenience, but attending a face-to-face course provides additional benefits.</p>



<h3 class="wp-block-heading">Dedicated time to learn</h3>



<p>Stepping away from the practice for a day allows you to concentrate on professional development without trying to fit learning between patients or into an already busy working day.</p>



<h3 class="wp-block-heading">Learn directly from experienced speakers</h3>



<p>Specialist speakers can share practical knowledge and insights that go beyond reading guidance or completing an online module.</p>



<h3 class="wp-block-heading">Ask questions and discuss real-life situations</h3>



<p>Face-to-face learning provides opportunities to explore issues relevant to your own practice, discuss practical examples and hear how colleagues approach common challenges.</p>



<h3 class="wp-block-heading"><strong>Team bonding</strong></h3>



<p>Spending a day away from the practice allows colleagues to learn together, share ideas and experiences, and strengthen working relationships in a relaxed environment. It’s a chance to invest in your team while gaining valuable CPD and returning to the practice with fresh ideas and renewed enthusiasm.</p>



<h3 class="wp-block-heading">Complete seven hours of verifiable CPD</h3>



<p>Professional Conferences’ <strong>Core Recommended CPD Update provides seven hours of verifiable CPD</strong> in one comprehensive course, helping busy dental professionals make valuable progress with their annual learning.</p>



<p>For busy dental professionals, completing seven hours of relevant CPD in a single dedicated day can be a particularly efficient way to make progress with professional development.</p>



<h2 class="wp-block-heading"><strong>Professional Conferences’ Core Recommended CPD Update 2026</strong></h2>



<p>Professional Conferences offers its Core Recommended CPD Update for dental professionals, with both face-to-face and online options. The course brings together experienced dental, medical and healthcare professionals to cover important topics relevant to dental practice.</p>



<p><strong>FMC readers can receive an additional 10% off any Professional Conferences Core 2026 conference, IRMER or Level 1 CBCT course using discount code FMC at checkout.</strong></p>



<h3 class="wp-block-heading">What delegates say from the most recent London conference</h3>


        <div class="py-12 bg-gray-light">
            <div class="quotes-slider slider-h-full  flex">
                                    <div>
                        <div class="h-full mx-2 md:mx-4 xl:mx-6 px-6 py-6 md:py-12 bg-context-white border border-context-100 rounded-xl text-center flex flex-col justify-center items-center space-y-4">
                                                            <div class="font-secondary text-primary-500 text-2xl md:text-3xl">
                                    ‘An excellent day. Excellent calibre of speakers, great food, well organised. Thank you and see you next year!’                                </div>
                                                                                        <div class="text-lg font-bold">
                                    Michael L                                </div>
                                                                                </div>
                    </div>
                                    <div>
                        <div class="h-full mx-2 md:mx-4 xl:mx-6 px-6 py-6 md:py-12 bg-context-white border border-context-100 rounded-xl text-center flex flex-col justify-center items-center space-y-4">
                                                            <div class="font-secondary text-primary-500 text-2xl md:text-3xl">
                                    ‘Excellent course as always, great speakers, well delivered and well organised, thank you.’                                </div>
                                                                                        <div class="text-lg font-bold">
                                    Sally T                                </div>
                                                                                </div>
                    </div>
                                    <div>
                        <div class="h-full mx-2 md:mx-4 xl:mx-6 px-6 py-6 md:py-12 bg-context-white border border-context-100 rounded-xl text-center flex flex-col justify-center items-center space-y-4">
                                                            <div class="font-secondary text-primary-500 text-2xl md:text-3xl">
                                    ‘Prefer face to face as much more engaging, thank you for putting these courses on.’                                </div>
                                                                                        <div class="text-lg font-bold">
                                    Lori W                                </div>
                                                                                </div>
                    </div>
                            </div>
        </div>



<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-4-3 wp-has-aspect-ratio"><div class="wp-block-embed__wrapper">
<div class="video-container"></div>
</div></figure>



<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><div class="wp-block-embed__wrapper">
<div class="video-container"></div>
</div></figure>



<h2 class="wp-block-heading"><strong>Professional Conferences’ Core Recommended CPD Update 2026</strong></h2>



<h3 class="wp-block-heading">London, Kensington – 20 November 2026</h3>



<p>A full day of face-to-face learning with top speakers.</p>



<ul class="wp-block-list">
<li>Seven hours of verifiable CPD</li>



<li><strong>£119 + VAT</strong> for the full day</li>



<li><strong>£139 + VAT</strong> including lunch</li>



<li>Additional 10% discount with code FMC.</li>
</ul>



<p><a href="https://proconferences.com/product/core-recommended-cpd-update-2026/" target="_blank" rel="noreferrer noopener">Book the London Core Recommended CPD Update</a></p>



<h3 class="wp-block-heading">Online – 7 December 2026</h3>



<p>For those who prefer to study remotely, the course is also available online. Attend on 7 December or watch the recording for 120 days afterwards, allowing you to fit learning around your practice and other commitments.</p>



<ul class="wp-block-list">
<li>Seven hours of verifiable CPD</li>



<li><strong>£109 + VAT</strong></li>



<li>Additional 10% discount with code FMC</li>



<li>Recording available for 120 days after the course.</li>
</ul>



<p><a href="https://proconferences.com/product/virtual-core-recommended-cpd-update-2026-2/" target="_blank" rel="noreferrer noopener">Book the Online Core Recommended CPD Update</a></p>



<h2 class="wp-block-heading">Plan ahead: Spring 2027 dates</h2>



<p>The following dates are planned for Spring 2027:</p>



<ul class="wp-block-list">
<li>London – 7 May 2027</li>



<li>Southampton – 18 June 2027</li>



<li>Watford – 21 June 2027</li>



<li>Online – 28 June 2027.</li>
</ul>



<p>London and online dates will also be available for Autumn 2027.</p>



<p><a href="https://proconferences.com/product-category/dental/" target="_blank" rel="noreferrer noopener">Book the 2027 dates – more information to follow on the website</a></p>



<h2 class="wp-block-heading">Meet the speakers for 2026</h2>



<p>The Core Recommended CPD Update brings together experienced leading specialists from dentistry, medicine and healthcare:</p>



<ul class="wp-block-list">
<li><strong>Professor Michael A O Lewis, PhD, FDSRCPS, FDSRCS(Eng), FRCPath, FFGDP(UK), FHEA</strong> – specialist in oral medicine with extensive clinical, academic and professional experience</li>



<li><strong>Lee Feinberg</strong> – consultant in dental and maxillofacial radiology at King’s College Hospital, London, and Eastman Dental Hospital, UCLH, London</li>



<li><strong>Stephen Henderson, BDS LLM FFGDP(UK)(hon) FCGDent FFFLM</strong> – independent dental adviser</li>



<li><strong>Pat Langley</strong> – clinical director</li>



<li><strong>Jon Wheater, RGN, RSCN, BSc (Hons) Child Health, MA (Education)</strong> – NMC nurse teacher, RQF/QCF assessor, mental health first aider and director of education</li>



<li><strong>Alice Gribble, Dani Tirel and Rebecca Peckham</strong> – resuscitation officers at University Hospital Southampton, with experience as advanced life support (ALS) and European paediatric advanced life support (EPALS) instructors. Rebecca is also an emergency department sister, ALS and EPALS course director and GIC instructor.</li>
</ul>



<h2 class="wp-block-heading">Don’t stop at your core CPD</h2>



<p>While the GDC’s recommended topics should form an important part of professional development, CPD should also reflect your individual role, responsibilities and learning needs.</p>



<p>Depending on your practice, additional training in dental radiography, radiation protection and cone beam computed tomography (CBCT) may be valuable. Professional Conferences offers specialist online courses to support further learning in these areas.</p>



<h3 class="wp-block-heading">IR(ME)R and dental radiography</h3>



<p>The online IR(ME)R Course in Dental Radiography and Radiation Protection helps dental professionals refresh their understanding of the regulations and responsibilities surrounding dental radiography and radiation protection. This training needs to be undertaken on a five-year cycle.</p>



<ul class="wp-block-list">
<li><strong>£109 + VAT</strong></li>



<li>Additional 10% discount for FMC readers using code FMC.</li>
</ul>



<p><a href="https://proconferences.com/product/an-irmer-course-in-dental-radiography-and-radiation-protection-2025/" target="_blank" rel="noreferrer noopener">Find out more about the online IR(ME)R course</a></p>



<p>A face-to-face London course is also planned for 24 September 2027, at £119 + VAT.</p>



<p><a href="https://proconferences.com/product/an-irmer-course-in-dental-radiography-and-radiation-protection/" target="_blank" rel="noreferrer noopener">Find out more about the London IR(ME)R course</a></p>



<h3 class="wp-block-heading">CBCT training: Level 1 and Level 2</h3>



<p>Cone beam computed tomography (CBCT) is increasingly important in modern dental imaging. Appropriate training is valuable for professionals involved in using, interpreting or reporting three-dimensional dental images.</p>



<h4 class="wp-block-heading">Level 1 CBCT training</h4>



<p>This seven-hour course includes four hours of online lectures followed by three hours of interactive learning. The speakers are Simon Harvey and Shanon Patel. Please note that the interactive learning requires a Windows PC, rather than a Mac; a link to the software will be provided.</p>



<ul class="wp-block-list">
<li><strong>£149 + VAT</strong></li>



<li>Additional 10% discount for FMC readers using code FMC.</li>
</ul>



<p><a href="https://proconferences.com/product/level-1-core-cbct-course/" target="_blank" rel="noreferrer noopener">Find out more about online Level 1 CBCT training</a></p>



<p>We do currently have a bundle including Level 1 CBCT, IR(ME)R and our recorded Core conference for £299 + VAT (a significant saving on the full price of £367). <a href="https://proconferences.com/product/dental-imaging-core-cpd-update-bundle/" target="_blank" rel="noreferrer noopener">Click here to book the bundle</a>.</p>



<h4 class="wp-block-heading">Level 2 CBCT training</h4>



<p>For those wishing to develop their knowledge further, Simon Harvey also runs Level 2 CBCT courses in London. Booking through Professional Conferences provides a £50 discount, reducing the course price to £599.</p>



<p>The next course date is Saturday 27 February 2027 in London.</p>



<p><a href="https://proconferences.com/product/level-2-cbct-reporting-masterclass-by-simon-harvey-2/" target="_blank" rel="noreferrer noopener">Find out more about Level 2 CBCT training in London</a></p>



<h2 class="wp-block-heading">Explore all dental CPD courses</h2>



<p>CPD should be an ongoing part of professional life, helping dental professionals maintain their knowledge, develop new skills and continue delivering safe, effective patient care.</p>



<p>Alongside its Core Recommended CPD Update, Professional Conferences offers courses covering:</p>



<ul class="wp-block-list">
<li><a href="https://proconferences.com/product/autism-and-learning-disability-training/" target="_blank" rel="noreferrer noopener">Learning disability and autism</a></li>



<li><a href="https://proconferences.com/product-category/dental/?disciplines=periodontics" target="_blank" rel="noreferrer noopener">Periodontics</a></li>



<li><a href="https://proconferences.com/product/the-pursuit-of-happiness-in-dentistry-navigating-stress-well-being-and-self-mastery-a-practical-resilience-guide-for-dental-professional/" target="_blank" rel="noreferrer noopener">Mental resilience</a></li>



<li><a href="https://proconferences.com/product/level-2-safeguarding-vulnerable-adults-and-child-protection-october-2027/" target="_blank" rel="noreferrer noopener">Level 2 Safeguarding – this course is online but does have to be attended on the day – next course 8 October 2027.</a></li>
</ul>



<p>And other areas of clinical and professional development. Whether you prefer face-to-face conferences or specialist online training, there are options to help you plan your CPD around your responsibilities and individual learning needs.</p>



<p><a href="https://proconferences.com/product-category/dental/" target="_blank" rel="noreferrer noopener">View all Professional Conferences dental CPD courses</a></p>



<p><em>This article is sponsored by Professional Conferences.</em></p>



<p></p>]]> </content:encoded>
</item>

<item>
<title>Dental practice sales accelerate as offers agreed within weeks</title>
<link>https://edusehat.com/en/dental-practice-sales-accelerate-as-offers-agreed-within-weeks</link>
<guid>https://edusehat.com/en/dental-practice-sales-accelerate-as-offers-agreed-within-weeks</guid>
<description><![CDATA[ Dental practices sales are moving from launch to offer accepted offer within two to three weeks as intense competition pushed some buyers to bid above asking price during viewings. The rapid pace, compared with seven to eight weeks previously, was described as one of the biggest frustrations facing buyers during a National Association of Specialist… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/sales.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 26 Oct 2026 16:25:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Dental, practice, sales, accelerate, offers, agreed, within, weeks</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Dental practices sales are moving from launch to offer accepted offer within two to three weeks as intense competition pushed some buyers to bid above asking price during viewings.</strong></p>



<p>The rapid pace, compared with seven to eight weeks previously, was described as one of the biggest frustrations facing buyers during a National Association of Specialist Dental Accountants and Lawyers (NASDAL) annual UK meeting in London earlier in October.</p>



<p>Participants said some buyers were attempting to secure practices immediately, leaving sellers with little time to assess competing offers or consider which transaction was most likely to complete.</p>



<h2 class="wp-block-heading">More banks financing acquisitions</h2>



<p>Greater access to finance was identified as one reason for the acceleration. Meeting attendees said more banks were willing to lend within the dental market, with competitive rates and longer repayment terms making acquisitions more affordable.</p>



<p>This was particularly evident among independent buyers acquiring their first, second or third practice and smaller groups expanding their portfolios.</p>



<p>Larger corporate operators were described as more selective, apart from the biggest groups pursuing substantial acquisitions.</p>



<h2 class="wp-block-heading">‘Dental deserts’ attracting buyers</h2>



<p>Locations with longstanding recruitment difficulties were also attracting acquisition interest.</p>



<p>Some groups were reportedly more willing to consider practices in areas described as ‘dental deserts’, as concern about recruitment had begun to ease.</p>



<h2 class="wp-block-heading">CQC slowdown ‘not necessarily a bad thing’</h2>



<p>The speed of bidding contrasted with the preparation required before a transaction could be completed.</p>



<p>Care Quality Commission (CQC) processes in England were described as challenging and capable of delaying individual deals. However, the additional preparation was not viewed only as an obstacle.</p>



<p>One participant argued that requiring policies and supporting documents earlier encouraged buyers to become organised from the beginning of the process.</p>



<p>This was said to have reduced the bottleneck created when applicants completed their interviews but could not progress because their documentation was missing.</p>



<h2 class="wp-block-heading">Capital gains tax uncertainty</h2>



<p>The approaching <a href="https://dentistry.co.uk/2026/10/23/autumn-budget-2026-everything-dentists-need-to-know/">budget on 28 October</a> also prompted discussion about whether tax changes could affect dental practice sales.</p>



<p>Participants appeared less concerned about a substantial increase in capital gains tax than they had been before the previous budget, when some feared that rates could be brought closer to income tax rates.</p>



<p>No consensus emerged about what the chancellor would announce. One contributor suggested that a significant increase could discourage transactions and prove counterproductive for government receipts.</p>



<p>Possible changes to pension tax relief and tax-free cash were also discussed, although participants said they had seen nothing to indicate that either measure would be included.</p>



<p><em><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access – plus the Dentistry Bulletin delivered to your inbox.</em></a></em></p>



<p></p>]]> </content:encoded>
</item>

<item>
<title>Biocon secures Yesintek biosimilar rights in nine markets</title>
<link>https://edusehat.com/en/biocon-secures-yesintek-biosimilar-rights-in-nine-markets</link>
<guid>https://edusehat.com/en/biocon-secures-yesintek-biosimilar-rights-in-nine-markets</guid>
<description><![CDATA[ 
The agreement with Janssen Sciences Ireland enables commercialisation of the proposed Stelara biosimilar in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan
The post Biocon secures Yesintek biosimilar rights in nine markets appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 26 Oct 2026 15:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Biocon, secures, Yesintek, biosimilar, rights, nine, markets</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Biocon has signed a licence agreement with Janssen Sciences Ireland to enable the commercialisation of Yesintek, its proposed biosimilar to Stelara (ustekinumab), in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan, with immediate effect.</span></p>
<p><span>The agreement builds on the company’s previously announced agreements with Janssen, which secured market entry dates for Yesintek in the US, Europe, the UK, Canada and Japan.</span></p>
<p><span>According to Biocon, the additional market entry rights for biosimilar ustekinumab will allow it to offer an affordable and effective treatment option for patients affected by autoimmune diseases in these markets.</span></p>
<p><span>Yesintek is a human interleukin-12 and -23 antagonist that disrupts IL-12 and IL-23-mediated signalling in immune-mediated diseases. It has been approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.</span></p>
<p><span>The reference brand, Stelara, recorded worldwide sales of $6.08 billion in 2025, according to Johnson & Johnson’s reported 2025 sales.</span></p>
<p>The post <a href="https://www.expresspharma.in/biocon-secures-yesintek-biosimilar-rights-in-nine-markets/">Biocon secures Yesintek biosimilar rights in nine markets</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Entering pharma drug discovery presents an opportunity to apply scientific capabilities to a new set of health challenges</title>
<link>https://edusehat.com/en/entering-pharma-drug-discovery-presents-an-opportunity-to-apply-scientific-capabilities-to-a-new-set-of-health-challenges</link>
<guid>https://edusehat.com/en/entering-pharma-drug-discovery-presents-an-opportunity-to-apply-scientific-capabilities-to-a-new-set-of-health-challenges</guid>
<description><![CDATA[ 
Godavari Biorefineries is advancing research into novel cancer therapies, securing US patent protection and expanding the geographical reach of its intellectual property following earlier grants in India, China and Japan. Dr Sangeeta Srivastava, Executive Director, Godavari Biorefineries, discusses the research outcomes, therapeutic potential and significance of this milestone.
The post Entering pharma drug discovery presents an opportunity to apply scientific capabilities to a new set of health challenges appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/26111455/EP_Dr-Sangeeta-Srivastava_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 26 Oct 2026 15:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Entering, pharma, drug, discovery, presents, opportunity, apply, scientific, capabilities, new, set, health, challenges</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/26111455/EP_Dr-Sangeeta-Srivastava_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/26111455/EP_Dr-Sangeeta-Srivastava_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/26111455/EP_Dr-Sangeeta-Srivastava_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><b>What do the Mexican patent for “Use of Compounds for Treating Viral Infections” and the </b><b>US patent for a cancer-treatment molecule signify for Godavari Biorefineries’ life sciences </b><b>research programme and long-term business strategy?</b></p>
<p><span>The grant of the US patent for our oncology molecule and the Mexican patent for our antiviral </span><span>compounds marks a strategic shift for Godavari Biorefineries. These patents reflect how our </span><span>R&D capabilities have evolved from bio-based chemical innovation to high-value, IP-driven drug </span><span>discovery. By focusing on cancer stem cell inhibition and host-targeting antivirals, our research </span><span>directly addresses two of medicine’s greatest challenges: disease recurrence and drug </span><span>resistance.</span></p>
<p><span>Securing protection across key markets such as the US, Mexico, Japan, and China </span><span>strengthens our ability to pursue international collaborations, co-development opportunities, </span><span>and future commercialisation pathways.</span></p>
<p><span>Most importantly, it reinforces our belief that science-driven innovation from India can </span><span>contribute meaningfully to global healthcare challenges.</span></p>
<p><b>How is Godavari Biorefineries leveraging its legacy in sugar manufacturing and bio-based </b><b>chemicals to expand into drug discovery, antiviral research, and cancer therapeutics?</b></p>
<p><span>Godavari Biorefineries’ expansion into life sciences reflects the company’s continued </span><span>focus on research and development, with work extending into drug discovery and the </span><span>development of potential therapies for cancer and viral infections.</span></p>
<p><span>The company’s life sciences research encompasses a lead candidate being developed for triple- </span><span>negative breast cancer (TNBC), an aggressive form of breast cancer. The candidate has </span><span>completed Phase I studies, with safety, tolerability, and pharmacokinetics among the </span><span>parameters evaluated. Preclinical research has also reported anti-cancer activity in breast and </span><span>prostate cancer models, alongside potential antiviral activity against SARS-CoV-2 and influenza </span><span>virus.</span></p>
<p><span>Beyond this programme, research is exploring potential treatments for other difficult-to-treat </span><span>cancers, including prostate cancer and glioblastoma, as well as potential antiviral therapies. </span><span>These programmes reflect the breadth of the company’s efforts to address areas of significant </span><span>unmet medical need. </span><span>Through its growing capabilities in life sciences research, Godavari Biorefineries is extending its </span><span>research-led approach into the development of potential therapeutic applications. The focus </span><span>remains on advancing promising molecules through the drug-development process, supported </span><span>by scientific research, intellectual property development, and opportunities for collaboration.</span></p>
<p><span>What are the next steps for these patented molecules?</span></p>
<p><span>Having secured intellectual property protection in key international markets, our focus is now </span><span>on advancing these molecules through rigorous scientific evaluation and translational research. </span><span>Our immediate priority is to build on the encouraging safety data from our completed Phase 1a </span><span>oncology study as we prepare for the next stage of clinical development, focusing on triple- </span><span>negative breast cancer (TNBC) and other solid tumours. This progress provides a foundation for </span><span>discussions with prospective partners who can support further clinical development. </span></p>
<p><span>In parallel, we are advancing our newer oncology and antiviral compounds through their </span><span>respective development programmes. Through our presence in Princeton, New Jersey, we are </span><span>engaging partners on clinical co-development, joint research, licensing by asset or territory, and </span><span>strategic investment. We believe flexible partnership models can help bring together </span><span>complementary expertise to advance these programmes.</span></p>
<p><b>Which types of cancer are you currently targeting through your research? Which viral </b><b>infections are you prioritising in your antiviral research?</b></p>
<p><span>In oncology, our primary areas of interest include Triple Negative Breast Cancer (TNBC) and </span><span>advanced prostate cancer. We are also exploring potential applications in oral, glioblastoma, </span><span>liver, cervical, colon, and lung cancers.</span></p>
<p><span>A key aspect of our research is targeting cancer stem cells, which are believed to contribute to </span><span>tumour recurrence, metastasis, and resistance to conventional therapies. Investigating these </span><span>cells is an important area of research in understanding these challenges. </span><span>In antiviral research, we are focusing on SARS-CoV-2 and influenza. Rather than targeting the </span><span>virus directly, our approach aims to study and interfere with the cellular pathways that viruses </span><span>rely on to infect human cells. This host-targeting approach focuses on cellular mechanisms </span><span>involved in viral infection, rather than on the virus itself.</span></p>
<p><b>What are the key scientific, regulatory and financial challenges a company rooted in the </b><b>sugar and bio-based chemicals industry faces when entering the pharmaceutical drug- </b><b>discovery space?</b></p>
<p><span>For a company with its foundations in sugar and bio-based chemicals, entering pharmaceutical </span><span>drug discovery presents an opportunity to apply its scientific capabilities to a new set of </span><span>healthcare challenges. Our experience in cosmetics, flavours and fragrances, and personal care </span><span>has helped build a foundation in scientific research, product development and regulatory </span><span>discipline, which can be extended as we develop our capabilities in cancer research and </span><span>antiviral drug discovery.</span></p>
<p><span>In cancer research, one of the key priorities is identifying promising molecules and </span><span>understanding their activity across different cancer types, including difficult-to-treat cancers. </span><span>This requires a multidisciplinary approach combining chemistry, molecular biology, </span><span>pharmacology, and toxicity evaluation. Similarly, antiviral research involves studying how </span><span>viruses interact with host cells and identifying potential therapeutic approaches that can be </span><span>evaluated for their activity and safety. In both areas, rigorous preclinical evaluation and a </span><span>systematic progression through the stages of drug development are essential to building a </span><span>strong scientific foundation.</span></p>
<p><span>From a regulatory perspective, each candidate must be supported by appropriate safety, </span><span>efficacy, and quality data as it progresses through the relevant stages of development. This calls </span><span>for robust research practices, careful documentation, and alignment with applicable regulatory </span><span>requirements. Developing specialised scientific capabilities and infrastructure, while fostering </span><span>collaboration across disciplines, helps strengthen this process. </span><span>Drug discovery also requires a long-term approach to investment, given the time involved in </span><span>evaluating molecules and advancing them through development. Prioritising research </span><span>programmes, allocating resources carefully and assessing scientific progress at each stage are </span><span>important to maintaining a balanced and sustainable pipeline. These considerations encourage </span><span>a disciplined approach to decision-making while allowing promising research to progress. </span><span>Our focus is on building scientific capabilities that can translate research into potential </span><span>therapeutic applications. By combining rigorous research, responsible development, and </span><span>collaboration, we aim to advance our work in cancer and antiviral research while contributing </span><span>to progress in areas where new treatment options are needed.</span></p>
<p><b>What is the potential commercial value of these discoveries? Do you see intellectual </b><b>property licensing and partnerships with established pharmaceutical companies as a viable </b><b>route to market?</b></p>
<p><span>We see potential in building a portfolio of therapeutic candidates rather than relying on a single </span><span>molecule. Our lead oncology programme has completed Phase 1a, while other molecules in our </span><span>pipeline are at different stages of research and evaluation, including studies assessing their </span><span>efficacy. Our patented compounds have shown inhibitory effects against cancer cells and </span><span>cancer stem cells in in vitro studies, with activity observed across multiple cancer cell types, </span><span>including breast and prostate cancer.</span></p>
<p><span>Our research focuses on developing original molecules and exploring new approaches to </span><span>addressing cancer and other healthcare challenges. Partnerships can play an important role in </span><span>advancing these research programmes. Drug development requires clinical expertise, </span><span>regulatory capabilities, funding, and market access, which can complement our strengths in </span><span>research and intellectual property. Depending on the molecule and its stage of development, </span><span>we can explore asset-specific arrangements or broader research collaborations with partners </span><span>whose capabilities align with our programmes.</span></p>
<p><b>Beyond these two patented discoveries, what other life sciences research programmes or </b><b>therapeutic areas are in your pipeline?</b></p>
<p><span>Beyond the two recently patented discoveries, we are building a growing portfolio of </span><span>proprietary molecules, with oncology as a central focus. Our lead clinical-stage programme </span><span>provides an important foundation, while emerging candidates are being investigated through </span><span>different mechanisms of action and for potential applications across several solid tumours. </span><span>Having multiple molecules at different stages of development allows us to explore a wider </span><span>range of research opportunities and work with partners based on their areas of interest. </span><span>We continue to develop our intellectual property portfolio and evaluate opportunities to </span><span>advance these candidates. Our long-term objective is to combine scientific innovation, </span><span>responsible development and strategic collaboration to build a sustainable life sciences </span><span>business. This reflects our broader purpose of creating value through research and contributing </span><span>to a healthier future.</span></p>
<p> </p>
<p><em><strong>sanjiv.das@expressindia.com</strong></em></p>
<p><em><strong>sanjivdas1@gmail.com</strong></em></p>
<p>The post <a href="https://www.expresspharma.in/entering-pharma-drug-discovery-presents-an-opportunity-to-apply-scientific-capabilities-to-a-new-set-of-health-challenges/">Entering pharma drug discovery presents an opportunity to apply scientific capabilities to a new set of health challenges</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Investment Banker Talks U.S.&#45;Chinese Deals, IPOs, and a Tough Climate for Startups Seeking Capital</title>
<link>https://edusehat.com/en/stockwatch-investment-banker-talks-us-chinese-deals-ipos-and-a-tough-climate-for-startups-seeking-capital</link>
<guid>https://edusehat.com/en/stockwatch-investment-banker-talks-us-chinese-deals-ipos-and-a-tough-climate-for-startups-seeking-capital</guid>
<description><![CDATA[ Geoff Meyerson addressed the growth of U.S.-Chinese licensing/collaboration deals, the recent growth of IPOs, and the still-chilly climate for startups seeking financing in a recent interview with GEN Edge.
The post StockWatch: Investment Banker Talks U.S.-Chinese Deals, IPOs, and a Tough Climate for Startups Seeking Capital appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/A-List_GettyImages2-1401171512-1024x682-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 26 Oct 2026 08:30:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Investment, Banker, Talks, U.S.-Chinese, Deals, IPOs, and, Tough, Climate, for, Startups, Seeking, Capital</media:keywords>
<content:encoded><![CDATA[<p>Barring something cataclysmic over the next two months, it’s fair to say 2026 has been the year biotech stocks have shaken off the post-COVID doldrums. The largest electronic transfer fund by total assets, the $11 billion <strong>iShares Biotechnology ETF (Nasdaq: IBB)</strong> <span><strong>soared 34%</strong></span> over the 12 months ending Friday, from $154.58 to $207.74, while the second-largest ETF, the $10.6 billion <strong>State Street SPDR S&P Biotech ETF (NYSE Arca: XBI), <span>leaped 39%</span></strong> from $107.56 to $149.54.</p>
<p>That bounceback helps explain the surge in initial public offerings (IPOs) this year vs. 2025–27 offerings totaling $7.776 billion, up a sizzling 573% from $1.155 billion in 11 offerings in all of 2025. During the third quarter, nine IPOs totaling $2.4 billion reached Wall Street, the largest number in five years, according to investment bank Locust Walk.</p>
<figure aria-describedby="caption-attachment-339794" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339794" src="https://www.genengnews.com/wp-content/uploads/2026/10/Geoff-Meyerson-Locust-Walk-And-Banyan-BioInnovations-CROP11111-RESIZE3663-300x277.jpg" alt="" width="300" height="277" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Geoff-Meyerson-Locust-Walk-And-Banyan-BioInnovations-CROP11111-RESIZE3663-300x277.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Geoff-Meyerson-Locust-Walk-And-Banyan-BioInnovations-CROP11111-RESIZE3663-1024x945.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Geoff-Meyerson-Locust-Walk-And-Banyan-BioInnovations-CROP11111-RESIZE3663-768x708.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Geoff-Meyerson-Locust-Walk-And-Banyan-BioInnovations-CROP11111-RESIZE3663-1536x1417.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/Geoff-Meyerson-Locust-Walk-And-Banyan-BioInnovations-CROP11111-RESIZE3663-2048x1889.jpg 2048w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Geoff Meyerson is CEO and co-founder of the investment bank Locust Walk. He is also co-founder and CEO of investment firm Banyan BioInnovations.</figcaption></figure>
<p>“Yes, we’ve absolutely had a comeback year,” declared Geoff Meyerson, CEO and co-founder of the investment bank Locust Walk. He is also co-founder and CEO of Banyan BioInnovations, an investment firm launched in May to nurture startups by identifying best-in-class or first-in-class clinical-stage assets, forming new companies, or “NewCos,” around them, then providing experienced, centralized support to help them accelerate drug development.</p>
<p>In its recently released 2026 Q3 Market Conditions Report, Locust Walk tracked measures showing growing strength yet continuing challenges for biotech companies during the third quarter:</p>
<ul>
<li><strong>Global licensing deals</strong> fell to a two-year low of about $48 billion in 41 transactions, from $71.5 billion in 43 transactions during Q2, with the average deal declining to $1.171 billion from $1.662 billion as deals focused more on clinical-stage assets than milestone-heavy discovery/preclinical assets.</li>
<li><strong>China leads in licensing, </strong>accounting for 58% of 2026 value through Q3, up from 48% a year ago, while the United States placed second at 26%. Europe and the United Kingdom slipped to 8%.</li>
<li><strong>Mergers and acquisitions (M&A) </strong>totaled $42.1 billion in 30 transactions, down from a three-year high of $80.7 billion in 35 transactions during Q2. However, total M&A value of $173 billion during Q1–Q3 2026 is already larger than all of 2025.</li>
<li><strong>PIPE (private investment in public equity)</strong> activity grew to $3.808 billion across 14 deals, well over the $603 million of Q2 and $1.151 billion of Q3 2025.</li>
</ul>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Meyerson addressed the growth of U.S.-Chinese licensing/collaboration deals, the recent growth of IPOs, and the still-chilly climate for startups seeking financing in a recent interview with <em>GEN Edge </em>(edited for length and clarity).</p>
<p><strong><span><em>GEN</em> <em>Edge</em>:</span> Public stock markets and private VC markets have shown strength this year, yet we’re seeing plenty of companies avoid them through licensing and collaboration deals, many reaching multiple billions of dollars. Why have licensing-collaboration deals continued to grow despite improving markets?</strong></p>
<p><strong>Geoff Meyerson:</strong> It’s a good question. It’s a complicated answer. In the United States, most licensing deals are early-stage discovery and preclinical. It’s rare to do a clinical stage license in the United States, because typically, if you want to get access to U.S. rights as a pharma company, you have to buy the company. In the United States, companies won’t do a license unless it’s a non-core asset. That’s why the M&A statistics show that 91% of total deal value was for U.S.-headquartered companies. The difference, though, is where global licensing deals are derived from: 58% of the total value is coming from China, compared to 26% from the United States.</p>
<p><strong><span><em>GEN Edge:</em></span> Why?</strong></p>
<p><strong>Meyerson:</strong> Because for Chinese companies, the Hong Kong markets have effectively shut down. That was a very popular route last year to raise capital. Now, because of red chip and other policies, it’s becoming significantly harder to raise capital in Hong Kong, and a lot of Chinese companies are in line, and the government makes the decision as to whether or not a company can go public.</p>
<p>If you also look at the M&A statistics out of China, approximately 1% of the total deal value is from M&A. If you can’t get liquidity as an investor via going public, and you can’t get an exit via M&A, how else can you either support your company or potentially return capital to the shareholders? The only other option that I’m aware of is licensing. The licensing deals have become the lifeblood and the source of revenue or capital for Chinese companies. That’s why that trend is so material.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>In many cases, you can even return the capital to your investors from a license, which in the United States would be double taxed, highly inefficient; that’s why you don’t see a lot of that happening in the United States. The difference also is that the upfronts in China are typically lower as a percentage of the total deal value compared to the United States, because in China, optics matter more. In the United States, the share of the expected net present value matters more. The Chinese companies don’t value the royalties as much. They value very large milestones that in many cases will never be achieved, so that inflates the total deal value number, and that’s one of the reasons why the number is so skewed in China’s favor.</p>
<p><strong><span><em>GEN Edge:</em></span> How concerned are you about Washington, both the Trump administration and Congress, tightening the rules for U.S.-Chinese collaborations?</strong></p>
<p><strong>Meyerson:</strong> It’s an interesting question and interesting timing for it, because [on October 16], the Chinese government made a major proclamation about <a href="https://www.jdsupra.com/legalnews/china-proposes-new-restrictions-on-5034995/">not being able to transfer certain technology platforms outside of China</a>. There’s just as much, if not more, risk in the actions of the Chinese government compared to the U.S. government. In China, one-party rule can make a decision, and it happens. In the United States, you need Congress, you need legislation. Yes, there could be executive orders, but it’s not the same force and permanence. So, there’s definitely geopolitical risk.</p>
<p>My instinct is that it’s not going to be something that is going to be shut down, ever. There will always be a way around it. I’m not going to cover that here, but all kinds of strategies can be deployed to minimize some of the regulatory barriers. Undoubtedly, it’s going to get harder before it gets easier, and it’s going to be driven by both governments, not just the United States.</p>
<p><strong><em><span>GEN Edge:</span> </em>What effect has the growth in U.S.-Chinese licensing collaborations had on the market and public company stocks?</strong></p>
<p><strong>Meyerson:</strong> I think the U.S. companies that don’t know their competitive set out of China run the risk of having their technology being surpassed from a data perspective. And what’s changed is a lot of U.S. companies have decided not to publish their early-stage pipeline, they’re not publishing patents early. They’re waiting till the last minute, because as soon as that patent is filed, 18 months later it publishes. And the second it publishes, tons of AI bots are circling, figuring that out, and within a week or two, you can design chemical matter or biology around it.</p>
<p>I’m not so sure that market capitalization of the companies is being impacted, but I do think that whenever there’s positive data in the United States, that spurs lots of Chinese companies to push harder. If there’s positive data in China, and that can be read through to the United States, it’s just like any competitor announcing data can impact the stock price of your drug if it’s in the same class, if you haven’t fully differentiated from everyone else. Is it a class effect? Or is it something that is unique to a specific drug? I don’t know if there are direct impacts of all this competition, other than data emerging that, just like any other data coming out in a class and having an impact.</p>
<p><strong><span><em>GEN Edge:</em></span> This year has seen one pause in biotech IPO activity just after the Iran war started, after Generate Biomedicines went public. The markets heated up again in the spring through summer, but have held back in recent weeks. How much of that is investors and others waiting to see what Anthropic does with their IPO, or are there other reasons for the pause lately?</strong></p>
<p><strong>Meyerson:</strong> My guess is that the recent swoon with the specialists has really caused an issue. That’s number one. And number two, with the inflation print and the increase in rates on long-dated treasuries, that has a real negative impact on biotech. My instinct is, the markets will recover for the specialists. Who knows how long the rates will be higher on the long-dated bonds, but I think it will be coming back. I don’t think the cycle is over.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p><strong><span><em>GEN Edge:</em></span> What effect is Anthropic’s IPO having on AI-focused biotech IPOs?</strong></p>
<p><strong>Meyerson:</strong> I’m not so sure AI biotech IPOs are actually meaningful, because at the end of the day most drugs—probably more than half of the drugs now were discovered using AI. And 99.5% of all drug spend happens after you have a lead candidate. AI has an impact, but not nearly as much of an impact at that point compared to the early discovery. You’ve still got to put a drug in a human and test it, and that’s not something AI can accelerate. I think AI’s impact on biotech will be certainly felt, but not nearly as much as, obviously, an AI company that’s been transformational.</p>
<p>As it relates to Anthropic, I don’t think that people are in biotech are really focused on that, to be honest. If anything, once Anthropic and OpenAI get public, that will be a lot of capital unlocked at LPs [limited partnerships] that could potentially recycle that into other funds. If anything, I think it’s going to be a huge boon to tech and biotech to have huge values  of money, or quantums of capital, being recycled in the ecosystem.</p>
<p><strong><span><em>GEN Edge:</em></span> Is that because Anthropic has made moves in recent months to position itself as a life-sci research and development company? </strong></p>
<p><strong>Meyerson:</strong> Yes, they’re going to dabble. But at the end of the day, it’s just like Google, when they started playing life sciences. They’ve got to either be selling tools to those that are developing, or they’ve got to be developing [drugs] themselves. There’s no way around it. You’re doing one or the other. If they’re just selling technology to other people, that’s fine, that’s a SaaS [software-as-a-service] model. If they’re actually developing drugs and putting molecules in patients, they’re not going to have an advantage from an AI perspective. Maybe they can recruit patients a little faster, maybe they can streamline some of the results.</p>
<p>But the reality is, you still need to wait for disease course to play out, and you have to have patients and doctors, and all these things that they have zero experience with. So, they’re going to have to build a pharma company if that’s what they really want to do. I’m not convinced Anthropic or any of these AI companies are going to build pharmas. And if they do, they’ll probably spin it off into a separate company, because it’s not going to grow nearly as fast, it’ll be a drag on their growth. My guess is they’re going to be a drug discovery engine, and they’ll license stuff out, which is fine, but that’s still relatively low value.</p>
<p><strong><span><em>GEN Edge:</em></span> What has been driving PIPE activity, and what companies are more likely to go that route for going public?</strong></p>
<p><strong>Meyerson:</strong> The rationale for a PIPE is manyfold. One, there’s been many more reverse mergers that have taken place as a viable normalized way of getting public. If, let’s say, there were 20 IPOs at one point this year, there were 20 reverses, which means, really, 40 companies got public, not 20, but those 20 that got public via reverse all needed a PIPE to complete that. A lot of the PIPEs are from reverse mergers. With quality investors, the aftermarket performance of PIPEs has actually also outperformed that of the IPOs. So, there’s a feeling that you can get a better deal in a PIPE than an IPO or a secondary [offering], and as a result that’s driving people to want to participate.</p>
<p>Then the question is, which companies would want to do a PIPE if you can get a better deal as a secondary? The answer is nobody. Why would you want to do a pipe at a lower price if you can get a better deal as a secondary offering? I think the difference is, for companies where it’s not clear how their data is going to be reacted to by the market, you can lock in the money and not take the price action risk, versus someone who is confident the market’s gonna love the data, you can probably roll the dice, release your data, and then, then do the secondary on the heels of that data release.</p>
<p>We’ve seen times where people came out with data that they thought would be great, and the market hated it, and the stock went down, and then they couldn’t raise capital. So, there is some certainty and some value in doing a PIPE to have the certainty of raising the money, even if it’s potentially at a lower price than you’d have been able to get if you released the data first.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p><strong><span><em>GEN Edge:</em></span> The report also tracked 46 venture financing deals in North America during the third quarter, down from 55 in Q2 but above the 38 of Q3 2025. The average deal size has grown to $96 million from $83 million in Q2 and $75 million in Q3 2025, with most deals concentrated in Series B, rounds. Doesn’t this confirm what startups have long been complaining about, that they find it hard to raise capital for Series A in earlier rounds?</strong></p>
<p><strong>Meyerson:</strong> Yes. I tend to differentiate between Series A, Series B, versus stage of development, because Banyan Bio is starting companies that are Phase II companies through a Series A round. I would think about it’s probably more driven by stage of development than round of financing. Raising money for discovery slash preclinical drugs, drug companies, is really hard. And most of it is going to clinical stage and beyond, which is really saying the market has changed, fundamentally, from 2020, 2021, where if you had a clinical stage drug, you were probably not gonna raise money, because everyone was focused on high-science white space platforms, really sexy iPSCs, and all the different, technologies.</p>
<p>I think what people are saying is that a startup needs to be incubated longer in academia and only spin it out when you have a full development candidate, or later, if not already an IND on file. One of the reasons you’re seeing a lot of NewCos out of China with clinical or late preclinical assets is, you’re able to in-license it for cheaper than what you would have done to develop it yourself on your own. I think that’s the arbitrage out of China that a lot of these investors are seeing. So, yes, it’s a tale of two cities. If you’re doing early discovery high science it’s a very tough spot in the market.</p>
<p><strong><span><em>GEN Edge:</em></span> Will that, in turn, compel some of these companies to try going public instead?</strong></p>
<p><strong>Meyerson:</strong> Yes, but the public market wants clinical data also. It doesn’t value preclinical companies very highly, so you can do it, but you’d better be a really great team, with great investors, and a highly promising story in a very interesting area. Ordinarily, that’s going to be very hard to do.</p>
<p><strong><span><em>GEN Edge:</em> </span>Where are startups looking as alternatives to traditional VC, as a result?</strong></p>
<p><strong>Meyerson:</strong> Family offices have been a big ask, but they’re not stupid either. The more a family office looks like an institutional investor, the more the answer’s going to look like it. So, disease foundations or families that have family members with a particular disease is generally an interesting way of attracting capital. The challenge is, without having them raise their hands, that they have a kid, or a family member, or a parent with that disease, it’s very hard to find them.</p>
<p>That’s where the disease foundations often do a very nice job, and if you partner with them, that can be an interesting approach. Some of the universities are actually investing in their own spinoffs to get to a point where they can create more value. But candidly, we used to play in that space, and we don’t anymore because of the challenge of getting funding.</p>
<p><strong><span><em>GEN Edge:</em></span> On the VC side, biologics’ share of financing value has continued to grow. What biologics are investors drawing toward, and what indications? Is it still cancer, maybe immunology, or has recent success brought neuro on the map?</strong></p>
<p><strong>Meyerson:</strong> Cancer and immunology are always going to be the two biggest, as a general rule, but, CNS is definitely doing okay. They’re the big three. I’m kind of surprised that rare disease has not had the same receptivity that it used to have. I think people are focused on larger markets, larger opportunities, because that’s where pharma is focused. I would say probably the most value to be found is in rare disease or smaller opportunities that could still be meaningful, just not mega-blockbuster.</p>
<p><strong><span><em>GEN Edge:</em></span> Looking ahead, what does the fourth quarter hold? Can you offer a preliminary look at what 2027 will hold for the markets?</strong></p>
<p><strong>Meyerson:</strong> Obviously, people are on hold until the midterm elections. I think once there’s clarity around what the balance of power is going to be, I think that will help. The hope is that there’ll be some bipartisan legislation aimed at improving the efficiency of the American drug development system. That’s something that I’m certainly supportive of and a champion of.</p>
<p>I’m not someone who’s going to tear down China to build up the United States. I think the United States should compete with China; I think that’s the right approach. I think that there will be, hopefully, some optimism to get some stuff done in ‘27. If that happens, I think the markets will continue apace.</p>
<p>It’s hard to tell: Does the interest rate continue to go up? If it goes up, I think we’re going to see a more challenging biotech ecosystem. Pharma has not gotten out from their patent cliffs. In fact, that’s a feature, not a bug. Every pharma, by definition, has a patent cliff they have to go through. The question is when and how much. So, there’s a built-in buying mechanism.</p>
<p>China’s not going away. There’s risk there with regulation on both sides, but fundamentally, I’m an optimist. I’m bullish on the industry, mid- to long-term. It’s very hard to predict one quarter to the next, for sure. But I don’t think the cycle has already played out. We only really started in earnest doing well a year ago. So, after four years of painful time, I don’t believe that we’re only going to have one year of a window, and then it shuts down again. I think the industry’s too large and too robust for that to happen.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/stockwatch-investment-banker-talks-u-s-chinese-deals-ipos-and-a-tough-climate-for-startups-seeking-capital/">StockWatch: Investment Banker Talks U.S.-Chinese Deals, IPOs, and a Tough Climate for Startups Seeking Capital</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Government sets up panel to review pharma marketing rules</title>
<link>https://edusehat.com/en/government-sets-up-panel-to-review-pharma-marketing-rules</link>
<guid>https://edusehat.com/en/government-sets-up-panel-to-review-pharma-marketing-rules</guid>
<description><![CDATA[ 
Three-member committee to assess whether existing safeguards against unethical marketing are effective and recommend changes to improve monitoring and enforcement.
The post Government sets up panel to review pharma marketing rules appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/08/13102945/Boardroom.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 24 Oct 2026 20:00:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Government, sets, panel, review, pharma, marketing, rules</media:keywords>
<content:encoded><![CDATA[<div><img width="888" height="500" src="https://cdn.expresspharma.in/wp-content/uploads/2020/08/13102945/Boardroom.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/08/13102945/Boardroom.jpg 888w, https://cdn.expresspharma.in/wp-content/uploads/2020/08/13102945/Boardroom-300x169.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2020/08/13102945/Boardroom-768x432.jpg 768w" sizes="(max-width: 888px) 100vw, 888px"></div><p><span><span>The Department of Pharmaceuticals has set up a three-member committee to review the rules governing pharmaceutical marketing practices and recommend measures to curb unethical practices.</span></span></p>
<p><span><span>According to a recent order, the committee will examine whether the existing system for monitoring and enforcing ethical marketing practices is working effectively. It will identify gaps and recommend measures to improve transparency, accountability and compliance.</span></span></p>
<p><span><span>The committee will be chaired by Dr M Srinivas, Member, NITI Aayog. The other members are Preeti Sudan, former Union Health Secretary, and Dr Naresh Trehan, Chairman and Managing Director, Medanta.</span></span></p>
<p><span><span>The committee will review the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), introduced in 2015 as a voluntary, industry-led mechanism to promote ethical marketing by pharma companies. The UCPMP 2024 replaced the original code and strengthened its implementation framework.</span></span></p>
<p><span><span>Its terms of reference include examining issues related to unethical pharmaceutical marketing and assessing the effectiveness of existing monitoring, oversight and enforcement mechanisms.</span></span></p>
<p><span><span>The committee has been asked to recommend improvements to the existing framework. The government order does not specify any immediate changes to the UCPMP or announce new restrictions or penalties.</span></span><span><span> Any changes will depend on the recommendations and subsequent government decisions.</span></span></p>
<p><span><span>The UCPMP aims to ensure that pharma promotion is accurate and evidence-based, and that doctors’ prescribing decisions are not improperly influenced by gifts, financial inducements or other benefits from pharma companies.</span></span></p>
<p>The post <a href="https://www.expresspharma.in/government-sets-up-panel-to-review-pharma-marketing-rules/">Government sets up panel to review pharma marketing rules</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>HDR Promotes Sandy Tkacz to U.S. Health Director</title>
<link>https://edusehat.com/en/hdr-promotes-sandy-tkacz-to-us-health-director</link>
<guid>https://edusehat.com/en/hdr-promotes-sandy-tkacz-to-us-health-director</guid>
<description><![CDATA[ HDR has promoted Sandy Tkacz, FACHA, AIA, NCARB, to Health Director for the firm’s U.S. architecture practice. Her responsibilities will include client engagement, operations, talent and business development.  Tkacz has more than 30 years of experience in healthcare planning, design, business development and practice leadership. She joined HDR in 2013 and has served as Health Director of the firm’s...
The post HDR Promotes Sandy Tkacz to U.S. Health Director appeared first on HCO News.
The post HDR Promotes Sandy Tkacz to U.S. Health Director appeared first on HCO News. ]]></description>
<enclosure url="https://hconews.com/wp-content/uploads/2026/09/HCO-Digital-Edition.png" length="49398" type="image/jpeg"/>
<pubDate>Sat, 24 Oct 2026 06:35:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>HDR, Promotes, Sandy, Tkacz, U.S., Health, Director</media:keywords>
<content:encoded><![CDATA[<p><span data-contrast="auto">HDR has promoted Sandy Tkacz, FACHA, AIA, NCARB, to Health Director for the firm’s U.S. architecture practice. Her responsibilities will include client engagement, operations, talent and business development.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Tkacz has more than 30 years of experience in healthcare planning, design, business development and practice leadership. She joined HDR in 2013 and has served as Health Director of the firm’s U.S. west and east regions, as well as a Health Principal. Across those roles, she directed strategy, client development and recruitment. Her project experience includes academic medical centers, community hospitals, pediatric and rehabilitation facilities, and ambulatory care networks.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">“Healthcare has been at the center of my architecture career for more than 30 years, and I am always inspired by the impact of HDR’s design work,” Tkacz said. “I am honored to take on the role of U.S. Health Director and excited to work with talented health leaders and teams across the country as we continue our unprecedented growth and shape the future of healthcare through design and innovation.”</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">In 2025, Tkacz became a Fellow of the American College of Healthcare Architects (FACHA). The distinction recognizes contributions to health care planning and design, leadership, research, education and mentorship.</span><span data-ccp-props="{}"> </span></p>
<p>The post <a rel="nofollow" href="https://hconews.com/2026/10/23/hdr-promotes-sandy-tkacz-to-u-s-health-director/">HDR Promotes Sandy Tkacz to U.S. Health Director</a> appeared first on <a rel="nofollow" href="https://hconews.com/">HCO News</a>.</p>
<p>The post <a href="https://hconews.com/2026/10/23/hdr-promotes-sandy-tkacz-to-u-s-health-director/">HDR Promotes Sandy Tkacz to U.S. Health Director</a> appeared first on <a href="https://hconews.com/">HCO News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Pharma Friday – October 23, 2026</title>
<link>https://edusehat.com/en/pharma-friday-october-23-2026</link>
<guid>https://edusehat.com/en/pharma-friday-october-23-2026</guid>
<description><![CDATA[ An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome Neurocrine Biosciences, Inc. announced on Oct. 22 a publication of expert perspectives highlighting hyperphagia in Prader-Willi syndrome (PWS) as a complex, neurobiologically driven condition […]
The post Pharma Friday – October 23, 2026 appeared first on Endocrine News. ]]></description>
<enclosure url="https://endocrinenews.endocrine.org/wp-content/uploads/pharmaaaaa7.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 24 Oct 2026 02:50:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pharma, Friday, –, October, 23, 2026</media:keywords>
<content:encoded><![CDATA[<p>An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome Neurocrine Biosciences, Inc. announced on Oct. 22 a publication of expert perspectives highlighting hyperphagia in Prader-Willi syndrome (PWS) as a complex, neurobiologically driven condition […]</p>
<p>The post <a href="https://endocrinenews.endocrine.org/pharma-friday-october-23-2026/">Pharma Friday – October 23, 2026</a> appeared first on <a href="https://endocrinenews.endocrine.org/">Endocrine News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Multiomic Study of MSS CRC Identifies Vulnerabilities Pointing to Therapeutic Possibilities</title>
<link>https://edusehat.com/en/multiomic-study-of-mss-crc-identifies-vulnerabilities-pointing-to-therapeutic-possibilities</link>
<guid>https://edusehat.com/en/multiomic-study-of-mss-crc-identifies-vulnerabilities-pointing-to-therapeutic-possibilities</guid>
<description><![CDATA[ Researchers analyzed mulitomic and clinical data from 2000 colorectal cancer samples and used an AI tool, iPhenMap, to help identify cancer cell vulnerabilities and drug combinations that could be used to treat MSS CRC.
The post Multiomic Study of MSS CRC Identifies Vulnerabilities Pointing to Therapeutic Possibilities appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/09/GettyImages-683401718.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 24 Oct 2026 02:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Multiomic, Study, MSS, CRC, Identifies, Vulnerabilities, Pointing, Therapeutic, Possibilities</media:keywords>
<content:encoded><![CDATA[<p>An international study headed by scientists at RCSI University of Medicine and Health Sciences, and The Institute of Cancer Research, London, has identified potential new ways to treat microsatellite stable (MSS) colorectal cancer (CRC). The team integrated multiomic, single-cell, and clinical data from around 2,000 CRC tumors and developed an AI tool, iPhenMap, to create biological tumor maps.</p>
<p>The study uncovered vulnerabilities in these tumors and identified the drug combinations—including drugs already approved to treat other tumor types—that <em>in vivo</em> experiments in models indicated could be used to target CRC, potentially enabling more effective treatments. The researchers suggest that their results provide a clear roadmap for repurposing existing drugs and for new drug development to create more effective, personalized treatments for patients who currently have limited options.</p>
<p>Research co-lead Professor Annette Byrne, PhD, head of the RCSI Precision Cancer Medicine Group, Department of Physiology and Medical Physics, said “Patients with MSS RAS-mutant metastatic colorectal cancer urgently need better treatment options, particularly when their disease no longer responds to standard therapy. While these findings remain preclinical, they highlight promising therapeutic opportunities and provide a strong foundation for further development. The next step will be to identify the biological features that predict response and determine how these approaches can be advanced safely towards clinical evaluation.”</p>
<p>Professor Byrne is co-senior and co-corresponding author of the team’s published paper in <em>Cancer Cell</em>, titled “<a href="http://dx.doi.org/10.1016/j.ccell.2026.09.014" target="_blank" rel="noopener">Multiomic characterization of microsatellite-stable colorectal cancer reveals distinct biology and targetable vulnerabilities</a>.” In their report the researchers concluded, “Collectively, the results present a rich resource for the CRC research community and provide evidence for combinatorial treatment approaches with translational potential.”</p>
<p>Microsatellite stable colorectal cancer accounts for 80-85% of the 2,500 new bowel cancer cases diagnosed annually in Ireland, but remains challenging to treat, with limited response to many newer therapies. “Between 40% and 50% of these cases harbor mutations in the retrovirus-associated sequences (RAS) gene superfamily, 8–10 with RAS-mutant (RAS-mt) patients consistently displaying inferior outcomes compared with their RAS-wild-type (RAS-wt) counterparts,” the authors wrote.</p>
<p>Trials combining chemotherapy with newer targeted drugs or immunotherapies have delivered only modest improvements over current standard treatments. As the authors further pointed out, “As MSS CRC patient survival in particular has not significantly improved in recent decades, a concerted effort to unravel disease complexity is warranted.” And integrated analyses of multiomics datasets could provide key insights, they suggested.</p>
<p>Using 2,000 patient tumor samples—including more than 300 MSS CRCs that had not previously been profiled—the researchers analyzed genetic, metabolic protein, and clinical data with the help of artificial intelligence (AI) tools, revealing previously unrecognized ways in which the cancer cells divide, grow, adapt and interact with their environment. “To our knowledge, no study to date has presented a global integration of bulk genomics, epigenomics, proteomics, and metabolomics with single-nucleus/single-cell RNA sequencing (sn/scRNA-seq) and clinical parameters (phenome) in the MSS CRC setting,” they stated in their paper.</p>
<p>To do this the team developed a machine-learning AI tool called iPhenMap, which can create a biological map of the tumor. Using this map, they were able to spot connections between the different elements of the tumor—such as the genetic and metabolic features—that have been missed in previous studies that looked at the data in isolation.</p>
<p>Importantly, they found previously unidentified vulnerabilities in the tumors. They then tested these vulnerabilities in laboratory models and showed that certain drug combinations could work well to target them and treat the cancer. For example, the targeted drug trametinib—approved to treat various cancers including melanoma, lung cancer, and thyroid cancer, with a specific mutation—was shown to significantly reduce tumor growth and extend survival in the laboratory models when combined with other drugs.</p>
<p>The researchers hope this work will accelerate the path to clinical testing of new treatment strategies for colorectal cancer using drugs which have already been developed and approved. In addition, the team believe their AI approach could be used to identify more effective drugs for other tumor types.</p>
<p>In their paper the investigators wrote, “In conclusion, the in-depth molecular characterization of MSS CRC has revealed biological insights and promising therapeutic opportunities. By seamlessly integrating genomic, epigenomic, proteomic, metabolomic, and snRNA-seq/scRNA-seq expression analyses, we have substantially advanced understanding of the disease’s complex and heterogeneous biology and in parallel have identified promising new contexts of vulnerabilities with further translational potential.” Given what the team describes as “… the dearth of available effective treatments for MSS CRC patients …” the newly identified vulnerabilities may represent “the foundation for precision oncology treatment frameworks aimed at improving outcomes in this intractable disease setting.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Research co-lead and co-senior author Professor Anguraj Sadanandam, PhD, group leader, Systems and Precision Cancer Medicine Group, The Institute of Cancer Research, London, said, “A major strength of this research is the scale and diversity of the dataset, which was only possible through collaboration with European partners. By bringing together data from patients across multiple countries and integrating DNA, RNA, epigenetic, protein, metabolic, single-cell and clinical data at this scale, we were able to expose connections between tumor biology and therapeutic dependency that would otherwise be missed. AI and machine learning will increasingly help cancer researchers to bring these complex data together, not just to classify tumors, but to understand how they behave, identify their vulnerabilities and guide the development and repurposing of treatments, so that patients can live longer and healthier lives.”</p>
<p>Rodrigo Dienstmann, PhD, Vall d’Hebron Institute of Oncology, Barcelona and University of Vic–Central University of Catalonia was co-senior author of the study.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/multiomic-study-of-mss-crc-identifies-vulnerabilities-pointing-to-therapeutic-possibilities/">Multiomic Study of MSS CRC Identifies Vulnerabilities Pointing to Therapeutic Possibilities</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Wirelessly Powered Electronic Implant, ECHO, Enables Drug&#45;Free Management of ‘Diabesity’</title>
<link>https://edusehat.com/en/wirelessly-powered-electronic-implant-echo-enables-drug-free-management-of-diabesity</link>
<guid>https://edusehat.com/en/wirelessly-powered-electronic-implant-echo-enables-drug-free-management-of-diabesity</guid>
<description><![CDATA[ Researchers developed an implantable, wirelessly powered electronic device, ECHO, that uses electrocatalysis to remove excess glucose from the bloodstream on demand, and could offer a drug-free approach to managing obesity and type 2 diabetes (T2D). 
The post Wirelessly Powered Electronic Implant, ECHO, Enables Drug-Free Management of ‘Diabesity’ appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/07/GettyImages-2174865889.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 24 Oct 2026 02:20:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Wirelessly, Powered, Electronic, Implant, ECHO, Enables, Drug-Free, Management, ‘Diabesity’</media:keywords>
<content:encoded><![CDATA[<p>Researchers at ETH Zürich, the University of Lyon, and the University of Basel have developed an implantable, wirelessly powered electronic device, known as ECHO, (electrocatalytic closed-loop health optimization)  that could offer a drug-free approach to managing obesity and type 2 diabetes (T2D). These two interlinked metabolic disorders often coexist—as “diabesity”—affecting billions of people worldwide.</p>
<p>The team’s implantable device uses electrocatalysis to remove excess glucose from the bloodstream on demand. Tested in a diabesity mouse model, the device was coupled to a continuous glucose monitor (CGM) via a smartphone, enabling autonomous closed-loop metabolic control, such that the electrocatalyst was only activated when glucose levels exceeded a predefined threshold. The results showed that the device rapidly restored elevated blood glucose level to the normal range, with repeated treatments maintaining glucose control for weeks, without any drug use. Lowering glucose also shifted whole-body metabolism toward the use of stored fat, so treated mice also demonstrated reduced body weight.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Research lead Martin Fussenegger, PhD, a professor at the Department of Biosystems Science and Engineering, ETH Zürich, is senior and corresponding author of the team’s published paper in <em>Science Advances</em>, titled “<a href="https://doi.org/10.1126/science.ady8560" target="_blank" rel="noopener">Wireless electrocatalytic closed-loop system for drug-free management of diabesity</a>.” In their report the team wrote in summary, “We believe that closed-loop electrocatalytic devices could establish a platform concept for regulating disease-relevant metabolites, offering a potential route toward drug-sparing, dynamically controlled metabolic interventions.”</p>
<p>Obesity and diabetes are closely interconnected metabolic disorders that reinforce one another through complex hormonal, inflammatory, and energy-regulation processes, together contributing to the global rise of diabesity. “The physiological relationship between obesity and diabetes is bidirectional and self-reinforcing, involving a complex interplay of metabolic, hormonal, and inflammatory changes,” the authors explained. Existing treatments rely heavily on long-term medication and lifestyle changes, while current glucose-monitoring and insulin-delivery systems face limitations in accuracy, reliability, personalization, and cost. “Current treatments rely largely on drugs that lower blood glucose or body weight, but these therapies can produce side effects, require lifelong administration, and may lose effectiveness over time,” the authors continued.</p>
<p>Emerging approaches, including engineered therapeutic cells and drugs that target both weight and blood glucose, offer promise but remain constrained by concerns of side effects, safety, and affordability. Another emerging strategy involves electrocatalysis, which uses electrode surfaces to drive chemical reactions that convert glucose into other compounds. “A subcutaneous implant containing a solid electrocatalyst that directly removes excess glucose from the bloodstream at an electrically adjustable rate could provide a dose-controllable, drug-free therapeutic alternative.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Using electrocatalysis, Debasis Maity and colleagues developed the implantable ECHO device. The wirelessly powered device uses a platinum (Pt)-decorated gold (Au) nanoclusters embedded in a porous, conductive graphite felt (GF) matrix. The electrocatalyst converts circulating glucose into gluconate, which can be excreted through the kidneys.</p>
<p>Connected via smartphone to a continuous glucose monitor, ECHO automatically activates when blood sugar exceeds a predetermined threshold, enabling targeted glucose removal without the need for external insulin or medication.</p>
<p>In a proof-of-concept study in obese mice with type 2 diabetes, the authors showed that wireless activation of the device at low power (0.75 volts and 10 milliamperes) restored normal blood glucose levels within an hour, and shifted the body’s energy use from glucose toward fat. Over six weeks of treatment the mice experienced reductions in body weight and triglyceride levels, alongside increases in circulating free fatty acids and ketone bodies. These changes occurred without detectable episodes of low blood sugar or adverse effects on physiological function, inflammation, or behavior.</p>
<p>“The CGM system tracked glucose concentrations and transmitted the data to a smartphone, which processed the data and sent instructions back to the ECHO device, which in turn rapidly adjusted glucose concentrations to maintain homeostasis in response—achieving this without hypoglycemic episodes or the need for small-molecule drugs or biopharmaceuticals,” the authors wrote.</p>
<p>In a related <a href="https://doi.org/10.1126/science.aem0762" target="_blank" rel="noopener">perspective</a>, William Bentley, PhD, and Gregory Payne, PhD, at the Fischell Department of Bioengineering, University of Maryland, wrote, “Existing bioelectronics devices provide notable access to the nervous and neuromuscular systems … future electronic intervention devices might help to manage diseases other than diabetes, modulate human-microbiome interactions, or maintain redox homeostasis in stress conditions, among many other applications.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/wirelessly-powered-electronic-implant-echo-enables-drug-free-management-of-diabesity/">Wirelessly Powered Electronic Implant, ECHO, Enables Drug-Free Management of ‘Diabesity’</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PACE: Patient featured in ‘Fight of Our Lives’ shares her story</title>
<link>https://edusehat.com/en/pace-patient-featured-in-fight-of-our-lives-shares-her-story</link>
<guid>https://edusehat.com/en/pace-patient-featured-in-fight-of-our-lives-shares-her-story</guid>
<description><![CDATA[ Seven fingertips and both lower legs. For Katy Grainger, that was the toll sepsis took—and the beginning of a second career spent making sure […]
The post PACE: Patient featured in ‘Fight of Our Lives’ shares her story appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/fight-of-our-lives.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 22:50:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PACE:, Patient, featured, ‘Fight, Our, Lives’, shares, her, story</media:keywords>
<content:encoded><![CDATA[<p><span>Seven fingertips and both lower legs. For Katy Grainger, that was the toll sepsis took—and the beginning of a second career spent making sure others recognize it sooner.</span></p>
<p><span>Grainger, a member of the board of directors at the Sepsis Alliance and author who now speaks nationally on sepsis awareness, opened the second day of the Biotechnology Innovation Organization’s (BIO) Oct. 22-23 Patient Advocacy Changemakers Event (PACE) in Washington, D.C. For a room full of patient advocates, her session was less a personal account than a demonstration of what a well-told story can do—the skill at the center of nearly everything else on this year’s program.</span></p>
<p><span>“I think most of the people in this room have seen a TV show where they have heard the term </span><i><span>sepsis</span></i><span>, and usually it happens in a really excited situation: you’ve got a patient in a bed; they’re getting sicker and sicker; they don’t know what’s going on, and someone says, </span><i><span>Oh my gosh, we have to do something,</span></i><span>” began Grainger. “But the reality with sepsis is that 80–90% of it actually happens out in the community. Meaning that you start getting sepsis when you’re at home, and it’s up to you to get yourself to that hospital to save your own life.”</span></p>
<p><span>Today, Grainger commits her time to raising awareness about the risk of sepsis, and the importance of the patient voice. She is featured in “</span><a href="https://fightofourlives.com/stories/katy/"><span>Fight of Our Lives</span></a><span>” BIO’s storytelling campaign.</span></p>
<h3>It could happen to anyone</h3>
<p><span>“I had a small infection on my thumb that was no bigger than a mosquito bite, but there was something about it that told me that something was wrong,” Grainger recalled.</span></p>
<p><span>It was a sunny afternoon in Hawaii, just days after Grainger had taken a vacation with her children that a perfect storm of events led her to the hospital with severe sepsis. </span></p>
<p><span>“I noticed that I had a bump on my thumb. It was pretty small, but it was a weird color, kind of purplish and it had this white haze,” said Grainger. “It just looked unusual, and my gut really told me that something wasn’t right.”</span></p>
<p><span>As so, Grainger did the right thing; she took herself to the hospital. There, doctors gave her antibiotics, took a sample to test and sent her home. But there were a few other issues at play.</span></p>
<p><span>First, her local town was dealing with a higher risk of infections due to past flooding. And second, Grainger was home alone, as her husband was out on a fishing trip for the weekend. Unfortunately for Grainger, while home by herself, her symptoms started coming on fast. </span></p>
<p><span>“I don’t really remember what happened that weekend,” she said. “I can only guess based on text messages.”</span></p>
<p><span>She continues, “I sent my husband a text and I said, ‘</span><i><span>Hey, I threw up, but don’t worry, I’m fine. It was just because of the antibiotic that I took on an empty stomach,’</span></i><span> which also tells me I wasn’t eating. I had these little clues that I just was not generally well all weekend, but I was dismissing it—and that’s really common.”</span></p>
<p><span>Her next text to her husband said goodnight, and that she was going to bed early. </span></p>
<p><span>“That could have been my last text ever to my husband,” Grainger said. “But luckily, I woke up the next morning.”</span></p>
<p><span>Even in her confused state, Grainger was able to call a friend, saying something was wrong and she needed to go to the hospital immediately. Upon arrival, Grainger’s blood pressure was 50/30.</span></p>
<p><span>“I have since been told that that can be called 50/dead,” Grainger said.</span></p>
<h3>Road to recovery</h3>
<p><span>What followed was an emergency sepsis protocol by the hospital, a week in an induced coma, the loss of her lower legs and parts of her fingers—she praised the doctors for saving her thumbs—and a long road to recovery. </span></p>
<p><span>“They extubated me in the hospital, and when they did that, I also was awakened,” Grainger remembered. “The first thing I saw was my missing fingertips, and I immediately went into a very deep depression. We spent three weeks trying to save my hands and feet, and amazingly, we were able to save my hands.”</span></p>
<p><span>But even throughout her hardship, Grainger found hope. And with her new lease on life, albeit a very different life, Grainger has committed herself to helping patients and spreading awareness. </span></p>
<p><span>“Because of the incredible medical care I got, I’m here today, and I can speak to you about the power of the patient voice,” she concluded. “If there’s one thing I’ve learned through all of this, it’s that there is nothing that can replace the story that a person tells about what they have been through. That speaks to people like yourselves in this room; it speaks to government officials; it speaks to people doing the testing and designing the products for patients; and it makes such a difference.”</span></p>
<p>The post <a href="https://bio.news/latest-news/pace-patient-featured-in-fight-of-our-lives-shares-her-story/">PACE: Patient featured in ‘Fight of Our Lives’ shares her story</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Autumn Budget 2026: everything dentists need to know</title>
<link>https://edusehat.com/en/autumn-budget-2026-everything-dentists-need-to-know</link>
<guid>https://edusehat.com/en/autumn-budget-2026-everything-dentists-need-to-know</guid>
<description><![CDATA[ The UK government is set to announce the Autumn Budget for 2026 on 28 October – Iain Stevenson considers what dentists should expect and what they should brace themselves for. The rumour mill has been uncharacteristically quiet in the run-up to this year’s budget. Early signals that capital gains tax could be equalised with income… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/budget.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 19:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Autumn, Budget, 2026:, everything, dentists, need, know</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>The UK government is set to announce the Autumn Budget for 2026 on 28 October – Iain Stevenson considers what dentists<strong> should</strong> expect and what they should brace themselves for</strong>.</p>



<p>The rumour mill has been uncharacteristically quiet in the run-up to this year’s budget. Early signals that capital gains tax could be equalised with income tax now appear to have been quashed, which is good news for dentists planning to sell their practice to help fund their retirement plans.</p>



<p>Speculation that the mansion tax threshold could be cut from £2m to £1.5m has also been dismissed by the Treasury.</p>



<p>The Chancellor has also confirmed that rates of employee national insurance, VAT and corporation tax will remain untouched, as will the basic, higher and additional rates of income tax.</p>



<h2 class="wp-block-heading">So, what’s left for dentists?</h2>



<p>More significant is that the freeze on thresholds as earnings continue to increase means more dentists are inevitably pushed into higher income tax bands.</p>



<p>However, the current economic backdrop means that moves to mitigate this ‘stealth tightening’ should be considered unlikely.</p>



<p>As things stand, this year’s budget may well be something of a non-event for dentists, though there are a number of policy announcements from previous budgets that come into effect in 2027.</p>



<p>Perhaps most pertinent for dentists is the decision that most unused pension funds and death benefits will be included in the estate for inheritance tax purposes from April. ISA allowances are changing too.</p>



<p>These reforms should prompt dentists to seek expert advice to help manage their tax exposure as soon as possible and not be tempted to make any knee-jerk decisions based on pre-budget speculation.</p>



<h2 class="wp-block-heading">Will the Autumn Budget address the £100,000 tax cliff edge?</h2>



<p>The Chancellor should use this budget to address <a href="https://dentistry.co.uk/2023/07/18/have-you-sidestepped-the-personal-allowance-tax-trap/">the tax cliff edges</a> that are discouraging dentists from taking on additional work, at a time when so many people are struggling to access NHS dentistry.</p>



<p>For dentists, the current tax system is creating significant financial disincentives for them to working additional hours <a href="https://dentistry.co.uk/2026/05/24/escaping-the-100000-dental-tax-trap/">when they approach the £100,000 earnings threshold</a>. Many tell us they are even choosing to reduce their sessions because the financial consequences can be so significant.</p>



<p>It’s an issue that disproportionally affects women returning to work after having children, who lose childcare support and child benefit as their earnings rise.</p>



<p>These are not the super-rich that this policy was designed to target when this threshold took effect from April 2010, these are skilled, hardworking dentists who are increasingly being caught by an outdated tax regime that has failed to keep pace with inflation.  </p>



<p>For a dentist who is close to the threshold, losing access to valuable childcare support while facing an effective marginal income tax rate of 60%, or 67.5% in Scotland, will mean taking on additional work may not be worthwhile.</p>



<p>At a time when NHS dentistry is under such pressure, a tax system that discourages experienced dentists from taking on more work is not fit for purpose.</p>



<p><em><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</em></a></em></p>]]> </content:encoded>
</item>

<item>
<title>Menopause and HR: what dental employers need to know</title>
<link>https://edusehat.com/en/menopause-and-hr-what-dental-employers-need-to-know</link>
<guid>https://edusehat.com/en/menopause-and-hr-what-dental-employers-need-to-know</guid>
<description><![CDATA[ Lara Brewood-Green explains the HR responsibilities dental employers have around menopause at work and how they can support their teams. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/menopause-hr-dental-employers.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 19:35:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Menopause, and, HR:, what, dental, employers, need, know</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Lara Brewood-Green explains the HR responsibilities dental employers have around menopause at work and how they can support their teams.</strong></p>



<h3 class="wp-block-heading">What legal responsibilities do dental practices have around menopause at work?</h3>



<p>Menopause itself isn’t currently a protected characteristic under the Equality Act 2010, but employees experiencing menopausal or perimenopausal symptoms might be protected under existing characteristics, such as disability, sex and age.</p>



<p>If someone’s symptoms have a substantial and long-term adverse effect on their ability to carry out normal day-to-day activities, they could meet the legal definition of disability. If they do, the employer has a duty to consider what reasonable adjustments they can make to support that individual.</p>



<p>There was a useful case, <em>Rooney v Leicester City Council</em>, where the Employment Appeal Tribunal recognised that severe menopausal symptoms were capable of amounting to a disability.</p>



<p>Dental practices also have health and safety responsibilities, so they should consider whether the working environment is exacerbating someone’s symptoms. For example, if somebody is working in a surgery without air conditioning or a fan and is really suffering with hot flushes, the practice should be mindful of what reasonable adjustments could be made.</p>



<p>Research published in the <em>British Dental Journal</em> in 2022 reported that 76.9% of the dental team were women, including 92.6% of dental care professionals (DCPs) and 50.9% of dentists.</p>



<p>It also found that 35% of DCPs and 43% of dentists were within an age range potentially affected by menopause.</p>



<p>More recent GDC figures continue to show the female-heavy nature of the profession: of dental nurses joining the register during 2025, 96% were female.</p>



<h3 class="wp-block-heading">What reasonable adjustments might a dental practice need to make?</h3>



<p>Dental practices are often very female-centric workplaces, so this is likely to be particularly relevant.</p>



<p>There’s no one-size-fits-all adjustment because everybody is individual and there are many recognised symptoms.</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p>The starting point should always be a conversation with the individual about what they’re experiencing and what might help them.</p>
</blockquote>



<p>Adjustments can be quite simple. They could include additional breaks between patients, better access to drinking water, a fan or cooler in the working area, flexible start and finish times or changes to uniform where possible.</p>


        <div class="my-4 rounded overflow-hidden bg-context-100/30 px-8 pt-8 pb-4 md:px-10 md:pt-10 md:pb-8">
            <div>
                <div class="inline-block space-y-4">
                                                                <div class="font-secondary font-bold text-xl md:text-2xl">
                            Symptoms of menopause                        </div>
                                                                <div class="w-full my-12 h-px bg-primary-200"></div>
                                    </div>
            </div>
                            <div>
                    <p><!-- wp:paragraph --></p>
<p>Menopause and perimenopause can cause physical, psychological and cognitive symptoms. These can include:</p>
<ul>
<li>Fatigue and sleep problems</li>
<li>Brain fog</li>
<li>Difficulty concentrating</li>
<li>Memory problems</li>
<li>Anxiety</li>
<li>Low mood</li>
<li>Reduced confidence</li>
<li>Headaches and migraines</li>
<li>Joint pain and stiffness.</li>
</ul>
<ul>
<li>
</ul>
<p> </p>
                </div>
                    </div>
        


<p>Symptoms and their severity vary considerably from person to person. However, if colleagues are experiencing fatigue, sleep disturbances, brain fog or having difficulty concentrating, practices could look at the length of clinical sessions or particularly demanding duties and whether things can temporarily be organised differently.</p>



<p>In a dental setting, you also need to think about personal protective equipment (PPE). Surgeries can be small and stuffy, and then you have masks and other PPE on top of that. Adjustments don’t necessarily have to be expensive. It’s about understanding what might work for that individual and agreeing a plan to support them.</p>



<h3 class="wp-block-heading">How should managers handle menopause-related absence or performance concerns?</h3>



<p>I think practices should exercise a level of discretion when applying absence trigger points where absence is related to perimenopause or menopause, rather than applying them automatically. Managers should consider the individual circumstances, whether the symptoms could amount to a disability and whether adjusting trigger points or treating some absence differently might be a reasonable adjustment.</p>



<p>If someone has previously performed well and suddenly starts struggling with concentration, fatigue or absence, it is important to understand whether there is an underlying reason.</p>



<p>Return-to-work conversations are important so managers can understand and document the reason for an absence and whether the employee is struggling with anything.</p>



<p>If there has been a significant increase in absence related to perimenopausal or menopausal symptoms, it may also be helpful, with the employee’s consent, to seek appropriate medical or occupational health advice.</p>



<p>This can give the practice manager or owner a better understanding of how the employee is being affected and what support or adjustments might help.</p>



<p>That doesn’t mean employers can’t manage genuine performance or attendance concerns, but they need to understand what is causing the problem and what support might be appropriate. Managers aren’t there to diagnose menopause. It’s important to take the time to have a good conversation with the individual and document what has been discussed, including any agreed actions.</p>



<h3 class="wp-block-heading">What simple steps can practices take to support their teams and reduce legal risk?</h3>



<p>Some of the most effective measures are quite straightforward. The first is creating an environment where people feel comfortable having a conversation. There used to be a lot of stigma and embarrassment around perimenopause and menopause. Although I don’t think we’re quite in the same place now, it can still be difficult for people to talk about.</p>



<p>If you create an open and supportive environment, employees are more likely to feel comfortable talking to their practice manager about what is happening.</p>



<p>Practices should also review their policies and make sure they are fit for purpose. It’s worth considering a menopause policy or guidance, although having a policy isn’t enough on its own. Managers need to understand how to apply it practically.</p>



<p>Training can also help managers feel comfortable dealing with these situations. Ultimately, it comes back to listening to the individual, agreeing adjustments, documenting them and reviewing them. Perimenopause and menopause can take place over many years, so somebody’s needs may change over time.</p>



<h3 class="wp-block-heading">What has changed under the Employment Rights Act 2025?</h3>



<p>The Employment Rights Act 2025 introduces a specific requirement around menopause action plans for larger employers. From 6 April 2026, action plans around menopause and gender pay gaps were introduced on a voluntary basis. Subject to remaining secondary legislation, they are due to become mandatory from spring 2027 for employers with 250 or more employees.</p>



<p>Those plans will need to set out the steps the employer is taking to address the gender pay gap and support employees experiencing menopause.</p>



<p>Most individual dental practices won’t meet the 250-employee threshold, although larger DSOs will. But that doesn’t mean smaller employers should do nothing. They still need to recognise their existing Equality Act and health and safety responsibilities, have conversations with employees and make reasonable adjustments where needed.</p>


        <div class="my-4 rounded overflow-hidden bg-context-100/30 px-8 pt-8 pb-4 md:px-10 md:pt-10 md:pb-8">
            <div>
                <div class="inline-block space-y-4">
                                                                <div class="font-secondary font-bold text-xl md:text-2xl">
                            The impact at work                        </div>
                                                                <div class="w-full my-12 h-px bg-primary-200"></div>
                                    </div>
            </div>
                            <div>
                    <p><!-- wp:paragraph --></p>
<p>CIPD research among UK working women aged 40-60 found:</p>
<ul>
<li>73% had experienced symptoms relating to the menopause transition</li>
<li>Of those experiencing symptoms, 67% said they had a mostly negative impact at work, while 53% recalled a time when symptoms had prevented them from going into work</li>
<li>67% had experienced psychological symptoms including mood disturbance, anxiety, depression, memory difficulties, loss of confidence or reduced concentration.</li>
</ul>
<p><!-- /wp:list-item --></p>
<p><!-- /wp:list --></p>
                </div>
                    </div>
        


<h3 class="wp-block-heading">What should a team member do if they feel unsupported at work?</h3>



<p>I would encourage them to speak to their practice manager or practice owner in the first instance and explain how their symptoms are affecting them at work. It helps to be specific about the difficulties they are experiencing and what adjustments they think might help.</p>



<p>If they don’t feel comfortable speaking to their immediate manager, they could consider whether there is somebody else within the practice they feel comfortable approaching.</p>



<p>Employees don’t necessarily need to disclose everything, particularly if something feels very personal. The important thing is that the employer understands how their symptoms are affecting them at work and what support they might need. If concerns cannot be resolved informally, the employee could consider raising the matter through the practice’s formal grievance procedure or seeking independent advice, for example from <a href="https://www.acas.org.uk/">Acas</a>.</p>



<h3 class="wp-block-heading">What is your main advice for dental practices?</h3>



<p>Don’t make assumptions – have the conversation. Menopause and perimenopause affect everybody differently. One person might experience hot flushes, while another might struggle predominantly with sleep, migraines or joint problems.</p>



<p>Ask what is affecting them at work, what would help them and what the practice can reasonably accommodate, and then review it.</p>



<p>For dentistry specifically, supporting employees through menopause isn’t only about legal compliance. It’s also about retaining experienced, skilled people. Menopause can have a significant impact on someone’s confidence and wellbeing, and some people may find the changes they experience difficult or unsettling. Having empathy and taking the time to listen is a really good place to start.</p>


        <div class="my-4 rounded overflow-hidden bg-context-100/30 px-8 pt-8 pb-4 md:px-10 md:pt-10 md:pb-8">
            <div>
                <div class="inline-block space-y-4">
                                            
                                                                <div class="font-secondary font-bold text-xl md:text-2xl">
                            Menopause Matters in Dentistry                        </div>
                                                                <div class="w-full my-12 h-px bg-primary-200"></div>
                                    </div>
            </div>
                            <div>
                    <p>In partnership with Colosseum Dental, <em>Dentistry</em> is recognising October’s Menopause Awareness Month.</p>
<p>Through expert insight, evidence-based information and the real experiences of dental professionals, the month-long campaign will focus on education, visibility and practical support, exploring the different ways menopause can affect those working across dentistry – as well as its potential implications for oral health.</p>
<p>Read more from the campaign:</p>
<ul>
<li><a href="https://dentistry.co.uk/2026/10/19/observation-without-assumption-the-evidence-on-falling-oestrogen-and-the-mouth/">Observation without assumption: the evidence on falling oestrogen and the mouth</a></li>
<li><a href="https://dentistry.co.uk/2026/10/14/menopause-is-in-the-chair-are-we-trained-to-see-it/">Menopause is in the chair, are we trained to see it?</a></li>
<li><a href="https://dentistry.co.uk/2026/10/09/perimenopause-and-menopause-signs-to-look-out-for-in-dental-patients/">Perimenopause and menopause: signs to look out for in dental patients</a></li>
<li><a href="https://dentistry.co.uk/2026/10/05/transition-not-decline-supporting-women-in-dentistry-through-midlife/">Transition, not decline: supporting women in dentistry through midlife</a></li>
<li><a href="https://dentistry.co.uk/2026/10/01/understanding-menopause-in-dentistry/">Understanding menopause in dentistry</a>.</li>
</ul>
                </div>
                    </div>
        


<p><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</em></a></p>]]> </content:encoded>
</item>

<item>
<title>OMM for COMLEX Level 1 and Level 2&#45;CE: Study Guide and Free Anki Deck</title>
<link>https://edusehat.com/en/omm-for-comlex-level-1-and-level-2-ce-study-guide-and-free-anki-deck</link>
<guid>https://edusehat.com/en/omm-for-comlex-level-1-and-level-2-ce-study-guide-and-free-anki-deck</guid>
<description><![CDATA[ In my experience, studying the OMM portion for COMLEX Levels 1 and 2 works best when combined with your typical medical practice questions. It’s important to learn the reasoning behind the findings, start early, and use tools like spaced repetition to master the material.    As an osteopathic medical student, I understand how overwhelming board […]
The post OMM for COMLEX Level 1 and Level 2-CE: Study Guide and Free Anki Deck appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/10/pexels-liza-summer-6347889-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 19:30:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>OMM, for, COMLEX, Level, and, Level, 2-CE:, Study, Guide, and, Free, Anki, Deck</media:keywords>
<content:encoded><![CDATA[<p><span>In my experience, studying the OMM portion for COMLEX Levels 1 and 2 works best when combined with your typical medical practice questions. It’s important to learn the reasoning behind the findings, start early, and use tools like spaced repetition to master the material. </span></p>
<p> </p>
<p><span>As an osteopathic medical student, I understand how overwhelming board prep can feel because you have another whole subject to cover within the same amount of time. Not only must you master the clinical material, but you must also be able to view its implications within the framework of osteopathic manipulative medicine in case you get an exam question testing these very principles. Then comes the other question every osteopathic medical student likely asks themselves: <a href="https://elitemedicalprep.com/comlex-vs-usmle-which-exam-should-you-prioritize/">should you take USMLE in addition to COMLEX?</a></span></p>
<p> </p>
<p><span>Depending on your specialty interest and program scope, it may be beneficial to take both exams. Suddenly, you have two practice assessments to fit into your schedule, extra costs, and another exam date booked. Even before dedicated, this can feel overwhelming. OMM is likely the subject you keep promising to review in the future. But I am convinced that OMM does not have to be the portion of COMLEX that worries you! It can accompany your medical education as another tool for understanding musculoskeletal mechanics, anatomy, and physical exam findings that you will see in almost every board question- whether USMLE or COMLEX. </span></p>
<p> </p>
<p><span>This guide shares my study approach, explains how to review OMM for both Level 1 and Level 2, and shares a free Anki deck. This deck includes 561 cards across 17 osteopathic disciplines, organized to make reviewing this subject more manageable! </span></p>
<p> </p>
<h2><b>Finding Room for OMM in your Study Plan</b></h2>
<p><span>Personally, the hardest part of studying OMM for boards was deciding where to fit it into my study plan. After reviewing cardiology, renal physiology, surgery, or infectious disease, it may feel daunting to squeeze sacral biomechanics into an already 15-hour study day. My advice is to integrate OMM into your study schedule before it becomes an urgent matter you have put off for too long. Not every student needs the same plan. Someone with a very strong understanding of anatomy may only require a few retrieval lessons. On the other hand, someone who feels overwhelmed by diagnoses may need to reframe the subject in a whole new light. It is important to recognize your strengths and weaknesses, and craft your schedule in a way that capitalizes on them. For a broader framework, see our guide to <a href="https://elitemedicalprep.com/how-to-prepare-for-the-usmle-and-comlex-exams-simultaneously/">preparing for USMLE and COMLEX simultaneously</a></span></p>
<p> </p>
<h2><b>How I used UWorld, NBMEs, NBOMEs, and OMM Anki/ Study Guides</b></h2>
<p><span>UWorld and NBME practice exams remained at the center of my study schedule for the clinical material. This would have been the plan even if I had not taken the USMLE. I believe there is no question bank with explanations and graphics as complete and attractive as UWorld. I supplemented that work with OMM Anki Cards and my study guides from preclinical OMM courses. If I had a question on scoliosis, vertebral anatomy, referred pain, or any other clinical subject that aligns with OMM, I would review the corresponding OMM deck that same evening to build those mental associations. </span></p>
<p> </p>
<p><span>Each resource had a specific purpose! Practice questions helped me apply my medical knowledge, assessments helped me identify my weaknesses, and the OMM Anki deck gave me a dedicated way to review material that needed separate attention but shared a similar underlying clinical basis. That distinction is important to make: NBME resources will not assess your OMM comprehension. Integrate multiple resources spanning multiple subjects so you don’t fall behind!</span></p>
<p> </p>
<p>If you’re deciding which tools to combine, explore our <a href="https://elitemedicalprep.com/top-resources-for-comlex-level-1-and-2-what-to-use-and-when/">top resources for COMLEX Level 1 and Level 2</a>.</p>
<p> </p>
<h2><b>Why does the same OMM Anki deck help for both Level 1 and Level 2?</b></h2>
<p><span>Luckily for you, the same foundational OMM knowledge remains useful across both board exams. What changes is really just in the context in which you apply it. </span></p>
<p> </p>
<p><span>For Level 1, the focus remains more on foundational biomedical sciences and osteopathic principles. These same principles translate over to Level 2, but this exam emphasizes clinical sciences and competence for residency. Level 1 focuses more on anatomy, terminology, and diagnostic patterns. These same fundamentals appear on Level 2 but integrate clinical interpretation, treatment selection, and the safety of osteopathic techniques based on your patient population. These are not exclusive categories, but rather overarching focus points! </span></p>
<p> </p>
<p><span>Both exams require you to connect the same OMM knowledge you learned during M1 and M2 preclinical years to patient presentations. The deck preserves this foundation, while your practice questions help you make the concepts more clinically relevant. The deck combines factual recall and diagnostic reasoning. Some sections reinforce terminology, foundations, and anatomy while others ask you to interpret findings or choose a treatment setup. Below is how I recommend approaching each subdeck. </span></p>
<p> </p>
<h2><b>Foundations of OMM</b></h2>
<p><span>You will want to start here if OMM terminology still feels confusing at times. This subdeck covers somatic dysfunctions, TART changes, motion barriers, planes/axes, spinal mechanics, and the osteopathic foundational models. Knowing this vocabulary will be helpful for the rest of the Anki deck and ultimately to successfully answer board questions. I recommend paying attention to how to identify restrictive barriers versus positions of ease, as this distinction defines the nomenclature behind osteopathic diagnoses. Always remember to recognize the motion deficits when coming up with a diagnosis- you’ll thank yourself when you go on to learn treatment options! </span></p>
<p> </p>
<h2><b>OMT Principles & Techniques</b></h2>
<p><span>This subdeck focuses on the different technique categories within this field. Examples include muscle energy, soft tissue, HVLA, counterstrain, myofascial release, and facilitated positional release. This deck also touches on the high-yield contraindications to these modalities, which is relevant to know when you get a board question on a patient with multiple comorbidities! I also recommend mentally organizing whether the treatment modality is direct or indirect. Then consider whether the technique in question fits the clinical profile of the patient being presented to you. This is more useful than memorizing a treatment without understanding its clinical relevance. </span></p>
<p> </p>
<h2><b>Cervical Spine</b></h2>
<p><span>The cervical cards cover anatomy, OA/AA mechanics, typical cervical motion, exam findings, and the relevant clinical tests. Do not blindly apply one coupling rule to every cervical segment. Translate the exam language into the cervical segment’s motion preference. Feel free to use your hands to help visualize it! These hand movements help build muscle memory, since you practice them in your OMT labs. </span></p>
<p> </p>
<h2><b>Thoracic Spine/ Scoliosis</b></h2>
<p><span>This section highlights thoracic landmarks, facet joint orientations, the rule of threes, spinal diagnoses, and key concepts in scoliosis. Work on connecting the static findings with motion testing. I found it really helpful to visualize a static exam on a patient first, then follow the motion as the question progresses. When it comes to scoliosis, there are certain numbers I felt like were really important to know, including the Cobb angle degrees that would implicate the cardiopulmonary system. The goal is to be able to interpret whatever findings are given to you on the exam! </span></p>
<p> </p>
<h2><b>Ribs & Respiration</b></h2>
<p><span>The rib subdeck addresses anatomy, respiratory motion, inhalation/exhalation dysfunctions, key ribs, and the key muscles used in the treatments. The key to recognizing rib mechanics is really understanding how to utilize the respiratory cycle to assess thoracic cavity motion. You must identify the respiratory phase that is restricted, then name the dysfunction and figure out which rib matters for the proposed treatment modality. Visualizing the rib movement really makes the complicated stem easier to follow! </span></p>
<p> </p>
<h2><b>Lumbar Spine</b></h2>
<p><span>This subdeck includes anatomy, nerve root findings from the lumbosacral plexus, disc pathology, spondylosis, and spondylolisthesis. These are not only relevant to the OMM section of COMLEX, but also to the neurology questions on USMLE </span><span>and</span><span> COMLEX! It’s important to distinguish between a mechanical finding and a clinical diagnosis. I think this section is especially relevant, since so many neurology questions involve the lumbar spine. Connect motor, sensory, and reflex information rather than memorizing each feature separately. </span></p>
<p> </p>
<h2><b>Innominate/Pelvis/Psoas/Piriformis</b></h2>
<p><span>This is a very high-yield subdeck! These cards cover hip maneuvers, pelvic landmarks, flexion testing, anatomy, muscle patterns, innominate rotations/flares/shears, pubic dysfunctions, and the associated symptom distributions. Anatomy is pivotal to explaining these patients’ presentations. Consider how a muscle’s attachments and actions relate to posture, movement, and discomfort. I also found it really helpful to visualize muscle attachments and origins when learning the treatment positions for these dysfunctions. I also found it helpful to sketch the pelvis when first doing this Anki deck! </span></p>
<p> </p>
<h2><b>Sacrum</b></h2>
<p><span>Oh, sacrum. The sacral cards cover axes, torsions, unilateral/bilateral dysfunctions, spring tests, seated flexion tests, and relationships with L5- which is very high yield! I believe sacral diagnoses can become more manageable if you interpret the findings in an organized sequence. Combine the sacral sulcus depth, ILA findings, and motion tests into one diagnosis, and practice explaining why this diagnosis makes sense considering sacral mechanics. You cannot just memorize buzzwords! COMLEX will present you with any combination of findings. You must recognize how the different puzzle pieces fit together. </span></p>
<p> </p>
<h2><b>Short Leg Syndrome/Gait</b></h2>
<p><span>This section discusses the gait phases and the classically tested OMM patterns associated with short leg syndrome/ compensation. Although lower-yield, I still believe it’s helpful to know the contents of this deck to better understand overall mechanics! </span></p>
<p> </p>
<h2><b>Cranial/TMJ</b></h2>
<p><span>This subdeck covers traditional cranial principles, strain patterns, vault-hold findings, and related concepts. This section is quite large, but cranial is one of those fields that requires great visualization and attention to detail. For every cranial question, I used my hands to work through the spatial relationships. I recommend doing that when doing this deck as well, to strengthen that muscle memory for test day! </span></p>
<p> </p>
<h2><b>Upper and Lower Extremities </b></h2>
<p><span>The upper extremity subdeck reviews shoulder anatomy/exam, thoracic outlet, clavicle and radial head mechanics, and common elbow, wrist, and hand conditions. The lower extremity subdeck reviews the knee and various high-yield tests, fibular head mechanics, ankle and foot anatomy, and injury-related patterns. This ties in well to the trauma and MSK clinical questions you may get on COMLEX or USMLE. Connect the physical exam findings with the structure being examined, the motion involved, and the likely functional problem! I personally felt like this deck was floridly high-yield during my OMM review because these topics overlap with many MSK/ sports medicine questions. </span></p>
<p> </p>
<h2><b>Viscerosomatics</b></h2>
<p><span>This section reviews sympathetic and parasympathetic anatomy, the organ-related spinal levels (extremely high yield for both Level 1 and Level 2), GI subdivisions (foregut, midgut, hindgut), and traditional OMM associations. Understanding the major anatomical organizations before learning the individual organizations is helpful for this section. I found it helpful to test myself in both directions. That is, test the viscerosomatic levels and see if you can name the organs, and vice versa! You must know all these levels extremely well. </span></p>
<p> </p>
<h2><b>Chapman’s Points and Tender Points</b></h2>
<p><span>These cards distinguish Chapman reflex points from counterstrain tender points and review their selected locations and associations. I did this subdeck multiple times because the points are easy to mix up. A location associated with an organ in a traditional teaching model is not interchangeable with a counterstrain treatment point!</span></p>
<p> </p>
<h2><b>Lymphatics</b></h2>
<p><span>This smaller subdeck focused on general lymphatic treatment sequence, central outflow, diaphragm restrictions, and lymphatic-related concepts. Lower yield, but still helpful in case you get a question on it!</span></p>
<p> </p>
<h2><b>Integrated Practice</b></h2>
<p><span>This section combines high-yield findings into short diagnostic and treatment problems in an open-ended fashion (I found that being able to answer questions open-ended made sure I really knew it).  It includes spinal, pelvic, sacral, rib, and extremity applications while integrating OMM safety principles. </span></p>
<p> </p>
<h2><b>How to Use the Deck</b></h2>
<p><span>I recommend beginning approximately eight weeks before your exam and doing a manageable amount most evenings. This creates room for repeated review alongside practice questions! Students with larger knowledge gaps may need to begin earlier. Students closer to their exam should prioritize weaknesses while protecting time for question practice. </span></p>
<p> </p>
<p><span>With 561 cards, doing roughly 15-20 new cards on study days can make an initial pass feasible within several weeks. However, cards to review definitly accumulate, so stay consistent! Reduce new cards when the workload stops being sustainable. During the first two weeks, establish your routine and review the foundations. Add regional sections as you become comfortable with the terminology. During weeks three through five, continue introducing cards while increasing application. Pair each topic with OMM questions. After a missed question, return to the relevant section and identify what failed: recall, interpretation, or treatment reasoning. During weeks 3-5, continue introducing cards while increasing application. Pair each topic with OMM questions/ subjects that you did earlier that day to form mental associations. After a missed question, return to the relevant section and identify what failed. Was it recall, interpretation, or treatment reasoning? During weeks six and seven, emphasize mixed questions and difficult cards because familiarity with a section heading can otherwise become a clue. In the final week, focus on recurring errors and manageable review. Avoid creating an enormous backlog of new material. Keep the facts you already understand accessible while addressing specific remaining gaps.</span></p>
<p> </p>
<h4><strong>Fill out the form below to receive your free COMLEX Level 1 and Level 2-CE Anki Deck via email!</strong></h4>
<p><span data-mce-type="bookmark" class="mce_SELRES_start">﻿</span><span data-mce-type="bookmark" class="mce_SELRES_start">﻿</span><span data-mce-type="bookmark" class="mce_SELRES_start"></span></p>
<p> </p>
<h3><strong>More steps</strong></h3>
<p><span>Before revealing a card, commit to an answer. For diagnostic cards, give a brief explanation. Recognizing the answer after turning the card over is different from retrieving it independently. If you repeatedly miss a concept, pause the cards and repair the underlying understanding (i.e., watch a YouTube video, refer to your preclinical OMM notes, etc). A drawing, short explanation, or comparison table may help more than another immediate repetition! At that point, memorizing a card helps less than understanding the underlying concept. Keep a short error log with specific entries. This will give you a concrete list to refer to. <strong>Make it SPECIFIC! </strong></span></p>
<p> </p>
<h2><strong>Final thoughts</strong></h2>
<p><span>Use practice questions to check transfer. You should be able to apply the concept when the wording changes, when findings appear in a different order, or when the vignette includes distracting information. That is what you will see on boards! I recommend completing relevant True Learn or ComQuest OMM-specific practice questions for your review of the topics being taught with these cards. For additional strategies for applying these concepts, read our guide on <a href="https://elitemedicalprep.com/how-to-study-for-omm-osteopathic-manipulative-medicine-questions/">how to study for OMM questions</a>.</span></p>
<p> </p>
<p><span>Finally, keep OMM within the larger purpose of medical education. It offers another perspective on structure, function, and examination. Appropriate use still depends on the patient’s condition, the evidence, your training, and treatment safety.</span></p>
<p> </p>
<p><span>You got this! OMM is a fun extra subject to study. Do not let it scare you! If you’d benefit from more guidance along the way, EMP’s tutors can help you work through challenging OMM concepts and fit your review into a manageable study plan. Explore our <a href="https://elitemedicalprep.com/comlex-level-1-tutoring">COMLEX Level 1 tutoring</a> or <a href="https://elitemedicalprep.com/comlex-level-2ce-tutoring/">COMLEX Level 2-CE tutoring</a> for personalized support throughout your preparation.</span></p>
<p>The post <a href="https://elitemedicalprep.com/omm-for-comlex-level-1-and-level-2-ce-study-guide-and-free-anki-deck/">OMM for COMLEX Level 1 and Level 2-CE: Study Guide and Free Anki Deck</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>In the biotech world, you can’t see everything</title>
<link>https://edusehat.com/en/in-the-biotech-world-you-cant-see-everything</link>
<guid>https://edusehat.com/en/in-the-biotech-world-you-cant-see-everything</guid>
<description><![CDATA[ Earlier this week, I attended a screening of You Can See Everything, the buzzy new documentary about the disgraced former biotech CEO Elizabeth Holmes.  I went in not really knowing what to expect. I’d avoided spoilers (and won’t be giving anything away here, either!). I was wondering what new information this film could reveal, given… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/YCSE_NP_1_1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 19:15:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>the, biotech, world, you, can’t, see, everything</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Holmes's charm is still unsettling on screen:</strong> Even knowing the full Theranos story, the documentary captures how effectively Holmes plants seeds of doubt—journalists who interviewed her in her prime later admitted she had fooled them completely.</li><br><li><strong>Peer review isn't a perfect safety net:</strong> Science's built-in fact-checking system has real cracks—10,000 papers were retracted in 2023 alone, and preprint servers, press releases, and social media now routinely bypass it.</li><br><li><strong>Reporters face the same vulnerability as investors:</strong> Even seasoned science journalists rely on trust and expert opinion to vet claims, raising an uncomfortable question: how confident can anyone really be that they wouldn't have fallen for it too</li></ul>" data-chronoton-post-id="1147610" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p class="wp-block-paragraph">Earlier this week, I attended a screening of <em>You Can See Everything</em>, the buzzy new documentary about the disgraced former biotech CEO Elizabeth Holmes. </p>



<p class="wp-block-paragraph">I went in not really knowing what to expect. I’d avoided spoilers (and won’t be giving anything away here, either!). I was wondering what new information this film could reveal, given how familiar many of us are with the Theranos story thanks to years of media coverage, the best-selling book <em>Bad Blood</em>, and the Hulu series <em>The Dropout</em>, starring Amanda Seyfried.</p>



<p class="wp-block-paragraph">Like many others who have seen the film, I came away feeling unsettled. But not just about Holmes’s fraud and the somewhat disturbing interactions between the subjects. The film reignited a concern I’ve had about covering science for most of my career: Despite our best efforts, we never can actually <em>see everything</em>.</p>





<p class="wp-block-paragraph">In case you’re rusty on the details, Elizabeth Holmes dropped out of Stanford University in 2003 to run Theranos, a diagnostics company she founded, when she was just 19. She went on to claim that her company had invented a way to run over 100 diagnostic tests on just a few drops of blood.</p>



<p class="wp-block-paragraph">Holmes raised hundreds of millions of dollars for Theranos, which was valued at $9 billion in 2014. <em>Forbes</em> named her the youngest self-made female billionaire—she was <a href="https://www.forbes.com/profile/elizabeth-holmes/">worth $4.5 billion</a> when she was just 30 years old.</p>



<p class="wp-block-paragraph">Things started to unravel in 2015, when <a href="https://www.wsj.com/articles/theranos-has-struggled-with-blood-tests-1444881901">an investigation by the <em>Wall Street Journal</em></a> raised concerns by former Theranos employees that the tests didn’t work. Some also said that the company’s device had not been tested properly, and that blood samples had been analyzed on machines from other companies instead. <em>MIT Technology Review</em> named it one of the <a href="https://www.technologyreview.com/2015/12/31/164066/the-6-biggest-technology-failures-of-2015/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">biggest technology failures of 2015</a>.</p>



<p class="wp-block-paragraph"><em>Forbes</em> had revised Holmes’s worth to $0 by 2016. That year, a damning government report said that <a href="https://www.technologyreview.com/2016/04/01/161208/theranos-promised-a-revolution-but-delivered-dangerous-errors/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">the company’s lab was struggling with basic procedures</a> and gave patients results even when they knew they could be wrong.</p>



<p class="wp-block-paragraph">In 2018, Theranos, Holmes, and former company president Ramesh Balwani were <a href="https://www.technologyreview.com/2018/03/14/241044/sec-charges-theranos-founder-elizabeth-holmes-with-massive-fraud/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">charged with “massive fraud.”</a> In 2022, she was sentenced to a little over 11 years in prison for defrauding investors. She began serving her sentence in May 2023.</p>



<p class="wp-block-paragraph">It was around a month before this that filmmakers Nathan Fielder, Lance Oppenheim, and their colleagues began documenting Holmes and her partner, Billy Evans, at home with their two young children. I’m not giving anything away when I say it’s an extremely intimate portrayal—at least of how the two adults interact with Fielder, who is also a central character in the film.</p>



<p class="wp-block-paragraph">As you might know if you’ve seen <a href="https://www.youtube.com/watch?v=HvW_N5p1q44">the trailer</a>, there are plenty of super close-ups. I felt as if I spent most of the film staring straight into the faces of those people. And almost the whole way through, they all seemed to be trying to figure each other out. Holmes is known for her dishonesty, but she invited cameras into her home in an apparent bid to reframe the narrative and position herself as an honest person with an unusual mind. Will anyone believe her?</p>





<p class="wp-block-paragraph">I couldn’t help feeling some empathy for Holmes, a mother we see preparing to leave her two kids for a lengthy prison sentence. And even though I have long known the facts, Holmes is clearly an effective manipulator. You can see her plant the seeds of doubt in Fielder’s mind. At times, I felt she was convincing me, sitting in my cinema seat. Maybe she really didn’t <em>mean</em> to lie?</p>



<p class="wp-block-paragraph">But then I remembered how other journalists felt after being taken in by her claims. “I blew it,” <em>Fortune</em>’s Roger Parloff <a href="https://fortune.com/2015/12/17/how-theranos-misled-me-elizabeth-holmes/">reflected</a> in 2015, a year after profiling Holmes and her company. “I’m pretty sure she lied to me,” <em>STAT</em>’s Matthew Herper <a href="https://www.statnews.com/2026/10/20/elizabeth-holmes-superpower-authenticity-vs-truth-matt-herper-take/">wrote</a> recently, having interviewed Holmes in 2015. Even the former employee turned whistleblower Tyler Shultz, who <em>knew</em> the product didn’t work, said that he could “have a five-minute conversation with her and walk away feeling like my work was changing the world,” he <a href="https://www.statnews.com/2022/06/01/theranos-whistleblower-tyler-shultz-lessons-learned/">said in 2022</a>.</p>



<p class="wp-block-paragraph">I didn’t cover Theranos in the 2010s. If I’d interviewed Holmes, would I have fallen for it all?</p>



<p class="wp-block-paragraph">One of the early red flags in the Theranos case was the lack of published, peer-reviewed data. Much of the company’s work was classified as a “trade secret.” Scientists tend to publish their work in journals—a slow process that involves having the work evaluated by often anonymous experts in the field, who provide feedback, highlight questionable conclusions, and often ask for clarification. Peer review is meant to add rigor to the publication process. You should be able to trust published scientific papers.</p>



<p class="wp-block-paragraph">Except that sometimes you can’t.</p>



<p class="wp-block-paragraph">Scientists aren’t perfect. Some will exaggerate their results or inflate their importance. Some manipulate data to serve a hypothesis. Sometimes these infractions are caught during peer review, but not always. There are plenty of examples of scientific findings that could never be replicated by other labs and ended up collapsing under the weight of real evidence. Many papers ultimately end up with corrections. Some are withdrawn—<a href="https://www.nature.com/articles/d41586-023-03974-8">10,000 research papers were retracted in 2023</a>.</p>



<p class="wp-block-paragraph">At any rate, there’s been a shift to sharing research in other ways. Today, many scientists opt to publish their work at preprint servers like arXiv, medRxiv, and bioRxiv before they submit them to established journals. Those outlets bypass peer review. So do company press releases, social media posts, and many conference presentations. And I get a lot of my stories from conversations and interviews.</p>



<p class="wp-block-paragraph">I’ll admit I’ve looked at a scientific finding and thought: A scientist has just said they’ve done that. <em>How can I be sure they really have?</em></p>



<p class="wp-block-paragraph">I like to think that I hold myself to high journalistic standards here, as does everyone at <em>MIT Technology Review</em>. I would never publish a story about some new scientific development without doing my own form of peer review, and asking scientists—ideally people I know and trust—what they think of a new claim. </p>



<p class="wp-block-paragraph">But the film is a stark reminder of how easy it can be to fall for an appealing narrative. While most scientists are, I hope, pretty honest, and Holmes is certainly an outlier, we should all continue to interrogate the claims being fed to us. If you’ve seen the film, let me know what you think!</p>



<p class="wp-block-paragraph"><em>This article first appeared in The Checkup, </em>MIT Technology Review’s<em> weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, </em><a href="https://forms.technologyreview.com/newsletters/biotech-the-checkup/?_ga=2.241810882.15113993.1664981064-43237434.1647441349"><em>sign up here</em></a>.</p>]]> </content:encoded>
</item>

<item>
<title>Ottawa Heart Institute reports significant reduction in surgical infections following new prevention protocol</title>
<link>https://edusehat.com/en/ottawa-heart-institute-reports-significant-reduction-in-surgical-infections-following-new-prevention-protocol</link>
<guid>https://edusehat.com/en/ottawa-heart-institute-reports-significant-reduction-in-surgical-infections-following-new-prevention-protocol</guid>
<description><![CDATA[ Canadian cardiac centre reports a 51.5% relative reduction in certain surgical-site infections in an observational evaluation involving more than 2,100 procedures. A new evaluation at the University of Ottawa Heart Institute suggests that a light-activated infection-prevention treatment may help reduce surgical-site infections among patients undergoing coronary artery bypass surgery. The findings, presented at the 2026 […]
The post Ottawa Heart Institute reports significant reduction in surgical infections following new prevention protocol appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Sterile-Surgical-Instruments-in-the-Operating-Room.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 19:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Ottawa, Heart, Institute, reports, significant, reduction, surgical, infections, following, new, prevention, protocol</media:keywords>
<content:encoded><![CDATA[<p><em>Canadian cardiac centre reports a 51.5% relative reduction in certain surgical-site infections in an observational evaluation involving more than 2,100 procedures.</em></p>
<p>A new evaluation at the University of Ottawa Heart Institute suggests that a light-activated infection-prevention treatment may help reduce surgical-site infections among patients undergoing coronary artery bypass surgery.</p>
<p>The findings, presented at the 2026 Canadian Cardiovascular Congress in Ottawa, examined 2,172 cardiac bypass procedures performed between June 2023 and January 2026.</p>
<p>Researchers reported that infections at sites where blood vessels were removed for bypass surgery declined from 3.3 per cent to 1.6 per cent following the introduction of a nasal photodisinfection protocol.</p>
<p>That represents a relative reduction of approximately 51.5 per cent.</p>
<p>The findings were announced October 23 by Canadian medical technology company Ondine Biomedical, whose Steriwave system was used in the hospital’s infection-prevention program. <a href="https://www.investegate.co.uk/announcement/rns/ondine-biomedical-inc-npv-cdi---obi/ottawa-heart-institute-reduces-cabg-ssis-by-51-5-/9837640?utm_source=chatgpt.com">Investegate</a></p>
<h3>A different approach to preventing infections</h3>
<p>Surgical-site infections remain an important concern for hospitals because they can complicate recovery, extend hospital stays and increase healthcare costs.</p>
<p>The Ottawa evaluation focused specifically on infections occurring where veins or arteries are harvested from a patient’s leg or arm during coronary artery bypass grafting.</p>
<p>Traditionally, some hospitals have used mupirocin, a topical antibiotic applied inside the nose before surgery, to reduce bacteria that could contribute to infections.</p>
<p>The newer approach uses a photosensitive compound activated by red light to reduce potentially harmful microorganisms in the nasal passages.</p>
<p>Unlike conventional antibiotic treatments that may require patients to follow a multi-day application schedule, photodisinfection is administered by healthcare professionals at the point of care.</p>
<h3>More than 2,100 procedures examined</h3>
<p>Researchers compared outcomes from two consecutive periods.</p>
<p>The first involved 1,678 coronary bypass procedures during a 24-month period when mupirocin was used.</p>
<p>The second included 494 procedures during the first eight months of the hospital’s photodisinfection program.</p>
<p>The evaluation found that the proportion of patients experiencing infections at blood-vessel harvest sites decreased from 3.3 per cent to 1.6 per cent.</p>
<p>Patient adherence to the infection-prevention protocol also improved.</p>
<p>Researchers reported 93.3 per cent compliance with the nurse-administered photodisinfection approach, compared with 35.4 per cent during the earlier mupirocin period.</p>
<p>The findings suggest that simplifying how preventive treatments are delivered could help hospitals improve consistency in infection-control practices.</p>
<h3>Important limitations</h3>
<p>The evaluation was conducted at a single hospital and compared outcomes across different periods rather than randomly assigning patients to treatments.</p>
<p>Consequently, the findings demonstrate an association between the new protocol and lower infection rates but do not establish that photodisinfection alone caused the improvement.</p>
<p>Other changes in clinical practices or patient characteristics may have influenced the results.</p>
<p>The findings have been reported in conference abstracts, and further peer-reviewed research will help determine how effectively the approach performs across different hospitals and surgical populations.</p>
<h3>Implications for Canadian hospitals</h3>
<p>The results highlight growing interest in infection-prevention technologies that can be incorporated directly into existing surgical workflows.</p>
<p>For hospitals, improving adherence to preventive measures can be as important as introducing new technologies.</p>
<p>A treatment administered by healthcare professionals immediately before surgery may help reduce the challenges associated with asking patients to complete preventive treatments independently.</p>
<p>The findings also underscore the role of nursing teams in implementing infection-prevention programs and monitoring compliance.</p>
<p>As Canadian healthcare organizations recognize National Infection Control Week, October 19–23, the Ottawa experience offers an example of how clinical innovation and changes in care delivery may contribute to safer surgical procedures.</p>
<p>Further evaluation will be needed to establish whether similar improvements can be achieved consistently across other healthcare settings.</p>
<p>Source: <a href="https://www.investegate.co.uk/announcement/rns/ondine-biomedical-inc-npv-cdi---obi/ottawa-heart-institute-reduces-cabg-ssis-by-51-5-/9837640?utm_source=chatgpt.com">Ottawa Heart Institute infection-prevention findings — regulatory news announcement</a></p>
<p>The post <a href="https://www.hospitalnews.com/ottawa-heart-institute-reports-significant-reduction-in-surgical-infections-following-new-prevention-protocol/">Ottawa Heart Institute reports significant reduction in surgical infections following new prevention protocol</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Amneal Pharmaceuticals inaugurates Rs 135 crore office in Ahmedabad</title>
<link>https://edusehat.com/en/amneal-pharmaceuticals-inaugurates-rs-135-crore-office-in-ahmedabad</link>
<guid>https://edusehat.com/en/amneal-pharmaceuticals-inaugurates-rs-135-crore-office-in-ahmedabad</guid>
<description><![CDATA[ 
The 3.35 lakh sq ft facility will accommodate around 1,200 employees and support the company’s operations in India
The post Amneal Pharmaceuticals inaugurates Rs 135 crore office in Ahmedabad appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 18:55:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Amneal, Pharmaceuticals, inaugurates, 135, crore, office, Ahmedabad</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Amneal Pharmaceuticals has inaugurated its new administrative office in Ahmedabad, with an investment of approximately Rs 135 crore ($15 million), to support its teams in India and strengthen collaboration across its global business.</span></p>
<p><span>Located on Cliantha Road, Ahmedabad, the office spans approximately 3.35 lakh square feet and will accommodate around 1,200 employees. The facility is designed to support Amneal’s workforce, bring key teams together, strengthen collaboration and provide infrastructure for the company’s operations in India.</span></p>
<p><span>Amneal has expanded its capabilities in India across manufacturing, research and development, quality and commercial operations, including its commercial office in Mumbai. These operations form part of the company’s global network, which spans the US, India and Ireland. In August, the company acquired Kashiv BioSciences, expanding its global biosimilar development and manufacturing capabilities.</span></p>
<p><span>“This new Ahmedabad office reflects Amneal’s continued investment in the people and capabilities that support its global business. India is an important part of our network, complementing our significant and growing U.S. manufacturing footprint,” said Chirag Patel, co-founder and co-chief executive officer of Amneal. “Across our operations, we are investing in scientific expertise, manufacturing and infrastructure to support sustainable growth and expand access to high-quality, affordable medicines.”</span></p>
<p><span>“Our colleagues in India play an important role in advancing Amneal’s research, development, manufacturing and business operations,” said Chintu Patel, co-founder and co-chief executive officer of Amneal. “This new office brings key teams together in a space designed to support collaboration and their continued development. By connecting our people and expertise across our global network, we can strengthen execution, advance increasingly complex medicines and better serve patients.”</span></p>
<p><span>Amneal is also advancing plans for two greenfield manufacturing facilities in Gujarat, focused on peptide synthesis and sterile fill-finish manufacturing. These projects form part of the company’s investment in capabilities to support its future portfolio.</span></p>
<p><span>The new office supports Amneal’s strategy to strengthen its global capabilities and expand access to high-quality, affordable medicines.</span></p>
<p>The post <a href="https://www.expresspharma.in/amneal-pharmaceuticals-inaugurates-rs-135-crore-office-in-ahmedabad/">Amneal Pharmaceuticals inaugurates Rs 135 crore office in Ahmedabad</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>650 MPs, 12 replies: a dental survey full of cavities</title>
<link>https://edusehat.com/en/650-mps-12-replies-a-dental-survey-full-of-cavities</link>
<guid>https://edusehat.com/en/650-mps-12-replies-a-dental-survey-full-of-cavities</guid>
<description><![CDATA[ Every respondent to a recent survey of MPs agreed that the current NHS dental contract needs to change. The problem? Only 12 of the UK’s 650 MPs responded at all. The LDC Confederation’s MP Attitudes towards NHS Dentistry survey found that nine of 12 MPs considered their oral health to be very important to them.… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/mps.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 16:00:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>650, MPs, replies:, dental, survey, full, cavities</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Every respondent to a recent survey of MPs agreed that the current NHS dental contract needs to change. The problem? Only 12 of the UK’s 650 MPs responded at all.</strong></p>



<p>The LDC Confederation’s MP <a href="https://ldc.org.uk/wp-content/uploads/2026/10/MP-Survey-Report-1-1.pdf">Attitudes towards NHS Dentistry</a> survey found that nine of 12 MPs considered their oral health to be very important to them. Eight gave the availability of NHS dentistry in their constituencies the lowest possible score, with half using private dental care themselves.</p>



<p>Nine MPs said constituents had contacted them about difficulties finding dental care, and 10 felt that current NHS dental access rates of 40% for adults and 57% for children were unacceptable.</p>



<p>Despite the unanimous agreement of the 12 MPs that dental contract reform is needed, the silence of the other 98% speaks to how little parliamentary engagement the survey was able to capture.</p>



<p>The British Dental Association (BDA) recently called out <a href="https://dentistry.co.uk/2026/10/01/private-dentist-share-exceeds-nhs-in-nine-areas-of-southern-england/">the ‘radio silence’ on dentistry in health secretary Yvette Cooper’s Labour Party conference speech</a>. Chair Eddie Crouch said the lack of clarity ‘gives little hope to a demoralised profession or the millions struggling to access care’.</p>



<h2 class="wp-block-heading">What action are MPs taking on dental care?</h2>



<p>In March, the government pledged ‘to fundamentally reform the dental contract by the end of this Parliament’. However, <a href="https://dentistry.co.uk/2026/08/11/james-frith-appointed-as-dental-minister-heres-everything-you-need-to-know/">since taking over the dentistry brief in August</a>, undersecretary for health James Frith has yet to lay out a timetable or detailed plan for this long-term contract reform. </p>



<p>In recent discussions on the topic of NHS dentistry, he has reiterated Labour’s previous changes such as the <a href="https://dentistry.co.uk/2025/07/02/nhs-10-year-health-plan-therapy-led-reform-and-graduate-tie-in-confirmed/">introduction of an NHS tie-in for dental graduates</a> and the <a href="https://dentistry.co.uk/2026/06/03/dental-workforce-too-many-graduates-not-enough-dentists/">allocation of 50 new dental school places</a> – but no information has been shared about the government’s plans for dentistry during the remainder of its term. </p>



<p>This week, we have seen the government suggest that any pay award above 2.4% for NHS dentists in England would have to come from existing health budgets. Prime minister Andy Burnham also placed social care at the centre of the government’s health agenda at the recent Labour Party conference.</p>



<p>With only 2% of MPs responding to the survey, the findings cannot truly be seen to represent the government’s view. But against the backdrop of competing financial demands in healthcare, it does underline the outstanding question of whether Labour has the time or budget to deliver the necessary reform of NHS dentistry within its term.</p>



<p><em><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</em></a></em></p>



<p></p>]]> </content:encoded>
</item>

<item>
<title>Lupin appoints Brian Savage as President and Chief Legal Officer</title>
<link>https://edusehat.com/en/lupin-appoints-brian-savage-as-president-and-chief-legal-officer</link>
<guid>https://edusehat.com/en/lupin-appoints-brian-savage-as-president-and-chief-legal-officer</guid>
<description><![CDATA[ 
Savage will lead Lupin’s global Legal, Compliance and Intellectual Property Management Group functions and will be based in New Jersey
The post Lupin appoints Brian Savage as President and Chief Legal Officer appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/23111055/EP_Brian_Savage_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 15:20:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lupin, appoints, Brian, Savage, President, and, Chief, Legal, Officer</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/23111055/EP_Brian_Savage_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/23111055/EP_Brian_Savage_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/23111055/EP_Brian_Savage_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Lupin has announced the appointment of Brian Savage as President and Chief Legal Officer. Savage will lead the company’s global Legal, Compliance and Intellectual Property Management Group (IPMG) functions and will be based in New Jersey.</span></p>
<p><span>Savage joins Lupin from Teva Pharmaceuticals, where he held several senior leadership roles since 2015. Most recently, he served as Teva’s Executive Vice President and Interim Global Chief Legal Officer. During his tenure, he also led Teva’s global litigation strategy and served as General Counsel for its US Generics business. Before joining Teva, Savage practised law at Dechert LLP.</span></p>
<p><span>Savage holds a Juris Doctor (J.D.) from Yale Law School and a B.A., summa cum laude, from the University of Pennsylvania.</span></p>
<p><span>Commenting on the appointment, Lupin CEO Vinita Gupta and Managing Director Nilesh Gupta said, “We are delighted to welcome Brian to our executive leadership team. His deep understanding of the pharmaceutical industry landscape, extensive legal expertise, and proven leadership will be valuable as we continue to strengthen our governance framework, navigate an evolving regulatory environment, and advance our long term growth ambitions.”</span></p>
<p>The post <a href="https://www.expresspharma.in/lupin-appoints-brian-savage-as-president-and-chief-legal-officer/">Lupin appoints Brian Savage as President and Chief Legal Officer</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bharat Biotech cuts malaria vaccine price by 40 % under Gavi&#45;UNICEF agreement</title>
<link>https://edusehat.com/en/bharat-biotech-cuts-malaria-vaccine-price-by-40-under-gavi-unicef-agreement</link>
<guid>https://edusehat.com/en/bharat-biotech-cuts-malaria-vaccine-price-by-40-under-gavi-unicef-agreement</guid>
<description><![CDATA[ 
The agreement is expected to generate US$50 million in savings and help protect one million more children with the RTS,S/AS01 vaccine between 2027 and 2029
The post Bharat Biotech cuts malaria vaccine price by 40 % under Gavi-UNICEF agreement appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2019/10/11180711/stocks-down-e1722252808109.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 15:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bharat, Biotech, cuts, malaria, vaccine, price, under, Gavi-UNICEF, agreement</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="399" src="https://cdn.expresspharma.in/wp-content/uploads/2019/10/11180711/stocks-down-e1722252808109.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2019/10/11180711/stocks-down-e1722252808109.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2019/10/11180711/stocks-down-e1722252808109-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Bharat Biotech International Limited (BBIL) has announced an equitable pricing agreement with Gavi, the Vaccine Alliance, and UNICEF for the RTS,S/AS01 malaria vaccine, developed by GSK and manufactured by BBIL under the brand name Mosqivac.</span></p>
<p><span>The agreement, executed by UNICEF and financially backed by Gavi, will reduce the vaccine’s price by approximately 40 per cent. It is expected to generate around US$50 million in savings for child immunisation programmes between 2027 and 2029 and enable up to one million more children to receive the full four-dose course.</span></p>
<p><span>Enabled through an advance payment by the International Finance Facility for Immunisation (IFFIm), the agreement will bring the vaccine’s price to EUR 5.50 per dose, a reduction of approximately 40 per cent from the price paid today. The lower price is expected to take effect by early 2027 and reflects efforts to establish a sustainable and competitive malaria vaccine market.</span></p>
<p><span>RTS,S/AS01, developed by GSK, PATH and partners, was the first malaria vaccine to be recommended by the World Health Organization (WHO), in 2021. Since then, GSK and Bharat Biotech have invested US$200 million in manufacturing facilities with higher output, product development and technology transfer to expand and strengthen supply at a lower cost. These investments are supporting access to the vaccine and its potential public health impact.</span></p>
<p><span>“The Gavi–UNICEF deal is a far-reaching commitment to expand malaria vaccination and according to Gavi/UNICEF estimates, can help ensure one million more children are protected from malaria. As partners in global public health, we have invested significantly to expand supply, strengthen manufacturing and support sustainable, affordable access to malaria vaccines,” Dr. Krishna Ella, Executive Chairman of Bharat Biotech International said.</span></p>
<p><span>“The opportunity is to turn this progress into public health. Countries and global organizations now have an important role to play in accelerating vaccine introductions so that more children and communities at risk can benefit. We remain committed to working with partners to help make that happen and reduce the burden of malaria,” Dr. Ella added.</span></p>
<p><span>Dr. Harmony P. Garges, GSK’s Chief Global Health Officer, said “This new agreement follows major investment by both GSK and BBIL to help secure long-term equitable access to RTS,S/AS01 for many more children. At a time when global health resources are under increasing pressure – both for international organisations and for countries – partnership matters more than ever and this deal with Gavi–UNICEF further demonstrates how close collaboration across the global health landscape can help deliver real impact for children most at risk of malaria.”</span></p>
<p><span>Demand for malaria vaccines has exceeded initial forecasts since rollout began in 2024. To date, UNICEF has procured and delivered more than 74 million doses. The Gavi-funded malaria programme is now part of routine immunisation in 25 African countries, which account for more than 70 per cent of the global malaria burden.</span></p>
<p><span>At a time of decline in funding for international aid, efforts to establish affordable and sustainable supply are critical to meeting the Alliance’s target of vaccinating 50 million more children against malaria by 2030.</span></p>
<p><span>One child dies from malaria every minute, accounting for nearly half a million deaths each year. In 2024, an estimated 282 million malaria cases and 610,000 deaths were reported globally. Up to 95 per cent of cases and deaths occurred in Africa, where around 74 per cent of deaths were among children under five.</span></p>
<p><span>A full four-dose course of RTS,S/AS01 reduces malaria cases by about 75 per cent when administered seasonally in areas with high seasonal transmission. New and improved malaria vaccines will be increasingly important as rising temperatures alter transmission patterns and extend malaria into new areas, while flooding and other extreme events displace communities, damage infrastructure and disrupt health systems.</span></p>
<p><span>Vaccines are one of several malaria interventions, alongside insecticide-treated nets, spatial emanators, repellents and other vector control interventions, chemoprevention, and prompt diagnosis and treatment.</span></p>
<p>The post <a href="https://www.expresspharma.in/bharat-biotech-cuts-malaria-vaccine-price-by-40-under-gavi-unicef-agreement/">Bharat Biotech cuts malaria vaccine price by 40 % under Gavi-UNICEF agreement</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cryo&#45;EM and AI&#45;Designed Scaffold Reveal How Andes Hantavirus Binds Cells</title>
<link>https://edusehat.com/en/cryo-em-and-ai-designed-scaffold-reveal-how-andes-hantavirus-binds-cells</link>
<guid>https://edusehat.com/en/cryo-em-and-ai-designed-scaffold-reveal-how-andes-hantavirus-binds-cells</guid>
<description><![CDATA[ Using cryo-EM and an AI-designed scaffold, researchers mapped how Andes hantavirus engages a receptor on human cells. The findings explain how antibodies block attachment and may highlight a potential target for antiviral development.
The post Cryo-EM and AI-Designed Scaffold Reveal How Andes Hantavirus Binds Cells appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/02/GettyImages-2186951140.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 12:00:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cryo-EM, and, AI-Designed, Scaffold, Reveal, How, Andes, Hantavirus, Binds, Cells</media:keywords>
<content:encoded><![CDATA[<p>Hantaviruses can turn exposure to infected rodents into a life-threatening illness, including a pulmonary syndrome that can progress rapidly to respiratory failure. Andes virus adds another concern: unlike other hantaviruses known to cause human disease, it can also spread between people. Understanding how it first attaches to human cells could help researchers identify ways to interrupt infection.</p>
<p>Researchers at Albert Einstein College of Medicine in New York, Institut Pasteur in Paris, and LSU Health Shreveport have now resolved that interaction in near-atomic detail. Combining cryo-electron microscopy (cryo-EM) and functional experiments, they showed how the Andes virus spike captures a human receptor—and how antibodies interfere.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The study, published in <em>Nature</em>, is titled “<a href="https://www.nature.com/articles/s41586-026-11184-1" target="_blank" rel="noopener">Structural basis for protocadherin-1 recognition by New World hantaviruses</a>.”</p>
<p>Previous research established that Andes virus and other New World hantaviruses use the cell-surface protein protocadherin-1 (PCDH1) to enter host cells. What remained unclear was how the viral spike recognized this receptor. An isolated spike subunit could not bind PCDH1; the interaction required the assembled, four-part structure.</p>
<p>To examine that assembly, the team engineered a soluble Andes virus spike using methods that included an artificial intelligence–designed scaffold. The scaffold helped stabilize the square-shaped complex outside the virus, allowing the researchers to combine it with PCDH1 and analyze the resulting structure using cryo-EM.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<figure aria-describedby="caption-attachment-339755" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339755" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_ANDVgreen_PCDH1pink-1-1-300x300.jpg" alt="PCDH1" width="300" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_ANDVgreen_PCDH1pink-1-1-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_ANDVgreen_PCDH1pink-1-1-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_ANDVgreen_PCDH1pink-1-1.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">rVSV-ANDV infected cells (green) and PCDH1 bound to them (pink) [Albert Einstein College of Medicine]</figcaption></figure>
<p>The images revealed that PCDH1 binds asymmetrically within a deep central pocket formed by four copies of the viral Gn glycoprotein. Rather than presenting a receptor-binding site on an individual subunit, the spike builds one through the arrangement of its components.</p>
<p>Mutagenesis experiments identified three Gn loops that help shape the binding site. Changes involving these loops also enabled the researchers to transfer PCDH1-binding ability from New World to Old World hantavirus glycoproteins, according to the paper.</p>
<p>The team also investigated four neutralizing antibodies. Structural and functional analyses showed that the antibodies prevented receptor binding through two mechanisms: obstructing access to the PCDH1-binding site or creating a physical barrier that prevented receptor engagement.</p>
<p>“The depth of this pocket also helps explain how the virus limits antibody access. What’s striking is how the same pocket can accommodate the receptor while restricting antibody access. PCDH1’s long, slender shape lets it reach deep inside, but most antibodies are too bulky to follow,” said Rohit Jangra, PhD, assistant professor of microbiology and immunology at LSU Health Shreveport.</p>
<p>That distinction suggests a direction for therapeutic development. According to the researchers, engineered molecules with a narrow, elongated shape might reach farther into the pocket and block attachment. The team intends to explore this vulnerability as a basis for antiviral strategies against Andes virus and potentially related pathogens, including Sin Nombre virus.</p>
<p>The authors wrote, “Together, these findings define the structural determinants of hantavirus–receptor recognition, reveal how a virus can mask its receptor-binding site by recessing it in a surface depression and how antibodies can counter this strategy, and provide a framework for the design of antiviral therapeutics targeting the hantavirus spike.”</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/cryo-em-and-ai-designed-scaffold-reveal-how-andes-hantavirus-binds-cells/">Cryo-EM and AI-Designed Scaffold Reveal How Andes Hantavirus Binds Cells</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CQC warns of persistent inequalities in children’s oral health</title>
<link>https://edusehat.com/en/cqc-warns-of-persistent-inequalities-in-childrens-oral-health</link>
<guid>https://edusehat.com/en/cqc-warns-of-persistent-inequalities-in-childrens-oral-health</guid>
<description><![CDATA[ The Care Quality Commission (CQC) warned that children’s oral health inequalities persisted across England, with five-year-olds in the most deprived areas experiencing more than twice the prevalence of tooth decay seen in the least deprived. Its State of Care 2025/26 report drew together evidence of unequal disease levels, hospital treatment and access to dentistry, despite… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/inequalities.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 08:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CQC, warns, persistent, inequalities, children’s, oral, health</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>The Care Quality Commission (CQC) warned that children’s oral health inequalities persisted across England, with five-year-olds in the most deprived areas experiencing more than twice the prevalence of tooth decay seen in the least deprived.</strong></p>



<p>Its State of Care 2025/26 report drew together evidence of unequal disease levels, hospital treatment and access to dentistry, despite a recovery in National Health Service (NHS) activity.</p>



<p>Citing the national oral health survey of five-year-olds, the regulator reported decay among 32% of children in the most deprived areas, compared with 14% in the least deprived.</p>



<p>The CQC reported that, across integrated care board (ICB) areas, prevalence ranged from 12% to 33%. Nationally, around 22% of five-year-olds had visible signs of decay, while 3.7% had advanced decay and 1.8% showed signs of severe dental infection.</p>



<p>The CQC said deprivation remained strongly associated with higher levels of dental disease.</p>



<p>Baroness Julia Neuberger, CQC chair, said: ‘Improvements aren’t keeping pace with demand everywhere, and where they fall short, it’s often the same people and places bearing the consequences.’</p>



<h2 class="wp-block-heading">Unequal burden of extractions</h2>



<p>The report also highlighted differences in <a href="https://dentistry.co.uk/2026/02/17/cost-of-nhs-tooth-extractions-up-by-five-million-pounds/">decay-related tooth extractions</a>, with rates of 403 per 100,000 children and young people in the most deprived areas, compared with 121 in the least deprived.</p>



<p>Recorded extractions increased from 31,165 in 2022/23 to 33,976 in 2024/25, a rise of 9%. The CQC said preventable oral disease remained a major contributor to hospital activity among children and young people.</p>



<p>These findings reflected previously collected national data, brought together in the regulator’s assessment of care across England.</p>



<h2 class="wp-block-heading">Recovery in activity, uneven access</h2>



<p>The CQC found that <a href="https://dentistry.co.uk/2026/08/28/nhs-dental-activity-is-on-the-rise-but-has-access-kept-pace/">NHS dental activity continued to recover</a>, with 37.6 million courses of treatment delivered in 2025/26, up from 35.4 million the previous year. This remained below the 38.8 million delivered in 2019/20.</p>



<p>According to the CQC, nearly 7.2 million children were seen within the previous 12 months, representing 60% of England’s child population. Access varied between ICB areas.</p>



<p>The regulator also found <a href="https://dentistry.co.uk/2026/10/01/private-dentist-share-exceeds-nhs-in-nine-areas-of-southern-england/">uneven provision of registered dental locations</a>, with lower densities in several rural or mixed rural areas. It warned that this disparity could produce further inequalities in access and oral health outcomes.</p>



<p>‘To repair a fracturing system, there must be a collective response,’ Neuberger said. ‘Providers, regulators, commissioners and government all have a role to play in improving care, and we’ll be judged not by what we achieve alone, but by what we achieve together.’</p>



<p>The report noted examples of practices attempting to boost access for patients. One included example was of a practice opening on Saturdays for a month so working parents could register children for NHS treatment. The scheme proved popular and was extended for another month.</p>



<p><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</em></a></p>



<p></p>]]> </content:encoded>
</item>

<item>
<title>PerturbAI and OpenAI Launch AI Reasoning Agents for Biomedical Discovery</title>
<link>https://edusehat.com/en/perturbai-and-openai-launch-ai-reasoning-agents-for-biomedical-discovery</link>
<guid>https://edusehat.com/en/perturbai-and-openai-launch-ai-reasoning-agents-for-biomedical-discovery</guid>
<description><![CDATA[ A year-long collaboration involving scientists at PerturbAI, OpenAI, and their other institutions yielded an AI reasoning framework that turns datasets into testable hypotheses, with thousands of agents analyzing whole-brain genomic data in minutes instead of months.
The post PerturbAI and OpenAI Launch AI Reasoning Agents for Biomedical Discovery appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/06/GettyImages-2224152938.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 04:45:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PerturbAI, and, OpenAI, Launch, Reasoning, Agents, for, Biomedical, Discovery</media:keywords>
<content:encoded><![CDATA[<p><span>This week, PerturbAI, OpenAI, and their collaborators shared results from a year-long effort aimed at developing an artificial intelligence (AI) reasoning framework that helps scientists interpret large experimental datasets, connect results with existing research, and generate testable hypotheses. Details are provided in a new bioAxriv preprint titled “</span><a href="https://www.biorxiv.org/content/10.64898/2026.10.15.759436v1" target="_blank" rel="noopener"><span>Distributed AI agents enable comprehensive discovery of biological insights at scale</span></a><span>.” </span></p>
<p><span>Besides the scientists at PerturbAI and OpenAI, other authors listed on the paper are scientists affiliated with Scripps Research Institute, University of California, San Diego, and Howard Hughes Medical Institute. In the paper, they explained the results of applying the AI framework to data from </span><a href="https://www.biorxiv.org/content/10.64898/2026.03.16.711480v1" target="_blank" rel="noopener"><span>PerturbAI’s whole-brain atlas</span></a><span>, published earlier this year. Specifically, the team developed thousands of agents to analyze cellular responses, search the scientific literature, and connect experimental results with existing biological knowledge. The system then synthesized the findings into a reasoning atlas that linked genes, cell responses, details from existing literature, and possible biological mechanisms. </span></p>
<p><span>When applied to the whole-brain atlas, “thousands of parallel agents thoroughly examined the dataset in minutes” and without access to the source manuscript “recovered its conclusions, predicted held-out perturbation effects, and identified perturbation relationships with shared or opposing outcomes across effect strengths,” the scientists wrote. In fact, the system completed the analysis in 32 minutes. Furthermore, “distributed agents scaled literature coverage with workload, retrieving 100s times more references than [a] single-agent mode.” </span><span> </span></p>
<p><span>To evaluate the quality of the agents’ interpretations, biologists reviewed their reports for novelty, evidential support, follow-up priority, and confidence level. According to numbers reported in the preprint, in blinded comparisons against reports generated by single AI agents, human experts preferred the reasoning-agents’ interpretations 75% of the time or 45 of 60 judgements. Single agent interpretations were preferred in 10 or 16.7%, and five were ties (8.3%).  </span></p>
<p><span>The work builds on a year-long collaboration that is now expanding into joint drug-target discovery that will leverage PerturbAI’s proprietary causal biological data. Using PerturbAI’s causal<em> in vivo</em> data, PerturbAI and OpenAI will now apply their AI reasoning frameworks to discover new drug targets. “Biomedical experiments are generating data faster than scientists can interpret it, meaning promising new discoveries are likely to remain hidden,” said Grace Zheng, PhD, CEO and co-founder of PerturbAI. “By combining large-scale causal data generated directly in living systems with frontier AI, our partnership with OpenAI is making it possible to investigate more biological data, faster and with greater depth, and to make target discovery more systematic.”</span></p>
<p><span>“By combining PerturbAI’s experimental data with OpenAI’s reasoning capabilities, we can help scientists uncover new biological insights and identify promising leads for drug discovery,” added Joy Jiao, head of life sciences at OpenAI. “The scale, quality, and speed of PerturbAI’s discovery engine make them an ideal partner, and this is just the beginning of what we can achieve together. Running nearly 2,000 agents in parallel shows how we can scale biological interpretation alongside high-throughput experimentation, helping researchers turn those findings into better medicines.”</span></p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/perturbai-and-openai-launch-ai-reasoning-agents-for-biomedical-discovery/">PerturbAI and OpenAI Launch AI Reasoning Agents for Biomedical Discovery</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Nvidia, UW Institute for Protein Design Unveil Open&#45;Source Protein Design AI Model</title>
<link>https://edusehat.com/en/nvidia-uw-institute-for-protein-design-unveil-open-source-protein-design-ai-model</link>
<guid>https://edusehat.com/en/nvidia-uw-institute-for-protein-design-unveil-open-source-protein-design-ai-model</guid>
<description><![CDATA[ RFD4-Proteina is an open model based on Nvidia’s NVIDIA BioNeMo™ artificial intelligence (AI) platform for chemistry and biology that combines programmable protein design with search capabilities. RFD4-Proteina generates targeted protein designs, enabling scientists and agents to search and refine those designs using molecular inputs, constraints, and scoring objectives. 
The post Nvidia, UW Institute for Protein Design Unveil Open-Source Protein Design AI Model appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages_1402266486_proteins-1024x538-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 04:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Nvidia, Institute, for, Protein, Design, Unveil, Open-Source, Protein, Design, Model</media:keywords>
<content:encoded><![CDATA[<figure aria-describedby="caption-attachment-339716" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="wp-image-339716 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/10/David-Baker-493455cCPMichel1212026-web-200x300.jpeg" alt="" width="200" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/David-Baker-493455cCPMichel1212026-web-200x300.jpeg 200w, https://www.genengnews.com/wp-content/uploads/2026/10/David-Baker-493455cCPMichel1212026-web-683x1024.jpeg 683w, https://www.genengnews.com/wp-content/uploads/2026/10/David-Baker-493455cCPMichel1212026-web-768x1151.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/David-Baker-493455cCPMichel1212026-web-1025x1536.jpeg 1025w, https://www.genengnews.com/wp-content/uploads/2026/10/David-Baker-493455cCPMichel1212026-web.jpeg 1281w" sizes="(max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Nobel laureate David Baker, PhD, IPD’s director and a professor of biochemistry at UW Medicine [UW Medicine Institute for Protein Design]</figcaption></figure>
<p>The University of Washington (UW) School of Medicine <a href="https://www.ipd.uw.edu/" target="_blank" rel="noopener">Institute for Protein Design</a> (IPD) has partnered with Nvidia to develop an open, generative model that uses biomolecular reasoning designed to improve how well researchers can design new proteins with specific functions.</p>
<p>RFD4-Proteina is an open model based on Nvidia’s <a href="https://github.com/NVIDIA-BioNeMo" target="_blank" rel="noopener">NVIDIA BioNeMo<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> artificial intelligence (AI) platform</a> for chemistry and biology that combines programmable protein design with search capabilities. According to its developers, RFD4-Proteina generates targeted protein designs, enabling scientists and agents to search and refine those designs using molecular inputs, constraints, and scoring objectives. Potential applications include designing proteins to interrupt disease processes or detect signs of disease in diagnostic tests.</p>
<p>RFD4-Proteina concurrently refines a protein’s sequence and structure alongside the structures of interacting molecules, so that a change in one effortlessly leads to changes in the others. RFD4-Proteina has achieved five-fold to 10-fold higher design success rates while generating protein candidates five to 10 times faster than previous models, the developers said.</p>
<p>Lab bench tests showed that RFD4-Proteina achieved higher computational design success rates and generation throughput than the evaluated baselines across four benchmark suites: protein binding, small-molecule binding, enzyme scaffolding, and DNA binding, Nvidia said.</p>
<p>The model helps researchers explore and prioritize candidates for laboratory testing. And by remaining open, UW and Nvidia added, RFD4-Proteina will enable investigators to build on its capabilities by exploring more potential protein designs and advancing promising drug candidates into lab testing faster.</p>
<p>“We are moving from an era of discovering the proteins nature has made to one in which we can design entirely new ones,” Nobel laureate David Baker, PhD, IPD’s director and a professor of biochemistry at UW Medicine, said in a statement. “RFD4-Proteina expands what scientists can create, from proteins that could advance drug discovery to enzymes that break down pesticides.”</p>
<h4><strong>‘New solutions’</strong></h4>
<p>“RFD4-Proteina will open the door to new solutions in medicine, sustainability, materials and biotechnology,” Baker added. “I think with these improved generative AI methods, we’ll see better medicines … and applications more broadly outside of medicine and sustainability, new ways of breaking down polymers, new ways of making bioplastics.”</p>
<figure aria-describedby="caption-attachment-339714" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-339714" src="https://www.genengnews.com/wp-content/uploads/2026/10/UW-IPD-dry-lab-RFD4-PROTEINA-300x202.jpg" alt="" width="300" height="202" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/UW-IPD-dry-lab-RFD4-PROTEINA-300x202.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/UW-IPD-dry-lab-RFD4-PROTEINA.jpg 640w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Members of the RDF4 modeling team run tests at the Institute for Protein Design. [Sierra Adler / UW Medicine Institute for Protein Design]</figcaption></figure>
<p>RFD4-Proteina derives its name from the IPD’s <a href="https://www.bakerlab.org/2023/07/11/diffusion-model-for-protein-design/" target="_blank" rel="noopener">RosettaFold Diffusion</a>, a guided diffusion model for generating new proteins, and Nvidia’s <a href="https://research.nvidia.com/labs/genair/proteina/" target="_blank" rel="noopener">Proteina-Complexa</a>, a generative model for protein binder design for protein and small molecule targets. Proteina-Complexa combines inference-time optimization with a pretrained flow-based generative model built on Nvidia’s La-Proteina AI model developed for atomistic protein design.</p>
<p>RFD4-Proteina is available through partners that include Amazon Bio Discovery, Anthropic’s Claude Science, Benchling, Databricks, Google Cloud, Hugging Face, Nebius, OpenAI, and Tamarind Bio. The partners enable researchers and developers to integrate the open protein design model into agent, cloud, and scientific computing workflows.</p>
<p>At IPD, researchers who have applied the model to their novel protein design challenges reported that RFD4-Proteina represented an improvement over past methods’ efficacy and speed.</p>
<p>“We were able to precisely control what types of glycans (sugars important for immune-system recognition) are attached to proteins in ways past models haven’t been able to achieve, and to do so in under just a week rather than months,” said Meg Lunn-Halbert, a UW PhD candidate in biochemistry and in biological physics, structure and design.</p>
<h4><strong>From months to days</strong></h4>
<p>Added Seth Woodbury, a UW bioengineering predoctoral candidate and National Science Foundation fellow: “In just a few days we designed a pesticide-degrading enzyme that performs many fold better than my previous best, which took months to design.”</p>
<p>RFD4-Proteina arose from a collaboration between IPD and Nvidia researchers and is immediately available for use as an open-source resource hosted through Berkeley Software Distribution (BSD-3).</p>
<p>IPD leaders of the project were three UW PhD students—Nathaniel Corley, Maxwell Kazman, and Rafi Brent—as well as Kieran Didi, a visiting student from the University of Oxford.</p>
<p>The development of RFD4-Proteina was funded by the Howard Hughes Medical Institute, Gates Foundation (INV-092109), Grantham Foundation, Fund for Science and Technology, Schmidt Sciences, OpenFold consortium (part of OMSF), Rosetta Commons, and additional supporters of the IPD. According to its website, the Gates Foundation <a href="https://www.gatesfoundation.org/about/committed-grants/2025/12/inv-092109" target="_blank" rel="noopener">committed $25,748,619</a> through a grant dated November 2025.</p>
<p>The Jen-Hsun and Lori Huang Foundation provided a computational grant that was critical to RFD4-Proteina’s development, UW stated in announcing the introduction of RFD4-Proteina.</p>
<p>Baker is a Howard Hughes Medical Institute Investigator and one of three winners of the 2024 Nobel Prize in Chemistry “for computational protein design,” along with Sir Demis Hassabis, PhD, and John Jumper, PhD.</p>
<p>Hassabis is a co-founder of Google DeepMind who is now chief scientist of Google parent Alphabet and the founder/CEO of Google-co-owned Isomorphic Labs. Jumper announced plans in June to leave Google DeepMind for Anthropic, the AI giant that has filed for an initial public offering (IPO) that would value the company at an eye-popping $2 trillion.</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/nvidia-uw-institute-for-protein-design-unveil-open-source-protein-design-ai-model/">Nvidia, UW Institute for Protein Design Unveil Open-Source Protein Design AI Model</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>EQT to Acquire Qiagen for $12.1B, Plans to Take Tools, Diagnostics Provider Private</title>
<link>https://edusehat.com/en/eqt-to-acquire-qiagen-for-121b-plans-to-take-tools-diagnostics-provider-private</link>
<guid>https://edusehat.com/en/eqt-to-acquire-qiagen-for-121b-plans-to-take-tools-diagnostics-provider-private</guid>
<description><![CDATA[ EQT has €354 billion in assets under management and a three-decade track record of acquiring, developing, and sometimes selling companies that include life sciences tools/tech concerns. 
The post EQT to Acquire Qiagen for $12.1B, Plans to Take Tools, Diagnostics Provider Private appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/S_1191_0_CC_GEN_QIAGEN_Employee_0267-16x9-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 04:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>EQT, Acquire, Qiagen, for, 12.1B, Plans, Take, Tools, Diagnostics, Provider, Private</media:keywords>
<content:encoded><![CDATA[<p>An entity of Swedish private equity firm EQT has agreed to acquire Qiagen for €10.8 billion (about $12.1 billion) cash, both said today, in a deal that would take private the global life-sciences tools, diagnostics, and workflow solutions provider following on-and-off takeover attempts over nearly seven years.</p>
<p>The buyer is EQT Private Equity, a holding company indirectly controlled by the firm’s EQT XI fund and managed and controlled by affiliates of EQT. Within EQT Private Equity, “indirect participations” or stakes are held by co-investors Luxinva, a wholly owned subsidiary of the Abu Dhabi Investment Authority; and CPP Investment Board Europe, a wholly-owned subsidiary of Canada Pension Plan Investment Board or CPP Investments.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>EQT’s takeover offer followed what Qiagen called a comprehensive review by its Supervisory Board and Managing Board evaluating the company’s strategic prospects through discussions with strategic and financial parties.</p>
<p>Qiagen said that its boards concluded that a buyout by EQT would offer the best prospects for the company’s next growth phase by giving it greater flexibility to invest longer term under a private owner while providing shareholders with attractive and certain cash value.</p>
<p>“After considering Qiagen’s stand-alone strategic prospects and the alternatives available through discussions with strategic and financial parties, we unanimously concluded that this is the best path forward for Qiagen, its shareholders, and other stakeholders,” Stephen H. Rusckowski, chairman of Qiagen’s Supervisory Board, said in a statement.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<h4><strong>‘Compelling value’</strong></h4>
<p>“This transaction offers shareholders compelling value while positioning Qiagen for its next phase of development under private ownership,” Rusckowski added.</p>
<p>News of Qiagen’s strategic review emerged in January through a <em>Bloomberg News</em> report that said the company was weighing a potential sale, attributed to unnamed sources, amid fresh interest from would-be buyers in acquiring the company.</p>
<p>Investors reacted to news of the strategic review with a <a href="https://www.genengnews.com/topics/bioprocessing/stockwatch-qiagen-shares-rebound-on-report-it-is-assessing-strategic-options/" target="_blank" rel="noopener">buying surge</a> that sent Qiagen shares to their highest levels since February 2023, a 17% one-week gain that saw its New York Stock Exchange shares rise from $47.57 on January 16 to $55.62 on January 23. Qiagen’s European shares, traded on the Frankfurt Stock Exchange’s XETRA market, rose 12.5% from €40.99 ($45.55) to €46.13 ($51.46).</p>
<p>Qiagen shares slipped since then as investors questioned whether the company would reach agreement with a buyer, and as the company lowered its full-year guidance to investors. In April, Qiagen cut its net sales growth forecast from 5% down to 1–2%, while lowering its adjusted diluted EPS forecast from $2.50 to $2.43. The reductions followed weaker than anticipated sales—a year-over-year 5% drop at constant exchange rates—of Qiagen’s QuantiFERON blood test kit due to reduced demand for immigration-related tuberculosis testing in the U.S. and Middle East.</p>
<p>Qiagen shares reached a 52-week low of €27.56 ($30.62) May 12 on XETRA and $32.13 the following day on NYSE before climbing back to the low €40s on XETRA and mid-$40s on NYSE.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<h4><strong>Cautious investor reaction</strong></h4>
<p>On Thursday, investors appeared to react cautiously to the deal. Shares on XETRA rose 5% from €42.82 ($47.77) to € 44.94 ($50.13). On NYSE, shares barely rose 0.4%, from an even $50 to $50.22. Qiagen has suspended its full-year guidance for this year due to the planned acquisition.</p>
<p>At €46.50 ($51.88) per share, EQT Equity Partners’ offer for Qiagen represents an 8.6% premium above Qiagen’s closing stock price Wednesday—but a premium of 40.3% to the XETRA closing price of €33.15 ($36.84) on July 8, the last trading day before news reports about private equity firms being interested in acquiring Qiagen. The premium climbs to 46.9% when compared to the three-month volume-weighted average price (VWAP) on XETRA of €31.66 ($35.18) per Qiagen share up to and including July 8.</p>
<p>The €10.8 billion ($12.1 billion) enterprise value of the deal includes approximately $1.1 billion of net debt, Qiagen said.</p>
<p>“Qiagen’s management team and employees have built an exceptional company with a portfolio of highly attractive products and respected brands, strong market positions and considerable technical expertise,” stated Matteo Thun-Hohenstein, Partner at EQT. “EQT brings deep sector experience, a global network and operational capabilities, and we are proud to partner with Qiagen’s highly talented and capable employees to further invest in Qiagen’s continued product innovation and growth.”</p>
<h4><strong>Track record</strong></h4>
<p>EQT has €354 billion in assets under management and a three-decade track record of acquiring, developing, and sometimes selling companies that include life sciences tools/tech concerns.</p>
<p>In 2019, EQT <a href="https://www.genengnews.com/topics/bioprocessing/eqt-agrees-to-acquire-majority-interest-in-cdmo-aldevron/" target="_blank" rel="noopener">acquired a majority interest in Aldevron</a>, which it sold two years later to Danaher for approximately $9.6 billion. Also in 2021, EQT joined the private equity business of Goldman Sachs to <a href="https://www.genengnews.com/topics/drug-discovery/goldman-sachs-eqt-to-buy-parexel-for-8-5b-continuing-cro-consolidation/" target="_blank" rel="noopener">acquire contract research organization Parexel for $8.5 billion</a>. In 2023, EQT co-led a €129 million ($138 million at the time; $144 million today) <a href="https://www.genengnews.com/topics/translational-medicine/going-dutch-vectorys-138m-series-a-to-advance-vectorized-antibody-programs-for-neurodegenerative-diseases/">Series A financing of Amsterdam biotech VectorY</a>, with proceeds intended toward advancing its vectorized antibodies for neurodegenerative disease treatment. Other current and former portfolio companies of EQT include SPT Labtech, Galderma, Dako and HemoCue.</p>
<p>EQT says its healthcare and life sciences experience includes around 100 investment professionals across 15 countries, with over €30 billion (about $33.6 billion) invested across more than 210 companies in healthcare globally.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>EQT Private Equity said it had obtained enough committed equity and debt financing to fund the offer and related transaction costs. Morgan Stanley, Jefferies, Deutsche Bank, SMBC, Crédit Agricole, and UniCredit are acting as bookrunners and mandated lead arrangers for the committed debt financing.</p>
<p>Both EQT and Qiagen stressed the prospective buyer’s plan for long-term ownership of the tools/diagnostics giant. Under the Business Combination Agreement signed by both, EQT Private Equity agreed to support Qiagen’s long-term development through “commitments relating to Qiagen’s strategy, business, key brands, operational footprint, R&D activities, employee arrangements, prudent financing, and culture of excellence.”</p>
<h4><strong>Mid-2027 close expected</strong></h4>
<p>Upon completion of the transaction, which is expected to close in mid-2027, Qiagen said it will continue to operate under its own name and brand. If closing has not occurred within 10 months of October 21 (August 21, 2027) because required regulatory approvals remain pending, Qiagen may opt to pay shareholders an interim dividend of up to $0.47 per share. Any interim dividend would not be deducted from the offer price.</p>
<p>Qiagen said its boards will recommend that the company’s shareholders tender their shares into the takeover offer and vote in favor of the deal in a position statement to be published after EQT publishes the offer document detailing the transaction. The Takeover Offer will be subject to a minimum acceptance threshold of 50% of Qiagen’s outstanding share capital plus one share, approval of post-closing measures and a decision to adopt them by Qiagen’s boards, merger control and foreign investment clearances, and additional conditions.</p>
<p>Qiagen shareholders who do not accept the Takeover Offer will receive a cash distribution in an amount per share equal to the Offer Price less applicable withholding taxes—which Qiagen said may result in a lower net amount being received than if the shareholders had accepted the Takeover Offer.</p>
<p>If the deal goes through, EQT’s planned purchase would end nearly seven years or on-and-off merger-and-acquisition activity surrounding Qiagen. In March 2020, Thermo Fisher Scientific <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fcoronavirus%2Fthermo-fisher-to-expand-coronavirus-infectious-disease-dx-with-planned-11-5b-qiagen-acquisition%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C28b88f85661e4c341de808de59e20c86%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639047025085584898%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=Rmudj4AreTISalol8OzJBF%2BKvc%2FBEflHXO3VafkxDxc%3D&reserved=0" target="_blank" rel="noopener">offered to acquire Qiagen for approximately $11.5 billion</a> in a deal driven by the COVID-19 pandemic. Thermo Fisher explained at the time that it sought to purchase Qiagen in order to expand its molecular diagnostics portfolio with a SARS-CoV-2 coronavirus test and other infectious disease tests.</p>
<p>However, Thermo Fisher <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fcoronavirus%2Fthermo-fisher-qiagen-part-ways-as-covid-19-fuels-collapse-of-12-5b-deal%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C28b88f85661e4c341de808de59e20c86%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639047025085609061%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=74Y6gYE7f9KBZz2HGpCBxudVZy9NZtgjMN%2FXaRY93b4%3D&reserved=0" target="_blank" rel="noopener">terminated its buyout offer five months later</a> when it failed to win support from two-thirds (66.67%) of investors, with only 47% of holders of outstanding Qiagen shares agreeing to tender their shares. Key to the deal falling through was vocal opposition from the hedge fund Davidson Kempner, an activist investor that raised its stake in Qiagen from 3.6% to 8%. The deal collapsed despite Thermo Fisher sweetening its offer to $12.5 billion by raising its per-share offering price from €39 ($43.34) to €43 ($47.98).</p>
<p>Two years later, in 2022, <em>The Wall Street Journal</em> reported that Bio-Rad Laboratories was in talks with Qiagen on a merger deal valued at more than $10 billion, a deal that neither company confirmed at the time.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/eqt-to-acquire-qiagen-for-12-1b-plans-to-take-tools-diagnostics-provider-private/">EQT to Acquire Qiagen for $12.1B, Plans to Take Tools, Diagnostics Provider Private</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Proteins Circulating in Blood Linked to Future Risk of Prostate Cancer</title>
<link>https://edusehat.com/en/proteins-circulating-in-blood-linked-to-future-risk-of-prostate-cancer</link>
<guid>https://edusehat.com/en/proteins-circulating-in-blood-linked-to-future-risk-of-prostate-cancer</guid>
<description><![CDATA[ The results of a large prospective proteomic study have associated proteins linked with the immune system, cell adhesion, blood vessel formation, and known prostate cancer genes, to future risk of developing prostate cancer, including aggressive disease. 
The post Proteins Circulating in Blood Linked to Future Risk of Prostate Cancer appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2020/07/Jul14_2020_Getty_1178748795_ProstateCancerCells-scaled-e1627958312296.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 04:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Proteins, Circulating, Blood, Linked, Future, Risk, Prostate, Cancer</media:keywords>
<content:encoded><![CDATA[<p>The results of a large prospective proteomic study, headed by Oxford Population Health, have linked proteins associated with the immune system, cell adhesion, blood vessel formation, and known prostate cancer genes, with the future risk of developing prostate cancer (PCa), including aggressive disease.</p>
<p>Findings from the study, involving more than 2,500 men, revealed biological differences between those who later developed prostate cancer, and those who did not. The results may may help guide future studies aimed at identifying men at greater risk of the disease.</p>
<p>Professor Karl Smith-Byrne, MPhil, DPhil, at Oxford Population Health, said, “Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease. Together with existing and future genetic evidence, these findings may help us identify biological pathways that could be targeted to prevent aggressive prostate cancer.”</p>
<p>The study, “<a href="http://dx.doi.org/10.1016/j.eururo.2026.08.014" target="_blank" rel="noopener">Circulating Immune and Cancer Driver Gene Biomarkers Precede Prostate Cancer Diagnosis by over 10yr</a>,” is published in <em>European Urology</em>, and was presented at the American Society of Human Genetics (ASHG) Annual Meeting. In their paper co-senior author Smith-Byrne and colleagues, concluded, “These findings identify candidate protein risk factors for overall and clinically significant PCa, and warrant further validation and mechanistic evaluation.”</p>
<p>Prostate cancer is the most commonly diagnosed cancer in men worldwide, but relatively little is known about why some men develop the disease or why some cancers become aggressive. Most established risk factors, such as age and genetics, cannot be changed. “Identifying individuals at future risk of clinically significant prostate cancer remains challenging because of the limited number of established predictors,” the researchers noted. Their previous research had identified potential protein risk factors for prostate cancer, “… suggesting that broader proteomic investigation may provide further insights into the mechanisms underlying PCa development.” This is particularly important, they noted, given the lack of preventive strategies.</p>
<p>High-throughput proteomic technologies allow large-scale evaluation of potential protein-disease associations. For their newly reported study, which was part funded by Cancer Research UK, the investigators analyzed blood samples from 982 men who subsequently developed prostate cancer and a randomly selected sample of 1,573 men from the European Prospective Investigation into Cancer and Nutrition (EPIC). They measured more than 6,000 proteins in the blood and looked for differences linked to the later development of prostate cancer, particularly aggressive disease. Participants were followed for around 16 years. “This study is the largest population-based investigation of proteomic risk factors for PCa to date, with comprehensive protein profiling and a case-cohort design enabling robust risk estimation,” the investigators stated.</p>
<p>Their analyses identified circulating proteins associated with future PCa risk, including proteins related to immune, adhesion, angiogenesis, and PCa driver-gene pathways. “Notably, these protein differences were detectable in the blood long before a man’s diagnosis with PCa, and many were associated with clinically significant disease,” they commented.</p>
<p>Twelve proteins were linked to prostate cancer diagnosed more than 15 years after the blood sample was collected. These included GZMK, a protein produced by immune cells involved in recognizing and destroying abnormal cells, suggesting that immune processes may help keep prostate cancer in check long before it is diagnosed.</p>
<p>The researchers also identified seven proteins linked to aggressive prostate cancer. “The long follow-up and detailed characterization of clinically relevant subtypes allowed the identification of proteins associated with aggressive disease,” they stated. One protein, ANKRD1, was consistently linked to several serious forms of the disease, including cancers that had spread or were ultimately fatal. Other findings pointed to processes involved in how cancer cells interact with surrounding tissue and how new blood vessels form.</p>
<p>First author Zhe Huang, PhD, a postdoctoral epidemiologist at Oxford Population Health, said, “Prostate cancer is not one disease. Many prostate cancers grow slowly and may never cause harm, while others are aggressive and can be life-threatening. By measuring thousands of proteins in blood collected years before diagnosis, we can begin to investigate how men who later develop aggressive prostate cancer may differ from men who do not. Ultimately, we hope this will help us understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future.”</p>
<p>The study also found links with blood levels of proteins produced by genes already known to be important in prostate cancer, including <em>ERBB3, KRAS,</em> and <em>NRAS</em>. These proteins were particularly linked to aggressive prostate cancer diagnosed around a decade later. This does not mean cancer was already present when the blood was collected, but the findings may provide clues to biological changes associated with the future development of the disease.</p>
<p>The researchers compared their results with other large population studies and genetic evidence to test the robustness of their findings. Several findings were supported by these additional analyses, although not all could be confirmed. The proteins identified are not yet suitable for use as clinical tests; most associations were modest and further studies are needed to establish whether they could improve prediction of clinically significant prostate cancer. “Studies integrating tumor genomics and circulating proteomics will be required to clarify the relationship among circulating protein levels, genomic alterations, and disease development, and dedicated prediction studies are warranted to support their potential utility for biologically informed risk stratification,” the researchers concluded.</p>
<p>Future research through the Prostate Cancer Aetiology and Prevention Programme (PCAP), funded by Cancer Research UK, will investigate whether these findings could ultimately contribute to better ways of predicting or preventing prostate cancer.</p>
<p>Professor Ruth Travis, DPhil, at Oxford Population Health, and one of the PCAP programme leads, said,” For the first time, technologies that allow us to measure thousands of proteins simultaneously are giving us unprecedented insight into the earliest stages of prostate cancer development. Combined with large, long-term population studies, they allow us to look back many years before diagnosis and investigate the biological changes associated with future cancer risk. Understanding these processes is a critical step towards developing new strategies to prevent prostate cancer.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/proteins-circulating-in-blood-linked-to-future-risk-of-prostate-cancer/">Proteins Circulating in Blood Linked to Future Risk of Prostate Cancer</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ABP Board Pearls: 6 High&#45;Yield Topics for Your Pediatrics Exam</title>
<link>https://edusehat.com/en/abp-board-pearls-6-high-yield-topics-for-your-pediatrics-exam</link>
<guid>https://edusehat.com/en/abp-board-pearls-6-high-yield-topics-for-your-pediatrics-exam</guid>
<description><![CDATA[ Welcome to high yield topics for the ABP exam! Today we’ll discuss six topics commonly tested on boards: well-appearing patients that may not actually be well; fractures that may have negative imaging findings; headache red flags; the diagnostic evaluation of fever in small children; foreign body aspiration; and systemic rash syndromes! We’ll use clinical vignettes […]
The post ABP Board Pearls: 6 High-Yield Topics for Your Pediatrics Exam appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/10/pexels-silverkblack-39219726-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 01:30:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ABP, Board, Pearls:, High-Yield, Topics, for, Your, Pediatrics, Exam</media:keywords>
<content:encoded><![CDATA[<p><span>Welcome to high yield topics for the ABP exam! Today we’ll discuss six topics commonly tested on boards: well-appearing patients that may not actually be well; fractures that may have negative imaging findings; headache red flags; the diagnostic evaluation of fever in small children; foreign body aspiration; and systemic rash syndromes! We’ll use clinical vignettes and lists of risk factors to help you break down these topics and nail every board question on them!</span></p>
<p> </p>
<p data-pm-slice="1 1 []">For help fitting these topics into your study schedule, read our guide on <a href="https://elitemedicalprep.com/how-to-approach-abp-board-prep/">how to approach ABP board prep</a>.</p>
<p> </p>
<h2><b>1. “Well-Appearing” May Not Be Well</b></h2>
<p><span>There are lots of reasons a patient you think is well-appearing may not be. There are dangerous diseases which present with only minimal symptoms. There are patients like infants and those developmentally disabled who can’t exhibit severe symptoms. </span></p>
<p> </p>
<h3><b>Case Examples:</b></h3>
<ul>
<li><strong>Infants with fever<br>
</strong>Infants, especially less than 3 months old, may have few symptoms or signs of illness. For example, a well appearing 1 month old with fever still requires blood and urine testing to rule out sepsis.</li>
<li><strong>Appendicitis with minimal early findings<br>
</strong>Even if patient has no fever or minimal pain, if any peritoneal signs are present → evaluate for appendicitis.</li>
<li><strong>MIS-C initially thought viral<br>
</strong>Many dangerous diseases present initially as non-specific viral syndromes, including MIS-C. Pay attention to fevers greater than 4 days and worsening systemic symptoms to trigger a work up. MIS-C has prominent GI symptoms, meningismus and rash.</li>
<li><strong>Orbital abscess without fever initially<br>
</strong>Even significant infections like orbital cellulitis may have only edema and mild pain, without fever initially.</li>
<li><strong>DKA discovered during weight-loss workup<br>
</strong>Patients with mild DKA may appear overall well with only mild symptoms of nausea, abdominal pain and weight loss. Maintain a high index of suspicion whenever weight loss is present.<br>
<b><br>
</b></li>
</ul>
<ul>
<li>
</ul>
<h3><b>Board Pearls – Red Flag Combinations:</b></h3>
<p><b>Remember the following patient presentations:</b></p>
<ul>
<li aria-level="1"><b>Pain severe enough to wake from sleep</b><span> – malignancy, fracture</span></li>
<li aria-level="1"><b>Abdominal pain with jumping</b><span> – appendicitis, peritonitis</span><b><br>
</b><b></b></li>
<li aria-level="1"><b>Persistent fever >5 days </b><span>– malignancy, sepsis, rheumatologic disease</span></li>
<li aria-level="1"><b>Weight loss + subtle symptoms </b><span>– DKA, adrenal insufficiency, malignancy</span> </li>
</ul>
<p> </p>
<h2><b>2. Refusal to Bear Weight = Fracture Until Proven Otherwise</b></h2>
<p><span>The classic patient is a happy toddler who fell down an hour ago, has a normal X-ray, but still refuses to walk. Maybe it’s just a sprain? Maybe not! Remember this list:</span></p>
<p> </p>
<h3><b>Fractures with Possible Normal X-Rays:</b></h3>
<ul>
<li><strong>Toddler’s fracture/Spiral fracture of distal tibia<br>
</strong>Watch for a twisting injury to the leg. On exam the leg may look normal with only mild tenderness!</li>
<li><strong>Any Salter-Harris type 1 (Example: Distal fibula after ankle injury)<br>
</strong>These may present like a simple ankle sprain, but aren’t! Focus on tenderness along the epiphyseal plate.</li>
<li><strong>Stress fractures<br>
</strong>These are true fractures that need splinting. Most commonly in the medial distal tibia, the same location as medial tibial stress syndrome, but symptoms will be more severe.</li>
<li><strong>Slipped capital femoral epiphysis (early on)<br>
</strong>Typically seen in obese children, SCFE may initially only have hip discomfort with a normal X-ray. Consider MRI.</li>
<li><strong>Scaphoid fracture<br>
</strong>Usually after a fall on an outstretched hand (FOOSH), any patient with snuffbox tenderness of the wrist requires a thumb spica splint.</li>
</ul>
<p> </p>
<h3><b>Board Pearls – Empiric Splinting Indicated if X-ray is Normal but…</b></h3>
<p><b>Each of the following on this list indicates a possible underlying fracture, so splint empirically and follow up!</b></p>
<ul>
<li><b></b><span>Refusal to walk</span></li>
<li><span>Fussy with manipulation</span></li>
<li><span>Localized severe tenderness</span></li>
</ul>
<p> </p>
<h2><b>3. Severe Headache Red Flags</b></h2>
<p><span>The boards loves asking about headaches, and for good reason – they are common, often benign, but potentially deadly! Focal neurologic deficits on exam are always a red flag – even if the patient is otherwise well, get brain imaging!</span></p>
<p> </p>
<h3><b>High Risk Headache Features → Consider Imaging</b></h3>
<p><b>This list describes headache features that may suggest increased intracranial pressure. Lying supine overnight increases ICP naturally, so any further elevation from a mass will cause night or morning symptoms.</b></p>
<ul>
<li><span>Headache waking from sleep</span></li>
<li><span>Morning headache</span></li>
<li><span>Worsened by Valsalva (coughing, exerting, etc)</span></li>
<li><span>Changing over time: Frequency, intensity</span></li>
<li><span>Associated with altered mental status, vomiting, ataxia</span></li>
<li><span>Occipital location</span></li>
</ul>
<p> </p>
<h3><b>High Risk Exam Findings → Obtain Imaging</b></h3>
<p><b>These are the most commonly seen early onset signs of increased ICP. If the patient presents with these findings, strongly consider imaging.</b></p>
<ul>
<li><span>Abnormal eye movements</span></li>
<li><span>Gait abnormality or ataxia</span></li>
<li><span>Weakness</span></li>
<li><span>Papilledema</span> </li>
</ul>
<p> </p>
<h3><b>Board Pearls – Classic Brain Tumor Presentation:</b></h3>
<ul>
<li aria-level="1"><span>Remember the classic presentation: </span><b>progressive course of morning vomiting and headache, with papilledema and focal neuro deficits on exam. </b><span>Get brain imaging right away!</span><span><br>
</span></li>
</ul>
<p> </p>
<h2><b>4. Fever Without Source in <2 Years</b></h2>
<p><span>ABP loves testing you on fevers! Remember, the priority is to get blood cultures and urine testing on patients at risk for invasive bacterial infections. The following lists are crucial:</span></p>
<p> </p>
<p><b>Fever: Risk Factors for Invasive Bacterial Infection → Consider Urine Testing and/or Blood</b></p>
<p>This list describes features that make a fever higher risk for being caused by a bacterial source. If the patient has a fever like this, consider blood and/or urine testing to rule out IBIs like UTI and bacteremia.</p>
<ul>
<li><span>Greater than 102.2F (39 C)</span></li>
<li><span>Greater than 48 hours duration</span></li>
<li><span>Fever that recurs after initial resolution</span></li>
</ul>
<p> </p>
<p><b>Patient: Risk Factors for Sepsis → Consider Blood Work</b></p>
<p>This list shows patient factors that increase the likelihood they may have sepsis, particularly in the setting of fever. Infants less than 3 months are one of the highest risk groups – always consider blood work and even lumbar puncture if indicated.</p>
<ul>
<li><span>Age less than 3 months</span></li>
<li><span>Ill-appearing</span></li>
<li><span>Unimmunized</span></li>
<li><span>Immunodeficiency</span></li>
</ul>
<p> </p>
<p><b>Patient: Risk Factors for UTI → Consider Urine Testing</b></p>
<p>This list contains patient factors that increase their risk for having a UTI in the setting of fever. Younger patients, especially females, are at highest risk. Remember, if there’s no identifiable fever source on exam, consider urine testing!</p>
<ul>
<li><span>No signs or symptoms of another fever source</span></li>
<li><span>Female: less than 2 years old</span></li>
<li><span>Uncircumcised male: less than 1 year old</span></li>
<li><span>Circumcised male: less than 6 months old</span></li>
<li><span>History of UTI or urogenital abnormality</span></li>
</ul>
<p> </p>
<h3><b>Board Pearls:</b></h3>
<ul>
<li aria-level="1"><span>Memorize fever and patient risk factors for bacterial infections!</span></li>
<li aria-level="1"><span><2 yrs with fever without source → </span><b>always consider UA</b></li>
<li aria-level="1"><span>Urine dip with leukocyte esterase alone → </span><b>may NOT be UTI</b></li>
</ul>
<p> </p>
<h2><b>5. Foreign Body Aspiration</b></h2>
<p><span>It’s easy to catch the kid who just inhaled a grape and is actively choking. It’s harder to catch the actual most common presentation of foreign body aspiration: a subacute cough syndrome with few other findings. </span></p>
<p> </p>
<h3><b>Historical Features of Choking or Coughing Episode:</b></h3>
<ul>
<li aria-level="1"><span>May be days or weeks before presentation</span></li>
<li aria-level="1"><span>Usually self-limited</span></li>
<li aria-level="1"><span>Followed by symptom-free or cough-only period</span></li>
<li aria-level="1"><span>May be forgotten by caregiver</span></li>
</ul>
<p> </p>
<h3><b>Clinical Presentation:</b></h3>
<p><b>Most foreign body aspirations will have at least one of the below findings, whether acute, subacute or chronic.</b><b></b></p>
<ul>
<li><span>Subacute cough</span></li>
<li><span>Stridor</span></li>
<li><span>Unilateral wheeze on exam</span></li>
<li><span>XR normal for small, radiolucent objects (eg., peanut)</span></li>
<li><span>XR with unilateral hyperinflation or atelectasis if obstruction</span></li>
<li><span>Fever if post-obstructive pneumonia</span></li>
</ul>
<p> </p>
<h3><b>Board Pearl:</b></h3>
<p>Obtain bronchoscopy if any of the above findings suspicious for aspiration are present, even if the child is overall well-appearing and without systemic symptoms!</p>
<p> </p>
<h2><b>6. Rash + Systemic Symptoms = Think Bigger</b></h2>
<p><span>Children get rashes all the time – so which ones are dangerous? Whenever systemic symptoms or signs are involved, think about bacterial and immunologic conditions. For boards, remember these syndromes!</span></p>
<p> </p>
<p><b>Board Pearls – Rash Syndromes:</b></p>
<ul>
<li><strong>Palpable purpura on legs + joint pain only → think HSP<br>
</strong>We’re used to remembering HSP involves GI and renal findings like abdominal pain or hematuria. But these findings are delayed in onset, and often missing early on!</li>
<li><strong>Rash with neurologic findings </strong>→ think meningococcemia, Rocky Mountain spotted fever, viral encephalitis, or MIS-C</li>
<li><b>Meningococcemia </b>= petechial or purpuric rash + fever. With these findings, rule out meningococcal disease first and foremost.</li>
<li><b>RMSF </b>= Papular rash of wrists, ankles with meningismus. The fever and headache are prominent in RMSF, but the rash is delayed in onset until days 3-5. Thrombocytopenia is classic. Urticaria is not typical and suggests another diagnosis.<b><br>
</b><b></b></li>
<li><b>HSV encephalitis</b> = Vesicular rash + confusion, AMS. For any vesicular rash in an encephalitic patient, start empiric acyclovir as soon as possible!</li>
<li><b>MIS-C = </b>Rash + GI-prominent sepsis syndrome. These patients are systemically ill with meningismus as well. Look for a recent COVID diagnosis.</li>
<li><strong>5 days of fever with late-onset rash → think roseola<br>
</strong>If well-appearing patient, no need for sepsis work up even despite prolonged fever. Remember, roseola may cause sterile pyuria (ddx: UTI) and erythematous tympanic membranes (ddx: AOM), so don’t overtreat for something that isn’t there!</li>
<li><strong>Kawasaki and scarlet fever both have fever, rash, pharyngeal erythema and strawberry tongues<br>
</strong>But Kawasaki has prolonged symptoms >5 days, while scarlet fever remits by days 3-5 and the rash fades around day 6. Kawasaki’s lymphadenopathy is usually painless, while scarlet fever’s is painful. Both may have epidermal desquamation.</li>
</ul>
<p> </p>
<ul>
<li>
</ul>
<h2><span><strong>Final thoughts</strong></span></h2>
<p><span>That wraps up our high yield ABP topic discussion! Remember not to be fooled by certain well-appearing patients, especially febrile infants and patients early on in their course of illness – they still need a work up! For fractures, remember the list of those with initially negative imaging. Regarding headaches, memorize the red flag symptoms and signs, and always get imaging for focal neuro signs! With fever in children under 2 years old, remember the risk factor lists we reviewed, because boards loves testing on those. </span></p>
<p> </p>
<p><span>Remember the classic presentation of foreign body aspiration, and its subacute counterpart. And finally, now you can distinguish different rash syndromes by their associated characteristics. </span>As you review these topics, practice identifying the key clues in each vignette and explaining why the other answer choices are incorrect. For more ways to strengthen your preparation, explore <a href="https://elitemedicalprep.com/common-pitfalls-in-abp-prep-and-how-to-avoid-them/">common pitfalls in ABP prep and how to avoid them</a>. <span>Good luck on your exam!</span></p>
<p>The post <a href="https://elitemedicalprep.com/abp-board-pearls-6-high-yield-pediatric-topics-for-your-pediatrics-exam/">ABP Board Pearls: 6 High-Yield Topics for Your Pediatrics Exam</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Patient advocates launch PACE by reviewing their big hits in 2026</title>
<link>https://edusehat.com/en/patient-advocates-launch-pace-by-reviewing-their-big-hits-in-2026</link>
<guid>https://edusehat.com/en/patient-advocates-launch-pace-by-reviewing-their-big-hits-in-2026</guid>
<description><![CDATA[ Patient advocacy is often a long game, so it is important to remember (and celebrate) the home runs as the hits come—and keep on […]
The post Patient advocates launch PACE by reviewing their big hits in 2026 appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/Patient-Advocates-B-roll-Scratch.00_08_00_13-Still002.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 01:15:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Patient, advocates, launch, PACE, reviewing, their, big, hits, 2026</media:keywords>
<content:encoded><![CDATA[<p><span>Patient advocacy is often a long game, so it is important to remember (and celebrate) the home runs as the hits come—and keep on coming. </span></p>
<p><span>The Biotechnology Innovation Organization (BIO) launched their 15th annual Patient Advocacy Changemakers Event (PACE) in Washington DC on Oct. 22 with a celebration of some of advocacy’s biggest recent wins during their </span><a href="https://pace.bio.org/2026-program/patient-advocates-leading-way-1?&filters.date=22-Oct-2026%2C23-Oct-2026%2C&sortby=customfield_6234%20asc&searchgroup=libraryentry-2026-program"><span>Home Run! Patient Advocates Leading the Way</span></a><span> panel. </span></p>
<p><span>Michele Oshman, BIO Chief Patient Advocate and SVP, Patient Advocacy Center of Excellence, asked a panel of patient advocates about 2026’s banner achievements.</span></p>
<h3>Hitting it out of the park in 2026</h3>
<p><span>One big area that advocates got a few good hits in was the vaccine space. This is especially important in the wake of the COVID pandemic, which saw some states restricting vaccine access in ways that surprised many public health professionals. </span></p>
<p><span>Sue Peschin, MHS, President and CEO at the Alliance for Aging Research explained how, even though her organization works primarily with older populations, when it came to vaccine legislation, partnering with pediatric and chronic disease advocates got policies to home base faster.</span></p>
<p><span>“We started something called the Our Best Shot Network to really bring the different coalition leaders together,” Peschin said, “so that folks could coordinate and amplify each other’s opportunities.”</span></p>
<p><span>As a result, advocates have been able to co-lead a number of sign-on letters to the Food and Drug Administration (FDA) to highlight issues that would not have otherwise gotten as much attention, particularly when it comes to the Advisory Committee on Immunization Practices (ACIP). The network has also brought in center-right politicians to help sway their colleagues when problematic vaccine policy arises.</span></p>
<p><span>“There was an initiative to require prescriptions in order to get a COVID vaccine that was almost up for a vote at ACIP,” said Peschin, “and because of connections that we had made with conservative friends, they contacted ACIP and pulled back on that vote and made sure that that didn’t come up. No matter what you think about COVID vaccines, that would have set a horrible precedent for vaccines overall. So that was a big deal.”</span></p>
<p><span>There were wins in the Alzheimer’s community as well. </span></p>
<p><span>“We have new blood tests, blood-based biomarker tests,” recalled Erika Sward, Chief Advocacy Officer for the UsAgainstAlzheimer’s. “There are two pieces of legislation that are advancing through the House and the Senate called the </span><a href="https://www.congress.gov/bill/119th-congress/house-bill/6130/text"><span>ASAP Act</span></a><span> and the </span><a href="https://www.congress.gov/bill/118th-congress/senate-bill/2379/text"><span>CHANGE Act</span></a><span>, both of which are basic common sense laws that will make sure that people have access to cognitive testing tests and also these blood-based biomarkers for screening once they have been approved by FDA.”</span></p>
<p><span>Another example Sward gave started in 2025.</span></p>
<p><span>“For fiscal year 2026, the president’s budget proposed a 40% cut to the National Institutes of Health (NIH),” Sward explained. “By the time they finally finished the budget in March of this year, we had a $415 million increase to the NIH, and that is because we all worked together.”</span></p>
<p><span>There have also been some groundbreaking wins that were a long time coming, as Annie Kennedy, Chief Mission Officer at the RARE Foundation explained.</span></p>
<p><span>“We, as an organization, worked for a number of years with our patient advocacy coalitions and our industry coalitions and crafted what was called the Speeding Therapy Access Today (STAT), which would have established a rare disease center of excellence at the FDA,” Kennedy recalled. “And while that momentum and those hundreds of advocates that were repeatedly going to the Hill for a number of years didn’t yield a center of excellence, it did yield the Rare Disease Innovation Hub at FDA.”</span></p>
<p><span>Kennedy continued: “We’ve had wonderful acceptance and championship from both Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) when that hub was first established. That has remained. Despite all of the changes and shifts in the different individuals who’ve been leading the agency, there has been unwavering and unflagging support for the hub.”</span></p>
<h3>Moving forward together</h3>
<p><span>So how do advocates reach these wins and then keep on going? Panelists emphasized collaboration.</span></p>
<p><span>“The secret sauce for all of us has been in the collaborations that we form,” said Kennedy. “The strength has been in the coming together and understanding where the opportunities are to lean in and where the opportunities are to pivot from what we thought we would be working on this year.”</span></p>
<p><span>“While you are at PACE, make a point to meet people that you’ve never met before and get their contact information so that you can follow up with them,” said Sward. “Figure out how you can create new networks that may help you move forward. Find other organizations with whom to lock arms—and ask questions.”</span></p>
<p><span>“Don’t be afraid to stop a speaker and say, </span><i><span>What the heck does that mean?</span></i><span> That’s important,” said Peschin. “That is a great way to both learn more and make deeper connections.”</span></p>
<p>The post <a href="https://bio.news/federal-policy/patient-advocates-launch-pace-by-reviewing-their-big-hits-in-2026/">Patient advocates launch PACE by reviewing their big hits in 2026</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PACE: Pushing past the pain to achieve access for the 21st Century</title>
<link>https://edusehat.com/en/pace-pushing-past-the-pain-to-achieve-access-for-the-21st-century</link>
<guid>https://edusehat.com/en/pace-pushing-past-the-pain-to-achieve-access-for-the-21st-century</guid>
<description><![CDATA[ Patient advocates are no strangers to the sometimes painful challenges of promoting access to medicines and treatments. The key, they say, is staying two […]
The post PACE: Pushing past the pain to achieve access for the 21st Century appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/21st-century-pain-points.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 01:15:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PACE:, Pushing, past, the, pain, achieve, access, for, the, 21st, Century</media:keywords>
<content:encoded><![CDATA[<p><span>Patient advocates are no strangers to the sometimes painful challenges of promoting access to medicines and treatments. The key, they say, is staying two steps ahead.</span></p>
<p><span>“We’ve all experienced decades of incredible innovation as it relates to the biopharmaceutical community,” Kate Mevis, Associate VP of U.S. Federal Policy at Merck told an Oct. 22 session of the BIO Patient Advocacy Changemakers Event (PACE) in Washington, DC. “But we really need to make sure that access, coverage, cost, and the policies that govern those, keep pace with this innovation.”</span></p>
<p><span>Mevis moderated the PACE panel called </span><a href="https://pace.bio.org/2026-program/21st-century-access-pain-points-patients--1?&filters.date=22-Oct-2026%2C23-Oct-2026%2C&sortby=customfield_6234%20asc&searchgroup=libraryentry-2026-program"><span>21st Century Access: Pain Points for Patients</span></a><span>, which investigated barriers to patient access.</span></p>
<div class="ast-oembed-container "></div>
<p><span><br>
So what have been patient’s biggest pain points in recent years? And what are advocates doing to relieve the pressure?</span></p>
<h3>Utilization management remains a major pain point</h3>
<p><span>“Eighty percent of people living with psoriasis or psoriatic arthritis report that they have been subjected to some sort of utilization management,” said Leah Howard, President and CEO of the National Psoriasis Foundation. “That statistic is even higher in Medicare. About 90% of patients accessing therapies through Medicare experience utilization management.”</span></p>
<p><span>Howard said she’ll often ask a gathering how many audience members have experienced step therapy, prior authorization challenges or other forms of utilization management. “Literally, every single hand in the room goes up,” she said.</span></p>
<p><span>These utilization management challenges are compounded by insurers using copay accumulators and maximizers, said Carl Schmid, Executive Director at the HIV+Hepatitis Policy Institute. </span></p>
<p><span>“Patients rely on copay assistance for over $20 billion to help us pay for our drugs. That’s a lot of money,” Shmid said. “But unfortunately, pharmacy benefit managers (PBMs) and insurers are stealing around $7 billion of that through copay accumulators and maximizers.”</span></p>
<p><span>And these two pain points together are often even more magnified by the fact that patients are rarely dealing with just one disease.</span></p>
<p><span>“Most people have multiple diseases,” said Pam Traxel, SVP, Alliance Development and Philanthropy at the American Cancer Society Cancer Action Network. “So one of the things that’s so important about resolving utilization management is it is not just that a patient is studying one time to get access to one medicine. If you have a chronic disease, you are doing this throughout your entire life in many different areas.”</span></p>
<h3>Pain points in the real world</h3>
<p><span>And these issues are not just hypothetical, they are happening in real ways. </span></p>
<p><span>“Earlier this year, one health insurance company came out with their policy for 2026 that took a treatment that was approved nine years ago for psoriasis and psoriatic arthritis, and said that for a patient on their formulary to access that treatment, they would have to go through 14 other therapies, over 42 months to get to that one that their clinician wanted them to use,” explained Howard. “And this wasn’t because this was some brand new therapy that had just been approved.”</span></p>
<p><span>Luckily, the National Psoriasis Foundation and their partner groups in Pennsylvania, where this plan was located, succeeded in getting the insurer to reduce the list to five alternative therapies and 15 months, a noted improvement on the original plan.</span></p>
<p><span>But as Shmid pointed out, there is still work to be done on many advocacy fronts. </span></p>
<p><span>Shmid’s organization, the HIV+Hepatitis Policy Institute, filed a discrimination lawsuit three years ago after finding that some insurers were not covering the HIV drugs people needed, or were placing all HIV drugs on the highest formulary tier—a clear violation of the Affordable Care Act, </span><a href="https://bio.news/health/how-to-break-down-barriers-in-hiv-care/"><span>as Bio.News reported.</span></a></p>
<p><span>The HIV+Hepatitis Policy Institute won their suit, but the problem now is that the ruling is not being enforced. </span></p>
<p><span>“I get a lot of calls from people who are faced with these thousands and thousands of dollars in charges, and they say, ‘</span><i><span>Wait, I’m looking at the literature. You won. Why am I being charged this?’</span></i><span> And they’re angry,” Shmid said. </span></p>
<p><span>“It’s hard enough to pay their premiums, and now they’re being stuck with thousands of dollars of bills that they didn’t expect,” he continued. “We cannot give up on this issue. We have to hold the federal government accountable. We have to hold the insurers and PBMs accountable for what they’re getting away with right now.”</span></p>
<h3>Pushing back against the pain</h3>
<p><span>But advocates see reasons for hope.</span></p>
<p><span>“I think the American people have reached the boiling point on this issue,” said Shmid. “It’s not just the patients. It’s not just the caregivers, our families. It’s not just the providers. It’s members of Congress. Everyone is experiencing this prioritization or step therapy.”</span></p>
<p><span>The challenge of advocacy, however, is the ability to maintain momentum on established issues, while also anticipating new ones.</span></p>
<p><span>“There needs to be an urgency around our desire to remove these barriers because as we are fighting the original issue, the insurers are onto something totally different,” said Traxel.</span></p>
<p><span>At its core, the driver of patient advocacy is to ensure that biotech innovation can actually serve the common good it is intended for. </span></p>
<p><span>“When people talk about the promise of drug discovery and the great developments that happen, the fact that those treatments are sitting on the shelf and the patient can’t access them makes it feels like this whole process is for naught,” said Howard. “We can’t let that happen.”</span></p>
<p>The post <a href="https://bio.news/latest-news/pace-pushing-past-the-pain-to-achieve-access-for-the-21st-century/">PACE: Pushing past the pain to achieve access for the 21st Century</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ASHG President Susan Slaugenhaupt Calls for Hope, Leadership, and Communication in Science</title>
<link>https://edusehat.com/en/ashg-president-susan-slaugenhaupt-calls-for-hope-leadership-and-communication-in-science</link>
<guid>https://edusehat.com/en/ashg-president-susan-slaugenhaupt-calls-for-hope-leadership-and-communication-in-science</guid>
<description><![CDATA[ ASHG President Susan Slaugenhaupt, PhD, opened the society’s Montreal meeting with a heartfelt address emphasizing hope, leadership, and the importance of communication amid the challenges facing science today. 
The post ASHG President Susan Slaugenhaupt Calls for Hope, Leadership, and Communication in Science appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/ASHG_Susan-Slaugenhaupt_rectangle.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 01:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ASHG, President, Susan, Slaugenhaupt, Calls, for, Hope, Leadership, and, Communication, Science</media:keywords>
<content:encoded><![CDATA[<p>The American Society of Human Genetics (ASHG) meeting, being held in Montreal this week, kicked off with the Presidential address given by Susan Slaugenhaupt, PhD, Professor of Neurology at Harvard Medical School and ASHG President.</p>
<p>Slaugenhaupt opened the speech noting that “it’s really hard to know what to say in a presidential address” and that one of her friends told her that, “right now, people just need a message of hope.” And another said, “You always speak from the heart, so just do that.” Slaugenhaupt proceeded to deliver her heartfelt address—emphasizing hope, leadership, and the importance of communication amid the challenges facing science today. Some of the highlights are here.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“Persistence is not simply how we survive difficult periods in science. It is how we protect our passion, strengthen our teams, and turn discovery into a better future,” she asserted. “I know I’m not alone in feeling anger and frustration about what has happened to science in the United States, how it is reviewed, funded, and perceived by the public. The very idea of education is under attack. Scientific priorities are increasingly shaped by political forces rather than rigorous peer review. We see people rejecting vaccines, distrusting physicians, and dismissing decades of evidence-based progress. As scientists, our instinct is to respond with data. We want to explain the evidence. We want to demonstrate what the science shows, that the data alone are not bridging the divide. Whatever our individual political beliefs are, politics should not determine the value of scientific discovery. So what do we do? We act, we persist, we communicate. The most successful people I know are not people who never encounter barriers. They are people who meet those barriers with persistence and determination and keep going.”</p>
<p>Slaugenhaupt told the story of the quote below being taped to her office door by a team member after a particularly hard day in the lab. The piece of paper has remained tacked above her desk for nearly 30 years.</p>
<figure aria-describedby="caption-attachment-339692" class="wp-caption aligncenter"><img fetchpriority="high" decoding="async" class="wp-image-339692" src="https://www.genengnews.com/wp-content/uploads/2026/10/Unknown-1-1024x768.jpeg" alt="Susan Slaugenhaupt quote" width="696" height="522" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Unknown-1-1024x768.jpeg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Unknown-1-300x225.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Unknown-1-768x576.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Unknown-1.jpeg 1440w" sizes="(max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">The quote referred to by Susan Slaugenhaupt, PhD, in her ASHG presidential address [Julianna LeMieux]</figcaption></figure>
<p>The message that stayed with Slaugenhaupt from that quote is that persistence and determination are what carry us through when everything else has been exhausted. “That lesson helped shape me as a scientist and later as a leader,” she noted.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>“Recounting this story brings me to an important lesson beyond persistence and determination, and that is the importance of building a cohesive team that has your back. Always pay attention to your team and treat them well. It doesn’t matter if this is your lab team or your leadership team. Those people make you better every single day. Give credit generously. Ask people what they need to succeed. Notice the quiet members of your team. Make it safe to admit mistakes and create opportunities for people to grow in their roles. At some point in your career, success becomes less about advancing yourself and more about helping others advance. When that shift happens, embrace it.”</p>
<p>“This career is not easy, but your work is absolutely essential. Never forget that. If there is one quality that defines scientists, it’s passion. We don’t do this job because it pays particularly well or because there isn’t anything else we’re interested in. We do it because we can’t imagine doing anything else. Most of us caught the bug early. Curiosity became fascination, fascination became purpose, and eventually science became part of who we are. No matter how challenging the current environment is, I still see this passion in people every day and all of you. Most importantly, I see it in young people.”</p>
<p>“For the past 15 years, I’ve run an undergraduate summer student program. Every summer, those students arrive at the lab and they bring something remarkable with them. They bring optimism, energy, possibility. They are completely convinced that they will make discoveries that will change lives. And honestly, some of them probably will. Whenever I begin to think about the future, I think about those students, and that is why I remain hopeful. Hundreds of millions of people worldwide live with a genetic disease. They often face diagnostic odysseys only to learn that their disease has no treatment. Those of you who work with families know that there is nothing more powerful than a parent’s determination to help their child. They do not stop. They do not quit. They do not lose hope. They embody persistence.”</p>
<p>She also emphasized the importance of communicating science and designed the Presidential Symposium to focus on exploring the barriers that limit meaningful public engagement and discuss what scientists can do to help bridge these gaps. Because, she said, “speaking out is not optional anymore. It is part of our responsibility. Protesting might not be for everyone, but communicating must be. We must all be more vocal about the critical role in science and more specifically human genetics and genetics plays in improving the health of people around the world.”</p>
<p>“Over the past 18 months, we have witnessed an unprecedented challenge to science in the U.S. Actions that undermine scientific integrity, public trust, and research funding have affected all of us. Sadly, I suspect we’re not simply waiting for a return to the way things used to be. We are being asked to help shape what comes next. So when the path forward feels uncertain, remember this, your work matters. Build teams that support one another and celebrate one another’s success. Tell people outside this room what you do and why it matters. Protect the passion that brought you to science in the first place and above all, persist. Persist for the students who are just beginning their journeys. Persist for the patients and families who are waiting for answers. Persist for one another and persist because the future of human health depends on what we discover together. I am absolutely convinced that human genetics and genomics will continue to transform medicine and improve lives around the world.”</p>
<p>“Every person in this room is part of that future. The world needs your science. The world needs your voice and now more than ever, the world needs you to persist. Thank you.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/ashg-president-susan-slaugenhaupt-calls-for-hope-leadership-and-communication-in-science/">ASHG President Susan Slaugenhaupt Calls for Hope, Leadership, and Communication in Science</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Back Pain in Young Athletes: When It’s Normal Growth and When It’s Not</title>
<link>https://edusehat.com/en/back-pain-in-young-athletes-when-its-normal-growth-and-when-its-not</link>
<guid>https://edusehat.com/en/back-pain-in-young-athletes-when-its-normal-growth-and-when-its-not</guid>
<description><![CDATA[  ]]></description>
<enclosure url="https://dynamicsportsmedicine.com/wp-content/uploads/2026/10/back-pain-stock-image-1200x500.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 22:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Back, Pain, Young, Athletes:, When, It’s, Normal, Growth, and, When, It’s, Not</media:keywords>
<content:encoded></content:encoded>
</item>

<item>
<title>From invasive to additive: rethinking the 3D veneer workflow</title>
<link>https://edusehat.com/en/from-invasive-to-additive-rethinking-the-3d-veneer-workflow</link>
<guid>https://edusehat.com/en/from-invasive-to-additive-rethinking-the-3d-veneer-workflow</guid>
<description><![CDATA[ Dr Jameel Gardee explains how an innovative 3D veneer workflow helped a young patient achieve a brighter smile while preserving natural enamel, offering an alternative to a proposed treatment plan involving more than 20 crowns. When a young patient presented to Dr Jameel Gardee for a second opinion, he had already been considering travelling overseas… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/veneer_workflow.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 22:00:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, invasive, additive:, rethinking, the, veneer, workflow</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Dr Jameel Gardee explains how an innovative 3D veneer workflow helped a young patient achieve a brighter smile while preserving natural enamel, offering an alternative to a proposed treatment plan involving more than 20 crowns.</strong></p>



<p>When a young patient presented to Dr Jameel Gardee for a second opinion, he had already been considering travelling overseas for a complete smile transformation. His proposed treatment plan involved more than 20 zirconia crowns across the upper and lower arches.</p>



<p>The patient knew exactly what he wanted aesthetically: a bright, high-impact smile with a significant change in colour and shape. The question was whether that result could be achieved while preserving significantly more of his natural tooth structure.</p>



<p>Rather than beginning with restorative treatment, Dr Gardee and the team took a digital-first approach.</p>



<p>Following a full scan and clinical photography, the case was uploaded to Avant Garde Lab and planned using the Align & Smile workflow. Combining Invisalign planning with Exocad design allowed the team to work backwards from the desired final result.</p>



<figure class="wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-3 is-layout-flex wp-block-gallery-is-layout-flex">
<figure class="wp-block-image size-large"></figure>



<figure class="wp-block-image size-large"></figure>



<figure class="wp-block-image size-large"></figure>
</figure>



<h2 class="wp-block-heading"><a></a><strong>Starting with the end in mind</strong></h2>



<p>The patient’s existing teeth were crowded and worn, but digital planning allowed the team to demonstrate how repositioning the teeth first could completely change the restorative requirements at the end of treatment.</p>



<p>By visualising the proposed smile before treatment began, the patient could see that alignment could create the space and positioning required for a zero preparation restorative approach, preserving his remaining enamel while still working towards the bright, aesthetic result he wanted.</p>



<p>He elected to proceed with Invisalign treatment, which was completed over approximately seven months.</p>



<p>Once alignment was complete, the restorative phase could begin.</p>



<p>A trial smile was created, allowing both the patient and clinical team to assess the planned shape, proportions and overall aesthetic before moving to the definitive restorations.</p>



<p>From the approved design, Avant Garde Lab fabricated zero preparation Midas Sprint Tray 3D veneers in a Bleach shade. The laboratory’s CAD team digitally planned the final occlusion and aesthetic design according to the patient’s desired tooth shape, colour and overall smile goals.</p>



<p>The 3D veneers were bonded in a single appointment without preparation of the underlying teeth.</p>



<p>Six months following completion of the case, the restorations were performing well and, importantly, the patient’s natural enamel remained intact. He was delighted with the final result and with the decision to explore an alternative approach before committing to a more invasive treatment plan.</p>



<figure class="wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-4 is-layout-flex wp-block-gallery-is-layout-flex">
<figure class="wp-block-image size-large"></figure>



<figure class="wp-block-image size-large"></figure>
</figure>



<h2 class="wp-block-heading"><a></a><strong>More than manufacturing</strong></h2>



<p>For Dr Gardee, the case demonstrates how significantly the role of the modern dental laboratory is evolving.</p>



<p>‘It’s great to see ortho restorative workflows now being completed in such a seamless and easy way when you work with a strong planning centre like Avant Garde Dental Laboratory.</p>



<p>‘Dental laboratories are no longer solely about manufacturing. They can help us plan and deliver exceptional care for our patients and, in many cases, reinvent what is possible.</p>



<p>‘Being able to combine orthodontics, digital planning and restorative dentistry allows us to deliver highly aesthetic, minimally invasive cases which, where clinically appropriate, may require no preparation at all.</p>



<p>‘For me, this is where the future becomes really exciting. I’m looking forward to seeing where this technology and ecosystem takes us next.’</p>



<p>In this case, Avant Garde Lab supported the workflow from the initial Invisalign treatment planning through to the trial smile and fabrication of the final 3D veneers.</p>



<p>It demonstrates an important principle in modern aesthetic dentistry: sometimes the biggest change in the restorative plan happens before a restoration is ever made.</p>



<figure class="wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-5 is-layout-flex wp-block-gallery-is-layout-flex">
<figure class="wp-block-image size-large"></figure>



<figure class="wp-block-image size-large"></figure>
</figure>



<h2 class="wp-block-heading"><a></a><strong>Learn the workflow</strong></h2>



<p>For clinicians looking to incorporate this approach into their own practice, Avant Garde Dentistry’s final <strong>Align & Smile</strong> and <strong>3D Veneers</strong> courses of 2026 take place back-to-back this November, offering clinicians the opportunity to explore both sides of the ortho restorative workflow.</p>



<h3 class="wp-block-heading"><strong>Align & Smile: Friday 13 November 2026</strong></h3>



<p>Learn how to plan with the restorative endpoint in mind, combining digital orthodontic planning with minimally invasive restorative dentistry to create more favourable conditions for the final smile.</p>



<p><a href="https://www.avantgardedentistry.co.uk/event-details/align-smile-1-1" target="_blank" rel="noreferrer noopener">Find out more and book.</a></p>



<h3 class="wp-block-heading"><strong>3D Veneers – The Workflow Experience: Saturday 14 November 2026</strong></h3>



<p>Take the next step into the 3D veneer workflow, exploring the digital planning and clinical processes behind minimally invasive smile transformations and a workflow designed to integrate seamlessly with Avant Garde Lab.</p>



<p><a href="https://www.avantgardedentistry.co.uk/event-details/3d-veneers-the-workflow-experience-1-3" target="_blank" rel="noreferrer noopener">Find out more and book.</a></p>



<p>These are the final opportunities to attend <strong>Align & Smile and 3D Veneers in this format in 2026</strong>.</p>



<p><em>This article is sponsored by Dental Excellence.</em></p>



<p></p>]]> </content:encoded>
</item>

<item>
<title>How digital diagnostics are transforming patient education in dentistry</title>
<link>https://edusehat.com/en/how-digital-diagnostics-are-transforming-patient-education-in-dentistry</link>
<guid>https://edusehat.com/en/how-digital-diagnostics-are-transforming-patient-education-in-dentistry</guid>
<description><![CDATA[ Digital diagnostic tools are reshaping patient education at Zahnarztpraxis Axel Wittmann in Germany, helping patients visualise their oral health, understand treatment recommendations and take a more active role in their care. Patient education has always been one of the biggest challenges in dentistry. Even when clinicians clearly explain conditions such as tooth wear, plaque build-up,… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/patient_education.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 22:00:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, digital, diagnostics, are, transforming, patient, education, dentistry</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>Digital diagnostic tools are reshaping patient education at Zahnarztpraxis Axel Wittmann in Germany, helping patients visualise their oral health, understand treatment recommendations and take a more active role in their care.</strong></p>



<p>Patient education has always been one of the biggest challenges in dentistry. Even when clinicians clearly explain conditions such as tooth wear, plaque build-up, gingival recession, or early caries, many patients struggle to fully understand what is happening inside their mouths. Dental professionals can see clinical issues immediately, but patients often rely on verbal explanations, mirrors, or radiographs that may be difficult to interpret. As a result, treatment discussions can feel abstract and important recommendations may be delayed.</p>



<p>At Zahnarztpraxis Axel Wittmann in Kiel, Germany, digital diagnostic technology is helping bridge this communication gap. Led by Dr Axel Wittmann, the practice has embraced a digital workflow for many years and recently introduced the 3Shape TRIOS 6 intraoral scanner together with Dx Plus software. The objective was not simply to digitise impressions but to enhance patient understanding and create more meaningful conversations about oral health.</p>



<h2 class="wp-block-heading">Making patient education more visual</h2>



<p>The practice identified a common challenge seen across dentistry. Patients frequently leave appointments without fully appreciating the significance of the conditions identified during examinations. Even when preventive advice is provided, information can be forgotten after the appointment. Dr Wittmann wanted a more visual, objective way to communicate findings and help patients better understand their own oral health.</p>



<p>With Dx Plus, diagnostic scans become a visual communication tool. Following a scan with TRIOS 6, clinicians can review visualisations that highlight conditions such as plaque accumulation, tooth wear, gingival recession and potential caries directly on the digital model. Instead of relying solely on descriptions, clinicians can show patients what they are seeing in a clear and engaging format.</p>



<h2 class="wp-block-heading">Bringing patient education into routine appointments</h2>



<p>The impact of this approach has been significant. Today, diagnostic scanning is incorporated into routine check-up and prophylaxis appointments at the practice. Patients first receive a scan and then review the findings together with the clinician on a large screen. This transforms the consultation into a collaborative discussion. Patients can see their own oral health conditions, ask questions and gain a better understanding of the reasons behind treatment recommendations.</p>



<p>According to Dr Wittmann, the most valuable part of the process is not the scan itself but the conversation that follows. By making oral health conditions visible, discussions become easier to follow and more memorable. Patients are empowered to take a more active role in decisions regarding their care.</p>



<p>The results reported by the practice indicate improvements in patient engagement and treatment acceptance across a range of procedures, including preventive care, restorative treatments and crowns. Importantly, the goal is not to encourage unnecessary treatment but to support informed decision making. When patients understand their diagnosis and the biological factors affecting their oral health, they can make decisions with greater confidence.</p>



<h2 class="wp-block-heading">Strengthening trust through clearer communication</h2>



<p>This case reflects a broader trend within modern dentistry. Digital technologies are increasingly being used not only for clinical workflows but also for patient communication. As practices look for ways to improve education, trust and treatment acceptance, visual diagnostic tools can play an important role in strengthening clinician-patient relationships.</p>



<p>For dental professionals seeking new ways to enhance consultations, digital diagnostic workflows offer an opportunity to transform routine check-ups into educational experiences. By helping patients clearly see and understand their oral health, practices can create more informed conversations, strengthen trust and support long-term oral health outcomes.</p>



<p>Ready to elevate patient communication and engagement? <a href="https://www.3shape.com/en/scanners/trios-6">Book a 3Shape Dx Plus demo and see how digital diagnostics can support better treatment conversations and outcomes.</a> Get in touch on <a href="tel://01183%20151%20300">01183 151 300</a> or <a href="mailto:ukenquiries@3shape.com">ukenquiries@3shape.com</a>.</p>



<p><em>This article is sponsored by 3Shape.</em></p>]]> </content:encoded>
</item>

<item>
<title>Endurance sport’s hidden oral health challenge</title>
<link>https://edusehat.com/en/endurance-sports-hidden-oral-health-challenge</link>
<guid>https://edusehat.com/en/endurance-sports-hidden-oral-health-challenge</guid>
<description><![CDATA[ Dr Ben Atkins shares lessons from crossing Iceland on why endurance athletes’ carbohydrate intake and dehydration can increase oral-health risk. ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/ensurance_sports.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 22:00:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Endurance, sport’s, hidden, oral, health, challenge</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"><figcaption class="wp-element-caption">Photo credit: Leo Francis</figcaption></figure>



<p><strong>After crossing Iceland by bike, kayak and on foot, Ben Atkins explores the oral health risks of endurance sport.</strong></p>



<p>When you think about the physical demands of endurance sport, teeth are unlikely to be high on the list. With months of training to complete, calories to replace, kit to test, hydration to manage and injuries to avoid, oral health can easily become an afterthought – and perhaps surprisingly, that proved true even for an experienced dentist.</p>



<div class="wp-block-media-text is-stacked-on-mobile"><figure class="wp-block-media-text__media"></figure><div class="wp-block-media-text__content">
<p>Dr Ben Atkins, a Manchester-based general dental practitioner and former president and long-standing trustee of the Oral Health Foundation, recently completed the Rat Race Iceland Coast to Coast. The challenge involved around 110km a day of off-road mountain biking over five to six days, approximately two hours of kayaking and a 44km ultramarathon-style finish.</p>
</div></div>



<p>He had spent around two and a half years rebuilding his fitness after serious back problems affecting three discs stopped him running and, for a period, left him without feeling in one foot. His preparation covered training, nutrition, hydration and equipment. His kit included a Philips Sonicare DiamondClean 9900 Prestige sonic toothbrush, toothpaste and interdental cleaning aids. Yet there was one risk he says he had underestimated: ‘I overlooked it. And this is my world.’</p>



<h2 class="wp-block-heading">The endurance blind spot</h2>



<!--free-wall-stop-->



<p>For Ben, Iceland was about the experience rather than chasing a finishing time. ‘I wanted to absorb every detail and not hare through every stage,’ he says. ‘It was much more about the journey.’</p>



<p>The journey took him through black volcanic landscapes, river crossings, snow and green valleys, often in complete isolation. He had relatively little experience of technical mountain biking beforehand and, by the end, his cycling shoes had deteriorated so badly that they had to be cable-tied to his feet.</p>



<p>For six days, the group saw nobody outside the expedition. Against this backdrop, he began to appreciate an aspect of endurance sport that research suggests deserves greater attention.</p>



<p>A study of 352 elite and professional UK athletes found untreated caries in 49.1%, erosive tooth wear in 41.4% and gingival bleeding or calculus in 77%; 21.6% recorded probing depths of at least 4mm. Overall, 32% reported an oral health-related impact on sporting performance (Gallagher et al, 2018).</p>



<p>A related study found that 94.2% brushed at least twice a day, yet only 40% had visited a dentist in the previous six months and 80% used sports drinks during training or competition (Gallagher et al, 2019).</p>



<p>A 2026 review by Needleman, Gallagher and Ashley in the <em>British Dental Journal</em> concluded that oral disease remains common among elite athletes. It suggested that, because carbohydrates required to fuel training and competition cannot simply be removed, oral-health support is more realistically approached as risk mitigation.</p>



<figure class="wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-1 is-layout-flex wp-block-gallery-is-layout-flex">
<figure class="wp-block-image size-large"></figure>



<figure class="wp-block-image size-large"></figure>



<figure class="wp-block-image size-large"></figure>
</figure>



<h2 class="wp-block-heading">When a healthy mouth becomes high risk</h2>



<p>Endurance athletes may consume 90g of carbohydrate an hour or more for sustained periods, potentially keeping plaque pH depressed while high airflow and possibly stress can reduce saliva availability.</p>



<p>In Iceland, Ben experienced that combination himself. Food between stages was healthy and well planned, but once he was on the route he needed enough portable energy to sustain long days on the bike. By his estimate, he was burning around 6,500 calories a day.</p>



<p>‘You couldn’t avoid it. You needed that volume of food,’ he says. ‘The only way to get it in is cake.’</p>



<p>What concerned him most was not simply the amount of sugar, but the frequency of exposure. ‘A lot of people were on isotonic drinks, and they have sugar in them, so you have a sugar solution in your mouth for 12 hours, which is not something we do at home. I do worry about how that affected my mouth.’</p>



<p>Dry mouth was the greater surprise. ‘The dry mouth was a challenge, without question. I wasn’t even thinking about it,’ he says. ‘I know about sugar, but it was the dehydration that caught me out.’ His conclusion was simple: ‘You suddenly become a high-risk patient.’ Even a week and a half after returning home, Ben described his mouth as still feeling ‘shot’.</p>



<h2 class="wp-block-heading">Prevention before performance</h2>



<p>The experience has changed how Ben thinks about conversations with patients preparing for endurance events. One member of the Iceland group needed root canal treatment only two days before travelling, after developing a facial swelling.</p>



<p>‘The last thing you want is toothache in the middle of Iceland,’ Ben says. ‘You have spent a lot of money and a huge amount of time training, so get a good examination performed before you embark on a challenge and review anything that could go wrong.’</p>



<p>Rather than simply telling athletes to avoid gels or sports drinks that may be necessary for performance, he believes prevention needs to fit around how they actually train. This may mean checking oral health well before a major event, looking at the timing and frequency of carbohydrate exposure, following sugary gels or drinks with water where practical, and reviewing the patient again after an intensive period of training or competition (Needleman, Gallagher and Ashley, 2026).</p>



<p>‘We often think prevention is what we do when we see bleeding gums, but that is treatment,’ Ben explains. ‘Even if you have perfect oral health, you are about to assault your mouth.’</p>



<figure class="wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-2 is-layout-flex wp-block-gallery-is-layout-flex">
<figure class="wp-block-image size-large"></figure>



<figure class="wp-block-image size-large"></figure>



<figure class="wp-block-image size-large"></figure>
</figure>



<h2 class="wp-block-heading">Keeping prevention on track</h2>



<p>Ben continued using his Philips Sonicare throughout the trip and, as far as he could tell, was the only participant using an electric toothbrush. His normal routine became more thorough rather than less, with brushing increasing to three times a day and often taking place as soon as he came off the bike.</p>



<p>The brush’s AI-supported coverage map, displayed directly on the handle, showed which areas of his mouth he had covered and helped him identify places he had missed. However, the benefit he remembers most was more personal than technological.</p>



<p>‘It gave me five minutes away from everybody,’ he says. ‘Brushing your teeth, it’s that two minutes away. Let’s just reset.’</p>



<p>At the end of long days on the bike, the familiar routine gave him a few minutes to switch off before eating, showering, repacking his kit and preparing for the following morning. ‘By the time I’d brushed my teeth, I was like, okay, we’re okay again now. Now I can go.’</p>



<h2 class="wp-block-heading">A different question for active patients</h2>



<p>For Ben, asking a patient what they eat may not reveal the whole picture. Someone may eat well, brush twice a day and appear highly motivated about their oral health, yet during training or competition spend hours repeatedly exposing their mouth to carbohydrates while also experiencing dehydration.</p>



<p>‘We should speak to our patients about this,’ says Ben. ‘We should ask:</p>



<div class="wp-block-cover is-light wp-duotone-dark-grayscale"><span aria-hidden="true" class="wp-block-cover__background has-background-dim"></span><div class="wp-block-cover__inner-container is-layout-constrained wp-block-cover-is-layout-constrained">
<h2 class="wp-block-heading has-white-color has-text-color has-link-color wp-elements-664c1c0c18ebdec40196ee00ea2fa6d0">‘Are you training for something?</h2>



<h2 class="wp-block-heading has-white-color has-text-color has-link-color wp-elements-37d2eb80d8048a2ca19d6d67804db21f">‘What are you doing during a sporting challenge?</h2>



<h2 class="wp-block-heading has-white-color has-text-color has-link-color wp-elements-ad6753b2060905721ee2397bd3f6d65d">‘What are your children drinking during a match?’</h2>
</div></div>



<p>For dental teams, asking how patients fuel their sport could uncover a very different pattern of oral-health risk. Endurance sport has become increasingly sophisticated in the way athletes monitor training, nutrition, hydration, sleep and recovery, yet oral health can still fall between the gaps. If a dentist can overlook that risk while preparing to cross Iceland, it is worth asking how many active patients may be overlooking it too.</p>



<p><em>For references, email siobhan.hiscott@fmc.co.uk.</em></p>



<p><em><a href="https://sso.dentistry.co.uk/">Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</a></em></p>]]> </content:encoded>
</item>

<item>
<title>BDIA warns of handpiece repair risks in new campaign</title>
<link>https://edusehat.com/en/bdia-warns-of-handpiece-repair-risks-in-new-campaign</link>
<guid>https://edusehat.com/en/bdia-warns-of-handpiece-repair-risks-in-new-campaign</guid>
<description><![CDATA[ The British Dental Industry Association (BDIA) has partnered with four handpiece manufacturers to raise awareness of the risks associated with the use of generic spare parts in handpiece repairs. The campaign aims to help dental professionals make informed decisions about handpiece maintenance and understand the risks of counterfeit and non-compliant devices. Bien-Air, KaVo, NSK and… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/handpiece-campaign-BDIA.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 22:00:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BDIA, warns, handpiece, repair, risks, new, campaign</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image alignfull size-large"></figure>



<p><strong>The British Dental Industry Association (BDIA) has partnered with four handpiece manufacturers to raise awareness of the risks associated with the use of generic spare parts in handpiece repairs.</strong></p>



<p>The campaign aims to help dental professionals make informed decisions about handpiece maintenance and understand the risks of counterfeit and non-compliant devices.</p>



<p>Bien-Air, KaVo, NSK and W&H are supporting the initiative, which encourages dental professionals to check what parts are being used to repair their handpieces. Together, they aim to highlight the importance of using original manufacturer spare parts and provide clear guidance on purchasing and maintaining these devices.</p>



<p>The BDIA acknowledges that generic spare parts are being used in handpiece repairs, which could ‘fundamentally alter’ the device’s original construction, and transfer responsibility away from the original manufacturer. </p>



<p>With patient safety and clinical performance at the heart of the campaign, the association also highlights that generic parts could put patients and dental professionals at risk by compromising the safety, reliability and performance of the handpiece.</p>



<p>The campaign states: ‘Counterfeit and non-compliant dental devices are entering the UK supply chain.’ Asking ‘What’s really in your hands?’, it warns that these devices could put patients, clinicians’ reputations and professional registration at risk.</p>



<h2 class="wp-block-heading">‘An essential part of dentistry’</h2>



<p>Edmund Proffitt, BDIA chief executive, commented: ‘Handpieces are an essential part of dentistry. Dental professionals need confidence in their handpiece and the quality of its maintenance and repair. </p>



<p>‘By working with leading manufacturers, we aim to help practices ask the right questions about spare parts and make informed decisions that put patient and user safety first.’</p>



<p>The initiative will be shared with organisations including the British Dental Association, General Dental Council, Medicines and Healthcare products Regulatory Agency and Care Quality Commission.</p>



<p><a href="https://bdia.org.uk/bdia-and-leading-handpiece-manufacturers-unite-to-promote-safer-handpiece-repairs/" target="_blank" rel="noreferrer noopener">Read the full press release here.</a></p>



<p><a href="https://bdia.org.uk/device-regulation-faqs/" target="_blank" rel="noreferrer noopener">Learn more by visiting the BDIA website.</a></p>



<p><strong>Interested in reading more on handpieces?</strong></p>



<ul class="wp-block-list">
<li><a href="https://dentistry.co.uk/2026/10/10/the-hidden-cost-of-cheap-handpieces/" target="_blank" rel="noreferrer noopener">The hidden cost of cheap handpieces</a></li>



<li><a href="https://dentistry.co.uk/2026/10/02/is-it-time-to-repair-or-replace-your-dental-handpiece-take-the-quiz-to-find-out/" target="_blank" rel="noreferrer noopener">Quiz: should you repair or replace your handpiece?</a></li>



<li><a href="https://dentistry.co.uk/2026/09/18/dental-handpiece-compliance-are-you-missing-a-step/" target="_blank" rel="noreferrer noopener">Handpiece compliance: are you missing a step?</a></li>



<li><a href="https://dentistry.co.uk/2026/08/31/five-signs-your-handpiece-is-holding-you-back/" target="_blank" rel="noreferrer noopener">Five signs your handpiece is holding you back</a>.</li>
</ul>



<p><em><a href="https://sso.dentistry.co.uk/" target="_blank" rel="noreferrer noopener"><em>Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</em></a></em></p>]]> </content:encoded>
</item>

<item>
<title>Southlake Health launches new initiative to connect patients with care before hospitalization</title>
<link>https://edusehat.com/en/southlake-health-launches-new-initiative-to-connect-patients-with-care-before-hospitalization</link>
<guid>https://edusehat.com/en/southlake-health-launches-new-initiative-to-connect-patients-with-care-before-hospitalization</guid>
<description><![CDATA[ New population health program will use data, research and community partnerships to improve access to care. Southlake Health has launched a new initiative aimed at improving how healthcare is delivered across northern York Region and southern Simcoe County, with a focus on helping patients access services before their conditions become more serious. The Population Health […]
The post Southlake Health launches new initiative to connect patients with care before hospitalization appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/shutterstock_2730576377.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 21:30:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Southlake, Health, launches, new, initiative, connect, patients, with, care, before, hospitalization</media:keywords>
<content:encoded><![CDATA[<p>New population health program will use data, research and community partnerships to improve access to care.</p>
<p>Southlake Health has launched a new initiative aimed at improving how healthcare is delivered across northern York Region and southern Simcoe County, with a focus on helping patients access services before their conditions become more serious.</p>
<p>The Population Health Management Advance, known as PHM Advance, will bring together clinical expertise, health data, research and community partnerships to identify gaps in care and develop more proactive approaches to supporting patients.</p>
<p>Rather than relying primarily on hospital-based treatment after health problems escalate, the initiative will explore opportunities to identify people who may benefit from earlier intervention and connect them with appropriate services.</p>
<p>The approach is intended to improve health outcomes, strengthen coordination between providers and potentially reduce avoidable hospital admissions.</p>
<h3>Using data to improve patient care</h3>
<p>Population health management involves examining the healthcare needs of communities and using that information to guide how services are planned and delivered.</p>
<p>Through PHM Advance, Southlake will identify opportunities for improvement, test new approaches, evaluate their effectiveness and expand those that demonstrate positive results.</p>
<p>A dedicated team at the hospital will collaborate with local healthcare providers to develop practical solutions that help patients navigate the health system and receive care in appropriate settings.</p>
<p>The initiative comes as Southlake serves communities experiencing continued population growth and increasing demand for healthcare services.</p>
<h3>International expertise supporting local innovation</h3>
<p>Southlake has also established a Global Advisory Board featuring healthcare leaders from Canada, the United States, the Netherlands and Singapore.</p>
<p>The board will contribute expertise and perspectives on population health management, helping the hospital evaluate approaches that could improve care delivery.</p>
<p>PHM Advance forms part of Southlake’s broader strategy to develop a Distributed Health Network, which aims to provide care across multiple locations and community settings rather than relying on a single hospital campus.</p>
<p>The model emphasizes bringing services closer to patients, improving connections between healthcare providers and supporting people in maintaining their health for longer.</p>
<h3>A shift toward prevention</h3>
<p>The initiative reflects a broader effort to move healthcare delivery toward earlier intervention and stronger coordination between hospitals and community-based services.</p>
<p>For patients, that could mean receiving additional support before a manageable health issue becomes an emergency.</p>
<p>For healthcare providers, it offers an opportunity to improve communication, identify unmet needs and direct resources toward patients who could benefit most.</p>
<p>Although the initiative is newly launched and its outcomes have yet to be demonstrated, Southlake intends to use ongoing evaluation to determine which approaches should be expanded.</p>
<p>Source: <a href="https://southlake.ca/news/southlake-launches-new-population-health-management-advance/?utm_source=chatgpt.com">Southlake Health — Population Health Management Advance</a>.</p>
<p>The post <a href="https://www.hospitalnews.com/southlake-health-launches-new-initiative-to-connect-patients-with-care-before-hospitalization/">Southlake Health launches new initiative to connect patients with care before hospitalization</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>1win Global App Mobile Guide – Registration, Play &amp;amp; Cash Out</title>
<link>https://edusehat.com/en/1win-global-app-mobile-guide-registration-play-cash-out</link>
<guid>https://edusehat.com/en/1win-global-app-mobile-guide-registration-play-cash-out</guid>
<description><![CDATA[ Practical Guide to the 1win Global App – How to Register, Play, and Cash Out Getting Started: Registration and First Steps When you open the 1win global app 
The post 1win Global App Mobile Guide – Registration, Play &amp; Cash Out appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/Bvya_4hXzkc/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 21:20:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>1win, Global, App, Mobile, Guide, –, Registration, Play, Cash, Out</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img src="https://i.ytimg.com/vi/Bvya_4hXzkc/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Practical Guide to the 1win Global App – How to Register, Play, and Cash Out</h1>
<h2>Getting Started: Registration and First Steps</h2>
<div data-affgun-media="video"></div>
<p>When you open the 1win global app for the first time, the onboarding screen asks for a simple email address or phone number. The form is deliberately short – you type your contact, create a password, and confirm you are over 18. After you hit “Sign Up”, an activation code lands in your inbox, and you type it back into the app to finish the registration. This quick process is designed for beginners who do not want to fill out long questionnaires before they can start playing.</p>
<nav aria-label="Table of contents">
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-global-app-mobile-guide-registration-play-cash-out/#getting-started-registration-and-first-steps">Getting Started: Registration and First Steps</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-global-app-mobile-guide-registration-play-cash-out/#navigating-the-1win-global-app-interface">Navigating the 1win Global App Interface</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-global-app-mobile-guide-registration-play-cash-out/#bonuses-and-promotions-what-to-expect">Bonuses and Promotions: What to Expect</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-global-app-mobile-guide-registration-play-cash-out/#payment-methods-deposits-and-withdrawals">Payment Methods, Deposits and Withdrawals</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-global-app-mobile-guide-registration-play-cash-out/#security-verification-and-responsible-gambling">Security, Verification and Responsible Gambling</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-global-app-mobile-guide-registration-play-cash-out/#mobile-experience-vs-desktop-performance-and-features">Mobile Experience vs Desktop: Performance and Features</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-global-app-mobile-guide-registration-play-cash-out/#live-casino-and-sportsbook-highlights">Live Casino and Sportsbook Highlights</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-global-app-mobile-guide-registration-play-cash-out/#customer-support-and-licensing-details">Customer Support and Licensing Details</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-global-app-mobile-guide-registration-play-cash-out/#frequently-asked-questions">Frequently Asked Questions</a></li>
</ol>
</nav>
<p>Once your account is active, the app immediately offers a welcome bonus that usually matches your first deposit. Keep an eye on the bonus terms, because the wagering requirements can vary between 20x and 40x depending on the promotion. If you plan to use the bonus, it is wise to read the fine print early, otherwise you might be surprised when you try to withdraw winnings later.</p>
<h2>Navigating the 1win Global App Interface</h2>
<p>The home screen of the 1win global app is split into three main tabs: Casino, Sportsbook, and Live. Each tab is represented by a clear icon, making it easy for users to jump straight to the section they want. The casino tab lists slots, table games, and a live dealer area, while the sportsbook shows current matches with live odds. A small notification bell in the top right corner alerts you to new promotions or pending verification steps.</p>
<p>If you prefer a more classic layout, you can swipe left to reveal a “Classic View” that mimics a desktop browser. This view shows a full menu on the left side, where you can access payment methods, settings, and responsible gambling tools. The app also remembers your last played game, so you can continue a slot round where you left it – a handy feature for players who like short, frequent sessions.</p>
<h2>Bonuses and Promotions: What to Expect</h2>
<p>The 1win global app rolls out a rotating set of bonuses, from a 100% welcome match to weekly free spin offers. Most promotions are tied to specific games, for example “50 free spins on Starburst every Friday”. The key term you will see is <strong>wagering requirements</strong>; a typical 30x requirement means you need to bet thirty times the bonus amount before you can cash out.</p>
<p>Below is a quick snapshot of the current main offers:</p>
<ul>
<li>Welcome Bonus: 100% up to $200 + 50 free spins</li>
<li>Reload Bonus: 50% up to $100 every Monday</li>
<li>Live Casino Cashback: 10% of losses returned weekly</li>
<li>Sportsbook Accumulator Boost: 20% extra winnings on 3+ leg bets</li>
</ul>
<h2>Payment Methods, Deposits and Withdrawals</h2>
<p>The app supports a range of popular deposit methods, including credit cards, e‑wallets, and bank transfers. Each method has its own minimum amount and typical processing time. When you request a withdrawal, the speed largely depends on the method you choose; e‑wallets are usually instant, while bank transfers can take up to three business days.</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Method</th>
<th>Minimum Deposit</th>
<th>Withdrawal Speed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visa / MasterCard</td>
<td>$10</td>
<td>1‑2 business days</td>
</tr>
<tr>
<td>PayPal</td>
<td>$20</td>
<td>Instant</td>
</tr>
<tr>
<td>Bank Transfer</td>
<td>$50</td>
<td>1‑3 business days</td>
</tr>
<tr>
<td>Trustly</td>
<td>$15</td>
<td>Instant</td>
</tr>
</tbody>
</table>
<p>Remember to check the <a href="https://nickodemus.com/">1win rwanda withdrawal online</a> guide if you are based in East Africa, as local banking partners may affect the final payout time.</p>
<h2>Security, Verification and Responsible Gambling</h2>
<p>Security is taken seriously on the 1win global app. All data transmission is encrypted with SSL, and the platform holds a licence from a reputable gambling authority. Before you can withdraw large sums, the app will ask you to complete a KYC (Know Your Customer) verification. This typically involves uploading a photo ID and a utility bill, a process that takes a few minutes if the documents are clear.</p>
<p>For responsible gambling, the app includes self‑exclusion tools, deposit limits, and a “time out” button that temporarily blocks access. These features are hidden in the Settings → Responsible Gaming menu, making them easy to find without cluttering the main gaming area.</p>
<h2>Mobile Experience vs Desktop: Performance and Features</h2>
<p>While the 1win global app is built for smartphones, the desktop version offers a slightly larger screen for live dealer tables. On mobile, the app automatically reduces graphic load to keep the slots running smoothly, which can be a plus for users on slower connections. Both platforms share the same account balance, bonus status, and game library, so you can start a session on your phone and finish it on a laptop without any loss of progress.</p>
<p>One practical tip: enable push notifications on the mobile app. You will receive real‑time alerts when your favourite sport goes live, when a new casino bonus drops, or when a withdrawal has been processed. This keeps you in the loop without constantly checking the website.</p>
<h2>Live Casino and Sportsbook Highlights</h2>
<p>The live casino section of the 1win global app streams real dealers in high definition. Popular tables include Blackjack, Roulette, and Baccarat, each with a chat function so you can talk to the dealer or other players. The RTP (Return to Player) on most live games matches the standard casino average, usually around 96% for Blackjack and 97% for Roulette.</p>
<p>On the sportsbook side, the app covers major leagues worldwide, from the English Premier League to the NBA. You can place pre‑match bets, in‑play wagers, and even virtual sports. The app displays live odds updates every few seconds, and you can cash out early on many selections, which is handy if a match turns against you.</p>
<h2>Customer Support and Licensing Details</h2>
<p>Support is available 24/7 through live chat, email, and a toll‑free phone line. The chat window often includes quick‑reply buttons for common issues such as “Deposit not received” or “How to verify my account”. Response times are usually under two minutes for chat, and within a few hours for email.</p>
<p>The 1win global app operates under a licence issued by the Curacao eGaming Authority. While this licence is respected in many jurisdictions, the app does not accept players from some restricted countries. Before you sign up, check the “Country Availability” list in the FAQ to ensure your location is permitted.</p>
<h2>Frequently Asked Questions</h2>
<ul>
<li><strong>Is the 1win global app available on iOS and Android?</strong> Yes, you can download it from the Apple App Store or Google Play Store.</li>
<li><strong>How long does a withdrawal take?</strong> E‑wallets are instant, while bank transfers may need up to three business days.</li>
<li><strong>Can I set a deposit limit?</strong> Absolutely – the app lets you set daily, weekly, or monthly limits in the Responsible Gaming menu.</li>
<li><strong>What is the minimum age to play?</strong> You must be at least 18 years old, and verification will confirm your age.</li>
</ul>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/uncategorized/1win-global-app-mobile-guide-registration-play-cash-out/">1win Global App Mobile Guide – Registration, Play & Cash Out</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>1win App Registration Download Bonus Guide</title>
<link>https://edusehat.com/en/1win-app-registration-download-bonus-guide</link>
<guid>https://edusehat.com/en/1win-app-registration-download-bonus-guide</guid>
<description><![CDATA[ Why Choose the 1win Mobile App? How to Perform the 1win App Registration Download Safely 1win App Registration Download: Step‑by‑Step Account Creation Verification (KYC) – Making Your 1win 
The post 1win App Registration Download Bonus Guide appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/uyv6WRV_RB8/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 21:20:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>1win, App, Registration, Download, Bonus, Guide</media:keywords>
<content:encoded><![CDATA[<nav aria-label="Table of contents">
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/#why-choose-the-1win-mobile-app">Why Choose the 1win Mobile App?</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/#how-to-perform-the-1win-app-registration-download-safely">How to Perform the 1win App Registration Download Safely</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/#1win-app-registration-download-stepbystep-account-creation">1win App Registration Download: Step‑by‑Step Account Creation</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/#verification-kyc-making-your-1win-account-fully-functional">Verification (KYC) – Making Your 1win Account Fully Functional</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/#first-deposit-welcome-bonus-what-to-expect">First Deposit & Welcome Bonus – What to Expect</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/#payment-methods-withdrawals-and-speed">Payment Methods, Withdrawals and Speed</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/#mobile-casino-and-sportsbook-how-to-navigate-the-app">Mobile Casino and Sportsbook – How to Navigate the App</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/#support-security-and-responsible-gambling">Support, Security, and Responsible Gambling</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/#common-issues-troubleshooting-tips">Common Issues & Troubleshooting Tips</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/#final-thoughts">Final Thoughts</a></li>
</ol>
</nav>
<figure data-affgun-media="hero"><img src="https://i.ytimg.com/vi/uyv6WRV_RB8/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>1win App Registration Download: A Practical Guide for Beginners</h1>
<section>
<h2>Why Choose the 1win Mobile App?</h2>
<div data-affgun-media="video"></div>
<p>The 1win app brings the full casino and sportsbook experience straight to your pocket. Unlike a desktop browser, the mobile version is optimised for touch‑screen navigation, fast loading times and push notifications about live odds and exclusive promotions. Players also benefit from a streamlined interface that groups favourite games, live casino tables and betting markets in one easy‑to‑reach dashboard.</p>
<p>From a security perspective the app uses the same SSL encryption as the web platform, so all personal data and financial transactions stay protected. If you travel often or simply prefer betting on the go, the 1win app registration download is the fastest way to stay connected to your account wherever you are.</p>
</section>
<section>
<h2>How to Perform the 1win App Registration Download Safely</h2>
<p>The first step is to obtain the official installer. The safest source is the 1win website – look for the “Download App” button that redirects to a direct APK file for Android or an App Store link for iOS. Avoid third‑party sites that promise “modified” versions; these can contain malware or be blocked by your device’s security settings.</p>
<p>After you tap the download link, you may need to enable “Install from unknown sources” on Android. This setting is found under Settings → Security. Once enabled, open the APK and follow the on‑screen prompts. iOS users will simply tap “Get” and the app will install automatically.</p>
<ul>
<li>Check the file size – the official APK is around 80 MB.</li>
<li>Verify the digital signature – the installer should be signed by “1win Ltd”.</li>
<li>Keep the app updated; new versions bring faster performance and fresh game selections.</li>
</ul>
</section>
<section>
<h2>1win App Registration Download: Step‑by‑Step Account Creation</h2>
<p>When you launch the freshly installed app, you’ll see a welcoming splash screen followed by a “Sign Up” button. Click it and you’ll be guided through a short registration form. Here’s the typical flow:</p>
<ol>
<li>Enter your email address and create a strong password.</li>
<li>Choose a unique username – this is how you’ll be identified in the chat and leaderboards.</li>
<li>Select your preferred currency (USD, EUR, etc.) and indicate your country of residence.</li>
<li>Accept the terms and conditions, then tap “Create Account”.</li>
</ol>
<p>After submission, the system sends a verification email. Click the link inside the email to activate your account. If the email doesn’t appear, check your spam folder or request a new one from the app’s “Resend verification” option.</p>
</section>
<section>
<h2>Verification (KYC) – Making Your 1win Account Fully Functional</h2>
<p>Most players can start betting right after email verification, but to withdraw funds you’ll need to complete the KYC (Know Your Customer) process. This involves uploading a government‑issued ID, proof of address, and sometimes a selfie for facial verification.</p>
<p>The app makes this simple: navigate to “Profile” → “Verification”, then use your device’s camera to capture each document. Files should be clear and under 5 MB. Once submitted, the compliance team usually reviews within 24‑48 hours. In the meantime, you can still place bets and enjoy bonus offers, but withdrawals will be held until verification is approved.</p>
</section>
<section>
<h2>First Deposit & Welcome Bonus – What to Expect</h2>
<p>After you’ve completed registration and verification, it’s time to fund your account. The 1win welcome bonus typically matches your first deposit up to a certain amount (e.g., 100 % up to $200). To claim it, use the promo code “RAZOR” during the deposit process – the same code featured in the video promo.</p>
<p>Be aware of the wagering requirements: the bonus amount must be wagered 30 times before any winnings can be withdrawn. Some games contribute at different rates; slots usually count 100 %, while table games might count only 10 % toward the requirement.</p>
<ul>
<li>Deposit methods include credit cards, e‑wallets (Skrill, Neteller) and bank transfers.</li>
<li>Minimum deposit is typically $10.</li>
<li>Bonus funds are credited instantly after a successful payment.</li>
</ul>
</section>
<section>
<h2>Payment Methods, Withdrawals and Speed</h2>
<p>Choosing the right payment method can affect how quickly you can start playing and how fast you can cash out. Below is a quick comparison of the most common options available on the 1win app.</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Method</th>
<th>Deposit Speed</th>
<th>Withdrawal Speed</th>
<th>Typical Fees</th>
</tr>
</thead>
<tbody>
<tr>
<td>Credit/Debit Card</td>
<td>Instant</td>
<td>3‑5 business days</td>
<td>No fee for deposits, small fee for withdrawals</td>
</tr>
<tr>
<td>E‑wallet (Skrill, Neteller)</td>
<td>Instant</td>
<td>24‑48 hours</td>
<td>No fee</td>
</tr>
<tr>
<td>Bank Transfer</td>
<td>1‑2 business days</td>
<td>3‑7 business days</td>
<td>Variable fee depending on bank</td>
</tr>
</tbody>
</table>
<p>For most players, e‑wallets provide the best balance between speed and convenience. If you’re concerned about privacy, card transactions are still fully encrypted and safe.</p>
</section>
<section>
<h2>Mobile Casino and Sportsbook – How to Navigate the App</h2>
<p>Once logged in, the bottom navigation bar splits the experience into three main tabs: Casino, Sportsbook, and Account. The Casino section houses slots, live dealer tables, and jackpot games. You can filter by “Live” to see real‑time dealers and chat with other players – a great way to feel the buzz of a brick‑and‑mortar casino from your couch.</p>
<p>The Sportsbook tab covers a wide range of events, from football and basketball to e‑sports. Live betting is highlighted with a flashing icon, allowing you to place wagers as the action unfolds. The app also offers a “Quick Bet” button for favorite selections, saving you a few taps during high‑intensity moments.</p>
<ul>
<li>Use the search bar to find specific games or matches.</li>
<li>Set your preferred language and currency in the settings.</li>
<li>Enable push notifications for bonus alerts and game results.</li>
</ul>
</section>
<section>
<h2>Support, Security, and Responsible Gambling</h2>
<p>If you run into any trouble, the 1win app provides 24/7 live chat support. The chat window pops up from the “Help” icon in the Account section, and agents typically respond within a minute. There’s also an extensive FAQ covering topics from deposit limits to account closure.</p>
<p>Security measures include two‑factor authentication (2FA) and regular security audits by a reputable licensing body (the Curacao eGaming Authority). For responsible gambling, you can set daily deposit limits, self‑exclude for a chosen period, or contact the support team for personalised assistance.</p>
<p>As an example, a player from Kenya once reported difficulty withdrawing winnings due to a missing document; after uploading a clear passport scan, the verification team processed the request within 12 hours and the funds arrived via e‑wallet the next day.</p>
</section>
<section>
<h2>Common Issues & Troubleshooting Tips</h2>
<p>Even with a smooth 1win app registration download, occasional hiccups may arise. Below are the most frequent problems and quick fixes:</p>
<ul>
<li><strong>App won’t install:</strong> Ensure “Install from unknown sources” is enabled (Android) or that your iOS version meets the minimum requirement.</li>
<li><strong>Verification stuck:</strong> Clear the app cache, re‑upload the documents, and double‑check that the images are not blurred.</li>
<li><strong>Bonus not credited:</strong> Verify that you entered the promo code “RAZOR” correctly and that the deposit meets the minimum amount.</li>
</ul>
<p>If none of these steps solve the issue, open a chat with the support team and provide your user ID – they can look up the account history and resolve the matter promptly.</p>
</section>
<section>
<h2>Final Thoughts</h2>
<p>Downloading and registering on the 1win app is a straightforward process that opens the door to a world of casino games and sports betting opportunities. By following the steps outlined above, you’ll have a verified, funded account ready to claim bonuses, place wagers, and enjoy secure, fast payouts. Remember to gamble responsibly and make use of the built‑in tools for limits and self‑exclusion.</p>
<p>Ready to start? The journey begins with a single tap – and if you’re in Tanzania, you might find the localized version of the site useful: <a href="https://minecraftapk12.com/">1win tanzania</a>.</p>
</section>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/">1win App Registration Download Bonus Guide</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>MSD’s Keytruda and Padcev combination receives EC approval</title>
<link>https://edusehat.com/en/msds-keytruda-and-padcev-combination-receives-ec-approval</link>
<guid>https://edusehat.com/en/msds-keytruda-and-padcev-combination-receives-ec-approval</guid>
<description><![CDATA[ The clearance permits the therapies to be administered before radical cystectomy as neoadjuvant therapy and continued following surgery as adjuvant treatment. Applicable to patients irrespective of cisplatin eligibility, 
The post MSD’s Keytruda and Padcev combination receives EC approval appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-22-10-2026-shutterstock_2518831137.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 21:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>MSD’s, Keytruda, and, Padcev, combination, receives, approval</media:keywords>
<content:encoded><![CDATA[<p>The clearance permits the therapies to be administered before radical cystectomy as neoadjuvant therapy and continued following surgery as adjuvant treatment.</p>
<p>Applicable to patients irrespective of cisplatin eligibility, the authorisation covers Iceland, Liechtenstein, Norway, and all 27 EU member states.</p>
<p>The regulatory decision also encompasses Keytruda SC, marketed in the US as Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph).</p>
<p>MSD research laboratories senior vice-president and oncology, global clinical development head Dr Marjorie Green said: “Building on the previous approval of Keytruda plus Padcev in the European Union less than six months ago, we’re pleased to bring this important treatment option to a broader patient population as the first PD-1 inhibitor plus antibody-drug conjugate regimen approved for people with muscle-invasive bladder cancer regardless of cisplatin eligibility.</p>
<p>“This approval represents encouraging progress in bladder cancer care and underscores our commitment to addressing the needs of people who are living with this disease.”</p>
<p>The decision follows a positive opinion granted last month by the European Medicines Agency’s Committee for Medicinal Products for Human Use.</p>
<p>The assessment was based on the open-label, randomised Phase III KEYNOTE-B15 study, also designated EV-304, conducted alongside Astellas and Pfizer.</p>
<p>In 808 patients, perioperative treatment lowered the risk of disease recurrence, progression, or death by 47% compared to neoadjuvant cisplatin and gemcitabine chemotherapy alongside surgical resection.</p>
<p>MSD stated that local availability across Europe will depend on country-level reimbursement processes.</p>
<p>The decision follows regulatory clearance from the US Food and Drug Administration in July 2026.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/msds-keytruda-padcev-combination-ec/">MSD’s Keytruda and Padcev combination receives EC approval</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>تحميل وان اكس بت: دليل الأمان الكامل للعب آمن في الإمارات</title>
<link>https://edusehat.com/en/%D8%AA%D8%AD%D9%85%D9%8A%D9%84-%D9%88%D8%A7%D9%86-%D8%A7%D9%83%D8%B3-%D8%A8%D8%AA-%D8%AF%D9%84%D9%8A%D9%84-%D8%A7%D9%84%D8%A3%D9%85%D8%A7%D9%86-%D8%A7%D9%84%D9%83%D8%A7%D9%85%D9%84-%D9%84%D9%84%D8%B9%D8%A8-%D8%A2%D9%85%D9%86-%D9%81%D9%8A-%D8%A7%D9%84%D8%A5%D9%85%D8%A7%D8%B1%D8%A7%D8%AA</link>
<guid>https://edusehat.com/en/%D8%AA%D8%AD%D9%85%D9%8A%D9%84-%D9%88%D8%A7%D9%86-%D8%A7%D9%83%D8%B3-%D8%A8%D8%AA-%D8%AF%D9%84%D9%8A%D9%84-%D8%A7%D9%84%D8%A3%D9%85%D8%A7%D9%86-%D8%A7%D9%84%D9%83%D8%A7%D9%85%D9%84-%D9%84%D9%84%D8%B9%D8%A8-%D8%A2%D9%85%D9%86-%D9%81%D9%8A-%D8%A7%D9%84%D8%A5%D9%85%D8%A7%D8%B1%D8%A7%D8%AA</guid>
<description><![CDATA[ ما هو تطبيق وان اكس بت وكيف يعمل؟ خطوات تحميل وان اكس بت على الهواتف الذكية المتطلبات التقنية قبل التحميل طريقة التحميل عبر المتصفح أو المتجر التسجيل وإنشاء 
The post تحميل وان اكس بت: دليل الأمان الكامل للعب آمن في الإمارات appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/qgw4nd_QWIE/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 21:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>تحميل, وان, اكس, بت:, دليل, الأمان, الكامل, للعب, آمن, في, الإمارات</media:keywords>
<content:encoded><![CDATA[<nav aria-label="Table of contents">
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#section">ما هو تطبيق وان اكس بت وكيف يعمل؟</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#section-2">خطوات تحميل وان اكس بت على الهواتف الذكية</a>
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#section-3">المتطلبات التقنية قبل التحميل</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#section-4">طريقة التحميل عبر المتصفح أو المتجر</a></li>
</ol>
</li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#section-5">التسجيل وإنشاء حساب جديد في وان اكس بت</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#section-6">العروض والترحيب: كيفية الاستفادة من البونص عند تحميل وان اكس بت</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#section-7">طرق الدفع والسحب في وان اكس بت</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#kyc">الأمان والتحقق (KYC) في وان اكس بت</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#section-8">تجربة اللعب على الموبايل: التطبيقات، الألعاب الحية، والرياضة</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#section-9">دعم العملاء والمسؤولية الاجتماعية</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#section-10">نصائح نهائية لتجربة آمنة ومربحة مع تحميل وان اكس بت</a></li>
</ol>
</nav>
<figure data-affgun-media="hero"><img src="https://i.ytimg.com/vi/qgw4nd_QWIE/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>دليل شامل لتحميل وان اكس بت: كل ما تحتاج معرفته لتجربة كازينو مميزة</h1>
<section>
<h2>ما هو تطبيق وان اكس بت وكيف يعمل؟</h2>
<div data-affgun-media="video"></div>
<p>وان اكس بت هو منصة كازينو إلكترونية تتخصص في الألعاب التقليدية والحديثة، وتقدم تجربة مدمجة بين الموقع الإلكتروني وتطبيق الهواتف الذكية. التطبيق يتيح للاعبين الوصول إلى مئات الألعاب من ألعاب السلوتس إلى الطاولة الحية، بالإضافة إلى قسم المراهنات الرياضية المتكامل.</p>
<p>من الناحية التقنية، يعتمد التطبيق على تقنيات HTML5 وWebGL لتوفير رسومات عالية الدقة وسرعة استجابة ممتازة حتى على الشبكات المتوسطة. لذلك عند <strong>تحميل وان اكس بت</strong> ستجد بيئة لعب مستقرة لا تحتاج إلى تنزيل ملفات ضخمة أو إعدادات معقدة.</p>
</section>
<section>
<h2>خطوات تحميل وان اكس بت على الهواتف الذكية</h2>
<h3>المتطلبات التقنية قبل التحميل</h3>
<p>قبل البدء في تحميل التطبيق، تأكد من أن هاتفك يعمل بنظام iOS 12 أو أعلى، أو Android 8.0 وما فوق. كما يفضل أن تكون سعة الذاكرة المتوفرة لا تقل عن 150 ميجابايت لضمان تثبيت سليم.</p>
<p>تحقق أيضاً من اتصال إنترنت ثابت؛ تحميل الملف قد يستغرق بضع دقائق إذا كان الاتصال بطيئاً، لكن بعد التثبيت سيتجاوز التطبيق أي تأخير في اللعب.</p>
<h3>طريقة التحميل عبر المتصفح أو المتجر</h3>
<p>لتجنب الحجب المفاجئ، يفضل زيارة الموقع الرسمي لوان اكس بت من خلال متصفحك المفضل ثم الضغط على زر “تحميل التطبيق”. سيتوجهك الرابط إلى صفحة مباشرة تسمح بتنزيل ملف APK لأجهزة Android أو فتح متجر App Store لأجهزة iOS.</p>
<p>بعد إكمال التحميل، افتح ملف APK ووافق على تثبيت التطبيقات من مصادر غير معروفة (يمكنك إلغاء هذا الخيار بعد انتهاء العملية). على iOS سيتطلب فقط الضغط على زر “Get” ثم إدخال Apple ID للمتابعة.</p>
</section>
<section>
<h2>التسجيل وإنشاء حساب جديد في وان اكس بت</h2>
<p>بعد <strong>تحميل وان اكس بت</strong> وتثبيته، افتح التطبيق وستظهر لك شاشة الترحيب مع زر “ابدأ التسجيل”. العملية بسيطة: أدخل بريدك الإلكتروني، اختر كلمة مرور قوية، ثم حدد اسم المستخدم الذي يفضله.</p>
<p>إضافةً إلى ذلك، يطلب منك التطبيق بعض المعلومات الشخصية الأساسية مثل تاريخ الميلاد والجنسية لتلبية متطلبات الترخيص المحلي. لا تقلق، جميع البيانات مشفرة باستخدام تقنية SSL لضمان سرية المعلومات.</p>
</section>
<section>
<h2>العروض والترحيب: كيفية الاستفادة من البونص عند تحميل وان اكس بت</h2>
<p>من أهم ما يجذب اللاعبين إلى وان اكس بت هو برنامج الترحيب الضخم. عند إكمال عملية الإيداع الأولى، ستحصل على بونص ترحيبي يصل إلى 200% من قيمة الإيداع، مع حد أقصى يصل إلى ١٠٠٠ درهم إماراتي.</p>
<p>لكن هناك شرط أساسي: <em>متطلبات المراهنة</em> (wagering requirements) تكون عادة 30 مرة من قيمة البونص + الإيداع. يمكنك قراءة تفاصيل الشرط في قسم “الشروط والأحكام” داخل التطبيق لتجنب أي مفاجآت.</p>
<ul>
<li>استخدم كود الدعوة “UAXB2024” للحصول على بونص إضافي 50 درهم.</li>
<li>الاشتراك في “نادي VIP” يتيح لك بونصات أسبوعية دون الحاجة لتحقيق متطلبات المراهنة.</li>
</ul>
</section>
<section>
<h2>طرق الدفع والسحب في وان اكس بت</h2>
<p>ينوع تطبيق وان اكس بت بين مجموعة واسعة من طرق الإيداع والسحب لتناسب اللاعبين في الإمارات. جميع عمليات الدفع تدعم العملة المحلية (درهم إماراتي) وتتم معالجتها عبر بوابات دفع معتمدة.</p>
<p>إليك جدول يوضح أهم طرق الدفع وسرعة التنفيذ:</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>طريقة الدفع</th>
<th>الحد الأدنى (د.إ)</th>
<th>وقت المعالجة</th>
<th>ملحوظة</th>
</tr>
<tr>
<th colspan="4">إيداع</th>
</tr>
</thead>
<tbody>
<tr>
<td>بطاقة الائتمان/الخصم</td>
<td>50</td>
<td>فوري</td>
<td>آمن ومشفر</td>
</tr>
<tr>
<td>محفظة إلكترونية (PayPal, Skrill)</td>
<td>30</td>
<td>فوري</td>
<td>دعم متعدد العملات</td>
</tr>
<tr>
<td>تحويل بنكي</td>
<td>100</td>
<td>1‑2 يوم عمل</td>
<td>يتطلب توثيق إضافي</td>
</tr>
<tr>
<th colspan="4">سحب</th>
</tr>
<tr>
<td>بطاقة الائتمان/الخصم</td>
<td>100</td>
<td>1‑2 يوم عمل</td>
<td>حد أقصى لسحب يومي 5000 د.إ</td>
</tr>
<tr>
<td>محفظة إلكترونية</td>
<td>50</td>
<td>فوري</td>
<td>مناسب للمرونة</td>
</tr>
<tr>
<td>تحويل بنكي</td>
<td>200</td>
<td>2‑3 أيام عمل</td>
<td>يتطلب موافقة KYC</td>
</tr>
</tbody>
</table>
<p>تأكد من إكمال عملية التحقق (KYC) قبل طلب السحب لتسريع العملية وتجنب أي تأخير.</p>
</section>
<section>
<h2>الأمان والتحقق (KYC) في وان اكس بت</h2>
<p>يولي وان اكس بت أولوية قصوى لأمان اللاعبين من خلال بروتوكولات تشفير SSL وتقييم مستمر للتهديدات. عملية التحقق من الهوية (KYC) لا تتجاوز ثلاث خطوات: رفع صورة الهوية، إثبات العنوان (فاتورة خدمات)، وإثبات وسيلة الدفع.</p>
<p>تستغرق عملية المراجعة عادة من 15 دقيقة إلى ساعة واحدة، وتُجرى بواسطة فريق متخصص يتأكد من صحة المستندات. بمجرد إتمام KYC، ستحصل على وصول غير محدود إلى جميع الألعاب والخدمات.</p>
<p>لمزيد من الدعم أو الاستفسارات، يمكنك التواصل مع <a href="https://criticalpath.net/">جروبات تليجرام وان اكس بت</a> حيث يجيب فريق الدعم على أسئلتك في الوقت الفعلي.</p>
</section>
<section>
<h2>تجربة اللعب على الموبايل: التطبيقات، الألعاب الحية، والرياضة</h2>
<p>بعد <strong>تحميل وان اكس بت</strong>، تتوفر لك واجهة مريحة تدعم وضعية portrait وlandscape لتناسب جميع الأجهزة. تحتوي المكتبة على أكثر من 1500 لعبة، من بينها:</p>
<ul>
<li>سلوتس ذات RTP عالي (من 96.5% إلى 98.2%).</li>
<li>كازينو مباشر (Live Casino) مع موزعين حقيقيين من أوروبا.</li>
<li>قسم المراهنات الرياضية يغطي أكثر من 30 رياضة، مع خيارات للرهان المباشر.</li>
</ul>
<p>التطبيق يضمن أن جميع الألعاب متوافقة مع أحدث معايير المسؤولية الاجتماعية، حيث يمكنك تفعيل حد الخسارة اليومي أو الإيقاف المؤقت لحسابك.</p>
</section>
<section>
<h2>دعم العملاء والمسؤولية الاجتماعية</h2>
<p>يتوفر دعم العملاء على مدار 24/7 عبر قنوات متعددة: الدردشة الحية، البريد الإلكتروني، والواتساب. يهدف فريق الدعم إلى حل المشكلات خلال 5 دقائق في أغلب الحالات.</p>
<p>بالإضافة إلى ذلك، يلتزم وان اكس بت بسياسات اللعب المسؤول، بما في ذلك أدوات لتحديد الحدود الذاتية، وتقديم روابط لمواقع الإرشاد في حالة الإدمان.</p>
</section>
<section>
<h2>نصائح نهائية لتجربة آمنة ومربحة مع تحميل وان اكس بت</h2>
<p>1- ابدأ بميزانية محددة ولا تتجاوزها مهما كان إغراء البونص. 2- اقرأ تفاصيل متطلبات المراهنة قبل قبول أي بونص لتفادي التقييد غير المرغوب فيه.</p>
<p>3- استغل ألعاب ذات RTP مرتفع إذا كنت تسعى إلى عوائد مستدامة، وتجنب الألعاب ذات الفولاتيليتي العالية إذا كنت مبتدئًا.</p>
<p>4- تأكد من استخدام شبكة إنترنت مستقرة لتقليل انقطاع اللعب، ولا تنسَ تفعيل خاصية “تأكيد السحب” عبر البريد الإلكتروني لتقوية الأمان.</p>
<p>باتباع هذه الخطوات، ستحصل على تجربة تحميل وان اكس بت سلسة، وستتمكن من الاستمتاع بأفضل عروض الكازينو في الإمارات مع ضمان أمان حسابك وسرعة عمليات السحب.</p>
</section>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/">تحميل وان اكس بت: دليل الأمان الكامل للعب آمن في الإمارات</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Astellas and AI Proteins sign miniprotein therapeutics deal</title>
<link>https://edusehat.com/en/astellas-and-ai-proteins-sign-miniprotein-therapeutics-deal</link>
<guid>https://edusehat.com/en/astellas-and-ai-proteins-sign-miniprotein-therapeutics-deal</guid>
<description><![CDATA[ Under the deal, AI Proteins is set to receive an upfront cash sum of more than $400m to design and optimise de novo miniproteins directed at targets selected 
The post Astellas and AI Proteins sign miniprotein therapeutics deal appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-2-22-10-2026-shutterstock_1924512515.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 21:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Astellas, and, Proteins, sign, miniprotein, therapeutics, deal</media:keywords>
<content:encoded><![CDATA[<p>Under the deal, AI Proteins is set to receive an upfront cash sum of more than $400m to design and optimise de novo miniproteins directed at targets selected by Astellas.</p>
<p>AI Proteins also qualifies for milestone payments and royalties on net sales generated by resulting therapies.</p>
<p>AI Proteins president, CEO and founder Chris Bahl said: “Every biologic medicine on the market today is based on a molecule borrowed from nature that evolved to do something else.</p>
<p>“Designing miniproteins de novo lets us work from the other direction, meaning we specify what a medicine needs to do, then build a molecule from scratch to do precisely that.</p>
<p>“It’s a shift from repurposing to design, and it puts problems within reach that traditional biologics can’t solve. Astellas has deep expertise in translating innovative science into medicines, and they’re the right partner to carry this forward to patients.”</p>
<p>Astellas holds an exclusive global licence to therapeutic candidates produced through the partnership. The company will oversee all subsequent development, regulatory processes, and commercialisation.</p>
<p>AI Proteins will deploy its computational discovery platform to design proteins targeting multiple pathways to generate the candidates.</p>
<p>Astellas Innovation Lab senior vice-president Morten Sogaard said: “Our collaboration with AI Proteins reflects our strategic focus on strengthening our early-stage research pipeline through partnerships that provide access to novel biology, differentiated technologies and new therapeutic possibilities.</p>
<p>“By combining AI Proteins’ advanced de novo protein design capabilities with Astellas’ expertise in translating scientific breakthroughs into innovative medicines, we aim to accelerate the discovery of high-quality therapeutic candidates that can help fuel long-term innovation and support our pipeline-led growth strategy.”</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/ai-proteins-astellas-miniprotein-therapeutics/">Astellas and AI Proteins sign miniprotein therapeutics deal</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>1xbet app – what you need to know</title>
<link>https://edusehat.com/en/1xbet-app-what-you-need-to-know</link>
<guid>https://edusehat.com/en/1xbet-app-what-you-need-to-know</guid>
<description><![CDATA[ Getting Started – Registration and First Steps Verifying Your Identity (KYC) Navigating the 1xbet App – Interface and Core Features Sportsbook vs Live Casino Mobile Experience Tips Bonuses 
The post 1xbet app – what you need to know appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/svqHnx9LYvg/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 21:20:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>1xbet, app, –, what, you, need, know</media:keywords>
<content:encoded><![CDATA[<nav aria-label="Table of contents">
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#getting-started-registration-and-first-steps">Getting Started – Registration and First Steps</a>
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#verifying-your-identity-kyc">Verifying Your Identity (KYC)</a></li>
</ol>
</li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#navigating-the-1xbet-app-interface-and-core-features">Navigating the 1xbet App – Interface and Core Features</a>
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#sportsbook-vs-live-casino">Sportsbook vs Live Casino</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#mobile-experience-tips">Mobile Experience Tips</a></li>
</ol>
</li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#bonuses-and-promotions-on-the-1xbet-app">Bonuses and Promotions on the 1xbet App</a>
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#understanding-wagering-requirements">Understanding Wagering Requirements</a></li>
</ol>
</li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#payment-methods-deposits-and-withdrawals">Payment Methods – Deposits and Withdrawals</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#security-licensing-and-responsible-gambling">Security, Licensing, and Responsible Gambling</a>
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#responsible-play-tools">Responsible Play Tools</a></li>
</ol>
</li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#customer-support-and-troubleshooting">Customer Support and Troubleshooting</a>
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#common-issues-and-quick-fixes">Common Issues and Quick Fixes</a></li>
</ol>
</li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#common-pitfalls-and-how-to-avoid-them">Common Pitfalls and How to Avoid Them</a></li>
</ol>
</nav>
<figure data-affgun-media="hero"><img src="https://i.ytimg.com/vi/svqHnx9LYvg/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Practical Guide to Using the 1xbet App</h1>
<section>
<h2>Getting Started – Registration and First Steps</h2>
<div data-affgun-media="video"></div>
<p>Before you can spin the roulette or place a football bet, you need an account on the 1xbet app. The registration process is deliberately short: you enter a valid e‑mail address, pick a password, and confirm your country. Most users finish this step in under two minutes, but it helps to have a phone number handy for the optional two‑factor verification.</p>
<p>After the basic data, the system will ask for your preferred currency and whether you want promotional emails. Choose wisely – the welcome bonus is tied to the currency you pick, and changing it later can be a hassle. When you click “Register”, you’ll receive a confirmation link; once you click that, the account becomes active and you can log in straight away.</p>
<h3>Verifying Your Identity (KYC)</h3>
<p>Many jurisdictions require 1xbet to verify who you are, especially before any large withdrawal. The app will prompt you to upload a photo of a government ID and a selfie. The upload is simple: take a clear picture, make sure the file size is under 5 MB, and submit. Usually the verification is approved within a few hours, though sometimes it can stretch to a day.</p>
<p>If the verification is delayed, double‑check that the document is not expired and that all details are legible. In most cases, a quick chat with support clears the issue, and you can start betting without further interruptions.</p>
</section>
<section>
<h2>Navigating the 1xbet App – Interface and Core Features</h2>
<p>The 1xbet app is split into three main tabs: Sportsbook, Live Casino, and My Account. The navigation bar stays at the bottom of the screen, making it easy to switch between live betting and casino games without leaving the app. Colors are bold, icons are big, and the search function works both for teams and for specific slot titles.</p>
<p>For beginners, the “Featured” carousel on the home screen shows the most popular events and newest slot releases. Tap any item to see odds, RTP (return to player) percentages, and quick bet buttons. The app also supports “Quick Bet” – a one‑tap wager on pre‑selected odds, great for those who like instant action.</p>
<h3>Sportsbook vs Live Casino</h3>
<p>Sportsbook is where you find pre‑match odds for football, basketball, tennis and many other sports. Live betting appears once a match starts, with odds updating every few seconds. Live Casino, on the other hand, offers streamed tables with real dealers, plus classic slots that run on the same server as the desktop version.</p>
<p>If you enjoy the social vibe of a real dealer, the live casino section works best on a stable Wi‑Fi connection. For fast, on‑the‑go action, the sportsbook’s “Bet Slip” lets you add multiple selections and place a parlay in seconds.</p>
<h3>Mobile Experience Tips</h3>
<p>To keep the app running smooth, clear the cache once a week and close background apps that consume memory. The 1xbet app supports both Android and iOS, but the iOS version has a slightly tighter security sandbox, meaning you may need to enable “Trust” for the enterprise profile after installation.</p>
<p>Enable push notifications only for the sports you follow – otherwise you’ll be flooded with promotional alerts. A well‑tuned notification setting lets you hear about live odds changes without being distracted by unrelated offers.</p>
</section>
<section>
<h2>Bonuses and Promotions on the 1xbet App</h2>
<p>One of the biggest draws of the 1xbet app is the range of bonuses that greet new players and keep regulars coming back. The welcome package typically includes a 100 % match bonus on the first deposit, plus a few free spins for selected slot games. Always read the fine print: wagering requirements are usually set at 30x the bonus amount.</p>
<p>Beyond the welcome offer, the app rolls out weekly reload bonuses, cash‑back on sports losses, and special tournament prizes. These promotions are listed under the “Bonus” tab, where you can claim them with a single tap. Remember, most bonuses are limited to certain payment methods, so check the eligibility before you deposit.</p>
<h3>Understanding Wagering Requirements</h3>
<p>Wagering requirements dictate how many times you must bet the bonus before you can withdraw any winnings. For example, a 20 % deposit bonus of €50 with a 30x requirement means you need to place bets totalling €1 500 before cashing out. Some games contribute at different rates – slots usually count 100 %, while table games may only count 10 %.</p>
<p>Plan your play accordingly: if you prefer low‑variance slots, you’ll meet the requirement faster. If you enjoy sports betting, look for “Sport‑only” bonuses that exclude casino games from the wagering calculation.</p>
</section>
<section>
<h2>Payment Methods – Deposits and Withdrawals</h2>
<p>The 1xbet app supports a wide variety of payment options, from credit cards to e‑wallets. Deposit is almost always instant, while withdrawal speed depends on the method you choose. Below is a quick comparison of the most common options.</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Method</th>
<th>Deposit Speed</th>
<th>Withdrawal Speed</th>
<th>Typical Fees</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visa / MasterCard</td>
<td>Instant</td>
<td>2‑3 business days</td>
<td>No fee for deposit, 1‑2% on withdrawal</td>
</tr>
<tr>
<td>Skrill</td>
<td>Instant</td>
<td>Same day</td>
<td>Free deposit, $2 withdrawal fee</td>
</tr>
<tr>
<td>Bank Transfer</td>
<td>1‑2 business days</td>
<td>3‑5 business days</td>
<td>Variable, often $5‑$10</td>
</tr>
<tr>
<td>PayPal (via partner)</td>
<td>Instant</td>
<td>Within 24 hours</td>
<td>No deposit fee, 1% withdrawal fee</td>
</tr>
</tbody>
</table>
<p>When you choose a method, also consider the currency conversion rate. The app automatically shows the amount you’ll receive after conversion, but hidden spreads can affect the final figure. For the fastest cash‑out, e‑wallets like Skrill or PayPal tend to be the best choice.</p>
<p>If you encounter a delayed withdrawal, the first step is to check the “Withdrawal History” section – it shows the exact processing stage. Often the delay is due to pending KYC verification, which you can resolve by uploading the missing documents.</p>
</section>
<section>
<h2>Security, Licensing, and Responsible Gambling</h2>
<p>Security is a top priority for the 1xbet app. It uses SSL encryption to protect every data packet between your device and the server. The platform is licensed by the Curacao Gaming Authority, which means it follows internationally recognized standards for fair play and player protection.</p>
<p>To keep your account safe, enable two‑factor authentication (2FA) in the “Security” settings. This adds a code sent to your phone every time you log in from a new device. The app also monitors unusual betting patterns and may temporarily freeze an account if it suspects fraud.</p>
<h3>Responsible Play Tools</h3>
<p>Every user can set deposit limits, loss limits, or even a self‑exclusion period directly in the app. These tools are hidden under “Responsible Gambling”. Once set, the limits are enforced automatically – you cannot place a bet that exceeds your daily deposit cap.</p>
<p>Should you feel the need for a break, the self‑exclusion option blocks access for 6 months, 1 year, or permanently. The app also provides links to professional help lines for problem gambling, ensuring that help is just a tap away.</p>
</section>
<section>
<h2>Customer Support and Troubleshooting</h2>
<p>When you run into an issue, the 1xbet app offers several support channels. The live chat button is available 24/7 and usually replies within a minute. For more detailed queries, you can submit a ticket through the “Help Center” and expect a response within 24 hours.</p>
<p>Phone support is also listed for certain regions, but the numbers are often toll‑free only for local callers. If you prefer written communication, the FAQ section covers the most common questions about bonuses, payment methods, and account verification.</p>
<h3>Common Issues and Quick Fixes</h3>
<ul>
<li><strong>Login problems:</strong> Clear the app cache, ensure you are using the latest version, and verify that your password isn’t expired.</li>
<li><strong>Bonus not credited:</strong> Check the “Bonus History” – some promotions require a minimum deposit or a specific game to be played before they appear.</li>
<li><strong>Withdrawal delayed:</strong> Review the “Verification” status; incomplete KYC is the most frequent cause.</li>
</ul>
<p>For a hands‑on experience without risking money, you can try the <a href="https://unclebillysaustin.com/">1xbet demo game free</a> and see how the interface feels before you commit to a real deposit.</p>
</section>
<section>
<h2>Common Pitfalls and How to Avoid Them</h2>
<p>New users often jump straight into high‑risk bets, forgetting to read the terms of the welcome bonus. This leads to frustration when the wagering requirement seems impossible. Take a moment to calculate the required turnover using a simple spreadsheet – it clarifies whether the bonus is worth the effort.</p>
<p>Another frequent mistake is ignoring the currency conversion fees. If your bank account is in USD but the app defaults to EUR, you may lose several percent on each transaction. Switch the app’s default currency to match your</p>
</section>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/">1xbet app – what you need to know</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>تنزيل وان اكس بت مصر: خطوات التسجيل وتحميل التطبيق خطوة بخطوة</title>
<link>https://edusehat.com/en/%D8%AA%D9%86%D8%B2%D9%8A%D9%84-%D9%88%D8%A7%D9%86-%D8%A7%D9%83%D8%B3-%D8%A8%D8%AA-%D9%85%D8%B5%D8%B1-%D8%AE%D8%B7%D9%88%D8%A7%D8%AA-%D8%A7%D9%84%D8%AA%D8%B3%D8%AC%D9%8A%D9%84-%D9%88%D8%AA%D8%AD%D9%85%D9%8A%D9%84-%D8%A7%D9%84%D8%AA%D8%B7%D8%A8%D9%8A%D9%82-%D8%AE%D8%B7%D9%88%D8%A9-%D8%A8%D8%AE%D8%B7%D9%88%D8%A9</link>
<guid>https://edusehat.com/en/%D8%AA%D9%86%D8%B2%D9%8A%D9%84-%D9%88%D8%A7%D9%86-%D8%A7%D9%83%D8%B3-%D8%A8%D8%AA-%D9%85%D8%B5%D8%B1-%D8%AE%D8%B7%D9%88%D8%A7%D8%AA-%D8%A7%D9%84%D8%AA%D8%B3%D8%AC%D9%8A%D9%84-%D9%88%D8%AA%D8%AD%D9%85%D9%8A%D9%84-%D8%A7%D9%84%D8%AA%D8%B7%D8%A8%D9%8A%D9%82-%D8%AE%D8%B7%D9%88%D8%A9-%D8%A8%D8%AE%D8%B7%D9%88%D8%A9</guid>
<description><![CDATA[ دليل شامل لتنزيل وان اكس بت مصر: كل ما تحتاج معرفته مقدمة حول تنزيل وان اكس بت مصر يبحث الكثير من عشاق القمار على الإنترنت عن طريقة سريعة 
The post تنزيل وان اكس بت مصر: خطوات التسجيل وتحميل التطبيق خطوة بخطوة appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/U3cvbkWEVEk/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 21:20:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>تنزيل, وان, اكس, بت, مصر:, خطوات, التسجيل, وتحميل, التطبيق, خطوة, بخطوة</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img src="https://i.ytimg.com/vi/U3cvbkWEVEk/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>دليل شامل لتنزيل وان اكس بت مصر: كل ما تحتاج معرفته</h1>
<h2>مقدمة حول تنزيل وان اكس بت مصر</h2>
<div data-affgun-media="video"></div>
<p>يبحث الكثير من عشاق القمار على الإنترنت عن طريقة سريعة وآمنة لتحميل تطبيق 1XBET في مصر والإمارات.  <strong>تنزيل وان اكس بت مصر</strong> ليس مجرد ملف تثبيت؛ فهو بوابة للوصول إلى كازينوهات مرخصة، بونصات ترحيبية، ومجموعة واسعة من ألعاب الروليت والبلاك جاك والسبورتس بايت.</p>
<nav aria-label="Table of contents">
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/#section">مقدمة حول تنزيل وان اكس بت مصر</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/#section-2">خطوات التسجيل وتحميل التطبيق</a>
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/#section-3">إنشاء حساب جديد</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/#1xbet">تحميل تطبيق 1XBET للهواتف</a></li>
</ol>
</li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/#section-4">طرق الدفع المسموحة في الإمارات ومصر</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/#section-5">كيفية الاستفادة من البونص والترحيب</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/#section-6">اللعب الآمن والمسؤول</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/#section-7">الدعم الفني وتقييمات العملاء</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/#section-8">الأسئلة الشائعة حول تنزيل وان اكس بت مصر</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/#section-9">خاتمة عملية للبدء في اللعب</a></li>
</ol>
</nav>
<p>الموقع يقدّم تجربة متميزة للمبتدئين والمحترفين على حد سواء، مع دعم للغات متعددة واتصال سريع لتقليل وقت الانتظار أثناء اللعب. في هذا الدليل سنغطي كل خطوة، من التسجيل إلى السحب، لتضمن لك أقصى استفادة من حسابك.</p>
<h2>خطوات التسجيل وتحميل التطبيق</h2>
<h3>إنشاء حساب جديد</h3>
<p>ابدأ بزيارة الصفحة الرسمية للمنصة واختر “تسجيل”. سيُطلب منك إدخال بريد إلكتروني صالح، كلمة مرور قوية، ورقم هاتف يُستخدم للتحقق. تأكد من اختيار كلمة مرور لا تقل عن 8 أحرف وتحتوي على أرقام وحروف.</p>
<p>بعد إكمال النموذج، سيُرسل لك رمز تحقق عبر الرسائل القصيرة. أدخل الرمز لتفعيل حسابك، ثم انتقل إلى مرحلة <em>التحقق (KYC)</em> لإثبات هويتك عبر إرفاق جواز السفر أو البطاقة الوطنية.</p>
<h3>تحميل تطبيق 1XBET للهواتف</h3>
<p>التطبيق متاح للهواتف الذكية بنظامي Android وiOS. للتحميل، اضغط على زر “تنزيل وان اكس بت مصر” الموجود في صفحة الدعم داخل الموقع، وسيتم توجيهك إلى المتجر المناسب. إذا كنت في الإمارات، قد تحتاج إلى تفعيل خيار السماح بالمصادر غير المعروفة لتثبيت ملف الـAPK.</p>
<p>بعد التثبيت، سجّل الدخول باستخدام بياناتك، وستظهر لك واجهة مستخدم عربية بالكامل مع خيارات الألعاب، الكازينو المباشر، والرياضات.</p>
<h2>طرق الدفع المسموحة في الإمارات ومصر</h2>
<p>من أهم العوامل التي يبحث عنها اللاعبين هي طريقة الإيداع والسحب السريعة. يقدم 1XBET مجموعة واسعة من طرق الدفع التي تتوافق مع القوانين المحلية في كل من الإمارات ومصر.</p>
<p>اختر الطريقة التي تناسبك بناءً على الحد الأدنى للإيداع، وسرعة التحويل، وأمان العملية.</p>
<table border="1" cellpadding="5" cellspacing="0">
<caption>أبرز طرق الدفع في 1XBET</caption>
<thead>
<tr>
<th>طريقة الدفع</th>
<th>الحد الأدنى للإيداع (دولار)</th>
<th>سرعة الإيداع</th>
<th>سرعة السحب</th>
</tr>
</thead>
<tbody>
<tr>
<td>بطاقة الائتمان (Visa/MasterCard)</td>
<td>10</td>
<td>فورية</td>
<td>1-3 أيام عمل</td>
</tr>
<tr>
<td>محفظة إلكترونية (PayPal, Skrill)</td>
<td>5</td>
<td>فورية</td>
<td>ساعات معدودة</td>
</tr>
<tr>
<td>تحويل بنكي</td>
<td>50</td>
<td>2-4 أيام</td>
<td>5-7 أيام</td>
</tr>
<tr>
<td>نقدًا عبر نقاط البيع</td>
<td>20</td>
<td>فورية</td>
<td>يوم عمل واحد</td>
</tr>
</tbody>
</table>
<h2>كيفية الاستفادة من البونص والترحيب</h2>
<p>عند إكمال أول إيداع، ستحصل على <strong>بونص الترحيب</strong> الذي قد يصل إلى 100% من مبلغ الإيداع مع حد أقصى 200 دولار. هذا البونص يأتي مع <em>متطلبات مراهنة</em> (wagering requirements) تبلغ 30x، ما يعني أنك تحتاج إلى لعب بما يعادل 30 ضعف قيمة البونص قبل سحب الأرباح.</p>
<p>يُفضَّل قراءة الشروط الدقيقة للعرض، فبعض الألعاب مثل البوكر لا تُحتسب ضمن المتطلبات، بينما تُحتسب ألعاب السلوتس بنسبة 100%، وهذا يؤثر على سرعة تحقيق السحب.</p>
<h2>اللعب الآمن والمسؤول</h2>
<p>يُعتبر <em>الأمان</em> أحد أهم عوامل اختيار الكازينو. 1XBET مرخص من سلطة جبل طارق (Gibraltar) ومراقب من قبل هيئة الألعاب البريطانية، ما يعني أن جميع المعاملات تتم وفق تشفير SSL 256‑bit.</p>
<p>بالإضافة إلى ذلك، يُوفر الموقع أدوات للعب المسؤول مثل حدود الإيداع اليومية، وقت اللعب المسموح، وإمكانية طلب وقف حساب مؤقت. هذه الخيارات تساعد اللاعبين على تجنب الإدمان والحفاظ على ميزانية اللعب.</p>
<h2>الدعم الفني وتقييمات العملاء</h2>
<p>خدمة العملاء متاحة على مدار 24 ساعة عبر الدردشة الحية، البريد الإلكتروني، والهاتف. فريق الدعم يتحدث العربية والإنجليزية ويستجيب بسرعة لتسوية المشكلات المتعلقة بالتحقق، السحب، أو أي استفسار عن الألعاب.</p>
<p>تقييمات المستخدمين تشير إلى رضا عام عن <a href="https://drinksoundspirits.com/">1xbet تغيير كلمة المرور</a>، حيث يثنون على سرعة الاستجابة وكفاءة عملية السحب الفوري.</p>
<h2>الأسئلة الشائعة حول تنزيل وان اكس بت مصر</h2>
<ul>
<li><strong>هل يمكنني اللعب من هاتف iPhone؟</strong> نعم، التطبيق متوفر على App Store مع دعم كامل للغة العربية.</li>
<li><strong>ما هو الحد الأدنى للانسحاب؟</strong> يختلف بحسب طريقة السحب، لكنه عادةً لا يقل عن 20 دولار.</li>
<li><strong>هل أحتاج إلى VPN للدخول من الإمارات؟</strong> لا، الموقع متاح مباشرةً في الإمارات ولا يتطلب أي تقنيات مخفية.</li>
<li><strong>كيف أتحقق من أرصدة البونص؟</strong> من خلال قسم “المكافآت” داخل التطبيق، حيث يُظهر لك تفاصيل المتطلبات المتبقية.</li>
</ul>
<h2>خاتمة عملية للبدء في اللعب</h2>
<p>بعد إتمام جميع الخطوات السابقة – تحميل التطبيق، إكمال عملية التسجيل والتحقق، اختيار طريقة الدفع، والاستفادة من البونص – يمكنك الآن الانغماس في تجربة كازينو شاملة تشمل ألعاب الكازينو الحية، الروليت، والرياضات.</p>
<p>تذكر دائمًا أن تتبع حدودك المالية، وتستغل أدوات اللعب المسؤول لتبقى مستمتعًا دون مخاطر. نتمنى لك تجربة مليئة بالمتعة وربحٍ مستدام.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/">تنزيل وان اكس بت مصر: خطوات التسجيل وتحميل التطبيق خطوة بخطوة</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Building the pharma talent India needs for the digital era</title>
<link>https://edusehat.com/en/building-the-pharma-talent-india-needs-for-the-digital-era</link>
<guid>https://edusehat.com/en/building-the-pharma-talent-india-needs-for-the-digital-era</guid>
<description><![CDATA[ 
Dr Supriya Shidaye, Principal, Vivekanand Education Society’s College of Pharmacy, discusses how AI, automation and digital technologies are reshaping pharmacy education, while closer industry-academia collaboration can help prepare students for the changing pharma workplace, in an exclusive interview with Neha Aathavale
The post Building the pharma talent India needs for the digital era appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/22143745/EP_Dr-Supriya-Shidaye_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 21:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Building, the, pharma, talent, India, needs, for, the, digital, era</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/22143745/EP_Dr-Supriya-Shidaye_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/22143745/EP_Dr-Supriya-Shidaye_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/22143745/EP_Dr-Supriya-Shidaye_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><b>As Indian pharma companies now move towards AI and automation and even connected manufacturing, what talent gaps are you seeing emerging at the plant level and are companies struggling more to find digital skills or professionals who can combine the pharmaceutical knowledge with technology?</b></p>
<p><span>With this emerging AI, automation, industrial internet of things, the entire pharma industry landscape is changing very rapidly. This change is happening not just at manufacturing level, but it is taking place at every stage of the entire product life cycle that is at the research and development, drug discovery, manufacturing, quality control, in process quality control, supply chain and further regulatory guidelines or regulatory compliances. Obviously the things are being done in much shorter time with more precision and more accuracy.</span></p>
<p><span>When we talk about industry, it is all data driven. Earlier also conventionally a lot of data was getting generated, because equipment is running, they are being monitored for various parameters. So data is getting generated, then there is a quality control happening, in process quality control happening, then supply chain the product is being delivered.</span></p>
<p><span>Everywhere there are logs, maintenance logs, batch manufacturing records, master files, data has been always getting generated. But in the past the approach was about using that data to understand whether the product complies with the required standard and what went wrong, but that was a kind of reactive type of approach. But now the industry has been changing rapidly and now industry is making the right use of AI, machine learning, internet of thing for more kind of predictive approach, responsive approach.</span></p>
<p><span>It is not only about AI or digital knowledge which will sustain or only the technical knowledge which will sustain, because AI has a lot of role to enhance your decision making, to expedite the efficiency of your work. So it is going to complement your skill, it is not going to substitute your skill. So every person has to have a very strong scientific knowledge, there cannot be a substitute for scientific knowledge, but AI is going to help you in a number of ways like the data is being studied by AI and it is helping you in decision making, informed decision making.</span></p>
<p><span>People should have digital literacy, AI literacy. Once the data is being analysed by the system and it is showing you some kind of results, you should have an ability to interpret those results and arrive at some decision. So if you are not able to observe it carefully, critically analyse it further and arrive at some informed decision, then somewhere there will be a gap in your efficiency as well as your delivery of the output.</span></p>
<p><span>The industry now requires a person who not only has a very good in depth knowledge when it comes to science, but also he has a very good smart way to work by adopting the technology and arriving at a right decision by using the technology and these decisions because they are based on data, there will be more accuracy, there would not be just the assumptions, but there is an evidence based decision that is possible.</span></p>
<p><span>Industry is moving in that way, in that direction and this person has the requirement of a person who has both science based knowledge as well as digital literacy to convert that knowledge into informed decisions.</span></p>
<p><b>Pharma 4.0 as I see it is bringing production, engineering, quality, IT and data functions together. How far should a pharma manufacturing professional be expected to work beyond their traditional domain and which capabilities will increasingly be required to nurture that specialised talent?</b></p>
<p><span>When we are talking about 4.0, it is all about automation, it is about digitalisation, it is about continuous manufacturing, it is about smart ways of handling the product and delivering the results. The industry when it is moving ahead with these skills, the personnel also should align themselves with all these requisites.</span></p>
<p><span>When you said that it is a blend of technology, engineering, this engineering is also very much important because these equipments that are being designed, they are not an equipment which have all controls and these controls are also generating lot of data, there are sensors, we call it as industrial internet of things.</span></p>
<p><span>These sensors are giving you red flags, they are predicting that there is something going wrong and you are able to understand that there is a beginning of something going wrong and you need to stop the operation at that stage and take some corrective action. So, all these red flags you are able to get because of that 4.0 and 4.2 talks about continuous manufacturing. Now, in India and abroad also more commonly it is seen in manufacturing of oral solid dosage forms like tablets.</span></p>
<p><span>This is the entire pipeline operation, it starts from raw material and then the mixing, then milling, then granulation, then again milling, then blending with lubrication and then compression and then further levelling, packaging, levelling everything is happening on a single line.</span></p>
<p><span>There is something called process analytical technology which is developing very fast. So, we have NIR near infrared Raman where those probes are able to at entire pipeline everywhere they are able to understand, they are able to monitor the micro changes in the pipeline, what is going to be the bottleneck, where these micro changes are happening, what is the trade of changes taking place and bridge pad will be able to tell you whether everything is going on well and there is a go status or no go status, there is some micro change happening, there is some kind of missing of some kind of required specification.</span></p>
<p><span>This is how development happens where a lot of core engineering knowledge is required. So, for designing these equipment and installing those sensors, the displays, the PLC boards. This is what is the integration of engineering with the science and pharmaceutical technology and that is only giving us a lot of data.</span></p>
<p><span>Data logs are getting generated and so when it comes to regulations, regulation is becoming very easy because earlier may be conventionally, traditionally whenever there is an inspection people used to run around and generate the data, but there is no such need every minute you are ready for any kind of regulatory compliances or audits because you have a data logs and there is a very high degree of data integrity because everything is available digitally.</span></p>
<p><span>You cannot manually say there is no intervention except that you have to read it and interpret it and take the decisions that are the intervention, but otherwise data integrity is going on very well, the trained analysis is possible, audit trails are available. That is how industries benefited a lot due to this 4.0 developments and automations.</span></p>
<p><b>As AI and digital systems enter regulated manufacturing environments, how should the industry balance digital capabilities with fundamentals like GMP and data integrity, validation and mostly cyber security? Is the current talent pool equipped to manage this convergence?</b></p>
<p><span>I am an educationist. I would like to share with you that the Pharmacy Council of India is an apex body for pharma programs in all India and now in this year 26-27 academic year they have come up with a revised syllabus and that revised syllabus is introducing AI and ML at almost every semester.</span></p>
<p><span>Students are going to start from basics of Python and its application and then they are going to also study data analysis, further they are going to study AI and ML and then application of AI in clinical research, pharma for vigilance, regulatory and healthcare. So, students will be definitely getting equipped with all these skills required with the new syllabus that has emerged. That does not mean the previous students who have stepped into the corporate are not equipped with that.</span></p>
<p><span>We always had a platform called Swayam. That is the government of India created MOOCs platform, Massive Online Open Courses. So, through that platform our students were studying all these AI and ML related subjects through self-study and completing some certificate courses.</span></p>
<p><span>Also there are number of online educational edtech companies like Coursera, UpGrad which has given many such programs our students and when I talked about VES College of Pharmacy and my role as a chairman of board of studies of Pharmacy of University of Mumbai, four years back I had designed one course on AI in healthcare which was a value added course for University of Mumbai affiliated pharmacy colleges.</span></p>
<p><span>Almost every college offers a value added course. In our college every year we offer it and we integrate it or we collaborate with our engineering college, VES Institute of Technology and their faculty members come and deliver that course.</span></p>
<p><span>That is how we are trying to train our students to get adapted to these new trends because that is important.</span></p>
<p><span>When you talk about cyber security, the government of Maharashtra also takes lot of initiatives and they always insist that our institutions should also conduct the programs on cyber security because students are now more available online because online resources are huge in number.</span></p>
<p><span>There are chances that while using digital transactions and on accessing online data somewhere their mails can get hacked, their data can get hacked or if they are working for their organisation there also such threat is always there of hacking of the data.</span></p>
<p><span>It is very important that students are aware about how to protect your data, what should be revealed, what should not be revealed, how you can have security measures and what are those measures, how you have to encrypt your files, password protected.</span></p>
<p><span>That kind of education is also equally important because we know that when we are travelling somewhere the Google comes to know where we are and Google starts giving us the information about the shopping malls, theatres and everything in that area. That means whatever we are doing on WhatsApp or online through any kind of online platform it is getting recorded and AI is able to understand your whereabouts.</span></p>
<p><span>Students should know. We also keep telling students when you are generating a research paper or you are using chat GPT for example, for redrafting or paraphrasing your research publication it is you should be careful you cannot directly put your entire abstract there or a lot of very big length of article there because once you put it in the AI chat GPT has also captured it as a data.</span></p>
<p><span>Sometimes your own data will be shown as plagiarised because chat GPT has captured it.</span></p>
<p><span>These are the threats also when the technology is moving on and everything is available through smart means that data somewhere is getting generated. So, protection of data becomes very important and we know that there is an act about privacy of data.</span></p>
<p><span>Even industry and employers are worried about what data of your employee or your organisation should be revealed and what should not be revealed, what comes under the umbrella of disclosure allowed, what should not be allowed for instance Aadhaar number you are not supposed to disclose.</span></p>
<p><span>Cyber security when it comes to this is a challenge to everybody, the employer, the employee, the student, the educational institutions, the management and we need to be careful about it and digital literacy that is indispensable and we need to train students and our syllabus is now framed. So, their students will be completely updated by the time they graduate.</span></p>
<p><b>India is no longer looking only to strengthen its manufacturing base, but also trying to enhance its capabilities in innovation and product development. What kind of talent will this shift require and is the current industry academia ecosystem equipped to prepare professionals who can contribute both to manufacturing and innovation?</b></p>
<p><span>Innovation since last 4, 5 years I can say that innovation has become a very important component in the educational systems.</span></p>
<p><span>Especially so, when our government of India and Honorable Prime Minister promoted Make in India, start up India policies and the Ministry of Education also incorporated Institution Innovation Council, Ministry of Education’s Innovation Council.</span></p>
<p><span>Through that Innovation Council every institution was required to set up their own institutional innovation cell and not just that to promote that kind of activity. The Ministry of Education earlier it was MHID, now it is the Ministry of Education. So, they also encouraged colleges to take part in the ranking framework based on your Institutional Innovation Council activity that is called IIC short form.</span></p>
<p><span>Every institution including our institution we are taking part every year in the IIC activities ranking framework. So, through that framework every institution conducts a lot of programs to encourage students to think differently.</span></p>
<p><span>Entrepreneurship related programs, design thinking then we invite people having their own start ups and how. So, how commercial adaptability is important, how do you convert the prototype into a commercially viable product, that kind of training is being given the entire business canvas is being taught to students while they are graduating and that is how innovation is innovative.</span></p>
<p><span>For entrepreneurship the skills and the kind of knowledge that you need that institutions are providing.</span></p>
<p><span>Now, when it comes to innovation as an attitude, we know that it is not taught in the classroom, but it is all about the kind of spark that you have about creativity, critical thinking, and problem solving. You are always very creative when it comes to thinking out of the box.</span></p>
<p><span>Students are deliberately made to think about the community based problems, what is going around and based on that do you find out some unmet need that society is facing and for which solution is right now not available and it need not be very hi-fi thing because at first year and second year level what advanced research you can think about.</span></p>
<p><span>It need not be about genomics, proteomics or bioinformatics. It can be about small small things like some kind of smart watch which has an alarm which takes up your vital and gives you some kind of indication like there is something wrong with tachycardia.</span></p>
<p><span>So, you need to consult a doctor or in my college I developed one film which was just a plain film of a polymer, but it was water insoluble and it was a peelable and biodegradable polymer.</span></p>
<p><span>Our idea was just to apply the film and then go into and do the work where you have to deal with some detergents or some for the agricultural community, some fertilizers, manure, soil. So, your hands will be protected and it is not a glove, but it is just a film which is mixing with your skin.</span></p>
<p><span>It is almost invisible. You do not have a feeling here you are wearing something, but your hands are completely protected and after work is over and you do not have to now deal with the hasardous material just peel it off and it is biodisposable.</span></p>
<p><span>Such types of innovations have a lot of concepts that are strong, but the work can be very simple: just dissolve, mix and make a solution. So, these kinds of innovations we are asking students to think about.</span></p>
<p><span>That is what is called design thinking. We are trying to create them about finding out some problem statement for which solution is available and what can be that solution, that solution oriented approach that is being taught to students by giving various examples, the contemporary examples in day to day life like food products, nutraceuticals, formulations, drugs, medicines, devices.</span></p>
<p><span>Innovation, We know that when there is necessity there is an invention, but we are going beyond that like we are trying to tell them that you have to whatever is your idea you just try to experiment it do not just neglect it.</span></p>
<p><span>That is what a tinkerer’s lab is. We are giving them the platform, we give you chemicals, we give you equipment, you just do it and see whether you are able to convert it into a product or you are able to convert it into some prototype which can be seen as this is how it will work.</span></p>
<p><span>We have heard about digital twins right, what is a digital twin? It is a mock or prototype of the simulated model which before physically we make it that digital twin tells you that this is how the process will appear, this is how the product will appear and this is how it will work.</span></p>
<p><span>We are also trying to tell them you make a twin which is in the form of a prototype and then later on maybe in the phases we have our own incubation centre Hashu Advani Business Technology Incubation Centre where you can incubate and we can convert it into a viable solution.</span></p>
<p><span>That is how institutions are encouraging innovation, VES College of Pharmacy has our own institution innovation council, we conduct many sessions, we invite speakers who have their own startups, we also conduct workshops on design thinking and we nurture that innovation thought.</span></p>
<p><span>Our second year student recently when we had a design thinking workshop she came up with the idea of a digital watch and she is saying in that digital watch we will have a strips blister pack of the anti asthma drug like salbutamol and it will also have a kind of sensor.</span></p>
<p><span>So when a person is having bronchospasm because of an allergen to which he or she has been exposed to, the sensor will be able to capture that anatomical change and it will show a red brick.</span></p>
<p><span>The person who is allergic to certain things will come to know, okay I am going to land up in an asthma attack.</span></p>
<p><span>So I will just dial the next dose and I will inhale it through the asthma digital valve. So the idea was so good that we took her to the Tinkerer lab and also we introduced her to some other engineering college students of VES and we found a team and we would now tell them, now go ahead and try to design a certain type of watch.</span></p>
<p><span>That is how we are encouraging students.</span></p>
<p><b>As India seeks to strengthen its position as a global pharma manufacturing hub, could talent become a constraint to the adoption of smart manufacturing and what should industry and academia start doing to ensure that the talent pipeline keeps pace with its transition?</b></p>
<p><span>Very good question. The Pharmacy Council of India is telling us, it is making it mandatory that every institution should have 10 MOUs with the industry and hospitals.</span></p>
<p><span>Out of that 10, at least 5 should be with the industry. Now these MOUs should not be just the on paper record, but it should be an active MOU.</span></p>
<p><span>My suggestion is that industry should adopt at least 3 to 4 colleges, may be based on geographical location or may be because of the, based on the research interest that these institutions are having and their research forte and then industry should hand hold these academia.</span></p>
<p><span>Each industry if it adopts 2 or 3 institutions and they hand hold them, it is like a sharing of the expertise, sharing of the facilities, sharing of the knowledge and that can become a very good collaborative model.</span></p>
<p><span>Because we know abroad in the US, so many products, so many vaccines, even for example Covishield vaccine that was, that has emerged from one institutional research. Institutions have got a lot of creativity.</span></p>
<p><span>Institutional faculty members have got a lot of new ideas, but they lack its commercial translation into commercial products, whereas industry has expertise in commercialising it.</span></p>
<p><span>What I feel is that industry should set up the industry training center in the colleges and they can identify one such college in the cluster of 10 colleges and then this training center should give training to all the students available in that cluster.</span></p>
<p><span>The host institute may be considered based on its location and its overall expertise and the trainers available with their experience in research and in that institution the industry can invest through their CSR funding or any other source and install all industry compliant CSR compliant equipment, having all digital monitors, sensors, then PLC controls.</span></p>
<p><span>So that it is not the primitive machine or equipment that academic institutions can afford to have, but it is actually GMP CSR compliant equipment that industry uses.</span></p>
<p><span>But this training should be provided while the student is studying here. So that is what hands on training.</span></p>
<p><span>Merely going for an industry visit will not help in fulfilling that requirement. But if you have such type of center and it is catering to 10 nearby institutions, students can be visiting to this host institute for some 2 days workshops, additional their work for which this center can cater to their need for scaling up, for giving them better product with proper log and proper data which is printed and available as a digital copy.</span></p>
<p><span>While they are studying they come to know what are the industry practices and industry also should talk about QMS.</span></p>
<p><span>Academic institutions should set up the quality management system through their instrument rooms, pilot plant. So in our college we have already consulted Mr. Sunil Putkar who is a regulatory auditor and under his guidance we are setting up QMS systems, quality management systems in our instrumentation and pilot plant and record keeping.</span></p>
<p><span>Then we are going to ask students to maintain it.</span></p>
<p><span>These are industrial practices. So in the college level itself they should come to know how the records are maintained, documents are made, done, then common technical data, CDDs, files are made. So everything should be trained.</span></p>
<p><span>How SOPs are made, standard operating procedures. So that training is required plus hands on training to handle the equipment because the industry has set up that kind of training.</span></p>
<p><span>My vision is that in our college there should be a translational research and development center.</span></p>
<p><span>This center will cater to translating your research into commercially viable products. That is one thing for which we are working on.</span></p>
<p><span>And second thing is that industry training center where we can tie up with the company and we can provide this facility for the nearby colleges.</span></p>
<p><span>We can volunteer to train them. That is what my vision is.</span></p>
<p><em><strong>neha.aathavale@expressindia.com</strong></em></p>
<p><em><strong>nehaaathavale75@gmail.com</strong></em></p>
<p>The post <a href="https://www.expresspharma.in/building-the-pharma-talent-india-needs-for-the-digital-era/">Building the pharma talent India needs for the digital era</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>My Retainer Feels Tight or Doesn’t Fit. Should I Force It?</title>
<link>https://edusehat.com/en/my-retainer-feels-tight-or-doesnt-fit-should-i-force-it</link>
<guid>https://edusehat.com/en/my-retainer-feels-tight-or-doesnt-fit-should-i-force-it</guid>
<description><![CDATA[ As long as your retainer doesn’t hurt and still fits over your teeth, you can wear it – even if it feels tight. Your teeth may have slightly shifted, and you may need to wear your retainer longer each day to prevent your teeth from moving. 
The post My Retainer Feels Tight or Doesn’t Fit. Should I Force It? appeared first on American Association of Orthodontists. ]]></description>
<enclosure url="https://aaoinfo.org/wp-content/uploads/2024/10/Clear-Retainer-Feels-Tight.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 07:55:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Retainer, Feels, Tight, Doesn’t, Fit., Should, Force, It</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">If your retainer feels a little snug but still fits fully over your teeth without significant pain, the change may be related to minor tooth movement. If your retainer doesn’t sit completely, causes significant or sharp pain, looks warped or damaged, or must be pushed or bitten forcefully into place, don’t force it.</p>



<p class="wp-block-paragraph"><a href="https://aaoinfo.org/treatments/retainers/">A retainer</a> is made to fit a particular position of your teeth. When it no longer fits properly, the cause may be a change in your teeth, a change in the retainer, or both. Forcing it into place does not tell you which problem you are dealing with. An AAO orthodontist can evaluate the fit and recommend the appropriate next step. AAO guidance advises patients to consult their orthodontist when a retainer causes pain, is damaged, or no longer fits as it once did.</p>



<h2 class="wp-block-heading">Is It Normal for a Retainer to Feel Tight?</h2>



<p class="wp-block-paragraph">Some snugness can happen, especially if you haven’t worn your removable retainer as consistently as your orthodontist recommended. Teeth can continue to shift after orthodontic treatment, which is why retention remains an ongoing part of maintaining your results.</p>



<p class="wp-block-paragraph">However, there is an important difference between a retainer that feels slightly snug and one that no longer fits.</p>



<p class="wp-block-paragraph">A mildly snug retainer may still seat completely over the teeth and stay in its usual position. It should not require significant force to put on.</p>



<p class="wp-block-paragraph">A retainer that does not fit may stop partway onto the teeth, leave an unusual space between the appliance and one or more teeth, pop out of position, or cause significant discomfort when you try to seat it.</p>



<p class="wp-block-paragraph">If you are unsure which situation applies, contact your orthodontist rather than trying to make the retainer fit on your own.</p>



<h3 class="wp-block-heading">How Tight Is Too Tight for a Retainer?</h3>



<p class="wp-block-paragraph">Pay attention to both fit and comfort. Contact an orthodontist if:</p>



<ul class="wp-block-list">
<li>The retainer will not fully seat over your teeth.</li>



<li>You have to push hard or bite down forcefully to get it into place.</li>



<li>You feel significant or sharp pain when inserting or wearing it.</li>



<li>One portion fits while another portion visibly sits away from the teeth.</li>



<li>The retainer repeatedly pops off or will not stay seated.</li>



<li>The plastic looks warped, cracked, or misshapen.</li>



<li>A wire is bent, broken, or loose.</li>



<li>The fit has changed and does not quickly return to a comfortable fit with the wear schedule your orthodontist has recommended.</li>
</ul>



<p class="wp-block-paragraph">AAO guidance recommends professional evaluation when a retainer remains uncomfortable, has visible damage, or no longer fits properly.</p>



<h2 class="wp-block-heading">Why Does My Retainer No Longer Fit?</h2>



<p class="wp-block-paragraph">A retainer can fit differently for several reasons. Finding the cause matters because the appropriate solution depends on what changed.</p>



<h3 class="wp-block-heading">Your Teeth Have Shifted</h3>



<p class="wp-block-paragraph">One common reason is inconsistent retainer wear. A removable retainer is designed to help maintain the positions achieved through orthodontic treatment. If you stop wearing it for a period of time, your teeth may move enough that the appliance feels tighter when you try it again.</p>



<p class="wp-block-paragraph">Teeth can also change gradually over time. Retainer wear helps minimize unwanted changes, but your orthodontist should determine what to do when an older appliance no longer matches your current tooth positions.</p>



<h3 class="wp-block-heading">The Retainer Has Changed Shape</h3>



<p class="wp-block-paragraph">Sometimes teeth aren’t the only thing that has changed. Removable retainers can wear, crack, bend, or distort.</p>



<p class="wp-block-paragraph">Heat is a particular concern for plastic retainers. Hot water, a hot car, or other high-temperature environments can damage or warp some retainer materials. Physical damage can also change how an appliance sits on the teeth. AAO recommends keeping retainers away from excessive heat and contacting an orthodontist when a retainer is malformed or damaged.</p>



<p class="wp-block-paragraph">Do not try to reshape a retainer at home with hot water or other do-it-yourself methods. A retainer that has changed shape may no longer match the tooth positions it was designed to hold.</p>



<h3 class="wp-block-heading">The Retainer Is Worn or Damaged</h3>



<p class="wp-block-paragraph">Retainers don’t necessarily stay unchanged indefinitely. Daily insertion, removal, cleaning, storage, and normal wear can eventually affect an appliance, making it essential to <a href="https://aaoinfo.org/whats-trending/taking-care-of-retainers/?_rt=MnwxfHJldGFpbmVyfDE3MDc4NDUxNzg&amp;_rt_nonce=a37d88170b">take care of your retainer</a>.</p>



<p class="wp-block-paragraph">Look at your retainer regularly. Contact your orthodontist if you notice cracks, distortion, damaged wires, sharp edges, or a sudden change in fit. AAO guidance advises patients to stop wearing retainers with certain visible damage, such as cracks or loose wires, and obtain a professional evaluation.</p>



<h2 class="wp-block-heading">Why You Should Not Force an Old Retainer to Fit</h2>



<p class="wp-block-paragraph">Finding an old retainer after weeks, months, or even years can make it tempting to push it onto your teeth and see if it will straighten them again. If it doesn’t fit properly, forcing it is not a substitute for an orthodontic evaluation.</p>



<p class="wp-block-paragraph">There are several reasons.</p>



<h3 class="wp-block-heading">The Retainer Was Made for an Earlier Tooth Position</h3>



<p class="wp-block-paragraph">A custom retainer reflects your teeth’s position when the appliance was made. If your teeth have moved since then, the old retainer may no longer match your current tooth position.</p>



<p class="wp-block-paragraph">Orthodontic tooth movement is planned and monitored. If additional movement is needed after your original treatment, your orthodontist can determine which teeth have moved, how your bite has changed, and the appropriate approach. Depending on the situation, AAO notes that options may include an adjustment, a new retainer, or orthodontic treatment such as clear aligners or braces.</p>



<h3 class="wp-block-heading">More Force Is Not the Same as Better Fit</h3>



<p class="wp-block-paragraph">A retainer should not need to be jammed, clamped, or aggressively bitten into place.</p>



<p class="wp-block-paragraph">Significant resistance is useful information. It may mean your teeth have moved beyond the retainer’s current fit, or the appliance itself may be distorted. Continuing to force it doesn’t address that uncertainty and can cause unnecessary discomfort or damage the appliance.</p>



<p class="wp-block-paragraph">If a retainer will not seat with normal, gentle insertion, stop and contact your orthodontist.</p>



<h3 class="wp-block-heading">You Could Damage the Retainer</h3>



<p class="wp-block-paragraph">Forcing a removable appliance over teeth that no longer match its shape can place stress on the retainer. Clear plastic can crack or distort, and wires or acrylic components can also become damaged.</p>



<p class="wp-block-paragraph">A damaged retainer may no longer hold the teeth as intended. AAO recommends contacting an orthodontist when a retainer is damaged rather than continuing to use an appliance with a compromised fit.</p>



<h3 class="wp-block-heading">Pain Is a Reason to Stop and Get Advice</h3>



<p class="wp-block-paragraph">Mild pressure and significant pain are not the same thing. AAO guidance specifically recommends consulting an orthodontist when tightness causes discomfort or pain.</p>



<p class="wp-block-paragraph">Do not treat significant pain as proof that an old retainer is “working.” If inserting or wearing the retainer hurts, or if you have to force it over your teeth, contact your orthodontist.</p>



<h2 class="wp-block-heading">Can a Tight Retainer Move Teeth Back?</h2>



<p class="wp-block-paragraph">A retainer’s main purpose is to maintain the positions achieved through orthodontic treatment. In some cases, very minor tooth movement may make an otherwise well-fitting retainer feel snug, and an orthodontist may recommend more consistent wear.</p>



<p class="wp-block-paragraph">That does not mean you should use every old or tight retainer to move teeth on your own.</p>



<p class="wp-block-paragraph">If your teeth have shifted enough that the appliance no longer seats properly, your orthodontist may need to adjust or replace the retainer. If more tooth movement is necessary, some patients may be candidates for a limited course of clear aligners or braces before returning to retention. The right option depends on an evaluation of your current teeth and bite.</p>



<h2 class="wp-block-heading">What Should I Do If My Retainer Doesn’t Fit?</h2>



<p class="wp-block-paragraph">First, do not force it into place.</p>



<p class="wp-block-paragraph">Check the appliance for obvious cracks, bending, distortion, or other damage. Think about how consistently you have worn it and whether it may have been exposed to heat.</p>



<p class="wp-block-paragraph">If the retainer is only mildly snug, still seats fully, and doesn’t cause significant discomfort, follow the wear instructions your orthodontist gave you. If the fit remains uncomfortable, worsens, or you are unsure about wearing it, contact your orthodontist.</p>



<p class="wp-block-paragraph">If the retainer does not fully fit, causes significant pain, or appears damaged or warped, contact an AAO orthodontist for an evaluation rather than trying to alter the appliance yourself.</p>



<h2 class="wp-block-heading">What Happens at an Orthodontic Retainer Check?</h2>



<p class="wp-block-paragraph">A retainer evaluation is an opportunity to find out what changed and what, if anything, needs to be done.</p>



<p class="wp-block-paragraph">Your orthodontist can examine your teeth and bite, assess how the retainer fits, and look for wear or damage to the appliance. If a replacement retainer is appropriate, you may need a new scan or impression so the replacement matches your current teeth. AAO’s retainer guidance notes that a changed fit can sometimes require an adjustment or a new impression for a replacement appliance.</p>



<p class="wp-block-paragraph">Possible next steps depend on the individual situation. They may include:</p>



<ul class="wp-block-list">
<li>Continuing your current retainer according to updated instructions.</li>



<li>Adjusting an appliance when appropriate.</li>



<li>Making a replacement retainer.</li>



<li>Monitoring a minor change.</li>



<li>Discussing limited orthodontic treatment if teeth have shifted enough that a retainer alone is not appropriate.</li>



<li>Discussing more comprehensive treatment when significant changes have occurred.</li>
</ul>



<p class="wp-block-paragraph">An evaluation does not mean you are automatically beginning braces or clear aligner treatment. The purpose of the visit is first to assess the problem and discuss your options. If active orthodontic treatment is recommended, that decision and starting treatment are separate steps. AAO’s current guidance similarly describes evaluation and treatment planning before an appointment to begin treatment.</p>



<h2 class="wp-block-heading">Why Retainer Wear Still Matters After Orthodontic Treatment</h2>



<p class="wp-block-paragraph">Teeth can continue to change position after braces or clear aligner treatment. Retainers help maintain your corrected tooth positions and minimize unwanted changes over time.</p>



<p class="wp-block-paragraph">The amount and frequency of retainer wear can vary, so follow your orthodontist’s instructions rather than relying on a general schedule.</p>



<p class="wp-block-paragraph">Good retainer habits also help protect the appliance itself. Store a removable retainer in its case when you’re not wearing it, keep it away from excessive heat, clean it according to your orthodontist’s instructions, and contact the office if you notice damage or a significant change in fit.</p>



<div class="wp-block-group is-layout-constrained wp-container-core-group-is-layout-408bf21f wp-block-group-is-layout-constrained">
<h2 class="wp-block-heading has-text-align-center">Frequently Asked Questions About Tight and Old Retainers</h2>


<div class="mdg-block faq-list mt-6 ">
    <div class="max-w-[800px] mx-auto">
                              
          <a href="https://aaoinfo.org/whats-trending/my-retainer-feels-tight-can-i-still-wear-it/" target="" class="block no-underline hover:no-underline">
            <div class="border border-blue-1 hover:border-blue-1/60 transition px-6 py-6 lg:pl-8 lg:pr-5 mb-3">
                <div class="text-title text-blue-1 mb-4">
                  1. Can I wear my old retainer after years without it?
                </div>
                <div class="text-blue-1">
                  Do not force an old retainer onto your teeth if it no longer fits normally. Teeth can shift over time, and the appliance itself may have changed. An orthodontist can determine whether the old retainer is still appropriate, needs adjustment…
                </div>
            </div>
          </a>
                                
          <a href="https://aaoinfo.org/whats-trending/my-retainer-feels-tight-can-i-still-wear-it/" target="" class="block no-underline hover:no-underline">
            <div class="border border-blue-1 hover:border-blue-1/60 transition px-6 py-6 lg:pl-8 lg:pr-5 mb-3">
                <div class="text-title text-blue-1 mb-4">
                  2. What if my retainer fits halfway but will not go down all the way?
                </div>
                <div class="text-blue-1">
                  A retainer that will not fully seat is not fitting as intended. Do not bite down hard or use significant pressure to force it farther onto the teeth. Contact your orthodontist so they can evaluate the fit.
                </div>
            </div>
          </a>
                                
          <a href="https://aaoinfo.org/whats-trending/my-retainer-feels-tight-can-i-still-wear-it/" target="" class="block no-underline hover:no-underline">
            <div class="border border-blue-1 hover:border-blue-1/60 transition px-6 py-6 lg:pl-8 lg:pr-5 mb-3">
                <div class="text-title text-blue-1 mb-4">
                  3. Should I keep wearing a retainer if it hurts?
                </div>
                <div class="text-blue-1">
                  Significant or persistent pain is a reason to contact your orthodontist. AAO guidance recommends seeking orthodontic advice when retainer tightness causes discomfort or pain.
                </div>
            </div>
          </a>
                                
          <a href="https://aaoinfo.org/whats-trending/my-retainer-feels-tight-can-i-still-wear-it/" target="" class="block no-underline hover:no-underline">
            <div class="border border-blue-1 hover:border-blue-1/60 transition px-6 py-6 lg:pl-8 lg:pr-5 mb-3">
                <div class="text-title text-blue-1 mb-4">
                  4. Can I heat or bend my retainer to make it fit again?
                </div>
                <div class="text-blue-1">
                  No. Do not use hot water or another heat source to reshape a retainer. Excessive heat can damage or warp retainer materials. If the appliance no longer fits, have an orthodontist evaluate it.
                </div>
            </div>
          </a>
                                
          <a href="https://aaoinfo.org/whats-trending/my-retainer-feels-tight-can-i-still-wear-it/" target="" class="block no-underline hover:no-underline">
            <div class="border border-blue-1 hover:border-blue-1/60 transition px-6 py-6 lg:pl-8 lg:pr-5 mb-3">
                <div class="text-title text-blue-1 mb-4">
                  5. Does a tight retainer always mean my teeth moved?
                </div>
                <div class="text-blue-1">
                  No. Tooth movement is one possible reason, but the retainer itself may also be worn, damaged, or distorted. An orthodontist can check both your tooth positions and the appliance.
                </div>
            </div>
          </a>
              
      
    </div>
  </div>
</div>


<div class="mdg-block faq-list mt-6 ">
    <div class="max-w-[800px] mx-auto">
                                        
      
    </div>
  </div>



<h2 class="wp-block-heading">Get a Retainer That Fits Your Teeth Today</h2>



<p class="wp-block-paragraph">A retainer that suddenly feels different is worth paying attention to. Mild snugness and a retainer that will not fit are not the same problem, and an old appliance should never need significant force to seat over your teeth.</p>



<p class="wp-block-paragraph">If your retainer is painful, damaged, warped, or no longer fits fully, an AAO orthodontist can evaluate your teeth, your bite, and the appliance before recommending what comes next. An evaluation may show that you need a replacement retainer, an adjustment, monitoring, or additional orthodontic care. It does not automatically mean starting treatment.</p>



<div class="wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex">
<div class="wp-block-button is-style-btn-primary"><a class="wp-block-button__link wp-element-button" href="https://aaoinfo.org/locator/">Find an Orthodontist</a></div>
</div>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://aaoinfo.org/whats-trending/my-retainer-feels-tight-can-i-still-wear-it/">My Retainer Feels Tight or Doesn’t Fit. Should I Force It?</a> appeared first on <a href="https://aaoinfo.org/">American Association of Orthodontists</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Can You Get Braces With Baby Teeth? What Parents Need to Know</title>
<link>https://edusehat.com/en/can-you-get-braces-with-baby-teeth-what-parents-need-to-know</link>
<guid>https://edusehat.com/en/can-you-get-braces-with-baby-teeth-what-parents-need-to-know</guid>
<description><![CDATA[ If your child still has baby teeth, you may wonder whether it is too early to think about braces or visiting an orthodontist. The short answer is no. A child doesn’t need to lose all their baby teeth before seeing an orthodontist. In some cases, orthodontic treatment can even begin while both baby and permanent … Continued
The post Can You Get Braces With Baby Teeth? What Parents Need to Know appeared first on American Association of Orthodontists. ]]></description>
<enclosure url="https://aaoinfo.org/wp-content/uploads/2019/05/baby-teeth-braces.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 07:55:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Can, You, Get, Braces, With, Baby, Teeth, What, Parents, Need, Know</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">If your child still has baby teeth, you may wonder whether it is too early to think about braces or visiting an orthodontist.</p>



<p class="wp-block-paragraph">The short answer is no. A child doesn’t need to lose all their baby teeth before seeing an orthodontist. In some cases, orthodontic treatment can even begin while both baby and permanent teeth are present. Whether treatment is recommended depends on your child’s teeth, bite, jaw growth, and developmental stage.</p>



<p class="wp-block-paragraph">That does not mean every 7-year-old needs braces. In fact, many children who see an orthodontist at an early age do not need treatment right away. An <a href="https://aaoinfo.org/child-orthodontics/">early check-up</a> gives the orthodontist an opportunity to see how your child’s teeth and jaws are developing and determine whether treatment is needed now, later, or possibly not at all.</p>



<h2 class="wp-block-heading">Do All Baby Teeth Need to Fall Out Before Braces?</h2>



<p class="wp-block-paragraph">No. There is no rule that every baby tooth must fall out before a child can have orthodontic treatment.</p>



<p class="wp-block-paragraph">Many orthodontic problems are best treated after more permanent teeth have come in. Others may benefit from attention earlier, while a child still has a mix of baby and permanent teeth. This stage of development is often called mixed dentition.</p>



<p class="wp-block-paragraph">An orthodontist looks at much more than the number of baby teeth remaining. The position of the permanent teeth, the way the upper and lower teeth fit together, jaw growth, and the timing of tooth eruption can all help determine when treatment should begin.</p>



<p class="wp-block-paragraph">This is one reason parents should not use the loss of the last baby tooth as the signal that it is finally time to schedule an orthodontic visit.</p>



<h3 class="wp-block-heading">Can a Child Have Braces While Baby Teeth Are Still Present?</h3>



<p class="wp-block-paragraph">Yes. <a href="https://aaoinfo.org/treatments/braces/">Braces</a> may be used as part of an early orthodontic treatment plan even when some baby teeth remain. Early orthodontic treatment is also known as interceptive treatment or Phase 1 orthodontics.</p>



<p class="wp-block-paragraph">Braces are not the only option. Depending on the problem, an orthodontist may recommend another type of fixed or removable orthodontic appliance. In other cases, the best approach is simply to monitor the child’s growth and wait.</p>



<p class="wp-block-paragraph">The right treatment and timing are different for every child.</p>



<h3 class="wp-block-heading">What If My Child Has a Loose Baby Tooth?</h3>



<p class="wp-block-paragraph">A loose baby tooth does not automatically mean your child is too young for an orthodontic evaluation or treatment.</p>



<p class="wp-block-paragraph">Losing baby teeth is a normal part of dental development. An orthodontist considers where your child is in that process, how permanent teeth are developing, and whether a particular orthodontic problem would benefit from treatment at that time.</p>



<p class="wp-block-paragraph">If your child already has braces or another orthodontic appliance and a baby tooth becomes loose, talk with your orthodontist about what to expect.</p>



<h2 class="wp-block-heading">At What Age Do Kids Get Braces?</h2>



<p class="wp-block-paragraph">There is no single age when every child should get braces.</p>



<p class="wp-block-paragraph">Some children benefit from orthodontic treatment while they are still growing and still have baby teeth. Others may not begin treatment until most or all of their permanent teeth have erupted.</p>



<p class="wp-block-paragraph">What has a recommended age is your child’s first orthodontic check-up. The American Association of Orthodontists recommends that children have their first check-up with an orthodontist when an orthodontic problem is first recognized and no later than age 7.</p>



<p class="wp-block-paragraph">By around age 7, many children have a combination of baby and permanent teeth. That allows an orthodontist to evaluate how the teeth, bite, and jaws are developing, including problems that may not be easy for parents to see.</p>



<h3 class="wp-block-heading">Does Seeing an Orthodontist at Age 7 Mean Getting Braces at Age 7?</h3>



<p class="wp-block-paragraph">No.</p>



<p class="wp-block-paragraph">An orthodontic check-up is not the same thing as starting orthodontic treatment.</p>



<p class="wp-block-paragraph">After an early evaluation, an orthodontist may determine that:</p>



<ul class="wp-block-list">
<li>No orthodontic treatment is expected to be necessary.</li>



<li>Treatment may be beneficial later, so your child’s growth and tooth development should be monitored.</li>



<li>A developing problem may benefit from early orthodontic treatment.</li>
</ul>



<p class="wp-block-paragraph">For many families, the first visit is simply an opportunity to understand how a child’s teeth and jaws are developing and what to expect in the years ahead.</p>



<h3 class="wp-block-heading">Can My Child See an Orthodontist Before Age 7?</h3>



<p class="wp-block-paragraph">Yes.</p>



<p class="wp-block-paragraph">Age 7 is the recommended latest age for a first check-up, not an age that parents must wait to reach. If you or your child’s dentist notice something unusual about your child’s teeth, bite, or jaw development earlier, you can schedule an orthodontic evaluation sooner.</p>



<h2 class="wp-block-heading">What Is Phase 1 Orthodontics?</h2>



<p class="wp-block-paragraph">Phase 1 orthodontics, also called early or interceptive orthodontic treatment, is treatment that takes place while a child is still growing and some baby teeth are still present.</p>



<p class="wp-block-paragraph">The purpose is not simply to make teeth look straighter at a younger age. When early treatment is recommended, it is intended to address a specific developing orthodontic problem at a time when treatment may be beneficial.</p>



<p class="wp-block-paragraph">Depending on the child’s needs, early treatment may help guide jaw growth, address certain bite problems, or create appropriate conditions for permanent teeth as they emerge.</p>



<p class="wp-block-paragraph">Most importantly, Phase 1 treatment is not necessary for every child.</p>



<p class="wp-block-paragraph">Many orthodontic problems can and should wait until later. An orthodontist can help parents understand whether early treatment benefits their child or whether monitoring development is the better choice.</p>



<h3 class="wp-block-heading">What Orthodontic Problems May Benefit From Early Treatment?</h3>



<p class="wp-block-paragraph">Every child’s situation is different, but an orthodontist may recommend early treatment for concerns such as:</p>



<ul class="wp-block-list">
<li>An underbite</li>



<li>A crossbite</li>



<li>Significant crowding</li>



<li>Excessive spacing</li>



<li>Extra or missing teeth</li>



<li>Teeth that do not meet normally</li>



<li>Teeth that do not meet at all</li>



<li>Certain tooth eruption problems</li>



<li>Thumb, finger, or pacifier habits that are affecting the teeth or jaw growth</li>
</ul>



<p class="wp-block-paragraph">Some orthodontic problems are inherited. Others can develop because of habits, injuries, dental disease, or other factors.</p>



<p class="wp-block-paragraph">An orthodontic evaluation can help determine whether a <a href="https://aaoinfo.org/whats-trending/if-my-front-teeth-are-straight-why-should-i-be-concerned-about-how-my-teeth-fit-together/">bite problem</a> needs treatment now or can be safely monitored.</p>



<h3 class="wp-block-heading">Does Phase 1 Treatment Always Mean Braces?</h3>



<p class="wp-block-paragraph">No. Early orthodontic treatment can take several forms.</p>



<p class="wp-block-paragraph">An orthodontist may use a fixed or removable appliance depending on the child’s needs. For example, some growing patients may benefit from a palatal expander. Other children may have limited braces or another appliance designed to address a particular problem.</p>



<p class="wp-block-paragraph">There are also situations in which no orthodontic appliance is needed at that time. Your orthodontist may simply monitor growth and tooth eruption. In some cases, the orthodontist may recommend carefully timed removal of certain baby teeth as part of an individualized treatment plan.</p>



<h3 class="wp-block-heading">Will My Child Need Braces Again After Phase 1 Treatment?</h3>



<p class="wp-block-paragraph">Possibly.</p>



<p class="wp-block-paragraph">Phase 1 treatment addresses specific problems during an earlier stage of growth and dental development. It does not necessarily mean a child will never need additional orthodontic treatment.</p>



<p class="wp-block-paragraph">Some children later have a second phase of treatment after more or all of their permanent teeth have erupted. That treatment can focus on positioning the permanent teeth and refining the bite.</p>



<p class="wp-block-paragraph">Your orthodontist can explain what the goals of early treatment are and what future treatment may be expected.</p>



<h2 class="wp-block-heading">Baby Teeth, Permanent Teeth, and Mixed Dentition</h2>



<p class="wp-block-paragraph">Your child’s smile changes considerably during their elementary school years.</p>



<p class="wp-block-paragraph">Baby teeth, also called primary teeth, begin to make way for permanent teeth. For several years, children commonly have both types of teeth in their mouths at the same time. Orthodontists call this stage mixed dentition.</p>



<p class="wp-block-paragraph">This can be a useful time for an orthodontic evaluation because an orthodontist can assess the teeth that are already visible while also considering how the permanent teeth and jaws are developing.</p>



<p class="wp-block-paragraph">A child’s smile may look fine from the outside even when an orthodontic issue is beginning to develop. That is why an orthodontic check-up can provide information that’s hard to get by simply looking at your child’s teeth at home.</p>



<h3 class="wp-block-heading">What If Baby Teeth Fall Out Early or Late?</h3>



<p class="wp-block-paragraph">Children do not all lose their baby teeth on the same schedule, and some variation is normal.</p>



<p class="wp-block-paragraph">Still, baby teeth that are lost unusually early or remain much longer than expected can sometimes be associated with orthodontic concerns. Early or late loss of baby teeth is one sign parents can watch for when considering an orthodontic evaluation.</p>



<p class="wp-block-paragraph">If you are concerned about the timing of your child’s tooth loss, an orthodontist can evaluate how the permanent teeth are developing and whether any action is recommended.</p>



<h3 class="wp-block-heading">What If a Permanent Tooth Is Not Coming In?</h3>



<p class="wp-block-paragraph">Permanent teeth do not always erupt exactly when or where parents expect them to.</p>



<p class="wp-block-paragraph">An orthodontist can evaluate the position and development of incoming teeth during an orthodontic examination. If something looks unusual, the orthodontist can determine whether the tooth simply needs more time, whether monitoring is appropriate, or whether treatment is needed.</p>



<h2 class="wp-block-heading">Why Your Child’s Bite Matters</h2>



<p class="wp-block-paragraph">Orthodontic care is about more than straight teeth.</p>



<p class="wp-block-paragraph">Your child’s bite is how the upper and lower teeth come together. Orthodontists specialize in aligning teeth and jaws and in how the bite functions.</p>



<p class="wp-block-paragraph">Problems such as crossbites, underbites, crowding, and teeth that do not meet properly may affect how the teeth and jaws function together. In some children, treatment timing matters because the jaws and face are still growing.</p>



<p class="wp-block-paragraph">Other children can wait until more permanent teeth have erupted before treatment begins.</p>



<p class="wp-block-paragraph">An early evaluation helps an orthodontist determine which situation applies to your child.</p>



<h2 class="wp-block-heading">Signs Your Child Should See an Orthodontist</h2>



<p class="wp-block-paragraph">You do not need to diagnose an orthodontic problem yourself. That is the orthodontist’s job.</p>



<p class="wp-block-paragraph">Still, certain signs may be a reason to schedule an evaluation, particularly if your child has not yet had their first orthodontic check-up.</p>



<p class="wp-block-paragraph">Consider talking with an orthodontist if you notice:</p>



<ul class="wp-block-list">
<li>Baby teeth being lost unusually early or late</li>



<li>Difficulty biting or chewing</li>



<li>An underbite or crossbite</li>



<li>Teeth that do not come together normally</li>



<li>Significant crowding or spacing</li>



<li>Jaws that appear to shift when your child bites</li>



<li>Frequent cheek biting</li>



<li>A noticeable imbalance in the teeth or jaws</li>



<li>Permanent teeth appearing in unexpected positions</li>



<li>A thumb, finger, or pacifier habit that appears to be affecting the teeth or jaws</li>



<li>Any other concern about the way your child’s teeth or jaws are developing</li>
</ul>



<p class="wp-block-paragraph">AAO recommends an orthodontic check-up no later than age 7, even if no obvious problem has been noticed. If you see a concern sooner, there is no need to wait until age 7.</p>



<h2 class="wp-block-heading">What Happens at Your Child’s First Orthodontic Visit?</h2>



<p class="wp-block-paragraph">For many children, a first orthodontic appointment is primarily an evaluation.</p>



<p class="wp-block-paragraph">The orthodontist will look at how your child’s teeth and jaws are developing and how the upper and lower teeth fit together. The visit gives you an opportunity to discuss any concerns and learn whether an orthodontic problem is present.</p>



<p class="wp-block-paragraph">If treatment is not needed yet, your orthodontist may recommend periodic check-ups to monitor growth and tooth eruption. This allows treatment to begin at the right stage of development if needed.</p>



<p class="wp-block-paragraph">If a developing problem could benefit from early treatment, your orthodontist can discuss the available options, goals, and timing with you.</p>



<h3 class="wp-block-heading">Do I Need a Dentist Referral to Take My Child to an Orthodontist?</h3>



<p class="wp-block-paragraph">No. You do not need to wait for your child’s dentist to provide a referral before scheduling an orthodontic evaluation.</p>



<p class="wp-block-paragraph">Parents are often the first to notice when something about their child’s teeth or bite doesn’t look quite right. If you have a concern, you can contact an orthodontist directly.</p>



<p class="wp-block-paragraph">Your child’s dentist and orthodontist both play important roles in oral health, and they can work together as your child’s smile develops.</p>



<h2 class="wp-block-heading">Should You Wait Until All the Baby Teeth Are Gone?</h2>



<p class="wp-block-paragraph">No. You should not use the loss of your child’s final baby tooth as the deciding factor for when to see an orthodontist.</p>



<p class="wp-block-paragraph">AAO recommends that children have their first orthodontic check-up when a problem is first recognized and no later than age 7. At that age, it is completely normal for a child to still have baby teeth.</p>



<p class="wp-block-paragraph">An early orthodontic visit also does not mean your child will need braces right away.</p>



<p class="wp-block-paragraph">For some children, the best recommendation is to wait and monitor development. For others, addressing a particular problem while the child is still growing may be beneficial. The goal is to identify the right treatment, if treatment is needed, and the right time to provide it.</p>



<p class="wp-block-paragraph">If your child still has baby teeth and you have questions about braces, bite development, or when to schedule an evaluation, an AAO orthodontist can help.<br></p>



<div aria-hidden="true" class="wp-block-spacer"></div>



<div class="wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex">
<div class="wp-block-button is-style-btn-primary"><a class="wp-block-button__link wp-element-button" href="https://aaoinfo.org/locator/">Find an Orthodontist</a></div>
</div>



<div aria-hidden="true" class="wp-block-spacer"></div>



<div class="wp-block-group is-layout-constrained wp-container-core-group-is-layout-408bf21f wp-block-group-is-layout-constrained">
<h2 class="wp-block-heading has-text-align-center">Frequently Asked Questions About Braces and Baby Teeth</h2>



<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="mdg-block faq-list mt-6 ">
    <div class="max-w-[800px] mx-auto">
                              
          <a href="https://aaoinfo.org/resources/faqs/" target="_self" class="block no-underline hover:no-underline">
            <div class="border border-blue-1 hover:border-blue-1/60 transition px-6 py-6 lg:pl-8 lg:pr-5 mb-3">
                <div class="text-title text-blue-1 mb-4">
                  1. Can You Get Braces With Baby Teeth?
                </div>
                <div class="text-blue-1">
                  Yes. Some children can receive orthodontic treatment while baby teeth are still present. Whether braces or another type of treatment is appropriate depends on the child’s orthodontic needs and stage of development.
                </div>
            </div>
          </a>
                                
          <a href="https://aaoinfo.org/resources/faqs/" target="_self" class="block no-underline hover:no-underline">
            <div class="border border-blue-1 hover:border-blue-1/60 transition px-6 py-6 lg:pl-8 lg:pr-5 mb-3">
                <div class="text-title text-blue-1 mb-4">
                  2. Do All Baby Teeth Have to Fall Out Before Braces?
                </div>
                <div class="text-blue-1">
                  No. A child does not need to lose every baby tooth before orthodontic treatment can begin. Many children are evaluated while they have a combination of baby and permanent teeth, and some may benefit from treatment during this stage.
                </div>
            </div>
          </a>
                                
          <a href="https://aaoinfo.org/resources/faqs/" target="_self" class="block no-underline hover:no-underline">
            <div class="border border-blue-1 hover:border-blue-1/60 transition px-6 py-6 lg:pl-8 lg:pr-5 mb-3">
                <div class="text-title text-blue-1 mb-4">
                  3. Can a 7-Year-Old Get Braces?
                </div>
                <div class="text-blue-1">
                  Some 7-year-olds may benefit from braces or another orthodontic appliance, but an age-7 check-up does not mean a child will automatically start treatment. The purpose of the early visit is to evaluate development and determine whether treatment is needed now,…
                </div>
            </div>
          </a>
                                
          <a href="https://aaoinfo.org/resources/faqs/" target="_self" class="block no-underline hover:no-underline">
            <div class="border border-blue-1 hover:border-blue-1/60 transition px-6 py-6 lg:pl-8 lg:pr-5 mb-3">
                <div class="text-title text-blue-1 mb-4">
                  4. What Age Should a Child First See an Orthodontist?
                </div>
                <div class="text-blue-1">
                  The American Association of Orthodontists recommends a child’s first orthodontic check-up when a problem is first recognized, and no later than age 7. If you notice a concern before age 7, you can schedule an earlier visit.
                </div>
            </div>
          </a>
                                
          <a href="https://aaoinfo.org/resources/faqs/" target="_self" class="block no-underline hover:no-underline">
            <div class="border border-blue-1 hover:border-blue-1/60 transition px-6 py-6 lg:pl-8 lg:pr-5 mb-3">
                <div class="text-title text-blue-1 mb-4">
                  5. Can a Child Get Braces With a Loose Baby Tooth?
                </div>
                <div class="text-blue-1">
                  A loose baby tooth does not automatically prevent a child from receiving orthodontic treatment. An orthodontist will consider the child’s overall dental development, tooth eruption, and treatment needs when deciding whether and when to begin treatment.
                </div>
            </div>
          </a>
              
              <a class="btn-primary btn--full" href="https://aaoinfo.org/resources/faqs/" target="_self">VIEW ALL FAQs</a>
      
    </div>
  </div>
</div>
<p>The post <a href="https://aaoinfo.org/whats-trending/does-my-child-need-to-wait-to-see-an-orthodontist/">Can You Get Braces With Baby Teeth? What Parents Need to Know</a> appeared first on <a href="https://aaoinfo.org/">American Association of Orthodontists</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Organoid Odyssey: A Glimpse Into the Past, Present, and Future of hPSC&#45;Derived 3D Models</title>
<link>https://edusehat.com/en/the-organoid-odyssey-a-glimpse-into-the-past-present-and-future-of-hpsc-derived-3d-models</link>
<guid>https://edusehat.com/en/the-organoid-odyssey-a-glimpse-into-the-past-present-and-future-of-hpsc-derived-3d-models</guid>
<description><![CDATA[ In this GEN webinar, our expert speaker, Arati Naveen, PhD, will trace the foundational discoveries that shaped organoid technology as a new approach methodology (NAM), while highlighting pioneering contributions and contemporary advances.
The post The Organoid Odyssey: A Glimpse Into the Past, Present, and Future of hPSC-Derived 3D Models appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Getty_1435534172_StemCell.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Organoid, Odyssey:, Glimpse, Into, the, Past, Present, and, Future, hPSC-Derived, Models</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/AratiNaveen_3-e1792592201588.jpeg" class="h-full w-full object-cover" alt="Image of Arati Naveen, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Arati Naveen, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">CIRM Postdoctoral Scholar<br>Cedars-Sinai Medical Center</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/AratiNaveen_3-e1792592201588.jpeg" alt="Image of Arati Naveen, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Arati Naveen, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Arati Naveen, PhD, graduated with her bachelor’s in biomedical engineering from the University of Buffalo. She then moved to L.A. to pursue her master’s in stem cell biology and regenerative medicine at the University of Southern California (USC). She received her PhD in biomedical and translational sciences at Cedars-Sinai in the Jefferies Lab, where her dissertation project explored the interplay between heart disease and immunometabolism. In the Sharma Lab, her work focuses on using cardiac organoids to study autoimmune mediated heart disease and for predictive modeling of drug cardiotoxicity.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Thursday, December 3, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-12-03T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">Human induced pluripotent stem cell (iPSC)-derived organoids combine the ability to generate diverse cell types with the retention of parental genetic backgrounds, providing opportunities to investigate human development, disease mechanisms, and individual differences in therapeutic responses. These models capture aspects of complex tissue architecture and multicellular interactions within a more physiologically relevant spatial environment. Over the past two decades, advances in stem cell reprogramming, directed differentiation, and three-dimensional culturing techniques have enabled the development of organoid models for the brain, retina, heart, lung, intestine, liver, pancreas, kidney, and many more.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, our expert speaker, Arati Naveen, PhD, will trace the foundational discoveries that shaped organoid technology as a new approach methodology (NAM), while highlighting pioneering contributions and contemporary advances. This webinar will examine the ways in which the challenges of tissue maturation, vascularization, reproducibility, and scalability, are being addressed. One example explored is harnessing microgravity to strengthen organoid performance and support the broader adoption as NAMs.</p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you the chance to pose questions to our expert panelist.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-full is-resized"><a href="https://www.corning.com/" target="_blank" rel=" noopener"><img fetchpriority="high" decoding="async" width="300" height="300" src="https://www.genengnews.com/wp-content/uploads/2023/11/Corning_Logo.jpg" alt="Corning Logo" class="wp-image-277211" srcset="https://www.genengnews.com/wp-content/uploads/2023/11/Corning_Logo.jpg 300w, https://www.genengnews.com/wp-content/uploads/2023/11/Corning_Logo-150x150.jpg 150w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/the-organoid-odyssey-a-glimpse-into-the-past-present-and-future-of-hpsc-derived-3d-models/">The Organoid Odyssey: A Glimpse Into the Past, Present, and Future of hPSC-Derived 3D Models</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Raman+NIR Spectra Improves Glucose Soft Sensing</title>
<link>https://edusehat.com/en/ramannir-spectra-improves-glucose-soft-sensing</link>
<guid>https://edusehat.com/en/ramannir-spectra-improves-glucose-soft-sensing</guid>
<description><![CDATA[ Combining Raman and NIR spectroscopy into a single framework creates a multi-modal soft-sensing option that is effective for fed-batch, online, and in-line glucose sensing, preparing the way for hybrid/continuous processing.  
The post Raman+NIR Spectra Improves Glucose Soft Sensing appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2020/08/Aug7_2020_Getty_626533919_FemaleScientistUsingFTIRSpectrophotometer-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>RamanNIR, Spectra, Improves, Glucose, Soft, Sensing</media:keywords>
<content:encoded><![CDATA[<p>Accurate glucose monitoring has been a bottleneck in fed-batch fermentation for years, and is especially critical as biopharmaceutical manufacturers transition toward hybrid and continuous bioprocessing for advanced therapeutics.</p>
<p>Fusing Raman and near-infrared (NIR) spectroscopy into a multimodal soft-sensing framework appears, however, to remove that bottleneck. This new framework provides high-frequency, low-latency measurements that aren’t typically available with existing commercial, off-line sensors. Its developers say it provides “accurate, online-compatible glucose soft sensing,” and that it is also amenable for in-line applications.</p>
<p>More specifically, Raman spectroscopy offers crisp, highly specific chemical fingerprints, while NIR offers broad, information-laden spectral coverage. Realizing this, a team including senior authors Xiwei Tian, DEng, of East China University of Science and Technology in Shanghai and Yinlan Ruan, PhD, of Guilin University of Electronic Technology, encoded each modality separately and then merged them using dual-stream, cross-attention transformer architecture (DS-CAT).</p>
<p>The team tested their system using 142 preprocessed, synchronized Raman-NIR records.</p>
<p>Writing in <em>Bioprocess and Biosystems Engineering</em>, they <a href="https://link.springer.com/article/10.1007/s00449-026-03437-0" target="_blank" rel="noopener">report</a> that their model explained 99% of the variation in true glucose concentration. Anything above 95% is considered good. Likewise, the root mean square error of 1.09 g/L was well within the level needed to ensure effective feed control. Furthermore, the mean absolute error of 0.89 g/L achieved by this model suggests it is consistently accurate. Such consistency is particularly important for real-time processing controls, where outliers could negatively affect feeding strategies. Results remained similar throughout five-fold validation, the scientists report.</p>
<p>Additionally, “Prediction-based perturbation…revealed strong dependence on Raman information, while Raman-block sensitivity analysis identified 1122−1335 cm<sup>-1 </sup>[which is associated with carbohydrate vibrational modes] as the interval showing the strongest prediction sensitivity,” Tien, Ruan, and colleagues point out. Those findings are comparable to other literature reports, while demonstrating the enhanced sensitivity, reduced noise, and reduced drift of this new framework.</p>
<p>Notably, the researchers note that the DS-CAT framework “outperform[ed] partial least squares regression, gradient boosting regression trees, convolutional neural networks, and temporal convolutional networks under the same evaluation protocol.” By performing better than these four industry-standard modeling approaches, DS-CAT has the potential to substantially improve soft-sensor capabilities for real-time glucose monitoring.</p>
<p>These findings suggest the DS-CAT approach to glucose sensing may enable reliable insights that lead to better control of a critical parameter in closed-loop mammalian and microbial fermentation. If so, the high-frequency and low-latency data measurements this method delivers may become a key element in a rational transition from fed-batch fermentation toward continuous manufacturing.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/ramannir-spectra-improves-glucose-soft-sensing/">Raman+NIR Spectra Improves Glucose Soft Sensing</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Patients Should Be Considered When Choosing a Vector Production Method</title>
<link>https://edusehat.com/en/patients-should-be-considered-when-choosing-a-vector-production-method</link>
<guid>https://edusehat.com/en/patients-should-be-considered-when-choosing-a-vector-production-method</guid>
<description><![CDATA[ Vector production costs have a disproportionate influence on gene therapy prices, according to researchers who say that, given this, choosing the vector manufacturing method that best suits the intended use of the product is vital.
The post Patients Should Be Considered When Choosing a Vector Production Method appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/05/Getty_1211253347_AsepticVirusLab-scaled-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Patients, Should, Considered, When, Choosing, Vector, Production, Method</media:keywords>
<content:encoded><![CDATA[<p>Viral vector production costs have a disproportionate influence on gene therapy prices, so choosing the virus manufacturing method that fits the product and its intended patient population is critical.</p>
<p>That is the view of researchers at Thermo Fisher Scientific, who examined the economics of gene therapy production in a <a href="https://www.nature.com/articles/s41434-026-00631-3#Sec21" target="_blank" rel="noopener">study</a> and concluded that choosing the right vector manufacturing platform is challenging.</p>
<p>“Optimal platform choice depends on indication prevalence, dose requirements, desired serotype flexibility, development timelines, and willingness to invest in process intensification,” study author Seyed Pouria Motevalian, PhD, writes.</p>
<p>Motevalian and co-authors compared three recombinant adeno-associated virus (rAAV) manufacturing methods—transient transfection, producer cell line approaches (PCLs), and baculovirus-based production—and found that the cost drivers for each differ markedly.</p>
<p>“On a per-batch basis, baculovirus infection is the most cost-efficient platform, followed by transient transfection and PCLs. However, when costs are normalized to vector titer, the ranking shifts, with transient transfection becoming the lowest-cost platform.</p>
<p>“Each platform has a distinct economic fingerprint: transient transfection is dominated by plasmids, transfection reagent, media, and endonuclease; PCL perfusion processes are driven by media and perfusion-related single-use hardware; and the baculovirus platform shifts a greater share of cost into downstream operations, particularly affinity capture,” Motevalian says.</p>
<h4><strong>Patient focus</strong></h4>
<p>With all this in mind, Motevalian and co-authors argue that, rather than focusing on material and reagent costs, developers must also factor in the needs of the target patient population when choosing how to produce viral vectors.</p>
<p>“Our analyses suggest there is no universally ‘best’ rAAV platform. Optimal platform choice depends on indication prevalence, dose requirements, desired serotype flexibility, development timelines, and willingness to invest in process intensification,” they say.</p>
<p>For example, for products intended for smaller populations, transient transfection, in which vector genes are introduced into producer cell lines, may be the best approach, despite the high cost of the DNA plasmids required.</p>
<p>In contrast, for mass market gene therapies, baculovirus infection or PCL-based vector manufacturing methods are a more cost-effective option, particularly in combination with optimized upstream and downstream processes.</p>
<p>Understanding these dynamics is critical for developers, according to the authors, who say gene therapy firms must factor them into process development as early as possible.</p>
<p>“Integrating quantitative cost modeling into platform selection and process development decisions early in program design will be essential for making rAAV therapies economically sustainable and expanding global patient access,” they say.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/patients-should-be-considered-when-choosing-a-vector-production-method/">Patients Should Be Considered When Choosing a Vector Production Method</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>iPSC Manufacturing Starts with the Source</title>
<link>https://edusehat.com/en/ipsc-manufacturing-starts-with-the-source</link>
<guid>https://edusehat.com/en/ipsc-manufacturing-starts-with-the-source</guid>
<description><![CDATA[ For iPSC developers, scalable manufacturing begins long before the bioreactor. Pluristyx leaders explain why starting material, process discipline, automation, and shared data will help therapies reach patients reliably and affordably.
The post iPSC Manufacturing Starts with the Source appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Mike-iPSCs_GBPN_IMAGE_15OCT26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>iPSC, Manufacturing, Starts, with, the, Source</media:keywords>
<content:encoded><![CDATA[<p>For developers of induced pluripotent stem cells (iPSCs), the path to commercial-scale manufacturing can be derailed long before cells reach a production bioreactor. According to two leaders at Pluristyx, one of the field’s most persistent problems is surprisingly basic: many programs begin with cell lines that were never intended for clinical manufacturing.</p>
<p>“It is difficult to find the right cell line,” said Benjamin Fryer, PhD, CEO and cofounder of Pluristyx. Researchers often build promising processes around readily available lines, only to discover later that the material lacks the provenance, consent, or good manufacturing practice (GMP) pedigree needed for human use. By then, Fryer said, teams may have invested years in process development, animal studies, and publications—only to restart with a new line.</p>
<p>Clinical readiness also depends on whether donor consents support the intended use, said Priya Baraniak, PhD, chief commercial and development officer at Pluristyx. Beyond that, developers face the familiar manufacturing demands of robustness, reproducibility, and scale at a cost that is “clinically and commercially feasible,” she noted.</p>
<p>That makes the choice of starting material a bioprocessing decision, not merely a research decision. As developers move from milliliter-scale work toward liters or tens to hundreds of liters, Fryer said, “the manufacturing process has to be somewhat similar.” Passage number and population doublings should be controlled so cells at small and large scale are effectively the same biological age. Production format matters, too. “You need to make sure that the cells are available in the process format you’re going to use,” Fryer said. A therapy intended for suspension culture, for example, should move toward suspension early rather than undergo a disruptive conversion late in development.</p>
<p>Baraniak put the principle simply: “Standardizing your input is really important.” Even high-quality cells can introduce variability if their passage history, characterization, or biological state changes from run to run.</p>
<p>That issue is especially important for iPSCs because their expansion potential can create a false sense of security. “We often fall into a false narrative that these cells can be expanded forever and they’re an evergreen source,” Baraniak said. “They accumulate genetic mutations and aberrations as you expand them,” potentially leaving developers with a process built around cells that no longer behave as intended.</p>
<p>The challenge extends beyond raw material into process design. Baraniak said cell manufacturing still relies too heavily on “golden hands”—highly skilled operators whose tacit knowledge can be difficult to reproduce across people, sites, and scales. “You can’t rely on just golden hands,” she said. Processes must instead be engineered to minimize operator-dependent decisions and tolerate normal manufacturing variation.</p>
<p>That transition also changes the role of automation. Fryer cautioned that simply replacing a human hand with a robotic one does not solve a poorly understood process. Manufacturers first need to understand why cells respond to particular media, handling steps, environmental conditions, and culture parameters. That mechanistic knowledge can guide smarter automation, closed systems, and process analytics rather than locking fragile procedures into hardware.</p>
<p>The same manufacturing discipline could expand the usefulness of iPSCs in new approach methodologies (NAMs), including drug screening, toxicology, disease modeling, and engineered tissues. Unlike limited primary tissues, well-controlled iPSC banks can provide renewable human material representing different donors, disease states, and genetically engineered variants. But those models only become useful at industrial scale if they can be manufactured, distributed, and reproduced consistently.</p>
<p>For Baraniak, that need for reproducibility reflects how far the field has come. “We’ve moved past the point of proving that these therapies have viability, that iPSCs work,” she said. “So now it’s how do we make them work over and over and over.”</p>
<p>That shift—from demonstrating biological possibility to engineering repeatable manufacturing—might define the next phase of iPSC commercialization. Better starting materials, deeper process understanding, automation, and more open sharing of manufacturing experience will not eliminate biological complexity. But they could keep that complexity from becoming the bottleneck that prevents promising iPSC technologies from reaching patients.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/ipsc-manufacturing-starts-with-the-source/">iPSC Manufacturing Starts with the Source</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Researchers Validate Buoyant Mass for Cell Health Testing</title>
<link>https://edusehat.com/en/researchers-validate-buoyant-mass-for-cell-health-testing</link>
<guid>https://edusehat.com/en/researchers-validate-buoyant-mass-for-cell-health-testing</guid>
<description><![CDATA[ Scientists have used measurement of buoyant mass by suspended microchannel resonator (SMR) technology to assess the immune fitness of T cells and predict patient response to immune checkpoint blockade (ICB).
The post Researchers Validate Buoyant Mass for Cell Health Testing appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2279568676-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Researchers, Validate, Buoyant, Mass, for, Cell, Health, Testing</media:keywords>
<content:encoded><![CDATA[<p>U.S. scientists have shown that measuring the buoyant mass of T cells can help predict patient response to immune checkpoint blockade (ICB) immunotherapy.</p>
<p>The team from the Massachusetts Institute of Technology (MIT) showed that measuring the buoyant mass of T cells predicted patient response more accurately than a traditional tumor mutational burden (TMB) approach.</p>
<p>According to the researchers, the new technique could be used not only to predict cancer cell sensitivity to treatment, but also to address the productivity of cell cultures used in gene therapy manufacturing.</p>
<p>“We’ve wanted to show people this is a new physical marker that predicts the fate of the T cells,” explains Jiaquan Yu, PhD, a research scientist working in microfluidic engineering and cancer immunology at MIT.</p>
<p>“By fate, we mean we measure the naïve state of the T cells and get an indication of how they will behave after activation.”</p>
<p>The team used suspended microchannel resonator (SMR) technology, a specialized instrument that uses a vibrating sensor containing a microfluidic channel to measure buoyant mass, Yu says.</p>
<p>The buoyant mass of the T cells is measured relative to water and from the buoyant mass, they were able to calculate the immune fitness of the cells, Yu continues. And, thus, whether they were likely to activate to fight cancer as part of treatment with ICB immunotherapy.</p>
<p>“For T cells, being in the heavier group suggests you’re better equipped to produce proteins,” Yu says. “And that capacity gives us an indication of the fitness of the cells and their ability to respond after activation.”</p>
<p>The team was able to test the performance of the technique in a clinical study of 28 patients with melanoma receiving ICB, Yu explains. And, in that study, they were able to prove that measuring buoyant mass was more effective than TMB at predicting treatment response.</p>
<p>“People are underestimating simple non-molecular signatures, such as mass, volume, and density, as we’re all focused on biomarkers focused on genes and RNA,” Yu says.</p>
<p>“What we’re showing here is that mass gives a result that integrates a lot of information.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/researchers-validate-buoyant-mass-for-cell-health-testing/">Researchers Validate Buoyant Mass for Cell Health Testing</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Using AI Agents and Bio&#45;Foundation Models to Automate Vector Design for Cell Line Development</title>
<link>https://edusehat.com/en/using-ai-agents-and-bio-foundation-models-to-automate-vector-design-for-cell-line-development</link>
<guid>https://edusehat.com/en/using-ai-agents-and-bio-foundation-models-to-automate-vector-design-for-cell-line-development</guid>
<description><![CDATA[ In this GEN webinar, Asimov’s VP of Business Development and Commercial Strategy Jamie Freeman, PhD, will show how Asimov combines bio-foundation models, AI agents, and synthetic biology to tailor expression vector design for each molecule. 
The post Using AI Agents and Bio-Foundation Models to Automate Vector Design for Cell Line Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/09/GettyImages-1150965935-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Using, Agents, and, Bio-Foundation, Models, Automate, Vector, Design, for, Cell, Line, Development</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/JamieFreeman_headshot.jpg" class="h-full w-full object-cover" alt="Image of Jamie Freeman, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Jamie Freeman, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">VP of Business Development and Commercial Strategy<br>Asimov</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/JamieFreeman_headshot.jpg" alt="Image of Jamie Freeman, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Jamie Freeman, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Jamie Freeman, PhD, is VP of Business Development and Commercial Strategy at Asimov, where he works with partners to improve the design and manufacturing of novel biological therapeutics. Prior to joining Asimov, Jamie was responsible for the development and initial commercialization of Horizon Discovery’s CHO Source platform. Jamie earned a PhD in cell and molecular biology from Cardiff University, followed by a postdoc at the MRC Laboratory of Molecular Cell Biology.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Thursday, November 12, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-11-12T19:00:00.000Z">11:00 PST, 14:00 EST, 19:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">Protein foundation models have transformed binder design, but turning those binders into drugs remains an empirical, trial-and-error process. Lead optimization, cell line development, and process development each still rely on screening large numbers of candidates, clones, or conditions, with little ability to predict which will succeed.  As pipelines shift toward bispecifics and other complex formats, that approach is getting harder to sustain.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, Asimov’s VP of Business Development and Commercial Strategy Jamie Freeman, PhD, will show how Asimov combines bio-foundation models, AI agents, and synthetic biology to tailor expression vector design for each molecule. He will highlight how scientists use Kernel, Asimov’s computer-aided genetic design software, to automate the design of optimized expression vectors, and how AI agents can take on custom genetic designs for uncommon requirements. </p>


<p class="wp-block-paragraph">Through a series of case studies, he will also share how AI-designed vectors outperformed Asimov’s own previous best designs, how rapid stable pool data changed which multispecific lead a partner advanced, and how a model predicted chain ratios to improve correct pairing without reducing titer. Key takeaways from the webinar include:</p>


<ul class="wp-block-list">
<li>How exploring genetic design space, rather than relying on off-the-shelf vectors, can improve titer and product quality for both standard and complex formats</li>



<li>How AI models trained on measurements from inside the cell can learn the mechanisms of expression and apply them to design better expression vectors</li>



<li>How model-guided workflows and stable pools bring better-informed decisions to vector design and lead selection</li>
</ul>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelist.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://www.asimov.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="53" src="https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo-300x53.jpg" alt="asimov logo" class="wp-image-216608" srcset="https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo-300x53.jpg 300w, https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo-1024x181.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo-768x136.jpg 768w, https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo-696x123.jpg 696w, https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo-1392x248.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo-1068x189.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/using-ai-agents-and-bio-foundation-models-to-automate-vector-design-for-cell-line-development/">Using AI Agents and Bio-Foundation Models to Automate Vector Design for Cell Line Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bridging the Translational Gap in Pancreatic Cancer Through Biology&#45;First Modeling</title>
<link>https://edusehat.com/en/bridging-the-translational-gap-in-pancreatic-cancer-through-biology-first-modeling</link>
<guid>https://edusehat.com/en/bridging-the-translational-gap-in-pancreatic-cancer-through-biology-first-modeling</guid>
<description><![CDATA[ In this GEN webinar, our expert speaker Josh Wheeler, MD, PhD, will discuss a biology-first, interpretable AI approach to understand patient tumor states and next-generation preclinical models that reproduce their biological complexity.
The post Bridging the Translational Gap in Pancreatic Cancer Through Biology-First Modeling appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Getty_2190808113_PancreaticCancerCells.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bridging, the, Translational, Gap, Pancreatic, Cancer, Through, Biology-First, Modeling</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/Josh_Wheeler_headshot_2000px-e1792604937405.jpg" class="h-full w-full object-cover" alt="Image of Josh Wheeler, MD, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Josh Wheeler, MD, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Vice President, Research and Development<br>Genialis</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/Josh_Wheeler_headshot_2000px-e1792604937405.jpg" alt="Image of Josh Wheeler, MD, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Josh Wheeler, MD, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Josh Wheeler, MD, PhD, is the vice president of Research and Development at Genialis with more than 15 years of experience spanning academic research, computational biology, and biotechnology. His work sits at the intersection of clinical development, translational medicine, AI and machine learning, diagnostics, and precision oncology. At Genialis, he leads clinical and research innovation strategy, biomarker and diagnostic development, clinical trial assay and regulatory strategy, and biopharma partnerships. Josh previously trained and practiced at Stanford across anatomic pathology, neuropathology, molecular diagnostics, and computational biology. He earned his MD from the University of Colorado Anschutz Medical Campus through the NIH-funded Medical Scientist Training Program and his PhD in biochemistry from the University of Colorado Boulder.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/Matthieu-Spriet.jpg" class="h-full w-full object-cover" alt="Image of Matthieu Spriet, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Matthieu Spriet, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Technical Specialist<br>Inventia Life Science</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/Matthieu-Spriet.jpg" alt="Image of Matthieu Spriet, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Matthieu Spriet, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Matthieu Spriet, PhD, is a technical sales specialist at Inventia Life Science with expertise in 3D biology, biochemistry, cell signaling, oncology, and assay development. He earned his PhD in biochemistry and molecular biology from the University of Nebraska Medical Center. His thesis focused on profiling and understanding RNA expression in cholangiocarcinoma.</p>
<p>After graduating, Matthieu spent many years working in early-stage drug discovery, developing cell-based assays across multiple disease models, including oncology, immunology, cardiology, hepatology, and regenerative medicine. Matthieu is passionate about scientific communication and collaboration, with a focus on advancing biomedical research through advanced 3D cell models and drug discovery innovation.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Wednesday, November 18, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-11-18T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">Pancreatic cancer is experiencing a renaissance in therapeutic options and improvements in patient outcomes. Accelerating therapeutic advances demands a more robust translational pipeline linking patient biology to preclinical model systems. The tumor microenvironment shapes both prognosis and therapeutic vulnerabilities, making its representation in preclinical models critical for translation.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, our expert speaker Josh Wheeler, MD, PhD, will discuss a biology-first, interpretable AI approach to understand patient tumor states and next-generation preclinical models that reproduce their biological complexity. During the webinar, he will present Genialis Supermodel, an interpretable AI foundation model that translates tumor RNA-seq into biological states that can be compared across patients, experimental models, and Inventia’s RASTRUM platform, which enables bioprinted PDAC models with increasing microenvironmental complexity through the addition of cancer-associated fibroblasts (CAFs) and T cells.</p>


<p class="wp-block-paragraph">Using pancreatic cancer as a case study, he will demonstrate how increasing microenvironmental complexity moved the bioprinted models toward distinct biological states observed in patients. You will learn how CAFs drove EMT and TGF-beta/SMAD activity with loss of classical epithelial identity, while adding immune cells produced inflammatory and interferon programs. These changes also exposed therapeutic biology not apparent in monoculture, including altered RAS/MAPK, EGFR, beta-catenin, and YAP/TEAD signaling. Key takeaways include:</p>


<ul class="wp-block-list">
<li>How technologies from Genialis and Inventia provide a framework to connect patient tumor biology with experimentally tractable model systems</li>



<li>How patient-centered models generate therapeutic hypotheses that monoculture may miss</li>
</ul>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://inventialifescience.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="82" src="https://www.genengnews.com/wp-content/uploads/2026/10/Inventia-Life-Science_Logo_HighRes_Pink-300x82.png" alt="Inventia Life Science Logo" class="wp-image-339662" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Inventia-Life-Science_Logo_HighRes_Pink-300x82.png 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Inventia-Life-Science_Logo_HighRes_Pink-1024x279.png 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Inventia-Life-Science_Logo_HighRes_Pink-768x210.png 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Inventia-Life-Science_Logo_HighRes_Pink-1536x419.png 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/Inventia-Life-Science_Logo_HighRes_Pink-2048x559.png 2048w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/bridging-the-translational-gap-in-pancreatic-cancer-through-biology-first-modeling/">Bridging the Translational Gap in Pancreatic Cancer Through Biology-First Modeling</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ASHG: Signals Based on Clinical Obesity Show Stronger Links to Cardiovascular Health than Those Linked to BMI</title>
<link>https://edusehat.com/en/ashg-signals-based-on-clinical-obesity-show-stronger-links-to-cardiovascular-health-than-those-linked-to-bmi</link>
<guid>https://edusehat.com/en/ashg-signals-based-on-clinical-obesity-show-stronger-links-to-cardiovascular-health-than-those-linked-to-bmi</guid>
<description><![CDATA[ Researchers also developed a clinical obesity polygenic score that combined information from numerous genetic variants, a score that was shown to be significantly associated with BMI, body fat percentage, and waist circumference. 
The post ASHG: Signals Based on Clinical Obesity Show Stronger Links to Cardiovascular Health than Those Linked to BMI appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2158974218.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ASHG:, Signals, Based, Clinical, Obesity, Show, Stronger, Links, Cardiovascular, Health, than, Those, Linked, BMI</media:keywords>
<content:encoded><![CDATA[<p>Conducting the first genome-wide association study and analysis based on a new definition of clinical obesity, a research team has identified genetic signals that differed substantially from those associated with body mass index (BMI)—yet showed stronger connections to cardiovascular health.</p>
<p>The researchers—nine from Johns Hopkins University, one from The Ohio State University—analyzed 151,642 people with clinical obesity and 128,874 controls without obesity spanning five ancestry groups, using data from the UK Biobank and <em>All of Us</em> Research Program. The biobank says it possesses the world’s most comprehensive dataset of biological health and lifestyle data gathered from a half million participants, while <em>All of Us</em> is the NIH initiative designed to advance precision medicine by collecting and study data from 1 million or more people living in the United States.</p>
<p>Researchers identified 127 independent genetic loci associated with clinical obesity. Of these, 63 had no significant association with BMI. The most discordant variant, researchers reported, was rs15285, a single-nucleotide polymorphism (SNP) located within the 3′-untranslated region (3′UTR) of the <em>LPL</em> gene that encodes lipoprotein lipase. That variant was colocalized to expression quantitative trait loci (eQTLs) for lipoprotein lipase, and associated with elevated triglyceride levels.</p>
<p>The team also developed a clinical obesity polygenic score that combined information from numerous genetic variants, a score that was shown to be significantly associated with BMI, body fat percentage, and waist circumference. Compared to a BMI polygenic score, the clinical obesity polygenic score developed by the researchers showed improved association with cardiovascular risk factors and proteomic markers of inflammation—such as interleukin-6, fibroblast growth factor 21, and hepatic growth factor—as well as markers of insulin resistance, including adiponectin, resistin, leptin, and leptin receptor.</p>
<p>The clinical obesity polygenic score improved risk discrimination over a BMI polygenic score for myocardial infarction (heart attack), heart failure, and stroke, the research team added.</p>
<p>Researchers then validated the improvement across four additional long-running U.S. public health studies:</p>
<ul>
<li><strong>Atherosclerosis Risk in Communities (ARIC)</strong>, a study of the NIH’s National Heart, Lung, and Blood Institute whose focus has widened from identifying risk factors for subclinical atherosclerosis to risk factors for heart diseases including heart attack, coronary heart disease, stroke, and heart failure. About 16,000 U.S. adults have been enrolled.</li>
<li><strong>Multi-Ethnic Study of Atherosclerosis (MESA)</strong>, an NHLBI-sponsored study of the characteristics of subclinical cardiovascular disease and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA enrolled 6,814 adults during its baseline period between 2000-2002.</li>
<li><strong>Framingham Heart Study</strong>, under NHLBI direction, was launched in 1948 to identify common factors or characteristics that contribute to cardiovascular disease. Since 1971, the Boston University School of Medicine has served as NHLBI’s contractor and academic partner for the study. More than 15,400 across multiple cohorts have been enrolled.</li>
<li><strong>Women’s Health Initiative</strong>, which first won funding in 1992 and is also NHLBI-sponsored, focuses on strategies for preventing heart disease, breast and colorectal cancer, and osteoporosis in postmenopausal women. 161,808 women have been enrolled.</li>
</ul>
<h4><strong>‘Biologically and clinically relevant’</strong></h4>
<p>“These findings demonstrate that clinical obesity captures genetic loci distinct from BMI that are biologically and clinically relevant to cardiovascular health,” the researchers concluded.</p>
<p>Findings were reported in “<a href="https://content-cdn.sessionboard.com/content/ir9aMTzTJWbLVh1FTe9F_SohailZahid_ASHG2026_poster.pdf" target="_blank" rel="noopener">Genome-wide analysis and polygenic prediction of clinical obesity</a>,” a poster study presented during the American Society of Human Genetics (ASHG) 2026 Annual Meeting, held October 20-24 in Montreal. Co-corresponding authors were Sohail Zahid, MD, PhD, an investigator at the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease; and Alexis Battle, PhD, director of the Malone Center for Engineering in Healthcare and director of the Research, Strategy, and Partnerships, Data Science and Artificial Intelligence Institute at Johns Hopkins.</p>
<p>The research team posted a <a href="https://www.medrxiv.org/content/10.64898/2026.05.20.26353665v1" target="_blank" rel="noopener">preprint version of their study on medRxiv</a> on May 22.</p>
<p>“Stratifying individuals into low, intermediate, and high inherited obesity risk groups, we found that clinical obesity polygenic risk reclassified 35% of individuals compared to BMI polygenic risk,” researchers reported in the preprint. “Unlike rare variant panel testing which already guides targeted therapy in monogenic obesity, further work is needed to determine the incremental benefit of clinical obesity polygenic scores for diagnosis, risk stratification, or management beyond BMI-based assessment.”</p>
<p>The new clinical obesity definition used by researchers was <a href="https://www.thelancet.com/commissions-do/clinical-obesity" target="_blank" rel="noopener">introduced last year by <em>The Lancet</em> Diabetes & Endocrinology Commission</a>.  The 58-member Commission set out to establish objective criteria for disease diagnosis, aid clinical decision making, and prioritize therapeutic interventions and public health strategies, by characterizing excess body fat and dysfunctional adiposity beyond BMI.</p>
<p>“We recommend that BMI should be used only as a surrogate measure of health risk at a population level, for epidemiological studies, or for screening purposes, rather than as an individual measure of health,” the Commission stated last year. “Excess adiposity should be confirmed by either direct measurement of body fat, where available, or at least one anthropometric criterion (e.g., waist circumference, waist-to-hip ratio, or waist-to-height ratio) in addition to BMI, using validated methods and cutoff points appropriate to age, gender, and ethnicity.”</p>
<p>In people with very high BMI (i.e., >40 kg/m<sup>2</sup>), the Commission continued, excess adiposity can pragmatically be assumed without further confirmation: “We also recommend that people with confirmed obesity status (i.e., excess adiposity with or without abnormal organ or tissue function) should be assessed for clinical obesity.”</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/ashg-signals-based-on-clinical-obesity-show-stronger-links-to-cardiovascular-health-than-those-linked-to-bmi/">ASHG: Signals Based on Clinical Obesity Show Stronger Links to Cardiovascular Health than Those Linked to BMI</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BCG Vaccine&#45;Induced Trained Immunity May Help Protect Against Dementia</title>
<link>https://edusehat.com/en/bcg-vaccine-induced-trained-immunity-may-help-protect-against-dementia</link>
<guid>https://edusehat.com/en/bcg-vaccine-induced-trained-immunity-may-help-protect-against-dementia</guid>
<description><![CDATA[ The results of a preclinical study suggest that the BCG vaccine, which is widely used to prevent tuberculosis and treat bladder cancer, may also have properties that reduce the risk for dementia by inducing trained immunity.
The post BCG Vaccine-Induced Trained Immunity May Help Protect Against Dementia appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/02/GettyImages-1440168032-e1707342315623.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BCG, Vaccine-Induced, Trained, Immunity, May, Help, Protect, Against, Dementia</media:keywords>
<content:encoded><![CDATA[<p>The results of a preclinical study headed by researchers at Johns Hopkins University School of Medicine suggest that the Bacillus Calmette-Guerin (BCG) vaccine, which is widely used to prevent tuberculosis and treat bladder cancer, may also have properties that reduce the risk for dementia. BCG is a live, weakened vaccine made from an altered strain of the bacterium <em>Mycobacterium bovis</em>.</p>
<p>The team found that in mice genetically engineered to develop biological symptoms of dementia (PS19 mice), those animals that received the BCG vaccine were less likely to show hallmark signs of the disease, such as neurofibrillary (tau) tangles (NFTs) in the brain, sustained immune cell activation, and memory loss compared to mice that received no vaccine. BCG-treated mice performed better in a novel object recognition test, and showed improved maintenance of body-weight and survival.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Research lead William Bishai, MD, PhD, co-director of the Johns Hopkins Center for Tuberculosis Research, believes that myeloid cells in the central nervous system and brain are using information from BCG to recognize and help the body respond to the formation of plaques and tangles characteristic of Alzheimer’s disease and related dementias. Bishai said, “We’re hard at work trying to understand the detailed mechanism for how it works, but this research points to early clues that aspects of trained immunity are likely driving this response.”</p>
<p>Trained immunity refers to the ability, in mammals, of innate immune system cells to take on an expanded role. Following an initial stimulus, innate immune cells, including monocytes and macrophages, may learn how to identify and respond to future threats that are different from the first. Typically, other immune system cells, such as T cells, take on this type of adaptive and learned response.</p>
<p>Bishai is senior and corresponding author of the team’s published paper in <em>Science Advances</em>, titled “<a href="https://doi.org/10.1126/sciadv.aej4603" target="_blank" rel="noopener">BCG vaccination mitigates tau pathology and restores cognitive functions in PS19 mice</a>,” in which the authors concluded “Our study strongly suggests that dementia protection by BCG is a credible observation that merits future basic research and large-scale prospective clinical trials to provide definitive answers.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Observational studies in humans—those not designed to show cause and effect—have linked off-target effects of vaccines to a reduced incidence of dementia. “There is a growing appreciation that vaccines may have beneficial off-target effects such as reducing the risk of dementia,” the authors wrote. The shingles vaccine has been <a href="https://www.nature.com/articles/s41586-025-08800-x" target="_blank" rel="noopener">linked</a> to a 20% reduced incidence of dementia, while several previous studies cited by the researchers found that BCG used as an immunotherapy for non-muscle invasive bladder cancer was linked to a 12% to 78% reduced risk of dementia throughout a three- to 15-year period.</p>
<p>“While less publicized, there is also considerable evidence that Bacille Calmette-Guérin or BCG, the live attenuated vaccine to prevent tuberculosis (TB) and treat bladder cancer, may also have dementia-preventive properties,” the team continued.</p>
<p>It’s been postulated that trained immunity is a mechanism by which BCG could protect against dementia, they noted. “Upon exposure to a first antigen such as BCG, innate immune cells, typically myeloid cells, have been shown to undergo epigenetic and metabolomic reprogramming such that upon exposure to a second, unrelated antigen, their immune response is greater than it was to the first,” they explained.</p>
<p>To test directly whether BCG could represent a preventive therapy for Alzheimer’s disease, the team turned to the PS19 (P301S) mouse model, which develops symptoms of dementia, specifically marked by tau pathology or a clumping of tau proteins in the brain representing late stages of the disease. ‘The overexpression of P301S tau is associated with AD-relevant pathological and functional features, including neuronal loss, microgliosis, neurofibrillary tangles (NFT) deposition, and cognitive impairment,” they wrote.</p>
<p>The team divided mice into cohorts that received the BCG vaccine and those that received a saline injection. An additional comparison group included age-matched mice that did not have dementia and that also received the saline injection. Mice in the BCG treatment group received the vaccine at three months of age. Multiple assessments, based on brain imaging, memory recall (through an object recognition test) and indicators of disease, including neuroinflammation and the expression of genes linked to Alzheimer’s disease, were conducted eight to nine months later.</p>
<p>The researchers found that those mice that received BCG were about five times more likely to have signs of reduced tau deposits in their brain. They were also four times less likely to have markers of sustained inflammation, signaling that their immune cells had already likely responded to tau by clearing out some of the tangles, and had created a stable or protective immune response.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The untreated mice showed activation of 716 genes connected to Alzheimer’s disease, cell death, and neuroinflammation. BCG administration normalized all but nine of these. Compared to untreated mice, the mice who received BCG were less likely to have signs of brain atrophy and also more likely to live longer and perform better on tasks related to remembering and identifying objects.</p>
<p>“BCG seems to be reducing the degree of hyperinflammation in the brain—which is a good thing—and it may be doing it through a trained immune cell mechanism,” said Bishai. “There are a number of other characteristics of trained immunity that we are studying in the lab now.”</p>
<p>In their paper the team wrote in summary, “We found that early BCG administration starting at three months of age reduced brain atrophy, p-tau levels, and neuronal loss measured at the later time point of eight to nine months. Simultaneously, BCG therapy restored glutamate levels <em>in vivo</em> and improved recognition-memory performance, body weight, and survival of PS19 mice, suggesting key disease modifying effects.”</p>
<p>This research, Bishai says, is believed to be the first to study BCG and dementia in mouse models with tau pathology (specifically showing how immune cells may play a role in clearing neurofibrillary tangles). “Mechanistically, our study identified BCG-induced trained immunity properties as playing key roles in the clearance of tau NFTs,” they stated. Others have found similar findings with BCG and improved cognition in amyloid mouse models—which represent earlier stages of the disease marked by plaque formation.</p>
<p>“This is a great example of translational science working in reverse—starting with an intriguing observation in people and then going back to the laboratory to understand why it might be happening,” commented co-author Barbara Slusher, PhD, professor of neurology at the Johns Hopkins University School of Medicine and director of the Johns Hopkins Drug Discovery program.</p>
<p>Slusher cautions that researchers still need to understand more of the underlying biology before they can say who might benefit, when treatment would need to be given and whether the effect can be safely reproduced in people at risk for dementia. “If we can identify the specific immune changes that are protective, we may be able to develop even more targeted approaches for the prevention of Alzheimer’s disease.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/bcg-vaccine-induced-trained-immunity-may-help-protect-against-dementia/">BCG Vaccine-Induced Trained Immunity May Help Protect Against Dementia</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Canada’s nursing workforce grows, but shortages and wage pressures persist</title>
<link>https://edusehat.com/en/canadas-nursing-workforce-grows-but-shortages-and-wage-pressures-persist</link>
<guid>https://edusehat.com/en/canadas-nursing-workforce-grows-but-shortages-and-wage-pressures-persist</guid>
<description><![CDATA[ New Statistics Canada figures show registered nursing employment has increased by more than 100,000 since 2019, while vacancies remain elevated and inflation-adjusted wages have barely improved. Canada’s nursing workforce has grown significantly since the COVID-19 pandemic, but persistent staffing shortages and limited wage growth continue to challenge the healthcare system, according to a new Statistics […]
The post Canada’s nursing workforce grows, but shortages and wage pressures persist appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Nurse-Caring-for-Patient-in-ICU.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Canada’s, nursing, workforce, grows, but, shortages, and, wage, pressures, persist</media:keywords>
<content:encoded><![CDATA[<p>New Statistics Canada figures show registered nursing employment has increased by more than 100,000 since 2019, while vacancies remain elevated and inflation-adjusted wages have barely improved.</p>
<p>Canada’s nursing workforce has grown significantly since the COVID-19 pandemic, but persistent staffing shortages and limited wage growth continue to challenge the healthcare system, according to a new Statistics Canada report released October 19.</p>
<p>The report, Canada’s Health Workforce: An integrated summary based on Statistics Canada data, 2025, found that employment in registered nursing occupations increased by 33.3%, or 102,800 positions, between 2019 and 2025.</p>
<p>Registered nursing occupations, which include registered nurses, registered psychiatric nurses and nurse practitioners, experienced the largest employment increase among the health occupations examined over that period.</p>
<p>In 2025 alone, registered nursing employment grew by 25,300 positions, an increase of 6.5% from the previous year.</p>
<p>Despite these gains, the findings reveal an uneven recovery across nursing professions, with ongoing recruitment pressures and wages that have struggled to keep pace with inflation.</p>
<h2>Practical nursing shortages remain a concern</h2>
<p>One of the report’s most significant findings involves licensed practical nurses (LPNs).</p>
<p>While registered nursing employment expanded considerably, the number of employed licensed practical nurses showed no net growth between 2019 and 2025.</p>
<p>At the same time, the vacancy rate for licensed practical nurses remained at 12.3% in 2025, nearly five times the 2.5% rate recorded in 2016.</p>
<p>Although the rate has declined from its 2023 peak of 18.7%, it remains substantially higher than the national average across all occupations.</p>
<p>Registered nursing occupations recorded a vacancy rate of 5.0% in 2025, while nurse aides, orderlies and patient service associates had a vacancy rate of 4.7%.</p>
<p>These figures suggest that workforce pressures remain concentrated in certain nursing roles, even as overall employment continues to increase.</p>
<h2>Wages struggle to keep pace with inflation</h2>
<p>The report also raises concerns about the purchasing power of nursing wages.</p>
<p>Among registered nurses aged 25 to 54, average hourly wages adjusted for inflation were 1.4% lower in 2025 than in 2019.</p>
<p>Licensed practical nurses in the same age group experienced a 0.6% decline in real average hourly wages over the six-year period.</p>
<p>While nominal wages have increased, inflation has largely offset those gains.</p>
<p>Across all health occupations, inflation-adjusted average hourly wages for workers aged 25 to 54 increased by 3.2% between 2019 and 2025.</p>
<p>The comparatively weaker wage performance among nurses may add to ongoing discussions about recruitment, retention and compensation across Canada’s healthcare system.</p>
<h2>Healthcare employment reaches 1.7 million</h2>
<p>Canada’s broader healthcare workforce has also expanded.</p>
<p>In 2025, more than 1.7 million Canadians were employed in health occupations, representing 8.2% of total national employment.</p>
<p>That was an increase of 81,200 workers from 2024 and 279,400 from 2019.</p>
<p>However, workforce demand continues to exceed available staffing in many areas.</p>
<p>Statistics Canada recorded 67,900 job vacancies across health occupations in 2025. Although this was below the 2023 peak of 90,700, it was nearly three times the number recorded in 2016.</p>
<p>The overall vacancy rate for health occupations was 4.5%, compared with 2.7% across all occupations.</p>
<h2>Implications for Canadian hospitals</h2>
<p>The findings highlight the importance of looking beyond total employment growth when assessing healthcare staffing.</p>
<p>While more nurses are entering or remaining in registered nursing occupations, persistent vacancies among practical nurses and other healthcare workers can create challenges for hospitals, long-term care facilities and community healthcare providers.</p>
<p>Population aging, increasing demand for health services and workforce retention remain important pressures.</p>
<p>The report suggests that workforce planning will require continued attention to recruitment, retention, compensation and the distribution of healthcare professionals across occupations.</p>
<p>For Canadian hospitals, the central challenge is not simply increasing the number of healthcare workers, but ensuring that sufficient professionals are available in the roles and locations where patients need them most.</p>
<p><em>Source: Statistics Canada, Labour market characteristics of Canada’s health workforce, 2025, released October 19, 2026. <a href="https://www150.statcan.gc.ca/n1/daily-quotidien/261019/dq261019b-eng.htm?utm_source=chatgpt.com">Read the official Statistics Canada release</a>.</em></p>
<div>
<div></div>
<div>
<div></div>
</div>
</div>
<p>The post <a href="https://www.hospitalnews.com/canadas-nursing-workforce-grows-but-shortages-and-wage-pressures-persist/">Canada’s nursing workforce grows, but shortages and wage pressures persist</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Permanente physician leaders recognized for driving care transformation</title>
<link>https://edusehat.com/en/permanente-physician-leaders-recognized-for-driving-care-transformation</link>
<guid>https://edusehat.com/en/permanente-physician-leaders-recognized-for-driving-care-transformation</guid>
<description><![CDATA[ Learn how Permanente physician leaders Kristine Lee, MD, and Khang Nguyen, MD, are transforming health care through AI, virtual care, and digital innovation
The post Permanente physician leaders recognized for driving care transformation appeared first on Permanente Medicine. ]]></description>
<enclosure url="https://permanente.org/wp-content/uploads/2026/10/Website-feature-image-Beckers_Chief_Transformation_Officers_Lee_Nguyen_2026.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:30:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Permanente, physician, leaders, recognized, for, driving, care, transformation</media:keywords>
<content:encoded><![CDATA[<p>Two Permanente physician leaders were named to the 2026 Becker’s Healthcare Chief Transformation Officers to Know list, recognizing their work to reimagine care delivery through technology, <a href="https://permanente.org/medical-excellence/driving-healthcare-innovation-in-10-steps/" target="_blank" rel="noopener">health care innovations</a>, and clinical leadership.</p>
<p><a href="https://northerncalifornia.permanente.org/kristine-lee-md">Kristine Lee, MD</a>, chief transformation officer and associate executive director of <a href="https://northerncalifornia.permanente.org/" target="_blank" rel="noopener">The Permanente Medical Group</a> (TPMG), and Khang Nguyen, MD, medical director for care transformation and chief health care information officer of <a href="https://permanente.org/southern-california-permanente-medical-group/" target="_blank" rel="noopener">Southern California Permanente Medical Group</a> (SCPMG), earned the distinction for advancing innovative approaches that improve patient outcomes, enhance the care experience, and support clinicians in delivering high-quality care.</p>
<p>Their recognition reflects Kaiser Permanente’s ongoing commitment to responsibly leveraging digital innovation, AI, and physician-led collaboration to meet the evolving needs of patients and communities.</p>
<h1><strong>Expanding access and personalizing care through innovation</strong></h1>
<p>At TPMG, Dr. Lee oversees virtual and desktop medicine across primary and specialty care, as well as technology, innovation, and research initiatives for the 10,000-physician medical group. Her work includes:</p>
<ul>
<li><strong>Launching</strong><strong> TPMG’s Virtual Medical Center, an integrated telehealth hub designed to provide around-the-clock care to patients.</strong> During its first full year of operation, the Center helped address 5.7 million patient concerns through phone, video, and online channels, resolving many routine, urgent, and chronic disease management issues without the need for an in-person visit.</li>
<li><strong>Advancing</strong><strong> one of the nation’s largest health system pilots exploring digital twin technology.</strong> The initiative uses AI to combine data from wearable devices, sensors, and patient-reported information to create personalized recommendations that support healthier behaviors and better disease management.</li>
<li><strong>Using digital tools to improve population health management.</strong> TPMG is making use of technology to analyze patient data and surface actionable insights, enabling care teams to identify and close care gaps, such as facilitating preventive screenings and follow-up care.</li>
<li><strong>Optimizing ambient AI scribe workflows across settings and specialties. </strong>By streamlining documentation workflows, the technology reduces administrative burden, gives physicians more time with patients, and improves the patient and clinician experience.</li>
<li><strong>Co-authoring a study publish</strong><strong>ed in </strong><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2817150" target="_blank" rel="noopener"><strong>JAMA Network Open</strong></a><strong> on a</strong><strong>n AI-powered system</strong> launched by TPMG categorize patient messages and help regional staff resolve about a third of the messages instead of directing them to busy physicians.</li>
</ul>
<h1><strong>Improving patient navigation and digital care</strong></h1>
<p>At SCPMG, Dr. Nguyen leads a team of physician experts dedicated to advancing care transformation across an organization of more than 9,000 physicians. His work includes:</p>
<ul>
<li><strong>Leading development</strong><strong> of the Kaiser Permanente Intelligent Navigator (KPIN)</strong>, an AI-powered tool that allows patients to describe their health concerns in their own words. KPIN recommends the most clinically appropriate next step, identifies higher-acuity symptoms, and directs patients to immediate clinical evaluation when necessary. Research published in <a href="https://www.nature.com/articles/s41746-025-01838-1" target="_blank" rel="noopener">Nature</a> found that the platform identified urgent medical cases with 97.7% accuracy while also increasing patient satisfaction.</li>
<li><strong>Driving implementation of the Smart Messaging Tool (SMT)</strong>, which uses AI to categorize patient messages by topic. By helping clinicians prioritize and manage inboxes more efficiently, the tool supports faster review of potentially urgent messages. A study published in <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2843966" target="_blank" rel="noopener">JAMA Network Open</a> found SMT achieved 81.0% classification accuracy and the time between receipt and initial review of high-acuity messages by 17 hours.</li>
<li><strong>Connecting patients with clinicians in less than two hours through e-visits via the Get Care Now initiative, a 24/7 virtual urgent care service.</strong> Research published in <a href="https://www.nature.com/articles/s41746-025-01590-6" target="_blank" rel="noopener">Nature</a> showed the program has delivered strong patient satisfaction results helping patients receive care in the most appropriate setting and reducing unnecessary emergency department visits.</li>
</ul>
<p>The recognition of Drs. Lee and Nguyen underscores the role physician leadership plays in shaping the future of value-based care. Permanente clinicians are harnessing technology not for the sake of technology, but as a tool to strengthen the patient-clinician relationship, improve outcomes, and expand access to high-quality care.</p>
<p>The complete list of Becker’s Healthcare honorees and their profiles are available <a href="https://www.beckershospitalreview.com/hospital-management-administration/34-hospital-and-health-system-chief-transformation-officers-to-know-2026/" target="_blank" rel="noopener">here</a>.</p>
<p>The post <a href="https://permanente.org/permanente-physician-leaders-recognized-for-driving-care-transformation/">Permanente physician leaders recognized for driving care transformation</a> appeared first on <a href="https://permanente.org/">Permanente Medicine</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Next Major Controversy in Sport?</title>
<link>https://edusehat.com/en/the-next-major-controversy-in-sport</link>
<guid>https://edusehat.com/en/the-next-major-controversy-in-sport</guid>
<description><![CDATA[ This week in the world of sports science, weight-loss drugs, robotic exoskeletons, isometric calf testing. 
The post The Next Major Controversy in Sport? appeared first on Science for Sport. ]]></description>
<enclosure url="https://www.scienceforsport.com/wp-content/uploads/2026/10/1b0f7546-ea7e-40d3-96c2-badddd5aff63-1024x683.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 01:00:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Next, Major, Controversy, Sport</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph"><strong>This week in the world of sports science, here’s what happened…</strong></p>



<ul class="wp-block-list">
<li>Could weight-loss drugs become the next major controversy in sport?</li>



<li>Santos FC introduces robotic exoskeletons for training and recovery</li>



<li>Is isometric calf strength testing an effective predictor of athletic performance?</li>
</ul>



<div aria-hidden="true" class="wp-block-spacer"></div>



<h2 class="wp-block-heading">Could weight-loss drugs become the next major controversy in sport?</h2>



<figure class="wp-block-image size-large"><img fetchpriority="high" decoding="async" width="1024" height="683" src="https://www.scienceforsport.com/wp-content/uploads/2026/10/1b0f7546-ea7e-40d3-96c2-badddd5aff63-1024x683.png" alt="" class="wp-image-34395" srcset="https://www.scienceforsport.com/wp-content/uploads/2026/10/1b0f7546-ea7e-40d3-96c2-badddd5aff63-1024x683.png 1024w, https://www.scienceforsport.com/wp-content/uploads/2026/10/1b0f7546-ea7e-40d3-96c2-badddd5aff63-300x200.png 300w, https://www.scienceforsport.com/wp-content/uploads/2026/10/1b0f7546-ea7e-40d3-96c2-badddd5aff63-768x512.png 768w, https://www.scienceforsport.com/wp-content/uploads/2026/10/1b0f7546-ea7e-40d3-96c2-badddd5aff63.png 1536w" sizes="(max-width: 1024px) 100vw, 1024px"><figcaption class="wp-element-caption">(Image: ChatGPT)</figcaption></figure>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph">The Washington Post recently published a fascinating <a href="https://www.washingtonpost.com/sports/2026/09/27/athletes-are-taking-glp-1s-anti-doping-regulators-are-watching/" target="_blank" rel="noreferrer noopener">article</a> examining the growing interest among athletes in <a href="https://www.scienceforsport.com/weight-cutting-tips-nutrition-secrets/" target="_blank" rel="noreferrer noopener">weight-loss</a> drugs, particularly GLP-1 medications such as Ozempic, Wegovy, Mounjaro and Zepbound. Although these medications were developed to treat conditions such as type 2 diabetes and obesity, their ability to suppress appetite and promote <a href="https://www.scienceforsport.com/weight-cutting-tips-nutrition-secrets/" target="_blank" rel="noreferrer noopener">weight loss</a> has raised important questions about their potential use in competitive sport. This is particularly relevant to athletes in <a href="https://www.scienceforsport.com/weight-cutting-in-combat-sports-what-is-it-and-how-can-you-minimise-the-risks/" target="_blank" rel="noreferrer noopener">weight-category sports</a> such as <a href="https://www.scienceforsport.com/best-boxing-shoes/" target="_blank" rel="noreferrer noopener">boxing</a>, MMA, wrestling and <a href="https://www.scienceforsport.com/olympic-weightlifting/" target="_blank" rel="noreferrer noopener">weightlifting</a>, where even small reductions in body weight can be significant. However, <a href="https://www.scienceforsport.com/weight-cutting-tips-nutrition-secrets/" target="_blank" rel="noreferrer noopener">losing weight</a> does not necessarily lead to improved athletic performance.</p>



<p class="wp-block-paragraph">The <a href="https://www.washingtonpost.com/sports/2026/09/27/athletes-are-taking-glp-1s-anti-doping-regulators-are-watching/" target="_blank" rel="noreferrer noopener">article</a> also highlights that the World Anti-Doping Agency (WADA) has been monitoring certain <a href="https://www.scienceforsport.com/weight-cutting-tips-nutrition-secrets/" target="_blank" rel="noreferrer noopener">weight-loss</a> medications since 2024 because of concerns about their potential performance-enhancing effects. In September, WADA confirmed that these medications would remain permitted in competitive sport throughout 2027, although research into their potential misuse is ongoing.</p>



<p class="wp-block-paragraph">The <a href="https://www.washingtonpost.com/sports/2026/09/27/athletes-are-taking-glp-1s-anti-doping-regulators-are-watching/" target="_blank" rel="noreferrer noopener">article</a> also referenced a recent <a href="https://link.springer.com/article/10.1007/s40279-026-02514-4" target="_blank" rel="noreferrer noopener">study</a> of sports medicine physicians, which found that 12% of those surveyed were aware of elite athletes using GLP-1 medications without a medical need. Another notable development is that tennis player Serena Williams has publicly discussed using Zepbound for <a href="https://www.scienceforsport.com/weight-cutting-tips-nutrition-secrets/" target="_blank" rel="noreferrer noopener">weight loss</a> and improved mobility, bringing even greater mainstream attention to the debate.</p>



<p class="wp-block-paragraph">Although WADA currently considers the evidence insufficient to justify banning these medications, their potential use in competitive sport raises important questions. The next generation of <a href="https://www.scienceforsport.com/weight-cutting-tips-nutrition-secrets/" target="_blank" rel="noreferrer noopener">weight-loss</a> drugs could complicate matters further, particularly if new treatments become more effective at reducing body fat while preserving <a href="https://www.scienceforsport.com/hypertrophy-training/" target="_blank" rel="noreferrer noopener">muscle mass</a>. With these medications set to remain permitted throughout 2027, could <a href="https://www.scienceforsport.com/weight-cutting-tips-nutrition-secrets/" target="_blank" rel="noreferrer noopener">weight-loss</a> drugs become the next major controversy in sport?</p>



<p class="wp-block-paragraph">If you would like to learn about safe <a href="https://www.scienceforsport.com/weight-cutting-tips-nutrition-secrets/" target="_blank" rel="noreferrer noopener">weight loss</a>, check out our highly informative blogs:</p>



<ul class="wp-block-list">
<li><a href="https://www.scienceforsport.com/weight-cutting-in-combat-sports-what-is-it-and-how-can-you-minimise-the-risks/" target="_blank" rel="noreferrer noopener">Weight cutting in combat sports: What is it and how can you minimise the risks?</a></li>



<li><a href="https://www.scienceforsport.com/weight-cutting-tips-nutrition-secrets/" target="_blank" rel="noreferrer noopener">Weight cutting tips: Nutrition secrets you need to know</a></li>



<li><a href="https://www.scienceforsport.com/the-severely-detrimental-effects-of-making-weight-the-wrong-way/" target="_blank" rel="noreferrer noopener">The severely detrimental effects of making weight the wrong way</a></li>
</ul>



<div aria-hidden="true" class="wp-block-spacer"></div>



<h2 class="wp-block-heading">Santos FC introduces robotic exoskeletons for training and recovery</h2>



<figure class="wp-block-image size-large"><img decoding="async" width="1024" height="576" src="https://www.scienceforsport.com/wp-content/uploads/2026/10/hypershell-x-exoskeleton-1024x576.jpeg" alt="" class="wp-image-34396" srcset="https://www.scienceforsport.com/wp-content/uploads/2026/10/hypershell-x-exoskeleton-1024x576.jpeg 1024w, https://www.scienceforsport.com/wp-content/uploads/2026/10/hypershell-x-exoskeleton-300x169.jpeg 300w, https://www.scienceforsport.com/wp-content/uploads/2026/10/hypershell-x-exoskeleton-768x432.jpeg 768w, https://www.scienceforsport.com/wp-content/uploads/2026/10/hypershell-x-exoskeleton.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px"><figcaption class="wp-element-caption">Hypershell Exoskeleton (Image: Fox News)</figcaption></figure>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph">An intriguing story has recently emerged from Brazilian <a href="https://academy.scienceforsport.com/programs/collection-vj75ibdi-da?category_id=141256" target="_blank" rel="noreferrer noopener">football</a> club Santos FC (see <a href="https://www.santosfc.com.br/santos-fc-recebe-exoesqueletos-hypershell-para-aplicacoes-no-futebol-profissional/" target="_blank" rel="noreferrer noopener">here</a>), which has introduced robotic exoskeleton <a href="https://www.scienceforsport.com/course-category/technology-and-data/" target="_blank" rel="noreferrer noopener">technology</a> into <a href="https://www.scienceforsport.com/course-category/technology-and-data/">its</a> <a href="https://www.scienceforsport.com/what-do-strength-and-conditioning-coaches-do-and-how-can-you-get-a-job-in-the-sc-industry/" target="_blank" rel="noreferrer noopener">S&C</a> department. The club announced that it had received seven exoskeletons from <a href="https://www.scienceforsport.com/course-category/technology-and-data/" target="_blank" rel="noreferrer noopener">technology</a> company Hypershell.</p>



<p class="wp-block-paragraph">These lightweight, battery-powered wearable devices attach around the hips and legs. By combining electric motors, movement sensors and <a href="https://scienceforsport.fireside.fm/146" target="_blank" rel="noreferrer noopener">AI</a>-based motion control, the <a href="https://www.scienceforsport.com/course-category/technology-and-data/" target="_blank" rel="noreferrer noopener">technology</a> claims to reduce the muscular effort required during activities such as walking and running.</p>



<p class="wp-block-paragraph">According to reports, the club’s medical and performance staff are exploring several potential applications for the devices. One is <a href="https://www.scienceforsport.com/course-category/recovery/" target="_blank" rel="noreferrer noopener">recovery</a>, where exoskeletons could reduce physical effort during low-intensity movement after matches or demanding training sessions. The club is also investigating their use in <a href="https://www.scienceforsport.com/strength-training/" target="_blank" rel="noreferrer noopener">strength</a> and <a href="https://www.scienceforsport.com/vo2-max/" target="_blank" rel="noreferrer noopener">endurance</a> training, including mechanical assistance or resistance to adjust training demands. In addition, the <a href="https://www.scienceforsport.com/course-category/technology-and-data/" target="_blank" rel="noreferrer noopener">technology</a> could support <a href="https://www.scienceforsport.com/how-to-implement-strength-and-power-training-principles-into-rehabilitation/" target="_blank" rel="noreferrer noopener">rehabilitation</a> and return-to-play protocols by allowing athletes to progress gradually towards normal physical workloads.</p>



<p class="wp-block-paragraph">It will be particularly interesting to see whether these devices can genuinely improve <a href="https://www.scienceforsport.com/course-category/recovery/" target="_blank" rel="noreferrer noopener">recovery</a> between demanding training sessions and matches, enhance athletic performance, or provide meaningful benefits during <a href="https://www.scienceforsport.com/how-to-implement-strength-and-power-training-principles-into-rehabilitation/" target="_blank" rel="noreferrer noopener">rehabilitation</a> and return-to-play programmes. For now, however, their effectiveness in these areas remains unproven.</p>



<p class="wp-block-paragraph">Overall, this fascinating development in <a href="https://www.scienceforsport.com/top-100-experts-in-sports-science/" target="_blank" rel="noreferrer noopener">sports science</a> and <a href="https://www.scienceforsport.com/course-category/technology-and-data/" target="_blank" rel="noreferrer noopener">technology</a> raises an intriguing question: how long before robotic exoskeletons become a regular feature in the <a href="https://www.scienceforsport.com/what-do-strength-and-conditioning-coaches-do-and-how-can-you-get-a-job-in-the-sc-industry/" target="_blank" rel="noreferrer noopener">S&C</a> departments of professional <a href="https://academy.scienceforsport.com/programs/collection-vj75ibdi-da?category_id=141256" target="_blank" rel="noreferrer noopener">football</a> clubs?</p>



<div aria-hidden="true" class="wp-block-spacer"></div>



<h2 class="wp-block-heading">Is isometric calf strength testing an effective predictor of athletic performance?</h2>



<figure class="wp-block-image size-full is-resized"><img decoding="async" width="939" height="1675" src="https://www.scienceforsport.com/wp-content/uploads/2026/10/a8de7e3c-2e23-4ffd-8cab-edad5b6aefc9.png" alt="" class="wp-image-34398" srcset="https://www.scienceforsport.com/wp-content/uploads/2026/10/a8de7e3c-2e23-4ffd-8cab-edad5b6aefc9.png 939w, https://www.scienceforsport.com/wp-content/uploads/2026/10/a8de7e3c-2e23-4ffd-8cab-edad5b6aefc9-168x300.png 168w, https://www.scienceforsport.com/wp-content/uploads/2026/10/a8de7e3c-2e23-4ffd-8cab-edad5b6aefc9-574x1024.png 574w, https://www.scienceforsport.com/wp-content/uploads/2026/10/a8de7e3c-2e23-4ffd-8cab-edad5b6aefc9-861x1536.png 861w, https://www.scienceforsport.com/wp-content/uploads/2026/10/a8de7e3c-2e23-4ffd-8cab-edad5b6aefc9-767x1369.png 767w" sizes="(max-width: 939px) 100vw, 939px"><figcaption class="wp-element-caption">(Image: Instagram)</figcaption></figure>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph"><a href="https://www.scienceforsport.com/what-do-strength-and-conditioning-coaches-do-and-how-can-you-get-a-job-in-the-sc-industry/" target="_blank" rel="noreferrer noopener">S&C</a> expert Professor Stephen Patterson recently shared an interesting LinkedIn <a href="https://lnkd.in/p/dgNM8ehY" target="_blank" rel="noreferrer noopener">post</a> highlighting new <a href="https://link.springer.com/article/10.1007/s00421-026-06462-9" target="_blank" rel="noreferrer noopener">research</a> that questions the effectiveness of <a href="https://www.scienceforsport.com/isometric-mid-thigh-pull-imtp/" target="_blank" rel="noreferrer noopener">isometric</a> <a href="https://www.scienceforsport.com/calf-muscle-development-why-coaches-and-athletes-must-stop-ignoring-the-calf-region/">calf</a> <a href="https://www.scienceforsport.com/1rm-testing/" target="_blank" rel="noreferrer noopener">strength testing</a> as a predictor of athletic performance.</p>



<p class="wp-block-paragraph">The research found that <a href="https://www.scienceforsport.com/isometric-mid-thigh-pull-imtp/" target="_blank" rel="noreferrer noopener">isometric</a> <a href="https://www.scienceforsport.com/calf-muscle-development-why-coaches-and-athletes-must-stop-ignoring-the-calf-region/">calf</a> <a href="https://www.scienceforsport.com/strength-training/" target="_blank" rel="noreferrer noopener">strength</a> explained approximately 9% of <a href="https://www.scienceforsport.com/drop-jumps-vs-depth-jumps/" target="_blank" rel="noreferrer noopener">drop jump</a> performance and just 2% of <a href="https://www.scienceforsport.com/vertical-jump/" target="_blank" rel="noreferrer noopener">jump</a> height and <a href="https://www.scienceforsport.com/speed-development-why-the-correct-technique-is-vital-for-athletes/" target="_blank" rel="noreferrer noopener">sprint speed</a>, with none of these links reaching statistical significance. Patterson highlighted a key limitation of conventional <a href="https://www.scienceforsport.com/isometric-mid-thigh-pull-imtp/" target="_blank" rel="noreferrer noopener">isometric</a> <a href="https://www.scienceforsport.com/calf-muscle-development-why-coaches-and-athletes-must-stop-ignoring-the-calf-region/">calf</a> <a href="https://www.scienceforsport.com/1rm-testing/" target="_blank" rel="noreferrer noopener">strength testing</a>: the lack of specificity to the mechanical demands of <a href="https://www.scienceforsport.com/speed-development-why-the-correct-technique-is-vital-for-athletes/" target="_blank" rel="noreferrer noopener">sprinting</a> and <a href="https://www.scienceforsport.com/vertical-jump/" target="_blank" rel="noreferrer noopener">jumping</a>. Many <a href="https://www.scienceforsport.com/isometric-mid-thigh-pull-imtp/" target="_blank" rel="noreferrer noopener">isometric</a> <a href="https://www.scienceforsport.com/calf-muscle-development-why-coaches-and-athletes-must-stop-ignoring-the-calf-region/" target="_blank" rel="noreferrer noopener">calf</a> <a href="https://www.scienceforsport.com/strength-training/" target="_blank" rel="noreferrer noopener">strength</a> assessments are performed with the <a href="https://www.scienceforsport.com/does-ankle-mobility-and-segment-ratios-influence-trunk-angle-in-the-squat/" target="_blank" rel="noreferrer noopener">ankle</a> positioned close to neutral, at approximately 2.5° of dorsiflexion. In contrast, during <a href="https://www.scienceforsport.com/speed-development-why-the-correct-technique-is-vital-for-athletes/" target="_blank" rel="noreferrer noopener">sprinting</a> and <a href="https://www.scienceforsport.com/vertical-jump/" target="_blank" rel="noreferrer noopener">jumping</a>, peak <a href="https://www.scienceforsport.com/does-ankle-mobility-and-segment-ratios-influence-trunk-angle-in-the-squat/">ankle</a> torque occurs at approximately 16–21° of dorsiflexion, under substantially higher movement velocities and within the <a href="https://www.scienceforsport.com/stretch-shortening-cycle/" target="_blank" rel="noreferrer noopener">stretch-shortening cycle</a>. Consequently, these conventional <a href="https://www.scienceforsport.com/isometric-mid-thigh-pull-imtp/" target="_blank" rel="noreferrer noopener">isometric</a> assessments may fail to adequately replicate the joint angles, contraction velocities, and neuromuscular demands associated with explosive athletic movements.</p>



<p class="wp-block-paragraph">Based on these findings, Patterson suggested that if the primary purpose of <a href="https://www.scienceforsport.com/isometric-mid-thigh-pull-imtp/" target="_blank" rel="noreferrer noopener">isometric</a> <a href="https://www.scienceforsport.com/calf-muscle-development-why-coaches-and-athletes-must-stop-ignoring-the-calf-region/">calf</a> <a href="https://www.scienceforsport.com/1rm-testing/" target="_blank" rel="noreferrer noopener">strength testing</a> is to predict <a href="https://www.scienceforsport.com/speed-development-why-the-correct-technique-is-vital-for-athletes/" target="_blank" rel="noreferrer noopener">sprinting</a> or <a href="https://www.scienceforsport.com/vertical-jump/" target="_blank" rel="noreferrer noopener">jumping</a> performance, he would stop using it. Importantly, this does not necessarily invalidate <a href="https://www.scienceforsport.com/isometric-mid-thigh-pull-imtp/" target="_blank" rel="noreferrer noopener">isometric</a> <a href="https://www.scienceforsport.com/calf-muscle-development-why-coaches-and-athletes-must-stop-ignoring-the-calf-region/">calf</a> <a href="https://www.scienceforsport.com/1rm-testing/" target="_blank" rel="noreferrer noopener">strength testing</a> as a measure of <a href="https://www.scienceforsport.com/calf-muscle-development-why-coaches-and-athletes-must-stop-ignoring-the-calf-region/">calf</a> <a href="https://www.scienceforsport.com/strength-training/" target="_blank" rel="noreferrer noopener">strength</a> but rather questions its usefulness as a standalone predictor of dynamic athletic performance.</p>



<div aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph"><strong>From us this week:</strong></p>



<p class="wp-block-paragraph">>> New course: <a href="https://academy.scienceforsport.com/programs/collection-xy44wcqbjsy?category_id=141256" data-type="link" data-id="https://academy.scienceforsport.com/programs/collection-xy44wcqbjsy?category_id=141256" target="_blank" rel="noreferrer noopener">Observation Before Intervention: Building Better Coaching Environments</a><br>>> New podcast: <a href="https://scienceforsport.fireside.fm/342" data-type="link" data-id="https://scienceforsport.fireside.fm/342" target="_blank" rel="noreferrer noopener">Moving Beyond Aerobic and Anaerobic Training Labels</a><br>>> New infographic: <a href="https://www.instagram.com/p/DebpWeQFZkW/?img_index=1" data-type="link" data-id="https://www.instagram.com/p/DebpWeQFZkW/?img_index=1" target="_blank" rel="noreferrer noopener">Nutrition Timing in Sport</a><br>>> New article: <a href="https://www.scienceforsport.com/essa-and-science-for-sport-announce-strategic-professional-development-partnership/" data-type="link" data-id="https://www.scienceforsport.com/essa-and-science-for-sport-announce-strategic-professional-development-partnership/" target="_blank" rel="noreferrer noopener">ESSA and Science for Sport Announce Strategic Professional Development Partnership</a></p>



<p class="wp-block-paragraph"><strong>Access to a growing library of sports science courses</strong></p>



<p class="wp-block-paragraph"><a href="https://academy.scienceforsport.com/" target="_blank" rel="noopener" data-lasso-id="59917">SFS Academy</a> is an all-access membership to premium sports science education.</p>



<p class="wp-block-paragraph">With SFS Academy, you’ll learn from some of the best coaches around the world as they teach you how to apply the latest research and practice with your athletes.</p>



<p class="wp-block-paragraph"></p><p>The post <a href="https://www.scienceforsport.com/the-next-major-controversy-sport/">The Next Major Controversy in Sport?</a> appeared first on <a href="https://www.scienceforsport.com/">Science for Sport</a>.</p>]]> </content:encoded>
</item>

<item>
<title>SickKids and Microsoft announce five&#45;year partnership to advance AI&#45;powered pediatric care</title>
<link>https://edusehat.com/en/sickkids-and-microsoft-announce-five-year-partnership-to-advance-ai-powered-pediatric-care</link>
<guid>https://edusehat.com/en/sickkids-and-microsoft-announce-five-year-partnership-to-advance-ai-powered-pediatric-care</guid>
<description><![CDATA[ Strategic agreement will strengthen cloud infrastructure, connect clinical information and support more personalized approaches to diagnosis, treatment and prevention. The Hospital for Sick Children (SickKids) in Toronto has announced a five-year strategic partnership with Microsoft Canada aimed at accelerating digital transformation and expanding the use of artificial intelligence to support pediatric healthcare. Announced October 20, […]
The post SickKids and Microsoft announce five-year partnership to advance AI-powered pediatric care appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/sickkids-microsoft-canada-partnership-azure-announcement.jpg.webp" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 00:10:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>SickKids, and, Microsoft, announce, five-year, partnership, advance, AI-powered, pediatric, care</media:keywords>
<content:encoded><![CDATA[<p>Strategic agreement will strengthen cloud infrastructure, connect clinical information and support more personalized approaches to diagnosis, treatment and prevention.</p>
<p>The Hospital for Sick Children (SickKids) in Toronto has announced a five-year strategic partnership with Microsoft Canada aimed at accelerating digital transformation and expanding the use of artificial intelligence to support pediatric healthcare.</p>
<p>Announced October 20, the agreement will strengthen the hospital’s digital infrastructure and support its Precision Child Health initiative, which seeks to provide more individualized care by combining clinical information, research and advanced technologies.</p>
<p>Under the partnership, SickKids will expand its use of Microsoft Azure as its primary cloud platform, creating a more connected and scalable environment for clinical systems and healthcare data.</p>
<p>The collaboration will explore how cloud computing, artificial intelligence and advanced analytics can help clinicians and researchers access information more effectively, identify emerging health risks and develop more personalized approaches to patient care.</p>
<h3>Building a stronger digital foundation</h3>
<p>A major component of the agreement involves improving the technology infrastructure supporting key clinical systems, including the hospital’s electronic health record.</p>
<p>By strengthening connections between clinical, research and operational information, SickKids hopes to provide healthcare teams with more timely access to relevant data.</p>
<p>The initiative is also intended to support the responsible development of AI applications that could eventually assist with earlier diagnosis, more targeted treatment and improved prediction of patient outcomes.</p>
<p>These capabilities remain areas for development and exploration under the partnership, rather than newly announced clinical tools already in routine use.</p>
<h3>Supporting healthcare professionals</h3>
<p>The agreement extends beyond technology infrastructure.</p>
<p>Microsoft Canada will provide Azure credits to support exploration of new cloud and AI solutions, along with technology partner assistance and investments in digital skills development.</p>
<p>These resources are intended to help SickKids clinicians, researchers and administrative teams build the knowledge required to evaluate and use emerging technologies effectively.</p>
<p>Workforce education will be an important component as healthcare organizations increasingly examine how artificial intelligence can support clinical decisions, research and hospital operations.</p>
<h3>Advancing precision child health</h3>
<p>The partnership supports SickKids’ broader strategy of moving toward more individualized pediatric care.</p>
<p>Precision Child Health aims to bring together information about each child’s medical condition, genetics and other relevant health factors to help clinicians better understand individual needs.</p>
<p>Artificial intelligence and advanced analytics could eventually help researchers identify patterns in complex health information, supporting new opportunities for diagnosis, prevention and treatment.</p>
<p>SickKids has already established an enterprise AI program focused on responsible development and implementation of artificial intelligence across clinical care, research and hospital operations.</p>
<p>The new agreement builds on that work while expanding the digital infrastructure needed to support future innovation.</p>
<h3>Security and responsible implementation</h3>
<p>As healthcare organizations increase their reliance on connected digital systems, protecting patient information and maintaining the reliability of clinical technology remain essential priorities.</p>
<p>SickKids says Microsoft’s cloud security capabilities will support the protection and resilience of critical systems and data.</p>
<p>The organizations also intend to advance responsible AI practices as they evaluate potential applications in healthcare.</p>
<p>The announcement does not specify a total financial value for the agreement or provide a timeline for deploying individual AI applications in clinical practice.</p>
<p>Leaders from Microsoft Canada visited SickKids on October 15 to mark the partnership and learn more about the hospital’s work.</p>
<p>For Canadian hospitals, the agreement represents another example of how healthcare institutions are investing in digital infrastructure as a foundation for future advances in clinical care, research and operational efficiency.</p>
<p>Source: SickKids — <a href="https://www.sickkids.ca/en/news/archive/2026/sickkids-and-microsoft-canada-join-together-to-help-teams-diagnose-faster-treat-smarter-and-predict-better/?utm_source=chatgpt.com">Official partnership announcement, October 20, 2026</a></p>
<p>The post <a href="https://www.hospitalnews.com/sickkids-and-microsoft-announce-five-year-partnership-to-advance-ai-powered-pediatric-care/">SickKids and Microsoft announce five-year partnership to advance AI-powered pediatric care</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New compression&#45;free 3D breast imaging technology receives Health Canada licence</title>
<link>https://edusehat.com/en/new-compression-free-3d-breast-imaging-technology-receives-health-canada-licence</link>
<guid>https://edusehat.com/en/new-compression-free-3d-breast-imaging-technology-receives-health-canada-licence</guid>
<description><![CDATA[ Regulatory milestone could expand diagnostic imaging options for Canadian healthcare providers, although clinical availability will depend on adoption by hospitals and imaging centres. A new approach to breast imaging could soon become available to Canadian patients following the announcement that Health Canada has licensed a dedicated three-dimensional breast CT system designed to capture detailed images […]
The post New compression-free 3D breast imaging technology receives Health Canada licence appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/KONING-CORPORATION-KBCT.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 20:30:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, compression-free, breast, imaging, technology, receives, Health, Canada, licence</media:keywords>
<content:encoded><![CDATA[<p>Regulatory milestone could expand diagnostic imaging options for Canadian healthcare providers, although clinical availability will depend on adoption by hospitals and imaging centres.</p>
<p>A new approach to breast imaging could soon become available to Canadian patients following the announcement that Health Canada has licensed a dedicated three-dimensional breast CT system designed to capture detailed images without breast compression.</p>
<p>Koning Health announced October 20 that its Vera Breast CT system has received a Canadian medical device licence, allowing the company to begin introducing the technology to healthcare providers across the country.</p>
<p>The system uses cone-beam computed tomography to create three-dimensional images of breast tissue. Unlike conventional mammography, which requires the breast to be compressed between imaging plates, the technology captures images without compression.</p>
<p>The resulting volumetric images allow radiologists to examine breast tissue from multiple angles, potentially providing additional anatomical information during diagnostic evaluations.</p>
<h3>A different approach to breast imaging</h3>
<p>Traditional mammography remains an important tool for breast cancer screening in Canada. However, researchers and medical technology companies continue developing imaging methods that may improve diagnostic assessment and the patient experience.</p>
<p>The Koning system is designed to address both image visualization and examination comfort.</p>
<p>By eliminating compression, the technology offers a different examination experience for patients who find conventional breast imaging uncomfortable.</p>
<p>Its three-dimensional imaging capabilities may also provide clinicians with additional views of breast structures during diagnostic assessment.</p>
<p>The technology is intended for diagnostic breast imaging and should not be considered a replacement for established mammography screening programs. Its specific authorized uses in Canada will be governed by the conditions of its medical device licence.</p>
<h3>Canadian adoption will determine patient access</h3>
<p>Although the regulatory milestone permits the company to move forward with commercial introduction, it does not mean the technology is already available at Canadian hospitals.</p>
<p>Individual hospitals and diagnostic imaging centres will determine whether and when to introduce the system, taking into account equipment procurement, clinical requirements, staff training and operational considerations.</p>
<p>Koning has not announced specific Canadian hospital installations or patient appointment dates as part of the licensing announcement.</p>
<p>For healthcare providers, the development represents another potential option in the evolving field of breast diagnostic imaging.</p>
<p>As imaging technology advances, clinical evaluation will remain important in determining how new systems complement existing diagnostic pathways, improve patient experiences and contribute to effective care.</p>
<p>The Canadian authorization follows the company’s recent regulatory registration of its breast CT technology in Australia.</p>
<p>With October marking Breast Cancer Awareness Month, the announcement highlights continuing efforts to develop imaging technologies that support the assessment of breast health.</p>
<p>Source: <a href="https://www.prnewswire.com/news-releases/koning-vera-breast-ct-receives-licensure-from-health-canada-for-breast-imaging-in-canada-302914525.html?utm_source=chatgpt.com">Koning Health — October 20, 2026</a></p>
<p>The post <a href="https://www.hospitalnews.com/new-compression-free-3d-breast-imaging-technology-receives-health-canada-licence/">New compression-free 3D breast imaging technology receives Health Canada licence</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Average cardiologist pay: $700K&#45;$1 million</title>
<link>https://edusehat.com/en/average-cardiologist-pay-700k-1-million</link>
<guid>https://edusehat.com/en/average-cardiologist-pay-700k-1-million</guid>
<description><![CDATA[ Average cardiologist pay is now topping $700,000, with surgeons now averaging $1 million, as the specialty sees big gains in productivity. According to data from MedAxiom, average pay for cardiologists was $727,712, reflecting a 5% bump from 2024 data. In addition, every cardiology subspecialty reported the highest compensation in the survey’s history. Leading the pack […]
The post Average cardiologist pay: $700K-$1 million appeared first on Today&#039;s Hospitalist. ]]></description>
<enclosure url="https://todayshospitalist.com/wp-content/uploads/2026/10/cardiology-pay-shutterstock_2674533403-10-21-26.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 20:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Average, cardiologist, pay:, 700K-1, million</media:keywords>
<content:encoded><![CDATA[<p>Average cardiologist pay is now topping $700,000, with surgeons now averaging $1 million, as the specialty sees big gains in productivity.</p>
<p><a href="https://www.beckerscardiology.com/cardiology/cardiologist-compensation-hits-record-highs-10-numbers-to-know/">According to data from MedAxiom</a>, average pay for cardiologists was $727,712, reflecting a 5% bump from 2024 data. In addition, every cardiology subspecialty reported the highest compensation in the survey’s history.</p>
<p>Leading the pack were cardiac surgeons, whose average pay exceeded $1 million for the first time in the survey’s history. Pay for that group was up from $942,700 in 2024.</p>
<p>Electrophysiologists reported an average pay of $803,000. General/noninvasive cardiologists reported average comp of $654,848, and advanced heart failure cardiologists reported average pay of $662,297.</p>
<p>Here are other data highlights from the survey:</p>
<p><strong>Productivity gains.</strong> All cardiology subspecialties reported gains in productivity. The biggest was among cardiologists specializing in advanced heart failure, with a year-over-year productivity gain of 11%.</p>
<p>Average work RVUs for electrophysiologists also jumped 10%.</p>
<p><strong>Volumes/panel size.</strong> New patient volumes and new patient visits reached record highs in 2025, with both growing by 18% over the last five years.</p>
<p>Cardiologists reported carrying average panels of more than 2,000 patients, and median new patient volume reached a record of 727 in 2025. That latter number was also up 18% from 2024.</p>
<p><strong>APP support.</strong> The use of advanced practice providers (APPs) by cardiologists has boomed. APP productivity in the specialty exceeded 2,000 work RVUs for the first time in the survey, exceeding 2,000 for the first time. That’s an increase of 30% since 2021.</p>
<p><strong>Advanced imaging.</strong> These studies grew, with median volumes for advanced imaging jumping 36% from 2024-25 to 38 studies for every 1,000 active patients. The ratio of imaging studies to cardiac cath procedures exceeded 50%.</p>
<p><strong>Ablations.</strong> Electrophysiology volumes have also jumped, with median ablations per electrophysiologist rising 140% over the last five years.</p>
<p><strong>Gender differences.</strong> Female cardiologists earned about 85% of their male colleagues: $632,368 vs. $745,998. Female cardiologists reported 78% of work RVUs of their male colleagues.</p>
<p><a href="https://www.beckerscardiology.com/cardiology/cardiologist-compensation-hits-record-highs-10-numbers-to-know/">Becker’s Cardiology reported</a> that more than 60% of female cardiologists practice general/noninvasive cardiology, which pays less than interventional cardiology.</p>
<p><a href="https://www.businesswire.com/news/home/20261013235222/en/MedAxiom-Releases-2026-Cardiovascular-Provider-Compensation-Production-Survey-Report-Revealing-Record-Compensation-Rising-Productivity-and-Growing-Workforce-Demands">More information is available from a MedAxiom press release, which offers a link to the full report.</a></p>
<p>The post <a href="https://todayshospitalist.com/average-cardiologist-pay-700k-1-million/">Average cardiologist pay: $700K-$1 million</a> appeared first on <a href="https://todayshospitalist.com/">Today's Hospitalist</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA approves Cosette’s Evoxac oral solution for Sjögren’s disease</title>
<link>https://edusehat.com/en/fda-approves-cosettes-evoxac-oral-solution-for-sjoegrens-disease</link>
<guid>https://edusehat.com/en/fda-approves-cosettes-evoxac-oral-solution-for-sjoegrens-disease</guid>
<description><![CDATA[ The regulatory decision represents the first new drug application (NDA) approval secured by the speciality pharmaceutical manufacturer. Cosette expects the therapy to be commercially accessible in the US 
The post FDA approves Cosette’s Evoxac oral solution for Sjögren’s disease appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-2-21-10-2026-shutterstock_2310421981.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 20:20:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, approves, Cosette’s, Evoxac, oral, solution, for, Sjögren’s, disease</media:keywords>
<content:encoded><![CDATA[<p>The regulatory decision represents the first new drug application (NDA) approval secured by the speciality pharmaceutical manufacturer.</p>
<p>Cosette expects the therapy to be commercially accessible in the US by late 2026, with further distribution details scheduled for release nearer to the commercial launch.</p>
<p>It conceived and formulated the therapy internally to provide an option for adult Sjögren’s disease patients who face difficulties when swallowing traditional solid capsules.</p>
<p>The chronic autoimmune condition damages the body’s moisture-producing glands, primarily causing dry mouth and eyes, which can impede a patient’s capacity to ingest capsule-based treatments.</p>
<p>The active ingredient in the newly approved formulation is cevimeline hydrochloride, identical to the compound used in existing Evoxac capsules authorised for adult dry mouth in Sjögren’s disease.</p>
<p>Cosette utilised a streamlined regulatory pathway that allowed it to reference historical safety and efficacy findings from Evoxac capsules, avoiding a full-scale clinical development programme.</p>
<p>Cosette Pharmaceuticals president and CEO Apurva Saraf said: “Evoxac oral solution marks an important milestone for Cosette—our first NDA approval, achieved through the dedication and ingenuity of our own teams.</p>
<p>“Today, we are demonstrating that we can also create value through our own product development capabilities. I am incredibly proud of our teams and excited about what this achievement makes possible for the patients and our future.”</p>
<p>Evoxac is a prescription medicine whose paediatric safety and effectiveness remain unconfirmed.</p>
<p>The therapy is associated with potential adverse effects, including heart rhythm and heart rate issues, lung complications such as restricted airflow and increased mucus, vision alterations particularly in darkness, and nervous system disorders linked to cholinergic reactions.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/fda-cosettes-evoxac-sjogrens-disease/">FDA approves Cosette’s Evoxac oral solution for Sjögren’s disease</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Sanofi and ScionxBio partner on mRNA therapies</title>
<link>https://edusehat.com/en/sanofi-and-scionxbio-partner-on-mrna-therapies</link>
<guid>https://edusehat.com/en/sanofi-and-scionxbio-partner-on-mrna-therapies</guid>
<description><![CDATA[ Under the arrangement, the companies will create extended-exposure formulations of selected mRNA candidates from Sanofi by applying ScionxBio’s TERA technology. The partnership divides research and clinical duties between 
The post Sanofi and ScionxBio partner on mRNA therapies appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-21-10-2026-shutterstock_1989605270.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 20:20:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sanofi, and, ScionxBio, partner, mRNA, therapies</media:keywords>
<content:encoded><![CDATA[<p>Under the arrangement, the companies will create extended-exposure formulations of selected mRNA candidates from Sanofi by applying ScionxBio’s TERA technology.</p>
<p>The partnership divides research and clinical duties between both organisations. ScionxBio will direct optimisation programmes through to in vivo validation.</p>
<p>Following this phase, Sanofi will assume responsibility for all subsequent preclinical research, investigational new drug (IND)-enabling evaluations, clinical trials, manufacturing, and global commercialisation.</p>
<p>ScionxBio CEO Dr Adi Gilboa-Geffen said: “This collaboration with Sanofi is a defining milestone for our company. It validates the revolutionary potential of our AI-driven TERA platform to overcome the historical limitations of mRNA durability.</p>
<p>“Partnering with a global powerhouse like Sanofi ensures that our innovations in therapeutic RNA reach patients with life-altering protein deficiencies and chronic conditions more rapidly than ever before.</p>
<p>“I am also deeply grateful to the entire team, whose contributions were instrumental in bringing this collaboration to fruition.”</p>
<p>The agreement combines the work of Sanofi’s mRNA Center of Excellence with the TERA platform. The discovery system uses deep learning models to assess structure-activity relationships from high-throughput combinatorial screens.</p>
<div></div>
<p>By incorporating chemically synthesised regulatory components, the engineered molecules are designed to resist enzymatic breakdown more effectively than conventional mRNA, supporting sustained protein expression in vivo.</p>
<p>While specific disease targets were not disclosed, the research focuses on conditions that require sustained protein expression, spanning both inherited and acquired protein deficiencies.</p>
<p>The platform is also intended to generate sustained exposure to cardiometabolic or immune corrective modulators for potential preventive or disease-modifying applications.</p>
<p>ScionxBio is a privately held, preclinical-stage biotechnology company operating as a brand identity of Eleven Therapeutics following a horizontal corporate split.</p>
<p>In June 2026, Sanofi entered a multi-year agreement with France-based agentic AI company Owkin to co-develop next-generation AI-driven biopharma agents.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/sanofi-scionxbio-long-acting-mrna-therapies/">Sanofi and ScionxBio partner on mRNA therapies</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Exclusive Interview with Dr. Villoo Morawala Patell, Founder &amp;amp; Chairperson of Avesthagen Limited and The Avestagenome Project® International</title>
<link>https://edusehat.com/en/exclusive-interview-with-dr-villoo-morawala-patell-founder-chairperson-of-avesthagen-limited-and-the-avestagenome-project-international</link>
<guid>https://edusehat.com/en/exclusive-interview-with-dr-villoo-morawala-patell-founder-chairperson-of-avesthagen-limited-and-the-avestagenome-project-international</guid>
<description><![CDATA[ 
On the sidelines of the Bengaluru Pharma Summit, Dr. Villoo Morawala Patell, Founder &amp; Chairperson of Avesthagen Limited and The Avestagenome Project® International, speaks with Neha Aathavale, Correspondent, Express Pharma […]
The post Exclusive Interview with Dr. Villoo Morawala Patell, Founder &amp; Chairperson of Avesthagen Limited and The Avestagenome Project® International appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/21154900/EP_Excl_Intv_Dr_Villoo_Morawala_Patell_Founder_Avesthagen__Avestagenome_Project_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 20:20:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Exclusive, Interview, with, Dr., Villoo, Morawala, Patell, Founder, Chairperson, Avesthagen, Limited, and, The, Avestagenome, Project®, International</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/21154900/EP_Excl_Intv_Dr_Villoo_Morawala_Patell_Founder_Avesthagen__Avestagenome_Project_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/21154900/EP_Excl_Intv_Dr_Villoo_Morawala_Patell_Founder_Avesthagen__Avestagenome_Project_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/21154900/EP_Excl_Intv_Dr_Villoo_Morawala_Patell_Founder_Avesthagen__Avestagenome_Project_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p>On the sidelines of the Bengaluru Pharma Summit,  Dr. Villoo Morawala Patell, Founder & Chairperson of Avesthagen Limited and The Avestagenome Project® International, speaks with Neha Aathavale, Correspondent, Express Pharma in an exclusive video interview on India’s biodiversity, genomics research and the journey from scientific discovery to commercial biotech innovation.</p>
<p>Watch the full interview.</p>
<p>The post <a href="https://www.expresspharma.in/exclusive-interview-with-dr-villoo-morawala-patell-founder-chairperson-of-avesthagen-limited-and-the-avestagenome-project-international/">Exclusive Interview with Dr. Villoo Morawala Patell, Founder & Chairperson of Avesthagen Limited and The Avestagenome Project® International</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Nucelion Therapeutics, VeGen Bio collaborate on CAR&#45;T cell therapy manufacturing</title>
<link>https://edusehat.com/en/nucelion-therapeutics-vegen-bio-collaborate-on-car-t-cell-therapy-manufacturing</link>
<guid>https://edusehat.com/en/nucelion-therapeutics-vegen-bio-collaborate-on-car-t-cell-therapy-manufacturing</guid>
<description><![CDATA[ 
The partnership will cover technology transfer, clinical manufacturing and commercial production of VeGen Bio’s VL-2511 in India
The post Nucelion Therapeutics, VeGen Bio collaborate on CAR-T cell therapy manufacturing appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 20:20:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Nucelion, Therapeutics, VeGen, Bio, collaborate, CAR-T, cell, therapy, manufacturing</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Nucelion Therapeutics, a cell and gene therapy contract research, development and manufacturing organisation (CRDMO), and VeGen Bio Pvt. Ltd. (VeGen Bio / VeGen Labs), a Hyderabad-based precision oncology company, have announced a strategic collaboration for the technology transfer, clinical manufacturing and commercial production of cell therapies in India.</span></p>
<p><span>Under the agreement, Nucelion, a wholly owned subsidiary of Bharat Biotech, will serve as the technology transfer and clinical- and commercial-stage manufacturing partner for VeGen Bio’s lead candidate, VL-2511, a dual BCMA/CD19 autologous CAR-T therapy for multiple myeloma. The programme will be transferred to Nucelion’s single-site GMP manufacturing facility, designed to meet CDSCO, US FDA and EMA regulatory standards.</span></p>
<p><span>The collaboration will focus on therapeutic translation, process development and manufacturing scale-up, rather than marketing or distribution. The partnership combines Nucelion’s manufacturing infrastructure, technical expertise and production capabilities with VeGen Bio’s scientific expertise and therapeutic pipeline. The framework is intended to support additional cell therapy candidates across VeGen Bio’s pipeline.</span></p>
<p><span>The companies will also focus on process optimisation, manufacturing yields and operational efficiency, with the aim of reducing manufacturing costs and improving access to cell therapies in India.</span></p>
<p><span>“Many CAR-T programs stall between a promising construct and a product that can be made reliably at scale. As one of India’s first dedicated cell and gene therapy CRDMOs, Nucelion closes that gap, taking partners like VeGen from process development through clinical and commercial manufacturing. Our work on VeGen’s dual-target CAR-T program shows that model in action and builds the capacity India needs to bring these therapies to more patients. As our facility is designed to meet US FDA and EMA standards, companies can also commercially launch their products worldwide,” said Raghu Malapaka, PhD, CBO, Nucelion Therapeutics Pvt. Ltd.</span></p>
<p><span>“CAR-T cell therapy holds significant promise for patients with serious cancers, but realizing its full potential requires a coordinated approach to technology transfer, manufacturing, scalability, and commercialization. VL-2511 is a key program in VeGen Bio’s mission to advance innovative therapies for unmet medical needs. This partnership combines complementary strengths, providing VeGen Bio with a pathway to technology transfer, manufacturing, and pipeline expansion, while enabling our CDMO partner to establish and grow its cell therapy manufacturing capabilities. Together, we aim to build an end-to-end ecosystem for Indian cell therapy innovation that creates sustainable value while making next-generation treatments more accessible and affordable for Indian patients,” said Prashant Bhavar, Director, VeGen Bio Pvt. Ltd.</span></p>
<p><span>VL-2511 is a Phase II clinical-stage, dual-target autologous CAR-T cell therapy with an established recommended Phase II dose (RP2D), designed to target BCMA and CD19 simultaneously. Multiple myeloma remains a haematological malignancy associated with unmet medical needs and treatment-access challenges in India.</span></p>
<p><span>By targeting two antigens, VL-2511 is designed to address antigen escape, a mechanism through which malignant cells evade immune recognition by losing or downregulating a targeted antigen.</span></p>
<p><span>With clinical experience in China and ongoing clinical development in the United States, VL-2511 has demonstrated clinical activity, including activity in patients with extramedullary disease (EMD), alongside a safety profile described by the company as favourable. Its manufacturing process is designed to offer opportunities to improve treatment affordability and accessibility, particularly in India.</span></p>
<p><span>VL-2511 is also being clinically investigated in POEMS syndrome and selected autoimmune disorders, including systemic lupus erythematosus (SLE). These programmes reflect the potential applications of dual-target CAR-T technology across haematological malignancies and immune-mediated diseases, while creating opportunities for further clinical development and commercial value creation.</span></p>
<p><span>Through technology transfer and process development, VeGen Bio and Nucelion aim to establish the technical and operational foundations required to address manufacturing complexity, process consistency, quality systems and supply economics during the development process.</span></p>
<p><span>Nucelion’s facility features segregated cell processing suites, continuous environmental monitoring, and chain-of-identity and chain-of-custody tracking systems for patient-linked cellular materials. Its technical scope for the VL-2511 programme includes process development and analytical testing to establish assays and quality controls; GMP cell processing and vector-enabled transduction under aseptic conditions; aseptic fill-finish and clinical-grade cryopreservation to ensure product stability; and quality control and release testing in line with global advanced therapy standards.</span></p>
<p><span>The collaboration is structured to align scientific development, manufacturing and commercial viability. For VeGen Bio, access to technology-transfer and manufacturing infrastructure is intended to support the development of VL-2511 and allow the company to allocate scientific resources to pipeline expansion without independently replicating capital-intensive manufacturing facilities.</span></p>
<p><span>For Nucelion, applying its infrastructure and expertise to the dual-target CAR-T candidate will support the development of a cell therapy manufacturing product line spanning plasmid DNA, viral vectors and advanced cellular processing.</span></p>
<p>The post <a href="https://www.expresspharma.in/nucelion-therapeutics-vegen-bio-collaborate-on-car-t-cell-therapy-manufacturing/">Nucelion Therapeutics, VeGen Bio collaborate on CAR-T cell therapy manufacturing</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CDSCO approves Sanofi’s Qfitlia for haemophilia A and B in India</title>
<link>https://edusehat.com/en/cdsco-approves-sanofis-qfitlia-for-haemophilia-a-and-b-in-india</link>
<guid>https://edusehat.com/en/cdsco-approves-sanofis-qfitlia-for-haemophilia-a-and-b-in-india</guid>
<description><![CDATA[ 
Fitusiran is indicated for routine prophylaxis to prevent or reduce bleeding episodes in adults and adolescents aged 12 years and older, with or without factor VIII or IX inhibitors
The post CDSCO approves Sanofi’s Qfitlia for haemophilia A and B in India appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 20:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CDSCO, approves, Sanofi’s, Qfitlia, for, haemophilia, and, India</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>The Central Drugs Standard Control Organization (CDSCO), under the Drug Controller General of India (DCGI), has granted marketing authorisation to Qfitlia (fitusiran), an antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and adolescents aged 12 years or older living with haemophilia A or B, with or without factor VIII or IX inhibitors.</span></p>
<p><span>The approval is based on data from the ATLAS Phase III clinical development programme, which demonstrated clinically meaningful bleed protection, as measured by annualised bleeding rates (ABR), among people living with haemophilia, with and without inhibitors.</span></p>
<p><span>Parwas Mahajan, Business Head, Rare Diseases, Sanofi India, said, “India carries a heavy Hemophilia burden – an estimated ~28.9k# registered people living with Hemophilia. Of those receiving treatment, a significant percent is still on on-demand therapy, meaning they treat bleeds only after they occur, living in constant anticipation of the next joint bleed, the next hospital visit, the next disruption to their lives and livelihoods. The approval expands prophylactic treatment options for people living with Hemophilia in India and (Prophylaxis) is increasingly recognized as an important treatment approach in the management of hemophilia, and today’s approval of Qfitlia® is a significant step toward making that a reality. Our vision is a ‘Hemophilia-free mind’ and a life where people are not defined by their condition, where they are not held hostage by the fear of the next bleed. Qfitlia®, with its unique ability to protect both those living with Hemophilia A and Hemophilia B (with or without inhibitors) with as few as six injections a year, has the potential to significantly expand access to prophylaxis in India. Sanofi is deeply committed to India’s Hemophilia community, and this approval marks the beginning of a long-term partnership with the objective of supporting improved awareness and access to appropriate hemophilia care in India.”</span></p>
<p><span>Dr Milan Choksey, Medical Lead, Rare Diseases Business, Sanofi India, said, “The approval of Qfitlia introduces a concept that is still largely new to India: the role of antithrombin in hemostasis, and the power of lowering it to rebalance the coagulation system. For decades, our approach to Hemophilia has been to replace what is missing (factor VIII or Factor IX). Fitusiran asks a fundamentally different question: what if, instead of replacing the missing piece, we removed a brake on the system?</span></p>
<p><span>“Antithrombin is a natural inhibitor of thrombin generation. By reducing AT levels, Fitusiran allows the body’s remaining coagulation machinery to work more effectively, regardless of whether the person has Hemophilia A or B, with or without inhibitors. This is the science of rebalancing and introduces a novel treatment approach that may be of interest to treating physicians. Equally important is the role of proactive AT monitoring.</span></p>
<p><span>“The dosing of Qfitlia is guided by AT levels – a measurable, reliable biomarker that allows physicians to personalize treatment and optimise the risk-benefit profile for each person living with Hemophilia. This is a new discipline for India, and Sanofi is committed to supporting education and appropriate implementation of AT monitoring, because the science of Fitusiran is only as powerful as the ecosystem that supports it.”</span></p>
<p>The post <a href="https://www.expresspharma.in/cdsco-approves-sanofis-qfitlia-for-haemophilia-a-and-b-in-india/">CDSCO approves Sanofi’s Qfitlia for haemophilia A and B in India</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ORE pass rate drops by 29%</title>
<link>https://edusehat.com/en/ore-pass-rate-drops-by-29</link>
<guid>https://edusehat.com/en/ore-pass-rate-drops-by-29</guid>
<description><![CDATA[ The pass rate for Part 2 of the Overseas Registration Exam (ORE) fell to 27% in September 2026, down from 56% in the previous sitting. The September sitting was the first under new contractual arrangements, which the General Dental Council (GDC) said contained ‘refreshed assessment content to reflect contemporary clinical practice’. The April 2026 sitting… ]]></description>
<enclosure url="https://dentistry.co.uk/app/uploads/2026/10/ore_pass_rate-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 17:25:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ORE, pass, rate, drops, 29</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"></figure>



<p><strong>The pass rate for Part 2 of the Overseas Registration Exam (ORE) fell to 27% in September 2026, down from 56% in the previous sitting.</strong></p>



<p>The September sitting was the first under new contractual arrangements, which the General Dental Council (GDC) said contained ‘refreshed assessment content to reflect contemporary clinical practice’. The April 2026 sitting saw a 56% pass rate, with the previous three sitting between 76-77%.</p>



<p>A spokesperson for the GDC said the exam was subject to quality assurance by external examiners and its ORE Advisory Group at every stage. They said: ‘Analysis shows that all four components performed reliably, that examiners marked consistently, and that the pass standard was set appropriately.’</p>



<p>Part 2 is the practical element of the exam, composed of four components which must all be passed for an overall pass grade. In the September sitting, the largest proportion of candidates failed just one component (36%), while only two failed all four. </p>



<p>The most commonly failed component was the medical emergencies exercise, with a 44% failure rate – followed closely by the objective structured clinical examination at 41%. In contrast, 96% of candidates passed the diagnosis and treatment planning exercise. </p>



<p>The GDC said it recognised the time, cost and commitment involved in preparing for the exam, and understood that unsuccessful candidates would be disappointed. It emphasised that detailed feedback would be sent to candidates by 30 October, and that those who failed could resit the exam up to a maximum of four total attempts.</p>



<h2 class="wp-block-heading">ORE technical errors</h2>



<p>At the end of June, candidates attempting to book a place to sit the ORE Part 1 experienced <a href="https://dentistry.co.uk/2026/07/03/ore-exam-booking-failure-applicants-without-seat/">payment issues, errors and overloaded servers</a>. Many candidates had payment taken but received no confirmation that they had successfully booked a place.</p>



<p>A Part 2 booking scheduled for 14 July was then <a href="https://dentistry.co.uk/2026/07/15/ore-part-2-booking-postponed-hours-before-places-released/">delayed by a week so the GDC could carry out further testing</a>. A spokesperson for the GDC said: ‘We understand any change to timing can be unsettling for candidates, and we apologise for any inconvenience this causes.’</p>



<p>Ahead of the delayed release on 21 July, candidates were told that they may ‘still experience some performance issues’. The GDC provided advice for what to do if they received errors such as a ‘payment unsuccessful’ message or a missing confirmation email.</p>



<p>Following the booking window, candidates once again reported similar technical errors, which they attributed to an overloaded booking system.</p>



<p>The GDC has said that it will be <a href="https://dentistry.co.uk/2026/07/08/gdc-to-fix-troubled-ore-booking-system-with-new-candidate-portal/">implementing a new portal for exams</a> scheduled from the beginning of 2027.</p>


    <div class="">
        <div class="flex flex-wrap -mx-4 md:-mx-8 text-left">
                            <div class="px-4 md:px-8 w-full lg:w-1/3 xl:w-5/12 order-last order-last-m">
                    <div class="relative w-full pt-[100%]">
                        
                    </div>
                </div>
                        <div class="px-4 md:px-8 w-full lg:w-2/3 xl:w-7/12 pt-6">
                                                    <div class="font-bold font-secondary text-4xl leading-tight md:leading-tight xl:leading-tight mb-4">
                        Read more from our campaign                    </div>
                                                                    <div class="text-context-500 mb-6 md:mb-8 text-lg">
                        <p>To read more real life stories and thought leadership on the ORE, simply visit:</p>
<p><a href="http://www.dentistry.co.uk/tag/unlocking-the-ore">www.dentistry.co.uk/tag/unlocking-the-ore</a>.</p>
                    </div>
                                                            </div>
        </div>
    </div>



<p><em><a href="https://sso.dentistry.co.uk/"><em>Create a free account for unlimited access — plus the Dentistry Bulletin delivered to your inbox.</em></a></em></p>]]> </content:encoded>
</item>

<item>
<title>Exercise in a pill</title>
<link>https://edusehat.com/en/exercise-in-a-pill</link>
<guid>https://edusehat.com/en/exercise-in-a-pill</guid>
<description><![CDATA[ We all know exercise is good for us. It builds muscle, strengthens bones, lowers blood pressure, and boosts mood. By deciphering how movement benefits the body, researchers hope to develop medicines that can offer some of the same perks—without the workout. The idea isn’t to replace exercise but to bring its upsides to people who… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/Excercise-Final-v.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 17:05:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Exercise, pill</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">We all know exercise is good for us. It builds muscle, strengthens bones, lowers blood pressure, and boosts mood. By deciphering how movement benefits the body, researchers hope to develop medicines that can offer some of the same perks—without the workout. The idea isn’t to replace exercise but to bring its upsides to people who struggle with frailty, disability, or chronic illness. </p>



<h3 class="wp-block-heading">The sticking points</h3>



<p class="wp-block-paragraph">It will take a lot of experimentation to untangle the myriad pathways by which exercise promotes health. But IDing the cascade of hormones, enzymes, and other molecules related to physical activity is just the first step. Scientists need to figure out how to turn that knowledge into safe and effective drugs. That’s a tall order: <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9293739/">More than 90%</a> of treatments that enter human studies fail.</p>



<p class="wp-block-paragraph">There are regulatory hurdles too. The FDA approves medications to treat diseases, not to enhance wellness, says Thomas Burris, a pharmacologist at the University of Florida whose work focuses on diseases that respond to exercise, like obesity, type 2 diabetes, and dementia.</p>



<h3 class="wp-block-heading">The progress</h3>



<p class="wp-block-paragraph">There may never be a pill that delivers all the benefits of exercise, but research could lead to new medicines that mimic some aspects of working out. Scientists have already identified many important exercise-related signals and have even developed compounds to regulate them. (Some preliminary results have been so promising that doping authorities have proactively banned the compounds.) </p>



<p class="wp-block-paragraph">Burris and his colleagues are focused on a receptor that’s always switched on, even without exercise. Working out appears to boost that receptor in muscle cells, which in turn helps bolster endurance over time. Burris’s lab has spent years <a href="https://news.ufl.edu/2023/09/exercise-mimicking-drug/">designing a drug</a> that cranks up the receptor’s activity directly, and mice treated with the drug ran longer and farther than mice that weren’t. They “become marathon mice without having to do any type of exercise,” Burris says. There are even indications—also in mice—that the compound mimics some of the cognitive benefits of exercise and could help treat heart failure. Burris founded a company called Pelagos to carry the work forward into a clinical trial.</p>



<p class="wp-block-paragraph">Other workout-mimicking drugs have already entered human studies. In June, the biotech firm Cambrian Bio <a href="https://www.cambrianbio.com/news-and-publications/cambrian-bio-presents-positive-human-translational-data-for-atx-304-the-first-ampk-network-activator-at-the-american-diabetes-associations-86th-scientific-sessions">reported</a> that its experimental drug ATX-304 boosted metabolism and reduced liver and belly fat in people with obesity and prediabetes<em>. </em>It activates a metabolic switch that helps cells sense when energy supplies dip and coordinates the production of more fuel—the same switch that helps us sustain long sessions jumping rope or swimming laps. Cambrian hopes it will help people lose weight without losing muscle, a common concern with GLP-1 medicines.  </p>



<hr class="wp-block-separator has-alpha-channel-opacity">



<h3 class="wp-block-heading">Progress meter ………… 5</h3>



<figure class="wp-block-image size-full is-resized"><img decoding="async" width="387" height="48" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/purple-20.svg" alt="" class="wp-image-1147277"></figure>



<p class="wp-block-paragraph"><strong>Our understanding of how exercise benefits the body is still coming into focus, and drug development is prone to failure.</strong></p>]]> </content:encoded>
</item>

<item>
<title>WHX Dubai 2027</title>
<link>https://edusehat.com/en/whx-dubai-2027</link>
<guid>https://edusehat.com/en/whx-dubai-2027</guid>
<description><![CDATA[ Het bericht WHX Dubai 2027 verscheen eerst op International Hospital. ]]></description>
<enclosure url="https://interhospi.com/wp-content/uploads/sites/3/2026/10/WHX-labs.png" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 16:55:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>WHX, Dubai, 2027</media:keywords>
<content:encoded><![CDATA[<div class="avia-section av-5pjryc-19691d8fe024ecd22f4cf1b0746f9172 main_color avia-section-default avia-no-border-styling  avia-builder-el-0  avia-builder-el-no-sibling  avia-bg-style-scroll container_wrap fullsize"><div class="container av-section-cont-open"><main role="main" itemprop="mainContentOfPage" class="template-page content  av-content-full alpha units"><div class="post-entry post-entry-type-page post-entry-20414"><div class="entry-content-wrapper clearfix">


<div class="flex_column av-4vqtes-8a6e6b2dd0d572ce1d6026a3282c73a3 av_one_fifth  avia-builder-el-1  el_before_av_three_fifth  avia-builder-el-first  first flex_column_div av-hide-on-mobile av-zero-column-padding  "><section class="av_textblock_section av-key24etv-8cf8563f9a5147bae87b81cc26a3527e " itemscope="itemscope" itemtype="https://schema.org/BlogPosting" itemprop="blogPost"><div class="avia_textblock" itemprop="text"><p></p>
</div></section></div>

<div class="flex_column av-4j6544-3dd207ac880e0091524d5c381bfaef43 av_three_fifth  avia-builder-el-3  el_after_av_one_fifth  el_before_av_one_fifth  flex_column_div av-zero-column-padding  "><section class="av_textblock_section av-key254dz-6dca32f8382240f7ccc291ef75096d96 " itemscope="itemscope" itemtype="https://schema.org/BlogPosting" itemprop="blogPost"><div class="avia_textblock" itemprop="text"><p></p>
</div></section><br>
<section class="av_textblock_section av-ke9srown-cfbd4a744a50962f9a592b08939de968 " itemscope="itemscope" itemtype="https://schema.org/BlogPosting" itemprop="blogPost"><div class="avia_textblock" itemprop="text"><header class="entry-content-header"><h1 class="post-title entry-title" itemprop="headline">WHX Dubai 2027</h1><span class="post-meta-infos">/ <span class="blog-categories minor-meta">in <a href="https://interhospi.com/category/events/" rel="tag">Events</a>  </span></span></header>
</div></section><br>
<section class="av_textblock_section av-23o2c4-8f397adbcbd64996a2025c8abf40a726 " itemscope="itemscope" itemtype="https://schema.org/BlogPosting" itemprop="blogPost"><div class="avia_textblock" itemprop="text"><h3>Date: 25-28 January 2027</h3>
<p><span></span></p>
<h4>Venue: Dubai Exhibition Centre & Dubai World Trade Centre, Dubai, UAE</h4>
<p><a href="https://www.worldhealthexpo.com/events/healthcare/dubai" target="_blank" rel="noopener">https://www.worldhealthexpo.com/events/healthcare/dubai</a></p>
</div></section><br>


<div class="hr av-klqcq5xv-fb118132a60cd57f133869cf62f2257a hr-invisible  avia-builder-el-7  el_after_av_textblock  el_before_av_image "><span class="hr-inner "><span class="hr-inner-style"></span></span></div><br>


<div class="avia-image-container av-1slha5w-ec52f72a365891ef6a11b6d8be2a536c av-styling- av-img-linked avia-align-center  avia-builder-el-8  el_after_av_hr  el_before_av_hr " itemprop="image" itemscope="itemscope" itemtype="https://schema.org/ImageObject"><div class="avia-image-container-inner"><div class="avia-image-overlay-wrap"><a href="https://www.worldhealthexpo.com/events/healthcare/dubai" class="avia_image " target="_blank" rel="noopener noreferrer" aria-label="WHX labs"><img decoding="async" fetchpriority="high" class="wp-image-20415 avia-img-lazy-loading-not-20415 avia_image " src="https://interhospi.com/wp-content/uploads/sites/3/2026/10/WHX-labs.png" alt="" title="WHX labs" height="945" width="946" itemprop="thumbnailUrl" srcset="https://interhospi.com/wp-content/uploads/sites/3/2026/10/WHX-labs.png 946w, https://interhospi.com/wp-content/uploads/sites/3/2026/10/WHX-labs-300x300.png 300w, https://interhospi.com/wp-content/uploads/sites/3/2026/10/WHX-labs-80x80.png 80w, https://interhospi.com/wp-content/uploads/sites/3/2026/10/WHX-labs-768x767.png 768w, https://interhospi.com/wp-content/uploads/sites/3/2026/10/WHX-labs-36x36.png 36w, https://interhospi.com/wp-content/uploads/sites/3/2026/10/WHX-labs-180x180.png 180w, https://interhospi.com/wp-content/uploads/sites/3/2026/10/WHX-labs-705x705.png 705w" sizes="(max-width: 946px) 100vw, 946px"></a></div></div></div><br>
<div class="hr av-1csd104-f216505c48d840050a0e988af6192511 hr-default  avia-builder-el-9  el_after_av_image  el_before_av_social_share "><span class="hr-inner "><span class="hr-inner-style"></span></span></div><br>
<div class="av-social-sharing-box av-ke9sz9xv-3e02cbd0889cb70a2a9058e399d76f75 av-social-sharing-box-minimal  avia-builder-el-10  el_after_av_hr  avia-builder-el-last  av-social-sharing-box-fullwidth"><div class="av-share-box"><h5 class="av-share-link-description av-no-toc ">Share this</h5><ul class="av-share-box-list noLightbox"><li class="av-share-link av-social-link-facebook avia_social_iconfont"><a target="_blank" aria-label="Share on Facebook" href="https://www.facebook.com/sharer.php?u=https://interhospi.com/whx-dubai-2027/&t=WHX%20Dubai%202027" data-av_icon="" data-av_iconfont="entypo-fontello" title="" data-avia-related-tooltip="Share on Facebook"><span class="avia_hidden_link_text">Share on Facebook</span></a></li><li class="av-share-link av-social-link-twitter avia_social_iconfont"><a target="_blank" aria-label="Share on X" href="https://twitter.com/share?text=WHX%20Dubai%202027&url=https://interhospi.com/?p=20414" data-av_icon="" data-av_iconfont="entypo-fontello" title="" data-avia-related-tooltip="Share on X"><span class="avia_hidden_link_text">Share on X</span></a></li><li class="av-share-link av-social-link-whatsapp avia_social_iconfont"><a target="_blank" aria-label="Share on WhatsApp" href="https://api.whatsapp.com/send?text=https://interhospi.com/whx-dubai-2027/" data-av_icon="" data-av_iconfont="entypo-fontello" title="" data-avia-related-tooltip="Share on WhatsApp"><span class="avia_hidden_link_text">Share on WhatsApp</span></a></li><li class="av-share-link av-social-link-linkedin avia_social_iconfont"><a target="_blank" aria-label="Share on LinkedIn" href="https://linkedin.com/shareArticle?mini=true&title=WHX%20Dubai%202027&url=https://interhospi.com/whx-dubai-2027/" data-av_icon="" data-av_iconfont="entypo-fontello" title="" data-avia-related-tooltip="Share on LinkedIn"><span class="avia_hidden_link_text">Share on LinkedIn</span></a></li><li class="av-share-link av-social-link-mail avia_social_iconfont"><a aria-label="Share by Mail" href="mailto:?subject=WHX%20Dubai%202027&body=https://interhospi.com/whx-dubai-2027/" data-av_icon="" data-av_iconfont="entypo-fontello" title="" data-avia-related-tooltip="Share by Mail"><span class="avia_hidden_link_text">Share by Mail</span></a></li></ul></div></div></div>

<div class="flex_column av-1ziaaf0-b945285943f655b3c584bc38c6af1f49 av_one_fifth  avia-builder-el-11  el_after_av_three_fifth  avia-builder-el-last  flex_column_div av-hide-on-mobile av-zero-column-padding  "><section class="av_textblock_section av-key26scb-767e6508335704b90077f977070d6be8 " itemscope="itemscope" itemtype="https://schema.org/BlogPosting" itemprop="blogPost"><div class="avia_textblock" itemprop="text"><p></p>
</div></section></div>
<p>Het bericht <a href="https://interhospi.com/whx-dubai-2027/">WHX Dubai 2027</a> verscheen eerst op <a href="https://interhospi.com/">International Hospital</a>.</p></div></div></main></div></div>]]> </content:encoded>
</item>

<item>
<title>Sun Pharma’s UNLOXCYT receives NCCN Category 2A recommendation for laCSCC</title>
<link>https://edusehat.com/en/sun-pharmas-unloxcyt-receives-nccn-category-2a-recommendation-for-lacscc</link>
<guid>https://edusehat.com/en/sun-pharmas-unloxcyt-receives-nccn-category-2a-recommendation-for-lacscc</guid>
<description><![CDATA[ 
The recommendation adds to UNLOXCYT’s Category 2A designation for metastatic cutaneous squamous cell carcinoma, assigned in 2025
The post Sun Pharma’s UNLOXCYT receives NCCN Category 2A recommendation for laCSCC appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 16:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sun, Pharma’s, UNLOXCYT, receives, NCCN, Category, recommendation, for, laCSCC</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Sun Pharmaceutical Industries, together with its subsidiaries and/or affiliated companies, announced that UNLOXCYT (cosibelimab-ipdl) has been elevated to a National Comprehensive Cancer Network (NCCN) Category 2A recommended option for patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) who are not candidates for curative surgery or curative radiation.</span></p>
<p><span>This adds to the Category 2A designation for UNLOXCYT in metastatic cutaneous squamous cell carcinoma (mCSCC), which was assigned in 2025.</span></p>
<p><span>UNLOXCYT was approved by the US Food and Drug Administration (FDA) in 2024 and is indicated for the treatment of adults with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation. The recommended dosage is 1,200 mg as an intravenous infusion over 60 minutes every three weeks. UNLOXCYT is the first and only FDA-approved PD-L1-blocking antibody for advanced CSCC (aCSCC).</span></p>
<p><span>The evidence submitted to NCCN in support of the change was based on the pivotal registration study, in which 55 per cent of patients achieved an objective response, including 26 per cent who achieved a complete response. Responses were durable: at a median follow-up of 24.1 months, the median duration of response had not been reached (range: 8.3 to 31.3+ months). In addition, fewer than 1 per cent of patients experienced a high-grade (Grade 3-5) immune-mediated adverse reaction (imARs). There were no Grade 4 or 5 imARs.</span></p>
<p><span>“The NCCN Guidelines play an important role in helping physicians evaluate appropriate treatment options for patients across different disease settings,” said Ahmad Naim, MD, Senior Vice President, North American Chief Medical Officer, Sun Pharma. “The elevation of UNLOXCYT to a Category 2A recommendation for patients with laCSCC marks an important milestone, validating the growing body of clinical evidence supporting UNLOXCYT and reflecting increasing confidence among oncology experts in its role as a treatment option for patients with this challenging disease.”</span></p>
<p><span>NCCN is an alliance of 34 leading cancer centres in the US. Its Clinical Practice Guidelines in Oncology, referred to as the NCCN Guidelines, provide recommendations for the prevention, diagnosis, evaluation and treatment of different types of cancer. The NCCN Guidelines are among the most influential clinical guidelines in cancer care, offering evidence-based, expert-developed recommendations intended to help clinicians make treatment decisions for patients with cancer.</span></p>
<p><span>One such expert clinician is Dr Francis Worden, Clinical Professor of Internal Medicine at the University of Michigan Rogel Cancer Center, whose institution is one of the 34 NCCN member cancer centres in the alliance.</span></p>
<p><span>Dr Worden said, “This guideline update reflects the strength of the published evidence supporting the use of UNLOXCYT as first line treatment for laCSCC. In the pivotal study, patients experienced durable and clinically meaningful responses. UNLOXCYT also demonstrated a low incidence of high-grade imARs—an important consideration when selecting immune checkpoint inhibitor therapy for a patient population that is mainly elderly and is often afflicted with other health issues. These clinical outcomes may be explained by the mechanism of action that restores adaptive immunity, engages innate immunity through antibody-dependent cellular cytotoxicity (ADCC), and preserves PD-L2 signaling that may be linked to the presence of some immune tolerance in non-tumor tissues.”</span></p>
<p><span>The NCCN Guidelines also have an impact on patient access because they inform payer coverage policies, prior-authorization criteria, institutional formularies and clinical pathways.</span></p>
<p><span>“For patients with laCSCC—many of whom are older, medically complex, and vulnerable to treatment-related complications—access to a therapy that offers durable responses together with a low rate of high-grade imARs is especially important. NCCN recognition helps ensure that appropriate patients can receive this treatment up front without unnecessary access barriers,” said Mark Gimbert, Senior Vice President, Head of Market and Patient Access, North America, Sun Pharma.</span></p>
<p>The post <a href="https://www.expresspharma.in/sun-pharmas-unloxcyt-receives-nccn-category-2a-recommendation-for-lacscc/">Sun Pharma’s UNLOXCYT receives NCCN Category 2A recommendation for laCSCC</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dr. Reddy’s gets CDSCO approval for Zytorvi in advanced esophageal cancer</title>
<link>https://edusehat.com/en/dr-reddys-gets-cdsco-approval-for-zytorvi-in-advanced-esophageal-cancer</link>
<guid>https://edusehat.com/en/dr-reddys-gets-cdsco-approval-for-zytorvi-in-advanced-esophageal-cancer</guid>
<description><![CDATA[ 
Toripalimab in combination with cisplatin and paclitaxel is approved for first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma
The post Dr. Reddy’s gets CDSCO approval for Zytorvi in advanced esophageal cancer appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/07/21134006/approved-logo.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 16:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Dr., Reddy’s, gets, CDSCO, approval, for, Zytorvi, advanced, esophageal, cancer</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/07/21134006/approved-logo.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/07/21134006/approved-logo.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/07/21134006/approved-logo-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Dr. Reddy’s Laboratories announced that the Central Drugs Standard Control Organisation (CDSCO), under the Drugs Controller General of India (DCGI), has approved Zytorvi (toripalimab) in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).</span></p>
<p><span>Dr. Reddy’s entered into a licensing and commercialisation agreement with Junshi Biosciences in 2023 for toripalimab across 21 countries. Globally, toripalimab is approved by regulatory authorities including the US Food and Drug Administration (USFDA), the European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). The EMA approval is for the first-line treatment of ESCC irrespective of PD-L1 expression. The approved indication in India similarly does not require patient selection based on PD-L1 expression, enabling appropriate patients to be considered for treatment regardless of their biomarker status.</span></p>
<p><span>In 2024, esophageal cancer was the fourth leading cause of cancer-related death in India, accounting for approximately 8.1 per cent of all cancer deaths. ESCC, the predominant subtype, accounts for approximately 80 per cent of all esophageal cancer cases in India. Through Zytorvi, Dr. Reddy’s Laboratories aims to expand access to first-line immunotherapy for appropriate patients with advanced ESCC in India.</span></p>
<p><span>The approval is supported by results from the Phase 3 JUPITER-06 trial. In the study, toripalimab in combination with paclitaxel and cisplatin reduced the risk of disease or death by 42 per cent compared with chemotherapy alone. At the final overall survival analysis, median overall survival was 17.7 months with toripalimab plus chemotherapy, compared with 12.9 months with chemotherapy alone. Clinical benefit was observed across PD-L1 expression subgroups.</span></p>
<p><span>M.V. Ramana, Chief Executive Officer, Global Generics, Dr. Reddy’s Laboratories, said, “Following the approval of Zytorvi in nasopharyngeal carcinoma, this second indication marks an important step in extending the reach of immunotherapy to patients with advanced esophageal squamous cell carcinoma. It gives physicians an additional first-line treatment option for appropriate patients. As we continue to build our oncology portfolio, our focus remains on bringing meaningful advances and expanding access to innovative treatment options.”</span></p>
<p><span>Esophageal cancer begins in the tissues of the esophagus, the muscular tube that carries food and liquids from the throat to the stomach. ESCC develops from the squamous cells lining the esophagus.</span></p>
<p><span>Risk factors associated with ESCC include smoked and smokeless tobacco, alcohol consumption, areca-nut use, consumption of very hot beverages, poor diet, and certain environmental and socioeconomic factors. Risk varies between individuals, and the presence of one or more risk factors does not mean that a person will necessarily develop cancer.</span></p>
<p><span>Progressive difficulty in swallowing, pain or discomfort when swallowing, unexplained weight loss, persistent chest discomfort and regurgitation may be associated with esophageal cancer. These symptoms may also be caused by other conditions and require evaluation by a qualified healthcare professional.</span></p>
<p>The post <a href="https://www.expresspharma.in/dr-reddys-gets-cdsco-approval-for-zytorvi-in-advanced-esophageal-cancer/">Dr. Reddy’s gets CDSCO approval for Zytorvi in advanced esophageal cancer</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Student’s NanoClear project explores magnetic separation of microplastics from blood</title>
<link>https://edusehat.com/en/students-nanoclear-project-explores-magnetic-separation-of-microplastics-from-blood</link>
<guid>https://edusehat.com/en/students-nanoclear-project-explores-magnetic-separation-of-microplastics-from-blood</guid>
<description><![CDATA[ 
Suramrit Singh Kohli’s research has received recognition at IRIS National Fair and the Regeneron International Science and Engineering Fair 2026
The post Student’s NanoClear project explores magnetic separation of microplastics from blood appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/10/13112310/Award.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 16:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Student’s, NanoClear, project, explores, magnetic, separation, microplastics, from, blood</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/10/13112310/Award.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/10/13112310/Award.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/10/13112310/Award-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>What happens to microplastics once they enter the human bloodstream? This question has led Suramrit Singh Kohli, a Grade 12 student at Jayshree Periwal International School, to develop NanoClear, a research project exploring whether magnetic nanoparticles could capture microplastics from blood. The project has received recognition at two science competitions.</span></p>
<p><span>Kohli’s interest in the project stems from his engagement with robotics, which began in 2018, and his interest in applying engineering to real-world challenges. With NanoClear, he has explored whether magnetic nanoparticles can bind to plastic particles, allowing them to be separated using an external magnetic field.</span></p>
<p><span>The project began to take shape during Brown University’s Summer@Brown programme under Dr Thomas Webster. In August 2025, Kohli continued his research at ReeLABs Research Centre in Mumbai under Dr Abhijit Bhopadikar, working with human blood samples for approximately 20 hours a week.</span></p>
<p><span>“Microplastics are a problem that we are still learning to understand, and I wanted to explore whether engineering could offer a way to address what happens once these particles enter the bloodstream. NanoClear is still at the research stage, but working on it has shown me that building a possible solution also means understanding its limitations and working out what to solve next,” said Kohli.</span></p>
<p><span>The research involved nanoparticles measuring approximately 91 nanometres, with a positively charged inner coating designed to attract negatively charged plastic particles. Building on this principle, Kohli developed an external magnetic separation system in which blood is intended to mix with the nanoparticles and pass through a magnet-lined coil. The system is designed to capture the resulting clusters before the blood returns to the circuit.</span></p>
<p><span>Early laboratory investigations provided preliminary evidence of particle binding. Electron microscope images captured at Brown University by Dr Webster showed nanoparticles surrounding a fragment of polyvinyl chloride (PVC). In a separate experiment using human blood spiked with microplastics, a turbidity sensor recorded a reduction in the sample’s cloudiness reading from 249.3 to zero after one pass through the system.</span></p>
<p><span>At the IRIS National Fair in January 2026, NanoClear won Gold and the Yale Science and Engineering Association’s Award for Most Outstanding Exhibit in STEM, one of three such awards among approximately 120 finalists. The Gold award secured the project a place among roughly 20 projects representing India at the Regeneron International Science and Engineering Fair (ISEF) 2026 in Phoenix, Arizona. At ISEF, NanoClear received a Special Award from Zydus carrying a prize of US$1,250.</span></p>
<p><span>The research has also progressed into academic publication and intellectual property development. In August 2026, Springer Nature published Kohli’s paper, presented at TIBS 2026, in its Lecture Notes in Networks and Systems (LNNS) series. The project also has an Indian design patent, a provisional patent filing and an ongoing United States patent filing.</span></p>
<p><span>Kohli is also the founder of 7 STEM Labs, an initiative focused on expanding access to practical STEM learning, mentorship and robotics education for students in underserved communities. He plans to continue developing his research interests at university.</span></p>
<p><span>NanoClear remains at the research stage. The prototype has not been tested on patients or approved for medical use, and further work is needed to assess toxicity, blood compatibility and performance at a larger scale. Proposed next steps include toxicity studies, scaling the system to process five litres of blood and animal trials, subject to the necessary ethical approvals. Kohli’s next phase of research at university will focus on addressing the remaining questions and developing the approach from a laboratory-based concept into a practical, real-world solution.</span></p>
<p>The post <a href="https://www.expresspharma.in/students-nanoclear-project-explores-magnetic-separation-of-microplastics-from-blood/">Student’s NanoClear project explores magnetic separation of microplastics from blood</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Zydus gets USFDA approval for estradiol and levonorgestrel transdermal system</title>
<link>https://edusehat.com/en/zydus-gets-usfda-approval-for-estradiol-and-levonorgestrel-transdermal-system</link>
<guid>https://edusehat.com/en/zydus-gets-usfda-approval-for-estradiol-and-levonorgestrel-transdermal-system</guid>
<description><![CDATA[ 
The product has been designated as a Competitive Generic Therapy and is eligible for a 180-day exclusivity period, subject to applicable provisions
The post Zydus gets USFDA approval for estradiol and levonorgestrel transdermal system appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 16:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Zydus, gets, USFDA, approval, for, estradiol, and, levonorgestrel, transdermal, system</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Zydus Lifesciences has announced that the United States Food and Drug Administration (USFDA) has granted final approval for its Abbreviated New Drug Application (ANDA) for Estradiol and Levonorgestrel Transdermal System, 0.045 mg/0.015 mg per day (URLD: Climara Pro Transdermal System 0.045 mg/0.015 mg per day).</span></p>
<p><span>The USFDA has designated the ANDA as a Competitive Generic Therapy (CGT). The product is eligible for the 180-day exclusivity period available to certain first approved applicants under the CGT pathway, subject to the provisions of the US Federal Food, Drug, and Cosmetic Act. Any exclusivity period, where applicable, would commence upon the first commercial marketing of the product.</span></p>
<p><span>Estradiol and Levonorgestrel Transdermal System is primarily used to treat moderate to severe symptoms of menopause. It is also used in postmenopausal women for the prevention of osteoporosis. The product will be manufactured at the group’s manufacturing plant in Moraiya, near Ahmedabad, Gujarat.</span></p>
<p><span>According to IQVIA MAT August 2026 data, Estradiol and Levonorgestrel Transdermal System had annual sales of approximately USD 45.7 million in the United States.</span></p>
<p><span>As of 30 September 2026, the group has 458 approvals and has filed 516 ANDAs with the USFDA.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/zydus-gets-usfda-approval-for-estradiol-and-levonorgestrel-transdermal-system/">Zydus gets USFDA approval for estradiol and levonorgestrel transdermal system</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From hair loss to hair health: Why diagnosis must come before treatment</title>
<link>https://edusehat.com/en/from-hair-loss-to-hair-health-why-diagnosis-must-come-before-treatment</link>
<guid>https://edusehat.com/en/from-hair-loss-to-hair-health-why-diagnosis-must-come-before-treatment</guid>
<description><![CDATA[ 
How is the shift to medical treatment changing how hair loss is assessed and managed, and what gaps remain? For decades, Indian men treated hair loss as a grooming problem. […]
The post From hair loss to hair health: Why diagnosis must come before treatment appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/21102142/Geet-Rathi-Co-founder-Man-Matters-and-Founding-Member-Mosaic-Wellness.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 13:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, hair, loss, hair, health:, Why, diagnosis, must, come, before, treatment</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/21102142/Geet-Rathi-Co-founder-Man-Matters-and-Founding-Member-Mosaic-Wellness.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/21102142/Geet-Rathi-Co-founder-Man-Matters-and-Founding-Member-Mosaic-Wellness.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/21102142/Geet-Rathi-Co-founder-Man-Matters-and-Founding-Member-Mosaic-Wellness-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p align="LEFT"><span><span><span><b>How is the shift to medical treatment changing how hair loss is assessed and managed, and what gaps remain?</b></span></span></span></p>
<p align="LEFT"><span><span><span>For decades, Indian men treated hair loss as a grooming problem. By the time most of them seek real help, they’ve already tried an oil, an anti-hairfall shampoo and at least one thing their mother swore by.</span></span></span></p>
<p align="LEFT"><span><span><span>That’s changing, and it’s the biggest shift in the category. Hair loss is increasingly understood as a medical condition with a cause. Most often that’s androgenetic alopecia, but nutrition, stress, thyroid and scalp health all show up too. Once you accept there’s a cause, assessment has to come before treatment. So the category is layering diagnosis: doctor consultations first, then scalp assessments, and now blood work to catch deficiencies or hormonal triggers that a questionnaire can’t.</span></span></span></p>
<p align="LEFT"><span><span><span>Man Matters has championed this shift, which is visible in our own numbers. We’ve facilitated over 32 lakh doctor consultations, and the number of men consulting our doctors each month has roughly doubled in the past year. This quarter, Man Matters became the first platform in India to launch a blood test for hair loss, because if a man’s hair fall is linked to a deficiency or a thyroid issue, he deserves to know before starting treatment so that it can be addressed.</span></span></span></p>
<p align="LEFT"><span><span><span>The gaps are time and access. Men wait until it’s visible, often years in, and acting earlier usually leaves more options open. Good specialists are concentrated in big cities, yet six in ten men who start with Man Matters today live outside India’s top eight metros. For a guy in a smaller town, a digital consult is often the most practical way to reach a qualified doctor at all.</span></span></span></p>
<p align="LEFT"><span><span><span><b>What clinical evidence guides the selection and combination of approaches, and how do you assess effectiveness in real-world use?</b></span></span></span></p>
<p align="LEFT"><span><span><span>At Man Matters, we start from the cause, not the cart. A doctor assesses the likely type and stage of hair loss, and the plan follows from that.</span></span></span></p>
<p align="LEFT"><span><span><span>For pattern hair loss, the foundation is treatments with the strongest published evidence, like topical minoxidil, plus prescription options where a doctor thinks they’re right for that person. Nutrition plays a supporting role where there’s a deficiency or a lifestyle gap. It complements treatment; it doesn’t replace it. And sleep, diet, stress and a routine a man can actually stick to all affect his hair, so Man Matters plans give him the whole picture, not just what goes on his scalp.</span></span></span></p>
<p align="LEFT"><span><span><span>Real-world effectiveness is the honest-to-god hard part. Trials happen under close supervision. Real life is a 28-year-old with a demanding job who forgets his routine on the third night, and hair changes too slowly for him to notice in the mirror.</span></span></span></p>
<p align="LEFT"><span><span><span>So we’ve made tracking part of the treatment. On the Man Matters app, men can track their hair loss, regrowth and overall journey over months. That helps him see progress he’d otherwise miss, which keeps him going, and it helps our doctors adjust his plan based on how he’s actually responding. Six in ten Man Matters orders come from men who’ve bought from us before, which tells us many are staying the course.</span></span></span></p>
<p align="LEFT"><span><span><span>That said, the industry as a whole needs to get much better at measuring outcomes, not just sales.</span></span></span></p>
<p align="LEFT"><span><span><span><b>What are the key R&D and formulation challenges for the Indian market, and how are companies working to improve delivery, tolerability, adherence and consistency?</b></span></span></span></p>
<p align="LEFT"><span><span><span>India is a tough place to make hair treatments work. Heat, humidity, sweat, hard water. A formulation that feels fine in a lab can feel greasy or itchy on a Mumbai commute in June. And when something is unpleasant to use every day, men don’t complain. They just quietly stop.</span></span></span></p>
<p align="LEFT"><span><span><span>That’s why tolerability has been one of the biggest R&D priorities for Man Matters. Traditional minoxidil formulations were alcohol-based, and for many men that meant irritation and a burning sensation on the scalp. They had a bad experience and gave up on a treatment that could have helped them. The industry has been steadily moving away from alcohol-based formulations, and Man Matters was one of the first brands to popularise alcohol-free minoxidil in India. Our own next step was cetosomal minoxidil, designed for higher absorption and a lighter, better feel after application, so using it every day doesn’t feel like a chore.</span></span></span></p>
<p align="LEFT"><span><span><span>Adherence is the bigger fight across the category. Hair treatment takes months, and many men drop off in the early weeks, before they’ve seen any change.</span></span></span></p>
<p align="LEFT"><span><span><span>Most men don’t quit because they’re lazy. They miss a few days, feel they’ve ruined it, and never restart. So the better players are building for the habit, not just the product: simple routines, honest expectation-setting, follow-ups and reminders that make coming back easy, not guilt-ridden.</span></span></span></p>
<p align="LEFT"><span><span><span>Consistency of outcomes comes back to diagnosis. Two men with thinning hair can need completely different plans.</span></span></span></p>
<p align="LEFT"><span><span><span><b>How can the industry strengthen evidence-based claims, pharmacovigilance and consumer safety? Where is greater regulatory clarity needed?</b></span></span></span></p>
<p align="LEFT"><span><span><span>Right now, a prescription treatment, an over-the-counter product and a supplement can sit next to each other on the same screen, with similar-sounding promises. No wonder consumers are confused.</span></span></span></p>
<p align="LEFT"><span><span><span>Three things would help. First, claims should match the evidence for that specific ingredient and dose, with cosmetic benefits kept clearly separate from therapeutic ones. Second, consumers should get to speak to a doctor or expert so they’re on the right treatment for their cause, not just the most-advertised one. Third, there need to be proper protocols for follow-up and escalation: someone checks in, side effects are recorded and acted on, and a man is referred onward when his case needs more than an online plan.</span></span></span></p>
<p align="LEFT"><span><span><span>Where we’d welcome more regulatory clarity is claims. Too many products in this category make big promises based on weak studies or internal reports. That bar needs to get much tighter. Evidence-backed claims should be the norm in hair loss, not a differentiator. Clear rules reward the companies doing it properly, and that’s good for everyone, especially the consumer.</span></span></span></p>
<p align="LEFT"><span><span><span><b>What will determine the long-term credibility and growth of India’s digital hair health market, and how can technology, medical oversight and longitudinal data contribute?</b></span></span></span></p>
<p align="LEFT"><span><span><span>Outcomes, not reach. Hair loss is a category built on doubt. Almost every man who comes to a digital platform has tried something that didn’t work. In that world, trust isn’t a marketing line. It’s the product.</span></span></span></p>
<p align="LEFT"><span><span><span>Three things will separate the players who last. First, real doctors making actual clinical calls. Not coaches sitting at the end of a sales funnel. Second, deeper diagnosis that pinpoints each man’s specific cause, so his plan actually fits him. Third, longitudinal data. Following a man over months, not just at checkout, tells you what works for which profile and makes the next decision better.</span></span></span></p>
<p align="LEFT"><span><span><span>That’s exactly what Man Matters is building towards. Our blood test for hair loss is the first step in going deeper on diagnosis. The next is helping men complete the journey: building the right habits, seeing treatment as a whole rather than a single product, and staying on their plan long enough to give it a real chance.</span></span></span></p>
<p align="LEFT"><span><span><span>Hair loss isn’t a product problem. It’s a system problem, and Man Matters is built to solve it as one: diagnose, treat, handhold. We don’t just want to be where men start. We want to be where they finish.</span></span></span></p>
<p align="LEFT">
</p><p>The post <a href="https://www.expresspharma.in/from-hair-loss-to-hair-health-why-diagnosis-must-come-before-treatment/">From hair loss to hair health: Why diagnosis must come before treatment</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Takara Bio USA, SPT Labtech Team Up to Automate NGS Library Prep Workflows</title>
<link>https://edusehat.com/en/takara-bio-usa-spt-labtech-team-up-to-automate-ngs-library-prep-workflows</link>
<guid>https://edusehat.com/en/takara-bio-usa-spt-labtech-team-up-to-automate-ngs-library-prep-workflows</guid>
<description><![CDATA[ The partners are targeting NGS core labs with a combined offering that automates next-generation sequencing library prep workflows using kits from Takara Bio and SPT Labtech’s firefly instrument. They are starting with RNA-seq with plans to expand. 
The post Takara Bio USA, SPT Labtech Team Up to Automate NGS Library Prep Workflows appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/12/GettyImages-1481209562.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 06:15:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Takara, Bio, USA, SPT, Labtech, Team, Automate, NGS, Library, Prep, Workflows</media:keywords>
<content:encoded><![CDATA[<p>Takara Bio USA and SPT Labtech have inked an agreement that will allow them to provide automated library preparation workflows that pair Takara Bio’s next-generation sequencing library prep chemistries with SPT Labtech’s firefly liquid handling platform. Under the terms of the partnership agreement, the companies will first optimize select SMART-seq<sup>®</sup> RNA-seq library prep workflows, a new offering from Takara Bio, on SPT Labtech’s firefly with plans to ultimately expand to a growing menu of new RNA-seq, DNA-seq, and immune profiling kits.</p>
<p>The target customer base for the combined offering is NGS core labs and customers who prepare NGS libraries from a high volume of samples and need to expand their current capabilities. With the new offering, the company claims that these customers will have access to automation scripts to easily deploy workflows that can generate high-quality, reproducible sequencing data and that are easy to integrate into labs’ existing processes. The partners also note that SPT Labtech’s firefly does not require a large footprint, making it suitable for labs constrained by staffing, space, and cost.</p>
<p>Both partners will discuss the collaboration during this year’s annual meeting of the American Society of Human Genetics.</p>
<p>For Takara Bio, the partnership fits into a bigger picture. The company is incorporating automation as an integral part of an NGS technology launch package. The company plans to start shipping its SMART-Seq mRNA long read extended kit in January 2027. This will be the first product launched with an optimized workflow for the firefly instrument. Takara Bio claims that the combined products will help labs standardize long-read transcriptomics at scale while benefitting from greater input flexibility, better recovery of full-length transcripts, and greater quantification confidence among other benefits. Automation scripts are already available for download on the SPT cloud portal for two existing kits, SMART-Seq mRNA LP and SMART-Seq Total RNA Library Prep with ZapR<sup>®</sup> Depletion with unique molecular identifiers.</p>
<p>Commenting on the partnership, Andrew Farmer, DPhil, president and CEO of Takara Bio USA, noted that the company is committed to making its NGS chemistries easier to implement at scale. “Through our collaboration with SPT Labtech, automation is becoming a foundational element of how we bring NGS products to market. As we introduce new library preparation technologies, customers can expect automated workflows to be built into the product experience from the start,” he said.</p>
<p>Paul Lomax, head of genomics at SPT Labtech, noted that by combining their products, both companies aim to help “more laboratories access the benefits of automated library preparation without the infrastructure requirements often associated with larger automation platforms.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/takara-bio-usa-spt-labtech-team-up-to-automate-ngs-library-prep-workflows/">Takara Bio USA, SPT Labtech Team Up to Automate NGS Library Prep Workflows</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Roche, Hansoh Launch Up&#45;to&#45;$15B+ Cancer ADC Collaboration</title>
<link>https://edusehat.com/en/roche-hansoh-launch-up-to-15b-cancer-adc-collaboration</link>
<guid>https://edusehat.com/en/roche-hansoh-launch-up-to-15b-cancer-adc-collaboration</guid>
<description><![CDATA[ The companies&#039; strategic collaboration will consist of two preclinical Hansoh ADC programs and “multiple” ADC programs based on Roche-identified targets, to be developed through Hansoh’s ADC technology platform.
The post Roche, Hansoh Launch Up-to-$15B+ Cancer ADC Collaboration appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Getty_2179548801_AntibodyDrugConjugate.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 06:15:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Roche, Hansoh, Launch, Up-to-15B, Cancer, ADC, Collaboration</media:keywords>
<content:encoded><![CDATA[<p>Roche and Hansoh Pharmaceutical Group have launched their second collaboration focused on developing cancer-fighting antibody-drug conjugates (ADCs), a partnership that could generate more than $15 billion for the Shanghai-based drug developer.</p>
<p>Roche and Hansoh have agreed to develop an unspecified number of ADCs “across multiple cancer types,” without disclosing the cancer types and targets they plan to focus on. The companies did say, however, that their strategic collaboration will consist of two preclinical Hansoh ADC programs and “multiple” ADC programs based on Roche-identified targets, to be developed through Hansoh’s ADC technology platform.</p>
<p>“Expanding our strategic collaboration with Hansoh marks an important step in advancing our ADC vision,” Boris L. Zaïtra, head of Corporate Business Development at Roche, said in a statement. “Exploring next generation ADCs is one of the most compelling frontiers in oncology today, offering the opportunity to address critical unmet needs and accelerate potential therapies for patients worldwide.”</p>
<p>Roche’s latest Hansoh partnership was announced October 19, a year and two days after the pharma giant was granted an exclusive global license (excluding China, Hong Kong, Macau and Taiwan) by Hansoh to develop its HS-20110, an ADC being developed to treat colorectal cancer and other solid tumors. HS-20110 consists of a humanized anti-CDH17 monoclonal antibody covalently conjugated to topoisomerase inhibitor (TOPOi) payload.</p>
<p>At the time, Roche agreed to pay Hansoh $80 million upfront and up to $1.45 billion in potential development, regulatory approval, and commercialization milestone payments, plus royalties, toward developing HS-20110. The drug is under study in advanced colorectal cancer in a global Phase I/II trial (<a title="Original URL: https://clinicaltrials.gov/study/NCT07283367. Click or tap if you trust this link." href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07283367&data=05%7C02%7CSavannah.Wiegel%40sagepub.com%7C457be5dcfb8f4fe223d708df2ec75245%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639281105751915276%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=YPNLp%2B1eB6Uvla0qKAAhjIbrqPgWLHKJmdmRyyva3Xc%3D&reserved=0" target="_blank" rel="noopener" data-auth="NotApplicable" data-linkindex="0">NCT07283367</a>) in China whose primary completion date is December 31, 2029; as well as in advanced solid tumors in a global Phase I trial (<a title="Original URL: https://clinicaltrials.gov/study/NCT06892379. Click or tap if you trust this link." href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06892379&data=05%7C02%7CSavannah.Wiegel%40sagepub.com%7C457be5dcfb8f4fe223d708df2ec75245%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639281105751944126%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=iosS%2FLGC1HyYtPliI45Dz9PnvZXIAZtYaBhi8VfQNxc%3D&reserved=0" target="_blank" rel="noopener" data-auth="NotApplicable" data-linkindex="1">NCT06892379</a>) in the U.S. and China whose primary completion date is December 31.</p>
<p>“Building on the ADC partnership we announced last year, we are delighted to further strengthen our collaboration with Roche,” stated Eliza Sun, executive director of Hansoh’s board. “This new agreement reflects our shared commitment to advancing ADC innovation and underscores our strategy of leveraging our deep expertise to accelerate the development of transformative therapies for cancer patients globally.”</p>
<p class="x_MsoNormal" data-olk-copy-source="MessageBody">Investors sent Hansoh shares on the Hong Kong Stock Exchange rising nearly 10% over two days, from HKD 31.38 ($3.94) at the start of Monday trading to HKD 34.38 ($4.31) at Tuesday’s close. Roche’s two classes of stock traded on the SIX Swiss Exchange each climbed roughly 3% during the period: RO bearer shares rose from CHF 384.60 ($463.21) to CHF 395.60 ($476.46), while ROP participation certificates went from CHF 379.20 ($456.67) to CHF 389.90 ($469.56).</p>
<h4><strong>Four ADCs disclosed in pipeline</strong></h4>
<p>HS-20110—identified with the placeholder name “CHU”—is one of four cancer-fighting ADCs disclosed online in <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.roche.com%2Fsolutions%2Fpipeline&data=05%7C02%7Calex.philippidis%40sagepub.com%7C5aa2b45fbc2a4779ff2508df2e1f490f%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639280384782719394%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=dMePOleHd17aiLs3XzYg04uQ8qh4N1ZUoHO9ufJGzgw%3D&reserved=0" target="_blank" rel="noopener">Roche’s pipeline</a>, last updated July 23. The other three are:</p>
<ul>
<li><strong>RG6648</strong>, a c-Mesenchymal-epithelial transition factor (cMET)-targeting ADC whose active antitumor payload is the antibody YL0010014. When released, YL0010014 is designed to arrest the cell cycle of tumor cells, leading to tumor cell apoptosis. MediLink licensed the ADC, which it called YL211, in 2024 for up to nearly $1 billion, including $50 million in upfront and near-term milestone payments.</li>
<li><strong>RG6810</strong>, a DLL3-targeted ADC with a topoisomerase I (Topo1) isomerase payload, being developed to treat small cell lung cancer (SCLC). Roche licensed the ADC, which it called IBI3009, from San Francisco and Suzhou-based Innovent Biologics last year for $80 million upfront and up to $1 billion in development and commercial milestone payments, plus tiered royalties on net sales.</li>
<li><strong>Tam-Peli (tambotatug pelitecan or RG6919)</strong>, a B7H3-targeting ADC for solid tumors licensed worldwide except China, Hong Kong, and Macau in January from Suzhou, China-based MediLink, which called the candidate YL201. The ADC was developed using MediLink’s Tumor Microenvironment-Activatable LINker-payload (TMALIN<sup>®</sup>) platform.</li>
</ul>
<p>Last month, MediLink released positive interim data from the Phase III TAISHAN-302 trial (<a href="https://clinicaltrials.gov/study/NCT06612151" target="_blank" rel="noopener">NCT06612151</a>) assessing Tam-Peli vs. standard-of-care topotecan in Chinese patients with relapsed SCLC who progressed after prior platinum-based chemotherapy with or without a PD-L1 inhibitor. TAISHAN-302 met its primary endpoint of overall survival (OS) with Tam-Peli demonstrating a statistically significant and clinically meaningful OS benefit, reducing the risk of death by 54% (median OS 13.3 vs. 9.4 months; stratified HR=0.46; p<0.0001).</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Tam-Peli also showed robust efficacy across secondary endpoints, significantly extending progression-free survival (PFS) (median PFS 7.4 vs. 2.8 months) and response rates (59.1% vs. 9.7%) vs. topotecan. The Tam-Peli data was presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) in Seoul with simultaneous <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2610229%3Faf%3DR%26rss%3DcurrentIssue%26referrer%3Dhttps%253A%252F%252Fwww.google.com%252F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C5aa2b45fbc2a4779ff2508df2e1f490f%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639280384782749883%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=OeWCYKS3VJxKecK82rPuRQMiW8s%2FHDlAg4cSveQXuEA%3D&reserved=0" target="_blank" rel="noopener">publication in <em>The New England Journal of Medicine</em></a>.</p>
<h4><strong>Ongoing ADC collaborations</strong></h4>
<p>Roche has several other ongoing discovery and development collaborations with Chinese partners focused on ADCs.</p>
<p>In August, Roche’s Genentech subsidiary agreed to license ADCs it plans to develop with Shanghai-based DualityBio based on its DualityBio Unique Payload Antibody Conjugate (DUPAC) platform. The ADCs would be developed against Genentech-defined oncology targets using payloads from DUPAC. Roche agreed to pay DualityBio $45 million upfront and more than $1 billion in development, regulatory, and commercial milestone payments, plus tiered royalties.</p>
<p>Through its latest partnership with Hansoh, Roche aims to multiply the number of ADCs in its development pipeline and product portfolio. Roche now markets two ADCs. One is Kadcyla<sup>®</sup> (ado-trastuzumab emtansine / RG3502), a HER2-targeted antibody and microtubule inhibitor conjugate approved to treat HER2-positive breast cancer. Kadcyla is under study in combination with Roche’s Tecentriq<sup>®</sup> (atezolizumab) in the Phase III ASTEFANIA trial (<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04873362&data=05%7C02%7Calex.philippidis%40sagepub.com%7C5aa2b45fbc2a4779ff2508df2e1f490f%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639280384782767152%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=tqWwZVSif8QrDwiGxFVZ5N9wyXSgA8O3rt1iX17UE%2B4%3D&reserved=0" target="_blank" rel="noopener">NCT04873362</a>) for high-risk early breast cancer.</p>
<p>The other marketed Roche ADC is Polivy<sup>®</sup> (polatuzumab vedotin), which is approved for specific types of lymphoma.  While a consensus of analysts expects Kadcyla and Polivy to rack up a combined CHF 3.5 billion ($4.3 billion) this year, according to LSEG data cited by Reuters.</p>
<p>Hansoh has agreed to lead early development of the programs through the completion of global Phase Ia clinical trials. After that, Roche agreed to oversee further development of the programs worldwide except China, Hong Kong, Macau, and Taiwan—where Hansoh will retain all rights to develop, register and commercialize the programs.</p>
<p>Also outside China, Hong Kong, Macau, and Taiwan, Hansoh has the option to select up to two programs and contribute to their development. In return, Roche will pay Hansoh unspecified “incremental upside” payments stemming from their commercialization in the United States.</p>
<p>Roche has agreed to pay Hansoh $400 million upfront, an additional $110 million to be paid next year on the first anniversary of the collaboration, and more than $15 billion in payments tied to achieving development, regulatory, and commercialization milestones associated with the programs. Hansoh could also gain from Roche tiered royalties on potential future product sales.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<h4><strong>Patent cliff pressure</strong></h4>
<p>The partnership is one of several collaborations through which Swiss-based Roche hopes to recoup sales it expects to lose as its aging blockbusters lose patent exclusivity. The best-selling of these drugs is its Genentech-marketed multiple sclerosis drug Ocrevus<sup>®</sup> (ocrelizumab), which <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fdrug-discovery%2Ftop-20-drugs-heading-for-the-patent-cliff-2026-2029%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C5aa2b45fbc2a4779ff2508df2e1f490f%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639280384782782029%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=RHVVkDomkTBk8KTqPamt%2B9hVynu2PkIAs3QfinxBAFI%3D&reserved=0" target="_blank" rel="noopener">heads for the proverbial “patent cliff” in 2027</a>. Ocrevus generated CHF 3.47 billion ($4.192 billion) in sales during January-June and CHF 7.01 billion ($8.467 billion) in 2025.</p>
<p>That sales pressure has prompted Roche to launch numerous collaborations: In addition to the Hansoh and DualityBio collaborations, Roche has partnered since August alone with:</p>
<ul>
<li><strong>Rona Therapeutics</strong>, another Chinese biotech, on an agreement to license its RNA interference (RNAi) obesity and metabolic disease candidate targeting activin receptor-like kinase 7 (ALK7), announced October 13 and valued at up-to-$1.16 billion ($100 million upfront and near-term).</li>
<li><strong>Defand Therapeutics, </strong>a Chinese startup, on a drug discovery partnership of undisclosed value (though <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fendpoints.news%2Froche-does-fourth-china-deal-since-august-teaming-with-defand-on-degraders%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C5aa2b45fbc2a4779ff2508df2e1f490f%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639280384782794666%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=3wwi8ubmEbjcOqrkDg3pFV6Y8090aBKnNQ9IfT9pvTM%3D&reserved=0" target="_blank" rel="noopener">reportedly</a> up to about $1 billion, up to $10 million of that upfront) to discover and develop molecular glue therapies for multiple cancer and immunology targets, announced October 7.</li>
<li><strong>Ataviastik Bio, </strong>a Cambridge, MA hematology drug developer, on a partnership to discover and develop small molecule therapeutics against multiple targets for cardiovascular, renal, and metabolic (CVRM) diseases, valued at up to $1.9 billion ($70 million upfront), announced September 24.</li>
<li><strong>Earendil Labs</strong>, a Wilmington, DE, biologics developer, on a research collaboration with Genentech to discover and develop multiple therapeutic bispecific antibody programs in oncology, valued at up to $1.15 billion ($55 million upfront), announced September 24.</li>
</ul>
<p>At up-to-$15.5 billion, the latest Roche-Hansoh collaboration is among the largest but not the largest partnership between a Western pharma and a Chinese biotech. That distinction belongs to AstraZeneca’s up-to-$18.5 billion collaboration ($1.2 billion upfront) with CSPC Pharmaceutical Group to develop “multiple” injectable next-generation therapies for obesity and type 2 diabetes across eight programs announced in January. That does not include a separate up-to-$1.77 billion ($30 million upfront) partnership by the companies to develop small interfering RNA (siRNA) therapies for kidney diseases, launched in July.</p>
<p>In May, Bristol Myers Squibb (BMS) <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fdrug-discovery%2Fbms-hengrui-pharma-partner-on-13-programs-in-up-to-15-2b-collaboration%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C5aa2b45fbc2a4779ff2508df2e1f490f%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639280384782815248%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=6dXHP%2BUSMzcHBa3SrGlzm5IsfPgBo1fJp%2Bo%2FvYo96As%3D&reserved=0" target="_blank" rel="noopener">launched an up-to-$15.2 billion partnership</a> with Hengrui Pharma to co-develop 13 early-stage programs in oncology, hematology, and immunology. The 13 consist of four oncology/hematology assets from Hengrui, four immunology assets from BMS, and five “innovative” assets to be jointly discovered and developed by both companies. Also in May, Pfizer <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fdrug-discovery%2Fpfizer-innovent-ink-up-to-10-5b-cancer-treatment-collaboration%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C5aa2b45fbc2a4779ff2508df2e1f490f%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639280384782826682%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=gps5ijxT%2BVzbPbuATAcMdIKK01rJbBMjQ4N%2FKrpK3lU%3D&reserved=0" target="_blank" rel="noopener">inked an up to $10.5 billion oncology alliance</a> with Innovent Biologics to develop 12 early-stage and <em>de novo</em> antibodies and antibody-drug conjugates (ADCs) designed to treat various cancers.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/roche-hansoh-launch-up-to-15b-cancer-adc-collaboration/">Roche, Hansoh Launch Up-to-$15B+ Cancer ADC Collaboration</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New Catalytic Reactive&#45;Hydrogen Membranes Capture and Break Down PFAS</title>
<link>https://edusehat.com/en/new-catalytic-reactive-hydrogen-membranes-capture-and-break-down-pfas</link>
<guid>https://edusehat.com/en/new-catalytic-reactive-hydrogen-membranes-capture-and-break-down-pfas</guid>
<description><![CDATA[ Newly developed palladium-coated membranes capture PFAS and use reactive hydrogen to break their carbon–fluorine bonds. During 58 days of continuous operation, the system achieved up to 96% removal and 83% defluorination.
The post New Catalytic Reactive-Hydrogen Membranes Capture and Break Down PFAS appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/03/GettyImages-2149301660.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 06:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, Catalytic, Reactive-Hydrogen, Membranes, Capture, and, Break, Down, PFAS</media:keywords>
<content:encoded><![CDATA[<p>Researchers at Arizona State University (ASU) and collaborating institutions have developed catalytic reactive-hydrogen membranes that capture and chemically break down six per- and polyfluoroalkyl substances (PFAS) in water. The approach couples contaminant removal with carbon–fluorine bond cleavage, addressing a limitation of conventional treatments that separate “forever chemicals” from water but leave contaminated waste requiring further handling.</p>
<p>The study, led by Bruce Rittmann, PhD, director of ASU’s Biodesign Swette Center for Environmental Biotechnology, involved collaborators at Rice University, Tongji University, the National University of Singapore, and Nanjing University. Published in <em>Proceedings of the National Academy of Sciences</em>, the paper is titled “<a href="https://www.pnas.org/doi/10.1073/pnas.2613985123" target="_blank" rel="noopener">Catalytic Reactive-Hydrogen Membranes for Rapid Capture and Hydrodefluorination of Six PFAS of Regulatory Concern</a>.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“PFAS are hard to break down, and normal processes that we use don’t work,” Rittmann said.</p>
<p>That persistence stems from the compounds’ strong carbon–fluorine bonds. Activated carbon, ion exchange, and membrane filtration can remove PFAS from water, but do not themselves resolve the challenge of destroying the captured contaminants. The new system instead brings PFAS and reactive hydrogen together on palladium-coated membrane fibers under ambient conditions.</p>
<figure aria-describedby="caption-attachment-339638" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339638" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_rittmann-defluorination-300x169.jpg" alt="" width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_rittmann-defluorination-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_rittmann-defluorination.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">A palladium-coated membrane uses hydrogen to help break down PFAS “forever chemicals.” [Jason Drees]</figcaption></figure>
<p>Hydrogen gas travels through the fibers to the palladium catalyst, where it generates two forms of active hydrogen with complementary functions. Surface hydrogen supports PFAS capture, while subsurface hydrogen stored as beta-phase palladium hydride supplies the driving force for hydrodefluorination.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>“The palladium attracts the PFAS molecule, and the palladium attracts the hydrogen and puts them together,” Rittmann added.</p>
<p>Solid-state analyses identified formation of the palladium hydride and associated lattice expansion. In the paper, the researchers described their findings as “a mechanistic framework for how active hydrogen is generated, stored, and deployed in catalytic membranes.”</p>
<p>The team tested PFOA, PFOS, PFNA, PFHxS, PFBS, and GenX. During 58 days of continuous operation, the system achieved up to 96% removal and 83% defluorination.</p>
<p>Performance also varied by compound. Long-chain PFAS were removed and defluorinated faster than short-chain analogs. GenX was more resistant, which the authors attributed to its ether linkage, weaker adsorption, and higher average carbon–fluorine bond dissociation energy. Nevertheless, the membrane enabled GenX removal and defluorination, producing 2-propoxypropanoic acid.</p>
<p>Practical deployment will require further engineering, including reducing palladium use. “Palladium is expensive,” Rittmann said. One potential application is treating concentrated waste streams generated by existing PFAS-removal systems, rather than replacing those systems outright. The researchers are also developing related hybrid membranes combining palladium with pollutant-degrading bacteria, although the current study’s catalytic system uses palladium rather than microbes.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/new-catalytic-reactive-hydrogen-membranes-capture-and-break-down-pfas/">New Catalytic Reactive-Hydrogen Membranes Capture and Break Down PFAS</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

</channel>
</rss>